<SEC-DOCUMENT>0001193125-15-114201.txt : 20150331
<SEC-HEADER>0001193125-15-114201.hdr.sgml : 20150331
<ACCEPTANCE-DATETIME>20150331162613
ACCESSION NUMBER:		0001193125-15-114201
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		31
CONFORMED PERIOD OF REPORT:	20141231
FILED AS OF DATE:		20150331
DATE AS OF CHANGE:		20150331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOTEK PHARMACEUTICALS CORP
		CENTRAL INDEX KEY:			0001281895
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36829
		FILM NUMBER:		15739560

	BUSINESS ADDRESS:	
		STREET 1:		131 HARTWELL AVE
		STREET 2:		1ST FLOOR, SUITE 105
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
		BUSINESS PHONE:		781-676-2100

	MAIL ADDRESS:	
		STREET 1:		131 HARTWELL AVE
		STREET 2:		1ST FLOOR, SUITE 105
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>d893535d10k.htm
<DESCRIPTION>10-K
<TEXT>
<HTML><HEAD>
<TITLE>10-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>FORM&nbsp;10-K
</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Mark One) </B></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the fiscal year ended December&nbsp;31, 2014 </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OR </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>TRANSITION REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the transition period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> to
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number:
001-36829 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>Inotek Pharmaceuticals Corporation </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Its Charter) </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>04-3475813</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Incorporation or Organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>131 Hartwell Avenue, Suite 105</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Lexington, MA</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>02421</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of Principal Executive Offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(781)&nbsp;676-2100 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s Telephone Number,&nbsp;Including Area Code) </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Securities registered pursuant to Section&nbsp;12(b) of the Act: </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:60.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:148.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange on which registered</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Common Stock, $0.01 par value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>NASDAQ Global Market</B></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Securities registered pursuant to Section&nbsp;12(g) of the Act: None </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8.5pt; font-family:Times New Roman">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8.5pt; font-family:Times New Roman">Indicate by check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Exchange
Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8.5pt; font-family:Times New Roman">Indicate by check mark whether the registrant: (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90
days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8.5pt; font-family:Times New Roman">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such
files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8.5pt; font-family:Times New Roman">Indicate by check mark if disclosure of delinquent filers pursuant to Item&nbsp;405 of Regulation S-K is not contained herein, and will not be
contained, to the best of registrant&#146;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> or any amendment to this Form 10-K.&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8.5pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated
filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act. (Check one): </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;(Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8.5pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8.5pt; font-family:Times New Roman">The aggregate market value of the registrant&#146;s voting and non-voting common stock held by non-affiliates of the registrant (without
admitting that any person whose shares are not included in such calculation is an affiliate) computed by reference to the price at which the common stock was last sold on March&nbsp;24, 2015 was $26.1 million. The registrant has provided this
information as of March&nbsp;24, 2015 because our common stock was not publicly traded as of the last business day of its most recently completed second fiscal quarter. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">As of March&nbsp;30, 2015 there were 16,327,003 shares of common stock, $0.01 par value per share, outstanding. </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>Table of Contents </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD COLSPAN="3" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc893535_1"><U>PART&nbsp;I.</U></A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc893535_2">Business</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc893535_3">Risk Factors</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1B.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc893535_4">Unresolved Staff Comments</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc893535_5">Properties</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc893535_6">Legal Proceedings</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc893535_7">Mine Safety Disclosures</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc893535_8"><U>PART&nbsp;II.</U></A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;5.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc893535_9">Market for Registrant&#146;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;6.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc893535_10">Selected Financial Data</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;7.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc893535_11">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;7A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc893535_12">Quantitative and Qualitative Disclosures about Market Risk</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;8.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc893535_13">Financial Statements and Supplementary Data</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;9.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc893535_14">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;9A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc893535_15">Controls and Procedures</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;9B.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc893535_16">Other Information</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc893535_17"><U>PART&nbsp;III</U></A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;10.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc893535_18">Directors, Executive Officers and Corporate Governance</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;11.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc893535_19">Executive Compensation</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;12.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc893535_20">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;13.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc893535_21">Certain Relationships and Related Transactions and Director Independence</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;14.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc893535_22">Principal Accountant Fees and Services</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U><A HREF="#toc893535_23">PART IV</A></U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;15.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc893535_24">Exhibits and Financial Statement Schedules</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc893535_25"><U>Signatures</U></A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties, as well as assumptions that, if they
never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this Annual Report on Form 10-K are forward-looking statements. In some cases, you can identify
forward-looking statements by words such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;contemplate,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148;
&#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;target,&#148; &#147;will,&#148; &#147;would,&#148; or the negative of these words or other comparable terminology. These
forward-looking statements include, but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our anticipated cash needs and our estimates regarding our capital requirements and our needs for additional financing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the February 2015 offering of common stock and convertible notes due 2020 and our expectations related to the use of proceeds therefrom; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">federal, state, and non-U.S. regulatory requirements, including regulation of our current or any other future product candidates by the FDA; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the success, timing and cost of our planned Phase&nbsp;2 clinical trials and anticipated Phase&nbsp;3 program for <I>trabodenoson</I> as a monotherapy and Phase 2 program for our fixed-dose combination, or FDC, product
candidate, including statements regarding the timing of initiation and completion of the trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of and our ability to submit regulatory filings with the FDA and to obtain and maintain FDA or other regulatory authority approval of, or other action with respect to, our product candidates;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our commercialization, marketing and manufacturing capabilities and strategy, including with respect to our planned sales force in the United States and our partnering and collaboration efforts outside the United
States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">third-party payor reimbursement for our current product candidates or any other potential products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding the clinical efficacy of our product candidates and results of our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the glaucoma patient market size and the rate and degree of market adoption of our product candidates by ophthalmologists, optometrists and patients; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing, cost or other aspects of the commercial launch of our product candidates and potential future sales of our current product candidates or any other potential products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding licensing, acquisitions and strategic operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential advantages of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our competitors and their product candidates, including our expectations regarding those competing product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to protect and enforce our intellectual property rights, including our patented and trade secret protected proprietary rights in our product candidates; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">anticipated trends and challenges in our business and the markets in which we operate. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
caution you that the foregoing list may not contain all of the forward-looking statements made in this Form 10-K. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any forward-looking
statements in this Annual Report on Form 10-K reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these
forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under Part I, Item&nbsp;1A. Risk Factors and elsewhere in this Annual Report on Form 10-K.
Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information
becomes available in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Annual Report on Form 10-K also contains estimates, projections and other information concerning
our industry, our business, and the markets for certain diseases, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts,
projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we
obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar
sources. </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc893535_1"></A>PART I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc893535_2"></A>Item&nbsp;1. Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma. Glaucoma is a disease of the eye that is typically characterized by structural evidence of optic nerve damage, vision loss and elevated
intraocular pressure, or IOP. Our lead product candidate, <I>trabodenoson</I>, is a first-in-class selective adenosine mimetic that we rationally designed to lower IOP by restoring the eye&#146;s natural pressure control mechanism. We developed this
molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye&#146;s trabecular meshwork, or TM. The TM regulates the pressure inside the eye and is also the main
outflow path for the fluid inside of the eye that often builds up pressure in patients with glaucoma. We believe that by restoring the natural function of the TM and this outflow path, rather than changing the fundamental dynamics of pressure
regulation in the eye, <I>trabodenoson</I>&#146;s mechanism of action should result in a lower risk of unintended side effects and long term safety issues than other mechanisms of action. Additionally, <I>trabodenoson</I>&#146;s unique mechanism of
action in the TM should complement the activity of existing glaucoma therapies that exert their IOP-lowering effects on different parts of the in-flow and out-flow system of the eye. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2015, we completed our initial public offering (the &#147;IPO&#148;) of 6,667,000 shares of our common stock at a price of $6.00
per share and concurrent offering of $20.0 million aggregate principal amount of our 5.0% Convertible Senior Notes due 2020 (the &#147;2020 Notes&#148;). In March 2015, the underwriters exercised 299,333 shares of common stock at $6.00 per share and
$1.0 million of the 2020 Notes pursuant to their overallotment options. We received net proceeds of approximately $36.6 million, after deducting underwriting discounts and offering-related costs, from our equity issuances and approximately $18.9
million in net proceeds, after deducting underwriting discounts and offering-related costs, from our debt issuances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product pipeline
includes <I>trabodenoson</I> monotherapy delivered in an eye drop formulation, as well as a fixed dose combination, or FDC, of <I>trabodenoson</I> with <I>latanoprost</I> given once-daily, or QD. <I>Latanoprost</I> is the leading prostaglandin
analog, or PGA. We are also evaluating the potential of <I>trabodenoson</I> to slow the loss of vision associated with glaucoma and degenerative retinal diseases. Statistically significant results for the primary endpoint of our completed Phase 2
clinical trial indicate that <I>trabodenoson</I> monotherapy has IOP-lowering effects in line with existing therapies, with a favorable safety and tolerability profile at all doses tested. Our completed Phase 2 trial of <I>trabodenoson</I>
co-administered with <I>latanoprost</I> demonstrated IOP-lowering in patients who have previously had inadequate responses to treatment with <I>latanoprost</I>. These patients represent PGA poor-responders, as evidenced by persistently elevated IOP
at levels that typically require the addition of a second drug to further lower IOP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are planning an End-of-Phase 2 meeting with the
U.S. Food and Drug Administration, or FDA, for <I>trabodenoson</I> monotherapy in the first half of 2015. We expect to initiate a Phase 3 program for <I>trabodenoson</I> monotherapy in mid-2015, which will consist of two Phase 3 pivotal trials and a
long-term safety study. Based on our estimates of the rate of patient enrollment and assuming commencement in mid-2015, we expect to report top-line data from the first pivotal Phase 3 trial in late 2016 or early 2017. If the primary objectives of
our Phase&nbsp;3 program are met, we plan to submit a New Drug Application, or NDA, to the FDA for marketing approval of <I>trabodenoson</I> for the treatment of glaucoma in the United States. We plan to submit a marketing authorization application,
or MAA, in Europe after filing our NDA for approval of <I>trabodenoson</I> in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to IMS Health, sales of
glaucoma drugs in 2013 were approximately $2.0 billion in the United States and $5.6 billion worldwide. According to the British Journal of Ophthalmology, there were an estimated 2.8&nbsp;million Americans with glaucoma in 2010. Once glaucoma
develops, it is a chronic condition that requires life-long treatment. PGAs are the most widely prescribed drug class for glaucoma and include the most widely prescribed glaucoma drug, <I>latanoprost. </I>When PGA monotherapy is insufficient to
control IOP or is poorly tolerated, non-PGA products, such as beta blockers, alpha agonists and carbonic anhydrase inhibitors, are generally </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
used either as an add-on therapy to the PGA or as an alternative monotherapy. Both PGAs and non-PGAs can cause adverse effects in the eye. In addition, non-PGA drugs can have adverse effects in
the rest of the body and have been shown to have poor tolerability profiles. As a result, we believe there is a significant unmet need for a treatment that effectively lowers IOP by restoring outflow and the natural pressure control by the TM, that
has a favorable safety and tolerability profile, and that works effectively in combination with other treatments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, no
existing treatments offer the potential to directly treat the underlying cause of glaucoma associated vision loss: the death of retinal ganglion cells, or RGCs, the nerve tissue in the retina that relays the visual signal to the brain. We believe
that a drug with the potential to make these cells more resilient to the stress caused by glaucoma would achieve broad market acceptance as the treatment preferred among patients and physicians. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own worldwide rights to all indications for our current product candidates and have patents and pending patent applications related to the
composition of matter, pharmaceutical compositions and methods of use for <I>trabodenoson</I>, certain of which extend to 2031 with respect to our issued patents and 2034 with respect to our pending patent applications. If <I>trabodenoson</I>
receives marketing approval in the United States, we plan to commercialize it by establishing our own specialty sales force in the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our
Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to become a leading biopharmaceutical company focused on the discovery, development and commercialization of
novel therapies to treat glaucoma. The key elements of our strategy are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Complete clinical development and seek marketing approval for our lead product candidate, trabodenoson monotherapy</I></B>. In 2012, we completed a Phase 2 trial of <I>trabodenoson </I>monotherapy, which
demonstrated statistically significant IOP-lowering and a favorable safety profile. We are planning an End-of-Phase 2 meeting with the FDA in the first half of 2015 to discuss our Phase 3 program for <I>trabodenoson</I> monotherapy and to confirm
the design and endpoints for the Phase 3 pivotal trials. Based on our estimates of the rate of patient enrollment and assuming commencement in mid-2015, we expect to have top-line data from the first of two pivotal trials in the program in late 2016
or early 2017. If the primary objectives of our Phase&nbsp;3 program are met, we plan to submit an NDA to the FDA for marketing approval of <I>trabodenoson</I> monotherapy for the treatment of glaucoma in the United States. We plan to submit an MAA
in Europe after filing our NDA for approval of <I>trabodenoson</I> monotherapy in the United States. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Complete clinical development and seek marketing approval of a fixed-dose combination product that includes both trabodenoson and latanoprost</I></B>. As many as half of glaucoma patients, typically those with
more severe disease, require two or more glaucoma drugs to sufficiently reduce their IOP. The initial treatment for glaucoma patients is usually the use of a prescription eye drop from the PGA drug class. However, as PGAs are often unable to lower
IOP sufficiently to reach the patient&#146;s medically targeted level, non-PGA products are used either as an add-on therapy to the PGA or as an alternative monotherapy in place of PGAs. There are currently no FDC products approved for use in the
United States that include a PGA. We intend to formulate and conduct clinical development in order to seek marketing approval for an FDC product that includes both <I>trabodenoson</I> and <I>latanoprost</I>, the best-selling PGA. We believe that the
favorable safety and tolerability profile and complementary mechanism of action of <I>trabodenoson</I> could, if approved, make an FDC with <I>latanoprost</I> a highly effective, well-tolerated and more convenient QD regimen for treating glaucoma in
patients who have a less functional TM and therefore need additional help lowering their IOP. Our completed Phase 2 trial of <I>trabodenoson</I> co-administered with the PGA, <I>latanoprost</I>, demonstrated IOP-lowering in patients who have
previously had inadequate responses to the PGA, <I>latanoprost</I>. These patients represent PGA poor-responders, as evidenced by persistently elevated IOP at levels that typically require the addition of a second drug to further lower IOP.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><B><I>Establish a specialty sales force to maximize the commercial potential of trabodenoson in the United States</I></B>. We have retained worldwide
commercial rights to <I>trabodenoson</I>. If <I>trabodenoson</I> receives marketing approval in the United States, we plan to commercialize it by establishing a glaucoma-</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
focused specialty sales force of approximately 150 people targeting ophthalmologists and optometrists throughout the United States. For markets outside the United States, we intend to explore
partnership opportunities through collaboration and licensing arrangements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Evaluate the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases or for additional ophthalmic indications.</I></B> Based on an animal model that
indicated <I>trabodenoson</I>&#146;s potential to directly protect RGCs, the nerve tissue in the retina that relays the visual signal to the brain, we plan to conduct clinical trials to measure the rate of vision loss over time, rather than IOP
control, in patients treated with<I> trabodenoson</I>. Should the results of these trials be positive, we plan to seek labeling indicative of <I>trabodenoson</I>&#146;s potential to change the course of glaucoma-related vision loss, beyond that of
IOP-lowering effect alone. In addition, this effect, if proven, could address the subset of glaucoma patients that do not have high IOPs, but still suffer from vision loss over time. We are also evaluating other potential indications where therapy
with <I>trabodenoson</I> may be beneficial. To begin this process, we will be conducting pre-clinical and proof-of-concept trials for optic neuropathies and degenerative retinal diseases starting in the second half of 2015. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Glaucoma Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Glaucoma is a disease
of the eye in which damage to the optic nerve leads to progressive, irreversible vision loss. Its characteristics can include structural evidence of optic nerve damage, vision loss and elevated IOP. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Physiology of the Eye </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The eye is a fibrous sack which must stay &#147;inflated&#148; with a fluid known as aqueous humor that maintains the eye&#146;s form at the
proper pressure in order to maintain its shape and effectively convey light to the retina where the light stimulus is then relayed to the brain and converted into a visual image. To maintain the eye&#146;s pressure&#151;and therefore its
shape&#151;and as a means to provide nutrients to eye tissue, aqueous humor is constantly produced inside the eye by a tissue known as the ciliary body. The ciliary body sits just behind the iris, which is the colored part of the eye. Aqueous humor
flows forward through a hole in the center of the iris, called the pupil, and down into the angle defined by the front of the iris and the back of the cornea, which is the clear covering on the front of the eye. This angle is the same angle referred
to in Primary Open Angle Glaucoma, or POAG, the most common form of glaucoma. Below is a diagram depicting certain parts of the eye, including the ciliary body, iris and the angle defined by the front of the iris and the back of the cornea: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g893535g87n98.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this angle, around the outer rim of the iris, is the TM, a natural, pressure-regulating drain.
It is here that in a healthy, well-functioning eye, approximately 70% of the aqueous humor exits and flows into a drainage canal known as Schlemm&#146;s canal, which empties back into the venous drainage system. The remaining approximately 30% of
the aqueous humor leaves the eye through a secondary pathway called the uveoscleral pathway. The diagram below reflects the TM and the uveoscleral pathway, the two pathways for the aqueous humor to leave the eye. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g893535g03j45.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Development of High IOP and its Effects on Glaucoma </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a typical glaucoma patient, not enough aqueous humor exits the eye, creating excess pressure and compressing the retina, the layer of tissue
covering the inside of the back half of the eye that actually converts light into nerve impulses. For people to &#147;see,&#148; these impulses&#151;the visual signal&#151;must be relayed through the optic nerve back to the brain for processing. The
cells in the retina require nutrients and oxygen that are delivered via blood vessels entering and exiting the eye through the same opening as the nerve fibers carrying the visual signal. However, when IOP is too high, it is more difficult to pump
blood, enriched in oxygen and nutrients, into the retina. The diagram below reflects the anatomy of the eye and how elevated IOP can impair the nerve tissue in the retina and the optic nerve head. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g893535g05b34.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The deprivation of blood supply to the retina may damage RGCs, the nerve tissue in the retina that relays
the visual signal to the brain. These RGCs have long tails called axons that extend back to the brain to carry the visual image. The optic nerve is a bundle of these axons extending to the vision processing center of the brain. When an RGC dies, one
of the connections between the retina and the brain is lost, and like most cases when a nerve is damaged or cut&#151;like in a spinal cord injury&#151;there is no known way to repair the damage and, as a result, some portion of vision is permanently
lost. Therefore, the root cause of vision loss in glaucoma is not high IOP per se, but the impact of high IOP on the retina, and specifically the RGCs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Definition of Glaucoma </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The two key elements to the clinical definition of glaucoma are structural evidence of optic nerve damage and vision loss. Common risk factors
include age, family history, corneal thickness and high IOP, commonly measured in millimeters of mercury, or mmHg. Currently, the only known way to treat glaucoma and slow the progression of vision loss is to reduce IOP. While treatment approaches
are based on an assessment of the patient&#146;s risk factors for vision loss, elevated IOP is by far the best understood contributor to development of glaucoma. We believe that the general treatment patterns in the figure below, relative to a
patient&#146;s IOP, are typical. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g893535g70c89.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Ocular Hypertension Treatment Study, or the OHTS Study, was a large, randomized academic trial
published in 2002 that followed a total of 1,636 participants who initially had no evidence of glaucoma-related damage. The OHTS Study found that higher IOPs generally indicate a higher risk for progression to glaucoma. An IOP of 10 to 21 mmHg is
generally considered in the normal range. Individuals with IOPs greater than 21 and up to 25 mmHg will often not be prescribed drug therapy unless they have evidence of both structural changes and some vision loss, or some combination of these and
other risk factors for future vision loss. In fact, the United Kingdom&#146;s National Institute of Health and Care Excellence Guidelines, or NICE Guidelines, for the treatment of suspected glaucoma (structural changes but without vision loss) plus
elevated IOP, does not recommend treatment of eyes with corneal thickness of 555-590 nm and IOP of 25 mmHg or below. Drug treatment is much more common when patients have IOPs greater than 25 mmHg. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Glaucoma Market </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the British Journal of Ophthalmology, there were an estimated 2.8&nbsp;million Americans with glaucoma in 2010. According to the
Archives of Ophthalmology, that number will reach approximately 3.4&nbsp;million by 2020. Approximately 120,000 of these patients are suffering from blindness as a result of destruction to their optic nerve. Glaucoma can affect patients of all ages
and ethnicities. However, according to the Archives of Ophthalmology, the prevalence rate (the proportion of people in the population that have glaucoma) increases with age. The most significant increases in prevalence rates occur above 55 years of
age. The prevalence in the population aged 65 years and younger is approximately twice that of the population 55 years or younger. Glaucoma is a chronic condition with no known cure and as a result patients are typically
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
treated for the rest of their lives. Patients with glaucoma report decreased quality-of-life, difficulties with daily functioning, including driving, and are more likely to report falls and motor
vehicle collisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to IMS Health, in 2013, 31.2&nbsp;million prescriptions were written for glaucoma medications in the United
States. According to IMS Health, approximately two-thirds of these prescriptions were for generic drugs, including <I>latanoprost</I> and <I>timolol</I>, which are the top two selling drugs for the treatment of glaucoma. Due to the lack of
innovation in medications for glaucoma, most of the drugs used to treat glaucoma are generic drugs. Sales of glaucoma drugs in 2012 were approximately $1.9 billion in the United States and $5.5 billion worldwide. In 2013, sales of glaucoma drugs
were approximately $2.0 billion in the United States and $5.6&nbsp;billion worldwide, and IMS Health projects U.S. sales to be $3.1 billion in 2018, an increase of approximately 54% over 2013 sales. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Existing Glaucoma Treatments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial treatment for glaucoma patients is typically the use of a prescription PGA eye drop. According to IMS Health, prescriptions for
PGAs make up more than half of all prescriptions for glaucoma medications. The PGAs&#146; primary mechanism of action for treating glaucoma is thought to be increasing fluid outflow through the uveoscleral pathway. A number of adverse effects are
known to occur in all drugs in the PGA class and, as a result, these side effects are assumed to be associated with the mechanism of action. Most notable of these side effects is eye redness, or conjunctival hyperemia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When PGAs are insufficient to control IOP or are poorly tolerated, non-PGA products are used either as an add-on therapy to the PGA or as an
alternative monotherapy in place of a PGA. Non-PGAs can include a beta-blocker, an alpha (adrenergic) agonist or a carbonic anhydrase inhibitor alone.&nbsp;FDC products containing these non-PGAs are dominated by beta-blocker combinations, including
a beta-blocker combined with an alpha agonist (Combigan<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) and a beta-blocker combined with a carbonic anhydrase inhibitor (Cosopt<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> or
generic equivalent). A third non-PGA FDC includes an alpha agonist and a carbonic anhydrase inhibitor (Simbrinza<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>). Non-PGA drugs generally have poorer tolerability in the eye than PGA drugs,
and some have systemic adverse effects that limit the patient population in which they can be used safely. Moreover, their IOP-lowering effect is generally less than that of PGAs and the vast majority of non-PGAs are required to be dosed multiple
times daily. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The existing classes of treatment available for glaucoma each have varying mechanisms of action, levels of IOP-lowering,
side effects and other adverse effects, as described in the following table. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of Existing Glaucoma Treatments: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Drug Classification</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B></B><B><I>(Generic Names)</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Mechanism of<BR>Action*</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>IOP<BR>Reduction**</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Known&nbsp;Side&nbsp;Effects*</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Other&nbsp;Precautions,<BR>Warnings,<BR>Contraindications&nbsp;and<BR>Adverse Effects*</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>Prostaglandin&nbsp;analog</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Xalatan <I>(latanoprost)</I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Travatan (<I>travoprost)</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Lumigan<I> (bimatoprost)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Increase uveoscleral&nbsp;and/or trabecular&nbsp;outflow</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">6-8&nbsp;mmHg</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">(25%-33%)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Eye redness (conjunctival hyperemia)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Visual disturbances (blurred vision, loss of visual acuity)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Itching (pruritis)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Burning</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Stinging</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Eye pain</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Darkening of the eyelids (periocular hyperpigmentation)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Permanent eye (iris) color change</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Macular edema</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;History of herpetic keratitis</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Ocular edema</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Drug Classification</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B></B><B><I>(Generic Names)</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Mechanism of<BR>Action*</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>IOP<BR>Reduction**</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Known&nbsp;Side&nbsp;Effects*</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Other&nbsp;Precautions,<BR>Warnings,<BR>Contraindications&nbsp;and<BR>Adverse Effects*</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Beta-adrenergic&nbsp;antagonist,</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>or beta-blocker</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>timolol</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Decrease aqueous production</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">N/A&nbsp;mmHg</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">(20%-25%)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Burning</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Stinging</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Eye lid swelling (Blepharitis)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Corneal inflammation (keratitis)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Itching (pruritis)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Eye pain</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Dry eyes, foreign body sensation</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Visual disturbances</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Drooping eye lids (ptosis)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Swelling of retina (cystoid macular edema)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Muscle&nbsp;weakness</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Anaphylaxis</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Severe respiratory and cardiac reactions</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Contraindicated in bronchial asthma (or history of), severe chronic obstructive pulmonary disease,
sinus bradycardia (slower heart rate), second or third degree atrioventricular block, overt cardiac failure, cardiogenic shock</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>Alpha-adrenergic agonist, or alpha agonist</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman"><I>brimonidine</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Decrease aqueous production; increase uveoscleral outflow</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">2-6 mmHg</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">(20%-25%)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Allergic conjunctivitis</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Eye redness (conjunctival hyperemia)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Itchy eyes (eye pruritis)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Severe cardiovascular disease</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Depression</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Cerebral or coronary insufficiency</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;High blood pressure (orthostatic hypertension)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Contraindicated in patients on monoamine oxidase inhibitor therapy</P>
<P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>Carbonic anhydrase inhibitor</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><I>dorzolamide</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman"><I>brinzolamide</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Decrease aqueous production</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">3-5 mmHg</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">(15%-20%)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Bitter taste</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Burning</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Stinging</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Allergic conjunctivitis</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Corneal inflammation (superficial punctate keratitis)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Conjunctivitis</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Eye lid reactions</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">-&nbsp;&nbsp;&nbsp;Sulfonamide allergy</P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">According to FDA-approved labeling. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top">mmHg, according to FDA-approved labeling; % from baseline, according to American Academy of Ophthalmology Glaucoma Panel. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The chart below illustrates the respective proportions of glaucoma prescriptions issued in 2013 by class, according to IMS Health. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g893535g42e44.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Glaucoma Treatments Currently in Development. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe there are currently two leading classes of new drugs in clinical development for glaucoma: Rho kinase inhibitors and adenosine
mimetics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Rho kinase inhibitor recently entered Phase 3 clinical trials and is the furthest along of the potential new glaucoma
therapies: Aerie Pharmaceuticals, Inc.&#146;s AR-13324. Like with PGAs, conjunctival hyperemia has been reported with the Rho kinase inhibitor class. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adenosine mimetics are compounds that mimic or simulate some of the actions or effects of adenosine, a naturally-occurring molecule with many,
diverse biologic effects. There are four known subreceptors that are specific to adenosine: A1, A2a, A2b and A3. Stimulation of these specific subreceptors have markedly different results. In the adenosine mimetic group, there are compounds
targeting three different adenosine subreceptors: A1, A2a and A3. We believe that A1 selectivity is necessary for optimal IOP-lowering effect. To our knowledge, the two compounds being developed by other companies that were selective for the A2a
subreceptor have been discontinued from clinical development for glaucoma. A third compound being developed that we believe targets both the A1 (IOP-lowering) and the A3 (IOP-increasing) subreceptors is still being studied. We believe that because
this third compound is dosed orally, the isolation of its pharmacologic effects solely to the eye is challenging. We believe we are the only company to be developing an adenosine mimetic highly selective for the A1 subreceptor for ophthalmic
indications. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Market Opportunity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since 1996, there have been no new drug classes approved in the United States for glaucoma. As a result, there are persistent inadequacies in
the tools that ophthalmologists use to manage patients with glaucoma. Thus, we believe there is a need for an innovative glaucoma treatment that offers: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">significant IOP-lowering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a favorable safety and tolerability profile; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a novel mechanism of action that complements existing therapies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">convenient dosing; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">specific protective activity in the retina. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Solution&#151;</B><B><I>Trabodenoson </I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Trabodenoson</I> is a first-in-class selective adenosine mimetic that is designed to lower IOP with a mechanism of action that we believe
augments the natural function of the TM. In addition, by enhancing a naturally occurring process to make the eye function more like that of a younger, healthier eye, rather than changing the fundamental dynamics of pressure regulation in the eye, we
believe there is a lower risk of unintended side effects that could result in safety or tolerability issues in the long term. We believe <I>trabodenoson</I> enhances metabolic activity in the TM, which helps clear the pathway for the aqueous humor,
the fluid in the eye, to flow out of the eye, thereby lowering IOP. We believe that <I>trabodenoson</I>&#146;s mechanism of action improves the function of the eye, and that <I>trabodenoson</I> has the potential to be used as a monotherapy in place
of current glaucoma treatments. In addition, we expect that <I>trabodenoson</I>&#146;s purported mechanism of action in the TM should complement the activity of all currently-approved glaucoma drugs that work in other ways to lower IOP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the following elements of <I>trabodenoson</I>&#146;s product profile will drive its adoption, if approved, in the glaucoma market:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><B>Meaningful IOP-Lowering.</B> After four weeks of monotherapy treatment in a Phase 2 clinical trial in glaucoma patients who had discontinued any
other medications, <I>trabodenoson</I> (500 mcg) lowered IOP by an average of 4.0 to 7.0 mmHg from study baseline and 3.5 to 5.0 mmHg from diurnal baseline, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
over the dosing interval. Moreover, IOP-lowering at week four was significantly better than IOP-lowering at week two. IOP-lowering for currently-approved glaucoma therapies, according to their
FDA-approved labels, ranges from 2-8 mmHg. A similar trend in improvement of IOP with increasing treatment time was observed in our recently completed Phase&nbsp;2 trial of <I>trabodenoson </I>co-administered with <I>latanoprost </I>in a population
of PGA poor-responders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Favorable Safety Profile.</B> In four completed <I>trabodenoson</I> clinical trials over a wide range of doses, no patients have withdrawn due to a <I>trabodenoson</I>-related side effect in the eye. In our
multiple-dose Phase 2 monotherapy clinical trial, we did not observe side effects in the eye that would indicate a tolerability problem at any of the doses tested. Specifically, there was no change in the background rate of conjunctival hyperemia in
the patient population when treatment with <I>trabodenoson</I> was initiated or continued for up to four weeks, even at the highest dose tested. Furthermore, in our most recently completed multiple-dose Phase&nbsp;2 trial of <I>trabodenoson
</I>co-administered with <I>latanoprost </I>in a population of PGA poor-responders, there also was no change in the rate of hyperemia from study baseline after four, eight or 12&nbsp;weeks of treatment. No systemic effects of the drug have been
identified, despite rigorous monitoring including cardiac and renal function, when administered as an eye drop. We believe this safety profile could be important in the potential for <I>trabodenoson</I> to become a preferred treatment alternative
for patients that experience undesired side effects with existing therapies. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Unique, Complementary Mechanism of Action.</B> We believe that <I>trabodenoson</I>&#146;s mechanism of action augments a naturally occurring process by clearing the path for aqueous humor outflow in the TM. We expect
that this mechanism of action should complement all currently-approved glaucoma drugs which work in other ways to lower IOP, including by reducing aqueous humor production and increasing outflow through the uveoscleral pathway. This complementary
mechanism was confirmed in patients already receiving <I>latanoprost</I> therapy in a recently completed multiple-dose Phase 2 trial. In this Phase 2 trial of <I>trabodenoson </I>co-administered with <I>latanoprost </I>in a population of PGA
poor-responders, patients on <I>latanoprost</I> experienced an additional 5.5&nbsp;mmHg IOP lowering from their study baseline and 4.3 mmHg from their diurnal baseline after 12&nbsp;weeks treatment (eight weeks BID plus four weeks QD). These results
make <I>trabodenoson</I>, with its favorable safety profile, a candidate to add to other glaucoma medications when a further reduction of the IOP is desirable. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Convenient Dosing.</B> Current Phase&nbsp;2 clinical data indicate that QD dosing with <I>trabodenoson</I> in PGA poor-responders is well tolerated and lowers IOP significantly. We believe a QD dosing regimen
minimizes the burden on patients to remember to take their medication, thus, we believe, potentially improving compliance with the therapy. If confirmed and approved in our Phase 3 program, QD dosing would make <I>trabodenoson</I> easier to use than
most non-PGA products, and <I>trabodenoson</I>&#146;s dosing frequency would match the best-in-class PGAs, which would facilitate an FDC with a PGA that could be dosed QD. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that <I>trabodenoson</I>&#146;s efficacy, complementary mechanism of action, dosing and safety profile make it well suited for use
in an FDC with a PGA, which could be an effective and convenient option for patients currently using two or more glaucoma drugs to lower IOP. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Trabodenoson Discovery&#151;Background </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adenosine is a naturally occurring molecule that has a broad array of biological effects. Its effects are mediated through activity at four
known adenosine-specific subreceptors: A1, A2a, A2b and A3. These subreceptors are present throughout the body on the cells of different tissues, and at different concentrations. When adenosine binds and activates these different subreceptors, it
can cause many diverse effects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 1995, a study was published in the Journal of Pharmacology and Experimental Therapeutics describing
how adenosine mimetics can lower IOP by activating adenosine A1 subreceptors in rabbits. In 2001, an animal study published by the University of Pennsylvania School of Medicine confirmed that stimulation of A1 lowered IOP, but that stimulating A2a
or A3 subreceptors increased IOP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our scientists began a rational deconstruction of this complex biology in order to isolate the
protective activity of adenosine and to incorporate it into novel therapeutics. Beginning with the structure of adenosine, we created a series of molecules to bind with, and therefore induce the biological effects associated with stimulation of a
single adenosine subreceptor. In this way, the undesired biological actions of native adenosine were systematically removed, one by one by eliminating the activity at non-target subreceptors. This rational drug design process relied heavily on our
understanding of structure activity relationships, which relate the variation in the structure of the adenosine mimetics and their ability to bind and activate ideally just one adenosine subreceptor. Ultimately, a number of molecules emerged from
these efforts with isolated and specialized activity, including some adenosine mimetics that only targeted the A1 subreceptor, leading to the discovery of <I>trabodenoson</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The high affinity binding of <I>trabodenoson</I> to the A1 subreceptor is shown by the small Ki in the table below, and its selectivity for
this IOP-lowering activity is indicated by much higher Ki&#146;s for A2a and A3 receptors where its binding is relatively weak. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Trabodenoson is a Potent and Selective A1 Adenosine Mimetic </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>A1</B><br><B>(Ki,&nbsp;nM)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>A2a</B><br><B>(Ki,&nbsp;nM)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>A3</B><br><B>(Ki,&nbsp;nM)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Selectivity&nbsp;Ratios</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:38.25pt; font-size:8pt; font-family:Times New Roman"><B>Compound</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="border-bottom:1.00pt solid #000000"><B>A1/A2a</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>A1/A3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Trabodenoson</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,835x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">725x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Trabodenoson&#146;s key characteristics include: </I> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Potency&#151;Ki in single-digit nM range (0.97nM); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">High Selectivity&#151;over A2a&gt; 1000-fold and A3&gt;500-fold; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Ease of Fat Solubility&#151;allowing corneal penetration so it can reach the TM; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">A high compatibility with the often sensitive tissues in the front of the eye. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe
that <I>trabodenoson</I> is the only adenosine mimetic with high selectivity for the single desired target of action, the A1 subreceptor, and that stimulation of this subreceptor in the TM effects a meaningful improvement in the metabolic activity
in the TM that helps to clear the pathway for the aqueous humor to flow out of the eye, lowering IOP. This metabolic activity takes the form of an increase or up-regulation of proteases&#151;such as Protease A or MMP-2&#151;that digests and removes
accumulated proteins that can block the healthy flow of the aqueous humor out of an eye with glaucoma. This metabolic activity is a naturally occurring or endogenous process that is enhanced by treatment with <I>trabodenoson</I>. We believe this
process does not radically change the way the TM controls eye pressure, but rather restores the natural process of pressure control in the TM, which is different from other therapies that decrease aqueous humor production or increase the
permeability of the eye to increase outflow. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Product Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product pipeline includes <I>trabodenoson</I>, as a monotherapy delivered in an eye drop formulation, as well as an FDC that includes
<I>trabodenoson</I> plus <I>latanoprost</I> in an eye drop formulation, which we refer to as our FDC product candidate. We are also evaluating the potential for <I>trabodenoson</I> to directly target optic neuropathies and degenerative retinal
diseases. The following table summarizes key information about our product development programs. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g893535g19j35.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Trabodenoson </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our first product candidate, <I>trabodenoson</I>, is a monotherapy dosed in an eye drop. Our clinical trials have shown that
<I>trabodenoson</I> has significant IOP-lowering effects, convenient dosing and also has a favorable safety profile when compared to the currently available glaucoma treatments, such as PGAs and non-PGAs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Trabodenoson-Latanoprost Fixed-Dose Combination </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As many as half of glaucoma patients, typically those with more severe disease, need to use two or more glaucoma drugs to sufficiently reduce
their IOP. Despite this market need, an FDC product containing a PGA plus a non-PGA has not yet been approved in the United States. The available FDC products increase IOP-lowering but also have unpleasant tolerability challenges in the eye, as well
as the adverse effects, safety warnings, precautions and contraindications that the two individually-dosed drugs carry in their FDA-approved package inserts. We believe the reason no FDC containing a PGA has gained FDA approval is because the modest
incremental benefit in IOP-lowering seen when a non-PGA is added to a PGA is too small in the context of the added side effects and clinical risks that come with the combined drugs. In contrast, based on our completed Phase 2 study in which
<I>trabodenoson</I> therapy was co-administered with <I>latanoprost</I>, we believe that an FDC containing a PGA and <I>trabodenoson</I> will provide significant incremental efficacy while adding very few side effects or clinical risks to the
profile of the PGA alone. We believe such a product would be well received in the glaucoma market, especially for use in patients with higher IOPs that currently use two or more glaucoma drugs to lower IOP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our second product candidate is a combination of <I>trabodenoson</I> with a PGA, <I>latanoprost</I>, to create an FDC. While our FDC product
candidate has not yet been formulated as an FDC or administered to humans, we expect that <I>trabodenoson</I> will not adversely affect the safety profile of <I>latanoprost</I>, or any other currently-approved PGA, because of its favorable safety
and tolerability profile from our completed Phase 2 trial in which <I>trabodenoson</I> and <I>latanoprost</I> were co-administered. We believe that <I>trabodenoson</I>&#146;s mechanism for lowering IOP complements the mechanism of action of
<I>latanoprost</I> and other PGAs, which work primarily on the secondary uveoscleral outflow, because <I>trabodenoson</I> is believed to act through the TM, the largest aqueous humor outflow path in the eye. In fact, our IOP-lowering studies in
cynomolgus monkeys have shown that IOP-lowering is significantly better when the eye is treated with both <I>trabodenoson</I> and <I>latanoprost</I>, as compared to treatment with <I>latanoprost</I> alone. Our completed Phase 2 trial of
<I>trabodenoson </I>co-administered with <I>latanoprost</I> also demonstrated IOP-lowering in patients who have previously had inadequate responses to <I>latanoprost</I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These patients represent PGA poor-responders, as evidenced by persistently elevated IOP at levels
that typically require the addition of a second drug to further lower IOP. The safety profile of <I>trabodenoson </I>co-administered with <I>latanoprost</I> is similar to that of <I>trabodenoson</I> monotherapy. Moreover, <I>trabodenoson</I> had a
sufficiently long duration of action, allowing it to be effectively dosed QD in conjunction with <I>latanoprost</I>. Assuming the <I>trabodenoson</I> safety profile remains favorable, a <I>trabodenoson</I>-<I>latanoprost</I> FDC therapy could
present a much improved risk/benefit profile over other combinations of currently-approved PGAs and non-PGAs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Trabodenoson for
Optic Neuropathy and Degenerative Retinal Diseases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The neuroprotective potential of <I>trabodenoson</I> is supported by the basic
biology of adenosine, which has shown that the stimulation of the A1 receptor can protect tissues of the central nervous system. A pre-clinical study of the impact of high IOP on RGCs showed that <I>trabodenoson</I> could protect this key population
of cells in the retina through a mechanism independent of IOP lowering. The loss of RGCs results in the irreversible vision loss associated with glaucoma. While we have not yet conducted a formal program of studies to prove neuroprotection, we plan
to study the potential of <I>trabodenoson</I> monotherapy and our FDC product candidate to slow the loss of vision significantly more than attributable to IOP lowering alone, either in glaucoma patients or in other rarer forms of optic neuropathies.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a pre-clinical model, designed to screen molecules for their potential to treat dry age-related macular degeneration, or dry-AMD,
<I>trabodenoson</I> eye drops prevented the loss of cells in the outer retina that result from the exposure to intense blue light. The cells preserved include rods and cones, known as photoreceptors, and retinal pigmented epithelial cells which
support the rods and cones. Of note, the retinal pigmented epitelial cells are known to express the A1 receptor. The rods and cones are two of several types on neurons in the retina, which along with the retinal ganglion cells, relay the visual
signal to the brain. Additional pre-clinical work is required to confirm the potential of <I>trabodenoson</I> to treat dry-AMD. We are planning pre-clinical and proof-of-concept trials for optic neuropathies and degenerative retinal diseases
beginning in the second half of 2015. However, once proof of concept has been established, the accrued clinical experience with <I>trabodenoson</I> in glaucoma will accelerate initiation of a clinical evaluation of the drug in dry-AMD. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Clinical Data and Development Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our planned Phase 3 program for <I>trabodenoson</I> as a monotherapy is expected to incorporate both the FDA-acceptable clinical endpoint of
IOP, and to include studies with three months of treatment, both of which are well-known and accepted standards for pivotal trials for glaucoma. We are planning an End-of-Phase 2 meeting with the FDA in the first half of 2015 to discuss our Phase 3
program for <I>trabodenoson</I> monotherapy and to confirm the design and endpoints for the Phase 3 pivotal trials. We plan to start our Phase 3 program for <I>trabodenoson</I> monotherapy in mid-2015, and we expect to report top-line data from the
first pivotal trial in the program in 2016 or early 2017. If the primary objectives of our Phase 3 program are met, we plan to submit an NDA. We are planning to commence our Phase 3 program for the FDC of <I>trabodenoson</I> and <I>latanoprost</I>
in 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Results </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Trabodenoson Phase 2 Tolerability, Safety and Efficacy of Monotherapy in Glaucoma Patients </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2012, we completed a successful Phase 2 dose-ranging clinical trial in 144 patients with OHT (ocular hypertension with no visual field loss)
or POAG, which demonstrated a clear dose response to <I>trabodenoson</I>. Statistically significant results for the primary endpoint of our Phase 2 clinical trials indicate that <I>trabodenoson</I> has IOP-lowering effects in line with existing
therapies, with a favorable safety and tolerability profile at all doses tested. The trial was randomized, double-masked, placebo-controlled, and evaluated the efficacy, tolerability, safety, and pharmacokinetics of <I>trabodenoson</I> over two or
four weeks of BID dosing with eye drops. Separate groups of patients received <I>trabodenoson</I> doses of 50, 100 or 200 mcg for two weeks, or 500 mcg for four weeks, and their IOP-lowering efficacy and safety data were compared to groups of
patients dosed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
concurrently with placebo eye drops, also BID. To enter the trial, otherwise healthy patients had to have elevated IOPs (greater than or equal to 24 mmHg and less than or equal to 34 mmHg) when
off of all glaucoma drugs, and a diagnosis of either OHT or POAG. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary efficacy endpoint was IOP (measured throughout the day).
The primary efficacy analysis calculated the reduction in IOP from the patients&#146; IOP at the beginning of the study (recorded before active drug was administered at the study 8 AM baseline). A second analysis calculated the reduction in IOP from
a time-matched diurnal baseline. The IOP drop from baseline for each dose group (50, 100, 200 and 500 mcg) was then compared statistically to the IOP drop of a matched placebo group treated concurrently. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Safety evaluations included recording of withdrawals or terminations and adverse events. In each patient, the treated eye was evaluated at
regular intervals with internal eye exams (including pupil dilation with slit lamp examination of the inside of the eye) and external eye examinations (of the outside surface of the eye, eye lids and surrounding tissue). Visual function was also
assessed. Overall health was assessed by physical examination, vital signs (including heart rate and blood pressure), electrocardiograms, or ECGs, for heart function and analysis of urine and blood samples (clinical chemistry), and plasma samples
were collected to analyze the pharmacokinetic parameters, such as the half-life of any drug detected in the systemic circulation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Results </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patient
Population: The characteristics of the patients in the dose groups were similar, including their ages, baseline IOPs, and diagnoses (OHT or POAG). The table below reflects information regarding the demographics of the patient populations that
participated in the study, and shows that both diagnoses groups had similar baseline IOPs, and that groups treated with <I>trabodenoson</I> had characteristics that were similar to the placebo groups to which they were compared. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Baseline Demographics and IOP </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Trabodenoson Dose</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Placebo</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>50&nbsp;mcg</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>100&nbsp;mcg</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>200&nbsp;mcg</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>500&nbsp;mcg</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Active</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mean Age</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">n</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Baseline IOP (mmHg)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OHT n(%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22(37.3)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6(35.3)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8(47.1)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6(35.3)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14(41.2)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34(40.0)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Baseline IOP (mmHg)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">POAG n(%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37(62.7)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11(64.7)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9(52.9)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11(64.7)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20(58.8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51(60.0)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Baseline IOP (mmHg)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Efficacy </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Both the 200 mcg dose and the 500 mcg doses at day 14, and the 500 mcg dose at day 28, met the primary endpoint demonstrating statistically
significant improvements in IOP relative to the matched placebo (p&lt;0.05 indicating a greater than 95% probability that the result was not a random event). Moreover, a clear increase in IOP-lowering efficacy was seen with increasing doses of
<I>trabodenoson</I> (i.e. a dose response), and the most efficacious <I>trabodenoson</I> dose tested was the highest dose of 500&nbsp;mcg. <I>Trabodenoson</I>&#146;s primary efficacy endpoint (IOP drop from baseline) measured after four weeks of
treatment (at day 28) had improved significantly from the same endpoint when measured after two weeks of treatment (at day 14). This improvement with treatment time was statistically significant (p=0.016). In the figure below, a clear trend for
increasing IOP-lowering efficacy with increasing dose is evident. For the 500 mcg dose, the statistically significant increase in efficacy between day&nbsp;14 and day&nbsp;28 is illustrated on the right side of the figure. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g893535g17v81.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On average, doubling doses between 50 and 500 mcg increases IOP lowering from diurnal baseline by
approximately 0.7 mmHg. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The IOP-lowering at the highest and most efficacious dose (500 mcg) was evaluated in various
patient sub-populations to gain a sense of the ability to generalize the results over a diverse patient population. The figure below compares the IOP drop from study baseline (the primary endpoint analysis) for all patients (far left) to various
sub-populations to the right of that. All of these patient subgroups responded to <I>trabodenoson</I>&#146;s IOP-lowering effect. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g893535g46f49.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When we rationally designed <I>trabodenoson</I>, our primary objective was to restore pressure regulation
in eyes with high IOP, a risk factor for glaucoma. A healthy eye has a natural circadian rhythm that dictates a pattern of IOP over the day. We found that this pattern, or the shape of the IOP circadian rhythm curve throughout the day, is relatively
unchanged by <I>trabodenoson</I> treatment, except that the overall IOP during the day is reduced by <I>trabodenoson</I> treatment as intended. We believe this indicates that the TM has been restored to an improved function resulting in a more
normal average pressure, and that this normal daily IOP pattern indicates that the fundamental biology of pressure management in the eye has been preserved. The natural daily changes in IOP still exist, but at a significantly lower average pressure
that we believe is less damaging to RGCs and the optic nerve. The figure below shows diurnal IOP for the highest dose tested and the placebo group at day 28, and the average daily drop from study baseline. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g893535g43g25.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, after 28 days of BID dosing, the IOP-lowering effect persisted for an additional 24
hours after the last dose of medication, which we believe indicates the potential for <I>trabodenoson</I> monotherapy to be dosed QD. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Safety and Tolerability </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no serious adverse events or patients that withdrew due to safety findings that occurred once the drug was given. There were no
signs of systemic safety issues in any of the non-ocular examinations, ECG evaluations or laboratory tests performed. Systemically, administration of <I>trabodenoson</I> eye drops was found to be well-tolerated. There were no changes noted from
internal eye examinations or visual testing during drug treatment. The rate of conjunctival hyperemia in patients treated with <I>trabodenoson</I> was unchanged from the placebo run-in period (study baseline). There was no maximum tolerated dose
determined because all doses tested were well-tolerated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Trabodenoson Phase 2 Co-Administered with Latanoprost in Glaucoma Patients
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2014, we received top line results from a Phase 2 trial in patients with POAG or OHT, in which<I> trabodenoson</I> eye
drops were co-administered with <I>latanoprost </I>eye drops. The objective of the study was to evaluate the safety and additional IOP-lowering effect of<I> trabodenoson</I> when added either BID or QD to <I>latanoprost</I>. This trial enrolled 101
patients who had IOPs of greater than or equal to 24 mmHg despite one month of previous treatment with <I>latanoprost</I>. These patients are considered PGA poor-responders, as evidenced by persistently elevated IOP at levels that typically require
the addition of a second drug to further lower IOP. The trial was randomized, double-masked, placebo- and active- controlled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following
four weeks of<I> latanoprost </I>eye drops, otherwise healthy patients with an IOP greater than 24&nbsp;mmHg and a diagnosis of either OHT or POAG were randomized for Part&nbsp;1 of the study. In Part&nbsp;1, the study arm consisted of BID-dosed
<I>trabodenoson</I> (1.5%; 500 mcg nominal dose) plus <I>latanoprost </I>0.005%, at the approved dose, QD. The control arm consisted of <I>timolol </I>0.5%, an approved BID dose plus <I>latanoprost </I>0.005% QD. Patients in both arms were treated
for a total of eight weeks in Part 1 of the study to evaluate the additive effects of trabodenoson BID to <I>latanoprost</I> QD, with an active control consisting of <I>timolol</I> BID. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the end of Part 1, after eight weeks of treatment, patients began Part&nbsp;2 of the study. In Part&nbsp;2, the study arm was switched to a
QD dose of<I> trabodenoson</I> (3.0%, 1,000&nbsp;mcg nominal dose) plus<I> latanoprost 0.005% QD, and patients in the control arm were switched to placebo QD plus latanoprost 0.005% QD. Part 2 was designed to measure the additive effects of
trabodenoson QD to latanoprost QD over an additional four weeks. The number of patients planned for enrollment was ~100 (50 patients per arm) for Part 1 and ~80 (40 patients per arm) for Part 2. This trial is outlined below. </I> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g893535g52a68.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary efficacy endpoint was IOP, measured throughout the day. The efficacy analyses
calculated the reduction in IOP from the patients&#146; IOP at study baseline and diurnal baseline (recorded after taking <I>latanoprost </I>for four weeks but before <I>trabodenoson</I> or<I> timolol </I>were added). In Part&nbsp;1, these IOP drops
from baseline, on <I>latanoprost, </I>were compared to the IOP drops of the control arm treated concurrently with <I>timolol</I>. In Part 2, the IOP drop from baseline in patients receiving <I>trabodenoson </I>QD plus <I>latanoprost </I>QD was
compared to patients receiving placebo QD plus <I>latanoprost</I> QD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Safety evaluations included recording of withdrawals or
terminations and adverse events, or AEs. In each patient, both eyes were evaluated at regular intervals with internal eye exams (including pupil dilation with slit lamp examination of the inside of the eye) and external eye examinations (of the
outside surface of the eye, eye lids and surrounding tissue). Visual function was also assessed. Overall health was assessed by physical examination, vital signs (including heart rate and blood pressure), electrocardiograms, or ECGs, for heart
function and analysis of urine and blood samples (clinical chemistry). Plasma samples were collected to analyze the pharmacokinetic parameters, such as the half-life of any drug detected in the systemic circulation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Results </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patient
Population: The characteristics of the patients in the dose groups were similar, including their age, and baseline IOPs, which were not adequately controlled following a four-week run-in using <I>latanoprost </I>therapy. The table below includes
information on the demographics of the patients that participated in the study. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Baseline Demographics and IOP </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Part 1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Part 2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:52.65pt; font-size:8pt; font-family:Times New Roman"><B>ITT population</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B><B><I>Trabodenoson<BR></I></B><B>BID</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B><B><I>Timolol<BR></I></B><B>BID</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B><B><I>Trabodenoson<BR></I></B><B>QD</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Placebo<BR>QD</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">n</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mean Age</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Baseline IOP using <I>latanoprost</I> (mmHg)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OHT n (%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23&nbsp;(46%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13&nbsp;(25.5%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15&nbsp;(40.5%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12&nbsp;(28%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Baseline IOP using <I>latanoprost</I> (mmHg)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">POAG n (%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27 (54%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38 (74.5%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22 (59.5%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31 (72%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Baseline IOP using <I>latanoprost</I> (mmHg)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Discontinuations: </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Part 1, there were four discontinuations due to either protocol violations or exclusionary criteria (three patients were in the
<I>trabodenoson</I> group and one was in the <I>timolol</I> group). In Part 2, there were two discontinuations; one was discontinued due to an AE and the other did not to return during follow-up, but provided no explanation (both were in the placebo
group). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Efficacy </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After eight weeks of BID dosing in Part&nbsp;1, patients treated with <I>trabodenoson</I> co-administered with <I>latanoprost </I>experienced
further mean reductions of IOP of 3.4 and 4.9&nbsp;mmHg from diurnal and study baselines, respectively, beyond the IOP-lowering of<I> latanoprost</I>. After switching to QD<I> trabodenoson</I> in Part&nbsp;2, and treating for an additional four
weeks, QD dosing with <I>trabodenoson</I> resulted in a mean reduction in IOP of 4.3 and 5.8&nbsp;mmHg from diurnal and study baseline, respectively, from the IOP on <I>latanoprost </I>alone. At the end of Part 2 (after 12 weeks), the IOP-lowering
seen in the Study Eye (the eye treated with <I>trabodenoson)</I> was statistically significantly greater than the IOP drop of the patient&#146;s Control Eye (the patient&#146;s other eye that only received QD <I>latanoprost</I>). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Part&nbsp;1 the IOP drop at the end of 8&nbsp;weeks of treatment, in this population of
<I>latanoprost</I> poor-responders, was less than <I>timolol</I> BID (0.5%) which dropped pressure 6.1 and 7.6&nbsp;mmHg, on average from diurnal and study baselines, respectively. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g893535g23x57.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Part 2 of the trial, QD <I>trabodenoson</I> lowered IOP an additional 4.3 and 5.8 mmHg from diurnal and
study baseline, respectively, beyond the effect of <I>latanoprost</I> alone in this population of <I>latanoprost</I> poor-responders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Consistency of Results across Phase II Studies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mean reductions in IOP from study baseline ranging from 5.0 mmHg after four weeks of BID treatment to 5.8 mmHg after four weeks of QD treatment
in the trial were similar to the 6.5&nbsp;mmHg IOP reduction seen at the end of the four week <I>Trabodenoson Phase 2 Tolerability, Safety and Efficacy of Monotherapy in Glaucoma Patients</I> trial (the monotherapy trial). In the monotherapy trial,
patients received only<I> trabodenoson</I>. The patients in the 2014 additivity trial represented a different patient population than those studied in the monotherapy trial. These patients had inadequate responses to <I>latanoprost, </I>as evidenced
by persistently high IOP, despite <I>latanoprost</I> treatment for four weeks prior to randomization. This patient population typically requires the addition of a second drug to their PGA therapy to further lower IOP. Patients in the monotherapy
trial, by contrast, were removed from all glaucoma medications, and thus represented a typical patient population studied in a Phase 3 glaucoma trial. Despite these differences in the patient populations, the efficacy of<I> trabodenoson</I> was
consistent across trials, suggesting that <I>trabodenoson</I>&#146;s mechanism of action is effective across a wide-range of glaucoma disease severity. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g893535g87g90.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Both OHT and POAG patients responded to <I>trabodenoson</I> with POAG subjects showing the largest IOP
drops. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g893535g29x99.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Safety and Tolerability </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With the exception of a single patient who received placebo plus <I>latanoprost</I>, no patients dropped out of the trial as a result of a
drug-related adverse effect or due to drug intolerability. <I>Trabodenoson</I> was well tolerated in the eye, with no drug related hyperemia detectable by ocular exam at four, eight or 12 weeks. Mild hyperemia seen on the first day of dosing in a
minority of patients was back to baseline by the 1 week post dose ocular exams. <I>Trabodenoson</I> had no detectable systemic effects in any of the non-ocular examinations, ECG evaluations or laboratory tests performed. Overall adverse events were
similar in the BID phase (<I>Trabodenoson</I> 36%; <I>Timolol</I> 29%), with the <I>trabodenoson</I> rate dropping to 26% without the first-day hyperemias, and were also similar in the QD phase (<I>Trabodenoson</I> 16%; Placebo 14%) between
treatment groups. However, <I>timolol</I> (dosed in one eye only) had systemic adverse events associated with systemic beta blockade, including: dizziness, headache, fatigue and symptomatic sinus bradycardia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients randomized to <I>timolol </I>also had lower pulse rates than in the <I>trabodenoson</I> group (the pulse rate was measured 30 minutes
and one hour after dosing). This difference was statistically significant in the overall data (p=0.033) as well as at the individual time points (p=0.041 and p=0.030 at the 30 minute and one hour post-dose time points, respectively). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pulse rates for both groups are shown in the boxplot below, which includes the minimum and maximum values, median (white line), and the
boundaries of the upper and lower quartiles (top and bottom of the box). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g893535g33p05.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Trabodenoson Repeat-Dose Safety and Tolerability in Adult Healthy Volunteers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a randomized, double-masked, placebo-controlled, dose-escalation trial in healthy volunteers, aged 35-65, with the primary
objective of characterizing the safety and tolerability profile of <I>trabodenoson</I> and identifying a maximum tolerated dose (a dose that was associated with limiting or intolerable side effects). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ten subjects were assigned to each of seven consecutive cohorts (six to active <I>trabodenoson</I> and four to matched placebo). Cohorts 1
through 6 consisted of sequential, escalating doses (200, 400, 800, 1600, 2400 and 3200 mcg of <I>trabodenoson</I>) which were given topically to a single eye, BID, for 14 days. The 3200 mcg dose was the highest dose that could be administered to a
single eye at one time due to, among others, the limitations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the formulation. Cohort 7 included eight step-wise escalating doses of <I>trabodenoson</I>, given in both eyes. Doses given to this cohort ranged from 200-3200 mcg in a single eye and totaled
1800-6400 mcg for both eyes combined. Dose escalation to the next dose level proceeded only after masked review of the safety data from the preceding dose level. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Systemic safety assessments included: adverse events, other medications used, physical examinations, vital signs, clinical laboratory tests of
blood and urine samples, extensive monitoring of cardiac function and health (12-lead ECG tracings, continuous cardiac monitoring and cardiac troponin concentrations), lung function testing
(FEV<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB>), sleep (Karolinska Sleepiness Scale), kidney function and withdrawals or terminations. No systemic safety signals were found at any of the doses tested. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ocular safety assessments included vision tests (visual acuity), IOP measurements, as well as internal and external eye examinations. No
significant changes were seen in IOP measurements and examination of the periorbital area, eyelids, eyelashes, pupils, cornea, iris and sclera. The only ocular finding was short-lived, self-limited conjunctival hyperemia that was dose-related,
usually mild in severity, decreased with continuing exposure, and was not accompanied by evidence that it was related to inflammation, such as persistent anterior chamber cells or flare. The incidence of clinically significant eye redness reported
as an adverse event was extremely low (1 of 42) in subjects randomized to <I>trabodenoson</I>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Early Terminations and Withdrawals
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Three subjects randomized to placebo were terminated early from the study for reasons unrelated to the study drug. Only one subject
assigned to active study drug was withdrawn. The study subject&#146;s laboratory tests revealed findings consistent with gallbladder disease (chronic cholecystitis), so the subject was withdrawn from the clinical trial (without unmasking the
subject&#146;s treatment assignment) and referred for a surgical consult resulting in the subject having chronic gallbladder stones removed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Pharmacokinetic Data </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pharmacokinetics data indicated that the exposure to <I>trabodenoson</I> generally increased in a dose-dependent manner. At the highest
three doses, there were no apparent increases in systemic exposure with increasing dose. This plateau effect suggests that little additional drug is absorbed into systemic circulation following doses above 4800 mcg (2400 mcg per eye), as reflected
in the figure below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g893535g16a67.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Conclusions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In conclusion, no safety or tolerability issues were identified in either the eye or the body as a whole. Due to the lack of clinically
significant findings following in depth safety testing for systemic and ocular effects of <I>trabodenoson</I>, no maximum tolerated dose could be identified. Systemic exposure to <I>trabodenoson</I> appeared to be limited above ocular doses totaling
4800 mcg, indicating an apparent limitation to the amount of drug that can be delivered to the body by dosing in the eye. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Trabodenoson Monotherapy Tolerability, Safety and Efficacy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a Phase 1/2 multi-center, randomized, double-masked, placebo-controlled, dose-escalation trial in 70 adults with POAG and OHT with
the primary objective of characterizing the safety and tolerability of increasing doses of a pilot formulation of <I>trabodenoson</I> monotherapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subjects were sequentially assigned to one of seven consecutive cohorts (eight to active <I>trabodenoson</I> and four to matched placebo);
consisting of sequential, escalating single-doses of 2.5, 7.5, 20, 60, 180, 350 or 700 mcg of <I>trabodenoson</I> given topically to a single study eye. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Efficacy (IOP-lowering), tolerability, safety and pharmacokinetics assessments were performed following study drug administration, and dose
escalation from one cohort to the next cohort proceeded only after masked review of the safety data from the preceding cohort. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Conclusions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In conclusion, <I>trabodenoson</I> monotherapy ophthalmic solution up to and including 700 mcg were well-tolerated. This preliminary
formulation of <I>trabodenoson</I> demonstrated activity at lowering IOP following single doses of 350 mcg and 700 mcg in patients with POAG or OHT. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Development Plans </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of our Phase 2 trials and meeting with the FDA, we plan to continue developing <I>trabodenoson</I> as a monotherapy and an FDC
with <I>latanoprost</I>, along with the neuroprotective potential of both to slow the loss of vision significantly more than attributable to IOP-lowering alone either in glaucoma patients or other rarer forms of optic neuropathy. The figure below
shows our plans for upcoming clinical trials. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g893535g40n54.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Trabodenoson </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are planning an End-of-Phase 2 meeting with the FDA in the first half of 2015 to discuss our Phase 3 program for <I>trabodenoson</I>
monotherapy and to confirm the design and endpoints for the Phase 3 pivotal trials. This program is scheduled to begin in mid-2015, when the manufacturing (in accordance with the current Good Manufacturing Practices, or cGMP), packaging and labeling
of the study drug are complete. The preliminary design for the program, which is to be confirmed by the FDA, is expected to include doses and dose frequencies based on the Phase 2 clinical data. The two Phase 3 pivotal efficacy trials are expected
to include between 700 and 1,500 patients, depending on the design and number of dosing arms in the study, and are expected to include patients with glaucoma and baseline IOPs in the mid-20s mmHg. Determination of the ultimate study design and its
confirmation with the FDA could result in a significant range of costs for the Phase 3 pivotal trials. Following a run-in period, the trials are expected to run for at least 12 weeks of active treatment with the primary endpoint of IOP-lowering over
the day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA expects that a total of at least 1,500 patients will be exposed to at least a single dose of <I>trabodenoson</I>, and
the complete submission package must also contain safety data from at least 300 patients treated with <I>trabodenoson</I> for at least six months, and at least 100 patients treated for at least a year. These longer-term treatments will be
accomplished in a long-term safety trial conducted at the highest anticipated <I>trabodenoson</I> dose, and are expected to begin in early 2017 when the long-term ocular toxicity studies of six and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
nine month durations are available to support the longer dosing time. This long-term safety trial represents the first opportunity for us to study the rate of vision loss over a longer time. If
the enrollment projections are met, the first data from our Phase 3 program is anticipated in late 2016 or early 2017. We are planning to complete the long-term safety study in early 2018. If the primary objectives of our Phase 3 program are met, we
plan to submit an NDA to the FDA for marketing approval of <I>trabodenoson</I> for the treatment of glaucoma in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Fixed-Dose Combination of Trabodenoson and Latanoprost </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also developing an FDC of <I>trabodenoson</I> and <I>latanoprost</I>. Upon successful completion of our formulation efforts and
stability studies, we will commence manufacturing of clinical supplies to support further clinical trials. We have not filed a separate investigational new drug application, or IND, for the FDC, as we expect to be able to rely on the existing
<I>trabodenoson</I> IND. Similarly, we have not conducted a Phase 1 trial for the FDC as we were able to rely on the safety and tolerability data generated in our completed trials for <I>trabodeonson</I> as a monotherapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of the Phase 2 trial that evaluated the efficacy and safety of the combination of <I>latanoprost</I> and <I>trabodenoson</I>, at
two dose levels, and when given QD and BID, will inform the design and format of the next study which will be structured to evaluate the safety and efficacy of various dose combinations and dosing patterns of an FDC of <I>latanoprost</I> and
<I>trabodenoson</I>, which we still need to formulate. Once FDC clinical supplies are available, we believe that the FDA will allow us to continue the Phase 2 development using several FDC formulations with various dose combinations. However, the
commencement of our Phase 2 program for the FDC product candidate will depend on successful development and cGMP manufacturing of stable FDC dosage forms. We expect to initiate our Phase 2 program in late 2016 and plan to start our Phase 3 FDC
program in late 2017. We expect our FDC product candidate to benefit many patients with higher IOPs and more severe disease that typically require more aggressive medical treatment. For this reason, the patient population for the FDC program is
expected to carry a higher disease burden. As with the monotherapy product development, the FDA requirements for long-term dosing data (at least 300 patients treated with the FDC for at least six months, and at least 100 patients treated for at
least a year) will require the program to include a long-term safety study. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Neuroprotection and Degenerative Retinal Diseases
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to study the neuroprotective potential of <I>trabodenoson</I> monotherapy and our FDC product candidate to slow the loss
of vision significantly more than attributable to IOP-lowering alone either in glaucoma patients or other rarer forms of optic neuropathy. While supported by the basic biology of adenosine, we have not yet conducted a formal program of studies to
prove neuroprotection and have not filed an IND related to this program. This evaluation may include longer longitudinal studies in glaucoma patients, as potentially smaller patient groups with rapidly-progressing optic nerve damage. Although
treatment times will be measured in years rather than months, this effort can run in parallel to the normal development trials, or may be included in the objectives of the planned long-term safety trials. The regulatory path for such an indication
is thus far uncharted, so significant regulatory as well as clinical risk is anticipated for such a program and close interaction with regulatory agencies will be required. Due to the speculative nature of the development, it is difficult at this
time to predict if or when an NDA submission in support of neuroprotection indication may be submitted. We also plan to start pre-clinical and proof-of-concept trials for optic neuropathies and degenerative retinal diseases beginning in the second
half of 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
pharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our experience and scientific knowledge provide us with competitive advantages, we
face competition from established branded and generic pharmaceutical companies, such as Novartis International AG and its subsidiary Alcon Labs, Allergan Inc., Bausch + Lomb, Inc. (now a unit of Valeant Pharmaceuticals International, Inc.),
Merck&nbsp;&amp; Co., Inc., Santen Inc., Aerie Pharmaceuticals, Inc. and smaller biotechnology and pharmaceutical companies, as well as from academic </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
institutions, government agencies and private and public research institutions, which may in the future develop products to treat glaucoma. Any product candidates that we successfully develop and
commercialize will compete with existing therapies and new therapies that may become available in the future. We believe that the key competitive factors affecting the success of our product candidates, if approved, are likely to be efficacy,
safety, convenience, price, tolerability and the availability of coverage and adequate reimbursement from governmental authorities and other third-party payors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical
testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Glaukos Corporation recently commercialized a trabecular micro-bypass stent that is implanted in the eye during cataract surgery and
allows fluid to flow from the anterior of the eye into the collecting channels, bypassing the TM. In addition, early-stage companies that are also developing glaucoma treatments, such as Aerie Pharmaceuticals, Inc., which is developing a Rho
kinase/norepinephrine transport inhibitor, may prove to be significant competitors. We expect that our competitors will continue to develop new glaucoma treatments, which may include eye drops, oral treatments, surgical procedures, implantable
devices or laser treatments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other early-stage companies may also compete through collaborative arrangements with large and established
companies. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. These competitors also compete with us in recruiting and retaining
qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more
effective, have fewer adverse effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for
ours. In addition, our ability to compete may be affected because in many cases physicians, insurers or other third-party payors may encourage the use of generic products. The market for glaucoma prescriptions is highly competitive and is currently
dominated by generic drugs, such as <I>latanoprost</I> and <I>timolol</I>, and additional products are expected to become available on a generic basis over the coming years. If any of our product candidates are approved, we expect that they will be
priced at a premium over competitive generic products and consistent with other branded glaucoma drugs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Trabodenoson</I> is a small molecule that is capable of being manufactured in reliable and reproducible synthetic processes from readily
available starting materials. We believe the chemistry used to manufacture <I>trabodenoson</I> is amenable to a scale up and does not require unusual equipment in the manufacturing process. We do not currently operate manufacturing facilities for
clinical or commercial production of our product candidates. We currently rely on third-party manufacturers to produce the active pharmaceutical ingredient and final drug product for our clinical trials. We manage such production with all our
vendors on a purchase order basis in accordance with applicable master service and supply agreements. We do not have long-term agreements with these manufacturers or any other third-party suppliers. <I>Latanoprost</I> and <I>timolol</I>, used in our
clinical trials, are available in commercial quantities from multiple reputable third-party manufacturers. We intend to procure quantities on a purchase order basis for our clinical and commercial production. If any of our existing third-party
suppliers should become unavailable to us for any reason, we believe that there are a number of potential replacements, although we might experience a delay in our ability to obtain alternative suppliers. We also do not have any current contractual
relationships for the manufacture of commercial supplies of our product candidates if they are approved. With respect to commercial production of our product candidates in the future, we plan to outsource production of the active pharmaceutical
ingredients and final drug product manufacturing if they are approved for marketing by the applicable regulatory authorities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to develop drug candidates that can be produced in a cost effective manner
at contract manufacturing facilities. However, should a supplier or manufacturer on which we have relied to produce a product candidate provide us with a faulty product or such product is later recalled, we would likely experience delays and
additional costs, each of which could be significant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends in part on our ability to obtain and maintain proprietary protection for our products and product candidates, technology
and know-how, to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own a patent portfolio covering the <I>trabodenoson</I> compound that includes issued patents in the United States, Europe, Japan, and
several other countries. These composition of matter patents are scheduled to expire by early 2026 in the United States and by mid-2025 abroad. We also own an issued U.S. patent and have pending patent applications in Europe and Japan relating to
the use of <I>trabodenoson</I> for reducing IOP. The issued U.S. patent and the pending foreign patent applications, if issued, are scheduled to expire by 2030. A detailed freedom-to-operate analysis has been conducted and we are not aware of any
third party rights or impediments to commercializing <I>trabodenoson</I> for use in ophthalmic indications in the United States or Europe. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our patent portfolio includes issued U.S. patents relating to combinations of <I>trabodenoson</I> with carbonic anhydrase inhibitors and beta
blockers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also pursuing patent applications in the United States and abroad relating to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">combinations of <I>trabodenoson</I> with PGAs, carbonic anhydrase inhibitors or beta blockers, in patent applications which, if issued, are scheduled to expire by 2031; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">polymorphs of <I>trabodenoson</I>, in patent applications which, if issued, are scheduled to expire by 2033; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">formulations of <I>trabodenoson</I>, in patent applications which, if issued, are scheduled to expire by 2034; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ocular neuroprotective uses of <I>trabodenoson</I>, in patent applications which, if issued, are scheduled to expire by 2034. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we advance the development of our <I>trabodenoson</I> products and clinical development we continue to look at opportunities to file
additional patent applications covering new and innovative developments to ensure we have a patent portfolio that is multifaceted. For such additional applications, we will continue to seek patent protection in the United States and other
jurisdictions that are important in the ophthalmic markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our patents and patent applications, we keep certain of our
proprietary information as trade secrets, which we seek to protect by confidentiality agreements with our employees and third parties, and by seeking to maintain the physical security of our premises and physical and electronic security of our
information technology systems. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>FDA Regulation and Marketing Approval </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act, or FDCA, and related regulations. Drugs are also
subject to other federal, state and local statutes and regulations. Failure to comply with the applicable United States regulatory requirements at any time during the product development process, approval process or after approval may subject an
applicant to administrative or judicial sanctions and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
non-approval of product candidates. These sanctions could include the imposition by the FDA or an Institutional Review Board, or IRB, of a clinical hold on trials, the FDA&#146;s refusal to
approve pending applications or related supplements, withdrawal of an approval, untitled or warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, restitution, disgorgement,
civil penalties or criminal prosecution. Such actions by government agencies could also require us to expend a large amount of resources to respond to the actions. Any agency or judicial enforcement action could have a material adverse effect on us.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon
the clinical development, manufacture and marketing of pharmaceutical products. These agencies and other federal, state and local entities regulate research and development activities and the testing, manufacture, quality control, safety,
effectiveness, labeling, packaging, storage, distribution, record keeping, approval, post-approval monitoring, advertising, promotion, sampling and import and export of our products. Our drugs must be approved by the FDA through the NDA process
before they may be legally marketed in the United States. See &#147;The NDA Approval Process&#148; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process required by the FDA
before drugs may be marketed in the United States generally involves the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">completion of non-clinical laboratory tests, animal studies and formulation studies conducted according to Good Laboratory Practices, or GLP, or other applicable regulations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">submission of an IND, which allows clinical trials to begin unless FDA objects within 30 days; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed drug for its intended use or uses conducted in accordance with FDA regulations and Good Clinical Practices, or GCP,
which are international ethical and scientific quality standards meant to ensure that the rights, safety and well-being of trial participants are protected and that the roles of clinical trial sponsors, administrators, and monitors are well defined;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preparation and submission to the FDA of an NDA; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review of the product by an FDA advisory committee, where appropriate or if applicable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">satisfactory completion pre-approval inspection of manufacturing facilities and clinical trial sites at which the product, or components thereof, are produced to assess compliance with cGMP requirements and of selected
clinical trial sites to assess compliance with GCP requirements; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">FDA approval of an NDA which must occur before a drug can be marketed or sold. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical Studies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical studies include laboratory evaluation of the purity and stability of the manufactured drug substance or active pharmaceutical
ingredient and the formulated drug or drug product, as well as in vitro and animal studies to assess the safety and activity of the drug for initial testing in humans and to establish a rationale for therapeutic use. The conduct of preclinical
studies is subject to federal regulations and requirements, including GLP regulations. The results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical
studies, among other things, are submitted to the FDA as part of an IND. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Companies usually must complete some long-term preclinical
testing, such as animal tests of reproductive adverse events and carcinogenicity, and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the drug in
commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, the manufacturer must develop methods for
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to
demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>IND and Clinical Trials
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified
investigators in accordance with GCP requirements. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria
to be evaluated. Prior to commencing the first clinical trial, an initial IND, which contains the results of preclinical testing along with other information, such as information about product chemistry, manufacturing and controls and a proposed
protocol, must be submitted to the FDA. The IND automatically becomes effective 30 days after receipt by the FDA unless the FDA within the 30-day time period raises concerns or questions about the conduct of the clinical trial and imposes a clinical
hold. A clinical hold may also be imposed at any time while the IND is in effect. In such a case, the IND sponsor must resolve any outstanding concerns with the FDA before the clinical trial may begin. Accordingly, submission of an IND may or may
not result in the FDA allowing clinical trials to commence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A sponsor who wishes to conduct a clinical trial outside the United States
may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of an NDA or IND so long as
the clinical trial is conducted in compliance with GCP, and the FDA is able to validate the data from the study through an onsite inspection if the agency deems it necessary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A separate submission to the existing IND must be made for each successive clinical trial to be conducted during product development. Further,
an independent IRB for each site proposing to conduct the clinical trial must review and approve the study for any clinical trial before it commences at that site. Informed written consent must also be obtained from each trial subject. Regulatory
authorities, including the FDA, an IRB, a data safety monitoring board or the sponsor, may suspend or terminate a clinical trial at any time on various grounds, including a finding that the participants are being exposed to an unacceptable health
risk or that the clinical trial is not being conducted in accordance with FDA requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of NDA approval, human clinical
trials are typically conducted in sequential phases that may overlap: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 1&#150; the drug is initially given to healthy human subjects or patients and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. These trials may also provide early evidence
on effectiveness. During Phase 1 clinical trials, sufficient information about the investigational drug&#146;s pharmacokinetics and pharmacologic effects may be obtained to permit the design of well-controlled and scientifically valid Phase 2
clinical trials. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 2&#150; trials are conducted in a limited number of patients in the target population to identify possible adverse effects and safety risks, to determine the efficacy of the product for specific targeted diseases
and to determine dosage tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 3&#150; when Phase 2 evaluations demonstrate that a dosage range of the product appears effective and has an acceptable safety profile, and provide sufficient information for the design of Phase 3 trials, Phase 3
trials are undertaken to provide statistically significant evidence of clinical efficacy and to further test for safety in an expanded patient population at multiple clinical trial sites. They are performed after preliminary evidence suggesting
effectiveness of the drug has been obtained, and are intended to further evaluate dosage, effectiveness and safety, to establish the overall benefit-risk relationship of the investigational drug and to provide an adequate basis for product labeling
and approval by the FDA. In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the drug. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All clinical trials must be conducted in accordance with FDA regulations, GCP requirements and
their protocols in order for the data to be considered reliable for regulatory purposes. Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events
occur. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An
investigational drug product that is a combination of two different drugs in a single dosage form must comply with an additional rule that requires that each component make a contribution to the claimed effects of the drug product and the dosage of
each component (amount, frequency, duration) is such that the combination is safe and effective for a significant patient population requiring such concurrent therapy as defined in the labeling of the drug product. This typically requires larger
studies that test the drug against each of its components. In addition, typically, if a drug product is intended to treat a chronic disease, as is the case with our products, safety and efficacy data must be gathered over an extended period of time,
which can range from six months to three years or more. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government regulation may delay or prevent marketing of product candidates or new
drugs for a considerable period of time and impose costly procedures upon our activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Disclosure of Clinical Trial Information
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sponsors of clinical trials of FDA-regulated products, including drugs, are required to register and disclose certain clinical
trial information. Information related to the product, patient population, phase of investigation, study sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to
discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved. Competitors may use this publicly available information
to gain knowledge regarding the progress of development programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The NDA Approval Process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to obtain approval to market a drug in the United States, a marketing application must be submitted to the FDA that provides data
establishing to the FDA&#146;s satisfaction the safety and effectiveness of the investigational drug for the proposed indication. Each NDA submission requires a substantial user fee payment unless a waiver or exemption applies. The application
includes all relevant data available from pertinent non-clinical or preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#146;s
chemistry, manufacturing, controls and proposed labeling, among other things. Data can come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product, or from a number of alternative sources,
including studies initiated by investigators that meet GCP requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the development of a new drug, sponsors are given
opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 1 or 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity
for the sponsor to share information about the data gathered to date, for the FDA to provide advice and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the end of Phase 2 meetings to discuss
their Phase 2 clinical results and present their plans for the pivotal Phase 3 trials that they believe will support approval of the new drug. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of product development, non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical
tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. The FDA reviews all NDAs submitted to ensure that they are
sufficiently complete for substantive review before it </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accepts them for filing. It may request additional information rather than accept a NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted
application also is subject to review before the FDA accepts it for filing. The FDA has 60 days from its receipt of an NDA to conduct an initial review to determine whether the application will be accepted for filing based on the agency&#146;s
threshold determination that the application is sufficiently complete to permit substantive review. If the NDA submission is accepted for filing, the FDA reviews the NDA to determine, among other things, whether the proposed product is safe and
effective for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#146;s identity, strength, quality and purity. The FDA has agreed to specific performance goals on the review of
NDAs and seeks to review standard NDAs in 12 months from submission of the NDA. The review process may be extended by the FDA for three additional months to consider certain late-submitted information or information intended to clarify information
already provided in the submission. After the FDA completes its initial review of an NDA, it will communicate to the sponsor that the drug will either be approved, or it will issue a complete response letter to communicate that the NDA will not be
approved in its current form and inform the sponsor of changes that must be made or additional clinical, non-clinical or manufacturing data that must be received before the application can be approved, with no implication regarding the ultimate
approvability of the application or the timing of any such approval, if ever. If or when those deficiencies have been addressed to the FDA&#146;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. FDA has committed to
reviewing such resubmissions in two to six months depending on the type of information included. The FDA may refer applications for novel drug products or drug products that present difficult questions of safety or efficacy to an advisory committee,
typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and, if so, under what conditions. The FDA is not bound by the recommendations of an advisory
committee, but it considers such recommendations carefully when making decisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving an NDA, the FDA typically will inspect
the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of
the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical sites to assure compliance with GCP. If the FDA determines that the application, manufacturing process or manufacturing
facilities are not acceptable, it typically will outline the deficiencies and often will request additional testing or information. This may significantly delay further review of the application. If the FDA finds that a clinical site did not conduct
the clinical trial in accordance with GCP, the FDA may determine the data generated by the clinical site should be excluded from the primary efficacy analyses provided in the NDA. Additionally, notwithstanding the submission of any requested
additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA
may require, or companies may pursue, additional clinical trials after a product is approved. These so-called Phase 4 trials may be made a condition to be satisfied for continuing drug approval. The results of Phase 4 trials can confirm the
effectiveness of a product candidate and can provide important safety information. In addition, the FDA has authority to require sponsors to conduct post-marketing trials to specifically address safety issues identified by the agency. See
&#147;Post-Marketing Requirements&#148; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA also has authority to require a Risk Evaluation and Mitigation Strategy, or a
REMS, from manufacturers to ensure that the benefits of a drug outweigh its risks. A sponsor may also voluntarily propose a REMS as part of the NDA submission. The need for a REMS is determined as part of the review of the NDA. Based on statutory
standards, elements of a REMS may include &#147;Dear Doctor letters,&#148; a medication guide, more elaborate targeted educational programs, and in some cases elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special
training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patient registries. These elements are negotiated as part of the NDA approval, and in some cases the approval
date may be delayed. Once adopted, REMS are subject to periodic assessment and modification. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes to some of the conditions established in an approved application, including changes in
indications, labeling, manufacturing processes or facilities, require submission and FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new indication typically requires clinical data similar to
that in the original application, and the FDA uses the same procedures and actions in reviewing NDA supplements as it does in reviewing NDAs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if a product candidate receives regulatory approval, the approval may be limited to specific disease states, patient populations and
dosages, or might contain significant limitations on use in the form of warnings, precautions or contraindications, or in the form of onerous risk management plans, restrictions on distribution, or post-marketing trial requirements. Further, even
after regulatory approval is obtained, later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market. Delay in obtaining, or failure to obtain,
regulatory approval for our products, or obtaining approval but for significantly limited use, would harm our business. In addition, we cannot predict what adverse governmental regulations may arise from future United States or foreign governmental
action. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The Hatch-Waxman Amendments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, a portion of a
product&#146;s U.S. patent term that was lost during clinical development and regulatory review by the FDA may be restored by returning up to five years of patent life for a patent that covers a new product or its use. This period is generally
one-half the time between the effective date of an IND (falling after issuance of the patent) and the submission date of an NDA, plus the time between the submission date of an NDA and the approval of that application, provided the sponsor acted
with diligence. Patent term restorations, however, cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended and the extension must be
applied for prior to expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Market Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market exclusivity provisions under the FDCA also can delay the submission or the approval of certain competing applications. The FDCA provides
a five-year period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug
containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an Abbreviated New Drug Application, or ANDA, or a 505(b)(2) NDA
submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a
certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder. The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if
new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, for new indications, dosages or strengths of an
existing drug. This three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year
exclusivity will not delay the submission or approval of a full NDA; however, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the non-clinical studies and adequate and well-controlled clinical
trials necessary to demonstrate safety and effectiveness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pediatric exclusivity is another type of non-patent marketing exclusivity in
the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity, including the non-patent exclusivity. This six-month exclusivity may be granted if
an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Post-Marketing Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following approval of a new product, a pharmaceutical company and the approved product are subject to continuing regulation by the FDA,
including, among other things, monitoring and recordkeeping activities, reporting to the applicable regulatory authorities of adverse experiences with the product, providing the regulatory authorities with updated safety and efficacy information,
product sampling and distribution requirements, and complying with promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting drugs for uses or in patient populations
that are not described in the drug&#146;s approved labeling, or off-label use, limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving the internet. Although physicians may, in
their independent professional medical judgment, prescribe legally available drugs for off-label uses, manufacturers may not market or promote such off-label uses. Modifications or enhancements to the product or its labeling or changes of the site
of manufacture are often subject to the approval of the FDA and other regulators, who may or may not grant approval or may include a lengthy review process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prescription drug advertising is subject to federal, state and foreign regulations. In the United States, the FDA regulates prescription drug
promotion, including direct-to-consumer advertising. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use. Any distribution of prescription drug products and pharmaceutical samples must comply with
the U.S. Prescription Drug Marketing Act, or the PDMA, a part of the FDCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, once a product is approved, its
manufacturing is subject to comprehensive and continuing regulation by the FDA. The FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMP. We rely, and expect to continue to rely, on third
parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. cGMP regulations require among other things, quality control and quality assurance as well as the corresponding maintenance of
records and documentation and the obligation to investigate and correct any deviations from cGMP. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with
the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money and effort in the
area of production and quality control to maintain cGMP compliance. These regulations also impose certain organizational, procedural and documentation requirements with respect to manufacturing and quality assurance activities. NDA holders using
contract manufacturers, laboratories or packagers are responsible for the selection and monitoring of qualified firms, and, in certain circumstances, qualified suppliers to these firms. These firms and, where applicable, their suppliers are subject
to inspections by the FDA at any time, and the discovery of violative conditions, including failure to conform to cGMP, could result in enforcement actions that interrupt the operation of any such product or may result in restrictions on a product,
manufacturer, or holder of an approved NDA, including, among other things, recall or withdrawal of the product from the market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, the manufacturer and/or sponsor under an approved NDA are subject to annual product and establishment fees. These fees are typically increased annually. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA also may require post-marketing testing, also known as Phase 4 testing, REMS to monitor the effects of an approved product or place
conditions on an approval that could restrict the distribution or use of the product. Discovery of previously unknown problems with a product or the failure to comply with applicable FDA requirements can have negative consequences, including adverse
publicity, judicial or administrative enforcement, untitled or warning letters from the FDA, mandated corrective advertising or communications with doctors, withdrawal of approval, and civil or criminal penalties, among others. Newly discovered or
developed safety or effectiveness data may require changes to a product&#146;s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures. Also, new
government requirements, including those resulting from new legislation, may be established, or the FDA&#146;s policies may change, which could delay or prevent regulatory approval of our products under development. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Coverage and Reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of any products for which we receive regulatory approval for commercial sale will depend in part on the availability of reimbursement
from third-party payors, including government healthcare program administrative authorities, managed care organizations, private health insurers, and other entities. Patients who are prescribed medications for the treatment of their conditions, and
their prescribing physicians, generally rely on third-party payors to reimburse all of part of the costs associated with their prescription drugs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to
cover a significant portion of the cost of our products. Therefore, our products, once approved, may not obtain market acceptance unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process for determining whether a third-party payor will provide coverage for a drug product typically is separate from the process
for setting the price of a drug product or for establishing the reimbursement rate that the payor will pay for the drug product once coverage is approved. Third-party payors may limit coverage to specific drug products on an approved list, also
known as a formulary, which might not include all of the FDA-approved drugs for a particular indication. A decision by a third-party payor not to cover our product candidates could reduce physician utilization of our products once approved.
Moreover, a third-party payor&#146;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels
sufficient to realize an appropriate return on our investment in product development. Additionally, coverage and reimbursement for drug products can differ significantly from payor to payor. One third-party payor&#146;s decision to cover a
particular drug product or service does not ensure that other payors will also provide coverage for the medical product or service, or will provide coverage at an adequate reimbursement rate. As a result, the coverage determination process will
require us to provide scientific and clinical support for the use of our products to each payor separately and will be a time-consuming process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of drugs have been a focus
in this effort. Third-party payors are increasingly challenging the prices charged for drug products and medical services, examining the medical necessity and reviewing the cost effectiveness of drug products and medical services, in addition to
questioning safety and efficacy. If these third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after FDA approval or, if they do, the level of payment may not be
sufficient to allow us to sell our products at a profit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In particular, our success may depend on our ability to obtain coverage and
adequate reimbursement through Medicare Part D plans for our products that obtain regulatory approval. The Medicare Part D program provides a voluntary prescription drug benefit to Medicare beneficiaries. Under Part D, Medicare beneficiaries may
enroll in prescription drug plans offered by private entities which will provide coverage of outpatient prescription drugs. Part D plans include both stand-alone prescription drug benefit plans and prescription drug coverage as a supplement to
Medicare Advantage plans. Unlike Medicare Part A and B, Part D coverage is not standardized. In general, Part D prescription drug plan sponsors have flexibility regarding coverage of Part D drugs, and each drug plan can develop its own drug
formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs
in each category or class, with certain exceptions. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may
increase demand for products for which we receive regulatory approval. However, any negotiated prices for our future products covered by a Part D prescription drug plan will likely be discounted, thereby lowering the net price realized on our sales
to pharmacies. Moreover, while the Part D program applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment
that results from Medicare Part D may result in a similar reduction in payments from non-government payors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The American Recovery and Reinvestment Act of 2009 provides funding for the federal government to
compare the effectiveness of different treatments for the same illness. A plan for the research will be developed by the Department of Health and Human Services, the Agency for Healthcare Research and Quality and the National Institutes for Health,
and periodic reports on the status of the research and related expenditures will be made to Congress. Although the results of the comparative effectiveness studies are not intended to mandate coverage policies for public or private payors, it is not
clear what effect, if any, the research will have on the sales of our product candidates, if any such product or the condition that it is intended to treat is the subject of a study. It is also possible that comparative effectiveness research
demonstrating benefits in a competitor&#146;s product could adversely affect the sales of our product candidates, once approved. If third-party payors do not consider our products to be cost-effective compared to other available therapies, they may
not cover our products after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements
governing drug pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement
and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the
medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products.
Historically, products launched in the European Union do not follow price structures of the United States and generally tend to be significantly lower. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Anti-Kickback and False Claims Laws and Other Regulatory Matters </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, among other things, the research, manufacturing, distribution, sale and promotion of drug products and medical devices
are potentially subject to regulation and enforcement by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare&nbsp;&amp; Medicaid Services, other divisions of the United States Department of Health
and Human Services (e.g., the Office of Inspector General), the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety&nbsp;&amp; Health Administration, the Environmental
Protection Agency, state Attorneys General and other state and local government agencies. Our current and future business activities, including for example, sales, marketing and scientific/educational grant programs must comply with healthcare
regulatory laws, including the Federal Anti-Kickback Statute, the Federal False Claims Act, as amended, the privacy regulations promulgated under the Health Insurance Portability and Accountability Act, or HIPAA, as amended, physician payment
transparency laws, and similar state laws. Pricing and rebate programs must comply with the Medicaid Drug Rebate Program requirements of the Omnibus Budget Reconciliation Act of 1990, as amended, and the Veterans Health Care Act of 1992, as amended.
If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. The handling of any controlled substances must comply with the U.S. Controlled
Substances Act and Controlled Substances Import and Export Act. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. All of these activities are also potentially subject to federal and
state consumer protection and unfair competition laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of pharmaceutical products is subject to additional requirements
and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Federal Anti-Kickback Statute makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its
behalf) to knowingly and willfully solicit, receive, offer, or pay any remuneration that is intended to induce the referral of business, including the purchasing, leasing, ordering or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
arranging for or recommending the purchase, lease or order of, any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as
Medicare or Medicaid. The term &#147;remuneration&#148; has been broadly interpreted to include anything of value. The Federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and
prescribers, purchasers and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly.
Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of
a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a
cumulative review of all of its facts and circumstances. Additionally, the intent standard under the Federal Anti-Kickback Statute was amended by the Patient Protection and Affordable Care Act, as amended by the Health Care Education and
Reconciliation Act, or collectively the ACA, to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the ACA
codified case law that a claim including items or services resulting from a violation of the Federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the Federal False Claims Act. Violations of this law are punishable by
up to five years in prison, criminal fines, administrative civil money penalties, and exclusion from participation in federal healthcare programs. In addition, many states have adopted laws similar to the Federal Anti-Kickback Statute. Some of these
state prohibitions apply to the referral of patients for healthcare services reimbursed by any insurer, not just federal healthcare programs such as Medicare and Medicaid. Due to the breadth of these federal and state anti-kickback laws, and the
potential for additional legal or regulatory change in this area, it is possible that our future business activities, including our sales and marketing practices and/or our future relationships with ophthalmologists and optometrists might be
challenged under anti-kickback laws, which could harm us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Federal False Claims Act prohibits anyone from, among other things,
knowingly presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services, including drugs, that are false or fraudulent. This statute has been interpreted to prohibit presenting
claims for items or services not provided as claimed, or claims for medically unnecessary items or services. Although we would not submit claims directly to payors, manufacturers can be held liable under these laws if they are deemed to
&#147;cause&#148; the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a product off-label. In addition, our future activities relating to the reporting of
wholesaler or estimated retail prices for our products, the reporting of prices used to calculate Medicaid rebate information and other information affecting federal, state and third-party reimbursement for our products, and the sale and marketing
of our products, are subject to scrutiny under this law. For example, pharmaceutical companies have been found liable under the Federal False Claims Act in connection with their off-label promotion of drugs. Penalties for a False Claims Act
violation include three times the actual damages sustained by the government, plus mandatory civil penalties of between $5,500 and $11,000 for each separate false claim, the potential for exclusion from participation in federal healthcare programs,
and, although the Federal False Claims Act is a civil statute, conduct that results in a False Claims Act violation may also implicate various federal criminal statutes. If the government were to allege that we were, or convict us of, violating
these false claims laws, we could be subject to a substantial fine and may suffer a decline in our stock price. In addition, private individuals have the ability to bring actions under the Federal False Claims Act and certain states have enacted
laws modeled after the Federal False Claims Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly, the civil monetary penalties statute imposes penalties against any person or
entity who, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, HIPAA created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a
scheme to defraud any healthcare benefit program, including private third-party </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or
payment for healthcare benefits, items or services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are also an increasing number of state laws that require manufacturers to make
reports to states on pricing and marketing information. Many of these laws contain ambiguities as to what is required to comply with the laws. In addition, as discussed below, a similar federal requirement requires certain manufacturers to track and
report to the federal government certain payments provided to physicians and teaching hospitals made in the previous calendar year. These laws may affect our sales, marketing and other promotional activities by imposing administrative and compliance
burdens on us. In addition, given the lack of clarity with respect to these laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent state and federal authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our
business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their respective implementing regulations, including the final omnibus rule published on January&nbsp;25, 2013, imposes specified
requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#146;s privacy and security standards directly applicable to business associates, defined as
independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also created four new tiers of civil
monetary penalties and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing federal civil
actions. In addition, state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The failure to comply with regulatory requirements subjects us to possible legal or regulatory action. Depending on the circumstances, failure
to meet applicable regulatory requirements can result in significant criminal, civil and/or administrative penalties, damages, fines, disgorgement, exclusion from participation in federal healthcare programs, such as Medicare and Medicaid,
injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, refusal to allow us to enter into supply contracts, including government contracts, contractual damages, reputational
harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to develop a comprehensive compliance program that establishes internal controls to facilitate adherence to the law and program
requirements to which we will or may become subject because we intend to commercialize products that could be reimbursed under a federal healthcare program and other governmental healthcare programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in law or the interpretation of existing law could impact our business in the future by requiring, for example: (i)&nbsp;changes to
our manufacturing arrangements; (ii)&nbsp;additions or modifications to product labeling; (iii)&nbsp;the recall or discontinuation of our products; or (iv)&nbsp;additional record-keeping requirements. If any such changes were to be imposed, they
could adversely affect the operation of our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Affordable Health Care Act and Other Reform Initiatives </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and some foreign jurisdictions, there have been, and likely will continue to be, a number of legislative and regulatory
changes and proposed changes regarding the healthcare system directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2010, the ACA, was enacted. The ACA includes measures that have or will significantly
change the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA of greatest importance to the pharmaceutical industry are the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services in exchange for state
Medicaid coverage of most of the manufacturer&#146;s drugs. ACA made several changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers&#146; rebate liability by raising the minimum basic Medicaid rebate on most
branded prescription drugs and biologic agents to 23.1% of average manufacturer price, or AMP, and adding a new rebate calculation for &#147;line extensions&#148; (i.e., new formulations, such as extended release formulations) of solid oral dosage
forms of branded products, as well as potentially impacting their rebate liability by modifying the statutory definition of AMP. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The ACA expanded the types of entities eligible to receive discounted 340B pricing, although, with the exception of children&#146;s hospitals, these newly eligible entities will not be eligible to receive discounted
340B pricing on orphan drugs used in orphan indications. In addition, because 340B pricing is determined based on AMP and Medicaid drug rebate data, the revisions to the Medicaid rebate formula and AMP definition described above could cause the
required 340B discounts to increase. The ACA imposed a requirement on manufacturers of branded drugs and biologic agents to provide a 50% discount off the negotiated price of branded drugs dispensed to Medicare Part D beneficiaries in the coverage
gap (i.e., &#147;donut hole&#148;). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The ACA imposed an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain
government healthcare programs, although this fee would not apply to sales of certain products approved exclusively for orphan indications. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The ACA included the Federal Physician Payments Sunshine Act, which required pharmaceutical manufacturers to track certain financial arrangements with physicians and teaching hospitals, including any &#147;transfer of
value&#148; provided, as well as any ownership or investment interests held by physicians and their immediate family members. Covered manufacturers were required to begin collecting data on August&nbsp;1, 2013 and submit reports on aggregate payment
data to the government for the first reporting period (August 1, 2013&#151; December&nbsp;31, 2013) by March&nbsp;31, 2014, and were required to report detailed payment data for the first reporting period and submit legal attestation to the
completeness and accuracy of such data by June&nbsp;30, 2014. Thereafter, covered manufacturers must submit reports by the 90th day of each subsequent calendar year. The information reported was made publicly available on a searchable website in
September 2014. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The ACA established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. The research
conducted by the Patient-Centered Outcomes Research Institute may affect the market for certain pharmaceutical products. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The ACA created the Independent Payment Advisory Board which has the authority to recommend certain changes to the Medicare program to reduce expenditures by the program that could result in reduced payments for
prescription drugs. Under certain circumstances, these recommendations will become law unless Congress enacts legislation that will achieve the same or greater Medicare cost savings. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The ACA established the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug
spending. Funding has been allocated to support the mission of the Center for Medicare and Medicaid Innovation through 2019. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the details regarding the implementation of the ACA are yet to be determined, and at this time, it remains unclear the full effect
that the ACA would have on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted in the United States since the ACA was
enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2
trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to
2%&nbsp;per fiscal year, which went into effect in April 2013 and will remain in effect through 2024 unless additional Congressional action is taken. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which,
among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers
from three to five years. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>European Union Drug Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Union, our products will also be subject to extensive regulatory requirements. As in the United States, medicinal products can
only be marketed if an MAA from the competent regulatory agencies has been obtained, and the various phases of preclinical and clinical research in the European Union are subject to significant regulatory controls. Although the EU Clinical Trials
Directive 2001/20/EC has sought to harmonize the EU clinical trial regulatory framework, setting out common rules for the control and authorization of clinical trials in the EU, the EU Member States have transposed and applied the provisions of the
Directive differently. This has led to significant variations in the member state regimes. Under the current regime, before a clinical trial can be initiated it must be approved by two distinct bodies in each of the EU countries where the trial is
to be conducted: the National Competent Authority, or NCA, and one or more Ethics Committees, or ECs. In addition, all serious adverse reactions to the investigated drug that occur during the clinical trial must be reported to the NCA and ECs of the
Member State where they occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The EU clinical trials legislation is currently undergoing a revision process mainly aimed at making
more uniform and streamlining the clinical trials authorization process, simplifying adverse event reporting procedures, improving the supervision of clinical trials and increasing the transparency of clinical trials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>European Union Drug Review Approval </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Economic Area, or EEA, which is comprised of the 28 Member States of the European Union plus Norway, Iceland and Liechtenstein,
medicinal products can only be commercialized after obtaining an MAA. There are two types of MAAs: the Community MAA, which is issued by the European Commission through the Centralized Procedure based on the opinion of the Committee for Medicinal
Products for Human Use, or CHMP, a body of the EMA, and which is valid throughout the entire territory of the EEA; and the National MAA, which is issued by the competent authorities of the Member States of the EEA and only authorized marketing in
that Member State&#146;s national territory and not the EEA as a whole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Centralized Procedure is mandatory for certain types of
products, such as biotechnology medicinal products, orphan medicinal products and medicinal products containing a new active substance indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral
diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest
of public health in the EU. The National MAA is for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MAA can be
recognized in another Member States through the Mutual Recognition Procedure. If the product has not received a National MAA in any Member State at the time of application, it can be approved simultaneously in various Member States through the
Decentralized Procedure. Under the Decentralized Procedure an identical dossier is submitted to the competent authorities of each of the Member </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
States in which the MAA is sought, one of which is selected by the applicant as the Reference Member State, or RMS. If the RMS proposes to authorize the product, and the other Member States do
not raise objections, the product is granted a national MAA in all the Member States where the authorization was sought. Before granting the MAA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the
risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other
Regulations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also subject to numerous federal, state and local laws relating to such matters as safe working conditions,
manufacturing practices, environmental protection, fire hazard control and disposal of hazardous or potentially hazardous substances. We may incur significant costs to comply with such laws and regulations now or in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;30, 2015, we had five
employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were
incorporated in Delaware in 1999. Our principal executive offices are located at 131 Hartwell Avenue, Suite 105 Lexington, MA 02421, and our telephone number is (781)&nbsp;676-2100. We completed our initial public offering of common stock and an
offering of 5.0% convertible senior notes due 2020 in February 2015 and our common stock is listed on the NASDAQ Global Market under the symbol &#147;ITEK.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended
December&nbsp;31, 2014, our research and development expenses were $5.6 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc893535_3"></A>Item&nbsp;1A. Risk Factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>We operate in an industry that involves numerous risks and uncertainties. You should carefully consider the following information about
these risks, together with the other information appearing elsewhere in this Annual Report on Form 10-K, including our financial statements and related notes hereto. The occurrence of any of the following risks could have a material adverse effect
on our business, financial condition, results of operations and future growth prospects. The risks and uncertainties described below may change over time and other risks and uncertainties, including those that we do not currently consider material,
may impair our business In these circumstances, the market price of our common stock could decline. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial Position and
Need for Additional Capital </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We currently have no source of revenue and may never become profitable. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company with a limited operating history. Our ability to generate revenue and become profitable
depends upon our ability to successfully complete the development of our product candidates for the treatment of glaucoma and obtain the necessary regulatory approvals for our product candidates. We have never been profitable, have no products
approved for commercial sale and to date have not generated any revenue from product sales. Even if we receive regulatory approval for the sale of our product candidates, we do not know when such product candidates will generate revenue, if at all.
Our ability to generate product revenue depends on a number of factors, including our ability to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successfully complete clinical development, and receive regulatory approval, for our product candidates, including <I>trabodenoson</I> monotherapy and <I>trabodenoson</I> with <I>latanoprost</I> as an FDC;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">set an acceptable price for our product candidates and obtain coverage and adequate reimbursement from third-party payors; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish sales, marketing and distribution systems for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add operational, financial and management information systems and personnel, including personnel to support our clinical, manufacturing and planned future commercialization efforts; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">have commercial quantities of our product candidates manufactured at acceptable cost levels; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successfully market and sell our product candidates in the United States and enter into partnerships or other arrangements to commercialize our product candidates outside the United States; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintain, expand and protect our intellectual property portfolio. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, because of the
numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses, or when, or if, we will be able to achieve or maintain profitability. In addition, our expenses could increase
beyond expectations if we are required by the FDA and comparable non-U.S. regulatory authorities, or other regulatory authorities to perform studies or clinical trials in addition to those that we currently anticipate. Even if our product candidates
are approved for commercial sale, we anticipate incurring significant costs associated with the commercial launch of these products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
ability to become and remain profitable depends on our ability to generate revenue. Even if we are able to generate revenues from the sale of our product candidates, we may not become profitable and may need to obtain additional funding to continue
operations. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations. Even if we do achieve profitability,
we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, expand our business or
continue our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We have a history of net losses and anticipate that we will continue to incur net losses for the
foreseeable future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a history of losses and anticipate that we will continue to incur net losses for the foreseeable
future. Our net losses were $9.5 million, $7.6 million, and $6.1 million for the years ended December&nbsp;31, 2014, 2013 and 2012, respectively. Investment in pharmaceutical product development is highly speculative because it entails substantial
upfront expenditures and significant risk that a product candidate will fail to gain regulatory approval or become commercially viable. We have devoted most of our financial resources to research and development, including our non-clinical
development activities and clinical trials. We are not currently generating revenues, and we cannot estimate with precision the extent of our future losses. We do not currently have any products that are available for commercial sale and we may
never generate revenue from selling products or achieve profitability. We expect to continue to incur substantial and increasing losses through the projected commercialization of our product candidates. None of our product candidates have been
approved for marketing in the United States and may never receive such approval. As a result of these factors, we are uncertain when or if we will achieve profitability and, if so, whether we will be able to sustain it. Our ability to produce
revenue and achieve profitability is dependent on our ability to complete the development of our product candidates, obtain necessary regulatory approvals, and have our products manufactured and successfully marketed. We cannot assure you that we
will be profitable even if we successfully commercialize our products. Failure to become and remain profitable may adversely affect the market price of our common stock and our ability to raise capital and continue operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have financed our operations with a combination of private and public grants and contracts and equity and preferred stock offerings. From
1997 to 2004, we have received non-dilutive funding totaling over $50 million through federal and private grants and contracts. Since 2004, we have raised additional equity capital with funding from biotechnology and pharmaceutical investors. In
February 2004, we completed the sale of approximately $20 million of Series A preferred stock. In October 2005, we completed the sale of $35 million of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Series B preferred stock. In October of 2007, we completed the sale of approximately $24 million of Series C preferred stock. In June 2011, we completed the sale of an aggregate of approximately
$23.5 million of Series AA preferred stock in four separate closings during the preceding year. In February 2013, we completed the sale of approximately $3.5 million of convertible promissory notes in three separate closings during the preceding
eight months. In July 2013, we completed the sale of an additional approximately $13.5 million of Series AA preferred stock, including the conversion of the convertible promissory notes, in two separate closings during the previous two months. In
December 2014, we completed the issuance and sale of $2.0&nbsp;million of subordinated convertible promissory notes. Our product candidates will require the completion of regulatory review, significant marketing efforts and substantial investment
before they can provide us with any revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2015, we completed our IPO of 6,667,000 shares of our common stock at a price of
$6.00 per share and our concurrent offering of the 2020 Notes. In March 2015, the underwriters exercised 299,333 shares of common stock at $6.00 per share and $1.0 million of the 2020 Notes pursuant to their overallotment options. We received net
proceeds of approximately $36.6&nbsp;million, after deducting underwriting discounts and offering-related costs, from our equity issuances and approximately $18.9&nbsp;million in net proceeds, after deducting underwriting discounts and
offering-related costs, from our debt issuances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our research and development expenses to continue to be significant in
connection with our product development activities, including our planned Phase 2 clinical trials and our planned Phase&nbsp;3 programs. In addition, if we obtain regulatory approval for our product candidates, we expect to incur increased sales and
marketing expenses. As a result, we expect to continue to incur significant and increasing operating losses and negative cash flows for the foreseeable future. These losses have had and will continue to have a material adverse effect on our
stockholders&#146; deficit, financial position, cash flows and working capital. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We will need to obtain additional financing to fund
our operations and, if we are unable to obtain such financing, we may be unable to complete the development and commercialization of our primary product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations have consumed substantial amounts of cash since inception. At December&nbsp;31, 2014, our cash and cash equivalents were
$3.6&nbsp;million. We believe that the net proceeds from the initial offering of our common stock and the concurrent offering of convertible notes due 2020, together with existing cash and cash equivalents, will be sufficient to fund our projected
operating requirements for the next 18&nbsp;months. We will need to obtain additional financing to conduct additional trials for the approval of our drug candidates if requested by regulatory bodies, and complete the development of any additional
product candidates we might acquire. Moreover, our fixed expenses such as rent, interest expense and other contractual commitments are substantial and are expected to increase in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adequate additional funding may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on
attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future potential commercialization efforts. Our forecast of the period of time through which our financial resources will be adequate to
support our operating requirements is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed elsewhere in this &#147;Risk Factors&#148;
section. We have based this forecast on a number of assumptions that may prove to be wrong, and changing circumstances beyond our control may cause us to consume capital more rapidly than we currently anticipate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future funding requirements will depend on many factors, including, but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the progress, timing, scope and costs of our clinical trials, including the ability to enroll patients in our planned and potential future clinical trials in a timely manner; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the time and cost necessary to obtain regulatory approvals that may be required by regulatory authorities; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully commercialize our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amount of sales and other revenues from product candidates that we may commercialize, if any, including the selling prices for such product candidates and the availability of coverage and adequate reimbursement from
third parties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">selling and marketing costs associated with our product candidates, including the cost and timing of expanding our marketing and sales capabilities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms and timing of any potential future collaborations, licensing or other arrangements that we may establish; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cash requirements of any future acquisitions and/or the development of other product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of operating as a public company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the time and cost necessary to respond to technological and market developments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of maintaining and expanding our existing intellectual property rights; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until we can generate a sufficient amount of revenue, we may finance future cash needs through public or private equity offerings, license
agreements, debt financings, collaborations, strategic alliances, marketing or distribution arrangements or a combination thereof. Additional funds may not be available when we need them on terms that are acceptable to us, or at all. General market
conditions or the market price of our common stock may not support capital raising transactions such as an additional public or private offering of our common stock or other securities. In addition, our ability to raise additional capital may be
dependent upon our stock being quoted on The NASDAQ Global Market, or NASDAQ, or upon obtaining shareholder approval. There can be no assurance that we will be able to satisfy the criteria for continued listing on NASDAQ or that we will be able to
obtain shareholder approval if it is necessary. If adequate funds are not available, we may be required to delay or reduce the scope of or eliminate one or more of our research or development programs or our commercialization efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may seek to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for
additional capital at that time. In addition, if we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our
technologies, future revenue streams or product candidates or to grant licenses on terms that may not be favorable to us. Our inability to obtain additional funding when we need it could seriously harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Additional capital that we may need to operate or expand our business may not be available. In addition, the agreements that govern our
existing indebtedness contain covenants that restrict our ability to incur additional indebtedness and incur certain liens, for example. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may require additional capital to operate or expand our business.&nbsp;The indenture governing our convertible notes due 2020 contains
covenants that, among other things, restricts our and our future subsidiaries&#146; ability to take specific actions, even if we believe them to be in our best interest. These covenants include restrictions on our ability and the ability of our
subsidiaries to (i)&nbsp;incur additional indebtedness and issue certain types of preferred stock, other than certain permitted indebtedness and preferred stock; and (ii)&nbsp;incur liens, other than certain permitted liens. Any debt financing
obtained by us in the future could involve further restrictive covenants, which may make it more difficult for us to obtain additional capital and pursue business opportunities. Moreover, we may not redeem the existing notes pursuant to the
indenture governing the notes prior to maturity though the indenture does not limit our ability to make open-market purchases or tender offers for the notes at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we raise additional funds through the issuance of equity or convertible securities, the
percentage ownership of holders of our common stock could be significantly diluted and these newly issued securities may have rights, preferences or privileges senior to those of holders of our common stock. Furthermore, volatility in the credit or
equity markets may have an adverse effect on our ability to obtain debt or equity financing or the cost of such financing. If we do not have funds available to enhance our solution, maintain the competitiveness of our technology and pursue business
opportunities, this could have an adverse effect on our business, operating results and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Development, Regulatory
Approval and Commercialization </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We depend substantially on the success of our product candidates, particularly trabodenoson
monotherapy and trabodenoson FDC, which are still in development. If we are unable to successfully develop and commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business and the ability to generate revenue related to product sales, if ever, will depend on the successful development, regulatory
approval and commercialization of our product candidates<I> trabodenoson</I> monotherapy and <I>trabodenoson </I>FDC, which are still in development, and other potential products we may develop or license. We have invested a significant portion of
our efforts and financial resources in the development of our existing product candidates. The success of our product candidates will depend on several factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successful completion of clinical trials, and the supporting non-clinical toxicology, formulation development, and manufacturing of supplies for the clinical program in accordance with current Good Manufacturing
Practices, or cGMP; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">receipt of regulatory approvals from the FDA and other applicable regulatory authorities outside the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishment of arrangements with third-party manufacturers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining and maintaining patent and trade secret protection and regulatory exclusivity; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">protecting our rights in our intellectual property; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launching commercial sales of our product candidates, if and when approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance of any approved product by the medical community and patients; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining coverage and adequate reimbursement from third-party payors for product candidates, if and when approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">effectively competing with other products; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">achieving a continued acceptable safety profile for our product candidates following regulatory approval, if and when received. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to
successfully develop and commercialize our product candidates, which would materially harm our business and we may not be able to earn sufficient revenues and cash flows to continue our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidates are <I>trabodenoson</I> as a monotherapy and as an FDC consisting of <I>trabodenoson </I>with a prostaglandin analog,
or PGA. We have no other product candidates in our near term product pipeline. As a result, we are substantially dependent on the successful development and commercialization of <I>trabodenoson</I>. If the results of our chronic toxicology program
were to identify a safety problem, or if our upcoming pivotal trials of <I>trabodenoson</I> monotherapy or our upcoming continuing Phase&nbsp;2 program for the FDC product candidate were to demonstrate lack of efficacy in lowering intraocular
pressure, or IOP, or any safety issues related to <I>trabodenoson</I>, our development strategy would be materially and adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We have not obtained regulatory approval for any of our product candidates in the United
States or in any other country. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently do not have any product candidates that have gained regulatory approval for sale in
the United States or in any other country, and we cannot guarantee that we will ever have marketable products. Our business is substantially dependent on our ability to complete the development of, obtain regulatory approval for and successfully
commercialize product candidates in a timely manner. We cannot commercialize product candidates in the United States without first obtaining regulatory approval to market each product from the FDA; similarly, we cannot commercialize product
candidates outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. We have completed a Phase 2 trial in which we tested <I>trabodenoson</I> co-administered with <I>latanoprost</I>. We are
planning an End-of-Phase 2 meeting with the FDA for <I>trabodenoson</I> monotherapy in the first half of 2015 and expect to initiate a pivotal Phase 3 program in mid-2015, which will consist of two Phase 3 pivotal trials and a long-term safety
study. We cannot predict whether any of our future trials, including our planned long-term safety trial of <I>trabodenoson</I>, will be successful or whether regulators will agree with our conclusions regarding the preclinical studies and clinical
trials we have conducted to date. Moreover, determination of the ultimate study design and its confirmation with the FDA could result in a significant range of costs for the Phase 3 pivotal trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining regulatory approvals for the commercial sale of any product candidate for a target indication, we must demonstrate in
preclinical studies and well-controlled clinical trials, and, with respect to approval in the United States, to the satisfaction of the FDA, that the product candidate is safe and effective for use for that target indication and that the
manufacturing facilities, processes and controls are adequate. In the United States, we have not submitted a New Drug Application, or NDA, for any of our product candidates. An NDA must include extensive preclinical and clinical data and supporting
information to establish the product candidate&#146;s safety and effectiveness for each desired indication. The NDA must also include significant information regarding the chemistry, manufacturing and controls for the product. Obtaining approval of
an NDA is a lengthy, expensive and uncertain process, and approval may not be obtained. If we submit an NDA to the FDA, the FDA must decide whether to accept or reject the submission for filing. We cannot be certain that any submissions will be
accepted for filing and review by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory authorities outside of the United States, such as in Europe and Japan and in
emerging markets, also have requirements for approval of drugs for commercial sale with which we must comply prior to marketing in those areas. Regulatory requirements can vary widely from country to country and could delay or prevent the
introduction of our product candidates. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and obtaining regulatory approval in one country does not mean that regulatory approval will be
obtained in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking non-U.S. regulatory approval could require additional non-clinical
studies or clinical trials, which could be costly and time consuming. The non-U.S. regulatory approval process may include all of the risks associated with obtaining FDA approval. For all of these reasons, we may not obtain non-U.S. regulatory
approvals on a timely basis, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process to develop, obtain regulatory approval for and commercialize product candidates is
long, complex and costly both inside and outside of the United States, and approval is never guaranteed. Even if our product candidates were to successfully obtain approval from the regulatory authorities, any approval might significantly limit the
approved indications for use, or require that precautions, contraindications, or warnings be included on the product labeling, or require expensive and time-consuming post-approval clinical trials or surveillance as conditions of approval. Following
any approval for commercial sale of our product candidates, certain changes to the product, such as changes in manufacturing processes and additional labeling claims, will be subject to additional FDA review and approval. Also, regulatory approval
for any of our product candidates may be withdrawn. If we are unable to obtain regulatory approval for our product candidates in one or more jurisdictions, or any approval contains significant limitations, our target market will be reduced and our
ability to realize the full market potential of our product candidates will be harmed. Furthermore, we may not be able to obtain sufficient funding or generate sufficient revenue and cash flows to continue the development of any other product
candidate in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Regulatory approval may be substantially delayed or may not be obtained for one or all of
our product candidates if regulatory authorities require additional time or studies to assess the safety and efficacy of our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be unable to initiate or complete development of our product candidates on schedule, if at all. To complete the studies for our product
candidates we will require additional funding. In addition, if regulatory authorities require additional time or studies to assess the safety or efficacy of our product candidates, we may not have or be able to obtain adequate funding to complete
the necessary steps for approval for any or all of our product candidates. Preclinical studies and clinical trials required to demonstrate the safety and efficacy of our product candidates are time consuming and expensive and together take several
years or more to complete. Delays in regulatory approvals or rejections of applications for regulatory approval in the United States, Europe, Japan or other markets may result from many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to obtain sufficient funds required for a clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">requests from regulatory authorities for additional analyses, reports, data, non-clinical and preclinical studies and clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">questions from regulatory authorities regarding interpretations of data and results and the emergence of new information regarding our product candidates or other products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical holds, other regulatory objections to commencing or continuing a clinical trial or the inability to obtain regulatory approval to commence a clinical trial in countries that require such approvals;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to reach agreement with the FDA or comparable non-US regulatory authorities regarding the scope or design of our clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to enroll a sufficient number of patients who meet the inclusion and exclusion criteria in our clinical trials. For example, we are seeking patients with elevated levels of IOP for our clinical trials,
which are more difficult to find; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to reach agreements on acceptable terms with prospective contract research organizations, or CROs, and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly
among different CROs and trial sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to identify and maintain a sufficient number of sites, many of which may already be engaged in other clinical trial programs, including some that may be for the same indications targeted by our product
candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any determination that a clinical trial presents unacceptable health risks; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lack of adequate funding to continue the clinical trial due to unforeseen costs or other business decisions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to obtain approval from Institutional Review Boards, or IRBs, to conduct clinical trials at their respective sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to manufacture in a timely manner or obtain from third parties sufficient quantities or quality of the product candidates or other materials required for a clinical trial; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulty in maintaining contact with patients after treatment, resulting in incomplete data; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unfavorable or inconclusive results of clinical trials and supportive non-clinical studies, including unfavorable results regarding the effectiveness of product candidates during clinical trials. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in regulatory requirements and guidance may also occur and we may need to amend clinical trial protocols submitted to applicable
regulatory authorities to reflect these changes. Amendments may require us to resubmit clinical trial protocols to IRBs for re-examination, which may impact the costs, timing or successful completion of a clinical trial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of our planned End-of-Phase 2 meeting with the FDA for <I>trabodenoson</I> in the
first half of 2015, the FDA may require us to conduct additional clinical trials before we commence our Phase 3 pivotal trials and long-term safety study or they may require us to increase the size of or change the design of our planned pivotal
trials. In addition, if the FDA requires us to change the design of our planned pivotal trials, the actual costs of these trials may be greater than what we estimated based on our current expectations regarding the design of these trials. If we are
required to conduct additional clinical trials or other studies with respect to any of our product candidates beyond those that we initially contemplated, if we are unable to successfully complete our clinical trials or other studies or if the
results of these studies are not positive or are only modestly positive, we may be delayed in obtaining regulatory approval for that product candidate, we may not be able to obtain regulatory approval at all or we may obtain approval for indications
that are not as broad as intended. Our product development costs will also increase if we experience delays in testing or approvals and we may not have sufficient funding to complete the testing and approval process. Significant clinical trial
delays could allow our competitors to bring products to market before we do and impair our ability to commercialize our products if and when approved. If any of this occurs, our business will be materially harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We have not yet successfully formulated, and may be unable to formulate or manufacture our fixed-dose combination product candidate in a
way that is suitable for clinical or commercial use. Any such delay or failure could materially harm our commercial prospects, result in higher costs and deprive us of product candidate revenues. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recently completed a Phase 2 trial to evaluate the efficacy, tolerability and safety of <I>trabodenoson</I> when co-administered with
commercially-available <I>latanoprost</I> eye drops. However, we have not yet formulated our FDC product candidate to include these two drugs in a single combination dose, and we may never be able to formulate or manufacture our FDC product
candidate in a way that is suitable for clinical or commercial use. Any delay or failure to develop a suitable product formulation or manufacturing process for our FDC product candidate could materially harm our commercial prospects, result in
higher costs or deprive us of potential product revenues. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Failure can occur at any stage of clinical development. If the clinical
trials for our product candidates are unsuccessful, we could be required to abandon development. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A failure of one or more clinical
trials can occur at any stage of testing for a variety of reasons. The outcome of preclinical testing and early clinical trials may not be predictive of the outcome of later clinical trials, and interim results of a clinical trial do not necessarily
predict final results. In addition, adverse events may occur or other risks may be discovered in any clinical trials that will cause us to suspend or terminate our clinical trials. In some instances, there can be significant variability in safety
and/or efficacy results between different trials of the same product candidate due to numerous factors, including changes in or adherence to trial protocols, differences in size and type of the patient populations and the rates of dropout among
clinical trial participants. To date, we have only exposed 233 clinical trial subjects to <I>trabodenoson</I>. The FDA expects that a total of at least 1,500 patients will be exposed to at least a single dose of <I>trabodenoson</I> before submission
of an NDA, and the complete NDA submission package must also contain safety data from at least 300 patients treated with <I>trabodenoson</I> for at least six months, and at least 100 patients treated for at least a year. Our future clinical trial
results therefore may not demonstrate safety and efficacy sufficient to obtain regulatory approval for our product candidates. Moreover, we still need to evaluate the long-term safety effects of our product candidates, the results of which could
adversely affect our clinical development program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Flaws in the design of a clinical trial may not become apparent until the clinical
trial is well-advanced. We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support regulatory approval. In addition, clinical trials often reveal that it is not practical or feasible
to continue development efforts. Further, we have never submitted an NDA for any product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may voluntarily suspend or
terminate our clinical trials if at any time we believe that they present an unacceptable risk to participants. Further, regulatory agencies, IRBs or data safety monitoring boards may at any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
time order the temporary or permanent discontinuation of our clinical trials or request that we cease using investigators in the clinical trials if they believe that the clinical trials are not
being conducted in accordance with applicable regulatory requirements, or that they present an unacceptable safety risk to participants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the results of our clinical trials for our current product candidates or clinical trials for any future product candidates do not achieve
the primary efficacy endpoints or demonstrate unexpected safety issues, the prospects for approval of our product candidates will be materially adversely affected. Moreover, preclinical and clinical data are often susceptible to varying
interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have failed to achieve similar results in later clinical trials, including longer term
trials, or have failed to obtain regulatory approval of their product candidates. Many compounds that initially showed promise in clinical trials or earlier stage testing have later been found to cause undesirable or unexpected adverse effects that
have prevented further development of the compound. In addition, we have typically only tested our product candidates in a single eye, which may not accurately predict the efficacy or safety of our product candidates when dosed in both eyes. Our
planned Phase 3 pivotal trials of <I>trabodenoson</I> monotherapy may not produce the results that we expect. Our planned clinical trials are also designed to test the use of <I>trabodenoson</I> in combination with <I>latanoprost</I> as an add-on
therapy. Accordingly, the efficacy of our primary product candidates may not be similar or correspond directly to their efficacy when used as a monotherapy. Our current product candidates remain subject to the risks associated with clinical drug
development as indicated above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the circumstances noted above, we may experience numerous unforeseen events that could
cause our clinical trials to be delayed, suspended or terminated, or which could delay or prevent our ability to receive regulatory approval or commercialize our product candidates, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or implement a clinical hold;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these
clinical trials at a higher rate than we anticipate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulators or IRBs may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may elect or be required to suspend or terminate clinical trials of our product candidates based on a finding that the participants are being exposed to health risks; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of clinical trials of our product candidates may be greater than we anticipate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our product candidates may have undesirable adverse effects or other unexpected characteristics. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we elect or are required to suspend or terminate a clinical trial of any of our product candidates, our commercial prospects will be
adversely impacted and our ability to generate product revenues may be delayed or eliminated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates may have
undesirable adverse effects, which may delay or prevent regulatory approval or, if approval is received, require our products to be taken off the market, require them to include safety warnings or otherwise limit their sales. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unforeseen adverse effects from any of our product candidates could arise either during clinical development or, if approved, after the
approved product has been marketed. In particular, we are aware of the known potential of adenosine and adenosine-like drugs to affect the heart if present in the systematic circulation at high enough levels. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any undesirable adverse effects that may be caused by our product candidates could interrupt,
delay or halt clinical trials and could result in the denial of regulatory approval by the FDA and comparable non-U.S. regulatory authorities for any or all targeted indications, and in turn prevent us from commercializing our product candidates and
generating revenues from their sale. In addition, if any of our product candidates receives regulatory approval and we or others later identify undesirable adverse effects caused by the product, we could face one or more of the following
consequences: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require the addition of labeling statements, such as a &#147;black box&#148; warning or a contraindication, or other labeling changes; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may withdraw their approval of the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may seize the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to change the way that the product is administered, conduct additional clinical trials or recall the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be subject to litigation or product liability claims, fines, injunctions, or criminal penalties; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our reputation may suffer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining
market acceptance of the affected product or could substantially increase the costs and expenses of commercializing such product, which in turn could delay or prevent us from generating significant revenues from its sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Trabodenoson</I> is an adenosine mimetic. Adenosine is used therapeutically to manage cardiovascular arrhythmias, such as paroxysmal
supraventricular tachycardia, a type of accelerated heart rate. All of our data to date reflects that <I>trabodenoson</I> does not have systemic effects, including no impact on the cardiovascular system when dosed in the eye. However, we are still
conducting additional trials for <I>trabodenoson</I> and systemic effects may arise in future trials. Furthermore, if <I>trabodenoson</I> has the perception of having potential adverse effects because it is an adenosine mimetic, it may be negatively
viewed by ophthalmologists and optometrists, patients, patient advocacy groups, third-party payors and the medical community which would adversely affect the market acceptance of our product candidates. In addition, the use of our product candidates
outside the indications cleared for use, or off-label use, or the use of our product candidate in an inappropriate manner, may increase the risk of injury to patients. Clinicians may use our products for off-label uses, as the FDA does not restrict
or regulate a clinician&#146;s choice of treatment within the practice of medicine. Off-label use of our products may increase the risk of product liability claims against us. Product liability claims are expensive to defend and could divert our
management&#146;s attention and result in substantial damage awards against us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If our product candidates receive regulatory
approval, we will be subject to ongoing regulatory requirements and we may face future development, manufacturing and regulatory difficulties. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidates, if approved, will also be subject to ongoing regulatory requirements for labeling, packaging, storage, advertising,
promotion, sampling, record-keeping, submission of safety and other post-market approval information, importation and exportation. In addition, approved products, manufacturers and manufacturers&#146; facilities are required to comply with extensive
FDA and European Medicines Agency, or EMA, requirements and the requirements of other similar agencies, including ensuring that quality control and manufacturing procedures conform to cGMP requirements. As such, we and our potential future contract
manufacturers will be subject to continual review and periodic inspections to assess compliance with cGMPs. Accordingly, we and others with whom we work will be required to expend time, money and effort in all areas of regulatory compliance,
including manufacturing, production and quality control. We will also be required to report certain adverse reactions and production problems, if any, to the FDA, EMA and other similar foreign agencies and to comply with certain requirements
concerning advertising and promotion for our product candidates. Promotional communications with respect to prescription drugs also are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the
product&#146;s approved labeling. Accordingly, once approved, we may not promote our products, if any, for indications or uses for which they are not approved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a regulatory agency discovers previously unknown problems with a product, such as adverse
events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, it may impose restrictions on that product or us, including
requiring withdrawal of the product from the market. If our product candidates fail to comply with applicable regulatory requirements, a regulatory agency may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issue warning letters or untitled letters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require product recalls; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">mandate modifications to promotional materials or require us to provide corrective information to healthcare practitioners; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require us or our potential future collaborators to enter into a consent decree or permanent injunction, which can include shutdown of manufacturing facilities, imposition of various fines, reimbursements for inspection
costs, required due dates for specific actions and penalties for noncompliance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impose other administrative or judicial civil or criminal penalties or pursue criminal prosecution; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdraw regulatory approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refuse to approve pending applications or supplements to approved applications filed by us or by our potential future collaborators; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impose restrictions on operations, including costly new manufacturing requirements; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seize or detain products. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to effectively establish a direct sales
force in the United States, our business may be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently do not have an established sales organization and do not have
a marketing or distribution infrastructure. To achieve commercial success for any approved product, we must either develop a sales and marketing organization or outsource these functions to third parties. If <I>trabodenoson</I> receives marketing
approval in the United States, we plan to commercialize it by establishing a glaucoma-focused specialty sales force of approximately 150 people targeting high-prescribing ophthalmologists and optometrists throughout the United States. We will need
to incur significant additional expenses and commit significant additional time and management resources to establish and train a sales force to market and sell our products. We may not be able to successfully establish these capabilities despite
these additional expenditures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Factors that may inhibit our efforts to successfully establish a sales force include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to compete with other pharmaceutical companies to recruit, hire, train and retain adequate numbers of effective sales and marketing personnel with requisite knowledge of our target market;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability of sales personnel to obtain access to adequate numbers of ophthalmologists and optometrists to prescribe any future approved products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unforeseen costs and expenses associated with creating an independent sales and marketing organization; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a delay in bringing products to market after efforts to hire and train our sales force have already commenced. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event we are unable to successfully market and promote our products, our business may be harmed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We currently intend to explore the licensing of commercialization rights or other forms of
collaboration outside of the United States, which will expose us to additional risks of conducting business in international markets. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The non-U.S. markets are an important component of our growth strategy. If we fail to obtain licenses or enter into collaboration arrangements
with selling parties, or if these parties are not successful, our revenue-generating growth potential will be adversely affected. Moreover, international business relationships subject us to additional risks that may materially adversely affect our
ability to attain or sustain profitable operations, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">efforts to enter into collaboration or licensing arrangements with third parties in connection with our international sales, marketing and distribution efforts may increase our expenses or divert our management&#146;s
attention from the acquisition or development of product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in a specific country&#146;s or region&#146;s political and cultural climate or economic condition; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">differing regulatory requirements for drug approvals and marketing internationally, which could result in our being required to conduct additional clinical trials or other studies before being able to successfully
commercialize our product candidates in any jurisdiction outside the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulty of effective enforcement of contractual provisions in local jurisdictions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potentially reduced protection for intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potential third-party patent rights in countries outside of the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unexpected changes in tariffs, trade barriers and regulatory requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">economic weakness, including inflation, or political instability, particularly in non-U.S. economies and markets, including several countries in Europe; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compliance with tax, employment, immigration and labor laws for employees traveling abroad; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effects of applicable foreign tax structures and potentially adverse tax consequences; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incidental to doing business in another country; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">workforce uncertainty in countries where labor unrest is more common than in the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential for so-called parallel importing, which is what happens when a local seller, faced with high or higher local prices, opts to import goods from a foreign market (with low or lower prices) rather than buying
them locally; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure of our employees and contracted third parties to comply with Office of Foreign Asset Control rules and regulations and the Foreign Corrupt Practices Act; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters, including earthquakes, volcanoes, typhoons, floods, hurricanes and fires. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These and other risks may materially adversely affect our ability to attain or sustain revenue from international markets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We face competition from established branded and generic pharmaceutical companies and if our competitors are able to develop and market
products that are preferred over our products, our commercial opportunity will be reduced or eliminated. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development and
commercialization of new drug products is highly competitive. We face competition from established branded and generic pharmaceutical companies, smaller biotechnology and pharmaceutical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
companies, as well as from academic institutions, government agencies and private and public research institutions, which may in the future develop products to treat glaucoma. Any product
candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. Many of our competitors have significantly greater financial resources and expertise in
research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Glaukos Corporation recently commercialized a trabecular micro-bypass stent that is
implanted in the eye during cataract surgery and allows fluid to flow from the anterior of the eye into the collecting channels, bypassing the TM. In addition, early-stage companies that are also developing glaucoma treatments may prove to be
significant competitors, such as Aerie Pharmaceuticals, Inc., which is developing a Rho kinase/norepinephrine transport inhibitor. We expect that our competitors will continue to develop new glaucoma treatments, which may include eye drops, oral
treatments, surgical procedures, implantable devices or laser treatments. Other early-stage companies may also compete through collaborative arrangements with large and established companies. Mergers and acquisitions in the pharmaceutical and
biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Our commercial opportunity will be reduced or eliminated if our competitors develop and commercialize products that are safer,
more effective, have fewer adverse effects, are more convenient or are less expensive than our product candidates. The market for glaucoma prescriptions is highly competitive and is currently dominated by generic drugs, such as <I>latanoprost</I>
and <I>timolol</I>, and additional products are expected to become available on a generic basis over the coming years.&nbsp;If any of our product candidates are approved, we expect that they will be priced at a premium over competitive generic
products and consistent with other branded glaucoma drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our competitors market products that are more effective, safer, have fewer
side effects or are less expensive than our product candidates or that reach the market sooner than our potential future products, if any, we may not achieve commercial success. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The commercial success of our product candidates will depend on the degree of market acceptance among ophthalmologists and optometrists,
patients, patient advocacy groups, third-party payors and the medical community. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidates may not gain market
acceptance among ophthalmologists and optometrists, patients, patient advocacy groups, third-party payors and the medical community. There are a number of available therapies marketed for the treatment of glaucoma. Some of these drugs are branded
and subject to patent protection, but most others, including <I>latanoprost</I> and many beta blockers, are available on a generic basis. Many of these approved drugs are well established therapies and are widely accepted by ophthalmologists and
optometrists, patients and third-party payors. Insurers and other third-party payors may also encourage the use of generic products. Additionally, in patients with normal tension glaucoma whose IOP falls into the normal range, IOP is generally much
more difficult to reduce. In these patients, <I>trabodenoson</I> may offer little or no clinical benefit, which may ultimately limit its utility in this subpopulation of glaucoma patients. The degree of market acceptance of our product candidates
will depend on a number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the market price, affordability and patient out-of-pocket costs of our product candidates relative to other available products, which are predominantly generics; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of our product candidates as compared with currently available products and any products that may be approved in the future; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patient willingness to adopt our product candidates in place of current therapies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">varying patient characteristics including demographic factors such as age, health, race and economic status; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in the standard of care for the targeted indications for any of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prevalence and severity of any adverse effects or perception of any potential side effects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitations or warnings contained in a product candidate&#146;s FDA-approved labeling; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitations in the approved clinical indications for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">relative convenience and ease of administration; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the strength of our selling, marketing and distribution capabilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the quality of our relationship with patient advocacy groups; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sufficient third-party coverage and reimbursement; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product liability claims. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the potential market opportunity for our product
candidates is difficult to precisely estimate. Our estimates of the potential market opportunity for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research reports and
other surveys. If any of these assumptions proves to be inaccurate, then the actual market for our product candidates could be smaller than our estimates of our potential market opportunity. If the actual market for our product candidates is smaller
than we expect, our product revenue may be limited, and it may be more difficult for us to achieve or maintain profitability. If we fail to achieve market acceptance of our product candidates in the United States and abroad, our revenue will be more
limited and it will be more difficult to achieve profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to obtain and sustain coverage and an adequate level of
reimbursement for our product candidates by third-party payors, potential future sales would be materially adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
course of treatment for glaucoma patients primarily includes older drugs, and the leading products for the treatment of glaucoma currently in the market, including <I>latanoprost</I> and <I>timolol</I>, are available as generic brands. There will be
no commercially viable market for our product candidates without coverage and adequate reimbursement from third-party payors, and any coverage and reimbursement policy may be affected by future healthcare reform measures. We cannot be certain that
coverage and adequate reimbursement will be available for our product candidates or any other future product candidates we develop. Additionally, even if there is a commercially viable market, if the level of reimbursement is below our expectations,
our anticipated revenue and gross margins will be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party payors, such as government or private healthcare
insurers, carefully review and increasingly question and challenge the coverage of and the prices charged for drugs. Reimbursement rates from private health insurance companies vary depending on the company, the insurance plan and other factors.
Reimbursement rates may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. A current trend in the U.S. healthcare industry is toward cost containment. Large public and
private payors, managed care organizations, group purchasing organizations and other similar organizations are exerting increasing influence on decisions regarding the use of, and reimbursement levels for, particular treatments. Such third-party
payors, including Medicare, may question the coverage of, and challenge the prices charged for, medical products and services, and many third-party payors limit coverage of or reimbursement for newly approved healthcare products. In particular,
third-party payors may limit the covered indications. Cost-control initiatives could decrease the price we might establish for our product candidates, which could result in product revenues being lower than anticipated. We believe our drugs will be
priced significantly higher than existing generic drugs and consistently with current branded drugs. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party
payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products. If
we are unable to show a significant benefit relative to existing generic drugs, Medicare, Medicaid and private payors may not be willing to cover or provide adequate reimbursement for our drugs, which would significantly reduce the likelihood of
them gaining market acceptance. In the United States, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly
from payor to payor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that private insurers will consider the efficacy, cost effectiveness, safety and
tolerability of our product candidates in determining whether to approve coverage and set reimbursement levels for such products. Obtaining these approvals can be a time consuming and expensive process. Our business and prospects would be materially
adversely affected if we do not receive approval for coverage and reimbursement of our product candidates from private insurers on a timely or satisfactory basis. Limitations on coverage and reimbursement could also be imposed by government payors,
such as the local Medicare carriers, fiscal intermediaries, or Medicare Administrative Contractors. Further, Medicare Part D, which provides a pharmacy benefit to certain Medicare patients, does not require participating prescription drug plans to
cover all drugs within a class of products. Our business could be materially adversely affected if private or governmental payors, including Medicare Part D prescription drug plans were to limit access to, or deny or limit reimbursement of, our
product candidates or other potential products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reimbursement systems in international markets vary significantly by country and by
region, and reimbursement approvals must be obtained on a country-by-country basis. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. For example,
reimbursement in the European Union must be negotiated on a country-by-country basis and in many countries the product cannot be commercially launched until reimbursement is approved. The negotiation process in some countries can exceed 12 months.
To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our products to other available therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the prices for our product candidates decrease or if governmental and other third-party payors do not provide coverage and adequate
reimbursement levels, our revenue, potential for future cash flows and prospects for profitability will suffer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Governments outside
the United States tend to impose strict price controls, which may adversely affect our revenues, if any. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pricing of
prescription pharmaceuticals is also subject to governmental control outside of the United States. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a
product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidates to other available therapies. If reimbursement of our products is
unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we are found in violation of federal or state &#147;fraud and abuse&#148; laws or other healthcare laws, we may face penalties, which
may adversely affect our business, financial condition and results of operation. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, we are subject to various
federal and state healthcare &#147;fraud and abuse&#148; laws, including anti-kickback laws, false claims laws and other laws intended, among other things, to reduce fraud and abuse in federal and state healthcare programs. The Federal Anti-Kickback
Statute makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration that is intended to induce the referral of business,
including the purchase, lease, order or arranging for or recommending the purchase, lease or order of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as Medicare or
Medicaid. Although we seek to structure our business arrangements in compliance with all applicable requirements, these laws are broadly written, and it is often difficult to determine precisely how the law will be applied in specific circumstances.
Accordingly, it is possible that our practices may be challenged under the Federal Anti-Kickback Statute. The Federal False Claims Act prohibits anyone from, among other things, knowingly presenting or causing to be presented for payment to the
government, including the federal healthcare programs, claims for reimbursed drugs or services that are false or fraudulent. This statute has been interpreted to prohibit presenting claims for items or services that were not provided as claimed, or
claims for medically </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unnecessary items or services. Many states have similar false claims laws. Cases have been brought under false claims laws alleging that off-label promotion of pharmaceutical products or the
provision of kickbacks have resulted in the submission of false claims to governmental healthcare programs. In addition, private individuals have the ability to bring actions on behalf of the government under the Federal False Claims Act as well as
under the false claims laws of several states. Under the Health Insurance Portability and Accountability Act of 1996, or HIPAA, we are prohibited from, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit
program, including private payors, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare
benefits, items or services to obtain money or property of any healthcare benefit program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly, the civil monetary penalties
statute imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not
provided as claimed or is false or fraudulent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the federal Physician Payments Sunshine Act within the Patient Protection
and Affordable Care Act, as amended by the Health Care Education and Reconciliation Act, or collectively the ACA, and its implementing regulations, require that certain manufacturers of drugs, devices, biologics and medical supplies to report
annually information related to certain payments or other transfers of value provided to physicians and teaching hospitals, and certain ownership and investment interests held by physicians and their immediate family members. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many states have adopted laws similar to the aforementioned laws, some of which apply to the referral of patients for healthcare services
reimbursed by any source, not just governmental payors. In addition, some states have passed laws that require pharmaceutical companies to comply with the April 2003 U.S. Department of Health and Human Services Office of Inspector General Compliance
Program Guidance for Pharmaceutical Manufacturers and/or the Pharmaceutical Research and Manufacturers of America&#146;s Code on Interactions with Healthcare Professionals. Several states also impose other marketing restrictions or require
pharmaceutical companies to make marketing or price disclosures to the state. There are ambiguities as to what is required to comply with these state requirements and if we fail to comply with an applicable state law requirement we could be subject
to penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may be subject to data privacy and security regulation by both the federal government and the states in
which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their respective implementing regulations, including the final omnibus rule published on January&nbsp;25,
2013, imposes specified requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#146;s privacy and security standards directly applicable to business
associates, defined as independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also created
four new tiers of civil monetary penalties and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs associated with
pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating
compliance efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Law enforcement authorities are increasingly focused on enforcing these laws, and it is possible that some of our
practices may be challenged under these laws. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that the government could
allege violations of, or convict us of violating, these laws. If we are found in violation of one of these laws, we could be subject to significant civil, criminal and administrative penalties, damages,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fines, disgorgement, individual imprisonment, exclusion from governmental funded federal or state healthcare programs, contractual damages, reputational harm, diminished profits and future
earnings, and the curtailment or restructuring of our operations. Were this to occur, our business, financial condition and results of operations and cash flows may be materially adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Recently enacted and future legislation may increase the difficulty and cost of commercializing our product candidates and may affect
the prices we may obtain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and some foreign jurisdictions, there have been a number of legislative and
regulatory changes and proposed changes regarding the healthcare system that could prevent or delay regulatory approval of our product candidates, restrict or regulate post-marketing activities and affect our ability to profitably sell our product
candidates for which we obtain regulatory approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2010, President Obama signed into law the ACA, a sweeping law intended to
broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against healthcare fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and
fees on the health industry and impose additional health policy reforms. The ACA increased manufacturers&#146; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate amount for both branded and generic drugs and
revised the definition of average manufacturer price, or AMP, which may also increase the amount of Medicaid drug rebates manufacturers are required to pay to states. The legislation also expanded Medicaid drug rebates, which previously had been
payable only on fee-for-service utilization, to Medicaid managed care utilization, and created an alternative rebate formula for certain new formulations of certain existing products that is intended to increase the rebates due on those drugs.
Further, the ACA imposed a significant annual fee on companies that manufacture or import branded prescription drug products and requires manufacturers to provide a 50% discount off the negotiated price of branded drugs dispensed to beneficiaries in
the Medicare Part D coverage gap, referred to as the &#147;donut hole.&#148; Substantial new provisions affecting compliance have also been enacted, including the Physician Payments Sunshine Act, as described above. Although it is too early to
determine the full effect of the ACA, the new law appears likely to continue the downward pressure on pharmaceutical pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control
Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021,
was unable to reach the required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2%&nbsp;per fiscal year, which went into
effect in April 2013 and will remain in effect through 2024 unless additional Congressional action is taken. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced
Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Any
reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legislative and regulatory proposals have been introduced at both the state and federal level to expand post-approval requirements and
restrict sales and promotional activities for pharmaceutical products. We are not sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such
changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#146;s approval process may significantly delay or prevent marketing approval, as well as subject us to
more stringent product labeling and post-marketing approval testing and other requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been, and likely will continue to be, legislative and regulatory proposals at the
foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict whether future healthcare initiatives will be implemented at the federal or state level or
in countries outside of the United States in which we may do business in the future, or the effect any future legislation or regulation will have on us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we face allegations of noncompliance with the law and encounter sanctions, our reputation, revenues and liquidity may suffer, and our
products could be subject to restrictions or withdrawal from the market. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any government investigation of alleged violations of law
could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate
revenues from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected. Additionally, if we are unable to generate revenues from our
product sales, our potential for achieving profitability will be diminished and the capital necessary to fund our operations will be increased. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to identify additional therapeutic opportunities for our product candidates or to expand our portfolio of products.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may explore other therapeutic opportunities with <I>trabodenoson</I> and seek to commercialize a portfolio of new ophthalmic
drugs in addition to our product candidates that we are currently developing. We have no potential products in our research and development pipeline other than those potential products that are formulations of <I>trabodenoson</I> or that apply
<I>trabodenoson</I> for the treatment of glaucoma, other neuropathies and degenerative retinal diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research programs to pursue the
development of our product candidates for additional indications and to identify new potential products and disease targets require substantial technical, financial and human resources whether or not we ultimately are successful. Our research
programs may initially show promise in identifying potential indications and/or potential products, yet fail to yield results for clinical development for a number of reasons, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the research methodology used may not be successful in identifying potential indications and/or potential products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product candidates may, after further study, be shown to have harmful adverse effects or other characteristics that indicate they are unlikely to be effective drugs; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">it may take greater human and financial resources to identify additional therapeutic opportunities for our product candidates or to develop suitable potential products through internal research programs and clinical
trials than we will possess, thereby limiting our ability to diversify and expand our product portfolio. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we have
limited financial and managerial resources, we focus on research programs and product candidates for specific indications. As a result, we may forego or delay pursuit of opportunities with other potential products or for other indications that later
prove to have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, there can be no assurance that we will ever be able to identify additional therapeutic opportunities for our product candidates
or to develop suitable potential products through internal research programs, which could materially adversely affect our future growth and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Reliance on Third Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We currently depend on third parties to conduct some of the operations of our clinical trials and other portions of our operations, and
we may not be able to control their work as effectively as if we performed these functions ourselves. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on third parties,
such as contract research organizations, or CROs, clinical data management organizations, medical institutions and clinical investigators, to oversee and conduct our clinical trials, and to perform data collection and analysis of our product
candidates. We expect to rely on these third parties to conduct clinical trials of any other potential products that we develop. These parties are not our employees and we cannot control the amount or timing of resources that they devote to our
program. In addition, any CRO that we retain will be subject to the FDA&#146;s regulatory requirements or similar foreign standards and we do not have control over compliance with these regulations by these providers. Our agreements with third-party
service providers are on trial-by-trial and project-by-project bases. Typically, we may terminate the agreements with notice and occasionally the third party service provider may terminate the agreement without notice. Typically, we are responsible
for the third party&#146;s incurred costs and occasionally we have to pay cancellation fees. If any of our relationships with our third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on
commercially reasonable terms. We also rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or regulatory approval of our
product candidates or commercialization of our product candidates, producing additional losses and depriving us of potential product revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our reliance on these third parties for clinical development activities reduces our control over these activities but does not relieve us of
our responsibilities, and we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan, the protocols for the trial and the FDA&#146;s regulations and international standards,
referred to as Good Clinical Practice, or GCP, requirements, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality
of trial participants are protected. Preclinical studies must also be conducted in compliance with other requirements, such as Good Laboratory Practice, or GLP, and the Animal Welfare Act. Managing performance of third-party service providers can be
difficult, time consuming and cause delays in our development programs. We currently have a small number of employees, which limits the internal resources we have available to identify and monitor our third-party providers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, these third parties may conduct clinical trials for competing drugs or may have relationships with other entities, some of which
may be our competitors. As such, the ability of these third parties to provide services to us may be limited by their work with these other entities. The use of third-party service providers requires us to disclose our proprietary information to
these parties, which could increase the risk that this information will be misappropriated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If these third parties do not successfully
carry out their contractual duties or obligations and meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols according
to regulatory requirements or for other reasons, our financial results and the commercial prospects for our current product candidates or our other potential products could be harmed, our costs could increase and our ability to obtain regulatory
approval and commence product sales could be delayed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We have no manufacturing capacity or experience and anticipate continued
reliance on third-party manufacturers for the development and commercialization of our product candidates in accordance with manufacturing regulations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently, nor currently intend to, operate manufacturing facilities for clinical or commercial production of our product candidates.
We have no experience in drug formulation, and we lack the resources and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the capabilities to manufacture our product candidates and potential products on a clinical or commercial scale. We do not intend to develop facilities for the manufacture of product candidates
for clinical trials or commercial purposes in the foreseeable future. We currently rely on third-party manufacturers to produce the active pharmaceutical ingredient and final drug product for our clinical trials. We manage such production with all
our vendors on a purchase order basis in accordance with applicable master service and supply agreements. We do not have long-term agreements with any of these or any other third-party suppliers. To the extent we terminate our existing supplier
arrangements in the future and seek to enter into arrangements with alternative suppliers, we might experience a delay in our ability to obtain adequate supply for our clinical trials and commercialization. We also do not have any current
contractual relationships for the manufacture of commercial supplies of any of our product candidates if and when they are approved. Our third-party manufacturers have made only a limited number of lots of our product candidates to date and have not
made any commercial lots. The manufacturing processes for our product candidates have never been tested at commercial scale, and the process validation requirement has not yet been satisfied for any product candidate. These manufacturing processes
and the facilities of our third-party manufacturers will be subject to inspection and approval by the FDA before we can commence the manufacture and sale of our product candidates, and thereafter on an ongoing basis. Some of our third-party
manufacturers have never been inspected by the FDA and have not been through the FDA approval process for a commercial product. Some of our third-party manufacturers are subject to FDA inspection from time to time. Failure by these third-party
manufacturers to pass such inspections and otherwise satisfactorily complete the FDA approval regimen with respect to our product candidates may result in regulatory actions such as the issuance of FDA Form 483 inspectional observations, warning
letters or injunctions or the loss of operating licenses. Based on the severity of the regulatory action, our clinical or commercial supply of our product candidates could be interrupted or limited, which could have a material adverse effect on our
business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to commercial production of our product candidates in the future, we plan on outsourcing production of the active
pharmaceutical ingredients and final product manufacturing if and when approved for marketing by the applicable regulatory authorities. This process is difficult and time consuming and we can give no assurance that we will enter commercial supply
agreements with any contract manufacturers on favorable terms or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reliance on third-party manufacturers entails risks, including:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manufacturing delays if our third-party manufacturers give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of their
agreements with us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possible breach of the manufacturing agreement by the third party; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product loss due to contamination, equipment failure or improper installation or operation of equipment or operator error; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the failure of the third-party manufacturer to comply with applicable regulatory requirements; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possible misappropriation of our proprietary information, including our trade secrets and know-how. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our manufacturers may not perform as agreed or may not remain in the contract manufacturing business. In the event of a natural disaster,
business failure, strike or other difficulty, we may be unable to replace a third-party manufacturer in a timely manner and the production of our product candidates and potential products could be interrupted, resulting in delays and additional
costs. We may also have to incur other charges and expenses for products that fail to meet specifications and undertake remediation efforts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If third-party manufacturers fail to comply with manufacturing regulations, our financial results and financial condition will be
adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before a third party can begin the commercial manufacturing of our product candidates and potential products,
their manufacturing facilities, processes and quality systems must be in compliance with applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulations. Due to the complexity of the processes used to manufacture pharmaceutical products and product candidates, any potential third-party manufacturer may be unable to initially pass
federal, state or international regulatory inspections in a cost effective manner. If contract manufacturers fail to pass such inspection, our commercial supply of drug substance will be significantly delayed and may result in significant additional
costs. In addition, pharmaceutical manufacturing facilities are continuously subject to inspection by the FDA and comparable non-U.S. regulatory authorities, before and after product approval, and must comply with cGMP. Our contract manufacturers
may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel. In addition, contract manufacturers&#146; failure to achieve and maintain high manufacturing standards in accordance
with applicable regulatory requirements, or the incidence of manufacturing errors, could result in patient injury, product liability claims, product shortages, product recalls or withdrawals, delays or failures in product testing or delivery, cost
overruns or other problems that could seriously harm our business. If a third-party manufacturer with whom we contract is unable to comply with manufacturing regulations, we may also be subject to fines, unanticipated compliance expenses, recall or
seizure of our products, product liability claims, total or partial suspension of production and/or enforcement actions, including injunctions, and criminal or civil prosecution. These possible sanctions could materially adversely affect our
financial results and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, changes in the manufacturing process or procedure, including a change in the
location where the product is manufactured or a change of a third-party manufacturer, will require prior FDA review and/or approval of the manufacturing process and procedures in accordance with the FDA&#146;s regulations, or comparable foreign
requirements. This review may be costly and time consuming and could delay or prevent us from conducting our clinical trials or launching a product. The new facility will also be subject to pre-approval inspection. In addition, we have to
demonstrate that the product made at the new facility is equivalent to the product made at the former facility by physical and chemical methods, which are costly and time consuming. It is also possible that the FDA may require clinical testing as a
way to prove equivalency, which would result in additional costs and delay. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Any collaboration arrangement that we may enter into in
the future may not be successful, which could adversely affect our ability to develop and commercialize our current and future product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to seek collaboration arrangements with pharmaceutical or biotechnology companies for the development or commercialization of our
current and future product candidates outside of the United States. We will face, to the extent that we decide to enter into collaboration agreements, significant competition in seeking appropriate collaborators. Moreover, collaboration arrangements
are complex and time consuming to negotiate, document and implement. We may not be successful in our efforts to establish and implement collaborations or other alternative arrangements should we choose to enter into such arrangements, and the terms
of the arrangements may not be favorable to us. If and when we collaborate with a third party for development and commercialization of a product candidate, we can expect to relinquish some or all of the control over the future success of that
product candidate to the third party. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources
that they will apply to these collaborations. To the extent such collaborators have programs that are competitive with our product candidates, they may decide to focus time and resources on development of those programs rather than our product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can
lead to delays in the development process or commercializing the applicable product candidate and, in some cases, termination of the collaboration arrangement. These disagreements can be difficult to resolve if neither of the parties has final
decision making authority. Collaborations with pharmaceutical or biotechnology companies and other third parties often are terminated or allowed to expire by the other party. Any such termination or expiration would adversely affect us financially
and could harm our business reputation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we are not able to establish collaborations, we may have to alter our development and
commercialization plans. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development and potential commercialization of our product candidates will require substantial
additional cash to fund expenses. For some of our product candidates, we may decide to collaborate with pharmaceutical and biotechnology companies for the development and potential commercialization of those product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for collaboration will depend,
among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s evaluation of a number of factors. Those factors may include the
design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and
delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of
the challenge, and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such collaboration could be
more attractive than the one with us for our product candidates. We may also be restricted under future license agreements from entering into agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to
negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the
development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our
expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital,
which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to
further develop our product candidates or bring them to market and generate product revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our proprietary technology in the marketplace. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We depend on our ability to protect our proprietary technology. We rely largely on trade secret and patent laws, and confidentiality, licensing
and other agreements with employees and third parties, all of which offer only limited protection. Our success depends in large part on our ability and any future licensee&#146;s ability to obtain and maintain patent protection in the United States
and other countries with respect to our proprietary technology and products. We believe we will continue to be able to obtain, through prosecution of our current pending patent applications, adequate patent protection for our proprietary drug
technology. If we are compelled to spend significant time and money protecting or enforcing our patents or patent applications, designing around patents held by others or licensing or acquiring, potentially for large fees, patents or other
proprietary rights held by others, our business and financial prospects may be harmed. If we are unable to effectively protect the intellectual property that we own, other companies may be able to offer the same or similar products for sale, which
could materially adversely affect our competitive business position and harm our business prospects. Our patents may be challenged, narrowed, invalidated, or circumvented, which could limit our ability to stop competitors from marketing the same or
similar products or limit the length of term of patent protection that we may have for our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent positions of
pharmaceutical products are often complex and uncertain. The breadth of claims allowed in pharmaceutical patents in the United States and many jurisdictions outside of the United States is not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consistent. For example, in many jurisdictions the support standards for pharmaceutical patents are becoming increasingly strict. Some countries prohibit method of treatment claims in patents.
Changes in either the patent laws or interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property or create uncertainty. In addition, publication of information related to our current
product candidates and potential products may prevent us from obtaining or enforcing patents relating to these product candidates and potential products, including, without limitation, composition-of-matter patents, which are generally believed to
offer the strongest patent protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our intellectual property consists of issued patents and pending patent applications related to
our product candidates and other proprietary technology which cover compositions of matter, methods of use, combinations with other glaucoma products, formulations, polymorphs and the protection of the optic nerve. For <I>trabodenoson</I>, the
composition patents are scheduled to expire in 2025 and 2026, in Europe and the United States, respectively. See &#147;Business&#151;Intellectual Property&#148; included elsewhere in this annual report on Form 10-K for further information about our
issued patents and patent applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents that we own or may license in the future do not necessarily ensure the protection of our
product candidates for a number of reasons, including without limitation the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not have been the first to make the inventions covered by our patents or pending patent applications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not have been the first to file patent applications for these inventions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any patents issued to us may not cover our products as ultimately developed; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our pending patent applications may not result in issued patents, and even if they issue as patents, they may not provide us with any competitive advantages, or may be challenged and invalidated by third parties;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our patents may not be broad or strong enough to prevent competition from other products that are identical or similar to our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">there can be no assurance that the term of a patent can be extended under the provisions of patent term extension afforded by U.S. law or similar provisions in foreign countries, where available; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our patents, and patents that we may obtain in the future, may not prevent generic entry into the U.S. market for our <I>trabodenoson</I> and other product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to disclaim part of the term of one or more patents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">there may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">there may be patents issued to third parties that will affect our freedom to operate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if our patents are challenged, a court could determine that they are invalid or unenforceable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">there might be significant changes in the laws that govern patentability, validity and infringement of our patents that adversely affects the scope of our patent rights; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a court could determine that a competitor&#146;s technology or product does not infringe our patents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our patents could irretrievably lapse due to failure to pay fees or otherwise comply with regulations or could be subject to compulsory licensing; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may fail to obtain patents covering important products and technologies in a timely fashion or at all. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, on September&nbsp;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act
includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
United States Patent Office is currently developing regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with
the Leahy-Smith Act have not yet become effective. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act, in particular the first-to-file provision, and its
implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial
condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we encounter delays in our development or clinical trials, the period of time during which we could market our product
candidates under patent protection would be reduced. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our competitors may seek to invalidate our patents. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our competitors may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner.
Our competitors may seek to market generic versions of any approved products by submitting Abbreviated New Drug Applications, or ANDAs, to the FDA in which our competitors claim that our patents are invalid, unenforceable and/or not infringed.
Alternatively, our competitors may seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend and/or assert our patents, including by filing lawsuits alleging
patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find our patents invalid and/or unenforceable. We may also fail to identify patentable aspects of our research and development before it is too
late to obtain patent protection. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance of a patent is not conclusive as to its inventorship, scope, ownership, priority, validity or enforceability. In that regard,
third parties may challenge our patents in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable,
in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. In addition, given
the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>A significant portion of our intellectual property portfolio currently includes pending patent applications that have not yet issued as
patents. If our pending patent applications fail to issue our business will be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success will
depend significantly on maintaining and expanding patent protection for our product candidates, as well as successfully defending our current and future patents against third-party challenges. As of December&nbsp;31, 2014, we own at least 50 issued
patents and have at least 40 pending patent applications in the United States and a number of foreign jurisdictions relating to our current product candidates and proprietary technology. See &#147;Business&#151;Intellectual Property&#148; included
elsewhere in this annual report on Form 10-K for further information about our issued patents and patent applications. Our intellectual property consists of patents and pending patent applications related to our product candidates and other
proprietary technology which cover compositions of matter, methods of use, combinations with other glaucoma products, formulations, polymorphs and the protection of the optic nerve. For <I>trabodenoson</I>, the composition of matter patents are
scheduled to expire in 2025 and 2026, in Europe and the United States, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that our patent
applications will issue as patents in the United States or foreign jurisdictions in which such applications are pending. Even if patents do issue on any of these applications, there can be no assurance that a third party will not challenge their
validity or that we will obtain sufficient claim scope in those patents to prevent a third party from competing successfully with our products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to enforce our intellectual property rights throughout the world.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United
States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the
enforcement of patents and other intellectual property protection, especially those relating to life sciences. To the extent we are able to obtain patents or other intellectual property rights in any foreign jurisdictions, it may be difficult for us
to prevent infringement of our patents or misappropriation of these intellectual property rights. For example, some foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many
countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from
other aspects of our business. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition, changes in the law and legal decisions by courts in the United States and foreign countries may
affect our ability to obtain adequate protection for our technology and the enforcement of intellectual property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and
maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for
non-compliance with these requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The United States Patent and Trademark Office, or the USPTO, and various foreign
governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or
patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In this event, competitors might be able to enter the market earlier than would otherwise have been the case. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us from
commercializing or increase the costs of commercializing our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends significantly on our ability
to operate without infringing the patents and other intellectual property rights of third parties. For example, there could be issued patents of which we are not aware that our product candidates or potential products infringe. There also could be
patents that we believe we do not infringe, but that we may ultimately be found to infringe. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, patent applications are in some
cases maintained in secrecy until patents are accepted or issued. The publication of discoveries in the scientific or patent literature frequently occurs substantially later than the date on which the underlying discoveries were made and patent
applications were filed. Because patents can take many years to issue, there may be currently pending applications of which we are unaware that may later result in issued patents that our product candidates or potential products infringe. For
example, pending applications may exist that claim or can be amended to claim subject matter that our product candidates or potential products infringe. Competitors may file continuing patent applications claiming priority to already issued patents
in the form of continuation, divisional, or continuation-in-part applications, in order to maintain the pendency of a patent family and attempt to cover our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may assert that we are employing their proprietary technology without authorization and may sue us for patent or other
intellectual property infringement. These lawsuits are costly and could adversely affect our results of operations and divert the attention of managerial and scientific personnel. If we are sued for patent infringement, we would need to demonstrate
that our product candidates, potential products or methods either do not infringe the claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not be able to do this. Proving invalidity or unenforceability is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome
the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these
proceedings, which could have a material adverse effect on us. In addition, we may not have sufficient resources to bring these actions to a successful conclusion. If a court holds that any third-party patents are valid, enforceable and cover our
products or their use, the holders of any of these patents may be able to block our ability to commercialize our products unless we acquire or obtain a license under the applicable patents or until the patents expire. We may not be able to enter
into licensing arrangements or make other arrangements at a reasonable cost or on reasonable terms. Any inability to secure licenses or alternative technology could result in delays in the introduction of our products or lead to prohibition of the
manufacture or sale of products by us. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease
commercializing the infringing technology or product. In addition, in any such proceeding or litigation, we could be found liable for monetary damages, including treble damages and attorneys&#146; fees if we are found to have willfully infringed a
patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Any claims by third parties that we have misappropriated
their confidential information or trade secrets could have a similar negative impact on our business. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability
to raise the funds necessary to continue our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may face claims of infringement, misappropriation or other violations
of the rights of third-party intellectual property holders. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pharmaceutical companies, biotechnology companies and academic
institutions may compete with us in the commercialization of <I>trabodenoson</I> for use in ophthalmic indications and filing patent applications potentially relevant to our business. In order to contend with the strong possibility of third-party
intellectual property conflicts, we periodically conduct freedom-to-operate studies, but such studies may not uncover all patents relevant to our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we find it necessary or prudent to obtain licenses from third-party intellectual property holders. Where licenses are
readily available at reasonable cost, such licenses are considered a normal cost of doing business. In other instances, however, we may use the results of freedom-to-operate studies to guide our early-stage research away from areas where we are
likely to encounter obstacles in the form of third-party intellectual property. For example, where a third party holds relevant intellectual property and is a direct competitor, a license might not be available on commercially reasonable terms or
available at all. We strive to identify potential third-party intellectual property issues in the early stages of research of our research programs, in order to minimize the cost and disruption of resolving such issues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In spite of these efforts to avoid obstacles and disruptions arising from third-party intellectual property, it is impossible to establish
with certainty that our products will be free of claims that we infringe, misappropriate or otherwise violate the rights of third-party intellectual property holders. Even with modern databases and online search engines, freedom-to-operate searches
are imperfect and may fail to identify relevant patents and published applications. Even when a third-party patent is identified, we may conclude that we do not infringe the patent or that the patent is invalid. If the third-party patent owner
disagrees with our conclusion and we continue with the business activity in question, patent litigation may result. We might decide to initiate litigation in an attempt to have a court declare the third-party patent invalid or non-infringed by our
activity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that we or our employees have misappropriated the intellectual property, including trade
secrets, of a third party, or claiming ownership of what we regard as our own intellectual property. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our employees were
previously employed at universities, biotechnology companies or other pharmaceutical companies, including our competitors or potential competitors. Some of these employees, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including each member of our senior management, executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure
that our employees do not use the intellectual property and other proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed such intellectual property, including
trade secrets or other proprietary information. Litigation may be necessary to defend against these claims. We are not aware of any threatened or pending claims related to these matters or concerning the agreements with our senior management, but
litigation may be necessary in the future to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in
defending against such claims, litigation could result in substantial costs and be a distraction to management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, while we
typically require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with
each party who in fact develops intellectual property that we regard as our own, which may result in claims by or against us related to the ownership of such intellectual property. If we fail in prosecuting or defending any such claims, in addition
to paying monetary damages, we may lose valuable intellectual property rights. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and
scientific personnel. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to adequately prevent disclosure of trade secrets and other proprietary information.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on trade secrets to protect our proprietary know-how and technological advances, especially where we have not filed a
patent application or where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific
collaborators, sponsored researchers and other advisors to protect our trade secrets and other proprietary information. However, any party with whom we have executed such an agreement may breach that agreement and disclose our proprietary
information, including our trade secrets. Accordingly, these agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information.
Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights. In addition, others may independently discover our trade secrets and proprietary information. Further, the FDA, as part of its
Transparency Initiative, a proposal by the FDA to increase disclosure and make data more accessible to the public, is currently considering whether to make additional information publicly available on a routine basis, including information that we
may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#146;s disclosure policies may change in the future, if at all. Failure to obtain or maintain trade secret protection could enable
competitors to use our proprietary information to develop products that compete with our products or cause additional, material adverse effects upon our competitive business position and financial results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Detecting the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a
trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be
lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be
disclosed to or independently developed by a competitor, our competitive position would be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Any lawsuits relating to
infringement of intellectual property rights brought by or against us will be costly and time consuming and may adversely impact the price of our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be required to initiate litigation to enforce or defend our intellectual property. These lawsuits can be very time consuming and costly.
There is a substantial amount of litigation involving patent and other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
intellectual property rights in the pharmaceutical industry generally. Such litigation or proceedings could substantially increase our operating expenses and reduce the resources available for
development activities or any future sales, marketing or distribution activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In any infringement litigation, any award of monetary
damages we receive may not be commercially valuable. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be
compromised by disclosure during litigation. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are resolved. Further,
any claims we assert against a perceived infringer could provoke these parties to assert counterclaims against us alleging that we have infringed their patents. Some of our competitors may be able to sustain the costs of such litigation or
proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to
compete in the marketplace. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our patents and patent applications could face other challenges, such as interference
proceedings, opposition proceedings, re-examination proceedings, and other forms of post-grant review. In the United States, for example, post-grant review has recently been expanded. Any of these challenges, if successful, could result in the
invalidation of, or in a narrowing of the scope of, any of our patents and patent applications subject to challenge. Any of these challenges, regardless of their success, would likely be time consuming and expensive to defend and resolve and would
divert our management and scientific personnel&#146;s time and attention. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there could be public announcements of the results
of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the market price of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We will need to obtain FDA approval of any proposed product names, and any failure or delay associated with such approval may adversely
affect our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any name we intend to use for our product candidates will require approval from the FDA regardless of whether
we have secured a formal trademark registration from the USPTO. The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. The FDA may also object to a product name
if it believes the name inappropriately implies certain medical claims or contributes to an overstatement of efficacy. If the FDA objects to any of our proposed product names, we may be required to adopt an alternative name for our product
candidates. If we adopt an alternative name, we would lose the benefit of our existing trademark applications for such product candidate and may be required to expend significant additional resources in an effort to identify a suitable product name
that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. We may be unable to build a successful brand identity for a new trademark in a timely manner or at all, which would
limit our ability to commercialize our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we do not obtain additional protection under the Hatch-Waxman
Amendments and similar foreign legislation extending the terms of our patents and obtaining data exclusivity for our product candidates, our business may be materially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of FDA regulatory approval for our product candidates, one or more of our U.S. patents may be
eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as
compensation for patent term lost during product development and the FDA regulatory review process. Patent term restorations, however, cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval by the
FDA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The application for patent term extension is subject to approval by the USPTO, in conjunction
with the FDA. It takes at least six months to obtain approval of the application for patent term extension. We may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to
expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension
or restoration or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain earlier approval of competing products, and
our ability to generate revenues could be materially adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business Operations and Industry </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We will need to significantly increase the size of our organization, and we may experience difficulties in managing growth. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently a small company with five employees as of March&nbsp;27, 2015, and we outsource to consultants or other organizations
substantially all of our operations, including accounting, finance, research and development and conduct of clinical trials. In order to commercialize our product candidates, we will need to substantially increase our operations. We plan to continue
to build our compliance, financial and operating infrastructure to ensure the maintenance of a well-managed company. We expect to significantly expand our employment base when we reach the full commercial stages of our current product
candidates&#146; life cycle. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future growth will impose significant added responsibilities on members of management, including the need to
identify, recruit, maintain and integrate additional employees. In addition, to meet our obligations as a public company, we will need to increase our general and administrative capabilities. Our management, personnel and systems currently in place
may not be adequate to support this future growth. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To
that end, we must be able to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manage our clinical trials and the regulatory process effectively; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manage the manufacturing of product candidates and potential products for clinical and commercial use; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">integrate current and additional management, administrative, financial and sales and marketing personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">develop a marketing and sales infrastructure; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">hire new personnel necessary to effectively commercialize our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">develop our administrative, accounting and management information systems and controls; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">hire and train additional qualified personnel. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Product candidates that we may acquire or
develop in the future may be intended for patient populations that are large. In order to continue development and marketing of these product candidates, if approved, we would need to significantly expand our operations. Our staff, financial
resources, systems, procedures or controls may be inadequate to support our operations and our management may be unable to manage successfully future market opportunities or our relationships with customers and other third parties. In particular, we
will need to build out our finance, accounting and reporting infrastructure to meet our reporting obligations as a public company. Because we have never had this infrastructure, there may be increased risk that we will not be able to adequately meet
these reporting obligations in a timely manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may in the future decide to move our primary office into a new facility
to address our business needs. This potential relocation could disrupt our operations, resulting in slower realization of efficiencies and capacity which could be associated with our use of a new office space. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are a clinical-stage company and it may be difficult for you to evaluate the success of
our business to date and to assess our future viability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company focused on the
discovery, development and commercialization of therapies for glaucoma. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, conducting research and developing our product candidates.
We have not yet demonstrated our ability to successfully complete a pivotal Phase 3 clinical trial, obtain regulatory approval of a product candidate, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or
conduct sales and marketing activities necessary for successful product commercialization. Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history and more
experience with late stage development and commercialization of product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as a new business, we may encounter
unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to transition from a company with a product development focus to a company capable of supporting commercial activities. We may not be
successful in such a transition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We depend upon our key personnel and our ability to attract and retain employees. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future growth and success depend on our ability to recruit, retain, manage and motivate our employees. We are highly dependent on our
senior management team and our scientific founders, as well as the other principal members of our management and scientific teams. Although we have formal employment agreements with our executive officers, these agreements do not prevent them from
terminating their employment with us at any time. The loss of the services of any member of our senior management or scientific team or the inability to hire or retain experienced management personnel could adversely affect our ability to execute
our business plan and harm our operating results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the specialized scientific and managerial nature of our business, we rely
heavily on our ability to attract and retain qualified scientific, technical and managerial personnel. In particular, the loss of David P. Southwell, our President and Chief Executive Officer, Rudolf A. Baumgartner, M.D., our Executive Vice
President and Chief Medical Officer, William K. McVicar, Ph.D., our Executive Vice President and Chief Scientific Officer or Dale Ritter, our Vice President&#151;Finance, could be detrimental to us if we cannot recruit suitable replacements in a
timely manner. We do not currently carry &#147;key person&#148; insurance on the lives of members of executive management. The competition for qualified personnel in the pharmaceutical field is intense. Due to this intense competition, we may be
unable to continue to attract and retain qualified personnel necessary for the development of our business or to recruit suitable replacement personnel. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to
assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that
may limit their availability to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the periodic reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Our
disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed,
summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission, or SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well
conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These
inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system,
misstatements due to error or fraud may occur and not be detected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we engage in acquisitions in the future, we will incur a
variety of costs and we may never realize the anticipated benefits of such acquisitions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may attempt to acquire businesses,
technologies, services, products or other product candidates in the future that we believe are a strategic fit with our business. We have no present agreement regarding any material acquisitions. However, if we do undertake any acquisitions, the
process of integrating an acquired business, technology, service, product candidates or potential products into our business may result in unforeseen operating difficulties and expenditures, including diversion of resources and management&#146;s
attention from our core business. In addition, we may fail to retain key executives and employees of the companies we acquire, which may reduce the value of the acquisition or give rise to additional integration costs. Future acquisitions could
result in additional issuances of equity securities that would dilute the ownership of existing stockholders. Future acquisitions could also result in the incurrence of debt, actual or contingent liabilities or the amortization of expenses related
to other intangible assets, any of which could adversely affect our operating results. In addition, we may fail to realize the anticipated benefits of any acquisition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our business is affected by macroeconomic conditions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Various macroeconomic factors could adversely affect our business and the results of our operations and financial condition, including changes
in inflation, interest rates and foreign currency exchange rates and overall economic conditions and uncertainties, including those resulting from current and future conditions in the global financial markets. For instance, if inflation or other
factors were to significantly increase our business costs, it may not be feasible to pass through price increases to patients. Interest rates, the liquidity of the credit markets and the volatility of the capital markets could also affect the value
of our investments and our ability to liquidate our investments in order to fund our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest rates and the ability to access
credit markets could also adversely affect the ability of patients, payors and distributors to purchase, pay for and effectively distribute our products. Similarly, these macroeconomic factors could affect the ability of our potential future
contract manufacturers, sole-source or single-source suppliers or licensees to remain in business or otherwise manufacture or supply product. Failure by any of them to remain in business could affect our ability to manufacture products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If product liability lawsuits are successfully brought against us, our insurance may be inadequate and we may incur substantial
liability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face an inherent risk of product liability claims as a result of the clinical testing of our product candidates. We
will face an even greater risk if we commercially sell our product candidates or any other potential products that we develop. We maintain product liability insurance with an aggregate limit of $10 million that cover our clinical trials and we plan
to maintain insurance against product liability lawsuits for commercial sale of our product candidates. Historically, the potential liability associated with product liability lawsuits for pharmaceutical products has been unpredictable. Although we
believe that our current insurance is a reasonable estimate of our potential liability and represents a commercially reasonable balancing of the level of coverage as compared to the cost of the insurance, we may be subject to claims in connection
with our clinical trials and, in the future, commercial use of our product candidates, for which our insurance coverage may not be adequate, and the cost of any product liability litigation or other proceeding, even if resolved in our favor, could
be substantial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable
during clinical testing, manufacturing, marketing or sale. Any such product liability claims may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Large judgments
have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may
incur substantial liabilities or be required to limit commercialization of our product candidates. Regardless of the merits or eventual outcome, liability claims may result in: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced resources of our management to pursue our business strategy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">decreased demand for our product candidates or potential products that we may develop; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injury to our reputation and significant negative media attention; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawal of clinical trial participants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">termination of clinical trial sites or entire trial programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">initiation of investigations by regulators; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product recalls, withdrawals or labeling, marketing or promotional restrictions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">significant costs to defend resulting litigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">diversion of management and scientific resources from our business operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">substantial monetary awards to trial participants or patients; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">loss of revenue; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to commercialize any products that we may develop. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will need to increase our
insurance coverage if our product candidates receive marketing approval and we begin selling them. However, the product liability insurance we will need to obtain in connection with the commercial sales of our product candidates, if and when they
receive regulatory approval, may be unavailable in meaningful amounts or at a reasonable cost. In addition, insurance coverage is becoming increasingly expensive. If we are unable to obtain or maintain sufficient insurance coverage at an acceptable
cost or to otherwise protect against product liability claims, it could prevent or inhibit the development and commercial production and sale of our product candidates, if and when they obtain regulatory approval, which could materially adversely
affect our business, financial condition, results of operations, cash flows and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we do not carry insurance for
all categories of risk that our business may encounter. Some of the policies we currently maintain include general liability, employment practices liability, auto, property, workers&#146; compensation, products liability and directors&#146; and
officers&#146; insurance. We do not know, however, if we will be able to maintain insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would materially adversely affect our
financial position, cash flows and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Business interruptions could delay us in the process of developing our
products and could disrupt our sales. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our headquarters is located in Lexington, Massachusetts. We are vulnerable to natural
disasters, such as severe storms and other events that could disrupt our business operations. We do not carry insurance for natural disasters and we may not carry sufficient business interruption insurance to compensate us for losses that may occur.
Any losses or damages we incur could have a material adverse effect on our business operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our business and operations would
suffer in the event of system failures. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures, our internal computer systems, and those
of our CROs and other third parties on which we rely, are vulnerable to damage from computer viruses, unauthorized access, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
natural disasters, terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption
of our drug development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or
reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the
further development of our product candidates could be delayed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent contractors, principal investigators,
consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading, which could significantly harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of fraud or other misconduct by employees and independent contractors, such as principal investigators, consultants,
commercial partners and vendors. Misconduct by these parties could include failures to comply with the regulations of the FDA and comparable non-U.S. regulatory authorities, provide accurate information to the FDA and comparable non-U.S. regulatory
authorities, comply with fraud and abuse and other healthcare laws in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and other business
arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws may restrict or prohibit a wide range of business activities, including, but
not limited to, research, manufacturing, distribution, pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct could also involve the improper use of information
obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We adopted a code of ethics, but it is not always possible to identify and deter employee and other third-party misconduct, and
the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply
with these laws. If any such actions are instituted against us resulting from such misconduct those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties,
damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring
of our operations, any of which could adversely affect our ability to operate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We and our development partners, third-party
manufacturers and suppliers use biological materials and may use hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our development partners, third-party manufacturers and suppliers may use hazardous materials, including chemicals and biological agents
and compounds that could be dangerous to human health and safety or the environment. Our operations and the operations of our third-party manufacturers and suppliers also produce hazardous waste products. Federal, state and local laws and
regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be expensive and current or future environmental laws and
regulations may impair our product development efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste insurance
coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or
injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The availability of our common stock and securities linked to our common stock for sale in
the future could reduce the market price of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, we may issue equity and equity-linked securities to
raise cash for acquisitions or otherwise. We may also acquire interests in other companies by using a combination of cash and our common stock or just our common stock. We also will issue common stock upon conversions of the 2020 Notes and have the
option to settle any interest make-whole payment applicable to conversion of the 2020 Notes in whole or in part in shares of our common stock. We may also issue preferred stock or additional securities convertible into our common stock or preferred
stock. Any of these events may dilute your ownership interest in our Company and have an adverse effect on the price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks
Related to Ownership of Our Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The market price of our common stock has been and may continue to be highly volatile
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on NASDAQ. Since shares of our common stock were sold in our initial public offering in February 2015
at $6.00 per share, our closing stock price has reached a high of $6.10 and a low of $5.60 through March&nbsp;27, 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading price
of our common stock is likely to continue to be volatile, and you can lose all or part of your investment in us. The following factors, in addition to other factors described in this &#147;Risk Factors&#148; section and elsewhere in this annual
report on Form 10-K, may have a significant impact on the market price of our common stock: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements of regulatory approval or a complete response letter, or specific label indications or patient populations for its use, or changes or delays in the regulatory review process; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements of therapeutic innovations or new products by us or our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adverse actions taken by regulatory agencies with respect to our clinical trials, manufacturing supply chain or sales and marketing activities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any adverse changes to our relationship with manufacturers or suppliers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results of our testing and clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results of our efforts to acquire or license additional product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">variations in the level of expenses related to our existing product candidates or preclinical and clinical development programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any intellectual property infringement actions in which we may become involved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements concerning our competitors or the pharmaceutical industry in general; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">achievement of expected product sales and profitability; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manufacture, supply or distribution shortages; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actual or anticipated fluctuations in our quarterly or annual operating results; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in financial estimates or recommendations by securities analysts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">trading volume of our common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales of our common stock by us, our executive officers and directors or our stockholders in the future; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales by us of securities linked to our common stock, such as the 2020 Notes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general economic and market conditions and overall fluctuations in the U.S. equity markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in accounting principles; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the loss of any of our key scientific or management personnel. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the stock market, in general, and small pharmaceutical and biotechnology companies
have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock,
regardless of our actual operating performance. Further, a significant decline in the financial markets and other related factors beyond our control may cause our stock price to decline rapidly and unexpectedly. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to securities litigation, which is expensive and could divert management attention. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our share price has been volatile, and in the past companies that have experienced volatility in the market price of their stock have been
subject to securities class action litigation. We may be the target of this type of litigation in the future. Litigation of this type could result in substantial costs and diversion of management&#146;s attention and resources, which could adversely
impact our business. Any adverse determination in litigation could also subject us to significant liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our existing
principal stockholders, executive officers and directors own a significant percentage of our common stock and will be able to exert a significant control over matters submitted to our stockholders for approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;30, 2015, our officers and directors, and stockholders who own more than 5% of our outstanding common stock in the aggregate
beneficially owned approximately 74% of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This significant concentration of share ownership may adversely affect the
trading price for our common stock because investors often perceive disadvantages in owning stock in companies with controlling stockholders. As a result, these stockholders, if they acted together, could significantly influence all matters
requiring approval by our stockholders, including the election of directors and the approval of mergers or other business combination transactions. These stockholders may be able to determine all matters requiring stockholder approval. The interests
of these stockholders may not always coincide with our interests or the interests of other stockholders. This may also prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest
as one of our stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for
our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Sales of a substantial number of shares of our common stock in the public market by our existing stockholders
could cause our stock price to fall. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of our common stock or any of our securities linked
to our common stock, such as the 2020 Notes, or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities or
equity-linked securities. Substantially all of our stockholders prior to our initial public offering are subject to lock-up agreements with the underwriters of our initial public offering that restrict the stockholders&#146; ability to transfer
shares of our common stock for a period of 180 days after February&nbsp;17, 2015. After our offering, and as of March&nbsp;30, 2015 we had 16,327,003&nbsp;outstanding shares of common stock and we have reserved 3.3&nbsp;million shares of our common
stock to be issued upon the conversion of the $21.0 million of 2020 Notes outstanding as of March 30, 2015. Subject to limitations, approximately 9.0&nbsp;million shares of common stock will become eligible for sale upon expiration of the lock-up
period. In addition, shares issued or issuable upon exercise of options and warrants vested as of the expiration of the lock-up period will be eligible for sale at that time. Sales of stock by these stockholders could have a material adverse effect
on the trading price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of an aggregate of 8.6&nbsp;million shares of our common stock have rights, subject to
certain conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. Registration of these shares under the Securities
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Act of 1933, as amended, or the Securities Act, would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by our affiliates as
defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if
they adversely change their recommendations or publish negative reports regarding our business or our stock, our stock price and trading volume could decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts may publish about
us, our business, our market or our competitors. We do not have any control over these analysts and we cannot provide any assurance that analysts will cover us or provide favorable coverage. If any of the analysts who may cover us adversely change
their recommendation regarding our stock, or provide more favorable relative recommendations about our competitors, our stock price could decline. If any analyst who may cover us were to cease coverage of our company or fail to regularly publish
reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Because we do not intend to declare cash dividends on our shares of common stock in the foreseeable future, stockholders must rely on
appreciation of the value of our common stock for any return on their investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently anticipate that we will retain
future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends in the foreseeable future. In addition, the terms of any future debt agreements may preclude us from paying
dividends. As a result, we expect that only appreciation of the price of our common stock, if any, will provide a return to investors for the foreseeable future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to substantially utilize our net operating loss carryforward, our financial results will be adversely affected.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2014, we had net operating losses of approximately $77.1 million, which may be utilized against future
federal and state income taxes. In general, a corporation that undergoes an &#147;ownership change&#148; is subject to limitations on its ability to utilize its pre-change net operating losses, or NOLs, to offset future taxable income. In general,
an ownership change occurs if the aggregate stock ownership of certain stockholders (generally 5% stockholders, applying certain look-through and aggregation rules) increases by more than 50% over such stockholders&#146; lowest percentage ownership
during the testing period (generally three years). Purchases of our common stock in amounts greater than specified levels, which are beyond our control, could create a limitation on our ability to utilize our NOLs for tax purposes in the future.
Limitations imposed on our ability to utilize NOLs could cause U.S. federal and state income taxes to be paid earlier than would be paid if such limitations were not in effect and could cause such NOLs to expire unused, in each case reducing or
eliminating the benefit of such NOLs. Furthermore, we may not be able to generate sufficient taxable income to utilize our NOLs before they expire. If any of these events occur, we may not derive some or all of the expected benefits from our NOLs.
In addition, at the state level there may be periods during which the use of NOLs is suspended or otherwise limited, which would accelerate or may permanently increase state taxes owed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The requirements associated with being a public company require significant company resources and management attention. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, the
listing requirements of the securities exchange on which our common stock is traded and other applicable securities rules and regulations. The Exchange Act requires that we file annual, quarterly and current reports with respect to our business and
financial condition and maintain effective </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disclosure controls and procedures and internal control over financial reporting. In addition, subsequent rules implemented by the SEC and NASDAQ may also impose various additional requirements
on public companies. As a result, we incur substantial legal, accounting and other expenses. Further, the corporate infrastructure demanded of a public company may divert management&#146;s attention from implementing our growth strategy. We have
made, and will continue to make, changes to our corporate governance standards, disclosure controls and financial reporting and accounting systems to meet our reporting obligations. However, the measures we take may not be sufficient to satisfy our
obligations as a public company, which could subject us to delisting of our common stock, fines, sanctions and other regulatory action and potentially civil litigation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We will incur significant costs as a result of operating as a public company, and our management is required to devote substantial time
to compliance initiatives. Failure to build our finance infrastructure and improve our accounting systems and controls could impair our ability to comply with the financial reporting and internal controls requirements for publicly traded companies.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we operate in an increasingly challenging regulatory environment. Once we no longer qualify as an
&#147;emerging growth company&#148; under the JOBS Act, we will be required to comply with the Sarbanes-Oxley Act and the related rules and regulations of the SEC, expanded disclosures, accelerated reporting requirements and more complex accounting
rules. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities
more time-consuming and costly. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain
the same or similar coverage. We estimate that we will annually incur approximately $1.5 million to $2.5 million in expenses to ensure compliance with these requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;404(a) of the Sarbanes-Oxley Act requires annual management assessments of the effectiveness of our internal control over
financial reporting, starting with the Annual Report on Form 10-K for the year ending December 31, 2015 that we would expect to file with the SEC and we will be required to disclose material changes made in our internal controls and procedures on a
quarterly basis. Company responsibilities required by the Sarbanes-Oxley Act include establishing corporate oversight and adequate internal control over financial reporting and disclosure controls and procedures. Effective internal controls are
necessary for us to produce reliable financial reports and are important to help prevent financial fraud. However, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over
financial reporting pursuant to Section&nbsp;404(b) of the Sarbanes-Oxley Act until the later of the year following our first annual report required to be filed with the SEC or the date we are no longer an &#147;emerging growth company&#148; as
defined in the JOBS Act, because we are taking advantage of the exemptions contained in the JOBS Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To build the infrastructure to
allow us to assess the effectiveness of our internal control over financial reporting, we will need to hire additional accounting personnel and improve our accounting systems, disclosure policies, procedures and controls. We are currently in the
process of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">hiring additional accounting and financial staff with appropriate public company experience; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">initiating plans to upgrade our computer systems, including hardware and software; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing more robust policies and procedures; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">enhancing internal controls and our financial statement review process. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are
unsuccessful in building an appropriate accounting infrastructure, we may not be able to prepare and disclose, in a timely manner, our financial statements and other required disclosures, or comply with existing or new reporting requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the evaluation and testing process, if we identify one or more material weaknesses in our
internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective. We cannot assure you that there will not be material weaknesses in our internal control over financial reporting
in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal
control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness in our internal control over financial reporting, we could lose investor confidence in the accuracy and
completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by NASDAQ, the SEC and comparable non-U.S. regulatory authorities. Failure to remedy any material
weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The recently enacted JOBS Act will allow us to postpone the date by which we must comply with some of the laws and regulations intended
to protect investors and to reduce the amount of information we provide in our reports filed with the SEC, which could undermine investor confidence in our company and adversely affect the market price of our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For so long as we remain an &#147;emerging growth company&#148; as defined in the JOBS Act, we may take advantage of certain exemptions from
various requirements that are applicable to public companies that are not &#147;emerging growth companies&#148; including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the provisions of Section&nbsp;404(b) of the Sarbanes-Oxley Act requiring that our independent registered public accounting firm provide an attestation report on the effectiveness of our internal control over financial
reporting; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the &#147;say on pay&#148; provisions (requiring a non-binding stockholder vote to approve compensation of certain executive officers) and the &#147;say on golden parachute&#148; provisions (requiring a non-binding
stockholder vote to approve golden parachute arrangements for certain executive officers in connection with mergers and certain other business combinations) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, or Dodd-Frank Act, and
some of the disclosure requirements of the Dodd-Frank Act relating to compensation of its chief executive officer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the requirement to provide detailed compensation discussion and analysis in proxy statements and reports filed under the Exchange Act, and instead provide a reduced level of disclosure concerning executive compensation;
and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any rules that may be adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotation or a supplement to the auditor&#146;s report on the financial statements. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of these exemptions until we are no longer an &#147;emerging growth company.&#148; We would cease to be an
&#147;emerging growth company&#148; upon the earliest of: (i)&nbsp;December 31, 2020; (ii)&nbsp;the last day of the first fiscal year in which our annual gross revenues are $1 billion or more; (iii)&nbsp;the date on which we have, during the
previous three-year period, issued more than $1 billion in non-convertible debt securities; or (iv)&nbsp;as of the end of any fiscal year in which the market value of our common stock held by non-affiliates exceeded $700 million as of the end of the
second quarter of that fiscal year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we are still evaluating the JOBS Act, we currently intend to take advantage of some, but not
all, of the reduced regulatory and reporting requirements that will be available to us so long as we qualify as an &#147;emerging growth company.&#148; For example, we have irrevocably elected under Section&nbsp;107 of the JOBS Act not to take
advantage of the extension of time to comply with new or revised financial accounting standards available under Section&nbsp;102(b) of the JOBS Act. Our independent registered public accounting firm will not be required to provide an attestation
report on the effectiveness of our internal control over financial reporting so long as we qualify as an &#147;emerging growth company,&#148; which may increase the risk that weaknesses or deficiencies in our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
internal control over financial reporting go undetected. Likewise, so long as we qualify as an &#147;emerging growth company,&#148; we may elect not to provide you with certain information,
including certain financial information and certain information regarding compensation of our executive officers, that we would otherwise have been required to provide in filings we make with the SEC, which may make it more difficult for investors
and securities analysts to evaluate our company. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a
less active trading market for our common stock, and our stock price may be more volatile and may decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Some provisions of our
charter documents, Delaware law and the indenture that govern our 2020 convertible notes may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may
prevent attempts by our stockholders to replace or remove our current management. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions in our amended and restated
certificate of incorporation and our bylaws as well as provisions of the Delaware General Corporation Law, or DGCL, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our
stockholders, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing a classified board of directors such that not all members of the board are elected at one time; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">allowing the authorized number of our directors to be changed only by resolution of our board of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limiting the removal of directors by the stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorizing the issuance of &#147;blank check&#148; preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prohibiting stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">eliminating the ability of stockholders to call a special meeting of stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">requiring the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal our bylaws. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more
difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, we are subject to Section&nbsp;203 of the DGCL, which generally prohibits a Delaware corporation
from engaging in any of a broad range of business combinations with an interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder, unless such transactions are approved by our
board of directors. This provision could have the effect of delaying or preventing a change of control, whether or not it is desired by or beneficial to our stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the indenture that governs the 2020 Notes contains provisions that require us to make an offer to purchase the 2020 Notes at a
price equal to 100% of the aggregate principal amount thereof plus accrued and unpaid interest upon the occurrence of, among other things, certain change of control transactions. The indenture that governs the 2020 Notes also contains provisions
that increase the conversion rate for holders that elect to convert their notes in connection with, among other things, certain change of control transactions. These provisions could have the effect of delaying or preventing a change of control,
whether or not it is desired by or beneficial to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our 2020 Convertible Notes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The future issuance of our common stock and securities linked to our common stock in the future could reduce the market price of our
common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, we may issue equity and equity-linked securities to raise cash for acquisitions or otherwise. We may
also acquire interests in other companies by using a combination of cash and our common stock or just our common stock. We also will issue common stock upon conversions of the 2020 Notes and have the option to settle any interest make-whole payment
applicable to conversion of the 2020 Notes in whole or in part in shares of our common stock. We may also issue preferred stock or additional securities convertible into our common stock or preferred stock. Any of these events may dilute your
ownership interest in our Company and have an adverse effect on the price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Servicing our debt requires a
significant amount of cash. We may not have sufficient cash flow from our business to make payments on our debt, and we may not have the ability to raise the funds necessary to make payments of any interest make-whole payment upon conversion in
whole or in part in cash, to repay the principal amount of the 2020 Notes at maturity or to repurchase the 2020 Notes upon a fundamental change, which could adversely affect our business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no source of revenue. Our ability to make scheduled payments of the principal of, to pay interest (including any applicable
interest make-whole payments on the 2020 Notes we elect to pay in whole or in part in cash) on or to refinance our indebtedness, including the 2020 Notes, depends on our future performance, which is subject to economic, financial, competitive and
other factors that may be beyond our control. Our business has not historically generated cash flow from operating activities and may not in the future generate cash flow from operating activities sufficient to service our debt and make necessary
capital expenditures. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly
dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could
result in a default on our debt obligations, including the 2020 Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, holders of the 2020 Notes have the right to require
us to repurchase their 2020 Notes upon the occurrence of a &#147;fundamental change&#148; (as defined in the Convertible Senior Notes Prospectus) at a repurchase price equal to 100% of the principal amount of the 2020 Notes to be repurchased, plus
accrued and unpaid interest. In addition, holders who convert on or after 150 days from the date of issuance of the 2020 Notes may also be entitled to receive under certain circumstances an interest make-whole payment. We may pay any interest
make-whole payment in cash, shares of our common stock or a combination thereof, at our election. We may not have enough available cash or be able to obtain financing at the time we are required to repay the principal amount of the notes, make
repurchases of the 2020 Notes surrendered therefor or pay the interest make-whole payment, if we elect to make such payment in whole or in part in cash. Our failure to repay the principal amount of the 2020 Notes, repurchase the 2020 Notes at a time
when the repurchase is required by the indenture or pay the interest make-whole payment, if we elect to make such payment in whole or in part in cash, would constitute an event of default. If the repayment of any indebtedness were to be accelerated
because of such event of default (whether under the 2020 Notes or otherwise), we may not have sufficient funds to repay the indebtedness and repay or repurchase the 2020 Notes. An event of default under the indenture may lead to an acceleration of
the 2020 Notes. Any such acceleration could result in our bankruptcy. In a bankruptcy, the holders of the 2020 Notes would have a claim to our assets that is senior to the claims of our equity holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our significant indebtedness, combined with our other financial obligations and contractual commitments, could have other
important consequences. For example, it could: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make us more vulnerable to adverse changes in general U.S. and worldwide economic, industry and competitive conditions and adverse changes in government regulation; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limit our flexibility in planning for, or reacting to, changes in our business and our industry; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">place us at a disadvantage compared to our competitors who have less debt; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limit our ability to borrow additional amounts for working capital and other general corporate purposes, including to fund possible acquisitions of, or investments in, complementary businesses, products, services and
technologies. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these factors could materially and adversely affect our business, financial condition and results of
operations. In addition, if we incur additional indebtedness, the risks related to our business and our ability to service or repay our indebtedness would increase. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The indenture governing the 2020 Notes contains restrictions that will limit our operating flexibility, and we may incur additional debt
in the future that may include similar or additional restrictions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture governing the 2020 Notes contains covenants that,
among other things, restrict our and our future subsidiaries&#146; ability to take specific actions, even if we believe them to be in our best interest. These covenants will include restrictions on our ability and the ability of our subsidiaries to:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">incur additional indebtedness and issue certain types of preferred stock, other than certain permitted indebtedness and preferred stock; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">incur liens, other than certain permitted liens. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the indenture governing the
2020 Notes includes a covenant that limits our ability to merge or consolidate with other entities in certain circumstances. These covenants and restrictions limit our operational flexibility and could prevent us from taking advantage of business
opportunities as they arise, growing our business or competing effectively. A breach of any of these covenants or other provisions in our debt agreements could result in an event of default, which if not cured or waived, could result in the 2020
Notes or such debt becoming immediately due and payable. This, in turn, could cause any of our other debt to become due and payable as a result of cross-default or cross-acceleration provisions contained in the agreements governing such other debt.
In the event that some or all of our debt is accelerated and becomes immediately due and payable, we may not have the funds to repay, or the ability to refinance, such debt. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2020 Noteholders may employ a convertible arbitrage strategy with respect to the 2020 Notes that could adversely affect the price of our
common stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that many investors in, and potential future purchasers of, the 2020 Notes will employ, or seek to employ,
a convertible arbitrage strategy with respect to the 2020 Notes. Investors would typically implement such a strategy by selling short the common stock underlying the 2020 Notes and dynamically adjusting their short position while continuing to hold
the 2020 Notes. Investors may also implement this type of strategy by entering into swaps on the common stock in lieu of or in addition to short selling the common stock. Any such strategy may have the effect of decreasing the trading price of our
common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The fundamental change repurchase feature of the indenture governing the 2020 Notes may delay or prevent an otherwise
beneficial takeover attempt of us. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture governing the 2020 Notes requires us to repurchase the 2020 Notes for cash upon
the occurrence of a fundamental change of us and, in certain circumstances, to increase the conversion rate for a 2020 holder that converts its 2020 Notes in connection with a make-whole fundamental change. A takeover of us may trigger the
requirement that we repurchase the notes and/or increase the conversion rate, which could make it more costly for a potential acquirer to engage in a combinatory transaction with us. Such additional costs may have the effect of delaying or
preventing a takeover of us that would otherwise be beneficial to investors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc893535_4"></A>Item&nbsp;1B. Unresolved Staff Comments
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc893535_5"></A>Item&nbsp;2. Properties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our headquarters is located in Lexington, Massachusetts, and consists of approximately 2,300 square feet of leased office space under a lease
that expires on March&nbsp;31, 2015. We have leased approximately 3,500 square feet of leased office space in Lexington, Massachusetts under a lease that commences on April&nbsp;1, 2015 and expires on September&nbsp;30, 2015. We are in the process
of obtaining permanent office space in the Lexington, Massachusetts area. We will require additional space and facilities as our business expands. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc893535_6">
</A>Item&nbsp;3. Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not a party to any material legal proceedings at this time. From time to time, we may be
subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of litigation and claims cannot be predicted with certainty, we do not believe we are party to any claim or litigation
the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of
defense and settlement costs, diversion of management resources and other factors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc893535_7"></A>Item&nbsp;4. Mine Safety Disclosures
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc893535_8"></A>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc893535_9"></A>Item&nbsp;5. Market for Registrant&#146;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market Information </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
February&nbsp;18, 2015, our common stock began trading on the Nasdaq Global Select Market under the symbol &#147;ITEK&#148;. Prior to that time, there was no public market for our common stock. Shares sold in our initial public offering were priced
at $6.00 per share. The following table shows the high and low closing sale prices per share of our common stock as reported on the Nasdaq Global Select Market for the period indicated: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman"><B>2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February 18, 2015 to March&nbsp;26, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;27, 2015, the closing price for our common stock as reported on the NASDAQ Global Market was
$5.74. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
March&nbsp;23, 2015, there were 56 stockholders of record, which excludes stockholders whose shares were held in nominee or street name by brokers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividend Policy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared
or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the
foreseeable future. Any future determination to pay cash dividends will be made at the discretion of our board of directors. In addition, the terms of our outstanding indebtedness restrict our ability to pay cash dividends, and any future
indebtedness that we may incur could preclude us from paying cash dividends. Investors should not purchase our common stock with the expectation of receiving cash dividends. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Securities authorized for issuance under equity compensation plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information about our equity compensation plans is incorporated herein by reference to Item&nbsp;12 of Part III of this Annual Report on Form
10-K. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Sales of Unregistered Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth below is information regarding securities sold by us during the year ended December&nbsp;31, 2014 that were not registered under the
Securities Act. Also included is the consideration, if any, received by us for the securities and information relating to the section of the Securities Act, or rule of the Securities and Exchange Commission, under which exemption from registration
was claimed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2014, we sold an aggregate of $2.0 million of subordinated convertible promissory notes to existing stockholders (the &#147;2014
Bridge Notes&#148;). The 2014 Bridge Notes mature on June&nbsp;30, 2015 and accrue interest at the rate of 8%&nbsp;per annum and are subordinate to all other senior indebtedness of the Company. Upon the closing of our initial public offering in
February 2015, the 2014 Bridge Notes including accrued interest, converted into 337,932 shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended
December&nbsp;31, 2014, we granted stock options to purchase 900,117 shares of our common stock to our employees and directors pursuant to our 2014 Stock Option and Incentive Plan at an exercise price of $4.342 per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We deemed the offers, sales and issuances of the 2014 Bridge Notes described above to be exempt from registration
under the Securities Act, in reliance on Section&nbsp;4(2) of the Securities Act, including Regulation D and Rule 506 promulgated thereunder, relating to transactions by an issuer not involving a public offering. All purchasers of securities in
transactions exempt from registration pursuant to Regulation D represented to us that they were accredited investors and were acquiring the shares for investment purposes only and not with a view to, or for sale in connection with, any distribution
thereof and that they could bear the risks of the investment and could hold the securities for an indefinite period of time. The purchasers received written disclosures that the securities had not been registered under the Securities Act and that
any resale must be made pursuant to a registration statement or an available exemption from such registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We deemed the grants and exercises of
stock options described above to be exempt from registration under the Securities Act in reliance on Rule 701 of the Securities Act as offers and sales of securities under compensatory benefit plans and contracts relating to compensation in
compliance with Rule 701. Each of the recipients of securities in any transaction exempt from registration either received or had adequate access, through employment, business or other relationships, to information about us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds from Registered Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2015, we completed our (i)&nbsp;IPO of 6,667,000 shares of our common stock at a price of $6.00 per share and (ii)&nbsp;the
concurrent offering of $20.0 million aggregate principal amount of our 5.0% Convertible Senior Notes due 2020 (the &#147;2020 Notes&#148;). In March 2015 the underwriters purchased 299,333 shares of common stock at $6.00 per share and $1.0 million
of the 2020 Notes upon exercise of their overallotment options. We received net proceeds of approximately $36.6 million, after deducting underwriting discounts and offering-related costs, from our equity issuances and approximately $18.9 million in
net proceeds, after deducting underwriting discounts and offering-related costs, from our debt issuances. The 2020 Notes mature on February&nbsp;15, 2020, are unsecured, bear interest from February&nbsp;23, 2015 at an annual rate of 5.0% payable
semi-annually on February&nbsp;15 and August&nbsp;15 of each year, are not redeemable at our option prior to their maturity date, and may be subject to repurchase by us at the option of the holders following a fundamental change (as defined in the
2020 Notes indenture) at a repurchase price equal to 100% of the principal amount of the 2020 Notes to be repurchased. In addition, on or after 150 days from the date of issuance of the notes, we will, in addition to the other consideration payable
or deliverable in connection with any conversion of 2020 Notes, make an interest make-whole payment (an &#147;interest make-whole payment&#148;) to the converting holder equal to the sum of the present values of the scheduled payments of interest
that would have been made on the 2020 Notes to be converted had such 2020 Notes remained outstanding from the conversion date through the earlier of (i)&nbsp;the date that is three years after the conversion date and (ii)&nbsp;the maturity date if
the notes had not been so converted or otherwise repurchased. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Issuer Purchases of Equity Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no repurchases of shares of common stock made during the year ended December&nbsp;31, 2014. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc893535_10"></A>Item&nbsp;6. Selected Financial Data </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We derived the selected statements of operations data for the years ended December&nbsp;31, 2014, 2013 and 2012 and the balance sheet data as
of December&nbsp;31, 2014 and 2013 from our audited financial statements appearing elsewhere in this annual report on Form 10-K. We derived the December 31, 2012 balance sheet data from our audited financials statements not included in this Annual
Report on Form 10-K. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selected consolidated financial data should be read in conjunction with Item&nbsp;7,
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and the consolidated financial statements and the notes thereto included elsewhere in this report. The selected financial data in this section are
not intended to replace our consolidated financial statements and the related notes. Our historical results are not necessarily indicative of our future results. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,592</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,330</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,112</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,307</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,704</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,654</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,849</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(884</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(213</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liabilities and convertible notes redemption rights derivative</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(847</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(81</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(&#151;</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,531</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,616</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,058</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per common share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13.52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10.05</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8.04</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,020,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,018,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,016,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible notes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes payable&#151;current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes payable, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liabilities and convertible notes redemption rights derivative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series AA redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(128,041</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(118,510</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(110,894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51,559</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,895</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,930</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc893535_11"></A>Item&nbsp;7. Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following discussion and analysis of our financial condition and results of operations should be read in conjunction
with our &#147;Selected Financial Data&#148; and our financial statements, related notes and other financial information included elsewhere in this . This discussion contains forward-looking statements that involve risks and uncertainties such as
our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward looking statements. Factors that could cause or contribute to such differences include, but are not limited to,
those identified below and those discussed in &#147;Risk Factors&#148; included elsewhere in this prospectus. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma.
Glaucoma is a disease of the eye that is typically characterized by structural evidence of optic nerve damage, vision loss and consistently elevated intraocular pressure, or IOP. Our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
lead product candidate, <I>trabodenoson</I>, is a first-in-class selective adenosine mimetic that we rationally designed to lower IOP by restoring the eye&#146;s natural pressure control
mechanism. Our product pipeline includes <I>trabodenoson</I> monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination, or FDC, of <I>trabodenoson</I> with <I>latanoprost</I> given once-daily, or QD. Our completed Phase 2
trial of <I>trabodenoson </I>co-administered with <I>latanoprost</I>, a prostaglandin analogue, or PGA, demonstrated IOP-lowering in patients who have previously had inadequate response to <I>latanoprost</I>. These patients represent PGA
poor-responders, as evidenced by persistently elevated IOP at levels that typically require the addition of a second drug to further lower IOP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
February 2015, we completed our IPO of (i)&nbsp;6,667,000 shares of our common stock at a price of $6.00 per share and (ii)&nbsp;$20.0 million aggregate principal amount of our 2020 Notes. In March 2015 the underwriters purchased 299,333 shares of
common stock at $6.00 per share and $1.0 million of the 2020 Notes upon exercise of their overallotment options. We received net proceeds of $36.6 million, after deducting underwriting discounts and offering-related costs, from its equity issuances
and $18.9 million in net proceeds, after deducting underwriting discounts and offering-related costs, from our debt issuances. Prior to the IPO we funded our operations primarily through the sale of preferred stock and issuance of convertible
promissory notes and notes payable. As of December&nbsp;31, 2014, we had an accumulated deficit of $128.0&nbsp;million and $3.6 million of cash. Subsequent to the IPO, we estimate that we have sufficient funding to sustain operations through the
next 18 months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are planning an End-of-Phase 2 meeting with the U.S. Food and Drug Administration, or FDA, for <I>trabodenoson</I> in
the second quarter of 2015. We expect to initiate a Phase 3 program for <I>trabodenoson</I> monotherapy in mid-2015, which will consist of two Phase 3 pivotal trials and a long-term safety study. Based on our estimates of the rate of patient
enrollment and assuming commencement in mid-2015, we expect to report top-line data from the first of the two pivotal Phase 3 trials by late 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception on July&nbsp;7, 1999, we have devoted substantially all of our resources to business planning, raising capital, product
research and development, applying for and obtaining government and private grants, recruiting management, research and technical staff and other personnel, acquiring operating assets, and undertaking preclinical studies and clinical trials of our
lead product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not completed development of any product candidate and we have therefore not generated any revenues from
product sales. Prior to 2012, we generated revenues primarily from research grants received from governmental agencies and private companies as well as revenue earned under licensing and research collaboration contracts. All previously recognized
revenue was unrelated to our current development efforts focused on our lead product candidate, <I>trabodenoson, </I>for the treatment of glaucoma and other diseases of the eye. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although it is difficult to predict our liquidity requirements, based upon our current operating plan, and the net proceeds from our IPO, we
believe we will have sufficient cash to meet our projected operating requirements for the next 18 months. See &#147;Liquidity and Capital Resources.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Factors Affecting our Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we continue to invest in research
and development and commence our Phase 3 program of <I>trabodenoson</I> in 2015. We also expect our expenses to increase as we complete formulation and manufacturing activities of our FDC product candidate and commence clinical trials in 2016. In
addition, if we successfully launch <I>trabodenoson</I> as a monotherapy or any other product candidates, we expect to incur significant commercialization expenses related to sales, marketing, manufacturing and distribution of our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, we expect to incur additional costs associated with operating as a public company. We expect operating expenses to increase
substantially to support an increased infrastructure and expanded operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Accordingly, we will need to obtain additional funding in connection with our continuing operations. Adequate additional financing may not be available to us on acceptable terms, or at all. If we
are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or any potential future commercialization efforts. We will need to generate significant revenues
to achieve profitability, and we may never do so. As a result, we expect to incur significant expenses and increasing operating losses for the foreseeable future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Revenue
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not generated any revenue from product sales since our inception and do not expect to generate any revenue from the sale
of products in the near future. Our ability to generate revenues will depend on the successful development, regulatory approval and commercialization of <I>trabodenoson</I> and any other future product candidates. Historically, we generated revenues
primarily from research grants received from governmental agencies and private companies as well as revenue earned under licensing and research collaboration contracts that were unrelated to our current research and development programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist primarily of the costs associated with our research and development activities, conducting
preclinical studies and clinical trials and activities related to regulatory filings. Our research and development expenses consist of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">direct clinical and non-clinical expenses which include expenses incurred under agreements with contract research organizations, or CROs, contract manufacturing organizations and costs associated with preclinical
activities and development activities and costs associated with regulatory activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">employee and consultant-related expenses, including salaries, benefits, travel and stock-based compensation expense for research and development personnel as well as consultants that conduct and support clinical trials
and preclinical studies; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies used in research and development activities. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expense research and development costs as incurred. We record costs for some development activities, such as clinical trials, based on an
evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or other information our vendors provide to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our research and development expenses by type of activity for the years ended December&nbsp;31, 2014, 2013 and
2012: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Trabodenoson</I>&#151;direct clinical and non-clinical</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel and other expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee and consultant-related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total personnel and other expenses</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All research and development efforts and expenses for the years ended December&nbsp;31, 2014,
2013 and 2012 relate to the development of <I>trabodenoson</I>. We do not track <I>trabodenoson</I>-related expenses by product candidate. All expenses related to <I>trabodenoson</I> as a monotherapy also benefit the FDC product candidate
<I>trabodenoson</I> with <I>latanoprost</I>. We have expended approximately $41&nbsp;million for external development costs related to <I>trabodenoson</I> from inception through December&nbsp;31, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process of conducting the necessary clinical research to obtain regulatory approval is costly and time consuming and the successful
development of our product candidates is highly uncertain. Our future research and development expenses will depend on the clinical success of our product candidates, as well as ongoing assessments of the commercial potential of such product
candidates. In addition, we cannot forecast with any degree of certainty which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our
development plans and capital requirements. We expect our research and development expenses to increase in future periods for the foreseeable future as we seek to complete development of our lead product candidate, <I>trabodenoson</I>, further
develop our other product candidates and expand our research and development personnel to focus on these product candidate development activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The successful development and commercialization of our product candidates is highly uncertain. This is due to the numerous risks and
uncertainties associated with product development and commercialization, including the uncertainty of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope, progress, outcome and costs of our clinical trials and other research and development activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the efficacy and potential advantages of our product candidates compared to alternative treatments, including any standard of care; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the market acceptance of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">significant and changing government regulation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing, receipt and terms of any marketing approvals. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A change in the outcome of any of
these variables with respect to the development of <I>trabodenoson</I> or any other product candidate that we may develop could mean a significant change in the costs and timing associated with the development of that product candidate. For example,
if the FDA or another regulatory authority were to require us to conduct clinical trials or other testing beyond those that we currently contemplate for the completion of clinical development of <I>trabodenoson</I> or any other product candidate
that we may develop or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development of that product
candidate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist of salaries and related benefit costs, including stock-based compensation for administrative
personnel. Other significant general and administrative expenses include professional fees for legal, patents, consulting, auditing and tax services as well as other direct and allocated expenses for rent and maintenance of facilities, insurance and
other supplies used in general and administrative activities. We anticipate that our general and administrative expenses will increase in future periods to support increases in our research and development activities and as a result of increased
headcount (especially in our accounting and finance departments), increased stock-based compensation charges, expanded infrastructure, increased costs for insurance, and increased legal, compliance, accounting and investor and public relations
expenses associated with being a public company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Interest Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense consists primarily of interest on our existing notes payable, interest on convertible promissory notes, amortization of loan
discounts as well as interest calculated based on the amortization of the beneficial conversion feature of the convertible promissory notes. In February 2015, we repaid our borrowings under our existing notes payable agreements with Horizon
Technology Finance Corporation and Fortress Credit Co. LLC with the proceeds from our IPO. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expense), Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Other income (expense), net reflects consists primarily of non-cash expense related to changes in the fair value of our warrant liabilities
arising from the warrants to purchase shares of Series AA Preferred Stock (see Note 7 of our consolidated financial statements) and changes in the fair value of the redemption rights derivative related to our 2014 Bridge Notes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Comparison
of the Years Ended December&nbsp;31, 2014 and 2013 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the results of our operations for the years
ended December&nbsp;31, 2014 and 2013: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase<BR>(Decrease)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,592</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,330</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,112</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,704</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,654</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(884</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(847</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,531</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,616</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses increased by $0.3 million to $5.6 million for the year ended December&nbsp;31, 2014, as compared to $5.3
million for the year ended December&nbsp;31, 2013. The increase resulted primarily from higher CRO and other direct clinical trial expenses related to the Phase 2 trial of <I>trabodenoson </I>FDC<I>,</I> for which we received top line results in
October 2014. This increase was partially offset by decreases in expenses related to manufacturing and testing of the active pharmaceutical ingredient needed to conduct the Phase 2 trial, as well as decreases in expenses related to consultants and
stock-based compensation for research development personnel. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses increased $0.8&nbsp;million, to $2.1&nbsp;million, for the year ended December&nbsp;31, 2014, as compared
to $1.3 million for the year ended December&nbsp;31, 2013. Included in the year ended December&nbsp;31, 2013 is approximately $0.8 million of executive severance and payroll-related costs that are related to the termination of our former CEO and CFO
in May 2013 as well as a reversal of approximately $0.3 million of stock based compensation also related to these terminations. This decrease of $0.5&nbsp;million was offset by higher outside consultant expenses of $0.5 million related primarily to
financial and accounting support, payroll-related expenses of $0.4 million related to the hiring of our CEO and VP of Finance, higher travel, professional fees and other expenses of $0.3 million in support of our initial public offering and
stock-based compensation of $0.2 million related to the 2014 option grants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Interest Expense </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense increased $0.1 million, to $1.0 million, for the year ended December&nbsp;31, 2014, as compared to $0.9 million for the year
ended December&nbsp;31, 2013. The majority of interest expense, both coupon and discount amortization, for the year ended December&nbsp;31, 2014, was related to the notes payable that we issued to two financial entities in June 2013. In addition,
interest expense was recorded on the 2014 Bridge Notes issued in December 2014. Interest expense for the year ended December&nbsp;31, 2013 includes approximately $0.4&nbsp;million related to our convertible promissory notes which converted to equity
in June 2013 plus approximately $0.5 million of both coupon and discount amortization related to the notes payable that we issued to two financial entities in June 2013. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other Income (Expense), Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other expense, net, increased $0.8&nbsp;million, to $0.8&nbsp;million, for the year ended December&nbsp;31, 2014, as compared to a $0.1 million
for the year ended December&nbsp;31, 2013. The increase resulted primarily from the noncash expense related to changes in the fair value of our warrant liabilities arising from the warrants to purchase shares of Series AA Preferred Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years Ended December&nbsp;31, 2013 and 2012 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the results of our operations for the years ended December&nbsp;31, 2013 and 2012: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase<BR>(Decrease)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,330</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,307</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(983</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,654</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,849</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(884</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(213</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,616</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,058</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses increased by $1.8 million, to $5.3 million, for the year ended December&nbsp;31, 2013, as compared to $3.5
million for the year ended December&nbsp;31, 2012. The increase resulted entirely from higher CRO and other direct clinical expenses related to the Phase 2 trial of <I>trabodenoson</I> FDC, which we recently completed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses decreased $1.0 million, to $1.3 million, for the year ended December&nbsp;31, 2013, as compared to $2.3
million for the year ended December&nbsp;31, 2012. Approximately $0.6 million of this decrease is due to lower stock-based compensation and included a reversal of $0.3 million in expenses related to the termination of our former CEO and CFO who were
terminated in May 2013. The remaining decrease resulted primarily from lower patent, legal and consultant-related expenses offset by higher payroll-related expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Interest Expense </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense increased by $0.7 million, to $0.9 million, for the year ended December&nbsp;31, 2013, as compared to $0.2 million for the
year ended December&nbsp;31, 2012. Approximately $0.5 million of the increase resulted from the interest expense related to our notes payable which we issued in June&nbsp;2013. The remaining increase resulted from higher interest expense related to
our convertible promissory notes which converted into equity in June 2013. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other Income (Expense), Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net other income increased by $0.1 million and is the result of the non-cash income related to changes in the fair value of our warrant
liabilities arising from the warrants to purchase shares of Series AA Preferred Stock described in Note 7 of our consolidated financial statements appearing elsewhere in this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since
inception, we have incurred accumulated net losses and negative cash flows from our operations. We incurred net losses of $9.5 million, $7.6 million and $6.1 million for the years ended December&nbsp;31, 2014, 2013 and 2012 respectively. Our
operating activities used $9.7 million, $6.5 million and $6.9 million of cash during the years ended December 2014, 2013 and 2012, respectively. As of December&nbsp;31, 2014, the Company had $3.6 million of cash and cash equivalents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2015, we completed our IPO and concurrent note offering and in March 2015 the underwriters purchased a portion of their common
stock and notes overallotment options resulting in net proceeds to us of approximately $55.5 million. As of March 30, 2015 we have outstanding $21.0 million of 2020 Notes. The Company estimates that it has sufficient funding to sustain operations
through at least the next 18 months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2014, the Company sold an aggregate of $2.0 million of the 2014 Bridge Notes. In
addition to other terms, the 2014 Bridge Notes had a maturity of June&nbsp;30, 2015, accrued interest at the rate of 8%&nbsp;per annum and were subordinate to all other senior indebtedness of the Company. Upon the closing of our IPO, the 2014 Bridge
Notes, including accrued interest, automatically converted into 337,932 shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;28, 2013, we entered
into notes payable agreements with two financial entities pursuant to which we issued a $3.5 million note to each lender and received net proceeds of $6.9 million. The notes bore interest at a rate of 11.0%&nbsp;per annum and had a maturity date of
October&nbsp;1, 2016. We made principal payments of $1.4 million on these notes payable in 2014. In February 2015, we paid the lenders with proceeds from our IPO a total of $5.7 million, which included $5.3 million for the remaining principal, $0.4
million for end of term and prepayment amounts and accrued interest. These notes payable agreements were then terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table summarizes our sources and uses of cash for each of the periods presented: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,743</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,455</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,936</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash provided by investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and equivalents</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,175</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,433</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Net cash used in operating activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities was $9.7 million for the year ended December&nbsp;31, 2014 and $6.5 million for the year ended
December&nbsp;31, 2013. Net cash used in operating activities for the year ended December&nbsp;31, 2014 principally resulted from our net loss of $9.5&nbsp;million and increased prepaid expenses and other assets primarily related to
$1.8&nbsp;million in deferred public offering costs. These amounts were partially offset by increases in non-cash expenses related to changes in the fair value of our warrant liabilities of $0.8&nbsp;million, increases in accounts payables and
accrued expenses of $0.3 million, non-cash interest expenses of $0.2 million as well as non-cash stock-based compensation expense of $0.2&nbsp;million. Net cash used in operating activities for the year ended December&nbsp;31, 2013 principally
resulted from our net loss of $7.6 million partially offset by increases in accounts payable and accrued expenses of $0.8 million and net non-cash stock compensation and interest expenses of $0.3 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities was $6.5 million for the year ended December&nbsp;31, 2013 and $6.9 million for the year ended
December&nbsp;31, 2012. Net cash used in operating activities for the year ended December 31, 2013 principally resulted from our net loss of $7.6 million and decreases in accounts payable of $0.2 million partially offset by increases in accrued
expenses of $0.9 million and net non-cash stock compensation and interest expenses of $0.3 million. Net cash used in operating activities for the year ended December 31, 2012 principally resulted from our net loss of $6.1 million and decreases in
accrued expenses of $1.8 million partially offset by increases in non-cash stock compensation expenses of $0.5 million, non-cash interest expenses of $0.2 million and accounts payable of $0.2 million. Our net losses in all periods were the result of
our significant operating expenses for research and development activities and general and administrative expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Net cash used
in investing activities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities was not significant for any periods presented. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Net cash provided by financing activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities was $0.6&nbsp;million for the year ended December&nbsp;31, 2014 and reflects the net proceeds from
issuance of our $2.0 million convertible notes partially offset by principal payments on our notes payable of $1.4 million. Net cash provided by financing activities was $17.9 million for the year ended December&nbsp;31, 2013 and resulted primarily
from $10.0 million in net proceeds from the sale of our Series AA Preferred Stock, $6.9 million in net proceeds from our notes payable and $1.0 million in net proceeds from the sale of our convertible notes, which converted into Series AA Preferred
Stock in June 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities was $17.9 million for the year ended December&nbsp;31, 2013 and $2.5
million for the year ended December&nbsp;31, 2012. Net cash provided by financing activities for the year ended December&nbsp;31, 2013 resulted primarily from $10.0 million in net cash proceeds from the sale of our Series AA Preferred Stock, $6.9
million in proceeds from our notes payable and $1.0 million in net proceeds from the sale of our convertible notes which converted into Series AA Preferred Stock in June 2013. Net cash provided by financing activities for the year ended
December&nbsp;31, 2012 principally resulted from the receipt of $2.5 million in proceeds from the sale of our convertible notes which converted into Series AA Preferred Stock in June 2013. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Operating Capital Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have not generated any revenue from product sales. We do not know when, or if, we will generate any revenue from product sales. We
do not expect to generate significant revenue from product sales unless and until we obtain regulatory approval of and commercialize one of our current or future product candidates. We anticipate that we will continue to generate losses for the
foreseeable future and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our product candidates and begin to commercialize any approved products. With the closing of our IPO in February 2015, we
will incur additional costs associated with operating as a public company. In addition, subject to obtaining regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval of any of our product candidates, we expect to incur significant commercialization expenses for product sales, marketing and manufacturing. Accordingly, we anticipate that we will need
substantial additional funding in connection with our continuing operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial
product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. To the extent that we are able to raise additional capital through the
sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders.
Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may require the
issuance of warrants, which could cause potential dilution. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future
revenue streams or research programs or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our
product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Commitments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summarizes our significant contractual obligations as of December&nbsp;31, 2014: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than<BR>1 year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1 to 3<BR>years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3 to 5<BR>years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More<BR>than<BR>5&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligations (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes payable (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2014 Bridge Notes (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Amounts represent our minimum lease obligations related to our corporate headquarters in Lexington, Massachusetts. The minimum lease payments in the table do not include related common area maintenance charges or real
estate taxes, which costs are variable. Amounts exclude a lease we entered into in March 2015 obligating us to pay $43 in 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Amounts represent principal, interest and termination payments on our notes payable. We repaid the borrowings under, and terminated, our notes payable agreements with the proceeds from our IPO as reflected in the above
table. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Includes principal and interest due through the June&nbsp;30, 2015 due date of our convertible notes. The 2014 Bridge Notes converted into 337,932 shares of common stock upon consummation of the IPO in February 2015.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above table excludes our obligations related to the 2020 Notes issued in February and March 2015. The 2020 Notes require the following
interest payments: $1,026 in 2016 and $1,050 in each of 2017, 2018, 2019 and 2020. Also, $21.0 million of principal is due in 2020. The 2020 Notes are convertible into common stock at $6.30 per share, subject to adjustment in certain circumstances,
at any time by the note holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We enter into contracts in the normal course of business with CROs and contract manufacturers to assist
in the performance of our research and development activities and other services and products for operating purposes. To the extent that these contracts provide for termination on notice, and therefore are cancelable contracts, they are not included
in the table of contractual obligations and commitments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Off-Balance Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures about Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to market risks in the ordinary course of our business. These market risks are principally limited to interest rate
fluctuations. We had cash and cash equivalents of $3.6 million at December&nbsp;31, 2014, consisting of funds in operating cash accounts. The primary objective of our investment activities is to preserve principal and liquidity while maximizing
income without significantly increasing risk. We do not enter into investments for trading or speculative purposes. Due to the short-term nature of our investment portfolio, we do not believe an immediate 1.0% increase in interest rates would have a
material effect on the fair market value of our portfolio, and accordingly we do not expect a sudden change in market interest rates to affect materially our operating results or cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because our notes payable bear interest at a fixed rate, a change in interest rates would not impact the amount of interest we would pay on
our indebtedness. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JOBS Act </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under
Section&nbsp;107(b) of the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, an &#147;emerging growth company&#148; can delay the adoption of new or revised accounting standards until such time as those standards would apply to private
companies. We have irrevocably elected not to avail ourselves of this exemption and, as a result, we will adopt new or revised accounting standards at the same time as other public companies that are not emerging growth companies. There are other
exemptions and reduced reporting requirements provided by the JOBS Act that we are currently evaluating. For example, as an emerging growth company, we are exempt from Sections&nbsp;14A(a) and (b)&nbsp;of the Exchange Act which would otherwise
require us to (i)&nbsp;submit certain executive compensation matters to stockholder advisory votes, such as &#147;say-on-pay,&#148; &#147;say-on-frequency&#148; and &#147;golden parachutes&#148; and (ii)&nbsp;disclose certain executive compensation
related items such as the correlation between executive compensation and performance and comparisons of our Chief Executive Officer&#146;s compensation to our median employee compensation. We also intend to rely on an exemption from the rule
requiring us to provide an auditor&#146;s attestation report on our internal controls over financial reporting pursuant to Section&nbsp;404(b) of the Sarbanes-Oxley Act and the rule requiring us to comply with any requirement that may be adopted by
the Public Company Accounting Oversight Board, or PCAOB, regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements as the auditor discussion and
analysis. We will continue to remain an &#147;emerging growth company&#148; until the earliest of the following: December 31, 2020; the last day of the fiscal year in which our total annual gross revenue is equal to or more than $1&nbsp;billion; the
date on which we have issued more than $1&nbsp;billion in nonconvertible debt during the previous three years; or the date on which we are deemed to be a large accelerated filer under the rules of the SEC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses. This
process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the
services when we have not yet been invoiced or otherwise notified of the actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however,
some require </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
advanced payments. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. Examples of
estimated accrued research and development expenses include fees paid to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CROs in connection with performing research and development services on our behalf; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">investigative sites or other providers in connection with clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">vendors in connection with non-clinical development activities; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">vendors related to product manufacturing, development and distribution of clinical supplies. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We base our expenses related to clinical trials on our estimates of the services received and efforts expended pursuant to contracts with
multiple CROs that conduct and manage non-clinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be
instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the clinical expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and
the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed, enrollment of patients, number of sites activated and level of effort to be expended in each period. If the
actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our
understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting expenses that are too high or too low in any particular period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in
determining the reported fair values. Accounting Standard Codification, or ASC, Topic 820, Fair Value Measurements and Disclosures, establishes a hierarchy of inputs used when available. Observable inputs are inputs that market participants would
use in pricing the asset or liability based on market data obtained from sources independent of our company. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or
liability, and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the
investment credit quality. The three levels of the fair value hierarchy are described below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 1&#151;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that we have the ability to access at the measurement date; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 2&#151;Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 3&#151;Valuations that require inputs that reflect our own assumptions that are both significant to the fair value measurement and unobservable. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair
value requires more judgment. Accordingly, the degree of judgment exercised by us in determining fair value is greatest for instruments categorized in Level&nbsp;3. A financial instrument&#146;s level within the fair value hierarchy is based on the
lowest level of any input that is significant to the fair value measurement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our material financial instruments at December&nbsp;31, 2014
and 2013 consisted of cash and cash equivalents, preferred stock warrant liabilities and a convertible debt redemption rights derivative. We have determined that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our preferred stock warrant liabilities and convertible debt redemption rights derivative are subject to Level 3 fair value measurements. We account for both our preferred stock warrant
liabilities and convertible debt redemption rights derivative as liabilities based upon the characteristics and provisions of the underlying instruments. These liabilities were recorded at their fair value on the date of issuance and are re-measured
on each subsequent balance sheet date, with fair value changes recognized as income (decreases in fair value) or expense (increases in fair value) in change in fair value of warrant liabilities and convertible notes redemption rights derivative in
the statements of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We measure the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of the
award. That cost is recognized on a straight-line basis over the period during which the employee is required to provide service in exchange for the award. The fair value of options on the date of grant is calculated using the Black-Scholes option
pricing model based on key assumptions such as stock price, expected volatility and expected term. Our estimates of these assumptions are primarily based on third-party valuations, historical data, peer company data and judgment regarding future
trends and factors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for stock options issued to non-employees in accordance with the provisions of The Financial Accounting
Standards Board, or FASB, ASC Subtopic 505-50, <I>Equity-Based Payments to Non-employees</I>, which requires valuing the stock options using the Black-Scholes option pricing model and re-measuring such stock options at their current fair value as
they vest. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Significant Factors, Assumptions and Methodologies Used in Determining Fair Value </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Determining the fair value of our convertible preferred stock warrants, convertible debt derivative and stock-based awards requires the use of
subjective assumptions. In the absence of a publicly traded market for our securities, we conducted periodic valuations of our securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Valuations
conducted in 2014 and 2013 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A third-party valuation consultant was engaged to advise and assist us in connection with the valuations of
our (i)&nbsp;Series AA preferred stock warrants outstanding on December&nbsp;31, 2014 and 2013, (ii)&nbsp;our convertible debt redemption rights derivative at issuance and at December&nbsp;31, 2014, (iii)&nbsp;our common stock options issued in
August 2014 and (iv)&nbsp;our Series&nbsp;AA preferred stock warrants exercised in August and September 2014. Because our Series X preferred stock is entitled to a contingent liquidation preference which varies based on the total value of our
equity, we were precluded from using a closed-form model, such as the Black-Scholes option pricing method, to value the Series&nbsp;AA preferred stock warrants. Therefore, we employed a Monte Carlo simulation methodology for all models used to
determine the fair value of securities in our capital structure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Common Stock and Preferred Stock Warrant Valuations </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our initial equity value, or EV, was determined by utilizing a risk-adjusted discounted cash flow model based upon market research and
management&#146;s assessment thereof, which is an income approach and was corroborated with market data, coupled with a series of Monte Carlo simulations which projected various equity values under different possible liquidity events including
(i)&nbsp;initial public offering, or IPO, (ii)&nbsp;merger and acquisition, or M&amp;A, and (iii)&nbsp;stay-private, or SP, scenarios. The first two scenarios assume positive results from our recent Phase 2 clinical trial, while the third scenario
considered unfavorable results for valuations performed prior to December&nbsp;31, 2014 and, at December&nbsp;31, 2014, no IPO or M&amp;A transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Key assumptions underlying the discounted cash flow model are described below: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Based on the research and industry knowledge of our officers and consultants, we developed projections of market penetration, product selling prices and required infrastructure to estimate our future revenues and
operating expenses to determine projected free cash flows from our two current product candidates containing <I>trabodenoson</I>, through patent expiration. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Probability of Success.</I>&nbsp;To determine the probability of success for the various phases of development required for submission in an NDA, we utilized the clinical trial success rates as published in certain
reports. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Time to Liquidity</I>. All 2014 and 2013 valuations assumed liquidity events occurring between December&nbsp;31, 2014 and April&nbsp;1, 2015. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Risk Free rates</I>. Risk free rates are based on published or imputed government treasury rates as of each valuation date. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Volatilities</I>. Volatilities were derived from historical data from guideline publicly traded comparable companies. We used volatilities of 60% to 70% for the 2014 and 2013 valuations. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Monte Carlo-simulated total equity values were then allocated to each type of security using a current value (waterfall) method under each
scenario and were then probability-adjusted using probability weights by scenario. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:36.85pt; font-size:8pt; font-family:Times New Roman"><B>As of date:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IPO</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>M&amp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SP</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Valuation models require the input of highly subjective assumptions. Because our shares had characteristics
significantly different from that of publicly traded common stock and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#146;s opinion, the existing models do not necessarily provide a
reliable, single measure of the fair value of our Series AA preferred stock or Series X preferred stock. The foregoing valuation methodologies are not the only valuation methodologies available and are not expected to be used to value our securities
after our IPO. We cannot make complete assurances as to any particular valuation for our securities. Accordingly, investors are cautioned not to place undue reliance on the foregoing valuation methodologies as an indicator of future stock prices.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Convertible Debt Redemption Rights Derivative </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2014 Bridge Notes redemption rights derivative required separate accounting and was valued using a single income valuation approach. We estimated the fair
value of the redemption rights derivative using a &#145;&#145;with and without&#146;&#146; income valuation approach. Under this approach, we estimated the present value of the fixed interest rate debt based on the fair value of similar debt
instruments excluding the embedded feature. This amount was then compared to the fair value of the debt instrument including the embedded feature using a probability weighted approach by assigning each embedded derivative feature a probability of
occurrence, with consideration provided for the settlement amount including conversion discounts, prepayment penalties, the expected life of the liability and the applicable discount rate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the issuance of the 2014 Bridge Notes on December 22, 2014 and on December 31, 2014, the Company ascribed a probability of occurrence to the Change in
Control Redemption Feature of 25%. The expected life of the feature was the remaining term of the debt and the discount rate was 18.9%. The Company classified the liability within Level 3 of the fair value hierarchy as the probability factor and the
discount rate are unobservable inputs and significant to the valuation model. As of December 22, 2014 and December 31, 2014, the fair value of the embedded derivative was approximately $0.5 million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc893535_12"></A>Item&nbsp;7A. Quantitative and Qualitative Disclosures about Market Risks </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to market risk related to changes in interest rates. As of December&nbsp;31, 2014, we had cash and cash equivalents of $3.6 million. Our primary
exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments are in short-term marketable securities. Our cash equivalents are subject to
interest rate risk and could fall in value if market </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interest rates increase. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, we do not believe an immediate 10% change in interest rates would
have a material effect on the fair market value of our investment portfolio. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc893535_13"></A>Item&nbsp;8. Financial Statements and
Supplementary Data </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements required to be filed pursuant to this Item&nbsp;8 are appended to this report. An index of
those financial statements is found in Item&nbsp;15. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc893535_14"></A>Item&nbsp;9. Changes in and Disagreements with Accountants on
Accounting and Financial Disclosure </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc893535_15"></A>Item&nbsp;9A. Controls and Procedures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Evaluation of Disclosure Controls and Procedures </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered
by this Annual Report on Form 10-K, the effectiveness of our disclosure controls and procedures. Based on that evaluation of our disclosure controls and procedures as of December&nbsp;31, 2014, our principal executive officer and principal financial
officer concluded that our disclosure controls and procedures as of such date are effective at the reasonable assurance level. The term &#147;disclosure controls and procedures,&#148; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange
Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act are recorded, processed, summarized and reported
within the time periods specified in the SEC&#146;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or
submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Management recognizes
that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of
possible controls and procedures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Management&#146;s Annual Report on Internal Control Over Financial Reporting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This annual report does not include a report of management&#146;s assessment regarding internal control over financial reporting or an attestation report of
the company&#146;s registered public accounting firm due to a transition period established by rules of the Securities and Exchange Commission for newly public companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inherent Limitations of Internal Controls </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement
preparation and presentation. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or
procedures may deteriorate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in Internal Control over Financial Reporting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the period
covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc893535_16">
</A>Item&nbsp;9B. Other Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc893535_17"></A>PART III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc893535_18"></A>Item&nbsp;10. Directors, Executive Officers, and Corporate Governance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement
related to the 2015 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc893535_19"></A>Item&nbsp;11. Executive Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement
related to the 2015 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc893535_20"></A>Item&nbsp;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement
related to the 2015 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc893535_21"></A>Item&nbsp;13. Certain Relationships and Related Transactions, and Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement
related to the 2015 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc893535_22"></A>Item&nbsp;14. Principal Accounting Fees and Services </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement
related to the 2015 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc893535_23"></A>PART IV </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc893535_24"></A>Item&nbsp;15. Exhibits, Financial Statements and Schedules </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) The following documents are filed as part of this report: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) Financial Statements: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><A HREF="#fin893535_1">Report of Independent Registered Public Accounting Firm</A></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">F-2</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><A HREF="#fin893535_2">Balance Sheet</A></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">F-3</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><A HREF="#fin893535_3">Statements of Operations and Comprehensive Loss</A></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">F-4</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><A HREF="#fin893535_4">Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit</A></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">F-5</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><A HREF="#fin893535_5">Statements of Cash Flows</A></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">F-6</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><A HREF="#fin893535_6">Notes to Financial Statements</A></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">F-7</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Financial Statement Schedules: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the
financial statements or the notes thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) Exhibits.&nbsp;The exhibits filed as part of this Annual Report on Form 10-K are set forth on the Exhibit
Index immediately following our consolidated financial statements. The Exhibit Index is incorporated herein by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc893535_25"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this
report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Lexington, Commonwealth of Massachusetts, on March 31, 2015. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>Inotek Pharmaceuticals Corporation</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David P. Southwell</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">David P. Southwell</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>President, Chief Executive Officer and Director</I></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each person whose individual signature appears below hereby constitutes and appoints David P. Southwell and Dale Ritter, and each of them,
with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person,
individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange
Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or
his substitute or substitutes may lawfully do or cause to be done by virtue thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities
Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="13%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:15.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ David P. Southwell</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">David P. Southwell</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">President,&nbsp;Chief&nbsp;Executive&nbsp;Officer&nbsp;and&nbsp;Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Principal Executive Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">March&nbsp;31,&nbsp;2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Dale Ritter</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dale Ritter</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Vice President&#150;Finance</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Principal Financial and Accounting Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">March 31, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;A.N.&nbsp;&#147;Jerry&#148;&nbsp;Karabelas,&nbsp;Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A.N. &#147;Jerry&#148; Karabelas, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">March 31, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Ittai Harel</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Ittai Harel</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">March 31, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Paul G. Howes</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Paul G. Howes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">March 31, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Devang V. Kantesaria, M.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Devang V. Kantesaria, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">March 31, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Isai Peimer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Isai Peimer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">March 31, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Martin Vogelbaum</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Martin Vogelbaum</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">March 31, 2015</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Inotek Pharmaceuticals Corporation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A>Index to Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Contents </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin893535_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin893535_2">Balance Sheets</A></P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin893535_3">Statements of Operations</A></P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin893535_4">Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit</A></P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin893535_5">Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin893535_6">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin893535_1"></A>Report of Independent </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registered Public Accounting Firm </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the
Board of Directors and Stockholders of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inotek Pharmaceuticals Corporation </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have audited the accompanying balance sheets of Inotek Pharmaceuticals Corporation as of December&nbsp;31, 2014 and 2013, and the related
statements of operations, changes in redeemable convertible preferred stock and stockholders&#146; deficit, and cash flows for each of the three years in the period ended December&nbsp;31, 2014. These financial statements are the responsibility of
the Company&#146;s management. Our responsibility is to express an opinion on these financial statements based on our audits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a
basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such
opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the
overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our opinion, the
financial statements referred to above present fairly, in all material respects, the financial position of Inotek Pharmaceuticals Corporation as of December&nbsp;31, 2014 and 2013, and the results of its operations and its cash flows for each of the
years in the three year period ended December&nbsp;31, 2014 in conformity with U.S. generally accepted accounting principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ McGladrey LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;31, 2015 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin893535_2"></A>Inotek Pharmaceuticals Corporation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Balance Sheets </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in
thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes payable, current portion</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible notes payable</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible notes redemption rights derivative</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes payable, net of current portion</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liabilities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series AA redeemable convertible preferred stock, $0.001 par value; 25,757,874 shares authorized; 24,057,013 shares and 23,204,783
shares issued and outstanding at December&nbsp;31, 2014 and 2013, respectively; (liquidation preference of $101,934 at December&nbsp;31, 2014, see Note 7)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series X redeemable convertible preferred stock, $0.001 par value; 2,902,050 shares authorized; 1,892,320 shares issued and outstanding
at December&nbsp;31, 2014 and 2013; (liquidation preference, see Note 7)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and Contingencies (Note 8)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.01 par value; 43,509,727 shares and 32,857,171 shares authorized at December&nbsp;31, 2014 and 2013, respectively;
1,020,088 shares and 1,021,972 shares issued December&nbsp;31, 2014 and 2013, respectively; 1,020,088 shares outstanding at December&nbsp;31, 2014 and 2013</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Treasury stock, at cost; no shares and 1,884 shares at December&nbsp;31, 2014 and 2013, respectively</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(176</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(128,041</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(118,510</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51,559</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,895</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin893535_3"></A>Inotek Pharmaceuticals Corporation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Operations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,592</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,330</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,112</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,307</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,704</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,654</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,849</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(884</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(213</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liabilities and convertible notes redemption rights derivative</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(847</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(81</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,531</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,616</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,058</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13.52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10.05</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8.04</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,020,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,018,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,016,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin893535_4"></A>Inotek Pharmaceuticals Corporation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series AA<BR>Redeemable<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series X<BR>Redeemable<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Treasury Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR>Paid-In<BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Par&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Balances at December&nbsp;31, 2011</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,458,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,451,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,018,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,884</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(176</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(104,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,029</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accretion of Series AA preferred stock issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accrual of Series AA preferred stock dividends</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,073</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,073</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,058</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,058</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Balances at December&nbsp;31, 2012</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,458,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,451,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,018,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,884</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(176</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(110,894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,930</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Repurchase of Series X preferred stock</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(558,864</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(343</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Issuance of Series AA preferred stock and Series AA preferred stock warrants, net of issuance costs</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,540,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Issuance of Series AA preferred stock upon conversion of convertible notes and accrued interest</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,677,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Conversion of Series AA preferred stock into common stock</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,471,965</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,253</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accretion of Series AA preferred stock to redemption value</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(380</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(380</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accrual of Series AA preferred stock dividends</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,232</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,232</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,616</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,616</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Balances at December&nbsp;31, 2013</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,204,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,892,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,021,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,884</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(176</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(118,510</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,895</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accretion of Series AA preferred stock to redemption value</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(864</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(864</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accrual of Series AA preferred stock dividends</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,401</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,401</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Exercise of Series AA preferred stock warrants</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">852,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Retirement of treasury stock</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,884</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(176</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,531</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,531</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Balances at December&nbsp;31, 2014</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,057,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,892,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,020,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(128,041</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(51,559</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:70pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin893535_5"></A>Inotek Pharmaceuticals Corporation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash flows from operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,531</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,616</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,058</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Adjustments to reconcile net loss to cash used by operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Noncash interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Change in fair value of warrant liabilities and convertible notes redemption rights derivative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(148</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,804</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(158</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(587</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,790</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,743</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,455</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,936</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash flows from investing activities:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds from sale of property and equipment</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net cash provided by investing activities:</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash flows from financing activities:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net proceeds from issuance of notes payable and Series AA preferred stock warrants</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net proceeds from issuance of convertible notes</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net proceeds from issuance of Series&nbsp;AA preferred stock and Series&nbsp;AA preferred stock warrants</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds from exercise of warrants for Series AA Preferred Stock</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Principal payments on notes payable</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,410</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net cash provided by financing activities:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net change in cash and cash equivalents</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,175</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,433</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and cash equivalents, beginning of period</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and cash equivalents, end of period</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Supplemental disclosure of cash flow information:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash paid for interest</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Supplemental disclosure of noncash investing and financing activities:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accrual of Series AA preferred stock dividends</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of 2,677,731 shares of Series AA preferred stock upon conversion of convertible notes and accrued interest</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accretion of Series AA preferred stock to redemption value</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Conversion of Series AA preferred stock to common stock</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Reclassification of fair value of warrant liability related to exercise of preferred stock warrants</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Retirement of treasury stock</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin893535_6"></A>Inotek Pharmaceuticals Corporation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share data) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Organization and Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inotek
Pharmaceuticals Corporation (the &#147;Company&#148;) is a clinical-stage biopharmaceutical company advancing molecules with novel mechanisms of action to address significant diseases of the eye. The Company&#146;s business strategy is to develop
and progress its product candidates through human clinical trials. The Company&#146;s headquarters are located in Lexington, Massachusetts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has devoted substantially all of its efforts to research and development, including clinical trials of its product candidates. The
Company has not completed the development of any product candidates. The Company has no current source of revenue to sustain present activities and does not expect to generate revenue until and unless the Company receives regulatory approval of and
successfully commercializes its product candidates. The Company is subject to a number of risks and uncertainties similar to those of other life science companies developing new products, including, among others, the risks related to the necessity
to obtain adequate additional financing, to successfully develop product candidates, to obtain regulatory approval of products candidates, to comply with government regulations, to successfully commercialize its potential products, to the protection
of proprietary technology and to the dependence on key individuals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2015, the Company completed its initial public offering
(the &#147;IPO&#148;) of (i)&nbsp;6,667,000 shares of common stock at a price of $6.00 per share and (ii)&nbsp;$20,000 aggregate principal amount of 5% Convertible Senior Notes due 2020 (the &#147;2020 Notes&#148;). In March 2015 the underwriters
purchased 299,333 shares of common stock at $6.00 per share and $1,000 of the 2020 Notes pursuant to exercises of their overallotment options. The Company received net proceeds of approximately $36,600, after deducting underwriting discounts and
offering-related costs, from its equity issuances and approximately $18,900 in net proceeds, after deducting underwriting discounts and offering-related costs, from its debt issuances. (See Note 11.) Prior to this the Company has funded its
operations primarily through the sale of preferred stock and issuance of convertible promissory notes and notes payable. As of December&nbsp;31, 2014, the Company had an accumulated deficit of $128,041 and $3,618 of cash and cash equivalents.
Subsequent to the IPO, the Company estimates that it has sufficient funding to sustain operations through the next 18 months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
will need to expend substantial resources for research and development, including costs associated with the clinical testing of its product candidates and will need to obtain additional financing to fund its operations and to conduct trials for its
product candidates. If such products were to receive regulatory approval, the Company would need to prepare for the potential commercialization of its product candidates and fund the commercial launch and continued marketing of its products. The
Company expects operating expenses will substantially increase in the future related to additional clinical testing and to support an increased infrastructure to support expanded operations and being a public company </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will require additional funding in the future and may not be able to raise such additional funds. The Company expects losses will
continue as it conducts research and development activities. The Company will seek to finance future cash needs through public or private equity offerings, license agreements, debt financings, collaborations, strategic alliances, or any combination
thereof. The incurrence of indebtedness would result in increased fixed payment obligations and could also result in restrictive covenants, such as limitations on our ability to incur additional debt, limitations on the Company&#146;s ability to
acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact the ability of the Company to conduct its business. If adequate funds are not available, the Company would delay, reduce or eliminate
research and development programs and reduce administrative expenses. The Company may seek to access the public or private capital markets whenever conditions are favorable, even if it does not have an immediate need for additional capital at that
time. In addition, if the Company raises additional funds through </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
collaborations, strategic alliances or licensing arrangements with third parties, it may have to relinquish valuable rights to its technologies, future revenue streams or product candidates or to
grant licenses on terms that may not be favorable to it. If the Company is unable to rise sufficient funding, it may be unable to continue to operate. There is no assurance that the Company will be successful in obtaining sufficient financing on
acceptable terms and conditions to fund continuing operations, if at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company&#146;s business, results of
operations and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Basis of Presentation</B>&#151;The accompanying financial statements have been prepared in conformity with accounting principles generally
accepted in the United States of America (&#147;GAAP&#148;). The Company&#146;s previously wholly owned subsidiaries were dissolved by December&nbsp;31, 2012. The Company currently has no subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Segment Reporting</B>&#151;Operating segments are defined as components of an enterprise about which separate discrete information is
available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment, that of
developing pharmaceutical product candidates with the intention of achieving marketing approval and commercializing the approved products. All operations are located in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Use of Estimates</B>&#151;The preparation of financial statements in conformity with GAAP requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results
could differ from these estimates. Significant items subject to such estimates and assumptions include the valuation of stock options used for the calculation of stock-based compensation, fair value of warrant liabilities and other derivative
instruments, and determination of accruals related to research and clinical development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Cash and Cash Equivalents</B>&#151;Cash and
cash equivalents consists of bank deposits and money market accounts. Cash equivalents are carried at cost which approximates fair value due to their short-term nature and which the Company believes do not have a material exposure to credit risk.
The Company considers all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company maintains its cash and cash equivalent balances in the form of money market, savings or operating accounts with financial
institutions that management believes are creditworthy. The Company&#146;s cash and cash equivalent accounts, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not
exposed to any significant credit risk on cash and cash equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Deferred Public Offering Costs</B>&#151;Deferred public offering
costs, which consist primarily of direct, incremental legal, accounting, SEC and NASDAQ fees relating to the IPO and issuance of the 2020 Notes, are capitalized as a component of other assets in the accompanying balance sheet as of December&nbsp;31,
2014. The portion of deferred public offering costs allocated to the equity offering will be offset against proceeds from the IPO and the portion of deferred public offering costs allocated to the debt offering will be recorded as deferred financing
costs and amortized to interest expense over the term of the 2020 Notes. At December&nbsp;31, 2014, the Company had $1,846 of deferred public offering costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Deferred Financing Costs</B>&#151;Financing costs incurred in connection with the Company&#146;s notes payable and convertible promissory
notes were capitalized at the inception of the notes and are amortized over the term of the respective notes using the effective interest rate method. Amortization of deferred financing costs were $219, $112 and $0 in the years ended
December&nbsp;31, 2014, 2013 and 2012, respectively, (see Note 5). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Research and Development Costs</B>&#151;Research and development costs are charged to expense
as incurred and include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">employee-related expenses including salaries, benefits, travel and stock-based compensation expense for research and development personnel; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expenses incurred under agreements with contract research organizations that conduct clinical and preclinical studies, contract manufacturing organizations and consultants; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs associated with preclinical and development activities; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs associated with regulatory operations. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Costs for certain development activities, such
as clinical studies, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, and information provided to the Company by its vendors on their actual costs
incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the patterns of costs incurred, and are reflected in the financial statements as accrued expenses, or prepaid expenses and other
current assets, if the related services have not been provided. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Stock-Based Compensation</B>&#151;The Company measures the cost of
employee services received in exchange for an award of equity instruments based on the fair value of the award on the grant date. That cost is recognized on a straight-line basis over the period during which the employee is required to provide
service in exchange for the award. The fair value of options on the date of grant is calculated using the Black-Scholes option pricing model based on key assumptions such as stock price, expected volatility and expected term. The Company&#146;s
estimates of these assumptions are primarily based on third-party valuations, historical data, peer company data and judgment regarding future trends and factors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for stock options issued to non-employees in accordance with the provisions of the Financial Accounting Standards Board
(&#147;FASB&#148;) Accounting Standard Codification (&#147;ASC&#148;) 505-50, <I>Equity-Based Payments to Non-employees</I>, which requires valuing the stock options on their grant date and remeasuring such stock options at their current fair value
as they vest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2014, the Company granted 900,117 stock options to employees and directors. Prior to these stock option grants,
the Company last granted stock options in 2009.(See Note&nbsp;7). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Fair Value Measurements</B>&#151;The Company is required to disclose
information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. ASC 820, <I>Fair Value Measurements and Disclosures</I> (&#147;ASC 820&#148;), establishes a
hierarchy of inputs used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that
reflect the Company&#146;s assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to
the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy are described below: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 1&#151;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the
ability to access at the measurement date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 2&#151;Valuations based on quoted prices for similar assets or liabilities in markets
that are not active or for which all significant inputs are observable, either directly or indirectly. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 3&#151;Valuations that
require inputs that reflect the Company&#146;s own assumptions that are both significant to the fair value measurement and unobservable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market,
the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#146;s level within the fair
value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The fair value of the Company&#146;s financial instruments, including cash and cash equivalents, prepaid expenses and other current assets,
accounts payable and accrued expenses approximate their respective carrying values due to the short-term nature of these instruments. The Company&#146;s assets and liabilities measured at fair value on a recurring basis include its warrant
liabilities and convertible notes redemption rights derivative (see Note 9). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Income taxes</B>&#151;The Company uses the asset and
liability method for accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of
existing assets and liabilities and their respective income tax bases. Deferred tax assets and liabilities are measured using enacted rates expected to apply to taxable income in the years in which those temporary differences are expected to be
recovered or settled. A valuation allowance is recorded if it is more likely than not that a deferred tax asset will not be realized. The Company has provided a full valuation allowance on its deferred tax assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more
likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50 percent
likelihood of being realized upon ultimate settlement with the relevant tax authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will recognize interest and penalties
related to uncertain tax positions in income tax expense. As of December&nbsp;31, 2014 and 2013 and for the periods ended December&nbsp;31, 2014, 2013 and 2012, the Company had no accrued interest or penalties related to uncertain tax positions and
no amounts have been recognized in the Company&#146;s statements of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Net loss per share</B>&#151;The Company calculates net
loss per share in accordance with ASC 260, <I>Earnings per Share</I>. Basic earnings (loss) per share (&#147;EPS&#148;) is calculated by dividing the net income or loss applicable to common stockholders by the weighted average number of common
shares outstanding for the period, without consideration of unissued common stock equivalents. The net loss applicable to common stockholders is determined by the reported net loss for the period and deducting dividends accrued and accretion of
preferred stock. Diluted EPS is calculated by adjusting the weighted average common shares outstanding for the dilutive effect of common stock options, warrants, and convertible preferred stock and accrued but unpaid convertible preferred stock
dividends. In periods where a net loss is recorded, no effect is given to potentially dilutive securities, as their effect would be anti-dilutive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the computation of basic and diluted earnings (loss) per share
attributable to the Company&#146;s common stockholders: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,531</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,616</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,058</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion and dividends on convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,265</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,612</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss applicable to common stockholders</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,796</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,176</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,020,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,018,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,016,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share applicable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13.52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10.05</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8.04</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following common stock equivalents were excluded from the calculation of diluted net loss per share for
the periods indicated as including them would have an anti-dilutive effect: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series AA preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,356,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,778,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,509,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series X preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">466,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">466,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">604,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants for Series AA preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">911,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,790,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,522,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,126,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Subsequent Events&#151;</B>The Company considers events or transactions that occur after the balance sheet
date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The Company has completed an evaluation of all subsequent events
through the date the financial statements were issued. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Property and Equipment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2014 and 2013, the Company&#146;s property and equipment consisted of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated<BR>Useful Life</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5&nbsp;years</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer hardware and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3&nbsp;&#150;&nbsp;5&nbsp;years</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated depreciation</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2014, 2013 and 2012, the Company recognized $0, $0 and $9 of
depreciation expense, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Accrued Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses at December&nbsp;31, 2014 and 2013 consisted of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Debt </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Bridge Notes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
December 2014, the Company sold an aggregate of $2,000 of subordinated convertible promissory notes to existing stockholders (the &#147;2014 Bridge Notes&#148;). The 2014 Bridge Notes mature on June&nbsp;30, 2015 and accrue interest at the rate of
8%&nbsp;per annum and are subordinate to all other senior indebtedness of the Company. Upon the closing of an IPO of common stock of at least $40,000 in gross proceeds (&#147;a qualifying public offering&#148;), all outstanding principal and accrued
interest thereon will automatically convert into common stock at the IPO price. In addition, the 2014 Bridge Notes have the following features: (i)&nbsp;in the event the Company sells new notes prior to a qualifying public offering, the noteholders
may convert the 2014 Bridge Notes into the new notes; (ii)&nbsp;if at any time prior to repayment of the 2014 Bridge Notes or a qualifying public offering the Company has a change in control transaction, the noteholders will receive either
(a)&nbsp;cash in the amount of twice the principal and interest due as of the effective date of the change in control transaction or (b)&nbsp;shares of Series AA preferred stock based upon the conversion of the principal and interest due as of the
effective date of the change in control transaction, whichever yields the greatest return (the &#145;Change in Control Redemption Feature&#148;); (iii)&nbsp;at any time after maturity, the noteholders can elect to convert all principal and accrued
interest into Series&nbsp;AA Preferred stock at the current Series AA preferred stock conversion price; (v)&nbsp;the maturity date of the 2014 Bridge Notes may be extended two times for additional six-month periods; (vi)&nbsp;upon an event of
default, as defined in the notes, the noteholders may declare the 2014 Bridge Notes immediately payable; and (vii)&nbsp;the Company may not prepay the 2014 Bridge Notes without the consent of noteholders owning at least two thirds of the outstanding
principal. Interest accrued on the Bridge Notes was $4 at December&nbsp;31, 2014 and is reflected in accrued expenses and other current liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that the automatic conversion into common stock upon an IPO was the predominant feature of the 2014 Bridge Notes. Based
on this the Company deemed the 2014 Bridge Notes to be share-settled debt and will accrete the debt discounts recorded (see below) to the redemption value over the term of the 2014 Bridge Notes. The Company evaluated the various features of the 2014
Bridge Notes and determined that the Change in Control Redemption Feature met the definition of a derivative and required bifurcation from the 2014 Bridge Notes. At the issuance of the 2014 Bridge Notes, the Company valued this derivative at $478
and allocated that value from the proceeds of the 2014 Bridge Notes and recorded a convertible notes redemption rights derivative liability on the balance sheet. The Company will mark this liability to market at each reporting date and reflect the
change in fair value in change in fair value of warrant liabilities and convertible notes redemption rights derivative in the statement of operations. In addition, the Company incurred $30 of costs associated with the issuance of the 2014 Bridge
Notes and recorded this amount as deferred financing costs which are reflected in prepaid expenses and other current assets. The Company will amortize (i)&nbsp;the debt discount recorded from the allocation of value to the redemption rights
derivative and (ii)&nbsp;deferred financing costs, into interest expense using the effective interest method. During the year ended December&nbsp;31, 2014, the Company reflected as interest expense related to the 2014 Bridge Notes (i)&nbsp;$4
related to the 8% coupon rate and (ii)&nbsp;$20 of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amortization of the initial redemption rights derivative liability and issuance costs. In addition, the Company reflected a $2 increase in fair value of the derivative liability at
December&nbsp;31, 2014 as loss on change in fair value of convertible notes redemption rights derivative. At December&nbsp;31, 2014, the principal balance of the 2014 Bridge Notes was $2,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the IPO in February 2015 (see Note 11), the 2014 Bridge Notes were converted into 337,932 shares of common stock based upon the
IPO common share offering price of $6.00 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Notes Payable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;28, 2013, the Company entered into two Loan and Security Agreements (the &#147;Loan Agreements&#148; or &#147;Loans&#148;) with
two financial entities (the &#147;Lenders&#148;) pursuant to which the Company issued Loans for $3,500 to each lender and received proceeds of $6,915 net of costs and fees payable to the lenders. The Loans bear interest at a rate per annum of 11.0%.
The Loans mature on October&nbsp;1, 2016 and required interest-only payments for the initial 12 months and thereafter required repayment of the principal balance with interest in 27 monthly installments. Also, upon full repayment or maturity of the
Loans, the Lenders are due a termination payment of 3.0% of the initial principal amount of the Loans, or $210 (the &#147;Loan Termination Payment&#148;). In connection with the Loan Agreements, the Company granted first priority liens and the Loans
are collateralized by the Company&#146;s personal property, including cash and cash equivalents. The Loan Agreements contain representations and warranties by the Company and certain indemnification provisions, non-financial covenants and default
provisions. The Loan Agreements also included certain provisions allowing for prepayment of the debt by the Company, exercisable at the Company&#146;s option, which require payment of additional interest to the Lenders based upon a stated rate and
the balance outstanding at repayment. The Company has determined that the various embedded features did not require bifurcation from the Loan Agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Loan Agreements, the Company issued to the Lenders fully-vested warrants to purchase either, at the election of the
warrant holder, (i)&nbsp;228,906 shares of the Company&#146;s Series AA preferred stock at an exercise price of $1.529 per share, or (ii)&nbsp;$350 of stock in the next round stock, as defined in the Loan Agreements, at a price that is the lowest
effective price per share that is offered in the next round. The warrants expire on the earlier of (i)&nbsp;ten years after the date of grant, or (ii)&nbsp;immediately prior to an acquisition transaction, as defined in the warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that the warrants should be classified as a liability based upon the nature of the underlying Series AA preferred
stock. The Company recorded the fair value of the warrants of approximately $222 (Note 9) as a discount to the carrying value of the Loans and as a liability. The Company will recognize any change in the value of the warrant liability each reporting
period in the statement of operations. Additionally, the Company incurred fees related to the Loan Agreements and reimbursed Lenders for costs incurred by them aggregating $85 and reflected these fees as a discount to the carrying value of the Loan.
The Company amortized these loan discounts and the Loan Termination Payment, together totaling $517, to interest expense over the term of the Loan using the effective interest rate method. For the year ended December&nbsp;31, 2014, interest expense
related to the Loan Agreements was $956, including $218 related to accretion of the debt discount and termination payment. For the year ended December&nbsp;31, 2013, interest expense related to the Loan Agreements was $501, including $112 related to
accretion of the debt discount and termination payment. At December&nbsp;31, 2014, the principal balance on the Loan Agreements was $5,800, including the Loan Termination Payment and the unamortized debt discount and termination payment balance was
$188. At December&nbsp;31, 2013, the principal balance on the Loan Agreements was $7,210, including the Loan Termination Payment, and the unamortized debt discount and termination payment balance was $405. Principal payments on the Loans were $1,410
during the year ended December&nbsp;31, 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Company&#146;s IPO in February 2015 (see Note 11), the Company
exercised its right to terminate the Loan Agreements by paying $5,347 in principal, the $210 Loan Termination Payment and $160 additional interest of 3% of the principal balance due at the time of the termination, plus interest $8 of accrued since
February&nbsp;1, 2015. Subsequent to the Company&#146;s IPO, the warrants issued to the lenders became exercisable for 56,408 shares of common stock at $6.204 per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Promissory Notes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;2, 2012, the Company entered into convertible note purchase agreements (the &#147;Convertible Note Agreements&#148;) with certain
of its principal investors pursuant to which the investors agreed to make loans to the Company in installments aggregating $3,500 in exchange for 8% convertible promissory notes (the &#147;Convertible Notes&#148;). The Convertible Notes&#146;
maturity date was July&nbsp;2, 2013. In July and November 2012, $1,500 and $1,000, respectively, of Convertible Notes were issued by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Convertible Notes plus the accrued interest thereon were convertible into shares issued in the Company&#146;s next sale of preferred stock
on or before the maturity date of the Convertible Notes in an amount of at least $10,000 from one or more institutional investors. The conversion price was at a 10% discount from the issue price of such preferred stock. Based upon the terms of the
Convertible Notes, and the intention to convert the notes prior to maturity, the Company deemed the Convertible Notes to be share-settled debt, and the Company accreted the Convertible Notes over their term to the value of the preferred stock into
which the Convertible Notes would be converted ($3,909), recognizing accretion of this $409 discount as interest expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the
terms of the Convertible Note Agreements, if a change-in control event, as defined in the Convertible Note Agreements, occurred prior to repayment or conversion of the Convertible Notes, the Convertible Noteholders would be entitled to receive in
cash, an amount equal to two times the principal plus accrued interest. This feature was determined to be an embedded derivative. The Company bifurcated the derivative and accounted for it separately determining the value of the derivative to be de
minimis. The Company reassessed the value of the derivative at each reporting period and concluded that the value remained de minimis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2013 and 2012, the Company recorded $381 and $143, respectively, of non-cash interest expense related
to the accretion of the conversion feature and the accrual of interest on the Convertible Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;11, 2013, pursuant to the
provisions of the Convertible Note Agreements and in connection with the Company&#146;s issuance of Series AA preferred stock (see Note 7), the carrying value of the Convertible Notes of $3,909 and accrued interest of $185 were converted into
2,677,731 shares of Series AA preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No provision for federal or state income taxes was recorded during the years ended December&nbsp;31, 2014, 2013 and 2012 as the Company
incurred operating losses for each of these years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation between the effective tax rates and statutory rates for the years
ended December&nbsp;31, 2014, 2013 and 2012 is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computed at statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.93</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.44</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.46</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expiration of state net operating loss carryforward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9.35</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.43</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.41</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.28</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.51</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.82</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27.73</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43.34</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37.64</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The tax effect of significant temporary differences representing deferred tax assets and
liabilities as of December&nbsp;31, 2014 and 2013 is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss (&#147;NOL&#148;) and credit carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital loss carryover</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44,878</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As required by ASC 740, <I>Income Taxes</I>, management of the Company has evaluated the positive and negative
evidence bearing upon the realizability of its deferred tax assets, which are comprised principally of NOL carryforwards and capitalized research and development costs. As a result of the fact that the Company has incurred tax losses from inception,
management has determined that it is more likely than not that the Company will not recognize the benefits of federal and state net deferred tax assets and, as a result, a full valuation allowance has been established against its net deferred tax
assets as of December&nbsp;31, 2014 and 2013. The Company has offset certain deferred tax liabilities with deferred tax assets that are expected to generate offsetting deductions within the same period. During the years ended December&nbsp;31, 2014
and 2013, the valuation allowance changed by $2,643 and $3,301, respectively. Realization of deferred tax assets is dependent upon the generation of future taxable income. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2014, the Company had federal NOL carryforwards for income tax purposes of approximately $77,052 that expire at
various dates through 2034, and state NOL carryforwards of approximately $36,094 that expire at various dates through 2034, available to reduce future federal and state income taxes, if any. As of December&nbsp;31, 2014, the Company had federal
research and development tax credits of approximately $2,698, and state research and development tax credits of approximately $571. If substantial changes in the Company&#146;s ownership should occur, as defined in Section&nbsp;382 of the Internal
Revenue Code of 1986, as amended, (the &#147;Code&#148;), there could be annual limitations on the amount of loss carryforwards which can be realized in future periods. The Company has determined that it has experienced a prior ownership change
occurring in 2006. The pre-change NOLs, although subject to an annual limitation, can be utilized in future years as well as any post change NOLs, provided that sufficient income is generated and no future ownership changes occur that may limit the
Company&#146;s NOLs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2014 and 2013, the Company&#146;s unrecognized tax benefits totaled $284 and $258,
respectively, which if recognized would affect the effective tax rate prior to the adjustment for the Company&#146;s valuation allowance. The Company files income tax returns in the U.S. federal and Massachusetts tax jurisdictions. Tax years 2011
through 2014 remain open to examination by the tax jurisdictions to which the Company is subject to tax. Since the Company is in a loss carryforward position, the Internal Revenue Service (&#147;IRS&#148;) and state taxing authorities are permitted
to audit the earlier tax years and propose adjustments up to the amount of the NOLs, generated. The Company is not currently under examination by the IRS or any other jurisdiction for any tax years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change in unrecognized tax benefits for each of the years ended December&nbsp;31, 2014, 2013
and 2012 are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at January&nbsp;1,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions for current year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reductions for expirations of statute of limitations or settlements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company does not expect significant changes in its unrecognized tax benefits over the next twelve months.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Equity </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Authorized Shares
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2014, the authorized stock of the Company was 43,509,727 shares of common stock, $0.01 par value per
share, and 28,659,924 shares of preferred stock, $0.001 par value per share, of which 25,757,874 shares are authorized Series AA redeemable convertible preferred stock (the &#147;Series AA preferred stock&#148;) and 2,902,050 shares are authorized
as Series X redeemable convertible preferred stock (the &#147;Series X preferred stock&#148;) (collectively, the &#147;Preferred Stock&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Reverse Stock Splits </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2014, the board of directors and the stockholders of the Company approved a 1-for-3.39 reverse stock split of the Company&#146;s
outstanding common stock and in January 2015, the board of directors and the stockholders of the Company approved a 1-for-1.197 reverse stock split of the Company&#146;s outstanding common stock. Shares of common stock underlying outstanding stock
options were proportionally reduced and the respective exercise prices were proportionally increased in accordance with the terms of the option agreements. The Company&#146;s historical share and per share information has been retroactively adjusted
in the financial statements presented to give effect to these reverse stock splits, including reclassifying an amount equal to the reduction in par value to additional paid-in capital. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All preferences, voting
powers, relative, participating, optional, or other specific rights and privileges, limitations, or restrictions of the common stock are expressly subject to those that may be fixed with respect to any shares of preferred stock. Common stockholders
are entitled to one vote per share, and to receive dividends, when and if declared by the Board. At each of December&nbsp;31, 2014 and December&nbsp;31, 2013, there were 1,020,088&nbsp;shares common stock outstanding and at December&nbsp;31, 2012,
there were 1,016,467&nbsp;shares of common stock outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated the tranched nature of its Preferred Stock offerings, its investor registration rights, as well as the rights,
preferences and privileges of each series of Preferred Stock and has concluded that there are no freestanding derivative instruments or any embedded derivatives requiring bifurcation. Additionally, the Company assessed the conversion terms
associated with its Preferred Stock and concluded that there were no beneficial conversion features. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Series AA Redeemable Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2012, there were 15,458,796 shares of Series AA preferred stock issued and outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June and July 2013, the Company issued 6,540,221 shares of Series AA preferred stock at a price per share of $1.529 for cash proceeds in
the amount of $9,961, net of issuance costs of $39. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with these financings, the Company issued 2,677,731 shares of Series AA
preferred stock pursuant to conversion of the Convertible Notes (see Note 5). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain investors did not purchase their prescribed
pro-rata shares, as defined in the Series AA convertible preferred stock and warrant purchase agreements and in accordance therewith 1,471,965 shares of their previously outstanding Series AA preferred stock were converted into 3,621&nbsp;shares of
common stock and the $2,253 carrying value of the converted Series AA preferred stock was reclassified to additional paid-in capital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the Company issued warrants to purchase 852,230 shares of Series AA preferred stock at a price of $0.01 per share, with an
expiration date on the earliest of (i)&nbsp;July 11, 2023, (ii)&nbsp;the closing of the Company&#146;s IPO, or (iii)&nbsp;the closing of a sale event, as defined in the warrant. The Company allocated $1,585 of the proceeds received to the warrants
issued, representing the grant date fair value of the warrants, and accounts for these warrants as liabilities. The Company recognized any change in the fair value of the warrant liabilities each reporting period in the consolidated statements of
operations (Note 9). These warrants were exercised in full during the year ended December&nbsp;31, 2014 for total proceeds of $8 which was recorded as Series AA preferred carrying value. The aggregate $2,250 fair value of the warrants as of the date
of each exercise was reclassified partially to Series AA preferred stock carrying value and the remainder to accumulated paid-in capital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the optional redemption feature of the Series AA preferred stock, the Company classifies the Series AA preferred stock as temporary
equity in the mezzanine section of the balance sheet and is accreting the value to the redemption amount. The carrying amount of the Series AA preferred stock at December&nbsp;31, 2014 was $46,253, including $9,976 of accrued but unpaid and
undeclared dividends. The carrying amount of the Series AA preferred stock at December&nbsp;31, 2013 was $40,685, including $6,575 of accrued but unpaid and undeclared dividends. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Rights, Preferences, and Privileges </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Voting: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Series AA preferred
stock votes together with all other classes and series of stock as a single class on all actions to be taken by the stockholders of the Company. Each share of Series AA preferred stock shall entitle the holder to such number of votes per share on
each such action as shall equal the number of shares of common stock (including fractions of a share) into which each share of Series AA preferred stock is then convertible. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Series AA preferred
stock accrues dividends quarterly at the rate of eight percent (8%)&nbsp;per annum, based upon the Series AA original issue price, whether or not declared, are cumulative and compounded annually. The Series AA original issue price was $1.529 per
share (&#147;Series AA Original Issue Price&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Liquidation Preference: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon any liquidation, dissolution or winding up of the Company (a &#147;Liquidation Event&#148;), whether voluntary or involuntary, the holders
of the shares of Series AA preferred stock shall be paid out of the assets of the Company available for distribution to its stockholders before any payment shall be made to the holders of Series </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
X preferred stock or common stock, an amount per share equal to two times the Series AA Original Issue Price plus any accrued or declared but unpaid dividends ( the &#147;Series AA Initial
Preference&#148;). If upon any Liquidation Event, the assets to be distributed to the holders of Series AA preferred stock shall be insufficient to permit payment to the stockholders of the Series AA Initial Preference, then the holders of the
Series AA preferred stock shall share ratably in any distribution of the remaining assets of the Company available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon
such distribution if all amounts payable on or with respect to such shares were paid in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon any Liquidation Event, immediately
after the holders of Series AA preferred stock have been paid in full the Series AA Initial Preference and after the holders of Series X preferred stock have been paid full the Series X preference (see Series X preferred stock below), the holders of
the shares of Series AA preferred stock shall be paid out of the assets of the Company available for distribution to its stockholders before any payment shall be made to the holders of common stock, a per share amount equal to one-half times the
Series AA Original Issue Price (the &#147;Series AA Secondary Preference&#148;). If upon any Liquidation Event, the assets to be distributed to the holders of Series AA preferred stock shall be insufficient to permit payment to such stockholders of
the Series AA Secondary Preference, then the holders of the Series AA preferred stock shall share ratably in any distribution of the remaining assets of the Company available for distribution in proportion to the respective amounts which would
otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Optional Conversion: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holder
of any share or shares of Series AA preferred stock shall have the right, at its option at any time, to convert any such shares of Series AA preferred stock (except that upon any liquidation of the Company the right of conversion shall terminate at
the close of business on the business day fixed for payment of the amounts distributable on the Series AA preferred stock), each such share of Series AA preferred stock being converted into such number of fully paid and nonassessable shares of
common stock as is obtained by dividing (1)&nbsp;the Series AA Original Issue Price plus any accrued or declared but unpaid dividends by (2 ) the Series AA Conversion Price in effect at the date any share or shares of Series AA preferred stock are
surrendered for conversion. The &#147;Series AA Conversion Price&#148; was $1.529 and subject to adjustment as discussed under the section &#147;Anti-Dilution&#148; below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mandatory Conversion: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All
outstanding shares of Series AA Convertible Preferred Stock (including all accrued or declared but unpaid dividends thereon) shall automatically convert to shares of Common Stock (i) upon the vote or written consent of the holders of at least sixty
six and two-thirds percent (66 and 2/3%)&nbsp;of the issued and outstanding Series AA Convertible Preferred Stock, or (ii) upon the closing of a firm commitment underwritten public offering of shares of Common Stock pursuant to an effective
registration statement under the Securities Act of 1933, as amended, that is underwritten by an investment bank approved by the Board of Directors and by a vote or written consent of the holders of at least sixty six and two-thirds percent (66 and
2/3%) of the issued and outstanding Series AA Convertible Preferred Stock, with aggregate proceeds from such offering to the Corporation in excess of $40,000,000, before deduction of the underwriting discounts and commissions (a &#147;Qualifying
Public Offering&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Special Mandatory Conversion: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that any investor does not participate in a qualified financing by purchasing in the aggregate, in such qualified financing and
within the time period specified by the Company its pro rata amount of the qualified financing (such Investor&#146;s &#147;Pro Rata Amount&#148;), then the applicable portion of the shares of Series AA preferred stock held by such investor
immediately prior to the initial closing of the qualified financing shall automatically, and without any further action on the part of such Investor, be converted into common stock at a conversion ratio of one hundred-to-one (100:1)&nbsp;(such that
every one hundred shares of Series AA preferred Stock are converted into one share of common stock), effective upon, subject to, and concurrently with, the consummation of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
final closing. For purposes of determining the number of shares of Series AA preferred stock owned by an investor, and for determining the number of offered securities an investor has purchased
in a qualified financing, all shares of Series AA preferred stock held by affiliates of such investor shall be aggregated with such investor&#146;s shares and all offered securities purchased by affiliates of such Investor shall be aggregated with
the offered securities purchased by such Investor (provided that no shares or securities shall be attributed to more than one entity or person within any such group of affiliated entities or persons). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Anti-dilution: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The conversion
price of the Series AA preferred stock is subject to adjustment to reduce dilution in the event that the Company issues additional equity securities at a purchase price less than the applicable conversion price. The conversion price will also be
subject to proportional adjustment for events such as stock splits, stock dividends, and recapitalization. As a result of the reverse stock splits in November 2014 and January 2015, the Series&nbsp;AA conversion price was adjusted to $6.204. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Redemption: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of Series AA
preferred stock shall be redeemed by the Company out of funds lawfully available there for at a price equal to the Series AA Original Issue Price per share, plus all accrued or declared but unpaid dividends thereon (the &#147;Redemption
Price&#148;), in three annual installments commencing not more than 60 days after receipt by the Company at any time on or after the fifth anniversary of June&nbsp;9, 2010, from the holders of at least sixty-six and two-thirds percent (66 and 2/3%)
of the then outstanding shares of Series AA preferred stock of written notice requesting redemption of all shares of Series AA preferred stock. The date of each such installment shall be referred to as a &#147;Redemption Date.&#148; If the Company
does not have sufficient funds legally available to redeem on any Redemption Date all shares of Series AA preferred stock to be redeemed on such Redemption Date, the Company shall redeem a pro rata portion of each holder&#146;s redeemable shares of
such capital stock out of funds legally available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain &#147;change in control&#148; events, as defined in the Company&#146;s
certificate of incorporation, are considered to be liquidation events upon which the holders of Series AA preferred stock have the option to require the Company redeem the shares held, at their liquidation value, as discussed above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Series X Redeemable Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2010, the Company sold 2,451,184 shares of Series X redeemable convertible preferred stock (&#147;Series X preferred stock&#148;) to
employees and consultants to the Company at a purchase price of $0.001 per share, subject to stock purchase and restriction agreements. Pursuant to these agreements, the shares vest upon the third anniversary of the issuance if the purchaser of the
Series X preferred shares remained an employee or maintained a business relationship with the Company. The Series X preferred stockholder cannot sell, assign, transfer, pledge, encumber or dispose of all or any of the unvested shares except to the
Company. The Company determined that the issuance of these restricted shares was compensatory in nature and accounted for the issuance as stock-based compensation. The excess grant date value, over the proceeds received from each purchase was
determined to be compensation expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Simultaneous with the issuance of Series X preferred stock, the Company entered into termination
and separation agreements with certain employees and consultants who purchased 392,189 shares of Series X preferred stock. The Company determined that there was no substantive future services required of these employees and consultants and
recognized all of the associated compensation expense upon issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The remaining 2,058,995 shares were issued to continuing employees
of the Company and the Company recognized the compensation expense on a straight-line basis over the requisite service period, net of an estimated forfeiture rate. The Company recognized compensation expense of $185 related to the vesting of these
shares during the year ended December&nbsp;31, 2013. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Two of the employees that purchased Series X preferred stock were terminated by the Company in
May 2013. Upon termination, the Company repurchased an aggregate of 558,864 shares of Series X preferred stock and modified the vesting terms on the remaining 558,862 shares of Series X preferred stock held by these employees. The modified vesting
terms provide that the shares will vest upon the occurrence of a liquidation event, if such liquidation event occurs within two years of the date of the modifications. The Company retains the right to repurchase the unvested shares at the purchase
price of $0.01 per share if a liquidation event does not occur within two years of the date of the modification. In connection with this modification, during the year ended December&nbsp;31, 2013, the Company reversed the cumulative $343 of
stock-based compensation that had been recorded related to these shares. During the year ended December&nbsp;31, 2014, the Company further modified the vesting terms of these 558,862 shares of Series&nbsp;X preferred stock such that the
Company&#146;s repurchase right will expire upon consummation of an IPO of its common stock occurring prior to June&nbsp;30, 2015. The Company has estimated the fair value of the modified award at the modification date and at December&nbsp;31, 2014
to be $950 and will recognize the compensation expense in the quarter ending March&nbsp;31, 2015 as a result of the Company&#146;s February 2015 IPO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table is a rollforward of unvested Series X preferred stock shares; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested&#151;December&nbsp;31, 2011</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,451,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repurchased</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested&#151;December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,451,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,333,458</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repurchased</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(558,864</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested&#151;December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">558,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repurchased</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested&#151; December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">558,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the redemption feature of the Series X preferred stock, discussed further below, the Company classifies
the Series X preferred stock as temporary equity in the mezzanine section of the balance sheet. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Rights, Preferences, and Privileges
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Voting Rights: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Series X preferred stock does not have any voting rights, except as related to the election of certain directors. When the Series X preferred stock has voting rights, each share of Series X preferred stock entitles the holder to such number of votes
per share on each such action as shall equal the number of shares of common stock into which each share of Series X preferred stock is then convertible. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Liquidation Preference: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon
any liquidation event, such as a liquidation, dissolution or winding up of the Company, immediately after the holders of Series AA preferred stock have been paid in full, the Series&nbsp;AA preferred stock initial preference as described above and
before any payment is made to the holders of common stock, the holders of the shares of Series X preferred stock shall be paid out of assets of the Company available for distribution to its stockholders a per share amount determined by taking the
product of (1)&nbsp;the percentage calculated as (i)&nbsp;the total number of issued and outstanding shares of common stock owned by the holders of Series X preferred stock determined on an as converted fully-diluted basis divided by (ii)&nbsp;the
total number of issued and outstanding shares of common stock of the Company on an as converted fully diluted basis, and (2)&nbsp;the remaining assets of the Company available for distribution to its stockholders, and dividing such product by the
number of issued and outstanding shares of Series X preferred stock (the &#147;Series X Preference&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain change in control events, as defined in the Company&#146;s certificate of incorporation,
are considered to be liquidation events upon which the holders of Series X preferred stock have the option to require the Company redeem the shares held, at their liquidation value, as discussed above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Right to Convert: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holder of
any share of Series X preferred stock shall have the right, at any time to convert any such share (except that upon any liquidation of the Company the right of conversion shall terminate at the close of business on the business day fixed for payment
of the amounts distributable on the Series X preferred stock), into fully paid and nonassessable shares of common stock based on the Series X Conversion Ratio. The Series X Conversion Ratio was initially 1:1, and subject to adjustment as discussed
under the section &#147;Anti-Dilution&#148; below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mandatory Conversion: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series&nbsp;X preferred stock shall be automatically converted into common stock, at the then applicable conversion price (i)&nbsp;in the
event that the holders of at least two-thirds of the outstanding Series&nbsp;AA preferred stock, voting as a single class, consent to such conversion, or (ii)&nbsp;upon the closing of a qualified public offering, as defined. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Anti-Dilution: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The conversion
price of the Series&nbsp;X preferred stock is subject to adjustment to reduce dilution in the event that the Company issues additional equity securities at a price less than the applicable conversion price. The conversion price will also be subject
to proportional adjustment for events such as stock splits, stock dividends, and recapitalization. As a result of the reverse stock splits in November 2014 and January 2015, the Series&nbsp;X conversion ratio was adjusted to approximately
1-for-4.06. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Treasury Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Treasury stock of $176 at December&nbsp;31, 2013 reflects 1,884 shares on common stock repurchased by the Company and recorded at cost. During
the year ended December&nbsp;31, 2014, the treasury stock was retired. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2004 Stock Option and Incentive Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2004, the Company&#146;s board of directors adopted the 2004 Stock Option and Incentive Plan (the 2004 &#147;Plan&#148;) for the
issuance of incentive stock options, restricted stock, and other equity awards, all for common stock, as determined by the board of directors to employees, officers, directors, consultants, and advisors of the Company and its subsidiaries. Only
stock options were granted under the 2004 Plan. The 2004 Plan expired in February 2014 but remains effective for all outstanding options. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the option activity for the years ended December&nbsp;31, 2012,
2013 and 2014 under the 2004 Plan: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise<BR>Price Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise<BR>Price Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise<BR>Price Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at beginning of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40.578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40.578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40.578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expired during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(877</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40.578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at end of the period</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40.578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40.578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40.578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at end of period</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40.578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40.578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40.578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average years remaining on contractual life</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrecognized compensation cost related to non-vested stock options</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recorded a total of $1 in the year ended December&nbsp;31, 2013 as stock-based compensation
expense relating to outstanding stock options granted pursuant to the 2004 Plan. At December&nbsp;31, 2013, all options were fully vested and there was no unrecognized stock-based compensation expense relating to stock options granted pursuant to
the 2004 Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2014 Stock Option and Incentive Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2014, the Company&#146;s board of directors adopted the 2014 Stock Option and Incentive Plan (the &#147;2014 Plan&#148;) for the issuance of
incentive and non-qualified stock options, restricted stock, and other equity awards, all for common stock, as determined by the board of directors to employees, officers, directors, consultants, and advisors of the Company and its subsidiaries.
There were 900,117&nbsp;shares issuable under the 2014 Plan as of December&nbsp;31, 2014. In November 2014, the Board of Directors increased the number of shares available for grant under the terms of the 2014 Plan to the number of shares that
represents 13.7% of the outstanding common stock after giving effect to the issuance of shares relating to the Company&#146;s proposed IPO (not including any shares purchased by the underwriters pursuant to their overallotment option). Subsequent to
the IPO in February 2015, there were 2,175,216 shares available for grant under the 2014 Plan. The 2014 Plan expires in August 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
August&nbsp;28, 2014, the board of directors granted 900,117 stock options at an exercise price of $4.342 per share, the fair market value of the common stock as determined by the board of directors. All stock options granted have a ten-year term.
Of the stock options granted, 59,142 were fully vested at the date of the grant. The remaining 840,975 stock options granted (i)&nbsp;would be of no further force and effect if the Company had not consummated an IPO prior to the one-year anniversary
of the grant date or (ii)&nbsp;upon consummation of the IPO, will vest 25% on the one-year anniversary of the grant date and remaining 75% will vest equally over the following 35 monthly anniversaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of each stock option granted is estimated on the grant date using a Black-Scholes stock option pricing model based on the
following assumptions: an expected term of 5 to 6.25 years; expected stock price volatility of 83.3% to 92.5%; a risk free rate of 1.63% to 1.84%; and a dividend yield of 0%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recorded stock compensation expense of $170 in general and administrative expense in the year ended December&nbsp;31, 2014 related
to the 59,142 stock options that were granted pursuant to the 2014 Plan </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and fully vested as of the date of grant. The Company will recognize $2,798 of stock compensation expense related to the remaining 840,975 stock options on a straight-line basis over the vesting
period commencing upon the consummation of the IPO in February 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has historically granted common stock options pursuant
to the 2004 and 2014 Plans at an exercise price that is not less than the fair market value of the Company&#146;s stock as determined by the board of directors, with input from management. The board of directors has historically determined the
estimated fair value of the Company&#146;s common stock on the date of grant based on a number of objective and subjective factors, including external market conditions, rights and preferences of securities senior to the common stock at the time of
each grant, the likelihood of achieving a liquidity event such as an IPO or the sale of the Company, and third party valuations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company recognizes compensation expense based on the estimated grant date fair value method using the Black-Scholes valuation model. The Company reduces compensation expense for expected forfeitures, as estimated by management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the Company&#146;s stock was not traded publicly on the date of the 2014 Plan stock option grants, the computation of expected volatility
was based on the historical volatilities of peer companies. The peer companies include organizations that are in the same industry, with similar size and stage of growth. The Company estimates that the expected life of the options granted using the
simplified method allowable under Staff Accounting Bulletin No.&nbsp;107, <I>Share Based Payments</I>. The expected life is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post
vesting termination behavior among its employee population. The interest rate for grants pursuant to the 2004 and 2014 Plans are based on the U.S. treasury bills rate for U.S. treasury bills with terms commensurate with the expected term of the
option grants on the grant date of the option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the 2014 Plan option activity for the year ended
December&nbsp;31, 2014: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise<BR>Price Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at beginning of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">900,117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expired during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at end of the period</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">900,117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at end of period</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average years remaining on contractual life</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrecognized compensation cost related to non-vested stock options</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2014 the Company&#146;s board of directors adopted and the stockholders approved the 2014 Employee Stock Purchase Plan, or ESPP.
The Company&#146;s board of directors has authorized the issuance of a number of shares of common stock issuable under the ESPP to the number that represents 1% of our outstanding common stock outstandiing after the IPO, or 160,276 shares. The ESPP
provides that the number of shares reserved and available for issuance under the ESPP shall be cumulatively increased each January&nbsp;1, beginning on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
January&nbsp;1, 2016, by the lesser of (i)&nbsp;600,000&nbsp;shares of common stock or (ii)&nbsp;the number of shares necessary to set the number of shares of Common Stock under the Plan at 1%
percent of the outstanding number of shares as of January&nbsp;1 of the applicable year. However, the board of directors reserves the right to determine that there will be no increase for any year or that any increase will be for a lesser number of
shares. The number of shares reserved and available for issuance under the ESPP is subject to adjustment in the event of a stock split, stock dividend or other change in the Company&#146;s capitalization. The ESPP may be terminated or amended by the
board of directors at any time, but will automatically terminate upon the tenth anniversary of the date the ESPP is approved by the stockholders. An amendment that increases the number of shares of common stock that are authorized under the ESPP and
certain other amendments require the approval of the stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All employees who are employed for at least six months and whose
customary employment is for more than 20 hours a week are eligible to participate in the ESPP. Any employee who owns 5% or more of the voting power or value of the Company&#146;s shares of common stock is not eligible to purchase shares under the
ESPP. Each employee who is a participant in the ESPP may purchase shares by authorizing payroll deductions of up to 10% of his or her base compensation during an offering period. Unless the participating employee has previously withdrawn from the
offering, his or her accumulated payroll deductions will be used to purchase shares of common stock on the last business day of the offering period at a price equal to 85% of the fair market value of the ordinary shares on the first business day or
the last business day of the offering period, whichever is lower, provided that no more than 5,000 shares of common stock may be purchased by any one employee during each offering period. Under applicable tax rules, an employee may purchase no more
than $25,000 worth of stock, valued at the start of the purchase period, under the ESPP in any calendar year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each employee who is a
participant in the ESPP may purchase shares by authorizing payroll deductions of up to 10% of his or her base compensation during an offering period. Unless the participating employee has previously withdrawn from the offering, his or her
accumulated payroll deductions will be used to purchase shares of common stock on the last business day of the offering period at a price equal to 85% of the fair market value of the ordinary shares on the first business day or the last business day
of the offering period, whichever is lower, provided that no more than 5,000 shares of common stock may be purchased by any one employee during each offering period. Under applicable tax rules, an employee may purchase no more than $25,000 worth of
stock, valued at the start of the purchase period, under the ESPP in any calendar year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may make one or more offerings to our
employees to purchase stock under the ESPP. No offerings of the ESPP have commenced as of December&nbsp;31, 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Restricted Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2011, the Company issued 24,280 restricted common shares pursuant to a stock purchase and restriction agreement for a price of $0.0406 per
share. The Company received $1 from the grantee. These shares vest 25% on each of the first four anniversaries of the date of grant. During the year ended December 31, 2014, the board of directors accelerated the vesting of the last tranche
resulting in 12,140 shares vesting in such period. The following table is a rollforward of unvested restricted common shares: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested shares&#151;December&nbsp;31, 2011</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares vested</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,070</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested shares&#151;December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares vested</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,070</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested shares&#151;December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares vested</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,140</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested shares&#151;December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recorded the excess grant date fair value over the proceeds received as compensation
expense. The Company recorded $7, $9 and $9 of stock-based compensation expense related to this award in the years ended December&nbsp;31, 2014, 2013 and 2012, respectively. At December&nbsp;31, 2014, there was no unrecognized compensation expense
related to this grant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Operating leases </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company leases office space in Lexington, Massachusetts under a lease agreement expiring in March 2015. Rent expense for the years ended December&nbsp;31, 2014, 2013, and 2012 was $54, $47 and $97, respectively. In March 2015, the Company signed a
six-month lease for office space in Lexington, Massachusetts at $7 per month commencing April&nbsp;1, 2015. The Company is committed to pay approximately $58 in rent expense in 2015 pursuant to these leases. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Indemnification Arrangements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As permitted under Delaware law, the Company&#146;s bylaws provide that the Company will indemnify any director, officer, employee or agent of
the Company or anyone serving in these capacities. The maximum potential amount of future payments the Company could be required to pay is unlimited. The Company has insurance that reduces its monetary exposure and would enable it to recover a
portion of any future amounts paid. As a result, the Company believes that the estimated fair value of these indemnification commitments is minimal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Throughout the normal course of business, the Company has agreements with vendors that provide goods and services required by the Company to
run its business. In some instances, vendor agreements include language that requires the Company to indemnify the vendor from certain damages caused by the Company&#146;s use of the vendor&#146;s goods and/or services. The Company has insurance
that would allow it to recover a portion of any future amounts that could arise from these indemnifications. As a result, the Company believes that the estimated fair value of these indemnification commitments is minimal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Fair Value of Financial Measurements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Items measured at fair value on a recurring basis include cash equivalents and warrant liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the Company&#146;s financial instruments that were measured at fair value on a recurring basis by level within
the fair value hierarchy: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements at<BR>December&nbsp;31, 2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible notes redemption rights derivative</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements at<BR>December&nbsp;31, 2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market mutual fund</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock warrant liability</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the Company&#146;s money market mutual funds is based on quoted prices on an
active exchange. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Convertible preferred stock warrant liability </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As previously discussed (see Notes 5 and 7), the Company has issued warrants to purchase Series AA preferred stock in connection with the 2013
Series AA preferred stock issuance and the Loan Agreements. The Series AA warrant liabilities were recorded at their fair value on the date of issuance and are remeasured on each subsequent balance sheet date and as of the warrant exercise date,
with fair value changes recognized as income (decrease in fair value) or expense (increase in fair value) in other income (expense) in the statements of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2014 and 2013, the Company used a hybrid valuation model in which a Monte Carlo simulation was used to calculate the
fair value of the Company&#146;s equity securities under three scenarios including: i) an IPO scenario, ii) a merger or acquisition scenario or iii) a stay private scenario. The Company then probability-weighted each equity value derived from the
Monte Carlo simulation based upon the Company&#146;s estimate of the likelihood of the exit scenario occurring. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions used in
calculating the estimated fair value of the warrants represent the Company&#146;s best estimates and include probabilities of settlement scenarios, enterprise value, time to liquidity, risk-free interest rates, discount for lack of marketability and
volatility. The estimates are based, in part, on subjective assumptions and could differ materially in the future. Generally, increases or decreases in the fair value of the underlying convertible preferred stock would result in a directionally
similar impact in the fair value measurement of the warrant liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions used in the Monte Carlo simulation models used to
estimate the fair value of the Series AA preferred stock warrants upon issuance were: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75%&nbsp;&#150;&nbsp;80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.5&nbsp;&#150; 1.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.26%&nbsp;&#150;&nbsp;0.31</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table details the assumptions used in the Monte Carlo simulation models used to estimate the
fair value of the Series AA preferred stock warrants at each reporting period: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65%&nbsp;&#150;&nbsp;70</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.17&nbsp;&#150;&nbsp;0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.00&nbsp;&#150;&nbsp;1.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.02%&nbsp;&#150;&nbsp;0.03</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.13%&nbsp;&#150;&nbsp;0.19</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the assumptions above, the Company&#146;s estimated fair value of the Series AA preferred stock
warrant liabilities is calculated using other key assumptions including the probability of an exit event, the enterprise value as determined on an income approach, and a discount for lack of marketability. Management, with the assistance of an
independent valuation firm, made these subjective determinations based on available current information; however, as such information changes, so might management&#146;s determinations and such changes could have a material impact of future
operating results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the periods presented, the Company has not changed the manner in which it values liabilities that are measured
at fair value using Level 3 inputs. The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers within the hierarchy during any of the years presented. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table reflects the change in the Company&#146;s Level&nbsp;3 warrant liabilities
from December&nbsp;31, 2012 through December&nbsp;31, 2014: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Warrant<BR>Liabilities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in value</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant exercises</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Convertible debt redemption rights derivative </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2014 Bridge Notes redemption rights derivative required separate accounting and was valued using a single income valuation approach. The Company estimated
the fair value of the redemption rights derivative using a &#145;&#145;with and without&#146;&#146; income valuation approach. Under this approach, the Company estimated the present value of the fixed interest rate debt based on the fair value of
similar debt instruments excluding the embedded feature. This amount was then compared to the fair value of the debt instrument including the embedded feature using a probability weighted approach by assigning each embedded derivative feature a
probability of occurrence, with consideration provided for the settlement amount including conversion discounts, prepayment penalties, the expected life of the liability and the applicable discount rate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the issuance of the 2014 Bridge Notes on December 22, 2014 and on December 31, 2014, the Company ascribed a probability of occurrence to
the Change in Control Redemption Feature of 25%. The expected life of the feature was the remaining term of the debt and the discount rate was 18.9%. The Company classified the liability within Level 3 of the fair value hierarchy as the probability
factor and the discount rate are unobservable inputs and significant to the valuation model. As of December 22, 2014 and December 31, 2014, the fair value of the embedded derivative was $478 and $480, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table reflects the change in the Company&#146;s Level&nbsp;3 convertible notes redemption rights derivative from its initial
recording on December&nbsp;22, 2014 through December&nbsp;31, 2014: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial recording</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in value</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Benefit Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Retirement Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company sponsors a
401(k) savings plan (the &#147;Savings Plan&#148;) for all eligible U.S. employees. The Company reserves the right to modify, amend, or terminate the Savings Plan. Employees may contribute up to the maximum allowed by the IRS, while the Company
contributes to the plan at the discretion of the board of directors. The Company&#146;s contributions to the plan for the years ended December&nbsp;31, 2014, 2013 and 2012 were $16, $23 and $28, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management Incentive Plan </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2014, the Company adopted
the Amended and Restated 2014 Management Incentive Plan (the &#147;2014 MIP&#148;) in which certain of our named executive officers participate. Pursuant to the MIP, upon a &#147;change in control&#148; (as defined in the MIP), a bonus pool will be
created from the proceeds received in connection with such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
change in control (ranging from 7 percent to 9.75 percent of transaction proceeds, depending upon the level of transaction proceeds received in the transaction), and each participant is entitled
to receive a bonus equal to a certain percentage of such bonus pool. The MIP terminates automatically upon the earliest of (i)&nbsp;March&nbsp;31, 2015 (unless a change in control has occurred prior to such date), (ii)&nbsp;the closing of our IPO,
(iii)&nbsp;the closing of a qualified financing, as defined in the MIP, and (iv)&nbsp;the date all amounts to be paid under the MIP following a change in control have been paid. The MIP terminated upon the closing of our IPO in February 2015. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Subsequent Events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Authorized shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2015, the Company&#146;s board of directors and stockholders approved an amendment of the Company&#146;s certificate of
incorporation such that upon the closing of the IPO, the Company&#146;s authorized capital stock will consist of 120,000,000 shares of common stock, par value $0.01 per share, and 5,000,000 shares of undesignated preferred stock, par value $0.001
per share.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Initial Public Offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company&#146;s initial public offering occurred in February 2015 and the underwriters&#146; exercised overallotment options in March 2015 (see Note 1). The Company used $5,700 of the net proceeds therefrom to terminate the Loan Agreements related to
its Notes payable (see Note 5). The Company issued an aggregate of $21,000 of the 2020 Notes pursuant to its IPO and exercise of the underwriter overallotment option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2020 Notes mature on February&nbsp;15, 2020, are unsecured, bear cash interest from February&nbsp;23, 2015 at an annual rate of 5.0% payable semi-annually
on February&nbsp;15 and August&nbsp;15 of each year, are not redeemable at our option prior to their maturity date, may be subject to repurchase by us at the option of the holders following a fundamental change (as defined in the 2020 Notes
indenture) at a repurchase price equal to 100% of the principal amount of the 2020 Notes to be repurchased and are convertible at any time into shares of common stock at a $6.30 per share conversion rate, subject to certain adjustments. In addition,
on or after 150 days from the date of issuance of the notes, we will, in addition to the other consideration payable or deliverable in connection with any conversion of notes, make an interest make-whole payment (an &#147;interest make-whole
payment&#148;) to the converting holder equal to the sum of the present values of the scheduled payments of interest that would have been made on the notes to be converted had such notes remained outstanding from the conversion date through the
earlier of (i)&nbsp;the date that is three years after the conversion date and (ii)&nbsp;the maturity date if the notes had not been so converted or otherwise repurchased. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion of preferred stock upon Initial Public Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the IPO, all of the Company&#146;s outstanding 25,949,333 shares of Series AA and Series X preferred stock, including all accrued and unpaid
dividends thereon, automatically converted into 8,002,650 shares of common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Index </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Exhibit<BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Description of Exhibit</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Seventh Amended and Restated Certificate of Incorporation of Inotek Pharmaceuticals Corporation, effective as of February&nbsp;23, 2015 </TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated By-Laws of Inotek Pharmaceuticals Corporation, effective as of February 17, 2015 </TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Common Stock Certificate of Inotek Pharmaceuticals Corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Third Amended and Restated Investor Rights Agreement, dated as of June&nbsp;9, 2010, by and among the Registrant and each of the parties listed on Schedule&nbsp;A thereto (1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Indenture between Inotek Pharmaceuticals Corporation, and Wilmington Trust, National Association, as the trustee, relating to the 5.0% Convertible Senior Notes due 2020 (2)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2004 Stock Option and Incentive Plan (1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2014 Stock Option and Incentive Plan and forms of agreements thereunder, as amended </TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Letter Agreement, dated as of July&nbsp;28, 2014, by and between the Registrant and David P. Southwell&nbsp;(1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Letter Agreement, dated as of May&nbsp;2, 2007, by and between the Registrant and Dr. Rudolf A. Baumgartner, M.D., as amended and currently in effect (1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Letter Agreement, dated as of August&nbsp;23, 2007, by and between the Registrant and Dr.&nbsp;William K. McVicar, Ph.D., as amended and currently in effect (1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Letter Agreement, dated as of August 28, 2014, by and between the Registrant and Dale Ritter (1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Inotek Pharmaceuticals Corporation 2014 Employee Stock Purchase Plan, dated as of November&nbsp;18, 2014 </TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement, to be entered into between the Registrant and its directors (1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement, to be entered into between the Registrant and its officers (1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lease, dated as of May&nbsp;11, 2012, by and between the Registrant and Farley White Kilnbrook Three, LLC, as amended and currently in effect </TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrant to Purchase Shares of Series Preferred Stock dated as of June&nbsp;28, 2013, by and among the Inotek Pharmaceuticals Corporation and Horizon Technology Finance Corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrant to Purchase Shares of Series Preferred Stock dated as of June&nbsp;28, 2013, by and among the Inotek Pharmaceuticals Corporation and Fortress Credit Co LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney (included in the signature page)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>31.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule&nbsp;15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>31.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule&nbsp;15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>32.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Filed herewith. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Filed as an Exhibit to the Company&#146;s registration statement on Form S-1 (333-199859), filed with the SEC on November&nbsp;5, 2014, as amended, and incorporated herein by reference. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Filed as an Exhibit to the Company&#146;s current report on Form 8-K (001-36829), filed with the SEC on February&nbsp;26, 2015, and incorporated herein by reference. </TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>d893535dex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEVENTH AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INOTEK
PHARMACEUTICALS CORPORATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inotek Pharmaceuticals Corporation, a corporation organized and existing under the laws of the State of
Delaware (the &#147;Corporation&#148;), hereby certifies as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The name of the Corporation is Inotek Pharmaceuticals Corporation.
The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was July&nbsp;7, 1999 (the &#147;Original Certificate&#148;). The name under which the Corporation filed the Original
Certificate was Inotek Corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. This Seventh Amended and Restated Certificate of Incorporation (the &#147;Certificate&#148;)
amends, restates and integrates the provisions of the Sixth Amended and Restated Certificate of Incorporation that was filed with the Secretary of State of the State of Delaware on February&nbsp;17, 2015, as amended from time to time, (the
&#147;Amended and Restated Certificate&#148;) and was duly adopted in accordance with the provisions of Sections 228, 242 and 245 of the General Corporation Law of the State of Delaware (the &#147;DGCL&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. The text of the Amended and Restated Certificate is hereby amended and restated in its entirety to provide as herein set forth in full. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE I </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>NAME </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The name of the Corporation is Inotek Pharmaceuticals Corporation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE II </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>REGISTERED AGENT
</U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The address of the Corporation&#146;s registered office in the State of Delaware is c/o Corporation Service Company, 2711 Centerville
Road Suite 400 in the City of Wilmington, County of New Castle, 19808. The name of its registered agent at such address is Corporation Service Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE III </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>PURPOSE </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of
the Corporation is to engage in any lawful act or activity for which corporations may be organized under the DGCL. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE IV </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>CAPITAL STOCK </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total
number of shares of capital stock which the Corporation shall have authority to issue is One Hundred Twenty-Five Million (125,000,000), of which (i)&nbsp;One Hundred Twenty Million (120,000,000)&nbsp;shares shall be a class designated as common
stock, par value $0.01 per share (the &#147;Common Stock&#148;), and (ii)&nbsp;Five Million (5,000,000)&nbsp;shares shall be a class designated as undesignated preferred stock, par value $0.001 per share (the &#147;Undesignated Preferred
Stock&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in any certificate of designations of any series of Undesignated Preferred Stock, the number
of authorized shares of the class of Common Stock or Undesignated Preferred Stock may from time to time be increased or decreased (but not below the number of shares of such class outstanding) by the affirmative vote of the holders of a majority in
voting power of the outstanding shares of capital stock of the Corporation irrespective of the provisions of Section&nbsp;242(b)(2) of the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The powers, preferences and rights of, and the qualifications, limitations and restrictions upon, each class or series of stock shall be
determined in accordance with, or as set forth below in, this Article&nbsp;IV. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A. <U>COMMON STOCK</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to all the rights, powers and preferences of the Undesignated Preferred Stock and except as provided by law or in this Certificate (or
in any certificate of designations of any series of Undesignated Preferred Stock): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) the holders of the Common Stock shall have the
exclusive right to vote for the election of directors of the Corporation (the &#147;Directors&#148;) and on all other matters requiring stockholder action, each outstanding share entitling the holder thereof to one vote on each matter properly
submitted to the stockholders of the Corporation for their vote; <U>provided</U>, <U>however</U>, that, except as otherwise required by law, holders of Common Stock, as such, shall not be entitled to vote on any amendment to this Certificate (or on
any amendment to a certificate of designations of any series of Undesignated Preferred Stock) that alters or changes the powers, preferences, rights or other terms of one or more outstanding series of Undesignated Preferred Stock if the holders of
such affected series of Undesignated Preferred Stock are entitled to vote, either separately or together with the holders of one or more other such series, on such amendment pursuant to this Certificate (or pursuant to a certificate of designations
of any series of Undesignated Preferred Stock) or pursuant to the DGCL; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) dividends may be declared and paid or set apart for payment upon the Common Stock out of any
assets or funds of the Corporation legally available for the payment of dividends, but only when and as declared by the Corporation&#146;s Board of Directors (the &#147;Board of Directors&#148;) or any authorized committee thereof; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) upon the voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the net assets of the Corporation shall be
distributed pro rata to the holders of the Common Stock. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B. <U>UNDESIGNATED PREFERRED STOCK</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Board of Directors or any authorized committee thereof is expressly authorized, to the fullest extent permitted by law, to provide by
resolution or resolutions for, out of the unissued shares of Undesignated Preferred Stock, the issuance of the shares of Undesignated Preferred Stock in one or more series of such stock, and by filing a certificate of designations pursuant to
applicable law of the State of Delaware, to establish or change from time to time the number of shares of each such series, and to fix the designations, powers, including voting powers, full or limited, or no voting powers, preferences and the
relative, participating, optional or other special rights of the shares of each series and any qualifications, limitations and restrictions thereof. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE V </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>STOCKHOLDER ACTION
</U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Action without Meeting</U>. Any action required or permitted to be taken by the stockholders of the Corporation at any annual
or special meeting of stockholders of the Corporation must be effected at a duly called annual or special meeting of stockholders and may not be taken or effected by a written consent of stockholders in lieu thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Special Meetings</U>. Except as otherwise required by statute and subject to the rights, if any, of the holders of any series of
Undesignated Preferred Stock, special meetings of the stockholders of the Corporation may be called only by the Board of Directors acting pursuant to a resolution approved by the affirmative vote of a majority of the Directors then in office, and
special meetings of stockholders may not be called by any other person or persons. Only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders of the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE VI </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>DIRECTORS </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.
<U>General</U>. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors except as otherwise provided herein or required by law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Election of Directors</U>. Election of Directors need not be by written ballot unless the <FONT STYLE="white-space:nowrap">By-laws</FONT>
of the Corporation (the &#147;By-laws&#148;) shall so provide. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Number of Directors; Term of Office</U>. The number of Directors of
the Corporation shall be fixed solely and exclusively by resolution duly adopted from time to time by the Board of Directors. The Directors, other than those who may be elected by the holders of any series of Undesignated Preferred Stock, shall be
classified, with respect to the term for which they severally hold office, into three classes. The initial Class I Directors of the Corporation shall be Devang Kantesaria and David P. Southwell; the initial Class II Directors of the Corporation
shall be Martin Vogelbaum, Isai Peimer and Ittai Harel; and the initial Class III Directors of the Corporation shall be Paul Howes and A.N. &#147;Jerry&#148; Karabelas. The initial Class&nbsp;I Directors shall serve for a term expiring at the annual
meeting of stockholders to be held in 2015, the initial Class&nbsp;II Directors shall serve for a term expiring at the annual meeting of stockholders to be held in 2016, and the initial Class&nbsp;III Directors shall serve for a term expiring at the
annual meeting of stockholders to be held in 2017. At each annual meeting of stockholders, Directors elected to succeed those Directors whose terms expire shall be elected for a term of office to expire at the third succeeding annual meeting of
stockholders after their election. Notwithstanding the foregoing, the Directors elected to each class shall hold office until their successors are duly elected and qualified or until their earlier resignation, death or removal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, whenever, pursuant to the provisions of Article&nbsp;IV of this Certificate, the holders of any one or more
series of Undesignated Preferred Stock shall have the right, voting separately as a series or together with holders of other such series, to elect Directors at an annual or special meeting of stockholders, the election, term of office, filling of
vacancies and other features of such directorships shall be governed by the terms of this Certificate and any certificate of designations applicable to such series. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Vacancies</U>. Subject to the rights, if any, of the holders of any series of Undesignated Preferred Stock to elect Directors and to fill
vacancies in the Board of Directors relating thereto, any and all vacancies in the Board of Directors, however occurring, including, without limitation, by reason of an increase in the size of the Board of Directors, or the death, resignation,
disqualification or removal of a Director, shall be filled solely and exclusively by the affirmative vote of a majority of the remaining Directors then in office, even if less than a quorum of the Board of Directors, and not by the stockholders. Any
Director appointed in accordance with the preceding sentence shall hold office for the remainder of the full term of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
class of Directors in which the new directorship was created or the vacancy occurred and until such Director&#146;s successor shall have been duly elected and qualified or until his or her
earlier resignation, death or removal. Subject to the rights, if any, of the holders of any series of Undesignated Preferred Stock to elect Directors, when the number of Directors is increased or decreased, the Board of Directors shall, subject to
Article VI.3 hereof, determine the class or classes to which the increased or decreased number of Directors shall be apportioned; <U>provided</U>, <U>however</U>, that no decrease in the number of Directors shall shorten the term of any incumbent
Director. In the event of a vacancy in the Board of Directors, the remaining Directors, except as otherwise provided by law, shall exercise the powers of the full Board of Directors until the vacancy is filled. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Removal</U>. Subject to the rights, if any, of any series of Undesignated Preferred Stock to elect Directors and to remove any Director
whom the holders of any such series have the right to elect, any Director (including persons elected by Directors to fill vacancies in the Board of Directors) may be removed from office (i)&nbsp;only with cause and (ii)&nbsp;only by the affirmative
vote of the holders of 75% or more of the outstanding shares of capital stock then entitled to vote at an election of Directors, voting together as a single class. At least forty-five (45)&nbsp;days prior to any annual or special meeting of
stockholders at which it is proposed that any Director be removed from office, written notice of such proposed removal and the alleged grounds thereof shall be sent to the Director whose removal will be considered at the meeting. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE VII </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>LIMITATION OF
LIABILITY </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages
for breach of fiduciary duty as a Director, except for liability (a)&nbsp;for any breach of the Director&#146;s duty of loyalty to the Corporation or its stockholders, (b)&nbsp;for acts or omissions not in good faith or which involve intentional
misconduct or a knowing violation of law, (c)&nbsp;under Section&nbsp;174 of the DGCL or (d)&nbsp;for any transaction from which the Director derived an improper personal benefit. If the DGCL is amended after the effective date of this Certificate
to authorize corporate action further eliminating or limiting the personal liability of Directors, then the liability of a Director of the Corporation shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any amendment, repeal or modification of this Article&nbsp;VII by either of (i)&nbsp;the stockholders of the Corporation or (ii)&nbsp;an
amendment to the DGCL, shall not adversely affect any right or protection existing at the time of such amendment, repeal or modification with respect to any acts or omissions occurring before such amendment, repeal or modification of a person
serving as a Director at the time of such amendment, repeal or modification. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">
ARTICLE VIII </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>EXCLUSIVE JURISDICTION OF DELAWARE COURTS </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be
the sole and exclusive forum for (i)&nbsp;any derivative action or proceeding brought on behalf of the Corporation, (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the
Corporation to the Corporation or the Corporation&#146;s stockholders, (iii)&nbsp;any action asserting a claim arising pursuant to any provision of the DGCL or the Corporation&#146;s Certificate of Incorporation or Bylaws, or (iv)&nbsp;any action
asserting a claim against the Corporation governed by the internal affairs doctrine.&nbsp;Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Corporation shall be deemed to have notice of and
consented to the provisions of this Article VIII. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE IX </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>AMENDMENT OF BY-LAWS </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.
<U>Amendment by Directors</U>. Except as otherwise provided by law, the <FONT STYLE="white-space:nowrap">By-laws</FONT> of the Corporation may be amended or repealed by the Board of Directors by the affirmative vote of a majority of the Directors
then in office. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Amendment by Stockholders</U>. The <FONT STYLE="white-space:nowrap">By-laws</FONT> of the Corporation may be amended
or repealed at any annual meeting of stockholders, or special meeting of stockholders called for such purpose, by the affirmative vote of at least 75% of the outstanding shares of capital stock entitled to vote on such amendment or repeal, voting
together as a single class; <U>provided</U>, <U>however</U>, that if the Board of Directors recommends that stockholders approve such amendment or repeal at such meeting of stockholders, such amendment or repeal shall only require the affirmative
vote of the majority of the outstanding shares of capital stock entitled to vote on such amendment or repeal, voting together as a single class. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE X </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>AMENDMENT OF
CERTIFICATE OF INCORPORATION </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation reserves the right to amend or repeal this Certificate in the manner now or hereafter
prescribed by statute and this Certificate, and all rights conferred upon stockholders herein are granted subject to this reservation. Whenever any vote of the holders of capital stock of the Corporation is required to amend or repeal any provision
of this Certificate, and in addition to any other vote of holders of capital stock that is required by this Certificate or by law, such amendment or repeal shall require the affirmative vote of the majority of the outstanding shares of capital stock
entitled to vote on such amendment or repeal, and the affirmative vote of the majority of the outstanding shares of each class entitled to vote thereon as a class, at a duly constituted meeting of stockholders called expressly for such purpose;
<U>provided</U>, <U>however</U>, that the affirmative vote of not less than 75% of the outstanding shares of capital stock entitled to vote on such amendment or repeal, and the affirmative vote of not less than 75% of the outstanding shares of each
class entitled to vote thereon as a class, shall be required to amend or repeal any provision of Article V, Article VI, Article VII, Article VIII, Article IX or Article X of this Certificate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION is executed as of this 23<SUP
STYLE="font-size:85%; vertical-align:top">rd</SUP> day of February, 2015. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Inotek Pharmaceuticals Corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David P. Southwell</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">David P. Southwell</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Charter] </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>d893535dex32.htm
<DESCRIPTION>EX-3.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BY-LAWS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INOTEK PHARMACEUTICALS CORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(the &#147;Corporation&#148;) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ARTICLE I </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Stockholders </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.
<U>Annual Meeting</U>. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an &#147;Annual Meeting&#148;) shall be held at the hour, date and place within or without the United States which is fixed by the
Corporation&#146;s Board of Directors (the &#147;Board of Directors&#148;), which time, date and place may subsequently be changed at any time by vote of the Board of Directors. If no Annual Meeting has been held for a period of thirteen
(13)&nbsp;months after the Corporation&#146;s last Annual Meeting, a special meeting in lieu thereof may be held, and such special meeting shall have, for the purposes of these By-laws or otherwise, all the force and effect of an Annual Meeting. Any
and all references hereafter in these By-laws to an Annual Meeting or Annual Meetings also shall be deemed to refer to any special meeting(s) in lieu thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Notice of Stockholder Business and Nominations</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Annual Meetings of Stockholders</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) Nominations of persons for election to the Board of Directors and the proposal of other business to be considered by the
stockholders may be brought before an Annual Meeting (i)&nbsp;by or at the direction of the Board of Directors or (ii)&nbsp;by any stockholder of the Corporation who was a stockholder of record at the time of giving of notice provided for in this
By-law, who is entitled to vote at the meeting, who is present (in person or by proxy) at the meeting and who complies with the notice procedures set forth in this By-law as to such nomination or business. For the avoidance of doubt, the foregoing
clause (ii)&nbsp;shall be the exclusive means for a stockholder to bring nominations or business properly before an Annual Meeting (other than matters properly brought under Rule 14a-8 (or any successor rule) under the Securities Exchange Act of
1934, as amended (the &#147;Exchange Act&#148;)), and such stockholder must comply with the notice and other procedures set forth in Article I, Section&nbsp;2(a)(2) and (3)&nbsp;of this By-law to bring such nominations or business properly before an
Annual Meeting. In addition to the other requirements set forth in this By-law, for any proposal of business to be considered at an Annual Meeting, it must be a proper subject for action by stockholders of the Corporation under Delaware law. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) For nominations or other business to be properly brought before an Annual
Meeting by a stockholder pursuant to clause (ii)&nbsp;of Article I, Section&nbsp;2(a)(1) of this By-law, the stockholder must (i)&nbsp;have given Timely Notice (as defined below) thereof in writing to the Secretary of the Corporation, (ii)&nbsp;have
provided any updates or supplements to such notice at the times and in the forms required by this By-law and (iii)&nbsp;together with the beneficial owner(s), if any, on whose behalf the nomination or business proposal is made, have acted in
accordance with the representations set forth in the Solicitation Statement (as defined below) required by this By-law. To be timely, a stockholder&#146;s written notice shall be received by the Secretary at the principal executive offices of the
Corporation not later than the close of business on the ninetieth (90th)&nbsp;day nor earlier than the close of business on the one hundred twentieth (120th)&nbsp;day prior to the one-year anniversary of the preceding year&#146;s Annual Meeting;
<U>provided</U>, <U>however</U>, that in the event the Annual Meeting is first convened more than thirty (30)&nbsp;days before or more than sixty (60)&nbsp;days after such anniversary date, or if no Annual Meeting were held in the preceding year,
notice by the stockholder to be timely must be received by the Secretary of the Corporation not later than the close of business on the later of the ninetieth (90th)&nbsp;day prior to the scheduled date of such Annual Meeting or the tenth
(10th)&nbsp;day following the day on which public announcement of the date of such meeting is first made (such notice within such time periods shall be referred to as &#147;Timely Notice&#148;). Notwithstanding anything to the contrary provided
herein, for the first Annual Meeting following the initial public offering of common stock of the Corporation, a stockholder&#146;s notice shall be timely if received by the Secretary at the principal executive offices of the Corporation not later
than the close of business on the later of the ninetieth (90th)&nbsp;day prior to the scheduled date of such Annual Meeting or the tenth (10th)&nbsp;day following the day on which public announcement of the date of such Annual Meeting is first made
or sent by the Corporation. Such stockholder&#146;s Timely Notice shall set forth: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) as to each person whom the
stockholder proposes to nominate for election or reelection as a Director of the Corporation (&#147;Director&#148;), all information relating to such person that is required to be disclosed in solicitations of proxies for election of Directors in an
election contest, or is otherwise required, in each case pursuant to Regulation 14A under the Exchange Act (including such person&#146;s written consent to being named in the proxy statement as a nominee and to serving as a Director if elected);
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) as to any other business that the stockholder proposes to bring before the meeting, a brief description of the
business desired to be brought before the meeting, the reasons for conducting such business at the meeting, and any material interest in such business of each Proposing Person (as defined below); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) (i) the name and address of the stockholder giving the notice, as they appear on the Corporation&#146;s books, and the
names and addresses of the other Proposing Persons (if any) and (ii)&nbsp;as to each Proposing Person, the following information: (a)&nbsp;the class or series and number of all shares of capital stock of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
Corporation which are, directly or indirectly, owned beneficially or of record by such Proposing Person or any of its affiliates or associates (as such terms are defined in Rule 12b-2 promulgated
under the Exchange Act), including any shares of any class or series of capital stock of the Corporation as to which such Proposing Person or any of its affiliates or associates has a right to acquire beneficial ownership at any time in the future,
(b)&nbsp;all Synthetic Equity Interests (as defined below) in which such Proposing Person or any of its affiliates or associates, directly or indirectly, holds an interest including a description of the material terms of each such Synthetic Equity
Interest, including without limitation, identification of the counterparty to each such Synthetic Equity Interest and disclosure, for each such Synthetic Equity Interest, as to (x)&nbsp;whether or not such Synthetic Equity Interest conveys any
voting rights, directly or indirectly, in such shares to such Proposing Person, (y)&nbsp;whether or not such Synthetic Equity Interest is required to be, or is capable of being, settled through delivery of such shares and (z)&nbsp;whether or not
such Proposing Person and/or, to the extent known, the counterparty to such Synthetic Equity Interest has entered into other transactions that hedge or mitigate the economic effect of such Synthetic Equity Interest, (c)&nbsp;any proxy (other than a
revocable proxy given in response to a public proxy solicitation made pursuant to, and in accordance with, the Exchange Act), agreement, arrangement, understanding or relationship pursuant to which such Proposing Person has or shares a right to,
directly or indirectly, vote any shares of any class or series of capital stock of the Corporation, (d)&nbsp;any rights to dividends or other distributions on the shares of any class or series of capital stock of the Corporation, directly or
indirectly, owned beneficially by such Proposing Person that are separated or separable from the underlying shares of the Corporation, and (e)&nbsp;any performance-related fees (other than an asset based fee) that such Proposing Person, directly or
indirectly, is entitled to based on any increase or decrease in the value of shares of any class or series of capital stock of the Corporation or any Synthetic Equity Interests (the disclosures to be made pursuant to the foregoing clauses
(a)&nbsp;through (e)&nbsp;are referred to, collectively, as &#147;Material Ownership Interests&#148;) and (iii)&nbsp;a description of the material terms of all agreements, arrangements or understandings (whether or not in writing) entered into by
any Proposing Person or any of its affiliates or associates with any other person for the purpose of acquiring, holding, disposing or voting of any shares of any class or series of capital stock of the Corporation; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) (i) a description of all agreements, arrangements or understandings by and among any of the Proposing Persons, or by and
among any Proposing Persons and any other person (including with any proposed nominee(s)), pertaining to the nomination(s) or other business proposed to be brought before the meeting of stockholders (which description shall identify the name of each
other person who is party to such an agreement, arrangement or understanding), and (ii)&nbsp;identification of the names and addresses of other stockholders (including beneficial owners) known by any of the Proposing Persons to support such
nominations or other business proposal(s), and to the extent known the class and number of all shares of the Corporation&#146;s capital stock owned beneficially or of record by such other stockholder(s) or other beneficial owner(s); and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(E) a statement whether or not the stockholder giving the notice and/or the other
Proposing Person(s), if any, will deliver a proxy statement and form of proxy to holders of, in the case of a business proposal, at least the percentage of voting power of all of the shares of capital stock of the Corporation required under
applicable law to approve the proposal or, in the case of a nomination or nominations, at least the percentage of voting power of all of the shares of capital stock of the Corporation reasonably believed by such Proposing Person to be sufficient to
elect the nominee or nominees proposed to be nominated by such stockholder (such statement, the &#147;Solicitation Statement&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Article I of these By-laws, the term &#147;Proposing Person&#148; shall mean the following persons:
(i)&nbsp;the stockholder of record providing the notice of nominations or business proposed to be brought before a stockholders&#146; meeting, and (ii)&nbsp;the beneficial owner(s), if different, on whose behalf the nominations or business proposed
to be brought before a stockholders&#146; meeting is made. For purposes of this Section&nbsp;2 of Article&nbsp;I of these By-laws, the term &#147;Synthetic Equity Interest&#148; shall mean any transaction, agreement or arrangement (or series of
transactions, agreements or arrangements), including, without limitation, any derivative, swap, hedge, repurchase or so-called &#147;stock borrowing&#148; agreement or arrangement, the purpose or effect of which is to, directly or indirectly:
(a)&nbsp;give a person or entity economic benefit and/or risk similar to ownership of shares of any class or series of capital stock of the Corporation, in whole or in part, including due to the fact that such transaction, agreement or arrangement
provides, directly or indirectly, the opportunity to profit or avoid a loss from any increase or decrease in the value of any shares of any class or series of capital stock of the Corporation, (b)&nbsp;mitigate loss to, reduce the economic risk of
or manage the risk of share price changes for, any person or entity with respect to any shares of any class or series of capital stock of the Corporation, (c)&nbsp;otherwise provide in any manner the opportunity to profit or avoid a loss from any
decrease in the value of any shares of any class or series of capital stock of the Corporation, or (d)&nbsp;increase or decrease the voting power of any person or entity with respect to any shares of any class or series of capital stock of the
Corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) A stockholder providing Timely Notice of nominations or business proposed to be brought before an Annual
Meeting shall further update and supplement such notice, if necessary, so that the information (including, without limitation, the Material Ownership Interests information) provided or required to be provided in such notice pursuant to this By-law
shall be true and correct as of the record date for the meeting and as of the date that is ten (10)&nbsp;business days prior to such Annual Meeting, and such update and supplement shall be received by the Secretary at the principal executive offices
of the Corporation not later than the close of business on the fifth (5th)&nbsp;business day after the record date for the Annual Meeting (in the case of the update and supplement required to be made as of the record date), and not later than the
close of business on the eighth (8th)&nbsp;business day prior to the date of the Annual Meeting (in the case of the update and supplement required to be made as of ten (10)&nbsp;business days prior to the meeting). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) Notwithstanding anything in the second sentence of Article I,
Section&nbsp;2(a)(2) of this By-law to the contrary, in the event that the number of Directors to be elected to the Board of Directors is increased and there is no public announcement naming all of the nominees for Director or specifying the size of
the increased Board of Directors made by the Corporation at least ten (10)&nbsp;days before the last day a stockholder may deliver a notice of nomination in accordance with the second sentence of Article I, Section&nbsp;2(a)(2), a stockholder&#146;s
notice required by this By-law shall also be considered timely, but only with respect to nominees for any new positions created by such increase, if it shall be received by the Secretary of the Corporation not later than the close of business on the
tenth (10th)&nbsp;day following the day on which such public announcement is first made by the Corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>General</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) Only such persons who are nominated in accordance with the provisions of this By-law shall be eligible for election and to
serve as Directors and only such business shall be conducted at an Annual Meeting as shall have been brought before the meeting in accordance with the provisions of this By-law or in accordance with Rule 14a-8 under the Exchange Act. The Board of
Directors or a designated committee thereof shall have the power to determine whether a nomination or any business proposed to be brought before the meeting was made in accordance with the provisions of this By-law. If neither the Board of Directors
nor such designated committee makes a determination as to whether any stockholder proposal or nomination was made in accordance with the provisions of this By-law, the presiding officer of the Annual Meeting shall have the power and duty to
determine whether the stockholder proposal or nomination was made in accordance with the provisions of this By-law. If the Board of Directors or a designated committee thereof or the presiding officer, as applicable, determines that any stockholder
proposal or nomination was not made in accordance with the provisions of this By-law, such proposal or nomination shall be disregarded and shall not be presented for action at the Annual Meeting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) Except as otherwise required by law, nothing in this Article I, Section&nbsp;2 shall obligate the Corporation or the Board
of Directors to include in any proxy statement or other stockholder communication distributed on behalf of the Corporation or the Board of Directors information with respect to any nominee for Director or any other matter of business submitted by a
stockholder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) Notwithstanding the foregoing provisions of this Article I, Section&nbsp;2, if the nominating or
proposing stockholder (or a qualified representative of the stockholder) does not appear at the Annual Meeting to present a nomination or any business, such nomination or business shall be disregarded, notwithstanding that proxies in respect of such
vote may have been received by the Corporation. For purposes of this Article I, Section&nbsp;2, to be considered a qualified representative of the proposing stockholder, a person must be authorized by a written instrument executed by such
stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders and such person must produce such written instrument or electronic transmission, or a reliable reproduction
of the written instrument or electronic transmission, to the presiding officer at the meeting of stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) For purposes of this By-law, &#147;public announcement&#148; shall mean
disclosure in a press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Section&nbsp;13, 14
or 15(d) of the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(5) Notwithstanding the foregoing provisions of this By-law, a stockholder shall also comply
with all applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to the matters set forth in this By-law. Nothing in this By-law shall be deemed to affect any rights of (i)&nbsp;stockholders to have
proposals included in the Corporation&#146;s proxy statement pursuant to Rule 14a-8 (or any successor rule), as applicable, under the Exchange Act and, to the extent required by such rule, have such proposals considered and voted on at an Annual
Meeting or (ii)&nbsp;the holders of any series of Undesignated Preferred Stock to elect Directors under specified circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION
3. <U>Special Meetings</U>. Except as otherwise required by statute and subject to the rights, if any, of the holders of any series of Undesignated Preferred Stock, special meetings of the stockholders of the Corporation may be called only by the
Board of Directors acting pursuant to a resolution approved by the affirmative vote of a majority of the Directors then in office. The Board of Directors may postpone or reschedule any previously scheduled special meeting of stockholders. Only those
matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders of the Corporation. Nominations of persons for election to the Board of Directors and stockholder proposals of other business
shall not be brought before a special meeting of stockholders to be considered by the stockholders unless such special meeting is held in lieu of an annual meeting of stockholders in accordance with Article I, Section&nbsp;1 of these By-laws, in
which case such special meeting in lieu thereof shall be deemed an Annual Meeting for purposes of these By-laws and the provisions of Article I, Section&nbsp;2 of these By-laws shall govern such special meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Notice of Meetings; Adjournments</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) A notice of each Annual Meeting stating the hour, date and place, if any, of such Annual Meeting and the means of remote communication, if
any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, shall be given not less than ten (10)&nbsp;days nor more than sixty (60)&nbsp;days before the Annual Meeting, to each stockholder entitled to
vote thereat by delivering such notice to such stockholder or by mailing it, postage prepaid, addressed to such stockholder at the address of such stockholder as it appears on the Corporation&#146;s stock transfer books. Without limiting the manner
by which notice may otherwise be given to stockholders, any notice to stockholders may be given by electronic transmission in the manner provided in Section&nbsp;232 of the Delaware General Corporation Law (&#147;DGCL&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Notice of all special meetings of stockholders shall be given in the same manner as provided
for Annual Meetings, except that the notice of all special meetings shall state the purpose or purposes for which the meeting has been called. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Notice of an Annual Meeting or special meeting of stockholders need not be given to a stockholder if a waiver of notice is executed, or
waiver of notice by electronic transmission is provided, before or after such meeting by such stockholder or if such stockholder attends such meeting, unless such attendance is for the express purpose of objecting at the beginning of the meeting to
the transaction of any business because the meeting was not lawfully called or convened. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Board of Directors may postpone and
reschedule any previously scheduled Annual Meeting or special meeting of stockholders and any record date with respect thereto, regardless of whether any notice or public disclosure with respect to any such meeting has been sent or made pursuant to
Section&nbsp;2 of this Article&nbsp;I of these By-laws or otherwise. In no event shall the public announcement of an adjournment, postponement or rescheduling of any previously scheduled meeting of stockholders commence a new time period for the
giving of a stockholder&#146;s notice under this Article I of these By-laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) When any meeting is convened, the presiding officer may
adjourn the meeting if (i)&nbsp;no quorum is present for the transaction of business, (ii)&nbsp;the Board of Directors determines that adjournment is necessary or appropriate to enable the stockholders to consider fully information which the Board
of Directors determines has not been made sufficiently or timely available to stockholders, or (iii)&nbsp;the Board of Directors determines that adjournment is otherwise in the best interests of the Corporation. When any Annual Meeting or special
meeting of stockholders is adjourned to another hour, date or place, notice need not be given of the adjourned meeting other than an announcement at the meeting at which the adjournment is taken of the hour, date and place, if any, to which the
meeting is adjourned and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting; provided, however, that if the adjournment is for more than thirty
(30)&nbsp;days from the meeting date, or if after the adjournment a new record date is fixed for the adjourned meeting, notice of the adjourned meeting and the means of remote communications, if any, by which stockholders and proxyholders may be
deemed to be present in person and vote at such adjourned meeting shall be given to each stockholder of record entitled to vote thereat and each stockholder who, by law or under the Certificate of Incorporation of the Corporation (as the same may
hereafter be amended and/or restated, the &#147;Certificate&#148;) or these By-laws, is entitled to such notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5.
<U>Quorum</U>. A majority of the shares entitled to vote, present in person or represented by proxy, shall constitute a quorum at any meeting of stockholders. If less than a quorum is present at a meeting, the holders of voting stock representing a
majority of the voting power present at the meeting or the presiding officer may adjourn the meeting from time to time, and the meeting may be held as adjourned without further notice, except as provided in Section&nbsp;4 of this Article&nbsp;I. At
such adjourned meeting at which a quorum is present, any business may be transacted which might have been transacted at the meeting as originally noticed. The stockholders present at a duly constituted meeting may continue to transact business until
adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Voting and Proxies</U>. Stockholders shall have one vote for each share of stock
entitled to vote owned by them of record according to the stock ledger of the Corporation as of the record date, unless otherwise provided by law or by the Certificate. Stockholders may vote either (i)&nbsp;in person, (ii)&nbsp;by written proxy or
(iii)&nbsp;by a transmission permitted by Section&nbsp;212(c) of the DGCL. Any copy, facsimile telecommunication or other reliable reproduction of the writing or transmission permitted by Section&nbsp;212(c) of the DGCL may be substituted for or
used in lieu of the original writing or transmission for any and all purposes for which the original writing or transmission could be used, provided that such copy, facsimile telecommunication or other reproduction shall be a complete reproduction
of the entire original writing or transmission. Proxies shall be filed in accordance with the procedures established for the meeting of stockholders. Except as otherwise limited therein or as otherwise provided by law, proxies authorizing a person
to vote at a specific meeting shall entitle the persons authorized thereby to vote at any adjournment of such meeting, but they shall not be valid after final adjournment of such meeting. A proxy with respect to stock held in the name of two or more
persons shall be valid if executed by or on behalf of any one of them unless at or prior to the exercise of the proxy the Corporation receives a specific written notice to the contrary from any one of them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>Action at Meeting</U>. When a quorum is present at any meeting of stockholders, any matter before any such meeting (other than
an election of a Director or Directors) shall be decided by a majority of the votes properly cast for and against such matter, except where a larger vote is required by law, by the Certificate or by these By-laws. Any election of Directors by
stockholders shall be determined by a plurality of the votes properly cast on the election of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8. <U>Stockholder
Lists</U>. The Secretary or an Assistant Secretary (or the Corporation&#146;s transfer agent or other person authorized by these By-laws or by law) shall prepare and make, at least ten (10)&nbsp;days before every Annual Meeting or special meeting of
stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be
open to the examination of any stockholder, for a period of at least ten (10)&nbsp;days prior to the meeting in the manner provided by law. The list shall also be open to the examination of any stockholder during the whole time of the meeting as
provided by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9. <U>Presiding Officer</U>. The Board of Directors shall designate a representative to preside over all Annual
Meetings or special meetings of stockholders, provided that if the Board of Directors does not so designate such a presiding officer, then the Chairperson of the Board of Directors (the &#147;Chairperson of the Board&#148;), if one is elected, shall
preside over such meetings. If the Board of Directors does not so designate such a presiding officer and there is no Chairperson of the Board or the Chairperson of the Board is unable to so preside or is absent, then the Chief Executive Officer, if
one is elected, shall preside over such meetings, provided </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
further that if there is no Chief Executive Officer or the Chief Executive Officer is unable to so preside or is absent, then the President shall preside over such meetings. The presiding officer
at any Annual Meeting or special meeting of stockholders shall have the power, among other things, to adjourn such meeting at any time and from time to time, subject to Sections&nbsp;4 and&nbsp;5 of this Article&nbsp;I. The order of business and all
other matters of procedure at any meeting of the stockholders shall be determined by the presiding officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 10. <U>Inspectors of
Elections</U>. The Corporation shall, in advance of any meeting of stockholders, appoint one or more inspectors to act at the meeting and make a written report thereof. The Corporation may designate one or more persons as alternate inspectors to
replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of stockholders, the presiding officer shall appoint one or more inspectors to act at the meeting. Any inspector may, but need not, be an officer,
employee or agent of the Corporation. Each inspector, before entering upon the discharge of his or her duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of his or her
ability. The inspectors shall perform such duties as are required by the DGCL, including the counting of all votes and ballots. The inspectors may appoint or retain other persons or entities to assist the inspectors in the performance of the duties
of the inspectors. The presiding officer may review all determinations made by the inspectors, and in so doing the presiding officer shall be entitled to exercise his or her sole judgment and discretion and he or she shall not be bound by any
determinations made by the inspectors. All determinations by the inspectors and, if applicable, the presiding officer, shall be subject to further review by any court of competent jurisdiction. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE II </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Directors
</U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1. <U>Powers</U>. The business and affairs of the Corporation shall be managed by or under the direction of the Board of
Directors except as otherwise provided by the Certificate or required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Number and Terms</U>. The number of Directors
of the Corporation shall be fixed solely and exclusively by resolution duly adopted from time to time by the Board of Directors. The Directors shall hold office in the manner provided in the Certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Qualification</U>. No Director need be a stockholder of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Vacancies</U>. Vacancies in the Board of Directors shall be filled in the manner provided in the Certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Removal</U>. Directors may be removed from office only in the manner provided in the Certificate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Resignation</U>. A Director may resign at any time by giving written notice to the
Chairperson of the Board, if one is elected, the President or the Secretary. A resignation shall be effective upon receipt, unless the resignation otherwise provides. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>Regular Meetings</U>. The regular annual meeting of the Board of Directors shall be held, without notice other than this
Section&nbsp;7, on the same date and at the same place as the Annual Meeting following the close of such meeting of stockholders. Other regular meetings of the Board of Directors may be held at such hour, date and place as the Board of Directors may
by resolution from time to time determine and publicize by means of reasonable notice given to any Director who is not present at the meeting at which such resolution is adopted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8. <U>Special Meetings</U>. Special meetings of the Board of Directors may be called, orally or in writing, by or at the request of a
majority of the Directors, the Chairperson of the Board, if one is elected, or the President. The person calling any such special meeting of the Board of Directors may fix the hour, date and place thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9. <U>Notice of Meetings</U>. Notice of the hour, date and place of all special meetings of the Board of Directors shall be given to
each Director by the Secretary or an Assistant Secretary, or in case of the death, absence, incapacity or refusal of such persons, by the Chairperson of the Board, if one is elected, or the President or such other officer designated by the
Chairperson of the Board, if one is elected, or the President. Notice of any special meeting of the Board of Directors shall be given to each Director in person, by telephone, or by facsimile, electronic mail or other form of electronic
communication, sent to his or her business or home address, at least twenty-four (24)&nbsp;hours in advance of the meeting, or by written notice mailed to his or her business or home address, at least forty-eight (48)&nbsp;hours in advance of the
meeting. Such notice shall be deemed to be delivered when hand-delivered to such address, read to such Director by telephone, deposited in the mail so addressed, with postage thereon prepaid if mailed, dispatched or transmitted if sent by facsimile
transmission or by electronic mail or other form of electronic communications. A written waiver of notice signed before or after a meeting by a Director and filed with the records of the meeting shall be deemed to be equivalent to notice of the
meeting. The attendance of a Director at a meeting shall constitute a waiver of notice of such meeting, except where a Director attends a meeting for the express purpose of objecting at the beginning of the meeting to the transaction of any business
because such meeting is not lawfully called or convened. Except as otherwise required by law, by the Certificate or by these By-laws, neither the business to be transacted at, nor the purpose of, any meeting of the Board of Directors need be
specified in the notice or waiver of notice of such meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 10. <U>Quorum</U>. At any meeting of the Board of Directors, a
majority of the total number of Directors shall constitute a quorum for the transaction of business, but if less than a quorum is present at a meeting, a majority of the Directors present may adjourn the meeting from time to time, and the meeting
may be held as adjourned without further notice. Any business which might have been transacted at the meeting as originally noticed may be transacted at such adjourned meeting at which a quorum is present. For purposes of this section, the total
number of Directors includes any unfilled vacancies on the Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 11. <U>Action at Meeting</U>. At any meeting of the Board of Directors at which a quorum
is present, the vote of a majority of the Directors present shall constitute action by the Board of Directors, unless otherwise required by law, by the Certificate or by these By-laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 12. <U>Action by Consent</U>. Any action required or permitted to be taken at any meeting of the Board of Directors may be taken
without a meeting if all members of the Board of Directors consent thereto in writing or by electronic transmission and the writing or writings or electronic transmission or transmissions are filed with the records of the meetings of the Board of
Directors. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form. Such consent shall be treated as a resolution of the Board of Directors for
all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 13. <U>Manner of Participation</U>. Directors may participate in meetings of the Board of Directors by means of
conference telephone or other communications equipment by means of which all Directors participating in the meeting can hear each other, and participation in a meeting in accordance herewith shall constitute presence in person at such meeting for
purposes of these By-laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 14. <U>Presiding Director</U>. The Board of Directors shall designate a representative to preside over
all meetings of the Board of Directors, provided that if the Board of Directors does not so designate such a presiding Director or such designated presiding Director is unable to so preside or is absent, then the Chairperson of the Board, if one is
elected, shall preside over all meetings of the Board of Directors. If both the designated presiding Director, if one is so designated, and the Chairperson of the Board, if one is elected, are unable to preside or are absent, the Board of Directors
shall designate an alternate representative to preside over a meeting of the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 15. <U>Committees</U>. The Board
of Directors, by vote of a majority of the Directors then in office, may elect one or more committees, including, without limitation, a Compensation Committee, a Nominating and Corporate Governance Committee and an Audit Committee, and may delegate
thereto some or all of its powers except those which by law, by the Certificate or by these By-laws may not be delegated. Except as the Board of Directors may otherwise determine, any such committee may make rules for the conduct of its business,
but unless otherwise provided by the Board of Directors or in such rules, its business shall be conducted so far as possible in the same manner as is provided by these By-laws for the Board of Directors. All members of such committees shall hold
such offices at the pleasure of the Board of Directors. The Board of Directors may abolish any such committee at any time. Any committee to which the Board of Directors delegates any of its powers or duties shall keep records of its meetings and
shall report its action to the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 16. <U>Compensation of Directors</U>. Directors shall receive such
compensation for their services as shall be determined by a majority of the Board of Directors, or a designated committee thereof, provided that Directors who are serving the Corporation as employees and who receive compensation for their services
as such, shall not receive any salary or other compensation for their services as Directors of the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE III </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Officers </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.
<U>Enumeration</U>. The officers of the Corporation shall consist of a President, a Treasurer, a Secretary and such other officers, including, without limitation, a Chairperson of the Board of Directors, a Chief Executive Officer and one or more
Vice Presidents (including Executive Vice Presidents or Senior Vice Presidents), Assistant Vice Presidents, Assistant Treasurers and Assistant Secretaries, as the Board of Directors may determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Election</U>. At the regular annual meeting of the Board of Directors following the Annual Meeting, the Board of Directors shall
elect the President, the Treasurer and the Secretary. Other officers may be elected by the Board of Directors at such regular annual meeting of the Board of Directors or at any other regular or special meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Qualification</U>. No officer need be a stockholder or a Director. Any person may occupy more than one office of the Corporation
at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Tenure</U>. Except as otherwise provided by the Certificate or by these By-laws, each of the officers of the
Corporation shall hold office until the regular annual meeting of the Board of Directors following the next Annual Meeting and until his or her successor is elected and qualified or until his or her earlier resignation or removal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Resignation</U>. Any officer may resign by delivering his or her written resignation to the Corporation addressed to the
President or the Secretary, and such resignation shall be effective upon receipt, unless the resignation otherwise provides. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6.
<U>Removal</U>. Except as otherwise provided by law, the Board of Directors may remove any officer with or without cause by the affirmative vote of a majority of the Directors then in office. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>Absence or Disability</U>. In the event of the absence or disability of any officer, the Board of Directors may designate
another officer to act temporarily in place of such absent or disabled officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8. <U>Vacancies</U>. Any vacancy in any office
may be filled for the unexpired portion of the term by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9. <U>President</U>. The President shall, subject
to the direction of the Board of Directors, have such powers and shall perform such duties as the Board of Directors may from time to time designate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 10. <U>Chairperson of the Board</U>. The Chairperson of the Board, if one is elected,
shall have such powers and shall perform such duties as the Board of Directors may from time to time designate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 11. <U>Chief
Executive Officer</U>. The Chief Executive Officer, if one is elected, shall have such powers and shall perform such duties as the Board of Directors may from time to time designate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 12. <U>Vice Presidents and Assistant Vice Presidents</U>. Any Vice President (including any Executive Vice President or Senior Vice
President) and any Assistant Vice President shall have such powers and shall perform such duties as the Board of Directors or the Chief Executive Officer may from time to time designate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 13. <U>Treasurer and Assistant Treasurers</U>. The Treasurer shall, subject to the direction of the Board of Directors and except as
the Board of Directors or the Chief Executive Officer may otherwise provide, have general charge of the financial affairs of the Corporation and shall cause to be kept accurate books of account. The Treasurer shall have custody of all funds,
securities, and valuable documents of the Corporation. He or she shall have such other duties and powers as may be designated from time to time by the Board of Directors or the Chief Executive Officer. Any Assistant Treasurer shall have such powers
and perform such duties as the Board of Directors or the Chief Executive Officer may from time to time designate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 14.
<U>Secretary and Assistant Secretaries</U>. The Secretary shall record all the proceedings of the meetings of the stockholders and the Board of Directors (including committees of the Board of Directors) in books kept for that purpose. In his or her
absence from any such meeting, a temporary secretary chosen at the meeting shall record the proceedings thereof. The Secretary shall have charge of the stock ledger (which may, however, be kept by any transfer or other agent of the Corporation). The
Secretary shall have custody of the seal of the Corporation, and the Secretary, or an Assistant Secretary shall have authority to affix it to any instrument requiring it, and, when so affixed, the seal may be attested by his or her signature or that
of an Assistant Secretary. The Secretary shall have such other duties and powers as may be designated from time to time by the Board of Directors or the Chief Executive Officer. In the absence of the Secretary, any Assistant Secretary may perform
his or her duties and responsibilities. Any Assistant Secretary shall have such powers and perform such duties as the Board of Directors or the Chief Executive Officer may from time to time designate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 15. <U>Other Powers and Duties</U>. Subject to these By-laws and to such limitations as the Board of Directors may from time to time
prescribe, the officers of the Corporation shall each have such powers and duties as generally pertain to their respective offices, as well as such powers and duties as from time to time may be conferred by the Board of Directors or the Chief
Executive Officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE IV </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Capital Stock </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.
<U>Certificates of Stock</U>. Each stockholder shall be entitled to a certificate of the capital stock of the Corporation in such form as may from time to time be prescribed by the Board of Directors. Such certificate shall be signed by the
Chairperson of the Board, the President or a Vice President and by the Treasurer or an Assistant Treasurer, or the Secretary or an Assistant Secretary. The Corporation seal and the signatures by the Corporation&#146;s officers, the transfer agent or
the registrar may be facsimiles. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed on such certificate shall have ceased to be such officer, transfer agent or registrar before such
certificate is issued, it may be issued by the Corporation with the same effect as if he or she were such officer, transfer agent or registrar at the time of its issue. Every certificate for shares of stock which are subject to any restriction on
transfer and every certificate issued when the Corporation is authorized to issue more than one class or series of stock shall contain such legend with respect thereto as is required by law. Notwithstanding anything to the contrary provided in these
Bylaws, the Board of Directors may provide by resolution or resolutions that some or all of any or all classes or series of its stock shall be uncertificated shares (except that the foregoing shall not apply to shares represented by a certificate
until such certificate is surrendered to the Corporation), and by the approval and adoption of these Bylaws the Board of Directors has determined that all classes or series of the Corporation&#146;s stock may be uncertificated, whether upon original
issuance, re-issuance, or subsequent transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Transfers</U>. Subject to any restrictions on transfer and unless otherwise
provided by the Board of Directors, shares of stock that are represented by a certificate may be transferred on the books of the Corporation by the surrender to the Corporation or its transfer agent of the certificate theretofore properly endorsed
or accompanied by a written assignment or power of attorney properly executed, with transfer stamps (if necessary) affixed, and with such proof of the authenticity of signature as the Corporation or its transfer agent may reasonably require. Shares
of stock that are not represented by a certificate may be transferred on the books of the Corporation by submitting to the Corporation or its transfer agent such evidence of transfer and following such other procedures as the Corporation or its
transfer agent may require. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Record Holders</U>. Except as may otherwise be required by law, by the Certificate or by these
By-laws, the Corporation shall be entitled to treat the record holder of stock as shown on its books as the owner of such stock for all purposes, including the payment of dividends and the right to vote with respect thereto, regardless of any
transfer, pledge or other disposition of such stock, until the shares have been transferred on the books of the Corporation in accordance with the requirements of these By-laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Record Date</U>. In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of
stockholders or any adjournment thereof or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stock or for the purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is
adopted by the Board of Directors, and which record date: (a)&nbsp;in the case of determination of stockholders entitled to vote at any meeting of stockholders, shall, unless otherwise required by law, not be more than sixty (60)&nbsp;nor less than
ten (10)&nbsp;days before the date of such meeting and (b)&nbsp;in the case of any other action, shall not be more than sixty (60)&nbsp;days prior to such other action. If no record date is fixed: (i)&nbsp;the record date for determining
stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the
day on which the meeting is held; and (ii)&nbsp;the record date for determining stockholders for any other purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Replacement of Certificates</U>. In case of the alleged loss, destruction or mutilation of a certificate of stock of the
Corporation, a duplicate certificate may be issued in place thereof, upon such terms as the Board of Directors may prescribe. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE V
</U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Indemnification </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1. <U>Definitions</U>. For purposes of this Article: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &#147;Corporate Status&#148; describes the status of a person who is serving or has served (i)&nbsp;as a Director of the Corporation,
(ii)&nbsp;as an Officer of the Corporation, (iii)&nbsp;as a Non-Officer Employee of the Corporation, or (iv)&nbsp;as a Director, partner, trustee, officer, employee or agent of any other corporation, partnership, limited liability company, joint
venture, trust, employee benefit plan, foundation, association, organization or other legal entity which such person is or was serving at the request of the Corporation. For purposes of this Section&nbsp;1(a), a Director, Officer or Non-Officer
Employee of the Corporation who is serving or has served as a Director, partner, trustee, officer, employee or agent of a Subsidiary shall be deemed to be serving at the request of the Corporation. Notwithstanding the foregoing, &#147;Corporate
Status&#148; shall not include the status of a person who is serving or has served as a Director, officer, employee or agent of a constituent corporation absorbed in a merger or consolidation transaction with the Corporation with respect to such
person&#146;s activities prior to said transaction, unless specifically authorized by the Board of Directors or the stockholders of the Corporation; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) &#147;Director&#148; means any person who serves or has served the Corporation as a Director on the Board of Directors; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) &#147;Disinterested Director&#148; means, with respect to each Proceeding in respect of which indemnification is sought hereunder, a
Director of the Corporation who is not and was not a party to such Proceeding; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) &#147;Expenses&#148; means all attorneys&#146; fees,
retainers, court costs, transcript costs, fees of expert witnesses, private investigators and professional advisors (including, without </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limitation, accountants and investment bankers), travel expenses, duplicating costs, printing and binding costs, costs of preparation of demonstrative evidence and other courtroom presentation
aids and devices, costs incurred in connection with document review, organization, imaging and computerization, telephone charges, postage, delivery service fees, and all other disbursements, costs or expenses of the type customarily incurred in
connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, settling or otherwise participating in, a Proceeding; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) &#147;Liabilities&#148; means judgments, damages, liabilities, losses, penalties, excise taxes, fines and amounts paid in settlement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) &#147;Non-Officer Employee&#148; means any person who serves or has served as an employee or agent of the Corporation, but who is not or
was not a Director or Officer; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) &#147;Officer&#148; means any person who serves or has served the Corporation as an officer of the
Corporation appointed by the Board of Directors; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) &#147;Proceeding&#148; means any threatened, pending or completed action, suit,
arbitration, alternate dispute resolution mechanism, inquiry, investigation, administrative hearing or other proceeding, whether civil, criminal, administrative, arbitrative or investigative; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) &#147;Subsidiary&#148; shall mean any corporation, partnership, limited liability company, joint venture, trust or other entity of which
the Corporation owns (either directly or through or together with another Subsidiary of the Corporation) either (i)&nbsp;a general partner, managing member or other similar interest or (ii)&nbsp;(A)&nbsp;fifty percent (50%)&nbsp;or more of the
voting power of the voting capital equity interests of such corporation, partnership, limited liability company, joint venture or other entity, or (B)&nbsp;fifty percent (50%)&nbsp;or more of the outstanding voting capital stock or other voting
equity interests of such corporation, partnership, limited liability company, joint venture or other entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2.
<U>Indemnification of Directors and Officers</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Subject to the operation of Section&nbsp;4 of this Article V of these By-laws, each
Director and Officer shall be indemnified and held harmless by the Corporation to the fullest extent authorized by the DGCL, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such
amendment permits the Corporation to provide broader indemnification rights than such law permitted the Corporation to provide prior to such amendment), and to the extent authorized in this Section&nbsp;2. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) <U>Actions, Suits and Proceedings Other than By or In the Right of the Corporation</U>. Each Director and Officer shall be
indemnified and held harmless by the Corporation against any and all Expenses and Liabilities that are incurred or paid by such Director or Officer or on such Director&#146;s or Officer&#146;s behalf in connection with any Proceeding or any claim,
issue or matter therein (other than an action by or in the right of the Corporation), which such Director or Officer is, or is threatened to be made, a party to or participant in by reason of such Director&#146;s or Officer&#146;s Corporate Status,
if such Director or Officer acted in good faith and in a manner such Director or Officer reasonably believed to be in or not opposed to the best interests of the Corporation and, with respect to any criminal proceeding, had no reasonable cause to
believe his or her conduct was unlawful. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) <U>Actions, Suits and Proceedings By or In the Right of the Corporation</U>.
Each Director and Officer shall be indemnified and held harmless by the Corporation against any and all Expenses that are incurred by such Director or Officer or on such Director&#146;s or Officer&#146;s behalf in connection with any Proceeding or
any claim, issue or matter therein by or in the right of the Corporation, which such Director or Officer is, or is threatened to be made, a party to or participant in by reason of such Director&#146;s or Officer&#146;s Corporate Status, if such
Director or Officer acted in good faith and in a manner such Director or Officer reasonably believed to be in or not opposed to the best interests of the Corporation; provided, however, that no indemnification shall be made under this
Section&nbsp;2(a)(2) in respect of any claim, issue or matter as to which such Director or Officer shall have been finally adjudged by a court of competent jurisdiction to be liable to the Corporation, unless, and only to the extent that, the Court
of Chancery or another court in which such Proceeding was brought shall determine upon application that, despite adjudication of liability, but in view of all the circumstances of the case, such Director or Officer is fairly and reasonably entitled
to indemnification for such Expenses that such court deems proper. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) <U>Survival of Rights</U>. The rights of
indemnification provided by this Section&nbsp;2 shall continue as to a Director or Officer after he or she has ceased to be a Director or Officer and shall inure to the benefit of his or her heirs, executors, administrators and personal
representatives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) <U>Actions by Directors or Officers</U>. Notwithstanding the foregoing, the Corporation shall
indemnify any Director or Officer seeking indemnification in connection with a Proceeding initiated by such Director or Officer only if such Proceeding (including any parts of such Proceeding not initiated by such Director or Officer) was authorized
in advance by the Board of Directors, unless such Proceeding was brought to enforce such Officer&#146;s or Director&#146;s rights to indemnification or, in the case of Directors, advancement of Expenses under these By-laws in accordance with the
provisions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Indemnification of Non-Officer Employees</U>. Subject to the operation of Section&nbsp;4 of
this Article V of these By-laws, each Non-Officer Employee may, in the discretion of the Board of Directors, be indemnified by the Corporation to the fullest extent authorized by the DGCL, as the same exists or may hereafter be amended, against any
or all Expenses and Liabilities that are incurred by such Non-Officer Employee or on such Non-Officer Employee&#146;s behalf in connection with any threatened, pending or completed Proceeding, or any claim, issue or matter therein, which such
Non-Officer Employee is, or is threatened to be made, a party to or participant in by reason of such Non-Officer Employee&#146;s Corporate Status, if such Non-Officer Employee acted in good faith and in a manner such Non-Officer Employee reasonably
believed to be in or not opposed to the best interests of the Corporation and, with respect to any criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful. The rights of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
indemnification provided by this Section&nbsp;3 shall exist as to a Non-Officer Employee after he or she has ceased to be a Non-Officer Employee and shall inure to the benefit of his or her
heirs, personal representatives, executors and administrators. Notwithstanding the foregoing, the Corporation may indemnify any Non-Officer Employee seeking indemnification in connection with a Proceeding initiated by such Non-Officer Employee only
if such Proceeding was authorized in advance by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Determination</U>. Unless ordered by a court, no
indemnification shall be provided pursuant to this Article V to a Director, to an Officer or to a Non-Officer Employee unless a determination shall have been made that such person acted in good faith and in a manner such person reasonably believed
to be in or not opposed to the best interests of the Corporation and, with respect to any criminal Proceeding, such person had no reasonable cause to believe his or her conduct was unlawful. Such determination shall be made by (a)&nbsp;a majority
vote of the Disinterested Directors, even though less than a quorum of the Board of Directors, (b)&nbsp;a committee comprised of Disinterested Directors, such committee having been designated by a majority vote of the Disinterested Directors (even
though less than a quorum), (c)&nbsp;if there are no such Disinterested Directors, or if a majority of Disinterested Directors so directs, by independent legal counsel in a written opinion, or (d)&nbsp;by the stockholders of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Advancement of Expenses to Directors Prior to Final Disposition</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Corporation shall advance all Expenses incurred by or on behalf of any Director in connection with any Proceeding in which such
Director is involved by reason of such Director&#146;s Corporate Status within thirty (30)&nbsp;days after the receipt by the Corporation of a written statement from such Director requesting such advance or advances from time to time, whether prior
to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by such Director and shall be preceded or accompanied by an undertaking by or on behalf of such Director to repay any
Expenses so advanced if it shall ultimately be determined that such Director is not entitled to be indemnified against such Expenses. Notwithstanding the foregoing, the Corporation shall advance all Expenses incurred by or on behalf of any Director
seeking advancement of expenses hereunder in connection with a Proceeding initiated by such Director only if such Proceeding (including any parts of such Proceeding not initiated by such Director) was (i)&nbsp;authorized by the Board of Directors,
or (ii)&nbsp;brought to enforce such Director&#146;s rights to indemnification or advancement of Expenses under these By-laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If a
claim for advancement of Expenses hereunder by a Director is not paid in full by the Corporation within thirty (30)&nbsp;days after receipt by the Corporation of documentation of Expenses and the required undertaking, such Director may at any time
thereafter bring suit against the Corporation to recover the unpaid amount of the claim and if successful in whole or in part, such Director shall also be entitled to be paid the expenses of prosecuting such claim. The failure of the Corporation
(including its Board of Directors or any committee thereof, independent legal counsel, or stockholders) to make a determination concerning the permissibility of such advancement of Expenses under this Article V shall not be a defense to an action
brought by a Director for recovery of the unpaid amount of an advancement claim and shall not create a presumption that such advancement is not permissible. The burden of proving that a Director is not entitled to an advancement of expenses shall be
on the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) In any suit brought by the Corporation to recover an advancement of expenses pursuant to the
terms of an undertaking, the Corporation shall be entitled to recover such expenses upon a final adjudication that the Director has not met any applicable standard for indemnification set forth in the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Advancement of Expenses to Officers and Non-Officer Employees Prior to Final Disposition</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Corporation may, at the discretion of the Board of Directors, advance any or all Expenses incurred by or on behalf of any Officer or
any Non-Officer Employee in connection with any Proceeding in which such person is involved by reason of his or her Corporate Status as an Officer or Non-Officer Employee upon the receipt by the Corporation of a statement or statements from such
Officer or Non-Officer Employee requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by such Officer or
Non-Officer Employee and shall be preceded or accompanied by an undertaking by or on behalf of such person to repay any Expenses so advanced if it shall ultimately be determined that such Officer or Non-Officer Employee is not entitled to be
indemnified against such Expenses. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms
of an undertaking, the Corporation shall be entitled to recover such expenses upon a final adjudication that the Officer or Non-Officer Employee has not met any applicable standard for indemnification set forth in the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>Contractual Nature of Rights</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The provisions of this Article&nbsp;V shall be deemed to be a contract between the Corporation and each Director and Officer entitled to
the benefits hereof at any time while this Article&nbsp;V is in effect, in consideration of such person&#146;s past or current and any future performance of services for the Corporation. Neither amendment, repeal or modification of any provision of
this Article&nbsp;V nor the adoption of any provision of the Certificate of Incorporation inconsistent with this Article&nbsp;V shall eliminate or reduce any right conferred by this Article&nbsp;V in respect of any act or omission occurring, or any
cause of action or claim that accrues or arises or any state of facts existing, at the time of or before such amendment, repeal, modification or adoption of an inconsistent provision (even in the case of a proceeding based on such a state of facts
that is commenced after such time), and all rights to indemnification and advancement of Expenses granted herein or arising out of any act or omission shall vest at the time of the act or omission in question, regardless of when or if any proceeding
with respect to such act or omission is commenced. The rights to indemnification and to advancement of expenses provided by, or granted pursuant to, this Article&nbsp;V shall continue notwithstanding that the person has ceased to be a Director or
officer of the Corporation and shall inure to the benefit of the estate, heirs, executors, administrators, legatees and distributes of such person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If a claim for indemnification hereunder by a Director or Officer is not paid in full by the
Corporation within sixty (60)&nbsp;days after receipt by the Corporation of a written claim for indemnification, such Director or Officer may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim, and if
successful in whole or in part, such Director or Officer shall also be entitled to be paid the expenses of prosecuting such claim. The failure of the Corporation (including its Board of Directors or any committee thereof, independent legal counsel,
or stockholders) to make a determination concerning the permissibility of such indemnification under this Article V shall not be a defense to an action brought by a Director or Officer for recovery of the unpaid amount of an indemnification claim
and shall not create a presumption that such indemnification is not permissible. The burden of proving that a Director or Officer is not entitled to indemnification shall be on the Corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) In any suit brought by a Director or Officer to enforce a right to indemnification hereunder, it shall be a defense that such Director or
Officer has not met any applicable standard for indemnification set forth in the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8. <U>Non-Exclusivity of Rights</U>. The
rights to indemnification and to advancement of Expenses set forth in this Article V shall not be exclusive of any other right which any Director, Officer, or Non-Officer Employee may have or hereafter acquire under any statute, provision of the
Certificate or these By-laws, agreement, vote of stockholders or Disinterested Directors or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9. <U>Insurance</U>. The
Corporation may maintain insurance, at its expense, to protect itself and any Director, Officer or Non-Officer Employee against any liability of any character asserted against or incurred by the Corporation or any such Director, Officer or
Non-Officer Employee, or arising out of any such person&#146;s Corporate Status, whether or not the Corporation would have the power to indemnify such person against such liability under the DGCL or the provisions of this Article&nbsp;V. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 10. <U>Other Indemnification</U>. The Corporation&#146;s obligation, if any, to indemnify or provide advancement of Expenses to any
person under this Article V as a result of such person serving, at the request of the Corporation, as a Director, partner, trustee, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other
enterprise shall be reduced by any amount such person may collect as indemnification or advancement of Expenses from such other corporation, partnership, joint venture, trust, employee benefit plan or enterprise (the &#147;Primary Indemnitor&#148;).
Any indemnification or advancement of Expenses under this Article V owed by the Corporation as a result of a person serving, at the request of the Corporation, as a Director, partner, trustee, officer, employee or agent of another corporation,
partnership, joint venture, trust, employee benefit plan or other enterprise shall only be in excess of, and shall be secondary to, the indemnification or advancement of Expenses available from the applicable Primary Indemnitor(s) and any applicable
insurance policies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE VI </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Miscellaneous Provisions </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1. <U>Fiscal Year</U>. The fiscal year of the Corporation shall be determined by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Seal</U>. The Board of Directors shall have power to adopt and alter the seal of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Execution of Instruments</U>. All deeds, leases, transfers, contracts, bonds, notes and other obligations to be entered into by
the Corporation in the ordinary course of its business without Director action may be executed on behalf of the Corporation by the Chairperson of the Board, if one is elected, the President or the Treasurer or any other officer, employee or agent of
the Corporation as the Board of Directors or the executive committee of the Board may authorize. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Voting of Securities</U>.
Unless the Board of Directors otherwise provides, the Chairperson of the Board, if one is elected, the President or the Treasurer may waive notice of and act on behalf of the Corporation, or appoint another person or persons to act as proxy or
attorney in fact for the Corporation with or without discretionary power and/or power of substitution, at any meeting of stockholders or shareholders of any other corporation or organization, any of whose securities are held by the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Resident Agent</U>. The Board of Directors may appoint a resident agent upon whom legal process may be served in any action or
proceeding against the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Corporate Records</U>. The original or attested copies of the Certificate, By-laws and
records of all meetings of the incorporators, stockholders and the Board of Directors and the stock transfer books, which shall contain the names of all stockholders, their record addresses and the amount of stock held by each, may be kept outside
the State of Delaware and shall be kept at the principal office of the Corporation, at an office of its counsel, at an office of its transfer agent or at such other place or places as may be designated from time to time by the Board of Directors.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>Certificate</U>. All references in these By-laws to the Certificate shall be deemed to refer to the Seventh Amended and
Restated Certificate of Incorporation of the Corporation, as amended and/or restated and in effect from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8.
<U>Exclusive Jurisdiction of Delaware Courts</U>. Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i)&nbsp;any derivative
action or proceeding brought on behalf of the Corporation, (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any Director, officer or other employee of the Corporation to the Corporation or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Corporation&#146;s stockholders, (iii)&nbsp;any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law or the Certificate or By-laws, or
(iv)&nbsp;any action asserting a claim against the Corporation governed by the internal affairs doctrine.&nbsp;Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Corporation shall be deemed to have
notice of and consented to the provisions of this Section&nbsp;8. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9. <U>Amendment of By-laws</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Amendment by Directors</U>. Except as provided otherwise by law, these By-laws may be amended or repealed by the Board of Directors by
the affirmative vote of a majority of the Directors then in office. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Amendment by Stockholders</U>. These By-laws may be amended or
repealed at any Annual Meeting, or special meeting of stockholders called for such purpose in accordance with these By-Laws, by the affirmative vote of at least seventy-five percent (75%)&nbsp;of the outstanding shares entitled to vote on such
amendment or repeal, voting together as a single class; provided, however, that if the Board of Directors recommends that stockholders approve such amendment or repeal at such meeting of stockholders, such amendment or repeal shall only require the
affirmative vote of the majority of the outstanding shares entitled to vote on such amendment or repeal, voting together as a single class. Notwithstanding the foregoing, stockholder approval shall not be required unless mandated by the Certificate,
these By-laws, or other applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 10. <U>Notices</U>. If mailed, notice to stockholders shall be deemed given when
deposited in the mail, postage prepaid, directed to the stockholder at such stockholder&#146;s address as it appears on the records of the Corporation. Without limiting the manner by which notice otherwise may be given to stockholders, any notice to
stockholders may be given by electronic transmission in the manner provided in Section&nbsp;232 of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 11. <U>Waivers</U>.
A written waiver of any notice, signed by a stockholder or Director, or waiver by electronic transmission by such person, whether given before or after the time of the event for which notice is to be given, shall be deemed equivalent to the notice
required to be given to such person. Neither the business to be transacted at, nor the purpose of, any meeting need be specified in such a waiver. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adopted November&nbsp;18, 2014 and effective as of February&nbsp;17, 2015. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>4
<FILENAME>d893535dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g893535g40w79.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following abbreviations, when used in the inscription on the face of this certificate,
shall be construed as though they were written out in full according to applicable laws or regulations:</I> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>&nbsp;&nbsp;&nbsp;&nbsp;TEN&nbsp;COM</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"><I>-</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"><I>as tenants in common</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"><I>UNIF GIFT MIN ACT -
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Custodian&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></I></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>&nbsp;&nbsp;&nbsp;&nbsp;TEN&nbsp;ENT</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"><I>-</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"><I>as tenants by the entireties</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Cust)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Minor)</I></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>&nbsp;&nbsp;&nbsp;&nbsp;JT TEN</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"><I>-</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>as joint tenants with right of </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>survivorship and not as tenants </I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>in common</I></P></TD>

<TD VALIGN="bottom"></TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;under Uniform Gifts to Minors</I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Act<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(State)</I></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Additional abbreviations may also be used though not in the above list. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>For Value Received,
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> hereby sell, assign and transfer unto</I> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="45%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLEASE INSERT SOCIAL SECURITY OR OTHER</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">IDENTIFYING NUMBER OF ASSIGNEE</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:8pt">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="93%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">(PLEASE PRINT OR TYPE NAME AND ADDRESS, INCLUDING ZIP CODE OF ASSIGNEE)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" ALIGN="right"><I>Shares</I></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE="font-family:Times New Roman; font-size:10pt"><I>of the stock represented by the within Certificate, and do hereby irrevocably constitute and appoint</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" ALIGN="right"><I>Attorney</I></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE="font-family:Times New Roman; font-size:10pt"><I>to transfer the said stock on the books of the within named Corporation with full power of substitution in the premises.</I></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dated
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></I> </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Signature(s) Guaranteed</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>NOTICE: </B>THE
SIGNATURE TO THIS ASSIGNMENT MUST CORRESPOND WITH THE NAME AS WRITTEN UPON THE FACE OF THE CERTIFICATE IN EVERY PARTICULAR, WITHOUT ALTERATION OR ENLARGEMENT OR ANY CHANGE WHATSOEVER.</P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="50%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="94%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>By</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE="font-family:Times New Roman; font-size:10pt">The Signature(s) must be guaranteed by an eligible guarantor institution (Banks, Stockbrokers, Savings and Loan Associations and Credit Unions with
membership in an approved Signature Guarantee Medallion Program), pursuant to SEC Rule 17Ad-15.</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:96pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">THE CORPORATION WILL FURNISH TO ANY STOCKHOLDER, UPON REQUEST AND WlTHOUT CHARGE, A FULL STATEMENT OF THE DESIGNATIONS, RELATIVE RIGHTS,
PREFERENCES AND LIMITATIONS OF THE SHARES OF EACH CLASS AND SERIES AUTHORIZED TO BE ISSUED, SO FAR AS THE SAME HAVE BEEN DETERMINED, AND OF THE AUTHORITY, IF ANY, OF THE BOARD TO DIVIDE THE SHARES INTO CLASSES OR SERIES AND TO DETERMINE AND CHANGE
THE RELATIVE RIGHTS, PREFERENCES AND LIMITATIONS OF ANY CLASS OR SERIES. SUCH REQUEST MAY BE MADE TO THE SECRETARY OF THE CORPORATION OR TO THE TRANSFER AGENT NAMED ON THIS CERTIFICATE. </P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">COLUMBIA PRINTING SERVICES, LLC -
www.stockinformation.com </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>5
<FILENAME>d893535dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INOTEK PHARMACEUTICALS CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED 2014 STOCK OPTION AND INCENTIVE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 1. <U>GENERAL PURPOSE OF THE PLAN; DEFINITIONS</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The name of the plan is the Inotek Pharmaceuticals Corporation 2014 Amended and Restated Stock Option and Incentive Plan (the
&#147;<U>Plan</U>&#148;). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Inotek Pharmaceuticals Corporation (the &#147;<U>Company</U>&#148;) and its Subsidiaries upon whose
judgment, initiative and efforts the Company largely depends for the successful conduct of its business to acquire a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company&#146;s welfare
will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company&#146;s behalf and strengthening their desire to remain with the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following terms shall be defined as set forth below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Act</U>&#148; means the Securities Act of 1933, as amended, and the rules and regulations thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Administrator</U>&#148; means either the Board or the compensation committee of the Board or a similar committee performing the
functions of the compensation committee and which is comprised of not less than two <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors who are independent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Award</U>&#148; or &#147;<U>Awards</U>,&#148; except where referring to a particular category of grant under the Plan, shall include
Incentive Stock Options, Non-Qualified Stock Options, Stock Appreciation Rights, Restricted Stock Units, Restricted Stock Awards, Unrestricted Stock Awards, Cash-Based Awards, Performance Share Awards and Dividend Equivalent Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Award Certificate</U>&#148; means a written or electronic document setting forth the terms and provisions applicable to an Award
granted under the Plan. Each Award Certificate is subject to the terms and conditions of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Board</U>&#148; means the
Board of Directors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cash-Based Award</U>&#148; means an Award entitling the recipient to receive a
cash-denominated payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Code</U>&#148; means the Internal Revenue Code of 1986, as amended, and any successor Code, and
related rules, regulations and interpretations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Consultant</U>&#148; means any natural person that provides bona fide services
to the Company, and such services are not in connection with the offer or sale of securities in a capital-raising transaction and do not directly or indirectly promote or maintain a market for the Company&#146;s securities. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Covered Employee</U>&#148; means an employee who is a &#147;Covered Employee&#148;
within the meaning of Section&nbsp;162(m) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Dividend Equivalent Right</U>&#148; means an Award entitling the grantee
to receive credits based on cash dividends that would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other award to which it relates) if such shares had been issued to and held by the grantee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Effective Date</U>&#148; means the date on which the Plan is approved by stockholders as set forth in Section&nbsp;21. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Act</U>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Fair Market Value</U>&#148; of the Stock on any given date means the fair market value of the Stock determined in good faith by the
Administrator; provided, however, that if the Stock is admitted to quotation on the National Association of Securities Dealers Automated Quotation System (&#147;<U>NASDAQ</U>&#148;), NASDAQ Global Market or another national securities exchange, the
determination shall be made by reference to market quotations. If there are no market quotations for such date, the determination shall be made by reference to the last date preceding such date for which there are market quotations; provided
further, however, that if the date for which Fair Market Value is determined is the first day when trading prices for the Stock are reported on a national securities exchange, the Fair Market Value shall be the &#147;Price to the Public&#148; (or
equivalent) set forth on the cover page for the final prospectus relating to the Company&#146;s Initial Public Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Incentive Stock Option</U>&#148; means any Stock Option designated and qualified as an &#147;incentive stock option&#148; as defined
in Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Initial Public Offering</U>&#148; means the consummation of the first underwritten, firm
commitment public offering pursuant to an effective registration statement under the Act covering the offer and sale by the Company of its equity securities, or such other event as a result of or following which the Stock shall be publicly held.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Non-Employee Director</U>&#148; means a member of the Board who is not also an employee of the Company or any Subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Non-Qualified Stock Option</U>&#148; means any Stock Option that is not an Incentive Stock Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Option</U>&#148; or &#147;<U>Stock Option</U>&#148; means any option to purchase shares of Stock granted pursuant to Section&nbsp;5.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Performance-Based Award</U>&#148; means any Restricted Stock Award, Restricted Stock Units, Performance Share Award or
Cash-Based Award granted to a Covered Employee that is intended to qualify as &#147;performance-based compensation&#148; under Section&nbsp;162(m) of the Code and the regulations promulgated thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Performance Criteria</U>&#148; means the criteria that the Administrator selects for
purposes of establishing the Performance Goal or Performance Goals for an individual for a Performance Cycle. The Performance Criteria (which shall be applicable to the organizational level specified by the Administrator, including, but not limited
to, the Company or a unit, division, group, or Subsidiary of the Company) that will be used to establish Performance Goals are limited to the following: total shareholder return, earnings before interest, taxes, depreciation and amortization, net
income (loss) (either before or after interest, taxes, depreciation and/or amortization), changes in the market price of the Stock, economic value-added, funds from operations or similar measure, sales or revenue, developmental, clinical or
regulatory milestones, acquisitions or strategic transactions, including licenses, collaborations, joint ventures, or promotion arrangements, operating income (loss), cash flow (including, but not limited to, operating cash flow and free cash flow),
return on capital, assets, equity, or investment, return on sales, gross or net profit levels, productivity, expense, margins, operating efficiency, customer satisfaction, working capital, earnings (loss) per share of Stock, sales or market shares
and number of customers, any of which may be measured either in absolute terms or as compared to any incremental increase or as compared to results of a peer group. The Committee may appropriately adjust any evaluation performance under a
Performance Criterion to exclude any of the following events that occurs during a Performance Cycle: (i)&nbsp;asset write-downs or impairments, (ii)&nbsp;litigation or claim judgments or settlements, (iii)&nbsp;the effect of changes in tax law,
accounting principles or other such laws or provisions affecting reporting results, (iv)&nbsp;accruals for reorganizations and restructuring programs, (v)&nbsp;any extraordinary non-recurring items, including those described in the Financial
Accounting Standards Board&#146;s authoritative guidance and/or in management&#146;s discussion and analysis of financial condition of operations appearing the Company&#146;s annual report to stockholders for the applicable year, and (vi)&nbsp;any
other extraordinary items adjusted from the Company U.S. GAAP results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Performance Cycle</U>&#148; means one or more periods of
time, which may be of varying and overlapping durations, as the Administrator may select, over which the attainment of one or more Performance Criteria will be measured for the purpose of determining a grantee&#146;s right to and the payment of a
Restricted Stock Award, Restricted Stock Units, Performance Share Award or Cash-Based Award, the vesting and/or payment of which is subject to the attainment of one or more Performance Goals. Each such period shall not be less than 12 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Performance Goals</U>&#148; means, for a Performance Cycle, the specific goals established in writing by the Administrator for a
Performance Cycle based upon the Performance Criteria. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Performance Share Award</U>&#148; means an Award entitling the recipient
to acquire shares of Stock upon the attainment of specified Performance Goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Restricted Shares</U><I>&#148;</I> means the
shares of Stock underlying a Restricted Stock Award that remain subject to a risk of forfeiture or the Company&#146;s right of repurchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Restricted Stock Award</U>&#148; means an Award of Restricted Shares subject to such restrictions and conditions as the Administrator
may determine at the time of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Restricted Stock Units</U>&#148; means an Award of stock units subject to such restrictions
and conditions as the Administrator may determine at the time of grant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sale Event</U>&#148; shall mean (i)&nbsp;the sale of all or substantially all of the
assets of the Company on a consolidated basis to an unrelated person or entity, (ii)&nbsp;a merger, reorganization or consolidation pursuant to which the holders of the Company&#146;s outstanding voting power and outstanding stock immediately prior
to such transaction do not own a majority of the outstanding voting power and outstanding stock or other equity interests of the resulting or successor entity (or its ultimate parent, if applicable) immediately upon completion of such transaction,
(iii)&nbsp;the sale of all of the Stock of the Company to an unrelated person, entity or group thereof acting in concert, or (iv)&nbsp;any other transaction in which the owners of the Company&#146;s outstanding voting power immediately prior to such
transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately upon completion of the transaction other than as a result of the acquisition of securities directly from the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sale Price</U>&#148; means the value as determined by the Administrator of the consideration payable, or otherwise to be received by
stockholders, per share of Stock pursuant to a Sale Event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Section 409A</U>&#148; means Section&nbsp;409A of the Code and the
regulations and other guidance promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Stock</U>&#148; means the Common Stock, par value $0.01 per share, of the
Company, subject to adjustments pursuant to Section&nbsp;3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Stock Appreciation Right</U>&#148; means an Award entitling the
recipient to receive shares of Stock having a value equal to the excess of the Fair Market Value of the Stock on the date of exercise over the exercise price of the Stock Appreciation Right multiplied by the number of shares of Stock with respect to
which the Stock Appreciation Right shall have been exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subsidiary</U>&#148; means any corporation or other entity (other
than the Company) in which the Company has at least a 50 percent interest, either directly or indirectly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Ten Percent
Owner</U>&#148; means an employee who owns or is deemed to own (by reason of the attribution rules of Section&nbsp;424(d) of the Code) more than 10 percent of the combined voting power of all classes of stock of the Company or any parent or
subsidiary corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Unrestricted Stock Award</U>&#148; means an Award of shares of Stock free of any restrictions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:10%; text-indent:-10%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>ADMI</U><U>NISTRATION OF PLAN; ADMINISTRATOR AUTHORITY TO SELECT GRANTEES AND DETERMINE AWARDS</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Administration of Plan</U>. The Plan shall be administered by the Administrator. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Powers of Administrator</U>. The Administrator shall have the power and authority to grant Awards consistent with the terms of the Plan,
including the power and authority: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) to select the individuals to whom Awards may from time to time be granted; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) to determine the time or times of grant, and the extent, if any, of Incentive Stock Options,
Non-Qualified Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Restricted Stock Units, Unrestricted Stock Awards, Cash-Based Awards, Performance Share Awards and Dividend Equivalent Rights, or any combination of the foregoing,
granted to any one or more grantees; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) to determine the number of shares of Stock to be covered by any Award; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) to determine and modify from time to time the terms and conditions, including restrictions, not inconsistent with the terms of the Plan,
of any Award, which terms and conditions may differ among individual Awards and grantees, and to approve the forms of Award Certificates; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(v) to accelerate at any time the exercisability or vesting of all or any portion of any Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vi) subject to the provisions of Section&nbsp;5(c), to extend at any time the period in which Stock Options may be exercised; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vii) at any time to adopt, alter and repeal such rules, guidelines and practices for administration of the Plan and for its own acts and
proceedings as it shall deem advisable; to interpret the terms and provisions of the Plan and any Award (including related written instruments); to make all determinations it deems advisable for the administration of the Plan; to decide all disputes
arising in connection with the Plan; and to otherwise supervise the administration of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All decisions and interpretations of the
Administrator shall be binding on all persons, including the Company and Plan grantees. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Delegation of Authority to Grant
Awards</U>. Subject to applicable law, the Administrator, in its discretion, may delegate to the Chief Executive Officer of the Company all or part of the Administrator&#146;s authority and duties with respect to the granting of Awards to
individuals who are (i)&nbsp;not subject to the reporting and other provisions of Section&nbsp;16 of the Exchange Act and (ii)&nbsp;not Covered Employees. Any such delegation by the Administrator shall include a limitation as to the amount of Stock
underlying Awards that may be granted during the period of the delegation and shall contain guidelines as to the determination of the exercise price and the vesting criteria. The Administrator may revoke or amend the terms of a delegation at any
time but such action shall not invalidate any prior actions of the Administrator&#146;s delegate or delegates that were consistent with the terms of the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Award Certificate</U>. Awards under the Plan shall be evidenced by Award Certificates that set forth the terms, conditions and
limitations for each Award which may include, without limitation, the term of an Award and the provisions applicable in the event employment or service terminates. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Indemnification</U>. Neither the Board nor the Administrator, nor any member of either or any delegate thereof, shall be liable for any
act, omission, interpretation, construction or determination made in good faith in connection with the Plan, and the members of the Board and the Administrator (and any delegate thereof) shall be entitled in all cases to indemnification and
reimbursement by the Company in respect of any claim, loss, damage or expense </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(including, without limitation, reasonable attorneys&#146; fees) arising or resulting therefrom to the fullest extent permitted by law and/or under the Company&#146;s articles or bylaws or any
directors&#146; and officers&#146; liability insurance coverage which may be in effect from time to time and/or any indemnification agreement between such individual and the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Foreign Award Recipients</U>. Notwithstanding any provision of the Plan to the contrary, in order to comply with the laws in other
countries in which the Company and its Subsidiaries operate or have employees or other individuals eligible for Awards, the Administrator, in its sole discretion, shall have the power and authority to: (i)&nbsp;determine which Subsidiaries shall be
covered by the Plan; (ii)&nbsp;determine which individuals outside the United States are eligible to participate in the Plan; (iii)&nbsp;modify the terms and conditions of any Award granted to individuals outside the United States to comply with
applicable foreign laws; (iv)&nbsp;establish subplans and modify exercise procedures and other terms and procedures, to the extent the Administrator determines such actions to be necessary or advisable (and such subplans and/or modifications shall
be attached to this Plan as appendices); provided, however, that no such subplans and/or modifications shall increase the share limitations contained in Section&nbsp;3(a) hereof; and (v)&nbsp;take any action, before or after an Award is made, that
the Administrator determines to be necessary or advisable to obtain approval or comply with any local governmental regulatory exemptions or approvals. Notwithstanding the foregoing, the Administrator may not take any actions hereunder, and no Awards
shall be granted, that would violate the Exchange Act or any other applicable United States securities law, the Code, or any other applicable United States governing statute or law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>STOCK ISSUABLE UNDER THE PLAN; MERGERS; SUBSTITUTION</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Stock Issuable</U>. The maximum number of shares of Stock reserved and available for issuance under the Plan shall be 2,175,216 shares
(the &#147;Initial Limit&#148;), subject to adjustment as provided in Section&nbsp;3(b), plus on January&nbsp;1, 2016 and each January&nbsp;1 thereafter, the number of shares of Stock reserved and available for issuance under the Plan shall be
cumulatively increased by 4 percent of the number of shares of Stock issued and outstanding on the immediately preceding December&nbsp;31 (the &#147;Annual Increase&#148;). Subject to such overall limitation, the maximum aggregate number of shares
of Stock that may be issued in the form of Incentive Stock Options shall not exceed the Initial Limit cumulatively increased on January&nbsp;1, 2016 and on each January&nbsp;1 thereafter by the lesser of the Annual Increase for such year or
8,000,000 shares of Stock, subject in all cases to adjustment as provided in Section&nbsp;3(b). The shares of Stock underlying any Awards that are forfeited, canceled, held back upon exercise of an Option or settlement of an Award to cover the
exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated (other than by exercise) shall be added back to the shares of Stock available for issuance under the Plan.
In the event the Company repurchases shares of Stock on the open market, such shares shall not be added to the shares of Stock available for issuance under the Plan. Subject to such overall limitations, shares of Stock may be issued up to such
maximum number pursuant to any type or types of Award; provided, however, that Stock Options or Stock Appreciation Rights with respect to no more than 1,000,000 shares of Stock may be granted to any one individual grantee during any one calendar
year period. The shares available for issuance under the Plan may be authorized but unissued shares of Stock or shares of Stock reacquired by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Changes in Stock</U>. Subject to Section&nbsp;3(c) hereof, if, as a result of any
reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split or other similar change in the Company&#146;s capital stock, the outstanding shares of Stock are increased or decreased or are exchanged for a
different number or kind of shares or other securities of the Company, or additional shares or new or different shares or other securities of the Company or other non-cash assets are distributed with respect to such shares of Stock or other
securities, or, if, as a result of any merger or consolidation, sale of all or substantially all of the assets of the Company, the outstanding shares of Stock are converted into or exchanged for securities of the Company or any successor entity (or
a parent or subsidiary thereof), the Administrator shall make an appropriate or proportionate adjustment in (i)&nbsp;the maximum number of shares reserved for issuance under the Plan, including the maximum number of shares that may be issued in the
form of Incentive Stock Options, (ii)&nbsp;the number of Stock Options or Stock Appreciation Rights that can be granted to any one individual grantee and the maximum number of shares that may be granted under a Performance-Based Award,
(iii)&nbsp;the number and kind of shares or other securities subject to any then outstanding Awards under the Plan, (iv)&nbsp;the repurchase price, if any, per share subject to each outstanding Restricted Stock Award, and (v)&nbsp;the exercise price
for each share subject to any then outstanding Stock Options and Stock Appreciation Rights under the Plan, without changing the aggregate exercise price (i.e., the exercise price multiplied by the number of Stock Options and Stock Appreciation
Rights) as to which such Stock Options and Stock Appreciation Rights remain exercisable. The Administrator shall also make equitable or proportionate adjustments in the number of shares subject to outstanding Awards and the exercise price and the
terms of outstanding Awards to take into consideration cash dividends paid other than in the ordinary course or any other extraordinary corporate event. The adjustment by the Administrator shall be final, binding and conclusive. No fractional shares
of Stock shall be issued under the Plan resulting from any such adjustment, but the Administrator in its discretion may make a cash payment in lieu of fractional shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Mergers and Other Transactions</U>. In the case of and subject to the consummation of a Sale Event, the parties thereto may cause the
assumption or continuation of Awards theretofore granted by the successor entity, or the substitution of such Awards with new Awards of the successor entity or parent thereof, with appropriate adjustment as to the number and kind of shares and, if
appropriate, the per share exercise prices, as such parties shall agree. To the extent the parties to such Sale Event do not provide for the assumption, continuation or substitution of Awards or except as may be otherwise provided in the relevant
Award Certificate, upon the effective time of the Sale Event, the Plan and all outstanding Awards granted hereunder shall terminate. In the event of such termination, (i)&nbsp;the Company shall have the option (in its sole discretion) to make or
provide for a cash payment to the grantees holding Options and Stock Appreciation Rights, in exchange for the cancellation thereof, in an amount equal to the difference between (A)&nbsp;the Sale Price multiplied by the number of shares of Stock
subject to outstanding Options and Stock Appreciation Rights (to the extent then exercisable at prices not in excess of the Sale Price) and (B)&nbsp;the aggregate exercise price of all such outstanding Options and Stock Appreciation Rights; or
(ii)&nbsp;each grantee shall be permitted, within a specified period of time prior to the consummation of the Sale Event as determined by the Administrator, to exercise all outstanding Options and Stock Appreciation Rights (to the extent then
exercisable) held by such grantee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>ELIGIBILITY</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Grantees under the Plan will be such full or part-time officers and other employees, Non-Employee Directors and Consultants of the Company and
its Subsidiaries as are selected from time to time by the Administrator in its sole discretion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>STOCK OPTIONS</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Award of Stock Options</U>. The Administrator may grant Stock Options under the Plan. Any Stock Option granted under the Plan shall be
in such form as the Administrator may from time to time approve. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock Options granted under the Plan may be either Incentive Stock
Options or Non-Qualified Stock Options. Incentive Stock Options may be granted only to employees of the Company or any Subsidiary that is a &#147;subsidiary corporation&#148; within the meaning of Section&nbsp;424(f) of the Code. To the extent that
any Option does not qualify as an Incentive Stock Option, it shall be deemed a Non-Qualified Stock Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock Options granted pursuant
to this Section&nbsp;5 shall be subject to the following terms and conditions and shall contain such additional terms and conditions, not inconsistent with the terms of the Plan, as the Administrator shall deem desirable. If the Administrator so
determines, Stock Options may be granted in lieu of cash compensation at the optionee&#146;s election, subject to such terms and conditions as the Administrator may establish. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Exercise Price</U>. The exercise price per share for the Stock covered by a Stock Option granted pursuant to this Section&nbsp;5 shall
be determined by the Administrator at the time of grant but shall not be less than 100 percent of the Fair Market Value on the date of grant. In the case of an Incentive Stock Option that is granted to a Ten Percent Owner, the option price of such
Incentive Stock Option shall be not less than 110 percent of the Fair Market Value on the grant date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Option Term</U>. The term of
each Stock Option shall be fixed by the Administrator, but no Stock Option shall be exercisable more than ten years after the date the Stock Option is granted. In the case of an Incentive Stock Option that is granted to a Ten Percent Owner, the term
of such Stock Option shall be no more than five years from the date of grant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Exercisability; Rights of a Stockholder</U>. Stock
Options shall become exercisable at such time or times, whether or not in installments, as shall be determined by the Administrator at or after the grant date. The Administrator may at any time accelerate the exercisability of all or any portion of
any Stock Option. An optionee shall have the rights of a stockholder only as to shares acquired upon the exercise of a Stock Option and not as to unexercised Stock Options. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Method of Exercise</U>. Stock Options may be exercised in whole or in part, by giving written or electronic notice of exercise to the
Company, specifying the number of shares to be purchased. Payment of the purchase price may be made by one or more of the following methods except to the extent otherwise provided in the Option Award Certificate: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) In cash, by certified or bank check or other instrument acceptable to the Administrator; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) Through the delivery (or attestation to the ownership following such procedures as the Company may prescribe) of shares of Stock that are
not then subject to restrictions under any Company plan. Such surrendered shares shall be valued at Fair Market Value on the exercise date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) By the optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to
promptly deliver to the Company cash or a check payable and acceptable to the Company for the purchase price; provided that in the event the optionee chooses to pay the purchase price as so provided, the optionee and the broker shall comply with
such procedures and enter into such agreements of indemnity and other agreements as the Company shall prescribe as a condition of such payment procedure; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) With respect to Stock Options that are not Incentive Stock Options, by a &#147;net exercise&#148; arrangement pursuant to which the
Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment instruments will be received subject to collection. The transfer to the optionee on the records of the Company or of the transfer agent of the shares
of Stock to be purchased pursuant to the exercise of a Stock Option will be contingent upon receipt from the optionee (or a purchaser acting in his stead in accordance with the provisions of the Stock Option) by the Company of the full purchase
price for such shares and the fulfillment of any other requirements contained in the Option Award Certificate or applicable provisions of laws (including the satisfaction of any withholding taxes that the Company is obligated to withhold with
respect to the optionee). In the event an optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the optionee upon the exercise of the Stock Option
shall be net of the number of attested shares. In the event that the Company establishes, for itself or using the services of a third party, an automated system for the exercise of Stock Options, such as a system using an internet website or
interactive voice response, then the paperless exercise of Stock Options may be permitted through the use of such an automated system. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)
<U>Annual Limit on Incentive Stock Options</U>. To the extent required for &#147;incentive stock option&#148; treatment under Section&nbsp;422 of the Code, the aggregate Fair Market Value (determined as of the time of grant) of the shares of Stock
with respect to which Incentive Stock Options granted under this Plan and any other plan of the Company or its parent and subsidiary corporations become exercisable for the first time by an optionee during any calendar year shall not exceed
$100,000. To the extent that any Stock Option exceeds this limit, it shall constitute a Non-Qualified Stock Option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>STOCK APPRECIATION RIGHTS</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Award of Stock Appreciation Rights</U>. The Administrator may grant Stock Appreciation Rights under the Plan. A Stock Appreciation Right
is an Award entitling the recipient to receive shares of Stock having a value equal to the excess of the Fair Market Value of a share of Stock on the date of exercise over the exercise price of the Stock Appreciation Right multiplied by the number
of shares of Stock with respect to which the Stock Appreciation Right shall have been exercised. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Exercise Price of Stock
Appreciation Rights</U>. The exercise price of a Stock Appreciation Right shall not be less than 100 percent of the Fair Market Value of the Stock on the date of grant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Grant and Exercise of Stock Appreciation Rights</U>. Stock Appreciation Rights may be granted by the Administrator independently of any
Stock Option granted pursuant to Section&nbsp;5 of the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Terms and Conditions of Stock Appreciation Rights</U>. Stock
Appreciation Rights shall be subject to such terms and conditions as shall be determined from time to time by the Administrator. The term of a Stock Appreciation Right may not exceed ten years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>RESTRICTED STOCK AWARDS</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
<U>Nature of Restricted Stock Awards</U>. The Administrator may grant Restricted Stock Awards under the Plan. A Restricted Stock Award is any Award of Restricted Shares subject to such restrictions and conditions as the Administrator may determine
at the time of grant. Conditions may be based on continuing employment (or other service relationship) and/or achievement of pre-established performance goals and objectives. The terms and conditions of each such Award Certificate shall be
determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Rights as a
Stockholder</U>. Upon the grant of the Restricted Stock Award and payment of any applicable purchase price, a grantee shall have the rights of a stockholder with respect to the voting of the Restricted Shares and receipt of dividends; provided that
if the lapse of restrictions with respect to the Restricted Stock Award is tied to the attainment of performance goals, any dividends paid by the Company during the performance period shall accrue and shall not be paid to the grantee until and to
the extent the performance goals are met with respect to the Restricted Stock Award. Unless the Administrator shall otherwise determine, (i)&nbsp;uncertificated Restricted Shares shall be accompanied by a notation on the records of the Company or
the transfer agent to the effect that they are subject to forfeiture until such Restricted Shares are vested as provided in Section&nbsp;7(d) below, and (ii)&nbsp;certificated Restricted Shares shall remain in the possession of the Company until
such Restricted Shares are vested as provided in Section&nbsp;7(d) below, and the grantee shall be required, as a condition of the grant, to deliver to the Company such instruments of transfer as the Administrator may prescribe. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Restrictions</U>. Restricted Shares may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of except as
specifically provided herein or in the Restricted Stock Award Certificate. Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section&nbsp;18 below, in writing after the Award is issued, if a
grantee&#146;s employment (or other service relationship) with the Company and its Subsidiaries </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
terminates for any reason, any Restricted Shares that have not vested at the time of termination shall automatically and without any requirement of notice to such grantee from or other action by
or on behalf of, the Company be deemed to have been reacquired by the Company at its original purchase price (if any) from such grantee or such grantee&#146;s legal representative simultaneously with such termination of employment (or other service
relationship), and thereafter shall cease to represent any ownership of the Company by the grantee or rights of the grantee as a stockholder. Following such deemed reacquisition of Restricted Shares that are represented by physical certificates, a
grantee shall surrender such certificates to the Company upon request without consideration. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Vesting of Restricted Shares</U>. The
Administrator at the time of grant shall specify the date or dates and/or the attainment of pre-established performance goals, objectives and other conditions on which the non-transferability of the Restricted Shares and the Company&#146;s right of
repurchase or forfeiture shall lapse. Subsequent to such date or dates and/or the attainment of such pre-established performance goals, objectives and other conditions, the shares on which all restrictions have lapsed shall no longer be Restricted
Shares and shall be deemed &#147;vested.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 8. <U>RESTRICTED STOCK UNITS</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Nature of Restricted Stock Units</U>. The Administrator may grant Restricted Stock Units under the Plan. A Restricted Stock Unit is an
Award of stock units that may be settled in shares of Stock upon the satisfaction of such restrictions and conditions at the time of grant. Conditions may be based on continuing employment (or other service relationship) and/or achievement of
pre-established performance goals and objectives. The terms and conditions of each such Award Certificate shall be determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees. Except in the case of
Restricted Stock Units with a deferred settlement date that complies with Section&nbsp;409A, at the end of the vesting period, the Restricted Stock Units, to the extent vested, shall be settled in the form of shares of Stock. Restricted Stock Units
with deferred settlement dates are subject to Section&nbsp;409A and shall contain such additional terms and conditions as the Administrator shall determine in its sole discretion in order to comply with the requirements of Section&nbsp;409A. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Election to Receive Restricted Stock Units in Lieu of Compensation</U>. The Administrator may, in its sole discretion, permit a grantee
to elect to receive a portion of future cash compensation otherwise due to such grantee in the form of an award of Restricted Stock Units. Any such election shall be made in writing and shall be delivered to the Company no later than the date
specified by the Administrator and in accordance with Section&nbsp;409A and such other rules and procedures established by the Administrator. Any such future cash compensation that the grantee elects to defer shall be converted to a fixed number of
Restricted Stock Units based on the Fair Market Value of Stock on the date the compensation would otherwise have been paid to the grantee if such payment had not been deferred as provided herein. The Administrator shall have the sole right to
determine whether and under what circumstances to permit such elections and to impose such limitations and other terms and conditions thereon as the Administrator deems appropriate. Any Restricted Stock Units that are elected to be received in lieu
of cash compensation shall be fully vested, unless otherwise provided in the Award Certificate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Rights as a Stockholder</U>. A grantee shall have the rights as a stockholder only as to
shares of Stock acquired by the grantee upon settlement of Restricted Stock Units; provided, however, that the grantee may be credited with Dividend Equivalent Rights with respect to the stock units underlying his Restricted Stock Units, subject to
the provisions of Section&nbsp;11 and such terms and conditions as the Administrator may determine. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Termination</U>. Except as may
otherwise be provided by the Administrator either in the Award Certificate or, subject to Section&nbsp;18 below, in writing after the Award is issued, a grantee&#146;s right in all Restricted Stock Units that have not vested shall automatically
terminate upon the grantee&#146;s termination of employment (or cessation of service relationship) with the Company and its Subsidiaries for any reason. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 9. <U>UNRESTRICTED STOCK AWARDS</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Grant or Sale of Unrestricted Stock</U>. The Administrator may grant (or sell at par value or such higher purchase price determined by the
Administrator) an Unrestricted Stock Award under the Plan. An Unrestricted Stock Award is an Award pursuant to which the grantee may receive shares of Stock free of any restrictions under the Plan. Unrestricted Stock Awards may be granted in respect
of past services or other valid consideration, or in lieu of cash compensation due to such grantee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 10. <U>CASH-BASED AWARDS</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Grant of Cash-Based Awards</U>. The Administrator may grant Cash-Based Awards under the Plan. A Cash-Based Award is an Award that entitles
the grantee to a payment in cash upon the attainment of specified Performance Goals. The Administrator shall determine the maximum duration of the Cash-Based Award, the amount of cash to which the Cash-Based Award pertains, the conditions upon which
the Cash-Based Award shall become vested or payable, and such other provisions as the Administrator shall determine. Each Cash-Based Award shall specify a cash-denominated payment amount, formula or payment ranges as determined by the Administrator.
Payment, if any, with respect to a Cash-Based Award shall be made in accordance with the terms of the Award and may be made in cash. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 11.
<U>PERFORMANCE SHARE AWARDS</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Nature of Performance Share Awards</U>. The Administrator may grant Performance Share Awards under
the Plan. A Performance Share Award is an Award entitling the grantee to receive shares of Stock upon the attainment of performance goals. The Administrator shall determine whether and to whom Performance Share Awards shall be granted, the
performance goals, the periods during which performance is to be measured, which may not be less than one year except in the case of a Sale Event, and such other limitations and conditions as the Administrator shall determine. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Rights as a Stockholder</U>. A grantee receiving a Performance Share Award shall have the rights of a stockholder only as to shares of
Stock actually received by the grantee under the Plan and not with respect to shares subject to the Award but not actually received by the grantee. A grantee shall be entitled to receive shares of Stock under a Performance Share Award only upon
satisfaction of all conditions specified in the Performance Share Award Certificate (or in a performance plan adopted by the Administrator). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Termination</U>. Except as may otherwise be provided by the Administrator either in the
Award agreement or, subject to Section&nbsp;18 below, in writing after the Award is issued, a grantee&#146;s rights in all Performance Share Awards shall automatically terminate upon the grantee&#146;s termination of employment (or cessation of
service relationship) with the Company and its Subsidiaries for any reason. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 12. <U>PERFORMANCE-BASED AWARDS TO COVERED EMPLOYEES</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Performance-Based Awards</U>. The Administrator may grant one or more Performance-Based Awards in the form of a Restricted Stock Award,
Restricted Stock Units, Performance Share Awards or Cash-Based Award payable upon the attainment of Performance Goals that are established by the Administrator and relate to one or more of the Performance Criteria, in each case on a specified date
or dates or over any period or periods determined by the Administrator. The Administrator shall define in an objective fashion the manner of calculating the Performance Criteria it selects to use for any Performance Cycle. Depending on the
Performance Criteria used to establish such Performance Goals, the Performance Goals may be expressed in terms of overall Company performance or the performance of a division, business unit, or an individual. Each Performance-Based Award shall
comply with the provisions set forth below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Grant of Performance-Based Awards</U>. With respect to each Performance-Based Award
granted to a Covered Employee, the Administrator shall select, within the first 90 days of a Performance Cycle (or, if shorter, within the maximum period allowed under Section&nbsp;162(m) of the Code) the Performance Criteria for such grant, and the
Performance Goals with respect to each Performance Criterion (including a threshold level of performance below which no amount will become payable with respect to such Award). Each Performance-Based Award will specify the amount payable, or the
formula for determining the amount payable, upon achievement of the various applicable performance targets. The Performance Criteria established by the Administrator may be (but need not be) different for each Performance Cycle and different
Performance Goals may be applicable to Performance-Based Awards to different Covered Employees. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Payment of Performance-Based
Awards</U>. Following the completion of a Performance Cycle, the Administrator shall meet to review and certify in writing whether, and to what extent, the Performance Goals for the Performance Cycle have been achieved and, if so, to also calculate
and certify in writing the amount of the Performance-Based Awards earned for the Performance Cycle. The Administrator shall then determine the actual size of each Covered Employee&#146;s Performance-Based Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Maximum Award Payable</U>. The maximum Performance-Based Award payable to any one Covered Employee under the Plan for a Performance
Cycle is 1,000,000 shares of Stock (subject to adjustment as provided in Section&nbsp;3(c) hereof) or $1,000,000 in the case of a Performance-Based Award that is a Cash-Based Award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 13. <U>DIVIDEND EQUIVALENT RIGHTS</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Dividend Equivalent Rights</U>. The Administrator may grant Dividend Equivalent Rights under the Plan. A Dividend Equivalent Right is an
Award entitling the grantee to receive credits based on cash dividends that would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other Award to which it relates) if such shares had been issued to the grantee. A
Dividend Equivalent Right may be granted hereunder to any grantee as a component of an award of Restricted Stock Units, Restricted Stock Award or Performance Share Award or as a freestanding award. The terms and conditions of Dividend Equivalent
Rights shall be specified in the Award Certificate. Dividend equivalents credited to the holder of a Dividend Equivalent Right may be paid currently or may be deemed to be reinvested in additional shares of Stock, which may thereafter accrue
additional equivalents. Any such reinvestment shall be at Fair Market Value on the date of reinvestment or such other price as may then apply under a dividend reinvestment plan sponsored by the Company, if any. Dividend Equivalent Rights may be
settled in cash or shares of Stock or a combination thereof, in a single installment or installments. A Dividend Equivalent Right granted as a component of an Award of Restricted Stock Units or Performance Share Award shall provide that such
Dividend Equivalent Right shall be settled only upon settlement or payment of, or lapse of restrictions on, such other Award, and that such Dividend Equivalent Right shall expire or be forfeited or annulled under the same conditions as such other
Award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination</U>. Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to
Section&nbsp;18 below, in writing after the Award is issued, a grantee&#146;s rights in all Dividend Equivalent Rights shall automatically terminate upon the grantee&#146;s termination of employment (or cessation of service relationship) with the
Company and its Subsidiaries for any reason. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 14. <U>TRANSFERABILITY OF AWARDS</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Transferability</U>. Except as provided in Section&nbsp;14(b) below, during a grantee&#146;s lifetime, his or her Awards shall be
exercisable only by the grantee, or by the grantee&#146;s legal representative or guardian in the event of the grantee&#146;s incapacity. No Awards shall be sold, assigned, transferred or otherwise encumbered or disposed of by a grantee other than
by will or by the laws of descent and distribution or pursuant to a domestic relations order. No Awards shall be subject, in whole or in part, to attachment, execution, or levy of any kind, and any purported transfer in violation hereof shall be
null and void. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Administrator Action</U>. Notwithstanding Section&nbsp;14(a), the Administrator, in its discretion, may provide
either in the Award Certificate regarding a given Award or by subsequent written approval that the grantee (who is an employee or director) may transfer his or her Non-Qualified Options to his or her immediate family members, to trusts for the
benefit of such family members, or to partnerships in which such family members are the only partners, provided that the transferee agrees in writing with the Company to be bound by all of the terms and conditions of this Plan and the applicable
Award. In no event may an Award be transferred by a grantee for value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Family Member</U>. For purposes of Section&nbsp;14(b), &#147;family member&#148; shall
mean a grantee&#146;s child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive
relationships, any person sharing the grantee&#146;s household (other than a tenant of the grantee), a trust in which these persons (or the grantee) have more than 50 percent of the beneficial interest, a foundation in which these persons (or the
grantee) control the management of assets, and any other entity in which these persons (or the grantee) own more than 50 percent of the voting interests. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Designation of Beneficiary</U>. To the extent permitted by the Company, each grantee to whom an Award has been made under the Plan may
designate a beneficiary or beneficiaries to exercise any Award or receive any payment under any Award payable on or after the grantee&#146;s death. Any such designation shall be on a form provided for that purpose by the Administrator and shall not
be effective until received by the Administrator. If no beneficiary has been designated by a deceased grantee, or if the designated beneficiaries have predeceased the grantee, the beneficiary shall be the grantee&#146;s estate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 15. <U>TAX WITHHOLDING</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
<U>Payment by Grantee</U>. Each grantee shall, no later than the date as of which the value of an Award or of any Stock or other amounts received thereunder first becomes includable in the gross income of the grantee for Federal income tax purposes,
pay to the Company, or make arrangements satisfactory to the Administrator regarding payment of, any Federal, state, or local taxes of any kind required by law to be withheld by the Company with respect to such income. The Company and its
Subsidiaries shall, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to the grantee. The Company&#146;s obligation to deliver evidence of book entry (or stock certificates) to any
grantee is subject to and conditioned on tax withholding obligations being satisfied by the grantee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Payment in Stock</U>. Subject
to approval by the Administrator, a grantee may elect to have the Company&#146;s minimum required tax withholding obligation satisfied, in whole or in part, by authorizing the Company to withhold from shares of Stock to be issued pursuant to any
Award a number of shares with an aggregate Fair Market Value (as of the date the withholding is effected) that would satisfy the withholding amount due. The Administrator may also require Awards to be subject to mandatory share withholding up to the
required withholding amount. For purposes of share withholding, the Fair Market Value of withheld shares shall be determined in the same manner as the value of Stock includible in income of the Participants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 16. <U>SECTION&nbsp;409A AWARDS</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To
the extent that any Award is determined to constitute &#147;nonqualified deferred compensation&#148; within the meaning of Section&nbsp;409A (a &#147;<U>409A Award</U>&#148;), the Award shall be subject to such additional rules and requirements as
specified by the Administrator from time to time in order to comply with Section&nbsp;409A. In this regard, if any amount under a 409A Award is payable upon a &#147;separation from service&#148; (within the meaning of Section&nbsp;409A) to a grantee
who is then considered a &#147;specified employee&#148; (within the meaning of Section&nbsp;409A), then no such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payment shall be made prior to the date that is the earlier of (i)&nbsp;six months and one day after the grantee&#146;s separation from service, or (ii)&nbsp;the grantee&#146;s death, but only to
the extent such delay is necessary to prevent such payment from being subject to interest, penalties and/or additional tax imposed pursuant to Section&nbsp;409A. Further, the settlement of any such Award may not be accelerated except to the extent
permitted by Section&nbsp;409A. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:15%; text-indent:-15%; font-size:10pt; font-family:Times New Roman">SECTION 17. <U>TERMINATION OF EMPLOYMENT, TRANSFER, LEAVE OF ABSENCE, ETC.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Termination of Employment</U>. If the grantee&#146;s employer ceases to be a Subsidiary, the grantee shall be deemed to have terminated
employment for purposes of the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) For purposes of the Plan, the following events shall not be deemed a termination of employment:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) a transfer to the employment of the Company from a Subsidiary or from the Company to a Subsidiary, or from one Subsidiary to another;
or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) an approved leave of absence for military service or sickness, or for any other purpose approved by the Company, if the
employee&#146;s right to re-employment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise so provides in writing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 18. <U>AMENDMENTS AND TERMINATION</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board may, at any time, amend or discontinue the Plan and the Administrator may, at any time, amend or cancel any outstanding Award for the
purpose of satisfying changes in law or for any other lawful purpose, but no such action shall adversely affect rights under any outstanding Award without the holder&#146;s consent. Except as provided in Section&nbsp;3(c) or 3(d), without prior
stockholder approval, in no event may the Administrator exercise its discretion to reduce the exercise price of outstanding Stock Options or Stock Appreciation Rights or effect repricing through cancellation and re-grants or cancellation of Stock
Options or Stock Appreciation Rights in exchange for cash. To the extent required under the rules of any securities exchange or market system on which the Stock is listed, to the extent determined by the Administrator to be required by the Code to
ensure that Incentive Stock Options granted under the Plan are qualified under Section&nbsp;422 of the Code, or to ensure that compensation earned under Awards qualifies as performance-based compensation under Section&nbsp;162(m) of the Code, Plan
amendments shall be subject to approval by the Company stockholders entitled to vote at a meeting of stockholders. Nothing in this Section&nbsp;18 shall limit the Administrator&#146;s authority to take any action permitted pursuant to
Section&nbsp;3(c) or 3(d). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 19. <U>STATUS OF PLAN</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the portion of any Award that has not been exercised and any payments in cash, Stock or other consideration not received by a
grantee, a grantee shall have no rights greater than those of a general creditor of the Company unless the Administrator shall otherwise expressly determine in connection with any Award or Awards. In its sole discretion, the Administrator may
authorize the creation of trusts or other arrangements to meet the Company&#146;s obligations to deliver Stock or make payments with respect to Awards hereunder, provided that the existence of such trusts or other arrangements is consistent with the
foregoing sentence. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 20. <U>GENERAL PROVISIONS</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>No Distribution</U>. The Administrator may require each person acquiring Stock pursuant to an Award to represent to and agree with the
Company in writing that such person is acquiring the shares without a view to distribution thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Delivery of Stock
Certificates</U>. Stock certificates to grantees under this Plan shall be deemed delivered for all purposes when the Company or a stock transfer agent of the Company shall have mailed such certificates in the United States mail, addressed to the
grantee, at the grantee&#146;s last known address on file with the Company. Uncertificated Stock shall be deemed delivered for all purposes when the Company or a Stock transfer agent of the Company shall have given to the grantee by electronic mail
(with proof of receipt) or by United States mail, addressed to the grantee, at the grantee&#146;s last known address on file with the Company, notice of issuance and recorded the issuance in its records (which may include electronic &#147;book
entry&#148; records). Notwithstanding anything herein to the contrary, the Company shall not be required to issue or deliver any certificates evidencing shares of Stock pursuant to the exercise of any Award, unless and until the Administrator has
determined, with advice of counsel (to the extent the Administrator deems such advice necessary or advisable), that the issuance and delivery of such certificates is in compliance with all applicable laws, regulations of governmental authorities
and, if applicable, the requirements of any exchange on which the shares of Stock are listed, quoted or traded. All Stock certificates delivered pursuant to the Plan shall be subject to any stop-transfer orders and other restrictions as the
Administrator deems necessary or advisable to comply with federal, state or foreign jurisdiction, securities or other laws, rules and quotation system on which the Stock is listed, quoted or traded. The Administrator may place legends on any Stock
certificate to reference restrictions applicable to the Stock. In addition to the terms and conditions provided herein, the Administrator may require that an individual make such reasonable covenants, agreements, and representations as the
Administrator, in its discretion, deems necessary or advisable in order to comply with any such laws, regulations, or requirements. The Administrator shall have the right to require any individual to comply with any timing or other restrictions with
respect to the settlement or exercise of any Award, including a window-period limitation, as may be imposed in the discretion of the Administrator. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Stockholder Rights</U>. Until Stock is deemed delivered in accordance with Section&nbsp;20(b), no right to vote or receive dividends or
any other rights of a stockholder will exist with respect to shares of Stock to be issued in connection with an Award, notwithstanding the exercise of a Stock Option or any other action by the grantee with respect to an Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Other Compensation Arrangements; No Employment Rights</U>. Nothing contained in this Plan shall prevent the Board from adopting other or
additional compensation arrangements, including trusts, and such arrangements may be either generally applicable or applicable only in specific cases. The adoption of this Plan and the grant of Awards do not confer upon any employee any right to
continued employment with the Company or any Subsidiary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Trading Policy Restrictions</U>. Option exercises and other Awards under the Plan shall be
subject to the Company&#146;s insider trading policies and procedures, as in effect from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Clawback Policy</U>. Awards
under the Plan shall be subject to the Company&#146;s clawback policy, as in effect from time to time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 21. <U>EFFECTIVE DATE OF PLAN</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Plan shall become effective upon stockholder approval in accordance with applicable state law, the Company&#146;s bylaws and articles of
incorporation, and applicable stock exchange rules or pursuant to written consent. No grants of Stock Options and other Awards may be made hereunder after the tenth anniversary of the Effective Date and no grants of Incentive Stock Options may be
made hereunder after the tenth anniversary of the date the Plan is approved by the Board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 22. <U>GOVERNING LAW</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Plan and all Awards and actions taken thereunder shall be governed by, and construed in accordance with, the laws of the State of Delaware
applied without regard to conflict of law principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DATE APPROVED BY BOARD OF DIRECTORS: November&nbsp;18, 2014 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DATE APPROVED BY STOCKHOLDERS: November&nbsp;18, 2014 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INCENTIVE STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR COMPANY EMPLOYEES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER INOTEK PHARMACEUTICALS CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2014 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Optionee:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No. of Option Shares:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Option&nbsp;Exercise&nbsp;Price&nbsp;per&nbsp;Share:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>[FMV on Grant Date]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Grant Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Expiration Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Inotek Pharmaceuticals Corporation 2014
Stock Option and Incentive Plan as amended through the date hereof (the &#147;Plan&#148;), Inotek Pharmaceuticals Corporation (the &#147;Company&#148;) hereby grants to the Optionee named above an option (the &#147;Stock Option&#148;) to purchase on
or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value $0.01 per share (the &#147;Stock&#148;) of the Company specified above at the Option Exercise Price per Share specified above subject to
the terms and conditions set forth herein and in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Exercisability Schedule</U>. No portion of this Stock Option may be
exercised until such portion shall have become exercisable. Except as set forth below, and subject to the discretion of the Administrator (as defined in Section&nbsp;2 of the Plan) to accelerate the exercisability schedule hereunder, this Stock
Option shall be exercisable with respect to the following number of Option Shares on the dates indicated so long as Optionee remains an employee of the Company or a Subsidiary on such dates: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Incremental&nbsp;Number&nbsp;of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:84.75pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Option&nbsp;Shares&nbsp;Exercisable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:61.40pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exercisability&nbsp;Date</P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;
(<U>&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(<U>&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(<U>&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(<U>&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(<U>&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the close
of business on the Expiration Date, subject to the provisions hereof and of the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U><B></B>Manner of Exercise<B>.</B></U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this
Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be
purchased. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment of the purchase price for the Option Shares may be made by one or more of the following methods: (i)&nbsp;in cash, by
certified or bank check or other instrument acceptable to the Administrator; (ii)&nbsp;through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially
owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii)&nbsp;by the Optionee delivering to the Company a properly
executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that in the event the Optionee chooses to
pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment
procedure; or (iv)&nbsp;a combination of (i), (ii)&nbsp;and (iii)&nbsp;above. Payment instruments will be received subject to collection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i)&nbsp;the
Company&#146;s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii)&nbsp;the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws, and
(iii)&nbsp;the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent
resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock
transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The shares of Stock
purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or
regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder
of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have
transferred the shares to the Optionee, and the Optionee&#146;s name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect
to such shares of Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) The minimum number of shares with respect to which this Stock Option may be exercised at any
one time shall be [100] shares, unless the number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date
hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination of Employment</U>. If the Optionee&#146;s employment by the Company or a Subsidiary (as defined in the Plan) is
terminated, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)
<U>Termination Due to Death</U>. If the Optionee&#146;s employment terminates by reason of the Optionee&#146;s death, any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of death, may thereafter be
exercised by the Optionee&#146;s legal representative or legatee for a period of 12 months from the date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of death shall terminate
immediately and be of no further force or effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination Due to Disability</U>. If the Optionee&#146;s employment terminates
by reason of the Optionee&#146;s disability (as determined by the Administrator), any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of such disability, may thereafter be exercised by the Optionee for a
period of 12 months from the date of disability or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of disability shall terminate immediately and be of no further force or effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Termination for Cause</U>. If the Optionee&#146;s employment terminates for Cause, any portion of this Stock Option outstanding on such
date shall terminate immediately and be of no further force and effect. For purposes hereof, &#147;Cause&#148; shall mean, unless otherwise provided in an employment agreement between the Company and the Optionee, a determination by the
Administrator that the Optionee shall be dismissed as a result of (i)&nbsp;any material breach by the Optionee of any agreement between the Optionee and the Company; (ii)&nbsp;the conviction of, indictment for or plea of nolo contendere by the
Optionee to a felony or a crime involving moral turpitude; or (iii)&nbsp;any material misconduct or willful and deliberate non-performance (other than by reason of disability) by the Optionee of the Optionee&#146;s duties to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U>Other Termination</U>. If the Optionee&#146;s employment terminates for any reason other than the Optionee&#146;s death, the
Optionee&#146;s disability or Cause, and unless otherwise determined by the Administrator, any portion of this Stock Option outstanding on such date may be exercised, to the extent exercisable on the date of termination, for a period of three months
from the date of termination or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of termination shall terminate immediately and be of no further force or effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator&#146;s determination of the reason for termination of the Optionee&#146;s employment shall be conclusive and binding on the
Optionee and his or her representatives or legatees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Incorporation of Plan</U>. Notwithstanding anything herein to the contrary, this Stock
Option shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section&nbsp;2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the
Plan, unless a different meaning is specified herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Transferability</U>. This Agreement is personal to the Optionee, is
non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee&#146;s lifetime, only by the Optionee, and
thereafter, only by the Optionee&#146;s legal representative or legatee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Status of the Stock Option</U>. This Stock Option is
intended to qualify as an &#147;incentive stock option&#148; under Section&nbsp;422 of the Internal Revenue Code of 1986, as amended, (the &#147;Code&#148;), but the Company does not represent or warrant that this Stock Option qualifies as such. The
Optionee should consult with his or her own tax advisors regarding the tax effects of this Stock Option and the requirements necessary to obtain favorable income tax treatment under Section&nbsp;422 of the Code, including, but not limited to,
holding period requirements. To the extent any portion of this Stock Option does not so qualify as an &#147;incentive stock option,&#148; such portion shall be deemed to be a non-qualified stock option. If the Optionee intends to dispose or does
dispose (whether by sale, gift, transfer or otherwise) of any Option Shares within the one-year period beginning on the date after the transfer of such shares to him or her, or within the two-year period beginning on the day after the grant of this
Stock Option, he or she will so notify the Company within 30 days after such disposition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Tax Withholding</U>. The Optionee shall,
not later than the date as of which the exercise of this Stock Option becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local
taxes required by law to be withheld on account of such taxable event. The Company shall have the authority to cause the minimum required tax withholding obligation to be satisfied, in whole or in part, by withholding from shares of Stock to be
issued to the Optionee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the minimum withholding amount due. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>No Obligation to Continue Employment</U>. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this
Agreement to continue the Optionee in employment and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the employment of the Optionee at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Integration</U>. This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes
all prior agreements and discussions between the parties concerning such subject matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Data Privacy Consent</U>. In order to
administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#147;Relevant Companies&#148;) may process any and all personal or
professional data, including but not limited to Social Security or other identification number, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the &#147;Relevant
Information&#148;). By entering into this Agreement, the Grantee (i)&nbsp;authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii)&nbsp;waives any privacy rights the Grantee may have
with respect to the Relevant Information; (iii)&nbsp;authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv)&nbsp;authorizes the transfer of the Relevant Information to any jurisdiction in which the
Relevant Companies consider appropriate. The Grantee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Notices</U>. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or
delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="51%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INOTEK PHARAMCEUTICALS</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>CORPORATION</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company&#146;s instructions to the Grantee (including through an online acceptance process) is acceptable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="56%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Optionee&#146;s Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Optionee&#146;s name and address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NON-QUALIFIED STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR COMPANY EMPLOYEES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER INOTEK PHARMACEUTICALS CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2014 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Optionee:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No. of Option Shares:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Option&nbsp;Exercise&nbsp;Price&nbsp;per&nbsp;Share:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>[FMV on Grant Date]</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Grant Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Expiration Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Inotek Pharmaceuticals Corporation 2014 Stock Option and Incentive Plan as amended through the
date hereof (the &#147;Plan&#148;), Inotek Pharmaceuticals Corporation (the &#147;Company&#148;) hereby grants to the Optionee named above an option (the &#147;Stock Option&#148;) to purchase on or prior to the Expiration Date specified above all or
part of the number of shares of Common Stock, par value $0.01 per share (the &#147;Stock&#148;) of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the
Plan. This Stock Option is not intended to be an &#147;incentive stock option&#148; under Section&nbsp;422 of the Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Exercisability Schedule</U>. No portion of this Stock Option may be exercised until such portion shall have become exercisable. Except
as set forth below, and subject to the discretion of the Administrator (as defined in Section&nbsp;2 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable with respect to the following number of
Option Shares on the dates indicated so long as Optionee remains an employee of the Company or a Subsidiary on such dates: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Incremental Number of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:84.75pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Option&nbsp;Shares&nbsp;Exercisable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:61.40pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exercisability&nbsp;Date</P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;
(<U>&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(<U>&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(<U>&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(<U>&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(<U>&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the close
of business on the Expiration Date, subject to the provisions hereof and of the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Manner of Exercise</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this
Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be
purchased. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment of the purchase price for the Option Shares may be made by one or more of the following methods: (i)&nbsp;in cash, by
certified or bank check or other instrument acceptable to the Administrator; (ii)&nbsp;through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially
owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii)&nbsp;by the Optionee delivering to the Company a properly
executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that in the event the Optionee chooses to
pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment
procedure; (iv)&nbsp;by a &#147;net exercise&#148; arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the
aggregate exercise price; or (v)&nbsp;a combination of (i), (ii), (iii)&nbsp;and (iv)&nbsp;above. Payment instruments will be received subject to collection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i)&nbsp;the
Company&#146;s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii)&nbsp;the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws, and
(iii)&nbsp;the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent
resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock
transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The shares of Stock
purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or
regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder
of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have
transferred the shares to the Optionee, and the Optionee&#146;s name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect
to such shares of Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) The minimum number of shares with respect to which this Stock Option may be exercised at any
one time shall be [100] shares, unless the number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date
hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination of Employment</U>. If the Optionee&#146;s employment by the Company or a Subsidiary (as defined in the Plan) is
terminated, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)
<U>Termination Due to Death</U>. If the Optionee&#146;s employment terminates by reason of the Optionee&#146;s death, any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of death, may thereafter be
exercised by the Optionee&#146;s legal representative or legatee for a period of 12 months from the date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of death shall terminate
immediately and be of no further force or effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination Due to Disability</U>. If the Optionee&#146;s employment terminates
by reason of the Optionee&#146;s disability (as determined by the Administrator), any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of such disability, may thereafter be exercised by the Optionee for a
period of 12 months from the date of disability or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of disability shall terminate immediately and be of no further force or effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Termination for Cause</U>. If the Optionee&#146;s employment terminates for Cause, any portion of this Stock Option outstanding on such
date shall terminate immediately and be of no further force and effect. For purposes hereof, &#147;Cause&#148; shall mean, unless otherwise provided in an employment agreement between the Company and the Optionee, a determination by the
Administrator that the Optionee shall be dismissed as a result of (i)&nbsp;any material breach by the Optionee of any agreement between the Optionee and the Company; (ii)&nbsp;the conviction of, indictment for or plea of nolo contendere by the
Optionee to a felony or a crime involving moral turpitude; or (iii)&nbsp;any material misconduct or willful and deliberate non-performance (other than by reason of disability) by the Optionee of the Optionee&#146;s duties to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U>Other Termination</U>. If the Optionee&#146;s employment terminates for any reason other than the Optionee&#146;s death, the
Optionee&#146;s disability or Cause, and unless otherwise determined by the Administrator, any portion of this Stock Option outstanding on such date may be exercised, to the extent exercisable on the date of termination, for a period of three months
from the date of termination or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of termination shall terminate immediately and be of no further force or effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator&#146;s determination of the reason for termination of the Optionee&#146;s
employment shall be conclusive and binding on the Optionee and his or her representatives or legatees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Incorporation of Plan</U>.
Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section&nbsp;2(b) of the Plan. Capitalized terms
in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.
<U>Transferability</U>. This Agreement is personal to the Optionee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is
exercisable, during the Optionee&#146;s lifetime, only by the Optionee, and thereafter, only by the Optionee&#146;s legal representative or legatee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Tax Withholding</U>. The Optionee shall, not later than the date as of which the exercise of this Stock Option becomes a taxable event
for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event. The Company shall have the
authority to cause the minimum required tax withholding obligation to be satisfied, in whole or in part, by withholding from shares of Stock to be issued to the Optionee a number of shares of Stock with an aggregate Fair Market Value that would
satisfy the minimum withholding amount due. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>No Obligation to Continue Employment</U>. Neither the Company nor any Subsidiary is
obligated by or as a result of the Plan or this Agreement to continue the Optionee in employment and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the employment of the
Optionee at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Integration</U>. This Agreement constitutes the entire agreement between the parties with respect to this
Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Data Privacy
Consent</U>. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#147;Relevant Companies&#148;) may process
any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of
the Plan and/or this Agreement (the &#147;Relevant Information&#148;). By entering into this Agreement, the Grantee (i)&nbsp;authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information;
(ii)&nbsp;waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii)&nbsp;authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv)&nbsp;authorizes the transfer of the
Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable
law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Notices</U>. Notices hereunder shall be mailed or delivered to the Company at its
principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>INOTEK PHARAMCEUTICALS<BR>CORPORATION</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company&#146;s instructions to the Grantee (including through an online acceptance process) is acceptable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Optionee&#146;s Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Optionee&#146;s name and address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NON-QUALIFIED STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR NON-EMPLOYEE CONSULTANTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE INOTEK PHARMACEUTICALS CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2014 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name&nbsp;of&nbsp;Optionee:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No.&nbsp;of&nbsp;Option&nbsp;Shares:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Option Exercise Price per Share:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[<B>FMV on Grant Date</B>]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Grant Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Expiration Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">[<B>No more than 10 years</B>]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Inotek Pharmaceuticals Corporation 2014 Stock Option and Incentive Plan as amended through the
date hereof (the &#147;Plan&#148;), Inotek Pharmaceuticals Corporation (the &#147;Company&#148;) hereby grants to the Optionee named above, who is a Consultant of the Company, an option (the &#147;Stock Option&#148;) to purchase on or prior to the
Expiration Date specified above all or part of the number of shares of Common Stock, par value $0.01 per share (the &#147;Stock&#148;), of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and
conditions set forth herein and in the Plan. This Stock Option is not intended to be an &#147;incentive stock option&#148; under Section&nbsp;422 of the Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Exercisability Schedule</U>. No portion of this Stock Option may be exercised until such portion shall have become exercisable. Except
as set forth below, and subject to the discretion of the Administrator (as defined in the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable with respect to the following number of Option Shares on the
dates indicated so long as the Optionee remains in service to the Company or a Subsidiary as a Consultant on such dates: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Incremental Number of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:84.75pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Option Shares Exercisable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:61.40pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exercisability&nbsp;Date</P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior
to the close of business on the Expiration Date, subject to the provisions hereof and of the Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Manner of Exercise.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this
Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be
purchased. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment of the purchase price for the Option Shares may be made by one or more of the following methods: (i)&nbsp;in cash, by
certified or bank check or other instrument acceptable to the Administrator; (ii)&nbsp;through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially
owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii)&nbsp;by the Optionee delivering to the Company a properly
executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that in the event the Optionee chooses to
pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment
procedure; (iv)&nbsp;by a &#147;net exercise&#148; arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the
aggregate exercise price; or (v)&nbsp;a combination of (i), (ii), (iii)&nbsp;and (iv)&nbsp;above. Payment instruments will be received subject to collection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i)&nbsp;the
Company&#146;s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii)&nbsp;the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws, and
(iii)&nbsp;the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent
resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock
transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The shares of Stock
purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or
regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder
of, or to have any of the rights of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer
agent shall have transferred the shares to the Optionee, and the Optionee&#146;s name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership
rights with respect to such shares of Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) The minimum number of shares with respect to which this Stock Option may be exercised at
any one time shall be 100 shares, unless the number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date
hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination as Consultant</U>. If the Optionee ceases to be a Consultant to the Company or a Subsidiary for any reason, any
portion of this Stock Option outstanding on such date may be exercised, to the extent exercisable on the date the Optionee ceased to provide services, for a period of three months from the date the Optionee ceased to provide services or until the
Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date the Optionee ceases to be a Consultant to the Company or a Subsidiary shall terminate immediately and be of no further force or effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Incorporation of Plan</U>. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all
the terms and conditions of the Plan, including the powers of the Administrator set forth in Section&nbsp;2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified
herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Transferability</U>. This Agreement is personal to the Optionee, is non-assignable and is not transferable in any manner,
by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee&#146;s lifetime, only by the Optionee, and thereafter, only by the Optionee&#146;s legal
representative or legatee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>No Obligation to Continue as a Consultant or Service Provider</U>. Neither the Plan nor this Stock
Option confers upon the Optionee any rights with respect to continuance as a Consultant or other service provider to the Company or a Subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Integration</U>. This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes
all prior agreements and discussions between the parties concerning such subject matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Data Privacy Consent</U>. In order to
administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#147;Relevant Companies&#148;) may process any and all personal or
professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this
Agreement (the &#147;Relevant Information&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
By entering into this Agreement, the Optionee (i)&nbsp;authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii)&nbsp;waives any
privacy rights the Optionee may have with respect to the Relevant Information; (iii)&nbsp;authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv)&nbsp;authorizes the transfer of the Relevant Information
to any jurisdiction in which the Relevant Companies consider appropriate. The Optionee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Notices</U>. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or
delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INOTEK PHARMACEUTICALS</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">CORPORATION</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company&#146;s instructions to the Optionee (including through an online acceptance process) is acceptable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Optionee&#146;s Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Optionee&#146;s name and address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NON-QUALIFIED STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR NON-EMPLOYEE DIRECTORS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER INOTEK PHARMACEUTICALS CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2014 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Optionee:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No. of Option Shares:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Option Exercise Price per Share:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>[FMV on Grant Date]</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Grant Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Expiration Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>[No more than 10 years]</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Inotek Pharmaceuticals Corporation 2014 Stock Option and Incentive Plan as amended through the
date hereof (the &#147;Plan&#148;), Inotek Pharmaceuticals Corporation (the &#147;Company&#148;) hereby grants to the Optionee named above, who is a Director of the Company but is not an employee of the Company, an option (the &#147;Stock
Option&#148;) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value $0.01 per share (the &#147;Stock&#148;), of the Company specified above at the Option Exercise Price per
Share specified above subject to the terms and conditions set forth herein and in the Plan. This Stock Option is not intended to be an &#147;incentive stock option&#148; under Section&nbsp;422 of the Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Exercisability Schedule</U>. No portion of this Stock Option may be exercised until such portion shall have become exercisable. Except
as set forth below, and subject to the discretion of the Administrator (as defined in the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable with respect to the following number of Option Shares on the
dates indicated so long as the Optionee remains in service as a member of the Board on such dates: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Incremental Number of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:84.75pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Option Shares Exercisable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:61.40pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exercisability Date</P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior
to the close of business on the Expiration Date, subject to the provisions hereof and of the Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Manner of Exercise</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this
Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be
purchased. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment of the purchase price for the Option Shares may be made by one or more of the following methods: (i)&nbsp;in cash, by
certified or bank check or other instrument acceptable to the Administrator; (ii)&nbsp;through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially
owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii)&nbsp;by the Optionee delivering to the Company a properly
executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that in the event the Optionee chooses to
pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment
procedure; (iv)&nbsp;by a &#147;net exercise&#148; arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the
aggregate exercise price; or (v)&nbsp;a combination of (i), (ii), (iii)&nbsp;and (iv)&nbsp;above. Payment instruments will be received subject to collection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i)&nbsp;the
Company&#146;s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii)&nbsp;the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws, and
(iii)&nbsp;the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent
resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock
transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The shares of Stock
purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or
regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder
of, or to have any of the rights of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer
agent shall have transferred the shares to the Optionee, and the Optionee&#146;s name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership
rights with respect to such shares of Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) The minimum number of shares with respect to which this Stock Option may be exercised at
any one time shall be 100 shares, unless the number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date
hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination as Director</U>. If the Optionee ceases to be a Director of the Company, the period within which to exercise
the Stock Option may be subject to earlier termination as set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Termination Due to Death</U>. If the Optionee&#146;s
service as a Director terminates by reason of the Optionee&#146;s death, any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of death, may thereafter be exercised by the Optionee&#146;s legal
representative or legatee for a period of 12 months from the date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of death shall terminate immediately and be of no further force
or effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Other Termination</U>. If the Optionee ceases to be a Director for any reason other than the Optionee&#146;s death, any
portion of this Stock Option outstanding on such date may be exercised, to the extent exercisable on the date the Optionee ceased to be a Director, for a period of six months from the date the Optionee ceased to be a Director or until the Expiration
Date, if earlier. Any portion of this Stock Option that is not exercisable on the date the Optionee ceases to be a Director shall terminate immediately and be of no further force or effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Incorporation of Plan</U>. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all
the terms and conditions of the Plan, including the powers of the Administrator set forth in Section&nbsp;2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified
herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Transferability</U>. This Agreement is personal to the Optionee, is non-assignable and is not transferable in any manner,
by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee&#146;s lifetime, only by the Optionee, and thereafter, only by the Optionee&#146;s legal
representative or legatee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>No Obligation to Continue as a Director</U>. Neither the Plan nor this Stock Option confers upon the
Optionee any rights with respect to continuance as a Director. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Integration</U>. This Agreement constitutes the entire agreement between the parties with
respect to this Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.
<U>Data Privacy Consent</U>. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#147;Relevant
Companies&#148;) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or
desirable for the administration of the Plan and/or this Agreement (the &#147;Relevant Information&#148;). By entering into this Agreement, the Grantee (i)&nbsp;authorizes the Company to collect, process, register and transfer to the Relevant
Companies all Relevant Information; (ii)&nbsp;waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii)&nbsp;authorizes the Relevant Companies to store and transmit such information in electronic form; and
(iv)&nbsp;authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have access to, and the right to change, the Relevant Information. Relevant Information will
only be used in accordance with applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Notices</U>. Notices hereunder shall be mailed or delivered to the Company at its
principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOTEK PHARMACEUTICALS</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">CORPORATION</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company&#146;s instructions to the Grantee (including through an online acceptance process) is acceptable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Optionee&#146;s Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Optionee&#146;s name and address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTRICTED STOCK AWARD AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE INOTEK PHARMACEUTICALS CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2014 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name&nbsp;of&nbsp;Grantee:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No.&nbsp;of&nbsp;Shares:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant&nbsp;Date:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Inotek Pharmaceuticals Corporation 2014 Stock Option and Incentive Plan (the &#147;Plan&#148;)
as amended through the date hereof, Inotek Pharmaceuticals Corporation (the &#147;Company&#148;) hereby grants a Restricted Stock Award (an &#147;Award&#148;) to the Grantee named above. Upon acceptance of this Award, the Grantee shall receive the
number of shares of Common Stock, par value $0.01 per share (the &#147;Stock&#148;) of the Company specified above, subject to the restrictions and conditions set forth herein and in the Plan. The Company acknowledges the receipt from the Grantee of
consideration with respect to the par value of the Stock in the form of cash, past or future services rendered to the Company by the Grantee or such other form of consideration as is acceptable to the Administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Award</U>. The shares of Restricted Stock awarded hereunder shall be issued and held by the Company&#146;s transfer agent in book entry
form, and the Grantee&#146;s name shall be entered as the stockholder of record on the books of the Company. Thereupon, the Grantee shall have all the rights of a stockholder with respect to such shares, including voting and dividend rights,
subject, however, to the restrictions and conditions specified in Paragraph&nbsp;2 below. The Grantee shall (i)&nbsp;sign and deliver to the Company a copy of this Award Agreement and (ii)&nbsp;deliver to the Company a stock power endorsed in blank.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Restrictions and Conditions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Any book entries for the shares of Restricted Stock granted herein shall bear an appropriate legend, as determined by the Administrator in
its sole discretion, to the effect that such shares are subject to restrictions as set forth herein and in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Shares of
Restricted Stock granted herein may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of by the Grantee prior to vesting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) If the Grantee&#146;s employment with the Company and its Subsidiaries is voluntarily or involuntarily terminated for any reason
(including death) prior to vesting of shares of Restricted Stock granted herein, all shares of Restricted Stock shall immediately and automatically be forfeited and returned to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Vesting of Restricted Stock</U>. The restrictions and conditions in Paragraph&nbsp;2 of this Agreement shall lapse on the Vesting Date
or Dates specified in the following schedule so long as the Grantee remains an employee of the Company or a Subsidiary on such Dates. If a series of Vesting Dates is specified, then the restrictions and conditions in Paragraph&nbsp;2 shall lapse
only with respect to the number of shares of Restricted Stock specified as vested on such date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Incremental Number</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:66.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">of Shares Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:41.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Vesting&nbsp;Date</P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> (<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> (<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> (<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> (<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> (<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequent to such Vesting Date or Dates, the shares of Stock on which all restrictions and conditions have
lapsed shall no longer be deemed Restricted Stock. The Administrator may at any time accelerate the vesting schedule specified in this Paragraph&nbsp;3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Dividends</U>. Dividends on shares of Restricted Stock shall be paid currently to the Grantee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Incorporation of Plan</U>. Notwithstanding anything herein to the contrary, this Award shall be subject to and governed by all the terms
and conditions of the Plan, including the powers of the Administrator set forth in Section&nbsp;2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Transferability</U>. This Agreement is personal to the Grantee, is non-assignable and is not transferable in any manner, by operation of
law or otherwise, other than by will or the laws of descent and distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Tax Withholding</U>. The Grantee shall, not later
than the date as of which the receipt of this Award becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law
to be withheld on account of such taxable event. Except in the case where an election is made pursuant to Paragraph 8 below, the Company shall have the authority to cause the required minimum tax withholding obligation to be satisfied, in whole or
in part, by withholding from shares of Stock to be issued or released by the transfer agent a number of shares of Stock with an aggregate Fair Market Value that would satisfy the minimum withholding amount due. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Election Under Section&nbsp;83(b)</U>. The Grantee and the Company hereby agree that the Grantee may, within 30 days following the Grant
Date of this Award, file with the Internal Revenue Service and the Company an election under Section&nbsp;83(b) of the Internal Revenue Code. In the event the Grantee makes such an election, he or she agrees to provide a copy of the election to the
Company. The Grantee acknowledges that he or she is responsible for obtaining the advice of his or her tax advisors with regard to the Section&nbsp;83(b) election and that he or she is relying solely on such advisors and not on any statements or
representations of the Company or any of its agents with regard to such election. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>No Obligation to Continue Employment</U>. Neither the Company nor any Subsidiary is
obligated by or as a result of the Plan or this Agreement to continue the Grantee in employment and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the employment of the
Grantee at any time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Integration</U>. This Agreement constitutes the entire agreement between the parties with respect to this
Award and supersedes all prior agreements and discussions between the parties concerning such subject matter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Data Privacy
Consent</U>. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#147;Relevant Companies&#148;) may process
any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of
the Plan and/or this Agreement (the &#147;Relevant Information&#148;). By entering into this Agreement, the Grantee (i)&nbsp;authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information;
(ii)&nbsp;waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii)&nbsp;authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv)&nbsp;authorizes the transfer of the
Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable
law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Notices</U>. Notices hereunder shall be mailed or delivered to the Company at its
principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">INOTEK PHARMACEUTICALS CORPORATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company&#146;s instructions to the Grantee (including through an online acceptance process) is acceptable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Grantee&#146;s Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Grantee&#146;s name and address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTRICTED STOCK UNIT AWARD AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR COMPANY EMPLOYEES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE INOTEK PHARMACEUTICALS CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2014 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name of Grantee:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No. of Restricted Stock Units:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant Date:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Inotek Pharmaceuticals Corporation 2014 Stock Option and Incentive Plan as amended through the
date hereof (the &#147;Plan&#148;), Inotek Pharmaceuticals Corporation (the &#147;Company&#148;) hereby grants an award of the number of Restricted Stock Units listed above (an &#147;Award&#148;) to the Grantee named above. Each Restricted Stock
Unit shall relate to one share of Common Stock, par value $0.01 per share (the &#147;Stock&#148;) of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Restrictions on
Transfer of Award</U>. This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or
otherwise encumbered or disposed of until (i)&nbsp;the Restricted Stock Units have vested as provided in Paragraph 2 of this Agreement and (ii)&nbsp;shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Vesting of Restricted Stock Units</U>. The restrictions and conditions of Paragraph&nbsp;1 of this Agreement shall lapse
on the Vesting Date or Dates specified in the following schedule so long as the Grantee remains an employee of the Company or a Subsidiary on such Dates. If a series of Vesting Dates is specified, then the restrictions and conditions in
Paragraph&nbsp;1 shall lapse only with respect to the number of Restricted Stock Units specified as vested on such date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:96.05pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Incremental Number of<BR>Restricted Stock Units Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:41.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Vesting&nbsp;Date</P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination of Employment</U>. If the Grantee&#146;s employment with the Company and its Subsidiaries terminates for any reason
(including death or disability) prior to the satisfaction of the vesting conditions set forth in Paragraph 2 above, any Restricted Stock Units that have not vested as of such date shall automatically and without notice terminate and be forfeited,
and neither the Grantee nor any of his or her successors, heirs, assigns, or personal representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Issuance of Shares of Stock</U>. As soon as practicable following each Vesting Date (but in
no event later than two and one-half months after the end of the year in which the Vesting Date occurs), the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate number of Restricted Stock Units that have vested
pursuant to Paragraph 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Incorporation of Plan</U>. Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the
terms and conditions of the Plan, including the powers of the Administrator set forth in Section&nbsp;2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Tax Withholding</U>. The Grantee shall, not later than the date as of which the receipt of this Award becomes a taxable event for
Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event. The Company shall have the
authority to cause the required minimum tax withholding obligation to be satisfied, in whole or in part, by withholding from shares of Stock to be issued to the Grantee a number of shares of Stock with an aggregate Fair Market Value that would
satisfy the withholding amount due. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Section&nbsp;409A of the Code.</U> This Agreement shall be interpreted in such a manner that
all provisions relating to the settlement of the Award are exempt from the requirements of Section&nbsp;409A of the Code as &#147;short-term deferrals&#148; as described in Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>No Obligation to Continue Employment</U>. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this
Agreement to continue the Grantee in employment and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the employment of the Grantee at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Integration</U>. This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior
agreements and discussions between the parties concerning such subject matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Data Privacy Consent</U>. In order to administer
the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#147;Relevant Companies&#148;) may process any and all personal or professional
data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the
&#147;Relevant Information&#148;). By entering into this Agreement, the Grantee (i)&nbsp;authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii)&nbsp;waives any privacy rights the
Grantee may have with respect to the Relevant Information; (iii)&nbsp;authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv)</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have access to, and the right to change, the
Relevant Information. Relevant Information will only be used in accordance with applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Notices</U>. Notices hereunder
shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to
the other party in writing. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOTEK PHARMACEUTICALS</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">CORPORATION</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company&#146;s instructions to the Grantee (including through an online acceptance process) is acceptable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Grantee&#146;s Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Grantee&#146;s name and address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTRICTED STOCK UNIT AWARD AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR NON-EMPLOYEE DIRECTORS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER INOTEK PHARMACEUTICALS CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2014 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name of Grantee:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No. of Restricted Stock Units:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant Date:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Inotek Pharmaceuticals Corporation 2014 Stock Option and Incentive Plan as amended through the
date hereof (the &#147;Plan&#148;), Inotek Pharmaceuticals Corporation (the &#147;Company&#148;) hereby grants an award of the number of Restricted Stock Units listed above (an &#147;Award&#148;) to the Grantee named above. Each Restricted Stock
Unit shall relate to one share of Common Stock, par value $0.01 per share (the &#147;Stock&#148;) of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Restrictions on
Transfer of Award</U>. This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or
otherwise encumbered or disposed of until (i)&nbsp;the Restricted Stock Units have vested as provided in Paragraph 2 of this Agreement and (ii)&nbsp;shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Vesting of Restricted Stock Units</U>. The restrictions and conditions of Paragraph&nbsp;1 of this Agreement shall lapse
on the Vesting Date or Dates specified in the following schedule so long as the Grantee remains in service as a member of the Board on such Dates. If a series of Vesting Dates is specified, then the restrictions and conditions in Paragraph&nbsp;1
shall lapse only with respect to the number of Restricted Stock Units specified as vested on such date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Incremental Number of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:96.05pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Restricted&nbsp;Stock&nbsp;Units&nbsp;Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:41.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Vesting&nbsp;Date</P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;
(<U>&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(<U>&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(<U>&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(<U>&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(<U>&nbsp;&nbsp;&nbsp;&nbsp;</U>%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination of Service</U>. If the Grantee&#146;s service with the Company and its Subsidiaries terminates for any reason (including
death or disability) prior to the satisfaction of the vesting conditions set forth in Paragraph 2 above, any Restricted Stock Units that have not vested as of such date shall automatically and without notice terminate and be forfeited, and neither
the Grantee nor any of his or her successors, heirs, assigns, or personal representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Issuance of Shares of Stock</U>. As soon as practicable following each Vesting Date (but in
no event later than two and one-half months after the end of the year in which the Vesting Date occurs), the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate number of Restricted Stock Units that have vested
pursuant to Paragraph 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Incorporation of Plan</U>. Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the
terms and conditions of the Plan, including the powers of the Administrator set forth in Section&nbsp;2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Section&nbsp;409A of the Code.</U> This Agreement shall be interpreted in such a manner that all provisions relating to the
settlement of the Award are exempt from the requirements of Section&nbsp;409A of the Code as &#147;short-term deferrals&#148; as described in Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>No Obligation to Continue as a Director</U>. Neither the Plan nor this Award confers upon the Grantee any rights with respect to
continuance as a Director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Integration</U>. This Agreement constitutes the entire agreement between the parties with respect to
this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Data Privacy
Consent</U>. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#147;Relevant Companies&#148;) may process
any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of
the Plan and/or this Agreement (the &#147;Relevant Information&#148;). By entering into this Agreement, the Grantee (i)&nbsp;authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information;
(ii)&nbsp;waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii)&nbsp;authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv)&nbsp;authorizes the transfer of the
Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable
law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Notices</U>. Notices hereunder shall be mailed or delivered to the Company at its
principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>INOTEK PHARMACEUTICALS<BR>CORPORATION</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company&#146;s instructions to the Grantee (including through an online acceptance process) is acceptable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Grantee&#146;s Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Grantee&#146;s name and address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>6
<FILENAME>d893535dex107.htm
<DESCRIPTION>EX-10.7
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.7</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>E<SMALL>XHIBIT</SMALL> 10.7 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INOTEK PHARMACEUTICALS CORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2014 EMPLOYEE STOCK PURCHASE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the Inotek Pharmaceuticals Corporation 2014 Employee Stock Purchase Plan (&#147;the Plan&#148;) is to provide eligible
employees of Inotek Pharmaceuticals Corporation (the &#147;Company&#148;) and each Designated Subsidiary (as defined in Section&nbsp;11) with opportunities to purchase shares of the Company&#146;s common stock, par value $0.01 per share (the
&#147;Common Stock&#148;). The maximum number of shares of Common Stock approved, reserved and available for issuance under the Plan shall be 160,277 shares of Common Stock, plus on January&nbsp;1, 2016 and each January&nbsp;1 thereafter, the number
of shares of Common Stock approved, reserved and available for issuance under the Plan shall be cumulatively increased by the lesser of (i)&nbsp;600,000 shares of Common Stock or (ii)&nbsp;such number of shares as is necessary to set the number of
unissued shares of Common Stock under the Plan at 1% of the Corporation&#146;s outstanding Common Stock as of January&nbsp;1 of the applicable year. Notwithstanding the foregoing, the Company&#146;s Board of Directors (the &#147;Board&#148;) may act
prior to the first day of any fiscal year to provide that there will be no January&nbsp;1 increase in the share reserve for such fiscal year or that the increase in the share reserve for such fiscal year will be a lesser number of shares of Common
Stock than would otherwise occur pursuant to the preceding sentence. The Plan is intended to constitute an &#147;employee stock purchase plan&#148; within the meaning of Section&nbsp;423(b) of the Internal Revenue Code of 1986, as amended (the
&#147;Code&#148;), and shall be interpreted in accordance with that intent. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Administration</U>. The Plan will be administered by the person or persons (the
&#147;Administrator&#148;) appointed by the Board for such purpose. The Administrator has authority at any time to: (i)&nbsp;adopt, alter and repeal such rules, guidelines and practices for the administration of the Plan and for its own acts and
proceedings as it shall deem advisable; (ii)&nbsp;interpret the terms and provisions of the Plan; (iii)&nbsp;make all determinations it deems advisable for the administration of the Plan; (iv)&nbsp;decide all disputes arising in connection with the
Plan; and (v)&nbsp;otherwise supervise the administration of the Plan. All interpretations and decisions of the Administrator shall be binding on all persons, including the Company and the Participants. No member of the Board or individual
exercising administrative authority with respect to the Plan shall be liable for any action or determination made in good faith with respect to the Plan or any option granted hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Offerings</U>. The Company will make one or more offerings to eligible employees to purchase Common Stock under the Plan
(&#147;Offerings&#148;). Unless otherwise determined by the Administrator, the initial Offering will begin on January&nbsp;1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>&nbsp;of the year designated by the Administrator and will end on the
following June&nbsp;30<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>&nbsp;(the &#147;Initial Offering&#148;). Thereafter, unless otherwise determined by the Administrator, an Offering will begin on the first business day occurring on or
after each January&nbsp;1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> and July&nbsp;1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> and will end on the last business day occurring on or before the following June&nbsp;30<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> and December&nbsp;31<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>, respectively. The Administrator may, in its discretion, designate a different period for any Offering, provided that no
Offering shall exceed one year in duration or overlap any other Offering. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Eligibility</U>. All individuals classified as employees
on the payroll records of the Company and each Designated Subsidiary are eligible to participate in any one or more of the Offerings under the Plan, provided that as of the first day of the applicable Offering (the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;Offering Date&#148;) they are customarily employed by the Company or a Designated Subsidiary for more than 20 hours a week and have completed at least six months of employment.
Notwithstanding any other provision herein, individuals who are not contemporaneously classified as employees of the Company or a Designated Subsidiary for purposes of the Company&#146;s or applicable Designated Subsidiary&#146;s payroll system are
not considered to be eligible employees of the Company or any Designated Subsidiary and shall not be eligible to participate in the Plan. In the event any such individuals are reclassified as employees of the Company or a Designated Subsidiary for
any purpose, including, without limitation, common law or statutory employees, by any action of any third party, including, without limitation, any government agency, or as a result of any private lawsuit, action or administrative proceeding, such
individuals shall, notwithstanding such reclassification, remain ineligible for participation. Notwithstanding the foregoing, the exclusive means for individuals who are not contemporaneously classified as employees of the Company or a Designated
Subsidiary on the Company&#146;s or Designated Subsidiary&#146;s payroll system to become eligible to participate in this Plan is through an amendment to this Plan, duly executed by the Company, which specifically renders such individuals eligible
to participate herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Participation</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Participants in Offerings</U>. An eligible employee who is not a Participant on any Offering Date may participate in such Offering by
submitting an enrollment form to his or her appropriate payroll location at least 15 business days before the Offering Date (or by such other deadline as shall be established by the Administrator for the Offering). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Enrollment</U>. The enrollment form will (a)&nbsp;state a whole percentage to be deducted
from an eligible employee&#146;s Compensation (as defined in Section&nbsp;11) per pay period, (b)&nbsp;authorize the purchase of Common Stock in each Offering in accordance with the terms of the Plan and (c)&nbsp;specify the exact name or names in
which shares of Common Stock purchased for such individual are to be issued pursuant to Section&nbsp;10. An employee who does not enroll in accordance with these procedures will be deemed to have waived the right to participate. Unless a Participant
files a new enrollment form or withdraws from the Plan, such Participant&#146;s deductions and purchases will continue at the same percentage of Compensation for future Offerings, provided he or she remains eligible. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding the foregoing, participation in the Plan will neither be permitted nor be denied contrary to the requirements of the Code.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Employee Contributions</U>. Each eligible employee may authorize payroll deductions at a minimum of one percent up to a maximum of
10&nbsp;percent of such employee&#146;s Compensation for each pay period. The Company will maintain book accounts showing the amount of payroll deductions made by each Participant for each Offering. No interest will accrue or be paid on payroll
deductions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Deduction Changes</U>. Except as may be determined by the Administrator in advance of an Offering, a Participant may
elect to increase his or her payroll deduction (subject to the limitations in Section&nbsp;5) not more than twice during an Offering and may elect to decrease his or her payroll deduction (subject to the limitations in Section&nbsp;5) as many times
as desired during an Offering, in each case by filing a new enrollment form at least 15 business days before the next payroll period for which such election is to be effective (or by such other deadline as shall be established by the Administrator).
A Participant may also increase or decrease his or her payroll deduction with respect to the next Offering (subject to the limitations of Section&nbsp;5) by filing a new enrollment form at least 15 business days before the next Offering Date (or by
such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other deadline as shall be established by the Administrator for the Offering). The Administrator may, in advance of any Offering, change or establish other rules with respect to a
Participant&#146;s ability to increase, decrease or terminate his or her payroll deduction during an Offering. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Withdrawal</U>. A
Participant may withdraw from participation in the Plan by delivering a written notice of withdrawal to his or her appropriate payroll location. The Participant&#146;s withdrawal will be effective as of the next business day. Following a
Participant&#146;s withdrawal, the Company will promptly refund such individual&#146;s entire account balance under the Plan to him or her (after payment for any Common Stock purchased before the effective date of withdrawal). Partial withdrawals
are not permitted. Such an employee may not begin participation again during the remainder of the Offering, but may enroll in a subsequent Offering in accordance with Section&nbsp;4. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Grant of Options</U>. On each Offering Date, the Company will grant to each eligible employee who is then a Participant in the Plan an
option (&#147;Option&#148;) to purchase on the last day of such Offering (the &#147;Exercise Date&#148;), at the Option Price hereinafter provided for, the lowest of (a)&nbsp;a number of shares of Common Stock determined by dividing such
Participant&#146;s accumulated payroll deductions on such Exercise Date by the lower of (i)&nbsp;85 percent of the Fair Market Value of the Common Stock on the Offering Date, or (ii)&nbsp;85 percent of the Fair Market Value of the Common Stock on
the Exercise Date; (b)&nbsp;5,000 shares of Common Stock; or (c)&nbsp;such other lesser maximum number of shares as shall have been established by the Administrator in advance of the Offering; provided, however, that such Option shall be subject to
the limitations set forth below. Each Participant&#146;s Option shall be exercisable only to the extent of such Participant&#146;s accumulated payroll deductions on the Exercise Date. The purchase price for each share purchased under each Option
(the &#147;Option Price&#148;) will be 85 percent of the Fair Market Value of the Common Stock on the Offering Date or the Exercise Date, whichever is less. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, no Participant may be granted an option hereunder if such
Participant, immediately after the option was granted, would be treated as owning stock possessing 5&nbsp;percent or more of the total combined voting power or value of all classes of stock of the Company or any Parent or Subsidiary (as defined in
Section&nbsp;11). For purposes of the preceding sentence, the attribution rules of Section&nbsp;424(d) of the Code shall apply in determining the stock ownership of a Participant, and all stock which the Participant has a contractual right to
purchase shall be treated as stock owned by the Participant. In addition, no Participant may be granted an Option which permits his or her rights to purchase stock under the Plan, and any other employee stock purchase plan of the Company and its
Parents and Subsidiaries, to accrue at a rate which exceeds $25,000 of the fair market value of such stock (determined on the option grant date or dates) for each calendar year in which the Option is outstanding at any time. The purpose of the
limitation in the preceding sentence is to comply with Section&nbsp;423(b)(8) of the Code and shall be applied taking Options into account in the order in which they were granted. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Exercise of Option and Purchase of Shares</U>. Each employee who continues to be a Participant in the Plan on the Exercise Date shall be
deemed to have exercised his or her Option on such date and shall acquire from the Company such number of whole shares of Common Stock reserved for the purpose of the Plan as his or her accumulated payroll deductions on such date will purchase at
the Option Price, subject to any other limitations contained in the Plan. Any amount remaining in a Participant&#146;s account at the end of an Offering solely by reason of the inability to purchase a fractional share will be carried forward to the
next Offering; any other balance remaining in a Participant&#146;s account at the end of an Offering will be refunded to the Participant promptly. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Issuance of Certificates</U>. Certificates representing shares of Common Stock purchased
under the Plan may be issued only in the name of the employee, in the name of the employee and another person of legal age as joint tenants with rights of survivorship, or in the name of a broker authorized by the employee to be his, her or their,
nominee for such purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Definitions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;Compensation&#148; means the amount of total cash compensation, prior to salary reduction pursuant to Sections&nbsp;125, 132(f)
or 401(k) of the Code, including base pay, overtime, commissions, and incentive or bonus awards, but excluding allowances and reimbursements for expenses such as relocation allowances or travel expenses, income or gains on the exercise of Company
stock options, and similar items. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;Designated Subsidiary&#148; means any present or future Subsidiary (as defined below)
that has been designated by the Board to participate in the Plan. The Board may so designate any Subsidiary, or revoke any such designation, at any time and from time to time, either before or after the Plan is approved by the stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;Fair Market Value of the Common Stock&#148; on any given date means the fair market value of the Common Stock determined in
good faith by the Administrator; provided, however, that if the Common Stock is admitted to quotation on the National Association of Securities Dealers Automated Quotation System (&#147;NASDAQ&#148;), NASDAQ Global Market or another national
securities exchange, the determination shall be made by reference to the closing price on such date. If there is no closing price for such date, the determination shall be made by reference to the last date preceding such date for which there is a
closing price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;Parent&#148; means a &#147;parent corporation&#148; with respect to the Company,
as defined in Section&nbsp;424(e) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;Participant&#148; means an individual who is eligible as determined in
Section&nbsp;3 and who has complied with the provisions of Section&nbsp;4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;Subsidiary&#148; means a &#147;subsidiary
corporation&#148; with respect to the Company, as defined in Section&nbsp;424(f) of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Rights on Termination of
Employment</U>. If a Participant&#146;s employment terminates for any reason before the Exercise Date for any Offering, no payroll deduction will be taken from any pay due and owing to the Participant and the balance in the Participant&#146;s
account will be paid to such Participant or, in the case of such Participant&#146;s death, to his or her designated beneficiary as if such Participant had withdrawn from the Plan under Section&nbsp;7. An employee will be deemed to have terminated
employment, for this purpose, if the corporation that employs him or her, having been a Designated Subsidiary, ceases to be a Subsidiary, or if the employee is transferred to any corporation other than the Company or a Designated Subsidiary. An
employee will not be deemed to have terminated employment for this purpose, if the employee is on an approved leave of absence for military service or sickness or for any other purpose approved by the Company, if the employee&#146;s right to
reemployment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise provides in writing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Special Rules</U>. Notwithstanding anything herein to the contrary, the Administrator may adopt special rules applicable to the
employees of a particular Designated Subsidiary, whenever the Administrator determines that such rules are necessary or appropriate for the implementation of the Plan in a jurisdiction where such Designated Subsidiary has
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employees; provided that such rules are consistent with the requirements of Section&nbsp;423(b) of the Code. Any special rules established pursuant to this Section&nbsp;13 shall, to the extent
possible, result in the employees subject to such rules having substantially the same rights as other Participants in the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.
<U>Optionees Not Stockholders</U>. Neither the granting of an Option to a Participant nor the deductions from his or her pay shall constitute such Participant a holder of the shares of Common Stock covered by an Option under the Plan until such
shares have been purchased by and issued to him or her. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Rights Not Transferable</U>. Rights under the Plan are not transferable by
a Participant other than by will or the laws of descent and distribution, and are exercisable during the Participant&#146;s lifetime only by the Participant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Application of Funds</U>. All funds received or held by the Company under the Plan may be combined with other corporate funds and may be
used for any corporate purpose. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <U>Adjustment in Case of Changes Affecting Common Stock</U>. In the event of a subdivision of
outstanding shares of Common Stock, the payment of a dividend in Common Stock or any other change affecting the Common Stock, the number of shares approved for the Plan and the share limitation set forth in Section&nbsp;8 shall be equitably or
proportionately adjusted to give proper effect to such event. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>Amendment of the Plan</U>. The Board may at any time and from time to
time amend the Plan in any respect, except that without the approval within 12 months of such Board action by the stockholders, no amendment shall be made increasing the number of shares approved for the Plan or making any other change that would
require stockholder approval in order for the Plan, as amended, to qualify as an &#147;employee stock purchase plan&#148; under Section&nbsp;423(b) of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <U>Insufficient Shares</U>. If the total number of shares of Common Stock that would
otherwise be purchased on any Exercise Date plus the number of shares purchased under previous Offerings under the Plan exceeds the maximum number of shares issuable under the Plan, the shares then available shall be apportioned among Participants
in proportion to the amount of payroll deductions accumulated on behalf of each Participant that would otherwise be used to purchase Common Stock on such Exercise Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <U>Termination of the Plan</U>. The Plan may be terminated at any time by the Board. Upon termination of the Plan, all amounts in the
accounts of Participants shall be promptly refunded. The Plan shall automatically terminate on the tenth anniversary of the date the Plan was approved by the Company&#146;s stockholders </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <U>Governmental Regulations</U>. The Company&#146;s obligation to sell and deliver Common Stock under the Plan is subject to obtaining all
governmental approvals required in connection with the authorization, issuance, or sale of such stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. <U>Governing Law</U>. This Plan
and all Options and actions taken thereunder shall be governed by, and construed in accordance with, the laws of the State of Delaware, applied without regard to conflict of law principles. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23. <U>Issuance of Shares</U>. Shares may be issued upon exercise of an Option from authorized but unissued Common Stock, from shares held in
the treasury of the Company, or from any other proper source. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24. <U>Tax Withholding</U>. Participation in the Plan is subject to any minimum required tax
withholding on income of the Participant in connection with the Plan. Each Participant agrees, by entering the Plan, that the Company and its Subsidiaries shall have the right to deduct any such taxes from any payment of any kind otherwise due to
the Participant, including shares issuable under the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25. <U>Notification Upon Sale of Shares</U>. Each Participant agrees, by
entering the Plan, to give the Company prompt notice of any disposition of shares purchased under the Plan where such disposition occurs within two years after the date of grant of the Option pursuant to which such shares were purchased. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">26. <U>Effective Date and Approval of Shareholders</U>. The Plan shall take effect on the later of the date it is adopted by the Board and the
date it is approved by the holders of a majority of the votes cast at a meeting of stockholders at which a quorum is present or by written consent of the stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>7
<FILENAME>d893535dex109.htm
<DESCRIPTION>EX-10.9
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.9</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.9 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LEASE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Landlord:</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Farley White Kilnbrook Three, LLC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Tenant:</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Inotek Pharmaceuticals
Corporation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Date of Lease: May&nbsp;11<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>, 2012 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TABLE OF CONTENTS </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Article I DEMISING CLAUSE AND DEFINED TERMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.1 Demising Clause</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.2 Defined Terms</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Article II PREMISES AND TERM</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1 The Premises</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2 Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Article III RENT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1 Base Rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2 Adjustment for Operating Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.3 Tenant&#146;s Electricity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Article IV CONSTRUCTION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1 Leasehold Improvements by Landlord</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2 Alterations by Tenant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Article V LANDLORD&#146;S OBLIGATIONS AND RIGHTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1 Services Furnished by Landlord</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.2 Repairs and Maintenance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.3 Quiet Enjoyment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.4 Insurance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.5 Access to Premises</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.6 Right to Cease Providing Services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.7 Failure to Provide Services and Repairs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Article VI TENANT&#146;S COVENANTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.1 Repair and Yield Up</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.2 Use</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.3 Assignment; Sublease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.4 Indemnity; Assumption of Risk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.5 Tenant&#146;s Insurance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.6 Right of Entry</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.7 Payment of Taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.8 Environmental Compliance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Article VII DEFAULT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.1 Events of Default</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.2 Damages</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Article VIII CASUALTY AND EMINENT DOMAIN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.1 Termination or Restoration; Rent Adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.2 Eminent Domain Damages</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.3 Temporary Taking</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="97%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Article IX RIGHTS OF PARTIES HOLDING PRIOR INTERESTS</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.1 Lease Subordinate - Superior</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.2 Rights of Mortgagee to Cure</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Article X MISCELLANEOUS</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.1 Representations by Tenant</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.2 Notices</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.3 No Waiver or Oral Modification</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.4 Partial Invalidity</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.5 Certain Landlord Remedies</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.6 Tenant&#146;s Estoppel Certificate</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.7 Waiver of Subrogation</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.8 All Agreements; No Representations</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.9 Brokerage</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.10 Successors and Assigns</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.11 Construction of Document</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.12 Disputes Provisions</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.13 Surrender</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.14 Holdover</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.15 Late Payment</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.16 Force Majeure</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.17 Limitation On Liability</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.18 Submission Not An Option</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.19 Security Deposit</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.20 Evidence of Authority</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.21 Relocation</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.22 Notice of Lease</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.23 Option to Extend</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EXHIBITS </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are attached
hereto and incorporated as a part of this Lease: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EXHIBIT A - Premises </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EXHIBIT B - List of Cleaning Services </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EXHIBIT C - intentionally omitted </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE I DEMISING CLAUSE AND DEFINED TERMS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.1 <U>Demising Clause</U>. This lease (the &#147;Lease&#148;) is made and entered into by and between the Landlord and the Tenant, as defined below, as of
the Date of Lease. In consideration of the mutual covenants made herein, Landlord hereby leases to Tenant, and Tenant hereby leases from Landlord, the Premises as defined below, on ail of the terms and conditions set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.2 <U>Defined Terms</U>. The terms listed below shall have the following meanings throughout this Lease: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) &#147;LANDLORD&#148;: Farley White Kilnbrook Three, LLC </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(b)&nbsp;&#147;LANDLORD&#146;S&nbsp;ADDRESS&#148;:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">c/o Farley White Management Company</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">155 Federal Street, 18th Floor, Boston, MA 02110</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) &#147;TENANT&#148;: Inotek Pharmaceuticals Corporation, a Delaware corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) &#147;TENANT&#146;S ADDRESS&#148;: 33 Hayden Avenue, 2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> Floor, Lexington, MA 02421 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) &#147;BUILDING&#148;: The 77,966 RSF building known as Kiln Brook 111 located at 131 Hartwell Avenue in Lexington, MA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) &#147;PROPERTY&#148;: The Building and the legal parcel (the &#147;Lot&#148;) on which it is situated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(g) &#147;PREMISES&#148;: A portion of the 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> Floor of the Building as shown on <U>Exhibit A</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(h) &#147;RENTABLE SQUARE FEET IN THE PREMISES&#148;: 2,440 Rentable Square Feet (RSF). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) &#147;TENANT&#146;S PERCENTAGE&#148;: 3.13% which is based on the 2,440 Rentable Square Feet (RSF) the Premises over the total RSF of the Building and
shall be adjusted if the RSF of the Building shall increase or decrease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(j) &#147;SCHEDULED COMMENCEMENT DATE&#148;: June&nbsp;1, 2012 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(k) &#147;TERM&#148;: The period beginning on the Commencement Date (as defined in Section&nbsp;2.2(a) of the Lease) and ending on June&nbsp;30, 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) &#147;BASE RENT&#148;: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="white-space:nowrap">June&nbsp;1,&nbsp;2012&nbsp;-&nbsp;June&nbsp;30,&nbsp;2012:</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Free Rent</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="white-space:nowrap">July&nbsp;1,&nbsp;2012&nbsp;-&nbsp;June&nbsp;30,&nbsp;2013:</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">$51,240.00 per annum; $4,279.00 per month; $21.00 per RSF.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(m) &#147;EXPENSE BASE&#148;: The sum of Operating Expenses allocable to the Premises during calendar year 2012, and the Taxes
allocable to the Premises during tax calendar year 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(n) &#147;PERMITTED USES&#148;: General office </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(o) &#147;BROKER(S)&#148;: Richards Barry Joyce&nbsp;&amp; Partners </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(p) &#147;SECURITY DEPOSIT&#148;: Security deposit is one month&#146;s rent or $4;279.00 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE II PREMISES AND TERM </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.1 <U>The Premises</U>. Common Areas and Parking. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a)
Landlord hereby leases to Tenant, and Tenant hereby leases from Landlord, the Premises. The Premises leased hereby are comprised of the space shown on <U>Exhibit A</U>. The Premises extend from the top surface of the subfloor to the bottom surface
of the ceiling, but do not include exterior faces of exterior walls and exterior window glass, anything beyond the interior face of demising walls, and pipes, ducts, conduits, wires and fixtures serving other parts of the Building; provided,
however, that Tenant shall have the right to use the space, if any, between the top surface of the ceiling and the bottom surface of the floor slab of the floor above such ceiling, and to drill into the floor slab of any floor encompassed within the
Premises, all for the purpose of installing ducts, cables and conduits, so long as (i)&nbsp;Tenant obtains the prior written consent of Landlord (which consent shall not be unreasonably withheld or delayed); and (ii)&nbsp;such installation does not
interfere with the Building systems and with the quiet enjoyment of other tenants in the Building. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) Tenant shall have the right to use the Common
Areas in common with other tenants. The Common Areas include the Building&#146;s common lobbies, corridors, stairways, and elevators necessary for access to the Premises, and the common walkways and driveways necessary for access to the Building,
the common toilets, corridors and elevator lobbies of any multi-tenant floor, and the parking area for the Building. All use of the Common Areas shall be subject to the reasonable rules and regulations of Landlord generally applicable to all tenants
of the Building from time to time. Landlord may at any time make any changes, additions, improvements, repairs or replacements to the Property, including the Common Areas, that it considers desirable, which changes, additions, improvements, repairs
or replacements shall be of equal quality to those of other first class office buildings of like quality and location. In so doing, Landlord (t)&nbsp;may use or temporarily close any of the Common Areas, or permanently change their configuration,
and (ii)&nbsp;shall use reasonable efforts to minimize interference with Tenant&#146;s normal activities, but no such interference shall constitute constructive eviction or give rise to any abatement of rent or liability of Landlord to Tenant unless
such interference is caused by Landlord&#146;s negligence, willful misconduct, or breach of Landlord&#146;s covenants hereunder, in which event Landlord&#146;s liability shall be governed by <U>Section&nbsp;5.7</U> of this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) Tenant acknowledges that its parking use of the parking areas shall be on an unreserved, non-exclusive basis, and that parking spaces shall be used solely
for Tenant&#146;s employees and visitors. It is understood that Landlord shall not be responsible for policing any parking areas. Tenant shall reasonably cooperate with Landlord to assure that Tenant and its employees and visitors observe all
reasonable parking regulations established by Landlord from time to time and to assure that Tenant and its employees and visitors do not use more parking spaces than the number of parking spaces provided to Tenant hereunder. Landlord shall not be
liable to Tenant, and this Lease shall not be affected, if any parking rights of Tenant hereunder are impaired by any law, ordinance or other governmental regulation imposed after the Date of Lease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.2 <U>Term</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Both parties shall be bound by all the terms of this Lease as of the Date of Lease. The Term shall begin on the Commencement Date, and shall continue for
the length of the Term set forth in <U>Section&nbsp;1.2</U> unless sooner terminated as hereinafter provided. The Commencement Date shall be the later of: 1) the Scheduled Commencement Date; or, 2) the date the Premises are Ready for Occupancy.
However, if the Tenant occupies any portion of the Premises for any reason, the Commencement Date shall be immediate upon such occupancy. The Premises shall be Ready for Occupancy when construction of the Leasehold Improvements is substantially
complete in accordance with the Final Plans pursuant to <U>Section&nbsp;4.1</U>, as reasonably determined by Landlord. Tenant may co-ordinate with Landlord or Landlord&#146;s contractor one or more opportunities to gain early access to the Premises
ahead of the Commencement Date to scope out the networking requirements for telephones and computer systems </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) Landlord shall use reasonable efforts to
have the Premises Ready for Occupancy on the Scheduled Commencement Date. If the Premises are not Ready for Occupancy on the Scheduled Commencement Date, Landlord shall not be subject to any liability for such failure, and such failure shall not
affect the validity of this Lease, but Tenant shall not be liable for any rent until the Commencement Date. In the event that the Commencement Date is not before July&nbsp;1, 2012 because the Premises are not ready for occupation, Tenant can elect
to (i)&nbsp;terminate the Lease by giving written notice to Landlord, said Termination being effective immediately or (ii)&nbsp;receive two (2)&nbsp;days rent free for every day beyond July&nbsp;1, 2012 that the Premises are not available for
occupancy. However, if the Premises are not Ready for Occupancy because Tenant has failed to comply with Tenant&#146;s obligations under <U>Section&nbsp;4.1</U> or under any work letter or construction agreement between the parties, or has otherwise
delayed Landlord in preparing the Premises or in obtaining a Certificate of Occupancy far the Premises, then the Commencement Date shall be the date that the Premises would have been Ready for Occupancy except for such Tenant-caused delay, as
reasonably determined by Landlord. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE III RENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.1 <U>Base Rent</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Tenant shall pay the Base Rent each
month in advance on the first day of each calendar month during the Term. For any partial month at the beginning or end of the Term, Tenant shall pay a proportional share of the amount that would be due for a full month, and with respect to a
partial month at the beginning of the Term, Tenant shall pay such proportional share on the Commencement Date. In addition to the Base Rent, Tenant shall pay all additional rent and rental adjustments provided herein at the times set forth herein,
or if no time for payment is specified, then payment shall be made within fifteen (15)&nbsp;days after Tenant&#146;s receipt of an invoice from Landlord or another billing authority. All payments shall be made to Landlord at Landlord&#146;s Address
or such other place as Landlord may designate in writing, without prior demand and without abatement, deduction or offset except as may be specifically set forth herein. Tenant shall not pay, and Landlord shall not accept, any rental payment more
than one month in advance. All charges to be paid by Tenant hereunder, other than Base Rent, shall be considered additional rent for the purpose of this Lease, and the words &#147;rent&#148; or &#147;Rent&#148; as used in this Lease shall mean both
Base Rent and such additional rent unless the context specifically or clearly indicates that only the Base Rent is referenced. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.2 <U>Adjustment for Operating Expenses</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Tenant shall pay, as additional rent, Tenant&#146;s Share of Expenses for the Property. For each Fiscal Year during the Term, Tenant&#146;s Share of
Expenses shall consist of the sum of (x)&nbsp;the excess of (i)&nbsp;Tenant&#146;s Percentage of the sum of the total Operating Expenses for the Property and the total Taxes for the Property for that Fiscal Year over (ii)&nbsp;the Expense Base, and
(y)&nbsp;a commercially reasonable charge for the provision of services to operate the Building during periods other than 8:00 am. to 6:00 pm. on weekdays and 9:00 am. to 1:00 pm. on Saturdays and to operate the Building on holidays (which are all
days on which commercial banks in Boston, Massachusetts are authorized or required by law to close) (such periods being referred to herein as &#147;Non-Business Hours&#148;) that are fairly allocable to the Premises, if such services are requested
by Tenant or are necessary, in Landlord&#146;s reasonable judgment, for Tenant&#146;s operations during Non-Business Hours. For any partial Fiscal Year at the beginning or end of the Term, Tenant&#146;s Share of Expenses shall be adjusted
proportionately for the part of the Fiscal Year falling within the Term. Tenant&#146;s Percentage may be reduced if the Property is changed or reconfigured, but shall in all cases not exceed the percentage that the Rentable Square Feet in the
Premises bears to the total rentable square footage in the Property, calculated on a consistent basis. In addition, Tenant shall pay, as additional rent, one hundred percent (100%)&nbsp;of any increase in Taxes not otherwise billed to Tenant which
may result from any alteration, addition or improvement to the Premises that is made by or on behalf of Tenant, other than the Leasehold Improvements. Upon request of Tenant, Landlord shall supply to Tenant reasonable evidence of such increase in
Taxes which shows that such increase is attributable to Tenant&#146;s alteration, addition or improvement to the Premises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) Before each Fiscal Year,
Landlord shall give Tenant a reasonable estimate of the expected Operating Expenses and Taxes for the Property for the coming Fiscal Year (excluding Landlord&#146;s cost for services provided during Non-Business Hours), and a calculation of the
estimated amount of Tenant&#146;s Share of Expenses. Tenant shall pay one-twelfth of the estimated amount of Tenant&#146;s Share of Expenses with each monthly payment of Base Rent. After the end of each Fiscal Year, Landlord shall give Tenant a
statement (the &#147;Statement&#148;) showing the actual Operating Expenses and Taxes for that Fiscal Year, a calculation of the actual amount of Tenant&#146;s Share of Expenses, and a summary of amounts already paid by Tenant pursuant to this
<U>Section&nbsp;3.2</U>. Any underpayment by Tenant shall be made up by cash payment to Landlord within thirty (30)&nbsp;days after delivery of the Statement; any overpayment shall be paid to Tenant within thirty (30)&nbsp;days after delivery of the
Statement or, at Landlord&#146;s option, shall be credited against the next due Base Rent, provided that any overpayment shall be paid in cash to Tenant within thirty (30)&nbsp;days if the Term has ended. No delay by Landlord in providing any
Statement shall be deemed a waiver of Tenant&#146;s obligation to pay Tenant&#146;s Share of Expenses. Tenant and its auditors shall have the right, upon not less than ten (10)&nbsp;business days&#146; notice and then at a time reasonably convenient
to both parties, to inspect during usual business hours those portions of the books kept by Landlord relating to costs and expenses for which Tenant has responsibility hereunder. If Tenant disagrees with Landlord&#146;s determination of Operating
Expenses and Taxes, Tenant shall have the right to pay its share of Operating Expenses and Taxes under protest without waiving its claim as to the overage. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) The following terms used in this <U>Section&nbsp;3.2(c)</U> shall have the following meanings for purposes of
this Lease: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The term &#147;Fiscal Year&#148; means any twelve-month period selected by Landlord for operating purposes. Landlord may
change its Fiscal Year and interim accounting periods, so long as the periods so revised are reconciled with prior periods in accordance with generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The term &#147;Operating Expenses&#148; means the total cost of operation of the Property, including, without limitation: (i)&nbsp;all
costs of supplies, materials, equipment, and utilities used in or related to the operation, maintenance, and repair of the Property or any part thereof (other than the cost of any electricity which is to be paid for separately by Tenant pursuant to
<U>Section&nbsp;3.3</U>): (ii)&nbsp;all labor costs, including without limitation, salaries, wages, payroll and other taxes, unemployment insurance costs and employee benefits in connection with the on-site management, operation and maintenance of
the Property or any part thereof; (iii)&nbsp;all maintenance, management, janitorial, legal (excluding those legal costs arising out of defaults of Landlord or other tenants in the Building), accounting, insurance, and service agreement costs
related to the Property or any part thereof, including, without limitation, service contracts with independent contractors; and (iv)&nbsp;costs (including financing charges) of improvements to the Property that are designed to increase safety or
reduce Operating Expenses (but only to the extent that such costs actually reduce Operating Expenses) or are required to comply with legal requirements imposed after the initial completion of the Building, all such improvements to be amortized over
the reasonable life of such improvements. Any of the above services may be performed by Landlord or its affiliates, provided that fees for the performance of such services shall be reasonable and competitive with fees charged by unaffiliated
entities for the performance of such services in comparable buildings in the area. &#147;Operating Expenses&#148; shall not include leasing commissions or other costs of procuring tenants for the Building including legal fees and advertising costs
associated therewith, ground rent, Landlord&#146;s overhead, repair costs paid by insurance proceeds or by any tenant or third party, repair costs associated with defects in initial construction, the initial construction cost of the Building or any
depreciation thereof or soft costs associated therewith, any debt service or cost of capital improvements except as specifically set forth above, any tenant improvements provided for any tenant, any costs payable directly by another tenant or any
expenses incurred by Landlord that are attributable to the operation of the Building during Non-Business Hours (subject, however, to Tenant&#146;s obligation to pay additional rent pursuant to subclause (y)&nbsp;of subsection 3.2(a) hereof). All
Operating Expenses shall be adjusted based on the Calculation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) The term &#147;Calculation&#148; means that if the Building is less
than 100% occupied in any Fiscal Year during the Term, Operating Expenses shall be calculated as though the Building had been 100% occupied, and the result shall constitute the Operating Expenses for all purposes hereunder. In addition, if during
all or part of any Fiscal Year, Landlord is not performing or furnishing any item or service to any portion of the Property (the cost of which, if performed or furnished by Landlord to such portion of the Property, would constitute a part of
Operating Expenses), on account of (a)&nbsp;such item or service not being required or desired by a tenant, or (b)&nbsp;any tenant obtaining or providing such item or service itself, then, Operating Expenses shall be deemed to be increased by an
amount equal to the additional costs and expenses which would reasonably have been incurred during such period by Landlord if it had performed or furnished such item or service to 100% of the Building. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) The term &#147;Taxes&#148; means any form of assessment, rental tax, license tax, business
license fee, levy, charge, tax or similar imposition, imposed by any authority having the power to tax, including any city, county, state or federal government, or any school, agricultural, lighting, library, drainage or other improvement or special
assessment district, as against the Property or any part thereof or any legal or equitable interest of Landlord therein, or against Landlord by virtue of its interest therein, and any reasonable costs incurred by Landlord in any proceeding for
abatement thereof, including, without limitation, attorneys&#146; and consultants&#146; fees. Landlord&#146;s income, franchise taxes, and assessments for off-site improvements shall not be included in &#147;Taxes.&#148; Landlord shall reimburse
Tenant for Tenant&#146;s Share of any Tax abatements received by Landlord less legal, appraisal and other fees and expenses incurred by Landlord in obtaining such abatement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provided that Tenant shall have first paid all of amounts due and payable by Tenant pursuant to this Article 111 and upon written notice of
Tenant within 30 days of the receipt of a final certificate (but not more than once with respect to any Fiscal Year), Tenant may cause Landlord&#146;s books and records to be audited with respect to operating costs applicable to the Building for
such Operating Year. The audit shall be performed within 30 days of Landlord&#146;s receipt of notice by a certified public accountant at Tenant&#146;s SDIC cost and expense and at a mutually agreeable time and place where the books and records are
customarily kept by the Landlord (or properly manager) in the ordinary course. During such time of audit Tenant shall pay its full share of operating expenses. If it is determined that there are any amounts owed Tenant or Landlord as a result of
said audit, such amount shall be reimbursed to the other within 30 days of said audit results. Tenant shall keep the results of any such audit confidential and shall not disclose the results of such inspection nor the content of such books and
records with any third party other than Tenant&#146;s consultants and attorneys. Failure of Tenant to provide Landlord with a written request to review such books and records in a timely manner pursuant to this Article 3 with respect to each Fiscal
Year shall be deemed a waiver of Tenant&#146;s rights hereunder with respect to such Fiscal Year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.3 <U>Tenant&#146;s Electricity</U>. With respect to
electricity for lighting and equipment in the Premises, Tenant agrees to pay all charges therefor. If the Premises are separately metered, then Tenant shall pay the electric company furnishing the electricity directly and, if requested by Landlord,
provide Landlord with evidence of such payment. If the Premises are not separately metered, then Tenant shall pay to Landlord upon demand from time to time, as additional rent, the cost of all electricity consumed in the Premises, as said cost shall
reasonably be determined by Landlord from time to time. Landlord&#146;s initial estimate of this cost is $1.50 per square foot per year based upon typical office use. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE IV CONSTRUCTION </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.1 <U>Leasehold
Improvements by Landlord</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Tenant accepts the Premises in &#147;as-is&#148; condition except Landlord shall, at Landlord&#146;s sole expense,
shampoo the carpets and touch-up paint throughout the Premises. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) In addition to the Leasehold Improvements, Landlord shall provide and install, at Landlord&#146;s expense
with respect to the first such installation and at Tenant&#146;s expense with respect to any subsequent installation, letters or numerals on the door to the Premises to identify Tenant&#146;s name and Building address; all such letters and numerals
shall be in the building standard graphics and no others shall be used or permitted on the Premises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.2 <U>Alterations by Tenant</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Tenant shall not make any alterations, decorations, additions, installations, substitutes or improvements (hereinafter collectively called
&#147;Alterations&#148;) in and to the Premises, without first obtaining Landlord&#146;s written consent, which consent shall not be unreasonably withheld. Notwithstanding the foregoing, the tenant shall have the right to install it&#146;s floor
mounted supplemental HVAC unit and duct the exhaust into the ceiling plenum if required. No Alteration shall violate the Certificate of Occupancy for the Premises or any applicable law, code or ordinance, or the terms of any superior lease or
mortgage affecting the Property, affect the exterior appearance of the Building, adversely affect the value or structure of the Building, require excessive removal expenses, adversely affect any other part of the Building, adversely affect the
mechanical, electrical, sanitary or other service systems of the Building, or involve the installation of any materials subject to any liens or conditional sales contracts (the &#147;Approval Review Matters&#148;). Tenant shall pay Landlord&#146;s
reasonable costs of reviewing or inspecting any proposed Alterations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) All work on any Alterations shall be done at reasonable times in a first-class
workmanlike manner, by contractors reasonably approved by Landlord, according to plans and specifications reasonably approved by Landlord. All work shall be done in compliance with all applicable laws, regulations, and rules of any government agency
with jurisdiction, and with all regulations of the Board of Fire Underwriters or any similar insurance body or bodies. Tenant shall be solely responsible for the effect of any Alterations on the Building&#146;s structure and systems, whether or not
Landlord has consented to the Alterations, and shall reimburse Landlord on demand for any costs incurred by Landlord by reason of any faulty work done by Tenant or its contractors. Upon completion of any Alterations, Tenant shall provide Landlord
with a complete set of &#147;as-built&#148; plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) Tenant shall use its best efforts to keep the Property and Tenant&#146;s leasehold interest
therein free of any liens or claims of liens arising from acts or omissions of Tenant, or its subtenants, contractors or others claiming by, through or under Tenant, and shall discharge or bond any such liens within ten (10)&nbsp;days of their
filing. Before commencement of any work, Tenant&#146;s contractor shall provide any payment, performance and lien indemnity bond required by Landlord. Tenant shall provide evidence of such insurance as Landlord may reasonably require, naming
Landlord as an additional insured. Tenant shall indemnify Landlord and hold it harmless from and against any cost, claim, or liability arising from any work done by or at the direction of Tenant. All work shall be done so as to minimize interference
with other tenants and with Landlord&#146;s operation of the Building or other construction work-being done by Landlord. Landlord may post any notices it considers necessary to protect it from responsibility or liability for any Alterations, and
Tenant shall give sufficient notice to Landlord to permit such posting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) All Alterations affixed to the Premises shall become part thereof and remain therein at the end of the Term.
However, if Landlord gives Tenant a notice, at least thirty (30)&nbsp;days before the end of the Term, to remove any Alterations, Tenant shall do so and shall pay the cost of removal and any repair required by such removal. All of Tenant&#146;s
personal property, trade fixtures, equipment, furniture, movable partitions, and any Alterations not affixed to the Premises shall remain Tenant&#146;s property, removable at any time. If Tenant fails to remove any such materials at the end of the
Term, Landlord may do so and store them at Tenant&#146;s expense, without liability to Tenant, and may sell them at public or private sale and apply the proceeds to any amounts due hereunder, including costs of removal, storage and sale. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE V LANDLORD&#146;S OBLIGATIONS AND RIGHTS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.1 <U>Services Furnished by Landlord</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Landlord shall
furnish services, utilities, facilities and supplies equal in quality to those customarily provided by landlords in high quality office buildings of a similar design in the greater Boston suburban area. Such services, facilities and supplies shall
include the services described in subsection 5.1(b) and 5.1(c) and <U>Section&nbsp;5.2</U> and the following: (i)&nbsp;cleaning services for Building Common Areas and the Premises as described in <U>Exhibit B</U>, (ii)&nbsp;rubbish removal,
(iii)&nbsp;window cleaning, (iv)&nbsp;restroom supplies, (v)&nbsp;sewer and water service to the Building&#146;s restrooms, (vi)&nbsp;landscape maintenance, (vii)&nbsp;snow removal for walks, driveways and parking areas, (viii)&nbsp;maintenance of
plantings in interior Common Areas, (ix)&nbsp;Building security, and (x)&nbsp;such other services, utilities, facilities and supplies as may be deemed necessary in Landlord&#146;s reasonable judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) Subject to the provisions of this subsection 5.1(b), Landlord shall furnish space heating and cooling as normal seasonal changes may require to provide
reasonably comfortable space temperature and ventilation for occupants of the Premises under normal business operation. However, Tenant acknowledges that because of the nature of its business it will require additional cooling, and that it is solely
responsible for arranging therefor as described in <U>Section&nbsp;4.2(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) Subject to the provisions of <U>Section&nbsp;3.3</U>, Landlord shall
provide electric power for lighting and office machine use under normal business operation. Tenant&#146;s use of electrical energy in the Premises shall not at any time exceed the capacity of any of the electrical conductors or equipment in or
otherwise serving the Premises described in such specifications. In order to ensure that such capacity is not exceeded and to avert possible adverse effect upon the Building electric service, Tenant shall not, without prior consent of Landlord in
each instance (which consent shall not be unreasonably withheld or delayed), make any alteration or addition to the electric system of the Premises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)
Landlord shall furnish, at Tenant&#146;s expense, reasonable additional Building operation services which are usual and customary in similar office buildings in the greater Boston suburban area upon reasonable advance request of Tenant at reasonable
and equitable rates from time to time established by Landlord; such charges, if any, shall be considered to be additional rent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) Landlord shall provide and install, at Landlord&#146;s expense with respect to the first such installation
and at Tenant&#146;s expense with respect to any subsequent installation, letters or numerals on the door to the Premises and in the lobby directory of the Building to identify Tenant&#146;s name, the name of entities affiliated with Tenant, the
Building address, and letters in the lobby directory to identify a reasonable number of names of Tenant&#146;s executives; all such letters and numerals shall be in the building standard graphics and no others shall be used or permitted on the
Premises, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.2 <U>Repairs and Maintenance</U>. Landlord shall repair and maintain the Common Areas and structural portions of the Building and the basic
plumbing, electrical, mechanical and heating, ventilating and air-conditioning systems therein, except for damage resulting from a casualty or an eminent domain taking, which shall be governed by <U>Article VIII</U>. If any maintenance, repair or
replacement is required because of any act, omission or neglect of duty by Tenant or its agents, employees, invitees or contractors, the cost thereof shall be paid by Tenant to Landlord as additional rent within thirty (30)&nbsp;days after billing
therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.3 <U>Quiet Enjoyment</U>. Upon Tenant&#146;s paying the rent and performing its other obligations, Landlord shall permit Tenant to peacefully
and quietly hold and enjoy the Premises, subject to the provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.4 <U>Insurance</U>. Landlord shall insure the Property, including the
Building, against damage by fire and standard extended coverage perils, including &#147;all-risks&#148; coverage, and shall carry public liability insurance and, during construction, builders risk insurance, all in such reasonable amounts with such
reasonable deductibles as would be carried by a prudent owner of a similar building in the area. Landlord may carry any other forms of insurance as it or its mortgagee may deem advisable. Tenant shall have no right to any proceeds from such
policies. Landlord shall not carry any insurance on any of Tenant&#146;s property, and shall not be obligated to repair or replace any of it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.5
<U>Access to Premises</U>. Landlord shall have reasonable access to the Premises to inspect Tenant&#146;s performance hereunder and to perform any acts required of or permitted to Landlord herein. Landlord shall at all times have a key or access
card to the Premises, and Tenant shall not install any additional lock without Landlord&#146;s consent. Any entry into the Premises by Landlord, under this section or any other section of this Lease permitting such entry, shall be on reasonable
advance notice, shall be done so as not to unreasonably interfere with Tenant&#146;s use of the Premises, and shall be accompanied by a representative of Tenant if Tenant so requests; provided, however, that such restrictions shall not apply to any
situation that Landlord in good faith believes to be an emergency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.6 <U>Right to Cease Providing Services</U>. In connection with any repairs,
alterations or additions to the Property or the Premises, or any other acts required of or permitted to Landlord herein, Landlord may, if necessary, reduce or suspend service of the Building&#146;s utilities and mechanical systems, or any of the
other services, facilities or supplies required to be provided by Landlord hereunder, provided that Landlord shall use best efforts to restore such services, facilities or supplies as soon as possible, and provided further that Landlord shall give
Tenant advance notice of such reduction or suspension if such reduction or suspension is planned in advance or if it is reasonably possible for Landlord to do so. In addition, Landlord may reduce or suspend such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
services, facilities or supplies in case of Force Majeure, as defined below. No such reduction or suspension permitted by this <U>Section&nbsp;5.6</U> shall constitute an actual or constructive
eviction or disturbance of Tenant&#146;s use or possession of the Premises, or an ejection of Tenant from the Premises, or a breach by Landlord of any of its obligations, and no such reduction or suspension shall render Landlord liable for any
damages, including but not limited to any damages, compensation or claims arising from any interruption or cessation of Tenant&#146;s business, or entitle Tenant to be relieved from any of its obligations under this Lease, or result in any abatement
or reduction of rent, except as set forth in <U>Section&nbsp;5.7</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.7 <U>Failure to Provide Services and Repairs</U>. Landlord shall not be in
default or liable for any failure to perform any act or obligation or provide any service required hereunder unless Tenant shall have given notice of such failure, and such failure continues for at least thirty (30)&nbsp;days thereafter; provided,
however, that if the nature of Landlord&#146;s obligation is such that more than thirty (30)&nbsp;days are required for its performance, then Landlord shall not be liable or in default if it commences such performance within thirty (30)&nbsp;days
and thereafter diligently pursues such performance to completion. Tenant hereby waives any right under any law, ordinance, regulation or judicial decision to make repairs or provide maintenance or perform any of Landlord&#146;s other obligations
hereunder at Landlord&#146;s expense. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE VI TENANT&#146;S COVENANTS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.1 <U>Repair and Yield Up</U>. Tenant shall keep the Premises in good order and condition, and shall promptly repair any damage to the Premises or the rest
of the Property caused by Tenant or its agents, employees, or invitees, licensees or independent contractors. Landlord may require such repair to be done by a contractor designated by Landlord at Tenant&#146;s cost, provided that costs to be charged
to Tenant are reasonable and competitive. At the end of the Term, Tenant shall peaceably yield up the Premises in good order, repair and condition, except for reasonable wear and tear and any casualty damage. Tenant shall remove its own property and
(if required by Landlord) any Alterations, repairing any damage caused by such removal and restoring the Premises and leaving them clean and neat. Nothing herein shall require Tenant to remove the Leasehold Improvements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.2 <U>Use</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Tenant shall use the Premises only for the
Permitted Uses, and shall not use or permit the Premises to be used for any other purpose. Tenant shall not use or occupy the Premises in violation of: (i)&nbsp;any recorded covenants, conditions and restrictions affecting the Property of which
Tenant has been given notice by Landlord (Landlord hereby representing that there are no such covenants, conditions or restrictions currently on record which will affect Tenant&#146;s use of the Premises for the Permitted Uses), (ii)&nbsp;any law or
ordinance or any Certificate of Occupancy issued for the Building or the Premises, or (iii)&nbsp;any reasonable Rules and Regulations issued by Landlord for the Building of which Tenant has been given a copy. Tenant shall comply with any directive
of any governmental authority with respect to Tenant&#146;s use or occupancy of the Premises. Tenant shall not do or permit anything in or about the Premises which will in any way damage the Premises, obstruct or interfere with the rights of other
tenants or occupants of the Building, or injure them, or use the Premises or allow them to be used for any unlawful purpose. Tenant shall not cause, maintain or permit any nuisance in, on or about the Premises, or commit or allow any waste in or
upon the Premises. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) Tenant shall not obstruct any of the Common Areas or any portion of the Property outside the Premises, and
shall not place or permit any signs (other than those permitted under <U>Section&nbsp;5.1(e)</U>), curtains, blinds, shades, awnings, aerials or flagpoles, or the like, visible from outside the Premises. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) Tenant shall keep the Premises equipped with all safety appliances required by law because of any use made by Tenant other than office use with customary
office equipment, and shall procure all licenses and permits required because of such use. This provision shall not broaden the Permitted Uses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)
Tenant shall not place a load upon the floor of the Premises exceeding 100 pounds per square foot. Partitions shall be considered as part of the load. Landlord may prescribe the weight and position of all safes, files and heavy equipment that Tenant
desires to place in the Premises, so as properly to distribute their weight. Tenant&#146;s business machines and mechanical equipment shall be installed and maintained so as not to transmit noise or vibration to the Building structure or to any
other space in the Building. Tenant shall be responsible for the cost of all structural engineering required to determine structural load and all acoustical engineering required to address any noise or vibration caused by Tenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) Tenant shall not keep or use any article in the Premises, or permit any activity therein, which is prohibited by a standard insurance policy covering
buildings and improvements similar to the Building and Leasehold Improvements, or would result in an increase in the premiums thereunder unless Tenant pays for such increase. In determining whether increased premiums are a result of Tenant&#146;s
activity, a schedule issued by the organization computing the insurance rate on the Building or the Leasehold Improvements, showing the various components of the rate, shall be conclusive evidence. Tenant shall promptly comply with all reasonable
requirements of the insurance authority or of any insurer relating to the Premises. If the use or occupation of the Premises by Tenant or by anyone Tenant allows on the Premises causes or threatens cancellation or reduction of any insurance carried
by Landlord, Tenant shall remedy the condition immediately upon notice thereof. Upon Tenant&#146;s failure to do so, Landlord may, in addition to any other remedy it has under this Lease but subject to the provisions of <U>Section&nbsp;5.5</U>,
enter the Premises and remedy the condition, at Tenant&#146;s cost, which Tenant shall promptly pay as additional rent. Landlord shall not be liable for any damage or injury caused as a result of such an entry, and shall not waive its rights to
declare a default because of Tenant&#146;s failure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.3 <U>Assignment; Sublease</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Tenant shall not assign, mortgage, pledge or otherwise transfer this Lease or make any sublease of the Premises, or permit occupancy of any part thereof
by anyone other than Tenant (any such act being referred to herein as a &#147;Transfer&#148; and the other party with whom Tenant undertakes such act being referred to herein as a &#147;Transferee&#148;) without the prior written consent of
Landlord, which consent shall not be unreasonably withheld or delayed, subject to the other provisions of this <U>Section&nbsp;6.3</U>. Any Transfer or attempted Transfer not in compliance with all of the terms and conditions set forth in this
<U>Section&nbsp;6.3</U> shall be void, and shall be a default under this Lease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) Any request by Tenant for Landlord&#146;s consent to a Transfer shall include the name of the proposed
Transferee, the nature of its business and proposed use of the Premises, reasonable information as to its financial condition, and the terms and conditions of the proposed Transfer. Tenant shall supply such additional information about the proposed
Transfer and Transferee as the Landlord reasonably requests. It shall be reasonable for Landlord to refuse consent to any Transfer to any governmental agency, or to any other Transferee who by reputation or expected use is not comparable to other
types of tenants in the Building, or to any transferee whose financial strength is not at least equivalent to that of Tenant at the time of the Transfer. Landlord shall respond to Tenant&#146;s request within thirty (30)&nbsp;days of its receipt of
such request. The failure of Landlord to respond within said thirty (30)&nbsp;days shall be deemed to be approval of the Transfer by Landlord provided that the request for consent from Tenant shall specifically refer to the provisions of this
sentence. Tenant shall reimburse Landlord for its reasonable legal and other expenses in connection with any request for consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) Any Transfer shall
specifically make applicable to the Transferee all of the provisions of this Section so that Landlord shall have against the Transferee all rights with respect to any further Transfer which are set forth herein. No Transfer shall affect the
continuing primary liability of Tenant (which shall be joint and several with Transferee). Consent to a Transfer in a specific instance shall not be deemed consent to any subsequent Transfer or a waiver of the requirement of consent to any future
Transfer. No Transfer shall be binding upon Landlord or any of Landlord&#146;s mortgagees, unless Tenant shall deliver to Landlord a recordable instrument containing a covenant of assumption by the Transferee running to Landlord and all persons
claiming by, through or under Landlord. The Transferee&#146;s failure to execute such instrument shall not, however, release or discharge Transferee from its liability as a Transferee hereunder. Tenant shall not enter into any Transfer that provides
for rental or other payment based on the net income or profits derived from the Premises. With respect to any Transfer, Landlord shall be entitled to receive seventy five percent (75%)&nbsp;of all &#147;Bonus Rent,&#148; which Bonus Rent shall be
payable by Tenant to Landlord on a monthly basis. For purposes of this Lease, Bonus Rent shall mean all amounts received by Tenant in excess of the Base Rent and additional rent reserved in this Lease and applicable to the space Transferred for the
period of the Transfer, minus Tenant&#146;s reasonable expenses in connection with such Transfer for brokerage commissions, legal fees, advertising expenses, and Alterations for the benefit of the Transferee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding any contrary provision of this <U>Section&nbsp;6.3</U>, in connection with any intent to Transfer, Landlord shall have an option to cancel
and terminate this Lease if the request is to assign the Lease or to sublet all of the Premises; or, if the request is to sublet a portion of the Premises only, to cancel and terminate this Lease with respect to such portion for the proposed term of
such sublease or for the balance of the Term if, within thirty (30)&nbsp;days after Landlord receives written notice from Tenant that Tenant intends to make space available for a Transfer, Landlord notifies Tenant that it has elected to exercise
such option Landlord may exercise said option in writing within thirty (30)&nbsp;days after Landlord&#146;s receipt from Tenant of such request, and in each case such cancellation or termination shall occur as of the date set forth in
Landlord&#146;s notice of exercise of such option, which shall not be less than sixty (60)&nbsp;days nor more than one hundred twenty (120)&nbsp;days following the giving of such notice. If Landlord </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exercises Landlord&#146;s option to cancel this Lease or any portion thereof, Tenant shall surrender possession of the Premises, or the portion thereof which is the subject of the option, as the
case may be, on the date set forth in such notice in accordance with the provisions of this Lease relating to surrender of the Premises at the expiration of the Term. If this Lease is cancelled as to a portion of the Premises only, Base Rent after
the date of cancellation shall be abated on a pro rata basis, as determined by Landlord, and Tenant&#146;s Percentage. If Landlord does not exercise Landlord&#146;s option to cancel this Lease or any portion thereof pursuant to the foregoing
provisions, Landlord&#146;s consent to a Transfer shall continue to be required in accordance with the other provisions of this <U>Section&nbsp;6.3</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) Any agreement by which Tenant agrees to enter into or execute any Transfer at the direction of any other party, or assigns its rights in the income
arising from any Transfer to any other party, shall itself constitute a Transfer hereunder. If Tenant is a corporation, partnership, or other business organization, the transfer of ownership interests, whether in one transaction or a series, forming
a majority of the equity interests in Tenant, shall constitute a Transfer, unless Tenant is a corporation whose stock is traded on an exchange or over the counter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) Notwithstanding any contrary provision of this Lease, Tenant shall have no right to assign this Lease or sublet all or any portion of the Premises and any
such assignment or sublease shall be void unless on both (i)&nbsp;the date on which Tenant notifies Landlord of its intention to enter into any assignment or sublease and (ii)&nbsp;the date on which such assignment or sublease is to take effect,
Tenant is not in default of any of its obligations under this Lease after notice to Tenant and expiration of applicable grace periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.4 <U>Indemnity;
Assumption of Risk</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Tenant, at its expense, shall defend (with counsel satisfactory to Landlord), indemnify and hold harmless Landlord and its
agents, employees, invitees, licensees and contractors from and against any cost, claim, action, liability or damage of any kind arising from (i)&nbsp;Tenant&#146;s use and occupancy of the Premises and the Property or any activity done or permitted
by Tenant in, on, or about the Premises or the Property, (ii)&nbsp;the destruction of or damage to Tenant&#146;s personal property, (iii)&nbsp;any breach or default by Tenant of its obligations under this Lease, or (iv)&nbsp;any negligent, tortious,
or illegal act or omission of Tenant, its agents, employees, invitees, licensees or contractors, provided that such cost, claim, action, liability or damage is not caused by the negligence or willful misconduct of Landlord or its agents, employees,
invitees, licensees and contractors (except as otherwise provided in the last sentence of subsection 6.5(a)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) As a material consideration to Landlord
for executing this Lease, Tenant assumes all risk of damage or injury to any person or property in, on, or about the Premises from any cause including, without limitation, injury or damage which may be sustained by the person or property of Tenant,
its employees, invitees, or any other person in or about the Premises, caused by or resulting from fire, steam, electricity, gas, water or rain which may leak or flow from or into any part of the Premises, or from the breakage, leakage, obstruction,
or other defects of pipes, sprinklers, wires, appliances, plumbing, air-conditioning or lighting fixtures, whether such damage or injury results from conditions arising upon the Premises, any other portion of the Property, or other sources, provided
that such damage or injury is not caused by the negligence or willful misconduct of Landlord or its agents, employees, invitees, licensees and contractors </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(except as otherwise provided in the last sentence of subsection 6.5(a)). Landlord shall not be liable to Tenant or any other person or entity for any damages arising from any act or omission of
any other tenant of the Building. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.5 <U>Tenant&#146;s Insurance</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Tenant shall maintain the following insurance at its own expense throughout the Term: (i)&nbsp;Property insurance including standard fire and extended
coverage insurance, vandalism and malicious mischief endorsements, and &#147;all-risks&#148; coverage upon all property owned by Tenant and located in the Building, in the full replacement cost thereof; (ii)&nbsp;Commercial General Liability
Insurance against any liability arising out of the use, occupancy or maintenance of the Premises or the Property, which insurance may be by a blanket insurance policy and shall provide the following coverages and endorsements: personal injury, broad
form property damage, automobile (by separate policy, if necessary), premises/operations, additional insured landlord endorsement, broad form contractual liability and a cross-liability endorsement, in limits not less than Two Million Dollars
($2,000,000.00) per occurrence, with a deductible not to exceed One Hundred Thousand Dollars ($100,000.00); (iii)&nbsp;any other forms of insurance as Landlord may reasonably require from lime lo time in form, in amounts and for insurance risks
against which a prudent tenant would protect itself in similar facilities in the general area of the Premises. Tenant acknowledges and agrees that such property owned by Tenant shall be at the sole risk and hazard of Tenant, and if the whole or any
part thereof shall be destroyed or damaged by fire, water or otherwise, or by the leakage or bursting of water pipes, steam pipes, or other pipes, by theft or from any other cause, no part of said loss or damage is to be charged to or be borne by
Landlord regardless of any fault of Landlord. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) All policies shall (i)&nbsp;be taken out with insurers reasonably acceptable to Landlord, in form
satisfactory to Landlord, and (ii)&nbsp;include Landlord and any mortgagee of Landlord as additional insureds, as their interests may appear. Landlord may upon ninety (90)&nbsp;days&#146; notice to Tenant require an increase of the limits of the
policies carried by Tenant if Landlord reasonably deems such limits to be inadequate when compared to the then existing customary insurance practice in the area. Tenant shall provide certificates of insurance in form satisfactory to Landlord before
the Commencement Date, and shall provide certificates evidencing renewal in a timely manner before the expiration of any such policy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) Upon
termination of this Lease pursuant to any casualty, Tenant shall retain any proceeds attributable to Tenant&#146;s personal property, trade fixtures, movable partitions, equipment and Alterations not affixed to the Premises, but Tenant shall
immediately pay to Landlord any insurance proceeds received by Tenant relating to the Leasehold Improvements and any Alterations affixed to the Premises unless Landlord has required their removal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.6 <U>Right of Entry</U>. Subject to the provisions of <U>Section&nbsp;5.5</U> hereof, Tenant shall permit Landlord and its agents to examine the Premises at
reasonable times and to make any repairs or replacements Landlord deems necessary; to remove, at Tenant&#146;s expense, after reasonable notice to Tenant (except in the case of an emergency in which no notice shall be required), any Alterations,
signs, curtains, blinds or the like not consented to by Landlord; and to show the Premises to prospective tenants during the last nine (9)&nbsp;months of the Term and to prospective purchasers and mortgagees at all times. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.7 <U>Payment of Taxes</U>. Tenant shall pay before delinquency all taxes levied against Tenant&#146;s personal
property or trade fixtures in the Premises and any Alterations installed by or on behalf of Tenant. If any such taxes are levied against Landlord or its property, or if the assessed value of the Premises is increased by the inclusion of a value
placed on Tenant&#146;s property, Landlord may pay such taxes, and Tenant shall upon demand repay to Landlord the portion of such taxes resulting from such increase. Tenant may bring suit against the taxing authority to recover the amount of any
such taxes, and Landlord shall cooperate therein. The records of the City Assessor shall determine the assessed valuation, if available and sufficiently detailed. If not so available or detailed, the actual cost of construction shall be used. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.8 <U>Environmental Compliance</U>. Tenant shall not cause any hazardous or toxic wastes, hazardous or toxic substances or hazardous or toxic materials
(collectively, &#147;Hazardous Materials&#148;) to be used, generated, stored or disposed of on, under or about, or transported to or from, the Premises (collectively, &#147;Hazardous Materials Activities&#148;) without first receiving
Landlord&#146;s written consent, which may be withheld for any reason and revoked at any time. If Landlord consents to any such Hazardous Materials Activities, Tenant shall conduct them in strict compliance (at Tenant&#146;s expense) with all
applicable Regulations, as hereinafter defined, and using all necessary and appropriate precautions. Landlord shall not be liable to Tenant for any Hazardous Materials Activities by Tenant, Tenant&#146;s employees, agents, contractors, licensees or
invitees, whether or not consented to by Landlord. Tenant shall indemnify, defend with counsel acceptable to Landlord and hold Landlord harmless from and against any claims, damages, costs and liabilities arising out of Tenant&#146;s Hazardous
Materials Activities. For purposes hereof, Hazardous Materials shall include but not be limited to substances defined as &#147;hazardous substances,&#148; &#147;toxic substances,&#148; or &#147;hazardous wastes&#148; in the federal Comprehensive
Environmental Response, Compensation and Liability Act of 1980, as amended; the federal Hazardous Materials Transportation Act, as amended; and the federal Resource Conservation and Recovery Act, as amended (&#147;RCRA&#148;); those substances
defined as &#147;hazardous wastes&#148; in the Massachusetts Hazardous Waste Facility Siting Act, as amended (Massachusetts General Laws Chapter 21D); those substances defined as &#147;hazardous materials&#148; or &#147;oil&#148; in Massachusetts
General Laws Chapter 2IE, as amended; and as such substances are defined in any regulations adopted and publications promulgated pursuant to said laws (collectively, &#147;Regulations&#148;). Prior to using, storing or maintaining any Hazardous
Materials on or about the Premises, Tenant shall provide Landlord with a list of the types and quantities thereof, and shall update such list as necessary for continued accuracy. Tenant shall also provide Landlord with a copy of any Hazardous
Materials inventory statement required by any applicable Regulations, and any update filed in accordance with any applicable Regulations. If Tenant&#146;s activities violate or create a risk of violation of any Regulations, Tenant shall cease such
activities immediately upon notice from Landlord. Tenant shall immediately notify Landlord both by telephone and in writing of any spill or unauthorized discharge of Hazardous Materials or of any condition constituting an imminent hazard under any
Regulations. Landlord, Landlord&#146;s representatives and employees may enter the Premises at any time during the Term to inspect Tenant&#146;s compliance herewith, and may disclose any violation of any Regulations to any governmental agency with
jurisdiction. Nothing herein shall prohibit Tenant from using minimal quantities of cleaning fluid and office supplies which may constitute Hazardous Materials but which are customarily present in premises devoted to office use, provided that such
use is in compliance with all applicable laws and subject to all of the other provisions of this <U>Section&nbsp;6.8</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE VII DEFAULT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.1 <U>Events of Default</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) The occurrence of any one or
more of the following events shall constitute a default hereunder by Tenant: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The failure by Tenant to make any payment of Base Rent
or additional rent or any other payment required hereunder, as and when due, where such failure shall continue for a period of five (5)&nbsp;business days after written notice thereof from Landlord to Tenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The vacating or abandonment of the Premises by Tenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) The failure by Tenant to observe or perform any of the express or implied covenants or provisions of this Lease to be observed or
performed by Tenant, other than as specified in clauses (i)&nbsp;and (ii)&nbsp;above, where such failure shall continue for a period of more than thirty (30)&nbsp;days after written notice thereof from Landlord to Tenant; provided, however, that if
the nature of Tenant&#146;s default is such that more than thirty (30)&nbsp;days are reasonably required for its cure, then Tenant shall not be deemed to be in default if Tenant shall commence such cure within said thirty-day period and thereafter
diligently prosecute such cure to completion, which completion shall occur not later than ninety (90)&nbsp;days from the date of such notice from Landlord. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) The failure by Tenant or any guarantor of any of Tenant&#146;s obligations under this Lease to pay its debts as they become due, or
Tenant or any such guarantor becoming insolvent, filing or having filed against it a petition under any chapter of the United States Bankruptcy Code, 11 U.S.C. Section&nbsp;101 <U>et seq</U>. (or any similar petition under any insolvency law of any
jurisdiction), proposing any dissolution, liquidation, composition, financial reorganization or recapitalization with creditors, making an assignment or trust mortgage for the benefit of creditors, or if a receiver, trustee, custodian or similar
agent is appointed or takes possession with respect to any property or business of Tenant or such guarantor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) In the event of any such default by
Tenant, whether or not the Term shall have begun, in addition to any other remedies available to Landlord at law or in equity, Landlord shall have the immediate option, or the option at any time while such default exists and without further notice,
to terminate this Lease and all rights of Tenant hereunder by notice to Tenant; and this Lease shall thereupon come to an end as fully and completely as if the date such notice is given were the date herein originally fixed for the expiration of the
Term, and Tenant shall then quit and surrender the Premises to Landlord, but Tenant shall remain liable as hereinafter provided. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.2 <U>Damages</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) In the event that this Lease is terminated under any of the provisions contained in <U>Section&nbsp;7.1</U> or shall be otherwise terminated for breach of
any obligation of Tenant, Tenant covenants to pay forthwith to Landlord, as compensation, the excess of the total rent reserved for the residue of the Term over the rental value of the Premises for said residue of the Term. In calculating the rent
reserved there shall be included, in addition to the Base Rent and all additional rent, the value of all other considerations agreed to be paid or performed by Tenant for said residue. Tenant further covenants as an additional and cumulative
obligation after any such termination to pay </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
punctually to Landlord all the sums and perform all the obligations which Tenant covenants in this Lease to pay and to perform in the same manner and to the same extent and at the same time as if
this Lease had not been terminated. In calculating the amounts to be paid by Tenant under the immediately preceding covenant Tenant shall be credited with any amount paid to Landlord as compensation as in this <U>Section&nbsp;7.2</U> provided and
also with the net proceeds of any rent obtained by Landlord by reletting the Premises, after deducting all Landlord&#146;s reasonable expenses in connection with such reletting, including, without limitation, all repossession costs, brokerage
commissions, fees for legal services and expenses of preparing the Premises for such reletting, it being agreed by Tenant that Landlord may (i)&nbsp;relet the Premises or any part or parts thereof, for a term or terms which may at Landlord&#146;s
option be equal to or less than or exceed the period which would otherwise have constituted the balance of the Term and may grant such concessions and free rent as Landlord in its sole judgment considers advisable or necessary to relet the same, and
(ii)&nbsp;make such alterations, repairs and decorations in the Premises as Landlord in its sole judgment considers advisable or necessary to relet the same, and no action of Landlord in accordance with the foregoing or failure to relet or to
collect rent under reletting shall operate or be construed to release or reduce Tenant&#146;s liability as aforesaid, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) In lieu of any other damages or
indemnity and in lieu of full recovery by Landlord of all sums payable under all the foregoing provisions of this <U>Section&nbsp;7.2</U>, Landlord may by written notice to Tenant, at any time after this Lease is terminated under any of the
provisions contained in <U>Section&nbsp;7.1</U> or is otherwise terminated for breach of any obligation of Tenant and before such full recovery, elect to recover, and Tenant shall thereupon pay, as liquidated damages, an amount equal to the
aggregate of the Base Rent and additional rent accrued under <U>Sections 3.1</U> and <U>3.2</U> in the 12 months ended next prior to such termination plus the amount of Base Rent and additional rent of any kind accrued and unpaid at the time of
termination and less the amount of any recovery by Landlord under the foregoing provision of this <U>Section&nbsp;7.2</U> up to the time of payment of such liquidated damages. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) Nothing contained in this Lease shall limit or prejudice the right of Landlord to prove for and obtain in proceedings for bankruptcy or insolvency by
reason of the termination of this Lease, an amount equal to the maximum allowed by any statute or rule of law in effect at the time when, and governing the proceedings in which, the damages are to be provided, whether or not the amount be greater,
equal to, or less than the amount of the loss or damages referred to above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Landlord&#146;s remedies under this Lease are cumulative and not
exclusive of any other remedies to which Landlord may be entitled in case of Tenant&#146;s breach or threatened breach of this Lease. Landlord shall be entitled to the remedies of injunction and specific performance with respect to any such breach.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE VIII CASUALTY AND EMINENT DOMAIN </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.1 <U>Termination or Restoration; Rent Adjustment</U>. In case prior to or during the Term all or any part of the Premises or the Building or the Lot are
damaged by fire or other casualty or by action of public or other authority in consequence thereof, or taken by eminent domain or Landlord receives compensable damage by reason of anything lawfully done in pursuance of public or other authority to
such an extent that it is determined by the Landlord that the Premises or Building shall not be restored, this Lease shall by notice to Tenant from Landlord terminate, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which may be made notwithstanding Landlord&#146;s entire interest may have been divested. The effective date of termination specified by Landlord shall not be less than forty-five (45)&nbsp;nor
more than ninety (90)&nbsp;days after the date of notice of such termination. Further, during the Term, in the event of (a)&nbsp;damage to the Premises which makes a material portion of the Premises unfit for use and occupancy, or (b)&nbsp;damage to
a material portion of the common facilities necessary for the practical use and enjoyment of the Premises (including, without limitation, any material portion of the common facilities which provide access to the Premises), or (c)&nbsp;a permanent
taking of a material portion of the Premises, or (d)&nbsp;a permanent taking of a material portion of the common facilities necessary for the practical use and enjoyment of the Premises (including, without limitation, any material portion of the
common facilities which provide access to the Premises), Tenant may, by notice given to Landlord within 30 days of such casualty or taking, notify Landlord of its desire to terminate this Lease. If such a notice is given, this Lease shall terminate
90 days after such notice is given unless, in the case of (a)&nbsp;or (b)&nbsp;above, within 90 days of the giving of such notice, Landlord delivers to Tenant its certification (a &#147;Landlord&#146;s Restoration Certification&#148;) that the
Landlord intends to restore the Premises and the common facilities, as the case may be, to substantially the condition they were in prior to such casualty or taking within 365 days of the event giving rise to such notice (the &#147;Outside
Restoration Date&#148;), and in the case of (d)&nbsp;above, the Landlord intends to replace what remains of the common facilities by the Outside Restoration Date so that Tenant will again be able to have the practical use and enjoyment of the
Premises to substantially the same extent as prior to such taking. Unless terminated pursuant to the foregoing provision, this Lease shall remain in full force and effect following any damage or taking, subject, however, to the following provisions,
and subject further to the additional right of Tenant to terminate this Lease if the restoration of the Premises or the common facilities has not occurred by the Outside Restoration Date (such date being extended by the number of days, not to exceed
90 in the aggregate, specified in a notice or notices given from time to time by Landlord to Tenant prior to the then applicable Outside Restoration Date, of delays in completion attributable to the occurrence of a Force Majeure Event). Tenant may
not exercise such additional right to terminate this Lease except within 30 days after the Outside Restoration Date (as so extended by such a notice or notices). Notwithstanding the foregoing, upon the occurrence of a casualty or taking of the
nature hereinabove described in clauses (a), (b), (c)&nbsp;or (d), which occurs within the last thirty (30)&nbsp;months of the Term, Landlord shall have the option to terminate this Lease upon written notice to Tenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If in any such case the Premises or any portion thereof are rendered unfit for use and occupation or any portion of the common facilities necessary for the
practical use and enjoyment of the Premises are unavailable for use and this Lease is not so terminated, Landlord shall use due diligence (following the expiration of the period in which this Lease may be terminated pursuant to the foregoing
provisions of this <U>Section&nbsp;6.1.2</U>), subject to the availability of insurance proceeds and consent of the holders of any mortgages on the Lot, Building or both, to put the Premises, and any portion of the common facilities necessary for
the practical use and enjoyment of the Premises or in case of a taking what may remain thereof (excluding in case of both damage and taking any items installed or paid for by Tenant), into proper condition for use and occupation. A just proportion
of the fixed rent and additional rent according to the nature and extent of the injury shall be abated from the time of the damage or taking until the Premises or such portion of the common facilities or such remainder shall have been put into
proper condition for use and occupation or until termination of this Lease, and in case of a taking which permanently reduces the area of the Premises, a just proportion of the fixed rent and additional rent shall be abated for the remainder of the
Term. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.2 <U>Eminent Domain Damages</U>. Landlord reserves to itself any and all rights to receive awards made for
damages to the Premises and Building and Lot and the leasehold hereby created, or any one or more of them, accruing by reason of exercise of eminent domain or by reason of anything lawfully done in pursuance of public or other authority. Tenant
hereby releases and assigns to Landlord all Tenant&#146;s rights to such awards, and covenants to deliver such further assignments and assurances thereof as Landlord may from time to time request, hereby irrevocably designating and appointing
Landlord as its attorney-in-fact to execute and deliver in Tenant&#146;s name and behalf all such further assignments thereof. Nothing contained herein shall be deemed to preclude Tenant from obtaining, or to give Landlord any interest in, any
separate award to Tenant for loss or damage to Tenant&#146;s removable personal property or Tenant&#146;s relocation costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.3 <U>Temporary Taking</U>.
In the event of any taking of the Premises or any part thereof for temporary use, (i)&nbsp;this Lease shall be and remain unaffected thereby and rent shall not abate, and (ii)&nbsp;Tenant shall be entitled to receive for itself such portion or
portions of any award made for such use with respect to the period of the taking which is within the Term, provided that if such taking shall remain in force at the expiration or earlier termination of this Lease, Tenant shall then pay to Landlord a
sum equal to the reasonable cost of performing Tenant&#146;s obligations under <U>Section&nbsp;6.1</U> with respect to surrender of the Premises and upon such payment shall be excused from such obligations. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE IX RIGHTS OF PARTIES HOLDING PRIOR INTERESTS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9.1 <U>Lease Subordinate - Superior</U>. This Lease shall be subject and subordinate to any mortgage (&#147;Mortgage&#148;) now or hereinafter placed on the
Lot, the Building, or both, or any portion or portions thereof or interest therein, which are separately and together hereinafter in this Article IX referred to as &#147;the mortgaged premises&#148;, and to each advance made or hereafter to be made
under any Mortgage, and to all renewals, modifications, consolidations, replacements and extensions thereof and all substitutions therefor, provided, however, that conditioned upon Tenant not being in default under any of the terms of this Lease,
subsequent to the Commencement Date and upon Tenant&#146;s delivery of an estoppel certificate accepting the Premises and acknowledging that Landlord has completed the Leasehold Improvements in accordance with the provisions hereof, Landlord shall
use reasonable efforts to obtain from any such mortgagee on Tenant&#146;s behalf an agreement on the part of such mortgagee to recognize this Lease and all of Tenant&#146;s rights hereunder as though this Lease were prior to any such mortgage,
provided further, however, that the mortgagee, or any purchaser at a foreclosure sale or otherwise shall not be: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) liable for any act or omission of a
prior Landlord (including the mortgagor); or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) subject to any offset or defenses which the Tenant might have against any prior Landlord (including the
mortgagor); or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) bound by any rent or additional rent which the Tenant might have paid in advance to any prior Landlord
(including the mortgagor) for any period beyond the month in which foreclosure or sale occurs; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) bound by any security deposit which Tenant may have
paid to any prior Landlord (including the mortgagor), unless such deposit is in an escrow fund available to the mortgagee; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) bound by any agreement
or modification of the Lease made without the consent of the mortgagee; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) bound by the provisions of <U>Section&nbsp;4.1</U> hereof; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(g) bound by any notice of termination given by any prior Landlord (including the mortgagor) without the mortgagee&#146;s written consent thereto; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(h) personally liable under this Lease and the mortgagee&#146;s liability under the Lease shall be limited to the ownership interest of the mortgagee in the
Premises; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) liable for any fact or circumstance or condition to the extent existing or arising prior to the mortgagee&#146;s (or such
purchaser&#146;s) succession to the interest of the Landlord under the Lease and such mortgagee or such purchaser further shall not be liable except during that period of time, if any, in which such mortgagee or purchaser and Tenant are in privity
of estate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that any mortgagee or its successor in title shall succeed to the interest of Landlord, then, Tenant shall and does hereby agree
to attorn to such mortgagee or successor and to recognize such mortgagee or successor as its Landlord. Any claim by Tenant under the Lease against the mortgagee or such successor shall be satisfied solely out of the mortgagee&#146;s or such
successor&#146;s interest in the Premises and Tenant shall not seek recovery against or out of any other assets of mortgagee or such successor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, any mortgagee may at its election subordinate its Mortgage to this Lease without the consent or approval of Tenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This <U>Section&nbsp;9.1</U> shall be self-operative. Tenant agrees to execute and deliver promptly any appropriate certificates or instruments requested by
Landlord or any mortgagee to carry out the subordination and attornment agreements contained in this <U>Section&nbsp;9.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9.2 <U>Rights of Mortgagee
to Cure</U>. No act or failure to act on the part of Landlord which would entitle Tenant, under the terms of this Lease or as a matter of law, to be released from Tenant&#146;s obligations hereunder or to terminate this Lease shall result in a
release of such obligations or a termination of this Lease unless Tenant first gives written notice of and a specific description of Landlord&#146;s act or failure to act to Landlord&#146;s mortgagees of whom Tenant has been given written notice by
Landlord, if any, and such mortgagee fails to cure such default within thirty (30)&nbsp;days after receipt of such notice. However, if such cure reasonably requires more than thirty days to effect, such mortgagee shall have such additional time as
is reasonably necessary in the circumstances, including time to take possession of the Property. This section shall not impose any obligation on any such mortgagee. Landlord shall, from time to time, notify Tenant as to the identity of
Landlord&#146;s mortgagees; provided, however, that Tenant&#146;s execution of estoppel certificates, nondisturbance agreements or similar agreements which identify Landlord&#146;s mortgagee shall be deemed to be notice to Tenant hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE X MISCELLANEOUS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.1 <U>Representations by Tenant</U>. Tenant represents and warrants that any financial statements provided by it to Landlord were true, correct and complete
when provided, and that no material adverse change has occurred since that date that would render them inaccurate or misleading. Tenant represents and warrants that those persons executing this Lease on Tenant&#146;s behalf are duly authorized to
execute and deliver this Lease on its behalf, and that this Lease is binding upon Tenant in accordance with its terms and upon execution of this Lease, Tenant shall deliver evidence of such authority to Landlord in form satisfactory to Landlord.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.2 <U>Notices</U>. Any notice required or permitted hereunder shall be in writing. Communications shall be addressed to Landlord at Landlord&#146;s
Address and to Tenant at Tenant&#146;s Address. Any communication so addressed shall be deemed duly given when delivered by hand, one day after being sent by Federal Express (or other guaranteed one day delivery service) or three days after being
sent by registered or certified mail, return receipt requested. Either party may change its address by giving notice to the other. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.3 <U>No Waiver or
Oral Modification</U>. No provision of this Lease shall be deemed waived by Landlord or Tenant except by a signed written waiver. No consent to any act or waiver of any breach or default, express or implied, by Landlord or Tenant, shall be construed
as a consent to any other act or waiver of any other breach or default. Landlord&#146;s failure to enforce any covenant or condition of this Lease shall not be deemed a waiver thereof, and its failure to enforce any of the Rules and Regulations
against Tenant or any other tenant in the Building shall not be deemed a waiver thereof. The receipt by Landlord of any rent with knowledge of the breach of any covenant of this Lease shall not be deemed a waiver of such breach, and the acceptance
of any rental payment in any amount less than the full sum due shall not constitute a waiver of any claim to the remaining balance. This Lease may not be changed or amended orally, but only by written instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.4 <U>Partial Invalidity</U>. If any provision of this Lease, or the application thereof in any circumstances, shall to any extent be invalid or
unenforceable, the remainder of this Lease shall not be affected thereby, and each provision hereof shall be valid and enforceable to the fullest extent permitted by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.5 <U>Certain Landlord Remedies</U>. If Tenant fails to perform any obligation hereunder, Landlord may, upon ten (10)&nbsp;days prior written notice to
Tenant (except in the case of emergency in which case no notice shall be required), enter the Premises and perform it on Tenant&#146;s behalf. In so doing, Landlord may make any payment of money or perform any other act. All sums so paid by
Landlord, and all incidental costs and expenses, shall be considered additional rent under this Lease and shall be payable to Landlord immediately on demand, together with interest from the date of demand to the date of payment at the &#147;Interest
Rate.&#148; For purposes of this Lease, the Interest Rate shall mean the lesser of the maximum interest rate permitted by law or three&nbsp;(3) percentage points above the then prevailing prime rate as set by Bank of America in its main office in
Boston, MA (or, if such bank ceases to exist, the then largest bank in the Commonwealth of Massachusetts), </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.6 <U>Tenant&#146;s Estoppel Certificate</U>. Within seven (7)&nbsp;days after written request by Landlord,
Tenant shall execute, acknowledge and deliver to Landlord a written statement certifying (a)&nbsp;that this Lease is unmodified and in full force and effect, or is in full force and effect as modified and stating the modifications; (b)&nbsp;the
amount of Base Rent and the date to which Base Rent and additional rent have been paid in advance; (c)&nbsp;the amount of any security deposited with Landlord; and (d)&nbsp;that, to the best of Tenant&#146;s actual knowledge, Landlord is not in
default hereunder or, if Landlord is claimed to be in default, stating the nature of any claimed default, and (e)&nbsp;such other matters as may be reasonably requested by Landlord. Any such statement may be relied upon by a purchaser, assignee or
lender. Tenant&#146;s failure to execute and deliver such statement within the time required shall be a default under this Lease and shall also be conclusive upon Tenant that (3)&nbsp;this Lease is in full force and effect and has not been modified
except as represented by Landlord; (2)&nbsp;there are no uncured defaults in Landlord&#146;s performance and Tenant has no right of offset, counterclaim or deduction against rent; and (3)&nbsp;not more than one month&#146;s Base Rent has been paid
in advance. In connection with any Transfer of this Lease or major corporate financing by Tenant, Landlord shall, within twenty (20)&nbsp;days after written request by Tenant, acknowledge and deliver to Tenant a written statement containing
substantially similar certifications regarding Tenant to those listed above regarding Landlord (provided that Tenant reimburses Landlord for its reasonable legal and other expenses in connection with such request). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.7 <U>Waiver of Subrogation</U>. Landlord and Tenant each hereby waive all rights of recovery against the other and against the officers, employees, agents,
and representatives of the other, on account of loss by or damage to the waiving party or its property or the properly of others under its control, to the extent that such loss or damage is insured against under any insurance policy that either may
have in force at the time of the loss or damage. Each party shall notify its insurers that the foregoing waiver is contained in this Lease. Landlord and Tenant shall cause each insurance policy obtained by each of them to provide that the insurer
waives all right of recovery by way of subrogation against either Landlord or Tenant in connection with any loss or damage covered by such policy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.8
<U>All Agreements; No Representations</U>. This Lease contains all of the agreements of the parties with respect to the subject matter hereof and supersedes all prior dealings between them with respect to such subject matter. Each party acknowledges
that the other has made no representations or warranties of any kind except as may be specifically set forth in this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.9 <U>Brokerage</U>. Each
party represents and warrants that it has not dealt with any real estate broker or agent in connection with this Lease or its negotiation other than the &#147;Brokers&#148; identified in <U>Section&nbsp;1.2</U>. Each party shall indemnify the other
and hold it harmless from any cost, expense, or liability (including costs of suit and reasonable attorneys&#146; fees) for any compensation, commission or fees claimed by any other real estate broker or agent in connection with this Lease or its
negotiation by reason of any act or statement of the indemnifying party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.10 <U>Successors and Assigns</U>. This Lease shall be binding upon and inure
to the benefit of the parties hereto and their respective successors and assigns; provided, however, that the original </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Landlord named herein and each successive owner of the Premises shall be liable only for obligations accruing during the period of their respective ownership; provided further, that Tenant&#146;s
right to make a Transfer shall always be governed by <U>Section&nbsp;6.3</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.11 <U>Construction of Document</U>. This Lease shall be
construed, governed and enforced according to the laws of the state where the Property is located. In construing this Lease, section headings shall be disregarded. Any recitals herein or riders or exhibits attached hereto are hereby incorporated
into this Lease by this reference. Time is of the essence of this Lease and every provision contained herein. The parties acknowledge that this Lease was freely negotiated by both parties, each of whom was represented by counsel; accordingly, this
Lease shall be construed according to the fair meaning of its terms, and not against either party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.12 <U>Disputes Provisions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) If either Landlord or Tenant institutes any action to enforce the provisions of this Lease or to seek a declaration of rights hereunder, the prevailing
party shall be entitled to recover its reasonable attorneys&#146; fees and court costs as part of any award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) Landlord and Tenant hereby waive trial
by jury in any action, proceeding or counterclaim brought by either of the parties hereto against the other, on or in respect to any matter whatsoever arising out of or in any way connected with this Lease, the relationship of Landlord and Tenant
hereunder, Tenant&#146;s use or occupancy of the Premises, and/or claim of injury or damage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.13 <U>Surrender</U>. The voluntary or other surrender of
this Lease by Tenant, or a mutual cancellation thereof, shall not work a merger, and shall, at the option of Landlord, operate as an assignment to it of any or all subleases or subtenancies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.14 <U>Holdover</U>. If Tenant holds over in occupancy of the Premises after the expiration of the Term, Tenant shall become a tenant at sufferance only, at
a rental rate equal to two hundred (150%)&nbsp;percent of the Rent in effect at the end of the Term, and otherwise subject to the terms and conditions herein specified, so far as applicable, and shall be liable for all damages sustained by Landlord
on account of such holding over. This Section shall not operate as a waiver of any right of reentry provided in this Lease, and Landlord&#146;s acceptance of rent after expiration of the Term or earlier termination of this Lease shall not constitute
consent to a holdover or result in a renewal. If Tenant fails to surrender the Premises upon the expiration of the Term or earlier termination despite demand by Landlord to do so, Tenant shall indemnify and hold Landlord harmless from all loss or
liability, including, without limitation, any claim made by any succeeding tenant resulting from such failure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.15 <U>Late Payment</U>. Tenant
acknowledges that the late payment by Tenant to Landlord of any sums due under this Lease will cause Landlord to incur costs not contemplated by this Lease, the exact amount of such costs being extremely difficult and impractical to ascertain.
Therefore, if any Base Rent or other sum due hereunder is not paid on or by the date it is due more than once during any twelve (12)&nbsp;month period, Tenant shall pay to Landlord, as additional rent, the sum of ten percent (10%)&nbsp;of the
overdue amount as a late charge. The overdue amount, if not received within ten days thereafter, shall also bear interest, as additional rent, at the rate of 1.50&nbsp;% simple interest per month, calculated from the date the late charge becomes due
until the date of payment to Landlord. Landlord&#146;s acceptance of any late charge or interest shall not constitute a waiver of Tenant&#146;s default with respect to the overdue amount. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.16 <U>Force Majeure</U>. If Landlord or Tenant is prevented from or delayed in performing any act required of
it hereunder, and such prevention or delay is caused by strikes, labor disputes, inability to obtain labor, materials, or equipment, inclement weather, acts of God, governmental restrictions, regulations, or controls, judicial orders, enemy or
hostile government actions, civil commotion, fire or other casualty, or other causes beyond such party&#146;s reasonable control (collectively, &#147;Force Majeure&#148;), the performance of such act shall be excused for a period equal to the period
of prevention or delay. A party&#146;s financial inability to perform its obligations shall in no event constitute Force Majeure. Nothing in this section shall excuse or delay Tenant&#146;s obligation to pay any rent or other charges due under this
Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.17 <U>Limitation On Liability</U>. In consideration of the benefits accruing hereunder, Tenant hereby covenants and agrees that, in the event
of any actual or alleged failure, breach or default hereunder by Landlord: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) The obligations of Landlord under this Lease do not constitute personal
obligations of the trustees, individual partners, directors, officers or shareholders of Landlord, Landlord&#146;s beneficiary or any constituent partner of Landlord&#146;s beneficiary, and Tenant shall not seek recourse against the trustees,
partners, directors, officers or shareholders of Landlord, Landlord&#146;s beneficiary or any constituent partner of Landlord&#146;s beneficiary or any of their personal assets for satisfaction of any liability with respect to this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) Tenant&#146;s sole and exclusive remedy shall be against the Landlord&#146;s interest in the Property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) Neither Landlord&#146;s beneficiary nor any constituent partner of Landlord&#146;s beneficiary shall be sued, named as a party in any suit or action, or
served with process therein (except if necessary to secure jurisdiction), and neither Landlord&#146;s beneficiary nor any constituent partner of Landlord&#146;s beneficiary shall be required to respond to any service of process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) No judgment will be taken against Landlord&#146;s beneficiary nor any constituent partner of Landlord&#146;s beneficiary, and no writ of execution will be
levied against the assets of Landlord&#146;s beneficiary or any such partner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) These covenants and agreements are enforceable both by Landlord and
also by Landlord&#146;s beneficiary, any constituent partner of Landlord&#146;s beneficiary, and shall bind Tenant and its successors and assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.18
<U>Submission Not An Option</U>. The submission of this Lease or a summary of some or all of its provisions for examination by Tenant does not constitute a reservation of the Premises for Tenant or an offer to lease the Premises to Tenant or the
grant of an option for the Premises to Tenant, notwithstanding any contrary provision of statutory or common law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.19 <U>Security Deposit</U>. Landlord
acknowledges receipt from Tenant of the Security Deposit to be held by Landlord or its agent, as security, for and during the Term, to be returned to Tenant within thirty (30)&nbsp;days after the expiration of the Term or the termination of this
lease provided there exists no breach of any undertaking of Tenant. Upon the occurrence of any default by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Tenant hereunder, Tenant agrees that Landlord may apply all or any part of the Security Deposit together with accrued interest, if any, thereon to any obligation of Tenant hereunder. If all or
any portion of the Security Deposit is applied to any obligation of Tenant hereunder, Tenant shall immediately upon request by Landlord restore the Security Deposit to its original amount. Tenant shall not have the right to call upon Landlord to
apply all or any part of the Security Deposit to cure any default or fulfill any obligation of Tenant, but such use shall be solely in the discretion of Landlord. Upon any conveyance of the Premises by Landlord to Landlord&#146;s grantee or
transferee, the Security Deposit together with accrued interest, if any, thereon may be delivered by Landlord to Landlord&#146;s grantee or transferee. Upon any such delivery, Tenant hereby releases Landlord herein named of any and all liability
with respect to the Security Deposit, its application and return, and Tenant agrees to look solely to such grantee or transferee. It is further understood that this provision shall also apply to subsequent grantees and transferees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.20 <U>Evidence of Authority</U>. Simultaneously with the execution hereof, Tenant shall deliver to Landlord evidence, satisfactory to Landlord&#146;s
counsel, as to the authority of the persons executing this Lease on behalf of Tenant to enter into, execute, deliver and bind Tenant to this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.21
<U>Relocation</U>. Landlord shall have the right, upon not less than 60 days written notice to Tenant, to relocate Tenant, at Landlord&#146;s sole cost, to space of comparable size, fit-up and finish elsewhere in the Building. In no event will
tenant&#146;s cumulative rent be greater than that set forth in this lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.22 <U>Notice of Lease</U>. Tenant agrees not to record this Lease, but
upon request of either party, both parties shall execute and deliver a notice of this Lease in form appropriate for recording or registration, and if this Lease is terminated before the Term expires, an instrument in such form acknowledging the date
of termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.23 <U>Option to Extend</U>. Tenant may elect to extend the Term of this Lease for two (2)&nbsp;one- (1)&nbsp;year periods (the
&#147;Extension Terms&#148;), by giving Landlord written notice of such election no later than six (6)&nbsp;months prior to the then current Term expiration. Failure to give such notice shall make this option null and void. Such extension shall be
upon the terms, covenants, and conditions contained in this Lease except that Base Rent shall be the then fair market rent, but not less than the rent applicable immediately prior to the Extension Term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EXECUTED as a sealed instrument in two or more counterparts on the day and year first above written. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>LANDLORD:</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"><B>FARLEY WHITE KILNBROOK THREE, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Roger W. Altreuter</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Roger W. Altreuter</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Manager</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>TENANT:</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"><B>INOTEK PHARMACEUTICALS CORPORATION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ James G. Ham, III</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">James G, Ham, III</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PREMISES </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Premises consists of a portion of
the 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> floor as shown on the attached Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#147;Premises&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g893535exj_stamp35.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CLEANING SERVICES </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I. CLEANING </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A. Office Area </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Daily: (Monday through Friday 6:00-10:00 p.m.;
holidays excepted). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1. Empty and clean all waste receptacles and ash trays and remove waste materials from the premises; wash receptacles
as necessary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2. Sweep and dust mop all uncarpeted areas using a dust-treated mop. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3. Vacuum all rugs and carpeted areas. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">4. Hand dust and wipe clean with treated cloths all horizontal surfaces including furniture, office equipment, window sills, door ledges, chair
rails, and convector tops, within normal reach. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5. Wash clean all water fountains. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">6. Remove and dust under all desk equipment and telephone and replace same. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">7. Wipe clean all brass and other bright work. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">8. Hand dust all grill work within normal reach. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">9. Upon completion of cleaning, all lights will be turned off and doors locked, leaving the premises in an orderly condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Weekly: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1. Dust coat racks, and the like. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2. Remove all finger marks from private entrance, doors, light switches, and doorways. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quarterly: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dusting not reached in daily
cleaning to include: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">a. Dusting all pictures, frames, charts, graphs, and similar wall hangings. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">b. Dusting all vertical surfaces, such as walls, partitions, doors, and ducts. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">c. Dusting of all pipes, ducts, and high moldings. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">d. Dusting of all Venetian blinds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">B. Lavatories (Common Area) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Daily: (Monday through Friday, inclusive; holidays excepted). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1. Sweep and damp mop floors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2.
Clean all mirrors, powder shelves, dispensers and receptacles, bright work, flushometers, piping, and toilet seat hinges. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3. Wash both
sides of all toilet seats. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">4. Wash all basins, bowls, and urinals. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5. Dust and clean all powder room fixtures. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">6. Empty and clean paper towel and sanitary disposal receptacles. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">7. Remove waste paper and refuse. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">8. Refill tissue holders, soap dispensers, towel dispensers, vending sanitary dispensers; materials to be furnished to landlord. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">9. A sanitizing solution will be used in all lavatory cleaning. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Monthly: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1. Machine scrub lavatory floors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2. Wash all partitions and tile walls in lavatories. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">C. Main Lobby, Elevators, Building Exterior, and Corridors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Daily: (Monday through Friday, inclusive, holidays excepted). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1. Sweep and wash all floors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2.
Wash all rubber mats. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3. Clean elevators, wash or vacuum floors, wipe down walls and doors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">4. Spot clean any metal work inside lobby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5. Spot clean any metal work surrounding building entrance doors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Monthly: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">All resilient tile floors in public
areas to be treated equivalent to spray buffing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">D. Window Cleaning </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Windows of exterior walls will be washed bi-annually. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E. Tenant requiring services in excess of those described above shall request same through landlord, at the Tenant&#146;s expense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FIRST AMENDMENT OF LEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>This FIRST AMENDMENT OF LEASE is entered into this 22<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> day of February, 2013 by and between
<B>Farley White Kilnbrook Three, LLC</B>, having a mailing address at c/o Farley White Management Company, 155 Federal Street, Suite 1800, Boston, MA 02110 (hereinafter called &#147;Landlord&#148;) and <B>Inotek Pharmaceuticals Corporation</B>,
having a mailing address at 131 Hartwell Avenue, Lexington, MA 02421 (hereinafter called &#147;Tenant&#148;)<B> </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Witnesseth:
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A. Landlord and Tenant entered into a certain lease dated May&nbsp;11, 2012 (the &#147;Lease&#148;) consisting of approximately 2,440 rentable square
feet on the 1st floor of 131 Hartwell Avenue (the &#147;Premises&#148;), all as more particularly described therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">B. Landlord and Tenant desire to
amend the Lease in the manner set forth below. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Term of the Lease is hereby extended and shall expire on December&nbsp;31, 2013. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">For the extended term, Tenant shall continue to pay Base Rent of $51,240.00 per annum payable in equal monthly installments of $4,279.00. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as specifically amended by the terms of this First Amendment of Lease, all of the terms, conditions and provisions of the Lease shall remain in full
force and effect throughout the Term of the Lease. From and after the date hereof, the Lease and this First Amendment of Lease shall collectively be referred to as the &#147;Lease.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of this date, the parties acknowledge that neither has a claim for damage or liability of any kind pursuant to this Lease, as amended, or at law or equity,
and the parties hereby agree to release and hold each other harmless from and against all suits, liabilities, obligations or claims of any kind or any matters arising prior to this date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WITNESS THE EXECUTION HEREOF</B>, under seal, as of the date set forth above, in any number of counterpart copies, each of which counterpart copies shall
be deemed an original for all purposes.<B> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>LANDLORD:</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"><B>Farley White Kilnbrook Three, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Roger W. Altreuter</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Its:</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>TENANT:</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"><B>Inotek Pharmaceuticals Corporation</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ James G. Ham, III</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">James G. Ham, III</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECOND AMENDMENT TO LEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS SECOND AMENDMENT TO LEASE (this &#147;<U>Second Amendment</U>&#148;), dated as of August 14, 2013, is entered into by and between WLC
Three VI, L.L.C., a Delaware limited liability company (&#147;<U>Landlord</U>&#148;), successor-in-interest to Farley White Kilnbrook Three, LLC, a Massachusetts limited liability company, and Inotek Pharmaceuticals Corporation, a Delaware
corporation (&#147;<U>Tenant</U>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">W I T N E S S E T H </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Landlord and Tenant are parties to that certain Lease dated as of May&nbsp;11, 2012, as amended by that certain First Amendment of
Lease dated as of February&nbsp;22, 2013 (the &#147;<U>First Amendment</U>&#148;) (as so amended, the &#147;<U>Lease</U>&#148;) with respect to the premises measuring approximately 2,440 rentable square feet (the &#147;<U>Premises</U>&#148;) located
on the first (1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>)&nbsp;floor of the building located at 131 Hartwell Avenue, Lexington, MA 02421 (the &#147;<U>Building</U>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Landlord and Tenant wish to modify and amend the Lease subject to the terms and conditions set forth below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the covenants herein reserved and contained, and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"><U>Term and Expiration Date</U>. The Term of the Lease is presently due to expire on December&nbsp;31, 2013. Section&nbsp;1.2 (k)&nbsp;of the Lease shall be amended to provide that the Term of the Lease shall be
extended from January&nbsp;1, 2014 through December&nbsp;31, 2014 (the &#147;<U>Expiration Date</U>&#148;). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"><U>Base Rent</U>. Commencing on January&nbsp;1, 2014, Tenant shall pay Base Rent in the amount set forth on Exhibit &#147;A&#148; of this Second Amendment and pursuant to Section&nbsp;3.1 of the Lease.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"><U>Extension Option</U>. Section&nbsp;10.23 of the Lease is restated in its entirety to read: </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Provided that Tenant is not in an event of default beyond any applicable cure period, Tenant may elect to extend the Term of this Lease from
January&nbsp;1, 2015 through December&nbsp;31, 2015 (the &#147;<U>Extension Term</U>&#148;) by giving Landlord written notice of such election no later than June&nbsp;30, 2014. Failure to give such notice shall make this option the (the
&#147;<U>Extension Option</U>&#148;) null and void. The Extension Option shall be upon the terms, covenants, and conditions contained in this Lease, except that the Base Rent for the Extension Term shall be the then fair market rent, but not less
than the Base Rent payable immediately prior to the Extension Term. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><U>Other Options</U>. Tenant acknowledges and agrees that, other than the Extension Option set forth in this Second Amendment, Tenant has no
(a)&nbsp;options or rights to extend the </P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Term of the Lease, (b)&nbsp;options, rights of first offer, rights of first refusal, or other rights to expand the rentable square feet comprising the Premises or lease any other premises in the
Building, or (c)&nbsp;options to terminate the Lease or contract the rentable square feet comprising the Premises. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"><U>Landlord&#146;s Address</U>. Effective immediately, Section&nbsp;1.2(b) of the Lease shall be amended to provide that Landlord&#146;s Address shall be: </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If&nbsp;to&nbsp;Landlord:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">WLC Three VI, L.L.C.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">c/o Walton Street Capital LLC</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">900 North Michigan Avenue, Suite 1900</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Chicago, IL 60611</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Attention: James Holmes</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">With&nbsp;a&nbsp;copy&nbsp;to:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Griffith Properties LLC</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">260 Franklin Street, 5<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Boston, MA 02110</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Attention: Marci G. Loeber</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"><U>Tenant&#146;s Address</U>. Effective immediately, Section&nbsp;1.2(d) of the Lease shall be amended to provide that Tenant&#146;s Address shall be: </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to Tenant:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Inotek Pharmaceuticals Corporation</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">131 Hartwell Avenue, 1st Floor</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Lexington, MA 02421</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Attention: James G. Ham, III</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"><U>Brokers</U>. Except for CB Richard Ellis (representing Landlord exclusively), each party represents and warrants to the other that they have not made any agreement or taken any action which may cause anyone to become
entitled to a commission as a result of the transactions contemplated by this Second Amendment, and each will indemnify and defend the other from any and all claims, actual or threatened, for compensation by any such third person by reason of such
party&#146;s breach of their representation or warranty contained in this Second Amendment Landlord will pay any commission due to the broker(s) hereunder pursuant to its separate agreement with the broker(s) hereunder subject to execution and
delivery of this Second Amendment by Landlord and Tenant. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top">The Lease shall be modified such that each reference to the Lease contained therein shall be deemed to refer to the Lease as amended by this Second Amendment. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top">Except as specifically modified or amended herein, the Lease remains unchanged and in full force and effect and is hereby ratified and confirmed in every respect. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top">In the event of a conflict between this Second Amendment and the Lease, this Second Amendment shall control. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top">Capitalized terms used in this Second Amendment but not defined in this Second Amendment have the meanings ascribed to them in the Lease. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top">This Second Amendment shall not be effective until it has been duly executed by the parties hereto. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top">This Second Amendment may be executed in counterparts, which taken together shall constitute one and the same instrument. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top">Additional terms to this Second Amendment, if any, are set forth in the attached Exhibits, which are incorporated herein by reference as follows: </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Exhibit A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Base Rent </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[END OF TEXT; SIGNATURES FOLLOW ON NEXT PAGE.] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Landlord and Tenant have caused this Second Amendment to be executed as of the date set forth
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="19"><B>LANDLORD:</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="19"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="19"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WLC THREE VI, L.L.C.</B>,<B></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a Delaware limited liability company</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="18"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="17">WLC Equity VI, L.L.C.,</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="17"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Delaware limited liability company,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">its Sole Member</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="15">WLC-G Holdings VI, L.L.C.,</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="15"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Delaware limited liability company,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">its Sole Member</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="14"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="13">WLC Investors VI, L.L.C.,</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="13"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Delaware limited liability company,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">its Member</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="12"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="11">Walton REIT Holdings B-VI, L.L.C.,</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="11"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Delaware limited liability company,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">its Sole Member</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="10"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="9">Walton REIT B-VI, L.L.C.,</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="9"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Delaware limited liability company,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">its Managing Member</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="7">Walton Street Real Estate Fund VI-Q, L.P.,</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="7"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Delaware limited partnership,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">its
Managing Member</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="5">Walton Street Managers VI, L.P.,</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Delaware limited partnership,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">its
General Partner</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3">WSC Managers VI, Inc.,</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Delaware corporation,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">its General
Partner</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ James J. Holmes</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ James J. Holmes</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Vice President</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[COUNTERPART SIGNATURE
PAGE TO SECOND AMENDMENT] </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TENANT:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INOTEK PHARMACEUTICALS CORPORATION</B>,<B></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a Delaware corporation</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ William K. McVicar</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">William K. McVicar</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">EVP, Chief Scientific Officer</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[COUNTERPART SIGNATURE
PAGE TO SECOND AMENDMENT] </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT &#147;A&#148; </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BASE RENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="12" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>PREMISES</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(2,440 RSF)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:22.65pt; font-size:8pt; font-family:Times New Roman"><B>Period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Annual&nbsp;Base&nbsp;Rent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Monthly&nbsp;Base&nbsp;Rent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;RSF</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&nbsp;1, 2014 - December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,680.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,473.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THIRD AMENDMENT TO LEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS THIRD AMENDMENT TO LEASE (this &#147;<U>Third Amendment</U>&#148;), dated as of August 14, 2014, is entered into by and between WLC Three
VI, L.L.C., a Delaware limited liability company (&#147;<U>Landlord</U>&#148;) and Inotek Pharmaceuticals Corporation, a Delaware corporation (&#147;<U>Tenant</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">W I T N E S S E T H </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS,
Farley White Kilnbrook Three, LLC, a Massachusetts limited liability company (&#147;<U>Original Landlord</U>&#148;), as landlord, and Tenant, as tenant, entered into that certain Lease dated as of May&nbsp;11, 2012 (the &#147;<U>Original
Lease</U>&#148;), as amended by (a)&nbsp;that certain First Amendment of Lease dated as of February&nbsp;22, 2013 by and between Original Landlord, as landlord, and Tenant, as tenant (the &#147;<U>First Amendment</U>&#148;) and (b)&nbsp;that certain
Second Amendment to Lease dated as of August&nbsp;14, 2013 by and between Landlord, as landlord, and Tenant, as tenant (the &#147;<U>Second Amendment</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Original Lease, as amended by the First Amendment and the Second Amendment, shall be known as the &#147;<U>Lease</U>&#148;; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Lease relates to premises measuring approximately 2,440 rentable square feet (the &#147;<U>Premises</U>&#148;) located on the
first (1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>)&nbsp;floor of the building known as 131 Hartwell Avenue, Lexington, MA 02421 (the &#147;<U>Building</U>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Landlord and Tenant wish to modify and amend the Lease subject to the terms and conditions set forth below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the covenants herein reserved and contained, and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"><U>Term and Expiration Date</U>. The Term of the Lease is presently due to expire on December&nbsp;31, 2014. The Term of the Lease shall be extended from January&nbsp;1, 2015 through March&nbsp;31, 2015 (the
&#147;<U>Expiration Date</U>&#148;). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"><U>Base Rent</U>. Tenant shall continue to pay Base Rent in the amount set forth on Exhibit &#147;A&#148; of the Second Amendment and pursuant to Section&nbsp;3.1 of the Original Lease. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"><U>Extension Option</U>. Tenant acknowledges and agrees that Section&nbsp;10.23 of the Original Lease, as amended by Section&nbsp;3 of the Second Amendment, is hereby deleted in its entirety, and is of no further force
or effect. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"><U>Other Options</U>. Tenant acknowledges and agrees that Tenant has no (a)&nbsp;options or rights to extend the Term of the Lease, (b)&nbsp;options, rights of first offer, rights of first refusal, or other rights to
expand the rentable square feet comprising the Premises or lease any other premises in the Building, or (c)&nbsp;options to terminate the Lease or contract the rentable square feet comprising the Premises. </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"><U>Brokers</U>. Except for CB Richard Ellis (representing Landlord exclusively), each party represents and warrants to the other that they have not made any agreement or taken any action which may cause anyone to become
entitled to a commission as a result of the transactions contemplated by this Third Amendment, and each will indemnify and defend the other from any and all claims, actual or threatened, for compensation by any such third person by reason of such
party&#146;s breach of their representation or warranty contained in this Third Amendment. Landlord will pay any commission due to the broker(s) hereunder pursuant to its separate agreement with the broker(s) hereunder subject to execution and
delivery of this Third Amendment by Landlord and Tenant. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">The Lease shall be modified such that each reference to the Lease contained therein shall be deemed to refer to the Lease as amended by this Third Amendment. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top">Except as specifically modified or amended herein, the Lease remains unchanged and in full force and effect and is hereby ratified and confirmed in every respect. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top">In the event of a conflict between this Third Amendment and the Lease, this Third Amendment shall control. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top">Capitalized terms used in this Third Amendment but not defined in this Third Amendment have the meanings ascribed to them in the Lease. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top">This Third Amendment shall not be effective until it has been duly executed by the parties hereto. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top">This Third Amendment may be executed in counterparts, which taken together shall constitute one and the same instrument. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[END OF TEXT; SIGNATURES FOLLOW ON NEXT PAGE.] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="19"><B>LANDLORD:</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="19"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="19"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WLC THREE VI, L.L.C.</B>,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a
Delaware limited liability company</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="18"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="17">WLC Equity VI, L.L.C.,</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="17"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Delaware limited liability company,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">its Sole Member</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="15">WLC-G Holdings VI, L.L.C.,</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="15"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Delaware limited liability company,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">its Sole Member</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="14"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="13">WLC Investors VI, L.L.C.,</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="13"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Delaware limited liability company,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">its Member</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="12"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="11">Walton REIT Holdings B-VI, L.L.C.,</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="11"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Delaware limited liability company,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">its Sole Member</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="10"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="9">Walton REIT B-VI, L.L.C.,</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="9"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Delaware limited liability company,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">its Managing Member</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="7">Walton Street Real Estate Fund VI-Q, L.P.,</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="7"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Delaware limited partnership,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">its
Managing Member</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="5">Walton Street Managers VI, L.P.,</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Delaware limited partnership,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">its
General Partner</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3">WSC Managers VI, Inc.,</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Delaware corporation,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">its General
Partner</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ James J. Holmes</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ James J. Holmes</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Vice President</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[COUNTERPART SIGNATURE
PAGE TO SECOND AMENDMENT] </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TENANT:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INOTEK PHARMACEUTICALS CORPORATION</B>,<B></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a Delaware corporation</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ William K. McVicar</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">William K. McVicar</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">EVP, Chief Scientific Officer</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[COUNTERPART SIGNATURE
PAGE TO SECOND AMENDMENT] </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>FOURTH AMENDMENT TO LEASE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS FOURTH AMENDMENT TO LEASE (this &#147;<U>Fourth Amendment</U>&#148;), dated as of March&nbsp;3, 2015, is entered into by and between WLC
Three VI, L.L.C., a Delaware limited liability company (&#147;<U>Landlord</U>&#148;) and Inotek Pharmaceuticals Corporation, a Delaware corporation (&#147;<U>Tenant</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">W I T N E S S E T H </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS,
Farley White Kilnbrook Three, LLC, a Massachusetts limited liability company (&#147;<U>Original Landlord</U>&#148;), as landlord, and Tenant, as tenant, entered into that certain Lease dated as of May&nbsp;11, 2012 (the &#147;<U>Original
Lease</U>&#148;), as amended by (a)&nbsp;that certain First Amendment of Lease dated as of February&nbsp;22, 2013 by and between Original Landlord, as landlord, and Tenant, as tenant (the &#147;<U>First Amendment</U>&#148;) and (b)&nbsp;that certain
Second Amendment to Lease dated as of August&nbsp;14, 2013 by and between Landlord, as landlord, and Tenant, as tenant (the &#147;<U>Second Amendment</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Landlord and Tenant further amended the Original Lease pursuant to that certain Third Amendment to Lease, dated August&nbsp;14, 2014
(the &#147;<U>Third Amendment</U>&#148;). The Original Lease, as amended by the First Amendment, Second Amendment and Third Amendment, shall be known as the &#147;<U>Lease</U>&#148;; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Lease relates to premises measuring approximately 2,440 rentable square feet (the &#147;<U>Original Premises</U>&#148;) located
on the first (1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>)&nbsp;floor of the building known as 131 Hartwell Avenue, Lexington, MA 02421 (the &#147;<U>Building</U>&#148;) for a Term that is scheduled to expire on March&nbsp;31, 2015; and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Landlord and Tenant wish to enter into this Amendment to (i)&nbsp;relocate Tenant to certain space on the first (1<SUP
STYLE="font-size:85%; vertical-align:top">st</SUP>) floor of the Building containing 3,500 rentable square feet, as more fully shown on <U>Exhibit A</U> to this Amendment (the &#147;<U>New Premises</U>&#148;), and to surrender the Original Premises,
(ii)&nbsp;extend the Term of the Lease; and (iii)&nbsp;amend certain other terms and conditions of the Original Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in
consideration of the covenants herein reserved and contained, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Relocation to New Premises</U>. Landlord hereby agrees to lease to Tenant, and Tenant hereby agrees to lease from Landlord, the New
Premises for a period commencing April&nbsp;1, 2015 (the &#147;<U>New Premises Commencement Date</U>&#148;) and continuing through the Extended Term. The New Premises are hereby leased to Tenant as is, without representation or warranty by Landlord
and Tenant shall have no obligation to perform any improvements or installation to prepare the New Premises for Tenant&#146;s occupancy. On or before the New Premises Commencement Date, Tenant shall, at its sole cost and expense, fully vacate and
surrender the Original Premises and relocate from the Original Premises to the New Premises. Tenant shall vacate and surrender the Original Premises to Landlord in the condition required under Section&nbsp;6.1 of the Lease for surrendering the
Premises at the expiration of the Term. Accordingly, from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and after the New Premises Commencement Date, Tenant&#146;s right to use and occupy the Original Premises and all of Tenant&#146;s obligations under the Original Lease with respect to the
Original Premises (other than obligations that accrued prior to the date Tenant vacates the Original Premises) shall terminate and be of no further force or effect and all references in the Original Lease to the term &#147;Premises&#148; shall be
deemed to refer to the New Premises. Until such date that Tenant is required to surrender the Original Premises, Tenant shall continue to occupy the Original Premises on the same terms and conditions as set forth in the Original Lease. Any holdover
by Tenant in the Original Premises beyond the Surrender Date shall be subject to the provisions of Section&nbsp;10.14 of the Original Lease. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Term</U>. The Term of the Lease is hereby extended for an extended term of six (6)&nbsp;months (the &#147;<U>Extended Term</U>&#148;),
commencing on the New Premises Commencement Date and expiring on September&nbsp;30, 2015. Notwithstanding the foregoing, in the event that Landlord and Tenant execute and deliver a new lease of premises in the building owned by an affiliate of
Landlord and located at 81 Hartwell Avenue (&#147;<U>81 Hartwell Premises</U>&#148;), the Extended Term shall expire on the Commencement Date under the new lease for the 81 Hartwell Premises. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Base Rent</U>. Commencing on the New Premises Commencement Date and thereafter during the Extended Term, the monthly Base Rent under the
Lease shall be equal to $7,291.67, payable by Tenant at the times and in the manner provided in the Lease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Tenant&#146;s
Percentage</U>. Effective as of the New Premises Commencement Date, &#147;<U>Tenant&#146;s Percentage</U>&#148; is hereby amended to be 4.55%. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>81 Hartwell Base Rent Credit.</U> In the event that Landlord and Tenant agree upon the terms for a new lease for the 81 Hartwell
Premises, Landlord agrees that such terms shall include a credit against the Base Rent first due for the 81 Hartwell Premises equal to the product of $583.33 multiplied by the number of months from the date of this Fourth Amendment through the date
that Tenant moves into the 81 Hartwell Premises, such amount to be apportioned for any partial month. By way of example, if there are five and a half months from the date of this Fourth Amendment until the commencement date for the 81 Hartwell
Premises, Tenant shall be entitled to a Base Rent credit equal to $3,208.33. Such rent credit shall be in addition to any rent abatement negotiated by the parties for the 81 Hartwell Premises. If Landlord and Tenant do not execute and deliver a
lease for the 81 Hartwell Premises, Tenant shall have no right to such Base Rent credit, which shall solely apply to the new lease at the 81 Hartwell Premises. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Brokers</U>. Except for CB Richard Ellis (representing Landlord exclusively), each party represents and warrants to the other that they
have not made any agreement or taken any action which may cause anyone to become entitled to a commission as a result of the transactions contemplated by this Fourth Amendment, and each will indemnify and defend the other from any and all claims,
actual or threatened, for compensation by any such third person by reason of such party&#146;s breach of their representation or warranty contained in this Fourth Amendment. Landlord will pay any commission due to the broker(s) hereunder pursuant to
its separate agreement with the broker(s) hereunder subject to execution and delivery of this Fourth Amendment by Landlord and Tenant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. The Lease shall be modified such that each reference to the Lease contained therein shall be
deemed to refer to the Lease as amended by this Fourth Amendment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. Except as specifically modified or amended herein, the Lease remains
unchanged and in full force and effect and is hereby ratified and confirmed in every respect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. In the event of a conflict between this
Fourth Amendment and the Lease, this Fourth Amendment shall control. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. Capitalized terms used in this Fourth Amendment but not defined
in this Fourth Amendment have the meanings ascribed to them in the Lease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. This Fourth Amendment shall not be effective until it has
been duly executed by the parties hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. This Fourth Amendment may be executed in counterparts, which taken together shall constitute
one and the same instrument. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[END OF TEXT; SIGNATURES FOLLOW ON NEXT PAGE.] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Landlord and Tenant have caused this Fourth Amendment for Inotek to be executed as of the
date set forth above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="19"><B>LANDLORD:</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="19"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="19"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WLC THREE VI, L.L.C.</B>,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a
Delaware limited liability company</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="18"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="17">WLC Equity VI, L.L.C.,</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="17"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Delaware limited liability company,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">its Sole Member</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="15">WLC-G Holdings VI, L.L.C.,</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="15"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Delaware limited liability company,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">its Sole Member</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="14"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="13">WLC Investors VI, L.L.C.,</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="13"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Delaware limited liability company,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">its Member</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="12"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="11">Walton REIT Holdings B-VI, L.L.C.,</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="11"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Delaware limited liability company,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">its Sole Member</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="10"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="9">Walton REIT B-VI, L.L.C.,</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="9"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Delaware limited liability company,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">its Managing Member</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="7">Walton Street Real Estate Fund VI-Q, L.P.,</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="7"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Delaware limited partnership,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">its
Managing Member</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="5">Walton Street Managers VI, L.P.,</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Delaware limited partnership,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">its
General Partner</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3">WSC Managers VI, Inc.,</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Delaware corporation,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">its General
Partner</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Laura Weidaw</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Laura Weidaw</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">VP</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[COUNTERPART SIGNATURE PAGE TO FOURTH AMENDMENT] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TENANT:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INOTEK&nbsp;PHARMACEUTICALS&nbsp;CORPORATION.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a Delaware corporation</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dale Ritter</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Dale Ritter</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">VP &#150; Finance</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[COUNTERPART SIGNATURE PAGE TO FOURTH AMENDMENT] </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLAN OF NEW PREMISES </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P>&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center"><B>


<IMG SRC="g893535dsp_053.jpg" ALT="LOGO">
</B> </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>8
<FILENAME>d893535dex1010.htm
<DESCRIPTION>EX-10.10
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.10</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.10 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT
(i)&nbsp;EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii)&nbsp;AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii)&nbsp;RECEIPT OF NO-ACTION LETTERS FROM THE
APPROPRIATE GOVERNMENTAL AUTHORITIES, OR (iv)&nbsp;OTHERWISE COMPLYING WITH THE PROVISIONS OF SECTION 7 OF THIS WARRANT. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>INOTEK
PHARMACEUTICALS CORPORATION </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WARRANT TO PURCHASE SHARES </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OF SERIES PREFERRED STOCK </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Loan
A) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS CERTIFIES THAT, for value received, HORIZON TECHNOLOGY FINANCE CORPORATION and its assignees are entitled to subscribe for and
purchase that number of the fully paid and nonassessable shares of Series Preferred Stock (as adjusted pursuant to Section&nbsp;4 hereof, the &#147;Shares&#148;) of INOTEK PHARMACEUTICALS CORPORATION, a Delaware corporation (the &#147;Company<SUP
STYLE="font-size:85%; vertical-align:top"></SUP>&#148;), as is determined pursuant to the next paragraph hereof at the price per share as is determined pursuant to the next paragraph hereof (such price and such other price as shall result, from time
to time, from the adjustments specified in Section&nbsp;4 hereof is herein referred to as the &#147;Warrant Price&#148;), subject to the provisions and upon the terms and conditions hereinafter set forth. As used herein, (a)&nbsp;the term
&#147;Series Preferred&#148; shall mean, at the holder&#146;s election, either (i)&nbsp;the Company&#146;s presently authorized Series AA Convertible Preferred Stock, par value $0.001 per share (the &#147;Series AA Preferred Stock&#148;) and any
stock into or for which such Series AA Preferred Stock may hereafter be converted or exchanged, and after the automatic conversion of the Series AA Preferred Stock to Common Stock shall mean the Company&#146;s Common Stock, or (ii)&nbsp;the Next
Round Stock (as defined below), and any stock into or for which such Next Round Stock may hereafter be converted or exchanged, and after the automatic conversion of the Next Round Stock to Common Stock shall mean the Company&#146;s Common Stock and
(b)&nbsp;the term &#147;Date of Grant&#148; shall mean June 28, 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Warrant Price shall be (i)&nbsp;if the holder elects to
exercise this Warrant for Series AA Preferred Stock, $1.529 or (ii)&nbsp;if the holder elects to exercise this Warrant for Next Round Stock, the lowest effective price per share (on a common stock equivalent basis and taking into account any
securities issued together with the preferred stock) at which shares of the Company&#146;s convertible preferred stock are sold in a Qualified Financing (the &#147;Next Round Stock&#148;). A &#147;Qualified Financing&#148; shall mean the sale of the
convertible preferred stock of the Company to purchasers which include instititutional investors in an aggregate cash amount not less than $10,000,000. The number of shares for which this Warrant is exercisable shall rounded down to the nearest
whole number determined by dividing One Hundred Seventy-Five Thousand Dollars ($175,000) by the Warrant Price determined pursuant to this paragraph. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Term</U>. The purchase right represented by this Warrant is exercisable, in whole or in
part, at any time and from time to time from the Date of Grant through the earlier of (a)&nbsp;ten (10)&nbsp;years after the Date of Grant and (b)&nbsp;immediately prior to the closing of an Acquisition Transaction (as defined below) in which the
consideration is cash, Marketable Securities or a combination thereof. As used herein, &#147;<B>Marketable Securities</B>&#148; means securities meeting all of the following requirements: (1)&nbsp;the issuer thereof is then subject to the reporting
requirements of Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act, and is then current in its filing of all required reports and other information under the Act and the Exchange Act, (2)&nbsp;the class and series of shares or other security
of the issuer that would be received by the holder of this Warrant in connection with a merger were such holder to exercise or convert this Warrant on or prior to the closing thereof is then traded on a national securities exchange or
over-the-counter market, (3)&nbsp;the issuer thereof has a market cap of at least Seven Hundred Fifty Million Dollars ($750,000,000) and (4)&nbsp;such holder would not be restricted by contract or by applicable federal and state securities laws from
publicly re-selling, within six (6)&nbsp;months and one day following the closing of such Acquisition, all of the issuer&#146;s shares and/or other securities that would be received by such holder in such merger were such holder to exercise or
convert this Warrant in full on or prior to the closing of such merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Method of Exercise; Payment; Issuance of New Warrant</U>.
Subject to Section&nbsp;1 hereof, the purchase right represented by this Warrant may be exercised by the holder hereof, in whole or in part and from time to time, at the election of the holder hereof, by (a)&nbsp;the surrender of this Warrant (with
the notice of exercise substantially in the form attached hereto as Exhibit A-1 duly completed and executed) at the principal office of the Company and by the payment to the Company, by certified or bank check, or by wire transfer to an account
designated by the Company (a &#147;Wire Transfer&#148;) of an amount equal to the then applicable Warrant Price multiplied by the number of Shares then being purchased; (b)&nbsp;if in connection with a registered public offering of the
Company&#146;s securities, the surrender of this Warrant (with the notice of exercise form attached hereto as Exhibit A-2 duly completed and executed) at the principal office of the Company together with notice of arrangements reasonably
satisfactory to the Company for payment to the Company either by certified or bank check or by Wire Transfer from the proceeds of the sale of shares to be sold by the holder in such public offering of an amount equal to the then applicable Warrant
Price per share multiplied by the number of Shares then being purchased; or (c)&nbsp;exercise of the &#147;net issuance&#148; right provided for in Section&nbsp;10.2 hereof. The person or persons in whose name(s) any certificate(s) representing
shares of Series Preferred shall be issuable upon exercise of this Warrant shall be deemed to have become the holder(s) of record of, and shall be treated for all purposes as the record holder(s) of, the shares represented thereby (and such shares
shall be deemed to have been issued) immediately prior to the close of business on the date or dates upon which this Warrant is exercised. In the event of any exercise of the rights represented by this Warrant, certificates for the shares of stock
so purchased shall be delivered to the holder hereof as soon as possible and in any event within thirty (30)&nbsp;days after such exercise and, unless this Warrant has been fully exercised or expired, a new Warrant representing the portion of the
Shares, if any, with respect to which this Warrant shall not then have been exercised shall also be issued to the holder hereof as soon as possible and in any event within such thirty-day period; provided, however, at such time as the Company is
subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, if requested by the holder of this Warrant, the Company shall cause its transfer agent to deliver the certificate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
representing Shares issued upon exercise of this Warrant to a broker or other person (as directed by the holder exercising this Warrant) within the time period required to settle any trade made
by the holder after exercise of this Warrant. Each holder, as a condition to the issuance of shares of Series Preferred upon exercise of this Warrant, shall become party to (i)&nbsp;that certain Third Amended and Restated Investor Rights Agreement,
dated as of June&nbsp;9, 2010, by and between the Company and the persons and entities identified therein, as amended from time to time (the &#147;Investor Rights Agreement&#148;), as an &#147;Investor&#148; for all purposes thereunder by executing
and delivering the Adoption Agreement attached to the Investor Rights Agreement as Schedule I and (ii)&nbsp;that certain Third Amended and Restated Stockholders Agreement, dated as of June&nbsp;9, 2010, by and between the Company and the persons and
entities identified therein, as amended from time to time (the &#147;Stockholders Agreement&#148;), as an &#147;Investor&#148; and &#147;Stockholder&#148; for all purposes thereunder by executing and delivering the Adoption Agreement attached to the
Stockholders Agreement as Schedule III. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Stock Fully Paid; Reservation of Shares</U>. All Shares that may be issued upon the
exercise of the rights represented by this Warrant will, upon issuance pursuant to the terms and conditions herein, be fully paid and nonassessable, and free from all preemptive rights and taxes, liens and charges with respect to the issue thereof.
During the period within which the rights represented by this Warrant may be exercised, the Company will at all times have authorized, and reserved for the purpose of the issue upon exercise of the purchase rights evidenced by this Warrant, a
sufficient number of shares of its Series Preferred to provide for the exercise of the rights represented by this Warrant and a sufficient number of shares of its Common Stock to provide for the conversion of the Series Preferred into Common Stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Adjustment of Warrant Price and Number of Shares.</U> The number and kind of securities purchasable upon the exercise of this
Warrant and the Warrant Price shall be subject to adjustment from time to time upon the occurrence of certain events, as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)<U>
Reclassification or Merger.</U> Except for an Acquisition Transaction that causes an expiration of the term of this Warrant as set forth in Section&nbsp;1 above, in case of any reclassification or change of securities of the class issuable upon
exercise of this Warrant (other than a change in par value, or from par value to no par value, or from no par value to par value, or as a result of a subdivision or combination), or in case of any merger of the Company with or into another
corporation (other than a merger with another corporation in which the Company is the acquiring and the surviving corporation and which does not result in any reclassification or change of outstanding securities issuable upon exercise of this
Warrant), or in case of any sale of all or substantially all of the assets of the Company, the Company, or such successor or purchasing corporation, as the case may be, shall duly execute and deliver to the holder of this Warrant a new Warrant (in
form and substance satisfactory to the holder of this Warrant), so that the holder of this Warrant shall have the right to receive upon exercise of this Warrant, at a total purchase price not to exceed that payable upon the exercise of the
unexercised portion of this Warrant, and in lieu of the shares of Series Preferred theretofore issuable upon exercise of this Warrant, (i)&nbsp;the kind and amount of shares of stock, other securities, money and property receivable upon such
reclassification, change, merger or sale by a holder of the number of shares of Series Preferred then purchasable under this Warrant, or (ii)&nbsp;in the case of such a merger or sale in which the consideration paid consists all or in part of assets
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other than securities of the successor or purchasing corporation, at the option of the holder of this Warrant, the securities of the successor or purchasing corporation having a value at the time
of the transaction equivalent to the value of the Series Preferred purchasable upon exorcise of this Warrant at the time of the transaction. Any new Warrant shall provide for adjustments that shall be as nearly equivalent as may be practicable to
the adjustments provided for in this Section&nbsp;4. The provisions of this Section&nbsp;4(a) shall similarly apply to successive reclassifications, changes, mergers and sales. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Subdivision or Combination of Shares.</U> If the Company at any time while this Warrant remains outstanding and unexpired shall
subdivide or combine its outstanding shares of Series Preferred, the Warrant Price shall be proportionately decreased and the number of Shares issuable hereunder shall be proportionately increased in the case of a subdivision and the Warrant Price
shall be proportionately increased and the number of Shares issuable hereunder shall be proportionately decreased in the case of a combination. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Stock Dividends and Other Distributions.</U> If the Company at any time while this Warrant is outstanding and unexpired shall
(i)&nbsp;pay a dividend with respect to Series Preferred payable in Series Preferred, then the Warrant Price shall be adjusted, from and after the date of determination of shareholders entitled to receive such dividend or distribution, to that price
determined by multiplying the Warrant Price in effect immediately prior to such date of determination by a fraction (A)&nbsp;the numerator of which shall be the total number of shares of Series Preferred outstanding immediately prior to such
dividend or distribution, and (B)&nbsp;the denominator of which shall be the total number of shares of Series Preferred outstanding immediately after such dividend or distribution; or (ii)&nbsp;make any other distribution with respect to Series
Preferred (except any distribution specifically provided for in Sections 4(a) and 4(b)), then, in each such case, provision shall be made by the Company such that the holder of this Warrant shall receive upon exercise of this Warrant a proportionate
share of any such dividend or distribution as though it were the holder of the Series Preferred (or Common Stock issuable upon conversion thereof) as of the record date fixed for the determination of the shareholders of the Company entitled to
receive such dividend or distribution. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U>Adjustment of Number of Shares.</U> Upon each adjustment in the Warrant Price, the number of
Shares of Series Preferred purchasable hereunder shall be adjusted, to the nearest whole share, to the product obtained by multiplying the number of Shares purchasable immediately prior to such adjustment in the Warrant Price by a fraction, the
numerator of which shall be the Warrant Price immediately prior to such adjustment and the denominator of which shall be the Warrant Price immediately thereafter. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e)<U> Antidilution Rights</U>. The other antidilution rights applicable to the Shares of Series Preferred purchasable hereunder are set forth
in the Company&#146;s Fifth Amended and Restated Certificate of Incorporation, as amended from time to time (the &#147;Charter&#148;). Such antidilution rights shall not be restated, amended, modified or waived without the prior written consent of
the holder hereof unless such amendment, restatement, modification or waiver affects the rights associated with the Shares of Series Preferred Stock in the same manner as such amendment, restatement, modification or waiver affects the rights
associated with all other outstanding shares of Series Preferred Stock. The Company shall promptly provide the holder hereof with any restatement, amendment, modification or waiver of the Charter promptly after the same has been made. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Notice of Adjustments.</U> Whenever the Warrant Price or the number of Shares purchasable
hereunder shall be adjusted pursuant to Section&nbsp;4 hereof, the Company shall make a certificate signed by its chief financial officer setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the
method by which such adjustment was calculated, and the Warrant Price and the number of Shares purchasable hereunder after giving effect to such adjustment, and shall cause copies of such certificate to be mailed (without regard to Section&nbsp;13
hereof, by first class mail, postage prepaid) to the holder of this Warrant. In addition, whenever the conversion price or conversion ratio of the Series Preferred shall be adjusted, the Company shall make a certificate signed by its chief financial
officer setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated, and the conversion price or ratio of the Series Preferred after giving effect to such
adjustment, and shall cause copies of such certificate to be mailed (without regard to Section&nbsp;13 hereof, by first class mail, postage prepaid) to the holder of this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Fractional Shares.</U> No fractional shares of Series Preferred will be issued in connection with any exercise hereunder, but in lieu of
such fractional shares the Company shall make a cash payment therefor based on the fair market value of the Series Preferred on the date of exercise as reasonably determined in good faith by the Company&#146;s Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Compliance with Act; Disposition of Warrant or Shares of Series Preferred</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Compliance with Act</U>. The holder of this Warrant, by acceptance hereof, agrees that this Warrant, and the shares of Series Preferred
to be issued upon exercise hereof and any Common Stock issued upon conversion thereof are being acquired for investment and that such holder will not offer, sell or otherwise dispose of this Warrant, or any shares of Series Preferred to be issued
upon exercise hereof or any Common Stock issued upon conversion thereof except under circumstances which will not result in a violation of the Act or any applicable state securities laws. Upon exercise of this Warrant, unless the Shares being
acquired are registered under the Act and any applicable state securities laws or an exemption from such registration is available, the holder hereof shall confirm in writing that the shares of Series Preferred so purchased (and any shares of Common
Stock issued upon conversion thereof) are being acquired for investment and not with a view toward distribution or resale in violation of the Act and shall confirm such other matters related thereto as may be reasonably requested by the Company.
This Warrant and all shares of Series Preferred issued upon exercise of this Warrant and all shares of Common Stock issued upon conversion thereof (unless registered under the Act and any applicable state securities laws) shall be stamped or
imprinted with a legend in substantially the following form: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;THE SECURITIES EVIDENCED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i)&nbsp;EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii)&nbsp;AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY,
THAT SUCH </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
REGISTRATIONS ARE NOT REQUIRED, (iii)&nbsp;RECEIPT OF NO-ACTION LETTERS FROM THE APPROPRIATE GOVERNMENTAL AUTHORITIES, OR (iv)&nbsp;OTHERWISE COMPLYING WITH THE PROVISIONS OF SECTION 7 OF THE
WARRANT UNDER WHICH THESE SECURITIES WERE ISSUED, DIRECTLY OR INDIRECTLY.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Said legend shall be removed by the Company, upon the
request of a holder, at such time as the restrictions on the transfer of the applicable security shall have terminated. In addition, in connection with the issuance of this Warrant, the holder specifically represents to the Company by acceptance of
this Warrant as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) The holder is aware of the Company&#146;s business affairs and financial condition, and has acquired
information about the Company sufficient to reach an informed and knowledgeable decision to acquire this Warrant. The holder is acquiring this Warrant for its own account for investment purposes only and not with a view to, or for the resale in
connection with, any &#147;distribution&#148; thereof in violation of the Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) The holder understands that this Warrant has not been
registered under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the holder&#146;s investment intent as expressed herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(3) The holder further understands that this Warrant must be held indefinitely unless subsequently registered under the Act and qualified
under any applicable state securities laws, or unless exemptions from registration and qualification are otherwise available. The holder is aware of the provisions of Rule 144, promulgated under the Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(4) The holder is an &#147;accredited investor&#148; as such term is defined in Rule 501 of Regulation D promulgated under the Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Disposition of Warrant or Shares.</U> With respect to any offer, sale or other disposition of this Warrant or any shares of Series
Preferred acquired pursuant to the exercise of this Warrant prior to registration of such Warrant or shares, the holder hereof agrees to give written notice to the Company prior thereto, describing briefly the manner thereof, together with a written
opinion of such holder&#146;s counsel, or other evidence, if reasonably satisfactory to the Company, to the effect that such offer, sale or other disposition may be effected without registration or qualification (under the Act as then in effect or
any federal or state securities law then in effect) of this Warrant or such shares of Series Preferred or Common Stock and indicating whether or not under the Act certificates for this Warrant or such shares of Series Preferred to be sold or
otherwise disposed of require any restrictive legend as to applicable restrictions on transferability in order to ensure compliance with such law. Upon receiving such written notice and reasonably satisfactory opinion or other evidence, the Company,
as promptly as practicable but no later than fifteen (15)&nbsp;days after receipt of the written notice, shall notify such holder that such holder may sell or otherwise dispose of this Warrant or such shares of Series Preferred or Common Stock, all
in accordance with the terms of the notice delivered to the Company. If a determination has been made pursuant to this Section&nbsp;7(b) that the opinion of counsel for the holder or other evidence is not reasonably satisfactory to the Company, the
Company shall so notify the holder promptly with details thereof after such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
determination has been made. Notwithstanding the foregoing, this Warrant or such shares of Series Preferred or Common Stock may, as to such federal laws, be offered, sold or otherwise disposed of
in accordance with Rule 144 or 144A under the Act, provided that the Company shall have been furnished with such information as the Company may reasonably request to provide a reasonable assurance that the provisions of Rule 144 or 144A have been
satisfied. Each certificate representing this Warrant or the shares of Series Preferred thus transferred (except a transfer pursuant to Rule 144 or 144A) shall bear a legend as to the applicable restrictions on transferability in order to ensure
compliance with such laws, unless in the aforesaid opinion of counsel for the holder, such legend is not required in order to ensure compliance with such laws. The Company may issue stop transfer instructions to its transfer agent in connection with
such restrictions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Applicability of Restrictions.</U> Neither any restrictions of any legend described in this Warrant nor the
requirements of Section&nbsp;7(b) above shall apply to any transfer of, or grant of a security interest in, this Warrant (or the Series Preferred or Common Stock obtainable upon exercise thereof) or any part hereof (i)&nbsp;to a partner of the
holder if the holder is a partnership or to a member of the holder if the holder is a limited liability company, (ii)&nbsp;to a partnership of which the holder is a partner or to a limited liability company of which the holder is a member,
(iii)&nbsp;to any affiliate of the holder if the holder is a corporation, (iv)&nbsp;notwithstanding the foregoing, to any corporation, company, limited liability company, limited partnership, partnership, or other person managed or sponsored by
Horizon Technology Finance Corporation (&#147;HRZN&#148;) or in which HRZN has an interest, (v)&nbsp;or to a lender to the holder or any of the foregoing; <U>provided,</U> <U>however</U>, in any such transfer, if applicable, the transferee shall on
the Company&#146;s request agree in writing to be bound by the terms of this Warrant as if an original holder hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U>Market
Stand-Off Agreement</U>. The holder of this Warrant (&#147;Holder&#148;) shall not sell, dispose of, transfer, make any short sale <I></I>of,<I></I> grant any option for the purchase of, or enter into any hedging or similar transaction with the same
economic effect as a sale, any Common Stock of the Company held by such Holder, for a period of time specified by the managing underwriter(s) (such period not to exceed one hundred eighty (180)&nbsp;days, except in order to comply with Financial
Industry Regulatory Authority (FINRA) Rule 2711 or a successor rule thereto) following the effective date of a registration statement of the Company filed under the Act. Holder agrees to execute and deliver such other agreements as may be reasonably
requested by the Company and/or the managing underwriter(s) which are consistent with the foregoing or which are necessary to give further effect thereto, provided that all officers and directors of the Company and all holders of at least one
percent (1%)&nbsp;of the Company&#146;s voting securities enter into similar agreements. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to such Common Stock (or other securities) until the
end of such period. The underwriters of the Company&#146;s stock are intended third party beneficiaries of this Section&nbsp;7(d) and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Rights as Shareholders; Information.</U> No holder of this Warrant, as such, shall be entitled to vote or receive dividends or be deemed
the holder of Series Preferred or any other securities of the Company which may at any time be issuable upon the exercise hereof for any purpose, nor shall anything contained herein be construed to confer upon the holder of this Warrant, as such,
any of the rights of a shareholder of the Company or any right to vote for the election of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
directors or upon any matter submitted to shareholders at any meeting thereof, or to receive notice of meetings, or to receive dividends or subscription rights or otherwise until this Warrant
shall have been exercised and the Shares purchasable upon the exercise hereof shall have become deliverable, as provided herein. Notwithstanding the foregoing, the Company will transmit to the holder of this Warrant such information, documents and
reports as are generally distributed to the holders of any class or series of the securities of the Company concurrently with the distribution thereof to the shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Registration Rights</U>. The Company grants registration rights to the holder of this Warrant for any Common Stock of the Company
obtained upon conversion of the Series Preferred, comparable to the registration rights granted to the investors in the Investor Rights Agreement, with the following exceptions and clarifications: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) The holder will not have the right to demand registration, but can otherwise participate in any registration demanded by others. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) The holder will be subject to the same provisions regarding indemnification as contained in the Registration Rights Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(3) The registration rights are freely assignable by the holder of this Warrant in connection with a permitted transfer of this Warrant or the
Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Additional Rights</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.1 <U>Acquisition Transactions</U>. The Company shall provide the holder of this Warrant with at least ten (10)&nbsp;days&#146; written
notice prior to closing thereof of the terms and conditions of any of the following transactions (to the extent the Company has notice thereof), each of which shall constitute an &#147;Acquisition Transaction&#148;: (i)&nbsp;the sale, lease,
exchange, conveyance or other disposition of all or substantially all of the Company&#146;s property or business, or (ii)&nbsp;its merger into or consolidation with any other corporation (other than a wholly-owned subsidiary of the Company), or any
transaction (including a merger or other reorganization) or series of related transactions, in which more than 50% of the voting power of the Company is disposed of (other than the sale of the Company&#146;s capital stock in a transaction or series
of transactions primarily for capital raising purposes). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.2 <U>Right to Convert Warrant into Stock: Net Issuance.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Right to Convert</U>. In addition to and without limiting the rights of the holder under the terms of this Warrant, the holder shall
have the right to convert this Warrant or any portion thereof (the &#147;Conversion Right&#148;) into shares of Series Preferred as provided in this Section&nbsp;10.2 at any time or from time to time during the term of this Warrant. Upon exercise of
the Conversion Right with respect to a particular number of shares subject to this Warrant (the &#147;Converted Warrant Shares&#148;), the Company shall deliver to the holder (without payment by the holder of any exercise price or any cash or other
consideration) that number of shares of fully paid and nonassessable Series Preferred as is determined according to the following formula: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">X = <U>B - A</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Y<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">Where:&nbsp;X&nbsp;=</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">the number of shares of Series Preferred that shall be issued to holder</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Y&nbsp;=</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">the fair market value of one share of Series Preferred</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A&nbsp;=</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">the aggregate Warrant Price of the specified number of Converted Warrant Shares immediately prior to the exercise of the Conversion Right <I>(i.e.,</I> the number of Converted Warrant Shares <I>multiplied by</I> the Warrant
Price)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B&nbsp;=</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">the aggregate fair market value of the specified number of Converted Warrant Shares (<I>i.e</I>.<SUB STYLE="font-size:85%; vertical-align:bottom"></SUB>, the number of Converted Warrant Shares <I>multiplied by</I> the fair market
value of one Converted Warrant Share)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional shares shall be issuable upon exercise of the Conversion Right, and, if the number of shares to
be issued determined in accordance with the foregoing formula is other than a whole number, the Company shall pay to the holder an amount in cash equal to the fair market value of the resulting fractional share on the Conversion Date (as hereinafter
defined). For purposes of Section&nbsp;10 of this Warrant, shares issued pursuant to the Conversion Right shall be treated as if they were issued upon the exercise of this Warrant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Method of Exercise</U>. The Conversion Right may be exercised by the holder by the surrender of this Warrant at the principal office of
the Company together with a written statement (which may be in the form of Exhibit A-1 or Exhibit A-2 hereto) specifying that the holder thereby intends to exercise the Conversion Right and indicating the number of shares subject to this Warrant
which are being surrendered (referred to in Section&nbsp;10.2(a) hereof as the Converted Warrant Shares) in exercise of the Conversion Right. Such conversion shall be effective upon receipt by the Company of this Warrant together with the aforesaid
written statement, or on such later date as is specified therein (the &#147;Conversion Date&#148;), and, at the election of the holder hereof, may be made contingent upon the closing of the sale of the Company&#146;s Common Stock to the public in a
public offering pursuant to a Registration Statement under the Act (a &#147;Public Offering&#148;). Certificates for the shares issuable upon exercise of the Conversion Right and, if applicable, a new warrant evidencing the balance of the shares
remaining subject to this Warrant, shall be issued as of the Conversion Date and shall be delivered to the holder within thirty (30)&nbsp;days following the Conversion Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Determination of Fair Market Value</U>. For purposes of this Section&nbsp;10.2, &#147;fair market value&#148; of a share of Series
Preferred (or Common Stock if the Series Preferred has been automatically converted into Common Stock) as of a particular date (the &#147;Determination Date&#148;) shall mean: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) If the Conversion Right is exercised in connection with and contingent upon a Public Offering, and if the Company&#146;s Registration
Statement relating to such Public Offering (&#147;Registration Statement<SUP STYLE="font-size:85%; vertical-align:top"></SUP>&#148;) has been declared effective by the Securities and Exchange Commission, then the initial &#147;Price to Public&#148;
specified in the final prospectus with respect to such offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) If the Conversion Right is not exercised in connection with and contingent upon a Public
Offering, then as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(A) If traded on a securities exchange, the fair market value of the Common Stock shall be deemed to be the
average of the closing prices of the Common Stock on such exchange over the five trading days immediately prior to the Determination Date, and the fair market value of the Series Preferred shall be deemed to be such fair market value of the Common
Stock multiplied by the number of shares of Common Stock into which each share of Series Preferred is then convertible; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(B) If traded on
the Nasdaq Stock Market or other over-the-counter system, the fair market value of the Common Stock shall be deemed to be the average of the closing prices of the Common Stock over the five trading days immediately prior to the Determination Date,
and the fair market value of the Series Preferred shall be deemed to be such fair market value of the Common Stock multiplied by the number of shares of Common Stock into which each share of Series Preferred is then convertible; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(C) If there is no public market for the Common Stock, then fair market value shall be determined by the Board of Directors of the Company in
good faith. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In making a determination under clauses (A)&nbsp;or (B)&nbsp;above, if on the Determination Date, five trading days had not passed since the
IPO, then the fair market value of the Common Stock shall be the average closing prices or closing bid prices, as applicable, for the shorter period beginning on and including the date of the IPO and ending on the trading day prior to the
Determination Date (or if such period includes only one trading day, the closing price or closing bid price, as applicable, for such trading day). If closing prices or closing bid prices are no longer reported by a securities exchange or other
trading system, the closing price or closing bid price shall be that which is reported by such securities exchange or other trading system at 4:00 p.m. New York City time on the applicable trading day. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.3 <U>Exercise Prior to Expiration.</U> To the extent this Warrant is not previously exercised as to all of the Shares subject hereto, and if
the fair market value of one share of the Series Preferred is greater than the Warrant Price then in effect, this Warrant shall be deemed automatically exercised pursuant to Section&nbsp;10.2 above (even if not surrendered) immediately before its
expiration. For purposes of such automatic exercise, the fair market value of one share of the Series Preferred upon such expiration shall be determined pursuant to Section&nbsp;10.2(c). To the extent this Warrant or any portion thereof is deemed
automatically exercised pursuant to this Section&nbsp;10.3, the Company agrees to promptly notify the holder hereof of the number of Shares, if any, the holder hereof is to receive by reason of such automatic exercise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Representations and Warranties</U>. The Company represents and warrants to the holder of
this Warrant as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) This Warrant has been duly authorized and executed by the Company and is a valid and binding obligation of
the Company enforceable in accordance with its terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors and the rules of law or principles at equity governing specific performance, injunctive relief
and other equitable remedies. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The Shares have been duly authorized and reserved for issuance by the Company and, when issued in
accordance with the terms hereof, will be validly issued, fully paid and nonassessable and free from preemptive rights. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) The rights,
preferences, privileges and restrictions granted to or imposed upon the Series Preferred and the holders thereof are as set forth in the Charter, and on the Date of Grant, each share of the Series Preferred represented by this Warrant is convertible
into one share of Common Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) The shares of Common Stock issuable upon conversion of the Shares have been duly authorized and
reserved for issuance by the Company and, when issued in accordance with the terms of the Charter will be validly issued, fully paid and nonassessable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) The execution and delivery of this Warrant are not, and the issuance of the Shares upon exercise of this Warrant in accordance with the
terms hereof will not be, inconsistent with the Company&#146;s Charter or by-laws, do not and will not contravene any law, governmental rule or regulation, judgment or order applicable to the Company, and do not and will not conflict with or
contravene any provision of, or constitute a default under, any indenture, mortgage, contract or other instrument of which the Company is a party or by which it is bound or require the consent or approval of, the giving of notice to, the
registration or filing with or the taking of any action in respect of or by, any Federal, state or local government authority or agency or other person, except for the filing of notices pursuant to federal and state securities laws, which filings
will be effected by the time required thereby. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) There are no actions, suits, audits, investigations or proceedings pending or, to the
knowledge of the Company, threatened against the Company in any court or before any governmental commission, board or authority which, if adversely determined, could have a material adverse effect on the ability of the Company to perform its
obligations under this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) The number of shares of Common Stock of the Company outstanding on the date hereof, on a fully diluted
basis (assuming the conversion of all outstanding convertible securities and the exercise of all outstanding options and warrants), does not exceed 35,000,000 shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Modification and Waiver.</U> This Warrant and any provision hereof may be changed, waived, discharged or terminated only by an
instrument in writing signed by the party against which enforcement of the same is sought. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Notices</U>. Any notice, request,
communication or other document required or permitted to be given or delivered to the holder hereof or the Company shall be delivered, or shall be sent by certified or registered mail, postage prepaid, to each such holder at its address as shown on
the books of the Company or to the Company at the address indicated therefor on the signature page of this Warrant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Binding Effect on Successors.</U> This Warrant shall be binding upon any corporation
succeeding the Company by merger, consolidation or acquisition of all or substantially all of the Company&#146;s assets, and all of the covenants and agreements of the Company shall inure to the benefit of the successors and assigns of the holder
hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Lost Warrants or Stock Certificates</U>. The Company covenants to the holder hereof that, upon receipt of evidence
reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant or any stock certificate and, in the case of any such loss, theft or destruction, upon receipt of an indemnity reasonably satisfactory to the
Company, or in the case of any such mutilation upon surrender and cancellation of such Warrant or stock certificate, the Company will make and deliver a new Warrant or stock certificate, of like tenor, in lieu of the lost, stolen, destroyed or
mutilated Warrant or stock certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Descriptive Headings.</U> The descriptive headings of the various Sections of this Warrant
are inserted for convenience only and do not constitute a part of this Warrant. The language in this Warrant shall be construed as to its fair meaning without regard to which party drafted this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <U>Governing Law</U>. This Warrant shall be construed and enforced in accordance with, and the rights of the parties shall be governed by,
the laws of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>Survival of Representations, Warranties and Agreements</U>. All representations and warranties
of the Company and the holder hereof contained herein shall survive the Date of Grant, the exercise or conversion of this Warrant (or any part hereof) or the termination or expiration of rights hereunder. All agreements of the Company and the holder
hereof contained herein shall survive indefinitely until, by their respective terms, they are no longer operative. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <U>Remedies.</U>
In case any one or more of the covenants and agreements contained in this Warrant shall have been breached, the holders hereof (in the case of a breach by the Company), or the Company (in the case of a breach by a holder), may proceed to protect and
enforce their or its rights either by suit in equity and/or by action at law, including, but not limited to, an action for damages as a result of any such breach and/or an action for specific performance of any such covenant or agreement contained
in this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <U>No Impairment of Rights.</U> The Company will not, by amendment of its Charter or through any other means, avoid
or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to
protect the rights of the holder of this Warrant against impairment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <U>Severability</U>. The invalidity or unenforceability of any provision of this Warrant in
any jurisdiction shall not affect the validity or enforceability of such provision in any other jurisdiction, or affect any other provision of this Warrant, which shall remain in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. <U>Recovery of Litigation Costs.</U> If any legal action or other proceeding is brought for the enforcement of this Warrant, or because of
an alleged dispute, breach, default, or misrepresentation in connection with any of the provisions of this Warrant, the successful or prevailing party or parties shall be entitled to recover reasonable attorneys&#146; fees and other costs incurred
in that action or proceeding, in addition to any other relief to which it or they may be entitled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23. <U>Entire Agreement
Modification.</U> This Warrant constitutes the entire agreement between the parties pertaining to the subject matter contained in it and supersedes all prior and contemporaneous agreements, representations, and undertakings of the parties, whether
oral or written, with respect to such subject matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of page intentionally blank. Signature page follows.] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has caused this Warrant to be duly executed and delivered as of the Date of Grant
specified above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">INOTEK PHARMACEUTICALS CORPORATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ James G. Ham, III</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">James G. Ham, III</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">CFO</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">131 Hartwell Avenue, 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Lexington, MA 02421</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[SIGNATURE PAGE TO WARRANT (Loan A)] </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT A-1 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOTICE OF EXERCISE </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">To:</TD>
<TD ALIGN="left" VALIGN="top">INOTEK PHARMACEUTICALS CORPORATION (the &#147;Company&#148;) </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The undersigned hereby: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">elects to purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of [Series Preferred Stock] [Common Stock] of the Company pursuant to the terms of the attached
Warrant, and tenders herewith payment of the purchase price of such shares in full, or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">elects to exercise its net issuance rights pursuant to Section&nbsp;10.2 of the attached Warrant with respect to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares of
[Series Preferred Stock] [Common Stock]. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Please issue a certificate or certificates
representing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares in the name of the undersigned or in such other name or names as are specified below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:36%">&nbsp;</P></center>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Name) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:36%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:36%">&nbsp;</P></center> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Address) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. The undersigned represents that the aforesaid shares are being acquired for the account of the undersigned for investment and not with a
view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares, all except as in compliance with applicable securities laws. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE="font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">(Signature)</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Date) </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT A-2 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOTICE OF EXERCISE </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">To:</TD>
<TD ALIGN="left" VALIGN="top">INOTEK PHARMACEUTICALS CORPORATION (the &#147;Company&#148;) </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. Contingent upon and effective
immediately prior to the closing (the &#147;Closing&#148;) of the Company&#146;s public offering contemplated by the Registration Statement on Form S&nbsp;&nbsp;&nbsp;&nbsp;,
filed&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 200&nbsp;&nbsp;&nbsp;&nbsp;, the undersigned hereby: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> elects to
purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of [Series Preferred Stock] [Common Stock] of the Company (or such lesser number of shares as may be sold on
behalf of the undersigned at the Closing) pursuant to the terms of the attached Warrant, or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> elects to exercise its net issuance rights pursuant to Section&nbsp;10.2 of the attached
Warrant with respect to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares of [Series Preferred Stock] [Common Stock]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Please deliver to the custodian for the selling shareholders a stock certificate representing
such&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. The undersigned has
instructed the custodian for the selling shareholders to deliver to the Company $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or, if less, the net proceeds due the undersigned from the sale of
shares in the aforesaid public offering. If such net proceeds are less than the purchase price for such shares, the undersigned agrees to deliver the difference to the Company prior to the Closing. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE="font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">(Signature)</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Date) </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>9
<FILENAME>d893535dex1011.htm
<DESCRIPTION>EX-10.11
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.11</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.11 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT
(i)&nbsp;EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii)&nbsp;AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii)&nbsp;RECEIPT OF NO-ACTION LETTERS FROM THE
APPROPRIATE GOVERNMENTAL AUTHORITIES, OR (iv)&nbsp;OTHERWISE COMPLYING WITH THE PROVISIONS OF SECTION 7 OF THIS WARRANT. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>INOTEK
PHARMACEUTICALS CORPORATION </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WARRANT TO PURCHASE SHARES </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OF SERIES PREFERRED STOCK </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Loan
B) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS CERTIFIES THAT, for value received, DRAWBRIDGE SPECIAL OPPORTUNITIES FUND LP (&#147;Drawbridge&#148;) and its assignees are
entitled to subscribe for and purchase that number of the fully paid and nonassessable shares of Series Preferred Stock (as adjusted pursuant to Section&nbsp;4 hereof, the &#147;Shares&#148;) of INOTEK PHARMACEUTICALS CORPORATION, a Delaware
corporation (the &#147;Company&#148;), as is determined pursuant to the next paragraph hereof at the price per share as is determined pursuant to the next paragraph hereof (such price and such other price as shall result, from time to time, from the
adjustments specified in Section&nbsp;4 hereof is herein referred to as the &#147;Warrant Price&#148;), subject to the provisions and upon the terms and conditions hereinafter set forth. As used herein, (a)&nbsp;the term &#147;Series Preferred&#148;
shall mean, at the holder&#146;s election, either (i)&nbsp;the Company&#146;s presently authorized Series AA Convertible Preferred Stock, par value $0.001 per share (the &#147;Series AA Preferred
Stock<SUP STYLE="font-size:85%; vertical-align:top"></SUP>&#148;) and any stock into or for which such Series AA Preferred Stock may hereafter be converted or exchanged, and after the automatic conversion of the Series AA Preferred Stock to Common
Stock shall mean the Company&#146;s Common Stock, or (ii)&nbsp;the Next Round Stock (as defined below), and any stock into or for which such Next Round Stock may hereafter be converted or exchanged, and after the automatic conversion of the Next
Round Stock to Common Stock shall mean the Company&#146;s Common Stock and (b)&nbsp;the term &#147;Date of Grant&#148; shall mean June&nbsp;28, 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Warrant Price shall be (i)&nbsp;if the holder elects to exercise this Warrant for Series AA Preferred Stock, $1.529 or (ii)&nbsp;if the
holder elects to exercise this Warrant for Next Round Stock, the lowest effective price per share (on a common stock equivalent basis and taking into account any securities issued together with the preferred stock) at which shares of the
Company&#146;s convertible preferred stock are sold in a Qualified Financing (the &#147;Next Round Stock&#148;). A &#147;Qualified Financing&#148; shall mean the sale of the convertible preferred stock of the Company to purchasers which include
institutional investors in an aggregate cash amount not less than $10,000,000. The number of shares for which this Warrant is exercisable shall rounded down to the nearest whole number determined by dividing One Hundred Seventy-Five Thousand Dollars
($175,000) by the Warrant Price determined pursuant to this paragraph. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Term.</U> The purchase right represented by this Warrant is exercisable, in whole or in
part, at any time and from time to time from the Date of Grant through the earlier of (a)&nbsp;ten (10)&nbsp;years after the Date of Grant and (b)&nbsp;immediately prior to the closing of an Acquisition Transaction (as defined below) in which the
consideration is cash, Marketable Securities or a combination thereof. As used herein, &#147;Marketable Securities&#148; means securities meeting all of the following requirements: (1)&nbsp;the issuer thereof is then subject to the reporting
requirements of Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act, and is then current in its filing of all required reports and other information under the Act and the Exchange Act, (2)&nbsp;the class and series of shares or other security
of the issuer that would be received by the holder of this Warrant in connection with a merger were such holder to exercise or convert this Warrant on or prior to the closing thereof is then traded on a national securities exchange or
over-the-counter market, (3)&nbsp;the issuer thereof has a market cap of at least Seven Hundred Fifty Million Dollars ($750,000,000) and (4)&nbsp;such holder would not be restricted by contract or by applicable federal and state securities laws from
publicly re-selling, within six (6)&nbsp;months and one day following the closing of such Acquisition, all of the issuer&#146;s shares and/or other securities that would be received by such holder in such merger were such holder to exercise or
convert this Warrant in full on or prior to the closing of such merger. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Method of Exercise; Payment; Issuance of New Warrant</U>.
Subject to Section&nbsp;1 hereof, the purchase right represented by this Warrant may be exercised by the holder hereof, in whole or in part and from time to time, at the election of the holder hereof, by (a)&nbsp;the surrender of this Warrant (with
the notice of exercise substantially in the form attached hereto as Exhibit A-1 duly completed and executed) at the principal office of the Company and by the payment to the Company, by certified or bank check, or by wire transfer to an account
designated by the Company (a &#147;Wire Transfer&#148;) of an amount equal to the then applicable Warrant Price multiplied by the number of Shares then being purchased; (b)&nbsp;if in connection with a registered public offering of the
Company&#146;s securities, the surrender of this Warrant (with the notice of exercise form attached hereto as Exhibit A-2 duly completed and executed) at the principal office of the Company together with notice of arrangements reasonably
satisfactory to the Company for payment to the Company either by certified or bank check or by Wire Transfer from the proceeds of the sale of shares to be sold by the holder in such public offering of an amount equal to the then applicable Warrant
Price per share multiplied by the number of Shares then being purchased; or (c)&nbsp;exercise of the &#147;net issuance&#148; right provided for in Section&nbsp;10.2 hereof. The person or persons in whose name(s) any certificate(s) representing
shares of Series Preferred shall be issuable upon exercise of this Warrant shall be deemed to have become the holder(s) of record of, and shall be treated for all purposes as the record holder(s) of, the shares represented thereby (and such shares
shall be deemed to have been issued) immediately prior to the close of business on the date or dates upon which this Warrant is exercised. In the event of any exercise of the rights represented by this Warrant, certificates for the shares of stock
so purchased shall be delivered to the holder hereof as soon as possible and in any event within thirty (30)&nbsp;days after such exercise and, unless this Warrant has been fully exercised or expired, a new Warrant representing the portion of the
Shares, if any, with respect to which this Warrant shall not then have been exercised shall also be issued to the holder hereof as soon as possible and in any event within such thirty-day period; provided, however, at such time as the Company is
subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, if requested by the holder of this Warrant, the Company shall cause its transfer agent to deliver the certificate
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
representing Shares issued upon exercise of this Warrant to a broker or other person (as directed by the holder exercising this Warrant) within the time period required to settle any trade made
by the holder after exercise of this Warrant. Each holder, as a condition to the issuance of shares of Series Preferred upon exercise of this Warrant, shall become party to (i)&nbsp;that certain Third Amended and Restated Investor Rights Agreement,
dated as of June&nbsp;9, 2010, by and between the Company and the persons and entities identified therein, as amended from time to time (the &#147;Investor Rights Agreement&#148;), as an &#147;Investor&#148; for all purposes thereunder by executing
and delivering the Adoption Agreement attached to the Investor Rights Agreement as Schedule I and (ii)&nbsp;that certain Third Amended and Restated Stockholders Agreement, dated as of June&nbsp;9, 2010, by and between the Company and the persons and
entities identified therein, as amended from time to time (the &#147;Stockholders Agreement&#148;), as an &#147;Investor&#148; and &#147;Stockholder&#148; for all purposes thereunder by executing and delivering the Adoption Agreement attached to the
Stockholders Agreement as Schedule III. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Stock Fully Paid; Reservation of Shares</U>. All Shares that may be issued upon the exercise
of the rights represented by this Warrant will, upon issuance pursuant to the terms and conditions herein, be fully paid and nonassessable, and free from all preemptive rights and taxes, liens and charges with respect to the issue thereof. During
the period within which the rights represented by this Warrant may be exercised, the Company will at all times have authorized, and reserved for the purpose of the issue upon exercise of the purchase rights evidenced by this Warrant, a sufficient
number of shares of its Series Preferred to provide for the exercise of the rights represented by this Warrant and a sufficient number of shares of its Common Stock to provide for the conversion of the Series Preferred into Common Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Adjustment of Warrant Price and Number of Shares</U>. The number and kind of securities purchasable upon the exercise of this Warrant and
the Warrant Price shall be subject to adjustment from time to time upon the occurrence of certain events, as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)
<U>Reclassification or Merger</U>. Except for an Acquisition Transaction that causes an expiration of the term of this Warrant as set forth in Section&nbsp;1 above, in case of any reclassification or change of securities of the class issuable upon
exercise of this Warrant (other than a change in par value, or from par value to no par value, or from no par value to par value, or as a result of a subdivision or combination), or in case of any merger of the Company with or into another
corporation (other than a merger with another corporation in which the Company is the acquiring and the surviving corporation and which does not result in any reclassification or change of outstanding securities issuable upon exercise of this
Warrant), or in case of any sale of all or substantially all of the assets of the Company, the Company, or such successor or purchasing corporation, as the case may be, shall duly execute and deliver to the holder of this Warrant a new Warrant (in
form and substance satisfactory to the holder of this Warrant), so that the holder of this Warrant shall have the right to receive upon exercise of this Warrant, at a total purchase price not to exceed that payable upon the exercise of the
unexercised portion of this Warrant, and in lieu of the shares of Series Preferred theretofore issuable upon exercise of this Warrant, (i)&nbsp;the kind and amount of shares of stock, other securities, money and property receivable upon such
reclassification, change, merger or sale by a holder of the number of shares of Series Preferred then purchasable under this Warrant, or (ii)&nbsp;in the case of such a merger or sale in which the consideration paid consists all or in part of assets
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other than securities of the successor or purchasing corporation, at the option of the holder of this Warrant, the securities of the successor or purchasing corporation having a value at the time
of the transaction equivalent to the value of the Series Preferred purchasable upon exercise of this Warrant at the time of the transaction. Any new Warrant shall provide for adjustments that shall be as nearly equivalent as may be practicable to
the adjustments provided for in this Section&nbsp;4. The provisions of this Section&nbsp;4(a) shall similarly apply to successive reclassifications, changes, mergers and sales. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Subdivision or Combination of Shares</U>. If the Company at any time while this Warrant remains outstanding and unexpired shall
subdivide or combine its outstanding shares of Series Preferred, the Warrant Price shall be proportionately decreased and the number of Shares issuable hereunder shall be proportionately increased in the case of a subdivision and the Warrant Price
shall be proportionately increased and the number of Shares issuable hereunder shall be proportionately decreased in the case of a combination. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Stock Dividends and Other Distributions</U>. If the Company at any time while this Warrant is outstanding and unexpired shall
(i)&nbsp;pay a dividend with respect to Series Preferred payable in Series Preferred, then the Warrant Price shall be adjusted, from and after the date of determination of shareholders entitled to receive such dividend or distribution, to that price
determined by multiplying the Warrant Price in effect immediately prior to such date of determination by a fraction (A)&nbsp;the numerator of which shall be the total number of shares of Series Preferred outstanding immediately prior to such
dividend or distribution, and (B)&nbsp;the denominator of which shall be the total number of shares of Series Preferred outstanding immediately after such dividend or distribution; or (ii)&nbsp;make any other distribution with respect to Series
Preferred (except any distribution specifically provided for in Sections 4(a) and 4(b)), then, in each such case, provision shall be made by the Company such that the holder of this Warrant shall receive upon exercise of this Warrant a proportionate
share of any such dividend or distribution as though it were the holder of the Series Preferred (or Common Stock issuable upon conversion thereof) as of the record date fixed for the determination of the shareholders of the Company entitled to
receive such dividend or distribution. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U>Adjustment of Number of Shares</U>. Upon each adjustment in the Warrant Price, the number of
Shares of Series Preferred purchasable hereunder shall be adjusted, to the nearest whole share, to the product obtained by multiplying the number of Shares purchasable immediately prior to such adjustment in the Warrant Price by a fraction, the
numerator of which shall be the Warrant Price immediately prior to such adjustment and the denominator of which shall be the Warrant Price immediately thereafter. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <U>Antidilution Rights</U>. The other antidilution rights applicable to the Shares of Series Preferred purchasable hereunder are set forth
in the Company&#146;s Fifth Amended and Restated Certificate of Incorporation, as amended from time to time (the &#147;Charter&#148;). Such antidilution rights shall not be restated, amended, modified or waived without the prior written consent of
the holder hereof unless such amendment, restatement, modification or waiver affects the rights associated with the Shares of Series Preferred Stock in the same manner as such amendment, restatement, modification or waiver affects the rights
associated with all other outstanding shares of Series Preferred Stock. The Company shall promptly provide the holder hereof with any restatement, amendment, modification or waiver of the Charter promptly after the same has been made. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Notice of Adjustments</U>. Whenever the Warrant Price or the number of Shares purchasable
hereunder shall be adjusted pursuant to Section&nbsp;4 hereof, the Company shall make a certificate signed by its chief financial officer setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the
method by which such adjustment was calculated, and the Warrant Price and the number of Shares purchasable hereunder after giving effect to such adjustment, and shall cause copies of such certificate to be mailed (without regard to Section&nbsp;13
hereof, by first class mail, postage prepaid) to the holder of this Warrant In addition, whenever the conversion price or conversion ratio of the Series Preferred shall be adjusted, the Company shall make a certificate signed by its chief financial
officer setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated, and the conversion price or ratio of the Series Preferred after giving effect to such
adjustment, and shall cause copies of such certificate to be mailed (without regard to Section&nbsp;13 hereof, by first class mail, postage prepaid) to the holder of this Warrant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Fractional Shares</U>. No fractional shares of Series Preferred will be issued in connection with any exercise hereunder, but in lieu of
such fractional shares the Company shall make a cash payment therefor based on the fair market value of the Series Preferred on the date of exercise as reasonably determined in good faith by the Company&#146;s Board of Directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Compliance with Act; Disposition of Warrant or Shares of Series Preferred</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Compliance with Act</U>. The holder of this Warrant, by acceptance hereof, agrees that this Warrant, and the shares of Series Preferred
to be issued upon exercise hereof and any Common Stock issued upon conversion thereof are being acquired for investment and that such holder will not offer, sell or otherwise dispose of this Warrant, or any shares of Series Preferred to be issued
upon exercise hereof or any Common Stock issued upon conversion thereof except under circumstances which will not result in a violation of the Act or any applicable state securities laws. Upon exercise of this Warrant, unless the Shares being
acquired are registered under the Act and any applicable state securities laws or an exemption from such registration is available, the holder hereof shall confirm in writing that the shares of Series Preferred so purchased (and any shares of Common
Stock issued upon conversion thereof) are being acquired for investment and not with a view toward distribution or resale in violation of the Act and shall confirm such other matters related thereto as may be reasonably requested by the Company.
This Warrant and all shares of Series Preferred issued upon exercise of this Warrant and all shares of Common Stock issued upon conversion thereof (unless registered under the Act and any applicable state securities laws) shall be stamped or
imprinted with a legend in substantially the following form: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;THE SECURITIES EVIDENCED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i)&nbsp;EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii)&nbsp;AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY,
THAT SUCH </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE APPROPRIATE GOVERNMENTAL AUTHORITIES, OR (iv)&nbsp;OTHERWISE COMPLYING WITH THE PROVISIONS OF SECTION 7 OF THE WARRANT
UNDER WHICH THESE SECURITIES WERE ISSUED, DIRECTLY OR INDIRECTLY.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Said legend shall be removed by the Company, upon the request of
a holder, at such time as the restrictions on the transfer of the applicable security shall have terminated. In addition, in connection with the issuance of this Warrant, the holder specifically represents to the Company by acceptance of this
Warrant as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) The holder is aware of the Company&#146;s business affairs and financial condition, and has acquired information
about the Company sufficient to reach an informed and knowledgeable decision to acquire this Warrant. The holder is acquiring this Warrant for its own account for investment purposes only and not with a view to, or for the resale in connection with,
any &#147;distribution&#148; thereof in violation of the Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) The holder understands that this Warrant has not been registered under
the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the holder&#146;s investment intent as expressed herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(3) The holder further understands that this Warrant must be held indefinitely unless subsequently registered under the Act and qualified
under any applicable state securities laws, or unless exemptions from registration and qualification are otherwise available. The holder is aware of the provisions of Rule 144, promulgated under the Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(4) The holder is an &#147;accredited investor&#148; as such term is defined in Rule 501 of Regulation D promulgated under the Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Disposition of Warrant or Shares</U>. With respect to any offer, sale or other disposition of this Warrant or any shares of Series
Preferred acquired pursuant to the exercise of this Warrant prior to registration of such Warrant or shares, the holder hereof agrees to give written notice to the Company prior thereto, describing briefly the manner thereof, together with a written
opinion of such holder&#146;s counsel, or other evidence, if reasonably satisfactory to the Company, to the effect that such offer, sale or other disposition may be effected without registration or qualification (under the Act as then in effect or
any federal or state securities law then in effect) of this Warrant or such shares of Series Preferred or Common Stock and indicating whether or not under the Act certificates for this Warrant or such shares of Series Preferred to be sold or
otherwise disposed of require any restrictive legend as to applicable restrictions on transferability in order to ensure compliance with such law. Upon receiving such written notice and reasonably satisfactory opinion or other evidence, the Company,
as promptly as practicable but no later than fifteen (15)&nbsp;days after receipt of the written notice, shall notify such holder that such holder may sell or otherwise dispose of this Warrant or such shares of Series Preferred or Common Stock, all
in accordance with the terms of the notice delivered to the Company. If a determination has been made pursuant to this Section&nbsp;7(b) that the opinion of counsel for the holder or other evidence is not reasonably satisfactory to the Company, the
Company shall so notify the holder promptly with details thereof after such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
determination has been made. Notwithstanding the foregoing, this Warrant or such shares of Series Preferred or Common Stock may, as to such federal laws, be offered, sold or otherwise disposed of
in accordance with Rule 144 or 144A under the Act, provided that the Company shall have been furnished with such information as the Company may reasonably request to provide a reasonable assurance that the provisions of Rule 144 or 144A have been
satisfied. Each certificate representing this Warrant or the shares of Series Preferred thus transferred (except a transfer pursuant to Rule 144 or 144A) shall bear a legend as to the applicable restrictions on transferability in order to ensure
compliance with such laws, unless in the aforesaid opinion of counsel for the holder, such legend is not required in order to ensure compliance with such laws. The Company may issue stop transfer instructions to its transfer agent in connection with
such restrictions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Applicability of Restrictions.</U> Neither any restrictions of any legend described in this Warrant nor the
requirements of Section&nbsp;7(b) above shall apply to any transfer of, or grant of a security interest in, this Warrant (or the Series Preferred or Common Stock obtainable upon exercise thereof) or any part hereof (i)&nbsp;to a partner of the
holder if the holder is a partnership or to a member of the holder if the holder is a limited liability company, (ii)&nbsp;to a partnership of which the holder is a partner or to a limited liability company of which the holder is a member,
(iii)&nbsp;to any affiliate of the holder if the holder is a corporation, (iv)&nbsp;notwithstanding the foregoing, to any corporation, company, limited liability company, limited partnership, partnership, or other person managed or sponsored by
Drawbridge or its affiliates in which Drawbridge has an interest, (v)&nbsp;or to a lender to the holder or any of the foregoing; <U>provided</U>, <U>however</U>, in any such transfer, if applicable, the transferee shall on the Company&#146;s request
agree in writing to be bound by the terms of this Warrant as if an original holder hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U>Market Stand-Off Agreement</U>. The
holder of this Warrant (&#147;Holder<SUP STYLE="font-size:85%; vertical-align:top"></SUP>&#148;) shall not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction
with the same economic effect as a sale, any Common Stock of the Company held by such Holder, for a period of time specified by the managing underwriter(s) (such period not to exceed one hundred eighty (180)&nbsp;days, except in order to comply with
Financial Industry Regulatory Authority (FINRA) Rule 2711 or a successor rule thereto) following the effective date of a registration statement of the Company filed under the Act. Holder agrees to execute and deliver such other agreements as may be
reasonably requested by the Company and/or the managing underwriter(s) which are consistent with the foregoing or which are necessary to give further effect thereto, provided that all officers and directors of the Company and all holders of at least
one percent (1%)&nbsp;of the Company&#146;s voting securities enter into similar agreements. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to such Common Stock (or other securities) until
the end of such period. The underwriters of the Company&#146;s stock are intended third party beneficiaries of this Section&nbsp;7(d) and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Rights as Shareholders; Information</U>. No holder of this Warrant, as such, shall be entitled to vote or receive dividends or be
deemed the holder of Series Preferred or any other securities of the Company which may at any time be issuable upon the exercise hereof for any purpose, nor shall anything contained herein be construed to confer upon the holder of this Warrant, as
such, any of the rights of a shareholder of the Company or any right to vote for the election of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
directors or upon any matter submitted to shareholders at any meeting thereof, or to receive notice of meetings, or to receive dividends or subscription rights or otherwise until this Warrant
shall have been exercised and the Shares purchasable upon the exercise hereof shall have become deliverable, as provided herein. Notwithstanding the foregoing, the Company will transmit to the holder of this Warrant such information, documents and
reports as are generally distributed to the holders of any class or series of the securities of the Company concurrently with the distribution thereof to the shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Registration Rights</U>. The Company grants registration rights to the holder of this Warrant for any Common Stock of the Company
obtained upon conversion of the Series Preferred, comparable to the registration rights granted to the investors in the Investor Rights Agreement, with the following exceptions and clarifications: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) The holder will not have the right to demand registration, but can otherwise participate in any registration demanded by others. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) The holder will be subject to the same provisions regarding indemnification as contained in the Registration Rights Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(3) The registration rights are freely assignable by the holder of this Warrant in connection with a permitted transfer of this Warrant or the
Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Additional Rights</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.1 <U>Acquisition Transactions.</U> The Company shall provide the holder of this Warrant with at least ten (10)&nbsp;days&#146; written
notice prior to closing thereof of the terms and conditions of any of the following transactions (to the extent the Company has notice thereof), each of which shall constitute an &#147;Acquisition Transaction&#148;; (i)&nbsp;the sale, lease,
exchange, conveyance or other disposition of all or substantially all of the Company&#146;s property or business, or (ii)&nbsp;its merger into or consolidation with any other corporation (other than a wholly-owned subsidiary of the Company), or any
transaction (including a merger or other reorganization) or series of related transactions, in which more than 50% of the voting power of the Company is disposed of (other than the sale of the Company&#146;s capital stock in a transaction or series
of transactions primarily for capital raising purposes). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.2 <U>Right to Convert Warrant into Stock; Net Issuance</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Right to Convert</U>. In addition to and without limiting the rights of the holder under the terms of this Warrant, the holder shall
have the right to convert this Warrant or any portion thereof (the &#147;Conversion Right&#148;) into shares of Series Preferred as provided in this Section&nbsp;10.2 at any time or from time to time during the term of this Warrant. Upon exercise of
the Conversion Right with respect to a particular number of shares subject to this Warrant (the &#147;Converted Warrant Shares&#148;), the Company shall deliver to the holder (without payment by the holder of any exercise price or any cash or other
consideration) that number of shares of fully paid and nonassessable Series Preferred as is determined according to the following formula: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">X = <U>B - A</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" ALIGN="right">Y&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Where:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" ALIGN="right">X&nbsp;=</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">the number of shares of Series Preferred that shall be issued to holder</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" ALIGN="right">Y&nbsp;=</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">the fair market value of one share of Series Preferred</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" ALIGN="right">A&nbsp;=</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">the aggregate Warrant Price of the specified number of Converted Warrant Shares immediately prior to the exercise of the Conversion Right (<I>i.e</I>., the number of Converted Warrant Shares <I>multiplied by</I> the Warrant
Price)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" ALIGN="right">B&nbsp;=</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">the aggregate fair market value of the specified number of Converted Warrant Shares (<I>i.e</I>., the number of Converted Warrant Shares <I>multiplied by</I> the fair market value of one Converted Warrant Share)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional shares shall be issuable upon exercise of the Conversion Right, and, if the number of shares to
be issued determined in accordance with the foregoing formula is other than a whole number, the Company shall pay to the holder an amount in cash equal to the fair market value of the resulting fractional share on the Conversion Date (as hereinafter
defined). For purposes of Section&nbsp;10 of this Warrant, shares issued pursuant to the Conversion Right shall be treated as if they were issued upon the exercise of this Warrant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Method of Exercise</U>. The Conversion Right may be exercised by the holder by the surrender of this Warrant at the principal office of
the Company together with a written statement (which may be in the form of Exhibit A-1 or Exhibit A-2 hereto) specifying that the holder thereby intends to exercise the Conversion Right and indicating the number of shares subject to this Warrant
which are being surrendered (referred to in Section&nbsp;10.2(a) hereof as the Converted Warrant Shares) in exercise of the Conversion Right Such conversion shall be effective upon receipt by the Company of this Warrant together with the aforesaid
written statement, or on such later date as is specified therein (the &#147;Conversion Date&#148;), and, at the election of the holder hereof, may be made contingent upon the closing of the sale of the Company&#146;s Common Stock to the public in a
public offering pursuant to a Registration Statement under the Act (a &#147;Public Offering&#148;). Certificates for the shares issuable upon exercise of the Conversion Right and, if applicable, a new warrant evidencing the balance of the shares
remaining subject to this Warrant, shall be issued as of the Conversion Date and shall be delivered to the holder within thirty (30)&nbsp;days following the Conversion Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Determination of Fair Market Value</U>. For purposes of this Section&nbsp;10.2, &#147;fair market value&#148; of a share of Series
Preferred (or Common Stock if the Series Preferred has been automatically converted into Common Stock) as of a particular date (the &#147;Determination Date&#148;) shall mean: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) If the Conversion Right is exercised in connection with and contingent upon a Public Offering, and if the Company&#146;s Registration
Statement relating to such Public Offering (&#147;Registration Statement&#148;) has been declared effective by the Securities and Exchange Commission, then the initial &#147;Price to Public&#148; specified in the final prospectus with respect to
such offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) If the Conversion Right is not exercised in connection with and contingent upon a Public
Offering, then as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(A) If traded on a securities exchange, the fair market value of the Common Stock shall be deemed to be the
average of the closing prices of the Common Stock on such exchange over the five trading days immediately prior to the Determination Date, and the fair market value of the Series Preferred shall be deemed to be such fair market value of the Common
Stock multiplied by the number of shares of Common Stock into which each share of Series Preferred is then convertible; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(B) If traded on
the Nasdaq Stock Market or other over-the-counter system, the fair market value of the Common Stock shall be deemed to be the average of the closing prices of the Common Stock over the five trading days immediately prior to the Determination Date,
and the fair market value of the Series Preferred shall be deemed to be such fair market value of the Common Stock multiplied by the number of shares of Common Stock into which each share of Series Preferred is then convertible; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(C) If there is no public market for the Common Stock, then fair market value shall be determined by the Board of Directors of the Company in
good faith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In making a determination under clauses (A)&nbsp;or (B)&nbsp;above, if on the Determination Date, five trading days had not passed since the
IPO, then the fair market value of the Common Stock shall be the average closing prices or closing bid prices, as applicable, for the shorter period beginning on and including the date of the IPO and ending on the trading day prior to the
Determination Date (or if such period includes only one trading day, the closing price or closing bid price, as applicable, for such trading day). If closing prices or closing bid prices are no longer reported by a securities exchange or other
trading system, the closing price or closing bid price shall be that which is reported by such securities exchange or other trading system at 4:00 p.m. New York City time on the applicable trading day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.3 <U>Exercise Prior to Expiration.</U> To the extent this Warrant is not previously exercised as to all of the Shares subject hereto, and
if the fair market value of one share of the Series Preferred is greater than the Warrant Price then in effect, this Warrant shall be deemed automatically exercised pursuant to Section&nbsp;10.2 above (even if not surrendered) immediately before its
expiration. For purposes of such automatic exercise, the fair&nbsp;market value of one share of the Series Preferred upon such expiration shall be determined pursuant to Section&nbsp;10.2(c). To the extent this Warrant or any portion thereof is
deemed automatically exercised pursuant to this Section&nbsp;10.3, the Company agrees to promptly notify the holder hereof of the number of Shares, if any, the holder hereof is to receive by reason of such automatic exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Representations and Warranties</U>. The Company represents and warrants to the holder of this Warrant as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) This Warrant has been duly authorized and executed by the Company and is a valid and binding
obligation of the Company enforceable in accordance with its terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors and the rules of law or principles at equity governing specific performance,
injunctive relief and other equitable remedies. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The Shares have been duly authorized and reserved for issuance by the Company and,
when issued in accordance with the terms hereof, will be validly issued, fully paid and nonassessable and free from preemptive rights. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c)
The rights, preferences, privileges and restrictions granted to or imposed upon the Series Preferred and the holders thereof are as set forth in the Charter, and on the Date of Grant, each share of the Series Preferred represented by this Warrant is
convertible into one share of Common Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) The shares of Common Stock issuable upon conversion of the Shares have been duly
authorized and reserved for issuance by the Company and, when issued in accordance with the terms of the Charter will be validly issued, fully paid and nonassessable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) The execution and delivery of this Warrant are not, and the issuance of the Shares upon exercise of this Warrant in accordance with the
terms hereof will not be, inconsistent with the Company&#146;s Charter or by-laws, do not and will not contravene any law, governmental rule or regulation, judgment or order applicable to the Company, and do not and will not conflict with or
contravene any provision of, or constitute a default under, any indenture, mortgage, contract or other instrument of which the Company is a party or by which it is bound or require the consent or approval of, the giving of notice to, the
registration or filing with or the taking of any action in respect of or by, any Federal, state or local government authority or agency or other person, except for the filing of notices pursuant to federal and state securities laws, which filings
will be effected by the time required thereby. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) There are no actions, suits, audits, investigations or proceedings pending or, to the
knowledge of the Company, threatened against the Company in any court or before any governmental commission, board or authority which, if adversely determined, could have a material adverse effect on the ability of the Company to perform its
obligations under this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) The number of shares of Common Stock of the Company outstanding on the date hereof, on a fully diluted
basis (assuming the conversion of all outstanding convertible securities and the exercise of all outstanding options and warrants), does not exceed 35,000,000 shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Modification and Waiver</U>. This Warrant and any provision hereof may be changed, waived, discharged or terminated only by an
instrument in writing signed by the party against which enforcement of the same is sought. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.<U> Notices</U>. Any notice, request,
communication or other document required or permitted to be given or delivered to the holder hereof or the Company shall be delivered, or shall be sent by certified or registered mail, postage prepaid, to each such holder at its address as shown on
the books of the Company or to the Company at the address indicated therefor on the signature page of this Warrant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Binding Effect on Successors</U>. This Warrant shall be binding upon any corporation
succeeding the Company by merger, consolidation or acquisition of all or substantially all of the Company&#146;s assets, and all of the covenants and agreements of the Company shall inure to the benefit of the successors and assigns of the holder
hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Lost Warrants or Stock Certificates</U>. The Company covenants to the holder hereof that, upon receipt of evidence
reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant or any stock certificate and, in the case of any such loss, theft or destruction, upon receipt of an indemnity reasonably satisfactory to the
Company, or in the case of any such mutilation upon surrender and cancellation of such Warrant or stock certificate, the Company will make and deliver a new Warrant or stock certificate, of like tenor, in lieu of the lost, stolen, destroyed or
mutilated Warrant or stock certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Descriptive Headings</U>. The descriptive headings of the various Sections of this Warrant
are inserted for convenience only and do not constitute a part of this Warrant. The language in this Warrant shall be construed as to its fair meaning without regard to which party drafted this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <U>Governing Law</U>. This Warrant shall be construed and enforced in accordance with, and the rights of the parties shall be governed by,
the laws of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>Survival of Representations, Warranties and Agreements</U>. All representations and warranties
of the Company and the holder hereof contained herein shall survive the Date of Grant, the exercise or conversion of this Warrant (or any part hereof) or the termination or expiration of rights hereunder. All agreements of the Company and the holder
hereof contained herein shall survive indefinitely until, by their respective terms, they are no longer operative. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <U>Remedies</U>.
In case any one or more of the covenants and agreements contained in this Warrant shall have been breached, the holders hereof (in the case of a breach by the Company), or the Company (in the case of a breach by a holder), may proceed to protect and
enforce their or its rights either by suit in equity and/or by action at law, including, but not limited to, an action for damages as a result of any such breach and/or an action for specific performance of any such covenant or agreement contained
in this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <U>No Impairment of Rights</U>. The Company will not, by amendment of its Charter or through any other means, avoid
or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to
protect the rights of the holder of this Warrant against impairment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <U>Severability</U>. The invalidity or unenforceability of any provision of this Warrant in
any jurisdiction shall not affect the validity or enforceability of such provision in any other jurisdiction, or affect any other provision of this Warrant, which shall remain in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. <U>Recovery of Litigation Costs</U>. If any legal action or other proceeding is brought for the enforcement of this Warrant, or because of
an alleged dispute, breach, default, or misrepresentation in connection with any of the provisions of this Warrant, the successful or prevailing party or parties shall be entitled to recover reasonable attorneys&#146; fees and other costs incurred
in that action or proceeding, in addition to any other relief to which it or they may be entitled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23. <U>Entire Agreement;
Modification.</U> This Warrant constitutes the entire agreement between the parties pertaining to the subject matter contained in it and supersedes all prior and contemporaneous agreements, representations, and undertakings of the parties, whether
oral or written, with respect to such subject matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of page intentionally blank. Signature page follows.] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has caused this Warrant to be duly executed and delivered as of the Date of Grant
specified above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">INOTEK PHARMACEUTICALS CORPORATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ James G. Ham, III</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">James G. Ham, III</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">CFO</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:4.50em; text-indent:-4.50em; font-size:10pt; font-family:Times New Roman">Address:&nbsp;&nbsp;&nbsp;&nbsp;131 Hartwell Avenue, 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> Floor
Lexington, MA 02421</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[SIGNATURE PAGE TO WARRANT (Loan B)] </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT A-1 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOTICE OF EXERCISE </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">To:</TD>
<TD ALIGN="left" VALIGN="top">INOTEK PHARMACEUTICALS CORPORATION (the &#147;Company&#148;) </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The undersigned hereby: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">elects to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of [Series Preferred Stock] [Common Stock] of the Company pursuant to
the terms of the attached Warrant, and tenders herewith payment of the purchase price of such shares in full, or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">elects to exercise its net issuance rights pursuant to Section&nbsp;10.2 of the attached Warrant with respect to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares of [Series Preferred Stock] [Common Stock]. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Please issue a certificate or certificates representing
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares in the name of the undersigned or in such other name or names as are specified below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:42%">&nbsp;</P></center>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Name) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:42%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:42%">&nbsp;</P></center> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Address) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. The undersigned represents that the aforesaid shares are being acquired for the account of the undersigned for investment and not with a
view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares, all except as in compliance with applicable securities laws. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE="font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">(Signature)</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;(Date)&nbsp;&nbsp;&nbsp;&nbsp; </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT A-2 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOTICE OF EXERCISE </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">To:</TD>
<TD ALIGN="left" VALIGN="top">INOTEK PHARMACEUTICALS CORPORATION (the &#147;Company&#148;) </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. Contingent upon and effective
immediately prior to the closing (the &#147;Closing&#148;) of the Company&#146;s public offering contemplated by the Registration Statement on Form S&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
filed&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 200&nbsp;&nbsp;&nbsp;&nbsp;, the undersigned hereby: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> elects to purchase
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of [Series Preferred Stock] [Common Stock] of the Company (or such lesser number of shares as may be sold on behalf of
the undersigned at the Closing) pursuant to the terms of the attached Warrant, or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> elects
to exercise its net issuance rights pursuant to Section&nbsp;10.2 of the attached Warrant with respect to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares of [Series
Preferred Stock] [Common Stock]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Please deliver to the custodian for the selling shareholders a stock certificate representing such
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. The
undersigned has instructed the custodian for the selling shareholders to deliver to the Company $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or, if less, the net proceeds
due the undersigned from the sale of shares in the aforesaid public offering. If such net proceeds are less than the purchase price for such shares, the undersigned agrees to deliver the difference to the Company prior to the Closing. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE="font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">(Signature)</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;(Date) </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>10
<FILENAME>d893535dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><U>Exhibit 31.1 </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATIONS UNDER SECTION 302 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, David P.
Southwell, certify that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. I have reviewed this annual report on Form 10-K of Inotek Pharmaceuticals Corporation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) designed such disclosure controls and
procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) evaluated the effectiveness of the registrant&#146;s
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the
registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over
financial reporting; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation
of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s
internal control over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: March 31, 2015 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David P. Southwell</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">David P. Southwell</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">President, Chief Executive Officer and Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Principal Executive Officer)</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>11
<FILENAME>d893535dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><U>Exhibit 31.2 </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATIONS UNDER SECTION 302 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Dale
Ritter, certify that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. I have reviewed this annual report on Form 10-K of Inotek Pharmaceuticals Corporation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) designed such disclosure controls and
procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) evaluated the effectiveness of the registrant&#146;s
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the
registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over
financial reporting; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation
of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s
internal control over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: March 31, 2015 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dale Ritter</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dale Ritter</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Vice President&#150;Finance</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Principal Financial Officer)</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>12
<FILENAME>d893535dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><U>Exhibit 32.1 </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS ADOPTED PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Annual Report on Form 10-K of Inotek Pharmaceuticals Corporation (the &#147;Company&#148;) for the year ended
December&nbsp;31, 2014 as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant
to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that to his knowledge: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) the Report fully complies with the requirements of
Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) the information contained in the Report fairly presents, in
all material respects, the financial condition and results of operations of the Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">March 31, 2015</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David P. Southwell</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">David P. Southwell</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">President, Chief Executive Officer and Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">(Principal Executive Officer)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">March 31, 2015</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dale Ritter</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Dale Ritter</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Vice President&#150;Finance</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">(Principal Financial Officer)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The foregoing certifications are not deemed filed with the Securities and Exchange Commission for purposes
of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (Exchange Act), and are not to be incorporated by reference into any filing of Inotek Pharmaceuticals Corporation under the Securities Act of 1933, as amended, or the Exchange
Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. </I></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g893535dsp_053.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g893535dsp_053.jpg
M_]C_X``02D9)1@`!`@$!+`$L``#_X0JM17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````4````<@$R``(````4````AH=I``0````!````G````,@```$L````
M`0```2P````!061O8F4@4&AO=&]S:&]P(#<N,``R,#$U.C`S.C$Y(#`Y.C(T
M.C(P``````.@`0`#`````?__``"@`@`$`````0```HF@`P`$`````0```T@`
M````````!@$#``,````!``8```$:``4````!```!%@$;``4````!```!'@$H
M``,````!``(```(!``0````!```!)@("``0````!```)?P````````!(````
M`0```$@````!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``?_N
M``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43
M$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-
M$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#/_``!$(`(``8P,!(@`"$0$#$0'_W0`$``?_Q`$_```!
M!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$`
M`@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@`,`P$``A$#$0`_`/54DDDE*20[A>6$4%K7ZP7@D<';HTM_/VH+F=3_`#;J
M`.\U..N[_C_]%_X)_F)*;.X2&SJ>`G5`#J(>X66TP0=&UO#MQ_F]OZ5WL_?5
MEHR]ON=7NUT#3$?FCZ:)"T2NTR2'4,@']*YCA'YK2W67?O.?^9L1$%RDDDDE
M*22224I))))3_]#U,N`,:_<4M[?/[BI))*1V%SFQ6[89U):3I^"@/7@38)UD
M^F?[/YREE?T6[6/T;M08['N%G[,;U"&->]H:/H.L,&7?FA^[W)*;T6\EXF")
M],Z3\TAZX`FP$SK^C/\`Y)4&BJMY<USZ'@!U1<Y[@=2';J7/][7N.STOYS_0
MK1Q[G6U[GL-;P8>PF8/\EP^FU)2F%X<2]VYO8!A$?/53WM\_N*DDDICO;Y_<
M4M[?/[BDXD-)#2XCAHC7[T)U]X,#&>[C7<P#4&?S_P`U)27>//[BEO;Y_<56
M=GE@BRDL?R6%]0(;_I-;?H(N-D>NTN#2T`@`[FNF0'?X)]GBDI+N'X2DG224
M_P#_T?54DDDE(<O^BW?\6[C4\%5&.)ML)>Y^C8+F["/I:?19_65S*@XUP)VC
M8[W>&AU5*MVZVS5YC:#O$'@G3VM1"EK21`)$/VB7;N6N]3BMJ=MEKF-=4[TK
M'/=.A+?:T?3;8UGL=M_-V)W[PT.!$M,P9@G5@_ZM1>!8UK+=I!L>3I/`VM;^
MEW?FN24W,7*9D,,>VQFEC.8/BUW^$K=_@[$=9IFS9<QVRYDAE@U!$_0=^_18
MKF-DMO:1&RUFEE9U+3_WYCOS'H4I,DDDDI8M:>0#'BDUK6B&@`'4QIJG224I
M))))3__2]522224BROZ-=W]CM/DJ@)-CY:6G30QYZ^TN5K+_`*+=W_1NT^15
M(@5VN:(J#B!)E_8_O;40IF\_HR3H!!,QV(3&2^N-IW%[AK((VUZ@MW(+K"[&
M>+RT;@\/`!^CN]-KO[;5,44L914\-].H.K:UVHT%8;_.']UJ*F=((J&Z`Z3N
MCB9.[;]%.ZMSGMLJ.R]FC'G@@\UV?O5/_P#4B:HL])NWZ)G;'$2Y$9],?%)3
M9HL-M%=I;M+VAQ;,Q(F)1$#!(=A4.'!K:1\P$=-4I))))2DDDDE/_]/U5)))
M)2'+_HMW'\V[G0<'E4V,#+G.VULWR26.F2`&RZ6L_-5S+C[+=(D;':>.G&JI
M>C4;B!CM8UK>75L@DG@;=WT-J(4S>RNPAKX>TAT@GM[5"`T-:]Y#0ZPMEP/[
MNS^MM:[_``B9V)6&L<*JAZ1+R/3!W`-<-G'M^DD]_IMI?17O:;"W]"0UH#MK
M=_M:?4_J;42I@<RBDM%UKG36TSM>_P!VN[^98_8K-3FNV/:9:Z'`\:'CE":Y
MQN!+7,L<)8'6/U@S[@6MK8UOO;]%-'`BMKOSMS=W'L+6F6_1<$AJM,A'=O87
M]#H_XMOY`C(>/`QZ@.-C8CX(B:N4DDDDI22222G_U/54DDDE(LII=C6M&A+2
M`?E_95-X?N+7VS]'5C=I$O'\M^[?&U7K6E];F`P7`@$B1K_)_.5:N@/:^ET,
MF2]@`!DGZ;/^#_T:(4UV4UE^10YX80YNTVRYWT&%I:YSQ]%$BQK-[WSM=:'/
M$M`)(C\YVUOM4G8=C7#:]IVDFMK@XQ/GZGT?]-[?TB9I+;K/2LWO@^M[3JYH
M:W]#^;^C_/2!U1(6"%'<2`=VWGZ1Y''ME0``<`XB=O?X^Y%T.HU'(*CKNF)T
MCM_%2AK6>K;H$45CP:T?@B*%/\RS^J/R*:A;2DDDDE*22224_P#_U?54DDDE
M+%1LKWPX':]FK7#\6G^0Y2=.TD"3X)@YT?0(^[_R22FFVRT[J7.FPC],\2W;
M/YM/M;NK_P!$]-36RMOIU@L(`#R#R!HW9_Y+^<1+ZWO?N;4\6-,UV#9H"!N8
MX&QF^MWY[%#]9$$X[W%PUVFO3^3[K&IPKJQSX^FQ91$`:`=DP";=?_W&M^^K
M_P!+)MU__<:W[Z__`$LG6.[%P2[%N4_S+/ZH_(IJ-8(K:#R``?N4E&V5))))
M*4DDDDI__]:?UO:T_6;/)`/NJ_\`/-*Q]K?`+NNM_4K/ZEU;)SZLJJMEY86L
M<QQ(VL95J6N_X-4?_&[ZG_W,H_S'_P#DDE/*;1X)`!=7_P"-WU3_`+F8_P#F
MO_O3#_%WU7_N9C_YK_[TE/*D)1_K*ZH_XN^J_P#<O'_S7IO_`!N^K?\`<O'_
M`,UZ2GEQ/B?O/]Z4NGZ1^\_WKJ1_B\ZM_P!RL?[GJ/\`XW?5_P#N5C_<_P#N
M24X&'73<YXOROLX;LVESHD%VVQTN=_@6>_TOYRW_``:N68/36B[T^K"QU;7%
MHG8'D$>G75:YVWWMW+4_\;WK`XRL<?\`;G_D4O\`QONM?]RL?[[/_(I*<`T5
M%^UO46P0(+O5;!/YC]-O]IO_`(&@94U,<*\LW@AVK'6`"![9]39])=)_XWO7
M)_I6-KYV?^04;/\`%WUU['-^TXI)!`DV=_\`K:2GLM?'_M'X]TE8^S/\6_S'
MI?/_`,BDDI__V?_M#X!0:&]T;W-H;W`@,RXP`#A"24T$)0``````$```````
M```````````````X0DE-`^T``````!`!+`````$``0$L`````0`!.$))300F
M```````.`````````````#^````X0DE-!`T```````0````>.$))3009````
M```$````'CA"24T#\P``````"0```````````0`X0DE-!`H```````$``#A"
M24TG$```````"@`!``````````$X0DE-`_4``````$@`+V9F``$`;&9F``8`
M``````$`+V9F``$`H9F:``8```````$`,@````$`6@````8```````$`-0``
M``$`+0````8```````$X0DE-`_@``````'```/______________________
M______\#Z`````#_____________________________`^@`````________
M_____________________P/H`````/____________________________\#
MZ```.$))300(```````0`````0```D````)``````#A"24T$'@``````!```
M```X0DE-!!H``````W\````&``````````````-(```"B0```"4`20!N`&\`
M=`!E`&L`(`!&`&\`=0!R`'0`:``@`$$`;0!E`&X`9`!M`&4`;@!T`"``,P`N
M`#,`+@`Q`#4`7P!0`&$`9P!E`%\`-P````$`````````````````````````
M`0`````````````"B0```T@``````````````````````0``````````````
M```````````0`````0```````&YU;&P````"````!F)O=6YD<T]B:F,````!
M````````4F-T,0````0`````5&]P(&QO;F<``````````$QE9G1L;VYG````
M``````!"=&]M;&]N9P```T@`````4F=H=&QO;F<```*)````!G-L:6-E<U9L
M3',````!3V)J8P````$```````5S;&EC90```!(````'<VQI8V5)1&QO;F<`
M````````!V=R;W5P241L;VYG``````````9O<FEG:6YE;G5M````#$53;&EC
M94]R:6=I;@````UA=71O1V5N97)A=&5D`````%1Y<&5E;G5M````"D53;&EC
M951Y<&4`````26UG(`````9B;W5N9'-/8FIC`````0```````%)C=#$````$
M`````%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<`
M``-(`````%)G:'1L;VYG```"B0````-U<FQ415A4`````0```````&YU;&Q4
M15A4`````0```````$US9V5415A4`````0``````!F%L=%1A9U1%6%0````!
M```````.8V5L;%1E>'1)<TA434QB;V]L`0````AC96QL5&5X=%1%6%0````!
M```````):&]R>D%L:6=N96YU;0````]%4VQI8V5(;W)Z06QI9VX````'9&5F
M875L=`````EV97)T06QI9VYE;G5M````#T53;&EC959E<G1!;&EG;@````=D
M969A=6QT````"V)G0V]L;W)4>7!E96YU;0```!%%4VQI8V5"1T-O;&]R5'EP
M90````!.;VYE````"71O<$]U='-E=&QO;F<`````````"FQE9G1/=71S971L
M;VYG``````````QB;W1T;VU/=71S971L;VYG``````````MR:6=H=$]U='-E
M=&QO;F<``````#A"24T$$0```````0$`.$))3004```````$`````3A"24T$
M#``````)FP````$```!C````@````2P``)8````)?P`8``'_V/_@`!!*1DE&
M``$"`0!(`$@``/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`
M#`@("`D(#`D)#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,
M#`P1$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`
M@`!C`P$B``(1`0,1`?_=``0`!__$`3\```$%`0$!`0$!``````````,``0($
M!08'"`D*"P$``04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"
M!0<&"`4###,!``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,'
M)9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34
MY/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'
M!P8%-0$``A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T
M\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%
MU>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`]522224I
M)#N%Y8106M?K!>"1P=NC2W\_:@N9U/\`-NH`[S4XZ[O^/_T7_@G^8DIL[A(;
M.IX"=4`.HA[A9;3!!T;6\.W'^;V_I7>S]]66C+V^YU>[70-,1^:/IHD+1*[3
M)(=0R`?TKF.$?FM+=9=^\Y_YFQ$07*22224I))))2DDDDE/_T/4RX`QK]Q2W
MM\_N*DDDI'87.;%;MAG4EI.GX*`]>!-@G63Z9_L_G*65_1;M8_1NU!CL>X6?
MLQO4(8U[VAH^@ZPP9=^:'[O<DIO1;R7B8(GTSI/S2'K@";`3.OZ,_P#DE0:*
MJWES7/H>`'5%SGN!U(=NI<_WM>X[/2_G/]"M''N=;7N>PUO!A["9@_R7#Z;4
ME*87AQ+W;F]@&$1\]5/>WS^XJ222F.]OG]Q2WM\_N*3B0TD-+B.&B-?O0G7W
M@P,9[N-=S`-09_/_`#4E)=X\_N*6]OG]Q59V>6"+*2Q_)87U`AO^DUM^@BXV
M1Z[2X-+0"`#N:Z9`=_@GV>*2DNX?A*2=))3_`/_1]522224AR_Z+=_Q;N-3P
M548XFVPE[GZ-@N;L(^EI]%G]97,J#C7`G:-CO=X:'54JW;K;-7F-H.\0>"=/
M:U$*6M)$`D0_:)=NY:[U.*VIVV6N8UU3O2L<]TZ$M]K1]-MC6>QVW\W8G?O#
M0X$2TS!F"=6#_JU%X%C6LMVD&QY.D\#:UOZ7=^:Y)3<Q<IF0PQ[;&:6,Y@^+
M7?X2MW^#L1UFF;-ES';+F2&6#4$3]!W[]%BN8V2V]I$;+6:65G4M/_?F._,>
MA2DR2222EBUIY`,>*36M:(:``=3&FJ=))2DDDDE/_]+U5))))2+*_HUW?V.T
M^2J`DV/EI:=-#'GK[2Y6LO\`HMW?]&[3Y%4B!7:YHBH.($F7]C^]M1"F;S^C
M).@$$S'8A,9+ZXVG<7N&L@C;7J"W<@NL+L9XO+1N#P\`'Z.[TVN_MM4Q12QE
M%3PWTZ@ZMK7:C05AO\X?W6HJ9T@BH;H#I.Z.)D[MOT4[JW.>VRH[+V:,>>"#
MS79^]4__`-2)JBSTF[?HF=L<1+D1GTQ\4E-FBPVT5VENTO:'%LS$B8E$0,$A
MV%0X<&MI'S`1TU2DDDDE*22224__T_54DDDE(<O^BW<?S;N=!P>538P,N<[;
M6S?))8Z9(`;+I:S\U7,N/LMTB1L=IXZ<:JEZ-1N(&.UC6MY=6R"2>!MW?0VH
MA3-[*["&OA[2'2">WM4(#0UKWD-#K"V7`_N[/ZVUKO\`")G8E8:QPJJ'I$O(
M],'<`UPV<>WZ23W^FVE]%>]IL+?T)#6@.VMW^UI]3^IM1*F!S**2T76N=-;3
M.U[_`':[OYEC]BLU.:[8]IEKH<#QH>.4)KG&X$M<RQPE@=8_6#/N!:VMC6^]
MOT4T<"*VN_.W-W<>PM:9;]%P2&JTR$=V]A?T.C_BV_D",AX\#'J`XV-B/@B)
MJY22222E))))*?_4]522224BRFEV-:T:$M(!^7]E4WA^XM?;/T=6-VD2\?RW
M[M\;5>M:7UN8#!<"`2)&O\G\Y5JZ`]KZ70R9+V``&2?IL_X/_1HA379367Y%
M#GAA#F[3;+G?086EKG/'T42+&LWO?.UUH<\2T`DB/SG;6^U2=AV-<-KVG:2:
MVN#C$^?J?1_TWM_2)FDMNL]*S>^#ZWM.KFAK?T/YOZ/\]('5$A8(4=Q(!W;>
M?I'D<>V5``!P#B)V]_C[D70ZC4<@J.NZ8G2.W\5*&M9ZMN@116/!K1^"(H4_
MS+/ZH_(IJ%M*22224I))))3_`/_5]522224L5&RO?#@=KV:M</Q:?Y#E)T[2
M0)/@F#G1]`C[O_))*:;;+3NI<Z;"/TSQ+=L_FT^UNZO_`$3TU-;*V^G6"P@`
M/(/(&C=G_DOYQ$OK>]^YM3Q8TS78-F@(&YC@;&;ZW?GL4/UD03CO<7#7::]/
MY/NL:G"NK'/CZ;%E$0!H!V3`)MU__<:W[ZO_`$LFW7_]QK?OK_\`2R=8[L7!
M+L6Y3_,L_JC\BFHU@BMH/(`!^Y24;94DDDDI22222G__UI_6]K3]9L\D`^ZK
M_P`\TK'VM\`NZZW]2L_J75LG/JRJJV7EA:QS'$C:QE6I:[_@U1_\;OJ?_<RC
M_,?_`.224\IM'@D`%U?_`(W?5/\`N9C_`.:_^],/\7?5?^YF/_FO_O24\J0E
M'^LKJC_B[ZK_`-R\?_->F_\`&[ZM_P!R\?\`S7I*>7$^)^\_WI2Z?I'[S_>N
MI'^+SJW_`'*Q_N>H_P#C=]7_`.Y6/]S_`.Y)3@8==-SGB_*^SANS:7.B07;;
M'2YW^!9[_2_G+?\`!JY9@]-:+O3ZL+'5M<6B=@>01Z==5KG;?>W<M3_QO>L#
MC*QQ_P!N?^12_P#&^ZU_W*Q_OL_\BDIP#147[6]1;!`@N]5L$_F/TV_VF_\`
M@:!E34QPKRS>"':L=8`('MGU-GTETG_C>]<G^E8VOG9_Y!1L_P`7?77L<W[3
MBDD$"39W_P"MI*>RU\?^T?CW25C[,_Q;_,>E\_\`R*22G__9`#A"24T$(0``
M````50````$!````#P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<```
M`!,`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'``(``W`"X`,`````$`
M.$))300&```````'``@````!`0#_X1)(:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87`O,2XP+P`\/WAP86-K970@8F5G:6X])^^[OR<@:60])U<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"<_/@H\/V%D;V)E+7AA<"UF:6QT97)S(&5S8STB0U(B
M/SX*/'@Z>&%P;65T82!X;6QN<SIX/2=A9&]B93IN<SIM971A+R<@>#IX87!T
M:STG6$U0('1O;VQK:70@,BXX+C(M,S,L(&9R86UE=V]R:R`Q+C4G/@H\<F1F
M.E)$1B!X;6QN<SIR9&8])VAT='`Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M
M<F1F+7-Y;G1A>"UN<R,G('AM;&YS.FE8/2=H='1P.B\O;G,N861O8F4N8V]M
M+VE8+S$N,"\G/@H*(#QR9&8Z1&5S8W)I<'1I;VX@86)O=70])W5U:60Z.&$Y
M,60R-F0M8V1E8BTQ,64T+6(P9&4M8F(V-S=A,S$X-&4Y)PH@('AM;&YS.GAA
M<$U-/2=H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO)SX*("`\>&%P
M34TZ1&]C=6UE;G1)1#YA9&]B93ID;V-I9#IP:&]T;W-H;W`Z.&$Y,60R-F(M
M8V1E8BTQ,64T+6(P9&4M8F(V-S=A,S$X-&4Y/"]X87!-33I$;V-U;65N=$E$
M/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H\+W)D9CI21$8^"CPO>#IX87!M971A
M/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*/#]X<&%C:V5T(&5N9#TG=R<_/O_N``Y!9&]B90!D0`````'_VP"$``$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("
M`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!`0("`0("`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`T@"
MB0,!$0`"$0$#$0'_W0`$`%+_Q`&B````!@(#`0`````````````'"`8%!`D#
M"@(!``L!```&`P$!`0````````````8%!`,'`@@!"0`*"Q```@$#!`$#`P(#
M`P,"!@EU`0(#!!$%$@8A!Q,B``@Q%$$R(Q4)44(6820S%U)Q@1ABD25#H;'P
M)C1R"AG!T34GX5,V@O&2HD14<T5&-T=C*%565QJRPM+B\F2#=).$9:.SP]/C
M*3AF\W4J.3I(24I865IG:&EJ=G=X>7J%AH>(B8J4E9:7F)F:I*6FIZBIJK2U
MMK>XN;K$Q<;'R,G*U-76U]C9VN3EYN?HZ>KT]?;W^/GZ$0`"`0,"!`0#!00$
M!`8&!6T!`@,1!"$2!3$&`"(305$',F$4<0A"@2.1%5*A8A8S";$DP=%#<O`7
MX8(T)9)3&&-$\:*R)C495#9%9"<*<X.31G3"TN+R565U5C>$A:.SP]/C\RD:
ME*2TQ-3D])6EM<75Y?4H1U=F.':&EJ:VQM;F]F=WAY>GM\?7Y_=(6&AXB)BH
MN,C8Z/@Y25EI>8F9J;G)V>GY*CI*6FIZBIJJNLK:ZOK_V@`,`P$``A$#$0`_
M`-_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=='Z'_6/^]>_=>Z@>_=>Z_]#?
MX]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7%6#"X_!(_VWOW7NN7OW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>ZXNV@7(O[]U[K@09-#`E1];?['_#W[KW67W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UT&4W`()'U]^Z]UW[]U[KHWL;&
MQ_!]^Z]UX7MZC<_X"WOW7NN_?NO==$VM?\FW^WO_`,4]^Z]UW[]U[KB&O?\`
M%C;_`(W_`+'W[KW7+W[KW7O?NO=>]^Z]U[W[KW75P"!?DWM_C;Z^_=>Z[]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7`O8FX('^J/T]^Z]UXR
M*%+#U`&W'OW7NO%P$#V-C;C_`%_?NO=<E.H`_P!??NO=>)`%R;#W[KW7@01<
M&X]^Z]UUJ.JVDV_U7%OI[]U[KE[]U[KWOW7NN-SJ`TFW^JXM[]U[KE[]U[KW
MOW7NO>_=>ZQO($-B">+_`.]_\4]^Z]UVL@8$_2QMR1^??NO=<_?NO=='Z'_6
M/^]>_=>Z@>_=>Z__T=_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7%KV]/UN/][Y_WCW[KW7(_P"'U]^Z]UTM](U?6W/OW7NN
M_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UTU])T_6W'OW7NN*H
M%Y_)^OOW7NN_5J(MZ;"Q_P`?S[]U[KE[]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KCH&K5S?\`U^/I;Z>_=>ZY>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KIE#"Q^GOW7NNE15!`'!^M^??NO=
M<K?C\>_=>Z][]U[KIE#"Q^GOW7NO*`H`'T'_`"/W[KW76D:M7-_]<V^EOI[]
MU[KE[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZZ(!^H]^Z]UQ$:@6M<7!YYY'
MT]^Z]US]^Z]UT?H?]8_[U[]U[J![]U[K_]+?X]^Z]U[W[KW7%1I%KWY/^VO?
MW[KW7+W[KW6)%96:Y)!Y!_V)_P`??NO=<['5>_&FUO\`&X-_]X]^Z]UR]^Z]
MU[W[KW7O?NO=8W+W&@<'ZFU_?NO=<E)*@L+'\^_=>ZY>_=>Z\""+CD'W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=<5!`L3?DG_;GW[KW7+W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW6-"Y+:A8?C_`&_OW7NN=Q>U^?Z>_=>Z[]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UQ`742"2?H1<V'T_'OW7NN[B]
MK\_T]^Z]UW[]U[KCI&K5S?\`US;Z6^GOW7NN7OW7NO>_=>Z][]U[KWOW7NO>
M_=>ZXE02#S<6_/'!O]/?NO=<O?NO=>]^Z]U[W[KW71^A_P!8_P"]>_=>Z@>_
M=>Z__]/?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=8
MW0L5(:UO]?\`K[]U[K)[]U[KWOW7NN@```/H/?NO==^_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>ZP35$-/&\LSK'%&-3R.P557\DDGWX!C\*D]:+*JL[L`@'$\.O
M4]1#51K-`XDB=0R2*;JRL+@@^]E66FH4/5(IHIT62%PR'S'#K/[UTYU[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]UT1<$?2X(_P!N/?NO=>`L`/K8`?[8>_=>Z[]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UT`!_Q4\GG_
M`!]^Z]UW[]U[KWOW7NO>_=>Z][]U[KCJ.JVDV_U7X]^Z]UR]^Z]U[W[KW7`<
M,WI(!-RQ^G`_WCW[KW78TL=0-R./]O[]U[KS-I4M];6_WDV]^Z]UY6U*&^E[
M_P"\&WOW7NNV.D$_T]^Z]UTC:Q<"WOW7NO:CJMI-O]5^/?NO=<O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW71^A_UC_O7OW7NH'OW7NO_]3?X]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW71N`2.2`;#_&W'OW7NO#D`_2X''OW7NN_?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UP+@,$YN?\`
M6M_O?OW7NN?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MJ//4)3H\LKI'#&I>21S8(H')/ORAG)1?C/#[>FY)$A1Y9G"Q**DG`Z"?<.?.
M3.B$VHXRR*`'N\BGTO,MP$O<6!O_`(\^Q%86+6]&D6K<>HPYEY@COP]M;R%;
M-1DBN:XS3RZR8/,R8MQ%()6I&+I)=O2#JNKQW`L_)X'NMW8^-K911QZ=>Y?W
MT[?]+%)J_=Y&FI-0//4!@@^M:XZ%B*198UD1@R.`58?D$?[W[("K*2&X]2BC
MK(H=&!0Y!^763WKJW7O?NO=>]^Z]U[W[KW71(')(`_QX]^Z]UW>_(Y'OW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KH$'Z$&W]"#[]U[KOW[KW7O?NO=>]^Z]U[W[KW7O?NO=>//'OW7
MNN"($N!?G^O_`"(>_=>ZY^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KH_0_ZQ_WKW[KW4#W[KW7_U=_CW[KW7O?NO=>]
M^Z]U[W[KW7KB]K\_T_/OW7NO>_=>Z][]U[KWOW7NO7%[7Y_I^??NO=>]^Z]U
MZXO:_/\`3\^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KJPO>P
MO_6PO_M_?NO==^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZXN"5(!L>
M.;V_(_(]^Z]U'JJF*EB>>618XHU9I')%E`M8?7DD\`?U][0>(P1023Z=-331
M01//+,$B7B>FF*IH-PT,VATGIY%:*:/60ZM_1@.4<$7!_'MV2.6RF42(P;!%
M1TABN=LWZRFC1Q):/VMZ^G#RZ"S-8*7$33!W>6GE9Y()S^EB^FT#E;,)D3_7
MUCZ<W]BFQW%+T)C]5>TCU^8'G]O46;UL]WL4LD?QV$N5DX::?A/K]GY]3,!B
M)<E(%%UIT*O-*RLZQ@K<)""+!G/-SR+_`.'MG<+E+=#0G6:TH:?MZ>V7:IMT
MNH@5_P`4`.IB.WACY$UX="C+44F(HAY)!%#"-*ZCZY&^ME!-W=C[#0\6=BRI
M5B?(5_P=2D'M-MLX_%D"0(*>G#CU,I:E*J-)8V5HW4,C+?F_X//U'NA!!((R
M.E4,L<\:RPN&C(J",]2O>NG.NB0/J0/]<V]^Z]UW[]U[KH@'@@$?X\^_=>Z[
MM;@<#W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=<6!.FQM9@3]>1S<<>_=>ZY$@?4V_U_?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=<'5F`TFW//)'^]>_=>Z[0,%LQN;_6Y/^]^_=>ZY>_=>Z][
M]U[KWOW7NN"(JDE23?Z\@CZ_X#W[KW7/W[KW7O?NO=<=/JU:F_UK^G_;>_=>
MZY>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KA8%M08\&Q`;TW
M'U!']??NO=<_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW71^A_P!8_P"]>_=>
MZ@>_=>Z__];?X]^Z]U[W[KW7O?NO=>]^Z]UQT^HM^2`/]M[]U[KQL;I?DJ?]
MM]+_`.\^_=>ZX('#&YNHN!S?\BU_\;>_=>ZR^_=>ZXZ?4&_(!'^W]^Z]UR]^
MZ]UQT^H-^0"/]O[]U[KIG52`3R?]]S[]U[KG[]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NNB0HN?Z@?[?W[KW7?OW7NO>
M_=>ZP5,T5/!+/.XBAB77)(38*H(N?H?>PK.0JBK'JKR+$K2.P"**DGR'GT#^
M;W(<O-XX28Z.,,8T.D-/)8KJF$@T$J%](XTW^OL36&W"*LDJ_J"A'46[WS%+
MNLCV]B0+)217AJ]3]GITU8S-/C:H2TO":XS61<DW+E2C(H"^K5J!N2/:V\M1
M>PGQ\$?"1QZ*=IW>>QN2;8`1%@2IP,<:?;QZ%V.6BSE!J4!H''J'`FAD0<J&
MYTRH?I_3V$FCFL9"BU#>O^7J4[>;;]_L-3*)+=N(/X3Z?;UEFDH<#CFF8K!3
MQ@$D_JD=OHOTYD<_[S[THFNI54DLY\NGU2QV>S>2FFWC%3_DZ"+.9A\W/Y'(
M\%--:&%95(1&L?+(5-M9`M_C^/8ILK);0'77Q"/+_!U$N][Y=;[<NJOX=C'E
M?0^M>G+`[F_ALOCJ&O1L^DEB5$#7`557DV))_P!C[3WVUF96DBB(<"OVGHSY
M>YBEL2J3*19$T)/E\U%?V?+H7J:9)XDEC<.DBZT8?0J3Q^![#!!#%6%&'4IQ
M2QS(DD;51A4'K*RAA8_\B/\`7W[ISKL"P`_H`/\`;>_=>Z[]^Z]U[W[KW7O?
MNO==&]O2`3_0^_=>Z\+V%_K^;>_=>Z[]^Z]U[W[KW7O?NO=>]^Z]UT2`0/R;
MV_V`O[]U[KOW[KW7`NH8*;W-OQ_7Z>_=>ZY$V!/UL"?]L/?NO=<%/D4ZA;G_
M`'JQOS[]U[KF!8`7)_Q/Y]^Z]UW[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KBJZ18?U)_V_OW7NN7OW7NO>_=>ZZ!!)`_!L??
MNO==^_=>Z][]U[KWOW7NO>_=>Z][]U[KCK&K38W_`-;C^OU]^Z]UR]^Z]U[W
M[KW7!M5O1:Y^OX_V/^O[]U[KE]!S_L??NO==^_=>ZZOS;F]K_P"'UM]?Z^_=
M>Z[]^Z]U[W[KW7O?NO=='Z'_`%C_`+U[]U[J![]U[K__U]_CW[KW7O?NO=>]
M^Z]U[W[KW7O?NO==6%[VYM:_^'UM[]U[KP%KV_)O_M[?\4]^Z]UU<ZK6X*WO
MS]0?I_3Z>_=>Z[/T-OK;CW[KW7E-P#]+@'W[KW7?OW7NN'C6Y)%R3?G\>_=>
MZY^_=>Z][]U[KWOW7NO>_=>Z][]U[I(_W^V0=Z/UQ_>W;O\`I!CP";J?9'\9
MQ_\`>M=L25DF.CW"<!]Q_%!A7KX6A%3XO"9%*ZK\>_=>ZY[RWWLKKK`U6Z=_
M[MVWLG;%%)2PUFXMV9O&[>P=+-75$=)10U&4RU3244,M74RK'&K."[L`+GW[
MKW3!L?N;J+LY\E%UIVCUYV++AHH)\Q%L3>FV]VR8J"J,RTLV23`9.O:ABJFI
MY!&TND2%&"W(/OW7NLE#W!U-E-I9G?V-[.Z_K]C;<GK:;<.\Z/>6W:G:N`J<
M:T:9*FS>X8<D^(Q51CWF19TGFC>)F`8`D>_=>Z<:WLCKW&;5I]]Y/?.T,;LB
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M&?PL(C$KG4MN?8LVS=H9HQ!=N!.`*#U_XKSZBSF+EJYL9FFVZ$G;I/(<8]/E
M]AKCSZDQS8JA5JS<&8Q6UL(D]'25.7SF2H\10)-5RK!2T"U>0J(('K:Z:0+"
MFK4[,+<\>W]QO$M(/$>A)^$5K^9Z*-HVFXWB_%M"VF%15W(.`,$?Z8^7[>A;
MS&Z-I[)&(Q60R^&QV3S4DM+MO"5N4H*/*;CJJ>.-ZF'#T5540U>6J((W5Y13
MI*Z*P)'(]A!1<7LX)?N;UX#_`(KJ6I#9<N[8QA@)A45HOQ,WJ?F3URR.[-JI
MMNJS.Z<KA=OX&G31E*[<.2H\1C:)F.A//D,A-34T`=OT,S+<CVY+'+87#!"?
M%5L'_+U:TN;7?;$"2`Z)%[T/%3_"?GY^G06U--C&AHLKA,E09[;V642XS-8>
MLIZ_&UT$A>_BKJ!YZ6H((L&1B&_!O[%&WW\=["U2!<(,_/J+=\V.79KEXRK?
MNV0]KTPM>-?2G6?:C;;S&X9\*V=V_-EL:@FFV]!F\=-GHT58V,E5A8ZI\G3Q
M+'(K,TL2BS@_2Q]I[_=?IXA&CGQV'`8`!Z4\O\L/N4L<EPJ_NU&PP?N:GR]#
MT.%35TV)I6GD(2")0J1J+LQ^B10H.6=CP!_7V&$1YY*5)D8]2E-<V>UV;R2C
M1!$OE_#PKGCQ'37M_>NU-TFMBP.XL%EZS%ND67H,7F<9DZW#SR`%:?*TU!55
M,N/GL?T2A6_P]UD0QR/&W%33I1;S"X@BG4$(X!%?0\#THIZFGIHI)ZB:*""&
M&2HFGFD6*&&")#)+-++(52.*-`69B0%`N>/=.GNHF+S.)SE#3Y3"9/'YC&5:
M&2DR6*K*;(8^J169&:GK:266FF4.I!*L0""/?NO=8CG\&,LF!;,XI<[+2FNC
MPK9"C7+O0ABAK4QIF^]:D#BWD":+_GW[KW4ZHK:2D,"U=53TQJIUIJ85$T</
MW%3(&,=-!Y&7S5$@4E46[$`V''OW7NN=14T]+'YJJ>&FAUQ1^6HE2&/R32+#
M#'KD95URRNJJ+W9B`.3[]U[KC-5TU/X?//%":B188!+(D9FF8$K#$'9?),P!
ML@NQL;#CW[KW69F"VO?DV'!//]./R??NO=0*7+8RMJ*NEH\C0UE10S?;5L%)
M5P5,U%46OX*R*&1WI9;']+A3[W3`/6JJ25![AQZ<?>NM]>]^Z]UTP!']+<@_
MT_Q]^Z]UQY4`WU#FY_-O\+?T]^Z]UT8PS![GBQM_K>_=>ZR'D'\?X_T]^Z]U
MTH(')+<_4^_=>Z[]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW75@+V'U^O\`C[]U[KOW[KW7O?NO
M=>]^Z]UTRAA9A<?T]^Z]UW[]U[KWOW7NO>_=>Z][]U[KWOW7NNB+@C^H(]^Z
M]UX"P`^M@!_MO?NO==^_=>Z][]U[KWOW7NO>_=>ZZ/T/^L?]Z]^Z]U`]^Z]U
M_]#?X]^Z]UTQL";$V%[#\^_=>Z\I)4%A9B+D`WM_A?\`P]^Z]UW[]U[KWOW7
MNO>_=>ZZ/T-OK;CW[KW7E-U!(L2/I[]U[KH7&JYXN2/];^G^P]^Z]UR]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5`?<O?O47QS_G9U/8'>N]
ML;UWLFI^!>W]I8S<>;H\I+CJC<62[5S>1BQ"2XO'U\JU,U)22R#4H0*AYO\`
M7W7NEO\`SD.R-E]N_P`L#)]A=;;CH-S;'WCV5TK+@-UT=+5S8JHQX[/QM!59
MAJ2JIZ6LJ,;CY:65IXS&IFBB=%N&!/NO="%_*^W'L#*U/<[[<[=^$_:>1IZ3
M9LU15?$OXYU'Q[K,-BHWW#>3L>.JR5>,\E=5#70$&):;1.UB)`1[KW5'OR3I
M>O\`>GR"^0_?_474';>?_E78OY"=0Q?-FDZ^SXH.N>Y.R=I9'+'>79&S-@04
M/W>=V'MS<5;CCN.2FO29-HGE#(*B.2+W7NKCOYNVZ.N-_P#\J;/9_JVLPF7Z
MSW;F/CK4;(R6T:>G7;TNW!VKLJMQ7\-H8(8HJ.@IZ6A$)IQ'&U-8QLJ,A45=
M%<`.H(!K^?7ND5_-^ZLQ'=NX/Y7W3N>R>6P6+[(^2E3L^LSF!,$>;PD>4ZHR
MD4>7Q$]3!/'2Y+&U:Q30R65T9.&4\BW7NBX_'/<?R8/\V_XQ],?+C'T=9VS\
M=/C_`-Z["Q_:U%3SIC?D%US5T536[&[>Q@EA=:/(9+%,U+FZ<5$LD>5@82+&
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M5(E7BL=CL94S4T,$#JD4,C*``2/>MILH+JQO(I%)N`_:QK44!(%/3''_`#]-
M<U;YN>S[UM:6]Z5V[P$9HFH0]0*FH%*FOD<GAT4?K',?RXY:;YJ4W\VO#XZI
M^:>9[M[6;*CLO!;ORV^*[KJJF<=.4?QLKL9031P8BGPR1+BQAWC=*@J\A$;*
M?9*T,L4DBR(1+YTQC-*'H<PSP7L$5Q"P:&50PQ_*AXTZ>>Z<)WQ0_P`A;J3"
M?(Z+>4.X\I\C^F,9M*D[)>*7L*FZ@S':5'0=?4>\-:15$.<I=OU'[*5?^4PP
M+`)>18>"M)I0*S4X`]QZW'#%$&$<:@-QH`*]-BY+Y%;*^?/\OCXL_)"NGWK5
M?'CMW?J=)=XY'S25?<'3&[,%1KM:6M>990^\MB)MF3%Y8B5I@/"9`05EF,D@
MO+>\-I-!15D5@PKW*>-3Y#_GZJ<!4A9=QAW#:MSOXY*M].`T=?@D%00!Q`Q^
MVG5EO=&:ZFA^=&V\7\O/[I-TG%T#BLK\>:#N)\:G1>4[@7>.<C[>ER#[B\>R
MJCM&AVF,(,9'E)&D3&R5+T::S,P/+X(]RZ2G0I0D$#\53Q/V4X=`[9[ZZMMN
MBN]K75=>.JRJ:DF*@-%'GW<3D^75F_QRB^-61ZWR%-\9L?UQ#U=-N[<1K*?J
MV/&)L==XR-33;C.).#'\!>4SO&TLE`33F6Y!UZO84J]O*6A?O!XCSZE$I#?V
M@6YMZ1MQ5^J,=XX6MVC\P^W._MR[?ZXV=T1UG_,MV@>Q_D+MO&5;?(/84Y^/
MO2V%P&U,YE&6DQM'\<-Y9_<='CMPU`GJGH$KI9I:58=53%X>)-(36K^9/D.K
MJD%G:R+%&JQ)4A105(X*OJ3Y#B?+JQ_^8CN;?M;\5NW*_94^[:.2.@VTFX7Z
M]6KFWQC^KJC>VW(NV<GLS^'*:V?/4G6KY22":EU5"+J>"\@4^Q1#8QVFWS2%
MO\8:,T9<GA6GY]1?-OO[ZWO;HKY%CMEDH8S7+`]A:N*%J*:^1)Z)]E-O?$K#
M9KXNY7X$R=00=X)W9U51;*I?CWDL35Y?-]-5^4IO]-B=QP;6JZNOKNNH^KTK
MJFNJ=R`F++QTIC<5I4,@W4;=&B101TN222<]"/EH\SW%S-<;G=`PFE5/DU,A
M:`#2,`?MZM2^;.R]L=C?&;L39&[.S<+T]A-QQ;8I!OW=0B;9]!DH=W8"OPF'
MWU2U61P]/DMD;LR])!BLQ1R5=*M9CZR:$RIKU`B"EL>8Z'/KPZ0?\OK=^T]V
M])Y^FVOU5UOU,^R>VNQ=A;LP_2TU/5=)[EWGMBNH:?.;\ZBK:2"EIZK9&Z_-
M%-$OBCEI*I:BFFUSPR2/[K714<?A.J-@?S`9-TUD/1G?%1W+WI7XO`[IIJG'
MCY6?&+N7#]555-DMFY5%JILGG.C)MI[;E6&.):-\+-D[SQU5-4).GNO=#O\`
MS#*F%=T_R]Z"61T;(_S!NF1$J$`2-0[0[+R!5]1`9;4W(Y)'^M[]U[I2?S.M
MO8S=_P`0-U;/S4F5BPN[^S_CGM;,2X+(U&'S<6,W!\ANK\76R8C+TEJG%9-*
M>J8T]3'ZX90K+R![]U[HEO;':G96R>T_AG\1/D/E:G<G9^(^:75FY^G^WUQT
MU)COD)TOM_`=B15&7RLT$?\`#<=V[U\*JCI-UT`,:U4DD&2I4,%2RP^Z]T>O
M^8GN?=>T_C779#`Y?<VV=KUG8O5&#[HWALL5B[KV9T)G=_8/&=P;HPE3CHI\
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M`ZC;_4\6]^Z]UR]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=='Z'_`%C_`+U[
M]U[J![]U[K__T=_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>(N"/Z\>_=>ZZ`L`/K8`?[;W[KW7?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NFVIQ&.K)/-5T-%52V"B2IHJ6HD"`DA!)+$[Z%)X%[#W[KW7*7%8Z>
ME6BEH:.6C1E9:66DIY*52ANA6F>(P*4;D67@^_=>ZPT^"Q%)]Q]GC,=2?=IX
MZK[6@I*?[E`N@)4&&%#,@3BS7%N/?NO=<H<)B:>A;&4^.H(,8\<L3XV"BI8:
M!TGN)T>CCA6F9)@3K!4AK\^_=>ZPKM[")0+BEQ.,7%(VI,8N.HEQRMY/+=:$
M0?:AO+ZKA`=7/U]^Z]U(J</BZR7'S5>.H:J7%2^?&RU-)3U$M!-H,?FHI)HW
M>DF\9*ZXRK:3:]O?NO=<)L;BIJ^')ST-'+DZ.*>"DR,E)`]=24]48S4T]+6-
M&:FGAJ"BEU1E5R!<&WOW7NHV8VSM_<"4R9W!X?/+12^>C3-8R@RBTDY*'STO
MWU//]O-JC4ZEL;J/Z>_=>Z<S31F#[<Q1^$((Q"`HC6,`!8U0`*J*HL`+``<>
M]JQ0@KU21$DC>*1-4;<1T`^8V-C=FI42[>PU!C<3/52UK08VD@HJ>*NK95:K
MJ9Z6CC@ADJ:M[EYB#)(3ZB3[&&S[@MP@@D*)*?,``M0>O42<U[5-MUQ'=UFE
MM!ITMARF?@TG@H\B?\/23IL5@OXWCLYDMNX'-Y7%K:AK,I@L=D:V@76)@M#7
M5M--64>ER&0Q.I4_ZY]J]PLDO+:12E)/)OQ?/''_`%?+HGVC?+C;)H9H9&9`
M*.I)(-23PX+@^71AI:+;F\,6D&5QV-SV.\]-5F@S./I,E!%64KK44TTE)70S
MQ+5TDZAXWTZD874@\^P--'-:R%:,K^1!X_9U-=EN%KN-O'<6S54\<9!\ZCCT
M%F^>N<))DL=N*3"8_(-B*J6NQD]3C*2NKMO5U2C15%;A:J>)ZK$M4P^B62!T
M8IPUU]B?;-Z+QK;W0_Q@=JMZKZ'_`&>HXYCY?N-NGFW/:966UG%)4'`#B<>?
MRZD4'6NWMY8R*#>>W,/N/`ZTJ(\)N;&4&;QE1*@/AJ),;E*6KI=408E7TZA?
M@V]L[K?J/%METM(P^T#_`&3T[RGL<DRI?3!Q"C?IUJI(^SC3[>A."8/9^%CI
M:.CQ^%PN-@\5#C<924U#14\2ABE+04-'%#!$H-[)&@`^OL/01/(R1IF0^0ZD
M2ZNH;.WEN;B@117[:>E?/Y=`5G*7#[D&;I,AAL+/B]R"K?,XF?$44U#EXJNF
MIZ.J_C5'/2O1YN6MIJ6**1ZE92\4:*3I10!?:[<EI$4EC!<TK\SYK]G4.;SO
MEQNURDINFAB4UC`QI^9/FQ_"?P]*O:FUVKUIV91%CJ.!8(!`HB000!(X*6ET
M%4AABC4)9%"A1Q^/;-]?I9IX42`.?+T^?2O8]BFWVZ6>Y<BQ_%4'4U",@T\S
MTOMM=?[(V=/75>U-G;6VO5920292IV[M[#X6IRC@AM>1J,914LU<Y?DF4N2>
M?K["C%F)9FJ2>I>C0)&B*.T"@]:#`J?,]/\`F,-B=P8ZKQ&<QN/S.(KX)*7(
M8K*T5-D<;D*69=,M-6T%9%-2U5/(O!1T93^1[UU?K#A<!A=LXJBP>VL/BL!A
M,9!]MC<+A<?28G$T%/J9A!0X['PT]'20AG)"QHHN2?S[]U[IIIM@['I=T5&^
M:?9VUJ?>]92+05N\:?;V'AW55T*B-5H:K<45$F8J*0)$J^-YBFE0+<#W[KW3
MOEMOX+.R8N7-X;$Y>3!Y*+-863*8ZCR$F'S5/%-!39C%25<,K8[*T\%3(D=1
M"4E1)&`8!C?W7NLV5P^*SM&<?FL9C\O0&HHZLT64HJ;(4AJ\=609#'U1IJN*
M:$U%!7TL4\+Z=44T:NI#*"/=>ZA9?:VV]P5.$K<]@,-FJW;.17,;<K,KBZ'(
M5>`S"P2THRN$J:NGEGQ.2^UG>+ST[1R^-V75I8@^Z]T\RK%,KT\J+(DB-'(C
MHKHZ.MG1U<,K(Z&Q!!!!L??NO=!MM+I+IG8.8J-P[$ZEZSV5GZM)8ZK-[2V'
MM7;F7J4G.J=)\EA\31ULJ3MRX+D.?J#[]U[H3_?NO=>]^Z]U[W[KW7O?NO=<
M"ZA@IO<V_']?I[]U[KG[]U[KWOW7NO>_=>Z][]U[KU[_`$]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=<0P8D"_']1;_`&WOW7NN7OW7
MNO>_=>Z][]U[KWOW7NNF8*+GZ>_=>Z\""`1]#[]U[KOW[KW7O?NO=<=0U:>;
MGZ<&QL+FQ^GOW7NN7OW7NO>_=>ZXZAJ"\W-[<&QM]>?I[]U[KE[]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>ZZ/T/^L?\`>O?NO=0/?NO=?__2W^/?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]UTS!1<\#^O]/]?W[KW7`2H2`"3<V'''/OW7NLGOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>ZZ9@HN?I[]U[KP((!'T/OW7NNM"DWTB_]??NO=>):XT@$?FY
MM_MO?NO=<O?NO=8*B".>)XI5$D3J5=&%U=3P01[\K,A#(:$=-R1)*C12(&1A
M0@^?0&[IVS)@I&K**.23'R%@F@:GI7D/$<M[ZH0Q%C]3^?8TVO<!>*L$M/J`
M.).&'^2G40<T\O+L\IN;6!OH9#4D"H4CR/GFN.F_#[AFQ%5!/$R-%*!YX2S_
M`+ZE`VHJOIN+\&WTM[=NK".^AEJ=,BX4TK3U^WI%MF_R[3=121Q.L;`:E;%1
MY'Y`\1T.6.KZ3+T4=72LLD4J@E6L60\AHY%YL5/X/L&3PR6MPUO,M)E&3Y?:
M.IALK^TW.TCN+=PUNW$>GV_GU[(5]+BZ5IZEPD=M"J!ZY&Y*QQ)?U-Q]!^/=
M8X6FF5(Q65L#_9ZM=W<&UVS7-Y,J6L:\?\`IZG@/GT!F=SD^;JU,K%8!*8Z>
MD`/CA4#4QD.L:G('J/(^H^GL9[=MT=B"[+6X]3Y?9U#F_<QG>YRAU1V8^%?/
M[6_I'S'EZ]*7;.VFR,HJ:M"M&KA4U`AI$4#5&@Y"*Y`O;@#CVDW2_%O15<&X
M/IY?/[>E_+G+PWIOJ+F(FQ0TJ<$T\J>G0O04\5.BQPHL<:($1%%E51]`!]![
M"C,SLSR-60^?4NPQ1V\*00H%B44`'IUG]ZZ<Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>ZZTK?5;G^O^PM_O7OW7NN_?NO=>]^Z]U[W[KW7O?NO=>]^Z]UQ
M*J3<@7'Y_P!;W[KW7+W[KW7O?NO=>]^Z]UX\\>_=>ZX(@0$`DW/OW7NN?OW7
MNO>_=>ZZ8A02?H/^1>_=>ZXJZO>U^/\`#W[KW7/W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UP=D%E;F_P#A[]U[KF``+#@#W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW71^A_P!8_P"]>_=>Z@>_=>Z__]/?X]^Z]U[W[KW6,Z_(+?HXOR/]CQ]?
M?NO=<FOI.GZVX_WQ]^Z]UB(ET#ZZKF_(^GXY]^Z]UF^HL?R.?^)]^Z]UC54-
MR%`*L1_MOS[]U[K+[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NNB`18BX]^Z]UZUA8#Z?0>_=>ZZ
M2X4:OK^?]O[]U[KE[]U[KWOW7NO$7X/OW7N'4::))5DBD17CD73I8!E92!J!
M!O\`GWM*JP=20P\^J/%'(K)*H,)&0<CY8/0)[GVR<+.M=")9:!Y+#2@9J5M#
M*L5E7@$$:6^GX/L7[3N7CP/;S-6Z'"OXO^*X=1#S)RS)M]Q]9%(7VYF_WCU^
M?'@/V=-^!STN%JE>,L],R,)8?TB:YUZE'XF)/'M1?;<+M:JM&I_/I!LF^+LT
MZ-K)MM%''\35P?D?LIUFS67_`(]4"I82^&-62*$L8?`I91J0M8M,]_J!S[9L
MMO:PBE$B_JGS^7'IW>-\EWF\6<*4A`H%)J/M(X5_U#I]P&UDR,AK*CR1TOD)
M*$%?*ZCQL@)`(B*BY_))/M/?;HUNGAHWZOK_`(.EFP<LG<YWNIE`LD_XV?,=
M"Y##%#'''%&L:(JJBJ+*H`L`!["Q8N[2,:N>)_GU+,$,4$210H%0`8'6;WKI
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZXNVA;VOS]+V_XK[]U[KM3J4'Z7_'OW
M7NN_?NO=>]^Z]UB>70UM-_\`&]O^(/OW7NN+^4FZ7M8?D?\`$^_=>ZSCZ"_U
M_/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NN*@B]VU?["W_`!7W[KW7
M+W[KW7O?NO=>]^Z]UA7S7&KZ7Y_3].?Z>_=>ZS>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NN*ZN=7^J-OI^G\>_=>ZY>_=>ZQC7Y#?\`1S;D?[#CZ^_=>ZYE
M5-B0"1]/?NO=<1?6WKO;ZK;Z7''/OW7NN?OW7NO>_=>ZXZ6UZM9T_P"HL+?C
MZ'ZCW[KW7+W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
MT?H?]8_[U[]U[J![]U[K_]3?X]^Z]U[W[KW6-U#^G58CD\7^O^V]^Z]UY/("
M0_T'T_3_`,1_A[]U[KD%]1:_U`%O];W[KW7M/KU7_LZ;?[&][^_=>ZY>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KBUK6)MJ](XOR1Q[]U[K&$9%(0W)(_`'^]DCW[KW65;Z1J^
MOY^G_$<>_=>Z[]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4>>!)TDBD4/'(A1U/T96
M%BIY!''ORC2_B`]W5'CCD1XY$U(V".@4W+MB3$5'W-*I;'N=*M;7)2WUMXV]
M)4)8^EC8^Q?MNZ"YC"3&D_K_`!#T^74/\R;!+LTIO;8%K)CVT%?#'FI\^.:\
M.IFW=L397Q5-2S"AC8,1]?.4)"I&Y^J$&Y(XOQ[:O]R%KX@B&J8C'RZOL7+M
MQO!@O'8I9`]W_#/D/.@XUX=#%#$D,:Q1J$1!I51]`!]`/86+.Q+2-5R:GJ7(
MH8X(TBB%(U%!UE]ZZ<Z][]U[KWOW7NO>_=>ZZ)('`U'^E[?[R??NO=>%R!<6
M/]+WM_L??NO==^_=>Z][]U[KWOW7NNB0HN>`/?NO==^_=>Z][]U[KCK4-IOR
M?Q8_\4M[]U[KLW`-A<_TO:_^Q]^Z]UX$D<C2?Z7O_O(]^Z]UW[]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NN*ZK'5]=1M
M].5OP>/I?W[KW7+W[KW7O?NO=>]^Z]UT2!]?R0/]B?I[]U[KOW[KW7'6I;3?
MD?BQ_P"*6]^Z]UR]^Z]UQ8,2+-8?D6!O[]U[KBI4.PU7)-[6/%O\?H??NO=<
MR0`2?H/?NO=<!ZRX/*W6P^GX!//!^OOW7NN8```'T'OW7NN_?NO=>]^Z]UQU
MJ&TWY/XL?^*6]^Z]UR]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=='Z'_`%C_
M`+U[]U[J![]U[K__U=_CW[KW7O?NO==6%RWY(`_VWOW7NN_?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]UQUIR-2W!L1?GC_#Z^_=>ZZ\B?ZH<_XV^G/OW7NN]:?ZH?6WU]^Z]UQ+
M1L0-:W!##U#\?0_X_7W[KW7B4U!M:V`(X(/)_P!;_6]^Z]UR#J?HP/\`K&_^
M\CCW[KW77D3_`%:_[<?ZWU]^Z]UQ+)J5M:\!K\WN/]?Z<$>_=>ZYAE)L"+VO
M_L/?NO=>UI_JEY_Q'OW7NNM:#^T/?NO=>\B?ZH>_=>ZCU,--602TU0(Y89D*
M21O^ED/U!^GO:,\;!D-.FI(8YD>.5`R,""#Z'KNDIH*6)(*=42&)%CCC3]*(
MHL`.2?I[W([2.78U/6H((K:&*W@0+`BT4>@ZDE@MKFU_Z^Z]/=<?(G^J'OW7
MNN]:VU:A8_0^_=>ZZ\B?ZH>_=>Z[+J+78"_(_I;^M_I[]U[KKR)_JU_VX_WC
M^OOW7NO>1/\`5#W[KW7+4M]-^?Z>_=>Z[)`^IM_K^_=>ZZU"VJ_']?\`>/?N
MO=<6*%>3PWT_QL?^*^_=>ZY$@6!_/T]^Z]UW[]U[K&8[R![\"W'^M[]U[K)[
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KBK:E#
M?2]_]X-O?NO=<O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW71`-K_`(((_P!<
M>_=>Z[]^Z]U[W[KW7$D:M)'U4F_^\$>_=>Z\J!+@?GW[KW7+W[KW7$A77^H/
M/'OW7NNP`"3^6M?_`&'`]^Z]UYCI!-KV]^Z]UW[]U[KWOW7NO>_=>ZXLMRIO
M^DW_`-X]^Z]UR]^Z]U[W[KW7O?NO=>]^Z]U[W[KW71^A_P!8_P"]>_=>Z@>_
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M<+04L@``DM[_``]:HU:U[>LO4/=E!NCK_NBBF[%V_F>R=A[W^25/5X6+/82I
MW3M?`;1[.WWB-HOE-OTLPR&-Q^/PU#11P25$"J\?C)9M8)]ULT\N'19_C_W!
MELQ\&MQ]G;O[GS&(W$NT]MYE>R,?VKM/Y"YS'[TKMK;=KL;0T&`P6W\/24F5
MW#NRKBI!LR2.2LJWJ_M4D5YD9=CCGKW2AVQW?W)DOB_\J>Q]_P"0KMC_`"0V
M9MG/',]/THH%Q/1.7Q^ROOMD1;8EJ8*M]QT&ZJ2HCSCYBHDJ:>JJ9Y:2,*M"
MR#=`32M!UX=+3M#M[MWJ[N3?F\HLA6;GZ0ZXZ:ZRKNS.OL;@(LEN/;T>ZLEV
M5)E^Y]GRX^G?+9NJVI%MV$9?"VE%5B5>:D45-.(JBIP:=>Z0]3W/NS,]/_!R
M3>';62ZYVGWEUU!G>S.ZL;/MS;F1RNZHNM,/N79^T:?>&>H)=L[%E[(R5=5U
M2U1@2:H&.-'3F)ZBX]U[J=NKL;*[V^"V\NV.O>S^X]M9GK?&=H_PG<]1N3KS
M*;JS&=Z_SFX-JS?QW.[9Q.:V1O+;JY'&L])540T5M.D4ID9F8GW6C7R/2_[E
MR^<Z^S?0O5.6[WW?U[UOOFI[%EW?W/N#+;6@WGDL_M[&X7)[*ZXI]]9?`1[5
MVJVZ#D*^J6=Z+[NKAPYI*=U>9F/@DTA811DJJZF(SI`.?R^?EUL#RKT'=1VE
MW'N/H+=R=;=OTM9GL;\I=E=.=2]^Y';&$W'C]Y[,K]][`QLV7SF)Q\6-VYO"
MBI*S.9+;^0K\8*1,A'023T[0SG6ONO=+[J/Y.[DW/V=WAAM\8'<N#R/174NR
MY.QNK<)MC)9W(4G8)W'V4V3SW7B4F.?/[ZVMV!MC$8VKV\\`D:JIR(S%'5I4
M1K[KW3QW-VWD\QNWX];4B["SWQ\ZZ[@P.]]P9C>F7Q.*VCOBIS^!H=JU>UNI
M8).P\-7T&Q-R9ZASF0R%0M32?Q)XL/)!3!&\K+[KW04?*SL?MO8_5G2=-\?]
M_P"]NV\]F]S]CT$VXME93JFKW=O6DV9T_P!G[QHXGKJW:]5L[-'";@VU3?>T
MF/H8J_)I2/31#[B0JWNO=3=T]W;DWCV)\:^N\AW?3]3]9=F?'K*=MU_<NSZ?
M`;=?M7L?%5.SZ!.O-I9SL'$9K"[1IHL;G*O/5%`U.V:GIX1$ACBIZSW[KW4#
M)=V=L9?XOP;ZQ?9.-K1M;N'>^!J-_83*[`V+N?OOI[K_`"FZJ--P=6Y/=V+R
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M^[HYP&CCJTGB391EHQ/8>O$Z15AV^O\`D_R]*CXS]IUN?W#LC'9SO3='<>X.
MS^D(>W!-28;JJCZEIO#E-NTN?I]E)M*GCWSM^;;]9N6GHQ19B:L62!@6J):J
M.8ALEC("G]D?]7'K096`9,J>!Z6O>79N=;L3H[J_;?8]'U;M/MB#L2LRO:E"
MFW*[*U60V9C\%48/KW8]=NBAS.SJ;<6[(\Q6UYGJ:>KD^QP=2E/%Y&,L3@4E
M-?EU:F">D]VUV+NS96R^D-GX'NZ!H>S^USUEN/Y'Y+%;(R<^V*"+"[OS\82/
M&XVGZVI=Z9[*;>I]MT-1647V,=?4ZGII:DI"_O(]4=79>Q])KQX_X>@AW=WI
MVSL7ISYN8W;_`&C3=@9CX][6P=3UMW;D,%M:NKX]Q;IVU4Y*NVWO+';<H,1L
M?<6X>NZN.GGG%+2T?FH\C3QU$:S!I9-=6'`9Z$[KWLGY33_(WKO9/<>-V'L_
M:&7ZJ[79MO;3F&X*K>NZNN\]UA0'M5,Y*1-MC:FX8-VR_P`*V^RO74D;2&NG
M>01*MB%"K_$>O?ET?#W7KW7O?NO==$7!!_/OW7NO`!187_V)O[]U[KOW[KW7
MO?NO=>]^Z]U[W[KW7O?NO=<5#?VB#_K"WOW7NN7OW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NN*W]5_P#5
M<?ZW%O?NO=<O?NO==*`H`'T'_(_?NO==^_=>ZZYN;VMQ8?[W?^M_?NO==^_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NNC]#_`*Q_WKW[
MKW4#W[KW7__7W^/?NO=>)`%SP![]U[KH$$7!N/?NO=<$+DMJ%A^/]O[]U[K)
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KJP_H/Z_3_7'^]'W[KW7010+!5`-[@``&YN>+?DGW[KW7M"7
M!T+=?H=(N/K]#;CZ^_=>Z\44D,54L`0&(!(!*D@&UP"5'^V'OW7NL/VE+^S_
M`)-3_P"3R-+3_LQ_L2LLB-)#Z?VI&25@2MB0Q'Y/OW7JD<.H%/@,%25M9DJ7
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M;6'O77NLBT5+%52UZTE.:^HA@I9ZU8(5JY:6EEJ)J6FEJ`@FDIZ:6JD:-"2J
M-(Q4`L;^Z]U`W#MO;^[,7/A-SX'";DPU64-7B-P8JAS.+JO&VN/[B@R,%12S
M>-^5U(;'D>_=>ZX4.V-OXNGQ%'BL%A,;1;?5EP-'08JAHZ7!B2":ED&'IZ>"
M.+&"2EJ)(F\(2\<C*>"0?=>Z:LWU[L/<>WH-J;BV/L_<.V*>J2LAVUF=L83*
M8"&JCDFF2IBPU?13XZ*H26H=A(L8<,[&]R;^Z]UGS>Q=F[FP=-MK<>T=K9[;
ME&:(T>WLWM_$Y;!4?\-31COML17TE1CX'QZ>F$K&/$O"V]^Z]URR&QMFY;,8
M'<.4VGMC);@VL)1MK.Y#`8JMS.W!.@CG&W\I44LE=AEFC&EOMWCN.#[]U[IS
M.`PS?<*^)Q;QU>3@S52C8^D*U.9I32M2Y>I4Q:9\G3-0P&.=[RH88[,-"V]U
M[KFN%Q292?/1XS')GJJ@I<759M:&E3*U.+HIZBJH\;/D%B%9+04E5632Q0LY
MCCDE=E`+$GWR\NO=)K;7677>S<QF-P;2V%LG:^=W"7;/YK;FU,'@\MFGDG-5
M(V5R.-H::KR'DJF,K>5VU2DN?42??NM``"@%!UWDNM.OLSM2+8F8V+LS*[*I
MS!]MM#);8PM;MBG%-*TU-X,#444F+@--,Y>,I$"CDLMCS[]UOKD>M]@/LQ^N
MGV-LU]@24AQ[;%.V,+_<UJ`SBJ-$VV?LOX,:4U0\OC\.GR>JVKGW[KW7>,ZW
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M]^Z]UR]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW70`%[?DW/^
MO_OA[]U[KOW[KW7O?NO=>]^Z]UT?H?\`6/\`O7OW7NH'OW7NO__0W^/?NO==
M$`@@_0^_=>ZX$K$H`!()]^Z]UR#J02"..3_A[]U[KO4I&JXM_7W[KW76M#_:
M''/OW7NN@Z'@,+GW[KW7+4M]-Q?^GOW7NO7'//T^O^'OW7NN/D3_`%0]^Z]U
MV65?J0/?NO==AE/((('U]^Z]UQ\B?ZH>_=>ZY:EOIOS_`$_V%_\`>O?NO=>N
M+VOS_3W[KW7?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NN`<%REC<?GW[KW7;-I4M];6_WDV]^Z]UX."NL\#_'_7M[]U[KE[]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KH@&U_P0?]B/?NO==^_=>Z][]U[KBZZE*_2]O]X(/OW7NNR1]#_0
MFWYL/K[]U[K'$0;V%@+`?U^G-S^??NO=<]8U:?J>?]A;W[KW7+W[KW71(!`)
MY/T_Q]^Z]UTH(%B;\D_[<^_=>ZY>_=>Z][]U[KWOW7NO>_=>ZXJP;5:_I8J>
M".1]?K]??NO=<O?NO=>]^Z]U[W[KW71^A_UC_O7OW7NH'OW7NO_1W^/?NO=0
M<E#5U%#5P4%6^/K)J:HAI<@D,52U#4RPND%8M+4`P5)II&#B-_0]K-P??NO=
M`=3]=]UQQA9_D1E*J0`WD?JSKZ.Y(^I2*G518_TM[]U[J7_<+N+\=]9'_P!%
MGL7_`*]6]^Z]UW_<+N+21_IZR%_P?]&>QO\`;D>*Q/OW7NN#;`[F*VB[[G63
M4#KJ>K=F3*$%_2JPRTQ#$GZDD<?3W[KW6,=?=W#3_P`9_A-K:C_HEVJ"Q'U-
MQDK+?_>/?NO=9!L/NU0Q/?<3M?TD=4;7%A^+C^*`M;_7'OW7NL9V)WI:,CON
MA4K_`)T?Z(-O7FO>QL=P^BP/X_I[]U[K@=B=[!BZ=\XW3;THW3NWV*GGFZ;F
MC8_CW[KW7%]B=\NY8=^8U%+$JJ]-X!M">KT:GW0['ZCG_#W[KW7AL'ODZB/D
M!CT!``7_`$.;=^OY;_CXR3?^GOW7NN+;![YTJJ]_T`*L"S#IO;I#+S=0/[R#
M3>_U]^Z]U*397>BV+=Y8AS>[$]/8@,PO]/3N\6L.+V]^Z]UEDVAWO>(TW=.U
MU"K(LWWG3<50TS,X:)E:F["H?$(ENI%CJ!OP1[]U[KC_`'7^0<<JO'W#UY/$
M(RKPU?2F4!,A!`D66E[:A*A>"!8W_/'OW7NI+8+O[@IV?UA<V%GZ?W$5N&.K
MA>WE;E3;Z_47_P`/?C4NI&(QQKQ/V>G50'KQQUSFP??Q9?MNR>KD6YU"HZBW
M)(2+"VDQ=N1`&]SS?\>ZJ'[M9'''V=6ZP'"?(FSA>R>HR3IT%^G]V^CU7<L%
M[C42$KP`-/\`7W;KW4A\3\@R"(]_=0J?P7ZHWBW_`,U^,>_=>Z;WQ'R8TRZ-
M_P#2.JY$&OJ??)!76FEI@G<%P_CU7"\:K?B]_=>ZXKB_DTJ@MOKHZ5KBX_T6
M;\A4@$W^G;<K\BW^M_C[]U[K(:#Y,W-MV=%:2Q*@]>=@7"<65C_I.LS_`.-A
M_K>_=>ZR_8_)'3SNGI#7_4;`W[I_]^23]/\`'W[KW7,47R,MSN?I0M?FVP]^
M*-/Y%CV*QO[]U[KJ2B^1I0"+<O2:RZG+22;%WXZ,AMXT$*]A1LK*`;MK(/\`
MJ1[]U[K'-2?)/PQI!N#HYYS(YFFGV;OZ.%8BH\2Q4J[ZD=Y%:Y8F9018`#Z^
M_=>ZC1TOR<TH*C+=#RE2-;1;;[#IU?GDK"VZ:C1<`<%WM[]U[K--%\E]:?;5
M_1A31^YY\/V`C^3B^@)FV&@_X\^_=>ZQ^/Y.V;_+>A]5O3_N+["M?_'_`'+D
MD?ZWOW7NL$D7RD8*$JN@C;5K+T'8RW.DA-*KDKBSV)N3<7''U]^Z]UF4_)JS
MAY>B-9-HM-/V$%6RF^O5.2]W_IIX_K[]GKQPM>N)_P!F@N-+]"D7YO%V(/3^
M;6D;DCW2DE?PZ?Y]>]*==-_LT>LZ&Z#\>G@.G8@?7<?4A[:;7_%_=^O=9$;Y
M-E?4.AV8:E?0>P5"L"+%;JY<:?J..?S^/?NO=9_-\DM5OM.CR+&W^Y#?RDD?
M3C^%L`#_`*Y]T.NN*4Z]UA>;Y-&P7'=%."1<-F.PHN.;D,N"D_-N+>[]>ZQI
M-\H!I#XWH6U^=&;[$-EM]!?;YN;_`))]^Z]UECJ/DWJ/EP_1)34-(CW'V`K%
M-"WU%MJD*_DO^"+6_/OW7NI7W?R+8Z6V_P!*Z?\`5#=^_%/_`"3_`''M]?\`
M:O?NO==R5WR(0@1[>Z5("_67>>^D);_"VPY/3_L3[]U[KBM;\CK^O;?20%CP
MN]-^$W_')V`+#_8>_=>Z]][\C_5?;727^T6WMOPW_P"#?\8^&G_87]^Z]UE2
MO^1&@:]L=+^7FX7?.^A'_@;MUUJ_V'OW7NHO\5^206-CLGI1F9F$D8[*WP/&
MH`LRR?Z+&\I8_C2MA^??NO==#+?)+D/L3I>Q^FCM#>U_S]2>J!;W[KW72Y;Y
M)@@?W"Z5T?D_Z4][%O\`8`]36_WGW[KW6=<O\C+'5L'IN]SIT]I[RL1;B]^I
M."3_`*_OW7NNOXQ\B^-77_3Q6S:@O:F\-7TXTD]3*.??NO=>3._(52`W6?5-
MN"Q7M[<QYL+A0_4=[?ZY]^Z]UR;</R#7]/5O5TGTY_TP[AC_`-5<V/4,G^''
M^OS[]U[K@=Q_(<`6ZGZM8_VA_IHW"OY_LG_0VU^/];W[KW7*/<GR#,JB7J;K
M%(+>N1.Z<])*#_M,3=-QHPO_`%<>_=>ZD'<?>XM_QBOKH_6__&8<R./P1?J7
M\^_>1]>O&M"0,]8TW1WQYF$O4>P!3@C3)'W)D7F92MR3"_5,2`AN+:_\??J'
MJBLQ%?#/[>L`WCWQJ93TEM32/TNO<L9#\_4`]>HP!']1[T:`@*VKJ_7EWEWN
M5NW2&V%>S>D=R0,O'Z1J_N"#S_K<>]]>ZX'>G?(6_P#H-VRS&P`3N6FL"3R7
M+[#2R`?ZG4?\/?NO=11OSO\`!.OX_P"$L#8&+NC$."+L+CR;.A/(`-C;Z^_?
M;U[J2=]]W@%AT+2D@-=!VSMNYLMT"DX4`EVXY*@>Z,X`J"-51C[3Q_+CUOJ*
MW8/>XCUCX\Q.UE_:';VTP]RMR`S8I8_2W')]ND*"0KU`\_7K77<?87>K*2_Q
MX,;!&8+_`*6]G-=P.(P5H+`M_7Z#W7KW7`=A][7Y^.Q`TDW/;FS?U"UEL*'\
M_P!??NO=3%W_`-TV;7\?ZD$1H0(^T=E.K2,7#H"Z1$(@`(8@$W^G'/NO=89.
MQNZ8PI'QURT]V4,M/V?UV753?4P^YK:5&TV^FH$DC_$CW7NO1]E]Q>%&F^-^
MZ%F8VDBC['ZKE6,7(U"5MRT^L6L3Z0??NO=<CV3VZ6#?[+CNRZW_`.:A]4\W
M'Y_W]7OW7NL3]G]OQ_3XS[SE%^1!V'U`6MSR!/O2G!^G]?S[]U[KG!VCV:R"
M2H^-?95/.68&*/>?2-1&!J(5O*.SH[W7D\<?3GW[KW4__29V)J`_V7GLNVI0
M6_O/TQ:S&Q8?\9-!LGU/T-OI?W[KW73]D]AD:A\>NR)2KZ0J[KZ84E6!N]V[
M,0!1;^M_?NO=<5[-['+*K?'3LN-";%VW7THRJ`.6(C[0D>W^L/?NO=>;M#L)
M>/\`9=NSF&@,'3<W2Q!)?28_5VBAUJ/4>--OH2>/?NO=<1VIV#=O^<<NUB`A
M8-_>+I2S,!<(`.U;W;Z`FP_J1[]U[K@>UNP5*AOCAVP`4=RPS_2SA2MBL1"=
MJEM<E["P*BW)]^Z]UD/:V^AI_P"<=^V3<`M_N7Z>NM_J/^9H6)`]^Z]UP';6
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M+V_U^;^_=>ZY>_=>ZX.+KI!`8_2YM]""?\?I[]U[KM`54`FY%_\`>R?S[]U[
MKE[]U[KK4O\`JA]=/U'U_I_K\>_=>Z\"#]"#;^A!]^Z]UBD!)!U*@'T)^MR/
M\>#_`*WOW7NLH(/`8$BU^1?_`&-OI?W[KW7F.D7LQY^BBY]^Z]UP(+,MB%'#
MD?1S]?J/Z>_=>ZYW!^A!MP?\/\/?NO=>)L+V)_P`N??NO==<E>."?]5<$#\_
M3\^_=>Z[`L`.3;^OU]^Z]UW[]U[KU@?J+^_=>Z][]U[KHFP)L3;\#D_[#W[K
MW7@;B]B/\"+'W[KW7?OW7NO>_=>ZZ-[&UK_B_P!/]C;W[KW7E%A:Y/YYY^O_
M`!'OW7NO7`-B0"?H+B_^V]^Z]UW[]U[KWOW7NO>_=>Z][]U[KJP/U`]^Z]7K
MUA_0?[8>]U/KUNI]>N_=0`.`IUKKWO?7NO>_=>Z][]U[KWO5!6M,]>Z][W2F
M!PZ]U[W[KW7O?NO=>]^Z]UU<7M<7_I<7_P!M[]U[KOW[KW7O?NO=>]^Z]UU8
M?T'^V'OW7NN_?NO=>L!]!;W[KW7O?NO==6']!_MO?NO=>L/Z#_;#W[KW7K`_
M4#W[KW7@%/T"G_6M[]U[K@%5-*69KZO40#:W/J/%KWX]^Z]USL/Z#_;>_=>Z
M]8?2P]^Z]UZPXX''T_P_UO?NO=>/T/\`K'_>O?NO=0/?NO=?_]/?X]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1ZA]$;L&TE$=[WL!I4M=O\!;W[
MS`\SP^?6JC-3@#/RZH`ZE^2_\TSNZIJJK8]5U(NV*C''-4>\,OL:EQ>S:>I?
M,24@V729J?,35F5SM'C'AGE=J:)'U.4.E1JN(W+%=-"./R/IU76ND.#53PIY
MUX'H=ZC,?S=Q_$*>GW5\8H99J>6/'5%7A/N#15+PF.&IDIH<E1K6I#.0YBUI
MK^@=1S[OX#_+KP=3U)IMR?S:PL,=9E_C$U4(J<3?;43+$TL5/&*F01/DY)%2
M><,P`D]`-A]/?O`DXA:CK98#I!3=L_S:J7LR'8TU9\:'7);+GW'0M_#M$8EI
M<U44E5-%6C,LKQTT*QQ/#(H?4_D5B+K[IX<H('A-2O6M8]#TI9-W_P`WPI6)
M'DOBS%*5=::5Z%IXX)&0^/5&,_2LUB0?43<CZ6/NSPRAR0A$7SX_ZOSZWJ'3
MG1[Q_FUPT\*5E1\8:^I6.DBJ)XJ3[57J4AC%5*(%W++XH)IU9M):Z!@-1M?W
MH1.6`"DUZUK'6!]\?S<?N5T)\7EHH8YED!A,M753-/!)%,LB;I2&F@@ITEC*
M^-S(TBOJ705?TD,L:@F,FO7M8I6AZ<#O_P#FM+&TPH?C;-+313U#4D4#54]2
ML5*T_P!M!%'NBFD\\K1Z4&H,Q;_8>]O"ZBM*];#@D#I,]?=L?S<]T[/VUN#,
M[4^/6W:[+X&"NJ<-N'"R8+<%)5G7&RY?"_Z1\DN&J974,U/YYO$&'J/T]Z2&
M9ZTB/568XTTZ8]U?(3^:9M#LGJ/8U5B?C7DX^RI]\PB:DIC#*K[6VW39I(DD
M??DE-2LLTA75(UIE/`4CWJ2-XB@<9;KRMCNX]"=%VE_--'+]?=`2`7#-3Y;$
M!'D*61@TF^ED&F9AKNOI'TN/5[N('-,=;+J.@DH?GY\SNH,CL3LWY3=)[?V]
M\<,Y6[BV]OVMVUB:A>Q^OJO'Y"*CH-[U-#1;ES]#7;1I/MZB6LIF1*N:A(JJ
M8NL,RBIB8`D\!U8&O#J[#:^Z=N;WV[@]V[4S&-W'M?<V-H\UM[.XBJAK\7E\
M1D*>.JH,C0U<+O%/35,$@96!_-C8W'MOK?3\J:68CZ-;_7N/Z\?CW[KW7;@D
M6!8&_!4VMP?U?[3[]U[KHV4JS$W("'^G];\\_7W[KW7)5`N0;ZCJ_P!O_3_#
MW[KW7+W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7KVY/`]^Z]UT#<7L
M1_K_`.]_ZWOW7NN_?NO==`@_0@V_H0??NO==^_=>ZX%`S!C>XM;Z6X-_Z>_=
M>ZY^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NNK"]["_\`6PO_`+?W[KW7?OW7NO>_=>Z]
M[]U[KBP)4@$@_@WM_O7OW7NN7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KBJ
M!;V+<_@GC_8"WOW7NN7OW7NNB?Q<7(X%^?\`7_K[]U[KR@A0";D?4_7_`'OW
M[KW7?OW7NNC]#_K'_>O?NO=0/?NO=?_4W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW70(-[?@D'_7'OW7NN_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U%K$#4U23_RKS@_ZQB<?Z_%_?A@@CB.'6BH
M.H$5!%#\QU4G_+9B,WQ+V85-XILOE6MH18]4BTL@\<8`NSEUUDBY8$_7V86K
M%M3+W-W:RWJ?,4IQQ3IAPJZ%"T04`'R'1^"%=)8PRR`2*Q=0R,;LBW:UK!+6
MN";CV]48[>'7F4'S(ZCM`JF)W4H%$RQN[/*K$^HLH%[BRD$W'U^@][JPJ5-!
MUM=2K0']O0*9$1/\@-IHR!ZE>J-SU$31@ZHXI-RT4#,`>-1DF0#C\GVR7<2J
MH;MI7K9J0,="X()@2@.DAD,DFB,Z6D#$+(+'5:P!'!`]NLQ([C4=5K7KDU.K
MD1I%=F+"0&[,UR02X1D&D$?U`/NH&"P-".MU`%*9ZXB*!%%M"J%,8`+:D+/H
M(DU:@=)!%CP`1_K^]DLV0U6].O#.#7KE3HL[:0\()E82:9'(N$/K(!`(*V'/
MT^EO?@Q!J`.O&E#Y=9(H5C+DHTD<BN6!U3,S1L@N]KE2.;D7MI]N4,H)8J:>
MN.JBH-=714>X(%3Y-?$4QJDJ)5=Q^56L65&V5CE8@J%*1\`&_J)/^`]I'KJA
M32*5/5@3CUZ-;3-&OGT^,",MXX]+>AB;6N6!>ZI?F_%O;^-14CAUXX/#/4#=
M>U,!OC;>4VYNO'4^<P6=IY*+*8VL4L)XY5!22ED56,-52R*LD4J$212*"IN/
M>G`8%2*#JRD@8'56FQMQ]B_RLNPO[JYN*JWK\`-XU<M3@ZJBI:JJW!\<]QY+
M(SU62J($U21U'7S13:Z[%0A3C?$];2%J=IH:<ODC*'^AUM7J:'CU>A@MP8C<
M^'Q6X-O9&AS>#S=#29/%9?%U459C<CC*^%:BCR%#5PLT-52U$+AE9200?;?3
MG3PPX^I%N;CZ\#Z>_=>ZX:XVLINW('(/#?2Q_P`??NO=91QP/H/?NO=>]^Z]
MU[W[KW7O?NO==$7%@2/\1[]U[KP%@!<G_$_GW[KW7?OW7NO>_=>Z\0"+'D'W
M[KW7!G5`"QL";7_'^M[]U[KHN=84+<&W//Y]^Z]UVJ!22"3?W[KW7/W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW6-G*L`%N#;GG\FWOW7NLGOW7NO>_=>Z][]U[K
MCZM7(&G^M^?]M[]U[KE[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZZ8D`D"Y`
MO;^OOW7NO`W`/^^'^'OW7NN_?NO=<%C52Q'U9BU_]?\`'OW7NN?OW7NO>_=>
MZZ/T/^L?]Z]^Z]U`]^Z]U__5W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
M0`%["US<_P"N?S[]U[KOW[KW7O?NO=>]^Z]U[W[KW7O?NO=<=7JTV8?T)'!_
MUC[]U[KE[]U[KWOW7NO>_=>Z][]U[KWOW7NH.1<I153"_%+5,0."=-/(>"?H
M>/?NO=5)?RR:6/&_$'KBFB^_D5GJJFGFRDZU-8R9&FQU5KJJH11"28QR<G2H
M"D`?2Y7VQ4Z]7F,_,CA]M/+IB4=P^WH^7D+,A6^B/4P%R``#$H1U8Z&,C@B_
M]#?V_P!:&2>H\KVC50&\8+M=;D+K4@FS!3:-B;<6`N.??LTZ]7Y]`OE9U_T^
M[:*16E'3^XPL\7E96MO'$,I+V#JA9`>!R?I[:?,R4].MZOET,K3,VF[M'XW\
M)"Z3&7`<ZP_ZRMC];W'M[2`#5@?SZV!Y$==J9'E$9<A7NS/J>]A8)&')*,5^
MC7_WCVVM#J'EUHBAK7'7"8#4A8CE+7)U%S_M3#TLM_I;Z>]@Z35<'K8X#T'7
M44P$<T4;+H*I$=+%'C9=06S7OJ>UC?@CZ^W'5JY;AUKYDXZZCE5'C='7QE#<
MREEU.0I)/#,NBUN>"3Q[H`#04QUX"M:]%5[>CFE^4OQ/,4R-''1=W5M0)647
M5=K8.)2R!0SNL4K%!_0$_CVG<`21!<9Z\,]&XB;[A(Y$NLGA!CNUW96&DMXP
MG+L$')%^?:MQWBE*D=;H3PZS&5[1>5'"*(RT6CQRQEF8CTJ`Y'JO<#202/;8
M4C+=>J:5Z:-T[7P.]<%F-J;FQU-EL!FJ2>CR6-K5/@E@<:H32Z@'IZZ(,7AF
MC*R0N`RD$>]%->"*J>JD#XB.[JJ;9N^]_?RM^T*3:.[<CD][_`7L+,"+`Y<T
MU559[XZ[KR>1BA#*T3)1Q=72+(6R%`B!,4S"JI@M,TD,2"6+PCCA7]G3BL<#
MRZOCQF3QV9Q]%F,564F2QV2HX*_'9"@J(JNCK\?51K44M91U,+/%44U3"ZNC
MJ2K*0?;?3G4DB1E!LJ$D/>]]+&]K@_6WOW7NLXN``3<V%S:US;DV_%S[]U[K
MOW[KW7O?NO=>]^Z]UT2%%S?_`&`O[]U[KP-P#_7_`&'OW7NN_?NO=>]^Z]U[
MW[KW71TMP;'_``X/OW7NO$V%_P`#^G_%/?NO=>!#"XO_`+$6]^Z]UW[]U[KW
MOW7NO>_=>ZXJ&!:YN+W'^M_3W[KW7+W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NM5'KU[W[K?7O?NO=8U<L6!6P'Y]^Z]UDO?Z>_=>Z][]U[KWO
MU>O=>]^Z]UX_X?7W[KW72WTC5];<^_=>Z[]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>(!%CR#[]U[KH``6`L/?NO==^_=>Z][]U[KWOW7NO>_=>ZZ/T/^L?
M]Z]^Z]U`]^Z]U__6W^/?NO=>]^Z]UU<7*_D`'_;^_=>Z[]^Z]UQ5U8D#ZCZ^
M_=>ZY>_=>Z][]U[KWOW7NO>_=>Z]?W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U`R@!Q];_7[.KM_3FFE^I_'OW7NJD/Y<5;_$/A[U?/
M1Q/#3U=."M)6T=90U*LF-Q*63'U\-+544BJANCJ+\$7#`E=;&/367[!3.?+I
M--QQPZ/<\L;,-4<:/ZIO3($#LE@Y="YU$B,GZ\_CZ6]JJTZ8X#CU@$ADBE;2
MB@/&+)*SFSZF#*I4LBF_-B!8$`_3W4\<]/(H(H./1:>P=PUVQNW]L;DGP,U5
MM^;KW*[:FW%4YK%;=VUC\U5;KI*FDQF0S.:JDQ^)R-=`-4'G\4<X%ED:0!/:
M8G]=33\/6U[&<G@:]#!M'>*[OQ^7KI,96X6KVQN_+;2RF,K*JAK6CRN(CQU1
M*]-7XZJJ*2MH*FFR<,BR*0WKLRBPN_&5E8H$`IQZL*%05-.E@SL9/TJ\;W+J
MKF34YL5#E2NKE[V!^@M?W9:9`(ZJRZJ4X]9)5C(BA0(KJBA8R\H&B0FSRG]P
MBQ8V`L>/?BJUJ3GJP6B@5ZX-:$2O&/''YU5G42%U-S=K:1;4P-B+W`Y]VJ*R
MD>?#]O6J\<9Z0&]LSN.%<=MO9,F(_OSN.DS$V)R6Y*:LKMK[?HL3'#]UNC/X
M[&U%!DLM1T^2KJ6".CBGIY*J6H`\J+'(PKECI'Q'_)U;&*=$MP_;R=D=_?$R
MHS6*KMN;\I8_D7L?LK:LE'63ML_L[9VT\`-U89JQ8/MEV_6I70U^%K))%3)8
MFMIIXKERJIM2ZE;CDU`X]:\J=6,4TH<,2J!H6(64:P96M<DJIX5;?2X^E^?:
MEA0]>J0,G/4AGULFJS:F8J;R2%FU^I;*/VHRPX#`D_CWX`YIY#K9%14]2KAV
MB'J\<;R2M&NH7C`(2;4Y#ZD_'(!'O0(-<=5!Z2.\]F[9[$V[E-I;NPU!G<!N
M2FDI*W'UL7D26.1)45H9"LD<5=")"$?2;W*D,K,I\8T*G4<=5:10*BO5-'3'
MRISW\O/N/=/362J=S]P_`S"9B6FK.V:.FKLK!\8,UE)'FEVW15R4M0NYMCX:
M>TF6H:>9I,%"9:BF$M+3SI&7R1Z7HA!2G'_4.E;Q36Y19T*EA45]/7K8UQ&5
MQ>X,5C\SAJ^CR^&R]#1Y+$Y7'U,%;CLKC*^FBK*'(T%93/)3U=%64TRR12(S
M(Z$$$@^VJ4ZUTY^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KI
MAJ!']??NO=8EA"D&YX]^Z]UE)`!)^@]^Z]UW[]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z)1U=\D=[]Q=1_(;>V
MW,1L'9.X>GN\^^>H<54=@97-1;(_A?2N\:K;]1O+>-9CJ892AI:O$T$]9+'3
M^A+*/($)<7=60@,0:@''S]?\O5(RY#&1`K5\L_SZ1>U_FKG,W\1.K/DK+L[;
ME;6=@=J]?=;"DV]N&NK-F9K&;T[WH.FX>P]D9RKQM-E*_:^9QU:N;Q0JJ:&6
M6FDCCDM?R&G5^C#_`"M[LJ?C?\=.W>]:3"4NY)^K]GUNZEP=?D'Q5%DEHI:=
M)(:O)14]2]%`L<Q=I!&P4+<BWOW7N@R;YI=6[C[\Z&Z/ZMWIUGVE4=LXWM/)
M;JKME=A8+<M?L.CZ]VIB\_05-5B\!49*\&?K<F*4/4/`%TW36UU'NO=<>D_E
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M,U4A%>M=`5F?YAV\JO-])8C:^R^E-ITO>NQ.ZNU=H9_OSNJNZLP=5U_USV)M
M79NQJBFK*?8NX!4;A[-V_NRFST-%Z3241*WE(8K[KW1U^I^ZZOL3LKN/KBMP
MF+H*GJ&FZE:IS.&SKYO%Y^I[,V%%O2=L<[X^A9<=BY7,%/,;FKBM*5COH'NO
M=3OCCW,_?G5U/V2^W_[K_=[R[/VHF'.0_B;1IUSV7NSKQ:YZO[6C]>6&U_NS
M%H_8,WCU/IUM9T:-RC?%UH$,*CAT%_9'RZPO7?R<ZH^.T^U\IDL;OJA5-Z=G
M03J-M]8;JW=+DZ;I+9V>1()6?+]OUVULW#1:I(A"]%""&^ZC]UZWTQS_`#(^
MWZ_RE;+L41=R4'R27XN4W4C9]F;(=B5VYX8\+6Q9Y,.9HML9#JRKCWDU6U$!
M%B%D-CHUGQJ--0:'KW0=;%^=>X]Z5GR(KTVITQ1[6Z&W'\C=N+C%[U^Z[=W,
M_P`?:C<%!4Y6;K,;$B.!Q&XJ[!<RM7SFDIY1+IE&D-[Y>?7NE%M;Y^;0WC\=
M\9W1B-H9:AWK3;QZ,V#V/TAN#(0XW>O6.Z>Z]W[)VSCJ;-RI2U$5=BH\?O./
M+8S(T\;46;H(U:"12SB+514BN1U[H1*OY60T/0?R8[SFV7,\?QRW+\@MOU.W
M(LS&)MV+T3DLS0M409"3'B/%MN9,1K1#%,*8R`%I+7.^O=)K;ORVW/N[Y&[@
MZ0P.P^OX,-LY>K)-R;CW3W)3[:WE4Q=G['I][PML[K8[-R,VYVPE-/X)`<E3
M>6138K8^_=>Z/(H8$EFU7^@M8`?C_8V]^Z]UR]^Z]U[W[KW7O?NO=>]^Z]UT
M?H?]8_[U[]U[J![]U[K_U]_CW[KW7O?NO==6%[VY_K[]U[KOW[KW7051<@`$
M_7W[KW7?OW7NO>_=>Z][]U[KWOW7NN#(&())%O?NO=<_?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U`RE_X=7'\"BJ]7]2/MI?I[]U[JJ[^7I)
M3'XE=72-(Q9\;3L9(5**\QPF%NR)H@8DE[^I1].;_4K+-1H=>)%3G]O2>8`E
M0?,]'%!B=(HU8JS-)>2-%*E1=@TK%VT+I:U[6O[5=P^("G5?"!/''2/W_N5M
ME[$W9NQ,)G]SR;7V]D,V,#M?'U=?GLP]%!>#'XNAH:>IK:MYG(9Q%#+(L09D
M1V`4Z8@*6)SU8*%PIST#VTX:SM7:>-WE@^^1N*BS%-/#5CKO&;&RG75/6L/'
M7[?J,9N3;N=S^4_@<VJ":+)U-+6,Z'[BG@;]M&5422!E;-*?+JZ$.6!/#HO&
M8^)'=6P7G[+^.OR$R6*[HAGR$^:V?O;"QK\;>V<5)7UE9B]K;KZZH)JRJZ]J
M<735+4]+G\#4K74ZA(V22EAB@B3QPSHTI,J'-,'_`"=;KVZ:=8<3\W.WL+2Q
MX?L_^7E\T\9OO$PFFW33]2[8V%VIUE49.'R0S5.Q-^P[[Q#;FV[7H#+2234M
M-5+%(JSHLJNH=EF:)0:9K3JA%#7CU('S_P`YY0E3_+^_F+P+%H$LC=&[5>[!
M&7]IT[(</*`@4VX%^/;XE0+F.0GY`4_P]>XG(_S]<#_,#KS/X_\`9"?YC5/#
M?5K3HG:[QF['3(\J=BN7D=%'`N0#]/=/&>E%MI-7V=;P233/2]ZA^1F9[E[M
MV]AXOB[\L^I<"W7>\J;+[T[KZPQNS=HXUZ+(X+.82EBRD.[<M+)6YBH@J:<0
MI`SN^AB50$^Z.'ET89&!Z;+HK!374>'0E]@?'G';A[.V_P!T['S4FP>U:"7"
M8O,;@CIJC/8;=>R\0:R"JQV7VD]?18RHW&F*R$E%2Y(21S?;,L$_FAB@2-V2
M,.R/%(BEJ#)SC'V=.%"IHU*_+ATX]J[ORG4FV8]XYGMW;\%-#4TV/IL1V308
MK$XK>-:^FVV=NU>S<51[JAW77T@8445%39=WG"AJ212Q&GJK#OJ1UH9&>'0U
M;=RT>X<'MO/T^/SV*3-8C'9=<5G:"7%9K&09"C@J$H,QC*I4J:#*Q1R%9HG5
M7C<&X'T]NJQ`)IQZ]D<>'2@8*2D,+NSOY(;)=2RL="JMBTC,/II^E_=13K9X
MB@QT37L;?&[NY=YY'H?I3-5N)V_CJA*7OKN+'H98-EXR99$?9.S*WR0P5N],
MLBNE2\)8TBW0,A$TD5'8L2D9HNGXAQKUL4!!TC!Z'2BZ8ZPQO6R]04NW*7^X
M4="]$V&(BD:>8KI?,5=<Z?<39ZHET2M5"[EET6\7[?O?AT01AVI6N37\^FV6
MC=K-I^9)_83P'RZ)W\9:?N/X1]T9?HV;&9+?/PVSF"W#V%MO/ODJ4U/QW:DJ
MS)6?9T5;5+5U/6VX)JO3+@Z'[F?`5D,U12PIC6(1).A5A1<=.A_7JZB-B\<;
MG3=D1CH-UNR@G2?RMSP?Z>V.G!UR()%@2/\`$>_=>Z\.`!>_^/\`7W[KW7?O
MW7NO>_=>Z][]U[KWOW7NNCR"+V_Q_I[]U[KP!`L23_B??NO==^_=>ZZ/((O;
M_'^GOW7NO`$"Q)/^)]^Z]UW[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NBA]?_&C<74O6O;VS>LNV9\+NGL_O/M/O&FWI
MG=BXG<]+M^O[5WS)O'+;5GVK4Y*DI<]AJ2">3'K*U33U+0MY%:-U7WH`#"B@
MZ]TQTGPUQ%'\?=H]&'?64D.#[FVSWAFMV1[=Q%#_`!O=>([JIN[\U18_:N.D
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M"B@[8RYR=;M!J?[BK3)46,B=H#,^@U"-<QK]/?NKG/17,1_+.ZDP7Q`W)\3<
M5N7>-'3;BW_)V//VI_$ZZ?L2EW9#N>@R.#R]'F*BNEK*6IV]LS#T6VJ;1*%C
MQ-,(U`!(]^Z]TNNZOB-G-V]E=2=B=5Y/I[!TO5G3N[>EZ#9/;74M1V=M1=M[
MAS6PLQCZG$T=/NG;;XFNP:["@ID.J37!*R\?GW7NG?;?0W>NQ^\]^=I[0[*Z
MGIML]L)TTW8&TLIU;N6HR$,_6.T8-GY6/9>8Q_86-H<+09VAB:2DCJ:.L:A<
MJ&:55(/NO=<?B_T9W[\?8DZ_RW8/5.[NEZ;<_:VZ*&*BV1N[$=G1U/8>_P#=
M&_Z.BJ<[4;PR&V:N'%5VYG@FD&/B::*,:0C7)VQ+$L>)ZJJZ0!7'05[Q_EP[
M#[4/=^^NR]P93(]_=D[\K-[[,[/PN:WOA\?UC-M*6E3X]TU!LJEW33[9W`>H
MH<+0U&JMI)#65[54GH695775NA@Q/Q#Q+?*G;_RMW%N>MK-TT75]!MW.;*QT
M,]%L7*=MTN+;:TG=4&*FGE--N9-@5E7M^G+:Y(L9,$+G3[VSNRHI;L7@/MZ]
MT"FROA/VAM:G^2&SZC<'0=7LKO7)_*',T.ZZ7J?.4_=FW:GY$9#=&5IL?D-Z
MG<K8S+XC;%9N0I)&*2-ZFFA5%*6!'@2""./7NECW%\$<=V3C>BLIMW?-;L/L
M+JJHZ+P^]<_B<:LV&[BZYZ;W=MC>D.QM[8*20"I2FW%MP9#!UVO[S#U<LJ(Y
MIZBIBDK0:B].X]>Z9]Z_$/NO+Q]Q]0;2[<V+A_C%\B-U;^W?V;C\UL3+Y3NG
M;LO:E::[L;:G7^Y:;<5'LY\%NFIJ*KPU>3QTU;B4KI%B$WBAT;Z]TX8_XJ=F
M[5^76]^]MM4WQUSNQ.P,GU)+51]@[#W'F>X]@XOK78E+L>JH^MMWT=='B\9-
ME(*=JB)I8R$ED.O5<^_=>ZL24@J"+V_Q%C_L??NO=<O?NO=>]^Z]U[W[KW7O
M?NO=='Z'_6/^]>_=>Z@>_=>Z_]#?X]^Z]U[W[KW7O?NO=8RY#A=/!_//OW7N
MLGOW7NO>_=>ZXJ2=5Q:S$#_$<6/^QO[]U[KE[]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NF#=,W@VWGYP`QAPF7F"L2JL
M8\=4O9F4AE4VM<<^_=>ZH@^#?3?;&[OBCU#G\)\I.S]B4%1MF@H/X#B=J[1D
MBBK8,'A8:S)F0)2@9*NTAQZ%CC)/I:_M5;I(X;0U,=,2T!!(\^C0/\=.\%4H
M/FCV^Z>B/55[6V9*[Z=-ED`'J<?DV'M[P)P01)_@Z\)(_3'62?H+O&-D1?F5
MVRA"JBG^Y^RI&'T=#+JD-K_0<CCWHV\C`AIB/]7V=>,JT%!BG0?=3=%9WK;Y
M7U.YZ_MC<VZJG*]9Y/-;O(QF(VU1;\GK,J,/01[PPN!<8C.Y7;]3`*JFRM1&
MV5BU&G69:=G5_)"(YE19SPS^SJC@=K+^?1_6,MM5@6(_L!F#-8L+W]1`O^#R
M;_X>W:!:Z5XG/5AQJW7`A#-&KB16/C41J)7!NI)(C8-H<%[L&_V_O0!H0?7S
MZV&TGCCKC4QW\I742UU+HY8LND`E$%@&!/-KGWLJS&H8];4Y..NE52;H=0<N
MT?!55E6X\>D.$:UR;#D?T]W):I[C7[>O!EX#KN*.1F5_(SZU8+I+(4$89]+(
MP*`.>.2;D_X^Z!?B'G]O6F(!(]>N33N3&PIR%>0EM;E],C!2`5])CX4'3:U_
M?@BBG:,=5P`!7'5=T6)[1J?E%WQN?K_9W7G96[-I9/:B4.[^X<QETRG76"W+
MM+&U^.V;U/'CY*BAVMA3XYGKVHZ:EJJV8^6IJ*DR:8D[:VG<#/RZ\^`:=#E#
MG?F<J(:C8OQR5TD+7?=N\B)03<2GQZ=$J@D:>0!^3[=!<UU+3[.G",+G/00=
MF;^^551NSJOIO/CK'K1.]MP9O;C;ZZ_K<_E]QX'!83;]=FMP/C$RTJ0TN0K:
M*+P02*!*C/J22*VKVQ=?5%%CMQ20N*'T`XC\^M!M+:3%5>CH=?;!V?U5M/'[
M,V1C8\1M["HTD46DSU60K&%ZO+9FJ;]S)9?)2_N5,[@ER=*A455"M5`72%I4
M_P`^M$-4_P`->EP)S&BJPC1G+"255)(B*2$(E@/4Q;BWT/\`C[W(ND`L]!7K
M9`_/HJGR*VO@LKDDS>:V_+6Y7"=0]LML?,_>SQ##;AI,0U/F5GHJ>K@-5%D\
M!FF$+S1S0^2,@JK:&+<H`"Z&)%./6@,_GU9[`-,,(^MHHQ?Z7L@'LMZ?ZR^_
M=>Z][]U[KWOW7NNB0HN;_P"P%_?NO=>!N`1^??NO==^_=>ZZ)L"3^/?NO=>!
M#"XO_L1;W[KW7?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>ZZ*J2"1<CZ>_=>Z[]^Z]U[W[KW7%@3:S%;$$\?4?T_PO[]U[JN?YI_(
M+M/JGM_XV==;`W#G-LX+M+#]X93=V3VAT=FN_-Y))UWAMG5N`CQ.SL$YK8:!
MZG/S?=U'C=5M&I*W%_=>Z5^*^:&T\)72[2S4>^NR=ZS[_P`WUKMW;NQ>J\GC
M]WY3/[*Z8V+VQNBFRN`R6;2*AKSA]UBK9Y304],\HHF19H2\ONO=-FZ/YA?6
MF&VIW=N[#=:]U;IQ_0^]\1UQN9<5M3#4S9?>F4WA@]D38+$15^Y8:_'UF+S.
M>@:1<O38TU-*PJ*3[BG>.5MA271*Y;]@^WKWGU*^9_R'W[U1\>=D=D[`7.;#
MSN\^W.C]C9"/,];U'8N\]JX+L;>^+P.XEI^LL!D*BJW'O''XZL=8,?2S3O)4
M`*@<V!T>O=(7;?S#R^S-Y08CLC,;LW=M"/X_[2WM0U4W1^Y.NNU=X=F[Y[VW
M+U=MK:V/ZKR209W'Y+,K14E+1T4L,0F-ZMY$A+LGN'7NAM'S4ZV:AIZ6+9G;
M]3V/-O#*;&EZ1AV&S=OT><PNW*#>&4FJ]OG*+A5V_2;5RU'7_P`63)/C98JN
M%(IWFD6/WZE.JJ:CY]..V/F+U3O3-;"V[LO#=F;HRF_<.,_#2XKK[.>3:&*@
MWKDNO,[4]A)7+13;/DVKO/$ST.3@J5\],Z%@CQJS+MD:,D-QZMT:Y&U"Y%N3
M_P`C]ZZ]UR]^Z]U[W[KW7O?NO=>]^Z]UT?H?]8_[U[]U[J![]U[K_]'?X]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=)K>9"[1W2[7TIMS.LVD:F"
MC%5=]*V.IK?CW[KW56'\M2ICJ/A1TU5Q/)4I/CUJ8)2)!(P?#X!$>:.6&GJ2
M[F-B=<4;<@E5_*VUC9A51TT0:G(X]'C!9BS:U4(J$)P!("Q(D<`%@PT\VX(]
MJR&49'53@?EU!9410WEF)<%M6F(>L$![RLQ)`4Z1Q_MO>@NH5\73^1/6U!`.
M.BT_QFJD^7\VVBJ+0#XV1[FC<ZEJ&K9>SWQ;AY1($,!@4^DQ@AK'41P$DCK'
M<H"_$4X'->M`TP./1D5D.FG#\S>1F46OQ=@RN0Q5]+6X%OK_`(^U+%E-/Q#K
M9(!^SJ<`7D,J%%:*,JOD-M<C"^A%!32@OPU^/Z^_:B5IY]:/\NL+.GD:*3TN
MP$Q"75`7Y(0M<67\?4$_UM[H@((KQKU[B:(,CKC%`B,[VM<5!1H4201NVJT@
M87N2#<GCWNA4DK0TZ\2QIGKT.I8R^EBHU7=_$D?D)4^-7!.O6OY_)/NVD@U`
M[CQZ\41F!/$<.O3,=,<A+J5T>1;+9V5PI'I-R@3Z\CZ#\>[H&*U*]:"`UUC/
M15^HP'^0_P`O49I$#9/ID!@%CD64]>.)%U!@65`P%QZ0..;>Z#$DF/+JU!Z8
MZ-.J!5B5HR514:+_`':Y:&/4QTW=2"!_7_'Z^_9KUJH..)Z(%\D-U5]#\X/Y
M;>UJ3[<8K=6Z_DYDLL*N-C4WVKTZF0Q4=.=:K#3FKR#&2X<NH4#38^VKJGB1
M>N.O5^+Y#JP/U,2&5!Z7=%36SI>.ZN26TD/;Z7_3^/;U?.N>O$F@(/7F;BTC
M`2,&=0ABCN8B2=">KQV7@V)'U]^`X_/K18#XAT!O=;J,4[S#QP)UGWC+K$0+
MI!#MO!%BP`,LTBP,2+`:OI^?;1.GPRW`$_S`'^?K0RP8&J]&:ZZ[F@WK@=CY
MS+;4S^QZ7L#"X?,[4GRU1A\MB\G#FZ"#(XW'-F,#75U-C\U/1S`BFJUIS(X9
M(3*RD>RT<!TIZ''WOKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]UT;V-OK8V_U_?NO=>6]A?ZV%_\`7MS[]U[KOW[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T$NY>G=L[K[;ZP[DR-3EHMT
M]283L3`[8IZ:I@3$3T?9E/MVFS\F4IGII*B>HACVS3_;LDL00E]0:XM[KW0<
MX?XK[`P7;([FIJ_<S[G3LOL3M7[6:LQAQ)W!V5UELOJO/4CPQXU*M\53;>V)
M1RTRF4S)5-(6D:,K&ONO=`YG/Y>?76Z]V=\;VW5VGW1N/.]Z[9Q6T!5U6:V=
M1?Z-L%@-\4O9&U/[F'%[*H)\MDMH;PH:>;&U>Y&SM134<"42L:0&(^Z]T8#<
MOQ]QF^-@=9;%WUO??&[:CK+?W6G9<&]<K/MVFW9NK=G5^XZ3=&(K-S'"[?Q6
M!,62R=&GW4=%0T:>+TQ"/Z^_=>Z3_</Q0V+W-N3<.\,WN/?&W=T9?9.R=HX?
M/;/RV/Q&5V97=<]@UG9NR]Z;5JZC%5QIMUX3=587#5`J*.:G'AE@>-Y`WNO=
M!;_LBV)@P^.RM%\@.^:'O&DWSE]]UWR1BKNNZCLW/9+/;4H-B93!9C$5_7U5
MUI)LMMH8BBHZ?%PX*&GHVH8)X=-0AE;W7NAAZ6^+VP^BLCC,EM+*;NRE70[#
MEV-5UVZ\O3YO)YY\AOO<78^X-W[@RC45/6Y'=VYMV;HJZBMFU)3G4JQPQA0/
M?NO=&4]^Z]UQ]6O_`&G3_P`G7_V_T]^Z]UR]^Z]U[W[KW7O?NO=='Z'_`%C_
M`+U[]U[J![]U[K__TM_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UT"#>WX)
M!_UQ]??NO==^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[I%]C2-#L#>\JA"8MG[HD`D`:,E,%7L!(AX9"1R#^/?NO=5E_
MR_YQ'\3NMO&T84P`A@S*7D?";?1I%//E!T@7-@Q^G'LQLGU1L\:UI@UQ]O\`
ML=)I`Q:M>&>CC+-^[(^M8F.E4;R$E/0"[^/0U_2Q%[6')_H?:HG7CAUKQ>!T
MXZ0^]-TU>'3#8S#4=)EMV;LK:W'X+&UE=)%C(ACZ<5.6W!G*RFIY:FFV]M^B
MD228Q1O-/+-#3QCR3*RMK*RN(H@Q<\!3!_/JP8O7'20VSUI-0]EU?;6X=W5^
MY=VUW6U-UJE/3XO#X#:=#@J?<DFYY*G'XJ""OS;Y!JXF,RU.2J1X!945C?VU
M1))1+\1'Y?\`%=;+*AI(:`G[>AB'E,BR22*56,1*-1)8.&5Y+:-=[*+?3Z#V
MX1*7U/%0?;U8Z1GK*!/*B^/QQZDF5ED9&ATH53R1DE=4CECZ=1*D^]<.'5"O
MG^'J.1*)TU.6**B?NZ#*0>1Q&%"V-Q8_Z]_>SP'6Q2I8<3U(:5UT)J(=!*TA
M61BA&AHBSW"<*'Y(OJ]^454MUK!!IQZX$,8T4`,9%*&'0'C,BL@8*8[6XYYO
MQS_A[\$=F4I+I`XBE:_S\NO*:DGKC*L\+VOXY1&X1G<N@4E58,Y;2SCZ?0#C
MGVHUDOI(SZ]::32:4Z+/U,[+W?\`*JLD4:ZK=?6,"M&_[EJ78$>J-E"!E0&[
M$WN2?IQ?VEC.NX=#BO5C4XZ,JSO)X@)_W([+XV:7RE-1(NK`J-07_#BWY]N5
M9"R@X\^K*N34XZ(_WYU[N_='S:_EY[_Q.%K<AM7K2M^5,N\<K34>4J*3"0;M
MZGQV$P4U?64E#4X[&13U\;(K5<\&MB%B\CDJ$LR]T.A#IU=5IER.#"G1Z86G
M!)U(XU\NTA%@L95-$H_#VM<_7^GM13.<=:4`4'\^L,OENK*"K(MB8V4",A22
MA#KZA)K/];>[(I;APZT4U>?0$?(&2IAVS6Q4-,F4S^0ZN[GP.U<7-D*>@_C^
M[=P8C:F(PN'2>J9(U%3D:V-)9+,(*?7*5TH?;%P-((/6XQ0E/SZ-9M?8.:Q/
MQYVIU]E:.CK-T[?ZGVY@)J*EJ@E(=W;?VS0PP?8Y*31X4I]P4*-!4$`KH63@
MCV7=*/+HJ4WR[^3VS:O82]R_#2DZHVMNS<%#M+,=@Y'Y";0W9A=L;ARN(R55
MAXY\!LK:V<W5F(,[N"ACQT/VE,YCEJXY)`(U8BR@&M6`^WK1-`3Y#C]G0GR_
M-#K[`80[QWQF]A8'85+`:[+;OBW5GJ;'T6(6KI\;59VD.[MD;1I<YCL1E*N&
M"OCHIYJVD\FHP-H<+1M2R!*`@BM0?]7^'IM)1)4H.WR_XKHXU)64];!!44\T
M,T53!%40RT\J5$,L,R"2&6&>.\<L4L;!E92592"+CWOIWJ5[]U[KWOW7NO>_
M=>ZQF2SZ+?D<W_J+_2WOW7NLGOW7NN.KU%;?1;D_['Z6]^Z]UR]^Z]U[W[KW
M7O?NO=>/T-C8_@_6W^/OW7NN(](];7Y^MK?7Z"P]^Z]UV38$_6P)M_7W[KW7
ME.H`_P!1?W[KW7?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KQ^AO]/S[]U[K@B@`E3PQN
M/KQ_M^??NO=8Q->_IYXL+DWN?];BWOW7NLMFU7U>FUM-A]?ZZOK[]U[KMCI4
MGZV_'OW7NN(*O8ACQS8&W^%B/R/?NO==!^6##3I%[WOQ_L![]U[KFHL."3<D
M\F_UY]^Z]UW[]U[KWOW7NO>_=>Z][]U[KWOW7NNC]#_K'_>O?NO=0/?NO=?_
MT]_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UT`!>WY-S_K\#_B/?NO==^_=
M>Z][]U[KCJ4G3?G^EC[]U[KE[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7ND#VI,(>L^Q9>;P[$W?*;1B4VCV[DGXC;TR'C])X/T]^Z]U3E\,^O
MN^:WXY=5U>VN[</@MKOM;#_P_'4G66'KIYLBN`P`R>4DR.9GS<M325<J,R1!
MKP>0KJ;0#[5VT4I@(6Z%%;NH!C4<'\OGQZ1O)4L@'=Y?;T:Q=C_(JE58H^_\
M5/ZI!,TO5FSW=HPGJM*,0Q7]Q^"18BXM^?:GPYU4:;@$'BU!2G7D"DE&'<.B
M>?(_J/Y8[BWGU3CME=];TI-SK@^RJFBW!LC-=>],0?PZDFV-49C;^1JLCU!V
M,,]5U\*05,,4=/2^.GHIR9'!*"CK-&Z,DO=Q_;C_`(KIRJIYTZ'/XK==_)38
M55O5>_NQMP=@466IL?)M]-S]C;7[`JZ.MBFA%2:%-M=-]618.ECIHW\A>:N>
MH>0>B/1=F+>V^G0+&33YDD_M/6@J'N`X_P"JO1RU$2$H@(+%?""09%.DFRNC
M`E'8$_46O]/:TFN*XZJ:*-2C/62,$K3ZD#V)6Q*OXS;5I59/3(WK^GUO[T65
M<'K:&1P:'^77-PH]$89&TS7:P\KJ>51!RC)I)M:Q4GCCWK%.K=P[2,](K?-+
MGLGLS.4NU9:BCW+40I_#9J7(T^%JD`KJ66IIJ?-5U)DJ/$U=501RQQS24\J1
M2.&L;#V\ZZ8RJ\3U?SKU[K^EW-CMK4L&\I*E\^E5DY##6YZAW+D*;$RY:K?#
MTE?N'&8S"4>9K:7&R0I),E-'JM8ZB-1I"&[@S4/6AC'2N:".>)B(BNEW2\DO
M)X_L@'TEW/JO]/K[L<.64U^?6BH)J1T7'J2*2+NKY4QRZ66/>?7NC7&K>.-=
MBQZ@1'<LSN22PL?Z\?5'!*OU%XJG]6,I_P`:!)ZKB@(DJQXK_#T9)_$LA,*2
M21RP1G47#J&3@:6U!K`\FY`Y]K4H^LMQZWI!P>/0-]K=^]6=+9OKS`;_`-TU
M6WLAVMN!MI;"H*;;^Y\W+N+<+U$*08>,;?Q65%-/7R5($)G*"4A@OT/NFH``
M,,C/7M+4[#0?MZ$[!9_![CI7R&W\E39'')654$TM.6:2EJ\?=*NAKJ29(JJA
MR$+#U03)%*@8$K8@^[,$<ZEESYCIDR,>TGISE<268CQ^9KH[`.L7I;4MC(2"
M6^G^O[VRIX=6:F?Y]5&JM%X]`C\B#&^TNOYJJ.G:6C[NZO%!4O3Q25%-)79.
MII)FI)2'F@%73S&*0HRAHV*MQ<>TLPB$>H$D]/QAP_>16G5B/LNZ4]$[^:!0
M;0Z<UF8`?)?I5E\$K0N73/U#QW="&*!U!9?[0%OS[U2KQ@@4+>?56%1]G04=
MO]+[/W;@MRT&9VFN[=B9[(U.XMW;'@Q]/DZ[$;CT37[0ZSHZI98(]X0+.[Y/
M'1J8<Y`TI5#5,XJ3"="C@PH#04H!_/IE2`[G_5^SHNG0OR+S/PUR^%Z<[YW=
M2;F^.NY5H9NC>]UEJJK'[5Q>3K!2X_;.[<K5M*PV.DDJ14M?,_FPDUZ.N8KX
M)I$;Q&):EJCIQ&+5'5S]-415<,=1`Z2P3(DL,T4B2Q312*)(Y8I8RT<D4D;!
ME9258&X)'NG3G6?W[KW7O?NO=>]^Z]U[W[KW7O?NO==$@"Y^GOW7NO`AA<&X
M]^Z]UW[]U[KWOW7NNB`PL?Z@_P"V]^Z]UW[]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>ZZ````^@]^Z]UW[]U[KH7MR;G\D>_=>Z\0""#]#[]U[KP4
M`W'UL!_L![]U[K@%)#%P+M<>DFVD'CZ_FWOW7NLGOW7NO>_=>Z][]U[KBK:K
M_P"#%?\`;>_=>ZY>_=>Z][]U[KH_0_ZQ_P!Z]^Z]U`]^Z]U__]3?X]^Z]U[W
M[KW7O?NO=<5O8ZOJ"1_KC\'W[KW7+W[KW7&QU7OQIM;_`!O>_OW7NN7OW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[H/.W#IZI[,8,J%>OMZ,K,2$4C;>3]36OZ5^I]^Z]U7Q\$:^GK/B;U'74DM-
M/0U>WL;68V:CD@FHJBAK,%A)*:HHI*5Y(WH9U)D1D8J4(/M?9`+JK@$=)WHM
M:C)KT;AIXD0-^S'K<%@ZR3N4D8JWBT690I6W)^A]O9JU?AITVM`6-<4Z2.Z-
MMT6YJ"DQ]:TU#4XK(#,[?SN.EB@S>WLY3I/#3Y7%SR05-,)6IZJ2&:&5)*:J
MII7@F1XW9?>@`5<`$/7!_+IP.I&#4]!/MGL/=C_(#</3.:&V,CB\%TUMGL^G
MW/C:')8G+U-=F]WY3:U1B<AA9,EDL0*1(:`3+/32([2$IXPH!]MT8$*[5?\`
MP_/K>2*^70Z(T7UD0*6<K"3K"-*=99V:ZV))'^PO[<;@,];J:$@<>LS.=89=
M"+&"S&-2%4#2=*EF82$\<_@@?CWLT.D')ZU4@8&.N;60R`V,NGE)"P+ZV(#Z
M@05B`'X`X/O9Q\6.O:2<C(ZP*R1ZC(I>$LSN3J\=T1AP"^L*"/2;`6X_/OW$
M4KPZ\"`*D]9$^WEE8JZED9=15O54.?4%]1)C7D`6LOU/U]ZKQ'GUX5H">N(4
M,'$UD6-7UOXB;$>HB,HQ!L"/\/=UD9:`**=>&!7HC,O:D_3G>?R%GS77V_L]
MC-WYW8%=@,KMG;S9"B>'#;'I:#(&IDJIJ")4EK)0L<D;31N0ZED="OMDRTN7
M9D_3/Y5ZN8BJ1GQ!7SQ_EZ7/^S=;2LLIZU[G\?DE81)LFF?]RVN[VS`5T(("
M"YX`_/O7CHE:P&AZJ./10OD+F<]\@OD!\'\GLKKW?T&.ZU^0^U,_N>KS."CH
MHJ##19"&LJ,N[)45\$.-QT%`S54DIC\0=-&ICZ6Y'64QF-2!7KW$4Z/5VINR
M@ZBW)MSL0[7W9EZ7>557;`WG%LO"G,3R*<1DL]L_<&<@:II((%P^2QLU$*UV
M#M#D%A+,!&H=D#>77M-10GH)<M\V>M=MT,>0S6R>W\)C7KJ/&"NR6V<52T?\
M0R61AQ-'#//5;BIH8$J\A/'#"S,/)+(BH&9U!]]0JH%=:BO#SZ\(E4EJYZ?-
MU]@UO;4>R=I;;ZL[CHLE1]I=>[EKZG<FPY,5CJ;#X/-S-62S5<60K7,P\JD*
M(S9`7<JH)#<KJRDA"JCUZV,'2O'JUX&XN/H>?:'IWJN?^9YOK*]9_'[96^L%
M3XZJS.W_`)&=#2XV#+0RU&/>?(;XI</(:F"":GEET4N1D9`'6T@4_BQVH)84
M&>M'@>C&UBF*KK*5D32*BH1*A&D211%,=.EEY5UTG^O+`?GV;D'2GS'2<<6T
MC`Z*]W#U'M;+8#=U+E-IT^]NNMRC*5^_]BICDR%7C:K*44D.8W_L#'5$<]%6
M5TU)-(V=V^8FI<_"SN$:H,L=4EE@(.M#5?Q+YU]?LZ>A+":H<(U#W'@!Z?:>
MBW?'GOO<_P`*M];:^/G<N>7<_P`9MZ/CX>@NYC535E#L.GR\A3#[=W'F:V9P
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M``<#^M_?NO==^_=>Z][]U[KP(/T_K;_8CZ^_=>ZZM];<7_WU_?NO=>464`FY
M`^OOW7NN_?NO=='Z'_6/^]>_=>Z@>_=>Z__5W^/?NO=>]^Z]U[W[KW71-@3_
M`$!/OW7NO`W`/]1?W[KW7?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MN-FU7U77^EOI_K'W[KW7+W[KW7O?NO=>]^Z]U[W[KW7O?NO=!MW(VCJ+M-[D
M,G7&^66UKW7:^4/`/!(M^??NO=5[?`EXU^*/4$93Q:MO8](R&2T8.WL(ZV5>
M`"/H"0H^G^'M?!J5?A\ND\A#9U#!Z-:LE+*@0B9P59+'@,5]#*[*RI9.""#S
M_L/:O`752OR'3*C4U*T'7%IJ?4GCE/(6,1^-6*:%]*W8ACJ!^OX^ONE0V0I'
M5BH7MU#HN6+PCK\N=];P->I2;X[;/VF,5]B4,$V.["S.7^_&1,Y6;S19,)X3
M&`IC+:B6L$U0;GC3'5@U``!T8T24\I4IY&8H9+J"%32NECI=@@''X^I]O!E)
M[6KU?(%#Z]<`6+PHT2Z`[)*X9!+Q&"`TFIB56R_4W-_>R`6U5ZW_`!"M.LH:
MGU$322*;%@2NMF\RWU7XT@`6!_%O>V)>E?3INC**:A3KI3'%+$[`-Y'FA(<^
M8`")O`VH!E026L;#Z^[R2)32$-?7JU<5ZYQ!7;2G!9;(`0/2LEC&"`2=*K<%
MN/S[;XUQ3K8/[.L8@4^0O(_B=@A0R?KNI`;ZCU2.023;@?T]^Q^?7@&T]2X"
ML,)$#%%0V(:VL.\:#5$JZP%-_J1S]?=F</52HSTUHH=0)IUC!+.+3R7,9DC;
MR2JR@:(SK77&DFHWY'-_\/?E(44517Y].U(IC'7A!=+*[LJZG<RS^1B`=-CJ
M;Z,RBR_C^OO>#("1DCRZW3Y=<VDU!'#>)1JBE\<J0MI`T@,JMKUM_0\$\^_,
M\>OXN'7B.-./0#?(?J$]Z=29OK)=R+MXY;.;"S*9BIAJLDE)+L+L';&_*%)*
M"&IIY)H*ZLVPL+E'U:9">;>VV3424H#QSGJH#'B<=#WUUNRL7>E-M[=5%2XW
M)YBCRM3AJ['9%LCM[<,M.%JLC3XZ>JIZ+(4.8HZ9_*U%41:FIPTL4DBI((V+
M@UCH1W=;7,F/(?Y^C-+:PM]+"W^M;CVB'3_56W\WF2#_`&5/;R3AB)?DA\=X
M8[)J'E_TD8F3U$D+&I1&`8\:K#\^Z.Y3105JP'[>JNVD#%:FG1PLH(X,CD=#
M26%75V).I5,E41K7AUY46(%B`/9P#_9U.1TUIXG5QZBR0K')J5Y()FO/>)%7
M5I4LGC*G4J:S>X^MN?=CW$D8'7JBIZ*]W9TCL[=VS]S;=SFWSN3K+=<>1J=Z
M;.HZ`UU;MNLS$,L.2WWL.@(>.I$J3N^<P84PY)6-1`GW(>.=F9"P('6E<8`X
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M:1<_U`_V_OW7NN7OW7NO>_=>Z][]U[KWOW7NO>_=>ZX!`&U7/^')N+_47O\`
M3W[KW7D73J))8LU^3]!^`!]``/?NO==%"7#:N!^.??NO=9/?NO=>/`/Y_P`/
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M2']6C;KZ5(!N+?\`%/;_`.L1H1@/M'6PB#+<#\^FR6D^>T<KSKO#XRS:DEDB
MC&'WI1R:6733B67^Z$B>0L+,X``4CTWO[:/CI0.X+?9ULI$V03^1Z<.CJ7MI
M>V=]P=T56S*_>G]P,#40S;!J,D<#-@),U3M1:8\IA,)4PY%*H5`G(6565TTD
M6:[:B47*D>8ZO6@H!@=&RU.T<0!=&60HHTLK>HR,8U4J/VT*_GZ^UIC*\5`'
M57)"_.O7<`)&E9DL&)%V#.YB`&NQ!L78`6^EOH/;;G0NH>O5!5ZECUT3.LRM
M^H(`A=&94$X))1BY)8+?@V`(^@]N:&IA!2G&O3U.`(QUR,4P<R2+^VFL6\I<
MDGU"7224"J`1P+CCW13IPO5:4X^?62!9$!5*A(2\8#H\BE2YN=7*G23'^01S
M[VS\`WY=::N",]>);UE6CF*,EUA=Q(`5`9N5`-TX`#?4^ZJ&`&KB?\'5G)T5
M''H*,_D^Y*3*YU-N[1V1D<!324Z8":NS^2CR5;3>*D>>?*0)+10TE4E494\:
M!D$**WD8L0M7676AB6J^GG^WRZ;4G6Z$U%.@^WWV=WKL;:66WEEM@]?28?`X
MV:HGAIMS9*2I:3]$*1+'6(&CGJGCC+,UXPQ>QM8L>+/I4O`$-2.-:_ZN/5R.
M/IT)6WNQYLGT?B.X6Q,%+4YWJ[#[_&`J<AJBAK,UMFDRU%@6R,,5YH?XE6)2
MB54U2`ZPMS;VJ5U6/6?B_P!7EUH,2^FN.D>NZ/DH=*R].;!-5XVDJ(CV&&CA
MG4?N1"05`#Z)%(#E0Q"WM^/=6+%"40&0C'SZW4@]!_NW<_S.R6V\C1[8ZWZG
MVEN&H:GH\?NB3>L>[X<"B3!ZNM.WLJ^,H<C4)2*RQ1NYB+M=_I8N,)D3,.E]
M-3FOIY=;`%0//H(<?O'YM=:;LZQW5W%EMDY[K<]M==;:J(,+A=@X_--EMZY]
M-IXES68-GKHJ5WS,JU$E-$MT.EDLS%4$A8H"X[CUY:"0_9U>(H(4`F]@!?Z7
MMQ>WM-T]U6)_-AQ>4SWQPV'@,)1UN1R&:^3_`,=J2/'XZ,SU=4(^P*"MG6.%
M3KD2"GI&E<*&*I&6L`I(VH!9:CSZJQQT:FOUO6U$JO&8)JVKE$JG45B\S2AB
MI<ZP5:S%1:_T]F"#B3Q/30&BM#Y]8(7<3,9?*!&D1C*I?4%4WNH-@`3ZA[>'
MSZ:9NX^G7,S31NFD!71HC$P;4YU(YE5=.L+=5L+<W`_/NK'!JU%^?3BJJG'5
M;_RB>NW%-NOJ?IW$IN''Y)IJ[NR>DP]3FZ#H"BS=Z7-;[V=#2)-'5;GRF.EG
M.<VPBR"NIO-)'$U2T\3I+@R!*0:F+=H*@'2QX,:^0].K@8-3P\NH_P`6>^=R
M_#'<VT_C/WQO.;=_Q\W#1XRA^.?R%S-;-EH\7'D9E7![/W?N666H^[V1FHI%
M&&R]3,3BJ@KC*IS']K.R:2*6,:6-7`%30"I\S08%?+Y=70U`P1\CQZN[CE65
M=2W^@/((X(N"/Z@@_4>]=6ZR>_=>Z][]U[KWOW7NO>_=>Z][]U[KQXY/T'OW
M7NN@0W(-Q[]U[KOW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UT0&%C_4'_`&WOW7NN_?NO
M=>]^Z]UC!?601Z?P??NO=9/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]UT?H?]8_[U[]U[J![]U[K_]??X]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW75P;V/T^O^
M'OW7NN_?NO==7`(%^3>W^-OK[]U[KOW[KW7O?NO=>]^Z]U[W[KW05]Z2)%TG
MW!)(RI&G5O83N[L$C1$VCF&9I':RJ@47)/`]^Z]T1#X7-22?&GK<T%13UM%6
M4;5.)JJ=UJ8:N@J<;BVI*N&KB/B>"IC(8.AT,IN/K[,[6CQDR'0/(_YO7IA]
M).I#FN>C0%3$CA8U6&58A&OD;AT!++Y0H:0%C];V'MQU5LB<M3R(ITVQ5U[3
MGK!XPFI!'&&.AG8L)&21]+HI8C22KCZ$BWOP;5Y4Z;HR]%RPF8J:CY;=E[;F
M2&*EQ_Q[ZVSL54)&,[3Y;>^X:":D,9`B6$1X57#`EB9""+`78<E;A`V`1CI]
M:D4I7'1AGU*L4+6)=76+2Q5DTDL6:Q97])L+\'VJHP4N'J*];Q0UIU,*(L9<
ME'2-C((X@'965%OJ(DU!U'T'TO\`GW311@@[@V?LZMIP?MZPB=9F)`(!'C9=
M:N-;J7C.F,6%EN&N>#_7W9HRKTT]4S3!P>L5O$-1_P`X7,D3A6THIO=6U7!L
M18@M;GWLJ3XW:?E^WRZU530#CU)C`,X\BV8J'8,`;7*^1P@!O=F]/^!]U<*H
M34>_R'K_`,5ULB@X]21#]NTFME73^A"=(D0FP9F8!@%!N`;FX_I[KJ+]W6OB
MQY]<5I-6A)&C9BQ(9[!Q'&WD"AA907!^H%_Q[]7R\NK`9%!GH$_DO0K5]'[U
MH8`M/]^NW:-FB1I#$F7W)C,;45!B!5I&BBE9]-P21R>?;4M!$X_9UX5I6N>N
M?7O3^3VYLKK#9>]\]C]PT'5NWMIX>AQ6W:+(XC`9?+;,Q-'B\?G=PBOK*^NS
MG@J*85-/1.*>BAJ%25XYGCB9+0HS1+5<=>8$(*#/0T/1QF21R5%2"Q&HZT>-
MB=?D-V;5:Y%K6!_U_=E0*X-10'K1+:<\:=1A3Q*\B,=;MR_B9FB$7!.O5&%+
M+^!]+^WY&#4IQ_U?RZHA:I!].B[_`"9BC?:/5L`1'I9OD[\:DDD'H]0[0H)%
MU+&4).M`?J!J]I+A"(R&%#TXM-=#QZLR]EW3_1)?FTB28WXW(P4G_9K^I)%5
M@UF>.'<K+RJL58-;2?H&M[VB&22)17XNJMPZ74CQ.\GE72HND5F".-4EIGB1
M;#3+_4_[$>S=D"@LI[!Q/\NF78"F1T5_L[L/.[:[9VSLS>^Z*KJCJG?D6(Q'
M7W9>VY,(3GNSJVHJ(:WKG?F?W-B\O0[$R&3A\+[<,-.(<W.)H#5I5K#23-L&
M9HE0=A%2?+K8`-"*=2NW^O?DOE=F?W,Z-[BPV&K-PYW&87<?8?9>$AK=^];;
M+JQ51[HW+UDVW<7B,#NG?4=)IAQE/EZ*.*DJ934M4R")8"W/%++&4C<*U10G
MAQZ]3S''H8^LNL=L]0;6P^SMJID5H<8%:LS&4K3D]S[GS`IXXJG<6Z<GX::7
M,;@R+H'DF95`/"JB`#WN-%`*E1J'$TQUK1JHU>'0%=V]);9KMK;CQ>3V]4[F
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M>_=>ZQQH4O<WO;^OXO\`\5]^Z]UD]^Z]UC1"I8EKW_U_Z^_=>ZR>_=>Z][]U
M[KWOW7NO$7!']>/?NO==*H46%_K?DW]^Z]UW[]U[KWOW7NO>_=>ZZ/T/^L?]
MZ]^Z]U`]^Z]U_]#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=<1JN;Z=/XM
M>_UXO^/I[]U[KE[]U[KWOW7NO>_=>Z][]U[KH*`2>?4;GW[KW7?OW7NNBH)5
MN;K>W^Q%N??NO==^_=>ZXDD$<K8_@WO_`+#FQ]^Z]UR]^Z]U[W[KW01]_%1T
M7W1K%T_T2]D%A8-=1LW,W&EO2UQ^#Q[]U[HD'PW$<'QQZW2D(@I(<50Q0HNF
MCB@@@H,<JQ)%!IC@76H(C`"CZ6]F</ZD2J!P_P`G^K'1?&LH:3."3_AZ,FQ-
MW1I7U/99$>1"8W]>GQFXDTL0/H.3[=;`_LV&?.G^?IT(RU)X=)'=&Y)<%3T,
M-'05F=S^;GEH]N;:HIZ6DJ<KD(XA4U1GK,A)%38_%8RC0SUU9->."']*O*\4
M4E"X6E1DGRZVR%J%>@TVCUSNND[DWKVWN',[;\N[.M-B;!I=M[=I,DR8F/:F
M?W'FYZZ3<>6K*>3+KD7SZIXTH*708`UVUZ5OX+U8N06K@_+IQ*"!X&&&:M?/
M[/LZ&>,-H(:5G,H,(#2+I<IJ)D"EK>0D#Z_3G^OO;1FM$/9_JIU4D(*TZG*9
M0`5TJK#3(`1$3'Z=8*1M)8FX)()O_3WX1R:AI(IUYR5J#Y]8Y:=@P",H8NSZ
MKE/1&I%@&:.[*K7)_P`?;V2*&M>O+A!US1Z@PR*'.N1'5#<'4OK)?AG!+D:;
MV!(/^'NCX!I7J@C8$9%.L@A=4$:22B01A6TB422*2UU`TG6BD_CFWM@,ZR*^
M"`#TYC`\NNO4SJ9=1L%</)(`RR*QC57B5F;2;7'IU?U]N48J)#2G6E%'U'AU
MG2*H#D%=;H\B*KN"T9CC21%6Q"$,I/(M<>[:D92`IJ?D.K'CT#'R16KJNF-S
MQP-'%,U?LUPT;E`X7=^%)A+@F1EF5"M@+'5[2SXB<TQUKY]#A51RQU+*I9T,
MLD;K=T9%64!DD4DV"W%[&Y'T]O0QAXU.HCK?D:=<#Y79@66\,U]?(UAE*F.X
M:[&UK"WOQT#52O6N%*UZ@5&J+Q@&<-(S*K@_M)J``+V!(<%?H;<&_P!/>PC,
M`5IQ\^O"IJ<=`9\CJ-JS;'5D0D,:CY-?'/5,A#JS4^^X:H`A70:7E0)]38?U
M^GMJZ+%=+'-.O*:29'D.K'_99T_T2?YT[%WGOKK'9-!L3/X?:6X:'N'9.1H]
MWYVKS=+C=K3/%E\;C,K(VWWI\F]1)G:^DI80D].JRU*EG*@HVPKMB-PLGE6O
M'\@3UZE>!IT26@^,GS!K<OCUW1\RLQMK;U/7QU62J=E-NW(;CJ9:<21_PJ"#
M=>33%4=!/.?WW8R2Z19`K6;V_HNI08"0+-UR>X-K!^8^'\_RZ2L8P270X^SI
M^W3\/=[[ZVWF]F[T^7_=V[-I[EI)L3G-M[@V]MS(8?*T%5$5FHZNF?*#RQB1
M-2,")(I5#HRN%8/&W>M/$IP_EUX.*`BH4]'EP]"<!@,)M]Z_)9./"X?#82++
M926.LR>03$4,%"E;EY=49DR,ZP^21UOKD8D\DGV]1U.E@/RZL!3%<].2RRE-
M.ARFM]7EM&SR*"D2@*QU`:OI>X'Y/NWJ#U[NJ"*?YNI"FHG:+0*D,"A#(Q]`
M$9#NI+*=#".]B?K_`%]ZKG'#K844);+=%$[IZ9P;;=W939#%3Y[I?=@K\COC
M9M/1+EJSK'+SB5J[LSK?#)3S/4X*N\SR;HV["`E5"9*FE0NU1#,A6S6'ZMHV
M+>*^LU_#\E^76LBGF?\`5^WH!/BS\EMR_#_?6&^+WR2SL.2Z*WQDZ7_95^_5
MK):S;.W<9N%H_P"ZO4&[<]55E8S;1K0ZQ;2SM3,VEF_A=:ZRI322M%&4T)!J
M*BF:@\#_`+''Y=/=R8=2,D=7D*X/%[,."#PU_P#6^O/N@-16G5NN1O8VM?\`
M%_I_L;>]]>Z\-5O5:_\`A>W^\^_=>ZXLX4Z;$D*6-A<`#_8_7W[KW7ED5B0+
M\<_BWUM_7W[KW7/W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW70(-[?@V
M/^N/^1^_=>Z[]^Z]U[W[KW71^A_UC_O7OW7NH'OW7NO_T=_CW[KW7O?NO=>]
M^Z]UTQ(4D"Y'T'U_WKW[KW72%BMV%C?Z6(_WOW[KW7+W[KW75P38$$CZBXO_
M`+;W[KW7?OW7NN*DDM<6`/'!Y'_$^_=>ZY>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NN/IU<GG\*2./\0/J"??NO=<O?NO=>]^Z]T"7R7K'QWQS[^R$2+)+0
M=)]K5D4;$*LDE-L3/3HC$\!6:.Q/X]^ZT:@$CTZI]^'6:^6]=\6^GLQ@=J]!
M38_/;/P>X(EGW)NN)J27*8^AK&@#^"&-A1&R64`6MQ:_M6ANDA+6T:L:T[JT
M_:.'35$<HSF@Q6GI_/HQLF8^:TS"^S?C])*L3>M=S;MB((N6*_MW9P'L/S]+
M>UNB:-5,D408C.EBW\J_SZVQ4O\`IUT=`[OC:G\P/<>ZL#N?:6X.D>NZW$;<
MS6WY8*4?WJ7)09S(XW)5LW@W?A<DE'4!L+31B2!X]<:E6!_+>N<2`Q^%2E.X
MT_E_EZV-*JS$9\NA6^.64^0E#N/?FQ?D/NW:^\-R8?%X'/X:JVKMS!8.BI*/
M(/#`(VJ\/!0_Q":H<DND],A@TKI=@YTNEID=%DB"J5KJKJ!^P#('V]5S2HZ-
MD?,D`\9*C4=>M5+%$M<HX#O=C?Z$?ZUO=A(?/AU4T8`'S].IQ+F(*7BAUH7-
MU9I)$8*2K:O4VAK%0%^GU][#5;!-.MNY3AQZQB29677(8P8YEDMPR`,%55#A
MV9)-5R;7N#86]N2UCI05KZ]:/ZB"N.N"U@5HAY)O*X8(I)(5AZ0UG0(+:;C^
MEKV_'NKZBI'AD?;U56D)`90!Y]3HY)?\YY3'+JED65KL9+/I4Q'2J1V%Q86'
MME$)KJ%.G*5R>/7`&5I/+%:)]$A4J(@K-<ZD]:D@A&N/J/\`8^W](*:/+K1T
M#XF/6<F5=/C&I)&`$BJQ-U*$2"47`+:;6MP/;;*(G%.'6F.D`CH'/D*8X^I\
MW%(4ABDS&RP8I;ZA?=V&D$0T6,DS*"$!:UQS8<^V;EC)$ZH!J\N/549B>\@#
MH:II:C[FHBD+*AJ)B`&Y5BS,-2OJ74YN>6(O_K^[1N41%'IG[?/J]:$@GJ,*
MB35*NEBS."R$1I<W73I0%CSI^IXY)]ZP22Q[?EUJC'BXIU$J3(6#^@,$NT;?
M19$5^8VM8.A'^QO;VXI<`D+V=;HV0M./0']\9BDJ/]$FTZ&I.3W-/\A.CZZ7
M;N%IZC,9:/%T6X7KZK)9+%8M*JHPN)IZ)6DEK*M8:9%`8O:UTT]7!-0,>?6P
M"#J/'JQ]2&4,"""`01]+'Z?[Q[+NGN@O[AK-H1=?[@HM[U>W*7;^7A3#5D>Z
MZW'4&'R(K7`?'22Y.>G@DEG@1V5582#1J6Q6XO&`76OE\R/\'6FK0TX]5@;U
M[??JKLWXU;2V?V_3=@;%[<[5R?76Z<+F-P;)W=_H]V[2=8;VW?CL]+O977=>
M/Q?\8VO28R*7*554#+4Q1>0LX#+.VU0$2,U6KDUI7T]/ETP"Q#!D\^C<S=B;
M-AY.^]CC3J#@;IVZK`(!K#LU>;`%?S:Q-_:DZ&[BXZI61=(5!0?(]*V&M:6*
MGD4+HE1-85UE5HWTB)S,P$<@<L&U`<@_T]ZJ"2S''3I"FM./4JTP=&9.=9(+
M,-!4(#<.;Z3J4@@$?[;W3.2>'EUI:\".LTM1-Y%\!4D6#>D.5,8X:/2H&E1(
M-0(X(]V\L]4)*L:>7KUC>HEU2+'(XD/I+.[(Z(N@O)#&JDJ1R1Q]?>B_@@2#
MB/\`BNK:9"PJ0*'RZ(G\E>BGSVSZO;6-V]MW=73.Z,]`>Q-L;@IJ^HK>J\1D
MIU.ZM^=<8R@A>3)X?(IJFS&W7`@$[??TYC995]IS;F*1_`3])^XKY:CQ8>A/
M[/ETZS$T\23SJ.DK\5N^=]_$'<^!^-?R/W<=W]([ADQT'QP[XR&1JLZN!QF3
M$,&%V'OG>U343-N7;%;62^'`YRI$4]("E!7N[?;U$J21)4<EP-'KU8,A%:]7
M8I('^E_H#^+&_P!""";@^Z];ZY^_=>ZZL/K87(L>/J/Z?ZWOW7NO!5'T`'^L
M`/?NO==^_=>Z][]U[KBQ('`N;C\$\?GZ>_=>ZY>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M8#Z"US<_Z_\`7_7]^Z]U[W[KW7O?NO=='Z'_`%C_`+U[]U[J![]U[K__TM_C
MW[KW7!PY`T&QOS[]U[KF/\?K[]U[KWOW7NO>_=>ZX)JYU&YU&W^MQQ[]U[KE
M8`ZK"]OK_A]??NO=>N#]"/?NO==^_=>ZXL2!<"_('^W/OW7NO.&*^DV/OW7N
MNAJ!741^D@_XGC_;^_=>ZY^_=>Z][]U[KWOW7NNK`V)'(^GOW7NN_?NO=>]^
MZ]T"'R8QE=G/CKWU@L5"*C*YSIGL[!XJG9TB6HRF:V7FL7C:=II"L<*S5M6B
MEV(50;DV'OQ8(I8BO7J8^71'?A)MFIV;\<.N^K=R108S?/5^(H]E;]VE)E<)
MDJK;.XL%2P8NKH,B<%E,G0P":;'O+3N)G2>#2ZDBX"^T=C!IE)#$U`''Y5'I
MTU)0*%4"O1IXXHPT@CNJQL+KJU78AW<B4ZD\B?1OS:UO:EBY(8UKTTR#2HU$
M"OEU#DI3,VJ12YCCC,))4#QZE.E7TACHN.2+<<>]M(J%:J*TZOI4`@,2#Z]%
M]VMDH:KY,]OX'[=X'PW5/5F3.0>IB(F7<&2S,44`@6+6CTS;?9F9F(<2J/38
MW:0I]6&.&92?MQUO``]!T8'0I5(FG9GE"6EC12B:VTR&^H>G23<#Z7]W*MYB
MG5!2O#J:\2,2WDF&@%*=;*1*T0".0UVT`7^A^MO>@2#Z'KQTDYZ[-/H,8,S*
MK-$S*H$P5V!T!6*(=)8"]R/J0?;OB-3N%:=>"$@'5QZ3N:RF/PU,]?FLE2XO
M$44HIFKJN414:5%34"EIX_,"Y>66HE$<48`+.X`O<>[))(5;Q'-/G_L]6%,D
M].6)K,?E<93Y/$Y*+)X^LA:II:FCE6:EK$$TE/-XG#$$K,C(P`#*RD,`1;W1
MIE&DJP(/5ORZ=$ITD1$DE.A=3J&*JP:Y#@>H$@7M?3;^ONNMFJ:T'5**U25S
MT&>1[LZ?Q&4R^V,QV)M_&9;`ULU#E:%ZFNEGQU=#%!52TE4U-1201RQPRHS(
MKM8L`1<V]M27(4%^)'RK_+K9!(IT!W>/<G3VY-A5V$P79.WLADJG<.TIHJ:&
M6N\ACH,]1UE9I6;'Q1L?M*=CPPO:P)-@:2RAX@P<5^0I3KP0+\3'AT-=7WKT
MU*U76?Z5=BK"K233RMGZ80PP+(0:AU=@ZPN[!=9`501?CV[$T:%5+A@0#6H.
M?MZ\!4@#C_JSTW#OSHYI?&W<'6YD9Y`"N[\/&IT1F+QDR3$NL;<75M+VXO[V
M&K`Q8H%U'/F!7_-Y=>\,5X9/GTE-^?)?I_:NS=V9_&]E;(W+F\#@,SD,)A,3
MN#"9BOR>3HL?/)C,?C\:M?3MDZJ6I*!:;6&F;T7!:_MM;N.16A1ZL!7X2/Y\
M//K3QL%!23A\^@K^,/SC^-]5OW:O7FVL+WBN?WWEZ?"Y7=VYNGL]#39G>^=I
MR]+E^Q=W4$N2IL++FIJ8P4SU?BI(`T%-%XXEC4)97!C5&!U<:]7C!H=1J:]7
M"I^A>--U!T_ZFX^G^P]IZ4QT[T1+YQX_&Y4_%O#9>DIZ_%9GY4;#H,C15B++
M25=)-MK>1FIJF)@1+!,(]++]&!L>"0;*JLRAN%>M$T'4>3HGI:?TQ=3==AEF
M\OFCVY34U1&T.M*>;72M#.A4DVT,""20?9G((F"#P@`!Z<?GTF#$ZA4UKUZH
MZ*Z>J(*Z#_1SM*,5WAAJ'I:;*4M3,A549O-#DG>#3>RNNAPRW'X/NFA"3VBI
MZNOD*GH.L+G*_H7(8_9>^<C-DNK,E5"DZ\[!JB6DVU4R6--LG>CA%2GAI8P1
M1U;?MNB%A9%=*;3&AHW[#UO\6./1F%_<MJFBE\5];+(SA`ZI("H`TRJ[MQ8?
M2Q'N^K5G@!UHD@BG#J4:6R>0:A*[QO(BKXU"D&WZ;VO;_7X]^\11PH1U6J_*
MOGUA9"L@D01HSAA$$8<1QJCN"6D:[@?6PYYX]Z)#@JPJ#\NKEOB[NN820)Y$
ME19EF1/-<"4<:F:34;2*WZ?[-@/;RLU#DT`ZKVD9()Z*IW1TCLS,;.S>W,[B
MQ4]3Y;[ZIR&'H<>M;-U=D\BQ?(;MVO1PJ)JC8>1?UYO$1D"E<?>TH0HWC3R1
MER78U0XIU:HX:A7I%?&/Y*;]^/\`O"F^-?R@R^-KMDE,72=$=]R9B6MBRV&R
M$0.!VUV)DZN*.F:EJXV6#`[@262&L$1IJWP5:J)$,L8B"G4"&/\`J'3PI09Z
MMZ1M2W-K_D#\?T_WCW2H]>O=<_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7%B0+@7Y`_VY]^Z]UR]^Z]UQ!)+"UK&P_QX]^Z]UR]^Z]U[W[KW6.1
MREK"][_U_%O^*^_=>ZR#W[KW6-`X+:C<?C_;^_=>ZR>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>ZZ/T/^L?]Z]^Z]U`]^Z]U__3W^/?NO=>]^Z]UT"&
M%Q_4C_;>_=>ZZ&JYU:;?BU_]YO[]U[KE[]U[KBJZ;@&]R3_M_?NO==D7!!-K
M@C_;^_=>ZQ!%B]9)_I]/Z^_=>ZR@@@$?0^_=>ZZ]6KG3I_V-_P#BGOW7NN7O
MW7NN#(&())%O?NO==6?7?5=.>/I;C_>>??NO=9/?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]TA.SQ?KW>-[6.WLDI!%P=4!%B/R#[]U[HK>Q]L;6Q&4[(W%B\#B,9FM
MV]D[V_O1F*.A6'*;BDP^[]Q46)?-5BZ9JPT=+,Z0ARPC5VM;4;F<`72LE/U?
M\G3)%#JZ6$BA=2JPA>_D&G7:>6]]4?\`9UI;U#@'VL5@YH#GKP->D9NW=M-M
M:GQQDI,EF,MGZ]\'MS;N)BBFRV:RC0R5)ABDJ9(:.AQU#30R3UE=4/'2T5,A
M=WU%4=J4$2*2JD?,]>)H<UIT%/7>QM^4_</:W;F]IMH8ZAWSLKK;:&`VIMC)
M9K/9+"MLFJW%/6U&:S5?B,+CJQLC_&HC&E)3E8BC:G8%26F16D$T@&K@*>G3
M0[U95&:US]O1@8HAH(C,:21J05-UL')+!7D;4UUX'TMR1[N5U:0KDGJS#572
M//J3`GIJ)&TEA#Q&[/\`M"1@RD@:]5K&_!*_7W:3#5)Z\J>34KU%D222H1E8
M'2JSW=VNWI#MK5@JLFL_7^OO95&09>OV8_;UOX<`<.D]F\!'NO"RX>NK,KBO
M+44==#D-O5\N%S&/K\9D8<C05F/R,,<TE+/%64JD$*UUN/H3[OI$D,K5P.-?
MMZL2!D].NW,+3;=Q&-PM!5Y.>GQD-8)*O+U<N2RN2J*JKFKZ[)Y#)RHAJJNL
MR-;)*[E5N7-@!Q[9C5(TC6-`2":UZ\#7SZ?4UPR3/)(DC)&2L>E555)+))IL
MJNK\WYOJ!/O<E234`8ZUA<CK%+1452'>IIL?*\B$NTE%%42_HU'4\T37X`)_
MQM[HJ*175CK>*4(QU`."Q,<D+_PO&K($C56_AE`B,!8I(%\-PZ@D7(MJ^GNA
M%/A`:ISUH'!/ITA.RNF]E]I[:CVUFERV#*YC#[AQV;V16TNVMRT&5P]4M90E
M*],=7055*9>)::>&>"50+H;#WYHD"@JH`KP^?5D8"17/"A'^;H']N=74V![<
MP.+Q'9G:&\IL+C<_F.P<-OG);*W#MV@V_48NJQ^W,9F::DV/C:FDS><W!61U
ME#`*B*;[:AEFMX["3RQHJQA10:JGJNJ350@:>A-[/V_34&Q]U9/;^$V719VA
MHZ?(4^6R.P,/NF#&Q09+'G-Y%\$[8HY6>EP(JI(X?/%Y'5=3&P'N\B1D?IX-
M?/K>JM<>722ZU^.O;=1VCAMRS_)2A3KVIEVIN+=/6&QNB]A[2VWV!-LW(+F=
MLUM1G1FMP9O%R><T\DDU%*!/'$BD<EBEN$736O#JRLH.GSZLS5[FUB"/KP;7
M'UL?:/ISHB_S7U'-?$"(E`LWRVV.KE]!"Q)LS?LQL&4^HM"`+<\^[)_:1G^D
M.O'@>A"G1K^))%4M(XJ4]4K"-&<JBL1J4,Y``^G^(]G1"R,>-1TF44+Y\^N0
MFK/$JP+`IG4"-G4AR(@$7R>KQDHR?D?['VV1&"02:]7X9Z9<S@<?N'#5>W=P
MXR@RF+S,+P9;%5_%+5QM=E$I'[D<U/(!+"\;"2&55>,AE'N@!%$1=3$C/GUH
M5.:]%SZYW+7===MQ_'*LR%;N;&U>R\EV%U_GJXE,CMO;>-R<.)GVEF]2(M?]
MK+(XHI$%UCC_``C+%$V3HG-JRD./V?EUN@Z-19D94U2&Q5$TF3U*7+(RI<DW
MYO<7]O`1``"M!TRZDD\*=>1T+D+J`<NP"JYYC'TT)Q&]C:Y!)M[V".'GUOPR
M0#Y]8AY"B+H(U:AX95?6`"&5XRW%P#RI%^>/;D92DFNO5?#/'J7I=3#H9V$:
MA[KY008V7F[L'5^1SR"./;-5/P\.MA`<L,CHIG:_4VVIL'6XK/8X5?4V0>LE
MD2#%Q96OZFR.:J;UV6QM#-'4)ENJ,W4:?XYA6C:*@;_*X/'"C&F8F#J&:&-6
MU"AU?A^8QQZ>6@*UZ9?C=\@=[_'WL''?&'OZL7)[$KXZ.'I/NJNW!#DH3_$Z
MF5<%UYN"MJO\KK]OUE"8EV[GIYFDDD+8VI_>@261!ID&9%`Z<#9I3JVI6#"_
MTYM8\&X_'^O[]U;KS+JM_@P;_;>_=>ZY>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO7]^Z]U[W[KW7%75[VOQ:_^Q_Y%[]U[KE[]U[KHD`$GZ#W[
MKW7?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZZ/T/^L?]Z]^Z
M]U`]^Z]U_]3?X]^Z]U[W[KW70`'T%O\`C?OW7NO,;*2!<@?3W[KW7"-RU[K:
MW^O[]U[KS.0ZJ!<&USSQ<V]^Z]UTS*]P";QDM;_%/Q_MS[]U[KM3Y`=2VY]^
MZ]UD``%AP![]U[KJX^EQ<>_=>Z[]^Z]U[W[KW7O?NO=>]^Z]U[W[KW75Q>UQ
M?^GY]^Z]UW[]U[KWOW7ND#VDP3KK>;%@H&W\AZC:PO"1<W('Y]^ZTQHI/5<=
M?OSY(4NYM[T^R.D=G;GVA!V-V`,1FJ[M#$XFKRU,N[\PTM3+CY7=XB9F95YN
M0M_H0?:^(RL$\!*KYDXQY_['3#$*0'.2<4_R]*WKOL;MW,;[EVCVCU-B^OJ.
M?:.5W)MS.8O?&(W13Y7(87)X>@RF$%'07J*>>EILY%4ZY-(*7`#?4.*[*S!^
MTTQ\SZ=6.*@=%_[\W7\A!\@L1@_CKM_:F9RVS^D*2OW6=\XRAGP6,C[,WUEJ
M?%3[>F?L79E<<S7?Z-)8ZU2D\0IXH1J4NP.K@R*8P#4TSUY33_9Z%/X];V[Y
MS>1WQM7Y`8+8&&W1MNFPV5HGV11U5&C8W*>*.%<F&WCO*CJ7D75*C13Q%+:6
M3Z,?*\CR1QR*`",'/7A\3&F3T9WE[2Q/")=8\<FE63FP+DL;%K@A@+6_/M5H
MT2``U'7O/IQBU:B1HB!,JZ@SAV]&B30'8KIY)'X8DV]ZER5QUXAL:>'49];/
M'`P36A^WB!1FU,4+!F.H6B/U_P!<_P"M[\KE0*.1^739+C!`ZY^.1F8QA9-(
ME0J6#D'4QT`76X5C9;GCW34Q+YH&ZN#ZCK(CS)ZIV4HVB3_.1R<ACI;Q*Q,;
M#@,#Q<>Z$FH`7KVK-=/7(B196D#0E9'(5B&_0P8@:#]`-1(_I?\`I[W3`S7'
M7NW30\.LK25:",S68%5M)Z6T(&_W:;(=13T_3@_X>]`%4('6FP"5'60F<ZG9
MKA-+%@JNVA`25#\C4Q((]/U']/=5!![CU>E%4UX_RZ+G\DJ[,8S!]34V'RN8
MQ%-GN_.KL%G&P^6KL+69/!Y6NR$.0PDE;CJBFJGQU="H2>,2('7_`%O>I*T`
MK@]5\B?+H=,'@,1MJD./V_AL;AZ&2IJ*NKAH8/$:S(5'C$U;D9O75U^0J?&H
M:HFDEE*J`6L`/=Z%<4J/7/7B=6!PZ;]S;AI=NX3*9W+F4X["T+U4L4,?W,]3
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MLM68T/6=9V4,JIJ`8:P0'9"OJ"D2AF,DFJVH6M8>]B@\B<?9_/K2EZCM`ZK_
M`,SN=3_,RV9LF."IBK?]DOW/O5JEXXACFI)>UZ;;B1).*A:I*Y9-3Z3&8C&2
M2P86*55I,TC5U?,UZMG%1GH_,<TH1/T\K:0AULI&MC>2)6O*0.1]>>?:H*@[
M2QKUNG6>*5[^-4=%=B0+-9V0VY-N+@V%B;6/X]US0@<>M$FHH>N$M14"T3:F
M6:3RAF&H`+8KH<D>*X;3_KB_M_054M4=;X<.N$D\K"G=M;E9#Y/4B$(Y#*)6
M1K(5N0+!M1^OX]IQUK3DBN:==F:8OK95LT-[GQJND$(Q*\@`ZS];$W^EO=P-
M5.M>8IPZ*IV]U5M>OVME]O[@QT=3U3415TD-8E&:RJZ9R-:UZ_)XRCTB?)=4
MYB0!LICPR/B9%%52M'&@:D9N0MO$TTHK&/(9.<"@_P`/RZOGUZ:_CK\H-W]*
M=@83XO?(],O78FJI(CU5WW534]7MJ:BJ*J&EVOLC>NY:BL1LA5YN"4#`YM$D
MBK8H_MZUH:Q+2(IDD1P&44*@U'#/5UX9.>K:@;VX(-@2#^+_`(O_`%'MOJW7
M?OW7NO>_=>Z][]U[KWOW7NO>_=>ZXN2JD@7(MQ_L0/?NO=<O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7!D#$$
MDBWOW7NN?OW7NN@JK]!:_P!??NO==^_=>ZZ8:@1_7W[KW78XX]^Z]UQT^HM^
M2`/]M[]U[KE[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZZ/T/^L?]Z]^Z]U`]
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M78V^DV+`-R=>=9;)Q']TJW.5?F_N1N'LG,5=;D*?-8ZEDQ*Y&+>M.L5.L]65
MDCD_<(L34EV>K5)IY]:Q3CU'VCD::L^1?>.V5AGCFP'7W461K:U'B-+/#N)<
MM]O#3E7,PDI!A)#*7"@B1=-S>U0`UR)/&;0HI3Y]6%?,9Z'I*=54>/B,AB%8
M`HS#QAQK)]1*ZK$\FWMXN[(#7NJ/MZT#QKPZF%51@-)4.DA!L/*P/(2X;62_
MTY''^O[T2W;4];)(7!SU%C0JS%IAQ(WI(_0OHT@KQ>[&P/U!]^0`DZNMF0!1
MJ!)ZSBGD55:Q#%I2T(<0RO=V=93*K:A&HX'J)^GO="!76A'RX]4S2OK_`"ZY
M1TDH+-(B!7,FHZ]3/=Y&$CJP%T.JP()/U/''NM`?MZ\":Y.>LZQ%00Q551@V
MA26C9=2HEN1KC9C;DWM[\2>M`:O//7(`L%BD,4H(B#IY#K2/6"^I5#`G0/SR
M/I[\9'U``^?6P*@U/4G[32S11,ZLP8*S.)&0HMF$D>K@`*1_K^_9I0\>M5/`
M_#T5WY+PM]ET:0P6=?DEU%ZC(H+PKE:E9DC#&Q.B4DJ+FRGGVGNBPB1AQUC_
M`%?GU;%.&.C(!'D>36;%)&\4C2,R`:M.J1CI`60CFU[?4>U3,U6%<5ZK7-!P
MZ2&^]HX[>FW\AMO+5>:IZ+(38^I_BFU<W6[=SV-K\1DJ+.XNOQV:Q<T5=155
M#DL=$Z30\^G2002/>@FH$'KU#Y#SZ+GG-E[AZDWM\?\`/[/[@[VJY,Y\@.O=
MF;@Q^\>Y-W;VVYF]J[E3,IGL/78'<$U3CYY)4@CE233YHWCNC*1?VDGKH()K
MGK:`^(:^G5M@^@YOP.?Z\?7VCZ?Z(7\V(I*G=?PM6..63Q?+;;LKK&Q4>.+K
M'LXEY=*NS(KL.`/K;WM?CC'J>JM6AIT(9%00\21RD^)G>(JS`.)'$+HYLB@J
MWZ2.0I^GLW<4-!P\O\W355!J:5/7A#5,!Y$EIP)-11R$DDC2/3J"A2(R6)*_
MD@^ZT-*TX=5\RWGT&^_-P9*GJMN;3H,]3;.R&[4RF0R&ZJBJQ4%?@-JX#[.+
M)R8!,QJHJG<.4R&5I*6EEEAG2G1IYV1FB12VTFAUB:M7%17RIU=2QIW8IU#V
MSU;U51[LJ>SL'@-MY;?[;6CV16]EU&:J-V[YJ=JME),TNVJ[<=?D\ED(<359
MHFI^W5HXWG!;3QQ8!:XZT6\Z]"G`DNF73(8@!K2".3QW9$.A&!`1;D&_]1[V
M16A/7O*O7IPP1/W(G5&!<PM9RS".WH=U#$,200!]/?B*X(QUZO`_BZQO'4!P
M[LC%M7%FDT(`INC!@6?4.?R+>[K15<4R>MC)-1UB&MJ<M(H.MB`]P)69'73Y
M=(.A.;"P/'U]UIGJIJWECK/XZAV>S)93H9G0(H+H'76+:G4G@$`$GZ^_*5!J
MX[>MT/$CKR+(Z$Z%NUPY(UHQ<.IO=I0\;`V86TG_`'CWX!PT;HM5)(/R'V=>
M%:_+HJG;O3.VJ_`5.W]R8?&R]2ST>2*YFJ@-9D.EJ_(3022U-!1:)*FOZAW#
M.@_B5"'4X9U$\)C@59*-/)`D*N&E;P*_L^7V=64@U0$ZO7TZC?&WY29[I'?N
M#^*?R;S4T53FG6BZ([+R<E5DL;GL?!#$:79>[=X^$8V2JJ(I8_[M9>H:+^.T
MX>G<BOIY8RC=40)H>JL*BO&GECCU9'UZE`RN#U;.C!A_0_D'@@\7X//NO5^N
M7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KBVHCTFQN/\`;7Y]^Z]UR]^Z]UZ_OW7NN+L5
M6X%S_3W[KW7E+&^I;6M:W-_^1>_=>ZY>_=>Z][]U[KWOW7NN#L5`(%[GW[KW
M7,>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NNC]#_`*Q_WKW[KW4#W[KW7__6
MW^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]UBTK(P<$^DV^GY4W_XGW[KW7,:KFX%O
MP0>?KQ?_`&'OW7NN7OW7NO>_=>Z\>>/?NO=<$0("`2;GW[KW7/W[KW7'U:OH
M-/\`6YO]/Z6_K[]U[KE[]U[KWOW7NO>_=>Z][]U[KWOW7NBW_,2&EJ?B?\E*
M6M@6JHZKHOM.DJZ5U9HZFEJMEYB"HIW5"'9)HI"I`()!XY]^Z]T6CXK4]-0_
M'SK""GHQ!3TV(EAIJ<)*5@BBR%?'#$I(,R1PQKI"N20+7)(N32&CU59)*EU-
M*XIIIP^W'2$H0[-7%?7H>?*"'(II/5XRBNWD,RJ6`51?4$0*23S];^U?AA!J
M*D"M,BG3@DC.17^?24W)N6GVE%2L])793)9NH;'X#:V$B@J<ON')4]/)6304
M4-7/2T5+3T-'$\U3654T-)20J7DD46!3RNNL`>G5P5:AZ![K#9&_,=W#W7VO
MO'';=PM)V1MKJG`[>VSB]Q5FYLICEV-3;@CRLVXLC)@\/AP]=)EHO#'2-5*A
M5_W3Z2:Q*GC:CZ=:?O"A3T8&60%1&(Y(Y%"MH:+]=R"`'O:Q#@?U'NR_$#JI
M\^O+A`",GK.LKJ5=8%8.C*&D4!3<EHFOI!158<'Z>]-4L#KKCK9Z[+2`*A@"
M,68/Y$CX9PILSG4NA22P-A];>[5#D!S1`,=:)?4:#'V]<E8A(XY(I0KO41J8
M])"@>56"#2IL\9X`X`_'MXF+22)BWRH>J@R$U8=O4E9HBK^.*1VTB-@Q1HD.
MMUC#(;.K/IO<\?[?VS+I6FFO[#U>@].N,JAG4(B.S1JKP&$@VC)+,`1;R@"W
M!L;BWNM**';"GK6IQ@<.I`E@@A\K03,&#0ZXU5BT>I=(IU*6'TL0;_7WH5-2
M.`Z]0&N,]=3E04"QAFE!`E:S$K=M5XY%&ER&N+$"_P"#[]^76\4/17?DA:HA
MZ/\`)&X5/D9U9)!-XR[QU(S$JJND*=&M"RGD<GC\`WN&U0#3Y.M>KQQAQ,?$
MICHQOW0*&)%O(2R.`!<,%OI(`+,0H!`)'^M?W8H0^HC%:]-@</2G7*]F&B(&
M-6_SFH@B50OHMIL"$!XU>[ZHV^/JU1T"/=):3._&Y5C#*WRBZKD<&RA'3^/J
M6"J@4'QACP;EO:"^*^&@3UZ\N)/Z-.K(1]!_K#VAZ>ZKY^=V.7+YOX?866LR
M-#%E_E)BH):C$53461CBAZQ[(KB])6*DJTTJO1B[,CKH)%KD$65#(P4-3KQ9
ME5]--5/,5Z;9.E]M6<MN?M-2-#:H][R(J,;"S:<8J.VLD-P;6N#[,VB32E9V
MK3RP.D:B9@`2F/*G6&/HS"+4U$D6_>V(BTD:CS[SBJ7C=U*@7FQ!&G2>"0P-
MA;W7PD/;X\H0Y.>G!4(`YS3RX=(G=/Q`Z?WW]L=^/O;?34#5/V0WAD-L;ICQ
MTE287J3C1F-I5<V,2L:!#*("@;0H(-O=9(4;PB`U1C)J/V=>1Z(%7)Z!OJ_J
M'872'S)7;/7V$BPV,R?0.6SF2IXL?@J"2HKCO"AHE%:<%AL,E734D5+KIUF5
M_!)),R$>5[^A54GT?B(ZW5F/<.K"%J(HD7QB3QJ8PT8@,OD9B?6[_I1.3R;"
MW^'MQ!3XAY_Y>FI14`*>L<E-3RV$J./')Y?&EO$R\'7'=!H`)M8>[UT+(!W.
M7J&]!U8..%,=9C)&1XH@&:4MHF8:5B4,`0%8@%@+\GWZNNI<T(X?Y>G`U0W7
MGJ*.-PT4>I4"HP"^AM=@)-*\+^@'\7YY]U+%S5NM-2HZQ1Q0F:0H?"KNI,SL
M/J!;RJK%P'!XMJ)X]OUUH:'KW$4\^LT85H5<!A&M],D=@X_SBF.4DA03]0?]
M8?7VVI\/+<#UL<>N,<^I@YT%!#)Y%D`E5X6#`0O%)&?(L@+!@00;VM_6SA<$
MGKU0,'HGW>W1VP]U;.JMI[NQ=#'UA:0[<W$D4LV7Z2R]=+'*T<LJR15T_3N6
MJUC>18I5EV[/:2)EI@KTB"6.,`R(CNY-,Z!I'K4GX1QIQIBG5UJ<^(4_R_+\
M_GTR?&'Y>[RZ1[-VU\/OEO7-_&,S4_W>Z/[@R,[/%O)XZ2LKL1M'=.19$@K,
MA78:@=\1FE_8R*1>&;15^EDA!!H1^?E^WJP()(ZN+!N/Q?\`-C>Q_(]ZZWUW
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>ZZN+A?R03_`+;W[KW70N"Q8\7N/\!;W[KW78((!'T/OW7NO$A1<W_V
M`O[]U[KB55P#S^"#^?K]/?NO=<_?NO==$V%S?C^G/OW7NNDMI%KV_P`18_4_
MCW[KW7+W[KW7O?NO=>]^Z]U[W[KW7O?NO==*=0N`1_K@C_>#[]U[KOW[KW7O
M?NO=>]^Z]UT?H?\`6/\`O7OW7NH'OW7NO__7W^/?NO=>]^Z]U[W[KW7$.K$@
M&Y'UX/\`Q(]^Z]UR]^Z]UT`!]!:YO_L??NO==^_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NBU?,MID^)7R6:GC,
MU0.C.T/!$LB0M),=G9<1(LTA$<)9[`,WI4\G@>_=>Z+U\8S51=%]>)5E$J$Q
M,BR1ZXY%2I_BN3691.C.*AX);JSKJ#6O?D>S6W*A5.GRZ2F)-9)6IX]#,&GC
M6UC))'()0)%:12`A"1QD*C2(P8DV_`O>WORGXJLQ!:N3ULJ`*#'0&]B[/[DR
M&_<'O7K?<O5V+2CV77[5DQ'9FTMZ;E>"3*9R#,9#)82IVGO?:249R,5%203K
M/'*^FE6S@$J6V60R*PTZ`/-J']E.MK@%5/'ITZPW%V%5;AWKLCLA-CUN;VU#
MMS(4N;V%0[GQ.*KJ#/TD\RTLV#W+EL]6P5U&\'^=2L9)5;]"E?5X.4ETC(/6
MJ<.A=1G\NA@&)=$1B]HS=8CI\EB1(;?2P]J3'I%2<=7^T]2E4AYFC,B69Y!Z
M2`INH57)N)5Y)!!(Y]M\.'7B5'`U/7&VJIC!UNOCU2%V4$D<VD3@MXU4D!>>
M?]A[W^E2AD.K[*_Y>M`TSY'KN,L8TE10D9C<1LP)F*L=:R>LV72#8#@Z1[\A
M:.E./6\5T@YI_L]>6!XZF5@S'[N)-)TE@LA+DDQZM4;^FUN/]M[L\C$@L]!U
MH'N:HR.I".X],GE5D#:6TG1Y6(62+42;62Q!^G%O>E8E]39'6SD@4ZR2?<!U
M+!&0!I"J+I&AB$!D,9*:R391Q:W^'NH-`5/GUJIH37KSEED6-0T<1MP'D=DT
MA1Y`;V`-R"3>W']?>LTIUX\<FO1?>^8)JRFZFID\YOW9UI51ZHW5&6FW#2SN
M6D!NRK!K:YO<@#^GM+?W26-JMQ,"8GF1*CBI/#'F.G(Z$2>6.AW4W)_;6)7>
M24,H]<I9E%F(:Z$ZN>.?9K(*:Q7ATV/A`'IUAF:2-GC96"_J!70R:R@8'1I<
MJ&6X8FW/^O[2=;&,TZ!+MS4VX_CD9("$'R4ZREB83LBZK9]6=@_U\:R?H`NP
M/]![2W0JJ@^1ZVBG5X@..K'1]!_K#VDZ=Z(E\RM9WY\+-")*!\GSKUCB,?Z&
M.UPK`'TO:0@<_P!;_CVY$?U$%.)IU5SI1F]!T(HL@1?%(SV$H!U+$+D>E5']
MM-5[MQ[-6%#I^73"$%=9\\]>D1V9M)<&2>TA)U,[(%'U6P47-B+_`-H6^GML
M4KD8ZOJ%..>L#2JB>$1R>0D_KA='359'&JZM<,/J>?=FHK1@C!S^S/3<<8HK
MUZ*@D<'^SOUM4ZDE/C7C85/B*S1)/OVO4F*>YC'E50'U*U](M:Y]L%B)I)1\
M80D+Z_G_`+'3F.-<=&U93'$C-',68QQ0E5!L[/(^O1JU-8K;\@7!]O`G2*C)
M`/V5S_+IO2M0?(]<]4X(U1#2CM:-55I-!M97?7J`LOT''MQHP%J.G.T`]1JM
MV$D),#'40QD#1#6C6"J2I;QE2OT_)^OMNAZIY'J0WDA#A%20,69"$1A8`:;J
MIL"38F]A?_#W=8]2@UZL!Z-U#UE?(4A$GJ]>HA`SEDU7LO+"WT%[GVR5)((:
M@!ZV17B>I*M.(W<!U0^-(]41$>D@OJ"C0=?)N3R/=L4'=7/IUZHI3KBNMF>?
M]R0QPLK!B&72?66LH'J((_'T_/O;$MQX=:U>:GK&WA:^N+R0E6IYD95=")$_
M<B=7#1RH\;D$$$,+W')'O6FHTD5%*=:K6@/KT3GOSH7:F\.O<MUSO>GAGZKJ
M(98=L;G$-1+G>B<I7R(8*>KKHW-56=25M4L.F2(I-MV9(F+?;QPRTJ:6)T32
MH&BO#JX)'`5ZY?#_`.6.Y^K-WX;X8_+S-#'=F44D&"Z8[5W%7108[NS#K!JP
MF%J<M4M%2UG8+4$>JF:,Z<S`FJ("=7C]I&5E_#TX#7JW0&XO_ON.#_O/NJDD
M`D4/6^N_>^O=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]UU87O;FUK_X>_=>Z[]^Z]UX``6'`'OW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKH_0_P"L?]Z]^Z]U`]^Z]U__T-_CW[KW7O?NO=<5U6]7UN?Z?3\?3W[KW7@J
M@D@6)^OOW7NN7OW7NO>_=>Z][]U[KWOW7NO>_=>ZXZ5OJMS_`%]^Z]UR]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1;?F&@;XJ_(I0=)DZ8[#
MCU"]QKVSD%!XYXU?CGW[KW0#_'^*1.EMB?0S1XRO>!58%I`^=R>F>4E@VNQN
M0.2;W]F=IW6Y>3M<8'S'ETS(*34`[:?SIT+LKS/(E]6HOXTNMF8CTWNPM?0;
M6)`M_7VJ$:%`:9Z\`30!J'K&OGD9UD"E!+(5E9A9?3^X=(5?*HT@?4CVQ)''
MK5M/=3KU"A/GT#&V_+)WQW'3U%'/3^#;?61I<A)-!]ID//B\@U1#3PQ3/4J:
M(1JKF2.,,SC06`:S"BMP*#RZT*]"Y'!S$H]0!+Q`R$CA2&4_TEC!XXN/\/:@
M^(.+$C[/]CKSTU`'X:=3TIY%CDC+!?0/$Y<Z5C/C&L,+L"^DCU?BWO0-3PSU
MK0P'::']O77C(2YL)'"@GS@,URH+>JYCNH.FX!(/OPP?AZW0J06/=UTM-+=%
MY0M=E,TH!0JS"[J+I^BW(!_Q]N(<3@^0_P`O6R3Q\NNR)%F"B8@M$I=^674"
MVA([-8>2YOQ^1S[OX`TJS\#UI10U\^L<7G=7T!5T%S#.Q#<J&<ER]U3U$C_8
M#W[PT].MT'4T2L@1]7D+J0%AO(H5$#2>=4TWNS$G3ZOQ[;,9*QE<,3UH4H`>
MN*@DQ1^1501ZI/'Y=8<DR_K+-Z3J!M_K7^GNAH.W3W#KS"@X8Z`SNM09^G&=
MYR_^FS8[111221R,XR<:,LQA?0Z")RVD^CZ7'`]TD=$5(Y%#"0T`(KD>>?/J
M\:M)XH09IT-,4<H5G:41GR2ZBY;A``K:7XN2&LUN!?VM`&`XJ//JJ@A0#\0'
M730SJX76W[JE)&4(1&S*2JQJ6U-J`%V^MS[9TA7,;_:/LZ\!Y5QT!7<PCI]V
M?%Y94FJC-\G.O*7]O68Z>48S=$XEJ?&="(KT]@6_MZ1]2/:>]4+$I4>?6U8Z
M]'X:=63#D`_U`_WKV6GIWHB?S+B>3?7PN$9*Z?DV\\C!5:T<72_;+O<NRB-2
M!RU_2+\'VY"`9H@?XNJ/E:>O0A&*H52(UL="A2&;T#7'8*S,;Z`O^!(/U]FS
MAW=J''5`!ITK@#KJ1)0/"S@D>N[<H7+`,SVNHD!6W!X!%_Q[;(88/'JFE34L
M.DSN?<F)VGC!ELW5U@26NI<7C<;0TE7D\SFLQ7%A0X3`XBACGK,GE*XPL4C1
M#IC5I'*1H[KHNBT:5J*`>KBH6@X>G17=I]8]GY'YF;L^1.9QD6U^N\Q\8-J=
M-X7;&4W)2U^[&WI@^U]R;VR.<J]OX.3*;>QF*DPF5ABCF^^EK7<,CHBJ/:9(
M9)KN.51(`%(&D`A@?XJ\.&*>O7J"FH_%7HXZPOHIW>>\:R1LZ\GRZ6(=N6#$
MFX^EN1]/:UHI*F@`/H/EU1:E*UZDK'.K`1D2-JUQ,A)UAQI9+JH>,O;BY]^+
M.M4D/=U?4!]O45XI)I8HP%7QOXI391<R!O("0.5B8DWX-[^]HJD/49%.M::^
M76,JY;QPZ2J#0_(T^0A606L9+W7\7`O[J&(P#CKPQ2IZ\4D:`J_DU:T&F(OI
M2Y2\HTB^NZWM<&_NK(^23CKP'`]2!Y="+ZR@Y#>32+'QFX(NVO5Q>W/-_>XT
MU.H'F>O$>G#KD_G0_J,37D!5I.&C5_U1@1G4!?GZ6_(M[\P*LZGUZKBHSUXQ
MMI;UR/XV(-I`L9#`BY555G(C)(O<7XMQ[U2NE?*O5A6N#UCD5Y4^W21&CEB>
M*=)HQ+'/'.&CGBF60-')`T3,I1DTNILP(O[T0JN0RU7RZW4T-!T2[Y&?&S8O
M8FS4V=OJDII^O:.6*JV#O*:%ILWT%N)I@<;#)E([9`=9MDV1Z.L1Q5;8K!&R
M,*98WIV)8G%!P!Z\"0*>5>GWXK_*/?W56\\;\4_EYF9GW8TE+B>I>YMP34<,
M?8,<D<,6(VCO#*4\<.)GWG6*",5E(W$.XE7QL(LBKP2(W72Q'3HX<>K8/=>M
M]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW71O8V^MC;_`%_Q
M[]U[KPO87^MA?_7MS]/\??NO=>()'!TG^MK_`.\'W[KW7A<`7-S_`%M:_P#L
M/?NO==^_=>ZZ()'!TG^MK_[P??NO=>%P!<W/];6O_L/?NO==^_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NNF.E2?K;\>_=>ZXHVM;VM]?\?\`BGOW7NN0!`Y.
MH_UL!_O7OW7NN_?NO=>]^Z]U[W[KW71^A_UC_O7OW7NH'OW7NO_1W^/?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]UU<7M?FU[?X?2_OW7NN_?NO=>]^Z]U[W[KW7&[:
MK:>/]5<?[U^/?NO=<O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]T63YHQ15'Q)^2%/.)6@J.F.P:>98)Y:6<Q3[;KX9!!4P2PS4TQ1SID1T=&L
MP8$7]^Z]4#)X=`ST#!#0=.;!IA)4211X.HCH?OI)):D1KELA&J3U4UZBHE$*
M@F1BTDANQ))))U;TDA5)8:,",_9Y])BRN6"Y<#_5QZ%-[:"NEG5!JL1Z)&CC
M=B54`7E4VN#SR+>WRL:FBMW=5C5@QJ,4Z].%413:"@.AWC52IC+(I8+S$=3N
M!>X-N?S[J648)Z>Z"7;&F3N;MV21288,)UJL7"NYD.+KWE8D!BL:NPL1S<?3
MVFU@W!H<@5_;PZ]FG#H6%1W>%M,9C>5B)M(5U('[ID+`/QIM_M1]NN5H0#GJ
MIH<5ZFLR`R(EXPT#*/VF6Z!E=;Z--C_K^V@"30<>M4-*#J`Y196`DD7ZNUDC
MT$)I5W!L65-'^O\`3VI4$+1L&G7B6&`M1]O7;L&75(2PFCE2*3R!+)S$Q9@`
ML;%3^;>])01MJ./]GKP<'X>/IUE69W\BG4ET2)(V"DHOK<`.SMJC51_3W5XN
M&C(ZUXAJ-8IUUIM;QRW1R/(X4QAOJPC:,?J8-R#:P]T*./PYZ\*4#_A]>I=2
MP6`RD.(4U!UC5=!",&UG58ER1]20/>U8U'ZH(].KBGEPZP1RRZ9&`!UZ2C(J
MH@N#Z;`@#3X_P;7)]N!U88/7F(7XCT`_<BF;*]+^CANXMI2.B12A2R5L=0J3
M>/46?4A)8'3<@GB_M/=1F2,>',%FU"A]%_$/]MT]9,C7:H\9DC9&[!Q8C\0_
MTO0Z%I132L[6`!O`0I)5W6ZA64@V+?@<_P!?:HLA>,+PKTSCUZ].+21%9&%T
MA(9`)7B90%UNKES&Q5B>0`H)]IVPD2GX@,_MZT:#-.B_]VT\D^_OB=30S,"G
MRCVE5R`N(XIHZ+:^\JB1;!+2'0I*C\L./I[379I;H/+7UM0Q?41BG5EB\J"/
MR!_O7M"<$CI[JN[YZY_,[8W%\.LS@=K9/>63I_DE6K#MO#5='1Y/)K-TAVTD
MBTL]>K4J&%?6VJWH4\CW>$TEC[*YZHY`%6X5Z2?^FGM";06^+':L1)4++_>+
M:3Z2XX9FAU+I4BQ%CQ^>/9F\C:B%C8?9GIH"-R3Q/40=Y=JZS(WQ1[@*SRV=
M/XOM$J$2[M+(!4(JL[+8`C4Q(XMS[8:Y56TEB''E0]6%%QJ[1T5'Y!?+_?\`
MUQO+KW<=1\?DP61I,'O:+&X#M?>M3M^U57U&!H:C=6#79VTMY-++#C:9\?+)
M,L?CAK9$CU>1K>EFUOJ/Q=76-F&M:%/M'^?H</BG\K,_\BLON_#9;K_;>T#M
M?;^&R9R>V-W[@WA0U4V2JTIFQ5=49?KO9E-0RC6\D"0559-)%$[2QPC3JW&V
MH-7B.J&JBA&>CM>(:O'9?&GK9VL2[KI8O^@\J#8?06]K(R"`H(KUI!10#Q'4
MX-'IE3455S(?)HC#*P&E6!+'2%2]FY(O8>ZZP$B"GN'6R*FM>H_`B=XG:2GA
MC_48E=9"TB@(7=D9E9R23I+7XO[TSF2E:T'6B#7ACKRK&$5FA$;ZS=]*K++(
M5,8;38L0+#DC^T?;1SGSZ\:`\.LB2E=)3UJSQJ4;3^M=*DE;"V@CG^OMUU9M
M-.&.K5(J1Z==E@Q26^EPK%R`"R+&6"+Z1I])/%['CVV=))#/0]4U,:@X'4=F
ML9"(PTBQL'C_`%,!(_#/=_U_6Q!^AY]^("TH<=;'$GC0=<H476D9BDB97AL\
M4GCD1""+NJDLS?ZPL#]?=A(:Z/Q4K^7KUX5S7K&\;IYB-**7#:A$"WID*!]0
M0D%@+_B]O?@[$UU4^?\`DZWFG#J>R05<$M)4TL55334DT-9#40I/!44E7$8:
MJGEI)HY(Y:6H@9UE1U(9"000??G+=I9ZGK1R13HC/R2^-VPNR^N*[K3?L%3)
MUT\F.DV'OJ:LJI-P='[CH<C29C;=-7YW5+DVV!!GJ6FGQF3#-5;;KHHV9C`L
M3QIYJNM'&I?(>G5DP7/D3TZ_#3YA;^VGO^G^%/S/R,5)WKBE%%U-VQ6BGHL/
M\@,!34TD])CZJ>%(<?!VQCL9`7F2*T&?IHS6TO[GFA1"RLOQ#/3E1CJVT$$`
MCZ$7'^L?=>M]=^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NN+$:3J-@>/]O[]U[KR?I7F_%K_P"M[]U[KE[]U[KJX!`OR;V_QM]??NO=
M=#5=@?H"-)_K<<C_`&'OW7NNP01<&X]^Z]UW[]U[KWOW7NO>_=>ZZ)`%S]/?
MNO=>!#"X-Q[]U[KOW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UT?H?]8_[U[]
MU[J![]U[K__2W^/?NO=>]^Z]U[W[KW7093<`@D?7W[KW7?OW7NL3,%D'!N0!
M?\6+?\5]^Z]UE]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=%9^;]6:+X??)JJ%-45IIND>Q9Q1TAB%55F/;5>PI
MJ8SRP0+43VTH7=$#$%F47(]3%3UIUK&<\>B"=9=\=K8K9FU<+B?B=V_N'%XN
M@CI8-TT^<VO1XG+TIFGG2IQ_E:MJ&IXUG,,DBW0R*=#-^#2%GMU!;OJ!\J5_
MS=)1*[2C4`5"TQCAC\_GTL%^2O9Q`DD^('>,*WD66[41D:476Y;^%*K1NJ<,
MNH6M>Q/NWC$MJ,9I3RS_`).G**]:C]G^KAT$G8?\PC&]69>#;W8'0W:VV,Y7
M8R',T6&R4]%!/D,;4U<V/@K(HUQD@6&6LIY4$DNE=43`'TFS<LZK0E#0?*G_
M`!?557233SZ%;XK=T47?V<[6[$QV`R6V<-5S[.PJ8C)R5SYB&JPV-KXJT9">
M;%XW%E9]22PBCEJ4$3?NLDET%K=DFDEE`HK(`#ZT\_EU>N<='"+L\D<<E/X]
M0,D:K&56RJ$!NNHD,"+F_P!?H1[<1=?:6IUL>=,GK)YKMI=);(R(-+.86N61
M45^%8I"@N1JN?S[>*>&#I%?GZ=-!ZZL9KUCDL\\89+R*A8"/ULT990;V0EFX
MXYY_/ORG4E0U>KGL4'H/^P]U5&SMK19JG7;ZO-F\/A/N]XY2OPFU\2N6K6II
M,CFJ_&XO*5U/2TJ@*&6&0M(Z`D#GVVVM(F!6OY_/JX0.=*+W9\_ET];'W'5;
MHV5M'>%;CJ;'U6X<#C<M)CJ>>>:GI)ZN'4XHJFJI<?73T5AKBDDA1WB92RJ3
M;W?4SJ`#3IM2KKD=WF.E6TK*%9Y&E94"E$1B0)6-N-"EBBF[7//]1[L*@`')
M]>MLM5TJ:#J28I7CDCEC!CLEX`+QRE1:+66!?QM;D?DBWXO[K$1J),=.K4Q0
M=<$$YD$<L0<B%!H\9>)06#*C.RJMP?\`6]V&E$T\,D]4)*CX:_Y.@.[?;/\`
M\5Z37#87(Y]J+M/'9.OH<;)CHJF/#X?%Y'*9*LC.4R&,I)%IXZ2ZA9&8L572
M;W#,K!3'2+46-*UX?Y^M@FHD3MD&!]AX_MZ>INU\=`T^.KL)G*2JI:EEE@EG
MV:D]-*CAOMZ@#=A,54BD:D:[1DV-C[J9$B+R%JZ:T'K3K0%/+J-+W)@--SC<
MW',[DLC5^QE)+"VI9EW>/*I'%C_7W265/%"^16M?GZ=;-2,"HZ1E?5U/8^_N
ME<S3/MW$8K8G=>R\U'C*W-TE?O/.0Y#$Y#;,U=3X7#5&0QN&Q-)D]QJADEJF
MF<PD&-?(GMBX<-&L8\C6O^3J\9P<>?5G8M86^EA;_6MQ[1'SKTYT13Y?2"3L
MWX5TQA,K2_(+=$\=IDB,9I.@>W'$Q0G7,J/(+@"WTO\`@%R&2-6$K-V`@?F>
MFYI(XEK(6I6F!7/^;Y]+UBXDB4QU!8JTGCC`-_(PE72@74;EB1>Q`)]G`0L`
MVM@#Z=-BK`-IH#^T_;Z=9W@D=RV@HI5'T&\A2[!AJ86"^J^K\6/MEUCJ:K5O
M4^?5BP.",>G0>[MQNY9*W;F\=D_;5>?VU392@JMN5E:<91[QVQF&H9\EA/XI
M)!(N&RM!DL535F-J9`8/N(VAG*Q3/+'9D56CDB(+'UZHJJI`$("_+IBV3W?M
M+>6_-P]1Q'=.V^TMJ;7PF_\`/=>[RP-7C,M1;+W#E<IM_%;CI\A2U&3V[EL/
M7YO#U5*DU'737D@86`'NCR*TX@4U8*2?E\NK$!:Z!GH8`C"/GQ@L&`:0^E2Q
M8`$L&%@/K<#_`'GW8+&&#,"33UZ\3@CSZPPFT4OE1AJ8"81@.RR(X#Z;KH,=
MEO<'ZD6]NEDD21HUJ`U*_P"7K=<5''K*Z&-_(K!U258PHMP=2L@&H$65OK]/
MZ^V@:!J^?7OPUZXM*99E5H7DD,P<R,=21ZI5"J'TZ0VI?H#8^]4%":]4)\^/
M6&F`*R(PTLSMYED*@F25F(])U$`J#Q?@D>W`I3OK4=:4M@Z3UF\L9CL8S"-3
M1H@:\CL55$;ZA@(@IO[9(U-7JYH,]<)6T-$-#23,2S&ZZK&]V'ZF%U^O]/;X
MT:02.MC(SUVFHAV_:(D="2CZ2%9E5FNP4D$C\BP_)]MCO'9E]63Z#TIZCK1Q
M7%>O(RVD+J_C)"0H[,P:0,2SA2-+`AC?BWO;A2!1C6OF*=4#FIJM.G".T++8
M(FDJ)5/%O+>[+=GOZ"0!8`CWIB32H\NK#-.H\[4LL,M//##/3SJ]--$\4,L-
M1#(LD$T$T14Q3P21LRNC`HZ-I8$>Z"DBN4RRFA'5_(!>'5:_SAZNZ=Q/2.?R
MO<E+F!UEM.C.4V7OO!T>5K]W=,96D?[[#X!J_"20[B79,V6I@<3E(Y14[>J7
M$/D\#)J32PU;XNJA@N>.:='P_E[=H;O[:^,VV]P;WS&1W%G<'N/>>PI-P9F6
MEGSN=I=B;CK]MTF8SL]%18ZDGR]?!0AYG2%2Q(+%WU.R3ACI\='<]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO==
M6%PWY`(_V_OW7NN_?NO==````?0>_=>Z[]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>/'/OW7NN*L&%Q_L1_3W[KW79^A_UC_O7OW7N
MH'OW7NO_T]_CW[KW7O?NO=>]^Z]UQ"*I)`L3]?\`;W]^Z]UR]^Z]UZP_I[]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KCH75J%[_`)Y//XY'OW7NN7OW
M7NO>_=>Z][]U[KWOW7NO>_=>Z*O\X+CX?_)@IPQZ4["`-KV/]W:T7M]#:_OQ
MX4ZW7%/+H'^@E=ND.J6EED=EVM3>N4%45(ZK("/6I!0%@I-[_4>SB.33&JJO
M=IQTD0",OX7`UK7H5&B8>!8FD4L3K=`&:]RUB+A@6L1^`/K]/;R.&4#A)QQU
M<&IZ2&:H\KA\]3;RVU1MF:R+$MMS<6`AKJ?%UF>V^E>^0Q\]#E:FU*,YM?(5
M%3)3PS2Q15457/$98V,;!F576X@F4U9JH=613CP]<];R*`=1]I=I[:WMF=W;
M=Q57N&GW'L&IPE)NW![GP64P]=@JS<N)&>Q*AZV`XZM:NQ;B1I**>IB4D*[!
MK>[(RR+X:BC*"#3Y=50DER>%>E]+([/9I;.R@O$SJ%$8"L%=E8*RV^@O]1Q[
M:ZLK$4((U4Z\^EI%FC,\9`9E75I;4H;T-')PR$\@BWT]W4IP:O\`DZ\/^+ZP
MR3ZI))E?3H*KK98KM&0EE#'40JSDO]3]/Z>WA0J&`QUY@&H#Y=<VJZFQ$#OJ
M*>HJRCR@'ERR>E@%-R%Y]U21I4(<X/7E9@21CK@DADD:61O*XC!\TTC.Q+F2
M21K^HHI$8'UYM[<%:`=>`"B@&.I$=229"3H(]1"$.H#C46N02I;BRW-B/K[U
MG&<];TL2*''7.&K,D2QAS*TCL[)HL?$C%06D_P`V55_J#;W=CJ()\O3KV?/K
MLR,X6,O,\89E:ZEG9M8:19"%OI'ZE-OT_GGVVT:R4U5J,CKWY=)#//$V\>LE
M#N(QD=V/)#)8F<G9V1C50]E(1"]_2"?Q[IXCU.*]5H[Y!'0\=,PH-I5^N+1?
M?'83%70*;G>68&KZ#4&`^OY]D\A+.U3Y].A:4KQZ>=M]G=7[RW?OGK_:N]]H
M[BWQUE-B:?L/:6&SF-R.X=DS9^FFK<'%N?$4\\E;A7S%)3R24XG1/*D;%;V/
MMNF*'JU,UZ`3O2`+W1T,\<8")7*K,JJ+%NQ>LR@)`!L=)-OS;W8&G7NC?J+*
M!];`#_>/>N/7NB-_*TQ)V[\,?*B,Q[D[#\)DD*%6_P!`/9MV2Q]19`5(-Q8D
M^W82H:C`:3\L?+K3%J$JQ!Z7YJ6+H8O5(BA!^WIOINFF.7EBCGZL?I87X)]F
MWB8`7A3IA5TJ6)-3Z]=^02I*?(0X$:Z9``C,QO+XR2=0%OI>_MMA4D^?7DJ_
M&E*]=*`(S*WAUJ^F((X?41IUC0EDOSR`/]C[9ERB48X(ZN221ZGHI.V,!AJ7
MYX=O;T@:I.=R'Q<ZNV?41&6]')A<-V-NG/T!2F149*K^);CJP92QUQ!4L-%S
M13_C3,HSII^WK1/"N#T;N&L9!&S+8#R72_[B.I8+9@6=00UE/T_VWMY6U(K'
M_53'6A5FH1CKGJTB=-+%E:1J=38NR.-2*0H90ZZR;FQ7GCVX6B)*@T!-:#&>
MFAXFI0_P_9UPE?Q(`K"X1'+#606#,%U*NKQM(C#U'\?47]T#1ZB#6G3OR\NL
M+U!+!Y5"ABFM7+NH-O1&S)'K9OZ?T(][)6N!CJZE%`J,]<_1(T1B36LS$(X*
MZD5"%+7)#D!U/!%R?=O%2E/$%/3K510]=W*C0LBD"[*R(LDQ9W9&U@L%+!1^
M#>Q]T8@TT#AQ^SK0*C->N!T<6#!_`P65@RM%KUJUQK=;'1Q<V)-O=V9::5^$
M];-:8'6!G3[:2,>=U706:X;]%QZ6*`L"#^?R/]C[UJ-.TTIZ8ZJ3D?;U)=C#
MJ,<8**8I'D%]9#&[B3ARA-^`+"WU][\1QQ8G[>MUK7[>I44VAIBD?[LC`JK-
M?]Q>=3:Q=4*GWYCJ0L>(-.O?,8ZX33-XZ1A"4;]#2QQBRFRMXQIX*@"YMPMO
M=1H*:#45R:8J>M<"/7I&]AM!_H\[!5PCK-L+>4,L+QF59X9-NY!9DJ$D!CFC
MD5B'0C25-B"#[K(`M548ZTWJ..H=!;_*H96^)%$5?R?\9;[N&HN)&.CLS<*#
M4X5;MI47XX/'LL;B>E'5D/O77NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KHWMZ2`?\1?W[KW7A>PO]?S[]U[KOW[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>M
M;Z>_=>ZZ/T/^L?\`>O?NO=0/?NO=?__4W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]UU<7M?G^GOW7NN_?NO=>]^Z]U[W[KW7&YU6TFW^JN+
M?3_;^_=>ZY>_=>Z][]U[KWOW7NO'CD_0>_=>ZXD:M)!X!#?Z_''OW7NBO?-F
MFHJWXE?(BAR0JVH,AU/N['U:T%544-:U/7XV2CE%+74LD5313E9_3-&RR1'U
M*00#[;<&C:*B2G'RZWY?/H)>B)%/3772TOD^WCV]X+RRB20P0UU8L1ED+/+*
MP4#R.Q;6US<W/LZMJ^'&7%:KQ]2.-.D[9#`>?0K,\O",CN"&*RN6C'C*^J,`
M`*K`/<DD<6]J:>@Z\BZ4XYZCZ#JTR:0U@&$@C8.81Z5)!U$6!-Q^1?\`/MMB
MRLITUH/RZ\5U&M>BS]6T\D??GRGFFQM5`E1ENG6H*SQMX,C3Q=7TU/--1RB5
MFD6EJPT3\*RLOT_);A4?57#@U+**!L`'Y4XTZUVA:9XTZ,7$M0\P*AG,8C<+
M8-XY&2PTD:R;+QR3[>E=M.76E1UY!VT.3U+65BQ,ADO)"6)*<HQT@1J=9LK,
M_P"!QQ[:#$#\^M$!ZFM#7J-+$JN!;4=2ZFDBNB66S1K;4`Q!N3[<1P0M6'5Z
M:12M>LI=7A!U-I>%]!56!#.YN5U+9DD``TBQ'MTHBU*\>F5U*W=\/61)(RB)
MY1&DJ+<R)Y0+AV>,@+J,9,?!_J/=&"D]ZD_9T\&K\.>N:E8XDTK8I&`EM+$Z
M=81F2P<CU_DGCWY0/(8ZKX8)K4@?;UF)*1?H)8^MQI"LJ_VA'IC"O$GY'/U]
M[>JJ>M."[(H.>O),S2Q1@"`>(*)BI60LME#&PTLJVM>U_P#6`]TA.7J?+K:J
MZDZB".D9N&21]X]8J(6/CR.]&],8+L?[GUI8ARH**LBD"UM7T/!]L&H=M75Z
M\*=$6Z)[8[;H\K\D:&ES<$6#QWRV[ZH-MTVXLEW]55-'AX=Q4A6AHSL_:6=V
M[2XN*M>5X(8)QXS*P903R6S4$LF>-?V];3Q*,213^?4G^6'E\MG_`):_S"\Q
MGI*2?,U6YNNHZ^>A.Y9*23[;)=C04G@GWC08S<S*M'&ETJX(F5KZ%\94M3YG
MCUM0:FO#JP?O*,/W%T:QDMX\G36C!LSEM_;`<&UK%%\//OW5^C9CZ#_6'T^G
MOW7NB%?+F=T[O^#D"PF8S=Q]IR%/67\</QV[/1_&%<!C>>YN&LH)`N`0[`*R
MQUX5Z;E9@O:M233H462HB<.]/41QZ0JKXI#'(K*6"(X1O2;DW_/LU96K515>
MDXC5<%^\^1/7`1U#!6%-*-#,3:F>0JMT+NVD!59K<6O8>_!7I\)ZJR`,:N`?
MSZX&2?2CI%,A5]"J()?*2-`N(V4+8J3;\$^V9E)/>*N1Q'#_`"=/!ZD4IT5S
M;[Z_F)VN133?<Q=!;`BF9(G5HT3>&0DA$T4JCQ2$5);C4Q'^M84D3Q;D:?X1
MP\\?+JRG!J17HU`%HHW=)?1$#K5"H34#(P=6!!%UO8G\>W.U<5QU51PSUD#I
MY)BJ7L"J.]E53=7/]E3>S$_X^]U#8ZH/%JNMQ3J+(`(RQ1$TNR.RHRA@W"FR
MJ;LX/U*G@>]$`<>'3AK@]="I<Z;+>2(7B`5E$RADNT6DV+:;D7`^A]OQ:=/E
MUL9%:=<5FE73Y86D*@H@GB0F)2Q*HJD:;Z.?S?Z^Z,H74\B`N.!`%.JZ`#J!
MX>7SZDF119UNJQ'4B6U:V(TJ/2P3]0_P-OZ>Z%ZD`BAZ\17B1UQB:[LC,06D
M<$B/_-F13XM;,;:3+QI_%S[<=ETBE*]>$>:JW73R%38%W4M(1Z&5;W!(<V92
MEP?38?X>V!H\,!T)?5BG\J];-00IZ\Z,&J'4U")($UQQPS-9F,A5FTCTCQ<$
M_P"`]NI0-D^76Q05^WKDDKC4H#:A]N(9=$J!2"1H8,38\`W^I'NS@$@U%.M'
M-,]2&<D1NL>B4'2TD2OIT$AW)(8E]>DBXY/NJL$+*!4?9UO&:'/2,[#$0ZY[
M"\Q5"NP-Y.-&N[:=OY$Q:F`X8AC?4`;'_#VU(>TDG'5:@#AGH,_Y5-"]!\1,
M;&^0DR7E[=[ZJ(YY*6FI#%`_;V[E@HUCI8XD>.BA18E=KR.%N[%KGV68S0U'
M2DTQ]G5CWOW6NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KH
MD`7)L/?NO==@@BXY!]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7CQR?H/?NO==`AN0;CW[KW7?OW7NN+:2"";<@&QL;_
M`(%Q[]U[KD!8`?TX]^Z]UT?H?]8_[U[]U[J![]U[K__5W^/?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UU87#?D`C_`&_OW7NN_?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO==$7!!^A]^Z]UT2%TBWU(4`?C_`(T/?NO=
M%,^=]3-2?#SY$5-/35=;/!UGG)8Z.A19*RK9?!_DM+&\L*RU%0#H12ZAF-K\
M^_=>Z(WTS\D:_']3[`IV^/'R+GE7;\2O-2;"AEC82558Q>`C)A'B8O:]U)*D
M_2US!+J.*V@!5F*L>`)X^G3.2>`Z7R?)VLC\DLGQP^3D:M#+*8QUK`Z\*3)I
M"9Z0B,ZRQ`LQO8<\>U`NE85$<E?0J1_AZL12F>H=3\JY*9-#_'7Y-*DZ&%O!
MU:'8%?UM<9ISH]0``LQ!X_-O>.2,QD=:QZ]/O0>\7WOO'N/=$.W-W;1,M=L2
MF7";YQ+8#<$,5/@\C3">JQ;23R00U#4;&,LQ$B:6'!]U05F,GE3ATRP(2A."
MU>C)-&ZJL=P'))94:0(Y<(-3-?2R:G]0X^G^P]^TG!H:=.@A=6.I;:HC.K>(
M$A81KUZ0=-DTG4'`T@:?R+_7W9BK4"U%.JB@+D^?7>B6>,Q))&SZE#K<WM*+
M/*MSI))8:O\`'WL1U`;4.MT)Z\E/4Q:(M0,:JHB8B0'@CTV4@%T87)`YO[<$
M@S3B.JDZE(&.L3TSM,P46*#6$N77R!C=U+#6CD'A?H1]?Q[\T@`U'S`/[>O*
MI6M?/K/&I6#3-&DA0E_*DC1R7));58R([@"_)M[N/(].=9@DP,<L,Z2ZQ>(E
M@(Q$^@L69M3EB6L>`!;VWV`@&WSZCK0X\.LR0S0NG/G"D1Z@NDVLMM8)N^AB
M?P+W]V#1Y(6G7AQ/2-SRS)O3K)9BBA*C>#,"&-BVU*D$`G669V?Z"W%[\>T\
MQJ\=/7KP/$#CU0^O36]*_<OR<[:ZMV?6/VPWS&[IV?C]QUTFZLUM.;;]9VAC
M<7Y\WLVN^*O;.Q=P+MY)VDB4Y;[Q`)$A:!F`]EDXU2$TX'IQ"".'1T_Y1N+R
M&`[[^>^-S[4"9S&;NV!2Y]\;A:K;&&_BAK^Q&G.*P>0VYM"MQU!(;2(L^-HY
M/W;>,@!WIU;JQ?N*J:O^1WQ]P5/54BQY!<K7--+(KI&NW\GCMRS11K&=4E97
M_P`$2"*[!5#NQ#$`>]U&DBF:]>Z.(OZ5YOZ1R/SQ]?>NO=5L?/38N#[-[/\`
MA9LG<4V;@Q&2[9[/JJMMO9FJV[E'_A'1V]LE#'!FJ&U91(]1$@D$9!EBUH>&
M(][BI),L61QS]G_%]4<D`$>O1<^Q/Y<FS]UY.@R>U?D/\I.IDI\>**LP^S=]
M[:W%B<G4M,\\>3GE[%VGNK)T]9#"!#HIYHX"@!*:[DF$ENFH`N^/0]:\22A0
MA:'S\^@\F_E>K+H`^<7S-61)3JTY?I^S%E`+G1U<J$`,";?U^GNZ6L>@?J/P
M]>F0[:R@44'KT_X#^6N,)E\;7U_S5^9&Y<=05U/49+;N1W+UE1XW-P4Y1YL5
M5U>(Z^H,O0T]:B^-Y*2>*95:Z.K6/MM82QTF0_MZ=QC'0J=';#Q/5GR>[HVE
M@JO<62QL?477V=BJ-V9^HW+F!4Y3.RBKII<Y71KD)Z"F%&@IHG=D@UOIY9KV
MB`BD)!)`%>J\<@<>CQB)W1&76(9!'*8P[B;6$!0L))"Y5"/K8W]NAE(4E3G/
M[>FRCLQ(8`>G4<I4E3Y!$?W)TN)7_<7R"S:1ZD)3DL2>/='!+ZH<Q^?6]0)4
M:3UYHWX>&%-<A06,ALV@V*1J6*DE&)(`L!:Q]N=M3JX=.Z@`PICK,T=V0,A]
M4:*"[E0I9[70+I.L$$_6Y'X]MLJDUR.J*"@IY]0(&FCE!4KZK*TW[I4V9H]+
M>4LHN`>1:PX]ORX31ZCJWED=9O%)<,WC52K/&I$FE1ZCY'*W\9)!L"+6N3[:
M;+`@?AIUK#`4ZY)#/$'CEC5#4E90S%F(8MZ61N=.@<@<'GWL::9!/6CJQ0T%
M>N1=D`0J7*MXY/&X\L2!0$NZJ?VM)-[\CVXL;54@XZV!YDYZE1WTB2-A<'U%
MGF/)4A&(=?&SI]3]+'Z>VY5`?N-!7K1Q7'7DCE=699%F:=%?]QR%#?J1$0HP
M?3J^G''T/O;,&*T\AUO[*TZRD31%7C1;2(L8>5WU(PM>UUL%1>`/?HU,K.J<
M0,]:''AGI#=D2-3===DO^Q%'%L'>4MW(+S$[<R!\;`D!$N?J/S[UX+LIJ*`X
M_;UL`N0FDC/0=_RK:M:[X<[7J@Z2/)V1WBD[('"BII^X=Z4U0FEU4JR2PD'B
MUQ<<6]D]`I9!Y$C]G3PX#JQ?WOK?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]UZU_K[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KUK?3W[KW7O?NO=8_&FG3:XOJY)O?^
MM_\`#W[KW7)#=1PR_BS?7W[KW79^A_UC_O7OW7NH'OW7NO_6W^/?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]UQN==K>G3>]C];VM?Z?3W[KW7+W[KW7%B0.!<W'X)X_
M/T]^Z]UR]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]T53YM!9/BAWSJ`*R=?96$*QLI9YZ5%!N=`#.P%S_L?>U5I'6)/[0\/RX]
M;Q3Y]!QTI03CJ#KQ2/2NVH0&\;J@/WM:0C,WH9886N.;$<@^S2!I!;+I8DUP
M/+CTP1ENA,-+ZU5R2C$A=&I1(RB0"6522)(P5'Y]J2Q9M29%,USGY=5"T_$2
M>HI6I5W99I(RMY4#)_J4)52H<#A3920">?>M*M\0SU:E>BX]65-+5=U_*>%)
MVEJL-N/J:#)V4ZXZBOZSI\I20*[I$D[R4M0K$*S*H8`V8$%,CR>-.%9?"C`!
MK6H:M:?9X94^M?V=:8:D(/\`:5J/LZ,.+K92R/Y'LY>ZF-QZA$$#`+IT>H&W
M/M]Y-:=J@I_%P_*G7CI(\Z=.0II"X857J6VE2CE`GI9E*W8E6_LFX/!]M48U
M*]>I@8ZB_<(/(8)6)\MQI)!`]#AOVQ^Z&M_4D?GVXJ'3W$];'D>O>1UBI@KE
MV)EE9PY+D^8LH:,_H1P;'C_>?>RJJ#3T_P`/6R:`T`KUR+%F,UVE4JI>0N5:
M!;G7>)6X4-QSZCQ^/=%;2R-Z"G5!6H!ZS1RM,[`OHT!@DDNDB2X9$5^!<D?4
M*"2>?;L?P\?/JV3QX]<W1V47D8*(K^-U++?R:&$8NI)\:VTDZ>;^]?4/D=OY
M_P#%]:%:YX=2!,Y42*"NJG52J$>DV":W(/ID5H^;7(_/NL@+(M:<?+[.M_X>
MD=DVFJMZ=>^)`332[O:[JQF6V`CB=U!0G0S2K^4X-KD7'M,WQQK7%?\`+U[.
M>JX-A8RKVKU+\HNQ,S58RCVMA?F_W959/,5.%ZNR4[_;=VX<?PZ.3.[%S&5G
M-570QTRK)*(HV"F22.-78)+AB\K\``3P^73J@**#IZZC^%_?C9KYCY7<VSL%
M3[1[_P"YNB][;#EI-V[:I*O/[!Q69W#E]V5N0QNV,?B*#:]=B,;N--%.D:25
M%1$7B]0#,SUOJPBO^,_3'6V>ZVSFQ-I56"RM+V5M:372[IW%]NT*PYLC[ZAR
M&5JJ3)0Q>1RL3HS"0AE(87]^Z]T;NMR5!B:&7(92MI,=04L'FJJZMJ8:2BIH
ME`U2SU53)%#!&"1ZG8#GW[KW5>GR*W7MC>??/PAR6T]PXO/T-#VQWGCZJIQ5
M=#54T.5QO1>Z8Z['32PL1%6TT<]_&2&LP-K$>W8#^JF//JKTIGH>U2:1]$H:
M,7(1R=:2?3QB_I'DTM;@WO>_LT8]S5`Z:(IW5_U4ZQS+/&%7QL26*CQ69@6"
M@!B;AKJ#^`..3[\?$-"I31Z9_P`_7E.-0`ZZDC=D?3$4D+>E%:-3&'50ATL0
MNE2+\FP_I[TATFIZ\*"F>BN;0"S_`#![L76XK*3I+J>GD:21?`BU&5RM2K0*
MAN`Y`#,;<KP#8>VM0+L%X$4_(]6X4&*=&E>:M<']O28Y"B&,V0F-%NQ<7)U7
MY'TY]W(HC\.T#_!U6M17KSM+(%$BK%X]3!D+:B/KX6NP#:@M^!<6]^I@:<#S
M`X=;)X@#KTD4IC4F^F1GD])9B-2Q`_4JL04BPN/R?J?>P`0Q].J>3=8ED?2T
MW[C$."HC<$!AP9+WLO(`O:YYX]Z.%U>=>G1HH"6ZXB)F2T@,CEVE'K(!TJ-<
M?JTQ^(./K<_X7]W+ZV752GRZH1745Z]-*ZHP`.J4A5#L5=U"AT32`+7!T_TM
M]/>W5`!I)U5Z;(=%=B!@=8999K!(XIDLB#R&\J![MZ#<AHUU$7L"-(_P]M'4
M,#AU>I$:O\NLLR2_MRI979[R$6N"`P<A%95*`FP#?CVZLC)0.!7R_P!GK>H4
M'V=<6,A%E29X@5"'6T3*H)T1B/4`R7)!-K_3WY'#N>T5IY\.MDX&.I%(CJP&
MEG1X5<@2/JC0$QD#@6(:WTYM[])0$4"\/+K1J.LK.1XHUDD"K?6T;"\DP0%=
M9;4"=!'I^MQ[L%J@IVXXCB?MZVN`/7H.>X%>?J/M1CH4R=;;V5O6-"#^[N1<
MO/(``IU?V?H/;(.E04<LP-:'Y=.!CD=)K^5R/^<.=F/XC")M]]T3"-F5F"R]
MO;U<:F1F4FQ_KQ[**$-)7CJ/5SY=6%>]]:Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NNC>WIM
M?\7O;_>.??NO==*25!)!^OZ;V^OXOS[]U[KE[]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>ZXNVD`VOR!_M_?NO=>#`L5`/IM<V]-S^`?R??NO=>75;UZ=7^TWM
M_O//OW7NNS]#_K'_`'KW[KW4#W[KW7__U]_CW[KW7O?NO=>N+VOS_3\^_=>Z
M][]U[KUP/S]?I_C[]U[KWOW7NN(:Y(TL+?DC@\VX-_?NO=<O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]UQU>JVEO\`7MZ?I?ZW]^Z]UR]^Z]U[W[KW7O?NO=>]^Z]U
MQ`(9C?@VL+G@C^@^@O[]U[HH7SZ!_P!DX^02I4U-"9=A54)K:&RUE&E1D<?#
M)54K%)%2H@1RZ,58*R@D&UO>U)5@ZFCCS\\\>O=)WI>GJ4ZEZ\B>M\@&U*-0
MTB--"PAFJY-18J'MI^I%K\\>S.W'^+)3U_R],'[?/H1I@XBYJ5B5N6NN@*&#
M.$`N48MJO]`+`7]NQDBI!I4=>%.DMN?<6,VI2?Q'/Y!J2GGEIL?04]-3U&5R
MF8R4Y/VV*P6(Q4%1D,UE)TC+K!!#*X12[61685U/4LQ/6ZT-*]`9TUM[=%/V
M7\D-[Y;;^8VY@>Q]W]?9'9QW$N+I\ME:3:W6N)VSE:^KPU#E,A5X>./,4DB0
MI5B&:5+.(E4W+<2J'<Z0-35;YFE*GUP`/RIU[\6JN1CIP[KEWI55/6&W=J;V
MS.QJS<F_H:3*9G#4>*KZJIQ\%%.\U'44V4HYX)Z*=2S%4,,VN-?W`!8ZN`5=
M6#5[APXTZU3)ZP1]/]PO%5"+Y/[^B"05$:3)L_9Q*%[K')&LRR!I8SJ*@J06
M`X(!NZ8C(6TL0OVTZ]K4%7U#`X=`37?%OY99"OJJJB_F1]S8BEJ9WEI<72]#
M?'&HIL2CNG^24L^4V575]3$/KJFFDD+$ZC^!8)*,"Y`'SR?V]6,R,=0CP?ET
MB=T])_+'KK&S;RK/YAW:N\*7&Y7;U"V`SG2G0>#Q5=!N7<>(VJHKZ[;FU,5E
MXI:";*O5QF&:)7DC1'!0M=MUD3N>X!B''%!^WJFMB1VG]G61,7\E9N[MM]2M
M\G-V4L.7Z]W1OBISG^C[:3:VQ&[<CM>GPZXV:+2-46.6K\ZS(5:31H92C*V6
M#,B1RC614"N2!Q(%<@>9ZTQ9&4%#GH\/5^T]];1I<G1[W[5R_:U37U-/-CI\
MGMW"[;;#)#"\-31PKAP6JDK)"KL9&'C*'3?4?;D,-PGBR&Z55(P"*_L^WJX<
M$D`=)G>W6?<&X]TY'*[9^1^=V'@:U\7'0;.H.MME[@QV+DHJ-:>OJ8LOEH_X
MA5)E:N]0ZR\(;(GI4>].CE"%?0W\6G4!^7GU1JTJ/]GK#\>L_OC.;.W-'O#<
M)WGE]N=C[DVI%N"HP^.P[5F-Q--AFAE%+AH(*-6^\JIG!TNP5PC,VB_OUNRU
M97-7'XJ4!^P>73I(H.'2VW=N?![6W-US6[EW!@\'3557N[&T51F\O28J*MR-
M1@Z=H,70FKF@%=DI$BDD6%?W/'&[`6!(W+3Q8C2@K3\^O`5Z#E.T^@:WKW</
M5/9/5^6WMMVKWYNO-Y6CH\+M#*;8W!55F_,CNK%[BIJJ/=E)-5R22303FH=8
MJ@RJRL/J"D>V9Y)/#8')/'Y_+K0;[>AFI/FMU9)64^&I-O[TAJVM'''D1LK%
M4R*L#5'[E57;UCBA+1IIC5K:Y&51];AOZ20&K.0/V_Y.K"0,:4/43>'R-VSG
M<IL*AQ6UMSY:L&\\-EEH<57]>YC)S45`M=!.V/Q./WS-E<C.L];%Z*2&=U74
MS!45F&Y+<Q#N>OY4_P`W5P0WPD'H6,2I[7W9_$L_M'=V)VIL:DI)<+@]]8/^
M%4>;W?DI*B27.KBI9JF+*+MC&TL45&\MXX*FKE=%\B(ZL=>Z(/NC"[DD^4_5
MV'R.T=RX9,-\C_DEV3_&,GC!'A,KM'/='46V,+F\-DDDDCK:63+9"."0`+)`
MXTLOT]WC<^)H5#6G'_9ZI(=*ZOGT=74XE,:RD,D9"^./R(H8ZBZARH(8_3\W
M]FR+)C`_/C_/IL-K\N'6:,R#R^69#XPL;_M6#*44`".UW.E@;K_C[HRU8X&K
MY=:7XF!X=16AG<@^<ZK^L12%2#9=<X#H>%M^GZ6^GT]VX@#Q*YX::?Y.M\,<
M3T5S9U/5P?+OO68"-HI.H^I%BD)!U.*VJ=UD$9)71Y@#<W_P]T$;"\8:#IIZ
M=>%`?3'1K4A=;L&B6%HQK4EE(CT@>LD:$M8W(NW]?>SDL#Z]:X@D=1H4J#IT
MRP$:PJ'5J4%N7!*W`(7](/OQ5@L?B`^*?3A^?5N/'SZZJ15L[1&950*IEM)J
M8*@`AY4<.0;D`$\VM[N!17!P:=:#!12F?GU"*R!8I(#"RQER5+D(;,!J".0U
MF)('YO?W:)-0TEA6O#JH>IJ8JC[.ID?E+LL4@DTIY"$&KQ'4K:5:X'I'TX/^
MQ^OO0C(()(H#U8')(;KC&\\D;,)%M>2?4>+-)=?&@)O<_P"'`(_Q][9`S1Z>
M`/6I"S+2I/461Y+I$LL<0D)U6\FB1B50_M@70J+@$_4^W@E-8!KGRZJCE5H5
M/7:O.BM<Q`QU`?0NN[`W0R(C!E,:LPM?Z_C@>Z-_9,))-3$]H"U(^1/^7K<9
M'<QX?/J6IF_;]2DB032M)*MG]`LL",I0LS*/K[3K&'C[10ALTZL"#4:NI225
M.A"7C!C*@A6*+H!5[:U;U-93?_C?N[1Z2*9'6Z9)KUP'D=2X,2DW9WC-K:9!
M9M7*E55EN;?U]ZI*/[13X?E3T^=.JA@!0G->@U[F^Y_T+]PM'X)EAZL[`>.)
MB41Y!MG(Z!(5]#!S?Z_CW6A4,2,TZ\Y(I3U'25_E6I4)\+=AM4S+.\V]^ZZB
M-UA$%J>?N3?,M-&T0=PKQ0,JGG\?CZ>R@5-:\:]*.(!/5B?O?7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KQ(')-A_4\>_=>ZZ%K>FUOQ:UO]XX]^Z]UW[]U[KWOW7NO>_=>
MZ][]U[KWOW7NN@0?H0?]8W]^Z]UV0#]1?_7]^Z]UU8<_B_U(^O\`K_Z_OW7N
MND#!;,02/R+\C\$W_/OW7NNS]#_K'_>O?NO=0/?NO=?_T-_CW[KW7O?NO=<=
M/J+?D@#_`&WOW7NN7OW7NL=U=A8FZ&__`!'OW7NLGOW7NO>_=>Z][]U[KWOW
M7NN(U7:YXOZ?]:WOW7NN7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z)?_`#$<B<1\*/D1DO%63BCV*9I(L?1U60KWB&:Q*S"CH:%7KJRJ$3$Q
MQP*TSM8("Q`]^Z]T7SJ?Y![13KC8-//ANQE:':U%2LU1L'*PB26&26-9=7F4
ML"5U$LMVOS[,HI%C@16!P:_E6O3)`R":'H2O].^R:@E),/V1&@0EIY-A9MEF
M(&FT,D:.`-7U(X_'T]Z2YC`4"I(!P!ZGK0]?+HM>_/D5GL-VI!N_;?2N^NT-
MO8W9]+A=L5\%;3[.J-MYS+Y'(OOF5://8J=I:K)4%%BJ5:B-[BFAEC4*))`]
M))F+K+&K%5'"F.MD8U4KT8KI7MZ3N/;&>RM;L7.=>U^`R[8K)X#.9#%YB=A+
M$\]+6TU;CHH`(IQ&_ID@B<%;C6I#>W()A<.553X@R1Z=>`!SBO4'M5VCWGT8
MD4FHCLD12R$%F*_PEV+$@68'R"XO;\?GWLBCJ:<:]64J#GAT8^*!X*>J9_LW
M27]4CL5(()*"%U`(;0-5OQ>W'N^HBB@GJFA"6).>FD-(B.MTDE=4CUE8@J:F
M5BR%0RO&2MR3<FP][8,`"PX]:H%I2M.B@_.'9V?W]\6>V-E;3:#^]&Z*/9F%
MQ<=;4S8V@GK*_LG:,5/%55U$CU-'3SM)IDEB1Y4C8LH+6!U,P-O+&PXBF/F>
MO&0+0BO'HG/Q$Z?W%U-\N]\U62GPD&W.Q^NLING9>T]O9RMS&#V53XO=&4VI
MF:7%Q/M?:6.QL&XLSB)<A*E-0PH97.H&P8IT(%U'"BK58B"?,''P^M?/AY=.
M2,796\B,?EU</2.7!5Y%?TJY=X466$69BX;4"`MK<_CVN<&1$HI4@4S\L=:`
MTL2.LD<4"O&6=6)<Z%.MG;46L\@!;0%%R/IS:_NIE4@BA_9UJHK3HN_QE=FV
MWV%%K7CNC?1#1J@5O\FP3C4+:BL:D<7`)'M.H!%/Z7\NO4!J:=-W?U/!)V5\
M1X:B!3*_?C5<9,?D,+T>P=TR&6-2&3SF,,`XL46_]>;3NI:VI7$E?RI3KQXD
M]&1A;6LQ$H5[MXC&I955K*RNA`)9&`Y/`_'M]8U704.:"O7OGUA$2QSEG,<C
M+(&=VA*@!$UL2A#7U26/]!8_U]ND*U`>M$A2K'@#_D/07=B)0R]F?%\9#Q2U
M"=U-5T#W,$D=8NQ]WI$4,;Q^=&III!XSJ4"Y*DJ"$%W6G<>J6_%1Y@?Y3T?]
M;Z5O];"_^O;V7=*NBD]T/;O?I=.;'9_:K,H)U$*FV#=0"+\`D_X>WK<TE4'S
MZJP!&>GF24M*X+(9(Q"QUQL'C564@!A>]K@?['V;%PM0W'IH:03I_/KTA,D>
MJ,K'^N2)]*H5\;V92ZVLRIR#_3WI$SKQ0]5#AF('$=1G"R:665F.E96L`-2@
M@#UAB"NLCB]_]O[99BC`+G(R.'7C09/'HM&T(9F^6GR"#,C$=6]+$,1(%)JO
MXRSI"3(2+F@!_2+$?6WTOXVB=B]<"N.JM5_AZ,P#''XPLP1/.%+6)"DIZRP=
M06+:K@'^ONM#@TP<C\^O!@H*D9Z[_<4U"12JS@@_YO4%,KV9F*:5TD*?H#];
M^WG=68,*T'3I%:=</$4,<".JRS2/JU!2H13Q9@."BK<\\`\^Z.X(!`X=>-/R
M'7<HT(W$?B]04`78,GI,H(T%5.H_UO\`4^ZJ""'"T?JK,%8#RZCHRZU,<@5?
M5Y2(QIB(],+QZ"92MDL;:N#[=,BLIP<=:&$?''K(&E'*.CEC(RQK"NH_0H_H
ML`GY/''^!]Z2H^PG'6T8$%?,=8I&8>1Y!$YF=2)8PI2.8L=+W+:BP3TVLH%K
MV][8LLC@<:4ZL?3K-XG<P.)8CK0B0F-=-M=U9E1V"K<6M]/S[TG;&68T'"H]
M>M`#(/695.I@7A`5%]4P-E"2E;*B`$D$V4CG^H][UAAJI2F,>?S/SZUI49`R
M.N0B90)5EU#5%;4%<.JW)TKJ0$WM^H`V]V+@`$@\:=6&>LQU`Q^%HY59F3QR
M)98V50[A%-@Q)D_U@?=?$8,5/KTT5JQ/ET%?=J!.D^YIHF\OBZM[`,:(O+:=
ML9`D:3(BW;1P!;Z_7GWJ>OAFO#JS'4BL.!(Z3W\JNNHLE\(NL*V@J*>J@EW+
MW$C34LL<T7W--W)ORDJXO)$2ID@J:=T<?4,I!Y'LDJ#D<.E(%`,UZL1]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7'U:
M@;^FQN/\?Q[]U[KD?\/K[]U[KI;Z1J^MN??NO==^_=>ZZ(!%B+CW[KW7@`!8
M"P]^Z]UW[]U[KWOW7NO>_=>Z][]U[KQYX/T/OW7NN@`O`%A[]U[KOW[KW7O?
MNO=>]^Z]UT?H?]8_[U[]U[J![]U[K__1W^/?NO=>]^Z]U[W[KW7%5TBP_J3_
M`+?W[KW7851<@`$_7W[KW7?OW7NN.L?X_JT?3\_\4]^Z]UR]^Z]U[W[KW7'3
MZKZF_P!:_'_&O?NO=<O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]T4'YZZF^(G>"*=+MMG'*AMJ_<;<V"6,%2#=2Y`(^MO>Z8KUXX75Y],?5*O
M3]<;"(,P=-KT*2)Z5A$\#2I4)XEX5$D/!-V(()-_9M#1HT>G<"!TR>!/GT(<
MDLZ%P&J665RFJ*61F03*3,0PN19VOS].+>U!SQ`(^P=,>(>%,=-*221/4:6G
M*PB.((L\K2.SW+M)K(>X!^GT`]MR=K*5P*?MZ<5R5%1GH#.N<U1Y#LWY$T5)
M/'45.)WKLG&96EC20U-%-/L6DR5'#,I-I)*C'Y"&=2EQXW%^>!2.HEGET!"%
M&1YU]?MZTH#,3K/63LIT;>/2&I))B>PJIVB*$L9(]O5DB$`*'`5HA;AO]YN+
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M?^.2G*6LUPY;6-%E4QZ(KNP+C])N#^>#[65<$GCU;4GF>I(\,8C`1RA*R*94
M`)9I`JI$%L02'O<_4>V2=0*T`ZK4U)\^@`^-BI1;7[">.S//V]O:=M!&AGEI
M,$OJ#D`,`E@GYO\`2_)9B[RX/K3KPXUZ4W8W7#[ZS/6>X(MQ9#;68ZOW55;P
MP]1%B<?E*/)UU3@\GA&Q^:@R6F48]H*YVM`\$Q8+9P+@JGB6B`>75N/3CMS=
M&0ES&5VAN2FIJ?<5)B8MPT.1Q,=1%@MU8";(-B9<IC:>JEJ*S%9/#Y!8X,A1
MR2SB+[F"6.1TG`5/%+,\TD+*HH*AOPG^C3CJ_EUKATNH]+AB\?\`GGT^5I2L
M8"F[KI*`#4HL"+<_Z_M\LRCN(U5\NM,%<4!/'H-]]QXVL[0^,224<=0]%V]-
M5T;U-,KM1SIL#=L2RP,P?QU"1SR+J6Q4,W//M+<G4A8CRZK$NES0^71^5_2M
M_P"@_P!Z]EO2GHGW=LB'OOI:F<M^YM/LJ954->3[=<&K)K"LJ7\P^MB?]@?;
M]L:3(:<#U5S13T\1R:)GC=##)9B9G`(EBD,9:G)0KK%_R!S[-I@TC-(`-(_;
MTEC8$L:8ZX(6Y@8F,DS^D_ITR(FE5$B$:N2`>0+>_`Z8U*CB//RZ]559F%2Q
MZQRD,"H5IWC0(64,KZ`54K8H-00J>`.;<>V\%@?A0>7E_GZNCEF%0.B9]9[R
MBROSO^6FR8Z,QKLOI;XO9B;)BK>66N;=:=@Q1XV2A$4?VC8UMN2$N)&,JS\J
MI0WUK$DQ(%*BAZN#CX:'HZ,LD#O=UUPJ?)$@C8R.=%PUQ(P-A86M_O/MT5/X
M13A^S'3+_P!H>L`F+--.XF12W[112NH)I9A,KAO]8?D_ZWN[$:"M*#I_K$U0
MA,;GSE8F3TLBF-B3I+A4]09D']+_`(^GNH55^?6J#TZR>>,+9T92PD,H"DF,
MRDLMTD+&VD7/!^H]V5@-?:,+7JDBBA<DU_EUP,E.J1@*X2$A=?I4Z9+MK9E`
M.BPL0./=9(6B4LIJ&%>FM9;L^77,3):-79E_;8`JI\*:R%LI5@0\A(M>W'OV
MD!HQZ"O3JI3->FY)BQ:.2-#+Y$5I=#(J$.64M(>-*`\\#VH51H,A%37JU:N!
MU(65+K'K=E=W"(RD+IOJ<@ZBI0DLP_.KC^GM.P!1E'`FO6Z<1TXO-2K%XKR&
MWI!*$#6/4K+ZCSZKJ.?K]?>H]28*BG7@*#KI:R$@OK2,!43TW5E9E9'60,=$
M=]/Y)^M_=F`?!'6^I:NH9`T[QJR*270Z5_2QD1$N&U?X?7_'WXHQ8MV4_G_Q
M?52,&G'H%?D*(C\?.[(*F0-3_P"B?L*GDB0FF#Q2;<KH79I;J(PT08,;\>VI
M\(R_+K:K6)0?D?\`+US_`)65A\'>H0J*B#)]J",+''$#&.W=]!6*1*J:F_)M
M=CR>23[(T^'I[JPGW;KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]UT;V](!/\`0^_=>ZX>50;-PWT/Y%_]?W[KW7)V
M*K<"Y_I[]U[KR$LH)%B;\?[$CW[KW7+W[KW7O?NO==&]C;Z_B_OW7NO"]O4`
M#_0>_=>Z[]^Z]UXWL;?7\?Z_OW7NNEU6]0`-_P`&_'OW7NN_?NO=>]^Z]U[W
M[KW71^A_UC_O7OW7NH'OW7NO_]+?X]^Z]UT>01>W^/\`3W[KW7@"!8DG_$^_
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M9Y\>J(`6IY4Z3.<SN%VMC&RN?R-%BL>DT-/+/5/+>HK*Q_#3T-)2P&:MR.3G
MF;3%3TT<D\I)TH0"0V[`$`BN.KM0'PT7)Z`+I3%[A@['^4.[\WMK-X+"[V[7
MV?D=EUV?Q\N(?<.WL?U)M'"5&7QE#6:<G3T%-F*:HIA]Q%!)KA)TZ2"6D=F8
MU/8>(^0X=;$84Y^+K/\`(#([HPM'U]O3:>R=U;_J=E[P_B-;M_9V-DS67J*:
MKHCCXV%%!(E;]K&L[O)+"DYB`!*$$E?2L[%<DCR^SY=>XFBY&JA^0\^D#M/Y
M-=I;OW#2[/B^-O86U\UG,=F,AC)]_4V:V7A:N+`00564B@SF6Q!I9:VBIJE6
M\)'[@-D-[WH+DE7BCA9I?*F/]7^H=7*QT*$D1CX3\O/^?0MC=_<4MO\`C"N.
M=F*`G_2'BXR'5E`;0*"\T;L238BP!)'MQ&N1&OB6C!J?Q#K2T"BF1TG]TY3N
MK<%'BJ:GZRBH*6ERBU]<N-[5_A-3E8(,=7TD="*[#K1UU-2KDYX9R`^F0T^D
M@W]VD6X*0K';L']0P_;TPK1UG#ZE4`T(&0?*GYXZ16W>M=Y[2W+L+=^V.N*W
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MIHI#I-BH`()!!.H30$^"X;5ZCK8'SST#?S5[/S77M!U++B=Z[\VGC\CN;<6<
MWA0]7)A9=^[BV7M+:E?D,Q!C*G.;7W=2XC&8FIE@JZVLEIX8PD0@,RRSPQR5
MOIYTA4JLBC4,A0Q(\_RZ\32G6;XQ32[QS;;YR.ZN_JS(8;;-')A<!V_GMD5\
M4>#[&IJ/)T^72AVGLG:]93MD<9C::5%J)7C","R"5?2HA\-Y%(<MP\O\/IU5
MV"E:#[>CEO*Y8R/&%LGB*!9"C%Y`5+&QCB92P/%SI_U_;HC`D8T\NO*4J0HH
M>@>R-*M-WWUCD-P8S*5XRNZ\'CNNL@F[:QL+M;(X[;V8J=W0UNR3-!0'(Y?&
M),L61$<TI$NCT#Z)+Q&H'5J)PI_J_+JX%#7SKU88/H/]8?[U[+QPZ<'`=$K[
MUR4&/^1/20JGA@AGV+VLJS5$BPIYE_N\4B21B$$DH8\-]0..?;]K3ZB&OPZL
M]-RFB_GT_OF\4AN:S&2`AG58ZN"62RZ25(2;0"C?@&Y_/LV8.S!D-#4_RZ9B
M!"L:>?7ES&,.I?OZ$GR%KFKIU*^34`+M*S!?KP2!_A]/?BVH`2/4CY]-D'4<
M=%_[8[-V/2[IP^P=S]I[:Z\PE1MV3=>YJJMWOCMJ9O<]-/738C%[3PN9>OHZ
MS'4%5+3U51E9Z1DJC%'#!')$)W;VPS!GTJX`Z>-$\NF7XZP=*U&]>^<MTHW6
MU515><ZZQN=RNP:W!9:6OFHMA8RIH8,GFL565M?D5HI*^4K]W,[K-+*22S->
MJZ4FEC3+)3/K7KTH9`C:OBZ-4XDC1&6-2%$I/Z]6M6NBM92L9_P'%O:Q"P``
M.>MA00"P[NN*^-;.JL)"%;4TDCE"Y97.B]F8J`+_`%YO^/:<ES7)IU;NIT%V
M[,;V)/OO$U.V<K]OM=:'"KD*096#'QTV7I=T1U>;KJ[&U>&K9LU2UNT-5+%$
ME1#XY3JLI]8].MSXD?@`%!\75&<J5[:KT)$,<8D"HR2^25K2<LP7R#21:]D(
M!`!)(_K[4$I0_,4/6II`5[>'IUQ*0/*K/JD<2+9E#`%B6OZ-%B00!<\6^OMJ
M0&(0^+\9.*9!^WK:JND$#K@R37:.6&R22#43=X54:0-!()L+`_XD>[_$?%+&
ME*=7ZY.J%8V"7,;*+&]EY%U?2UB6XY8^[LY6.BM2O7J<3Y]<U*<!H@I.H$%5
M((^L?"V5Q;\C^O/'O2AJ*Y;TZ9U,'`/"O68I)-$JQ0A5C8B-$++ILP1@>`H.
MDV_/]?=49B'#/7/GT]P.>N5,@*)'*DA1I5,@<ES8!K1EK!=(%AR+G^ONU#6E
M<]:+!?*O4U*E0%9U"\K=E&H$#6$15D3Z6`''&JWME55I')KIK_+KV&H3T2/Y
M_P`/=Y^.&]QT>^"IJC^`[P_O^NX(::I,NQYMEYZ&=:.*H>(B>/,/222>)C*T
M*NJI(3;VGNVN"/$5!H\_6GX2!ZG\76]1%0":=#;_`"K8LC!\%.E8LM40560$
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M>ZX);U6O^LW_`,#Q?W[KW7/W[KW72D,`1]#_`,B]^Z]UW[]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[HF_\`,#R%%BOAYW=D<C.*;'T>"P5173^)IS'1
MQ[RVV:EE@C@JI9G\&K2B122,U@BEB![]GRX]58$J0./1=MA?*GIJ'8>QTDSV
MYE)VYC[J>O=]&33I\KNH&W6]!0J1ZK"YYN#[,8);<0^'G77TZ;TG13'#I05W
MR[Z(@DD1]V9V!69M0J-A;[_LKH,8D7;+"0Q*PU`7*DV//MU9HU)+-0?/JBH5
M.HTI3HM>ZOFUL7%=O5&3I^N.ZNSL!BMG8?'[+SNQ-B8^?!X+-Y&JS<V]ZZ>#
M=N:VMFX=RU5,F.HTG2FEB6B1D213),&;-Q`TRZ9*FG^7JY%`K'X3T;'I?NC;
M_>>V*[<F%VWO'9ZXK,/B<AA>PL9C,-FX'T,T-6:/&YG-1&CK3'((BTB2WC?T
M`6)46\\$K3".0:AZ_P"K/5I4DA=%EB*LRU4D4!''!X9ZG=D]KX_K'<?5NW)=
MK;CW3F>WMX9+9FT:+`/A:>CILIB=LY+=-;5Y[)Y_+8JFQ6';'8IT69!43&9E
M41'D^Z/((Y(D6KG3\7PA?D%^?28@EP/!_18$L00#4<.EAM+!9YLC6;VWF,3#
MN*HQU1@\#MW"UU5DMN[/V_55HJ:J$Y>KH\;/G=PYQJ.E>OK?MJ>(+31001B.
M-I9F1%KNA))(5*B@I\^E!,:I&$KD=+%H/$`D15FL&D.@RK=AR68,=,2(W^-[
M_2_M8KT31/D>7^3JH8'/46G1(UA,:D%50R$,!&`I<`JK<AK@G_D7MPCM)P5'
M6Z]3FCE>.5+JJ&,$:#'>Q<HLB_I_MBY///MOQ$QGKU12M>L#FP]84R-#$(PL
MSL03<%O&MEO*;@DCWL'B:XZWT&=?C]V[4S&2S.SL13[HP>Y*V;+;EV=_%J/"
M9W'9X4L4=1N+9V0RQCP=8V;%/$N0QU=/1H9E%1#4*[RQ2)1&L,[E%JC>O6L'
M'6;IWMO`]R[/.]-N8[/X&DI]Q[OVEDL3NRBQM'GL5N'8^>K=M9BGJZ?$9/-8
MJ2!*VC8Q2154B2QD$<@J'NR=20E".O$8/1'^W)MQU%5_,7K]UP86(T70%9C-
MC2Y"HK8][TG6,^Q'K:3^[6,IJ9]N?Z,,EO$9"6HJXZD92IST#19")%IZ(!HO
M('D[0S:#@D5&.('$_.G#KR`L2*5('0[_`!J\(BRUI[J.L>@A(A6S>%.N<652
M/5_:F-V91]&O_K^V+6M&61M3#1E<`8&3Z]:9"01CHU@F3RK&&0M,AU+^TX]#
M6">0FQ8G^S];6]KQ60!E)TD5!\OV]-HK!JGAT'F[YBO:_P`:HY=-ZCL_.A6#
M(NJ2/86X2JN%*ZRL2$`<D'FWY]H[T`1("Y+:NGE!,A`'`5_P]'J#JH0'ZE1^
M/\![+SQ/3O17?DUU3U5V#B<1F>S\+15U)M9,M4C*U^?S>`I,-BA#3Y#(U59/
MB\QB*=J:%L='(7G+&+2=!74P95;(C:@Y[>/Y]4<A5U$^?1`'^.G5.ZLSL>7K
MSJ'<])LNOS\C;TW1GMQY[;^*RNSA!+413X;#;@W@=X""KR])`89J>AI9I87U
M!O"[:GVT>+"[JQ16_":>7VYZJWP&AX]"]%\/?CK)(6JMA-JDC!!;=^^P6(8!
M#<;F5M)0?Z]K<^W/"AE7'&OG_GZ:#```MD==-\,OCI-*IJ.MA*L1DE42;QWY
M4*CE$1S")-SR(-4:VNP(X%O=_IHE75Y=:=PRT5B#7H2^K^D^L.GY,K5=>;4A
MVS)N&.BBS3QUV4JA5?PXR&D0ME<E6>'1]P]]`4N>"2%6R=(UB?M\SUXF.@#.
M3^70P2'3$`&)+LK7:4N?7Z0I5E!4^@$_4\^UBJ"YD,A'Y=;U+4A30=1Y)"$!
M5DDUQL8XU.G5)!("_!N-3J;"X_3[T[QT`\0'5PITX1Y=19'9PTD2Z&<Q^0N%
M&K@VT69B"XXX!N#S[?D4Q*-?6F8+QZ[82)*AA)CT@R1Z9-.D@:F0*R6!#7-B
M.;&WNH$1'<*],MX;FI/4B.2>1U9HH]&A6,0.@&8N1K<E2/&5Y(L>3_A[T2?+
MJZ.L8TL<GK%))/<!)V!:.0NLFGQAHU1E0A@24!(!_)_'NCD=A^?3E:CY'KAY
M7D^XD4PA7C0.-+!4:!6U>,BZD1L.2`0?Z^W&16TD\?\`)U500#7UZR1*Q"LY
M;7))(A1KJJ"Q96N8RZZR`#P!I_I[K(-10`54=6.>I=,K1^6*9W!:0L%%D36J
MMRQ.EKEK<@`7M?WIT12AQ0G]G6Z4Q3KE')=78E2[QA2D8)8RAAP";(0H87']
M3[U+B0'^C3JOGUDL[1!'10S6"L0@8R([*I)B+#0I!L=0X^OMI(W4(8Y.[S`\
ML]>&6('ET"/R0EF'QZ[L#1&6I7J_=^F1=3ZO]QDH*A]2M>358>FW-O;DX%&;
MY'^?6Z@$$]2OY7]3%6?"#IJI@55BDF[&T!&#@A.T][1WU#CDI_L/I^/9$!2H
M^?3W1_?>^O=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]UQ]6H&_IL;C_`!_'OW7NO/I"G5R.+_[<?\3[
M]U[KJ,W0&P'UX'T^I_U_?NO=<_?NO=>(!%CR#[]U[K"R.#^V;+_2_P"?S[]U
M[K,/\?K[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZZ/T/^L?]Z]^Z]U`]^Z]U
M_]3?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=<573?_`!8M_M_?NO=<O?NO
M==``7('U^OOW7NN_?NO=>``%AP![]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NB?_/=G7XE]N/$KO(D&S7C6.H:D=I%[#VDR!:E'C>$Z@.00?Z>
M_=>ZA=>RU!Z[V2?*RNVU,>4`!5@?'>+[A%X$A`-_JQ^M_9M;A/#1M`\NDS!^
MYM72J$)=566,G53NSF4AE!50T9U,A,1F/(-O]?Z>U1"T_LUI\Q7IL*TH8:_+
MHJ?:'2/4F1W_`%O9O9W5VUM]8'.;5PF`R.:S>W&W-/L#([7JLK+2U\E(D-56
MKM7<5!E]%3-#$5HZJCCDF'CF:2-/(EN)5DDB!.FF,?X.K:6>-5U4TG[>A-ZG
MQW3V.VM44?2M%UQ2[9I<U5"OINMY,(<6-Q_;05%1%F#AI)3#FA25$+/'4:9T
MB=/2%T^[0B-<0M&Q\P!W#Y'Y]6,TLIT.[$+@5-0!\O3I!=Q8;(Y/N;XF92)(
M9:/!=F[SR661JD(;5W6^:P5)]LLP+2M]_DDU*=&E-3#D6+4KAG%%IGJ]:5SF
ME.C4`?Y,P*N)8TD!"S`1`J0J,+EU8V7T\@L;CVZ0$E=B>F3^!:X`/4!=3SJF
MLO(-)T3VT'6MK+(UK%53D'41_7V_59%6JXZ>4:10=0UDJ8U:\0"N5DD<@.DV
MER%U>H,'`3BP%KW]Z/AZPRQ4IUZG4B.;4FA$E?Q_L&99#>VD,',=P-$9_/+?
MF_NU8S\0IUOKPF,T;`!^92LRJ^L:AJ.E]1TE0R`GZ"WT/O1I4TX=:ZYHQC%&
M%33(TD<8(D4ZR"6".2S@@:!?F_NC:I#7P^JEB!6F.BE_"C`UVV^H-QX?)"GE
MK!WKW[DF:EE9Z=J/-=D9?.T1,@A@M.M!DH_+&!9)`RBX%RW;D!6+&F>MU[]'
M''2S[PZ"P?=]/C!6[BW'LW+XS![HVZ-P;3?&4N=K=K[OIZ:FW+MBOJ,A2U(J
M-O9/[.*5J=OVUGC20`2HDBZG@CD>&9#2=00&XX;B*=6%02>D!MOXU;PVL2=N
M_)GM_'F2@P>&9QA>N*P&@VSC:;!X>(RU>V)6'V=#`L>LG4VG4Q+$DM1VAB:0
MI,<@4%,"F/7/3;%ZUTXZQ[EVSVKUS/M#./\`(;L7=E!+V!M+$5F"W#@>N8<9
MD*/*UKQUIJ)L-MFBR#?Y.A!5'46)/UL0W)&T*PLUPQIVT`H,YK2O'KRMJ;AT
M/FZIU?MSXTPA%,8[*W(R>5K2(1L#<7CTZ0;Z4B-@;<'WN\*R(E!P%?MZO&S+
M(WS'^?H]BJ"J$@$A1;_;#V7$\3T]T07YO[_R^*7K+86V-K_WTSF3W1!V#D=L
M5E/D9,+F]M[$ECK!B\G+AJ?*98:MSRX^M\<=!5030T$L<S1*REG89&TAE7/6
MFT@=W1<:7Y+=WT67BJMZ?'7+R;8O4U&7J>OQOS<>\88U=(Z23";;R>R,=%N.
M6IJ*CUT_W=/)'`DDESIT,ODGE+04ME,(^,UR/F!3/3`4`GN))S]G1C>M.X,#
MVJNYSB=K=C;0K=I9/%XK,X;L_9-;LG*RQY:BEK\=E,3CJ^66;(8JH@II(TJ$
M_;\L+H+E39R*XBF1UC0JZFAJ./3+#O/V],2_)+J.3N:+H>#-U,O8TM358G[%
M:/R8Y,WCMJ1[WK,++5K,:B.L@VR1,#X3`7_;\GD!4::8>((AYGJY0(*USUG[
M3[[VKU!D-J8C<6W>SMT9C>YW",-BNM.O<UONLBI=ITN-JLUELK38HO-B<;3G
M+4T2SR"TDTP0<F_N[!$>A'#JJJ&!/`=0*3Y";<R>.H,I#L/NNE3)115*TM?U
M;D\=DJ,/&6=:ZBJZI)J*IC():-P'!-B+^WO'C`/::=4*C51FQ]G2RV5VA@=^
MS99<'2;AQM9M[^'?Q?&[@PRXFL@;)QU3TJ?;M45;QLPI6+1OIE5'5M.AU8L"
M>-U:V5`BCT7)\^E0^WI>O50FHTMY0GEX4:7,<JC]6DA4'J/`]J'+.A4"K&E!
M]G57770DX'7/S.[/'-!(JAE*Z@2595+%I5&IE:5CQ:UQ[LX`*A3^$=-(FI:U
MH:]>+L"[H'.L)>X+$JQ]08VUJS?1?Q?Z\D>Z#CU1\N#Z=<9-%B"2Z`!`9`S`
ML%0-JE`NNE>3_5A_A[\Z5IW>?3Z/K[2O`=9$E9@(UL8QY--F5@_"W%FNRC4?
M];W84;54Y`Z<IPZP2FH1K%F#<>D:3]6)]1=T/[?`/^O?^GMO40-:^0Z;#N=1
MT8'4N'4X1RA:4AR\NEU5W;59"[%M9>P//]>/>Y*#2JBBMD^>>M*VHZ0*=2A(
M"19)(TC9Y)FC"L@++<JQ&AQ<V!YT_3W24$T-<CIPBIJ.LKRQHK*$F$)`5)/\
MX7LK-Z0LEU4DV_I;W:*JC6F&/'KS"O#!Z!WY!&7_`$!=S,6,6KK7="I*D@+1
M^2CU#3RI#1'FPYY]TE^`C53KQ%0*\*]2?Y8\44/PBZ62"&.GA;_2'/%%%''%
M&L=1VIO>=2(X@$1I!)J86OJ)OS[)G`#&AKTXI)&>CZ^Z]6ZZ50HL/H+_`.\D
MGW[KW7?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NN+"ZD6!^G!^GU]^Z]UY190+`?7@?3Z^_=>Z\205%K
MW-C_`(<>_=>ZY>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KH_
M0_ZQ_P!Z]^Z]U`]^Z]U__]7?X]^Z]U[W[KW7O?NO=<5+$FZZ0/H;WO[]U[KE
M[]U[KWOW7NNC>QM];&W^O^/?NO==+?2-7UMS_OA[]U[KE[]U[KWOW7NO>_=>
MZ][]U[KWOW7NL<8<7UW_`!;D'^M_I[]U[K)[]U[KWOW7NO>_=>Z][]U[HE?\
MPR+)5'Q![<I</DH\1E*I^O::@R,U#'DHJ6HF[1V4H>6@EGIHZN-ENK(9$N#]
M1[\>&./7CA:]<^NZ6HAZZV,X9TFDVEA`%B)(>,TR.=`(ULVAA<\`+?V=V8#6
M9)R0W_%=(&=JMFO''2[O.I*^22/3'=PZZ@X=0ND*;R:`H_%[#Z^W0>(/55>0
M8\/2.L1:J=Y'CDBC2,`:U&A]106>/6HMR;W!%@./?JFA]*];#,!@XZ*=\?L:
M*3L/YBSTIAB^\^1-//4-%$(FFGBZGZ_5ZF=HD"SSS(`&O=AIL?H+)XB!/*%`
M!,@X`#!6O^'IY2@`-.[_``GI<=E^9^S.@6"`1_WQW!8>F%7O@J>0.R%0@%Q:
MQMP3[;GC9)(*G!(KU9M04D'/1@T$PHV8-JT<'Q@:P$/K5M2L60M;2>/;Y`:1
MATPQ.K5YCIM:.H:SF1#Z$$L3+&;NRZF5#*RZ%6QL3^/;M`#1<#I]22H)X]8T
M=',/H`FFBC$7C"R,TA;QLS1QKILBI<?@`^]Z*+EL?[/30D((J<=<U<I'*R1@
M.4NYE!5F4<(?J%#`+]?H;6]^E55?2/A].M&752AZCAF+6F<Z0D:2:8BR/9&`
M-TTJ#ZO3^/K;W=%4+6F.G"Q$0(.>LD;RN8XM=M+^4%OJ'#%1;2=;:PWJ_`]Z
M1I2R>&%+5&&X<<U/V=6#HP`(R>B]?%_5_H\S<H9HUE[7[):4!?(+IFHT=[KJ
M7QRZ;J#]1R1]?:"&6.X+%211F!'X11L$'CPQQZT]0=2BIX=&*+"5D"L"[KH1
MP`2586L018W;_6]J=#?@-!UL:B*L-)ZQDE8EN4$97A3&@5W22VD.A)?A;\V(
M//U]OB%\5Z:+R&H)[:]%I^3>R.S-^]:G'=15]#BNP,9O';FY\//EZ_'8VA,.
M*JII*J".IR6`W'0I*1*KHDM-HET%#)$&+ANY@D\$E%JP(_+/5`U#QIT#'36V
M?E\OR$Z0R/>^7Q.:VI#NC<1QU'C,QU[/64V7;8^X*J3)-38#;>#R,])3T5$R
MRVD98_/?025L677C!F6848'`^5!_L]/0U+]W&G5T2_I7_@H_WKVB^72KHD?<
M4\\?RMZ<C@%@>J>SM<NEKKY):1D6X)5@TE.!8@?7Z^W8#IDC7\)/5)-)1BXJ
M`.ES)]PDWAC,Q&N`^1TD*`E)0X!+>/U%K\?2WL0F*K/I-%I2GRZ1PR5B)49K
MT'.Z,7N/&[BI][;1HDW#43XA=M;IVY-7TF*GRV(HJ^HR.,R&W<C5Z:&/<N!F
MKZL)3U3PTU;3U;QF:&148I9XY>^0-V#C@"I\NJ@XSD]538#$[_@_F%U6_)^K
MNREQ]-O+=&]&Q`P6#.?AVEF>G*SKK#YVIH?[PK108?([OADI89S5F[)K8B)@
MQ+8_$6YC::(Z/EQZ4/E#GJU/:>"W%5;ERG86[*:/%Y:KV]1[5V_MFFK(,B-L
M[9BR39BJ?*9.D(H*S<VXLHT4E=]JTE/3P4=-!')*4DD=>ID\>34RE#2E./#S
MZ9!(X&@Z$)@X:G`,NB/4K.TEE)9/U(B&Y`<7L2;CVM74W:D(J//UZT69Q0FH
M'0']>B4=M]],[*]I]D@!-<K,6PD]["S:)=*@`C](/^%O;&D&]GJM5`Q\NG\A
M8C7N)ST-,TDI6)]*$JX1T],GI340&X)<GFYXY'U]OX5E=(ZD=-^,1JU''4Q6
MMYEN@<@J%EC9T`9`T=UU7!TWYU?CWZFFLLB8KPZ]J/%#V]>BEN/(X&F0+"$5
M3&C-3A=%DY8<`D'GCVV/#".)FH/7T'3?F2>'6-R=4GC4L[*)'"H0$<K90P'#
M+J/'Y!_K[JA0R*-0!]&X$>OV];5B.!ZZ19F<J&&F6$#7H-UN220/IY;&Y'Y^
MOX]N!%)<G36M,<*=6UOQKCKJ17<H[1ESY#JDOINWC8:3K0,JD<\?T]IY,,J@
M]OIT^"2!ZD9^P]9TBT_=-$_E93$A1XK,$)%G\;`LA`/!'U]N8QTF)TR'2:#/
M7E9C984:PM<1AU9^`KWU`*X71RMO\;^]$5%&&.K:GID]<D\CRNILYY))!"HR
MVXN`R:P@/T_'O8"BE.'7@Y'%N@B^1#E?C_W07:1(1UGNAI'$2@JHID#R`,;.
M=%K`D>V;C^S;'GU>-F+4+5'4[^6$^1E^"?Q[GRM+24==4;=W'434]"[24X$^
M_-V2Q3*S4U*VNJ@99'!3AV(NUM1):9/KTJ%/+H^C.J_J-K_X$_[T/?NM]<O?
MNO=>]^Z]UQ9E7]1M?_`G_>O?NO=<O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UT6"B
MY-A_OOZ>_=>Z\""`1]#[]U[KOW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW737L;?6QM_KVX]^Z]UQCUV.OZW_J#Q8?T]^Z]US]
M^Z]U[W[KW7O?NO=='Z'_`%C_`+U[]U[J![]U[K__UM_CW[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]T2?^8CG,-MKX@]J9_<5=28W`XBLZXK<QD*YV
MCI:/'Q=J;)^YJ)70,X$:'C2"U[6!/OP.:#XNJN.T]`YL+Y/=`P;(V33CM+:D
M593;8Q,$M/\`<5<CQK2TBJ58""S%`O\`9(!]F<-Q"L,9+BIR/R-/+YXZ2&-Z
M:B,4Z5K?*SX^QW>3MK9L1M)(SSY!TT1@\HTBIY`9%/U^HL;@&_MXW<4N&84^
M5>M*&K@9I_+K!)\J_CY*NJ+M?:*781W^]F<2*4)4!6I@K`+8@W(-[^[ZXDI^
MI_J_/KQ63X6'^#I-]!;\VSNW<O==)@-XX'<AK=_5&[\92X=XH:FGVCD**GPE
M)6U&F::2>"ISE!4!972%P&T^,)I=V("&EO&K56`I^73S*VE!Y#CT][_S../<
MG1VVZ2OI9,O297.9O)8B&HBDJZ7$U>,DH,3D:FG++)!15U?33PQR-PSPN%U:
M3:LC1^/#&J@.`*Y'GUX%6-%/ET9BCFA6"1IF8R&$F/7(4#2,VGT!;O:,C^R2
M;'GZ&S\P/B$4SU:F13TZ;))(Y&U%;1LQBYDLP`L3H&LHH4W(+VXY^OMQ<*`>
M/6BP7B>HZ!(V5M5P(E"D$B$R'T1,K)I%Q>Y%S<^W5B=48M0#YD#_``GI,`3P
MZYB,B^E-0*H&,OJ!5E))8ZAZ0P;ZVN3[:!-2"I_9C\CY_ET[%P)\NN4:PJ"N
MKQZ]'B56)ND:E'+@#1?ZBQY!_K[M3!ZI)\3=28Q!]Q%)KT*X5Q,S(C$H;Z=/
M%TTC@\$GCWHY!'GT\'4T`.>BT_%!?)UGFQ!.9`_:O9;^J3QDQG.LP+#2MR%/
MX`/X]L6P(4DCSZHXU4`%2.C)G1$$\;:RVFR);4-5U,@(`%F=2;'Z7]O`'74\
M<=4*J31S1NL'@`IM0TA5+NR2,`SLS,['R'1XFYU'ZCGV_*(F9:1I]M#7_!QZ
MN),A`,<.FC*#(''9*+%'&PYV6BJ!B9\O'4U6+AR;*32RY.*AJJ:KJ:#6`SI%
M-%(RBRL/J&6(AJD!K$34_;TZ:U%.%.F?HE,U!OCP]KOBJCLE<%D5VY7X!9X=
MA5.#^YHGS*[$HZN^2QV3U)3G*1Y-Y\BR",Q324JG277C%J%N/7@K:P:8IT<S
MVAZ>Z(_W!]P_RKZD\42RP#J;L4L1-X9%D:JB`);4"L1C5KFW!]OV]/&2O3,_
MP"O"O0FB$K'&B%'5A&&9W#J%-PB,%9CZ%)X^G'^Q]G$N@"0R-3../ITG&NG;
MD=8IPC(BQQZD258E".BQZ4;4QTK_`)T:2!J_'ORKI1#3'6E(#.66G1:,<($^
M86\J518Q_';:U0"61YS_`+_FN1?$X!*4_D;@,;ZOQ]3[8,A2Y1J9H?\`!UI?
M[(T&,=&1CIXY!$&B22.+D:"4D"%5U*;LBE2;EA>U_I[?;0K(_J#7[>K'4X4`
MUIUS6`1@V>X.H%BX]/I(C4(0&9?QQS]23[;2,25(/=UH]E0>/0!=:Q:.V>_`
MJ)$9LULJ1[D),&3;TB#@$L(S>VDD$MS[:AQ-*XS3IQF70*'CPQT.RT<`BL%(
M`D);4XUA?T$`J6+!6-C?GVK+LP%5H#TR`//K,(%#/):0A9-6F1TU.%7U+P[*
MP!4?3CWX`GQ`9J5&./7J4P5X]8?'$3`&1D!6Z!7.N,_VW69#8DWL!]1[U72J
MZO/`Z=`*T9L#KMOVV=0WFC=+D&9PZF-6)%PP$EP/S<CWH?9Y]68AP-&:=8GN
M`D:*ZAE73=AXF5P3I#$!0W/O3%0`2<=60%5.KUZR>,HD`T`J(G#2.[,5D#,%
M4J&`8E?[0_//O:4(8GX:5Z:/QU.`#UE1&#2.TB@N8W&G5Y%74"^L_0<6`N?H
M#_A[V"M!Z=69T<:0:GKM[HBF\4!,P!1IB=>EE*2:F)9@PM<6MP/=6B!()/ET
MVH8UH.L\9@8"2!1^X]DEELK<WURQKZ02K?2X)'ORD&J+\0ZV4?\`AQT"'R2C
M+?'?O4`N(QUCN8D1E0[*T<`)!86$SN03]5)_P]M3R$1-JX=653&=3#I\_EHU
M$55\%OCA402K-%-LBIE2194F!5]SY\Z3)$3&SH1I:WT8$>R1:Z17CTK`IT>C
MW;K?7O?NO=>]^Z]U[W[KW6-/)<Z_I^/T_P!?\/\`#W[KW63W[KW7O?NO=>]^
MZ]UQ]6O_`&G3_A^J_P#M_I[]U[KE[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NN#`DH1^&N?\`;>_=>ZY^_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KH_0_ZQ_WKW[KW4#W[KW7_]??X]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=<`EF+$D_T'X4?T]^Z]US]^Z]U[W[K
MW7O?NO=>]^Z]UQU>HK^0`?\`;^_=>ZY>_=>Z][]U[KWOW7NB;?/IXT^+>^1(
MBN)=R=3PH'76@EE[<V,L+LMC<1RD-_L/>T'Z@)ZJ_P`#?9TR]>[4VO-L'93/
MM;;?[VU<1,5CV[AM:S+2*6E9FQ[NTK2\EF-SSS[-[>&)((_#@2HJ"2*UJU2?
MY](YB>P#X<=/;[`V/4&05'76QY-#"-A-M+;+@%BTKA)&QA"K+*VMM)L6))Y)
M'M0$5B!X:!0?(4ZUJ(!_9UA/6VP5DUIL+93B!@3JV7MAP7:R!%OB;`)>P`M<
M'_#W9EB-*0@T]>K+(VH-DD=)W,;)HMH;BQ>]=B[-Q<3P465V_N[!;9PN%PV3
MSNU,M/C\C%58YZ:/&P5^9VMEL8D]/3S2K]S33U44;"4QJR)QI9M`T\?]7V=/
M@AL@\>BCPO3Y[YUTN?PU+/448V7UIA8<I6X.OQU4E72X[MNOR6'U9.CHJA*F
MG^[IY*BG!_:,J,XLRDL2F,W,3JBAF`&`?+K0`X`9ZL5B<A7DG32K(%E;QM(5
MDBE?7&JZ"1(9"?\`:0H_-P?:ECWECQZVU3@<.H3K(I+QRQEI-?EC93<JX14D
M!7E05!!4\<<>U`(8`TZI(FL"AZP:&,'C<%=2I;2CZBS,VDR:@/W2HM?\#W8M
M5&CD`93Z\.M+'I/'%.N1CJ?&)8V=;R+JC8*%4J"-9`5G#`"W]#?WZIH%U'0.
M`]/LZNBA%TCUZRI2:)1,S:W*'C4^J3]<B$<@(W)%K$W'/NJD%RA%.JLA+$UQ
MUW!%--)$)4#2(J*MT<,KN9'<:V*H`!;CZ_GW4L:$A.M)&58$\.BW?%:G<]55
MRW;U=E]D-^X1?4=P2*RZ5()0HOIXL#[9MM0#:UI4]7H=3,?/HS"Q(/)*R+&&
M`*1N-),<A0J&4,-3"UN1>WM0#5]/GU5DU&ORZPD7L\C!VE=S%$$9O$NG3$@D
M(==,?T_)M]?=HQK$E#4BO#/[>%/Y]56.E#7SZ!CO%NV\7L6OJ>EZ*@K.P*BK
MH:>@-7CL1DEHJ*1W:MR(H<QG,#BZEHXD"7DF<IKU"&2VGW1Q*5_26K=.,:4^
M9Z+GT3N'Y5S]_P#4V/[\,.*P]3E]TU^`CI=J;$QDF6JJ/:5?BJ^#[_;>9SD]
M/2+!GXGEC=8?)I4HY964EETT@4>*M&K3IQ31@OG2O5QA<*$4@^I1_L.`/:3J
M_1+.UH6;Y5]7E./'U%OH*6Y74V150.'5P=-[V!N/K;V_;U\52!TU-\'#SZ$!
M5<NQU*6?26D60JY(9EC72M]*`<$_D$\^SM@C*06%6SPX=)E4L#I-`.O7D$CL
ML>FT3Q:O42BEF>QC<7)`%@?IQ[TY!6-0.+4_9U3))KQZ*_CX4D^9.[3Y+LOQ
MQVN``I&N-M^.4):PT6))/^)_VZ)M372"E!0].E=",..>C*R)^XT,81M5PVG7
M:/A&-].H!B3^;`V_K[5F0!22O`]5632"2.L<M/42IZ73RJ%X,[JWIC!9E0J0
MQ(_LGZ<F_NX41LU!4'J[)XAU5Z`SKH2'M#OF+R,J'/[,!12NK2VWV&I@24U)
M(O\`K&]Q]/:-16YE53@]68#PM-?AZ'+1JUF,IK#!CP6C*J0?&>&`>4FQM_4_
MGVK+ZB!Z=-*FHG/7![HD6H:=-T,%EU*9'_05*DWOS<GGZ^]4((/6G6A('7&H
M$@9@1&)(R#'+&/(\:L4;T?1$5A>YY(L?=C%J6(&08/5C(&6E*=9=$B^EU.F+
M2T?IO&9W))96Y%@3;\>VV;2VG3QZT%9C0,!UTYEEB5>5"SI(Y=9`VE-+-968
ME1SS86-C_7W9CC25K4=/JNE#J<$UZX%I!P7TJ+(5-_27]5XU==(-FL1<#^H]
MW2-M!+"BT\^D]0&)I@]=RQ3#S+Y`I148QR.\B6;]2JH`^KVO>]B/;9574*>K
M`ANT"G7DCDD<GQW`A1T*QJS$HBJ$0?H]3#U6'T-_>]*J`%'5T*J#5O/J9*)W
MIX?&\8_=OK9>06NQ-Q965/IS87]T9,@J:&N>O&2,=NK->@/^3<[Q?'7O:H<E
M&_T<9M9@03(&>:A1;6XTL#<VX_/MJ[77"RUID=.Z:XKT]_RP:"@QGP)^-%'C
M*.EQ]#'L2I>"CHXHH*:'S[HW!4R&..%4B7R2S,S6`NQ)/)]D_P!G3O1]/?NO
M=>]^Z]UQ#79EMRMO]Y]^Z]UR]^Z]U[W[KW7'5ZBOY`!_V_OW7NO,&_LD#_7%
M_?NO=<O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]UT38$@7_P]^Z]UX$D7((_P/OW7NN_?NO=>]^Z]UQT^O5_M.FW^QO[
M]U[KRMJO_@Q7_;>_=>ZY>_=>Z][]U[KH_0_ZQ_WKW[KW4#W[KW7_T-_CW[KW
M7O?NO=>]^Z]UP5]5[`@`VN?S;@^_=>ZY^_=>Z][]U[KH&]^&%F(Y%KV_(_JI
M]^Z]UW[]U[KWOW7NO>_=>Z][]U[KQXY]^Z]UTIU`'^OOW7NN_?NO=>]^Z]UQ
M5M0N/ZD?[;W[KW7+W[KW7O?NO=$K_F$+D)/BMO2/%U-+1Y"3=O3R4M56TC5U
M-3NW<6Q`TLE&E12-.5COI`E0AK&_'OP#L0L?Q]5>ND].6P)&AV)LL:QJ_N[A
M(W126)>2CA(4N55BI):YM;GV<6Y80(K&AU9^WI`S!\$8'#I42R-H(1P-:LJ6
M4:;H=-0ODL-*A^;']1'M3G^?5T4,3J].N`#.&8$M-$IDB+*R('206:RV1@56
MUBQ)'/MIW((S0TZ=,:U'IU[RDQC27)$LAN@)U*WD.@K<6$;G2!<<'VSEC4G)
M/5Z```#'0);]DGE[5Z()F,9AS.]V1)];JL:[<0&.-"UQ(;`WY`T6-P??I^XH
M"HP1Y=:_%PZ'&FDJ)0#)(^D<*FLD.A&IVLK!`LC7^O(][<?J\,'KQK7ACJ')
M.S.T4B:%5%!<JX,BH_I59#=/2;@_@'VH9'5%*\.M\.'66(R%58/$"L:%%<LS
M>J1059SZB6Y_(L??JC-3UOKI7EB=Y4A,I>6-5(9FL\@%Y&70/0P!O^./>^O=
M=J[ZU+NH5XPK$(5<JH+&.X`()4^HCCCGWJ@!)\^O=2T:9`P8ZQKY(N!%)$`Z
M#@EFC"_4W/OSL2A!QCK1P#T7#XM:WZPG.MF2MW]V9.5*W4A=UUM*Q0D/Y%0P
MC_:K7^GM/;"BMQK7JH#&FD]&(+,J2*&$ZE6N["0D*I?2(N/5KN-(7Z>U-%U5
M''K:@C+<>N[-'%`CF%5,<;/Z9&D35<EF52+2`D\<V/O8/B`L_<1P^76\TP>L
M+4[R5+>7QN69E8`$MH!%E1M6OR%5M:W-_?@Q7X3TTX<`$L#GH,=P0,>_?C.L
M>A(Z6I[0>:*76LBZL)MF*/Q?0,ZN6N/II_K;@MO^$9XY_9U:)BSU)\J='N`%
MA_@!:_U]H.E/1-^TZ`R?)G863`=WQW5>Y(HXQ&SH#79:JU2W#!05%,%/%[/[
M46K^',I\CC]O3,_P?GTJ[U*S!S"UM*,H\3:VA+FZW8`7L?I?Z?3V;D*6($98
M?;PZ8!TJWV]9@*I>88II&9)(U<KJ`L^K4RL'MH#_`-1_K^_$``$"@!J/D>K1
MJK(I(ST5.@@E/S7WE4%)"Q^,VT853P&))%7L"I:0EC^2Y`Y4\6]LK(6NAK&/
M#!_;U9P2I'GT9\R2>6'Q0N@:.14D"N#Y/T*5-AJC.H<^WV5#4#ID>=1GK@7D
M!/CIG:1=3%9M9%XE#`*P7A9%-^/J1_A[WE@2>MAW`%#CJLC?_P`Z>A?BOWEW
M-@>W)^QZ/)9>?:^:%3M[JG>&Y=OT&,IL,],K5NX,3C&Q<$\U14JH0N[`K9B&
M.D%K3"&XGN)W\.'LH*?Q#-*\<].&*HXT/62K_FV_#:F>2FJ,[VQ25U+0QY:>
MBGZ2W\*J+%/,84RKHN-<G&M,-(E/H)!%[@^W6O85=HUC;4`"2<5!X4ZN(G4&
MG[>F9/YR/P<R$KB'=':AIVA,T-;%TGOB2@KXRBD&AJ8Z4>9^=,>E!J8?4\7K
M)N%ND9+!M6I1CY]-^'(:ZSFOIUE'\X/X*1^."+?/8BMJ16>7ISL+5<C4R/JQ
M@"@W)N3;C_'V\MY;!JA:T^9_P=>\(\3\/1H?CA\S>D/E8^]?]#.7W3EEV%+@
MHMQ/N78NZ=FP)/N)*^?&QX^3/T=/3Y4218R0R""1VIPT9=5$B%J+<I+*!$E:
M=;>B4*\3T:@222:[IJ0<",NKLRE``BL'9TU:1]/P+^UI)Q5:$#IMFKDFG61Y
M3^H1@,A+!KEDC)32=3$@/(!):P'!]U.A@#-533&>/ICJND,!X6`./^7KB%8)
M#ZF<_N,[?165KM^C](9;`?XW^GOU!0=:Q3/'KD9G0,X"11H;*QC*.CCT,MP+
M,Y:UP>5_/O7S.1UK33(K3[>LL+*KO#(@]42LHO=9%>/B$&Y`5V/+7]MNQJ*G
M0*\?7IW5JTA``1Q/'H$/DK%-4_'SN:FB"B6?8&4IBS@R1>2?(XL0%U-U91JO
M;^G%_=+N11"VGC4?LZ=B9M>>GG^6#)52_`;XQ25L$5-4R=>:Y8()#-#$6S^;
M*HDK10L]DM>ZCD_['V3]*.CY^_=>Z][]U[KWOW7NNBP7ZFWOW7NN_?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=='Z'
M_6/^]>_=>Z@>_=>Z_]'?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7$`C4;WN;@?TX^GOW7NNB&:.WZ6('^PY']/?NO
M=<_?NO=>]^Z]U[W[KW7O?NO=>]^Z]T1[^8K-2P_%3=C5F4HL-3MOGI6-LED:
MM*"BIW?N;88A\]7)Z(%FFTQ@GZLX'U/OVG6=.J@]>JO\#=(OH/N#8':/66!S
M6TMR8N2FPE-1[3RJY.6DQ5=1YS%XBAJZE&HJJKBF:G>'(0212`FZO_9]G=O(
M541X(IQ_U>O3("Z033H9US6$_:,>4PK)<L7&;QH5.3KT+]TP;D$B^KD^W"^B
MI''\O\O7M:?Q#K@N6Q+N)&R.(D5R4U/EL7H6(!C:T4ZD,1;Z@V'^W]TU%\M3
M37AQ->O5!K0U'7"3,8M@J?Q3"JAG)LN5H5B86-M5JH+K-P0?S[LT2!J:J?*H
MQ\NO4!'&AZ!C?F9Q'^E#I/\`W(8SS1Y/?K&U?1.B$;<+B-F6<^-W47N;7X]I
MF$9ECTR@FO\`@X_LZ\(P"37R]>ANCR=$57PUN+"NC-)(N1H%TESI,:H9T9V5
M!J!_IS[4.P$FK&G_`"]>#*Q-#PZPC(T>HF'(T-F\L91\G0V>0%U#J#4W$A0%
MN/S]?Q[MH$C-WBOR/5J>=.DON?L#:FQJ&CK]P9%S#D:B2@IJ?#XW*;HR<K4]
M!4Y*H,>-VS0YG("&GH:"65YC$L**.6N;>VW\.(DO+P'^K`ZKK4D=V>EAC\OC
M:Z""NI,ACYJ&HIJ:II:E,C3H)Z2MI4J()E34DD(D@F!6XO<_3W97AFCU)*I!
M%1G/[.(_.G7F=12K4ZD.ZRPLT1IF9`!I6LICJ0V#`O)4:A?5<@`$^Z1]C9(I
M\^MK0]P8$'K)%*#$DC&E$OEUE?O*=V:32R6'[Q.ETM<?ZHFWMP*H.)`3Z=;8
M$5-.B^_%:LII>JVJ"8HH?[^=F!$CEB90/[Z9B(:65O&P`C^AN3SS^?:.(AM2
M*`2#FIX?,4X]5U$D`BA/#HQW[<P6%7@\LWH2*2>","`*2&O&S:).!8$^U8*@
M98G[>/7C(0>T5'69*6L="QI%2,^4DM+"[RH!951A(3;_`!_V_OS.AD$:MW@5
M(]!Z]6&16G4>:DJ&B'^3.LR>,(PE!#>)5TA@7.F[_JXN1S[L644JU.O5'GT"
MTF[MMY/Y+=)[<H\K%69O;S=I8[,TL5)E'BI<G483:E?#0MDYZ),,^0%'23RF
M*&=YA'%(2/2]BZ^[@FDU%>K)3504X=']`]('YL!_O']?:(\3TX>/56';74.Q
M^PN]MH4N7R6]L/E-Q[%W=6SYW:O86YL%G=6/WMNFHDIJ"2:NKJ>FQ[LJB6*"
M","-54:4`7V];KJDI\O6G56%1PZDK\/]AP./#V=\@D5_&T?F[?RLXU*Q)$+3
M8V621BU@;D\&Q]F1MF(\0NX4>K5_P4Z:9A&0I&#UQ'P]V5/*7/:7R)&F=I95
M3MBICCU\E].O"L(P/'P%`&D^ZB%FH`:CUKQZUXPX!,=,DWP@ZZ&7JMPT_9'?
M,>YLCBJ3"3YU.S(QEY,)2U/WM/C/OFV]*\E)%4W;0!HUG5;4`10V4!?66/U'
MEG%/.OE]G6O&\M/4NG^'FU:56C/<7R+:_(,O::V52R.JQL=MJI#/QP`?\?;B
MVGEXSC_2D#]M>M>,..G/^KY=97^(6`20R4_<_P`BHI%=&4MVA$"3&O(T3;<=
M"EP#?\VL".1[=^E<`'Q'*^I<?YNFY6#+@=W^KY=)#K+:VVNM]W=O[7;;'9/:
M?\.S6WZB7<^4PT?8>1D\M'D9(Z:OK*WPP4%1$LVD1T]/$LJ(I;4XU>V$CCBN
M'`C9F_;3TP<=/5!743@=+C,=H]/T6XL5LO*]/[LAW9N;'/683;L_3%'45V7Q
ME/\`>+6214AC9)(42"4&.4J6,;!0;$>WI)"S!2I)'\2C_)U8,6J$-3UW_"^E
M*A5DD^*-=)([JZ"3XR[;:5&()^JXMG4LK\VM8^]*$=2&BJ?EPZJYHI5C1NFV
M7"]"0-,!\0JF%I7\CL/BKMR9M<ME$LDHQ#:KL3R;,!S[HRP*"QA/'_+UZNFE
M>/2?^.QVU'WQ\CX=K[#GZYPL>+Z;C3:=5LBFZ\>&;^[V4\V2&W*6FI8HDKBF
MKS:`TY4,6(`]IK8%+Z\K`R+X<8!^8+U`_:#^S\M.`PJ30='80QN"(J<&60J4
M4J1(RZ!RXTM9U!6]K@?[?VO*NTJTDI7&>JKH`IJZ[>,22!PKAQY`0-2HS%M)
M]6@/K`X_/T'MV2-@VB05-<=5,A&I:4'^3K*"9(FADCDD8-&SET8%U#7D8D`#
M2%4`@!O>M+9&DT'7HN.>N<RG6P$<J,)`)`D)TM&VHH68!59P'O<"][>Z,LHT
ME6`!^SIX^G7*H@=67Q4KJ`!SI:_[>DW/U=&*DAAP?]X][4'`<`D=)FP[5IQZ
M!'O2:;)['W)U?B,/ELYO7?\`L_+?W<PN$H#-4318?-;;7(5,]555=#CJ*GC?
M(1!5>=&D9B%!L3[9NP*5"]GGTHXA2N17I<?R]<#G-J?#?HG:.Z,#D=K;JV?M
M*?:>Z]MY<4?\4P6Y]NY[,XO.XNN;'5=?CY9J3(T[KKAFEC?ZAS?V2XJ:=/C@
M.CG^_=;Z][]U[K&`WD<\Z2!;^GT'OW7NN37TFPN?P#_7W[KW7=["YXXY]^Z]
MUX$$7!N/?NO==^_=>ZQH7);4+#\?[?W[KW63W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW71%Q8WY_IQ[]U[KP%A87X_KS[]U[KOW[KW7O?NO=>]^Z]U
M[W[KW7B+@C^O'OW7NN*BP(Y^I^IO_A?_`%C;W[KW7+W[KW7O?NO=>]^Z]UT?
MH?\`6/\`O7OW7NH'OW7NO__2W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW70%B3<FYOR>!_@/\/?NO=>)-P+$@WN?P+?U_U_?NO==`
ME@>"O)`O^?\`$?X>_=>Z[464`FY`^OOW7NN_?NO=>]^Z]UT"#]#?_C7OW7NN
M_?NO=>]^Z]T33Y[005?QQS%)4Z3!4]@=.12*Z>16_P",K[.=5*`$N"Z#CW4M
M2II6G6F74*=%OVE\./BYG]H;;RV;Z,V57YK.;<P57E*YY,_#6554V,IRT\TL
M.:IT)\:!3IL2``>/9K"L+>$W@@$T^W_B^F:5733\^GA/A-\6H$2,]#[5AAA:
MRK'D=UZ-+:64,R[C1C<2_CF]A[4O#`U0%+#YGJ@5U-5I^?7.'X9?%>F>H5.C
M=J(OK`\>2W1=G"D+H`W(S*2MP+GVV+:,*8PNE"U32O5J,?BH/LZ@UWPQ^+!Q
ME:W^A/;3+3T59+`_\4W6"I2&5T+.FXF(82+^1;_6O[LUO;H"4CJ?4DU^T_/J
MU*_;T%'47PX^-FX^M]H9G/\`3^WLUD<C35LE575V:W8))Y(LUDJ5?*B;B2$F
M**"..]N=`N/:>&"L2O*`QU$_[U_FZ\&,8#$9Z%:7X,?%*HT&3H_;(:%KI&N9
MWE(L<VD#41_>(`.H``'``^GM2MI!&^O00U*8X4]37S].FO&+&K"IZCGX1?%X
MD1+T?MG1'&&'CSN\(_6+MJ$:[ALA8V)MSJYO[V+.!4'A6Y/S/$]5,A.1T'G:
MOPH^,=)UYO#(T/3>$H\M3;=J9J3)Q9[>IJ:.:/31_LK)N9HF$5/4R*JE=&B0
MBW)]L/:PB*32FF33@AB*>N?2G'Y5Z?!DK4Z1TL=J_"+XQ18';[KT_B#*,%A6
MDE_O3O=VFTXZE;7*8]SJNGUG3I'YX`'N\-E9Z$N5R[J`Q6E#IX&O$\?/K9=F
MJ2%/3\_P=^+=4"K].XLA',TL7]YM]OJT$@W5MU:;$-]+@V_'MWP(:&A;^76B
M*_;UQ/P3^*C,[1].4$1L[M*FY][QE-"DV5QN>X4N!P#<?X7]TDM+61"C*2#Z
M\#TV=8RQ[?ET6WY*_#/X[;2V_P!4+L[8L^V6S'>FPL/D(L!N_?5+'D\3E1EI
MLOCY4.Y'T+7+3JSR`+*=`"L#[221&W5%CDI$32A(`%?GY=>\?2RE4KGSZ,XW
MP;^,JRR:NMJA?W?0&WUV%,0P(TW\NZ6*.`HNHY_K<\^U26]LA,2AS0\?\H/I
MT[4FNHBORZR-\)?CE*(Y%V)F1+'Y%98^Q^RQ#&IL=,=]V+$H91]!P/=?H[,2
MERCZR:5^73:!E+9J#UB3X5_'.(^3^XV15V+JQ;?_`&%."`Q=3KGW+-KL+7M]
M/I]/;OTEL<(7K\Z=7SGI0;'Z:V=U9W?T5CMC0;HIL-(O:F:EP.1WYOO<>VZ'
M(?PW;U.,YCMM9_/Y+!XG)"'/5<1J(*>)M-9(/J]_:&Y01IBNFM/SZVBG63Y4
MZLA+64&U[BW]>;&U_J3<^T/3IQT2#?G5>[,EN?K[N79>?V[!GMI8G?.T4VCN
MVBR38#-P9W<&8J)JBJS^$J!DL//3CTHRT=6H)NR&Q!46VOQ*QD`@5STU,Q50
M1Z]*+9.[IMRSYK%Y/%2;:W;MB2CBW/MBJJXLA_#Y*ZGFEQV6PF5@A@AW#M//
M)3R-15L<<;%H989HX:B*6-3,7'C=LBD2+P]".->F/#9M)U?9TNOU*LBK$))$
M*26C9E"_F-P[:KMR2&L/41]./?F`).LG7\N'Y=-D$&E>'4=F+N-;)<.RJBQV
M9?&V@K>Z\!OH0/IR/>U-"$0]GSX]:I3.:]<I9&D9#Z&>S6:P6.\9OS;T>JQY
M^I]N"@*AFH3UNE*=0WE1G\D4(EDB`CA4W*Z'LS%P3H77^`?H/>Y$H-!5J_E3
MUQUH'H#>M(F;LSO]YHC^[NS;)C"#2[Z,!7JH4AK./(64\GD6_P`/;=0;EV!Q
MT^:"('UZ75=L?`Y/>6&WS6PY!,_M['#$4YAS.2I\5/2">NJ*5LE@UJH\3DZC
M'2Y.H:GDEB:6)IVL?I;<D<3L6=6+?AIC/SZ:!*<./2S<>AC3"(,K@J%C0>.5
MG9FE>QU(FFYX//'OT>I'_56B^OEULJTF2?EUB*.Y4IXSHTM+&MM,D7I*LF@$
MEY)&-KD#CW60,R.JC!_S]7U:G0'%.BJ==8V:'Y6?*.6*>NFDJ-O]#@TDU69<
M?2QP;=S*A*"E:T=(9M;O.XN)6"W)TCVV"K7=P/,$=>=T=$/\6?\`)TO_`)$U
M9'4V;B@J*JF-3G=CTCR4S_;S%9MTXN.<120@NJL+JP/Y/]/;MW(WT^N@HK?G
MFG306M!J'Y]81\>>NUJ9UBDWQ;R%G63>^<+'3(=.IONPZ?N>H\7)Y]M20ZU`
MUGAZ];(*G!%0>L%%\==BT4+JM5OL0_=U,[//V'N"=XFGJ)JKR1RRU$D@IQ+-
M9(QQ$MD4!0`+)9VY72?$#C-=1(_,'KS2R$:33J=!\?=B0U<\ZUO8$;5"4D4M
MM_9YZ>-8/N`IIZ-IC!22,M2VMX5C>7T^0MI6UOIHTX,U3D^GY=.*Q4`-D\>I
MK]';-FT4\F3WQ=5]!.]\Y$`RLY`:0-J8D-_:.JUOK8>[?3GXJ-IZ:<ZRU#2O
M22W-TAL6'?GQHS\<&>RF2VOWC#_#9,MN7(Y*-:?.[6SF4R'W2SS*U6E+D-GT
M%13JQTQ21,;,&8>T=VFF&J,:5''[>E4:A5C4Y('1S.D)!+M//.H(![2[C'J*
MDDIVENZ(MZ>-+%+C\V^O/LMZ>Z&'W[KW7O?NO=>]^Z]UQ;5_9(!_Q%_?NO=>
M-B-+?VN/Z7_UO?NO=<OIP/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>/`/Y_P`/
MZ^_=>ZX![WN-)`O8_P!!^?\`6]^Z]UVSA0#]02!?^@/Y_P!;W[KW7:G4`?Z^
M_=>Z[]^Z]UT?H?\`6/\`O7OW7NH'OW7NO__3W^/?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7$-<D:2`"1?\`!L??NO=<O?NO=>]^Z]U[W[KW71('U-O^-^_=
M>ZX*XMZG0W>RV_W@<_GW[KW63W[KW7%-14:N#S?_`&Y_XCW[KW7+W[KW7!+6
M.D$#4?K_`%O[]U[KG[]U[KWOW7NB0?S#/XN/C5D?X"V*3+'M#HS[9LVE9)C`
MJ=P[*>J^X2@>.J+?9K)X])MY=.KTW]^!H0?,'KQR*=/NPGCI]B;'L6C4;0V\
MICNOE-L32M_1TD5P;<&Q]FH$ATM0"N?ETQ0JQ].E0@4QR+(0S(X>",%^`K`%
M?3R&/U`-O:E@T32:G!0$</GGK>:]<&@I$ETJ'BCGTSN1JU*X9D_M!0"=)`^O
MT]^5M5:'/6^F_--%%B<D5=RT6.R1T:G60_Y'4%@UK@<`$@6!Y]^?X&IZ'KW0
M2]"JJ]-=?I#:7R8VOJ7",VH/-G\O->/Z(`-5M/Y_J?;5J=4`SPZ;:NO0W#/0
MS.\;/)*5FTR\EBY"Z4'JNLA!`4_7\<>U)8X/3;QD%='71EB+*VO3J"HRV.D@
M%N0"-27!^I^OO56X:C3JZQC2NKXN@T[@,%/UIOMION&E7;KA2PY534TP;2;,
M+.K`?I8_X>TUV*VES6G]FW^#IX"IIT(>W51\-@RDEHOX'AY)H81HNQQ-,/2Z
M@2+9K<DD6^OOT*I%!"JA:Z``%X8`-?VGILM1P@&.G9XHW<B>1T1`KLQ(#EB&
M,#(P(*J"2>.3_K>WU64J":9ZK(Y1]->NE9/VM,A*61U%W&J][JCK<1NWX'(M
M[MU=Z!#7AT63Y3QT[XCI>-PTL0^1/7:\L8W,K4^X2H\B-=A%J;GZW)'T]H[N
M*.>,0RH&C8U*GAC/7HBB@E<D^OET:$HS/8U*2+KL]BZ*B,/W`%+A%M;@@&Q_
MI[=+N"-,>`H`IP`'`#K0:-2=1.KKK1!((E6<ZPDQ\?[L9<%M+"["VNR?C@BW
MMSQ"JDN*$C'6R>TD=1UB1&Y#21A0K2ZOTD#7J()TJ1Q].2+^[$D,`K`=M<]-
MJ[,:'I`U]3'3_(CH&FAE<K487M^*2S)I8_9;+F1`'8,8[1`^BY!`XM?V77S$
MQ)VD=WG]G3J,==.`IT=0CTD?X6Y_UO:#I[JLCY"]B=KXK=77.S=EY[>&W=I2
M[5W-N/</^CSJ+;?:^_:[,2[GS5%B!!BMS/)146$@@QLQJ98TUB2:/4UFM[LD
MO@L&K3RX5Z;E3Q%IT&FP^Q<_MG?DV_-ZT_RR[)K#L^79E)1Y'XL;?V71T^/D
MS])GA45(V=]M592I@J:>18!*?'`M3,5%Y#[5&YB:C-)0_)3TWI<`+Y?9T.#?
M(G&H5D;J+Y&,M0I9T'4V05HM6IS&T7WOEU`D6!/^O[>6XB(!K4?LZ;\.4L:C
M'6"I^2>'B4LG4'R:?T<Z.G\E(4>QCL`,D23?FPN=/NINXDJ=8_P_RZMX+GC0
M'H,NS?DYE/\`1YN['=:=0?).EW[)@:B'9^3KNE<E'04.;G>-H*FJFJ1EZ:&*
MF4-ZFI*D7/\`FW-A[<^KB:(E6!<^HI3[.M&!]5*XZ''#?&WO;+X3!96;Y8;Y
MQ%;78S'Y"LQC]6=<#[&HK::"IJ\>ZO14]0CTKNT3:F\@(YY!'M&MS.HIKZ=$
M"?/HOM5T_P#(W&=F]B;?V%V'V3FLGA%VY4[AW2-O])8.#?$F=QD^5PV7CH,[
MGA(M-B29\89X*6D62:EE!C<QB1JB>579U:CGKVB-E"5X=&`V[\:ODC7;>P55
MNOY59;#[FGQ&-GW!BL3UAL+)8K&YN6CB?)T&.R%3''/7T=%6L\<4S*ID0!B!
M>PVUU</IUS$TX=>\!/GU`H-I]B]9=NX#:N\NYLYV;AMQ;*W'E_M*S9^T=L0T
M-5C*FEB2H,F#HOOJB6-9/V_WEC4,P9&NI53;7$KR4<AA\^M,OA)1>AII?$=+
MQ,WBD4KHDOY6:-!;7(^DE=5SR;?T]F1>HT]-B-JACD5Z1U!U[MO";VWGV+20
MU0W+OVAVO0;GGJLC6S44U/L^CJJ+!_PS'/(U-0R0P5\AG\2KYW`9N1RR$7Q9
M91\34KZ=5>1BJ0A5")6E!G\STB>]<=%E]B87'54U4]/E>TNF\?5M25$E'5FA
MK>S=L0UG@EA_<B+4KNIM<,I(_/%Y8VDA$=.UF_P=-TJ"*TZ&256\Y=F!>9RX
M<,5;UL[.DFHZ%L"0#8\CZ>[R#PJ"GRZWY?/KL1QR%SY).00K-J0%@%8WD8J-
M(((%[@GZ@<>]`D=5(J>LL<@0S1K(&,6DR:B!&@<C381W+L;_`%'UX_I[\:FE
M>GU4,.[B,=9E41M'*\@B<M_F[Z-+V],@+7_L\:A]+6]^!_3:LX!!I3TZV8UX
MCCTC]R&--U=&HDOE5^Z:,JVDGU?Z/>QB5#%;J%!/^O<^T=[B.GE4=6B=F;(Z
M&?I$`;/S!":`W9W<36TZ=6KM3=YUV_.OZW_-_95THZ%TLJ_4@>_=>ZY>_=>Z
M][]U[KWOW7NNB`2"?P;CW[KW7?OW7NNBP7ZFWOW7NN_?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7$J&Y-[V(X_(/X]^Z]UW86M;C^GOW7NN_?NO=>]^Z]UT?H?]8_[U[]
MU[J![]U[K__4W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO==74FUP3_3@G_;>_=>ZZ(4<66_)`L+\?D#Z_7W[KW7:DE02+$_4
M?3_>_?NO==^_=>Z][]U[KWOW7NN@0?H0;?T(/OW7NN_?NO=$K^?TT%/\=*N:
MHJ::DBC[.Z3O45D\%-`C/VSM")`TU0R1(SNX5>;LY`7U$>_9\NJ284]/NP8I
M)-A[$\\:M_OSMM/)KCLMSA*34$8^I?5SIL#]![.XR/#3[.D53_%TJW:,&RQ`
M$:T68JOD9ETJ"5!955&'^!]N:M7<5H#_`#Z<0T;+>77#R*-8\<GD8'QNX1BS
M:8RE@M[E@YX^H!][%.(X=/57U'2>SJZ\7EY-*EGQ.3:1"J@,#15`4#2?VV1U
MN/\`;'W[3KJ@/^KAUL$>O1'/BQE>S\_M3?.:VOO5<KC]G[_.Q\+UKN#'81MJ
M5&$P6Q-G;@K\9B=PX_%T.Y]MY[*9K<E7(U?45.0I5=U#TK(AL7PL6\4)\,;4
MQP/E_+KSA5E(H0?G7H\V*S]'N3%8S/4<-1'15]"L[PU$($]+,&"34%2BZT2H
MQDZR4\NEF77&UB?:N(UU"M37K51@DCIU\\1L/`I,<88.44(90'M&=*ZR6N3?
MG\#VX:U`I3IDZF8Z*D5\N@S[E$0ZFW\(XB9'P<JZ'7R$O)44H4J2>-*F_P#4
M'W65"T3U6J^?IUN0@Z0&_9TM]O/31X#$1O`YE@PF*TB11I:-\;2Z7>$ZF86!
MX!_U_=0JIX8*@#_5PZJ&T$LY_;T^QK3L62>F'C]+Q"P52C0\MP"FD@G1<W%^
M?:@DDU4XZ<$B2`.P`/\`FZ3.ZMS+MO#1-08ILQF\QDZ/;>V\.*D4"9/-UBR-
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M!==`2*-_(X0D,QL4*N7`<%G<CBU[>WI`Q7@22QI]G7IB!IS0GR_V.N#/"LCQ
M1A0671)<(6*V##78!$NHL/J0/I[O0.%%*L!^?32G0:LIIT'=<8)/D9T'>\<G
M]W^WS$6#>LQT^RCXU8+I`6&XM>Q`_K[*]P;"`MFO3T3!WK3@.CJGD6_K[0]*
M.B78NJ?`]R[0W;D,#NA=K_Z*MQXH[CQFW<WD]OXS*1=@YZ26CS5;BZ2L%%+-
M!5I)&)4TZ=3W`4GW[KW1IJ[>VV*':%=OM\S15.U<=B:K.568QSG)TO\`#*&)
MYZNHI_L1/)5&)(F]$89RPT@:N/?NO=.^#S%!N+"XG/XJ;[C%YS&T.7QM1XY(
MON,?DJ:*LHZCQ3)'-&)Z:96"NJL+V(!N/?NO=.GOW7N@]HNS]H5^\ZSK^ER+
M2;JHEKVEH&H<E#!)_"H<-491*;)2T:XRJGQT&X:)YHTF:1%J%.D@,5]U[K/@
MNQMD;HW=OK8.V]SX?+;OZQJ=O4O8&WZ&H,F1VE5;KPT>Y-N09F)4"TLV9PLH
MJH1<EHC<V][H:`D8Z]T%K;]ZE[/V3G>Z>O>S\0V)V#_?_#U_9.TZV@K<;C9>
MNLAE,?OS;V;:KIJB@R.,V]F\%4+64\J'Q30,T3HUV.NM4`X#H0>F-VUN_P#J
M+JW?N1FHJBNWOUSLG=U9/C4:+'3U>X]MXW,3SX^%Y)6AH9WK"T2EF*H0"3;W
M[K?0(=I0@?(CKF9V8K%UAO@.JOQI;*8VS%2;N3>W`O:_]/:FS4&X4L:#[:=-
M3?V9KTJ=4$@:6"%WB9$8F2UK,IU-Z2&T"P%K&_YX]F["A/H#TD!>G$]%?ZVR
M^2K/DA\G*#(97,UF,QE)TP,7AJG(5%3BL3YMK9%ZML3C9)'IL8U>Y\E08@IG
M<*7N0/:8%_K;E?P@CK2MJ6JY'KTI?D9#`_69:-94:#?_`%?6T\L<U13SPU6,
MWMA\E13T\L,T,R/!50(Z@,+Z;$$&WM1>-_BKZ&SJ%*?['3T>DKI&:<>C!5`I
M9JR>&P61ZR0:T02M`YF;QLC6LJM<^G\^W`K*OB4+*PKPKTT7CU_$*5Z*QB/D
MAB<YB*#+QP[0H,?EZ"DR4=-E.R<=2Y&BQM:1+3RY%%VW41451-%9FC$KV8Z0
M6^OMAI`4(/QBA'V^5?EUYE)<,/A_ETC)OES0TV\6P/\`<3"2;6GW#BMJ_P"D
M5.Y^OHL5#E,G#13QJV%JC!NR?'P25T<+5$=&R"0E@"BEO;$MT3+*6AR*5S0<
M.(\J?/UZ=616)7@R_P"JO^ST*LG>NV6,J"IV)(6\:HDG:V%5W>1@%4^3#%07
M3UJ.+\6Y]WCN`Z*Z*F@\.!_GY_;UID)9B6I^?3OA-_4F_-Y=04^&I]O5>-Q_
M:5#4U>3Q>\\1N9J27_1QV;)01/0XZ*.I@.02!S'+(RK9&LK6-D]T[NGQ*5^5
M.MPAM0-.VG1G>E`PV9D2PMJ[&[>9?KRI[6WF587`NKK8@_D>R_I7T+=@?J![
M]U[KOW[KW7O?NO=<6;3^&/\`P47]^Z]UV0&%C<`_[`_\:]^Z]UW[]U[KHE1^
MJW^QM_Q/OW7NN_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=<'OZ+7_6M[?TYO?\`
MP]^Z]US]^Z]U[W[KW71^A_UC_O7OW7NH'OW7NO_5W^/?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=8&U*-9T!KVXOI()X)OS?W[
MKW653?Z@7L/4/TF_^I/UL/?NO=<`WJDY9M)7T@#B_P#2QN;^_=>ZR^_=>ZXJ
MVJ_#"Q(]0M>WY']1[]U[KE[]U[K@J!22+\_UM_Q3W[KW7/W[KW1(/Y@]#19+
MX[K1Y&EIJVCE[<Z-::FJZ>&JIY#!VOM2HB,D%0DD+F*>)74L/2RAA8@$>X9Z
MJX+*0./2NV/4^38.SY/+<IL_;2MJ?27OAJ'RNX4`#\F_`O\`CV;Q`A*D&E.D
M5`3I)\^E-'+&Z``+J*M)Y0#8@$E7;4G/(_!)Y]J/$0J$84'S'6G4IDY%:==)
M,-,D[,=/E:2R-Z7=0J6>,W;4#]/H+_Z_O<A$1"Z3D>G6PA8>@Z"'<6Y]PYVK
MW#MK8&WJ#*S8U*G"9_<FY<I-A-JXK+55()'PM*,7C<OE\_FZ*"MCEJHJ>*.G
MI=8CDJ!->(4\0`J8U-?/Y].4H9:-6J@#\O7IKZ+ZLI.HMES8-)HZS,Y_<M9O
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MQRL`=,@TG3[;%L^FC7,I'S:H_/'2CN."J]<8.F*^ECABI^V>U8(HEIX84BW*
M!%'3Q1(L%,(C3`+`(05!6_`'-^?;I@0A?U&H/]7KUXX(4*#7U\NGJBZEKZ2M
MI*E>W>WK4U935)C7<U,RU$-/*DK4<\=70UD,=+5:!'(=&KQL0"I-Q9HU-0KM
MU5HS4DTZ67^CU*C=6T]S5&[]^9#^ZR;E\&#R&=Q];M[(S[BQL>*>OR=-!@Z6
M>:LQ=*LHHW695A:HE)#7%FRG8SAR0.MJ@!K3H.N_OC%UQ\C5V_'V$<\&VEB=
M[X>A;`94XR9L9OREPM+G()R8Y"*H)@X?MI5.N`ECSJ]T$`E,>IU4&O'IP$YX
M="COG9N.WWLC-;%FK,Q@L?FL?1XR'*X">GI<[A)<=44=;BJW#U=535P@KL95
M8Z%XF=)!=;D'VZ8@*JK`@?LZ8",7*BE>BT=B-O(_(;J/K.@[5[$H<1OG9'8V
M>S<<5;B4J$KML4\%905-)-CL-BH(9IY%:)UF^X3QDZ%1F+^VW!+0KK:@Q^WK
M?AT9=!T`'-,U_;PKT)D75&YXWG*=X]KHP6_C.0HJAD"20R2,@>FT,550I!N/
MQ]"?=6MY%?4DAIP_+J[MI%:5ZA;>VMF-N_)SHR;([[W?N]*S9_<,:T^YIZ=X
MZ1TCV;,]5!'3Q1!)YRP5A8*%``'M->HBHE:GN\^O0MJ:M*&G5B7XY_V/]/:/
MI1T3/?\`\EX^D<-MW$4G37<O;F2J\-DMRU\75V-V;44^"P:9K+TS5V8R6\MZ
M[.H8P:BD<%(7F=%L[A5(/OW7O3H@.XOYB74VY_\`3CLZ'9>]^JTW5C:SK'+8
M_>^X.E7HJ#Y!USQ8_&;>8[0[6W718[/;CP5:):V.9HI'6ACE5)&D9V]UJN6'
MF.C6]5?+VNH-I[;VGD>E]U4$>R^O:"+([CDWOUNV$JY=G;-7(Y^"BI*?<D^Y
M5EI*+#5A5JC'P0324<T<4DCH`V@R$,5<$*:'Y'T/6^ETOS+JY:..3_0;O9<M
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M]$=18N>>$.L,\V/Z_P!O4DDT*R@2K%*\)90P#`'GGW[KW0:]UU]=@^Z-C;A@
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M,;C6IIJ"2KIS_>/-$R2J552K&O4:PQU-?CG_``]MIR]9F5(_$N-.H#X_GZ4X
M=*K;G+>&=$D%N02`*1BOR\^/3IMG8N*PN%Q..Q==N#'8ZDP]!!1X^BW)GUH*
M6B6ECB2EI0<B?'!&@M&"2;#@W]TEV*P$C:6F##'Q_P"QTD'.N_\`B.':`*2=
M/9Y`^>>DD_1>P/[YCL*==S/N]*R'*?Q3^_V^UI3D*&DAQE%6R;>7<<>V9:RF
MI8D6.1Z1G!C5B=2A@Y^X[&5-!EFT5\VS_@X=;?F_?1K):#45Q^F,9^WH34P=
M0U12Z=T[JN+.W^_DRJP2A`++J^]LI`')72;^V#R_M>F1_`DP?*1A_("G2D<[
M;RS(28M9%?@&?Y]0Z3:4-'V9U1N:3/;CKJ^I[&I<?6PY'-5];25(INL>U#0+
M)2SU$E.?M4JI6C8`,K,;D^R#=[&ULHU6%'#D^;5%*^G0MY;WO=]WO9/JG06Z
M*:J/4\*8Z,KTX2VRYBQ#-_?;M`:A]++V;N]5'^NJBWL/=#CH4O?NO=>]^Z]U
MQ+@`GD@"]Q8@\D<<_7CW[KW718D*4*<D7U'\?D"W]KW[KW7/W[KW7%6#7M^#
M].+_`.V]^Z]UTX)M8(?^#B_^V]^Z]US'^^M[]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KH_0_ZQ_P!Z]^Z]U`]^Z]U__];?X]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7`G1_30!]`
M#>]Q;_"UO?NO=>1E:^EM1'U-K7O>WX`/OW7NN?OW7NN*DG5?3]3IL;^G\$_X
M^_=>ZY>_=>Z][]U[KWOW7NJ__P"975;IIOC.7V5286OW3_I<Z3&&H]QU]5C,
M'/4CLC`R,,C5T-/4UJPI!&[!(E#RNJIJ0,6&UTZOU#1/EU[/ET@]F5GRN7:&
MT6AV[T1-%_=3;H05F0WGS&N*HR#,D>5`+E>6L;7)'LUBDNB*,B!.`XU(\C_@
MZ3$6]:U;57Y4K_FZ4,F3^59D!BVYT)3@$*\<=5O<*38:E5VS?#$\BW'O;FY5
M,QQL:^9I3YU]>K,$8?%C[>N_[P?*R2J--3[:Z$J'9T3QU.0WG$YL\8T6CR\E
MH[V+-_3GVPOU3:B]"0,9K^6.KU@T`DR5K3M0,/VZAU6G@.S?YF\F)9]H;;VI
M+@I\]N;)8^6?XMQUK5"Y#<^:J<G))DY?E[B)<C*U<\B)+)2TC3``R)&?2+V]
MQ<JKGP%)H<?X//K9@M]3,)'I\P`?L(S_`(>K>]@U&[:S9&UJS?\`04]%O&JP
M]%/N:@IJ>GH*>FS)$VN!*"',[CIJ!C&(Y&@BKZU:>1VC$\P&LJ$>9P&GA\.4
M&FDFOX02:CJGGQQTM8Y`LBPM&TH92Y#IY(F*(6&EB?4;GF_T8>W:5Z9FXKUX
MU#ZQ?2UT*LTCA5.I2`P*AR/TV`-O?LU/6T0%0:FO7$RZV<LC%WC2(DJ9>==U
M#@Z4LM_3S[T305Z=;#A>O2M/+K1`TLKNGJD,<**H2R'Q@EU_1^`1[\2JA/G7
MKW;4:CUE9P771,\@$9\T>N(N5"K(Y"LEV"EK?TM[L::B`33K=0<CAU(CJ'=2
M5DC4"R1QI(%*@WU%%TEB?IP/ZGVV1IC85_U5Z]UF#.&E82JR$'4CH'TAU!8L
M=2LY/%KWM[;C(U('&`>J`GAUBJPLI3PPL-`1G5&#W2[E$LX8W7U#BQ/NRU!;
M0.RIZ\"!)0G)'11MY&6J^9W0D-)3UL\F&Z9[;RF7:GIYYZ/#T.4F_A&)J\Y4
MQ(U-BX\ID@U/2>9XVJ98I!&&\4FEE]8N`I';@]6\ST::#48P%0L[*X4M9"EF
M"E5<AAH<CZV.J_M6>'RZTRAA0GH/I9'F^2_0@$7FBCVAW"QF=B3#**?9H9OU
M1OKTL%Y5A8W_`,07;A\,>.M(H5](].CNGZ'_`%C].?\`>/S[0=*.J=^].J*O
M-_*+K#L^EK:S(U.TOBAVCM'(;2@VDFXH:C#;YWC7R5&Y?XY#NG%U.)3!#'!I
M8A05;3N8#&ZO&5?Q-`:"IZ\.(/IT13Y,?$[<F%Z6WK\N-J]D9"AV7#VAL??D
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M':N^:RKQV1RL&_(MN39:NH9MK-#1I7TM#2386MPDN`QQH_M11RQ$!D)+7]WU
M$-6@J.O?GT#5;MG^7H<=1XS(_*"IBQVWLIA,U''/W7'0*E5MW:>(VKCXLE4Q
MP4TN6H1M2DIHJBFJWGAJHI/).DADU&M./7NE'7;=^"6XMP8+)Y+Y1R5&:HI]
M\5V`H7[PQ>(2>?<6Z=R[CWA6PX&DCQM/G6IMS9NO<2S05/\`#IETPF%HAI]U
M[IYRV]OY>^P-NXRBVMD=L;S_`(5#M7#8K9/5&Z\SO7=--B\S]KC]N54>W,'N
MIJJDP!@DB(K9A'2I$RMKLRWKJ%0`>O=&#V;G-H[&J,A5;7Z%[IP]3DXJ:EKY
MIMM39.:>"A:5Z2+S5^\,DT<$+U4A58V52S$G\>[>>#GKW0B=8;IBW?E.QLM3
MT.<Q*IGL7028K<%$<;E:"IQ^`H*6JAJ*(2SI%JGB+*5=U=2&!YXT5+@*6('7
MJ5Q6G16X*@I\B/D=1NCBJ;)]>Y".*H)IYGQ;[#P=*F2I(9E#5N,-;3R0^>(/
M&L\;1E@X*@;\IU6VNS(P"^(*5\^T#J*_<,@WVV*S8>`CY`@\<?+H1`QFBNJ2
M#QV$C+8'@G@/:S:!^3R/8M+,C9"U/4=/)$\:B+)4T;\O3I&;^EAI-D[KJ*J0
MQ4\&"JIZN4!G"1IH$C+XQ)(VD6-E4D\V%_;ROIE@9B!5AZ^O5[1T>YATR&@<
M8I\^'2JQVK^%T+E&'BQM!8%]86)Z6%4=EL02B<"U[>TDP'B-GB3^WJ\@B:22
M,5HK$CUSU-0'6^I!Z4C?EDU<E=08$E=-Q_CJ]MDE-*\:]-!M3``U'4A8/5&5
M#(T9]8E4AM)8V$:H-+#@\^]&0`.M<G_#\^G=42FIU:E%/EUBD(&\NGH[O9NU
M&*JX1"QCZN[.9Y%!L\@2UN/I?V%.9&_3AJHKYD<!T/N15IN5T_U89&C&E:9)
M_%^SH8^DI3/L+S:=(FWKVE*HY_2_:&\2K<@$AEL1P/81].I4!U"O0M7`^I'O
MW6^N/J5@+,P9F)8D>C@6%OJ03[]U[KH1JI8@?J`!'XX]^Z]UC8:HP"BI<D69
MA<?X@C\D>_=>ZSC@`?X>_=>Z\%47(`!/U]^Z]UW[]U[KWOW7NO>_=>Z]>WU]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW71^A_UC_O7OW7NH'OW7NO_U]_C
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7`,"]
M@6X'_()O_C_4>_=>Z[8V4D"Y^@']2>.?\/?NO=<;,/';2+6U+^"+>JW]2/Q[
M]U[KF0"+$7'OW7NO!5%R``3]??NO=<6+#2%%R6`_P`^I)]^Z]US]^Z]U[W[K
MW1%/YA52*;HO":HA,*CNKI:F"D!K&3?-`0RH8Y`[JRW`M]?Z>Z2"J-U[I<;5
MI_M]G;-3RF=TVAMUV*@M$SQX:B,JF1BRD`L#;ZD6'LUB_LXJG\(_P=,:L4(Z
M?Y*1""_G#M(J.+KXXD?38%5YN"W)XN;^U,;4:NK%.O:%`K3'6..&&0H=>BX/
MK9+NIUA=;R,RF1B5N@M8#WMW(.'/565<"G091;:W%M*?,/M3^&9G`5\N1SL.
MT<O45.)J,9FJVH:MRB8#/P4>4I5QF;R+3534=33^.GJI7,<RQ.4CHB-%J:-P
MRGB#P%?E_FZT=-2:#I2[/S%1NC:FVMS28FMVY-NK;N*S\F!KWIJG)8AJ^'[C
M["NJ*&2>BGFHUL"T+%6_P^GMSQ5H0J@*#_/A_@ZN@[0>E6:<.AE#33`R:A)%
MIC*&Z^O3,ITDGBZ@CC_7]LZR:YZTR&2A]./7=/`EY7\FL3*EEE"%"]IGU,_Y
M9>1Q<DCWXEZ#)ZWITB@)H.NY((G6F72K*S(2;NVA`%];*5`8+)R3[\2Q%#4]
M:%6:I/=UQBUMJ6-RG[MY%&H'T6N`3_NM[?C@7^GM2U"JX'5B`>/6/P`,LCN-
M4,?Z?7^?(`L0B0`1F]F)]Z,@%%T]>H`,<.G$1"!E,:#2OKMH*!25!%U*Z@Y8
MD:O\/Z^VC)J%*=>PW;7K.T$ABJI$+*BEP[:1H4E20>6]7^'^`]Z0#55@,=;T
M:#75QZX`1N09JIUA32)M*$U&B/3Y"PC-[DWL+78<#WXEE8A"0ORZJ=)H:5/1
M+]O[]VMTUO/=M=WWGXMK]E=UYG<F\J*L>*6MV7M_J[8F5;:?6.QX-RPF<Q5<
M.W7;*3Q-!'Y\ME<@]AZ=5=1+%GU&GF./6J'Y]"KB/D-T5EFDI<;VOLFO,,?W
M#K%DIW=(3*B!K?:$K:5P%/\`6WT]V:6("I9^O*K+DDD=9-N[MVGNOY(])2;8
MW/B]Q"FV/V_/4''5+5`@BJ3LV.G>9FABT&1HF`4V8V/''M%=2)(JT)('KT\M
M.-.[H_3&RD\<`GDV'T_)_`]H^K=$`[N^+6_>Z*?;FX-B=VY#J\G8-?L#<^%H
ML)422;QV[D:O.2U.+FW1C\W25VWJ>8YABYCHZPEX(R`/4#930@]58R4_3IJ^
M?IU@[OVMM?<WPP[5Z4S>V9,2>I>O]HXZ?9BY,Y"FFAZYDP&Y=@5F.S"PXV3-
M[4SD^U*=/,T-,[F*HIY4CEBD4><ECJ/$]:8,4%#1^FSK7XJ[C@G_`-*F)W-L
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M^-IMJX^&&!*'$U&(P--]U1R&:FJI$O*C`*!7KW10-XF+!;&WYV5@]IX?L+)=
M0P?(+>^=IYSC\77]>8S87;_=.]*6';NZYA4?P')[]IRU)44203/-14J2,BQ,
M&]^(!%#PZ]T$>]MQ4N(ZIV#V+@MBPYK;F_$^)G6NY-\4(P^'R&.SO:67^/&T
ML=M":OJ/NI=[;<V%+B8*F:GI4ACI:NH>+R">GF27P51P'7NKR`B\E@"=1-_\
M";B_O?7N@0ZD<2;A[GFTV;_217PM:PU?;4T,*'2"Q!T*!<_6U_>QQ'7J5Q7H
M%?E##0U&Z]E+CY,[@^PJ7&9.JV+O2APE55X+"U;5,,-3B=X9:40X0[6S[/'%
M68VJF#U42F2`+/%'*@LV!T%A="2-F'CCX30CM.?]5>H_YN@N)+F*X*1FP6W(
M<%@'TEA\`/%JTP,].Z)6&"D-<U/!6&")L@*,S/2)4LD?W"X]I?W_`+,5&KQE
MQK,=K\W]BV%Z!-8U`C_)U%<D4&N0VQ=8CPU_%3YCIKW+@8]S;?RVV9YJNFI<
MUCYZ&:JH9(&J8XY@P\E#]W3SP>1"EQY4=#;E?=G>/4&8`$&H-.%//\N/3T#&
M$QZ7&A:8)H*>A(R!_/IBCGSVV9J"FS%93YK`">@Q!R0I%Q^;Q%34/3T6-J,C
M!1VQN2Q4L\B12ND=/)`SARKH&*)6>Y24R1LLB'U\JYJ.G(H[6[-PRHRW.:"H
M*$^E2:_9CRZ7\\,A(6.3TE]+"Y*ED8?4\@E38BY%Q[?62,_VM0W2=HH_#C:"
MM*TJ>-?.OR!X?+KAXZ@65ZG7:1D`$A0MJLP2_P!;<_[Q[LK1$D",$?9TH,40
M(K(=7VXZ;)T)[%Z'=G9B>R,TY#"UC_HK[(`$=K7%^3[#6^LIL)U1:('7_#T+
M.3E(WFR8L#6.;A]@S]G0Z])(\?7E"KFY&X=_'CZ`-V#NEE`_X*I`]@GJ7NA7
M95-M0!_`O[]U[KKU!R3;0;?4_3C_`(D^_=>ZXCRVL=(_VHGD>_=>ZR%0;`B]
MB"+\\C\_Z_OW7NN_?NO=>]^Z]U[W[KW7O?NO=>]^Z]UT0"+$7'OW7NNP`!8<
M`>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZZ/T/^L?\`>O?NO=0/?NO=?__0W^/?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO==!0HLH
ML+WX_K[]U[KOW[KW7#1Z@VH\7L/P+BWOW7NNW;2I:U[6X_UR!_O%_?NO==WY
MMSQS]..?\??NO=>L=1-_386%OH?SS^??NO==^_=>Z][]U[HA_P#,-PV,W!TG
MM+$YB@HLG03]^=%SR4>01I*5YJ#?E#D:61D5D)EIJNDCEC)8`2(">![\,F@X
M]:+`"IZ$G::,-F;29&\C0[6V[)9B4:1I,31+<<ZF9E`!`%PWU_K[-8S4)0</
M+IAOPFF#PZ>)8F="B^@$*TBN`"@90UV8>0G2@XX''T(]J>./!6G6Z>H'7?A#
M(`AU`!3=@;:!I,14VNI%[`?FQ^OMJ3B.T#'EUJM./4&H6"**LG:41TU'15==
M4S+?S014R5%14JJHK2E50$D`%C]`/>_$54.,@=>TJ0#IS_EZ1_6E339SKOK_
M`"%!,LM#5[)VY50221O32(AQZ1A9$GC2:`HR,K1N%*.IN+^ZQ.)(L1`:LM]O
M6\$TZ7$-/,&*-4NP?A+ERRR,K#457TZ;`Z1Q_7\^ZLH4KV']G6Z`?;U'91:S
MNEXW]2M'(59FUQZXBJCZFYL0!<\&]_;XDK2@-#UL9S3K)I\42(]E#:4+R.&C
MBCX>/5%I#&YY`'];<GWY'`!J:D_Y^FRO>#Y=>6GG@<G6OA>3279@Q0BS(&15
M($9-[`#FPO\`X4D-=.*?;U;!IZ=)G'[UVAD]V9W96,W3@\CNS;E#2U^X]JTF
M5ADS^%QLTJ109"NQ,3_<P4T\\BH&9=&N0*>;#W>-@2(Z]W\NMUP#U(K=\[%Q
M.=;;N5WKM?$[DCPU/N"?;V4W!CZ',)M^OJ:FAHLK-C:RIIZE,?55]'+%%-;0
M\J%0;CVQJ&H@@TKZ=:T*&J#GIDW#WAT[M&&E;<_;'7NWDR#RTV-_B6[\+$]9
M-34QJ:J&GA:LEDF:GB'D?0&T(>>+>_'0*4;CUO34C4>DA+\G/CQ4^$OWMU2I
ME\9@\>^<.$G9U](BM4(]R)/J;FY_H??A<P(*-**CUZ\:`T533[.A&CQ6R]_8
M;`9Z.CVIO/$5U"M5M[,M2XK<-!48VM,4Z5.+R$U+5Q+35@0%FBLCA5O>WMU7
M5SXI%8R*?;^S-.M5IGY=0I\!LO:]'6Y1=JX&F312P&DPNU<4V8KZN6KA@H*&
MAIZ2DB-?6UU=)''"A(520S%%!8:F,,2"01*`33&K_*>O`L3D8ZD=>==Y6O[+
MVMV%68S:.TQM;#[KQ=3MC#0R9&OEIMR+BA0SUF?I8,9C),E03XQQ,D4$].5E
MM'*Q&MBVY56`>E!PQT\F<#HWC6*-_30?K]+6_/U]IJ:10>0ZMY]$_P`C+V;N
MGL79VR=H]JY3K/;<?5U5NJO_`('LW9F<R>7S$VYJG&T_W%5O?#9Y:"CI*.F)
M6*&!&=VU,]@![L`@CKH;Q*C/E3TIZGK:F+0RZOUJ\/EY].M9\<,YGX.Q$WWW
M9OK>M1O_`*XJNM$JJG;76V!_@&'JJV?(+D*:FVWM3%TV6RM%5U,A@-:DL,:R
MR*$_<8^]"A\QU7'KT8_;V*I]O8/"8."6IGAPF'QF'@FJ`AJ)H<9104,4TYB5
M(S-*D`9M*JNHFP`X]^QZCK6I>%?Y'_-T]&0$<:AR.=-_]A[]4>O6\>O\C_FZ
M#+:G7_\`=;>&^MU)GZZNI]ZY*'*C!U-%CX:?"51H\?1Y!J2OIHDKZV.N&,A;
M3.S>(@A.#[T2!3/6P">`K_J^?0G>5/\`'_7L?>\G@#3K6?X3T7N'XX[`AZG[
MBZ>$N?;;/>53V_5[[K7R<9W!+)W7+FFW0,5DC2&&BCQE)FWIL6K12+24\,2'
MR:"6W0]:KP[3^P_SZ#/>7Q"VC4?%/8OQJVGFMT4U#TW2]6YCK;.5^3QLV>K=
MY=&YW";SV!7;MK9\4<9E8\SNK;=.^9M2PK4QS3:/$2I7U&_A/6^'''47>G<V
M>W[N;X][*ZWWY-UCF.P=W;TQ?9./DP&V<GV#M1]I]7;HW2^VZK;^\*'+TN(F
M7<6,A$E0U+*M13!6IY&BF24U#*>!_P`G^'KPS6@J/E3_`#]"=\?,=D,*W:N,
MS&?R&ZLG2=CY2.NW)E*3#4&0S-4\,4LE74T.WL=BL-2FS!%2""-511<%KDZ8
M$J<4ZT#YTZ!_N'.9+MOL;<O5.#.3P&T=EX^AH.SMR1O]AE]Q29VE;(TVR-DS
MP/-44-'4X]_]S.798I8H)!34?[LDD\`LY>1I8)U5RJ"4:L<13\JY\NHXYTDM
MH=PL;B>-9&$3:5/\0;B?2E:CI7T]$ZPP1PQQ4L-)'3P4\45UBBIXH1'%3I`Q
M+"*.%-())-AS?V,@\*`(E=('G_AZC>5)I&+N=;5X^9_U<.H&;I,E4XO)4N-J
M_M,C44,J4<\,RTY@J`0`R54D%3'3RN.!(8G53S;WI71VTT.CSK_JS]G5P##X
M;4B9Q0Z2.)_A;'GP/1+,SM_Y8)AZC^+[FV[+BC/2TM="M7CZR2>FJ,C24T!A
MABBAEJ)?-,@T*8W=B`I4V]E3KN#!79B&U&HJ*4_#D#C3H_CDV!#;J(U$R?PQ
MFK%A4U).`IP#T8%\!\@4>I@_TD=<2HY;T2[`R*%N"5+20UBW95!_K<\'V\D=
MU5763AQK_P`7TA`VH1EO`D$C$DU8GS\O\W6=L/WV)H?'O[K<.JD&.?9&096%
MA9F9:SR+*6(!_'].?>I(;XCQ8[D:*YQ2O\^FTCVIJM,LFCT&?V=3<!1=G4W;
MG0Z[QW1LK*8T;\W.R4."V]78JN:0=3]@>"6*HJ:J;RHKEFD)'Z;`?GV2[W%,
MUG-)4^$K+4>0.K3GYUZ&G++[7^^+7P$D68+*B:B?)`S8+M0:2/+CCHU_1,XJ
M>M,7.KF19,]OU@Y`%[]@[I%K*`!IM;V#NI,Z%U@"+Z0Q4W4'^H_H?Q[]U[KS
M*'4J;V-OH;'@W_XCW[KW6-R+:&9_\2!R;\VO8_U]^Z]UF]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO==7%POY()_VWOW7NNAJNUSQ?T_
MZUO?NO=<O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW71^A_UC_O7OW7NH'OW7NO_]'?X]^Z]UT2`0#^38>_=>Z[
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UT&!)
M`-ROU']+_P!??NO=>(!%B+CW[KW7?OW7NNKBY6_(^H_I?W[KW7?OW7NO>_=>
MZ(-_,6K\QC.C]K5N!Q=-F,I%WITXU-0U=9'10R:-S:YIO)+!.DSTD*M*L-E,
M[)XU=&8,/#!!ZT144Z9OB;O+L;?O0NT-P=L;<I-G[IFDK,73XI8\C01R;>Q<
M%%#MS,)!E<;CJ@292C_=8O`%)N%9P`[&-L79"=/>/+Y=,GN-&Q0X_;T8<(Z)
M(P%V>0L-;/JBL56X8:CI*W-[6(]K%;5I^9IUNOR\^LJO3LTI5H_&)+DRZXN+
MKH8,%(0\W;D7]MR"C$#KWG4C'28STRI@]P>%8[P[<S<:VU`ZY<97B[.22PE;
M\D&P'O1CJA)/E_DZ]3TQT@.C8HTZ;ZJC98]8V;BPVAY'5=/W/]E`;@WM8_G^
MH]UMJK!5&H<=-LVDD#ATCNS-U]C3]S=9]9=?9S%[>@W5LC?.Y\OE,AAX<X8*
MG;<E.U!&M/*LTHCGBBDC58VCL26)-@/?G><NM'QU9#J%2*'J1-M'Y#1MXE[=
MV;&(4)1Y=A^HR!G"JH`D0Q_6_`8FWU]U,=S6NK'5LYH>@8S--\RY:_M*MVMW
M'T_28KK18J"3%9_J?+UE9E:H;`Q6]ZF;[^AS>.6FI&3++#&@A=DT:_43I%C/
M>$RJ2G:0*T'F*_EU7R^?0D[:QGR1S&V]NYF?LGK:FJ<Q@<'E6ITVEE6$$N6Q
M<&1EI3))1(X2%JK2C,JWT@D<GWLI<L%+-7JQ`KCAT7_J[(5NU/F/V-6]B5.'
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M-`1J$B,K1GD<@>ZR*BZSX8[0#U1Y9$-(\MZ=1/C/&(OCUTA(DBJS==[;J+WM
M*//3M/*$939[F4D<EF!NW/MZ"37!HT@`Y_;U906H7&3QZ5F_<)F<[A$3;78U
M=U?D*'(?Q&KW#28+;6Y'_A\=//'5TLM+NFDJ\;31$2++YM`>,)8-8FUY%8Q#
M3)2GR!_P]>)(<IZ#H,/C/6=O4?9&0?>_R3INV=OYC=._MC8_8%5T]M'K[-;8
MDV/7YD_QNHW#@*]:W/S2TE#2"5?LHJ1/OE(-V3V67%9%!=JD<*`#IR/&?.O5
MC!%E(`N0I`']>.!_L?:;SSTYACG@>JZ-\8K>.-^2V'VGB^Q<K@*:CZ!&3@R6
M$QE!1UZ*>Q\O1BEJVK8\Q!6Q2Q5:"P2(J].'%M3#V(]DVNROK*XN[F%V?QE6
MJL1@HS\.'$4Z!'-.^[EM=Q;V]DZ*HA+M50WXU1:5\CJ-?L'2M;`=G0LVCO[L
MQAY%MY8-ERE0JZ9/2-J+9"POS8@\>S,;#M#U!6=:?TO]CH-)SSOE`*6Y/S3_
M`#$=9EPW9ZDJO?G9#,HY$N+V219V!4_\>P6+1J;<$CWO^K^U<=$Y7Y2#_*.J
MMSQO>JGZ%*_P?]#=,NW4[5S.(3(MWMV!%*];5TY@CQ^R*A$2DJY*?5Y&VHDA
M,RQZN`0`>/;]SRQM4%QX2BX:/0#74`:G^6.MR<][M'4*L+$?T#_T%T_KA^T1
MXXW^078;2ZF!087K]`=1MIU-L]B?&&&DW_U_:0\O;8Q.E;A1_IP?\G5EYWW@
M@EO!_P!X_P!D_P"3J"N&[<C=5/R+[&+*NJ13M_K5XKL_I52-CB1K`$<,?\?>
MSRYMN2!<::^;+_L?X.KQ\]W]=!6/']#_`&>F[+'MK#KC77O_`'Y5MD<QC<4R
M/@.MM$,=>[K]S$W]Q7O)%I'!#"Q_V/O<7+-N[@^-*(PK$A@H)T@FF/LZ<'.]
M\^J*2&)7>C(`I[*D8J2:BA_$.IN.R/9M3DL]BZGN_L%FP];04T=53XSJV-9X
MZ[#T.3/GAFZ[;1/')5L@"7!1;GGVW_5RUD#E"_;3S-<_ZL=.1\[[G%'!(T-N
MQ<MQ5L:33%&'28R>0J*3=%/E*WLKL');MPK-C*+<=)U/L'.93%1U]-`]504^
MY\?TU634L$U+4JLRQ3JEB5<<$>_-RS8I'K,MSH/H1_E%>FCSAO=TCRP?2HI<
M4X"FGR[F)[O/^73ULWMG)["DW-0T^`[!WC)ELXV<J<_7;5>GJ<G6U]%#)6.\
M*4&WZ:-TK-::8J6.)5"VOS[]-R_8Z8V19B--?+R/^K\_+IT<U;PQ*FZL(ZU-
M&J#7C@CC_FZ3G6^>;=>]NW]Y28_(XJ;.[AP,D^,R<0HLE0FBP\^,5:BB+.U)
MY_L5=`Y):-M7%_9GM5LEJDD$>O2:$Z@!3[/7CT'^9-TN-Q@V^XN!&9%+"J5T
MY"L<G/G0?+H99)+/'(Y%T\:`:CZI#^LL2ME)_LKQ?V:B/344J.@X99%(:,T?
MI+[NW!5;;VCG]P4,%#75V)Q,M31P9">>&BEK"RQ04]>]('GCIVD<%C&"XYL+
M^]F$R-H3#4_R5ZM;2N\@%P_83DZ14"M"1\QY=>Q^'RE=)19#<U?15TM,*2OI
M<9B:)J+$4.1$1:&J_P`KJJO(9.:C,I\#2&-8[!Q'K`84[5C$;4,E<_['^K/2
MB:6VBED>R&I`0%D.&.*$$#'2JC"VTHX+LVI"[2D@ZN`"VH@*K6^MN/>RQH!I
MHIX]%^J33WR$FI_GU*81ED\Y,4@,9?6]RW]H-<6M^@6N3;VTQ94=$)TYH>E$
M=Q$-(-=0Z34#TTG<'4;U&#W/FEQ3Y[-8NKP%)'54N'RF5H*K9BY+=DDDBR0[
M?AQ.;J%#1BZU#(QNH(]DN^W#6UA>VJJM)WC#5XC0?$J/F3Q^70SY,MC<;U;W
MA#GP8YNZ@T:I`!D\:TP.AN^/;H_5&":/]+9??+"UB"3O[=&HC3<6+`GV!>I=
MZ&GW[KW70(87!N#]"/\`;>_=>Z[]^Z]U[W[KW7O?NO=>]^Z]UZ]OK[]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>ZZX^IM<?G_7]^Z]UW[]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KH_0_Z
MQ_WKW[KW4#W[KW7_TM_CW[KW75@;7'T^G^'OW7NN_?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=$=^>Q`ZMZ^,FGQIWYU+*Q?QF-5I\K75#-*LA4/$/%ZE'J(^G/O
MPRU.O=+7;V1QS[9VZL==C]1VU@70M6TS,$&'I$4W:?0GA*:KG\"WX]G:!434
MI`)2G\NF6`8@GB.GDUV,MYUK:1;`(DHJZ:6\;.%,EQ)HN%O;Z"WNL9S2HIUH
M$UH>L;5U$5.FKI0@UIJUP,U_JOE0^E4/XY(O]?Q[<HIJ32IZW0>G3#NZHHGV
MIN?U`EMMYTJFJ)78IAJP(BLK$C]5^/S[:D9N\`XH>O''GTBND46/I_JL3+*"
M-DX(#4@5@SPLTC2$Z+N1^+W!]UBJL&?EUH!6)+"O06=K=,[9[4^0G2\F\(8J
MW!XKK3M9*G'(DU!EVJ(\YL,8]J//4=5!78^B_P!S<WW4"`FJ,,0)"!@U#'KE
M@KPK0YZ;(8!BAP#UAV;GLA0?&'8VWZ;(UN9W]N;9F:V3L>CJLG+5[ARU=+59
MW;V)R536F?[R/%[9Q:155=DI2%IJ:F+LYF90VX65%_5^*I``_$*G)Z>>FLT-
M!C'4JE^%GQ_I<:U#4;6S-7(*#&T.8R3;PW5#4;BEIL9#C9\EF)X\O%+7U-;3
MPVD:75J4A3P+>[):Q%\25+$5XYI@?L'6NT&OD.E#L>KINN=G;JZJBJYL?F.M
M<-O.HV3C,E/)4Y/(=>1+ELML3.XJ:K9Y<Y086AJ4QM2$:22CJ*+QS!0\3/1P
M8UN@90I4-IP6X`G&?+^?6BP+"AQT$_P737U_7SSU=7+/48#JS-UU76M-)D*W
M+[@Z^I,[FJRKJZEC5U;U>5RD\GD<NY5].HJJ@,;:QD197?7)X:YI2M0"<=:G
M``C`..CW(\1\2PR%KQ$^%AY$&E$;R?4\L/2>;`>U2(/#(H<<.K5%:]2G^W+/
MQ^XR,"39>4_VF_Z`?S]![U0\3U4$$@=(+L@QGK[L!"P]&P=ZPHK&Z^G;.43Q
MD1A5*N2"6!!O[MH9XYS_`$>K(/U"6X4Z#7H7*8;#?&GJC-93(0X_#8?JG`U]
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M4#YQ6=<>GE7/0I!`RTZJ6`"R&0HJB4LR+8%E+>@@F]^;VY]F>ID+!V)KZ]`5
MH^PHI[QBOK\^N/Z6)4JSJI4%V^I$A/+J?46U?X^]`5'P\?ETU'WG0<,/7S/2
M(V2\9V]3QB;UQY'+6$4:J-)KZ@,%5KF\0(XX^@]F-RC?4:C'J7PU[B3Z<*?/
MKUS+J!'^KCTK&D0@DR,9=;JLA0%U758/*!:,\BWU_P`3[3B-LB-`/Y5_S]-1
M,&J9%9OLZR$QD1E7DC<<:F745*A2'=3Z65^>!;CZ>Z`2!V,D(*C]O3ZZ"*HM
M*^N3TCMVQQ2I@0PU"'=N"D4L$5@"SZHU"Z2UK7!^G]?I[5V@I(X-?[%CFIR0
M17^?2GQ(D`(7X0,@5/'R'V]8LALW'9#*UN43([HQE37&E:K&&W#7XVCJ&HJ9
M**GF>GIW6&&<4\2(S+^L+S[2&$!0PNW&H#`('#[0:]7%X$2*"2R@E"U(.AZC
M5QK1ATZ8S$4F$HWH8:K)3M)635E34Y+)3Y&MGEG6*-RU75.9I`L<*JJ`A0H%
MO:A&D&G]5F(&":'\L`#'V=(9Y+=Y#2T1!Z!2!]O<2<_;^73F8D;3IF+.S%P?
MW(T4"U];6"ZPPM]?K_7VXDCJ:,3IH1TR\:50*BT8TX`\?MZ"782E][=T,[$Z
M-Q[<3UEAIT8FHX)9AI8D@*>>#?W174W85>!B4_F>/2V=E_=EM#2A5G/["`/Y
M8'RZ%#P.3&PF3QV*R!F>Z@?N%G%R?)I-E]OK+IU`BI!Z0%&8*0?+I,;[BISM
M3.(ZB=I*2$"&50T.E*ND%_&19@Q()O<^[0L[S(1'@M0_9T[;4)9:?J#`_P`_
M[>E12I&::D8/8)3T*ZUT!B1`FH"R%@HTGDV]M&NN10E:5Q^?3$E(J0J*`$_[
M/Y=2WA-[B4*"]E"%0P8L&B0W(N;?D?7VWJ(!5XZ#RZL541^+H8KY@4_XOKTD
M"R:5!TD7$H^NG19M;,0JJ2I^MKV'Y]Z255U+IQZ=4!UH"H(4C%14CKO;U+1Q
M]L=9SJ/)5Q0;YH8JI'E@D6BDP,%3-1RJC!:FFEJ((Y-$@($L:N`&%_8>YAK+
M;-.80#K&?Y?EU(7)%8]Q,,4Y\(1$L/(MC/Y'H2_CP+=2;>!)8_Q/>MR>+_[_
M`,W/SQ[!74K=#9[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZZ*AOJ+^_=>Z[]
M^Z]U[W[KW7O?NO=>]^Z]UPN?);FVB_\`A?5_O=O?NO==L`0;BX'-O];W[KW7
MDY53:UP#;_7Y]^Z]UR]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=='Z'_6/^]>_=>Z@>_=>Z__3W^/?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5=_\`,QVOA-Y=!;9VWN+'PY7#9/NW
MJ],ACYVJ(X9X:>KR=6$>2EE@J$4O`.5=2/\`6]U=@BZV/;U[I-8+X7?&";;V
M`,O3>WRLN`P[SAJ_='@,G\-IF*R/_'_458W`8WOSS[,HU#(I!P5!Z3-7-!U*
MJ/A#\6J@M(W3>&EFC0NG@S.[%<>2I64,\1SXB+>06```\=U(]V6-/S_EU8EB
M5)%!3_4.H\GPB^,8E<R=245,8I/)&M)N7>$`TRJA;4L>X`Q1'6X7Z!KV]N^$
M#PIUX:CQX=)K/_";XM4&'SFXZ?JBG:NQ6*S&;IYSN7?52ZU^+H*BNI:A*4[B
M99GCJ(E8*0P>UK?CW4VL!5R&DU@&M#YT^WK=?/HP?25?!ENG^L,BC23+E=A[
M?RL;R4TD+-#E,<E?!)]M.B3QAXZA6TLJL%;Z?CVW;))X"L5<`CS((/\`/_)U
M4BIZG9*G([BV54(NDTW6W9KJP0LS3/FNLPH*L0UDT7`6_/OS+J=,=M,];JZU
M*RD,.I^W=@;)V4]?+L_9^V]JR5LKMDWPN(IZ*IKWJYYZN9:JJT&JEA-7*T@A
M+>-6:ZJ/;PBT@!!5>O#4U6D-7/2U=%+Q1M'*G$9"M&P.B(V)+$-K=6?@<$`>
M[)7PR?.H_P`/6S4`]);=&R-H;VQ[X?>&W<3N;&12S/#1YK&I71T[U=/X*F2A
MJ#:LHII:=S'))%)&[1DK]"?>Y1'(S'2&QU4H'(;R''HH77^-[XQO8_>6`Z2V
M!U1D-E8#>&`Q$%%N#+9;;%5@Z7&;?7&XW$8Z*F6:CEH::AI$\9BBBB2+3"-;
M*[`NCN/`8M"//[.G`J,-0\^AF7%_,X^,S=4=(2!'+A$W_N"+2.`L:G[9P;MZ
MB3;^GMY+U@K5XGK?AK_#U(%'\TM3WZLZ35&/`._=P2V#`*PT^.$#0H`%N#^?
M=6O9&X8ZJ85(^?33NC`?,W.[>W!M^'JKI5%W!@<]@VK'W]FT:A7-8VHQPJ5I
MUIW2I>G^X+Z"5#$#D>Z_5R9R>O:-.%X=(/'=._+S'=!TW2*=?=-U`BZX/7KY
M^7>><I]43T$F/DR+8ZF!+$I*6T)41,2+!D^OO2W!TN&/'K1B4U[1^=2/SZ+'
MN#IKY:;8^6G56Y>P\UUQ@^HM]]NU>\\5U]@*&KR^0H-]4.&K,AD:K+;Y_BT.
M8K<+4>9S3TB4,;AV1)*HI%&K54ZGB"FK5_R'K3"D@+H6;3\5<#AVTX_G\NCB
M=>4F[Z#Y<;.H<YMO:N'P4FQ>U<WAZ_`9?+9.MS61R^=QS9+*96+*U55+1-61
MHC*@("D%;``7M>=HR,ZNK1`AC5:9ZLC^B_ZR_P#$>TIH:^G3I(R3PZ(MO")9
M?F74`J0%^,V&UOZ>-?:&<LR@D\)IL;BQO]?8RY?9DV.\<#](WR@'U/A.?MX9
MZC#G.9QNT-L)3I-B6"T/E.N:_F.A-CIR%9HU*.^I$6Q!B15!5E8'0SN"+K_L
M/IS[-2Y-%9J(17UST!=#@G'Y]<H:-7>P10(BI!5&"W("DK;@J?J;$?Z_O8FD
MT:F7N(ZJ$$K^&ZFH/&A_D1C\^D/L6F27;E"9%6XR&8M($929#E*LIR`0R!1Q
MR3_K^S&]E<3L?58_^.=;N(V,Y)'8#0GT/2R""-E!12C^0>H,OJ!*L%`NLEXV
M)U'Z?CV6!A)(TE>Y?\O7F!B']`^?^KRZPR0K`T4CJ/'(C:G97=&5V!.H+J3T
MD_U^A]OB42!_XCCJL@6%H6;$9Z2>\!"\6VD!D8'=6#*OH<FVB<`/I*^CT#Z_
M['\^U%HSB60@8\)Q^8X]/1+$11""ZQ4/VC/YT^72DFB!]8U!-2E&4E2'52P"
M`FW/]+^VHYF$<=13M_R],*'TQHJ]Y%>/EY?ZN/77@4"S1(0`I>1EU%6;U-]5
MOPI(TCZ?U]V\61SV29].FU+$O(5/;QZXRQC0VE/V^%9W1PT@*W#I&0?T_BWU
M]^$Q)"EL$YZ9<`H\;EO!`)!''UQ\^@;Z^4/OON]XXI#?=.WO(+*&"Q8)UN#I
M!_K8\\K[=?1XJ:7!<H.'H>EDLCO9V\87],M4&A+<*9/IT+Y@O=@@)?4?6'`"
MG3^M6`4VY/!OQ[]K*$J#TG\-F"C3D'/24WG`K;:S#2"%$$%/&\G/C\4M?3*N
MI#;0RFUOZ'_;>WH)6\2-8CDFO[.)Z?B+^*T=,Y_9]O#J7#59MH*5?[LJ\:10
M@2#+TREU1(SZE\=T>Z\\?3_7]V:&V83:KOOKZ'K55$H+U"CKDD^8$[VVV61Y
M(U)_BM*Q#(JL&U,H!N">5M[TQC\*-?K5!`_$K'_`.JF)>]P#X)\P/\G'J:U7
MG9?(3M9D;4P0296FTNMM*V8Q,MU12;G\>VQ%;TJ;X%OD#_JIUM$`\-(YJ(14
M8(Q^S^73ALZ/(579VP):[$R8^.A@WJ\$AKJ:J5Y9L/1P,/VD21U*,Q#$?7_8
M>P_S`D3V,LWCUE#J**"%\_6GY=#GDIHOWS=B)6$?AX!4C.*L*@#N_;T*?Q_5
M5ZHV[H8.K5N[9-2WL3)O3<<AM?GAFM[`O4J]#(Q8?I75_P`A`?[W[]U[KE[]
MU[KWOW7NO>_=>ZZ8:E(^E_S[]U[KRJ%%A[]U[KOW[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=='Z'_`%C_`+U[]U[J![]U[K__U-_C
MW[KW71(`)/T'OW7NO!@PN#<?[[^OOW7NN_?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1)/
MG?MS?.YNJMGT77VV:+=N>I.W]DY:3"UV?P^V8I,1C:/<-1EJM<OGIJ;$T\N.
MHU:=1-+$'\94,&(]ZHK5!&.M$T#'T'2@Z:S>4W!T]U5N'-4M%39W-=9;+RN9
MBI9@]'#F*W;U!/7149:6:&6C6I9Q&P<@H`02#?V:P@D*NBBX_9_J_P"+Z8J2
M>EY&EV4:UUAY$!\H(`C",IB"CAF9C8\`$?4^U+1K^%2#\Q_L]6ICACJ,QU%B
M([.RFS^4-J8.KLSLY$A-O]8#\<>]JND>O7@*=)7>66Q6(V?N6OS%=CL/CZ7`
M9V:IK<KDZ*BQ<`&)K9G05-7+'$AM&7MJ)XO_`%M36J-)Y@U_S=:X$_/I@Z8R
M%+7]0=25V/GH\C35_6NQ9X*RFFAJ::II)=J8UX9::>(^&>G:/A9$NK+S?WN/
MNCC9110.'5CC%,]9,A5*G<^RZ2X8MUAV3+)$S@M&/[Q];0EV8+]+R6'(U'\>
MTR!3,%9J,1CJO&OV]".Q+%B/&7>Y,?I`46MR7^E^2?K8GVJ[@M-)QCJU1GKS
MK&PB=FD:74J$*S6N0Q+.`]R6N>0.;>ZA7TE"*5\^O8P/+KD-2/(BI$KLI+!+
MJ8_TQF]VU^52+GZ7!^ONI0(0W%O+Y=>-"#7JNOXWU^8D_FK_`"#QS9J8[?3X
MX&;^`F?*3K/FSW+)#-FIXXY5Q%(L%#%'#`9T:>8S2^%@(YPQ5*")"&:I_9U:
M-=*@5ZN8]M]7Z][]U[KWOW7NO>_=>Z)1\I3+_I9^(JQQF16[2W/Y@'T$1)LV
MJDO<@J5\B*#?BQ_K;V];_P!O%]O5'X#[>I-+)`WREZTB":)$ZJWR\>E!I"'+
MT2,"Y]0Y_L_7Z$^[WO<^CK:'!QY]'-/T/^L?:4X!ZMT0_=AJ9OF3EG>`FCIO
MC-MR$2H"P%35]D[IF\$C<+J,5,&47O8$\@7`XY=I_5ZYA)&H;@I&<T\!AJIZ
M5Q_EZC/GE$BW.WOO%HHL74XP#]1'0:O4BK</+H649-3*C:%O<A9!)RND%"1P
M6/'T_P!;\^U#:E(+"M3CH&&X1A(GC*T8354#C\OEUA-XRLT(<68:E#69#JT@
M,!R20M_];_7]JE0%F1L*//I`TA58Q$[*,4SY=([8<GEVICW:,Z?O<HRZ26!U
MY.K:'2B@.%?AK_7GVY=!OJY"'!!5*5J*=OV=*9948HL;KJ#$G-:UZ6TA!]!5
M[(A_;"6:2Q)9(E!YO;DW%OI[81"@>A!!].J23F51"5K*>'S`XYZ8<SE)::*"
M"BID^^KIA08]YE+PPR-&\U54U4>J-FIZ6GA9B@<%G`46U7%XH&TR2I^``M7%
M%]1Z_9UKQH99(BSKX8QGRI\OM\^BD]X5FX-IYW"U&.WAN77+L'M'+U!JLG:B
M&9Q3;+_@N0H,53QPT&/GQ?\`$J@0F)-:K*UV8\^UEG%HN0)6_39)#Q^?1G;2
MQ7$3!+15=70$J*DZF*X&.&GUS7HR5.M7A:K'TS5=;D,37U,>.D-=.)\CC\G/
M3:Z*9*MU22KQM8\6AQ(6DCE="K%=0&BNE65,L%KZ`K7/YBOY]%HFA?QV=UC&
MJ@\R!2M-./\`#TK)BK`<,%='/)YDD6]K\-86O].![K$M6U*.TC'20NKJJB1U
MH?P_B'[,=8U.H*\<52SJX73J9H0`BC6+H!JL+AK&_O<H=25HG#&<D^E.O"XA
M#3!*EUI0$?$/,_ET$77\,?\`?GO%V,H:7=V%;6IN`8\/,I5M(M8W/!`M>]N?
M=0725)"H/Z:C&.'G7Y]&MS<0R6EH%8T3!IC-/SZ&.5T22&15)55"J!<>,D%0
M9+'C1?\`/X/'NL:L20QI5O\`#T7-(M#(K"GS;./RZ16^@AV;N(:Y([P0N-4L
M4D:^.MI20X`97+6/!Y/`X]K;<".>*HJM'KY>1R.KP2Q.=!3O8_MJ>%:<#Z_R
MZ5,1"PTJN3H-/$54C2S#[=&760%*BXL.+6)'M(@C+.\8-:];NI(T#HLB:`<B
MO#J6LB.`%8G4=-PP4AS^FX93Z!>UP/Z>]2(6-6QTG65)$11*:**=I_PXX]9(
MBA1FMI5I%<7E9TN/0_ZE7U%FL+BU_=74QA313^75T96UIFOD?,#T_P!GIRVY
M;_2-LA5$Y`I-X.K/9HPO\.H5:S,0P)9A8<_G\>R7>7IMTZC\4B_Y>I`Y*UR;
ME<.7)C6(`5_U9Z6?Q_A6GZDVG$LC2@?Q]_(V@$^;=&;E*VC54M&7TCBY`YN;
MGV"^I0Z&7W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UT2!8'\FP]^Z]UW[]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>ZXLNH6O;D'_;>_=>ZY>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NNC]#_K'
M_>O?NO=0/?NO=?_5W^/?NO==$`@@_0^_=>Z\JA18?3W[KW7?OW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[H"OD$%.QIM5F51N-VC)MY0G7>^7\0%CJ+E?I[]UJE01Z])K94
M5._7VP66GE%MC[/:)8F;2E]N8P^-E/I0*%L.0+#V:QN551Z@=,D$*:'M'2D>
ME61VF=!&KJ65=-W%K`%"K&)BQXO_`$/MSQ%'PEJ_,U_ETTC.QX^745?$IDDD
M"J*<.LQ-V_;CLU0IL-1_:0V`X!][UM3/6W+J0-70)ZMEIM!.V>SGV]C:%L3_
M`!^HR.^9,.=O[%P&9D5L9BDGK]>-I&6BJ(HYI;O-554K+K961`W16)8@T\^G
M`KD*?(_+H5\,,=6X^@K\$]!68:JQU)5XB;&K"<75XR:,R4%10_;!8EH'IRI3
MQJ%T<``>W]2:?TVTQ?MZL:U].@7WUU+NVO[HV#W5M/>>W,3)L[KK?/7];L;<
MFW<KE\3N*7>N5P&33--G<-N/%UF#GQW\#6+Q_9U:R,T;^GQ:72/"7D66%ZN!
M_L]>!5<'CT).U=RRYN7*X7+XEMN[PV\*.3-866NBRM((,@L[XO/8#)I'2OE]
MM99*.989FA@GCF@F@GB22,@OK),@H]-7V=:)4BJGI:M"K2>H%9F(+:2KIK9&
M7R<+<WOQQ<#W82L2`QQ]G5&:BX^+KJ**-@3-$QD^LI93K"OZ0PL`3IX^M[<G
MWMJ$5/38D?JK3IO>&U^M_P":-WON/?62PVS]JUWQZJ\7%O?<N67#8B;.P]S)
M-_=U*ROK*3$(PH6-4VI7E)8$O&H"N43_`-JW2B$EHP3QKU>4"&`8$$,`01R"
M"+@@C@@CVUT[UW[]U[KWOW7NO>_=>Z)3\GB1W%\/XG#/]QVAO"(,@;T$;$KY
ME=K&Q`\1X((_VWMZ#$@;TSU1^`^WJ130*/E;UL=2L\/46]V:S<WJ,Y1A20.-
M02.Q'^Q]OW8KI>G=UM>'#HYI%P0?R+?[?VBZV14$=`OVAU=_>X4N?P%2N%WK
M@P&Q63/%+DJ=#(QPN90`^>CE\L@BD(9Z=I7L"CR(RNSOY]OE\:+N%*%?XAZ?
M(_,<.BW=-IL]XM);.[C!5N!_A/K]@].@?VWND9*NKMM9?'RX'>.$A2HS>WJV
M'2TU*K"&;*X:0EX\GBUFTJ[PO)X'9-1T21NXMAOK6]"D2BI\O0^A^SJ(=TV+
M<=D$T;0JUJ.U9`*!E^SU!Q7IW;)PI5MCZ*GKJZN6*">JCI8H]-#'4&\+5]3/
M-%3TKS(;I'J,K*-073R3"IJ3(P">1QGHE6(3`.H[?Z6!^1Q7I)[=V3#!AZ.#
M*0U=+D!)525*TN4,M.&:HJ7C59:9(XG(BD!/'ZC8W(O[5O>N96?!CTK\0!\@
M!Q^73DL9U4"*#2M0`/+Y=.R[0PA6-%7*M*(CR<E4'4P9N1<E=0?GZ?7WHWC$
MDJD>@'^$=-*9$0,Q&?.F?R/^JO6#&[%PV*R$60ITR\U?#%4!5J<UD:RE89"R
MU!6FJ)&IVD"QZ5:P,8N%L"??FO\`Q4$8*B,&N%`/V'U'R..JRR'PVC-NI9^!
MH/+J%NO8.V=Y&D?<>%7(24E/E<;&3K1UH\\*(9"F`50PAJ/X=#J(L5T"Q'MI
M45VBE<DE`:9IQX]5AFNX0P20@,5)(`K522*?F3^73OG-O4.X\=-B,@*M*6H>
MBFU460JL96I-C:N"OI9*:NHI(:J)TJZ1`P#`,ET8%6(._%1XU)KI#?X/*O\`
MAZJADC?6D8:6OXU4_+\^FV+9>/I89(4;.2>2<22B7-5E6VMTBA98S,'>"'3&
MITI8%KGZD^U*WP:0E"NFF,"G5M<ZDB2)2YS4``4^P8ZYG9^+B`2.;-HMV8C^
M)RJKLT@8K;QN+J5O]+V]Z:9IG1I(8^TU!''[?GTZLKH:QHNK21P'G_E^?4K#
M;5PVW1EYL=%5T]3FJFEK*ZKEG,TU9-"LD$1E<QH"ZK(PN02ZV#$VX;:9I)@<
M5X?ETF;Q&C<,X`&>'$\.GG0!93J0#2)+PMIX.D+RHC5G!Y!O_7W74=3-Y@]6
M6,>&OB0@$CS\^D+V/A:_,[+W)08*AK:S)UE#$*.CH*ZFQ]1-)%D*69DIJZMJ
M*:C@G$4+D,TD:G1:_-O:B*Y6)TDN5+(*U`XD'B!\^E5NBH\06BBHS0&G^3I3
MQ349E2EN\=6D044=7%X)V@IM*-+3EU>*KC4&[&-FT`W/!]MJTJAZ*O@L:@C-
M/DWSZ031:)+@QHL@)K6F/]CIY%&'15A5V+LC!VYL!?@-_J2?\+#W3ZDKJU\>
MKQI#*%`B9)=/X1BM>)ZSB&,.$CNSZ5(+'4([D7`0D!O58\CZ'VTSF05/P]7@
MC`!1I*-0U8XTGT(ZG;7!/86S6;5I%%NZQX"&846/5U0-ZB%7DV_)^OLCWMU^
MD95_B7H>\DAEW.96J28N/`?LX=+7H._^B;:.I2I,.6;25TD!MPY=AZ?Q<'V#
M^I4Z&'W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UQ9`XLWTN#_L1[]U[KE[]U
M[KWOW7NNF4,+'Z>_=>Z\```!]![]U[K@Y<$:1<$?T^AN.3_L/?NO=9/?NO=>
M]^Z]UQ]6H"WIL;G_`!_'OW7NN7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>ZZ/T/^L?\`>O?NO=0/?NO=?__6W^/?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=<6U`>D7-Q_
MMK\^_=>ZY>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z`CY",$V'4N2H
M58MSEBY`4!>N-]F]SPH!MS[LI`85-!7K1*BI9J=)[9\-4NR]FM3EO%%M#;`>
M-8"X6%=OT3J8[:-#$$6!O?Z<>S6)(<D(=5,=)V=-)TGI0*9V(9UG=2;Z@&+#
MTBXTLFDE2U@#:P^GO>@,=)X],5].L2/.')DBGD1F2+QO`QD0AN(IUM8HX"_4
M_0_T]N&-D0X^?3D3*-53FO5=F>V%O#LKL]>L,=N^CRNQNIY%&'KXL)4OMSKV
M"KDJ5BGSD516S46_NY:2AK#B\9()(*'#4D$D\$:UK3U$)8!+*5CCDK!J:I]/
METX57#LU//CT??;N#@V[@L-@<;+6RT.WL?28JA>OG-1524U%`((9*BH6*)IJ
MG0MV.D:FN;?CVNTK$D42FH`S_L]49G=:T-.BW?)?(=L8&HV;NO;78&Y=F=3X
MF/)0]HQ=>[>V5FM_I)4S1KB=S"MWUMG=^-BVSA8@_P!S2P4<<TCL'>=$`(33
MK-J#*_\`BU!51Q)U#/Y+UY$QK)R/+_-TL>K^O*K$9X]G5?=>_.W#G=FQX7#U
M.ZJ?K6##Q[<GRD.X(*K%?W"V%L^2LGGJXSH:IEF6(22JJ*S-[5A(V+,D@85-
M#^9Z;9JDZAGH=XIBPDF`9"RQ,J*BAHV<E2J@QMY$L+FW]3[\48\%->KJK5&K
MAUEFE%/!-6UE=!24U)!+4U4]5,D%/!3Q1-).U54RE(X8(T35(S'TCZ^Z-5:Z
M\#JPTDT\^JC>YL1NWLC8?RJVIUYA(<QA_E#M/<.S8=Q9G;N[:ZEVQ!-F\W"N
M?.'QVSL_0;B6:GK?-'2^>DDTJA$B2$^,MD*B<S(:U`X=*$!44I0]6-;>^8W6
M5)!B]KC;_8[9/&T%!C32C9>6\VNEEJ,$&:.37)%Y,IBJB!5D;R&2%AR0?;*M
MKK6@<>7^7JYZPX#YV]8[LGR*;7V1W)N"EQF4S&#JLKB>OYZG%+F]OPT51FL/
M]RU='*M?C:;(122HT:^EN"WNW6NEYA_D]09Z@_B>*Z:^0=31"KR-`9EZPF/^
M78G(56)R-,$7*,Y>ER5#-"[6T!T/)%C[]U[H5>LNU-K]JX6JS&WFR5%/C,M6
M[?W!MO<..FPFZ]K;@QTC)587<V"J2:K$U_CTS1A[I/321S1LT;JQ]U[HMOR>
ME)[H^'**2=7:6]S)&-+.\4?7>4-A'I=F!G*+Q;U,`3S8O0$"5"3BO6F4D$@8
M&3\AUSSF5I=F_(3K'=FYHI\;@,CLO<FRZ?/U%$8,72[AK\G35M%0U]0%M123
MT=BKN0I02-?3&Y6]XP)8@]O3*%6<$/7'1UE<,%Y%RH-A_K?B_P"/:48`!X]/
M]<B+BWO?7N@C[0ZQ@WO0TM?BZE\+O3`WJMM;BI519Z:H6Y:@JR4?[C%Y!"8I
MXV#*T;L""I96LCF(B1?B!KTQ/;VUW&]O=Q%[=E((]?E^W/1)L9GN^]NG(T60
MZKI)<A/ELM7Y6IHJ#>-5'5UL]?4!*B*KIZ(PK"M!'!%"@,RPQ(%6210'8^?F
M`B,+X%32A/\`L?SZC]N0O$F$4NXL8:4`"`@5X9U"M*]#?LG/3[BV[@\[44\5
M%4Y"E:>HHJ.K7,0I5-(\4D461$5(*N(,ILXC7\@CCV*GB*N0PRP2OX:=M?AS
M_A^?4>3JMKN+P.?U8)`FJN'53\0^7KTJ!)(=846!2\BJI6-"K.)&(2YL1;Z>
MZ%-%0#7I()@4BUXP?\)ZQZG#.MQPJJCH#=56.P<OQ<:_K;WO0C#54:CU5FJ=
M1./+KB6"*%8L+B/]M4TJ"8P7NY.HEG'U)%K_`.'O;C4R4X#JZLOTL8U=PZAH
M9'879@L;+Z2&!53(Y"_Z@D6%V/)'MR-:`XZ;KJ%2W#KI)'-1?GAU!O$`"[$A
M7C(9`6`^H^G^O[>**8AD=5<G5\1K3K,K2,P+%F-B-=F`.K@@J68<!KW]UI&*
M:6JWIUY?U&"&M#CKD\CHKJ(T=-&D`IJ>5-;:@7Y(*$<6_/O5%:@8D?/KS7"1
M]KYC'\NH_DE<LWK10CB53P\FL`C7J"ZB@_3_`(>[QJJK1345Z<&@1^(K5B/X
M>DQNC<`VUM_*9UT@E&*HWJA'49*FPE+*Z&-%BKLK6PU%+CH"6!>9U9%YN.?>
MV611^G'K9O)L9/D".'RZW!2>1&;$(/\`('/[!T!5=V_-N*HQ5#14>SZ+*-FL
M)-05@[5P%?4T\GWU/YDIZ*GQB29$5]"SP>)'C,JS:;\CVL%G-E&DB5D6K)K-
M17(J*=&2V!@>X>:9JQD&1@"`0WPX(X`<?/Y=#]%N6+[AHVHLSH5FEDOCSJ2)
M6!*^F4E";'C^AY]MR634_M(:G_AA_P`W1=#`11@`%J3@G()K4_EUFFW;0JP(
MILI*09!%&<8VI0-.I9&##U!;6/X^OM@;?.1\<7_.0T_P=.&/55EG&D^7KTI]
MBYFFRO86UTIHZN(QXW=$\BU5*\`O]MC8?V68G4=3>K_6]AOF&&6&W4,4T5IC
MUZ'O(C`7URC?$8@1]E:8Z$OHV*.+JG9BQ(L:''5$FA?H&FR==,[<D_K>0G_8
M^P=U*?0L>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NNB2!<`G_`>_=>Z\.0#:W^']/?NO==^_=>ZZ)L+@$_X#W[
MKW7@;BY!'^!]^Z]UXD#ZFWU_WCD_[8>_=>Z[]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW71^A_P!8_P"]>_=>Z@>_=>Z__]??X]^Z]U[W[KW7
MO?NO=>]^Z]UC1"I8EKW_`-?^OOW7NLGOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@#^1<LM/UYD9X7B22
M"DW9.K3P155/>'K7?4BB>FG_`&:B$LHUHX*NMP002/>T*AAK^'K952!JX$]$
MTVY\)^HXMK[>FBF[,IYJS;^`JLE#2]G;CA@EJIL3222&&"*2&%8(Y2PB50H4
M6`"@``R5$8BA('^3IAM2E@&4J/EQZ9NSOB9UGMO8&_=S8[*]GC)[:VAG]Q4D
ME1V5N*MHHZ[#8JIKJ1ZNDGEDAJ8!)3J)8G!61"P;ZGWN2"WTYUZ_4-3_``>7
M3`+2'20*<>H/3?Q*Z\SW5?7F>KLWVQ)DLKM3"Y63)0]I[FCJ))*Y17N\3"=I
MC"'G]"$V\5A=ORW%;QO`=4K&-Q_&U0>'6_#)`H>CF;+V5@MA8+'[7VSCH<?B
M,=&7"R/+/5UE8^E9<EDJFH+U-?D:FP\DTI+G2`-*JJAV."."-1$/T5%*'))]
M:]..I954<0.E4$F))5FUK(SHB%;:D0C]L*QU77Z#FX]^H:T)ZTBE5*UZ3>\M
MP8O:6V<_NK/I)_`,'AJG(9<TF'JLY5M00QJ:B"/"XZGKZS*U$Z.4^W@@D>8L
M$"F]O?JK0JQQU24L`""./#HDO7VY\YM;?E9MOI[87:M?U]NJ+)5[=?\`8G4_
M9/6V)V!N!)XIVJ-M;UWMMO'X2BP&868ZJ!YF>*1-*+]&#0617(MP6@.6'G7Y
M>0ZL(@"JD]WKT+_5'=F_^SIRF,ZSQ6*HO+OJA2KS>]IHVER/7._:GKG<5#%1
M8?;N;G"+N"EF\4[VCDIT#J"&'M[ZDL.V)@?F5_R'K<I4%D$B-WZ:@DUIYY4=
M(/=F5W=VKN&#$5M1M>'J+:V3I*O<E-M[<N4GP_8F5@RT=-%B:W=E1B=O5M+L
MN3)4TM`V9I8)\/3YJ(4M3)ZC-2()Y9&<J>'5DB(<,3U8_LK.[=S>$@.WHCCZ
M3&/_``FIP3TO\*K=M5=&JQO@LEA[*V+JJ%;+XP/&R:7C9HF1V3TIT_T76GU'
MLW(11RN(Z?/[;J&56*H&G[:[?,SN=?[A9819;7!^GU-K=M,#N]?EU[HF/4-'
MAMM=N]][0Q\TDU?D.P:7N++TDLI=J)^UOC#TE$-"$CQ1U.6V?7R/]5:1R00;
MCW4D"E>O=67=,"*/8"VD9X_[Z=J2^1VTZ5D[2WG(VIB2`D>JW^`'NQ%#3SZ]
MT$.V,1#V/W]3]R=?TLNVMGX'"Y':&ZMZT\CI3]^3PO+#C,53X<G[3([;Z]KU
MDDI=Q2K]S+4,]+1LU)Y7;77NG_Y+=?;:W+A]H;LW#2/7'9F]=KQ1Q//-3XZ#
M#;NWAM7"[IKJ^:E:GK:3[+"J\B5<-13M2V9RQC+J=&N*'SZ]GA7!X_9T''8G
M1?5N.WGUWMRAV]6'`;ZHNP\+NS#UNZ=TY3%YW%T6UUKJ))Z/,9G(4T55CLB4
MJJ2IB5)X)XP4:Q8%J1Y&N]O3C&SD'_>20?Y=5"H@9@.'2>Z[[_Q?5';<'QYW
M]V)M?<&/RM118CJRO7(:MY4]=3TT[Y+:>Y<<`?NO[OPQ4ZU-53F6''O4P+4-
M"*B."G?-02":FO6E?4!49ZL$!!%P01_4<^]=7Z\0&%C?_8&WOW7NO6"K8?0#
MWX\#UX=$QV'%/!M3%GPIXO-E!H9=`0-DZPDM&J(J:1]+:0/I;@>Y5W-UDN]2
MB@,<9X@_@7_/_+K&^-+BV%RMT"7\>0*2#6E3EB>-?+I9KJN`M[!690H8%68V
M_P`VY5F!6_J)YOQ[1<>`/5U<:`'913U'7!HP!^;R$7NP1FTJ+6-[#]/(Y//O
M=<CY=;=8Y$'<*_(8_P`_7KNT.LHZ^34'("?55OJOK:Y)')L/>@0&)ZL&/A`!
M5U'Y<///2`K]V-!NBFVX<7KHYJJFQHRO\4HO,<C486JSD:C"M`:YJ9::G*--
MY+!S^FW/M7&5()<Y\AZYSU7PC+"SM(M*^0)./7I7PJX"NQ&B)RQU1*&.I;JB
M,&81HI(``/('OS%66B@@UZ2,BR5.L`4I^SK,#,OK#)&H'B+<``Z20RK>Y)OS
M]+_7W0Z:<.X?MZ=B=UD1W`UG#'R*_(>O#/72KK+L64@QLG#`:?\`56&DW+:?
MJOYO[T6``I2AZ;6-721XF%2?,<.O-#)*J\A#=0`4=UD%_2X+:2RQJ0#8$'WH
M3*K"@P.K-61%4BA`Z8\I64.+Q]959FIHJ+$4T2BKJ:P`4L8J*I(@9@P9#'/)
M.J68$7:QO[>U)*8F"-D\/L\OSZK#1BL4<FEUU`\<D^GITFLCA:?.38W'4>VZ
M&EQ<5=09'*91\70T<DT6.JH:V#&XA&I8JUIZNJI8EEF<)%'`K!279;:*1ZI6
MJ!*W$Y\N%?RZ4PSSAI6EF9I/FQ()'PD@\13\Z]"'%([-ZBP9Y9%4@Z-:D%6O
MP%%XQ_P:_MED5:EF-1TS;DQ.4H2N:_:3_@].I"QRZ6X4'2`/'H4W'KL[D$F4
M7Y/`)MQ[:64<=3:>E20:A1.(\O3J%B-SXS$]N[*P64GJ(*K)X7-#`T]%CLCD
M5KZZOE$=3'6U5'3R4V,I,?18AW\M1I#.X4$6Y#>]@M&KJY9`_&OK\OET/>28
MTCO'5O[404_G7H5NCCJZHV0QMZL,#Q].:RK/'^'L-]29T*_OW7NO>_=>Z][]
MU[KWOW7NNF.D$_T]^Z]UTC:A>UOQ_7_>??NO=<O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]UQL=5[\!;6Y^I/U_I]/?NO=<O?NO=>]^Z]U[W[KW7O?NO=<"I.NQMJ`
M'YX(^OY_(]^Z]UVR!@`;\?X_[#W[KW7+W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=='Z'_6/^]>_=>Z@>_=>Z_]#?X]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]UQ;4!Z1<W'^VOS[]U[KE[]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HO'R8=?]%F>D8Z5AQ&]9#<7U*O
M6>^E<6NOU1C;GZ_X^]QH)9(XF!TLP!IQI0]>IJ5D/PG'3M@!HVWMB.,6=MMX
M-B6N''CQ%-;5K5F0:1?@$DG\>S"(!%4#R%.F-(`TD^5.@S[M.GI_MB-D+PR=
M<;V2ZAE4J^W,FK:A<:'D'T!;D_T]W.HJY'&GG\\=5554XJ3UPZ5F$O4'5;TT
M#(K==;&``B:%M*[?QNI!<(S(K#@`_4W^GMN*'PH40$TZN>/0IB`/&0IE21P$
M4L3IUNA9M+LKJI6UP;6O[?#$J8_P_P`^O4P!Y]=*M2C))8&-P06=A&=15?&6
M8`-Y#ILHL5M_K^]4XD]:]1Y]0LGCZ',XK)[?RL#5V)RU#4XO(4;EM%315T4E
M+74\@ATO$DL$Q2]]5S<$&Q]U&:U`ZTRZL$'36O0#97<V[^FZ[8.%W1DL)N'K
MO(5]5B)-[[FR=7@]V;5PN&QKU*U>XW%#+MS=(I***-9,@SXRHF(+2)+,VIFW
M8QBNK2/*F#ULUH,YZ*=T5A.X\_M/-Y7-XR'9'3>3W;W;0[=RJ5U3C\QO?#]@
M=UYO?='+FMP4ST&6Z^V_OO'Y**A2O@C:3%RQ1QS/>IJ/MTLDM.P4XUX"O\AT
M[5RBQ.Y*`UXGCT9"*A%'#30X:GDQ\^/GRE%_#H=N4=-7(E+1+#F*FBV73^'%
MQ;LQ]#'''O':D2I0;HQ-LGCAYUC;VF!+.Y)ZMT&F>[@SVS\U@,%UQEJ/$[BR
MC8G#Y?<]:TV[=E=?X.NDC%$,QF(TEIMR]>U%-7&JVU554W\6P3(]#5QE)$IO
M=BLARHQTV[``J'I*>&*]"E3_`!L^4W\6GW#%\H=H5%?55=!D(*B/IO""E>*D
MS.X-QTLCPI7RI*6R>YZI[JX1HV1?[-SOIP5H*\>@7QGP-^3N&[OW/V[0_)+8
MR3;OZJVAL;/.W55+]U6Y?8[/A\'D):-:@TLL";0G:#R&198YU/I9)/1HBM.O
M=9L1F]Z;<[$'2/:O>!WAT]BYJR?L/*;"V'2;;Q3[RW7NC(9V;8>ZMX4TT]1C
M,7)55<IR5-2.LSTTP@)58JPQ79T*D4_5K^77O/Y=6I25V`VUAONZB?%X+;^)
MH(B*AY*3'X;&XREA5(=#WAHZ2BA@550#2@6P7\>Z"M!7CU[I'3]I==U>,-1D
M<C/3[?KT2F.5SNW,]C=MU<.0)I`D^4R^(I\2:.H\N@M*XA96^I!][Z]U57\L
MN_L_UAEMO8'J>JS&ZMN;1W'D=GG=&+QM;DJO:&0[%V]7X^EV+MS<`HJW&30X
M23'QR',U32Q[>Q\D[3>44):+P%&1Q\2FH^VA'^`GK1`/'HT_QL^/?4G6O7>1
MWAO'>&S>P-Y[ZVU%3[WW_%G\7-M3$XN5ER<^T=A9%YQ_"=H8[)CS/5RR?Q#*
MUD*UE8YD$4</CG)ZTJ*N!T)?4G:-!BUI<14;GHMS=8Y*JJ<9U?V)%%7+0Y"+
M$5'\&JL1E,Q61I25LL64IY(J>M5_%56O&TD=I![JW1KU:ZZO^1\?7W523JKY
M'KW08Y_?V23(Y/;VQMLS;UW%B13IED;)T>`VW@:FLB@J:6BSNXJJ.LDCKI**
MJCJ#34=)6U*4[*[1J'C+W%#4'KWF.@+V%MJKVIL[%8&L-%)6T#Y:288V>JJZ
M`2UN:R&1D@HYJRFI:J2)&J^-<:<@\6M['_B>(T<N@"3PT'_&!_T".L?-QFF>
M>XU2$C5CT^-_+\ATKI3ZP4C.HH%(96"HI!8$1D_AK\'^O]/>U<^9X=,M$I5&
MTUJ.L)?2KN58_N,R:D/IT(`?(-(N3?@6_P`![OJJT('`\?V]-`?J%?"-!Z=8
MU$OCU-J#.H_;*@%2%MZ4!`''YO\`[#VYZCKVOPF>0D"HH?3\NFLXS&RY&'+-
MC*%LM'Z(LC+0TW\1@IS&8705I@^Z9'0L"H>P4V_K[W4TH.'EUH!X79`Q!IFA
MZE%7&M`IBU.00UAJ8_0-?Z6MJ!''^W]O(5IK/<?0<>D\B!14%J_,]2KLSDMQ
M+^WJD,3%6,:!2(PAX9BQY'^I_P`?::E6KY5K3I4"`J@J-8R?LZZ,DD918_&"
M-1TEE9G+,S%K\V8FQ((_V/OV@5IGCTV96BB;Z=0,UX5ZXEY(AKDD9>#'8*K6
M+L2Y#<*NG2"+`^[J!KTTZ<.D1*\L@#D=!_V&AJMGYRF5YD\QQ*/+`L35"K_%
M:%W:(U$<D.H:/42I)%[<^UENLGBVHB-'#GYBE3Q'V9Z];B(2&@%=-:_/CT(6
MLDKZ6U2JEV]%@I])'UO9;_7V7E34@U-6)KY8X=6(C0$H"23G/7.(312"0@L&
M+:;H2JJ&92P-CI=B1<'Z>W&&H!2V>O14JQ$=,^?64R2LS"(65W#:7`NY0C4I
M"@,00/J#^/;8C4?ET[XA!8@4/G3KEA*J:#LS8)I]<7\4Q^[<9D6B!(JJ#'8^
M/)T5-5<A!#2UTQDB-M0=R+V)]A_>(U\%I!QU#[.A]RBR-N4I%:^%^7EQ_/I=
M=#:3U!L$I?3_``&*P(L>*FI^H/(Y]AKJ2.A=]^Z]UCN_DM;T?UM_M/\`7_7]
M^Z]UD]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UT0&%C?\`V!M[]U[K
MP%@!_3_8^_=>Z[]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=<"2'0?AM5_P#8
M"X]^Z]US]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW71^A_P!8
M_P"]>_=>Z@>_=>Z__]'?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW71O8V^OXO[]U[KI2Q'J%C
M<_3Z?Z_^Q]^Z]UW<`@7Y-[?XV^OOW7NN_?NO=`GWMA!N7:,.W)8\T:7<-5F,
M!6S;>QSY3+4=)G=D;OP\U=2TB,NN2D-<'4DVUA0?K[LO'T/D>&>O8]#7HAGQ
ML[/[GWCLVKV-UELW8&YQU)DZGKW,IW!W;OK:?<=+-@JJ2C-;OC9\O4>ZZG"5
M.1E#&FC?(U-J=8E)5AI#PETGA6G3?A+6IK^WH;-XX+Y<[KVGN/:<_3W1M'1[
MGQ5?@*ZNH^]MWY2NH<?EJ63'U5?18NMZ7PM'DJRD@J&ECIY:VDCE=0IEC!U"
MYNV'!.M>"OD2.E#M#;GR#VEMC:^V(.N-D5E/MG`8?`K62;SDI*BN3#T,%%'5
M/3PI410//]N&*"1PH:US[U]23Q'6O!'J?Y].6T]X[_J.W:+JCL+K_%;;J,SU
MCN'L/"Y["[L7-4SG:VZ=K[<RF$J:%J=)HY67=M/415`9@0KH5'#'WU!].K!2
M,>7779FX.Z,)NV+;O3G2VT>U10[?HLKN;)9[M<=?#"U66R.0I\1BZ:BEVQG_
M`.(R5%!C9ZAYKIX_0N@ZPWO1N#0^O6M`:@(/3LU3\@$$_@Z>VIJ*L(FD['BY
M+1FS`?9-H*26/(///NCS,Z%.!/GUXH5^"O[>D;1?&7$[[CV?1=F["@BIMK#%
M97-5^9W)6[FR^Z]S4D5.9!CHDS>1QF%PLM=3>>IG=?O)P5BB6%=3^VS4QQJS
M5I\_MZVL=&)K@]'*_A6/7'-BVHZ(8LT@H/X?]M#]@M!X_`:+[0I]O]HT!\9C
MTZ-'%K>Z^=?/ISHB&_=N;ASN^)^H^H\DDM2M/2OG=ZBHGG;K/$4DTC8W#9&L
MA\<];N+!,_GVS70U`RF(9&II3+`VGW[KW1I-D=*[&V1LJMV11XJ#)8W-K4R;
MIJLI!#-7[HK:Z26>NK\O*D<>JHJ*F>250@4122%U_<+.WOSZ]4XST".U]\CI
M/<55L_+9B;<?3T68GP>$WJPJZH];YV.1DDV1N[(?;K3#%TSCQP5&MO"X*OI`
M98_?8.JER'"Z"5/GZ?;TEJWOKLCO/=/8'374NTL]L0;1W56;:W?W)D6%7AZ?
M;$-*DK9G8%100-2Y;,9I9&BIC#/,U(5<,4J$<4_NK=&'ZMV!U-%U-1;5V304
MN8V#EJ:JAJZBNIJDU.Y*@3R4N3R>5FK8:6OJ,G-74[ZIF"NDB#1ITK;5!U[H
M`]V[/H]J8#)=(]NC,;CZ$WK+!1[8WG33UU!F^O,E29.#*[>I*O.8UXJW%56!
MR])35>*R,6@TE33K,OH1TAWU[H4^@]T;XR8WGUIV+D<5ORMZ^EHL?CNUL1]B
M^+[,VQF(*DXJJW%BZ%!C\%V%C*:D-/G:.("BJ7:.LI52"J%/3^Z]T+%!U?L3
M#[,FZ^PFUL+@MHRK5JF"PU%#CJ"E-;(\TTM%#3JJTDPF<M&R6\1"Z;*H4>Z]
MT4[.]<;,ZM?)8K+]:[+W!/7X//GKGL_*[(VW79+%;EHL=,<%BMU9JMQLIDR+
M5LX%)5U#:V4.68KY&7W7NF[MKNGKCK?H#K78AVY2[_WGOSK_``']RNM(<M3X
M*IJ*;#X2CJ\QO/=.X8P5V/L_9DJM4Y',2`>*9##"LD[B/WZN=/XNM$@"I-!T
MY?`7M'?7:G4$64W)5ON[;^+>#&[?[5IL>,/M'L3(QR5<FX)^IH)8Z7)[@Z>V
MY,T6.PN=JZ6C_B_@EEIA/2"&H?W6^EA)M?Y#=<X_<55CNT^B:;;3[@W1N::I
MW+U)OBJSDPW!G*[,F/*Y*B[AQM)79**.J6EC>.FA1DBC5(E4!`Y%$\[I%$I+
ML:`#.>D]U=)9V[W$C`(OKZ].&ULO69G;F%RN1IX*;(Y"E>JJ:>A%5]E')Y9+
M34Z5FJL%-.B!E$A8J6`NPL2._!,#,AD4HJ`5]3]OV=05N`@^HEJKB1V9Z$J:
M5KB@SBO#RKT^,(7\<C*RZ4:ZA@LEAP&DL+Z?7S;FXX][4G\*U_*O2;PK=X5F
MUL'3RKG/R_+J.%0+(H<L0X^I)5%*#2Z,6U@BX_K[V0QR%(].F(A"I),C"G')
MQ7KB-"E?6[N98P)&^O`&H->QY!N3^?Z^W)68D`+CK<?ATHS@FE:'T]>N;'4T
MC.2GHFCY;4ZZ1>Z"W)]-@/S_`%]T8D1L*YZ=51*X;_1!P/E\Z_Y.HXC6R`H!
MK#D,^K6S.%MZ+$%2!S;Z6]O"A4-2AIQZ8"PQZER.XGN_U</3KC(!$P+)Y`FE
MCXO3Y%4*05/!50'%[$W`]UKFGGU[X:N4JGGY5'V^G61_0TKZE61O(8U4H44-
MP5<$<W#7M[L!@=:$<!'BH`K#-*UK\J=8D8M)'J>T:QZ="ZUC6PD!.L!K$JQ^
MEFYM[OC0_P#'_/JPC#-E:H?/R'RZ2F^8DDVMDE0`H9:%KZ3:PR$$:%%YD*LH
M^EN3[4[:[?762^>0?V>?^'[./3G@(A)IV#C3T^72V*($B;2JE4\*R"UD4R,&
M5CJ;E?Z?BW/LO1I`6UR=G^6O7BC2+0D!JU!&,>AZZ1UD?Q^0ZTD=FX&IOH?H
M`-:DGGZ\^[,.W!X=79(]<8F)'IGCGY=<UCB\PTAE*V8EI%)(+V9PQ!6Z'^SQ
M?W4AC"!^*G5Z0QNVEJ&O!O/Y#J;AXT7L389-S*:?>1#E>'5<;1*H4#B,!6O_
M`(_U/LHW/2;"Z.*UCI\C4UZ&G)RH=P\158-H8$?LX_Y.E=T*".G^OM5]1V[3
M,;_7U35#7/\`KW]A+J3^A=]^Z]U[W[KW7O?NO=>]^Z]UQ()*D'])-Q_4$6_V
MX]^Z]UR]^Z]UQ8D?12W^M[]U[KE[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KH_0_ZQ_P!Z]^Z]U`]^Z]U__]+?X]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW70(/T(/^L;^_=>Z[]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7KVY/`]^Z]UT"#R""/\`#GW[KW7BH)4\W4\?['W[KW7?OW7NDSGF
M85VV@`;-GE4D7L!_!\RUR1Q^H#Z\?['W[KW10/D5\==S56],1\EOCQ-28'Y"
M;-I8X<GB)9QCMN=X;0@1#/L+>CJ5B7)"*.V,R+^J%P(I&$15X?=>Z&;X\?(+
M:GR!V;-G,13Y#;^Z-OY"HV]V!L+<$2T6Z-B[KH'\60PF9H&<S1H)@33S6TSP
MV86-P/=>Z'_W[KW0#;PV%ONI[BVQV9M$[-E@Q766]-@U<.YJO-05-+4;GW9L
M7<$&0H:?%XZH2NIEI]JR)/$U32LSF.S$:BONO="1L[:B[6I*]JJO?,9[.9&7
M,;ASDT0IY,ID9(8:9##2+)*F/QN/HJ:*GI*97=8((P"SN7=O=>Z6`(/T(/\`
MK&_OW7NN_?NO=8:B$5$$L!=T$T;1EXG:.10XTEHY$(>-P#PP((/(]^Z]T3%O
M@/\`']ZNOR#TW8#Y+*U'W>5RDG9V\I,GE*@#2DN1KY,@]56O$MPGD9M&IK6U
M&_NO=28O@IT="SO'/V6NO0/&.T=X"*)4##1%&*X*B/K)9;68\GWX8:OE_J_U
M<>O=-M5_+]^/=;3U5)40]A-2UDCSU%,.R=T^"6KDJ%JC7-$:K1]^M5&LJSV\
MJRJK@A@"+*Q5@P.>O=<L;\`?C_AZ6FH<7'V!CZ.EHJ/'14]+V)N)(S2T%%!C
M:43KY;U<R45,D9EF+RL%NS$DDZ.23U[J;1?!7H?#8Z/$8B/?6,QL:RI%0XS?
M&7H((1.S/*8HZ3QB)Y97+%E`)<DWO[UU[HMN=^(74';6X\IUEL7+=TTFW-O9
M?%Q=C=AP]E[H&/BJ*1Z7)MLS:&4FJ)ON-RR(T+553"I^PB?4DB3&-Q8%=)!&
M>O=6;;-V;@MB;?QVV]O4STV.QT"Q*9IY*NLK)=,:S9#)UTY:JR64K#&'GJ)F
M:65R23]`*]>Z57OW7ND3O]]FT^T<]4;\>CCVK!12567FKVTPT\4#+-!-$R?O
MI7Q52(U*8?WQ4!#%Z[>_#!!Z]U4UM3X&_P"D?$R[QW#D-S;AVANCM&LWMNK8
MN^<A38S,=T]64F4S65V9U+E:^GIJN+8?36&K\A#DAM6F_P!Q^<E1Z>K:*AF=
M9;,[,>``'6F&JGV]60T_86YZ.E7"X7HK>VWTQ-`((),W6]?8396'Q^/@:*G5
M:W;FZ=Q59Q]-30*$AH,=/(L=E6,6L&ED#:B00!Z_97K8&0HX]`!M+(;[[8QM
M-ENS\G35^#AS^7R>"PE#@HMNP9&B?)L<0,E0G)Y:6>CQE$JQPF64S3`MY>2W
ML:;/9BRMVF*@W<RBA/!5.01CXCP/IU%G-.^)=7#V0)6WA;AYM)P((_A'D:U^
M70U>0*O^:\2Q^F(*(P@$=P(T"@%8Q8!;<6]KQ&6HM01]O0*D>(,7$7E2M:G\
MNH\3*6=YTTD*5*QWN"#JU0L2[-I_((_/N\H*:0AQTTBI(LAT`K\S3_!U@GNH
M*'4=4IE01V70[*77R%3R/]4/ZCZ>[Q5;%>X=)L(LL82E?V?MZYJ97D"E8SI"
M)XI=-]+"ZJUV!`!;D@?3W?`%:\.E)DU*C#20$`-.-:CACK&Z/')<6MJ5;J$*
MAE;A>5#(W%]5R/=4*-4$<.O-'("-+@&GSZQ'SN99=9'D&K6P0E$46_3<E`1Q
M^+WO[O49`ZJ\#Z-;N":$^=<?EUR+,CJ&N_B5)!I:YL2"6C4$(%_U1-@#Q[W5
M2#1:'JKNJ*"SC33[3_@_EUW*7.J;2JEETFVG3R;_`$#-<7L"U[`GW6M"`<FO
M6M90+)"G:<5/^JO\NN'D:/R7LUA8KJ$9A8$>I%N48'5^KGW;0Q(`X^O51.VK
M7*0(_0=)7?-01MVM,09HT-(\Q8ZVD)K*>P!6P*AF!M_JAQ[5;=$3?0$D`U:G
M^\E?\/\`+I2TFNH4U737\J=+;RKI4('#A0P1E%F(-ROB:UI&L;$GZ^RSPY&!
M;&D,:^O'_!TUK1T,>FI^>!_+K,(F9CXV6,3:IAJT.Y-SK4.KL$^EPI'!]Z:1
M45@0Q-:8_P!GI4MLTD:A="E!G)-?LQUU$PE)1T:X!9(PJ^H$\?N:OK<?G^OO
M3ZUTG5C'5XU2:1F<&HS2AXCJ1M^S]B;.=V5F&-W48P23(J_9XX:`+:;('()X
M_P`+\^RS=546-Q0?Z(O^'H9<FLS;F^I@&\,FGGFE/]GI7]#A1T_UZ%O;^[5%
M:YO]6F)_WD^PEU*/0N>_=>Z][]U[KWOW7NO>_=>ZQJ2OI;G4S:3]>/J`2?S[
M]U[K)[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO`@_0W_UO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=='Z'_6/^]>_=>Z@>_=>Z__T]_CW[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7CSQ[]U[K@B!+@7Y_K_P`B'OW7NN?OW7NO>_=>Z\>.??NO
M==`Z@"/H??NO==^_=>Z]:_!Y'OW7NN@`!8"P]^Z]UW[]U[KWOW7NDMN"15R.
MUD9@#)G6"#DG4F$S3D<`@#2O^'_$'W7NE-I4K8@<K:]A>UO?NO=$=^1_0V]Z
M7/R_)3XST]+1?(/:V*FCR6T)Z^+";6^0.WL?3R2P[!WI42QR4=-F9C&(\9EY
M$+4S$1R,(M+1>Z]T+?QQ^1NUOD+LY\O0T&1VEO/;]4F![%ZVW#%)2[GV!NZ&
MGB?)8'*T\T<,L\-/4.5@JU18JE`&6U[>_=>Z,5[]U[KCI&K5^;:;?CZ_[W[]
MU[KL*!]`!?\`I[]U[KOW[KW7O?NO=>]^Z]U[W[KW7O?NO=<6;2I-P/Z7^GOW
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MO&LD]/)$C2:`6T!GYM<V]MR(64T-!3'YXX=60@,#DD$8_/HE_5FYA)BY]DYC
M!_W7WEL-(<5N7:U9+"]90L=?VN7H9:?]G)87-1?O4U7#>*16_#7`D(R03QVT
M]M=AD*J!0$9``*$?A(]34'J!MSAN[?==Q;<+4(Q)D(&:)J-7)_@X!6`)K4$=
M"B$2555M(33J(0@JJII8ZF-_\#_6X][!*FM>D`B5XWK)QI2G7%8XAK+1R3,'
M):5'*KH!,;1WTF[QGZ_3W9C(^FA'32QQKJ!)_EUZ1'!*LDHA$@'Z2P]*$,P8
M</\`@``?C^OMV(Z02?CZ9DB"J2@>GV5_G4=<5$8J`R1A@"G%O0"`P(U'UV8#
MZ-S?VSJ;/\75S(L+!$C5G/GY=<U*%K/$ZFF*L&?]31N=3,JFXT#BWX][U-G2
M!D=/$,T2ZR,&M>L,S^(H0HF"AK-8/>($H8225`!!%KWY_P`/;B:C16%">F&9
M:>)&Q*T(S_/A_+K!Y")5<Q!1H(,;$7139AIL0&X^A'NY24]N*=>80PF*11W@
M5_EUS$X+66)F4J5")I!D4%E/`LJ/&R\?AK>]*A4U+5Z2R7"ROVI1_,FN?]7V
M=125#`>$N9-0+NQ];.2&D!4>H$'G\`BWMP.=1/F.KTC-$=0>FG/XNIRN$K,9
M1F))I3&T4DX(A26*IAE74I];(%CN/ZG\@>WXB%GMYRY&EJ^N#QQ_DKU>W<(9
M"5++0BGG3ACYTX>729-)V>2O^YS:1DB=`H.WJ]KA@I9EME%)*D6(!(XO[:2-
M@909J1U-/TSP^?=TI)L#I>&";3Y@LM:_[SU+2F[.)N^X=H1I&[&Z;>KW.A-8
M(TMDU9?K]>>?QS[H(U4LWC$DCAH-/^/=/.;9@A6WG_WI?^@>'7.>C[(9T,>5
MVSIL257!Y",.Q(9B=&6NI/T6][?T]T$*,$!G(`_H'U^WJM8-;O'8L9&XU*<:
M>1T\?GTI-AQ[R@[.VHFXLA@*NDDPN[3%%C<364-5%/%%B`"\\V2JXGCT,05*
M7)YU?@DN]*!9LT<Q9?$_A(]?F>ASR:EM'N,@9)%N_"X,0V//(`Z%GHO1_HAZ
M\,?Z&VOCG7Z?1U=_Q8?GV$NI-Z%GW[KW7O?NO=<03J8$&PM8VX/'//\`6_OW
M7NN7OW7NO6!_'T^G^'OW7NO>_=>ZXLNK\L/^"FWOW7NN7OW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KA;0ITW)Y
M(!YY/^M;W[KW7,?0>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NNC]#_K'_>O?
MNO=0/?NO=?_4W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7@`!8<`>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNDMG8]65VJUV"C-S%@+!6`P>7`#FU]`+`V_J/?NO=*GW[KW7%AJ4BP)L;7_K
M;@^_=>Z)%\@NC=YXW<[?)7XYQQT7>>V<7,-P[*^X2@VYW_MW&TA:'96X6F>/
M'8_=C14RT^)S$@!A8K%.WA$;P[`KY]>Z&SH#O?;7?NPJ'=^'HZS;N9@"XW>V
MQ<Y+"NYM@;OI1X<WM+<-/&04KL37QR1"0*$F5-:@`V]^(H2*]>Z'/WKKW7O?
MNO=>]^Z]U[W[KW7%2W.H`?TL;^_=>ZY>_=>ZXLP4'Z7_``/R;FPX')N??NO=
M`-G-R9OL;.5FQ=CU%;C\!0$1;T[#HFIVAI6D$;';.UI7$T=7G*B%R)YPC)1Q
M\FS-'K]U[H7-L;8PFT,)C]O;?Q]/C<5C(1#24U.I"J`+-([L6DEGE^KNQ+,Q
MY/OW7NG\@$6/(/OW7NF7.YS%[:Q55F,M4Q4>.H@&J9GU,1K.B.*&&-7FJ:NH
ME98XH8U:261E1`6(!]U[JF?YG_('MK=.0ZOVET)0;?W!\@]Y[PQ>X/C9TKNC
M#2;@Q6>H]HY17S?=O:5309*@;8'5G6M1/%73[BDDF6KKZ:/$8V*H-1/+4;4`
MDDUI3\J_Y^O5Z,1T!\4*S8_]TMN=X=EY3O[N3;?5N8W!V5WSF\?AL%E9=^]C
M;FHZ@UVSZ;&T5+'M3%43;8KTI%TO4S4,%/%5RS11111^5G$?AZCH/\^M$`Y(
MZG[3[#CZL[%S>U<%NC;.]/X=%BJG/X+:V=Q=:*G#5V2@VMA,F])3Y"I;;>;_
M`(M&F-IEJG"I4M%CYF-(]!4TFNM_;T?O;.X<5NW"4.>Q$KU&/KHW,3SP2TU1
M')#-+35=)64=2D=115U#60205$$BJ\,T;(PNI]^X&OGUH$'@>@<[AZ8&^JG'
M[PVCE!L_M/;-+/3[<W3%3^2FR&->0U,^TMU4X1CD=L9&>]P`9J1V:2'DNDAA
MMVZ2V,TG;KM7H'0\'^0]&'DWGPZ(M[V&VWB$%NV[16\*0<4)&0X!JZ-YK^RA
MST'NQ]W39]:[#9O&OMC?&VC'2;NVS4E'DH:@W*5V-*!1DL)DM:O35*C0\;7Y
M]BJ22&0^/:$M:.>TU[A_1=:T5OFM0>HF?;KG;BEM?HJ7BI4X[=).G5'059:X
MU,!\J$-J7'V;L&4R%?W'9H[Z0PO<A?ZMJY/U-_;BS(%#`AOLS^WHO>%V201R
M*SJ1FE./^'\NL#4Z+*2QJ)2K*INBE8OJQT(EN&XOS]?]C[<$SD:55>FVA*H@
M<5;6*^E*9ZX_;O%)*QDF%_4+)&Z`%>+L2RL03]+>]"12U`F/SZNUNJ$2`T5L
M<*T_+KB:*8NH\C,NG2P8V8W-P;6TV7\?2P]NB6-0Y*CJ_@^("HGU`#A2G6"2
M*-"M@0NGQL"JM9E:PM]/JO''-O?D:N:9Z3N%BT$E5CKE=/\`/\^HE7'3I+!(
M96ENA*LL8#*VI6C%O2;1@_2UV'M^)RX(*TSTW<!!X16=-6@F@%#QQ_+KD(1:
M1T9X[D,I0+<A6<!=5B3:_P!+\?T]^9@IJPKTTR`R34D5:,*8K7'E3KM8D9%3
M67C8LRRL@7TC@E0IT\J#]3?_``]T\1*U"9Z=0(%JSJS?93KB(5CE1'8LI5/&
M&*W+A>0Z@?IT@6O<>[M*E*:.JQ)I8MX@7SKZ?/J6*($*QDTMY2=&FQ),@4+8
MFX6Q!^OMGQA4+IZO'"JN^EU:N>%*Y&>I!A71I)8-'(58DG6G#%6N6)`_XCVT
MY5\KTOT]DG=0ZR!]GR^7IUQ0$!_',5:6ZZN+:^;6!(T*2;?6XO[\"@H-&1TU
M'$U7&N@(X_EU*VW';L;9Q\KCQ8;=Z>$!2C!HL$Q9W%SJ60M87^I-_I[)-X8"
MVTJM$+5_/SZ&O):P1[C(BSAW\+&/2E<_*HK]O2TZ(71T]UPH)-MIXKD\'_-$
M\_X^PQU*/0M>_=>Z][]U[KWOW7NN+'2I-KV_'^\>_=>ZY>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KHG2+F_^P%_?NO=>!N`>>?Z^_=>Z[]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UP<.0-!L;\^_=>ZY"]A?ZV%_
M]>W/OW7NN_?NO=>]^Z]U[W[KW71^A_UC_O7OW7NH'OW7NO_5W^/?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW75Q
M<C\BU_\`8WM_O7OW7NN_?NO=>]^Z]UQ2^GU&Y)-_R/K^/?NO=<O?NO=<0MF+
M?U`!'^M^??NO=)C.1QOF-ILRN63-5!0J+JK?P',@F3@^DH2!].3]??NO=*GW
M[KW7O?NO=<64.I4WL;7L;?0@_P#$>_=>Z(]\B>E^QMO9;+_(GXITF*B[YQV-
M5MP]?96KAP^S?D!B<:BO'MC<U8RBGQ&[?MHO#C<T0&C.B.H8Q*C1^Z]T+_QK
M^06`^1/6V)WC18RNVMNJ"-,;V%UWFBJ;CZYWI2QB/.;5SE.RQ3A\?D$ECAG:
M-%J8TU@`W4:!!Z]T83WOKW7O?NO=>]^Z]U[W[KW7$L%M>_)`X%_K]/?NO=`!
MD\W7=NY7)[2VED9:#9>%KZK#[ZW+"C1SYNJIP8ZO:6V*U7*1QJ[:*ZM0-I6\
M4)$@9TH'!-`#U[H9MO8#&;9Q-%A</2K18['P+3TU,DDLH5%_4[S3O)45$\SW
M>261FEED9F=BQ)]V!8_%3KW3W[WU[ICW'N#%;8P]?F\S5BBQ]!`99IR-<C,2
M$@IJ6!;RU=?5SLL4$$8:6>5E1%+$#W[KW56GR,WKO_L*CQ+Y1ML[5ZX["DS.
MS^OCN#?U9M',9+><P,5%38BDQ,$M=DY\G@36LN7IITHZ6KA`::+$BHJ:[W6B
M:<>A%Z'PU-V#NS=&Y,IVGO+&[XS"OMG$KC]M[$VKNG!==[5J7^PZDJLY5;?S
M>Y*;(;)JYGJ,I1QRTAK*JL.4C0PU$?AV2=.D>O7@0<CITIME]5XZ7LW>N[=O
MR]B9[-;^RFV]GT_:.YLWNVB&%ZQQ\.UZO<62?<.0R6.QNT\=N!,G55E1#3:0
M:@011O4310MX,0*5QUOIUZQZU??^5KJ@8X;<VICLHC9:>@QU/MBHR>2I*=13
MX3"8_'*D6!&)I:R6"6.*_P#`XYWIXW;,29&J@UUH@'CT>?$8?&8'&T>(P]#3
M8W&4%/%2T5!10I3TE)3PJ$B@IX8P$CB11P!_KGGW[Y]>``X=.1^GOW6^B=?*
M"KV[A$VOE,6<D.Y9JZ#%]?TVW5BGS&9IIYF_B..S=,S*9]I1QEWED>WV\OJC
M8`R@K+"ZN;:23Z<:T/%6X$>?V?(]%.ZV5C=VTAN@`RJ3J\P#FE?0MP7ATJZ4
MU:T="^16"/(M2P#(Q4$[34D%84U57@J'4--`L@8![`,?IQ[&$(5T#2*`2/Y>
M0_+U\^H/N((T:9XI&\(-CJ44TJX?@IQ$P`8AB23K:]D`1>#_`(_7W?'E2G5`
MDH4T-0.NO"S.WC=B)50LK!-6D@6"27]?Z>0..?>ZA&&KKRQ%NY9"17SZX"02
M*XB#JJ-I8E+!KDDLK\\6_L\<>]M'1E=N'3SU=WH^F@'3;/$CE&>7R)J9M++H
M`-B1J*D'A@#8BUOK[?4BG:,=%TSG7WL2G\^O24[EX[N&#JSD``ZS90_C/Z5`
MX(_''MU9$53JZTZ(S/,W`#'622!XD$(=I"5$AC32=*\_7@*6+"_!_'MCQ`SE
MAPZWX195=66A^?462VHHQD.J[.6N+HME7TF_()_'X]J$[EP*9Z8D0ZO+K(6D
M+@Z=2Q(P1U"D.0`RJBVL71W(^G'T]["+6I7SZ<`#*A4@D>1^7EU)C#&*/6SE
MPQ*'61(4`#$-=05#,W(`_P`/I[9D">)T^0JQ@:SDC[1\A\NI$EA+$97TN3K+
M>/T,;E@ILW!4_1;6/^\>VT0IK"_#7I4Z!-(,E017/72_NHS/^EO2-5E70FE3
M<?6]N1^"5X]MEJ-^?54.MGTGX>/^QUQVXY_TH[,#>E$P6^1&H3Q@Z4VUK)0@
M<!2+'GZ^R??6C:UMSI_4UG_+T,>2=1WF01J/IEMWR?BU%XP<>ATG^7KT(O1X
M(ZBZ[!M?^Z>()L01<P7)!'!!O["W4K]"K[]U[KWOW7NNB0"`?R;#W[KW77JU
M$W]-A8?X_GW[KW7+W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UP<,
M1Z#8W_WBQ]^Z]UR%["_UL+_Z]N??NO==^_=>Z][]U[KH_0_ZQ_WKW[KW4#W[
MKW7_UM_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]UT``20.3]?\??NO==^_=>Z\0"+'D'W[KW72J%%A]/?NO==
M^_=>Z][]U[I-YFW\6VL+^K^+U6GZ7XP67)"_U]/U_H![]U[I2>_=>Z][]U[K
MWOW7NL<BW'`N3900`Q6_U(#<<>_=>Z(_WYT9OC;V[*CY*?&>."+NK%8\IN[K
MJHR(P6T?D%@Z&!S#MO<=1XI:+%[NABNF-RSQWUZ(YF"B.6+=?EU[H<.A>^]D
M]_;,?=.TVJ\=D<=7/A-W[,S<?VFZ-C;JI%"9/;6XZ`EFIJZBJ590XO'*%NIO
M<#77NAS%["_!MS;^OY]^Z]UW[]U[KA(X1;D@?7ZD`<<FY_`M[]U[H`<WG\UV
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MOKT*/6?5>W?CSO'K/`=Y]S8_LCN3=,78/>?=79N_\ECL'@ZFLI<+BNO\3LKK
M':F2K5Q?7'5>)J=VQT^&V_C(XTEI<2):MIZGR.U?,`L-752*]-&_&VUB-]T>
MY.C\EE-QT1Q4VXY9:7$;KHML#';:05E/C*O?]5B%V]'E*56,.U<C%55%<M5,
MF'J8ZBBJ8Q%OKP%.D324O9>?JMD]-]<'<3;UWQCJ_.U_9?9T%*B[-PF.R:5&
MZMRYVGPWV6W<AOC"9S<,D6-VOM^62EH,G,\TDYJ5JJ_&^-!3/6^K%<15]3?%
M+JKK[9.=WB^&VUMF@P>R,'E-VU\V2S>5F\D-!%D<O/34SS22UE;-YJRL:..D
MIS(7D:*,`CW7NA[IJF"KACGIY8YX98XY8IH766&6.5!)'+#*A9)8I$8,K*2K
M`@@^_=>Z!;N?NS%=44-#0TN-J-V;^W+(]%LS8N)96RN<K2"//-S_`)#B:1@6
MGG?@(K%;Z7*6C4R$A5)(/34\T5O&TLLJJ@!.?\GKT!FPMDYRBKZSL#L;)#/]
MF;E9&R=73C5C=I8WQ$0[3VP"P6/%T:L1+.H5JE[_`-C]0NLMN2W1V9@7KPZA
M_>^9;O>RD.O38+W",8-3^,MQ96_"IX5Z%M;J`(/0S+R&T@A3I5V(LP5%6]K7
M]J]!P-6/\'1-1%1EU$J?Y=<F56\B!-*6)<ZD5238*!^WK(;5;D_4^]=RT`%>
MF\:)C6@_V.H0),047700!&`!]NH!!MI(:]C>X%KGVZ268,!TU$\;QN5+!!ZX
M/6%0SO*5\VA[Z&/H#!$LK%+*!)8'D^[ERX4`4ITR4!D9EE.C_#UPDCE7PL28
MU^I)TS'3IL@?6-6GTC\^W(SBE./5)T!5B2?E\SUW)'K$)<L6]2MRUY7E]6A6
M06`<L;_0$<6]Z5R*>G6O!HFIB2*9`ZP-3M_9U*VFQ:(D2B2[$*D:J/\`.*6!
M%P"/;A=1P%2>/V=-/;,`"IHOV]8/%*K)JUN&,@M<$JEB`RRWNB7)_K[<\9/(
MX_9UZ.(**,23UETQQ@4Y:03'Z3J1Z"9!Z;_[3P/KS[HTA%33'6XH!K;22&KC
M[?(]9RH)T*'+@MJNP+E0+.GJ4,JD`6^ER?S[9,A9@Q`KT[X`#:I2:GK,$L#I
MC=0"JA9741<DJ!ZR"2G]?ZCWKQ"#@"O2I88R#5F;YGR^7V=<ZA74`J6!1"H!
MTOJ%G"6+?4E3S8<>ZUJ=752DF4C"A>%<]8L'"L78FT7(U2?W:WW,C7%]3P;8
M5P0M@0H0`<>R3>B7@7``5O\`#7H7<B#1NLJ^(K5MR<5\WK_DZ7_0^K_0SU=K
M!#'8>V':_!N^+@8\7-N3[#/4M="U[]U[KWOW7NNK`VN/I]/\/?NO==^_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KH_0_ZQ_WKW[KW4#W[KW7_]??X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW71O8V^OX]^Z]U
MTI)'J%C_`$]^Z]UR]^Z]U[W[KW26SB@YK9Q-_1G*UE`8J+_W:SB&X"L'_7]"
M1_6_%C[KW2G9M.G_`!8+_M_?NO=<O?NO=>]^Z]UZ_OW7NN#JK?JY`O<?@_ZX
M_-O?NO=$$^1O1'86VMSUWRC^*\*4W=^'QA.^.MTE@HMN_(;;6-03_P!W<K'/
M)34-%OR.&G\.+R<DD0=BL50^D1O'=60*RLE2>!\QU[HR_1W=&W.[MF4FYL.D
M^(S-*D-#O39F3DC_`(]L;=21(<IMK-1!48SX^K\D:3JHBJ%34GY44`(`KU[H
M968*/ZFX%A];D@#_`'OW[KW52W;W;O9'S&W!O;K[X]=N3=$?$[J2GW93]_\`
MS)Q2XT5FZ]^[<2>(=4=#9;,I-A:S:^R\K2L^^MS*OVX\1Q&.J/N6JYJ;W7NC
ME_$'=/9N[^AMCYGMO8V%V!NU4R>*3&;?CK:+$YS;N(R%3B]K[YH<#DZ.ARNT
MZ;?6$I(<G%B:M!54$52L4H5P57W7NC0>_=>Z9,YG\=MS&U67S%0E)0TH0-*`
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M,Y/3S9*''1UF_J1:R?R/>2)$L\WC0LK%&I,BH`Y\^GN(J>/6;;>%SW=&XYJ[
M+-DZ7:6+R$IKLC+Y,?692OI0T4>-QT2NSXRL@$\H<1LQP$!\*M_%YJJ:DOUK
MHT^1V-M#-;?I=KYC;.$K\#1P4\%+B)L?`^/HEI8UC@%#"4`H_`HLC1Z&4<`^
M]%0>(Z]TU475G7>,Q66P]%L[!)C\]224&;AGHUK'RU#-'XI:3(5-69ZNLA=/
M[+R$7Y'//O?7NBEG*[V^,>\Z;K+:U'4;_P"M]]4>7KNL<1)6>?*]5YJD5YZK
M%[@J99A72]9U51(?M)!Y)X:IEI8^&]+L,+3R+&@.H],7-Q#:0R7%P^F!1D^G
MV>9/2RVALZ6EK<EN[=.47<&]<_9\GF9UB$E/375(</CXH08L;C*:(*NF)BK$
M6N4`]BJ&U2S1(4@+2D=S>A^7_%=0ONVZW.\7IDN)XTA1B$372J^1*TXGCQZ6
MX60R*"S%!K\:R&.X`#>,%KD@V_%K^U6M5((C&KHJH&:56.`:_P"K_-UPCIK*
M6:6\EK#2Q(`-[HX^H/TN/I[>,B`H=..J*`!)XDIU#@.N:1R.C:Y%C)*(JA0Y
M9BQ"M?5JT!K-_7CWIW4/1>'3D:NT?>:$\1UQT&.4BH9>8W,K1R*T;$("'`>Q
M65&/(O\`7WXR`J5`[NM:"H:.3N[3Q^P]8FBX*AV:);.QD9(W6-@I*ZPPO]>>
M/S[N2**:9Z;AC4V\5$)[:FG\^H$PE=I%24H=*HK%DX.AI-/INJ<V%K'V_$R!
M:,,CI)*36G=I&17/^#IQ,EE#.R0JD3F0@$@`LJLC%[A1JY!X-_:<ZBQT^O2P
MD(L3^?$_[/3=^]>7UQRD2K8AT0A1=XUUJ?UVXY'T]J`%"U*@$CI*)F:-V0:I
M*C/R)ZE?O2A](COI`7Q,'Y93K61C]7#-8?X7]T"*!\..K)J)?Q!2CTI\J#K!
MXZC6J(R#2Q>9_1JTAE]36_M_[#BU_P`>[4%.G**,KCJ2S2N4_=7U.=!8@D`6
MN"A4LQ7Z\&QO[KH&3I\NK$S*0023Y5ZSZ99(?U`LCL0A$<<>@$`.NI[_`-J]
M[?4^TNK0_>,=*B)'C!8T?K"Z3^56.E'D*`EGO$RAT;4DA($;W-A]#I!XM[>+
MVXR6-1TB/C*XB*=Q.&]!U(Q-QV+M<R79TVQOIBRFZD?[]A2+CTW!-OZGV1[N
M5:VU*M!K'^7H><F!ANIJ?^(S>GDT5/\`CS?M/2ZZ0C:/I[K!'%G78>UU8?[4
M,337%_\`7]AKJ4.A3]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UQ8,=
M.D\:AJ_UO?NO=<O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW71^A_
MUC_O7OW7NH'OW7NO_]#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=)C-<YO:`)8`9>O(T@V+?W<S/#FX`6Q)_U[>_=>Z4K+JM_@P;_;>_=>ZY>_
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M([AS>X3MV'.[JRF1VSM/'TQJL?3Y#.TFWJ+`2Y+,YNAC:84M9((2XC*-ZQ[K
MW2OW%W[T]MK=^0ZVKNP]L_Z3:#`TVY#UQ19&GR6_*G$UM53T6/EH-J4DDN7K
MILC55<201)&7D\JM8(=7OW7NH+I'2I6=K]M9*EV]B-NTL^4P6$K*F(X?8M"D
M;H^8R\T;R093>M=#,8VD3R1TH?[:DU,TDLWC@5/7C@5)QT7QTROR(S%)O#?5
M#/CNJ,96K6===9URQWS]7B:MFINP^R:)6=9JTSPA\7A)M<>-11-4*:LZ81-M
MUJML#]5#^L?7BOY>1]?/J->9=Y:XG-K;R'Z=:<`<GSQBOR-13T;H0=U;:H:J
MBJUFI)J_$U<AK\ECJ,`9*BR1@DA_O;M*2=7@AW!#32.M32LC4N5IB\,R/K*O
MNZM1?D5`69>#UQC@#Z?;Y?9TFVO>/W(WARE6LM0J`I++KR63`IQ[A0:CD#H*
M.K>L?[U9?<&%PN=@DV;A=W563W5G<)E\S)49?=%=34&0%)0PYY9,M09*GP]5
M31B,2KC=M0%8<<D]:?NZ(-7$3Q.4D0AP?/'\_P#!Z]2;;W,5S!'-!*KPL*@C
M((Z/QB,7CL)CZ7$XFEAH,;00QTM%0TT:Q4])30QK''#!$H`6-0O^)))))))]
MMK6F>GSY=.7NW6N@;[3[279L5+@=N42;A[`S<;/@\`?)]O2TX+1R9W/R1%7H
ML-2L#8762JD4QQD`221NP6TMVXCA'Y^0^WU^SI+>WMMMT$ES=2411ZY/V>OY
M=!)M;:E705=9N/<]<V>WCGY%;*YH1K''&5!$.-QD9$8IJ"D1],:`!0O``N=0
ML@MX[%%2!?U*9)XG_8]!Z=0[O.\7.]R*[7`^A$E54`\/.OY]+L(0I4@JRRQD
MJ4+V"MZ1^#R+'^G'UX]O`@T(Z)2FE:LN:^6>HWCUS2`*5U-Y'!&E%<``@%23
M<!?\+@V]JFH%JWPCX<^732*LGBM7)(U5\O\`/^77M,;60+-K`:3]M0RD<'4;
ME0I6W]?=-2L,=6B\-A(*9^PCKD4CC);42!&[D%68$*Q4:9"%U%;#Z@D?U][I
M^1ZH\!T:HY:/Z=1U2*Q71/&KW9-0/J#*"S@&YL2;7_I[M5D8$?%7&>G(2\FD
M::5X]-/\9H(\I'B)#6M-454])2B6D9Z*2KI,8,E64RRAB-4=$NK4ZV)N/KQ[
M=9&55E%`S"O$<*T_PUZO'&0TL=#X0R/M/'J?($202!?&K?J-@4,AL0K#20-)
M-A]+D<>ZHYDCT4[_`$Z0R1M&X<N5C/"@KGSZZ"K$)0?4S%]9*EO(&LUF`C]'
MUN?]:WO;2#4I7%/Y=:8Z@7,C:S@X\NN,2(6!^W`U!9&9(R%!0?5F;3J+6(O>
M_JX]V9R:%I*];C0+0@8/62.+R)/I)-B6&DM8DW8*KD*K>/\``^M_==:M@].K
M"TE6$E.NC`FJ)#=GD9"%"O81%"74E+DVXL?Z7][,CJ*@]HZV#&1I8US3A_D]
M.LGA92MAJ?\`S2$6&@Q&Q?58LS-I-K7X%O=1,6%2>RG\^K*S,Q!![!V]2DTE
MP5,AMK4EDTH#J4$BW(!'U^M[#VP10%CPKT^`[@R%F4DYP:?MZBHY,I!4&/7*
MQ-BRO<E067E;V/#6XX]OA4,88'/3!D-8TK5=9K]A%.F[#Y[$KVEC,%4Y/'4.
M5CV-N">@Q]94Q09'.OEO!.T>'IV8RUQQ-)@9I:K2!XXW0V/-@_O.H6T7B25?
MQ"/EZ\>'`]2!R6JG<96$-%6VH#]K)_T"?Y="IT=K'3?52R"T@ZZV7K'(L_\`
M=['Z_J2WZK_4D^PWU)?0I^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NN+ABI"FQ/%S^/ZG_`%[>_=>Z['`Y-[#D
MG\V_/OW7NNP;@'GGGG@_[$?@^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NNC]#_`*Q_WKW[KW4#W[KW7__1W^/?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW26S6HY[:`4,0,IDF>W*V_
MN]E0&8?06+`#_7]^Z]TIPZL2`;D?X'_6_(]^Z]UR]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW3!N3/8?:N$R^Y=QY2DP^WL#C:W,9G*U\@@HL;C,;3R5E=65,IOHAI
MJ6%G8V)L/I[]U[HEO5W1U-V!\BZOYA9S!938]#6;*J-H;!ZUK%:F.=AJ\A35
MS]V]AX&1GIL7O_+8ZG6BQ=*$%9C\3(QK)/NJAX*;V/3KV*4IGH\5!64E=3BK
MQ]73Y"DF17@JJ2>*HI9UNZEH)X7DA=0RD$J;`CW[KW04=P;.W[N3'X;+]6[E
MV_M#L7;]771X7,;KP]5N';T>-W#0-ALZF0Q%!6XZKKI:.G>/(T<0GBBDR%!!
M',?`\EO=>Z`7>VP>F/CCUCA=W9;,4E!OC85?EMTXCMG<E'09CL'=O8.X*..F
MWMG<]7.M+595NP*=?#F8H9*:FBH?'%#]O%34PBLJES1`2>FYI8K=3)*X"`5/
MF>%30=!#_']\_)+-;6W'NO#2[6V/A*>GS>TNLY'JYUR6?C2$2=@[SED2F<P8
MRHU##4$D2R4NORNIK6M1B?:[&.V*W<P#/2@!&%/KYU/IZ'/0$W;>Y+E98+>,
MIIR:FF".TC&:C-/+AGHT^%Q4&"H#CJ*,'R5$]6\Z0I":ROJEO5U+10`+`977
MTH.%50+_`%/M?(WB,'U9)H?,@#A4^9^?0'EG9G9B:&G[>G.1Y##*TO[1&@HC
M@L2T:HXN`&*E%%@#;@GZ^Z+&JO2M5K_AZ:D9_#?Q9&#.001Q%.@>W+M7.[5W
M7)VYUDPBW5#31Q;NVB\U1!@.Q,)`KR2T-;X0RTN=IED:2AJUBDE@F!L&1Y8I
M=75K#=VT-O<9DC!6)O,5S1L]V>!-*<.CK9=ZOMMNH?#E9MO)[XB0<_Q1``9(
MX1_B)K7&30=;]C[<[.VU2[IV[-(L,DDN/R&+K5--F,#EZ01_Q#"9NA?]RCR=
M"[C4OJ22-DEC9HW1B#YK>:U>2&=?UD/=]O'J78Y8Y8UGC;5"V:C('R/H1P(\
MC4>739V;VE1;$IJ+'4%(<_O3<!:GVWMJG=_)/)J,;Y/)R1(S4&"H7_ST[6U,
M-">HDJY9VTE[,(8\>I\@/]7EY]4NKN&Q@>XN'"JH_/\`+H&MH;=FQTF2S6<K
M&RFZ]Q5`K=P9EE=C+5+XT@H:)"O^3XZA0*D,(LJHH`']17':16<(CBRQXFG$
M^OR^SJ&MWWFXWF],WA,ME%41@\*GB?*M?3I9/+((O2HDT,SJ+/')JT@$!F-P
M1I^G!M[>16#:F-!2G13]2S0LCPDM4'4J]H^WY_X>LRS/J=WDN2J`H8K+*I4A
M8U!;@EC^.3>_MOPE!-4J:]>@EF9LE2IZP25`(OI=+Z$(8.&4I9VLJJP8@+IM
MP2?:A858J`>`/SZ;=_#E=S"1&?RSUQ$IE"@NIB8E8ELZL0EM2E2H/KU_7^@]
MV":2P\^J&:5UC>@*FORI_GKUC2:1@R!RKQ.BI^V=*+ITNZ*19E""W^(Y]^&#
MU42:@]4R/GZ]=QU&E&13&[,"69_(B@V72J-I4<D<VX/NN@R,M6IGIUBT8TJ@
M+?;3_)TFTPF.CSR;A,)_BVB5Q425>0D@BDGHUH*B2&A>K..BFEIE$;2+$'9?
MJ>2?:C0I2.-V)*+0'\R?]0ZK%-/$6HH(;''IV>H+"S.(XO\`=@!<WU6UEB!_
M:*^FWT/O:`A@S&I_U4Z3R2S.ZAZ!!U)CG#LC#4C*'4%B2'74RJ;7N2`UC_7\
M\^ZE#6I/$]6\?Q%=0H%<']O6&*I=HWT21DQ2%E!20`L6)`!)(1%!L+WO[T8B
M,5ZH"S1.0G#Y]>%7)?5^V`RNI_SA!=1=SH]/*GZV^MQS[V(L<>O))*FJD?%?
M7A_+KBM2-22AM?T+OZ[*0"!Y$92454-A:QY'N_AU7PZ^77EE/:P3]>E..*=9
MEE9K.TP!:96_9#+X]+E-0N!82?0B^JU_;(C(K&N33K<MQ/$NIZ`?M_+K)'5%
MF\L92.Y;7=&*B$$JIM9K-JN2;<BW'O;1.05?!Z]'-,TBR"4T`X>1_+KL3DNK
M#P%RUXRH8C3Z5]"V"E$:S6`N/SQ[HL3:65VH*'RZ4%W9]7AK4GRP/V4_R]-F
M&I(4[1I\@T%/625G7FXH5DJ<?1U$F,J,#54B0U.*R,D(R6/>OI]P3PSHC^.:
M-5_*\DF[Q$6:R!Z1^/33]JMYU\M'IY]2%R7=$7MQ82C]5;>M?4!E_P"@_4\.
MA4Z.9I.E^I9'4(\O6VR)'07LKOMO&LRBY+65C;DD^PWU(_0I>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K&LFIV6UM-^;_6QM]+>_=>ZR>_=>
MZQB2[E+?2_-_Z?X6]^Z]UD]^Z]UQ8$E2&T@&Y%KZA_3_``]^Z]UT9$!L6YO:
MW)Y_V'^O[]U[KD;_`(%^1^;<?D_0^_=>Z\";GBP%K&_U_KQ^+>_=>Z\;V-A<
M_@7M?_8V-O?NO==^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NNC]#_K'_>O?NO=0/?NO=?_2W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW28RW.?VJ"Z`BNR#HC!2Q_W"9)7,9OJ4@'DC\<?GW[KW2E"*I)
M`L3_`(G_`%_R??NO=<O?NO=>]^Z]U[W[KW7O?NO=<5)-[KIY_K>_OW7NL513
M4]7$\%5#%40R(\<D,R+)%+'(I22.6)P4DC="058$$&Q]^Z]T"_8_7VUJ+KK>
M245#7T=''M[,2O04.<SE/CZ>!J65JN>GQ4>0&.5J6GUR1QB+QZE`TV-O?NO=
M`?VWWMN7K?`5O67Q$Z>H.ZM^=<;,Q&8R>V*7-+MS8NPMG0T5'483#UV7I:.O
MGRN_]T;>1Y-O;;H4^ZKU19JF:CIY(II:L6`JJU/7NI?6?SHZ,[+Z(IN^J'-5
M.&H_X932YG9>X8X<;O?;&:J8M3;8W#@E>>HQV5I*D/%,"&$;1L#ZUT>[1+))
MIQ2O3%Q.MNNMS]@_B/IT#>"ZUW7\@LU-VYW**_#)-"7ZMV#:".JV31-*9Z#<
MV7QU5'/$F?0".:EI)TU0M^]4+]R42G$]I"EM"GB*#*<-\CQJ#^749[W?7,UP
MSP2,WB9^00'``X<>)XGUZ-;B,!1X:DIZ>B$B-J3[RJE`\LTL-H5>1(UCCC1=
M&F.)%6.('2J@>U!N1\)X`=$,]O+/IDDU!Q7-3Y_G3[/3RZ=G37&);-),#(T8
M/I\;W()!N+,$!/-P/Z>VEDI(ZIA",@_[/6GMB51Y$?4#BG#_`%?;UBD72NA9
M22575:Q:6T;,Q`>W#7'/];V]J8G5L>8Z8>)XNV0TU>OE7IODC9^?7$L835'<
M&ZM8+958N6(!^@(L?]A[4(W=5\TZ23PGPFTRU8''D0?4$9!'D1GH'MPX#=^S
M=Q5O9O5!@3<-33)%NG:M7&T^(WOC8(W2)7QZU-"(L_C78O3U*RQ2*H9&8QO(
MCL7]I#?1*2X2=116.0?.CGT_A/&N.'0CY8W>XVZYABG8-9S,%>I("KDLX'"J
MFE3Q8M4UZ5.RL1CJR2LW5)E)=R;DS4@_CF?JO&]89!%Y3BHJ=!IQ-%1>11'3
M1A45"-(L1=N"V7;K;3I(8BIKQK3B?\W#IO>]SEWJ]9W&FU0E10X8`FA_/CTO
MX0CLRHH2-9'/Y9UD46:2^@L"+"]^0?:AW<")P-3$5Z((Q76OB%0#09KC\_\`
M#UU)1K-XS`\CV<O;44$@]368_P"K`X_I_7WL3-2K)3IV2U;1V2FA&<GC]G#K
MHTPD4,44NEF(#!"I]=W8@#2Q(^GOPF%<J*=)X+%G)T-I8?S_`,G79I@(`T@9
M592W#>FZ*"'3FY=K#Z\'W;QP)5\,\?EY=;^D54/B02Z_4DT_PTZQI`KH:D*K
M+J\?I.IED8^D(7%E8"][6`_'NLLA$OA*3K\OL\^O0VB_3B9P=*GRKY]=QT3*
M"PLX\@8.7`!2U@I!TL_H5=5@/\/?I9D"@J.JV]G("S2-VMY?X/GU$:%?.\;.
MS(;VB`N%F158>,E>%7\"_P!3[=252*GCTU):+J5A75]I_P`_7132BR2:I;?V
M5/KC-BQNH&D`,?K[<\34:)^?29HI$5W))1:5_/KF],BP%F8"1R;N6NQ\G(UQ
MA;JNI>+?0'\'WY6.JE>GGA5+93(YU'/Y>76'PR1B0)&2$50?2NO3I#%T%](!
M(_''^\^]^,O`\0>JQPL"H3B>N$E.%5R;,)%72B@*K``MZ[-<@2"X`XM[LL@D
M)`Z<%J]'0MEN'V]>,(G6(M%Y/%]Q%(BJ#9);,"3PJ?3@\6]U<L"-)H*=-QVV
ML`U-(CW\<@\.N_$J!W#7NZHT9X<@%;DZFN;L`;VL;>_(S%B3FG7FA(:E<=2T
MA50%D8!F]"+PRJ';T_J+@G^G/^Q]LZB7.ML`5I_L]/"!'$=!G4!UF\"O&40J
MJ1ZZ>2^I&'))(96"D`VO]?=!,RY_`<CI2UL`Y-!Z=<1'XY)$*J@)C`G9@P62
MQ;@!25!"_BW^O[M)([(M6Z\MO$59F!UZO4X_GU#QZSGL'`R(Z"F?8'8@FC;_
M`#C2_>;0\+I<'T%0Q-S<'_#V5;J2=OD%<"Y7_CLO0WY-M&_>SW8EU1_1D?GX
MD?\`D'0C])G5TWU.UK:NMMD&W]+[:QAMP![#'4F="=[]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NN+:K>GZW'^V_/]??N
MO=>)(6^GG\BXX_KS]#[]U[K'R65U6X(YY`^O]?Z^_=>ZS>_=>ZP$@*#/9=+`
MAB?JW)'"_2P]^Z]UVPNRR(-7)OS:]K`?7_6]^Z]UF]^Z]UQ9E078V%P/H3R?
M]:_OW7NN7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NNC]#_`*Q_WKW[
MKW4#W[KW7__3W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2:RI7
M^.;;0MI:2HR2H+-ZM.)JV8,5!%@#<:K#CCGW[KW2E'``_I[]U[KWOW7NO>_=
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MH?M_R<>H>O%N-ONIK5JK,LE:MQI_$?D?48J>A]EJ9B':-FCUG3$S`.A8@Z[E
M6".I``'^)]IX[?M\-AW5KU::^6X1J9:@%?(]8Y9C<RE9O65"Z0D:&10$'I!L
M-2MR6(/'NZQQ4((2H]:UZ9DE7L#^)6@X</YGK%H\;Q%FDE1G>[.;NFH&R@ZB
M%6RDW%P?;Z$=R8KIX=(9992<S2>'YUX4].F]RS3"SL8G$A5E,4;`G0452>0M
MKW`^OMY!04<TZJ-;2(8Z,?\`)UE=Y$=F72"BJ"ZE`[%`H*G6"0&8<CC_``]^
M$2L#5N)Z<>=DH=&".@EQ.TXL1VCF]Q[<JY,-0Y'%0U'8.&B$+8C<.YZSQ?W>
MRD43MKQN>H*"G8U<\(5:FG>)&4D:A=@6&D9"C_B^E/B`VH+PTE8]CBB!:?%6
ME2VKAFE?ET*@DF)9?3H<,K!66P,BJUB38FZ<\F]O>]*1+&-7?6OY?X.BS4S.
MQ%*4\C7\NL]FCBB90'=5NK*?\U8@K&P'Z`NG_8D^V@0'E+'!-1]E.E!"B.%C
M\8!Q]IZEI+*C,2RC5#&&+^.-I&?4Q+@'E[&Y^GU]L2)&Y;2PZM#/*TTX6/.B
MGI_,_+K&[EC'I!"S/*.`FN-;670Y5E"L>`22?=T1P@QGKT\DC?3@5TD<5R/V
M\.H`DDC"BTA:Z$Z2JKPK.`;$$@6_(_'M7HJH4TZ0F9("YU2ZO(XZRRS3*J%[
MO)(=+!EL2S+]57](70O`!(X_K[:C41UC4U->MS7DZJKN292:&O&OE\N%.H#R
MLC2R,H"JX.B2VD%A8J>0RDJ/];V[I#47UZK)(H1F8U'H/MZ[J#(\@(0>$J`Q
MTOI+@\(K`M^W;\V]W5(P2"PU=>+/(X:"(Z2!7Y]=>:34C-(8E>-HW!4-9XU!
M9C<@KKT@7/U(][(C*%=!;YCJCO))XRF0+%2GY^?7*:6I)9?(RJ_I4QG]"AQI
MU,P`$;`>H>ZQI&&4UI3^76O$D8:%!)`Z\&?5"IC(TC2%0H5%B2"=!_W8>"!R
M/K[N%179U<'JR--0]IZY*95B+*&50QTQNRQ@R-<*!?ES&1_B/=7T.QJWET\'
MET\/\'7&(%V+R'4A8'D(&MZGN6)5K%_TV)'NQ("!0<<.JZ259CPH3PK_`"\^
MN<<CN;ZBY@C)TLD8BLYN#&&-XSI-K'Z?@^VM!%*BE3U2)@"=(%?DFG^=>IJR
M!8WURA1(4>/2H#,I\=@=5PA9;J/K;GVQ*M3VC`%#]O2Q'9XA'3!:O7-ZE3(J
M@R$+*BZSI36I#!E1;6_/UM_L/=5B(4$GRZ?-U;1N8RM=+4)S^?4"@CG;?V'D
MDA54@ZZ[$TV*_M^:OV4``#>12XC)_L@^T6Y%/W3-0]WU*?\`'9>A;R8L@W2\
MU1R",0MI+4H1JC'D?4$?MZ$?I<@]/=4$7(/6VQB"3<D';&+()/Y)!]A7J2^A
M+]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO==``$D?DW/OW7NO7%[7Y_I[]U[K&%/D9SQQI'^(X/]?Z^_=>ZY2-I
M7@^H_0?UY%_][]^Z]UR%P/41?\GZ#W[KW79(`N>`/?NO==$GBPN#^;_3_'W[
MKW7"1F73I^I/_$>_=>ZR#_'Z^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NNC]
M#_K'_>O?NO=0/?NO=?_4W^/?NO=>]^Z]UXD`7/`'OW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NDEF'*[FVBO[EGJ<P/24"'3AJIAY+D.X'X`O8^_=>Z5OOW7NO$7!
M']>/?NO=<54+P+_[$W]^Z]UR]^Z]U[W[KW7%5"\"_P#L3?W[KW7+W[KW71!L
M=-@?ZV_V_OW7NN,G^;?_`%O?NO=$IV3L_"[ZQ'2V%S<<\4D7QZCRV*RV-F%)
MF=N9NGS6Q7I,[M[*I&9\?EJ"9`4=28Y%O'*DD+NC>KU[HK_;O5G8NR.P=Q]L
M]:X2;+=QXG%OG^S>I,$T>#P/RWV;B(]%/V-UK2-(M+M3Y"[9C@2*MACLE9(4
MAD+15%).37:]T;;GD64%[-^*_P`/])1_%]N",?/H@WS8;3>(ED>,"^0=K^OH
MC^J?+R-#Y=&$^.O?FV._-CX3=N"J*I8Z^FD63&YBC&-W+A\S0,L6=V7O##%B
MV!W[M:LU19"B8\A/+$61N#Z7Z:2'ZJV):-E%,Y6OJ.(^S]O49/9W]A-+:7$,
M:O$]"`*9XX/XA3S'0[S-)%-<"/1^X;-Y`=!!4G01?FUN2+?B_NL*1^&-(_;Z
M])KB:=)"U!P'61_(%0,8RW[95D!T*`MP"&_"GZ^[HW>6(QPZTWU"IKT+D5SD
M?G_FZA&VMKD'6UF/K8#4!PBGA4MPOU%O;]/$QZ=-(E629HUU_P!''EUCE72[
M(AU2MI)%QR;`-(ZLUF)/X`XM?GWN.I!U+2,'CTU+'+$B1P4K3S^9/^JG0:;A
MGS6!RU53X2"FDR6]$H7C>9D_W%5N)I(\;/7?9V:2KADH8XBCV\<<R6;]2AGX
M(PYD=#6,>?#JDDSLEM:SH0`:GYUX@>E?S'2CVG@8]LT+TZRS5-34RFIRM94U
M$\LE;73,?)4!)C*JEF8@6^H/O=PQEH=(`'5(GNT9T.8J]HH*@?,@9Z6=S"R&
M.)3Y5)D#$LP"LA)!!.@G\7M?G^OM"L9>M<`=*V6:,J8DJ&R?EY>G73,VA"_(
MU>5W"V%N-)1O&;`$@6N>/=T0!CYGATT\<LI"LV*^77B"&8(L;&./3J$@?Q6-
MW6PL"[6XXXU>ZJ:4.<L1PIPZM+'/'XB*FM%XG5E?3`H#^SJ.VM$$R*S`ZSXY
MOU!P"H"*05T@W^M_;Y1&8J]:_+I+IN(XS.JAE/E_L]8I7F9(S*`9"ZZBEA)(
MP%@`"MD\8^A%KD>_*BH]5/;U4&Y,2HZC7KU5^7D,]89(CK9I(]1509=*V4Z5
M&DJ#=3Z2;V_`][6IX&AZ>9)2M&@CI\AGKH:I&D972+6NI22+,NI=)#+IN5"_
MT%O;I`95QGS/2?3*@9F-*TI_EZX`S,VM4$Q>(J7!4HK*3ZI&('ZC(?K^/>SX
M<9`>3/'K1U2G6L5%IPKY^9_/KF'9Y0Y<*NAOVT!5;K>XNR\L3?Z6N/=?#TJX
M&1UZ2274D@[0<4IZ?/K.UV2&198T5-2@.2NL`'0D8"VD*AK'Z\^V=5&T,"*^
MF>G29I(G;6,9]/EU$(J)$B,92VN0D,ZA(P2?4MP60`$7Y-['V[1!Q<@_,4Z:
MTW+`(B+G^EUF"_H"2*8_+ZBL;$*EBWJ/-D4FR_3ZC^ONIJ`6I4#(_P`G6U\6
M)=!C=VX'&!ZY]/GU*:%#4KI2\,L:(KN_DT!TU'2I"@%&!%K<?@^VE9W"ECD&
MM/LZ4JC:XT"8?%?3KLQE/!^BS1V4$,Q54>TA*D!HPWX'-_=E.L2^1KUIUEB,
M9&10_P"'KMI`7\HC.@:)+V.E[H$`MSI;4O\`3Z^ZB-NU1)U8NPB-:5/6/&3:
MMZTFLD23=<[X:S.A;1%D]K6:UBX(,MCS:_LGW1J63QJ5*^.IJ#_0?RI\_P#5
M7H=<G.7OW/EX#G_JHO0D=1(L?4_6$:*J(G7FRD5%+%55=MXT*JE@&*J!8$\^
MPYU)'0A^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NN+J66P-C_7W[KW7'Q@A=5R5'UN??NO=<G;0I8@FUOI_C[]
MU[KL68`BQ'X/OW7NNF*VL]K'CG\^_=>Z\PNI&D,./238'_8\^_=>ZZ"BQ6Q`
M^M[_`-?P.;\>_=>ZZ$8T@,2UB2#?G_`?[`>_=>ZR>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NNC]#_K'_>O?NO=0/?NO=?_5W^/?NO=>]^Z]UT0&!!^A]^Z]
MUW[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z2>7N=S[2`74!-F78W`\8_A,R@D$B^MGMQ?
MW[KW2L]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7%S9')Y`5C
M;ZWL#^/S[]U[HJ72*#[CI%^+CXT1*%OSIDRVR&O;^GI_V'OW7NA[WOLC$[WQ
M<=)7O6T60Q]0F1V_GL34+1YS;>:A5TILSA:N2&HB@K(DE9'22.6GJ8'>">.6
M%WC;1%12O7NJM.V>G]][$[6K^X.N<8P[G@QLN1[7ZMVXL>'V=\P=BX>,&;?V
MPJ%F^SVW\D-E4P266F5S+6`"GD:6FJ()PML+Z7;GD:)%*/36"*U`/$>A^?IT
M4;ML]MNL5)2RS*#I8'^1'F/\!Z-1U+VO@.TMHX;/T+5*#,8^ER%)#E*:/%YJ
M+RQZY\?FL87FDQ&Y,8Q\5=0NQ:&5&MP"%%SJ'5+BW75`X!%/+Y?E^WJ)GC2%
MYX761V0D4(TD4_$?D>(Z%UHE)_=*Z%@9M15C<%&L?2S*00P-^!Q;VEKHK0$'
MTZVT8DJ-14!*@$\3_L]-S0+.42<@W9VU`DJ^A?65.FP4.IM_3VH#M&QT4^#I
M,_AR*!'4(/GFOV])K+9JDQ<]+04YCJ\QEC4C#XTRI#YXHDU25E3*666*CI4&
MIF_4UBB`D\*HHS,`H>A"ZC_@X=)R:HQ<N5!I@&O#UZE8O!I232Y"LJ'KLM61
M2+59!R0!$GD?[.DCN%I:*GO=%'UO]222;23CPA!!0)4?:3]O7E"=K4)`'XCF
MGS]#TZM2$*C0Z`7:/]P2`.`A4,R*.!;_`!^I/MKQURI^/IHQ-36C=GR:IZSQ
MKX[$$J2S"PM)J#,0Y/Z;2`+]22`3[J*-\(ZLC%%8.YH3Y]=C0VH,24\L<8&A
MM11N&#:"57DD7!]^>J=P'=UH+K$C4>@;R)ZY.(4:0QA&#,H!]1956P4$#TE3
M>VKAC[HI<Z5:0D5)_P!7R^73CZ(2Z(%I\C5A_IO7TSUQ$9\9BCDTK&3*JDG]
MP_J(#2,%5!KY!/NTA&K41QZI!&&1TC:HJ*Y_P=>FA(#J\0TN%E20:=99@6L"
MMN!J^OY^GO:^'3$@'RZU,I!HR,I'XJX/_%<.L/A8C4LA9?4"&(1K6-C^E;\D
MB_\`A[<#1CX!W#KP5B:2*P3UKUC:.)G*$."!Y5'I;4NK00SBX!!Y`^EOK[]J
M8TJ<=6TQD$`,U>.>NFAC52@73&-+L$.H-,00I50P'ZASR![V7+&I4$]-D+%5
M5JH]*YZX/#&6T3".-&`U'0"X;F^K238DD?[?WL2,&%!^77IQK\+Q%&@>ASUU
MX(E9QZ)?2"NB^I9+$$`7#:=0%R+6'OQ=J@T96ZHQC*,JI4'B./7,TJ!7=8F#
MJDS:(KWL"%]`!D"C^M[>_+,-5)<_,YZW&J+'XGTM*8K6I_WGKBE-"VAO"_Z0
M?,I8.&`NQM=?6--_I;W8N:Z0!\L=.0I$-4BPM6A-34?/AY?9US2F)$;,&(<A
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M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO'_``^OOW7NL'E9?UJ;
MGZ?0<>_=>ZS*=0!_K[]U[KIRP7TBY]^Z]UR]^Z]UBD!U(0I;22>/]A;W[KW6
M7W[KW6(FX(DNH#<&]@?K8<'^GOW7NLEN;\\\?7CC_#W[KW7?OW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KH_0_P"L?]Z]^Z]U`]^Z]U__UM_CW[KW7O?NO=>]
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M%JBCRN*=S)B=QXAU:'(4+VD@E1N`+JINHC<![=J0D^?G\OM/4>WUM<V=S+%*
MP,H5:@>5!FGR'2BWEO.':]*CF,5V9KBE+@L%3W-;DJ^50((XTC4R^!I>'<<`
M7N0`2'HX-:F0M6$<3_D'SZ+H_P!60JO;J\^`'^KUZ25%U_75T53GMQY)O[[Y
M,(4K:&4&EVP8F,U)C,1$&,?C@90*B:VJ<W`(0*/=T:..344.DB@']'Y_G7I^
MYN9(8TALBI16_4/'4?/3^5/SZ4FV=PUU0[X'<<4=%N3'+;Q>.U+F(=0\>0QT
MGTD5U_6JDE?P`+@6FMHDD$D;U0K4YX?;TE?Q2=*4$;]RU\JY`/S'ITLPTBR%
M[*?4;(0NDN$NP)/^;"VXM]?R?;1A4`-7J@,T9U2("X]`.NF>5V`50P=6(UK&
M`&879&4"W#6Y/]??EBH#5J=7>YDE*-$HR,@@=9UJ6](G5C)9"B0KQK`*%+*0
M#9F%SP+>VS`23Z>O5DF(8ZJ!SBGJ?EURDUV!5"LD*$ZD&H.2""5+D+J0VX(/
M)]M*%5W!DR>&?\'5IICH1UA%!Q(4>?KCK'9G+\LS#5=KJ&N=(!`]'K_U5A]#
M[=TZ:9J".FX`_P"JRIQ/6<E2H\NHM&(R'\>L%@ME%SIU:3R>?K[:8`DBF.G3
M5A1ACY]8I/4_C/IT(SD:48NJDV,FD!0Z\D`?@_U'N\()2OIU=I-2A95[3U$+
M!78-PX)7RA595U,K<.0RMP1^;@_7V^BZ]5>F1/X1TU!F]:>7E^SKJ=IG'H0J
M%TO_`(Z5N)%)=KJ`1^+DCZ>_1JNLJ[TZ;F:YE_LE_D/SZXJS/-(S1`ZE`5H]
M(0Z"5`)8'0V@6YY-_;E:9KY])@S2RM6-?%`%*X'Y_P"?K.%AT++(KF96+./2
MGBBTZ5&JX!D-[>VJNSG0^/MZ52-`D:AVI+Y@#M_(^?7(R4Y2\<+Z39Y3(58<
M"Q0-'RUG`(_!^GX]^_65ZNZ_+K2L#%HC4^&Y-3Z%?GQ'41:EUD*)3D.B@?N.
M""0?W6'%SJ23A3]#_A[4>&[+7QETGJD=Z4)[:L_E]O4Y*Z=4IB(M+*[IK4(4
M?3QHN%L68?3\>T;VH+L=5<=/_O!XQXJP87ACSZR2-/5$K*ZF,L'<.$,FEWY]
M*E5#A@;D^]PI'&A`-0>GIC<Z!KE0Q4K\S7)SYTX=8XI0;1/$[2R"P+JB&VHZ
M256ZLK@GD\@CZ>Z-'(2SK(H6OKP'587C8")XR#3%?,?GQ'3:LSTNZYID8>=.
MKM_5*EE0_P"9K]LL&5`1J`.G^@-_:'<6#;6U&XW"D?,!9,_S'0VY4-=QGID"
M%OR[P0/V<.A:ZN01=9]=QB]H]B[10:F9S9,!CU%W:[,>/J>3[#/4@=+KW[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]UZP/U%_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7%KZ38`FW`/]??NO==K
MJTC58M;FW`O_`(>_=>Z[]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=='Z'_6/
M^]>_=>Z@>_=>Z__7W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UT1<$<\_T]^Z]UTJZ1:Y/^O[
M]U[KE[]U[KHBX(YY_I[]U[I!;KRF-V]D\%FLO5I18S&T^?J:NKEU%8E-)311
MHJ(&DFFGDD"11HK22R,$12Q`/NO=,VW>S#6[CAVSNG;65V1E,W#-D-EKFJFB
MF@W5BH46:HA@FI6T8_=6-A/EK,1+>HA@/DC>9%E,7NO="L"#]#>QM_L??NO=
M=^_=>Z][]U[KWOW7NN*KIO8DW/Y-[>_=>ZY>_=>Z][]U[K!5$BFJ".2(92!_
MK(Q]^Z]T4[H][Y7I5.`?]E<QLA4D%P'S.T@#P;Z3I/\`A[]U[HW'OW7NO>_=
M>Z0V_.OL%V#C(*+++/29#&5D>6VUN/&.M-N#:>?IXY8J//;?KVCE-'D*=)G1
M@5>&IA=X9TDAD=&]Y4ZUI%2:=QZKRWEU_O3:>]\YN':&-HZ;M%UGW#OSK_&Q
MS8S:O>F,H$19>W.J;R21X#LS':D.:Q"2%YY+&37Y(:BJ,]OOGM)`@=3&?)O(
M_/Y?9T1;[M*7]NSQ1CZA*D8^(_PG.1\CT)'44N*W=0Q=B3Y1=R[FRD<E%65#
MB:!]L1AECFV]!CY`HQE4C0_Y4[)'++(I4!8E"`7M$J,%5OTPM4']$Y)/J:\/
M3J)KZ;0G@HC+!JR6S)45KW&A5./9ZT(X=#N&C.CQ$O'&S("VDWY96!*_4*03
M?VF<Y/\`%3IM8T,1,;X/&OK_`*J=,6<P5-E)**HJ):VCJ<:SS45?0Y&HQL\+
M3Q&)]<E+*@G0J00DH=+\VO[=A=3&P8XK2G3!6:!2^FJ4J<U_P</SX=-^.KZJ
M+(2X;(3C)RM1MD:&O\<:2U5!#4)35,-4(],35E')-&7=`HDCE4Z;@^WVHND1
M$4`IQ'2<,MQW(@!IY,`?YGI4/4@@`0!S&B,@A4Z1I<D*=5CRM]6D?G^OM+'$
MU7*OVDYK_DZ>:8HJ(1WJIS]OD>H\=09&!8.;:1)K/ZI%LP1'CTZ5*?FU[^U'
MA%5PV/+[.D,+N[6K-Q1B3\^G*61U9;HVDJ6#)Z2J!;O:[-&6L;`$W)^OM($B
M(>I!D'IT;-*P4A3V^8ZPWB7Q2+K"%5=W90Q:8+I9F`;TL1QQ]??E5F)U=5T0
M0U,1?4^3G&.L,JR^-"@\>KA[>DE"-:D`&S.?Q_@1S[O&JGM89Z;"W#@JIHOJ
M3UP+#S(QD)`C=682J)B1:VI4)-N?P/=U`4%5(T'JB!)%)+OCSKIS_A_8.NRQ
M10/`=8.DAVLSA9`RZPM@%9/SS[NH))(84ZI(75DCE)!S2K%C]IJ.LD\Q5``$
M0Z'8^K40KHZGU"_Z?J2;?3\>ZJ@\0'CTI9P`%0G50BN:9_S=8(BOF\L;*X:(
M(R*-5F(UB1-7-BUB0""/Z^[-$VEJG'3"Q,CEZU.D=9"[.%9U0H2'!(!.DDJM
MD+"[?7ZW]U%%`5>/6_#>0L6II`ZX<11J5OZC*KBT>HJ68(Q2X6X=@201P/=F
M45HPS3KR_I@R(37T\NN#/J:&S(T7E+DJ!K;0#J.G^V+'Z_G3[<C%%8'TZJ8V
M>19J@4%?^*Z[C>./2[1IJ4!Q''81O*H.BZA2KWU`VM]?K[9DC<J*$`5S]G5X
MR<`C51M7[/7J1K:97,0CCG:0A]8MI%AI(;4+7TV()M_3W41H*@?#Y?[/3DDK
M3-)3BQK0<!\NLRR-H4,BH0HN]U#BVH@,`74@ZSR";#VR85U%@Q^SK5)0NDT\
M0<#Y`=)V2\N\JR9F2T/2_9"Z%)+NL^5VHUU)-@B&$C_7;V4;O!HMX9,@>(13
MRR*]2#R7,1->6Q0$^$K:OSI3_+T./68(ZWZ^!^HV1M0'\\C`T`//Y]A_J0.E
MO[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NN`<%REC<?GW[KW7/W[KW7O?NO==,=()_I[]U[KL<\
M^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KH_0_P"L?]Z]^Z]U
M`]^Z]U__T-_CW[KW7O?NO=<"X#!.;G_6M_O?OW7NN?OW7NO>_=>ZXLVD7L6_
MP47_`-\/?NO==@W`-K7%['\?X>_=>ZXO($L"#S_2W_%1[]U[KD#J`(^A]^Z]
MUW[]U[KWOW7NNF.D7L3_`*PN??NO=>!N`>>?Z_7W[KW7?OW7NO>_=>Z][]U[
MKWOW7NO>_=>Z`;N7,87;^2V5FLU44%')CGW94;=K,U3YBKV_2;L.`$>!J,O3
MXB"I8K%*TI1VC+Q@,T1$@!]V`!^WKW21KNQ^J][;%Q>![(WKA9<])C\=/793
M:6.W/C8,7NVBB6:/<6SJNMQLN2Q55B\B#-13%O+':SZE+*:]>Z5>P.Z]F56S
M=NR[@WK0U^:_AZ19#(#%93'G)3TLCTIR3T34"?:29`1"9D`55:0A0%L/?NO=
M+%.XNM'76N[*$J38'P9`<WM:QHP;W/OW7NL\7;/7<S1+'NFA9IA&8@8JU=8E
M?1'IU4JCU/Q[]U[KE)VOUW"%,FZL<@=BJ$K5>I@0"!_D_/)]^Z]UCD[<ZVB7
M5)N_$HNIENSSCU(0&'^9^H)]Z-:@"G7NO#MSK8H)/[Y81492X9YW3TC3>^N-
M;$:QP>>?>\#CU0L0>(Z8,IV[MU<OMPX?>&PFV[)/7KNF;*9.LBRL4`I6_A9P
M"01-1S3/7QLLXG*A8N5Y]^ZOT_3]J==/32!-XX)C-3R&+_+%M(&1E4J;68,W
M`M]3[]U[HA6QOD?T7@,+U=N!>V)]M;FV[T_B.N,WB,OTSVKGQ35-+4XJ7(1R
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M.+I]QU&$B3L;;]/L3>-%CMX99(:6.KW9BMOS8I%H,^Y#2M2&1Q5'Q`RJ]VF/
M=KW,1.MO=9B;`;S7\_X<<.@QOFQI=@W5M$IN:C4I(`<<*UH>\#`/"E:@]"EB
M>XL0]ZN??77.X\9DDIJW`UM+O3:6SZZ&AJJ?]ZDSN$S^5I:ZFK2[+JB>-)82
M"DBJX(]FG[TVQ>%SJ'GVG!KY?+Y]`L\K[Q<0J;>P$3D`]TBL,CY`4/RSCH.^
MXN[NM-M8*DW5O^MVE7[.PF1@&4HZ+>6S]X5,M3EJBEP^+F@P&"K<ME*N"GK*
ML-(ZTTGV\;&1]**S!V'=-LD#QBFHG%<?M)P/M)Z;3E;?K-3+&`&I4@=Q!^0S
M7[*=`M@_FY\3-IU2UV"H,?A9Y:=J85N,PU52R/2S%97I08L0);2RQ(S+:S%0
M3R.'EGL48D20H:?[^B/_`%DZ1OM.]7I*7,,\D0SI\"7B.%-,:FOYT^72GI_Y
MCGQPK*BLB.XJVGEH76(Z\=EPGEE@AGBAAG?$)#(ZI,C,RGQ@W4G4"!6*Z@);
MP[B!O7]:(4_:_3(V;<FMXIFM)P2"`IMYA0`T_A.>N-?_`#&OCEC()*^KS\Z4
MGFAB>6*"KE::2HG6FA"TZX_RR-(SK<JMD!]5K'V\]U&J+^K`2?\`AT/_`$'U
M6VY>O:C7!.%)_P!\S?\`6OAU-F_F,?'*$RPU.ZXX&1M*H)UD]!`120L&GQJ5
MY^A]ITN;0,VF:'6?^&1C^98=+OZN[KJD1X&"J0*A)34G`('AU('$^@ZC4W\R
M+XQY&:HI:3>]')-02TM+4Q-5>,1S30BHA,;20Q)-&]/(&8HSZ3Z20P(]W6Y@
M)IXL-/\`FM#_`-!],ML^X*A;Z2;#4_L9?VCLX'RZ<9/YA_QIIJ6IJ:S?5!$E
M-#YW(K:61A'"S(A1=:R2DZKV0,_'NLEQ`E'$L.?^'1?Y'Z:;9=PGD,8LI5H`
M:F&;_H'KG%_,,^,T\CNG8.&++<F1LACXY"]PNI-4D;,JD_J^E_I^?;@FMSQG
MA`_YK1?]!]7.Q[@`S264C$<#X<I/[%BSTB\%_,>Z1DWQNW`YS>>T,;MS&X^"
MLQF6_BN$:ME%1/&E(U35#<LS2?<K'/J3[2$Q^/EC<72MN%N9HXPZ:!74?&B_
M*G?_`)^E";/>>%$IM)C<R+528)Z"G&M8EQZ4/2KR_P#,5^*^/HLC55O:NVZ:
MBH:22KJ*H9W;[V@A35++&(LIYB@CNPN+R`>D'Z>U,=_:1G4SQF/U\6+_`*#Z
M9EV3<)BEK';RB0FA/@S4_+LQUG_X<)^+Y\*-V1@74T_F5$SNUHX]+Z'$A<YP
MD74CBXN#Q[L]]:Z21)'0^DL1/[-?7OW-N8(3Z:6HQ7P+BF,<3$!_.GSZQ#^8
MU\6?XBV$'9FWI<A]K#D!3MG]J0Z:&6=J99A)-N!$6-)QH%VN+7(Y%TK7UFJE
MFD"TSEXJ']C];.R;O3$!'VQ3#_GSKDG\PWXN%*R4]D8...F%3+.9,]M!8HXX
M(I)I0)%W$7DTHCDZ0QXM]1[L-QMY*,G<*<0\5/YOQZU_5[<3'W1O6OE%,?\`
MGSJ(G\QSXJ214=6G:6W&AK8@U,4W5U^0T4T'FB9A)NY6B617`%P"+@&W(]OB
M\C9`>T#YO'_T'QZJ-FO5!6AU#%/"F'Y5\.@^WAU[_AQWXGI6P8D]F;<6JDHZ
MRNHZ<[MZ_>9Z>">EIJB6(_WQ$3K#/4QBQ.HZB;:02&#N$!;2QHO'XD/\E<G^
M5.MIR_N#^/(E?!C8!B(YAI!XU'A]WY=.S_S%OB?2QR?==K;.I45`;S[RZ[C5
M@G#L(CO/R!DLQ-[7_'X][^LMRI(E%:].IL=\LD.B*L3G#>',"13C0H"/V?/I
MSA_F!_%BO%--0]K[+J*6HIHIZ>KBWSUH(9*:>F5XY5\N]TE"MJ'`2]_Q8GVX
MDT4@0"9=;#"UR?G7@/SZ;.W;BR3RE`MM$2KL4:M1Z`T)_9T(G5_>G7W;^8WE
MO38&Z]J;DV=@=C[NV#F<U1[TV08=OYRHQF*W')!5P8[.Y>HR-56B&F5-#PQ4
MZ%RP8G@CWB6)TBC6<F0.25K7-*8(Q@#[>AKRE9W-L9I9X&"-$H5C@,`:\.(.
M?/H\O6I!ZYV`5(*G96U2""""#@J"Q!'!!'LAZ&W2U]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MK?G\^_=>Z][]U[KWOW7NN+$A20+FWTM>_P#L/?NO=<A]![]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NNC]#_K'_>O?NO=0/?NO=?_1W^/?NO=>
M]^Z]UU87O87_`*V%_P#;^_=>Z[]^Z]U[W[KW7O?NO=<6!.FQM9@3R1<#ZCCW
M[KW794'Z@'_7`/OW7NN[6X'`]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]UZPO>W/TO^;?TO[]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>ZZ(!^H!_U_?NO==^_=>Z][]U[KWOW7NO>_=>ZZ
MTB]["_TO87_V_P!??NO==%5/)521^2`?S?\`WOW[KW6(TM,U]5/`=1U->&,W
M;^INO)]^].M4!%",=>2FIHV#QT\",M]+)%&K"XL;%5!%QQ[T``20,GJQ)/$]
M9_>^M==$`BQ`(_H1<?[;W[KW7BH/U`/^N![\17!X=>^7EUP,,1^L49_UT7_B
MGO6E1P`Z]4^O7$4\`^D$(O\`6T:?]&_X^_4'IUXYX]>-/3GZP0G_`%XD_P"C
M??B`>(Z]UTU+2M^JF@;_`(-#&?\`>U][Z]UADQN.E1HY:"BD1Q9TDI8'1P#<
M!E:,AA?^OOW6ZG`KCJ+_`'>P!N#@\00;7_W&T7-OI?\`9YM[]Y4\NO5(I0\.
MO';V`)).#Q!)^I.-HB3^>3X>??OEY=>J?7KK^[NW]1;^!8?41I+?PRBU%;@V
M)\%[7'O5`.`ZU7KK^[FWAP,#AK!BX_W%T/#-?4W^8_4=1N?KS[]0<*8Z]U$?
M9VT)&+OM7;;N227?!XQF)/U)8TI))]^H,8Z]Y$>77O[F[/X/]U-MW4ZE/\"Q
M?#$:21_DO!MQ_K>_4'&F>O5/"N.H\VPMC5-ON-E[3GL21YMNX>6Q/U(UT;6)
M][\J>76PQ%"":CK@.OM@B]MD;0%_K;;6%%^+<VHN>![U0`4`QUHYR<GJ')U;
MUE-(TLW76Q)96`5I9-H[?>1E!)"L[8\L0"QXO^?>Z#KP`%:=+B**.&..&&-(
MH8D6.**)%CCCC0!42-$`5$518`"P'OW7NN?OW7NO>_=>ZX.K,!I-N>>2/]Z]
M^Z]US'T'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NN()U$6X`%C8_7_7^GOW7NN7
MOW7NO>_=>ZZ)`^I`_P!<V]^Z]UW[]U[KWOW7NO>_=>ZZ/T/^L?\`>O?NO=0/
M?NO=?__2W^/?NO=$H^1O\P7XQ?%/>V*Z][GW=FL#NC,[<I]UT-'C=I9_/0-A
M*K(U^*@J):S%4=130R/68R8>-F#A5!M8CW[K0-21YCH!7_G+_`?TJ>S-SJSZ
MB%7KG>1)4<%KC%%=-^/K]??NO$T\CUX_SFO@,J%SV7NBRLJ'_C&V];ZFM;@X
M@7Y(!_H3[]UOK&O\Z'X`$`MV=NB,'@%NL]]&[ZPGC`CPKDOS?C\>_=>ZDP?S
ME_@%.\B?Z4]QPB/ZR3=9[_"GU:0`L>`DE!/]"H//OW7NG!/YQ'P`D1G7N+*!
M5-F+=;=C+I-@;$-M<$?7W[KW7,?SA/@$UF'<F2T_2QZX[$'UMZN=L@@<^_=;
M((X]<U_G`_R_I76+_395Q,7926Z[['LFFQ+.5VJWIL?Q<\>_=:ZR4W\X'^7I
M/=4[[*Z5!)DZY[2`Y>2.UUV6P#`QW(/(!'^P]U[J2G\WK^7K(66/OZ.0J`6$
M?77:C64_VC;9-@H_)/`]^ZV`2:#K,/YN/\O9U8_[,-01A#ZV?8W9::%']M@V
MS;B,_P"J/'NP0MPZJ_Z9`8'K)3?S;?Y>TZ73Y%8D`6MY=F=D1EKZB`H;9X))
M4:O\5Y^GOS(RBIZ\#7J:G\U_^7[(RJGR)PI+&P_WZ/8@4?XLYV@%51_4FWNO
M6^IZ?S3_`(!,)2WR1VI"8?UI48/>T$EK?J2.7;"R.M^+@$7X]["EN'6B:=1X
MOYK/\O\`F(5/D=MH,S.JK)M[?,1;0NMBIEVNBLMN`;V)X^OOU#J*^?3<DRQ+
MJ8&GR%>I'_#J/\O\N$'R5V@?K=QB-YF)2`#I:3^[6@,;_2]^#_3W8QL`21@=
M6\1:J/7K)+_-,^`,!`F^2NSHRWZ%;$;S#27-AXQ_=F[W_P`/Q[IU8&O7C_-,
M^`"C4?DQLL#26YQN[P0%`+7!VW<6O]/K[W3%>KA2>'69/YHGP%D*A/DOLDLR
M"0#[#=@)CX]=CMT>D7Y/X]ZZKUQ?^:/\`HSI?Y-;&#%_&`*+=;DOS<63;S'B
MW/\`3\_7W[KW4EOYGOP)17=_DQL-5C36Y-/N466]KV_@.H\_T'OW7NNQ_,[^
M!)0./DSL+2;6/AW)?D`BX_@5P"#]3^>/J#[]U[K+%_,V^!4R:T^3O7(6X7]R
M3-0L&/T4I-B$<.?Z$7]^Z]US'\S/X%FX_P!F?ZU&DA3>KR@`)M8$G%@7Y]^Z
M]UG7^95\$6+*OR=ZSNMM5Z[(@`D`@:CC0I-C[]UO2:5ICKE_PY/\$KZ?]F>Z
MP!N%`.2K5N6X`6]`-1/^%_?NM==Q_P`R/X*'R`?*'JYS&+O?+5(\8!"G5>B%
MN2/?NO=<_P#AR/X*`D'Y/=6C2"S7R]2`J@`DL31``68?7^OOW7NN2?S(/@K(
MH=/E!U45-[-_&Y0#IX)%Z07`)^OT]^Z]UDC_`)B_P<;45^3W5C``L;YQP%`-
MOJ:4#ZGW[KW64?S%?@X03_LS_4P`U7ON)5_3^K]4(-A[]U[KS?S%/@[HN/E!
MU&+KJ4G<L0%CIL1^U^=0_P!O[]U[KE)_,3^#L"EIOE#U$@%P2VYX/J+:K#QW
M-K\_T]^ZV`3PZRQ_S#?A!,NN/Y0=0LER-7]ZJ4+<$@BY4"X(M_K^_=>(IQZD
MG^8%\)U4,_R?Z;C5DU@R;SQD8*<>H>21;CU#W[K76;_9^OA7I5O]F?Z7L[:$
M_P!_QA[LUKV"^?4>#_3W[KW4AOGC\,5TAOD[TL"_Z1_?S!7/-KV^ZN!?W[KW
M69?G1\-W61Q\FNEM,1TR%M_8!=!_HVJL!'O>DTK3'6JCUZ['SD^'5]0^3O2A
M4ZK7[!VYIXO>Q^^M^/>NM]9D^</P\D*JGR:Z3=F"E0O8FVB2'OI('W][&WOW
M7NN2_-WX>L2!\F^C]0OZ6[(VLK&P!-E;)`FP/X]^Z]U)B^:?Q&G_`,U\E>DF
M]6CGLC:RC5I+:;MDE%[#W[KW4G_9Q_B:0#_LR72-BQ4?\9,VCR1:X'^Y7\:A
M[]U[KD_S$^*$9L_R2Z/3C5Z^SMGKQJ"WYRX_M$#_`%S[]UHD#'7-?F#\4G_3
M\D>CSRH_YFALWZM^D#_<QSJ_'OW6^&3U)B^6GQ<FOXOD5TE)9E0Z>S]FFSN=
M*I_Q>+ZF;@#^OOWSZW3%?+J0/E5\9&;0/D+TKK)L$/9VS0Y/]`IS())]^ZUU
MD3Y2_&=P&3Y!]*L&(4'_`$G[+Y)M8"^:^IO[]UNA].L@^4'QL/\`W,!TO]2.
M>SMECD?4`G-"Y%O?NM=<U^3GQN<Z4[_Z78\FP[/V4>!]3_Q>OQ[]U[K*/DK\
M=&L1WYTO9K6/^E'9`!OP!<YP<D^_=:J*TZSK\C/CXY4)WMTVY8A5"=G;)8DD
M@``+FR226'^W'OW6^/4O_3YT9>W^F;J@$WL/](VS;FWUL/XU^/?NM@$\!U[_
M`$^]%'Z=T=3'FQMV/LW@_P!#_N:^OOW6NI$/>/2M0VB#M_JZ9K:M,78&TI&T
M_2]DR[&W^/OW7NI7^F3J'_GZG6]KV)_OSMBP)-@#_N4^I/'OW7NN/^F#J=I!
MI[3ZY*C@@;WVR?\``\#)G\^_=>ZSIVYU7+_FNR^OY3>UH]Z;:<W^EO3E"+\^
M_4Z\<<>L_P#I3ZS(1AV)L5A(2J6W?MWUD"Y"G^)68@"_%^/>Z$\%)'6B0OQ$
M`=9#V=UN!<]@;(`_QW9@!_O>0]ZZWQR.'72=G];2*'C[!V1(A^DB;LV^R&W!
MLPR)O8CWXXZU4>1ZY?Z3.N;%O[_;*T@V+?WKP.D?ZY_B%O?NMU`XGKDO9/7C
M,B+OO9C/(XCC1=TX$L\A^B(HR%V<_P!!S[]UZH]1U/&]-H'D;JVV?];.XH_[
MU5_GW[KW7-=W[4<V3<VWW-_HF;Q;6_V`JR??NO=9DW1MR0H$SV%;R,5CTY;'
M-K9>6"::DEBOY`Y'OQP0#Y]>ZD?QS#&ULMC#?^F0H_\`K][]U[KO^-8@_3)X
MYO\`6KZ,_P#7?W[KW7+^,8G_`)V>//Y_X'4O_7[W[KW79R^*'UR5`/\`7K:7
M_K][]U[KPR^+-[9&A('U(K:4C_6XF_'OW7NN7\5QA%QD*$_7Z5E-^/K_`+MM
MQ[]U[K(M?1/^FKI6']140$?[Q(??NO=<A5TK&RU$#'_:9HC_`-%^_=>Z[:HC
M`!$D1!_)EC`_V!U<^_=>Z]YH)5MY(F/YTR1M9K<_1_J+^_=>ZR*ZZ5`.H6`!
M!!_P_!^OOW7NN8-_P1_KCW[KW7?OW7NNC]#_`*Q_WKW[KW4#W[KW7__3W^/?
MNO=:A'\^H@_,?KXE=2Q?'_;S2JY(0HV^=[7"!"6,@4$\BWOW50M"3Y]4E5,L
MD+)*D,$PIY9+PQD!E62)WU*K^J1%>YM<$C_'WXC%<UZ>4`CAGKB*R14,8BB"
MQLDD:3'2L<DNE2UU)4$OR`WUL/>_*O6R@S0YZZJ2I(":(528,S,2#*EI%8#D
M%6)%[@V]^H.M"/L#5X]=S2SB.72R#QTZ:%DUQQ']9BD$RW,A!'(//(N?>FPA
M;SZ]H'KUPBF9@2\XDF8*S!02P])#LUB0@&O_`!"V%O?A4@5].GAP`H.'6-YJ
MA+AI/,LTJ%UDJ"=,22*MP5LRN@YY/-K>]T]!U0J",^O74M2K"\I\(03JS1R2
M-%^Y^F)64M:26,V-[?7GW['Y=4T#Y]8Z>>%!9`S1-++P9!'(S?1]$BJ+*5?2
M5M:X_P`/?L9^WKS(`$H>/6&.H==;Q^:G\J3!E?3&7A5A:-Y$`UK?@>GGWL#S
MZWI"GB>I$-4$0!U#&.1AK<Z9)D=;*BI8LS(&.DG\^_''#K3FIKUFD\+-K?6]
M.41M8C*()T\K`$QE5O&EK&Y/XMS[HRE@,]>5:BM<]=_<(D9<2U4@E=H8R@,4
MJQ\DLZ@LK1ZOIJY_/O?3?4:MJY)6$Q=%9ETCU\-Y&T3>5D.N7Z`\`:?Z^]CT
MZN@K7K)#4QQ,8YBH$0TB/427D6XU`FSZ&D'XN>.??B=0IUI@-7#KTE9%'$Q,
M81U&N-8RI9F-F!ANHN@+C7=3Q;Z^_8-*]:H"14=28ZM:B,'3YFT&R,-`IW5=
M;E@6"@#R\6X!][(X'IPJ"!U"KJJ)HDB$@3QJA-0"DB,S`JD08'4&06/TM<>_
M#@>M@`4^WJ,TY#0:%+%!84QT1,8V56D:13^"GJ`O8?T]^IUHH,DGIP66%4`*
M"5+75HV$1C8B5KLQ]&F0VNP(^ONO376%9*.=9(F:5OV1&[RZP5D4C3XX2;/I
M-^%/(L??NO=9&J&@B@E+O)$C:XT8/XHHU=?'()``"9`3Z0"$!X]MF2C::=6"
M^O"G4J*JC"QEBCQS,^@(S:O,OK=I+WU&+R#20!_3W=C05ZTHJ>LT<R0T\JZW
M?E5=$4N)1K*ZK(C%VD`/XY)_I[U&==>K:<GTZC2U3T\FGQE(F0L#/8&33<%M
M`*N65"/H+@CW<8\SU>A`(K@=2?1H-3*-3@<+%*)+6-@VGU^DK:WT:_\`7WKI
MGK@7C=%#1PP_M@*R<WU/$$.A1K-K<@\W]^H3U90#7J)65=.6:H2)2Y"I*RK(
M\5TA%PFE-!+L_((/(_P]^X\.K:0//J-]Q&H*!HFF6-9?%ZRJTK-J>(%5/C:]
MN2+\>]TIQZ]H'SZC15S%9%C\L#2U"@R,C^,^1;EM)+"Y!L2`.?Q[T<<.O:!Z
M]1YY:<P@:$#S1EC)&2SR6NB1*I/-T.OZ7X/OQQUO0*C/7J.KUK]O)"AB#+&O
MJ(<D-_G2775J7ZZ018^]OVE:<#TUYGK/4NHECC.B5T$T\1TN&B*$NR!]'C;4
MW'!_PM[VHK7J\9HW7.CJ'@BDCT)$BS23D."/''("2$1DX"_B_P!?K?W13J+8
M\^KE=52/+KE+)!)'%$(6J@5DN-.K3$R(R^,J+%7>W'X(//O?3/6>"=/#%)(@
M\[.=<;1IZ!$#&P*Z=2@WLI'X!]^Z]UU454<40_R>`,OC0#Q698F'J-]*LQ\A
M-KV*'ZCZ>_=710P))ZA_=*14:[(SK`?W(B)%E<+HT26/D]#W(-@?;@DH*4%.
MJ%`&-/7K%][($#R#QPRHY]$6@`*Q0.MP`05!-_J#_7VV<$=.,FD5KT[4QIG9
MWA4>I5$3ED-P2)(B`WCMI6X)O]1[V!4]:50:D^77#QP$J\T">.*Z:CXY?%J%
MQ+?02A\=S>_/T]ZZJP`)`X=3PK.M-)'Y$!?Q*C*JB8@E5+*4)UMI#6N`H%[_
M`(]^ZUU+IJF(?N-`(W:63RNWJD#J5Y4>-=3M8DM]+'WL=650:U..N#2T[A%F
M8R"8D2)$L<M@LC@,J>)]#H_Y/OQQ3K9HIH!7J)%*:.29C:1?1K9@A$DINBM8
M)^WJ0CZ`V/O=.O%`<`\>NU>G<&I:GC6=EG58U.CPE(OIP@O=#Q>YN;GWXB@%
M.ML-*!?*O3:7/E5S$AO(XT.L3I$.$:W[?D+OXM0)N.3[T!YGAUI5U"O4B.2E
M1IXF2`A4\<>F(,ZS&Q+-(+!/&5(NPO\`['WZE<CJ^`M#UAJGI]-O"LQA(4(D
M2WD/%R'(*KJD;4P4$\6][TT''JH13P.>L\/V]-HD:&)/*WD`$:(%`9BFI6BT
MV;_7M<>]4Q\^MZ!ZXZY>&.<@SZ)BC&3R6C2!"7T%2QCT`B+U?CD>]4%`:GK8
M`X4ZS(T+S?;E(Q+'%Y6>**(QZ5]46B70.9>/I8W-N;>_?;7JNCJ0AIFUL4B#
M2,T4EX4+"2Y=W!(]"V.FX^OOPR?EU9>T$#SZ[CIJ3R+%((-)UABD$;J[L&_4
MZCTK8?FQ_P`??NFFXGJ$P@626ID`FLS%_)$%&A5LJB,%AH1R&`XN1?W[K761
MXZ>GETLM(QGF22"+1!(Q>1%DTW:,`!3<@`'D_7W[KW62F\4AD3[6)&3R:R$0
MR*78:6"H@)A!M<W)'^W]^Z]UDHHJ3[E7C4J=)$B%%*ZP5#!6T<,)'-@;^_#/
MGU=U!%:^77(Q:))^&B8R$Q*MM*!$8ZR%'I<E-)^EQ[LKR)70Y%>/SZ;95;#J
M&3T\CU@@U%!#-.JO)(6D8R<&Q(D(#W8:`?2/K?Z_3W7K>."BB^0].NQ4*C-&
M)-"1QZ58C1-*TDFM2R`LCJZD\VO8CVV6)8#Y].*J!?AR>LD-6@80P:8D)D8>
M21F)FLA;3%K*OXXEY//]?;M,$]:,:M@BHZRP(BM)*_K,(-B&C#,TGT$=SKU>
MD6N?\?>M-:4'7O"1<!1UBER<]+H5JNK62*IB4FGFJ&\2/=!'82@67Z,+_7D>
M_'%*<.O:%`QPZQ'+U91W7)U,<@9+#^)5#L6)(>SB5S;38V(`'OU*\.J@5-.L
M=3E\E&\S+EZIY&;S+>KJ4NL=@7C,14+J+>JPMQ]3[LQ+,A/Q+U9J`:?7K"FX
M<J6#/F\D3,$6/1E*[ZA"8BTC261+I:UK7Y/O1-<];6/M!ZC_`-Y<K'(ZIF,K
M:55D<Q9>K<W!`T"4RHKAFOJ_(]^(`'SZT5`%>I$V[=QV+/FLCXP9"T:Y.N"B
M*/3H:-#/KB=M5@..1P#[\!QKUI5U$CJ-3;KS<YEUY_,1S*"-+Y?(Z&IM;ZCX
MWK--P;<BYN!]/>R,$]6*"M/+J33[MSR,[4V9SDQ4ZGC.8KJ=8?192-%9>5E]
MZIGKV@>N>I@W?N:G5F?=6?4R!8[1YW(I9U<R!XGCJAJT-);C\6_I[\1PIU5E
MIUZ+>F[TEC>'=NY(5\Y=Q_>7-M^FS^,#[M/."(_Q<DF]O>O.G7E6HKURB["W
MQ/5^:'>.[:,LZ%#_`'CSJ.D<FK4RNE<HTKILH/\`4_X>_=5\R.G6H[&WQ31&
M1M\;S\TLFA8O[TYXEH`SAGETY!B01>XMR?I[]U914]8V[)WO=8%WWO(Q*`R&
M+=.>91(9&*ZPF0705M]+C4"?Q[]U?PQFAZS1=J=@)42!.P-Z0!!?]C=^Y`-:
M6"L&3)"2Y<@KP0!Q^/?L9ZUH_;T(W6?9/8[[ZV)%4=C]@U--4[TVM3FE_OON
M9ED%5N"@CG41/EF_;(=B5L0WTL1Q[JQTBM.FQGKZ)`_I_3WL&I(].O=>/T/^
ML?\`>O>^O=0/?NO=?__4W^/?NO=:=O\`/WJQ!\TNO8W(*/T%M8/Z2Y53OG?(
M(6WZ"S'CBY/T]^Z]U2,THF9_#>6`I(7C$T8\;:'>0:V4.TIL."2!<C_#WNM.
MMU(X=1Q41ZU4Z],@C1V/ZPX5/2P!)<*1^!^?>QF@)S7IV@I^74IJQ71U(.O7
MY%9A($TQQZ';]Q.416_XU[K2DA`/6U^?`>77FGCGHY(-14QF*5D8$(J%6O:6
M-=+I86`X!U<^VI"P-!6AZUBM3U'UTZ&I:F:/1(ZEP+%2^D!XM(&NT;&W%PU@
M;_GVY4Z,#RZW4L*`^77%:O2@FC,4D;+I9%5AZPWI(4D%`+WY!!(]T0O7)Q3K
M0!'$XZPK52-Y":J$VF;SI&$D,<RA2-9(!BUCD_4?TY]NBM!3JK%L9ZE":G\<
M47E":7E*M=GLRK?U`\#7J!N+:K_Z_MDEM1H,5ZVW",^=.L=%53:=4RQ@AI=9
M8ZR$>,.A15+B-DE`*\&X^OMX^G6WJ!UZ.5#.QM%,B*@60N>7TWD<Q_JD(MJ^
MND`6M?WKIHDGB>LL<\,D1=VD:*!V16O(&(/)=E:P<R!2.>%''OW7JGUZCT\Z
M.:?TLX8MI?6H98X?2!XRIC#,['B_U_/OU*]:H>IT<J3@>9O$Q$L0=T5&;Z!B
M73TMPH%^`??A4'CUNC)^+KJH3[=:PD1.Z+"89@[ET"2('#`:K(T;'\&_OPH.
MKK2@8Y/40RU%5(H@$(F"#0ZQ`Z%%F!L2"/(O)_UN?I[]U4&C5IBO69VTD1SR
M1NKA)V9"MF\@1?$@!-S)IM:XM[LQ\NK,2,@]-SF*/2!Y)`L0.IV6.6.?U,(Y
M-2AT0\!0"?KR3[U48)ZVF14GK))(C302)Y"TCM%%(0MD1;*Z.S,#$I<FY-N/
M?B3QZN<+@XZR4-49R83*'4NT4GA]0%DD62RNEE);2!R/KP??J8Z:8"F!UGAD
MTJ[`GQPRR!879B47U"Y90ZDZ_P"I-OQ[UU3J/335$\MI5,8T":5/(42$R?YI
M`"R\1HI])O93[UI`[BHKT\*4'KU.$L'BO))&T$;EE.H,FM=2L"8E8@..1SR1
MS[M2M00".O44''4@5<4$,QITE0R^*.%2RR`2126DYL>!JTG])-OI^?>@NGAU
M5SGM..FZ>K6:J7Q:P4.EM89_6.;N&#Z4T64G@-S_`$]VR>K+72#UFAFF@@<&
MI@18BR+JD,CS`>,Q6$;"-;>0'\DV^GNM.!!ZJP4#'6$531LGFE$<KQ.MO6B+
M/XR1(#>QL2+&W)'//OU*^76XZ=WKUPGF++(BSH-(AD+#4Z7],;*45O0S+?DK
M_K>]U'X>'56)!ZA1.(7>TD2*ZF+7+(ZL=:NT8C4BVFY!8_BWOPR17KRDEA4X
MZQR5+4D2L!J=F\8E9@Z>0(`[A25B-XWN/Z>_?(]7]>LS3P,@G5"'="0XD"LC
M(JJTX5/+XP6/''/^M[WY"G6Z4'''4F*:,)'H=FG=M=4VM%&HN@\C6_S9"@BQ
M^O/T]U.2*\1TR>)ZCR5`CGJ8:>LEG$$S>A2L@1#Z"4C?4FE@">#8'WL$CAUX
M5&1U(IZI55N/W&1Y=4^EF*,@U!XU9N54\G\$@$>ZT]!U<$D5)ZQ15%2)8Y(G
M2*PLTI4H"UQ$)!2HVD^/Z@6Y][ZH>)ZG"5II6DFD;69&75R(AJTC6MV9V>33
M^FP`)Y]^ZUUC:/4*J=)Y##H1(([*]S*X?R1DZ[(=!U*W(_P^OOW6P2.!Z@5I
M=]<*O)'ZXHV?4@C57LP*.2&+QN@N/R#_`(>W5T:0:"O6B23QZDJ:66)8/,7,
M+LNJ5O(AL+.Y4N`$%](``:YO[:ZV23Q/7<;112(E,-+PNCKXGC4%A'(RIK9O
M)J*D@W&D@V][%?(]7CQ4^?4K7J$6NH]+%'9&4$.X(8"P1KA&!!N;`>]<.JN"
M&(/'KF*BI10L,L)<2PM(7U*I16NTEO3^G3Z;<$^_=:H?3J5)61/,)99="0%I
MV\+`R^5O2/42=8=3>P%A<>]T\CPZLE:\.NWGF,JF*3S,$G60Q*(P[2%2@!!U
MBX%V``%Q[U^76FK4XZX3U$:Q7&L.$$+HK:G:54)1-(N56X/JY/OU/7CU<D:<
M<>H<]3*XCE:ZLC*JP2J%*ET0S74D%3"I`N+WO_C[]TV2?/J)1UGHJ(Q4&;QR
ML6,4;LB/IN8W4J2&&O3Q]/\`8^_=>J:4!QUA%1+++,OF9V9O44&AE=PLBFRD
ML0A/JXX-Q[W08'G3IZM0*]9VJ*N)YF41EED4O*[HP"`.&:#2>'C+@>H_4"_O
M8SY\.M5'4FGJ4+OJ8)9O3#,"'5@A9I$56LP5P;#B_O1XUIGJC$BF>I"5RS^:
MGNS?O@SZ6#74%0Q$2^IE"N;V_3P.??L\3U9:&E3UZ&N0U"A9/!+$TD,<#.J"
M:`:C'JX!3T@?4@W^GO9X<>MLU`=)H>O5%7-#Z!/K64L)'U`^*8LFB,AR"ZG4
M"223Q>WO6?+JJ&M:]1ER50'>!IFC:Q#ZE]<DJ*Y$-H]7D60#@^FQ/OQX5IGJ
MQ45-1GJ0*R4J\CNY#>%A9H=0$:V\;$,AN[+:P!8CW[[>MA5%:CK**O2\E5JN
MRLD4*O&NN!K`2GQD-?T&X'UN>/?J@C`ZHZ@`$==3U1JO*\<AA<E8E0QL&*QO
M;4X8#A+7(-K_`./OW$4''KRA2N>/77F=)M&H()DTO4<E8WE74244DZ04O<6M
M]/S[T,=5!)(!..LSU(*R`53F<6"03*`)0(F9-"@V=C]0;\K;W[K;@<1U@DFD
M6HIXHQ)%"ICF=O3860#3I90&UDV))_PO[]U3K!/5&G!J&0"19PGU\@0^10FM
M6N"(PR_7BQ'%O?B@JIIGI\`:1CJ0&J$4.T85)2IAEUI)'&DA)>,D`,0"0.;V
MO[V>M/49&#UX5\DR2(H84VBTB:5\+,RLFK60LCO&P%K6M>WOP^WK2FO$YKU'
MF8?YF6:=G#$M#H"\@(%D9V'"1.+?2Y_/O75"6J<XZ@Q2I&LQ$7H2""1W&DKY
MAID>%75!Y&EC%C?@6/OW6TIJSZ=>6>H80N$6%6"1H[7#%9"CQQ@*&)NH)`.D
M6^OO=#Y]7(#9/6&6:2+]N-_UL0/0L<=^2ZH7)"EN";6L#8>_`$<>M@@<.H#U
MC,\(IY?$R"SN\<;:5D8$72UG"R6T$@\'W[)KY'JIIY\.LL59*LDP:>.1!Z)%
ME!TB6,D-<J;,'9EM^%`Y]^I\^O!3@H:'SZBPNZQSRO(4(8AM1,A,<QU$(RZO
M'&7O8GZCW;@N3UON%`3GKQ6H\:RK*P\#3>=8X=7,@M#JD74UCIL18D>Z5!-3
MUNG$#K)35E3*1]SXWMJ"Q%1$8(9'4,)9`"6D=@&%AR/Z>['AU5\@9Z<I,A,D
M8=%\\K*RHDK`)Y(=:JY41J]XSP+?4CGW7IL%@*`]1X\A-$BL4C?0Y;QPLJDD
M)(-,FN,78.1Z;^FY(]VIC/5R%`X9ZY4M095,^I(6,H8_<21>E(UTN+BQ'J(4
M"UR>?I[KUI.)KZ=3*>-5>29/$HE`\FA;(69%N+_I;2WZ?KR3[HY<&H/EU<T]
M?+K.A)JCKJX$E*ZB[Q^,JB!S$&"75G<7&D<>W%X+7B1UL-Y^?0F]23-_I*ZW
M\DLMG[!VDC%H08E;^\^-4/J10^EA_06]Z90>(Q7JC"@P.OI#>]4`Z;ZZ/T/^
ML?\`>O>^O=0/?NO=?__5W^/?NO=:;/\`/\B9_FOLF0S%$7X_[16)5747E&]M
M[R79>-03@V_V'OW7NJ07C>*F\<<I9G-BCJ%#E@X,NE?K(?)IY^GOU.K!6-"!
MCKE$DL86,F-=!6S*&90D9M-']"H#2@'Z_0\>_=5ZE2%FIM8/BE#LH7F14"\6
M4'21J>U[$$#WL5%:=63CU@;6T+!&$$<4:&.S%F8,ZZU$9C-U9A]"38^_9.?+
MI[U^SJ.ZRQN^J0NLLH+M)9B$OI#H!PBL"+$\FW'OPJ3TV$:M:8KU#-1*Z)KB
MF>/R>..2Z*\6N1HXB/2RZ5*\WN/Z^]T`KD]6)QGAUF551&`=0S<2.Q1BS7!+
MC0?W;D77@7O[\,5].O"C<.LL=-,JQI&X<0LRQ^16C+J9@&=B1?TL2#^1[UBN
M.'31PW72FHE<(GJT3)>(OXW]>IRJ-IO+H#D7X`'O9\ATXU6'7":$K/$$\;2Q
MSA7\4JL8UT#R$*=)'Y%OS_L?=>FR"*5ZDU(G94ALL8;QE(`;*R%B&U6U>K4#
MP;GW[K76*"F=)95=A&8I]3(K/IFBD`!D9$4KIC*W_`O?W;RZ?;((!/68OH6:
M,@22@.ZOK:/REOT,RV8$>H"P/T]ZH>F=)].LT*RU22BH9/((D9_&6$?ZR`R\
M`LY`L2.!8^]=>(H:'J%(\T=0:<OY%T1HH5OW";,P`)]0O<V7\\GW[K77"MC=
MTBBDU1-3E=&F)%$L2A'02Z%=G<,UA;\`_GW[K8!/#J-,6*B0!29!%J7ZNLDA
M,;!"/4I#+J8<E;B_O8R.&.G44X^WK+.C.L*!;G1*782$LC*%13K`;0UVOZKV
MM^/?J>?5&4@GJ/'!5"*!7,BA1I?1J0NL4FIFN"&+2@@ZOI;\^_"GGUI2`<].
M2@F/5$S-'(@*B1I1(-+$.EKN+/Q]+GGWK\^O,0>LL-/(]2LU-,PNX!74K)<0
ML)%7C06N/SP3_C[L#P'5M0H!Y]=/&T"M'%Y)99"C%IW#K%,RMK30+`<+<`#3
MS[KYTZKH;TZYK23^6-R;KJCDBTM925!T^5250ZP[<-<>_=:((X]9)*66\LQD
M/FG10.?JZ.UT!C!"OI:QOP![]J(P#U;Q$"T/'KTL$<4:ZY_/(J$36`5%?4+R
M-<("&8@$W)(XM[]QZ;!#8''KDLTBH(6]3>-#:1$+)`A0M(JHI(UNI"VOP.1:
M_OP/5P-)!/#IL,G^4S21Z(U?AVTA60$G4K,1;RH0!QP+FWOW6Y&U-4'J`LT4
MX1G+IXY&0:O0$0R!5*\D%F+V_I;WL<1UX*P(/7(P1LND54Q:($D,1H`.DHRI
M9BSVX^G^OQ[\:4ZLV0!YUZXE&)2%9O/3B6TKK"J3D!;E#J1`X$EK`>]C&/Q=
M>44'74CQU#&%-42:?&;'U2:78L7`"Q^2][6_V/-O>LG)ZKD,&/EU@#-998]"
MZW165RH=!=G5#8FY>.,C_6]ZJ3QZ\S`C'KTY**D.D$T",DIU1E;E8Z=G<EY.
M!9B/4?P#R??NM!217K!3K5#Q3R.LJ3.5BAU>2-@JAE%E`>.1N#];`CW[JO4T
MNX>/ROXO%+K(U>J)1_M+`ZRS+8@'\@^_=>ZYO4B-)%5B$,HD1'(>6%P`L;&-
M=2&.X_-[V]^Z]UY@U2PFC\WHC"@1Z0&+FTA/`4V*V''`O_7W[KW4.JGJH)51
M3<RIKNR"("8>GU%"4-BXN/\`BGOW7J5ZRTI?2P(=I)"EXP%\996OJ2346\9C
M6Y/X_/NPP:GIU01Q''K/44E6%A((%+%Y+4Z.BBG'H:[@LI<MJN"3R/=>J-EC
MUVL-5Y0Y,CZQ'HUJVN.-G8G_`'8=-G4V'`YX]V!"D'@>G0:5SUQGBE,D;D*D
M44I<2J=(#\F,?6Y0E6'JO:_^M[V[5(`SUX\3CKN"2JCBE5!(9U;U:@#'+3RH
MTJR+)P$+2)8FU[<?7WJA(^?7O0CAUFIY995#PZA/%&(]<[`"5I"6>50K!F6.
M,\$>H$>ZT\NFE^,5]>N$LE;#+$TDRU:NSZ'*ZI(U4QF[J')4,H_.JY`/'O?R
MITXP)``]>HXEB,;G7;Q&8N$&A#Y9%\>HM_G)!I+?7GWNF,]:04-#UBGJ&D"K
M3.J05#:C^TQ9$!"F^B]W+`#ZK;C\>]4XU'5C0U%*'K*U3,T*J)#$Y,R"06$?
MDD)$C6L67Q.1:]]5_KQ[]0\>FBI7CU%#RCR$,DY]$#.-'E20O^V=1*DAE(+$
M#@#\GWKJO62EBF@622FB,FNZF5F$'[D@0:6=F`D0LH)'-K>_=>Z<X&G\R^:*
MF$B`S$#25E"6/CUW+(+"VK^H]^Z\!7`ZS*LKR(Z`F'7(CLH=+JVD(5++82("
M55[^]\/MZ<4A:ZNN*LL;OH:SGU78&13*/U,##ZQ=!^/J;_3GW[TKU?RU>9ZQ
M!7GB8)%K)9@T:(=(4/\`YS7]550@_J>?Z^_!0>!SUK`I7AT)76W5':_<.8EP
MO576>^.P\S2I#+58_9.V<CN&MHJ:0>BMK/L:>=*.&0KI5YG4.00"2#;1JI1&
M\S0>GYGRZ;=EI4<!QZ,A2?RZ/G;523%/B5W3'4)2LPEFVY34A9=1(59J_*0(
M9G#<JK%B?QQ[W3+"HP?]5/7JE?D>@LZI^+7R4[XIMR9?IGIOL'L;%[.ST^T=
MPU>UL705-+B-U4M/'5U.(K9*BK@)J8::=2^G4`'7FY'O76WK&:,#7Y9Z$+-_
MR_?G%B*.3(Y'XK=YP45$#45DU+LRJR+%$74\@IL3-65>A`;#0A;T_3WL@@*:
MC/\`JSZ=:_A^8K_Q?H?ET`G7_4?:_;.\Z[K[K7KG>&^>P<9%DYLGLW;N$K9]
MPT$>":G@RW\0PE4M'5T4F+JJR%9XY0DD1E4,.1[UUOH<1\"?FR&*5'Q([\B=
M&EU/)UUF9(E5&]-VC$R%W,>H,"PTV'-_?B2<#AT[K6@'0";QZVWYL3=U+U[O
M_9NZ-C;TF:!L?M/=^$R&WL_4Q5M2M!255)092GHIZB"?)2+")D!A9V"%K\>]
MBE*4Z\&7UZ,B/Y>'SQ@AE#_$[N=HS&Q8+M-I9"RG7(1XJDN2>;6!+$V`/NIQ
MY=-NV:](_,_"7YC;3PV5W-NCXR=VX?`;;HLCG<[FLKL7,4N*PV$Q-++6Y+)U
MU=*!'3TE+21/)*Y]"1J2?I[M7]E.G`RZ0*^76"@V!L>H^$/8?<0H/-V+@ODO
MUAUQ09MJZO6CI]F;FZYWGN#*8J'%K4?PF66LR6+AE$[Q/*I32&`8@U/#IEA4
M4Z*36U4OA#^9J?7(A+GT1^DQZ6:\=UUH2!P!Q^./>_/JY)(%`2*>G41IA,[Q
M-JDA55^W!U:97*^E(V:Q=E/]>"#]/?NJC/EUS*21>L+$[K<0V0Z%LI9BR!3=
M3_J?J#]+>_-1>/[>G6%10<>L3&5G9H6!OKU(600D1*?H]KKH?_57/U!//O0:
MO`]5`T\>L35,J^18X=9U1M))K5TU.E@\2Q:A<'ZGZ6_V/O;=RC^+K1HST`X]
M3_-+"KQL\LCSA$.D`H-.H$HX(NJNWU//)O[W0T'3Q)!R<]-M9)(9QH73HDU&
MY#RF2*^H65W55(7EC;WJH].FWII'K7J:LM3]H4)TS.2[6]#):1BBL^HG4-18
MCWORK3K:$:?GUZG>6*-6('HTRN\KG1(SQ,YUD`A%:QL>`/\`7]VK6@'$]:+X
M()ZQTM1YM'A6+Q)9EMI>-Y&=KL)8D7RB71<D_P"L?=7K'\1IU5"*]/-%454(
MEO"&5!*I"FPF.J,6!0JQ<*#8`&XO[J&J*UZVP)..O3M5!ZL-)"NB(&%&1CKE
M=6\8%QY`K!KWO>_O?51AA7UZ%#IJ6J;LKKN&72FKL'9A8`!K:-SXQ]08L"A(
MO>P^GO9HHR0!TX^06'KU])SW6H/`]-=='Z'_`%C_`+U[WU[J![]U[K__UM_C
MW[KW6FY_/S<GYO;,B(9@>@=GB-8U]8=MY[X!*L`66UN>0+>_=>ZI)<-Y!"(E
M#:BP4:&*(5)1VU#7I:0D<_BQ]^J0>KAR%T]1*@S13:G<!%D",`Y,<MKW+HER
MR_A?S]/>^/#KQ44K7/4J1U:G9U4)XI[M%*'76S:382$$!?&02IYL+_7WX=>3
MCUW]S)-J3Q1RF."XD0LI-GU65K#R>,,!?Z$^ZLS`TIY=6U%:CRZ@K;U&02I=
MBC!B2Y=$":4_.D-]#Q;\>]U[5ZM3`/GQZQN^@_MIKU%_)8%O0ZA68(/3<+_3
M_7_I[VHJ#UH@-BO6:.<&*E5X#'*246-H5C*!/4'9E"E6=6N!<^_5IP/52=!H
M,CKG'+.7=HP2Z2NR0"0'7&A.AE=M3,[6O?Z<>]=4\^LZI(K22&6.[Q2OZRQD
M!1@JPJ`%L!>Y-S8>]GT'`=.DD*3Y=0GG,9D0*)GU7TOHM(UT.J/Z6TE2"Q)]
M^KPZ;)KY=<EK87;R(BQA1'I*MZU>1KRDH=7C.K])%[CWKJO4H3,T@?QNTS-*
MA!3]MX5#GUAFLP%[D<<D7M[WBE*5IT]6F:==(ZO!4N8Y$,)"B.1M"E6`9%54
M9]'Z3;BWT]^\@".J:_EU&C73)*\`,;*HTI'^[Z)BPC0\$!&YOQ];^]TJ`>MT
MUD$GJ+!3AJV:JF9HWA\9%0[L4$;((W47.IF02?TN+6O[KTWT[K`;!(&28*TC
MS$$M.R6*E_5<KRU[?07/OV/,=73CU`G#1H9!$R:B69B[+)([6-E8D+9OJ0.=
M0'O=>('ITYGSZ[J$FABC4O#,TT7ET6-KLO\`8DU$,_X-OI[UYCILM7%.LJ/4
MQ1*R,IA01,58Q!3+(K@1N2S-Z>0?I]?>Z<>MA*USU'E9?MI!&!J0%BS7D]+N
M@+1&,:@5D-@;V`'TX]^IFA].M:.ID212!HR)@M1$@8JBA8OTV(=>06==2M].
M/I[UU7@?SZZG<4[*\LS1(*DMJ)YE$:!G60?2Q'T_'^W]V)S0=*#4CC7J<9XS
M3SQ>)TUA`3+<B4"]@P4A4*AOJ"#8>]&OGTR_ETW,996LBO&$/C9?,"ZOIL&A
M.DE@[KZN3_O'O76@1BJUZY53GQ`2/-4F%1KU(K(2NF\@(0BY5K'^MK^[+3-.
MKD"M:=9+4_C2>7R)(B65"6OH*E`K_P!H\"_Z@#]?ZCWHXICK9&J@KU":.%I*
MF25Y+QR1ZHTY1EDC=655]0/C-B1_C;WKII@`:`]8+)!'JC58B-,9>P="S`W,
M9<%%<-];@6_']?>P>%>KAB32G6-96AA<E$ELQ7R1%7;Q``HVH,WH<N;V_H?Z
M>_`C(XCJ]!YGK&"))IPK+]NQ\D,BIJ_>9-0"HP!=0/KJ']#[]7!IU77W%?Y]
M82\A"-IC,+IK7TL\\4A)$A)"LMK_`)/('OU2>'6BY/:>'4R!R?+&881$\KF-
M/(WD:.VF\;(K+J#,;#@_TX]Z/RX]5*T\^N<<L_W$8F\@@2*5%4N3(ZJ/&JK<
ML1I_H"#P;CWL4I5AFO5TX=2EL$]`T+%J5S4N`KN=+&2E46+1\@`_3CGWKIL\
M3UQG2)1"_D4L[D@&[$H0ILWIU*`R$`?F_P!1[]UKK'YR-80)&&'^4OSJX4:6
M1GO9$!)(/-O\??NO=<FJ8Y6J%(TE7C?@']M!R`&/I];`DKS_`,4\W:JGUZ\N
M20>'7IY8F)1%D"1D68/;R-<:_39P0S$#4./J?I[\#3K8-#7K*OCI/MI3&DCI
M)*(P93$L*GEUG)#:ED.FWXY^OO=*USTXI+8`Z<7F@EB0S+JJ6,BD(EX`0BRQ
M`R1KZM$G/^L/>N/'JC<3TU.X01R1P$-,40.[W'I;4\JIK_9!N.0NHWXM[W6H
MH>K!ZD8ZDJ])::%O%*=2%:9`VID;5J$>HDLP=?IJ^OO9\Z]6TXKUQF"M%'+`
MDZ6.B)G$5BB%F6&2Y++*H/Z3]1_K^]4TUIUO.#7K+1E%"/4.8$7S^$NJ*@,@
M*(G%O0K_`%^I]^]"!U32:UZP1H7FU/3E38QO)&!^\4"G40KN04;@:@![\3Y`
MYZV25H:=8](EC*_MJH29G24:6#3%O&P`(0"X)+`@`>_<:>O5E;%:9Z;9A2TS
M/X]?EC\);2R-&L]E5C&[@"TJL"6N?\.?>\UH.O?,CCU,HW=W>1X29K'1"64&
M0(/KY&UQZ'TW`MR1;CWK-,\.O24T\.N?C'DFC1@?K)P5#()-=BT)-S9']5KD
ML/\`#WKICKI9/$K1Q10'Q1AUBD]`EMIM(3Y&_"D_T][&:]7"U%:]2())(G!I
M8)?(RNJ27CD#0LMDLQ5R`OT/!]MJ^HTIUI>/7%)WECDC*21`ZOW0&#JT9`*W
MT'7J8@VMP/K[<^+SZ>P0=2U/7HII"R!8VDBDC)DE)=!`UF1)(0+@NK`ZA8W]
MMM)I-*=:KI/#M'3QMZGFR62Q>%I2D59D\I18BE2UQ+-DIXJ6E64%P%5ZB=06
M-@?SS[<!(..'57%!QZVXOEAWKC?Y-GQ.Z'ZCZ`V+MC,=H=DU5=B_[P;L@JI,
M*V7P&'QV1W]V#NFEQ-9C\AN3+5F3RT$%!0)5PP0B9?4((/&]BU3J85'^JG36
MG4&%>J@)?YVG\P^<*(^Q.K*-X%\\ABZ8Q7[L<FE0)A59JJ\:QV)`2S^JQ)]T
M53W`OG[.'5S&,4;^75H7\B*'<]5\4/EM4[2GQR[ZR_<VY<EMZLKD5,;_`'QR
M?5NV*S%5-<K13+'0#.U*,Z:'5(;J`0+>]&M"`U&IQZIFM2:GHSGQTP7\Z2C[
M7Z]E^2&^?C/D.H8\A?LJDVYB:9<]4XB/%5(E@VP^'PV*J$RU3E3$8'D=88T!
M\@8<'9I5-(HH4`CC4_Q5^?IPZV^DNIC73&%IIXY_BK_DX=%MZ8[`ZQ[6_GT]
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MJ%1][]SIL;>/W6@IQSU4CAG%.J<OE_VE_.IZF^-W:NZ/D2GQPINEJ[`2[*[!
MFVKCL)DMPG;_`&/-!U_)38BGAS%+,*B>?<JJLR*9(/\`.6(4J=9\N/6_\'5+
MN&\\?P![/H(&*0_[.UT.'#+831+T%VO($(Y5G1X8[_4:EO[W2M2O`<?MZ]U9
M]'\9NHZO?'\G3L';>V=IY&CRM+T7UU\I-@OMC%OB=P)W#MK=.ZNJ^Q-VTDE*
MT&=DW%EMD[@Q%5-.)%FG\"2798Q[UUL,P%%-!U6'N7XH=F[PG[J[3V72[`Q&
MW(.P_DOG^O>JJO=.+P?9^_.M>AM\YG&]E[IZJZ[E`FSVTNNJ>(Q2^NGDD%/*
MM-%-XC[L@4]I:AZ\2Q-3D](7<_Q&[HP&X]Q[7?#8RLJL!WWT#\=JG(8C+"NP
MV2[&^1^SZ?>W5=1@ZUJ>*/);3S6WJ^FEJ\@%7[1JB(:"'!]T<U6AZ<4AC1L"
MG1K?Y>7756O;GS'V?%U/L#OKL[J/XU=]S];;,S6U,?V;M+<';>P-TX7"X=L'
M@L@*7^\:5>=5HZ<H8FJ8)"`ZAK^VU-*CSZH:D*QX'H,<]\8OE5W]O+M7L'=_
M5/2/QSR'3PZ<VEVEM2OQNV/BAL_9$?:#5Z;)W'7X/<&1>@9MQ%P:JJ2<2RDP
M)'%*Q`]N#.>M`Z2#UAVW_+N^2N5W5O+9=9@^O=F;JV7W-@^@*G'=@=K[5V?%
MNOM7<N&H-UX;;?7=573M2[ZJZ[:>1I\FGVQ622EF`1&G#0CW^'IXE*5KGHT?
M9/0._.V/A_\`RY>H=I;?VO3=A0=@_/W';PS==D,+MS;.W,)TSV7DH-U[DWOO
M>5(*:#:FUJ3$NWW<QD#:E"*2P'NX"D]QITRS!B!2A/16/^&^/D:<SD,+_#^M
MJ;^'=2["[LJMPU/<6PX=GOUCV3N_);*VINS^^LV67:\V-K\EBY9PZU9`HVCD
M&IG6/WX@!AI-1UJ*1BIUI0ACC_5Z]"W\5O@UW]@OEKAZ#?\`LK;6"@^/OR*Z
M5VGV/0[OWGLZBH,SF-S5V'W=A]M;';*Y2/'=F97+;)=\FM#CC42/17#(9&$1
M]Z$#JQTTPV>B3_)N''Q_*3Y,T=%118^AH?D'W%3T%'2T:T=/24$?8FXH8:.F
MI(TCAI:6)4T+&BQA%4``#WJ1BX`\NMIQ/01""G>;29+5!N;3*7IG*(QC,9NI
M_03];^KCVT2(P%I7IRM,'/7*"+]^9IF$CQ2(B7;]H@J/4OI"MY6_L_BWNXK0
M8ZII!:OET)O5$32]I]<P@0TZKV!LE2Y!9U!W1B[@LUO(Y`YN?2!]?=AVE6`!
MH?,5ZL:$4IU])D&Y;_`^]4H:^O31&!UV?H?]8_[U[]UKJ![]U[K_U]_<W`-A
M<_TO:_\`L??NO=:;O\^7]WYS[10D1F'X_P"SI$?ZL6.[-[?LK>P_<Y'^'OVI
M5^+KW5(\RS"68,=2!C"1&BQNLBW:0(0;N+Z>+@_3^OO=5:A48Z<0*0-0ZS5#
M!E&JG8S!(V*E%235PQ6Q/Z&86X-['WZM:5ZJ"2P'E7KC+#+.#9;KY`E1!)ZF
M5M(*L%)4@J5Y#6X_K[]PQU9AI-5Z[58E61XQX670966,/&&0:6\7+*J/SZ?Z
MB_\`A[J0&X]4+%LD]89/"D4S2Q3-'-*)`TC+Y`%U.K.Q5;QD<'ZDV'Y]W!4`
M#IT?ASU&T1MKD,MB8]2"2X"DM9(RBLKNKK]`>?\`#W7`XC'6R*>74T@,@:>1
M_2KF.0LIE0NJ`*L5@SD%>+G4+'WNM:8QTV_$=8(V?PW`M(NIO(B6N(N'M<7T
MN7_I_K_3WKJGF.L*SR1NBP0E_P!AGD!#*"UR$TA;CR$@6/!N/>\TSQZ><U4F
MG4=DB-0[RV*$A4(9VE0@*6+`!K<,+B]C[UTSUD)A41:'$WFD34`@"'0OIN00
M4)*@F_U(M_7W[KW4Y!&"L:2:D$D@=6)4!C])/+J`=65C;Z?UM[W4];+$\3UC
M>G\WW*I.TMY(IOII`C52`QB'IX"V-[7N#_K:ZUU@162I<*C)Z2)-1#ZD`'A7
M0#J(>Y-[&Y'^Q][J0...GE^`=9_$-<J/&Y$J*#H6QBX_<4&0DZ0JW/ORBI`Z
M:XGK)'XY?^`:O"*?UF82!0;J`4ED.G69`00#86'NH-)&!X>73@`\NNJBF+@Q
MRI(T@1$C>0H\*Q?J>81AEO=0+&P;Z_Z_NV`/7JX%#GTZ[1:F9::&*)"88IM4
MC&-82')U6"NKAU1KV%[<>]X`'KU4J"<#K$M,L<D<`N(VURN60)&20=2LVHZE
M.G@#FWMMR0*@_+KU#D=2(5,,#0%(6_;8($C*2"(MK1H^6#J7'(^O/O2$L"6-
M3U0DCSZQ01ZA$-;K>#3*/*B2N44LA,7T3_`^W`,=6"@C53/73(DI)="KJ\2.
M0JNY*EE3A"H=00#_`%L/I[L?Y].`>G7/S.?NE<+]P[!/6CQ@2A-%F4G0>`!>
MW/NK5KQZ9?B.L(AF\\,<1*NK(RE$OH`!N2$<@*P)YO\`Z_O75.I$HC6`@"I,
M?[BR2`Z_T^@!BP;2X,9-K_2_OW'IX_"2/+KC'1P21D%%FGIP)$C60WM(-9$@
M<@*GC(/XY)'U][`K]G6HSQU<.HTZ4]/-K%0L<:Q`21@$!B=3%AR'UJ[6(^EN
M?>\&GKU8J.ZJ]1(?#40!)VD)F\IC<@KR\PNEX[AWD5CI]-Q[UY\.F1Q'4-'B
M@CDCC:60R!XA-JL5$9%]#D:@H":;_D'CD^Z2$J*#SZ?.0`,9ZD-%)&%9"5+H
MBE;A2DD0`":[,Q#:K&P(%O>U+,`3U4!3GSZ\L?BD83SRNPCO=E/D5B;LHTD%
ME6-R";6L?>_7IHX)]>O0RK%J64,L9EBF24!U,91W;Q&..Y-P+'Z'WL,1P/7B
M2>/4E/MBPE5Y?*T<RB(.Z7DO>^DDE68'C_6Y/O9)-"QZNF!7K%)'K*']R="A
MB0NQ!COZY5XL1K8$?Z_Y]UZH>)ZD1TPD8*9(DNL[R1S3*BN(A(5$I.I]0D32
MBWLQ8#Z^]BE<]60:C3K#)3"8F,QG25CB4#A21H(]()(4.">1]#^>??C3RZ\Z
MTICJ0L;K'XH0\A,K23H]Y$32"`RA?[)(X'`Y]Z.0`>`ZH,5(ZSL4DIEE=/+,
MB!$)]$:EG`*@(?4PT?C_`%OK[]U[KG%'`%=Q(T@98SH`]`BL/62;ARI%A<&W
MU-O>ZGRZV"1P/61(4M&0SE`K$RN-!9@I-V0`DD@V%N/>NM=8JR%ECB,C,2)5
M$;>-K`*"KZAITAF(-CI/TM[W72>GJ+6M.HT%0T9>\4T@\I#2(NIC9@AC0$+X
M_3R3>Q)]^-:@CB>MUH.G;[AG23RDK&_T!5@[#U!))'CC82-Z5X-[$_6WO1K6
MOGUX#-//J%)Y4F]2*\8"FX55:*0*DA5QI9M3N1;B^E>?>_($\>M-@'KB)B7F
M91(YB1Y"[%U6X9=)<:5!9F)'XO[UTT23CRZX*JDR@NX+QQ@ER@2.[W35&%]:
ME7//XO\`3GW8$4/5UK2GEU"F@D1WT6<,[QACI!0.48*H\9&@`>G@@_2_O7KZ
M4Z<S0Y\NI0\CPE/')J4!BBR1P:BNCP(''J`X8FU[EO>NF"Q(H3CKE')!(`\D
M;K*2&/B2X#D.J1RA5\CV;\#ZGGW[K774$<$<J$5CF-O0#*^EXF9^/&?'Z4DN
M5`^E[<^_'X33I]<I3K+!,'>?TRQR%_`C:T3TWXE("IJ5E-C87O\`ZWMF,G5C
MATW2@J.N%1+-$A\<5[H\"F0ZDC(5;RE0AU%W-BWT/]/;X&/GU="34D]=!"8X
MSY)%?Q1&2.%+(9`/78*MU0_DBX'NI53QSTV2:D>73ABLC78^OH<E31K'D:.I
MI\C3.JJ?"<?,E522#6!_F98XW!)!)4^[^5*].-A2//K;/W%N'XB?SKOC=UWU
MKNKMNFZ<^2.P:K$[EAHUEPD>^]H;U&+.#W*V#PNYS24V^^NMY4VORI13"5X_
M`SO#/"![K6G30)'#HMK_`/"=C>Z0L:'Y:[7D>4".U5TUD_`:9&9H3JB[*:1Y
M&1N;$*/Q[V&0'N%3U[4WD>AK_D5X++;A^)'R_P!H;>SU1MK/U_<V\=HX;=,$
M4J28'-/U5M?"4&XJ*&*HBJE.-R.FKB02K(NE5#W&KVT"Q)]*]>Z,!\<_@%\V
M.ENTNONQNYOYCF]^RMA;&JI\MN_:.0J][C';PIHL16TS8_+R[OWWF<+28F6H
MF6>=W@=XQ%>-D:SJY2I"CB>M=!/T=V;U#VK_`#T.TL_TQD=O[AP>+^)]7MC>
M.Z]IR4-9@=S=BX7<.RGS==!EZ#52YRJQF'R&.QTU6CRJ\E(T>L^+W[()4\1U
M[JF[YG_*KY-;2^;_`,JJ;9WR2[[V?C=F=[;DHMK8'"]G;RCVC@:3!4N+^SHZ
M+:0S#;:&(\D+O)2/2FFE,C!T-S[]U[JU'^<94GL#XL_RZ>TLK2T$F^-Q]R]-
MU+YV*AIQ51#?G7,N>SM#22R1EZ;'9#,4--,\(LC-3QDJ2HM[KQ%00>!ZLH^?
M_P`:_E]\A$ZI/Q0^3S?&^;:=7NU]^D5V[*$;RI,Q385-OH)-K,)#)@*B@J6`
MG!0BK-N1[W7RZIH4N'IW#JG+Y/\`\N'^9NG0';>2[E^=F%[:ZJVCLO.;_P!W
M;$S>>[2JH]PXKK^BDWDM%'1U=#)0S5\53A$EIC,XC%1&A8A0WNIJ`:&AZ<XF
MIZI_H$@G_E][[K@3IK_FSTR(HY`!-$*/X^=E3F0$ZF,DRUJ@E18@'D>W$!,+
M/&>/]HO\)KVG_;'KQ!U$?AZLE^-OR^Z6ZZ^8OQ#JMW;YVU6]*U'P1^/75':M
M95UCS;<ZR[CZUR^[M_;,R^<FLJ4&Y-G;BBBH'E(98(\P]V%V'NOEU95U55<O
MZ=!E2_)C;QZDV3GMF=Y_'+JRIZHV[\Y-K;BCWIT[MCL/Y/;DSO8O:'8.Y^MJ
M7H*#.XQ\E5[([JP.]8Z3(5-'7TL%"!/+5+<`>]$4/SZJRR*2LJ:7'$=+WJCY
MM?'VFV#T51[VWEMN#<&$^*U'WKV?!4R13B+YB?$<=8=;="[0E"1++!NC=^U>
MOZJ6@#7::EF#J!K4^]-P.13KQCD\(L8W)'\.3_J]>B"?RY\[MC%5'R>V[O\`
M[AV%TIN/MCX6]S=:[,WYV7NJ?9^W9.R=]Y3:1IS7;AIJ>NR%%,M0)ZEI(8Y9
MT1&=%9@![J@#*S$5/^#KQ!*1E7.D5JIXBOK_`*O+ISW))LOK+X,?.3H3*=]]
M+=N=E[X[2^&.Y=LUW5V_LAV)B]\X3:FZ,AE=S+A\MG,5A<UF_P"X]'&K9,^#
MQ46M5$A)"C:JTJA(VHXZL$9C55%#U9OG.Q^D_DC\E^O(=E=]]4XN;K;^:ITA
MV=@JG-93-TL';>V<QT9T3M*?&]096CP=?0[Z[`QN[=IMBY<;`Z24<-299VBA
M4R&WY]4Z0M'\@NAINOMJ=&Y#N'KK;&]MS;;_`)PO3>6JL_N.CHL5U3O3N3OC
M)Y3K-.SLJ(JJ/9F!WS%BV@IZJ=3&1.I8$&WOU&/PG/7A@@^8Z+G\FNS>CZ+X
MI]E=5;;[MZHWWN+"_P`N;X&=14O]R]TP9.'<?8&Q?E!N/<.\=L[<G>"A?)+M
M?&2+4N/MD84#13Z%C8>]4*CN-3U1V()->C==T=L_'_OCNBCH<#\C^B]H473W
MSU^(/R/RN\=\;_QN*P>\NML-\:^MMB;AK>OLLJU=#NS=VP]YX!Z&:C@,+TTE
M4S2,JAB'O$9$TR1<10'^=>K:1CUK7JBWOS.4.ZOD'\@]Q8.KH\MA=R][]MYK
M`YB@F%7B\AB<MO[<%;CLAC:J)Y(:FBJJ.17BE5F4J^KD$>VQQZ=CXMCRZ#N*
M$3+&P=4D"D#7$ZE!&#=R6_2S)?DBP'O3*I:I&>M-52*'RZR1JM)52*8F,5@V
MI1J*H#(1H(8L^J_''-_\??AY#K0=AY]"_P!%LC]L]4DA/++V=L$Z65F`63>&
M'4QDRV).DVL0?K[V>T$UZNQ.EO4#KZ/Z?J?_`%Q[V>"]4/PKUR/T/^L?]Z]U
MZKU`]^Z]U__0W^/?NO=:9_\`/GDB/SHP*21EO^,"[$0_N>,A9=T;V(=&_+)R
M?P!;W[K8!/#JE!JI8K>72\8ED.F.022QGTLI8M9I;"/_`!M_K>_=;T-Z=2UE
M22&2=T4N\H4REN&0Z=+K&>;L1R+W]^I7APZNP[@>I$\H:``K$59T1N"VDO9%
M>-V!9N+7/T!]^_+'5U-14#'34"&-7!%Q]#&&8HS7(*(51A_:OR1?W20$GM'5
M>-6'#J.\@8LKB-3I90K/(3S<%V#_`%"%"0!8\^[@"B_+K8&#UR>%#!`X6-@'
M'ED#J6"*Q!(72#KTWL;\6][%#@=:KCY]<14L7#(IE@NWH57$C@&0ZM12]E>P
M'J'U_/OQ%/LZHP)(H.LT:0RAW$TFNX0QDK'"+ZM!5O5>5"MS<6(/O1[:5ZIU
M%B>R2B155OTNP9]<1C8`S!!$0"^G^H//O=#^?5U4UJ>'7-1)++JC:S`/XUTB
M,J-(]3L%8O(0;A1_M_?B"*5Z\YJ17K%!&R%?NV#Q"5G$:J2+APT4DC:493Q:
MQ(T\_CWKCU4*2*@8ZF>)795\L44?F#QN(QXW/[.J,O(UPB-8!@&X/]!?WL#.
M>K`%37K(P2B5@82&5W29CRDB@!X?4/TD/_K7_I[]@\>/3@()H,]<G\<P::+4
M@58D9EU@G3=KZ9+7'(X!^O/O;5%*<>O5J3U)9ED#F74CM:8K&VE[A19GUBX1
M0/I]1<GW4D^?5"U1I!ZYR1>)3IE5:=%7RZ!Y7F$M]*6)9)@J_0@`@_X^]T/'
MJFD^G4/6SJ79I7F"(DA+71N#XRX=G(4+<DG_`'OWX#/3@4J,^O61F9=5U69P
MFA4C**Q8`,##J*C@\`W)/YX]^H14#AULF@-.FLS.9DD>)YI1I8)')KC]/&F:
M_I*@?06M<?7WKJB4)-?3J6DAB0.L+,)7D5Y`K>2,'C3%;U(JE@+?0?@^_4KG
MY=.T]!UD%E*^$Q2%D9%4V9HFNX=E=_258$<'Z-[\>W37@>M5K3K''$5\<L<H
M)9@MB51?*K(G#A=)(U?TM_3W;\1^76P!D@=99'DDAJ?$H>2-U#!II%)8$ZG\
MA065CQR+?D>]&H)%<'K5<U'7&-K$PKHU@QQ>20WC,PCX=7"AF2,FW)YOR/K[
MUZ5/6CYTZDK54PA1%6,*?U3*&CB=P"TR6>RB274+V^@''%_?O\/555E-2.'3
M?"@CDDF&MXGA)8:RS#QR`K%94)#$'B_%OI[\Q`X^?6Y`21C/7F6(:Y#$C2+'
MZ-;$`ARQ59D+&4,2P4#@W^GO2D-D=4"L>`ZPL#H*2HS7L\;KY?H^EM(1B4.F
M1;#U?3@_GWOKRTU"O7%/1$JJ!,)'"R72&/5=BX6)`AU78G5_4_3W8>1'3I->
M/7JF::2FTI%"O@DD74SFRJO!!6-23&QMI(N;GW5"1+J([>'7@2,#K)"908C(
M8=;)9`DFET4\O]2%9"2"Q)N+?[#VWI;57Y]-5SUFC57D)DFCD2.3479@^MXM
M+L;V58U$=QP3>_MWRXYZVQ!X'J.D:/41)"]HPKF)V0"1&TMI_39I'G'!)_']
M/>J?MZ]Q2@XUZEFXA12S1K&'#O2VD\@+"RDOQJ5_J?J#_7WX8\NFT&DO7SZB
M&>%Y%ECBJ)(Y#I606?5(UD3R1"Q;7("6/^L??NK`5X=95D,$_C"(IX4ROI6-
MUC8N[H?H`I:R@7)X_J;6&!GIQ`14TZ\];+"LBB-D2.1'C<LLMEULB+92"ZZF
MUD?6UO=3TVPH2.LZ2QHAEF=A`ZRL[11N[*P72KD7!5@"#<64G_6]^I7RZLH(
M()'6,21B:&*1Y(')5RL@"O=EX:P9E1`O.D?7WO)'RZ<%#]O4DU<-)JEAJ$8M
M)IETE>3)I1"P8%2!8$@&XO\`7WKYUZ:?XCUD:>)A$$+QA"A<NP=I6-])8:]*
M@...0#;WOB`!TXU*4''K!)5R1.6D#R/Y1XW&F..TBW]7C+`Z+-Q]0![]0]-E
M6'$=.+S4\D:R/-H$BR.IBB7RAB2Y4I8&-;H+?0V/O7''7BK#B.H4<J2#44'E
MNQ%T)=F@<*&<N1J#$&]^??B*`UX=>T$\>'6.8Z'=]5M;W4@+*A2XU"0(S(P\
MR\?6P'/NJL&../6PJQD^O4.8K*64,/T.LDBQ(M_7Z4#L7`EUF_\`Q/NX\J=7
MJ*@C/7"U23+/(I=@6#H2`8XHT4>1$!_<+6YX'^T^_')I7K1:M0//J),IFF/B
MF$4D<9:#U,0;"XDD"EBPN-1*@#GWZAZIH8>73I2SU+30,7B,L;#R/*%1)H]?
MJ>,*4975CZ6(N2??J'K>AJ5ICJ1.\)D96B,\MF,:($8J0547:(*7L`.`2>.?
MZ^T[4U'UKUX5I3RZZ>M\4E.@6RL6"L`BJ747*MSK28DV4&XO^?:FH'V=.::=
M14BJ+/42S)-96?PJ'9@GD.@&Q%W5"./S8_U]U+#@>/7@5%:\#UD@\8CLC2M*
MU*UM!_S(4E?(P4)H+7'/XO\`FWOW$5KCKRUI6F.N;5%HU\;>68V&J6)HS*$B
M%H5:12K,7%RUQP/]A[]TUI8"M,=3BQJ_)'+&`$/D37&"JS!;$QO,I97N38QD
M%3]#[JP)I0=;05KG/4V'*9J!(XCG-V0>%49C2;KW-'&JI>X$<>4186(-P@4(
M/H/?E!`H>/6F!!->/7&DRV1QKSIB<UG\7'65$<]6<5F\WB(:F7QQ1+4U5-05
M]+#-4%`B!P"]EL?=A2@)Z\L2`J2<5Z>GS^3K:6:"LSN>J:<KJ2+)9[-9*F+2
M*`_^3Y2MJ(O4?3]+6'^'O=#Z'JS(`!I:IZ:()I::JCGQV1J\1)%%+3+4XC)U
MN'J5IZD(:B"&HQE11M]O4F)-<;-H.GZ<>Z@@Y'5""./7='!HAG:EFDJIIZJ6
MIJ:JMJJFLJ*FID<O/-+4U<LL]7-4,?4\DC`V^OT]^U@5!X].$@J/7IZR&4RF
M7IZ6AS6>SV2H<8\4E%0Y'<6:R&+H9Q&(HIJ"DJ:^>&AJ*>,>-'A6-XD`52%X
M]^!!Z;`)Z>*[?_84U*\?^DKL7[>)%!B_TB;SB6,ZB0X<9P2,S6^NH\7][^76
M]+<:=-U9OO>%=15^+JNQ.QLCCJNE:@KL=5=@;UKJ2HB:RS4=;0U.<G@K**7Q
MZ7AD5HY`.00;>]D8R>/7O"'Q&O2_/:.W8_BME^DOM<K'NFN^26U^W(:TTT/]
MW_[J8OJ/<VR*NEEK#5"J@S,6>R,31P&G,;PL6\@TV]V"QA**>[JNN5G\,)^G
M3C_J->@,,E0&@D,KR-(L-W")IB@T_N+(+74^0$``"P_/NN?SZ<4$5QTU2M43
M+%4>>.1E>6-Y8PUV]17]3V%V"#D6O;\^_5`'"G3NEJ'J.JU9G5:?5()+33%3
M;1$K7:R#2%4%V;5SQ_K>_'YG/5'J!U-4\%$*%"RLTJA)#93H@A5`64ZBOJN.
M0![UBG54\\=0XX4*RJZ1F9YI6_;CTD+K+^B-@P5HWO>Q5;?@^Z,A+&@QU8^H
M&.C-].?++O3X^[<;:/5^ZMOTF#;=8[#PM/NCK_8N^WV)V/'B3@9.Q-@5&[\!
MF:C9^]GPI6F^]HRA:.--0+*&]^16#5(QUK30`,<=%M>0U-1-4U$TCU]175<V
M0FG5YY:VLR=5)792NR#R*#/59"LJ'E:2UGD<L/K[\P:HQUI^`ZZU4RO(J&*0
MBQ5O'YC)-`[(T>IPJ+H"<G@?@7][2H%&]>M`@#CU,B,-]4L,>LN:N*GT1>(2
M&(J2$?6&0`G4!Q<_X^W"00*=6;MJIP:=-D$D+FITS1^F:S4ZZ`D>DR))I``U
M,+V`%N1[T*>?54X\>I44D$3LHDO=/$&E1F=8A(H]+*S!I'0$#@G_`'GVU("Q
M!`\NG#P;KD:R,U$X,;AF75'<+$QC91P-.L^AA8#D7X'O:NN%)_XOJII2@Z&?
MHV:*I[:ZHTQF0)V?UZI@*:_W9-Y8ADD-D!NKCZW6Q'']/=^F])'EU]'[W[JH
M(->NC]#_`*Q_WKW[K?4#W[KW7__1W^/?NO=:8G\^R4#YV8/T*_BZ#V(P!^I_
MW\^]FL;\Z+'G^A]^ZLK4KU2ZT/B=CXE_0\DA]`:(.KAHTT^M@PN/\1S[V/D>
MG`VH4\NNG:.C@#ZP%DMIN==G;Q@-`0I4,4)Y(/J][IQ)&>M$D@]=?M\QR%E5
M)%D9=+:U53J165;!FN"23;W2@K4]>1A30%ZS120_M5,Q1#KCD66T;%%0,@C=
MU4:[@<CZ\^[</MZT:)V]0JF.,I-8Z7CG87AT%PTC*3&W!!#C@&_I!X][I0'U
MZOD]97`52%C!!,7!6ZJVIBR,O)TLK>H?2_/OU<`=;TX)/7HT:H)>,AKEXV,2
ME/'&2MBK.(T.DH/J+GWHMFA&.O<*8\NLL@0B*`JD;:QH;0RJS68QVD'I630]
M^";D#WYB7HOITWIJ20<=-_FG\GB*%$5?4Q;3(MB'UJ2&!!O<7XM]3[\`!FO5
MJ5SUEA`B6=/,Q4N[Z(^`8BGJ5N%))L#J_+'WZE*=5D/`>G7`_P"4+$\BR"+5
MH2.(J'9(P6'J8DN;?0MR2/S[]7%!UX/0`4R.LEH8UIV`2<(SI(C(49%(&B31
MJ'[LH;2--@2/>@.'7@=9T\*]<)1Z7>9E7RE'54C<R!N-).HE.+'^IY_'O9%"
M.M?#Q\^N]47GN0"94$<A4L%$@;4K/&OTC5!:U[W^ONW'-.K5J*]2`975WN"I
M?2SDF/\`X#HVH:E]37U$$$@$6L?S[KYXZT%H0:]2?VB$,;.K)ZH;M:R"QTF[
MLID#_I'/%_?C2M#TX2*XZB3J$BFNL!0`1!F.ME#'4'<+9%!"_D@<>]^M>O&N
M!Y]<))(HX=,0G=9&3]X>35$PCL2%;]2L2.`.?Z^]`#-#GJK#!SY=88Y/6KZ7
M9-*!F>(@E`']13ZZ@23R>0>/I[UYCJB&C=2$E6)>5D2Z$DH2MW<!DD8^EK:6
MO].3]?>ZY/5V:E,8ZX3Q2QLBZ"8S"'&LMJD-U8R(L1+NSGDAC:_TM[J_<%SP
MZV*T!ZSPU*ZXH9AXV7]0YX4L2#^M%'+#B][>[5I0TZV>%1PZS3!6:0:RR1R0
ML!&P%^3;QB,.P92.0>/>P/XNM5\AU@8,JEBS^3SRAT>-RNEV\:NJGU%P5&I@
M"+'\>]:CU0M0\.HD;2AY(GD5F\:E4*!.+EM7C864H5%[<$#WJM<@<.K\:DG/
M4]HXJ>\<=G+Q(K*))=1(!O81W]?T/'T^GOS@L!G`\^JGB".H:M&SO"C"-7==
M<9!_6I+!I68B1?K].!8'WH(5P.'5EJ!URJ"J&ECFY,WD4-&K.!_94@.`/&&(
M/!(%_K[VQ*BOGU333/6!F=(X:=''F$I=8FLAU*`CNI55`1%(/`//NJN6)JO3
M@+&O;US=F2!EUQB4Z"[^JXL"OH15XD*L>&-^;GVY0GCPZ\&X#RZRM*K100)2
MQK3HK2AP$CG97<"1Y'7U2.]KV/XM8#W7I@\3Z=0Z>G16JH_&@IKL2UCXWD!\
MBK&3<EP#S;D?GWL"O7@*^?4D$&H06NL2NKDQNDX0@-_G&7_=9L+W!%[$6][\
MJ>?3I!C2H-03UD/GUH(R[0A-4@:W(#$Z1J"ZV<+P03S[:UYI3'31S4]18HF:
M1#<PMYQ&ME;RPL?5Q9AR5^HL#^?=^MJ0#D=>F5"&UR)I$@50^J-BZ%59A?\`
MI(>#^2+_`.ONOJ>G5:N/+KAH\2N2AE0$>-WU6CU@!A*O`/F*@W')M[T>/334
MUGJ4LJ,FGRA3I$+QF$E?058?1M++;Z_7_>_>R!BG#IUF&#IZP-"TE6@GM(_^
M<\X5UAC1U9D0-I951@!;\?CWXD4(Z\&#_*G69*-5C@N8PH"Z$C).L,7)E0N%
M8^K1>_`(]Z/SZ:<U8]<46.2,.`70JCRF2RNHC9@0;K8ER/QS?WNHH#T_Q&>N
M<C/*R)2LL,;$^%I&;U,!I1W"@A=1M;Z?U]^H>/GU3'GTY!0T/CE"^5#<RH&5
M6)"MI+E2QO(;!1?^GO39X''6B]#0CKE#X;EP5(E:5WU`(]V*DJ`Q%U9G''U-
M_>F-%8>5.K`>?3=*C37TF3Q,S*$**J7+7OJ(8'2RV8?V;>V8\NU?3IIJ]1!Y
M$'B(5)`#&!"OC25V<!C=;(550;W^H'M1@9ZLE:=<4FJ5EG=Y6#%GB2$DAG%.
MNEE,:BQ72;@\\>]5J1Z]7[*?#GKPIDM'*Y96=7:0N--O'K&A"+D`L38'\6]V
M)ICK1>E"!U(@$!U.]1))Y)&B8NHUH"6:.%2&!(6_-S]+>]<>'KUY:M4]<JBE
M]?F+LX]$:JI(=!"R2!GT@("O^')!]ME"3JKUNGE7KA%&'FD#JKJ-4@4)>2Z$
M:+J^E0+@L&!N;\^W:#RZV*\`<]8F5DU02SMQ&UV2UE@#*7/[85W948W^MO=&
M&L@@Y'7F`-`!U*I5$6AC-YHS`T:R:/`%BYNK.?W'8(0`+$?GWM10`'B.O5\Q
MUQCAF`F;6[JQ_P`G;1I2,)&3^XH7E0AOZ1Q[L:9ZH]0C8R!7H?:;844N]*S:
MSX?<]/@L115,&/W?-%GVHMTS10X55S..?";3W-0RXZI@R,N1HXZ'[D"F"K6.
MJK/+'0&NH4_"3^SICQ5`8Q,20H)IY5K_`)NFFGV))4;)PE9!DJ`[KR6YL_@*
MS$SY=(8*"CQ5+6"'-9>II<16XK';<JLCCC3Q9"*NJ1+5RB$0HC0S/Y"76$L*
M-)P'7F9@NLKGI/1;#SN03"+1.L596#('+TF4QF^Z7*4]'#G<MCJ6NH]N2;/D
MS=3JDQWB-)'"<A:T_@\!+C?F:CIPRM3X#U'S>P=W[;P78=?FEQ+ML&@IHJ[^
M"3;BS-#2YJ;-['1:2IS@VY18>&*+"[O25$EJ(GJ=;M#K-/)9U'`!J*UZT6UL
MBZ:5('[>E]M3K&CW0,X:RESR5F,HMC5F/"ID*6DK9MP[*J\[E/N7RFW,33""
M*NBTT[T,M=2F*.WG=F8!LTKVB@ZVZE))(R:E33H*,EMW<&#K:+!92EAIJR?"
M?Q]$.4IJ"F-+!49BFKEI:W-)@8:Z6EGP,Z!(N9IOVX%E.C6S)&5`:O$\/EU[
MQ%&`>E14;54X:2NQ-=5Y:2GVA0;BS6)DIZ>@K,)7Y?>TFVL.,:B&9]W83)4L
M)\SIXJF@K2HE1X98I#M58$Y\NO!U_P!]T/4#+;<EH=X)@:B2I;$551MBE^\J
M(<E!,U+GH\?-+*XK]OX6`D3SSBG^T%=3,D8M42MK"N_EU?6-)-.N69V;-ISN
MXME5<64V9AURE5497*-G:8(<)-N.GRD%%E:?9=-09M4J]M50IT6*GR%0K(XI
M_"T<SZ/F:9Z;\0G\!ITH,QU!O2EK<OC<55;1SL>/Q+[C>5\SEL>QP)K,]C,?
M5UL62VW$*2MRN2V]50TU$)9YA9))?%&ZM[JA9B0T9I3RS^76T*ZNYJ5P/M\J
M^@^?ET&F4PN;P]-%654>,KJ8US8:NK<+49+)4V(RU)A,-FJO$Y2HDQ=#2P5,
M=+GD4%9)%DDBDT%E4GWM6U`U4@U\QUO602C#O'&F1GT/G_DZP5F,P\VV,SE3
ME*RAJ$BV>F!Q(B!J,UE-Q;$BWG)#-`,//(V.,1FC%0M12)2PH97,Y(B._3K6
MHD^@ZC8_;FXDDV[-6-C8<1N3.83"X^LBJI9ZZGCS$#55)45=&U)2T$L;8R&2
M;QQ5LK)+'X)_!(;>],X52U//J\IB5@B2:CZTZ?\``[5BW+BLQFJ6KW)MZ2DK
M<7C*#`9NFH(\M45QQN\<ME150Q;>I(HZBDQVT],D'FA6DE\A-1.56%]J>!ZJ
MK::]8^P-H8[:GWM)1;HER50F[ZG`T9EF5J/)8JGP&ULXN3QN6H]L#$Y^FDDW
M)X6D2IQH#H$5)98Y?=&D5333U82>5,CIM_N%O:L6A&$Q,4D=?B(\TL%5)+1Y
MT&"BI9,UHIZBACQ:T&/?)T)45E73U4Z51>&.98VM8L33M)ZJTIUJH3)Z=QL;
M.XB3`2;@J\'34NZ=RM@Z&7#9)\]]Q%C\AG=OY/)PSR4E#3S4>,W5MZIH)K6"
M^,2(7C=&/JDFA%.M-(78J%P./4C)=7[LQ<DRR?P`%40+]QN''T=949),M1;=
MRV-BQ<*U532FFWOD)<+1,US65%-)(WBALYK+(D/@M(:1LU*^GSIU448`J>/4
MBIZ^S\.5R6,$F%R8QU/M6I^_QE>P@J'WDRXS`TD#UM-C9WRDV;1J&2F"F2*1
M=1O&X?WY'$D8E48U4I\J\>G9'C:-7U]W"E/\O26W)MRJV3F\AM[-28Z'(XR6
MGE;^'5R9#&U0K:=*RGEAJX@%F\E-4(0+!E<$,`00-H2XU4X&G6HP2-5.F2XJ
M'GU(S7`,1YB5OJ2`$UKJ5N0!R?K]??FDH:%>K'R-.NTBBI_$*N>,NQT//',=
M/[KQ.D:J[&[@>FP``/'N@C).H<#UZF?MZ&+H73+W?T[X#5$2]M==0B2G)4J!
MO'$,/$BFQ,<@)"_GZ>WOE2O5J5)!\AU])(#Z_P"/O728"E>O'Z'_`%C_`+U[
M]UOJ![]U[K__TM_CW[KW6F/_`#WT6H^>F*0@%AT)L-$+:@L;2;BWBRNQ\;)8
M<_4_[#W[KW5+-2E2LDAC2-XS^T\C%;O9"Y*7N2JD7!3BYL?>ZD=;#$=8+R*0
MJJS1"6)U]!17#@R*!R=2H!;C^OOQK4=.@5X^?6242`.76$,TED:0$V-B7+$^
MIB0"!]=/T]^.,4ZUITU]>N4=,Z25-S%*D,,1$":@4$K`1RP+?3*6746^O`Y]
M[Q0UX]6*!CU@5UC#"-8Y$,S)I>\KR!5<*Z$'U:;?6U_\?>NXBAZV%-.'7&*6
MH*(ED>-PUP;J4U/J]8<A[BP"GZ\^_#M&>O"HSUD%1:\<4:!V9UD;R:$4Q64Z
MBS#7Z1J/(OS[T?GPZ;9B.'7,3M*B@,5C:1EBB9%76P"(&')8$FYU7-_\/?J=
M5#&HZ;8C5>26GN)6AAU11I8,8V.EU9G_`%R+(+W!O:_O=*D#IT\:]2X%G:;0
MT8(;0OE8A;!D5OW"53A?\?I_A[\:>N>J/3&,]=LC$P-`R'3951KADD9;@7-@
M&+``<_0$W]ZZ;ZY.DP>(MHF#-&I92K+=P7D&DG593<7-S?W[APZLN6'7%5ET
M/(J*)8B1&Q9515DT*)#$Y_401I`OS[W@FO3I`Q45ZE$,L=20D#2`:ENIOH5K
MN`I&H*P;U?6_O1Z;)*F@X=0S'K9I`^B)+.PB4@.'5!ZU:Q\5O2;@_P!;?GWX
M8X=:U'K/,KD%1'J(;R1M:0D`+J636&5'_:%B.0-/'OQSU[6>N+.`(H'MY)81
MH,0L'O9CZKD,S*`!P;6]^`X]74X!/668R,D*^E27)C$3CQD&,E]6I0B!A]1R
M"??J5S7JQ.&SY=-T>MBH9X8-7D\4>K4H7PLJK9CJCTL=2W'ZKBWOW3(-.'7$
MR3*6?0LLOCT*GD\BL20A?DFQ5+V'X-A[]Y=;+J?B&>I*S3B2&4RQEH563PM:
M[H2R.B,;@$L/Z#D`WY]VQ@^=.KC*XX4ZQR5$DGE54IUDDD:*ZA@Y`8>N[:@@
M"`@D6]Z'&O6D8E@#D=2(O)'`\C$%E=?W+WU1D#Q-9F4M,7'_``4^Z.[+2AX]
M.'AU(J&L01$ZRL0)/1(7N0.6_2`)#^!P#^?>TJ54GCTV`#0^?4U:ATA4R0K+
MJ+!WT^*0(&+,!SITC@<CZBWO=3Y=>5S4`\.H25#L)(V@0?N"+4Q"R>32#(RJ
MN@FP4\W^OX]^HN:GJ_YXZZJ/N[QRE5F:3T"5="E4(L%OP0P7^MQ?ZV]^(ICI
MMF(..F^0RM'")$#>*65%4DR-:ZH;B-U!9/Q8_GWLD,*'J_!2?EU"D@0>$JB&
M59&NC([2A8QJ"*C:SIE6Q(//'UM[JJ@5(ZJK$G)Z[URLL4J0,TL;:I$!TMJT
ML#PK%'&CZ7/N^.!/3A/E\NI*M,C2*L7J/C,LP_>$:/\`MJJQW`Y)/TN3_L/=
M>DYXGK)'4>5EC%.23(Y<L"BW5KF3E>"RFQM8G\_3W[K8)'#KL&2-`CK+(TBL
M1>0#B7EF^KE0+"_)M_K^]TKFO3@[E(/K7IP22>>)D*JEH&1D5E41Z%%F(3\K
M87_/NFD`UZ;/$]0[3O(;VNDZS$#4!(UK*WE=B6>Q`Y6UO=NM=8*K6GK2XD$R
M-ZD5T"QV>X:0?JU&X_!/OPH#\^MAPO'K#*E5.&DBU:"T3SLS&-I$<$`2>HW<
M$WL+CZ#\^_=:KJR.L]1:&-H_&*0/%$EP55R7]#3`<2*=8_U)^I_/OWE3JQ8D
M4/6=:K2048QJJ^-H&)EBDT%B2@L`;<:6'/O?D>K1\>'4G5IB=U;2PB9`'6,/
MIC"!([D#U<7O]25]ZZJWQ&G7F26R(R(0\D:2L)$"0D,3P8[^7U`@L"/Z>]U\
M^'3A-`:<.H2PP"I!AD)1#<,OJAAU:QKY/*H]N#<CZ^_9-,5ZJ"6K7IRJ"S0Q
MQ()45RP?6NE>5U$J?6/[-P;?[#WK\^JMQZA)$TGC12494()TA2HU7:%='*ZH
MP.#8F_OQ[A0\.O!C4#KN..90YCC?[>(MJ]8!N+7\(TDEBS*=-[D?7Z^]44'M
MZLYQ\Z]-,5<9V\,T!U+Y8C)&RBTA=F!,8MJC$2D<G\W_`![WYUZH&(X==.X@
M+A3I=78ZF-P'"D!VY?A5:_Y'X][8<#T[FE?/K/YF"H`#)(GE)U)XE>REF"*M
MR+D6X!Y//O731)/'J$YD-HIE9&A976.)B&9_UW+7)$A$GU8@GWL<>/5T^8Q7
MJ>K&&5]8U)&@(#G45!`9&8>HZS(ND_@K^??JYZN_;I*\#UE@J)"MQ3.CF,HD
MCDO%)J.DG3)=+BQ"M_A_K>]>8[NO'B>L]5-+!&BB*&1BKJX$6K6CLR(S-IU,
MFG_`<CW84P*]:KCK+`TZ1PF>-5CEC6339A^RBL!'=3Z.-.H6)X_I[U0Z37KW
M7%*A)BH,!4J?THH9UC<%8W&DZ1RH+,Q_I;WL<,\>ME"PT'`ZRQZ:>?3)':2`
M3K%)'=BDDZWJ&<W41+(C6D*>E[\W/NN*U^1'[>/5#15HJ@8IP\AUZ:&!*?RS
M4T#6B2']V,%7IY'7R0M?]-+(P7T`:"5%Q<>[:C11Z#'R^SJA-12@IU@$_P!]
M*9FBCDEIV31),7/C=%9%>*2634A"MI!!%E/'U]U.:'ITX&.FRG5::AK(8H!3
M!G43I3J5IGT@T_,-T20(M[<M?_6X]^Z;+$E3Y@U'62BR#HZFHFGF:`)#"HDD
MM'3Q%6IX4:]A$2+(%`"W]-O?N/6F8LS.WQ$U/66)HRRD0!VEB3G25D987E$+
M5,Q8N^G2P`M8`\<^VB^J4,W'A_J_S].8],].1F$CK),@O"\;P1U*H[15$22+
M$:<$AH62%V(/_%3[=_/KTF%'4^7+S5M/`L]34R04D%J0-.]1%1PQL3%%#%+*
MRT\,3#5H4!5)-OK[V*_EUI5#*03TT5=?4L(*-6>.A61ZF*D7S"B65D\3U$=&
MC>(S2Q>DZ1J9+J?3Q[UU6I7M\ACKN//9>*J\E+DLI`R+-3-54];5PR1TYCJ%
MFBB:.;7#35"SR#1>Q$K@BS&]XV97!4D'K04,=)K0]8?[Q9FAQ^3Q%!F,C38W
M)1Q4^5QYJI?LZ\1RT%5HEIWTQ>1Y,73%B%N3`BW(4#W:3+U))8].!`JJ@%$'
M`=0:#<>3I)86AKLE!+1X^LP-++'-4+'0X?+455C:[%P+*\D-'CI<=5RPO%%H
M`25E%@;>VZ=>*+Y<.HU8)?X;CL8U;42X^B-9/28F2KFDQD,E5+.]7)244LGV
M\4M1)-(9"B`N7:]]1O5U#BA.*];")@!:#J9_?C==6A6KW%N"J84M+0S_`'&9
MRE12RXVBG-11TDOEJ76:DH:A@\43>B-_4!?GW;M`IPZJ5'D.HM%N3)G&9+$4
MV5RZX>JF:HJ\;%752XJOJ5JFJ2\]!YOM:AC52&8L5N)"2>3?WID0G5I)/5@E
M"33J7_>#(O-7SMD,PLM?/!-7O)D:^22OGHZ<45+55+FHM65%%3DPQ.^IE0Z5
ML./=%F<M35UJI8U\QUACS%7)%#2S5]2E+3U$KPT\]7.8U,TCSSU`AD9HHYIY
MII6<J%=GD9C<DDO,Q;JC(!W"O4B;*92>@H\7#E,E#1T%1)78VEAR%0M'2UDE
M1#5SY&GI6E,%)4354"/(Z!9'E19&)87]TIZ@$'R(ZNJ!@"13J2,MDGQZTDN9
MRLT<SK/'"<K6O2QU"K2EYXJ5Y9()9?\`(XCY.'O$G/I%O+VUTCIK`4I3%>H.
M2KJS)RU.1K:K(5];/)%45U;D)WK*ZLTQBG)>MJFDJ96\:`+J9M(X''O0&@$#
M@37J\8\O+KT4L5.C*ND1*/+9K//KGC_;DU6!=HKV`O;\#WO3J)+#IW'V]<H_
M`U7"SHI42%G<QB9O(JV1E"M948I?2WU)//O8/EY=5SPZ'GX[U`'?72"(R)'_
M`*8.NRVE%70/[Y8<@-]01*TIXOZ3[]2G#KS$K2G7T?!_Q)_WOC_>/>NF>O'Z
M'_6/^]>_=>Z@>_=>Z__3W^/?NO=:97\]IQ%\[J&33RW1.P(;6N9-6<W@1I4F
MS%`3S;B_OW7NJ7BD,9D74[:2TT)5B55B'+G2I5F(`L+'CW[JZTID]8S31OJG
M=94=&634&`B*D6T:+Z@]_K_0&_NWKGJVH`$5\NL=0J+"D@1RPDD4+)JU"54(
M+AM7Z7#?4@\CW7-#0=44BIU'KBLA8*@:(N@AC"ADC(B8FT0F*@70`_0DGW;-
M1Y'IP,/XL]<Y`695];.3ZEB72$5&LI0@@DJY]5[6_I[K7]O6]2F@KUEJ0I@`
MD],T;(%3Z:69G$7T`8O=OKR+'\>]@G.,=>IUAHX#3EVED)DOK4/I]:E;-'<%
MC(KLPY/T4?GWKIMZ5`'69Z>-F1E.F-)&*HCH660)=PNJRA2Y^E[?[U[]U6A!
MIY]=`>%9+>F22-C,7"E&TZB=3HJR:G4_ZP^M_>QY$].@@(0W'J+')%)H%.0S
M268.[L5:10+1BS,RH;%?ZZAR>?>OEU1Z$C3PZEQJZMY)(PR@HH$;C4C:KJ79
MT)<@6`_/U]^ZIU+7PV(\A%3Y`S*0"=2OH54;2NG@6:]_Z^]CCCCUM>(ZZ\:^
M.;4(G.H*40K8)^V0RW-VD1S8^_,:CAGI\X4:CU%#NHG8A%,:*`3(K!3(URHC
M*ZKL%(^GO0X9&.M#234]<:2(RS3/&RFQ!DU!@[%C8"3DB..-6X'`_P!Y]^Z9
MX-U/GC,:C0ZC2%53YAH50I&K@J@O_@.!]/>R:^75W*T%.FIY(U>-G%WC",[(
MA>,2`R*)ED`X]`_-K7YO[T:4XYZ\O#KBPAB1D60VD>$>0K?0K6)4&Q`U7N3:
MQ]^ZH?/K$(Z=]!,9)UN)9F9`)&C4:70H3P3<_BPX/OW6NHQ>.178C1+&^@20
M7+,ZMZ?2-2H0XL#SP?Z^_=>ZDE(Y9VUHK,BH7X97?A;_`(&IC>Q!/!%_K[]U
MZI]>I$:10RP,(V>E1R[*SC69I/(4%R&/H4L"`?I;W[\^K)0'CU/CDC5C&9>?
M2\7BB4QQA2+1!E%F:S68<?GWO'''5P5\^'7&>-O)+9N=2-%J?582JS%65F92
M-*\DGT_[Q[]]AZM4:<'KM8C'$^J$EP%!/W!!=74,K1QA;%%U7)!''T]ZZ:7X
MA4]1)XM$;S(Q5I6633)(#<@(MTU?738W/OWRZVQX4/7,TYJ9/'&8]`5681Z2
M[IXB0Q;D1N#<_P"/T]^ZIUCJHA)(41@@+MH4^DR*--E5M)0!F6Y'X!]^TFHZ
M=7X7#8KY]1B50(9_'Z2?)HE(UCUH$<G2VIE6U[C\6'OP\\];&E?A:O6-`E,[
M*%.B8:40*$>+U#2K>LEPZ_J/UX]VH*<>O%EJ#UTCHC,"7%,A"S!%"QQ&.7R1
M`R$E[%_R";6]UZ:.2>L<M+%4,\BRN65P6!<21I,25\/,D98/&.#S?_>??NO4
M/IUU.K/+"[I+I6*1#`TJD$LMXX%]8(54-Q]0>?Z>]T%./5E("TKFO6:D,*K'
M3JQC$NIIH_UMJ>ZHB27+Z"Z^IOI;WKJIXFAZGHS74E@P\\AC`TH&2,:&TH2V
MI2W]D_TO[]UKKM%I&CM,=1\@=(*DZ%0@$D,Q(98E;Z6^MO?JCK51P/6*<1^1
MHS*@B3R/$'X<B-U`"@:KLS6^H^GOW6^H;JCP*]0VB0QEHG8"36BRL%#$AG12
M/H?\??NO=9H/JJ&IT_;G5I<H03J+"S!C^?ZVM:]B/>P*]70J*ZNI*J#H.K49
MBMP@`#/J#*^M3R5+>JU@5`]^;CU5J$XX=9Z2%"H<*SAIO'(H,:(8Q(Q>RZPI
MD`)8?4CWX^@X=6)%#GKD((8GN',*Z56=Y$1TCBU,Y5=#V<N>02+@?CWKJG4Z
MHAB6)3&\DD2J%B9@"A`*BZ$$ZE<`7!L1S?W[KW440E5D`+'4_D$EU40Z%)"@
MEM+!@;$G@>_=;4T(/3?50S\2KJEIG8:]#Z3,51$8:5;_`#90\DGD&WT][/`=
M..5*BAS7K"FASJ58(9OT1@*NF+TE@DHUL.1P+_6_O7373;IB9YUT@QL)."%U
M,SKKLC*^D>-X[7O]#;WNAZM1CPKU,662!%8)^W&U0D+2,EB6"V5F7R?YRYN"
MQ^GO7G3SZKYT\^L%*)A(D9%-XFF!$RZ#K+3,91&%9K`F.Q)O^!;W[JZM04KU
M.F4BIE=]<+RZ*<0:2\<27#B1;Z"RL+\`7%_?A_/K1!-3Y=.%I(FCA)C(TNT$
MJQ@QK`3:5)26#II!X'U#-?\`'OP^SKRM0UKU&6"Y4DD`A@MP0DH1W*%"%U'U
M/;DVM[MZ`<>G*@@9ZEBF\BJBPLX51J+%M(*N7)5B;JJDVX%C:WOQ.>M@K^?6
M.D1(YY+^@!FT,I)_;D72R"-N"=8%K_4>]<`<YZUJ`.&ZSNB>9U$I4,8UT*-,
M:W`4!V6ZAG8WM<#G\>_<!C)Z\2IX\>H=32PC[B*=I$3QJTS1L6A3_*"((B-,
M@'JY(L";7!_/O7V]-L:GKA$M+*XE\RF=4X\E-H%R0KL""(2+VYM<@@C\^_=:
M%3@==-3K)XUC;R``/*9+A+IK)5V4,KE9$)4&QO87]^Z\01Q'400PM4N9`Z*J
MQ,'8$QHS`+(VK5^GR-93SI]^ZUU)C>"+RHTR.R,$.J(QDI(6;]QA?1J+'Z6N
M?;(4Z@:8KTXQ&D"N>IL]!%3TT;*SN9&<M(TK-X%T-(&*L.6!-@;_`.'M\4\^
MM*>-3Y=-D<,)8Z:EA)XPS0R(BL8G5"MBG+1M]?ZW]ZX'U'5JJ*9Z[J8@LB:S
MK);@W95$J*2G`N6#_0V^EC[L<BOEU:@-33RZ[CI)&A_R>-%J1K>5'`D5"P)-
MDC>-HVD`])_('O6>(Z:TL/+IOJX"NA)]9F>10Q"H=),89K@@@1A;'D^D\#\^
M]5KY]:-1QZ;6Q^MQ)#5,KHSNX68A2GZN-+2DL0.;#Z^]_%@<>G`PTT)ZPU-/
M&)$`!XC,<#B4'QQW!E:0M=M0<ZA^">?S[]Q`KQZ\S#30'KN!DC5HHPE09V*$
ML=))``,C2@!6!TCCG_7'OV<TX]:05U'K)]M'&M1!HCB\4:R&2%;HK2$AKE6`
M5&4<`<D'WX9\^KZJG36O4I=`2*$HB*BQE`CF0R1KI.I%'U;TFX)_XI[\5^6.
MMU45ZY$4LGB$JP2"4A0*;R"6)]8U%CJ5F>-.0]BMP1[T.'#/33$&E.NI`)(]
M:,\'D$Z*5TD75;1%F_4SLZ<G^GXO[]Y$=>4T''KU-IB4%VB681CF)O2SE%9C
M^K0+,;\CZ&U_?NJ'CUW'"JRLXE9FC1RRR-J65@"HO;^R+V%@/\/?NO=.FB,S
MA8_!$K0QQFF4$K;2+,2$,BNI4GZG_'Z\-.')Q\-.K@D"OX:]1?MU:2HLZ!%9
ME=Q*&0>E3Y&O^X+_`.(L">?;JX4#Y=6J*<<]#M\<((G[UZ5F5Q_S-OK9"/(A
M!4;SPC!4"K_G&('!^OX'OU>FR#Y]?1\_XW[]UKKH_0_ZQ_WKW[KW4#W[KW7_
MU-_CW[KW6F'_`#VE#?/"%K2)XND.N[O&".!E]X.=3LK+90>?IQ[]U[JFVH@2
M`EUC&MU"*',D)\3*S(6<J0C#46XY-_?NO=1G>F,3!6CATE6B*,)/*I.AWUZN
M0`+6-B+^_=>ZX3?:^HQS)$$+)*YJ(@X`N4_:*A=)MR?KS[LI`K4=>ZQ12T05
MG>JHR42G4J:BD`TAK$E7?G^MR..??F()QU[K,TM$BF6.MI7U2^EA/"+/*6T,
M7C)#"34".+<_7W7K8XCKF%I0%,]=1(%TJ[/50$N7+?N!PYY6_/XXY%_?O\'3
M@=:Y!IU`::BC6WW-))Z2(R]3$DJHIN?&$8^HZB.?J??OLZ;8UD#>77%IZ;4@
M6NH8B-<GE:NBC?U+J1&.O^R0/H2;^[*I<D>?7B:M7J1'D*1A'Y):9@H+RJL\
M),C-J!*,K^3R@&X_''O6*`=69@1@=9D>`2*(ZJCC#!`[O4T\;1*""SV:ZL2"
M;V`)/O75.I,4U((EA^YIJ@AS-&JO%&BV8Z7U-+=B5()M]&^GOW7NL,<D!J6"
MUE*.&=V6:-]-SY&!.H*%OP0/Z_7W[/EUM>(ZZ<>EPICCU#R+)YHA'KN7BT$.
M;@6)N+@7_P!M8D=7D(-".H2BC>69WJ*5G>0FI,E9&+2H%*('9AY";_C\W]UX
M=:#4`'4R:JH8ZAA'-!=EY:*5"95]<:B3U@%O5;2>23_A[]U3KD!!(O[4\3?Y
MG0(I8RH4L/(`@8D.?H03]"??NMZ25=A3M'K3J#-X@XBEJ(X5T5$97R(K3*]_
M59G*L?3:WZA;Z>]BA&>G$J4&./Y_X.LC14[+H,SLK1N5=A''=X['R*`T92RW
MM;B_TX]ZZ;/$]<TT>,7>-D>Z*99(6<@7'+\(7DY(`L>/?NM=<5BIC2OIJ469
MU>,(2D(14XX`"AI&8?UN3^??O.G6PM>N,-/+(\;":,H;%8GG$8CLC*BLX<W!
M`NQ^MS^??NO$4-.L[.L<;(LT=E(BT(%-KEV4B1K2>M;'^G/U]^ZUUG#+'`Z^
M<1RA/*%/C57CU.BN_JU!HR0>+&Y^GU]^Z]U*<PM%)Y:GZ1B1"HC0R2D%O3IL
MQ"N;@?3^OO=:`TX]7#@"E.I7BUI$0I\+A'9XI8VC>3068MZQ9U9B"AN+>]=5
M`JI;J%4THE1E^X5G0JH9T0%8U%M,2JP`46OR/J?Z>_=:ZARS+1S02PA?)(+O
M;3J,3.H"MI95!%QJ%B>?K[]U[K'5T\<RT[55HU21F70T:^25WU(VDR?Z@@@<
M6_I[V":$'JY8$$4/6&,4Q1F\&E3/-&)'`9F9F"H;!QXPQ)Y(MP/\?>O\'6EQ
M4]<ZF"G8Q6J75@%8F5DD=6MP%(?B4R?3_`GW[K1(;(ZR2TMX:L,4_<"ZYF6/
MR2-K1]*E@1R5Y_')'OW7A@@]-QC>-7=%B.L@S(4"@,95TLER1)=?I:W(_I[V
M3\L=69ZBG60B**"4/HF6-WD$8.F6,V(5=6HLNIK:2VH?46]ZZIU$2G+/Z2T1
MG#L/H2%NI5-=U).G3RO^)M;W[KW6<1J\B+''XG'ZY-4JL`2ILDADU"2RB_XY
MX]^Z]U.T.T\R>9@LD1X9C(6`1RFJ0LP!U?46OS^?>Q3SZLH4UK3K@::4V=>0
M`')60D(25:Q<O=DN#^#;\^]''#K0`)(K0#KF**2%3&X60E2ZN'*NJ/(I4#23
M9="BP;TM?Z>]5KU0.">'6`T*PR+,B!F/@E_<TF0+8&1W0EE']H@#]7X]W4TZ
MN!7SZ[:&>,($!:`C1ID/]F5HP3P54*I6YO8W^GO3'42>M4ICIQQT<CRQ2QW3
M7+H;@F-?0T3#268D.%N!]?>NO=39Z>SO3)Y)*9V37*@95+DZ=<9`0N-8TMQQ
M;W[KW7I$JC!,54Q*ACE]8_<34JGA/[*GFX^H!_Q]^Z]TUI3R/)IJ&*QJK_MI
MI3R^1"PT!BL;J`XU7-_Q]??NO==QB>)E&KS10E56-$\;@DZ7_2OC^AT_F^GW
M[KW3;)Y)FECDC*0M#YDB$3"1HGF8V+64!@%!TD<WX]^Z]UGJHE:&5U#1I(%>
M2.-0AIWCLND<J;<6XO\`7WXDT%?7I\87B,"O6>*-#0:&\969G\4<2ERCEOW)
M'C4K$&L2+-_L3?WKSKTG-2^JN.H8HW+QZ2UE5HE96,3`JX#J(E0`WAL;@<L;
M?U][ZWU*I*<I.[3,PMHT69G=KR_I>1M'C,8XN+"Q]^]*=7U"E.IGV\K.I]$R
MPB7Q*Z2*CQ!AK57)!U%S<'^G%K>_=4ZG)&X0>%0DP#EP^LJ%;_.#U-8"Y%E(
M/NK-I'`GJZD`&O'KRB2E=@S*JL(7C26,E'0ZU$<,A^HC7GD<&WNU:YZTQJQ/
M4<THDD=V\BNWJ<#2\9]-T:)5(9V=.;`6X]^ZT!4TZXRTLJ%=-UA94U"1+369
M@&`:T@#,3QJM8CWX!B0%0D_ZN)\NME#Y$$?;UC:!YBZ)Y'`\1+E`?*R$>-$)
MU`!1P3Q<W_Q][./7_!U6G^KCU%FBJ`L@9E4#4C%48@12@>.Q_1YI7_4%'`'O
M6?3'5])%">L5.*N=Y8213@(J15#(2+@%7/CM'XXS$`;\V+>_>=>O.P;AUG>-
MO*KF0&5P2('-E=EO$[L'`B".C7`X^GT)]^ZITZ4=$[0.\4;:-"7#*X?1<CR7
M9F<H#Q>Q_P!:WNFO(6AZL1I`.H9ZBPPU2PQJ9R%$[!%GLZ<DGQ"0#4Z_2S'D
M<>[G`ZKCU%>L`I%AU)*D9E9F*2E]:K<*I2\=[J/P/?AGJP4GAUU'3R+`9`S3
M?Y1(OA$;,LKK^IT#`:&0BUR1:WO9.*=7U*!IH:]8Y4GA.M+@NH36B%77TZ3$
M+$DLLB`\FX'T-O>B0JXKQ'7J@`FN>HD@=5=9A'+4327E>0%46#4J$MH4,0`+
M$F_-OZ^]^G39-:=0$I6D$DR)$AIED4H!)&;`2+%I4<2H"?K_`(^_)16)/#K7
M7I*>7QD2H="*=198RHE1E\B!2`"63D*#_6WO77NN$2Q.=$44FO7X0'"EP55G
MTQDC2C(6NPYN#_7WL&G5E;3UC%/4QQ5,($;Q%`K:PZ-&YT.L"$H0K6:_^)]Z
MJ?SZ\&&L-3'6'[633&:=R'(6:S1FU.+)<.VI"9"%XY]VI7@<=7;@33'6:6F\
M;WB5))BV@2L'/@$JI^VDB,=*WY-OS[\RE:5Z:ZDKCI?W4U))&!&0KR%O!K?U
MBP+,0S&UQ8_GVV30\.O=0I*2.0>!CI<I($M"L:^/EVAC*A@%+)QQ]!;@^[=:
M)H">N4450D<:,_C>-E@];!@\88F,"ZB,@D`#DD>_>G5E&H`^73J=3)4CU"1"
M$D$L01T<%0T:1BQF4WU!M0'!_'OU#4>G3@':1Y]-$E/4&LT,!,&];%6,D)C)
M"&QU"\J$7%_K]>;>]\#TWP/1A_C115[][]%0/"Y:3N#KA5%V/FIQO7#:"AT6
M5^/4/J#Q[\2#Y=69@1PZ^CW[UU3KH_0_ZQ_WKW[KW4#W[KW7_]7?X]^Z]TGL
MCM+:V8J#5Y?;>!RM6T:PM59+#8VOJ6B35HB,]52RRF--9LM["YM[]U[IIJ>N
M=@3H$EV)LV=`1Z)MKX*51;Z65Z`@6]^Z]U@'576-K'KG8?T^G]S]NV^@'T_A
MMOH/?NO=='JCJXWOUML$ZAI-]G;<-U_H;XWD?X>_=>Z;VZ3Z;<L7ZFZR<M>Y
M?86U&-_ZF^(YM_C[]U[KR])=-*H7_1+UEP!]-@[4`X%N%&)L/?NO=>;I+IIA
M9NI>LF%K"^PMIFP_POB/?NO=8WZ3Z>#`KU+UF>+$_P!P=I\#^E_X1]/?NO=<
M)NBNE:@@5/4'5E1&IU(LW7NT)=+V*ZAKP[`$*Q%QS8GWL$CAU[J$/CM\?A].
MB^G!]/IUCLD?3Z?\N3\>]=>ZZ;XZ_'UR"_173;%3J!;K'9+$-_JA?"&Q_P`?
M?NO=09/C#\;)GDEE^/O2<DLK:Y)7ZLV,9&;\DO\`P+5S^>>??NO=8!\6/C(&
MU#X[]'AOKJ'5.Q0U_P"NH8(&_OW7B*]1Q\3OBZ'DD'QTZ/#R@K*W^BO9%Y%/
M)5_]PGJ4D?3W[K0`'#K(OQ3^,*-K7XZ]&JUP=0ZIV,#<?0_\6/\`'OW6^N9^
M*_QC/U^.W1QN03?JG8IN1P";X+D@?GW[KW7?^RL?&6UO]EXZ0`X-EZKV.O(^
MA].#'T]^ZTRA@585!Z99_AM\2:J5IZCXR="S3.VIY9.I]CL[-91J9CA+DV0?
M[8>_=;0>&NE,+UPD^&7Q&F`$OQDZ'<`%?5U5LD^D\6_XLWTM[]U[KB/AA\11
M'XA\8^AA'_J!U5LH+^>;?P:U^??NO=<&^%?Q!:P;XQ=#-;Z7ZKV6;?ZW^X?W
M[K88CAUQ/PI^(!%C\8>AK7!_YE7LOZCZ&_\`![FWOW6NN7^R6?$.UO\`99.B
M>0`;]7;--P!8`WQ!N`![]U[KB_PH^'\GZ_C#T,_X]75>S#Q_3G#_`.'OW7NL
M7^R3?#UG#?[+%T6&B-D(ZPV@NBXM=`N*`6X/X]^Z]UT?A%\/3>_QCZ-Y_`ZT
MVH!_MAC`![]UX8%!PZPCX-?#<7(^,'1H)))/^C;:UR3<DW_AM[W/OW7NL`^"
M/PP&K_G%SHLZR2U^MML-<DW/ZL>;7/OW7NH\GP'^%,HL_P`6>C6YU#_C'6W`
M0;6N"*$$<>_=>ZQ-\`?A*RA#\5^C=(-P!UYMY1?ZW.FC%S_K^_=>ZCR_R]_@
M_/\`YWXK=(/S?G86$'-[W%J86-_S[]U[K+_PW]\)?&8C\7.E3&18J=BX9N.2
M1<P$\D^_=>ZCR_R]/@[,-,GQ6Z28<<?W%PX'IX%M,`M8>_=>ZP+_`"Z_@NJL
MJ_%7I95:^H#9>-`.J]_HG^/OW7NN+?RZ?@PVF_Q:Z=.@!5/]TZ0$`*$`!!O8
M*`/?NO=81_+B^"@(/^RL]0$B]B=L0L1?\`M(;+_@./?NO=8V_EN_!%B&/Q8Z
MAN-1!7;:+;6+-;3,/J/?NM$`\>L+?RUO@:Y)/Q9ZFN?KIP4BWY!_LU0'U'OU
M.O$`@*>'6(_RS_@00P/Q6ZDLQU-_N"DN2+&Y/W=_Q[]UX*!P'6/_`(;*^`VD
M+_LK'584`*%&*K``H^BV%>.!^/Z>_=>(!I7K')_+%^`DBZ'^+/5VGT^E<?D$
M`TD%;!,DMK$7X_/OW6^&.O+_`"Q?@*EM'Q<ZR2Q4C11Y1;%/TGTY0<CW[KW7
MF_EC_`AF#'XP=;W#!A:',@!@VL$*,N%'K%_I]??NO=8)_P"5]\!*EG>7XQ=?
M:Y+%WC?<4#-:X%V@SD9^A]^Z]TW-_*J_E\L&#?&+9)#$EO\`<GO$7+`!B;;E
M!NUN??NO=8O^&H_Y>MF'^RQ[-`=%1@,QO8713<+<;HN`#_3W[KW6+_AI[^7D
M3<_&/9Y)M_R_-]6LIU*+#=86RMR../?NO=<)/Y37\O"4W?XQ[1U!@P9<]OM#
M=2".5W6...1]#[]U[K'_`,-*_P`NWU:/C#M"-GL"\>?WZK@!@Q"G^]GHU']5
MK:@3?Z^_=>Z@G^4/_+LNI'QNPJZ6+JJ[R[)50Q=GU:5WD!<%N#]0+`<`>_=>
MZ[/\HW^7DH55^.&(8>JY_OKV22=1Y#D[Q)8?Z_OW7NN)_E$_R\R58_';&:T;
M6A&^NSP`1^FX7>:JP_UP??NO=19?Y/W\O">1Y7^/T*-))YF2#L7M:"%9#]2D
M4.]T1!_@`![V"1PZ]UU_PSY_+PXU=`E[7L'[,[<<+J%FT!M]G1<#FUO>NO`4
MQU&3^3O_`"["/&WQZ`2RD$]E]M-;390`?[]!E(`'T]^ZV"1PZZG_`).?\O.=
M%0=&U=.H5D/@[-[54NC,C%7U[TDN!HL#];$\^[HP6H:,.AXAJT/Y`CIDQMX:
MQI.Z@'R(KGUJ#TV)_)@_EY1QO''TUF41U9;#M'LWTAOJ%)W62+>Z4`K04%>'
MI\A7RZNH8+1I&8^II7^0'6,?R7?Y>8;6O3V<4\6"]H]EA05!`8*-TZ0UC[W4
MTITZ7)K7KH?R7/Y>0M_QAW.G2-*:NT^S6T"^JRWW4=//O75.N#?R7/Y>32@G
MI[/:D46_XREV7I*W^A!W2;@6]^Z]UPF_DL?R^I$2.'JW=-&D?D"BF[3[$(TR
M$L4_RG<-19%)-@+6]UT"M>M$5()\NH1_DF_R^RK+_HWWB"[B1V':.^+L0JJ.
M/XOI``7\`'D\^[@Z>`ZKH&LO4U_EUQ3^27_+^C!"=>;U4'@C_2CO8BQ8,R@-
ME&`#?0_X'WZM37IP,0*#ILE_D=_`>23R#:W941UNX6/M'<@0:WUE;.SG3?\`
MQ^GU]ZZT<UZ;Y/Y%GP$DE:7^[W::%B6*IVEG?'<\DZ6C;Z^ZE000>M`4-:]<
M?^&*?@&5G!V_VJSS>,I,>U=P>6GDCECD\L%D$09TC\9#JZZ&-@&LPN233Y=;
MZC_\,1_`D-J&,[>7AO2O:62"W8AG:WV/+,1S[UU[K`?Y#GP(,C2G']PEV;4;
M]H5VC5Q9M'\,T:ETBQM?W[KW6`?R%/@*)&D^P[C+L=5SVE6V!YY4#&`+>_T^
MA]^Z]U(C_D._`>(DC'=ODE@YOVA7#U+]"=&-2Y'^/OW7NNH_Y#GP'B)*8WN`
M75EL>T*YQI:Y*C7C6-@3Q[W7(/5BQ(IY=19?Y"GP,="D<?==*";L:?M"34W(
M.EC-@YKKZ?>RQ/'JO6!OY"_P8(=5J.\T#BQT]D4AM]""I?;3,"".#?BY]Z#$
M"G7NH4O\@SX-2%"<EWRGC+%-'8N,4`."'5K;5NZL#S>_^%O>N/7BNH%?7KJ/
M^0=\'$C6$97OEXU9F*OV'C'+:S<@O_=36!Q^"/?J4XCJP+(JKY#KG+_(.^$#
M*1'E>]8F.EM<>_\`$LP*W`OKVF02![\,=;UGT'4)_P"01\*V,A3<7>R>2Q).
M\]N/I8?1AKV@3<`6YN/]C[]U0Y->E1LC^1Y\4=@;KVAO+![Q[N?*;*W!A=Q8
MN&OW-M>HI9ZO!96ER]'#6(FT(99*9JJE42!'1F0D7'U]^Z]U<X/H.+?DC_$_
M7^OOW7NO'Z'_`%C_`+U[]U[J![]U[K__UM_CW[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=='Z'_6/^]>_=>Z@>_=>Z_]??X]^Z]U[W[KW7%EU#]3+_`*QM_M_?
MNO=<O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6,*^O5
MJ]-SQ<_T_I]/K[]U[KN2^@Z;WXM:]_J/Z<^_=>ZY^_=>Z][]U[KWOW7NO>_=
M>Z][]U[K@]_3:_ZUO:_TYO>WX]^Z]US]^Z]UT;V-OK8V_P!?\>_=>Z\H(`!-
MR!R?KS^??NO==^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z\;VX^OXO]/?NO=="]O5:_\`A>W^\^_=>Z[]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=8W5R05:P'U%R+\_X>_=>ZR>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
<NO>_=>Z][]U[KH_0_P"L?]Z]^Z]U`]^Z]U__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g893535exj_stamp35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g893535exj_stamp35.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@"[P'``P$1``(1`0,1`?_$`+0``0`"`@,!`0$!````
M```````("0<*!`4&`P(!"P$!`````````````````````!````8"`0,#`0(&
M"0P)#@,9`0(#!`4&!P@`$1()(1,4%3$B02,6%Q@*43(DU9:7.%@98=2U-E9V
MMM8W5W>W<4(STW0EE=>8@9&RDY2TY#4F)[@Y>9E28C145778*1JA1*1%9J9X
M67+20V.%I4;&1V<H$0$`````````````````````_]H`#`,!``(1`Q$`/P#?
MXX#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@=
M7-3</7(MY-S\FRAX>.2!9_)R+A)HQ9HB<B8*N7*QB)))BH<`ZF$`ZB'`[%-1
M-9--9(Y%4E2%4243,!R*)G*!B'(8HB4Q#E$!`0]!#@?O@.`X#@.`X#@.`X#@
M.`X#@.`X#@.`X#@.!4)Y*]CLI8:R=KQ3<<9=O6-V5WJ.P%FM;''^OMMSK898
M,;TEK.U863&ITRZ/T$UY]8&SE!)L9P=%3W"!T(/`I^T7W_\`(MDZ=LK3'^4)
M*[XMJ$+18RYN-A-2LZ6FZ5;,^393/]ED8(CNAPU,GST^O-J?`M57AF+Y"/\`
MK*3?H`(',D$U+YF#RP![E6E<G4XN07\5+!2GN!M4\]PE+<2=HDH&+IRMK5R5
M1\B11S4(["5=RZ2T[!)23-^V]L[<[4WR@Q)"YU\J-9K<G%94LNQ+O);:A$D(
MN=IFN+-W0YN:>N&[B+E&U=A\7VETR7^(5<KF(=32"Z)!()CE5`4Q#L[%E+R1
M-I5$*IES:*XNF*S5VX@HO!PPJ!F`I24HL,G(734>MPSPS(AD6CENPDQ644%,
MJ`GZ*J@'EXS+_E,?UTB-NRQLNG=X"?<$<QE+UI3J#JWUF3<M'T1+MF<O@+)%
M'8&BH9ZD@X;C:2.CNTEQ$A`Z%('ORY9\AL@K4YMU>MYJPJH4S+(M,9ZY8KL*
M572.HX;-WL,\/C]@A99DXMTW)0:OCLQ25,1043@7@=2_R/Y-:7`HR<GDS=G*
M3N!:O9=JYA-8<-X]_+0KA=Y*GA)REH0N1WT2>#BRI-VRS>4*H_.)@,DFH``8
M/SD*\^0>L7:/8U_)WE,N=#<3=G-/6&LZW:C)R<6@W3;3L.W@XR<A(]20B9+Z
MFLS;F5`JS9M%=JIEG+@O`[>(V)\K..9A2ONJEL)GZ%>H5Z;-DB>PG1<5O(TS
MQ=6,=P!<>5].WIM&,6BDFN\6+,2+MRLJ*B:+=+JD0/<8LVA\PETL%,C[OA>O
M8W8P[:TFFIA]C^WR55M2S9Z^?5L\X^9,3VIDLI$L"L5F[.);IJ/G1%"N"H@)
M^!XMAN!Y*KA2H=&5L[:BY`E6\#+C8(;2?;MC7&P$<-I:7BW^/I7#-V<Q*!(E
M5.*6`;.Z<JR)EUT0*@0@<#DO]U]Z:)$'NF1<C,V$'C:AS]ON,M(ZI[/U*HR3
M!M("\;(3*<G@)V#BQMDT3-0(UEH]$[=1,>TR@F.`11U+\C.]FR>"ZW:H;,M^
MG).#^N.YQ[6=3\G)N9M.UV"QV6K)HS##%^3X^>C65=CR1+%Q[,,*2Q>U<J_:
M94H2*5V4\B+&)CA4ON>)J65(15\>,U>R@S21[$F#M5N9D_U6*1)98CI1J4Q'
M*Y".&ZAQ$4_;%0,6XUV5\M+DM+CLE9#S,W=/Y^QR=DM2>FM]KT$G4$$W$?!U
M@\+#X>O\U!6,LFD5V:3*$@B[:&!/XJ!A]P`R#,[.^2-2NVN6J=\SM&2#-J\@
M8*$M^GV2YVPR3X7;9$UXB(N'P1!U]9@5D"QF3![-,U#'%,ZXE^\D(=$KGKR>
MR%>DUJWL?G1I,GM4DM'?G(\=61:PZ85)!X+V-B`A*92,BQTZ_>PK46AI0\K'
M"21=E,+'V$#'4#J$]L?**#JO-7=RV3<Q3B26<3GT_06SQ\I!1#^#AU2HA9',
M(_0MTE!S@/R%0)"Q*2Y/9*+@`$RI0XD=L[Y.6B=<DI3,6X<^LG&OT;94&GC.
M-64'<L*SH(R0A+N:8L*S%D5M[)EVJL.L83@<I5N@@(!VTSM/Y.7[6QL8+-.T
M-:9'L9PJ*S_Q,S5JM36J_-9G36L%A)EVN0K^8!D+@HHHPR"?<!`]WU,8`XD9
MLMY/VS:/</<V;:7B1:0_M*U-OXO%,5MI:5%8'CMX\R(ZNV1`9HM6_NI($3@N
MJI02`?O@8QP]038CR/R:U<<O\N[EX]*Y3B)&5@&'CJB<JD>QTNY,1-LA:%)K
M'8P3Y`O0BI5X]55$/QBJ:8?=X$=\,[]>3G*%IS53*4KM7ERY:]YTB,"7VNQ.
M'<`4YL,O:V]VMB%F=S*[F<CX9C6J=#Q*CPCA5($%7XM^JJQDA,'F'?E<VTE,
M/[59*K<WOZM%:IW7*./,AW&"P3K'::&C,UU6<8N9:(M,D\J;&4B*C,LVB)A:
M$>+I).#&517%,ON!Q==_,C;,M5[&6.I_R+6.3JF<L+V:TV+-.+]>:7:]DM:<
MGX>E&2UZBK#0H)A9(\<9VZHK?,9V%]33HIK%.0I>@]2A/3-6T-=QS`8*B<B^
M6_=;%!+0[<Q5!NC70]-C,9]G#)L'\94W*4[KC/-;;<9QJ[$\8UK4;'J2")1*
MBF=0`[PY\CN/69N^Q]CB_([Y#V:4#%A6IC%E=\7.7GL$K+QP((.I>UQB^J,I
M=XJR.#R"!SD!^S;#[B8D;@4P=0^$-N;68:UVF:>>1?R-3K>RUMQ].ILUXK<T
M!`5!LET]ZU5@D9J7&SXN&WMCU5?O7[0OKU3_`&`Z6,VA8KUJ<HC?R=^3^0L4
M@J>;2MJOBMR9^6\!'R1V1V#2*12TR0KOTTW4J;3Y,:Y66%QV]ZAC$Z!V-DV,
M4G(NF1+?R5^4FEN*2U5:3D]%^*;*+.0O*[9@G*K.+RM9-,)2)2??3V*BO;&(
M113$4.($]2=H<FK;J520R<QR#$>1?R*V^"K,2W;S.)4O%?FF0QQ(_#CE(Y>9
ML?TG4UO>V[QTXZNEA0FVB`.2_=3(GU3$/OC'.]NE[1;*S0O()Y*\V7:TTF=M
ML-CZZ>/N,Q4]K5-5D&$(YO>/W63->L+1DVWJTK9X])(%7\L('61%5%8HG$0E
M#1\YRV2M=:=BY>2\C5HLT=+@WL&RU7HN-ZWDY:6I>6G)Y>*LH-JA!T!JX(_J
M0QDQ'L:ZL9".!5J594YSKJACG=3,T;D[56_5-_B;R1HO,:TQ^9_*0N,@).7!
M@\)$O5)RQ,8=S&Q5X%)&/,;XK$J2S4XJ"9$@<"2N'MDX.&/(Y/J^&-Z;JAEF
MDXG6&`EZ0)*34H^K5([2(>T*M3LQ$EK)[2C+**2A$SK'7<-4SJ`0`3$X>.K-
MK95H<G%'&'D[GV^4&,VR=-;$[BGJ=,/-KG<'?X^6;V-F\K;Z-4$@,Q!55-$J
M8%[#%$X&#C,K#'L\)S^$#8T\H3Z,L$@,BM?GDC&&RO'G]U)8&D-=T;*@ZCF(
M'1``3*GT[1$!'H(AP/?R2-1RJ\Q1%3<9Y!\;IX7075C[BU>V6';VYHUAP?N3
M9&:5EQ,KWI1VJU!H4BD<=P9T?\6`$$5.!W-EME>1V(BLN.ME]_FE:8.G4@37
M.!UYE7>!'GT>M.X5XWDW##5)[DYPU=*'/($2/;0!>0`AD>I`(CP,:4*P1-&C
M,KFE-HO*)>D;W!)0$1'WG7]N^D<2KRJ)W;:;Q>ZK&J$(N::BT5R-!6EG$V@0
MY0,J0YP.MP.`A=4(?"EFPJGL'Y5;#:U+!$6)CGY;`-<',S0C63AC.*E6W[G6
M2-Q6K`D31]IX60KRQUT%7`I.#GZ'`.UM<_#9/;8*:,]H/)[C>>QLC7XV?;57
M`@P;[*<F_7B)!9SFQY*ZJ3-'D'#`(M1-^I7UHN/*FHN1$#"HD`A7GO/M+G57
M;C"R%)W$W0U9P]G_`!+'PN.\60NO5'"PR^PU<DGTA<X!,F3]<K9()),\7)(2
MBR#21E%G<D)TVR2:('%,,277,N=K50'`M_(;Y1X7#4J+NT9,R/9='(:GW*&Q
M_"U><.:'Q;:\?X#!LW?6&PL42N5W)6YD$U`]IVGUZ<"3^A6W&RN-LP950V:R
MEMYL-BVT:_XER[C*NY!UG@FF5JS.6_(N3XUVUB:]@O'43[U:>45G!.#J22BS
MA!?O*J#9411$-@_'=YCLE4JNWB*B;1!,;''I2"$-=*W+5"TQON=2G9S5=G&S
M23C'J"A1*8BA`Z].I1$H@(A[3@.`X#@.`X#@.`X%/ODJ)"&S-K`WFK/E&L)R
M&--R/9=8C7>PMT46@\/,9U!:OVBKNHV]-):-=-DW!&C-RFW=I$4!8!*'00]E
MX;<=5.IZ*8MNT;`Q;6_Y=<76[9>N#8BRLQD.]J9(NZ$A9YZ2>+.7SUPX6%0R
M15%#%0(H)"``<"U#@.`X#@.`X#@.`X#@=?*Q,9.1[J)F8]G*Q;Y/V7L=(-DG
M;)VCW%/[3ALN0Z*R?<4!Z&`0ZAP(`>+NB5"HZA4.5KM+JE1EK5,9(=V92K1:
M4<28<QF6\A,(U=\H""+AVJU8]"%%3KV`(@7[O3@6'\!P'`<!P'`<!P*K=4QV
M.V2Q"QR(]W=R#7;:A9[G5<@42'Q)K:L&.KC6K1)L'U&D4Y'%+J5:R$+'E:]Q
M'2AUS$4*H8QN_J(<7&&+M:_$]&YWRIF+8V?G[/N;GI:]6&T91+2J_)WK+:M*
M>A&46@5^GP55K9)5_6JLL#-BFD11TJB/WA./J%`WZ>4KA>.\@9M?<24]HYC=
M[L>Z#7.A94KN/&S:?C[S9,JR>2+A%RN+6V*+2\F&$7:SR"!YI67.*Q"-$1<J
M'46$+D->\,T[='&.8=<=D7F7,QX<MV#\<$E87+6$\6:[3,0TR`$C*1+2';8Q
MI%2OE?LD%%Q"12F6F9$42%2.H8JYC=0AC5VEDUMR$Y\3WDTG[OD_7&Z2\7=/
M&=N<$18W]TKA\6-37!&L9&R?779U<;9$U^6A8X\%**H)"Z9C[R[OV2J`F%K>
MJNP^?J#>K+K'OV7&%>R@UE_<U_R[1#69K2-C,6E]R+AY2:?6,CJ-K&;4',6I
M]4@3R!E7!%4EFA5B^Z)0LWZ`(]1`.O3IUZ!UZ#]H=?V!X#H'7KT#J/H(]/40
M#[`Z_P!3KP/[P/R4A"=>PA2]1ZCVE`O4?V1Z`'4?7@0GR9,*QF\&O;5-%%4L
MO@[/;151515(S<C-[1I8#I'(8"@*JT>0AN\#%`H]0#N`!`.C\:;U62U+K4FL
M@FV/)Y-V#D001>'D6Y"/L]Y(=)_&D5")&D&QB*@*:_:`+$$#A]O`S!N796-/
MU0V)LDBLR091>(+THLK()"NS)[T"\:I^^D4IQ4**JY0`.@^HAP/7ZX=P:\X&
M`XB)@PQB[N$PB8PF_(>#ZB8PB(F$1^T?P\#,_`<!P'`<!P'`CEM1JSB;<+$4
MMAS+\?**PKI\PGJ_8JU,/JW=*'<X10SFN7>DV:+6;R4#98!Z/N(+)G[3E$R2
MI5$3G(8-07>*F9'QM6LP:K[D4*PR.6ZCBA2%TEV2HM/+.H[_`-ACK*S=X]IU
MMB:]5IEEC*]0#MVDO:A<O(YLN5$SM`P%ZF*&QIIS@;*6$\U,KGG"5D\HYJV&
MPM)S%_N<41Y$8EP5!XVL%/&BZ[XGJPO)(C6OE<Y)F7[B5DG;^=G'S59RZ=*A
M[9$@M3X#@.`X#@.`X#@.`X%.?DC3L$9L[HU=*B%:0LM6H6_[J.D;C+OH:L,C
MAK.+DAIQ_'D7>LXOO:]RJR*1U$P*'V%Z\#.'B0DFTUX[=:9EF2-3:2\!=)5J
M2&445AR-I'*%X>($B55OQJL65)8`;F/]XR/:(^O`L<X#@.`X#@.`X#@.`X#@
M0;\<15T]0<<H*,FS)JWL&6DHL&KPSPKJ-#+][.@]5.<QS).')SG$Z?</8/I_
M4`)R<!P'`<!P'`<!P*_[AJEE3&=]NV8M*\@5#'MFR59I2]Y8P_E"%D)C#N7K
MW*H,&2]ME9J$!Q<<?V'XC`GO.XE%Q\SVR%52Z=3<"`$!G0WD(V'S'H;L%:X[
M5W:746UQ4T6MXVDX2Y1&P6/IZF1\C*Y*QC#9/JWUYI6:P]FVK=.7202D(]^I
MV`H4W>3@4WZWX5NVW=(\ET^6!UES0VKOEBR=G6Z4&WS-MQG<,1Q=*@;'5([,
M4G,1\8J\L,_"UI@A*5)LH8K4B[590X=7!NT+8=)]EJ#JUBO;#>?:5:`Q1BC+
M<U1KICMZSQ)EJM6>PP[AFXKE=JCNVW^3D$\WY3N<P"1V:5>;)(#[X"!>PX>V
M'AI7QX['>4]\GN%OB>T8T@(QO=(37#1%&PV&#@ZSA.\5VUTVU6#*[NL.&4TW
MSYD*JS;1^U,F99.$=QK5L9,R:BX<"/LAG)_A*L/?&UY(,LVF<U:?2F,:!K!Y
M&8^,9XRR+JSE:M42&R7AO'>TK226D)&B9\91[>+D(>;=`#.<;K>VX$0<*=`N
MSUPV4M6)<E0.F>VV5$<@91F(=E*:][#N*.K1ZYM#3TH1"1?'.YCB+T1IE6M]
MX)R$>R=`#X@D<MR#[ABE"S;@.`X$#\NJ`EO7K(J(%,">&=AE!*<`$A@(WJIA
M`P&^Z)1`/7KZ=.!RO'&[9R6IM,F&"*39G.W3,\\@T;&C!8LB369;Y)_!C"0[
MAU'H13,7(I-DDSC[2!2E-T,`@`>FW_443TLV7]I1-$ZF)K.W!51RDT*F#IL5
ML8_OK)+)$.!%1[0$H@8W0OIUZ\#-&!6A6&#,,,2'.H1EB?'30AU2>VH<K:GP
MZ)3J)]1]LY@)U$OX!].!EC@.`X#@.`X#@.!%[=0A`U3SV\`A0>1^+[>ZCW8`
M`.F#KZ.Y1^2R<!T6:.`25,4%$Q*<`,(=?7@?/')LIGL&N9HX0/AXVM<L:Z'.
M9L98V1!_-"-#$14$7QNZ"&?$PEZDZ_M_7MX$I>`X#@.`X#@.`X#@.!3)Y,7!
MF^TWCV[X(EHCW$-OJQG*T+*3?J3T$_U<>-)&*;H1+5X[]YV58H"84S)%3[N\
M2E'J`9_\2#!O$^.W6F*:(,VC2,@+I'-6L>1NG'M6S'*%X:H-F";/HT39())`
M1(J7XH$P`"_=Z<"QS@.`X#@.`X#@.`X#@.!`?QGL9&/U'J23U-DBV5OF:7,*
MDQ4>G(2%7S!=CM072>-6J;5T*ON"=-M[C8.H"0YA$W0)\<!P'`<!P'`<!P'`
MK7\B?CUC]S*E#W;%^0I[77<;$35^^UZV8HJQV%EJDBL'R%Z9;DT.B=OQ;:5T
MRIR<0\*NAT-[R9/<`0.%-NI.S>ENOF`/('%;)U*NZ)>0BMXDM,/NMCVPY0R,
M\K%_ESM+XVQ[E_#;R_3DS`2%>RHZM8NHY"O`J>.!Z@Q$%&[=J<P9%\?>DN8/
M(&UURVR\E&(5<;XGU[JU">Z+Z9JVE5["U^09PB1'NP&<(EO7JVYE\A3JS9LY
MAHYQ[;>/:J&*X;J&-ZALZ\"M#R':(8XV=P[G%T3$M>R7=KWC`E8MU`F'JL:S
MS'"4Q.<F:E76$FN=Q%4;*45)RBQ*Y;B-3NH]9<$'0K,>B:04S8RV)A,8Q5,\
M<N_KVVSFLF0U65<U=VWM\(WH%AUMRAB:"BI6-PAG:1,FW&O9LQE:4T`KUK1]
MF,GVZ97!>Q!0P"%ZF!<^9`J>1IC6_:B5KC"WGDH9AK1EU[)4^M(;@55O1V<S
M9Y6KTZ/LTJ^:9"I;YFZ4G6!$FZ2K9=)VR1^,"P(!/3@.!!'+8`.]NL0&Z"4<
M-["@8!#J`@+>J`/4!`>H=/P=.!WOC]C"Q&KU28)Q:D.@G<<OJ-62C5FR'X;C
M+MW<-'1&K%-)NBB^;JE6(`$(;L4#N*!NH<#D>0I`CK2G8]JJ43I.L;R354A3
MJ)&.FX=,D5"%51*99(QR'$`,0!.41ZE`1`.!(C$K1)ABO&;%$ADD66/J8T23
M.JNN=-)M7(U%,AEW)2.5C$(0`$ZA0.8?4P`/7@9!X#@.`X#@.`X#@1@W5_DE
M[#_Z*+?_`&+6X'78YBTE;5K9,CD)&/69:Q3D<3%HOG2;BTIR!\,N%+N2.+()
MLW*-,-'%9F6.U542&:*4JJ8*&*H$L.`X#@.`X#@.`X#@.!2QY-I]6J[4Z#V6
M0<UV-K4+2=_G*\K92/U81"<6UG%M&L[&FU=QZ'Y/R"*JJ1A5<H%^2*0=X?8(
M2&\1*JZ_CFUC7=-3L7*]:MZSEBHJ1=1FX5R;=E%FAUDRD(L=LJ82"8H`!A+U
M`.!9#P'`<!P'`<!P'`<!P'`KV\8+R2>:G1(2)612,\IYS8QGPF/PA-%(9;MP
MM3/3>ZI\U^)CG]QQT)[GI]T.GJ%A/`<!P'`<!P'`<!P(^[,[087U%Q7*Y@SE
M;4:O4XYW&Q3)%)!62G[)/S3]M%0M<J\"S!21G)F3D'B9"I(D$$R"954R:)%%
M"AKB4G6:Y>45ILYY(/)1@2NI8VQMC/(#3Q]ZX6JMK)$IE3;8O?R5IRW?V3]X
MNQOEHL\XFU28HS#5PVBGT*9VR(FFNCVAL>ZI1<W"ZTX(BK',1D_-,L5TI%]+
MPR3=&+>G^A,S)'9)-")M2HD;F(3\64"")1$``.!(#@.!6SY!=)FFS-!L;N#:
M*SCJ2J\C6,FX?</_`*?4\^T!R4BSNMO%@[1J^3H91`CFK6=L9-Y&2":::ICM
M#G3`*@-.<XNL$Q$'H;Y",B[#6VBY=R!,PNC>ZF1$$ZU<L=*&9HQ$5@'*N2HM
MR%HPULK0IINHR8/':_QIM%5%5BO\10"@%\&&\Q6NJY!;ZQ9[4=.,KK-+M9\6
MW6/BY5_7LK8BK4\#*(F)J>9P;2OU[*$1#O6B<Y%**$%PL`O&O<BL*2(3%X$&
M\J(F5WDUQ,)4Q:IX3S^+PYT?=,1`YZ<GU24[#%0.)S``B)DP,7J7J/7H(>LT
M:/'FUKIJ<0X7=0K2?R2P@W"\:2).K",,DVQI$F(R2=ODR(?`13!,X+*`J3H?
MN'NX'PW[*8VF^P12G%,QJ&X*50H%,9,QI*.`JA2G`Q#&((]0`P"`B'J'3@2-
MQR4Q,>T0AU3+')3:P4ZQRD*=4Q81B!E3E3*1,IE!#J(%`"@(^@`'`]EP'`<!
MP'`<!P'`C!NK_)+V'_T46_\`L6MP.DQXOBXMWUE;2C.1/F175FR+4U^FH["*
M0QXBOA$M^:NTB/",3OG,^K`&0,H@HH4B:H$.0!.4X2ZX#@.`X#@.`X#@.`X%
M/WD<9RKW9?1YN@]AQA5Z;O2G,P,LTCGY)Q)+7,79.YM/E_)P&T:+?WSG<CU`
M0`"@("80#,'B)7>.?'-K&YD'BDC(.*W;UW\BL9N=60>JY-NRCM\J9I^Y#*.W
M!C*&%+\6(F^[]WIP+(>`X#@.`X#@.`X#@.`X$%?&XT*VU$H+@C3X82MIR_*B
MF<CA)P<SK+]Y**SM%R`"DY5%+J)2?B^WH)?0>!.K@.`X#@.`X#@.!B#.6=<:
M:Z8]D<EY4L"4#7&;MC$LB%25=RMAL<PM\6!JU<C&Y3NY>Q3[X00:-DBB=10?
MP%`1`-<;"]#QUYM=L;!D?9_(%_=4#4Z^BYHVDTK6J>GBUM)UZ240:Y&K&7ZA
M)%E\AD._5:M)]7K^)??+A50*FV*8P;#NS:"#35[81LV12;MFV!,L(-VZ!"HH
M(((X\GTTD44DP*1))),H%*4H`!0#H'`]%@1FXC\'X?9.E#JN&V,J,DLHHFU2
M.8Y:U&]1.FQ`&A3?L^W]T>!EG@.`X%9&]/CGQ_M4PM,TC&-GLE?8ZHUG,N/9
M=ZY;TS--)J4PI)0:BYT5"JTK,./57BSVHV]A[;Z->%!!;W6JI@3"F;"&W-NP
MIF'&7CFWHFLA9@ULR!E^/INH&[#.5FZ[DND95Q]:4[#7-;MGY$XQSRN92J[=
M@VC5%Q[F\TR*13\<BZ$2A?\`XESU:JWEM]J]L&N\>Y6^FR5VHV48RBR%6Q3D
MVBO)U1I"P\7.*J+0J&48!%4J$I#$5]U3V_DH%.B?J4.@RJS;J[[ZR*"W3,X>
M8/V%ASN#BMU*Q<J4IVJ@!2J%1$%'#1,PB8IC="^@AUX'O-(X=S6=?HFH.13'
M\B;_`)FI#3V6)HYN$;4,OW>O18-FQS&4%L$?')^VH?H=8G0Y@`3"'`XV_'\C
MO/W]XRO]E(W@2.Q]_:%2/[T*U_89EP/7\!P'`<!P'`<!P(P;J_R2]A_]%%O_
M`+%K<#Y8VE;$E-ZYPK?'C>0JKW6R2DI7*9FYS.JK.1X8C;PM(2=`B*:2%T92
M+UZ<@G*)S0I1`H]HB`2DX#@.`X#@.`X#@.`X%3_D%F)JH[":77J-A[+;$:JU
MV:E%:E6`AD7<LDUQ:P-),WCJ;AYMFK$2\2JJV=M_9!51'K[1@/P)">.DL.34
M/'!:\Q:Q=?+9\VE@8QBS0CV4;"AGC)H14>SCVI2-F#1DP!-)-%,H)I$*!2@!
M0#@3<X#@.`X#@.`X#@.`X#@0A\<CI=YIQB9PY!4JRC_*@'!9D>/4Z)YCR"F3
MN9G67,D`D('01./>'0WIUZ`$WN`X#@.`X#@.`X&MGNUH[Y'MZ]V'-)M-B7QK
MI/7):HRM*R14[XPI<M38".?).+<YHS"IV69OUDS1=&8J1QGDFQ@(^%CE#*,7
MHN!Z"%E^1,64/`^:?&Q5<.Q#;&]8A,D9=P\QK->92:T<\QQ+:X9@R'(U=\Y(
MLL9-NXO-`B)A9V_45%R_9%$YCN%BGX$I]I/Y,NQ?^@G+O^K^P\#V>(O\D^,/
M]'E*_P`&XW@8-S[=+]-6RFX+Q794\<6RU3-<FI7(4W#IO6"%/@YE&P6RNU>-
ME'L(A;IRSU:#?1:@1KM5Y"&?(O5412*(\#G8HMV0:YE"SX3NLZSR?',&SZQ5
M;(4##JL'E6BU':2S/&N5&Z+^69MK;&PL@S68R0JMS3K8YU?B("D;N"4_`<"O
M#?31NC;68[FV+JFM;4^E',2ZN%-&<3JI<@L84K=*,E8NQA'NG55S%C]!N#NF
M3[=>/58R29$'+DK!9<"A2[@/:I;!IH33?R47"R/-?IG*0!H=N_L.K/0&38G+
MM?D%7%,P[GYA$Q\,UH65L-''W6=@F9&-B;*U`@H+N2J]Y@M#H,IDU[O9KK0L
MPP60IRU8OUMS,JGL8%+B(C#N>1E)C'C$K^M%IUPN;"ES:[-V+D6$R9D[5!DN
M9L0R)BF,$X-62,4L9S:$<W,U:M\T;"MRI'-*'.*K?.60$7"IU)A9P^5,NX(8
MXG$XIG[NJ?1,2AP/(;\?R.\_?WC*_P!E(W@2.Q]_:%2/[T*U_89EP/7\!P'`
M<!P'`<!P(P;J_P`DO8?_`$46_P#L6MP/IC1G>CR.O#]B=P&-V^N3UK9"%?,B
M-C7!TGBA6I&4C3K!(.5RQ+67[%DTS)(E$Q5#%,HF!@DWP'`<!P'`<!P'`<!P
M*@O(ZW?*;(Z*O8Y\1DO"0^Z$J!G%@D8>,573P"D5BSF&=>L-6M,NRDURBW(F
MQ>MQ(L<IE#=@"`A([QGR!)?2K$,LFU^"G*R>7))-C[X.?A$?YMR.[*T^2"S@
M''QBJ]GN>XIW]O7N-UZB$[^`X#@.`X#@.`X#@.`X$(?'(=XIIQB8[\CHCH9#
M*GNE>_%^2`!F/()4O<^$1-MT%("B7M`/N].OKU'@3>X#@.`X#@.`X#@.!19E
MO:^-PQYD:/`;?LD\.8(DM9)^LZ:Y?MUIK4?B*TY;E+#%36=3V63DY)@C5+XS
MJT9#1D*+I,#@R=2!$E3$>JE3"UC9U9%SJ_L*X;JI.&[C`F65D%T5"*HK(JX]
MGSI*I*D$Q%$E"&`2F`1`0'J'`]QB+_)/C#_1Y2O\&XW@?+)^+*OE>O\`T.Q%
M>M'+1VQE("QPKL\99*O.14@TEHJ:@95'HNS>,I*/15Z>J2P$[%"G((E$.TH=
M$A<>UUA7H<\@]^*D8'DU-O5I6P3CU=PX>O96<EG1CNI&1?OW:RRASB/WU#=`
M`.@<#VG`<!P*QO(;H+0=J\:7EDO1*+:&MYC$HW-='M'M0[3+%0B(YX2)<1UL
M/[C6@98HCI0CVMVH[=P>/41%!8IFRA@*%7WB2\C+7'%7ROK-F/--!RYK3J5/
M8XQ3BO<(+*FXLC*LVJ$M;:IXZSA"UVMKUQG/8P6Q\\B)BSIO&T,G^XU5!!%R
M14H7R:F/59+$*TD=VSE&TCE+.+Z*G(]VR?L+)!.\R7E>"M#-[&/'L8[;62).
MB](HU.#8Q5P%(B9.TA0@OE[?#63;S`NX.,,&WJ1L<EC2ERR4Y:7],N<)CR3&
M$MS:LSPU.\OX).!M0P-E:'8.R,E55$G`?M13^_P+3\>_V@T?T$/_`"0K7H/V
MA_Q*R]!_J\#U_`<!P'`<!P'`<"+6[IT4]1=BCN)1G"(%Q/;A6EY!L9XRCDOI
MJH'=.6A'T8=PDD7U$@.$>[[.\/MX']H-38+VS7>XMK='=L%K;.UIE5W+%1"=
ML#&?5P^_"SMC!)F29L88*\FBY0%!<PJR"718@$$%`E)P'`<!P'`<!P'`<!P*
MDM]`05V[T6C79FPM;'$;0UHPFKA;4Z8.9/%B*3*13C1.BDP9$7,!'+YPH5!`
M@@'[8P<#-GBVA75:T1P77'HD,]KP9-@GADP$$S.HC,608]P)`$1$""LV-T]1
M].!8#P'`<!P'`<!P'`<!P'`@SXVDI)'3'$:<NN9Q(%D,K>^L=9)P8X#F?(9D
M`%9'\4;L;B0H=/L`.@^H#P)S<!P'`<!P'`<!P'`@!Y*X_39#5VW7W=B8KM0Q
MIBU5I>X#(#]O&N+;2KU#JE_)>3QL@]:/G$E=W$FJFW9L$$%Q?J*@B9,Q3=0#
M7FTL\F^Q>',$P>IWD<PWD;'&/-J,.9Y2T6V=S+,NY>PYN66B[;-1E$S-&IMF
MZ6,;!-5.9CU8-BJ9,/BKI-4^H`F8`VU,1'<GQ5C47C(\:Z"AU(CB/.W<-#,E
MDX)BFHU%LZ$7*'LF+V]IQ$P=/7@9$X#@.`X'@K)DZAU"SUBGV6RQT/8;BA+N
M*\Q>',3YJ4&BBXD3J+@44&1$T%1,0RYDR*>V<"B)BB'`UWMZ=GLH;XS^2\%X
M05M%'\?."9NQM=N=E*=8&K*V;(RF/&YW=SU<ULCFBY)ZUH"N@9I9)2.[T#HF
M%LFH'>(F"`6<*W&S^O[=KABB)TR_;&TN`QKXW-3\/QES559/"1\I,S5OR7@>
MUQ,:TH]#:8\9(L;A)3[AVTD&#ER5$WO'3Z!8;A/2?R1QF.9_Q^;,[%XEIFIA
M+A"S<9L'C27;T+8C*=;DI>*NT[A'#M)AW+>)P]CR.MI#Q19!PHM-A&KG1;$[
M#$'@3\V9QMB?$*6OF(J/$5S'U.C,-[25BLU@K$AZ@G"Q^-8=^X3D8([IJVGW
MR+X$W:97*@G<.Q,H<XG,)A"=>"[?5YW&N.XJ)N%;LLU&XXI2DLA#RT4Y>I"%
M?C$%';J,8/'2L>DLY`0`IONE,/:`CTX&9^`X#@.`X#@.`X'A<G,3R>/+FP3:
MQCT[NNRB!&DU$?7HIP8[4X`E(0W0?J38P_MD>@]X>G`QW!N*P7(&'6KU)U^6
MRV$;2O$*(NR(QB=?1?XO)8DE8WM*99P>17CQ14#H")"G*(??#@9^X#@.`X#@
M.`X#@.`X%)7E;;73\\NI4U3H&%GI2O8ZW1<1$1+6NJ59*RRDGB*!C7<`YD+B
MNW@XYDC"J+O1=.?<0(J@0ABE,8AN!-#QN"Q-IMBTT6FHC&&G<R&C453@HJDP
M'.62A9I*J`1(JBB;82@8P%*`B'4`#[.!.7@.`X#@.`X#@.`X#@.!`SQDLW##
M27#S1T<%%TI'+@G.4CI,!!7-N1U2="/46[D.B:@!]X@=?M#J'01">?`<!P'`
M<!P'`<#"FPNP^'M6,26_-^=;S!X_QU2XU=_*3<X^;,BN7!$55&<+$I.%4SRD
M_,+)@@S9I=RSE<Q2$`1'@46ZNZY93\L>Q-.\EF\E$D:-K#CSWG&@.D]V2`SQ
M-L)G"([$;'5-;YT(]NLPHH=6#C#"(L42)G4+V%(+D+9O(/J_@S:[4#-.)L\4
M=I;Z2A0;+9XQ)%LJ$U6+'5("0E8"R5!TQ69R$9/Q#EL'LBV61%4@F0,(I*'*
M(5!^.?>3.^HV3J)X^O)??5["SR-5JE)Z$[@V6AOL:5_.]6<5]JY7P_D`\F5L
MU@,VU`5"MTVKE-LH\03*`"JH8AE`V4P'KZAZ@/J`A^'@.`X&"\XYJ88>AH-T
M=!JL[L$^C"_59<TJUIE09$;K/Y2TY"L43%3):C68]BV,0'CI--LH^6;MQ4(9
M<I@#4JV8S_?/(W/YPQSB":R&QT:Q":&3VTW%Q[CK).,+/LYDB%^L0URUBP2K
M/+W"8K]!>RQ$CSID$7$?55(922*N9.4("@?"XC1L=-J+)0^"J[:,A2DC-ZZ^
M-G2G'T-=8:2>4#(U6@$9J\Y`687*"6)08FV1H2T_=SL8A^\125;-S*F5$#!L
M$Z#^.R,UAE+;LYGVU?GGWLS?#,'.?,SO5P_)"MB@118V-<#5H[".:XUPY6$C
M%;,F*:8N%4T/=75.90X<"%6^FR^&\W;K>+K#^+7&*\G&R5GC.=96R'(XUE\@
M-:E*8FPI4\_L)?'5]BKO6(P[UHZ+%@H@V9SK:2,HLU]UDNW5,(8RK<'^F-2M
MN]Q<NWJ8SS;,%T&0PMA>LWW"B^!,>8]37A&2F6;9'XAF;]>#2TI=G*8J$=3C
MIRHBW0(DBF!1`.!D'96A8CS$[P[JIHCBFJ0FY:..8'(CW9G%,V.&HC3YJVJ<
M6I4\BYN=8Q9LSY.EIF2D$!B:!,L9!I,"<ZJ[=NW(=RF&PM#-I!E$13.6D0EY
M1I&L6TE+%:D8A*/T&R23R1!DFHL1H#UP0RGM%.8$^[M`1Z=>!V7`<!P'`<!P
M'`Z2R'43K\THDT._5)%O3)LTR,E%%S@W4$I"$DE46!S=WKT6.5,>GJ/3@8GK
MEDE2VO$5><55>QI3.&IR>DLM_3!01CI**<8Y;$KZBS2,5C6"UX^LK/P;%>(]
MP18^VDJ5,3)!G/@.`X#@.`X#@.`X#@:ZOFVV<P]C:6I$7+_G-7N^/<<9]<S2
MV.\979>R04/;,<P;]@_K>0W=/>44&QQ8$+(E:N7SE`AP(=$BABB4/$^)+RRX
MFD\"9-:99N4HZI-(S)96&-I2CZR[*/+(W:9#M>0;])56^5^`K^4Y%O.U1XHH
MV4>**II+'`Q3&]S[A0MD8^3G3F20*Y:7#+1TC*J(`*NJ6V;4_N)*L$3@*3K!
MZ*H%!231Z&$O:(&,("($4$H>D>>0S55@Y09NK3DTJ[EVV9(E3UKV9<D,X=J"
MD@4R[;#ZR"29CA]XYC%3('J8P!Z\#F*[_:O(IJJ*6?)($16]A00URV1.(*_?
M]"E)B0QCE^X/WB@)?ZOJ'`QP\\FN!XR?D8N7QUM+%P49(S3!>^*ZRY7?5!4L
M,$P`2#7Z-`R=H<Q\LK"*$9G+&=ZAE$NXA"J%-P/J;RF::&1;*-+/FA^L^(J9
M@R;:D;;$=O%$C&3%N4'F$&J#98ZA>TOR%$2C]O<`>O`_3OR582,9P>L8RVGO
M4>T<+,G4K6M;<ELV2#YNU9NG+3VKA%5637,@5Z4@J)-U$#J%.4BANT>!\X/R
M6X7ET7#EYBG:VM-6R->>J.+#K=D1$#1EBD!8)R22$6QE7:J$44IEWJ14Q=(-
MRB;VC&$I1#LF_DWU#^F)2\Q9LIU1@Y,C\-:UZX[$0WS$5R%.FX2(MBXYDDNI
MP*8%O:.0WH8H=0ZAZEKY#]0WKAPU:90EG"[=!%<Q$L3YF."_R#)D1;,5`Q[[
M<C(G45`OQ6XJN0-U**?4!``[)7?36!$\,4UPNQB6!>1;Q+E'!6?7#%RM%S#2
M!=D/((8P48M`&5>I)(BLHF#D#=Z(G3*8P!Y>3\DFH\._4C'ULRH5\DR9OS)(
M:O;2NTA;2#-1^T$KQIAA9B*IVR0B9/W>](WW%`*80#@0#\<'E&T\/I#B^?</
M\NU>)3OV<Z4U:#KEG&SNEI:L94L<A+.!:XRH5Z3BV2R=B;G2^<=JX.8QRF2*
MHFH4H3$#RRZ4"V^0-FSD4?F?$^,;3O<`'0$^H?!^:*?YBA+\+V_W3W=W?\;[
MW;W_`'.!U[[RXZ;,#P_>OL6X;340XE47K33G:Y=NS,V.Z2/%R1`PZ5VSE3+M
M1(5,4A(83D,!^PW<`=1)^8C3..4]M)OL[*A\)H\]V*TOVN62[W1#',P[G.(6
MAOG,^G:L7IV%,(`!C>O0/DX\PNI:;-"0:57;.49+.%FJJ[#3?9$IF:R`M3G!
MTU?XZ8O0(+-=1P4Z:2A#)ME0`?<]M-0.N+YD=5OB#(.,=;DLXX%*ZD9ZOIKL
M"8I#V./&22ZM&U*<20EBT.TKT00$&ZIP)]XW4`#G-/,5J"[C&4I]`VN;I/':
M+$S9SICLZF^9NEC*]J;QL7&!S)D*DE[AE"B=("F#[W</:`?UUY>];T'#YFCB
M?<U^]8.&J"K5GJ)F<3*D=_512=-G#FO-F2[8$XH3G$%>\@+H@)0,<0*'5RGF
MJT8JU$DLEY%DL]XGI<-#K3,S/90U>S[38Z(3(J[:H,9%_)4$&#61?OV9D$$S
M*]IE!*8QBIF`XA0Z;9L_DCVMHNV6\>$-H8G0+$5KC972'4F(UBO>0$<\3TL4
MR->V1SB5@QD(#Z.FH(?2XMUW)H',FJ<2I`8Z@7Z%\N.OY',1'(81W.65F':D
M;%D8:M7]XV.Y;NY>/435=,4UV4<BF]@':7N.%$4N]`0[OO$[@QAE[RUX,LF&
M<Z1<#A'<X\XSPED6;18RNK&2X%NNR"I6%/Y`2\PR9PQ"H+MNBJ9G`+E*8#`F
M8OJ`0GG\_>/_`'<\>V&]5LM:X;FVRD6_#="L53DX377)[J9H]G3CC.H.SUV^
MLQ;?3;16II`RI3INRE.4H$,)DSB`AT.B'F-LVMBJFE/D'J^9[):Z!9J/C/7S
M9^MX6G(VM9NI]@K30<=5/(\*[.U?TG/;:*C%A>-5@5^K@DHL004)U<!;JS\G
M&+'ZJR+77_<Q0[<ZJ:G?K?:&Y>Y!VX9*=AW3Q$BI?D-3@`E$0,4`.'4ABF$.
M@/Y4L5/XEX\@L#[?%<$>!$MU[#K;>(6)0E%1,1(THX<F27:Q*0D$RSL"&123
M`3";[.H:S>Q^V5L\D&2(+%&+<9[:2'B_F\BY$=;SY_QMC*N$O^QN2J*9%53$
M=*-6CTB>J5>91U8&HNI%F_<M7\6\;'<)HNA7.J'6Y'RCJ.C<-=*@E@7;J59J
M1<6EKEHX.C=;4L=NKE*@DY1G<*^>;RW:TJU,Y`M-K9M[U=I=%TWDR$=)J("4
MJ9N!,CQ4[+8'Q?L+M%:]J]6LZ8U\K-KDY&=OF("8X1M+^@ZXL)%**QM7<"?3
M),L$OCJ&@4FXR)X;H11SW!]\I```O3L'D`K[NJ.C.]:MW*PVL7U:O1TRG@B/
M?2#(R\4Y4;6%&.:VR762:&^UN+EN'58`*JF4!X&OQ4+9AG4+8SQWP<G2=H,W
MW&K9$SE8J2^R'JP:GW;ZC:,9X:P_+%QI5,>-X6OR%A5K[%Q+SUBFUQ.BHY=F
M4,<'@>R&5*ENO<-$M)<VP61M9\XRV2LK9_RJS:3\RGEM;"V-Z'?9^<0QQ;[O
MDW-##-\I6(NJ0"2!W+$(B1C4WPD;$Z)&!7@8(\9'E9Q/X]XN,P+LM3\QHIYI
M@U]@I3)UHQGC2O90C[S=W1$F\-D4D+DIE-7BOVF,AEW=<D1JM?>,HI)N"[-1
MLK\EN&P@[\F2#0MJ.&B/D/>$J0R7RC,<%4=R262CRN5D7%>.7,`$F$)9F@5=
MH*8]5$UTP,!%!,0H><'RD3H*I(CXQ_*3[BSM=BF'YB<,"47+9^$8L05`V.%,
MA`>F[2J&$$SD_&%,*?W^!Z*`\ECV69*R\QX^/([2:\W<OFCF>M>$\7`W;JQ;
ME5M(B:(KN=;%:54&PMU3`JG'G37(F/LF4$2@8/01ODOQ5+1B\FSP5N$)4EF"
M1&;C7*V,W[E-^T,]*Y;MW2Z(&;MD>P%NXQ3D.J4O:)@.!0[!IY),-K,6D@]Q
M5M3#MW$L]A7`26N60A7C7C-8K8IGS:.8R"X-'C@W:BNB59(W03&,4G0PA]WG
MD7Q:RFRQ"N&=KSMCR3>-+84-?+<M`B9R8A"//>3,,@5@0Y^AU!;`)>@B(=/7
M@3FK4^QM4!#V2,3?I,)R.:2;1&4CW<5)(HNT2K$1?QK])!XQ=I`;M424*!B'
M`0X'=\"`^]6Y5.U8H5F3N&,-DKDSDL:VBQ#8<#XV7NQ(A%DX:PZC!:10DFPQ
MMC5-)`NW2.D)5$$E#=X"7H(1#Q1OY,4O,UTKUFQ%N!*X5B<":[5K%T<77!\S
M-^<&IO<LQ^9)Y`H32LL=&5BG52`R:HG2;BD`$,)C'$0N1J%F9W2K5ZVQS.7C
MF%EAX^;:,)^-<0TVS;R39-TDVEHET`.8Z11(H!5D5/OIG`2CZAP/1\!P'`<!
MP'`^+EP@S;KNW*I$&S5%5PX64'M3100(9154X_@(FF41$?V`X'EZ-?:9DVKQ
MMUQ_98BW528!R,9/P;LCV->_#=KL70(KI^@F0=MCIF`>@@8H\#UW`HG\Z+AN
MSPW5W+F1&/(..=C&")EA>J1YWLI5*BQ8F>M&`"X<F;N52G1$/]S5`#>H`("&
M5?##KE%X<UXR)E(\Q<)2\;(9VS)=K\VM3^/>-X>5IN6LA8]:,Z\G&MVS5&+D
M$8(\B8W;WK+O3G,`"/3@7!\!P'`<!P'`<#Y+((N""DX1273-^V363(J0>@@(
M=2'`Q1]0X'%+%19/;`D:P("*WR$0*S;E]IQW"?WT^B8=BW>/7N#H;KZ]>!S0
M(0I2D*0H$+V]I`*`%+V"`D[2@'0.T0#I^QTX'ZX$*?'BQ9,=1L9D8LF;$B\K
ME%TNFR:H-$UG2V6[T*SE4C=-,BCA82@)SB`F./J(B/`FMP'`<!P'`<##&P6P
MN&]6<1W'.>>[]`XVQA1(Q24L-GL#Q-JV2*7[K=BR2,;WY*7D5Q*BV:HE.LNJ
M8"E*/`U\\&87SMYP,N,]MMPV=GQUXQ:5<UIK3[2^7:2-;>;%(P#EVSKF?=DJ
M^Y[%WL#*(+*.HB$<#[8D5`QB>V!3*!LS1T<PAX]A$Q3)K&Q<6S:QT;',4$VK
M)@P9($;,V31LB4B+=JU;I%(F0H`4A"@```!P-,1]N]F;1Z4V%4UL>4#)URS-
MY),=5RV718V0K`DYJETG=J7V1(VRI92GE6D!*X[KV)TF#%E6DF[(KKHH"9R.
M3&`+5,!V_,U[<^3&(NMVS!,5R"P//M(.`R_=(^6/'V^PP^6CS3FKU^!.K7JE
M4&T>T8-D$DC?(2<IN4E`[$4A$(_[E>6NXZ:ZWZBZ;Z>XV4SGY'<^8OI]<QYA
M[XB0.,7-"U5DN[O.0JZT<$<L?AQPG=,62@I@J1/WU^UN4PB%>=4U=N]+P7L3
MCZ<R3M'M?E6R2E2RQN0SSM%'K6`-DKY:)A%48'17(DN\;JU38.LO:^JA2IQ%
M5)A-*QBC/N]HP\"RSQJ^4F6J=WK.JVVN;T\QT/(<G*06GFZEHC4ZK.9!E:S(
M2\/8=<MKF1O8C<:;:4Y:$.*K%W[*DZF)ED@-Z"(>-\BFZ%ZWC4S]K/K-E%IB
M?27"]>C&^WNXM5<NY&S92FI:319/]7=79"*5!HYMRX=S&S3`&.E#E6[1,4.\
M1",&4L@T_&B./YMGK],S]R5@<;8Q\<>AT!;L>S%^OEMIT9E*HW6=L"&,'["7
M1I$5*LF"MMF9E$/K<._66(J<2$.`3TQ%C+(&H]Y3N=H>8JV4\UVY-:HL:\JB
MA%F&)]9,0P41\!V@Q8UP[F=I.M&,6=>(Q>/VA4W=FL(MDTP,=SU(')R)B>6W
MIMJ5.RNM`ZH>9#2Q^>U8.SS18&QQV/LD5=)^]6KDW37EAZ*Y,P)D`Q_8L5:<
M++O8EP8X*)E,4#'"<.@_D+_/Y/V?5;96&C\+^0#"+,6V8L0*-Y"+KUY:,A23
M-EG`K^;[%+_B^72<(*F<-#*FCUE_96`H=IC!.RZ8,Q=D/)>(\NW*KMIV^8*5
MN3O%4RZ6<A^2$E?HAE7[-+,&Z2J:)Y%]`-#,@.H!P*W75*!>I@$`J\\FF[ML
MBX:V:A:;I8YR1M!.UB4>Y8?V]\W5QUJMB,8Y):9RAEI^J@[A8VPN&3OI6(9Z
M/NR<B4HF3]HHB8(J8;UF\4-NP+:_'A+P&0,H1F2(0BEZW!R'#/9Y&ZYRM]79
MINRU+:U\@M%*Y>K::X*L(R-<BTB4T?C)%$I#I"'9Z8;6[/\`C]VB@O&!Y'9P
ME\H-W*G%>/7=-"+/%1&6:Y7JZYE7F',K.W!R-6.3J1`1Y4S.CF#Y*A"D#W2.
M&IQ#8U*8#`!BB`E,`&*(?8("'4!#^H(<#^\!P'`<!P'`KU\L#ITR\;VY+MDZ
M<LG:&#K6=!TS<+-7*!^QN'>BX0.FLD<`'[2F`>!*&:81JFP>/9-2VD:2[7$^
M4V+.CB5?W9R.>VG%2\A9"G*/QRIUYPP;-S%-]\1D"B7T`W`S3P'`<!P'`<#@
M2DG'PD9(S,L[0CXJ(8.Y.3?N3@FV91[!NHZ>NW"@^A$&S9(QSC^`I1'@1'JN
MZ^H^?FBM/P_L)C3(LM<BVNHP@5&9-86+B>C*XYE):.6D(M!PQ;.(V+$5UB*J
MD,"8#TZCZ<#$7B4Q8MA;13%.-Y"^P63)^O3^50L=PK$T>?@)"4D<J7&4;M8N
M2,V:E.A$PCQFT,F4@`BHB8@B)BF$0LDX%)OF%QD;,ZV!<4K,)N7B;Y1MN(&;
MAJM91K5KD8T<114@<*LY(RD3GGVRK`JB!O9,5#M%0QDP#O`)+>)1O!-?'[@A
MO69B0GH1-[F/X4M*V8]SDW8FSSD\[H9"U'=/C3SU%X91-5S[RH*'((@80Z#P
M+'.`X#@.`X#@.`X#@.`X$+_'N54NI&,?=4(IW2>4#)=B7M>VB.7+W[:1OQA_
M<.F'H)_N]W[`<":'`<!P'`<#&69LR8SU[Q9><U9CML91,88VK[VT72VS!U"Q
M\)"1Y0,X=K%135<+&ZF`I$TR'44.8"E*)A`.!J>;`TW>#S@,?TR<=8>8):9Z
ME9$KN3-+-.LZ(HP$/Y))NHV&00M&0<E+NW;23Q[6'E51.6F(R#-9F]<.RBZ*
M!#+BD&R;I1M_B_<+$#&W4>)DL>VZI+GI.6L$6YBE`9'P3D2N_P#%ECQQ=*M^
M+5C%X&0;*(METR?">MB$6;'.D8H\"7ZBR27;[JJ:7><"$]PY2=YS?80O<(=Q
MQZ>@!Z\#5VNVOC/R-Y`6-K/J_J%AH^KV[T=>,VGGK:U@)[/$'%.,\4"<MIR8
M2JMK,WNTRN_E?IKBW-&LLV=B[-W%2,114(*Y=WDO?C1G=V,55W`L+9=T-SK1
M*VG$N.74?1862HF%GE@>5\39$9PMVF;'F2RPA[B]<L2P[$ZDL1!XY%,C9LL8
M`D!XZ?$]3[A=<O7"3R#<[;DS**4>TVQV3;1IVEFQ];XEDS:R6N&KF29Z6O@L
M'3=0GL6^=9JN>V.5&,0.V.)DTPN1U!I]$V2Q_N;8K['51[BG*F?+-A_'4>P!
MFX80F'M>H*#QM4&T:_DD'D>WFJED&+L#ED=F)VT6Y(F*($<I+#P*-]]L/4.H
M6O+&((&]X%V>L%VQE8<@9.PI-VFEUQUL9"8&+;)"Q98L(04M&$P;NYK=7'C5
M=CD)=PWC+HS:*-W147A!;D#RK3(&!L54C%$1CO'N,%'.0*FHGHCH7CB,ODGE
M;+`V6?82C^5DEY.PLV]-<7D!.[N,_-0B\4[53.1J\.B)3`%B&O6$RZDYB99*
MR<SJ>QOF_P!QJ$1O'5YZ1T&*-9L75&/2CR56+EZI'VX^'->*!%G1:.I43+R-
MD=D(T9E46<>P<+G]:=7H[`Y[W=;1;7N7,]9@GE+1EK,M@AXN-EI9R=-`D?1Z
M<S;$<OJ?AZFD1%*OUPSY\2.3.H<ZZ[E9==0.=L]K/"[&UVIG1LLKCS*>*K2C
MD#"N5H%,CJ6Q[>FK95F1^>*7518V&ORS%8[.4C'`@D^9*&)W$-VJ%"K//^/H
M'>">QMA2]Y-_1.\LVLR]BR1@?,U+ILY"H69*K"G'3DWC!W<&T>&3\"WUI,MD
M;-7BO'0-A.N10IRH$<*!Y6G^3W;_`#%7CZ4X]PC7X+RQ46W1F.-EV4]!7*0U
M?P#775<<60FRSB]0+&9B)RG7*!.Q7J]=-(I2DB_>G;&Z$9N3@&*W6.:7A;6/
M9S676:R2.6968B<@V;R+;\.6<+:GEISHY3C6\C0GB*-VKKN7R'8R2JL=[$>Y
M<-*7'(E27`SCJEP+MJ7J]@Q[J+1M9BX\KL5AQ+$\)4V%1@8YM#LX-D\@4P6?
M5T6B13PDV5V\5=)O4!*X([.*W?[@B80@+G*@T')+=;QL>0EDC9<>9181C;4'
M:,[EY&V^RVV';/I-"`=6XL4T1QGL[CL(8'+!U'O1+9HD@KD$ISOV"01CU=VQ
MV5\9&?8/0OR;WZ6RGB?+5TLZ&F>^EE<5UA$V*%/+')7,49VDSS3-*O9&,V7;
MMXY(C0"KF'L*=8@%6$-D0I@,`&*(&*8`,4Q1`0,`AU`0$/00$.!_>`X#@.`X
M%=WEJ_\`5K[G?Z#+7_V+;@2DFUZ078?'C9[]?_.*IB7*BU=]A,!K/Y(HVG%1
M+5]35]H1+-?55HKX9>\O5'Y'H/3J`9MX#@.`X$*=T,W;'X;@,8/M8L-5'.MA
MF<OTBMY/K=AO\32'-/Q1./?C66^,!D'*2LDY@43`J#<A#B<H"/3H`B`30;N6
M[M$CAJNBY;J!U37;JD614#[.I%4S&(8.O[`\#'.:13+AS+)EDSK(EQG?!51(
MI[)U4PJTJ*B9%NT_M'.7J`&[1[1'KT'@:W?ZJ/&U:0\<F546RT3).9W9C,R=
MJ6B$Y".,]*[DE6S8SI,Z<:HT<GC#^V`H(M@`I0,7U'KP-D+#>'L?8"QM6L1X
MLAG-?H-0)*)5Z'=S<[8W#%*8FY*PODU)NS24O.OP/*2RYRF<N5CE*8"@/:4`
M`,G<"H/R06E6G;`Z87%*#BK8SQ_7=OK;.P#PS)1P@V6PRQ@828.B]'X[1@A,
M2'0[E;M3+VB4HB<0*(9B\3<P\GM#,0R+YNBV6&W;#,DRM@4^&NRB=ELP14:^
M8G50;*+1\E',DG#=02![J*I3^O=U$+&N`X#@.`X#@.`X#@.`X$,_'W_)(Q;_
M`,.R;_K;OG`F9P'`<!P/%9%R10<14FR9(RA<*[0:%4(MS,V:VVJ4:0T%"QC-
M,RJ[IZ_>*)(I@!2]"%`1.H<0*0IC"`"&MG`U+-WGYS,A>LK14KBWPO8GNH/<
M:XDE64M7K]O]::T8/@WG)#;Y[62KV&*_:&8.(QB<B82B`%,9,PF!PF&S="0L
M/6X:)KM>BX^#@(&,8PT)"Q+1"/BXB(BVJ3*-C(U@U(DV9,&#-`B2*292D33(
M!2@```<"I+9GQQWQIM5$;\Z!7>KX.VUM<E6ZCL0&1!MUEP=GW$,=&-X9%GD3
M',+-Q@N++34(]!>+>12\2_44[RJ.P[S"(91LWC@Q7DV$2L>WF7\VYIM\66PS
MLA9S9PR?AJ@U%S,HE<23FDT/&UVJU5IK"M$2,6*?J@XEV#8/O/CG[E!#7QRA
MY,H#QPWG/&-O'_#9!V.<YLD:Y3-=JWD*.4R78LH[&S=[2B[3>:=;.L?E_*>"
MZ77G,F8UCGYQ\PE+.(LV3E-'Y+DP0AUAKI,/1>:L_P!PNBT[Y0\CY2S1C?R2
M2>RL#*TV\8%K-]H]XD<;8YQ]4(6)R=`5F&R^U325C;<U!W")-&A&XN6I%VR8
MAM9XQPUM/BS6:LOY_9RFXJI6,L/&DZ]2,%XN@&[%!C'5+Y<%$SUUSE)Y3?3;
MP%A`73U,K`'CL0%,B"9O;X$3W&NWCET\T>Q=L/N_9<@/JFUQ4%TF:=D_*F5)
MRLS-RRC(2F9[W&5W7IE:3T5S<[):;>[2?),8@A%""*:OM-A.'`H5C]L[1G3%
M5OM>3,5Z]5J)S5?9>BZ-^/+7-W6E-@=@\:7.+K9\54/)\'3;18'.!<`SS]DS
MLUY>IKPTA:$6@LG2@1H)%$+P,':[95U"D7NQF<8BH;2^9#9*CPM'Q[5J!45H
M?$^N6+XM%K$1V/J;)$9N(&@8JQI'K&-*S#I9B[LQVGL)$6/T+P+I];]<(W",
M=-V:QRHWW.F2E6DWF7*[U-9-[;K(1BS:*(0S%==PC5JBP38IILXIG[35(J8'
M$@JF.80DWP'`JZW@C:[GW(&&\-8H34_2CQKE*L7NIY:AEFC5]K(W48OE+!<9
M5XXB;&BY/8*"$FDT@)*-5A;44AXYPX:F635*&'\/QVWRM8K>LU<K5AQ#FE[=
MLF3>W.Y,C48V8KTS#&MEGD4I?!IK'8K`Y<VG)\E:4)"M,I!!Y#T^';N&8MQ!
M)JF`2%V(PGC'6KQT9<Q5C*#B:I3JW0W9Q!NUCHLTM.2T]'NYNRS1V:#)J[L5
MGF7)W+QP)`,X<K"/X0#@3SH)#I46EIJ$.FHG4JX11-0IB'(<D.S*<AR&`#$.
M4P=!`0Z@/`P!NT36@=9<H'VZ!D&"R1"*5G55^KEFDG\@];1=;"DK5OI:T,@.
M;`^;H0AH@2R?U%5(&X@H(<"L6C1-EVJTT#3GRWXP&D0.QL=.QN)+K(66&),.
MJ6XDP>8CK^0[%'0=>AL9;75Z"%DHJU:`NUD'B1_C+'5%9J`85U)VUV<\:VSU
M/\97D7L#O*^(,@*#$Z)[T%B9-`EFB&YDXBCZ[YH;Q59-%DRZ9HS%)DY*[.J[
M!$!/[A5B&1#90X#@.`X#@5W>6K_U:^YW^@RU_P#8MN!*2;DUDMA\=PY:(Q?(
M/,2Y4D%,DG@E5Y&MJ,+3BI!*G-K&!@1C6EM*_,[59F`3.SQ":A1Z(&X&;>`X
M#@5U[H92R_/9&P=IQKI+2]6O^<'\K9,TY4@FD>K*X)UD@8^3CK)=:\[EA5CF
M.1;?<%V,17#':O0()'[CL(=LD?@5%>4GQM:I8[IVC22F.HW*E_R!Y!M3\>Y+
MSCL`I.YOS?D*H/YUVRDZU9LBW"1D9A[5I=NC[3F(.;Z8=`?;20)Z<">N?]?Y
MGQUU67VNTGD+M7\4XO=IW;832N,6=7##E\P\P]A*_2V%Z--20#A;(^/ZD1U,
M1#2IKQD3,.6OQGS%T91,R86NNTZ_EC'#M%C)'<5?)%+<MVLM&*(F45@[="*(
MIOV*IR+H>Z+%_P!Z8F*<H&Z=0$/3@:CVK62<H>(3R<X9\(^!@;9?P-G"(L&8
M9#+.7XR:3RG4Y6RPUBFC1M0>5:5:4)2M0<DS2`P+P8J=#G!54Q@`>!LU:5U7
M:ZG:_P!<AMU<D5'*FP'UVYOK'9Z/",(.NI0+ZU2KBF0C9*-B*\T?N(:JF:HK
MNBL&HJJ@8#%,)144"5W`I`\B5AAZ[N?KNXFI3Z8V=:X[$-TR)C'&<23@S%)!
M)D5I,"6(DVX"Z$ZK=?KW@`"0.X.!)_Q$HKM?')JXQ<.U7RD;4;+%?,7*4JSA
M**R)<8Y!10I/NE,*#4OH'V<"R#@.`X#@.`X#@.`X#@.!#/Q]_P`DC%O_``[)
MO^MN^<"9G`<!P,49RS?B_6[$M\SCF>VQM'QCC6OO;-;[-*J@FUC8IB3O4,4G
M7W'+I8P@1%%,#*K*&*0@"80#@:\^$,*YO\WF9V>W.WL?=,;^,:DV:"L^G.F%
MB32AW6>Y&!8M089_SHW8E9OI.IOIM):0@(9^!@,W<$]PG87J<+?/(9L1=-.-
M2;/D["E6HLG>8J9HM,H56M@/8>F'?6NRQM?3;KJPA$B12;)@Y540,?L:@JF0
MJGW3=.!_?Z0_7,D?88JKV2S9LR-C:K8KM.6,;X?I4G9,ET.LY7K"%IJUZN-%
M$63ZN5:0AE/EK+',8&:8]IP[BB`!,RF6AK=JC6K@RC9J'9VB#C)YK%6-@,5/
MQR$JS2>),IF,%586$FW(L!5D>\WMJ`(=1Z<#7L\\^VM8CD\#Z(TR6NUZS9G*
MWM;G.Z\8JKTI9[7E#&M61D5VE2LA8=1((RH6BV-FR<@BZ520=L$506$$>X1"
MN#5C36XX)PAL+EC(\O.-]L\AXF5QQD;>''EKB4T\:YVRS>8:N8JT)U7JHD<0
ME/J^/+K+QY+!+L448]N_]EJEU`A@X$GM_-$]B,6,<WY9K&8*W%W9Q@J[4K#V
M;[534)C\M\))UF:-=-*-OI)R91"ZGDH1X8<<6]8I7\7))"F)R]A0,'D:5MC?
M-C-5LDZD6*S9$R94K3E?`V(J["Q&+IQCL)@*G+1->L5XP1LA'-7C-_#V.M'A
M2.&5Q4.$=*0#D#^X)RF*(2)V&P@_KN5+%G?9FY0VS.X=IA(K%V!,?!66/YH=
M6*GD2+>PUEQ9B*EI/5&V1]ALM0\N\9-G3E%5V=$B3Q0S5@@<RH>EUWP$VT,Q
M=6,$X!PEB.#WSR36_I>*L3UUC'9&B=0\62$U*,$\H9>RBJU-/W<L.+PK^>DW
M+A+\HYXWP(],&!">V%T&L&MK+7>HR:<Q<Y_*^7+X_1LV8\QVSM)/Y$N9FJ:#
MI^C&(*'CJK6F?:*<9#,0(RCF_0A`$>XQ@DUP'`A!FO/EDMMX/K/K:Y+)Y45E
MF,)F*]-V3Y>,UQI=B@'[U*\+.%$$X>9NP@4OT:-]U9$[U/M>E33`0,$@L(8=
MK^$,<U.B1*ZDY(0,$VCYZZR;9NG8[K-J.'4K/V:=72[A^98+')O'YT"&^.V4
M=&31*1,"E`,N\"L_S$F,3QN[,F(8Q#?2<>!W$,8IN@Y@QZ`AW%$!Z&*/0?V0
MX$SL[Y]Q%K-C*PY>S==HBA4*LH$.]EI-0YEWCM<X(L(6#BVQ%I*>GY5R8J+1
MBT26<N%3`4A!]>@5Z8!UYRAMKEJ+W3W@@&;.,I=HE9K1C691%=&,PE1))-LC
M&Y=RPQ,L4EGS_D&*8LWXM9!-5.EE,9HU`'!EU`"Q;-N$L;;#XVG\498KR=DI
MMA^`NX:^^NQ?QTK#OV\M!6""E&ATGT-8:_+LT7;)V@<JK=PD4P#]H"%4V;]9
MV>R=0L>B6]#JRW%XA-+Y*TZV[41CZT\@+9$I*M<>ECYRO.&KJ.SCBPRH"H\?
M"5:R)+J*$ZG,8O`Q1H3O/GO6O,TGXV_*W>:<VS?%NXMAJ7LBC$.:G2=OZ`#9
M(B@HO7)OHD=DFKG>L&;J/,H5TY46$P]R@")@V!^`X#@.!7=Y:O\`U:^YW^@R
MU_\`8MN!*V+/?/S\7%-^J^_-N.-:2>M(^\Q^G!:PGK>%I4]CN^H@[&.&-#NZ
M>SV=0_;<#,G`<!P*AM@:9FNV^1QE`8CVO>ZKR]OTXJ80AD\0XPRR&4U*%F+*
M+ZXQ\4VR&DHM#NZ&RND2X=BT]'",LB*G^Y%X$%_)QK%M;!534*TYB\A,ODN)
MA/(%J6UK[9SJE@*NFJUELE_"O1UP1<0Z**DF:!&0%48]P(LWO0"+!V]!`)V9
M=PCNUB_%N0LB9#\L,TPH],IUBL5J<N=+-9W*98.*BG3N13*S5;$*_67;)&(F
MW`>Y<Y@3`!$P!P))^.2JV?$_COTUI^4$%X*VT#5G#D/>D9=4/D1<O`8\A49W
MZDL8Q@(HV6;J&5$1$"]!_8X&JKG#(N,,N_K3VK&8<1NF.1,95[%T&2_YAI3*
M9G:77Y.'H=E<)ISU[;BK58AO$QB0?+(59(B11[5P%0>!NJXWR5C_`##2*_DK
M%EQKU_H%K:K/JU<*I)MIFO3C-N\<QZ[F,DV9U&SM%)\S52,8AA`%$S!]H#P/
M;\"D7R#J(*[K:_,'C>JR/77#.TQ"P-B"#2/8IJ"$CD(]"9LS)W#UOXZ*H+$6
M$JJCE0OM=@`'=P)*^(071O'#J\9\42/1JUL%Z05RN1([')5U^207)")E<=B_
M<'N`4H'Z=0`.O3@62\!P'`<!P'`<!P'`<!P(9^/O^21BW_AV3?\`6W?.!,S@
M.`X%('FJT6ROM_4==;Y2&LAF&C:M9989FREI8M,_1ZWM?789_"N5JNJ(JL&C
MVY5R-9/',"V?.B1[E\I[*I!,HF=,)ZZ-;KX"WGPHSR;@9ZZCT*T^+1LBXLL,
M<2OY!P=D*'8M#3.*<BU4IC#7+162+$3.B03MU$NQ5`ZB)R'$,>>4?#6Q.>-.
M[KC[521)&9Q<6K&\W4%W)*(>,53KUWA96<:3),CM)"K#$.X-NX(M[C==<`$!
M1(94"\#7ESH;$^/]L_+AFS)]OK[:!QZ\TQPO+_D?=LN0F1X)2\XYI<!4*?E.
M4Q_1LB.%Z+/KS4BM&*-:^[CWSPBOS%6_M%*<+=-]?)94-`<+XNU]PM$1^2MU
M\@TN`J6"]=X%":O\W$OOR0DG<#-W2NX_@)&UDK[X*TY:10DBT1F)`GMID(F1
MP9$*,-6,`U#%EN':W:S<6"Q]N]GZU3R&W^YMZNU3K<9@5FN[1&\:&:S4VQOC
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MN>M5>U&F<?U&&Q*TR#Y$[54+W.8,QM^5MQRU1]0*#8(V!KCS,6<\C9`L#\HV
MV;<Q46WM-B243D9WV"PM;9*(-CBZ"[G7[6NLX0-9[D_DW>0,[Y3:5-3.6;9Q
M!-K8\G3-/A2P<$=2,:'^DUNM5Z.[FT5%LDR(M&WJH9=R==RL$DN`X$&]C-@[
M,MD*%U,U[>KM=D[E#1=[&PS=2DW.-:1B>&M<4TR/+R]R<`T@#W`L&Y(R8Q3!
M23G&+R:C9%:,4CO<4$,/6S*&/O'):=7<)Q=-R/DRR;N[%S=?MN17,D_FWJU]
M>UMU9[EDRW-&34\:S?R;2,(*B,9'QC%=4!,5,A^H"&4EO))JTZI%9R-2I/*^
M7Z=9K?,X^^L8,P!F[-!*O?("0CXJ5IF0FV-J%9'F.[0VD)1!(&,TFQ<',H'8
M4P>O`GD4>X`,'4`$`$`,`E$.H=?4I@`2C_4'U#@5G>8K_P!6YLU_]"<=_P"N
M''O`PHGC&1SCY*K*CO3%5J1K6")R"R)XT*:=FLQI\T<]>:C?,HO79K"JWO&;
M:-+HJMTF3ADD6&BW0.$$U3',LD%SO`<#'F4<6TS,51<4J]1HR,0I(P\VR.BL
M9N^A[%7))M-5JQQ+DH&^-,UZ;9(NVB@E.4BZ11,4P`("%(6TVOU4W+@&/C_W
MT"/B=J(*2NF4-!=MDVK>$C;C/UF<?358L5`6AY`3Q>7,95(8=I;820;%+*=B
MLFQ:N&Y>J`<K13??8W`N8ZIXW_+7+52/VRL<6\G,`[`UGZ5&8AVAI3(X-$6<
M*[,Z:/&V58M=%4CZ/<,62KGM]U-/U'J%^W`<!P*[O+5_ZM?<[_09:_\`L6W`
MD="P;0NSV0+$-GC'3U;#V.8DE13?O0EH=LC:+\Y4G',:HT^`9C-*JE22627]
MPIV9RJ$Z"0>!(/@.`X$-]Q-69'8:OTNW8RN26*-E\'3KJZZ_9</'A*,J[87;
M,&,W5;I$%+[UCQC?(TI6DW&E.F=4A$EDS`J@3J%?>V<1Y`-B,18%I=LTJ5<Y
M(Q%M=KCG"[S&*\YX2>8TME<P[?$;/80H+O)ENI=N;R<PP:]&S67AVI$EE0(9
M8Q2^X(2$O.&MK]U+A!P>>Z[2L#Z5M9"K3UNP`]?QUVV"RQ.U-R>RL(RY7:ES
M4SC6EX^&X-(P[AG%O)9[*,FCA!15J"Y3\"7.X"A&.HFT2I)TU239ZX9M4+9D
M6SAV>LD;XRLQ@G4FC4BKIR:%*3Y!4TRF4.*7:4!$0#@4B?JXE7JK?5?,=59:
MY6C6RHR4SCI=7`&4A?S<V]:6'&3)21RK*A:(R.DWL'GHIQFFR+IF1(&J@$)W
MI]!X&Q-4*93\>UN*IM!JE:H]0@D56\)5:A!1=:K<.W7<K/%D(J#A6K*,CT5G
M;E14Q44B%,HH8PAW&$1#TG`H`\ET+8)_?C6^%I32G%R#*:NYV6I$[.R9F\G7
MY"O23>8EED8X(2>.]0D((%T&Y2)H>XZ-V'5[1`O`FUX@U&BOC@U=5CVIV3!6
MJVM1DR4;BS49M#Y*NIFS11H(`+0[9$2D%+H'MB7M_!P+)>`X#@.`X#@.`X#@
M.`X$,_'W_)(Q;_P[)O\`K;OG`F9P'`<!P*1-V-+\YX,RFZ\A/C3,]A\TLI4U
MFV<U-BWZ$1BS=VL%2:(SAY"#734K\%G]",9!]-LQ$"OG(I@@LJ/>;O#VV2,_
M2_DHT-_+'1A[<E+G(7NLP=[J,9E8VO.6L6SM4GFQ\A8]M4K*4JXJP\Y#N$3-
M7T>ZC01DF1CB0PIJ%$0DU#Z'X&M.*HV&R/B&G4W(5WA\23N?9;",C)8S>9$R
M/C:IH1,6M:[ICE*@3^0H>HR"[@(?ZH3VT"E253;H'*4I`KA\GGBPR_-D8[E>
M,F]S>)=]<7O*'8W2,O87UCKVTD9BF!7JU'HN6!O$G)1TK(5BMRC]*,>//14S
MLY')S#[*J`5U>*K>S4''^1LQY'R/2ZEA"P'MDFVV^HN3Z)'N<V::;)6BQ-Z[
M91);JUC)[=KUKSF>\?[C+S$H=.M/3D;N%2LQ(H(77[([P:^ZT;6WC)N=LCPN
M-L5:OZAM9"WS$B_.[5L4SLGD9J^QW$5&L,$5I2?F?IFN\X(?"3<]J*HG5%!$
MASF#6FJ^]+_RAY7W/V)V>PAE\V/<-X`D[7XY\%WJGH(86JE9RU2+'%4K/MO1
M)6KFXR#G?(;YDBXJ:*</,`V3^0HA[;-(SA,+NJM$HX`G,86]3'D=EOR29_Q-
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MC%$>QMV>K'(%<6*,DJG=:3"1\HXPAE@]HH=8B#(OV\-*J5LS987:IWR!BG`@
M;I7`K-\Q7_JW-FO_`*$X[_UPX]X$O=@->J#L73V]:N*3J-FZ^_-8\;Y"@09(
MWC%%[19.6<1D&@2CYH]1B+5!_),=NL9)1,?4IR&((E$(^X2V8LM-N[76';1A
M$XVRT66)5L%WI]<FTW7=M*O&Q3A5C;:U(K0%52B<N+,H=PYL51*BNK'G$%FK
MAVW5[D@GOP'`J7W\O:6QDB^T1UR81MNVF;KT2ZS&4&OT.1B=&(V8D78PF<;8
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M#@.`X#@.`X'E+W4V-]H]RHTGV!&W2J6&IR'N()N4_@V*(>0[OO;+`*+@GQWA
MNI#@)3AZ#Z#P*>-*_&[N-HR6]0=)WBALX5O(T\C/6"Q;)8NN&0,P,T8*J.*Y
M2:G7[\TR[$QC.H5;JB5NV=1+T46B0H(BF40Z!:E@&$S77,/42$V,N]-R1FN.
MB54,@7C']5=TBGV*6&1>J-WD)5GLG,.8A$D4=NDH0SA0#KIG4*!2G`A0S!P*
M"_)I&EFMS\.Q$+69R6M;W4+/Y?J4`%EC%VD:60;#&DEK15WT;(P]32G0*>4.
M58H)H&*8P"`].!F[Q,9^PW5?')J?#9`R[ARDVUO0)<LO7)3(=4@G3%XG?;>U
M=$&/FIQ.3+T>(*%,=8!5.H4PG'O[N!8G^E!K1_.(P9_&W0/]G^Z#]C@?S]*'
M6@?LV(P7_&W0/\8.`_2@UH_G$8+_`(VZ!_C!P`[0ZS@`B.Q&"P`/M$<MT``#
MIZ#U'\H.G`S+%2L7.QK*9A)*/F(B2;)/(Z5BGC>0C9!HN4#HNF3YHHLU=-EB
M#U*=,QBF#U`>!S^`X#@.`X#@0S\??\DC%O\`P[)O^MN^<"9G`<!P'`<"C[=+
M2K*VON6Y/R3>.>*EU,^1"2+O8?5:.L$O&8OW&H49&N8]6,/3XU1&'9YH@T'J
MKZ'E0*11X\2(DX,8!#J%D6G.VF+MWM?:7L9B%*RL:E;W%DB5X&Z0RM=N%5L]
M-L<I4;95[-"JJ*F82T+/PRZ1@`YBJ)@10H]IPX$G^!KG^8?Q39$R-.,]_?'8
MC7L?[TXU:*C=ZT9LP943;'&"*WU6QXWRW!"S/'7:0D$FH)MP?`;Y1!]@QRC[
M9RA31(Y$@LO:\Q.2,NUG-F&<6[3+XYIF8,0.K7%9+V"SYF2J2E\KM8\=FDM1
M=DD'F,L8MK/,3#^[N9DK>38P+AFR(8I#*F.%JV.]39[5O'&T6;-I;JTLF[6W
MF%,N16!]=Z_8I-UC#7'&M/PW8%*AAJ@L54E8N.3QW"`JU5F122:")`:,S%`2
M@<+M=0]?*AB.DEO;=27G\DYBBJQ<\@7"SOCRLN9X]JT$F2K0"BP#^3E%@_B`
M#&);=K5`PF/T$YA-P)><!P(3YYV7<H7%EKS@<JMOSI..Q93[J*!HM!8:C3Q/
MU=M.WR8=E<14)+2S<>L(R=HJ)2KA%1N<4Q$!$,QZ]X,A<"T,M<9O74[9YZ0=
MVS(=ND'#AT^ME[G5#/[),`=V=5=I%*RKA;X#+N%*/9^VW2Z)IE``SKP*\]R-
M1\M['9ZT/R70LM1&.*3JWG>1RSE2MKQ\HXF\JP#BM+036FQSUBHFU8M16<'4
M7^1U(<#`(!U*'`_%C\8VMDY#PT-%R69J`E$93L&9#OL:9=M5)E)N]VAHSCIJ
M2L#^'626E47D4S!F*9^G1JHHF`]#CP+#B@!2@4.O0H``=1$1Z`'3U$?41X$/
MM^HVNR^HV88ZV0T=8*^Y8U,)&(E2`I'O"IWZJJMRN""FJ!@1=IIJ%^Z/WR!P
M)A<#$N9L'XUSW434[)=<9S;%N[1EH*2["(SU3L#0>Z/LM3FB%^?`3S!3U3<M
MSD/TZE-U(8Q1#`V"<O7ZIW&,UDV)*BMEHD+/3E!N]:A[&O3,D8ZK4D2(CY24
MLLB55BPR6JR]MS*1?>0"BH)T>XGV!BO;[;&^I7G]"W3R+BKSN%=JH2:GG\F[
M=-*;J]C&Q_*B&6=<H.6J97#E`)$HI0L0S4^H2+TH'`H()G,(2$U'U2HVH^*6
M="K4G8+O<9AP>R9;S-?I)2R94S3D61,HYG;UD2W/2C*3LBY=N#ILTE3BC',"
MI-6Y2(I%+P,K9<Q%1<VTM[1L@0C68BEETI*,753*+ZNV-DDN6%M4"Y'\9'6&
M`<+BLT<D$#I*AU#TZ@(4XY9U^J.?Z(7Q;[U.<D7S)$C4[$\UAWRDJ0S:3$W.
M-6[^4B)NIWYJ?I7=DL:1:!74@@B1LV?M6A5P,?J<O`\EXU=^<^8YV'F/$GY&
M*\]B]G<35,\EA#9U>3D'N/MS\6Q"5?;15FCIV?!-9;,+AO*'<RD:D<W04%DP
M*59LKWAL$<"`OE+>,H_QX;>O9%HR?,6V%K.JY9R*"KEBX2*5OW).4$#$652-
M^$"B`\"0-9GDW.R&7*V2AMHY2)Q7A:6<9((F8CNU!,V#,#=K5'"AON.$*A](
M5<)`7_<AE3]W[<O`SSP'`<!P'`<"/N"\]-,WRN;XYG7'E?)AG,MCP^JL\>MG
M9I]U6F$4Y=3B!&P!\-JZ7D3%32.(J`4@";[>!(+@.`X&O[Y3:FSONZ.LV/I2
M8NT)`7_6C9N!LCZAPCZ9FTH]BTBIIDX3<I/&\;5R,Y-JF<9)XFX;)@(D424*
M/0`ZWQX>+;QW;`Z0X'R-FO4/!N5;Y9X2[J3]UM].CI:>FU%,G7PBCE>0(")"
M_(%4ZG1`J20**&,0I1-P)?'\'/B*.LV<&\?.M0JM#^XW,%$0*4IODG=]3)E<
M`FJ'OG$>AP,'3[O[4`#@<A?PA>)!RDFBMX^]:3)I)I)I@6@-$Q`B#@728"=-
M4ASB"YA$1$1$P?='J7TX'R4\'OB-5%$3^/K6H10.FHETH;<O:=(RYR"/:N'>
M`&<']#=0'J'7T`.@8@S[X9?%7C_".:,C4_0S6^$NE'P[D:R56<2Q_'N3Q$Y6
MJ)-/(.239OC.HUPM'NFB:A0614(8Q`$X&]>!-7QKBP'0;4<T9#J0#`V"J$=K
M#*LBQRD<F>(1-\86!`*FS`IA'HF4`*4!````Z!P)N\!P'`<!P'`AWH*T=,=3
M\8-7K9=HY3>Y*%1NY2.BL0%,L7E5,3IG`#%[TS@8/V2B`\"8G`<!P'`<#AR#
M]A%,7DE*/&L?&L&RSM^^>KI-F;1HW3,JX<.G"QB)(H(I%$QC&$"@`=1X%+/@
MFL<&^TDN]M:V"ON*9>-VMW[5CN2:&+'L)&E3FQM\?0+EJHY7!!\F];"=PBHW
M`J1FRB8%+]T1$+H&<S#R"IT&$K&OETB]RJ+-\U<JIE^Z/<=-%4YR%Z'+ZB'X
M0_9X$-=]=[<5:`85)EG(L+<KU-6&S0M`QEB;&,,6S9,RAD*SJ*MJ[5JE72N&
MZCI9XZ2Z*KF,5%`OJ<P=0`0IFU1UC+JW;)C>#9?%RF7?)1O/D^8REBK5FHP3
M./JFN;VY1E;KZ;EO6S*O&M.G(&IQD0ID6ZKB9P@HDX!/U*I[P6H0FN,EBS`V
MS&9\Y6EU?]B<LX>R-/90F[#<RR-%QBT=4)\[D,,84GG%:J[ZFX%J<@W4,R%T
MW,_4$QWCQ514W0@3NQF9(^-\?'0%$4#TBJ&1%NZ^<W%(T"P%,4'H>CQ$2"':
MK_\`M"]#?AX'I'$W#,UC-W<O&-7!`*)T'#]J@L4#!U*)DE52G*!@^SJ'KP(M
M[*9FL,'#0^/,0M7<SD+)<Q$U)M;(@R;J`Q7%S;LQ):]6V2:$D5()-A7F4B:+
M<':N&WUA-JFX`J2HCP/KJ]@^C:Y4-&)D+]"9-RQ.JKRV6LZR[*`@;KEZVO%O
M<>VFS-H]\[:L'#LB:75FT.FP2.03(HI]PEX$F/RDKO\`\_X7_E1C_O\`P'Y2
M5W_Y_P`+_P`J,?\`?^!]$YZ#6$01FHE40Z=03D69Q#N'H7J!5AZ=1#TX'!E;
ME48)DK)35HKT3'HF3*L]D9F/9M4S+*$22*===PFF4RBARE*`CZB(<#@1.1L?
M3OLC"WBI2P.4%G3<8ZQ1+SWVS=ZK'.%TO8=G]Q)!^B=$Y@Z@54HE'U#IP(G^
M0V15?Z9YV9U5V,A9'%:BPA&<))B256?)VNOJIF:#'D>/C>P!!44!)(YQ2(8.
MGKU`)FP)W2D'"J/ET7+T\3''>.6X'*@X=&9HBX71*I^,*BJJ(F*!O4`$.OKP
M.VX&%-@L(0VPF,)K&\K:;M0G;I9G+UC(&.)Y6N7JA6^'4%U7;A6)($W#092$
M?=%2HNT'+-<.J:R)R&$.!X#4[4;'.I-&>5ZK/['=[U;'H3^6<SY`E7EAR9EZ
MY*"J=W:;A,OG+D$U%%%S_'CV0-HQ@0PD;-TB=0$)5<#\E,4W7M,4W:82F[1`
M>A@'H)1Z?88!^T.!BW,F'*3G.BRU"O#)RLP?HG-'RD9)2L'/UV5*0?A3<!.P
M+^*FHJ09+=#=R#E+WB`*2G<D<Y#!4+F37V,V\IL=X]][IJVU_8ZHQ<C=M6-X
M<;1S''<[:'=)?U`Z&5,8/(ZP6(M&R7'/W3)G9*LX>=\JQ2573[4%TU$`_?CT
MWSR11,I-/&!Y$Y<D7O#CVM/Y2A924CTXC'>UV(XN8>Q%.O-/FUGJJ3S(Z]>9
M(JST>8J*QGWOG23^Z<A`GCY(8Y[+Z);21D=%-9Q^^Q)8F[2(>F,1K(KG!`"-
M5C$35,!%!_8*8?ZG`SS`NLAFSGDEG*Q!DL7IX[Q8XIDY\6+3(\MZDUDTEZC1
M>)/3S+LS*-3A5`(LW3;H@MU3.<RB@%#,/`<!P'`<!P-8#-^Z&9M()'9Z=Q?-
MXPBGTSY`LGJNJEE&O7>Z1EMA&>,<2656K,);&S%Y9*L^L2,\Y>)+MHV:=(NC
MH,B-E#G$2!LP5.86L-6K4^X0*U<3D!#3"[8B;U(K9:3CFSU5`J4DU8R*143K
MB4"N$$5R@'0Y"&ZE`._X#@:\'F*H/YU,LO*B5&LO5F7CQVREDX.SF1=,K*U=
M&BT91F9BVG8:=:(13&.%=5ZV*O[0'`.P1X%A?B2<5YYXU=,9"JQ<7!U^4P?6
M)>.A(5%RA%PZ<N9W)+13,CQ15R*4>Y='1$YC#[AB"8.@"`<"Q3@.`X&`MKOY
M+FR?^@+,7^KNQ<"/OBK;OFGCETS;2)B*.D,!T1(ZI'B#\%B%C"@BL9TU57;G
M451[3&`BBA2F$2]QNG7@3_X#@.`X#@.!'?5)7W\"TE7Y)W?<ZNG[H4>*/SJ=
MM]M!>@NU6C)17L[>T.J1>T`[?4`[A"1'`<!P'`X4C)1T/'O9:7?LHN*C6J[Z
M1DI%T@QCV#)JD99T\>O'*B3=JU;(D$ZBBABD(4!$1``X&J/LC:=M_P!87:YK
MP!I)D.*UL\;U+DT*?8MIK=49F;L&T63ZA8$W,[5<;U^/L5?.XPS&O8_XC]VN
MJ9&6((E.F)#"EP+BM=?&%B+'].JS78I"J;,72NU*JU2+962AP</@O'C*KQ2T
M<BAA?`*17F.\;&=G?NSN7[1I]6>%<G(NY,GT(`0M\HE4U,UDJ%?I>K^)V>./
M(3G-28C-:8W561B,"Y`-+MXE%&2ROFBS5=JQAD==<9MX-J\L+JTMWD,HBQ(V
M(F=01`@59>/')]_V6\I6,MO-@'RF=:ACU_=M40VXDH@*UKDSSE-PK!E2\2:F
MU.5GK`:;C)BX0SU9:Y(&*I)RJA4O99E.DF(7OY3,GHGN1>]Q<E0$KDK#6TRF
M$,%.+W`5A&:NNJ\Z$XXK\>$Z]=2R3AOKU?9N:9+R[A@D!XJ49H+N$%T3^ZW"
M>&U+EC*:E[(.VDA[L;(:[9A7;RD0L#KO9N<:V(Z;^,7:`N#@11."B)D^_N'H
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M5JL3;)W'`F!0<*%6`&ZAP*/4`$0#MZ%LIBFS6"8IUL\"KRAW"E'12R7"&H&#
M;N-(5EF+&0JQ%W-!KMA+('L+>03$J9"D61^^)R=J:ABAY*6WCTIKE]J5$L'C
M&UO0F+5D*8Q>6N14;59F\1=UAW3**_)U_#H8&2K);!*3SL[5G&A-?/6!B]5]
MDJ;-<2A-^O3;*!<OD:QX7HN.E/FU8DD6`B\)PB*$1,I/7D?-OY*7@:XV?)Q)
MTQ%9FR,]D4#*=/8[_N\#^S\]D2+[)-#P?05NAU.BD>-;M^MYK**`P"SQ)5S!
M6B/K3=@922(1D!!>"H0J@*&*4`,0`2E[@XF%5&;\'U]80T?)N71TW$/IA]/^
M3(V]I%,G+!(<J%^1+S*::3\42IE6.J**"?O.#@4`BAD6>P-NCHYLW;Y+1&DZ
M^X@8XDQM:<9[#1;&AJ2LC(WJ=AW3X^/E5<:(.Z]:\;>TD5T^]AXQ3DP!(AET
MR&.(6OZZY[O>.+G2-2-I';)QD68J\B_P+G)HHQ8U#9.GU=-N8&!VZKLBL1GF
M"K*R3R<AD"*MGR"*\FR,#<%4&P=0AY+:5=K7?*_KCK;M3MG`8SM4M0+GD_!=
M1Q:UQ@PR%7)!Y%6FDQ-FS-F#$*EOEJO(,C(OW$,WD(Q)8?:!T90IR$#N?TYL
MJ_\`YM#R!_\`)FH/_P!-]P`[XW=B!G=F\>._-5@T`%20GWM2UPL+6-1#T]]:
M(H>S5NM;PG<(!VLXYRIZ]>WIU$`@ID[?V9V>R+=<30^*]],/Z[T>*1K]]N.-
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M>H0=./7VT3*Q[U4HR\**9(QRH!BE`/Q:B889INW6:@Q7G+Q0;_T^NN=N:9A<
M&&)\NW=]68C"^[L"D\18U>:K<A<)F(@RY,?MVR3B0@3/3.B+)G4Z%[>I@O\`
MHF&NZ6P%VGE;U#O,=O,84.-:8Y(LX6G8&UL[!=EW5K61,\.U81EBC'1&R8D0
M3.Y48&[CG!$H$#-7`<!P'`<!P-9?:;'.:,@-MOAU]U(=;&9(K_D)9O&:N-<W
M5[6G)N*XQ_@+%,;(WNC7U_$.(I:1EEE43S;5Z@\;2#=)0SAL\7]DQ`V*<5P-
MAJ^-J-7K989ZUV:(J\.RG;#:%8!Q89.429)`\6EW-6@JS7G3U-813.JTCVB*
MO9W@F7J(<#W_``'`U_/)5>*+0?(/K++7C)D-0D)35S/%.;,+))P3*%LD?=)-
MK!V*.%.9@Y4`>N&*B:1%`40]#]H&`Q@'@=;X?/)9HRTT(Q[C17.L/7K!K$C8
ML49)K%DC;&UE:*YK]QN:%>B7@A%NDW""E;B@%F9-10ZR#<1Z`)1``M21W_TY
M<%:'1SU4#$?,SR#8XM[`0AV:9D2'<',>&*5%,JBY2_?[1[A[?M`0`.E0\D.D
M#B91@$MAJ@,HXC"S"*!V%I215C3B($=$?*P!&`D.("`![O<(_8'`Y3GR*:4L
MWIX]QL%3B/"(Q[@R0-;(H'L2CDS1@L55*#.B=-=P0Q>H&$"@41-T*`B`8/SO
MY`M.,C:Z;#UZF9\I<I-R&$LJ13)D\0LT.15_)T*Q-F)%EI&NI&1:J+CT46`A
MRI%`QA^P>!@'Q;;LZMT/QX:A4FW9MB4K33=9,82EF0<L[A+N&K%_&`5J^5DR
M5]8D@FL<.T#$,8X>G<4O4`X$L)ORP>/JNLH.0F-BXEJSLC1T_A5R47*CL'K1
MD^7C7*W8RHKA1N"3YLHGT5!,PB0>@"'KP/._TQ?C<_G,1G\6^9/^;O@9%IGD
MUT4O[%Y(U;8FKNVC!V5DY/(0=VKRA')T2KE*FVL58BG+@GM&`>],ATP'TZ]?
M3@>P_3YTZ_S_`%'_`.V2O[V<!^GSIU_G^H__`&R5_>S@?HN^^GAS%(7/M'$Q
MC`4H>Y*^HF'H`?\`BS\(CP(Q:<[T:J16N>/V5@S;08J63=7L[AB@O,J(I$5R
M1;U6QB'5BRJ#[S8Y#CU#[3#^#@2;_3YTZ_S_`%'_`.V2O[V<!^GSIU_G^H__
M`&R5_>S@/T^=.O\`/]1_^V2O[V<#JD?(II,XD5HE'8BC'D$!<@JVZ3@"06A&
M"CC\8:(!$?;)*(#Z&'K[GIUZ&Z!53YJ-A,,[7Z)93UGUZV4HJ>8L@.*8^853
M\HK)4U+[38:V,7MUIR-D;P:K1@M/5]HY3(18Y"*F(!!'[P=0YV$_*YA7`V(J
M)B3&FGERIE,QW3X^&B*K4GT$TBHQK$1A57X,F#&)$ZG51)590X%,HJ83'-U$
M1X$TZ_Y:]0LA8?8W2DYAJ,5>[71!L53K%H@\C2<4PFI6)>/:PWM+VM5!5P2&
M>+H$.HL@!3';]QDNH].!J,8I`F\]MN;G8S8D^%UK7:4K)Y$]GI7&69&N9,WU
MB2E'J49IAJY*MZ>T94?4>!@*Z*::T>FB,B/>Y73,JJF40O9W,V^\8%,\;,[K
MYJ]DS%E#)6J17Y#5:MM*=D:H5^`O-4LD<\I,I`6%Q1#(P-B1FT#"B_6/\KY2
MAE#"8QC"(6@#Y,]$Y^MBSMV7(<2ODVT)98-?'^4IF)2EWB;!!_"_)4QZ1M*M
M47DD1(%P("2A3`?[H=>@4X9F\EVO>I=+SMC?#F86.T.N.8*1=H7%V(&-7R%6
M)+6.P6^ISW_$1;DVQ^Z-/:]SKI_W@X,N5U4>@HD$[<Z)$@DWJ-O+XX,/1XY0
MREMS#Y*V.O%3JL1<[P?&F7ABZG7XB(9DBL6XS9EQV9.OX^KPA]P$P(O*+=7C
MH3JG#M"!&LVSWBYUAS#NAB+8;)>-,T8.W5L=_P`S*[97[&N1_K#].ZS3&NGU
M0S4_L./B+$>5MK/J*TATV<`BZC07;E*FZ;$[P\)K]Y/,2^*G99###+9K(&WO
MC+SG./Y>FY&N$=DPTWXZW83\@9:GW"6M5&*[G<(O(V;BV\4L+KY7RD'*I@[P
M6]T-@!AYF/&?+,V4E$[35^6C9)!)U&R450\MR<=)-%P[D'4>_8T!=H^:KE'J
M11(YR'#U`1X%1N<O(MICDS-&7<<:PY@9X^HVR)%V>V.R<;$Y^2=SCJK8=O[&
MO0M-<UJFI2-(=UR:9QT7-O&:K>06+)$(AV&14,8.ZF\R^/2ZY*>5B_[SU:U:
M3+82:0$=K])X/S')9#KVR3"SFGH;9&"SB_H2EO:6^I-W3A*)6[Q=-5!2/[G5
M(O`QCJSOGIIKA=8C"^XVS-8V6PA@"2JEJTUW5RS7\GKYB1MMLF7S-UCV]19<
M=1K"+?X[1Z@REUEEG#YFH!C]QN@`%V#GS&>-EF45'.ST&DB5!%T+D:#EL6GQ
MG"*;A!P#LM`,V%!5%4IBG`_:(&#UX%*FZ?D\PWO9/6C`##8C#6+-'X11JGD[
M)\B?(\NI<\KTO+57LN/\49./!T^*G\15"X1]'<+O%!40<E:/2$5/WG3*4,K;
M*^4_Q_H^,*5P]7'Z^%)PU>QMB24P91,9WRQ_H_N9.S1)F:4VVCJY$H,J&FQB
MU5&DHD8R*Z2J0I>XH;L$)Z9-\@7B'SYCY'$.5,TU:ZU8S5JS:IS&/LPLG48Z
M9M/AH3478BT-F[KTHV1`1!ZBX0,0HF[C]@F`0IBV!\R&$<IR%[P9H3O#4M.-
M>-9(C%5(HSW&E%B'<[L%(6F0KHS\U096V8VL<=3,:X4I@.2J)@FG(V.2`Y2*
M>V4!$/>8HS]OE8\)X@NZOEURH[D[UBVEVXK2$\;U7R"UAY;N4,G%V"QC7(UU
M(JK,"E%]U("[I4>XYNT>G`^R>4-QJRLK<;%YH,\0!H>/D#MG^1?',##$[&1D
M1?*J/+='Q$&[>OH]BX73!BD!!*0"`F<0(`"`6':7^1;237G!$31<S;TP.;,Q
MR=LR#?,HY6C\)Y>IL?=+9?+K.691ZPJ;6@KLJ\QC(F0:QZ+9`WM$29E[0`/0
M`AKLIN:$WL5>\JZ3^87#^MV/,IQU+?7JAWK2/(&8YIU>JE7F5,+,P]BF:4W,
MPB'=7AV9?B=@]'15#]>ANG`J%S!Y!MZ]D<_/-.3>9?'$QJK+4]O8\A;@XKTI
ML5-85:^U>3:S".'8Z:I=5<32-P5?L4/G$*NV!!JL9%8IC"<G`G/K;Y?-J'.Y
M6R5`R=Y/=8[Y@["]7QS^2LC+:6Y*K$-?+)E.`F9!9-J[I->;7F%=XT7A@]PK
MPH-90[H/;$4TCB(3.<^32^K'*9OY3M3F90123%,FFV?5P,J0@%4<"9:NB8#+
M'^\)0^Z7[`].!7=Y.\]0NVVNE@3O_D<U5G)?$R_YUL<*UK3/-C/(<3:*RQ4/
M\"@7J0K82-(F+,U%5D:2;J)JH$<B/<4I>X`F!XP?)II55\K[$Y`L.:;=5:3:
ML"Z<M1;W^5S9F)4,JMK+MF&0R05LEZW-3\I$BDE']KA4B*9@`J8`91)4>!M%
M8WR-3,N46KY+QW-DL=(ND0VG:S.ILI*.)*13PO>V=E8S#./DVP*E#]HN@FH'
MX2AP/;<!P'`<!P*]])OFAE[R%_4'_P!17_3`<"DN""3?V60X7Q-\!CV(@!3#
M'M.Q'O'[Y^SN-ZB/`L(X#@.!K@>9$[(,[`*DBPK2[31?(DB[N5EB#V>F5J&:
MYSQX9U)6"ML(J6L3YNV4$O<2,2,Z<%4[![4RF,`1@\1<O1=;:[NO+T&8P3G&
M&L?D94<;'11IR>;63%,IE_.,M0J@K7X)6D.ZC(*-H.5>2*#1*1*N=`"HDZ&5
M*`AM=_DC45$E"#5ZZ9)RGV+)FA(T2+)F5,Y[%2"UZ*$%<XGZ&`0[Q$?M'KP/
MHI4ZLLT(P6K4`JP3!,$V2D-'*-$P2,)D@(V,V%$H)F'J7H7T'[.!\RT^I$(5
M,E6KA$R)F1(F6$C"D(B8BJ9DBE!J!2IF37.42AZ"!S!]@CP,![=Q%38:O;*6
M.1BJ^U/":\YH=C-NHZ/(K%LVF-[.NNX!\=#W6J#=$#G,(&``+U']G@1T\/T=
M")^+_17Z8UCCL!UNQZ9FJU,+U!1JZC$W7>B\<>XNX2<'$%!,8PB<?4>H\"RD
M``/L``Z]1]`Z?:(B/_7$1'@?W@=+*5JN3BJ2TU`0DPL@F9)!64BF,@JBD8W>
M9-)1V@L9-,QO40`0`1X'5_F_H?\`<34?X-PW]9<!^;^A_P!Q-1_@W#?UEP`4
M"AAZA2:B`AZ@(5N&]/\`[BX$*/';4J++Z>XID#U&INC+O\I%]X]5:-Q-[.8<
M@(=/9D2O7A`)[?3[RA@'IU+T*(%`)K_F_H?]Q-1_@W#?UEP'YOZ'_<34?X-P
MW]9<!^;^A_W$U'^#<-_67`_OY`43IT_(JI=`Z=`_)N'Z>G7IZ?#_``=1X&,,
MP6W6G7VBR&2LW2.(\5X]C7<>PD+;=V]:K\`@_EG)&44P.^?-TD3OI-X<J+=$
MO<JLJ8"$*8P@'`@1EW)4SM77+!@G37#=SI[J]QD?$2FW=GQ(O0<98VJT^/6R
MS%(D;'&0\KD.X_DV5PU9MHI,Z*+URG\E=`GWA"T2BT.I8VJM=I=*@V4%7JK6
MZ]4H5DT2*!F\!58M"%@6"KD0%PZ+'1K8J9#*&,;IU]>HCP/7\"!.].J>5MN(
MO"5#I&9D,&T6B9KHV9+]/0\$2Q7>QCC:0--5NGP$=)D"KMHV0F`36=KO@=$)
M[).C57ITX'D$O&5A>+B+2Y=9RV]4M5H72E;=E23V;O86^05CF<@0CE7\>A28
M9J@>06<G38Q#-N*O03%%,A2`&KMF']8HRCCA39733$#G'.Y]7QIC:WTZL[8.
M2S5$>92<6V1&EKRD9%XLJE[QY!,<-I.WR[F7DGK%O8VD:=XDF@4WJ%]&E'CH
MV1U*J%,RQB_>3).P63LIP,5;-D8'9F=>VC#F6YV0@$EH*2Q>E"-'\K@;Z#\H
MJ)%HQ.50D6**::C8GW#)A)K8G7/;G;_'3O!^4+=@'#>*+6\9H9+<XY8VW+5U
MME1272<2%9K;F[U_'K+'<O(^R":4^U.[D([O%9L0BY$S@$\[_C:D95Q[9L69
M'KL;=*'<Z\[JUJKEA;DDH^<AGS;XSIL_2<@H"QE"]#`<?OE4`#@(&`!X&H)E
MA3:/P^Y'I?BLQAF.Q6G67R#7)S5=2,^6O*#Z2S!H^+QDFRLU)&I%AI28G**S
M?.1>1\JBLBFT25%-,A54A``O_P!<\ZZ'ZKX=:8N8;;X:L\M2*V%ER=;G61X!
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M&BCK$AZ[9Y(6[UFJ4IEBHHD`QPSK8-Z,C^;7+N#]-L(1>PFHVEMM7R;#;+[`
M)*#!6+.DWC6FS:5\U8PY:?B.B/8QA(I=)^QLGI%0:I_B>[W0`X95\8+C%.@=
MNVQQ3LQC_(&#Z'-;,9*A,"WG,VO5NH^&(_$%0N5DA<75*$S=8JY^2TM"MJ8K
M%HPSM_)G7E"&ZE46,43"&SDP^#\%F,8#4(T6K<S#X0)%9_",D06PM`0`$0;"
MB)>SL^[V].GIP.7P'`IH\C>[>4FF5\<>-?2%RV<;M;)U^7EI;(1T/J==U&PF
MT^.WL.<KLT3.G\B<4;NCHUR.!0BJ[[L6-VI@03A.G2G4+&^C6O%,UYQD^L,_
M&UU25G++=KB_&6NF1+[9WRDO<K[;Y4X`K(3UDF5SJG,<3BFD":0&,5,!X%.6
M@48X6_6"?-_-)V-X1LTH6DD<\K)8M\FSD'3W$S<[.5<2;E15NHX@FL69!$$N
MPBA'QR@7N14,(7E9(V1PIB2ZTO'60+[$P%VR`SG92KUM4'+F2>0E8C7DK8+`
MY1:(+_3:_$LF"HK/7`I-RF+V]_</3@51>13=G'>:=%\KUS"$!>\KTG8[5C(=
MFH68L>B"=/4B3@Z@4P%XW7"U%</9)$R!"M6*QS=?L[1Z\#SOB-CV<;LEM:G'
MFA2(O-<M1WB[2$1*V^(Y+G#?IJ",PBFH9'ZL5%$I@$I4P^.=,.W[1$+\.`X#
M@.`X#@5S:)D2)E;R(@BQ+'E'=&:.9`KPKX%53XDQ:95\*Q5EP3-(*"*PH]0%
M`3]@E*)>T`L9X#@.!K5^7J[2%1W$KC6H/XVG90MWC[S-3,;7TT6WG)U&U3^5
M:V=C#0\`K#W'Z\NU;1CE^1):$69MSH^^NN0I0`0@?XAJO5LX8WW9GLB;C:UR
M^.<G^0#'5SNY+=7JW&QV2&^+8W&EZJLY5;+"W;%44G+9$D`2)-">#.F>0;K&
M(B!UE``-JR7W)U*K@,49#9'"11=3'Y.I)1^2*K,&:R22"BRR4FG#RC\\,T8H
MI=7#EW[+5MW$!50@G(!@Y:VXFI#<5"+;1Z[$43Z]Z0YKQL*X"`=>T$"V45C*
M"'V%`HF$?L#@?A3<;4I!T9D[V;P&P=$9L9`4)++=$C#F:215C,UD_J$ZV!7W
M`;G[BEZF3$.AP*(AU".VVVW6I,[J[M;5XS9G7NP3P:Z9F:N*M#9FQS+6!4\G
MB:QOF3$L(PM/U-1U*1[@BC=(`(==-0IB#T,!N!ASQK[&:C8<T-TYQ&KG#$U+
MD:Q@G$-?:4B;NC.&L3!2=K[9S$,CP%EEEK*F9<JW4PK"H*(CT4.7@3>;;K:B
MNV\HX2V3PNF:%]X)1B[R#7&,RR4;OG4:=%6!>OV\U\DSUF<B:0-Q45ZD$A3%
M43$P>6-Y"-(P1;KAL]B!1)THW1;G0MC-P"JSMRLS:HE!#W#>ZX<MSD(40[C"
M0W0.@"/`[YEO-ID]1,N&U6OS%,J"3K_CO+5(KJAVJZ@().TD9Z:C5EVIG`^U
M[I"F3!8!3$>\!+P._;;@:E/2IG9[1:ZNR*H*NDC-LV8T7*HV0,H5=PF*5F,!
MT$3(G`QPZE*)1ZCZ#P/@EN3J$O).H9':K6]:88N$FCV*2SCC%22:.EQ[4&SE
MB6T"Z0<+&]"D,4#&'[`X&!MI/)IJAK7@')V<FN8</Y76QM$1\HI0*/F?&KBR
MS82%DA:V";4"SSL&J+->:(LY643%-!!,YS=`#@0Y\3WDEUER-K<C4[)EK"&/
MY/&TA("X=R.=\<.XB<3OUVR#9&1(UP[E(9\1Y%HMS$<D4;@F8#)J(J*IG[@"
MT'],;43^=1KA_'AC+_&?@/TQM1/YU&N'\>&,O\9^`_3&U$_G4:X?QX8R_P`9
M^!U_Z;.G/[J__P"J->?W&^1CE_\`SQ4#T=+E;&3!+_C_`/=*'1V3N63[T2#W
M`8P"0_:%.'GLV<P#:?'\=/'>><,W.Q1.S>J$RVBZGDFI6V2(>*S=5I(J_P!'
MK#RQS#@B)61E!*@R=*F*0W8BJ;[A@LWQUY.]!\C)6%O!;78="3I)B,;:UG+"
MK3C,I9$$DI)C'ENL=5U9Y>,>*`DZ(Q25.U4$"+D2./9P,K,-W--Y)1=)IM3K
MV)VY0,K\C+]"9%Z&<O&8>VH]G6Z:P^^P4]""8>WM/^T43,8/PAO!ILX5712V
MIU\[V\D,2K[F7:*B3YH(_(Z)J+3B::S;V_\`[8()F_=]WO[O3@<)3?#2Q+ZI
MW[58##Z,LL@_Z92J!^BB#<'2GQ.R5-]23!$?0[;W2&-]THB;TX&JOY;/)/:?
M)/F6$\:7C[R8%0ID78!C]MLUVR1NF,J*SJMBB)!)%\K<ZQ;ZC-*XJA8!)XZD
M5%P"-F7:\>T$%6RJH\#[Y'I/C=\96I6L./\`!^R&$+?$0UTSHCM!E.2FXB2M
M66I.R:J98K;*.E(VLHOC(P4C8Y..BH"/=`$&U:E(V!8R_P!Y0)$^,#R)8LUC
MG]8=8V6T3[:'4;:)F">#\NY4F9N'RMK+D8<<$R%^8;(I;BQ2=V_'D['-W*E=
MFDU&S.%2;_`.*A03-P-ADN]^EAX\90NU6`A9@#4>X<I4\''1XZ49H=&)I4'P
M]5TC=W1/\63H<_:00,(1RV?\L>H."<:S$M3LR8_R]EZ9:SD1A_$6/I9>\V;(
M=W9'9QS5NC&4QO-R*%1CY2304DI?L!D@S37.14YTA)P(%:<PNE1Y?)^R>_FQ
M&IFP^X.R$G"/+S#OY6(O>(\`5R,#X-5P1A./O[5_(0M7@W2IC.73E-!W*RBB
MAQ*4`*7@5^1+/4_&&/+5C(E>UK;1,!AK(5IJ]+J^&X*?CSRP;^_E,IUC[-4;
M'^4"@5;Z$DV0<G?H,#MS)-46Z92(@$)'.*M48K$Y:1EO%N'+5?,38%\X>-JI
M:Y/7^`"7M%?J$?3W.G=J?38U%=,QZC38:0-6G#A\YE(@HE,B*8'54*$]Z%B?
MQX52?@7]PU_TL)37FP^HD#*)S^J]=D)$M/G=;860FZ]$HL\*R9W,A/7+O>/0
M46*D\-W*BL<PB00G=MS??'E;JRXQWKW>\$Q%MB<?2`6G417&EBI%'SCBPYF+
M=NWF(RGXZ:W&AV6IR$<W7IMQC4C&KLRBB<$ET^Y`P153SQ0+#79*,;98PY=U
MXBF0]1ILYL+B[-%HB=LJM-1M2>,-:]SXN;IL.]B-E:3-HPQJ_;%$UG;I&0;.
MF\<4ONMCA7%G'+^N^2*SD[,UTN^2(S6G!$5C7%[B_2./LNTO+^V-,E)>G7&G
MX^R],(U*MU?(^!-5K>E)1AG[]B[D)ILB5$H@4W4P6*:$[6:^$IOB:M\-EF$;
MTNAV+R`V&[LZNE--VD!5[[/9N6H9+#2X:JV&18QSI.RQ;AJQ64C3,2+(*G4.
M4H(J!:OD/S(Z<GE+;CIGB/;[/,"W0>URUO,=Z29]OE!D"/4W4?*P+Q:0H+-K
M+LW*`*I*?B%&;I$P]AU4S=1##/CBWYQ)4JOFG$M[F]C:=BS$F1XB"U[DMI,,
MY=JF5I;&]DIL3;1@)!G+4L\Q)1N/IJ2<0S-^Z.HL[;-B&$0+VAP+*&OD`T_<
MK%25S9"128@8RDA8X&YU:&;%('43O9VR5N*AF)!_`*RZ8"/H'KP(N;T^6;7[
M6_`4K9L&9,P[GW8BZ2L9CS`.%ZQDBHS4G;\D6J</5H.5L,=&V-M(Q6,*Y*E.
M[G)I0[9@U8-SF%R3O(<0CSX\[OI/IEBJSWC,NX>-,T;;9FFD+EMUL@L_&?7L
M>1)`J9D*='S\1#*I5S%]&*Z".K<094C9LU2$4P,85#`%@LOY+]%H('ZDGL74
M$FL:X*U>R*$9;7T0DN=`KE-,LRPKKJ*7%1`P'**:Q@,7U#@:[N)-IZS5/)I^
ML17#$F;(F*R-?<):@J:\@0,<P41.7<^LDPM7K.RG,B%84U_8Z=)2S0[5M89*
M-:.EG9F3I,WMD,D&&+WM+%679S'4%L5E//<'EZ9\=NS%/L$[:&V/&F.)TCE7
M.4T>0M<U0,N.\.1-QFHN38B:'BU92.,*35JDNS!(!$,;QDOJ8&@FC\#!6&.G
MLZU?QJY/=59)]5<SQE67/C1N,U$M[$\K62CX82-#S$BNNE^4D-:Q554.9L^3
M(4H<"T[Q<;`X"QIG;<.\3%JAXB&DL2:A0$D^@H*WS<K/W)?-^\400ZD/$P4A
M*S#L&RC-(SN/0<1Y&A4CF6``.)0V.<?Y!J64:I&W:CR:TQ69<701TBM%3$*=
MS\)VLR<&!A.L(R233!RW.!3'1*50H`8@F*("(>SX#@.`X#@5B^.TS<V1_(\+
M9-9(@;X7TIRK*E6.9<N/\=`X4*8B20%246`QB%Z")"B`")A#J(6=<!P'`UI/
M*O0L;YG\D^`<799_.D7'3;2+,MNM['&^0SXY96YL?(D;#PU5O4NR!&67JYI0
M16.W0<()N3?BU^],>P0E!X'L&1]5\>U8N=PK\(>SYURGD_*TW71H]2KL#3DH
M:>3PS3JW5(.$CD6C2`9T+$42Z3,I[CE5T[75.?J?H`7(A1*045!+3:J`J^[[
MHA7H@!4][M][W!!GU/[O:'=UZ]W0.O`^`X[Q^)NX:-3A-U`>X:S"B;J'3H/7
MX77J'3@0K\@F0*GK]KTZL,(SQ53[OD2_XPP50K9=(.MI0=9M69[Q#8_C[1(*
MR'PVJ;&GI3BLJNHJ<4$$&9U52F3(8HA'YI&:`X*U`S!BC#F;=<KK=7.(<LO5
M+79,JXFMN1LA7Z3I$X!K#9Y<\LN_E9!PZ]I%-,`]EJS23;I%*BD4H!9A1*73
M7E+H[]U5*B[?#4:R87R<%"K]QPAF0@=LY(T,`H]?4@D'M[>G3TX'K#46D&5.
MX-3JJ9=4P'46-7H@55#E,!BF.H+/O.8IB@("(]0$.!^0H5&+T`M+J90*8IR@
M%=AP[3$$QB&#HS]#$$PB`_:`B/`^*V.L?.!`5Z+35Q*3V@%:L0B@@GW^Y[8=
M[$W0GN#W=/L[O7[>!_28[Q^D``G1J<F`$,F`$K,*0`3,(B8@=K(.A#"8>H?8
M/7@?DN.<>E64<EH=,*X5.515<M7A`644+^U.HJ#'O.<OX!$>H<#&N8M9L/9N
MQG;\56JLDA:_=&"$?)RM".2D7!BFVD64J@Y@K7`(M9B%?)/8],P+(*%/T`0^
MP1X$-O%_KAC>B:LUR85-9\B3=VG+D^FI_+]@6R5.A^3U^N->BF3"3L+=5:/C
M&L>T#HW2`J?NG.?IW',(A8I^;K'W]PE-_@Q"?UCP'YNL??W"4W^#$)_6/`?F
MZQ]_<)3?X,0G]8\!^;K'W]PM-_8_M8A/ZQ_J\"ECSZURLU#Q\.;97:3!A,U?
M974VQQK&'J[`KB9?0V>J6[:0QW;-N@,<E)*E]D7"A@3()^T?VW`R;I9H[?<1
M;)Y=R5>*+68+$EVJUB=5:E?7(*VQ[6^7?(C>]6NVGAW5?3E86QV8JG;(]7:K
M8#-4RIE#J(\"UO\`-UCX?_Z%IW\&(3^H'_S#^P'`?FZQ]_<+3OV/[6(3[/V/
M_D/`?F[Q_P"G_D+3O3[/_)F$]/\`8_</`K-\@OCFD<[.J?LAJ598/`.\F#62
MJ>+L@$BD`HV1JJK)1LG8,*9QK;%%)&Z8WM[6.,U]IP!_@JK^Z4.WN*(4N9ZV
M\B=V=>:0C8-1\@4K:[5)_G")W;U9JN-8AS=L;J3^N>6\7L\M1=<F7\"3(FN[
MV[2Q%F\J@X=(-#%`%.Y=NF<X1EV*R?F7$<+I?L;5=(]M\>XTT&>SN49/(^Q^
M&6EAQ$3'5DP[#T3Z59X:B9!:7.2&L.U%20TL"IBLHU8I#IF3`2\#<[QU!T.\
M8\HMV-0*2W6N%+K%H%%.JQ)$4%+!!L944DTU6RJQ$DQ=]H%,<Q@*'01$?7@4
M7ZI`A@KRJYSB/(?#T=GM!GQ@G":&Y5AXI)A@V5UKAI:QR7YA\/M'S(J-&RW$
MO#'?V=HLL:1L0&0<BHH!"$X&P2%"HI1,8*74P,<Q3G,%<AP$QRG]PIS"#/J8
MQ3_>`1]0'UX&KK5JA=Y#%\W,R.-AA)!'6K:R.M0GK5@;6%Y+J^3MTKC$J;-=
MC]..V0I,;(.4U$^KKVWA!]$3%X':[$12=ER+Y.L3TC',K'.L6U3;VW'8C6Y$
MAGT?EKQKX=<-IEBZ507:*KVG)+J728MVQR`K[)Q*4#@H`!VN9GF1<78/GKS2
M*U$KY)QSGC5VP4R'M%5L-B9(7M;72FQ].>V"N57ML4A7XM-Z\>.VB)16601_
M%@`@`\#T6+8>RSWE=6SI&_%LV?H7QY#B[(H2&*[50\$7^X)R]MON.+='VF4M
MJ*%:I3PL>Y201/`&D4T%!^4O[I2&$,76FK6;S>[$7C`]5AFF*=)L=TB/I&]&
MP^'3I!&[&["U>W05G@L,8+N#PKEI.UO&SVNLG+VX,4@>H_>8D6,FH0H!+K?[
MQRZ$:K>/W/UJP[I_@*$G8.FT"OD?/J#%RBLJP6R718A8)TSPJ@RJKA)V=54R
MG455Q$YNHB/`FV\\.WBR?R#R6=:"ZN'DI%0ZSYXEB:LME72JI2$5.J+9HD!A
M4*F4#?L@4.OV<"'VQWCLM&F%H@-T_$Q2*?C2]8QK$E$9MU'@H.02QIMEBD'!
MY5Y`LZ_#R+!.)S177'5U7Y0@@98Z7PE/Q:W4`LKT^V]U]WPPY#YHPS*H3+-1
M9Q"VZJ66(2A<A8VN42J=E/TC(=.D#KS%1L\*_2425:.0`P=.I1,4>O`Y>W6Q
MFO6H&%;1EW-[BIL(6.8NT:W5':,4-AR9;P:+*P./:/"K-UG5BMUG?$(U9M4$
M53BJJ`F`"@(@$)/'-IY<'\[;/(#N1CV*K^VFQL(#&'Q`[CJXZA-4<!EEUY+'
M^#X%".BVS)*X'A"LGMO>@!EW,X95$RAR(%$P20W>V=P1I1B1U9IRI42<OEL"
M3B\5XI*C6XR7R1<6<+(R4='-V)T!>N&`.6A$5ET4%C)'73(`=RA>!6AC[8OR
MWW+%M7OEBU,UDHJMGK5=L:^.EM5-A+/8X)U-M_>6@I$C+,,6S</H--1,JJQ2
M)E4`PB4A>T2\"`E"H/F(USWFW3VZK.A&/MCS;=*8@K\A4C3$ABK&E8K^%Z75
MX"(GZW3[=+6&:3DK`X7FBBD^7659K%!0IO9=&(`>TV0\BV_>LE5E]J=EO"GK
MY4F-)0"!:WR2RE5I&P"VF')VD+4:XU",<RDO/S/N"DFR9D,=P?N[2]H#T#">
MZ[W?W.FI&5MJ,W>'C3^BL@UEL,Q!Y(D<WKM,@XXPM(MV-GK4-+T0(HB*^2*X
M_)\XT>(@@BJ8@$$#`8.!:3X<CV.8S[LNI?(2FQDJTUCTV^+`UU5O+C6/?R_O
M:\E(65E2MD4'\LPL+EX0CE$A$UV0-S@4.O0`V$4DDD$RI(IIHI$#H1-(A4TR
M!^P4A``I0_V.!].`X#@.`X%7_CF_RB^2#_\`+VR)_@)CW@6@<!P'`UI/+^FE
M5=L7.39H&*%<9^/2SUXLK+0S29C(:5'9.G.5)A=A*V*IQ<JK&1SXRJ;3YHKG
M-]\J*H%$.!]?'CHCDK,NG&"K5![TYLK=1@;;GZ/K]=BF,&]8IH5?9#,D!".V
M$K"V!FW.U!NU]WVC?+2/W].X0`H`$N6/B<R&S<R9AWYV`482;(C$[(K=V10J
M8J(KN>KT]V64$%W+<IP["IG(`=H&[1$!#D&\5>5RHJE:^07/C=RZ0>%?.#Q/
MR"N73I))`KDB"ES`K8B:2)0%-,0`W3J`E$1$0@?Y$/'QG?'.O\;)+[8JYX)<
M-F=7820@-A:`U>XKK<O,9=JU9JV2["1J]M[^.:8]GY-I(*BV9_%4024!Z0[8
M5NH>:O'@XVZR"JRCKC;/'Q;JE"S+&P1D6MKC"TAY)/4&PQKQI*RN.\60$NWC
MW\-+R;8Y47AP,15,W;W]#IAL$Z4X#GM6M3L`Z[V>X&O\_A[&M?HTI<3*22H3
MSF'1,D+M)286<2AFQ2"":7R#F5]LA>X>O`E#P'`<!P'`<"&?C[_DD8M_X=DW
M_6W?.!,S@.`X#@5K^6;3/)N^^EUTUPQ'<ZU0KM8;90++'6"VRMDA81$*79F=
MC]E>2JL//S#5<SABF=$Y6:Y"K)E$Q?3@:]2/B"\PD#8NETVSO3+'T6DY=3N0
M:UY!LNKGBX]DW.LK-MZS-X$C7"S5E[?OJ(&[3"B0Q2@)NT!"Q3Q2;\;$T-OA
M733R;R:Z^:,Q5B6ONI>T+TIF=`VFQX9R9Y'4X)R5:03Q7-U>AQ^<HS68-%I&
M!<,G9$Q,<PG#8IX#@.!K.^?K&M:K.1-*=DZ=\FD9REK%FC7&=R-`F4+)6+"%
MLU]RY8IG&]ECQ5+'V&NK3C4'+=)R10K5T<5B@82@'`EOY?TB(>"?;9`@#[:.
MFC)(@#VB/8G#UDA0'M*0O7M#\``']3@6?:T?R<-?_P#0EBG_``$@>!4_Y")B
MH;*[UZP^-:[P!;91\JXHO>=[?+Q$,K7LBX*D\=RYT,<Y9Q/F-C)&D*S='=F8
MN&@MTV1BI(LQ$YSD<&3`/3_T)>.>_O\`T^?*=W]W?W?IAK_MNO7KT_(#M^W\
M'3IP/!#^K]:[G:-V"FZ'E`68M6,Q%HM5MS)I5(D?8;`WM,XT'OIYCG3D[`T2
M=*&$1.!R`4ABD^[P.NL_ZNOI]>+=-W6[['>1"US%B9H1TP60W!MK!K(1K))T
MVC8]Z6O0D*Y?,XQH^600(NJJ!453$'N*(AP.7(?J_'CYI<%:+0T6VEE9J-)(
M7)%_)[:YK"1-+04*LG"])-K8T727T=BW!JS6^^NT;&%,A^S[O`U7]R-2M>(/
MQEH^2Z@W/8N+R!EV?M>)ZF8ERLT??JG(5]]<V4@U>Y,M&77TS=,</0IZ[)V@
M"7R7C!RH9)`%B@40WUM#\?T?%^F6L%*QS5(*E5*(P;C+Z=7ZZP2CXUL=U3XA
MT[7!),.]9T\=+'5664,=994YCG,8PB/`P!YBO_5N;-?_`$)QW_KAQ[P+,N!!
M/8_="R8.R]5\+475S,VQ=NL^-[%DLA<6RF-V*$9%U^78PAF,@G=KA6W8.GSZ
M12*FJFF=N3N^^H4?3@4UVB^9DP1L?D'R"XXT:S5IA'7*G,(_<AGER9UI:X6R
M%7*1)-)"$RG+.H;,:;R(RBW9RKR.*M$M9*;G3%;M_BJ&'W!"46H^N\WY#,W0
MGDXW0I$HW@J?,S;7QZZX7>%D(=AA_'"<JT<1>P-UJ$N*+E3.F0SL051.^;E-
M#QH)D1)U4`X!:5M=LK6]5<2+Y+GX2Q6E](V6LT2G5:JPDI89BP72Z2:<1`M`
MCH=N[D0BFBJAWDBNFDH9M'MEE0*82`40U,:P^V:R'MQ8O(AD[7"`W"V-UC4N
M$GDZN_EJXKVN.C^"&"S9PEB+'<4]:RZ.2]UVU+45G)4$A;EB"H_'=%*Z4(!0
MW,\?7NKY1HE-R329).9I]]K$';ZQ*)`)2OX*Q1K:5C'(IC]Y%11HZ()TS=#)
MGZE,`"`AP.RM%HKE)K<]<;A.Q-7JE6B)"?LECGG[:*A(*#B6JKZ3EI:2>J(M
M&$>P9H'5554.4A"%$1$`#@4B8<KLYY8]E(#;3*E1A/Z/G6BV2#S1JF3)7;J0
MV(RNP$8Y[M[:HE8I(\*!&-S*-:$T6*914AEY%0G:LD'`EKY@0`OB\WG*4`*4
MNN60`*4`````C.@``!Z``!P(2^(9NV1V@W$4;ND'*CK`>I#AXFC[W>R<_GDW
ML1^*Y!5,A07^.B13\6)R=BA?7KU``O\`>`X#@.`X#@5F>.\#EOWD2*=!JB(;
MW9'$#(]0<KE-3*&<JKXHG,(+=!Z$^Z7JB!!Z"'J(69\!P'`UK/-_1*E8\T8?
MF+$NG$*DPI;*\E.(SUH@YI8TA?H)_%U2$7KKY@0CFRR[!,JBJJB9TR)![8F$
M1+P)S>"Y\]E/%MK5)R3MS(24E*["2$@_>+*.'CY^]V?S0Y>/7;A4QE7#ITY5
M,HHH81,<YA$1$1X%MO`<#&.:,45K.>*,@X@N`NTZYD6J3-4E'4>=-*38(2[-
M5J62BUU4U2MI2.5.5=NKVB*:R93!ZAP*]E-I]KM/*Y,H;H82E,V8[IL-.S8[
M7ZNQ\(>#1IM58V.9D)S-V';A<(FT8_F6=9A6ZJ[BOKV2,=NE51`K$@$2$+!\
M)YFQQL1B3'><\06)*W8PRK5(B[4:RHM'S!.:KDXV*[CGP,I-LS?M152-ZIJI
M$.40$!#@90X#@.`X#@.!#/Q]_P`DC%O_``[)O^MN^<"9G`<!P'`P=L/L?AO5
M3&C[+^>+<:DX]CI6&A'<XG7[/:%22D^\*PB6J4-4(:?G7)G+HW03)MCE3*`F
M.)2@(@$&L@7;9;=Y\&%\;8CO^O.KMF3*AE78_(3BJ1-_N]+72,L^J6#\?)2-
MCDHP+8T[6JT_.-VPM&ZYA09JG^^0,X;;>.[67<C7ZNZ\9*J;B`@,>I50^&;S
M1'",#E/!<M2%(@U6L&([VLU?S-.FHM&#;H"L@?JNW(*:O>4>!";3'<_.&NV5
M8OQW^3B50;YN3$6.L6W"S%.#Q5NK3&J2'P4$Y("DB*OL#`H*E;S-?6436?J)
M_*:%.13IP+O^`X&O-^L`KU=O"Z#*72+=357-M-;4):,9/8B.=NDW>NN7&K8$
M7T\FI$-#)/5DE!46#[H$$2"4_:8`S]YE"(I^#O<A-N4Q$":A@1$AU2+G(B6/
MKI4RG63$4UC%(``)BB(&'U#TX$EKQ8;A4O%Q,6C'KYW&7JO:/HS-/D6$Q%UY
MZPLD;A1N[AWC6=FRFAXA=L^2(<KET'L(B'<?[H#P*;=7/(]G>GTW7O"UIMM&
MKR=EU;N&P]CV5O?PLJP2EV>9AR[$"G;H"H96EK4OCI[5J>[FVSR.<N2J&:`W
M4DFX`H/`OETLRM;LUX*A\C6_(^/\MJ3LW/#`Y"QAC>4Q;2+/66SSV8>4@JW+
MY5S$\69.D2B8CP9C]T%$!]A$0$O`EEP'`X,G'M9>-D(IZ05&4FQ=Q[LA3"0Q
MVKU!1LX(4Y>AB"9)40`0]0X&E]^L7ZRXUT-\:>+J+A!>6?4B?V$"F0F/,KY`
MG[+6*5'7"J95LMIF,90TG,L&B=M:_.?K-45SND@!=0R2!ERHB4-P;#32+88B
MQ<QA#*'AF>/::VB3K1Z42J:.0KT>FR,K%H"9".4,W*43($$2I#]T!$`X$<_(
MGCYAE333-=!DR2RC&PQ]02<$@W<4PE3`QR'490GQ'<V8D6B8%6)>[W1`!)W`
M7[PEX$U>!7CO+A7*R\ACW;K61]48O8[7")MK`(Z]*LF%+RI@>VOJK8\NXFL\
MNNS57A7,P3'[!W"2A7#0L7*MBG65^(JZ34"DI7=S77RD[3X'O6?IO->$-`<6
MS.,'F#*3D[&^0<>T':O=*?EG#B"^JWEA'.ZG=ZAC,[9-.&;E?@QD)8IUB"H0
MH=0VP^!'79W6NJ;3XY0QQ;+9D2C-V5CCK1&6S%=G/3;Q#2L<UD&!'$)946KI
MW#N%&,JNF#AM[;I`3@H@JDJ4ARA@V2QEK'XWM$LE53'\&AC3"N.J#?9,[87\
MK89VP6JXIOBK.7LK-O9">M]]R!<9E-(JCA=5R_D79"=>I@``R1HC3K+C_3K7
M6J7*(=5ZS1N+Z^O,0,@3V9*$<RR2DR$3*H#_`/)9:-1D"HNDNH^RX(<G4>WJ
M(5BYNFWOE\V`7U%IM>NAO')A.RO76V6<HBP253J^R^1JB^?1!]3:<HU1CIBS
M4:'L*97%KEH]R=BJHQ4C@.50.\0O6KU>@ZE`PU7K$1'P%<KL6PA(&#B6J+&+
MB(B+;),HZ-CV;<I$&K-DT1(FFF0`*4A0`.!7WY>E2(>,3>151NB[(GKKD`QF
MRXJE16`(P?N*"@HBL!!_#VF*/]7@0U\331PVV7VG572!,C[6O4AVU.#!DS%=
MO^?;?UM[QEFBZRLD/O-SE]]P5);[OM]G80AC!?-P'`<!P'`<"MSQ^N$G5Z\@
M:PJ.UWP;Q9$;/UW;D'/>+.HT=K'I-^JZRB#5I%I(HD3,"?:!/NE[>@B%D?`<
M!P-?[RA,*N]W>U4C++\F*2LV-YU$EK*E&6%*"0IMQ_*ERZ1I4Q!6!H]?-Q$@
ME=H(E>)E.()*)].[@2'\#?7^BDU:ZAT'W\]=0Z]>@_I,9EZ^OKU]>!;UP'`<
M",>[$(%FTSVWK9G`M"V#6//4(9T!/<%L$MBNUL!<`0?VXH@X[NGX>G`PCXF\
M>EQ1XU-(\<%DAF`IVNF.87ZH*'QOG"WA41%Q\?N/[0'$_P!G4>G`L*X#@4,Y
M(R]N3DK?G9C6C`FPK>AJT^TXLDJS!3E;JTQ#U2K?HXT*\RSM$CZ/7EY3\K[G
M-N45453BT0`HG`HG'T#+;3!7EODY!:0>;;8VKOU*+=HFC5*#$S,-#O&YWCEF
M4J;!K'/W'U)X1N*BZ*J:B"'5(O4G>4P?IAK;Y5YR*D#3&Z5&IDN_8G/&?`HB
MEA3@7Z+%DX8$?$!S'M980FWKHJXI`BDLU:ID,4>_[H1T)$^7W3.]Z\Y2VS\B
MV)MBM>YK.-$Q7F:CUG4W'N)W,=!9%"5@(FVA?&SIS*,&$+:CQR:Q0[57'R``
M#`/W3!+BAY/E\'>**Z99A)Z,JL[C;&^PEIBK%,H-7<3!RT)D+([AE(R+9Z11
MHX:,WB93*$5*)#``@(=.!&[Q([2;*9BVCWAPGG3.43F>"PABC0^RUD6L5#1D
MO7;KFO#5BMV6491*+@(11HS>V5BF$>V,9RF5DB18BG<NH`!*C=53<#*VP&$]
M?-,MGXG628A:'>LOYSL[S%M&RZ[7J<D\95'$[`M9NZ*[9JUE[3$3H&<)!UZM
M!#KU*7@1^:Z>^9TII-.P^3K$MT'ZP9:"E5-<'&/WR$$M(1WNQ\M%XZMD+`O7
MR,2DX]I<J!.CHY!,`I@<A@[M[I]Y91=NACO(5C<K#Y'[A*^QC>U'@-??/Z.U
M&]\20.X^+V^I"E+[G4>G;T#@5\>1[`N_N*->E+GLQM+C;/F'F>3Z&T>8WBZA
MD&J2[Y202?M(^2"97NLFP%]#SJH.4TU&XMU$2=IP$_0W`V?L;]WYNZ%W#W&_
M(NK=QA_VQOH;'J/_`%1X'M.!%G<73[#>[^$9W"&9XITK&.G;2QTRX03DT9>,
M69&@_=7I^3\>3Z71S`W2GR9P<LW!!$IA`4U2G2.<A@@OX:-DL[YNQ;LABW8.
MYMLI7'3[9Z_ZPQV7E8Q*'L^4JW04V)8:W7F/9`G%DMSMHX*5XJV(0CA4HJ"'
M<81$+CN!KH?K&![#$8ETLN%9+(I2]8VV.JSD&*1'!&3AU@S+BA07;"@L9<%T
M6"GIZ$]LBG>`@/H$DO,BY5>>#C<9VN8#K.M0B.5C%*4A3*KQU=54,4A0`I0$
MYAZ`'H'`F0UJ^.;MX\HBGY@^N_FIM&H4#`Y(_)AU/L;'^1$KB)BRL_T-Y51"
MS-97Z.LM["D?^["J=!2^_P!O`H:M*U)P>GC78C4RG6^+TQQ]H4[PK@TT/BI:
MY6[+=HQ#-[&)5#&MQR=(/V>>Z)#J(/VDDU.Q0<2CDT@[.H!#E7[@N0\1>2T,
MK:"8)LZA'K&Q!#/F-UKSZ<RU9S5&WIR+EQ+U5O8\V-T+]--887)"%67%1`!$
M2(G,F4!X%E7`<!P-3K]<&<V=+QT85:P=>=S4._V]QPA<7S>#?2[>NP2=4O*[
M:6?NFA#H0:*DXDU;)NE^THKKD2((*J$X&TKCQJT94&DLV!3D8M:E76[,BA7Q
M5"-D8AHF@4Y90ZLD4Y4B@`@X,98!_;B)NH\".N^1P2U&S8L+!A(@A78Q<6TH
M5N=B0$+/!*B]73=)+MU`C0)\DI3$,!CI`'X>!*6"7*ZA(9R20^K$<14>N25]
MH$/J95FB*A9#V2@4$?F`;W.T``"]W3@43;$9,N'E'V7_`$'-;;TJ.D>(YJ:B
M/)'F&@/G,5+S-K@WCUA^A;!65=(@>_9_8*-S^G`5TVAG!4BKA\@Q1"0'D:UM
MQXYPMJ%6*FFYQO7<(;1Z_-Z1`TM)JR@V]69R812U,6B%4SL!A'<<S13[@)\A
M#VP,D<IA,(A;=P(F[H9>S)A+#3*YX,J="MMTD,L86Q\LCDF6E8NK0,%E/*-6
MQO)VQTC!F1EYM:NFM"3@C!NJ@HY[1`%"].!'V'TAS!F>]P]]WVSM!9VK58ET
MK%3M7Z%CYG2]:JW;(J1:R56NLBPEW,W?LA6BK.VA5XY2=DG2#!R'NHIE/Z@$
M</(9GW*>TN3%?%KH[9;C6\SRKVBS>WFPU5[&$!J?@"6D$9659/I9XB!)?)N8
M*VR=1D-%,C@X(DN=R<Y"$$0"VK!F#,4:U8FI.#L(4J'Q[B['D3]&JE3@T3),
MH]L=RX?O7"JBAE'+Z3E9-VN[>.ESJ.';M=194YE#F,(99X$%?)W5F=T\>.YU
M9?NG3)G)ZZY0]]RS]CY*96=9?/P]H7)3H`)SM0*(F`0`!$>!41X#-A(C9#*6
MS5PAY6!E_HFK.@<3/'K+B37B(6V6^0VQS+8*D5.9K\!+,G-5<Y2*T,1Q\PRZ
M9".DW*C=PB!0V8>`X#@.`X#@0-T\6>GS!OZ@\CG,25MM:W*T9.'4<[[FJ^#\
M1NB2:)XQ--!)O-F7%V1(X"X2!;M6$50,/`GEP'`<"@WR471U6]]-6$UI[Z54
M8_$-MEK\@P;H-[*XK\C;?H39.#G2F4D&+5Y)JD2DDDDR@JT]!4+]G`SOX&P$
M/%)JT`AT$%\]=0#[.OZ2^9/L_J<"WO@.`X&`=K_Y+6RG^@',?^KNQ\#'GC\_
MD1ZL_P"A*A_V$;<"8/`<"AO#3M@IYRMP&8)LDY5O`XM5.=(J17J\<KK#C7VS
MNA'JX.FFZ`Q2#U!,.G3IW=1X%\G`<#P63\:5'+]%L&.KS'$DZW8VZ";I(2-S
M.&;Q@\;2D/,1QW2#I!O,04PR0>LUC)G!%T@F?M'MZ<"AZRTO??)/C)S3K"VQ
M+6LWEREB'+5!QGF2D90I=>M0+R5NNL8M*9EK66&-%@PLZA3(KG5A2OV3HY%C
MJ`D<Y""'G]-9K9MAMEY&\KX%Q1^>VK3J.E^MF/7]AN.)J!5<<VK#VL41;[6O
M<SM)8+S:8&,=YGC1=K-FCIZ9;WV[1(R:`&`+@M6=?LBXP"WY'V#R'7,Q;'9)
M=E3M^0*S3RTROP]-BW3E:G8SI\0J]D7S>K5)%VIT455*H_=JJNE4R*JGX$O.
M`X%.OG01%QH=*)%402$V6\7#WN%B-T0]N4>*"!E5!`A1,!.A0_VQA``]1X%J
M^./7'E#'_P#`RK_;_P#0-CP/9\!P*(_"A$K05X\L\0X;"S69>3O-Y3MA6.X%
M+WHNO.B?CE")G4!1-<IP$2AZ&_ZO`O<X&NY^L>OG;;6W5=LV54:E=[@0GNOD
M5'!%FP)X-SBCT)\94BAR+HNCE.4"'$Q.I0Z=1`0D/Y@D#*^#O;=LBD=V=745
MDW102`Q%'1U&-92302#M[R'<&,!2^G4!'[.O`L1QI1T+CJ;CC'4RM9*HA8M?
MZ34Y-:OR[B$MM=)(8^BHQV,3.(D^5&3L7[AO:<E+WI+$`W3J'3@4N7^BUK`G
ME>T=PW!-[IDBK,*-&2<>O9IC*LM(XYN%KE=L9M_DVP2T;4PQ#*R%],#N-`KY
M\SE4P:")$E$A(/`V+N`X#@.!J\?K9V+\JY!\;=1G\>P]BF*OBK8*HW[,"<#8
M@B$F6/TZO<(!&0G(D96--:(EO;IJ,ZMRE<F;*B1V5(10`Q0V/,,/6$CB#%DA
M%QSR(C7V.Z8[814BZ>/G\:S<5V.5;,7KV0,=^\=-43@1158154,43&'N$>!@
M?R``[-IMG\K$617)Z4!"'D3.2LDBGF8DJRK@6:2[H2)(B8W0A#&,(`'3UX$'
MMP-G\RVN6PKX]M![$R7V<R1`T^:S+EU@DTE(34G7B)+7#6S(=R0<`H6(NU[B
MG1HRIL5B_,5?.!<$2.#<>!9%K!K!AK4##E;P?@RIM*K38`[Z3?*@91W.V^W3
MKD\E:[Y=)QT=:2LMSMTPLH[?OG2BBJBAP(7M2(FF0,*>0'_)GB+_`/*=P;_A
M&OP)V\"'>]:R*.`V?O+(H^[GS4Q%+WE4TO=6/M-AWL12]PQ?<6/T'H4O4P]/
M0.!AW?G=*SX2-4M:=8HFN9/WVV#8.D<%8GE9-%LRK5=(H\:6'/.2$P$SB.Q3
MCPC)=5RN)0*[>I)M"")E!Z!F32C55?5/$SFOVW(,GFG-E_L#O(6>LZ6*+C8N
MR94R3+H-T7THZ;1J2:$?`0K1NFPAV!!%)C'H$(4.X3B8)A<!P(H;V1Z$MICM
M)$N5'J2,K@K)<692.00=/R#(U629D.S;.E$F[AP518.TAS`4P^@_;P*@O!)B
MM]C7*GD6;2U@BY":B9O0;&$M#+1CV-NL<\Q=X]<`1:LM9DCA]+083BTH<C)L
MW$5&JK-T53H44N!L6<!P'`<!P'`AMK:T29YXWQ31[NU78*@.S=P)@/NO-8<%
MN5N@))I%$ON*#T$0$PA^V$P]1$)D\!P'`UP_)C)1L3Y2=6'2]AB8)XKJ1E%A
MUDXJ;?BY;/\`)D2W!FFXH9HC(;'ZBH84>]O,1S,`Z^Y[@]2\#!OCRE/+\PTR
MU\A=%JIHA*8$^F[&R+&:SV]RY!23"TJ;=9A;H5>.-1YJVK/H2,AFJZB3HZ)S
M./DH%%3\2HHL$K6]G_61ES'1G:?XT*S\=-J*#RI0F9\EIRJSAJBX=$<-IS*V
M)U(,D<HI[0&*9][ZH'``(0A%%0]$O+?K`I6C4[:4T75?G;-#O6RVN.0$&J#P
M[D2O4&[LNZ:RCENV9]#IJ"DF*J@]@E('W^!R%Y/S]EE4T6TSH\K"BR,HK(+:
MU7U&1)(@DJ)6J<87=I5!1H98I"BL+DI@*83>V/:`"&-,JAYX7F`,XRV7K+X_
M&5$94F<2MU7K.%LNMKW/8H>P<DVR>ZKDPOL=-UZ"NL/6/EK1B3E)XT75]H3F
MZB9+@6;>,1](27CXU`?2BQW+YS@JCJ*KJ*1JRJI?II2H'54AU%HLRQFX$[_8
M,9/NZ]!X$[.`X%$.%WQ1\X&XL9\%H!RL,62`R@'F/GG(?5;&+4(XR9D?R>!D
MF9/W2F*H+[W#"!B^SVCP+WN`X#@0]TS6BE]2J6K"23R7C#$RA\>0?N63MVN)
M<CWDK@%7#!X]9G!!R4Z9>U4W:0@`;M,`E`(7>'-LY:0^^2+M,$EAWA76[`),
MIA[+G4G4]PV/VST9$2/XQNJ4>H(_',(]6ZBR`IJG"Y/@.`X%/WG`264TA.=%
M5R06^8L:KG0;H,W(/DBJS"9VCE%Y%3!3-A]SW#"1$%2BF`E.3H)@"TS&W^3J
M@_WE5;[/7_[QL/P]1Z_]<>![7@.!2AXBB&3S+Y?R'547,7R=Y=ZJJ]GN&[JG
M3#`!O;(F3[@"!0Z%#T`.O4>HB%U_`UI?UGA+(#G5C5-KB:;K-=R<KN;33U"8
MNJ4@I3HY=#&.4E9)Y8S,6$B!&",8"H"`IF5'N_%E'H80"N7>*P^9BUZ*[&4G
M*FX?BUR;@Z_TZ,PR\@<9U/+RN2F:AK#6:8X;50(-58D=<&T](H(R8/`DVS!0
M.O8F`_=#U="V]\[L+1L@1R.7M&L25O7C%F(V3U[DF+'*L+>WLW<+SA>#/ARS
M8BF)EHX1<V:@MV3I&><F?)3#P45`3!%8"!(3..IOF]QQ*.=X[UE[Q89ER7K=
MBBYW2#RA>-9;LTR94ZC4*[9+;+U"GRT(\1.W8RC1>01[_?253^H+]AR^X81#
MNM5,G?K#>\VLF)-F<2[1>.2K5S)S27E6T:I@W*Y"IQ:JQD62[:2D9*5&5^*X
M1,FGVH-R!T-W'6Z!P(FVW;S]8WGO(W`>/7&>==([Q>(JE5RXYVNV(<.6:2QO
MKM`3*[I9%YE)];E#NVMEDXT4E64:W7,X=@=(/92`W>8+-$M</UDLQ4Q6\@^C
M*9Q?.$U2IZY3RA21I%'`-79#&!,5'BZ94A.B(%(F)S`"ANT!,'._1L_6.O\`
M\XCI)_T99G^N^!!'R5:X>;R0T^OF.]CMN]7LRT/.5SPOK_'TN@XM=XLDC7+-
M>8*5CNG3,K:7L/9Q+6H2P3S=R_;HH)N%VR9BIJD-]H;&NG>P&$;9BW$>(8+,
MV)[#F&F89Q:2[XQKUZJ#V]59PO2(I=,L[2(R2--P!%TDS*)%6:H@*8=2AVAP
M(<>:_<J*UZU?F<+4R`D<E;(['QRU4Q9C6L$/)3T+!DEX9C:,VV6*9Q\N\;8U
MQ:I)-G4DY4;@W4,)41.7J<Q`EAH-HKB[1W$ZL)6TD;3F+)*L?<MB<XR1W,A<
M,U9.58)IR5CEY:0<.W2$"Q.8Z$-%H&2CXQB!2((D$RACA)K*F<,+X+A"67->
M6\:8AKJ@*"G/9-O-9HD.<$5F;98225GDXQF<$G$@W(;H?[IUTP'U.7J$1MVK
M/6KKA+!%NIU@A+75+)L7@*9KUFK<HQFX"=B)"<5<,96'F(U=S'R4<];G*=)9
M%0Z:A!`2B(#P+"N!1G^L#W9K0='H*TI,9B?M-5SI0+[1JE5HE6PW&R7''D?9
M;A6FU;@V:3F14<-;!%-%%7R*"PQ*0"],001Z"'@-0++0->5;;NKY&K;(6[<[
M*$E*5YU?XC".9KG2]?\`%/S4PINN^*[3%X1AF\2Q8LUDAFUTT4W,]-F6.JJX
M["]`LQDO(3K3%N'S-RYS<J\CVP.UF<?JGM)*NUT#1HRY#1S:,PZ[6E3*QI3*
MD*V*J<Y2&[0$2F``ZZ$\C.M5@%8(YALN`H'2(I]1TEW+A@[EB*G)[8S&!V(*
ME[43=PEZ@4>@"("8O4.&W\F&HJ[][&#9LLM'T?$?E$Z0D]8=G(H25@H&%>UI
MGDL0-4UZHS`AOD2:8F8MQ(8%%2]IN@1#W&\J/C\M^K.<ZE!;-5A>5O.NN5[/
M6';2D92L<<[JT)&+Q,[<R%KM%EUI"I5:0=)_5'2!%4FB0B942DZCP(G_`*O;
MF?&&:,D^2*PX[M\%=5%;EIBK*SD-&62O`[")TVQKCU9P6LS[:,"%BU;7C^8!
MF4C-%4R11!41["%3#9CX#@.`X#@.!#_7C_+YO;_IXQK_`.BS@?@3`X#@.!J_
M>7!VA&^1[$4ZZ>RK0D'I'+I('C.U=5(MFV)B(:141CURJ-';Y=L0B21CE,9(
M#&$G0P\"R;PAQ,E">,/6N/F&7TV2(\SJZ=,/B),"M32.R&7Y(B*;)!11)FD1
M)V7L2`0["="]I1#M`+6^`X#@8"VN]-6]DQ^S_P`P68O7]C_S=V/@8$\6;)*.
M\=.F;%".1B4FVO\`C],D:W74<HLRA$)C[*:ZKEXHJ4!'KU%4_P!OV\"?'`<"
MB#"Z*_\`3@;BN/<9_&%ABM`$@0<!(?(#5;&2AE#.O>^*+$4A`"I@F"@*=3";
MM$``+W^`X#@5\>.!1-WH9C(_U1K-IJAFHHR+1?Y+9R4,R9-3,4BY0#O]CH*1
MO3T,00_!P,%^)"2E)9KO<YEVZ[5VCN;$QB2#AJT9J)QL-IAJ!$PW:@R<ND/8
M-$LT12/W^XHF)3G*0YC%`+>^`X#@4T^=]VBQT$F72ZPH))9=Q0!E2@J(E%:;
M<($``1*93[YU0+Z!]@^OIUX%L>./\GE#_O,J_P#8-CP/9\!P*/O#\[34SAYC
MH\BA5QC_`">95,=P7H'NB^J%0=#]Q-!)L04C")![#GZB`B;M-U#@7@\#7K_6
M%5G3;&6B[IDB61>MMXJDNS@@*V45FG:6*,K*-F::2O:X4!58A4A`ABD'W0`_
MVEZ!XN7P#,[*Q&.-/VV8+YCK'&><Q;694S;/0K7$LME9A,59Y4K'5JE4;DV@
M)@U">5&XI`J#EJ9.9(B4$W"@F'KP)4T;P[)8W5L[.M;Q;8S=4R+/T>5RC5LL
M/<9YF2ND30YFU3\54VLWD.BS,]2X!Q,721=K$AUV:@O%2N"F!9,A@"?>ZC;W
MM,]MXXS=91H?5O.S8!;.6Z+M;W,56Y!1N@9T3XK=;VP+V**"*8&-]X.@#P-?
M[47R`L]>/#9XO,*8(K+S(NW6W.%$,4ZPXK@7\.W6A)J+:RC&>R5>'K=%N:#H
MV.$DSR#Y\9L87#A+V.\5#"<`N#\7WCW@_'EKL2@2EK6RSGK(=BE\F;(Y[F"+
MK6;+N5;*Z4>2TP\?R!UY4(2,(<K:/:JJF*BF0Q^@**J=0LBX#@5O>4>*DI;`
M&)DHIN#MXRW@T)EP;F%P4JJ$/MSB*1=%,JV:/#-P^.V-^,.3VB?:<Q2@)@"G
MB'N>E^$O'_F#(>T>'X[)T[;\T16-\1TRJ,&,=F[)N9KQB#'<'1Z?BVT-S,[#
M"W9\]21(RE$%RFB#)D=`8HI@/`\)@#$EEQMJ;Y+[/LPG=KUY*JI`8UK.9,A6
MRSR]JEHG#MV1JMUPGC/%TZU>(S,74ZS19!!I-_#^/\V>:N57"BIP$0#:+G[]
M7\3X2DLEW%ZA$UJ@8U4MMA?O5RIMV,97ZX$D_6<N7"PE(FDBV-W'.IT#[1-^
M'@5]ZSZAN)[%MQV2VSGG6:MC=@*C.W!5_>(>/?0^NV/[K7UW];P/B*K/$7$5
M6H&B1#\B<@N0@KS4R#AXL<P*$*4(+XQR!3L=^'WQ/1-CE'#=]8;!JK$5F.:1
M,M+2,PM'OS>_[#6)8O!;MV;10BJRZWLMD4QZF.'H`AL`Y:RI1L'XRO67LESS
M&L4/'-8E[;:9R1<(M6S&)AFBCM<?<7.F0[EQ[8)()@/<LL<A"@)C``AJP[B8
M)R_MC5<8^378Z.M=(<JW!NVU3U;?Y1DV5;Q7KYD#`]Y&6M>1JB:/-`3&>;ZY
M>)/9)HDFD>/9-&S4%Q.W4]P-CRI:A:O,8AJ[9X'QBBO,L8A]*'"JQYP?O$6O
MN(NG1%4U"KKIJ.E#%.8!,`G$>O4>!Z(^J&MJB*#<^$\>&1;**JMR#76?1!18
M"@J=(0+U(8X%`!Z#]GI]G`^+/4C6=@!@981QZV`S5!D8$H!L7JT:G.=NW'_]
MTB<XB4/P"/`_J&I6LC1%NBA@S&:2+)NBU;%"KQO:W9MD7*"+0@BD(E9IH/%2
M^U_N?:H;J'J/`U:-LL78-\A+_:.UT_!%#8^,?Q]T++J+.>Q,I^;Z=V3V^K#)
M./F:[%V*EI1$R?$N-$ESD>LTES,)>63*59-0"$,4+1O$`NR;["^3NM0L8YKE
M>K65-3&\54CM&,='5<TEI=AV4>1L-&,V;,8QI[KD#*HJ`8X.Q5,/3NZ<"]G@
M.`X#@.`X$+=8WZDCG3?191N5L9'8NEQX)D7,X`Y(W6G![)-P)S-VPD,Y(@"@
MI]I@3$W:!S@'<(32X#@.!K<>2*,G7WEAUR+#5F%MX2.G,W"OH*Q7"NT>+-#*
MY[8/K%8RS=D<MV8R%(BVH/TD"`==0.HI%$Y0`0R9X,=JJLYTUFL99$MN-85/
M`N8,MU6-N;7)32:BKA$VW+E]NS)VL\FDHF2:/XM2Q`Q-\E(AW0$36*`"H)0"
M[=YES%C"&5L3W(E+;0:+25?*2:MDB2M"LX-0$IER"GROO(Q:A@!P8.H)"(=W
M3KP/.GV*P.F5F<^7L>E)(!+F8F&T17:Z+``49DR(_)Z'+&@</='_`&O7@>*#
M='4T?4-A\3=!_P#PRB/ZXX&(MA-JM:;CKWL%7*[G#&\Y+R&!<TBWBXFU1#J1
M<I,L96F0?"U;_)`%3MV#5540$>G:0>!&7Q8["X0Q%XV]'*)E/,F-:K=8O6G&
M2\G#260H66<I)/H<%V3CZHFJFG().6X@8JI2@!O^IP)[_IH:G?SAL3?PRB/Z
MXX#]-#4[^<-B;^&41_7'`I+Q]LW@*D^6O:[-UQV"Q#6L*3\C1*M`66:MT#&Q
MTG<:_J3BF1GP92SEVG\E&/AW2)54P^X13J/7NZAP+*T?,1XL'#M1@CO_`*J'
M>(NDV*C<,Q5`%2O%7162382FD0ZKJ.S`F4OVB<>@>O`Y9?+SXO35UQ;@WVU;
M_)EK+-()Q-CEZIECD9A\W6=,XX[@T@!0=.6[8YR%^TP%'IP*6Z/FS8C9&W9]
MSC3/(9>H?`##8+9I_79&C9%Q&A2J?@W#N2;A'0$G#0<I'JSUAK[BIP#-0H(&
M6<R)'8J)?BB]_`R?X'-C)B_T_=2B.MCELS88QM'86G\&S%A80M8<5R-S)5LH
MWNU1QD$6\7[[IS/'(N<ZA0'U*'H("(A-[Q2S<-6*OMT\L]OKA22NQV-Y1O-N
M7$)`-9@@Z$Z7`]>)-T7ZK4RZ+U%9)R<IS&.X34,?H<3!P+3(C+N+)][)1T)D
M6ERKZ&:1KZ5;,;)$N%8]G,-/GQ;ET";H022?,OQJ8C^V)Z_9P,5K[F:HMEU&
MR^PN)DG"*RS=1$]SARJ%7;F,1=+M^1U$Z1B"!@#KTZ<#\?IH:G?SAL3?PRB/
MZXX%:_E4VQU;L>L<9&L<X8CFEE<N41))DM<H$&QGCQ&>CH@[A1VL9HF4LT\;
M=@J?=%7M`.IA`.!895]M=:*U5ZQ7[)GK%D?8(>M5Z/F6+BWPZ:[61;PS(KI)
M4@+%`IBJ=?3H'V_9P.\_30U._G#8F_AE$?UQP'Z:&IW\X;$W\,HC^N.!33XF
M-C]?*=E;RX2%IRSCFKGG/)CD^2;E?6R'31=L92IUUQ"O6AD'BK!5K)LVBJJ1
MT!$IP*;N^\!@`+EOTT-3OYPV)OX91']<<"@7]8(V)QKD["&J,)@2RQN=,B1>
MV4;9FU`Q#,0\WD=>#@\-9><V*>@&QUR)IH5>+$\@Z.=5,A4FX=1$>G`ZWQA;
MKXISG?J+F1%G#X>PUCRU[/,7MNRG=L(4NPV"XW-[7X]U",,5TFUSEH[8Y[''
M44G9(B1I0#^Z/KT#@;!GZ:&IW\X;$W\,HC^N.!"3R->1O3#&6DVS$A*9MQS<
M92P8<O5(JV/ZW9HV9M=WL]\@7E-@(2&K[)R:4DD5)6;2.].BF<K5@FLNIT32
M,/`JA\`5#UNPMB!';+9O/6&9C:+(<$WHE7KC^<JBL=JYB6K/'S=EA_%3EL]6
M0B8::443D)(6Z3=11P;VSF4`#&,&QS^FAJ=_.&Q-_#*(_KC@/TT-3OYPV)OX
M91']<<#&V7O)!ICAG'%HR58\]8^DXRL,`=FB*[8HZ6L$PY563;,XJ$BVZYG#
M^1>.5BD(F0!'H(F'H4!'@5+[W>32HEQ'BNUY7G\88JQ&YV%Q5;I$E/RNGD/+
M\#'X<L[3-S%Q8(>CMGE6D:[>8W'YXQU%-WYY,P2!4?:$PG[0A]X76NIL'C?'
M6Y&\^QNOD=F2X4>-R9A/6E]>X!;'NM%)FV,!$.LD0=0G9*9=L\BY#<Q#5XN^
M.NNK!,UF[`ATUB+``>L\N&0O'_8;+8]HZYNE!QR61,*Y#P_E5E4,H!+U)_)4
M=O09RB/6=,JJB$O(9!A6<DN=%;W7/LM!,?V!`!X''M>KGC<MZ\KCS+?DUE[#
MKK<<,.K)=3,LZNZG.,R1USQV[CXM646LDLDWJUGK$TLSDT'$;VN&B_9T3$WH
M%^*'DY\=`(J1Z.XFO@HL3QL2LU_+^#[$%),K1O&,E$?=`I1>`\1*0G3H;W`#
MIZ\#6>S#$^/C7J?U"CM6_)K*RE?I.0+$SN3:3S>QM<)4,*S;FO6*72D0*G]-
MJ=9B@8@FB_*@3XS4XI]>@B(!++])[1SRR;0.++LEM'4(#437_(CFMZZ:K2-U
M"LQVSUXKRZ#B1V$RW'`LW6M.,O<(1&I0ZY?B.TP5>JB/XLI@L0\C&S^M-DU^
MC/R/RCA&[6.KY!K,W7ZV_N22:"RJ4=.0[ENP0B#+++/G<3*KM$$13.D8S@`,
M`!]XH3MBMSM42Q<:538#$S=0K!F!VXW&)**!P;I@9'M,N!B^V/W>@@`^G`Y_
MZ:&IW\X;$W\,HC^N.`_30U._G#8F_AE$?UQP*C=^-ZZ!M3>$/'1K#M34<5'M
M]:+9MK=I(*T`T'!>)72Z)6%.QW-)I'A9O,V33IJ-2L#N$1C(HYW2IBB=(.!Y
MGR.;:Z/:-^);)^*L#/J%<8<U,K^"Z9CO%;NIO))Y9,E/FE4;VR7B7$M&)2O?
M+.AD9=<[@73@14.)S''KP/->+W>#5"B9J\E:&3\I8WQU<)S9'6B8DI^WY$AY
M2:F'%YT[P'78>D/)IBNI"21*5=JY,1+9PV.9)=R=8A3J=@&$-C"HW6I7V(1G
MZ788JSPCDB2C>4AG:;UBN1=%-PB=)PD(IJ$505*<H@(@)1`>!ZC@.`X#@.!`
MO3U:;7S-Y`S3QVRCLNUC!%H9JV%JF$(A@;#R4"11,7#GW')(@B(*J=Q054ZG
M`A.O:`3TX#@.!K/>4&NMB^5K6&U2,+4;#%.]-\A51W5K?7:_+MKN)\P1,LO`
M1;V8JMS6CI%O'MU%E#)M&X&1'M,Y*41*(25\/&IM!5U"L5UR-1\)7:K;%9AR
M1EFN4DF(XYK'5&`3R+;HZOP<^QEI:?JD].QR;,%!?Q\3"E]0(*1RI)"F%N/Y
M@<$_(://S+XH^6P+*$8N?S>5'Y#(DVD*$R1JM](]QN671'L=`00!<OH?N#@=
MB7#.("%*0F*L;D(0I2$(6CUDI2$(`%*4I0C.A2E*'0`#[`X&-<QL]=L&XPNN
M6+MC"B!7*1`O9MZUC:'574S+*-DA%G!5]@JS;_5+#./!(U8M2G`[ETJ1,OJ8
M.!"8NF&7=H#S4OGJ5KFMF';+&6RN-M9L*XXQ$O;9VC6J$/"`VS?EBR5N_$&Q
MG8R#H56M2)&D9K>R*<@M[9Q4":V%=0M>\#XEQYABE8TJCJHXRJD53JXO9*[7
MIN=4B8=`&[0TK++1*:C]Z)`ZG5$H"<WJ(<#)_P"9O$7^:S'/\":U^]G`?F;Q
M%_FLQS_`FM?O9P*!,=8AQ3=/.!MO0;CB_%5KH4)`XNL<)3;'CK'\W&Q%CD-8
ML;Q[^<CVLA&.9%H=[')%1.!4BM#"41`PJB8.!Z_SDTO7/4/1N.V-IFJNO+Z5
MQ3M1I]:'$"3$F/(E"U0[78B@IS54D'S:JK*HQEAC%56KCH0W5)0P=!Z\#Q>4
M-/KKAQ22G[WK)XF:E3KW?7C:&=71'+\X]>VN:^H6&&AF#9.IM8^/.<\.<S=N
MQ011:)(B"13"7[X<G&^B.4;P6)M=<U\\0N6*6FV%FHYC4;A>(!X=PT:1T_$*
MF1JTC%.@.DFJ83K^\8C@0,*)0`"$"$.IOBFWC<UFP93U,R[H=@G#^<82+A9R
ME?HX1^58Y:9Q):\K5=M.QB+R+JK)B\.:5%LLH?Y3E8&B9U%3&3*0`S=CSQ`>
M6&APSB#:;3^/-5DM/*6\"2.C%:F0);FM7I]1;6!NFLNR;L9:;BJBU,_<HIE4
M]]`#_C._[@9=;^-WS%-&"R+3<;0%J?YQG*3)OH?7D62I@.+=-\J=.;**;T6)
MS=>B9Q`?N=PE$3<#MTO'CYE3G`SC=S14@LG"Y(PZ>B<$L=-H*0(D5*)[(D+-
M95$3$.F03%`@=.X0'H`<S^CW\RO\^C2#_H)P?^-?`JXV<PMOGD?.L%H?DC<S
M"LA/F=5[*,ID7'7CC0>8DQJ2K$L,VPF\GY8C+2]K>/F$6]K3Q-;ZQ\<I72`%
M^T`'@2H-A7RI/+AB:N43R,>-:[TR\UQ"27R&&MF-WRLLM)6QE2*DGCF#K=SL
MLKD!*:F7()/Y)<L5'-7QRH$674/T`)/_`-'OYE?Y]&D'_03@_P#&O@?<_CV\
MQQ2-C);V:2G5$AC.2GT-@4R(J@L<$RHG+<#F7(9`"F$P@00,(EZ"``80\3^K
M^8C8GA?)"SS-%8SR?DZ(\A.582YWIEBRK52*LDS$0\&T7?P]3;HR#2M1/?W`
MW9)+*$1*(CU$3&X&PM^9O$7^:S'/\":U^]G`KS\ENB>'<Z:XV.SM9:V8*M.O
MU>R5F:F7'`L7CRN69><A\572)6A9M2=Q];TY:L2L3+.$73)-%)1?O`2G*H1,
MQ0KAA?'V3QS:/V6_8PW`MT9C!5@QRZSK%^U^P7D.\*7_`"E]"=2D#7YIG2(1
M=Z>S65^4K9@E#J*(E.)$R#T$W`NSR`YUTUVUZE,W["U/%M5KV.L=M+/D>==4
M2L)&!^RAVZDFUCHU"/44>S,K+"+=DP;^XLY=*IH)`<YB@(49/=4KWMYCG:;R
M5;+X%J>'XNNZA["Q_C\UG2Q_'Q&4<45RPXBNS62RAF]@K722+?.5R#VC,(MD
MX,A"LU@3,51T;JD'+TI\@&C&O&HV!\297U]3K&1L>8_J%5O\4QCL27]$UR+6
M8Z3EI)E8WV19J7FF$D=S[OR5E.I%3&1."9R>V`2H2\L7C:,RD9-;"\LE&0[%
MO*2;AOB+&TP\1C7,BWBTW3"!@IZ4L=A5%XY*0K:-:.W:H]?;2,(=.!(Z5W/T
M(AE)!)Y@_,YS1CSX#D8_QN;82R9U_D/6W<R6BM<7B,BU]V/4$%VYE41()#@?
ML43,8,!T'-6M&QNZB=IK]&F<<X#U*U]F<H6^Q9KUBO\`KM3R9&N5@/$-W[EU
MFK'&-Q,YI]/BOGINC?(3;^\)TRI&`5A"G_:^[Y$WMS#JYM_8L+!7/%UB3>?Z
M+0J!1:#.2&3=@KY6X:T_1-Q\I1YJPE`V#71&:%-"-:M2NW,A'JO5P5746;HB
M%FFGGBM?WC6;5W*5RVGV-QUDJ6UMQRUD:W`86T:@4<<,K34*_*V/%]7:W[26
M7R'7J9'21"H%BY1ZN[*1LF5V918AC<#S&]?B(J"&L63['8=IM@,D#680CF,J
M]Y@-)Z35';J9GZU'/QEIVAZ:U^88E<LT2)BL"A@+VAU`0Z\#.V)/!UB'"[^1
MMV%MK]Q<8V2YPZ+:X22=EUVRV^ET5SF=C'H3N;]<,FOHF$;^Z"*;*)/'QID4
MD_W/]TH@&;/Z,2<27^:[\@VXKDJ:ORG(/:7H&**Y2']U8':I=(DE?:5`!]PP
M'*;H(CW`/KP*I('5"0W@W+ONME(VOS[E?2K7U"`;;79!N=.U$DJ+L19Y=VVF
M5M6<87?!^O6+;+`MZFXCVZMS>A,.!$>L:+3J(KB&T@A4*HVK#*E(5J"3I\;%
MLH1A5PB6)J^TAXY!)JPC$(@R!F";%FW1(1-("=A"E```.G`JH\JM"QQ4]?<?
MRD#C[%T//+[&X8A*_)KTG&X.T)^PSCF%A&D0>T1CB.))3,H]28@!&<@Y52<G
M32;*F.``%E++#>*/AM/DXLQU\@&K<%^M)K/7W@1("@>D0D'H?K]A"A_4#[.!
MR?S-XB_S68Y_@36OWLX%<GD)S33-=(3'F$]>\'87R)NUM)(62BZQ8WL5=@HR
M`1FXFN/I:<RG?G3.`?.&6-\9MB)O9$>U(SPW8U24(HKWD#,6DF@>.=5<$1>/
M[BUKF9,IV*>G\DYGRM:*=6S25\RO>I!2<N,PV:%CA;0\"C)N3-XQ@@4B#-BD
MFF0H=!X&#O,!KSKM.^.':>5MV)L>&0QUCM[E>NO20TC7?H=VQTH2Q5*Q?4,?
M/JQ9Q&%EVY%O:1=D(KT[5"F((E$,'^(^GXP9Y6\G>,(FA8V)7JWL!KXFDW1I
MS%Q/24).Z9Z]V)JUM=E=I.36^)0G_EO8Y-R995HY<NE!,/O$[0O78,&,6R:Q
ML8S:QT<Q02:LF#%NBT9LVJ!`31;-6K<B:#=!%,H%*0A0*4`Z`'`Y?`<!P'`<
M"NW1IFW8Y9\AR+50%$U=RI)X<P+P3CHX?8?Q4[<D$]=679$%-=4P"180?)B'
M:[*5P"A0"Q+@.`X&OQY4K$YBMTM4V%=<2[*ZN\-9=5AWT))34,])&&EXAI.Q
M"LE%';)IQMCCUSH.3*+IB@F3O`Q.O=P,1Z4;X;/8@UAQE0Z1H]3KICVORV5X
M:KWM_M:[K)I.*89>R2C&.I.NM==[BO"*2I8Y?XJ8/G_>FD4ZBI14*`AE5MYF
MMKU3OU7'BDR<A',HY$Y7R6=4')EYU=MWHQ`,_P`R:2Y&BCE)9,'@=Q`*F!Q(
M'>!>!]$O,KMJI&-G:GB9RVU?L9AQ'7*.=YP8)DKS,9%-G&2T4]2PZL6U-Y5L
M8RQ2H$1,EV]I^G7NX&"_(;Y)I_(^M2[B2U\N6$X+&6<-9<P6"Y9:C+1,T%]`
M8QV`Q]<)&I6"+@8*!FGS>Y(Q'TX&[94ZKD7'M`4!.!BA'9?]9(R0[)7@KX:P
M2#>PK0)@GT,5[=R<#!1DE+-6DJ]EE&,0D=9Q!19UG)V[<Y_<,F"95.INH!L_
MZE9=LF?-:L*YGN$=6XFS9)H,);)F/IY[$>KMWDFB94WT(;;&0UF+&JD`#IE?
M-47)"F[3EZAU$)$<".NT>S./M3\0V7+%[+(32T8T%&HX\K!6\AD+*%L=+-V4
M+1\>UPRQ'MBL<Q(O$4P20(I["1CKJ]J*9S`%+^BV.[=.>7O.NQ>P$8ZQ_LAF
M71W#64+%@B(7:R53PM7'EQF\9U*JO[.43.[1?252G-SS*I029)OE5`03*0"]
M`[O]9\=I1_B/R8_749HHLL[ZH.UEI%`74<DDVV&Q\LHK(-2H.3.61"$$54P2
M4$Y`$.TW7H(2,GMYM2]NLU::8ZQ+9[)?+$TV%6N[^OSF"\X5AI%Q,)@+-YPE
MY:5O.-(&M1IHJ9>,RE]]V0WRCIE3`QQ`.!ZN_-,&Z);H8\RDWL->PW0]WWBV
M)LC5Q1J\:U>W;`02,:&'YJ#CXMFZ;Q]\MT<^=1;I02MVSAJP2,H;W0[A#^ZU
M[)X$U`\<>.<R[%Y&J6(<505FO,%)VZ08S+2OLI>SY\O4)"L2,&K.4E@7D9=X
M1(1!(Q?<,901*GU,`6!9)S9C+$>)9S.5^M+.#QA7J^TL\A9U4W"K<(F1^(6+
M50022,Y65E%WZ"2!`(!C*+%`>G7T#)C-V@_9M'S8PG;/6R#MN<0$HF0<I%62
M,)1]0$R9P'IP.3P*S*YN=`;UXAW?QUJ;#Y1B,N8>8Y6PS$2%V![A5O,9(;N\
MEXQB[-CK(D:YG9%I`,\@4&220G4$$UVRS+W2)]P%X&M(&#]IM;M\_'C0,TTZ
MYS67\CU[=UQ;IR'RICG.1[35,J6C9/(*E.RQ,V2B0-ERU>4(R;KZ-;^I?$JZ
M+I9VFX16%=<W`F5@"$CL)YD\1NO>6\9U*,V!04S+,5)++6-\*Q.9L08DB+<6
MUG9*J5NN2M5QK#/DCJ-6!:^_C_FRPI-V[<I_QP!L&)[L8//G78?7=1Q;&V0-
M8,15'-V455JN[&MHT2Z(6)Q$KP,V@JLG,2R:=8<BLT`B:I?N]H'`3"4(70'F
M8QM:W%30JVD_D?L:5[B*]8*9)0^LL:[A+)`VR-0F:W,1\Z7)!8<C&8BG2:Z9
MEETC)E.`*@F<!*`=/X;<+9@QA'[X7K*V(KKA5CL)O-EG,V,ZAD9"'C[J?'MB
M:PQ(F4G8:%LEM;0R[Q9%3H@9^NH':/7H'0.!=#P*@?,QN5.ZFZ[5:M0&/HJ]
MNMH[)=->W:LY)NXZ+K,=9<0Y`D7$PI\)%59RY%6-33(0?N@F*@B4P@``&0Z+
MJ=:+G9<0YWVES,SMF-<%4FF6G#&`JS"%J.&\?6JO5%J`Y?O#I\\?6#(=WA&?
MN&CSR+@(N&$!7:M4EA,?@0\J%:>>:O,N.<^7:)L%2\<^K&67UNU\J3L!;J[I
M9>J*EFJ[/-DTZ0<MG;'">/9A,5:^P,CW3,BD*ZQA;$!,X7^&(0Y#)G*4Z9RB
M0Y#@!RG(8.TQ3E-U`Q3`/00'[>!T@U>M"/4:[!"(_A&)8"/_`%_C]>!^RUNO
M$,4Q(&%(8G:)3%BV)3%[3`<O:((`(=I@ZA^P/`[D1`H"8P@```B(B/0``/41
M$1]```X&OGEVZ6_RZ;29#T[I-<9K^.O5JW0Z>V&2$)DXQ^UV5XD&\NPUAJ<P
MP(D5"BUERHFYMSANHY3=&3*Q,H4#J)B%^<+7("N0,/5H"%BX:MUZ,CX6"@8U
MBW9Q,1$135)E&1L<P13(V:,F#-`B229"@5,A0````X'=<"*.\8E#5#-!C+%;
ME+6V1A<F,<I6P%L,,;Y(G3*90GQNG?W%`3%[>I?7IP)+U\X*0$(H#KYP*1$:
M<'O>LK\P#,D3`Z]QP4JZGR`'O[C@!QZ]1#KUX%0?D"SUF/.&5Z_XP=-9Q]6,
MKY9JRMFVAV/KSEH[-J%KPX<F8/7T>0AED"9LRF=-2+K[-T9)9DU64DBIG`J*
MA`LEUUUVQ#JKB&I80P=3(BC8_J#0R;.+B6I$#2,H[-\B;LDRN'5:4L=CDC*.
MW[Q8QUG+E4QSF$1X&;N!#3?-@QD=?V:,@S:ODDM@-1W:2;M!-P1)TTVKPTNU
M=)`J4P)N&RQ`,0X=#%,'H/`F7P(K[H[9T'2;73(6PE_9R4^WJ$<1*L4.NE%S
M<<FWB572C:ECNE1B23AU*V>US3E)LV1225,`G$XE[2F$`AGXX--;9"S]D\A.
MVZ<C8-Z]H*Z1W.LK$W;E1U=P_..64Y5]6,<M$EG247"TMHT9A-.BG,O+3:;A
M<YNPQ2`%NG`KP\M4FG#>-#=R5517<)L=>,@N#H-7:C!PJ4D4?J1)XC^-;G'K
M^V+ZAP(J>*$$4]F?*VF%ABG"Y]A];3!5$9MFM-0R".CVO)`FGU;(F5[%1TZ=
M44FSHYC)/#LE2$`HH'ZA=UP'`<!P'`<"MG0.N3=7RAY%F$_&+Q3Q]N[9[&T;
MN/:$[B$L^+\93L#)$]E14OL2L0_1<)]1`W8H'<`#U``FKF',V.,"4E?(N5IY
M6LTUI+P4([FDH2>GRM9"RRK6$AB+L:W&2\F5!U*O4D15!`4DA.!E#%(`F`,H
M\!P-<'S"ED)+<36F$9.)<0+K#LW/FBZTTEW,O*IPY(11TUEG<<W51@:H=N?]
MTO%!`H&`"'Z%'KP+*?$S_P"KUUP]>H?1KP`"'V=`RG>@``#\``'`L5X#@1*W
M=PT[S=KS9(.&AU[+<*'8J'G+'56(LU39VS)F!KI!Y;Q[59I)]U8O:_8K=4&C
M-\V6_%+MECD-Z#P.JUNV+ULSU0J_*5EC4<?VDL/%FN.$[@QK=:R/BFR.F1',
MM1;C5#E05CI^NO/<;NBI%.B*B8F(82B`B$QDO:]I/V/;]GL+[7M=OM>WT#L]
MOL^YV=OV=/3IP/IP*8/*6QJ3_-NBR=(DGM?WJ+:,NETDL5@FHZ*PQ'6=Y&42
M-R:3+#&<`(NVLS5!ZFX:P[,Y;"\1;._I7>N0R9PZ;5XN86GEFR3$[`R>-9[,
MD7XV,,$NU@Q3%S$/4I=RYV)RFX9*-64\/U,GQFH^V7W/7L``X&,?UG`C=7Q-
MY!2=F$C17/\`J2FZ.!7!Q*V/L7CPJQ@(S35>'$J8B/1(AE1_VH"/0.!L#<"E
M7S<._8QAI`BQK]@M=@'R4:H2<37*A7W5GMTFUK\I9YJP!`0K`AGSY=G"M%7"
MJ:7WA02,/J`#P*;=J,E36=/%'MDROC6J1V)<3X@OLU@W#B,M^4.:[O>+GL%8
MZ[7\TY.K,8S6)2J_5)LZC:$B@.=V=ZH*KLR`IIE,$Q<[[-*;P8`V"P38(.&Q
M)AG7#".3I6UXVL\FFMF_87)VMV,5[(_@*QCV+5!Y6*!B:_O*K*K+G='?N)MB
M$>HA[9'``&RA3G!3TRK.E3"F0U8A'"AU^B0D*:*:J',L!N@)B4!ZFZ_9P/2)
M*I+ID6143624*!TU4CE434(8.I3D.01*<I@^P0'H/`URO'WM7KAJ\.?IW8/+
MU(P[#O+)?D&TO>)$D''R;Z6\D'DQ;,&C)VJG[<A(KJ,S%!$@F6Z`'IT^P+&9
M+R6>+X(^$S%+;2ZV&8N#MX>KY&>3<&LH].\*[5)&5NPG:J.W9BB@X!5!JH84
M3IJ`H4H@;@>*M/D=\0]@?X\RQ;-GM6I=ZG[TCC7(<A.PSP5A[UHQ8*_80;G*
M^,@JH<!1*HH")RB?M*8H&`(H:>W?&>6/.!Y%;)2[C5[Q7K#IAJ"6,7AK#]3C
M9V&4F,C)RCEK%HE4BIADU4<(HKN3&$S8ZY40`06/T"4^(,K/=`E3ZQ9WI4_5
M]:*7)/X_6[9Q%9.5Q5#XB41D)FHXORS,**)NL=6+%D.S4@T7DC^Y9=HR:KD4
M]Y8Y0"P?$N<\.9YA)"RX6R;2LHU^*DSPLE-4>P1]BC64LFBDX4CG+R-6712=
MD06(<2"/<!3`/`RKP->/]8XH+3(FN>GU??3TO6V;_?3$L:]EH=BDY=-(]WC[
M++F153767;)-W`LXXZ9`,<"G!0PCZ%X%:-DT&QIY-=PX'"NONPV6<EZT87A7
MB.[&RT!E2R-CL[T,"T;4773'*4-:VE?<SCA!$R]A=HMG*3)H'L'*)C]1"WIE
MX&-;HVOU^KQV3\Q1L-4V;*-K#2(N5N@T(&+8M)5FE%QC.$MT=&MH]0DRX.HF
M"'WE3`8!`2EZ!])#7C(7BFIN6\\X+O-$RE7;?9,(UZ4QKF!G=XJR.T7$_"XZ
M;M(+);2SWI_/VZ:E[1[S)NM&,&95E3`LI[8=Y`O#9++N&;1PY;&9.5VJ"SAF
M<Y%#M%U4B'5;'43$4U#(*&$HF+Z"(=0].!R>!2IO)GG)>TF?(WQ;:?W>>IMI
ME(YW-;VY]J44JX?:RX(FZP1Q7:W79MXD2#0R]FQS*?'BRD6.ZCF#-VX,F412
M,`6A:\:^XJU:PU0L#X6JK"GX[QW!-(2$BF*?11P9%,!?3,JZ.)W,G.S3P3N7
MCI8YUG#A0QC&'KP,T\!P(E;V./B:CYS=^V"OQ*BFZ]HQA(57XTW$K^T8P`(E
M*I[?:(@`B`#P(U[P;K6W"V-L086UKBF%RWDVB0K%7UZQTK$R%D@JJ614@D;;
MF'*GTY,WY-XDQ7`R*\B_?O112=&;`V2[UE`*`9ST6TFQ]I'BF5JU?<O;9E+*
M-G7RML9E^?>.96UYBS;88]BE;[A)R;\!?(0GRVQDH:+`0;1$<!&Z)0Z',<)K
M<!P(>[RX\S?D[!;:N8`9TV3O$=E_`M[>P]V?KQ;*;J.,LRTG(MHA8F23(9LP
ML4I&U<R+15R)6Y#'$3#U[0$,01/D:KE&E)*`W.PKDG2!^S:RDM'VO++NM6G"
M<Y"Q;!"254C\\X]D9W&B5@^*H<QH=P\1D2`D;\6/V<"#.FU0R-Y.=I'7DBS+
M*7%GI=C2R,G/C=P'/HMXN)EYJOLY.N2^WUABBH%D'+RTINW:=91=G,1-DL5V
M4A%"I&$-@?@.!"/R2UYI;-"]LJV^)"J,YG"5T8ND[&L[;P:B"L>;W$Y-=@4[
MQ)H<H=#"F`F]>!!3Q3K0P[A>7QLD:/3GB;$:U.UV/TU!E-L*Z]TRPH:`;NUD
MT3?(8-_9602*5PL0JJ*ANT@G'N"\?@.`X#@.`X$/M=S%'/N]X`8HB7/.-0,`
M&`1*(ZL8',`&`!ZE$2B`]!_`/7@4C;!:936<?+V^M<'M7@9Q98>3QA9F.*+%
MFO-<'FC%4#6HAM,/5ZGA:%`N)[DXD_;.JBH],<H-U.Y<OIU`-GK@.!K^^4N#
M0LNY>O\``_4+$HYE-5-EV@04%*5*)34:&&'4=RDJ_M,W76[6+2*D":W[H7%8
MH]B;<ZG0>!.SQ,#W>/77`?V8:\CZ`(?_`.4[U^`>@AP+%N`X#@0-WXUNU]RA
MK[GC(.1L046S7NF8+RK+5G(2M99IY'KB\-19V29_D_=XI!O<H]-)TT3/\=L[
M*FJ8A0,0W0`X'<>-Q"0;:$ZCH2LG89F1)@B@?+E+8E*(V1\L:%0,*\TE-_\`
M&Q'Y@,'>#C\;_P#"]>!-K@1WVCU@Q;MQB"QX?RFP=D82J:+RM7*O+)1=_P`9
MW",=-I.M9"QO:`05?52Z5>:8H.VCQ`0'O2]M0%$3J)F"G70J;S-!>5[:'$VQ
M]H/?L@X;U8P?@J#S+'PS)O!YS8,'\KEV+M<TBA$QSNBY20H]S8C884BTE$KN
M^YZS=E!46R8?+]:'?GB?$)E:527%JK&9NU7D$G17'PS-E&>P5`<$<%=@8HM3
M(F3[@4ZAV=.O7TX%D#'RC^.=1A'K2V]NFT3)N&#)T^C#[-X=<"P<N6J2ZS4'
M!;:F1R5`ZG:"A0`J@`!@]!#@5V^1/R#Z#S\SHW9ZON)K-=WN)-Y<<WVP0%*S
M'C2V6A&N1F.<L(22S9C%6A=ZU]UTNW:$[B`1P\<H("8IE"=0I5F]I;'EC5>4
M0E,#;N1<W/XBEL<8\B*WKW$5B2:U"R;2P^>EI::E93-<U7)*9FJ[`>V5BHP;
MO6Z;1P04UCK$1,&2Y+8NXGJN3<5JZO;86[$32D^0FX8%=U3"N.%LC,\B;@Y2
MR@+^/OI7>:WYY:KU=SD%^H*3:+0#VW#0CQ1NLR<(G#-]Q\L&\DBZE8TVO6PB
M6%K'$2-6A,+L],*^M;U<.V:NKP<#<+9FTVWK)G5;*Z;!\M$HUY)$Z:Q$R(G4
M$!X'/QOY,=N\0P^*:15\5[`U&CXQK]*P]'8+OVJU%OF5,H7N.C%IFU.9+)S?
M<"NL*;\V+,V;PK-=FH_*8_>N@KU`@A&*^+[-0^)+6ZP'@*\LMB6DK=]CL/6"
MSY+UBC*#C#(^1-G_`"6UY&NYB8Y5SG5DF-SH>/,Z-9AJW@DIA&%M35L9XF51
M(R:H9:N=\V>943&5MU8T?R?7]WJ,OD_,-2:7:PZ%_HJ,K5GJUTI'-5LJL=$[
M3N7D(VG&M6=,8B5^.X7<DD7*R1$Q='4*'G,PK;+8IJ.%LC:W:0Y0I&P&O![K
MB>?8;(V[Q^TS71C"98R=&Y!R>2D5TVSLK*14LSF'!F<`Z3!5L_;JBBNH<#&Z
M!^?'?6+?0OUA^/7_`#;Y&P_3<@^.RQNJW`9.L6OLQ<+76I++)\@KV1TPUOO%
M[Q_%5:2L4]WQ0)+-A60:@<$Q`!,8)U^93:W0G+^P.L/CXVN/CZZX`;Y)E\K[
M1/['.WJ*B*9)T>@3AZ+26%BQS(1[T;S[5K/)S$;\E-Q'Q#AFX4)[;DH@'K/U
M<V`P%5Z%Y":]JJYCGFM<3OSDII@]U#N9%[$+8["N5I2$^EOI8QY)ZQ1]PZ::
MJYC*'`G4PB(]>!L=\#7(_6=(&YV?1S7V!Q[9):G7&1WQP4G"VJ!8Q\I,P!T:
M1F-R^E(R*EI")BY5XVC$%Q(U<.FZ+D?Q9SE`PCP+C-+=7L(ZBZ[XYQ%@>C1%
M*J;&N1,G('8Q;=A,6FQ2C)%_-6JV.2+/'4G8IE^Y45747<N3)]WM$/[9"``2
MKX%.ERL,1O%Y,6VOR:]LBL<>+Y_2,S9<A)*&:H57+>>,UX^5DL&MX:82DGBL
ME&8CI[Z1D))JY:-@,_EFADS*>R(@%Q?`JC\CNY=\QU*XOTPU*=,Y[=_::05@
MJBWCTF$Y(8`Q01%8M^V?M4#)&;P2\-CJ/`RD<PDWL>6:D>Q!`RHD4)P)+:/Z
M78^T<PNABZH3]JR':IR:D[MEG,V17Q)G)N8<CSZPN9VXW2=$GR7B@G,#=@V.
M=0D='HHMDS&*GW&"8W`<!P*M/,=M%BS5[1'+LMD&QL(^T9(C4L;89J*B;AW,
M9(RO/.VH52H1$<R35<J)O'Z9/F.C`FU9-A,HLJF7H(ATGC&TP?X';W38/,UG
M4RQM[L'4L>#G+)CETV/$4MI"PY)"M:_8NA?J,Z^JU`QTWE>JZ*COH_?'*[[1
M`Y02"V;@.`X&!-E-G,(ZAXFGLX;"74M"QG6C)$E[`$'8[*NB=5)=<"MX*I1$
M[8)`R;5JJLH#=JK[:*1U#="$,8`U@]T]Z<&>8_(DQIAC>^S2OCQJ6.K;>-AL
MT5>C96B;%?LVUJ+DG6-<#LEYVB1K>JPS"<02E9!RN1=*5.@DT2,!N\HA>;I#
MN%KZ\TLUTL5PS%B&AK,,4U*`E8V>MU:I"D.XK<<-?(C)04T\B7,`\<H0OOG;
M*((]@F'M*!`#@2;<;BZE-._Y6SN`&WMQ[>6/[^7Z"EV13M1))K)&]R?+VL'"
MJY"D5'\6<QR@`B(AP.P<;7ZO-%%TG6QN#&ZK4CA1RFOE:C)';IM%4$71UBGG
M"BD5LLZ3*H)NG890H#T$P<"+VXVUVH<UJ]GR!>;)X&=A(XFO9SL&^2L>3CMP
MTC6GQ9)5*$6L:))-)@\6337(8Q2%.<"G$!$.!!_Q!94HV9=JO(-D.I7O$5Y2
MF6FK%=;R6/,A8]N,O(_D7B$%)2RR,?4'8.HROR_Y6,FC`_L&;]T8JV,NHLV.
M!0V`.`X#@.`X#@0AUD64/L?Y$BJ&CO;0V)Q41/XK59NZ*F.H&NRIOJCA4`3>
MN>\XB11,1*5#L(/WBCP*\-FK!IYE3?W7R=S7MLAE.V8,O:-CUTUDU>Q'+W6_
M4FYF;)Q%@LV<L@XL2R?D!6O,G*WN':E_)&(1;=?G(O2E%0`OMX#@:_'DNB(^
M=\@FND5(RT+',%M/=E'4H$W(QL9%$91TG"K)/;"Y6KDT^^@M'"G>8O7VC*E`
M"@1004X$_/%.@@UT#U]:MGB<BV;,LA-V\@DF=))^W0RU?4D7J22@BHFF[2*"
MA2F^\`&Z#Z\"PO@.`X&`=K_Y+>RG^@',?^KNQ\#"7C0=`[T<UV4Z*@*=!C4#
MBJ#(#G.@!DCJ=6**('*<Q1$#*]S@0_W4QC]1X$Z^`X%#,)D_$^)_*UM19\OY
M`HV,H,F1*$SA[/DFTU"D5P\H]TFPXFXC(N?LTK%G<SCAJD4RC5,3%^.!3].O
M7@>W\C>S^L67,<:XT?&6P6"<JVV1W\T1<,J/0,LXYN]IF$&&S&/W;L(VLPM@
MDG\B9N@B*A@*B<I"E$Q^A2B(!536;+GV$Q5<\D973SI"T.CZY0F2[W'2.%ME
MZM?:\[QS$YTM]PC&M\E\PK5YO?75"@&#&PF,T-%)R*C-XT`![2)!XJD2^ZTL
M>H6.)TI\B=KQ[+3%.M+68D%XF7_*2K,_HEB96,&$MLYWD3MOPTA4C0,F@B4Y
MCD[2J&)P,9R&4M@,>XDN&8F^D^X#6!"LW)_4I:QTRKI4ZSY^LF3;!&T"'>6Z
MF9__`#A8NQBQ>SYHN6^DE446*(^R1(X`H(>4PO!;C&D,ILY*N84I->UF@]I'
M^*;A;<A[H94H6<;)KO;KW:,SUMC*)[*0@5^\2,_EAT#E!\VE!?C%..]3VXXB
M(ATC_$.T..,K7G7>SJ8(A*U+*4[`47L)7:9M6?`61+?#X!ALS5BJS,;`;21\
M?5,UPC2M'8G=KQ#AP[>,%E7#T?<,CP,KW2,WGOMRPS7$(/"*R.:9O5QM8LZ8
M5H^R2%1HDYL.?WH]]>)BK;,U*53C'$M6V+1PDBP=I&3=K+>\V*!BG#+6"]6,
MQ;O3.6<?UAAJ'4;O3H)";S!:K_0\\WR$O%L7VNWVP,_6H\`RS775JG5E6V`6
M,JFT>.'RY'K@3>X(E$1"8K/Q&;]L5WSMML!HZ5])UD*D_E%,"[(+3:T*9\XE
MG#9&;4V;-)LBNI9VHN<J*A2_>[``$P`O`^5)\0F^M!DHJ3KV?M&D5X=HBQCC
M2.O>PL^,8FF+KJZATYS99\A&/P!ZH8BB90]LX@8/4.!2YLO1LG:X[X9'=7K:
MFN4_:3#.-M2\%8_FL$6%AA2_YLUVD<+[-6>2PO6;%G"Z6IO6\@623Q!4XU>[
M2:[EHR>J"(^TI(F]P.8GLE0&^<M$ZW)S<=$1^$LM9Z31H^+[YK'"9PHD5D_2
MS5"W3\?EBWO/R%Q?D2QP>2+5,QJEF:C[<XJQ`6SI<4E``-FWPL7#,MRUJR*^
MS//SEAD&>?,D1]+=V?(^"LF6'\WJ+Y(:JI(36!&25=;)N6!@.B@]<.GX$]3"
M0G:`A<+P*"_UAQT9GJ_JLJ1B_DE5=^L+,D&$8A\EZY<26,\Y1S=-)'W$NI07
M=%%0W<'8F!C?@X%YM*240IM205)[:J-8@4E$^O7VU$XIH0Y.O4>O:8.GV\#T
M_`IHTBE%5/*SYFX86"!$&MPTQDR2@':BZ<*OM5*0V48*$*/S00:%8%4()P]H
M3+&`OJ!N!,;=G<ZA:?XS5DW:S.V9JNH?DY@;!T6Z,ZON7,@2:I(^%B("O,$'
M\PM$-7[@BLD_!O\`$8M2&,LH3J7J&-]`M))'7%C>\YYTL;7*>[FS!Z_:-F\M
M((+M8167AFKUO7,>XT@'#ATWI>.:#$R`1[9JT$GSU$1=N.]93[H6,\!P'`PO
ML'L#B?5_$EOS5FFY0E(HE.CEW;N3FWR3/ZC(>RJ>-KT.B8#N96P3CE,$&;-L
MFLX<*F`"$-Z\"B$^$\I;#:]9^\E&X,?,L,CWK%\U&ZQ:^V>-*VAM8,)25H9.
M8%X:OO1="VS3>8@B#B;DNH*II&(W)V@!@X&PKCPI2T*E"4I2B>I5LYQ```3G
M&%8@)S"'[8P@`>H^OIP/8\!P'`H9\M]SE-MY_'WBNUHEK*TV+R5;:ED'*F::
M:RE'4=IIABOEDI.3R18;+`V.$4@<B7`2MX6"AUP<?4&<NX662]@A14#!VQWA
MD\9^G.L5]M]7K&>8*Q$K:M;I%4H.R><JXMDS-=M`L3446=-K5_B&$O9;)<7:
M2[H6Z(J)M?D*]`23,`!8SK?XV<*0.#\,--@<9U*]9MB,;T)GD^<=?4))A+W*
M'382DF+A.1>O`EQ1?(_!6<N!45?LTQ(L)B*&*(91/XR="')W#B5U8Q#/OW4%
M*UA66L5483DO^3\N]CI)S$DDY(CAXFR0?Q2"S8A3A\50G<EV"(B(=.?Q/^,U
M6(3@%=#M55H5*2<S)(U;"M&6:A+/&K5D[D134AS`=ZZ:LD4U%!ZF.5,O41Z!
MP(?[\Z4>*?5G3_8#,5EU%TXH)8''MH6AI*8Q%CJ.&8MKN$<,H6O18+PICR4]
M8U@(S;MDR*G6.<`[#``AP(B?JX;&94?[UV+)&M^-]:,HW#(&"\F16/J%!'KJ
M]8P3DG`U/+A6H3$8V9Q\,U&'K%+!P=!N@D9*5>R`J$3%0$R!M`<!P'`<"%VX
M^1(_#U3+D^Q[56;7VM0D>LR"KU.CXOOEDR/87KD@0L-4J[<J5;K58KA)K@#-
MC&Q)>KA10.XGH)RA@KQQ!OI?H:W9SW%OE^JU?NMAF4L,:R7JA80@K?2\8)IQ
M8U6V95G,<TF$F&N3ITY7:KN&(\.RC45$TC@HL!C%#,V#:_6[+FCR)UR9AX^6
MA[+FF@PMKBG[(JS&<CI743`\:^82:*R?LOVKV(6]A0H]Q3)#V#^$.!'JC^(+
M!&#L\5'/&KN2LS:Z.ZH:>:(8MJMCC+CA,M>MKY%_;ZY7L9Y)B+;`T1E8E40]
MU2$*Q71-U.B8AQ$>!;+P'`H`\C1K0X\B."&T1(4^HP;/2'9%6RW_`"*T?3-$
MA8::LM?A9)M.148V.JU440.44'+E0C4ZAP2'[P@/`]WXT=\-3Z7ICBBDVO+U
M8K-BIZV6(J8C))N\@TDWL/FV\Q3I"+;/$^]5N+A01;$()Q,W3.8!$$S"`3@)
MY(]+#N?C?GUJA1^*FZ]XYW!6W10YT_8]\4?;^43LZF3_`&Q2B`_AX'$?>3'2
M*.<.VKC/51]YNR=O$`365/\`5C,VQ'1X^#_%@:7E5"'Z)MT`.J<X"`!Z<#S;
M;RK:/._<!OF%LJJ@)"NFY(>3.Y9*J)E5!N]0(@95HX`A@$2*`4W]3@8BV-\E
M.HEMU[SM4ZODMI*6>TX;R=6ZU%O&$G%M92PSM*FXJ$C%Y)9N5)BG(2;M)$53
M"`)]_7\'`QEH]Y'-5,;Z?:_56_623H%V@<85AI;:"]0<V>1JEA(T33E(+ZO$
M-3,I1-B[$P)J)B8#)=!$1]1X$[L3[^:T9MR)%XRQS;)>;GII1RSBWYJO,M*T
M\FFE=F;<K6TK"X;DC_RC&K5U_(E:"8%3M&:J@`($'@3/X&O3/ZSX\V7\GFTM
M:R<O-/:LRR53OD5AN%?=0DHJ\T<PRD5T]9S\!.$(\:%Z^VLC[2@=0#NZ!ZA*
MRY>%#0W(482(N5$G99BA8V=K8BQD8*IR<5.QZT<YCWT/8*36:U8HE1@XBD#I
M"W=IB0Q.H#ZCU"`7F/\`'-I?KKXP=S,O8\I-PH=PJ."96+AK'&Y@R^^6^1.3
M,7#]D@QE[M*1TF$S]4^$Z!=$Y%&JIDQ`"\#8/P,DZ0P?AY%]&MH=XEC"B)NH
MIF1LFTCERUB,!5FV39G.U(B@<!*4$S"4`#T'@4A[>2-UH?@ER5?,;1J3BU8E
MCK-E2.9V,J`-TTJ)L%.6=^YD6Z"O8X;-FC1184DS=ZB9>@?>'@1TN6&KQJ_A
M;.8Y;JT<TQGG#&VRV>\"Y5I%MF+!C[&^S^R6(<F3N2Z??ZU96C*PUR$O$W,G
M=0Q&Q%8E5ZZ^.94KD2%,'L)G&64TU,)[*YTJ=ARAJQFZS8USPYCL')2)WV$<
MW'PDMBVB6K*&-RLP(\Q9:86S.0L[R,<K$;S*H.7(D;B0W`\1J;'9^A-;]7=N
MIJNHV/7*R*815R[6<:VQ.'E<1U#7#*5MB*I</R9FT2DM,/$)$2)+HPZZ\A(L
M"J![90(4PA,?P]0SE#)NTT^9=)1A*IV2.:IIE5-VK1'DE\IRSI8''M_&537)
M*I=H$.80[>H@`"7J%E]YW)Q-C[9[&^I<[&9(<Y0RG6TK16I"!Q]89ZALXU5S
M8VH?E3=(UNO#U14RM8<`3YIDBJ"8@%$1,`<#WUYV8P!C/(U#Q#?<N4>JY/R?
M+M('']$EIMNA9K5+OP,+%A%18"=PJL[[!]ON`I3]/01X&M#F_P`=^K_D9\UG
MD2QALCBN-OBM>T=UID,:V=V]DX]]0;1)2UX9%?1;N/,":2CPX)BKWE4,9)$0
M*7U$0#)FF7A-T`S[A'%$SDV'RA^>##E>BL,[`8J=Y`CI"%K>3L?UQK4;50+"
MR?4Q)[,5F)<-S*PRX&32=,%$'*!C$4*/`O%TST3UHT$Q[/XOU>H1,?4VSVIU
M=)N,(]6??,L3QL@S7?"=8"^WU;-4R`0H`4I2@```<"7_``->7]9.M$U2]-]<
M;37ZE-7N6A=[\*ND*E6SD)/S2!\=9L;R*,,90Z:823>,6671[C`43I``B`<#
M(K'RJ[514:,;5_"_Y![?`5@(ZO,+("F'88+.@UA6RZ,[#1\W=F<@]AW:`!VN
M0)V&5-V>A^I0#T\'Y1-SYY=%!#PG[S1HK1AY4%9^Z:]PR":1._\`<:RSO((%
M2E3=GHV'\8/4/V>!#;`6V5_U8V?\FF\VYNHVPVLF(<]%U%5QW6Y&F-LDW:?O
M5;J#?"#RH,)2@O9.#G+!/2K2+5C(MDNLH*;LXCT5*L4H2*\<=#MNU6UFQ&[V
M[.$+QCO:;%5J2Q7@'&61V[%2"U]UYL,8-DJ+O':;=58Q+KDF-=F<6I\<04,[
M(#<A2)D$O`E%Y"O)PST'L-5@3ZZ9(SDE)X8S-L!=I^G6[&],KN+<680?T.,M
M5BMTMD2PP+<0>2&06*#))L*JJ[@P)@'<8O`GS@[+=9S[AC%&<:7[WY(9@QU3
M,F5CY!T%%P@+O7H^QQ(+*-E%6RBH,9$G<9,QB"/J41#IP(KH[L7"<M638"B:
ME9ROD3C+)=KQ>\M\&O3$X&=FJ@Z(RE7,,9[.(NE&A')A(/N$(<ARB4P`(<#P
M]O\`(%E"@)7.8N.@VT$13*5!,+"_NI38^>0JS`\?.2<\K^*LX+,D:NUABB[5
M7`B?<Y3`@B/7H%-SW9?,/DRR;4=ELA^/K+V3_'[B875VTVQJ6FR-@F,SY\C$
M*TO3]BKL:(?G@'F+84RTB6N@45.AP46,10Q@3,$F]KM_]CK/BC->-[]IC><0
M56X4:<CL>6#(24I6E9ZS,74"[CJR9^_;%KYY230^3[22*QC*&(0"]?O=`R['
M;][XP\-6(B`\<V2I*/9T^).E(J1=L<MW*;9@/L>P[C8]=HHJNP12$$P-W&6,
M)0Z@)1$/=U;R$;L)ROP+GXR<\2Z;J5KT4U/0DTH])@E++]9&=EI._KP,4:(@
MV!3*+%;J'<"H`)E()C`'`E6.V.8^[I^@]L'TZ].[YE#Z=.O3NZ?E#UZ<"O;*
M?FCG\=GR1A"RZMY"Q[NW:\B1V*].-;IAY$6NSYL<72O/5Z?EJ=&LNG+&I8CA
M9N/<!-R;A8K=H1$$A/[IPX$?<AVC+7BLQ0RK4Y>DKOO1N9-WC9[:G<A&I4*5
MQ_1W]7M6&Z,M5!H-JGJ]-.,>*CD*%H]%9-#'4:J@DLL`%!;@7"4K1['TEF*I
M;0YIMUWSYFFKL7:N/9.]O_A47%Q9LYW:R^.\7Q2PUBNS!4')D/G*"\>%3Z@1
M4O`G9P'`ZN<FX>M0LO8[#)LH6`K\6_FYN8DG"3..B8B*:*OI*2?NUC$1:LF+
M-`ZJJAQ`I"%$1'H'`U7MBH^Q>8\V6=A;Y17:GBVU0J%EO6J+&;!>$>[7;(U(
M'T<IF*0C&SGY%JUVC8M59.#16^.23>`*Y#=H#P)F>,Q^T4\C_DV]Q^@D_G<0
M>.B5;P1AD@D2-(W#-Z:/9F12>**,2.G+R0(U.#013`S02G_&%-P+Z>`X#@.!
M2%YA2>,UF?!EGW]9Y$?6JK3:[[`37'(7PE@5M[QVWC430[NHE(Q83"+QRG[;
MIVNW!H4PJ`H0`$>!A'QC:E*Q>SDEL1BW"#W">`Z/"VK%35OEO:')F;,W6VR/
M&;.0<R:5:9V.SXDK]5:$D$O;%=VK*G%<PB!.P`$+"HU')2<QY0S8<2DI/*CS
M)%0)0&"$G!1RI+2KJ-@AG$DCGUF5:P,44KKHJ*CH_MD/W']1Z%$*J@\A.UM.
MV+QAKCF'(T51,S.K?CYC/8EGLWZ$L;(_++L4"C'J0,?D=Q9'A9V.4.\3;)@1
MTO\`=4*4HB4O`V=N`X%!WE(A6EJVEQM5+.A-3^.)W3?8YE?J+"8UG,EN+G"K
MRM=`(LD!#6NJJR<B1TFFLS("IOB*I&<*?BRFX&,=.F.%9C4?`':3(4)8:Y0,
MRQ;Q9AHY8\SU6R+O\SVT8FTOK`QQ//H3$[7"Q;D&;6.G/84+(*F.18!1.`32
MAHK7B`<L&4Y0\I9#?M)_\HX]"'T)=5AM*P[N&KR3>DVJ0E<,A%O&I7;U1Z55
M%S%K)'%5%4X&0$HA'+.^*L;3^3M>KQ!:?[,6)KBZ4RK1)%2JX"UR8R\>GD&E
MLF$9GLC6WUEA#O5X!VV,S1`I3/4#'$X12I!]W@>1Q+B",BK7L38;!JULW5VF
M2-F$;Y2(RI:\ZKM)YQ2X[&-.K"K2RR$M5)N.4JUAGXYPY$AW24FFZ(80!L@)
M2J![/->-H7)^-'-)H.INPC>WN(3'M1CRY#P!KHC4I]^SRY19J:OMH<04?".T
MKFC66+TGO)O6$,#8#@=H<XE`P7$,=<\!)LF::V"\/"LFU;IJ]V,:/W>X1$A3
M]WMPIDP'N#_:B(?L>G`KG2QI#POD_J;'&^,Z_`5*H,:U=[A)5"J(Q,9"2\E@
MG86D5\)0E?B&$6R<2R$\LFDY>.5#&`HHIMQ%3WDPN%X%,&(173\LNUHE(^7;
MN<B49%7L.R"/8G;Z0X963<+D4,F^.X>>X*9?;]P@`3[Q2_MA"Y_@4Y?K`K9L
M[\.6^*+IHJ]1_-`@M[")7YS@JWN-77;K]L;'R;KL;.$RJ&$4O:`I1%4Z27>H
M0+"-25EG.KFO"[A91PNKA?&QU5EE#*JJG&I174YU#&.8YA_9$1X%36V\0+WP
MF9'QVSG8JFQF2V%AQ9,V5:-.HQK]<R-G>8KUADTV,C*(@5=*.DUNTRKDI`4-
MW>@=``+.-E=3J7M)J!D#4&RVRUUVHW_&C#':ETILB2.MD,,.E&*0L_&.TA%(
M'C.1B&ZYTNH$6*!DQ$`-U`,A-\"T]IKF36ANJ_-1TL0&PTDZ=*^_*_D^-2-4
M"OE5R"B)Y,K,?=]PHD$%@[@$H]!`/#:J:F4G4O4G%^H%(G[).4?%>/5\=PUC
ML"C(]G>1SA216/(/%6K9%G\\BLF<2"5/H':7KW"`B(5_ZU:?V;P_:O[;9%2S
M+([3Q6.,*W"Y8OK5WAFF-)UG7<7R.?,\?DI=\C?E':H^PRUINN6)/Y5A/&1X
MH(F*=1!7L]`I5F?(I9=AO)-XI,ASM4;U.QY=/LE"1*VONU<)=\8K5BAOLXQC
MUO>H5.CUNN9!GVS*"BU8"4=RI(>-<_)(N01(H8H6&ZOYFR+:9+0R?R_FR>=9
M8R/*6?&5[9S.,]4IBY91LF,<Y*3K&QSF0L?Y1%.`.PH:R<*O'U\LX5..4,Y!
M%)R)1$+:L>Z7QN/][]A=X&^1)J0?9]PSB#$3S&)XI%K!UX<4R=FD"V<LPG(J
M*S#R93GR)$1.T1^&5)3HHK[W1,.ZR;IY7K1D"7S+BC).1]=LR6,T;^6-SQE(
M1CN(R.WA6+2.AXW(]#N$98:G.-&+1BDF#EDA&2XID`@/@)]W@1`\7VWFQFQ6
M8_)%AK8*;QW:#Z8[2,<!T2UT*D/J"M9X%&GHSCJ:L\$^N%R[)EVY<DZF173;
MCT,"9``!``N!X&OW^L5N7">K>K[=LFU(+G>7%XJR,FLZ;0L:U2Q+G0KUS).(
M\JLB0J3%955,J!.]0R0E`R8B!P"]7'P)A0J0"*R;A(*A6@2<)`H"2Z80S+L6
M3!8QU@35+T,'<(FZ#ZB(\!D"_4W%5&M^2\B6.+J%#H5<F+=<;3-."M(BOUN`
M8KR<Q+R+D_W46C!BV.H<?4>A?0!'@4BZW46X>4O95'>C86I9"JFHFOUX][QW
MX+NL>O4XG)CHM>C47FX62Z:,^_7L$JYF5'Q:)]29L`80S@'!6YU%Q6,$V\V*
MY<UVV<@=BZI6']^UUR54T:-LS7JQ$NI.[XXF*O[B]!S=`P$#'R%AO\8BP4/"
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MMAHF?E:U`YVR91G2Q"ZB8\>,1CW=IK+>PF;*W.28KK,0;M5HTQ@54X%[U2J=
M9H55K='I4#%U:GTZ"B:Q5:U!LT8^&K]=@F*$9#0L4P;E(@SCHR/:IHHI$`"D
M3(``'0.!47YH/\C.)/\`2FU_[V1X%LV/O[0J1_>A6O[#,N!Z_@1JVXVAQ[I]
M@BZYNR&]:>U!LCQ]-JQWI&DQDK(\H@NC1\95-`$G+N3M5VG")LV;9LBX<',<
M3%2/VB'`HPP)@?<_&V8<9>9':+'A;?F_+M1L-!V1P"HT82U@TOU6FY4;#C^'
MU^BZS$OI6V7JB+)E7N!U5U):;8/7#9)LBLC['`Q7Y*-A<?YRS)<K;K[;<=Y_
MI+/5JC5.Y0E9LE,F%H.Y-]N\?NXAQ8(NPD<,FSV@.6"TB]CG7QWR!4/>`@^T
M(<#:EA1,,-$B<Q3G&,8"<Y.WL,86J0F,3L^YVF'U#IZ=/LX'9\!P*%]M+U)^
M4C8:V>,O`]WMU6U[P^Z:O/(GG2AGD(9X1\UD!!EIM59Q\Q:M'-BO+(2NK,\8
M*O"1L7T;*%]U90A0L)VQH]9Q9X_,WX[QY5T8ZI4?7:RU*HU*%38MT6L-#U52
M+BXEBD\<Q\>4"-DBD`%5D4S#^V.7J(\"OCQA5?',3N]N4E!U&?@,D5+6K0"&
MO$HYFH$M4?0UBQ)/.JS"UFDQ,$H>L.H*1K4JJ_4"<D4G2KXG:)@(!^!?-P'`
M<!P/+W6D4[)%4G:+D&K5^[4NT1SB(L=5M40QG:_-QCH@IN&,I$R2#ED];*E'
MU*<@AUZ"'J`#P*DZQA74/QX;EZHX8U\HV3\2,MLW^;F$9C#&]Y?EUS;V:@XL
M>WF9M%GQK8WLFC#RKV!KGL-E8,S-,SPB9ET3B8ZG`FIKQ_E\WM_T\8U_]%G`
M_`H=SS%8>NGF788;L(Y.N#*WWBK763KVO.6,:W1S3+I%4=I%.I_8+$DWKXED
M''6.'42B1-Q(Q]W>]ZHI@BDD)C$`-J+@.!1MY%66.GV[NM9<IP\?-5-EK3LS
M*@F\B&DPYBIU@PCCP5DBTGY09,G\$\/[I7*ATRH]?M]0X$LO$MW#X\];^[]M
M]%O'7_9_.G>O3U_8X%B_`<!P'`<"M?*4*W@O)IJS/M9>R(!?L29HCYNM-I!(
ME2D9:E015:]:)6*414,XGX>(G)%BU<)F(HD@]5)U$ASE$+*.!%2NZF4VK[69
M"VMBK1;BSV3*U7HVS4%PXC7-(&V5NOQ]+:9#CB+1YIR-L3BB0[.(712=E8*H
M-BJ"A[XF4$)5\"I_SG?^J/WT_P!`=D_[YC^!-74+^2MKG_H4QK_@C%<#`V&H
M_7ZXZ'Q\1G=CC![@.>:Y"C;Q&Y5)76F-'L.KE&VH.6ME2M!D:_\`!7?D]0<"
M!#*=!^T0X$-`S;JSKML=KVYTWV6PM,8FRME-C@O.NM%"S)4;C`0CFT0=EB,:
M9+QM1F%ED"5">B;_`%-E!R:,>FV;O8M][RA3F:MRJ!>?P*XMW_)Y@W0R]87Q
MIDW'6P61[OG]2;:XPKN"<;,\AR,[)U\43R,0+9>SP"J$B1HL+@I>TQ#(D,/>
M!@`HA'Q7S14!=-1%;Q^>419%4ADE4E=38M1-5,Y1*=-1,^3Q*<ARB("`@("'
M`J%V/VK<94\G&E.V=/\`'AY!V.%L)42X0&8&SC6**BKC(2K,UP=XN:5R';WX
MP/X)O(Y!F#R:17#=)P#@@KD7]I("!G#)>QFMMWS?KQFFJZ0>5C%/Z-DK+6"B
M8[INCN('5`+9[+86,Q;+>G%V2?F7,'<+-%-#Q+F4C5FCP&#A0"'*H('`+#?Z
M:>B_S`/*/_T4(W_G0X#^FGHO\P#RC_\`10C?^=#@1R\#5G+E'+?F)SBV@[C2
MXW+7D-F9=ACS(T8A7,ATL(S'M>9N&%WJ*+R2&M6%=97[Z/R5RG233,4WV\#8
MJX&O_P#K$P&7U<UB8J(#\!YNYCM-\^[T.UD3\S>>B%`R#@!26]\BI_VWW"]G
MWO0>!>5CT4&F.*.8RJ:;5M2:T)EU#)))$01@F0BJH<HE133*F7J(AT*`?U.!
M1C`29/-7L-/R#"V7(WBQULF0K#JJ,605>O[G;,52V22-KA[J9ZT=R%WP!BLL
M0P79_!<M&,M,KB58JQ&PAP+_`-!!%LBBV;I)(-VZ2:""")"I(HHI$!-)))(@
M%(FDF0H`4H````=`X'UX%'GF2I%$J&(:);JY2*+#6N\9QJ</:K(E"PT5-3K%
M"L6@$$'DRFQ^6]<(`D7V$S&$RA@`@"'7KP+HZW`P<%%L6\)#1<.@6/8H%1C&
M#5@F"#=LFF@EV-DDP]M%,H%*'V%`.@<"GK>O83(VT.2)GQB:/W*UU;,DB:L.
M-M-CZBU=H0.J6$9HQ'<_%Q]P0,W0'/\`>H,Y&\)%M%RNV"+H7JPD*0"F"TW!
M>%,>:YXCH6$L503:NT/'<`U@8./;IID57$@G<24S)JID(+^>L,LX7?R+LX"J
M[?.55E!$YS"(98X%+?FT8JR>"<6L$'[V+5<919%)(1XI@];"F5HL)D!5(HGU
M4*F)#=0'[AA_#P+=L?CUH=)'H`=:C6QZ!]@=89EZ!_4#@<ZVVJO46KV*ZVV6
M9P-6J4)*6.Q34@J5!C%0L,R6D).0=*F$`(@T9MSG,/[`>GKP*&M;\:3GE8VL
M@?(UF6'NU7U.U[M+0OCJQ!:$S0I[I+PZ+YG9]K+S5U6Z2Q3VE\Y.E5FSL#JM
MHU,J_<!CAP-@40Z^@^H#Z"`_AX%1'EHQY4#8-K<PR[\?RD[E&J0MNO%(AH-&
MXR%$A("_VR2JRCEVR43?Q,FHT5*H@KU`!6,<@D4Z'`+8H(4AA(<4.[V!BH\4
M>\``_M?$1]ON`/0#=G3K_5X':\"JKR`[79*:6NDZ$Z966`9[P[$QKIVUM$K&
M.K#"ZOX33(Z;6S9"ZQ#44D7AXE1(&5>C5ET1DYA9/J/M)'`P3*U3UT@]6L(U
M'$<789Z\3,<F\F\@9+MSUQ)W+*F3;*[5F\@Y+M\D\7<NGEANMI>N7[@3*&!,
MRWMDZ$*4`#QN_K%.2THVB8+(KN$G>%+V@H@U08.'"Q#PK@!201E"*1QE3AZ!
M[Q3)@(]3`(!TX%8/BJ^8AOQY$VLH4S:0_1X\9BA&+B5C)=TWCR8MS,#)$TC$
MQ\0PD@9,54$CKHMDTS&Z=>HCW&"_O@.`X#@5#^0W8@V.,NXUQI5]N]F\)WF3
MQ9=LG2F,-<->L%YK6=8UILD@E9,O7:2S)C.X?DU`UE13XG8S?)'7$1[6JIP`
MW`]/@?4&<R)D_6?=6Y[YYGVM@*=2)VYX/86G&&NE!J4A7LYT!)FE:#GQAAG'
M]J6,_JTLBNW(NN3L[@`Z?J8O`SYA234A<Q^0&72B96=5C<U8^>IPL$BU<3,H
M=OJI@E4K&+0>NV#15\Y$O8F51=(@F$.IRAZ\"M+,%&<Y'V$_3%=Z3[[9CSEA
MNU07Z,>/;L;#>&L=8QE'!FL#;9F)MM(R6C89^K3T8Y4?2!;$$TD)V_M-T"@8
M!`-@+@.!0CY1+W1L6[;X2R5E.RV>HXLHNG^V=AR!/TDC]>W,X--M6V":<,RC
MV4@M(@Z?R"2;A#VC=Z)A'\`\";/B9(=/QZZXD4`I5"0]Y*<"CU*!@RI>@,!1
M_"4!^S@6*\!P'`<!P*F<Y9$*S\L.C],DWE<:,7U$SQ`5N/34E75UF;1+8LLU
MW>/E&22`Q$;2(>LT%TFJ\54!4\DY;H%#\9P+9N!5?![:Y,-Y6;GK/.(-4L(+
MXDCJOC_XR_NR3C-=;J<%FJ]R,DS*CW-(H<<Y`C&R"YS]JCA$Q"AU`W`M0X$2
M=[M7U-TM1\YZLDNZV."YKIIZ6YNK>&;6!Q!,7<BP<R#AO$/%F[9VNLQ:J)$[
MCE`AE`/]I>!`#'GCH\D%!J->I4=YA[HT@*?$1]<K3-KJ)A9V*$%"Q[5A$(O7
M#^:,JX<(D0[5!^PY`#H("(CP(D8>\:.Z>T>DM?Q]D'RCV@V.;W^5;"SX^/JW
M@RS0#EO&92LAGR))15^FX>)O)&/,Z*"G7VS&!,P="^@8OW4UEWTTAJ>!\ATW
M?S&,G-90VMUVP',NS:#ZU5!6N,\R76&J#J[0LO`L4GQIFJ2CT[QL5=0B9TTR
M=QR'`3"%G2^BGDD%(?B^8_(H+").PSC47`ZB/;WE]P3$2D$CF$4NO;T,'WNG
M7TX'G:=XL]@%=O\`6[;;8'R%W78^3UI)>VU0H5EU]Q;3(!1OD&!<0DT[!Y5G
MX.6\XFF<GQW8D440`OW.@_:%TG`@UG/?_">!]E<):F6!&S2V:L[2=*"IP,9#
MNPCRU2W.LE,7EQ4GED`AU6-/=8S<?56P+%=-T7K54"F*KZ!G*Z[-:_8YLU<I
MMXR_1*U:;<^BXRLP<E.M4W\T_FGOTV*:L4B&4]U5^_'V4_4`%3TX&6;(VEGM
M=G6<"])&SCJ'DF\/(J$%1-C*+,UDV#PZ90$QR-G1BG$``1$`X%76F^-'V?=?
MJ+<[9M'M@;*<<Q+4<V1+++RT.2M9DK2:3#(4!]'3@"DCF[.>*H9J4@>THS41
M43$R9RF$)1:K:38<U`EL]6'%[[(4S8]ELI'S)EVPY&NCVZ2]@OJL.T@E91%R
M\0;ECT5(YBD044B@3J0.G3H`<"7O`UXOUCN4B8[6?51.73;F:.MU:054ZRBJ
M8BD.'\UM#,R"0IT@"15>D2$Q@'M$P"'X>@=QDW*.6/(ME%3QXZQ6:5Q?@77Y
MEC*#\B68VJKB+F[%5+I2(^79Z^8)MD65=U%W29AP,>4ETA`C5F<4NH&,('"\
M3%.+*#A'&]*Q)BZM1U0Q]CVNQE6JE=BD"(,XV(BFQ&S9,`(4!6<J@05%UC]5
M5UCF4.)CF,(AD'@.!47YC&)9?`V,XE=T];,ELOM9-R1BLFW4=*UNDW&QQK==
M4Z*Q_AFDXM$5B%[153`2=P`(\#N/(+NO?,6%Q[I_I\VA;WY!]BXEDOBBF2"2
MKRO8LQPVDV<?=]A,MJ-R')`8\IS(5TVQEA*I)2@IMVY3F`P`$A="-0_T-\$-
MZ-8[J^RQFB\V29RKL3FJ8`1F<NYMN9D75SN*_>BBJRB5'")&\8QZ`FP8(I(D
M``*/4)K\!P*2/.:"XZZXX!M#_7UQR?&>W#_NK]W#[T=W%_<1BNA]DG57[@@/
MW/7TZ\"XJ@_VB4KUZ_\`DE7/O>GK_P`3L_7T]/7@45;$G=>97/@:I8=R-'N_
M'1KC<WD;OS;ZJ^>L9/-^:Z^Y9R5:U:HMJCE6T@R8T!\S1D+HNCWLW";LL<H;
MW2B40OQAXB.@(B+@H=HBPB86.91,6Q;)E2;LHZ.;),V31!(@%(FBW;(E(4H`
M``4``.!V/`JU\M\@^B-;JS+1C9X\DHO)OU&/9QR)7$B[?,<6Y0<M&L>W,10K
MAZNND4B1!*('.(!T'KP+,*VJHO7H%94ATU5H6+54(J4"J$448H'.10H``%.4
MP]!#\`\"$_D)W3B=,,)!.0\0]O>><HRR>,]:L/P;49&Q9/S!/I'1KT4W8DZF
M0K\6L8'<L^4[6S%BD<ZAB^G4/)Z`Z-):W,;?GK,ZS#(&]FQZ#&=VFS819RY)
M,2J*ZCF(QS1&RZRC6KXHQZV.FQB8YH5-,Q4/D*]RJ@B`6/<")V]C9)[IOLJS
M7G2UA)WB"YM3SYFQGA(KY$4LB#H[4A3'6(4QP`Q0#KT'@5H>.`M-CO(WY!H,
MB!QR+'8-T4B'_P!&3>JT^*J%8QG9H1G&H/71"E--#:4Y),Q2]2_%:)#U$1-P
M+X.`X#@.!7?LMX_V>P>P4'L7$YNO>)[A%:[WO6EZTJL7#23"8H60[$UL,^HX
M^J&ZHR7N-@21.!3>V`]Y>A@#@>TUFU,O^MD9C*F--G+]?<58KH4'C>NX[M%6
MJR38:Q5:PUJU526G&)22?S(=E'MS"MZF7,F(']##P.\UX_R^;V_Z>,:_^BS@
M?@4T;3[:XJP/N;EV'IP[MQEYL6:\35BX#3<U5>`QC=+Q&XTB;LXJM$QWD@1;
MJQI\;+@:26BNP'#HIBI]S@.@ALK\!P-?KRQL\;S6SV%JEEF-C9NC9!U7V1QL
M\A)D;$G"SM@N3BM-ZA7I9[5$5YJ,1FI]HDF18GME`Y0`QRE$1X'>>/[R,:BX
M6T2IT1D?)#J%LN%[E.XQRI3(''F2K79J/=KAEG,)X"'=5>K5:P3YXQX2H29D
MGR:2[(J#%0YUP*'<(9J:^=?QO.W'QDLC9K(IV+G[G&GFWC5'HV1474#Y#G!Z
M2'>8B0@0O=U4.(%*`F,`"'I3^:C0%-JQ?*7+.2;"0-!E1?J:?;;D8H_E(F56
M&._=FPF#>-2>IFZ@=P9,I>@]PAT'@=S!^93QWV7\FCP.;IN4:6Q>S-HF3:89
MS>I#D6J,A)14VG+R_P";H(V`$DC$KHM_G*MP>'(`(>YW%ZAW$OY=_'W`-8!Y
M,YU4CF]EMAZ5$F=8TRNF8\^"#YPDD\3&D>Y&1[PL>H5N]<@DS<J"0B2ISJ)E
M,'8K>5C25(Z)"Y/E%@4=.&ZATZ'=P*W20*<4WBH*P*9Q;NA*`)@4#*@(_?(0
M.H\"M2_;3X1R7Y3M#\\U7*U3B,:,C9CQY;E;G-,J%(,))]K7F6<CE58VWM&:
M\M%)OX]!N99DL4J;MRB!CF`1((7@?I9ZN?SBL)?QGTS]^.!2A5LN5G)OGJAJ
MQCZZ52]U"NXEOV;']AJ[V1G(R-7LV$\4X=;UX]B:2LU4@?&=5%1X9NB$<J5-
M0#'26-U6$-BCYS+_`.:VO_="7_Z_`?-9_P#S6U_[>E_4_P#C_P!7@=18+96Z
MM`S=GL$W'14!6X>3GYR4=.4RM8V&AF2\C*2#DQ1,)6[)BV45.(`/0I1X$`_%
M]L;@?/>K4`OA3(E,NS&EV"X0MD"I(S\:QA)68N-CM$>R686QLSFVR[V$ED'?
MXTO0Y5N\GXLQ.!#K]8,<L!U"P6*YDW+<N^.GAG#=%VDBJJ@&6XH54TUNU;V3
M'3`0[^PP%Z]>@\"]!B\9"T:`5RW#]S-P`GR$CF#\43H41`P=PA]G7H'7@<@S
MYD0IC'>-2E(4QSF,X1*4A"@(F,81.`%*4`ZB(^@<#%+O8/`\>WE';[,V+6C6
M$71;3+AS?*PBA%.')4#MT)!523*1FLN5RF)"J"43`<O3[0X%/6ZM6N>;=J,6
MY2PC6F.0<;TFDT>X7#*-(R?3%6<?7ZI&[(21%9:OO]C*HQG(%.PSL,>/`E5<
M?(>$<E5D/C@<J`0ET9J]QHV.-&?RAR4C`Q[G-V18;,&/\AN=8,D6:VHM,P1U
MZ97PF4@S.W<Q[!B[7!@LWIZ-M9)1RWQBH-ER>_P-D%QM9K&U77:N=A<+(.6R
MRK=P@MDRG)K(+H',DLBLF:8`Z:J2A1*8H@`@(=!X$!<P06O+S(-ASKJMO]B_
M5O.-O<Q[G(+\UNI&5L,Y4&-;-(]J[R9AB:O-<;NYUE&,R-T)2#EX!^*8`5RH
MY*1,I`Z?0CR/6+*]CW6QYMA8\(TEYJ-LZ;7""RO#SJ5'J>97*-,96]>>CZY:
MIN0/7W7PGJ:@-$Y%^7VCB)53`03<"PW]+/5S^<5A+^,^F?OSP->G]9/R_7<N
MZ48-KNKV::M-YFCMT<2V:"?XJDXK)-VJ$#6L>YBFKK=V%3K1YJ9E(^HU1BZ?
MO4TFYP,V;F`P<#V^MGEZ\$_C]Q95,+4O+5AQN^GHZ!NEJ=/=9-KEK9DBY72$
M)/NKU:YF3Q+)S<Y.6Q(57J7R7"@I-!`B!2($(4`S`7]:)\'Y_P!IN.]/^'[F
MN^SIO0/M'[N'!^SKP/Z'ZT/X01#J&XK\0]?4-=MGA#T^WU##?3T_#P`?K1'A
M!$.H;C/Q#]DNNVSP@/\`L"&&Q#@5B^5G]89\9&<->XJ(UBV82NF5*S99>RP\
M#.X&V%BX>04)CZY1;*.?O)K&\"@U1EY:2;M/?(JH=M[_`+PIG*0P"'T\?/F6
M\2.&YK+FW^VVZ$'DO=[8^87+?\@T[6W;1Q3<7XKKB,,RHFN^+7<MA-@*-*H<
M6@T</EDV;9>1EGBKAP*PF2.(6;__`%T/X0OYXLA_T==GO^9O@>.F?UJOPO1D
M@LS8["WJPM4HWYJ<K$X`S>BQ<N^Y4/I"2<Q0XJ0*]Z$*/>=`C?[X?C/0>@>?
M<_K8GAQ14*1'+65GA!1;JBJC@C*!"%460355;B#BNHJ"JU4.*9Q`!()RB)1,
M7H80K<\F7ZP_XKMJ\,TZK4/*F0G4A"9#C).5AY'%.4JP[5B`^,<\@TF"0C5N
MF1HLAU.F#I-<Y0$"E.`B`AWVXOZTKJE:\"X^PMI-F^VX]R+=W<%2\C;`SV';
M4JG@+&\?`&/;\B4VN3D"9M>[P0&0M8:.!(Y%7:Q3'``#@9_UF_6"/`YHSB&L
MX"PY=,EQ==BFK:RS,NABC(%IF[S;[7'LIBQWZ[65NQD3R][M;Q?Y,L*JH*MW
M9CMS)H^U[*89^_\`KLGP[?YT,M_Q%Y)_>/@>_JGZT'XEK7'/YU#)&9V-8AE"
MC8;2KK;FZ1@*ZR$O09.:?0-*EOB,B.#$2$>T5.]0O0HAU'@0;\F7ZPIXKLSZ
M]IU+"6U,T^R9'V1*PP3<N"-B(%TT&1Q_<X6&GV[^>Q7&,")Q\A9F3P!]P3G;
ME$R93F[2F";;+]:'\*\146O?MQ+S,Y%UQ$#QS?7S91)S*RS&,+W,D'+K$2+)
M-=Z\2]LIU%")%,8!,8"]1X%0&H/F^\4V5=P+WY+=Z]A)G'N94H]UC#5O6R6Q
M;L%DN+UCQNT(K&3]S9V2I8O>TYWD#,:`$6??%(I]/;%!$%E#B)B!=%_]=#^$
M+^>+(?\`1UV>_P"9O@/_`*Z'\(7\\60_Z.NSW_,WP,![1_K+7AUOVON5Z+CS
M:63L]VN=0DZQ6H@N$\Z5A):6F4_AM57<_=<<5RM13-L=3W%57+Q(I2%'IU'T
MX&2O'+L3J])[?;>[-RVRV(X9/8+$>F->HM6MUYK57MLK&8]QQ<CS%N+"S3UF
M^=PL](RIBL7"(>TJ5DN8.X``0#8<A)Z$LT8UFJ[+QL[#O2F.SE8AZVD8]T4A
MS)G,W>-%%6ZQ2J$$HB4P]!`0X';<!P'`H9\J6]N8,![!8NP)CC:?6W3J#DM?
M\C[#V/)^P<-7YI2[S%#L+2'J&&*.SM>0L?Q*KR\R@F2?J-E'L@U9B*J:(?:(
M?;Q?;=6#99WBJW9H\G^J67LX91I`Y!D]+-<U<9M6>/4I>GLY/\BS`>ZVK)\_
M*XY;G46F'*B;4/J)52B0J"0"H$JM?IU,<Z^7L+-?UZ76ZYGO'1%+BD^BXI7&
MD%^@'K/*RMC;RE@CWL#'J01W*\H#AXBY:(F#N6(8A3$X%.^'L^:F96W2S?2L
MW>8JOY9PK@>XZYV+5Y?)F7]"I[\X%YM-&5DKVFQ=N=<D26(\/8S(QZ;^OR$?
M)L3JF9B)3]%!#:^X#@:M_G5N!\2;4ZBW6-Q)KCDB*L-4NT7DMGL5C-QE.H`P
M/,5^`K%@"CQMFH[NRV.`D90I68GF616J1CF[C]`3$)?^(SQN5W`&*\FVC,--
MUQM-KRMDZURI&&-\,EJ%=K1*GD')\.+5NSL%IO1UDQ4F%TF8H+-B)1I$2'2]
M\5CG"W3\P&#/\S^-/X$UW][^!^OS!8/Z=OYHL;B7[OW!ID!V?=_:?=^!V_<_
M!^Q^#@?$NO>""%[28:Q@0OJ/:2C5LA>HB)A'M+'`'43"(C^R(]>`-KU@<_0#
MX:Q><`$!`#T:M'`!+^U,'=&CT,7\`_:'`_7Z/N"O\SF,OX$5S][N!^#:\X&.
M)3'PSBXYB"(D,>BUHQDQ,':84S&C1$@F*/01#IU#TX#]'G`W^9G%_P#`:M_O
M=P-:K)V#Y&6\U%\HN#:5K#'RDI7I91#\^>&GUZIT/[&JN'P7B&<%2;70)Y>&
MD2.A=*H"[28E>'44*L=P<Z)`GP?Q_P"VJH)@I3_#:<$DBHI`;0_-H@FB03"5
M(@#M7]TA1,/0`]/7@<]UH7MNJ7V$*KX>OABBD44'6BV;%OQ@H-".>@$VH3)[
M1U69.P.G4$TR`(B)>O`Z=UX[-HY:.F823K'B*81EAK]BK4D\JVDF;X*PH1UD
M@I&!?C$S*>TZJL:Z,TD3E!4@=Y2B/:(#T$`CEI-XP\^X9P%7HW$KKQ_69M/V
M*SV>?G]A];=D\K79W8FZXT<%6<W9]JAFH^+;P591:H-U%%`*V(0"B!?3@1?\
MP^KN<Z1K1A26S/!:!O(@=XM18IN77S6?(V,[8:,DLDHLI2/&8MV:<BL3H/CG
M;E.3XQ2F0*H00,)RB0-EV*T\U78J-I1OKIAQI+"HRD5'J6/*VD]"2;%]Q%V=
M8(X%OEH*G,)3B/>41'UZ\#GM]1=6VKU22;:^8?0?K)BDJ\2H%;(Y42,L=P*9
MUBQX',05U#'Z"/3N$1X':L]8-<8]%=LQP5B9HW=*HKN4$*#64TG"S<Q3(*K)
MEC0*JHB8@"43`(E$`Z<"H7:S02:R/O=J<M1<$6!GJQCEG$-\@05+L6**5@N:
M:A%Y4C)%*^4;\BUL@3CN)8W!L1@FQDF[+W"%,*7>7O`),1'B)UCQ_.Z[#A.%
MJ^*Z!KX6V(L:$KA_#F47EF;7!\,C*HFR9ENE73)]2*Y7,*:WT>59@N@;M'H8
M"G`)VH:X:_-2>VWPGBM$@]HB5.AUHH")$DT2"(!&^HE22*4/ZA0#@?`VLVNI
MC+&-@O$IC.`("XCC^KB*P)NSOB`H/TS[X$>G,J'7[%!$WV\"E+Q&X)Q>_P!B
MO-`I.8VJ$I%D\E]S90#*6J$*XC8MI%X]J20MX7Y!')2(`JY.8Q2HH%(8X@'<
M`]>!=NGKI@)$@)I85Q8F0!.8"$HE:*4#*',H<0`(T`ZG4.(C^R(\"C/SZ8CP
MY5-;]6UXRD15,0F=\,.UJ:?8V<ABVW2\#8<9YOBY2H1EUJ3RLS\6-S;N/I9R
M-WS8[HKOV.\/<X%E.GWC1TBU&PLPQ;A37JO0-/EY7\O7\1D!22R?84;-,QZ!
M')GECR,^M$_[C%`PMTTODBF@0!(0``1ZA,."P]B6KB!JUC#'L`8$G"'=#4VN
MQIO9=J-EG20F9QR)A2<*LTC'+]AC)E$?4H=`[5CCR@1C$T9&T>H,(TYW2AH]
ME6H9LR,=\LJX>F,U19$0$SM=<YU/N_?,<1'J(CP/[%8\H,$Q1C(2D5&(C6_>
M*#",K<.Q9HBH<5%!2;-F:2)!.<PB/0`ZB/7@=C^2E6_N;@/^1X[^MN!2SOW6
MX!'RC>%I%&`CTVKRW[H&?I(-X5"-=J,L0T/Z<:3BSMP=2CAF+U<6BI>I&8JK
M=W05B\"Z;\E*M_<W`?\`(\=_6W`?DI5O[FX#_D>._K;@/R4JW]S<!_R/'?UM
MP*YO*YJUKQL-H]EJI9KQ;$7>H5DU>R*UKR$C,T\CJR5&8;+0QWDM3GT+-'8D
M.[4!5`%P36(82G`0X$P,$8:Q'C3#&+Z)CS&U0I])K=(KS*MUB+B&IX^$CCQZ
M+HC%J=TFLZ5324<&'O5.=0XB)C&$PB/`RS^2=6#[*U`!_P#P:._K;@/R4JW]
MS<!_R/'?UMP/*9!K\"VQW?00@X9$/R-LYA*2+8E()B0KTQ1.0$`*?H8H#Z_L
M<"ICP(PS.6\7^LKV>8I3#M?'=&6(O/?1)V0327Q_45CD^H-2KC\95P<ZR22G
M8JB53L.7N`3&"XU*FU!`#E0JM;1!151=0$H.,3`ZRQQ466.!&H`954XB8QA]
M3"/4>!]?R4JW]S<!_P`CQW];<!^2E6_N;@/^1X[^MN`_)2K?W-P'_(\=_6W`
M@]Y)-=,(9TTAV)QWE7'4+9Z:_P`?2LD[B6YG%=74?0I0D8IRA,P"T9+,E6;]
M`B@&273$>WH(]HCP*K_#9@K%M)SAO)KNYQ51)JI8BIFGK"GV.5JY922D*W(5
M7*,>RK\S)V!Q/'E9"O!4TU%%DG`IG%T!BD*42]0V/(6$AZY&-(6`BX^%B&*8
MI,HR+:(,6#1,3"<4V[5L1-!$@F,(]"E`.H\#M.`X#@5.;S6S-^0=HM8M-L*W
M^IX)'+=0RED*^YRD*32[YDF-IU':M&;NF85BKPA*03&Y2ZLB"SF0<1SU-BS)
M[@$[^G`Q7@RN9[TVWXPYK3D'8&&VKP]G+!V5)G']IRQ6L8U_:[%UZQ[)5Z7L
M)7$_C^J51*^8AML,[]HPK,TW+"301`RZB8E(`9UUBL=?IVQ_F+MUM=IL*K5M
MDL56.S/E6KE\DRK\'X]M5Y.9=JL63=V\>)MHYJH<R222JJ@%[2D,80`0[*'\
MD?C[FG<2VAY.ZN5I1RR1BEB::[2H-%E7ZJ1&2I)%?`:+%!NJHJ0P+G5(D4H]
MXF`OKP+,.`X&IW^LA*-HS).I\N])"G54@;4Q@65NBT']-G9!"^T%Y+,)U==9
M(C4D=$C\E,!Z@JIVAZ=.!L]8DC'</2$&#U87#E.R7Y8RHI,T1,F\OUF>H`*;
M``;`)$'!2]0^\;IU/]\3<#)7`<!P'`<!P'`U5]\++NYI]Y2;)LWK7X[\T[>I
M7ZLUHZ60J3!_6ZG"5,V**[CJ7H#AQ`K_`)2,I:+M%//+%;+)@W4^H>X!AZ_=
M#-<%Y0/+C.5NS6$?$W=8=:JP8RCRO3<#D9A.S,B9$7*$!46IB&+9GBC<H]RJ
M(E226Z)&^\(<#O9OR4^66,DV<)'>+>R3TG(0<=.M5FD!DQG74DY"028#%RMG
M=I%C8F=8E4%==JJ`G30()NO`\18/(?YRD,C4)K$^*$)"DIDAYF]M(>UBW<2,
M>L>3;V"M1UDLR[9A&6"/-\11LK[9T%R@H(CT$O`\1KSY`?-36Z"6-7\.<PYJ
M<<^>FJ#>2RVR:7^3:O[?87=@-8RJ'7@8Q9C\@H,P(L<%TB@8>WN``"'OD7V=
MWEVRPKKKKYY!O&[:-:<;9*V3QK!VG(%8S-6AIJ]U2E)*3IT:,^].C9:U"?36
M#ARLJ0`=NGK=-JB(`MUX%V[/P/\`CO,1@\_)',7R4F#5!)8NQ&8A[$",RMBI
MD[;85,Q`0'M`>WJ(<#^H>!3QSMA4,A3,Q)"J@JV4$NQ.9A[T%R>VLD/=;S?=
M4(/0?P_L#P/C_0&>.'^X?,'_`$B<S_XX\"LUWXP=-(KRI5/4Q"F9=6Q;9-?K
MU=U2*Y^S0Z5B;!4R4=VV79/0M@$C"2A+FY352,)O?]HIBB`E$.!9PX\"GCH=
MK*.'-,S$LNJ("HH;8G,H&,)2E(7J!+>4H="%`/0/P<#X_P!`9XX?[A\P?](G
M,_\`CCP.4S\"OCA9N"./S?Y6==A%B^P]V#S,X;&]Y!1#N.B:Y`!CI>YWD'_:
MJ%*;\'`C=X&L75_"&4_,%AZBJS"6-L;>1"?JU%A9FU/+.YA8QGCZMK.$55I9
M9U-@[=.''N*N'2RAW8"40'[@]0V)>!KJ?K+]HDZ9ISJI9(8C`\DP\D6JR+8)
M-@WDF8!*,\E1"YSLW)3(G52;/SF2-^V26`JA1`Q0$`V%H(.D)#!U,;I%1X=Q
MS"<YNC1$.IC&$3&,/X1'U$>!VO`<!P'`I4W_`!_^JE^%`.C8>MNW;'J=Z*3H
M.F(,<^C=A[9BO$AZ_C%!,7V!`OH/N>@75\!P'`B%OQ_([S]_>,K_`&4C>!([
M'W]H5(_O0K7]AF7`]?P'`\5DHW;CJ_&_^#2K4;_K03\>!6EX0JB%%\8FH58%
MQ%N%4<$8=GUQBA=F32-=\44F[I(NSODTW!GZ;:Q$!7]LF4WHF(D`O`MBX#@.
M`X$9MS2>YJGL`0!*`GQ=:B`)C`4H":/4+U,8?0I0Z^H_@#@4O>$*:J=KVC\F
M<_5LB5BVGA)77'%UAKT`#U!:LV.AIYO>2#A=L[.9-5I*)6Q%$CE(.UPNR6-^
MU[``-CK@.`X#@4]^3-WBZ^91U>UW2UTN6==G+Q(7:XX;M%"R$UPM/X+K=3BB
M?ESD53,)U"OJXP7;K)LO@-R+'DU%`3]L1*'`P9I'5\?ZR;V1^"\Q:W9?K^RN
M4<#W.>Q#M/F#/*6SJE]QM0K+6E;SC&#O<@5"?HTPP?3[5^\C5&R!7K9NBJ!U
M`*`%#-]/B[A*VCSN1>,)I&,R7,9#B&%'DEWC>$1@+T\\:.M[.I/5YJ3_`.+6
M*;28.V<&=*_B&Y?O*>A#<"JI+!6RB>,,?Y`QKM-GUGGS-$?K93*KB.W[B4ZS
M4W4ZZT)TW7S1D?(\FQLB[3(3/)OTUPFV;L`4.(.TDB)!W=H!MN\!P-3OSFU]
MWE???7S$DG+IQD2TTORM<<=JOZ^K+037.,MF_'=:J2\U(HQTJK#MG4:V<(@/
MLBFN<0(J($Z"`;1V/4VZ583(U*0B`SEN4(5-=1R4#*VZ<54_'*F.<QA5./4.
MO0H]0#T`.![;@.`X#@.`X#@.`X#@.!#+Q\E*74?%I2E`I0?9-Z`4```ZY<O@
MCT`/3U$>!#?R]%96&8\<&+I:#D):%R;Y`<>Q<FZBVC=R^AP@\:91GHY\BL^1
M?1T>F$PT;^^X79O`(V!0I$RJF(LD%R**8))))!UZ)ID3#KTZ]"%`H=>@%#KZ
M?L!P/IP'`I/3:,I'S015H=R"+>:A:EF7&47&?'2,$E6FV!-3LAG=$5.X*NC(
ML9VYN2K'(4Y%6QT2"4@I]Z@78<!P'`H-\(BRDYD[R_WAZ8P2]M\F^6OJ2")C
M%C4/R?K]>A&7P&QQ4.W%1FV**W4Y^]3J;T^S@7Y<#7,_6-XU&[8ET.Q1*BH2
MMW7?S%DU*JLCE0EBOJ!4KS8(%-BZ5*LW117D#]K@#)',HGZ%$@^O`V#8&6CB
MPD*1:1CTU_I,:"B1GC<IB*"S0[B"05>X!`P_9P/3`/7U#U`?4!#\/`<!P'`J
MCVCAIF[^0G28$V#%9AA"<"XM'OU.+8/FR>7:;FZK6<J[%\DI(3J)@QU$_'*R
M40%H85C+E7*JG[`6N<!P'`B%OQ_([S]_>,K_`&4C>!(['W]H5(_O0K7]AF7`
M]?P'`Q3G:75@,*9;FD$DUEHS'%T=I)*B8$SJ)5Z0$@*"4!-V=WV]/40X%2^E
MVZ6$];M>\`X'M%.SXC'XVPG@2D6#(\3AZVWV@UERRHT#C^H?EK9L>1UD3JR=
MBA:@666?R*36-8H.4RN%TCG3*<+EZ9=J=D:L0UVH%IKUUI]A9D?P-HJLPPGH
M"89*")2NHV6C%W+%X@)BB'<F<P`("'V@/`]/P'`<"#'DTO3W&7C^VZO\<T;O
MWU3P;=IALS=B8K9PJVCAZ)K"00,!!`WX!#@5&?J[N/J[$6/RF9$9@P0L-BW@
M?TB09H0R$6^"%I=$@9V#EY`S]Z[M)W,V:^.`."P)1AOB`HQ`Q3JFX&RUP'`<
M!P*]MK]2\K9`SA@[;/6G)59H&?L(15DH[J"R)!N9S&66\271PV>63']H7B?_
M`"BJCU.2:)/(^78D=';."=#MEB#T`,/P,)>)'R,88M.V^7\35K)2&%<X):IZ
MOX@0NTU'R$*+K&C?,>4KKDJTQ=<3LL_7VJC%E'1Z<0P(T;2KE0#N!Z^V'N--
M6$)DO)7DX>6F'CY6-OVVTI1;56GZ<=(PDG`TK7[$>'P8O6(IF46:S]:K"9GB
M#P#"<ZZ@%_$B0.!FFLZ?^/UG85ZY4-7-/F]KQNXK\FZAJ_A'#*=BH[MVD,E5
MY)=FPK`25>=N4D1<,5S%24.!143,/3KP)D<!P-<+S36U9OL;JUCZ$8+3EGL^
M/,AV)A`$N<I"`_=4NS5B7@#)14?-LE4%BRP&*,@@S?..TWL^V)!$.!>CKK,/
M;#A^K3LC&IP[^7=VV0>Q"0)]L6Z=72Q++QPF3:LBK*,E#"F=3V4A4,43B4HB
M(<#-G`<!P'`<!P'`<!P'`<"&?C[_`))&+?\`AV3?];=\X$9_):WC1R]XSYRQ
M*5IO5*3NLQN%A<SHI?.1(CB7(]<A3P*:M?ECKO4['9&AU"(N6:P)%$X"<A#]
MH6QE,!B@8H]2F`#%$/L$!#J`A_LAP/[P'`J'1:_1/*M%F%XHX&[O,WRA&S4]
MB20CPKVLFG$09"43:J)UUVNN)/=0,[(J=,AQ!N)3"MU"WC@.`X%!'@K_`/'G
ME7_]IOG;_O>&X%^_`HR\Z^&L8YOPK@:HYAJU`G*(&7;5)*2619?+,-#,;%!X
M4R3:(.`;/<09(QA/M)&Y)5YTT26<R`,P$OM"'N+)E.%=,K^J\:T9>J<-<HIE
MC?&MZMC.F6]#)L!-;?6FZP+K_B>:%9@SR7M=;JD_=BU1^,'U&.=I%(;J*8B4
M.@;9T%%)P4)#PB*JBZ4/%1\4DNMV^ZLG'M$6A%5>T`+[BA40$W3TZCP.UX#@
M.!7MEYB$?NOAR=<LTA1G6N/*VRDG)'C11!]%L]BY15C%R#8CA!\=XW?@9VR<
M?'*)4D52&5,42IA83P'`<"*F[TI2(;5?,+[(TK,0=+&#BV,W+U]FJ_F8].5L
M\'%LW,>T1:/E%ER2+Q'[$C]I>HCT`.H!)J'C_I,3%Q7R%GGTR.91_P`MQT%=
MU\-LDV^0N(>@K+^WW&_^,(\#L>`X&$ME0[M>\V`/V#BZ\`/7^K7GX<"MCQ"6
M!]>JIE^UJK$?QS0^+<<KGD%&SB?A)ZAT1!)W4WJB3)DLI#-Z]+Q<HP!<%CII
M2YB`H8A2@`>XK$W5=-=][GB=)[6J)@#:;&D[L+#Q\K9H>KURH9PJ$F+#+*-/
MKCUJW3<%OD,HUGY0&;H!"147<';_`(T5!"PH,W8A,R1D4LCT]RR<$4.BX9S;
M)XFH1)@24,8OQ5%C=!8J%.7T^_W`4O4P@'`[%?+6*FK@[-SDS'S=VFDDNHU7
MN=<1<)H+)NU45CH*2152)*I,%S%,(=#%14$/0AN@?0N5<7G5*@3)%!.L=S\,
MB);A7C*F=^W[OQ2IA(B<SGVA[NP`[NWUZ=.!6GY7\LXTNWBJW=D:G>ZO,MI7
M6O*:L<HWEFQ3+$C6#EN]5,W541=(I-EVQP,)RD`0+U`>@@/`CKX4B5V9R[Y2
M;]6KE6K1'VC9_"\>BE7B1Z::2=>U%PB!YHA8EPZC5HJ:?2BZ;1PFHH9R+)55
M0PG,/`OSX#@.`X$%MD,_[/8_R"C3=>\+:XY=:Q]%"]7`<H[;IX.M]8B4I91D
MYEU::CA_)#I2H>PD)`EUEVS8CGJ00'M$!"(N,\0[F;$>036C<[/N'L%8>Q9@
M?7C8"ETXV)ME'N=WU]EL^RF+7\++&,KAK'D:C6V5:I:IRKMW*OR%G":A/Q?W
M1"2NA*IE+'O`F,8DR!'=;*Y"O$W*JQY<IH^N*?+614*5-H=`3BW`A!,4Q4@.
M(]3"`!Z7#FK]TQQO5N7L])6"'?4C9&H:[0E:K[525+,P<EAZHRM:F5I1`Z_T
M91&3._*=!1-/WP*`E,;MZ!P)T\!P-;OR_P!1K[W?CQ^90BW4/#Y5Q!!WM[7W
M<G'3DJ6>@[U8X"L.(U9FP3*Q4;5UVF:0*F*I5EEC%+T[`$>!?)@<PGQC$+"D
MN@#F<O;LB3D"E<$2=W^SN407*4YRE5%)4!,'4>@^G`S!P'`<!P'`<!P'`<!P
M'`AGX^_Y)&+?^'9-_P!;=\X$&/,P_ER,-1(>(10<?5L]@,D19.5540CVL$MV
M/(\68A'-)`DHNV2*L[$"`DLH0GWSAP+IHT!".8`;]L#)J`]?V003Z_\`V>!S
M>`X%54FFYC?*+CXJ+9$[6R0>>7SYR\5?F]@\3A;5QBS+!IG.5BE(+C[@/P(4
MPBW(V$>@B/4+5>`X#@4$>"O_`,>>5?\`]IOG;_O>&X%^_`BQO!4*E=]0=E(2
MZQR<C!)X4R5,F(+9!VX:2$#4)B8BY&.2<=$QDF#]FFHB'4.\X=@CVF$!"#VF
M^U>V=\L],IT'K_(YNU6<5'$B4%MN]?P>#)&+2>U-,ET+*8NLY"NL@IU^8;`F
MBM72)D[>I%`$_0>!<1P'`<!P*G-J<J2##R!Z6X:&`54B;);Z]>S6,BSLB2$E
M7J/LA&)1BQ`+\01%O)&.0H&[C]PB<.A"<"V/@.`X&)\XORQF*[8^-]4[6Z,6
M(_12"I)_?G(Q+]RD!)<3&^_][[@_<Z_[/`RQP'`<#"FR(==?LTA^SC"[!_\`
MB^_X$(O#M6*G%:.4>VU^.BV\YDRWY*M%]F8UNJV4LUH@[Q-XX:R4D"JJHJR$
M=4Z-&1AC@(%,1@40`.!'O]8(QO$6'0JS9*B,11>2\TXXF8>%Q/-FC@=V:AL<
MG3T!6LH2%:>`L@M'DF*,U6;OC$$1.U*(=.H`(!EJD>&7Q;6&DTJ=E-*\-OI*
M5IM3=O'IF<\4[I8]?C0!8_MSI`,82%#UZ=1Z>O`[X_@_\3*BAEE-%,'*+&*4
MAEE(J945,0A52$(94\V)S$(1=0"@(]``Y@#]L/4/Z'A!\38&`X:+80`Y5/>*
M<(R;`X+=O;[H'"<[@5[?3NZ]W3TZ\"(?D'\5_CTU\T0V^RCA?3S"U7R!7-?<
MBA!2(1$FZ:I_-B#MG2+IB]FQ9.&:Z*IO<(<.@AUX&3_$73*;C?.WE,Q]0:17
M:I4:CLM@&)KSJM,VK:+=1*.DFO!6L,Q5(J=ZO&PHE,L@"I0*`OSF*8QCJ=`O
M`X#@.`X%*6ZFI.U=OVSR3FO`5"Q3?JKFC0*QZC6I&]W%Q2GU?FY+)#FSM9(I
MXY%5_-1JL2_.!@`2"F8G:'[;U"3VDT7N3C:DX<P?FC"V'J7CO%.'*7CI&T4+
M([ZQO5WE!J$/6(PC.#>-$E$HUZ$7U`3J&.D3H`]1X$7\&9`OM#QWY<+A0S2#
MVX4C;[+3ZELV<6PGW*+\E+Q\[3;L(65=Q\<^,HZ<J']I99,AC'$1,'`B3KQY
M%-V\B9[Q!3+@_OZ5.LUQIS&T(+ZN5"O-S1\FHHRGXM:Q!D*07ADHSM*[.^(@
ML*A1%)$@B'`V9>`X&L7YE+%\'R=^*:NM%):3<S<1L(O(TU*T.F]=GVL=%0RL
M([L-/7,K7I9"%FS>^5TZ05.B`&`GJ'0P;`^N?Q?S.5'X8I&1]VS`8S=PF\:'
M<A;Y\'IV#M)JP3=1IWGN"V5!!#W$!(84DQ'L*&;>`X#@.`X#@.`X#@.`X$,_
M'W_)(Q;_`,.R;_K;OG`@UYDV*KAAJP\+]0238Y;=F57;*$*R7]YI')ECI$BC
M97W$UQ_'$`ATC@=`!ZB'4.!='&?^+8__`("T_P"]T^!SN!$C.6X^.L.7=GAJ
M$K]XS5L1-5/\M:Y@7$D$:=NCVM'F$X!M8+%,/E8VCXWK#N7.9!.6LLI$QIE4
MCE!;J40X%3"NVWRMG(+86:U]O,;D:J9QSYKNTP6]M&,7E\C;6[Q?@V#5,>TQ
M=RFJ`A^5C:F,E&R02;5LF5<IEU1]3E"W/#6U<+D=]7Z9D7&^1]<LQV$9HL?B
M#,4=%(3DF,`V4D90U5MM2E;-CB^I,HD@.ESP<P_*V2,'N]AO3@2KX#@4$>"O
M_P`>>5?_`-IOG;_O>&X%^_`JN\N$=D.XZX,L45=*[LJ%DR;FXW-%GQU5+;<K
MC$TF!I-CL4%$PT728Z4GV06?(K"%0>/$T52IQB;E`Q!^1W%#CL?+%I)BC$=5
MFLCY$NM4A*]'5ZE35AF\(9IC(5G:XZ+BF4A#KO75$(D@^:KKD%5(X@=(A@$_
M0.H\"TY@^:R;%G),52KLI!HW?,UR@(%6:NT2+MU2@8`,!5$E`$.H`/KP.7P'
M`<"F;9@Q7?EHTNCW[R2%@SI#N:CHY)1PM'?7DV>8623YPS!VBU15+'N5B`X$
MBAPZ@3IT-U`+F>`X#@1%WPM#^F:FY?LT60%)"+CZP=JF,BI$E.JXO%89@4\B
MD4RC4@@X'N,`"(AZ=!Z\"7!.[M+W@4#]H=X$$3%`W0.X"F$I1,4!^P1`!$/P
M<#]<!P,+;'!UP#F</V<970/_`.0/O]C@0`\'D@A)^-3";ILU.S2"][.-!1.J
MW6,*K#:;,[%=?O;,F"7:Z7;F5`OM]Y0.!3'4,`J&#Q'G\M\Y0_&-F*U5]X_C
MGL;<L-D<OHPK`T@WAI'*%8BIX&@R7>U37=0SU=`IQ35,05>H$'IU`+<<?A'A
M0J0$2DX0B@J-;"-0=J%5=HQ_T9E\-)TJ0`(JX3;]H','H8P"(<#UW`<""'E`
M!D/CQW)^HQR$LQ#7_(AG46Z0%RU?HDA%SG:.6X%.99NN!>TY0#J)1'H(#Z@$
M'_#_`#-8D,Z>3YJR?5UK;R9QU9EYZFP;MF'Y-U^8T0UU"K.$8<RCN=CH"1<L
M))"/4=.7":Y6*A4C"9)8Q@O/X#@.`X$++KNQCK&.V3C6;)ZL'CJ+_1W;9]C,
MJW&WP$!6)5-7):6-G%001DW+94LNU>N$W`F$_0R:@`!?P\#.U`S_`(,RM+.8
M#&68,:9`G&4>>6=P]-NU=L<FVBTW"+0\BNRB9!TY29$=.4TQ5$H$`YRAUZB'
M`@3HK5JA<+7Y,JI9(*-M]3GMXK^QGZ];X.,EH682<8]QR:1CI&%?ED(V3BA<
M=0(58A@53`#&(41Z`&:*Q@_QIU&W24I3<*Z35>]8KNE?KDI)UK%V$(.U8^R#
M-II.ZO#N'\9`-9:LVN426(HQ2[T72H&`R8#UX$Z^`X&N-Y5OI:7E(\8+Q5VM
M'VR-HFS$WCN3)*FBRM+7`P\([^FH)(1<DO+R%H8+':(MC`5/T'H8AA[P"]/7
MY\,GB6LOCIJ)*N'5J,X(LS:1RWRBW"?([.K'LDTVS)11R4YC)%`13$>TQCF`
M3"&9N`X#@.`X#@.`X#@.`X$,_'W_`"2,6_\`#LF_ZV[YP*]O-[>:5CNK:T67
M(%KJE'KC?)\L*UEN-BC:Q$I*M(QE**L4W\R^8QZ[Y:.8+K$;E$[E4K<WM%'H
M8.!*=MY??&4Q;Q;%YNEA!L\7DHNJL6RUA<IKRUA=N6\4VBH1([`#SCE=\L0A
M0:`L'10INO88IA#R%B\Y?B0JT@YAYK?7`36::$<_(B"V)^YD$%V:[MJX8N&S
M2*<*MI!%TR43.W4`JY#%]2!U#J'O_&K5U;!BR\[:V66B;1?=TLCV/-0V:&"5
M/$DPZ1XM5M=:U6U)V.BI)O7F&&H2)D#I%;HME9B4?ND@,#CW5`HRN>7XEIY+
MIO72:L..8VY/O(Q*25/QP=RQCLRS$G<,?U:](V92!;/#OYBB3-#;(G:2SQ$B
M21FIT"&*4J8J!?1Y+Y"6Q_JY:MC*A"R,WD+5QY&9PI[*%8J2$Q($K#]J%J@6
MK9&-EW"S:>JJSI%P1-LJ<Z0=``!]0#H&OEW\=#\[=..V8@907*,BY3&*I&4Y
M1,K.(@G5GE7ZZL?17*36.C:ZS5?+N%1(@DU(*AC`3UX'@W?G,\2,>NFVD=[\
M'QJRKL&!"2<A/1W[M$B*@M3F>P*!$UBI.4SF*80$I#E,/0H@/`BOX#9-E9X_
MR6WR`44DJ9>/)#G&=I]F2;.DXBRPZS:#$DC#.W"")'S7[X`)B=>T1Z&Z#Z<#
M8&X&NU^L8XKH>7\*:3TK([-Y(U&S;T8^J5CCTUIAE'NZY8L=9-^L)R$E"O&+
MUD9/Z:BHC[:A5C&((IF*8O7@1G\F/A#\8F)=-IG)6*];8&@7EC/8A6C+K6IV
MV_48[Z5+L5@>LF<E/KQYE))%'H\[R`9Z!A]XXFZ&`-F["4J>>PQB*<4,F<\S
MC"@RISI("U2.>1JD2\,9-L+I\+=,PK=03]Y;L#T[S].X0R?P'`<"E[8]]#I^
M8#3.,>R+-O*O,433V(C#RT6P?R!8]3)R;Y=JP?&^7+M6)'Q/?(U**J8JIF,(
M%Z]0NAX#@.!"CR*PKZPZ8YNAXQ5-%^]C:D#4ZON^W[J.0JDY`IQ0:/E2E4!$
M2]01/TZ]>G3UX$U2B82E$Y0*<2@)B@;N`IA#[Q0-T+W``_AZ!UX'ZX#@84V1
M.1/7[-*BARIIIXPNRBBBABD3333K[\YU#G-T*0A"@(B(^@`'4>!7EX)GT+*>
M,/!,E7GC:1AWUWV<=LG[(P*,WI5]J,TJ*NFBQ7L@FZ:KKF,9-8BHIK$$#D`A
M3`0H9B\JFGUWWMTPOVM>/9JI5ZRW"QX]ED)FZ(R*T,S:5"YP]H>@`193/4WK
MM"+%!(Y.G8*HC^#@<C'>U]]QK8J#AO:77.=P,62:'K%9R_7;M'94U\?/X8K"
M-KD/*Y`&(IT_3YZVM!]QLA*0Z34BQ?C_`#%51*)@L.X#@1,WQ5>(:8;/+1[5
MN]?)84ORC1HZ7!JV<+D@79DTEW`MG@))','01%)0.GVE'[.!5_X8S*.<\^3Z
M2<P,8R>/\J:<J.IUI%(MG<DJ.A>`5CPZLFBT:%=Q\"JX,9LW`I"-?EJ"4A/=
MZ"%^?`<!P'`IEVGQ5IO>?)CB4^T5?HN;)NS:=7&LTK!]YP2RRC!TR%JF5VMY
ML^=I^TSB4K`U.*2!)*'3`S,JZBW3L5'KV"'H-"+WXE;GDQNKI+@S$&)\M2V.
M[Q.5R2K&K(X1L5RPM4;U!T^SV>HVXE`KT?8\>J7*;CB^VW?G.<[E!51N4#%-
MP,@:HL+O)6WR81]3L#"M79WMK.HU:Q3,4G8HV&=J8;Q6,*\?PJ)8#ZFR;)"3
MN0]PAS$#M%<YOQ@A3-DS%$&MY2Z=>LJ7/8^Z6VF93P7%9ON6,\$2M?TGL.7(
MR$7-A22S/&HYL;,)JZ45F[,G%/RUZ2!@JL0%3'$`$`VT^`X&LOYGY>*A=^-$
M'+YW!QLLYUYW/C:9*S*CL%HR[/ZS5DZZ\@D6G[>>2=E[D%#B!4>T3?AX&PUA
MAG+L,5T1M8#@O/\`Y/,UYQX5518LE,/.]W)RQ5%0!02R[Y<[H`'U*"O3\'`R
M=P'`<!P'`<!P'`<!P'`B/HJ2&3U:QL2OKR+F(![D7XJ\JD@B_.8<I787/OIM
MNB)0*[%0I.GVI@41]>O`DI9Z;4+LR1C;G5*W;H]LY*\;L+/!Q<^R;NRIG2*Z
M1:RK5V@DY*DJ8H'*4#`4PAUZ"/`\T?#.'U#M%%,4XV448+%<L5#T6KF.R<$[
M.QPT,:+$S98GMEZ')VF#M#U]`X'#/@G""CA1VIAO%2CI991PLY/CRHF<*KJF
M$ZJRBQH@5#K*',(F,(B(B/41X&3&;-G',VL?'M6S%@Q;(,V+%F@DU9LV;5(J
M#9JU;(%(BW;-T2%(0A"@4A0````#@>96Q]07%H3NZ](J"]T2]OVK>M6H52T)
M^RV^&C[<^=D:6)[33\47HJ':G]T/N^G`]6JDDNDH@NFFLBL0R2J*I"J)*IG*
M)3IJ)G`2'(<HB`@("`AP(]YDU1P#GBBO<=9#QO7W5:?"J)R0K-"N2*'R(QW"
MN0:2D*FS>MTW<.^6:K$`W8JW4,F8!*/3@5F[$^/WQWZEX(S/EZ\*7JBXP:PS
MB2LU7C,AJ1L5;995!.,KU.AH]>->*J3EID1;1K)!#JHHJJ0.G0!$`[3P@:<9
MWT\UYRXRST\@%)G.>>;9GNK1,--/K"]K%/OC*-<05;L<N]0:?,GX>-010<'3
M2(05"#]OV\"Z;@4">?63]BE^/^)=*/D(:3W[QVYEW;91+XS9",QOD\05<-E#
M`+AP1)XH9`0^Z02F[OM#@6);P:X7?:O466P[BBT4^L7"61IDK69[(,?-2-3*
M>$6:/2%FV5;7;RYT'38HA^(.`@<0_!UX%;U=UG_6(*K7X6K06^7CO9P==A8J
MO0K=35?(3I9C%PS)&.8D%=2RE%TNFT0(4QCAT,)>O0.H\".FS.3?.IJ?=<+P
MV2-PM4KC6L[W6?H$-(XWUVCX"4H\J_>42O4V;G$;W(/&DW$,I2RG</F[40<K
M%[DTA]4P('18UW1\N>),CP.8,\YJP'L)IWC#<G(>J>XC7'&%$*A:,-0]:<IU
M>-S.6::.@7&C%G7K1TY3.07+$BX`N)T^O8&U:W<(.T$7359%RV<HIN&[ANH1
M9!P@L0JB*R*R9C)JHJIF`Q3%$0,`@(#TX%-NX%8@I3R^>)J8E(2*5>Q6-MZW
M</-*-3)RA9-E`X,;HMBOS"";A%FSF7)DD"]3IBY5./H;@7+\!P'`A-Y&)!G%
MZ7YO?2#AHU9)1E2(X7?,3R34B;C(51;"59DFLW.N505>T``Y>@B`_@X$UR$*
MF0B9"@4B92D(4/L*4H`4I0_J``<#]<!P/`Y68I2>+LD1RQ4CHOZ%<&2I5T$W
M2)DW5>D43`JV6`47"8E/ZD-]TP>@^@\"K7]7_P#HW]#CH/\`061&#`<+)F.W
M3:&9%-)&M-D-,NA1,4HF.]EQ76,IT_'&4%3U[NO`L8V'V`H^LV,)G+&06-PE
M*]"B<JL90ZO(7*UOE$V#^452B:Y%@+Z162CXQ=4Q4P$W8F/`K!SKY(]*<YXB
MGL29;P9M58*9EO&1K&>MSFK63%$Y&JOH=M8HV=_<[,2M%X\BK=XB/ND726(4
M2AW%]`Y&I/EDTCK^NFOU,SCN'CAAF)C5(+&MB;7BS/5+K*W.IO&]!6+;G3B-
M3!2]RDDU1&4(8>[ZDNJ'4>@CP)?LO)CH/(1,K.LMJ<2KQ,&Y59RKTLXJ5-FY
M0,0JJ2A#M"JF,0R@?M2F#UX$0-V/)7II?M)-P&V&]FL'VRZ0^!,B.&,;+61^
MQB/GA4Y%^U3E'*3-%V1JH@@8QA0[C@`>@=?3@85\#N3:)EV5W_ON/LL4C($%
M/YAUB70@ZJ_4D'L&+#137"#?V!XX6*DJO#6.?B7S!DJ)"]Z\$[]1Z=>!L(<!
MP'`<"@SRE-L',MI,438Y:W!QYL*_UHRA6K?':I8M1RT21U`5L[%]D>0R3'OV
MJS*D0+2RE3!">2.5\V6^ZB`FX'::&UK%N0=D,!YQQBQW5<X9QWI<OA#5%#*F
M#(Z@8)J6(7S?#;IQ84,A"L2UWZTY6C:)$/63J13,1PBW74+VCV]0E]H4R68Y
M3\BJ2[ALZ,KNQ8GA%&J9DDR(O<5XP=(-SE,=3JX;)*@14W4`,H41Z!UZ<"I+
M9S&4L\\G=DR^UUVH$O>:1F/`+;'$$ZQ!E.3F<Q0CZ$(,_D=W?(J32HWU>GJD
M,#5THCV,"M0(L!C#P-H[@.!K1^9ZIUJR[R:3.)\L=)K0.KN^UCBHET,FU6C9
MB`H%7>1%H!^V*DU23CW2AB%`5#J%,;O%,2AUX&PKAY5PMB?&JCI%JW6-1:L`
MI,I)28:`F6%9%0,A**E(J_340*4P*F#N/UZCZ\#(_`<!P'`<!P'`<!P'`<".
MNI\,VK^`Z1$,XLD,W:NKJ*<:F!"D;_)OUI=G$`3>R!`]]1<5!Z+&]3_[7]J`
M2*X#@.!C"WYLP]C]\VB[OE"A5.3>$74:QT_:H6,?N"-3$(Y.DS=/$W!R(&4*
M!Q[>A1$.O`\D&U&M8E[PSOB@2`'43A>:\)0#IUZB8'W:`=OK_L<#^!M5K2;M
M$N><3&`X`)!+>ZZ8#@(]`,40?CW%$WH`AZ=>!77Y1O(NXU\U4G[_`*DYAP3*
MYF;3D:6,:V@I,BQ9*\Q0>S=N>'JM?L\!)/E&->C%U0,1R7V^WN[3=.W@4Q0W
ME>S_`&B[O:2IG;2/8>)QW/:^Y1OTUL&\QIC*%L;_`"#3X`'54U>KUBM;:(IV
M2L)9#83@2:%FDTW8MP069JBJK[!0VD=9-N,)[91F176'+6I:7&'K\^Q/DL?H
M<U#M8?(<-'L7TQ%1SF69-6\ZP13?D,D]8G<,EBF`4U3AZ\"3O`UU/UB%%N:B
MZ#N7R'NQK?=.*)(*)HJF<D:K8FR0*Z3=</W.B9P@D?T/ZG$H=OV&X&P+2A1&
MFU(6P&*W&LP(H%/^W!'Z4U]H#?\`Q@)TZ_U>!Z;@4H>7-NLZR#H,@W3*JJ;/
MR1P(91-(IBHV_$RRGWU6SM,!!),1#JF;J(=`$H]#`$?]>T7T5JWYD'D9-8DL
M`_IU;<*7AYG$)A;"SNIMDHPMA;NH2L25LL:*:T)W("F5)-5=\'<GW?<$`L4\
M1L)D>O>-[4N+RNSFXZY$QLL\&.L,JZFI".JLK:;#*X\CTY"0*G+&B&./7L6E
M')/B$D6T>1%%V0CE-4H!EW872[&^Q65L#9PFKCE7'F5-<5KS^;>WXNM$7".T
MH[(["(C;C"3+"PURU0\A%S#:":]_:V1<`*0=%>GIP,60>1-J=?<\UZ@Y^E<=
M95ULRY:#4W$&:(?I3,IT:\R0*.:ICS+U5?.`K]J3L2"!V<=-02HNG;X@BY8-
M$Q`PA8CP'`@AY-*\2UZ.9XKZDD:')(QM**,D1"$<';>QDNENP$$;&Z90QQ4%
M#L_'JE`.[J7J?M`0G?P'`Q+GC,M4UYPYD?-UX;SCVJXRJDG:Y>.K$0YGK+*I
M1Z75O#UZ%9@+F4FYAX=-JT0+T]Q=4H"(`(B`0<Q-C;<?:BE7>[[.9:E]=Z)E
M^.9.,28)P`S8062L8XVEB1<LS3S#DJ[0=F)*94GHLZK2:CHZ+;L8DJQT6[E5
M8OO$"6^J&LF-=-==\5:Q8?4LJN-<.UHM5J2MQF@L-F4C0?/)$3R\P5HP3>.3
M.GR@]2((ID+T*0A2E``#MMA=?J'LQC61Q;D1Q:F$$_<I/DI6D6:0J%IB7Z35
MZQ(^AY^,,#EBY^%(KI"/0Q1(J8!#[.@5I91T'PCJIKI;KK*;>;YUW%^#<<V.
M5*U-L\NH6/@HZ,$QF!9";@!7=*+>PDB@9TY.9,PE*0Q>O`]SJ[XW-:9K7'#$
MCG?!56M>4)FG05QM\A8#38S'Y16%,;$09Q)&9*Q&V1*4F1N^<H%*51\DJH0>
MA@$0D0/CATC$0,.O=1$P?889&U"(?[`_E!U#@0:\F_CWU$A/'KN7+U7"%&AK
M-':[Y-=5^7DEK0_8QLPA7':T:]=M%+(DFNW;/2$.8IC%)T+]X>WKP.!X0(?%
M]8K6VM4K\=C^,R]7\F:T-<P-Z>SJ31R<ROC[U'5KCIL%<*9S^;]Y)?6580JJ
MJK471I%1N8156.<+T.`X#@.!4#NE@J7OFV4+<J=&;-RD_*ZAWK$MO9Z]Y9U=
MH";W'LU?V\N=I8(_.%C;VTRZLL`IH/X^.&.2]WL5=$4^YP/8Z*8FRUA]U1<>
M2]:W0K>):#BJ)J5'89TR[J5>J+78.IUZJUBKTURUPQ(2-VFK`UCVZIV\EU^"
M)6QP5.(BB*H>3U9RE3L!M?*_F3(SIO$T7&&V^5+_`&Q[!)'ESMZ]`8GQ_,R+
ME-JR4=+.9<[1$150*('!R(D$I!]`"'T-M1;KQGR\YJQM9O(10<`2UTP.]RE%
M7K'N*ZUCO&[F[Q,6]K:->JV5K7&9;<5^\0;]JO**5V(?HIE5*`=BP"/`V.N`
MX&LOYF5W%IW%U9?4BUT`H8.P1M)8LUM&F1*9$Y.88[NL'!UEXR8525EDYNP1
MW>R.NY;,D4G*()@J9=`@"?@6W:>;RZ@YRP#2[?C#,^/V5<C4EZBM%6;(-.;V
M.(E*[[;9PUG2!9Y5$9%VV41>&%-V[+VNB@*IC@;H$GOT@,#_`.>S$?\`&13?
MWYX#](#`_P#GLQ'_`!D4W]^>`_2`P/\`Y[,1_P`9%-_?G@/T@,#_`.>S$?\`
M&13?WYX#](#`_P#GLQ'_`!D4W]^>`_2`P/\`Y[,1_P`9%-_?G@?)?8;`+9%5
MPYSEAYNW;I*+KKKY,I:2***1#**K*JJ392)I))E$QC"(`4`$1].!Y/\`3#U'
M_)]M;/TI=<OR5>.O@M+-^>[&?Y/NGW54/AMIG\I_IR[KJW4#VRJ"?[AO3T'H
M'E0W_P!#Q;&>!NQJ0+0JY&IG0;(8<^,5RHF=8C<R_P"6?M`N=),Q@)U[A*41
MZ=`'@?PWD`T.*@FZ-NSJ.5JLJJ@BY-LCAL$%5T"I'7136&Y^V=5$BY!.4!$2
M@<HC]H<#S%_\DFC&/\8W?+1]I,&7>K8]CT9.QM\897QYD.PIMUWS&.3390-:
ML[U^^=F<2"71%,HJ'`?N@8>@"$??'!O7KSE7"4S35<M,8Z^8/M<C5\IL<FNX
MRD3$).WB?MMVJ<6Z1F90"J.W%/526!,IQ.FD``8"F`Q2A8+^D!@?_/9B/^,B
MF_OSP'Z0&!_\]F(_XR*;^_/`?I`8&_SV8C_C(IO[\\"DRUZ2::9"WCS=F"!V
M8EM?D)Y;`^8I65U_V)J6+BY'ORD;FBEY!A+#)P,F6>/!3L6Q@'DLV;K-0>/6
MS=0YS??*8.-3L(:KQ.Z\S0ZSN3G:PXL@<.GLF68*Q^0"\_F[0L]R58P%!K%?
MB(_(,;+-9*,@:VZ?N").P8E;221?;[NA2A.QI@?09@FR28YWFV:4:W2:1R;;
M>[,2)&+5!P#M!LT*GFXH-T$7)04*4O0`.'4/7@=T.*])A^W9&X#_`/I;^9K'
M[0Z#Z#G(?M`>G^QP/Q^:72`?3](NU#U'K_+VS./4W[/^7#U-_5^W@5V^%N^8
M+QE;/*;6&^4L?1$`U\D.7AJYYS*\;-KR<&:"K0M9-*RV:R2$Q94W9^\QGBSE
MP913N`3B)1``O+_2`P/_`)[,1_QD4W]^>!K^_K`-UQSD7%FI+FJY%Q;/1V/]
MD)&_WF28Y9Q_'O:U2H/#V1"2TDW&1N<,V<+KJ.TD4$BG%RL[.BD@(**E`P6]
M:E[S:J[":V89S%C_`#)26E/NU#@GT(UN=PJ5>M;9NU:$CCHV"!<6)V[AY0BS
M0WN-UCBL3J'>`"/`D1^D!@?_`#V8C_C(IO[\\"JOR=C)9;<ZQVS7FW8LOUEQ
M/D%]<WT(UOF.).0+&'?UMXUF$Z_-9$I"4U#`O3G;9<Z4DB=!00,'?V'*`4XY
M7M^4HO*VNF!\O,:9A;7+=7R41%JRSCZM1]#5A=E(B[E+9K/3\C6ZO9TOLA5J
MM"(P*4TL!$BH38J`S<*"EV]0VW4L]8`:H)H(9HP\W;-D2II(I9%I:2#=N@F!
M2)IIDF"II(HI$Z```!2E#]C@5%;D^4^W5S->"<-:4Y*TNND5ERKWBU268[_D
MB"OM-BB8S<IKWBMPS"FYAQZPD;/%5M<)'V7,TS2!%)7W%$P*)@"OO+?D@VJO
MTK4*[;<M>-G)&(H+*=*L5T5J=YQ1B[)XUZ`MB3@D_BM:4\CEVB5[,TC$?DBD
M^%HFGWBF!E?7J$_<H^:ILP0AUL$XRUFR`95.5/8F^7/)1J/A->+.S75",3A@
M@Y_,"<\,LT*0W50S($53"0>H%[S!@J<\ZN>*_7Y*Q.M7-$';>*BW$L[CHOS+
M:TR$R+=H@]<N46L>WQF8[UZDBS]$4A.=0RJ92`8PB`!CC:7RZW?)VN*U<<8R
MT1LL?EX*BP806'/*]B.S9.9KKR,;:6:;B"O&K!ZC$G2/$>T[&4$$D/O@`@H!
M3`'LXCSX9KLE<K5DKVIFG#UC9$W3A)64\N>N-3!LU;RWT;WC,[;CF%GSE(];
MN_<,9BFF*;45$#KD.F8P>H=^;_8!JW473UCT#?&(H9,K5EYHM8Q<J`51R3W2
M`XQHW1]LP-P,'4X#VJD].O<!0POG7RY9ZS;B6R8_5P5HE0'TN]KKB/E7?E-U
MHS%"@M#S32;`MFHT3*X7E)B%*O'I]Z36PL5CG`/O]H"!@\$Q\R'DQ:O&R[R1
M\5EH:$63^5#165*]'/'#83=%U"/:7N1F:S(%;)=5#"TK,JIV%'\5T]0"]G2K
M>^B["Z^5;)64,F:YUJ^/I:VQ<ZPQ[EN&F**Z1AK1+,*].522L;N*GW418:ND
MR?%%VU;JE47.3M$I2F,&*?*%Y&H_3W2[*&P.`+[KO?,G4I_24(2J7.YQTY"R
MR%CN,+79(GTFJW6OS[]XU82:CA)-LX[_`,4(B4Q0-T#CQV-\)9TFJCD_:S<R
MO9KB6SVH9"I^`C9!QU1<!T^>8M8Z<C%I2CUN0:R>3G49/$([0_*R0FF[=9!(
MR"")BG%0+"$MA<`KD]Q#..'UD^]1/O2R72U">XBH9)5/N)-"7O25()3!]I3`
M(#ZAP"6PN`5@,9'..'U2D541.9+)E+4`BR)Q362,))H0*JD<!*8H^I1#H/`K
MW\K.>L"SGC4WJCXW8;&,<N;7#+$:K*UVV5.XRT,\_)IT0YF]:C[`F[EI!J*I
M1^&0Q%E!$"AZB'`A=X+XAJUV!\E$ZU!C)-;0EXZI.%N,=(&^'<*RGH=BUM$2
MK&O*.%G$+''73<*('6`%ERK=IA-[(#P-CG@.`X#@4^[<XHS*CN19\STK`ENR
M]4+UXY<KZQM9>BR=':2]=R=9,D)66";RR-LM56=-8!_%J']Q\U.N=N)?]S,/
M0.!GW0:T9L@,(:[X$R_KIE3'$_BC6O%-+N60;9.8^F*S+9`H5.KM1GF$4O7;
ME.3LDC*.(]1X@]7;(^Z41`Y2F]1#`6GN*L?YP)Y4L1Y4K3.X8ZR#NUD^MW&K
MR"CI)C.0CZB8[!W'NE&2[9T5%<"AW=BA#?U>!)5CXY-3XE=RN2`R6H24?4]U
M+,I38;/DG%V%U1&K2.HZ<_%2>2W,;/I5F/8(MF"+M)9-!!(J1"@0`+P)V\!P
M-6OS=8FQU.[B:HK2N-:]/_E;A[8F!L[L(EBB^42M;2!KRTN^FC*-5D@9M%SE
M]3F,H!^A0#H(\"TC3_QBZ&8GUNQWCJH:SXJ_)N'5LLDB5]#N;`Y7EY>;<%F)
M%S,6-U)2[YT[,P2*8YUSI@5$I4NB0$#@21_0%TM_FR8>_@=&_P"]\!^@+I;_
M`#9,/?P.C?\`>^`_0%TM_FR8>_@=&_[WP'Z`NEO\V3#W\#HW_>^`_0%TM_FR
M8>_@=&_[WP'Z`NEO\V3#W\#HW_>^!R$=$--4$'[5+6G#Y6\HS-'R*`TV+,D\
M9&70<F:KD.D8IT3+MB&$/PB4/P<#(:FLVNJR[9=7!>)5#,UB.&B9L?U86K=P
M1LJS(NBR^F?#36*V7.3N`G7H8?V>!W2&",'MFJ;%OAO%2#-$$BI-$L>U)-LF
M5!/V40(B6(!,OM)?=+T#T+Z!Z<#ZC@["HD*F.'\7"F0QCE3'']3$A3G`H',4
MGTGM`QP(4!'[1Z!^QP,2YYTWUCSOA3(V%,D8?J3C&V0H,8ZYP]5A&%3DI:-9
M.FLN5LA+UQJPE6RHNXU(0,BH0XB4`Z]!X$+?'EHWI0;2W%477<`1+JDRDC:K
M*QA\H+J7^R-)!O:[-`IJR=BFP5DG[INR;F23%8YC(I&]L.G0>!,+]`72W^;)
MA[^!T;_O?`Y2^B6F[E!DU7UKQ"HWCDED621J=&=K9)PX4=K$3Z)`(`HX5,<>
MO7U'@&FB6G#$S@S36O$*!G3-U'N!3IT8`JLGJ0HNVYNJ0_BUTA$IOP].!1G0
M-4GFT.[GD=I>*<-Z78-QUAW*F%L#R^3%L;R^1LXR,?%X6J5X&6K,-(2I<803
MY*/OJS-%1=H91)1%/J`J(F'@7#XZ\8^CN.JXW@VNNV-K#(G_`'3/VRRUQC*V
M>U3"GWG<S.R:Y#+.73A4PB4@""2).A$RE*4`X'N_T!=+?YLF'OX'1O\`O?`?
MH"Z6_P`V3#W\#HW_`'O@/T!=+?YLF'OX'1O^]\"FSQ-ZWZ^9.RKY:JU=<.4F
MVUBB^2W*+&CLY>G03FM0,<K5:Z52.J<LU3`'S=LJ4P+I="E:*&`@=>HCP+D_
MT!=+?YLF'OX'1O\`O?`H5\]FLVM6-L6ZH5:L8=K=1K&4MC9NM79ACVLQ#.;L
MQ4,"Y<&KQR:JR!_;.$^](0%2?C44UCG3_&@00"XC7CQHZ/8WP'A;'L5K5CU:
M)I>,JA`QHVB))9;"1JA%(N3)2\_*%/)2[XKETI[BZYA5.(^H_@`,Q?H"Z6_S
M9,/?P.C?][X%8&V>B>B+_=#7.`V=UCH$[KSD#%+C#^#I,\:]A*5C3.T1=[;=
MY*I6)S!.6!4%\VPES($2#P_QU7D"X2(8JJH%4"9&/?#KXV,77*E7RFZHX[8V
M/'(*FHSAZ67F6M8=+,%(L\C%1\Q)/63>2".6.@5?L$Y4S"`"'IP,[AH+I:'3
MIK)A[T^S_P`CHW_>_LX%>F;,1XRC/*IIW6H;%5$1KD#B*5<QT,PJ4(SB8'W2
M92B5Y)K'M&2+5,ZK%Q\101*('25[3`/0O0+<OS%81_S.8K_B]J/[T<!^8K"/
M^9S%?\7M2_>C@8FSYA'"[?!>:7"&(,7(KH8FR,LBJGCZI%4252I\R=-1,P1`
M"4Y#E`0$/L$.!K;P.(:5DS2S!.0;I7+'8V[VM[0RK]O&RRD'7ZV[QN,`VQ\#
M!U781HC"*L!.=-H<QBG./>!>X3&X&Q_K[J;KAC#">-*-5,/44:]"U9FK'!8J
MY"6B8#ZXHO8WWS9V8CEY&04/)S"Y@,H;J`&Z``````9B_,5A'_,YBO\`B]J7
M[T<!^8K"/^9S%?\`%[4OWHX'C,BZ[8#FJ%<8V2PCBA\S<UJ:*JU/0:VB"O;'
M.#E+[S*-1>)=3E#[R1RG#\`]>!4)X==6==<M:+8OG,HX'Q?9K'%)%@DGLI5B
M.W36/;1,0Z3C?DRJ?U19%FY>*@0SKJY[1Z*"(AZ!B_S\Z=:L8]\6^?;52L!8
MPK-DCIK$P1\U$5=BSD60NLIU-FX,V<I%*=(RS1PHF80_VAQ#\/`MPI&CFG\]
M2*1,2^N&)'\F_I=26=O'%0C3KKJ%KL:D4ZA_;ZF,":90Z_;T#@>F+H'I60.T
MFL6'"%ZF-VDID64O<81,8W:5(`ZF,(B(_A$>O`!H'I64!`NL6'"@)C&$"TR,
M*`F,/<8P@5(.IC&'J(_:(\""_E&T\U3I7C>W-EJU@#$4"]B->,J'8O$8)E`%
M:#+Q7_&BAI=BB#MD+WVR^XL7J?T#UX'G/&-!P%3W8\@5/K%8KE6K]5PKXWH"
MO1T(@9!9O6HC!EYC8...D0H-FT/#LV?QF"("95,B9^\>T2<"\?@.`X#@.`X%
M1.GEY98?4\J&1[+!VF1B:5NAD^V2416X->6L[^'9XYQY('4A(0QVJLHLLQ_&
MHE(8/>3]2"/4.H4WVV&E,X>1BP;!N-?7=VI^6,AX)3JD/M?I-F=*\X=4BH!B
MR;MZSD&IYGCX..C)SL"0:N%HQ9!J<I3'*("<HAN#<!P-:7S<-WKO:#45LR5(
MV%;'N4BO7BJ#5PC'1GU6$*_E')'A#H$:1J1P554'H!"%$1$`Z\"\O48T@.N>
M+TY22C)EXVB))B:8A4F:,3+MX^Q3#)E*QZ<>U9L"M9)DW36+["8)=#_<$Q>A
MA"1_`<!P'`<!P'`<!P'`ZN<442A9A5)86ZJ<7(*)+@!A%!0C18Q%@`H"813,
M`&]/7TX$-?'`L1QI5@U<A%B>]%VU4_R%E'"ZBJF0[<9==195)!0YG*PF4^\0
M!#NZ?@Z\";W`<!P*BO'%0$XO:_S"9/<1<G"RM]WEJM:,Q6*Z1AW,)CO5O!:4
M/.1;99DU1!S.N+,[7=+$.H*QA)W>@%.<+=>`X#@.!1IX9G#-UDKRY+QX,@9J
M>3W-GL?34?CL1`D+64SF;H]``@&4(83?9U.)A_#P+R^!KO\`ZPA`RLU6/'L$
M>T541/O!`0ZCT47:C)I(3N+\A-HI)V=D)71?EJHJ=I4A!4X)F[/O`'`V`JJV
M59U>MM%^WWFL##MENP%0)[J$<W24[07$5P+WE'IW_?Z?;Z\#ON!X+)V+Z#F:
MCSV-LG5EA;Z39D&Z$S`R)G*2+D&CQO(,G"+IBX:2$>_CY!HDX;N6RR3ANNF5
M1,Y3E`0"E+;:IY5TMV(\<2^#-I]BVV,LU[M5#"N0L$7FT57(&,7F.K;`V%XY
MA8=S8:8OD6*58/F22B"YY]RJ``)3"/7KP+ZN!5IF:(3;^436*P.&SM8DCABU
MPC54%VR+1%W&R=B?BJ!2**O5U2(2(E.F=)-(0.02J&,4Q0"TO@.!B+8+_(+F
M[_1%DG_`R:_9].!J6XNGMD&GC_HB<7F#`4-1U,;;67EG5)*B6R?O;NGU>X02
M\PW!FID"`9R3-TF@<BKQ=D]4;F/VHF1,'><-O/%DTWLF,<<6)HW;M&L_0ZA-
M-FK0JQ6K9O*5^.?(MVQ7(BX*W137`I`4'O`H!W>O7@>\X#@>3OBQFU&N;@@"
M)T*G8EB@!A((F2AWAR@!R_>((B7[0]0X%0/ZOS-.K?XP,!7]5NY1:7V,_*%@
MHZ6<N5'(),8Z$E#@Z>`5V\!M/Q#MN*R@=RQD1/Z]>O`ZS]8I374\2NR1T&SI
MV9H\QA)K(LFRSMR#&(R75Y6273;-R*+*E9QS)58X%`1`B8C]@<#.N-_+?XQ&
MV.*"FZWSU::*HTFID70>9BIS1PV4"!8@*3ENXDTUFRQ!*(&(<"F*8!`0Z@/`
M]HY\NOBY9IKJN_(%J.V3:J,4G)E\ZX^2!NK)-E'D>FM[DV44SO&J1E$P'IWD
M*(AZ<#KOZ8SQ3=.O](EIWT$>G7\_N.NG7[>G7Z[TZ]/P<"#/DT\G7C@S9X_=
MO,2XRWTU#L^0+_@N[UJI5YKG_&Z;F6FI&.%)DR3.I/`FD*R@@'<<0(7[1$`]
M>!DGQ8Y7QAF7:GR#VW$63:+E.H1T)I74E+#0+%&VB#/.06%ITTI\*8BU%FD@
MQ$'J94G"1SHJ'34*0>I#<"\+@.`X#@.`X%7OYMI'.[/RJXHB<BI5"6OV2(JG
M15_8L6JJ=0D7&J^$V4>JZ9N55T'98%TF1!WU,0ZI4SB7VCB':%1^(,/WS:',
M-8PNE@7%&N>P&G-IP1%;F;2RUNGYIM=!B(M"RTNO:I4<UG>%F8[)%503<N)B
M739,V":RJ"8.5R=O`VLN`X&MEYKO=-LUJFBTBXU](KXTRDFS?/J\$^O#@,O"
M`X6;"1)=W$-7A3%2>.FY#+@A]T@"80`0OJU\:.&&%L=,W@+`\;UU!-Z"K.;C
MP^:"Z_R_BL;(@TG6D<+D3?%3=))*E;=@"0GH4`S'P'`<!P'`<!P'`<!P.NEQ
M3")E!6.DFB$<]%51?W@1(F#97O.L+<2K@D4O43=@@?I]GKTX$6M%`,75'$0&
M!D'_`!?9A)]-7F'+`R)KO9A0.T7L#V1F5$%$1*8OR%CJ``]/0.@`$MN`X#@5
M`^/"W]VZ_F%Q4W>,G;*E;5XGNJX-8]-LJTG<HZXX[=R+5T]43^HR"@1U:8G'
MWEG!$S',")DTA*@D%OW`<!P'`H]\.)A/E+R[&,NLY$?)[F@?>70=-ECA]!JW
M;[B#U)%TF)"]"@!RAU``$.I1`1"\+@4$^?..=*T;028CHU8\M%;^XW0C)Y1T
MW"(A7DCC?*8MT96.651,_+).628D-U`B16Y^\Q0.`\"]^OBX&!A!=F3.Z&(C
M1<G2*4J1G`LT16,F4ACE*F93J(``B`!^$>!V_`<"F#RRA_YY/$:/X`\E^(_\
M&[5P+G^!7%EBL-W7D?UKL17;A5TEAS("*L<Z.J,:T0C)(YD9".3052[99RI.
M'35,J!TQ13*';W``@%CO`<#$.P8],"9O$/M#$.2A_P#Q,FN!H(U/8:Z*ZP;7
M8:';"1QM):SY1SWC3$F+YG(.H%,H^0,>W7\AYYFS2J&5L<!F>[QUS1DI&%.[
MB+(N9!PR]XBR!A$@A_H)XO0C&N-,>-H0&X0S>C5)"(!H<%6H1B4!'IL`;*`8
MP*-P:E)V&`1ZEZ#UX'N>`X'D,A?V@WC^\^R_@Z__`'E>_@_#P*2OU9D@%\)V
ME8@Z,Y]R%RB84U)0LLLR'\]&0R_%463<+(-"]"@HDU*5(6J*A$E"BJ4YSA;5
MLQKM1]J\,7+!F19&VQ-2O#!2,EI&C6!Q5[0W:+I*MG9(R<:IJKL1>,7"J"HE
M`>Y%4Y?P\"MS)/CDUGP#A.=L%[V@V%I.)<9T:.9+KVC,%2B:]%UVGPWT:KQ"
MDA.5,K+N:M`(R9%5,<QE%0(4#&/T$,QZ;Z?:\V[5O!MOR]K%C2=O]QQ]!VZ:
M>9DQ)B6=RL@VM"1IZ!A\B3$9185A)W"O5Z1:L'RQ&J'>X;&$Q0,)N!)L=)--
M!0!J.IVMHMBK&<%0'"&-11*N<A4CK`G^378"ITR%*)NG42@`?8'`@9Y2=:-:
M<6>.O=;(E`UNU[K-T@==LBN8J?8X3QG\QNI]&%(P&]RLG3<(J)!VF34`Q#E#
MH("'`QOXEJ=C?%^T_DHQI0*+6:82-D].K<1.H@V3B3U^YZ](KQT:[8MH2/)#
M33*RQDRY59@Y=D(@^14*"0*]I@O:X#@.`X#@.!"7#5;KUOR_Y`JO:X.(LE;G
M<UX\CIN`G8YI*PTO'N=5\$$<,I*-?)+LWS1<OH=-0ABF#[0'@9#::8:A1[N,
MD&&KFOK)_#/F$G$/6F'Z`W=QDE%&`\8_8N$8`BS5Y'&`!04(('2Z?=$.!)?@
M.!K5^;]W$PVP.LLQ*6.!9NS8NRI'5RK&>E0M]B?GD8ES*NX5!5,2`R@XM'W5
M7"1BN&YS`8O7@7\X$0!#"F*A!9TX!U0JQ)E5?.57KT2R\4VE"E=O%S'6=N4P
M>=IU3")E#`)A^W@9;X#@.`X#@.`X#@.`X'73#`96)E(L'+AF,E'/6`.VJAD7
M347C95N#ELL3[R3A#W.XA@]2F`!X$9])H52MZO8IKZJ;9-2$8V.*.+0I2I+F
M872R-A>#VJ*@9P^]KWE3"83&54,(^HCP)4\!P'`I\\>R)F&ZOE"BTG*BS%')
M>(Y!`BZYW3XKF499(6>GDG"G515SWIE31`1Z),4FZ9?ND#@7!\!P'`<#4QT?
MONT^NN1,\YDJ-HP_*X&V9\YMKP)>,>3=1L(9$CD[E=F.+Y&>@+8SE$X=,S-Z
MW3?H)*MSAV%,F8PB/3@7Y[]9^ON`<'Q+G#HUU;..6,N8@P9AUA9DC/(L]ORM
MD""JKF=?12/1U*Q%%K+U_/R2270_TZ,7,`@(`/`IS\G.GWDJRU@*,G\MV+7#
M:VEX-L$[FQUC"I,K#KC:X^:J.+[^A!9"KV1_FS?R'=%DI,KLL*=(B<J?L`RA
M!2+U"#[NL^1Q"NIV(FI&TL%0(JC1UC/?W.R]+!D[CH^H-I!U*/(B>$7\0VD%
MB'64]]?JV#TZ]OIP.PIF$,U9.W?CM<)G:>]4B.L>C>+MRX>^CE#+49%0%2GK
M`QB+56W#.%NS3%DD\82,XR*I+.V8J*(G(")P(93H$[6GB0S#4Z?9\E5SR'Y<
MNS%.A6^045FLJWFTU$SMFVD9=)U!N#3KQI&(-GGNHBZ(*B[=LFF0@_B^G`K'
MQ+"5>XAX8=@#V+-TC<\E;G:TV0(?(^>LLY<A&,=+5J]1\U(ILK[)/8!H\E9N
M-]UDXCBD%9B("J`'#IP-X+@5$[.YBI>,/)!KDYO]L3IE9A\%WBPR<S-62/B:
MXVC59269OWCAG).6Y10:+MFQ':S<%%1.X:%,`!VCP)E5S>74.W6ZN4*K[!XU
MGKG;I)E#UNLQ<X5W,2LI(-SNF;!!FDD94CE5LF*G:<""4GJ;H`AP)'6FT5^D
MUJ?N-LEF<#6*M#R-@L,W('%)C$PL0T5?24B\4`IA(V9M$#J'$`'H4H\"KO,?
ME&TALN`<BK0^:X1TE<<67YO!*`FJ";A"3IJ_T>2.H'4B<=-!*I?%4ZB*@@8!
M*!@Z"%$%+OV#I#0JO8OG;GBHUSK&%]P*;/IW6L5ON=VE[,-28X)$762C'SM.
M8<J-E19%17$5&XE$3E_:@%U^*?,;XQ\=XHQ31KEN/BB%M56QECZ`GXDY[(]/
M'3,;2X!.0CE'4;`/&*KEDHJ4JI4U3^V80`W0?3@>W)YQO$TH"ID]X<0J%054
M06,F6W'*BND`"J@L8M9$$ED@,'<0W0Q>OJ`<#VU1\M^@V19)BQQGG6(R.S>N
M()D%AI\?(/ZZUD;,Z(S@8UY).D&/M2$DN80(D!#&*!#"?M`HCP,@Y,W6UY;0
M&3*U*W9"$(V>R^)V-DD#-!K4]DB:1CX*(J%?D(]Z^<R$J_EK(U03-[!$`5,)
M3*%,'00BMX-I!E;O&#J38J5:JT[J[G%N*FC1]2T(IS#.5Z3C&HT.^5QP@1DV
M2CYN+R'6I1I+&*F#CZHV<&,<YCF.8,^>53;Z_P"BFD&6=F,7UJI6Z\45W2&D
M)!7DTL2KNU;1=8&M+&E1@W#24%%%O*&.'LJ%-U`/7@=3!Z@7G/ETH6;-JL_6
M7*5-CRUK(%/U;KL%"5+7B!LX1Z$E%25FBTV:]ERPI`OW/R6);"Z<)-G222I4
MP,3U"R8I2E*!2@!2E`"E*4``I2@'0```]```X']X$"O*/')2WCLW*C5U*ZBD
M\P#D!$ZEM441K1`&(5$!F5$C$4(QZA][M$!_J\"%?B[<LGFZWDY7=HSB5L^)
MH<1X5\].2'2JIM94G%>:QD`KU5C7J$RXE_EN.XQ7/<D3J)FYN!>3P'`<!P'`
M<"&^N3MLXV!WW016(HLRS[C)%VF7KW(*J:I8#<IIGZ@`=QD%B&#IU]#!P)D<
M!P'`UE/-C%0]DW.TGKCMO(EFI?%F<8&NRH(M6L'&O;:X@X%525G91L>+9`9(
M_HD*R"RGIVG`!X&QKC6"7J^/*-5W)52N*Q4J_6U??.U.L<\#%-8D55!8KN6@
M'7^'WB!%#%+W=.OIP/;<!P'`<!P'`<!P'`<!P(PZ;*-%M<J`HQ.51J+N]@D<
MA2D*(ER-;BJ="E^Z'14#!P)/<!P'`I=\<[E1UO[YA%'#2RIK_GMP25.0L<&^
MKI))BCC.7:M#03%\T:B^@V1FYT$I!+N2>G3,8HCT[C!=%P'`<!P-4W3O`F8,
MR8RVK>85<P=CM^-_/E*YU7J5\GW=>JK&M8>R!!S$ZWC9!HC*KMW4P@?WSE3:
M@910!Z`<W3J%X.-=:LM6[.[+9/;BQ8TL]LH$;,0.`,58Q86-QCS#3>QI1R-K
MN2UDM@1DE?LCV5"-(@C(+0T;]%8JN&S;W`<**\#F^1K8["VLNHF8+;G.\L:#
M6[K3+IBRO2CYI(/RR%WN-`MPP,*W:1C9V\6</$HQPH`%)T`B)A$0Z<"L7:'+
M]KW"U#2P-"NS:D:@6_'M.QQFG<W9*IRE33L:$\SKD/6:3KEC.=DZQ.9`D+[-
M*)M_JCT[&)58*F*U5<+F!/@=5:*Y@O&?D1-B;<')VGCW'\QHYCC#D?!S^0JC
MA_),^G\F[%F*Y5->XQ21GH[#CB&J[8R2*\\H1%RW.=J"Q$7`I!P,'[TX<QYH
M]Y%<;M%]<-?X;72S;D8QU=QS5;-:%$+-3:)39EQ"V9_&Y",QL$B^M61E9,1!
ML)F+A,"_#4,B*9A"MJA1YR3_`(:)9K<7<A#?I,:A5)/'L#59&*Q;CZ9J%5G2
MS"%9LCLQV$]89!Y,J'D",C'01$?VQA]>!NS\#']PQ/BS(;V/DK_C3']YD8AJ
M\8Q3^X4VN69[&,I!1NJ_9Q[J:C7J[)J^5:)&633,4BIDB"8!$H=`X\5AO$,%
M,)6*$Q7C>'L"#HSY"<BJ/6(^81>G1!N=VE)M(M%ZFZ.@4""H!P.)`Z=>GIP/
M>2$>PEF+R+E6+.3C)%LNRD(Z0;(O&+YFY3,BY:/&CDBC=RV<(G$ITSE,0Y1$
M!`0'@8M+K[@0C)*,)A#$)(U!$K=&/+C6F%9(MR&(8B"30(4$$T2&3*(%`H%`
M2AZ>G`BKO/A?#D1IQG$D5B7&4:G&TMPO')L:%5&J;!=268G.NR30B2$:K&.J
M8PF(!3=QA'KU'@2-QOA7#;7'E%;M<28Q:MR5:#<)MVU!JC=NFN\B8]1VLF@C
M$D234<J)E%02@`G$H=>O0.!ZU/">&42K$1Q'C%(CE=5TX*G0JJ0KARXZ`NX6
M*6*`%5U@*'><W4QNGJ(\#YL<'84C`Z1N'\6QP`\2D0!CC^IM`"00*8B#_HWB
M4P^8B0Y@(K^W*`B`#Z\#EML.8B9*>ZSQ7CAHJ*IUQ5;4>L(*>^H\;R*BW>E%
MD-[JD@S17,;KU%9(AQ^\4H@'?TVCTO'-=85#'M0J]$J<7\@8RKTVOQ-8KL=\
MMPJ[=?`A(1HQC6GR7:YU5/;2+WJ',8>HB(\"HSS^5"R7WQ=9XJ51BG$W8I:9
MQ::/BVG:+AR6+R16IJ0,3N$I>C6+CEUC=1_:)CP+8<7'(KC/'2B9@.12B5$Y
M#%$!*8AZ_'F*8!#T$!`>O`]UP'`BAO7&QDOIOLO&3+,TA%O<-WA%ZR*NU;&<
MHFAG`^T#E['RK1#N,`??4;+$+]HD'@5M^*^+=/MR?)%?'WU(KQ]5O'[0')9!
MZJ];J+T[6A6R+NH)Q]-8M7<&JMD,Q2.$E%@7<IK"/9T`O`O3X#@.`X#@.!!W
M6`$?TDO(M[;M)PH.QF*17;IL#M3L3_H>ZZ`5!9R9RL62.JD!505*1$"%."?:
M(D$Y@G%P'`<#72\Q=1E+1MOH^E$RM9CY)RSMD9#,YNRQL._DY56?A7*81L>K
M\N5>-V)$`4=.$6CA-HF8#J`(?=$-@&C)S*=4AB6)NP:SOL*FET(V30FF2<@=
MTN=T",JV@JRB^$RIA$YP8->IQ'J3KU$0]9P'`<!P'`<!P'`<!P'`B+HE,2<]
MJQC66F'BK^1=/<C`X=KB`JJ@VRG=FJ`&$H%#\6W0(0/3["AP)=<!P'`IT\>S
M5TQWD\IS%2.8,(YOD?"JD&HR,=-228R$1D:4?2$A&"W3)$/?R@?/4?;(LY*Y
M22(Z$Y#.#()!<7P'`<!P*,?"![WPO)2!T%2(_P!)ULQ["YUI0Z;CJZ@O=!))
MTB2*1]D_W3?#.<3#ZK=I^@<"\[@4"_K$[EPTU*UW7:.%FJP;H4-(%D%5$5`3
M<8-V(;."`HD('`B[=4Y#@'[8AA`?0>!5!L7E/.6>]._'A2<DUW=>P1L[FK3Z
M0>I-X;0L]5ODU&VYQ)51]7$97,8WI=\8D,D+)*41C8QPNCWNG*"8"3@=%L!?
M\LY-\G>N%H+;,U8+RTRBY%:"M-LLNI..<C.#US`&U3XI6LE',=I==_B2%6FI
M",9%F`1<]55A$[0YDE3AZ:O1^PS?1+:@TKN[LFBRMI=\W5O@RYL\=%RJ2C:'
M+E=HXC;+,K:_KY%LECM"40@E)M8)5@1'YX_`4;`5/M#]8].J]1\1%JE6]=:6
M/(F\^J%ND25JE8UK;62%MBU[".)F0EJ58)6PRTRLH@DFY2F640J@</N(&]5!
M#=.X#@.`X#@1"WX_D=Y^_O&5_LI&\"1V/O[0J1_>A6O[#,N!Z_@.`X#@5\>4
M*-/+Z99=CR5A&Y>[5;FLI6UW_P!+^H-V6.;L_=*MY#L4^-(Q;5L=XT$2B`NF
MZ91]!X'WUIV\U+A]7-?7$GM#@N-:Q^!,1G>.+9FK&S"39I)X^KP&4L1W5C0*
MUD2!T^3W@3M5[NO3@9L0W.T]=.4&;;:_6IP[=-GCQLU0SKB]9RY:1T@I$R#I
M!!.TF56;,91$[98Y0$J3@@IF$#@(<#I&>^>C<BF[6C]SM4'R,>FNJ_59[$X@
M=)LDFI2F<J.SH7`Y6R;<IP$XG$H$`0Z].O`C%N1N[IU:]3MBX2D;8ZL7.ROL
M.7SZ77(G8?%KMY*G2AEO>033B+'*R`)@50`.=)NJ8G<'W1$0X$6?#M>Z;D+8
MWR'63&UHH5XQY+-M)'M;LU`R"C<&)%&>N*%6EJS(12`F+#/:_(5@W1T80/(I
M+E[BA['J%^7`<!P'`<!P(,:NL'3397R..EVC1NA)['XF=,G"#5J@N^11TYUQ
M9*+O5D/QSQ=)PU.D4ZWWRI)E('W"EX$Y^`X#@4;^6:MFG]@?'=)L:Y`61:H9
M@M3RQ1\A'1CV>=5^R0K*#C6U>2`A+=)@,^0AG;:)72%-`OO.>Y$G00N3QZ>7
M4JS<TZ$<$F,M:`5^DL'$:Q%N6TS)8\2-'0BN588\$A6./W55N]0OW3!P/:\!
MP'`<!P'`<!P'`<!P(CZ*J.UM6L:J/GP2+HSW(ON/"L4(T%0#*5V*F'PFQC(I
M>TD!2=0'[_;W#ZB/`EQP'`<#7PINX6/]1-VO(Q8\D4'*$S6[;?\`%59KDEAV
MHHY.9.+11\7S%OG:W+EK[ID>`N4DRN+15O'+IF66]T3G4`0.(!^WGGFD$)*;
M:,_&EO%+,(R=E8MC,1\'1E6DJQ9/E&S"3`GY1@HP5D6Y2JF:J_CFYC^V?J8.
M!Q4_/A)+(@X1\9.]*K<1,`.$H&AJ(")#"4X`L2S&3$2&*("'7J`@(#P/T;SV
M2Q&9)$_C%WM)'J@H*4@>O44C!0$42.%A3>&LH-E`1;JE4/T,/:F8##T`0'@9
MQKGG$UN;4:`MF<,*[::^2MAGY:N,*M;\"VVX.73V*^(L=9C*8T0MK!5D=C)-
MCBHO\82*J&3Z&%,3"$=?U<Y&0?8HWYNI8Z:952\^138*:J"LW$N:Z[<L1>1Q
MG8+5M^[=24$\;K."E70<=JG?Z^O7T#8MX%&OZP!78R>TVQLZD#6`%JOLU2;+
M$_0X])ZU&4;XQS%&)!9EE1`T76_B2JPJ.4^IRN00(`=#CP*9GLFD;6KQKE0:
MY[?)J9EU`2<K)ZQZVA"1\=79:;091/Y4&L!+%).V*;M4K%@\[D'8#VK@`&'H
M$<]ICY4I>\V#[/JXK;*)DNIQ-PF*[)Y'Q#K)BY6(D0U[V<A`=3=(EWDGAUQ2
M99(R1%Y)R'U,&BZBB0)J((*`'UG?(AEC$FKN4-9,\M;[3<H98PGM);'+^C6O
M3?8;%5QLUC@[C)Y+E@M\5%2=RQFS=S\X82P_<1%DFX(G'J%3]HA0D]2(.?A4
M_#'%3!FY&M7V\U2CXHS*]FM#"90MU$D+:K*L8(86-+6DHY0/AFZ.'OO&ZCWA
M^UX&Z9P'`<!P'`B%OQ_([S]_>,K_`&4C>!(['W]H5(_O0K7]AF7`]?P'`<!P
M*]?*/-62NZ59JFJC'#+6-C1,B&C8\%"(BL*^*K^U>'!11)8A1:QZZRWJ4>OM
M]/0?7@1SUL\4/C@R#J)K>WNFG&"[5'3F&L.723BYFF,GL0^LTAB^ME?3*T:J
M)FAW3]0_OJB)1`[CHJ/53[W`R@CX3/$B@19-'QXZJI$<(?%6`F**\7O;>\FY
M]@1!#J"0N$BG$H=`$X=?MX'P'P@^(<>G_P!3IU.]/V,1UL/^OT;!UX&`=K/#
MOXO<=ZSYYN..M!-3ZY<X/%=P=P$S^:B&1(Q?%BEO;5748$;O`;_@4!,Y1,3J
M'7H(\#$_A:94^C;7^37$F/\`%>.<5TR`#3._0['%M0CJ14IA7(6)KBUEW["#
M8'7$B2$M4%D2*'4$%"DZE*4.O4-B/@.`X#@.`X$&-7504V5\CA`5EE/8V/Q,
M04W[A19BB)M.=<5.R%2.0I6K(P'[E"E$P&<F4-UZB(`$Y^`X#@4<>3)E4[=Y
M!_#A1I6PQT;+AF[/5D&'<DER/IR%1PZNQ!O'N(@[5<HEEQ1$_P"Z$@3`.\WW
M0]0MNP@^<26.(UXZ1E4%E)^^IF2FC.C2!2MK_9VR0J"\`KCV#I(E,AU#M!`2
M`7[G;P,L\!P'`<!P'`<!P'`<!P(R:=(P[?76A(P+E^\BB/+W\9Q)-!8O5#&R
M-;CN?>:BBA[8$=&.4GW`[B`!O7KU$)-\!P'`IK\?<+7)/>;S,K/8QL^D&>WV
M%6X).W,6[C6K5+4/$KEDX8UDK4%(B46<6&2^3(G$RLD1?V^[M0$.!;6E1J2B
M54J-.JR15USN5BI5Z)3*LY54]U1PJ!&@`HNHK]XQQZF$WJ(]>!^4J'1T$`:H
M4RJ(M0$Y@;)5V(30`RAC'4,")&8)@)S&$1'IZB(\#Z'I%,48)Q2E1K!XM$%0
M1C3P$49@D"Z";5<$V9F@MR`LV1(F?H4.Y,@%'T``X'<1T5%Q"!FT3&L(ML=4
MRQV\<S;LD#+'`I3JF2;)I)F5,4@`)A#J(`'['`I#\(2D8HQ\DX-G":LJ'D[V
M;-,(@=4ZJ/>[@ACS+`=8Z117;=3!V%)U#]MU'UX%Y?`IJ\Z#>)<:6102LH:+
M,GFFI*1A@>*-4W<D-/R$D5HNDD4RDB@#)5=86X`(F%$#``B4.!16&O>+EM;O
M&W(EIDO*$DLXZGA;U$](<E,F]D46FYTT_,I7PUT.PF6SX3E.$4U1]UT!`(0Y
M14'H'PR!6*7C3R:X/-#4=&5HL13[K8K'4K7KO7\4PQXH=;-E6<F_F<7YUMGP
MIV-C@1(Z!T#Q(SY8@-DR?BC"8,D9CV<PC<-9]CX?#N/<(+S$AAS/E(DK#1=>
M--*>M()0V+K>G;$@F8[+JKV`4K\W%*H.$$R.)`KIKVH('/[8\#R%*<//J/A@
M+,NV4M)3^S.F]HCITDQ.N9)]"_D#*13B%>0,@P90%?9TN23!BU"*$Z;E,XJ+
M_CN!NK\!P'`<!P(A;\?R.\_?WC*_V4C>!(['W]H5(_O0K7]AF7`]?P'`<!P*
M7_U@:\WC&_BIV4M^-[`ZJMV:-*K#0=A9)`X=1@W*S1U*DU44#)K`N9>%L3E$
M2=AQ,"@@!1$>G`M%P!#?D[@C"E?]P5OH6),;PWO&2%`ROTRG0S+W#("FB*(G
M]CJ)!(7MZ].@?9P,M\!P(L[O)F6U"V.2*J1$5,1W(@J*(?*(4IHE<#]S?W$A
M6*)!$.T#`(_@'@5K^)2M*PV?=YGT[\EE;743JI%_0GSR/._CJ!%42\.L=.'L
M<R8MOIQWD7+K$1ZJ+=[-!'W!!P5?J%YW`<!P'`<!P(=ZZE6#/^^0J*@HF;/6
M-!03!/L]@@:K8%`Q!/W&]T3*@8W7H'3NZ=/3KP)B<!P'`I-\B]9:._(UX9K6
M1HD$E"YVSE'+2+N7.W*:+E,//`^G1$,I(IH24F9^FFLNHFU461:)F$5"D]!"
MS[6Y51;$<.HJ^A9$XV?)Q1=U]H#*+.!,HW,A4TFP,H\"N6Q"@DY-[0=[DBAN
MX_=WF#.G`<!P'`<!P'`<!P'`<"(FB/TT-5\:?2%5UX_YN1O85<,_IZQA_.I=
M_>[VGSY/VNUQW@'X\_<``;[O7M`)=\!P'`J?\?#*)3VX\PT@@1$)MWN[CMM)
MJ%[?D&CV6FNMYXDJO0.[VB*NW79U].HFZ<"V#@.`X#@4Q>(:O5ROW/RI$A'2
MBCM?R?[!%E&)Q0(#`$8VHG8]C5%NW%N#I-P<_J'10.A@]!ZB%SO`IZ\XC=JM
MI`Y5<MT%S,LFUMXU.NDFH9JZ3K%V3*Z;F4*;V%RI+'*!R]#`4XAUZ"/`J'O.
MEFRD)J)XUF3:\ZS0U:G-@-,JQ"UC(VK&49[(E;LTM9)-ZR?6BS*;.5]L^A/G
M.S'?1\?#P;EZW[4@>)``&X%BF.O$KFA[N;1=@MG,F:CY>Q-2HL9!IBBA:GSF
M.4T[C'8WR'BJ%(W+<,TY=:GKSR!RK)R$H5PHX*\E&K57XY5@%P4.CTZP!K5?
MM:O)0$Q@O"UF:,]MMZ:^))#'6.I..32JT[-,&4:UC6]<23B4H11@1/VE`,L9
MPD9<3"90!X%1>&)V>LE-\`T_/-73AU8,Q:L3SJP+UZ*C63J6?/LA-I%E!2D<
M\3$[$4X]$Z[$6**+=8@"D?H(EX&[SP'`<!P'`C5N+&-)G6'-48_(].T=4IZ5
M<L=&EEWHE3<-5@]B./,0!71@.F`B`NT>TO4W4W3M,&9<>#UH%&$>G4:?61]!
MZAZPK+[!Z!U#_J!P/8<!P'`<"MORXZHY,W;\?^>]:<.)U`<G9$8U1*G.;U/3
M%;K$?*0EUKT^+^1E8*/E))$B#2-5``31,81-]WH8"CP.51=P#8)A,>8SW"Q9
M9-<5VQJQB^&R[(349=-=[78&L7%PT:HAE1BX1D::E8I7HW9C;8V$]]PHFD55
M54_3@6-<!P(X;@.W+#5[.[QDFW6=M\9V=1LBZ:-G[958&"GMI+LWB:S5RDH8
M0`2*%$I@'UX%8'C%&/<[T^2J3;M'+A\[J&D3:0L*=B0F8)1:+I>7V+FHQ#1.
M+8JQQZ9+I.TG!3J+@0S@K8@]C4#'"\[@.`X#@.`X$--<&A6^P>_2X+.5#/L_
M8Q7.FLL91)`4]4,`M@3:ICZ()&*@!S%#T%0QC?AX$R^`X#@4`^8F^IX[V]\0
M]L:.6AIJHYMV7M[:+,JQ4D';.#UTFGCWXL<[=M!=BHV043*`&+W*"!0,!Q+P
M+,=0LYX"M^L6)<D4/*-%>4/(L0]OD%)J6B':I">_S,K=W<8L5X]25:R4:ZG5
M$5VQ^JJ"B9B&$1+W"$B`S!B03"4,I8Y$P?:4+O61,'7H(=0^I]0Z@/`XY\UX
M;3BI"=4RUC).$B6HOI28/?*J2*C60*@@+R0D#2H-&;4%C`3W%#E)W#TZ]>`5
MS7AI"2/#+Y;QDC,)HE<*12M\JJ<DF@=%FY*L=B>5!T5$S>1;J`82=!(NF;KT
M.41#I)39'7>#^7]:SWA>(^GG9I/_`*IE*CQ_PE)$QBQZ;OY<ZE\8[XQ1!$#]
MHJB`]O7@>9#<748Q"J%VGUQ,0[GX9#AF_&0D.[Z`;XI3!9^AG/0P#V!][H/V
M<`XW%U%:'*F[VGUQ:J&*)RD<9PQD@<Q`4.D)BE4LY1$H*I&+U^SN*(?:`\#C
M_IH:=_SL-:?X]L7?XT\#V%;V-UZN+9P]J.>,,VIFS7!J[=UO*%(G&S5T9,%B
MMG"\9..DD%S)&`P$,(&$H]>G3@>B_.]B;_.ACO\`AK6OWSX#\[V)O\Z&._X:
MUK]\^!Q7^;,-QC%[)R&6,;,X^.9NI!^[7O%:(@T9,D%'+MTN<9/H1%NW2,<Y
MA]`*41X$//'SFW!,IJ)B:1K.9<93<$^-?7T;)M+[6G*#MK(9+N,@BJ5473,X
M=Z3HI@*9(AB@(`(?A$)F_G>Q-_G0QW_#6M?OGP'YWL3?YT,=_P`-:U^^?`?G
M>Q-_G0QW_#6M?OGP*2_'1GS&*/DL\W5(D<H8N9G'8W6ZXUYBM:JJTFI>.E-5
M,<0TK*M%CR)'<W"LW\(DW[D_<19N1.0PE.J("%UJ6:,/+]WL98QHMVJK(&]J
M]U=3M7;*"BX1-V2H]%6ZQ1(<OVD,'0>@\#CL<YX3DTE%HW,.+)!%)=5JJJQR
M#4G:2;I`W8NV44;RZA2+HG]#D$>XH^@AP.9^>+$7K_YT\<>@`(_^7%9]`'IT
M$?\`C3T`>O`\XRV3UTDFD@_CL^X5?L(A\6+E7K+*=&=-(R3.H@B6.D'*$ZHB
MR?&5<IE!%0Q5!,H4.G4P=0J/\6V8\&5K*/E2"8R=C6NR\WY-LSN2JS.2*NR4
MGFKR"I3:!<1T>^DFXE;J@0Z**B0J%=*%-VCW%$H!;,?:'6=)ND[4V)P6FU7;
MK.T7)\MT`C=9JW65;.'*2QK`":C=!P@=,YP$2E.0Q1$!`0X%2?G`V`P*MIA)
M5Y/-F*59U?)5"9DA65Z@)><]ZTL+1!0'97H1Y)V!R64E7R22/L-53*";[H"`
M#T#$]R\L?B@V`Q!C[&V4<K7^')BZ3QY=8>:C7DIAZT0V5<1%;BS/79)Y8JM;
M6TY`32)TSD%%-)03=O<8!X'@IGR8^*]BF[2#<W=E^"9.T3PNUEQ65.)R1YNU
MJ<<M(&!4OSQ#_:B!FZW_`,`.X.Z@/,;XK\881RQCC&%WR,*V0T,IS;YQ;I:N
M6*9E;Q>H:0<2$I+34SD5R[44FI1SZ&.<>Y43?9]O`JBP\ZHN,J-X*I*SY.Q-
M!2$=EW4QEDF`/E?#CF5ILU3VV0SN%;<TK]A?S;`D7`R2(+.Y!P+-M[@(IB4>
M!N1?IH:=_P`[#6G^/;%W^-/`?IH:=_SL-:?X]L7?XT\!^FAIW_.PUI_CVQ=_
MC3P'Z:&G?\[#6G^/;%W^-/`?IH:=_P`[#6G^/;%W^-/`B-O'Y`M4JAK;D(E>
MSSBJ^V"SQ;FKP41CK(=!O$HG*OFKAVBYD(B'O$=()Q*:#!455DU`$G3IZB(`
M(>IU8\C^B>Q&L>*<DP>R6%V%2M]/;198S(.0Z-1IX7%?2+7YQG)5>?LR<G&F
M2D&9P]I7[_M&(;U*<HB$D`W0T[#T#;#6GH'_`/O;%W^-/`?IH:=_SL-:?X]L
M7?XT\#LHC;?5*P2#:(@=F]>YN6>G]MG&1&:,;R4@[4Z"/MMF3.R+.5S]`Z]"
ME$>G`]P7-.'#)?(+EG&9D`6,W]XM\JPI?(*N+4R'N!*]GO%<@*8EZ]P*?=Z=
M?3@8?S-NSK+@W%-PS%:LM4N9JE)BCS$LVI=LJEFL#EFDZ^&M])B&LZFI(KHJ
ME/W$(8#`"1_PE$.!!+*/D8T4V4Q%/XXR7C^>R%BS)E<12DX.PO<!.HR5BI!-
M"0C'IV,CFM-=LZ:K>RY0,<B:[=<A#?<4+Z!FS3+;S#S+6O&41FO9G#3*_P``
MTGJPN6\9HQ0WNSVL5FUSL!CV8N*3*\S"/Y53U`C8Q[(&%RLHH[74,H83B;@2
M?_3$U&'T_2GUQZ].O3\]^,OL_9_MG^S@1JW*W#U*_15V`%/9[7QT=/%MM5!J
MQS+CIZ]7]B-54.BT9-;"X=.W)RD$"))IJ'.80*4IA$`$(4^("J5&"V8WML-7
MMZEO/>ZSJ]8U#HI)Q\;&UB9CLLWFDO6\8H0'HJ6!OD!ZE\GJ#=R6*!1(I2G`
M.!?SP'`<!P'`<"(FO;=TEGG>=5=F^;(NLZXW59N'3!XU;/T2:NX+04<1KER@
MDWDFR;E(Z1U6YE$R+)G3,('(8H!+O@.`X%#/F>U_?2+S6G:6-P9><V4'7:R9
MCFMC:QBYI4YO(DEB2^XL>4UX,-"6>9CY^38Q,FX2?.4*T"LL1%NHHDB8>[@1
MS\:.'-0\U>/O6/(&OF/*UEC$]4D+1#Y+UYB#P1&:$JWO\]#OLGR3>R6!K:*I
M>*G3G1I(T,"BK]ZU>(M#-"+B00"YFMZA:*93QO2WM7PIB6T8Z<1:4S3WT5&%
M.V6CIDRLN1<L@V73D%C*GD3F$CA0RB0F[!`O:!0#)BVH6KKB)M,`O@/%BL%=
MJU$T^V0BE/B#1$_68(Q#Q<-(QHMQ9+M&JB93=.P#*'*!CB80Z\#O[-K3KU<F
M4BPLV$L72J4M'IQ4BNM2*\E).8])%@W3:&EVS!"6(DFWBFR8`58H@FW3+^U(
M4`#S\7I[JC#Q"L$TUOPBK%.#1ZCIK)XRJ$T+U2)231BU'SB9B7[E\I'II@")
ME3G%(>HE$!$1$/D&F>GY2%3+JEK84A'/S"$#!F,`(1WT`ORBE"K]"N>A0#O#
M[W0/MX!SIGI^\.51WJEK8Z4*42%.YP9B]<Y2"H=42%,K5C&`HJJF-T^SN,(_
M:(\#C_H4::?S2=9/XA<5_P"*G`\[,Z!:43JR*[G5W"K`R"1DB)UNB0M0;'*8
M_>)W+.J-X5H[7`?0%%2'4`OW0,`>G`Z?^CGT?_FV8X_[BD/WQX#^CGT?_FV8
MX_[BD/WQX'Q<^-[1AXV<LW>LV-'#1XV79NVZT>_41<-72)T'+=9,T@)5$ET5
M#%,4?02B(<"$_CF\<.BR>G^+U&VMV+U0<RF35EEVD5(M45U$,J72-2$$1E51
M(*#)@BA^VZ=$@^S@3>_HY]'_`.;9CC_N*0_?'@/Z.?1_^;9CC_N*0_?'@/Z.
M?1_^;9CC_N*0_?'@<BQ^._1^UTQS0YC5_#XP+MB^CEUX^HL(>S*-)%!TW=)*
M72**SN"I3IO#].]\;M,4@AT%-,2A"G%NLNN^%=FK?IYD_$5(LM#S57XK+FJL
MS)58KZ6>0V)*76*EF:DW2UIHME'=NK5JF23B2P`DFZB["W(<RSANJ8`G[^A#
MJ&6)8P:.N>)6<3'&F#M&4?3XN.2(K8")$F%U3,$6ZCER_!`O>HJ8Z@"'4H@(
MB/`Y!=+-3R$CDRX`QD!(ER[>,`_)MJ/LN'QGQW2AA'J*X*&D5ONJ=Y2]_P!T
M`[2]`_"NDFGRL*WKGZ,>#&\"VG&UF")8XRJ4<Q<6!F]9R+:8D4&$6V)*R"3Z
M/05]QS[IA.D41Z]`X%4WC1UQUFR1D3RD,+?A?'5MD*QY2LM2":-AI5??M8->
M!CJ7,4\8!1:-]UBC'.%%%P13/[)5CF$"!W"`A;%(Z7:@RS95E(ZNZ_NF:T?]
M*.U/B&A@W"-&4<S9V2:)((J:+966=JKJ%(!0444,)NO7@4B_K">KFO\`7_'C
M(K4S$E!H5BM>S.KD"\O-(IT#!7]BWF,JP<&=S"6V/BCV&-?L&;P_Q#(*=4#C
MU3+U$0$+`]=/#EX],$XR8T9MK_5\OIK.K!-*7#86/B\QY#6-<WB<Q+1Z]RML
M2I,+1J3P1%NFH(J(E$0[O4>!))EX_-%8]&+;L].M94D8:,-#1I1PACE46\:=
M(Z!FPG6KJAU^Y)0P"=03J>HCW=?7@?MMH!HPS=1KQOIWK(FYAV4A'QR@X/QN
M<&[24>-7[Y+VU*X=-45G;),X&.!CD[1`HE`Q@$*>O)=I+IWC7-WBJ>8_U<P'
M3G-I\DM`8652O8JID6%@C;+7[,M.Q,TDUB$T)6(D542&.T7*HV*)0$A"].!=
M)^A1II_-)UD_B%Q7_BIP'Z%&FG\TG63^(7%?^*G`?H4::?S2=9/XA<5_XJ<!
M^A1II_-)UD_B%Q7_`(J<!^A1II_-)UD_B%Q7_BIP(8>0'033F?U5R;)(:\82
MI[N@QWYQHAU5*!0\>%>S]61<GB&M@GH"G+2QX$57A_>;I]`6$0`>OIP,S:W:
M&Z<5?7W#E<+K-@F>9LJ#7I!NXM.)<<6:336GHMG,/R&EY&H(O7I`=.A*118O
MO&2(0#B/:``&:?T*--/YI.LG\0N*_P#%3@/T*--/YI.LG\0N*_\`%3@<1]HY
MIC(-'#)75#71LFY3%,Z\3AK'T'(IE$0'N:2T-`,)1BKU#]NBLF?IZ=>@CP/$
M!XW-%"I>R76'%Q4?=%Q[)8IT5'WS+BZ,O[0/@3]XSD14$_3N%0>[KW>O`KE\
MJV@FL&-_'WLS,X'PW@_#^02XRLB,1<7JB%,9L&;9D^L4NQ1FU8V?29R$LWC5
MDVA"M3&7?+$)W$%0Q^!E_6WQ'>,&Y8&U_P`ASNB.N;VU67"N)[%*R<ECB&6D
M'4I*XYB#NW4CU031</EOJ*OO',F`G4.)Q#NZ"`9L?>&[Q7R0G%YH1K*J*C!]
M&'Z8RA$NK&1]GYB/XE)/H*OL$Z'_`&Y.GW3!U'J'Q7\,_BJ<-2LUM!M9CMB.
ME7I4PQI#$$'*Q%TU%/<(0J@@8CDX=HCVAU]`]`Z!%'=;Q`>,FCZ?[$V"BZ.:
MZUNS0>(;(K`349BV-D9&*=1\0L@Q=-&_SXQ99=JFH/00=(G_`-L*@"`#P/,^
M(KY\7N;Y$*9(4JJTL*9BG0F`@V%;]YR#6DPM2SI6\?0J$JH^>`]K<32*^P/&
M)CW*($<J`=543=0#8&X#@.`X#@.!B5_GG"L7$90GY'*E#9PN$Y;Z#EZ57LT4
MFQQK-?2XF:^DW5R+GVZ](?2)YDY]IR*9_9=)&Z=#EZAZRA7ZDY2IM<R'C>UP
M%YHEOBT)JK6^K2C2:KUAB'0"+:2B)5BJLS?LEP*/:HF<Q3=/0>!Z[@.!^%"B
M9,Y2]O<8ABAWE[R=1`0#O)W%[R]?M#J'4/P\#4ZLN%<\>.K#5EWUT"HP7F$M
MZ^UB&PF$ZTWMUJ;U:\VG,,B=IL5BN@+6V;3D&#&=QQ%-[96F11<NH;W56:B2
M[=,A0L7P3LKCE>-EMAM)F%GNF.+T9GG38[7^TUC)^-;-^2USFK>E;=K,!UC*
ME0C)ZTKVR3@06"';J1\1,QK%5TS3+*K`B^"X#'U_I^5:15LCX_G&EEI=TA65
M@K4ZQ!8K:3B9!(%FSDB;A-%PB82CT.FH0BB9P$IB@8!``]CP'`<!P'`<!P'`
M<"'.@3A=UJ;C!=RLJX6.^R4!UEU#JJF[,L7HA.XYQ,8W:0H`'4?0``.!,;@.
M`X&KYNAJ+Y,+EN%EBTU!?<^RX0NF4(F:I$OK#OOCK`\)2<1NL58XJ[^`<8HR
M3C6RFD+U7,@UN=ED"-7[%B]3EDQ5<"8#$($=<+8JWUH.]N*V=UPILA2\P6'`
M>PC#6>QY\\EM$S%2)5"D2&*%LF!,Q3#5/)+O'%CNT-/Q*KMZT0=HF,Q(@FEV
M@)RA:"CCKS0':K-G#Z@HG^.Y%%ZCO!5EG0N3/"O6Y#%/XGTFZ:8$+\7O[#B5
M`1'M,IT/P.T<5'S/+2#)Z2*Q*V1:)NB*QJ&\\8+*0,X`@)JNQ6\5:SP%&8D$
M4_:53#J8>\#>G0.E5QCYH#QS<23U,3DB-92+61+NW3`;F3=('^%8!=G\3:AC
MS3)=T8$T@1(U*5ND8Y5>XY>!Y[P2Q5[KO])=5LJ2:ECR=7O(AE)E?;>]G(^R
MS%GL)JI3E7+R5GX*DXPKDNJW*8J2:["L0")R%]6A#>HA?GP*,/UA9=PST+IK
MY%ZU8HQ^Y^FKY^LZ0?+%^"VSE6E5?:4C'K%^U534`BGNHG]T"$,!.AS%.4+Q
MF2A56;14B@*D4;(*%5*"H`H4Z1#%4`%S'6`#@/7[XB;U]1$>!R>`X%,'EF_R
MR^(S_P!I?B3_``;M7`N?X#@.`X#@1JW'3>*ZKY^(P5<HO/S76LR"K*&E;"[(
M8D:J<3-H6$*>4D%NPH]I$BF'KZF`2@8.!D'!:GO81PXKWK*>[BO'JGN.$R).
M#]]2B#=ZZ2::1$EC=>IBE(4"FZ@`!]G`RIP'`<!P*GO-HS>2/CDSPP82#B)=
M/(YHV+*-%4$7<<@K\DCQZU4<L)-O\ELR%0Z93H'*<X`7[O7O*$_M=FZ#37[!
M;5L\<2#9MAS&+=N_=ID2=OD$:3")I/'228F32<.4R@<Y2B(%,80#TX&8^`X$
M,/(I\/\`08VH&0?'C6(87N8NI!-@G*G9HA'&$[@L:J=))\*0!U]HQ@`_V#P*
M^_&U'DC?(IY+%SIP442>Q9H4M$Q#28AADWJ$72<PN9*?_)IJX+*1,=)#9&CD
M#';)M2*NS()',*)P*%Z?`<!P'`<"@3R";]9RH>>-I=8J/(56CP>(=:=0]D*]
MD6/ECQ60F;J_;/S6/\D1\DA*.%X*0I@5&NI"*Q$VZK4YU2']\%R>R'"T1HV+
M-DT/-Y4KE*POYG\R[U62%=6RJV6-^`LP<:UX`B#6R)L"KJ4BDI5K8&7R4S+`
MJS%XD`&0.B(I&"Y76;`&/=5\`XGUWQ3]2''6(J;%TZI*3#MN_E%XJ/(<Z;I^
M[9M6+)9T[56.J<44$40$_1,A"`!0#.?`<#\*G%--0Y2&5,0ASE3)T[U!*41`
MA>H@'<<0Z!U_#P(G:137Y4ZTU.7<1;6+-(VS-)7,2BS3:(M#HYNR.S7:+-2&
M42%P4Z)@<&`1*JMWG^PW`HPWSP;LOXO<[0V_FI,AD7(6E*ERK<QM?J;6W$E8
MI'$<.!I1K;LM8/KSY:1CT*M*Q[M!.<A$&B@-Q2(Y;$*)"F0">FL^R]1RW*RN
MPVF<;7;/C%9RW-MIAB)=M&ENK\G)5,+14,F4=DQ6E(QS9G%<(5)U70^&XDC*
M%[C).4C`8+8J)=H#(U/KMXJ[H74)98IG*L_<%$';0'2)%%8V30067*QF(Q8Q
MF[QL8PG;.4SIGZ&*(<#UO`<!P'`<!P'`<"&?C[_DD8M_X=DW_6W?.!,S@.`X
M$),Q;]X/Q3DJ=P9"1N2LX[`5N!A++-8/P51WUVO41"V8LB-;D)Q=TO!U&`;S
M@1#H6_S91!10C=0P$$I>O`\QK'B3,]HS9E3;?:*FUFF9#LD?%8UP/CJ$LR]O
M4Q!@:*2+*N&$[*_'9PRN1KY<7SN0F7#%`A2-RM&(J*D:$,(6!<!P'`I4\1_^
M6GS`_P#M.\M_X(4O@75\"B']8OZ_T=+42]G<&U>I@E]P5`)U#,]<Z=XHI+J@
M3K]O:F<W3["F'T$+R8+K]$A^[H`_2H_J!1,(`/Q$>O03D2.(=?V2E']D`^S@
M=KP'`I@\LW^67Q&?^TOQ)_@W:N!<_P`!P'`<!P(P[IKSK;4_/Z]:8M)*=3QE
M9!CF;]XBP9J*BT$#G<NUWL<DBDW1$R@B*Z?7LZ`/40#@9/PD<5,,8C4,LFY,
MIC"@G%PB!BHN!-5(DPK)%.8Y@35$>XH"(CT'[1X&3^`X#@.!5IYE):7@M",H
MRL#4WUZF6LS3"QU1C6T4^>3KAW/MF7Q",)U1*%D$4TW)EEF[LP-W""9TS_=,
M/`L-Q419+%V-TW+=)HX3H-/(NU08LHQ!LL2O1Q56Z,;&B,='I(G`2E0;_B$@
M#L)]T`X'ON`X$=-NF3B2UDSBQ:-3/7+K'-B209I^Q[CE06@B5!('2J+<RJ@A
MT*!SE*)A`!$.!5WXZ9%Q9_)?Y1+-+5<T+)$QSHK&M5I2O'A["U:A6,VM743(
M*.!6<IJ`2&:++M?>4226,)B?=.`B%Y_`<!P'`<"MC+6!_&MM5MW:L7YMU\PQ
MF+::C8-Q_;[$^ON-HV>G6F&)JZVMM1F9K'(-%"NXE&XPTFLDR[S`BMW*=H"8
M!X&0[3X_]>VNLF9M8<"4.HZUU+-0&=61SB*N,:HH$^K]";+6<J<.5D)K`,77
MFS8CKN!9,B28E-]PO`D3@_$,9@O&U?QI$6_)5Y8P"1RIV/+.0K3D^Z.S+"4Q
MR/+9<)"3FG#-`P=K=`ROM-DNA$RE*`!P,M\!P/FL)025$YQ3("9Q.H`]HIE`
MHB8X&Z#T$@>O7@0XT`<E=ZKTEP1Z>225N>=10D%3D45?-PS[D\K9VHHFFD15
M1P@4IS'`I>X1Z]/7@3'612<)*H+I)KH+IG1616(51)9)0HD4253.!B*)J$,(
M&*("`@/0>!JZ[;ZE6_Q-9:<[KZ68EF;#JS==@*#FC<#$^(V#LU\Q3$UX9=;)
MN0J37&SM1&\4S($<[32L#$Z)EH1JU%PR3-W&`H3JU9S7`J8XNNVVM./KE$XB
MLUBGKUF+6V(IBTW,9%N%N3J<N[V$P?:%IE1=_".:BX;NW,&P8E;N7*KHA_8D
M6ZB2@6_U&XU2^P+&T4NPQ%HKTD0QV4Q"/4'[%P!3"4Y2K(',4JJ9P$#D-T.0
M0Z"`#P/2\!P'`<!P'`<"&?C[_DD8M_X=DW_6W?.!,S@.`X%9FKL!-0_D.\E4
M@_81+>+LL=J/)P[]J_:KR\BDUI&1XUR268H]7+)NQ<-C`U%8?QGN*B4`#KU"
MS/@.`X#@4J>(_P#RT^8'\/\`]4[RY]GK]E1I?7_K#P+J^!1-^L4%7/X\(XC5
M)-PZ-MCJ05L@J*I4EW!LUUL$45#(G36*FJH(%,)#%.`#Z"`].!>!76Y&D!"M
MDTB(%0BV"?LIJ*JII"5LEW)D574564(0W4`$YC&$/M$1X'<\!P*)/-K-R-;L
MWBQG8E8J$E'>2?"BK58Z952D,LTF&JG<F;[IP.@N<O0?V>!>WP'`<!P'`BAO
M2(!I_L.!OI0@IC*?0$)OX/TH?D)IH='PR2J#$$!]S[5#``#T$.H]`X&9,+MO
MAX=Q.T[42_%QI1&W:W,!VY?8JT4EVH'```Z(=OW1_"7IP,E\!P'`<"K;S*BY
M+X_,V*-/<^2C'IKH&3`XF351:2"B:O5,#'("1R@83!^UZ=>!.?7=59?7_!BS
M@_NN%L.XR574[C']Q92E0AU3]YOO&[SB(]1]1X&8N`X$;-Q>OZ+>=^@`(AC:
MQB4!,!0$P-!$`[A$`+Z_A$0`.!5WXO+:2R[P>21Q.IOZ]>'D5JV:0H\I/*3+
MEA!P;7-$%$6!N+I--VHA8$D07][H9(4CHD3,8A"F,%Z_`<!P'`<#6<S[BC:+
M+'G2SK`ZN[:I:HVY'QM:Y3;ET_P]$9687^.B-ALL)/6BB4[(1;:+:PAI)(JY
MVZBJYA=IIF(4AQ.4+0:'K#NJQU*SMAS,>ZJ68,[Y$9S;?'.9VF+8O&K"@LUJ
MM#1$57W4'7GT@M(,7LM&N5Y!\F8CSVY);V0*=-,>!F[1W#.2]?\`63&F)LP/
MJ=+9&J<<Y:6:;H=AO-FKDX^4=JK#,-9+(J2-I*L^(<#*(*@*:!ONIB)0`>!+
M3@.`X$.M"?Y,56_T@[!?^D/E7@3%X'R700=(+-G**3ALX240<-UTR+(+H+$%
M-5%9)0#)JI*IF$IBF`0,`]!].!K-;4ZWY$\1.5K/O!I%B<EWUKO4X_GMBL)U
MROO;+9L'V6:B)J"/EK%%>+=*7#DPX=:=,_M=?%8$&SE!%^B+=))91,+`\:9#
MJ;&X9'V$TFM..<R84486)]L%K5B:S4RR7`V2$IR2=,,X8_7J4S969Y^]5QD`
M&@'*C$DO'IMW380>E,W<!:-5;3!W."86*O2+.3C7Z0&*LR=-W96[@H`5TP<F
M;J*$1?L%^Y)=(P@=)4IBF`!`0X'H>`X#@.`X#@0S\??\DC%O_#LF_P"MN^<"
M9G`<!P*T-9KF>?\`(KY'ZT%4D8I&EUK4!F%J44,>'M*\M5LKR*K9D'P4$TI&
M!(8A71077-V.$1$"=0`0LOX#@.`X%*/B++VYF\P`=A$__JGN7Q[$_4@=U4II
MNX/ND^\?KW&]/VPC]OVB%UW`H7_6/6:LAXW#1Z"9E5W^T&JK)!(BAD3J+.\P
MP#=),BQ$7!TCG.H``8$U!*(]0*;[!"[3',>UB:#38QDDW0;,*W#M$D6LBM+M
MTO88HIG32DW!$UWI2J%$/<.4IC?A`/LX'M.`X%!WG2_^7^+_`/\`:1X0_P"P
MDN!?CP'`<!P'`BCO+%2DWJ3G>+A8U_+R;JC.?C1T8T7?/G'LOF+A;V&K8BBZ
MOM()&.;M*/:0HB/H`\#/F.E$U<?415(Y%$E:;6%$U$S`<BB9X1B8AR'*(E,0
MY1`0$/00X'LN`X#@.!@/9[7*B;98/ON`<E2%OB:;D2&<PDS)4.PK5:ULF[E%
M1$ZT/.((N3,G()JF#J9-0A@'H8IBB("$*0TCLF`,3)%7\HF\].Q;B"BHH`]G
MI33I9I7:93(8J*'U"?L.ISAVLE'1+`I!7=.3J&`H=QQ$>O`DOH=/9`MNIF&[
MCDJTW6[6"ZPLO=8NUY'0JC2^3E`N%GG++BQ];F5)JU)K;">/C24B0<MT8IBH
M@H`IK)@N501"7?`C)N>`#JCL"`@`@.++6`@/J`@,<IU`0_8X%/'ACCZ+-[-[
MW7AR_D)G-3.&P15;"\DGTN[688Z"5S(6DLTSNA%@HBHM!ND2`4ZBJ"+)-/HF
MGV`8-B+@.`X#@.!5UN)OYFC5[+C6@8Y\<.UNUD1(TJ#LKK*6#V5'5JC=\]D[
M`Q/4'B]@GXN1--0R4<5RH7L%(J3Y/M'J)@`/I4=F=L]KM-]A;MC/5;,.HNQU
M6"9AL08^V#/2XR<NTS#0<#9V+^+=MU;/7&419UG2\*@X>D]M%X0YU`(F7W`"
M1NE]OV'OF&U;;LYC*UX;R7-W:U.D\97*5QM/3-0K`+MDH*+"=Q5/V2JS#`")
MJ';N/D@[43.'OIIF^Z`2TX#@?A0PD34.`"82$,8"E#N$PE*(@`%[B]1'I]G4
M/]G@0[T%$3:M4I016$Z]RSFZ4!=F=@J15UGO)SE5,S0[AT9$$E%1*'XPX&``
M$#"`@/`F/P'`^+ELW>-UV;Q!%TT=(JMG35RD1=NY;KD,DN@N@J4R2R*R1A*<
MA@$IBB("'3@:R>>=5<E>&2WY>VLT%KUE=ZF9XRYC'(VU."J:R0G'.OJ585L*
M=_RMBFFOTEX5QB^S5V4*2U1J+<\K'HL&JL8HBF@!$PF[A[-=*?,8W:G4K(>.
M'V)+)!OKOG#5&CSM;NP'AI:ZRLC:]@\=1=,78S;3),Z^<=K\KUN#-^5,X*$!
MV7O$+;J=<ZM?Z_'VFFSL78H*2135;2$2^;/D`,HBFL9JN=JJL5N^;E5*"R)Q
M!1(_W3``^G`]/P'`<!P'`AGX^_Y)&+?^'9-_UMWS@3,X#@.!65A/(M,Q_N!O
M@>\W6ITZ+E;GAXK-U<+G"5ILH^:8MCOW/%L9DS('JJZ+@QEU4W!_;]I,IB!W
M`(A-XN><&F247+F?%!D4FR;Q58N1:@*2;18>U%THH$QV$;*F]"G$0*8?L'@?
MIYG7",>H"+_,>*F*PG$@)/,A5%LH)P]L1(!%I<AA.`*E].G7[P?LAP!<[80,
M/:7,F*C&]TZ'0N0ZB(^^FHFDHCT"7Z^Z154A1+]H&,`#ZB'`^?Y^\%]>GYZ<
M3=>Y`G3\XU/Z][H1!L3_`,<_MG`@/MA]I^GIUX%3WA[E8N<RQY=9B$DX^9B)
M'R:Y:<Q\K$O6TC&OFYJE3"@NS?,U5FKI+O*)>XAS!W`(?:`\"[K@42?K%17Y
M_'<P)%.!9RA]K]221CL.P!:2!LU5L&3D!5,5(!;N1*?[P@7T]1`.!=1CITP>
MT6J.HUN=HR6@V!DD%&A&!R&]DI5Q,S3$Q$!4<`8W0HB'KU`1Z\#V?`<"A/SF
M(+.93Q>(-D5G"ZODDP@5)!!(ZRRAO;DS"5-)(IE#B!0$>@`/H'`OLX#@.`X#
M@>"RH_0C,99"?N4?DHMJ59U#MNAQ^3_Q,\*5L/MI+F*#@Y@((]A@*!NHAT`>
M!\,0F,?$V+SG8EBSFQW23'C"*IKECC&K48)F)5D0*BL5H(^V!B`!3`7J'IP,
MB<!P'`<"$WD<VHG])-(]A=J*M5HBZV'#=.9V*(J\^Y?-(67>OK-`UY-"2<QI
MBR"31/ZR*AA1_&"!.@`(CTX&,?T;\S[8EQU;=H,T0$A@QPQI5Z=:N8LH+&'Q
MS?Y%)FTLD07*=JN7Y0Y#L43&S*B2BD0W>,8F0(@4CML<HF((62)IIHIII))D
M222(5-)),I2)IID*!2)ID*`%(0A0````Z`'`_?`C+N=_)1V!_P!%MK_L<IP*
M9O"Y`+P&VF_3AV*"1KCBW4NU1J023%VNXCR9"W'@5'/Q&X@X8%3>1)B&26`5
M"]2G$>U0G`V,^`X#@.`X%1F]'F6UW\?.64<3YJPOMY:UG5-JER:WG"V`IC).
M.A3MT]/5UA7W=L;2L8P9V=.2A"E,S$3*&!VAV]14`.!D3!_DNH&TVK6Q.Q6%
ML49_I3S!L)=`;4S8O"%RQK9;'9H*A_E=`FB*H@>0F[+7)=XX29]\>87)UR*I
M%*4P%,8,S:![$7[:K5/%F<\GTUE0+S=8UTXL%3CH2Y5YC$O6KQ5J=%M%7]HQ
MM;=/JE_]M)%,(_9U#H(A,G@.!Q7R*3ED\;KD]U%PU<(K)@0RGN)*I'(H3VR"
M4Y^\AA#H`@(_@X$._'TW9LM3L=L8XJ2;"/L68XYDDE'NXDJ#6/S?D=D@W-&O
MU5W;)9NF@!%$SG.)3E'U$/7@3.X#@.!\'+9N];N&;QN@[:.T%6SIJY237;N6
MZZ9DEV[A!4IDED%DC"4Y#`)3%$0$.G`U=-G-9\D>'C,;_;[3##[V[::7NW54
MV<\$X[L[BEO=?OF3+Z0M61(J-CJG*FL>#IJ:D?J%DBG#U%M%F*=PD4B8_="R
MO&F6(BO0+C9?7\U"R15K-#Q%FS[C'`C66GZ[D)("@U;9BUF>/$XS\K$(2,3?
M%DDFC0/KAF"A0$'2!"J!:-4[5`WBMPMNJ\@C*P%@8(R,6_0Z@59NL`_=.0P`
MH@X04*9-5(X`=)4AB&`#%$`#T/`<!P'`B)HBU;,M6,:-F:JJS=-[D84U%CME
M%#"IE.[*'[CM#G;CVJ'$`[1^P/7UZ\"7?`<!P*C=K?"]JON!FB8SIDF_[,UN
MV3C-HU>1&-<QGJM+*HU81\:>0;5A>NR[-"4?,XEJ1=<![S@@4/0.H"%=$9X4
M-)D=ZL=873994V5Q=2\,7ZV['TO87)SV_4^M.[<XKL;@1G&L(=A5Q9VIPXAI
MUV9)54XH1XHJ`D)'!3@%GP>$WQ4?72V8^DF'EYXA_<+).D;*[6*I[*3?O`KJ
MPK(]XHHD+U[>O0H?L<#Y_P!"/XI`<-78:0X=!PSF'E@;*@C9BF2F9!PT=/'X
M`%B`IEG#EBB<W4!+W)@/3@<J+\*GBLA7"SJ,TDPTU<."1Q%E`9SZHG+$IJ)1
MOHM/*%`S(BI@3,``)>OV\".7A;IE4QS?/*_0Z+`QU6IU2\D^5(6MUR(0^-&0
MT6VJ--,BR9(=3>T@0RAAZ=1]3"/`O2X%&GZPHJ"&@==7,0RA4=P=.UC)D11<
M'.">=*L<2$0<&*W7.8"]`(H($,/H;T$>!:GK"T798"Q<U<H2#9=.M)BHA*B^
M&02%1V[5`COZD4CTJH%.'H</NAZ%^Z`<#/'`<"A[S>IG5L'BT33<J-#F\E&$
M0*Y2<%:JH_B)4>XC@YTRI&$/3J(A]O3\/`OAX#@.`X#@8XS&Y!GB+*CP44W`
M-<<7AR+=83@BN"%8E%?95%,Q3@FKV]INT0'H/H/`ZC7QV$A@3"#\K9%F5[B'
M&KLK1OWBW:@YID*L#9`53'4]E`#]I>X1-V@'41'@9>X#@.`X%2?G;8RS_P`1
M^\)82(D9Z08XKC9TL5$H'<R#II7+[3[!)_&1(`F,*$9&+*F'IT*0@F'T#@6+
M8(L#>V8/PU:6C=PT:V7%./+`V:NQ(+ILWF:C#R*+=R*8F3%PBFY`I^T1+W`/
M3TX$:H'R1:D3EYLU"7R"_K#VJ7VQ8QD;'=:K8:G1'%XJT@A%34#&7B98-JT_
M<-I!<$@,1Q[9CE,`&ZE'@3H343633614(JDJ0JB2J9BG343.4#$43.41*<AR
MB`@("("`\"-&YW\E'8'_`$6VO^QRG`J8\4>/*O!;"9+R2PDYE_<<@XK>0=E;
MO46B,5$P-%RS8CU2+B5&YQ7=>VYL\DNL9<H'*9P``(E^P-@'@.`X#@.!K_\`
MFRWKHF,\:WS5-?&FS-@RC)P>$\PU66Q7@O(.0*3/0T)F1C,S,.:[U*/=Q$!/
MP[>BG,JD]41$#.VIB]P'$2A/G%7D9PYF?5S-^T6.:5G=2HX`8VX]MKN1\-WC
M%-\E'%&J#.XSHP%6O4;%R<VT2BG8='+<JJ*CA)5(AC*)F#@2%UBV1H.V&(X7
M-&,D9Y.FS[EVVBE;%$KPC]X#(J'O.R1[K]TI-%%%A!,3@4Q@*(B`<"07`<!P
M(=:%?R8JM_I!V"_](?*O`F+P'`<!P.%)1L?,1[Z)EF362BY-HX82,>]03<LW
MS)VD=!TT=-U2G27;N$5#$.0P"4Q1$!X&M1L9K?:?$O=Z;FW6G'M%F/'\TR!$
MV2_0%IL65W=HT$LUAFO@6?+F)6\#(6"8L.NUQ).KK7.H(I%0;KD3=)D!L"HH
MA,?%FQ%F!I7-AM8['3LWX!MUJHLSM%3:B,C-Q$22^Q2K2T["ZN6%O,/6,A42
MW-RFZLE?=`FJS1CY1<Y49))=NJ%P-:LU<N4%&6BHST/9ZW--2/HB>@)%I+0\
MFS4Z]CEC(L55VCI$P@(=Q#B'4!#[0X'><!P'`AQH7-.IG6FK@\0=)*Q-LRE"
M`J]5;*N'J;#)EL!-X<690:D*J17H4I!/VE*'4W=U``F/P'`<"MN6RUL7FO:[
M:35;&=\IN$H#".+]>K2E?W&.GE_NTP7/A<P-)5:O_.N5>KE?EJL7&Q3QSERQ
MEFPN5^Y9LJ1,4CA)[7/7:%U[J\LQ-<K?EC(=QES6')V:\E%K*F2LG3Y4BLF#
MZTNZE7:M`E:P$,BC'1C1HQ;MF$>V213)T*)C!(;@.`X%$WAZL#Q_LUYM:ZJ@
MT(QK?DSN*K)PFJ<7JZL[CVIOGI7B`E]M-)`Z1`1,4PB<#&Z@';U$+V>!!KR,
M:HT;<?5*^XIOLW?:\P@EXK+<!+8U?5UA;&MVQ,N>ZTT[(]KAIVON40L$6@*B
M#IO[*Y0[#F(41'@5@7/"VS&,]'S;1VGRU;>8X)6<-!<)F";0.EURK*-E68_%
M@X*'E*YKRWCCLW]A<M6A"ME7)2F4$I5#=.O`O)P"KD!?!&%%LLBX-E1;$F.%
M<EF=BQ%V;("E.ACW(70QC5C&BX&QBY[Q;HHH=W7VR$+T*`9;X%./EAKT#9;[
MXVV<S,OH5^PW@I,Y2E&"+U523O\`$0TBYK,$N+*%G1092AQ6*JJLDDW(4OXQ
M=$/O<"X[@.`X#@.!B[.'^17+_P#HNR!_@G+<#I=:_P"3G@'_`$*8K_P%@N!F
MO@.`X#@54^;^6C83Q2;JR$U)6^(@PQ<P9S\A0`;FNR-?E+Q4XN=)5BNUVK8T
MVYB'BR3<#JI@*AP#O+]H!,+7G)F'W.N^&9>IWZ"7HY,5T9.!D9F?A$)!&%9U
MR.9,6]@,E,R39M/,$4"H2!`<J^V]34*)A$.!#_0S&%/R]JWLY1\E0\;D+$><
M-G]QXU]!23U>6K=LQW9LFV:KR\>V.D#=-*(D3-7B?[C6.!5!.H14JHB!`[G1
MNTL,$36PVE5QR*^D8/5*[5&&PS8,FRXI6:3P9D:B5R]46%5LDXZ*O=&^-EI]
M6K%DS&.X6-&%*X,9;J8P9FV\RMB>4U^R_16^5<9A;;9C.V(UVOKWZIM968$C
M!<%31[-S+)+.2(^V;O,4!*3M'J(=.!2QX6*_93;)3>P%HE:B[)M%@7+L+48"
MJ1U@:N*S5M3]R\IXV0?VJ2F9B7CIJ9N2MV]],\85BU11:]#-BG,*RP;/G`<!
MP'`<"OO-GDGP#KALU#:V9S@LP8V;V2AU^[0.PT[B^QK:P.WD_9).N#293,T4
MA(5^HVN%-'%=R`S01T<T:.VQCN^]8A!"0UPV#PXWU\R/L!#V"O9AQ#2L=W&]
M3[[&TQ5[Y&S]3JU=?3UB;Q3EM+&KTPHI!M%1!`[DI%@'MZ_>#J';:_V_"=[Q
M96[9KZI0S8VG&Y)./;X\)6T81@_D4&[^1CWC2J'/%,;`T4=`5\AU]Y)?J53[
MW`S1P'`<"&F@,TE8-7:I*H/C22:N0]AFX.S>YW'-';&98C5$A]XA%/W,HT%+
M[.G0GIU#H/`F7P'`<!P'`^#IJV>MUV;QN@[:.DE$'+5TDFNW<(*E$BJ*Z"I3
MI*I*$$0,4P"`@/0>!J\;;ZM6KQ'6IMM3J^SN(Z"ERFWR5GS#&,8->U774RPV
M(+O%7;8#`]&=N7-7LE$GHJZ$8V2KNX]PS:HMV[](I!:%40"<.&<XTS$M/'.6
MM3N+R3B#+TNSSMD/">-G[&UI15%R78'1)K:'$3!E&Q<XDSMDVJ+^QP8'=-XQ
MQ[Z::";DI^\+B:A<*M?ZW$7"E3\79ZO/-"O8>=AG:3Z.?MA,9,3H.$3&+WI*
MIF34(/0Z:A3$.!3%$`#TG`<"!/CE+&$P%8BQ3QP_1#.F;_?=.8QE%'.]&^R8
MN2D;LSJ&522./855<??4`O4WITX$]N`X#@56:YQPH>3/>JP(,EG#JPU;#]?G
MYTUS^:W3CJ)68U[2:XG3".ET8I6.6OLZY,X%-!4P/0Z@<IRB`6I\!P'`<#77
M\2%@/5]K_P!8*L3I!Z[B:UO_`"=A!FAT`'"D9B=N_DD&1E1(W^:X19I%-U,'
M0>SNZ!TX%K>@FW*^\FL=+V26Q3-X52O+^QDCL>V>=1GK/%1$1,NHZ)?SZS:'
MAFK%]/QZ";\C9(KA--LY2$%U.[J`9\S>6Q'PSE@M14A4;0..+H$`I8V[UU`D
ME?R=D?AC+MXUVQ?K1_O=/=!%9-3MZ]#`/`UO=>K!-6,FCC?RU-#1]"E'K>2U
M51H<HI*Z8R.4(QR+6BES,H^BPN;#+:C90BT(VMDI*UX\B`F8BW<E!,P;2?`\
MO=+K4\<U6<O%ZL$75JE6F*DE.3\PY(TCX]H0Q$P,JJ;U.LNNH1)%(@&576.1
M-,IE#E*(49;KGN?D0R3I7$:YX6S',437O<C%N;;UF&[5K\UV+INBUQ-\G.%I
MDM97[:Z2\RR%TF84#0:!%""/:H/IU"_7@.`X#@.!B[.'^17+_P#HNR!_@G+<
M#I=:_P"3G@'_`$*8K_P%@N!FO@.`X#@89V#PVSV!P[=L/O[99:,UNC)BT-;*
M>>/3LT&K'3$=-M'T.I*,Y!@1VD\C4^@J(J%[>OIP*U7WBYI>-:LO9+9Y$?(%
M6JA26\]:+#,3&WUMJ=08,EG1IR<DIXI7L;7H^#:%*L;VU`3:-4E#]H%#H(!(
M;Q7XX;XJT9Q!4(UQ,2->^L9@M%+G["<%K#;\?WW-F1;UC^]6!V*SA20G;U3+
M&QF'CI0WO.W#TZR@`<Y@`/49M\<FH>P>6QSSDO&"KS,7Y.Q=3#(D!;;?4;,6
MNPKU.0C8HK^M3<68&S=TF!NG3J;[!$0].!C2X^,;36,J&5Y%.D71@>VUFT.K
MF]B<J9*;2L^1>/5=R"CETA9P<K.7)FQ3"("`F,4.!5'X#XJG!B7QWV:JJ/$P
MFM/-Z(UK&R2()2C.G0^_8NJ@K)>\!G_S5DYIRFJ190XD41-TZ&$PF#:)X#@.
M`X#@4!^9>;W-IZT+9L8[EX5PSK*G5D#Y,P0]L^-,*[%Y-6CG<JM-?FRSUDYO
M98V`2D4%V"0(-8DK@OQEB>_^Z`[`YWAW@/&?,^/7+5?U0URS/BG5R?L%I1S+
M3MD:A?'L[D:2G\?UI:V6!JK8I*U2.1J?+U9ZV:-WL68[)<J!DFZ1>SL`+?M=
MLJ8.S#BN#M>NDY#6'%+-9[58%]7XF3A8A)2IJ_0WD:S92T;%.NR+6:>P)@2[
M!%/H!C=.!G#@.!^%54D2&564323)T$ZBIRID*`B``)CF$"EZB/3UX%=OBJ<N
M%M(J0X?J#[Q<N;<E5.JN*W:FWV_SPDGWK'*GT!-!,H=!`.P`[?P=>!8@99$I
M#*&52*0@=3G,H0"$#H4W4QA'H4.TX#Z_@$/V>!\_F-.WO^4V[/<]KO\`?2[?
M=[>[VN[NZ>YV^O;]O3@?,9*.`W:+]D!O7[HND`-Z"`#Z>YU]!'@?<[ENF?VS
MKHD/T,/8=4A3]"$]PX]HF`>A$_O#^P'K]G`^9GK(IE2&=M2G0*)UR&<)`9$@
M`41,J43]4R@!@]1Z!ZAP./\`68CN$GU6-[@$X"7YS7N`4Q("@"'N]0$@J%`?
MV.X.OVAP..\?UUY'N4I!["NHMXU%!VF\<L5X]TR?)."&1<D6.9NNU>()*@)3
M`)%"%.'J`#P-7C/FL&8?$KD^R[$ZDRL0MH;D"SKS>0V9J?+Y/N&AMQFH]P-G
MR]6XJ*6._L&JT@DS3)8ZNU+TB#.C2*1?Q0G$+#L`Y_:U>%3S%AMC#7O%EM85
M_(>9,+X,8*7A-DTO+=R+;9K7Q.$!1W9:)>9)N*\E#)I@X:IH*F!(KHAR'"W^
M%FHVPQ3*:AW1'D<_2]ULX(!@[@*<R2J:A#@4Z2Z"R9DU"&`#IJ%$I@`0$.!V
MG`A)X]XZ.9ZT0T@QAE(A>R7_`"Y89=10BZ034P[R9:&KN=2;N>B[=%^1B0"D
M,4H]"=0#H("(3;X''5=M4$EEUG+=%!N(@X6563320$.G4%E#F`B0AW!^V$/M
MX'#>S<+&J$2D9>+8*J)^ZFF]D&C511(1$H*$(NJF8R8F`0Z@'3J'`HHSIL5%
M>.G>JV[`93@EY;5+:5*@5RR9V@YFOA3\#W\%8&H`ME)!,RDE'P3Z.A6YTW_1
M3Y*BI$2``HB`A=Y#Y`H]@@8&T0UNKK^O6F(9SU=ET99D#*9AI!$CAE)1ZRBQ
M`<M'**A3%.7T]?V>!S_RLJO]TU?_`.68[^N>`_*RJ_W35_\`Y9COZYX#\K:K
M_=-7_P#EF._KG@:\WBYEXP,\?K!"0&C(8SC?>Z(M;8]D$7#&7>/L-LSM6I8]
M\LG%G^AI$*82D-^Z2K#[GH'7@2K\(;2+HOCWQHREK.Q<&E[3D";:R<U*&:R\
MTF>R.(I]+/8^4=B>*2<SD2[!FS0Z,VL>1NDAU2*4PA,#>+;;"^J6J>:LZ9.G
M';NE5"GNVLFC2V*EOGU'EI51J<`W:PD,+E\J#^Q3;1L*@$%-$5@.H)2`8P!2
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M";06VJCZA9J^(#Z@(3,;Z_\`W3P/Z-KJX=.MD@`Z^H=9B.#KZB'IU<^OJ'`_
MI;55S#T+9(`P]!'H68CA'H'VCT!Q]@<#\_E95?[IJ_\`\LQW]<\!^5E5_NFK
M_P#RS'?USP(V;<[!86Q%K_D:=R-DJHU:'GZU/TB+D)"99_'<6:TUV89049W(
MJJF(J_=%$A1$.T!^T0#@?'37,V+<AZMX'GZC>*Y+1*.*J%"&=DE&:)?J,'4X
M>.D40(LL13HBZ0,4!$``P>H>@@/`DS^5E5_NFK__`"S'?USP'Y657^Z:O_\`
M+,=_7/`Y#6PU]\N1JRG(=XY4[O;;M9-DX74[0$QNQ))<ZANTH=1Z!Z!P.XX$
M(/))MA.Z,:-;'[:UFG1-_GL&T0EOC:=.2;R'B9Y8T_"PYFCZ3CV[MXT1*C*&
M4[DTS")B`'H`B(!A)A@/,^^&(L:S6UN2ZBPP=DZL8_R+;M9L3U9P-:MK&0C8
M6WQE6M^2[,=K;I6MF<JE3DXTK))M(I`9,X@0>G`M$:-&D>T:L&#5NR8LFZ+1
MDR:(IMFC1HV3*BW:M6Z)2(MV[=$@$(0@`4A0````#@<C@>5O3A5I2;BZ0^+[
M[>K6!=#YQT4V7O)1+LZ0.SN#IH$;"H`=XG,4@%Z]1`.!KB>"TLLIB;Q[OK1"
MIPUT=:O>0DEK;LHHK*):2Z>_[1:0AHYVBHHU42B)5TY(#1,1!HF<@]1!4.@;
M,O`<!P'`<"OW.WCVTCSYM!CC:K8FB0&2\M8DJB%;QK%9&GB2E$J2!)M><+88
MW'LDL$"M8EI`W0SQPDMW$1(7M^X`\"9SIK!3-.F*Q5K`UKC(*V\K[&4I[J-;
MK4]NK%JQ[![#`W!1C&+0B/:HU`2`DD*1?N]H=.!CS6K$$7@?#=2Q7"7F:R+#
MU9-\A&VNPJQCF9D&[Q^X?F^H/(E)!F]<$7<G[E@*!U!'J;UX&=^`X'ALDXVI
MN7:7-X]R!%KS51L22"$Q%MIF<@%7:39T@]1($K6Y*(F&H$<MB&ZHN$Q'MZ#U
M#J'`J_U)T>UNR;K9C)U;:S?UPJ>0\]'A&<3G_86MQB9T-B\K+&-)1==RI%L+
M!\Q0Y_DA()NBN2J'(J!TSF*(3$_0<UL%!)L>IW)9LBS,P^,XS9G%PV6:&2CT
M/:=H+Y'42?=J,4V(4RP*&*5$@`(``<#J9/0#52802;/Z#9U&Z+A=VF@AF;-[
M)'Y;E%)NJ\.FQR.W(H[]A$I"JF`5"%#H40ZCU#B2_CPU$G$WJ<GC.;7"0C7L
M2[.EES-#-<[&1.FJ[(1RRR&W<(+J*)%,"R9B+$$/NG#@?V.\>FJ48:340I=[
M<N)A%9O(/9?/^PT](+H.&!XM=,LC.94D'S<J\<H*!_;4)W)?='J``'`[,FA6
MK)',H]_("P*.YM%)M,.%\MYE<*R3=%NDU(@].OD%07")D$"%.0W4JG8`F`1#
MKP.&'CXU$!4RX8H6!<YESG6_.'E+W3G=';J.3'4_+;O,9RHT1,H(CU.9(@CU
M$I>@>7?^,;223>-'K_#\DX%DZB7C=D;+F;"PQ5(**L$)#I*0">1R0:[*/C+5
M(IIME&YFX"Z.?L[^TP!V+CQPZAN)AC-?D)>FBC%@\C!B(K8+8N&J$FPD$UD7
MS:Q4:(RNRIEI([;N#HJ#),'8G1'VQ'L`"@&O5N/X]<2>+O,<'LW$W3-]<T#M
M*DA29NFTK(VQ3>MZ36NU3#*QEN_Y-XJO\`5]K';Y"&".L3$OLO(51X1XT,HJ
M4.T,]X'UFU@RA2L9YKHC3+S?'*]&:V+8[7ZN[A[ZR:2*$H24LY-F]>\BL<\,
M9_)%#?+/7/N-HZ,>!.B^(#@[*5CW34X6QX_T'T@O-`AK-CQYF2UT"]0]?G8&
MQ1.ZVXTNQFX9%NW6A7\9-'S\N[*@LBD05!25(*X]P+=QA-P,$:<:%ZX9,U+Q
M@I;V>:GBJCJ[I'6B]K=JZNL<D+E>\HQ_<K5LTPIQ,FD0"J&Z]RX!^-$_`EFC
MXZ]64'$R[3A\T"YGT7+>175VSVS74!%V>-4<IQQE\WJ?12JGB&XC\+X_[0>G
M[<_<'\0\<NI",9,0IJ1?GL187J<C/QDOL-L;-L)Q\D0Q"N)=K,99?(R1S=0$
MWO%.!SE*8P"8A!`."IXSM*71_=E\/O[,Y!-)!)Y<LKYGNS]LU0`2H,F;^VY#
MFGC*/1`P]C=(Y$2?@*'`X4KXO=&)>N6BJJ8-;Q\1<8-S79\D+>LEPSI[%N%$
MG!4Q>1UR;N"*LW[9%TV.!NYN[026)VJ)D,`4P'UTP3X^-B66#]Q,$GN6C-X9
M,8[7+=B^YTR-+LL96%JU8LV^!,T-+7=C-:3,3CD5%XZ50<MXNQ/C**)((.E3
MM$0NA:>-#0Q\U;/F>`JXX:/&Z+IJX2LU\,FNV<)E6063-^5?WB*I'`P#^$!X
M'(_HQM%/YOE?_A)?/\:^`_HQM%/YOE?_`.K9+X/_`/=?`H?\;FFNOF4<Y^>G
M'<SBA2TH4'>&P1F.X(UOMZ;=BJ[PT=K"M(YH:T,&)I5!=95-)Z[5.MVN.PRI
M$R\#R^IVM.)M4\::^8$S3H<I-7O*=UEV$8MD[+Z6,;:Q8^]B6MKM83&R.7LD
M6:=;-KM<9$'+QNX/'@HD+D5$$7C=,H6->3'P[X5S-HSL!CC5_&6.\:9RG:W"
M2%)O=KN63&,/5G-2MU>N<D^,YBWEE>@\4B:\NW;B1J(E66*;O3[>X`UPL3^-
M',6KFJ,CGZ;UMNMGQ^_-&9=GK5'^2V1C<803B643B']VKV*+9KX[>!9G;U\"
M;MO(JOEGB':G\WKTZ!?W#>!Z+<A"V%;9.W-7BM=:)+P\WC^*?BQ<2*M=F)5!
MU\*QP[5RY0>1*K5)04"G29NUT^HG$JA0],MX**^,S)33#8%>'6EHP8]XQ88W
M=J1?R"E33:S+5E)9)D",99FFGVD%$2('`1%1(YOO<#PKW]7KJ,\UJK:[;-6.
M]FI%H3O%3?SN.FL9+05R:M2M(ZQ,Y6FW2KOQ<QJ0"*2"BAV1Q,;W45`$0X'D
M-H_%"TP3A2_9D#+![TXJECA;Q(U:-H412I2SPP6B(5FL=0=D=W%W`5&/L+$R
MS--VLR7%D5P8P&^Z3M#W.I7B'I=KULP9=[!.5UK9LB85QC:KTK,4NZRUF7ND
MGAFO0#Y^J_=YA"&8J(S*!)51!G&M6ZLB"AS$$JIP$,@Y)\%F/,HU^!K4QDN'
MK3*'<HO'3^@42[52=G7K51NHS?2LLWS:X5%9B=$QDTDBI,U#*F!P@N3M(`3O
M8^,#1YNQ9MWN"(&1>(-&Z+N0//WA`[]TDB0CAZ=!"U%11.Z5**@E(`%*)N@>
MG`Y7]&-HI_-\K_\`"2^?XU\".NV/B.T5O^`;_%_FH<4P]<C7>1&4S3YYVI-_
M5Z-#3,G&,_>NR=TC4(]TJJ8CCVFI'!B#]Q4A@`0#E:M>++1EC@'%4FZPJTGI
M.W4&C7&8DYB=FVKM>4G*37#.`^-57E9A$4DTVY"A[3-,QS`8Z@G4.8PA(#^C
M&T4_F^5_^$E\_P`:^`_HQM%/YOE?_A)?/\:^!Q7OB]T9=M56Z.$E8)54O0DM
M3\H9BH]D9C_\.,M-.R#!V2)6'[!.U=(G$/3KTX'F?Z)O2S_YS[(?]/#>_P#^
MF3X%9?F9\:>ON/?%GNY9L,U/8&;R0VPV9&MQ4EM/M]EQN]<+V^J@LD%!OF:K
ME69U0&Y3F`J\<X$@`)B@`AUX$P=8/&MIADS6[`5Y79Y_?/+!AK&J\FXB=UMV
MJW'?6&M.AX^90;0$)L#$0\.5I*M%DC-VS5!!(Q!*0@``!P,Y_P!$WI9_\Y]D
M/^GAO?\`_3)\!_1-Z6?_`#GV0_Z>&]__`-,GP/,W3Q)Z0NJA:$'U7SK+-#0$
ML9:-LNZ6Z%I@'@),5E2HS%<M6?IRM3<>8Y`]UL_9.FJI>I5$CE$2B%7W@=D,
M[C9:E@7*^"T\1M=/,#YF>L;"M<HJ<=9(K>ZNTEBRSC.>;5B,8ME:C&A7\9/C
MH$<G%1TV516*0A#=I0VB>`X#@.`X$+<OZ]Z59_S:E7LNU:FW7.K3'36;1@'M
MFL,?:B8UCIUQ'MY<D-$3T:12$:V"8.B+CVA$%EP*8W[4`#)V/]5-?\5T6X8U
MQ[C>.JU+OQG!KA$1TI8O<G`=,$HQPFXEG$PO-)(J,403]M)PFF`";H`"<XF#
MWN*<1X[PA3&./<65M&ITV,</73"#;OY610:K2"YG+L45YE_(O"IJKF$P$]SL
M)]A0`/3@9'X#@=?+23:&BI.8>>X+2*CWDDZ!$GN+"V8ME'2_M)B8H'4]I(>T
M.H=1_#P(GZ%HG+JMCA\/;[%BELI7*/Z#]\(>\9>OMPA`<%Z=$GA8B<0!=,!,
M":W<4#&`.X0F!P'`<!P'`<!P'`Z*SUBN76NS=1M\%$V:K66+>PE@KTZP;2D-
M-1$DW.U?QLG'/$UFKQD\;*F(HFH4Q3%$0$.!JH[4Z[9;\,^8&6U6M[]J&@/T
M56CR]9-CQU?IC0W\KGZ:LQ>*\Z;/R3?Z+$O9FL6:T5ELFLV:IB>4*0KB/:JI
MA;%B&_O<0.#Y4HU;L3?"-FDXYQG;!-.:UVTU_"]ROT7$VIAFS%4G%)LEI?%5
MW0F1E93XZIDB-W`/4V::AEB`$EO'BZ:OM/L1OF+E%XQ?*9$?,7C8_N-GC)YE
M6\.6CMNH'0%&[INJ4Y#?[8I@'@33X#@.`X&-LP8?QEG[&=QP[F2E0&1,9W^&
M<0%NIUF8(R,/,QCGM,*3ANL40*J@L0BJ*I.U5%8A5"&*<H"`4UXXQ+Y1]-K)
M>,.XBME#S!JU'6A@\P/-YBK%VS3DBAXM)#E9M\5J!!Y5Q'*.'<#+?[E(2+Z0
M(+`A")ID$OJ&3I[.7E&QM`W*_7Z)UOG:?C>D66W6.,K6LF8ZS*V(8.!EY@C>
MNV&7V\LS&*0(9HB5PHYCW`D+WB4!ZE[0J@Q7^L`;V9CA*/.U+5'5.':W]VTB
M8!M>LVY`@I)_.KXJIV;7L9'1\)4[4[?D@L99!AY!^N!")-A=B0>H$,?@3R\6
M.,LIX^U[\A6Z.64L31=FW?RMDO:B"?83R18+I3TZ@CCSZ36"QMJ<1=2EVIV"
ML4OV*(E0<%.83@<A^T0"'FBEOJ6QU+\-=[RED&T/<PRL#E[,\O9<B+X^R2:N
MK.+?$UZ!QS9;7G)];<^4E?(CV!;#6PC9<%9:3:K*+_(5*04@V`=Y=EZ1JKKS
M:LC7V`O-EBII3\WL?$X\AHV=L3BP7&+E6<.!&,K.5YI\4SA`2',+@#`8Q0*4
MPFZ<"O7"6J&S6RM`UTQUM-7F.%=5L'L*[-2V"XNXL+O,;53\:)I:N%S,FE78
MUG5\:UJ4*@Z/6@6??5'291=*>VF4G`O(X#@.!7_Y1)MK`Z-YQ=.Q<E!W&UV&
M:G:I'64)(SEM@HF-4,"8E.DB1\\3%13J'MD`3?@X&4]$V]H::4ZEM;M)/)FX
MM]<L-(VB6D'SV3?24^GC^`)*OGDC).GL@^<NGH'.=5=9550PB)C&$1'@2MX#
M@.!X;)[=@\QMD!E*+_%C7U*M#%\X]QNB9)J]A'S58Q%'93M2*=BH]ON%,3NZ
M=0$/3@<3$,6T@\38OA6!ES,8?'=)BV1G7L?*,TCZU&-&YG/QDD&WOBBB'?[9
M"$[NO:4`Z!P,B<!P'`<"!'DZ:!+Z.Y^K29&:KRQTYTW9HOROC-C_`$`0NLFH
M<(\R:_<T@:L[7*`J)%$R0`)O7M$.-H5D?&U=TRUO:3.2L=LG#K%L7.)$5O-8
M^]'2I%+$@L8WU,"@9&*ET%%R_:@8_:?M$.!+T^7,4)J()*9.QX15TR-)-DSW
M2ME4<1Y$U5COT"&D@,LR*D@<PJE`2`4AAZ]`'@<<^:,.ID,HIEC&A$RD;JF4
M/>ZN4A4GA1.T4,<94"@1T4HBF/V'`.I>O`\5DC.^#XS&-_L,CEFA?0(BJ6%Q
M+OXRZ0#L[1NWAW3AR)18RAE`53;@)^@"`@4.H]"]1X%.OA8HUFC<T;OW*V/D
M[4^;1NMF*6EU9NF[F#5:U.#R3?$*G7"LYR?8-8^M064HPJI6RXMQ55Z%`H$!
M,@;!7`<!P'`<#79\P#JM679S5O&VK>,KW)^65:.<6G7'-U1;2$90L*8Q9V>-
M;W.:V0GD/?A[#AR24`[-6!D6;U-RHY,HA[3@J8F"S[26O>0B`B+L3?G(FOV0
M)MPK6!H*^!*=/5!A'M4H0A+0G8$9YZ^5>O7$WU.FHF8B7;U[2)E$"`$Z.`X#
M@>1R!_:'=O[T;)_89[P([:'?R/\``']X33_OY]P);\!P'`<!P'`<!P'`X4E&
M1LS'O8B8CV4M%235=C(QDDT0?1\@R<IF1<LWK)TFJV=-7"1Q*=-0IB'*(@("
M'`U:LA84SIX=<GYWSG$W6%FM"[--N;IC(9A"R2:6L,W:I%.-L..,@1D<9_+V
M+"KB%*@VACID,V@A(4ZHI()*=0G]X^LNTO$&EV#<BT*0R5D#6:XU6S9$=.+;
M+M[[EO'KO(62Y):LI1$#5&@,I+$2[M9^5BJP*K\=J9%<>C<#B4+GT'"#I%-P
MV61<(*E[DET%"+(J%ZB'<FHF8Q#EZA]H#P/KP'`<!P'`\)E&B-<HXUR!C5](
M.8EE?Z79J8[E&:22[N.;V:&>0RSYLBO^(5<-4W@G(4_W3&*`#Z<#5MKOAYRU
MI@PQC:;'2V6UV/\`7R"0DH6W:U6JWX:V\@)Z&QTEC->Z0M*]ISCO)4VYQBP;
M5MTDDLG*244Q:)`D8Z?7@7^56T8LF]"@MV/EYA_BA?7FP3%?5O$$9]/%@FM3
MDUQ3MM;018*.Y6/50.1\R*1,YU4CI_:/7@5^>$S&NO.=/'YJOL2]Q]BBWY"<
MJ6:VA<8:%,JRB;DWLZ\:O)5:+FR*3%%:NOR?:RB$(N(_1G;I04`*!P,8/>>=
M%*"=Z<46+LT<K(04MM?KDR?"5T]8-6*I+>L_BWLE(1W[L8L`F63=(RA`$`.J
M0#!V";@6^5AR#RNP;D&SIF"L6Q'XKU)1!TAVMTR"FLDJ`*%,`E_#ZB'0?P\#
MO.`X#@5T>5IRNRT>RF]:S*\"Z9SF+G35^W3(HH9RWRC4%46/8HFJF))%0H(&
M$Q1`"J"(\"3&J(B.L6O0C]HX6QF(_@]1I\0(^G^SP,_\!P'`Q3G-O".L09$0
MLD2RGH0]7DAD8>1:R3UD_133!0J#EK$?\9K)BJ0H]$?O]0Z\#UE%,0U(IQDT
MP13-5:\8B)0.4J1!B&8E3`JH`H`$#TZ&#N]/7UX'JN`X#@.!@K8S"">P6+Y;
M'9;O9,<OW:P/(BZ5,K):8@W_`,%_&'639R2:T=(MG$?)KHK-UR&2534$#!P*
M1[AX(<1TG'LO,/\`<K.%0A:96GLG(V!>/I'TJ$AHB/\`DS+H(QPU1BVK-1DS
M,)TP[4@*`!T$`#@>JTA\5^O&6=:<,Y>R@[S?,6BZU24FXQ_,7I_6W$UCRPV.
M>DL93<I5(]#X=?E9S&3^+7=LTC`FBJL=/ITZAP)A+^(+2]PW1;&KM](1%!%`
MQT[]*E4<$;J*'0%R84S`L9$JG83J'0A````.G`BYNYXQ-2<4:9;+7"MU>\JR
M=>PO:'+$@Y'E6)Q>,VIE"R!7GMBDWDUB#[2CDY#`*/W3!V\#T?B+P9CW$N=/
M)V]H$+;82/2V%P?B]JA(VP]@IRL+3-5,1Y!9GKS$O:R96+ZWF:2-+.D"@1ZB
M=CT$02#H%X/`<!P'`<"MS8[:W4S6'*F6,AR-896?9F@XDPLC?6L$DS9WHN$\
MJ9@=4NC`I-2Z[:+)6T;P5ZZ41[RF$S8QAZF[.!D+5C,63LBY\\@5!O\`,1$K
M7\%[&X^I6*T(N))&J0]$N&K&!<N?2Y5P!S*2\FE8L@OC*.#=.H'`A0[2AP)P
M\!P'`\CD#^T.[?WHV3^PSW@1VT._D?X`_O":?]_/N!+?@.`X#@.`X#@.`X#@
M==,0\188J2@9^+CIR#F6+N+F(:88MI.*EHQ^@=L^CI*.>I+LWS%XV5,FJBJ0
MZ:A#"4P"`B'`U$:=,Y@\2&!*!L>%BNN2]5;)/W6IM9EV[BYNOZOHV'.,]&5G
M$]TKL*SD;-/:[R;P$4&<I!HJ2E27-V@U7:]4N!>ECW,%9Q%`2.=Z_:K?<=3[
M:>/KZ%`H])#(+?7NX0EA4K5HGD9VJ24S99?&\Y)++/'KDC)S'Q;9N,A[Z;)0
M1*%D$=(L)B/92L4\;2,9)-4'T>_9+)N&CUFZ2*LW=-ETC&36072.!BF*(@(#
MUX'-X#@.!6IE7RRZ5X=RQDG"UWRO6H*^XDD:W$7F)LELI-)6C)"UQP2D,#5M
M>+-7'TK'.&YR$^<V159`X.5$%14'MX'BI7S+Z4,(:S2<=DNBV.1K[*[.6E6@
MLUZ_.++:7E":(N9R#J\<OE9O]2G%#N")MF_>0[@P]Q.I`$W`K<A_UE[&]F8M
MYN(UBS9#14J8[F(CK5BG8,]D2C%53?`-,?D5A&Y50'Z[?M.<L?*R#8!-T(NH
M'WA"2OAEV7K&;=$MH\YV&.BD-=4]I=L'F/*O/OW*S""PY'2A'KBB/8>_0U8:
MP%?CW:SQNV9/B))@BL(+D1ZF+P)V>,W)=&R_JS#9"QMC#&F%:38KE<G5;Q)C
M"N4FM1U!AOJ*81,/96V-Y29HKVZ.XOV7[]Q&.#MQ^8FF/11,_`A9^L.G=MM!
MZC(LVK*06BMQ]0WY(U^W?N4)%0N8H5NW;@G&R48X!<KMPFJF(F4+WI@`IFZ@
M(!>1&G54CH]1<HD749-3K$$#%$JID$S*%$IA$Q1*<1#H/J'`YO`<!P*Z?*XV
M^5HOF!/Y2S3L>X[<>X@;M.I\;(]57^,8?;5ZI.O;]LX=`ZE,/J'V@$EM4/Y,
M&O/^A7&7^!T/P)`<!P'`P_L#,N:[A/)\VS=JL7,;39ERD[08J2:R)BMC`)D6
M*,Q`JN51*80*!7:)@$>H"80[3!ZS&ZXNL=T)R)EC"XI=67$S@%"N#"M!L5!,
MN"Q2+`L(F^\!P`W=UZ@`\#VG`<!P'`A?Y`]Q(G0O53(VS\U3)+(#&@*5IO\`
MDG$R#:+?2KFSV6+K+---\\(HW;D2=2I#G,8!^X4>!B)'$NSFWYRL]J4\-TS4
MVRQ$-/IX.QA-7NPY#OJA7$//04?D[)#E"EQL?5G"0JIR\%&L':3T"%2%Z9(Z
M@<"RE%%)NDD@@DF@@@F1%%%$A4TD4DR@1-)),@%(FFF0H`4H````=`X'TX$'
MO)8R<2.@FW#%JNLU7<X-O"1%VZL8@NF`QAQ4%%6:36BBJ"F`@'R"F3$1Z"`]
M>!&OQ?VJKSF2/(/&U*+6:1;39S'D^#EQ8:LX=$/.:;ZNPB,:ZJ,"_/(58C-A
M3D0(5ZU0$ZWOII]/:.0H6Z\!P'`<!P-?#R#^-[=S/^T^:,LZ]R6HRF,LTZY:
MZ8LGXS/+O*(VLEHU\S1=\N-8LD?3ZQ)00T2WJ6%HV?*F74>E!(_8F``'>%@.
MA6"-H,4SFV>1]LY#!+W).Q><ZQD9@WU_-=/R2BZK4L"8BPY#1\F2[QT?(%GT
MBXX.*AD0.@JB9,_W#F,F4+#N`X#@>?MC$9.K66-!=!J,A7YEB#IT<$VS87<<
MY0!=PH/0$T$14[CF'["@(\#`6F4,:N:Q8AKIWS&3/7Z^]@CR46X([C)$\//R
M\<=]&NDQ,FY8/#-A414*(E.F8#!Z#P).\!P'`<!P'`<!P'`<!P(1Z(1,7.Z;
M8[AYN-8R\3)*Y29R,9)M$'T>^:.,L7U-=L[9N2*MW""R9A*8ARB4P#ZAP*C[
MMB.V^&W*KR[XXF)FTZ!9RGHO'410[<$S8,>:7V*^7-24DXFQD-/-6T3K+=Y>
M<>%1DCD$:-(._<.*\495F8)]Z_3,5A:4RW=L:V:UVC!+^4B;5DO"UDN4U>K+
MKC=;>G&R+9EAN/2<S5>C\&R-6EF,A'P\.HC%(-3J/&IBD,9$`M,;KHND$739
M4B[=RBFN@LD8#IK(K$*HDJF8/0Q%"&`0$/M`>!]>!#FI^033"\;$734^L[$X
MXD-A:!*,X.R8R-+F9S*<V^B&DXA"Q3MZ@WA[!-A&O`449,'+AVEV*`=,/;/V
MA%K>+5:WTS*,=Y$M5!J\/G;&\'[&P&.+1,(UC'>V^$:[&N/_`")R!,/$GD/!
M72C,Q5<U>PN&BZD>J`H''XZ@@`31U5S1BW;37K$VR&/Z>K"57*]83LT7$6:O
M,8^P0RP.W<7*QDDW*D<@.8^6CET?=3,*:Y2`H01(<.!)`K%D4`*5FU*4H`!0
M*W2`"@'V```3H`!P*4_#0YIMJQMY!:&N@WEQC/)/N#%W*N2+874-\*S6..>L
MV01[DJD:=C)PZ_59(A`(<PG[P$1$1"XNDT2E8VKD?3\?5.NTFJ1*?M1E;JL.
MP@H2/3Z`'8TC(U!LT;EZ%`/ND#[.!27^L0BL;1;&31J@==Y);SZ6Q[(!DRQK
M1-VXS3"_'4DTS.FH2<=[A`*HVZF[NX%.@>WW%"]AL4Y&S<JO8"A4$BJ`GU!/
MO!,H']L!$P]G<'IZCZ<#[\!P/FLLBW15<.%4T$$$SK+KK'*DBBBD43J*JJ'$
MI$TTR%$3&$0``#J/`H_\BN\6IN7]?+I@'&><(&Y9+O;@JE(;U1I<Y"H6]SBB
M6;9"R!"P.5H6O.L82LO`4ZHR3QS'%F1660:*D[!]0X%HFJ'KK!KP/[.%<9?X
M'0_`D!P'`<",.Z/=^BQF_M:@]-^1#SHU,>*3!4?E-/03S:2\67M_;?C2"'IZ
M?>Z#P,W8\_M`H_\`>?6?V?\`YRLOV?7@>PX#@.`X%)7ZP\PD)+Q/;%-8N.DI
M9X$EBQX#"(CWLK(*MHS)M6DY%9"/CD'+UP5E',U5U?;3,)$DC&'T*(@%NF)G
M;:0Q7C-^S6(X9O<?4QVT<$Z]B[9S7(U9!8G<!3=BJ1P,'4`'H/`R#P'`AIY#
MW[&+T<VFD)*6>0+!IABYJNIF/%R5]&I!&G`7;06;.0=`ND(]2^V@J;K]A1X$
M(/&0R%SM'OA=)*!DJS8+/&:OP#N)>)NF:2K+'U,NL<RFCQ!RJI1TE8&\T1\L
MH98RKL')1Z`"7H%U7`<!P'`<##>1-B]?,0R[6`RQG;#>,)Y\R))LH3(F3Z32
MI=Y'*+*-R2#6-LLY&/'#([A$Y`5(04Q.02]>H"'`B%I%E<N5MB_)BYALDM\D
M4*L[08C@Z`[A[8VMU2@HEQI1K).3,/57<<^?Q+)D>URSYTZ0;'`H/W"YC@"A
MC\"R'@.`X'S612<(JMUTR+(+IG1614*!TU4E2B11-0A@$IB'(80$!]!`>!C3
M#;(L;CR&CDUV:Z#%_:6C08]1JJR09-[;.),6+86::+8B4<S(1N"92A[?M=@]
M1*(\#)_`<!P'`<!P'`<!P'`<"'6@BB"NIV,#MFWQ$1>Y*[&_OJ..SIEB\E./
MO*]%#]YP$WK]G7I]@<"5=CKE?N$#,5:UPL79*U8(YU$SL#-L6TG$2\6^2,@\
MCY&/>)K-7C1RB<2G3.4Q3`/J'`UJ,I5+(_@PO$+D*AV[)&0?&+DC)=>BL@8_
M6HDGFJX:F5T\3.$5@*H[;"K:Y#%-PMTFU3;)*F7-`ID%!,0;B4`"T:MYN=XQ
MA8;*N,:P>U:K6-=@ZO%:91`U^Z:[-BUU_,S5T4A5G4G,6R+L\H\:*+QXB#IB
MGT%`IB`<`#&.WVQ\]LFRR3IKIID1`N5+(,7C&T91H<X]++8ADK,WAK-,6EM+
MQK9>.3@ZMCI9=1\\26.?Y\@S9(?NDYP(&=L.>,'2_#NNE+UJ986JUKI]2^/)
MKV&WM/K.0;%=0!=61R!-WU04[6XN$F^>+JG>E=D5)[HD()2?=X'<-O'9KJH5
M['6HV4,D4Y\+0R^.,DY3MUNQZ)V#<6K(_P"3+]\#93XR?02E4,<@G*!C`(AP
M)KPD)#UJ(CH"O1;"$@X=FA'Q43%M46,='LFQ`30:LVC<B:*""1`Z`4H`'`[3
M@:[/ZO9>:]DV&\F.0:DNZ<UFV^27.TM".'K12/=K,A&.:`HX9+"*K505FI_N
M&^\`=!'[>!L3<"A/]8P0<AHCC&71<OV[>L;T::6&2*S5;$0<1S/+L>W61E$%
MR'5>QQ%7A%?:0[5A732,`]I3`(7IM9Z'7:MEPE8[HLW16`1>MBB(*I%.`B45
M>H=0-P/O]:A_0/JT;Z_9^[VOK^'T_&_L<#\!.P@B)0F(H3%*!C%"0:"(%-U[
M3"'O=0*/0>@_U.!7QM*_D]ALY8OTHK5Q3K],L%0DLX;%/:W.@C;9G$$!/)5B
M*QVT1:G`[:N9*M*AX^7<]Y508D.1+[QC<"'7E5I6/,1U[0RB46L5?']%A<E;
M0PE=J]=BF$%7V3EQXZ-O8^'9,(UDBBU^>\>KD32Z%%99=0/4QS=1"R[5?(N/
M66LVO31W?*6V<HX5QF15!:U0)%4SDIT24Y#D,_`Q3$,0P&`?4HE$!]0'@9\-
MDS&Y%!2/D&D$5`0**9K7`E4`QA*!2B07X&`3"8.@?AZAP/:D.10A5$S%.0Y2
MG(<A@,0Y#`!BF*8HB!BF`>H"'H(<#]<"+NZR:2NJF<4UDV2J1J0[[TY$C=1D
M8`=LQ#WR.OQ!@`0ZAW?[;IT]>G`SECS^T"C_`&_VGUG[?M_\2LOMZ^O7@>PX
M#@.`X%=_E/K$K<M),VUN$EV\!*R%$R&HTEW38[M!D,;BR^RRQC-TSIJ',LV8
M'2((&`2'.!O]KP,WZA6&%+J9JX+B:C$EE-<\'JF(XDVH+?CL9U@Y3'%18#F%
M3NZ]P_MOMX$C33D*0RA#R\64R(=5BFD&A3)!W`7JH`J@)`[C`'KT]1X'*7?,
MFJ!73EXU;M3]G:Y7<(HH&]P.J?:LH<J8]X>H=!]?P<"`GE!DV3SQ\[@L(Z51
M4E%,&W(C="+D#?5`5,Q**9FI(Y0T@5<.H&**0=_X0X&$-!G2,IMWOC+%38&(
M<-?HUC+1=A/-MIM6,H\HUG?DF()FZC^/<IME%#B('36>JI].A?0+=.`X#@.`
MX%/F]^-/"E+[`X[G/(57=17VQEMK3"O8X7SLI#J766J=<>SCZ/81361<?^)H
M^1F'ZB8J)E2%90X@(F*':$U-8,<ZKX5=YAPSJ[C.HXN:T6[PBN4H"D5TL%"C
M>[10:I8X]9THE^*?S"E$D(@Z@A]Y-N=$H_@X$K^`X#@.!BS##Q%_CV.<MVGP
MDC3EW3!M\A9UV&;WFR-U#^\O^,-[RB0GZ#Z$[NT/0`X&4^`X#@.`X#@.`X#@
M.`X$,_'W_)(Q;_P[)O\`K;OG`F9P.FL5>@[;`S-6LT4RG*[8HQ]"SD-)($<L
M)2*DFZC1\Q=H'`2JMW+94Q#!^P/`U'MW\7;S^'RH!1=$ZQ4;9H1G/80+%?GD
MFQF7%PUUB,AS</&V3'UPMTA/R,FWP`%>(Z3:38*)N8([@2F,FGVB(7#:+85U
MA\>V")2`UV8%DL</,A2%XRX=M:4YYUB5"^IS-A&6BX0;%:U8'$Z@DCEHB)8N
MG)2,7JD@95QWJK&"VMF\:R+1L_8N$G;)X@DZ:.D#E40<-UR%41624*(E.FHF
M8!`0^T!X')X#@.!J^?JL2S4^K>Y**3=-)TAOWG\7:Y4#IJ.05G!,W%18SM8C
M@$4P$I>U)'M#T'O^T`V@^!5UYFL"0NPWC?V6J\K76-D>TVH?G;KK=\QM4N:,
ME\9.$[,YFXF#J%NH\G-6:,KC60/$-U9)!I]4%NHN/8F(@%=51\!>!,E8=J4M
M`Y*>Q2-^QQ39%*V%?;0*7:/^JP#-VXG(MV7=)U7(ZQNTW0'.)V3YHBY`1*D8
MGW.!-3'7@I\=5(HT+4IK'.3LAS#."CHFP7BV[+;,C8[8]9JMW;B9?EBLPQ\;
M'.GCYN!Q*S10*5/\7]XO=W![ASX5_&R[D&TJO@2S"_:*>XBLGL;M$@'7Z@XE
M`*LBAFE)!RB5ZZ4,5-0IR%*;L``(`%`)$ZX:!:DZE6^TW[`.)QI5TNE:B:=9
M;+(7W)M\EY"KP<@YE8N#([R+<[:=A'MI)VHN)&WL^XJ;N/W"`=`R)LCJQ@/;
MO'Z.+]B,>,LBTMI/Q=ICF"LS9:S)P]CACJ&CIJ"M%,FJ[:H&10*LHF*K-Z@9
M1%0Z1^Y,YRB$9*+XC/&]C:G'H50U-QTRK!Y=.<%I).[;97Y9%)&JH$,G/V>R
M3-@1:`E2H\/C$=%;"*:PBGU=.Q7#U=I\86@5TK#FGV35K&+Z#>.V3YP1%G*1
MDHHZCI%"59J_E#%2C&PD%%^V(?H5T!3`4"&`2?=X$Z&;-M'LVK!DB1NS8MD&
M;1NGU!-!LV2*B@B0!$1`B21`*']0.!R>!&'=%T5GJQF]R:)5G2I4AX(Q2#ET
MS5=]SIH3M(Y9='27M=W>/9]H%Z#Z"/`S=CS^T"C>O7_R/K/K^S_Q*R]?3T]>
M![#@.`X#@5V>5"Q251TKRU9XFT(4R0@8&PR:-E=PZ]@9QZ;:EVLSM)Y#-HJ;
M7?LI1G[C-8H-'':FX,82]"B(!`/&GB?M&9L2X@RDXWKSS"2=HQ+BFUULL/4\
M6`VJPR=#KJJM=;-TZI%Q4M2"L^Q!NT4CV[M!,A1(X(;NZA[M3PG/G0S1''D`
MVP9HVVNUVJW(8,F-VCV:B(J?@)N6,S?3%5L"D+*2A:TV10=)E.=J!EC'^0"H
ME`/I,^&"]V>#>UJU>4/>RPUUV2*<!7GTIB?Z(29AH#Z.PEOB)8](LW!!R8[D
M&[55J@(B!!*/3N$,-[!>)"QXVUZS_?%]_=K+)9VV(+LU%PNRPRT:2+52M(L3
M,I1F\QK-IJMI$S,IGITO9<&*``V4:CW"<,F^'G7:KZRYFW0I%6M>6;HWGHC5
M>P/I/)-M;6HD>_-B`S]VW:?382M13)U)/[$X5,J1B1P[(D'O'-[)`*%\_`<!
MP'`<#29\Z<[A&J[I;]L\L422G,B9>\36)<:ZV3R.';/D44[\&7LURLW'UVR1
M-:G8JD6`K))NH#I99FJ/4A"*??[3!?EX7GFI2^I"+756W90R0NQGHHF>\H9I
MA<DQN4L@YO>T.H2<_.6^2R;$Q,I..VL$]CV2`LP4CV#5JFQ2$!;&(4+=.`X#
M@<9Z;L9NS=%1[6RYNB`*"N/1(X]$02.FJ*H]/N]IBFZ_8(#Z\#!6K[U&0PA3
MWB'S`27>7,P!((/6S\IBWNSD4*]0D3J/TW15"B"GO'.H)@$1.<?O"&?N`X#@
M.`X#@.`X#@.`X$,_'W_)(Q;_`,.R;_K;OG`F9P'`Z:Q5Z#ML#,U>S1+"=KMA
MC'L-.0LHV2>1TI%2+=1H^8/6JQ3I+MG3=4Q#E,`@(#P-53.+7,GZO$XF[OA>
MI7K87QZY?NC`KF*<2$`O:]1I<LA/2L319.<F8!_\O7&4-,JLHY911LYKQCG`
M5US*(D,%ZN%<FFDC*YAQ'?HC-VIN4'5DN*UN0M\3*%QG:EYXS&8@<;-8*B)O
M+G2'MD5=N'+J1FUBQG:8C409ID3($Z&SIL];HNV;A!VU<ID6;N6RJ:[==%0`
M,FJBLD8Z:J9RCU`Q1$!#@??@.!JZ_JL1G8ZT[IINQ<=4-],YH-R./<`46Q)M
MP8J2)5.@E0*N=00`/0#";\/7@;17`P;L_P"Y^C5L-[11,K^8W+7ME*7O,93\
M@;!V%*3H;O$3=.@=!Z\"OO$F$=CM/M=JJ\U@R_5+W@.GXDAK-"8$V$AG\^^H
M\%$T\)M[5\89MJ\C#7$S%\\.JL*MP+:UD1$$4%4$2E(`3?TWV`6VIU>PEL2X
MKR537RY1H^X*5Q!Z:11B#/57*7Q$GIB)F<D*"'4#"`?;P)+\!P'`<!P'`<"(
M^^**Z^H&?$FR2RRYZ,L":3<BBBQNDE'&-V$2`QS"!0$1Z!]@<"1./O[0:1_>
MA6O["LN!Z_@.`X#@4R>?ZUR-)\66Q-CBD2.9!N-*C$&ZA8\R;@MFM\35G*!P
MEH^7BA*JTFU"C\EHZ0]?QB*A>I!"TC!D:$+A/#T.#<C0(G%F/HT&J9V1R-@8
MU*(:@W(>,CXB..1'VNT!;M&J`@'W$DR]"%#*?`<"+^ZP@&I6Q`B(`!<3W`PB
M/H``$6L(B(_8```>O`A)X^`>CMCO(X,$.,0[HFD0Q;AL\:*R[I=#"<N:2%XU
M39D=$C44W386RIG"R:AE%`(1,2F%0+>^`X#@.`X&%<[9RP)KG1WV4MALD8\Q
M318TR39Q;,AS41!1PN%3=&[!JO)J$4?/5C&^XW0!14WJ(%Z`(\"-/CPWRI'D
M,QED'-6)\49`Q]AF(RG,47%-SOT4A`_GTK$+#0;ASE:I0J:15F50>SK]W'M#
M*J*J./@&5ZE`X)E"P#@.`X'#D>[Z>^[`,8_PW7:4A2'.8WL'[0(142IF,(_8
M!A`HC]OIP,&ZO*>]@VE*#U[C+6P#@8&Y3D4+=;&51)0C115JFJBH`E.5,QDR
M&`0*(@`<#/W`<!P'`<!P'`<!P'`<"&?C[_DD8M_X=DW_`%MWS@3,X#@.!Y:\
M4>GY+I]FQ]D&M0MRI%RA9"N6JJV)@WE(.?@Y5L=I(1<G'NB*(.FCINH)3%,'
M]4.@@`\#6C6Q1E7PKY7H="QLZEY'Q63Z[^,AI&]VJROJ!JY8LCW2T6*TU;)T
M/"MU7TU4;7*SAD8.?<&]F)<.6[9YU0#O$+5L?9E7QQ2*/F/']?G@U*LLBZC[
ME1)F#>#?,"2#Z4%DA9(1-DJ])*XS&06(J\1(=9-@R5*Y;&,D)R%"RALZ;/6Z
M+MFX0=M'*1%F[ILJFNW<(J`!DU45DC'352.4>H&*(@(?9P/OP-=3]7)ME;MN
M`]H#UI*;02K>T>0*=-(V-FBSF4[+!S4V>7![\<I$W9A^<F)5^T!.40`P=Q1X
M&Q7P*?/.CM+F73WQYY#S#A!*C+696VTG'<X3(;5RYK9*;DZ0<4B=<KG:K(JL
MUV1IE%<%^HE3(F;J`]>!B"F8@\ULQ@"`Q]%YH\:;RFSV*6]6929L=[#+/58"
M>JXQR+T#DFDFRZY6+T#`/84B@AU$``>G`Y6J&DWEGUFUHQ7K_';H:LE0Q)5`
MIM=4C->9EY&KP\>[>*PAGRTI+HR!W2+-P1%<Q"E*?VN\``QAX&<L173?C"6T
M.,\;[EYQU]R;C'.C7)T-C1QC7',ACV?97&FQE2GJ_#RYY.1=DDY:;B'$VL<C
M;HB"+$@E+W`<>![/RP;/Y2U,U?A<E8?E$(:WS.<,28^-(K04'8A;P-LFW"4^
M#>.L:J41\M6-9G(FJJ(@D8P&Z#TX&*,0U_RI9CQ3C7+D5MU@BN1.4:)4\AP\
M!*Z_L964AX>YP3&QQ4=)R49*H1SV1:Q\BF1=1`A43*@;L^[TX&1/S,>6#^>I
MKS_T;P_?K@19VQL7ECU6U_MN<+-M_KA+LZ;$/'<RQB->4V2IG8HJ&C!C',U-
MBQ2:_(3`'`NA#HF(B00-TX%RF!+C,9$P9A?(%A.T4G[UB?'5QG%&"9$6*DQ9
MZ?#S<F=DBF=1-)H=Z^.*92F,4I.@`(AZ\#+'`B)OJH=+3W/ITSG3.6C+=ITS
MF(<O63C@'M,40,'4!X$C,??V@TC^]"M?V%9<#U_`<!P'`IR\^&,<E9?\6VQ5
M'Q)3+1?KT^5QR_BJU3(8UAL;E*&R-6)1^[CH4@@:24C634[@4OL.5,0'TZ\"
M;>#]E,&S4?CW$:.5JRIE5G3*O%O*9+*A7;2YF&%:C3231"#D4VGOR#<P"*[=
MJ*WL&ZE_!P)9<!P(K[Q"<NGVRADQ$JA<-WHR9@Z=2J!!NA(8.OH(E,`#P($>
M,K%+!3-6SNR,JE+EO-N88#P<9TO8C*0,M2,6:QX%N,3,QE9;?N!.6=6O*LR@
M_=#^-*#1!/T*/3@7/\!P'`<!P*9]^O&TXSAL/3=X<%2M(LNU.%<6S%2A\"Y_
M`;AK?EV"+]<D:Q'62INA=EQ[;$)N4=)LK4P;&<I"L!5>Y-$O:'JO"DUSG3M&
M*/A#9#"E^PKF/`TK*T*X,[FJPD(JZ.I,R5Z;W.A3D:/Q9FJ.VMM(V[^TAT'S
M5P@<.Y,1X%MW`<!P.*^`XL7@)IBLH+5P":)1*`JG%$_:F`G(H0!.;T]2F#U]
M0'[.!''3XCTFO-&+(Q;B$>@_OWR(IT9L9PQ..2+>/LJF9,(MJ8W:(#U(W2+T
M']KP),<!P'`<!P'`<!P'`<!P(:^/TAR:E8N*<AB&!]DSJ4Y1(8.N6KV(=2F`
M!#J`]?\`8X$RN`X#@.!YFZ4NIY&J-EH5[K\5:Z9<821KEHK4XT3?1$Y!R[51
ME)1D@T5`2+-G398Q3!]H=>H"`@`\#6;?QV>/!7F!HZ=Q;G+_`(CK:M-1I<C.
MULC7/(FC#6R33>39TBY0[FX3K&3UU:R29&S28;Q1W<"S6/[IC)D*@J%RFOUB
MP[A[',`\PJI8;7@G*&3;+:_J[9Y)3M<PG&W"DR.5I&9EYZ6F)1./Q?(.2H*1
M9FGM13-"::@U`&9B&`)W,W;60:-7[%PB[9/6Z+MHZ;J%5;N6KA,JR#A!4@B1
M1%9(X&*8!$#%$!#@4&^"A(B,SY54DDR(ID\F^=P(FF0J:9/Q$,8P%(0"E+]X
MW4>@?:/`OZX&NU^M,M"O?#KFU$44UCCD+#?L@JY10*192\,4"']A4IOJ7^ZB
M46Y1*8X&$W7H4>!>[AI(Z&(,5('`H'1QO1DC@1/VB`=.L19#`5(!,"90$/0O
M4>@>G`R1P(U;48`<[!8X80]:LZ&/\HT2WUW)F'LD'A6LZK2,@59R8[5V+-<R
M2YXFPPSEY#294%45U(R17*0X&$.!2[Y5JUOKLGJ'7<!3&JM@?9F@LUX5R/+7
MS7*TQMRQ9,5JCS+B6MLE3WEI&KWJ*F6[,?:)&RD0@LLLJ)6YUTP]T0O2USA7
ME;U[P17I&/E(B0@<-8OA7T3-M18S,8\BZ1!L7,?+LA$19RC)=`R;A(1'VU2F
M+^#@9EX%4GFQF(N`\;VP<Q-MV[F(9Q44603>(P[AD1!])(QI7+QO8'+.#<-&
M:STBRB3I5-%4I!((]3!P)UZQL`BM;->XL'[.5"-P?B=@$G'Q[>)82(,Z%`-P
M?L8IH=1I&LW@)^XDW2,9-$A@(41``X&<.!##R!Y)QAC'4W+,MEBRT.MUV9A2
MUE@.1KK%T"O3-@E%R'BX0MBEUV[5&1<F;'412`1.J*(E`.G40#-FOV1:!E;#
M&.+QC"[U7(M+E*I#HQ=NI<Y'6.N2BD:R1CGWP)>*7<L77QGS51(_8<>TY!*/
MJ`\#,?`<!P'`ZJ;G(6M1+^>L4O&P,'%-E'DG,3#YM&QD>T1#N5<O7SQ1%LU0
M3#[3G,4H?L\"NO;":T5VAQ@[J]JV$PU"7"/.TEL2Y6K64J%"Y'QCD!B]:2M4
MLN/[FJN_=0$B2=8-A4`A5$':("DLFHF82\"1^F^7;)G/6;$>2KK^3QKU*UU:
M&ORM1?*RE2<WZF2TC2[P\JLFJV:#)UMY:J^[58N"D]I=J<ATS'()3"$FN!%O
M=PPDU#V0.'7J3#UX.'0H&'[D(Y-^U,4Q3=.GV"`@/['`K&\+RKB7E=E9N182
M<6[*3#R32*>R$PHUCV[^`L"KEXRB7RX,(Y:PD8MG*QT6Z1E"%1)U]I)(I0O=
MX#@.`X#@:I?D2\AL-X[_`"8;H9.E,CP<1>G'BRPN]U]QA?I:1)0\A9(A,U9A
M<OV:<8U.CUL0LC(D*"*R*[A`3``'[`$@7ZZ5;C89W/P_&WW$^5<=92EH!I`0
M64UL:2IY6OUO(;JNQDS,P:"JHBL"")W_`%1$PF$R?3J/4!X$O^`X#@>%R=2X
MC(N/KA1YY[8HV&L\!(14D^J5QM./;&V:KHB*BD1=J3*0MLK3H`+T^4P=H.4R
MB/:8.O`K#UU\<>"9G#E0DE<F;EM3.#6,/CU[R!;KQ\&D1&USK=,L4U:9Q9HD
M9>VD`IF]LIU"CWGZG,81#-G]&?@7_.IO)_[P_>#_`)^N`_HS\"_YU-Y/_>'[
MP?\`/UP']&?@7_.IO)_[P_>#_GZX#^C/P+_G4WD_]X?O!_S]<!_1GX%_SJ;R
M?^\/W@_Y^N`_HS\"_P"=3>3_`-X?O!_S]<!_1GX%_P`ZF\G_`+P_>#_GZX'<
MQN@5)K22C6F[`;E5]DX4^0\;R>V&;,C*N'0%!,BR<EE2WW>7CTRI`!?8:N$6
MPC]\4Q.(F$.Q_0E1_G/[<?QW3G^\\!^A*C_.?VX_CNG/]YX'W::5MF[MJX5V
M6VS=I-W3==5HOF^P@@[316(JHU7%`J2X(.2%$AQ(<AP*8>TP#T$`B[ISJ6I<
M-=:)8G>PNUU>6D9'(9OHK+.%R4:QZ2&3[FV;MT59QQ)2ZJ96Z)1*9==4X@(>
MO3H`!)O]"5'^<_MQ_'=.?[SP.,XT::NA;"IM#N`06CI-XE\?.]C;`=5(JA"D
M<@@4@.FI@5'N14[DS"`")1$`Z!_5=&VJR[1R;:';\JC(ZQTBIYVL:2!Q71,@
M<'3=,I47A2D-U(54I@(?H8H`8`'@=6.@D8)FYOTJ-T0%L]!^GTV,NA0,L5=Z
MX!-<H+@#AH*CXX"@?N2$A4R=O:DF!0Y;C0Z*=N3O5]GMR/F"V29HJ-]B+JS;
M(-R.1=*]L8T<(Q:SEP?M*9=5$ZQ4R]A3%*)@$.LNGCFQ3E&D6[&N6,L;.9*Q
M_D.(?5S(50LNP&1"PEPK#]H=DXKSYM$2\8:-CU4CC[AF!FBZP^IU#<#7_P`@
MZ^O/#IF6Y165\J[I27BNO%5-"8`LM/V4SV_:X'R-.0TI7H35ZU5^E6)Y9J;3
MYJ6?)NJC;HJ,?/$7B!6+TJRJJ"A0G3CK]'E\.-[CBC>S8YWK->Y*Z0^28W*&
MUN5X[,F&;Z9[`P]4K$A&YFM,3E.M5D\D$FS?I2+1229N!:+('!!;W"A'GP\Z
MN5#,"'DB9,,S9_J+2L>2K,:,99<2["WJ)5LT:PC(=)HI-S,38'C*UF<&."JS
MQ0RJ[DX?C%#!U+P+I'F@<6^/'*+;4;I)FC'1W;<&NQET9D5547%P8C]-JLD2
M2;`<>A45P43*3[H!V^G`I^\[&FD)6=!D'0Y2VAR9(DV-UF;$;6?.65["BRK[
M/)+->P/$:O`RR366D&,&+IT#LS-U)(G0(HW,"B:?`LWU1U_H&:=><*Y0B]D=
M@KW5;50(%_%R5.V1SBE5IXC7YK0DVPE9V5B+\O\`-*``LF^.F(*I=!2+TX&3
M2>/+'1W!7K_/F[#]^6*7B17'<C8"/;'2.1%-L[-%1%XCXD)-D5N02N`0!50W
M<*HJ=Y^X/HIX^Z(:27>(;`[I-F3NQN+"ZAB[<9O68G(XD8Z6-!-UW5M7DX^"
M3?1WW$6ZZ0D;+*M@-\<WM\#J%]!\15=C+2MIV-W))4VC>1=.PL.[>P$'%PK9
MR_\`GF<KV9ED.&FD$8\3>VF==^)2(]"&$0X'IHK0K"9HMS\'*>W<E'3K^*L*
M#T=Y]LI`1*U%R[8%B90N9#KI0SL'YCJ(I*B@[(*8*`<B:0$`CX^L.)%.F;*&
MXZZ7MIHMTU=X]M>K5!,L4(ID72S`FZ<J*+1)5#*N#K+B*RQ>_P!M4Y!"MGS*
MZG8[QYX]]HKS7;/LS8;-*UUC&,X.>V^V4FJNJZG+5$"8A:K/7RUUU$@&`2I%
M1BSG2`0*D!>!-K$&@V(I_#U`E9:][?Q$C;L1XO3FXR,W@V^A&D,JSK58>"V@
M(YCEV(1JZR3F.(FL9DV8JJIBH14O:JJ0P9.CO'SA:,2;)-\D;BJE:J(*)B^W
MJW!D5#F;C)"0'"C[-3A1R0PRJG>503`H!$@-U!%+L",FS_BFHV0<,3U9Q]L;
MMOCJ4;V:N7]]8+)M5LUEPKAC1TIMZO7&+&[YC=NJRVG$Y(Q'#F&<Q[TZ9"I^
MZ*?4@AW&OWBYQ!6\(8UKL[EG:IVZ85Q@[*^H&X^X>,(EX248,7(*JP$)GQ8/
MDB4H=1565$G7M)VD`"@&;/Z-_!G='F_.?NSUC2E*@'](%NIT5`KI5V`OB_GT
MZ2!A45$HBO[@BF`$'[A0*`=@/CRPF9`S<<E;E>V;XG4P;X;C`L'PD#MTNC@,
MV`L7W"*"*O0WXXX`8_<8`'@<M'0;%D>@J$'EG<"*?&<MW:$FMN=LY9%6J[8J
M)"`1A;\H6"'6;*$0`%$56ZB2@B83%$QA$0[R1TXB'B(I-,^;2Q*@KE5!PSSO
M=5E02*02BV[7[UXB*1S#W"/;W]0]#`'IP(];6>+^L[-X1O6''V?\^-6=Q9)-
M@2N.2+;?:F11`J(%+,51[.1Q)MBHHF<YT3N2`)E!]0`"@`5,0WZOEFV@TZ"9
MDW'P_)K4"+11;6JV8)S*?YL%!NQ=H(V>O5_:R!JCM-K`^XS,=NQ;&%))$P=#
M$,)PE1H]H5?<N:IXFNTGY"MRXIO+O+7,5P^'K5%XKQK-U-ED*TH4*T4:G255
MEIV*HEUI[9C+,6C]Z]459O2"LJL)A4,$JU/%Y9U80]?-Y(/(P#$YTE!<)YQ@
MDI@#(OD9`@$G4Z.67(05T"E,4%@`Z(F2$!3,8HA@#<7QOV1AJEG=>1\@F_4[
M'Q6-K1*K0\AF&`0:3`,&;A_],E7493(Z45BGIR^TND1P3O0$2=>WH'`\+X1Y
M5K9<G;;S3RTR#FUQ]*U@K4K2T'AB5R(@X&$R17JQ9DH=,@,R6"R-J\L1Z]`Q
ME7AVG>IZ^HAL+\!P'`<!P,9W_"V(,K+QCG)V+L?Y"<PJ;E&(<72H0-F7BTGI
MD#NTF"LPP>*-$W)VR8G*02@82%$?L#@=Q1L<8^QC$*0&.*14Z%!K.U'ZT13Z
M_%5R-5>JD(FJ[591#5HW4<J$3*`G$HF$"@'7TX'M.`X#@<1^FHJQ>I)*B@JH
MT<IIK`'445#HG*14`_"*9AZ_]3@8$U48/(O`U)CY"7<S[UJYN:3J8=III.9!
M8+Y9Q.NJFE]P@B(]`#[>@!U]>O`D-P'`<!P'`<!P'`<!P'`BYI?9T[EK9CZQ
MHH239.0=WTI49<K8D@3X.2;A'"*Y6A2MP`YF@F)VAZIB7KZ]>!*/@.`X#@.`
MX&*,X8-Q1LCBVV86S=2H?(6,KNS;LK)59Q-0[)\5D^;2D<Y(H@HBY:/XN49(
MNFRZ1R*H.$2*$,!B@/`IS3\*UFC!<L8C<1.9@TG:Q(1;+6H6N.9,@-H!!<P5
MZ%LN3[?$#:;TXKD61%DC(21E'JJ+<@J',8.O`Y6%?"[>L$O+H^QUY&-D<>IY
M#NB5SME4P_2L3XDQHX=E9D9N20^/JS!'AH%])`F4SEZ@;Y"Q@#J/IP)"^-VU
MY)K60]Y]5<U9KR!F^^X%V&AK'1[7E%PP5MSO7_+.*J/(4$2_3V;)JK%,KW6;
M6V(9,I^ADNIQ`Q^G`B3YGIF\'VD\3^/VMEM[3$.0LI;8DRC3(.46C:[;9ZCZ
MW2-^Q3(68K=,57[FHV2O.'$>B)R)F.NKW`/IT"6O@^74=>)G11TL83+.<'Q;
ME8PAT,95>;FU53&#\!C'.(B'[/`M5X#@5T>75%RY\8V\S9E[GS'.N&2&S,$C
MF35%VXA546Q4CD$#E4,L<H%$/4!^S@9\TH8R$7IKJ3&2Q%DY6.UDP*QDTW!C
MG73D&F*ZHW>D6.I^,.L5RF8#";[PCUZ^O`DWP*L_,Y`%M/COSS`B[^"L\BV"
MS!W\4ST4)B*<C,P1@;%42,<QIN.;E`>XO8)N_K]W@37U<E[18-9M=9Z\`<+K
M-X*Q'+W`%'!7:@6B2H%?>6`#NBB)7)_JRRW50!$#CZ_AX&=>!CK,!A)B7*)P
M,Z()<=78P&9&3(\*):U)B!FAUOQ)'0=.J8G^Z!^G7TX'4X!.*F",*'$STXGQ
M)C@XGDCHJ2)Q-3H81,_4;_N=1Z;KU5,3[@J=1+Z=.!EO@.`X#@1+WKVR@=%]
M2,Y;:VBH3-^@,'U)*V2=/K\@QBYF=05FXF$!HPD)(BC%JJ566*H)E"B':00`
M!$0X$2X9[OIO+"5EC><;U/2C6.Z1%<F[L2&R\3)NR.1JG+L?K9ZS4;-0F\=2
ML<P%F8KH,)5=85Y9-LJM\4Q3"!@"T>HU.N4*IUBC4^(9U^I4NO0M3JT#')^S
M'PE<KL:VAX2(8I=1]IG&QC-)%(O4>TA`#@>AX$8-U2%4U*V(3.8"$4Q-<4SG
M'IT(0\2N0YQZ@(="%$1_ZG`I4\),?"PVV.^$965OJ44GAO3KY\]V.2)S,JWM
MFV3=-VQ04*FG',@9A[/M=#>X9`52"!3B4`V2N`X#@.`X#@.`X#@.!\7*2*[=
MPBX3%5!9!5)=(`,85$5$S$43`I/OB)R"(=`]?7TX&(,`)D1Q174$2))-FS^W
MM6:")")D;,&MTL3=@U%,@![:C5FDFF<IOQA3E$#]3]W`S+P'`<!P'`<!P'`<
M!P'`A!XXFL:STWQ,VB)5Q-1Z<AE3V)-V+H5W`GS)D%1<#B];M7/1NX.=(O<0
M/ND#IU+T$0F_P'`<!P'`<!P'`<""^SVKN1K=;V>QFIUVH&'-NH2GEQN6^Y'I
MTY?J3?<2_6T[2ZQ3<*]&V>%+$L'5F:H.V\ZU;NY.,,54J2:A%U""%*^_-HVB
MM^TWC4GMC]:HW%;S%ESV7J@7>%RW6+SB._WN_P"I65'REAQ7$1\Y$WMJPJS6
MD"FLI<X2(4,61$C<`!-590+,_!D<RGB-T(4,)1,I@2"4,).WL$QY28,82=AU
M"=@B/IVF,'3[!$/7@6N\!P*Z_+B?V_&5O$H*RC8$M<\BJ"Y2*J=5L5.'4.9R
MD5`Q%C*-P+WE`ABGZE^Z(#T'@9_TQ7(ZT]U0<IOEI,CC6K!2Y))R5R1Q($5Q
M=5E"OG!'BJ[LJSL#>X<%3G4`QA[C";J/`DKP*OO,>[58>/7/K]!0$5V%=7?(
M+"F@J"*S-D^<I*BDY,1LJ"2B0&[51!,W3H80*(CP)8:;2;B:U!U4F';@KIW+
M:W8-DW3HJ+-L5RX?XPJ[I9P5O'G48(%645$P$0,9$O7H01*`#P)(\#%V<?\`
M(KE__1=D#_!.6X'2ZU?R<\`_Z%,5_P"`L#P,U\!P'`<"G#]8)54;^&G?MRB(
M%6;8<9ND3"4AP*JVOM.72,)%"G3/VG3`>A@,4?P@(>G`LAUGDEYG7#7Z8<B<
MSF5PCBF2<&4%(QS+OJ)`NE1.9!!J@)Q45'J)$DR=?L*4/0`S=P'`C)NA_)0V
M"]>G_FLMGK^Q_P`7*^O_`%.!49XH62R>\&Y<BDX?Q!);6?3]Y-U)2+D!:)RJ
M61-LXN.DS2KUJR;M%5H>-(Z20:D,@Y))G4[S*)*"(;!W`<!P'`<!P'`<!P'`
M<"/VKUU:9"PQ"6IC&DB&SNUY6CBL"!VE34KN6;Q6UUN@'/ZO'$098?7[5/P?
M9P)`\!P'`<!P'`<!P'`<!P(3>.MR[>:>XI</EVCETH_RE[BS&:<6%J<"9AOZ
M:?MR[IHR7="5(A0,!DB^T8!3#J!`,(39X#@.`X#@.`X#@.`X%07D[]C\^/C%
M!=-DH)MJLE`A\P[HAR+_`**F<.AV(-C`FH]]ON`"K]4!3$XB'<!>!S/!/<ZI
M<_%-J$>J3L=.DJU&EZ/81CE?="'MM6M]AC[#7WH=I11D8AX'MJD_`/3IU`0'
M@6X\!P(4^1M)-?1C9]NLUDWR3G%$\V490T:M,2;LKDS9`6S2,0D8E9\HN"G:
M*97"74HCZB'H(1TT7WBU3A-5\$U')6V^N%=R+%5-]`OZC:\YXN@+9%IUJRV"
MO,XES6Y.SLI5C]%8PQ6@(F0(*)6PD$`[!``EH.]^CP(IN1W+U2!NLY:,D7`[
M$8B!%5Y(($=,&B:HW#L.Y>ME2J(I@(G43,!B@("`\"N/RO;2ZQYET*SU0,/[
M&X'RM?++6).(KE)QME['UYM]AEW->FW#:*@JU6+#*3,O)N&Z"BB:#=%14Y"&
M,!1`HB`6/:))*H:0:;(K)J(K(ZJ:\I*I*D,FJDJGB.H$4343.`'(H0P"`@(`
M("'0>!*O@8NSA_D5R_\`Z+L@?X)RW`Z76O\`DYX!_P!"F*_\!8+@9KX#@.`X
M%.WGRK,[>_%#M?CNLILU9_(M;K5+BB2+Z1CV'RYBYP'8J[6BV[ER9%L"`J]I
MB^R(D`51]L#<"R372!>577W!E7D?_E]9P_C6NO3`9`Y5'<'38:+<+)G:KN6Y
MTEE6HG()%#E$I@Z#P,R\!P(R;G_R4-@O0!_\UEK]!^P?^+E/0?Z@\"G+P^]S
MW=+>*12L4E8D4,#ZE,'*DLVCS.8QV&1=MRI0K=PB[=/F3".0:""*"HF,L0P*
M#[902(`;%'`<!P'`<!P'`<!P'`<"(&B+A=WK/5UW*IUEC7_/Q#*'Z=PE2V#R
MDBD4>@`'0B292A_4#@2_X#@.`X#@.`X#@.`X#@0F\=:XN=/,4+#&24,)W^4@
M^G2\>,7(-^S,-_)U78F$PHE7[?<3'K]],Y3?[;@39X#@.`X#@.`X#@.`X%+G
MEUFFE1O/CEN<BF4&T+M5?F,4L[DF$+#N;M8-5L[QM(K<G+R/1NS-;9L08-0+
M^-4=+)@4!]0$,4?JV%ADKIXVEK_*5UG4760-IMH[<:K,EDETJ^,AE&2;K1)S
M(II)@NR=,U"'`"@'<'7\/`OZX'G[9:ZU1*Q8+I<IV+K%3JD/(6"R6*;>(Q\1
M"0D2U5>R4G(O7!B(MF;-JB8YSF$``H<#6IA+!G/SRY@;3M9F;KAWQ%8COD.*
MD3*UN1K4AY!W,%++.I!VA+^\TFVN&VPH$231*)$GRR9'`"("``%O$9XN=#82
M2A9:$UMQS$O*\E[,.HS@6'[C1,K*N'"93+MUU5"O74TX57[S&%54W<81$.!\
M4/%OXZH,\5+'U+P8B6HV)I?HIU(TR$.UA+3"2`SC.VIBZ0^.WDHUT4QRKF]$
MTA,3T3ZAP*X<@L]8-CULB8.\:NL]1R'D-U8)*1GML8*#8TW77!^3P?O2.;.X
MR-&LT7V1+7&R:B@R-?KPBH\:"=$5BD.8O`NAU5Q';,#ZZX@Q#>[NEDBZT2F1
MT/:[LTB4X",GK`)EGLLO!0"1U$X*M-GKLZ$8R`Q@:1Z2*74>S@2!X$>\UY(Q
MTOBO,$"GD"C#-%HEY@3Q1[?74GR,VYJTJFA$N&RLD11O(*G'H"2@%/\`U.G`
MZ/7C)>-XW!N$*V_R)0FL_%X7QB21AU+G6AD68MZ;"-%C+-B29U"I$=$%/O`!
M()@Z`(\#,9<JXO.D=<F2*$=!,5BJ+%N%>,DF9L8Y'!3J!(B0@H'3,!P$?NB4
M0'ITX'X_.QBP6GS_`,Y>/_@BC\@'OY95SX@H#Z@M\CZE[/LB'^VZ]/ZO`Y,#
MDS&]ID"1%8R#2+'+*,_J"<9`VN!EY!1AU,'SB,H]^X<F9]2"'N@7L]!]>![?
M@5^^3'6K-.UFK<OB_`5Z@J/D-M=*9<D"V=H+FNW:#K$@HYG\>2RY"**12-KC
M5CI)/`*8&SDJ1S@*8'#@5&44V2)_/\;JU:M[-O-1]@H*OH)5S!&:Y>-?4G)C
MY\BT>UY_@S+-381=,RO48B&C5VCR-;@WD&;D03]DP@8>!80OX[=DEYMRN/DG
MVO2A5GPJIHH6T$I!-HHZ*=5,H%0^`FJ1L)P3`I`3*?M].T!#@>35\?F\1G,K
M')>2#,(5M5'W8IT:8G@MB<@T;>U'D>R)%P:EC5U/O.R(D*=4?4!`>!Y>U>/S
M;N(IV1W-D\BV>YN!5QO>&(,"N7-H=&?O8,4(Y?Z)/%=1+TK=<RIA`4Q4#H02
M=!`W4(@>#BHCC_;G:&MO+S=+;8G6INJ3RW2=@5B_BW.S0.3-FZI(71R@Q;D7
M"1>DC$U@%0W<5=\[^TAD@*&T!P'`<!P'`<!P'`<!P'`AUH3_`"8JM_I!V"_]
M(?*O`F+P'`<!P'`<!P'`<!P'`AEX^E%U=1\6J.5$55C/LF]ZC<JY$3=,N7P"
M]I7+Q^N'0@``]53>H#TZ!T*`3-X#@.`X#@.`X#@.`X$9=P\/XCS9KIE"K9IH
M<%D*H0]6G+PTBIQBX=J1-FIT-(S-?L\`YCR&F8>S03U#W63U@)'J"G7VAZB(
M"&K/HGG#-7B/_0FQ+F"USEVTTV,IUP=X:N"IZS`0KNZV5D[NRV/[>M/!`Q=`
MND'87BBP3TY,G2FHX1((E=B).!MLPF<\3V##J.?8R]5QSB)6JNKH:](RK->O
MHU^/2<'DGJDDBJHU$L>HT625`IA[5DC$_;!TX%&UZ8Y[\T>5/R*A7-QUT\:F
M$LB)P^9*[=ZL$'E7;W(E`M[Y2>Q99Z7(2T=:Z'AQNUC8EZ51T@@M+IO3E.3H
MF9+@7]TNE5/'-3KU$HE>BJG3:G%-(.M5J#:)L(>#AV*8(LXV-9(@5)JS:I`!
M2$*`%*4.@<#T_`^#IJU?-7+%\V;O&3QNLU>,W2*;AJZ:N$S(N&SENL4Z2[==
M(XE.0P"4Q1$!`0'@5@8=P+LQHP\D,9Z]TG$67M,DI:<L=#Q9&/B8JSAA\UBF
M7\Q)T6KN)<#8SR15@?/CN&S^7EX.00%04#E6*4JO`QUNAN7OYK[1H[-]5U;Q
M!6L,U:UTQ#)S/+N:&1\H*P,W:(F"?)02&/VMEQI!MEDI$PC*R<^FVCC`55R0
MK<%E4PFWIWN;A7=_%\AD[#$H_.E6K9,8_OU2GVI8ZVX^OM?!N>5J]FCBJKI)
MK_$>(.VCE%15I(,'*+ENJHBJ0XA3RST3T=M&1O+57<EX)JESF,79"<9@4R%;
M)"R,I-Q,9[PLAF7Z8LYBK0R;#%T:0DO@1IP3162:`"8B;[1"8N!/%-X\9S#F
M&KG(ZJX^-9YW#F-EI282>W!%^N#RI0K]9J+LEF!R#(':@G*CWBF4>@@'4.!E
MPGB5\=":"C5/5>B)M5C.#+-B2ET(W5,[.=5V95`MH!)0SI54QE!$!]PQA$W4
M1'@?/^B0\<?P?I?Z*=`^E^Q\4(T)"XA'@V#T!L#+\IOB@W`/]IV]O]3@8HRA
MX7].9.GO_P!&JLN=,\Z,$H]7&VQ^#'DVUR#C>4B7A'K%1DRD9\T-8(%0Q3I.
MHE\0[%TW64()2B;N`(]57<[R,:3)$PAOO@M+/BT]-1V/-=]V=?VT<SQ==K)8
M%9&MXTB-GJO.34=(X:MUGGD(U-]*HD5KQG4@?\:W*"8'#/&BN^.U&R&O-)RQ
M;=<,;9,G+)&(K226KN><?R[.IR2/N(OZ]?XO+\WCF0K=O;+I_CV;,\DV1/W%
M!P8``>!ETV%MF-D\UX_O^Q</BG%V"L-W6&R7C'$,.U89`S/)9!K*IW%?GKKD
MKVUZU38Z/?\`M.#,:ZH[.\]@$EW()F$.!9!P'`P[L)]8_,=E?\GY!K%37Y"6
M+Z9(OA>E:,W?T];VUW!HXQ7P)D_"*0@?]C@42^&R0:K[E[K,TTG3=PVP'JZF
MH5T@X2*\%/+6WBYGC$ZC8Z*[,J;Y(G>18A14`P`0X@8Q`V/.`X#@.`X#@.`X
M#@.`X$0-$4BH:SU=,CA!T4+_`)^,"S<512,)]@\I*"4HK)(J=R1C=AON@'<4
M>@B'01"7_`<!P'`<!P'`<!P'`<"%'CM:`QT^Q2U*J=8$W^41!0Z;=(QO<S!?
MU1ZIM4D$"]HGZ?=*'7IU'J/4>!-?@.`X#@.`X#@.`X#@8>V'<F9X`SD[(N+8
M[7#V3')7(&[!;F0I4VJ5<#^PY[!2$O=U]M3IT_:F^P0AQK7@O$VT'C'PIA7.
M5-A\C8RR-@>N15GKTX@5PW?-WC(5"/FRX)HKL9-HN(+MG2()+(+%*<G:(=.!
MK9[+:Z;28AW>U@T$W'VBED_%G8XJSR6(Y2.N#_'4WL+(XZ3KRM,U^SQ<WD1)
MT./GJJW512C(I5:!B+.R:G5,H>245/P-QS"4KA:PXZAK3K^_QY,8QM2LA88>
M=Q>Y@'U2G7LB]7/,RJ#^M'4BWTDYE2J_-4[C+"Z*<%1]P#``98X#@.`X$'_)
MA0OSH^/3=?'95U6BMRUAS37VSU!@WE',>\D:%-H,Y%I'NWD<W=/(]T8BR13+
MHA[A`^^7[0"KVBDMWC_IVD>WL'1LGY>HV7]=<(:W;>UK%5"L.1,LW&Z5?&I`
MP5L2G4ZRZ&(]\QXI>"GWBJ2)DVDI&^\N5!H8R83WQAA3(%4UJVVR/FURP',6
MRB65LIW%A'Q46B2E5=6I2$;C3%2ZH)NF\^KCFBM&T8J_6`RCE4#F].A1X$Q-
M<#E5UYP,J1(B!5,,8N.5!(3BFB4]'@S`DF*IU%1(F`]`$QC&Z!ZB(\#,_`<!
MP,!;68AD-@=8=BL%1$@QAYO,>#\JXR@9J31478P4_>*/.5R"GG*:("N)(.7D
M47?5/HJ440,00,`#P*.]\Z7MOA;`0[&X_P`4X4UYV8QLECIFUSEC78B_OXB_
M3+-W&UU2+ROAMIA.`K^5*S86:RJ:B4R[5<,""51-VG[/>`7_`.)K',V_&&/[
M/9&Y6MCG*?7Y&P()M#,6Y9UQ&-C3!F30SI\*,<K(^X=L'O+=4#$$#F`>X0R%
MP'`QKF6-:S&)<E1;Y)PNT?4>SMET6A%%72J:D.[`4VZ:31\H=8P^A0*BH(C_
M`+4>!KZ>'6),WW6V!DFL+>JLFZT>U&5L+&]MF[.1M%A=9/V5(6RMD6AA*K&,
M6S`S!L=?W%B@B8H',F!1$-E7@.`X#@.`X#@.`X#@.!#K0G^3%5O](.P7_I#Y
M5X$Q>`X#@.`X#@.`X#@.`X$0=#5FR^JN,U6@LA;F>Y(]OZ<X0=L_NY5O!#^R
MNV9L$3C[A1[NB1>T_4!ZB`F$)?<!P'`<!P'`<!P'`<#">RR@(ZY9_5$RA`2P
MGE503I"4%2`2B3QNY,3@)`4+TZAU#IU^W@8;\=1N_1C5<_4QN_#%-/U/T$X]
MT>4W4XE^Z)AZ^O3TZ\#,>P^O&(]IL26W">;:9"W>AV]D1%W&S+%N\-'23-PB
M_A+##JK$,>.GJ]+M4'C)RD)5$7")#`/0!`0HIQ/-9\\9.PN+-:<H6FK66G95
MEV+2GY^L#%A0JSMBY>3$C!(U?*,TLFO7:!N-CJIM6K\[ID2.@[S$`FB!/GMP
MX&P[3[C6K]78ZV5"61FZ]+%6.PD4$W*!%@;.5FC@ID'B+=V@HBY0.0Q%$R&`
M2^H<#TW`<!P(:^1.7;5_0O<B;>-7KYI%:U9F?N&<:X,SD'2+:A3BJB#)T19N
M9NZ5*7H0X*$$IA`>X/MX'N--VA&.I>M#4B3Y`$L%8K[DI-RF\DBJ'I<,HM]0
M=I.':3IZ94YA54*JH4Z@B(&$!Z\#)&9BIFP_E<JI0.D;&MZ*H0RAD@.F-7E`
M.452@)DP,7T[@`1#[>!U&O!4B8`P:1`@)HDP]C,J*8*F6!-(M*A`3("QBE,J
M!2``=P@`F^WIP,P\!P'`<"MKRSN?B:09.7ZR1@(_K!3-XIB>0>/"JRZ*)FY4
MB'3!-+HIWG4,/:0A!$>OV<"3.HK][)ZRX1>R+".C'BV/H(%642LDO'H@B@*"
M0MU40!(WO(IE.;I]AS"`^H<"1G`<#P&5GA8_&=_>G!$2MJ?853`X;.GJ/:$6
MYZ^ZT8J(O'!>@_M$SE.;\`A]O`H"\*U9D8[9[;>6L#]"3>K:W:A)5A?ZLT>R
M3>KK9.W%9NVTTQ:JJ*Q4F:;@#*"W<B9=-(Z9@'VU2=0V/.`X#@.`X#@.`X#@
M.`X$1=%V+B.UKK#1V4A5R7[/:A@34(L7L<[`90<I""B8F((BBL41#KU`?0?4
M.!+K@.`X#@.`X#@.`X#@.!&K4%S'.]>:&XB4S),%'=X]@AUO?,`DR';$UA%4
M4TN[N<%,/[4.@#T_!UX$E>`X#@.`X#@.`X#@.!A;9)<&NNV>W(D%0&^%LI+B
M0#%()P2HTZIV`8Z:I"B;MZ=1(8`_"`_9P,->.U3W=&M650`2@KAJGJ`41`1+
M[C$#]HB4I"B(=>G4``/Z@<"9W`PEL5KQB7:O#EVP/F^K-K?CF^QGT^9C5#BV
M?-%DE2.8Z;@91(/EP=BA'R1'+%\W,1=LNF4Y#`(<"A[%^8LT^,/:UM@S;_(%
M@M^-LPQ2$/@'/#R%E)NOY^)2V*;*L8QL2,2M+/:)LY2:K[;0HF;$9W]%/Y'N
M?-((<#8MJ=J@;O78FUUB03DX.;9IO6#M,JB1C)J!T,DX;K%3<-'C90!3615*
M15%4IB'*!BB`!Z'@.!79Y=0(;Q:>0XJ@I@F;3;8@J@J^J12#BZR@<RH=0ZI`
M41$W_P`7KP,QZ')1R&D>HB,0ZAGL4EK5A)..>5P.D`Z9$QS72MEX4/<6Z1:J
M(`9#[YOQ8AZC]O`S%FPXI89RVJ`%,*>,;Z<"F[NTPDJLJ8`-VF*;M'IZ]!`?
MZO`Z?7%45]><#K&*4AEL,XO5$I.[L**E(@SB4G>8Y^T!'H'41'I]HCP,S<!P
M'`<"M?RSG.72C(($,<O?,5A,X)F.45"&D#=R9NP0$Q3=/L_#P):ZRJF6U[PV
MH=TT>F-CRL]SIB:/,U5$L<B7\4:*_<`]G3M'V_\`;`/=][KP,Y\!P/#Y,;M7
M>.KVU>BQ*T<5&Q(KFDESM8\J:D2Z*)GKA,Q#HMB]>IS`("`?AX%#OA\I_P!'
MV/S#-1OP8AD[T>T[+9XYB"3L]NMRN;MV8PUTDY#V@$CTJ%961(BB=1`&RR1>
M]3VP-P-AK@.`X#@.`X#@.`X#@?DYA*0Q@*8XE*8P$)V]YQ`!$"E[C%+W&^P.
MH@'7\/`BYI@O(.=>:NXE&3B.?+6_,JJS%V@BV=-0/FO(9D47"+=[(H%6(@)>
MX2+*%,/W@Z`/0`E+P'`<!P'`<!P'`<!P'`C5J#:@NVO5$LP*&5"1=W@G>=)^
MB8?I^0[9&>J<G,3[TO3X?3[[M7J'J7L+T3*$E>`X#@.`X#@.`X#@.!@K:%9)
M+6S8$%5$TS+82RRDB4YRE,LK^;ZQJ^TD41ZJ*>TD8W:7J/:41^P!X&+/'HS7
MC]'M66;GV??0PO2BJ?'=-GB/48M,X>VZ9K+ME@[3!ZD.8.OI]O`F1P'`P;LA
MKIBC:[#-UP3FBN)62AWB.*U>)%,5O+0LDU63>0EHK$H!#.8*U5J502>1[Y`2
MK-G*13E'T$!"F/7+/&Q&@.:S:?[E3KC))KA)+V#"&R[V#&$A=FJHR*]3<U=1
M^Q69U2K[38^K:39:8BUVZ/Y=-6AG;%07P*IJA>WCS(=+RO2Z[D/'E@96BFVN
M.1E(.:8@NFDZ:K=0$BS5VBV?1[YJJ4R3AJY21<M5R'263(H0Q0#V?`K[\L#9
M)YXR]]V2Y0.W>ZF9U9N""'4#MW>/9UNN00$!`0.DH(#_`+/`E_B&B5C%V+,=
MXSI,,%>IN.Z76Z-5(0B;9%*-KE4B6D%"M4$FG1NFV3CF*?M@4"]"=/NE'[H!
MP\X?Y%<O_P"B[('^"<MP.EUK_DYX!_T*8K_P%@N!FO@.`X#@5N^6!NY7TJR&
M9NW6<`UE:R[<>RD=4$&R4CT4<+]A3`D@F)@`QS="AU#K]O`DEI_'#$ZPX.8&
M^1U0Q[!"/RE7:Z_X]$SC[ZKY9PZ,'17[O<<>A>@!T*```20X#@8OS;,-J_A_
M)LT\8EDVL91K,[<1YX]S+$=HIQ+H5$3QC)%R[?%,4?5),AC'#T`.!3MXH8(M
M8SOEN"92J=BBVVD.E+A*=%\@X67^?G7?^1:(`FUC6"(%10>F2.4Q2JMC(@DI
M[IP.J(7L\!P'`<!P'`<!P'`<#A23(LE'OXX[AZT)(,G3([N-=K,)!L5T@=`S
MA@^;F(NR>H@IW)*D$#IG`#`/4`X%?5?\<-.K+WZA'[7>0MTL5G)-$F\YNWG"
M>BTSR;-PT.]&(E;"YC5GK4SD5T3J)F]MP4JG[8.O`[.W>/:JW221EY':??R'
M=D8,V2R%-W.S53(AP=JD"9GIH2OV!E&)/'1NIE#$3+W"/`[IQH?5EX6CP@;*
M[RH%HCAZY92:&WV8RS5A4>N/DB2\21IXZ]S;M3AVHI/_`'DTT_N`';U#@98L
MFML3:(W'L>\R]L7%GQXX2=-Y"KYPO%9?VU9-M(MS!?UHB0;%N#549,RAD'A3
MI>XDB(%#VB=`PY'Z"55A+4J9'9W?!\XI#1FU0:/]QLS+Q%E%F[</`<W6'+/)
MQMH=.3N1(L=RF;W$BD3$.TA0`//O?'%3'TV]G#[7>1!LJ^>NGIHYEO+GII"-
MS.C*&,W91"-G*S:,D14Z))$*!$P```/0.!\V_C>IC>+D(H-L?(HJG(JM%3O7
M&]&?%Y1J+0XG*2/D5+.+IBDN(]%2IF`%"^ANO`ZO^C)I'\[WR4?]/G87_&K@
M>HKOC_BJ:A*_DSMIO>=_*D9(F?7;;#*.2TV*#1<ZQRQD;>)67CF"SSO[55DT
MP5$@`'7IP.\3TSLY%$SCN%MBH4BB9S)GR5]Q0I#@84S]&(#V*`'0>GKT'@3<
M:-P9M6S0JKA<K5NBW*N[74<NE@13*F"KERJ)E7#A0"]3G,(F,81$?4>!R.!T
MM>KD#4XAK`5B'CH&$8F='9Q44U29,&QGKQQ(.S(-D"D23%R^=**GZ!]Y0YC#
MZB/`[K@<*18EDF3AB=R]:%<$`@N8YVLQ>I=#E/W-W;<Q5D3B)>@B40Z@(A^'
M@1$M.I4]8K',SK+:C9ZLM)5\=XA7H/(RJ4/$$.0A?AQJ2[159-J4Q1,4IC&$
M.X?7@=!^AC:/YXNV?\97_@'`?H8VC^>+MG_&5_X!P'Z&-H_GB[9_QE?^`<!^
MAC:/YXNV?\97_@'`?H8VC^>+MG_&5_X!P'Z&-H_GB[9_QE?^`<#^#IA:!`0_
M3%VT#J`AU#)7J'4.GI^X/0>!T4UH=+3]9EJG*[A;</8F;@I&O2!763A<.'$=
M*1Z\8\!5=5@)U%U6KDX"<?41'@*KH2XI%6K5,JVVFV477ZK!QT#%M`RBJX$K
M6.1!%,YU%F0F[CE`/NAT*4`Z``!P.^_0QM'\\7;/^,K_`,`X')5TVL!VS5)/
M;K;!%PC[OR78906.9YWG$R?>B=F9%#V2?=#L`.[[1ZCP.L5TFLRSEFZ'<O;X
MAF0N1(BCE-1)JX^2C[)OFMRL?;=@D`=R7?\`[F?[P>O`QEF[Q>TK8_&=BQ+F
MO9#:>[TR?&+>$:+Y4=Q[V&G8*4:34'88:28-$7S"5BI%DFHD=,Y1].@CT$0X
M%#]SQOY<-1)_(>`[:;R9;<5=U49)UC'8W2N_8ZC&4PA.Q*5;KL;=HC+!GLI2
M\I45",,J]?L#F82+H2/3MU%')@3#O\;YXW]J53J%,L&G7GYLZD#!P\7)Y"L6
M2]?Y>TSCY-^8TI)S+1"2;).W2;%0"@J0X"X[1^ZF<`,8./MM<=V\I:_YZPW6
MM-_,K<C9JPM<:I396:OF(W,!`6";K,Q$HPV0ZD,BUD6[1Y*R*)7J8J/"@U;=
MR1A!4Y>!Q:-M-Y,*UB+%</E#0WS3W3,+:@UN.RG;:1D3%-8J,IDQ>'(TGUJY
M`/G<VO'UYI-M"JM5#=J:B;PX*%*"!"J!]<F;#;[WF@7#%_Z`?G9AI:X0,DA^
M4T+FG!)W;"NSS4T<5J19<CR#:R!2J*^XD=-5RF(=INXANX`]=2,H^0?&6(,9
M4J#\?_F4GVE=KL!"PLU*[9X')<Y*-A'#"!+&WBODCSQU.6.T3,J4Z7O`5J0!
M`Q`Z=H=].[&^1XJSXL1XZ?,:`1RAE'7L;6X$,@N0\85<S:)5>QSA25*V=KB0
MITR@90[</P*"4`Z=+:?R%@V53B?&3YLE#F?.'!G,SM7AA!=4JB:0JG(C(-7!
M&21W*G<FT2`R2)>I4S=I1*`<]INCY"Z3*RMTAO&YY?89C$RS\':^4LNXWS'4
M81630C&2,JGC&-68V6]5^`5:KKD:LG1$CBX$QC&``*0.^;^2;R%OVS4"Z8^2
MV=`621G;YEKC1ZVTDUUIF:*$O'-R6$DK$M5BNE4$F:AS"F5!#W.OM$,(1ZV<
MW#WMV!U2S'B\NB?DVMK"T*UUF:/LV"L9$@EFL7>JM9[#!33^1DG$X=JO`19$
MVRZ::AD5C&[1'W#!P/Y6=N?)'6Z-0(NQ:A>3BL)13!\_,QK-'<1,<W@E'LQ+
MH0#(L/<E4'KV.BB,T&GNI)I=A5$^P.I>!VLAN;Y&6D*2?L.I_EA9.IB2>+-E
MHBM2J,#\=W'*/(]!M$HWAQ)L>UZLF80,4B(-0,F3HH'H'8*[F>2-!-M8VFHW
ME8&-/&*H1@OZH_<-G#I8J:,,YD8Y*]`HJD>+<@9P<R953O.ARB7M$`#RMAW&
M\BTA6)NNVO67RUU@T[49:II6"ETIZ:8AXZ2CW,4G8XXLM;Y%HI<&,BZ*=-VL
M0WH4!Z=0`>!95X2DLCR%JS0^LV`]D\/4['>`]7,$UJY;90\7`9GS?.TR?V!N
M=ONTO'5H2P"D>UD\B_<5,470NGBXB($,`<#8,X#@.`X#@.`X#@.`X#@.`X#@
M.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@
5.`X#@.`X#@.`X#@.`X#@.`X#@?_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g893535g03j45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g893535g03j45.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0WH4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@`````````````!XP```E8````&`&<`,``S
M`&H`-``U`````0`````````````````````````!``````````````)6```!
MXP`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"TP````!````<````%H`
M``%0``!V(```"S``&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!:`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#TR_I^-D/WO]1KIDFNVRJ8T&[T+*]W]I0/2<0[@77N#V&MP.1>?:8'
M>[Z?M_G/YQ7$DE--O2L5L0_(TX_6;SQ/_#?RD'[%47OKI;8]M+12X.R;@(->
MV-FY[=WI6?SO\[O_`$G\M:/"I4Y>)4"7O%;KB+8<0##Q[=TG]WVI*:K,?'<1
M4VYSWO)@#/OW'N[;M=^:U&_9QW.<&6-+B7$-R[VB2=[O8WV_25C'R<9U5<O:
M7AHF2)F/<GR7![J*VN(%CR"6&#`98[M_*"2FN>G$EQV/;N<YY#<N]HEQW/AK
M-K?I?FHN/1=C!PK87!QD^ID66?YOKMLV_P!E%&(-L>K;/[V_5!QWW,#PVJVR
M"!+[&NU_/8W7=[/Y22D^_+_T3/\`MP_^DDM^7_HF?]N'_P!)(5F<ZIH-U8J)
MUVOL8TP/I%ONVNV^U,SJ5$N]9S*`V-765D>X[6?1?^<DI-OR_P#1,_[</_I)
M+?E_Z)G_`&X?_220S,1S@UM]9<7;0`YLEVOMY^E[4FYN&[Z-];NVCVGR\4E*
MWY?^B9_VX?\`TDF-F6`3Z3-/^$/_`*22;G83CM;D5..A@/:3[OH]_P`Y.W*Q
MK=]=5S+'M!W-:X$B-#N:TI*?_]#U5))))2+)W^@YK(W/A@)X&X[-W]G<@V54
MON>7@$Z#7PA%MA]]3)@MW61XP/3U_P"W%7OQZ;+WNL#B1`T<YND?R'!J2FMD
M.Z8RPU/9O>/I!K)C_P`E]+\WZ""!TYUNS'R'5/K#B6-W`]O<UC=S?S4:_IS7
MG?CY%N/;M#-P=Z@(!WM:]EO\K_1V56?RT',Q^IMVV@59PK.[9M]-_P#*VSZ_
M_@/Z1)39KR,VMN^M[,NH:>T@'3^4WV?]0GQ^J8CLQU1<66VMW&E^CM[!KZ=?
MTK?4J_T/J?S*Q\;J6+=7ZU62:++'RTU;G5M!&X-LHI<VJW;M_G+JL:UZ#U;T
ML[`L=U`478U;@76F_P!+T8(]/,%K:=]/TF_G^HS_`,%14]&,FFZRX-#<@AXJ
M8QI#A+6BQSK/I-KV>M[]W_GQ(MLJ@/9C@O&T!K3N,?3VUQN>N?Z)0[)RW-ZF
M]CLLU,LIR,:]Q?;2[^:R6VTMJ8VNW_15WV;_`.>V?X1:W3,/K&*]S,W,KRC(
M%>0^O](YD_S+FL-3:G,V_P#"^I_.?SF_>%)V93/5:14`"1[A1<#$$_2]+;^:
MK5?V7)&X5S!'\Y66G3W-_G6-1B0T2X@`=RH?:<?_`$K/\X>,)*5Z%/\`HV\S
MP.?%.]C8+H&X`@&-=>?R*/VK%F/69/AN'Q\5-Q!82#((Y"2G_]'U5)),2`)/
M`24BJ.ZZU^V((K#O$-&^?\ZQS$&X.-E@:[8Z1[H#NW[I1\8.%+2\RYTN=\7'
M?']G<J.;E9-.2]M-#+00T[GVFO7]W:*;4E)FAP:`X[SW=`;/]E2D,:7N(:UH
MW.<3``&I<YQ6>,SJCS_-8U`\=]EQ_P`WT\1O_30K\5N6UK<YSLIK=?3=[:B?
M%^-5MKM_D^OZR2GF<RCI'4.I696%]IS3?<Y[68M9J`EI<[]:?Z?TW[K5>K_;
M.!;6[`Z:\V^F\,]?.:\Z.J>=TM_Z'J+3LQF[W!E[*FSN](.<T-)_D5Y%3/<W
M_@U)][*[*F[7W&MAE]6QP.X;=OZ2[U-^ZO\`EHJ>(Z_]8_KR,,X>;2[!QVGW
MWT5/#CL,^[+W75M]S??Z?IJ[T#_&4Z64==G9&T9]`EL1#3EX8#VN_P"/Q?\`
MME=<RQS7/-612*[#NVDR1N]O:S;MWM^CM6-U;ZF],ZK6ZW;5AYI`]/*Q&;6'
MQ^T8^[TKVN=^>W]-_P`(@IZG#%-M%.2RUF<UPWLO!#FDG_"8_N?76S]UC/\`
MMQ3'3Z'MTLL/GNU'?;J%Y7TSJW7?J-U1V%F5FW"L.^S&:Z:[&S_3.G6.]K+/
M])7^CW_S>5Z=FRU>HX?4<7.PJ^I8#SD47-W5E@U?KLV;7;=EC7^QWJ?S7^%2
M4E/3ZBX$OL.T0!NT_-_-^C^8I#%96=[7V>T&&%Q+8V[/H?12].^T!_K.J)&K
M&;7-D%W>UCG(Q!%9!,D#GQT24__2]50<K::?3=Q<17`Y(=H__H;D95[;0,JN
MKP8ZSM,C;6T:G\[U'I*;"RL^VIF6X/L8PPTPYP!_Z15ZR]Y)KI:=X;+G$2&_
MR?Y5O_!HE=;:V[1K)ESCR3^\Y)3C>OC_`.FK_P`]O_DDO7Q_]-7_`)[?_)+<
M224X1?A.=N<ZASO$EA/WGX)P_!T]U&G&M>G=;B@ZRIIASF@^9`24Y!?A.,N=
M07'DDUD_>G];%`@6U`=@'M`_*M-N32_Z!+Q^\UKBT_U7@;7)"VQSMK:7`?ON
M+0/^J=9_X&DIYSK73>E]9P'8.5=6T$[J;@YI=59$-NK]W_;M?^&K]BXOZJ=<
MR?JGU>S`ZH=G3<FXTWO!W5LO:&;<NEXG<Q]5E'K_`/`656_X!>L?K!=&UC6Q
MS)<9_JPS_JTWIWETNMAHX:QH'^<7^I_T=B2D8R\9KI]:N'?2&]O^=RIV9>*U
MAW75@0=2YH_BI.QVO^FY[O+<6C_-KV)'&QR034PEID':-#XI*?_3[OKO4<MI
M^Q8#VTV0#=D/:7[0?\'56Q].ZU[?\)ZOZ'_A%DU69-.UKVG)<YCVV9!(!U>U
M_P#-G\[9[6._2?OW;_S[^30UG5LEC_\`#%MS9\"UM)V_U74J3\5OYNJ*G/P\
M_J/26[K'/R\&/UAA:&VU_O9..YMUC'L;_A<7TF?Z:JWU/T-O4BR]SH;5#?WG
MN`GS:&>I_P!+8N9SJWBI](!<^UIK:P"27/\`T;&_YSEU5;-E;&3.UH$GR""D
M;AE./M<Q@\-I<?\`.W5_]2G=2YP@VO`[@;1/]H-W?YJ*DDI$<:DMV.!>WN'N
M+@8_>WD[E)E5=;=M;&L;S#0`/P4TDE*22224I))))2DDDDE/_]3TOJ&)C9%.
MZ^6FJ7,L;HYO[VT_ROSEEXN'G75BVFQC6R1%@,Z?U5J]0_HK_H=OYSZ//YR'
M@_T!O\WW^C]#E)3'#Z8*K1D9+Q=DB=IB&M[?HV^[W;?\(KZSQ_Z"?ZA2'TO^
MTO'S24WDE4QOYX_S'T?\%]+_`,Y5M)2DDDDE*22224I))))2DDDDE/\`_]DX
M0DE-!"$``````%4````!`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`
M:`!O`'`````3`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``-@`N
M`#`````!`#A"24T$!@``````!P`(``$``0$`_^X`#D%D;V)E`&1``````?_;
M`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``
M$0@!XP)6`P$1``(1`0,1`?_=``0`2__$`-8``0``!@,!`0`````````````"
M!08'"`D#!`H!"P$!`0$!`0````````````````$"`P00```&`0,"`@4$#`<)
M"`P'$0$"`P0%!@<`$0@A$C$305$B%`EA<3(5@9&Q0M(C%I9W&%@9H5)R,S87
MN/#!T?%B0[4H.()3DR0E)D@*X9)C<X,T1%0U1B<WM*569F=X.:*RH[-TA)2D
MQ$55UE?'UVB8$0$!``$$`@$"`P<$`@,!`````1$A,5$"01)A<0.!(C+PD:&Q
M0E(3P>%B4]$C\7(S0__:``P#`0`"$0,1`#\`]_&@UB?%KDLM8[X<9;Y"X9Y`
M98PE=,"T"S6J*C,?I8Q<U>]R#]]66S-'(3*_8VO$J[90*;58698A[#GW>K^>
M=8/*!*5KKOC"@7G(G/O&Z]\6N*5"AK=S-RAR8I%_S$ME#D/F''^,UJ'!T1MC
MM6QP8ML98!B8N;AP8V!<\80C0CTCTY2+JJH*&5;#$N;LQBSY\7J^-)+D[A:M
MTW'=8FDN.WQ`)["F5L79E'+-AI-]XFXKG[2P?9$CB8L:XC:3<VFFC()Q4/9[
M(Z@'*(,IA!-4X`+*SKM5353XMN0<!X9AY+F1AEBTG!X!53F!CJT4')J5S?9>
M;-ST2D256R`P/CRH,,8Y'L=PNL:_4!@$W`M6L@H1)VLHU[%F4]<[7RJ^M?%Q
MO4_#I4-'CI7GW).R<@L48!QS#QV2KJPX^7!;,5*ME\CKXGEZV84KEL3A,<QE
M&EV=E8-ZL[>ED&:1&@K)O4E$V3U^=&34;SCRS7<LX'P5F_C(WQCDO+.*.2V2
M;"WC\SP=VA*Y^KT\A4(X:Z_@JH<MGKV4HV;2?LUWAH>2B43`D[8&6`Y2C'G+
M"?$'Q.,EY2S,IF0T5'5?$$E\(2(Y>L,`V?)M*KM.BLJ#R/R32CO9S.5LK-7:
MP31_7ZZU9.9)ZBDP:-P%4&AU2[*"S&GRA@?C49!G8IY6H+C)0[]F4_+/C]Q7
MKT;3\\6F&Q387/)?#=[RS0+XRN^0<!5:UDB81:E&C9-$]>*DX14%_'NG2(H)
MKLGK\^%R/C"9VYC8DXC\79?`5I1PIR2RIR*QCC^S1]4"'OT,,S.8,S/;9G&S
M"4LU;*68K[J^59FU2DBL&CI5)$BP)$[CH"IUQFYV8,T;XO61[ES/D\^!?Y!S
MP'A^+&7KJSQ;78NO.#V"\X+XYX5S%D9PUE'+$TV><8W7,2M;22,]2:I/8DZ:
MP%.18",M>NF/.6:])^+]=I_!N>\DRG%I[(W'$E-P[DFOP^-;+DF\8\L-(S'-
ML81VK.70^"H>W1TY@TSM1S=&T/6)_L8(^]1AGR)S"DRSZ[:K:3?Q)>0&;P^'
MO;..7]3,E-Y:Y19MPU>J'2LV_E%A[(#>G8?E++`+V;(LGAU')V.8I!-XSL3B
M*=U)E:FC<I$%&1S+)`HROK)G*JP^-JXB,25C(-LXO/6,]=<:9J4H]7B<L)R:
M5]Y)X1Y'UGCM+<>:N])CKWM8]I=W:)F8V9]V45%LNL@,>8[;S564]?E5E=^,
M<&5(:(6P=@-E<I3)5_XMX4PH^F\M$@JC9,T\@<$..0.0*_=99OCZ2?5.N<=*
M<JQ2FG3-O+R$G)/"M$F+90HFTR>O-3"4^*MEDSNCXDJ?%2N6#E!/\I\K<0+9
M07N>Q@\<57(F-,7L<J(WB&R$OBIS(V['5BK$JW=D*M$Q$HBF"J7DG7(0BK)Z
M_.BW'P^/B495S#RRS]PUNL*E?LB4_E1S/?VNSSEQBZE`87P;B_(%=IV.\?X[
M:M:*#[-TVREY0Z"J8!'*1\:*3QX[,=8J!19IED9\1SXELUP1E62$1C;&&1F4
M=C-UEFT1%@S<]J62I.O,K4E67$30L;5+&.3IY8Y4S*NS3]@^H:P0K=1N5ZJY
M(HFFR3KE;W(_Q9;K3K[E\D-QGAIG">`.0G'G!V2LA2&:U8N\23;DE#41W4K+
M2,;(8LD8]VZK,A>2!*LWT\U(***7NSA8SA;W!D]?G5:S+/Q%N1>1LI\<C8AI
M,=C'CB_^+%6^&<QDXM^835\RTSH[;)$1D:OS>+I+'ON]2H5VF(OSHM^WG#S"
M7U`<'"#<KQ'<N))><,C/B\<K;;@+%&(L3XDSE0..N;^3N56=*J.8<DS=1KU5
MQE1Z4S_+7*-]DY2^&)4DT6D<U80B:;LP"L[L"":(E6,0Q53K,ZXT4/B/XI=E
MRSQM^'Q,8BQQ5<L\D>9[BU4,:S:,AGQGCVL73`U*F9_D%/6.V0U0R-)LXN.6
MJSA6*:M8MTN\;OFZA-PV*HR7KK>(J'C[\5]SG*R81K3WCNM1GF8*SS.GW:;G
M*[2PN*<YXA75&FKPZY&%":,9Q:\*JBJ99%RDE%F()""_*(*Z9+UQY8^2OQT%
M5ZEA>R4WC:A-S-PXW5WE'DVAGR59'EEAZ=9K_-4:-Q[B!2OX=E6V2LI+-JX_
MEBI2Y:I$BV030!Y[PX*5-E?7Y7]R;\52<J#_`#ODBH8%C[=Q/XJWC%./,]Y2
ME,F.:KE)&:R@RH,D^DL<8?4H,HVL$3C-ED:.^MTY:<A'CE45R-$SBW$5&4]=
MM=56M?B?^\_4?_L/[/KKXL%J^&!_[R^[W;\F?RR_]N'_`+OR^=[[^27]&O8\
MOWC_`-*G\OVQC^3CX?\`Q,7W)ODQD7CU9\9TG$4S5$;ZLSI$_D^QM>0<"-%M
MQ:T@C?\`$-UQ/0&#E&WPX_7;=]3YRV1D<U43;N7`JB<Y&2]<3*S>:><.;,2\
MS^>6+F-6SIE*D47BEB*XXTBL2TFF62-Q!<Y^NY-=35UM#R9EJ[(-X^4=1C-4
M!4/))@#!3M1*`""@Q,3ZI;Q[^*%=H?C]6T,D49QE._4'X.L9\2:X9#=W-C6'
M.1[!%KW.&D\<KP,;0W<?6U9IS2C.1FT3N$T!=]A8PP)=RC)>NOXI?DGXS&1J
MO7\J7BH\2X"QT?`6/>"^3<MO97D`K"V%:)YSQ=8"G5C'\&3#KQG,V.L6.R'1
M<.)!]',5F,>=<3(JKIMR,DZ_*YA?BE9/8.;SA^?XX4Y#EA$<NZ'Q%IN/8;-K
MV2Q)-3^2\7GS!#7F?RG(8MA+'$UBITUH[^MTFU9>.UG;=))J0WO6[=D]?.=,
M),\^*UF62M^/>/U#XF5>Q\K+3GSD+QLM5'E.0(U_&=5O/'[%]5S"_MD+D!?$
M[F2MU"MF/[-[\T%:+AY)%5`S4Z!E3`;3)ZSG1>?X@-VS(CFKX>N%L>9GON"8
MOD-FK(M/R;8,4EH;NTJP]<PW8KJP90\CDF@7B$0*C.PZ>ZIXH3*(F,`E*(@)
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M]E*(H'%.O7BA8BY$X'XZ2MAG,^*4^UW*S\DZ96+!C5W6:NGB.P140WC9>R`W
MFQD)4$V[<J*C8[HZRY&3*>ORD=6^)E=+IR'X^4K)%4D<0O:=R<^(%QXSY`8X
MR5&73%4Z]XK\9F&80M!E[-A6*OMQK:S">;N(M%HI4WS5^D91T5VE_P`3T,:5
M>.B?$/Y/V/C;:^6\IP4<O\,2F`76?,)$QKG"-O=]LK4TTV8P-"R72R4&+L%1
ML<W5G/Y2K.Z^UMK"-BDUD5#*/DRMU63$SC.K(O@!S/;<UL7VJ[]N)"R-0NKB
MI/#X=R=-Y$KSU`(J.E&<D]C[OCO$N3J%)JF>*MU(FPUV/>%,U%4@J$/L2I9B
ML[]$-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-
M!__0]_&@M5G#"^/N1.)KWA'*L4YF\=Y(@U:Y;8EG*2,*Z?1*RR#A1!"5B7#2
M18G%5N0>]%0APVVWZZ$N-4B?<=,4R.6<39N=P;U3(F$:-;L<X[EBS<L1K$U2
M\HP3>QL7441V$=*K.TJVT`B[E-15+RQ$AB]QMRYNS$-I\)+A8S6>@G4\A*PY
MX/D/5*_4G.8<E.*50J?RIKTY7<X53'M34L8P=/AKD2RO7A_=$2.$7RQ52*@"
M+<J4POM5353X7O#VL1]_AG=,N5ZA<@81-QK5B,FY7R3D!I3,`G=-9,V),:'L
MMF?/,?U!.<8-W[=.-5179.VS<S55$C9N1*X3VKF)\-+C<?&S['DK(YNL;YSD
MBD9>C\JV7.^39K,]9R/C*#"KXYM-1R,\L!Y:M/*75^Z.9IM`3;F:**%736,H
MH8S![5U''PO.):T7BI@WALFQ,EB>1RU),[E`YHR?`Y!O"F?7J4GG!#*%\B;,
MSM-Z;Y2DT@7D_>G7>F?<K0S9,1(+![43^%GPJ+3G=!7QA)/JJ]XQQW$):,?W
M>XNP#",/D*4RK#PR2ZLR+A*>B;[+*2#>7*8)%-4B9?-[$RE!@]J[-7^&3Q5K
M-E8W52*R5;;PVS'AG/[VZ7[+^1;I9Y[+N!:?;:)CJX3\K/3[M615CZQ=GS99
MF(%CED_)+[N4C=$I!FLH<O8%QIG1QB5SDB'=RZV$,QU3/6.C-)>3B0B<ETJ,
ML,17IAT6-<MBRK1HQM+TIF;GS&JHJ`)R")"B!,L7J%\+KA'C:(JM=JF'DFM;
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M5D19NW$$P!$@`,UT6WPV^)$5A)7`=7H4Q2:4CF9]R(KLI2KO;ZS?*1G!V]</
M&N3*3>XR81LM=LD,FX%HS,DN*"4>'N9DSM1,D89NZ=T;X?W&7'SC%$G!U6QN
M[)B#+%\SM!W&PWNWV*XV?,>3JRO4;YD;(]BEY=U(W^S6.!7\A562,LFD1)(J
M)$R(I%(,W5W:[P,XT5*\0V2JY3I:(OD!R$S#R;B[2TM]F)*M\GY]9'C\OE,L
M,F8J],O+02%=P2A31>Z"1B(D,D00&:D/([X=G&+E3<YF]99@KNI,6S%Z>&[Z
MVIF3[YC^'R-CQA..[17H"^15/G8AM8TJK9GRKY@=4`.582E6%9%--(@EL=R8
M^'OQ=GHC*4)+4V;=L<S9$Q!E3((#=+2FM,7;!;:K-,<2B*Z,HFI&I12--8><
MW;BD@\%(PK%.)S[C-4\K\-/BDKE\N:?R>OB=@;YW1Y/1E61ROD1+&$+G]1P9
MU/95B<:$L(5!K;+@OVC*K"U.5P!3`4J8+.`6&;C#(2R<;L/7+-]:Y"VVJDLN
M2J=CJ=Q=574X]>R=>@*O9YV/L-A4C:D[65KB$_,/8EJFM)>["]%J@5`JA4A,
M4PS=F/M@^&MQ6FTY<\;7[O0YF0SY/\FHBTXTR9=Z#:J/F.X0"%6NUCQ_-UR8
M9.JBQNU=0]UE8UKVQKL#"J9`%P*J5@]JQVX_?"'Q#0L/XCH65IFS3=MPG>>2
M$G2KCBK(V3,:/U\;<B+Q)6"R8PM$Q"6*/LMFK\G7SLF<@#IT=<ZR!U$5DS+*
MF4F%O;A>60^%9Q!<PN+(&)@LF4QAB?&#7",::A9FR739"W8996U:]M,6Y&EH
M&QLY.YU!K<'*L@DDY5]X2764[%BE4.4UPGM5:9!^'1Q>R9E&6RE9Z]=/-MDW
M0K/DC',1DR]0N&<M6G%J48CCJR92Q1'3B%-NDI4T81D5(7+84716:(.TW`)E
MV&;$H2^&=Q21RROF(L#D$9\W(8O*R.K/];>1BXT@N0*ZQG$[DZ'QJG8DZ<A9
M+4N(#(K*M%15+W)I^4DJL11@]KC"K<4<!>.N',JQ.8:K'Y!D[/4F^1&>,XZ[
MY6R%>ZCB!EEN5:S62VF*ZI:K!*0].2N4BR3,Z%!,RA4@%%$R2!C)B,W&%T5>
M,>'E\CYJRNI`/ANW(+'%<Q1E&1">F0;S5)JC&PQT)',XX'@,89PV:6EZ4SAJ
M1)=05`$QA$A=AF[,9;-\*OAY:(V@PKFM9$AH>@<>2\4THZIYBR74D;CQ^0=.
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MR!W<*Y5;F`K@`%)0Y?`Q@$2X8?\`);X;<3:>&5]X:\9(^@4RNYTOC6R9JOF:
M9O)N3KJ\?/)>$L%@RXWL$K,S=GO>:"R]6CE62LS)HM"'0(/F)IH)HC,+.VN:
MRSB^&>`8>5P7-,JL]2DN.6%)[C[BE9&;DF;:$QC9J_7*Q-0[B+CUF<2_=.HF
MJLR%<*(>8@9,12[.X=5,W5C;/?"$X0S]8KU+4IN08>IP>$FW'B0@*QF/)E98
MWC$T58Y&X5JM9#^I;*S<7$*I:Y9=^Q6=J&6!4Q2+&61322),+[5>&0^'OQ=E
M#VY5_39MPM>LP89SM9E372TE._R7@*+@X?&<V7RY0A6K>(8UUJ5=HD!&KPQ!
M,N0XF,(U,UW:_P`!>,59RQ'YJBZ3(EO\9FW.'(1M(.[79'T<.4.16-X?$V5Y
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M&@:!H&@:!H&@:!H&@:#5'\:'+$GC/@C>8.O`X-:LSVNG8CA$VRHI*'BGCQS?
M,G"82J)JBDAA:@654W8/<!4^[J4!U*UUW9)_N\^#_P"RYAK\SH_\'53-Y/W>
M?!_]ES#7YG1_X.AF\G[O/@_^RYAK\SH_\'0S>3]WGP?_`&7,-?F='_@Z&;R?
MN\^#_P"RYAK\SH_\'0S>3]WGP?\`V7,-?F='_@Z&;R?N\^#_`.RYAK\SH_\`
M!T,WD_=Y\'_V7,-?F='_`(.AF\G[O/@_^RYAK\SH_P#!T,WD_=Y\'_V7,-?F
M='_@Z&;R?N\^#_[+F&OS.C_P=#-Y/W>?!_\`9<PU^9T?^#H9O)^[SX/_`++F
M&OS.C_P=#-Y/W>?!_P#9<PU^9T?^#H9O)^[SX/\`[+F&OS.C_P`'0S>3]WGP
M?_9<PU^9T?\`@Z&;R?N\^#_[+F&OS.C_`,'0S>3]WGP?_9<PU^9T?^#H9O)^
M[SX/_LN8:_,Z/_!T,WD_=Y\'_P!ES#7YG1_X.AF\G[O/@_\`LN8:_,Z/_!T,
MWD_=Y\'_`-ES#7YG1_X.AF\G[O/@_P#LN8:_,Z/_``=#-Y/W>?!_]ES#7YG1
M_P"#H9O)^[SX/_LN8:_,Z/\`P=#-Y/W>?!_]ES#7YG1_X.AF\G[O/@_^RYAK
M\SH_\'0S>3]WGP?_`&7,-?F='_@Z&;R?N\^#_P"RYAK\SH_\'0S>3]WGP?\`
MV7,-?F='_@Z&;R?N\^#_`.RYAK\SH_\`!T,WD_=Y\'_V7,-?F='_`(.AF\G[
MO/@_^RYAK\SH_P#!T,WD_=Y\'_V7,-?F='_@Z&;R?N\^#_[+F&OS.C_P=#-Y
M/W>?!_\`9<PU^9T?^#H9O)^[SX/_`++F&OS.C_P=#-Y/W>?!_P#9<PU^9T?^
M#H9O)^[SX/\`[+F&OS.C_P`'0S>3]WGP?_9<PU^9T?\`@Z&;R?N\^#_[+F&O
MS.C_`,'0S>3]WGP?_9<PU^9T?^#H9O)^[SX/_LN8:_,Z/_!T,WD_=Y\'_P!E
MS#7YG1_X.AF\G[O/@_\`LN8:_,Z/_!T,WD_=Y\'_`-ES#7YG1_X.AF\G[O/@
M_P#LN8:_,Z/_``=#-Y/W>?!_]ES#7YG1_P"#H9O)^[SX/_LN8:_,Z/\`P=#-
MY/W>?!_]ES#7YG1_X.AF\G[O/@_^RYAK\SH_\'0S>3]WGP?_`&7,-?F='_@Z
M&;RA_=Y\'^X?]5S#?T2_^I\?ZS?Y.AF\HOW>7!_]ES#?YGL/P=#-/W>7!_\`
M9<PW^9[#\'0S3]WEP?\`V7,-_F>P_!T,U:K(?`CAC'6[!+1CQJQ(T:SN59>*
MF6Z%49)I2<:CA#,DXDQ>D*``X;)S$,T<@0VX`LW3-XE#0S=7_]/W\:!H&@:!
MH&@:!H&@:!H&@:!H&@:!H-)?Q05"Y(M-ZIX)E6B>-'!S.F=IKP5]VOV<WI,)
MXF<`7M[6:B=%JF24Q,(B=4KH`+VE*?OE:ZMVFJR:!H,7+_FC)QLPS.$<(8_I
M5PM=)Q55,O7Z2R/?IFA0+"'R-9LA5/&-:@3P%$O;^5F;?*XCLHNW1TD6T(A'
MHG.1V9VFD0N)C-="2YCXKJ*X162FUJHD]%)1<1>TG%;E[!5:%DR0Q2WS,KB2
M7R#7F3ZGO+HE1G*;A#W9RHR>JKMFZ"YG;QJW6&'6@^;6%)R:J,'[IE.#<W!Q
M0FK5S:<09#K<;"+Y7F;#7\5HVQ_+0+9O6G&19BMJHQB+H2+"+AJ*Y$"ND!.,
M5\JW.+`%WC923J$K;[(5G&4RPQ3.(Q_;GCZVU/(4J^AJ?=*NBG%"1[4))Y&K
M'<2"YVS>):`1W(F:-%D%U!BK\8IRI2<UT&"R7CN45F*E8C2R+!ZNP?1CDKR`
MFY*M3T>Z8R*#9TW=Q%@AW314!*)#*(&,F8Z8E.8FRXF@:!H&@:!H&@:!H&@:
M!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:"$/IF
M_DE^Z?01:!H&@LUD_P#IMQS_`$RSG]GO.VB\O__4]_&@:!H&@:!H&@:!H&@:
M!H&@:!H&@:#27DU0M^XU_%SY`G3*="\V7(&&*:\+L<JF/>*M6;8?7;).>T/>
M6X9Q:WUV02_BR>^B4NX@8YXUYD;M-5DT#08Y9.PK6+YD%K887+-_PYE.3H#R
MIRLCBV?I;"S73&,7,'=IQTM#W>I7=HK'U&PVM91A,,&;25AG,PL5L^0]\4(H
M7*W#[@?AITW5@&LUD>*QTX+"/7>+&EDC7E/>VNLX>98*K=Y>2,[7YB_N;)"8
M]AXY--,\X,6O)1K>1<,UGX*.%!E=J0XY8^DS21G2D^8):0X^R3LA9!KV"OQK
MNT=?<>$(4T<8`1<3D6F63*._O3<3$(*(CW`,L=(7X;''^O5;\CXA_<FT(Q6Q
MZ6L,U&F+WS"KQ&,)B5F*E`C`2.,W=7OS5JI*@FJ]N#&R3*Y6;-4[T7+1NNG,
M+[7.65N$,-U3`6-87%=)<3+JMP4G;Y9FO/N63N5.ZNMSL%ZF`77CHZ*9BBG,
MV5P5`I$">6W`A![A*)C5G==C0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0
M-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-!"'TS?R2?=/H(M`T#06:R?\`
MTVXY_IEG/[/>=M%Y?__5]_&@:!H&@:!H&@:!H&@:!H&@:!H&@M5G7*L/@O"F
M7<U6`I#PN)<:7C)$FBHKY(.FE+K4E8E61%-C&\YZ$?Y*8%`QC'.`%`3"`")K
M9&O7(V+I;#'P>;;CFRE,%TA>*D@_R*L=($#OLI6F'-;<IRJB.VZ2LQD.=DW1
MBF$QRF6$#&,;<PSPUOV;7]5DT#08"6K_`.U(P1_]03EE_:(X6Z+XOU9]Z(:!
MH&@:!H&@:#1?:^3>?<=7?-G*2/H^5C8GR=`\A:#BN3L;RH3V&FS_``SCI_*<
M8[9$4^&O[C(L4QR;<,97)1XZ=P$3]:'O$*T,X,5JT.:-8FWE<3-.<^5.-<D5
MJ.D;$RNSS&66\E$BXFCU:6HT/G`S[@E=\HT'%=AB%;!8BNI!_E]HO'1":+I<
M[DZC`024D&OFJ#$X3O`_*3DMFBV4*JM+1C4M=D\CQ;6=R'$TIK92R<"CAF>R
M)9*4V)6,BS%/@YM&PQS`H+C).W\;'2GN;UF5^B5VN,2>%+8LY@YM&$Q!&>\T
MAI/N87!\$C@:0KMF<W^R8ZM'#VI9<M.>(RQS5REK(K`T[)LE(QJCMTB]8*MH
M!Q&NG/UVZ!9`8WN%],CV;+;OBCQTM&6+Z[;Q%WN^'9SE#=L81MCQ0YJ^)KA$
MN9B5:1CN`L<Q;J35(^]O(.,G9="12<LJNH_<N'+5,B[M(:9N%JC6!TYM4,GP
MQS-;7-,AW?(V5;67(:UMSCB*1DH#%>&91*N8JFY.XLG=LQXC:%A`SKZUDVL?
M+.)QC&G0\LB;(?6*1G/B"9N')%6B*]&5DS&PDMS*9J4A66"$A5`BN!5HY-1L
ML@@AD>1R'+(ERS"L(<9:2@X&&=LI4C%HBY=%3DEF5]9AWLH9\Y=UJ%LL9/V^
MDV.%EIG^KI8*MB>Q4^QI,<@\++WFH;'$SZ&1)LT+)T[)5=29Q_:@N'U>J*3A
M15X9-RD3$X21QS7SW6JA!LH6TX[O]()9,8UR1Y,L(.%KE)KLA.X3N]SM>.IQ
MW=\FMZ8ULE8NM:AVRTE)2[82I3R<.JB,V*;A0N/C5FUP_P`K9WS8%ONF5%:M
M6X2(C\60++'<'1[!#/$+5:N/>"LOVJR'L=HFC32D,2P9&D&#&,7C&[IHBD!7
M2RBZ9@"LW$9N:(:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:
M!H(0^F;^27[I]!%H&@:"S63_`.FW'/\`3+.?V>\[:+R__];W\:!H&@:!H&@:
M!H&@:!H&@:!H&@:#!;GF=.V4S"/'HI/>5N3?)?$6.)1B0I55'6.J/)/>0.8T
M%D!$=HR5Q/AJ8BW"IRF23&2(4?:.0!+/-5!\0W_8?Y1_H;N'_P``-H3=F3HA
MH&@P$M7_`-J1@C_Z@G++^T1PMT7Q?JS[T0T#0-`T#0-`T&(/%W+5[RS?>:"=
MIDF[FJXIY5O\-XOCF\*VC`C:K5,'X1FYTRSX@>_33A[D2V31CK.1,)1)V)""
M`)$(6^&7VB&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H
M&@:!H&@:!H&@:"$/IF_DE^Z?01:!H&@LUD_^FW'/],LY_9[SMHO+_]?W\:!H
M&@:!H&@:!H&@:!H&@:!H&@:#!654+DOXBE4AP3*YA>*G&.<NKX2['11R1REN
MQ:?3U53"!@2E(#'>"+00I""!P:V,3']DZ>Y?"H/B&_[#W*3]#=P_^`&T)NS`
M%\R+])XU+\[A(/NGT1\^L&'A[ZTW_P#RE'\/01@Z:F^BY;F^99,?N&T&!5H.
M4WQ2,$"4Q3!^H)RRZE$!_P"D1PM]0Z+XOU9^Z(:!H&@:!H&@:#7S\.(AI+&/
M(&^]B7D9,YU<V[+'.$VHM3/8BN\B+QBR&<K^8LLZ5<?56.D4S&6[#$%/RRD*
MD1,-%OCZ-@VB&@:!H&@:#5AS/Y.Y"QEF2N_U>)Y'>TOC=3HC-O(!A1:-,V^&
ML5;M]Q90+JKVN2B6$@C$EJN#ZY>[*DT,!'"TR2!5*<B0&!:-2?Q,D<ZLJX^;
MV"[)TW%%AQ=(7K+&,J'+M;/.,EHN1H$G%H1F3<AV$Z3R")C(\2K(R,N+!+NC
MHR-]\*Z5!<R#<8GXK(7WG[EZEYC6]Z4H=M8X]AN0^+W<=C>6>*8VNUJ/F/X4
M5/I.3I1.;DDUF,ACEKRML`.XHTND@D8CIC]9`)P?%&)^WXLP4>360K1Q!R#E
M(8..IF2H>X63#[9Y&OJ]-Q418"Y00Q*QR$M&,I^VM(4:^K*$E9.`?/G;B+=,
MW+!99P"0.%JF-5FI7D_<ZSS%:+I/,CK<9:M>J5PZG%W=8G)'&A;S:HD7(YA?
MY.7;.6SVU-LZS]5QA[HX=$%)TM)KK&44%(-1<:?*FE>9/(VP$XP_6@8RQXUS
M9,<.\FA(UAE,V,JN-<X/<@I6?&,RA8G;!9">)^342NG+,C)@;WY=D5`WD`Z=
M#$<V+OB$YLR[6H=Q`8QQY79[(K3CI8**M9YY%Q&UJ&SOD"4IDE%6JOUJY3-O
MLJM+;1:BC2830@&DY(H.V*C6,.T,HJ,15,)S9R!&2]MC%HBD.&5`SFRQ[.UR
M=L<T[R1D,N4>;.7^.<6^Q>0_NR+*'I2-.3<,FJS22^M#IKQ9%(\&0.EAA<BS
M9^S@XX-7?/[P]+I=FE$FLO!3%-:O91MBW$DK:J]`6+(LZ6XD=QTO9\:4MQ,6
M9R!VHQ0`Q31.BNFFJ9:IIE1=GMT]2KI6,>\?^4LAE>R2^2,&DF*ODR5+D"&I
M4;<:_G,7LY-7FJ1S&3DH_(B-13>)5@S]$$5X`JC08]J_.H$7ZQ34?\0R_K6K
M%,0]IE#.C-Y/PQA+)<5!.;(^7@;]D^^V.@R;YK;;`I4XEBV8*0J<O$PT>PM<
MD_BSJ'?JQ!2%54&)AS5[FYR&5C\;VZQ4?#8TZXP'P\KE*M(9_=4[$RA>?N?G
M6`86"C5GIU8Y:6QRX;DGW;Y4A4'J:OU8DV*8GUF88BV^.^?N7ZQAS#4588ZE
M95O%YP]Q7FXR\U9^XFTH&6R_,3%%D&N8&+^P5IJ\O\D_JBJ\>U0D85&7L#AQ
M#E,W,T(\>#$_!<MCRQSQF/&F8K!",,=8J;XJXOO\QKS2%E&U2KC*5?RER>I\
M&*3ZO2LE3VN,'3SC$W>RT8X<O)$T?/.(QPJW<,U3JC$RVD5Z5&>@(.<%HJP&
M9AXV5%BL<JBS(9%DB\%HJH0`(=5OYW880``$0Z:K*<:!H&@:!H&@:!H&@:!H
M&@:!H&@:!H&@A#Z9OY)?NGT$6@:!H+-9/_IMQS_3+.?V>\[:+R__T/?QH&@:
M!H&@:!H&@:!H&@:!H&@:!H,%>%"A;W+<KN1!TP4)F?D_?:Y4WO004QKQM0CN
M-E<39'[2G-#RMLQE89UL([@<9Q10H]ARZ+?$3OXBO^PORJ_0K=?]&'T)O%0[
M;CU^3;?KON/CT].NKB^=/E\`V^ST$/`>F@;]/3MX!\GJW\>H[:#'27Q%9GW+
MC'N>T'\(2H5'CEF/$,C'*.GY;*M9<A9,P5<X5ZQ9DC3QBL&UC,8OTW2JCQ-<
MCA9N5-%0AE#I,:Y:S^6SY9*)O7B7\V\<I?*FX5#_`.]/XA\FB.^C89U';RY>
M1#QV`SM8Y>@`(;E4.8NVWR:8G!F\IFC=[*B'_I'S0\>U9LV/Z0``[A1`^WV=
M3UG!FIJCD><3V\UO'KATW$45DS"'I]I-?M`?]SJ>L7VJ=-\FD\'<2<-O$[=T
M!O5_FE$2;?9/IZ_*^WPGS;(%=7V!55RT$=@'WAN8Q0$?\IN*X;?+TU/6K[14
MC6:B'NWNLDR6,/@0KA,%/^",8%/X-3%X7,3/4&O?X51`5X`<=)X&Y&WY?0=Q
MRN*:;8C0AC9?R7=,HF<`W*LX,3WLUO%414.=8PG[E3"H)QTB]MZV$:(:!H&@
M:!H)<6'B"GE5"Q<<52=,0TXH5BV`\R9-DE&D-*F!+ND3$CFZ;<!6[]D"%)]$
M```Q2KUJQ1G*S\D^+GY(V'&\_@Y]68.6)#+-:;*.ZKEFB-K!5\G8VGJB\*Y8
MPDZ8LK$&-W)J&=0SQJ[1,D)T3EQC%7'Q5QNQ+B&JR%5@*VVF49MS8G=BEK6T
MBIF7L!K4UKT;.-)`Q8UI&-X9Y#4^&8?5K-JUC2LHAFB5`"MT]AE<"9QO1IS'
MTSBMW68MOCZ=K<I47]6B&Y8*,+7YEFX8/X^/2AO<1B2G;NC]AVHHJ(G'O3,4
MX`8")FQJ4"SKZ-:5C6,C&%5,\>)2$;%J$EI=>2-./YZ4:-V+:.<3<K85%)%R
MN5`@JOU3K[`<V^@+4VH.6K1BXJM;<,F#>%:,6:T'%JM636MO4I*NMFC<[4R3
M=O`R+=-=D0@`5JL0IT@*8`$`XHZC4J(5D5XFGU:+7F)E*QRZT=7XEDK*V%%0
M5D9V14;-$COIE)81.5TJ)ERFZ@;?0%:-2EY6(G%Z?5EINON9=[`S"M?B5)6$
M>6!RN\GW<1(':"[C7,X[<J*O%$3D.Y44,903&,(B$^:L&+%FE',F31G'HI"@
MBQ:MD6[-)$=]T4FR1"(II#W#[(%`.N@IV!H%$JK0L?5Z54JVP)*#.$90-;AH
M=H2;,@+4TP5M'LFZ)90S813%P!?.%,>WNVZ:#@4QOCM67;6!6A4M2>9)-T&<
MVI5H,\NT1:3061HBVDC,1>()-;$`/TRD.`$>AYX;*^UH)H%3JP((-@K5?!LU
M1K;9LW"&C@0;MZ;(#+U!!!(&WEHHU65'WJ-*4`*Q<?C$0(?VM!*FV-<<LXB9
MKS2@4IK`6/R_RA@VU5@D(B>\E!%JC]<QJ3`K*4\IJV33+YY#]J:92AT*``$M
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M[VQVM5X^7.38AEG!A*`%$``7>K0_$C*)^!7+8@;@)\%WTH"'00$T.L'0?7UT
M)NUO!BQT/4SAZ(^G=PN(C\HCW^.O7^#ROO\`56Y_\X>?_I"WX>@B2QM+-#>8
MTD99L<.H&;R#Q`P"`[[@9-4@AL/S:9'=_)R^('*JWN=Q24)U*=.R3)3%'U]'
MH>&VFG"Z\N\F[S"Q.*C?(EQ,82["#J8=OR;;>A)\=PF4=_2`;ZF.O!KRF3?(
MF>XORP3N2SU-+N_%2,/"NN_</\ZL,<5T<0]'XS3'7@S>4[:\@<VQW:#N/JDL
M4I#`)EXI\U6.;?<#F,QDT$@[?4"8:GK%]JJECRNL3;M+.8V35+N'F+14ZHF8
MH`00,)&CR.6`XB?J`"L78/2.GI.3V^%;1O+#'SCM++Q%K@3].\SF,0?-BF[1
M$P%4C7KAP<@&#8!\D!'<.@!J>E7VBYL+F[$\\<B;"\0B:JFQ2H2:RD*N8XB4
M.PJ<PDQ%0^YP``+ON(=-]M9Q>#,Y7-;NFSM)-PT<(.D#@!DUD%2+)*`(=P&*
MJD8Q#%$#`(#OX#HJ@<W7V6H&#,SVYG)O&Q:KB?(MC`"G662+]25"8DP,+4%2
M@J(>Z_1`2F'T"&LV3%T:F\2G@]*RV..'?%"BK,V:B=0XX81KBR0I((+@XB,:
MUEBZ.HK'G,T476<HG,HH4#@HH83=QA-N,]=(M[7-^K,ECD:'<;%>(N6!QVW-
MV^\H!Z_;2`%=@_[WJ>M/:*S92<?(E[F+UNY#;<025*8Y?Y:>_F$'YP#4Q6LY
M=[4#0-`T#0:UN57;QZY6\8.8K4A6U0NCYGPHY'.O-!)LVI>6K(G)<?KW*F6%
M)D@TH&>CI1!W2IRBV975T;Z`'$(U-98V4ZK)H&@:!H+89<R_2,(5-E=+^_<L
M861O.-,=,/<&2TD_>VK+.0JSC*G,&D<V[G3KWFSVQKYXIE,*#4%5A#L2-H;L
M#KKQCQQ-?%"Q#DMYAN,D6!^,6:[]/70]:<K0X9OIV:>*:&++#*3()#&)W^%K
M))@(@5#@[*S([%(!(140+G1KVR[R,^)5COB/A*^U^V<C;CGV^T;.^7)UFEQV
MH)ZO%S6.7]6;TG!TQ6*/Q*R-8VI+'`&?R)&<@I4WDJFC(.4[9'$:-HY6:M2=
M=<JLC\C\S\99RY2(\?H[-%YL%BY.\J[.PPA<\%2#+`TMCUAQ'<V7%V4*_GJ1
MQZS7-8Y;D16Z]6R1+6VJ-7322.3ZI0/_`,HG&)B9=ZJ\C>?*V(*S+9"O>9Z]
MCV0S;)1-HS]1.+T_>\_U:LL^.ZUK8UE;$-LX8XEAY"MRG(5,E?\`KEGCUT1N
MDL$2>4%ZF>8T,3PO0ZY-<O([+E>QZ[:YI$EKS-P`<0CEYQ>D(:%_J3OU#@R<
MF%;+/,Z;;*A1'PW\CY.58/;(YEZXX$46K@C<A%3$Q&*/';-7-C&43\,_$T!7
ML[P-/C\5<+*SFBN6C$3UY3YJ*R2\L57R=*2T\YX^VRQQMCH(HQP2*[W(E+/!
MN#-^^'ED7:JR+A;)^:LI[6CRAR%\&KD;8\L6C*N2>0>4./>89)K57..JQ3;3
M5I-2/G8:`I=-IN.*'4;`HLHV8(.`%\60DG#QP<Z:B:!D6Z3PFGM&MW&$#SYQ
MMFNVY$KN/,I3]XXT<4N9'"7!S:=KUKF(*XQ'%F5X\.,/9409&C'3*VS.2&N3
M)IS$&.FY>V5:!5;D\\4CD*:N-/JR4R-R3^)G!X#Q[<*G8LBV55/+&;6J4C6,
M#7)[EK+5#@JUCYQBJ*EE)WX>T=7H:P/KO(6-D@V_JQI#"VL&[$&ECCG*;A1T
MU3'7*X=-2YPQN4\CEQE<<K8T:\B.7W+RG*5>SXHH4Y5,9BOP@<W_`!+F4DO.
M5"RR+5Q"YRIT9%$%6>>TV0\U5C[JX<*%<&&GE;/%G+KXMN45[;-,\3VRN*2.
M!,W<IL:T2V8E@H9)-Q3*O<\`T#BS97[J!;O37*S9OB6F2FZ97R,L[B%4F?O:
M;!4R)6ICK%^H+*?-V[OL?4>E9AY%'QE:N7N-J&7DK=.*]%QGE]_BV8XI9MON
M6XY[C:_8!@ZC7:G3,TUFOL(NRN:HCL]=?5BSB0.@L=Z-.$[^&!/\I87)V7L7
M9WC[U5\4ISW)6Y<=8U>GMDZ[;(MYS:SVK>['D6W3583MT-DIJK/1`5R%0D6\
M*_I;E&1;(.3^<HU1+C$QNV34*\<FIBYH161./V.J-1C_`%EY]P@>0;N]32/D
M-USQ?93E<,5)-;ZQ<D335_Y3+[L4XF_&]O::IIRTZ8>XE9Z2N6;>4D*E6\4S
MN,.5WQ*;_!2T14+XKR`S;#RETY#UK&='LY9E\C29O$JKR=B9Z(2-%2Y'J<1&
M>ZE3`PJC%S-G:F[/SPK4-4;.PO&4[#EN^<2.!4G/Y/=\><2&LU1N>8>9U`@,
M[5&.C8;#3"%1CJ3C"S3*PP\FW>+PK'O?.#^>D+T"Z<:.<V=/B$XR1M[N?N'(
M3+T4>)^(E3H]-IQZQ82TU[]7#DKB_&_'3*L.%*P='-I&WY#QG;9B9>"O%RT%
M+QT=[W$U]4S95-V,2X3[`N1OB&YVE<(8[LN8LP8<;/7?/5.WY1;X(QTO.3\?
MC:W\>#\8'5M7RMQ?Q]!L32M:R#-=BK>D4I>Q,6S@PQS1V@)V@N)X9!\`,X\M
MN3.),_Y!R.^1@++4V43QTH]3?0E9CXQ+D3A#'ZE?Y$91(]BH1H^<URX<A95Y
M&,VJKM5HU85HID&S8RZ_G$LDL8D8)K5IKZW&)3CKC+D/3>355P/F(O.>QY&H
M>8XI*SY`1P%--(QO?+CDV,3QCF?)DSRK"(D:Z[CG4VW/"HOUF1R1"Y/,+?.;
MHIU_G'EOGJP8#?3-DY54F@T.T_#)G<@O(3C;+T24/D6U5KE;%\GG,G`6K`JL
MQ9JXUR!`5!"2138.8")<"@JW(W!0JPC&%M\*X\Y:8$>V7*V/X_-V1\U6/#WQ
M0YV4M.0<<QTU8%+#^\.X]TFH3/Y/U.B4IG>[>[P=17UNK<0\0>/)DQE6D24L
M($?&,QI=_A?J^9T^).C2XXV"[1EN^UZ^\A[%Q;Q!EK*''"ITJ^.8'+6/,-SM
M"Y795QP\Q%0BP%-P!DF-O4*#TE?BH>PQKALX=1JHE:N%FICJNTGG7EO=/A0\
MK^1^4FMQQKD^U4O+TQ3*<\J[*G73`^.*O6H_&U@DD&[&(82Z\HV=5.QWMB\>
M^]NR)2B!$C>[(MT2/"8D[2,Y&N.N4"-H;4IG8^-#[B0_CT*DE3"4O*<?EBKX
MPCX1"";PS"\-<DOJU=I.TQ20E.[&.@@A@6W3^L13`QZF9^+4<UP$E7,78RRW
MD+&N:5./^:^;F3;OG;!U7B,U726I/'>IX?Y%XRXJU^1QQ"+S]S<19KLRJUFG
M13;=QK3.I+N"BW9-3-HUG]Z)]@;D-1,$8>R':YC-F0.0N1N`K>&SCB&+;3Y+
MX%*Q9AG$LQF>G/L@>]/Y5+(.0W%&94N`:%9'E(J]9#F;`@H_!%=%,9F?C+.'
MC9F&UY.Y?4>?+45J%$WOAKE5+(-1CWLNXJ)%\"<M#8QX]9"J[::@:L]1K.8J
M=8+A-P+A:.:N74`+0BH&!NF.B6:?BVM:K*S63_Z;<<_TRSG]GO.VB\O_TO?Q
MH&@:!H&@:!H&@:!H&@:!H&@:#!;F\=.YGXP<=BD]Z'/G*#&XV1@!2B13&N`@
MDN35Y-(B<2E+!S!L0L(!T`#W+#.IH[;*F$"SS6=.B,+?B,%[N"G*TO\`&PG=
MR_;BU`T6;Q284E/TH!]H/\`:[9<<(OR(3'_,`/V`]/AZ/3IDPXQHZ8_Y@NW\
MD/[P:>QAUE*,F.__`!<OVO5\X:N3#HJ4-,?_`"</EV`/'3*82Q?'Z8_^3^/V
M?'3)A)G..R#O^(]/3V0V^YJ^QA3SK&Q#`(>[E'_<_/ZM],IA2;[%R9]_^*%'
MY@#?5]C"B)+$:!P/NT#P'[P.H_8#UZN4L4FGCR=KZPN:[*2\&X`>[SHF1=QY
M]P$!`3"U62$W4H#U]0:N<[F,,?N:^3,WUWAQR9AW%@4L,;9,*WZCJM)EBP=N
M3)7NOO:88$9$WN;M-<?K[V555SE3,`&$#``E''>3UNFK?2WWZYY9QT7DFK4H
M."K-EH#E&/@8J-A6[VM.T%`!I&,46"`A$/"M$T2@F@'LD<;%#<`#H`"O3BL^
MW,7W@N0N)9XZ*!+2A$/%0*'NMA:.X7RSG``!,[UXB2*$X&'[UP8/EU/6\+F<
MKSM':2R:3QBY353,!3HN6RQ5$S`8/9.BLB(@8!#KN4=956$==I^/`I1=@\2+
MT!)Z45MP#U+>RX#I_E[:EZRM9JOH[(T:OVDDFZS!3;JHGNY;]/$1[`!<F_H`
M"F^?6?6K.T\JW8R3"23\U@[0=$VW'RC@)R;^A1,=E$Q^0P`.LXPT[V@:"S7(
M?"E9Y'8,RM@JWG6;P&4Z-/T]U(M-@?P;J48J)Q-DBCFZ)3-8F"H2#)0=_+=-
MDS>C19<659_@AFRRYOXX55]D?RD,W8PE;%@CD'&IG.?W#.&')1:DWUR43D*'
MN-J>1R<\P$HJ%-&RS<P'-OOH68NFS,71#0-`T&O+G8`6B_?#\Q$B4KAU>^<E
M$N;IH99ND'U!QWQIE7D&[D#%7(<%BQ]BQU$]I2]AO-4)VF[^TARSS]&PW1#0
M-`T#0-`T#0-`T#0-`T#0-`T#0=&4C(^:C9&&EF;>1BI9B[C)./=IE6:OH]^W
M4:O6;E$X"55NY;*F(<H]#%,(:"G*!CVB8II\'C[&=/K=!H]:;K-8&I5&&80%
M?B47+MQ(//<HN-0;M$57TB\6<N%`+YCARLHJH)E#G,(5CH&@:!H.E(QT?,1[
M^(EV#*5BI5DZCI.,D6J#Z/D8]\@=L]8/V3DBK9XR>-E3)JI*%,10AA*8!`1#
M0<,+#15<AHFO03!M%0<#&,(:&BV2146<;%1;5)C',&B)?92;,VB!$TRAT*0H
M!H)B'TS?R2?=/H(M!3[:J5EE9YBZM(&);V^PPT#79RS),6Y)V6K]6=S[^MPC
M^4!/WQS$P+^U2:[1N8XI(+2#DY"@9903!4&@LUD_^FW'/],LY_9[SMHO+__3
M]_&@:!H&@:!H&@:!H&@:!H&@:!H,%6IRY,^(K)J"F#F%XG\8&<8@J;86Z.2N
M5]Y^LY5-,G:'=,5S'7'N.'S!$11:6<Q2[`NIN7PSJT1AC\1,-^#/*@/7A>YA
M_P#%I]%Z[Q='ZI3_`(@_P:UJYXK[]4I_Q1_N^QJ_@8O"$8E/^(/S[?<WTUX,
M?"`8A/\`BB'V/$?EZ_+IF\&/APFAR#Z/X-Q_OZ9,?#KGA"#X``_[G;3)HZ9X
M$H[^P4?'P_QZ9,1T%:Z4=_Q7\`#\WB'RZN4PE2]92'_-`'3^+\_J'Y=64PDC
MFII'W_%E^T&W^'3*84R\I21P'\24?'[W;_#JY,-?GQ#:0DXX[DK"3,7#K(F<
M^+F-VJ`I-SIJFNO)7%,*[34%THFV3\R,77*0RG<F"HD[P$O=IVNC76:Y^+_)
MDO*8W3/W![N4WCXEZ[AU]0ZWESPM?-XI05`W<U`-]_O-65+-U%-*[=*6L9Q4
M+#-P1N[N,E'O5R,U1`=P\]B8QV;D-_0HF;QTTN\39<V`Y(Y*KADV]P@6%L9D
M$"G>,_\`D26VVV%4WDI+QJYP#KV@@CO_`!@U+UGAK-9"5+D/C&V&2:FF!K<H
MIVE"-LZ98LPJ#L!4T7QE%(M<QC#L4H+]YOXNLWK8N8OHU<G2%-RT<'((AYB*
M[=42^R(;E.FHD;V@,'I`?#Y-9:5[$Y#DVG8E()DD40V#O$01=%#U^:4HIJ[!
M_&*`C_&UF]8L[7RN=$VB&F.TK9T5-P/_`)*YV17W]1`$1(M_N#&^76;+&I95
M0ZBM:['?C9\1N1B^XC'%/Q!:,I88U'S#D9QG+7C]7VS*Q)(-BF39-'.7>/J+
M1T8P%\UPYHRQC"8ZO2>6M^OS&RC59-`T#0:\LH]MT^)GQ)JI#&!##/&;E1FZ
M2+YX`09:[6;"&&J?^(\HXF5"*DK+VF`0]GNW,78"*O*_TUL-T0T#04'7\IXQ
MMMHLM'JN1J'9KK3#BG<*A7[?7YFT510JXM3)V6OQT@YEH(X.0\L0=(I#YGL^
M/305<,I&%DTX4TBQ+,*L5I1*)%VW"34C&[A!HO(IL!4]Z.Q0=.4TCK`04RJ*
M%*(@)@`0XHF:AI]JJ^@I:,FF2$G-0J[R)?M9%JC,UN9?UVQ1*KAFJLBG)P%@
MBG3%Z@(@JU>-E452E43.4`F>@:"61$U#6!B63@9:,FXTSF09%D(A^UDF)GD3
M(.HF5:%=LE5D!<QDJQ6;.$^[O1<(G3.`'(8`"F+3E'&='F*Y7;KD2BT^P7%V
M#"HP5IMT!7YBU/C*I(%95R,EI!H]G'8KK$(";4BI^\Y0VW$-!76@:"61DU#3
M7UA]3RT9+?5,F[A97ZL?M7_U9,L/+]^B9#W557W.39^:7S4%.U5/N#N*&X:"
M9Z!H&@:!H&@:!H&@:!H&@A#Z9OY)/NGT$6@:!H+-9/\`Z;<<_P!,LY_9[SMH
MO+__U/?QH&@:!H&@:!H&@:!H&@:!H&@:#!/@D8EV@N07(Q1/N6Y'<FLJ62$=
MG,)U'&-L1O&7&_%BR'0"(QDW3<-H3;=,GL[S!U!W.H<1+?$9V:(PS^(A_L-\
MIOT,7+_1QM*O7>,@@;D#PV_[4-7\7/V/=R?;^0-/Q/9\]V)UU<WE?;X/=4_[
M@TS>4S4`M"_('V],U?;X<8LB^@`W^QTV'3-,N(S'IX;_`&A_@TS\&8X3,=@\
M/[W@/730T=<S'_)W^P&W]\=-.3'RZ:D<0=]R!]K8=74Q705B$S?>[?:VTU1A
M5S`Q1;LAK\68JJ5U[.L(3F!A^]WAPR28F3KM.Q_'W*Y*6"1.]52\A@E986-:
MB9(JBXK.DRD*'<)R2^%F-?HRB=5PAMP\H/M;_P![?6LLX4N^J:1P-LF&_P`P
M#Z?EU<IA0TG1TC@;\0`^/4`#?[FM93"VLQCI)0#_`(@H@._02AOT^;5S\IA9
MVPXK05[]VH>G[P/N[>&M93"E8E;)>-C@:H6.1:,TA$PQ#D_O\,H&^YBC&NP5
M03[]MA,D!%/48--+N:S:K[U+E>R2,DPR37G$&X#9-2<A4UW\2<X=!5<1YA/(
MLB"'H3%UX^C6;TXJSMRRFKMGKUL8)RM9FHZ;8'$`!S'.DW`)J;=WEK%(;S&R
MY0'J0X%.7T@&L[-+FP]VF8L2IJ*_6#4!V\AV83'*4/0DYZJ$Z>`#W%#U:S>L
MK6:L#SEITOG'CE+R.*"$3Y`8+LM6Y(8`:/"I^:YR]AE\>T0E;1,H8K9=KD:%
M)(U9T4Q@*=A.+%.`%,.L7K8WU[3+*O!V7ZAR`P[C+-U!=&=4_*E(KEY@3*B3
MWMJSL,8WD!C)),@C[K,0ZZQVCU`VQV[M%1(X`8@@$6S%PNGHAH&@UZXC$UR^
M)-S+MBIS';8EP!Q+P1%$*=P":,G-R&;,W7`3HJI@W!PXCKU7-U43#YA$RD.&
MZ9=%\1L*T0T&-"_*6A.>3,?Q5J,59K_D)A5G5TRQ*U)I'O*;@6O+QZSFFAEB
M?=2+,D38\DO$O)@X5H1[++H`=ZJW18%]Y$N-,M=D;B#E!7EI6&Q'C#(]56@J
M1R33@XW)"W'>988<LUZ-)339/B?GNM)5B^SPY0N#I-PV+>V+HJ;=3SY1Q%+M
M4F9HMLY5=:\'YEMSN^7['L/RGH#^CX+S.;C^VNF=WKVZ/<HH.<5VBA0UA>IW
MB;G;#4)J[UJ52)`7*8GHYPT77,X\MHK'-6`S]%LX3#'.FK7DK.KNKK2Z2MGO
M.5ZJ#6`CTK#$-760/B7\H,J6V;O+*/Y08<KJU=O/'B[5)\4D_`W'LC`>)1K9
MA-%\A\7,Q^W"XMHP9RR0BY"VUNX<AU[RK#66SMX<V<[&>N)Y!B.3S1:D$0K#
MBX$K2<,;`DL_;+0OD_D^_9)(G?-%I)!!<I,SR6C!G+)"+D+;6[AR'7O*L-9;
M.WAS9SL9ZXGD&(Y/-%J01"L.+@2M)PQL"2S]LM"^3^3[]DDB=\T6DD$%RC,\
MKU7VB9UJO+/&DGBB!N[S"IY&KJ6:LQ-@<5/'D2-BL.5)K*=W6=,,I,X&6E3/
MK661EHF<HLS(3;L[$T9,,CI+@@,S%SNXLGTJVUG)W*]_+<79;E)#\BZ'0:_2
MDDGN-B5=:%A*<^J,C@?([Z\V*.E:=0T;<9S9%7J+"28"G9GBJ*"KY`Z"U3C5
MC]DBJ\\I7(68GE*;Y>K4?-X]YBUN'187ES*QL?//*%+,N-TW3Y^7R@A36[J4
MG(EB]A_JZAQ$A7USF1F)9VLNJ*\70Y#8LYEP,?F"CX0=9^F8`DAF22P;83Y<
MMMJE8V4>X(XO)X_A9"7?9NQMD&5;/,QO,@.XZ1L=ED8&#%L\1=P[Y!6&20$L
M\LYN'U)R#3*UF)7)$,YAIRZ<@<@WUH#HT=YDG$V-A63(3!48U51!J1Z\:K[)
M"5(Y!*("0H;:J7PRYT0T#0-`T#0-`T#0-`T#00A],W\DOW3Z"+0-`T%FLG_T
MVXY_IEG/[/>=M%Y?_]7W\:!H&@:!H&@:!H&@:!H&@:!H,<^7>6WV"N,.=<KP
MR*KJS4_&MF<TF/0!,5Y;(4BP/"X\A&_FF(G[Q.7B2CVA.X=N]8/'PT6:V*NX
M_8EC,"X+P]A2'.1:/Q1C2DX_1=D%0PR*E5KL?#.I551<`77<RSMH=RLHI^,5
M55,<_M".B76U=[089?$1Z<&^4X^K#%S_`-''T7KO%\_?_E#[?JV#6L3EC0]_
M_P`H/DZ_W==,3DT?0?[]-P^;<!W^[IB<FCD]^#U^/]WR;:8^3$<3F7;,FKEZ
M]72;-&;=9TZ<+'(1)!NW3,JNLJ<WLD323()C"/0``=,&(PK'G=CJ2F:62'83
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M'@H+LK!1TB=,JPD!,5"B4!W`0U3%=9Q#$/OL`>GH(=.NWSAMIE%./*\0V^Z8
M;?R0V_Q:N4PHV1J::@#^*#U;;;_9'TZN4PMM,41(X'_$@&_J#?\`O?)K64PL
MG9<9)+%5`S8H[]W4"[^OY-:RS8QZE:3:*;(&FZ7,2M<E4NI'D2Z6:G.`")O*
M<$(().D!-XIJE.0WI`=:S+O$VV5K5N;UHHRR<7F:K*SD6002&WU1LDA+H$`V
MPK2E>4,BR>[;[G.U4;F``]E$YM@UF].&IVY9W8WR[C?+D1]=XZN$-9VB?8#Q
M)BX`LI%JF#<K:7B'`(RL0Y$`Z$<))F$.H=.NL66;M9RQPX7W1[QRSKR+X8/T
MR#26$TMRBX\,3'3;D0Q'FZPR3G(]/KS9$HHMX_&&=2RP>1O^(86&.+V)%.03
M<_76QTMTZUM,5R71&8,/K:U0<`K*.2,H]O8)-E"JO7ZFW8P9?6"Z";UZ??HD
MB90Y@\`'4Q82RJYU%-!KTX%`I8K/STRNZ3[W60^>67:^U>B#D#+07'^H8WXU
ML691<&'N1CY;$<@`"7<H'.<"[%`I"EOB?#87HC`CE-R4O[6Z0W$KB86MV'EG
MD"$&?DIB?+]9TKC)B=5<L?(9URC'H#O(N"NEBMJO7#'27L,H8!'9BW=G`LGF
M[+X\9^-M(XP8W+1JHZE++/S<O(W/*.4+4HB]R!F')UA4!U:\D7^933(>4L,\
M]^B7H@R:$1:-RIMT$DRBW+(;1#0-`T&#O(/F.WPEF.O8>VP#"NYS&;K)7Y4<
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MHC%5@?F#QY%XV9,[Q(S2CNHT"[M7%9Q]DJU1J\'E68+`8V13EZW3Y6*-9+S+
MBHC%POG?7+P6[@R;4Q6S@R8Q4&.N4%0R[D>R4/&[-6?:0>+&606]B?FE:T*T
M]_6KEO#MCQ[-UJ>K[*R5.PTR[X@D&4H1ZW*Z9NP405;$50.!AA0[#FO1UJ]@
M>PRT!)P*66:39;G=&#M1[(2N)%:C*5/'LY1I"+@X24D[?DP<]WZ(H[&"8(%?
M2LJHZ%F5<[44%&3UNJL%N8&$VY5)->S'"N@UAFR?DUC(KF^C<)K(LYBUO1W.
M*T**>ZL[,-U@U(TK`Z'UJ,AN@9F00(=08J=5WE=@:VR5/B*W<WTN_O$=!RD0
MDTH^03)1C>RV"WU*!0O#L]5(SQI*2MMQ_.1*+&QJ13TTK$.V?E>\H*)%&*R)
MT0T#0-`T#0-`T#00A],W\DOW3Z"+0-`T%FLG_P!-N.?Z99S^SWG;1>7_UO?Q
MH&@:!H&@:!H&@:!H&@:!H&@P6YCG3O%XX><>`+[PCE/DC7\CV]F<I3M1QUQ;
MBWV?'"[](1,+EFXRQ5:;&G2,0R2GUD`*>SN!BSS6=.B&@PP^(H.W!CE4/JPM
M=!^U&G'1>N\58-B('^>#??PW]'V_5KIARR^!8B?[\'CZ],&49;"00_GB[]-^
MOKU,&7*6P)C_`)Q/[?W=,&6O#E5F?E/C+)%6:4FQ8KC\590GJ#0*Q+WG$DC=
M:=5[5:)]A6;)&YBEF.8\;2,2P>Q4DI)5MRW,5I-2:`0"PM7CB/4DI8W/6YT2
M<N'\)<0\?5?.G*+D"LLRPI4I*B/)J2(I7<2'Q$^&9-!X*AL76B9RI99RN(2Z
M\4]CT7TW8[@\F(%@FC(BS3)&@QC>F<Z1;Z$^(QS%Y`M_KOAA\.^TV+$SLI!K
M&:>264ZW@6&LK-5+L93-;QL[CI.WSE7>&.#EN^07!-9JF)1*DJH4I)F^%Q)O
MWU5]%Y;^,:_;`NXXR<(HA43G+[E(\@,D*.2@40V4$\1191GV*;]-EA-ZP#5S
MVX/R\U)%LU_&!82`3$IP*XGW=S$E<MH=2M\EC0\RD9THFW6=QTK:ZR<C=DNS
M[_,2,#950A@WZ@*9IK_:OY.:IBQ<K^9OU3?X?-WP5[LI!Y0K[RH9)?8=Y&X2
MRO*7RK*PSRMJM9=&LLJU9W2!H>0=-VR*ZX.&K=79,Q!,.TUX,=;MV8]WGF!P
MEDIFP3')OCE\2KB<TGUK6YL:>6,.Y&'$3$U\3@&>09B"AX1YDRM-8VY(5T6+
MMTRC$3JD=OQ2(D9ZX44?6'KV\6+O2.5.!?+B'L`8?Y\X*<35PN^7<I+U#(DR
MC0Y"WWC(N/H3%E:BYJ#LTO2;TG4H'%;!S5GR*#!1ZZBY0XE4040!-5I?*8[=
M?Z:S`QAQ-M3K.S3*UU)5H3&[R3O.48O&F%\B6IOC.`R"_C>,U6QXNW")C\>!
M>E8^,PM.S+UTZBFL:N]LH(^YJ':B[<L)>VF)NE]FX]2-CS[R0Y%9-I&()^BT
MZ?IK2KUW*/'UEDJYV.A8DPY5+H6T8LOJMSC7U$E1RA:K$Q;'^J),I5XWSTT3
M'4(<M/;218/%_*W,.+,5T"E.2X[N]ZJ%2E<53>'I%>R#G,,A8RXIRN;+%F>\
M3C^WNE&=`MMS@B-"1QJ^B8D;/QSU.5.NX1BSLUK2YX_W9;8&YJU3D+D&8HE1
MI$TA[O9K0I!3"LFP>-9C#M<I=#DVF:'8-419Q</=,A7<8&`8)N7BTLS8JRZ*
MHM0.FE<RI>K,Y>-(<!W('S@'7^[;5U9PD+N$*?N`"@/CZ.NF4T47)5=-4#_B
M^O7Q*'K'[?76LHM18:$FX*IL@'4!WV+OUV]6M2LV,5,BX;0D$7`"T`1,!M_Q
M>X#OT_AUN5FQK2R/AB]8_G@NF,9VP4FU1QCJ,YJMOG,6]*`&[S(*';F*5TS5
M$-E$%0.BH7H8HATUK2ILL+??B890QWEOC)DS/6.'SV<P3>Y2$MF8:.BF@2S8
M`R=&)P&5ZY=:.@@@164BG4?#6.,<L%2MU)""(@9JCYYEPX]YZXN'?ICM.TR]
M%V)N1_&;EK47JV)<F8US)5Y*-*2=KS)_&2[M!@_2`3L+=2I,@3$2"R:G:=O)
M,D1WW*8NX"&IF;LV6;Q)%N.B5.[GG'O*V5^.SY`#&9P-!MJDMBM(W4P-T,,9
M":7?$L,W4.`%.:.A&J@%\!WVU,2[S1?:K8#S8YN8*EG41F##,#FNLQ[99V6\
M5.K76C+*Q+,#G=R:\_0&>=*D[<HH)B8P3,9041$1'8B9>\R]9XJSMS%!_"M^
M(-QI8<0Z)$7N>G,<6)Q*Y(R;=IZSUN2=T/Z\S/D^Z9AE'S[)-76M]-K^RUW$
M@MYZ1BI%("`!FJ1.PNL>MQG#?:SVL9N9VYO,WK>CXHX3O*!R.Y'9PC)%_CC\
MG[.PLV)<:4J/<H1L_GG-EIJCR02A<9U-V[*FW:I*!)665`L;'E,KYZC>7^*R
M>;LO;Q5XM5+B_292.:2\G?\`*N0I8MTSOF^U@5:]YFR2Y;@E(6:P.A.N:/AF
M!1,UA(5`_N$'&%3;-R]%%%26Y90:(:!H.E(R,?#Q[^7EW[**BHIDZD9.3D72
M#&/CH]B@=R]?OWKDZ39FR9MDC**JJ&*1,A1,80`!'0:O7G(3-W.N3?TKA-*N
M\5<:V[MU#WOG?+09'+VY`S<&:3=:X:U*=;"RN+OSDU&:F09-$];CU2K'C$)5
M9),P1K$F^[))UQ5DHRUT.YX^SMD^HS]'PI%X+4EIY*LY2FK;6(B7;S;>;ML_
MD6'G9F6M[I^W\QV_,L!W)SF,<-QU4RM'9N"C_+4[GM'+V5K6]I&1+TYM=8@*
M^UIS(#S4OPIHG%.5OLPX"I%DF<PB8E@>-XA%R>+!R#-R)>P%&HC/PJ2>X!T:
M;R3>,H-\BWFLV&WRR-F3/4(?&]<$MNC,K8SS+4K+<U6%((.69#'EPQ8Q;P`V
M4LB9C".WC!0RZ:J9T9A?;3&$IO7P[J#D^R*7K)60;3D:\F)BY4LKD*IXLO%=
M,^Q;.\K)*+(ZH5FHTE4',&X@^7=@ATV7NQ/<&<;&+-E4WS=1VM4RJQOP5QY%
M8V>8RK]HGX6$>QF#HMVBQ@,?QD++,\(SSZPI1T]2*W4:[1'M=R&ZE'*=@B6\
M:SC7""YR-T6Q=@`9URG/&3A?0^+DD^DJ?9)^9.^K5@K)VDC%U&#BV[:RY]S7
MR(D%H^$IM>KD%#D1M^<Y-FU:,6K5@TBVK5%)`HIF.<6Y2"U\`\.6]KG]G*/I
MQ1GGFS4*UJ1CR.ID]`8_DJ!DM?.+=K5:S9:M,UV2AK;G*5E+386LRUDTYEY+
M.&Z^[0K=!"87VV1X_P"!N+<=+P[J`DW,<K&V.LVI=I6Z=C2@P#N6K&4YS*C,
MJ57Q_3:Q`,&?OLT$;["`NSQS1$5W"[OS72M3+KO>!F/W>1*5D1&YVJ,E*3D>
M<R3'KQ</0V5D2=SN?[[R&E*K%9"3J?Y?05"LUBOJL/8(5O(A'3E?:)-EDBK'
M<.5AEG5HAH&@:!H&@:!H&@A#Z9OY)?NGT$6@:!H+-9/_`*;<<_TRSG]GO.VB
M\O_7]_&@:!H&@:!H&@:!H&@:!H&@:#!6KG+DSXAN4IXZ95XCBSQVI>*(5=79
M4K;(7(^RFRCDYLV(("5JX:4'%M`.<X""BB<CV[`0/;+X9U:(:#"KXCANS@AR
MQ./@3"%Y-_VL4J/][19O&.!LH,]__&TO^$`->CU>?V?/ZT6?_G:?_"AI@]G.
MGDYF;;9TG_P@;_=#3U7V3!+)+8VW_&2?]N'V^@AX:8^#+F?VN#L$:\AIMK'S
M,1)(':R$7*-F\A'/FRH;*-G;-R15NY04#Q(<IBCZ0T]3+5AR2<4W+OQ/N(N-
M,\IMIO"\'@S)&3,14B<*1Y3[MR2A;$BU?(S\,Z;_`%;,KU+&A/K)D5<R_EKE
MV\LI5#@MSLSWDNSIUOY.UF^6U*DO9/);%6?B[5*QID9*6B5XYBX*!(=Y#2"\
M:YBUFK=P045&YFP;=W54ABG``[P`=W33#G-5I\Z\IL<<5)6HP^;^1=:QR[O/
MO'Y*_EE'R(,I(C-0B+DZ\NC$R4?&I(JJ%`ZCI9$@`.XFZ#M+Z^8U)VNS(NNW
M7(LU#1MBKCZEW.NS#9%]$3L._0>1LNR<$`[=Y'R#%XFR=MERF#L.F)BFWZ:8
MZF:J1/)=]CQ`);'[A<A?IJ1KDZHE``W$P$32=[!MX;F`/EU/67:F;YB;-\Z0
M*8@25B+'$*!T/[PP*HF40ZCU(L"H@7^1X>C3UOBGMA8_(V#.`O(`RRN6<%8'
MNTFZ*8JDU;<7UY*RD[S&$WDVQ6$;3K0QQ,(B*3L@B/41U+UOGJU.]GEC"A\'
MSA5'.%9+C/DOD9Q-F5U#N!D>,/)V]5XIW!A[S^;%VB5O,:+55785$$T4DS%#
MM#M#6;T_!OWSOBIJGP\^)YBQ0RV#OBA#D>%;%W8T+E5Q_IUQ!R8@%*0);*U3
M>,;NH42B.XI-B=0`1`PCN$Q9Y+Z_V.N?+?QC,8.7#K)O!OB5RI2+'FC)*=XV
M9Q>8IF7M=%9=15O]3YZCI!S)G02,952/34*FY6,)4=A.&TUX3'2[=K%)U7XD
M^(<%RSZ5S/\`#;YB<1YB1K%.JECO$;QN:6S&"-+QTVD&-)@1OV,'3@'<)1F4
MR[2:-$HP$V#58"IE`IRD!GX/6W;M*RCQ?\6?X;F8C-4:ER]Q%&O7:@-THW(T
MH^Q%)"\$2D!D#/*L?3E5'9E3@F0A.[S5/93[QU9>*8[S?JSGKUEJ5TBDIRFV
M:O6Z%7V\B7K$S&3T6MN4I@\J0BW+IHIN40'H<>@ZUG*;NZNT*("`E`0^7T?9
MTV3&%//(DBF^Q0$/5Z0TE3=;V:JZ+DAP%(.N^X"780_Q:U*F&-][Q8TD$5BF
M;%,`@;H)0$?#UA\^MSLQ8U<<B^*,-;(R89/8E)TU?M';5RD='<JK=P@=%9)0
M`#J55,X@/R#K>ET367,W>9I[@/(N+9Z<EL;62S8_S+@JVOZRM:JI*/ZS91:$
M;)R-0LZ+R*<-7Z"%GI\@V.90#B"J@+$[C`!@UQ]-/^4>CWVS,]:V]_#.^+3R
MVR5F*L<5>0-FQ/**R22HQ&4\A)OZW=G)8<4GBT"@$$W2K=XG):.;J(-DG*<2
MZ,)CK'>+*D(BI.MOMZ]COUZ^OMUV;MN;O(J!Q)Q4Y#/9&>CV5W6PI?6U1J[J
M0C&=K=V29I3J.B&[2(4<E6E3,YJ5:*.!:`N9))41[!`H=VK-+8Y]=>T^K##D
M#G_B;A?`E(QE`XWB<Q\DL<TO&^#J/7XZMV&O3%*G(_'T2=C+63+L"6*F*!2:
MM744Y20/'3R3@&8D*4Q"JBX2S;ZXGEKK+VU_I8U5K#]&XTQ3?(DG)\U<99/L
MJ#.Q97Y)9+Q39JLS>6'W!%-R#*YXDR-1\MUB-*5J"3:#<2EN;D03W-'.5CK*
M+ICS,U;;M/#8=A7G-S!@FZB]/NE'YCTB*:$>R;1`$,@7:%8G.0K5K(SN'*G3
M,Y5<X`<04&8PY9%$^Y,59`_\XJ]>M\X3-X_;]OEGCB/XK6`;JBLWR?$V3"TE
M&KE83LP^,SR'C"'D@+W+H361*`,J./46VP@<;Q&5!P0P=IT"F$`'-ZW\%S/Q
M;(:K;:K>H"-M=)LU?N-7F6Y7</9*M,QU@@95J?Z#F-F(ER[CWS<WH.DH8H^O
M656IY!<D<1\8Z4E=LL6)6.3E)%"OTVIP<<\LF0,E7%][,11L;4B'2<S]SMTN
ML($1:M$3@F4167.BW356(62W9A-$<?<X<Y9-C?>;\6XQ=QU1=M96@<"XF83=
M_E2@T<)O8:S<RK1#NE&-^E#N$TW2="CU!K$:9-$LBI*."*E+%S)MNVA1T='P
M\>PB(A@RBHJ*9-8Z,C(YJ@QCXZ/8H$;,F#!DV(DV9LF;9(J:2292D3(4"E``
M``U67=T#0-`T#0-`T#0-`T#0-`T#0-`T#0-!"'TS?R2_=/H(M`T#06:R?_3;
MCG^F6<_L]YVT7E__T/?QH&@:!H&@:!H&@:!H&@:!H&@P5X`"E;L6Y*Y""43.
M>4W(++N:&3I0>]9Y0&<ZEB/"+DRHF.!DW>"L6UIP4A!\I,5S`03![9BWAG5H
MAH,+?B,($=<%.5K903`FXPG=T#B0>TP$5BU$S"4VP[&`IN@^O19O%)%X2X:`
M-E)*_*#ZQLY"]?F)&@&NW^2N/KU^47ZDV%@\'U]`?'?\J0^??_T=I_DIZ]?E
MUUN$6)#E,5M8,A,SB'0Y)]FN8OR@5>(4*/V0T_R4]>ORI]QP8K.W_)>5+XT-
MON'OS>"D"?\`:I,HX1'_`'6K_D^#TG*G7?".U-Q,:$S4FI_O:$K4#E'I_'<L
M[";Q#T@CI_DFFB>G_)AWRO\`A>YCY`4Z%8,KW5XF_P"/K&TN^(\GUR1DXJX4
M&Y1IBG;24>#J/217CWQ4RIO61G9$W!"D/W%51143G:]>TXK76=NM\6,`9S(/
MQ".'LL>P<F^.V4:](MRI-)GE#Q6AV&7,37B-BTO+:3&8<5,RRA:]VI%$AWKE
MNT=$.J8C$&R8@`SWTQWGXM?X\Z]+^%7MIWQ1,9<B:X-6E[)PXS0@_!-5.N7A
M*>HR[_M02`I'6.[]^53T[@'`'$RZ:?:F"@%\L!#N/J>MV[LV=^N_2LZ,<\GW
ME8K<76:EQOH=3@(Y)9*,@*%D:O,ZFT:KN5ER#%-28_KY$B.2KBJH7W0A/,4-
MMW=3G>GRS[KIJ\@,I2@IO(?&V/V[,"$%2$ELB2:<N[4$A_-,$O&4MW%1X@H)
M>POD."B!1$3!W;%>LDUI[?"=M.15;2$"9!QQ?Z/OL524""2OM;%0J8'$R,G1
MSST@DU*;N`%G\>R``ZCVB([2];C2KF,?L^NRY`L+&Y<?'[2S3$3QCY+Q$5;<
M>P,!?5:S>)N_\71K*"\<:+L<0-I59P\HNTC9)NN94L>Y_$G*BL!<WVE^6^OK
M9KS&/N4*EG7&F2[&TIS',%GK37*4:T.K6L4Q*5HRK&(XLXFHFL3NZ57C_::3
M,3B<JXLD4498E,BE4@<I!/M"0B2+![=LF.MD_;EM0)C63CA`T%<K1%]H?S9'
MRGE%$!'<`*15OW[B&VP@'@(C_%#7M+X9Q?%6SRCGEGQU;0;O+?)+%V.65D>N
M(^N*9:L=4IR$Z]9I)KO&L>]L3IL+M9JBJ05`(J(D`Y-]N\N\_+YACM?E,J5S
M$A;<\0C*I?,&93>+%`6[7'N3*M,R3PO:)^YNTBIV366$"%$?90\.O@&GKUNU
M-9O$&3(3C7F0JY>0G%.AWDZR`MEWUZQA2[VLFEMT%"4L$,#YL=$?:341.51,
MX`8@@8`$)Z$[V<L+9KX87PI+#(+6>ETN>X]VTP"/Y5X?RGE3$;^/Z[[MVK6Q
MJ4QH!2G,7<K+8"G$/5M/\=X;GW?^3O17P\LGPS<7'&OXMG,V)9`0`CFF2[G0
M.3L!&M]RBBS9,K/$Q>T<U:F,F@F983$*!!$YNSVI>MGFK[];_3*F2F%OC%4?
MV:YSPXQ9O!/M*"F9>+PXV4<!^*`QUB8@GW*:9^J@[$Z")2^'</;,=N3/2_TW
M*4KY%^-152[V;C[P'S`9(!45_JDRUEG'XNP*"JXMVO\`6E&NP;KK)B1N0RHB
M0JY3'-^+,';?S'Y.:M!EWG3\1O&5#L$_</A3R;9Y&(-2L9NF\F<=99AY-\L^
M8L"(EIU0AVUZ*I+OGR35FV12<.U%ENXB:PIBF=GM_:DZ]+?ULK,,76S\A,2Q
MU]OV`,D<=K*_*=*1QYE$D1]<H*E025.ZCQ8NBRBT085NQ-22CHAZ8Y3=S0@`
M`FZ];:Y]NLFDN6N_D!Q%E%L\M<G5EM%#4[=C>3I>5XYPJ+=RM)UJ23EL:62-
M;IMUBR$BV)+R\<Z[S);-%TA[C>20H:GZL^&<SUO7SG1J$R_QXJ^+\LT[*,_B
MR)RG7:?9V4[.X_E7CV):6>-:*F,LU!_'J)'1=(&$JZ)%@4:+*HE2<IG0.H47
M;K+K)EKIWLSURV:9DYI8'YL8!BZ!6;O!-;C/SM)E;E0[.!F^:*#`PF7(6U7B
MJ5ZFHQS5ID,LC3('ZI8-VI#+*I'26%=8YR@?.G:8EU7%Z66S1D9FW#V'LC8R
MC,BX^OKR)RB\K+B@5W-U7K<S.&O2J;..CI*%R5`8SA&JIDI>8CT5GA"MT3-%
M8HB@'0!,X:MZY^J3MCZ,C.'V2N1=^5M%%S&Q<1$O2C,4(%_+L&C]K<HI8)!%
MR*%A!K&FM[>-]R3$)A-&+742=D0<H&=-7#MU-IK"XMTJO\F?#PX=YG<%D[+0
M7&#<EM7)W#+(^+W:]#6;RCG?WJ7*>.05IB\RY1`2G?R<<J[)OL"AA#6<<;-3
MM?Q8K9G^&!SFK48K;<6\G<;\CX>O1RSF$A^7\1,%NT+$LD2*;U_E7CN2:9SA
M$E6)#[EBY6KL=R!YNQ-E"8SQNW,8UFC2=;.?]^X>Y(L=&?PMZXQ\FF4M!LK"
M_@,@5JZXK6/-LFCQAD&S7O%L?(IY`J<1$R#=^G#6RC92GG;-3M++H+&`#+W\
M=IJUZ9UZW1LPX9<U&]7O,ERRY"-Z]S)R1-MF4(XY$IV*K5L^%X.20(A_5GB!
MN69L/&S'L;-O$EUB,)2QXZMLJ0XB^9.%!["IUEV[:I;9IZXCT1XEYR\:,P/X
MJO1.0F]-O,R0AHS'65&+O&MVES'`!-^2T;:R1[._M$Q$`%[77,O'FW`2+F`0
M$999X3.9EEQJ"7N9:+9/(^/>24>T?RRJJ$4Q<O&Z#R370;+O5T8]LJH19ZJB
MS:JK'*F4PE23,8?9*(@$PT#0-`T#0-`T#0-`T#0-`T#0-`T#00A],W\DOW3Z
M"+0-`T%FLG_TVXY_IEG/[/>=M%Y?_]'W\:!H&@:!H&@:!H&@:!H&@:#%?F]D
MJ:Q-Q-SM<:J)@O*E%>TS&I2J"D*V5LG.V>,\4MA4*`J$*ZR-;HM,1(!E-C^R
M`FV`2S6Q>;$F-H##6*L:8BJA/+K&+:!3\=UXGE@D(0E+KT=7(ON3`ZG:<64:
M03!W&ZB/4?'1+KJN%H&@PR^(ETX-<J!Z_P#N7N?AU'_T<?P#KUT7KO%UC*IG
MZBO-&^8'J/\``5-+;6\3AC3Y0@9(.OFS@?.K('_@[CAZ/5JX/WN3WD"]`>S!
M/G:+J!]DRK!4/X=,&B,'X%__`'NN3M_\Y0;D+Z_:$[1`P_;#4Q#1V$I%P;HE
M)QRP@&_;Y(]P_9(^]D/E[1TQ#$=LK^1)MN@V5#TBBY4(<?E`BC;L^;V],&'8
M)-&)_/-7J(!Z03*Y#UC_`.)G<GV^<`TU-6+&9>%'";DBHY6S/QMPK?)I]YOO
M%BDJ5#1=Y-YH&!7MN<.WB;FB)Q-W#V/"^V`&^D`"$^L6=NT\L&)GX#W"5$RB
MF&+?REXR'$3*-R8-Y#6]BU;+'4$ZAB-[^3(&Z;A,?*4*)P`4N@=H^UI--K8O
MOG>2K*6OX2W./'I57W'3XE=]FF[8H'0K>:,6T"\/W::78<&1YY^9LF8[CR2$
M,N!6RA0$X@.YAUJ7M_?_`*I?6_T2_BQJF4/C"X2>_5\];^+]L%(`3(OE/&^1
MZ<G($3$I#JMY''+]Q$>>N1+N*(&,B"BI@$`(4NV\=[MVE8S]OSU[1TU>0G-=
MNY;R^1^`&,,LNF"8G_+WCWR#BJ?:XQ,Q`(<T,QL[%G=':RJQ>J39VF8$SAOW
M=AMW_LF_4Q]N[=_X*]B_B>5?'^Q,L5/XA?%]%N=0DA)Y2Q.YROCX3.2B!SLK
M<\9Y$E)-F@HJ`E.@"0%.4"``E`2ZS[3SUPOI?Z>\OXLML4_$MP3DX(YO2>:?
M%6TK.@.FRB[XVEL47&3.!=D0-'6JVPK@SXFP&.FC#D$Y2B)2)@`[,]+Y/7[D
M\,HKF5KFRFA!9<XY8TS=1)!!1=NSB[+4\@PK\X=B:;UDSNL/56*!E"%/VJ(.
M!.D8`*4P_3*Q.6<WABU1OA[<%,<Y/J>8:'P6MU;O]'G4K+5I:+E&+5G%3C?O
M%H^2KQ<Q#7ECL5#>8@"C8Q4U"E,4I3%`=/6?&6O?M9C-PV"'RG%-^X)^@Y*K
MB8"H4ZKFCN;&F4A4O-*H!J$O:1'SC;E`.H@8/:*`["+%\89S$K%SA7)0*0R4
MK5Y*0D`6;G@'1B-;`<$B;KE<5^2!K869BDW,("W*)4Q[Q`2]=/S34TK7GE7X
M,G&S(5F?7.IVW,N%K<^7.Z7FL1Y+L=<.1R83'*NG%/I"3CD!\P0'M122Z`&W
M3Q6R_5J9ZZ:6+13O`[G?QUA7MEPW\6"Y,ZU!$!PZC.55=@;G56S,IB$*22N=
MB?O3QC;O4*05$VA!W,`>R(AJ?2KGK=^G^CM0N:OC08U1:O;5QVXU<O:;Y2:Q
M;5@/*S?'DQ(L=PW=MBWET2*D'1D1!0J;-B)%?HD-N/1KP8Z7S9^WPJ!7XM4+
M11%+DIQ<Y<<;BMP`TC8+IA>=L=$;!OV+*M;;21GTY!JW$!$RA6Q1$-MB]=7,
M\RIZWQ95TJA\3CA/E!),:MR3Q491R4?)96*SM:3+']OR@(,+=0KTJ143CL!!
M1`P[AL'4-67K?*7KVF_6JRE<CTBX1RKJOV2OV%FH!@*ZA9>/E6IO9[O9<,%U
MTA]@0'Q\!W].NDYC%^6N?D)#0\FS=E$B*A3@KOT#H!BF$0ZCZ1#??6HRUX<6
MN5F&.#.6\G6/,<1<).KS<?&2]7;U;'V/[<1C<8D[YBL\"5G%6ELK+Y>+>IE(
M=DNDT4(F8%=S"7;EVQ+;=G;K+VDD918!S-C_`)Z\R[)G;$F5>3^.<6X3A*@X
M<49A%XFH]!>&/$S#Z3%TP_+GWM->P62`("CM2.E%7)I!-BN9LT$G=F7VMLNB
M]NOI)+(W@8ZR@_MF4K)6HVJ7Q&,PK:X:'E+K*S=695^VR<MCB$FEFD7%5&47
ME)U%J2ZH'>E>-F;-&0;"*1C^3V!JN?\`;6Q)DSC+3&)N@1!0BB7M&`0\Q,X;
M@<H``J`!T#!L)3D[AV]0"`\]F]%.2=)>M(:8A8]=)[69ID^C)JI3*0RE>DHU
M^W4:OF+I@N=,Z:3M-42K`B*8B4P]QA#QN<[[F+X>>NS_``<XE/&'/[&*,_7V
M5#R[*0^8.+&*W%9?3(8>RS6(R:7E'^-)8]MJR$'.6XBK:$]VW00<Q96Z#GWL
MC=,"SMUESAKK]RS&=Y_%K$P$6S5WA9<^4&)\26C%'Q(/ANY-;2?*&S3$\E2W
M6>,(Y/O%_M,VQS%CZ7".972.2@14B71%T"RKE",3,@NZW(BCC%DE\NN9;BW\
MM>CSC]QOX@\_>)F(L]5)G5<=SV5Z!49?*++CY*P[&AP66)*N1DAD6I63$D]$
MVW"DS.URS.UVR_UY5G$F`$`QG`B<%#ZG:N5DSBIBU^%EEZ-;$@ZKS3E8C'Z)
MC%C:LSKO(R-CV['L%)-N6`I/-BF8E3*4O446E3:1YC!O[J&GM_QACYO\/_"]
MF`/A?8SP=DJN9?-DJXV:]UURL\3.QIF&Z7$2#AP@NW7^M9.#QRIE27;+(KF*
M=![:G2)R[`8IO2O:W3P8;.-94T#0-`T#0-`T#0-`T#0-`T#0-`T$(?3-_)+]
MT^@BT#0-!9K)_P#3;CG^F6<_L]YVT7E__]+W\:!H&@:!H&@:!H&@:!H&@:#!
M;E>=.]9NX0X"[/.0LF;I?D-;D!*50@T?BI6#7")<BB(]3L^0%KQ\<J@^RD/4
M/QGEZ+/-9TZ(:!H,,?B)CMP9Y4#ZL+W,?_BT^B]=XNE]8H;[`=0W\ENN?[7:
MD.^M8KD?6"(>(K``>DS1R4/MB@&F*(BR#?Q\\I?D4`R8_:.!!TQ5U1^_-_\`
MSEO\WG$W^UWZ:IJY!%%<OMIHK%'K[12'+\@]0,&F:./W5H'4B/DCZVYCMA^V
M@=/3*Y1@FH7^:?.2[>!5?*7)_NA53\X0^8X:N3+Z<SLQ>U9)D^3VZE,!D!$/
M1LFJ#I,P_P"Z*&F5RXR*HI;``/XLW@'8(F;!U]1?>F!`^<"CJFB:(2#TH=R:
MC602`=A,D8&Z_3;H'MJMU3_)W)!J8,<.PZ6A)UHK%SC!F]:N`\M>-FF:*R"W
M=N42BDZ(HV<>.VY1,`>O3-B?6:,0,I<+*S/%=S>(I8M!LH@HL2'>"Y>4^07'
M<WEF3(8\E"F4/T\Q$5TB!X(:WU^YSLS>LNV[5MD3,^5.-UI+4<RXOMD`IW&]
MPL+-@\F:?.-2&,4CN&M,:BYC')3E+W&2.9-RB`@"J1##MKIGK=JQBS.BT<_D
MS@?G)9=#+^&L0VJ5>;IN)&T4:IO[$0QB]ISHSB[!M8V+CMZ=R2Q#[>G4].MX
M:G?M-K<*9BN#/P_W#@\O@?).9>+DX[5%RK*\?N05ZH[P7IBD*1S[I9)"T1K<
MY"IE`"H))$`H!L`=!UF_:GB7+4^[;OB_5=^*Q+SPH92J8&^)TPR1&-=RLJ/R
M7Q12;J5T4I!!`)7)]5<M+N<X>R4XD;@)Q$3CU#M'/IVFU:]^EWZ_N;(N-]WY
M$+8]*7E*?#(921FI!`RV"E[<>B/J\DDT+%/TRW<WUZA+.U?/,X3$`2('8!`\
M1%B_U,VS^G9+L@9DHDOR`QOQJM6/V-C').,LCY00M;IRU*6!'&,]0X@K%%H#
M(S_ZP?JW<BZ#M%T@=J+4=@,)@$K-EQ#&9:N(G&9#J`J?D)<&=KA0'S$:IDYQ
M(/W338X&]VBKVU%S.$14+N7>20E3ICVB0Q2E[1NGG=-5(9+E\29LH<WA;E!B
M]:)I%T:(LK!'7$4G-`EW$:\:2K4C:\5]\FT8BC*,TEV*KWZK<J+)%$B9%`*0
M7KQJ9Q6L*R_`]JU46D+'PDY<\@N,#MZHJN2#K.1)MY2`6$>],H_5DDRF7"*8
MFV$%7BH@7IL/7;.)\QT][YDK;KQ?Q[E?%F%:9CW/&8V>>,KUM"30G,D$@@@'
MMA9'E7JL)[Y&-W*CE=W'PJK=JNZ5.*SLZ0J*=QQ$1,W?2:++\P,#\37>)<CY
M:R3P_H_(B2J,`\F%*_5<45FS93L2R)D4?JVNRB+-I8DY(WFE$YB.BJ))%,8=
M^WMT^L66S2=M&F;C]\/SX37/HUL>80QQR5XS9$HHL%;[2'+Z^4*QU%66,X%D
M)374,@U!4JCAFJ":;%T=1($P,HB0HEU,=;XQ6O;O-[F+KV/X%UFA"F;8IYY<
MF(2()U:Q=[&/R&W2)OVE*1$JU1CE@,F`E$"()AN`"(=`+K4S/ZZS>TN_VXP&
MY`?`BY6^[PKJ%Y$$S(QE+C7X*SL5L<1-7L5?JDV]39REP9IO+J#*RA6S+IN7
M3$KMFLJR*H=`RBJ94%)9VNGM_!KKWZS;IC\4ZP3_`-7OH5RA86Z/.7;G(]%L
M:(KMI;"$)!)P-BB?>%6BIXJZ?E!>(=ZU.HFHD*A&RZ13E,`_))TZ_P!VA?N]
MMO7%>E#BWQ9QSQ6Q?!XHQ?#K1=:ACO70K/G"\K,3$O*+F=2LW-S"RB3B0E)%
MR/<H<P%3*4I4TR$233(&M),39SMMN;NS$J(DBGADBJ&!J]5*(E\P>Q%UW``K
MII`(D3!82@"@EW'NV].^\NNY/X+N=N^Y0-VI@4!$VVX"KN(`7\6(D(`@'4!V
MWZ@(:RTI^<K<?--SMW:8J=Q`(8H>9W`782B)"%`=P$Q]]]^NP#W;EU9;#&5C
M[7C>MR%;OM(N]*@KY1\G5L:A>F[N-8&LDS6`1=MD8M])+HF&;8LB/UQ1;N@.
M!!4.*9B`)@UK?%\L[*/^'WPLP!P=QSD6B<>92RR=7OF1Y'),A#V65._D*](2
M$3%PJ4`U9N@;J,63!C#)ID%8!66$HB=538HABS'C#>;VUMRSJ;,/8\\#"T<J
M&$QS-$C-2*@!C=@KLE162%42CL81W$?0(=-H)@@5P4@E<*)*G`QNTZ21D=R;
M^SWD%14.\`\1`0`?4'AJ*Y]`T#0-`T#0-`T#0-`T#0-`T#0-`T$(?2-_)+]T
M^@BT#0-!9K)_]-N.?Z99S^SWG;1>7__3]_&@:!H&@:!H&@:!H&@:!H&@P5QR
M*62>?O(N\@458SCIAS%/&R"6W[R-KODM9?D%F))-0#>60'50>XS`4]N\IVQA
M,.QB`4OB,ZM$-`T&&/Q$QVX,<J1VWVPM=!V#;<=HT_0-Q`.NB]=XKX7[TP]I
M(MR'3J*SABF4/LHN%S?P:Z:,9!>R!0$1CCF#T@F\0$_V`4\HO_W0:DL,OOUF
MX#8#Q<@`#N("`QY_#T;$?&-O]C5TY,SA",LV$/QR+T@;"(^;&O#$+MX[G30.
MF&P?+MH9B`'<$J?8%(XJ@C]'O107WZ==MR*@.VAH[P(D\45W20>@2.3K%^P1
MR*Z0!\P::&(C`7A/HN$E@]3A'L./SJH&*0O_``>I@PC!VL3^>:*;>D[4Y7)`
M_P!SLDX'P]"8ZF$P["+Y!4W8FL45`#<4C[IK`'K,DH!%0^R&FJ.0Z+=4WF&)
MY:W^_I"*2P>K\:F)3F`/4.Y?6&F5RB$79"B012D$!#8R2X$36$OI#N`ONRP^
MH!*3Y3:JN5HX[#"1BN9!0H=PQKWO$FP#_FNX151+OT`R8G2#T%'2PQE/`=,I
M1%2+EFB9BKD$JC)V4ITUBAXG04#V%0+X@8@@<G01`HZF4ORTR_$%K')3`49-
MYCI%9P/GGCS&HGD+E3\LXN?R]PQU'D`QWC]2?KTB#>3IC8A=SO58LZT:G[;K
MS4RG<!TESO=4Q\-2\%RPX3Y*;E=7WB%+T1[Y6XVGC!EF'EHX@F`H>]I5_P"N
M,?->PG4P)G8/#E`-MC=Q@UJ9QI6;.4TB[_\`#ZG'HM*%\0:Z85G!,(!7>05(
M6;-8]41.)6RTRYBJ%$>6B.Q1,$FN':7?O'<#:>^-U]+=HR+J6/LYV!)-;!/+
MOBMGAD``9(*_DP[&252Z"`^XPOY9M43B42[@9V':([=?'5G><)>O[UB+E^NY
M2.;>##3V+GL[=&^`<YA7V%2MM<L9I2M&M6)/RCD&GG2Q5$DX]V5D4R2B::J@
MK`)"&`IQ+FWK>_7Z-27T[:^8S`0Y@Y\J)2_E[@3,$01("^\.)C%=O19E$>@E
M++,HPD:8P;#U`YO7X:W^6L?FBL83XBN,Y(QXBW1SR&66(*+IC(I@F<R:@=B@
M*Q\JFS/Y9@$0$!$VX#Z=/6>*9\6*RA<UXQ:+.;!@G(E;HEB<%][=U"40;,J3
M;G2+0B""4U%J%:BU?J-TB)$?L'"3@A2E[O-(0$Q8MWAEDMCFWTR[RT!D9&W.
M46%XB??OJM$P.%XF3DFZD=(PS^8:K"@F,1)E61$A4^Y-='M$=@VUFYQC"Z9F
MJXN$7$4RF+-#-963E7!E3G;"X9E;(G8L5S('741(LX$LAYRP%4,;RRCT`"AN
M(:G;.)3KO<5A+RY^,KQ!X69<FL*Y,B\N3E]A&,))S+>A4:*<Q2!9V/0E8]`\
MK/V6LH/G01CI%13R!43("G8)@4*<H<[9,9KKUZ]NTS&-<%_UC[@#+R\=&R5<
MY"UED\=I(.)Z8H%4<QD6FJH!#/GR4#?IN:]U1*/<<&K5PL)>A2#]'4]NO*_X
M^[>51KO2\I4VMY"Q_9(JWTNX1+6=K-GA')'D1,QCLG>@Z9JI"4AR@(B4Q!**
MA%"B4Q0,`@&G/ZM)7-'EIQN^%Y<[PVP.U27Y#Y@>43)ECXS)Q>1GV-;9'JR\
MW$V*T5=O5T2TS$>4[VS*(NI))!XE(?5"!G4:HH<'1IMLW)>V^T53\+WXL,WS
MLR=ES$>3<20.$KQ2(>+LM6@$K,[=R\Y%++N&L\Q7@YZ/AI91]``#9=0[5OY7
MN[C<Z:0E(91+G,LP=NOK)9<QN_22`^Y1$3F$`Z$$I0ZAT](="B'7VQ*'3[!E
M<:">B]8I#W=ZZ9U6RAO,*"AEFRJC8P@4Z2G<"9DN[;J4!'?Y1F%W3DO<)@(`
MF*80,!1[%`$.@![13E[3=H!](#>UN._3J(0*H)*%'S"IB&P]YQ)[([]H;&*)
MTQ$AP_C"(%$-^O3<*#EZ>4J_UI"O',5+)[@21CW)TE2%(7;L6*8I2+)B)0`2
M&[BFW`#;AX7.F$QYB:0N3744J6,OB`(;"!&]E9-S#'KDV`"'E&Z(J_5ZJGB*
MA/Q`CN.R8!I>OGJOMC=>5!=!TBFX;+).&ZQ`41704(LBJF8-RG353$Q#D,'@
M("(#K#3ET#0-`T#04S;+E5Z+%M9NWS3*`BGUFI=-:/GYCD07M&1;C`X^I$*0
M2$.87MDNEGCXYL&VQG#H@"(`(B`(NY5>:L=IJ,5-,GUEI/U)^5<.@8XO(/\`
M*1BI)P7OQ1(4I/K-@D95+83;E#KMH*FT#04S;KE5Z%!GLEQFF5?@DY.OPQY-
M^8Y&Q92U6"+JM>9"9,BAO.EK%--6B0;;"JN4!$`W$`J;04S<+E5\?UR1MUSF
MF5=K43[I]93$@8Y&;/W]\UC&?G&(10P>\/WJ21=@'VCAH+:Y,Y(85P[.-:WD
M>\-ZW,NJ\XMON9H:QRH,JJT??5KJRS#F#AY-I!0+5]NFH[>J-VY!`1,<``1`
MN+5V"V&`/`%M9)R'/5SPX6$MD+)LC0!H`S+ZR+.%F`6&.-#FCA\\'(*>2*/M
M]W;UT1*ZG>J?>TI5>G6&,L;>$>Q<?*.(M<'*#1Y-U*LWR)1,L4/*4^L*=<HN
M12,03%,V>I&`>H@`59H&@A#Z1OY)?NGT$6@:!H+-9/\`Z;<<_P!,LY_9[SMH
MO+__U/?QH&@:!H&@:!H&@:!H&@:"!11-%-1990B221#**JJ&*1--,A1,=10Y
MA`I"$*`B(B(``!H,&_AY$"Q<?G>=%D5$W_*O*V5>3/FK%,15>H9*MKPF&0.!
MQ$QC,,!PE4:=W@?W;N*`%$``MWPSGT0T#088_$3_`-ACE3^A:Z?Z-/I5Z[Q<
M7<?6/V]5R-Q]8_;'0?-Q]8_PZ#[W#_<`>G[&@@.4B@"51,BA?`2G(!BC\@@/
M0>FJ.G]6,-]TFX-3;]3LE%&1A_E"U,D)_#T[Z9H^@W>)!_Q>25'U)O44G28!
MUZ`9,&S@1^4R@Z97-Y1`\D4?Y]B5P4-MU&"Y1/\`RC-G/DB3;U%44'5S\F7*
M1]'O3`W4%,ROB#9XD9%??^,1%R0B@@'\8H;?+JKF5VRI*)=6S@Y?^XN!,X1'
MY`,8WO!/DV/VAZM3!AS%?"D(`Z3%M_W4#>8U-\OG`!?+_P#"%)\F^IA,8=\Q
M47)2@H4#[>T0P"(&(/H424*('3-UZ&*(#JRF>7T3'3)Y;LIGK0!`WG;#[VU,
M'T5!\O8RG8(;@HGLH7Q$!ZFTK7\DX0<$.B+&1*A)14BD=H"BZ:;ANZ0=$,F=
MD_1$ID%B.$C"4!$.Q4![3``B'=&=OH\P7Q-.)'#WAQ8:K<R<'[W<<3Y/>R+=
M2UX0R39J^O1+D3S'RE:D*@K.-(1K'RK'N<1BA!\@P(KHBFGY)!5Z3MXQJNN;
M^;'U:NY&!^%%9VI'MKXO<X:X;RP46<IGK$GV%$.AU'1+4H].3<?``WZ:MDN_
M5)>TTG>+5+XY^"(V=&=.;1S4JPE$1(T5@F:JB"@;#VIK-8Z07*8@B&VXCK'K
MTX_FW[?<OF?P4V6Z\$*5GG',CA?G?S'Q=0F&.LA-IJ^.F>15K?3[&[F*8K`U
M.$:0#.)?'KEJ:(/%Y$J`&;BM'M_-W$2:F>LLUN/Q:QWO6_EF?P;&*#S_`./M
M52*1K\9OD4\<>6"0_EGQOE[4S`NY1(.UHQC/.BJ$VV[@<"([COOK7OTY_;]S
MG>G?^S]OWLAHGG]@>V"W:/?B.\=<I-@$"K?U]<,K*5<"F(!#I&FJVXQE'LR&
M,8![C([E`1W$0#I?:>*EZ=O/5?:#0PYF,A`IE:X)YQ*L0HK?U'YU7QS=#=Q=
MS*LJR]CK$@W<'W]E!Q)(@!NAE/3K4O%8LQO$]@*@RXR05X09T+/U0QS/P]ME
M(R.FXQ*_.<-7J9:R3T]LI]AQO)61.;JC^:="]68.5A782(B\;D`%W(`QI<4\
MS,90<&LE7W,'$G%N1VQ(J7NULP?BF9FKF*;4'MCN1JG"%N)'4J^574DIDLB5
MZ"RJBICIO=RJF`_=K,QCKF^%LL[=Y)Y73R-Q#Q=RIH)8;DOC:#M,D<QTFCU\
MTC3V!DS2(4C,Z[U(BBJ#A$0/V>6?N(00Z@.X:6S;&A,[YU:@^0W_`%<;CW;X
M55?`=MG,:VHO<"03CMY*5HRAS>R+ILLF]>'23WZ@@9,1VV`?2&+.E\8=)W[S
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MUAR%Q]+T.#:J9`EI5"NJ1>04@F,9W..=N&*X*.X29?MFQ4P,Y.D0=QM7&V+*
MS*QWF/$68()A:,593Q[DVLRKI^PCK!CRZUFY0CZ0CT4EY*/;2%=E)-LZ=QC=
M9,SA$IQ40*<HJ``#K.B6<[KB;EW*5,0\L`+L/<).TIP*8I0`#D$"[^!2[^SZ
M`WU1$([&()3";<HE*(J'*4NP@3<`]HJQ@$/9W#;M\.H;"$OD8MH_3,FZ32,F
M;<>XX)E`FPB452AV&$@"`]-MC!MZAV%DJ@4HRQT5RL_JATUF2ZQU'L"Y`?J]
MX(E((N4A*9,S9\<I0#S4P-W;@!@$H`&M:7=-9LNU5;O#6M,4VXJ,99!,IGT(
M^#RGS0W@<2;[)O&Y3=/-2$Q>H`;M-N4,66?1J7/U5EJ*:##/*'/?C=C>V.\9
M1%GF<VYK:D$38+XZUN3S5E5!4`,8J=A@Z6F^C,?HB0HG%W9GL*P33`3G7(3V
MM%DM6Y/*_$5S\)@@8+&G`['COM\B8NWU1R/Y-NFG>N?SDZ7`2++`&-)!P@9$
M"^\S-[!$P'\QMOL0)JND^4ZNG$FU1''^5I53RAE+..22YQX[<@W5@Y`9,=2;
MVY3W'[.V(,S*T^)&.A6U%Q5$VYCBD8ULW@H%A$LW;WWE5N<?,.-3.JTEUX^\
MI[9,Y@S_`(\1AL09JN%YI3/']5E;BWF"1F/D,02F%;3,7J2@$'%?<R</)W-:
MXQD2T5=IN'-4BT3O$%'C@C6+F;>%"6+A9R79Y:NZF+\@6&FPQXBTP.*,FI9#
MCD$ZE1%>*:V'*!3K$W6J\YDZ=5J.5$VLX,,F[1@S.FY;*1^6:\Q@J,SRIG(_
M$#D!98BR/*#C,V-ZXN:ODIN!T\O0%KJ<9=XG&MGK\_D&UM)=JV1?0EXFI2+;
MJRM?L-<O$4O!DG6RAI%^[1(7,Y7"R7Q:SS=W,^V?8ZJTQ>);,..,@O\`-R>9
M+,U8/<>UW)V$[B.,V%.==K^21J+6DNT6<?,(GB4BL`E&ZWUO(KIE)G11==X1
M\BY"4L\9D24E9N#L5GI!LE+CDF)CJWF%C'\T,39=DY]S#5RNL+C-*M\)52>8
M"$]*-E6#::7KB#>3C#).D!E3F0^%7)ZUW>\N:_`0E=K,NTS?7W3-&\-EH>UP
M\[R!QK>,)NEY&;DK3D.RJUK&M%7(NG-/8^-K+YX,97HM&*V.0N9HS?S%Q9MV
M8.33+((Y-R/C3'*?'E[C*;4Q=8JM"3=KDY'(`S;RN3@S]0L\DV@58(YQ!U&+
M1[Q)8X^6N4P%,6LYT8F9!X2YKE<KMHG'U8KU5P_#.,A4-J![>5]"3>!I?@C<
M,`4&F3:MB?6O(+]O'9=D8EX_KC5&%J+%&+)*)LY6866?:BYF$VH'`2V_4[`T
MI$FQ;/VJR1M<NTM3[LN26@\/*_#+A^,SZ$C$H.12ACI0_(&$9R[5DU\I+WR.
M:RH""Z1#E&5,P7%?G*[C;G+Y.DZQ;I*[0,CE"8J"&3;<$<RS9E/(=+K=\IE>
M/#RM`37IV(^-V/",JXV.^BH.QS<Z\))MV[=9THJ7,2N'P#GZFN,78J<SLG'3
M&9\RYEIMQJS>7;G:5GAI<I2FY=M$[Y..8!M2:'.UY.@.Z1&-&`-(R(D,@JD9
MO'?:U5<C,W;?;/7+[*ROO5:R1^2D<#1!(T9^1\-.]SDJBXJ.O?7ZZ:X>:4Q0
M[-NTO;N'B.JSIPN)HAH&@LUD_P#IMQS_`$RSG]GO.VB\O__5]_&@:!H&@:!H
M&@:!H&@:!H,/>?-SFJ9Q'S*E4W)FE]R-"16"<:+)@*CA+)W(2RPN$,>.FK<B
MB:KI6.MU_:.C)D$#"F@8>@`(@6;QDS1J;`8ZI5/Q]5&GU?5Z)5J_3:VP[@-[
ME`5B):0D.T[@*0#>[1S%,FX`&_;X!HBJ=`T#088_$3_V&.5/Z%KI_HT^BS>+
MAZKDD=FL]>I=?F+7;)F.KM:K[!>3FYV7=),HR*CFQ>]P]?.US%1;MD2=3',(
M``:&Z>:!H&@:#[H/F_V-M4<:R*+@@IN$4ETQZ]BJ95"[^(#L8!Z@/AH.J#5P
MWZL'1R@'@T>&.Y;F#K[)%3B+I`=N@"!C$+_$'PU<FVSM-Y+=4K9VB=HX.(E(
M0X@HW<"`"(@W<%#L4'M#<"F`B@E`1[=M5J7+O%;F1]MD<J?7<6Y]Q;''QV*4
M-Q;F'UD#;KN)1U*EB8M'0+"8@E,FLF`>:B?Z10,/0Q1`>U1,PE'8P"(#MMX@
M(`BQV2E(BJ*)R[L9`3)*$#H"+LX;E.3;Z!7.W7;;94"B'4PCI>2\K'\L,`1O
M*[C)ES`TU+NJ_(V>N.T*_;(]L=S)56Z0X)S-/MD>V17:++JL99LW540352%P
M@91#O*!Q'3YB1X+PQQQV.FYCYKXM-H;"V469/(U?C+F9=TV6;J'2<MEF_P!:
MD[%4E""4Y1'?<!`=:U_[+^YOC_TS]ZBI##7PY(XWG6WXC&6;.HIW'%&J\6;G
M$KK#N('\M6R2GE!UW#<1$-9OKY[UK\_C[<6GDHKX8,+DZKIIW7F1E+%XU6TG
MM[F+KN-*G<%KN60@0IK:M-YA15F6NN8XTF,B+@1<%6!MY705-L_DSO:U_P"S
M&TE7_JSKX<,J[)'8W^'ORRS$\,<B+<MRS>[KCER<2E[1798^B7@I&-W`(@3N
M`-^@;:U)UNW2_M^+.>\W^Y&158Q=1IA9-"J_`KR"LB/LE=RF;N3CI<2;A[0O
MF=0`FXB/B`;!\P:OK/[9^]B]K_V?P7A9\2J/,"4TY\'+E53"D-Y@.L=Y_P`N
MV`Z8AU*=M%7NGD8@8AOHE-T#8.NM8_;*>U_N_@RYQ52K9CDS9#'W[Z'`C1`.
MU&%LU'H68\;,"D(':@%:7C9-PNR)ML!00`XATW#2:_M&<_$_BGW`>=N5:XX8
MA&KY(+5)"$K/Y,*).N->=\?/`-39"0JA&%FO<1%73%5^>1Q(0$%7;RNK.$E"
MG(*@*%,.G7],SL=Y^:WRVPUCE%:JU'L5LIHXZL,;U([L.-+'(A)MTT^S_C;F
MB6J,K\I+$0(8IW/N2@."FZI,C#VDUKUGAGVY924'+F-,Q0S]]B_(E=LQ4DE&
MKIW6Y:+E7L`^63,4B<M&*^8M#R3=3VO=7[8ABG+L8A@W#7.QO.5HN#F4;GF?
MBCAF^Y+?-I?):\!)53)LLU:Q<>G(Y)QS99S'%_?C'PS6/A62KRW5-Z=1NT00
M;H',*9$B%*!"R;1>VG:SPRQ`@;>'<)@$0[3@<3`'03!U\Q0P@&X#N&WJ]&J@
MK[NV;K.WB[9LS;)J++NG9B(HMTDRB995PZ4$$T"ID+N83F``#J.H/+]\9KXS
MU$KN/K!Q9X=9#9VF_P!P2>P.5\LTN02?U^D59PBLTEZK3[*S449R5QGB*BW<
M/F1U"1;7S")JE=G`6^>W;&UU=.G3-S9HTT<)?C:\K>*;F)J]WF7F><0H*)MW
M-9NLDJM;XB.$X`J6LW5T5V^,":?0C62*^;@0H)H^[@/>"=[_`%:M]OMRZ]=*
M]5W'W/7PQOBC46(8.,;XIMLQ4GC^RC0[C4X>K9.QU.68D<A/RL>>/<DFHQS-
M_4[,CR5A7J[5ZHS;@HN)VZ0$UB76:N7Y^EU9RV3B<_=!4'O'_E/R)X]&I-2C
M:E`UNMV6O91QF]B8MV^=-3V6EYKK.2!F'RR+XZ!WS>19OS(I)`#C\44`S8OM
MS(J[\H>:-:S#)-9?'N#,F\?YB9DCPMEHMOM&/LPT&`38N73!I9*)<&-MI>29
M!9=$C'WMA/0)5EU06,S;I`8I&J:8TN*^X8YI86S'*SE0%'(>(,E5=E'R-JQ5
MGW'=FQ)=X-E+S<77HA\!K0P1K-D82LU-LF;5U"R4JT77=MTR+"91,!0O6R?#
M+$R8*%4*8#=0`HF!-(I=C"`"!3"J<P)F+XCVCZ_#8-7\4^&.6><C8+PC7T+Y
ME_*E*Q!'-E%"P]BMMIA:V\>OT>P!95L'B@/IF84`Y`*S9D67<',4A4Q$P@-S
MC.3%[;;L6F7.CDYD$JS#CEQ:M-SK"P>4PY"<D6,_QOQFD@H)P;S\31G\%+YN
MR1&&33%1,B%;@F[HAB"1\!3]Y9C/Z8NWZJNA#\0KIR`9)3G+CE;?,UP3WM4<
M83P<,EQIX\(`H"+E:$GH2F6![F3(C5J[3*4R5FMSIBY3('F1R8'43'.+Y:]I
M_3&;6+</8IP?4V5$PYC>D8NIL>4GNM:H58AZM#E4*F5,72S.&:-$G3Y8I`%5
MPJ!UUC;F.<QA$1)G.ZX^@Q:YGJK)<=KEY=[F\9(GF\<?65XAHRV2:$/")9,J
M#F>:6T]$G*U<H''%FAD%XBSS4:_9NH*OOWDB59(&IE"EF[5^RY;Y3Q-056&.
MAK"%2<9*R^F;,2^7'_(+CXZE*=B?$5AK%-PGDG*\OC69=5&V35CF%WD.J_E7
MS6<K\[#PCA8GNXL(UB+^6;F5FB)0N+IY,T.J9%C20K1EQY=8NO\`;K3!U%]A
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M&+?/60-H<4$RG>)+.!)9)X7:HN?N1F=.*/)?*-`J#>`RK`8[O5,PI3%8TOU@
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MW9*%BK!J&/*]D2>LD%22LL@6+*,A=;F\"L1DV^D%K`XIC2*0$S4104KY_*53
M!5T16IIB,6>8MZR-!4.'LEXE(G'')*N1SVT8QQ+C/..7GE,O[*%M%7=RT'BZ
M7_(##L=F7DO9DHXD1`5R8CE(]LE.&1<H*L'+U9U%GQLHV.:W;)V7);'57RW=
MXS)4[?>8Y^0,+/7"^NHVN8JH7)"&>\>(B9J$?.1L;CFO7O%S&+AHEW%_5$E+
M5*;DWS59RX%PY*/E7/&[)L@6]Q>#<AR]KR(3+F+ZM5Z/;1N,S'R;C#D'3<L'
MKV3&%;5>/)_ZGR(_I<])2-R+)DDFGY2TV'="Y>)F<-A>6</%&WV&_<:<%7.U
M2BT_8;%BVFR4G9G#8C-6VK+0K4"7(6R0`@B2XH%))D*G^*['8=GL[:J7>IYD
M_P#IMQS_`$RSG]GO.VAR_];W\:!H&@:!H&@:!H&@:!H&@P4Y*BED+DYPBP6!
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MIELJKM/')JF666D*G49IG9(UFO$*-HII]5N72YU`;IKN#@,S\&4O$ZKY-IV+
MWL%E.)-$2Z-XMKF"1<2;IY*.:F^>INXI[,1/]9678&HR"KA5<H14+/.(9NW(
MDHW08^:=BV,W&=&36B&@:#[H&@ETL<AFGNP"!GC@Y`9)@/XP'":A#IK@`#N"
M;4Q0.<W@`%UJ;_`J%+TA\H#I6[L^+AV*-ER_SI5TT`*'BJDX.!%4Q^0@!YGR
M>7ZM](S$V6*!FCC<>WM1,J4_^]G1`54E/3U(<@#\X:5J[)ZQ,)990`+T68MU
M%0]!#IKJD*(_*H4XA\Q-)M69M7BGN7&WAE/9LS$[?<!;K;G:V6,BJJ34ER*R
M#`Q,RNK<I@RDE'0]>:)MV4<_,85442F$$DS@0-]M=)]N7%L/\O::3MHNC7.,
MO&"*!-6'^&UB!@`=4EKQDO*5^('7<14;S:B2:HA_%[NT=7_'UXC/^7MS73BX
MJ*H'-G!2^/\`CAQEQT<F#<VJA!5G&921$B8EFQ2G]:RR2K\%7L_&)G%)DZ$0
M,@DY7+L/F#L]>L[]9-L+[6].UO,;2D,DYOD%TPKJU4IRZH=I0IM#@R.SB(`'
M:5>19RKC<1#;V-A'IK6.KGFKH0F-^75R(5RM<\B,F8AWG>R,P6FM`*(![8))
M&B3J)>G=-(P:F>DX7':ZZJQ9X!R^54@S?(1TT43-W#Y.1;5+.$Q+T]A!HKW=
MP"(>`ZGMU\=3%_N5FWP3+AVJ2?)C)RAB`(_\E!;#B4WH[%W\F*8EV#KN7KJ>
MW_"+B_W,).$2V,Z7QU<PMXY/Y'H2]'SMRMI#^+=WZB5J.02JG)[+D5%BB>>[
ME3'<0R;55=0A^T[I4^QA#KK/7./TSRWV_5G-VG\E=W?FGPJH!'(3'.^VO`8@
MIW-8C(>+K4Z3%$!$Y#)UJEV.35.7;P4[SF'UCOK7X1,<2M<V9?BL_#Q2?HR"
M>4.0N4)9@0107@JU4(.3%%5,#BB2TS6(ZG*L6ZY#A[2+Q,1`VX&W#H]Y)O/X
MK/M]KX_BUA8P^,#0\)M,F0-,HW),82Q9:R5>J@E&\AGM-2C:QD&PKW!*&EXU
MK%V2.-,HSTP^4</6P$%P"Y3#[6^_/_))F>OETOVNUQ?;&B96+X]N1V$>0,78
M\OS";424*O*91Y,9IR`@DJ;;L50BHV?J4:H!0Z=HI$V]>W33_)UFW4GV;Y[:
M-2_(#FCR>Y/2KM_F7,U^M4:NJ8[6HN+3/_D7$I"(]C>-K:TDNP3*F`[>8J"K
M@_B=0P]=<[VM=>O3KUVC%W66C05+3[G;<?62)N-%LLY3[7`NB/8:Q5N3>0\S
M&ND_HK,Y!BJ@Y1,("(&`#;&*(E$!`1#5SC9+)9BS1Z;>!'_6);A25(?'W,J-
M6LL(3RVC?,U3CTR3K,@%2235N=/9))LI9,`)NH\C")+@!0W:+&$YQZ3O+IV<
MNWV[->O[GKRP7R6Q-R`ID3?,67NMW:KS*)564S7I5M(,B#L43M%R;]S%ZW[R
ME<-E@36;G`4SIE,`AJXOX.>N==UR\@XYQSFBESN.\ITFKY#H=B;)-IZG7*&C
M;'7I$B2Z;QF=W&2@.VWO+1T@FY;*=A%T%TR*$,50H"$)?WL1Y3B9DW#F-6%(
MX0YI7Q1'PEALE@#'>;QNF<<>RL?8XJ#C2TN'LLY=4,JXGK<$XA5GL66!EQ;,
M7<B[.+)<%$TTI]%SFYL8)X'G<4X(^(+B_C!/<4I6]\C;/A5"[YCYB2UQMW):
M0J%X&LA+HM&V6\@H3%_KE!L#AH^8I>^L*2@V<"P\EDN@](9!M<8:N?6W.C>P
MNU07V*J0JA#!WD`X@8@GW[3F`Q=R#[)@`-OOO``WW&L+?NJPZAWQY:JO3PT@
M8!.<K<`]V>I%]LR:[-4P-'!1,;81."@D[MRB`[:UG.\T3&NBM*MDI*0=(PEG
M9#`SJG:1!81[H654W,7M8O!,;W9T<2]&ZPE..X`03CN`9O7&RR^+NNIK+1H&
M@:!H&@ZSUHD_9NV"YW*:#ULNT6.R>O(UX1)RD=%0[21CEVL@P<E(<1370536
M2/L8ABF`!`*?I5*K&.ZO$4RG11(:NP:*J3!D#EZ_7,HZ=+OY!_(R<FY>RTS,
MR\D[6=OG[Q==Z_>+JN'"JJRASF"J=`T#0-!3PU2OC:T[P$:D2U$KRM4-,)*N
M$5G%?5DD9<D:^126(TD$F<BB95J9=-11F*[@$#)E<N`5"H/OA^8OW3:#[H)9
M-0["PPTM`2J:RT7.1C^'DDFSQ['.%6$FU59/$T)"-<-)%@L=NN8"K-U4ETC"
M!B'*8`$`Y8N,CH2,CH:'8M(N(B&+2,BXQ@W2:,8Z.8-TVK%BR:H%(BV:-&R1
M4TTR`!2$*````&@M1D_^FW'/],LY_9[SMHO+_]?W\:!H&@:!H&@:!H&@:!H&
M@P4PV*62>;_+;*7:9>,PQ5<.<2ZNX#JU1GVT*ZY#9<<LS]Q@65D@S!48]T(;
M%36KX)[`<JFY?$9UZ(:!H&@PQ^(G_L,<J?T+73_1I]%F\7$U7(T'S5#^[?0?
M=0-`T'ST>KT]?`/GU1T#23;N%-OYCU8H]HI,R^?VF#[U18!!L@;_`+X<NF.0
M!*2=_P`X8D>B/WB(@N],7KT,L)?=VQNFP@4JH^HP>.G\Q,&K%NVW\I,`.<=U
M%#"9194?6LNJ8RJHAZ.XVK]6I.7>.JFV*`J"/<8=DR%`3**GV^BFF7<QAV^T
M'4>G72\%OAS-D%5%2N'!03$H&*@@`@84@/\`344.`B0RQBAMTW`H"(`([B.D
M)RF1B^>JBR*.X'[%W0^@C5,^X%-Z-W*A.S;TD`_JTI:D%XM3*H4:U6Q[*%AQ
M59*,(>0.R<R(HO7)#L854D<R`7;X!D7'G^6GL8R0B(B4`$P63.B;=;6I2D<;
M\<1+4IY7+>3K(X7$5ES150/#G664,*BBF\VX=&*)SF$=S!]G7;-_MCEB<KK+
MT'C]46(25D;7U1@F(`9]>KE`5B+`PCL4IEVZ[8"F,(=`W$?5K.>UX7'7Y:P\
MP<IN*>.N=N`KA7:W!6>MU[CIR`AI./B%9"^-GL[-W7#QX)<7LL>/AW!TD8-Z
M'F)NCHI@(]Y@$2`,L[7MUS?#<L].V.OF*JN/Q@;LF<\;B'$M9JZ!%A;$7DA:
MM5$2G,H@DLO%1#$GN1`414`#?6!RF$FP&]H!U?2?+.;XPPGR'\1/EE>7*B0Y
M3<Q15UUN]&M1C-B>.;;E,82%D6LI9#BBDF90#D-Y8=Q0$3E$1#4DG@_%C#-<
M@^0,XF^<2V;,HS+=`AP`S.^6MMW()IMW"ZGNZ4@<$SKD=BCW`0$^XH=I2;@)
M0M%8;!;950%Y:TVB8,H@N)EI26DWCEL*8`@=4YEU9)'S`>N>X2K#LHF`=IA,
M4VY6,U5A$3M+HB5J[6%/(]D:+(M@*JN!'#]&3`5%%W2Q$@,$N8#$,?KVJ=HF
M^GK'7^KZM]KM?A3\C65#?B![B'>$!9)R"IBMW`&11%9$[8Q@27,1(H%*IYJ>
MY"[&V$VP+#*T]CIZ94P*DP$Q'G<\]HY4EU#&4,;N=@9,AB(^ZI%+[()!W`)1
M$P@`!FR<-RZK$2U=.D^<-#$$5E8]HY*(@DGL)53)"FF':F4?.`R0@/0>HAW>
MOG9K\NDNBCW<8JV$P')VF`QR@0!#<PD,('*`=PF[B&`0[=A'IU\!UFS#64J$
MIBCL8!`?4(;>G;[NLJ^:!H&@:"_''_DWG3B[<VM\P9D:P42;142,\0CW0K04
MZ@F<I_<;%7W0+0\XR-V_0<(G$@^T02'`#!9;-F>W6=IBQ[!_A[_]8,Q=ET\-
MCGD]]7X4R0L#:/:687;H^++6\.)"]R,H_<G7I+YRIOLA(*';``%*1Z<Y_*#K
M.T[;Z5Q[=.W7;6/3!7;=%6!F@]8NV+INZ237;JHN"';'35`IBJ)J#WD!)5,X
M"'L[B4=_FEC&<JL$``H'$2G`O8!3;`GVFV[A`JA$@$HF-U#L`#!XB(ATT\*B
M]`";8H&ZE*4HF`=P#<#=NW:7MW\?F].^@@*5/M$2B)1$?H"53V@*8WF="]HE
M5[N@B8-M_'Q$=!(I:OQTPU406024[MR^VF&Y3%$"]HCMYA"@8P!W;;`'\%EI
M5,QECL5%6*V=@ZL-7[NTI!*JK+11``NXLW"ASB^;IB;;R5!*8/`@@`;"LEVW
M26SZ+WPTW%6!@E)P[U)\S6W`%$A$#$.7Z:2R1P*J@L0?I$.!3!ZM9LLW;W37
M4#0-`T#0-`T#0-`T#00_?#_)+]TV@BT#0-!9K)_]-N.?Z99S^SWG;1>7_]#W
M\:!H&@:!H&@:!H&@:!H.E(R+&(CW\M)ND6,;%LG4C(O7)P3;LV+)`[EVZ74'
MHFBW;I&.8P]`*`CH,+OAXL'+OB]5<KRK-PSL/)BSY!Y3S:;T@I/DD.0-SF<C
MTR+>(B8PMU:MC69A(8B0^TFC'$*;<X&$2W=F]HAH&@:##'XB?^PQRI_0M=/]
M&GTJ]=XN)JN3YH&@ZRKUDC_/.VR7_?%TB".WJ`Q@$=M7%'#]9M#=$C+.?'JU
M:N7)1$`WV\Q!$Z?\.F*/OO+M3HA&KAOX'=JH-DO$/'M.X<!OO_O>F/D?00E%
M=N]PU:E'Q*V1.X5`/\EPX$B7VT1TTX$81#8__C1EGP[[C[XJ*B0B`>/NI`39
ME'YD]77PN*F9$2D*!"$`I"]"E*4"D*`>@`````#3"X1**(H`'FJ`43?0('M*
M'$/0FF4#**C\@`(ZNRZ1\+[TMT23!JF/^<6`#K#OZ2(`(E)T])S;AZ2:EK-K
MO-F2:)A/L918P;'64'O5,&_@)AV[2;]>T``H>@`TD)'8!4ZAQ09D*LJ4>U14
MW_BS<?2"IP_G%"[?S91[O6)0'?5:<N[=%N[,HZ(BR0(JYG)ETLF@B1!NF)W)
M?/,)$D2)(ICWFW!-!,!Z@;?;++S[\G_C+8LF[>\IV':#-9*KM1?/FD?:I-^G
M6Z78)9LDDDG-0R3=M)3$W#N#KBBQ5%)H58@BHF)B*$,/7K&>VK`2]_$4Y*VS
MS8]I-06+XIT"B)4*+!^[/DD3(*J$<H3TJ>2D5TR=R7>N@Y0#81`"[[B&\1EA
MK:;5<;M(IRMHM5CG9YPV4^JWUCE7THY,N53M[57J[IR@FL!UP`AC%."PE3+L
M8P'V"S#ME)R6?<?LJU'RDW,/,<W<$&;8`?/)%\,I3!>%*T:-%U#-$#D/YB)4
M1$$DS>T8O0,W]?7Z-_\`\[GF,^JYPBY!2T.UG%JRQJC1RPD'`A-NDPD'S!FT
M^L'`?D_%-I>73?+1C119!,[5$79BBFEN8Q0UIAEOC;X7LLL=8N3+RJS(A]:D
M6B::U0206?>[2#9FLG891H"JOO$NB'O'ELC?BU0.FL8I"E&6C**J?#9X\1#>
M&4L->>65X6.KS>Q-7UFL(1*SR/2DAGUHMO&NHA1'ZX<R8D2[@_XLBW0`I?,!
M919E52P_P]N-;-NV2D*!&2ZY'$85XL+^VLBOV3>IQ4,[;JE3M*AVR[Z=;.I(
MBJ2I`0%P5`"&*ENHR,(\!?#OP)8,C<M:-:8)ZH\QSF:KQ*<O`6.Q1B3AA8N.
M?'JZM%FL:=XY;-79)R5E7BWF>\^6N](F0QD4.U3,NO;3RUVVZ7X5M/\`P>,,
MO"K)UFU7BMG!>2,V<#+P\RF9NZ9QJS%NHR?5E$Z`MY4BZ*@D<>6=J1!3RQ,9
M5(MT9S6+>0O@LVP?>S4C,#8S0&JQTBVFFN#.3N519QR8.W%;>33LRBBIU%1.
M@S,4B!@.)``@E28_>U[6>&L;/OPS>3&(K?CQ!]6X.=5NDY-4^%5J,VDL`3J4
M%=;HW1,>7;078[7A<6RKY``.9,Z)$U"[%<(@IB]=>NK?7MI?V^&%N6>-F:\<
MN&ZV0L876HIJ@4S26EZO)-HYUV@9V4Z,F")(P5@!9(=T7"A#>:02@('`33MU
MK?7M/%8OR<`5N)#I`NHF9)-4Q5FRR*Z`*?BP%<?*%$H;IB!=MQ$P&'MVVUSL
M=)V4DLB*9A*)3@)0]KN+L!3%'M.`#X'`#@(;ATUG#3@VV\>FH&@:!H&@VV_#
MY^+UR$X0RL76)21DLK8**)&KK'<W)&&1K#4RI3*/*#..?,<11D"[B$<J<T:M
MN(`1!0PKEW.V-+K'/M]N=M9I7N>X9?$'X_\`,NCL[9B.[,91=LBU1L%6?]D9
M;ZJ^52,I[A9(`RRCMD8#)G\M4A56;CRS&0653+WCO2ZS9QN9<=F?2"Z3@"G3
M,D8IRB<#]Q3>6;H81$^R9.TGKV'T>K8(.T`[]P=1+T((F`2$$">T42;@3<1'
M82F+W``=0].AN@$>\?`0[P`.G<&V^X=`\\#&$=]@$=A`W7U[!PKMTW`&!0W<
M7Z(F'RBF`>T`.111#O[#=>@F'Q'8!Z[:&E6\<PDW79%:?JCL[541[W;%R4WU
M?(I%$#`@]*8I@'L$3@4Q3`=/NV((!OO=+I4UFL73J%WC;6D9$"C'S+8F[V)7
M.4RI0#M*9RS4#8'C$3FV!0H`(;@!RE'IK-F/HU+GZJUU%-`T#0-`T#0-`T#0
M?/OA^8O3[)ONZ#[H&@:"S63_`.FW'/\`3+.?V>\[:+R__]'W\:!H&@:!H&@:
M!H&@:!H,*_B$STDQXH9&H]>>.&-PSZ[IW&"F.&0E"0:6+DG<H+#!)EB8_P"+
M15JD7<W4PHJ?V$&\<HJ;<""`EF[+RO0,358"#K$"S2CH.N0\9`PL>B`@BQB8
M=DA'QS-(!W$$FK-N0A?D+HB<:!H&@:##'XB8`/!CE2`^`X6N@#\PQIPT7KO%
M>_4[(!#M1.EMX>0NY0'[(HK$WUTUY8]?D&):CT-[T8/4H^D#E'YR'="4WV=3
M!Z_)]31PCN9BV4'J&ZJ`*CMZ0#S._MU=>3U=I)DW0_F6R*7_`'I!-/IZO8(&
MH>KL^4/I^3Q'_!IB&(^^6!0W$2E*'41'H`>CQ'31<1P>]--]BK`N;P$K<IW!
M@'?[X&Y5!+]G;53*(%'!]_)9F*'H.Z5(B`AZP*GYZOV#%+J9,HP:N5?YYR8"
MC_FVI/(*(#Z#*G,HL/SE,33*9=M!DBB(B1,I3&^F?J90_P#+5.)E%/LCJ:TQ
M47O"7<*;<IW2I1V,FW`#`00VW!181*@D/R&,!O4`ZN%Q(C.F/LB_6!(JF_EQ
M[,5#JK[?>F.4`<+!ZP(4A0#Z6X==,\+]5.W:\TS&M3E+GD:RPM"H\`U,ZDY&
M7?MX]L@@7H1-PZ[P`%%S[$3;-^]98X@0O<)NP9BW;=F_P>7'X@GQ2+AR>1D<
M*\<5)BC8%5*LRM-G\A6,M>3XU,#E=-BE#RU*Q2%4!*8K7N!Y)D-VJ]A!,@'7
MKU\W=G.&K2'B0*D#*/9NW@G0=%;(MD555'*W;[NU1:HD5.1955DHJ0?)2[3=
MH`!AV[C;1EMCCB/GO(!H9TPHSZ$0>RA(%I)6M$];C6[LJ"SA%(63WSI!-.(.
M*B`N$VRC1)T;M54)VD$I&>F/_AC,I!BS?9)O\NZ?/D6;L[6KQB$.T8H.%T%)
M-D[6F@=RJS]^P3]W(*)$4T2J@H8>X!2(M,*F8X'QQB[GKQ@KM5J437`4XT\E
MGDH>'5?E/+N$KCA)HB$H^>N%7TAY:,DX(83"F14%3"*91.<3<[?SSZ-S_P#.
M_6?ZMJS9F@S(1-LW30*1,"D(W211(1-(I4DR%(F!"@5)`@$*7H!2EV#;;5SR
MR[12"8`WZ@``4.H`!C#MOUW$-^XWI#?YQZ@'TI`$NP[CVAOW`(=H[[F+Z1$-
M^W;T#T]730?13#<1W[1$`V[A$0#P`?$3;F'J.X[;]?#5&%&"RIL>9'.N-+[D
M!GWZLMM4!OT=[2V+Y:K%%ZF3L%38*&()*CT,4>W?\7TS/U=FK^GK^+-@Y=_4
M7J'<)B^:.PF+N`!]$OTA#Q^UL.K]&<'E]`,)OE';83;;CL<1#<1,`CZMM@T&
M$'/M%*,P_1\HG;D=I81Y#<?<IO$E``"*5U#)T!2+Z!U#[D20)CRZRQE#&*</
M*`X"4X>P,NV>*WUWLYE9@O:Q"2)-G,:W4)YS9<Y02V*L"!6*)47`%$/-;+MX
MQLDJD8>Q9)LD0X&*F0"ZRPPTRE\.?B%F!0'%WPK3W+I2/AHY_+0D<-,GG)85
M-LW1=FE:4XK@*.731`07!5)0JJHE/[/84`8E\++VFU:G,V?]7YI,LUD9?"^5
M9^I2#:(</&=9NT>WO,.^G472"A(UM,QY:]*149)^>H)5ED7QVX)B"A3@)#%S
M>DRW/N]II8TS9P^%!S+PV:?=I8U-E&O5H^TQ:<2N5[8U;]RS-+RU:X9HPN:#
MAN:5:E7*,:)4A<)]1*8IC\[]OM'7K]WK?.&N&4B9*%>N8Z58O(Y^S4%!XR?M
M5V;MHX+T.W<MG*:2[==,>AB'*!@]6N>+'7,NR7:@:!H&@NCAW-64\`7R(R7A
MZ[3E$N<*J!VLM".C(@X;B<IUHV59'!1C,P[OL`%VCI-9NL`;&(.P:LMFLJ63
MM,6/<'\+7XW=`Y1,Z_B?-C^'QWR!*D@P".76+&5+(RY5"I$?TAVZ,H5&75(8
M#*0RRWO7>(^Z^\D`PH]99V^KS]NMZ?\`U>B2.EV4BB5=!0@@)/,,!=C%$3%V
M,?S!-L8X%V$>H#ML'AJ(FQ1$>FW3P#8IMSB8FP'$XG'<"]0`.XP`'R[``0]N
MQN\#=XB<"@4X'-L`]I>SS/,`4_9$=N@@)NH]=!`<A1[?.(!CBH`IB4P`?8O3
MN(<5C*=H[C]';H(^R(==/D458:K[XHG)1RRD;,M#BHRDF2XD<ME>T2;`*A%@
M5$0'VBG*!#%,)3%$N^]E\>$QFJKIE\&5<C7K"FE'V9`AA(`#LUF$4MP.X9"(
M%\MR7M$5$!V,`>V7<F_;+U\S99<Z7=<S66C0-`T#0-`T#0-!\^^'YB_=-H/N
M@:!H+-9/_IMQS_3+.?V>\[:+R__2]_&@:!H&@:!H&@:!H&@:#!;//DY'YA\-
M<._^-1^//ZW>75O:!WE03_J\J[;"F,V\B<.T#^^W+/+B59I`(][BMF4$-D>I
M9M:SIT0T#0-`T&&/Q$O]AGE1M_\`T7N?^C3Z+-XNCY;\/$6I@]0)KD_A\U3[
MFM9<\T[7P_>M2_+^./\`P;)_=TR9IY3\?\ZU+_\`FJY__P!K)IDS3W5V;Z3L
MQ?\`O*"!/_QP+CMIDRB!@)OYQP[/_P"'%$/_`-5!'34U1EC6H"!C()J&#P.L
M`KG_`.$6$Y]_LZ:F*[!@10+W*'32(`>)S%3(&WRB)0#8-7!CY<8.4#;`@55R
M/H]W1.H01]7G[`@'CZ3AIA<1S`1^H`B5%%H3;<5'!_-.4.OTD4#`G_\`A=71
M?P=?M:'W!1=Q*G]*+?;W3?TD.*8IM!+\BJAAT1T9RQQ-9B7DQ89J&J4!&(&7
M?R4@^9L&;%L0-S+.Y20,WCV*10Z"(AL'H-J;F6GODC\9K!V-7#FE\=(9WG_)
M+T%&;&4C@D&F.F\D*Y&3<KFT"W6DK2(.ER"1.-24:K%'M!XF(AK4ZWREK33>
MZQS[Y]VF-L^765ID81%V=S!UE=V3'N,*U[PSV:)Q,"^=#^,7\\J9WJAG#PPN
MD$%5CBLEOTQAF]F86`OAA0:+5>1RQ)'7=E,0$8N"36:0_8DQBUD%"O'I2RK\
MC@I&Z/>E[J@5)-80.J8J8C;HSFUL^J&"\749^VDZG3*Y6UV\*,(8(&&CHPBB
M"LZWL*YU5T$2R*ZSAXT20."BYRF8D!`Q3$[N[.:K7U3,U9\C%;EE%RAF6RXW
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M5VW"2<Y6OX>R4R5QL\BZ_%,T7;6-(=K9&[L)1D#A=4C`%VKE[><).OSK_OA<
M1OR*R:IDF-Q"MB>EDO87R,KUB5;9<EW=-C*B_P`;/,D#/Q,V;$K>>E[&DA&K
M,?JA>*CTQ,9NY][*DMLG<ZXPF)C.=&8X$V-Z0`V^X;D`0Z``B!0-Z1.(;B&_
M7Y]M5ER`4>TIC#L7M`"F,(;[F[?6(;``?9^78-086TLPQ7Q!^0$<*J?EV_BE
MQBM)2*I*IKD/5\G\GJVHDT.)RD5;(DDB'7_%B8AUT@Z!].?U7Z1N_HGUK-,2
M[%]'0O3J)OI```(`4!$.XQ?7\ORC6'TI-S]P;;]NX@(]`'M`1]H`'?H'K]'H
MVT&/W*W'1<K\9N0.-RH$7=W'#V18.+WW[D9Y[5I0(!XGV=@^<SFDVZY!\/,2
M#N`0Z:G:6RM=;CM+\I_Q]OY,M8'POE$KA-8^1,4T"ZK*(G,8GO=EJL9,O$C=
MPBH59N[='3.0P@H4Y#%,`&`0TES$LQ;%W/++MW=PAU`-^T0Z;[F$0\`'M+T#
MQZ;^K>I_-#Y("7\8'LAMN`[="@&WATZ>GI_!Z`Z#F/;/4U2.FJ+@CA)PU517
M226(JT=D3!TW."A!*=)P5$G>7<0.!"[@.P;48J9TX/<9>1_D?UO8IK%M6:1C
MN,0DW#$T=8D$Y*<-//WR5LA5HFV%D%G0%2`QGIB)(=Q"$+YB@FEDN\66]=JT
M"<C_`/J^\NR:+S7&?(JCR3%^V(:@9(,@G'K$EGS%NV1KM[C42*]L6=\8BY9.
M.1*5!L9P=R!3``<^WVY_377K]ZYQVCS\YAP-F#`-B"KY@Q]9*+*+'>_5IYA@
MH2*GF\>]68.)"MSB/FP]CBO>4!`KIDNN@<H@8IA`P"/.];UWCMU[3MM5H]9:
M-`T'.T=NF#IL^8N7#)ZR<(NV;QHLHW=-'3=0JS=RV<(F(J@X05(!B'*(&*8`
M$!`0T'JF^%'\=J5JKVM8%YE61R^CE5VT-3L\RKI,SABF9,B+2*RD\<%%=T11
M<A2EGE%#&*8^[[<.YX3K.V=.V[AW^WC7KL]EU7MT5:XIC)1C]N_;2#8CMJY:
MJH.FSI-<A515;'3!4JR"B1]^X?1Z1W$=6QB716)A$Q.T0(8H#U*0W;MN)NX#
M&*GL!3!X]@@)CB`@'HU#@`>O<)MS[@4!,)BF`H"(%(54$0$`W*;83"`[B/H'
M0P^"`^)]S'$!]CN+V^GJ8%5"D.(#L41+W#OXCOUT,J.L]9;OT0<(`9N];'(X
M9O&QS%<-W:)N]NNBNW(42F(KL/00WV#8-]][*EU^JI:+=U9<YZ_/D!I9&11`
MIC`5)*;;)EZO6A`V*5P0H;K)%W`OTB[EW`DLQK-FI?%W7,UE30-`T%.,+A4I
M6>EZM%VFN25GKY$%)ZN,)N,>3T(FY*F=LI+Q#=TI(1I'!%2B05DR`<#`(;[A
MH)L>1CTI!K$*OV2<J^9/Y%E&'=($D'D?%+QS:3?M61C@Y<,HYS,-$UU2%$B)
MW2)3B`JD`P=W0-!#]\/\DOW3:"+0-`T%FLG_`--N.?Z99S^SWG;1>7__T_?Q
MH&@:!H&@:!H&@:!H&@P5X_"EDCEUS0S.8IEV-&?8HXATYV?HB++%=6<Y?R&[
MC4RF[>UWD//:T4\5$.]1>N%3$>Q`FBW:,ZM$-`T#0-!AE\1+?]1KE1MX_P!2
M]SVW\-_JX_CHO7>+P^6^_P!Z:&^7SU2?<;J:Z:,8^(`F_P#2W:!\SM4W\'N1
M=#'P^"F]#Q,Q2#_*,J<0^;^;WU-%<!C*%$04E(Q/Y/+V.&WC]-\.X?8U3\4'
M>B;?_E=57?T,D45@W#Q`/*:N#A]O1/Q`]T#VBDE7`^D3JKMR[#OXIN5VB?0?
M\G0T0"NV2-YA&4<W-_OBJI#+AMU]HB*)P$?_``F@HRWY3HU$8*2=XO\`5ZA&
MIE$YWLU+PU=9E+N4NYG4V[[?I&`/9,4=Q#TB&F+X,_+7MDWXN7#&C*GBJY;Y
MG--B[CD;0>+8*0N0N%R&[0*C./SQ]7*!S#N44WH]P?1`=PWOK:F?A9O]<SFM
MGMV]AL;XDA>,$#[V>():,IMG5^R`#U:.2F&0-Z5&&AH:L'7AC++@K*'<-@59
MJMM_>133/J=9C-9O9;@_"*>RH_C)CD[ES)>='C.8@)M2$N=O=A1TSJQ\L%C9
M0]-@$XN(AU64A[D=@JF7R52"KYK<H]I-:TFR9998\X[8DQJBQ&HT2IP+I@=9
M8CV%K\7$KF.Y,H=P551@W1559BL8JI4E#'3*L@FIU5*)QF35>-A$1D4BJWCF
M#-@DJJ"BR39NFAYRFP;J*%(D4%E#`383&Z]OS:91,@#?<QNAA[C`.P;CN`#N
M'B';]CIJ*Y"EZ]#"`&V+OMXB4!\!W$!$0]/4?7\K\!C+4<PTQS+N:K2,,WU7
M'$CD>\U%QDBKU&G#B]_D%Q:;&MD==U$1=E_+]5M(9&+*I2]@5KGU.YEC.'*S
MTR:AG)YGXT:LO*@,>S?`K(.&(Z<@('C(QQ;(J5&U2U5DHG#B,76+9=JRC'PC
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M;L'<2_1'[T-Q$@@;<"C]'Z)>O0`VT/JPL7*+#XB\4GYBI0M7"FQ'33%N84%#
M8^SI5R'4;.?+["*MOZS2`LF8_<<%DC%+T,.L_P!7X-[]/Q9J]O43>ST$0#<N
MVV_LE\-S;]VP`&^X]?5K3"("CL.P;^&YA`0[=A`QAV\1'<!Z!OX:*Z$E(Q<)
M&R$S+OF45$Q+)[*2DF^<)-(^-C8]LHZ?OGSIP=-!HU9-D3**J'$I4TP$QAV`
M-+H;L).(-IQ]C+#N/<(1LS=9U2KQ1W=)>3F&;_C<+%C2SY-)$4R0K\39(I'W
MR%IK*YPT=(+D4*HV0!-ZY0:H.$@',VDRUVS;:R9HF8*#D:D0&1J],*(4RTUJ
MFVN!GY]DXK;.1A<@5N*M5:71&;39"*KR*ET.](0\Q!<PI'`#E,35SG7+-EFG
ME7OUK#_6(PP2T::8(5(YXH'S09$A#IJ*D.=CY@.@(9%(YP'M]HI1'[T=5%LL
ME9DI>,BT[ZX2LTZZOLK)0M2BJ+59N[RLN\BJ[+6J0!K&UUG(+G(U@H-TN)NW
MM-Y?:'<82E&9PLF51U6_4Z[P-;LT#.-W$9<&RSBN_62#V!E)#W,5"OF9J_/M
MHVPL):)60.F\9N&J;MDJF=-9,BA3%+<YQ@LLM2];)5))?6>,33K4UP>5V6LY
M8T@"=).,A9BM0;])T[)_Q1O(DD[>P(FV4.1=4%@,4@E`1TTSCR8N,^$AR9AC
M$V;X!W7<F4FH9!@%EEVSR.LL/%S\>91LH8HMSD=HKJ-EX]Z4%$Q2.FLW=)]Q
M3`<3=S>?":S67%>6OG;\#VR8\B?ZRN+"[ZWLTVIE;/B1R!U9A!][\\3*;&D@
MLY<.["DK'(D<'BG>SU(.X4%W(F!NCS[?;WO7]SMT^]M.[SQR,=(1#][%2S%Y
M&2D8[<,)&-D&RS)_'OF:QV[MD]9N2)N&KMJNF8BB:A2G(<H@(`(:Y/0Z>H&@
M:#>O\*3XQ5^X>V>$Q1FZP3UPXX2"C>-:+NUG<Q-XC$$Q;-7D$0WGO7U*2`2@
MZBDQ[VR9?.9`!BJ-G73KV\=MG+O]O.O7=[XL6Y3J&4:O#7.GV&(LM?L,8QEX
M>9A9!O)QLE%O4".6CYI(-5%VJC=PB<IR*%-L)!#<0#8`U8XRKJ>V83"'>(;!
MML4#E*&X""1A*;N$W8.X!V$#_*$>H17T1*.VP>5W;E`"=Q%#CMT$I.X5#&`/
M4?H([;;^(\';L.W:&X#OXD^D`@`&[D1*8!$Q=^IOD'8NAA15DK*4H0KE%1PS
MDD#@JS?LQ*V=-E4Q*<JJ;DAQ\LPCXB(@<=AV,(B&]E_<6*DHMV6E%CUFP[(V
M=B@*@*@GY*$VT2[2F?-B?12<D[@\Y'Y>\@=O<4DLQK-B7Q=USM9:-`T&D<F*
M\_5"X6Y7!6);DTNS)3F39X@F4:'BQ3^J2\Y(J^6;-6+GA'DC%IUAEE2)R?F&
M9@4TZ];VDX\3BY95S*N6*T,+8T:S\H<KT_DL_O57R!Q_K/)@C&KXBSQ3F]@S
M*NSD[O&05\SM\,.?OL)44WLE&Y#`L_C['>0SQJ4A(A.GE(V0/!N$6@09`+IC
M57<97>8Z]"DI^7GN0\J_I6'>3C['L'6'T5C6?L]F>WMC'X<0FD[D;*\E,S,+
M157AH!2T,WLJ=H*3B5BG,PF`"33+*GA0.;R1.>VN90MAHIMGM8,)+V]I;FSU
MSB)QAC##I1=@.0YRQ9%5B39;6M@(C/N228``@+5BV]V9(5+C3#-3[X?Y)?NF
MT1%H&@:"S63_`.FW'/\`3+.?V>\[:+R__]3W\:!H&@:!H&@:!H&@:"1V>QP]
M.K5AMUA>$CX"JP<M8YQ^I_-L8>#8.).3>*=0]ALR:G./R%T&)?P^JW*1'$W&
M%KLC-=E<\W_E5R5O39YVB_:6WDC;YS-DI$/Q*`%!:L%NZ<20A=R(H,$TRB)2
M`.BW=FAHAH&@:!H,(_B3/DHO@/RYDURF,C'8)O[Y8I``QS)-(9=PH4@&$I1,
M)$QV`1`-]%Z[QJK)\;_BCY9E'U5RBU`J:JHBI28@R2A4DSJ?B7!+'Y"XG*3<
M.PP[%,43;`8!UV]7+7AVOWW/$1,H'&MY/(0R8K>>-%C!1`@F[4S>:6R&*/G;
MD$FV_<"A1]/1Z_):E#CXY?&7W9=U&X[RZ_00`XE6&H5YFDIV#V[I*.+)L8@F
MV`3!N!1'8VPE-VO7YT/P6]F_CR45L"0USCYDR2*J7V!DI:JUX"G.4#-Q4`BD
ML9-!<=R@J(=@'#M\1`-/46@G/COY2=BLG6N,,:P(78Z;R;R@]EA%N*!W(J*1
ML32(XZ1P1)T`RX%$V^YB@`F"^L,_*U+SXJOQ#LI.58C&]#HL.X>.!CXM6GT>
MS7:4%XHBN8@>1(RDFDJ)/=%53"+0I2HICN41[A+?6:Z:)F<I6#+XKV=F'O-K
MR_>:1"S:J`,9)&8BZ$R$KDK95)HSB,>-$IURN9%R*XI'14-[HBL<1)Y0B-Q(
M9^%VJ#\)I*9DVT[G/)UGNS\6@K.B-EG0.'3M&;0;/63^7FW,G)O&TS"@<Y%2
M)MC)D[2F$3B?N:);>&QC%G$["V(HA2-J-`K<8LY2;HO)-NQ\^<>D:INVPB[L
M#U1S+N#.4W?<IY:B)1.7<A"`(ETRGU9&MHUHT,J9!!-)1PN9=<Q$P!1=<X%\
MQ94P%**JRA0`!.;VA[=17<*78-R@!=MP$=P$NQNT>T!Z`!]MO'H`?9T'+V@<
M-]N@]I3"(;B(@&_LB/7V@-U]0AOJ'E%V;>)@`1'<1$W3P(':/0@"(CZ0](Z"
M(H`(F[1`=A'Q$H=O;L._I$3_`"^.X^&BH@*!A*`]2B'40V(`#Z=P[MO'KZ-@
MT3Z,9JI@[(U*DFL)6,P141A]#)EJR.-09XV6_+]5.WVZ;R!+4=7)#B].X+\D
M5;?/+@8I*P5_]5"5H5T0X"YU,8TSHUF<:K;&X:2C*`H\16\J%@W=/Q7QUQ6Y
M?-ZM88M6<BL!0N:(I!<TC1LF4F[UM"P.<O%=I)Q,XT6CU(OR%'#QH\=("P>V
M<Z<NQC_A@E3:M#UYSD!"=6B4..:24H>G*(G,?CWR*OF>TG12O;9+.RK6I*\'
MAQ.9PHHR\DSL3N?-%N23KA;V^/VPED5PIFXM^X:%RM#N*;-RM"F+A$_U;/&U
MLD5L:<ILM\HJRWKUQ3R(+*NMUIK*01#[SHF16.U8G7:G:+N`\AZGM\:_M'7Q
MUP4+0Y.KNG>3GEF8T16B,J8E*M,B2SYC6:->F=Q1BY`;IF.YUQJ]?H0L:W%6
M!BZ^P16;J+D8]JJ;=%)\E[Y\-@92@`CW`(``!L(??_>]`$-PV#Q#<.GSCK3"
M,A`W`!``$"A](PAN81Z#MU,`B`[C_@T%B[%AZ2EN2>+<ZQ\RU9,:7B/,.+K%
M!'254=SB>1;1B"SP2[-7M!!JC#OL;N#+]P]ZHKH@4>TAP&8UERU+I9CROWY>
M_0=_9[1$2@`AZ-@V#8`'IU]/4=5$8@780'VA]8F#Q,;8=M@#IO\`-ZM!;S+F
M-XO+^*,G8FF7CIC#9/Q[=,<RS]F!#/6<9=JU)5M^\:@8"$,Z;M910Y`$0#N*
M'RCJ766$N+*L9*X^Y(9%3@XS(<KB2OPM9G\/3:K&FN[1.#>9W'V<,99*E+<]
M=SE6@W%%*%:H;YG'P3<TTD=W+F,YD3$;)&&:U<]9EC#$<%<JPF*L88^_*/',
MFK4,?XUI<XHL'NRBCZE<::Y@Y[,P$U.XTNSY@Q7DXYXJ9NS;1,C(1SHJ7UDS
M+[P@XF+HU[:V_MN@EN)]UQ;B!$:>$.MR9?WS`C;'.3*C4I*QN8"5KO'#%/&V
MYRUOG%8AH[CJ:RJ-:M;SWA\NV:D1=-RD$T@NDS6N,3Y/:6_\61.:N-3R=A..
M$%C>OU>4K''^5<%:TVSY%NV-47M92Q/9\:0;%E=J36;=.LW4,66;KB06HD<I
MHF3.<O=I9I,;,RXSG=8J'X1WZ&KM>JZS_&DPBK6,:5<L^]<V!&<P4QQOGB^Y
M?ATL-.58"6E;,XB8"Z-(-B_DI"&DA<5UG(O5WJBIFZ+"^T4Q/\1K5CR`L%G_
M`"=ITE,T/$-OJE&L>-X*P67+.4,KFS70,Q87OMYB4:PU9I2,?D"J).9(#O';
M1JY=NWSF139JK'9S"^V=&P/#6/W^.\85*JS3E%]:$8]S-W:3;"H+6:R);9!Y
M;<BV%J10XF30L%YG9!X1/Z)"K@4.@!K<TF/+%UJXCAJBX2,DX(FLDIT.0Y"'
M(<0W+[0"`CV]-NNWSZ?S1IQ^(1\)W%O+%&9R!4Q88XS0L9BNA=&<<4[&S22I
MB,Y`V2&[8Z)GD8+-NDH:1134DDG1E5U3+)F.F,[=9V^K?3O>EYZO'!G7`.5^
M-N0)/&>8:F\JMGCA540[SI/8B<CTWCE@69K<VT.K&SL.J\9+(^>W4.!%T5$5
M`(LDHF3SV67%>KKVG:9E6;U%-`T&XOX6OQ7\@<%[='4>[NYBX<<9N3)]:UXK
MEPYD\>.'KHJCRRTU$RGXQF<YA5?Q8"5-S[2J(IN!,*N^O?&EV<^_3VUGZGZ#
M&%LUT;-=$K5_H-CB;55;5$-I6"GHATF]82+!R0IBKD$$B>7L!1!1,0*=%4IB
M'`I@$-;L<,^+%Z"B02]_<`AL7RS&)[8@(]Q2$(4G<&W01*`B`>(;#N.HN$7M
M`41[2E'Z0&$`$.\`$>X!5$%3'/MML'<`%`-NFX:HA/VF$P[F]L>_M,"B@%`?
M$O<91(XE].P[[C\A=@@HNRUWWTB;R/6-'R;10'3!XV[4W""R8%\M4IR(CWE#
MH'9[`"3<##V^SJS1+.%842ZC8$E8F8\AG:(TH@\:%'RP?-BB4B<LS1/L8J"P
MF`%"!W>2H/:(["41S9CZ-2YTN[`_*_(W*?);(5KXM\%YQE$J5&05K7)/F.I'
ML;+1,`NEF)E7&.<5,57B4?E#D<9%4@K-RBK#U$%"*29CNC)L=9;QC6L\L48V
MA</XZJ.-*]+6^?B:A$IQ;>=O]MG+U=)M45573V8LMKL3M[*R\M)OW"JZIC'*
MBF)_+0210(DB2LVY7"T#0-`T$/WP_P`DOW3:"+0-`T%FLG_TVXY_IEG/[/>=
MM%Y?_]7W\:!H&@:!H&@:!H&@:#![XA[Q:2XRSN'X]VX:3?*"Z8WXL1AVBAT7
M9(S/%TB*/D22;K)@91`:UB1]8)<YR@)RI1YNP!/VAHLWRS79,FD:S:1S!LBS
M8,&J#)DS;)E2;M6C5(B#9L@D0`(DB@BF4I2@``4H``:([6@:!H&@:#"CXD"9
M%N!G+1%0I3IJX-O:9R&*4Y3D/$+%,4Q#`)3%,4=A`0$!T6;Q@,;B7Q['W!,^
M(\>*,6::@+M3TNM@5^)'2#^/.]?)124B;ZO=H;F(DND#U(YDG?O"9NT/1EY\
M*4#@UQM\F(24QA452QJ)43+D@(MJ>132.^4]X?ILF[9HK)+B[2\QP5(HF!JG
ML4HB<1N3\73'@=QD.XEW7]5E8!>2,)4@!F[(E'(BF1(J;9!)\FD=0!.MWJ*E
M.*PJ?C.[L+M,K/JY6/!7C5'-Y)%#&=:\R0:O68.3,53N&*;N"0ATY"/*J^5*
MG--UTU'A7)RJ@+A;<2;$2[;E/Q7(BN,F"H%9BO%8RH\?[B**?EMZK`)F>-FS
M$L9[D_<&C3.G;)=`%3+$,?\`&J*^8;=0B9RS-,+L,ZE!,"'2;QZ)?.130<',
M40!<"(,V1E52%`I#+JMHQN0YP*!E"HAW:97"?D023`2$203(`]Y`3(!2`*A0
M+N7MV$HG#UAN.P>C0<W;[._=L`"`&$!*&W=W"'AL`"(&]8C]G4'(!`]H0$.O
M<;80Z`(`<.X>X/I"!NOCH/I2;`;KL(@(B7KT`@&'NZ"`["'WVX#TVZ:#D`"E
M$H;%#P'<.X-]S`'TNNP;^`"/^'01;``%``WVVWW`H=2AOU[?:[B[COTU1](7
M;Q$P@`"'LB`"8P%*<-P*4=Q`!].X]>OIT/JC,`;@``/M&#?P$1]HVVQ1-MMV
MCU^4`Z;"`:@C$H;^&X]>AQ#<.OM;>`@(E'KN(>C0``-P'?T"!@*/;U'J(;E'
MM$1V^70<A2[#U#VSB4`V$PE'IV[!ML41`1WW'0?0`2AO]'[_`+1V$NP[@(@7
M8HAW!Z@_OAIPKD`/0`=``!$PF[1[>@F#;H82^U\FA^"(";CV[;CL!0$"F$=Q
M'IT``*&_;N`CX;==$<I2@'0>FV^P"'3H(@/00'I[7KT&LBX\F,TT[DAD3&=3
M;UJW_E+R0P7A6CQ=Y?O(.O4:/M_$Z_9DL,X5W7H=],2*IYVB>89NJ"GG^>=,
MJB`"51/-MS9'2=9>LOQ_JQ-G^87)_)$Y!9&A;8QQ?228BX-VX^/JL=A,)GL&
M>.;Y<%Y"-(2T[4A?RS-["5"59M@*HT!LQ<H*%(+HRQRY]K;GQ_NU.LFEWS?Y
M,B9/XB.0FK.X6!CC#'\G#M*IR.OE=J\7>)>5R=6:QQ2R=#TO)@9;J1*\R)79
M6S5M5\\BTVKA;W&510C5@<G6\XM]KPSZ335<#B3SLL7*C+5BH+'';"`@*Q'W
MJ[2%B.]?KJOL93CW'K[C'9(M$P"BJKERE6B6D'8GV3;*PJJ28";N`EG:VX.W
M7$SG]O+96)!'N`=Q`0$O:(@&WWNQ1V\>G4=PUIA][1`!`0`O3Q#8Q`$.TP>H
M1-MOX==00]OLFZ`'@80W$1`OEF`H!MTV#N'I]G5`2`;VA\-Q$-@$WL]0V`?7
MMUZ>KT:?`"0!*8-R]O0`#KMV[@'4?:`HCL(CUZ[#\NGR(.S<2AL4"@/J$1WV
MWW+N`B.X%^?<-!US%]G<0#H`CN'T?#?M`1'MZ@`;!X;Z"$Q1`.A`Z"!0`0$>
MG4>HC\AO`-_#[.@ZID1``[``0'P)L.XB.YM^AA$"[_+MMHCIK)[E'[T`'8>H
M'`=Q#M*`F'I[0=>OA]K08<\LN%.$>7E*6JN3JJBY<MT'18&PQHI1%@KLDZD9
M%^:=BIENT5=>\M7<T^<E;+`NQ=K.5/>$3B<#%62S%V6=KUN97B3YM<",R\)K
MH$7<V*D_0)A8P5')$6U4&$D3#WG-!S!B"LC"6QBD3=9H90Y%4Q*NW460.50>
M';I>OT>KIWG>?+!K6&S0-!N0^$[\4^W\%+\VHUZ?R<]QON$JF-@AP4<O'&/)
M1VJ4BESK+,!4!1D8P@:48%3-[RF7SD2^\$`JV^O;&EV<^_3VUGZGZ%&*LJU+
M*U1@+C3Y^-L5<LD6TEXB:B7:3V*E63Y!)=J]8KD56;.&CA`=R'$XEV$.F_76
M[,.$JZJ8G'Z)3!T+[7F``[;@(^8($V`>[H;80'8/`.@:BH1]G<!(!3&'N$I^
MXQ@$3%#<"@4!Z#[6Q3#XCMXCN^@^+JD;HJK.U$DFZ*)W#A=9R9L@0I""JLJJ
M<X)(ID(B43F$Q@[0ZCT`1$-/]WO.1OB`6:5JO%>RS6->+M4DY2!R-R_KCM9I
M9<PR\<JV9SF-N*<LVD"'2JAP.NPF\@D3.W,<%6L,58Y#.RLYT\+CUUOZFTSC
MG5,88WQ35L58EID/CBI8XC&U?9T2&061;0(!YC@ZQE':KF0DEYERHJ[6?.EG
M#Q\Y556<JJN#*G&68^A[>VMW7UU%-`T#0-!#]\/\DOW3:"+0-`T%FLG_`--N
M.?Z99S^SWG;1>7__UO?QH&@:!H&@:!H&@:!H,%LN>3DCG-Q3QG_XS&8/HV8^
M5MD;G[C-FMG>Q;;CMB`%T0W277D([*%Y=-Q4#9%6&\POXP"&*6;5G3HAH&@:
M!H&@PK^(W_L(\K_T(WC_`$4IHLW64$@"'7?M`1Z^'<(]W:;J(;B'<.W3KZ=^
MFO0X(]NO@;VC;#[($'?;8NX]0$3C\OH#UAJ#X!>W8>I0W]KT@`"/=T[Q\`#<
M/5Z=!&)1Z]`]KM'<0'81[A+N`["`]>NP;_X*':&W@!]Q`VY@VZF$1WWWV*(`
M'COOJ?S`"]P["!>XP=1`IA,(]>INF_M"(?+Z-O`=7Z#Z7H.P;]H!O[11'M``
M$0-W>'4?#PW'?01E*`%[B^P`AN/LAL7UB'L@(;@(;_8^70^B/?;H4P"```%Z
M#TWW#H!MS`)M]@Z[#MJ*=NVVW3NW$0[!*41Z]"CMN4`\/#KOJHY`*4W78H!O
MW"`;=!$/`1,``/IW#T^K4'T0WV)V[B42G+[7H[0VV#IU`0#;?H/HT$0!VB'=
M](0$0,':(@.XD].P&Z&\-Q#357*7KL&W:/0!-W=/O=P$1Z``!MMZ.GCHAMT$
M"B&^X]>\1*(;B(B8`'N$=M_5OX?,%I;EF*J4=SD(DP1V9EBK%RN5[S(-P042
MBH)P>RD@V*2)U0=R$K.)TR7.DBB0_EE9E!02BY0`[.,KBU((+DCBU?&E<R9<
M[`SQ@QG5;#'/X6^OF$5-5JQTAY*Q60JY-II.7"!'-`E()\C*.2'.R;%:G6,J
M"&QQF9A?6[16[3,N)'K%C)-\D4P\=(2$W&,Y'\H(PC)5_6ZXYN%@;`[.LDV!
M2'J[-5^ZW-L@S2%4VQ`$09F-TQ4A4Y'8&;0061?+-':P99)Y#K/'$XU;F;R,
M;"M[)((/6RIBNH\L?6'24HX46(1-&,53=G,#8Y%19G*^MSLJ=SE[%;(AE'F1
M*<T0)89.J&<+S\<W:)6.'H3_`"G*PJCI1P5JD\C<;QKB<7(8P>7%(J.3"5(H
MF!F)B\*5M7(3&L!A?+^<8.71O-6PQ3[Q;K:PJKEJO,IGHE,/>I&NF:O5F9(Z
M?>UT6SALD\%`%$'K=?<$5B*&9F+5];F3E3S[)?']',K6H24?1#VQXQK&0FMX
M5;51RDXM4E-'P_36:<N43RWY=.$IM2,8'V!7W)V=NFIVJ&(9F9,7#IR^0.&U
M2308S<S@6!;G72K*35ZUIC%JC_5AE>9A$(I<#-2-6;&@YN:O6Z!5>Q&-LIC%
M3$CU0.YI\&.UY3./R9Q*([&R1EEPJC(9@5=0TC-MBU=O)78[&>)07D;:GI&Z
M3MV+.V*E@U4I,0[9,P,1#SQ\K4T,=ML71U)++''[%N.LU90QM$TV;1PI"JUF
M^Q6+V%882R7]4A).$C\>*NFQ8MB4]+52>1S1DLN"$6J"Z``B(*E!F8M7%MDO
MESQW*BC1MBME.RZQ7PC:*DECMRLQND_4)&.GFN5/ZPBTH*Y,52?G$'LL_7Q7
M/$4CER-I%,&7F>2=!=NLHS/*>MNRO"\A,&*-K$\3RO13MZBNP0G5BV%B?W-6
M9L+BI0Q2$!43OAFK8S4B67NP+`[E$S-$A.Y**87,YT,7A3>+^4F&<I5.6N41
M<82/BXBS3M?<_64U$=ZD>TSKDGC[3K2DHT>+H&K>4+UBV3)`+"?N>$*!``%2
MG(62YV+ULN'+9.46$:_*P\$2Y1]@FYC(];Q<6'K"S>6>LK+9)B9@VYWR(.$"
MIQ$?+UU^U>.4_.*@[9JM]A<$%(+F&+PG,-R"Q'*EI[5U?:?#V*Y5>OVN/K3F
MSP;Q\#6RUQW:HQL5]%/WD2]<NX-@[=-@;KG!\U:+.&_FHIF.#,T,771*T>2>
M'Y6&:66GW*%O%=_+:B4B;F:C*QTLUKCK)SQE$4:6DBIN`6<0-BGIN.;(.VY5
M4CD>>\`84$7!TYF&+POSV@`[FW`?`3#Z>T!';KOOW=/'_!K2.N8@!L(@`".W
M4>T=B]>GK`P>'7;;Y=!QJHB;8-Q]`&+X=NVP]WL].X1`?X=,CJF(&X;`8`*`
M[EW`!W$=_9`-_EZ[^'IT'4.EL(@($*'<(E`>@=W@`AU';8N^F46BR[AK'^9:
M9;J1?ZI"6F(N%5=5>493C4731PQ4=MY1DF<2]CEHJSE6:2Z+EN=)ZU,!CMED
MU![]/B[$S+F75XG?B1_#&O/#*T25UHS2?NG'.3EA:Q5M69K.)"C/G)&B[>L7
M9=%NBD!#"^*BPE?+2:R*B2J9=E4C@;CWZ>NLV>GI]SVTOZFJ'7-U-`T&]3X.
M7Q59GAS?(W#.7IN1?\=KG+MV[)VZ>'.EB*?DW8@K/-"J"!DZA)N5P/*-P-Y;
M8P"\2()_/*MTZ]O%V<N_V\_FF[]`>HVN(MT(QF(Q\S>LY!NB\:O$#(JHK-UT
MO,:N47*)A242404*9,0$P'*8HE$0$!UJS#E/IHK4"B4/8`%"[``@D("F`;;`
M(?BTP[S;^`=WAT'T:@QPY(<<XGDW5X#'=SO-XKV+D[.G+9/I%*E1K:&9JFE'
MOT5,9W.PLDDK2TI$O*+MUI5O&.V2D@S0.S6,**Y]I=5EQ]5]H.NP58@8>J5F
M%BJ]68"+8PD#`P;1E%1$+#QC--G'1D5&L46\>PC6+1(B22"92)))`!0)VAL%
MV3514TQD:])M[=6B%4>->Y)ZR`?Q,C'B43+-%C%[#;&$`%/<#B0_:8/`1&[Z
M5-9K%\H*;C[%%-)B,5\UH[3[@`VP+(*E'M7:N4P$11=-50$BA!ZE.`AK-F+A
MN7.J;Z@:!H&@A#Z0_P`DOW3Z"+0-`T%FLG_TVXY_IEG/[/>=M%Y?_]?W\:!H
M&@:!H&@:!H&@:#!7C&*60^2'-W.PE,LV2R/1N*]+>K#WG/3N-]34EK.5K[1T
MVK=+/68+HS.1,=U#1Y3J;&V(0MVD9U:(:!H&@:!H,*_B-_["/*_]"-X_T4IH
MLW6;$@#U$>X"B7U;=Q?1TV`!'OW]6WK#7?\`%PT?`#<0$O<.P[F[@`1Z;`'W
MNX"`_=#5$?;W;^/8`?1W#<!]GP*`"`]WI'KTU!\[0`1WV+Z!-TV$1ZAW$,&W
M40]/CMX@&@B%,H@(B4P;EWZCX[!Z/$`.(B/^#01?2*40`VPF\>T!$P].G0`$
M`]K;PWT`I#")MP*&Y=Q,`]VQ>@;CTV#;H(>._P!C2B(I#!ML'0`#V1V#??<!
M.`"(;?2`1#U>'70?0#?N$1,?8``=P,/WQ=P$!]GI]@!Z^&@B\0VZB83;>`;[
M%VVV#?LW\.O3H`^.J/NW4O7N#;H(^(@;PZ^(AL/H#8?L:@Y-A]GH!>A3"40`
M1W#O[=A'M'KV[[>/V-.1$!0VZ]0`H[C]+H/>&P;&]D0W\/\`)^;01E`H#Z2B
M41[`-L81#?\`C;=VXB;T>KY1T'(!!#;V0.&W0PB(CU`=NINNXF'KX;_+H,2\
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M8*DXIUU@:%$RS`*Q8,H2ED6LB,KCM@_;2#VP/4&PG7;`S%HKY);C'G5/;QC1
MPM."$=$KP,!!Y$%CBZMV-Y<H>FO:/$V.=+9W_$:6X?K&D[)8Y24KTY7?R.F#
M2_U:[KZI%)0RJ:ZBK(Y&R+U/;XU_WRK>.XH/2<>,_P"`YG);Q\RSG4[S44'<
M;%6$*UB^+NN,6N.%F-"J]RO][FH^$9+$6E0CCS@LRNW2J;<C5$2D!C2SDSK+
M)LBO_#6EV"XEO=%5K.,9V.B\=!!-H6@L#0*-GQGEV"RW!S<_&0LM55I]B_<0
M@QCQH5=LN+%RH=%T@L5,Y&"=M,.&K<.F\+7IZ*DK^XG)&RR\U89F4+5FT<W4
MG9_E+=N4TJZCXL)AZ#-H2R7A:.;(&65.@V135,J=3<`8P>WQ^V,).\X3^8IE
MEM%Y/]U@L].K0RRY%R=*2EW,A3;!E;(>4&L'29).T1J-.L#'^M2:CE915O)D
M<(JMU@:(K-4C:8/;;39=^T<<(JTX`RQ@)W/*$B\JO\VO'\TI"MW(,2YGR-<L
M@2+7ZH6?%;R*$0I<5&@=ZI`=$2[S`03B4K&EB9Q94VBN-6(Z<XQL7%="H.)(
M+'F1Y')AZWCBA5BH0ECEGN+LAXS$KYE7640V2<D;7TSOWH45E!,S(GL!3B<C
M$TP9NN:L:VX6.VY<>";*3==Y@6O5.I8`<FH9>ZMU^HW"L6AFVR<4MR%3*CV2
M:4>+CG+ANI71!%)9PB5%VN*Y6/E?;?3=)FO!:1:DEBES"U%2^3\+8LKN28U0
M0=V-U4N6.7.7=40J*;>YIQ]*;-[OFF7CY`SAO-+OXSR1*JW<E,N9A??X_;&%
M>)\4[01&B1'];S12K8EO-9MF,X,V,XP%VS6%MSVPNHZ[SR=C"6M+Y2%>C&,W
M,>:!:(`4'3MF_7`H@QC">V^FJ017"88NM0>/4<G>=CQ%QA>PVB*>4LBUFF[]
M@O'%#Q[5)J"M!;0FVJU=?HXP@7KZ*^KGRAUVS@J;U(CM4-3![><:JCLG&=\T
MB6$+5I`7@6&N<4L76A\9FQB21-,XZ7BSW::M6_OJCA[,6Z$F3P[1%)-46+LS
M5814;D5%.X,_ZLQNSJ/3<=CB&P=NP[#OU-MT[>@!U\=5EQB41`0$/9Z[AVB'
M<`>`;``@'@/I`/#;0<*B9A\.H=NP".^^VQ0`!W';QWW`?X/$0ZIT=NH>`?1-
MU#N``Z"(!W=H]?#<.F^WIU=QU540]HNPFVZ^'LFVVV^@(]P]P#T$-!T5D@`1
M`"`&PB(!L`@&P[;[>R`"4-NG7I\VB*%R!1:[D*HV.FV>/8RD-:H&6KTHRDVB
M3YF\CI=DY8/$%VBI3)+%6;.U$^FRA2JG`@E$P[WX/EXM_BG?#$=\2+*OD_#C
M&9EL#3SA\X?12Q'LI(XB<$D(:.:MIN7,10CNH3\A.I)0[Q50S@JA3M7(BLF5
M5?AWZ8UFST?;^Y[:7=IEUS=C0-!ZB/@5_%=F<>6:J<.,[67WBF3+IK"8-M,N
MJBF%>EW*RP-,;R[XQ06<Q<P\<%)"&4,)VSP2LP-Y*K<K?KUN<=;OX<?N=,?F
MCVW1<HE)-B+HG[NY,%.TW<0O:?V-S*@5,X'4$/`1$.G</KU7/1-2]H#[(E$Y
MNX`,4J6P#N`*"`(;ATZ`81[!';J/345&)=_9[._<2B)@3'N#U')WCL7H(]!+
MVCZP])(ZZZ2:R?EG\OKMVB<@;G]!R![9-Q,(;==Q#;K]'?06\:/G>.9H'8%4
M/595P`S:)2BJFQ6$OEDEFNRX^69'M`%RE*(G2)T*)BEVOZI\IM?AD*FHFLFF
MJD<JB2I"J)J$,!B*)G*!B'(8-P,4Q1`0$/$-8;1Z!H&@A#Z9OY)?NGT$6@:!
MH+-9/_IMQS_3+.?V>\[:+R__T/?QH&@:!H&@:!H&@:"CLB7F!QAC^\Y*M2XM
M:QCRG6:\V-R7L[F\#4H5[/S"Y?,.FGNC'QZA@[C%#IU$`T&.O`VC35"XD84;
M6Q`6U\NM;>9FR8D?<RJ>4L\3TOFC)2*JQR$5<"TN]\?(E.<`.9-,NX!X`6[U
MEWHAH&@:!H&@PL^(W_L)<K_T(WC_`$4IHLW6@$`,/L@.^X=_TC=!Z"!>T>H"
M'I`?1X:[N"#VP[1W,00`PB43%#V2[[CN!=]Q[0^<?M:#D#8`$-^H^T`;%-VB
M`]HB(=O;T$?`=]O7H/@D`1[NNX"("`;]P`(@(@`=!V](^K;Y-]!$8A=QV'<0
M+T'Q]/T@,/@41\0#TZH`!=RB'B83>':(@`CW;F*(;`'B/B`Z@BV'<P]W</M;
M`4O@4``.@A]$.WPW$1+N'AX:IY?2[`._<7H.X@8!VW';T`&X@7IMZ?X-0?![
M@$!`!$>G0-B@(`([[]1$"[!MZ=!R%Z=`#U;@`!L!O$PCMN(@7NV\>GS:;"+M
MW,)-NTNP>(@(#T\.G4"[B/3J'AH.3J8?0`E$1Z`/B`=`/UV$1'YNH:#D`IS`
M&Q0WV$#[>@/9WW';H(@/KVV].BOI0#J7M]GJ(>T`B!MO9](@'8'S#X]?6X$7
M;U\`VV`1[MQ'N*/=M[.V_4?7XZ#E$F_4?#8!$0#H'I#??<XAV>'7QT#8WTO$
M!ZCW;@8"[@```]W;O[/3[7AOHB+H`#L'0.@@`COV[`/M>/4`V'J/AH(P`!$P
MB(AL.X;>GZ(^UN';[6_0=QZ_PS97(!=NX!'?J``/B43=1$?XWM>GQ#80U1$F
M'3;;P`XB;^(0-P[=B[^CIU^QOJ",.FWB'HW#?J`B`B(&](CV_)MI\CD`!`!V
M#8?`.H]Q3!VB(=>@%';Y/'[&@Y0``ZB&XAL(CMMXF$3;#[0?:#KZ=`WVV*.V
MV^Q!$=@`1]`?,.V_KWT$92[>KY?0!MO$`#KT$!]/^(/H?1Z^([;[@7P]GH(;
M]!`0'T>&@C+N`;AN`"!Q`/$NP#L8!VV[3#N/H#[&FX"`[&'NW^D`>.VP"._7
MNV`=A\0\`T'WT=NX;]VX==Q`"@`@4`^]'N#;_`.@^"4-B[[!L&P"`]##OU`=
M@#<H`'I#P#TAH(?+,'40ZB7IOX]H@/<!=A'J4?0`!Z?GT$!@V#P'M^SOZ-PW
M'J`[`'4.OS^D.,Y0$!+L':&VVP;>/8'KZ=/0'3KJCK*%$H#N'H'<INI1'8/:
M`!\0V$0WZ[#OUU!UCI=!'?;8>WN*`?2W\3`)=PW';</1XZHZ)R#MUVV$H[CL
M`CU`-]^HD^EX!UV\?7IP.J=/;<N^P!Z=@'8"I]H;B/4.FB+>Y*Q_6<G4FQT.
MV0["=KUGCU8Z6A95(%XV3:'$IE(^0)[2@,GQ!%%?R]E/)44`HE$=])_`>&[X
MG7P[9_A3DC\H:D@[EN/]]E'04B9,LJ_<U&8!LUD9#'ED=G22.=[%)/BF8NCA
ML^8B0PF%8BQ2\>_7UN9L]7V^_M,7]35IKFZ&@YFSEPS<-WC-=9J[:+).6KIL
MJ=!PV<(*%507062,51%9%4H&*8H@8I@`0'?0>\?X('Q1R\H\?$PKER<*.?,9
M0[5-Z\=K]JF0Z6U%",97%O[RY4.M.M!41;S```E,Y437*4H./+3[2^T^7F[]
M?2Z?IKT;MEBKE[@,93N*&Q5-^\W;VAL)?+3(H8H[CL43B!AZB`ZB.QVH]0$H
M#N.X%["";NW'<-CE]DYC=1VWW\0`?$0B,;N#<3@`@4I3!L0#`)=A*`"8N^Q@
M,/I\.NX#OH>4KDV*$DV,@J4BIC$V`#*`7O[MS=IA,)@,("0=@$0#<-QZ;Z%\
MI#0)U6NR1:/+J?\`$UC'/6'2A@]CZ1U8900*4H%+VF.V$!,`^TF`@`)EU>TS
MK"::5>_6&C0-!"'TA_DE^Z?01:!H&@LUD_\`IMQS_3+.?V>\[:+R_]'W\:!H
M&@:!H&@:!H&@P6^(6)+-@B#P,10Y77*W,N).-RR28CYCBE7>U-YK-A"$*`^:
M=OQ^JEL7`@[$.*.QA`HF$"S?+.<I2D*4A"E(0A0*4I0`I2E*&Q2E*&P%*4`V
M``\-$1:!H&@:!H&@PL^(W_L)<K_T(WC_`$4IHLW6E`H@&_0=@WW*;H.X!U-L
M8>@%`>@CZ==W``OB&XAT[]MMP`1$-@'H/38?F\-M!"4HCVCN`#U]8!N)MQZB
M/CL`>KT>G0`#<![1`1$0ZEV,(;;`&YAW$0+X!L([;CN(^&J/NQN[M`HB'L@`
M??&`=R[EZ#L`;^@-0```\1`2AL;T%$#&`!WVZ!OT]&^^W70?=MBB!>NPB8H_
M1$`WWZ;`.WAZ=NGR^(<@;"41ZE`=MQ$1#KL<IMMB[[;;>K0?0`1V'8`'Z&P]
M=MQ'81`1WV`QO2'CI]1]`I0$1`-@Z`(`'B&P=/\`)$H"/@/V-!RAZQV'8-QV
M\/I>'0`';;;IN'KT5$`!N`[@'CMUW'8O0P=1'KU]>^WR>!$7WN_T0*`#ON._
M;N'=N(!N(#MHJ,HE$0`0``$/X"AL(B'@)O#T>C;41%L`CU*!^H`'3?;I[(^`
M$```!\/DZ[ZO\Q]#?KU'?N'M,``'\<2[@4=P````]>VHJ(-^GL]-N_VAV``Z
M@!=@[>PH@'0.H_;ZU'(``.V_;U#?J8`#M*(B``(]P;B8?L[[>G?17(!2[E]`
M_(781WV#8!'PWWW\-]_'KJ"+Z7M]!-N8!V[S#L.P[COVAZ-_D\?`.E',0@#Z
M@'<P@'B'^;$0'MVZ`/VQ^SJ9$0`(E.'4`$`,(``=H;[@/VQ'Q'YQ]>@C$-Q+
MMOL(^`&#J;8?:-Z-A^?J/AH(BAT$`[0ZF]0>R`_2W'QWV]`>/V=!][0V+L;P
M$.I@#IT`1,`AX@`CM_BZA&!=^T!,(`.X^`"`B`@8!^GTZ>CTZ#Z!>TVP$]GM
M[A*;T[@&WTMO6&_^+301["/0O4!$V_R#UZ`.V_AZ`]>^@&W`O78-O#J`^'I`
M/#;IZ/3]C8/NVP^R4VWM`'0=P`IMAW$1*':&W3IM]K0`W,4`V*'7?J4![0``
M*4!'<!`P"7_!MOH/NV^_=OZ`V'M\>@[;`&W7_'XCH.,0,'LAU*'<&_M>'3<.
M_P!(]>N@@$H].NP"!C=IMN@"("([!U$!V'<.GAMMH.$0VW[A`0[=A`=@`=^G
MB)A$.H?-H.L=/KMV_2$1-[)MC&Z^SX`4#E$?FT'45+L`[?2[3;&$0'Z0#VAO
ML/;UZ]=M@'U:#J*$WWV[C!VCMN/4!$0Z&W`1W+X]0V#Y-4=-4H>`@';L;V0'
M;<`+T'N`.X1Z_(&^^D18OD!@RB\B,56_$F0(AE,5ZX1+N$<'=$V<Q@.W#!XE
M+QK@ATG*$E$244R?(B0Z957+)$JANS?9O,78S999N\"/-+A_D#AGEYSCRWH.
MGM>EVHSV/K>9J9%E::XHIY2@`<O<@2:@7O<SD42&,4CA,%$Q,W6044\_?KZW
M'AZ^G>=YGRQ#UELT%T\)YEOW'W*=+S#C&94@KK1IA"7B7A0\QNN4H&1?1<BW
M'V'D3+L%5&SI$W11!4P=!V$++998ED[3%V?I3?#PYM47FO@"H94JRR#65=-P
MBKI6SJ(N9"HW&,20&<@W?NR2:@E2.L5=JH8""Y9KHJ[`"G:'7>9FSS6>M]:V
M))&`I3?0-[(G'M*8%`*(=P@'M=H@4"`/7L'MV$=_3!RCN(&`0.;N`1%,3FV$
M#;#[0B)S)E[NH#U'8NX!ML.@@`1`OM@4H]``I$S&2W'M[O%+<`.(;>QOL.PC
MN.VQ5%6V!3EVAQ14%-Z@H15LNW,<RC1RF(*(J$.0XF14!5/N*?<H`;J)1'J-
MEPE5Q0K6:R1BC=^)4Y^'%-I,(=@I"H82CY$BDF8`V;ORD,(;;E*H4Y`$>W6;
M,?19<_57>HIH(0^F;^27[I]!%H&@:"S63_Z;<<_TRSG]GO.VB\O_TO?QH&@:
M!H&@:!H&@:#!:_>3D?X@>`J9_/1_&W!V3^0TRG[1O<[QF&03P'B)WVAVII>\
M4ECDY+N$3&-ML4`#O'1?%9TZ(:!H&@:!H&@PL^(U_L)<K_T(WC_12FBS>+2F
M]CIVF`FP@)MQ$H!X@(@4H`'T?#;H'JVUZ'!%L!1Z=?HF,`^'4`$2@(=P!WAN
M/34'W8`.'3Z0B`@(@`B&P&#80`-NH#X]=%.OL"'I,'01`H>@0$-^H[[?8#T]
M=M$1[[&#?<2AX["`^D!^EU]D!WV#KL!>OCH(>GKW`^^X"4?#?8Y@$!^^[A';
M?Y_#3Y$?8.YNXQBAT*&VQ=Q'H.PFW^]].X"`==O1H/H%Z"'7;<"[B4>X.H=`
M`P&`=M]]_M^C01%#J(&W$P[!L!AZAW"`"/7?<.N_S?8T5$'=N4PB/RE'V=@]
MK?H?H8>FP[>OQZ:(Y`W';IW!TVW$`#Y3CL(F#IOM\V^BFP@(B)?I`4`'M$#!
MOT`!VWW$!W'T?8Z:?@(P(`!L;TCU`V^VY1Z"("("H/<'AX=>FE$1?9$.G0.@
M;]=@#;;Q`WWH!N/AX^K1$8@([@4`V\0V[N@AZ0`!`0,!@VZ>KKI]5"]>H#T)
ML`"&_CZA+O\`.'R_8T'T`$0,&P"8!`"B8``0[NW?8?`Y@#T!TZCOJ(Y2E$0`
MNX!W&``';?H'@<-P'K[740](:*Y.W;;<>OCZ!VV$P@`EW$3`(%#QZ?;T$0`)
M0Z;CL`B&^X;AT`1$NP!N`]!'PT'*`B;??IX`;IVAN'B4P!MN)A#UAU].@BV]
MD0]KNV`.@%$1$H>O???PZZ#Z.W@3QW``#<1#KON/H[N@]?1OH.4OM;`.Q1ZC
MON!0[M^X0]`#T#J/IT$11Z;]O<;?<.O<`%$H`'T1[P`>NX_=T^@^@`B'7IL&
MP@'B`B4.[U!TZ::#EV[A\-A$2@.VWJ*`[A_%`P^OK\^@^``=`V*.^P[;@)0'
MM`1-X@(%';Q'J`^O0?0`1$.FX!UZ@(`!NIB_)L81Z]-PT$?8(>`;@.P`(%Z=
M-NX-_$H#W?+X:#Z`=W@(^`]P`'CMW!T-OL7QV'Y1Z:`(>GKN&PF$`VW$NQ>@
M[[&`3"&@A.3<=AWW,.X&#<0'T;[`)0W$!WVV]._IT''V]1[1$/0;KV]=MC>O
M<1$!#T;=-!`(CN'LB!ODV$!V'KOZ=Q#?<-@T'`8-NXV^_CXB)1$1#T@(AV["
M;;;IT#UZ#J'(/<)@Z`&X&$1\/'Y_I=O7?T>'70=50@#N7V3E`=MM]]A'<#!T
MZ`(COX[AU^?5R.BHF&PB'B(EW*)O9,`E+OT#?;<1^7Q^30=)0H`(=``!';?K
ML;V3`)?:^CN.P;CZ?M:?*-??Q"^&56YD81G*3(M6;2UQS21L=!N)P55DJE=H
MR%=!!@V;-T'"KR"M[@B$3+H)`*RC8S=4A3J,T2@LG:8:Z]KUN8\#61,?7#%%
MZMF-L@0;RM72D3LA7++!OB@5Q'RL8N9NX2[BB9)=`XE`Z2R9C)+I&*HF8Q#%
M,/FLLTKURRR6;*-U%-!L_P#A4<^9;@MR(CI6;>N5<*Y%7CJ[E:)*51PG'MB+
M*%A[PP:D-N,G55W1Q4`H&,O'K.$P**@I&)OKVQI=F/N=?::?JC](_']WB+K6
MX>>A9)A*Q<O'L9&.D(]RBY:OVKU!%TQ?-'*'>1TW=-E2G34*;8Q3`8H;;;[L
M<,J^,4!*(F()O$>X"B8ICB&Y=NQ1,`5`FP[B)@'Q`>H[P0E`NP`4`$QRE[?,
M$"J`'LEV%03`85``>HAUZ]3>&X^B,P@`@FH)B"<!*/43$^B)SE+U-[6X"(#U
M`0#[`#ZK83(/*E.-;=$D,L5ONC,QZ`AN^C3F_'M`(3=+WA+^<2$-OQJ8%'H.
MVM3682YFK()@^:R;)K(L52KM'J";ENJ7<`.DJ4#%$0'82F`!V$!Z@/0>NN>S
M>[MZ"$/IF_DE^Z?01:!H&@LUD_\`IMQS_3+.?V>\[:+R_]/W\:!H&@:!H&@:
M!H&@P3XC^7?<O\V>07MJ-KAGM'`U.7-VG(-#XHUY+&LB@FL'14A,^R6052]O
ML$(L4NW>!S&+=I&=FB&@:!H&@:!H,+/B-?["7*[]"-X_T4IHLWBU7:/;VAN(
M=!,`"8`[MNTP=O<`%`1Z]-A'KKNX!=QV+L&^_7O-V@8O7H&P;[!]@#"&@%WW
M,'9T^GUV$!#<VQO#H!=M_0`AH(A(``4.H@7<W:`@`C](!\0V#J0.@]0\`';K
MH(@#MWZ#OX@`B.XB8VP"`")C!MZ?\6E$0]P`&XAV[B.Y=Q]D#;=.WIL(%^R&
M@^CW;`(``;@)M]MA[@'MW*(#M[(#MU]>GPJ'UG[0W`.H"`#Z!$.O4"B&WS_)
MH(@*(#L(`.X"!C!W"(`78I@`1ZB&XB/3QTX$8E`2]=PZ&*(#N&PCN'00'<`^
MWZAT1'V]`$2@`;;`43"`]`[0#80$WC\V@^@.^X"'I]DH]`[1_C;`(%ZCZ@Z?
M.&BH0`"[[`(@(%`1\"B)C>`B7N`!]KP';[6B.0""(EV$=P$?3MX#]\(E';?N
M'IO]C3X5R!MX[B&W;OL.VQC;F$!`0V$-PW^0`T$8@3<1[O7V[B'78VY@*(@&
MV_7['@&I_(1%]K8=BC[(B(%W#<3;[EV$`'H`^G;<.N@^@`"':4.H".Q1V$2B
M&P`;Q#U;[>.VK]1RE`!``V`1_P`H=MMO$>WTAN`;!Z=O3H.0@B("/TO$0#QZ
M=#!W`/B7T;>(>L=!RE]&X;@&XB8OHW#<1VW`!V#<>O7IJ"(`,&P[>D1#J/;L
M(%*`=P")@'N$0\-!]*(@)3=O:'M`/LF$0Z`(";KN/4VX>OU^L(MC=XB(`4"^
M)]@]H>I=A$0Z%#?0<I0'<0#?H(;;;^CKVCN`[[`8!T#;8``=P+OX=W7?N$>F
MQ@#N[0\?E]0[:#DWWV]D1'P$!Z;=H[B`;[`'<;0"`4.[NZ`)?`P^`AN`")>A
MC"7P]`>KU:#Z.^X]?H[&[NFVP=.WP$1`!\-O#01EVZ@`^UL'0-A$A2[=P``]
M1-L.W7?;;0?`*&WS[]>H=>T>T.H@`&#Y-_X=!%VEV'J(%#<=A#V1,&P"`B(`
M'0?#<?2.@XS%`0#8VVVQNH?1`P=#?1[B^T.^@@,7N$I=@\`,4QP^F)=P$NWB
M38_\`?-H/AMB]0WV`YN\1`.X-AV$0\`[BB`;#X_=T'"8H^C<1ZCZBAT`?9]&
MPB'V.N@X3E'80*(>!>T0,`$$3``"/:&X]1'Y]!U#EV#T;%W\!#[X1$`$>T=Q
M$3?X-4=)4!V`/`"AML`]NY1#81Z]`-N`Z#I+D$O<``!=O0(;EV$I>W?80$1W
M'?I]G?KH.DH0"AV]P@4`$!-W#U'8H"!>G=Z!'T@'V`'1'FG^.!P*5ND')<L<
M=L'+VZ4QD=SE%L1!0[FQ8[;M8=G&RP&2`?K&?HCIO(KOUS%\P81=#S#C[H3N
MQ]SKF>TW=?M=\7UNU::^!'PS,H?$(HO).?Q'<J[%W7`<+2Y.%H,ZS5(;)DA<
M/RN52@V5D]_;LJN[(WIZI&ZSI%9LNZ7235.V2[UR<IUS+J[=NWK9HUX6BL6*
ME62>I]NA9*MVFKR\A`6*OS+19A+0LU%.E64E&2+)P4BS5XR=HG34(8`$IBB&
MHW+G6)%J#UZ?]7P^)*]=)(\*LL3@'>P,>N_PA*OG`%6DZZU.HYFZ&HNLL0ZS
MVMMS&>1I2]YC1Y5D@`I6I.[KUN9CS'#[G7%]IM7L*8.D'K9)P`"NFH3OW``,
MD)3@)MUO/(94X]0$>I0'81#;P$P[P"'0Q`()3$V$2B<QC&[@*)@_$"82AOV]
MW40[O5OH/I3=H#T,GVB8!#82@!A`IRA^+2Z"'B'T3AMN&X>(=1ZU2=HJI+$\
MU$2[&3.!R`8!#I^+-W%`H[>D!#V=RAOT$*/H<J>ISQJ<]$I(:755<5]3N#RV
MDD?N6<QQ-SF[4'X;J)AL0"K`(``BH&U[3,SY)I<>%^=8:0A],W\DOW3Z"+0-
M`T%FLG_TVXY_IEG/[/>=M%Y?_]3W\:!H&@:!H&@:!H+:YFR=!84Q#E+,=G.4
ME<Q5CNYY%G!,?L[HJEUV1L3Y(A@*8WFK-XXQ"``&,8Q@``$1`-#=:GA7C"8P
M[Q3P30[/WC=FM`B['DA51/RCNLJ7T[B_94?"D/MI^_Y$L\FOVF$QP!38QC&W
M,);K:R@T0T#0-`T#0-!K8Y;W.<Y.JWK@9@)FVEYNVP#BN\D<U/&[A_COC/2I
MQFW66C7AFJK9"Y9[M,6[3-!U%)T@HU;+EE)51NQ!`CTLTUJ6_J1\F=]_UW@W
M\-_U;:#OML(;!M9PVZ"/AZ];]ZSB<`\(N3`^/-X!$=]Q_5MH'4#>(;!9@+M_
MAU/:F)P^_J1\F.G^N\'0.G^K;0-_M_E-N(?)Z=/:F)_:^APEY,AM_KO[[!ML
M/&Z@B&W3IM^4_7J'IT]J8G#[^I+R8Z[<WO$-A#]6Z@;"&X#_`/*8.O33WJ>L
MX?`X2\F0_P"F]OMOX<;:`'B``/A9@_[&GM>3$X`X2<F0\.;VWS<;:`&_4!]%
MF]8:>]7$X1!PGY-;`'Z[P;!O_P!&V@=>N_7_`)S;CU$=/:GK.`.$_)H`V#F\
M'4-A_P!6S'^_AMT'\I=PZ>KQ'KI[5/6</H\*.30_]-_;T].-N/\`H(>D`_*7
M;PZ?-I[5?6</OZE')K;8.;W3PZ\;:`/3Y-[-I[4Q.#]2CDU^V]O\_&Z@#OOX
M^-F'QT]JGK.$0\*N30CO^N]U_P#JVX_V]._3\I=MQ`=/:KB<`<*^38;;<WQV
M]0\;L?B&_CN&]E';3VIB<'ZE?)KI_KO>'JXVX_#T``"&UE``T]J>LX??U+.3
M6VWZ[H?_`/-N/_\`^9!$!ZCU#;QT]J8G!^I7R;WW_7>'?8`W_5NH&^P;[?\`
MK*&GM3UG"(.%O)L-_P#7=\>G^S=C_P`/3T&RB&_V-/>\F.O"+]3#DX.PCS>W
MVW'_`&;<?!L(^.W_`#D]D/FT]J8G#Z/#'DZ([CS>W]7^K;C[IMX;?\Y-NGH]
M6GM3UZ\/OZF7)W;;]=[H/00_5NQ_X>KK9!\/1I[=N3UG#Z'#/DZ`[AS>^R/&
MW'V_CN'7\I/#?^'3VICKP?J9\GN@_KO=0\!'C;C[Y/1^4>WHT]KR8G"+]37D
M]O\`[;H;>K]6S'NW@(!T_*/Y=/:F.O#[^IMR>Z[\WM]]O^C;C[KMMX_\X^OA
MI[4Q.#]3;D\(`!N;H&`!WV'C;C[;</`?Z1^(:>U,3A]_4WY.B&WZ[OJ_Z-V/
MO0._B%C`=Q'3VICKP^CPYY/C_P!-[KZ_U;L??;_I'_<.GM3'7A]_4ZY/]=^;
MH#OZ?U;<??+_`/./QZZ>U,=>`.'/)[I_KN^'_P#K=C_[?6QCL.XCI[4QUX1!
MP[Y/A_TW0Z=0_P!6['W00^0+%MXCI[7DQ.$/ZG/)_?<>;NX].OZMN/=^F_\`
M\XMO#[FGM3'7@'ASR?WW_7=VZ"`A^K=C[8=P$!'^D>_@.GM3$X?!X<<GAV_U
MW=M@$/\`9MQYZ=O':PAOX:>U,=>'T>'')X=M^;OAOM_JW8^\?`!Z6/T!I[4Q
MUX0?J:\G-]_UW>NWC^K=C[Y/'_G'L/A]K3VIB<(!X9<G1WWYO;[^(CQMQZ(]
M=]^OY1[^G3VICKPA_4PY-_MN^&^W^K=C[IOX_P#K'U^YI[4QUX<(\*N3(B`_
MKN^`;=.-N/@'Q`0W_P"<>W0?DT]J>LX0&X3\F#>/-T0\-MN-V/\`IZ]O^<GB
M.X]?'3WIZ]>'&?A%R6.&WZ[HA\H<;J!OO\X64!$.H]/E'3VICKPINR_#XS[;
M8A[!SG-0CV/?(+MUT%N->/%4S%<-U6QC&05L9VZPE36'8JA#IB/TBF#IJ^]/
M7KPQ,X7?`[OW!/(&2[KA#F^_BV63XQM&3=<<<>:R\9(I1LJM*0XMS2V099N4
M(HSURDEVMR'!)<2B;H/=F:9PU;G&8MMS'_ZNXWYE934S3<^71Z_D64C6<9:I
MB$X\59FUM)8M+W>+DY2.@[]7D%)ULS[6ZCL_F*KMT42&_FBB,NJSMC231B2/
M_5+H'T<Z)??Y>/+(?_[S!J8B^]X551/^JS/L9W2K9"HOQ`[%7+A3)V-LE;G&
M''MFF[C9B)=)O&3E,?ZYQ(H0JJ0`=,X&353$Q#@)3"`V8ES"]\RRQOE@>,O+
MF&CV[-3G(DX431*1=5+C/CQ%)5;M`#JI(N+(]51()MQ`HJG$`$`$P[`.KFYR
MQB<)\/'WEJ(;?KMD$/2!N-F-3%'H(`(@:9$PB!1V`=]]OL:F::<(0X^<M@W_
M`-=PH@/H_5MQJ4/``$`!.8)L!A#<0Z[C]O5S\FG!^KYRV'??FX4P#U]KC9C<
MP[]W=MW#-[B4/0&IF\KIPD,SQ<Y4S1$_/YN"DJBLBNBLCQOQR11)=!0%4ETQ
M+.!LL10H"!O$/0.KFIB7PK-/"?,`"$!3FZF=0"E`YR\:L:$*8P![1BD&8.)0
M$?1N.WKU%TX4I;ZGG_'C#ZWR!\1"H4>+,540D[?A'#59CS$:E*=P8'LU8F38
M00*J`G'N]@#`([;Z?B:<,67_`"L@47#MG7OBNU#*+]BLY:NHS`_&"L<AY9%X
MT02<.&)HG!3?(DD,@FFL7_BX)"L)MR@43`(!/Q7'_%TS9HYHSP*DQ9(\U,E'
M,99)DXD.".$\!QZZQ$BJ(JNC<J,HX+EV#!03AW*&9'5*`&`J1S@!!&)\/HP/
MQMK7N2JV[!F,VIBJ_P#*>;'M&DIIN(L^YMVTK#F*[W#R!@?*@54HVEH`$2/V
MF-W$'34_*KA_QB^*S.P4+.SG/SCXID>FS!K-3(ACP]!"FH3SFNSE0?&F[$IE
M128?,5*W;)%-,J<4F)'`I*CW``D!J9Z\/__5]_&@:!H&@:!H&@:#!7GT"5PQ
MYB3CP!C'<<HN1F(L3R#-$.]R]QW7)=SG'-K4B0%4`&[_``GB*P,E%3E,BB+L
MHG`VY2&+.6=6B&@:!H&@:!H-?V4<T9(S]D.=XS\3YA6!8UQPXA>2'*]B@TDH
M3"2AD4#.L6XB]];O(*Z<E7K)V4Z@*D<Q-(143=2:3EV9O&+%VUK*G"6$L<<>
M<<06+,607U'5H/WMR<[EVYE9ZPSTJY4D+#;[?89!1>6M-RM,LNJ]DY-ZJJ[>
MNU3J*'$1Z"W*[&B&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H
M&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H+&9)Y/\:\->\AESD%A+%ZC0IA<HY!R
MG1Z>Y2[%2H"06U@G(]P*HN#E3`@%$QE#`0`$P@&BXMVBR(_$0XS2@BCCI_EW
M-[HP*G03P/QTS]EZ,730<>ZJ+C;J3C:5HS-H"P@!5W,H@@?<O8<W<7=D]:?K
M4YULHF+C3@)R/D&_<N5*P98MG'O#%=7%-5)-+MCY++]GRB@5<AC*`*U73`I2
M[#[8]H#'RB4F?B-VHJXQ]"X;841.=<C%:PY(S)R'E$TBJ%(W<R<%!8[X[1B2
MRI"F.9NWF7!2@8I?/$>X0:GY?E"I@'F':O.+>N>LK5D7)G(+-^-_&W$6-RIH
M.%4S%08NLZK\JY)F+=`IDR*^>=8._N[N\"F`9G`IP)QM/B8<HYCY<9A`Y7`*
M,K?RHS)5:\N+HI2*F>4K#%FQ51I`H$`P$(XC%4D@.;L*7<-AE5]0X'\+:))&
MG*WQ7P,A95%3K*V^4QC4[)=G"ARID,+FZV2,E[6Y*()`/:H\,4#;CMN81$9O
M+*EFR9QS5!C'M&S!DV(";9FS02:M6Z8"(@F@W0(1)(@"/@4`#1'9T#0-!__6
M]_&@:!H&@:!H&@:#!2P`EDSXB./H0#&<17%7C;:,DRB:/MH-\B<F[=_5WCY=
MTJ)3I)OHO'^&KJ0J)1*L",R50VQ#I][RO]+.O1#0-`T#0-!KHNN5<@<O;I.8
M+XQV5]4<&UUW(UWD/RYK#I('@2;-?W.:P?QBF"^>RE,FE,15I8K<F5Q'4S\8
MV;"M.E\N/+MK6:N*<4X\P?CRJXJQ558RET&EQA(JO5Z*(H"#5`%%'#ERY<N%
M%GLG+2;U95T]>NE5GCYXLHX<**+*'.8F^M7"T#0-`T#0-`T#0-`T#0-`T#0-
M`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T'4?/V,6T6?R;UI',6Q
M2F</7SE%HT0*8Y4RF6<N#IHI%,H<"@)A#<1`/$=!BE;.?'"BE2)8.=Y48)/9
M3F3*E3Z_DFLW"[KBLJ9!(6U(J,A.6QR51<HD`4V9@$X=OCTT7%X4P'/''\Z'
M_LNPGR]S#OY!4755XM9;I<$[477.AV,+CG2`Q#2'Y$3`4RBR,D=NF0X"*GLG
M[!CY!SSS'LXD&A\$'-61<$2%!QR/Y*XIQX9`571D?,?LL#,N5+E$B+;M<&(3
MO5[1[.T%`$NAB<H2P7Q&[9V%D,D<.L)M5"D,Z2K.+LP<@9M(2O%#BWC;!8\E
MX"AD149%(05W$$Y`#"<00#V1*-/E#^JEF^S$_P#:=SYY+RR9_P"?@L55W`&$
MJV;_`(QYP^[OJ_B"9RHU_%E*ETM8^P!OOC".AF<(Q^'?Q?EBJ#D2&REFY9SO
M[[_7WR$SYF>,>%!V#Q-(U4R%DF=I3-JBH0I2HM8U!$"%V$@]QQ,,U?/'/&GC
MEA[R!Q+@+"V,#-BE*@?'V+:/354@(J1<O8K78..4`P+IE4WWW$X`;QZZ&;RO
M;HAH&@:!H&@:!H&@:#__U_?QH&@:!H&@:!H&@P3X7^7>[5R[Y%CWJHY?Y+VR
MCU%R/;Y']7/%]BQXZQB<>;VCJQDGD6AVJ914$PE5^N!.0`()0T6^(SLT0T#0
M-!"8Q2%,<YBD(0HF,8P@4I2E#<QC&'8"E*`;B(^&@UK3MYN?/6?E<<84GY.G
M\+H[W^$RUR0JTFYB[/R`DV[LS&9Q'QJL4<Z1=1%#9G;KLK3?6VYUC&5CJ^J5
MR1>4:1K;?=G_`$2B4W&%-K./,>5F&IE'ID,QKU6JU>8HQL+!0L:B5NRCX]DW
M*5-%%%,ORF.81,81,(B-959H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&
M@:!H&@:!H&@:!H&@:!H&@HBZY,QOC5D62R-D&D4".,4YBO[K:X&JLC%(110Y
MBNIU^P0$I$T3F$>[H4@CX`.@Q>7^(OPL5<G95/.\#EU\14$/<N/=?N_))Z=P
M**BWNZ+3`58R0X7<`5(Q13(4QP5#RQ#S/9T7%X=8O,VRV+RB8NX5\SL@F=&1
M]W=S>.*3@6,2262,M[W)?K+9*P]8&+=$A!!1,L:L\`X@4$!$=#'R$R-\0*V]
M@5SB_P`?<5,CBU.>1S%R;L5ELC=-9)85T2T3$F#[!7G;AJJ!`,/Y8(D'P)W@
M/<4:<HD\7\][2'?;^66%,<MS^Z_\G8-XNO599J!"*>^%&WYHS1DR*D3N%%0[
M#A6FH)@D7<A^X^XTX?"\*Y&=\L^4N8O-;)BQB-P=D:9CA\"LUU$O,%;R$.*=
M'P*Y9(K^;V[$7%0"$+^,$X"H89^([49\.?A(S=LY&:X[4;),I'G;K,9?.!YW
M/\RT<M3+';O4)C-TQD"33D$CKF,#@%?/[MA[]P+LP9O+*NHT2CX_C"PM#IM4
MI,,0J921-1KT16XPA4@,"12L(9FR:E*D!S=H`3V=QV\=$57H&@:!H&@:!H&@
M:!H&@:!H&@:!H/_0]_&@:!H&@:!H&@M3GC(#W$V#LS94C6+>4D<9XIR)D"/C
M':AT6LB]IE0F+&U8N5DRG42;NUXTJ9S%*(E*81`!'088?"]BLP,.&?$=]9)3
M&;JA67C1BR\MT86$M3>^N;#D2GP-[D)6QS,A87<"_D)*5L3UQ('08H%6=K"=
M,$R>QJ1KMC-;''H/!9NPCCMDY`6RX,#O4U569'@I']U.[204174;%7[14*0Y
M#B3<`$!ZZK+''W'F-_\`*?C1^8F4O_\`(NBZ?*^-.)<4ZY'$O[JLO;<7WOZV
M<TYA*1E<4W?.A8?5S&:D9:30[(P42K>:X4[EP.8O:02E`BD,I+979LV4CC>?
MQ57H^-;3#VW/\I1-DD&:#-LDT7:.V3J!LM<0C6S)!)V=XHZ,H3L\L2B0"G[B
MS#6!".>4GQ$S&@WUCQK7^`YIY@VMMXHT/D:EVGF94R"X1LU2QS(*W1>QU3!+
MA=($'5B(=HO<$>]"/WAU#O'L72?5M\K]?@:E`PU6JT-%URM5R+80=?K\&P:Q
M4-"0T4U291D3$QC))!G'QT>S0(DBBD0J:290*4```#598T6J]<@L?Y`QJA9%
M\.3./LB9:3Q\FU@X&[1MRBXR4@+?.Q+\\D_M,C".GS4M=23<@#0B:HJ&$@$V
M`-%T97Z(:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:#'_)'+
M#B[AT7!,K\C<&8W7;&63597;*U&K4B9=N4AE6B$9+SC60=/OQA0*W22.L<QR
ME*43&*`EQ;X6>-\0SCE*>:GCA/.&;W)#+$2_J.XS\A,FP;A1%(JHD"^5[&R^
M-F95`4(!%'4RW2.)PV-MN(#%!Y1<@[-N&->`>?%D.U4$YW,M_P"/F'(%94&8
M.6Y2L&N4\AY)1254.1,YUJVEY9C#L!Q(<H#$Y1_67Q'+6)#-ZIPQP:V6*IL:
M5N6:>2\FS*9L(-SNXN+J'%V-5<%=["J@C)F3`FY2N##[8C1`/'KEO:!`,@<^
M+5`ME3&%ZRX[<?,+XP163,V*E[LT>YC8<FYZ-;BX**@G3>BZ`#"4BQ![3%&9
MP?J"XJFS"IE#*?*_,ZAA*91M?>5><(JLN#@V,T.+O'>+KACC&3T%4CFW*M"J
M$*8PB4"B.AE6])X,<,\=/1EJ=Q:P)$SYO=_.M)\6T^4N#H6K9-HW,^N$O$O[
M._.BW2`H&6=J#U$=]S&$1F\LI&S9NS;H-&B"+5HU12;-6K9(B#=LW0(5)!!!
M!(I4T444R@4I2@!2E```-M$<V@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&
M@__1]_&@:!H&@:!H)5+3D-!(>\S4K'Q2`[]JL@\0:%.(>)4_..053]?`NXZ8
MSL9DWK7QS<Y58$:\6N3]6)D6#>S\KQ\S3#LXMDN55VH_D,<61DV2!%04CF`S
MA8H"8H&`-]:].V+<,SOUS)E97@?S>P=4N#O#"J2RUQ-*USBAQU@)0653?NV:
M<C#X@I\<]*DZ3/Y:J173<P%/T`2]=6?;[62G;O)V[3Y9FQ/./C?)JD17O2<$
MH<0`I;$V&(.(C]Z5-9455#?(4IA^33_'VX3WZLA*SD>AW))%:L6R#F2N2@9N
M1H_1\]8H_?)-E3)N#EW](%VWUFRS>-2R[5/;!8(&IP,S:;3,Q=<K5<BW\Y8+
M!./VL5#0D-%-57LG+2TF]509Q\='LT#JK+*G(FDF03&$``1U%:X$(JT_$7D$
MY6SLY:I?#V!LDYKM,?MY&O7/FDL*XJM[/>V3E-A/T[C*3R"+1<&H#:0NZ9RN
M9(J<,<C%]-_HU^G_`.S9<R9,XUFTCHYHV81[!L@R8,&2"35FR9M4B(-6C1J@
M1-!LV;()E(FF0I2$(4````-5EV=!+)&%AI@\8K+Q,9**0DFE-0RDBP:OCQ$R
M@W=-$):,.Y25,PDT6CY9(BZ78J5-8Y0-L<P"$ST#0-`T#0-`T#0-`T#0-`T#
M0-`T#0-`T#0-`T$OE9:*@H]S+3<G'P\4R("CR3E7C:/CVB9CE3*HY>.U$6R!
M#*'*4!.8`$P@'B.@Q1L_/_A-4I,\%(\I,)R5E2*N92HTZ^PF0;HF5LX*T7,>
MF4-S9+24J;H_EB(L_P"<`2^("`%Q>%.?KW4V<[OZK^/_`#(R\7=<J#NO<8,D
MX[A7QFZJ2"@QMHY"L,+561;BJH($71?';J`0XD4,!1'0Q\Q$IF_FM9BKDHO!
MF,IQCG<)LW'(_E!CNE^20%"IMG;]EQ\KG*8!W3,*AD$7!A'M[/-#<#@,3E"K
M6?B,6WSB/<N<1,)LE3.?Q%3PQE?.UB12,JG[F5E:;5EW#%?;N$T>[S%%ZT[(
M<VVR10WT-.`_$S+]G$Q\F<\^4LXB8K@@06.&6",)5Y(KDI0,*+VBX=)DD54A
M+^*,K95?+#P#N$QC#/PC-\.WBI*B"F0:E?<W+B+DRQN0>=LZYY9.!=E2(X3-
M`98R/;:RV:'31(4&S=DBU(`>RF7<=QFK^8ZX[\?\/@D7$N#,.XN!OW^0&.L9
M4JD@CYI")J>4%:A(P$_,32*4VVVX%`!Z`&AF\KQ:(:!H&@:!H&@:!H&@:!H&
M@:!H&@:!H&@:!H&@:!H&@:!H&@:#_]+W\:!H&@A.<B9#J*'*FFF4QU%#F`I"
M$*`F,<YC"!2E*4-Q$>@!H,;;ORSPK1A4!S85YTB+"3DUGU=;I.8`C*(29JOU
M$[;).HJH/%6XR")5$6[]59$#&.J0B22JB>IT[7PE[2-?E@^(_?\`+U@FJIQZ
MQV-/JU=*D2V9JRS(1<17(]55JF[5:UZ*;OU7\PY9HJ@1T*QHY)JH/1<ZA#I!
MN?;D_4Q>U\*9/`8_M<0O?LR9^;Y'B/),[D)%M94I&FM4"'`ACNDZ\HM#@V2.
M;L*H[%0X>`G$1'?><?IC&.;JMER8LW&6J<9N0$1`?DXG(O<%96:PR:3NOM'K
MATYH,ZBS.TB5Y!O-K@"JQ#?BVQA`O7PZZE]\7+77'MU^KL<),B49GPQXD,U<
M<7>4<,^,>!6KZ1C<=6R38KNV^*JHDZ73D&4(X:+I*+$,8%"G$I@'<!$!U.LO
MK-?"]\>W;3S5_)')_'-V[;Q%EC`@W+[<B2,["+Q:AC>4Y6,7W:000="!$FAN
MXP)B4IC$*80.HF4UQVFU9TOA0]UI_&>KUB:R:GDB.P_"1#!W-2EQ&<<TB-2:
M,D5%G"Z[I8T>UDP3*@;\3LN*AB]H$,;8-/:S]4T3$NV[$(F1N3&5H^KY`S-3
MY_./!R`E4[)6>/\`++1%?R5F)M''0=US(N8JB_;L$)*JQ"J82$%1'SN.(L?W
M=]--3ND4(]'-ZSO<XPZ3M>FF<UMCP#\37CQGV.9+UEE=HMPJ\<QJT2XK;EQ*
MQ+I@]=Q3V/?UEN5.YH2$9),3MUVY(HXEW353%1LHFN;/I<9FR^TSB[L\*W=J
MC;VYW-:L43+E0410=H-7:7OT<Z72%9-C*QJ@IR$3(BF41%NY227+L/<0!`=9
MQ8UE5&H+2Y2R!)T20Q(SCF3%X3(66H;'\F9Z#@3LHR2K%OG%7K'R%D0!\FXK
MJ1"^8!T^PYMRB.P@%VM`T#0-`T#0-`T#0-`T#0-`T#0-!;Z]Y:Q7BUH+_)N3
M,?8Z8@D1<7M[N=<J+0$5#JID6%Q8)*/1\HZB!R@;?81(8/$!T,,9#_$;X9/#
MJ(TK-#7,S@ATDBM^.=*R/R55<+KN5&:+=H&`Z?D<KI91VF*?:01V,(=VW<&Y
M<7AQ!S'N=B,"6+N$/,B^"J5(R4G8J;C+`T(@51P*)U9$O(?*^+;<BD@F`J&*
MVAG;@2[=J1A$=ACY@%^^(1;.P(#C?QMQ*Q.!#&D<J<D+C>K&@(O%"&2-1<8X
M03KRIBL4@4$Q;>``HJ4H`8"F-H:<A<3<\;2!5+CS"Q3CQ)4P">,P+Q:1;R#%
M,CGO!-.UYPRWF1A)N%6Q>TZPU]J0!-[*("7N,-.$0\(R3Y5"Y3Y9\ULJE<[^
M^HGSL.#FKH#.P=G1]VXG5?CX5LU,4!0%-(2`9N82&[A]K0S\.]&?#KX1,9!"
M8EN->-<A3C4RAVM@S/'/,[6)LLJY!V=RVL.9WU\FF[L5PW!8BY52A[(&`HB&
MAF\LKJS3ZE2HXL13:M7*E$DV[(NLPD9`QQ.WNV[644U:-B[=P[;%](Z(J/0-
M`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-!_]/W
M\:!H&@QUR2XQQ+K.W[NOUJ<58M_^5[%8$DUJRT;1H*KE,^165383ZD681.0R
MH"@T.'?Y@*)=FM3/+-L>?',7/C@KE%MFC$>-N4&&JI9F-C81:5QRJSL4Y4+/
M/)R<;/SLVRG/RJHSVV,?-16BV3UI/-VD<+=`S4#,TTDU>D[3;,REZ=M[UN&*
M&6LJ4BL5B(-QCXVL+HVJ3\DTXRNQD8S(17,@"*H'<PJ;'(]M=(LWCLYER%E7
M<@1$3`<$2N$RN";QYW9^MPG'`:ZYCYEY=M59R9+VS'=$QA6HZ?GZ@G%14-,V
M5-X^/'0L,RFVJ+I5E#B5FL+Q9NJ1X1(A$TA0.J"R<]KQ@O637.6W+D9#5VI<
M5>2L94:]$U]F;`F8477U>V2;N7HEQY8BBM(.R%,\DW1O$RKI154YO:$PB.^I
M<V75>NEZ_5+^#CMV'"GAZ4%4]B<6N/Q2=R!#"!0Q-4@*'<81$=@#3K/R]?H=
MOU=OJO;DW*%-QAC^T7?*TW#1&/:]&G?65]/$\Z/]T`Y$D698T4W0R[^1=JIM
MVC--)9P[=*IHHIG5.0HK,3*3-N&F#D_A7,]WQO8N8$97V>*J)3[#0;#C3B3,
M5@E@<SL4K/-J^QR7DRMR;M6K0.3W$C/LGL75D6CN+K[1D4ZJ)ITP*M,Y[7%N
MS7Y9I-^5I*9R%O[NRQ-AY&T"E4UL=HX25L<W9:AC^PO8U\B1JH_!6P7.NMV;
MAHW23!N<$5#-0#9$$>\5`Z9_NT8Q_;JJ>D<Q_AV<19*8S)_71CV[9(<*SA[3
M5\.0^4K3+7IV[/'H0R4:TG\NW_&\',H1;4[>5?F?F:2)=@2<-B`""F+WDSGL
MW.G?MB>N&]_A?R>XH<@Z\UR9QDG:5=XY@1+ZPJHI)1EVQNJ[1.DK'(UR2[)&
MC*+)@H`H`BFP?"43(*]@BJ./U3=<7K<6-F\%8XFQ(G4CEQ%9#L!VQ7+Y+]D<
M^_:5RW,(B!3"4P$4()T5.T1(<P!OK-EBRRK5YGI]CMDK@QS7X[ZP1IV<8"X6
M,_O;%K]75QE3;W%.I'M>NFQWGE/YELGY*`*KF\SN`@E*<2Q>5\=`T#0-`T#0
M-`T#0-!CID3E_P`4,1J&;Y0Y+X$Q^]*<B18VW9<H<#+N'"B0KHM&<1(SR$F]
M>KHAW)HHI'54#Z)1T7%OA:DOQ"./\UY2>-(C/^;5W`HBW/AWC!R!N5?51<)&
M51=FR"7'3#&39HJ``!3K328'$P"7<`,)1BA.3G(ZT]@XYX!YM1:JF:@A-YQR
M=Q^Q#$+D<)+*J+C%U[)&6LBLDFNR13E=5YNOW*"!4Q[!W&)R^INOB0VL._ZF
MX4X+(M[J9,CF=SARA=LTSD4%V1V@UA.);1PZ2,)-BI.03W`Q?,,`E/H:?+Z7
MCIRKLGE_U@<_,A1*0D;@[8<?\%8%Q>Q=G2\SSR`ZRK5.1EG8M70B3<&TFBX)
MVCVK!W=!F<(4^`.'97R5,F9!Y19I61,V4!')G*K/"U=57;*J+>\.<?4V\TW&
M;I58YB@?S(4Q>T@%*!2B8##*OZ%PBX=8O<IR%!XN8#K4RFJDN-C98II2EK<.
M4!`R#I];'<.YLD@[1,&Y55W2BA?0;0S>63Z:::*::**9$DDB%3223*4B::9"
M@4B:9"@!2$(4```````#1$>@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:
M!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:#_U/?QH`CMU'H`=1$?1H,5<Z9SI-#I
M%KO=UMD;3<24B)>35MMDDZ]V9/F#)(QENQ4FZJ\0H;9-)-(#*R:QRD3*=(Q2
MN-R<L6YTCQX\E>4_,_XO<[,8[XWM)3`?!]@]<0SVV6!1U`.<I(-E@0<.;$I'
M`>2G6ITTQ\FOQXF8([@$BN*@I^2D[=_TZ=6_R?;_`%:]N$DH_P`$KC[$,F_Y
M>Y'R?<Y<I2>]GAEZ]4(14W;N;R8P8BP2B("8>G=('Z:W/L]?-9OW^WB2,A*E
M\+/BM191M/5!#*5:L+$W>QL,#E2TP4VS/T]MI)0KB/<H&]GJ)1#6I]OI-F+]
MWO=\89HXNI%FQ%9TK17<CSUC>(LQC$EL@1D#/S244HH@J[BE;7#1]7L<\R?J
MMB'5^NG$LJ"A"'3.0Y"&#6-]6,_&JX7);D4HKQNSY%VC&,_[U)85RK&)3E'>
MQ%@AFIGM%G&B#R492SN`L<<AYRP&.1FTD2I)]PF4V#<<]I9+BM];+VZSY6_X
MT<TN.6(>$'%YS?Y^_P`,>N\=,#5QPF&&\S+HRUG3QM5XEI`5J31I?U'87TY+
M)@VCA:.CH/E%">2H8ARFUF7'6?@U9GOVDWRD&/\`+']>.0FF;,Q8NRY,-JS(
M@]P9@*8IRM/I>(G;4SA!EDK)K[)+NLFNV:'R3@?+7B&DK&U5`QDHT7;@5)%5
M)>US4MDF)509^KF6N4/N<!=,J67$>*&+HCT<:8(FGU?F;,[3**0!D#*[ENWG
M9^'[#&$D='1T(@!S]RYG1TT5$]^ORS[8SB:_*@:CPBXM52/-'L<%8YES+=7D
MI<:VPO5@D5/%1:2L5R2G)A\HH;J/>N(;CT``Z:OKUX2]^W]U6ZR-\,7AKDAN
MN5YA2`J;Y4A@1E,>*O*.X:*G*)06180*[6!7.41Z%79K)[^)1UF_;Z7PU/N?
M<FW9JPRQ\-GDEPKLC?D/P:RI>9.1J!E'QXB/,DRR7'1J0E7<(HIQJ2<'DB'7
M32V=QJC)(S@@`0&KH!$"\[]N]=>E=>OW9V_+WC?C\*/XP%6YL(LL4Y4-&XPY
M9UEBL=-LR_Y/@LG,V"8FDI:GMW9SBWE&Y$14E(%85=B%%=$54B*`VS+G3!VZ
M7K<S9Z+*E:D["W.W=$3:S;(A!?M""/DK)F'M3D&'>8QS,G!@ZE$1.@?<AA'V
M3GEF/HDN?JK#44T#02F;GX*LQKF9LDU$U^'9D,H[E9N19Q,:U3(0RAU'+Y^L
MW:H$*0@F$3'```!'T:#%"Q_$&X25B2<P;CE!AR?LC,JIG53Q_<(_*%R0%(IC
MF25IV-C6NSD<&*4>Q,6GF*"`@0IA#1<7A(QYTUV<W_JMXV<T<N%,546[B)XT
M77$T:^%)F#PHL)OD\.!8-VW<;@FDX(Y%JHKT*H(>UH8^41LT\WK.`$I'".K4
MH'!%@([Y%\IJ?5%(\?=1416>16`*+R:3>G*YV(*"+XA3B&WGIE'S"C$Y0_DE
M\1.VB`2^;.*.&H\YC&69T/!>2\P68A3-BD*BRN=XS'CNNHF2=&.H*JU3<=Y2
MD+Y9/:$1H?JC93L@BKE#G;RNM!5#%\R#H:F$\&UE)/W8R)T62^+L00V2$2JK
M*&5$ZUF<*E,!`*<H%V,,_"(OPZ.(\@`FON/[3FY=4B)7JW(O,N:^1*<B=)J#
M,3O(W-60KS#=BB(;"@DV3;%`>TB92@!08/:LBL>8)PAB))%#$^&\58P0;HE;
M((X\QY4:4DBW(D9$B"*=;B(TB:)$3"0"@`%`HB&VVB+JZ!H&@:!H&@:!H&@:
M!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:
M!H&@_]7W\:"T^0K"4X*5EJKVD%(BUA<%4`A461P\Q.+,?<I2G?IAWK@(^RUZ
M&#98HAKK/+-OAYE>4LG(?$=R:E`/I)\QX+XBLJA(>!C72[(W*+(E?=+-7]KD
MW;91%<N'JG()G:Q!4Q_Y87(J[(?R/=E`Z=>GMK?T_P`TO;TV_5_+_=?Z%A(F
MO14?!P,8PA86)9H,(N)B6;>/C8YBU3!)NS8LFB:39JV;IE`I$R%`I0``#;75
MQ38"?)MX#MZ-Q'Y=!&!.OA]GU=?X`#;01@ET]'IZ=!\/#?KTZZ"VF:J[*VC#
M66ZU!,SR,Y8<8WV$AF"9T4E'\M+56581[--1=1)!,[IXX(0#'.4@".XB`=0G
M;]-YPUUTLMY:G^/Q>5-#88[>9AX:Y4R-/XDHU0QYBR'BKKBMA1*!$U&K1]76
MM$5#R-N<*R.1K4FT44>S3@`6:MEO<6946X*BXY]?:8STN8[=O2YQWDE9FDY-
M\CR_]`7,O7_Z1L/_`">NS^H=:]NW]E<_3K_V1WTN3_)`/^@#F<P=-_\`VCX=
M#J`>/6SZ>W;^RGKU_P"R)FCRCY)^CX?>:3?-DC#?]^TZ>W;^RGKU_P"R)D3E
M+R6VZ_#US6;?_P"DG#/\'_.K?4]NW]E/7K_V3^+@<\G.2BI!*/P],UEW#Q')
M.&1V^7I:/6.K[=O[*>G7Q]R-+?-?"V>9?(D;RLPSQ,S!QTR#3I`EPN%CC[5C
MV0;*2D,L@^C[S&LJC8'$G'V1DX2[GRJ2"B3M/\<L!3D6.MR[RV^TZ65VZ7K)
MZ=N\L;L>*?Q.N3',1KBR"K7#>\V?-7&K)$"YSW+1>0,74B*1LL35KO`/H^4J
MM]L-7L5<:VF2`P+(JIJ$:N$%D4A5703+J9SO"]9UN?9O<C\D_$#R&Q+(5'`G
M%W$\4X]\3:R.3>0E_P`D64JJ+D&Y1?4;'6$H"OMQ;&15*LFG;E3"K[("4"B8
M^;D_+R[Y\.\Z;4)CV[FECZ@HJ%<`5EQ]XJPL(]9@H4I6X#/9YRAR#9R+AL)1
M,*OU2U34$PAY)0``T-.$9N#\;/"7^M'E'S5RL03.1<MWG(>:PPR?D=%2*H@]
MCN*D3Q]CU6@>6.R()%2$JABB42#V@,_$3.&^'EPBB))&;=<9<4W.P-E7"[:S
M95KQ<R6INNZ*V(Y<-[1EA:Z6!!PN1H0#*%<@<0`0W]HVXS>65]=K%:J$:2&J
M=>@ZQ#I'%1.*KL2PA8U-0Q")F4(QC6[9J0YDTBE$0+N(%`/0&B)YH&@:!H&@
M:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@
M:!H&@:!H&@:!H&@:!H&@:#__UO>Y9)DD!"O902`JJB0B31`PB4'+]TJ1LQ;B
M(;F*15TL0#F`![";F]&K)FX2W$:</B"9"L!*/6./=/FGK&\<B9.2:W&QQKLC
M&6KV&X)2/=9BLS%P"Z:[&2G6TJSK;`[83+LW4XFX2*4C0YR=),V1C.,UC+#0
M\9`1,7!0C%K&0T+'LXF)C621$&<?&QS=-FP8M$2%`B+9HU1*0A0#8I2@`=-=
MG+=.2%^3U^CU#]OKH.P1,WJ^;QZ^GYQT5S@D/AMMT^3YP#?;;PT1R`D.X#M\
MOW/#Y0T'*5/P\1Z_8W'Q'[>@YBDZ[CX^'AZ!]&@[12_,']_Y_0/CH.XB`>`;
M]?'IT#UCTT$W;``;;^OQZ?)OZQV$=03=(P`']X.GVQZ>O1?#F.("'7IN'R_X
M]!1=BC6DBR<M':"3ALZ06;.$%TRJ(+H+IF16153,`E4253,)3%$-A`>NJ-0#
M[(#WAM\87CUE>'4&,H/,6(C,/YB;%5.E'S%T&3CZ::<7+O[L$F@NZJ,XZ<B'
MF'<O7HF$!74.;AWF.\QM7?K?;[=YCV*XW?G1E96',/XA\U+--B=V_8X:G;Q\
MF8OCVD6(NT'M`>T#@<?$PCK/;;*=>%XM9:-`T#0-`T#0-`T#0-`T#0-`T#0-
M`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-
M`T#0-`T#0?_7]T>35S&-7&'@4[N0E#;#](6#0K$I#`(AW$WF>_\`E$`=:Z^6
M;XCSS9LM;NY_$;S/"O%3FC<2X2PI7*^V`?9;R4XK?;99G701$#R+2XQI#E#V
M3`S2$>I"ZZ]-[]&._P"F?5<9!N93;QV';[8;?<WUU<TY0CC']&W7[OKV]>H)
MFG&#Z2[^`#T\0](?+\F@[)8L?'M';T^O[/SZ*&C3`'AM\P;;B.B.L+,P>CIZ
M1V'^#;PT`&_;\OJV`?\`'Z=%<H)#_!ZA\0VZ^KTZ(YBD$/1TWWZ^K1?AW4AV
M`.NWS>(_W>K41W2+`'JZAX_-Z_5H.05^GCZ?[_7;Y=@T$BD%0$AM_E^QX[[=
M=_'55H[^,O!.VN&<9Y>A0,G/8=SI2W$<Y(02F8IWV`N3MY(`H4`$O=,8IA$S
M#OON"?J#7'[LTEG+M]C?M/%CV$XBM"%F2Q=;6G<#:XP#&23/OT]QL%15GD2F
M$``-CKHH_()@#Y-2[5)O,LJ]<VS0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`
MT#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`
MT'__T/<UDS_TI6>G3W*Q>K;?SZ]MOO\`<UKKM6;X>:BTJ*_O2>9[$R)^U*B8
M'DO,#N%,B,I181BV3W-L`"=6ON-@#H/:.NOV_P!5OPSW_3U^K*^/;B<"_8^7
M?;;Q#?\`[&NCDK1C'"8"[E_@W^7Y`U%5(C$[A]$/#PV^3U]1ZZ#L_5(!]Y\G
MA]CIZ=0<"D7L`^SZ_F#IL'3Y@U1*EHS8>A0V\/#U_8'P]>@EZC#;?<FW7U#\
MGS==$=<6FVW3?['^$-_$=4<(MQ`?#IX^`^OQU%0]@AZ^@?+T\>GR]-$<)C"7
MQ$/N=/LZ*ZZCC8/';IX>'_8]&J).Z<=P#UW^?U>O[.VB-6?Q9FZ+GA3EDRW;
MW-'6.Y-L`@'?[VWRC3HH#@.^P]K.>7#P[@[QVZ".N?W?T.WV?UQZ3N)95R8&
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M@\=O'['VM05PUBP$I1[?$/DW_O\`HUG*IA]3^HGH]6WW0WTR8WT=5:(VZ]NW
M^Y#Q]?AIDPD3F)VW]G_#JY,:I&O';;^S_!M]WKXZ(E2K+;?V?L[;>KYNN^J)
M:JT$/1OZ@^YOMH.@JWV]'JW^7H'IV'TZ"3.""7<=A]`_8V#U?W]5$D<*"&X?
MP>G^'Y]%29<_3Q_[`_WQ#?0:J_BQIO9KC,C3XD>^4OF6,38YCVP)]QW4I;IJ
M5G8=J3VBF.*Q\>N#=I0$?Q0;[;EUS^[^F1U^S^JWB/6/BNMMJ[_5E5F91!G5
M8IG'(ICN/:S@JDZB6_=N/@BMY/R`;;7.W2DWC*C6&S0-`T#0-`T#0-`T#0-`
MT#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`
MT#0-`T#0-`T#0-`T'__2]XF060O*K(JD*(JQ?D3*?:'<?RXQ8CIZ1,OWRCB.
M(LD`>GO]>KUWB79H4^*/CQ-I=N'?(IHFW(O0\JRV&IETLX!BW08YYATXBANI
MA^8Q2-X1KF.OUUN[,<>TC207'<G4P;EQ969K.T^$]I4PVE6+&00\PJ#QLDX*
MFY3,@Z1\P@'%!RW,/>W=(&$2*IF]I-0!*.P@.N[EMNO[!=I^WKX_W?P[:RL7
M1CD"&(7T_P!W]_4549&13%#V?1ZO\7AOJ*ZZS`A@\/1ZNO\`"&FL$A=1X;"/
M;Z_[OGT3"FG4?U'I]G[7IZ>.JF%/.&`@(CVC]K^[KJIM]$L4CS#OL7^#U]/M
M:>1+5HPVPB)1\/';P'?[FJ*4DF@IE,(AL`!]OY]_GT%!/#]I^@[;C]H?DW`-
M5$C6/O\`-Z?F$?3\N@PCM]3-R$Y\<&L%HD%[#TZ]VGECD5$I050:U'"925O&
M;QT@`FW^L,L&GXPYC]H"51/8H]>[EWOYNL_%VZ3'3M>='J;QTR%>>DI(P!V1
MD8G&I'`>_N7E7";UTD8^W0[="-;FV_BKA]GGV6;U>?66C0-`T#0-`T#0-`T#
M0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#
M0-`T#0-`T#0-`T#0-`T'_]/W[F*4Q1*8`,4P"4Q3``E,40V$!`>@@(:#71RN
MXY0W('!N9..%B74CV]KK3J,KLV03`Y@9)!5.;QW;68E,111Y6+#&LW`'*).Y
MTQ.'AKIO&)I6G;CID^?LU<:NKRR"%R$QL\]C+-5='M*:H<CZ-YJ61(Y0A0(1
M.)R:V:#;H8Y/-!=-V^$3E(5N0W7K<SY8[S%TV9\UR4(8$Q$X>CT^'3Y?$-]7
M#*\T1))]I!#Y/3]@?N?-K.&HK1!\F(![10`=O[NGSZRKE,Y*._4!^UX?*&@E
MZW:8!#?[?@/7T=`$-5$F<-@-N'K]'V>H;!ID2L\=W#X;@/K#^X.FJ8?"PXB/
MT/\`%M]O8=!Q.X7M3$>P`Z>/][UCIE%I;(W*B"F_J'UA_!\FM)5DI%3\<<-]
M@[A]?3[&^P[ZJ*2F7XL&*RY#MBKCV(-1?+D:L@=NE2-VIG[PX@DQCTUU2F<.
M%!*DW0*=4XE(0P@5,/A98U3MDMG3G1-I+^Y9J?,<;8%7E&YFKQMQMQ$=>%B;
M<=NN)%F#C,-K;/+&^3$3`H=1)8IC`H`ZX9S;>7:Z23C^;T!4>*-%5YKYJ:B3
MR3.>7>D6(*:Z:S\"'2;+I[F[5F#$J+8WK%'?Q'6+NLV5=J*:!H&@:!H&@:!H
M&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H
M&@:!H&@:!H&@:!H&@:!H&@__U/?QH+;Y#A#.&:5@:)G.\AR'!XFB&YW<.<>Y
MP42@'<JI''_XPF'M&`@*D(43*;:UUOAGMRT)<\<2&P5D:1YE5B)DY7#61(B`
MI?-&KUM(R\M%Q->61/CCE#5VJ*+H3V7$;E-%.44(FN)XA))P9)0K(W=N7"8S
M,>?'_A-:+;5#E*S<R$;*+)LHV38SL*IYD!;JU-)'<5NZUQ;SW!5(*R,TC&(4
M%5P:NDG#0RJJC<YS=9JY687^BK$`%(/F!Z!'K_"/RZ8,X\JX:60!*`"?YNO\
M(>K6<+E/$9T#_?@/AZ?[O#3"Y3)*3`X]3!Z/3MZO3Z-,0RF2;@AP`=_'IMK*
MN\D0IMNF_H_O[!\FJB9D12+MOM\O4/L^G4W5T)<R16Y]MOHB.X^CQZ>&WHU<
M#&VXNBAYH;AXF#[O0.F_IUN,589XL)U3#OXB/3???KJ^$8_V:@6#E)=XGC13
M7[V.B;='$D\SVV*.*2M'P`]6=Q=H70>E`?=+;G`&KFIUPGTSPYYV1%,R";)5
M7'>V_E\.G28_-7H%QCCZ!C6==I59AV<+1*'%0L6UB(YN5K&,8R%:(-J[66B!
M=D@;)-FR9E$P`P$:I@0P`"Y1URM:DS?AD]K#9H&@:!H&@:!H&@:!H&@:!H&@
M:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@
M:!H&@:!H&@:!H/_5]_&@:"P-YI;6+1>F]R1>U"53<MI..<(IN&L8F^*=-RV7
M;J%,DK7GA5!+V&`2-A,)!_$B4$MRY^K%F-9LT:9;XH2_%%P2<QB2Q3'%QI(3
MDVC$0K!U9K[Q3>SJR;Z6&J0+<R;O(G&65=MTSR]7*(2D%V$<Q[DB221X[?6X
M+^;??^?^[FK.0BJA!(R+N(/^4K(LE3[#7Y1.;H^1(GW;WOZWH-F2*DA,$(S`
M57+%0J4FQ)L=9`$#H+K=)<N=EGT7D83PB`!W]>GI_P`']W3595.VG!#[_P`-
MMNOB.HOPJ!K8!#;<_P#=]D?1MJ8,JF:6(NQ=S_PB'K_P:87^:I6L^78/:W\/
M3X]?MZF%RFWY0)E#Z8!N'K_NZZF#*EYZS$\DP>8`^R/IVV\?EW].K(6L;K=8
M$`*X5672112(=1==50J2229`,8ZBBAS%*0A`#<1$=@#U:VRLRO'WB^6!KCC'
ML(22NTXT;OTF,PG(-H6LUMRX\HV0,HKL56<I7:(?R%DF$:15K/VY=,Z,=[JS
M(O+-\]NWB-3KG?9M-XY\=8+"\$ZIU0<.['<;5)GM>2LCSZ;,9JSV!TDW9*V*
M>"+09,64='1[)*/A(AFFW:,8]H@R:D2;H&,GRMF];W9YPD,R@(Y&-8@<4TQ,
MHJNL)3N7;E4>Y=VZ4*4A3KKGZCL4I"AL4A2D*4H8MRW-$VU`T#0-`T#0-`T#
M0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#
M0-`T#0-`T#0-`T#0-`T#0-`T'__6]_&@:"$Y"*$.FH0JB:A3$.0Y0,0Y#`)3
M$.4P"4Q3%'80'H(:"RMDH[J(\QY`H*OX<>XZ\.D4RKZ-#J)QC2>V>08;>#8/
MQR7@EYA1*FGN6>=V;,;-9V3N&489S/VS`0UR(;6J05FKY@ZT)+GPID*9!V+U
M6RQ"<<BO(X?R6G([N"3L(GV&>"9=RT4>"1VAJ7&66/$+59-![*5UH^G:/:8)
MHN^>XTSL1=L\:QZ(F$SVL99KC:<C[E6F2"92IK>[S#@ZAA!S)"L4Z8=)?Q8L
M=ES,R4"H@A9HUS7Q=K^ZQ[IXNQ=0TJKYADBI15@BW;^$>NE3IF[6H+@]*!=U
M$2:LL3&$[2F_#VQ#K_&VV'U?)TU431"PBGL/F=`]`CZ.HAZM,"<I6TI`ZJ[?
M9_[.XZF%==YD)DV.DW4>)$<+B)6[<52^\N3%`!,1N@`BJN<.X.A2B.XAH+8Y
M.RU"X[AR3^2[+7\5P"ZR;9I(9'D?J"1E72AB$"-KU+!)Q=Y^:5.J0$&R<>D5
MP8>TBN^I;(LZVOF+\;YJSZ^:3%1K=CPUC03IN2YLS!648_*,VAW=X.L+8#F$
M7C:A>:D`';S]U(XDFBFXH1JZ*@'#-[9:G7'U;4<)X,K6/H,]4QE%':,EY%61
MM=UFW+R<FK'852)(2$[9K')+*S%TM3@$"D,=9<X(II$2$Z*9$DM8MY:DRS`@
MH&/KS(&;`AQ[SBLZ=KB51X^<F``.Y=K%*0#J&````*!4TR`!"%*0I2ABW+<F
M$YU`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T
M#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0?_U_?QH&@:!H+.Y$9Q
M#9_%JM6I$9J25<K/U4!.D5S&,VWE*K/$$S`@Y<@\7:D344**H$`P%-VE$HZZ
ML]O'+`'E-,MU5:Y!M/QDA'G=2BAT0*=P0RGNQ6;5`!W!1;SDB.%$#=%FR9P#
MY.O2.?;Q&.0J+0[9.(*)5X=(BS"3:"5-RRE&$*V7<V:)7;.BJ(N&\EYR[]OW
M%%,P*`4=Q[0+ME\M&&\@'AH*8QYQOKERC7#4Q)!O$9TM&'GY7#8A$1>PE6C%
MHVG$8OERG,D3SVA0+L/8)1#6+VDTEU:DS-5FGE0Y*-E!23X&9?ET^\#%('*G
M$[./*7VR^2#YED6.GA0W'?<QA4V$/:Z;:>Z^OS'898TYHS:HH5_A'BBF$4[B
M^_9BYBW6=9-P-N)C.8*J1&2T9`H!T\H3%*8/9W`-2]K^W_POKUY_A_NN3%\-
MN9%M3%'(?*C'G'JH+`1*2IO$7$41"RRS,A1[FZV4,CEE")F*7<I56]<:G3#P
M'?QF;RND\?M_!E1@#@5@'$DXG=J7C^9R=E)4GEN<YY;FG^2\A+=!(J9K?[JN
MX0@V@B?8S.#!LB0``"M]@VU+IO5UNGAL%B<;%,)5[*[(\`-A"(CA51C@'<!$
MKQX8$GTF7<OAVMDC%,)3IG#KK/MP>O*Z"**+9%)NW22001(5)%!%,B2*29``
MI$TDR`4B9"%#8`````UEIRZ!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H
M&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H
M&@:#_]#W\:!H&@:#&>UV!%>1GK(L83,6@&8L0*`"*C"+.JDF"'4"*FD9%191
M$P=3D6(&_0-=)-HQ;NUJSLL[M5OD;`J<BARNO?FICCW-A<HKMVU<*!S=01)*
M2K)T@H(>TP?JIF,()[:ZS28<]TD@(I.?LT;&-06/[PO$,6O>/F=C(KD7S1VJ
M!@$3N&Z[+ZG<FV[2D``'?N`-7:92:XC:+780CM_!UIH95HS304%8S<J7G-8F
M,:`0#(BLDLF`G=*MD1$Q1V*M_&VUPOFNL7/'&49__'+$'CT\V&';?Q#VH01Z
M[_/J>UX7U^7.EC6`+M[RZG'P!Z%)55EOX>)H<D8IMN'AOMI[5?6)VRI=58*$
M60@F"CA,0,F[>I#)/4Q#P\M[(F=.DP`?04X!OJ9O)B*GU%-`T#0-`T#0-`T#
M0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#
M0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0?_]'W\:!H&@I2ZRZD-7GBK904Y!Z)
M(N,,7^<(]?B*)7*9?OQCT.]R8OI(B.K)FI=F!6<;*E#5].NLE3-P42315]UW
M!5%$K9=4?(Z["XCXEHX=)E$0$7":`;CW@&NO69U<^UX8I'13CXMTHX2*4#B[
M4>I-0*($;QWUBP<-6Y!`""1%PZG568CO^)C6X?>@`[\L+FX#ACO[>5TZ(FH=
M@#M^\7(7N*H\64$CTJ:PA_,K2#%G()E+L&S[<-3M<1>N[9'C5EYKZ=EC@`@W
M*TA6X[;>6KY9)*2[-P`3$73<,]QZAW)"`==]<>VT=>OE=W66C0<*;ENJJX02
M<(JKM#)D=(IJD.JV.JF59(CA,IA.B91$X'*!@`1*("'0=!S:#J@]9"]/&@[:
MC(IM4WIV`.$A>D9*JJH).SM>_P`\K51=$Y"J"7L,<A@`=P'02=I;ZF_?+1C&
MSUU[)-Y56"<1[2:C7+Y";1;2+U:'6:(N3KI2J3.'=JF;F*"Q4FJQA+VIG$K`
MJ+0-`T#0<2#A!TD1PV62<(*!W)K(*$624`!$!$BB8F(<`$!#H/CH.)J^9/BK
M&9.VKPK9TX8N#-7"3@J#UHH*+MHL*)S@DZ:K%$BB9MCD,&P@`Z#KM)J'D'LG
M&,):->R4*=NG,1[1\U<O8E1XF99HG)M$53KL#ND2"=,%2D$Y0$2[@&@F6@:#
MB4<((G;IK+))*.E1;M2**$(=RN5!9T9%N4P@994K9LHH)2[B":9C>!1$`Y=`
MT#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`
MT#0-`T#0-`T#0-`T#0-`T#0?_]+W\:!H&@LGD1Z]<3C9H6*GEX^&9&=@X9U^
M;?LW$D_W(82.&<>X;G.P8I]H&(;</>E"^("`:FV[-SG9K%R#8['*6EZ_<T;(
MC0C-10[$S^@VE%HH^,LQ58$.H,<!3-RR(1*?F!L`(1[O?V3=>\QXL<KOLM;9
M;O`,#-8\%)1CY*B"#`)F#EVQO(B#%BX`RPKLDDSIOI./6%;NV#RIH1'?J(6&
M?AE_QK/$/:^\FXEXDZCW)4"MG._M^[&+V,B+@H!#$6;5UC'^87;Z0B/CN.L=
M_HO5L)H;$6-6BQ.42K2!%9A<#!^,*:66.^215]:C1LLFCZ=@3`-QVUQ[;UUF
MRL-15F,AXTF;?8&TLRFFR+,*XY@!8OO>B%AGB[I5P2TPQF0`HM-)`H0H)+'*
MT.5`H*$4$2&1LJ696UOV%\H3ELR+8Z?=$ZT6QP\XYK8,+;;J\JA=&]`JT%19
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MNRLW]KR@S^I!6BW,RQKE_O3%.1=0])R;#M%V,>E7X\\(1Y9I^`=R+5!][B_-
M'JK^0CV(M3,SQ#';D9X.SS#-7/U9DQU(.7K>/BG:<]EG*[Y/ZG4K6&6T\I&.
MWR,J>&L@VJN6UZPD"(*'0"4;%5*JU,NQ39G!B\N\WQ-R)-4VT;*Y":/[7]2X
MP;2%A;9)OD0F[-7:O1H^]5])E%UELR9?7]RAI6:+9$$$I9TD]".5;H-E#BFS
M.#%Y263P)G.8BH:OSE[1LL56W;";3=RF3;TPEK=,,,M8+R2P).J0E49)P*T#
M'8[G(UE(,Q<'2&4*L@V:E55039AB\IFGA_D"UI\[`$NK![.2+6"91=F#*N2X
M-Q!131A6TY:(C&#"O/(Q&67G(Q](ISRR#IVHF]%BJW%N`&!F<&*J3%&)LNTJ
MRPDO8[3%2K-P>W.KNV:VJQGBW\A8'TE+(2L/4D:[!11K"I*.$0<OGKA9(K,#
M(H-"*`5QI;*LE=1WBC,J./:O18&4K<2O48):OEL43D"X5>1ML@>ORD:TO\^:
MO4MN[;2[*>5)++0YG#]E(NWS@5W(&03479F4Q<*>;XKSNWO*K8MVGG#5:1D+
M0K;G>1[P$+%I2&=[19647&4P6CBO3;U#$WU?$*1*Y&<4TV_%&6#\8=F8,7ES
MQF&^03<?/=9#24%I0;)"M(E;*64)%B_OD@RQU'-+K(2H1\5+-TGC>)GE2L0]
MX:0CIT@JU37,JOY;,X)+RIPO'C/?US%V$N16B-A"AL*M,V$^0;L[D7#B!@.3
M,3`D6;I5F,C)KR'.6JXX&141:NDG,6Z<D1%<Q169G!B\KA5[$>9V5K_*22OK
MA*/;3-%=0=6)DS(5CC(2$8VS(KF_PSY68CF*-V/.U.Q1B;5S*M5%DG+?RR"W
M(R:+F9G!BLLM9:-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-
M`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-!_]/W\:!H&@:!H.-7^:4_F_H&
M_G?YKP'^<_R/7\F@LM9?HO/_`')>"W])?H_S?_EGR?Q_\G6I^+-\[+TH_P`T
ME_-_S9/YG^:^B'\U_P!S_B_)K+3DT#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#
M0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#
10-`T#0-`T#0-`T#0-`T'_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g893535g05b34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g893535g05b34.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[1*F4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@`````````````!00```38````&`&<`,``U
M`&(`,P`T`````0`````````````````````````!``````````````$V```!
M00`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````$`D````!````;````'``
M``%$``"-P```#^T`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!P`&P#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#L7XP9EY3VXW4_5+WO;;6]FTM+CZ@QR^QK&M=^8RW]+Z>STD0NG$W6
MT]5-1N:Y[#M+RUK;'O:]E;S:[%?Z6VVIOZ6RRROTV?I%T"A;:RFIUKYVL!<8
M!)T_=:WW.24X-U3O0&:RGJ=;K'OJ=C5.8U[0YUEOVAU8?Z3MKOH6>KZGIO\`
M\(F=9:UEC#C=6=O(9O#JR6EH/Z2IWJ[_`'^IL]3_`(-:K>L=.<\5BV7N+0!M
M=KN#2S\W\_>U)W6.GL$OL+?I$#8^2&ZO+6AONV_Z^])3FV5W#]'_`)5C'D&Q
MCV'U2-L<G<YNNQOMJ_X7]]#AWV=^^CJMI>6/<UQK+@&/?L9M<]E;VV>I^FH_
M2,]'^=6]1D4Y#2^EVYK7%A,$:CZ7TE*X32\2X>TZL^D-/S/Y22G!83B/955B
M]4=76X6;@\.%C[MCW^MZUN[]$Y_O_P`!_/)4M-'K4?9^JW5W&RIP>]CF_IBY
M[KJWFX6,V?0K?O\`T:O8]^77<3;7DV-/M;665[6#<WW^HU^^WVV?YE+T;]HV
M;]GV+($.#7.VM@3L]P_2>]K?4_,_X7_1I*<9E+VX[+V5]8!:QS6U;Z]X#0RJ
MMFQUFS=^L;Z]W_<?U+_YIBNXU!ZC8Y]AZABBJVNQK;G!@=Z9`V-8S?\`H7NQ
M]]N_](_UO^$5_P"VVE@<,2Z3$M/I@B7&L_X7\R/4_P"+4'=0M`D860[V[H`9
M(]K7[7;[&-W^[9M:DI$.AUAKFMR\I@<[>-MD;3$.V`-V^_\`/_E_I/\`"6J3
MNCL=:^P9>6UKW/L-;;B&AS]OT?SVL9L_1U[_`$OIHKLVT`D8EY`:'0`R==WL
M'Z3Z7L_Z;%8JL-E8>6N9,^UX@B#"2FB_HK76MN^V9;7M8:_;;`()>_W5[?3W
MM]3^<V[_`-'6E^Q6?8?L?VO+^GZGVCU3ZT\1ZT?06BDDI__0]52678SH5KG/
M?8QKB=[OTKF:R';]H>S;NA.ROH;OT3;&$L+]/5=N$@;_`,_=[=G_`%M)3?N=
M:UDU,]1T_1F-/F@?;;6.;]HQW4UN,&TN86M)^COVN_.=[%59B=.EIQZ;8,@W
M;[&-;`>S?OL>U[_IO])]3;?])_PBK=0MZU72:L>ZD[YK<[(:7-8`W>ZV_(KK
M]*OV'^;OQ_\`TFDIU&W-QK[*KWAM;IMJ>XGB1ZM;G._<L?[/?_A=C/YI!R^I
MX)QKFBS<36_Z+7.'T3W8TK`Z9U;!R;QAX](S,VG^:M<\W@-`VONLO>W';4UK
M7[';:V?\%ZJV['7;',NOJJ98"R`V-"';OTCWL_,_D)*;%/4\`L:/6#=!].6=
MO^$#5-^8XO+<:LY&QVVTM<&AIB?I/]KW?R53>_*LH(Q[:;AMVM.W61_HW%UE
M+K-OT?4]F]8S.IXEA.)TBS[%FU;FFL2XL>-_MR<1[=E[W?G[;?5]?\])3T^1
MFXN,6B^P5EX);/<-U<@_MCIOI"[UP:W%X!`<=:P76-@-_-VJATW*SV5#&?CU
M_;2`_*87GV[AM;E76N9ZE_K^G[-F/[/YG]'_`(/1=3GFPOJRF>D>*W53^]_A
M&/9XU_YG\M)2S.K].L$UWM?[=\-U.V=F_P#J[W;%$];Z4#!R6-/>9$>3Y_FW
M?UTQMLIN<V[.IC?N])[6M<&.]S:Y]3_1LM]^S_J%>:YKAN:0YIX(U"2F--U=
MU;;:CN8[5KO'[U--PG24_P#_T?5-K?`<S\TSBUHW$<*2R>O=0MQ,0F@[<BUP
MIH=`.TG^=R-KOI>A7O<QO^$LV5_X1)3G]8ZKU/.R;.E="<VJZH[<[J=@W58L
MC=Z%#/\`M5U#8[?L_P`!_A5EXGU"Z'0XW79>=DY;SONR/6-9>\ZNL/I#=[OY
M=MBV^GXU=.+736-M3`=K29)+COLL>X_3MML=ZEMG^$L5L!%34PNF8.)=Z]5U
MQN@M]2XML<6F-U;[7,;<]CMK?IVJVYMEDAU5-S`9:2^.W>NRJW:[^V@93>H&
M/L;Z6^W47M<X%T^-9]OM5.QW5V6N:<C!#0#&YEH=)!]/=M=L^EZ:2G1_3-:Y
MK6TX\R0X$V^X_G>DUF,S_IJD.B=,>Q[<IEN>;'%SWY-A,EWTMM=7H45_];J3
MTLZJ^HO;DXSK`;``VMQK,EQH!W$7,]-OI>I_UQ3+.OQ#;<($N.I9:8;[X]N[
MW/\`YG\[_2)*<3+_`,7W2?5^U]#R,CHW46:TVLL<]@,?1<+"ZWTW?N,NV?\`
M!*YT#KV;E9SN@_6`'"ZUC#U!74X,JS*]=N3CO;[]WMWV556L_P#;G'Q]RL6&
ME@OVFW:WU2R0S?'Z3T]WO]/=]#<L?ZR='JZCBC(9+.J=.:^[IN2SZ3+0/58W
M;]&QC[*J]];T%/2#&Q'L:/28YK6AK06@PT:-;K^ZB,8QC0UC0UHX:!`6;]7>
MK-ZQTC#ZFQOIC,J%CF=FV#V75C^K8UZU$E*22224_P#_TO55Q_UIN<.K]+HF
M&&JYQ'B=]'_4[5V"Y#ZY5OKNZ9F!L^F;Z'.':6LR_P#J<&Q)3M4M'IM^`1MB
M%@6-NQJ[&F0YH5L-14A].3'BN>R,K?9=<#[/4V@_'=M_Z-:T_K!U6OIN)#71
MDW@MJ'=H_P`)=_8GV?\`"K&ZIBV=.Z%C>K[;KKB^QO=OZ-VRH_\`%L_Z:2G5
MZ3<7&^AVCZG`[?O8[_I-6@L3JEC^C=5JZB&EV+E#;<T?O$#U6#^5M'VBK_KB
MVV.996VVIP?78`YCQPYIU:X)*5*KY3RV'#D:CXCA'*I=0L+0QK=7.<UK1XDF
M`DIJ?XOPZOHUN,3+<3J&92S^J+7N_P"JL75+FOJ)5'0:LB9.;DY643XBRZWT
MW?VJVUN72H*4DDDDI__3]563]8,!^;@6UTUMMR*RW(QJW':UUE1W^@Y_YC<E
MN['>_P#<O6LHO;N$<$:@^:2GD_JUU"IKCABPOJ<T6XKW:%U3_=7O'YMK/YNZ
MO_!WUVHWUB^M=71\BC&J:+KC-N0R0-M9:X4M+H=L?;;ML_XBK_A*U2^LW2LG
M`M/5L)N['%AMRJFCWTN=_/9%?IC>_$N?^GRZ_P#`W?K=?Z._)53I.#]6L^ZS
M(ZF'YF?>[?;;D6DL<3QZ5='HT^GMVLK_`)"*G0^KW2,W/R1U[K4.?9%F-21\
MZ[G,_P`'76W^BT_]>M_2I?XP[?2Z7C.\;W#_`,#L708E.+BT-HQ*F44,^A54
M`UHGF&M_>7#?XT<W+9]DQ+&M^Q6[KJKA(>VRMKJ<BFS_``;F.9=5?4[Z?\X@
MI[K,PL?.Q78V2W=58ULQH00`6O8[\VQCOH+B[\[K7U3=;@61?CW!S\*T_1W`
MM+G#G9N^AEXW\OUJ'KK>A96=E]*Q\SJ#&4WY+!<**P8K8\;J*7%_O?:RK;ZS
M_P#2)NI]"Z)U%WK9^'5=:!M]4@ML@<-]:LLL]O\`624MB9^-U##JSL4S3<)`
M/+2-+*G_`/"5/]CUA=;ONR;AAXAC(M_0T<_SMH<RM_M_[BU^MG6?\#B6*O?9
MTOZMLR:NFW6FO((<<>Q_J5UV?0WTNCUM]K?T?I[[/4_1K4^KG3;Z+:\OJ+2S
M*RF.^S5V1NJG:Z_?'_:C)J8Q_I^_T::'U[_Y]%3T&#B48F/5C8[=M&-6VFEO
M@Q@#!_U*LI@`T`#@)T%*22224__4]532!$]^$Z%D8M&2T-N;N#2'#4C4>;"U
M)3)S9,@PX=US75/JE5<76=.+<6UQ+C0X?H2\\V4N9[\9S_\`">G^KV?X3']1
M;HZ5T\-K:*1%1)KU,B3O<)GZ&[_!_059MOV5K\4L#'#=Z!;]%X)W/<V3[;6;
MOTE?_7:_T:2GF,?JG5>E"RO,K#JZ'!CG;P6@NUJBW3^=:?9N57K/4</ZR8=6
M'90;&57UW@LETAIVWU>S_N1COLI6UBX->7G9-UHG?9Z&.3#BQK&MJNR*&@;:
M[7V,]EO\[^A6JWI?2^H!]F7A8UF2UQKR"^EKG%[>3O<UKG->W;97_P`&]%3A
MY/UR-;_3=4VBR)VVN#('YOM="J,ZAUWKC6C`8^REY(-@#JJ@!^<[(L;]'_BO
M4M_X-=77]7NBUR*\#%JGDU4L8[XBQGO:_P#EM1'Y'V,1F[[6@Q7<UCG[A!_G
M*J6NV6Z;?H>G9_@_]%6%.3T3ZIT8=PS,MPS,UIFMY;%5/_A>MTN?;_W8M_2?
M\2MZW':^LMD[@0YKQ](.:=S7)L?+HR2X5%TLC<',<SZ7T?YQK/!'24T_M]H$
M.P[]TP0T-([?1=O;[=4XSWEF]N+>1`,%H:[4N$;'N;]'9_Y[5M))33=GW-?M
M.'<03HYH:1&TOW'W_O-]/:K'JGT/6V/G9O\`3CW\;MFV?YQ$224__]7U5)0=
M;6PPYP'Q41DT'AX\4E,WNVM)[\#XK'ZIFT4L>\O9&-JS=!_2_0J_M^H]:POH
M=H'@\_@AD85L`MK?NXD`RDIS>C8[:*6,&V*F>[8(&X^YSO\`I*QENRV7!M'K
M@O8P;ZVM>P&72=EI;_USW?Z/_K=UF-CUSZ=3&3SM`;/QVHJ2G(;?FR2X9CFC
M7;Z=(,@O>YNX?FO;LJ_]6*1?EU;I^V6,<TPUK:B6AP_>=[O5K<?W[%JI)*<J
MC)RVN8Y[<RT006OKI;)$>YVSTW-^E_45IV=<UH=]CN<#&X#9(]AM/MW^[;_-
M?\8K:22FG]OM^T&DXET`QZH`V:G:SW2/I?2]G\VFJZC;8T3A9%;C.C@V--WY
MS;'?2V_]-74DE->C*?;9Z;J+*X'N>X0V0&.ACC#G?SG[GYBL)))*?__9`#A"
M24T$(0``````50````$!````#P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H
M`&\`<````!,`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'``(``V`"X`
M,`````$`.$))300&```````'``@``0`!`0#_[@`.061O8F4`9$`````!_]L`
MA``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`@("`@("`@("`@(#`P,#`P,#`P,#`0$!`0$!`0$!`0$"`@$"`@,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1
M"`%!`38#`1$``A$!`Q$!_]T`!``G_\0`KP```00#`0$!`0````````````8'
M"`D$!0H#`@$+`0$!`0$!`````````````````0(#!!````8!`P(%`@0"!@4'
M"@<``0(#!`4&!P`1""$2,4$3%`E1%6%Q(A:!,I&AL2,7"O#!T4(DX?%2,T,E
M&&)R@E-C-#55=AG29+3$-D8X$0$!``("`@$#`@8"`@,!`````1$"(3%!$E%A
M<0.1,O"!L2)"4J$3X6+!T3/Q_]H`#`,!``(1`Q$`/P#HN^0Z\R\)S+Q57)O*
MH4+&;KC';YLT9:>8_*;B!C^0O2&5*XP9ORSW&5^VD+3<48!=PFDSD2"B#(55
M`-W)D#4:G2+LE.<OW.<4;E6\\Y5R-3I#Y"\SL8S%E<E,V13+(&-N-G#2X9YQ
M#CBOOH?-B$9#5"^R<26)=I,V!&MFFGC=]/$FTD`BU2\8ZYP=&C_)EROM&+(N
MQV=+'F,X*2R'&P<WR2M&`[A,4*A*.<"6+)KK',WBV@9UNKM2>/E2!0JS>1/9
MTG299-&/=Q;:?])%<8F7G:N;G+G%%=Y;6:+NE5M5EC^9&.8V#JF1<39!@G&.
M,%7/A_1,D0JM3J]OM=`:U]I=;RU/'1K.X2]535D&<R0KA2<?MV2`Q./LFGR2
MY@YCHF.^+5HJYX'$<=FS%%JR'<\D9=P3D6T,:I>86@TBTT+!TIBNKW^(GZ5>
MLM3-G?MT6KR9?N6IH)S&-P=R+ALH!))R1W".V\ILBY`YT9<R>^L;6[#$8"8X
MUX_V9S=HVFXDG[/Q!Q!FM[0V4(\NSZE@YAK[DE>&F)5K$-95^^8N%EW0(G08
M,A<8B%JV4)8>*-JF<1<CN9LMRL6P5QNE,\QEVLV79W'F-<YSW(G$<1?FTQ&3
MBD;(8=R8D_>S$6K2:E)5R%7J:;LQV!R>@\*7SU,)&U+F7SDE\BY=I",)CJY/
M>/&-^8UN?Q%>PY<8R5Y%67`&3"4S&5,IA'&4)-/'4GD)C*MBJ*^I8`.Y1$R"
M($6[428G#7U/FYS!R#*8UHU&M6&[&WR%G["V."<BVG'/)\9CUBVR)QRY,Y5R
MICTF-IW,#.7?7+"EPQ!`M5Y#[\W02+8$F#UL#]JZ*<8AIJ+\AG)2>@X?)4TV
MJN&FN5J?PN?9)RK;:AFO)V)\$JY#XX9[R39)1+$9<G,4(1C:\H4:&JS=6/-'
M>@O/(#*KR#LC+O+B)?\`,;/.8ZC3^$&6Z#*S:,W)Q7(+(-L@XR`R-3:E;Y*O
M_'5R8R76HB[XSL2D1;TJPGDN#C'C>#L)"2#-\W;%4!-\B4Q23'*/[_GWR]K$
M<ZKN0IK#-,3;VK%PSG(]7CYE.5QU1(3(?$8<^Q54G,91&7)*=>R\_D]L%59R
MI9I%%3W1&Q6GW-9FFJ,1M<D\Z^7]5JV9\DL6]1+CRK\J<<<=F+M'C]9D9O&-
M,LG&[%V;9[.-Q9Y2S;AQLI#KV^X_M-O%3BM:/$/I-!1\Z57;'8*C$X:BD?)3
MREL>>^.]"F<?0$*C?(.D1^6,=/\`#U]B'4+*7+C;=\N,\@T^\(W^T6M_4WE[
MK\=%IMCT]5-#WJL4D[D99NHH0N)R9%I\KO-(<0M)J1H%:)9/\0IJ"FLHP^"'
M[_#\6\;XA"\U?&L8>;Y,U9:8G+3?/7BU_?NX*UP[9G]N5KB\V[;B#)ZS*0-?
MY;\DLK<]>+&/[F[_`,&X)GG2[Q=DXYQ%8R3'VE]15?CVO.2H2^Y*R(I86E(O
M-'FLK6)RUC8U6!;IMI2MMC)J?<6$@1,F)BM;F#)-X0Y@9NJN8<KYPQ_P\:\N
M*]$7BUTR_9;HS6H,B_'M@*SX_IB60\<R4;8\18IMN4IF<D)1W%2$.U<V,B*2
M[@%'BQ5BSJ8[1W81?,[D%<H;'&.;KGB8B7."^6#SCQD*Y<K.1_&%TSJC#E&>
MH<=<_P"4VM%AW4IF*<AJ6]0!".LT0JK8J\1%XX*=1P)CCB+-.9G)3/?&MIAZ
MKP-CI4,:0P[E&U63,U[P]>LFUW(F9,61^/$J?@:%JN.;;4G-3MF=7-BEG[-=
M5RNJ=O#+M8UJY=")D"22FXPOS'Y;73DI2JS?JC2*CB^Y\E;/Q[E,;+T"SER/
M0%(KX_ZERW5GY+)Q;R:N2HP^1%W57%`*ZBDJ554PN3*D1(F+)CZF/RMDKEK(
M<T;KBNG\@7M84;?(WQ]K-!AI"F6F0K%7PG;/C9S'>IA6?JL)D*GDR/CJ9R>T
M,!6Z[QNP"WU\SM8ZAP29-2S&.O#,XO\`R6<L,V9PXV4NWX=AZU!92Q_A2<M$
M`UHDBS--P^0L`CD>^YGIMQDLIK6:&K="RJ;]MC$KU"3C4DF+M-U/)R"[-(I+
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MI='BVLR*B*]?08N3F</`^W$5,F,0X^/\KY_F_BC99(5OF2IRZS')7(,=DK)]
M2B\@N<EP?'QW\C5RJF2K?C6O3!K7D*(2I7'@7:D"R,=T]@H1FB5`3&:)%%X+
MCV,BZY?77"F6D:K@+D08>'.3<QTFB57D/R>;9JY.1E.L#?C1G_)>9(NEVRZY
M#@,@7BMP\O0J8HD]=6&0BHJ4F9!)0X(-5VR1<3&;.1`\MN6%PRI4YW)SV2IA
M\GUOX>K7$8&;1N4J"VBDLL<M;#0L[72IGBKW`6G["@S7:J3D3,E?-UF4S$Q<
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M=:7&^2<MFH5*HK`A66S.06*LG^Y"3AOM^AB=D2I\EW+.WX8O;=_+4&F,C6S)
M]7C.1B.%K\6/=0R?%"JY@QS6(BIT3,=C+"Y!N^2;%)U^,G&%BDV0*PPMFR2\
MF='U65]9PM5_<]^_^UG^\_W#;_\`%'_P`_N?]U_=IK]_?O[_`,.OW7]P_??<
M?N']W_N'_B?=^K[WWO\`>=_J]=5GR__0Z\.5?R%8YXE9"GJ'D-E`,O:\7,D\
MA*G*SUZ2K/[VM5$FVD-'8@BV*M;E/2D[3[DRB<B5986_9V^S5W[@+)DJXWG]
MQ^"!C)"T34G7)M2QTFB3\$C`V&;3@L@W7BV?F"TK24LUAFZ$LU;87;K/!?II
MD;G<)@V'L<F!'0Q6DQO\E_$K*=BK=5K-FR0UE[:]CHV!_=.!<X5"-?2,]B9]
MG.J,"3=CQ]'0OO;OBJ'?S,$E[COF&L>O[0%3`F"@Q7TV^2CBR[A@E&\EEA62
M'+\-@K]BDP!FTV4@R79L8V#,-9A/\+@H8WP49_'U9=OD'01XMB>D9-8Z2I%"
M$9/6G,L?-+CU7,08GSB%IG[/1,YQD?-8F)0\>9!OEQN\.]ITAD)S)Q6/:G69
M:\)LH&CQ#N3E#KQZ/VU!N8CCL7,FD<8O)++_`"$\26Q'KAQE9FDPC74J+^5-
M#S@Q36N0_'QARD=9`/(%CS-E,=+84EV<FVFDS'9.G#M)BB<[XWMP&*<C%O*/
M%^8EF+2D,\EJR)[9.4>Q1-@Q!DVH2^.+/"4V*R"$;E:+M-6B'V-/OU.L$<^B
M%9DC1&72D6P-#K'6(41@E.1?+>J<:+I08B^0JW['L>+>2>7+G>FSUVLXHU4X
MV4>!OEB60J;"#DGUK6EHB66[4T7#=5$S8`(1P90"E$F3)R/RB\<4;EC>L1R&
M0E(RV6C)]>O]DM.-LBXZ3PJRQC@N&Y!N[+D."O-/A9Z,@)['-IBI1D[500:*
M13E=YZPE9KI@R>M.#7/D.XTVNQ4"FP;[*;F\9'MSZFPE#<8(S+&WF,?Q\%2;
M>M,6^H2=(9V"FTY2CY#BIQ.;DF[:*/%KG4!?O0733&*U=4^2CBQ=Z_-V"J2F
M6)M.%KE?MR<2RX^YQ//V*KV6WS]#C['38@U`*YN%=;VRL/FCV1CO<1\?Z`JN
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MR36E3=OD3XKX\AY2<MMQL,8QA9[,]9DRA0;F\>M9K`#RML,H,31S.&7?**P;
MNV,B)`1,WO#*&!#U!(;88K<&Y[\:6=L:TRP62Y4R84C$G<JO><392I\'4)ES
M1)C*+*AWNQV"H,(*D9+D,;5]W.MZ])N&TLM&D35*@(NFA5QBLR`YP8%MW&S*
M7*RK2=L?8FQ)4[=<;'(3="N5%?OHJHTQ*_+*5QG>X2N#8D9BM.VRK)PS%=LJ
MJY*W,H5R19%,8N<>3*,/DLQ_!7BSXRS%B[*N/[[5;-@K&:\)5*+D/+Z=BS'F
M;"%CSDXH5*-3J"G+6)M4H"I2*)I$6+?W0-A74;M$CI]XP7DO\C_%>`F+O79R
M?R1$6"A6#'=?E:](8,S.VL<PIE7):^(*+*4BMJ44+!?H:>R$W/'H+PS9Z*HB
MFJF4Z+ANHJR>M;"*^0_BQ.R&'8:&MUOE)_.!YM&FUN/Q-E)Y8XYQ6LCN\.6!
M"]0;>H*26/\`[)EA@XK[M273:(-7K9=14Y&J"SE,8O+7H_(_Q4>QD`_A[5<K
M&]M%6I-H@:O5L5Y'L]VDCY$L>0JM4JDWIL#6I"Q&O[^3Q+:3K0GM_N#%E79!
MVZ30;-CJ@,5XOODKXA,H^RSI;[9I&J5'&^.\J6"ZP^+<G2M-BZOEL[=OC)K(
M6-E4E8Z,MEVD7(,F4(Z.A+"^(JW.W(JDJ4C)ZWX*=GSYXSO)3'D.%FNC)WD=
MO3W#(\OB'+$(SIY<C7V:Q9C0F4W\M3&3/%9LF9)KCZ%KAIX[!.=>-Q%D99$Z
M2IQBEQ<.6>$J'DA]B.SV"589#:SV#JZTK1:U/.7<Z]Y#SUJKF-'->4;L5&TO
M#NI.B382+U,_M8=*)=*/%$2)]PC%1JIWRF\89;'-1NUKL$A&/)S$\5DV<_8U
M+S!?\?PCZ5Q3*YM:8]99(?8HI+>0R%+8N@GDW%0+Z/B+#)1Y$C$CB*NVB*TR
MOK<MQ</DQXY,ZSE>0Q9+N,Q6_$3?,[V?H]=:S4>Z=LN/%)H62LO.&,RM!/H[
MTH:EY'BOMRYP*RE)IXC&$<)KBL9"IBK`(F5CIV*C)N'>(R$3,Q[.5BW[8W>W
M?1T@V3=LGB!]@[D7+98IRCYE,&B-AH$A8*#3;78:':[%7H^6L>,)R6LM`EW9
M#F=U:>G*G/T67E(LQ5"%3<OZC:9!@H)@,`H.S@``(@(`K]`:`T!H#0&@-`:`
MT'__T>V[)O&'&V6+;;[I:%[,G,7;CK?>,,R6*E&C1F7&V1I-M*V!=DBM&.E$
M+,1TT)[=T8YTDR;@9$_CHN4>IKXS>/TW;&UK6L67F9$9"K3SBKL;JP3J,C;:
MCQKF>)D9<G\0O7'*BEC4PK+)QZAR+)MP69(K)))&.[!RP>U9Y/C8X[%;PK4S
MS)1D(.4QG+-02N"+%<[C%/%VX\1:R4S^,AF,BV*KBF\O5'*C99!P,N"3I%1$
MI/2$9K`PW\97';![RE/ZC)9(=.Z)E6C9BB#S$[7/06MN.\,9"P'64W<=!U"#
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MFXMY/)H)9(<6I`K?%.?<.)_MJ69Q8_M+D?2&=`R$H87<5);RZ,$Q(,<MT(V7
MW.=-8![0$N#/W3XW..E^LUDM%C4O[AS<K$ZF;='(V5BC$6*&F>,E>XCVVB2#
M48(ZI*A<\.5INW?@@HC)D>BHNT>->[L`9KUP%\<7'?CA:*)=,?!<367'[B^K
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M";\JKV47<-FJR#![5O+O\9O'Z\T'$N.'5BR_`U[$?'BO\6V)JQ=6$7(7+#M6
M6I#^`@;TNK7'B,DYCYS'T:_%=DE'F77*JDL"C18[86#-Y;NU_'=A:VI9?C'%
MTSG#U/,$W8[>_P`?U_*#Z-Q_3\@7+(-9RO;LB5&HC'KQ*UMGLDU-M,BI-DF6
MC)VL\!DW:I/WJ;@9I%7/XL>/-^FK5,66W9M>)6R2R?..X(EXATJ]'6+-`U%Q
ME*PP\:%2$&LI<96E,GJPG.JBW<"J5JF@@?T08/:G*M7Q[\<;AR2D^4\G$6-K
MDZ=18*SRD+-(PK25L,/1CXU@[A]ZCXY&_0T_"TD$&;<D9-L8[U&;9T=J=Z@F
MX*,W&"=J7QO8!H7'/DCQPJJUK)7N44#:8C(]DFGD4ZFUG=AH"..FDVU80$15
MZT28A81DV.+PK(DA*.T`<R+EVY,986#VN92@B>$-.DLGTS/V0+1;GN8(VSXE
MRM<6-<EV#;&<YF?&."[Q@4ML8PTC75["UCG]/R-)(F:E?HI'%%JJ*9%2*BJ,
MFRIWQ2\8Z/9_W9#2655)(EYQU?&Z<A;(=TW1D<69_8<E*DQ5.6JI/Y5LGDIH
MH9X[?+NIB08N5$7+U02-U$)A?:M_/_&/QLL[?%K"=<9(D8C$N2[[E>`AG%M:
MJ1SNUY!SU+\D)-RL4T&+FNN8[)<RH+61KRL+-FBTR1[E\Y:]R9[A/:L.T?%A
MQ(M5?RQ!NZW8&RV6^0Y^4$E-%D8B8?5;*AVEA:G5J$7:X"Q5%O5A&\61;[1(
M1DBQ!S9I)4"=ZJ0HL'M2\@?C\P'5J/D_'U95O\!7<L4#$N.K"6+MZC=ZSA,,
MM)9K5%HMW[$YE7,B:;<*2Z+\'T?+`H9%PV,U450.,FBJ'Q$\-:-:,56^O5JR
MM9C%+AD\:]TC`F9VEW%9-MV88=2;9DK":-<:1.0KW*O$F-6"N1QVSDK!9NK'
MH-VB4POM>4L+SQ7Q!D3D+ACD[9HF1<Y3P1#W&'HSE&341@CIW&,=PYG\]""F
MHWEY6LQTQ*IPZYC$,P^\OA`#&5*)*F>+$6,8?$KP\Q1<Z%=J_7+))2%#I%/I
M165DD(&69VP*)CDF):S8K>["LMK`\EV>/FZ$>JU:/F4&[]J@NO'J.4B+`P>U
M)Z'^)_!6)\99.J?'U_9JA<<D<9;1Q4/<KA/*6LT32LC72Q6S(E[]H:.2^YY/
MGG-J477>K#Z+]:(C$UB%(DJH>87VM[6?0$'%UB"A:U!M2,86O1,=!Q#%,1%-
MG%Q+-%A'M4Q,(F$C=HW(0-QWV#59;;0&@-`:`T!H#0&@-`:`T'__TN_C0&@-
M`:`T!H#0&@-`:`T!H#0&@-`:!EN25\L&+..N?,GU--HK:L<86RG?*TD_;`\8
MJ6"H4:=L,,F]9F=L"NFAY&.3!1,5T0.3<OJ$W[@+.XCLRY,WS%ERJV/L^0#:
M/?96M[YGB-],2%+J]F?0#>[<6<7)QD_"U.V7^M2UI=7//$S(-2QK]$YX."3!
M9JFL=5<HQ\&4IWR'3^4;#@=G6:K4(B/RD]@'3YU`75'*5?""G93B>NI%&LC.
M$J'VR_PD3R%7;2$<5!RBQ7025%9<JQ"EF5]>UKNJR-`:`T!H#0&@-`:`T!H#
M0&@-`:`T!H#0&@-!_]/OXT!H#0&@-!JR3D(I-N:TG,1:EC9Q;*<=P!)!H:;:
MPDD[?L(Z8<Q15A?(1;]]%.D$7!DP156;*D*83)G``RR/6:CQ>.([;'D&K9H]
M=,"+I&>-F;]5Z@P=KM0.*Z+9ZO&N2(J&*!%#MU`*(B0VP>0RD8633A32+$LP
MJQ6E$HD7;<)-2,;N$&B\BFP%3W1V*#IRFD=8""F510I1$!,`"'E,S4-7(I_.
MV&6C(&$BFRCV4F9E^UBXJ-9HAW+.W\@^50:,VR1>IE%#E(4/$=!I:G?Z)?F:
M4A1;K4KHP7CFDP@^J=DAK&S6B'\C-1#&42<P[UXBI'/):MR+5)<#"DHX8.4R
MF$Z"I2@K=!@LI2,DCODXZ18OSQ;Y2+DR,G;=T>.DT44'*L<^*@HH+1\DW=)*
M&14[5"D4*80V,`B&=H#0&@-`@,KY`88FQ;DK*DJR<R47C2@7'($E',CIIO)!
MA3:[(V-XR:**_P!T1RZ;QIDTQ-^D#F#?IH((M^>LM"Y"?T^Z4=([>#NF2J9.
M!7X'(\8LX#'A481&=H]MNE6@\69"<6+(DM"P@PL=.C(Q0SJ3IX9-LR?*)1K!
MRX;ES@C&="=P32GW:CP6&L=/CKTC[37UW54K^,V'):(=5)F:*MLO$/G]?;\/
MK2U3!L^<-5>QD9-PHFX.HE4P4\?RVCIRV4^EQ6+<AL9N8L+"&N1;&K0&K3'"
M<A?LQ8V8%GG4%>[`G-2,S9<'3H-$X/[L@1!))1VLU!9,##'U(6.YYT=WE/-V
M.DH%U81QI8J74Z8VILI%/[7D.P2V58+`][C_`+19'55A*W_A[F*TQL8Y5=R9
M4%&SH'0'`@=HC'3\BOD/P_.+NVD/1\Q2#U$])AVC5*MU5(LG?KW,XLKD9C)"
M1<W="'CK8QL.8(ADY<R+EE7Q6*Y%"273;F4%D]656>>M`>8ZMM[NE(O-*=TE
M&^2$]5Q"LS\@2,I<+G:W%,Q?15B-%/9"1J.`99;T@5(1)XJBCZADS&7*,%?"
M<Q:59"Y2:,Z;D*!E<7TG)%LD36B)@CPKQYB5VG!9%K;>7J5GM#4DS3K<L$8N
M1<R",BJDNM%*R#1!5R48?4)R\KMFHN5+I7Z!=W2&,Z#D>Z,3R2E2BHO(KC%4
M[=:=<82IN$;1+3,6K'W6C.8_UIN/C$U"K)+H>NB)S$&#8UOG]"#6S3&0,09%
MK,G(V.>KU,B(=UC^P?O=_7['!UV8AXER%Z9IQDY75;&U4D!E?M\:*8G%D\>@
M0PA,KZG1L/(NPS9\>$Q)`U0$+I@F4Y&+269IJ:QVU:4E@I2_8UYVV1@Y5[`3
M#Y&WB>4?O"BE7`;I^LT>"X[4*F"3><^<6DL,K58:A9=M,XUMMXI4`V@X6E)L
MKM.8R;Y/=9!2KD[/7Z$KS-*KI8BF1-]X=Q1WX$2,P*[(<3%&&EK_`,@^/9&P
M3->F<>9*C%8RZ2E?+(1;&OV..1K1[C)T*CW66(PL"<XSCK_98)^BB@BQ<KQ)
M6BJTF#1F0'9V3UIVY3E?38>LXWM#^E9%2;9(Q[9LN(1Y6U)5DJKBNH2%$96"
M]VD$[R:/-'LD,EPKH&,4XE)I5!V()LC+(K(IC!NG_,*5IM"Q!>\A8UD8\,K7
M>_U[]KPDA"/;+!L(F4L+.B-BB,^K5Y2;G"LV";M095LT2,X.KNF!11*,=L7_
M`,<]=<(WZ*:4:TMK?2(/.-C0;3I:]#UFR*X*OF2JO8J%#3*MI5D)6[+1^,'B
MCA6-924;%^NDX75,D=--483G8/FDHQ92;!8KEC(M&SYDX*4Y2KM':)'#98I5
M"D4*55%0#`!@`0WZ@`Z(R]`:`T!H#0&@_]3OXT!H#0&@-!7=D?AKDVV9*OV9
M*[GJ;@;ID%.XTES!`RB&55J^(YFL5V*@HBI6&$KK'*K&ULK3CJ!G55%)Y2(0
M<O)HC5DDJ^%UHN?H;_('`*_RMBE)B@936J;&0C(J"29,+).Q+QM"5BY\K9RC
M1OW5_`7148^AL>04&O&()$0]H[J")&JC50[-_'1<E3/\-,MN)2#G&F5$+2+6
MWYPM%TJ=IM>1X2O91#(=GO1L:M+/(5V0<R,83$M3GX,S/V:7<5]6&J;8[4#$
M=MZF8=!AQ>N;'"TU2)'(J5UR,OF#'N6V]XMY9UZVL:^*<LTS)]8K]C;.)*1=
M1K&6)30CW!FHKE8`[,X227.D4IQGDF9+BKDZ<R#><R_NK'U*R;9*K48>K&IC
M*YLX&IO:].\B)%U]_5AYNHR60C2<?E^+3>OU`BG3Y>/<J))L/52*F,F_IW![
M*J4RLXON5B2M62M](EX6E-+':%H^-JT>Z:JY#K3_`.RQE!K$L>\L74HS<J(0
M4<W=-7YR+H"*K@RL7,^#>K<,\F8UQ[-2%SY!P%99(5.H_P")]\7N-EA4LKRT
M9*\</NPY+D+FPM58@HQ5CAR:CTI`\=*F<HW5V5PT],9!*7&<^$Y^->#K1AB/
MNHW:]R.1K%:WV/O1L$O*34L_90-)PUCJAA!J.)A<X"DI=("=F0,BFB"ZDT=9
M4ON%%1&I4F=$&@-!IK'7H6W5Z>JEDCT9:NV>&E*]/13D5`;R<+-,5XV4CUQ2
M.FJ"+QBY43-VF*;M,.P@/70,;C&"Q+FO#M&LDGC*K2\%96TI;21ETJU2G72L
M[:8>=JMLL4L0L.2*<6:W0D[)-95VD@F9\VDG2*FZ2ZA#%YE[*H_'C`"@LQ4P
M;AY08^`E:FP$^,Z486-6G4+6UG*TS[H0?;0$RVODXF[9D[6SA.9?%4(8';@%
M"9*=;%V,W,[#VAQCNBKV:O.Y)_`6):HP"L[!OIJ1D9B8>P\N>/-(1CN6EIAV
MZ<J(J$.NX=+*'$QU#F,"6O\`Q_P[DRL0].MN/JH]KL!8:W9(B-)7X5-LQ=UK
M(56R<1DV1-'J(H0\[;*<Q5E6I"E2D4TQ(L!M]P+EL6>#L*1SYO)Q^'\6L9)F
MVJ[)I(,\?U-L^:LZ0XJ[NEM&[M"((N@VJ#JCPJL6F4P$CU(=D9`$Q:("F3+$
M7X_8&=2$C+.L)8B<RLPTL;"7DU\;4U:0E&-P-9S6YE(O5(4SE\TM)KM-#(IJ
MF,1\,N]]8#^Z7]09*-/%V,TI.U3:6.Z*G,WIBYB[O+IU&`))W&->(IMGD=:G
MY8\'5A8NFZ14U$79UDSD*!3`(``:#.B:%18!JJQ@J74X5DNA--EV<37(>.:K
M-K),O[%8FZK=FS1140G[!*NGST@@)73QRJLJ!E%#F$$V&$,+%KK6GEQ#B\*D
MQ2.BRJP4"J!76:*LG!S:B36$")^V-TE)FL1KLQ2)``NH]LJ/ZT$C$+F_+)L&
M'<1VV,K<):L68XLT-3FGL*C$6"D5F9C*JQ!HU8`RK;"2C'+2#:>Q8H(^FU(D
M3TD2$V[2%`"!/#N(DIY[:DL68X3M$C(N9B0LB='K))Y_+/(J?@G<H]F"Q82#
MJ1=0EKE&:BYU#*G:R3I(QA3<+%.&(I@W"BLJG.JX?Q:I-I/%I%*84Q_4SRJ<
M@X81D4X?IR!H@79'B\7",FQU0.!S-VB*8B)$B`4N;\MM,8LQC86M58S^.:'.
M,J(=DI2&<Q4*_)M::I&BP&./56[V/72KQX\8MKZ`M`1%+VR7;MZ9-B,F3QSC
MV:9P\?,T2F2S"NO32-?8R=7A'[.#D#JBN=_#MG3%5&,>G6,)Q50*0XF'???0
MR1L]Q[PG8&]H3<8PH\>]N<3:(*S3\%58&$M$M#7E[+R-XCUK-&QS><3)<'EA
MD59%1-<B[A>0<+B<%U3*Z&3RZ`T!H#0&@-`:#__5[^-`:`T!H#0&@-`:`T!H
M#0)^V56NWJK66DV^(96"IW&OS-5M$#(I^M'S==L,<YB)N(?I`)15924:[515
M+N'<0XAH(Z\4;58B5:SX-R'+O9O*/&ZP(XSL$]+*>I+7ZD#'(2^'<LO%1`@/
MWN0<<N69I=PD4&Q+6RF6:8C[,VQ:E5H@T!H#01HX<?\`^8,+?_1K;_\`5O-%
MO=27T0:`T!H#0&@-`:`T!H#0&@-`:`T!H#0&@-`:`T'_UN_C0&@-`:`T!H#0
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M(P'ET1)%9`G'T`\6;S+]B1R8@*1[1%1B]>CC'"P7590LY'.D\%Y(QSRT1*="
MJ1Y(W!_)`40*"88?N-C*-"R3(E[BBN3!.4Y@'"RIA*C'56SV1X?O,DF719SP
MFGHC5/9R&CMP?2L>U,'BFL[1(KY^"0G]01Z#Y:8IDG'.2*:U[NZ8*H8H;[(-
M7J@"'X*@W!`=O_.U?6_">T)I3.6-TA[5)U$IO,#*-2"`AX@('<E'5]-OA/:?
M*/7#K+E%#C;AN/\`NP&=(U!LFHFD4JQB&!T\$=R(J**#L'T#3UN%NTS4LV]^
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M*H[0)*R$1`NH5C.2C-@90'3F/B'MDCTG*Q"BF@H^0*<0%4@&#U<R;!H[CF#E
MTDB\EE7",:W.(@H\5:-5'KDB(``@)D6J)CCOM^DHZ#V=NVK!JY?/G+=DR9-U
MG;QX[63;-6C5LF99PY<N%C$10;H(D$QSF$"E*`B(@`:!L:5G/$&17;>/I&0Z
MQ8Y%X9_[..82)!D'B,:U8/W#YHQ6!)VYBE8V5:NF[LA#-7;1RDN@HHDH0X@Z
MV@TZ%@A',_)U9"58K62&AX.P2L(FX3-)1\)97MACJ_*NV@#ZJ+&9?U.31;J&
M`"JJ,5P+N*9M@])>;B8%NV=S+]O&M7<I$0C=RZ,*3<\M/R36%A&`K"'IIN):
M8?(-&X&$OJN5TTB[G.0HAM-`:`T!H/_7[([#S2J52RY?\>6**BFT!C6W.JG;
MYZ-MAYNYP"#/CQ`\AUKQ,8OC:VK*M\?K1E@0@&KQN]=OGMB7;M$&2AG*>BX9
M-ZYWX$HT-9W;EQ>9*QU7&&1\I2%#:XWO3:W(1&,6ML6L,?)1LC7VGV)Z9S2)
M%!-=Z9!@!B-SG<$3D(T[P8KX><_>+Y"7%M%7YS-SU,F9&N/Z\PI>0G,JK-14
M?D.0DRD81]0D94(F'0Q/9%'[TK51)FWAEUS@*1VQG`Q2RCN7V#I)Q$,6\[8U
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M)3,JYS%6"&:II>LV-+`"P)BU?`U&*F-H@T#'YPP+4LY0\.22?S=,OM+?+SF+
M<O4A9C&Y)Q795TDT'$O4)E\QD6OM)9JD#66BGJ#N'G(\3LY!JY;',GHLN#48
MVY&SE9MJ.".4R,#1\T@R>/:3<(5!U'XIY'0$:59=[/8C&1>2$DPND'&D(M8Z
M:Z56E883&7;*R,7V2)DS2XG,Z:7-7)S#[^!MN-)*,9Y"8V>#FJE:*6FR_<AY
MN%GH]S$3<#+13-4K!FVDXUTJDJ20=M@,F<0,'Z@#72?CM[<[^23I`O`>=N2U
MFKDG@E0AT;)@M2-IBU@NSQW)V.TXZ=MU7&)+S)1L8O'M'<M-4IJFSDWRCAVF
MYL<7*`7HF(:NNNLS+X3:VXLZI^D\-YAM(^I9\FVE(AQ`?:UY=*J(I%$W?Z15
M*\C'/%2[CMNJJH<0Z"80UKVUGAG%OEM6W$"LN-SS`O)=0_\`UJDJ^>2*BHB/
M<(J'>++&.)A'<=]]QT_[/@],E$AQ$QVD3M)`QW3_`/*H_P#X=3WJ^B/7&;BA
M09WCYBF3<0K$SEW5FZYE?;I@IZGNG0`8#`4#`8.T-A\=2;W$7;3.U.TXXG)1
MPF5K5@L]=7V-VJP-BF8@X=W4Q>Y@];[E'S`>@^>M>\\QGU^K7'I/(6F&]6OW
MY:;10'N19VB+:28=!$Q@-),R1L\?O\/U.QV`/T[:9UO@QM$;\A\L\V9+GIKC
M6K&S\11H5VPC.3F4\?2#F1D8BOR<<A,#AZFO%A:3=>O5[A72`3#MH\<OJ]67
M_KMC(23V-<(9NDMQJW-KK,[=K4,(YNPG(U>!IF/_`+!68"H0D57H2KP2!(Z.
MJ\%$,T(V'B4Z\+=E(UZ/8LD$T4$E6J::9"@4#;!K-TL6;R]]I-HKHN4B+MUD
MET5"@9-9%0JJ2A1\#$4()BF#\0'6&D<\V\B6&,Y>$QG1JTYRYR#NT>ZD*+AV
M!D$X]Q]H:KI,G=]R193-)%EB_$\*\<$(]G7R*@JJB#2.;2$BHBR5+)G[$7F3
MB]8LY6"G7J<RS-T.V8_J-<_9$52HYF^I\)DV/O-;R5,V:R(S)4I6_55Y:\>5
M<B,4"D*J#"+=HJ.C%DU2MQ+A%#+WQ[3XU-M`8[<56RR%EQ1)XJL[R9HD&2*9
MW>7.]30Y(.XQW>(-PWRM!PYFD='V=!>8FX5@T.V28R*;X#1D67Y/U@K@Z.%<
MT2^71R>-I&4DKI)$BCU)_"2K).X(1C8U93L+>]/6CNBL%(W[@$4XC52&FUCO
MRJ)*=I"U,\8:FO\`"6P&EL;7"4R]:J_9\)/H2-QJPC&$,_K9XFM9*N,Y8[%9
MD'"BDS(S>=:38OMT\#-]%>W;B1(P.%$/65BY-_\`_;#KS:HTJO1.0*Y'2U5K
M+6!DI_\`PB8J?N=XK$\326N<D&3:ZL7)7F0I_BP"L[ZCMP>2B[7*,5CF4-[T
M[![-LT^.!LS@T6*6561Y=.^5BUKR+C';M['RU2J6,J)2(O"4ZPD,B.Y>4PBM
M-5:3=+UX9,C8(>QOHMN+<QS/E&#V.S0>$U=K6/\`D%1;-9V,V'(*MVRFR4M5
M:6SI2M$IMQA)B(>4J@MWDU<#P]+KH32GV.,,LJVC&R*"(@MZ8J'J9Z?M[XEV
MS,<G&SV:,ET"WS%?HURJU5"$P8W@(JM6*RP<:UB\C1B,[D6[3R-OK%E:*235
M0LF1-N`($9@R7(Y=O!G!D)GXVY:TR.6']IS76Y$<E0]G2:DCL&1T%]CN$S!9
MSB87(CY-CD$8Z<N%6?Y8BW[=ZDVCW9G=925]8B[@JS6+GCIMI7XX&3J5G7$%
MDR%IK*9KV3:LQD*MBLD3?Z77;S=N7MQA*[C^[,[X@VJM:K)>4Z+)=BG&*(R"
M%92[/:`Z(5E4RV5<X&+T2$O1(VT5ZR3UWB,8TF&78U!6G,L20$;FFT7_`"38
M<9DD[9>E*P[G8>SM'81K$6[5U/UQHY6$WK![0963Z(-`:`T'_]#NY?XMH$G&
MY*B)"M,G<;F!ZI(Y(:+*O#)VA\K3:WCXSIR/N0.R7+4*C&LR&:B@*8-"*%V6
M[E#`V#_B5@"60%M,T9S-H*Q]OCGJ<Y=;_,A+IWN.OD/:GT^,I:78V&=DX?)\
M\T+)/A<2#9K)*)(+)I@F4A<ULO\`PPX/,"Q'%-</TE9&P2Q&\K;KO+M6+^V5
M_(M8LZ\0TE+([;0A;##9:L1'I&9$$W*THHX4*9P1)5,9KVA.-&$*Y/L+-#T=
M)M+Q$VM8H(ZL]:7L?6YEX]FI.6>U>%?SCF%K!K',6%X^EB1[=LG+R"H.GI5W
M!$U2#-?EXXS81R1(6B1NU)^^_O9%<ENBEK);FE8L;MQ3'&/#3LQ3X^?:51];
M$J0X",1F3LAEF[5NV*DX)[1L*0S6!=^*F!,BR<O+W"B&E'EA&*-82HVJZQ#&
MPC`V->W003\5"6..BILL)9'2SQF#I%4&JJZOI=@*J`89K(E.+V#)9RU?N*2=
MK),',J]CI>&M-SKLS&O9I;';B2>QDQ`6*,E(UZNOB>O'!5!5-1(T804Q+WK>
MH,U]1?%_!<+]O3B:(E'L(E6@N(J$:V"UIUF,>XO>8]?463CZL$[^W&4Q`K8I
MKQ0>)M2NG"$8FBNHJB94AQFF_F.)T1`/)2RX9S;G+C[)NW4E-2+6N7[]^XQ7
M</#J/'GK8ESDRR;CFL12KD157"MLJ\Y'<PD<I&,)M#/S$<K#RXY&X@:.9-6G
MXYYH8^AQ03G<B8#:6S$,_#)"Y3B4P&`N"^2<2WZ6/+*D3=%B;Q'+(`(KC'(H
MB!27%3.I@[?\MH5MU',[U`%P99WIX5LTQGD&NR\.9S)STA)14<JYY!V8T=A!
MU4B+^W.Y<0_W1V((J>U(X,=))34UGE,WQRC)BE7EWSSDD<@\A)ZN8XQ2C8%Y
MJC8WQZLHY<JM2H/8IC+3^1WR2%BEUW<+(ND3$8%B(]=H\424:&*;M#I)),WM
MSMS<1993*[QSQ>\CZ8M<\<P]D%#N:5MY9J\SL#HB)`,H=M#+/22;GM+U$2)F
M'6;M:363DX%IR=Q\Q.A)Y(LS^L58IHZ)@)>^S$>SK3=6(8/91U!PTC>)]&'B
MS1S&1F7JK1LL^]--9VL9,@&5.)IB^6LSB!;D=2S13:;C75=3AGC-J^:2DM>*
M<S9.VD@@1W&N62D5+3IW2$BT5(J@)2[JD,`E`=PU?7ZI[?0U*_,R`/9FE<C8
MQM/E<)&4<2E3L41.)QYC%<^W26A%3QEM>F<JH%3*=G'.40%8@F.!04,2^OU/
M8JD>0%D?=QXW&N3GR13"456N.KFLGN'D"A802F_@.GKK_M$EO^IM<29/DL.X
MVJ&/9ZLWLO[/A4X]Q+R./;=!-ETTEE53.A(]C3$;I@"O7=4P!YCIZ3_:+=KF
MW!=1',C';Z3;1:TA&$<.U9=%%)2;B6#E%2(,U%1.33G7,.VBSOT7A%6?JK@5
MXF!Q1,IZ9^U=<)-FCS#R,F[`WK^*\&-)!#)&2Q>M_P#$I6O?NVD8;I4<=!O;
M<E2KR#&;@9VRQ8/$V=>A/46&0G73<[I,L6WD'".;+G$;EG=Z.CC''6"<;T*#
MQC37\:E&Q)'2BJEAE4EK79)Z:?.96Q6RTO9,&LC.VVW6!ZXD))ZH3U'3YPHH
M(!W``)+.DN+SD@<I\8*I:D#24,X<P$XD47$78*^_<1$PP7V[DG4?*QJS=XV5
M*8`$ITSE'IK4WO58NL\*<\Y_(7S=X6260<=P[<^=:S4T(,ECR]7ZL@^MN#@E
MEXM^!+7!N!C,>9:M*5*>"^:P?KPTH"*S9S(O4T7;==2;27/K,NFG_M<?_*QO
MB3G:-Q_&2S^I#6LXS&3Y-K:+CEBT/Y:FYGRK*OXIO+P[^>L4BULE9N05R%F4
M6C",C0@(2!BQ!"-9M6J)&QI_U^92[\XL6<07(2@/QCFUJ+.XKEY15!LSB<H1
MJ5:2=OU_4`L9%VM!Y)X_L4F55`Y#(1DP]4W`I@`2*)&4QBKF''LE[I-.<5MG
M;+=6JT\N4ZSJ]09SLW'1;RU620'9G`UQJ]<HN)N7<%W,5NV*JKZ93'$O:41"
M*@3E/D?;J5+<B)=QDO[39,5(Y0)2>.<?38R3F;Q3JEQX7R;!WHDN$'.6FOO9
MBX-7/H6EP5W3$D$"PBL:M,'];4:DZX-Q6/D"N<-9XRHW.EL9E_*YD)2W;M[/
M$IZS*E/,E4FAFLU6ACT\R5G5K#2_HOG[!&1>2BR;`QTT"M5W#J,&$E<)\IKE
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M(2S:.?G413<@@CZY"`?L)W=H5EN=`:`T!H#0&@-!_]'N>C<Y8PE[C)49C8':
MDS%N)QBYD%JQ;&=*7EJP58UGK\7DA[!-\>3=GK16K@9&+92CB18^T<^NBG[5
MQZ8*AYD.D,HP9<;/$OFAJS)7%HG".0L,E+UF(9(R#^8K\-`A)3%C;)-'*1B@
MP0<G5%9,J93&4(4P;=[9:Y&H(NI&?A&#9PJQ00</95BU076DW98^-1167733
M45D'Y@00*41%580(3<W30(^?S)B^M2Q:_+7:#+8C_?`+7(YP>;L9E*U%QDW/
MH!`0B<C,"YB8>:9NEDO1]0B#I(_;VG*(EQ:6#FRUQFXC6;N?A&KN9<(M(AJY
ME6*#B5=.6RSQNVC4%5RJOG#AHV45(1(#&.FF8P`)2B($;!^_8Q3)W)2CUI&Q
MS!NJ[?2#]RBS9,FJ!!47<NW3@Z:#=NBF43'.<P%*4-Q';01/<\V\'R[IU$X;
M5N/)J?:N/9GC^-]3?9.KR+\B@HKQLMEQLI'8)J<BU5*8JJ$U:8U4AR'*(=Q#
M`!<7SPPR+<M<RO(EI,4>J<9,9*2;"0FEG&37=ZY#2$:Q=`Z5@$XK'C%GBO'[
MF1!$B2CU"V6]/T55`!N!BE$PX^>2TGL6U%21)_B#9;KFAZF<RD+3[N^@G-7B
M4%/7%$SNHUF#JE/D?:]^R,E.-)*5*F4Y$G!Q.H4^IGQ&:8>/Q6QJ#Z-/:)=?
M)V4G%1)7K!E>Q0=*@K*M0V=EG)F!IK5K1:S4X!C$Q;V571;`W9HB1LW#O,HJ
M/JAN,WX4YV6G8EY?\M<X8)A,R<H,97"DO)C]Q05BP;1G%)G:JH6"@+A&8UO5
MUQE;8_\`919&&CCH&DSHNU7+DZL2HNR.H1-GG&:8Q)<1XYUX.<1<`P#./-F'
M/51L$].0\W/0&+;`I%2UV9P:GO4&<_C+',37<",("8<("61D[)3I11\F04DS
M**%],R3-7WL^O\?JC3C+E_4N.]ADX:`N.*W]/D_=+.80E:Q3A7)[*29LD&31
M15_3+10*H]:&;(`9TT8UB!04>'4>>D==8`3U))<>TK-MLSZU.#`^><J<P;*_
MK6)&R2E9AB,3W2[62P6^<IU4:O2+*LR$:NR+05CL#A-(PH,F2YU3%V.HHBAN
MJ&K=8S)>>5GU9XY8W@DVJ]K1=9)FDTR`H[NJH.843@4`4)'4EMVUI!L"O5('
M#=ZJ0G3UC==^=VMG'"^L/8R7CXA#V$0U:QK5/N]-E$M6T6V3_2'BS8$+V=""
M`#Z6_P#5K/;67J$H8_<4Y5'':(?]>!N@^/Z#K-T@.4OU[AU<)E]EEU"G'M.X
M(!-@[$_6(F`;=!*)&H%4,&WAN(:?R,M+-P]2N2)FUIKM>L[?M*`)S\-&S)T>
MIC`HFY<).G+19,#`)#E,F<@@`D$!#<$MAPCE=^,9")#.X1G&]0M"2I%&T3:W
M4M.5)V'5-1)E.I+.;G4G(IJ*>BN@X=I);B0&R9![BZF_C9/6>+A61(\OFU`R
MG,Q67..UD3S%0DW57=3`-[HM-,8I1=`J"32^Y&J]=QNZA9Y%P5TB1I97[)VA
M_>B8Y1#5SKXAZ[=9?LQGOC[EAO)OH,ERQ[='0E9.KMCPCJ"R$W7BP;*2",A9
M\$SKF+L#([5KZ)FJYH]+TC"(/6^Q5"L2]7DYG&."TRRWJ;O#T19K9G[-K?&+
MN,18660;8WF<NRHG<,S@A*1E&@,.Y(R;]A</4EDI,\M,G-$"JU34>G5.!5V;
MJ23:W@V7$3C30N+4OC+);?D9DO)^'K[57MRQ[-N<+C2<4XTHKIK/9&5F\@9!
M<1+9G1X&3<R`*>VG'39PH[(T2.D"2/:3.>_AN_W>)E81/3&0>4HG>\0HI_C:
MO240$!,<IKXQ7;4"9C(QO96S!CBK"D^R77SBVA)NVNG[%[,,XFDK.>UVBXFB
MIBU/C/PLDG??PECQDXH8&PC+!9XZ*>6C-[EG(-9')V1RQ,A=_8OO;A)Q5"0B
M&$32,=49=!FW)]EJ$;"Q0)()>LU]0O=J65<IO:@-!I$*W`M;!)6QO$L4K+,1
M<5!R<X5`GW)[#P;F4>1$8LZ$!5%C'NYMVJDD`@0JCE0VVYA'0;A11-(H&54(
MF43II@90Q2%%190J**8"80`3JJG*4H>)C"`!U'0:>?K<#:62,;8XEC-1[>4A
MIM%E(H$<M2RU>E6DY!OQ04`4SN(J8CT'*(F`>Q9(APZE#0;O0&@-`:`T!H#0
M&@__TNSV=XL/IFOWC'Z65YN,Q9:[5D6_M*:UK,&L[0M^3+4^O\^TLU@>'7-;
M<?I7Z:D9-*%%JR55!Z9HY>N&::2!"Y,I<OC]9OL>Y9CJ[985]D3)</DELG+R
M5<CJG6X:6RM7^1=?LB\:W@H^<E(VO1RG)23>MF`'<.''VMJ@Y>'467?:&>BI
M#@36GS!G%66^OK%&0=+FL>5=JZJD(0(JK/:OEVK1`O156=IREAB$,O.W)WH$
M;D7=-R"1%!,WIE&6//\``.M3\Q)22UX(V2=?XJL60H8_K'[@0A<OVFY7RTC+
M7(RG[ELEF);[846[YTN+5.,;'1%D+UZ]DEQEYJ?']7V:M)+7<HV>&94S(+2\
M,VIHB/4]JTJMPPW-XOJT*6+=P<>A"4"GX$K-8(A*MIMH\C69G1FZ<H<K\@R>
MV:X>\?[C<)"\Y-IKO,TV\FW4\P89JM-IRQ2:F\75]1N%"QC>9B;QI0PC"`!&
MZD1$,W)2AW&5.H8QS#-2111813%%NW2:1L9&M$T$$$4T6;%@Q9H@FDBBD0$V
M[5HU;I@4I2@4A"%V#8`T0A)"T/)7N;P`J,V'<!%)Q1(HK.BB'Z@AFZX=@$$3
M``.5@[3?]F0X"50-8QVF?T06YG\YN.O`+&#K(.9;*4DG(@[)4:)%N$I/(.0I
MLB8G,UB6"[HCMP3U1(#M^Z.1FT`Y165*)B@:WZDEO$G+D/C_`/,<\G#<@+EE
M"Q8MH]EQE.PC>M5C#K>5D*^%481DO)245*A<4F,LZE;&X1E#I2"JK,&S@")^
MB@W`FQL^_P!.'3_JF.^4KF7^8%I.7(<:]DC#^8<4)O2%*Y<XDL,?8C]X%(0`
M^XJV#%=C(T$53>J1)P<%2[`*)AZ:WKM/,Y<]OQ6=;0E33G#;DLHHE!<G;769
MYVJ8K>,RQ8KECX/7.1--LJE97C=)FJW3.<$RH*VUL(`3])"D`##US*YXVU\&
MWMWQ]\CJ2P/.5:WW'*4`J'NH9S5Y6U3,6[9&W,BLJZ6S=,-'R?3M[R*IIJE'
M?](CK.+XV7WE[U_C]'1'\2S!"&X;5N"=LUX[(,3;KZEDUC(-#LI@EN/8W*C9
M=^U7G+*H116JF8"W`7K@@MBH["40["9VXQE<RYL6&+E-ZJAE"JJ)"(`'9W'#
M?8`,5RF7=513OW_F`Q2AMX#OO)_RC\3,D8-DC$$I?]T@EV+OOX@7^7KOJH@3
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M:B!D3;$%*3?#TW4.&^XWUD_B)[;7^*<4_P`KN.^+\<+C'=`Y63SXZ?MUG^2X
MFLU*(>'2[2MT7$?^^KU$*$42(1$'!&2;DK8A"%.'8GVR[8G34TNU[B/N6?\`
M,:YSOE-DZE7>-V#XA9^NS,$I=BS.1H]'[<[;R+%\2H2!HN%/,,)5FB[;*.3.
MD&[A(A_2.8I3!SN^>HW/Q8[V,YPG^>_F!QEL"K#+TT]Y+XMF9B0EIF!O$F*5
MVAW,P\6>R+JG77VZZ[-`72XG+'/$G+`A`!)L5H4>X)-KY:OXY_CQ79YP[^0/
MBOSYIY)O"]W:.K$P:H.[%C2PJ$@\ETMP<`[59&%!R=P"23D.Q*18*N&2AP$$
MG!C`(!N7XO#E99<5/!A8I6&'TY$5IF(+M_Q92]\TQ2`"]5D4B`$L@F!NHE`K
MG8HCLN80U+(F<=G%9O&L@V2>,G"3IJN43)+H'!1,X`82F`#%'H8ARB4P#U*8
M!`=A`=9:1;LW,+%K>RR>/\4L;9R1R=#/?MLY1L"QL=;DZE(@4QCL<BY&DY>O
MX?Q?()%[3"RL5AC9%5,X&0;+!HN+Y:3F)@RR9NKU1:5NM5ZRNZVXMSI)">EJ
MNU*SD)JJ/86,6"&R'C#+V/9R+>+.#-)$7,0G*LF;@Z\:[35*JV=B7".-YXV<
MR;`2J.HF\59M>:A?[K=/WFYR->UZ:JSD<+YPQM1*]0,8NHQRKC7]O1&164*^
MDV4JF^=JE/,*@[=E+V1<PI1PGS.)"=JUY;3#TU:K-7:1CO+^58IM#QA\I<A+
M38G)7=;FX6R2ME0IS_&,4G)R$Z_EV[6(D2&DI,3O?OXS$^L9M;DQQOCYCD5P
MT>9!9TBJ-;V[8.A?,75R;P+!&SN&3TS..,\:+S9%S)JBW0%0@@;TR;]H5DM]
M`:`T!H#0&@__T^_C0&@-`:`T'FLLDW25<+JIHH()G6665.5-))),HG4444.(
M%(F0@"(B(@``&@:F1D%;2L510BB5?;J@HQ8J%,F:653$12DY!-0A5"MBB&[=
MN8.@[**!ZG85'4F/NSVH]^5GYF<;<$XF1Q-BP8G)/*"3C@%I7/5]U6\9IO4`
M,SG\@*MS$,=V=(X*-(A(Y73DG:=4R")B*'6XC6NMV\\.07&?&3Y!_E=RI-Y-
M!C;LGR$O)G2LN8LB27V#'E>[E`4^U,YAZ1*+;,HL'!>R&@6KA9J@8!3:`3;6
M9+MS76W7287MX-_RS-1CV+9]GKDC(24NHD074%BVI-&D8S7$J)E$T+/;UWSB
M41[RJ$[C0[7O((#VE'<-:DD<[^2WKI8/5/@/X#5HK?WBN9K0=%,"&&<OD0W(
ML8!`>\R5=J,"4@@4`*`$[=BAYB(B.L_$8MM\G@;_``P_'FD4"!C.UF`!`=S9
M2OP"&VWAV3A`V[A$=O#N,([;Z>U0J8WXL<%4%H=3CWDS.>`ILHBJFO6L@.+;
M5W[@.X4QL]#OK:PUNR-2&-OZ2J:?<(!^KIJ^U,2GMQ]QWS)CQV25)EBAW6:.
MW3:2,D7';W&BTT@B83I_N!E#6>VUR44(8YO3%M&QITMQ`I^TQ@&^TO%3UYXI
MQ9[*H4,JRF6:?9*C',TTQ5NT9'/+;15"%1%1Z\<3]92?R57B6($W6<S[.+0Z
M@)3&`!$,X^#GRWU1R#C')3`DK0[]2[Q&*=H?<:Y/P=B9;&,<HE!U&/#DVW*8
MH@.X]P>&G,/N6963<IC=JQ!'I^DBSOL`O@`>D7O(EL'D`:G(_/8-OUF%5`P%
M$#;+'57[5`\!`BZA")#]-MMQU<TP:V[9RP?C%RVC+OE&EU^:?K"VBZJM.QPV
MR;>;`8C&NU&.5=6>PR"@B``W9(++G'H4@@.G-#7Y`R=R,MD<K"<9L01T2ZD&
MX>WRWR$=NZ-1X<JZ>_OX[&4:E(9@LTNTV$/9RT=6F_JBF8'2A/4(5Y[6(-5C
MX=\86FVR>4^7.8,C<ELFVAS]TM:SIV2C5-T_6`OJLV#*#.:Q,(6/*!4&3=G(
ML6[9JDFDF@DF0B9+GXZ7*SS%^&\'X5CFD7BS%]#HC=D@*"2U=K<6QDU2'*4B
MJCZ9*W-,2;EP4@>JLY7565$-SF,.I<U,GD6>1,JV59235E(,UR@5=H^;H.VR
MI`$![54'!%$E"@(;["`ATU!#_,GQR\!.0R+@N4>+&'I*0=D,FO8ZW64,?6]0
MHE*4GJ7''RE7LROH]O\`=@=V8I!$=@#N-O./,:FUGE21R?\`\L9B>RHOY[B)
MFJ=QS,F(X7;4#+Q3W"E.'!@$6K%C<89HVM]<8D-L4RCEI/K"'7Q#89=9X=)^
M2^7,5F#!',7XU<ZPB-WB[G@W*5?<C-T6]5F6-]JGV;5<"#+4^WPJZL388EP`
ME([:B<QBD4]N];D,8Z.L\ZUO^W:?1UT?%+\Y<+RL9QW'WD4ZKM%Y/'C58ZC6
MUV08O'^899)HX]D14C8.VM6PYDR"Z8%$J#[]1F0E.8&J6I<_=RVT]>9TMN)Q
M?M]W6-,<D\NS^88YTJ1S*8-H9'^%^.[U,AS"#:0I\!/R-QR*J"/859*X6.;A
MGID"G^W-0$"$N,]LYQ^V)[4*#I%9J4)`8YKE>J-,AVA8Z#K%6@XZM04$U:"*
M'VMA`Q35DPB4V9R"3T$DB%((;`&LXPN<EAH#0&@-`:`T!H#0&@-!_]3OXT!H
M#0&@-`U,M)GLSDR::@EKC14`2*'\LZZ1.`^[.(%$QXQHL4/1*`@58X"H/<3T
MQUK&)]6<Y4G?,-\H[3A)CYMB/#QTK#RORS'^SHT(U9%ES4.(D53Q87B5CBIN
M"NGAGG<WAF)RG]\^+W"F=%%8HLX^[6NOM>>E-?`?X59G(<V')'Y"G,Y8;':Y
M%6V$P[,2\@M8)F2DEA?*3V9K$F["2]^\65%8\,@J"VYB@]6(8%F6KKIYO:[?
MD\:=.HNM-ZS1H&*K%4A8:L5R"9(QT+7Z]&LH6$B(]L7M081<7'(MF+!FB7H1
M-),A"!X!K;CEMCW02=""H<?$`(`CY#Y`&W40'3!ECC=7G0"(+F$>H"`!UVW`
M0W,(%$.GY#Y:>OR9?@7.0#;^X7W$-PZE'\`V'<=M]M],#-0O;I/85$UB`.W4
M0`?$!W_EWZ!MI@R43/(*6^RAQ*`>/<`A_P`GD.IZKDM&%R9N``!5*("'@/@.
M_3J`AJ87)A<@\1N(^79W]V7O`F,IBVG_`.NMS*`0KMK=@*@+%!_9JR:'G9`J
M:H=Y`674!,XB8NPB(C,U<D8AP)XKL!$(2%RY64QV`6U0Y1\H:DS-^H#;F95O
M,D6U,(B'B)-]NGAIF_)29DOCCX<RKP9"PT[)%N7$0$Q;IR2Y*7!LL0`V%!TS
MLF7)-H]:G`?UI+$43-YE'5S4/5CO">`\'-U$,1XDQSCH5BF]V\J=2A8B6D3'
M*4%%I6:;,RRTNY5*F4#JNEU5#@4-S#L&B9_4MW=G3+N!3@&P;AL/78?#KU\]
M60)I>PN%]P3`YNH;=/J(!U^GCJX\(Q`4E'`B8AS%WZ>`;`(@']>P_309I"2Y
M1#^_$?`1#8/Z`';KIP-FA)2S80$QC&#H/3Q_/IT\-3@*:.MRA1`JX"'781\@
MV\_'<.FI8N2`Y!\>L%\OL72^)<[4>(O5/EB>J@1V4S::KTH4@@UGZI.MA2E:
MY/,Q_D<-5"&.03)*`HB=1,\L^6I;W*X$/DR^+?+_`,<F0F=@CWTG=,!V6=$,
M89>8)BTD(J32$\@SJ5V(Q["U^[1Z#<5&ZZ8D:R:2)EVHD.FX;->=F/L[Z[3;
M[NCCX//F#/R3C8KB=R8L*9L\U^+.GCF]RBI$U<PP,6W5<+QLHKLF0V0(".;=
MZAAW-*-4S+CNNFN)]:W/%[<]]?7F?M=*Z#A>!>C,,B**MEP($U&I?K.Z1+^D
M)!LF``'W-F0=^TH;KI!Z9MS`F8E[X8S@ZK=P@[;HNFRI%V[E)-=!9,P&3515
M*!TU"&#H)3D,`AK+3VT!H#0&@-`:`T!H#0?_U>_C0&@-`:!`6N3,\6&MLE1(
M4Q"*3SE,X`9!FL413C4S`.Y'4@40$_FFWZ]!4(.M2>4OPA3S>Y<T[A9@2;R;
M.,EK#97B[:H8IQ[&$%:;R+DJ;`S:K4^'9MTEW*QGCS]:YDDSF1:I*J`4PE`I
MJD[PI.X4<*;$3(TYS3YCK,LB\O<F2)[*9)Z5!_`86;.TDR,JY6&Y5G<<:PQ+
M`"-!=I&42CD$@:LE!*"SEUN:^;VF^^?[=?VK@TGAP(":7CT#</+<`\N@AOM]
M-:8;1JR7<B43]P[COX["'CXB'B(E_KU,A0(QB1/Y@`P@4#`&W@/TV_E\?KOT
MTRN&>5HF7KV@.X;[B7;P`?KL/C^6H/3VB0AN)>I?J782AMU'H.V@_#LD1\"A
ML'TV$-Q#M'Q^OT\-!B*Q2)]]B[?D'3KUVZ>8:9&$+!=$=T3B&PAX#N4.@;#T
M`>NJC*3DIEJ'Z1$X!]3#OMMN&_0>G3\1U,2_=>646QS`=/1$W7;<#[>700#;
M<0Z:8AE^&GI=4-A2.7R']>_T'IL._3?3$[&,(R3O_K!$I1`1$`WW$=P_,/`1
MU1D(Q7>8!5'<0Z=1'KL(=1Z[B(?B&ID;I&.23VV*'7;Q`-QZ`'GOX[?PT&S2
M0`O@4`V$-O(`VZ[=.H"/]@:@SBIEZ=`V^H#MM^&_\=![BW(<!W*``8!\0\!$
M/SWZ:#7.(TA@,)0V'8!V#QZ[=>@COX:#";.W,:H&PF`H"._7IT_CUZ=?PU>Q
M@97QGC/D3BVWX?RY6(^Y8_O,0K#V&!D0,!5D#&(JW>,W*)DW<9+1;Q)-RS>-
MSIN6CI(BJ1RG(4P8L_1J7GB\OYVW-?AMFKXXN5TE58"0M:C2H*L<LX9R]`-G
M31VYI;::;$@[6H^C0,2$G:K/&2CI+N%(J4@0IB!Z#EL97GBR\/1KM-X[F/B9
M^0V"^0+C9&V.578,\WX\"/JN::TV[$`)-%05-'6V,:`!#A`71FU.Y0#J1%R1
MPV`QA;F.;><S+EMKZW"U2NR'V:2+$+''[7+*J*1IS"`$8R9^Y5=AU`!*A(CW
M*IB/0%^\OBH0H+SRS*<O66AH#0&@-`:`T!H#0?_6[^-`:`T&DL$P6$CC.@3!
M=TLJFSCFHB(>Z?..[T4Q$H"8$DRE,JJ(`(E13.;8=M63-+<&P,JU@8I_)R[]
M(B;=-W+3,N^.FW2`Z9#N'[YR8PD2012*4VP;]J2>Q2@!0``TPYID<K'YO\J9
M/E!-`9QAO%3Z>Q_Q%K;T@&9.4F[Q2+OF>U&BI0'[S:I%B>.AQ4*51JQ;*"*:
M:X$4UTTU\V<)O<3UG=6:5=-11!'MW,)P*._4=P'SZ@'X]-:KG#PQ,4`%*8V_
M_E>6P`(>`>&P]/QWUFUHL$$"EV#;ITZB(@.^X>8[;?Z]167L`#TZ>`_D/B/X
M;:#Z`/IMT#H(^0>7AXAH/H`$=N[KX@("(>)@'R#?;<1'\M!$KEPYM;6+X^?M
M)>Q-UEN6O'QM/A759-)1:J+V\"V!O,?;#%,I75F?1X1?=L*?10.W4N>/NUKY
M^RON@\LN:Q<7P\I>R1[E[;\(\/<L35ZC\%6%-3"3/-64\B4;,RSREL)I^O=%
M<;5.HLI50A@0.P5>*.W+86!`;ESFM^NN>/FE1+\E^8X5O,%QJ3G]Y1>,,$<?
M;5#,2\;+5496]2N6<FY8IMWR$UJUCLXV-BEC#'M1:VA6$*=;[GV$,06C9T1(
MS-Y3UUXS\D"MS=Y;HJX-31@7[E29M=;3G1><?+O#P>3\:S?)`F,7MF2L+A1<
ME=L<'C$P2KU)JW:021A1E6\D]9R+..(S>#UUY;.3YE\QXU?DBP&COI=.FWFM
MQT):*[@VX&KV-\?2.:'].FK`[)<%J=8IBT1N-_;2/VU]$JLTO[R;^X.(8H("
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MBS3DBB#-S#UUQ?NT6(^;G*%Q2,<6K*==GB1BF=K;0<A62+P3;_M"L`]XNW*Y
M49M6?MK5W8YTG_B!8Q\*=Z:OPR[=PNG#.D%'A%G*\EOE;K,\?##)RQYSN,7&
MR2BS]%")PCP1G+5$-,)KR4G"SO(6K,Y3/&12(KR\<LX2QBLV6[(L$O;1*CH7
M$B)VC51+3-_X,:YQ]:M/XH7_`"#E+C]CF^92BR1-WGF,R,HD2MV&G_<&<=9I
MN(KUC4JUI:,YB!5ME:8-)0[8Q5&Z1W8@V67;>DNIJ6X^K%DEQ$BM@\P`/'J&
MP^.^_P#+OT_CHC4OV8*D'8/U;#X;^0>(?AMOMJA.M7:C);L$P@7?IU'\A'\0
M#;50RN>\6T?(2U)O]IKD;9'6+U;:D^CI-B2096/%^1ZL]I&8*1+L3@(R<-,U
M1\$@5H`#Z\K#L=P,4IB&F,K+AQXXYO$K\*?RWSM<:S,FO@![8HR)G?455<(V
M+CYDQ%E/5:=7-VJ_<YC'1))%11=,H*+/(ITB02D7.4>7[=L7IW__`$TE\N_H
M#M)^)0<L7)'#*3:M7\<]:K$,`%63(Z82#1<OJ)F.F;M52.4=MP`0UMQ.76Y5
M28B&SIP!"/D^]G))$Z%3D&AA1<]I=Q,1)8Y?53`>HI'*/GK-[:C?:BC0&@-`
M:`T!H#0?_]?OXT!H#0-;+NAEK&X'N'V<`4(]L7<=EI!R5)>3<@`#VG*B3T6Y
M!$.Y,Y5=NAAUJ<1FJJOE3R1,J8GA.,U*LH5:U\ATK2SG[`0X^YKN)*9#*3.1
M'S<I51.9[/I':0+4G_:+RQ0`1,``.]8BNKCY78>%9U^N5=N+6NU]@P@H-OZ2
M:2@1$0W18L5G)$S*=SY=L@51PH)CG57,<YS&,83#WZF'&W-S5KU*BP*W0,(;
MB"9/KT$0`>X/KL/]&N=;AX6Z`)E``#;IX;=!`/'?^;IOK*LP`VWW$!#Z^`?]
M+R$0\M!]@0/'8P>(]`#<!'IL&W@`[>&@^P3$-O+R\/P$/`.G3\]QT'T*?00`
M=M_+\?,1#Q$!'0?78.P^```#UV'R_+R$!_T\-0`EZ#MN&X_B(B/4-]@_,1T`
M)>F^_AOMW`.W3RZ=0$=_KH&''.\.4YBA!2)R@<Q0$KEL`&*4=@-L(=P`8OAO
MX;ZWZWY3V?H9[A__`)!)?CNX:B/CT#?\1_LT]:GL^@SU$;?_``"3#SV!TU#^
M.VVX`)0T];\GL>R&DDIB+C95`HD3D6+5Z1(X@8Z7N42*>D8P;@)TA-VCMXB'
M36;PTVA0\/J'0=@$`V#IOX[#MJ#V+OOU'RV_@&VV_P".^@RB=/+?;KX`.W].
MVV_]>I_(99#?[H=-OQ^FX!L&WGT^NJ,@HB'XAMN.W38=NN^_UW_KU%>H&\Q\
M/Z?(?KOTWT'PH'<([A]?$-_'\MQ$1`-7^H1DRF"8^H7S$/+IN/\`'H7;^W5B
M$ZM)"FGU,(``;AL`@(&`-_ZMOXZN!R'?Y@G%+5-U@#,42S4-^VG-VXW6.0*0
M2M48V`;0&7L31R9BJ*=ZC2N9+EF(F6`JZGVP3;J$$HEY?DG,KO\`AO%CIG^&
MK.3C/OQS<<+/)/@?3]5JSK%UC4,/J.RO\:RCRHM%GI@`P^[D8.+:.S&'?N]P
M!AV$=)S)6=IC;:86J5%7V\S.,1,(%>(,)9(NP`518H*1SY4-NO<"2#4!Z]0$
M/`=]+X2'"UE1H#0&@-`:`T!H/__0[^-`:#X44(BFHJH/:FD0RAS;"/:0A1,8
M=@W$=BAH&9A/5/%M%W(&]R_*:2>=QBB(O954[YV/]V0I1_XAP(``=I0`.@!M
MK=\L>/JY;N;N5WEZ^2;D7#%=JA&X-P7AG#T.W*FV<),[7;;`GR3D)9`5BF,V
M?.8K&B;-0P=IP9BKMT'8UU_=)X6R33/W/IQK9D<"Q'8/`@FW`>FP`'Z=_$H#
M^8]-=ZX1:]56GIM$?T[[IEW\O$O38=@ZB(?\FN=;G1>D2WWV#R\/QZB'UWV$
M?#45D%0'S+L&P;#MY;[;AX[;;?U:@]RH"/00Z_A_*`^0[>0AY:#[]MT#<!WZ
MAMOL/@(?3IH/KVP;?ET$?QZ@/3R*/7\-``WWZ@&V_3S'SZ]/`-!\BAMTV'Q\
M?K^/7K_5H$Q<7X0M4L,J<=O91#]9/]0``N?;J$;@)NHAWN#%#IX;^&K.;"J[
M?NJ7AL41_P!0#U`>N_4-=7,?=D0V\!_COOMY_A_'17T$LCM_N^/CUWV_+?03
MCPQ+IR]`BC%.!CQ[A[&K;#OL9)T=9(H^'@T<I^(_U;:Y[=M3HZH!M^>WU_IW
MZ;=/X#K*O4-MQW'KT\PWZ>70.O0/ZM![%W`!'?Q#J/GL&X?0`_Y-!D`;?8?J
M(@(>0;?41'IL`?\`)H/4#;>0!MN(^7B'C^7]NGW5Z@;PZ]=^NWC_``'?81ZA
MJ#Y,;IXAY;B&W781\?IL&J-!,`!D3].H%'RZ``=>GUV_UZ3[H9Z;<&33,`;A
MMOL.^^V^XCU$1$=AUN)5(GS'8_)D'A5R&F%6BBCC&3GCME2N@FD)P</H[(%S
MQE=7J0%3.`.&%:RTQ%V?<AC-DT=Q$B(`'/\`).,NGX;RW_\`E<LDKR_'#D/B
MMTNHN6CY?B[9'D465.#2/OE48L3MD$S%%-!N60ISA8`(.XJN#B(`(@(XUZ;_
M`"3^[^3J$C5/;VF"5+W?\:G+Q9P`P=OIJ,RR93"!MQV*I#[!MYF'KMOJWIB=
MPZNLM#0&@-`:`T!H#0?_T>_C0&@T5H5.A6;$LF(E41@I=5,P;[E.G'N#E$-@
M$=P,&K.X7JD&W*!&Z!``2]B*91$!`2@4J>P;"`[;E#J&^JRXM,I3S9]SB^32
M2.H19X3EQQKB4'&P[`S:<=.6E5=H=P_K``6%N`@&Y!%/<.@%UK3]_P#'PNW_
M`.<^U_K%F_%=,JB300#<.T@?I```#?S;@!.[H81'QZ]?/7HV>>=K9ZXW#VJ0
M#Y%*'GL([%'?H/7KKE70LB(>.VXC]0Z#L/4.H;>>_AX;:R,U-N(@&_3^/TVV
M`=^@@/Y:#*(VZAT#?\MP#_8.GRKU!KU`0VZ^`;>&WEU#;8=0?H-=QZ%V\]MO
M+<?Z^N@^?:B`"`AXB'7;<.@_0-@'\_+3@>9FVV^P"'3KU'S'8-_'_GU1&_D[
M/%KV,UFI3]BU@F8V+*`=%/21.>57,`E'?M_[M`AOJ"FP]!UK3]S.W2NV.>+R
M<@PC6H@=S(/&K%N3K^I=VN1ND&V_B*B@>/CKI>.V&O&;$`#]?]8^?XZH]UY)
M=KZ(+CV>NW2<HCU$#HK%[DSE'KTW`0'Z"`AY:"9W$FS!(-[C73J[F;+1TTV3
MW$>XKDBC!^;_`-`6S</_`$M<]YU6M?*97;L(>`CU`!\!`=QZA^6L-/WM$/P_
M,-_'KX!UW_V=?Q#[`/RW\.H;;?4?QT^1]!MUWZ^/3J._3S$VWB.@^^X`$!Z`
M'3SZ=!Z#_'0?O?MN'D;QVZ^?CN`&#45\B;J/F`>0"`=/+^C51JI(>Y$^X]>T
MP[!OT_'RZ^7^K2!D;*H!4S[B'^]Y"&W0?T[B'U#6Y_RS5?\`RIK9L@87Y-T8
MR3AU]VX4<JG$,R3.=,CNV0L;CZT5I`?^R%<TE6R&*!AW],BFVP=VL[S,;_'<
M7^:K;_*Q6-9#*W+2I"\[6\I1<96`K(3!L=6#G+:Q4=%(([@"99TA3B`;?J+N
M(=-<=>J[_D_Q=G!S'1D8%RF(=Z,XP(`F[/TD?^K&+[?I+L<R+TP?^ETWUKY<
MO)W-9:&@-`:`T!H#0&@__]+OXT!H$Y</_P")6G??;]N3>^WC_P##'7AX]=6=
MQ+U2)2+NFB41#?TTQ$-QW$HD`2B(@(!T`.G0-:1P\9+,#3G9\DL.X%,'3[EO
MB&7;I;E/ZC:/P]RCF`.`;AOVHN$C"&W3?;H/0;I^_P#CX7?G\>OV_P#F+;>)
MJP'39?JZB1+Q``$=P#<-BB8`-M_$1#^.N^SSSM<!7";M4NFVZ8#U\=Q`/I]?
MX:Y5T+1)$W0>O@&VP[`.P?AOMMMY;:BMHDWZ!TWZ;]0#R_U[:AAFD;^&X?[/
MH`#Y"(==%>_M_P`.FW0?X[^&H/WV^W@'7I^'Y?3IH9?(MOPW\/+;P_'^&D,O
M$S?I]`Z=.@_7ZAY:HK%YT75(EIJ%,06#>(B'<X_(0X"4'$TX!LT26`!W*L@U
MBS'`H["!'`#U`W3K^.<9<]_!B>-L>>U95C2=OJMH&)G[(\Z;^F2,BUTV*@B.
MX`!9ATV#K]?KMK6W2:]F!&;\1[@_(1';6F3U9,8&C<?80MA"B5&QU":C53EZ
MD%Y`6J4.8YC`(['.TETBAX`)4N@=!UF=[3ZK>I2AXIWQ.%S-!,G#@J36T-9"
MM*G.;]'KNTRO(PFP]!.O*L$4B^>ZGXZFT_MJZ]K?C)[``!U^O7<0\QZ]1W_/
M7'[NCX[?/P'\``1V#Z?J\0'^(:J/SMV'PZ_^;O\`AOY=?I^&@^/#J(]=O/I^
M(^8AO_;H/@PB&WGMU\O$=_/H'4?$=!\]_B/CL(["/AMX>'7P$?PT'D)^HAX[
M@'3QWV`-]A^@`(:#6OS;IF'???R`=AZ[;@'X[#_3H&.M*G:FMUZ`8_@("&P>
M6XB(_P`-;C-1-LBWN+$G%J'.1K9*CF2I+B38#E+)84R)+@<#&[OUD3KIM@VV
MW'<?#86_2Z=J-O\`*Z)JFY2<AE2)G,F3"$<0Z@$$R::BETC3I%.(!L`G!$P@
M&X"/:(^6O/KY>G\O^+MQ>@`JP^XB8?W#6QW$-M^V=9!N/;^D=NH?A^/3;?RY
M'AUAH:`T!H#0&@-`:#__T^_C0&@U4\V!Y!S+0?!U%2+8>F_1=FLD/3SZ&\-6
M=PO1N&"OK,FBI!W]9LW4*/B`E41*/B4##OV^']>K6'$YR6C4*M\L'R+UV4!D
MDF_IU"S'!O'':4Q)%.GT6F^@U`.J;UTWRU(I%VZF`HAOL8=]:<?D;V__`"BQ
MSA[+D5+'%%0I@$J?Z0_W!#;J(B(`8>[IU#K_`&^B]/-Y7:U/91F@;S$A.F_3
M^7;SZ?EKC72'';I#V@.P_P`>HAU_Y-95MD4>OAU#P'<0_/IMJ+_5FIH>&P=-
MMP\1_A]!T'N"'Y=/[?#0'H;^6W0?X#^'X[:*_!1_L_IT3#2STI%UJ%E[#-NT
MV$/!1KV7E'JVX)-&$>V4=NW!]NO:D@D8=@`1';;;<=,<\=CFWRKE9WDW(5JO
M#SO1-/RJSAFU.8#&8Q:)2M(=@8Q1[3&8Q;=),Q@V`QBB;SUZ=9B2.-N;E8KP
M-H:R..\BY1D&XE&PH/*Y7U%";'/%PK==>8=H''^9L]E5"(CUW!1@8/H(\][S
M)&]9Q54!IH-]Q./](^'^H==<.:T*:H:U[X$4J;CTC+2U'92-Q;`0HF45C6$[
M/MI]'<"B;TR1*RCD0#^8[8@=/'7+./R7XK>,Z*PV%J=13]C*1[H[5]&O&S]B
MY2,(*MW;-8CALNF/D=%9,IBC]0UUPRZ)<19$BLLXZK%\B3I"$Q'I?<VB1^X8
MV;:A[>9C%"[B<OM'R:GIB;83HB13;8X:\]EEL=)S,G%,F(=/`=MPZ[!T#KX;
M[==_SZZ*\S$W`!\`#Z!_1L&VW7?08YB^/0=PVZ=.@;=0'IX;&_HT1CF_24-M
MQ#KY!TZ?JWZCL(Z@QQ$=]OIMTWZCY==@U1CF-U'<=M]_/KN/TT&N>'_NC[#_
M`+H@(=0\?(=Q`>@?A]-4,'='((H+B)M@W$1#;8`#IUW#Z@&M1FH*Y!N*$`Z<
MS2BP(IURMYKLKER)!439M8/C%GUZX>JA_**2(D*`AYB8`\]-^ET_<K3_`,J_
M5W*]]Y>7$Z909,:MB>N)+#MZ@NI*6NDBNF3]0"4I$8X@FZ==PV'H.N&O5>G\
MO^+LE5(*LA7T"$(90\XP,!=NO8T4-(K#L(FW%-%J)N@^6_EJ^*Y?!W-9:&@-
M`:`T!H#0&@__U._C0&@-`R=?2%M$M&9A,=2,(K$+]XE5,#B)75CU2G4*'88Q
M56I@$0``'RUN]L.1'Y:ZHCC[Y<,>6UP9!E!YVXQR"$HLLT;*I/IS&7[GLJ$=
MZ:B:IGJLRZI<(P*"92N-W``D(G[`U,XVUKI.=-I]2VXBV=>%FR0T@8474>].
MT<(@<JGHN&RZB*Z7>10Z1Q36*)1,41*;;IOKT]QYKVZ',;2)7L6T,`@/<D7K
M]0[?X_7QURV;A[FI=RE\1#;Q`1Z_V@.L--TDGY;?C^8>&_X:#8D2\!V_/1>&
M25#IMT\.O\/SVT,/T4/PW_A]/,=##Y%'I_*._@/^GAX:"G?Y)^3+6.3)Q[J3
M],[Q?V,MDIVV5W%H@`I/X.IB8N^R[HP)/W8!L)4RMR`(@HJ0.GX]?\G/:^%5
M6,ZQ8<KWVK8\JJ?N)RU2J$<V$P*"@S1'N6?RCSL`QR,(F/25<KF`!,5%(P@`
MCL`];<2VLXS<.G^&HT-CG%K:D5]+TX>K5!Q%-!,`%47%M'+>N^<]NQ3/)!T)
MUUC!_.JH8?/7GSFY=<8G#D]&<_\`:#_2/U_/7I<727PO21DN*V*/723<(.X*
M;2617(55)=$]HGTE$E4S@8BJ9R;E$H@("'0?'7#?]U==>HH[Y4XG>X`R_/4\
M"./VS(#^X*2]6$Y_=5J165%LV.N.WJNX=PFHS7$0`3'1]38"J%WZZWVU^KG9
MB_0^'`CDRVQQ?#8VMD@"%)R&_:I,G3E7L:UZXG!-I'O3&,/IH,IM/L:.CFV`
MIR(*&,4B9]\[S,SY:UN+ROG,D/Y>(AMOY_AUZ=-<FF.*0AOL`^&_7?KX[#T\
M1'08IR?7KU#J'7?\/#8-48*I?'H'01`.G\N_]?\`4&B,`VX>`[;CTV#??J':
M/B'A_7H,4PCU$?(!`-Q#8/U=-^O4>GCUT&ID5.Q`WCMV@([AXB(^70NPF`=4
M18R?+%:,G1S'``$JFXB/:`#MY"!1V$>P.OCOK<8JJ[/%J2;X>Y9S$D@G]LC>
M&G*,[)^;<5B3L_48;$L<U:B`#L)ELOIG4-N':4H`&_=J?EZ_5T_%^[^<+/\`
MRO\`C-6O<4<VY1>(BDID?-7V2/,)4_\`B82AU:&32<`J&ZG:,U8)!(2#_**/
M<'\VN&O3K^3G;'T=,\>4R]HKR)`$/:!+R:@=H[`BC'FB_``[2=RTP40\-P^H
MZMZK$YIUM9:&@-`:`T!H#0&@_]7OXT!H#0-*JB=K.V%B8>POODY)KL0HF,VE
MD"K*'VW$>W[BFX+W>?:.M>(SYKG*_P`PW2GM1IW$#F;$19Y1[Q@Y"PBDZS*4
M@D<U.UOH>7=(O144%NLR>S]'CV!DE4SD.60,`_H$Y3+U+\-Z=W7YB`;)FAB#
M,4M7HR4-+0T-+$;0$R;W8K3M5<,XZ8I%C>*O#F67D[GCJ7AK`X.)A`5)7MW$
MQ1$/1I<S#AO.<N@7C5?49ZOQX@N!C"@CT`W7^4!+T\MPV^G]6L[1-;X3LCE`
M43(8-C=Q0$1VVZ[;]0ZB'X:Y^73X*1$OAM_I^&HK:I$W`/\`9OMY`/EUT&:1
M+_3K]?KYZF3+U]$-M]M_I^'\?IH9_1";FURYKG%G'BIFCAE(Y6M;5PUH5:44
M15%JH8#(+6V;:]PK)P$.?N$H"7_C712MRB4HJJHZUGM?HEVQ'*[-765L4O)S
M\Y).96:FG[N4EI-ZL9=X_D'RYW+QXZ6.(F57<+J&,81\1'7?CIRY=#WQJ\5G
M>,Z3_C5?HT6]\R'%H_MN-=IC[NK49UZ3MN==,_\`[M+VD2)N%2]5$&A44Q$B
MAW"8<M]LW$=-9Y\K);2GM6[".VW;!RP^'T8+C]?PUAJN)\9S_P`O_3^&O0XN
MJC@2?W/$/"R_CZD'.#O^5PL9=OZM<=OW5TU_:QN:/&A+D9BETPAD6Z61JC[F
M:H3]4Q$`<.A2)]PK3I<^Q4V%A00*3N,)2I.DT%3"!"'`S7;UOT-IERR23Q_#
MR#^)E6SF.E(MZZCI*/>I*-WC%^R74;/&;MNKVJH.6KA(Q#D,`&*8H@/4-=LN
M3H#^/'F8US#`ML-9#EDPR?5HSLKLD^6V<7NLQZ12@(K+CL[M$$W*`.2B(K.V
MI?<[',1T<O+?7',Z=-;GA:$9#\!Z".X>'G_;T_+6&F(J@(?AX[]`$!Z_B`]=
M4PU:R8]?+?NW'PZ"`@`_EU\^NB-.OTWW\]AVZ^?7Q^O7^O51K3FZAY?4?J.X
M?I'?;^/Y:H2\XX])N<1-X`/F/0`*```CVCUU85`7.=F*B@Y3!01+L;?M'??;
M;N`.H"/B&W;OO]`'72.=4R\^[\%*^/[D<[.NH"N:<FX-P#"I'6,D]925?D)'
MD#?7#5--0>Z(EZC'59)0QBE`QE!+WF*;MUQ_->X]'X=>JZ+_`(C\'K\??CQX
MR4.19BPGG]$)?[&U61]%ZE-Y+D'E\?,WA%`!0SF,+82M#`;^4$``-@`-L=20
MVN=K5E]41!Q8)A[L82Q[!C%I&$@?H</#G?R"?J`(B)Q13:&$H["`"'380TO4
M2'%UEH:`T!H#0&@-`:#_UN_C0&@-`W=P;F;2L-*D``2>)KPCP0+W&,J/<_B3
M&'_<23.FY((]=SK%#6IU6;\H=<[..[/E;Q(SM@5RFF=Y>J+*)5M18Y2%:7.&
M*6=I;\P";8A6%HC&BI@'](D((#MOOJ_0EQ97)UC22DLM\)L$9<.@JC>>/#T.
M&N>(AX8$I&"F<>.'!L%S:J)DN]LA-4V4"J/!`IG#Z93A6X'$C0VVOQ[8XOV7
M\D[Q]UE'#3,`MW+*,7<[)*>GZ)3'W`!$0'M#J'4"[_T^6VN]F8\\X7NTN<1D
MV#=5,X"!R%'QW'<0`?'IT#7"S]'6'3;&`P!M^'GOU\_QUA6Z1$//R\O]`ZAU
MU6C5Y#SC2,:7C#^.9QX0UMS5:7U;J<41=!)8J43#/)B5FW?JF#MCV9T4&@`7
M=15V]1(4-A,)4F<_1FWDW'+GE]C3B)CU6TVYRE+6V5270HF/VCM)*;M4J4H@
M"AB]JJD978\X@+U^=,R:)!`A`47.DBHUUMN$M<?V7L^7S.5^G,CY%G%IJQSB
MXB(F$R;&+CTS']A"0S,!%*/AXQ(_8BB3\3G$RASG-WDDDC.,]K1OC#X.OLT3
M<=R`RQ$'+B6LR0K4Z`DT#E)D>R1BI!(\6;+D`KRE0+PO]\([HOWB7MA]1)-T
MF.-]L<2K-73$<FX_T_TC^/GKDWDE+>3MJUE-L/2`F1_HCG/A^&K%<%HSP_\`
M2^G^GCKT9^KCAV!_'.?W/"K`SCQ]2!L`[_E=K.7\=MMM<=OW5TG432,E_I_'
M;6!25\H'!]Y:6,IR2Q!$BO9XEF9UE.J1R!05L$,P;")[I%(I=IE9R':H@#]$
MH&,[:E]8NRJ)RN.FFWBI9YPY[Z_>YNJ3D19JW+/82?@I%I*PTO'+G;O8Z18K
M$<-';98A@,FJBL0!`?`?`=P';71GAU(\">>U:Y30:5'N:\?`9T@&'J2,604V
MC"]1S1/9:S5A$1`I7B1`[Y"/)^IN.ZR0"@(@CRVUQUTU+G[I>J9CIJ>='''U
MVY!E>#8RALHQ";A5$J,]"O[%:*Y)LX\HB!S2,"K7DUUDQ_4=N\`Y`$J2PEF.
M,U?ZG%=(E*!O+IT$.GD/3Z:)29=E`HCU_P"</#;\@U>$:-93MW\-@#_I;=`\
M1\]]]M4-/>9<K1FN(G``[3;COY"/4>@B/4.@;;:U$M519XMY'#Q9L#I!$#JE
M1%9PL1!JD!A)W+.51#L(DD4_<8P]"@41'PUOPQW]U;?*S&DARBY<?''\=#5D
M<@1[)WG7/#0A5$).!_QED29"FZE9E3&(89S&^":='QK9P(AWB[2(7<1(0/-M
M_=M/U>O7^W2W^3ME;-FL3&MVC<B3=C'-$6[9$A>U%%JU1]-(I"AT(1-)(-MM
M@``_/3NN9:4MJ*,"B[.0"+S*R\RKU'<2/C`+`#@/\JJ461!,P?\`2(.I>UG1
M6:BC0&@-`:`T!H#0?__7[^-`:`T&FL$7]YB'L>4X)+J)E59KCOLW?MCE<L5Q
MV`1$J3M(@F`/YB@(>>D2]&Y8.0?LTE_3%%0P"59`^PJ-G*)CI.FB_:)NU1%P
MF9,X"/B0=M;1R_Y9QU7>&GRD9%QA?$UVG$7Y8JN]:.56BHQB-/Y!M7(#[^(D
M4DE"QED/99?WK)TF":Y9*<;*E-NQ#3_+[_U:[USYU_HC02&NO'/,UCQQ=#)D
ML%.L)XN0D&#$\;%S29TFLC$VF`9=QDVU=N<"];RC1!,ZR;+W)V!E#N&3C;OI
MMF<]N.TDZG"_GC7E%I8X1@/NR*G%-(!`3!OOMMU-X]0Z#XZSM/HFM3RC'I%D
MRF`>X!`-_P`>@"'U^NN3IE^7&]U7&U.LM_NLRU@*E4(60L-@F'A^UNQC(UN=
MPY5[2[J+JF(3M32(!E5E#%3(4QS%`7:N,?)OR(WJ]\RXKE=[$CI*B61!;&E'
MEG*GVN%IT,=X2%K[M1N4Q^]\5VHYD5$NTZSQRL9,R8"GZ?7UDF&+<W*+V9.1
M&1<^9!G,G91LCBQ6N=5+ZBQP%!C&L$1.#&%A(]/_`(>*A8U,XE0;I@`!N8YA
M,H<YS6228@L@^-;X\K%RPFFF5,G-I&`X\P,@("I_?L)/*<HP7['%>KBX"DNW
MKC5=,4Y.33$!`P&:M3>X]55IG;;'$[,.NN&AHBN0\57X"-90\%!QK.(AHF.;
MILX^,BXYNDT81[)JB4J3=JS;(D(F0H`4I"@`=-<6F<.W7IT\OQ_JWU0EKGL%
M1M(_]&MS@^7_`,L<B(A_#2=Q7\[D;!_Y9@_CKT,.V3XQ5!=\$./"_CZE<L@[
MCY[7VV%`1^H`)=<=NZW.D[Q2'J/^@_[>NH/P$/P#P_IT'-Q\GWQJ2U:<6#DA
MQRKR\A6W2KB8R=C&!8"JZK*Q^Y9_<JA&,D_47K:I@,M(L4R">.,)G"0"T%0K
M3IKMXK-B@^LY%L-+L,-;*G.2%>LM>D&TM"3<4X49R,9(LU"JMG;5PD8#)J)G
M+^1@W`0$!$-:1)S)'/7,.1<XXRY%N',7!98QK6ZM!IS<,W,W86!W67<NLM*2
MD0F*+5%.R-9A5O(LD>QHLD=0A")I*>D6223'@^KKNXX\@:9RAPO4<PTI0B;2
M>:"VG(85TW#RJVMB5-.>K,B).T?7CG1@,D<Q4_<M%$7`%`BI-<\8N&LG'??I
M,/38!-Y[]=O(!\0[OIJLDA).@22.83?4/$=@\M]_+?\`LU8(<9JN9(]@[$%N
MTPE/V@&VX=`+U`?+M$1'_3;IK&+>59\`C!9%R:!;T_)'XNJ\59L@Y;EW914B
MV&(,=QI;%DM28(;L!U"340"-==@F?UT!L22Q0'L'3\FV-<-:3-R<;X.L8V?D
M7FCE=\JN5H4S25SY=9REX5:R)#++1%#BY-)&9%DX,8R3AC'MX6)KK98NRA1@
MW1?Y3]?-,\WY=]_&OPZ37;<9)=C`EV`TJN*+@``_]W$H#ZTFIU`XIB9JF*!#
M#T!94F_D&M?5CO!X0`"@!2@```````;``!T```.@``:PT_=`:`T!H#0&@-`:
M#__0[^-`:`T!H&NFF9HBP"H4-HZP&,LD.VQ&\RBF`ND.X#$[!D6R8+)@&_<H
MFL([?IUJ<QF\*[?D[X7-^;O%BTX_A5DXG+5,71R-A*S)'!H]@\E5=)=S$))2
M13IK1[>>1,HP67(<#($<^J`"=,NG<76XLN'/Q9,V3W,+C'B_,$_"_9>0/'=[
M,\=>4,0K'`RM"-ZAY6)<4%:=8;%790ITF]K5:"HD"3.3E7+!,16-L?II<W/E
MG?7'$Z[AV>*W(!:LOV35RY_X<3I)+$,80,D83"`B;?N[NO\`7U^NNN,N/3H"
MQ3DIE98UHNDZ(<%$R&`0.&Q@,4!\0$=A#?\`+7+:8=)<N?3YMN?;>R3Z7#[&
M4V"L!5'K27S9*1SH3(2UL0`CJ$H(JI;)K-*IW%>2).Y0@R9D4C`FLQ4`9K/+
M??ASS!8P_P#6!_276LF+\)1\/K#Q9#-]:<\OY.Z-,/LQ,Z>MJ=$&E$I24351
M%DRM:T>_0L<?4NWO.[-%-GD@L!2HIE3`YEDY;?'9BN^/"64,*Y.H$#,8$MM%
MM>.V$<PBX0,?O8Q:&@V+-L1NQ@QBX[TQKJD<V1!+V"R+=9MZ?IF3()1*&+#!
MV_5#R'^O^P/+??4/N._???PV_+;^&VAT3%V,`4RW"/E6)X?+?I$NAWT5_-'_
M`'%_[3^S7;E,.\OXGU?=_'KQI7WW]2L6<=P\]LB7`OE^`:YWM8L0!+?\@_MW
M\/X_EUUD?8);[]/S_@'AMOHF6CL]GJM%@)2V76QP51J\*V,\F;'9Y=A!P44T
M)L!G,A+2:[9BS1`1`.Y10H;B`>(Z&7#E\GUTX*6'-1K+PRFY5VO+KR*^36<1
M7%HK$JL\JX,J:7H;N7<,)=%TY<&4*[;-HT(4X>FLR6`!.4_37..45D&L(;?]
M9_64-5<?1:3\5//)/B_FPM)O4J*&%<QO8R#M2SE8I6E.LX',UK5Y`5-BMV+=
M1R+25$#)E%BMZY_4,S1(,O)C'AV(R+DGZC%,!B&+W=P"`@)1#<!*(=#`(#Y=
M-1@R=VLK=@V7[E=NTIA,._EMN(;;`(CL'G_KUN1+<*I\_9)&0=*1S(YUW+I7
MVC9%']:BRJQP2333(0OZU5#B!2@&_7723#':">9X"_9`K^)>!F&'(IYQ^0!]
M!VG)DHF@Y];$_$*G2:\M!2DR@FLB=JKE&02D;"XW%J\=0+5C$/$/6!`3>?>^
MUQEZ-)-9F]3^KKAP=ARD<?L18^PUCJ.3B:3CBK1=:@FJ?:)S-H]`$E7SU0"@
M"\B_7`Z[E<?U*N%3G-U$=1.;V>RFLA<&=6)8O_OI?8Q(&`>XD2W4W.X*)@`?
M^]'9!4W#H=%-$VXZE^%GR7FLJ-`:`T!H#0&@-`:#_]'OXT!H#0&@U<S%(S4<
MX8+&%(5`*=NY(4#*,W:)@5:NT@$0`5&ZY0-L([&`!*/Z1$-)P69-FS6<'!=J
M[0!&0CUA:R*`!ZA"."@0X+(G$`,=LY1,55(P@413.4=BCW!K;'T<Y7R68'L/
M"7D$X^23#U*1O>#,CQS3'G/K!B;$CV'ME*?G08H9,+!J>M'+OHHA$Q75$J1F
M[I%-43%2=2"H2_/ZMSF>M[\*W,CV;'2F1Y6U88D6SO'\\,)9JVHW?3+Q`*_<
M4XQ6HR[:2MCM_;)R#GE))M$/U7KQZ[@[P46"Z@)3T*U9=-=K+);Q6-M,RV3E
M(./YB94QOB6:+A^M2U[R9,M?L%&BV307;6*G9)`Y4[%-'6$C%M$P:9#N-ECD
M277(F@)B@KW%Z;=9QRYZR9YN(@AB;X?^<6>9)U:;O+8[Q\O/R+F9FYG(%]_<
MMCDWDJNH^?29T*,TN)'TB]=KF45]T\;G,<QA,8#;AKEBQV]M?"T[$G^7?QDS
M]L[S5R0O5M,($56B,:UB#HK=,P&[A;FF;(O?7+Y`Y0V,<K1FIL([=H@`ZF;\
M'M\19?BCXC_C[Q3Z#EI@6*O<LCV=\ME29G,@`Z],_>GZ]=G'ZE*`=_'THM/O
M`=C]P;`$3*PNFTVCX]BR05!IU4H\*3TQ)$5"NQ%:BR>D44T^V.AF;)H'8G^D
MNQ.@=`TR9+(KCSWZ=-Q^GX:&7L"_X_Z>6X#H90X@^9N`<NSF>L&P%S0A,V8I
M+?:Q;,3W$&]>O!_L<9(F_<5<BEW2J=LJ<E&D(^0?1JKHB;1=(SD$%#^F%5_-
MZ_<X?^L'^K_;J_SC>+\NY_@?S"X]\4/BIXL7S/.1X>HMG]3N!:_7P.,G=;B\
M1R9=$@CJ?4&'K3D^Y%4Y"'.DE[=OW@9=5)/]89O;.+FX780<@K,0T1*KQ<A!
MKR<6PD5H67(W)+1"KUJDY4C)--HX>-22#`ZHI+E2653!0@@4YB[",9O#=%#I
MO_IL']NVHC634!!6:-<0UCA8FP1#L`*[BIN.9RL:Y*`[@5PQ?HKM5B@/@!B"
M&B('Y6^+#@!ET'*MCXS8_@I!QW&^YXV1D<6.TW!NT3.A1QX^KD<[<&,7N,+A
M!8%#"(F`PB(C9;\M2WCE5]E[_+K<?YH73K#N=,J8W=*@8Z3"XQM=R5!MU`*8
M"HM4V:=#FT6YA[=_6?.E"CW#W"`@4NLU<WRJZR]\!_,RC>Z=XZMV),P1J8&]
MJV93\A2+2X,0IC""L7;(Y"M-P.&P%VFU-S"/<!0#<7*YU\KB/C_R;R7K>%CX
M1Y;XVN=)R1AQLTA:]<)M-O,0E\H293-84"7*"<RU:D+)5@;@R7(#PR[EF5NX
M#U3"X.74GRY[XG,O#3\B.03.&1=MTW@=X$5``*<!$!+L!P#MW,/ZAZ[=?#\]
M=9)'+M53/9D>5=P.=[?"O)?$>*[+5YC)RS4Z1Y".@YA^DPKYV+)RJFU=2\Q9
M7L>FTCW*K523:"Z5;F,DU<JI9WWFL[=--/:X7M_%MQ(O-56R?SEY,Q!4.6'+
M)XG892#<I@JIAO%!"HEHN*(M9?=5LI'P;)E]P*()F_X5LV4*8[05#\,?JZ6]
M2?MBWP62DT^2@D#J%35#W$PY3,(&:18*"440,`D%-Q*&3%%(0$!`O>H&_IB&
MKURGT.XFFFBFFDD0B:21"IIIIE`A$TR%`I"$*4`*4A"@```=`#6&GWH#0&@-
M`:`T!H#0&@__TN_C0&@-`:`T",M,*NL*<Y%I"I)LTO2<M2[`,I&@8QSMPZ"(
MO6IC&4;#N`"83)B(`?N+9?'A+/,(*5BH"YUZ2A9N.83U;L<6\CI>+DVI'T;)
MQ4@W.T?L'S%R0Z2[9PV6,FLDH40,!A*8!UI'&'\A7`6V?'E;UKI06:L_PSLU
M@DW5+EGC5].$XXV.[%<,;'BO(+9-^24L''G*#=RHR<B+A(6IG('(HD]`YY1Q
M.+^W^G_AOO%_R_K_`.3-8YMTH#)M9V9WCQB>04C7KD[Q*3>1$TFS?3!(&YO6
MAA0^^2$+&N'L/,`"4=<XQJJ\:^WDF\K#Q_33:_MO;EOI+_=KTMFXX\K_`+21
MHQE70JH[ID!;?]1!Z``&'?M[0V\0W#8!UTLRY]+=J#FB%L35!1!XD?U"D,&R
M@#_.!1\0$-O'7.ZM2G^CIY!V0IB*@.X`(;"'T#;P'</'6<8:R42;T!\^GD/F
M.VW0.FXZSA681U]!_I\_^?0RRR.-]NOT^GX?D.@XX?\`,D<>IC&N9,/<SZ,#
MV):9'9M\;7:9AUUF#J,R52&2SZE3)GS<47*4E8J.W5;(F34W(G7-_P!(B`FF
MUP[:8N97+=]\6^AOZ0_VZS[.GK%P/PK<?YGE]SRQ,TM1GTUCGC\Q)EVT)RB[
MAZQ;Q-'F$'=*J;8CA0[9-A+9$F&9U&/1%5G[TW88.\!LN:QOB3ZOZ*Y%M_/I
M_IX_T;:TY</<%0V_HZ_3_F'41^^KL'C]//\`LTP8>"SDH%$=PZAX;[]0_CUT
MP8)"5DDT2&.<^P``CU$/``W$`Z]?#52H[9`R+'0J#DZC@A>PIS?SE#<"AN/7
M?H&WYZW-6;53'(;E*QCR/&C)[ZBO:H79)0FYC[?K+N`[@!1'8?\`;KK)AS[4
MW9-RNI,2R"DHY0=/I,CQS!UY=XFV]XTCS+&D;!-J'=-!C*5"MVZZKYXJJU1.
M1HL3UVZ2+QXRSMMCCRZ:Z9Y\+2OC@X76GEE$4G,')J/<R?%"BR<K;,!83LK%
MRC7\LWV<8FBY3.MKJ4D@@!:>P9E.E4&KUN1=T#A>6.@T%X"!N/?+K>.)W_'"
MY_B_9)BD%MG%*X/)2;O^!%X6+Q_)34B9[.Y.P#92R`X6O;I^N(N7TC$Q\$_J
M]@>KB996:JSU^J!$GB'=(E^9Y3^K\(2$9&2.H#E^Z5,ZDGO9V"Z='Z?H((F%
M-LW3`$T2;_I3*&^YA,89;DDPWNHHT!H#0&@-`:`T!H#0?__3[^-`:`T!H#0&
M@;NPP2S!PO-Q2!EFRQA7F(M$@F.*OB>68)E$#&<`'5PB7JN'ZR[J@(*V7Q6;
M/@B[)7:MD&KS%6M4-#VNH6F*=1,Q"3#)M*0LW#R38[=ZRD&+HJS=XS>-U#%,
M0Y3$$HB`]!UI')YS9^,/)7")W<,O<6W=IFN/DHPDTI6&B4'EIMN#(1PZ1F31
M$O65?N#K*.$HN=8M9)N=,BD]5'C)N_0*[,U(JBX_DUWC/?\`5$+&+:WWN(E;
MACRO2LHC"1BUGFX"F-W-\<-ZR45%/W17H2G*V:ZSU+*AVB,@6.,W15-[7UEE
M4S'-V]YY<[I<I'XIY(2D(,<Z:RY5F3U,KA@]8/4'T5)MA/Z)7#!VW.LT=H`H
MF8@&2,?M,0Q#;&*8`U+-IF,676K6<+<MF4N#5C).BIN!["@8RH>FJ(]H")?`
M`'?Q#R\`#4NI+5A]5O[&:;I*HN"&`Y2F+L8!ZF`.GZ1W`0`?ZM<[*W+DYR$@
M4Y0[3`8!`.O<&Y>@?B&X;^>HN6Q(\`/]X-_SZ?T#X:BY0I^1KC*VYC<-LTX1
M0:).[=(5Q6SXT.<Z2*C;)=.$9ZGII.ES$2:)S+]J,8Y4,/Z6;Y;Z[ZEF8NMQ
M97\S%PW7:+KM72"S9TV64;N6SA,Z*[==$YDUD%T5"E42624*)3%,`&*8!`0W
MUQ>IWD?Y=?BTE@_AN^SE/L`;7KD_8`LJ2BQ.QRTQ?359&"H3`Z9R[D^YOUI:
M7*H0W:NTDFO<`"GOKIK.'#\ESMCQ'081X4-A$W7IOL._\>OUUIAZ>_(`?S_B
M.X_T_708BTRBF`]RA0_,VW^OQT,_4CYR[1\>@H=1RD78!W[E`#;8.OB.P"&V
M^KCE+4*\P\EH2MMW'_>"0&*!P`I5@[@$`VWVW#8`^FNFNK%V4[YOY7R]D<JQ
M\2X<B=PH+=!LU!19TNJJ;TTTDDD2'.HHJ;8I2@!C&,(;!KIQ/NQVJZREEI5J
MX?M&2T=8[B5LJ^49.I1!.L5&.!N#M6PWR=36%DR8($.F)4!63(/<<YCF,V6:
M*<[OXG;KKIU=NEI'QN?%3.9J-'9PY31TFXQG*GCYD*K;(Y[%67/JS!9"0@C6
M*O/P;.Z!Q[K3QHV5A:NH1)W8%$$'<JDBU19L"\K]6\XZ_P#Y_'RZG3"RAF+1
MJT;$002!&/CHQBCL)S`5,C=BR:(%*78I0``*&P%)N([%#?1GI&_D93K#C']F
M<PZ\T>R=VP.,J?)56@VYWJ]PXT6@K(F7*6P:H;KR<Y2DXUE=8OTBG</I:M%C
MT@(C(*!K-K>OQ?*<L3+1D]%1DY"2#*7AIF/9RT1*QSE%Y'R<9(MDWC"08/&Y
MU$';)ZU6(HDH0QB*$,!@$0$-0;#0&@-`:`T!H#0&@-`:#__4[^-`:`T!H#0&
M@-`W\Y6W31966KR0*^J<5I&"[B))NU#&[E'L<HH)4FS\PB(J)F$$EQZ[D/N8
M]E^4L^&@;.&T@W4$O:HF'<BJBLFJ!TSE'TW#=RW5`AD54S!L8AB`8H@("&^M
M(I.Y<?$HVD+8[S]PEF4L,Y>1EG=ME<>QTK(TZDW2QN2*E?S]1L<`4\GA;(\J
MDIVJRT:BYC)(X$+)QSHO]X1*?$JE3*KZV_?K6?/V*['0<M03@DOE>_46BQ3>
MW*.E@.V&V\BN.$;+UVF91A9%4@E)DW'<M"N5T4DTSK2#KU(TNIF<ZG'6W7\?
MH3E8M$I$,H>Q0L]7[36YE\\90ELIEA7L55EWK`KEPI!I/Y"(JMIK%\3CVBCY
M:JV:$K]C3:?WZ#5ZT26>%Z:[^W?;&^F,V=+!L%<MGD.#5I(NCKH%],O]X82J
M$#M3`P"4VP]`#<1V_/6\98YBTNB<DZM/-4!^Z(`H)2]Q%%`*8H]-P$!$.I?Z
M]<[JLV^3R)9=KQB`<))`0$-P_O2[!OX@([^(?U!J>JYC(+E^N%-L,HAT#<?[
MPOAL.X[B/C_5OIZU<QQ%\^^#I)+Y4([%^/>V.H?+"\1>1(.09))>UJS&V2CI
MWEXZ::9#-TDJ?)1\O)D;%3`$(X[<@$$.T3<=M+[2?+T:_DG_`%W:WIVVT6XX
M\H-/J=!J`LXBJ4FMP51K,0W,;T8FO5J+:PT+&MP$1,"+&.8II%W$1V(&NOIA
MY[MGG+?O<U5YHF)S2*`!UZBJ7^/01#P$OAIZTS@T5DY65F*!0A9!$YB;]`5`
M3;=>NP#MM_'6IHGLC/<^;+=`JQ&2_AW=IS+%*7;QW`!'O$.O7P`!VUKTD9]J
MA?DGFI,.4UTR28([E,&Q51`0$=@VWW`-RF';QU<1.T+;?D:2L$2YM]RN#"DU
M(%A01EK`Z,,A-.!,)"-*K6T06L=M=@KO_P`-$M'S\Z:2YV[9Q[=8A9MM)]VI
MI:B\M,Y&R=?4,-8;H-T4M=@0.1O4FD4C,9IM;95=N5P6PL067K6&J2X2=&3?
MR%@<)KGCS(/48YBZ+^KG;;WQ'6:R<]_7^.W0/P'^&VN8G=PV7N4J,#=<BMI!
MK9J_BF/66F,=46PI`19&PVF3?)-G>7,G-E"E64EY%(&C1X*BK-N14QG)\6^(
M6KV5G1$#-HYFU,Z?+E,5G'-2$%50A![3*[B)$6K)'N+W**"5-/<`$0'8!']2
MV@*W]O4^YR:J;V:53$GJD`?:QR)^WN9QI3E*<$Q[`]18P`HL(;B!2@5,N;<_
M9<%28I3E,0Y2G(<HE,4P`8IBF#8Q3%'<!*(#L(#J*B9QBIUJPL^R5QY=PLJ.
M*<>2D=9>/%I]F4E?;8AOJTTZ987;NR**"25P38(A[%-6YP+Z=2<0.QE5?<=A
M;\I:Z(-`:`T!H#0&@-`:`T'_U>_C0&@-`:`T!H#0&@2TW5FTHK[]HL,9,%*0
MOOD4RJ)NB)@()H2381(5XB3_`'1[B*I_[AR@(@-EQ]DQ^I$*KN(YRFTFVP1S
ME7^[16]3U8U\8HAW"Q=E33[E#]3`FIZ;C8-Q+L`#K4^B&;S=QRQ#R$AH^)R=
M5$I1_".%']2MD:\>0-WI4L=+T#35.N4&X96&MR)D1%-51HY3!=$125`Z9A(+
M(H#Y&_#?)UAW89S$V7VU6M,]'KC'65W'DK$7?HN&41DTZEFBNU1!E67,G#2;
M1H^C+'#LXPS5XD1RDR:RC<DNIK'MGY3V]<?"NNE8HY#M2V^$NF-[$M<,9Q[.
M3R"VK46,I8X.)=`J\BK9+TZ+4=2]IJ,U&CW(3E;1>KG<@JW<1*!43R;O<NTX
MO*6:W]O99M+/=*\15RFF]%O'F,B^<LC*NFD:Y*4!]G)JH#[F$?@4`[FCXB#H
M@#L=,@]-=,_#G84C+/-P5.DT9GEGBBG=V)L?=.U%>ST]_23;D.L<OUV+T\^H
M]1@HB92RJ=0A`KMY$ZXB"8!`SXBJ;TS*&(F`,]U1*0G=T`1Z".F88:![-VJ:
MMM7NC^@6U[;J0SL#"KR:M=GU9*%;VI%@WGR->QINA]Q;Q2":G<&P@40Z`(CI
M<6R^8LSS,\%".=;XU%VFLSM"!X]`[Q\5:-DTA9-DS@DJY=@=$`;-B+=#*'[2
M@80#??3,3!..N1-GE@43;K/U^P@JN%5%E$FS=#U$TC.';A<2-V3,ACE[E53%
M3)N`F$-]],R)C+5W"=N]<8(S.29B&Q5$.$DG2)LD3T3CF;F6ZO\`+^RJ_D>3
MI;K(1E"@*B0PQW:+A,ACD5,4IA#%_)K\ND_'M\&TA[]1K`1.84L%]NU?3<'1
M<6*JTB2@Z05TN"`$B;3;<TRN`82G':G(N(OX^3LC98$TS)IB0QA#/OMXU7TU
MG=:J>M=5OR\/3\#T^U6F[@"J9(J@FBL]6R753!$B2#BP-<3T?'D$V4.&Q7C!
M"W%;%6`ZYW/;OJ\^:N)_KPG[QM^'?D9DN4"Z9PLBO&FLRR2"4G'5Z;#(/)BV
M1:A.Q=E.Y;F59$M(26:J%1%&(%-J*8"F>/2'<1Q;C[JZ"^-W$GCYQ$IPT_!F
M.H6CL5@17FI<A3/+-9G;5,4BR=FLS\Z\Q,.2%,(@*ZQBHEW*F!"_IUG)]:D8
MR1D[`)`B"@A'B&QYQRF8&O:/41BFX]IY)0P&Z*`)&X=1[S"'8,XAS3APT"PA
M$E"M2G5<N.PSV0<F!5\].F`@0SA;8NR:?</8F0"I)]P]A2[CO+<K)AN=11H(
MY\BU\ALH_&KC'MXMU.7D<LX_J-B)5H*C3@/:O;[/%1<V^>DN5(N)F*L+'`J=
M!=O[=)(53F7!4"I@0L0^/RKY&4VIPK^S8^6NDH6^6<C$\*@Z@E)VK%A>8)H6
M+N[4*%*D9G9O,%0BGN(@&2BBDRS[C&3(HE)C@I[?RIS_`!->RD57%3%-SCVH
MY;8NI6IK3_WB<N%1IW(B;K<]16U@IUBAFT=(/<%MDTVS]M+!ZUF:`/N"MO3D
M1P3F1.<V9L?XUE[Y(X=K#10F+)#,$(WDI*Z$8KMHRMY`?-<2/U&=9<RW^)5O
MG<?BA'KMV:K9(DFBF9LLX*BF^BR3Y.MR;Y%9:H<_<\?XUK,228)C!Y*527?H
MS<C99.PRE-RQ.!9ZG"LZ[-P$G!8U>X\9(RB;\024<3C<JID3`S;2]22$OF',
M/)W'V>J%C2G*5RQUQ:F4"2=.[/`.@<7*7;8KYF3F2%WTO6X1LV:-D9_%](.M
M]N:-`9OI1D@!$T9'TC#C#:0G*O+-V)R`C&V)W='=T3%F4[/47:SR-G9V,L--
M3095`L]`MW#YXHGDT'AIF"(^CXD5XYD8$B/^Y<[48G!CR<J>4V(XN<4OE$F;
MK..?\+3QD%;).B)-HIA,XVRE=I>RMKQ5J+AVKN8G(-CI[.IQ40=%_-P\^DZ5
M5]X#R&C'T7$;>N\O^2J,U>(>2QDRG)J%_P`294C9VE+Q-?B(:B98YD?;*X5K
M&5%><_>5CQMA.NM2.7#]=JJ6:CI!)F7O4))C$2PP1R,ELNY5S909"IGA(K'3
MEJ-9F@0=D-,(%O.2Z1+Q<P159P>)L$:2BL)0[1^E%2)6M@0V9':D0D7U2Q+#
M1'__UN_C0&@-`:!A,O7^XP%KQA0*5)4JK2F15KDN>ZY#AI2R5N-1I<&WF%*Z
MPKL1;**ZF;98$79W+9,99JFC&Q<@X$%10!,Q9Y0Y#Y$91UCEC8XC$1)2P.)F
MI4DKA"ZU_P#:LQ<9N"Q5='DM7T?=_ND^,'U`R465BIIXU:&<%(V3700!Z@J:
M97U_1(CCARF:Y[=*L4*\>-;MH]V1*?D)"O0#V>GX2&QY8+*VC<;JV>>MK6#B
MXW*D.4D@"SUN=QZP*F015BUI*I9A#7&/R?6&2@L>MLF8?<IY*LV(<4727I&.
MV5FG/4FLETK)F58FRP3HC.7>?X:67&&-W"[!<S9R5C8/<0[QZ"C)XY0F5]?A
M(65^06AP4(XM$KCG(1*\\/>DJ<9@2!DK!<%\725>+D-BQK2$J5ZE+5ZIS;JQ
M$9D.X<NH2!E5B$`[0J:U3"0&*,U1.9*!:K))4N<K`UB9<UZP5FTL%TE5W1:W
M7K>Q%DA+Q\4^=M7\+:60%,NR;=SOU"I`L@"+E=$LPWT>DLC'L4'(@HY3:H%<
M`7OV]<B8>H1,14/VD(H(@&XB(@'CN`ZVPC'R!DV<HZC8%<Y?M[%%](SW;_>J
M&AF2;22FD03`3B?UFQ6S$Q0_4;[F`@.X=-Z>:SM\*5<IY:HF(>5]ISGE.PO:
MA!4J"PIC.P/HLDA+*6=.TPW,'(M\QJI#QK9XZGO>VJ%I[*.0#L4%RFT`Q2)G
M3$[,EM\863.LGG*,>=(WE3S`K+'E"RI5:X[4+%T;+SL8W+7F-YY'VC&Q&A+/
ME"^*L'R!ZD\.A"3!)>!A!+WB\00:MW2R3HSHR^W><+/7..RSEOB*LV0:(VN,
M+R@SUGR3=U=E;T:M%U_'IZ_+C9FC:1:,XTUNOD-15V3@JH*-_6,5))OW"B`@
M($,X[MN";6<36*R[/P0Y/T%Z[3G.`^6(UD5PZ8**U?CIQQSFXDVI0`B;]P\9
MS,D$<Y,(BJ!F'MP*(]HK*$#ICC_7^CIF\8VG_+5M*;F2GO$R.^&?(":5;-13
M2CYWX7^'$DQ6[0%%-5=]'4/W3A0IDQ_6*IQ./ZC`??<9B?ZW](9O^^OZW_[+
M6(E>7*[98E.^.^^JE,506H-?BTXS8M>(/"!VM)!A8(_$+^0BI!DN8%$7#8GK
MHJ`!TS@8N^G'^M.?.\_Y;&I<.?E/R5-Q<\UXG<@FSR/!!Y%2&3.2L%2(Z&=%
M3(W%PPBH)GCJ6A!,3U2&)')MERH*&2,?TS*%4N;YU_Y/[9_E^D.E&?%'SGHT
M[47V:[!QOXO4[*%R?L9?,E?IY,W3](M4[,)#4(&_6&W^\6K2=C<O@CH::3E`
M;J/D4&S]^F^>-?=S-GQ/L?VWQ;?JN#Q+\`G&Z*F6EOY)97S1RLM[5)!(3WZU
M/8VN%(@*/:V;QS%TXGR,TS(B'MU959N"?Z/3V#59]K]EQ6,<)X4P%7TH#%>/
M*1C6O-D4_62KT/'0I5Q13`@+R#Q),CE^[$"B)EG"BBIQ$1,;<=,VLG4:C)RW
M_P`'C%G!!';[A(`I&10;@.YR*J(BZ>D$/`S=%4HCT$X;[@X\J53*F->_UYQ<
M9M;N*<C91($(A`Q>H>G&@=4K@W=U[ES*["`"4"ZS;\+@M-11H#0&@-`:`T"3
MMM"HM_:L&5[I=3NK.*D"2T6TMM<A[&UC91-%9LG),$)AF\29R!&[A1,%DP*H
M!%#%`=C"`@K-`:`T!H#0&@-!_]?OXT!H#0&@T=CK%:N$2O`VVO0=I@W1T%',
M-8XEA-Q+A1LL1PV47CI-NZ9JG;KIE.03$$2'*`AL(;Z!',,,8ICIR_V1O0*P
MI.92,D6_23^,0E5[(S1J=4HY(9W]S!XFA6QK-(BVYXM`J4<H=MZQD!75654&
M2KC*?4H627F8:K5V)F'4>UB7,K&0D8PDG$4Q.91E&KOFK9)TM'M%#B9)$QA3
M3$1$H!OH,*2Q]09F.+#S%(J$K$$CXJ))%25:AGT<2+@EQ=0D:5BZ9*MBQ\,Y
M'U&J(%]-NI^I,"CUT"+S"-PJU#D;1B?'%8R%;JO*?O!*A/A:0TA;D#`Z1N+"
MGS:PHQ</DJ>K<@^1BW,@)&#IZL#9ZNV;.5G:!9]S<XNR3B'*^.:<^P8A&1M!
M<.920E*Y'5TE.>5&P0\RX;3E'M],,TC75/NT/<BN2R\:Z01>-7[)4BQ.XVYK
MK\L[9SBG'EGY(N/=/U/U@@F'8EW`!EECB)&Z!-_^T56,5,H=!W,'7;PUYPR@
M5:9-:2D9&2#M>/';X_M$MS]C]G7)8$6B!3#^I$+1DA^DD0-P*Y8M2AN($UUD
M848U3#/_`(@_D"N]PG[1,R6-(W)N4(:>K@NW#6MHXRXS5BD83MSTS9)<"/E,
MU94KDHSDU-MCQ\>NFD8J3E<@YG>VWRWM<377Z+LF+,7K!5)RV(B>PN(VMN62
MA`338C95%;]>6!@#^1HC5DVK(`W[2@V*3RV#3!6<.&2&$I.Y<3I$GLTZHS;9
M8P:5<X@K)<?[J]%NRJK<YO3(=Q@NX$<U<6R?>9E7AKZJP^H^+OR\X\.O<E_5
M.9Q)-FZADQ*Z763(4ZJ3!@^D%$DCB8"*+D9-G`H%.8H]HG`.[;8-_-A'@658
M&`-Q<E[MA_O(Z1`0,.YQ,<#-]R@&_3<`^@>6B/D)5F7M*F@_7`3!LDWAY)P(
MF$0+L)4&:A^[KOMMXCX>&@RRNG2H[-X&Q+'`H'`IX=VR+Y@``I(HLT#"(AOL
M)MP`?#P`)_-6+.4]W<X66JUBI,+*UJPQ+V'L$+<%HM_"3$/)MC,9.'DXILC.
MM9)F^9+G35153]%5,1*8=AV%F?)S\(EP36V<3IR`QWE2XRLKQHLDDQKV*\M.
M%5).8PY/2KPC"`PQF*SSXR+M[3Y%TNDRJ-P>@*JBQTX>85!^+!]+3..,-8SS
MY3ZCZE`1RQ7*3`KAX00,1[(JK23M,X#OWMU7JBXM!$?$$?3+T#IT#3-3$*/4
M4:`T!H#0&@-`:`T!H#0&@-`:`T!H#0?_T._C0&@-`:`T!H#0&@!';J/0`ZB(
M^6@K@R=1[CCRWVOE/Q^KJ]CG;.Y:/LR8/B1CF#?.]2@VK:)BK/63R#IA'P>?
MJU6V!#QKY51-O8F:9864,!2Q<A$:QA,Y[;=QG2G9BQU`W'$MA3G(.Q@$;#./
M;.F$E'6]PX<1+V$L$%(IMI.!L=`6;/!F8I\@@^C7C44EDTU4CD+K7%Y8VXX\
MHQY<R7"88Q;D?,;EN+N(Q3C^>O<3&E*NX6FF])CG\%B>KD(GW&=NKU>':JS(
M>IE%U$P$0\=;VN);Y369LB(G!O%+BDUZ[)V!<LA*P;>A\;)F97%`#R=@JC&3
MR]RCFEE$"`W(29S!>[*B<2?I$[8H'$PAT28DAM<[59328U:7G(0JZ1R@I'#+
M/4#;`8);(\O[]5L8PB8R3FO5B.,D'ZMRHK``;]-*DF<%5RNJL['0]%Y$4&-<
MR60^,TU)74L''E65E+UAZ88IQF<\7M$DP.=Z]L5,:$EH=H``5>U5Z&`QB)E,
M8.5^D=9\8X3)Q9)Q-BH\'<H*0;2\-?&;:[0\LQ5]9C*05B:-WM=D&1P$2F:N
MZ\9H<@AT,`[^>I23'?9P]11H#0&@T]@K\#;(&9JUIAHNQUJQQ;^#L%?G&#65
MAIN&E6JK*3B9:,>I+LY".D&:YTED52'353.)3`("(:"!5PMUXX15JC5(D[*Y
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M@N5!RX1!5,P$4.78PD+S0&@-`:`T!H#0&@-`:`T!H#0&@__1[^-`:`T!H#0&
M@-`:!(79Z9"&%@B82NIU8(A(2[]R:"Z2JDBN':(&(*4:BKVF\`5$GUU9VEZ(
MF0>(Q,<NZ,7^Z:M]DD2=@"<^Q2(M4R_I*8ZRH@0H?4=NG3?4[15Y?,:VJ#S=
M^^\-OX>-_>5DCJ]G&FR3N4:5RSV:U1#I.6RU34V;=XW@LN8_JB3?U%Q1!O88
M8!9OC%<-F+IOJ3',9MSQ3`<S[3!H,</49X1+]I25WG>260(H#&,V=<=^%$2R
MM\!!.$4NXZ["Z9Q=4Q)!$Y3)N`D%DP*<VQ17FS5=>)ML>C!-$E*MB?&]+GRJ
M*V:1K;-W>E5"G]9YD7-TNYO^5%G!U%#G*_BX[W8@8WZBD<AX[ZVQVFWB)H$E
M).)P2]Q)>0F+(0Y1,`%9[(5NKG3`!$3$=P#/U0#_`*7<.V^VL;<-:_)_Y4%5
MF8LD53)KRJ[>)15`IP.@>273:>N!-C``-B+"J([;@!?P'65^A$XO9X;XP1\'
M@#_%F!8&EK1897%>/K=9Z\PGH"M7JW2\C7,>4^,57;2CNG5Z5=.(BNI'*H*+
M1!&.0,8K=),N'3F\X2;T1@K2D8V?L8IQ(L4).32>+QL:L[;I/Y!&.!N,@LQ9
MG4*X=I,`=I"L9,I@2!0G=MW!N&=H-#+6BN0,A7(F:G(N*D[?*+PE6CW[U!L[
ML$NUB9&=<QT2@J<JCUVA#Q+ER8A`$021,(Z#00^5,8V"WRN/X'(E(FKU!)/5
MIJG1-IA)&S1*<8Z:LI09"#:/EI)H,4[?MTW15$RF;'<H@J!!62[AAG2#V@R=
MBA(R4=U"0ME<F5)&MQ\@O#.[%!6%S5IIHJ_A&C@ZDE%S+BDS,BD95`I%SQ3M
MR41%!54#`ULGC#BO6Y=&!F<><?H&>N]9MC)O"R=3QS%R]NIT05C(WEHC'.H]
M!Y/UF,(\;+RR92*M4052.X`.X@B7-^2C:8?P)8:LBT8XNQ#.4FPK1%K0:M*3
M3).K3CA*.K24!944$8Q>)DUDXFK0Y6;PH',#:-9@F?L;H=A#A5JL5JF0C"LT
M^O0=4K<415.+K]:B6$%"1J:[A9VNFPBHMNU8,R+.G"BIP33*!E#F,/41$0WF
M@-`:`T!H#0&@-`:`T!H#0&@-!__2[^-`:`T!H#0&@-`:!KI9X62L;M0!,+6"
M;&BT![B^F=\Z]N[DU";?S"D0B"/7?M43.`;==]3IF\TU&1;"C&(.%7`F.RKS
M$\T]02(`*.7_`&J$B&**8F[%5C&`QP3Z&];TA#QUJ3]4J,/HOT4W9?4`9Q$"
M5U-9N8X@;(>0E49"QOT!'N,9.M1*Z9D3!^I-OZI!'8NML*U+RW:YMY*W.,8@
MFI5YO+N,>&E20*?TBDP[Q71-G_E!+M.IE"MY[*SYE3WQ_P#M?LR9#=I=N_&O
M-NU;O&NL6)(N73PCZ5:J&3=2C)U,QRIBF#TYO)4@E5:(J!/T!Z\/66']Z4#;
ME*MOT`=]=&$PL;Q#6-8O2MTBD;L2L(!B7KV`RAV28`0H&V*7M=.E"[^8D\P#
MISVY;ARXM$KZT1B?:84HIH\F#CN!B%<K)EC6::H"&XBJF]<*%\@,CTV$-2\2
MM>3>6/%%O2RQ9+U6;K2XV`O\=BHEVB;A3SV.6C&F(+++S#EW471YZ.C$RV"(
ML'M2'>ME4X"1*633!V906FL-9X1)8<,<W)?X4TNSY`JMT@ZM19J'?9#>QMI2
MDJG.UJM\.*31+76(5U?G+@V5GP86L]@9S)O4;0SR2.W,"P*+*2$7,Y:S'W`W
M(\A2<4?OZXUZIO4(?""^7<90;";F:S<W]+E<,3N14KP[>6^497:UY&C\?R,!
M/R"H+,I5@N@"R;@H.!="TX&*^,N2Z#R*H<RKV/:+0*A',W-_>)QQ)&Q(1&`L
M:X=B\<0YFUY=V!K4&5G@92TIL9&&.V0E'[U9%V15P(.A;P6^%^'CC&V0JG?[
M'8ZI:9.DP)(*-D6]0<,[%/S2L+8H>U9=L\Q(3DKW9:RHA.-RV=\U32&0)%-@
M.=0@)IH5+<D'E;B/E.5I%=JU8M%1G8;&61Y_(5`A30+^M6"R/;[?GKR<B,D6
M9C:XYF_JD12KI/)R2#-)NZLSWVCQ11LY;B1Q%S"/1^.B<8K3#B)R'4(A"RY&
MK&2K1`1U)DVM?L<?7UY3;!,TW"S**RF$6];%I6V3)<5"M(!1RW(V*D*2`#/D
M]F3^'+K)\1BLJUWBZA:\183R=C^D66HU9V@A4+_=9;#4C7KA5XF8LDNY:U6`
MC\7NX9]!KO5ON]?F7$>JY(@JJ!ZF324?X\[!7S,XNV9>:7JI%<5-*QPDM3VZ
M`7NN0MJJL^O4+G]O>,D[37H*"KR]>A4IS[X+&#>"V;BT0%X@_F%]BDB^#E^C
M[3B6T/N0,S9GM`M,/*32M@@D7:\G$TNTT-.I*P#\79IZKV:;Q%CIG6[2Y9R"
M"-@<NWCMPF=FZ>Q+X96/:K(T'DBNBY2(NW62714+W)K(J$524+X=Q%""8AR[
MAX@.@]=!\%43.90I%"',B<$UBE,4QDE!336!-0`$1(<4E2FV'8>TP#X"&@^]
M`:`T!H/+UT16%L"R7N"I%7,AZA/6!$QS)E6%+?O!(QR"4#;;"("'EH/I11-%
M-1990B221#**JJ&*1--,A1,=10YA`I"$*`B(B(``!H/O0&@-!__3[^-`:`T!
MH#0&@-!K9B22AXM])*E[RM&YU")`/:9PN.Q&S8@[#_>.G!BIEZ?S&#0-:T*,
M;&B9\L0RI"*/9%QOV$6=KF4=OW!N\^Q`47.<XAX!OXB&ML^$2[Q;(]T]1!VY
M25;M/<9$GVQ5D14438'!&G0!DS'_`/?73]-$R8`(@8[`X?[P:W)PQ:9W+N3V
M.`\4Y`RO."TEAP=BVUY*D(]#U%_W/E6QM'HP%?CT6X^X.\E954T>W2`0,(R:
M)2B`!OIMQ+5UF;(ACQ>Q7*U.9;TR:>C)6#!^&*CANQS)/16&6Y(\G99+./)R
MWMWB1S`9^B:5CEU.PPG+WJ%.<1W`&O$AM<VU8M6$$)">BQ[4TV)I:>NFR8E!
MLA"5MLE3JDD(``"5J];]SY(/`#IF$-MNM92\JC4[6!CA.GVJNT/?KI]I@$CB
M1.9\L0Q.XPE$JKH0'QV```?#7.WEN=%Y2D/4-.2Q@_4[?DC43]H%`[.&(=(/
M#<=R2;IV`]=@V\-]Q'-\-3S42<TX5O>0<QS,VG!P]SJ\8WPC8&]*N!2MJ1?(
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M!I[%E1L<G>YJ2AI2?<O>2003Q.L+P2;#%U885?*%<8'9QOJHF<L7:HH'4`7L
MC4S.&WB./^6HY:NM*>N]QK6H9&ZV*2BXN>H5)=3^1#6;!2^/'LNVP-0,=0%B
MJT94Z[<&KMC*-W*;D\BF1RFY2]`&@R9RA<<N;-:7A:@K;JW`XW:15&ITH6J9
M4R)'284]MD;`$Q<%X)N3:,A+.ZHE>O\`'IO8II!R2"DVV,5^Y.*:D;%S".2Q
MOSTN=FR.VI=]M-<AH=M5XSW=]M.68!.PY39R7(8LID"CA,1L4G7:S&)R='4<
M0C$UGH[U-`1!M+%:K-9(O$P>JS8"YI/93(TY4<WJP5@F9>^/L>NY:^6R3J=:
M/9++RVC:\M)44&*E><Q5>QQ9<2IIQY6IT$'\"^=(E"0.X>OR9C7M>-O+2T5^
M\0]TRH^CFDI3DZU08F.ROD8[*N_NH<ZP^0OW*X4D)>QV85(.SU56-7EY>Q/H
MM=D<S%VW.BGN,P\4AB//"S[#S**G7T/4Z_C_``G6)2.8Y;N$2M3WU<GESYT/
M-'CV:Z^77&0\;BU@H9Z_6!W"R30\BV4:.')GB=3,Y,Y9^$MM?5CC?3H)<D7`
M8UQ5@3'UM9PV3+Y621CC&/)'C;ENT/ZV,.X;K*R<Q6<<3J;:72.SED7A&@%6
M3]0%FT7/9W,$8NY55'+`365\CL;702X[@83VR%DLKYPXFH^@XJB1(]A999W!
MJ2C>\PMJ?KRS-M'/7R<FD9RN[*HDRB:EL^$>)?C?FW&]>H#NF4J'C[)4(['6
M,\F7'#]RE:[DKDO^\N2.`#7V]VJ<:UI.P0"2N.H"SS,U(OI)U-1KV<>E9R2:
M0.9-S%S.7U7.*/*R`M,Q8W5U)*'L\9#NKF\;Y;N"-OFFRL/P<K5GI%=NWV>/
MEJ;,OH#C_<DW%ABRQ:LPI*L%%`9N.QS%C,*/E/Q#SIFZJM9NF6*MUS+D7PZR
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MR.C>U=X_B25Z';NTD#/P2:M1E@M*UR7E\W*O<AQ]D3QQ`U@MHL$='WF8LE&D
M:K:L@\R1F,9(4)A4FD;E&[KXZ=8\;.D5/4&'.V1]DML`_=XO&$RL%PUPKF$L
M.U[(;A5W?X+%F/8:\NEWRTFLYN$74HAC9G"TDX7=+R"JTT@N8RYU5#JB/>)C
M"(B-9IT]`:#_U._C0&@-`:`T!H#0:B;A&4^S(Q?F=%0(Z:O"^T=+-%/79J@N
M@)CHF*)R$5*!NT=RB(`.VX!JRX.R3E<;Q4NR=1ZTS94&KQ(R+@C>32$QTCB`
M*$!1TS<G*"B8=AA`=Q*(]=^NK[7X9]9T8:3X78MDG3EZ:;O:3AW)QLHX_P"^
M(M=%52(`IH]H<B\$<_L&[D@+^F!RB*VX]VPB&M?]E^(G_7/FFTR'\=>,,E0!
MJU8+O?U(AQD2EY)DV@/(WTIB5H-E@[77HF5218MTGE=1E*XS]1J8NRI$"@8V
M^XZEWSC,)ICJ\M#7OCS"H!8%:WFZQ)O[#=K_`)">2$M66[YR:T7856[5VH+*
M?BDSHUN%.1@W(4I.]ND0!$NVM?\`9_ZIZ?\`L7-8XHWBH.W*C+(49+L31<)7
MVK!ZSD8TJ4##(J)$9F525D^U90[I<X*%+L7O*':/;N+_`+)?!Z6>4F/L]M;(
M"!H>)7.4@BF2.FU%-S%#8B>\A%QA";"'3RV\1UC,^6L4NJY'JQ<'%L7`%!VD
MT3.^$G;V&D7&[B04+VB)>U1ZJH8-A'Q\1\=2]UJ=-UJ`T!H#0&@-`:`T!H#0
M&@-`:`T!H#0&@-`:`T!H#0&@-!__U>_C0&@-`:`T!H#0&@-`:`T!H#0&@-`:
M`T!H#0&@-`:`T!H#0&@-`:`T!H#0&@-`:`T!H#0&@-!__];OT64]%%5;TU%?
M23.IZ2)>]93L*)O32)N'>H?;8H;]1T##*9ZCV2<"O*U&R-T9QG?7A3,B(/CM
MDJ'&QDV\.<BPL`4(YB7;@>@@H5TT.@0BHF*;5PF6ML?)6LP3&==(U:Y/U8N#
MBY2/2^SK-D99],1UFDVL5ZY"NE6BC9O7-G0@DJJW57%$41<MW*"3%,O9_G\K
M.6B`0HEA>U20@PGWMD153*XBVIZ3+7=)NK%&;BS=/SQ\0L04$GXJE,F?<._T
MDUF/KR9_0?\`B7I!T1=-H&\/616UC=&>-X1@"0)5:34BI78CB9;N3F!R0!2`
MJ9O63.!B[_J`K!ELE>0]((#D4HVVO!:J*(BFSA".%EU2/[(QV:H%?`LY34_:
MSA0JI"BB(*MT^_W#E%$[%,L6+Y%U&6F&D>UB9TC!\23%I-.21S=@J>*FDX-T
MHJX5?E8LF(N@5])9PX1]RHF5%N59PJ1(6*9?E>Y"U^S)V,\?`S3<L,]CFS-6
M4*1BV=-WKFJ13F0E%>U92&90DU9C%>JE3=()LFBCHBB@#Z15F#+)F>0=1@5D
MVKV*L3I<R#]4[B,;QPPQCQDLTA%R-9J9DX-HN#IZY]1J!O25<,P(Y!,J3AJ9
M=BF7TOR%IJ2*BX0UT,`.:BQ0(M75&2[E_>$Y-6!8E9OG#9^@[*6*4!ZFLBFI
M'+;H.2I.$UDDV*98T7R)JS]O#J*U^W(*R\](0($1BTW;=BI&@[67?O'GN4$Q
MC@:-@,11(%0<J>HFU]P9NX])@STD!J*-`:`T!H#0&@-`:`T!H#0&@-`:`T!H
M#0&@-`:`T!H#0&@-`:`T'__7[^-`:`T!H#0&@-`:!%W/_P#JG_UI!?\`[K0+
L30&@-`:`T!H#0&@-`:`T!H#0&@-`:`T!H#0&@-`:`T!H#0&@-`:`T!H/_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g893535g16a67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g893535g16a67.jpg
M_]C_X``02D9)1@`!`0$#P`/```#_[1]04&AO=&]S:&]P(#,N,``X0DE-!`0`
M`````%4<`5H``QLE1QP"```"```<`E``"')R,3<V,S8R'`(%`#1-:6-R;W-O
M9G0@5V]R9"`M($E414L@+2!&=6QL(#$P+4L@,#,@,C8@,34@-R!032YD;V-X
M`#A"24T$)0``````$`1:DP@(_"\\`L5B)M&)AAPX0DE-!#H``````.4````0
M`````0``````"W!R:6YT3W5T<'5T````!0````!0<W138F]O;`$`````26YT
M965N=6T`````26YT90````!#;')M````#W!R:6YT4VEX=&5E;D)I=&)O;VP`
M````"W!R:6YT97).86UE5$585`````$```````]P<FEN=%!R;V]F4V5T=7!/
M8FIC````#`!0`'(`;P!O`&8`(`!3`&4`=`!U`'````````IP<F]O9E-E='5P
M`````0````!";'1N96YU;0````QB=6EL=&EN4')O;V8````)<')O;V9#35E+
M`#A"24T$.P`````"+0```!`````!```````2<')I;G1/=71P=71/<'1I;VYS
M````%P````!#<'1N8F]O;```````0VQB<F)O;VP``````%)G<TUB;V]L````
M``!#<FY#8F]O;```````0VYT0V)O;VP``````$QB;'-B;V]L``````!.9W1V
M8F]O;```````16UL1&)O;VP``````$EN=')B;V]L``````!"8VMG3V)J8P``
M``$```````!21T)#`````P````!29"`@9&]U8D!OX````````````$=R;B!D
M;W5B0&_@````````````0FP@(&1O=6)`;^````````````!"<F1456YT1B-2
M;'0```````````````!";&0@56YT1B-2;'0```````````````!2<VQT56YT
M1B-0>&Q`6`````````````IV96-T;W)$871A8F]O;`$`````4&=0<V5N=6T`
M````4&=0<P````!09U!#`````$QE9G15;G1&(U)L=````````````````%1O
M<"!5;G1&(U)L=````````````````%-C;"!5;G1&(U!R8T!9````````````
M$&-R;W!7:&5N4')I;G1I;F=B;V]L``````YC<F]P4F5C=$)O='1O;6QO;F<`
M````````#&-R;W!296-T3&5F=&QO;F<`````````#6-R;W!296-T4FEG:'1L
M;VYG``````````MC<F]P4F5C=%1O<&QO;F<``````#A"24T#[0``````$`/`
M`````0`!`\`````!``$X0DE-!"8```````X`````````````/X```#A"24T$
M#0``````!````'@X0DE-!!D```````0````>.$))30/S```````)````````
M```!`#A"24TG$```````"@`!``````````$X0DE-`_0``````!(`-0````$`
M+0````8```````$X0DE-`_<``````!P``/__________________________
M__\#Z```.$))300(```````0`````0```D````)``````#A"24T$'@``````
M!``````X0DE-!!H``````S4````&``````````````$O```!S0`````````!
M``````````````````````````$``````````````<T```$O````````````
M``````````$`````````````````````````$`````$```````!N=6QL````
M`@````9B;W5N9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L;VYG
M``````````!,969T;&]N9P``````````0G1O;6QO;F<```$O`````%)G:'1L
M;VYG```!S0````9S;&EC97-6;$QS`````4]B:F,````!```````%<VQI8V4`
M```2````!W-L:6-E241L;VYG``````````=G<F]U<$E$;&]N9P`````````&
M;W)I9VEN96YU;0````Q%4VQI8V5/<FEG:6X````-875T;T=E;F5R871E9```
M``!4>7!E96YU;0````I%4VQI8V54>7!E`````$EM9R`````&8F]U;F1S3V)J
M8P````$```````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO
M;F<``````````$)T;VUL;VYG```!+P````!29VAT;&]N9P```<T````#=7)L
M5$585`````$```````!N=6QL5$585`````$```````!-<V=E5$585`````$`
M``````9A;'1486=415A4`````0``````#F-E;&Q497AT27-(5$U,8F]O;`$`
M```(8V5L;%1E>'1415A4`````0``````"6AO<GI!;&EG;F5N=6T````/15-L
M:6-E2&]R>D%L:6=N````!V1E9F%U;'0````)=F5R=$%L:6=N96YU;0````]%
M4VQI8V5697)T06QI9VX````'9&5F875L=`````MB9T-O;&]R5'EP965N=6T`
M```115-L:6-E0D=#;VQO<E1Y<&4`````3F]N90````ET;W!/=71S971L;VYG
M``````````IL969T3W5T<V5T;&]N9P`````````,8F]T=&]M3W5T<V5T;&]N
M9P`````````+<FEG:'1/=71S971L;VYG```````X0DE-!"@```````P````"
M/_`````````X0DE-!!$```````$!`#A"24T$%```````!`````(X0DE-!`P`
M````%58````!````H````&D```'@``#$X```%3H`&``!_]C_[0`,061O8F5?
M0TT``?_N``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/
M%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!
M#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`&D`H`,!(@`"$0$#$0'_W0`$``K_
MQ`$_```!!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!````
M``````$``@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%1
M81,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"
MHW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W
M1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%
M,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55
M-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=W
MAY>GM\?_V@`,`P$``A$#$0`_`.TR</I6.Y[JLT]-`>YK#4/2:STZ\?']%NC:
M7U55U^RI[?2_3?\`!(3_`+"^RASNM6!V+BMH>\2&O;9[KK3=]+U[_1I]-_K^
MO3Z/_"V+=/3L!UC['8];GV$N<2T&7%HK<_7\YU;6L>D.F]/#]XQJ@[F=C>9F
M>/-)3AN972QME?6KWUOM;C-(#KH>X%VQ[FN=[75N]6FY_P#A;/Y_(Q_LF'6G
M?8*6Y#1UQQ?<VD&PV.L],5B_)<_=7;^BKR&UY'Y]/T/0]3T_1QUL5='Z=56Z
MMM(+'W?:"UQ+@+(#&[&N_FV,8QK&5L_1J+.A]);4VLXM;PUGI2]H<XM)>YS7
M/?+G;W76O?\`\8DIS/2Z(PL8.HCU*/7FP/FS]8M&;:[UFNWL]K+:-]7^G].K
MT_YM5KVU8CKC=UC)WUMK-SVUW.TL>ZVAL5.=]%K_`-'Z?Z3]'^M>OA^IAV="
M_IG3K&[7XU1&OYC>\[HT_E*7[/P=Q=Z#)<UK7:<AFE>X?R/S4E.!73B`>J>N
MVO9:2'ACC]-SF5M=:ZMY=4[=7^E_FJOYST/LN'ZV.K=?2<K)IKR*.L7656M<
MYKVD[+&VFNRI_P"CL8[_``>[]7?1_._JWV7&_5UHMZ5TUI!;C5-@DZ-`U+O6
MG3_A?>CX^/1C4LHQZVU4UC:RM@#6@#LUH24YS^B6.%.[,LM-.4,K]-+PZ&/I
M](M:^IK6?I/5V,_0,M9_,(7_`#?R@X%O5,D>W:XESB3[+:_I%_M_27^M]'_S
MWB_9MI))3C6]%SF/8[$SK`/7:][+'OVBH/\`4V,#7>^S;^C]_LOW_K?K[*T[
MN@Y'J.LKZCD5%]YN<&N<06^K]H%&VRQ^W;N=5^CV?H_T7I_9J_LZV$DE.+_S
M>R&WW75=0NI]>UUCMG(DVO'TGO8Y]?K^FS?7]G]'^<Q;+O0OH9GU?RG4WXU^
M=8<>P5>F&DDM>RUV5DV_IS<[]8_14>E>_*V5T_SEGVFY;:22G$_8&<&;&=5O
M:T$D-$Q'I-QVUZ6;_2]OJ>Q_J_Z*VK)_6K'L^K^4[>*NIY%(L;=+6N,!]V_]
M-7+][/2WMV,W_P"#_P!,^VU^TDDIRK^BY&0ZP79]KJK:Z:S4``)J>VVRV"7,
MWY$.99[/H?Z1!M^KN07?H>I9%-;6N%+`YQV%PM;O+C;NM>SU_P#"?^DO2VTD
ME.55TGJ%5YM;U*RP%P=Z=C2YNC&UM;_.-_.;ZEG[_P#GK52224__T/1QF7'J
MWV,/:6"LV.9Z3PX`;1N^TNL]*S>]_P#@Z/\`2>](](QRXN]2R2[<0'")DNXV
M_P`I!JK?_P`XK;]CFUOQFL;8Z-KMK@^*FM_T?J^]]G_6T9UG5]QVU5;9,$DS
MMGV_G?N)*;9J:3,NU_E'^]+TF^+O\YW]Z"W-J>YS665.VD@_I-1!=7K[?WJW
MI?;*]I?ZE.UNCG>H(!_E>U)2;TF^+O\`.=_>EZ3?%W^<[^]#.2`8+J@=-/4\
M?H_F_G2F^ULVEV^K:(!/J::\?FI*2^DWQ=_G._O2])OB[_.=_>@'.I#BTV4@
MAP:1ZG<M%C1]'\YCMZD<MC?I/J&DZV=N9^CY)*2^DWQ=_G._O2])OB[_`#G?
MWH1RV![F%]0>R`YOJ:@GB1M_E)?:V;2[?5M$2[U-!,AL^W^2DI+Z3?%W^<[^
M]+TF^+O\YW]Z`_/IK!-EM+`UQ:2ZT"'`P6ZM4W9`:2'.J:6F"#9$$C='T?W4
ME+4/Q\@/=38YXK>ZMQ#G:/8=EC/[#D3TF^+O\YW]ZJ]-=::;2T-(.1?!W'CU
M7_R5:/JN!:YC"TZ$%Q((_P`Q)2O2;XN_SG?WH&>]^-B67U#U'L`+6/L<UID@
M>Y[18YO^8A=%:ZOHV`RNMC6-QJ0UH,`#8WAH8I=5-O[/NEK>!^<?WF_R$E-L
M5M!F7:>+B?XJ:H]3ZFSIN.[(O;+1,-9+WF/<XMJ:W<_8SW>U9G_.')OC[-C9
M#P0"3Z8J`G7^<R3^;_(24]"H.NJ:X-<]H<3`$B9*Y:SJ6?:RMSLC$QW7PVNJ
MZWU3N<Y[&[?L]@9;NW8OL9^?ZO\`P:*S$S&VMNMSK"6.#O2J8RNLP9V.!]5_
MINV^[WI*?__1[Q^$YWUDIRA0TUTU>FVPN:'-(:_WL:UQL?[;O1V/_?\`4_X1
M7CU7!:XL=9#FG:1M=S);^[_)51E#_P#G._);5%?V3TWW0X2_>QX&[TQ7;[/^
M'?L]-:8JJ`@,:`.T!)3G6=.I>ZUSSAFPO+JB:/HDN]_K-]?]/9M_/_0^_P!Z
M=O3\46U$_9/28P->P502X!PW5O\`6VUL]WMK=7;^?^D_2+3224Y#^F565R]V
M&[(+ANL]`AI8&BOTC6,G=^8QKOTOIOJ_1>DINZ=B^I:X?9-CVGTPZK<X.(V;
M[[/7_3_G_F5?3_G%J))*<L]/I/H[G8A+(]4^B1(;`J]#]8_5WUUMV>I^F4'=
M+QW57U@X=9M,L<RG86@F7;RS(#GV^UGZ5CZ??[UI79%%+JFVO#'7O].H'\Y\
M.?L;_88]R*DIR;,7!?F-KNLPW.MKWOI-?Z1Y9[77,F_^9999]#TG[/5?^E_6
M$F].8VL@68GJ/<TV?H3Z1;6/T>S'^T[:[6S_`#V]6K?^5L;_`,+Y'_5XBLW6
M>G4^R)V-+HXF!*2G'9B-LZEU![K,=S?T?H-?4#L<6[M[WML8^_=OL]KOW_T?
M^$]2/4&=.P<<]3S[,44XX-F;8,=SB1+&;ZV56V/K=[6,^AD+FOJ[_C(LZGUN
MC&/3!2WJCVM#_M&\LVUN?]#[/7ZG\W^\Q=%]?_\`Q&]6_P"(/Y6I*:?U<^LO
M3>H&[IO3<^LY(=;?2QV)=6UE`L_X5]3+/9;5_A*_^*5WZQ?63_F]CU9V0?M6
M/:]N/Z-#!ZGJ.;99ZOJ6Y+&>E^B_F_\`IKA/\5__`(K'_P#A&_\`\^XBZ/\`
MQM?^)_#_`/#]?_GK)24VOJ?]97=:P/LN,?LMG3&T5W/OJ:6O#FN;MI;5E';_
M`#'TW_\`;:I_7SZT]5Z-=1B8WV;(HSF6N]['[F>FZD-][+]MG\Y^XQ4O\4/T
M^L?'&_)>@_XW/^4.D_\`$Y/_`%6*DIUN@7]4^M.+C]<R,BFFZI]N.W$8US:_
M8\[K6/=9;9ZMOZ/?]/\`FV+I6]/O<9>]H^]W_D5A?XK?_$HW_P`,Y'_GQRZY
M)3G8W0>G8\&NIK7#NUK0?\^#;_X(K;,3&9Q6#YG7_JI1DDE/_]+NL=]3OK3D
MUUV![JZM]M0<TFMSVX[=S_3LLL;Z]=57Z/(JQOYGU:/4_26*Z>EM)W'(NDDD
MPZ!J2_Z,(>\_\X=CFM(^R36_8-X/J#U6^KMWNK_FOHO]-&?=U,/(9CM<V=';
MQQ)\8_,VI*;)K),[W??_`+$O3/[[OO']R8OL$G8('?=V2%EC@'-8"#J"'"$E
M(<RW[)C/R(LMV1[&%H<9(;IZAK9W_?1_3/[[OO']RR/K%UOIO3\0T]0R:<6R
M\34RUX:7!KF;]NGYNY7\+J6-U''&5@65Y6.XD-MK>"TEIVNU24PS:W"["ASC
M^L?DJO5KTS^^[[Q_<O(O\8.5EM^MV6QM]U;65T.:QEKVM:XUF7-;6]K5Z5]5
MK;K/JSTA[Y>Y^%CN>]SI))J9+G2DIXCJ7^,CJ.+UO(K9@TO;A77X3'.M>"X>
MLRKU7`,]KOU9J]&RJR,6[WN/Z-_?^25X7US_`)>ZG_Z<K_\`VY>O=,MUGV:X
M;-/3?K/\DI*?$_J/_P"*/H?_`!K?_/-J]1^OK-OU-ZL=SC^KGG^LU>7?4?\`
M\4?0_P#C6_\`GFU>H_7USS]3>K;FP/LYUF?SFI*>'_Q8B?K6_4C]1OX_XS%7
M1_XUV[?J_AZETY]?/_%9*YS_`!8$CZUO@3^HW^7^$Q5T?^-<N/U?P]PV_K]<
M:S_@LE)30_Q1C<[K`DC7&U'PO0?\;38S^DZD_H<GG^OC(W^*,N#NL;1N,XVD
MQVO0?\;1<<_I.X1^AR>\_GXR2G=_Q7-GZK-,D1E9&G;^<*[!<?\`XKB[_FLP
M`2/M61)G_A"NP24I))))3__3[\,:?K0YVQ@>,(>\M]Y!L/M:^/H^W]__`*VK
MKNHX37;76PX$B(/(.P]OWE0:QH^M;GR2YV'WB`-[?8T_N>W?L_G-_P#P:U'4
M4..YU;23W+02DIQ/K=]9V?5W`IR1C#-^T7C&=5Z@9$LMM<_Z%V[^9V;%4^HG
MUGKZQ@68WV5N$SIC:<=OZ0.#AL]I:T5U>E_-_05'_&U_R%@?^'V_^>,M5/\`
M%#_-]8_XVC_SV4E-7_&RYKNH]*+2#^@R.#_+QUT'^+.QC?JE1N<!^GR>2/\`
M36+G_P#&W_RETK_B,C_J\==%_BR_\25'_'Y/_GZQ)3PO^,,@_7'-(,@TX^H_
MJ.7IOU3MK'U6Z,"]H/V'&TD?Z*M>9?XQ/_%EF_\`$X__`%#EZ?\`5+_Q*]&_
M\(8W_GJM)3XSUS_E[J9[?M*\_P#LR]>Z9=M?V:X;VR*WZ2.P*\+ZY_R_U/\`
M].>1_P"W+U[ME_T6[_BW?D*2GQ'ZCQ_SCZ'_`,:W_P`\VKU+Z^V5N^IO5@UP
M)^SG0$'NU>6_4?\`\4G0_P#C1_YXM7JGU_\`_$;U;_B#^5J2GA/\6+FM^M;R
MX@#[%?SI_A<5='_C8>Q_0,/:X.C/KX,_X+)7._XK_P#Q6/\`_"5__GW$71_X
MV?\`Q/X?_A^O_P`]9*2G/_Q1N:UW6"XAHG&YT[7H/^-IS79_22T@_H<G@S^=
MC(_^*'Z?6/CC?DO0?\;G_*'2?^)R?^JQDE.Y_BN<T?59H)`)RLB!/_"%=@N0
M_P`5O_B5;_X9R/\`SXY=>DI22222G__4[ZBMCOK-D7,:]OIT"JP['-8YY]*W
M=O.-Z=KFU.I:VQG4/])5]E_0>HKEF%:^\VC)L:TN:[TP3M$;1MY_/V?Z_IO6
MMH=K[&.K#&;P]VUYF-K8/O24\5_C9:1T/!)<3.>W0Q_H,OP"I_XHP35UB'%O
MZ6C41_HW?O!RVOK]T;J77>F8^+@UM991E"\F^QM;"QM614[:YOJN_P`+O^@J
MOU"Z%U7ZO5=1^WU,M=D.K>QN-8VT@,:YCFNW^C[OW4E.-_C9!'4>E2XN_09'
M,?OX_P"Z`NA_Q9M<?JE1#RW]/D\1_IK/%I5+Z_\`U<ZOU[,P;L%E3!CUVL>W
M(M;63O=4YI9L]?\`T2UOJ9@9W1.@58&73ZES;K7.-#VO9^DL=8/<YU3O9O\`
M?[$E/GW^,/3ZXYHF?T./K_8<O3?JFQQ^JW1CO</U'&T]O^BK_DKC?K=]3>O]
M7^L.3U'#90*;64UAMUP8\%K=ON:QES?<YWM]Z[3H+,C`Z)TW`MH<^S'Q:JGO
MK+',)KK96YS'^HWV._P:2GQGKG_+W4__`$Y7Z_\`H2]>Z9;'?9KCO=]!^GM\
M#_)7EO5/J%]8LGJV;E5#%%-^9=D,WY`:X-=<^\->P5N:U^WZ?O7I]]MUE=M+
M<>S<YA`)+`V7!S1[O4\DE/BWU'_\4?0_^-;_`.>;5ZE]?6N'U-ZL2\N_5SH8
M\6^#0N,^K/U%^L/3.M=-R\D8SJ<.P%XKO#GF*WU>QCF5M_/_`'UW/UHQ<SJ_
MU?ZATW&H<R^^OTV.M<QK).U^XO:]_M_LI*>`_P`6()^M;X);^I7ZB/\`2XOC
M*Z/_`!KM+>@8<N+OU^OF/]%D_NAJJ?4CZJ=;Z+UUV=FLI=4<:RD-HN%C]SWX
M]F[:]M/LVU_]-:_U[Z3U+K_1\;&PJ15;7DMO/VE[:V[6UWL<)8;G;_TF[Z'T
M$E.)_BC!+NL0XMUQM1'A?^\'(/\`C:!&?TF7%WZ')YC][&_=`6M]0>@]6^KW
M[2=GU,L^T>D6-QK&VG]&+FOWA_H?O>Q1^OWU;ZQU_)P+L"NM@QJ[FV#(M;6?
M>Z@@L]/U_H^G[DE-G_%<"?JLP[B`,K(TTU_2'R78+F_J-TO/Z-T1N!F5M=;Z
M]KR^E[7U@/=O'N)8_P#\#72)*4DDDDI__]7U5))))2*_&HR:_3O8'LUT/F"P
M_P#0<Y-1B8^/N]%NW?&[4GCCZ1*,DDI!?AX^0X.N;N+1#=2`)UX:5.C'IQV>
MG2W:R9B2?^J1$DE.3U-_3J,MKLRAS@^LO^T3+6PZG%]'9OW_`*3[2SVM9Z7\
M[^?_`#D,?ZQ=--;ZL>NW]7I-KV.;&T`L&RQ[W;6V?I=UF]_Z'])]I]);*22G
MGG=4Z`YKK+*[#:\D>F-Q+GRUSO2]VS8_U&7UV_S-]7ZQ5^CI_1V7_63I[L4W
MULMNI-GH2&[07;7O<UGK&OU/;7^CV?SMEM-=7TUL))*>?IZC]7*[::ZJ[&O#
MJV4#9;'NL^SU_P"8]OOW?S/\W;^F_1*QD=;Z7;NQ<EEA:YVW5AV%S7PS],/T
M;/\`2>Y_L_/_`$BV$'%_FG?\9;_Y\>DIH=(NZ3DVV.P*RTT@`N,@>YU@V['.
M]KMU=GTF>SU/])ZJOY&+CY3`R]F]K3($D:P6_F_R7*GT3^:M_P",L_\`/MRT
MDE(:,3'QRXTLV[XW:DS&C?I%1R,#$R7MLNK#WM@-=)$0=[?HG\UX5A))2.C'
MIQV>G2W:V9B2=?[2(DDDI22222G_V3A"24T$(0``````50````$!````#P!!
M`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<````!,`00!D`&\`8@!E`"``
M4`!H`&\`=`!O`',`:`!O`'``(`!#`%,`-@````$`.$))300B``````%&34T`
M*@````@`"`$2``,````!``$```$:``4````!````;@$;``4````!````=@$H
M``,````!``(```$Q``(````>````?@$R``(````4````G`$[``(````)````
ML(=I``0````!````O````.@`#J8````G$``.I@```"<0061O8F4@4&AO=&]S
M:&]P($-3-B`H5VEN9&]W<RD`,C`Q-3HP,SHR-R`P.3HS,3HQ-P!R<C$W-C,V
M,@```````Z`!``,````!__\``*`"``0````!```!S:`#``0````!```!+P``
M```````&`0,``P````$`!@```1H`!0````$```$V`1L`!0````$```$^`2@`
M`P````$``@```@$`!`````$```%&`@(`!`````$``````````````$@````!
M````2`````$X0DE-`_T```````@``````````/_A`4A-30`J````"``(`1(`
M`P````$``````1H`!0````$```!N`1L`!0````$```!V`2@``P````$``@``
M`3$``@```!X```!^`3(``@```!0```"<`3L``@````D```"PAVD`!`````$`
M``"\````Z````\`````!```#P`````%!9&]B92!0:&]T;W-H;W`@0U,V("A7
M:6YD;W=S*0`R,#$U.C`S.C(W(#`Y.C,Q.C$W`')R,3<V,S8R```````#H`$`
M`P````'__P``H`(`!`````$```'-H`,`!`````$```$O``````````8!`P`#
M`````0`&```!&@`%`````0```38!&P`%`````0```3X!*``#`````0`"```"
M`0`$`````0```48"`@`$`````0`````````````#P`````$```/``````?_A
M0`]H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O`#P_>'!A8VME="!B96=I
M;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^/'@Z>&UP
M;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB6$U0($-O
M<F4@-2XQ+C(B/@H@/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S
M+F]R9R\Q.3DY+S`R+S(R+7)D9BUS>6YT87@M;G,C(CX*("`\<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@("`@>&UL;G,Z>&UP/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C`O(@H@("`@>&UL;G,Z<&1F/2)H='1P.B\O;G,N
M861O8F4N8V]M+W!D9B\Q+C,O(@H@("`@>&UL;G,Z9&,](FAT='`Z+R]P=7)L
M+F]R9R]D8R]E;&5M96YT<R\Q+C$O(@H@("`@>&UL;G,Z>&UP34T](FAT='`Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B`@("!X;6QN<SIS=$5V=#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E179E
M;G0C(@H@("`@>&UL;G,Z<W12968](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B`@("!X;6QN<SIP:&]T;W-H;W`]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B"B`@('AM<#I#
M<F5A=&5$871E/2(R,#$U+3`S+3(W5#`Y.C`X.C4W*S`U.C,P(@H@("!X;7`Z
M0W)E871O<E1O;VP](E!38W)I<'0U+F1L;"!697)S:6]N(#4N,BXR(@H@("!X
M;7`Z36]D:69Y1&%T93TB,C`Q-2TP,RTR-U0P.3HS,3HQ-RLP-3HS,"(*("`@
M>&UP.DUE=&%D871A1&%T93TB,C`Q-2TP,RTR-U0P.3HS,3HQ-RLP-3HS,"(*
M("`@<&1F.E!R;V1U8V5R/2)!8W)O8F%T($1I<W1I;&QE<B`Q,"XQ+CD@*%=I
M;F1O=W,I(@H@("!D8SIF;W)M870](FEM86=E+V5P<V8B"B`@('AM<$U-.DEN
M<W1A;F-E240](GAM<"YI:60Z-S8W.30S14(S-40T130Q,4)"141!140V1C9%
M1C<T.#(B"B`@('AM<$U-.D1O8W5M96YT240](GAM<"YD:60Z04)&,4$T.40S
M-40T130Q,4)"141!140V1C9%1C<T.#(B"B`@('AM<$U-.D]R:6=I;F%L1&]C
M=6UE;G1)1#TB>&UP+F1I9#I!0D8Q030Y1#,U1#1%-#$Q0D)%1$%%1#9&-D5&
M-S0X,B(*("`@<&AO=&]S:&]P.D-O;&]R36]D93TB,2(^"B`@(#QD8SIC<F5A
M=&]R/@H@("`@/')D9CI397$^"B`@("`@/')D9CIL:3YR<C$W-C,V,CPO<F1F
M.FQI/@H@("`@/"]R9&8Z4V5Q/@H@("`\+V1C.F-R96%T;W(^"B`@(#QD8SIT
M:71L93X*("`@(#QR9&8Z06QT/@H@("`@(#QR9&8Z;&D@>&UL.FQA;F<](G@M
M9&5F875L="(^36EC<F]S;V9T(%=O<F0@+2!)5$5+("T@1G5L;"`Q,"U+(#`S
M(#(V(#$U(#<@4$TN9&]C>#PO<F1F.FQI/@H@("`@/"]R9&8Z06QT/@H@("`\
M+V1C.G1I=&QE/@H@("`\>&UP34TZ2&ES=&]R>3X*("`@(#QR9&8Z4V5Q/@H@
M("`@(#QR9&8Z;&D*("`@("`@<W1%=G0Z86-T:6]N/2)S879E9"(*("`@("`@
M<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#I!0D8Q030Y1#,U1#1%-#$Q0D)%
M1$%%1#9&-D5&-S0X,B(*("`@("`@<W1%=G0Z=VAE;CTB,C`Q-2TP,RTR-U0P
M.3HS,3HQ,2LP-3HS,"(*("`@("`@<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O
M8F4@4&AO=&]S:&]P($-3-B`H5VEN9&]W<RDB"B`@("`@('-T179T.F-H86YG
M960](B\B+SX*("`@("`\<F1F.FQI"B`@("`@('-T179T.F%C=&EO;CTB<V%V
M960B"B`@("`@('-T179T.FEN<W1A;F-E240](GAM<"YI:60Z-S4W.30S14(S
M-40T130Q,4)"141!140V1C9%1C<T.#(B"B`@("`@('-T179T.G=H96X](C(P
M,34M,#,M,C=4,#DZ,S$Z,3<K,#4Z,S`B"B`@("`@('-T179T.G-O9G1W87)E
M06=E;G0](D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I(@H@("`@("!S
M=$5V=#IC:&%N9V5D/2(O(B\^"B`@("`@/')D9CIL:0H@("`@("!S=$5V=#IA
M8W1I;VX](F-O;G9E<G1E9"(*("`@("`@<W1%=G0Z<&%R86UE=&5R<STB9G)O
M;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P
M<V8B+SX*("`@("`\<F1F.FQI"B`@("`@('-T179T.F%C=&EO;CTB9&5R:79E
M9"(*("`@("`@<W1%=G0Z<&%R86UE=&5R<STB8V]N=F5R=&5D(&9R;VT@87!P
M;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F(B\^
M"B`@("`@/')D9CIL:0H@("`@("!S=$5V=#IA8W1I;VX](G-A=F5D(@H@("`@
M("!S=$5V=#II;G-T86YC94E$/2)X;7`N:6ED.C<V-SDT,T5",S5$-$4T,3%"
M0D5$045$-D8V148W-#@R(@H@("`@("!S=$5V=#IW:&5N/2(R,#$U+3`S+3(W
M5#`Y.C,Q.C$W*S`U.C,P(@H@("`@("!S=$5V=#IS;V9T=V%R94%G96YT/2)!
M9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD;W=S*2(*("`@("`@<W1%=G0Z8VAA
M;F=E9#TB+R(O/@H@("`@/"]R9&8Z4V5Q/@H@("`\+WAM<$U-.DAI<W1O<GD^
M"B`@(#QX;7!-33I$97)I=F5D1G)O;0H@("`@<W12968Z:6YS=&%N8V5)1#TB
M>&UP+FEI9#HW-3<Y-#-%0C,U1#1%-#$Q0D)%1$%%1#9&-D5&-S0X,B(*("`@
M('-T4F5F.F1O8W5M96YT240](GAM<"YD:60Z04)&,4$T.40S-40T130Q,4)"
M141!140V1C9%1C<T.#(B"B`@("!S=%)E9CIO<FEG:6YA;$1O8W5M96YT240]
M(GAM<"YD:60Z04)&,4$T.40S-40T130Q,4)"141!140V1C9%1C<T.#(B+SX*
M("`\+W)D9CI$97-C<FEP=&EO;CX*(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M/#]X<&%C:V5T(&5N9#TB=R(_/O_;`$,``0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_;
M`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`2\!S0,!$0`"$0$#$0'_Q``?
M``$``04!`0$!`0``````````"08'"`H+!0$$`P+_Q`!S$```!@(!`0$'"PL,
M"PH(#P`"`P0%!@<!"``)$0H2$Q06%R$5,3E!5WB6E[?6\#A1559A<7:5M=37
M&"(W=X&1H;&VP=/5&1HC)DF'B+C(T?$E)R@I,S9"6-CA)#(U1V)R>:4T0T1&
M2&1E9F=H:8:GQ,;_Q``5`0$!`````````````````````?_$`"$1`0`!`@8#
M`0````````````#P`7$1(3%!D:%18?'1_]H`#`,!``(1`Q$`/P#8$W5U\>L]
M1'0Z$,FUF\T+AFWLTVFQ:T2@>WMT0Z,H4]4Z]+9]$4<`86*2)&J$H4\D;R5*
MU(U),$+2A'DF`#@X0\A:JQ=G=PM5=E^J8XU"I:;MIS4&B=()L]1W9*Z;2<5+
M)%6>F9ZLE:2LFU$WR!*.S;;`VK)#,YNYJ6E*X/T61+I*BDSB]$*6D*[MWK2S
M.-W#.$58U!$9-4-(DZ^>="..QUG.&P5@"O&+Q&<R%12K-"H:^P@KS.128)%,
M@;INYI%$S6M;N5%U):4E*J5!)WU#]I$6F.F&P&Q!RE.2]PF"+DL!3J,`.`X6
M9*#"(K72(240P&+$N9@\M"IV*)[\TEC2NBT>/`)31`"$SIJ=0285=KCU":NG
M&R#1NW:FFE%O.VU=6DY6:OL-/9D57485.97`3Y:<Z/CV>UU;;[4OA;HI-<5)
M[<EE+8E;NQN(;>_"_A/4GZA3W+D\'8=?=243Q.]%">H-`%KW:MK'H8A4#>H3
M-[K#[`(;X0`V360[.;S'$R!-%%+/&6`+@K-/?Y,4WB.."MV'J;[0;*)8H1IM
M1E,G/L=TUJS;Z\T][3J6M[<F.MIL='.+TA6*B)-!9RV3+DD;?%@)_)`)HDD(
M,;B75O0K?#DY"Z51=4DR\)BE(A5<-Z"#O/2];-_FD][<UPI(BEZJPYO`W*KW
M3"<@A`I9F95#S2A2%$04>X'X-4I20HSDV.!:1BZF.V-R"H.(4'2E""L*YNG0
MCWM>'&TIM.VN&PO":8)8P]1=(BC3,YO4I`J4N;(ULJ82N/&EGNRE[<GK"-DR
MTNH4CJQO5M?MAOMJ2YLB."1'7BWNFLZ;"2ZI'"6R(\YF7KKBBD)E,N:AH(=@
MJ2S]JFC>T1B$H7]R1Q]+5SO*WG*UFE:]8RO`9Q;*[4;(I-HXYISI_7]-R.V2
M]?W'9N?RF_I%+V*!,]>YG2FMHG&&!-!D*U\=)C+I8VO(1K5`B&:,M35A8O+7
M&.*8@`1;SC:'8'?C87HP/%?C%55#WZ7L%/+-K9KO2VJXDRVQM9I4W1N[6>0O
MM6M"`4F9*T*:SEE&)PO!3'9<F<W]%8:*+1L#4ZJPS"ZWD$DS!J=.]FZ]V`V@
MIZQ*V/HV',3=3&P=E59!ES?.]CJZA<@<9%#H8]M+4^R`V/3EY0IGM:$:U.62
MUA"/)3<07P*@NZR=@]*9QJ)I7J,@_5#6#M&#9I_;;$W>OVU)F9"CZ<:*TER@
MV03/*:3SA]C:AGDSVWMS`W@RH1.868*0U,WB=#`A;)LZJMM(=XX#KG)6'6V4
M5Q8&Q,PUP#BHY/:TML>$/;`SR!<RRN:S040Q1!"YU4L&2Y#3S?+S[%A/CHR%
MV7,QF=#@!8723>K;JLZ^H:0W*T1>U-=KPZ@UJZ@I;!D=J3Z7['-DNL*[;%8Z
MRD1J.1-QD82U9%7IJ)K?$5*?W5\0LR5O?VPUO:`Y9$09#1'JB;!/B>J=FW2F
M*E2:#7?M9G5B#NZ*7RL[9!J\=LR04K'KGD[`>U@A8HFY69&'!*Y09L$*8,S&
MI3.!*EXP2,1X8VVAO9N/L*Q:5WM$F2(4[J7;?5AH*FH&Z0.U[!9[ZEL`B]^2
MBKY*WW#'T+8@ASO7MIK(E)TSU"T[]GU-+0LJ-V:Y<VN1SHV!?ZF>KS/;9V9C
M,4155"%^N]@[)S[6:.&Q@VTG:^(@JAZJ1L3%=%B(LPKS8)ZUF4MCN60]J020
MAZ@Z9Z:G1Y<''^ZH\A_*@>J3L_9B[2BQYU1=)Q_7C<2[K-UQ9#(Q/9F[6ZS3
MJ!NMEM2:;JVQRCZ*)H8:M<ZS?6<V.8<7=]$207(_5I*%P(CJ</:JKJA[`S$.
MLVQ4IIBI6O1W<79-+K53:]DE\L5[%QISETKE4&JJPK#8UC65!CX_-Y/$E!+G
M&V!5AZAS>]-RQ>M7B0N!/`I*M>L!.W'<"54)=\>I6AFV-32XF9;4-B$W7%=@
M@P.N&EZ<XO8D-EKA#U=(6X?/D;+AV;(1%G9D7F-3HE,87N29*(-=`N50G4?V
M6E<FT\GUY4I4$.UFZ@3\\QO7]1!)M*9!<59NRF-/<WK$JYD;BUD11_+L6+L"
MO(SH+E(7$5Z@@M\%CP9A!H410/5)V?LQ;I38\[HNDX]KQN+=]FZXLAL7GLS=
MK=99W`W6RFI+-U;8Y1]%$D,-6N=9OK.;',.+N^Y*(*DF'I*%P)CB<'5ODUK!
MVOZ<580)=MZ[1JQV7<]9-ZNTXOA;0U@V";!XE2;K%U:M^%.Z_8%Z6&J5[HZX
M+>WC)J=N6/:9I#D]S.)4!4P;YN'2S7/7<B%T]L._61M#O/&M?$,&Z@6RR^RY
MW%U%C5Y+<L[^*T6!^N'++`$[K6K0O!'FP3R-"E=I>ZI(\<_.)254&+-W=07J
M"2M'4=?1%GH>N;JKWJUPW32V#(_,[`25?;.5-?J;0KUI*7*(8_3:-U?+B`+"
M;4,3!,EB8R.L")J2O#'*Y2R-@9"_V7B>K]LY%74>JN#OE"0[<<>E4E2MYMI.
M6PZ>1MCFGB4LO8#<U0M=6)-112=J<LZYC/?QS-2Q(%4F+\`G.(2A"RFS^_6V
MU@ZN=3.QRH3$*NUZU1M6X=<62:U7=-DP;9V8V55&Q5?1%HD$:?X^UA:ZZB*^
M$/9^)(L`X.$A7/R=8U(&XF.NPEI`7GV8ZI.T%/.6\DN@M%TG(:7Z?]LU+&[2
M72B>3-OL>QX;9K%7C@:@KID:X^ICS3+&)3+UBI:^RA\]1LMH6Q,WQQV7^/9*
M#U]D.IOLW`#][[)I.CZ6F&O^@ZY'7T^%8$^E\=MN=V8NB\<?G-WAS6S1]PC"
M.$0E1+F@AS;GUP2/,K;4;JNC[PE<<IF3@7@ZL%\;&5?HS$+-UQ?(]#9U*[<U
MOC\D<W1T<6LY%$K*F#,S.#9'G!O87U6G5/$B=H['G=<`MN7MD(<92\,KCB1M
M[2W.`836+M]O;0>R_5,GD<;:PLB*:T45I!:UF5U85N6MYO(+D5,SU^LV,ZW1
MU-'E!*-SL9T3/#D=*G=#%2#@P]B/E#"\N3N3ZB!<6_\`K,SN$6_.8[3]/0V7
M0FB8)KK.+5B,F66.9>%DF[!1-DL@,7HM%!XC(80G=J^KJ0M+T\*IZ[)DTC=5
M)[(QD@$@/5&!D+UF["GL7T[K][J>57!&G68;.ZT1<9E(3IZJBTI+%IK.$S>Z
MP^.2A&[Q=8R.4L;U6&I.!T<VQ$2O4IA.XTY"<W)88$T/LY86F>R^P#C>`]ZX
M!1L?T.L*]8M1&[%SE["SRT['J25H7*3/U-V"AD-A,<53L<,,(CKY#UD[(/7N
M$M;Y.K9B&IG.7(PR>,ZI&Q.O22-2/=ND*D9XS=FIUT[4T0GH*;RJ0/J0ZC(.
MR61*Z4LL4L9RF[$I4Q*5Q[**>QT940]6/'41:%41_P"&)PM0V[)=1>1;?ZAK
MK!CM8QMVL[23:VZJSI6I;<LM;6,]E`HA`)'6\+NJ.O:)G:AS6%.*YO93YFU+
M)$S9S)G17&#&XM">%R#,33SJ5N&Y-I:_0NOH,QDQZ6::E;);!/1JYS-5U;8+
MA/%%5-E/M0`X"0>Y^7,7L@Q0)X"6OQ'8F%:8D1J%Q!9@1I;YWFHA&_\`M\=:
M[[U2'RB*:UUU_G!;/H-=,IA49JG+VCF0I?,K&8$UMUZV(6ES);4*K+T@;G8*
M4#2\.+[E(D(R>8%SX#U`MF=<M5-!:ND3_6EF;";-QJZ;-;+:OJ?R>PXC&:%A
M#V&05X78,VHEBECK9MG26&S"%10+]%"U36E>4+N[R98K"GPH=`NQ;G5IN%NU
MLUMNF!0.BZNEMOU?:D[EU;[#O%QN<Z32>HWT,3>X'7%55-`72SI,WO#^A>C6
M^SG9D:8@W,>6)<Y%^$>D91@5E'^I/M#L@IJ.-:<4333E.'K2.M]UK2:KQL64
M,+44GLIS<&=AI*NW6.L/@39<N5L+RJ(G4LRWPU&A4,^'<E`>)P+1A8RV]M=X
MZHVUW[G=>1N'.D8H;1K738NQ*5NZX9ROAU:!8HC8\RLR(U6R09O=HTXV+*DK
M.[M1LV3CC\?5K(HVJ70+PE<404(>G;?6PG;1/7LNH*6ALCA-2U5K#9]K0>3.
M5CK+OL`W92"QRU0P^BR8/#'N$!=:XKJ4-+L\.$^<$":3NIY[.QI21(3U`PKG
M8CJT612>Z1U`/D;I.GJSR_4VAKN2;&DW?$OU1<<L-`S.,OE%>W!&86^U+6OD
M2)X/:@LUC)U0E;E'W-,ZN+$Y&&,[:$B>]^QTMU?I-OGL(44LAD;[8<2@2)SO
MB6R*.0IJ#(\.9I[@E986S/T\LJ1DE-@@--;P9#Y3OH#%B](:%,T+`&!1O3<W
M&DN[%#RJP9G%H[&)G7%W6A14J%#PS)+$)*[ULX(2?*Z+LUBLD<L.,L[ZA=$1
MY<9G3.@EC.>!0E>TB-:$Q"F#7<U"DVW]OUMK1.J6DG5<FNR:[9YS'-[,L&UY
MO(^GZ[5%&MBINP3-'($T^G+DPN[(TU6TEQM2UL;$0^ESIK6IV8S*U,4%0$A4
M,W8NVF*^WVE)5@5U(7Y'U@;LH:!K]IK,L13$Z^KTFLJR?&J*5W$HJ@EEAS(+
M4X>.>3-.5@VI3`X>GU^1ITY"-RPJ"WL#ZC^YFT5T=+<ZO6VJX(SV3?NY57W=
M"S'^R6&(60[Z\0.1EOKOA.]5\"PFF,(8(J6SJN8?*$3<[#MLAE9[#;FQ(Q)9
M`W!?W6;J\3Z_MA:Y8P57"#==KQMJVJF@"Z)&6DZW57`:X5RMIB]B7*F4PPNM
M2XK:#S#U:!,WQN0X60,QV:@OKD[8PH,P%)U;U@K:D.P)=72Z*:VRJ,SRL]II
MK`55%2ZUY?Y"O>ML=5RT+!.;1D$*9*CM<F5-";Q90MI-V<,Q=SSDN0$H2CVG
MU7#+.H.H9,K(?^E:S+J\C#:7U!:-NVV9B>D='8T=?.-55I7LZ;VF,A.#V.B)
MU5S12A6GNN0J"4Z-.:1C)IAO8$K?`<!P'`L?/]>ZYLNX:!O.4)G<V>ZU.%E.
M57J$3J:C:TJJUX,HKN7Y>6T`!%O`#XVJ-+0`.&7A"L[U6#OAA[W@6MFFCE#3
MYQV[=9"WR<Q7N_`(%6E[92R10E`OBU;Q62PZ,DQH`21>3BTIEE;P6L5ILG#5
MJ#"%`\!$0''`M'+NEMK++K$06$)TNR+X/04T@L."0>XI9$ZXNT6OZ!M:JE<+
MCB[2<2&6N42:65F:TRLA8T^-H&I"G7`4A)_7!DW?VLM6;,!J=+;*-Y>6>G+?
MB5X1J.(W8Q!'W:>0;"T47-E[:64,J3,C8H7J%F&!P%EK5*_`GK"#Q)R/!A:J
MY>G[K9=\X5V%)8V[1Z1NM!6_K/(#(`[!AR.45!=C(M99?')&B:T82G4:3*TQ
MXC2L[L-8WXI.YD>$&2$'`]=NT;H9JE3!,4C?)\/4:T^.T<:S#)&H&G!0Q[BR
MNAC><GR1WATFRK8&_/E&+.%&"PFE^`[#A9P%@I7TE-6Y"P5DP,+[?%6>;>C6
MW694\U'<DB@C[9VO[488<FJFV5S<487+HWX52X&"4%IFM]QZIK2BGDDD1!9(
M5?8G3!U:L"15L_(DMFU<GK:B"]70QJF[2EE<1R=:YI3S5;;35B$,BP+G(X2W
M+U*Y<6F*=&UP<%"]9A\<7=.9@D(5]5VA&OE/R&OY/#&Z5$.M9ZGF:7Q8;A)U
M*\@FD39,TRT:%8280$*R2>K#(@%B0CSA1XN`PCP/>F9SP*.K3ILZ]4[.];K"
MK-UMJ'OFL51NU$PY.T6*M):9A5#M(#I8*&VD@$B'Y9-*.4G8D20@1K>$3PD;
M52["W+6W82A66R^BU2;.S&)V4^2NYJFM2'Q=^@+?:5`V:\U7.E]<R=40X/U=
MOSLUEJR'B(N#FE3NH4"M$)4W.A7C[2N;U)IHS`].)Z-:Y0%]U2>X-#UD3!I?
M$+.A%$,K.]+@LK(Q6^QL3#.,/J=6-6KDSDYIH\C6Y=W9<:X#>%#BZJE*M:O/
M-R%S-CM>JXVHIZ3T9;29V60*7.$,<WA.Q.IK*Z#50*=1JQ(_E.Y$@-,(`7)(
MFT&*PA!GQI&`](+(0GY%@/DYU[KFP;NHG8*1IG<RQ==&^V6RME*-T-2M*9+=
M+''H]-PO#6$L13J,]MC+6%M&:,O+><`\TOOQ'9Q@,2(MTJ]9X=84.GS*^W@!
M-6M\O^QM7UPJMI[5557-CR\]W63(V+PDPCQ++1*%SVXK%R1[.>5K:-4L(C3B
MQ(71W2N`?YKGI2:K5A8$#G<>47(L05S9LHO".U?(;>E3Y3N+RD[D_KQ7(JKI
M8=ZBYL!B32):RQQQ1X1M[>V$-YIK6J=TN'40>A'NEMJ[&;C;K:;S;9/9H_<#
MCL-$:$<+3D:[7*%WRZ'J5JJVXM5)H_4]MEI;JN<GEL+$O41]B=W!2O8F-L.`
MDRE#Q$W27U/26`SSHE1=&&V);",FT=>54.XY<;2U8W2TS(B>KY7`:S,49C[+
MF32,HXU\2&E+2"43F]-D>"P-[VZIU@5S#>FYKU`;[Q?<9=[E1&$6+-+A::;\
M[<J'K\P6W8B=63-;%9JKP>%K3OSZ:O6N`TBA4KCC:Z*1N3,Q-JPL@XD/<AW3
MUUR@L$UJKI@;9:7&M3[@E5XU"4JE*I2K1SV9/%@/KVH?E8R,#?&P:^S)0),V
MGX++3%&HB@#SA$7G(4+`>EMJ[7%LQRSV,RVEC'`K$D5O5;1#]:<B>-=ZGM>5
MG.*AZL6O*L4BPW,LC,5/D@6-V%"QP:&)>_.BYA:FU:8F4)@_0T=,?7=LL^+V
M"ND-W2V.P.UGJ\:_I&;VL\2VD(+:[ZD=4:B81J(O2=2ZISD`7QX/8F19)5T8
M85#@I,:6)($0`!#^=&]+O6/7^S8=9$/56^^I:F-F9U`U=/[7DTSJ'74RP@K"
M9@.F80Z&9)CIKRB<%S;DYV6OYZ!`J-):S4(LX-P%:PWIZZXP6":U5RP-LM+C
M6IUP2N\:A*52I4I6(YY,WJ?O[VH?E8DX1/C8-QLN4"3-IX2RDY1J(L(Q>)@S
MD/;VBT@JG;&64_/)M+[MKZ<T638B:N9I15NRJG9:T)K3219!-$XI'$#TCP82
MZH8@THAEEK"`91B7IC<'$+CB^!X+5H%4B>*U9%998.Q5N`IK9>-;6P*0W9>L
MVM>8-=G1**JXBQ-XI3-%;J[#@*)O<G-8&%EGE-07IT<W4O`%2Y2(T*3M#ICZ
MWVBBG!:QRMR&ODZVEC>XY\TKNQW"*3.,WM%8GY#-4DAKVG1*!,"0$7,5-HV\
MLA1@(EJA<E.2N`$RM,'I"Z;6O>-@#=@TKS<[6N6VNFOMYJ9FMN4-%#R"]4S,
MF8<6Z]U>W&IFM9,U3>E`%T'A24R/1HSC7AE7"-%VA[T@Z>NN4FHG9/7-U;9:
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M#/M?1=Q`[&)L'(I4L9)&[J)&_@"8H>GA5ER.++,#@.`H"Q.EOK18TT;9FI=[
MOAPAQ6I87847K>Y);!(?=T>HO`<54EN)E83DXI6JAX2R2VYT2*V9TRG()2G+
M#4I>".!D=M!JU6.W%8I*HM(^8MD=;)E$9\SN5>RIP@TK8Y7!7##K%WACDC1V
M.#2K:7$):M*>B&2H(4$$&D&E&%`'P+#5OTS=;8-*I=.)8Y7AL++YE5,IHUQD
M&SUZV5>R]OJ2<Y_OT@C!F;OJXAD993C.2W?Q(DM::28J()6$$+EY:H/&J+I7
MZM52H?3'`RV[H1.--R/72.,M]VM)K-9*TH*7I!-LGJ.M6]Q-2@C$5>VG!#*M
M/R)=)!LJ1.TEOY;?@Q.8'YZFZ:E*ZURB*756BFY[8N6E:OGE<TP"[+\E<C;4
M,)>VI(7'*=3.#L@>D$1@3"<V$MD95-T;6K(XF=G-<O)DAI:8@`4CTN]'I-J@
M@V@M2SXE!(+<&W&PDON.00*NI`JEL6JZ$+7)S<8/6""4+&9B$^&1U=(I<[+5
MS>U-K)E1(\(VEM1I4`?"AFRT:U52SW9<%^`:%CA.KT@D&K:QD[NKPZ1=WB5?
M$R`AB;BXXJ(,1%A.3R9V3NWA/#%.9!X"3R\A!D(@Q(%TG=84%9UA6$(?KWJQ
M)1LPM*54?,JRN*0Q6Q:@;KIQVV97T%EI1:E4AKB5&=AZV,N)+GD"@!9Q"TH8
M"\@#UI#TM-97@JJBF5UNVOQ5723[K?A;7UR2Z//5A4;*70#])JYLJ1Y/6R)_
M:7R1!,D*UP;75CD1;P<)4A>D>"$9:4*9FG2+U7ET0K&'MSY?%<E5I1H-8C)!
M5MOOD)D]CZZ`6FN'F6M5R;TPR9G!AJU"LP:4U&C<^Q8K+`Z!*5'@&%["NGSK
M.B1WBULT7>(^Q[`:U134N;,++(%B5I04I"87):_C3!%2#`GG,B]NB\J=$(7?
MQA4L-&%(H.$,Y/WPPM7+NE+J[+'^-/13K>4,1MD%IBN)M%:[N>6PB)79%-?$
MI".HTES-+$<F'+EL.(2IBD+NE5,KJ,D@I.<L,2EX(P'OW7TS-?+[FDUDDWDM
MX$1"TW"%NEO4BP6P](*/M1=`%*-7'#)3!5*=>)N)`>WHC'5!"76)-S^:08H?
M$J]2N<CE@7VV:U4KG:EEK]NG+O/HD^U/8S-:]93ZL)49#YS")NRHG)K)=6=V
MRC<T)I*QI>'1J<FYU:G%`L1+!X&F"<`A04']M8]5ZNU*B<VAM5'3-4V6%:4M
MN65+IY,7>=2%SGTZ(:0RMW4R-^,4/*P;RL:"W98-Q6K5)KJN<50U6<*`EEA4
M.N.O5<:KT[&*,J9,[)(%$7"9N;,G?74UZ=`*IY.I+8L@RH<CBRC3P&226.YJ
M4&08PE2"3I0=H2`BR&,,JZ9.N4C.=W=K<[:@$U<=J9EN.@L:OK"5,$XC%SV%
M$VB#34^-N1S>X-Z2+22)LB-E<8TM:W!)E.(\P@PA09@X(>$Q]*C6:)D4YY&O
M]ZQ)WHF][*V"K^5L]O2`Z9$RZX2"$EHLC[*GDIU>Y'$9VA3B;Y*B=UBIZ=D"
MQS2JG\PIV<L*@J6O^FAK?6EPBMJ-K[BR@2/MERR-4JXVW+%E`0F67"8L.LF1
M1*K/&"FE`LDY[BO5&(%9[@Q-"Y4)P8&AI7ED*2@I2INE!J[4,EJR0-3M=LM1
M4BQVQ#:DAEA6R^2R"0&O+I87*.SJO&&,*2"$A<87('(6"CE0E4E[4#,0MD*U
MO9FU$F#_`%372KUPH:1UO,H7(;TD4EI&/V1$J3\Y5U3"8LM7PNQXXHC2Z`P]
MG6#"@88FUHE`LM64"8,@P:4A.=GMZ]2F<"`,O=:*F?:*H2JJCD\Z>[+D<$B+
M>ROTZD+@[.SK)'@.3%+BO.<7U<Y/:M/A8I-3MYKPY+W3U-(2!7K%2H)QXPOG
MP'`<",74Z?3J1]1#JQ0F0S66OT,KF6:8)J^B+S(WAUC$#32G5YGD$G(AC`N6
M'M47)D;Z:8]OI3&D1`>'@9CFXA4+!Y-R&)5Z;Y3_`%AV*ZES[&HU(K1453(^
MF!#XU7LTMN1!KW'ZH@V51A\%`XT<@5,U5N2G"@M6_N;20O(ESRG:G1_3CPU`
M),"AK3ZIF^5(%;I*)]K_`*INJ/I\RZCEE\N$2L^UL^7T`V`;XK(HFPU`W/$*
M3&I9K'([),&2:3S9:C8%"_)1#1%30%'X&%L]M=KMK(=+]Q6?7:9N32\1[J5Z
M34LI'9%KS%RCQ$7LF$09P#$X`U$Q=]\UD-E<F5-S=8B6("3KSF5;(WUN-6.R
MTQH6A>A[WVN+7Z9[MNJ:)*+/F[#O%IGKT1`Y==$P75HWKKNK6")WTBK,NS";
MBKX\4\NB@XA.E9%:1>O-,DKRV#6GJ$.0JU^ZI&R5:)]CJ9LFEJ5<]LZQVFU6
MU<K!/!YO,R*'ETGW)CB&65<Z2A]D;&5,V9LB#$:M.F2LEM+R[K"4R-M2,@#C
M59(9DZ>;4WW;6PNV^LVPM=U;#YSJDR:X*UDCJ.42:21">J+VC]BR@3JT!EK2
MRO;,VH&J*L9`&AS0B<$3RH?D@G!Y;4S4].`0S[UK=CH5L%MK;=DN.\3[24<?
MFA73.TVBFP)C]%-.F&)PMB6S6+VSJ4QS6*M2Y7'5'C<@MATG1X@2&'NY:HX2
M='C&1AGI=_5:?:%5[#Q=3$XM8SVPZY:R7MI>[-:EQ;/U5K??<D:JF,&L9PC&
M9'ST%P/3&G+;6C(S`19Z*<EV&XLD!IP498G5<NBJ]V46KUI16@*0;`SNJ(8S
M9ND=X1H5YLDQ:68Z8V-4-S,\0?:<8VYH?7%<SQB)388EKPK9SFYXDC$[G*T3
M6%F(3U(]MJ,@>_\`8ET)ZML=:AZG9^G.NC<IE<X`R0Z>/B"O&8F.OY#9`B36
MVAX!"A(9JB7Q](NG\SF*N<(G9L0+W5%*'`+X(NJ_>7F69'3-'UW(KN/WMJ'2
MY.%N>;+B-'V6FNIM,4PBU8!)YI"TLN9V-6[FE,;VV.C%(%L7/;7<Q3AUR8WD
M&!1AO5-W<A1=I/EF4'K(;#-8MR*^U2OMVA%DV8<]S4RT7Z)-+)(*=87R))T[
M(**(YS&U[WF</*\$B-.5(FU(R>+&*`!Z==[VVY%DMF5E4[$.Q+XNOJZ;BZOU
M3^J&MJ;R6N8+'JPRY2N02(Y<E:54@8J\BS&S!2PZFHIA(E;O53*-G>"B$IP3
MPEAK27[!/VO,L>-B*^BM2W(R-]C-;@BK2<BF<.=2X^6YD,4[AC[X%"^-;9(T
MQ)#JB9)"E1RB/'^$1.@,*20F#"!+I.-UT6W%]1;1LEEZM4H5R!&WRV0W?+]X
M3I!J_)%C28[.!+B]U8X7@XRMVA+TH;4S"HCCC!CLJSU/>KT`4`C5(`PPF,QZ
MC$@J/<&PWFSF5!)K.ZK[%IK(U<;VHV8:4D<;H_<?DTNJBMF1#&&]F@-0HW93
M&HVVV1%$;);+W`%LJ`_-!9^,,CX$H];=52QXW=K%1395\/D=)5'LC%]!I@`F
M6WM8^R!<MB"9HKV:7V=(WR'.K#)ZKC%@]^U.:N828^UY0SHEDZ>#0*W$Q.$,
ML*@W'W+V%M"7R:FZ$I%]U2B6S=FZOK%[W:$ACUZ%FU<M7QQ^O43:O8BX6HKT
M$I0&A#`D!Q]DG,F0J4Y!I_A0IPCEJ#J5[TU!HHCV`N.,P"R/*_<:XJYD%W#2
MVW8T6HZ"L$XGS>]R*R:\KF&,\GQ$6B21]-`:U1P@"1L`PFM+C)5#2_*B(XXA
M.'HKLF?MEK5"+J6/E/R)PD"F0-[@Z4;))/(X"H.97M:W$&IBIO'8M,XPYJF\
MI&N=8=*F<#S'5*K*,Y8Y$^+KE`9?\!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!
MP'`<!P'`<!P'`<!P'`<!P'`<!P'`<".JR>F?3=B7?:VP*"X=NJBG]UG0M19'
MF#V<LNF8_)%-?0MH@,44.#'!G%K2JSVN.,R=.0:M$I&6<H7GDY*RN/"(*AF?
M3AUNG[C;CO+"K!=W:\%FKKC8KHKG+DH<'APU".-45`O\=4%'*0+<*#SE$M5&
M&''R<\P9RPPLP8A9#T[2Z>NN5PH]O4,S;I<<GW@\TGGWPW2E2@$O\R;$Q1R#
M>3(@)QYCG@&R.MH'/Q?P_JB<$XT?>9-SC`>#;'38URM]NOI*]G65'G78:W:N
MO672N%3I2P2F/6A3C<R-<"D\"<O$59,;5-2-@1!R7E(O*,/&>M"$I9XN<G#]
M+ETX=<'HR:*7H%@O#A85V49L'+G5SFZU4Z.]G:\M,?9Z_>#UAB;PN2!IXTW'
MR-)GM"^KAK%2@8!J18P%H=U.GNTVC76US]34%A4VN;:"74!-YXQVY.;"B$:<
ME^O;6S1F'K*[F=<+$$FJ.?,\<:"%4;E*4I]9CY$GPEE#*L87=R`4%/=,C2ZV
M=<["VTO2X&$F#2#9I51"%%7RZ_YOM--FEOI"'R=A52RR+ZGK''GF;S">ODP=
MW(:=.@]2HXQ(F1E;A$IDP$"(+AW!TI=;KAG=M3)1,-BJW9]@CR%>PE5T[>,K
MKJI+Q7@;BF9<X6##6GO@*%K\SD%M<E/8%T?%)$F5/JSA8<X+SU06HO#0F47Y
MOWI58+E4U6036#0MG=W>#R9MFBMSG=F.ZE@BN*[K\NO28FA;87%:BF\5;Y&E
M4N<CDV').B*PRX9U#LY)R`OW:73.U^M^P)5,)A)[R.B-@3R%6;9-$)+:?`T/
M84X@+BV.\>>Y#`UI"\U+C#HS-+BZM,8>8\QOBUO3J79L5GA$8,/XOG3!UKD6
M=CR')QN##-LS:S%?,GCB"T'IJ9H!>D?<FIX1W'3X6TI*X0&Q#W-B95"^0)G%
M:8J3M*!HR4!B3@:\![4=Z<.O[)!X3"W9ZN.?J83L_"MP<3NR+2?IE84HO&OW
M(#G''R4R%R#DM4QIS2BBC8JT(&9A&4$P9:$E6J7*5(>Q)^GIKE+V*[8X\MLM
M&V;`;`0S9>Q`)Y2I(.4VA!%D-7,"EJ-PG%EL90*((P96,Y6#"50"U0!&8PI%
MG`4Y*^F?K1*(9*HF7BRHJYR+:>;[FL]C0FP'2,V;7FP5A*U"F2RVO):B)R:Q
M(E1:Q8@Q'5:1U8AH%(BU:%4:G1GI@OAKYJA4NL]/.E+5R3)U3#)7J:2J;R>9
M29PEE@6%-[%4'*YM.IO+G+.5SY+)"H.[]:YC`0$("$Q"9.20G**P&--&=+JG
M]=5]<BK*_-WF^*5:O;%D4JQ?MS;:VGRT;4K\=)CSA66'8B(KXLH.R,*^.F-F
M&M82<<4<G$$P7`N4JZ>NN2R(2F$'-TN]0ICM^HWB>@`E*D*H=\*IL@GYR].I
MPG[Y/&!2)N2F8C80Y3X2!&E\-D(\BX'A&=-S7K]4&?L(B=KE9EJ^V"+\>*D8
M[<E330S[>A#.G8L6V\5@A/*;EDQ4MR8LIS'XX!E>Q".,>F9>(T>1!XN>ESJ_
MF^RKW"9:X"";L-V9#1H+/?PZZ9V2/)&6;>XJJ]*'SC#4F#<\KP.`&G+F(:O+
M-WQZC!P>2U=*^@HU&W*-0ZR-F804&[I)?D#<XE>#ZT.5/S*8JG5=*VNM@!1&
MM*6%R1:]+UCY%)4U2U`[+#"USAE0L3ISB@RLUKUHK/56NE=<5@7(%"-ZF<NL
MB8R>8/A\EFD]L2>.HWF7S>8/QY:?U3D#XM$7XR<0D1)"DZ9*E2HDZ<@!?`R"
MX#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`
MX#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`
MX#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X'DOS^Q15E<Y))WIICD=
M9$1[D\OS\Y(V=E:&Y*#)BE>YNC@<G0H$2<O&3#U2H\H@D&,B,,"'&<\"F5-I
MU@C31%:LL>!I4=@%$'P)6IE\>(33<A2%`).=$3S7$)4D*4!=6L1!C,-:`T+D
M@R7D6%B?P@?X%:]6@!.S1V5``%U<((;-,%,8Z$%="$D&O"&=CRXX#$1"0EC6
MAQ(,M^<I`#48_N(<CP%6LSRSR)I;'^/NK:^L3TA2NC.],RY*YM+LV+B`*4+B
MV.*(T]&O0K$QA:A*K2G&IU!!@#23!EB"+(>EP'`<!P'`<!P'`<!P'`<!P'`<
M!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<
M!P/#D4FC<0:%3_+)`QQ=A0AP):]R)V0,C0C"+/9@2IR<E"9&G#G/HQDTX&,Y
M]&/3P/%@UE5S9[48^UK/X38;(4:$@UX@TJ8I:U%GC+P:`DQP8%[@D`:(K.#0
MEB.P,1><#QC(<XSP*=NM*J50!;E'6QUJJD;[#71/%D)D+"^)%#1+V-R2S:+%
MV&6.&JY;6ZE(38,90O9J0M8]1I&0A4EN9B,!@1=QW7V_8N.H7UL@UR"L-I(E
MY$<?G)XU@=X:W()=M?,;(7"V+BKBV'N3-+9!5STQ2.R'37YZS'%D@*?F*MV&
M%2&-5SXT'I^8:Z`"@1N*7>0_J?%Q6)\$M56_?;/+A[E5=>B:7PT0)7G)ZI@9
M(1-+D2D3GR=7'SNS<Q0HQ-)QRM:W!G;04'GT<I9,T'E%UG(GFS+ML$EB<FMG
M?SXO&;/NZR;)C$2<4;&]Y82'=DC$N8VMT`RO+BV('%`J1H%BY(64J,"YGDW:
MGNGLOQ<D?.K@/)NU/=/9?BY(^=7`>3=J>Z>R_%R1\ZN`\F[4]T]E^+DCYU<!
MY-VI[I[+\7)'SJX#R;M3W3V7XN2/G5P'DW:GNGLOQ<D?.K@/)NU/=/9?BY(^
M=7`>3=J>Z>R_%R1\ZN`\F[4]T]E^+DCYU<!Y-VI[I[+\7)'SJX#R;M3W3V7X
MN2/G5P'DW:GNGLOQ<D?.K@/)NU/=/9?BY(^=7`>3=J>Z>R_%R1\ZN`\F[4]T
M]E^+DCYU<!Y-VI[I[+\7)'SJX#R;M3W3V7XN2/G5P'DW:GNGLOQ<D?.K@/)N
MU/=/9?BY(^=7`>3=J>Z>R_%R1\ZN`\F[4]T]E^+DCYU<!Y-VI[I[+\7)'SJX
M#R;M3W3V7XN2/G5P'DW:GNGLOQ<D?.K@/)NU/=/9?BY(^=7`>3=J>Z>R_%R1
M\ZN`\F[4]T]E^+DCYU<!Y-VI[I[+\7)'SJX#R;M3W3V7XN2/G5P'DW:GNGLO
MQ<D?.K@/)NU/=/9?BY(^=7`>3=J>Z>R_%R1\ZN`\F[4]T]E^+DCYU<!Y-VI[
MI[+\7)'SJX#R;M3W3V7XN2/G5P'DW:GNGLOQ<D?.K@/)NU/=/9?BY(^=7`>3
M=J>Z>R_%R1\ZN`\F[4]T]E^+DCYU<!Y-VI[I[+\7)'SJX#R;M3T=EGLOK^G_
M`'N2/6^Y_?5CLS]WT_>SP+D)`*"TJ8M6>!4J+3D@4JBR/%0*5`2PA./`F\(=
MXN`XS`C`D>&-\%@6"_"#[WOLA^C@.`X#@.`X#@.`X&$>R-#:)V=8D5ENVS54
M$SDD>CI".'1"^9JC<8(WMH'-X/,?FJG)K(<URH>W%4O5MSG,3(>J?G)"WMS(
MJ=C6]F0HDP8PZNT[I@\[GWPMU\H^AZR-UM9Z241.Q-6S@URBF>+>BL]'+8U9
M3+53PTUQ/VALRPD!;F>2QUS+:UIX7@L!+\C;G)($O7`<!P'`<!P'`<!P'`<!
MP'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P/GT]'H^GT
M_="'36Z#6L9U-]O8W(-NMI)G6^O\=H6Q8=4LJEU?*Z[=%>S;#L""21N3MK?6
M#8\K(M`#HI'UE7HVI^9G1G5MI!DF>)>5CP/`F,X#@.`X#@.`X#@.`X#@.!$'
MU<X51S-4L:O.<:SZDW'8)<ZK>E&VR]O22FVI:<BL_E"I(7+;%E21I=9`W0)K
MDCFF2+"F@!7BCA)BG=4:4WI%XLA_'I)M,2:H]=P8JCZ5Z,L]Y@PEW]C!GSG.
MF(8RT,G\!FX#G)`BRVNP0C,\C2BL&A4H\R,8Q!\"$.0F"X#@.`X#@.`X#@.`
MX#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@16]7D%F1O5G%N53L!=5&2J
MO;)I:/`#4SY%FAMEK9=%_4[4+Z"9$2"&RA8O''(]*WESB&6E:R@0R`X*IX*?
M6X(FHP)%ZSA*NN8%%X0NG<ZLY7&FP#:?/;,<&9VGLH&`PTS+I*'&/,,795;H
M9X3!0S6]@:TV2B2L82A'@0Q!7?`<!P+=VQ8R.I*^DMBN$3L2<HXPE2JCXI4\
M'?;)L)X"J<4;:$F,PB-)U;Z_JB1K0JE1#>F,,3MI"Q<;C!"4T80L7J+N96>Z
MD/>)_4T/NM@A[6J2I4$BMBI916C1+Q'*GA`K.@CE($Y2&8)61R8E[7(CV-0J
M+970!3>X9)5&8*X&7'`<!P'`C*UU]E$ZF/[373Q_(VT7`DUX#@.`X#@.!^=4
MK2(BA'K%2=(0#TB.5'%IR@_^L8:(`,?NYX%!.ELUZT]_@^3H%`P]O86V^%=,
MBSC_`*.!H"U!(<_=,-`'ZXL<"W+IL=&4_?8:F1X<AA[<!$J&F;"#!=GZWO!X
M&N.P'.?1WPTP,XSV_K<XSCO@MPZ;&2U5@0&MM96LL?9WIA@%"]2'`O1CL&:<
M4FSZ?:$CSG.<9[`^CO1A0"BV+`5JDZE9)G$02%)1PDJ4PML3'>!$$W!)A3>6
M0$9)G>]Z()F!]\$78((\>C`2%)5!2Q,G5D9[XE404H)%Z/UQ1Y832\^C.<>D
M`L9]&<X^MG/`B,ZMB@V65I":T*@$D,5L5AUW=;1;<EU>L?:77J-+82].R=?'
MK)A%2IY-)C#7-F/6HEGE%!UL32,S_AT3.J&1I$#FPAZG2K=FIVC=Q&(+0T%L
M%26[0SQ]KTAJ0-+N40,REDX"TEUPI<Y*9.A>G`9)_DF5)&IF4DD-\B`00=GQ
MC)(2;3J>12M8RMF$V=PLS"A4-2$1X4;@Z+ECJ_.B-@C[&RLK.E<'I_D4B?G-
MM8HY'6-N<GR0/;BA9V=O6N*Q*F,"V1VT%$I_(#PL^3A\Y9H"8SG#%*1X2G&2
MA'!0$S40&,>*S-%/UZ.O,%V3F)B\X9P8#WN)>$;*$/X9VHH7&)V+$^*%YNEJ
M9LD`01V7&&.#BLF9U;)$,$)+8!&VDK466G.K0E/60)>:.R`9@`0^5^0LH@NU
M"YI&+$C#3,H<[%/4=>BCS$"XLA6C-"8C6'MSBWN#<XIT;HSO#0Z)%C0^,;NC
M0O#(\(5S0[H43DB5)20JK@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X
M#@.`X#@1E=8'Z@BPOVY=-?\`/4U[X$FO`<!P'`<",OHZ>QQ:Z?XW/EVL[@2:
M<!P'`<",K77V43J8_M-=/'\C;1<"37@.!0[O9,%8S#B7&3-8%!`S"S4R4T3@
MI*.*SWII1J=O`I-*.`//>C*,``8<]O?8Q[06V<]BH@EP,#8W/+H8'_Q1Y*3H
M4H^W(O\`XTXXU2'MSC_I(?1CM]O&<8"W+ILA(S\#"T,32W8S_P!-68J<SBP_
M7"((D!'A/K>$(&'U^TO/KX"W+G;5ANO:$^4+$X1![`E-F"&OO0B]'9@:$L@X
M6,B]&!&'",QC.,8&+/IX&+%E[(5G!HK%9_)Y8Z2EFG\F10^!J8&QRJVG.;2Q
MT0O3FW,T<0UZURMP<SU:2//!V%V"P-23Q`XQ>X)`@[_`>*Y[+TW'U#(T2J59
MBDQ?X8*=H*W?&MT+LK#.!G>WT*$R%(4RU[S)E""+2<35%DR91('TZ-OA$?0.
MA[0N\$&,+QU*:>3LC/*8]$K#>HD7,IC#+)E"R,NS<Q5*KK]/"7.6%SAP;6V0
M$-3BDC$\;98A3..6QH4LC9(_&G]O=F8;4-)]S&*1FWFRR29+VYN6E31,X,2Z
M'*ZY?8*\2I\ET_J/:JQ*&LR.PB8U<&$L$(?)S7CS`ITS2%W9':/DB;FA26U)
MVY0^K@A7U"LG4`2SS6Y))%L\3U1"(1$H)+/51/$32'_S>.]C5Y8+M:6)A+F*
M?G229HVROK`ALOC\;F6'Q*8V'(_4U*MFC@Y!M-54Z>J]?1=3G/:,EM"W#^O@
M3488VX[[_P!(0$H!]N?2+`\"SG/;V\"+;JR;,2.NXU7M(0<6YD7>)S-:ZDEA
MV+J+3$FG$R:J0Q*')IG37#K`0L#]'(;8(!(TCN$IR2*%HXVD6%)$2P]W1)%(
M5;TNU$#<&Z['2'67U%+.6J'&!)GMVZAD;6,4E1@2(Y5EJ25PH7UO7JEP9\X4
MKAR`/>.Q:-3ZDX`-")2,"D)';.(G*F&.9%=-\9=Y*8H:0!:94_R*(MKDR#=D
M`),E22V*I'%\BTAS',N@XJ_(FU>%NDA;4<H)+38.5)PCJCVGUW1B'FPIMQ!S
M6NV8N@@5B'N5C2UY=Z<BK-LM<-U,A\2DCK"U+[<LK1P&[7V'.<QF:B.R276%
M"8?,I4XKLR.5/+<'[Q:J7UVP(?@J]$+6@0D%1@Q-W_`+J:5FQM5V\X*['QF"
MAQ!WHJ!5$R,C8)%F6I2+/DDB>#A&Q9I;1OH9A4]5\UBM3E1J12@Z)3%YL.W;
M-?5$#4,S^E:%EN6[/[741)N=)O#5J=X;8[F<%L(7DV+M"MTRS%KR4C62I,0X
M"M?(&5^[=9_XIIC]$7`>0,K]VZS_`,4TQ^B+@/(&5>[=9_XIIC]$7`>0,K]V
MZS_Q33'Z(N`\@95[MUG_`(IIC]$7`>0,K]VZS_Q33'Z(N`\@97[MUG_BFF/T
M1<!Y`RKW;K/_`!33'Z(N`\@97[MUG_BFF/T1<!Y`ROW;K/\`Q33'Z(N`\@97
M[MUG_BFF/T1<!Y`RKW;K/_%-,?HBX#R!E7NW6?\`BFF/T1<!Y`ROW;K/_%-,
M?HBX#R!E7NW6?^*:8_1%P'D#*_=NL_\`%-,?HBX#R!E?NW6?^*:8_1%P'D#*
M_=NL_P#%-,?HBX#R!E?NW6?^*:8_1%P'D#*_=NL_\4TQ^B+@/(&5^[=9_P"*
M:8_1%P'D#*_=NL_\4TQ^B+@/(&5^[=9_XIIC]$7`>0,K]VZS_P`4TQ^B+@/(
M&5^[=9_XIIC]$7`>0,K]VZS_`,4TQ^B+@/(&5^[=9_XIIC]$7`>0,K]VZS_Q
M33'Z(N!&SU;H;(T&BT]5*;:L!Y)!<.GH!-[DVU64B,&?N302<D\P;/6;4X>%
M1'&EKTP2EQ9(E*4@"TE6B$I1J0DF\@97[MUG_BFF/T1<!Y`ROW;K/_%-,?HB
MX#R!E?NW6?\`BFF/T1<!Y`ROW;K/_%-,?HBX'SR!EGNW6AGTY].6FE_6]'K=
ME18];VNW'U^^SG'9P(VND1#)&OZ>&OBM+;-@LJ<[SL>#;&QMJLU$E[R\++*%
MX`;S6CLXB\,,`E!GC+@H[#S3`E>"38*(*"27$!E?9CMNZS\_=]2:7_FJ'&/X
M,?>X'WR!E?NW6?\`BFF/T1<!Y`ROW;K/_%-,?HBX#R!E?NW6?^*:8_1%P(V=
M?8;(SNIIU(40+:L!,H1T]T_AJ'4AMJL2]T`J:=FA$$.!2FLSVL!3=@DT*,36
MVMQPPK5'JB<O$!()($DWD#*_=NL_\4TQ^B+@6.O^1O=,00Q_-NNQU;X[+B&*
M,-2AKIW!2]U5`-.,&HPEJM(MPA0(25"Q68F4IQY$4G2EJ$YRLD?`A'<^IA3C
M0O;&!&PS9\>TFSC#K'/"E:1$RG0UR>G9Q9<6<K*7KCU#W7>'9K?4R9T;`"5N
M0H^_J"DX42'QDX*EL/J-4C`4-PJ2XU9\E6T8G:W:PVI%&$+`Z-D5>7=XC:29
M)T$T>XVY.4=S)&E.U8+0H%$@5DOL>?6B/.<:7DO&$I)V+`.N[&P;JH=([4[-
M!7B02"1.ZZ).S\`RTHOE`^ZB->S-61",**X-KDMY1RN01FU:N1R)S<W!5EP8
M2I"B52$U8AC`YAO)Y[R%*39^ZD$XC3.1!";"721KD69/%Y@U,,&JN+2!GD=:
M4Y:4.:+`BTN<6ER$A;98[6Q3;L<B?7)/%F]C3GS:%3V6+6QU249,DZ:.$QUK
M9J'FXV9L1P/9=;:D``J`-[2"K!)L(\6*RPF3)&A6UAPJ7U'(7>J70IH<L)40
M%6'`A4N++&6;)\VYYTH*SDO3_H"16<T6*4UJF!N;(A&H6JKA@:X0GA#DV0Q%
M(6J,C3"6Q!QET.4(663.S*M,KN4Q`;JW%MB9;DPI&K`Y45K#])-7X>V(&T%2
M1Z7^IJUJ=$KG9QB^TG@MS8XXU0]I7DN-@JY$H2J$<58H_'2O$AIBLLL;C3>:
M28FCK,!#.9->,*C*).E3)<&A2IR4H3U!ZL["<D!.#52D0C5"HW``!P8H/,%D
M9IH\",,,$(9HLY%WN+*6'^\^OG[^>!F?KBZ>,19X:19[3&QWPH#CVPIW),#P
M8>SLQ_\`*$:L7;Z>W(LX]KMR%,[B;(2+6&KV*90JHUM[SR8V;!:J@U3M,S:(
M*]S&43MP.1HDC0]OJ!Q:P'H4Z96[K_'"TR)"QMSJ].;BVM+2N6D!'1K#O-:(
MMTK#KC8?5;8F@WF]+$KZMBTTYVCK"^*GJZS&?7^56'#8K`Z^B)Z577<=MNOJ
M[ETE7RV+ER2+2ZQVEU3N+@C>$+N4V!.+P'`<#`+J:QMRFVI+C`FF52&$*[$V
M$TDK<<LB;HO99$QH+#W:UYA;LL:G-K5(UZ51ZE/JPH7BZDK)Q)IB<8LE&CQD
M(^%>TTX>KP8=I9&_!@B*L-,-JX*^1-Q(E<@@$;O2C8M1\TNM^=(O'#D*V5ML
M7M*=CJEQ+1]X^)3:AD21J5LQCFN,/"JE/4-V&BD:N'U*;&FSK#JJVZ\C,5JN
M4-<)Q8]NL=A4U(II(V)'C6F:W5&&MUK`Q@>+D\993']W75+%'R#O,>!/EC:^
MY"I$.SUTOEOOD!JRSJJ4HY:,E\7W>Q5^K?T\]21G1NF+I:I7%6);.ED<:6Z4
MR1_RG)([]U(3U^I"V$G'R@),S`'K5KNQ?Z195B>R)+7CVBLJ&].&X9!("H8*
M&LL'8]V';9&-2V"M^#)0YA*9HT\TC&"85(9&[.+X>Y3%:V.RMW,&SEDA14KW
MSV0D,(MF>5G,ZD0,M7P/<6UH\N+@BB:-%AM5#[S7%K[6#8:Y)IRW)S(=**JA
MK(ZR%VCBI,\/4@&E?HX_,;.>I:%X9L1B^;AB-6[]JI"0GNR?:<RN8L\*`R1T
MN*.ELB1:C4ELZP,"MA:52Y$C>%,@MQ77J`33WN5;6U,RQ06:\*'!2I#"`74&
MV5BT!D;\UI(9<LJ8UE+.4*A)B6O?*Z[2[9KRU9%-(W$&[6>UMC43(UUBU0=M
MV!C[RK4.<JD-/)I+!W&-.<CQ&K&D(7)0;I6MB?/^&"YJ@N1MB=GZ65M&*R@T
M3;T$HO6+[)U]5<CG-OQP_P`MG5T;VII12V8VA!DS64L9VJ"5O.D4G5RP1);Y
M'PH$G>S8-57=:N\?M"BYS*[UUJ@5[+T3>DCL,!0<RDMT4+7BBGFYSE$P4QPZ
M03YJMB=1>EB+H5,F0VW3$D#-WI0Q+W"/1$/1<^H_8,<H2WYZLD4/32"":6;6
MVG$3['B+)!G-\V`H6V9U6#1"G-HCEHS:%2A:WNK5$HQ*TM73M_CDPECD6Y0A
MT:6B3,;$C"K;$VJV@9'V3*FY^0&Q.2[J2S52-(XG!:R2O%;QJ#0"7V`GE!TF
MN:W8'!7V<V$]L3?7[>"5/+'%T2=P3996)\FZEG9)('OWQ.['V#Z=E-2UV<XI
M&9#:>Q&E40FOJ8U,TTA4PBDQWFIRK',&6IKFC_'5\.GS(ZI7M_BZ6;3*/.\6
M<G:`F21_:'4R1&!C-;VW%L2G6:2%"G4#6YM[6?:.4NM75ZR@C$OU:6TT^,,?
M8FI0Z-4G7.X2V,]S'6L[\H6]$L-LLM*KC`XRU`514H/5CFV]M5M#MGDC99T"
MA1%#+M\-@XFWV4U"D3GL!(4_4HWQA2>G6Q<OD[8XH8U$V>K()#LHX4A52Q&\
MV_6Y+2=A$WIHI)PN'.^H)L=%[*E%3I8=$")*PS&04*`YUCST8`F]]EE$LG&A
M^%V$;J%(*-1^KXJ@:[T'A4D"\RR9,ZYF41=`(*,L*:>=O=@(K`=DY#`G:`19
MJUWKOJ7;%*&(Z#KG\^PWC6[>'9B#L48='=QE_?1]FFL>@!9LV5LS?EQ#(7<]
MRB)T5:TI+",+],&W]D.6SU,5^LLVL4/G+W`V>UYENM*B.H\6="ZVHZIMD)A`
M+23O`92"0%#L;S3UU8B]8\1I1'ED*M^&-<<(:SD:M\E(6^VAOZR5]K*HV.S8
MK$FZM-_=/*KBU"I6U*ALBTHJ\%TQ:*J8$2`R5D.RH4I>Y)*F)N);615"S85!
MY"SNS>IE07M?&PIYKWFOU=6\'?F>TZ'FLHNC5F%;`KR24+1#FG7B9R.[-?ZV
M-J<QU>)8X-?C\X;+?G,9IW%OFM`BK>IF0>7[Z&*K7AHA84JT;M73)Y)`DL=<
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M<-=N:X:H8F5SN#`A=3-8%DA1)(2-BL!=B:"0/<JG:IA.@,-73PPE>.Z&J8O#
MT0]LPT<!:0_#L!L-L!8;%=AH+J9_)V,:A[[Q2/.$1:EK3$+;DE-7I74*C]KL
MF&R:#((?4:)S3-;R:P*%92%SBL\)CRMJ9I9XJR!*W7-QW%'VS=1@F)Q%VR[6
M)U(-A1T?C">&/=AE.FNL"N%'$U#(V*W1N`[&RR0N\>95J`)8S&90QI%R9<[(
M%SR\AA%7?4*N9DB1UK6JY0]UIF"I=9[*N:7"2U,%TC]:;$%69"GA;'VVE;RN
M5O9X-#YVCK:?1=_F[F3+?-DALYMER%R.0-4T)#V(GNOMF9<44AM@Q%EBK@FG
MNJL(E,`4%5*TM+DV;'1J(RV7OA;G([L:KK/>JW.FD@A<1\AJ>E,3D;]05@I7
MEP4G2)S75.&(>QFTEH7;II?$1MQ_8'A_3O?3LM1C'#6B#N=>.+3,]ZZO:7&0
MUG8L$L23N+C6JU4Q-R"*16Y8+7-TLZMMD2I^Q(DAY0(\&S3P'`<!P'`C+Z.G
ML<6NO^-WY=K/X$FG`<!P'`C*UU]E$ZF/[373Q_(^T6/X\9QP)-/I]WVL?N_[
M,8]/`UQMJMHT]Z;(.35&G/*NO:M5*X;&S"3<B1.CNF4A!+)&GQ@0R3"W!U38
M;T"PD8REC,SM:TO(/&18P%EVSIUT?:TXD5MRQZFPG=_?)0\X:X\XH&1"4"6P
M2*Q0U&X'&MS@J</)M^8I#/H8M3&M*QAE,_E8C!."!:)/P,L8]IOKQ&Y:]31+
M!#G)]?9&]2=3Y1RJ7R-D1N#]8C;;J\#3%WE]71EL0!M)J26`WHDC266UR@&7
M!N"F[[`0)+B_D<B,5AR'U,B$7CT5;>T0\MT;9FUB0>$&<<I,'XHUI$Y/:8I4
M*#Q9"7D0CSC3O^4.-$8[FPPQVQLZP839U'Q!IN^/Z^UW8L:NO,@LI[CD.<R6
M6<01DC$FA:)R=)\<.,-\;<V7,W5O!0TZ9Q4XCZ=(@=T.5HU"(,::VV[W#M@R
MK`HJ_2Q4ZQ(K5N2VHBE9^^M[FU3FJ'!\F-],]JJY.WU['6"%6&F\09*SF02'
M-]9$K>A7/(%\W8E:`*"%4O4BNF#0XI]DLVB:R)2:3Y4+7JU$U/3>1.,AAL0S
M'9<,BM8N]L3>U59/8](D_J%(&Z>,LB0S=Y<FEB?6ICBY"\)P",&`))`>;@T\
M)183C?UN/"&X!C!AG8`!0<=^/M%^M++#Z?UH`8[`X#^W;CUNWT_6X'JMT>?7
MD00M+*Z.7?9SCOD2!4J#CTYQG.1E%&!#@.?0(0QA`#T]O9C'9@+VPB#VU'"U
MYK9'@IPN7BGA<+'1O1FB\5\9\'_<?&!FA[/&1]N#0%]F<_K<"[1=Z%K.J:3$
MW76-MALBIS-TO=C734<!J]H':#A1Z2&VW(I*$J`V.NN9FP-^K@F*.Q&!I79B
M)4N[ZYK&^#I$JG,K$2(,1>FEK374>MRQH]<NM2>)[9ZI2*,SE9<7ZHBQ]E&V
M>.>P5;.L/3R0,[GF6MYQ,H]!X0XQ93"Y&S9\A8_(F]Y8"DY4Y$X+`G;X#@.!
M9:_[6;*6K1TL!WA[U.$;2Y,8<,;&C)5J<*CG5-XBXG"4!&4C);5@"%8%V2C!
MD+0(\$8P>,HP`895WU!(794[B$"!K]/V\<Q?01HMS/;VM<D;?*Q<`ES6+R`)
M2Q8:CE!N%TD.P/O<I"E*Y2!1DC(!!>>_[TK[49-`4[922]Y(>B'I`RAK^.,K
M2V1Q$T91FG(,'IT8"T65ACN,Y*W)"`%F`+7GCR'..PT*6UNVYA=[3HV#LU&R
MF#G)V1Q>PO3@T-?J22!+A$@.3J3DJ9.)$-8F4%IB!YP,*C!848@X#D/8'D[(
M;>5_3LS=JCD6O\CGR`^,L)+B<6Q,QD7>6<TM2K;V<M(N1+"'9H:\GJ"0E'%>
M*)'(3B00E#DHPXX+P:T7M%-D(]*7)MJEX@J:.K2&`]+)6ANPC=4SH`UU-(0'
MDD%E*``4Y-4.B`9&`%&*T:H8C3%V?!AC=*NI+&(9+Y;&@4!9QJEJD;DVKUP4
MZ!N-=%;4/#/AP/3Y3F&]^<F;4Y1&3SCC@HB$Q/?^#)++`&4U96)!G&AAWK&J
MC71!"%HG$X'"D$3;6^5J7!(:X8?#42-N3)P+G25C9BSR7$'>C>B3D)ZL><_\
MF$=42W;HF'SZ7V)'=4IXCFE@.S8Y/CT`EL5+25;=$8[!22H^`])_N$F41N,,
M:1<VLPD"5T4)@JUA9JD\P\02%W;.Z[HZI'ZQ%%-&21KG;JUBET58XBRD+WY?
M*"L^,.$]3C3"3JC,%!RB<53L6X'&N!J1N,$+*D)H`Q>J[=6K+3G=:5@#6*1-
M)`G(;'$U:J-1]<UPH*YN4-YZAO0EMI.&5KPW"/2.YS;E,6G9!K,G`.3`-3""
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MCU!HEF>P,7I)U)(<RR1\;#==+)4JFA\/2&+5:%L1K#U;*H/0I5AQ`TJ@Y,I(
M"`SQ?`SCCD81B*`8'&19X&9#5:L9>-?E5[AK5\);5D%D,G6P<^/I!2A<A\*Y
M+G9J&CP7DI8G>U@5;EXR;CQ1S2+O5E05G"HS@16-&UM+@N9LM]52&R#Y(&R1
MO4DBK"\317((Q#)7,&=WC,@?XE'E@0G!<%S'*)8V-C0N<UD?CJ>729-$6N.@
M?EO?A)_L=9\*H^+L]S/E3K)\^@<VJ)MJEHCS6IE+(D=,*WS&5+PL3&K6=G(6
M-`,F%E&9+R_'-97@0G'`4%AC+3&Y]8VE8959-FM<CC/G9=7$4J<C(XPFMKRN
M/;E)JUVF25,WI_5@M00G$0YN+D)48!,/(U'ARP9!D+K;#;'P/5=9"(H11[S(
MD2QDR>R>1S`T-L>8$30XAPC:4(P)<D)STJL(%P&]&G)+0A&D4@[3%`<`"Q46
MDE0=0A^D4&E%>7A7S,B@TC1RUM0RQPCT#L")R]:2T26*RM&U9)2A=GU.ZKB2
MGMI*:YF>PK9:V))0E:UKLB<`N#>F\L0J2PGVK'6B)M+01@E(DPXD-[86RJD[
MPPD&&A:DZM,?X1N,;W(QJ-,["RE)(5A'@LIN^P8&1FM]Z-.PD0>)VV0*200:
M=_-85:>3(2"%#J-`B1J25J1<0$&'%(46NPER(P(1HU)2A/V=Y@(QAKYS;J+;
M%M6[+A2D0KFGF;6:5MH[+E];/FMIXK-D,`B,J@$`FL/D+DGL1)'U<CD3<XN"
M=NE#G%5J*,`"U-"V/O92,0C`GY43JOQ4"Q7T;3JHY#&:^/?XU"C(>TBED=:7
M9$F1N#(QHQ)L@:4"U$40!:-O\70K&%.4K/)&D++)"&(S3U.HHK=4Y!&O=HE'
M/+BA3J3D"=`J7JC#<DH2C`I2DQ!KDK+*P4G3)\G!&;@!"8!Q>.\[T+Y[B*ZK
MK"H"D[[6$F?(=+['9U,KBE5)D4;32U87E2_J4]@*&](4)QCD@.:2DDC1&BP=
M)RA!:7`\YM4KB#0H*G-UX'>ERPR/9U]EK/+5"9\0LD[>&9H<E,91Y:U3@XDY
M=0HP.;2U.0$.4RP252$DTX:?"DDPL7?@#$'K4V]"Z;UKE57,M3+4[C95AZQV
M2]2Z-L36SL*Y?&=M*@=SBGAP2)RC7F3+28L-*>:JR)0D`Z,Q@SSP*?!E!([K
M1MPU[).TG:$%;3:$CC+>C<1K9"608VK`*U(TN$@%1`2L$K@BQX4M*,L?ATX#
MS<##X`01!:^X.H,R5'9$HKI33%DOQ\86)T1KPE`E1HG$1R%*L\90EF$G#&A'
MA4#Q52(>,*RNQ0$)818!P,E-?;V1W[7:JP$4*ED-(1OCJR"9Y(C`%:N&UI4*
MP2YG$3D(7%O/PO"B+/"43G#JB<4&09$D\,8&$RGJD1Y.H/(QK]:^,$''%8PI
M\23*`^"&(&`J$_BQOBY_8'/AB<&F^!'V@\(/LR+`9PO]X(V*A//R.%S!4B\C
MV:78A1+>$,M+*>@M^0(5*3OAEIQ(,+PJ'-3VF%)6].I78P,LKO!!!]TI]^&2
M&Z>Z\52=3UC/)Y;I.FW+VRE)E:<X4AN><KBS4B/P8#5(TF'0!!A`3P",-)'@
M(P^T$TVR>Q"#7&+L4F7P>638M]?/40":,$%9"@$%"I6^&<%9N!@(\*%/DM(1
M@L0E&<*!X$#"87?!9.B-\6>\K+9ZV25!8D74/*9X4`?7,M.J:&_U(:U3J++H
M,HH@:1.J`D$B3J<]]C+DJ0(\E=JO!I85'LAN>TZZS)KARZK)[,CW*/IW\+NQ
ME$$,X`*5R]"%"2I.+.RJ6$"0B,6!"``4X%*7`1&"-&$L(TG7NCW1"#S:95[;
M3+<T`D\-<"VQ6E)A7E2F4J_!B,5%!.;UB8P@2<(D^<>&3X`;@_LP8')8@\".
MZ#=T'Z9UUN_N9?">-VM)*^O2":K1*$J"H^G:G42JDFRXTTH5N;6H4J#$:58H
ML)L"U=^:,\XE,>8<42+/@2PS0>^NY5NX--695FC\`OJ1[/N\)=CT4;;H`O6J
MXA$?5-K9)3/4+BQ*5BQ6K9&EZ":T`;$`W!(^*4*LQ-A&B4*,A%/1JIQ9UQ3:
MZHES4X(Q@+5M[BE/1+DIF0`'X-0C4@*-('D(@B[PTO`NS.,YQCOL<"<*BG7"
MIK"2(>,]^3CLSZ^.^"''K^GL[<=N<Y];MQC&>W/9VX#(K'9@./K8]';ZV/1Z
M/W.SZWM<!VX^OC]_'ULY_BQG/WL9X'DNE<LUB&-A+O`VN<F,B_#HS%.471R<
M;0[>+GHO5)L*5H5N4#CA$H4H_'$O@5/BZ@Y-@T)1QF,RWY[EQ>9MI>Q73(<X
M8A-Y0O7/<U*9&''H[/UZ<1^5WIQV]G>INT.0AR+T=[RYR5G9<9JUL=Q]X)YD
MC>CQZ,B*;4IZ\7U\XP:H]3@A'_Z7@C`XSVYP'..!<5KU[@J+O1N`W9Z'Z/"!
M5+`I$XLX].>\+;RDJ@`!>MD`E9F>S_I]O;VA<=K@$*9<A$VQAF(,!G&0J!HB
ME2H.<>MV*U>#U..S[AO`J[&,!Q@(<8"$.,8"'&,8QC&,=F,8QCT8QC'HQC'H
MQC@?>!&KU"*INJXXZ1!DNK--;HZY/"-B/F-&R6YY3KY:B:<LKVY+DDM89V40
MX0>418#8:W$&0YZ-AC@C=T1B\$@?$CEA"QAA1H]T]R:^V)KF]&+I=4)HB778
MI`>=)G_9^:[$7.OQ)X9)HBO:X5'8,]!JJ.85(WXU`ZR&52B5B):E2P+7%CG$
M].X-03EV%/&>MHLJE3RB?G0@I<RM"%FBK&ND<C?'N1O*&/L+.SL[<6,]0I7N
M[FC).5J!)6AG1"5/<@<FE@;G-U1!9AIVRK"0+H.T,#79;V^3<<Q+PQ--:RM<
MZPXRO;$,JB:YL`DA`,J)$1^P$SI'5"YP/$WK#F5U7M:I>U)<+C0_`+<6H<!E
M`L);`%ZAKDS='`^0;Z'-JJ5EEHZ:)S5(C"`%RM+BTW%JB)R\1C<@2A>6&7JE
M)-?R!BESB%]J]GT?LZ)-LSC/JD6VN"AX;CD3RV*V9Z9GR-/CE&)1'7MI7`+4
MMSY&I,S/#`\I!X,+)<FQ4`DY21@H\T*U[/7^F?;^GM>W]?@??IG@?/I]/IZ_
MM9X#Z?3ZWK?3L](/3Z?I[7\6/W?;]&?1P'U_ICV_IZ_[W`?3M^G\'\7UP9[?
MX_\`N]?'T^[P/OWOI]/I]?@?,]O^S_5_%[7MY];TA]^GT^F>!\]/T^_]/X?N
M<!_']?\`V_NX]OU^W@/3]/I]/W?0'WZ?3^#][@?/3]/IG^#Z_K9SZX.S_N^G
M\'M>CT9[>`_[L^U]S_5]W/UO:X#/T]K^'Z9]/HSP/GI]/UOO>O\`<_=]'I[,
M]GIQ[6,\#[V?Z\??^GW<8SVY[?K\!],>CZ?<]';Z?3[7K`]/WOIC[GW_`+_U
M\<",Q\]F2J_'_P"F7?'M_P#YIM<O7QV]OUOK=O9V9R+_`*(29^GVOW_I_'V9
M^]G@/;_B_P!O\>/3[6<>G'`>G]S[_P!_Z?S^C':&%F]F^5(=/"HX[=5^))TL
MA\GL=HJYM*K]A;Y$\ADKW&9?+$9BE$YOD?3E-F&N$O(3E0%IIQ:H:(D*899X
MS2`UU-_.Z#=#]E]7I73]=,]^D2QYL+7J4(S))7T<;&C#;5^Q546I),'+$D^<
MCP*AQJ%.Y;84%&,*IS$C2&G)2CQJB`S*_MH;IL>G_<+9GT__`(71/]S_`,YG
M\WM_OA/_`%M/&2U*Z@-GQ@*X$;L>%Q:>QX#HG+2.0&.8,:"0M('%*2>I*3+@
MM[B0%406I4%DJ/"%A.."#!@@K;Z?3[_TSP+#;3RR0P+6/8Z<Q%S-997#*'MZ
M61AX(*3'G-4ACM?2%X97(DA82I2'&H')&F5%E*DYZ<P16`'D&E9R$0<W;^SH
M=5_T_P##'F?W/[S*G^8'9]SUL^CM^YV!;RJ>KSU':0@+#5]5[12J'P*,>JOJ
M%'$45K=8F;O5IY<9"Z>"4NL+7KC/''EV<5P_#JSL@,4C++\&0$HL(;LG<\^U
MVP6XFEMG69LE93I:4Y8MH)I!6J0NS9'FE2CBC95%*OZ%G`GC3.R(!DIGB3OJ
MX!QJ0Q7D;@8`Q0,HH@!03P?S?6QV?N?OX_>[.WZ_`>O]/:^GK^MG^/@<LSK)
M]N>J)NICM_\`/,Z^MZV,>I+1G/K8]K';VX]?.>WT9SP(R^!L9=R]>GJ4/GO9
MK0_E76G[W^SLSV^L&_?/*AJZT"0$V%`(G,,DEY`E4OC(@6N2#&<"QVMSJ,GU
M2;3.P0\8-0JTX\=]GL'CM](6'*TQK1B6>.01>^10O(L_[E&J1/[447D7?8`F
MPXFA=P=F,B#VJ'A3ZQ?9@/>C\*%P&O7:'I.\$Y.#PZC#C&!%^%(0I1]F/3VE
M)R1*<8S]8*S'9CT=N?7X%Q6NLX$S9P)#%FKOP]G>FK",N1P<X[?2$UQ$J&#/
MISZ0"#Z^>!6Q911(`E$E%E%`QV`++`$``A^L$`<!"'';[6,=G`_IP'`<!P'`
M<"-WJ$SS>>N4M,/6HDDU-C\?>+3@T-L,W9=]D$6/5.DPF3%&8='F!T0E.*!Q
M99@X/`V)^;FAO(LA(?ZFC@>'Q:X'I6L*9Z;.Q=X;,K-@YK;>P6GMNM$;D$,K
MZ,P/3MPFS_$ZR?HV5+C)RZR62V3$8I-'1PGPW*.%M9&<OD3)10PYQBSJ/U9=
M2"@SJO1EM^1UF_L5&2:-PZPW83:B0RB3%JC$S*SG.*8,E5M`DS8^%)I5EA\?
M(BKDYL;ZSL[\<A=W9@D"!">R+PPO6Z.O3JBJ9.4QT#%5,+9&)G.DI4;E,^M>
MNG2/6VYV2KGM4W7*53?-5\XL-.Z.`YF\2THER'/G5?/75VF8E3RQ2`/0SII9
M6,Q8S$Y@(C:"SE'K=GR?DH,#8E=YU[<3LVVJ++\9X98NCU60RK"G./E*O$A%
M/ME`2&JWI+!V,,IJNILZ*5<FA,O?%3@\N$ULJRI*XP=ZE\%1AE=KV9-+5D3<
MR*V20))#B.-3W.7%J:BW!T,-7-R%"L<4X5F<%)PJGS113[+6?\=US_/[@/-%
M%/LM9_QW7/\`/[@/-%%/LM9_QW7/\_N`\T44^RUG_'=<_P`_N`\T44^RUG_'
M=<_S^X#S113[+6?\=US_`#^X#S113[+6?\=US_/[@/-%%/LM9_QW7/\`/[@/
M-%%/LM9_QW7/\_N`\T44^RUG_'=<_P`_N`\T44^RUG_'=<_S^X#S113[+6?\
M=US_`#^X#S113[+6?\=US_/[@/-%%/LM9_QW7/\`/[@/-%%/LM9_QW7/\_N`
M\T44^RUG_'=<_P`_N`\T44^RUG_'=<_S^X'D/U#0&3,CU''I;:2MFD#4XLCL
MD!?%Y(A*FQV1G('!.!6@L5,M2B.2GF@"H1J"%1`AX.3GDG!"8$(GNF9J=3C#
M9V^[\UBMXITJS<NR]=X&H4[);'.);#3S?5>ND]1Q(*1RM96C<1DRMZ<W3$C=
MT[A*QX5";QOHFLHA$2$O'FBBGV6L_P".ZY_G]P'FBBGV6L_X[KG^?W`>:**?
M9:S_`([KG^?W`>:**?9:S_CNN?Y_<"-E[K2.AZP%9M&'&P,I#>FS>3D(W-LV
MH-TPI(V?UX2@++>A3/+P0@$4H&(YK*7EMBE0$E6H2&JDJ<XD))L5%%/LM9_[
MMW71_//NW]_@/-%%/LM9_P`=US_/[@/-%%/LM9_QW7/\_N!K:]U&P1DC&@%0
MN#:MF2D\[<.OT8P2*Q;!ER+!1E+;!GB$4VRR3O3<0JP,@`0+B$I:THD1R<L\
M"=0H*-#0PX'S.?\`Q<?^M]SLSGM^MZ_;CTYSGZW9[6.!UA]-*KC"S3_5-6<Z
M60`U5K91BDT"6X[>0I0F'UA%S1A3(D4X3HD9`1"S@E*D3D)4Y>`DIR2B@``$
M,D_-%%/LM9_QW7/\_N!C7N95481Z@;6+"72R!&I=;;S4E`57);RY*,Q/6$H-
M`%2A6SD]$L($(.`G)5:<]*I+[XI22:4(1>0Y/7`<#?.[ES@C))]`+><')=,D
MR@G<.?HPE1VQK!B*+))=+:_'!&<VQ23LC<<JR,\P)BXY(:M-(P2F,4#(3)RB
M0V2_-%%/LM9_QW7/\_N`\T44^RUG_'=<_P`_N!S"NL`W)FCJ9[EMJ4U>:G1W
M$Z$DF.CJYOC@,`6MHSVJG9Z5KW1<9Z<_W=:M4G]F`@$/(<![`C;X&POW,S'T
M,EZC+TW.)[VF3AUNLU3@U@DTDBB_)A4IK8(0Y=(L[,[F)/G!@O")1*\ICAX`
M(XDS)10@!T`?-#%/LM:'I[?_`#W71[?_`.__`&NST=GK>G./3G.<A<A(F+1I
M4R,D1XRDB<E,4-4J4KE0BR"PE`$I6K3E"Q8>((<9.5*SSU*@S(C3SC#1C&(/
MT<!P'`<!P'`<!P'`C$ZM)=<$ZN-3[/+6F%./D4N"!R&H9;`ZJ6WA*3+:)32%
MO8VEIJ9`>@4S14?'W&4K24H'=E]1CV\J48="1L023PQLZ+B;78Y)=SCKW(+I
M?(\Q5YJ35361;M*'4R)LKNOZVE3G"%#?A0J--GSU.'V<6%:K_-,)&].:SSZ&
ML[<4H:6IO5GA.=P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P(RNG)_SWZG
M/_M-;8_S>]8.!)KP'`<#$ZW][M,]?YF?75V[.4M5<Z3-Z!U41*<SUACS\2VN
MA8SFY<8VN"LE2%,M*`,:8W(.\-"'.09SC&>P(JWCJ,Z'G=5.O+5*VXH,RMV[
MI]W+7RZ;ALB.9C2.</.QE$2-IBI[OA;XH6^N3"PO+NE;1&A4'M[4L4A!DI./
M(0D[K?J':+W%.(_6M5[8T/8%@2I0H21N'Q2QHZ\R%[4I$*IS5$-C8C6F*59J
M=O1*UA@"BQ"`G3G&9Q@`!9P&97`<#68[JN]CSIOWYM>?(AL3P.?]P/F?7Q]_
M^;/`ZY^E/U&VI7O9:&^2R*\#)K@8R[K?4;;:^]EOGY+)5P.1CP'`Z`'<J'L>
MER^_,L+Y$=>.!LT<!P.61UD_91-U/VYW;\EL_`C.X&QGW+S[)0^>]FM'^5=:
M<#H:\!P'`<!P'`<!P'`<!P(R]_)-9"AXJR&1K1J]=GV6)2^`7NQ6%3=LUO61
MT%LJO)6L4M#,8=+I,QO*C*UL3GHI`4C)-;'B)2IT8SC@#5*!$A;_`*5=('5(
MGO5R7ZU[.:[*I$?6<?C[3LE=T'N4*2MH,CF9<#J^H@PA>M30JKJD#(GM*QQ]
MVRH<PXE60"=7(A*4%($NG`<!P'`<!P'`<!P'`<!P'`<!P'`M-<U[4SKO$2Y]
M>EG0JI84<\(H\5*9X_((XQF/CB0L5(&D+@XFDIQ+E:=O7'$)L#\(86E4""'.
M"Q9P'Z*@NRHM@(818E(V/#[4@JEP7M1$M@SXAD+":YM9@"G%`!Q;S3DXE2(P
MP`%!.!]^4(0<"QCMQP+H\!P'`<",KIR?\]^IS_[36V/\WO6#@2:\!P'`YRO=
M+WLHLK_:;J#\BK^!`#P)9>A?[+!IO^&<T^2>?<#J!\!P-9CNJ[V/.F_?FUY\
MB&Q/`Y_W`^9]?'W_`.;/`ZY^E/U&VI7O9:&^2R*\#)K@8R[K?4;;:^]EOGY+
M)5P.1CP'`Z`'<J'L>ER^_,L+Y$=>.!LT<!P.61UD_91-U/VYW;\EL_`C.X&Q
MGW+S[)0^>]FM'^5=:<#H:\!P'`<!P'`<!P'`<!P,/'6^[,5;SQS5^(1*&CKI
M@UZ#?-QSF1O#FGE19<RF,QK^LHQ6S&B*$B<E>)#`G]RFRUX%A"WL)S<`D]*Z
MJVY.[A^+738"UY[?.V6O]RPN"1Z14'(H')H1(:XD3J_,4MI2ZASY15HY&0]H
MT;@Q6<S(J]=TT_;`A`UFJ5+:YL1`&1P0'K`R9L*4/</BRIYC<)?+$D`ES*U-
M$485#>A4K5CX\H&8*UP=74].W,L=8BUIC_*'@_*@]OCS8YGMC8]N^&]C<0Q,
M1;PM#BW(79%5LH4MT?-<!W8L+DD+&14+4@O2;Z\>K_A0O`BINSJYS6EAOZ52
MQ#(&97$+?)#X+RC,9(6\A_;.[*'T8#5,H[^:J"P:_A%(XAC%UH,V_&*45O9'
M@W,TR'-3;(YM#9@N&Z%KU9572AKD@$9LG(>X.S!DU4MC)[6@R*8%,J^-J\/<
MSB3]'G)2WKE;#+ZYFLAKJ;,V7!I4JFUS3M<OBSVA1.J([*=T1$IUX24^%.2"
M@N5P'`<!P'`<!P'`<!P'`<#%?>1M;G/3/:\MR0(G`M/K?>2U.6N2D*P$+4U6
MRP2=60!068$I41G(A$G@P$TK.<B+&'.<YX'^M'6]`W:9:GE-R)&@*.UMHU6<
M6C3$I2S5:FKXJ:I5&@(`6$Q0H,SDP\\6,FG#SD1@Q"]/`RFX#@.`X$973D_Y
M[]3G_P!IK;'^;WK!P)->`X#@<Y7NE['_`!HDK_:;J#/_`+E<,?Q^C@0`\"67
MH7^RP:;_`(9S3Y)Y]P.H'P'`UF.ZKO8\Z;]^;7GR(;$\#G_<#YGVOO\`\V>!
MUS]*?J-M2O>RT-\ED5X&37`QEW6^HVVU][+?/R62K@<C'@.!T`.Y4/8]+E]^
M987R(Z\<#9HX#@<LCK)^RB;J?MSNWY+9^!&=P-C/N7GV2A\][-:/\JZSX'0U
MX#@.`X#@.`X#@.`X#@0Y]3&C;6N&=5PLK+0]UV#=8M#7DALV!KS>_.E5J5\?
M(G0TI[K](M:(XXO<JC2Y*V-#\82[+EL;"O5"`2S%+2%*I2'M=+!,P0$6PE$O
M.J<JU9OZ$N]<6+<9$TV`+VID5M-5JM<J;Z[LAROD_)#Q)U)X:XES`?'G!L;$
ML3&S9(;$V`.)^0A(I>E<2>V:S?Z_B=D.U5.$A&VIELN8F_*]VPPDN252_L*4
M9+HR.+6"4-)*N.K7MB>&B2-#>YJUT;=V=]*;W9$%@LZ;$GL\/8\V"1'6=%"8
M95MCQJO:WB40AMA5;64Y=)K6\';XX>)_Q`&Z.$OC_#E@V%P4@=(?*Y8F3IFI
M[5QY^BX?ESI.ASC`L6M*?"0I06.@!#C</%BE$7G@C%V*V9/@#8`R8M;E(X3#
M(@O`[&HE8ZOBS7'"EA,F/?)N[AD!!:3BD6KE#7<D(1V0GQ(I?.'UQF+`P*RG
MR<V!,Y+84PD6&,M!AF:_'I;+Y`L;4*%-@+0@5%-Q2@\).5!X>MBD:8QZ/-%6
M'H_^X,4_JG@/,C3'N15A\`8I_5/`>9&F/<BK#X`Q3^J>`\R-,>Y%6'P!BG]4
M\!YD:8]R*L/@#%/ZIX#S(TQ[D58?`&*?U3P'F1ICW(JP^`,4_JG@/,E2_N15
MA\`8I_5/`>9&F/<BK#X`Q3^J>`\R-,>Y%6'P!BG]4\!YD:8]R*L/@#%/ZIX#
MS(TQ[D58?`&*?U3P,:]S*;J%#J!M8N1576Z-:CUMO-6D5I8-&$ZE*J3UA*#4
MZE.>2U@-(/(.++-).+&$PHPL!@!!$`.<!]TTIRH5VG^J:U;5=;K%JS6RC%2M
M6J@\84*E2I16$7.4*5*@YK&:>>>:,9IQQHQ&&F"$,8A"%G.0R3\R-,>Y%6'P
M!BG]4\!YD:8]R*L/@#%/ZIX'SS)4Q[D58_<_O!BO]4_[?6].,=N0U1W_`+I'
MT88'UZ8CNGDYJ#65V<FDT\M/3X2SS&Y8<C&<6$3%WP0&")R,(1?KL!%C&?3P
M,2M;NO9J!2[[M`ZRG2!SEZ>\]GY;>,23%$U<(4+B4@KRK8@CA9F'%I,!@Q"Z
M01V=LX;?`MW>O0,E$X/PIR,-@?I=;[ZJ]43%X^0>I#'5OF.\V?JKB71RN7GU
M<\YGG!\1PW^HS,#Q;U,S`%N57C.,X/\`5%-DGTE'XP$L_F1ICW(JP^`,4_JG
M@/,C3'N15A\`8I_5/`YYG=($=CT6ZFLJ:8RPLT=:PT_4IX&YA;$30@"><SK1
M''81("$Z;!IV<=IIF"\#,S@.19SWHLY"!G@2J]$9G:'_`*IVH+0^M3:]-*V8
MS$M:UNR),Y-RP`*JGAH`*4*THY,>$!Q99P<&ECP$T!9@,!&6'/`Z8GF1ICW(
MJP^`,4_JG@/,C3'N15A\`8I_5/`UM>ZC:ZKZ(Z`5"Y1."0V,.)^X<`0GKX]&
M&1E6G(C:6V"4F)#53:A3'F)3#TR<X:<9@B1G$E&"!DPHL00T,.`S_P!'[F<^
MWZ_;VY[,8_A]'I[>WT]F>]X'6&TTIRH5VG^J:U;5=;K%JS6RC%2M6J@\84*E
M2I16$7.4*5*@YK&:>>>:,9IQQHQ&&F"$,8A"%G.0R3\R-,>Y%6'P!BG]4\#&
MO<RFZA0Z@;6KD555NC6H];;R5I%B2#1A.J2JDU7RDU.I3J"6L!Q*@@W&#"3B
MQA,*&'`P#"+&,X#D]<!P-\_N7*NJ^E^@%ON,L@D-D[B1N%8"`EPD,89'I:4A
M!2VOR@M&6J<D*D\"4LY2H.`G"/!(33S3,`[\PP0@V2O,C3'N15A\`8I_5/`>
M9&F/<BK#X`Q3^J>!S"NL"UM;)U,]RVAF;6]I:D-PNA"%M:TB=`@1$X:FC."D
MJ-(`M.05@0A9\$46`&,B%V!"(7H"-O@;#'<S,9C<KZC+VURB/LDE;,:W68K"
MW/[4@>$(51,IK@!2G"-Q(4I\*"0G&A).P7@PL)AF`YQ@P6.!T`/,C3'I_P!Z
M*L/O>0,4]/\`[I]O&,8]/M8]K@7(2I4R%*F1(DR=&C1IR4J1(E)+3I4J9.6$
MDA,F(*"`HA.04`!1))0`%EEA"``0A#C&`_1P'`<!P'`<!P'`<"('J9+];(B]
M1*;WMU(=L-/7$,8`QQFH-8+=96%_LXTQ[<!D/;=4B.K;+GTQ?SURT+#EY9D0
M&=*F1H4R_*3"<]4(/+Z0.(;*XQ>5TP:([@.T=M&1Q-$T[+;NV/&9C=&P#?7`
MIE$L(DT9CA:7R!@]7.Q;TVQUO<&UL5.JF3O"DY$G5IEB<D)DN`X#@.`X#@.`
MX#@.`X$+_4KHQBL+9_I\G+)_>T2(N"[72C+`:JQONVZO8WR`,-,7M:;>2)D@
MDM86M-(/*]`@/52I.E+D*QL;T+&J<#6E(0D+"99"D*;T2-`0(X9*)*G2$C4G
MFJE`RDQ0"2Q*%)XS#U!P@`QDT\X8S3C,B,,&(8LYR'ZN`X#@8R[K?4;;:^]E
MOGY+)5P&E/U&VI7O9:&^2R*\#)K@.`X''*L?]D.>?AG*/RXNX%&<#<T[D8_P
M@O\`DH_Z2G`W-.`X'.5[I>]E%E?[3=0?D5?P(`>!++T+_98--_PSFGR3S[@=
M0/@.!K,=U7>QYTW[\VO/D0V)X'/^X'S/KX^__-G@=<_2GZC;4KWLM#?)9%>!
MDUP,9=UOJ-MM?>RWS\EDJX'(QX#@=`#N5#V/2Y??F6%\B.O'`V:.`X'+(ZR?
MLHFZG[<[M^2V?@1G<#8S[EY]DH?/>S6C_*NM.!T->`X#@.`X#@.`X#@.`X&#
M^TW3]HC:^5Q&TY.NLZL;YKEH4L5:[!4;8\BK6UX*U*U"Q6H;FMP;SU<<=6X]
M2O6&'MLIC3\A,`K6IO``3KEI9X?BT-U>N74"OY%2D\O-IO:L61Z4NE,/:F`E
M0FQV-'*9#*I9.&JQ5C>\NC)+E9TA?B5S5(6],SG'^&<P*FI$3A`F)#.W@.`X
M#@.`X#@.`X#@.!&5O;]4OTJ_?FR[_-3V`X$FO`<!P(_NJ3M98>D>B5Z;/52S
M0R03ZLO-EZ@M%@MSXZQ!7Y9W%7U?.GJN@C<BB;T?DAFECBJ;_$I`@\$Z$(CU
M'C24L]$I#3%M#NF[?*VJSL2JY%4NHR*/69!9;7[\L98'<B=Z2,TS8'"..BEH
M4+[[<4*=S(1.1YJ`Y8W+TI2H)0U*-64$9)@*O[INWSJ:M*[JN.5+J*MCU9P6
M)5^PK'N!W*I>5;-#&!OCC6I=U"&_&U">YGH6T@U><C;D"4U4,T:=$E)$`@L-
MUKIN;+3O</22@]D[,:8DQSFTX_(7:0-,%0/#9$T:EIG,HC28#,AD#])WA.2-
M`R)3C@+GUQ&)68>86842,L@H,X>`X''*L?\`9#GGX9RC\N+N!1G`W-.Y&/\`
M""_Y*/\`I*<#<TX#@<Y7NE[V465_M-U!^15_`@!X$LO0O]E@TW_#.:?)//N!
MU`^`X&LQW5=['G3?OS:\^1#8G@<_[@?,^OC[_P#-G@=<_2GZC;4KWLM#?)9%
M>!DUP,9=UOJ-MM?>RWS\EDJX'(QX#@=`#N5#V/2Y??F6%\B.O'`V:.`X'+(Z
MR?LHFZG[<[M^2V?@1G<#8S[EY]DH?/>S6C_*NM.!T->`X#@.`X#@.`X#@.`X
M$;?5.56DDUE:SJP5[3%%^>BIR[,;=+6.0NVRS]49S\85.&RL5\70+G2,.A2<
M:1Y5OW:WIC6UG5QX]V;0O^%A84CTP/47+#<'J/\`V5'O?5:&^,?V3_R^]7.W
M*.1=YYG\3S^[>I'9WWEEAM_N?CGD]XS^N\#C(22SE^?(O$GQ]C<,>;#D"!)@
M;/"F!P8&ISD+B>>2F2(2G64.C*PMB?!IP3W!Q<G$DE"W$JU02EAY12-0&#Y.
M\;PK!JR8EK./H6^_:;K&W)G)Y9,K#9HG6`+34Q5OC<:+D,4HRQ6!P<W%R>GA
MN;%M@O=21Y<ZMK$S>KA;I+F\A,'^<[JS+.8\$-5QG!EV#\9UG#FP'7/E4QI[
MO@=,N;O9^?(0.(*-N;;-@UI";FD4I4JF-R>H6E$9)(Z6K?@RCJFX$LWK5+.)
MD2QP-Q2R^Q*\DJ$V1E+&%),ZKL:7U=*"F60.:*/F.K.KD,)=UK`K5M+6X*V<
MQ(>L:T2G!Z8H*W\Y5=?;]"OA4Q?GW`><JNOM^A7PJ8OS_@/.577V_0KX5,7Y
M_P`!YRJZ^WZ%?"IB_/\`@/.577V_0KX5,7Y_P'G*KK[?H5\*F+\_X#SE5SC_
M`.?\*];M_P"=3%ZWI]/_`,/];T9_>SP(U-Y9Y!U>R/2W/2S.**2&_<:6JEYR
M>1-!Q2)-G5F_",*%9A:P0$Q&3SBB<&G9`7X4TLOON_&'&0DK\Y5=?;]"OA4Q
M?G_`><JNOM^A7PJ8OS_@/.577V_0KX5,7Y_P(<NOY-X6\=)#;-N:9?%W1P4>
M8CQ="W/[4M6'^"V8IH\WP*9,K-/-\$04:<9W@!=X4688+L``6<!S6>`X'37Z
M'DZA#5TJ]/V]SF,5;EZ:&S,*E"OD+0C6)Q#MB?F!">F4+"SBA"`((PX,`'.0
M""+';C.,\"5SSE5U]OT*^%3%^?\``><JN?M_A7PJ8OS_`('']L001V!.A@$$
M8!S&3B`,.<""((GM=D(@BQVX$$6,XSC.,YQG&>W'HX%'<#<:[DPDL=CWZOWU
M??V5C\;_`%*WBGJPZH6SQKQ?]4?X?Q?QT\CPW@/#D^&\'WW@_#%=_P![X0':
M&XSYRJZ^WZ%?"IB_/^`\Y5=?;]"OA4Q?G_`YW7=)3NU/?4ZE2]E<V]W0BIZH
MRPK&M:F7I!&%LR_!A>%"0TTG(R\YQ@8<#[X.<XP+&,\"!'@2M=#YP0-?55T^
M<'-:D;D":8S,2E:O4DHTB<(JIGI81'J5`RR2@B&((`Y,&'&1B"''ISC'`Z;/
MG*KK[?H5\*F+\_X#SE5U]OT*^%3%^?\``UK.ZF)=%'_I^4\C8I/'GI67N-7R
MDQ*TO3:XJ2TP*4V$*&H&0C4G&@(`:<26(T0<%A,-+!D6!##C(:#_``/F?7Q]
M_P#FSP.L_IC84`2Z>:H)E,XAZ=2GUJHHA0G/DS*2>0>35T6+-).*,6A,*-*,
M"(!A8PA&`8<A%C`L9QP,E?.577V_0KX5,7Y_P,:MS[#@"G3S:],FG,/4*%&M
M5ZD$$$29E-./.-JZ4EE$DE%K1#---&(("RP!$,8Q8"'&<YQC@<F'@.!OO=RS
MR^)L'3]N%&^RB.LJLW<6?J2TKN]-K:I,3#I37TH"@!"Q22:,@9A!Q830AR6(
M9)H,"R(L>,!LJ^<JNOM^A7PJ8OS_`(#SE5U]OT*^%3%^?\#EY]89:B<^ISN<
MO;E:5P0J;D=34ZU$H*5I%!>6QH#@PE00,PDT&<XSC`P#$'.<9QV]N.!&QP-B
M'N8YY9V+J//:Y[=6UF1"UKL\@*QU7)6]+D\<IK80"<*%9I)631A`,02\#[\0
M0"SC&<!SV!T$O.577V_0KX5,7Y_P*P(/(5$$J4QQ2A,H*+/3J"#`'$'D'`P8
M4<2:7D19I1I8@C+,`(0!@%@0<Y#G&>!_7@.`X#@.`X#@.`X&`?4CA]LS77-,
MSU>PV--68NU*T<;PKBFYJ"N[>LV@D3_@RQX'6TOR]1<YOD#R2)M-6MJ*5Q5Q
MED91O\.02!$K?R<&ACYTHHN\L7ZHQQ@U77W0VI;C(:Y:Z!HS96P#YU:4&F4:
M8Y"@O1P"B<[`M.00"(2!R/@Q#/!G^>.JQ*_,4LD)*%F12,A&$)?O3].W[O9[
M>>WZ9]?'9P,53-0Z_P`QVLX6GE]J(H-7-<U[4ZV#IIB5F)V3!JO4-RV(-E@,
MZEI4D&*DZQNQEZ>(;Y&/$K:ECC$Y4N>86K%'0A^'.FE;]C_WLKLX(SUA"VNC
M,2)G$*C#"+1;;I\7J?!L;,*(;S[.8V"0K&V>E3Y`K:8\PU\>F,K%I1PHH+ZP
M&LHU7D);H*WX7/S>C7OSXN<I4<G>'F0R>62%WE\ME#V=A(E0#>9+*W]Z?W`+
M<WMK4F6.9Z=G;&QL*2H$X53Y-1S[7V3\5(/Z#@/)J.?:^R?BI!_0<!Y-1S[7
MV3\5(/Z#@/)J.?:^R?BI!_0<!Y-1S[7V3\5(/Z#@/)J.?:^R?BI!_0<"('J?
M]5:E>F$_4^Q3N@'NT#;@:9B[MI\24Q-F+:"X:LCR-42M`\I!B/&L%("1D9(S
MC`,)S`CQGP@<\"`;8#NB;7>XK2U&GS/JG/8^WZYW@\VI)&Q6]P<T^6-;G45C
MUP4R-XDJ,))*HEQFJ)VR:OP)+E.WG%X#@X1(PAG74?=,>LEN6Q6-3MVG=@M#
MA9]B0JO&]V6OE?GHVQ9-)(VQM,XK"2$6#SDR(]R+4GDDY\*826,!>>^[.T-H
MSR:CGVOLGXJ0?T'`>34<^U]D_%2#^@X$-?=`K&RH^D7MJI2,[6E4%^87P9Z9
MO2$'%]]LW3)8^\-+*`,/?EC$`?>Y](,B#GMQG@<T;@.!TZ^AJQ,BKI3:>*%3
M,U*3S8;,\FGGMR0XXS.+8L`.,C,,*$,6<!P$.,YSG/9C&/6]8)8O)J.?:^R?
MBI!_0<#YF,QS[7V7\5(?N>WX#'\'_=P./+8V,!L&=A#C&,8F4GQC&,=F,8P]
MKL8QC&/1C&,>C&,>MP*-X&Y-W)*V-SCGJ`>J#>B7>!_4I^!\<2$*O!>$SLCD
MSP?AP#[SPG@P8'WO9WW>@[>WO>!N3^34<^U]D_%2#\WX#R:CGVOLGXJ0?T'`
MYU/=*:1(AZG\K(1)DZ,C%-U"+!"4@I.3@0F==D6<%E!"#OA=G:(7>XSG/;V_
M7X$!'`E@Z&R=.JZK.GB=402I(-F<SP80>4`XHP.*GGXL8&48$0!XP+&,XP(.
M?3C&?7QC@=.WR9CGVOLGXJ0?F_`>34<^U]D_%2#^@X&M#W5(T-+?T]Z=.0-;
M<B.%N57I0C4:),F-$6*DMAA9+$,DH`LEY&``\AR+(<B"$6<=H<=@:"'`?6^[
M_JSG^;@=;;2V.Q\W3G4TTUB9S##-9Z(&88-L1#&,8ZMBHAC&,1&1"$(6<B$(
M6<Y%G.<YSG.>!DOY-1S[7V3\5(/Z#@8S[I1V/E:<[9&%L3,687K1>XRS`-B(
M`P#!5LI$`8!!(P((@BQVA%C.!!SC&<9[>!R2N`X&_AW*XT-+AT^+B.7M;<M.
M#N581035:),I,"5BDM>1A+P,XH8L%X$(8L!QG`>^$+.,=HL]H;+ODU'/M?9/
MQ4@_H.`\FHY]K[)^*D']!P.7!UC2"4_4^W1(3E$IR"KE=`%$$%A**`'#4SXP
M$LL`<!`$/I_6AQ@./3V>UP(T>!L4]S"(T:_J1OA"Y(F6$8UIM`>"59!2@KOP
MRJM.]'X,X(P=\'OA8P+L[<8SG&,^G/`Z$?DS'/M?9/Q4AQ_$1]/N<#V@``4`
M!98`EEEA"`L``X````8P$(`!#C`0A"'&,!"'&,8QC&,8QC'`_P!<!P'`<!P'
M`<!P'`CIZH4/D\@UC)F$5L>J:S6T?:]:7H:[7G-W2N:C=#*[>3%C`V3:8M*1
MQ5M9""8K(S+(Z5ZFKBG69QB-LPR09<`J2`Q+Z)="0.IH-;LJJ2ZJ7NBLY6R4
M#"PR2EY<YRA/*K7K>"O3K=%LV(B=4:57%[%L29V/EJ-9EN#G4<&@4#<W0P2A
M<''`G*X#@.`X#@?/IZ/I[?\`KQV^G'`@[U!U!UHKCJQ;\2B$4W$(U(*UK;4B
M301V;2%@%49?;R9=D2[:<VW)JPT(%4[PT-P'P1H3`F!1D8(`1V"R()Q>`X#@
M:2W=;/[(FD7X&7C^6ZUX&H!P,F-+/JR-2O?-4/\`*C%N!UT.`X$,O=!OL0FW
M'^(3_.=I;@<S'@.!U`>A=[%!IQ^!DU^5JP.!+/P'`XY5C_LASS\,Y1^7%W`H
MS@;FG<C'^$%_R4?])3@;FG`<#G*]TO>RBRO]INH/R*OX$`/`EEZ%_LL&F_X9
MS3Y)Y]P.H'P'`UF.ZKO8\Z;]^;7GR(;$\#G_`'`^9]?'W_YL\#KGZ4_4;:E>
M]EH;Y+(KP,FN!C+NM]1MMK[V6^?DLE7`Y&/`<#H`=RH>QZ7+[\RPOD1UXX&S
M1P'`Y9'63]E$W4_;G=OR6S\",[@;&?<O/LE#Y[V:T?Y5UIP.AKP'`<!P'`<!
MP'`<!P'`C5ZJZ>%HM86NPIK;]4TT"E[HJBX(N\7FQ/<KIV5S&'/APF2`V+%(
ML$R5R!ADN%ZK))$73JWYH>D#5)D"10-B$7D,=^D+8D,OB3[9[#-]SZUV)9%B
M+:1CU@PG4J%VI$J<KQOK]AG22&N65ENQF)2B73R;EO;_`(D\B,9$Q86B*Q-D
M+QXLT)<8";+UN`X#@.`X&M!LOW2W1^M.P-R:_/FL]K29YIRQ)/7CC(&J71%(
MV/2R,.A[6H<42585E4G3*AD9-)*/R(T`18"/]=VYR$<59=TB4G!-M=JMC5>M
MMI.#+L+!M:(FS1I-+8F4Z1U112*W$KLK<UAI.4BHA^'9"(;:!)C!B;#:KPI_
MY0CM";KII=;^K.I7>LLHN#T=8%9NT4J5]ME0^RN11UW;E;>Q3""0\UI)3-)0
M5):T]3.T:PL\?]P"0A5%CQX0PK/`G"X#@:2W=;/[(FD7X&7C^6ZTX&H!P,F-
M*_JR-2O?-4/\J46X'70X#@0R]T&^Q";<_P"(3_.=I;@<S'@.!U`>A=[%!IS^
M!DT^5JP>!+/P'`XY5C_LASS\,Y1^7%W`HS@;FG<C'^$%_P`E'_24X&YIP'`Y
MRO=+OLHLK_:;J#\BK^!`#P)9>A?[+!IO^&<T^2>?<#J!\!P-9CNJ[V/.F_?F
MUY\B&Q/`Y_W`^9]K[_\`-G@=<_2GZC;4KWLM#?)9%>!DUP,9=UOJ-MM?>RWS
M\EDJX'(QX#@=`#N5#V/2Y/?F6%\B.N_`V:.`X'+(ZR?LHFZO[<[M^2F?@1G<
M#8S[EY]DH?/>S6C_`"KK3@=#7@.`X#@.`X#@.`X#@.!&CU60E)=9XY*4%C):
MNL"!7U3<VIV1%4\_7[*W"V661F`B42KRHHZN1.,TFTQ\:71Q"W9`L2E-+B\K
M%!24M-ZKM@>#TQ]AK3OF/V&HMO86-W<^IXKKU8\?:FK7I?K\ZQ*!7U5*:UH:
M[N"%3+)B@E[?*FAZ`TD/#,ZFM[5*H+-X^%0L$WY5F!)!.3YLEB;X=7#7&WJ<
M828+C3?,GEQC\6&Y''%$!4OKJSLL@="&Y`48:X*"&]H4JU^$N$"<:,U5A:0$
M>"+;"ZWRMJSLAM!`T!$?U6U<V5N-E51-[<3K#'?SJ[MSQ#ZX6$R]#B'J(\V0
M:;+FU0YII88=(G^ODZL)K2C?4ST'Y1;5WUVP(&#:]"/9<>5]2"Q"'[O*5:$>
MQM5U$X)+'$*=9\N'LV`VXQO;6%#B)IE%GQJ1LYN"HL[-I;$&7].VXXOE3E2N
MS#$13\S6';E7/KA&(Z_`:WIWJ6W9]5(Y&WQY.=)G1F0RG$&%(BVQ0Y.H&?U3
M"W9=E^"BE1X5MYY*_P#LB]?`N;_-W@<MKJCN"9TZC6[#DB&8-(NV2M=2F&:G
M4I#1D'2I>,`C$RPE.J3BR'..TH\DLT/;V#`'/HX&!G`V2.Y<Y,SQ7?\`M]Q>
MSE1"0[3VP$98TC6ZNYF5!ETZ^G@"),T(5ZD`,EICA9/&2$@(P@+$;@PTH`PW
MT,7)7_V1>OW85-\?_P"<X#SR5_\`9%Z^!<W^;O`TP>ZM)>Q2RP=+C&-0M/`B
MAUV%J,JV=Z:,A$>]5ODO!87AO0"/P()8N^RGP8$O.,8,SC)@.T-27@9)::JB
M46WVJBQ1D02$NR-&J3Q`*-/,P419T8,-R600`P\X6"PYS@DDHTXW..\*"(0L
M!X'6&\\E?_9%Z^!<W^;O`>>2O_LB]?`N;_-W@0\=?2RX?(.DOM@T-2QS.7J_
M,5X`M3%Y4W$"\7V5IM4;@:QR94B,CL)),$`1J@K)@L!+)R,[(`9#FW<!P.F%
MT1+.AK'TLM0VER6NA2Y'#ID$\!$6E:\D(AVK/30X`K0,JI&?^L&'.<D*#,!%
MG(!9"8$0>!*MBY*_[,?[HO7P+F_\\=[?W_3P/GGDK_L_\HO7ISG'_,N<>CT]
MG;_S=[?W<>CZV>S';P.0S88PF6!.3`9SD!DQDPPYSC(<Y")Z6B#G(18P(.>S
M./0+&,X];.,9]'`H[@;A?<GLRC\2_5\>KJA:G]4/U+/BGB;(^/&1^*?JC<GY
M-RS-R_Q?O?&2>\PHR3@[M%X#P@@'=Z&X;YY*_P#LB]?`N;_-W@//)7_V1>O@
M7-_F[P.>;W2`_M<EZFDI=&@U0<B'3]2DA&J;W%K.\(2T+<#QE*Z)$2O`>W/8
M$S)/>"QC]8+(<8X$#/`E5Z(SLB8^J;J$ZN1AQ:%',9B8>-.D6+S@!'54\*QD
M"-O3JEAV<C&'&<$$#$'&<F"[``%G`=,/SR5_]D7KX%S?YN\!YY*_^R+U\"YO
M\W>!K:]U&S^+RK0"H6]D5N)ZLG<.`+#`*X[(V@K"<JEM@B!""I=VA"F&/!BD
MK`22SAG#"(9@"Q%E&C`&ACP/F?:^_GLQ]WLS^]V]GK_6QV<#K#Z:6U!46H&J
M:-2O>`*$FMM&)3P@A\R.`$Y/6$7*-"$XA@,)-#@8!8":28849C&!%C$#.!9#
M)+SR5_\`9%Z^!<W^;O`QKW+MF#+=0-K4:=P=Q*%FMMYIB`CB$Q(+$<?6$H**
M"8>>PE$$AR,6,"-.,+)+#GOC1A+#D6`Y/?`<#?.[ERGT8BN@%OM[VK<"%9VX
M=@+"P)(](G8O*<REM?B0"$H:&I<F`/PB<W&21G!/"$(1B+"682(8;)7GDK_[
M(O7P+F_S=X#SR5_]D7KX%S?YN\#F%]8!R1/'4SW*=&\PTQ&MN)T.3B/2JD1P
MBQ-31C&3$JTE,J(%VX%_<STY8\!R'.<8[>S@1M\#87[F9D33&.HR]N3R:I)2
M"UMLU+@:5M<W4SPILIK@0`Y2M*-:J[S."Q=IN2<%`SC`1CP(8,9#H`>>.O\`
MVG%Z^!<W[?X8[Z<_?^_P+DI%1*U*F6IA"$G5IR51`AE&D#$2H+":4(9!X"CR
M19`,.1%'%EFEY[0&``/&0X#]'`<!P'`<!P'`<!P(<^K%:;TRLM85>=JQLA:K
M=)Y[7CM5UUZX6K6]=3^N-A,O[TVP=O@Q4R-7K5TQ*;`.:]68JBDBB!<1<GM1
M(TH6E`Z*T845T9H.W5>GO^L'RKMF*ZMVN&376$2<W:BSJQL&<+*LC4-EK71\
M:A:&KDK>Q1NJ(2S)Y.BC`"$:A$XO[E+R@/;F]-<B);0G`]O_`%?P^GL^][>.
MW&/6]&>T+$*=9:-6$U8F/@27"2F&6,QNOD1#S)4J%OCL+5,3C#V!^1)7DE).
M66+/,7CLBCS3.BI*@9I2RMLJ;R")$D)<PA^3]2O0O>SH.("6'SBKDSG(!`D4
MN`8WN*.9G62E704T#_@VKE:>RSS;,*45F.(FALD7E_@7E>$+R$+LPJ%1>NXP
MTPV&M);+'&4H\M"A`>K6&B-6*U#BXKU[BXJ%;H\/#NYK%KN^/;LL7/#X\KUS
MN[KEKFM5JC0JK@<I?JL>R4;Q^^:MO^5KA]/WN!'_`,#9F[E1Q_QAER>\SL+/
M;_COUW^[[?H_@[/1D6,AT`N`X&DOW6S^R)I'^!=X_ERL_P!__;P-/_@9,:5Y
M_P"&1J7]W9FA\?OVE%OIGZ_K<#KH<!P(9>Z#>W'2%VY^]0F/W]G*7Q[7W_K]
MGM=F?3P.9CP'`Z@'0N]B@TY_`R:?*U8/`EHX'S]SZ9]?VN!QR['_`&0YY^&<
MH_+B[@49P-S3N1GM[.H)C[NJ.?W_`-4G[7K>U]S/W?1C@;FG`<#G*]TN^RBR
MS[M,U![7_P!CK<^CZWK>UP(`>!+-T+_97M./PTF?R33_`('4"X#@:R_=5^/^
M+SIOWYE>8^]_O([$=OM^WC^#M]OO>P.?_P`!];Z?O<#KG:4_4;:E>]EH;Y+(
MKP,FN!C+NMV_J-MM?>RWQ]_MQ5DJ]/;V_O?=]/`Y&/`<#H`]RH^QYW'[\RPN
MW'^)'7?U^W^;T=F/K]O`V9^`X'+*ZROLHFZF.WT>>9T]/UO]R6?M];ZV<Y[?
M1V]OK]N>WM",S@;&?<O/LE#Y[V:T?Y5UIP.AKP'`<!P'`<!P'`<!P'`CIZGI
M=?..NC!$YA6,JMN93N[JHB-`Q*#VBIHZ7E[`+GH]?`)&P74CR)55:F+DMCX^
MJY>G2N9Q#6B7-9+,\F.86M6%CNE5&"JVD&S=5696MGPS;:-FTQ(;WE]K[-.6
MVTBM"%2QBFA%+2!%;SHWL"PMD:A1RRF1)"%,89%$85IEZG.75,]I',\)A^`X
M#@.`X'*6ZK/LE.\7OF;<_E:OX&`'`V9^Y4?9#+D]YE8?RWZ[<#H`\!P-);NM
MG]D32+\#+Q_+=:\#4`X&3&EGU9&I7OFJ'^5&+<#KH<!P(9>Z#?8A-N/\0G^<
M[2W`YF/`<#J`]"[V*#3C\#)K\K5@<"6?@.!QRK'_`&0YY^&<H_+B[@49P-S3
MN1C_``@O^2C_`*2G`W-.`X'.5[I>]E%E?[3=0?D5?P(`>!++T+_98--_PSFG
MR3S[@=0/@.!K,=U7>QYTW[\VO/D0V)X'/^X'S/KX^_\`S9X'7/TI^HVU*][+
M0WR617@9-<#&7=;ZC;;7WLM\_)9*N!R,>`X'0`[E0]CTN7WYEA?(CKQP-FC@
M.!RR.LG[*)NI^W.[?DMGX$9W`V,^Y>?9*'SWLUH_RKK3@=#7@.`X#@.`X#@.
M`X#@.!%KU9)_7+?KHW5%*HQ1\]D=T6E5,#CK#>EF.E8P2!JY!+0X:;GF$GAK
MRR69&8["WEI+*122`.31(\2A<SM38[I3EIN!!:+H^Q]-5_ZINBE,.H13+J]D
M-5R":W[KK:=HW#";E=9[&'XY"QO<LNB232PVZ;UBS1U`!VB2V6.K&SLDSC;B
MQ$-V'U:68$T_`<!P'`<#E+=5GV2G>+WS-N?RM7\#`#@;,_<J'LAER>\RL/Y;
M]=^!T`>`X&DMW6S^R)I%^!EX_ENM.!J`<#)C2SZLC4KWS5#_`"HQ;@==#@.!
M#+W0;[$)MQ_B$_SG:6X',QX#@=0'H7>Q0:<_@9-?E:L#@2S\!P..58_[(<\_
M#.4?EQ=P*,X&YIW(Q_A!?\E'_24X&YIP'`YRO=+OLHLK_:;J#\BK^!`#P)9>
MA?[+!IQ^&<T^2:?<#J!\!P-9CNJ_V/.F_?FUY\B&Q'`Y_P!P/F?7Q]_^;/`Z
MY^E/U&VI7O9:&^2R*\#)K@8R[K?4;;:^]EOGY+)5P.1CP'`Z`'<J'L>ER>_,
ML+'_`/".O'`V:.`X'+(ZR?LHFZO[<[M^2F?@1G<#8S[EY]DH?/>S6C_*NL^!
MT->`X#@.`X#@.`X#@.`X$0_5FJ^LG"`5Q89VKVK=Y7=*[5J[7:#S3:2"NDLK
MZND%E2-T(;5TK-C(294".J)6K2,"!*WN38E!)Y@W*5JPE*)1X0,=^A393/.V
MO8]L05+IW5#FSH-?7Z0M.G53SNLV-L?)C'9^I=J^MW,\D+ZL47)5[VTN\9E<
M7;QX110O*%<2X.1,K3#3AL`<"+>\=B[CJRV+JD^'9^>(!`PR>$UA7T)?Z(D<
M<?[/9=17+89$S6_%BXJZ[`Q]T=CR'10WHV*:1Q6E:D5?RA7$5]=2EZDH`_05
M85R8GS/K\#9I]=T3U8T;)SL<WQ&C`2;U/=]9;"M\^NF9`""K:J"M,=(4V6$B
M7K80\/A=3/*EL&:I4C;[$(#,6F[6=Y;KK1ULRMH<%\@L2J*QF$@01!B6N."7
MR8PEID+IE&UHS%RA,V$KE:@LKOE"D*<L1!0E)PLX,&%5^=1#]I=H?%[(OS7@
M<MKJD+0./4:W77@3K$@5FR5K*`IG%*:A7$!-E2\7@E:,_`3DR@';C!I)H<&%
MBQD(L8SC/`P,X&R1W+D_$QS?^X%QK6_.H3M/)^EPGCK,M?%H!#NK7T[!YJ1`
M`PXM*'!&0&*!8P6$TTDL6>^.#C(;Z'G40_:7:'Q>R+\UX#SJ(?M+M#XO9%^:
M\#3![JUDY$EL#2TPEGDK1XI#KL`($D8'!A,/R:]UN+`D@%Y18E(`8+S@T97;
M@O(@8%V=^'@:DO`R2TU4!2;?:IJ1%'G83[)4:>(E*2-0I."39T7,R4F3EXR8
M>>/`<A*)+P(9I@@@!CMSZ0ZPWG40_:7:'Q>R+\UX#SJ(?M+M#XO9%^:\"'CK
MZ3Y*]])?:]L*C$\;AJ?,3WJQZASRU-I/@=EJ<4B\97JTX""/"8)\$3WX\>$4
M#))!VC,"'(<V[@.!TP>B)8*1HZ66H3:9%I\N&DA\Q")6T0M[<VX_O[6GYG?)
M5Z9.(A0$/?\`>#$4,6`F!&#/8(.>!*OYU$/VEVA\7LB_->!\S::'[2[0^+R1
M?7Q_]4S_`!?=]'9V\#D,6&/PD_G)F`C#@<PDP\!,#D`P]\]+<]Z,`O2`>.WL
M$'/I#GMQGTXX%'\#<+[D]E)$9_5\>&99.[^._J6>]\FX\XOWB_BV=C.^\=\0
M*-\5\-A1CQ;PO>^'\&H[SM\"/O0W#?.FA^TNT/B]D7YKP'G40_:7:'Q>R+\U
MX'/-[I`>BW_J:2EP*;WAL`*GZE*PE?6I4S.`<E-"[&1B1+"RS\%C[>THS(>]
M,#CM#G.,>@(&>!*KT17(#1U3M0G$Q(XK@)9C,1B2-*$]R<3L"JJ>E]ZE0I0C
M/4#QD>!""6'.0EA&//ZT.<\#IA^=1#]I=H?%[(OS7@/.HA^TNT/B]D7YKP-;
M7NHV:)I)H!4*$J/3)J$5N'7ZK*B119U8T0PETKL$3X`I6N)+),5"R?@P"<.?
M"C*+.,QCO21YP&ACP'UOX/WL_P`W;P.L-II9B))J!JFE%$+(/$FUMHQ.(Y)`
MW]2E.R36$7+R:F4%)A%J$YF0]^2<7G(#2\A&#.0BQG@9)>=1#]I=H?%[(OS7
M@8V;EV6B5:@;6I0Q"R2!*=;;S3X.50-_3I2LG5?*"L&J5!B;!9!!??8$<<9G
M`"B\"&+.`XSG@<GK@.!OG=RY35-'-`;?0G1^9.PC=P[`5X4QV*NSXB`$REM?
MBL$&JT!!A):H.4XAC3B%@T!1A!@L=Z>#.0V2O.HA^TNT/B]D7YKP'G40_:7:
M'Q>R+\UX',+ZP#@%UZF>Y;@6G7HP*[A<S<)'1&>WN!.,M;1CP:I$I"6>G-#G
M'I*,!C.,=F?3CL%D(V^!L,=S,OA4>ZC+VX'-KVZ`%K=9J?Q5@:5CTOP(R45L
M+!N4:$!AP4X,%]AA^0X+`(0`YSVCQC@;_P#YTT7VEVA\7LBQ_P#U<_3Z_`N2
MD485I4RH)1Y(5*<E0$E408F5%8.+"9@I2F-Q@U.>7@7>G$&8P849@18\8$'.
M.!^C@.`X#@.`X#@.`X$?V[A=P6BDC5-:C6C`X=MA7,OJ+9A#&K*DUFQ&OY%5
M\:G3BSNK18:RMXT^.<DA4R5('2-N$0).2&+CRBERA0C`A2&FA<;4YMW%;4-@
M"VZB^HL9=71];WB*8U.76BM0O"A:G6`ECM8`[-C$;4F/IYQ#&%O6-H5QBM.6
MLPY'`&0D",,N^!0@JNK,<Y'9PZ[@HK*,;,,IEA"B+!F<#9L$C38:1RW+?ZOC
M;/%C#$_B`G#*3P`QD^"\&(6,A2P==-?0P=16(:*IP-:JWKRD5UZ&L82&#*I#
MV%!]7E$3PR>H)[U@*<C'JH:WB7=Z24'P_86'&`N^002F()3)B2DZ=.460002
M6`HD@DH&"RB2BB\!+***`$("RP!"```X"'&`XQC@?UX'*6ZK/LE.\7OF;<_E
M:OX&`'`V9^Y4?9#+D]YE8?RWZ[<#H`\!P-);NMG]D32+\#+Q_+=:\#4`X&3&
MEGU9&I7OFJ'^5&+<#KH<!P(9>Z#?8A-N/\0G^<[2W`YF/`<#J`]"[V*#3C\#
M)K\K5@<"6?@.!QRK'_9#GGX9RC\N+N!1G`W-.Y&/\(+_`)*/^DIP-S3@.!SE
M>Z7O9197^TW4'Y%7\"`'@2R]"_V6#3?\,YI\D\^X'4#X#@:S'=5WL>=-^_-K
MSY$-B>!S_N!\SZ^/O_S9X'7/TI^HVU*][+0WR617@9-<#&7=;ZC;;7WLM\_)
M9*N!R,>`X'0`[E0]CTN7WYEA?(CKQP-FC@.!RR.LG[*)NI^W.[?DMGX$9W`V
M,^Y>?9*'SWLUH_RKK3@=#7@.`X#@.`X#@.`X#@.!&#LITYT>TVVJ"[9Q9EGP
M2OF375FJQK34==$_J*?K9BCLN5RU<?(3(DE1HG6'897Q&!`!0_FK"WLI3G+0
M20$M8>&2FK^HT%U003!OA-@WQ/BIHK9ECB=>5RS&X%;:8R$N)*8N.*)<L5F,
M2=4%S.$Y$(<E@7F$(C#\"$E*S@,JN`X#@.`X'*6ZK/LE.\7OF;<_E:OX&`'`
MV9^Y4?9#+D]YE8?RWZ[<#H`\!P-);NMG]D32+\#+Q_+=:\#4`X&3&EGU9&I7
MOFJ'^5&+<#KH<!P(9>Z#?8A-N/\`$)_G.TMP.9CP'`Z@/0N]B@TX_`R:_*U8
M'`EGX#@<<JQ_V0YY^&<H_+B[@49P-S3N1C_""_Y*/^DIP-S3@.!SE>Z7O919
M7^TW4'Y%7\"`'@2R]"_V6#3?\,YI\D\^X'4#X#@:S'=5WL>=-^_-KSY$-B>!
MS_N!\SZ^/O\`\V>!US]*?J-M2O>RT-\ED5X&37`QEW6^HVVU][+?/R62K@<C
M'@.!T`.Y4/8]+E]^987R(Z\<#9HX#@<LCK)^RB;J?MSNWY+9^!&=P-C/N7GV
M2A\][-:/\JZTX'0UX#@.`X#@.`X#@.`X#@.`X#@.`X#@.!RENJS[)1O%[YFV
M_P"5J_@8`<#9G[E1]D,N3WF5A_+?KMP.@#P'`TENZV?V1-(OP,O'\MUIP-0#
M@9,:5_5D:E>^:H?Y4HMP.NAP'`AE[H-]B$VX_P`0G^<[2W`YF/`<#J`]"[V*
M#3G\#)I\K5@\"6?@.!QRK'_9#GGX9RC\N+N!1G`W-.Y&/\(+_DH_Z2G`W-.`
MX'.5[I=]E%E?[3=0?D5?P(`>!++T+_98--_PSFGR3S[@=0/@.!K,=U7>QYTW
M[\VO/D0V)X'/^X'SV\??S_%G_7P.N?I3]1MJ5[V6AODLBO`R:X&,NZWU&VVO
MO9;Y^2R5<#D8\!P.@!W*A['I<OOS+"^1#7C@;-'`<#ED=93T=43=7M]'^_.[
M>O\`=:F?L_?]K@1G<#8S[EZ]DH?/>S6C_*NM.!T->`X#@.`X#@.`X#@.`X#@
M.`X#@1MVQ8SXU[.F-15D2)GG[186K4<J:F$LN,0,5@U+9,F6H+SF2RO@&A13
M8Q!&";/=E,A=$CBN@N:0:E<;5QH*Z2AEH9W3V4OL/9`.T>K:;6HO$N3I!1F!
M+Z[;GP"<XL\9CH-19T_K>-Y0I1DEDJ`%R`QSR-21E,W*20J34P6;\_-I_P#4
MIV:^%6FW_:UX&D]NOT->IKLAMQL=?<'U^;&J'V_<$YL"--LKN*DT4E0LTF>U
M;D@2OJ-HL)\:TSF20>`"PE`\N:4LW`@DK5`<8&(,7_[7*ZK_`+AL,^.VI?G;
MP)@.BETR]^^F_M//[PO'6AZE43E6O\JJIO;ZIM77M\D1,A?+%JJ7I%JU)+K@
M@K:4REML%=R%"@AV4+@KE#<66W'$'*E*0-F24;.3V'1F12Y_TQV=2,,58G>2
M/2HN1Z>*C$S2QMZAS<E`$R;;(Q0H&2C2GF!((+,/.$'!90!&""'(?N:MB[(>
M6QN=V_2W9PU`ZH$;DB,%)]."A&)%R<M4F&(HS;0(RQ#)-`+)8PA&#.>]%C&<
M9QP->WKCZ%[P]3&5:[/E$:ORV))*CC]CM,D+MNS=<&)2M4R]QAZML&R`AUVS
MPI0205'UF%PUYK<8688E"G*4A,-&0$#_`/:Y75?]PV&?';4OSMX%X->^@5U1
M:FOVC[3D=!QY;'JTM^M+`?D;+=%-J7I6S0V9LLC=$S2G73IM0GN9Z)N.*0$+
M'!`D-5"(+4K4Q(C#PAO0^?FT_P#J4[-?"O3;_M:\"DXOM=,IBHEB9@TUV>5'
M0F6+85(@&2#3]+A'(4#8TNZE(4)1MB6%46%"^-IV%:7)J8>3Q%!,R:4:$`85
M=4F&;+;N:)7GK!5.H5SQ^>V;YLO4%WL&>:I-,/1XA=Q5]83IZKKXWLG+'I/X
MPS11Q2M_B4?7^%<SD1*G*5(8>L3!I_\`]KE=5_W#89\=M2_.W@/[7*ZK_N&P
MSX[:E^=O`W(.FXP[':>:24'K99FG]VODYJR/R%JD#M!9SJ<YQ-8H=IQ*)*G&
MS+I!LO&7=026@>TI1PEK$W#"K+4%@*,)`6H.#+59M=,D,XCM<J=--GP2N512
M9S5E0XD.GXR5$>@+O`V*3JS%H-L<I$YB)RLF(DDI3S@*5@5YQR0HTI"L&0%5
M^?FU/^I3LU]S^^O3;]W_`.EK][_NX&@_+.YW^JN_2J2OB.BHD6D>9`\NJ4M3
M==0@4%IW%Q4K"`'@*F)Q03@E'!":$LXT`1X%@!@PXP+(4_\`VN5U7_<-AGQV
MU+\[>!/_`-"_2#=KID?JH_/SJW-);Y[?,EY*^:*S-;7[U/\`-MYW/5SRA\LK
MQ@/BGC?EZS^I/J;ZK>'\7<_',(?`I?'`G6F^UTRKV.*I5*=--GD3*D7,3:>H
M)D.GRPP*N1OS9&VDO"=+MB:>+"AW=T)`QA!D!(#1''"`268,(59Y^;4_ZE.S
M7PKTV_[6O`U/>KUTH.H9O[N4^;#TYK<MC<*<X!`XJ0V69;%!,\I`XQ=O4I%Y
MQJ*+6O,FH*,TP\(D9@'LPXP`<B4)B,XP$01@?VN5U7_<-AGQVU+\[>!F_P!-
MWHO]273W=N@]D[,UX)?(-5DAD#M(&F"V]1CG+%B9V@\HC2<#,AD%EQEG4'EK
MGI(:<!<^-Y>$@%!@#3#@%)S@W(O/S:?_`%*=FOA5IM_VM>!2<,VMF4_9UCY&
M---GEC:AED\A2DXZ0:?)!@D-;3B15S+DF"56V)1HRD$KBKT@)5`#E.N(3EK4
M9IJ100:,(JNM;KMMQU']5X#1]'ZGV;%99%=@(K:K@X6M8FL#''CHZQUU:T15
MHT:N([!3ER,>C'*<M)Z=.>TIT0T*=Q--<2E!*9,K#5__`+7)ZK_N&PSX[:E^
M=G`?VN5U7_<-AGQVU+V>U[?E;Z_[F/1V=G;Z>P-Z'7F<W94U`T=5<CTSV'6R
M&LZ?K.OWY8R3'4!2S*WF&0MDCCHI:%"[:AM7'MAZYM/-0'+&Y`J-2C*&H1)3
MA#(+"M$>UTR7SF15TFTTV?'*XK%(9-7I#F0:?`)31Z?.\[8XPK+6BVQPD4&K
M7*MI<2:E(-&I1A;R3E1912Y$,X*)V&G%V6U05XU7'=,]AT4BLRG[,K]A6/4Q
MU`3,R1YF4,>HXUJ7=0AVH<EQ#8G6N1!K@<C;EZHI+@X:=$J-P`@8:,']KE=5
M_P!PV&?';4OSMX#^URNJ_P"X;#/CMJ7YV\#:`Z*>NVW'3@U8GU'WAJ?9LJE<
MJV`E5K-[A5-B:P/D>)CSY7-51%(C6*Y=L%!G(MZ+<H,['J$Q#2H0@0J&XTIQ
M-4&J4R0)59=M?,H.G8U4CTUV>2$R.61N%-(BI!I\KRHD,M<R6AD2""FVQ,R0
M6I7'%EF*C<`3)PYR:>8`&,YX%6>?FT_^I3LU\*M-O^UKP-+[?SHE=2W:G<K8
M;8>O=>D3/"K9L!;*XXV3*X:0;I2B;U*%O3`(>T+)8TB:$ZP(TIN1%H'MQ)[T
M0!>,B%D0`!A__:Y75?\`<-AGQVU+\[>!*_T;.EKU`^GCMRY7Y=6M;G)X>LI^
M9U^6VU=:^O[S)0O,B>X@Y(51B.5VW"6L+841'UH%9X7D:L!IB8)2(\`S1D!M
M0^?FU/3_`,"K9KX5:;?]K7/W_P"#T>G@9&M:M0O;&Y<K:US(J6H4BM2RNAC:
M<YM"A2G+..:W$UE<7=G-7-Y@Q)%9C2[.C:-048)`XK4N2E)H?NX#@.`X#@.`
MX#@.`X#@.`X'YAHTIJHA:8E3C6I2E!"58,DH2I,2KR0)42G/$#)I)2D29-E0
M66((#A)R<F!%X$OL#]/`<#"&PMKIC7KMN`!ZJ4IM8M;*.KRW86M>)HT@6VKF
M8N-Z-:S(TC"7(<QED`OJ-&ECJ4072=/HW)67B')W0;*T+PLWG>FQ3H,]R-L@
ML-6+ZKAVP=GVV!\Q8D"5+81KZ\Q5"K;(Y`I9&DD^@,VG;9(G1R;&FRVTD^-F
M1Q,8J;W^-S*.RH(9"5IL/,)G;9<9>8Q%FZOI<\;'QNOW-M=WA5+4[[K%:R"I
MI03+$2EK):#4\V<`R621\UJ4$@CK7'T;:XG/;A(`FM0902B-M4QC,BB+\0-4
MQRIB=XX])BSSDQBAI?$"AL<2"U"<19Z<9J-4<6`\D8#B1"P86+`PXS@/WM;:
MD9FQN9T`!%(6I`C;418AC-$6D0IRTJ8`C#,B,,$`DH`<C&+(QYQWPLYSG.>!
MC-LW=%CTFTMTJBT7@SU&DWBA"U))Y,Z-LLL2;/C\TQ^#TK4S&S-3D8LL">JE
MZPIF=W?(FE&[IV1H/:E:!\>I)#`L<X;EV$A5!SB"04Y#9KO+V&AQ^44C`>2J
MBNV%3:E)W6S\Y8!8"VR%\NR&6(2EC10'!G9$K]$E6%KB2ED1P?QQN997]]8!
M0:`9-H$7C>R/9(9,#`F)5>EATXU.55A]0C<'*UT>JN:6F:V2`U5XD(EAK8:L
MU8\JIPR!(_P*3B\*C\.42Q2PI34QLVEBR:R$1JI0IPJD*]L:6E2J*">8,*4H
M:%D;BL)$^"TX!%#-"#`SC,B#S[)<YLSQ!P6UVT1MWE?C32F28F#T:PQ5H;U;
MLB3/\H?5J4A0N4(HJP&.DAPS-Y9"N1*FXAA`Y,0',Q^;`PH8]XW%\9=?BFR$
MM#_);8L0AIE+E'GAQ.@D?I]PN*35#`[I9758V)UKBTWN<QI)A2C,H*+)D\/,
ME;\A?WEM@ZQ4[A^)JW*LMQ9HLL'!J_)<+[C503O7``)#)C4V(A;MEL4'*%:8
M1,10R'B'Q661*QUR=@/3$R)0YO%>(A-2B.IYG(0S$H^PW2T*\3R5^:VYGD3=
M+K.KV2HV5:K7LF9/4=FS"J)(O8U+@D0KQ,;L^0I>ZLQ:]*!<F;5J5,L$<H*-
M/,"L%D)CR^<1VQ5*0T<KBL4F<*9EV%:D!*>/3YW@3[)T@T(3,)%!BURK6)'%
M*CRAJ$84!Y*8PLI>LP<%5_O>U].WT>WGT?\`?Z`P*:MD;P<7^XX`Y0VJ(=,J
MP::VFKY()=))@P5[7D$GB:S7)\<Y*XR./1Q58Z.O6^N$Z57.*[.35[*)%*C&
M,#[%\P.;K6X*?@6YEAS8B&S$ZN(JPUT%SU^AEC>,OTH,EH9AL@_H8W"7>!HE
MT69@*H2E42RKGLHR4H6=_?(Y/W%0N;X>ZP0]IE`78UHV&E]S*4N)A&(O'DDV
MI:JMAZV'&W=Y<U&(!;"B5`11F6`=&M"6&5Q1(QL2EU=FX934\J)0<C;6M(7'
MCUSJ&24WA,=L..*HI*DAJUE6+V)R/3DJE"(P2N./S9)&DS"A*84>#!#LT(3Q
M@"/`3@%B(-P(DP8,A5G`PVNC;9NJJV857J.,G2)A\-+#;AEY"@P*:OPM=#7#
M=L6C3>G`3DM[F<E9ZD=7-:U@5!-C$9/8W)X2@#.(DH/"W[;M'=Q[I$ZK=H35
M;3=ED+:J<HH,B1RYVKMAA]J5I?-FDYD9V&-O?7:01H&MEGPX0&OU,0216.*R
MO.8PD=5D;;`_Q6NYDQLA5!Y6G@D49ZP6R^I*?L0HV2/2^;1RWK9JZ,V($F.]
M['D;(_1&)N<\K^&J%BD#<LD/J\_2A.8R)X@2R2P)#.!2<,A4>@+0L8HRD-1M
MJ^63R:J23E2E8,<ALJ<R*QI:KP<J,-,`4OE<J>EQ"4(\)T!*@M$C+)2IR"BP
ML-N#L?G6.D9E8+-&O+VP$L8F+C7\`PK$WER1TB$/?)L]+7IS+*/$R0^*QJ/N
MTEEKUDHPXIM;L-#(G=):]1MA>`L1;.^)E2WC/X(\P]*J@M;-<E/?G-.5+!.B
MC,:UIDFRBEV22\J/FU:G=3D,>\BTM**Y)BY5217FW2V(-:%IU:\/8SLEL+Y9
MXH3R!I[]4+X?,D[S,NF.*R\W>(!B6>$RX^3.7S$F\M18JS(,%91>IW;;6"/!
M]E7\#,BK)^V6O6-<VDR)U"1FLJ!Q"?M"57V>-)FR8Q]OD2!.I[`AQXP2E<2B
MSNP(<>$"+L#CUN!Z".%1Y#.9%8J9(:"5RJ)PR%/2[*I2,A1'H"\3Q]C*0M$(
MW*1.:B<K)EQQJLDH"A8!>04I,-*0I`$AX%RSQPJVH;2LIGB[E-WBOZ]F4R9X
M4RIUREXF+M&HZX/+7%&I,V(7-Q/<Y&O2)V9`4@;7!6-4M*"G1*3<A)&&!LOW
MPDT>A[(0B9H6MM5V<+5/7L1L+V>"BB[-44>@;\\M<JA)=(9NF/21U\YL$5X6
M/5?-L<8*\D@[7RMD#.UH6&3!44UW=E,-126P<0B%/M4'/]GUC6@FR8.@I3)[
M7K2I)#9X`NS@GCZ^-H(/+G"#S^'('AM]4S&<MBCLOR:^(IF:RQ0,JJ4L*733
MSH1N?MT:13:H;'!74C60U0ZG19[-<*WKJUFAV9T[X04[-P?)NS65M<6]6>X>
M!>6YR-2N)Z,Y/@L+B2V%1Z<$,::1I#E9,<ED;FK4$I4I1Y)D,3<BG=D5C$E,
M*$>4F7$%F&)3LB3J0A\$>684+(1!5O`C_8]WVA5:EG-TC#'XY4%=@NAJ.?EC
M/:Q4K42"B9$VQB68;%ZF`$5M-5SD]!E*='7$`E\@L9O:FB)2+#4\E3A>U08*
M%_5QVLKJ[SA!J&,1EUB,5V^MFU85*Y2XF.\?KS5F\7>K@0UL6,#8XM9UG2]A
M:W!S7.(%CG$8U)F!8RD^KS.]-TA2!?VM-AYA,[;+C#S&(LW5]+7C9"-U^YMS
ML\*9<F?=8K605-*"98A4M9+08GFS@&2R2/FM2DD$<:X^C;7$Y[<)`$UJ#+W@
M.`X#@.`X#@.`X#@.`X#@.`X#@.`X%GYA1E>3Q=8J^3M[DL.M&`PBN)1E*].3
M2:6PUT_S^40]<P+VA0B=8Y)65_LB0.S?)69>D>&]Q(97!N5(US.D4!"U3IIA
M43ZC"4]N-CN;JY#EI4^DI\^>29!;+-/T4%:YM%[*6(LI$KU&Y&RUC7T?-;6U
M$S>H\;B;='(V:RL9[HWN`7%B&OL`A%CO%G,IDI&\.(9SZFLKC*'5PB,2-M*3
MLTVM!3$HZ>;E(UJ+`F,?:I/(##1+/`.A2S+"%F2O#TE<0OAP'`Q\M'75AM.P
MX)9JV=V7%9)7#:\-T6*B3VQD,J(3^<F$\.X6B01F1)29$N0I0,8Y"APB>"8\
M>XLB980WN[J2M"G5.H%0*EDO5J!SHP4G5/KBS%>73^$BLW>46<T79(GFL`A4
MA'%7-VN".QJQ#CO"+RTKW&V)`VDHHRVDL(0_CC3JH<!C`/&9^+U#7*G&1BS/
M'X/G44K++5W,?BU`EG`+EB3SIN+I+RF\(6Y`G"\OT13)RJ_?WN).`95\!P+3
M7;3T=OFN7FKY8[REGC;^I:#7D43=$S6N<T;4ZI';+$Y"7-[H@=(T\F(RV^3Q
MQS;UK-)F(]<P/:):SN*Y$H"V#YIGK_-"8*JLR"1^UIG7SU'7IDM"PXI!7NS3
M<Q.2J91'&APE2>)MYQD>:%BG*-*RI4Z-#ZG%`(,+&>)0I/#^:33FH4+9*&I.
MJL`)#X*'ACQXYZ^FJ:M05[.S;.@K15@C3AE11GBT^-\H$*#)+@4M3HV>)/?J
MI!(Y'8NU!?:O("P5C$6V&1G#B-L;U#RXG+7IS6/3V\/DE>W&3RB1/CLN,,5.
M+Y)9,\O#^\JQB``]R<E0R"4Y`BR"@K;@?/W\_3/W?YON^GV@PM?]$ZAD$?5Q
MPV36\E1'JZ_*2FCL5?(#VR(U8XOCW`ZX2DS-))VY7`F.0OZF0&M+TWNJ]]=F
MZ-FR)W=TT3C29K"XI>L4%,F$8G+S(;&DC]'RXH:YA>9@HPRSM\@*EZ6P*5SR
M.-25J8'J2PY5('!2T+TS:W$J%">.J7M([J87"C(Z'NU#K[`*24O*F&&2@_+F
MQQ>'MY4DE#K(4\5@$&42-5":^B9#@:,MIBD4.ETC]2D^<*702=P*1.+JO0M3
M*F;`OCP';P,=YUJ=KC8]BQBVY?3%;.UE1:3`E9$W.@\5'*GAR)@;_7"(F32(
MUH,>GYO:XW(!>I*)<O&6VN+)&G!'DHY@;L%!3+7IU5S-'265ND%J$O+8]1AX
MB]@GV0_.-BPXN$QE[A$08X[)G,:T9<?8H3)Y7%PMCHF=0O*26RIUDIKW)Y"Z
MORH/6CNIE01*209_C::5M2"OFV(I&2&%3.1*(2L=8!#%->0F72)B6K569'+H
M["U8V-.]NZM48X^)L+P^E.TAB<1=V$,F.`X%E+SUVI;9*&N<&NFN(?/FA<QR
M5A1*9'&V)Z>8P5*VH;.[N4/=G=M7J8L^B2Y(,3O#1E.M3JDB)2`>3$9&0!1J
MG4"BU,B,=_)I8ECAQ249]5-[LK;J@-=F^K2Z0;'[%>H1$,B=>U5"G10!L0(P
M)XXA:6QH<$[&"1L[6]I`\;.F56^H.&KRGN'U?\H,OWG)\ZLIQ9O@?(;S8^3F
M)?A3A7B,XKWLCN&S!6!X<L!L+QGSJ_W]\#*%B8VF,LC-&V!`G:F*/-3>QLK6
MD#D"5M:6E(2@;4"8&<BR!.C1IR4Y(<YSD)98<9SGL[>!ZO`I:;PYDL*'R>#2
M3#EE@EK&Y1]W]1GIXC;N%`Z)3$BDQKD#`M;7QD<2BS,F(79G<$3DWJ0EJD2D
MA04`S`8\..G%5NK6!.K>[1Q)E$@D4AD%E([&?VRR9:9,(A'Z^EK5(9.V&(QC
M8I!!HC#XT>V-25J*:28=$WJ-B9)5'6A_1A^E9IO1J]=)A*FB19C$HCLACYM=
M)Y<_M]>,0I;`D-7R9_B4;;EB0$5DKM7[<GC.'5E4I,M)*E]=(^2T/\LEKL^A
M=VL:N8JK:GI`SN4ED#E)Y"?*Y9*YD]GR"4RF1'-3/'RG)X<30$$=\AC<=CT<
M;DC>B;V]"S,;:E(1X$6:::%RN`X&,ZC4:C726262R:+F39JDSA(GQ16TY6"E
M]2-LDF8FTV;2=HKA]+6QM,^RU0TI5KJK/2*BTS@JD+BR)VA=,IHHD(46ET(U
MJ9XZ1$HA#3Z\C0GJW'%^8ZV7X@35,F2])6U2RS8/+T$83-J-YAT@/CD482D6
M2"'5FAL59(<RO+?'2UB!:%VXAK[`(18[Q9S*9*1O#B&<^IK*XRAU<(C$C;2D
M[--K04Q*.GFY2-BBP)C'VJ3R`PT2SP#H4LRP@9DKR])7$+X\!P'`<!P'`<!P
M'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<#YV?3[GTSZV?1];Z_`A^;;\ZAAG
M4/4Z<+IKIB.'M>O\<VF729)K_=Y$E55X]7@_5:=7B0P[:-2UIIF2UQ\UP*FI
MK2J9/'U1>10X:<@28T+PQCJ?T1+)TT1=K@5\`ADTL6PJ;J*]%D`:2*7NNX:R
M3R4R25E6L@Q+3)(?(E*N%RYFBR^61&)Q.8OD9=VN,25V5)N\&%@:-ZNX)GII
M#MK[)U8V#*S*Y]?C`I8:IA[$]1MAB-.2N0$^6#K8$]G<'A+<T$QM$CCBI1(Y
M'&WZ86FP3J/5_#70EI(+R%\=;=\5.R^V;K6T'1QU1K^[Z3T+M774A4,KTVV0
ML6W')Y,W&MDE&?(53$0A0,[2@#AI2L*=Q0/&7`"AZ<"/!%$A1@K\W6V2V!VG
M@6I\CUSJRM-299'ZP.>+EKB=VE(;IN8^%L$[DT=/*B]G5F16-?,*:1-L=,D*
M9-,)"O<<*W%`C"FS@A&%.U5U?(!.Z1HB<"H>]9_;MGT].[AGM,Z]19GLMZJR
M*5'8CM3]E2QU4/DGA93O&D]E1U^8XFW1@<DG4KR@,)8XHYJ@`"<%]9WU-M<J
M\BFVLR?VRU@-.F#11+U;Z<4#&TOIB/8>)1F9P$F.QV2NK"^>J:5HEC65*V:5
M((H[1US`N;5*(Q4D,!D+7Q#J*2Q"[;GYGE-3*QVS7W<(6N->L6NT'-=)0LC@
MJSBTX#*;.>YY8#)7<61HUKJYI7.;2*45Y#B<#9&H!(GA>1A<'HQ'JWZ^63C7
M!-5E8;'VB^;00V53J`1F#UU'7)W8V"`V:=4T_/GIRN=M[)&00N5HG/U<</5A
M>R"0-IHVIU<EJUH0N85)N/L5LS`]I-)]8];UE%,*[9]GV@=Y-+[OKVP+&2,`
M:%BM;RAG(8F>!VU4YX!/)<J>D;D8X.#C^O`UG)0I@IE9:X+251U0U[9'9A`=
M@ZR<I=M="-LYSJ.VU+JPR'2`5U26)0ILM$N>5NW6/+&-OBD1Q6[F8_R8-@V(
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ME/1K9XZ0Q"K3JC`]ILZK-'R6"5=(H34NQ\\LBV9K=$"8=<HI!8<KO)I?==EN
M4-U"DS>OL9MKAK;X$>:U!7*RK)6Y=SI`R((R6]N:P:$@$_ZKM!P(.#,U9L_*
M2V+7YLV<MT,>II0A<-?*E>PNV&ASN>/S1^B,F8GA>:QO&01Z.,TL=4[4W*9>
MM3I(,#$GR%P:(W!66GL](J=6(DH858>JU';F:Z.OJ8)JD1E7S\9\.G$8G!/J
MRZ)CY#&Y>D87U*I;BB"@-L[+9E&3Q,B=Q<0S\X#@.`X#@.`X#@.`X#@.`X#@
M.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X&,).L3$3N:Y;F8D[L
M*3.6L3)K&.%Y1H\,1;$RVL_VJ5*`N';ZH9=CW!_-:C$>0^)@1IRSP9\.(6,!
MB/6W2WC]?S.J$*F\YK)]9]>KYFNR^O\`K0LB4-;VR`VW-%DU=2U3Q9"))Y6S
M&*0=^LF>/L!CZDEJ7MC@]IPR"02E"V)T1@6%.Z)K2HKBFZH5;.21QA-$3+8U
MPKQG?::K&5(VR$;+O*V12MO-:Y<6_L"BUXD^.SVOKNZ1LV7"*8=5"=+$S"@A
M#P,OM1NGC$M2IS'YTQ6/(YBMC^I]1:G)T3LSMC8E/C5/OC\\L\K-&C./."^N
MV'S*5S2@'ZGX\5`<F+*\)X$`?EL'1:QPW)=-PZS;9S;691LFEC([RC"&N(-:
M#.\2F)QU+"VNR*\,F'@%-:3\<.1I&5Q<$8GR.NI[>V/;E%UCNA+4Y"V9W2G8
MZ]*J8_4[8.QM9I%7>M;IJ2_RY`P1JQ)%-Z;>9>LL18NPND.&\43ME'83Q(IF
MQV*R=\0T/$C=`@BZA#E*D3!2-[=(0FYUVS[:FVPMB*UYM_!Z)CMYQI3$(%,9
M7*I/KO$8_#(',<V*^H0N:(3HW1EJ<)RU(6I,?)'H"E6E>V1*L4H3`]ZV.DK$
MK(=+!D"*YWMH>)WN0EW%-;9-7,'LNO02(NN$59FP^0UK+P'QB:-2-L2>KT9=
M'\DQ7&I5A*[ITJO"7Q4X*QU)Z74$U(E=`R:-VK,9AC7NH;[IR.))`RQ]":_,
MM\WFKO5U=WY2S%HTH7AB>EAS*B"T-K8V*FWP9HT"8X&<#"\.T^G$@V!N+6Z^
M8%?4DH:S-9T-UML1>&."PJ?)'5)>3+"V"3%NK/.$RQL[Y(V0X!"$84XQ8$Z*
M#NT!J<@7`L(1TK6*.-$&F$"V"L5FVLA&PEE;.9VAE,7@DQ>999ET0P%;6LAE
M5;E-4;A0H!)*\(;HFV1*-%QHR+(F-D4,SN!60XFN@>#,.DC%G^CX]4Z&YSW1
MX-M.X+NN&17#25/79$[UMF]%YCK-I]+JRDK$W-,;DC$X&9\V3A`7F,F1!`$*
M%V\KL]^I&%`/G1$JDENIM)7MOO#`OK771AU?D+[9%1U#?3K*Z]C\I=I<W2*.
MALV/.#97-FM;A(7UL894T-SHTL\85(([B*JT+*V8)#+G<76J3RZ`:JNM+L:5
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ML(TMA7'8X4Z14I=HPQ"E"&'PV/LCYXJZ+SHP^O1S>0W',RUS"4?@.`X#@.`X
7#@.`X#@.`X#@.`X#@.`X#@.`X#@?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g893535g17v81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g893535g17v81.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0S@4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@`````````````!60```AL````&`&<`,0`W
M`'8`.``Q`````0`````````````````````````!``````````````(;```!
M60`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"D0````!````<````$@`
M``%0``!>@```"B@`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!(`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#TCJ6+9DM8UE8?&X.=ZUE#@"/S7X['N=N_/5+]F9FXN%1!C:#^T,F(
M$[/:*VK8<_:6B"=Q(D"8@;O<L/J7UEQ>E9#<;J'4</&N=7ZNRUKV':26LC](
M[<W<Q_O_`)"2F9Z;G%CA;1ZD/WU[<[)W#9N]$@V-.Q[O5?ZNVS9]#^=]-$JZ
M?F,R/4-4M$QNS<BWZ1<P_H;F>C_-/<FQ.M,S'5UTYE!MMDL8*GND`%^YKFW;
M?=6/42ZIU<]*JKOSLO&QZ;'^F++F/K&[Z6P?I7[G;&V/_L)*85]+RG!U;Z"Q
MC0-GZ]D/$@-V^E[:W5?\;].NS_!IATW+<&^QSA])KOVEDR=&M#A^BVJ&/]:,
M'(I-S>HXIJ!(%C:WO:X`>YP<VT?13VX.+TFBW-<['IIHBQQLI<VNO;`]5C_4
M=8QW^E]S_P";J24E/3<K<'?9F.<&$-)S<B9<UU=C7/=4_P!3^<=Z;_\`KG\X
MBT=*<YSCDFVN-NPUYN0^>'/EK_1]/W,_E^SU%0QOK;T_*=MHZEAV[8]0U-<_
M9(_/'JL_.&QJU*,C(R:6W8^13;6^0UPI?!+26.U]?]]J2FWCTBBEE(>^P5@-
M#['%[S'=[W>Y[D1<TSZX].?<,?\`:>$<@O\`3-+0YS@0=KM/4;N<SW^Q:N%U
M`9;G.IR:LBNLQ8VNIX=J#L]SK7_]0DIT$TB8[JJ/M_>ZJ?\`B'_^EU@]8ZQT
M4YAZ=U3J&%7D4%NQI:YMS'6!KFEC'NL8Q^Q[=F_U$E/42#PG6)TS+QW.=3A7
MX]=U[GY%U+:7DE[B/6L=MOVN=N*T0<T$$V5N:"-S12\$C\[:[U7^[^RDI__0
M],QLL9;?4H$5MLLK>7Z&:RZL^G$M?^D:N2^NOU,MZYU;&S!G-Q1;6W###2ZR
M"#D9'J[FV5_O^G[O^W%T?2O1.//K`SE91K#7Z&;KW&N"&_S+?\'_`(+8M`;9
M^E/S24\5]6VEG5,*N9-8<R?'94]F[^UM3?XV7AO0\$O('ZZW_P`\Y"E]7_\`
MEC&_K6_]1:NRL:U];F!\%P+9.L2(2*GRCH#@[ZO2TR)OU'Q*[[Z\S_S1ZMX?
M9GK%^L__`"CF=_T;?_/35T?UEZ==U3H6=T[&>QM^52ZNLV.(8"?WMH>[_HI*
M?+?JE/K9G]2O_JGKU/ZM3^QJ(_>M_P#/MB\_Z;]7.H]#LL=G.I<,H%M8I<YQ
M!H>:[=^^NK]_]&N_^K<?L;'DP=UND_\`"V)*?(,"?^<S?_#M_P#U=R]1^J$Q
MF1^]7^1R\MZ>YO\`SG:-P)^VW]_Y=R]1^J,;<R3'NK[QV<DIZ+W>2\=^NO\`
MXNLS_CL3_P`]8R]A]G[_`.*\>^NO_BZS/^.Q/_/6,DI[7ZN3^VO^M6_EK77>
M[R7(?5R/VUJ8_16_EK76^S]_\4BI_]'T7I9J;0:Z6NL:W(O8YQ=NVEK[-VXO
M%3OI>W]&RS_T8K_R5#I.]^(US7$#UKS8+`"2399P6BG;[_?_`#?_``:O0_Q'
MW?[4E/-=(Z'U'%ZG5=<VOTZB]SMKY,/;8QD#:/SETWR4!4&O=8T-#WQO>&P7
M1]'<[\[:I0_Q'W?[4E/$?6A[!U+-EP$,;()_X)J[CY(%N&VVVNUVV63(V-.Z
M1LA[GAS_`&_\&]B-#_$?=_M24\Q]:J:J;,-E-;:F$9#BUH#1N<ZA]CH;^<]Y
MWN6I]6O^1:-)]UO_`)]L5#ZV57OMQ'-K?8UK;0YS&.<`2:-N\L#]N_\`-6C]
M7J[J^D4,L:ZIP-DLL:6N$V6$2U^UR2G.ZWT;!Q\;+S*\3'K,4FI[*F-L:\VG
MUW^HWW;K/4^DG^J'&9I/NK_(Y;6;A,S<9^+>XBM\26:.]KA8V"=WYS55Z+TV
MO"H<^KU&.O,O;=&X;2YK-*_:WVI*=+Y+S#ZW?5?ZP9/UKR^IT89?A.?1<+O5
MJ'LIKQVWO]-]K;OT;F._P:].A_B/N_VJIU6H'`R;'!I>S'N#71J`YGN@_P!E
M)3SGU;(/69&H-5A_&M=?\EQ_U8G]KMC_`$-GY:UU\/\`$?=_M2*G_]+U&QM9
MLK+@2X$[")@2#NG;[?H_OI]K?/[RD]U@<P-:"TD[W$Q`CVP(]WN5*KKG3;F.
MLKO8YC8D^X<ASV_29^[6])3=VM\_O*6UOG]Y5<]3PPXL-U8<TD.;NU&T[7Z;
M?S7)OVIA:?IJ_=]'W<ZAO[O\I)39VM\_O*6UOG]Y54]7Z>`2<BH`23+^(.UW
M;]Y3_:&+O:SU:][GFMHW<O'+!I]))2^90Z['=74XM>2T@F3]%S7]RW]U&AOG
M^*37E[0]H!:X`M,\@_)/+_W1]_\`L24MM;Y_>5"EK16!J-3IJ.Y[;G(DO_='
MW_[%4.#8ZW>YS'UAI:*',&R22X6?U_<DIM;6^?WE"RL<7XMU`<6FZMU8<9,;
M@6[MOS4F5/J:6U,K8W4@-$#MX*7Z?^3'S\?_`""2G#Z+T5V)G67NO%@IW4[0
MPMDD5/W[MWYOT%N[6^?WE1K9:S>7$.+W;H$`#0-VB&^[Z.[WJ<O_`'1]_P#L
M24__T_55RW1_J^SH_K4UYV;DC)-;2_(R&AS0QMH/I-].M]?\_P#^>U\_))*?
MI,V/)<\6V!A)</TS`T;G=B:]^UGT=OT$@YY>&MNM=$2?59K^<[V^G^:OFQ))
M3](M-A#?UB\:`D>M7J8,;OT>YN_9^;LJ1-SBU@?DVLEON>+&$@M:?HAM/Z1V
MUWJ+YJ224_4];-H/N<_=K+C/8#3[E-?*J22GZJ27RJDDI^JDE\JI)*?JI)?*
MJ22G_]DX0DE-!"$``````%4````!`0````\`00!D`&\`8@!E`"``4`!H`&\`
M=`!O`',`:`!O`'`````3`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P
M`"``-@`N`#`````!`#A"24T$!@``````!P`(``$``0$`_^X`#D%D;V)E`&1`
M`````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$!`0$!`@(!`@(#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#_\``$0@!60(;`P$1``(1`0,1`?_=``0`1/_$`,```0`!!0$!`0$!````
M```````(!08'"0H$"P,"`0$!``,!``````````````````$#!`(0```&`@$`
M`PH%#P@'!04)`0(#!`4&!P`!"!$2"1,4U!65%E:6UA<A5%<X&5$BTI.45=6V
M-W>7MWC863'3M788N#D*02.T)35U6#(DA]<:85(T-B=Q0C-#LR8H>9F8$0$`
M`@`#!P0"`@,!`0$!`````1%1`@,A,7&!$C)206$B8A,$D3/PH>%"T;$C_]H`
M#`,!``(1`Q$`/P#OXP&!IQ[5([D/")#Q0F5+<LK=I)JN/E7QFXF2F#0QBJ=T
MC@6:W)Y)$4CLA&?-:^D[Z7.B&U60G(")7MKT6B*V)+L>S!#B766MMP_4?:"S
MRF9MRLHEYK,=BQ?@)!*RW:G+.XKV@-:MTZ?[%IV'6#!_.*/,U;Z4M4CE[V^J
MVT\+,V+DY0TI)A!1AZXEO`*NIQ0]E?:BVWR13\1)%2U=2ZN+$8.T@/XYV=2W
MO$D<6C-HI4]&R:;-*-RF$SK6OI.37;X%T1+30O,12.282(8M-QP])PGK3TQ%
MW@EE%>UDD]BDU]7=;\5U,@Y42>R^4=7S&DW>[&&-PJ!/G$(3.7:YWOI,A#BG
ME"5P425M(8A)F`H*\Y2/O@2,H@9N+1T^^Q&CDWVNLGNGB78*OB!5,R2/[QP$
MD'*J:V<XV4BK1\X],SR]RBNV;42()C[RJLF<,DPB;DH&%*I:$NF]%HXE48I,
M`CQ:8RU.W%EUC[8R(0VYZ6XP.4`>)RL"GXMUK;5G'30PN7MMAWY7<<D;;(6*
MNRXB[F3B%QP<A;12=W4OC0I1&KQ[2HW#1!N]+1T[)FUQU/VPJF7RVM`69QI4
M5C4]LN7,UBB5EM-PM]@.>WGA2W2V3S_;I`@5_%5;>R/L.AZD]$I[_&H"X@$E
M$F$3HI:<LG+[[5.3]L7)T4&<Y=)N&$])<I3Q'0<TN/<2@ECMMFOEJT^X3&'1
M'89>DCL**<*ODC*FG")\<R"$TC3HV$M2<$\U4G$CVLZ??U7@I[6!S?8G59U-
MT7"+UL29\=K>Y4S9C@7(YO*K:%T[3<V!!GXYBM%_JMK<IE.G%X,[V(8U,<8S
MDC@6:F<#4?<3#0K.G?;&4^[;0+`T3:QH+Q<<YU25:4#Q1Y*3V;N%P-<.EK/6
M_*%2%$G1M]>GP%[+>IE#%)X.LC+=P(W`!2C??J;8$^E2SI]V<>U'LOE!4>J7
MGE=N%]L'%&/@LIPY:2SB?&JEE_(6(HDC(TJZ\D[<R6]$YBU[K-@5IW%7)#VY
M&):4C*ZPS"RM?7I,M;<4+2>TJLFDN1',ZV2"Y'RGXCQ:#=EB\!E*JR44('7T
M0Y+Q56PZM&O:S'#E+9(7FT7R6H'5P:TFH^1K23Z\TK7<PA)K9&.U-A5VH^RK
MHU%$]`.:BB-\V?H]O?D*RF<I]UR7&C"62DW4((T>X:K?SE%XL->_''?)8];/
MT@$3KIVM'3LW[:11,[>]G1M1A+EQ>=$T[24S+)$Y0DJW"CMH>23+R/E''R.\
M7!.RBLD1IK]+10Y8]`>=(];3)S$I.VXS:D)H5IZ/=G%W[9NMX[RM<^.CW5JL
M,;B5FK*0GUALDR5OTBC=I-<`U-'E0AJU+`BECS4K6Z_[B'(S'9$K&Y[#U&H1
M`M&XM'3LNT<H/VAW*FY>5-26G%*"DS56TX[/&][_`*9XYE\@XWM/>6VVQH21
M`Y!-E2R/M$2J^<G,IP_K3]O)"!"X`ZJPXW9Z<I::B(G;ZMJG."V[/K#L_.1M
MU132FK;>B'&Z8SIJ*[K'Y0L@,W1PXYS[S[Y,3.L8?5,<==B*[L$H](H&5UP:
M$#>LES$7,1Z-=T<Y.7;P\N/CNDN'D?/^3%&WQPFO+DW8+-/XG5N[,I%UH2M(
MC:#U)V1_J^!UR%R@TV2.RQJ0('9.=LM:GUH"K8^MW2'51-U&VUXJNV$EL>AT
ML=IEPRFB.:F<5ZWYE4_!X39B2S-SVB[&L..UWI[FKI&:_P!N-9NL)5RE(Y/J
M9.V2,*5J"><0:I$2(O:T=/NH=S=N)7]2QBDG)LK*)6I(K,HQ5R(DS?7%Y!>(
MFW5^EL)=7(&>J9@.K"5ELV4O>6%W[DR+VF)Z3C:3TZY2C5]4C:SI9GYA6-:]
MA<L.S<HZH.0=H4/6G)V$<M9K,GZKFFMP3%Y!6E<5/,JW%LZU*YL),UIT9\D5
M:4I@)"AG%JAA'L)@"AE"-D3-(@Q;M@YQQ_JAZA5XIF#D3>,<YC<K^,,*L52Z
MM=%0JV87QC8HK+7BSI,ZQ:$3-C8)$IW/$$=*;V1B-1*GH.P[$F*+4*`K3T^L
M;F:9#VR$D5-\CDM2<0WB?Q""\*X#SBL!PE-SM%82&*UT_KY6DG<2W%G"`2$Q
MUG4&)B2DQ,22J[S>-D'@[X1["FVL6CI]U;;>VLJ.3<I(!0D-K)Y?H5-)Y3M7
M*K#.D^T$S:9K>$)9YE$EB:I"(HY@<*]93Y.UM3X\J)"WG(7%4/N")6F)$H$L
MZ9I0:G[9\4G05S.+<XPN-5T];=1<S;3K^<1RW6^T)"Z?V&%#F*Y&=R@1,`AJ
MEH3J6MG4&-*H2XTY8I"$G:4`!:48LZ<)VH^$]J5;$%Y$67R2Y!UQ*ZOH]G[*
MVJ.0D%X[1ZWD-DM\I<[4Y,G1*M)PL/#'XDP1&>S`$J;V)S`:G4^*"4PA;4JB
M`@V):>GTC%(6*=LF[3V/5XE@O&5OD]J3OE;_`&5RXLDO,U%70W)UJYXLV*6)
M&+6=*=1'2>(.9+7M"N+,86]:W'DJMA*4[)(+5K1T^ZDP;M/>0]ZWQV;K)6E)
MPV'P#DNY\M8Y>D.E=E!<9$P23C/(V^(3\B-2I!7AR1>V0!(8)]:AED)AS`U2
M!O.VRA(&I/6=,1>U;G,OG/R/H2YNT7:8%+D>FZL:=X+(*B)D[0S+(944OY'6
MB\5G*[3>NLA`J<43*2XIUVR%QRA$)2D)+&7HD9O23$1,0QUS$Y(<P.#2GD_2
M2+E1,KT6G]GO(.45?69-8)3Z.S:8LB(VQ%:T?C#4T&@48BA];STJ4*#6C3FV
MK%+:O1:2DGF]49VQ$1-37JG1V:TYY2S.1WONU'GD#->.Z5II==0=@<J*LC5/
MW(]2MZC+TNNAI31MAK^L7-[KUE>=MWBQS=6-`<(1HRTXUA`>[%H1FKFQGQ7Y
M]RV#=CI3'-;D`=(;LLEV9"6U6F1;CL>?;#G<QO9SJF!L^U12-KC3"G4.+DWD
MJ5FR`E)491A^RS1AZ@WH3'RF%7>.UH6UVZO$9NSCG[NY-5W*>J^-O(<IJM]-
M-8U6+;>-7N%EU1:D:DZ6NF8N?L<BTE(;%*!0F8%:!:L)T(1FQ=7%G3A+"T5[
M>"+/%52BU)#QO>XVDKFC"[!M*/D6>C>'>"7!*.4$AXS531B\XV!L[68;.U,9
M520]\-/3!:V,.AZ0JMB#L2T]/NNR$=LO(K/5TG"JQXE*+`MZW[FO>DPQ)CO)
ML;(8G=J4KN,6MJ:Q*R9E6L5(F-=R2#2$U2)6H;&9Q1'-RA.%"J-[D$Q:.G?M
M>>$=IG<2:PW&FHA2CG?UE65SY[0;CI6Z&;W5#*W:H\U\3VU!,D*,#VQ4842D
MB"N.F*BTQ:TEU>4.D^M'+W0PT/<Q48^CT:[:;<LJB#613O%QXGZY3PDL#G?<
M<;?K>98$35M25W*93`'5O8GPZ%2'=CR1;-H.[%)B0HVG0VU)I5OH.,"CQ9TX
MSZMPM+6)[WZ=J:V?$_F][T*T@EB>(/&'C;Q'Y[19JDOB?QKWBV>,_%GC/N/?
M'>R?NW4Z_<B^GJZERR7@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M#__0[^,!@8GMFCJNO(BO4UI1?SH)JJV()>,"!XZD3)XAM&LW$UUA$HZT==F@
M;IXD7G",[R6[4-RGIZJ@@T/1K!N8PFG"CC!8FN2`9M5:*1`Y<>[L7(,I=))I
MW&>G5*R-<?KA6221)"2H<X1%M9$>TJAATUGZ5)BU0AB4AT=A-SL8E.[+C@PH
M8]Q\ZF'$Q%NV07N)6*X+RW(!7&7"`UX"QQ2OWE^=`I7J,@UTJMK.OMP_WCO_
M`'C_`-ZQ1U3BK[OV;?"EZK&OJA54@B20RK'.8/,#,8IM9<9FK$Z6&(S=AK?>
MC&YFU6>Z'6"`W9;]M:\*-/).@EK.[EA"'0N<7Y63V:G!ZV6F'L4UH%A-:8'4
M2BA(TAC,EGL`*)IM1O1I==NNX!*XP9)HVVN&N_T!+GM9MM==B7I1$K1"/V+F
M/5>@.#?&)/9T8N)LKYV8+!BB."($KO%K.MF)M\@35BV(&:O]6)%HU.6J)VL=
M$FEK3)D1LG0NYI1!``=;80ZU@N=RFQK@_P`08.[U"6QUDU(G6G9)>\ZJEM<9
MM.'CQ4^<B$#PUWFXC97Z6N":6(9@@DZLH],YDKT*`*G_`+H4FZ`=47*THKV9
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M0+2I4KD4X,3`EP40D0')8:K&Q=R\W3EH]J#$`S_]9@N<5Y+^(G&1IN)UY)'Q
M$Z,V*[.9#O*'INLNQXE!Y0^FLA4,(?)O6C5-6NII@_J&41:'2UV9E:LP/4#W
M38M!W@N:IAII[*/@"QDR-*U<?DJ1#*:ZG]1.;:&Q[?,:DU86<](Y',(%'6H^
MP#6Z(194_(@JT:-I*1$M"@T\;?I+M2HV;%)ZIQ2UF%%U5/*3>..DIB93C3+]
M7^ZL=(42[/S42?`MLP(]J/E/3.Z-\D1%!9R@D!/(6%*@ZUUM&Z%]=DHO;?JP
MS3O`CB51"Z2.U>U$F&^2Z!^ZR0R.P9?8-R2AQK'>]['7.Y/<4LGC^E@9WUNC
M&@E26WF:++T(K>BB]!$S,K,B_9E\*81'I5&H?4CS&$4P019F<W-CN2]&V7-L
M>A#H<]1**0R>)++*F]=PV/NIXSDS-'W!L:P"W_\`#]&M:THZI5!Q[-WA>NC%
M9Q%)38XJT5!''J'P$ZNK'MFKY"V1.2/QLID<9=9?7,[BTMES!().I.<ER-X7
M+TZM>>:H-`,XTP8E'5.+(7(#AKQYY0/U9RFYXE)GR34Z3-$U<2&+6S<%6/4<
M36(FCR*;)=.=43V$+79-(T<60DJ"UPU(-E%"`'00G':,$3,;EL.?9^\/W*K:
MXII/2S7%H%4+HZ/E8IZ[DTZJ^40=Z?BE9,C=H[8E<2B+6(@<906N-\:G!=>Z
M.FQ]*O9V]:WH7-W:-LO[)F@K.Y*N]M6HF4S:I]<:*GX[1:HE$MM9M5HF^L)*
M]/(3IC,6JQ$3G9<<>D"Y(G4M3]I>0J-1A.5;4#Z-ZBD]4U26V^%_&TJYD]_-
ME?+8S9Y1T<4JW&%3^RH-&)`KB#,1'8JLF-;0Z8,=:3A9'F!(2B1G/#0N-3I"
M2R@"T`L`0RBYJE`BO`/B+#$%-M3#3C>!IH%LOUEJII=I5/)(UQ]HY0K5+A?#
M6Y-LDE+LBF3?8*E8;W8E\+<BT99FRT>DY>^I@N5E0KLO^"=?H9:V1RA&\3;.
M:J-I"3M\DG5H3A"X50*0II4DA)"2;3>0IVII8GY&2>U;1A3G,^B2RT(TY0`@
MT+G%?T<X*\9(NDK=&AA<L=`U';>[TKQ7,;HO"P'6.VAYJ#@X)`![G=CR-X<T
M9$5'M&4UK#U#02#H$!*$S6AZ%RIS7V??$9C'31S+5*AG6\?K0G=QU"ZM5C6J
MW/<1GEGR,,KL94%\1S@EX?8W.7L`1NL?<SUD?7$@`G-1"3@"5H7.+($EXE\=
M9G*+IF,OJYFE#YR(@$8JZYMR!<_/#1.(+#`.X(PQJXTX.RB--GBC;ZI&6I0)
M$JP1HPF#-$,HH0!<L.,/9G\)(Y!+8KE!2HE<;O"(M4`LY3(;)MR6S&101B$4
M-DA)%CRJ?/-AQV(L^TY?>K:UNB)&1HH&@%AT`/0HZIQ3A;6]&T-R!J;R>]T#
M8B2MZ$CNAIO<$:(@"9,3W4\9AQG<R2PAZPQ"%OHZ=[WOX<(:]:\[)S@)5T7E
M\&B5'..X+.H0JKN2P65W/?=A0=5%%<G8)H)*WP^P;0E$;8'5+*XNA7I7-O2I
M71&I(ZY"@O8S.NI/5.*_C.SIX;**)L+C8LIWQC4EKREIF]DMKK8-INLQFDO8
M7*/.S-)9!;+C-U5M+WEM615!HE0)\[H`A/W#6^XC,+&+F[7"3P/XCD(.0#4&
MDHV8U<HUT9<[T:U+A)5C;-5\,V,V)JB6]6^'I(D;'%QHEB/Q(!MTG<1;6`Z%
M6^[8+G9MW/VA7"#C7`7ZH)2Q0Z5+9/0TDL6755(YG<=UV.^QE_M>$$5Q/%9S
MO8=B2EPDB=WA*8M`4E=3%R1O+!H:,M.;]?@N7]1C@[Q<AMC1ZV8W6'BZP(I<
MM[<@6!_\];#6=X6[R78A1J[9;XJ7RU4R*O/5D'LGO`Y,8V-O3UT"9*9]=@N4
M`N3_`&-E:VK`ZMI^A!571E:5_5$^I5.N?HO>5C6=&X)83\MD3VBB$P0\E((A
MD203H[JU1+;-D$K;$KB(I822$PH`=128S)Y\5.'-?<3]V<LB3L\R5\M%SK_3
MO()$%+MU2P^HJPBU0U5!R3TH`;4-,-AT5!U##/KSEJU4=T`T;HL$HF;I+K"#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`_]'OXP&!H?[0*VIM2O.1
MRL^"N04LCJ[L@>=MJQ9,O`->PZF5?N<8DD:7.C*,T"1Q*3.3<7UP#UTC*V('
M3K0MY#N(N.;!#AVGO,VGZ\O5RGBVH[4DB;AWPPY40"1MU8/L'B=0%\F[`1U_
M-"9ZQ-LYD[U-H15R!R\=C6DJ42HX*$P)H"$YPC$:SIB:2E@?)SE'*N9])\;J
M]Y/\?N0E;&\6WWDY:5M0JLV09=B-L1Y%)X([0>L01*T'^,QV1N#$_(6H*I4Z
M+DJ?1!YXRM*#`"+(J*F:0%JKMI.2\IKZ[K2L<F*P>&%52IDC3XHAU-2&74':
MH[_B52QZOCJ^WRL33*6QMS99JG(=)!.DL#(9)$1HQ00%$<6FVMUTQL?WKM?^
M68.)'O0D<QH"+.=7<Q+HHRY[#8=U-,9N_P!55C!*]ES1-Z<J)QOJ)UY<;IXX
MLY`A?RHM*EPM(0E*6THX*@1Q*SIBZ20>.U(Y*NO:"@HFOX,RJ:SCUM4Q72RN
MI:GJB#36;UG:M;M,L770C>9Y?45M`B3H720D*&A@:((YMZQG1J2SU8''K$$K
M1TQ5^K`?#+E'8W+KM$>!5P6C:50R65R?CIS.=U]+UK'361_XTF&RF+L8*OL)
M4ME;V].[R!'&R3=&N+>TK=*0*]]0U.).(#U)BLLPNZL69CE':T\V_'9?%<<F
M9.1]2):]D]TWO*8M>$)=SZ*A*AF5432:6,N$:M,),C$2>-(K=FL)RKI*Z=];
MIV]2=T("<<:%E]AU;V4@I1.J]?FSD_SYY:SZS&R24+%)%Y[3*K7B[4#5(;74
MN+[O=N."<J+.@6S;J#06@IW*+*T,*`'=V";[N"='$#G-;)]:\'J8][=+<2HM
M;$2YG6J_7A;;$MF#)-I+6G,N;P1KHZNC;`M-@0H)4I8EACVZ&+7!>;I#U0(2
MD^M!#HB8WRN>.=KU>2CF3:U?10B.WG4&HMSC60&!IX?$X-:[3->),??)*PQ<
MAACMNV#8!;?-CV,UC)52]FCRM_5EF+VU$E3@&E+6=.Q>:WM%KZKCB10//)VY
M%T7R-JHZ>5:Y<O*\I:N6YO%1U=W5$-H"&`3@AG4^EZ1\K&SEK>B,VXD)'%8,
M\X)J;6PA(`*BYBD@9QROY:T-V=7$OE]=*^,ZEHK"H*:<Q&U%"R&M&S4%=,N"
MU/S.R,IIARJ/2FN&R<L(3CQ'BZ3FY7W7>M&]<LBHF9B&K]_[13F1??$WE_'K
M:8XBSN''SA7)9GR&9$3`Y,X%5D7G9A"FA(@8ZL#\TOD<0HZ(*7G']X*TRM:>
M26HV8'0]AT=5$3'%9'->R+NDC!VR,#G7(X$E98P#LQ7^KZ/D2,6TS&V3FRN*
MLI(E\'9CY>:X-,/A;@]&,[\)N3`)?W9P+6*U"=7W,H3$BOCLQ;HZCOZ\;`A7
M:D4O=\DB$SE'%QSEL0CEB0>&JZV3/T9FW']'8C6E51`Z3S$3:X1A8[')@*0N
M9XU!&B]CUW0`C#6+F8[:1(I[M#XO3W8\<?)!2%NTC8%X0"I^+T&LXMUF[/8`
M>/*:PI)$:\D-IWK"XO+$LR:V.##=C1J"E9J$0EVBRS1A!W3'HFOENV*3&.T*
MYCV+:%9<?8#<%'/Q;_S9MKC&AY:1VH!R:N;2A,7X\$VL2^LD+2V84UFSF#2)
M0:WKSFQ\TS'*2R/]486`\H\5'^F,=]KYR9>:.H&3/5A\>./TB>>)G,:^I/8-
MDP]0XQ*];2XQ73**5B]&ULU+9Y%"H_)IT7'-/JTD@]R7%Z5EE(R#-`[D>LZ8
MN7O<^URY@BF?%J*1Z*0HUXDW&+@9=4C8)$FJ*(M_(IWY+,S2MMP49E=D7_6#
MS"VV,`5'HXZ3&(Y+SSI.3M*XA3IC$^CEG3&UL=XASBY^:ZGGE&.1CI7DBXY1
M#DYR?XB1:N([&GZ,3-P8*[L-4U`>)7.FJ2I3#"CX:Y)FXLI`0E4]V(,5#4B&
M:$LHB:BJWM25-IDO"7CQSKY,\:HTPMM[0OM2;0X:P-YG[U/9E&FRAE_*.JHF
MVUVM9'&4J2-M:!%HH(7`L&W@L(.MI2(6]Z$3OF(G=24UK]HOS4J3FO%N)QR.
MO)8[5XKXFL,OTH8ZIKAMY,^^\TE-9TQ@:^RN1T3FL1"P+'`#7%6N.1V9"5R)
M"H2N!P=&IBS!45;"&NU,Y(W3:G*.G:YLI@/KV5\=>;LKI68-D#BD.N"L93QU
M6NZ!NV7#XQ=$ZG+.F=T:!2B0GRQ$P/JU2`EW1I2".A+M9TQ$1,O.Q<[N9D.X
MU\8D=9<EJRL->@[)"S^9\\G<SKHJS'M\F=",L->E-6OCTBLA*MW-$A(E$:D+
MRX*52XU<%4K4(BUXM:(%1<[/5?SSVK/,"K:MY+O\V15I8DA8:=X$W?`Y'$Z\
M%$8Y3K+S-/VAEJ&5LLFM8M!*XY5FQ!$UN#E(68"I6,O3DH(2FC-3+.F)I[(;
MV@W/6UUW%^LV.8U)6\@MI\[0-H5VHY0.M;4U,H?QHK^G+)JR:;A51W_-X/")
MDY$S5P9'EK*E;DF3*R1J=%&%][EB%1M5;B#RYY#<B^=/!F=6#?+?74)OGLRW
M&SG.D"DPDM=3ZT6ZWF6+RAFA;0\2HA,9/W/Q<9($RXHA>\-+"D4MP=&I3#U6
M"8B(G9ZL`<NE'%\')CMMI7?5FFP6YJTC?&)1Q&=&&V9+"+B9K+7<1&!='4-)
MLL9DS4^O+D[V.-LTJ3)4RA*/9XA*^H0(TS3$B_CLV,E6'VHO*FAJSY(0ZVIC
M74-Y&5I0_91OU3PN9L;*WRJ8SV^`QYOYAG-4>7+4RV>DQI;IQV;WF6:6Q;*'
ML>]:!OH65$[MVUEB9]H1RDC,5YTV7(+1KJ(0*H.<3]P=H=J:Z=9Y!+S9XJEE
M6.+"^3:5SFVZPJJ/Q--"I.I;]NCTN0(6X\TY>M-4Z*3(QBHV(^5;SIY2\CK&
M[*&=37D)&*3:Y)R2YG4?;HXJ0WE4]:3S4D/=BX@>_$%6"?#9"KLA`I)9V-+I
MP<$260J`.C5L\W:=/I@3$1U;'Z4QV@ER0?BCPWBS/8])\8F^TXCVA=J/=Z7.
MPR":0MRD-!<A[&2QNG8L5)K(;#2GZ4)S^_G0:IP5J0MX.YM9(#-EE@%1,SR?
M[,^U=YVGUI<=^-!=75HT4/Q(X/<FI+2TFJMU>5\Q>+Z?U#'-(NV2\^;-SI"H
MF]I.LX(3%*)W<2"1)"PFE[TH&>LZ8_VZF\EP8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8'_TN_C`8%N.T/B3\J.7/D6CCRM4,;E&#UCLR-C
MBJ/C3SH.GB/'*%B4XTQC==!UWRD%O:<_HUUP"P/\20V((%!BM#%(VB5&L*.*
MFJ4C&UIU!D8;@F!;XX8<2E`8-A0A-%HE'O>TY6A;ZH-=.\#R,%>P&*'HU47@
M\0C:EN:5+"WJ6"-,K.>A8ECCIX5LJ,YN1)C$S2J=]:5&)@;"2-3KNH@[']=@
M?D96]=FJY,O-@4+-731)M!,5ID68QJY8A$#18D4F4B0[.?D@BPZ#LM5LT&]:
MZ.C`_$=75F9WKW2NH*/O%[#)477B,?%WG(PHT3>&0)>LW[[W>PH&Q,1I6#H/
MT2G+!UNJ6'6A:K.$-B#L_-<J=(I&W*3L90B621N#$UK'YG)&,9@RFMX4)3'!
MO*$88(6PDF`UO8M[_EW@?DC@T);W?<@00^+(7[:UY<MO:./M*9WVXR("(N0+
M]N1*0"SOU]+;$P5AO7ZZK2<O1FQ=0/0%)/JBK54H#-U5:P!3-`K4SB&7GPZ.
MG2@+@C`46D7A?S&X3KI:E+(`$LWNO7!H`=!WK6M8%310*"MQ+`G;X7$T">*+
M7%QBY"*.,Z4F-N#N)6-V7L!1",`&=:Z#7G[4&I]%C/V<9L>Q=<72'G,K>NS6
M1MC1L"A9D<9G$3PSQ\R+,8V1J=AK5#D-T;6H2':!"XB<59JC9Y183=G&C'UN
ML+>]AZT\&A*1YW(TD/BR60B<%[MM]3Q]I)>=NKJA(;'1SVZ%I`KMN#DVI2DZ
M@[K]T.(+"6/>PAUK01\OKAE1O(N+LL#G;*XM=?)[19+7FT"@JU-#(K<[U'PG
MG(&.YT#.@*-GL2&\=ZN*A$<:7M4M;DNS3!E%B*&3$S"2SPP,4B:%<?D#*TOK
M"O)"F7,CPW(W-H6IP#`8`A6VK23T:@D`RPBT$8-AUL.M]'P:PA25$"@JLJ1$
M*X7$U),P);TTM)41QG.*E"=I1EM[41(BS$8@/9+8@)`0G"IT:$DD.@`UH.M:
MP/,ZUK7+ZK4.#Y`(4\KUC2B8%:UUBK$XJU3$V.:-[;F50I5H#CCVEO>6].K(
M3"%LDI406:$.A@"+05DB,1I,:_GIH\QISY6,)DH.(:4!1LD,"C"W!,?S"TX1
MO`PMX-$:VHV9O1.M`_[/P8%M1ZI:KB(70$4K.OHP!\0C:WL,>AD<90O#89H6
MC&YT"VMJ;3@A'H8NDDWKE[Z=].OAP*LD@D';R(VE00V*(DL--4'1!,DCS0F(
MBIRLHY.J-C9)*,!;&:I(4F`,$ET5L8#!:WTZ%O6PB_R*X.5-R2CT6A<AD5E5
MU`HTDF3>=`J:D317T3DC?/@A+E2=^;TD<6'EJ'),8J)[];C6]P**<5H2SP]]
MG]<F)K:D&T4]5;)'*^B2"OHF*/U0QLL;K=`X,J)Y%"V6.MB)F944?6/!2]>@
M[P;&X@D)@3>ZB"4'K"WOX<(M>32P,3`%Q"Q,K2RA=W9>_NP6EN1MP71]=3-'
M.;TXZ1DDZ6NSB:'0CU)G6..%KI&+>\"DF0*"FH'!J-A<3,:W=_'+'5M,CC.-
M`YRDQ:2Y&25P1B1[3K7\QQ3EJ!+#`B4[/`$>Q];6MZ#T/$-B$A<V=Z?XI&WQ
MYCQHSF!V>&)K<W-C.,V'9AK.O6I3U38:9L&NL(D8-[Z-=/\`)@?@E@D'1.HG
MU%#8HD>QJWI>-X2QUH3NHUTD+1%2):)P*1@5B5OY3:G"M,V/KJ@IR]&[%H`>
M@*:DJJKT"7O)#6\"1(O$[U'N]$D/CR9+X@DAPE$B8^]R6X!7B=_/%L:U-T=Q
M5#WO9H1;^'`JR6$0Q#M<)%$8PC$Z,B&-.8DK`U)]N,<:TQJ)M8%VRD@-JV1N
M1GC*(2F=8@DH8@@#H.]ZP/`V5K7+*%G`S0"$M((Z!X+CX&R*L2`+$7(224[^
M6SA2H"M-@'Q.G+`LT1U-*0`"$SK:#K6@_=-7L!1BC`TD'B"44)`I*A@DT:92
M!1$M:7LE87&-E(@[80*RM]4W23N6C`_`+IU@?D.MZ[,E0YV9`H69-S!$",F0
MXLQBE1@DJ8A&E$.0B0[=Q"3(TI11>]G?6%EA#KH"'6M!^S[`('*%VG.30F(R
M)RTW:9].#[&V9W7::-+2W+37I6X(E"CQ=IQ*"H[AUNY=V#H?5ZVM;P/[-@D'
M4-K\S'PV*'-$J=#7R4-1L>:#&V2/9XD8SWA^0C1B2O#H<-O3[&H4!,.%L@O>
MQ?6!Z`_$ZNZ_4IR4BB"PX](GDADR3I3HRR&IR)><H,6'2LD@:$194D-5FB-$
MN#K2H1@MBV/K;WO`_P`,KFO3H^BB9L$AIL5;7#;LW1DR+L@X^@==K5+EMR1,
MPD.VY*X;<5ARCNP"PF=W-&/IZPA;V'[.L"@KZ)\&]PN)O(Y.B;VZ2C=8XSN`
MI"WM)PE#4@?!*T9VW9$V*!;&G*4=T`2/>Q`UK?PX%V8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`__T^_C`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8&L_C_`-J91]\KZD+65C?E&QR_XW+I31E@WE%X$QUY:+=!F9?)
M9.0RRF#V98*1A=&V+M"URVE?M-!PT2,T80[WH(11;J<LPES$N4W&.?`CAD$Y
M&41-03!\>8Q$AQ*WJ^D8)3)8XT&O\ACT<$SR%9I[?&)A(&M6I$W=5"5(`1QH
M`EZV+)14X,;<@N<E!\>..(>5;H[/]KTPI&FVV2CC\Q&7*@=$*@ES4F/Y+U$5
M"F*MT30D,RGOAX7N*-J+/`!-WQM4>G(.$1,S7J]][<T*5X\VS05)3E1)%UA\
MC)BWP^$,\59BGD#.-T=T#`@D4W4F+T)<:C"Q\<2TA"@7=351X3=$%&Z(/V6*
MM+'"#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$->1',Y@X^V=7-/)Z
M0OZ\[!LJ%3^Q6N/T7'J^?5;5#:T7Q1ME+P[$SFS*]/4C)53)$%.D;`.*Y3L0
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M<EFDT2L"`N?BJ4QMU)0KW=E6'-ZD0-Z4MZY<B-`9KJ'"WH6@B8IGO"#`8#`8
M#`8#`__4[^,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@:2*<[+&^(Q5]!U
M;9G+2(JF#B;7%L13CF75=$+HRN9+$L>M996K)==CNLSMF;DSJ0UXVSAQ-;6A
M$A8VT9VPC/$;O?0"*=3FC;4(CWKV4EV5U2%A)XM/EMK\@;OO?B1(XI;31X^8
MV2@)-4L1E<(LZ[K7EE[7C8LUD$3?ZP>7E.L"D<CEI[JY)DJ)"40,DE.I,9HO
MV;B[VX5L=C<`9-P1KA_3U]'%='QZD8A(W!J&^%L#/&&]E:VQ>O;$RUK-=%`D
MC,'9W0>4(TT8A[%T[WTRYB=ML0\HNS%A?(._8#R09;5M"OK$8[@H.=S,EOE[
MT9%Y##Z&W(S&"+L3`D5(2(T]EJ9,L/2.&AG`2GKUIFB1#5&;R*3&:HJFT+)<
MF`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P("<D^+]\V)R+ISD30%SUE
M5$IK>I;?I]PW9E0R&W$AC1;;U7SR?(V%I8K4JPHN0QT^`E"3`6J%*(W9N]&D
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MUJ*2U@&3L3TBDEL3NT6R-0J-.\-K*K44W-;3Q5M5D5?I?.G=EA32M1'+=`.<
MC=GN3@K/"60`T)!<HF;30P@P&`P&`P&`P/_5[^,!@,!@?BI4IT:<]6K/)2I$
MI)JE4J4F@(3IDY`!&GGGGFB"62226'8A"%O00AUO>]]&!JY8>U4AUCEKGZ@>
M'O.WDC6)3BN;6*Z:DIJ#IJMG!C8J/0.*V#.UI6Y6C])&=(XI34^UI3;I*,XH
M80&#ZN]Y%NNG&85[Z16;?PS.TN_17Q[_`'GL<BOM!](K-OX9G:7?HKX]_O/8
MY%?:#Z16;?PS.TN_17Q[_>>QR*^T'TBLV_AF=I=^BOCW^\]CD5]H/I%9M_#,
M[2[]%?'O]Y['(K[0?2*S;^&9VEWZ*^/?[SV.17V@^D5FW\,SM+OT5\>_WGL<
MBOM!](K-OX9G:7?HKX]_O/8Y%?:#Z16;?PS.TN_17Q[_`'GL<BOM!](K-OX9
MG:7?HKX]_O/8Y%?:#Z16;?PS.TN_17Q[_>>QR*^T'TBLV_AF=I=^BOCW^\]C
MD5]H/I%9M_#,[2[]%?'O]Y['(K[0?2*S;^&9VEWZ*^/?[SV.17V@^D5FW\,S
MM+OT5\>_WGL<BOM!](K-OX9G:7?HKX]_O/8Y%?:#Z16;?PS.TN_17Q[_`'GL
M<BOM!](K-OX9G:7?HKX]_O/8Y%?:#Z16;?PS.TN_17Q[_>>QR*^T(Q\F$G+C
MM2X6LXIQ[CI;O"?C/,E;6._;QY#ZKA/:KU'F)41(4M<U+4D)G4VV<H?Y`@0[
M6/BYT3HBD!1Y'<S!F;+$WD5EVW<LJUARRYH\?XLU4]RDX*<C[RG4!;D4937_
M`,5!5'8\`NUL9BM($=AK6>96A64FKV0OJ8@!B]J6)S1A6=U,+ZA`R@Z%1.V)
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MQI"VPZ(63R'JB),]4+YJ]J0HF"(N4[KFR[+;(N]R!8/12/QMI`G/,WT:-^#?
M0LZ<);+,ERUZ6?VCM;0RWI71M74AR=Y7V'7/>A-J)>,=9L<QCE6.K@C*<&^.
M3B<36;UW"T4I5H3@F^+4J]6M*UTA-++&`80DULNUN?2*S;^&9VEWZ*^/?[SV
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MB!:H1K7(T@HQ*,\.@C*;4W$[$UOI%9M_#,[2[]%?'O\`>>QR17V@^D5FW\,S
MM+OT5\>_WGL<BOM!](K-OX9G:7?HKX]_O/8Y%?:#Z16;?PS.TN_17Q[_`'GL
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MZ`/?UNQ&^&JY'?K3)`-U>3B])+1->1-[Y'-,NMV.<CGFT(_-K;@-9\>+!KU!
M77(5[9X*Y2B*L\5MQ^6*F+:!`!7(8:X-J@A00D5`4PZY)`3CDYR-B-7<:M-K
M17J>T[`X@6=?=D^\B.27O9+-Z<KZGI2\Q,ECC,@C9S%YS/,X7H#S1;.\4"[F
M>%.I[W$C4RBHVJ:Y<P[E8CF*%S%TH.OI+*[<C<0)MN0L\J%4$&CDGXRNO(=*
MVR-F=;&B:]]E0')E-CB-5I_9R'0(_&.D:81>VP<)I6>.7,Z9W[R@F=3-CO3*
MR"U\AMD,L(C6C%LO3.4+ED$B%?K&=X4V:%4_L-C@=']X,4%10M*TI&Y&G$J4
M:<DBTZ43%0V6X08#`8#`A7VBTT?:XX0<H;`BEJNE.S"$49:\OA<M9%L60.I\
MRC%>R9]BD>1*)8T/*79KZ_-Z<G9:0LMR.#T@2G%&BT/1,;X1WMF[5:Z_5AD5
MOQ6AD+);7!IAIVKHM(DJR.6-4-Q6FQLEW2\R'(U@R+12/4/<I.4)WUI25%2X
MD%<GVGVG7"50F(V;E2X&6K(K`?H4K,NA\MTV><1JIMN\FMT=?'"&M+_D;LH(
M=6EM;M'F>ZH;QUG9`=#M`3@:]1DO8B`*Q+#E(G@M&GN:'**=QFF[#D+-0940
ML2K^STN-Z:&9BL-')$3)SUM5551,(:W!=-'-KTZU=IO->1/AI!A+SUP-VFM%
MU=N0A4;5'FW:02.(5JW6.XSGCPT"FMUR6KDT'5MCHXSNA4T=0\A5:`BW&,=Q
ML&I9)I6OI5.V=S$9"B&E:L5]/?\`M($LX4VDT\_2V55-6<HGH8V7-I+`HE(9
M63#C0*(FGD#TPH7-V2QM44^R<E:R)5JH9:906XK"U!00F`-&$6MY+ED?`8#`
M8#`P#R=F5>P*F)5)K1L"4UQ#T@V@A4\P:0F1>:.KDN=D:-@B$4=DHB74#_+W
MP].WI2D1R=4H-/T7HTL`A[PF-[5JVVW;#81!VZ=<F%*FZ(;%N#JBO8;%)BRO
M3+::NVN0DIAEJ)7E/'34[3>XUT<;=Q5T="0G$,@F<UW3]YJ3#59D.MF#/W"N
MU9%.)_7AWOH?;2<;#XT/ME<D8@X.GCALIF^T<_@[2T1)L:=GG!JKJ;>I>P[C
MQ9:4!H(@%2868J"I4&RYG@M%DYH\HG*-M]B',]!ZARRLI%<AC&4PV&7)BF"O
M+C3U7)X*!V%-3FLUXEK<O+=T#]M*$EF/+$WFM3D$6G`,)J'NEW:#O<1KN;68
M]3B@6%,EO=RJ)-7K@W.ZRQZ;8HM?<BJ-[F%J-0;2;!2Y2^,4;VXID`"8@%"K
M6D)0J'(>RN^!2?O&Z;S6RZ&J:P[&#$2IM-X0R2J0IH(,@V)H%KZF"Y!;&=0E
MET\1K"FM.H`F,4$.ZXA0>4,PL>@#"`,HG?+-N$&`P&`P-;5NS^1UUS*A3@\6
M&@ED!F[G2U6QBFHE?3G&+$A4Y?7*;A?I:[T(W1<YOLZ&N+8]M;DY+%3VD/:6
MIH/4Z2GD%"WN'4;D+H/R$E#FQT6>NY12=?%+IK+BW)>7$K-E`DVJ4LNPI8N2
MOD>97TM<4/CN;9;^0=#U#&7M"<P%H`C(TE=1G+3":W[$S(M?5FQ3B=7\HCLC
M:K%D<LY6/''Z"3^Q4;D\(G.L9+S"F%(U/8;KMA=F-98`DE5!9W,M>4N2!E6@
M:5]\$Z6]W`16UCQSYM<A(''0N5C-5'"-D3S8D&:'J/MDW;HU7KS3_-ZF^%<X
MM"P3'V8#$ZUF,5N"G*A(4>SFQ]F9E")0XK>OXS)E%*LT\X)Z^<J*UXV1V><;
MYH)P514V82:+HE`DLMBY[3;CO,I/`N_+P#MD6MCC#61B*:""Y@:4XN"PX2D\
MM`J)3PFMEMJ^2Y,!@86Y#T#7/*&G)G1=L(7%?`YTG:BG@MF<SV5Z3'L;ZUR5
ME<F=X2ZVI:W1J?&9,I(/+^O+,*UO6$Q-;6:<(84I&@*[X_-]C(*\2N9/O6N*
MQ+VG*UX<-N;@\6+9[H6ZRET,4[)(V!,(P@HE,1K753)2"R0?6`#K1,S;->$&
M`P&`P-%\)NZ51IE%3UB7\6^K!2[B\9<W*&N>1KM9\`.@MI2^TF(IM;'Y3'H4
MDXWRZ<R>"D-2E.@[N`EK?DQJ)S"I+*,20ZKV49#?<^4M\A"KY*R[;_73=&U_
M%9#MU`@4W\!PY^\J:;CPWE"6H(+Y#I)E2-;05I-5:TJ*`G>_'X0E*G1$J*%>
MR;U_\D[WAMV3"MJH;*D&TP6)\)W5<*PVV8JW&0/',GDS;G'),!(ZQN0MR:/-
ME=>[TA['H:!Q-=NN8AUM'W0*TB41$+?C/+VQG:<5G7$LD]"5D[JU]\)I9*9F
MW/K?'+464IRH7\<"8E3S>Y64RJ8O*92E;0NR@*E7*ALY[H@2:3KM&Z4"%*GV
M?W+^:\Q&N7S=S55:9"D,6JMQ:6^#)3BI#')G,VA\?9E#)(I4V5*UKNBAJ8MN
M3)78YECGC<\Q2,"0KN`R2Q,4V,808#`8#`8#`PB^<?*X?[_@?)A8D<R+6KNO
M9G5K*Z('$2-`NA4Y<V5Y=V>0("BO]]$I79A(4HM&CZB0_9@P!ZQ@M[)O93-V
M$/_7[^,!@1PY=MLC=^-UL-T7;9.]+U,>("Y,D)*7J9@^Q$#PV&SUBC"1J`8[
MKWYZ@Y;BE2IT81+%!QH2R-;.&#"8WPL7AO&6^.(N0!L.@C_6=/2*_CGZD82^
M09[JM.SPGW*4HR2HV.55)6"*O]>,#Q=;)+%P4:EM1[6*E)[D4`1"XHP8GT96
M5L%R-,XF[[%#Z_<&"4*(^>@1RASE)*UK\4L"-K5%@(;6Q4B*"K6E&&_6"^'6
MP[W]=O>=?&HN[<[;FGM[KR&^]],^5YO^`\?'W/E[-*_:E]LA:79HS>LZ\E?'
M6MKC#:T,?)-I4UV9(HRD;TC:[Z8SVQ8B<H`^:7Z5Z,V+>^L`/5^MV'><S.6-
MUNLN6<U[6J7?^:L=1-Z1IWP!KW;4@.`I0MF[G4[;T2@H8S"STB/=0=[)SBS#
M1"",`="T(6]ZWT[WD7&#O\<^7^?RJ!_^;!E*H83%/!2&*#`$J$P##[S<31@3
MK-%A5D!$94@A!)5!*#HP.OK1Z#KK:WT:Q<8(_'/E_K_J[J__`,SC-;FF\8K!
MNX05@VJYH](6\*V0VX[/;02<F*$8E4+&TBKT1J@24*4.BM]?I+ZNNC^36=9:
MS3$4C-EZ8G-,I-Q+FO.81/AV5'N-M0DR<#M9;^V@<+VOI[C<??KED>I=:;U&
M(<])W")QQSG$CZRI8<C1$C"(TX)/<BU"@!MOX9Q5?EAGKZ7#DY\AM#^OU@^R
M>3^&<4?DC"3Z7#DY\AM#^OU@^R>/PSB?DC"6T'C7=/('D+050WB3%:<CA5JP
M&.S<#"9(9LM,:0OR`I;W@)6%@+"HVG[IU>OH.NGH_DRKX^[N;B?1F[NO(;[W
MTSY7F_X#Q\?<^7LMF(L/(6*,OB;KU,[_`.]Y(Z]^N#S-Q*?_`-Q21VD/>G3X
ME%_W=M\:=[$_#\!)0=?!_)B>F<41&:%6<V^\7I+M"\1VB79$(8#!(W-7+UZ4
M1A>^DLS:=5'S2MC!O?P;Z.G7^C'Q]T_+V<PG);_,@27C#R,M>AE/":MI*[4-
M/)75Z66-EM+V4I45&W%0TGJ&9$952M2RH%VB=[[W"<+00[ZN][SF9C!9&29B
M^IA-%_FNY&VB6#;N!T(0#<%9J]>)%>"]*)<N/WTGK5@B*C+VI5G;^$9@^L,7
M^G>1<8)_'/E_G\OY*_S7,A)**))X&08HD@EN3$%%7<N+*)3LYNSVD@HL-1:`
M62UGBV-,'6M!('OI!H.\7&"/QSY?Y_*\:[[<Y\YQR],P)>',%@3[6BM1;#1*
MV[D-:,8D*>2'M3C7*E:D?ZTBT+>A'K8I-W%">!2:H)-3*1?6Z&$L8>\F7KF8
MASG_`/YQ<S:=L#[3>\:QA,2KF"\=:!CT+@L<9XG%6-/8EF*BFI@8$!#8UHM*
MW"-JW!:,A&F!H9Z@XY0>/I&:,9@A"W9^&<57Y(]UV?2X<G/D-H?U^L'V3R?P
MSB?DC"5J3SMF^2D$@\SG"N@J.7I8;%)%*U*%/8,]*4+4\=:%CN<D(,-B>RRS
ME):/8`B%];H6];W\&1.E,1,WN3&>)F(Q;VNZ\AOO?3/E>;_@/*_C[NOE[*!*
MFCD+*(O)(UT5&U><+`\,?C-"\S<*UN\;-RA!W^C%XE#U52/OCNA>^G70,.OA
MQ'3$Q.U$]4Q,;%72AY#)4J9-WG39O>Z<DCNICQ-]C,[B6$ON@]^)-_7CZO3O
M_P!N\?'W3\O9^#DAO-X2#0.\?HIU0FB`(U$Y+)@N2&"*'HPL0TRF/FDC$68'
M0@[WKX-ZZ=8^/N?+V<AB?_-5NJ0;88DX`UXE,90*2V<Q/<ZDD;26LT,*PML$
M74`1(`*@F"T9HKJ:'H6^MT].\XN,%OXY\O\`/Y>M)_FNY&WFK3T'`Z$(CG%1
MM6X')+P7IC5ZH73H2E:8348!JE&^GX1CV(7_`+<7&"/QSY?Y_+^=?YKF0A*T
M2'@;!@DZ),3:*U=R[16DYINCS2-%ZJ+JZ)-/UH8@]'5$/73O73BXP/QSY?Z_
MZSY7G;%3CG%7ZV7BXGU7#4L:M-.K:E2*[+1CLV;IM%(RA-:Y6EF,`C<7<C%*
M1NF)Z8`#!"),)&84<684,016Y,G7%PKSYOQS$3@DW7G:77;54.9X%`^.]$LD
M680KO%R`RS[6>5/=G1R6/3JN7O+ZPN;V\.CL\.*A6K5K%)ZI4I/&::8,8Q"W
MU^&<7'Y(]UY_2X<G/D-H?U^L'V3R?PSB?DC"66:$[2KDA<EVUK4"RH:18PV*
MYR5J(>4TUGBO;:?'J]F,^[J:E-BY6CBE),0&GZ-"UL(C@B_DUO.<VGT1$S.Q
M,9NJXC>VK=UY#?>^F?*\W_`><?'W=?+V6S)&'D-(C(V9UZF;?-Z3())U4;S-
MPZ<N\4J]-XL6?[E#UD1_?W6'KX?KBP_!B.B+WH^7LN;NO(;[WTSY7F_X#Q\?
M=/R]D->>/**W>#W&6S^7S[5-,6,;5*6$(ALC=)).PR!R1S>RHG7Y21))5D0=
M!($J!7,^_!E[+&`P)8PZUH0^MJ)Z:]4Q&:9B+<Y'_JKG?2=R2:X!U]WJ]*#E
M;PF]]"GO=V5*!:$H4N1/N@[FN4'BUK8QFZ&(6]?#O><W&"S\<^7^?R]O_JOY
M/WNF2?V$H7WJB$E$C3>_)P[W2"0B`)$),3[I.YD"1B+#LK8=:[GL.NKT=&L7
M&"/QSY?Z_P"OR-_S7,A.*-).X&08TD\EQ3'E&W<N,*.3O!NCW8@TL51;`82Z
M'AT-2'>MA/'KI'H6\7&!^.?+_/Y2!K3M&I!?!42Y*H^*-4,2Z2ND9FB>,G7U
M>!<7\XZN,.B]>O[U!6=`@KUU?8:WLX`(#Q-FM`[F08((C4J49%V72G-$9H59
ML\99G*F3]+AR<^0VA_7ZP?9/.OPSBY_)&$GTN')SY#:']?K!]D\?AG$_)&$I
M)<1.?G(KD];<OJI55M*Q13%ZY0V"!V3S"<N)"LA9)MQS;<(@R-$&%F@,UW7K
MZWO6]?!E>;+&2:S.HGJBX;'>Z\AOO?3/E>;_`(#R/C[I^7LMDYAY"G3)MEW7
MJ8'BZ,O<;\3A>9OXN4^.76/N?C,X/B7X5J+Q#W(O?1\`%!GP_5?&JVHK-=KF
M[KR&^]],^5YO^`\?'W3\O8[KR&^]],^5YO\`@/'Q]SY>QW7D-][Z9\KS?\!X
M^/N?+V.Z\AOO?3/E>;_@/'Q]SY>QW7D-][Z9\KS?\!X^/N?+V.Z\AOO?3/E>
M;_@/'Q]SY>SC]+_S5CJ2A6MA/`&O2FUS.-4N3<7<ZD"%P4'Z+T>>M2!J#2=6
M<=HD&AB,"(0M!UT[^#6<7&"W\<^7^?R_87^:T?1FM9P^!,#$<R`&6RFBNQ8(
MUH+,*+(,+:S-U#L;>`P@H`!:*V#6P!UK?P:UBXP/QSY?Y_+T&?YK^3FG&*#>
M"4+-/-"A":>9>3@,XP+8J-6MH3#!5)L8PMRT\9Q&M[WW$T8A@Z!;WO%Q@C\<
M^7^?RE'Q_P"WJM?E,RR!Z8.)%*1E#$GG2+2.3V/)WU7MQ>DJA<N<4"MOK]N`
MC,5:/'HP00:-&,8A;'OK;RS)DZ[F%>>?QS$3ZKMISF]/Z&&<=6W'&HD!XX7"
MJV3*9#>U]3I2TUW7!D@,@D&8E$X32$UCC$7%*%W>Z5+LH(]G])NS!`!L/?X9
MQ<SJQ.+.OTN')SY#:']?K!]D\G\,XH_)&$JS$^UBY(OUA59"5M)4@F)LJTZ^
MK+2]+.YX8:UG3V3MT:)=-DFQ4`#RV\UPT:('3K8PAWK6^G.<VGTQ<SL3&>,T
MU&]N6[KR&^]],^5YO^`\X^/NZ^7L=UY#?>^F?*\W_`>/C[GR]CNO(;[WTSY7
MF_X#Q\?<^7L=UY#?>^F?*\W_``'CX^Y\O8[KR&^]],^5YO\`@/'Q]SY>QW7D
M-][Z9\KS?\!X^/N?+V8R]WO(7OCOCQM6?Y3/>/W/QW-^I_POQ;YM?\'_`."_
M_F]7_P!__1DWDPG<BLWMO?_0[^,!@,!@,!@<.O\`FOOG"<3OS-37\=R<YE;D
MW2Y/LAV8$D^'OSFZ9_KBG_V-9G>GWY>+C4_KS<'3]F]@,!@=*_9G?X?O#W\P
M-=_T$FS`USO3CP@P&!\K#M4_\2/F_P#M+VQ^-;AG,[U^7MA`/(28&S_LL/RP
M6'^;8?XT,&7Z'=FX*/V.W+Q;TLULA@8=Y$?-_O/\SMF_B4]YSG[,_"763OR<
M8=SF8F@P&`P/C:9PT&`P-]?9;?-_F'YXI!^)5?9KT.R>+)^QWQP;)LO4&!)_
M@Y\]CC!_6^R_[N5V93K=L<5FEOG@ZF\S+C`8&FS_`#`G^$7RU_\``;^\U3&1
M.YUD[H?-'SE<8#`Z9>$/S5Z@_P"3//XUO^;M+^O*PZO]F9*S+%9@;".R7^>'
M;7[-3)^M$69M;NC@OT^V>+HRREV8#`8#`8#`8'QM,X:#`8&[KLJ?R?6M_7)F
M_H06:OU]V9E_8WY>#:OFAG,"OUW^7OBM^U?QS_6M&LKU>R5FGW<G8WF1<8#`
M8#`8#`__T>_C`8#`8#`8'#K_`)K[YPG$[\S4U_'<G.96Y-TN3[(=F!)/A[\Y
MNF?ZXI_]C69WI]^7BXU/Z\W!T_9O8#`8'2OV9W^'[P]_,#7?]!)LP-<[TX\(
M,!@?*P[5/_$CYO\`[2]L?C6X9S.]?E[80#R$F!L_[+#\L%A_FV'^-#!E^AW9
MN"C]CMR\6]+-;(8&'>1'S?[S_,[9OXE/><Y^S/PEUD[\G&'<YF)H,!@,#XVF
M<-!@,#?7V6WS?YA^>*0?B57V:]#LGBR?L=\<&R;+U!@2?X.?/8XP?UOLO^[E
M=F4ZW;'%9I;YX.IO,RXP&!IL_P`P)_A%\M?_``&_O-4QD3N=9.Z'S1\Y7&`P
M.F7A#\U>H/\`DSS^-;_F[2_KRL.K_9F2LRQ68&PCLE_GAVU^S4R?K1%F;6[H
MX+]/MGBZ,LI=F`P&`P&`P&!\;3.&@P&!NZ[*G\GUK?UR9OZ$%FK]?=F9?V-^
M7@VKYH9S`K]=_E[XK?M7\<_UK1K*]7LE9I]W)V-YD7&`P&`P&`P/_]+OXP&!
M;<AD1;0E<$[:4D?):!D<W5AA@7EJ:G>2J4*12>F;T0W-000F"O4I^X]\F]"<
MG>]B,%H(1;T&->.-O++YI:#VPXQA-#'"6)G<:^,(I";*T;0L9I"[QY40DD1[
M!%3W=,8>T",+.&W(Q[`/6MEAWK"9V2RHKDD=0*#$BY_942HKJ=U3*W1"F4%=
MT`$T'="3CP&`ZY8]"UTZUTAWK?\`)O#FXQ>;SPB7I3'/+;9X5@N,7$3_`)J]
MU:W7D#Q2,:W)`Y%E4Y-`&C0+$ZP!8Q34D6@&"3F&!`+8?AUK?1OHR)6Z<Q,3
M4N4W.5A@23X>_.;IG^N*?_8UF=Z??EXN-3^O-P=/V;V`P&!T==FM*(REX!\0
MDRJ1,29010E>%G$'N[>2<28!B3:$6:48H",L8=_!O6]:WK,+5,Q<[4W?/")>
ME,<\MMGA60BXQ//")>E,<\MMGA6"XQ//")>E,<\MMGA6"XQ?+-[4Q00J[1SF
MTI2G%*4Y_)2UC"3R#`'$G%CE2_83"C2Q"`8`6OAUO6]ZWG,[U^7MA`G(=&!L
M_P"RP_+!8?YMA_C0P9?H=V;@H_8[<O%O2S6R&!AWD1\W^\_S.V;^)3WG.?LS
M\)=9._)QAV\^>$2]*8YY;;/"LQ+[C$\\(EZ4QSRVV>%8+C$\\(EZ4QSRVV>%
M8+C$\\(EZ4QSRVV>%8+C%\=?.&DP&!OK[+;YO\P_/%(/Q*K[->AV3Q9/V.^.
M#9-EZ@P)*\*%R)NYH\8U3@K2H4H)C9(1J5B@I,0#8^.EV`!H1QPP%AV,6]:U
MT[^'>\IUNV.*S3WSP=07GA$O2F.>6VSPK,RVXQ//")>E,<\MMGA6"XQ//")>
ME,<\MMGA6"XQ:=>WYDD=7]DGRQ2(7]E6JC?<3W),D=$*E0;W/DO31H^YDDGC
M,'U"P;%OHUOH#K>_Y-8G<ZR3'5&U\V'.%Y@,#IEX0_-7J#_DSS^-;_F[2_KR
ML.K_`&9DK,L5F!/GLIG5K:N8%KF.CD@;2S>-C,`H:]8G1@,&&T!"V`L2@PL(
MQ:#\.]:Z=]&9M;NC@NTYB,LW/JZ'O/")>E,<\MMGA64N[C$\\(EZ4QSRVV>%
M8+C$\\(EZ4QSRVV>%8+C$\\(EZ4QSRVV>%8+C$\\(EZ4QSRVV>%8+C$\\(EZ
M4QSRVV>%8+C$\\(EZ4QSRVV>%8+C$\\(EZ4QSRVV>%8+C%\=?.&DP&!NZ[*G
M\GUK?UR9OZ$%FK]?=F9?V-^7@VKYH9S`K4"4$);TXMJ51Q29.1RLXZF''GF`
M)))+!:L;V(PTTP00%@#KX=[WO6M97J]DN]/NY.OWSPB7I3'/+;9X5F1=<8GG
MA$O2F.>6VSPK!<8GGA$O2F.>6VSPK!<8GGA$O2F.>6VSPK!<8GGA$O2F.>6V
MSPK!<8GGA$O2F.>6VSPK!<8GGA$O2F.>6VSPK!<8O__3[&K3Y6W%'9O(X)2G
M!?D??ZB(JTB1\FB9WIBFJR5'*$B-8:1#I7=EF0M?.S4!:S19YS8W'MX%`!DZ
M5;-*."436,LRT-=SI=#0_&R.D+IH24Q5Q3-3[#+FCS"@5&'*4VU!3E%)5"I-
M-8%.(\<(L8`JVQU/V6('54%D&;T7@GBR+(H%'G]6H?RT2%DG@8\YQQ@LUM8(
MHMGL/3N25<0%3&W:3,$A1%&H#G$T\I.K3*V\PT6]'ICBQF%C(6705*MO'VMF
MVKV29S6;L3,X.RQG<)[YFC>FY,\K3'14TE'PB&PAN4-X'54H4@$>E.5:&I&'
M9VR@E%E"=K*Y[.T*C1GJFIN4GF=7KG'H4QQH^J'0`]<PPH0Q=4`=:UT[^#6N
MC!3\?-]A^\C1Y-1?S.$5&##=G<5.+UV+FMTN7C=0EMN;(D.0,KC9U/5Y/5S0
MA4':4*$36KE4==5"!(>HUW0990@`$/Z[>M[^'"8V;F,?HZ.SX_Z$N&W_`/S#
M27L/A-SC+67V//"7AC9O9YTK-;)XC<8K"F3K+.1J9TELXH.JI9)G).Q\G[F8
M&4A>_/T47NJPEG86M*B2A,-$%.D3%$EZ"66`.HA.:9O>]_:C\/\`B53%"5]-
MZ>XN<=:GFA'(FI6XB7UK25:064$M[@H>2UZ`I_B\9:G4M$N+!H)Q6C=`-UK6
MA:WK6=Y._+Q<YIF<N;;Z-6>;64P&!TA]FFR,I_`'B"<>T-9QQE!UX,PTU`D,
M,,&)B3;V(8QE;$,6]_R[WOIS`U3$7N3@\WV'[R-'DU%_,X148'F^P_>1H\FH
MOYG!48'F^P_>1H\FHOYG!48/EA]J<441VCW-PDDLLDDODK:X"RB@!+++`&5+
M]!```-:"`.M?R:UKHSF=Z_+VP@/D.C`V?]EA^6"P_P`VP_QH8,OT.[-P4?L=
MN7BWI9K9#`P[R(^;_>?YG;-_$I[SG/V9^$NLG?DXP[A?-]A^\C1Y-1?S.8E]
M1@>;[#]Y&CR:B_F<%1@>;[#]Y&CR:B_F<%1@>;[#]Y&CR:B_F<%1@^.7G#28
M#`WU]EM\W^8?GBD'XE5]FO0[)XLG['?'!LFR]08$F.$B9,KYI\8B%:<A22*8
M65L1*@HLXH6P\<[L$'8BS`B!O81:Z=?!\&\IUNV.*S3WSP=1?F^P_>1H\FHO
MYG,RVHP/-]A^\C1Y-1?S."HP/-]A^\C1Y-1?S."HP:<NW]9VA+V2'+,]*U-R
M8\OW$=0XA"F)-!UN3%-`%U#"R@C#U@"WK?1OX=;Z,B=SO)'RA\UC.5Q@,#IE
MX0_-7J#_`),\_C6_YNTOZ\K#J_V9DK,L5F!/WLH4*)=S!M@"U&E6`+XULH@!
M5)RE`0"W:`M;$`)H!Z"+>O\`3K,VMW1P7:?;/%T3>;[#]Y&CR:B_F<I=U&!Y
MOL/WD:/)J+^9P5&!YOL/WD:/)J+^9P5&!YOL/WD:/)J+^9P5&!YOL/WD:/)J
M+^9P5&!YOL/WD:/)J+^9P5&!YOL/WD:/)J+^9P5&!YOL/WD:/)J+^9P5&#XY
M><-)@,#=UV5/Y/K6_KDS?T(+-7Z^[,R_L;\O!M7S0SF!6X`44?>W%DDXLLXD
MSE;QT`84:`)A9@!6K&M"`,`];",.]?RZWKHRO5[)=Z?=R=A'F^P_>1H\FHOY
MG,BZHP/-]A^\C1Y-1?S."HP/-]A^\C1Y-1?S."HP/-]A^\C1Y-1?S."HP/-]
MA^\C1Y-1?S."HP/-]A^\C1Y-1?S."HP/-]A^\C1Y-1?S."HP?__4Z`>U]14[
M9L\X]J7M+1'(A+12VVVJTN,;KSFBW$"TS%=FL<`.B$C0RY78<*`2CC0XN,Y8
MU+U*0Q8%:E-)%L!9@#8EUE]62.QRXT690$*>WE3*XR[4U9];0Y\;H_$+Z=.0
M,09;I06]R$*FY</E:IV?6H)#-5RR%,+XI;U!:)UD3*K/*()T'8-(,TVW7Y+D
MP&`P&!'#DMR02<9XHPRM92?(^\0/TAU'@Q_C33SW<TK:![;5SEXY?F)C4)U#
M7'M:0[(VK'O8.^32B^CI'K"8BVK7L6+JEL3X^5-Q`L;B?S1J6>QA7?TJ=9U;
M'&V;U[3I225WE9-F,C<&?20"$KQVMCTQ2``F$F!L:L)I8-BT#0Q1"<T;;MG7
MMD?FN0/]I6F?]K>\[R=^7BXGMS<&BG-K,8#`Z5^S._P_>'OY@:[_`*"39@:Y
MWIQX08#`^5AVJ?\`B1\W_P!I>V/QK<,YG>OR]L(!Y"3`V?\`98?E@L/\VP_Q
MH8,OT.[-P4?L=N7BWI9K9#`P[R(^;_>?YG;-_$I[SG/V9^$NLG?DXP[G,Q-!
M@,!@?&TSAH,!@;Z^RV^;_,/SQ2#\2J^S7H=D\63]COC@V39>H,"3_!SY['&#
M^M]E_P!W*[,IUNV.*S2WSP=3>9EQ@,#39_F!/\(OEK_X#?WFJ8R)W.LG=#YH
M^<KC`8'3+PA^:O4'_)GG\:W_`#=I?UY6'5_LS)698K,#81V2_P`\.VOV:F3]
M:(LS:W='!?I]L\71EE+LP&`P&`P&`P/C:9PT&`P-W794_D^M;^N3-_0@LU?K
M[LS+^QOR\&U?-#.8%?KO\O?%;]J_CG^M:-97J]DK-/NY.QO,BXP&`P&`P&!_
M_]7=5VFM/S*57U`YRW=D;0<WB=<<EH-8\WY'3FWN$<#4\I88VU3+XVLK.6@M
M!8S3#:%2]2%&/29^&N),W&BAA3""$@943P=Y9V=S=5PM7M+GQHK5<Q\?H!Q:
M:C_/'O6B*NDU4S&"P7N4_E1)_B.1TA_]+W'SG4%C>5/BS_\`!6.!I2G_`+V`
M_)<SOWI/GGDIB3E*DXI.G3E&'GGGF`*)()*!LPTXXTS80%E%@#L0A"WK6M:Z
M=X0\S8Z-CT@2NK.XH79K7%:/1.38K3KT"PG>]AT<E6)3#4Z@K>P[UU@"WKIU
M@>[`8#`8#`U-]LC\UR!_M*TS_M;WG63OR\43VYN#13FUF,!@=*_9G?X?O#W\
MP-=_T$FS`USO3CP@P&!I6NKL">SSOVV[&NNPXY:JF<VE+WR<2Q0U6>YM;:<_
M2%::X.)B%N*1#+1)A*#A;`6'>]`U\'3D4ZC-,;&N'M"NP;[/WCAP_MVYZSCM
MI)9O#?,'Q(>\68Y.S<7YPV?"HHY=\-YR(LM1UFA\4!!T[UU#-A%_+K%)C/-I
MG_\`IK.S!]%;E_2Z[_@_%0=>9KRY.]G1QJ[/;D;5K-QR:Y>V(K0I.T'.5AEL
ML5RDPY5%IW5B5IVB,5$$;1``4^']?0>GK[V'>_Y,NT.Z>"K5F9R1>*RLU,Y@
M8=Y$?-_O/\SMF_B4]YSG[,_"763OR<8=SF8F@P&`P/C:9PT&`P-]?9;?-_F'
MYXI!^)5?9KT.R>+)^QWQP;)LO4&!)_@Y\]CC!_6^R_[N5V93K=L<5FEOG@ZF
M\S+C`8&FS_,"?X1?+7_P&_O-4QD3N=9.Z'S1\Y7&`P.F7A#\U>H/^3//XUO^
M;M+^O*PZO]F9*S+%9@;".R7^>';7[-3)^M$69M;NC@OT^V>+HRREV8#`8#`8
M#`8'QM,X:#`8&[KLJ?R?6M_7)F_H06:OU]V9E_8WY>#:OFAG,"OUW^7OBM^U
M?QS_`%K1K*]7LE9I]W)V-YD7&`P&`P&`P/_6WM]N0Y0%MM3@B.>'<0DJ01/*
M,255SB33B44'H(&.G`*$JRO*Z$3)GN9'GG$#:W41I*!H"4>2:+9K@G`*)=Y?
M5LZ[-U7&EW"ZF540/XT*(Z;[Q/%QW#Z/RN+<=!]2UYT6K]W;#-U"J3H.JN`;
MIW[Z,%W5]TM,+Z"AEZU+F=\LW7.HF#<RR=U-A,?MBJD$`D*B35`DAZB4V38C
MR0B<C4<8C)+F^)(4K2OAFDJ?O9Q2[!L6S-C.`#>M@#&W"2%AA=-N(#HRXPIY
MEME6!84EAQT*=X!'(F_3EZW(5,7@4>?&QF<!PN.)EA*(AP&D2[=E1"A<).F&
MH$F)$I)N89SM:?MG/B@&[_5][!<TKP8MU_J2^[=W&E6%$;Z3^MU>J'7UG1T_
M#TX<[?2G@ZEF?&8+]Q/_`.$,G8CY>QU+,^,P7[B?_P`(8V'R]CJ69\9@OW$_
M_A#&P^7L=2S/C,%^XG_\(8V'R]FJWM?`S37&B`[?#HN-!_:2IWK!:DSL4K[K
MWT]]SWH:Q6<3W/6_^U];T_4SK)WY>)-].:ZW-*.;&<P&!T3=FV"P-\!^(NV]
M1#@H?<-7W>H5B1Z&KT1XC3]STH$0M`2(W0?Y=AUK73_)K,.QJGJN=R;74LSX
MS!?N)_\`PAC8Y^7L=2S/C,%^XG_\(8V'R]CJ69\9@OW$_P#X0QL/E['4LSXS
M!?N)_P#PAC8?+V:W.UU!/M=GER#VY'Q`2+_Z4=V"A2/0%6__`*WUKW/N0CUI
MA6O];U>MTZW];T]'PY$TZRW<739'U+,^,P7[B?\`\(9.QS\O9H%[6/4CUR?X
MX^<1C(8/W"W?WKXE)7D@T#WA4QW7OCOX\_8A;WU>KU>C71T].6Z/=/!SGOHV
MXM?.:5)@8=Y$?-_O/\SMF_B4]YSG[,_"763OR<8=L74LSXS!?N)__"&8]B[Y
M>QU+,^,P7[B?_P`(8V'R]CJ69\9@OW$__A#&P^7L=2S/C,%^XG_\(8V'R]GQ
M[LK:C`8&^OLMOF_S#\\4@_$JOLUZ'9/%D_8[XX-DV7J#`D?PPTZ[YF<9-,HV
M\#AYXV/W(3H6I-1Z#_9UNONO=`)#"C]BV7T]7H%K76_E^#*=;MCBLT]\UA_\
M=./4LSXS!?N)_P#PAF?8L^7L=2S/C,%^XG_\(8V'R]CJ69\9@OW$_P#X0QL/
ME[-/?;Y!G.NR8Y7[>#XH-N_^A7?(6Q*\%K=__P`E:<[CW`:I8:1KH/ZO6ZP=
M_6=/1\/1D3N=Y+ZHNGS<LX7F`P.F7A#\U>H/^3//XUO^;M+^O*PZO]F9*S+%
M9@3N[+#4AWR^M3S>,9BSO[-K-WQMY)7'%;*]YXNKHG2$\@83.O\`R];>]=&9
MM;NC@NT[Z9K%T)=2S/C,%^XG_P#"&5;'7R]CJ69\9@OW$_\`X0QL/E['4LSX
MS!?N)_\`PAC8?+V.I9GQF"_<3_\`A#&P^7L=2S/C,%^XG_\`"&-A\O8ZEF?&
M8+]Q/_X0QL/E['4LSXS!?N)__"&-A\O8ZEF?&8+]Q/\`^$,;#Y>SX]V5M1@,
M#=UV5/Y/K6_KDS?T(+-7Z^[,R_L;\O!M7S0SF!5H/WYN\.+VF_:8*[^U5QV[
MU$L":-+H_P!ZD;[GM0$@0#A%=;_M:#O6^C^3*]7LEWI]W)UU=2S/C,%^XG_\
M(9EV+?E['4LSXS!?N)__``AC8?+V.I9GQF"_<3_^$,;#Y>QU+,^,P7[B?_PA
MC8?+V.I9GQF"_<3_`/A#&P^7L=2S/C,%^XG_`/"&-A\O8ZEF?&8+]Q/_`.$,
M;#Y>S__7Z1^UTM2S8A,N)=>5_+[L8$-CBOASDS+Q?XR1?E!R'?2X&TUN>T+(
MW%9@SNC4PUVR*I&9J1+"=Z7"4JVP``#([Y&3$NLOK*>G`U4_+>*%5*9,LO%>
M^&>?/?JODC4#+0MTF]2R)@6F\\ZGCR)N9XIW-(`L+=W$D'?S2%*L'TC4"%N4
M3O2]P@P&`P&`P&!J;[9'YKD#_:5IG_:WO.LG?EXHGMS<&BG-K,8#`Z5^S._P
M_>'OY@:[_H)-F!KG>G'A!@,!@0YO?L^N%_)V;%61?O':O;2G)#&@C1,FE"->
M>Y%L+6H7*V]K"-,O3%][)5#D>,.NKT])HOAPF)F-TLE\?N+O'[BK&GJ'<=ZJ
MBU31B1/FY*]LL43J4Z-R?A($;7MT4A5*E0Q*=M[>25TZWK74+U\&"9F=[3#V
MOOSHN-7Y@[R_6'2N7:/=/!7J=D<6M[-*@P,.\B/F_P!Y_F=LW\2GO.<_9GX2
MZR=^3C#N<S$T&`P&!\;3.&@P&!OK[+;YO\P_/%(/Q*K[->AV3Q9/V.^.#9-E
MZ@P)/\'/GL<8/ZWV7_=RNS*=;MCBLTM\\'4WF9<8#`TV?Y@3_"+Y:_\`@-_>
M:IC(G<ZR=T/FCYRN,!@=,O"'YJ]0?\F>?QK?\W:7]>5AU?[,R5F6*S`V$=DO
M\\.VOV:F3]:(LS:W='!?I]L\71EE+LP&`P&`P&`P/C:9PT&`P-W794_D^M;^
MN3-_0@LU?K[LS+^QOR\&U?-#.8%?KO\`+WQ6_:OXY_K6C65ZO9*S3[N3L;S(
MN,!@,!@,!@?_T.EKG]"WVW+%BA=J<1.>,KBU1JY/[GK9X&7]7S(X/Q-A-T5(
MD89W$7&U*>FT><6_;%WJ5O8')$$@1HRU70J.*)AU&S=,)F\%6F>Q:E4D'E-/
MW!448B3BZ)X`1R(NUAO"^)0TOKZ]RAR>K$?8V\R]M:!$.#UWLW(Q/KHI(0E`
M*,[@$HLO)1._>FCA!@,!@,!@,#4WVR/S7('^TK3/^UO>=9._+Q1/;FX-%.;6
M8P&!TK]F=_A^\/?S`UW_`$$FS`USO3CP@P&`P&`P.>;M??G1<:OS!WE^L.E<
MNT>Z>#C4[(XM;V:5!@8=Y$?-_O/\SMF_B4]YSG[,_"763OR<8=SF8F@P&`P.
M=7_TPG9N??SDO^E"*?\`EKD5#OKS(<\F/\OYP3J2X>$D%BKO?1C)R#Y"/M83
MP;M8,<5KB8VVTA:=AIQL!Y,#2%M[GM_AJ30C3`*`;3[,!U-;%H85)C-,Q*8W
M_IA.S<^_G)?]*$4_\M<5".O,U@-_&NN^(=L\F>/M4GR-1`X!>8TK$=+7-*[O
MXRG&I:H=E'?[@B;FE,H%I4M'U=A3E]`.C7P]'3O5H=D\6?6F\T<%WY<J,"3_
M``<^>QQ@_K?9?]W*[,IUNV.*S2WSP=3>9EQ@,#39_F!/\(OEK_X#?WFJ8R)W
M.LG=#YH^<KC`8'3+PA^:O4'_`"9Y_&M_S=I?UY6'5_LS)698K,#81V2_SP[:
M_9J9/UHBS-K=T<%^GVSQ=&64NS`8#`8#`8#`^-IG#08#`W==E3^3ZUOZY,W]
M""S5^ONS,O[&_+P;5\T,Y@5^N_R]\5OVK^.?ZUHUE>KV2LT^[D[&\R+C`8#`
M8#`8'__1WB=HUS"[1_B?=4SD+C9E%TWP\[H@/KJ:M\*J>T+'VA-:&T+D&8U]
M8?(2I)R[J2)`G7!3ZB[6\&FEB++T28<((<C:[B,LQ[MP7!FQG*W>*5/68[7>
MDY'+9LSOC][Y4%1KZ*13!(LETAVW`25:YF'+XVGC3<$IH`88+>W(*#O[^13K
M)<SOW,W3>?-D=)=&)I?X+NRA1AUD49ALJE6F0]U(;TJX[Q@H1MB!^E&V$@3>
M=L]0C;58@A),T$.Q!WT$,6\4[X5\B*R<IPM0QM,<SV'/X!W_`!%W7.D?D(8-
M(5+%J1-Z5Z;FF21T+GM/O8VUS3%K$I@1?7'$B)/-)F*9S7S"(M2LU`YRF.-J
MXCJ=W1+WML1JR>ZE@.*[JG4*BSB^Z$F!&'IUKI"+6]?!O634X.;C%Y/>!`O3
M>(^LK-X;BIP+C&#W@0+TWB/K*S>&XJ<"XQ@]X$"]-XCZRLWAN*G`N,8/>!`O
M3>(^LK-X;BIP+C&&JGM@)9%7CC-`D33)H^Z+!<DJ<,"D;GEN6J=EEJGO9@]$
M)E)INP`UOX=]'1K.LD3UY=GJB9B<N:I]&DG-C.8#`Z,.S8FT,0\!>(B-;+HP
MC5IJ%KTE0E5/[4G4)S@,:<(RCB#58#2C`"UT;"+6MZWF&IP:IF+G:FY[P(%Z
M;Q'UE9O#<5."+C&#W@0+TWB/K*S>&XJ<"XQ@]X$"]-XCZRLWAN*G`N,8/>!`
MO3>(^LK-X;BIP+C&#W@0+TWB/K*S>&XJ<"XQ@]X$"]-XCZRLWAN*G`N,8<_W
M:T/S&^\H..`V1Z:7@":A+O"H$U.*-P"0(RPJ7V6$X20X[16S-`WU="Z.GHWT
M?R9;HQ,9IX.=28G)LGU:],TJ#`P[R(^;_>?YG;-_$I[SG/V9^$NLG?DXP[;O
M>!`O3>(^LK-X;F.IP7W&,'O`@7IO$?65F\-Q4X%QC![P(%Z;Q'UE9O#<5.!<
M8P>\"!>F\1]96;PW%3@7&,'O`@7IO$?65F\-Q4X%QC#6SSAFD.4\C^R\.32R
M,J"47,26*%II#\UFEI$XN+5]D!/5#+5""G)$<:$&A#WH.Q"UKIZ=ZR)B=FQU
MEF*S;?1LF]X$"]-XCZRLWAN34X.;C&')WR&7(G+F#S+7-RQ*O1*+[2"(6(E!
M2I*>$-*T\`0B5!`S"C-!&'>M[#O?1O6]9IT>V>*K5WQP8WRU68$DN%CDW-/,
M_C&N=5Z)L1%S&R`F+'!40B2EB,XZW6`L(U"DPLH.S!BUH.M[^'>^C64ZW;'%
M9I[YX.GKW@0+TWB/K*S>&YGJ<%MQC![P(%Z;Q'UE9O#<5.!<8P>\"!>F\1]9
M6;PW%3@7&,-._;ZS"(NO9+<L$#9*8XY+C_<3W!$@>VQ8K.[ER6ILXWN2=.J,
M.,[F26(8NC6^@(=[W\&MY$Q-;G628ZHVOFU9PO,!@=,O"'YJ]0?\F>?QK?\`
M-VE_7E8=7^S,E9EBLP)Y]E6^,C'R_M4UZ>&MG*/XVLQ9!CHX)&\LXP-GB$(!
M0U9Q(3!A#\.]:WO>M9FUHF<T<%VG,1EFY]70S[P(%Z;Q'UE9O#<JJ<'=QC![
MP(%Z;Q'UE9O#<5.!<8P>\"!>F\1]96;PW%3@7&,'O`@7IO$?65F\-Q4X%QC!
M[P(%Z;Q'UE9O#<5.!<8P>\"!>F\1]96;PW%3@7&,'O`@7IO$?65F\-Q4X%QC
M![P(%Z;Q'UE9O#<5.!<8P^/%E;28#`W==E3^3ZUOZY,W]""S5^ONS,O[&_+P
M;5\T,Y@5B"JDJ&\N+JQ:I(1I$W*OCJ<H5*CBTZ=.2"U(V(9IQYH@%%%@#KIV
M(6]:UK*]7LEWI]W)UZ>\"!>F\1]96;PW,M3@NN,8/>!`O3>(^LK-X;BIP+C&
M#W@0+TWB/K*S>&XJ<"XQ@]X$"]-XCZRLWAN*G`N,8/>!`O3>(^LK-X;BIP+C
M&#W@0+TWB/K*S>&XJ<"XQ@]X$"]-XCZRLWAN*G`N,8?_TMM?(2@."<VYJ6Y=
MLKM.^:-Y!N/.&"<8WE^A%ST*V')M&\<Z\L1MM)&SV?3LL<HO7"9(Y$MBE.`T
MT!SBCV9M1L(^XEP[B9B(PINY[/::CG_%.'/HY[8-I:06!R&A1-B6E(XU+9Q,
M$M:\C;8KI&^NL@A\<B4;<$BU)%0";^]4!(2F[N!8A&C`(XR7,[TJ)5#6F5HE
MA)XUK,[GMYK>BEL>.*:Y>Q`,%LP)S&^A(.4(AEF[V+9>]&)S=;$`TLPL8P"(
M6S5%11FGVB0-T?6R-Z<9A+'*=3.4R]Z.?9-+9:Z(6MH/>G=:(M,C*&2QL2!"
M00D3I4B=(B*++*#U=[V&23$:,T>S#4J8PP71UAF$%#&+HUH.ND0@[WOHUKH_
M^S%C^/%[?\11_<Q/V&3<XAXO;_B*/[F)^PQ<XAXO;_B*/[F)^PQ<XAXO;_B*
M/[F)^PQ<XC4_VQJ1(3Q?@8R4J<H?]I6FM=<LDL`NC:M[Z==8(=;Z-Y.3OR\4
M3VYN#1CFUF,!@=)O9HH41G9_\/QC1I1C%05=[$,:<H0A;VQ)NG8A;!O>][S#
M<M<[TX?%[?\`$4?W,3]ABYQ0>+V_XBC^YB?L,7.(>+V_XBC^YB?L,7.(>+V_
MXBC^YB?L,7.(>+V_XBC^YB?L,7.(>+V_XBC^YB?L,7.(Y[.UW3D$<H>->B"2
MB="H.\MBT46`O0MZL.ENC8NH'73T=.6Z/=/!QJ=D<6N3-*@P,.\B/F_WG^9V
MS?Q*>\YS]F?A+K)WY.,.Y#Q>W_$4?W,3]AF.YQ:#Q>W_`!%']S$_88N<0\7M
M_P`11_<Q/V&+G$/%[?\`$4?W,3]ABYQ#Q>W_`!%']S$_88N<1HXYANO:!3KD
M;0+Y6?9FO$R@'%/D5*[%9IF5RHXS1TFYXPIJ^QJP;%""/2&1MS]"N_\`SU*<
M=%N!)QQ0"-DC+T,76#$VZBJFY;>J;>YG.:TBDKM>FM4=8+PD5G26JETJB-A*
MX>J)<UR1*B.F4,&HC#X):W)R5>C$@Q`+THT6+Z\`M8N7+ENY(%@*YD\SP%@`
M6`-^(]!``.@`#KW)TYOHT$.M:U\.\TZ/9/%5J]T<&+\N5&!)SA`46=S6XPEF
ME@-!N865O8#`!&#?1QSNS>ND(M;UOHWE.MVQQ6:6^>#J2\7M_P`11_<Q/V&9
M[G%<>+V_XBC^YB?L,7.(>+V_XBC^YB?L,7.(U]=J?Q4GO,;@;>W'"G2X@BL>
MQO=AYNJI8M.8X^5YHW)7D[=_&#JWM3NK2]=BC"H)743F=<_8`;ZH1;$&)N83
MEFIB7'=_Z83M(_OYQH_2A*__`"USFI6]>5AA+_E^^=BOD0]\9"G>A?>.P4O%
MKW7'CL&1ZC6X1+YQ,*_:BB'/4#VJ,?`OT(6[.(VF"6!/LL>C1;%L`5'5%6S/
M_P"F$[2/[^<:/TH2O_RUQ4G7E9PXT01[JVFX[6,F&A,DE<O=@P20#:SS%3:-
M[B%CRV/NHVY4<0E-4H1+V\S9)@BBQ#+Z-["'>^C6W2_KRL>K_9F9XRQ68&P+
MLG""#^85LZ/)*.T'C4R[#HTL!F@[W:`M;WK0];UK?1F;6[HX+]/MGBZ+/%[?
M\11_<Q/V&57.+L\7M_Q%']S$_88N<0\7M_Q%']S$_88N<0\7M_Q%']S$_88N
M<0\7M_Q%']S$_88N<0\7M_Q%']S$_88N<0\7M_Q%']S$_88N<0\7M_Q%']S$
M_88N<1\<#*V@P&!NZ[*G\GUK?UR9OZ$%FK]?=F9?V-^7@VKYH9S`KM>@".^.
M+`!A",`N5W'0(@#UH01:W:L:Z="#O6];UO*]7LE9I]W)V(^+V_XBC^YB?L,R
MW.*X\7M_Q%']S$_88N<0\7M_Q%']S$_88N<0\7M_Q%']S$_88N<0\7M_Q%']
MS$_88N<0\7M_Q%']S$_88N<0\7M_Q%']S$_88N<1_]/</R^C,4N/EW;O&N.<
M#>.TKY@V=R&@J"'799_%^0S&&Q7B3JCJZD$SY,6/8"Q0&)V))&B9;=HVV,Y"
MQM[DH2)TQX3#@@"IAW&R+O8W%=FR<6/AE5"(NN*_JD<?=[?AZN(53$U4%K@3
MC"KNL>(NDOAD27*%:MC8;(<F0V1D$F&C%T.O6WO?6R8<YM\ISX08#`8#`8#`
MU-]LC\UR!_M*TS_M;WG63OR\43VYN#13FUF,!@=*_9G?X?O#W\P-=_T$FS`U
MSO3CP@P&`P&`P.>;M??G1<:OS!WE^L.E<NT>Z>#C4[(XM;V:5!@8=Y$?-_O/
M\SMF_B4]YSG[,_"763OR<8=SF8F@P&`P&`P&!R+\D_GE\T?S^(_U)4YFG1[.
M:K5[HX,6Y<J,"3_!SY['&#^M]E_W<KLRG6[8XK-+?/!U-YF7&`P&`P-:+'_C
M%V?_`/UHT3_>DY&9'JZ_\\VR[)<N+!%_QVTOS_<C_P!?ED9KTNS*HU._,JN6
M.#`V$=DO\\.VOV:F3]:(LS:W='!?I]L\71EE+LP&`P&`P&`P/C:9PT&`P-W7
M94_D^M;^N3-_0@LU?K[LS+^QOR\&U?-#.8%?KO\`+WQ6_:OXY_K6C65ZO9*S
M3[N3L;S(N,!@,!@,!@?_U.PKEUS80\6YM1$/,K.XYONT;`0LL@<(!05S6JW(
MXJHB=C.9J6.O%<1EX:UME:>XBE&!BZY[@)H&H5]Z[)+V<`F(NV9^+MSN=^U4
MNL5V9@,!X+HY,UTB:_%SNSJBV&E>2EM4Q&5+PTOHMNS9(W*.0!*I<TYP2MDN
M)QP-%%!T$H`F*2'PA3&EZ9GY,8M8W9L>49*U<W&JVE>E<4Q3@UJS4#D@,/1F
MG%`6MRX@PD\K>]#)-`(`]:%K>L"IX#`8#`8&IOMD?FN0/]I6F?\`:WO.LG?E
MXHGMS<&BG-K,8#`Z5^S._P`/WA[^8&N_Z"39@:YWIQX08#`8#`8'/-VOOSHN
M-7Y@[R_6'2N7:/=/!QJ=D<6M[-*@P,.\B/F_WG^9VS?Q*>\YS]F?A+K)WY.,
M.YS,308#`8#`8#`Y%^2?SR^:/Y_$?ZDJ<S3H]G-5J]T<&+<N5&!)_@Y\]CC!
M_6^R_P"[E=F4ZW;'%9I;YX.IO,RXP&`P*2_M(7]B>F(3B[-`7II<6D3LP+S&
MI]:PN*,Y'MQ97,G0C6YV1:.[HF/#K8B3@A'KX=8'/G'N$O#U_P"7,EJ)C[0O
MM,#N3C;"S8P^R0CFXZ^<RN'Q4\J5I8`.7DIQR1<G;724.RTE@%TB2'HG16-.
M27L)ZB'5S6Z*=$62Y<6"+_CMI?G^Y'_K\LC->EV95&IWYE5RQP8&PCLE_GAV
MU^S4R?K1%F;6[HX+]/MGBZ,LI=F`P&`P&`P&!\;3.&@P&!NZ[*G\GUK?UR9O
MZ$%FK]?=F9?V-^7@VKYH9S`K]=_E[XK?M7\<_P!:T:RO5[)6:?=R=C>9%Q@,
M!@,!@,#_U>Q;F3R9I^@'2C6Z<TU='(*SI'+)-,Z7J^@JV.LRR"W&NXYMJF-@
M(VH;U'6MN:8DQ6*6D5*5*P'1MX``LLP0_K28B[VLN<5[`IJV*/C%GT(V*V6N
MK"?K)F>FES8W"-/K=/9)9\R=KA1RB/NG_?F>8D6^J?0O*<6]A+=-*-`WL'5W
ML3=[7Z7O'.1DAC\A14;.ZUC)CE$53*F02F-2=%)R9`XJ#4JB1L5KM4@?VF(&
MM;,H[JA`H@LAT%Q(",SKE#V661L8:[/NI)]2-,3.OIU6L8JHI#?][.T'BT3F
MJZ=M0*^D5B/#W%UA+RX1.'K-ISDJX04VSDW?*A&`I2H"G4'FI$Y,S:7;FW3(
M]:>:TRAE;F\7<^]T:N*'N:@GJDEA-[HM!)F\)_=#M"'KH)!U0BT'X>CK;G9@
MYVXO#XIL/TUCGJ*J]LL7&!MQ/%-A^FL<]157MEBXP-N)XIL/TUCGJ*J]LL7&
M!MQ/%-A^FL<]157MEBXP-N+!O(/C`CY.P,BN+9DJ5PC222L<O2!8&B1Q5S2O
M\=,/-:5J=W89\B7E][C4#Z0=?J#UOH%K>3<;XC:;<8_A#_Z("A/2NP/7JU__
M`#3R>O-C/\HZ?:/X0QJ/L[*XF'-GF71KO-IZ;"*4KKB5)(8CU,;$+&D<;?07
M<HEQ@U2>P4[FITJ,@J'H"I4J0%]3?<@E=8?7=>:^Z?Y3.2*C9%\$SOH@*$]*
M[`]>K7_\T\=>;&?Y1T^T?PG?4U,.5)UG!JCKV3LS9!ZYC+5$8JWK8L[NZM&R
M,J4"-`0I='*<J7!><`DO6A&G&#,'OX=[WO.;C!/RQAD/Q38?IK'/455[98N,
M#;B>*;#]-8YZBJO;+%Q@;<3Q38?IK'/455[98N,#;B>*;#]-8YZBJO;+%Q@;
M<3Q38?IK'/455[98N,#;B>*;#]-8YZBJO;+%Q@;<6@7M8TK^EY/\<M/SRWO`
MQT+=^TPD#(:RZ(#JPJ8[J$T)CP[=\;,WL/1O6P=7HW\&^GX+=&NJ:CT<ZE]&
MV?5KYS2H,##O(CYO]Y_F=LW\2GO.<_9GX2ZR=^3C#MB\4V'Z:QSU%5>V68[C
M!?MQ/%-A^FL<]157MEBXP-N)XIL/TUCGJ*J]LL7&!MQ/%-A^FL<]157MEBXP
M-N)XIL/TUCGJ*J]LL7&!MQ/%-A^FL<]157MEBXP-N)XIL/TUCGJ*J]LL7&!M
MQ<HO(,I>3R_YE%.:M.O7`OI+I0K2HA-Y!PMTK3VPB+1C5KA$:T7O6MZV:/IW
MKIZ==/1K3H]L\56KOC@QSEJLP)'\,"7-1S,XR%-"]*VKA3&Q]E*UC>-T(+#K
MCK=>S`B1@7-PC-F%ZWK6^ZAZN]]/1OHZ,IUNV./_`-6:>^>#IQ\4V'Z:QSU%
M5>V69[C!;MQ/%-A^FL<]157MEBXP-N)XIL/TUCGJ*J]LL7&!MQ/%-A^FL<]1
M57MEBXP-N)XIL/TUCGJ*J]LL7&!MQ6"DI8I!/U]K(@5JELIT;E;.Y3LBK0%R
MI>U+T\52JFU8]!ENERA":GA#2'N0Q[`'2$OJZUT;Z6S`^6*_O%-A^FL<]157
MMEBXP-N+CE:@G`=K,`I-`>H#?/(L)YQ16R"SC@WS8^C32R-FG[)`8/6]Z!L8
M^KK?1UM_RYJT^S*IU.^5:RQP8$[NRQ2OJKE]:@6)W0-!H>-K-L\Q>S&/(#B]
MV>+00%E%NS3LD01?#L6Q#Z=?!T:_ES-K5U1<>B[3OIFL70EXIL/TUCGJ*J]L
MLJN,'>W$\4V'Z:QSU%5>V6+C`VXGBFP_36.>HJKVRQ<8&W$\4V'Z:QSU%5>V
M6+C`VXGBFP_36.>HJKVRQ<8&W$\4V'Z:QSU%5>V6+C`VXGBFP_36.>HJKVRQ
M<8&W$\4V'Z:QSU%5>V6+C`VXOFG?0;=JS_T>3/USJ?V_SBI:.K+BQ[/.R,[1
MBL5E>()WQ@E,=66O83;5->D*937"D4EL%X8I%)6V-)1()FK`E5*F.).*C1JC
M9*?04HM",T(0`B4=48LA?0;=JS_T>3/USJ?V_P`5)U9<4T^&G&*]N)>K0JWD
M17CC64^4.,4E9,<='%A=%(X^[MSDC;G+2F..SRWZ*5*6I0#0=G:,ULK?2'6M
MZWO3H;LS+KS$SEI-[-"@P*M!P*S;PXO%H5!218/E5QV"F5'IA+"2#MVI&]%F
MFI0J$@E``"^'8-&@ZW_O:RO5[)=Z?=R==7BFP_36.>HJKVRS+<8+MN)XIL/T
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M[FV#)<F`P&`P&`P&`P-:/'C_`!/NTJ_,UV>W]$<H<CU=3VPV79+DP&`P&`P&
M`P.>;M??G1<:OS!WE^L.E<NT>Z>#C4[(XM;V:5!@8=Y$?-_O/\SMF_B4]YSG
M[,_"763OR<8=SF8F@P&`P&`P&!R+\D_GE\T?S^(_U)4YFG1[.:K5[HX,6Y<J
M,"3_``<^>QQ@_K?9?]W*[,IUNV.*S2WSP=3>9EQ@,!@,!@,#BP1?\=M+\_W(
M_P#7Y9&:]+LRJ-3OS*KEC@P-A'9+_/#MK]FID_6B+,VMW1P7Z?;/%T992[,!
M@,!@,!@,!@:T>T5_^=NS,_\`[+JK_N]\GLC!U'_K@V79+ES+]I+\^*=?F:I;
M^D+-S1H;LRK5_P#*%N7JC`K]=_E[XK?M7\<_UK1K*]7LE9I]W)V-YD7&`P&`
MP&`P/__7Z:NUE:4,G<^+$3F?"=[YH5*[2NSE,\9H,%6P6K!'-)%V5O@R^MK'
M;[GJM;&G61OKR),M;.]W$I[;"C^D]&:C)+71+K+Z[:E/SB"7'DW&^K$$3X^R
M?BQ&6=G<F%BH29H65NDU?M;!(GEE1D.J=@>)`VB-?R4&G8!VEJD]24O`<>/9
MXS>B43OWI)808#`8#`8#`8%LS2.'S"'2R))I-)H4IE,9?HXGF4+5MZ"8Q(][
M:U385)HFN=VM[:D<F83%6E2`U4B6)RU10!&$&@T(L0:T89V6*>#6I(KE:>?/
M:$*9U-?=^GG[@Y671!Q4]:*P.>3(='Y2!+QP1G*F9L)D;@1H!!B<W9*TW6C-
M"V$08IUU>T-JF2Y,!@,!@,!@,#!MM\9^/]\N+"[7+4$#LITBZ)R;HZX2Y@1N
MRQF0/!Z%2Z(F]0H!LU,F<%#8G&:`.^J,9(-[UTAU@8F^CQX._P#2U37J<W_8
MXVXC6MV:?#OB[9;1S?.L"BZ[F)L'[2GF36L/,D+"0YCC5?PV<-Z&*0YF$IV/
M:&/1Y&8(I(E+Z"B0;WH.M:Q<XNI].#9&I[.C@JL3GI%?%.E%2142:F5)5,);
M#TZE.>`11Q!Y)I8BSB3BQ;"((M;"(.]ZWKHQS1::.$&`P&`P&`P.1?DG\\OF
MC^?Q'^I*G,TZ/9S5:O='!BW+E1@2?X.?/8XP?UOLO^[E=F4ZW;'%9I;YX.IO
M,RXP&`P&`P&!Q8(O^.VE^?[D?^ORR,UZ79E4:G?F57+'!@;".R7^>';7[-3)
M^M$69M;NC@OT^V>+HRREV8#`8#`8#`8#`TT<Z^-'9=UY(VZZN4-#NDOF5N3U
M1HES9IQ8A:]5,0LJC25T"U!M6*,;/I<M$D9RCDA99:=6ZD"/[@C[Z5D0ZB_1
ML_HVKZMIJJ8=7=*,H(_5S.B6N,1:BW9_?"R44J=G"7*U!;I*')V?50'!T?3U
M.N^%`]EZ-Z@=!`$(`RY<]_:2_/BG7YFJ6_I"S<T:&[,JU?\`RA;EZHP*_7?Y
M>^*W[5_'/]:T:RO5[)6:?=R=C>9%Q@,!@,!@,#__T-RW).MJFE?,'EQ(.9_9
MH<[^:*ESE\1BU`36H*Z.F-20BB&ZFZVV6VU\O-N>O=L4O7V>JD:UV5(TPS`J
M1%]10`S1Q((Y.XW14MNO9GE66DX2TNV6RP6M%Y6PFV9&6]@O-(:BM]MKJ+V_
M/X]3I-AD&GJA;DXZB;&,:@P)IQ9PA=T`8,`@CW+F=\LQ\A;L,KB&3IEK1;"I
M9R2)K2436J*1<GQ`=,)XK9F]R/2&-D%3/C1+)&T]\M9^C-(A%[-[@86$X`];
M$$1_I4>.UH#M6"KW1?,&>822.RIYB,OVUU'/:,4QJ1-A2%<;%GZLK,E4QE["
M]H&UT2G",/6C)6IU)*E/KO<XH0B&3G.<Q1G6GMSF])TBU/W/NZ<PM2(9?=B2
MSR^G99`P;ZY)H1?!O^3>*1<1OEX/>7!?2))]J6>#9-2CJRXGO+@OI$D^U+/!
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M&QN*$E$)?IR:>^`'[/[V*[GW(:IP3.;)/_IN<]Y<%](DGVI9X-DU+GJRXGO+
M@OI$D^U+/!L5)U9<3WEP7TB2?:EG@V*DZLN)[RX+Z1)/M2SP;%2=67$]Y<%]
M(DGVI9X-BI.K+B>\N"^D23[4L\&Q4G5EQ/>7!?2))]J6>#8J3JRXGO+@OI$D
M^U+/!L5)U9<7*+R#<$3KR_YE.#>>!4C4WTE&0>#0M!,"&E:>+%O6AA"+70,&
M]?#K7\F:='LGBKU9N8F,&.<M5F!(_A@ZM[+S,XR.#HJ`C1E3&QPF'F:&((1&
M\=;K++UO181C^N&+6OY,IUNV.*S3V3-X?_'3C[RX+Z1)/M2SP;,]2LZLN)[R
MX+Z1)/M2SP;%2=67$]Y<%](DGVI9X-BI.K+B>\N"^D23[4L\&Q4G5EQ/>7!?
M2))]J6>#8J3JRXGO+@OI$D^U+/!L5)U9<3WEP7TB2?:EG@V*DZLN+G/6]GA?
M*20SI0RS[C6XL\ALVTYJTJG2P;69W+Q;/K&E$V0IG%L24*^)4BY"ED`"#@EJ
MU!>S"]["/>MZRW+J3ERQEZ7.:,N;-,]2//)JA+MXPU@"T9(JH"6MHYQ74&TT
M16U+)\:Z6V/-66$M[AOQQ0#8C[P:UCV!0I_UO=.X%B[F$8^@.Y_-/A_O_B(T
M\LS77_K_`*D%]']R+]+^+OZ5+=_=PR?S3X?[_P"(Z,OG_I,;@3QCFO&Z[I]:
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MK5DIE:E@?5J(9@`A&)*K.*WOJ&"UN*3U1BO3WEP7TB2?:EG@V34HZLN+F^[0
MYZ:W[FO.US0L+6I=4_3)&SBPF!#HTM?90A@Z#0`%TAT/7^C_`$Y?H[LSC4F)
MZ:1`R]48%6@ZQ,WWAQ>7+#0D)4O*KCL>H.%H6PE%%VI&Q#&+0="%O0=:_P!&
MM[RO5[)=Z?=R==7O+@OI$D^U+/!LRU*WJRXGO+@OI$D^U+/!L5)U9<3WEP7T
MB2?:EG@V*DZLN)[RX+Z1)/M2SP;%2=67$]Y<%](DGVI9X-BI.K+B>\N"^D23
M[4L\&Q4G5EQ/>7!?2))]J6>#8J3JRXO_T=['(+M<Y#0W-R;PR:WAQK@M(U+R
M'J*A930LIC4O]^TEK^QH56CY+N2J.<IW4R.MC%7K[8PC`-^D>RU+*RK]CUWS
MH@1L6[C+<>[>I3UQUA?]<QVW*9FC-8=;2WQOYMS"/FG'-#QXA?7.,O'>AAY*
M<T7B]^9E24SI!KH-(%K73KX=RXW;UX26/()8PND<=%#XE;W=,)(K41J3R6%O
MQ10A!'L;7*8<[,4G9%/2#70>B6)SM:Z=:%T;WK86M6540:H&-PC\$;G-&D>9
M`Y2I]7O\IEDYDTBDCN%,4O?)),IT^2272)S,2(DZ8!JY<H&2D3$IR]@()*+`
M&1<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#D7Y)_/+YH_G\1_J2I
MS-.CV<U6KW1P8MRY48$G^#GSV.,'];[+_NY79E.MVQQ6:6^>#J;S,N,!@,!@
M,!@,#4]VT'S*B/VE^(O]XZN,B767>VPY+DP&`P&`P&`P&`P&`P&!S+]I+\^*
M=?F:I;^D+-S1H;LRK5_\H6Y>J,"OUW^7OBM^U?QS_6M&LKU>R5FGW<G8WF1<
M8#`8#`8#`__2WSW_`"U)<W+OE7"K>[0^)\!$''ES@26JZ_\`$-!1Q]GT?<JD
MADU-OJ;S*ZF=>?9\-629]6LP65O.)0H"6/9*G99YFQF0[C9$;+;-NSEM28W5
MPNI"R9YMD5R1^;I>E-D4;B@8*PS]GC=B2^+1>UFF'@(2DQU#;T69$4H+2E%%
M$E:=^@L`"^J'4N9WRFWA!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,#CGY86'`(OS8YGMLFG,/CKB*]6]2%O?9,RM"W:8VE*?`4HTE<%J<_9!@BA
M:"/J]7>P[Z-_!O-&C,1EFYC>KU,LS,5$[F%/?-3_`,JU;>O47_"F6]67RA7T
MYO&3WS4_\JU;>O47_"F.K+Y0=.;QE+KL_;`@<KYR<96Z+S:(R1P)DUG+3D+!
M)&9X6%(R^.]S$&*S$S<M4'%IBSE!8-F;#H.A&!UO?2+735K3$Y8J?5WIQ,3-
MQ.YUDYG6F`P&`P&`P&!H^[4.@H_/7I@*O7M&K7X_5):4W@94`I*/5;!Y9'RY
M]6>V>4-SVB=0Q)WF(=$25E3N)QBM0%"%:H)3?#W8HD<2ZRSA#9QQEJFRJAK]
MPC]H\D9IRD>W>3JY*UV).8Y!XRYM\>7LK`B0Q9`C@#6TLBMG2*VQ0N*4#+&H
M,,<#`['LL!>M2B9OT2)P@P&`P&`P&`P&`P&`P.9?M)?GQ3K\S5+?TA9N:-#=
MF5:O_E"W+U1@5^N_R]\5OVK^.?ZUHUE>KV2LT^[D[&\R+C`8#`8#`8'_T^H3
ME=P<Y7\BK=6S));/"E=!&1:E.JJ.7KP4A]ZS*O4H$"+OTE).9/+"E`CE+V6H
M5!,3D)>H$T(.C>P=;<.HF(CU;%:%C%L0RI8A&+OG,3LBSF<EV32&90:#AK:*
M.B<3\ZGQPAGA('5[`Q$LT6-1(1A"I,"<<F&=K0-&=0,HG?L966K4;:C5N+BK
M3(&]`F/6KUZT\I*C1(TI0SU2M6J/&60F3)B"Q#,,&((``#O>]ZUK"%KP:PX%
M9S&&3UQ-8K/8V-0)*6_PY_:I*S&*`D)U?<BW-G5+$9@C$:PD\'0/>C$YY9H>
MDLP`A!>.`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!:ZZ$0MT5G+W.
M(1=Q7*1!$H6KF!J5JSQ!`$L(CE*A(8<:()8-!UL6]]&M:U_HP6ACVA\!@J/@
M!SE5I(7$TJM+P\Y,J4JI-'&<A0F4$4K-C2#R#RD83"3B3`Z$$0=Z$$6M;UOI
MPF)FXVLQ<>*]@)U`48<=!X@::;3U9&&FF1IE,,,,,A3((9A@Q(MB&,8M[WO>
M][WO>\$S-SM9P;H9#V=66O:(I&VI<4$82EK<Q-:%66$T&RS`EJ4R4HX`3"Q;
M"+6M_#K?1OX,(7)@,!@,!@,!@,"-O)B)\9GF-1.4\G]1%)%X1-V!3$9!,9"N
MC*!CGDD7$1>-=Y.:)T:M^.'5T<RDJ0L0Q==287U-=TT'>B8OT2/+++)++))+
M`444`)91180@+++`'00%E@#K00``'6M:UK6M:UK"']X#`8#`8#`8#`8#`8#`
MYE^TE^?%.OS-4M_2%FYHT-V95J_^4+<O5&!7Z[_+WQ6_:OXY_K6C65ZO9*S3
M[N3L;S(N,!@,!@,!@?_4[^,!@1`YD4U;UW4U:L#KR;,[>@EE7OT=\PUL<;@J
M)<]GZ4'Z;CIVZJW%M8FN1(P@;3BE+*O2Z+-,$<$PL8B]$Q,1*Z.,35<;6P6,
M*VO.](V.5GJW"GX[9#_#Y59L4J[<$@*(UFL"1P-R?8NZO*JT$4F<D>T[DY;3
M,J]"G,4;,)&44)9L<V:2JUIZAOF2AJ2&=S[B@+8V=8`CJ$E@,Z%*HD:@SNIH
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M_5J/>#XY%3Y'F[,?E"5^K4>\'QR*GR/-V8_*$K]6H]X/CD5/DA[VAK%*R>`/
M.0U3.E2M.5P]Y,F'I!1]B)"J)!2TV$:G$<21HTK1X-;#L0=Z$'IZ=?#D3NW.
MLL3U1\O5F'CPP2X=`4:,N?*R2Q4]68BRM1Q@'HH`H4R;"7H8T^QCT`.^CIW\
M.^CX<<D3$W/R9A\W9C\H2OU:CW@^3R14^1YNS'Y0E?JU'O!\<BI\CS=F/RA*
M_5J/>#XY%3Y'F[,?E"5^K4>\'QR*GR/-V8_*$K]6H]X/CD5/D>;LQ^4)7ZM1
M[P?'(J?(\W9C\H2OU:CW@^.14^1YNS'Y0E?JU'O!\<BI\CS=F/RA*_5J/>#X
MY%3Y('=HYQKO+D/QM*KJLWL,NDX;GH"8[:'`J)1I/IC@=PPZ72)Q\9KAHB-G
M-;*T'J"R.OUU`R]%A"(0M!W$\'66XG;F3Q\W9C\H2OU:CW@^3R<U/D>;LQ^4
M)7ZM1[P?'(J?(\W9C\H2OU:CW@^.14^1YNS'Y0E?JU'O!\<BI\CS=F/RA*_5
MJ/>#XY%3Y'F[,?E"5^K4>\'QR*GR/-V8_*$K]6H]X/CD5/D>;LQ^4)7ZM1[P
M?'(J?(\W9C\H2OU:CW@^.14^1YNS'Y0E?JU'O!\<BI\CS=F/RA*_5J/>#XY%
M3Y'F[,?E"5^K4>\'QR*GR/-V8_*$K]6H]X/CD5/DYONT.2.*+FO.R7-W,>E/
MN?ID>EAB)(A%HL2^RM!)[@B``GH!O6]];HZV^GX?Y,OT=V9QJ7\;E$#+U1@5
M:#E*#[PXO$I50D*DWE5QV`0L"24H$F-%:D;T`X)!^A$F[+W\/5%K8=_Z<KU>
MR7>GW<G75YNS'Y0E?JU'O!\R\EM3Y'F[,?E"5^K4>\'QR*GR/-V8_*$K]6H]
MX/CD5/D>;LQ^4)7ZM1[P?'(J?(\W9C\H2OU:CW@^.14^1YNS'Y0E?JU'O!\<
MBI\CS=F/RA*_5J/>#XY%3Y/_U>_C`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8&M3M)3^84SIBT./7&GB@QWHQW]0EMU?)K(=N0\.J,RL7:
MPHH]PA(I)ADFC#F?.`(D;UM?L)3@W@,V5W#9A>Q=T"3%;YEDG@U*>5CA7H('
MR<XKLW&_W70VLHC"'5HY`1.[_>;XN9')FDK@H0Q>*QWS&\2^(V\P!1YRWOOQ
MF((!Z[V&(P37I*<6$&`P&`P&`P&`P(+]HCR+L#BWQS*M2M"8\?)AW'0L#V7)
MVY2ZM?B2R;=B$'D0])4C@V'=_`97P[:8SNO5*/T$0@CUK8=I3$7*=&$&`P&`
MP&`P&`P&`P&`P.9?M)?GQ3K\S5+?TA9N:-#=F5:O_E"W+U1@5^N_R]\5OVK^
M.?ZUHUE>KV2LT^[D[&\R+C`8#`8#`8'_UN_C`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8&)+ZF,VKVE[-F]<18Z:SJ+0U[>8M&$[2OD!KH
M[HD@S4P=1UH7MCU(P)>C9XVY`H*<'`!6TZ7??!A>L$+<XRV/9UKU`Q3:X*T6
M5'.W%SDJ9T@R\A2E4,Y3;(7%O2)A%+52I8?WH0GTFVM%W(EU$1MP3%%)%2<L
M),L_808#`8#`8#`8#`CWR<9>.C_5X&_E(=$R*K\^:Y5@,FC\JC;)Y^(9JR*J
MV!IS1N+6=XS'."D.D9/=>JH4[`6((]"V'9,7Z)"808#`8#`8#`8#`8#`8#`C
MK9W$?C+=$IW.+6HVN)]+Q-:%D%(Y-&T3D[C:&PU8>WMPUIH.[#2(CG`\10-[
MWH&S1='\N\#'WT>/!W_I:IKU.;_L<;<1`'LL.&'%2U.SSXGV'9%"5M-YS+*J
M;W632R2QY.[/SZY&.;H4-<Z.*K9BA6I&64$.QC%O>]!UB)G%UFV3+8Q&^"7#
MB'R./RZ,<;:C9)/%7END4;?$$1;BG%D?6A26M:W=N4=38DK@WJR@FDFAZ!%C
M#K>MZWK#FTL<!@,!@,!@,#__U^_C`8&,IC,$PG<-8,,E41>R9(PJ76,.:F"R
M&4,2$E,)5LU:M5%$((N,TL+>=KO10Z)3Q_6[T'?7!U@Q/Q#G=EV?5SM/[#D+
M#*FF26)-!U%(6.*&0_SBIQE7%1J'R]:UB>7P@XJP5+*MD36H*."$U@=F_0@:
M-"9O9,L\N<U8&A:>WK=O7?*?N?=>](M*7)/_`*TDL\'<UK<S*T1W^K-UT]0P
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M[QXM]61^I$V]GL=,EP>\>+?5D?J1-O9['3)<'O'BWU9'ZD3;V>QTR7"`/:5P
MR1\D.,Q5:U,T/#[+@7;QYF@D"V/R-C(\WZ_N:&3&4*N_G=G2(^ZHF%F4&@*Z
M_=#A!T`&A#%K6TY93ES1$^O\)_>\>+?5D?J1-O9['3*+@]X\6^K(_4B;>SV.
MF2X/>/%OJR/U(FWL]CIDN#WCQ;ZLC]2)M[/8Z9+@]X\6^K(_4B;>SV.F2X/>
M/%OJR/U(FWL]CIDN#WCQ;ZLC]2)M[/8Z9+@]X\6^K(_4B;>SV.F2X/>/%OJR
M/U(FWL]CIDN#WCQ;ZLC]2)M[/8Z9+@]X\6^K(_4B;>SV.F2X/>/%OJR/U(FW
ML]CIDN#WCQ;ZLC]2)M[/8Z9+@]X\6^K(_4B;>SV.F2X1ZY"<@KB@C-'E?'7C
M\FY!/2]S5)Y&SRR>RRC$\>:RTNC4KFD=E5+V,%].5*][*$GT0FV6'77ZXO\`
MLXZ9P3$QZW_"&'9=.7)Z@Z2JGBSR%X[,<"A=,5.-B;+CBMG2BQ'"9RA#($6T
M34=62:E&`R,HE[4[+5`E>WM=HD:$!7<Q[4:&4C+."<V;+,W%_P`-JGO'BWU9
M'ZD3;V>QTRYN#WCQ;ZLC]2)M[/8Z9+@]X\6^K(_4B;>SV.F2X/>/%OJR/U(F
MWL]CIDN#WCQ;ZLC]2)M[/8Z9+@]X\6^K(_4B;>SV.F2X/>/%OJR/U(FWL]CI
MDN#WCQ;ZLC]2)M[/8Z9+A__0[^,!@>%T;43RV.+.XE"/;W5"K;5Y`3CTXCD2
MY.8E5%!4)3"5)`C"#1:T,L8!AZ>D.];UK>!Y8]'V2)L#'%HRU(6*-QIG;(_'
MV1K3EI&UF9&9$0W-34W)"=!*2H6]`F+))+#K00%@UK7P:P*Q@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@07[1'D78'%OCF5
M:E:$QX^3#N.A8'LN3MREU:_$EDV[$(/(AZ2I'!L.[^`ROAVTQG=>J4?H(A!'
MK6P[2F(N4Z,(1KF4^Y'M3G8">'T;'9,ULKY7:&"N"RQ$[0=*620+$B6>ORI'
MMK4"1#@R4\U4!)L0#%^B.XEBZQFAA)V8OQE7*F"0V>R6#/L=FR<F)N:1D>)H
M%/$_-`EZ758^7`C;M#,EQ4F#W6(1Q7L2DQL+0DJ"^J:>6#>C,%,9J.;D;>)%
M'DE>1XF51D3_`%TPR]Y42!&F6H%-I7%7-,QP$;2,I,B;'H;0YV$%S=]'K4@T
MB),4`(#!+2S"12G2_F1)(^582MNK5H7(8ZANETBQBR6N*-6N0<>;CBE,6-YV
M(RHHI#'5SX]2C2Z,EDF*RW-N(&8::G_DP5[LTP+D(CG-S36J@QY:S)H]YXDQ
MA]6Z6#W.#ZU<((RV8>E3]X$$L:6'R"PVQ('2@P?C0"L"A((8"U("!21V$&`P
M&`P&`P&!C>XBK"/JJPR:F/`ELHR(/H(2H$4U'G%2$3>?IO&@+?E"6/[=M&__
M``>W$P+<%7W/:KI3Z,UL,;<4D?(]#3Z--RK=&-XM\$IFVW)='DK,E:S604G<
MA,'>`6#86\QF[PWK;5LPI.XA9MI`.1>G(*P0B9KT21P@P&`P&`P&`P/_T>_C
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`CWR<9>.C_5X&_E(=$R*K\^:Y5@,FC\JC;)Y^(9JR*JV!IS1N+6=XS'."
MD.D9/=>JH4[`6((]"V'9,7Z)"80U:<L.>S_3UR0B!UFPHY8R19Y*674>+19A
MBU"I).2F0N.J1;"6D?&LE1WZ<HZW4`L+(3"WU=*R\MR:?5$S,J\V>IJ$V(#`
MJ6DTD/Y&11B87^3V(E9WE#.UC8@6O;>D31=-$RT;$X*D>W:-@,:$NTZY*687
MO9W=0FAT+8PY5,5.W>LB;B*W,F/D(ADG<V-ZDD1C$A>8P):*-.SXP-3LYQX3
MGM'MR$QKUZ10J:1.&VY/W?:<9?=>X%];IZ@>@+?;Z=J-I2/2!JJRN&Q!)&MG
M8Y$B;X/&421^9(\A(:X^SO29,V%DNC6QMB8M.C3GA,)3$%A++"$`=:T%PH87
M#FR2.TQ;8G&6^7/Y)29]E2%A:TDD>DY!:0D@AV?"$I;FY$DDH"``"<:,(0DE
MZUKH`'H"YL!@,!@,!@,!@,#!W&J_H=RGHBL>0M?-LF9X7;$9(E4=;)DC:V^4
M(F]0H4I@$O2)D>9"U)ENC$HM["0M4@Z-Z^OWOIUHF8J:9QP@P&`P&`P&`P/_
MTN_C`8%$DDDC\.C[W+)8]M<;C$;:USY()`^+DS8SLK.V)C%CBYN;BL,*2HD*
M)*4(PTTP00``'>][Z,"C02Q8/9S*;(8#)FN4-*9Q5LZU0VG;$<V/*#10EK,\
M(3@DKV=W2%J"QF)511*@!9H![!H(P[V%Z8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$`>TKH6S.2'&8JM:F9TC[+@7;QYF@
MD"UW;&,CS?K^YH9,90J[^=U21'W5$PLR@T!77[H<(.@`T(8M:VE.6:E=/*#E
ML71KH*OVZG.4<VDSW$$DA;)E3W&*YKJ@3.6YNKRS;0KI-6D0E+<DF#=XF&IV
MVGZ"860H2G&:[F<#0IBKV[D5,QLWH1,5#*)I4:^^`P:TDS3XEF$K61:6UA8$
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MDTB$P#&RMX4^U#L6J2B3A%I07TBMM,&T]SMBURV-':V;N-O..`+9)XW[C+;A
MXA7'5U<M/B=B<WXSSBG4J843"Q]_E-8DR3NYH>^5QQ*<'28:#6Q5>L+FO[F+
M'>/<Q;86[T+R]M)2YQE')P2"@>,5I73#D9"UT>6H+.Y2F$,SBU(),G,91'G-
MY@]*"DJA.<(.@'E[V(B_5E6"W:V3RE-7@EKRZ(TV;8Y:_>[J=53+8?=?<H@N
M>T*AMW4SRA3R[3X^B8Q&-*/N'=G,A2F,(T(*@O>Q6VF!*>YVQ:Y;&CM;-W&W
MG'`%LD\;]QEMP\0KCJZN6GQ.Q.;\9YQ3J5,*)A8^_P`IK$F2=W-#WRN.)3@Z
M3#0:V*KUA>'('EY'^/$E98P[T7RSM,][8]/Q3QQ^XU6==<:;BMKUC?XM>G^#
ML[BWM+YH:+9NT9P@G=[F%F='5&'>Q$7ZLEP6[6R>4IJ\$M>71&FS;'+7[W=3
MJJ9;#[K[E$%SVA4-NZF>4*>7:?'T3&(QI1]P[LYD*4QA&A!4%[V*VTP)3W.V
M+7+8T=K9NXV\XX`MDGC?N,MN'B%<=75RT^)V)S?C/.*=2IA1,+'W^4UB3).[
MFA[Y7'$IP=)AH-;%5ZPO#D#R\C_'B2LL8=Z+Y9VF>]L>GXIXX_<:K.NN--Q6
MUZQO\6O3_!V=Q;VE\T-%LW:,X03N]S"S.CJC#O8B+]62X+=K9/*4U>"6O+HC
M39MCEK][NIU5,MA]U]RB"Y[0J&W=3/*%/+M/CZ)C$8TH^X=V<R%*8PC0@J"]
M[%;:8$I[G;%KEL:.ULW<;><<`6R3QOW&6W#Q"N.KJY:?$[$YOQGG%.I4PHF%
MC[_*:Q)DG=S0]\KCB4X.DPT&MBJ]89,X<<=O[)?&"EN-_GAY_P#N@AJ:(^>?
MF_YJ^</>ZM8J\8>;OCN2>*>OWWU>Y=_*>CJ]/7WT]&A,W,RDOA!@,!@,!@,!
M@?_3[^,!@18Y55/:%JUC9,=@$L2FER>L)'#?=@^(6%%'9(N>TZU&H=-303*O
ME$:D:=N6[VV'E&]YIG%.F.-!U-&[$3"D\-JHGM1PNR6B=`?-ADEQ2"8Q%5.Y
M*S3:W5\6=(I"4(E=Q36.AVQRB9:E+4Z%(CDYA_>T7+:49IHSTQN\$S:2+FPO
MZU:>I13=Z9TQG<^Y-R1KBRE.GZA)98^YG.+$L6C[L8#9F^N8+H$+>M=`=:UJ
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MAG3U^Z]?NO1YM]7K=3ZSHZ.KT?#T=;X<7&!4^3__U._C`8#`8$$>T<MVSZ2X
MQN<UJ"6>9$W-L&K8RDDNF&/R0QO;I3.&=F>-DM,H;7=D/./;E1A81')Q]SV+
MK!Z!:UO4Y8O-$$[(F?9HY_MN\^?^K)W_`$+\?_\`RUS1^'+C*K\L^,']MWGS
M_P!63O\`H7X__P#EKC\.7&3\L^,-UR3D59C7V;=1<EE*QH>[6D7'WCC.W]R<
MV@@EH=)18S77(I4X&,C.-J2)"U:B2JC2R$_<22!B#H`=`#H.9EU;:>#^TG<X
MHJ'D+I57I=-[Y0`X^"JDR&R,=@!C?]J,/$PR8;GA<P[V\^?/;I>],^H]LG3=
M_NKZY=_W[8KT]5.X&\F+OY#(F%]G!35(X?):?9YXZ2=FJ*=5@U02R7%_&B'6
M+5(I4].C#:[<J8=#5A5-`>ZM`D6]K3C0N:$)(F&,H]S4NJN*)X]\FKH<8'/J
M_O:-3!X>H%`X`XQ"=0ERCU#6U?I(XB\N5BOS5+V,IGJ14W*4JQ&D5$]]@7"6
M]R3FD#A-1N296<WHPV"&H=*GM-"RL">LG"SWTPVM1HZD:KFE2B/UPMF"4%A^
M-'$U<TZ3/;F0R$.QK0UK"]G:$HT-.&44KE7<P(_9DMB4?W6EAQ)BL60VY#JZ
MGK^;!CHW+9A2+_)62<QTIO9)BZ3!F4")B+FL;CUS8G3+4S:JWLPK?>FE@I&F
MH^=4E1!D+[=\0GB8F56QS52,J5O/JQ1"*GJ#A-=RRI)U)UZQK5-TM5@2,B<3
MBY]\'O2U<Z(E!;80!,<D`9"9C!F=3SM86Y8UQYYI*X&*?2-73XHI7[HHJL3Y
M)6"]CY^@KR1(W)JLIUBR!/MYKEP0NR9:O2JVH_18S"QISB#S912Z:(YD1N\Y
M;'8@565E5XLF<+M69P]5-]P4Q,^E4-8\2J*ZFC1<0FLI5MKC`[#G#:AT)264
MG<RS1*$9AQ`=#$)BD;G'FA>,`ATB6S>&-3Q>*2Z>,4!=>.@XBMK=1!XE??)1
M@HA-+(O9<AG3S&+PB[R1("2FU\:!$HR'S6_&)2``CF]#":CDSO*>>%501O>'
MJ:,DJ8&*,V!?L"E+L84U+$[%OCG3<INV>2$XM&Y&'JV<R+Q%44DT2$1YBGJZ
M$`(-['J45+'D9YG2IJORR8Y<M?2^KZZ1_P!F>.M264G5N=NM'6XFKD$X%S"<
M2")2E^1^;DL?8`Q1H`-+%!R&1+R20E;2F&+-BL%%Y$\O[59X9Q=E].QJ1L>K
M[A-B6+N,+J5D%Q6*4ACM7);`AT=4UY%I=%7%&L=#5Y)3J4%4%0EWO9.C"C-;
M'D)B-]KT:.T'KTEWIB(R)E-?I1;]7(IJT**?D4.L]N=I'_9]>>1RI@C468Y*
M;:!S6^P*+.@X^N7LB+3P<0266#H5)C#I12UI+VIG'N(Q6#2=[!HH4LASQ9#H
MQIK,HI6]1F`LLK51!6X%)"[2T*=R[3DWK>F,QKQN_@,:ER0:8+@6F1JUG3*V
M(-SV>8TGEVK+;'R?KT5PW/!HXP0J+QEO?G((NU.L3@O3C&A>W6:QJ.F*B4"F
M.I3@+4J,`M)35JARV,T8=0FO\Y+LF_:A4A7#?W.;1]_CDT:%MK$3FNWB84^S
M2>+)::D37'98H:O'=D-;?8K@\C>25<?;(\<XNKRET8$*<I46)-DHI(&YN6<1
MIY2[$`A4\L4J(5(MONQE,$+B75@-.HSG,@$Q<4TMED56OQSCXA<S4C:T%KW$
M\EI5]!6CN]250JU#KWF9$;#L1C@Z2`3QI9Y99%UU)#K%<#H6IB,HG=&*9$;)
MFYO3M,M<)4F;W:/19<X-RQ4W$$'!2FE#V69W'NXI@]UY)W['F^[KH5/U:N58
M5#RB!2*RJ!0%Y1R=WA0IQ7T"\:QVQ"I^,LNP='3$2TA*H95:-T4%!;RP(]J`
M*TXJ-C(3/V@E6.TSFD+!&Y#WS`Y=3;#('AHD-;3*/)&"\+%>JDBTN/>H+-I,
M@2)&*PV<*1]2'&%JFE,K+4C"()2T*19TRJUQ<G)8FX6R[E52[8PH!M<2?[$B
MB>SV-U>FN3P1H7.8H^^$MD:E,86A26/'DJ-R;#MKP;3(7$LTTHT8-IQBMM)O
M808#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`_
M_]7OXP&`P&!`/M+J_<[)XJOK$T3:G*_7(9[5TE*D5]6&HJNM`!CDY9G0QO>)
MPFC$Q.:%;H61LA'T-RCNRH8"]]70NMJ8FIB<"KB8Q<_WN1L+_J6[)_\`_P!"
MWO\`=<R[\_U_W_QQ^*/*?X_Z>Y&PO^I;LG__`/0M[_=<Q^?Z_P"_^'XH\I_C
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MXL5#2]4KNO4``(2;ED-^XUTO)9(R2MYB*I0[,:*#MY9*>6S5N8'Q'63LJ?ZZ
M)F\2;)&CBEB>8KZL-6M`G]$Y";U8^[$;`9K0M"V/>/?#VO:'&4][6O,TG2>1
MW&^()$[OTVW'F$FXK0DUC/!$/K1XFDE@<(=MD/I3<O=&A&C6NX$PC#Q:TH,)
MT)FU_L?'FB6EU2*&F'-ASA&G"^5X4:M\?'M.E5\JIV9:]Y%NS,ZO*]`M36+,
MU(EXDRP@TA&4/9"$"9)ON."Y4B.\2J"B_BH;;#712J8Y#`)*SN<AL&RI<]MJ
MRJBGTJMFM(^RR7O3R3#H1YT.8VQ@T?XB2&N2HP"31BDX0Q<KJA_'ZHH$^Q.2
MQ.)>*7N#LURQ^++?'TG7>*VCD%8T3MFWDG>SD]+$BWSNL"#M;AW106<:@[U[
M@B$F3&'$F"UF*N(-"N+=*FYYCTPD1DQ%"=NC]*;BN>53-N]V\U361`00V>R*
MP7.;5X5#[`1$/3<!@<&P"5S(*4@UHTL`@BY?ZNX?<=G6:.$^=H`<[R!U7R)V
M<"7::6`Z194Z3"MUM13%R'`U\J40;3A,J\7F-[P<%NT8Z]!9ZK9RDHHX`N6-
MY_P1J.40235S'DIS2P6FMJ5HNMQFK[8-NRF:UG3S^[RJ+Q%G?K$GCRICCXE=
MG+O9(\C[\/;FX8@$%Z.3MQR(7ZLW6_0=26]J)N%BI)&D-K[QX&+/$/M&RZB<
M&0F5-94>?4FGNKYG"5ZAO=FL($XTR@XTC8>CJ@T+X<%TLY!PRXXM$C:I2PP5
MTC3C'W$IZC2"*V/:,6BL5?B*3<N.9$BB<'CTT;(7%9(12KL<P@<6]O3+0$=S
M-T;I222>6+EZ6KB#0S">SKX^P32//;0N>G$R51ZYKJ89K)U4B?2I,\[L6;M%
MAHY=:2=<]DA/V3)%KJ2#HZ@`!+WL.Q<@N(''$"D3B.O0@4`F.[#$H%+YR$(9
M8'D]_;-$\B#N3Z*"$/)+7G)LC>N]=?\`#^Y^*_\`N6"Y>H_BS1+J[CF+:R21
MD?W20RJ9GRRO[:MB!/;LOL%3'G24`52"!3J/N#G&'];&&Y2)H,.,9M')0&%I
M@BZ1;%RN>T./=1W*O1N5B1=2]*4S&Y118%#*9A&$<FASPK1KG:#SQMBC^QMU
MBP-T4(0[4,;\4XM)P3#@#3[`H/"8+?VU<?JB9'>.OS7$N]7:)V795PQ]7X^D
MYW>%C6^EE*.Q)%W!0]&IE7G"FFKF'O0\!B%)WSTIB2=EE;+%K22<1Z$23I;8
M?FK(5[XOL0RW#VA[M"UI!79=H"-2*"+`15&^S=QJIMES<L0DJ$2].RE*$"HL
M)Z811NNO@N6+93P+I_=7SJL*N2*("DLJN&&BY([OTAL6T%$?H=J7NQFH#6+=
M-Y\X-=>BC;=(G`$5VB*\61I6>6>4@.*(`F$+GU2=D]1US,*L<:3?HND.JUTB
M1<$5P]`I<6-"&(DH"FLAC1*6)8VN38D3MY`"2]ICR3"P!UH(M=&$,CX#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'__6[^,!
M@,!@:.?\Q9_A37?_`%SI3];$4R)W.\G<^;UG*TP/IEQ),\*^Q/XR)V`AS4NY
MG#;A5WH0SE*CG$?4C%,C/[W*1!$I%U4P1['U=?`7H6]_!TYUZ*?_`%/%3.\Q
M[=`%F,,S%SY_MGE*AR(F.S(#K[A-<HA*@]:7@2C92>*IG$@@2?20:WQ6)3KO
M?9>Y7OJ['_XOKLRJ,G,0KNN+9D;+&*S32:AHW&WF#1)0]'.EF2PQ[&_F7-=!
M#M%H@0BM-,BV-``LHEQ5=P6J=*W1:$*0"82A;7CJKA?&FA9GQ3BTA9N3D#IF
MV9KR8D,8@#^D8'!*Q<<+C5IVV^#SF5/%+!M-QO3<6.96]=M=*#%11AX`^+0N
M6QDXWN3<E5R\HHK)F=C-E#VYRA.U<>GF!Q-%39!D>Y!JK1L!RU=+6Z/B-G<!
MPINJF);"C1@2.:-7&DR8IX?CW8A6`L1%0<6>1UQVM9<0*53ITGB)XF')^,VQ
M!#:L*C$5J**U59\WAU43-CFZ6,-JE:]RPZ-I&Y0E7.CDG>]J52MN)2A:U@=B
M8B+83I`KDE5QPTM?.LFE#]8MR]JQ9,V*F%>5XG?[%=:&Y9.;!04-5S1G@T2/
M:6^Q8T#:8E<OVOV6T.)I3/I$C3M86T37_P"+^9KZY/OJN+,$5G\ID\8ETLXO
MLD@M=UHE)#WV"RJU!6VGOBN&B./,80-)7NS;6*.K4?C1`O71E<NTE>E#L(0T
MX!4,J<6+5Y*/5E5BQV[)'&7,=CUER[<GO2NNV:&H8?)>+_(VIJ8KU<VGLS6D
M5EJ[G@L[7/KFG<%*D@Y<@$<T%(D&A)0":0XI1$REP:@S:,B+VAY(I+`MIVY+
MR*.PJ0M;4NK,M-=9DC;^1;[MI1Q:9.KXX*F<N/-SJ<N?C'8:18C*TC2KE!),
M^M[F7:<Y+\@T2.CJ^D:1\;7R42+A"8W,Y55+BT@:1G?':%'6^ZG.26-F-3*V
M-UTE.C<>H5*"#VI7LE'TE:.2@,(K?*SDM^\X@\<FBV%T\>SYJW=FL'FXOC".
ME8LB+?[H2Q\N6HZ#<D1[`X.29D6I-#;'%,B[UD1ZK85"0]!H.THQ47[6HG*B
M];QL"67553*SS5YJ)Q:9^R.$>D,4V7((9.J:OFEF>.+F5-'JI9?%,3L9@7NS
MJU#=I7)5LB9^]G),E:4Q>P*Q$>JN\\6N0G\PD3NQIF]=(&BD>.2VNV=/`I@\
MVM)I"@Y*6.OET=X^V;&W'O:GYLXQ<DDEZ<U;4[-PV@X&G(*5``Q2$1N7),N5
MO)91;=PL,"?#8M7::%W&M3/5NQX#2;6LOI?DO057&L:!8TT2>R0D5L5E8C\X
MQ)5(7"P]J>YMCZM0(6L*AO5BHV/.9R2Y6SV<,[`0PR*`PUUA-;!002\V9DA\
MRM.OYI1#/)K.F3H@8*P6[.N6'3F0KFW;;'GQJ9V]9'ADK6W1+DD4EBH6GQ<D
MO(@E'1--1UTD53QR3CX_PV2RQKK:/K)(TQYE[,BOYVH4D*YK&7U@)>2;+CQ+
M8)6XHEH"=`VAV5UP@T`32[JIY5<T+"GG'I)(FEA@8)#&..*U[89(V&1&,6VA
MF3>G,Y"25H+<:^E$BU*HCK:T3$Q-DB:Q-"QN+T\@5H7-,I)%0DE8-SWRU\AG
M.*LBEZ2:;+KHN$U_4)%:F.D8MRA)D@K9;>E[.]D"9CEC"[50=)9,60!,ZH6Y
M&.*ITRU(K4OR`0)144IW#^V.1LJ?J6*N-^=9.CN/BHMN"1$.,!98>EKJQHK,
MX-&=1QF,9&9K5@*EC!-1JUJ1W.6*-+VTPY'M*D,VC($TA)Q]=V"$5+Q0FM&0
M*PAW+`8/-9OS).JJMY#M9*(8PT1:RQYC%HEF-S7%K+O206]YN;C#4L/4RD]S
M#LX&P-NG(0H3/JO]JY;<P&.(S.4:`.PVIMNC=(5PH/84*\R8K+^I>&N''B8.
MTH;ZDIME=FR*<EG$B*N2EG9DS0G:WX[9ZAS-:=+U(J&W+1=H)G2)1@YNBLHA
M1D8VAGUD+)R]0^PO'Y+6L3[61VO([72U@5%/#@4088>"3LPT&E)HB"1[3E`/
MERP5P8:G1AHE\8W4,A!MFY/\YVIG!*%SXYO`8BW<W>0R.#A$Y2-2L>G!N##2
M4&D)YQQO=4/<1`&(&PBV3.],+"#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8'__7[^,!@,!@1_Y/T#0O)>EY55')B-))733@)L?Y
M6U+Y5)X6B"&).*:1M[@KD<0?XR]MZ=L7MQ9X]@6%%BT#JF:$#8@[)B9C<UC(
MNPN[%YR6QYM;^-K,N72V..DOC"5)R)Y(J#7^+LBB.)'>0-(2KK'W\TMRF7M8
M#CR^L``EY&M[_P!8'IBH3U9L7YRKL,^Q>A`&@R6<9T+$!^7.;8SB77YR=#IP
M7LT2DL[=$I'4N,?2:BB$.=%X^GHUHA$9OX=ZUK:H.K-BW%US7T0J:O8)5=?-
M'B"!5G#8O7T(8>_W-U\21"&,B&.1IH\:/:UR>7+Q:S-I)/?"M0H5'=3KFF#'
ML0MRY7(V.C8]($KJSN*%V:UQ6CT3DV*TZ]`L)WO8=')5B4PU.H*WL.]=8`MZ
MZ=8'NP&`P++CS!"*Q9FV+QQO;HLRKY"^'-C4DT86G42.7O3W,GT9(1"-%M6\
MO;@N6F].^C9A@]ZZ-=&L"],#PJW1M0*&M(N<4*)4]KC&ME3*U:=,H=W(IM<7
MHUN:R3C`&+UQ3.T*U8B2M#,"F2G&[UU"QB"'NP*&TR5A?5\G:VAT3+W"%OB>
M-2E(0(6S61^51J/3%.UK=""'05)L8EC<MUH.Q:[BK+WT].]ZT'I>GEKCC,[2
M%\6DMK*Q-B]Y=W%3O84Z!K:TIJUP6G["$0M$I4A`S!;UK>^J'?P8'J1+$KBC
M2."$\"E$O3$+$:DO>]EJ$JHH!Z<\O>]:WL!I0]"U_P"S>!Z<!@,!@,"AQJ2L
M,Q86N3QAT3/3`])@K&IU1B$)*N2B$(`3B1#"`6P;$#>OAUK^3`KF!9Q%AU^I
M-F!":<PY0?7I7=Y\21)F4TV#DZ(6JN[3`LM:(<:*[U;5!G66Z(UW,@P7\@!;
MT%/;[:JMV<(^TM5F5\YNDM2*%\5;6^9QQ:X29"D4K4:M;'T:9R,4/*1*L;%)
M1AB8)@`&)S`[WH18M:"IO\#B,I?H;)I$QI'AZKYQ<GF&*EPCSRH\].K4H8EC
MV@0".\7:>],JU0D)6#*$I3)U2@LD985!VC`N[`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`__]#OXP&`P&!27YB9I0RNL<D3
M8C>6%\;U34\-+B0!2A<6Y<2-.K1JB#-;`:2>29L(M;^K@15N#B>SV,ZU&"/K
M6.(PNL&-'&!0LN/]]-+M'">0W%6Z%C%WN2L2)`-+FP\=%3(H3FEG%'A>NN;H
M991A1Q-HVR3L[)0]LI[,5;$>&:`VU]1V3.L)<ULP@D>G/&N[..\5K.%/9,M3
M:9JOA6K23/Y+8$KHVY$+>H(&E)`D@MDF0\.[)=F^(-;=:L)93(S;!UE.\P3U
M<2=8<]5IIZS31@>Y-+CGX;LCE[<S(%C`J-;CDJ1<4X[4Z*(2)P,PQ:RXWV?#
MK'2V1F#8K5N%,E4R>KT\.CD>,@*+1;DAM]I`\$/D54)YDVE3)OL].8_HT#HB
M%M>TE*RU!QH$.V\6RP_<4IU((C$XXNL^-C<&>C)G4&WXFND;0;!9%)DPD[5;
MM0M4:=6)DB$T8DFPI#-`3@T>62G,2F-V@*$ZP6LE?P.-D#RF>9#*(:%$5*(R
M_HX,P0E8W0"&M;=:M)2^51*`,2N0K_$#'/855SNUNX`BT6M53!U,&5I&J.1&
M"V/X[P7MQM>K!2MMB1")HDZE616TW40)/,'LF.*ZCE<#:8.6Q.\I/C@*SCRF
M7)M*&-Q;ST2S4<3AV0:6<0-!";A=D8X"OK.V*D[W:*5_<#7DPQ*J*;).P[:H
M:)7?1I,`8W!HEZ=^CC&B;K::D)(VU6D-*(C:81?<Q%I>]5%^SQ+.`T[=(_MB
M<KCC?6&6NT!W:JW#'7EK83ZVD%;-]/-Q\9D#&S>Y]M\<$2,U&%O($NEJ4QR&
M66-04!%*+]F4)UPS-E<&B\,:YBV1S4(ONU+=A+@CBY0C8$UV;#[AAB-#!"Q*
M]D1F35N.W1/;&L)+VG)=VE-T$%@WUBA:E2;BY.T]5ZA;*.NWI2]\DJ@M-=$$
M497QZHHO#8?JMVF3QIGAR^7KS_$+X5!E3RM2A5#TH=GI68,A6(1FU(M8K)P*
MLMB=6!2BY`HTZ-NMZ)VLX'HJY(+DA)S!&.,\27,40E+G('E^BT?4QBCG9D3M
MW?*I%ME?R25X'$2`H0X3>_8_MYX%31\8XZR*;8C[82U5H*OG7<8@Y3)MZ?DR
M9:2HMH3FN6O\R12^SM*@D35.4\!\?H"$Z54L4DEG@5RBU6;^"LI;U+:<DL^+
M-B-,YE;(9&.`O#6S0H*1+2J'4_K!-Y^*38Q;CN542LU2Y'#5$%GR4X6@&;3K
M=OD)M2+ZXD6'<UY`7(3D[3$3+9BUI.]@OC4T"=2HDPTI[ME5)19U9[!/EJR(
MN$J"%_$@6LK<@*<USBJ">(T)(5HB:7Z'AU,6V?M\\CMG1]J4Q>PI;-F%$"%N
MA1,K2S"?.<G0LMK[03%'J5I:?A[P=&H7WMI%XL;.L6+>R3=)R91?LL&B>(=R
MT[)3G=/)88O4PN4U,VQZ3+&IW322S(9&N(7'KCS*"I0YI9<Y&I(&FD\4D$F3
MQLPD)BB1MK>H[X+"(Q2H%LHL_&>;./(:YK0>)$3"X^^W"EEL7=8>!0DLJ4Q'
M?%>F:F,BKK+0/RQ,W5ZCG\>=G;;.-M`(QX;TBT'4UL9BD7N63-N#4V?-O88Q
M=I+$!5/]/\=.=(.F?'.+0]K>YC8$.C[$[&.R=<P/D1L:SI&(AT;!(5!S*:VH
MC.DIN,+6B_921\"I^7%D$,9;\\UVPA,I7&/#7#EBF0))2?QTMKCZ0H:N^)82
MU%1Q,38*-Y,1F$"4'JD1@`J2-F%'$PF_9(-CXV.J*H8G7BV>*!+XV_220+$)
MJ`M;64G\XGAW7F126P%BW!27JNT*9V$%.PI3VMM+&`L.RAIB])]RBV.G/AM(
MUS9;C.DL=A;4EBLEPQ9E-'#'9>:P,-Y6Q.;GF`7HDF:M)$H4,\HEQ"%L*UWD
METU(SP'%B$O%I.+W+V@_&J31&=1F;E3I.V+/.VP)O8VHSJ7MI,T%-Y/9\I1U
M\='SY<?"E,1C;I96U!+@N:U;KWVC./3[2&N`Q)1:8.$&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!__T>_C`8#`8%MS%I>7
MZ)R1DCDB41%^=F1R;V>4)4B9>IC[DK2&D(W<A$KUM,I-0GCT9H`_@WL/\NOY
M<".CLR6]3D8L6T7>Y%UD)85QS4`;(=(8RT-S*;9$':'M\=IZN4L.VYU6AEND
MJ4@Y%L\`4Q9`]DF:&>8/">2RH7=?)>35E*)PFK:+O.HVK9'E"H41*TJZ?IO&
M4D6@4QET?@U3R9.\/;P_+A+WU@9W<Q[3H#7(E*J+2+2`F)SAL8<<[XY<RV61
MB"K*>ED3:SW+CU+Y%)(Y7%FLJA@.5\BN(CQ+H-J5B52"'RV,ETY;4D;)`I+4
M(%8%,.?QG("&XONFA4/V:>4O,AU:88+7'<:!U<VR%`E"EYJ:Z&QH;9PJJFOI
M'+(6)$6)PD#4QK+"?WUO3RL!#HT,I#)W$\#@I/)$9":C%DBV[PY7Q.3V`A@=
M1-,BC[=;:*$0-R55]9KJ6KC1''^#6&<^2!9%'-P7+FF46G*U[`4^M[7MK8-,
M)Y"DM<M/"63*(B,6!4=U<YZZU<S>DJA98*I*IY8V##7235U=*WSG41F;\D4-
M30Z/>*7]_:&-I`RUS"]-C0`+:*1M;\$U"8)8?I8NA.Q(6P;-Y.IHSRN8(^TA
M!,*TAT'?*=FD2H^?+VF2GKV$)TP2(FN3O#@584Q*?6=P,*9V`MP3-K<K;BQK
MG%><>G3RC9L5N)V=?4\6V=%'IF<*_1D1"YBF:>H:6L%N<8(\L$Q/BU22%K12
MU:\,ET*K'A1@I86V-!8#6,:,+6O":H5`ZHV([(>0?(N$H%:HZM))$HFU11@3
MKIQ/83R&M9MVN99'S(/DD@2,#^[Q2QP-TG(KB(J`]_D$*HRV/Y`G`Y:W!:U0
MX34*JV\GN:)T)CTN.HUO=3)6P2)RTWL]16H6?"]L-IT9%4SLY)//%S<9FEDD
M!LI^>D#:B)0+5`(V<808H)"HV2*B]Z_(#9W)N<7+3R2?Q)S@S`D<'0<K8HU7
M%K)(RX-JZ@$3\FDS]9,A&FC`FQ38SN>B1Q]4@2/#2K1@*5#,/"+IE&RI1\JF
MX^9E8L58H)+5-H2Q^FL.XQ/TH12B-V]9S42"1I4#?<SVMG13"VNM0VTZN3LI
M,5PM8WKH[%`1WOC:DDMU)*%"=DKJ=+WYM:=>/;TZU,\F)5\-I^SK,U#*EM-`
MTPY';$'LY+9L'E4(.E#\\SJ4T4YQ-&X>+$RYO=U1SLD3`0=^:3@7"HVLQV.]
M755EAWA,:\BECSA.<;1S9%T;RHM>P(0PI)H\R0=I22.UVWR``)(:S[;&THQ*
MS]R-9@*0FZ[BC[Z+.&S8H[9=/+5YLZKV%\B`8E&=6;3@K"6Q:CK7D<9'!)[Q
MWM!;+8RX3"5!8'$3DQW^T-A`W5K:D[?&T"IJ-=51W=G1O)E%0M75B7S#A.DB
MC3#?,FFB:YN3B*P8]*:YM&2UW[JP7'8<8H>01)M7I&LEP-96U;$5!*>$*^NO
MB/C9<H3KE:=/O!L99HCD%?-AS^-PNP:\CT0UJF8M<\_&C8IDG<XH&3-PXFW5
MLL9)`L1/[-,7JQ8S('M(:L0__+20I#M*-=HY;H3$([EVARF=G6LG*%G<B=0*
M27`[#);;%HA\8K"2P8B7\;(PG+G!)M3M"!E"_-JZ<OR4A[W'VU&S/X.ZKTSA
M&QM:2$[$@;.NWE7%)!8C9%J=0OC!"9)'6QOEI$&G,C!)V"PW:,+F"21R-Q^0
MA=I$&LF,EZ9Y0E1C&<<YJ$#F7WBA)4I#91$1BLXV_>:"=B0NY]01T]W<7QPC
M*>&,E47$YN7C+=9PAW9WD,C>'R*QM)!M6/)5J5P<W@;(:0V-H])DJQ;H\E/"
M:C%>U?\`(2^99;,4:'2K'9HJF0RQYC8G-92=SQV5$)4_'ZH;";Y*\KIAXBC<
M-B::T'B7,*A8O`-8K5(VY`B0&BTO<2I14;6%6"R^0T-;0OD;C]YR5_-W:[=8
MS38]87!)X@V2AUY#Q>,4](&1K7-[=+%D>;ZZ6/"I:"#&+&Q*PI!+E*,Y5IN*
M6PG8SWQIO*\;J>I`R6'!V>M`Q6!0UVE/>#<[@?6Z9VW!H)/(Y#TX'Y8N2L4G
MJ1*N>VZ3-[FC,5JE!C2M"0A3'[3*)1+%Z:><LFMEX='.<4MAR8PN#$??<A;8
MO&%\F>!.#7.D+HCGL5."URV-,T53-B-S/$TLYASJL6IB2!$F)^\W*$[-K9$B
M5E+T:1>0!260M3$*R0+42QM6`*4E`.+`K;G$A*X(%(0#UHP@\HLXH?2$80BU
MO6I<O3@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,#_TN_C`8#`8#`LRQOR>SS^IDH_H1=A,;X5J.?_`"\Q?\F:_P#82,(5G`8#
M`8#`8$'.?'Y+ZV_/]6'_`.J\9$NLN]./)<F`P&`P&`P,,UM^4'D+^<R+_J2J
MG"<&9L(,!@,!@8:I?_X&QOSRV;^,)N!F7`8#`8#`8#`8#`8#`8#`8#`8#`8#
;`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g893535g19j35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g893535g19j35.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0JH4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!U````!@``````````````RP```C\````*`#<`.``P
M`#$`,0`U`"T`:@!P`&<````!``````````````````````````$`````````
M`````C\```#+`````````````````````````````````````````````#A"
M24T$$0```````0$`.$))3004```````$`````CA"24T$#``````(!`````$`
M``!P````*````5```#2````'Z``8``'_V/_@`!!*1DE&``$"`0!(`$@``/_N
M``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43
M$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-
M$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#/_``!$(`"@`<`,!(@`"$0$#$0'_W0`$``?_Q`$_```!
M!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$`
M`@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@`,`P$``A$#$0`_`'9_BTR7L8_]H@;VAT?9G_G#=_I5;J_Q?%E;6O=C7.:U
MH]1U&2TD@^Y]HJS&,>ZS^3Z:[\"T]/K]&39L9M@AI_-_.>U[?^@@;.HMDAUS
MH&@W422/^L[?<DI\_M^HCL:T6/<V]CP9JKPLBUC8>U_^!RFWUN>T^E_.?S/J
M*+_J6U[7UM9Z;W-VMM;@9<M/M9ZC-V6^KU/SO>S]]Z[;/MZRR_;C"]S=C-Q:
MUCO='OET-;N_J>Q4GY'UG_-;D_YE:2GDL?ZCO99+W67"P`;+<"_:V?SM]636
MZI^[^4FN^I+GV%S76TM8XEU5?3\APC3V[K<FU[V^S]__``O[BZ=^1];OS6Y7
M^96@/R?KK^:W+_[;J24X^!]1';75O++H(?ORL+(K=^YZ3+*LJKV_G.K2=_BV
MO+BX9K&`B`P8]D`G\X;[G.6B_)^OGYK,S_MNG^Y:'U;N^N5G4XZFVP8`;^F.
M2UC3/^!^S>A[W6^I_.;_`-#Z/_">DDIPZO\`%X]E0K?9C7.`(]5^/D!^O=WI
M9=;'[/S?8@O_`,6N0YSW#/8S>[<&MQK(:))V,W7.=LU7J*J=2=E,I:[%;8^P
M/$MI%9<6_G?TJRFO;_;]1)3P%'^+UU5898_&R"#)LLQ\@.()#MI]#+J;^;Z?
MT?H*N/\`%GD@.!Z@TEW!^S/TUW>W]+_97?U?M5]PK>^QC`#-AKJ@N(;8SZ-U
MCO39[Z+6^E^DL_F[:T6RGJ#:'SDFRW80PUUL!W?O-;8[T]W\FQ_II*>#J_Q>
MNKJ%;WXUSA/Z5^/DAYG][T<RJOV_U$/+_P`7ECZ][+Z<8U-<YWI8]WOAH^EZ
MV3;M^A^9_I%VMEG6@):W(DD#:*\8Q_*]V2WVIA=U0O>V]F0*'UV.][*`UHV.
M]EME&199NW_S>RK_`,FDI__0]-H:]V%4&.V.-;(=$QH/S2JILS&N(^T>H&@0
MYK:@''R#K6N2Q\C/&/2!0"/39_U(_E)MEO\`W!J\?H!)35R^LNQ+!796Q]AK
M8]Y>X-=)'=M?J5_F_F/51_UJV\8])_ZY_P"8+4?D]3J@48`M!T(#FL#8`VCW
MGZ.W]U(YO6!N_P`FS!.V+&:CQ]SF[?ZJ2G#=]<BS_M+3_P!NG_R"!9]>W`1]
MDH_[=/\`Z371#-ZSK/38$F(M8?\`OS?I)?;>M:[NF:'B+:S_`)\N;M_Z:*GE
M[/\`&(]H,86/\[B/_1:Z_IV4SJ'3L?.]!^/Z[6O]&T0YLGO_`-\_D(/VWK,D
M?L[2-";&<^!&Y,[-ZT1_R=!F1-K.Q$<%WTD%.EZ5?[H5;J%PQ*FVL94XEP:1
M;9Z0@R3M?LL]_M]C';/^-K069O5W.A^`:VZ^\O8[_HL?N]R)]HZA/\P/]?[2
M2FG^VJG,'IMQ7W$EHI^U,DGAH8\,<QSGNV-V_P`M7LI[J<-V0*F&ZMF[TWOV
M,F-6NOV/V-_X3TE'[1U#_0#_`%_M)CD9\B:!H=/N_K)*:+NN0-PIQ2W@..4U
MHF?H^^L?O)QU49#[,8LQAN99#J\EECBT,<[=72UC7O\`^$_<_EJ]]IZA_H!_
MK_:0\C(SSCVS0(]-_P#U)_E)*?_1]&%U+^GUULNK#S6R)?MX#?SJW;T#TF@G
M;D@B/;.59SYZKYK224_0O4V=1?:!A7PQM;&DC*V^X#W?2=O?_P`8]93<+ZU.
MRZ7,SO0:'@FRS*]5C0-7;\;?^G_XK\__`$E7\XO#TD5/U(,O%C^>K_SA_>D[
M+Q=I_35_YP_O7RVD@I^I?M>+_IJ_\X?WJ+\K%('Z:OD?G-\?BOEQ))3]2_:\
M7_35_P"</[U2ZJ_'R,=M3?3O)>/:=CPT0?TKF/OQ?:S_`(.SU5\SI)*?HAE3
MR6N+:V.:YMNX,VP6V-L=7IU+?NL]-KO]'_IF6?S*L#)R\EEU%UWIAU0]-X#<
M=PL.OMR6WYGYO[F/[%\WI)*?HQ]>88(RX)^D!F"!YM_4T@,BM[G6Y&^HLL+@
M<H/`):?9Z1QZ=[=W_"_HU\YI)*?_V3A"24T$(0``````50````$!````#P!!
M`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<````!,`00!D`&\`8@!E`"``
M4`!H`&\`=`!O`',`:`!O`'``(``V`"X`,`````$`.$))300&```````'``@`
M`0`!`0#_[@`.061O8F4`9$`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#
M`0$!`0$!`0$!`0$"`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"`#+`C\#`1$``A$!`Q$!_]T`!`!(
M_\0`T@`!``("`@,!`0````````````4&!P@$"0$#"@(+`0$!`0$!````````
M`````````0(#!!````8!`@`%"0\*#PH*"04``@,$!08'`0`($1(3%PDA,=,4
MU!65UE=!49*35)15%E8W&"AI&JIA<;$B,B5VMK=X\(&1P4(C9$5E=3:6&3FY
M4G)SLR1T-2:7"H*R,T-CA,1&=SBAT<)3M68G9[AB--5'AQ$``@$$`0,#`P0#
M`0$```````$1(5$"$C%!81-QH5*!(@/PL3)"D<'AT7+_V@`,`P$``A$#$0`_
M`/FLU@]`T`T`T`T`T!:9)!IM#2VHZ7P^4Q4I]3"6LALDC[LQEO*,`21#5M0W
M1(E"X)@A4EYR83D8,8,#U?ML<(%6T`T`T`T!<H7`I-8"F0)(NC)6GQ>&RF>O
M(3EB5'A/&88TG/4@6%B5&E!4')6].(820<8TW..*`.<YX-5)O@C:424W4*6F
M/P::RQ&\N,6A\IDK?'4V5L@7Q^/NSRC8D>"CS\JWE4W)%)#8FP0E-'RAX@`X
MA8L\/`'/`!5M`-`7J7U=9E>C/*GU=SJ#F)E#0D4ER^(R"-#3JI!&FV:,*8\#
MTWHA%*'N'/2-V1@%P"4MBLE47@1!H!B`K*)B>W)O>79N9W5>U1U.D5R!S1-Z
MM4WL25P7IVI`I>5I!)B9L3K7164F)&>(`3%!H"PYR,6,9`B]`69]A4QB[;%7
MJ31*31UGG3,=(X2[/K"Z-#;,8\G=7!B/?HJO<$J=+(68A\:52,:I(,X@*M,:
M3D6#"QAP!6=`6F;0R05[*GF&2E*4BD#"H+2N:4E4G6E$G&IR50`@5)##4YV,
MDJ`YX0BSCJ\'7U6H</DB::E<%6U"EFBT+F,Y7FM4)B<FF+H0F&M/;8LPND@7
MDHRS"RAJS4;2E5J"TP#3@!R9D.`8$+&.'ASC0'[40::I(D3/U4/E*:"*92XP
M9/-5$?=B8D?-6=L;GIWAY,D,2!9S92UL[ND5J6\)V59"942:,L(#`"$!5M`-
M`<E,B6+`JA)$BE4%$F&M6B3$&GA2(RS"B1JU62@"PG3`-/`')@^`&!##CAX<
MXT!QM`-`6D^&2!/"6NPS4I08L\2I]AB!;A4G$<;((VTQQ\=DHD6#,JRBB&Z5
M(AA-$#!8\F9"'.<@%C%BDDE3'4JVH4_999AQA9))8S331A+**+"(9AA@Q8"`
MLL`<9$,8Q9QC&,8SG.<Z`R0&EKC'(AQ`%368*6%QQZF!D7#!)2*1%Q*.-R]X
MD,I&RX:LN08XPM#4J5+5V2NUDJ9,:::,("QBP$F--`-`?LLLPXPLDDL9IIHP
MEE%%A$,PPP8L!`66`.,B&,8LXQC&,9SG.=`?H\@Y,<<F4DFIU"<TP@\@\L91
MQ!Q0\EFDG%&8",LTL8<A$$6,9QG'!G0'JT!:8C#)!.%KJW1Q*4K5,T5EDS<`
M&JDZ0)4?A,><)1(501J3"P&FI&9K.,"4'.3#1!P`&,BSC&JE)&TN2K:A1H"T
MA@TV'%C)R"'RD<))4X1'3$,?=A18I9D\M+A(9(<),M(%.5)H2^3R=@?*"P'@
MX<XQH#\2^%S&OGY1%9[$Y-").D1,SBJCDO872-/R9OD;*WR2/+U#.\I43@2B
M?8Z[I%Z(T1>`*D2HH\K(BC`"R!6=`-`<@U(J)(3*3DR@I,M":)&H-),+(5A(
M-R2>),:(."SPDG!R`60YSQ18X,]70''T`T!:9I#)!7\C6Q24)2D3VWIVI4J3
M$JDZPL!+TT('UO%A0E,-('DUM<B1YQ@6<@R+(<\`L9QJM0X9$TU**MJ%&@&@
M+"YQ&5LJ!C=7F,2%I;),G[;C;DYLKD@02%+C(,94L:Q4F*3NR?&3`XXY`C`\
M(L=7JZ`KV@/(@B`(0!A$`8!9"((L9"((@YX!!$'/!D(@YQP9QGK:`\:`:`:`
MM,'AD@L681J"11*4NDDM>4#`QHSE2=$4I<W(\"9(28K5F%)DP!FCQC(S!!"'
MKYSJI2X1&TDV^"K:A1H!H"?=8G*6%N97A\C4@9FF2)A+8ZZ.K,XMS<_(P\7C
M*V5:L3$IG1,'CXX3"!&`QPXZO5T!`:`:`:`LP(7,38<JL0J)R8ROT,F00M;.
M@,+H.'(YBZM;B^-D352<*7+(GDSBR,ZM80@&?A4<E2G&@!DLH8@@1K@QO;0F
M9UCLSNC8CD+<)X8%;@WJT29\:0."YI$Z,YZDDHIS;@NC8I39/)R,K"A.:7QN
M.6+&`(O0#0#0'__0^:S6#T#0#0#0#0#0'U&7=TB.U6^=ZU9[?9T2TR_9T+</
M3UI6M;-JV@]6=7BU-%-O2J`GM5901PBC0UTS"@*Y,H"\)DHG-4YNR,"@:D(,
M!)!>IA)K'N:=U79?1_SRB'J:V;$-L-:2!V1;L5-[5(VP:P4EJJ)&\UZB1;-D
MFT%[[3F*")1V+S=,4-WRI=T^<F!6FO&%R901@(L.3L4C-&;&(725(W38-/T3
M%]NJFS>C*1129V#3]KQJSWB-3.)2&3;IAW-);)BR&&6.DE;^PJ7)(;&#W-*"
M.Y*%G);>I;<&B.9:7<TG@$LZ-Z:[8MS#Q9J';=&[.G4#W5FU77<4C:J".%/3
MZN(*W%[9D$.=54$G5CSY59#DR`5Y5GSAB8\'F*D[BF<UJP(<"UE&<RK<Z*A-
M-8*Q#JG9HXQ!/N2VG5K()$JB<F+7G[<K/VE-KMNKG;D>W/J!$8_0J^D&$*)W
MPEPH85!AN$8,#-&<)0GW'2GMH):TU@[D4[&;R[*1MGW3DLY_'R;RS65`'X#>
M;RHL!$9RB0(,\;.,9SP\.M8<Y>C&?&/_`-(TTU@V=TG1V;XZ^V9;5+X>G$^3
MOUJYW/[7Y[7]:0NXWVF'64HH$PV^I=G"4.[#&9&KE=9-[DN0IGIAX407,*TH
M(E``@R$=,M-M6,JU#='1WS)!LN37_"=O,<D,X;MV]I;AK"10)]5N$4O159FX
MD6VV'V8A8R7DH=,E()NT+3&TIH7X4EM[,6O&-L1&I]!6IQK&<^CZ[9W=XI`&
MTIDMX#52A4-7V\EF$KHZ21-'3TL2;A7#;DCC<&2QN)VU(;*"S*DJ1Q1$)41I
MJDMB."2``L!6DFU4OO[H];.N&*.=H3*G[`B1^XRF'"5II5AT6L;C6T3Z)2"U
MDLRZ%$%ICL,[9N!CP6K)A(BE)3LF#DL8>($S%H9^[I^JFJ;[:'1^OM2SE[7M
M]50=\MO9YL@46E7U,H'*-`!<4?WUD&7VRP.."/6HF&6%[<8TB7JB"1]KBR/*
MC'"<:/AAJL_4S[6#AT9Z3<Q:+_:\LV'.FWX<DJMAJ.!5O!I''T*S;O*++L)(
M_2&=2RR*4GLZ27-`H.:UC>FYN3-LD=35*7DY*UITBI0%0CF.LG5_T@]@TU+(
M;LOAU,2UIDS-4-(V?`W%(V*U:XV-A'NGO:219K<5*T`3SE*N#OC:M`,0AB&2
MI`(6>-G.-&7&:R=:FH:-E-X/_F4M?^/47_P%IUO/^61C\?\`#$UKU@V=I_1G
M;D:SVU1_>Y(K"?)6WKY3MJ9HW`V&OK3<Z6L28RDJ]:G>Q,<+LMHCDJ7QAQ(9
M6M4L4&%HQC.0)CR0B+R9@P%1G)-Q!V%5?OMVN;DX281NSC5"-J3<#O\`]T]F
M6A#)61(7!?5=>2C9C6\2@DWBS\D6-ZA!(WBR(B0G'(!%&.*IV2F'<!.#S\&"
M--<6*Q$E/1;->W?;LBD6=N=MVQ#Y)M&F3L!Z<U].J9:W/#7(_A#UE8PX=31#
MPW-T7=TJ%&H<Y)(9D-W6YRM*2,K2+`%05EERABCH>FZ3;G\R*8T_8RQ39K8L
M2(W^!H:O9GVC#:(9D2B$T>]Q&LE<*B\]A]OKG4"Q_8&]C5OZEN0+4H<H#U1!
MJ@^ZAU?;&=PR*M*7Z0>HYC8B>+0VWMF\P01.)K1`)23:ZB+2I?VJI$XB4HU*
MQ^2PPE^RD`:9@DH@2K(>*(P7&&FJI]SK<U"C0&RCQ_Y/JZ_.4NC\E]":U_5>
MK_T8_N_1?[-:]9-F4J->6N.W73\@?%I+:RL5I5^\N[BISD*=`UMDL:%K@M/$
M'`A8)2I"!F"SC&<\4.=`^&?1E)^E1IV=;V;.:C0H1T36KITG\HA=B7':DGN)
M+;4@O.IY9#8?&(DH-8X>LK.C)LHC[>%EAK8+DT877BB7&'![9S9,:N$0U#/'
M1+.-J()]:JO;2W1:RZRV0IK4IP4>,CL0B$PF53O!6YB0P>1+:YM5_C`8I8)B
M9*JCT;.CJ\M6(I9E_0)"5)AB@>QBVOS^BE+8-D0K0?:BB14:D,S8[1BL?CZ^
MSBY>K,KBQ7:O[JNJ=-]?(K.9V=%:BN/-C["5(WMI.!@1R`'>M,H$I4+]U36F
MQ!TBKZ1BMS=JNX>M]H,;3Q"-))GN6A$F=FN!Q678A[NR6=.:]*AL8BQL:=I3
M'SA%IF9H(1(`O2HP"=2D3&8-(!3%481Z4ZRH[:V\&4RB(3R+6G%D4&JV&1ZS
M6*2GS*2V&TU]`V2$))Q;<K/9V/#Y<4L+8.WWXPLD9)*A0$@!QX2L'#%7!UU:
MA393:[_+"ROS:]SGY#)UK6/+]'^QC/A>J_<UKUDV-`=YD>Z0V$T3T:^WVCH4
M0YS^U9/6>]FJI]',VN]-%;5XP77,SFY(\6+2B6-'-%G2Q5''0:Z,JEKJ0F9S
MR1&Y3*!B!DJ]#,?<WT-G[GN+H\]R=J%GV!+MOD26Q"X]@C4PWB1"GB52.95@
MEV9IF"]4-A-J\]Q8IC'HG9<298^#MAO`C93"@G")/+RLRH4(MD<*5N?10/,N
MLM4Q"VYUV@G&RNN\N$^2'(K04U3N*:)%N'23='!JC541`:^L!XF;!&H>D=E$
M;9H<H;%*I(N8LB(5KE6@J:F;RUO1QCV55HGVU\WSM9QB>@^]QC:4XQV[X<](
M:U<R]PB*X4[A#$69XADU@*<'@5=]E*1`I)2`9?O>)446*IGL<+=%?<2DG1BT
M)0DHW'1ZW;>AUNPV71ECBUAW-<!B6M4=4R6*#;)1BXH>P-FWL-;84-S.CC<1
M6Y;7D8C52A&?A*D7E@E5N#IAU#0T!LINZ]_Z7?Q%6?Y+(5K>?\G^NAC#^*_7
M4UKU@V-`<YKSQ7-N%D](FP%<DSVRO2E+D*?@4%YY=:B/(5$*TA7W1A0RC`&`
MQD.0BQG@R!]6I>]_;CC=UM=NJTMP-/R&U7UGW40JVDD>GM]7MLWKI!8^WT46
MK6S(2R7-!&QXV_O%AV.2G9GV.L!#DWH(L4(*C"$H6$P:8APS7.*S[HYZYVRM
M$T>W;;1-MS,.E-"74PJ8K!TK#AGF2?=FT)KIK%IKYIJ=`[R^'QBG%BQ42>_2
MY<A<T7:PVAD2Y1F'Z"L]C,&9[T;MS[O;6GEUV'LT`V(>DP.NERDIL&DA4>N/
M:'8-7/(6!B3*$=?+/;),2IXZHCYHE<0(R2Y!VXO..&6')XU!#BECJCW;G;45
M^S[9RHJ!=5L9NYKCC:R6_7,`;TLM>7]3[2F9R=[<FUJJ(?%Y8R2-XE*PQ"LA
MSFI=TK<N+.$T'A;B@"/&E,LZQ-0HT!LILX_\U6WS_P`6(7_\93:UA_+'U,?D
M_AEZ&M>LFQH"\U@\Q6.657DAG3%[:80PSF)/,RC/``7MCBK6_MZZ0L7%,$`L
M7?=H(.3\`LXQGE.KG&-`?1+8V\^EV1SW!2V\MTT+WVU#>NZF@K.V_P"WQ:V6
M#*T=2U5$;K#+YZIED%L6&-D:I;*6@LJ(("/,8U`U1B\`BP"2MY)N:82=$E%"
M3E+[T/4&=ZF;8.*B9YAKW/[2=O<]=7.'"4MKI2;+9L:OW<)N168=T"A.-A<$
M[JLKDU4'E%:UC2C+Y,!``9$H/N*A"9AT4LVF=<2F;-FW.JIF97&[6&L:)DAK
MRJIAMF$;O]@0[<GRSXBZ-T]9%CP]4*L><('9Z2JT*Q4%.H=!"/*),PH/NJ8N
MD]D='*Q-2YG@%+[89.5->DE7C<VZ;R2:%+8QM5:H;MRF)S7$+6:6=.\Q*L)G
M9T9D32F7GL[@H;69<N3ED@">><8+7K8VG;+WZ.2(.;_4@Y'MTM*B+7Z07:Q)
M)K#I/7B:-16LJA<-M%DQ2X)!$2:X1P6..#G5K^]@:`RU"A))4JUQBM.ER;DI
M0`2OU@QY1$<VDV=3B@3'\&J2/]"='>YJ54BOYKE<AKJM+3'TA:HJ*N4Z]K36
MY2!.H6U]+48,93ISD1I#D$*XL:(U6`05FMSI<WS+MOCENLM];M93LZ:CCW1@
MS%"XVED""*&.X(='"[`5PQOE1*>0M\(76.!W/94ZLLLTAJ,3E\4.`XQ@:4Q4
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M?M2/M+J_VDX-C$EX.#M9F0*XL<E;$_!^P(``/U-/&[CSX_%E>^;Q[FO+91/I
MM@>)NGC=T//C9CYO'N:\ME$^FV!XFZ>-W0\^-F2S1T`6[>/F+C6'<-3[(:Z-
M+DP.9K0[68VF.+$])1HGAE7#11,D2MI=D9@B5*8S(B3RA9`,(@YSC3QY7'GP
M?.+(GYO'N:\ME$^FV!XFZ>-W0\^-F/F\>YKRV43Z;8'B;IXW=#SXV8^;Q[FO
M+91/IM@>)NGC=T//C9CYO'N:\ME$^FV!XFZ>-W0\^-F/F\>YKRV43Z;8'B;I
MXW=#SXV8^;Q[FO+91/IM@>)NGC=T//C9CYO'N:\ME$^FV!XFZ>-W0\^-F/F\
M>YKRV43Z;8'B;IXW=#SXV8^;Q[FO+91/IM@>)NGC=T//C9DF\?[O[NSD+DK>
MG_<%3;X\+S`FKG9X<[*<W)::$L!03%:Y;$CU2DP)180XR,8LX"'&.MC&GCR?
M+'GP7&+(SYO'N:\ME$^FV!XFZ>-W0\^-F/F\>YKRV43Z;8'B;IXW=#SXV8^;
MQ[FO+91/IM@>)NGC=T//C9CYO'N:\ME$^FV!XFZ>-W0\^-F/F\>YKRV43Z;8
M'B;IXW=#SXV8^;Q[FO+91/IM@>)NGC=T//C9CYO'N:\ME$^FV!XFZ>-W0\^-
MF/F\>YKRV43Z;8'B;IXW=#SXV9)C_P!W]W9F,Z:/&;@J;,CZ-R6O21C&YV4)
MG2O#DE0(7%V3-@HEE$0Y+T34E)./"#!II28H`A9"6#&'CRN//ASJY(SYO'N:
M\ME$^FV!XFZ>-W0\^-F/F\>YKRV43Z;8'B;IXW=#SXV8^;Q[FO+91/IM@>)N
MGC=T//C9CYO'N:\ME$^FV!XFZ>-W0\^-F/F\>YKRV43Z;8'B;IXW=#SXV8^;
MQ[FO+91/IM@>)NGC=T//C9CYO'N:\ME$^FV!XFZ>-W0\^-F/F\>YKRV43Z;8
M'B;IXW=#SXV9)M?^[^[LV,Y2H9=P5-LZA:VN;*L/:W.RF\Y6SO:$]K>6E2:D
MB1(SVUW;%1J=40+.2E!!@BS`B`+.,O'E<>?!_P!61GS>/<UY;*)]-L#Q-T\;
MNAY\;,?-X]S7ELHGTVP/$W3QNZ'GQLQ\WCW->6RB?3;`\3=/&[H>?&S'S>/<
MUY;*)]-L#Q-T\;NAY\;,?-X]S7ELHGTVP/$W3QNZ'GQLQ\WCW->6RB?3;`\3
M=/&[H>?&S'S>/<UY;*)]-L#Q-T\;NAY\;,?-X]S7ELHGTVP/$W3QNZ'GQLQ\
MWCW->6RB?3;`\3=/&[H>?&S)-W_W?W=G('`YV?MP5-O;JH+3%'N3NYV4Y.!Y
M2)*0A1EG+%L2.4&%I$*8LDK`A9P646$`>`(<8P\>3ZCSX+C%D9\WCW->6RB?
M3;`\3=/&[H>?&S'S>/<UY;*)]-L#Q-T\;NAY\;,?-X]S7ELHGTVP/$W3QNZ'
MGQLQ\WCW->6RB?3;`\3=/&[H>?&S'S>/<UY;*)]-L#Q-T\;NAY\;,?-X]S7E
MLHGTVP/$W3QNZ'GQLQ\WCW->6RB?3;`\3=/&[H>?&S'S>/<UY;*)]-L#Q-T\
M;NAY\;,?-X]S7ELHGTVP/$W3QNZ'GQLR39O]W]W9QUU;WZ/[@J;8GQH5DKVI
MY9G.RFMU;%R8>#$ZUO<442(6(E:<P.!`,+&$8!8X<9QG3QY7'GP='BX(SYO'
MN:\ME$^FV!XFZ>-W0\^-F/F\>YKRV43Z;8'B;IXW=#SXV8^;Q[FO+91/IM@>
M)NGC=T//C9CYO'N:\ME$^FV!XFZ>-W0\^-F/F\>YKRV43Z;8'B;IXW=#SXV8
M^;Q[FO+91/IM@>)NGC=T//C9CYO'N:\ME$^FV!XFZ>-W0\^-F/F\>YKRV43Z
M;8'B;IXW=#SXV9)H?]W]W9M:9U1-FX*G&Y&^H@-SVD0N=E)$SPWEJTZ\M`ZD
M)XD64X(@+DA1V"CL#!@TH`\8XP<9P\;N//C9D9\WCW->6RB?3;`\3=/&[H>?
M&S'S>/<UY;*)]-L#Q-T\;NAY\;,Q_9?03[AZPCC;)7>WZ8<$KG8%35X40W&3
MC*@MSMZU(;4[(N,[9B9!?:#8\S5.I5<`LF=JE&<F$8^*`1X-=2K\V+Z,_]+O
M^V2?^3':+^;#0?Y*HGKMC_%>APS_`)Y>K-GM4R-`-`-`-`-`-`-`-`-`-`:T
M[N[L?=OM#RBR8NW,CA)2GF"Q%@.E9BQ/#&-XL2=1R!-\GFRI`,I8GB<:4R,*
MU;@LPH9Q9/(A-*$9@P$;A2:PQVR2-'G?=#;\3F[%5#E<JN23N.;O-M-?68H4
MT`V52S&5I;I5G84(XT<]R*=ER"+2D4"-/2.J8:9<F))QD*D>#>$.9<Q/4WJF
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M5224N5AP-S;HNY796A-J52YJ4[>IY9:@<8RJ)$]"!D!;,(T.`F+,A-P6V[!_
MCI1F2=MN^J-[@E=L-Q\*608^KX3&;*+>W)U<?:-+8%+2),8UR5AELHB<'"J:
M238HJ"<Y)TJIB,+X#D;@K*P8(%64R3+#6*F'HWTGK;)V22F-5'2E?+66R]O%
M>LC"0^JV9DG"?<XX/C164FBDHG\,@IJUH4.L?/+.5";P-1I.0*$:Y6G'@S4W
M[&O'WI#]BLVQTD,D<*(EBBI:ID31=F*0W83=[(6R2$&H:1/VXNRZMW^6]OOJ
M93'[,[U6`<0I1-R9,,2]"0,1I(<Y"G-/*E%4+\:E2Z2O<S_/;IN!;\#>J8%*
MXM#)QN1A[_)I%:LMBA<J3M)$`KN-2MZ:X[#DKQ%6I?,)>X2((TX##PI4B!(M
M-"09DL`<67]JZLB2^]M411:7WNV'+W]JI%5737:EVM4]NZ+2N2PUW1UW6J^!
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M+[6*$^6M2:"S:J4K9MR9[:CK?.XMD+N:N/G4E1N*),IRJ)"FRJ1X%RF30`TV
MY;5"^/A)UC_9DHKI%G)$N5AE.W25,+-$S=KY-I.Q$\B[HK@)^ZEO8A0]$&.F
M)&U\D[C'7]_+1.92,K&`@+&<2,W(>2TV[$\=LK^Q5A]*W!S6.RY4TU!-'J+P
MUI>'R+NJ)PP'$M0QVWH_43FB=A'L93;"Y`Y*W[#JTHS5:S"UN)'@\U&JP-.6
MW5:%\;I4YLOW_6I5%DW4GM^AV^+5K4="TO9*U&U3AK?IZDG%OOSC$FJ+N2Q$
M,Z,.3>KG10&8)R3!9;>%*<X&G*2%!))#9J95`L$TH=6PZ=)FI(8V-2P[=I3(
MY$K2;D%KZT8F:".,Z!!MKC]<3.1OD=D,KCC*=+HW)HC8I)K:I+0ICLKR,I#2
M`?MQR=OV'CY^ZWN3T^Z09`%%;K1'8@]0L]BVBR'<?6\NF:@EI<Y\$--BM)+B
MLXVOC[G%IN7#R51:=X^^V342].:`Q$8E!E0)MSZ$6'%>L%LAV_)OD$HB+*.M
MWPR&O-JP+;TYV'A^9\.":ZIQ43-;*-"5`2TA;FJAA#<\%I%+N$XKDU?&&6D&
MD+,4EW;M0/")K6))':7ODQN>?&1B<*>?ZO-F%(M%]0A4X2V/2M*_0Q7+ET%=
M0*\,Y:50R."&1H\93EFEB$J1&A-'A.;@:<)93T&6&O6:P;\:T<QH!H!H!H!H
M!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H
M!H#6'=U[U43_`#GMDG_YG4'J/CZK]S6/+]'^S/_3^E[8C1T\=MC^S5U1D-F4
MCGM3V\."7)CD6`S*9;4404D9&#(,Y`/)1F.''F9UM9*$<\L&\LGW-J_@_6)Z
MG:?"A?8]7=&=,A\'ZQ/4[3X4+['INAID/@_6)ZG:?"A?8]-T-,A\'ZQ/4[3X
M4+['INAID/@_6)ZG:?"A?8]-T-,A\'ZQ/4[3X4+['INAID/@_6)ZG:?"A?8]
M-T-,A\'ZQ/4[3X4+['INAID/@_6)ZG:?"A?8]-T-,A\'ZQ/4[3X4+['INAID
M0KY3LTCQ"!0Y$MP2W%Z9F!-DE>`W.7!^<4[6WA'C`,<0H2M2'`Q=8(>'.JLD
MQHS\2C:M()M'GB)3&+Q"51:0H#VM]CLA$WO#(\-RH/$4(7)L7ICT:U*<'[H!
M@!!SJ;(JPR55R8*B?1>5-!2BR8A1=7L`"I3$IH'*#(0&9DT#"]@A;F8<,8SC
MLQ8N2+P(2AB$0F`K,"`&,"SC4G&Q6OR/EG%;^BNIAK9)'&V_;[4:5BES`AB\
MC:RDR;M1TC[4^9DK*UG%BP+DTS`_<54W<GQ!-YA9?:V2L%EX"G"PC\ESFYZ,
M"IO:['(F&AJF+C\.D[A,XDW$)DA`8S)7?*?+PZ,"@D!:MH$\81E85E$&%DJ@
ME`":`>`XQA.-A'Y.9)7/1MUUEYL:1!I*JBGVW&"21>QW=.C;TR^5L$R($1+V
MUP4IR2S"R94`7&<LDY*&N,P$PX0QA"+"<:T$9T4\'+.Z.R&J3CU"FIJ_4F*I
M+!Y@J[94=L%J9+6T43P>#.R@@X0R3SXW$4I;>1@8<E]KAXHPBZN=-L;",[GJ
M@'1R02K29`GKZG:UBR>61A#"I.F;L)^UY!$VOOJ!NC[P0H">2X-:%.]*4Y11
MN!!`E'@C'`2666%MBN@:S?+(>-=&+5T."$,7I*M6/@>ZTDF1(#A%&&OU-KE[
MC5KJH-Y7)JE9!E+F=WO&9D7(E9"5U2BRP!3C8-?D?+/,BZ,2J9<TM['*:'J6
M1-;4]3>1-B5Z1H7+"!YLA>I=ITN2FJRS3R#),[*A*U(0CP#*H!9P0A,)*$!.
M-A'Y%PRPR'9%&+LKF-1>7UK!9=`FTEM4Q9G?^0-[PY:DHFYM5,QP@]\&9<D0
MX$0$Y.<6=R(A`R+(1"QFMX\-$2S54ZG"7]&]7CDT5NPJJ1J?#33ZL:ZKT:5`
MV-^(*I.5D+UHHX:@3IE#<6[+TI9ZXL`^37G`P-0$T>.'4G&E"Q^2KGD@1=%Q
M4&72:/0*$J=.[6(VS)FFZ]&2G1*)(TV">@53-M<AH\$<HAD*QM+//*QQ0=L"
M,-#@)AQPC$XV$?DI4Y2CHQ:L521=,#J.J_,G<LR42Q[!@LI<:.9PQ77LO'@T
MG(,%&2F&K3$+B(&`B6E\41V1F%EC"G&PC\D1-#)+ALG"ZQJ$0YPA,35QBMW:
M$OL%937#.4<9=ZW/1JH,O;0XS@8#XRH;R1ILBR+`<EXX<9U=L;$USEOJS"UR
M=%^@N="H87="WL,3EML12V[DCS&<QY#=#O"$C45'6F6N;JVN+BVM0%4;:NVA
M-8T:I2D1=K<L`LTS.8WBRI9KU@XY?191I=N&G.Y&8P^&3N=2=RK5YC(Y.C:%
MW-VZUI'#(^VN$:5FD&'#5J1Y+6!&:'(DBLD!I'%,#@>$XS)?OU6*X+0/HQ:K
M$JG:P%&58E/L['!/>T"R&XF3BS(F^7''."5!VLE[962=J3+U)I8`&*51`##1
M#%CATG&Q(_)2O!;IAL!C-@21RE\XJ>M99(WF#*:T>G1_3M[F:\P%4X]]S(F\
M$JB#$SHS`=.%044>`S!!PA"+XN1"SF[8OH1+-43*0R=';6+2<3!V6H(&B+B,
M3E:9&A+5']K(8S>)1L=FR!.>8>,9I<N20(LA8$6<BP2E*P'(<<&DXQP6,YYJ
M20^C2KDU4YK3Z:KI0J=Z_558N.5*!*19@"^(-<`7QM)A0:8%M2N$)94C6H,3
M8*4'H4X"C#!!#C&I.-A'Y+DN@Z.Z%-D_:+404Y5Z:QF%J0LS/,BTC=E^0(6Q
MF#'&[)*X1`C.WD4>#V@4K%PJ@(>$C!F"LY!J[8\P(SB)H2<%V$LU9*V!?`JY
MA<761>"`K&/J&Q>(LQJ@);V.2`BR7)@S<!:POIHE.`YX1<IG[K@ZFFV*X1'C
MF^698^#]8GJ=I\*%]CTW1-,A\'ZQ/4[3X4+['INAID/@_6)ZG:?"A?8]-T-,
MA\'ZQ/4[3X4+['INAID/@_6)ZG:?"A?8]-T-,B,=Z5G#(D*6KB&T)!SHR-`,
ME.`#!=N2!Z0,+<'(<`QP%B<'(K`Q?L09R+S-79#1DG\'ZQ/4[3X4+['J;H:9
M#X/UB>IVGPH7V/3=#3(?!^L3U.T^%"^QZ;H:9#X/UB>IVGPH7V/3=#3(?!^L
M3U.T^%"^QZ;H:9#X/UB>IVGPH7V/3=#3(?!^L3U.T^%"^QZ;H:9#X/UB>IVG
MPH7V/3=#3(?!^L3U.T^%"^QZ;H:9$8STK.'UO+<D!#:)*:<M3@R:X%ECY1`M
M4-ZCA!D&<XQA0E'C&?-QP9\W5>20TR)/X/UB>IVGPH7V/4W0TR'P?K$]3M/A
M0OL>FZ&F0^#]8GJ=I\*%]CTW0TR'P?K$]3M/A0OL>FZ&F0^#]8GJ=I\*%]CT
MW0TR'P?K$]3M/A0OL>FZ&F0^#]8GJ=I\*%]CTW0TR'P?K$]3M/A0OL>FZ&F0
M^#]8GJ=I\*%]CTW0TR(Q[I6<1]E=WYQ(;0M[(UKW=<(EP`::%&VI#5JH116`
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M`(IU=^.S-JKKZ$?'U,IZA1H!H!H!H!H!H!H!H"@U;[WT4_BL'^--U<N61<(O
MVH4:`:`:`:`:`:`:`H+=[Z4Q_`&MOQBM?5Z(G5^A?M0HT`T`T`T`T`T`T!0;
M)_DZW?A]5'Y4H=JHCX^I?M0HT`T`T`T`T`T`T`T!0:R_D:B_C24_C6]ZKY(B
M_:A1H!H!H!H!H!H!H!H"@VO[UMD_@#,?Q=<=5<HCX?H7[4*-`-`-`-`-`-`-
M`-`-`-`:;;[?>2@_YY/1T?V@^V'0JY/_U?LOZ.C^KXV)?F;;8?R)0?0KY?J;
MDZ$&@,$;HC6Y)MQO%V=(U[<D\<JV:RU/%<-Y[L:_.T/85LH8FQ,TI<94.BU2
M]M"<)"8&!"4'<4O`1<;BY%7*.OAW%:NTK"&L:G<2HQ6=>5YM7CLSEYU=JYFS
MN=L7%*YQ7%EW//GM4`,E?6ZOH-!6IT.2HU"7*EZ=&P:]8F;P+BE$+1\\F$7>
MS-S<HD4/F3!*[0YSHE7&[ABV_`FU'Q\$HN*92;=0S5Q6$5G+6EK^-0Z&QA'%
M:)1.DM6%MS"_,D7E(C\JTO$4&Y%A6,MJ=V>YM,2.6)"I")*[-3HWW*P2"F7`
MB(;.I`_;@JHK:!YRN0M3?))Z\0ZJ)-)Y'*TYKF\(EN&-.Z%&,3*L385"0C&]
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M3)D55ULRG3>$5G''>($1)Q:$]G6)'P,"XUM=E2DE&[-IAS@>B-<`!"^IMW>+
MM.A;18^^S7DV:RQL%4NDNPR@5-937.##(^ID(6HL1YBQN*1OHCL$AR8(PH(<
M8R+.<<.NGX_Y?0YY\.#JV46;9..'@L*<8Z_6EC]C^Z_=^O1CCC/".$NY$*+1
MLS&.I8DZQUNM+I!CS<_PAHL<=N$)=R&4VI9^,9X+'GN.IYDPD./,QYSCHL5/
M"$NY#GVQ:>`]2RI_CK]:92+'F?QCJK%2Z(2[D.HMNUL8ZEFV%CK=::23'FY_
MA+18J71"7<AU%OVSC.."T+$QU?,FTEQYG\9ZF..-:(2[D2HN*W,=:T[&QU?,
MF\FQYG\9Z+'&M$)=R&/N6W\"ZEK63CK]:<RC'F_QIIJHX0EW(HVZ+BQP\%LV
M7CK=:=RGZG\*ZN6.-*(2[L@<7);R,@"9):ED)4Y(<`*(33B3D$E`QC.<!+**
M=`@`'A\S&,8T:4J@EW(T^[[IQP\%O6ACJYZT_E>/-Q_"VKKC/\4)=R+/O*[,
M9ZEPVECZU@RWZG\+ZBQQK1%3<\D0?>UWXSG@N2U<?:^98<NQYF?X7U-5"HB2
M[D0;?-Y8R+@N:U\=?K6)+_._CC5A4HC4N.2+/OR]<9ZETVSCJYZUC3#ZG\,Z
MFN,\()N>2'/O^^,9SP79;F.OUK(F7U?X9T6.,.B(FZU(L[<%?>.-P7=;V.OU
MK*F?U?X:U-5'"$N.2(/W"W]@.>"\;@QU,]:RYICSOX:T>*GA%ESR09FX&^0*
M#58+MMT*HX@A.<I#9,R"H-3I3%)B8@P[#U@P9*<Q6:(`<YR$`C1YQC&19X4*
MR)+EU(\_<9N#QP\%[7+CJ^99\V\_/\.:0JT++AU(<[<?N'QGJ7S<^/K6C.,>
M=_#FBQ5:(K;CDB3]R6XK'#P7Y=..IGK6G.<>9C^'=2%#H67<B#]RVXW&,\%_
MW9CJ^9:LZQYO\?:0HX)+GDB#=S.Y#`<\&X*[L=7'_P#:\\__`)[2%8)N74A3
M]SFY/&,\&X6\<?6MF>_W/\?Z0H5$660Y^Z#<OC&>#<1>>.KGK6W/O/Q_\P:D
M*R$NYG_:UTENYS;1:[7.EUD3RV(@<(IOFU<V!.)'(6:1L`S\"/PW&/:UTQ'I
M(BQG)B%P(!QR3.$!@3DYAQ!D>*?2I4VC['JSW,U)NQHN+VU3K_WW8'"P:J1.
MC8M"4ED<2?B+.A1BZ-2IJ+/49:WE%@T(N+@9A)Y(P'D&&D&%F"Y0TX9IN4O4
MV]UDT-`-`-`-`-`-`-`-`=;^\'<Y,]HNS@=QP%IC+Q)2[=@\$3$2UBF4H94J
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M.]/;B`S*UO4X"?DHD1N4C6M3-C=THNWY1<\CIU\B-S0PB-SK<)69]LRJ)QI/
M4;A.=L4,<;)M9@;7QIFSQ)1&MU<M9SVF//:"$AZ0&2LF@6!$F#9)K23EU1TC
MD!O-DN0R$51=$*D=6[<H]N60(;FB\<BB"70"P&^>N%:NK0*/S:5.64TH100:
MT8#R$IR5*L)+."6M`J2)@B(J=:%>=,-N8FE65M/S*KK^6M\JLK8,D<Y934/L
MLUA-3;H9XL8+/VX-379C@R%/VX"!L[>')#@S.[FPX/<4X%&2#.`LV2:U5S>^
M5=,%M@A-?5)9LIC5KL4;M.8RZ!+4;L74;7,JSE$"LS%1S1!-*^<K>23J1%1:
M9BP4O/A;=+"$B<0#C1@+,+R-)-62CQTMNV)D17(M6-DX)#4-]M&V<M(Y/=%Q
MAUL&XG9SE3?B/1YGF-U1QU@#8C(A+HO$[6&3"6E0UHS%:12H("(>$C5EVG6^
M3$EV.(=ZNV1H8YE&%Q)SB)MGS99[BO1HVN2/$"D#05&J#@MRRE_E+-8S<!J4
M!0D&M"<D*EP-<`HDV33*2*PS,T'MHZ^ME[#=BED;HTJM?;F"P%4=:)2U3=L8
ME,JKX;PH9T4N8^!ID2=M.5B)"K(P$!O$X>*'/"'%7*,Y*%DB)WI;A9=MAKJN
M;2862-N\2,W$T+7MR+)()Q*!%*CMBQ&BM)#,V<]`L2%D/<;>)2W'EY58-2"*
MP:`P&.,$P$-)3)U@;:^F5DUM/!2RRX)!J[@\%A6Z'<!>BT@$C4R.);9:^K6@
M+0VZ35F:37DXT]\MV-[@FXX01E'DK<I#2D183>,$J2:>,>IMX]=*S3L>9$HG
M>D-SI-D*KEKFCPT0AA%?/MO%RNXZ=EUX5,YY;X]:KK#%$9GT,ABD"=00]FGM
MR\>"7,E!@A:-*DFO=&L,AZ6B51#;%=+VH@KW8&Y9E;ND3D\#9JT@Z9UA<"KK
M:39LPKB*6C<Y#S.6-6B@J-W`QIW8UO/4K59IB@1"4``YXB1K+[4,G).FDVUQ
M.*MA=KL5ILM@-K)<14M9T45BH2U,FH7;Y"=PTDRPIS+`,,+:[7ALS*,@W;0R
M1NAI9Q2KM+D1#TD:LM;MTH<?C;_;<'7UG;$JM!KM]?6=8U)":T8PSXA,R[8Z
M]W!S%VF672XE,?=$=<HI<=EY5$GM)O#DE`A0+E/%.5!'<H-`=,73+U#]I\5N
MM6;SV756NV]XL=SAH80U0.!3W<D2!/7[(LCTFL='9BY/('#(33!L#/(DK$C5
M)3G92B*4DC,2->8.!<?2;6U772#*]I;#$*I?8PBM;;!6**/N"2R4-IS!/?<<
MS))9*H]-TX%%0,V:R:"5"[+4\"1*7=,F&6D-$?P`TD+&5)-%=,E3\.IS%BSN
M`W+8#FSQ.\+1GR>G:RCB4JO:JK'<G9NW6.R66-4INA:4A]MTMKXUN0Y2NS@8
MM.(4+SR&Q$`\"-(U.(EZ5A=`;`W6U]:516!*W&OMQ]\5/0;S7T88T,&EF*BV
MWP^]D%6R65OLX*5)[0?$>'U0%1AO+;`H@)\&&%FB`$U(UXJ9FV_=)U![?5[-
MH#*JHL*`7-NWV]L.X)%%W-UJE!&8Q%G43BC*<$#W(K/9'>PT4@4,YKBUM\7;
MWR2IX\J2KWEK:0C.+(2->;(SKOM]Y*#_`)Y/1T?V@^V'5(N3_];[+^CH_J^-
MB7YFVV'\B4'T*^7ZFY.A!H"$DL@;HG''^4O!F26B-,CK('0T.2L"*;F9">XK
MC`Y/-))QD"9,+...,`>IU18QU=`:EP_?=24SSM-(1I)RTN.\%IGSG!&A^86]
MO<8(HJZ$/4UGS';X0/BE-#7R,^UQ>TGDDFKP9>$9Q(!B**,/"+#J98+W1;<#
MHW[<$]YU4KB^7_VJ!?4,XCRYM,DPV)RE"1A*4I%YP#G9UC32>X("`\)C@B"$
M]-@TLPL0PADR'<#10U<&0EW)6!BNS6R/O5=D%SF-&#FS/+5/:43=(OQ'(6'I
MOE2[&4[8<1D9;@HQDI/DPS&0Z"'8UH9^D@VNO,PB[#B?L;#&)`FW1DJY_,GM
MIB$>8Y)M5N.JJ:ET>6B>E*?!OMB<K.[[-ZH)F"0LC<:K/P67G.2TC5FSKK>]
M+,;[,XN\6K`&Z1UW%G.;3MB5RIG*=8C$V1L1O;V_2!")7VPUM[,RN:18L$:$
M.4J1:F.-P$M20(P(9P4VXNA%BE"C27)6JE6YQARFK6E)F3$8H=(DSMY[NYR-
ML)"MR8XLZ)G2F+1GDX&#"(.5'#R/V^@AV/,3W$T-.W5`QPJXJWECPZ.QC$W-
MD=F#&[K5KR7'W66=[$Z="M/,,6FQ=A7N)1>,<8Y$A4G`XQ9!H@!#L8EW02:/
MS3:^IF$2>&^11:5$0:11J0-*DM8TOK"].;2XM#RU+2<B)6MCHWJ"STYQ>1%G
M$F!&'.0BQG/3\7\OH8S_`(LZ:U/F_I_^UKT8\GG(53UOU/LYT7\@0BKK"^M^
MMC1<E(11]S^K]C57+(0JG[G]3[.=%RP0BGKX^O\`K:8]00ZGS/K_`*VHN&"$
M4?=?J_9T_JP1!W[+]+];5RZ`A%'F_H_8Z/E`A5'F_7S]G&KU!$*.OG]'G:BZ
ME7*(8_KY_O?ULZG]40ASNN/]/[&K8UT(<_K_`*>?LXU.H7*(4_KY_3_7T7#(
MNI$G?LOT_P!?4Z%Z$,H^YS];/ZVJ^1_8ACO-^M^OG4ZCJR'4>;]?]?.@_JR%
M/Z_Z/J:+AFGP0Y_F_6S]C&HN&4A3^L+Z_P"OH3K]"&.^YS]?&G0G]F09_6S^
MC]CH^$:(-1UL_7S]G&H"'/\`-_1^RT'0WMZ*RW+2CF^>EJUK-RDQ\9G<^A@+
MG8F8"E;&S8:Q2!&N1.DL2EEG(TW>60&I<)5IG)#3*%`2@F8[9R4;SR:-I43?
M!]_.N1H:`:`:`:`:`:`:`:`U(L2CJFW"[>A5U=1SJD@WMU3RP3FR3=\KEX9I
M'"[2.DT0>FN9QMU9'IB<6J3MJ4Y.<G5%&8.`'&,\/!JY<A.#&TLV%;2W^/2J
M*V8XSJ:B>:`>*(F;]:-^V-,)VOI=\M!3:JI)(IM,)@XRL\*>:*N*E<U*K)Z5
M$44A*-`F*+*#"RSCV-L$V325]?&J9MSLPRJ\+H<;QCR1KO>S(%*"[S00IY0R
MZ<TL%@GK(\Q63.\,.4GR(F/\BF<DJ8!R\@TM*5DL)9=7/H_=L+O#KH@CE$I,
MOCVX"JJGIBTPN5C3YX>9)`Z522)'`$A\F>9$XR3#RB*E2X2MTRK$Y.1IW**C
MSC,8%H)9SSMB6V\4AS+00D2F0`M:];N)R]O<B>F$^Q]QM;.53VJX/$>->$Z-
MW89#"G4Y)EK$("0G`\B(P49P#P$LUIV1]&81M@%>JNP[$;+&'=-80&CB(W$T
M=Q,L5@M1URDG;8SQB/K+COJ_9V`"ILF^2"B"GE,W,Z5$0G0)BPA,,,D%>4P;
MF*MJ-)K:FH:D5$<<!UWMJ?*,D=1-.)$^!5,+MMR.9%%3GK74*[#D^@8S8\ER
M<!88<!=Q,X48,XPN&DEU9KQ)^BKV6R\L\MX@,O!A<.P.^V&>W;4CY,@2V5<.
M+]D;7)D3%+F]ODC,5;F,/2%&N*4)T*H(.2`$)9>`H&S)V8]&;M!L1YG\HGT)
MFLRF5A.T7>54ZD%T7&MG</4P9TD;U""*PF>)T7)*R;XBXRUQRA3LBE$460J$
MF$$:4("`R"[,S&\;4*K>:6BM"C=[I:(/#E9:YH<XKN+OJ(6.I4Y"]%KO;%:\
M8L5ILB6I'D$B6X6)71T5I%&3@BR5QR$PB:2:R3BFLX)3.VMWJFL(VAA]>U]3
M[_%8A&6T2DQ(S,31%5Z5$C`H7'JUZPT)8.,:>H-.4*#1",-,&8(0LU<HSE59
M,L=XTI7.XRIIQ25M,ALBKJQ&CO)*&<AR<6=2J1@5I7`@:5U:5*-R;U:1>B).
M*.)-`,!A8<XSJ&DXJC!\3V"[489(;.DC153><JN.E(?MXL5N=W-X>8_(:@@\
M,;J]98>-@<5ZAJ1HSH:SHT"P:<HHQ:4D)Y80Q%ASH)=R/A?1[[68`DA:>.PR
M3&+()=<7W`LTAD]GV9.Y@KLF#UX]5-"%;_,YU+))*9"P0ZMWTUG:VA6K-;$2
M,!>"B0B#QLH#R;*K+.C"V;39A*CS]7LG"D`KO8U0J8+8M6'NCNV;DY,LF=Q1
M.2.,0F+$HE4%EDK5!7#8W/*MJ*-(+"`C!6!EC0-FCBS3HS=D$SDJM[F59E.$
MDE2NE#<C6S64$'N"O;G&<1R!X0(@OA18\@AB,M`]`*+SAZ;4Q9:[!Q90>+(+
MLT72<='MM6L632:9RF$2,4NEEJF7*Y2B.V=9L&D:>:+:V9J>?\-;_!I;&WAL
MC,MK)B)9GAG*/PV.:00^7(&9G`\4DM$'$NC5VBP.45-,H7"IE%)#3L6KJ%1]
M3&+CMZ-()/&*D`:&N&JT6!@F[9'K5)BHCOVK+^D7C/)#A.HR<EQR&D"69%FF
MRO;W/Y?.9[)8HYJ)=8-BT!;+Z]I93(F]4GL#;&H(44Y(V/"-Q)*8U,<R1Q#0
M)P@*7%C&%0$S`LZ"6=<6[GHD:9L!GK*O8;9<%V[5H\%2NI90J?E=OK;/L%!;
M-W/>X)UK2-/S=N0KB!3`,EL1Y=%38S2J-RTMI6'Y6-Q&#"`%8D&ED['8&OV2
M[7'&7*W%SBN5LD>KPG.Z1:UJY@^F=\K*G%3):!F4C-9<NN`G1Y;79Q3:-%@O
MO>2<;@T(`GBP+-,RR'B_1X[98I\'HA*U66\LVUCO691L5E]XW%,8?"UD<<9<
MNA[F&+26;.;([NT'3S56@9U*TE0<A:B$"(`NUVQO+3!+J2V^WWDH/^>3T=']
MH/MAT"Y/_]?[+^CH_J^-B7YFVV'\B4'T*^7ZFY.A!H"AVG#55BUC8U?(7D$<
M6SN!R^&HY"8V8>BV%5)X^X,B=Y,9LKFO#L!K-78/RF[93\O@'$Y4OC<?`'7_
M`"#HSHO(C9RD/M>0M\9G3\OY5D:(^F0JHQ`Y70E]5/9<6ASN%Z&-DD,_GVY2
M63,]\Y$T9*Y62F[5,[7+5:D&MN*&3RMG,C>[2A]TV);+)(+`B\ZJ)[4>U2KU
M$*B#G"J3A6X:-0Z,DQA78LM&URI4];D'EQ<7T*PTI04E1I"FY.40`8:2:04&
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MM3;8*!LKXHM5LK1FC;R^V*.3#6GQ,3WWSR:F/=1MW:I*`$^QAJ2[%[CDU301
M"_282BZ'V*;3:=)FL":F*N2]MU;TL38YTXE"HU9/)J;/IZ\0NVY?%C%#.$*1
M<:\I2DZ!L0#<E^$%E5L;:[TCF&MMJCTF;6D"&.QD4#8VEF:2BB2&]K1/;.V-
MB!$2(99125$E+`6`/#C`0!QC&NOXOYHY9_Q9T+J+NCXN-G#2\=3A\Q%]7]U?
M5UZ51GG(=1=C!G'^B7?S/,1>9G_.OJZG]@0JFZF'.,_>IWZOU$7U/W5HE4K(
M=1<[#Q>#O4[_`*B/S>IZJT7+!#J+E8LXX.];MYGF(_,X?W5JKJQ!#GW$QBS_
M`*+=NOYR/S.IZIU$X!$*+B8\YZC8Z_J(_.Q^Z=%1,$,?;[)G/#WL=?-\Q)YN
M?\YTZ`B#K>9,</WL=.K]1)YG!^Z=&^!!#GVXR]7[V.GZB3SLX]4:/E".A#GV
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M=?SDOFYQG_W^DA8-]3,.W:F[HWI6DT4CMWB2APECR68L>9`[&"1QF#1D@THM
MQE<H=DQ2T+2T(LG!!RG$,/./&60F*.4FE%BR\J4*L>)/N"VD]'M3&P&AV:'0
M1$FD5CO\VI]3:EON+<G)E,\>@VC#31IP&YR>H9H<UJ!"PVM)9PR4X<Y-,$<J
M-/4&\IEER<_Y.S?4*-`-`-`-`-`-`-`-`=3O2%4;(=S6R-BV],;/+'=MN#<Y
M0T0GAD1:CWA1'ZT%NECKQ/I>\)23"<%L$1CC2>X*#C!!**$G`(8@X^V#<N2X
MN*^ITD';6>D(2-=WWC8-,6$^WK</1R650"=G:HV782-LDM&3+:-7D":7%B6H
M7..C4VV35LMFK<ER0I,4!D!O[7Q2Q"#DW*I#I)ORI@V^V:=)%54YFD:NMR35
M+N=WIFP-;)X]$_@@0NFY+M4L^*[69`W/D30@GYCM)UJXM)*31*#Q%N:D:<\)
M)XFT)CJ2FIDG<I%9].-[FR%)(=LT\261";"KJ>7/O0I.OK,>H(U,C(_OI$6H
M:&OIF>!'#9H:]$BL)>[&)F]"PA-QD"T_!(4@*(=3&W1X;1;6)L^;QZ]*@L^'
M1U]VT36MMYLAE#L]1UGW1[G7C<:YRJ/V=')&QRWOO.D1-7!<BAO:8[DPM3XF
M:C#>*1E.`@VNA@2<[2+2?>C'Z.:OGBA[5E=]TC6\_<HS1;[MSBUMUDZVFJ:L
MM+!#=QB&?O\`%DM:L#H!P,`2\"/*$W`&>JP,)Y"4H\6:NM#Z?XP2O3QJ/)W5
MN;&=T(8VDER:&4\Q4S-:\I`G`L;FE4<G2&J6Q"H"(H@P110AE!#G(`YSP8IS
M)S0#0#0%!M?WK;)_`&8_BZXZJY1'P_0QUNOK!JN7;7=U:O#$XR=+)ZXDQ::/
M-+B]MBYZ>FQ`8]1UM+.CR]M<U92N0-J4!J+E,IW`K(DJ@LY.<:2.&E1H^>:X
MMJFZ%ZIW9$Q(*3MI\G<;Z,_:;4>WQT94AR;.TO>I$)=7+C8D_G7+O;6*L%R:
M"HD2=0\*"B\#2L2UK$8+*G)`X:35?4R1&]DM^V?N?N"+/L6M:I'Z>O'2"MFY
M#=&<GRHA%RT]<<CC9FS:+,!PI0`$_;H)'"2088"QD>UE`W+6\9J02_A&$T,U
M4=7V\O;7>4`;8Q7J6:U=*I_+XU'Q*JNDT:8*[J6;;J'&2VXUQ%F;YY(6+;9$
M&J,O:J419O<SUPGN,L468,\DY-ZD!@.&N2G[Z]N<YGET;UPR/:?8NX:QKNJJ
MK(WT>=V1)I9%S1MKE[%"5#2OX]C.,C:EFW9SBEVF>W)<\E918?6PX*7!RD:?
M"40)T53'-HAZ92,V-/*MACI:<HC""TUU3M-M-#82K;72-[NH*V2!BM^.'KV<
MC'M;V?3Z-FM!QQA@.]"1UR,\1N,C$%4?:9AE0.E"C-OV/,ZJD-V2HLC=1N,J
M*LZLL)BCRFD5]+(]FV9E3%DOCD=$TDE(;G+<R4E;._N7@"+&2QI0`#@U5@]4
M?;8Q-4P>E9L6%UO$YU,]SM6D2O=A0<9GS\GBZ$ZW*^K=SH*_T6XM^]MDFJ!!
M!#(&YV(BBRMJ/3M[PU1]Y/XJ8XQ/E(5A4?:K'YE$!WXW=)2H1823<8[LL6Z3
M/;I8$,O\F)$PY7%:O)>[JR_^U"HIG!75EAZ>G&)<TIU4E)]L46>,'HSP&F*2
MU630ITL8ON2P>D)JFC2[TG0K8C=B5SLOO>!J[A=:]BK7-`S%%TGE.1"HTKB\
MN$<0MN93/MNK2%PPB-R2@>B!B7'$BX<&!"DQW.ZOH]EFXA;!;E,O11<JR-!O
MB3`V^K=QC+%(_>RNG,Q:&FA-G[9#6QF:2`!L(U^`U\JE(69;0%<8&">U]$3*
M*07;?;[R4'_/)Z.C^T'VPZI%R?_0^R_HZ/ZOC8E^9MMA_(E!]"OE^IN3H0:`
M:`:`:`:`:`:`:`:`Q/<!!*EDBA"@DH\DRTJO"82<6`THP.9LS<(1ECP(`PY\
M[.-7'KZ$?'U+[[6HY[`,G@I#V#4*/:S'/<^R>"D'8-`>/:Q&O<\Q^"4'<^K+
MN#Q[5XU[G6+P2@[GU`/:O&?<ZQ>"&_N?27<0CQ[5HQ[G&'P0W]SZLNX/'M4B
M_N;8/`[=W/J2![5(M[FF#P.W=S:`\>U.*^YF/^!F[N;27<%"K"*Q<R`189D;
M8!C$U@R(0V=N$(6>5-ZN193YSG.J^61<(OGM1BGN8CW@5M[FU"GCVH1/W+QW
MP(V]S:`\>T^)>Y:.>!&SN70#VG1'W+1SP&V=RZ`\>TV(>Y6-^`VSN70'CVF0
M_P!RD:\!-?<N@'M+AWN3C7@)K[ET!X]I4-]R49\`M7<N@*$W0R'YL^8`S%(U
MD`8'7`P@RQ->0A&.0VI@8L![5X,"'@L.,YZ^>+CSM7HB=7Z%[]I$+]R$7\`-
M7<FH4>T>%9_[GQ?^;[3W)H#Q[1H3[CXM_-]I[DT!X]HL(]QT5_F\T=QZ`\>T
M2#^XV*?S=:.X]`/:'!L_]S(I_-UH[CT!X]H4%]Q<3_FXS]QZ`E&N/,#&(X;*
MQL[0)1@`5`FML1-XCPEY%DL)V4A!.3<%Y'GBX%P\'#G@Z^@*S9/\G6[\/JH_
M*E#M5$?'U+]J%&@&@&@&@&@&@&@&@*#67\C47\:2G\:WO5?)$7[4*-`-`-`-
M`-`-`-`-`4&U_>MLG\`9C^+KCJKE$?#]"_:A1H!H!H!H!H!H!H!H"#DD8C4R
M95L;E\>8Y7'7+M;OBP21I0/K*O[35D+TG;K4Z)U2%5VJN2E'%\<L7$-+",/`
M(.,X`G-`:;;[?>2@_P">3T=']H/MAT*N3__1^R_HZ/ZOC8E^9MMA_(E!]"OE
M^IN3H0:`:`:`:`:`:`:`:`:`P_=:PQ!&8XM*0K7,Q+9E9G@;FT*82]:(N:,X
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M_BQSE._DCM/UG"?'G2.Z$OXL<Y3OY([3]9PGQYTCNA+^+*19EANBJN+`3#JN
MS$8%$(E9`E:M)#@I4H36%>6)2IR1-#S\)R,"XP\@`,?%QG@#G/4U4JJJ(W1T
M9=^<IW\D=I^LX3X\ZD=T67\6.<IW\D=I^LX3X\Z1W0E_%CG*=_)':?K.$^/.
MD=T)?Q8YRG?R1VGZSA/CSI'="7\6.<IW\D=I^LX3X\Z1W0E_%CG*=_)':?K.
M$^/.D=T)?Q8YRG?R1VGZSA/CSI'="7\6.<IW\D=I^LX3X\Z1W0E_%CG*=_)'
M:?K.$^/.D=T)?Q8YRG?R1VGZSA/CSI'="7\6.<IW\D=I^LX3X\Z1W0E_%FH&
M^&P'173$**'5UDH0@W?]'LIP<L2P\)(QHM_6VE86C!E/,E!G;3@81A.1C(<`
MR>:#`Q`!QAA-=T5.O#X9_]+[+^CH_J^-B7YFVV'\B4'T*^7ZFY.A!H"E6-)W
M2%P>32UG9F]_61UL,=Q-CJ_XB[<8WHAEG.ZI8^Y:WKM`EM:0GJ<YPE.$9R/$
MQCA%C.`-;()O,@2N*QMWNH+/1DFE-<,UR)(8Z2%;*U3'5,A0)QLTJFSZW1=M
M8HD:K?\`)S-A.H-$`QWPG1D''*EJ8@8L6(:0[_J&CTI@;<L=W%%$)5%+LD\C
MES_$[(C3A7@*1EU70M_!,((ZP`N5QQDPZV4(Q:]O!32RM*1K4'*%/$R'.`AU
M,Q9W3;?P.DL:3[-9$1L*:Y4]/;@XIGAMCA[=`WQNB\\.C4L<&U-%YJ;!)4[I
M&E\)9EB\YG=E9")8`E4:64((=C%\;WTTFY%SQSDZ]V@T<C-END"CCE((G8B)
MYD#/&8;5#O-I_)X8YP1JE-61"%3FSO:\Y.#XF(:DAJ4A4<M++7IP82-67I!O
M!VVN1TJ(2VDU_P"IQ2P;L>I:),A0K#6Z>`JQP011Q7,B=OG;PALP\B/G(6,U
MQ6%O2Q(B$5A0K2EFA#)9CW1T3(U+6D:9T$Q2X-<N>G`A7&I>U&0=K@:A[0RY
M5;(76/HN9@+*YQIQ1&!EO>48UZ$]*7@:@H96`AE74[U=M*-JP[*;$4EX-=A,
MJ-E]H=D#F+JLS%7*=)3F*!EP\4U?VEWA+,K=V]>B;ST+DV)S%*4XXD.1Z"&7
MZ=OS-*896\GCCFB>H](Y[3K\PO+<>!4WNS,[RI@<&MS0*2\Y+4(EZ%0`THP.
M<A&`>,XZF=5=?0SE_LS3J%&@&@&@&@&@&@&@&@*#5OO?13^*P?XTW5RY9%PB
M_:A1H!H!H!H!H!H!H"@MWOI3'\`:V_&*U]7HB=7Z%^U"C0#0#0#0#0#0#0%!
MLG^3K=^'U4?E2AVJB/CZE^U"C0#0#0#0#0#0#0#0%!K+^1J+^-)3^-;WJODB
M+]J%&@&@&@&@&@&@&@&@*#:_O6V3^`,Q_%UQU5RB/A^A?M0HT`T`T`T`T`T`
MT`T`T`T!IMOM]Y*#_GD]'1_:#[8="KD__]/[+^CH_J^-B7YFVV'\B4'T*^7Z
MFY.A!H#'MMP$-K559=7&/CA&2K(@$P@1TC:2R379@)F$><8\<\M1:C_)Q.;8
M4XY.3\IC)?+`#QL"#PXR"HS!=I;3F>Q)2[3=MF;G#Y,,>W`R+]I,;.XQV.!V
MSSJP)_#4*F.'A3)WYI<'JR%XCR##"1$&$I#DYA1J4H019Z&*DW1\QT)"QJ<[
M>G[^P3!CLR)6\D=VZ+C>+0B%IWU.+\E\=5/R1K2'11%,76>K&608:R2"W)B`
M20F`WC(),+A9/2HZ/=D/98JUCN2>*#*B[TD;?S5[1%U:.MT#1<U<7ID$F0!0
M)S+5<WF6U2QHG!:Z'@/,:$(0D=KN!RQR5!)[V/H]80V36(SU^F:BRI"TR&;/
MDO5VC`:_F89?F67I,+Z1'-Z%4S)F:#OT?D$O$VE+FU('&6I$B"620I0H5*5`
MV.>'8/&$S'5Z5NLJ6(9-3->U'%J_DG>]J6)D\MK.?CLN03N0QY;RR*0CM>4)
MT0GQ`(PD``)`F(SDRL"96FI)(]YZ/2(2=))&J2VE/%:&:0:]HQ-'=H0QB.3B
M8/6XH+SBPGB3R5M:L-KU&49CP$YEC)[8-E;CF]%QRU!1(RC0DLAVR<AVFTIM
M>4V[*GZW)=5]HUNLFA;&Q,J=BS.6")Q>)/,08&P)29GQ6+.R.HD!"@Y<8J6R
M=R/./X!D%$A/2*&0;Q)2TUM^8$T-1IP(:L4U>CBR!P",Y(!'#G9C1LR1:!(8
MB,-(`F0%@'@L16<XQGBY#YF\%.4=C&;A-FF!^_JX2_N8W6F?KL\H\_@\R98U
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M8A\(O,`''U-7Q8MNK'D=D>\WI<=R`.M":1Z_FQN>>?GSK)QJ>+&)ECR.R(TW
MI?=RH,9SB$4;U,\'5C4^_6LS&GAQF)8\F5D1YG3$;F0=:#45^G&9_P"=_P")
MV-/%C6K+NY9''=,GN=+X>""4/G@SGKQBP?.^I:&-3Q8TJQY'"HB-,Z9_=$#K
M0.@_TXO8?U/_`+I8\_5\6,Q+&[F#@&]-3NF!P\$!H#J>?%K%\_@\RU,:GBQN
MR>1V1&F=-MNK!GJ5_M\\WKQ2Q_,__P!7QIXL:597FY@CS>G`W7E]:OMO.?KQ
M.R/.X?,MG&GBQNPLW4JH>FRW4I7]RD1<`V^Y6NK0QLJ@H<5L;*4"5@62!>C,
M)`&U@FA4&'24_!N1#$'(0%\4(<X%D3QXQRP\FJGO-Z=C=P#AX*ZVY=3SXC9G
MG\'E>QJ>/&[-;,C#NGDW>EX^UKG;=GZ\0L[S_J7!C3QXW9-W4CCNGPW@E_<U
MOMKSU/-A]H>=GSKBQYVGCQGEA9N",.Z?S>,7G@#6NV?/6Z\.M+S>'SKEQIX\
M;LNS)*)_[P?N;22EB.G]140[PH#BGS)FZ'LU@1Z4J6G(L!5!8GEZLF3M*%Q`
M$7&+RH0*"A9#Q<X#QN.&/\:Z,+)GU!4/?=6[E*SC]LU#)DLEB3^1C/"`193J
MQN98`97QV2-F###F:0-1@\`/3F>>$PL1A(RS!\VFG#-IR9CU`-`4&R?Y.MWX
M?51^5*':J(^/J7[4*-`-`-`-`-`-`-`-`:G3S<+7^V"@06M9)4G51\F<)8>D
M;89'%\ME#S)Y_:9T-B;(RL#=CMIP7.T@>4Y``XSCJCZ_F:N7(2DQC"^DNVMS
M6<02!DOTBB+E-F:X%:Y=9S,EJU%74IHV6P6$SVLK+1S]UCTCC5BD2"PD):1$
M!`I3JR\#,`HX@B,G0L,W#26G6+A+'Z!(+&@:V<Q5OR[2>&))?'U,LCC5C!0L
MN3]'27`;PSM^,'@SRR@DLO@&'J]7&A(=B"37Y12UGC,A1W34RM@FC\?%H<^)
MK&AY[/+).E-&0ICD9<RGD:)^?DYQ8@&(THS5`!!SC(,9QG00[%&N7=I2.W^6
MPV(6N[S&-J)NXQ=I;Y.15%JO]:,B^;R;VEPY/.+7CL,=:U@!LEEHBV]*!Y=4
M(Q'&@$+`21<KH5)O@Q[/=]%;U[N18MK3I66XEWLJ3IR'*.KXO3$C?H.]1T/M
M1`_RUMEJ4>$*N*PE9-T"9\7`#DEL4B&6;G`@9T$4DRD9NDHK,OC,1;['ASYF
M2QNPY3[9F.80YRB,?;*R0PMVD@9,\D2'[U*.\T[1+2<<D87VF$PXT90,%Y,"
M'8B'7=K322>;;8+'GS%B8W32>QXG6TSK=SBLN@29SJZM9-:4D,D4B0R0/(I#
M&***4R?*`EP,RO$66:`HO(C0!')LSH0:`H-K^];9/X`S'\77'57*(^'Z%5NF
M^H#0:6M%UA&/*=#:MRUY14;6-+2:Z)TLZM)R.98=W^&4,&6EC7O19:0:P6!`
M)/4%8%C`19$&&DI->J9Z1S:]?LF@D4K"22%]<;#F.X"%L)YD:5HFXA=MI2QI
M99KJ\+%)H`M<>)*F35A`K,QQ5@UY6`X#G.>!(U:DV3Q?E%"BB:>!NFI10=8\
M.,>23/%C0[,45/[0VN;R[,::18>>]![PUM#*L5J$P3LG$)DAQHPA`4,01(=C
M7<[I!]OB#;E:&YI]7/,7AM7NVXU@.B\G4PEDL"=/NV-UFK1.F6N&19-`-4G=
MGM1!%8V5-E>G.4E&DY4!2Y$,)8L.8,Z1+<=2$QA[+-D-GP-N:WEC=7TQ,\36
M(I'%C+C,=;I5-FZ0DDOBI.V.U?,CH2>_DY-%AI+'@9X@%Y"/(0[$('=121;3
M9K^Y35A8F&KI<V0ES?7V21)L9I&_OD&C5@1]-#W,^0X1.XI$S2I.6@`8-.<K
M4A,"66(&`F#"&>NE=U=,7C7=&6"QRAOB1VXF`-%D5C7L_>XHPV:\1YV;R'+B
MEQ-'(G83@M;2#PX5X;SEQ!(^''*YQU=!')BJ<](5MXKB_'';S+160@DK'*:D
M@TFFR>LY4YU+$IG>Y:?-2QN66&VHE3/'%LU/5E$)3E?)(PGF8`:<7P#XH0XD
MS#']T5&/$'9;!>+&B%?Q^0N=B-;,*Q9?#XH>XF5;)9%&)DJ1B52`U$K1-:F,
M*E)@RCAY(1XP8?@K/'``(91HGO@V\21=N(;G69HJ^5[9;"GT`L-+8#K&&9>M
M+K.#0BP)?.HFSH)"[O;Q`&QDGJ,L2TQ,F485%'%B3AQ@H1H0Z&1*ZW.[>[6B
MM0S."7%7[PRWTP@D=/@.DK8T/<^;NU^V%I3!&'H]ODBAX8Q!&2YM^4@5[6J)
M-3JR23RC"PA#1BS?;[R4'_/)Z.C^T'VPZ!<G_]3[+^CH_J^-B7YFVV'\B4'T
M*^7ZFY.A!H!H!H!H#K"E0++?-Z^X@Y`ND:V#U=0-(R)&6'<M=E>MD(?']#N)
M-4NC'1T.;EE76>MD"J.H0K1OJE!D@",H0.7R'`,"]#2^#7+-D]%TM(]J=TVK
M=<E=MG+-*-V2TFUYQN<%6;PM2TT%PG[/[=7FSQ1S<"T)':6*VF(H1`[\A1JA
M'M"KM-/Q(:O*ZG9HU2:$-&WV[95LWM(F]9I&X@_21F*?;ZG.Y!.KG+%'%KJQ
M1)>IE%BS)PB/MI.0]J#2I#$>"AG9.PG&,OB9IGJI-'IMOOM^:1F:&QMM9&F/
M%-:[<!!WY!B6-PY/MA?K6K6N=N3\8\Q^3,+TTN]N.BB2/`@A,)+/9V?*<98@
M'&AU#4(K""S-Q+G;C*UI;^C+E8\'W#](4V@:)3#U;L1#(E$6=T=ZV8I;!V2P
MHXXJ6Q[BA;>N8Q*CTN"VI2!01A0$8#AB4ZHWMM:PE%M[&(/:RMN):%=FU_3%
MA*FE,:,].UJ)HCC,D.;B#S<8,.)1&.62PB%]L((<9SU==?Q?R7H<_P`G\6=3
MZOK_`*O_`!M>G'J><@E/W7ZGV,ZS<I7U/7_4^QG5_JR$&IZXO^%]C&K_`%!`
MJ/\`G/T>=I\00A_6S_??KYT_L@0*GK?J?9SI_9@@SNN+ZV?U]'P@0:GKB^OG
M[&=/B"#4?^UG57+!#*.OGZ_Z^=9Z%N01_6S_`'WZ^=7^R(0I_6Q^G]C2YKJR
M$4_LOKY^QG4L1\(@SOT?^C3J7^Q"G^;^C]EJ$Z$&?U_1:MBOE$*I_1^IJ(+A
MD&?U_P!'G8U$7+@A#^N+]'[+3H:(%3UOTOU\:&>C(-5YOUOULZ=2K@@%/W7Z
MGV,ZA2"4>;^C^YT"-K-F^_"S]AED&6'#E8':$N@4Z6R:X=5QZ:.S9G3F&<AC
M(RBE0FJ3-N3QB;7$DDPY.8,18@')S3DYN<TFJFL9K!_0*A<G2S:'1.9H4YZ1
M#+HRPR=&E59+RI3)7]K2NJ=.IR4(963R25>`CXN<AXV,\&>#7`V6;0%!LG^3
MK=^'U4?E2AVJB/CZE^U"C0#0#0#0#0#0#0#0&@&Y;:^HW?;7&BF2I"5&4QMW
M5W.WEP$MD#6I41ZL[^03M_:6IYBJ]KD3$]O+0Q')D2]&I3J$2DT!P#`"!@6+
MER,7%37#<'T1M86*6!BJMHKN&0MNVH;S:88FB:-3Y8+NBNC=&7$SVJ\%<GE2
MR02)TDD<=6)2H5N:E8<\F94!Y(_'%X,9@TLF8D3]$C<;A=9MI6%=E?V:T)JO
MO:JD$4D;7:[:V.4*N/;6TTLA@[RR1JPVB+MT>CTA:AJW)S:4:&4R-,MR8J<R
MU"5($M!=J(QK*.A2O.4PZM6-[W2,$G(BT*LVFG*!RU@FZZ+L5)3J>QR8,,6A
MTX:)8QS]S?X@FC*=,>Z._*K'DLA&`9J7#>G'E`V5CL0W>;7=RU^V;MX(AMDU
M05MJJ"0PZP9S4-E-4W=72WK&ADCPZQEPF[TP.*7+]&(5EN0.K8U&#*3JY$3A
M2Y85DDIR0")I)TJ9YEVWQYD>\BE=S9$A;$S%5M'794Z^,&I50W9U<+4E%5/[
M>[(U@,]IDHFHFO3BS@#QQQB4`R'J!%JDZ0=9K/T1$^AE3T=$JPMFM:VL>LZ9
MWWP&5V0RUR!<HF4UW;KH9[6IDO0JP$Y>C8E'8B!K5F.`SE.$V"0IL\4@L&)!
M=BY;6>BVG]`6-4$Y>;2BKZEKK>%N,W/N+2B%93TJ4MM];2FB@`Q-+)+)EDTE
MCL\,DO2J754Y.3@;EP)-R,):<8^0*0'E)W5:ID:`H-K^];9/X`S'\77'57*(
M^'Z&$-[6W=XW3[:Y]3<7DZ.#3AT6PB65U.ER4]83#+#K6>QBQH7(\E),A6Y`
MAD$6(P;@D01F$#,+ZH1BQF&DX<G6M4G0Q)J]<MPC:JM\2:$6]LN;]K,1*CS:
MO]L,"E,GHRE:9NFU,"7+"F]>XSOF"85X@!R4<HSE04>;Q#.I(+MQ2I,LW1,/
M[R="G:WI72$M4$[N*`OVPZ[BU3+(Y23I!MO6VR;;>6",,E?O;Y+4QLME@9"E
M=G9:L%VL9E.!*$OD4J?.4#:QC^Q^AOL28Q%S9VZW*>6.4@8]_D&<4EG50]6+
M&8U&=YUO*+::YS6:,,LCAD+NN"&)4C;AZR!67R8LG@*'VL60>@+*"LVAT'TP
MGDD?G!EO]IBL;<54:&VQE)'7$1+:DM"@(KMPWM)@*BU)1@>>^%0AM6M^>`6$
MSL#ECL8R66+*"[=C.%H=%%*YC;4UM&,V#3Z5*[[AI-9T<K:RJG<K*JPB#3K:
MG"=L#LW2"%IY5$"5DTA":,&NT=4%*`IBLFY3&8``XPP""+(Q57O0Q6+")WMI
MDBZ^X])(S5\+V@,%@QE2TS=J<4LAVC*%*V.OM321CE3;EO;7I<K.4@;W)((M
M(N5*E`AG@4FIA(&W-#8JWNC$<;$W=3/>`US6-H9^*\]GEJ5LF>$\D<&=JCM`
ML^8S9T3E,>[='%G5=.V-4:-F=,H3E[&N*(4)C4YH>4P"=(.KC=ST6^XF.UVQ
M4Y5\2*OV6VC3]T4RXOBBHXY(:YK0BQ=[E@;H629,,[E=P0APJF8I&RQL('=<
M-H="5"=I)-2X-4%%)A(-+)=3L>E_1,AFEIS2R'.2UP4YSG>1=M^NL@]I&%TP
MYH[;VD&[=4]5G.R@!:AP"RR=6>^"3&'X;#0FBQ@.#1B%I!G84UT9]R5A-MA\
MP26=4L.>-J%,Q&B+)DM:1:<(U=V5C`WN?JD,-=(3(Y*YP`D,P)?&UU7O>4I;
MVW20UV5)CC2E24I(@;*M#=[?;[R4'_/)Z.C^T'VPZI%R?__5^R_HZ/ZOC8E^
M9MMA_(E!]"OE^IN3H0:`:`:`PF/<+5;<=;@Y=)VNNF.E[`9JTEDOL5ZCD/B"
MF3/E;U_:",ME?79Z*3J4@6&R$"<0U&$P\N!:@D`!X*XXA89Q6O=!MS>16QAO
MN^KS":+>V:.V^N431B0-=>N\B:&][8TTE=UZQ,UH2G1$YEA)/Y;)`U19Z7C]
MLIE!)00[%T;K<JEX>6*.M%G5ZZR"4H\N,98FZ:1M<\R-O"P-LKRO8FQ,Y&K7
M='B+O*-RR:G`8#M!42HX>1-`,0D$>.\:4+97:2&7!5H(ZPOB^,/K\.P(F%E9
M9*U(E3DZ1YV=!.^$+<^-K<A.4*$AQ@%!)!(QC!@(!9P$.QRU=Q5&@)&I76G7
M"-.7$<3\9ZN<1E.2"!B`A,#-AFG.8`!B(@.B86'+.>T\X4%9Y3]L!PBP['X<
M+FIYH1-3DZVO6K8W/L5>IVR.#A.HNB1/,(C;7E\D4R:E2ET+(<(JP,H<K%KB
M2(:1*EQRII@2_MM"0[&LNX>UZXM39Z"W*_F3')JVG"6$R*+R]&KP2U.;4YOK
M<),;D2T*50A5`,SDD]*I`2J2J0#(.++.`,`>GXOY(S^2F+.FY5+8KGAX)-'_
M`#?WY;O[K_.=>G'J><A%,LBW&_E+'_,_?EN\[_.=9N4@%,JB^<_RD8?,_?AN
M\[_.-7^K(0:F51CA%_K&P_LOWX;_`#L?NC5_J4@E$HC/V_\`K$Q=7K??=O[H
MT?\`4$(HE$:X,_ZQ,7W7LNW^?G]T:=40@E,GC><?RA8_,_?9!Y^?W1IU8(0Z
M31OAS_K`R=;/[[(/J_NC1\(I!J9-'/MO]8&3KY_?5!YV?^GT^((-1)([[/LO
MW6?WU0]GTZL$.HDD=X<_?]EZ_LHA\_/_`$^IT%R"/DD=X,_?YE^Z]E$/G_X?
M5_LA#L0I\CCW4^_S-YO[Z(?._P`/J7+U9"J9''L\/W^9NOG]]$/G?X?2P?"(
M,Z1Q[V=9O"B'ZG_3Z=2]2%42./<.?OZS>%$/]U_A]0D.Q!GR*/\`#_IUF_9?
MOFB[/I8K3E$,ID4?]G6;PFB\[_#Z$2=:$$?(H_P_Z<9_":+SL?\`3ZBX---\
M$(?(H_\`;??UG\)HO[K_``^G0L.Q!*9"P<'^G&?K9_?-%Y_^'U))#AT(-5(6
M#V<9^M[)HO.S_P!/J]0DXX(%3(6#C?Z<9_,_?-%YV?\`I]25<L.Q7'"3Q].2
M:>)Y;C`E`R+($ZQ.H.%]SP!+)),&88+.?,QC_P!&HVKE2=CNEZ*GHA'S=VO8
M=R^Z=H=(WMP;G`ERKJKE(#FYXNH:0[(L.[V/]J5ME<",+P#E`<50[AR,*<1*
M?_*#^664G1))=S[2D*%$V(D;:VHTK>W-Z5.A0($*<I(B0HDA0$Z5&C2IP%D)
MDJ8@L("RP!"```XQC&,8QC6`<K0%!LG^3K=^'U4?E2AVJB/CZE^U"C0#0#0#
M0#0#0#0#0'6[O!ON?;<]H"6<5R[QB'OD@NNO*J6VG.&\#M"J5CUM7VBK]^M^
M4M1RQO3.+7!D#\)1@L\\M-VQDH1_&)"8`5RY+BI,'WEOBFFQ]G10M=.FS>(_
M(J7OK=1*+2MZ:5A1)*NLJ3/KU$[5/68J>J'$+G5MNBB9<LTM@D2(X)&,95*C
M.5*%C)4I*G-.E8NM);\CK>M]K4*DK-SQ*J*A3_.KP>Z^?5$Z4;68]NF:SYA%
M$-/34#$S((L8Z(EO(+U2@2X"<L``!R:;@(75E9<^F@>\$PV6,6WN+*H`Z;?M
MG.X.7(GR[\,MIHV;=58;G62F*5C"B:Y=$5K2:$O_`&H>`&5[(%>EXX>`I2>G
M)RD:JM3#[7TN%DT=)[GJ]QK2=;DIX@W2[[WIG;DR"T7-V#3E/[E5-90VJ:U3
MU935J$J94C;#S<I3)"8P,"!,A)*6.99B].(*2ZI]2\M/2RWI7C-;1EO5S7<D
MDR_?O9>UFFVJ*'70Y$15G@D'<IRO364Q5K05C6:<K"W-:=,T=[F!R<G5<X*C
M%2=O0MIIV4B$X]"LWITJ=SV8W5O&JPJQ=MS4I9UT<[C<)EE6,?$+N9UVZ*V&
M-6OKB$5,NKS)TZA::)L3@VO#RJ7LAYY3A@Y.CP%,>'*1K$UN?1CJF!H!H"@V
MO[UMD_@#,?Q=<=5<HCX?H4?<ZY64R;?+??Z@ES#!+%CL%?))'97)8>*>M35F
M.ILO3MPQ;VP1DE>XKF-`I3(33E0DR-<<2I/3+223$9\-+FIT:6ITD6ZF+U#M
MTGS+-X0TO;5T:6U[>W.&)[A+`J.W267;TZA,%E=3LHA+&X402%%K#3B^\))*
MLER?V\.!93@R2*2:6*KZEO2[Z-[TRN*<1"J7:NYE);*DG2(UA6E`GQJ-M,CH
MQZV:R1BC-<R]WDBQ])&^NEG$K!C6IGXTIF[YNC;A.:G1X/XX0J&<J&Z0>P6Z
MVF^J-Q;).L`331XJAHD#=%ZS/,=U\[W-KJEIF8VXOB\K3-B)^2MA\<C+NEA2
M!8C;YJKDI3JD;"6DC!(C2Z%.WA;O;]B-@;^'*%;D8;0"'8C559SNO*?D<)KJ
M3$;GWB7UXJL(T,N72S`IT5');),@@S(3%%;,L*?4YAIAZK(RTV025*<E(GG3
M<2JNI'*:]D6UY639<;E5EUP.+G2]>WA!9;C#6:Q-J$1<EBJ+B);EU]PTQT/4
M`$+(FY0VC)3=O8X3,)+KW,LRGI9)I6=F6(W6)MY9CJ7K6[KXV\O,Z@UF.;Y8
MR^Q:0VO#W3K5#-5BZO6]`MC+O%$1C<4;W_"M$N4`XJ;(2LX/2350JU*1#>F!
MN*Q87`5\*VAX63.T[YI"FZ\')93;U;U1*B+XI6Y[0;7)KG]J[=X$].RZLGZI
M!-<CRUL;FVG(UA"YO5J.VB4V$EU5RO7!TCFX&;O\8@4)@""F;@A/2';=:N!3
M\AGLQ8'RRZ9G[S<+,R/4]EQ]-+X:CJVVP08A:E=8>?-2RR.6*&')Z8L*Q(U2
MZT.)(.F!F;5&X_>AE7*TB%)M!NRRI331UCQK$'!8E3;]:KVA2`Y-+C*N)EA^
M`'NKFM;7`U<E08;QA`H:\*!Y4DI&O[G:3LVW12+<PTW6EF4$BT'FE$7<]TM*
M,5W8A]MUE(%R")0V<(WB$V(?#H$>\D@9IPF3+B#FM(I1KB#`&%AXP<8IEJ!O
MM]Y*#_GD]'1_:#[8=`N3_];[+^CH_J^-B7YFVV'\B4'T*^7ZFY.A!H!H!H#J
MTM+8I;,Q56*[1JSX0AD%E1[=HPB>9/'G9Y/KAPOR1I$D6G=<EICTH$LW:Z:C
M[5$UBI3QLH@DC4)<FDC4(%D-22DCV8W3[8UTHA%@U:U.R>>;EI1#S'Z*/[JW
MQ5SN*,UM%JEME`T%N)11-O;?87"5T2:\EFA0J6-Z4G\<DP0D@@DAEG1P*54)
M61!HL='!E[C,G9\]O$;8"U,L8&5DV)R#9-3C?'52C"#"<=:)WD$H)*XQ9&70
M!V`9#A6I$:@;$(_[2KO+NJFYHU,M)C=V4V-O@&ILBLB::"K-HVXUU9-:TLU=
MYRW0<ADLN->]T$AD*3(,-V`DL"!`$TGO64Y&A*AEGAG1ZN55,K2*#RZ(2.2P
MZWJ@G[.*=Q<93-8$3JC;\.LVR%6*!AR$3:2T7)*Y#8S)WK(RC9WO+>42GP42
M/2!L>]/L6LYD9;!:(C:T3C+K.MO=]UN^31NC#R$R6V/=DMLNS61[<H2J>EC9
M$8'2UHW%*%\;0M;B-PPUO0FTY3R1&#30G_!LW=E9,4LHZ&U3*&Q,@85TBIZ*
M.S/&%RPM`@2$2./(#F]B<59)2_*!)@KDTYII83<E!#D0<"X<:WBVG*Y@QE5?
M4PL+HP]JX\9P)IFO5ZO\L5G<^M>7.9,^/$]`NB[VI#^Z:)O_`#S6]S_4T\N8
MTQ/0+HLMIHNKEGG'\]%O<^GERB!X\3CBZ*G:0/KL\ZZO4_ELM[FT\N8TQX/0
M+HH=H@^NS3O^>Z[N;3RY#3$XX^B8V?C^Z9I[_/A=C_LVGER&F)Z!=$?L[%P\
M++/NK_\`/2[N;3R9#3$]`NB'V;"Z[)8'\^UW<NGDR&F)QQ=#[LQ'UV2P?Y^K
M^Y=/)D71%-A/1&;.9#$F)X<F6?B6N"$)ZD14Z7%%Y,R,P.>(7A-G`,<&.MH_
MR9218KDL@NALV4#Z['8GZ4_<.Y=3R9<EU1QQ=#'LC']TQ6-_M!<.Y-/)ER-4
M<<70M;'A]=AL?_:$X=R:>3(:HXXNA1V,BZ[#9/\`M#<.Y-/)D'BF<<70C[%!
M_=,%E?[17'N3ZNGDR&J..+H/MAX\\(H_9G^T=QQ_V33?(:HXX^@TV%#^ZC]F
M_P"TARQ_V/3?(NJ../H*]@H_NH]9_P"E9+EW'IOD-44Q-T'&PQ3.)$PFQ^S<
MM[;%(:[I0AL=QP:%:]N\[1+A#-[3X1EB(CZ;BAZP<X%G]EINX1$E++$+H%^C
MZ%UX[:7^TUS\W_J>IOD6#CBZ`WH]1\/#'+4ZOG6<Y]Q:;L0<8?0!]'@/[J-V
MM^E:#GW%IOD54../_=^>CJ']U&K8_2M%TQ_V+ZFILP3T,Z!;HZ(9+8[+@5[-
M9,=''=$\D,,PGSF^Q9T4-YP5"9,_L8R""'EKR>`.34AV<IU`<<F<`PH0P";-
M@[E"224Y)2=.460006`D@@D`2B222@X`6446#`0%EE@#C`0XQC&,8X,:@/9H
M!H"@V3_)UN_#ZJ/RI0[51'Q]2_:A1H!H!H!H!H!H!H!H#%</8&*4UH=').RM
M,CCSTHF#<\L+\W(W=F=F]5)WPM2@<VMP)4(5Z)07G(3"C0#`,.>#.,XU<N0B
MIMVT[:PT1B-PEIVT[?VN&0V3FS>(1%NINND48BLS/R3D^71M@31PIJ8Y.=E.
M7QUZ4HI6+B!X3/M<<$++N6Y31U*+'T^4*Z?JU5)54L-GJJ1*:_B9[ZIG1\1%
M7YTT/=S6D3@=+#H&++()Q$9E8)HSE'DSM?\`:]"&"&38/M;8KT*OQ-54-4R-
MEKVJZXKN*KH-79T!IMJIYQFSA$'>G&,N'$KZ\D8,3M4G.4(5@"\)B2"R"B>(
M/)@LNYE&1[6=L<Q3%HY=MRH>5)"IE(;&*2R.H:^?$Q5A2YU+?)7.RR'./*B@
M3*3O905C@Z8QA<M5!P:<:,S&!:"7<YDDVT[<9D7."9?0%)RHJSG1H?+)*DE5
M01\+L)[CZ%4V,+Q.`.;"J#+'1D;5QZ=(H7X4')B#AEEB"$8L9"7<_+CMFVWN
MZN*+W;;]2+HN@;,P1R#K7&J8&M5PV/11Z;I)%F***5+":='6:-2)G2+V]*CR
M20C6I23R0@-+`((2[F;M"#0#0%!M?WK;)_`&8_BZXZJY1'P_0N+BW-[PWKVA
MW0(G5J=42IN<VQQ2D+F]Q;UQ`TRU`O1*0&IEB)8F-$6:48$0#`"R$6,XSG&H
M4QBNH"B',JKB'*E*D<":.`W%TJ2NK>'*RJ?+9T;>WM!=7%J&8P%?@:T#2E(3
M8:<),$$IB@`XH2P8P++N3++4=4QN>RFU([6->L-GSA$C;IK8[+"XVUSV8-[=
M@@+>@E,P0MI$AD")`%*5@DI6H.`5@L/%QCBXX!)=SCJ*9IY6\1"0JZHK52_U
M\K>%\!?%$%BYSQ"%TA6#<7];$',QK$MC2M\<#!'K#$0R1J3A9&9D0LYSH)=S
MCR^CJ4L*7Q*PI]3]6SB?0$83(+.)?7\3DLOA9@5`E83(E)7IH6O4<&%4+)F,
MHSR<X,SD77ZN@EW/2[4+1C_(G.8/M+U.]2UZE,"G+S*':NH>XR)VFM5D'):O
MF#F]K&<YS7RFMTJ@PMA<#31JV<L8@I#"<9SC(LNYR,TA2V7,3UFH:OR\CG3I
M:(W;,`BF7,=F/D7#!WJQ!+^]/;0IT[PH`6=4[Y'WP4->,)##1$8Y/0DE<C&V
M#;3"<I<PS;Q1D1RBFZ*S$68Q4L!8,I+(;6QW96ZP4N6J/I.UYN@9I`O2$NP.
M!>4F7*"@FX`<8$0LNY^V+;)MMBQRM3&=OE'QQ0OL!NME<>Q5/`V@Y9:C.->8
MTV8K-;V!.-18#6-T593/(\Y<2,J3<@.#R@^$)=S%]U;%-L]UU-):?65K%JY9
M9*QJ(P9(ZHAL`B,R9HTZVPQ7=*8\P.YL0=4C>QS>S8\2[O:3*8Q.Y+Q#5'`R
MKR$\(2S8JOZUKFIHV1#JK@$)K2()E*M:FBM?Q5BAL;3K%YO++E9#''$#:V%*
M5IWVYI@2L#,%U19SG0G)K9OM]Y*#_GD]'1_:#[8="KD__]?[+^CH_J^-B7YF
MVV'\B4'T*^7ZFY.A!H!H!H!H!H!H!H!H!H#%EM?Z(B/_`(IU=^.S-JKKZ$?'
MU,IZA1H!H!H!H!H!H!H!H"@U;[WT4_BL'^--U<N61<(OVH4:`:`:`:`:`:`:
M`H+=[Z4Q_`&MOQBM?5Z(G5^A?M0HT`T`T`T`T`T`T!0;)_DZW?A]5'Y4H=JH
MCX^I?M0HT`T`T`T`T`T`T`T!0:R_D:B_C24_C6]ZKY(B_:A1H!H!H!H!H!H!
MH!H"@VO[UMD_@#,?Q=<=5<HCX?H7[4*-`-`-`-`-`-`-`-`-`-`:;;[?>2@_
MYY/1T?V@^V'0JY/_T/HXV,V9/$&R;9XA1R=S3I$6UG;XD2D%C*P`A,GJ6(DD
M$@QDK.>(64#`<?4QKHL5"H<L\LMLJ]3:;G6L7W6NOHRNQ:NJL9VRN.=:Q?=:
MZ^C*[%IJK#;*XYUK%]UKKZ,KL6FJL-LKCG6L7W6NOHRNQ::JPVRN.=:Q?=:Z
M^C*[%IJK#;*XYUK%]UKKZ,KL6FJL-LKCG6L7W6NOHRNQ::JPVRN.=:Q?=:Z^
MC*[%IJK#;*XYUK%]UKKZ,KL6FJL-LKCG6L7W6NOHRNQ::JPVRN1[C84T=BTQ
M+E(G!86C<$#JF`:,O."7%K5%+6]6#@+Q^VI59(3`^9Q@XU=58;97.4IM^>HT
MYZM7-%Z5(E)-4J5*E0F(3IDY`!&G'GG&EA+)))+#D0A"S@(0XSG.>#4UQL-L
MKD!%-Q3I/&KO[![9;YFR=M'H>_,4D#-(FKMU+D.%2/OBT&K$G;2;(P\H7Q^.
M#AQPXQPZ:XAY9+EDZ;<,[).3)SILN*4+!&`1D&J4Q9RH9)0CS@)BA`P,\11`
M!#%@.,Y"#&<YZF--<;#;*Y'L%[R:5LK9)(M9(9+'7I(4O9WY@=FUY979`?CC
M$+6QT;LJ4*](<'J@,*,&`6.MG37&PVR7+()3N@[3%*0K+KCZ04&.:TTV"IEL
M=(%#U#YD&&4B4X-4AS'SGC)@>U0J^1$HXV.3P+AQI&)9SIR77G6L7W6NOHRN
MQ::JQ-LKCG6L7W6NOHRNQ::JPVRN.=:Q?=:Z^C*[%IJK#;*XYUK%]UKKZ,KL
M6FJL-LKE3<[R<J\CCFN>+$*BL:B$;=I,[*7!Q1(D+%%6!.8N>GQ:-1C&4S0U
M)@",//%^UE!QPBSC1I<L)Y429R#MP[PF01QU56FF1MLO5M+?%%JQZ:T::2.#
M\G$K9&YB-4B*"ZN#NE`(Q,01QS3@!SD`<XQG2,1ME<LG.M8ONM=?1E=BTU5A
MME<<ZUB^ZUU]&5V+356&V5QSK6+[K77T978M-58;97*T/<0]%3!+7QEG8!.%
ML:7S))%!."/#ZIBC6Z-S(XR$ENR#M@;2B=W=*F,.P'B`.4`#G/"+&FN/$%G*
M)FA"L.ZY%*9"Y1&,7O%9'*V8Y6F=XPPS6,.\A:E#><:F7D.3*WK%#DA.0J"1
MEG!-*"(H8!!%C&<9QI&(G-5<P7_G6L7W6NOHRNQ::JQ-LKCG6L7W6NOHRNQ:
M:JPVRN<,%CS@M>I=`25Q"X+$:%O5*\#+Y4Y&VG."A`G'GD^#DTI[LI$'J=<X
M6FJL-LKG,YUK%]UKKZ,KL6FJL-LKGX';5A%`&89,',LLL(AF&#-(````8R(8
MQC$5@(0A#CASG/4QC356&V5R%2W](%SP..HK.(62`MC;I.8QI7IJ4/`(T\*E
MR%ID(VPH0UH6-T6MBDE.KR#M<\U.:``Q"+'C#7&PVRN3O.M8ONM=?1E=BTU5
MAME<H\CW1EP]Y:(Y+;NCL6D,@P$3"PR.7QQD>7L(S\I@":&MS5)5SE@2G')X
MR26/A']KU^II&)9S=5)=1VU810!F&3!S+++"(9A@S2````&,B&,8Q%8"$(0X
MX<YSU,8TU5B;97(5+?T@7/`XZBLXA9("V-NDYC&E>FI0\`C3PJ7(6F0C;"A#
M6A8W1:V*24ZO(.USS4YH`#$(L>,-<;#;*Y.\ZUB^ZUU]&5V+356&V5S'JG<B
MF>$TV+66TTGHJM>$.+",5OK6G1P5Y9DK1-T690J/&2G8SF]"<C<>%0,`0$B`
M8+[7.D8EG*A^&W=LU/,;<)DSW]#W6(-)Z=*Z2IMG4471MM5+%12)(F<'Q*N-
M;$9ZI:>`DL!AH1#-&$`<9%G&-(Q$Y\5DR+SK6+[K77T978M-58FV5QSK6+[K
M77T978M-58;97'.M8ONM=?1E=BTU5AME<<ZUB^ZUU]&5V+356&V5QSK6+[K7
M7T978M-58;97'.M8ONM=?1E=BTU5AME<<ZUB^ZUU]&5V+356&V5QSK6+[K77
MT978M-58;97.&@L><MB8"-!)7)*E`8H-`24,O``F*E!JM0/'"7G/":H/&//U
M19TU5AME<YG.M8ONM=?1E=BTU5AME<<ZUB^ZUU]&5V+356&V5QSK6+[K77T9
M78M-58;97'.M8ONM=?1E=BTU5AME<<ZUB^ZUU]&5V+356&V5QSK6+[K77T97
M8M-58;97'.M8ONM=?1E=BTU5AME<<ZUB^ZUU]&5V+356&V5QSK6+[K77T978
MM-58;97.&X6/.'9`N:W&2N*MO<D:EO7I#1EY*5(UA(TZI.;C!>,Y+.(,$$7!
MG'4SIJK#;*YS.=:Q?=:Z^C*[%IJK#;*XYUK%]UKKZ,KL6FJL-LKCG6L7W6NO
MHRNQ::JPVRN.=:Q?=:Z^C*[%IJK#;*XYUK%]UKKZ,KL6FJL-LKCG6L7W6NOH
MRNQ::JPVRN.=:Q?=:Z^C*[%IJK#;*XYUK%]UKKZ,KL6FJL-LKCG6L7W6NOHR
MNQ::JPVRN.=:Q?=:Z^C*[%IJK#;*XYUK%]UKKZ,KL6FJL-LKFK.\.S)XMJ6(
MDJI.YGE`W3;&580#&5P!4H-[.WQ<C.QP%8^W3JTX#`__`*@XU'BHX-8Y92Z]
M'^Q__]'O^V2?^3':+^;#0?Y*HGKMC_%>APS_`)Y>K-GM4R-`-`-`-`-`-`-`
M-`-`-`:K;TZNFMQ[=)G`X"W(9"_+7>OWI1"W-S2LC98D<B5AQ:5RRN5[RM+,
M2MJ:<1IF5-N1FY`G&)1@M0,*<9N=9R4J#>#2R39U>WS'+:@J*V]P-:U-/MI$
M7GTEV55.RU=$I'6\'LNPI*QWV:GE,N5!K68O4#BPGJ.3`J+HPK701;@B)Y1:
M`M+D`<Y<U:4<'3&'&+<NO[%WANW+<FY7#M9MBR63<*X1.`;BKR4LD??;R1/%
MFU=3,R88IFK06@Y-=DF()DW`F36Y]_R27%\6'1M42VJL+BB^0RARF[D>6,9)
M1,%PVFUONXB,@VXH]PC1N">XTQ4G`6=JS$K=8D<6@EG-KC88K&.W&,1UC-3Y
M99;FRGLH6LXLI_0IP%A*`FPHQDP%Q65)&3P>VL3/Z@UYW/;)=R4AG.[JVJHB
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M92.S2[?`95,AKM?6<P7;7V6E*];YXM>JZL6N7,M&H6N)3&T*TXVX_)S@X95)
M1A/:K]0M'JJ=/^D7&XMOCD572%T8V'<4JA]B*-M`$**;WT2ZVJT*S(M+5-WV
MU7SC7FX*LEJ>$N[JN8"T$=,F#*28+)JT:-*G(.0FONCJ7[$ZQ-?UP4C.U;=O
M)&0Z6VK&+DF=HR[HXMR-"N2X-J-IB`-OG&6:U01AL-@!8"=H>FB70MV0B2&`
M)<T8I$(A>IR6J+$L+0^O,#;'A-1LF9D:J-WH1'O+#HHZ6>XQF-7?LUEL363F
MPQ/R1G96^G7MNO=&K/P_`=Q5TUSPI%A8Q%8[3^V%A"FR5G.,(R_8DX<N.&8^
MAU8=(WS+6Z@G+UN*99VH;JB+PW-<CC\J,E<\89(]/4[>(9+4^[Q-+8W!)XW#
M2MSRGC*J!A;TQI!C4C*&2M)TC*'?]=RM_CE1$?KL;)[J(MO)EE![?(Y64+GL
M:L;-?/@K&75Q=LF4/U>6*UU^TBB#0K?CKUJ@VQF]SE12DE8\/;C*$Y':^1G-
M[J<J+'FO:%')G%X)Y3P46+UGOE,MJ,V9(9#=19B>Z-H!+M%LV61BMC:N6[:8
MJS;GE2NO"'X47.*)M9*H&;C"7)Q#D`:IO`')YYQTC*9]"MX0U3A_O0Y6S.D]
MT4>W3M-H[@H[:AKJEVX7#7T]GDZLN+SB'/UD/-\5Y+&@VHV-FECXOA5>.\):
MPC1-XT32!.)"868E`<$2A7<4YEV)F\=8QCDQY`MM5TKGRNXNBVSFU_-JUWQV
M9?;MN>E+C5R)`.LG&UYO+4T6B:B*RYYM66E65%'@EJ<$*E`WMY28><FFY$`D
M09#I3J5Y*KVHU$&->]W2!5?4-LRV]YS84&;F]54!-L.#M<$*BK=*"#KL:Q3Y
M\H"X)9N-?6BKGN7P-W$U)4A37!&8@1B4E.G)<`CX7W0Y9?L;4+]=Z?\`I6HY
M\/&XZ>C4OIJ2WI*:Q<;,W6M\>=V>V&Z16HR##8S:P4=*7&1&[A*IC-H1"*L3
M6L3IP%/[S&%*C!ZE4B7)C$QY<^YJG!?L3AI33]<&V*2J=^#?:KC/VN:6<>]J
MMQ=J1Y$VR*>C54F52SCME3&PV5GU<9(75H0M0=PN/VH)!1KBB``1900IQ"$9
MJ,N>YF<(B%Q_O_PQ7750=(>[5R.-3J1[AH:ZO5P[6&F8GDV0UCD;8P$2)U1[
MCY]7U@8OVW5PF!SC3B2J/0!0L;.2H))[U-`.(<F*D91U*W^.:1P_^$K.:,WM
MSJW[9B@$5P,],RV(;DZM$0ONE[>8I*&7-:C)H27]\GJ]9*H:7N524@K#F!JB
M<5*1@4&)%IKCQU)@364NP66"2XFG_>A'M-![PXU$(*YUFW7U%'2H-I^VEQ8X
M+);F&H]N5UU/N`L:26E4\B.3V(\MCU&Y?7KL-&WD*E`VLMF4MB7BE@1A1D(R
MI%AMC+F*M_L?N:TYTDS8S[?DS/+K4>E:RM0/TY?8S.\O;O7VXV96:JG$A+EC
M%(=PE2LTTK"+Q)4DCC<@5#D;$B0HU7)MP3CDZC",J!/\?W<?\_P7SI"=IUV7
MO;LPEM>Q@A^CS?M$+C`6E:V0A:58\D07."3N=6-CU)A#=X!('N)\J8D?F["=
M2C.XG)J`BX0Z98MNEB?CR6*4OJ5:2TAOLLRU+_CLI/M!JK&=1O<`UQ##?.22
M:]?:XDU<+&JBX,M)QN$P*`3.+R8AO"ZJD$(PM<S1N`5[DJ0*0"+1DV["<$L8
MB?UV(4BB-X;-5S1':W;MP<$/2;2=HD!*3K;>)42UCM")[OW5]NPAL>@SY_3%
ME(ZJ7*!(Q!/&ES%#4[6`&"B^]Y:,HI8LX36.7^Q[K;JSI`4T`D-=UT7?#O[7
M;:W1KJKL4N[GI3/$D43(HFZ;?VV1KS[YK`R6QMX<S'4&%\G'+LH4R7*8;,>8
MH3YP:R">$RXX7_3+1U"W^^[<NDD8GR$KS[$OY&4OA+>)='2#IF\*=LM81-T&
MD&2Y%MJ`8YJS+DG%/&G#RA6<AQR>0"S8<979G;';\=:+_P!,6S/;]N#EA-N6
M;3.WB2;:U"_;I5M3-L81R2M8I8ULV`R73`96OGCBUU9,7N/LI,)AS*ZMR18X
M.Q;JL2.!A>2L$\F#$:=6E%"K+%0GE-2=LN!](4.4;GBJU16A((K(;2BTD8GJ
M3V<HA\I6UPEL1P#):BIB.1_<0DB#$P%0Y(E5HI$@.KJ3*VY08D5GB<QA-2'M
M6`GA&,QQ^NG_`*4EZ@/229;Z1$SIKNR\0YOBS\*2J9^0A<'%*KW!O)T@@MMQ
M$G=4_05Q,C5+JDH0+'!MG[N]%&$!,4MZI,M$%]U/U_LL_CKQ^EZ7]"S3F!=(
MAA5?Z>"MUK22-/%XPV5EO,GM%;$9_(*K(?IZHEE5U/&HSN4;XE%F1C3C8AIG
MI@<ZX=7MJY5,<#*W.1%&LJP1/\?VS$Q^NG_ID:NX/O;9[)V<.<I47-.V=DB*
MICN)NF,G;H'$H^B<9G8J]%-I.9`=Q4H.GMJQN%`8FM2TOK;,6IR*,*5$*TCC
ME<<FJVE$;PC*(_7T.WO6SD-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`
M-`-`-`-`-`-`:P[NO>JB?YSVR3_\SJ#U'Q]5^YK'E^C_`&9__]+ZV>CYI:OG
M781LA=%K4J,6.6T+;4O5F!='$L)BE93,+4'C"6!0$`,"-,SG&,8QC'6QK2R<
M(F6..V5.IM[S#UK[#J_"[GW3INR:8V',/6OL.K\+N?=.F[&F-AS#UK[#J_"[
MGW3INQIC8<P]:^PZOPNY]TZ;L:8V',/6OL.K\+N?=.F[&F-AS#UK[#J_"[GW
M3INQIC8<P]:^PZOPNY]TZ;L:8V',/6OL.K\+N?=.F[&F-AS#UK[#J_"[GW3I
MNQIC8<P]:^PZOPNY]TZ;L:8V*'8-209@;X\H;&U02:X3R"L2H0W)>=@;:^2=
MM;'$G&#3Q8`,Y&H&'`\<`@9SPXSC.-59-R1XXV+YS#UK[#J_"[GW3J;LNF-C
MT*=OM5K"PE*X\-44$TD\):EQ7GEA.3F!.(."`T\0<&D&@P(`N#A"+&,XX,XT
MW8TQL>_F'K7V'5^%W/NG3=C3&PYAZU]AU?A=S[ITW8TQL.8>M?8=7X7<^Z=-
MV-,;#F'K7V'5^%W/NG3=C3&PYAZU]AU?A=S[ITW8TQL>H^@*N5$G)E+"<H3J
M"C"%"<]S<#23R309+-).*,4"+-*-+%D(@BQG`L9X,Z;L:8V/V"A*Q*``LMD4
M%EEA"`LL#JY````,8"```!4X"$(0XX,8QU,8TW8TQL56"4Y`GR(,#LY-:DY<
MO0`/4F@<W`H(S,F&!R+!92@)8,<`<=3&,8U7DTR+#&."V<P]:^PZOPNY]TZF
M[+IC8<P]:^PZOPNY]TZ;L:8V',/6OL.K\+N?=.F[&F-AS#UK[#J_"[GW3INQ
MIC8<P]:^PZOPNY]TZ;L:8V',/6OL.K\+N?=.F[&F-CTJ-OU6+"#4JM@-5)E!
M8BCTZAR<#R#BAXX!EFDFJ!%F%CQG@SC.,XSC3=C3&Q[`4)6)0`%ELB@LLL(0
M%E@=7(```!C`0```*G`0A"''!C&.IC&F[&F-BJ(Z=@1T[D;&8UJ<MS=$H4[)
M2<.;A@8%KR\3Y&X&"-PHY0832&%-C`<YR$.09SC&,B%PW9P37&70MO,/6OL.
MK\+N?=.INRZ8V',/6OL.K\+N?=.F[&F-AS#UK[#J_"[GW3INQIC8<P]:^PZO
MPNY]TZ;L:8V',/6OL.K\+N?=.F[&F-AS#UK[#J_"[GW3INQIC8<P]:^PZOPN
MY]TZ;L:8V',/6OL.K\+N?=.F[&F-BI36G8$S,Z-8WM:DH\Z6P%I,$)S<#<91
M/T[CC&YEX"8H$'`CFYQ-!@7W0,BP(.<9QC.JLF1XXV+;S#UK[#J_"[GW3J;L
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M!B$Z.(\93.N_?;4UK0<4:C.,9,1K#`XSUPYSPXX,XQG1Y,N..,\='^Q__]/[
M+^CH_J^-B7YFVV'\B4'T*^7ZFY.A!H"MRZ81B!1UQELR>T,=C;0%,)R>'(W)
M*)'A8L3MR3E1X"+.!*%RLHH&,8SD0S,8QU<Z`@ZTM6N;DC)<SJV8,DZBARC"
M9/(8\J[=:5)HD2)R!VJL"$)2HHQ`XD&A,+R(L8#0YP+.@)Q;+XXW2J/PA8Z%
M$RJ4L\E?V%FY%28I<&6'J(ZDDKF$91!B=.D:%4M;2C!&C+QDQ:4$/&$+@T!9
M-`5MCE\;DKI,F5B=D[BZ5[)$L0F:,D)X3&"2+8A%)\E:5>32BRQJ#H?.&I=C
M)63`<DM!C(N/@80@630#0#0&(KH7(FR.1QR<EB5O;D%EUHL7+UR@I(B1)")F
MT&'JE:I0,LA,G)+#D0QC$$(<8X<YX-:QK/H3+CZG-'=]+E_\I;U7E_W\_B@?
M^,[8TUR^+&V-T<4=^T27_P`I=52E_P!_8\.#_P`9YQIKE\6-L;HXH]Q>WPOA
MY2]J;+X.OQ[/A(>#Z_&?,::Y?%C;&Z.*/<SMO+_Y3<%2(/[^UX&'_C/V--<O
MBQMC='%'NGVQ%_\`*;C:'!_?V]7P?^-(<::Y?%C971Q1[M-JI?W>YG;Z#@Z_
M'N:N0\'ZLDQJ:Y?%B5<XH]X6T@O_`)3=)MS!P=?CW=68?LR?&FN5F)5S,<-G
M,)L5A32JOIA%IW&%AJ@A)(X;(&F3L*HY(:(A42F>&16N;SS4QX<@,"$S.0"Q
MG&>#.IQR4M.@*#5OO?13^*P?XTW5RY9%PB_:A1H!H!H!H!H!H!H"@MWOI3'\
M`:V_&*U]7HB=7Z%^U"C0#0#0#0#0#0#0%!LG^3K=^'U4?E2AVJB/CZE^U"C0
M#0#0#0#0#0#0#0&A>Z+<A\$?8C=FX-.-F"^0"-S(4++D9G),"FQ)-.%L/KE(
M^#[829PS*IR_MX%>>6)X$V1YR87C&1AN7+&*EP:94QTL#E,ML%0.I451;@MT
M%D6-N6IP3+M^<(>U0!>];:"9/)IE93`_6#,$D;Q$#ZO2L[ZV)AN)Y[H-X3$%
M?:#&<7F36M>PVN]*^ND41VFUC;T#D<EW#7O!MGKNVNS8./,;58[;N(B-D/\`
M/+7:&="C((9XG38J@?A/I)96,!P63@G@Y7`0I&O,<$^Q=-!6TD+EC>PT58LC
MES)9FWNO(HPQB40%U9[/#N7F,GK^N7J!SU2\-D*=$P9A%3T*P_*L+1@P8#$S
MBI("::6D:]S--:=)8TW&NIF&5IM]M"16[91MQJ)M6RB0UJQ\S4>V]V^V4C;L
MCE$N>)8EC\E2-4X="BVI.R"7*W4D6!Y+38P+B)&O-36)DZ95#$JA@LTFM,6-
M9^,T2_[C+3FD+*@$/10RJH_N+EM!O#V=#WV=*5;BZ-3DSI#BV]L5KCUI1XC/
MVC`!X"D:R^3;"*])%%YGN?B^WACI>Q_:[,+\OC;:QW:N=X&1#5MG[:ZXED]M
MMN+C:62KIT2A:E<8RUHE*A`04N49.,QD`"`<ND:TD[)M4R-`-`4&U_>MLG\`
M9C^+KCJKE$?#]"_:A1H!H!H!H!H!H!H!H!H!H#3;?;[R4'_/)Z.C^T'VPZ%7
M)__4^R_HZ/ZOC8E^9MMA_(E!]"OE^IN3H0:`Q9>:&<NE)W`UU>E3K;*<ZOGS
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M[G[&-/U[@Q>\?\Y^C^ZT_7[`Q<[_`'(OK"^QIU9>AC%VZPOK_P#KU'U#Y,9.
MO_.?\+[&HRV,7.W[/]/[(=3H:1M'LEW]6;L=L$YT9`'2VK)*>GYPJQ5+AID3
ML`H(2BW]@4#`>4R2YO(QQ2U."Q%J2L<BH"(."Q%9RQ62[EQ<'VMT1?%7[DJS
MCULU')$TDB4A3X$$0<@)=&5Q+"'"^/R-MP88<SO[4=GDSTYF<^8,L1A0RS!\
M&FG#.LR6.K?>^BG\5@_QINF7+(N$7[4*-`-`-`-`-`-`-`4%N]]*8_@#6WXQ
M6OJ]$3J_0OVH4:`:`:`:`:`:`:`H-D_R=;OP^JC\J4.U41\?4OVH4:`:`:`:
M`:`:`:`:`U&G37MW<*@A2W<P[P-D@\4N!MG<<<+'FJ>#1E/9<'L%ZE$$5&KE
MSXPMKLM;'=K[<(;U0STQXT_&&09@OJ7+D*>A5DNU;85N):Y'-F:!U#<+!-[;
M56Z_26+R?$OC[I;948105_?B'&/2)8THW!ZB:(EL?424125W2XY)Q(48$+&8
M66C)$9V;;8H<_P!-2B.T]&4$@V^UNXU#3KH,UX7J816[JWFM*^*HLN3FK`X(
MCFQ0<GP8MPI4`*4'A`8'!YW'"7<H4.Z.C9;7Y[:IA]$,+(<SOU425K$3()NH
MP@=Z,ESM.JB-2@6R=262DK^2O:@UN2XQVH41D"7)>4I))!82[G'G^UK8[`6J
MOY-8,'A4(1P>X764UW+G&522,.C);=]V2@>7A*T2Q-(D+T(=H6:N29.9Q*1M
MS@KR05E,((2P!"60\VV@;!*\K*:HI]7\"B=7L5#2*NIWE_F4F;6IFH%QL!RM
MB1MSTM42D"IOC9L_.5.1BX1@#@&\<L)^"@\G@)9CV(=&]7J7>\EWU>W=N5JD
MCW.I]!H5$:\C\40`E-J5YS=R.42B5I')Q.ERAPB:P_.3$R)I.7*32U#@:M,3
MD9!(+M2#L5ELRB$`8%TJG<JC<*B[8$L3E)):^-<;8&\)Q@22A+GAX5(VY($T
MX>`AR88'C"SC&.KG5,E":]PM#O3UF.M%RU@XO?\`]/<%-Z2<1PXY8*VDC\OJ
M\INR!QR6YG6$ABSD<S`3B-&XE(3Q$8&$L6<"P[&0Y-*8Q"F19)9E(V&)1QN$
MD"X2"3.[>PLB`2]:G;4(5CJZJ$B!*):XK"4Y6!F!Y0XT``\(A!QD0K]K^];9
M/X`S'\77'57*(^'Z&E'2AR^:51MA0[@87+IE%O@V7C0MX3A##7QZ9A3FIHM9
M\?;+;@\E3,JQ)F21-UKM_<E"ML4X-3*1I"\Y!R@"A!RS>/,'2AL_W"[ZT<YL
MDJ92"Z+@FVU/:_>&]TZK%<YF+V@L^3;L*!VX610%$2!%A?A9)&FJI*[3]M:F
MS!!^4)R#'>TDPWM;B#32_P`FUS+TCF[N?1J`LE5R3;W,UUA[T*1VUQ#<CFH[
M)9ZADK9;.UJR+AL!`B@"JQU#RMEE#V+&T[6I&F?L$K``PB5%HUF%0RTDU2YL
M:;6;O$OF`[1+DIQCFK!`F*T2>F)<^=FQHY8L\D,WEL&O2>1*%;<Z:>(O+XUB
M!V6KC$B6.C:Y+1.*="4UDY*1Y*(.",$E,^ADZ1]*MO&HA$94Z"NXG.G*O6QO
MBI$C.CCVK`:7N&VNP65;`E[J<1)0GN"F07EEYC<ESP@&Y93!R0-,;RN0)+JC
M*MG;WMQU5V+N"J@F35[$DSUNS<ZIE-^6%&;ILR`1%8Q[&:CL5GA<>@R*T4&(
M<_WK8APVEA3-BUM;4HQGC);UCLHP,X2$^AB7:GTDFYF%)NCVVWM,(9W=DE-&
M;*2N^UE.,(;GJ]$5OIA)+6E,4L2PMP=>OYLAK-O3@[0;&2)356Z.2986O$B+
M.1&:!I5?J7;<O:FXI@Z3:Q'1GLZX(K2-=;G.CAKI^D+-?,Y+KNLX[=K&26^Q
MQ[VO&`*JV<1BXY'DEI=)&L6I5\:/7%*R"%><B"`%$=S$LLZ6#<Q1^VM`]QUQ
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M'F5:[B("#)R;`Q'81\7&,F%\/#]T'KX`ZR(_TD#XG0[9%5C1"(QHAVCUT+-Z
MSPWKW5:UT(YT[6-[R7MR-H^5,>'&/3J2[<)6H:<GE*E)K`A"<'!F30'9DFM>
M399SWM15D>&V%O5.W<UVJ\2:#1UKJ%6BJK$W5IK/B]PR>NY0)63;!T$0QF69
MHB3-Y9BEZ(5(G%O$6N3I2\#.!20<-FW[U!(&5GE+1&;*5Q#+/63M84J[U1-,
MTTN.V90LAL7:;**5S1.[C=$DA;SRW4,>2OY#2G!A6J-*1F%*!A!K6AZ2.;$R
M5H?I9M[L!EK1GBG27O$_:6(ZL)+,"6S8QN@INED]@MB@-KHD'>%IB\CD`Y"V
M!P<Z*7LD!+,4XI0)E*^277N9DE?2>[6(E);:C:J0.#L.GX/;<V>EL><Z\=CW
M[-'UZHL^QHQ'8>5/0646^-$50+!%*71C:V18I0GD$.`S`8P*R35E^F6^&M:X
MF,3@-B1*;0R7S6&S"8L,9<WREG"4FXA%<36UWEB60R-V\^S1N<!0NO74XI<>
MW`8>V2`I3'$M0<44,((UJW]5&<^Q=DEL3LRL2I>TQ*5-#]8"&#(8^7`I_"K5
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MX$LP68(D.4^`&F\,W+.B22[GT+5;[WT4_BL'^--UG+EA<(OVH4:`:`:`:`:`
M:`:`H+=[Z4Q_`&MOQBM?5Z(G5^A?M0HT`T`T`T`T`T`T!0;)_DZW?A]5'Y4H
M=JHCX^I?M0HT`T`T`T`T`T`T`T!H=NCJ===W1_;FZR8(:WSR;2RC-RK)6\=7
M)&A0<ILAXC%CLT*$SGO8BD#4^"?7$HM*L$:1VN89QN5!CA%BY<L8T:]30W<A
MM\WNL,-H");7HI8,<:6K:NEB<<9Z-M>,4>S5/O-&[5X<CMO<0U%3&'H;7J)!
M$FUT3JVT"65DG*0*`FM"DY6C4$9-J*R83LG;QTM9ER3Z$Q&S+N/I%TNC%2L4
M\;;H6M+TDI?<C9RJX;*NIG-53M9(&KX,T:96Z&QO..6?D92]2E0``C"8<8J$
M\8[G(L.MNE:=;6WONL19;YAD1GE&;Q(G5+.S7LY.\<#8R&814W;-,:M=I#N-
ME[A!Y5)X:J5'!.98[7C<UYR)$:0H4D'*LJC[:'ZW%;0-\#]9<-C)@=TEYUG&
MYGL4FU=29QW!PX^!,14*O1NGVZ8=[5^\32,NLWL(#VK3+X\L2L;@F;V-`6C;
MC41*(U*H"5'23)6]?9K>,QOWI&)I`*\MJ<(=S_1Q-]85HY-5II,UQFV8QF:,
M3G7+U`G^?M930XN36O:%S$:%H,:"%:IW4A4IU:Y=D\1-0O4Q';%!=*7"`S:`
MU$\;B9WM]C]P0-[;DV;K/4WDZQ1YVE1%,]&P:8E[@=O\N-A$$W'C=#3XT7+6
M=,-04F"4B6M(524]4J>/7DW`O"B-P;FS=&G:MITZ][RSMML8E`=R%-&FU*V3
M216/.*EC499;H(@TQL`RE)A/:S?6QT)-1%R@X@D]^4*FM4?R19F%B2ON,2ON
MWS<\NW=J;AK*E9Y3M:S"WNBF>5L;1R"`QM0Q5=3\>W1$WA#)$V5_.76/*&F!
M"G;*E<V]$I7-ZL2@&$G;198A`"5'-S7(K;9TI""F75N')]T<IF%C[7'PV:M<
MNOXR1BCU^Q/?+5ZNN4\*.<YP/$*7J=L!3R8K,:SR4SBE*SV\8:MR'`Q91V2T
MM%=P[%(M\B_<<T7\ND3L?>:ROY\Z6K''O:LZTDN>'A13D<J:HV>PU3C7TYCL
M+`2G>3'"+D.!YQ)XU#LLP>1C5QY1C*-7%CL/N"W()0]:RRV[-=%S/!H4A(<'
M]P;(_(96XE%*UZ1J1E(8[%&MZD+NK5N2\DDLE*E.,R(S&<XP'`A8#DUJDO2+
M;2H@TT8^2"PW9&U;A*ZA-O09>FKZP7=&RU98JR+-$.L2T5K+&7%'44->I'-F
MIJ+<9(8V)<.2S!&1X$6=R:2ZL./2,;0F>:6O!'>SUK6[TVV6$XRQ>N@%B$19
MT.J)2RH+98*_E^8KF-6;+ZT<Y*VHWIGCZIQ<T2Q>20(C)O'"!(U9FFJ=R-1W
M6L+;:[?USPZE(9>J?FA5'GUG=86M@E@NM5R:/SEO=V]$JB4D2S^.NS<0B6A*
M-7#9EQJ7EB$QAN`B#$5W[_=N6WV;OL&L!TGAZJ"L4;E-N2.%U=/IY"J.C$R4
M*TL3?[DE<3875J@K?(#$!QA.%`Q'%I"Q*SBRD>.7T"39L"*\:4"C4N`K@JT*
M!&3-5*M<*P(GA&E3UL:A(L4]2IR[<B03`3G1,!Z$(6`M0E!6%62LF`X1#FM%
MP5+()1B$,-HUT]S3)*Y3B(-$VC3E*,IVP"4QR/PP(W,YUR2WEKB!'BY+BE8.
M!D6<<</"$$/C<#0PHZ.8!NVHLQ(M^<(L9*,63#<QT$G:6IP?G6.#>\/7>P+\
MV,;0K6J$>3>V"4B4TX8,%EC$$6'8TCWE2#81)Y#5ZW<`<*V5K=?-<[>5D7AM
MS.X(?`YO/'-VD4:,W$UHR6U$8,OBK6YP@Y4<"3-CL>0)-QB4AF`#XH*>AN*I
MW(TXDE;#&3IO'`HI)6"RW&B<9DL6Q7ZJ')Y?$X.F5%28;Z$D\;Q()HA*1#*+
M,2J,F<7!V#!%EC"&90B<RB$]9BI'!I7&YG'CU"Q(0_1-\:Y$S'*F]28C7IBG
M1G5+$)BA"K)&4<#`\B*,#D(L8%C.-"<&K6^WWDH/^>3T=']H/MAT*N3_UOLO
MZ.C^KXV)?F;;8?R)0?0KY?J;DZ$&@*S-(BRS^'2R"20I2?'9M&7Z(OY*)<K;
M%AS+)&M4S.I21R0&D+F]28A6F8+/),`:4/.!`%@6,9T!@)QV8[<'9TD3LY5V
MF7GRZ4LDLE"98ZO*MM?U<?IM]H1O:G5M5+SD2R,CK.4NB-2VB!E(L/<E*H\!
MB@\PP0LLD6/:;2S"[,$A):I4\2:-32.3EKE,PL6?3F4!<H9%IO"H8U*9%,I&
M^O"J*Q..6*]%(FL9V40%3BI6C+&O5*51P20S7LKV\L^&(IOB;VF0L@HZ(]F(
MGDZ31Z5YATR>+`B'M_CB20IV&>AC$N?E*M'AV3*\!P,)(^.0664`)9Y'LQH0
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MX^9G'C"`@*HE(W.SH`@H"Q46M(D%VK)E;>V1*EFWR0M\)9^_\H<I!"FUG9\%
M#.&O5K94UIP$%E@4)1"-%Q_M?MPXX==/QN,I?!SS_BSI`<J,WKG\/$V^O`O.
MXK69]7SY%KN\\:_<<=<K%"<=NF^(_&>)MU?Q=3@^U:Q?4QYLATWQ^1='8H3E
MM?WW'\;B;;9(+C</W+5]3/GR'S\Z;X_(:.Q0W+:3OY.P+!>V65#X>'@XK5CS
MOPA\_3R8W&CL4-QV:=(,=@7)[7)>/KYQP-(.KGAZG_>+SM3?&Y='8H3CLAZ1
M4WC\GM2F@^'C<'`TE_I?]X]3?&Y=#'[EL,Z2,WC\GM)G0^'AX.!H*ZO#P?\`
MS)Y^-3=7-+$['^CBZ%B;SB9-U[[\8IF/1B'N^10C;NZ$IS#)<Z-Q@<@D5AE$
MKEA2:(IE9?[2U#R8<\#!PJ>30!P2OQEG,0S6*CU/J_)))3DE)TY19!!!8"2"
M"0!*)))*#@!9118,!`666`.,!#C&,8QC@QKF4HM6^]]%/XK!_C3=7+ED7"+]
MJ%&@&@&@&@&@&@&@*"W>^E,?P!K;\8K7U>B)U?H7[4*-`-`-`-`-`-`-`4&R
M?Y.MWX?51^5*':J(^/J7[4*-`-`-`-`-`-`-`-`=?.Z+=*NV=[2#+I;(_#I$
MN*M*)P-.58<X.K>!LXK-NY/`Q2F9S1/'I2<PQB+%OV5RX\*(WDTQ`Q=3&-7+
MD8J:&+MOO2K59:"&M&2P(L[1VPK+E-Q1J,J*E(DUUTO+V.C9S&X/-+CAMM-T
M1C9)E(BS)BW,,@=&]M1)4*57@TW(TX>6S)IXF263I0]ID@CRA];WJQ0*UB6I
M'2`1%PJ>>M<YN2/WZ]NT;I&45#%G%E3.4TCMF/;$L(1*B\%!1A3B-<,(B.*:
M)(U9BA!TG\:L?=1MYI:GV07-//:HN&X;AM^QHI+XVA@;75,I.K5UA)V5N65'
M")/'+,2'M;XL?<90I%V4:(H)AKDF.PD:PG)L=8/2";:*YGQ%>.4DDDB<.+6Y
M+I(H)"Y%-()'G>Z3W-'2D<?ILPHE<>1/UN.+2:F9"0GF!&:,C*D:8M2F,-I(
M;,#[5^DD9;3VD6#NTO=`PU,S-BN^IS!Z[P6X-4[=*2I9M7N"EQ3MLI<B5,^D
M_(1IT$J5LY)+8$\O*0(<&)3S!PK581D&#;R[*9*C:K[W2T_$*<@5I#JI'04'
MK2PYA>MXS"3VXHRGB5>2>%-U11!@;9R[=MHA@+:7=X0)LFG]LJ2B$IBK-)'1
M$#+>EFV=PYCC$C7O-H.;3(8+-+'<C8W3EA2%97\2K&Q`U7:SG9S2V,A[O`RJ
MPF_'1O0EY!8"3`8P4(X1R<)TDNK,D27I$=M$776\!6[3IQC='"2-,^L=DK69
MNE7DV`YK80VLM/Q^?D-6(Y*[=>E]C,Q*=B;CE*KE%G`9R?)G<G9)JS&CWTLV
MT1B9VIW/56ZY&+&2Y7Q\8XY3$^E$E@*?;V^QUDN8NPF&/-+DOB@8"7)2%ZI4
M>'O><V8[83J#@G)<*))=62<!WP1+<Z^;V:BAT!F[8ST!#&H""S75O5%Q"RFN
MQJA13UH>&$XUO2@;TZUID!"EM`,X\;HTF%.`.3)-`'57*,Y*,7Z&\=GQ-1/:
MUL.#)%9*!7-(-+(FE7J0#-3HE$B8'!G)5GEE<!AA*8Q9@8@A^VR$.<8ZN@.G
MN>]$_/I;65+5BV7/#FAG#L5H/81N;&X0U_>%,JK2DY"Q2OVS4^I3R9F*BTJ?
M%>'QNR)S(5D@2.I)^<9.1`+-D&MNW4R3"NC!$1=:IQM69PNQ-M,5E>\.;U?5
M(H>\I)@<\;W7I,\V:SV3+%<G7-[S'H,6>Z)&`2)(F7G!<@*%)V#T961A-N3P
MR=&?)H9<T$M&O+C5PMO36;SA3UA0.$V6G9`@N8NR!M\=<G.0K%DB76E"2C(S
M-US^:I/>%3H[OO\`I!V6@-0-BR[@MB%UV'.=UP:DO"!P2I=^4)BL'W(M,OK1
MTE\]BZ9@KOF>?GNF'Q#,&-B(<)S5(2FLTAZ1*B&I:G"X$9-&,Q/D$U2E4:@6
MAT'RR7VC,WJ)74AC=1OUM1AY8JZ7LKBY+&JEK"@!40WC5XXNX5187-XN=[:F
MUZ;EO%!A(L18[:Y?(N/A!=NU3*M@]$6JGDXLB9I[!B,*?[%W7W]<P["BD5,2
M6=&ZGNC9PKVRH*_99*7A,M"XQ*3.)\@)*RH`V\87VH0FB$+2";<&/:GZ&20Q
MQNK1KMF>53:"2';DMN=IRUM4Q"5'1&?5UMSI>[JECD>5P*6/\IC31(5Q5JHQ
M""2`2/"-J*(,&<$E/R:"[6+FR=$W.RWQ6C?K'K513`M[%1[J&Z@\1J3RB"-:
M6%/]G22QBV]78#I)7U&NM5WL$I2-B$>>P-*I(<:GR(2LS`4$V_R:U[@.B9N6
M$[5I''X$Z1NSGU@VYW314?KV+Q96,3GF[>D>KK=6SGM[0O5(6X<;@=?,AK:K
M09,*P;R&>1R$G&,807:IW!;(MJ\@VOQZZC):^5^OE-YW@]7.]1^GX8X5W44*
M.70V$P9)'X+#G%]D*E$4:WP<I:N4F'\JK6JC.-CBE@SFF6Y)+?;[R4'_`#R>
MCH_M!]L.@7)__]?[+^CH_J^-B7YFVV'\B4'T*^7ZFY.A!H!H!H!H!H!H!H!H
M!H#%EM?Z(B/_`(IU=^.S-JKKZ$?'U,IZA1H!H!H!H!H!H!H!H"@U;[WT4_BL
M'^--U<N61<(OVH4:`:`:`:`:`:`:`H+=[Z4Q_`&MOQBM?5Z(G5^A?M0HT`T`
MT`T`T`T`T!0;)_DZW?A]5'Y4H=JHCX^I?M0HT`T`T`T`T`T`T`T!JK,*"@>Y
M&E6&O+'[\"CC;:L>LDHIE5I$:A0_57<>+`C:98):@<B%#.H>X^0!81DO&3TV
M1@P,&18%BY<A."XRO;C6LTN2%W<_I7%5)H-5-E4PULF%"/$/6P>UU\.7RQ&[
MLHD`S5:@8H0C*($$\HLLD1H1%CX^,AA9-363HI-K#!%UT=1JKA/<$P*A15O.
M'&UI`Y3VC&';^]O,AI*+4Q(E@3A1*.5LZR)>-$G-*6Y4EJS"EHE96<`Q(+LS
M*E6]'_MSJ*2Q"31QE?G<Z)4S9-)&-DU>"IFTR]BMZW&.\K'D\Y*?V]8LDLWE
M-ELF'`]68>%/CMDXL"<(,E8*I&VSUR[H^]N$PN1AN=0SR=A7-+C4KX[U]$)0
MMC%23B0T&O7.E'O\V@#662VNSC5C@NR8UX*$F3CP426J*4E$$@`@;.(+M5VS
M7;_5M-1BC$L(;IK#HFPSN+M2ZPV]DDDJQ'K)=Y*[S!G%(`M"!20A=A2U:G&!
M.$C`DQG$%QL\(LA-9,.-?1NT^W5;S.JK3W*2"#Q]\KB2T\FDUQN#V\[>'VHW
M%0XUVXTI)5;7E_8#HUVQA,7AQ4.P3D!1:0[!B</):D%V9&*>BVVO'11QAQ'.
M0B:WG;7<VU][4@F85[R]P_<!9C5;]JS%W>'MI=5[A9<FL%L$O&XF#RF+$J.`
M%+@O)82T#9GNE?1@;:9FV71%7M9:HZUOLYL?[`J9//U!-=BLMH5P9P17)&VG
M+<8XQ:S^WJZ;#3EB%82C4\4\)R4PM2>`:!LZ&N\FZ'J!N4VI]FCUDSV*47"Z
M<W%5Q8*6)R9N@%IV`JO=[J\YR;'1QK^"1Z*N,+=HO"EK:ZE#3)U?)G)A)Q!-
M(*.(0-O\FY!6U"JJ-%N5M2LQ2F.GVO3;#&I1!0/V55=$AJ"J2*Y@[TRQ]2D-
M6-3X@@4>0-1A@%>23DJ0&<E<KD9@]+E&<G.+-U=0#0#0#0#0#0#0#0#0#0#0
M&FV^WWDH/^>3T=']H/MAT*N3_]#O.V6_"_\`@=;3?:S_`$L'M;^#11'M?YN?
MZ#/F][R<UL5[U>T3G;_^JWM-[0Y/O7[9_P#6'M'DN^/^6<MJ&W$OCW-E_CM?
M+)_1\="4[>X^.U\LG]'QT%.WN/CM?+)_1\=!3M[CX[7RR?T?'04[>X^.U\LG
M]'QT%.WN/CM?+)_1\=!3M[CX[7RR?T?'04[>X^.U\LG]'QT%.WN/CM?+)_1\
M=!3M[CX[7RR?T?'04[>Y0;#^&?WNCG;G]+]Q/;_`N1[[?T!G(]M^VEM[4[3[
MQ?M_?7E^+VKVQ_D/+\7MG]IX^JIKSP1QV]R_?':^63^CXZA:=O<?':^63^CX
MZ"G;W'QVOED_H^.@IV]Q\=KY9/Z/CH*=O<?':^63^CXZ"G;W'QVOED_H^.@I
MV]Q\=KY9/Z/CH*=O<?':^63^CXZ"G;W'QVOED_H^.@IV]RHP+X:7M.C_`&I_
M3!]K=H`Y'O7_`$`O>_B<H9_^T[]_?7DN'_W_`-OP_4X-5S(41T]RW?':^63^
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M?X:7>9%VU_3!\E[;Z^XO?+^@%[7[8]OL:[3Y/O/_`)7WP[;XG:G'_P`E[:Y/
MMG_)N5U41QV]RW_':^63^CXZA:=O<?':^63^CXZ"G;W'QVOED_H^.@IV]Q\=
MKY9/Z/CH*=O<?':^63^CXZ"G;W'QVOED_H^.@IV]Q\=KY9/Z/CH*=O<?':^6
M3^CXZ"G;W'QVOED_H^.@IV]RHP7X:7M:2]J_TP?(=OO_`!>]G]`+VGQ_;`Z<
MMQ._/WPY7EN-RO&^TY7C<G^U<35<R%';W+=\=KY9/Z/CJ"G;W'QVOED_H^.@
MIV]Q\=KY9/Z/CH*=O<?':^63^CXZ"G;W'QVOED_H^.@IV]Q\=KY9/Z/CH*=O
M<?':^63^CXZ"G;W'QVOED_H^.@IV]Q\=KY9/Z/CH*=O<J%@_#2]H4W[<_I@^
MU/:A)>VN^W]`+WK[7[S+>7[Y=X_OWWOY+AY;M/\`RKD^'DOVSBZJY1'$/CW+
M?\=KY9/Z/CJ%IV]Q\=KY9/Z/CH*=O<?':^63^CXZ"G;W'QVOED_H^.@IV]Q\
M=KY9/Z/CH*=O<?':^63^CXZ"G;W'QVOED_H^.@IV]Q\=KY9/Z/CH*=O<?':^
M63^CXZ"G;W'QVOED_H^.@IV]Q\=KY9/Z/CH*=O<UHW9?"_YK8K[8/Z6#M#X2
M^RWM?V]_T&?>3OW\,6B/:SVCS9?ZR>W+VR=J>USMG_5[VP]I=_OO%WQT*H[>
#Y__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g893535g23x57.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g893535g23x57.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0^T4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@`````````````!3P```8`````&`&<`,@`S
M`'@`-0`W`````0`````````````````````````!``````````````&````!
M3P`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````#1@````!````<````&(`
M``%0``"`H```#/P`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!B`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#KWTUY%U=>-U+-QJY>XM8)9[7U_3>_>ZK]+]!C_P"<W_I*_L_\Y#'9
M1<X6_MO.FQC=U+H#FM/K^UWIU_HGV;]WJ?3_`$=>RSTOL_I=0DYK7-+7`.:X
M00=00>Q24\VQK'^G8.LYCJ7ASQ8&@-<)=5[CZ6YKMUC?]?3].%M>*^[$]?JN
M7M96)?#J][J73NMVAGOM^V5_H_1]*[TO^#74(=YN;18[':U]P:XU,<=K2^/8
MU[M=K7.24\Z'8U+F>IUK+<:@W=<1+3M-;+`]C:_1_P`)[[/1_P`+_.?HTKJZ
MK:VXXZWFEPHV@,&Q[W;;,QM[K157^F?C_P#"55_H_P!]7[NJ=1QW5LN9AML<
M3ZE3\AS#$5^GZ/Z%_J>]UF[V_P"B_P!*KF';U&PSET5TM+)]EA>=V]XV^ZNG
MV^@*7[O](_TTE.(&X%U=!HZOE-%`,6MW.>YK;=YESV._0>_[/9O;^E].C])^
M@_2&KOQ?2R,<=7R'V6;8L+#->QWI/V%M;?YRRJSU?^N?S=6ST^@3!K6B&@`2
M3IXG4I*><LI;9BU''S<TFVEAMO9LWO:T7L=ZK;MC:[;/4_P-=;Z_0K5X=%RM
MCV/ZED6;C6071(V%V_;MV^^W?_UN[_!^G^A6K`'"9^X-.P`N@[0=!/9)3CCH
M&9M(=U7)<7L<QSB1KN994SZ.W^;?;ZW[^^JM(?5_,`+1U?+:P@C:TM$3'\VZ
M-[/SO3]WL4K.I=6H;4<FG$I<[<7LLR"PZ#]&VO\`16;W/=N_S%;Q+^I6BIU]
M-3&6;B_T["_:)L](ASF5;_4K^S_F?Z5)2_3,+*PZ[69.6_-<^PO8^P`.:W:Q
M@J]OL^DQUGL;7_.?S:N)))*?_]#U5#II%37-W.=O>Y\N.HW'=M;_`"6IOM-'
MVDXN\>N&>ILUG9.S=_G)V>O#M^T.D[(DB.V[Z*2FGURV[%Z)U#)QWEE]&+=9
M4_G:]E;WL?M?N;[7#\Y>2-^O7UP+03U1_'^BH_\`2"]7^L8M_P";O5=Q;'V+
M(X!_T3_->&-^B/@$E/5=%^N7UIRNITT7]1>^IX?N;Z=(F&.<WW,I:[Z2Z3]M
M=7_[EO\`N9_Y!<']7?\`EG'^%G_GMZ[!$*+T7U;S\[+S+J\F]UK&U!S08$'=
M$^QK5T.P>)^]<K]5-WV^_:0#Z+>=?SUU,7>+?N/_`))!35ZM99C]*S;Z7EEM
M6/:^MW,.:QSF.ATM]KEY"SZ]_7`L:3U1\D`G]%1X?\0O6^MBW]B]0W%I'V6[
M@'_1O\UX/7_-L_JC\B2GJ>E?7/ZUY'4\:B[J3WU6/(>WTZ1(VN=])M(=V73?
MMKJ__<M_W,_\@O/^A_\`+.'_`,8?^I>NT1"B[_U=ZAGY7474Y%[[:_1<[:8'
MN#JFAWL:W]YRZ38/$_>N2^JV[]JNVD`_9W\Z_GTKK(N\6_<?_)(*?__1]"%3
M#]9'V.;N<W#8&/,';-EN[9^<SU/SO^+5^NW>'D,<-I+0"()C\YNZ%GU.<?K'
M>TEI:W%9M&P;@=[MWZQNWN:[_1;%I-LK=N+7`[3#H(,$?FN24YOUC>X_5WJH
M+'#]2R-3'^B?_*7AC?HCX!>Z?61S3]7>J@$']2R._P#P3UX6WZ(^`24Z7U=_
MY9Q_A9_Y[>NP7'_5W_EG'^%G_GMZ[!$*+L_50D9]Y`+OT+=!'[_FNI]1W^C=
M_P!'_P`DN7^J9`ZA>28_0M_ZM=3O9^\/O04T>MO<>B]0!8X?JMVIC_1O_E+P
M:K^;9_5'Y%[UUQS3T7J`!!_5;N__``;UX+5_-L_JC\B2G0Z'_P`LX?\`QA_Z
MEZ[1<7T/_EG#_P",/_4O7:(A1=;ZK$CJKB`7?J[]!'[]/BNL]1W^C=_T?_)+
ME/JL0.JN)T'V=_\`U=*ZS>S]X?>@I__2]%]>T=?-`8XU'%#S8'':UWJ.:UKJ
MM_I[G_Z3T?4_X17:ZJJ@6UL#`3)#1`GCM\%0K%+OK!:[?6;V8K6FL.'J!CGE
MS7O9NW[7O%GYGYGT_P#1W:J36'AUC[-[BZ7D2)_,;L#?8DI%U/#^W]-R\$/]
M(Y5-E'J1NV^HUU>_9+-^W=]'<O/<C_%7]EJ:^WK3&M+F5@NQ@W5Q#.^5_:7I
M6P>)^\I;!XG[RDI\Y=_B^?T!S.INZB,H5'9Z(H].?4'I3ZGKV_0W;OH*:ZWZ
MT-`Z2>?YRODD_G+DD0IVOJE_RA?_`,2W_JRNK7*?5,3U#('_``+?^K74[!XG
M[R@II]=_Y$ZA_P"%;O\`SV]>"5?S3/ZH_(OH#/P_M>#DXK7[#D5/J#S+@-[7
M5[MLC=MW+SB__%5EXN.'GJE;X=76`,=P^F]E,_S[OH[]R2GENA_\LX?_`!A_
MZEZ[1"/^+K)Z*YG5']19D-Q7-)J%!87;SZ/T_7LV_P`YN^@BHA1=?ZJ_\K._
M\+O_`.KI77+D?JL)ZJX?]UW_`/5TKK-@\3]Y0*G_T_16N8.NV,VOW.QFOW$C
M9]-S"T>W=O\`:W_"_P#6_P#26Z?M$/\`6V@[CZ>V8V_F[M?I(3,!C>I6=1WN
M-EE+:=A@M:&N=9+/SF[]_O1:<AMPL+6N'IO+"'#:21W;N_-24SBS]YOW'_R2
M46?O-^X_^22WN_<=^'_DDM[OW'?A_P"224UNH=/;U#'./<\M87-=-8`=+3N'
MT][5D6_5?"9;36+L@BPN#B`"``V=7MIV5^[_`$BZ#>[]QWX?^22WN_<=^'_D
MDE.=T[H='3KGW46O>ZQH819M(@'=IL;6M&+/WF_<?_));W?N._#_`,DEO=^X
M[\/_`"22E19^\W[C_P"20[L=N16:KVUVUD@ECV;FRT[FG:YWYKAN1-[OW'?A
M_P"22WN_<=^'_DDE.9]8P_\`8U\D$37P(_PE?FN/7<]2Q#GX5F*=U8LVG>-I
M(VN;9PYW\A8=GU7:Q]3?M-GZ5^S5E?[K[-/=_P`&BI#]5I_:KHT/V=_.OY]*
MZR+/WF_<?_)+(Z5T+]G91R1;9:36:]KFL`]Q8_=[7?\`!K7WN_<=^'_DD%/_
MU/55!EU;PXM<"&':X^!@._[\IIFM:T0T`#P&B2EO4K_>'WA+U*_WA]X65]9N
MHV=.PJKV95.$'7!C[;W,:T@LL/IM==[=^]K%0Z)UK)Z@W*V=3Q+_`$17#F.K
M>&%PN_G/1V;=VQKO=_H[$E/2>I7^\/O"7J5_O#[PL[U^H$--&7B6RR27`PX^
MWW5^F_V,_G/]-_@E,V=0W$5Y6*X;HAS73,_S?MN24WO4K_>'WA+U*_WA]X5%
MMN>7@MR<9]0LAVAW0?\`!R+-OJ;?TB&;.K%KQ5E89<T$RYKCSN=7OVVM]NU)
M3I>I7^\/O"7J5_O#[PJ;+LP@.^T8KFRXDM:[5DCTX_2_2V_3>EC6Y;GFN[(H
M>6[8%?TO^%:_W?YNUC$E-SU*_P!X?>%!XQWN:YX8YS#+"8)!_D_NJ;7->T.8
M0YIX(,A224Q]2O\`>'WA+U*_WA]X4DDE/__5]527RJDDI]W_`,:W_B=Q_P#P
M[7_U%ZPO\6GT>L?S/&-_2/H?1S?]7_\`!>HO)4DE/T3G?S=/_)G\S_A>/^TO
M]#_X'_Y7HF5]-W_)?T#_`#O/]K^0OG)))3]&6_S^3_R9]+_"_P`Y_-_]J?Y?
M_NL@W_S5'_(W\RW^<^C]$?S'_=?]Q?/*22GZ*_TG_)/\T..?YQ_\Y_W7_P#1
M_K*8_P"4*O\`D_\`.X_G?HV?1_X+]]?.222GZEQ_YD?0[_S?T>3]%%7RJDDI
M^JDE\JI)*?_9.$))300A``````!5`````0$````/`$$`9`!O`&(`90`@`%``
M:`!O`'0`;P!S`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H
M`&\`<``@`#8`+@`P`````0`X0DE-!`8```````<`"``!``$!`/_N``Y!9&]B
M90!D0`````'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!`0("
M`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`__``!$(`4\!@`,!$0`"$0$#$0'_W0`$`##_Q`"W``$``@,!`0$!
M`0$`````````"`H&!PD%!`L#`@$!`0$!`0$!```````````````!`@,$!1``
M``8"`0`%!@4+$@0%!0$``@,$!08'``$($1(3%@D4%956EM;457875R'3MC=W
M&#A8F+@9,5$BTI-4E+27M]>(R-@Y20H:,B-UU4%A0C0V<5(S)7BU$0$``@$!
M"`(#``,``P$!`````1$"42$Q87$2,E(#02*!$S/PD:&QT4+!8O_:``P#`0`"
M$0,1`#\`[\TPJ\1-V\3>SN,$L\1E^DM741"Z7OEY:A\5N-K099,7F4O$-\J9
M8XM,53/L60JF1`8@\\HUIC@`)^SBP@-`'>3Y:V=-TV77_C.,]B<7R^6*3B]-
MX15+E(6**Q24W)=G'BF(?-7H\RSB9D&*RNRK!CA3TDA#C7I#89I.F,6N#NZ=
MBF3"(1+%12SIVU:/+]XJ,XNOD+X:-J<583==C5G?]8<PS)'QB8W&N(Y()=/*
MN(21U"3)GR52QL@2%LA;\C5+0.>GCL1H.J846<>8!+M:]-1-I?Q#Q?*\MR,T
M.BHBA+@M.^;X*MXQ%Q\$L@D%DE>?,.ZGLUF[LF73&2MT18M(W$CLFT)!RHYQ
M,-+!LL@8A!`M.G?<[&M9EXRD#LZJXPEXLTQ>5KVI:/&^YKS=(M'^X$5E7'R"
M5F^26KI+,I]WPF#6V&N<>M%E/1)$2`]2)R$FV-,,>S$Q9ZSIUE'^F_&P@-`\
M2.):._5DAN2])3Q7*Y%VL\+K"J""N6H25+WN-=NVG69-85\Y%KOQS6>-KB+"
M2J>%Z5&8:$``[*[5:SC<S6Y)"VO&XJZLI9>*1GXZ7I:57<=VSC=,+2NB!ZAX
MHI&JVY.U[%9]7\R6M$B?6*2=LK*EA24IN*3G'FB2J33!IP%AZZTZ=VULVYO%
MOK"J))=RAII>VK,I/BR_5M'.3=]1$^$D1FLW.TO-/F$##$WJ2M\YLHIC"^)A
MO8FM#_\`KP&=(-'_`*F+(Q_V]=/XL5(GW9R?K,Z+O+7"^(<-E<QN"R'J75XU
MO.T$0B2:9+G2#4FHDNKAG,*<&Y<0G0OR%K$A5+CRP`_Y)Q!YJSIFH:__`$Q,
M/8XU)WRSN-=QU.M/XE/_`#3I5FE3W7+D;=%+Q]*6O5$IUD/D\D3P6>A;E:=4
M8SN>NT(3&[$,SK!T`2SIXO7J_P`6MLLY=:$72\1.2[+945XLM',2IZP4M<1>
M9ER"I-Z<D4>;GNOFR,R)Y4)UZ^2.!2=.A4@TN-*%L6R0*`B2!6=/'8U[XM_+
MKD#1U.\+9124YLGCPZWUR!@T+L(+%2D&NZV&&)2JOI%('&,(ZME+)+$3U-61
MR2E!$B;QEJ#E:?9(#]@%OK),8B;0^D/+#G"_7-X8E#1:;\G[7C=R!NVV[+G*
MBO:!X<W;;R>L9\\-0:^DM=3-O3)*WAU7,K`%>ZA*3HU,Q87@C:`TQ<'0B"U&
MV9.&GBPS6N^/+OR2YCK[!DLZY4<E9M75#PR6VGQTK^FF5HKAPE1#TFBSV\O$
M+9JCA%?IBB6M^=).N4JWATTB&D+/T>(\U9..VH3^C_C`5S;$<X^$\9J&MKD3
M<'(**6!.&^FHH^5;&W""12J)6M@D_>YM/)7-VZOT[<FF+<<B:5"-<K3/6P:&
M08$)I/:+3IG;:*]A^)ORG4G^+G$I-4KS3D)X;QI"C@=P5TXU9()O`E[RT%'Q
MY3(&&43*2-DWD=AHE_GIK&B0)D#2WIMI5^TS@((MKWKTQ]=J1@O%ZA\7W):\
M>JBL1[N:+SWAU5D/B*ITC#<\WDX\P8H.1U_,HN>B0I61.A)0-;@:[EDD]B@4
M)1D]`-[`'%IT\63,/C*<9I)RQ3\76M$N.VKOQ]XO))X&<54>J4W2P(51ZA.7
M4".;*KG!5ZYX1C94DR&R`8U#UK1`3.R%I1M9TS5O3Y;>+)6O#N6\BX98U53=
MR>:-A%'V-&4[&YLHSK@A]N/[K'WUSBY"G11C4*M#XXZ'.`5'7`>0WF"`,'ZF
MED8W6UJ:;>)@"P>1%&0JIR[*8H.EYPRKC,I>6`JNG&+\A7F-4>=+GUE4'2I"
M-WB\197>5-VBUZ$X"@]62+6^IH.C"EG3L_"`+[XJW-FS./W'"XGRI9/5ZXOQ
M@:5H-:VTN[PE<HORLO+KI)G7'UFC2Z>OSB"3HC(:UMZY4YK6UJ>W!P(&A4!3
MEGB*6O3%SR=M>/WB!Q.]Z"Y'W(?55AUG*>*<DM>%7)3<T$QGS%CF%2Q4F7N[
M2A7QQ>\,[JG<VU266F4DCV$:C1@=!$$`1CK,Q5.4Y?,/Q%ZWXS\>?$XL._:M
MF]+778U7]\^&#)34=:&R$5)<\U#'(]JO+F2*3[)DEEQM`XHS#R7()B,1PS="
M`9I+ORJ<6JBYBDPX;XRL#DMKQ""NO&V\8S7TOY@2?@VDO=6;"EM<%<@VY]<F
M:*Q4!!,@)E*H$K);O*1'A0A(1%G!#H9YA:@)*TZ>+/V3Q7($]0R^[_\`F-MA
M#PUH9%8A*GE*L=*V*8+'E=;R!%$W"*UO78IF"P'CO+)E>T+,Y*$J1N5*"Q`.
M-3"UL(5G3NB]K^W&?Q>^)M]-UH*YM.:ZX^#JE37?GMTL2^**=Z^<4%KL[R\P
M@+1:T-G[U`%$I&".."9S8Q+0N;6L2#+,+&'H,VLG&82,Y*\TH!Q]C-)N#%'W
MN\IAR8F\?K[CW":P=(N:&RGN2M!K^WO),S?'ILAK1!4[&6%8I>#%9A($QI8R
M@':%]2I$6A6\^,O!FUFA")!QIO&0W+(.2]D<0I50C,HA"N=PR^*[C1#^)B`Y
MEOXXA)HM(1N"0*9\3+P("TIIBDW8`IS@!EKT\=C"/$^G_.>LY'PMG%$\N'[C
MO&>4?)_C+Q)D=,FT30UDCKUYN8$T72.Q-S.:1Z1.KV]L6FHA'MI+-);S1$;&
M6>#K"V))C6W8R^W_`!/V_@4SV]4O)%)8-Z6KQSK*BYT*QT#/`X0X<E&*VI(]
M,4@ED>A4;)1Q^&&UP./N0W!,6#:<U.V&#`(&]]&+(QNJ>9,O$S;9[R,HF'5Z
MOL&$5FBYR2?C2^3)M)KURA5WJ8Q2)TPE1#F=)F\U[C$(BZZ4H#/+F\X*D]0G
M'K]AH.C"EG3L_#/6GQ>H`HX]VES(D/'ZY8AP[A[2J4UI=[XYU@2MO=\*L1!6
M#?'816(IP7-F,;_)U@Q(5SV2WMXD2<U0<<0``^JLZ=M7M9_QW\6;B/=$6L5^
MGMGU/Q]5U;/V6NY*.P[^HQU@+J\2B+"F46/@5QQ*>.]83TEV8TRS1A+>XF+$
M2MM6$GD@V1UA+)QF$(GZZ^>MM\@/%(74QS,;JTA/"`5>/M458[T?3$XK2<MK
MQ1ZBRW)HF4T41Q%9J1K>US,8$+BB>A&I`K.U`$PLH)`FJU$=-PS60^.57]34
M%QDNZYZE$C;KII.M[4F),9M^DV^5-"N7.Z^-2`FMZ2F%B-MR6$R1]V:358U1
M;>4E\W*">S4J#BU025IT[9B&C>4G.VWR;;MJ*U;=%E-K?"/$O\.FIP(3&J$M
M+`W5A=<`<GB6P^+N+0UER9[CTU,;]+'#;T(2DHX>BR-@!H6QEB(V7'PGK"?%
M9ALUM>%4,GI:<MUU23F';G$I^KY6^L)CA$PTI$6^>S:Y#E"<)@7>N@1!V3K$
MAA(`"5!'O0!=4/7VM.G9=[&LKEG7,RW_`!/9YQ-H_ETX\:J_@W#2&7JVIVZD
M*8M9*\SIVLYTB*D,B%8$84R4;(I1#([4A`[(1]4CH*&4,8C,?)LC&)F&*<8_
M%SFECU%0T.>J+=KMYI60\W[&%U=TTYQB&P)U;^-TF61^7VCWPLV0M#1'([(4
MY1.D*;M%)JEU$:G+`67H&]+)QVSMV-BQ+QI**LZ6\5X/5M;SEYDO*".KI.A2
M3^3UE3:2%E,5J.%.RF('NMA3!L;9S:K!,&9:/<88#5[DL;2`*DVC0*$X3%G3
MON6K(;XJZJNG>V(X]PJ]N2LHD?B?\K.'=8Q9F;ZH8GZ/KZHC$6?X["(N!*?&
M&IU@H53II,D<WM6%T*`><H7'B+)#K%G3_P"&X6'Q@X#-JZI597G'JYIGR(O&
MYK=H2.<6"%U?L4_:;"H%"6[W/J02N1REK@C;&X,QJDJLY>-9K6RUI/:%D]!^
MR%G3OV[$Q>$7+^/\W*97W+&X'+*W0(+(G];GQ:;'-1LD2N,`>=LR\YQ+9E*Q
M`D.//UOK$`..[$8=A[0?1UMU)BDP,(8#`8#`_]"[#%^*U>Q+E1:7+QN>9D?9
M-N5G"*KDC(M<&0R#HH]`EBA:SK&1M(CR9^3/*DU2+2DP]S4D##K74)+W]79;
MV4B(Q>$7Q\B=%\3Z.B%F\@XL'A?-Y]/:0M%IE5>CLYO>;+DDFDTK)?C'.K7&
MOG=(H52@XE.,,>(5I""2MDG@.T8<9*7JFYG5B#+X+?'F(M5$I(!>?+6NGWCB
M&]]U=.X79L(:YPVG\AI%WAG"IS>3ZL6D/!J3KFHD(#B-D[1GCTK`K.ZIP5'5
M.C.#/"-XT-,!HB)5E,[_`*1F''@JPBH->M3V<0S7>Y:MU4)PM4<VE;]&I*S2
MTV>N8Q*50E+7THC=_P#Z_P`C#H(=*.J=K'GCP8.(9K'3+'!7R^Z7^9RL)=2P
MWNG;:6P^36K5$_D#Q+YQ!+>D`VES<I.QRF8R)Q=5.D@VTX*U:9LHPHL)19:C
MJG:_T+P<N.3<Q44C@EJ<DJLE]"5$&B&6TJ]G4';9W.*J*D3A+$D3LDIXK)]@
M[\G;Y`ZJ5*<]*RMZHDPWI"9KJ%]11U3M9[8OA9<?K.2\VTD@F5RI@<]8YQRC
M-PF-,@@Z<V/(>,4>1QJ!J*W\JKM:6SK7A"B"-X$YA=RSSM[VF`D#T`U:3JG9
MP>!:?A$\8[:FTQDSU+;[8(E;!U9++[I2'660PTSR!<JC3-*2&.=I18,;4NIJ
MT@AC3>5;97%E+7&%:-.",[_F9*7JEF4S\,6@+3OQUOZY9+:MP.*B#6W6L;KV
M:/,*25Y`X+=T960V>Q>,ZA,!B$_7LQ\6<U:-O3OC^\%-`%9@T02#NH8"I<U4
M-7Q_P;^-C5%[`C,@M#DS90Y?QS>^)T2D%EV<PRE[H^A'T)(54%IHL4$2,#&4
M0!*2`E8Z(7E<`DD)&SA$;$4*4O5+93WX8E(O$CU+"+&ON-OY7`=G\.Q&Z1*;
MQN/.+;33'+$,Q0S)M<T$'`Z(K;\Z-X`&+P'Z:!IA"+VV?LM[RTG5_P"68<H>
M`-=<JJYH.OI3;?(.O5?&^8Q:>UQ9563M@:K5!+(A%EL4:'QZF$OA<V&O==I5
MPU1RHL@A4:NUHW9NND01")J]CR*Y\.Z#0:U>/=U22_>4%VV3QM;[F:H5)KNL
M"'S)R?&V[VU`U2)#,ER&N6%>XIH^E;@^9P(S4&DVQB[;RC6]:T+V536^O"(X
MSE<>:PX]H)?>+.72MJS:Y*GN%FF<8:[G@LSL)\>WN4>:WQ'!2H>M8W'3^<D,
M0+V)6F.2`*T<$TTO1N2EZINV42SPQZNE!-)OJ2].4$)NFBHY*(='>24#L*'Q
MZZI1#YF]*9!(8M/U(:W55W)&-4YJ>N43J.I_).H'R?96^G8E'5.W1\%B>%70
M]C2CE;)E]E<A&(KF=54<K"](K'I['`PU[511+%6YDM%M8'R"OI*"U4K5%0I/
M.`QGH^P7+>A'H:@0]*.J=G!EKCX:/')UY-\<^5ZX^>G63QGK5CK*(-6WF/AA
M$L11./RR.0Z56(PABNE3[-X>CFS@8VKTJM`%.:8#_E"`46`-I.J:F"#>&_3U
M7\C9+R)K6QKS@^II8[Y;TRI!FET74T3);*DR8TN1RU7&7R#.\N;5SVN-TM4$
MMSZB2"6%EBT2$!8`:%S5/>Y"^'CQ\Y.7W6/(:T0S)5*ZP@$\K9-&VIY:DD%F
M,;G;!*&#6ITRJV!P<'=;#P31S5,HTZU&!*L5C&:`\/0#0B9B*:TK+PI..%3Q
M+B?$8S)K>4%<0[EG%\0U]>)##5DCL.P[!-=QO[A;C@G@",B1$Z(=^P)\VDM!
MX"$I`!&CZF]BE+U3-\7B-GA%\=F56TEM5C<ADL4C/.&`<_(;71D\B[C!H1<D
M`73)S!'(HW.T`7N396LM7S8\UY1[6&.:D:5-V3@1V8^T4=4_\2NHGB36/']W
MY).T76RF2ZY371*[QLEKG*F/O+.FDLR:T#0\L4=0MT;9NQB`T3>$(4J\3BHW
MUQZ&>,.]!U4NZ0\@O@U\4X)+X,X%2_D;*JBJNPM6K4_%2;W.Z2/C!6<^)7+W
M9OD$6K@YK)<1C:7=S/5)D[@Z+D@3CC>L4(!YX#92]4_EFR3PKN/:*.0Z,%3&
MY1((3XA"7Q)VHXR0PC:Q1>:1>XN!<4<#`UX`DVIQ'.9FA(2RRGC8=!UITUO6
M][4=4_\`'^6#PJN.T=;+N@*.97LHX\7TAGI,LXJ.%B(E5`L+M8[@G>)#*(&S
M=V`3F)/Q3R1M8A[!_$C0*AB,)3@%H'54=4[-6Z.,?"N%<98W((F79UQWLS/0
MHX6WE<A7>"S<Z)-T62N*-K:HX>P5[#3!)]DN0NV/<?."\_99>QJ-]7ZM29MD
M/*'B%5W*Z(P6-S)RG,#>ZHG++9-26344A(AEB5?-F!&K;FY[B+L>UO+0$'FY
M<:0:B7(%K>>7L/:$"V67L`B:1VA7A4<<((KI%Y:Y/<SE+:8Y&33E8LG$DF;&
M_P`ON2[)^R%Q^3RFY'9PB!OGH*UL3$`"2T%L@"]D!WKZNS.O*7JG:DSR4XK5
M[RE^8'YP7F9,_P![GR7JOE3".YS@R-_G2PJA\^]VF:5>>X](?+H:N[PG>7)T
MGD*XWJ@[)63T"ZU2)JVK>0OAX\?.3E]UCR&M$,R52NL(!/*V31MJ>6I)!9C&
MYVP2A@UJ=,JM@<'!W6P\$T<U3*-.M1@2K%8QF@/#T`T(F8BFKZX\)WC56$+X
MJ0ABD-M."+B5<$\O&*.K^^PMQ?;*GMC#>>\BNXE9=?I4LF2&)7C:8H+>0T&Z
M3IB`#,'H`NO*7JF;XO.C_A&\;V&H[5XYCGO(=_XRV6TKFUFXZ22ST;G5],JU
M4[062BD%,;U%D\XC#XQ3)N`L1#7/3H06,9NAE&:.-ZZCJG?\I/<=^)44X_PU
MVABZQ;3O\AT>T[T%]Y#+H),Y$V;2-I36E;FY7&H!"47D))`!#ZYZ<]68<<8,
MP\>Q[RI,VBS9'A(TC9UK\A+*=;RY7QR/\J%T757U2D#M*,PNH[#112+(X:BC
M[PG8Z[36'W>6L*8TE6E!(@Z/"K/!TZ+$$`)2]6[8\>[/!GXK7*NGGD,KNZF8
MM9E+UK0LVKRF)1!V*$O%?T[MOW6*(I)+*XFKTS#B6V='V9*!<E;UFTH-K$RG
M>Q[&HC*64R3PF>.<HEDWF3A-+K)<Y]R$XT\DW@A'(X*6@33KBO&%D3KYJ;2C
MJX4*"8F\-RT8WD@TTY8H.UK:94D#T@VHZI8EQ[X-3('B4<HO$&N2&0B#*WQ#
MNH:$A\8DJF9*W:,M:-@CCMR$EZLU$W-L:G5C1"'M3>6VI">U0-P3DJDP\80J
M5`F=D1#:U\^&S7]Z\AW;DP3R"Y54I8$DJ%IHV5):&L:'P5FDU>-#ZZ2(MM<%
M:ZMI%,4:E6Y.G2<<@=T8NJ05V>BQ:&(=I(FHJGF27PJ.,)T,X_12HG&V^,#I
MQB9IA&ZAL3CM/01&Q6:.V+O1MALSP^29EFB&4DS5=L:M:>XHU*P*TTQ0G.(-
M,&+<I>J=K%GSP@>,3U`:(IL$LNMIH>@SHZZLM(MTHAAT,F,M89P_V(IGDS?G
MJO7>TD\RE4FD:@;PKC\B80+DX2D^RPDE`!I1U3MU9-'?"NX]QFQFRSD$QN4Y
M^:N<=P\_4Z17(808T#N.[&)HC\JC1R<FO$ZT59MZ)F*$WHPJ`NA1HA[.<3P[
MT$*CJG_B*_(_PM#(3"8F[\2X_9LYN&/<KKIY.L\WWR;C7'NS*W?^0+6C2V2V
MP*;%T%8L2<(*^"9$*-6RNC(:K.;M#UIQZ_\`Q*(RV[=R9?A@<1)OPIXGL=/V
M7)&:36&Z3FPK+F2F.N#R\L3:]6!(U+R)C;)!(DZ-_D@&I%LDLYP6$E'JU7:C
MV'HWK>["93<VZ%X0P&`P&!__T;+=27U?=[60@XX`N"35\-_OCQ/9'([4C[#!
MCIP14/%?EJW4E7=05XHED1E$/;W#:6S&O:YQ4-*QR(:&878G%JU05A4:F(C;
M6C7=Z\E+QJ%S>N.TNY`V9MM@?,;C5!'#D+"Z]B#G<S_0MZ5%8D]U#GB/Q>K9
M/'W"RXI*(,(I0XL,73FKF8U",28!IJO9HJ-])M4UR!FU5\3;:O?D^IL1SA]9
MR>TWJ`2*:0!#";QL2C61QT"MG2:5FF8X`D8;*E1HQH$B,]JCQBHKR-0K2H35
M!P05)C;4-9<D+XY1LAO"QUW3KA7,DF_--EAWS7,%TLCJ;8L/=N*W)Z3E1>R7
M]*R-3!'435+(\VKG9,0)^3$";`GHS%YI111D6HV\GIS3Q*6V%T:*V'6M&!GE
MD<L6ZJOL*II;=$:CDD0RV@W1R0SIIK)41'GLVW5BQ"W:<&SR1&B3[0J"C'`Y
MMZ3-%BMKYYGXFB!D;[,G$2HN3S.GJ7JBBKZM&P#)G'HRY,]/7G%%$Q;WIAAC
M@C4KI'*HPPH52M<T[4I2A)4H^S6;4#)3&K*X[68V_P`^G"NC;BD,5HA\L6I:
M%L^'4E9%C)Y[&HTJ*M*8JZY2;;8Q#5Z-8Z/\6B)]H-9#RYC.2&E+-G%I$BT!
M!IP*D1Q8W#/%$J6=<CVVC&!F0KF1[N">4*V2U%/H^NF!-BUT9+V]\<GZI4R8
M;XRU>XR6$K&EM?=KCCU2LQ,:8@(0J2EFY:].QJ"]^5-L5'S#Y43F4QF42*@.
M&?&WC]/66'PFWU4:#)GF\7>Z6!\?I+79<1$AGSVXJ(UY`W)'%UTB9/,!*XD(
MU+D+R,1&R-92#EO.>>Q$%F[.XR/+R;QQ@#59/*1.QVM#E!U8LKVT/LQ11J$:
M6($(+8L)NK=F`^N*$O;0VE%+"4R1Q6J1=GNI7%C$]\20R*/MMJ(QQ]D]D5;3
M5M4%4\DL:.V!#&M2]K^3M?4=)Z=<HA$I1YF/<RG&67LU,[H!6M0%MJ<PI>$Y
M0`:DA'%I(BJN0SG<]8\@#W*&+:MLNBYE8=13^,%21)*TC-,X]!X].VATC4N;
MT+0%[9GJ%SIE<TQXT:)02)4(DTD!A(NFI6V-$0.&/-JP-T%PO:;_`*XD#.Y7
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MB6=J6%*Q-A#.XM`"%BTPQ3I45_R<%,O8O%+CC;`(S;%UTK**BKFR.(\HYA5*
M\ES&,S=SG$&@Z:LCI'%U3,@*:`1:8K_G?83F4I4I$F7(UP1*CF]26>D)6=.D
MMV\3N=$.Y/.MJQWS0P1E[JEFB4M=5\5L9DM."+XA-12HIM4$3=D;F9,EE+"I
MAJPM\:34VMM^C$IQ1ZI,J)/W4F*8+'/$.\Y,5>SV1T7)(A5G("N+`LGC+,%T
MUC;BYV6W0>K7J[&]KF420)A+JQ=)_5$?6/K,'MWD(4:0XM?M"LT4E.BUQ9[Q
MTYG.5W3N#PB5TN\U09;W'5'RAIUP631@E_>FL@.D'99"1)43.E2#ADL8E]DL
M1FD7:.!*A&XA'Y06>4H3%5)BOE'QLY>2FG%7.1^DK@PSONQST4U=7,7L>WT=
M=D-D6*XB\:[!/B<!&X,DK='I6%W=G9<G9&IN4'&J5QZ@?8D:4*"XM;N3UZUY
MWV3<O(.C]U]`(P'C!;G!O?*L3Q+9HGB\\8@N#U%BO*'E&?'U[*0;&#G332>C
M"Y@1F^4'.'ENRDY91@JHG6WF1[Q5XP_,%C";ZK+EDXKZS>+=?E1RL+2CTYB<
MT3<NY\OKJIG>'6<J9(O&W169(69:4M*$`MN)$46(#B:0;VX%G3Q;43<]5^Q.
MU=+J.=">3Z'D83QE;Z/16!'US([S)71B7DPFEQ5IGMC>B2UJ31IQKRJ7&-7G
M(@Y,-$%O-4C(`;4KCL?*7S\>'-ZA=:1Z@W9QO>0VW;]#R2MUUBQUK8X39U1U
MHR6\IVOGY34Y(W.!R6NY(@=T3F0ATX:1+20F-NENS$1<6N.Q\\>\0L^6S"EJ
MZ8J*>RIW82[D^QV8TR"?1QI:Z.?N(L_JJ%VZ6_R!*A=T<K81H['&X,R]M"+;
M@$E&6,E.%:<<@J4^^#>(`.2IZJE<@H2=1JL.2$(FD[XQ29N?V&7S"U$$2K9V
MN1M9'BMF@!3K"Y58M4L:Q[CR(M4[;/)2F)UPT"W928T5Q:>D'/J\YC%N$DZI
M&KZB=6CD1RB<Z?F+3N]D$E&W,R2D+*L9#%%KRS0!2&'STM;#U6WU,H3#4L"Y
MB$VB*4Z<=+4D6HVVEIX@%CS:HN'=ZV/7+\HB\VBL8;ET??DJ="J4-JLZ3L2$
MTXI.Y)5J$T0TBLP'084/70+IZ.GHWE2-Z-SU!K=5<^$E-D<O^3+97;YQSF%\
MC8&];280MTG07/%8JBC[:L5TDK6EPY*QOQQ(4YIARS?4`(2K8M;V*+\;GV<?
MHC;)G,WD?7\CY8\C)K!Z":^.S_%XO)E=-[;Y"=9\;GSC)D$R/8J;8W-P;M*H
M\FVG"C4(#2M:%K9@^GZ@G=&QU)RLF`P&`P&`P&`P&`P&`P&`P&`P/__2N6+.
M#-0C9DZ5B?[/A4L:+KNR^HE:$,F!3)8<-FO(.;/\[M%N9G$+0>QN4'D#G(C2
M#6-X;W1M.3$)=GE''I2#P%N7HM/">FFE'$M>4SIVD4;OQCY+O$\D,L.?YS8M
MMQ^+.$+;7F?OSJD4B<6I+&%P$*=M1%MZ!`D2)R$128@K16Q:0]C5Y#K:@,RK
M"PF1/)(//XV\1*5L2DQ006YL3ZA.;W!,%4C.3+D*C:<_>RE"<TI0G-T$TH8#
M`!%HC0+9Q$BY0JE,E5JWA9A](6TWW!72RQ9BROJYI>VJM;&JEO9%J]+%&M8]
ML)46M!QV:8L&>[*U99!RE<<(L6C"VU_(/#MHQ^>'>0$R.WHR]R*1<A':1ND0
MGXX^L?8]RA>(L_7)7:TU&U?\B&R%VA+2<0-+I.\H!H0;3N!?6,ZXMZ(_#]HD
MRKKHJ(2N>]U+XH:KN.LW,U(&[SL5`*B@;M745.8UGF'L4$A,8'DX2M284>4<
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M("U(+1PC@[4Z+,)T:#LA<[&S891$(@IM\G,AKX,?(NQ7.S[`\N7IS]$R1VK*
M`5.J!'M%H2/-S9J+UNWB`4;Y0/2H1QG7V$80`%[D8F+PT^.[=!BJRD;I;=D5
MVTT7*>.<(AT_L9P=&>M:OG<9;8E-FZ![:DC(O:7:1L342F\O./5*FQ'H2)M&
MB0"$EVHZI9I&>$L6B&K*<F&[>1B:=VRGK9--;043]B<)PO*JM!)F>,%)MN$,
M515"D,9)0:E5I2VO2,_L"E'9!6;.4G"^#YXEP,J&L#X@92DJMND$\:AL'@#T
MVUM-RDS78\7KK:_NHGL%#)V64$N#RA`[*BS'A!IN>5"<_L#58R"B"RA<_+VR
M.$M-IYX.Q2U4T\_CM:YKCV`3V@VW][;UJYOJ*;%Z3:9=&^:"HJVEB0D]IUR%
M?28,PT.^ST+>:?P*X^.4+I&NY"V2.3PNAN,4XXCQ9B>GLL1#W4=@QNIHK(02
ME2W(&Y>IE/FNF6@25Q0FMYB11L\XL(3!%;)%RW=4E1'U4@=VY7;%OVP0Y>0$
M(S+?DS1*5;"VMI:LI,UMBQMC<?4*P&%J]Z4JW$2]S6[+`)2J-$'6\$S?PT!&
M/#_I"+Z1MY+U:;Q$HI"YY7U/U_(IV>[PFAHI8\?4Q22-]3M!S>$]$:5%UAS6
MV*'<]Y4,K2:8WH!ID)@TPA<MKP7C!6U>RZF9HPGR8;Q1?'5TXP0H+@Z)%",V
MMG=SJEV5GOA!;8G,7R;2JG&CJ*BQD%:`)1K9.^T#LL6UG(.!]0/<U?[(02BV
MX;/9!<LKNPZ60B=BCCPWOT\J*N:0FT>:C4[680EBTD@=6M18]"+&YHU@1J42
MU*=L`@"Y>8G\/'CZCBE:P=$9/T,5KGCK,>)Q[0CEGDQ5@4!-VA.UNT`GJ@IM
M"L4$ICD9*Q(O:C&ES3JR^G2G90AE"%R^%C\.RF&I>L>7.:W3,W]Q?N)4A7/L
MSG2%Z<#U7"JRI#9U(HR@`CB1`W-25VD1B1T3I""`."0D)F^HN-5+%`N6>R[A
M94DND-E3,QTG\>GEBW#"KZ23J+28AHD]<6E`J9C]!LLBKI5YJ4)$!*JL6$3<
MXH7,AU0.1+BM*4DF)U&R`BY:`GGA]EG3SC&MK2;SV,-M<VA?=LVS;`;"5?/C
M(I[:]3KH2DFH'EQ9'AADCH<N\D1'(%B(+(E94Q20E%I*02G!%O>D?7_#FG:T
MD]33&.:EATAJ-@OMG0.;Y(1OJZ:.?)B6P6=7#-+%<')*>Y2B92:60!*K\J[8
M@DCMSR@$Z([`HBI<L6@O!*H:\<6-4PRBWC&BOHS,8C1<2<[#6+(OQU9IPSFQ
MYW#32/2(I:TN#>P'C;VA8ZJ'=4Q-@QH6XQ,B&-.(7+YR^!E2`9PA'+;7/L#=
M^-/)E1=!LG9M6>LN%FKGYG4DB4GDQ<J%>2;J09D=&A`R`1B0FC-T7I:+:O!;
M.7/C.DL+C?*./ETSJ73PFP5<K<YQ+$[HJ2O)BF76(Y6.8T1DY\,D6V.,1=4O
M+:F9#K0TZ!F1D)B2RBRP``+VVV8;3D2-O%%R!$8\=^T%4NE.$$Z6$:8-Q)WE
M[/-E9AC?Y'M2)XT\LA.@'>4:!HG8@]GO>]"T3@1:G(E#[6MFXVDQX%+;F;JY
M:Y>6K6$',Y2:KFY_:XUMG1@1DGHC3$TD4>5;&<=HT6@;#H'1O6PVM@,!@,!@
M,!@,!@,!@,!@,!@,!@?_T[_&`P&`P&`P&`P&`P&`P&!K-1=-.))HZ5NKMFLT
MMB,C8<]/4"43N+$S1H9T[24_'NSI%C'4+XWMA#$>!:,\T@!04@PG;%HO>A8*
M><R\@*&DDI;X-';MJ)_FKNUM;XU0]ELF&NLI<V1\8D4H9'AOCZ%Z/=EK6\1E
MR3.*5062(E0A4%J"Q"*&$>PR%?:=8M;LH8'.QH&W/J.31F%JV5?+X^C=DLQF
MJ,+C#8FH;E#@6L(DTM;QZ/;$`@:5+R=Z&0`8=]."F1Q^1QZ6-1#[%GYFDK(I
M.7)DSS'W1"\M2A0UKU34YD$.#<>I2&G-SHA.3'A"/8B5!(RQZT,`M:#R7F?P
MF.RR&01]E3&TS*Q>\7<2,+W!.F>I;W1;2GB3^8$!@PGN7F%J/`H5=GH78E"T
M(71K>!Z[C(6!G6L[<[OC.UN$A5F(&!`XN:)"M?%Q)`E)R)G2J3RCW-64F!LP
M19(1C"#6Q;UT:Z<#V,!@,!@,!@,!@,!@,!@,!@,#6?STTYHZ>)]VS6?E%6$F
M*;.([]Q;MJY3E!-&:?/"O.O7B!)8$YFQ"<-)PZT`6][^IO`_XTW733_!W2S6
M*VZR>JV9-*A/5@M,]BKC!V@*'8=+1.DL1NIS"@TCV/6C=FJ`=GTZZW1TX'I@
MM&LS'<Q@!8L%&^E2=%"360$NCXG<J9N3`IE;=$3&W3AM8"3KXLB.<B4&P:5F
MMY0U`2]DA$/09U@8A#K`A-A)GY7!I4QRQ+%I?)Z_D:AA<4[B4R3:%.IS'+8J
MY#3C'I(^1QX3F)EB<?080<#81:UO6!_)79%=M[:K>5\]A:)H0/QD57.JN4L:
M9M12<H6@&QQ6N.7`2IGXL>]:$C&(*C6]]&P8&:8#`8#`8#`8#`__U+_&`P&`
MP&`P&`P&`P&`P&!7BY">'!R>M'G9>EW1EIBWS>3&SX-9$4<I1.V/4:/01S@X
MHXXO:8V"-T2.G(K,,EKJ:!F6'/J1@0I-&*U*92<$@O<;B8J(834/AD<IVIF+
MJR4P"IV!([//A:S+7(0R<H'.8U&OX3\>N.,+LU-6#"@B[B\*)K(Y74[JR-ZL
M2UL0":7(X\TT01]@:HZH;YYX>'GR%N;E"_W;1IL83L0(+2UW,*1XDH6I4KYJ
M<4G>S6^DE"A,8D,"@CSQ"K1V2L<0#ZY`F<D(M;_Y?5)$Q$;7EUKP9\0JGIUQ
MZC-=7V3&:5K3CE!(86G;I(]*&5EMI%5LX06LX6!61KZV0ZP44]N*1))`0[C;
MG=V3B("40:W$D&Z<1<;=B-;QX>WBPR"/4L_N]TF.=L50_P!V.[DZ.MU2]2Y*
M&^75!7,9?HM6UM*I([V1"&^]'^,NJ0IR3B;C8AMT&K;D#6#L"$C:MXZ;$Q><
M?`^_.3_)OC'<$.8H>UQ2OXC32!Y3S&<*#':-NL1Y#0RYYLWV`22@D;G+VLB.
MPY*4QJ(@\,3PHDI8@NKBJ93A%!)$Q$2[>Y63`8#`8#`8#`8#`8#`8#`^5:0:
MJ1*TI*LY`<I2J""ER;10E",TXH99:L@)Y9I`CDXQ:&'0P"!L6M=.MZ^I@5>I
M3X>',-QKF&<9MT3#8ZMK#A-R]HA#R4@$XB[FP<FY[<:-G1QLNVB75.PV+`6]
MQ''@R5<8X)WDLV4*0%EJ=`+,..C=QOMT;JG@W.Y6@YN+;>A=>T\S<N..E:\>
M"*F@K\1)R"]P>NK$A[S;5A/39%V)H,GDA-GQ21,%N`KVB:F1+LQ6H-$64D)<
M;$*.-WAC<UX79S9:DQED+C4\=Z)MNQW"2F2$,N00KG6[HKVI6II`0VE(MF2*
M-QSCY:;,!:O,+,&-;']Z`'6CP$E*6<HIZ97#KQA!UG6+1ODS(6YX0V-.'>>M
MQ-PS1SD;.>Z0^GT$0E49FSE8)CG/8*T3*-RE>9&)$X;;`Z>Q;"S&)O)6MO;2
M\=NQ+/@]Q8Y9\?.6')F86@YE/W'^YK7Y,V%6,?CMAN")MK%?8?(65V*B=Y57
MI+B3'IR[VA#GUOZKL:0:Z1DUJV@++"G6*#QDF8F(U:-F/`B[H9Q8Y,<>*AXW
M4+(4]V<QKRDT`TZF0`EIHCCG:,>88J.75G'7QI\RM]HD1),L;F=$$21.W'&A
M/4#-)*VE/%[8F9=OJPCI<0K6O(F2UK60J+P:)1TIE<7H,D<&@MD8&]M`UKY$
M'00ORU`%-HHU;K6M*A@V;_ZLK+.<!@,!@,!@,#__U;_&`P&`P&`P&`P&`P&`
MP&`P-.<@U=C(:4LE549[BELLJ,+>Y:IH9FZ0N:5\,$46F5(F-W0N;8Z*$VA[
M&$D].<4/J_L@[UA8W[44W-\YY1Y,XQVO4[98@8Y84Z9=3>V:VARR22F):)C#
MU#W8146N7B]$P`3&/;@VA/;F<XM22W%[-V!0$XQ0-C7"UAY%*KKN";7O1ZZP
MX$MXYSE$SPF$3!P>HY)S85,8H[UO!FF&>2C:6.P)RL(7+U!YJ]6:G-7[3&+5
M*!M(.R+LV5*>''JJQ4K3,"K8]64O<V%J4*I"L2[4:;5$MDCHOE4P,8TRDT\Y
MLC>Y2]K/-B+8QA0M_8IP[V$K6\K,MS8#`8#`8#`8#`8#`8#`8#`8#`8&G.0:
MNQD-*62JJ,]Q2V65&%O<M4T,S=(7-*^&"*+3*D3&[H7-L=%";0]C"2>G.*'U
M?V0=ZPL;]J*;F^<\H\F<8[7J=LL0,<L*=,NIO;-;0Y9))3$M$QAZA[L(J+7+
MQ>B8`)C'MP;0GMS.<6I);B]F[`H"<8H&QA<LCLA7VA<TE7U),;4:%G']V(E5
M9DP6S8'%I-=K%(:O<8,P*7J6R23PVUC9:])EHVAZC.T[;!6AO5$N9Z[RXLY.
M-$[:,J\BEZAKZKB7,U[-AL;1-CB^&@,)V]O@^NMD+T6D-/4^;D[L^JE"@I(`
M8BDA9@22^@LL.M$G:VM@,!@,!@,!@,!@?__6O\8#`8$2.=,D?8GQ9LY[8G]Y
MB>BCH$@E$LCSBL97J*5L]V7#62V)0WR!N,)<(R=':Q<7=;YU(,+/:PD;5EC`
M,G0]%C?##^%[JV*)!RLC\"F+C.J2A]\LS+4KRLG+O9+:W$JJ+J!\L"+Q>:OC
MR_N#M'F6QG5R'LK:Q24@<E*Q(`8-$>3)Q/QJG/A&(+G*;E*U!;=%&-:B`9O2
M94IEZA">>7T:Z!F)`Q98%.+>_P#TZ-'_`/7+LU3;H^3SM8?J5'/;I5[FXJ-3
M;H>=K#]2HY[=*O<W%1J;=$9.9/*^4\.>,]K<E9#4C9,6:JVEI=ET::K)&V.#
MJ6[2=CC)929>I@:PA.(HY[";O8BQ=(0;U^KOITFJWK%S,12NK_NSX9^([)_Y
M?FK^B/,VZ=$ZG^[/AGXCLG_E^:OZ(\6=$ZG^[/AGXCLG_E^:OZ(\6=$ZG^[/
MAGXCLG_E^:OZ(\6=$ZG^[/AGXCLG_E^:OZ(\6=$ZG^[/AGXCLG_E^:OZ(\6=
M$ZIWUOXXDVM&"QFP8_Q$BR-FE;86ZMR9XY,.R=S)3F&&%A`M)1<;G!*6=H16
M^G0#C`]'_CG7'U991$Q,4XY9XXS,3=LX_3#V=^*;!/RGI!_=BR_ISUA/V8\?
M\_)^F'L[\4V"?E/2#^[%C].>L'[,>/\`GY/TP]G?BFP3\IZ0?W8L?ISU@_9C
MQ_S\GZ8>SOQ38)^4](/[L6/TYZP?LQX_Y^3],/9WXIL$_*>D']V+'Z<]8/V8
M\?\`/REGP\YVSSE?)+7B^Z'C,%<*L9*S?U!R:Z7"6(W='9:^S&Y$6`Q33L0.
M0J6PZLU&S-=F<$P*D&]"UL(M9G+#IFLI6,KB\4Z_.UA^I4<]NE7N;F:C5=NA
MYVL/U*CGMTJ]S<5&IMT/.UA^I4<]NE7N;BHU-NAYVL/U*CGMTJ]S<5&IMT/.
MUA^I4<]NE7N;BHU-NAYVL/U*CGMTJ]S<5&IMT/.UA^I4<]NE7N;BHU-NCDYX
MH/BYJ/##^8[OKQT%9WSW_.7YL[O6X2P>9/FU^;_RWRSRZN'/ROSEW_*[/J]3
ML_)Q=/3UM=$FHW2UCC.5N3O^[/AGXCLG_E^:OZ(\EM]$ZG^[/AGXCLG_`)?F
MK^B/%G1.I_NSX9^([)_Y?FK^B/%G1.I_NSX9^([)_P"7YJ_HCQ9T3J?[L^&?
MB.R?^7YJ_HCQ9T3J]R,_ZK&,2N21^+MW")^)<)(^-+`A.6\@6\M&4L>%Z=N3
M&*S"*=4'%IBSE`=F;`68+0=;WH(M_4W8VS$).%1,VZ%_IA[._%-@GY3T@_NQ
M9U_3GK#C^S'C_GY/TP]G?BFP3\IZ0?W8L?ISU@_9CQ_S\GZ8>SOQ38)^4](/
M[L6/TYZP?LQX_P"?D_3#V=^*;!/RGI!_=BQ^G/6#]F/'_/R?IA[._%-@GY3T
M@_NQ8_3GK!^S'C_GY/TP]G?BFP3\IZ0?W8L?ISU@_9CQ_P`_+I1QIY"SGD;2
M\4M])53!%BY(OF;8:Q&6:J>?(5D)G<F@;ALETW7;0):E5+XP:<2,24@?9&!T
M(`1:WK,5$3,3.UJY^(V-[>=K#]2HY[=*O<W)4:FW0\[6'ZE1SVZ5>YN*C4VZ
M'G:P_4J.>W2KW-Q4:FW0\[6'ZE1SVZ5>YN*C4VZ/_]>_Q@,!@?X,++.+,).+
M`:4:`19I1@0C+,+&'81EF`%K81@&'>];UO6];UO`^="@0M:0E`V(DC<A3!$%
M.B0IB4B0@(AB,$$E,G`624$1@]BWH.M=.][W^KO`^O`8#`8')_QR?\*;F'\C
M(9_.Q`,D[FL>Z'YBF9=C`8#`8#`L_</OP9*9^1J7^-*\]WJ_GB\'L_IES23S
MHP8#`8#`ZJ>#K]N#E[]S;BC]E'+#/-[NZ.3OZ^W\N\V<6S`8#`8#`8%-G_5M
M?Y?_`/6K_LW9)=/7\J;69=#`8#`8&R:9^W!5/W28+]E#7FL._'G#.7;ER6R,
M^@^>8#`8#`8%CSPO_P`">K_E?R`_.-MK/%EW9<Y>F-V/*$_LRI@,!@?_T+_&
M`P&`P&`P&`P&!R?\<G_"FYA_(R&?SL0#).YK'NA^8IF78P&`P&`P+/W#[\&2
MF?D:E_C2O/=ZOYXO![/Z9<TD\Z,&`P&`P.JG@Z_;@Y>_<VXH_91RPSS>[NCD
M[^OM_+O-G%LP&`P&`P&!39_U;7^7_P#UJ_[-V273U_*FUF70P&`P&!LFF?MP
M53]TF"_90UYK#OQYPSEVY<ELC/H/GF`P&`P&!8\\+_\``GJ_Y7\@/SC;:SQ9
M=V7.7IC=CRA/[,J8#`8'_]&_Q@,!@,!@,!@,!@<G_')_PIN8?R,AG\[$`R3N
M:Q[H?F*9EV,!@,!@,"S]P^_!DIGY&I?XTKSW>K^>+P>S^F7-)/.C!@,!@,#J
MIX.OVX.7OW-N*/V4<L,\WN[HY._K[?R[S9Q;,!@,!@,!@4V?]6U_E_\`]:O^
MS=DET]?RIM9ET,!@,!@;)IG[<%4_=)@OV4->:P[\><,Y=N7);(SZ#YY@,!@,
M!@6//"__``)ZO^5_(#\XVVL\67=ESEZ8W8\H3^S*F`P&!__2O\8#`8&..DPB
M3&\,D>>I3'&A_DHSBXXQNCVV-[P_F)^IY06R-BM44M=1D=J'KZ(`9L/6UT]'
M3K`T+QEM^R+8+O%%:48AL3DM47H\U>4U09Z>9&T::$]>UK.F\:E_>VQB4O#L
M1W\&G4*"V]`0;LC6P$`U]4192=PC$%TZCS:K4(56WSRA,9LLWR:)2Q<1U]:U
MO_EJT3(H2'AZ-_\`$6,0?_/+4REP^3YQXM^O(_8B;>[V.F2X/G'BWZ\C]B)M
M[O8Z9+ARK\;B<1]T\+/EX@1[>_*5,.AP2O*HI*F\CI#:L",WVBQ>RID9&NJ#
M?1L9@=;W]37U=ZUDF)B):QF.J'YH68=S`8#`8#`L_</OP9*9^1J7^-*\]WJ_
MGB\'L_IES23SHP8#`8#`Z;>$?)&N/W!RT\Y;<=>5UMQ7['S>QO;S_P"WE'*O
MM.V\S-R_R;_\P>KVG4Z_U>KT]471Y_=$SE%:.WKFL?S_`.G<KYQXM^O(_8B;
M>[V<>F6[@^<>+?KR/V(FWN]CIDN#YQXM^O(_8B;>[V.F2X/G'BWZ\C]B)M[O
M8Z9+@^<>+?KR/V(FWN]CIDN#YQXM^O(_8B;>[V.F2X/G'BWZ\C]B)M[O8Z9+
MA3V_U8$D:Y!]X1YMVX[\D^^E[;S@QO;-_P"X^]S[/L?/+<@\I_\`PBZW9]?J
M?4ZW1U@].<HF*MT]<W:GOF74P&`P&!LFF?MP53]TF"_90UYK#OQYPSEVY<EL
MC/H/GF`P&`P&!8.\,^<1]KX9UL@6;>_*4TQOX)ODL4E3@1TBY%6P9KLUB!E4
MHS]=4>NG8#!:UOZF_JZWK/'E$SEESEZ(F*CE">7SCQ;]>1^Q$V]WLSTRMP?.
M/%OUY'[$3;W>QTR7!\X\6_7D?L1-O=['3)<'SCQ;]>1^Q$V]WL=,EP__T[_&
M`P&!YRIG:%RQ$XK6MN6.#8(8FY<J0IE"QO$9U>T$B5&E#/2B'U==.RQ!Z>C7
M3@:.I"@`4BZ68[%6Q:%DJ;7EP)[*06&1511()CMA9(NL?6L-<U=7@TAKE'XR
MVIC4XQ&H@:1!,*)*-,/,.+:06$,!@,#D_P".3_A3<P_D9#/YV(!DG<UCW0_,
M4S+L8#`8#`8%G[A]^#)3/R-2_P`:5Y[O5_/%X/9_3+FDGG1@P&`P&!U4\'7[
M<'+W[FW%'[*.6&>;W=T<G?U]OY=YLXMF`P&`P&`P*;/^K:_R_P#^M7_9NR2Z
M>OY4VLRZ&`P&`P-DTS]N"J?NDP7[*&O-8=^/.&<NW+DMD9]!\\P&`P&`P+'G
MA?\`X$]7_*_D!^<;;6>++NRYR],;L>4)_9E3`8#`_]2_Q@58N?>Z.I#D[.X,
MV<9>$4XF"-AIB:,\FY5W)>J/E7;<CO2?2&)FD40[DMLZG\X%#WQK,.7A8UQ0
MFU,:$E*4::':4,=(N8WR[_<+K.(N'BU2D\(CCI$?*X<5'E,=>9D^6,X-CC`W
M!?`G0HRQ)/L4EL!.<Y1DTTA\<=[7.Z<8%:C>S3A[W6)WRD_A#`8#`8#`Y/\`
MCD_X4W,/Y&0S^=B`9)W-8]T/S%,R[&`P&`P&!9^X??@R4S\C4O\`&E>>[U?S
MQ>#V?TRYI)YT8,!@,!@=5/!U^W!R]^YMQ1^RCEAGF]W=')W]?;^7>;.+9@,!
M@,!@,"FS_JVO\O\`_K5_V;LDNGK^5-K,NA@,!@,#9-,_;@JG[I,%^RAKS6'?
MCSAG+MRY+9&?0?/,!@,!@,"QYX7_`.!/5_ROY`?G&VUGBR[LN<O3&['E"?V9
M4P&`P/_5O\8%5>67X@<N<@(Z]^(5S9,IB+Q=U>V*:&\(#GARB=]FVF:P*JEC
M;BHX6N#NDAH()K9FGE.'9!H0ZUMS'O?5W/RZ?':M497,P&`P&`P&!R?\<G_"
MFYA_(R&?SL0#).YK'NA^8IF78P&`P&`P+/W#[\&2F?D:E_C2O/=ZOYXO![/Z
M9<TD\Z,&`P&`P.JG@Z_;@Y>_<VXH_91RPSS>[NCD[^OM_+O-G%LP&`P&`P&!
M39_U;7^7_P#UJ_[-V273U_*FUF70P&`P&!LFF?MP53]TF"_90UYK#OQYPSEV
MY<ELC/H/GF`P&`P&!8\\+_\``GJ_Y7\@/SC;:SQ9=V7.7IC=CRA/[,J8#`8'
M_]:_Q@5JN?%F)4WB,2*&S&6E.4;8ZCX^+HG$YWXGAWA]1B+/3])[-W)%<%B3
M&-=J\5TB)0MPW+2XE.M1&)R$^]C2J4FPSY;CM65<K#^1YP$Y)QYFC1`(*,.&
M$@@Y2<(!8-C%HE,F+-4*#=Z#^Q`6$0Q[^H'6][UK`T=4?(2'7#(9K#FM@L2%
MS.`M<+D;]$;.@SS!9#W0L84H*@DP0H74O6E3#)5D(>4I?[(*M*M:E2960G/)
M$7A9BF]L(^4:U$6(0#%:4`P[Z!`&H*"(._UA!$/6];Q0_P`^<&_]_(_X23^W
MRU.@><&_]_(_X23^WQ4Z#E%XXJU&;X5/,(LM6F,&*&PW00`/*&,71:\`W]0(
M1[WOZFLDQL7'NA^8[F'<P&`P&`P+/W#[\&2F?D:E_C2O/=ZOYXO![/Z9<TD\
MZ,&`P&`P.IW@]*$Y%P<N^W/))Z];<4NKVIH"^MU91ROZW5ZXM=/1TZZ>C]?/
M-[NZ.3OZ^W\N\'G!O_?R/^$D_M\Y5.C9YP;_`-_(_P"$D_M\5.@><&_]_(_X
M23^WQ4Z!YP;_`-_(_P"$D_M\5.@><&_]_(_X23^WQ4Z!YP;_`-_(_P"$D_M\
M5.@><&_]_(_X23^WQ4Z"F_\`ZM50G/\`O`>P/).ZGWU76[(T!G5ZWWM_5ZW4
M%OHZ>C?1T_K9F?AT]?RIP9ET,!@,!@;)IG[<%4_=)@OV4->:P[\><,Y=N7);
M(SZ#YY@,!@,!@6,_#"6HRN%-8EF*TQ8PS#D!H0!GE`&'IY&6UOZH1#UO7U-Y
MXLH^V7.7IC=CRA/OS@W_`+^1_P`))_;Y*G13S@W_`+^1_P`))_;XJ=`\X-_[
M^1_PDG]OBIT#S@W_`+^1_P`))_;XJ=!__]>_Q@5Z.:A]@3CQ!)3!VUAY02N+
MP2IZ!D2-)Q,XV<4IXI8G292.RT[PINJ;\E$!,@5I7%-$TNVD4=5'IDR4A46(
MLE448(Z-QN6%\K#!9/$7)Y?(](VZ82YG,C`5QP(HU.S8V1.7'G@!M.EE^E$;
M?'020HPK00C2&%#+",6^J9OHU@1WXL5K=\0<;)FW(:-U2"V;05L+I+9M6=I3
M.>(7(#&4Y(H[`F*/RZGJT'!ZXKML6C+:$P%CH>K5+ERY7O2Q8I..+,Z;DPL(
MQE7"X<X*3EJ^)QE:L4#V8H5JV%K4J3S-ZUK8SCSDHS31[UK]46][RW.J5&CY
M_F_@7J1$?9IF^!8N=2HT@^;^!>I$1]FF;X%BYU*C2'*GQNX;#VWPL.7RYNBD
M;0+4\.APB%B)B:TJH@0K5@0!")4$)2S2]B`+>M[#O73K>]9)F:WM8Q'5&Q^9
MQF'<P&`P&`P+/W#[\&2F?D:E_C2O/=ZOYXO![/Z9<TD\Z,&`P&`P.GGA%1]A
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M9D-A[EPPK5<XQ2-KUJB8W\(]8M8FM4J/$'D5;``B.4'I3#3-A`'6M;%O?1K6
MM9XLIGJRV_,O1$14;/B$]/F_@7J1$?9IF^!9+G5:C2#YOX%ZD1'V:9O@6+G4
MJ-(/F_@7J1$?9IF^!8N=2HT@^;^!>I$1]FF;X%BYU*C2'__0O\8'%B_O#PMV
M][=/L2Q:D\.FZ9"0:D11NX[-@O()EG;)'&=<>IC*%SKV.6$ZQV0.+"G&$!AR
M1_92%I^A'!(2A%HD,:B:CY=BXPDD""-1Y#+7IODDJ1,;2DDTB:6,R,M3_($R
M!.2\O3;&S7>0&QYO=7$!AY*$2]<)(69HK:@[8.T%67N8#`8#`8#`Y/\`CD_X
M4W,/Y&0S^=B`9)W-8]T/S%,R[&`P&`P&!9^X??@R4S\C4O\`&E>>[U?SQ>#V
M?TRYI)YT8,!@,!@=5/!U^W!R]^YMQ1^RCEAGF]W=')W]?;^7>;.+9@,!@,!@
M,"FS_JVO\O\`_K5_V;LDNGK^5-K,NA@,!@,#9-,_;@JG[I,%^RAKS6'?CSAG
M+MRY+9&?0?/,!@,!@,"QYX7_`.!/5_ROY`?G&VUGBR[LN<O3&['E"?V94P&`
MP/_1O\8%'11;-+K>:TIBC%R)MNXZ\*NYQU8C%SIY8V-QC31M4IF!XQE5FYU]
MRL9I'.$36I.V<WHU=7EEJ0%)];4Z*'OM,NNVEXO-.1@,!@,!@,#D_P".3_A3
M<P_D9#/YV(!DG<UCW0_,4S+L8#`8#`8%G[A]^#)3/R-2_P`:5Y[O5_/%X/9_
M3+FDGG1@P&`P&!U4\'7[<'+W[FW%'[*.6&>;W=T<G?U]OY=YLXMF`P&`P&`P
M*;/^K:_R_P#^M7_9NR2Z>OY4VLRZ&`P&`P-DTS]N"J?NDP7[*&O-8=^/.&<N
MW+DMD9]!\\P&`P&`P+'GA?\`X$]7_*_D!^<;;6>++NRYR],;L>4)_9E3`8#`
M_]*_Q@5<K,LCQ$4K#':AE,YH,ABNE/9E#5/8+OX@D-:9)8EC"Y-:EK38$.:-
M0O3PYS>N8XAU"!,"-W,-(4C`2-62?LM(*-[%HW*P8#`8#`8#`Y/^.3_A3<P_
MD9#/YV(!DG<UCW0_,4S+L8#`8#`8%G[A]^#)3/R-2_QI7GN]7\\7@]G],N:2
M>=&#`8#`8'53P=?MP<O?N;<4?LHY89YO=W1R=_7V_EWFSBV8#`8#`8#`IL_Z
MMK_+_P#ZU?\`9NR2Z>OY4VLRZ&`P&`P-DTS]N"J?NDP7[*&O-8=^/.&<NW+D
MMD9]!\\P&`P&`P+'GA?_`($]7_*_D!^<;;6>++NRYR],;L>4)_9E3`8#`__3
MO\8'#2?^'GQ*KQRY!%V=R$G(MJ*G<Y/!FF5L3([(^*_']PY'&WI/RZS$R1-.
MJ6G/]N*3"PNRX];(42`A$G*,$6C`(4:N=FQW+RLM=S1VG+8O:O,\4BCU`A)'
M4ZP7IQFDK:)@Q-R=/V@!0R$QJLIAWY7*"-&])`G9F.",(0E;-&/H"'/3@&PQ
MN/W=RG^;QHK\^MW]AHAW9991];2*F*8*<D:6R&E7"15L_F/!&[F9FXA*NDKV
MB>EYC@@<6A.M2-@T:?2R-3NAU/RLL0719>L5J%14WE[<6>9L842$<:TD3:WK
M6NS3Z5QI6I[/71_ZS![_`//+?"$KB^3N:Y_2).OW2)>Z6+X05/E)W-<_I$G7
M[I$O=+%\(*GRERK\;B,+T/A9\O%9LUESF63#H<(2%P''-HU&A6K`@:"?I%'$
M2KJAV+K:ZAH-];6O_#IUN3.R=D-8Q]HVOS0LP[F`P&`P&!9^X??@R4S\C4O\
M:5Y[O5_/%X/9_3+FDGG1@P&`P&!TV\(]F4N]P<M/)Y$^L'D];<5^OYE$T!\K
M[64<J^KY3YT:'7I[#LM]3L^S_P",76ZWU.CS^Z:RC9\.WK[=_P`_^G<KN:Y_
M2).OW2)>Z6<;X0W4^4G<US^D2=?ND2]TL7P@J?*3N:Y_2).OW2)>Z6+X05/E
M)W-<_I$G7[I$O=+%\(*GRD[FN?TB3K]TB7NEB^$%3Y2=S7/Z1)U^Z1+W2Q?"
M"I\I.YKG](DZ_=(E[I8OA!4^4J>W^K`9E+1]X1Y1(GU_\H^^EZGGH30+R3LO
MO<^MY-YK:&KH[?M==?M.T_X`]7J_5Z<Y3=;'3U_.U3WS+J8#`8#`V33/VX*I
M^Z3!?LH:\UAWX\X9R[<N2V1GT'SS`8#`8#`L'>&?&%Z[AG6RLJ:RYL+.F-_"
M"A;QQS2-/H/(JV`;"1I;'%JKJBV'K;ZYH]];>_\`PZ-:\>4_;+9&^7HB-D;?
MB$\NYKG](DZ_=(E[I9F^$+4^4G<US^D2=?ND2]TL7P@J?*3N:Y_2).OW2)>Z
M6+X05/E)W-<_I$G7[I$O=+%\(*GRE__4O\8'(?EGQCX1R^_)FNLR]:[J2\;J
MX^R6'-C!(IPF1R(A&)0<2X6REC;Q.VDA2W(64@QN[$Q*2W#$6,>C.W"+HC43
M-;G7C*R8#`8#`8#`Y/\`CD_X4W,/Y&0S^=B`9)W-8]T/S%,R[&`P&`P&!9^X
M??@R4S\C4O\`&E>>[U?SQ>#V?TRYI)YT8,!@,!@=5/!U^W!R]^YMQ1^RCEAG
MF]W=')W]?;^7>;.+9@,!@,!@,"FS_JVO\O\`_K5_V;LDNGK^5-K,NA@,!@,#
M9-,_;@JG[I,%^RAKS6'?CSAG+MRY+9&?0?/,!@,!@,"QYX7_`.!/5_ROY`?G
M&VUGBR[LN<O3&['E"?V94P&`P/_5O\8%8+Q36*&N_+V0R<Z!<I9)#ZF8>/\`
M*.3VZ<0\87>'/;%+5,X@M<LJZ5V=.H]859FOK>Z.S:[)PEG-PF\8'`)",0]N
M1LEO'<L04-=,2Y$5%!KG@Z5^;XW.FHY>F:)4WD-4H8'!`X+61_C4E;4JUR1H
MI#&9`V*D"TLA2I3A5)A]D<:7U3!5B=FQMW`8#`8#`8&)SF!06SXH\0.RX7$[
M#@\B))32"&3F.,\MBCZG3*TZ].0\1U_1N#0YDD+DA1P`GDC"$TH`]:T(.MZ"
M,7Z.CP^/Q$N&WY,-)>X^%N=9/T='A\?B)<-OR8:2]Q\%SK*/?+?@%P0C?%/D
MW(H[PHXD,$@8./=T/3$^LO'"G&IY97EJKB2+FQV:7-##2%K<YMRT@!Q!Y(P&
MDF@",`M"UK>")FXVLKH7P^>!#Q1E+N[OPAXA.KJZU/73BYN;CQKIE<X.+@NA
M[.I6KUZU3"S5*Q:L4FB,--,$(9@Q;$+>][WO!,S<[6V?T='A\?B)<-OR8:2]
MQ\%SK)^CH\/C\1+AM^3#27N/@N=95?TK*S1MRFL=CK2V,$?8+2MYE8F)E0)6
MIF969JM*8(6QI:6Q"40B;FQN1$`)(()``HDH`0`#H.M:SU^OLQ>?V=^3[\Z,
M&`P&`P.JG@Z_;@Y>_<VXH_91RPSS>[NCD[^OM_+O-G%LP&`P&`P&!39_U;7^
M7_\`UJ_[-V273U_*FUF70P&`P&!LFF?MP53]TF"_90UYK#OQYPSEVY<ELC/H
M/GF`P&`P&!8\\+_\">K_`)7\@/SC;:SQ9=V7.7IC=CRA/[,J8#`8'__6O\8%
M;/Q%9]62SQ"HTSSF+\(XL_U)"J5>XA87(VEN3UPS2>K'J5RYZ(9&\5#26.0E
M`V5VYHBE"-OE9#GHM:YA6D!"`8]!C<;MZQ-#X9$Z^CC=$(-'&:)19H\K\UQZ
M/MZ9J:&_R]<J<UODB!(64G(\K<5IQYG5#KK&F"%OZN]Y6&38#`8#`8#`8#`8
M$&.=4@O5=3]FT[3/%BQ[Y56_2UGPD,KB-@T%#&"&OLMB[Q%FLB0IK<MBOWU8
M5VCD%2,QN2+2PDAWK8NTZ`;+%?,O>X?3:[U\%BM<V[Q4LN@!5S6D(CY4EFM@
M\?YFS2UW8V=O8EZ1C34_;5AO2/L]H]J-&."9(4(H6M:%LSI!H37Q*9.$,"F2
MX?\`RJR_NRW;_.Y-<]?K[,7#V=^3^>=&#`8#`8'53P=?MP<O?N;<4?LHY89Y
MO=W1R=_7V_EWFSBV8#`8#`8#`IL_ZMK_`"__`.M7_9NR2Z>OY4VLRZ&`P&`P
M-DTS]N"J?NDP7[*&O-8=^/.&<NW+DMD9]!\\P&`P&`P+'GA?_@3U?\K^0'YQ
MMM9XLN[+G+TQNQY0G]F5,!@,#__7O\8%;SQ3WFR(YRLBKB1SF35"C7--<,,'
MX^HN<;EQ5Z6AT=7`QTMJ41..#3+9RV():VG(%J90+:U]:U?DS:<F.;1=I);Q
MJMRR'E8:UGEQ5?5YZ%-84W88@:Y-ST[H_/:K:,HUKCB3:]]<-GB!L@E(U(@[
M-.&,00@!K>]_4P5:&?"#EK).3%@<AR7Z0P(Z.M*BLYA4,/C*IN426,5A/(RJ
M<6HF=&IW%6K4S!4G(2+'@@198&5S7FMFNOY-HTTLQ5.BV$8@N43X*M0%L:8@
M>@T9O24U=(7I*K,*Z-=`E"=/&%A)1G3T_4":/7_GEV?-IMT?)Y59GQ)!?:F0
M>Y^/KQ/MI!Y59GQ)!?:F0>Y^/KQ/MI!Y59GQ)!?:F0>Y^/KQ/MI!Y59GQ)!?
M:F0>Y^/KQ/MI!Y59GQ)!?:F0>Y^/KQ/MI!Y59GQ)!?:F0>Y^/KQ/MI!Y59GQ
M)!?:F0>Y^/KQ/MI!Y59GQ)!?:F0>Y^/KQ/MI!Y59GQ)!?:F0>Y^/KQ/MI"G\
MHV?N1V+M4`HM3NX+IVH`08,T@!^[9F?:@)-,*),-*"9TZ"(0`;%KZNPZW]3/
M5Z^S%Q]G?+_N=&#`8#`8'3;PCS9,7<'+3NXA8EG6K;BOY9YZ='!M[/HE'*OR
M?R;R%G=NVZ_2/K]?L^KT!Z.MT[Z//[JZHO1V]=].S7_T[E>569\207VID'N?
MG'Z\6_MI!Y59GQ)!?:F0>Y^/KQ/MI!Y59GQ)!?:F0>Y^/KQ/MI!Y59GQ)!?:
MF0>Y^/KQ/MI!Y59GQ)!?:F0>Y^/KQ/MI!Y59GQ)!?:F0>Y^/KQ/MI!Y59GQ)
M!?:F0>Y^/KQ/MI"GM_JP#9,9]X1WC0L2/J_?2^1^971P<NTZ?O<_*/*?+F=I
M['J=`.IU.TZW2+IZO1KISE6RG3UWMM3WS+J8#`8#`V33/VX*I^Z3!?LH:\UA
MWX\X9R[<N2V1GT'SS`8#`8#`L'>&>?/`<,ZV"TM414-^IC?WDQSA('E(L&'[
MXJV-BV>F31E<04+1G3K6@FCUL.M;Z>G?1KQY5U97>^7HBZC9\0GEY59GQ)!?
M:F0>Y^9^O%?MI!Y59GQ)!?:F0>Y^/KQ/MI!Y59GQ)!?:F0>Y^/KQ/MI!Y59G
MQ)!?:F0>Y^/KQ/MI#__0O\8%;G<`GJ6K+-\2I=SON00'-V(K^>1Y9Q6X0.4N
M=4%,7Q,J=C42\G<J_P!M*-Y)?WI6428`U.]J4JA,F4&&')TQ)4;X4LC96'\C
MR"5))R9224H3J"C"#R#RP&DGDF@V6:2<49H0#"C`"V$01:WK>M]&\#7D2J"M
M('+9K.8=#FF.RFQ`1TN8N;8$\@+N7%$!K8PEZ0=N)L;0(D9P@[TD)(T>+?7-
MZX]:%@;(P&`P&`P&`P&`P&`P*9+A_P#*K+^[+=O\[DUSU^OLQ</9WY/YYT8,
M!@,!@=5/!U^W!R]^YMQ1^RCEAGF]W=')W]?;^7>;.+9@,!@,!@,"NKX^WAJ\
MG_$.^]/^]O:H:Y_-!\^W?/O=+TD5[#O_`/,WW=\W^5)S_+^T[DKNUZO1V75!
MT]/7UDF&\9B+M75_VUGB?>JM-?RNM'_;\E2WUXG^VL\3[U5IK^5UH_[?BI.O
M%K&Q/`)\0RKWJHV&5QRJB7"[+/*J*"A0V>V+2E$R-@,^LD!#D:!$'3<W]V*V
M<Q]N+I#VP"R^CI,UO2CJAL[_`&UGB?>JM-?RNM'_`&_%2=>)_MK/$^]5::_E
M=:/^WXJ3KQ>4[>`WX@7&P#5>MG1VK4L`K*50N2RE0S68VN[H4UD2]C3F#1-I
M*(LQ8=VBD/0#0M;WK-81]L><,Y91..4<'2_/>\)@,!@,!@6//"__``)ZO^5_
M(#\XVVL\67=ESEZ8W8\H3^S*F`P&!__1O\8'$^H(UX9_)OF._2%IXMSIKMC4
MDL.XX18L^:)7':#OR64E83/6UD7#5\)36$MK29S&%SQW0>4/;I&$+T>8J+7D
M#/#L2C4V-?:(WNV&5DP&`P&`P&`P&`P&`P&`P*9+A_\`*K+^[+=O\[DUSU^O
MLQ</9WY/YYT8,!@,!@=5/!U^W!R]^YMQ1^RCEAGF]W=')W]?;^7>;.+9@,!@
M,!@,!@,!@0#YM?;2\-K_`/OQ!^9US%R:-1_]<D_,K)@0:\2C\"&^_P#HD8^S
MZ)YK'NQYP?$\E:K/:\I@,!@,!@6//"__``)ZO^5_(#\XVVL\67=ESEZ8W8\H
M3^S*F`P&!__2O\8%3ARH"HTA,AYV(N(=9H>)T*OB?0W3:GYV<WF#DXC;3^0F
MZQG,[88LT3PJF8ZYR*?-GGG=?%^3F+$VB$HU0582RA1N_B]JV/E8,!@,!@,!
M@,!@,!@,!@,"F2X?_*K+^[+=O\[DUSU^OLQ</9WY/YYT8,!@,!@=5/!U^W!R
M]^YMQ1^RCEAGF]W=')W]?;^7>;.+9@,!@,!@,!@,!@<C>5LKY<3^VN.Q\&\/
MV[)+&.-'+5PM95+2;FX?-3=9$*:*;OZGT#E#6Q^Y$-<B;S9"LLY`YIT[RC;5
M!*$!@5!9*D.B=QJ*V[72NJ)A,9W"6Z2SRI952,E6*'$I97<TD%>RB0-)*1<>
MF1JE3S5TOG,-4%.J4H*DH*=R.,++,T$T)9FA`#69YMCX$&O$H_`AOO\`Z)&/
ML^B>:Q[L><'Q/)6JSVO*8#`8#`8%CSPO_P`">K_E?R`_.-MK/%EW9<Y>F-V/
M*$_LRI@,!@?_T[_&!PL>?#FY+.'(]5R+)KCPH!R_=B&SQ+(5W'KDN-_/=PNN
ME:&;O+.EY#IZ]<[9((+`?WA&S[6A<M;4@&$>^G(U<56UW3RLF!%OB5R55<K*
MM8K@2U/*:RALQC,,F$&42F65I)%DE8)M'4TH0GFHJ\F$K/C+@@:G!()2B==(
MUA0U(0]GTA'U2S%;$I,(Q!=,"D"M0C%'9>JVG,V7M0ACJQ4D-Z-:WUTZ@O\`
M8&E[Z?U=82^$OD[]D^JLZ]E5^6DZN$G?LGU5G7LJOQ1U<)._9/JK.O95?BCJ
MX2=^R?56=>RJ_%'5PD[]D^JLZ]E5^*.KA)W[)]59U[*K\4=7"3OV3ZJSKV57
MXHZN$G?LGU5G7LJOQ1U<)._9/JK.O95?BCJX2KZO?AL\BS9--'%FD,*&TR"?
M3Z6-FG.)660XDH9?,WV4)4JXM*SJ$VE:,EWT49LL8@"$#>];Z-YUQ]O3C&-?
M]9RQC*9G;_IY_P"C9Y/?'U=^R]I_]@S7[I\?^IT8ZS_H_1L\GOCZN_9>T_\`
ML&/W3X_].C'6?]--51P]Y%6O(;VCS<I@3:=15RG4V[GG,UD+0O+H36%86?MU
M3E)H_HQN(V@L].G[`[I-ZZ<1G_`8#)^[_P#G_I/KB*VS_IN7]&SR>^/J[]E[
M3_[!E_=/C_TZ,=9_T?HV>3WQ]7?LO:?_`&#'[I\?^G1CK/\`I.O@%QILGBM+
M;QE=DF!D9EI1VG8\SHH/$9?H#8"LW.X')<J<CWY&B$8)S%9I0"@%!WH&DH]B
MW^RUK7+/+KFZ:QK&*B_].E_?LGU5G7LJOS-+U<)._9/JK.O95?BCJX2=^R?5
M6=>RJ_%'5PD[]D^JLZ]E5^*.KA)W[)]59U[*K\4=7"3OV3ZJSKV57XHZN$G?
MLGU5G7LJOQ1U<)._9/JK.O95?BCJX2=^R?56=>RJ_%'5PD[]D^JLZ]E5^*.K
MA)W[)]59U[*K\4=7"3OV3ZJSKV57XHZN$G?LGU5G7LJOQ1U<)0E\1J8%+^%M
MYH]1V7I=J&>+EZ4+HZL2I"NF>Q3?7/4&?L"B_J?J[RX]V/.%O?LG<KLY[7F,
M!@,!@,"P?X9\N*;N&=;(A1Z6K-D3&_@[4M\>6+$9O6Y%6P/I(4E_L#0ZZW1O
M>OU!:WK_`,,\67=ESEZ(FHC9.Z$\>_9/JK.O95?DHZN$G?LGU5G7LJOQ1U<)
M._9/JK.O95?BCJX2=^R?56=>RJ_%'5PE_]2_Q@5>O$V(I!F\0M*YVTZ\/[%?
M))6E*)HE7?(&`<T;>FE9I&J6RA`-VB2?CC!7^#U^3.WU\)UY.[*-GJE20A3_
M`,LL[H'&XNMBT+E88%*Z_;Y.\,4GT[2ILDD3*<!QOS=/;)98>)>L*#HHZ9U_
M$9M%8O8B%.>4`6DSN2HT$'6"4,G8Q"P([\=N,[Q4EF6?;#^IJEF=;'AU;0DV
M#437*RL:[(*KM?.734S>VM9)9"=(YZ^G3H:(2X6DWDS0VHTNM&]01FRS/PF+
MA#`8#`8#`8#`8#`8#`8#`@'PE^VEXDO_`/?B_P#,ZX=9-6I_^>2?F5DP&`P&
M`P&`P&`P&`P&`P&`P(->)1^!#??_`$2,?9]$\UCW8\X/B>2M5GM>4P&`P&`P
M+'GA?_@3U?\`*_D!^<;;6>++NRYR],;L>4)_9E3`8#`__]6_Q@5D_%-M&FHG
MS(8X-*ZO4G2"4IJSV>XL7(>6U-;MSNLF8YDP1ZN(##&:+.3=)*=D:B/(F.6G
M#5B,<78;:D"6D$E"M#);QNEFS*P8#`8#`8#`8#`8#`8#`8#`8&N+7J.N+QA+
MC7-KQ5#-(2[J&Y4XQ]Q.7$)%2AI7$.3<:,UN5HE81)5R8!@>J9K6]A^KTZ^I
M@1BAOAJ\&:]EC'.85QSA<=ED<D[/-&9[;UDG"K22J/JT"YG?!:-?S2%2Y"I:
MT^PB.`9K>B0!%K8=:UA;G5.3"&`P&`P&`P&`P&`P&`P&`P&!!KQ*/P(;[_Z)
M&/L^B>:Q[L><'Q/)6JSVO*8#`8#`8%CSPO\`\">K_E?R`_.-MK/%EW9<Y>F-
MV/*$_LRI@,!@?__6O\8%-LZX9S.>9JB,L/-WD9S2BL>NI_(VOKF?P[ALGH`+
MC)U+<Z-*1YNRF75FG"&+`UYO5ZC4R9M.2=/K00C`/R04=*V;J7),KF8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$&O$H_`AOO_HD8^SZ
M)YK'NQYP?$\E:K/:\I@,!@,!@6//"_\`P)ZO^5_(#\XVVL\67=ESEZ8W8\H3
M^S*F`P&!_]>_Q@1UD'#_`(E2UP5N\JXN<=9,ZN"U.XKW.04E6CRX+7!(>2J2
MKU:UQC*E2I6IE*8LPLT8A#`,L(M;UL.MZ+<ZI%80P,+C=D5W,GJ41N(3V%RN
M10A60@FC!&Y2QOCU$%RK:D*5%*&MK7*ES`K4B1':++5EDC'LH?1K?5%T!FF!
MYASTS)S1DGNS80<7OJF%'+TI9I8O_M&6,T(@[_\`+>L%P_GW@8?CMH])(OKV
M$N-3O`P_';1Z21?7L%QJ=X&'X[:/22+Z]@N-3O`P_';1Z21?7L%QJ=X&'X[:
M/22+Z]@N-3O`P_';1Z21?7L%QJ=X&'X[:/22+Z]@N-3O`P_';1Z21?7L%QJ=
MX&'X[:/22+Z]@N-3O`P_';1Z21?7L%QJ=X&'X[:/22+Z]@N-3O`P_';1Z21?
M7L%QJ=X&'X[:/22+Z]@N-3O`P_';1Z21?7L%QJ=X&'X[:/22+Z]@N-3O`P_'
M;1Z21?7L%QJ=X&'X[:/22+Z]@N-3O`P_';1Z21?7L%QJ=X&'X[:/22+Z]@N-
M3O`P_';1Z21?7L%QJ=X&'X[:/22+Z]@N-3O`P_';1Z21?7L%QJ=X&'X[:/22
M+Z]@N-3O`P_';1Z21?7L%QJ=X&'X[:/22+Z]@N-3O`P_';1Z21?7L%QJ=X&'
MX[:/22+Z]@N-3O`P_';1Z21?7L%QJ=X&'X[:/22+Z]@N-6O[3AU4757\GJVR
M3&]_@\Q0EMTA:4TM<HXI6)25B9P)TG?8L],LA:SR5B,HP!R160<$0-=`M?5P
MMQJA/^C`\/KU2F7Y6W*+^G7-=>?E*5CI!^C`\/KU2F7Y6W*+^G7'7GY25CI#
M6MS^&_P3BM/6O)XY&YHBD,<K6=/S"L#RMY,K!)'EGB[HX-:H*19=RE&J$G7)
MP#T6:686/HZH@B#O>MNO/RDB,=(8UQE\.[A!/^-W'V=S1@FCI,9K2%42V6.8
M^5/)5M&XR:20-@>7Y<-N;;K0MR`2MT6&F;(3D$D%;%U0``'6@Z=>?E),8W.R
M&[_T8'A]>J4R_*VY1?TZXZ\_*2L=(/T8'A]>J4R_*VY1?TZXZ\_*2L=(3/J*
M!U#1->L%65=M#'H/&1O)C.U+9D\2I82=(7YTD[TH5R&7OS])'52X/STJ4F&J
MUAYG6-WK6]!T$.L[5N&R>\##\=M'I)%]>PEQJ=X&'X[:/22+Z]@N-3O`P_';
M1Z21?7L%QJ=X&'X[:/22+Z]@N-7_T+_&`P&!JZQ4%M..B4M<O$(:6U0SOZ5Z
M,D39(54@"X*4`RF)3&W!I>FY"VB2K!=<X2@A1O>M:ZG5WKZI=GR@7X<35=4,
MC45K.3M%E(*V@?'"FF-X26W5L<K5XAE_H#'])8=?5^XQ^(0PVS8*UI`%*E+^
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M&G*/4]<,BKB/21K>>T`O!)VEFUM,]'&IC1$=<W6]Z(%L'ZF\+$T\_CGQ'BG&
M;L4L.M?D/,(^@B#;!V&'6Q<<CL*'1=A9_-Y;47&8\[:"B9E+<B;"TI)A6M;+
M2[$5K75%@F;2MPA@,!@,!@,#_]*_Q@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#__3O\8#`8'\CSR4Q)RE
M2<4G3IRC#SSSS`%$D$E`V8:<<:9L("RBP!V(0A;UK6M=.\##8G9E;STY8F@M
M@PB:*&XHH]P(B<K89&<A)/&,L@Y84SKU@TI1PP""`0]!T+>MZU^I@9O@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?
M_]2_Q@,!@8-)`SXY^CJ-A;(,X0A7Y81/!21Q>B'XM&8$LL@N.MB)F<&AT[<L
M1FC@+#TX.CHUKK:WOH"*G$JI&YKGG(2_!5>W52=94T!65=Q(B#E0%Q:J1HUR
MD$;C;PZQ\3,RJTSC:$^<Y'*BSS"2S5+`Z,Q1NM[2`WHL_$)R81B"Z/R%4K4*
M$L\?&U.:9L12!,TQ,\A*#HUKLBS5K`I5C#K>NGI,,$+ZOZN6XT2IU?)W7E/T
ME2/T)"?=G%QXE3Y'=>4_25(_0D)]V<7'B5/D=UY3])4C]"0GW9Q<>)4^1W7E
M/TE2/T)"?=G%QXE3Y'=>4_25(_0D)]V<7'B5/D=UY3])4C]"0GW9Q<>)4^1W
M7E/TE2/T)"?=G%QXE3Y'=>4_25(_0D)]V<7'B5/D=UY3])4C]"0GW9Q<>)4^
M1W7E/TE2/T)"?=G%QXE3Y'=>4_25(_0D)]V<7'B5/D=UY3])4C]"0GW9Q<>)
M4^1W7E/TE2/T)"?=G%QXE3Y'=>4_25(_0D)]V<7'B5/D=UY3])4C]"0GW9Q<
M>)4^1W7E/TE2/T)"?=G%QXE3Y'=>4_25(_0D)]V<7'B5/D=UY3])4C]"0GW9
MQ<>)4^1W7E/TE2/T)"?=G%QXE3Y'=>4_25(_0D)]V<7'B5/D=UY3])4C]"0G
MW9Q<>)4^1W7E/TE2/T)"?=G%QXE3Y'=>4_25(_0D)]V<7'B5/D=UY3])4C]"
M0GW9Q<>)4^1W7E/TE2/T)"?=G%QXE3Y'=>4_25(_0D)]V<7'B5/D=UY3])4C
M]"0GW9Q<>)4^1W7E/TE2/T)"?=G%QXE3Y'=>4_25(_0D)]V<7'B5/D=UY3])
M4C]"0GW9Q<>)4^1W7E/TE2/T)"?=G%QXE3Y'=>4_25(_0D)]V<7'B5/D=UY3
M])4C]"0GW9Q<>)4^1W7E/TE2/T)"?=G%QXE3Y'=>4_25(_0D)]V<7'B5/D=U
MY3])4C]"0GW9Q<>)4^1W7E/TE2/T)"?=G%QXE3Y'=>4_25(_0D)]V<7'B5/D
M=UY3])4C]"0GW9Q<>)4^1W7E/TE2/T)"?=G%QXE3Y'=>4_25(_0D)]V<7'B5
M/D__U;_&`P&`P&`P&`P&!P*:_&=M1Z;&YY;N(5?^;W9`D<T/EO*B1IUGD:].
M6J3>5D$<5UA)"GL30]H`!QH0BZ=:&+6NMOK'JRF(FXVL3GC$S&U]_P"F*N#\
M4*MORKI1_=/R_IRU@_9CQ>6]^,_;3$RN[VHX?5T<G9VMP=3RB>5TE[8TEO2&
MJS2RNOQ1`#M!@)WH/3O6NG?U=Y)].41,W!'LQF8C:ZPV!RKK6J2Z^%81+\T:
ML"KYO:2-4V-X7Y$@;H"77@71@$2C.+D+Q)WQQLQN1LJ-O;E1SDJV(K02S1$@
M-Y.E,!EG-V.5^C5IY_2%[0R=&JZI3Q&KGE+3Y\NL8FW[JKV@&!?"WEEN)VK,
MQ.PV5:;$F?2W*0MJMH(<2#SR=%GD;-%,J<^7,,;*9<K@-@EEGJ&:XHE0+K59
M*2#`LE!;DUNN)4(QQ$TQ9/4M;#[6;S=N,$X%R,;5ML/\I`I&'75V*>M%^5M6
MN"^1QVQC5O'V<11YBC*\P2]':"Q5Y&=/D4D<8"J8'UCF4I@$R135'#7G:`3,
M\N!G:LZX@X!*A&H)+%,Z3\@:&5IY@K27;42I)7KHW,<^5)[)AIR>#O3P\BCC
M0SS`XMZ$7&G1UD(=H$R=;L@T];K9``B-_8X2F!VCRZH:L:'=^1@K"ATTK-"N
M1,;2^0J;P9Q:)1*G21)XBV1AEE2Z2ML+"XG213I,>8J<DZ9!HLXU4:240:,!
M8B9FF2IN2U$%QE5)9%<=0Q8AC2QK<T+=;8KT2:#NDJTX%M+))'E+(C69&M7.
M#,O3)1;/[-::A/\`)Q&:+'O0J7IO?(>@(TH:4<CO.GH^K?FE._,25[LV%-2A
MZ8UC6<^)'II(7O9!KBTJF1.8L+4DZ&2-*6(W0MEAV+0J='FSKD-7$.K:-6FT
MN`;,C4YDD,B-?CK1VB;Z3.Y!/I`DC<91QR2.<D8H)Y.N<%7_`+M8[I$6M`V'
M1NS1%EC%/`(Y94@DL`JHIQ,V&J[<!!8A/W:MK$E<%;)$Q-DZDBN(QMK7+&>5
MOL77R%=(4H4^DK:XKND2E-L(Q:5)]FBI_#,)QR!I2O(Z[R:66M6[*VL[R]14
MX;I/(FU:.FK"W'.;C!23G)W2D;F2=*3L0VW8M*R];Z1%ZU]7!4R^.HN0E6W+
M7E5V#&Y9'$Y-N-C2;&H\KDT=.D`9*OA.[`<X`:D0.:L"B<Q>-$*5+DW)Q&J$
MI",\T8=%%"'HE-6Q#FE6THL20P)QBT\@C>QNUY,Z2R9N.ND5>/YW'*0EQRVU
MR14RV&_2J-L4;5F:-\X2)I9$1Q'U0&['L)>RTW0V7U1CTEABYGN>IW9#8[LN
M8*\6-EBP]>EGCZUJ`)'-EABA*\&DRAV;E1H2CTR'9YQ)@M!&'6]ZUA&$R+E1
M3;8K9&^+3&,V:Y.%RQ.CGUMKJ6Q.3+X--)>)Y`A335*B>AF1\:<QA4!-(4:`
MJZP!:T7OJBZI:>Q$N3%$RY/7!:>V*R;9+:L>BTBAL&66A6CC+G@B81ANF#*C
M:$D7F$A;)0H4Q]U)4E',JMS0*TPPJ$JA0F&6<,5.C/(=:-9V(MD[;7]B06<N
M,)=/,<S00Z7,$F6Q%[ZZDOS/)TK*X+3V!T[1$<'R=6$H[I*'KJ](1=!&+(>1
M/'YSC[Y+&V]*<<(M&71,QR22H;.A*N/Q][6;V%&SOCR0]F-S2Z*Q!WHM.>86
M<9O7[$.\%3HQ^P>2E>0RK8Q;D8\KNJ,3B:0.`P;5-/,$DG?&16+-&^`QXMAD
M#Y,HQ!34(9"X:`I4G.Y))`"S.D6QAZFRT\-BY=TT--*2[/>BN.DCA$A98O+(
M??[]!(*ZM3M)F8R0Q?2-]23!^@,K0R1F3GFHU3(\N:8P:141L85"1244*GX;
MM;[&KUW4MR)JG<-<UCN^2F,-*1OE#(M4NDE@QRU--8\W$)EQAJU\AZAL4ENB
M0K0E#>-.8$\!>RQ:T1BD,N:-S:SK5J=`SRIKDM1)(2XORA^:2&YI>&R?#EI#
M"YQD_2\]<O0B5PAP*&,].EZW9@,*[4DP!H@V[@,!@,!@,!@,!@,!@,!@,#__
MUK_&`P&`P&`P&`P&!1QADSA[5#XHV.<KC3<Y-T:8D#@WKWUK1KD"Y&UI4ZM$
MM2*%1:A*K2J"Q`,+&$(P##L(M:WK>L]>.6/3C]HW.&6.75E]9WLD^<*`^O$0
M]I67X;FNO#RC_:=.7C+%9W.82L@\R2))C%E2I5%)"G3)D\A:3U"A0>T+"B2"
M"2E8C#CCC!:"$(=;$(6]:UKIR99X],_:-RQCE<?6=ZU#:_$TKD<R46[KY>=$
M2X-2DJCR`:5G*<75OF4K54=,X),T85J@MO&.OY?3Z5:-"I),*7[%HH>P`T+K
M>-Z+JV-VWPLL#D:I:7V^+/A#G(HNNIYJBJ>M8#*X%'VZ$1+E+QZY)7"0H,76
M=+)4.26Z9QO8&U$>G<DP(T!.$9>UI@C#AQ;K<W;</&EOD5$-5.4L7$*MU&+>
MHNXHV!1'U3A&=O\`3W)2O.1SF!\;FMR:71Q4SY]A*@#BNVJ\L.5N1JPT9QVQ
M]>I$[;EJTWAK*)5=E?\`(:S[,8Y#9$>M*,RQ[31:%+HI%4=<P'CURQJ"OJXA
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M3U7(5C.R-H5!Y<<0"**$8M`7OKQ;2$9>.#[&:#F5,IE-3SPF7W+R'L9S:+=K
MA9,ZY=HE>G(BTKO(@KM$BY*W@.[L(+`3-P5)@E*8T3=L>D@0F@"34O;:/KAX
M?<RW'D#"AO%(Y*0TK65<+GV4PMY=34LFHZ^7;D%5+FQ(AS\Q<7`FR0O8F4]D
M6N*Q>"/(4A);H)0$Q2.+?![C/PELMHD3S/BK:@2J<3-1R-;ID2ZU>^NL(U%>
M3"RH7>4DQ:/BLE(X-3]&7:I$P$QYZU4G<T"@1*PK8RR#B*EODXG<17VH;A.?
MW<+@5":KI>KZMB);D2V)TL_N=#6-<UI;]\,+,A=G<]AC[M75-0QA:2UP@.0%
M)+\+J!3+`'+!,[&-M_A[3UCG]L6'"+8KNK9;,Y)R2D[%8D"J-6BMEX/OZ0N#
MXV1^UYN&<(1RZ%UMI9K:%"0G3J_+R$JQ*M;S$F@'Q;W/0@?A_P`XA<N:I@DN
MDIND(;O?+2>9FR;N)5/C(/*V>G4<VI(,GF]US-3+81.#JN,+6BDWGHQ$-0G<
M6L"!P1I3":E\'FU+X;'S8AJC1EA$OKC3D@HM+'Y4M=+T>W=_K6DC)*H:XJ[1
M^Q;TL2#QE:>?(.N5N/-S4@2GB5#)3%)U0$::4O4^BMO#E<8'3K!6)MGMRQR9
MTGAFHC92WQ=8U+#D_`"05.[O(4HRGTQ<C%9:2O5A"/83][:/.@MB\IT$>C!?
M_P"LWX]<`FFFX)-8!()HY2;3_0[3QL:9TV2R[^]Y%7M+6^MJ()K99-S6E!HR
M\MOGL9Z0,=;&E"E6"4&D$$IU`42>I,OD/X.363/$-D=@6C"')V@*OBJRQ]#"
MJO<89%U,%XR6]JUR`OK*X3^7C72N2K=B(1&%G$H8^4(P*<@[9YXQBV9/_$J8
M;J=QA$4GD;2R0',A=RRC[D_QIT5QU*)1R/47^7#7%J;7Y`O-T8:I&C/5D*"N
MT.,&HT7K8M@P6UU9W!NX+1U8+V\<C$C?++H3J&"U4L7BE@02%G0=L@[C$*ZB
M\:(@ES1R?B3P%5(7MR.+=9"O;Y`XORDQ6C+3D($:2+<;-C(^+?&"05O=U@V!
M("G5/%HY$8Q7U;H7KS:48[SA5#:XC'("W6=O;'5W\W16S@4Q#@MA"\9;H2O0
MO:L0`E.VA'5)G8E+%*F41N][DN0;V2K36I"J9B:=A`A&2>S&54HL\]0M.<-J
M3"UH'K5A`T``2B]D>2BZ1#Z^NJ-&Z\(8#`8#`8#`8#`8#`8#`8'_U[_&`P&`
MP&`P&`P&!1AE7^J;Y?L,GD;&FX\\;3D[,_/#20<>39_;&DMS@H1E&'=G/@`[
M48"=;%U=:UT[^IK62W3HC5X/^ZPYB_BZ\:/W&TOZ0,EKT1J?[K#F+^+KQH_<
M;2_I`Q9T1JM\VQR^CE)@JG<SC+FY!LNJIK8!0XZH3"7"?8JKJ-D98*Q-#B-.
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MER"5,<,:XA.8R"`O=B5ZH(>Y&CVMTLCQBXA,>6(E&I-/2D'BMM/?;>75+C:%
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M!='*Z?"A:7M[`ZD*&A6$2'>P$Z/%-POG)ZBXX[HX^ZSPD#\XR:&0UM943#*7
M=V<Y38<-D%A0QC;&YH8URQQ<'V&15Q<"P$@'U"4@^TZ@^@.Q4O)C?+CC_,?.
MH8G-G"2&M3`ME!:5E@5C.2V1,;5(D4/>UD"0I(D:LL@<=ESDF:7,F/@<U#8Y
MJ"DBH!*@P!8A4O\`E;\EHG:]MNU=PA.4\1Q!3\7M)-.`+5J0Y0O>K,M2KWV%
M.,1<V1O=8^]PY^JQ22O`K-`K(6B-2'I2#4P^N*V(\\4O$0B').`N%@*HB2UM
M:&L*6M0S5/R-ZY)[;$UWHWI6S5A)6ZO(`CES/>\-"R]:1Q<AH7";2%J4\"H\
MHW8@"8I)AOY34"[%*%C79#6X,S?7!=LO<I1M[\HA46@1S<K=T[Q,YP4TBB$*
M5JVEO4*B6YV6HW,Y,F.-`G$`HP014M+3GGE64:<&C3"F\\L`X5>THF3O*>]M
M;.]>.M'):C<UD7EL&D\#[Y-#A(&.W$:\K:M&E,+1;3*"R5!"THT(IMP'+CCI
MM\DC`?:#2W*HC\Y8)$X/39(F*+MRRFU*M/:30*9O+,AB"E_@A*(Q8XMQ*XQ<
MG;.JOV3Y$86>(5+)6CD+3SQ`979A<Q`U1""N:ADFJF5L<EA3U$WTA,TK`,$C
MB$P9F.8,S^XHY`W'(4*A`6K<"G)&-*6<%4GV8*8@MY@<>V]J;G-7-G,M0Z.T
MCCZ:*AKVRSK')D409FJ32>..=6$0XRR661L<5?$CPH0+&HA86S'A7[+\CZ3]
M"I?#9'(IT;7*@V6E(K#K=6\A4,FD$,>'>RE<&A)T1C4-23;3ZDDS'`+,4NFW
MYK<4_F\!:$"<X)G7&H+#K76%;[?/"N8-72!F:%$N22RLY(JL5YI^01N1QA[>
M$,0M%EFX*\+B\@GL002"O&P$NE"I&7&E*MS2Z?RW-$%.#RD_R8`IMN`755UI
M&-14!ER*2FO5;PRW4!:-(Z$F;KNPU+ZCA<C6`6H4HFP$A61AR*(3*NQ6:,;U
M`1DA$29H)*>#.KH[C6_2-5*H6]KDUUNDN9&Z;DN+$2QLCQ%(%+;!&V*6P:\<
MB6*%31#S]",TE*3%[/)ZII@MF`**WAA#`8#`8#`8#`8#`8#`8'__T+_&`P&`
MP&`P&`P&!^/-8WVPIY\LY1__`+:[,/1&Z&&X#`_5,MVGJ,M%EH53<EJM]>J$
M5(RR'Q1O,E<9B;ZM5SU;0^TDVB:Y_-$:7*:ZGL8C9K6:6F5$%N[@C`<69LTD
MHW3CMN:85?W'JEW=$4Y<TN3T-=EI(*J6,JFUBZIKJ&HZNJOE-QSM2:L0H@[*
M$;,\M]SV?%H%')>X*C#D9AJQG1I4R,:@I.J$3I"0ERP*J+*X\Q6+Q&QH!5$`
M*LSC5+*NFD<!$3X`GEM><B:LL"HH\PH27)HC#NCG-EQAJ8DJ!(I*,<#G(*9+
MO:DTH.ZD;VJ#>/U0I+U@,PL[D.DE/(INLV.V"XH9$\06-N\D9@\:N8-45]5D
M5@#8:VN$:KQLBT_LN4M8`^<756J9WM2<N5%)58THO9NV([VSQ>AY=<4,VQKE
M0QO+E&S^(D6XIK9+)JC8"V'CO%.<'"&=RF11-P,1&H+EF3UN"P-K;W$\I2WN
M;H-A;R$>ECR:-QBQ._8E&[4A6!]871%IQ?+2MD<MY&T]8EZ6&I60M@"UV]&U
M_'9TKR"K&`A44V0H;O!H1!VEL;%AQKFI0.*-3LQ4>M+-.J7MC8_D11=<[DIK
MA7W(!M9+7#R/N>R8RM2*89)1HIE+H@!DL^L'&&*5HMOQ;#'32U:D@`TKJWFE
M$'#,`3VI1POAL:IBW&3C(T,TD;6+DLS.Q*FPN#[K*79;,*Z<'(RQZ-YF/5KP
M\+Z:TGMC2BD?(7D(H<H]M$0E1EB=A&H&M-H\K28$6YT;-=:+K531"2$1F_X\
MRI"N:DXN.-V*I.BCZV$WD]<VIS<RRIAHO/C>V.SHPW*]JX<8V!5%.FUB(248
M`+0C+U4O;N^&O;`XR\<7"5OBN]N2R%TLQU#/'FVEDIE]=0QZ7PJ5\9+=JHN,
M-4>2B:B:\K^#U<ZR=_;=]BI4:VD<G!:K5[TK4:%S6[8]:"<<*PCUQ5C+))RC
M;9[:L;MJ`RIN9E)U<,*Z4R%@X><D*@B$30QEA4$+`*'BD[`>)9LLH)ZE6&/*
MEQ.@-VC"TL6]^QBCQQ:HQRAM,-S-RI:60JNJ7Y"-L9>4[]!5C1.ZY?>1_&>W
M;9>9(AV\$II+6$;D=5,T5E2<@\M`:V2@Q&M4$&*2="%[]C/N$U&\<:M=5SY0
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M>98P+Y[J9L<8TWH7/1FGO:A*B`D$0H*($+F]S)811=9L-^,DV?[_`&R:\@$M
MA6#)Y@SF*X4RN,@D\FH^NX83&V^!M*KSC&6R%5%'6-<0DWY8N,3*M+E1YH50
M3=U+V;F/Q;C_``QMK;@'&Z=Y,1Q$IHNEV^&T=--(X;.";O@)-,Q6'*)9'&XJ
M0(VU^`JAS8E=RUC68L1%%J0F["80(.]B]]PTC87$OBF6NB(9IRY8R`[M2.Z5
MBM.5TP]/\HY,QB^SK@>WN+K'A,SML(MZ=2R0%,$@;X^WI%.V)*TM#>2VI4@"
M#HL3.C?O$>OJOA4$OQ[D4DK)T)L^8V!94XB()W%+`C%24])9#.%#-5[V\$CT
MP@@K$N#*5)R<1?F9`X+79`E-/1H]&;J3\-H)(5QXD;GQ.D]832L8[#Z^E]A/
M5)1FLEL'30BP%CW6%D1.2LL+2QY04UN`&5K?'5V4`:`&B`-"<8;K0`G"T-NU
2+/"&`P&`P&`P&`P&`P&`P/_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g893535g29x99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g893535g29x99.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0_R4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@`````````````!(0```6`````&`&<`,@`Y
M`'@`.0`Y`````0`````````````````````````!``````````````%@```!
M(0`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````#58````!````<````%P`
M``%0``!XP```#3H`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!<`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#T3JSO=2WTKWGWN%N/(+8;MV[@'>^WU/T2S;,5]0+++^JSZ;7D5$61
M8=OL#F5?3:YOJ;OYC^=_J+HU6LZCB5V.K<\E[##PUKG08#]I+&N]VUS4E.0&
M^U@KNZH\,)8]W?5MFYSMU?OVO]OL_FW[%)^)6['#;+>ID18T621:`Z'Z>DSU
M&_NU_P#@BU/VGA_O/_[;L_\`((.5U%CJ2,2[TKNS[*;'M^;&^G_U:2G.<*B^
MQH9U-M#*0S:UK@QV]U[;-M>S?ZOZ9GZ3_@Z/\'7;OF[#K;>ZYMO4HH>0*Y+F
M.,^I[&/8_P!9N\,9ZMG_`!GJ_P`Y:BLZAF&T3DU^FUS`\.Q+VDM#6^MZ5GJ[
M7>H_?Z5OI[*_^&5RGJ5(I8+K"^T-`L>RJQK2Z/<6L+7[6_VTE+'JM;6AQQ\B
M#Q^B=S.W_JDXZGN#@S&OW@$@/86`D1[-VOBI?M/#_>=_VW9_Y!+]JX&T'UA)
M<:]D.W[@T6.;Z6WU/YMS;/H?024FQK;;:]]U7HNGZ$SI_FL154_:>'^\[_MN
MS_R"1ZGB1])P\)KL_P#()*;:2Q/VAU`%H^U5$DO)_4[W-`T])K[6V,V?VOY_
M\Q6Z.HM'\_:'G8T'93:WWC^=<&N]3V._,;N24Z"2J_M/#_>?_P!MV?\`D$]7
M4,2VUM3'_I'@EK7-<V8^EMWM;N24_P#_T/4K;F5!I?/O<&-@$ZN,#A"S.H8.
M!0<C-O9C4`AIMM(8V7&&C>^&^Y%?9L+1M<[<8T$QYN7*_P",UP/U4M$'3(Q^
M0?\`2-24WW?6/HF5D`8G4<2US6@M:W*Y@S9NHI_<;^>M3'ZGT_*L->/>RUX!
M<6L,F`0-W_27C'U8_P"5Q_Q-G_?%Z']5G1U5Q,G]7?QK^?2DIZC(R\;&H?D9
M%@IIJ:766/\`:UK1RYSG?16/;]8OJ[EW,9C]4QK'D0&LRRPF#ZFE5#O?]'_,
M_P"#4OKD\.^J?5A!'ZI;R"/S5Y)T#_EK%_K/_P#/=B2GVK%ZITZXUX]62RVX
MMT:UVXG:/=_*<K6YDS&OC!7&_5\QUG'/E9QK^85V7JCP=_FE)3G9_P!8^AX5
MEF-D9^+3EL;/H77-J=+ANKWS[Z]_[^Q"P.L=%:'VUY]5M5OT7_:'7"07!VS?
M[&M_XM>9_P",'7ZX9Q_D4?\`GIBO_5W_`)%QOC9_Y\L24^I5WTVUMMJ=OK>-
MS'-D@@]PL_JO6^BX<XN;G4XN0Y@L95;?]G<1)V'?/JLK>^O9O:B]&L`Z3B"'
M?S3>`?!>;?XTB'?6>DP?Z#5R(_PN4DI[[`ZWT9QLN9U"FVMQ@%F0;VS^?]+V
MU[?W*UIT9>+E5^KCV-N8"1N9[A(^D-%Y7]5O^2C_`,?9^1B[_P"JKPWICI!/
MZ>S@$]PDI__1[_HEMK:,AUANM<_.R6CU#OV@6OK:VN!^CQVM9[-ZR/\`&<9^
MJEH@C]8Q_P#SXU;'1KK?LUD5AY.7>UVR0T`V.._]*YSN_P"DV_3M]3TU3^N_
M2>H=:Z#9@X%8=>;:G@/<&-(8\/=[O=^ZDI\O^K'_`"N/^)L_[XO0_JL8ZJ\\
M_J[_`/JZ5R/3?JMUOH^6S-ZA5770\68[2RP//J0XQMVM]OZ"SW+KOJL2.JN@
M3^KOT']>GQ14Z?US=/U3ZMH1^J6\_P!5>1]`_P"6L7^L_P#\]V+UOZYN)^J?
M5I:1^J6ZF/W?BO).@?\`+6+_`%G_`/GNQ!3Z%]7_`/EG'^%G_4%=GO\`Y)7&
M?5_3K./I.EFG]@KLM[OW'?A_Y)(J?'?\8/\`XL,[^I1_YZ8K_P!7O^1<;XV?
M^?+$/Z]='ZQD_6K,R,?`R;J+&T!EM=3G,)%;6EK7M&UWN]JL=%HR,;I=./DU
M/HOK+P^JQI:]LO>]N]CO<WV.W)!1?0^C.CI.)H3^A9^1>;?XTC/UGITC]1J_
M\^Y2])Z,YPZ3B>PG]$WP\/BO-O\`&D2?K-3(C]1JT/\`QN5X)*8?5?\`Y*/_
M`!]GY&+T#ZJ&.F.T)_3V<?$+S_ZK_P#)1_X^S\C%Z!]5'$=,=#2?T]G$>(\2
MDI__TO0>DY63=7D.#&O#<Z^J0]VC&6.KWQ;O]_M_FV?H_P#1K2E_@/O_`-BS
MNDE_V9QHV:Y5OK`Z_GNW[7-^G8[^<]__`!?L_FZ]'W^`^_\`V)*>=^LV+CXN
M!BUX]+*6.RR\MK$`N=3D;GP`/<Y5?JM(ZJ[3_M.__JZ5TN9@X^=6VO+I9<QC
MM[`XG1T.9N_S7O:JO2>DU831<<6JC*(<QQKL?8-A=O#?5MKJ=^:S_!I*;'4L
M"OJ6!D=/R011E5NJL+'0[:X0=KMJXA_U.Z)TUF1U#$^TB_"R!57ZSG["U^RE
MSMME57K?SEOOK]G_``B]`]_@/O\`]BS^OXV5E=+LIQZO5M+ZR&-<T$AKV.=_
M.FMGT1^^DIYSZO\`_+6/\+/^H*[.7^`^_P#V+E>A=-ZE7U.G(MQ7UTU^HUUC
MG5P##J]L5VV6?3_D+JO?X#[_`/8D5(LBAUXK!<6>F]M@VD:EOYKM['^W^JN)
MZQ=4WJ^:'6-:1;J"X3]&M=W[_`??_L0KJKK'TN:6-%;][@X%TC:YD-U9L=[_
M`*7O24U^BN)Z1AEL$&ED&?)>;?XTI_YSTS_W!J_\^Y2]6]_@/O\`]BX[ZZ?4
MP]9S6=5.;]GV5TXOHBK?,W._2^IZE?\`W*^AL_,24\O]5_\`DH_\?9^1B]`^
MJF[]F.@3^GL[^87)LZ'^P'/Z9Z_VK:?5]4LV?S@^ALW6?1V?O+K/JIN_9CHC
M^?LY^(14_P#_T^^Z*_)MHN?6XAGV[)WB\$O]/U;/;5JWTV_Z+?\`X%:A%LZ.
M;';0_P#DDGM>=NUVT`@NTF1^ZGA_B/N_\R24M%O[S?\`-/\`Y)*+?WF_YI_\
MDGA_B/N_\R2A_B/N_P#,DE+1;^\W_-/_`))*+?WF_P":?_))X?XC[O\`S)*'
M^(^[_P`R24BHQW4-<UCRX/<YYWRZ"X[G;=1M9N_,1(M_>;_FG_R2>'^(^[_S
M)*'^(^[_`,R24M%O[S?\T_\`DDHM_>;_`)I_\DGA_B/N_P#,DH?XC[O_`#))
M2T6_O-_S3_Y)0MI]9GIVBNQA@EKF2)!W-]KG?O(D/\1]W_F24/\`$?=_YDDI
MXWZQF.L6[CKZ=?:.SEL?53>>EN+2`/7LY!\1YM6GF5Y-E36T['.%E;B'DL&U
MCVVNU:VWW>Q'A_B/N_\`,DE/_]3U"ZJRPUEEKJA6\.<&@>\#_!OW`^W^HJ_4
MLZOIV/\`:;W/<S<&AK`TF7&!]/:KJY[Z]_M;_F\_]D>O]L]:F/LT^IMWM]3Z
M'NV[?I)*;>#UW%SF6OJ-S!06!^YK#_.$M9_-^I[?;[T?]I8X<UCK+6.>&D`U
M._.V[0Z*_8[W_GKEOJ+_`,Y/LW4?VS]NW^KC^AZ\[MO^%]/U?\%_I]GYBZ1G
MVS>STOM6W:S=O]*/S-WJ>K[_`%?YS?Z/L^G_`,"DI,WJ%+F%X==`$D&EPB?C
M6H'JV(`X^I=%9`>?1?I(<_\`T?\`(_-0S]L^RNG[9&P1/H[YDS]#])ZG^O\`
MI%/]>]0[_M/I;73_`#$3/L_F_P!/O24S;U+&?9Z8MMG74TO`T&X^XU;5)N=0
MYU;!99NM`=6#602#^\'5_H_^N[%6'[3C_M7,B/Z+Q#MW_2]/Z7Z3_P`&1,G[
M;N&S[3OWNV;/1VQ&F[=[-G_'?I$E-VLFVMMC7NVO`<):`8(G5I;[5+8__2'[
MA_<AXV^;=_J3N;'J;?W*Y]/T_;MW?3_X;U$=)3#8_P#TA^X?W);'_P"D/W#^
MY3224PV/_P!(?N']R6Q_^D/W#^Y3224__]DX0DE-!"$``````%4````!`0``
M``\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````3`$$`9`!O`&(`
M90`@`%``:`!O`'0`;P!S`&@`;P!P`"``-@`N`#`````!`#A"24T$!@``````
M!P`(``$``0$`_^X`#D%D;V)E`&1``````?_;`(0``0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#
M`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@!(0%@`P$1``(1`0,1`?_=
M``0`+/_$`*X``0`!!0$!`0$````````````*!08'"`D+!`,"`0$``P$!````
M`````````````0(#!`40```&`@$`!`<+"`D#`@8#``(#!`4&!P`!"!$4EM8A
M$A-5%E8)%96UU78W5[<XF!E!TQ=WUW@Y"C%1(M*T=3:&N+886".783(D)=@:
M0I(F$0$``0($!@("`P$!`0$``````1$A\%$",C%!<8$2`V%2D3,B8A.QT:%"
M_]H`#`,!``(1`Q$`/P"?Q@:C<[&F2*^*%X2.'V?9%2RBM:TL&TH_)ZP>FUC>
MSWF"P.3O36S.JAT9'TA7&5R\HL2Q.`LHTWR0/%-!T;Z28XN?=5<H;IH]BX6U
MN-_%=!=]\391S%NZZ>2-B.@'2LXU"([23S/BXTF@M?*S7MD3MTS6[;&K:8)Y
M:HP`S%>R@&!%":5K+4.5>UFNNZ&:)I6!KAU.R"O.97`P:>7'6<\P*L+8IWE#
M&+C?8\UV,<I;'F30>'+O0`"AP`M(.5K&Q4E-&W)#^E-I5/C1L`Z>V7FA%2QV
M=DU/3[(]ME#<E+WF0IE<#JSP2SR>,MUK:6=J^XSR@J&J#9Y)+-5MACFSJ%!(
M=(R%*,H:97M1Y8"IXW6-:?M/K-EG**GT;&TIZZJ*J^4ULP695:TV"XCY.VBA
MJWAY.+8?2Y?2B9H(:!5X]O+TA"QBTZ*!#<VU.,01:6%=75/&*2N6L?;%W;;\
M)AKO"N/4`-?+1N3C'6D`>G:5V&T5B`7)9FL@_;'()"M@)+\?(ZF>(6E"X+6Q
MO6-KVB5B-1A)&'9854>,1/%6G?VR$X1T[#K`W4=2QF2IN/O)>^[`:;`MIWCD
M?EZKBW?+S0DFJ"B78,.4J9/8$[>8\H<&W2LK0F].I0E')E(U.S"E4^/RO&8>
MUPE4(E')%@D],L<3<JV2UNXU'%99(GM(?*X18%LU72RNY;!L5A99'`(C"H%,
MK-T&2M(1B>V0Q'M*<$1HCC$RJ/'@IKS[4Z^%J:/QBN*@HZ63X5E\S*T>I.=9
MTKU3DD!Q$K&'6RMF]=O[+$WAY<6F6,T@4M/4CR=[1OJ0PD2P1)(SA*E(;)5C
MSJL:Z*'Y&V]!H35BUY@W$2F>1=0U=$;._2%;QDHN/C,MN]L@ERP%(SLAL&4*
M9#M,@CX@*#=R)!L:H.D_1H&2BEXARPGG+J[Z^I5Z=*?YNR?D\Z6A[,"\N4-I
MOHU=7+5W'.WX<TUL9!YS"C(%%8_N`QZ:2"8N[,3%U^E8DIS+HP(0FE*QF0M2
M*WCFRE++XYE6_..3K)9:RWN&ZJH?9B13DA`(I6UU0";G269L,CO?R%D.C^S1
M1>WI&^<#9B4#BT#+`LT4S%#\J7HP.]BT?ENDQ7K/N)'L\>/G)*4RR:WRWR15
MQEG?(B7V](2GB2PJM+P+@+%8\FB&XZQL@#6RNW"3%N:9O.).\1$%5LT[>M:,
M`12LT6C2/M+[;G%H\-XE;E-Q2H(;RTKP,UCDK-=)))5*Z1S(5B2:L*K3H&5*
MKW!YBMJB,-;ZH/D7543EM>K(1""-#O1XF(O2>#!Z.S^>$MY]\E_T,+KQF<$H
M?DTQQZ4QYS?J83\9"*'*XPQ2;O=;(XTZF_IF67I)+#=TIK0N9TO4DX58>MJM
M$B4%Z)I%(4#C)S/F["\\+[4EW,%SO]%R(X\7U=_-:KW`-:GL?&A/553EV.O?
MHC'HA'F"1U0WUM/RO0)8WNZM4%T/4^5,UM80<?H3'&S5J@/:;\M6+C9S>>9S
M(['%<2VI:1Y=TDYW!4LG:2ZOJ:\[%;:XMQ^A4=DL3CX+$J+CDC=DSXUN21,X
MLCF`!NO*GE`,"-5,Z8K#LOP%N6-RRSN3]),MSWI?RVFB:3D:NU;6L&AK%ADU
M:K;;+`5,4FJ5RHU`@3,S,]>A2DU8V.)9`T?_`-/I.G)!L>AE9CA+IQDJF`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P/__0G\8&/[/EM?0Z(C4V@<A+ATID
MD$JM2F=&59(6UZ?+IG4;J"&QAQ:$;<Z]90RR9SAO;#A'D[1$EJ]FJQE)0'&@
M#!C'<W$UUES&Q-)$?(>(\S3JN(%(U50R=CAZQDAZ-4?85<U':#I"&^`RY,S-
ML"4FN#'&G5;_`/3,)XQ$;+;SMDDTE;-$CX-7BQKT=.5/69C09':^FRR.O7&]
M;5:AQATI1S4583,B)6-6\,<WF)NZ5PD9;.Z$I#D(Q'.11)OCC5!V)JS!)FN@
M")=3=-26`P58\[:Y5+::C:VOV=Q9XJDJS411O+A%MF-!S3#E;("7MH$WD-IC
M1`'T$].BQ>*+W7^IJZLUDM!/E==055.BE;<O*FBF(Q\^6EKF=K=6-H6@D9K>
M)X`K:V5]6HTQFCO'(2K#R@;"6:8$1"AM%#T<P*#U;#354LBI5)VB;*5+17<0
M;5"B9Q\*T+#+CSD;.28;)V0+DHTC7BWM6FT>9Y,P/CBZ15]AU,4\H;8XSGU1
M6I[1#WY?*8BU'06+F-L6D[HYJWMSD<<0C:Q)61^<7E>>K/6)@E*#E1QAHQ[&
M,0MACZ.IN/#E:]RU[&:TB9LZ7LS8LOIX;JK1IF>0BDR,"MJC5AS;W`(:)A)G
M1B=NNB:U"E:J+;E`3CP%EJ"MFDWHR.DJ&IT#=&&=#6%=HFF$MSXSPUK20J-)
MFZ)-,G1C;Y*UQA$2V`3,+=(4!@B%Q"4)12LD6P&A&'>]80JL6KZ!0;:@4)A$
M0AXEC9'&56*+1IFC^U3-#FH+%$6E1MI1)-GMD69`:1MI`NDI"EUHHD("]>+@
M8GKF+\;9@VW&S0&L*V+9UT\E5?7.U)JTC[,VS&7M`""Y,EEZ$;(F2S0!H'/6
MC%"D*DI1HP6O&%X<)OS9855]`5RQR<5T(B"QP>8@77SPO51IE4+':`E&N!Y4
M(<E1R(9ZZ(%GNRH86PT0T6AJ3=Z+Z3!])"SK17U#`:R1LEBQ^/?HK>'ZJZ5(
MB!\32O<44*+9L&'TO7L2.B93>J;-1Y;+)DV(!%C3]22)A^.9H!!8MA)?;'8)
M43VZQ>UV>LXJDE;;&P1V*3!SK0B,3Y@B98%*0J.(#W^/-,QC;($@XT`$.PIR
MO)&;Z"_$'X2%[M,8C3"N?W-CCS&RN4K<RWJ4N#2TH&Y=)7DEO1M)3L_JT:<D
M]X<RFIO3I@GJ!&&A3D%EZ%X@`ZT%GDTM3B8V<G)ZFK-.=9Z9:BLHTF"18HVP
MT;B480X))R8!J"*6IEY!PP'%K]J`&@%O0M;UO>!0[",I:K$C'8$QBL6;A#6U
MOQ\8WY/#$"]W2H+JM"$U9#:]2J$3:<X(H:^6!*6@E0D#L+<3KQ3S@A+)V,)-
MWU-,6HKC^B$?'(E6-/()I*8U'CAQB,1N$IY/+Y,]:9HJVJM,;>WA=7EV?7S9
M"71FAF"/5"T'PC%TD7EE[`8#`8%O/TLC4741Q+(7MN9U,OD)$3BZ=>I`0<_R
M52VNCR2R-98M^.L<1M+(L4^3!K8M$)31[_L@%O06C8UQ0&J3XHCF:]\*<IRX
M/;5$&:-0F<3Y^D+E'8N\31X0M;#`HY)GE0I21F/K%6@:(Z3=$[`7XY@@@$&!
MM<]>-FZX06YIRN,5<NC\DC*"4AXK\J!(E+TX/Z"*-R4!`:7VOT4XRAS(;4Y^
MR=)SUX^K@&(X(@:)I/!MA'WQ%)61JD#<0\)D#RA3N*0B01Y_B;V2G5%Z-++=
M8S*6QFDC$N"$708E7)$ZDD7]DPL(M;UA"L8#`8#`8#`8#`8#`8#`8#`8#`8'
M_]&?Q@:]\FZPDENUO&XI%!MA;HT\A.)%GJA.RHU&EW&Z1Y6TO=$R`4:2F5C&
MYFQ"`K@HBM@T`]9LHL0RPCV8$F&I#+Q6O(=5\>N-[\EK=)6O%X;;Z/V6WS61
MN<ULQNKFN)=7E2)%<24PAM2Q&0.A;NA72Y>8\.)0AIE"=(4I"XB/00FL5JRK
MQ]XC+Z=X[)(B7-I&GY`/'&BOJ3>[872!7*3H<M@D$=&:,HH(E,3L[2V1."RR
M2N*]`6G1)3U@C=&+!G&:`($HK=K$Z<!WN=,%=,<EH#CE"$\(H[D;!GQMC+^=
M,6J86Y9$$IN.P^V%+@ZUE%'A>\^ZL$6#&[.8%#Z1HI.H&8)1T>3A->*S;?X.
M\L;2D1#TI6U(E<4U8SBN7.4MKE'FM]L".33@38U*!9["=BZ1,M&3.R3DM)4C
MJ<:HF>XZ%A1MYY3,-Q3>.G%85>P^,#E23T*7+8'7<RHA59-<2)SX]#89N^0J
M<S(?'R0U]*II)8Y!*DL]..2$3M$WN1)SFT'I'59K2DPX#SIOT<*L=<?N!MVN
MY/&BPIV>_1Y`P1NHGQM8D\DA,:G='.D2MF=6:^-:,JS.-5@6*0AF[3(41#X4
MVR&*.SR48>T/)`""BS21,\6SLZX&%RZXK7GAD%J52T6?RNH*U7X2MM0@=)14
MT!I^.1"?Q>6:+8!;>2GZ6HUQQC2I-/0.1"DP2G?_`*QH-BMF)I3P$N]\C3C'
MFY-54:D14<FC+.;;898^DSSE8[26TX#,&"46WLB#,ZMC<XXUQM8OT8:YO:MM
M=S^IMAY2`9YIPK#-57<)'.I^0S;:,)C-;PR-(^15M231$4++9ER7CY.>.S-'
M&NMFYO;V5*D0L8>03<.1F,1(RVPE8:8Y`Z59YWCB9K"PE?"^[T=H6+/H-%J#
MCTQ<KMY!7-&;=?WE[=WV6LM@4K.ZZ@-&V1&4<#`K4U>9/GUJ?WY(%X4HM)F[
M>TJ3;D8!6G%8HL*%\"KYCB]O<26RMTON9R6C5SP5@>7RN'FNJZ9C:_JB*3D+
MK4L3XRU_7+T_J%$,<5C0LCJ",O[2[C)/*?!:<'DY0*P_J+^SNN=F<U[T\2K3
M[,OTQ\>9=(96HE]=IX];K%77.^BN3+_-)>QQ/C9`K"7V4Q0.KW-.T>D4JD8&
MM0\JFU*H/3*=K2!6'UQSV>=IH"0/;LDK=5/8A#.'395$HVYJE+K`Y+4/-GD1
M>=T.$:=3F#2R.>EU1V4S-HC4OBC>-EJ&]5K236]FBK.?$3AS8]'VE.[`GDO=
M7:2/<7FT9<9FV2*L%#;::R63])+VB?S&,L/'*NYPXSJ+I6XPM&9))5)P,I;N
MO0I#%B<[K)<HF:L%E>S[MU=%H/%%K!3<90QU+QIB]U'QN2O3J;S&6USRUXQW
M!8]UW,!?!6949+#:NJ*5)D:=S5R!P<W*=NJ-:OVF+*7+836&R)/%.>-O'75*
M,A<0:D[%SIKB\X,Q(%IR*,1>C8/[0*!<F4T39DR9J`2S',U8QU2E;FE.2%"E
M5:)1%#*3!",$HK>OPT[.]G?>\G/ELCLJ#<<Y6<\2?B?9#K524J$M]5RRRJ0N
MB82>UG9D:6;C[%0QI#/J\F2UN;%,@U+)"I1FA0.SH,G?_HPFL+GDG`WD5.+-
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M>#S!I`(A7YY-R7.&V9;DEX66^^Q-LKQQKQ_EE@6;`UTD&^.D4W.J#L&$)HTC
M=$[(WI'UY99#,$I*W>BTY`=%G"*&:$`-F2C.&+B.,%DE\)(?Q[$?&?3QBL*N
M).M.TZ*_<#;;%.44<N%T"0X>YFE)BD43:C0E!VG#H:SQ2]B"'?E-"MZNA&$&
M`P&`P&`P&`P&`P&`P&`P&`P&!__2G\8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`_].?Q@,!@,!@,!@,!@,!@<R/
M:2UQRZL)HJ@OB<?8I+HUF6?J2CK^S@UMU=U=(>0BKIQD"D=UT\2K;&V4Z\KU
MD]--$C7T"4'QA]+UMN41*VFEZL`H:5YX"NM]=','(3:51;$=>:RFJ?DTA+J&
M"P9#[3+F=9=@IK%JHJZ@"FK?+^#\P@#.SMPXH]B2I"T#4$QF.;!B0"SXK4H'
MVDCCRYE;A`)Y81?&UQO>L!Q\P=XFM*1'3LK%`KAO%:8T)INFD+<3&I[3@H,U
MI2FY0N2L,Y5^YI74A+O$7*Z:?+Z&E;[9QS8*]0RN,Q=$>ZS%\168-L443MS:
MFX]%49(AEFHYDB2KJ9/&KG.V8]L.1V`@,`T[7EK=)#Q.ZY_%\:B!>U'<?9Y0
MBMW!'+6;E;&YNU,<@<(C8U=;$NK)BK)T]%%#+)FVUJP?GXHR3E,B"1'.$O:'
MW3[IT<RQ/3*2F9GA<_C7X=I8B6^$Q2,$R<0AR4J/,I<A$)8E<!"?`-J8+L(2
M]"V,B)<+:_1G2<2B2%&__,`DH.]`#*JX<!@,!@,!@,!@,!@,!@,!@<N.3S-R
ML0\@F=_@$?NZ1Q)\F7%1LK^95G9*)KJ^G8^VVX,?(\F[*6]-&AQL@$U@2D12
M=QU'9(4G(.+#UAAVBVX#A:*484HZB.=*3BU;D=>E_(2"6^JX642Q1I/:O)DJ
MSI9).<=>QJ<.UCSN(S=)<5I$P.M[`E(8XW*DXW=N1.)8%(QM:(K1IBX6K\58
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M3E+T+$B32!8[F1E[DK&<L4.91@A#(<G#0^GQA*3Q[$:(3Q9BP@P&`P&`P&!_
M_]2?Q@,!@4&52B/0B,2.:2YX0QZ*1!A>)1)W]T."F;&./,#>H=GIX<5`O[*=
M"V-J0TXX>_``L&]_DP.<3=[6[BJ]MZ!Y8(IRVD#$[HDKFROS+PIY2N#,]M*\
M@"IN=VE>35>R5K8Y(S0'$'`_LFE#"+7@WD56\9?9^*WQK^CWF3]QWE3^RK%3
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M?N.\J?V58J>,OS,]K7Q&;3$1TN2<CZX8%+HSM"N;6;Q,Y'0*`L"A]=4;(V*9
M3,Y+6J"/QEK/=7`@D2Q:>2F)$;K9@PAZ1:5/&6_-G69!*9KV96M9\E0P^O:^
MCSE*I?)G(*DQ(S,32G&I6JQIT)"M>L-T6#Q2DZ<HY0H-$$LHL9@@AW*O%H*1
M[6+C*I))4IH%S%4)U!19Y!Y'"'E.:2>2:#1A1Q)I=6"`848`6A!$'>];UOIU
MD56\9?K^*WQK^CWF3]QWE3^RK%3QD_%;XU_1[S)^X[RI_95BIXR?BM\:_H]Y
MD_<=Y4_LJQ4\9/Q6^-?T>\R?N.\J?V58J>,GXK?&OZ/>9/W'>5/[*L5/&3\5
MOC7]'O,G[CO*G]E6*GC)^*WQK^CWF3]QWE3^RK%3QD_%;XU_1[S)^X[RI_95
MBIXRU`XY<_;RK:T.2<QY@<?^8T:I.]Y^19G#P\BB+5M%;&JP;@+J^40>9PZ"
M,\J?*9DSD3$4,F`RN29.,S3TH.Z>C8-F*E(FE)NV_P#Q6^-?T>\R?N.\J?V5
M8J>,GXK?&OZ/>9/W'>5/[*L5/&3\5OC7]'O,G[CO*G]E6*GC)^*WQK^CWF3]
MQWE3^RK%3QD_%;XU_1[S)^X[RI_95BIXR?BM\:_H]YD_<=Y4_LJQ4\9/Q6^-
M?T>\R?N.\J?V58J>,GXK?&OZ/>9/W'>5/[*L5/&508O:I\3W650V*/15_5N9
M.Y8R0:/2.W.+]_U;!S)9)E6F^-LCC-IM7S/&F=2^N8P)4PE2DHL1Y@=;$'72
M+2IXRZ/Y*K__U9_&`P&!C.YJFB-\5-8]+3X#F9"+4AL@@<M*9G$UH=#X[)VT
M]I=TZ)R(T(U&<>A4C!H>M;Z-"WX-Z\&"+77LP,C;&6)EC;,F`C9X^TMS(U)"
MP@`6E;6E&2@0IBP%A``("$J<`=:#K6M:UX-:P*M@,#`UM7,Z5Z\I(Y&H,*</
MFJ[L"U75*?)D423)XA7*B,(G1$UKER!Q)<YB]K9606VI#M(FWH).$N<4`?(;
M/)AJTM]H:TKX=))7!*M>7_T9JWE];ZDN4JY?`F5RB7$JSH]7[B4P2M963PRO
MKY.$,@`X%)4HC=-!I>T:T8#.DP(HZ'-1CJ<VH37Q&WMSP8F)&Y(6IR4O+:D6
M"!K9Y"%U5M+$J<$Q9G3H!QB)*,>O#LL']&$*A@,!@,!@,!@<_JDYLR.YVR(;
MAM+)%S]-ZX66VPE%V@E]#E$.:(Y63M(6+<U50M&'5H1YZM=K:5C3I#MK3+?*
MZ.=BO(FA+)H_6)>T&K"P7V:QV#M![PZLZ6@MPE&K?FUM5S);?I4."W:=4025
MRN$M,%7V$SDOBA0!4>#9YH$J94I*`F.%&X%:39/8<.;Y2G41E0)0X2-H6^B$
M@72AA2N\5DKQ%7QL3O;E'(DO4+6AY93TJTLYN2F)EI)I&PB\GXXB%^8#`Q9=
M]-P?D+45B4A92-6O@5HQ5UATJ2-ZO:!P,:'<C9"D2!>$LT:%<3TZ&2<$.Q%&
M!"(/AUK!$TNH-U\>:WY`4F\\?K(2.SA6\@2Q%"\H4+J<WN2]!#)%'Y,VHSG0
ML`U&B5:Z-IRU6P]`SB!&!T(.Q>-HF)I-6<<(,!@,#22W>9)531^RYRKK5<]P
M"OG&U8HG>$<E))D#_.*GIZ5VZ[HPQ,+(K4-\1<-0M<QD.6E"AP]U``.]S-M@
MPK\)H^]GY7.\LMU+7<3K(`X^9;RVIE<EFK],*]DR90S4=![U>WL-</\`5.W8
MLDM@F6T:,A6J1B6J4P3/'*3'@.T*6;F808#`8#`8#`T2B',QWG4T>(%&JI0K
MWG]+MAU'%G75B"]$37>L)A?D<E0)\^E08Y1"Y"0T40)T`S($DA6Z3R)K$=Y$
M@TQ2`FBCHO:(5@ME2J(!CKF%^14H.SE;)I^C@G]/-4TL8XBNI\QO$L+1B?"5
MLG;SRW<"L;*>C-,4!/ZNG.-"*-P*WG)DW120"_<0(D,/ECA#92T0V5N<O2,#
MZ@0-3H)K<W!WA\'7I7838\I56R!(=`VE4DFEF&%FA%A#(N`P,.WW1<!Y(U:_
MT_9J9S4P^1.$3=EGN*Y&LSPE<X3,&&=1MP;'9.$2AO6MTDC20\!A?0/7D^C6
M]=/3A,31F+"'_]:?Q@,!@,!@,!@:UVP\\8I-*DT"N!RA1\D:6EQ),1250H:R
M4\;E;`[R![BT@>]B1-)L6G46KUP6+F!P4B0/S?'E)IZ522VF[()NLF1+N.!A
M,=9&BN4=F16U$MZ5FUOM>KH;(XF\.5S%2&WKAK@U27-D:P#A9R^`GK5@PD>Y
MY*D!76%20L6Q!%VR%;S]JLV*$2UH0.[20)[ET:7-+\2B)=FJ0027OL%E+6L]
MRW!V:5.VZ31M62!0C5JD2HL`3DYQI)@#!$+ZP&`P&`P&`P-0%SKPR=V!NKAW
M>JR;XY3R%57;2W/;R*)-L?9616XUE(("W/KFK9RGJ/:/AA[$_-!:I4B5%I=)
M7$DPL8`#)NLNR)EQ<A2%0TRFIB5$731E7+H8^M^J^U#I5';9N&I5<@D,.E)D
M\;VJ+I=6Y*XN[[<'<]A`4J1@<&TX>FX1Q`BN;;^O8O&(?$6MGA[8:T,1QKK(
M@)5+JH?EISI,7APE\B='-]5.KZH>WA[D3XJ6K%@UJL2I4H,-\J9X_C;(7I@,
M!@,!@,!@4&52B/0B,2.:2YX0QZ*1!A>)1)W]T."F;&./,#>H=GIX<5`O[*="
MV-J0TXX>_``L&]_DP-:5:7AU9CVO-=E-6NLDLT$GCJ^-R%X(97V1N;@VNU)R
MPX<`>EK8XE3E8PM*R)*W+3>6]C;4PVL1^TQ?D-$W4J'VK14HL6"*FVOW-JL6
MR9W=SL!0^'0II>&6>4L(KC?/UKL0?.MFO+LI:(+[EI0,);R,UK;!*#`$E`$;
M@;DX08#`8#`8#`U:?7WBB4JD54R!_A$?5P*6R*P'E.L>ED/-A4]EJMKFDID#
M=.>MM&XW,7;=]HU2SJ+D0NZG+BRQATF<-`-)NM)<7QO)%':[CE$M<]B4S;I!
M(H*7!FVL7JN)JJ8*U04S(&!H(/F:%K**;:B5A8C-N*9''PMI&D05/E]$D"%V
M;:&2UPHKAEF]8-;LWQ^U4;-8YJF1KWIVE#NH>8PPMK>MD;M(79^=7!P0QAF;
MVXH0EBD@E$A()3#VF*)PB69<!@,!@?_7G\8#`U8@?(IVF5M!AA\+;&V!R%PO
M2/0&8D2E6OD#M)>.<]:JXL-+)8D;%V]+'43C)5+EII,(<G#1J5F$<=LH2T@@
MLFC8AXE,<CYA)+V]MK4:H`(T@M<K*3C-+"+Q!#+"8+6Q!T+P=/\`7DTG)6L1
MQE2/TDP#UPC_`+YIO[^*3D>49PP;-N<_"RLY$KB%C\MN-M?RQ`4E/71>;797
M$4D2(E>F+6(3E;(^R-`Y)BEB0X!I0AE!T86+0@](=ZWD<.*8B9O'!:?XDGL\
MO_.KB#]X^H.]^$TG*6&I)RH]E'+9B">/_,[B4MD8'-K=^L!Y45NE3B6L\"LF
MM$(Q)4D[()\0N(6T^)]AUK6A#4@-W_ZA)0@Q9--64OG4W][,5\<6E]9><=$,
MXF&.RZ+,VXCRZA21(T%S1(-)('9J-+FRH]HEHTYA>BG1*:2O3A*+"68$'2$4
MHOSAE2O^9/L]ZUAD?@D;YF\9=,$80Z;&@"[D#51ZDA``XTU.E$:5(DX!%)`&
M^2+_`+&MZ+`'6^G>M[VH7R7C^(%P2_\`,WBS_P"_=7=Z,(I+*L)Y&4#9;0=(
M*XNFKK`84Z\YK/>X3.8Y*V@ES3D)E*AN.<F)Q7HRUY"9828,G8]&!`:`6]:T
M(.]S2<D3,1QE>/Z28!ZX1_WS3?W\4G(\HS@_23`/7"/^^:;^_BDY'E&<'Z28
M!ZX1_P!\TW]_%)R/*,X:\R'V@7!*(OCM&)7S-XLQB2L*]2UOL>D-^5<ROC*Y
MHS!$JVYV:7*4)E[<O2FAV$PDXL!@!:WH6M;R%J3-XA1_Q)/9Y?\`G5Q!^\?4
M'>_!2<I8')Y'^R1*7:<1<Q>)1ZC2FQEFO*\KJ^T7I3:UF.=NS4SQ2;`)W_\`
M<)R[GJ2]=/BIRQZ)+T$H.@ZBR::LI5I-R`]FVF=9<^M?.>EVU5.&>*,3@:V<
MM821M#'X>E2HX^RQQ<"8"<F-D3)"U'0E3*`I_+N2Y4$.E:P]0.:(ODR['.</
ML]XC'F&*1KEUQ09HY&&9KCT?9T5\U>6C:F1E0D-K4VI`;E(M@3(4"8LHO6][
MZ``UBA=6!>T$X(`"(8^9W%@``!V(0A7[5H0A"'72(0A;E&M:#K6NG>]X12<F
MP1%H5TJ))4IIM&E"=046>G4$.Z,TD\DT&C"CB32S1%FE&EBT((@[WH6M].LF
MDY(K&</U_23`/7"/^^:;^_BDY'E&<'Z28!ZX1_WS3?W\4G(\HS@_23`/7"/^
M^:;^_BDY'E&</R/M"NDI)RE3-HTG3IRC#U"@]W1E$D$E`V8:<<:8:$LHHHL.
MQ"$+>M!UKIWBDY%8SAK-^))[/+_SJX@_>/J#O?D+4G*5J3OGA[-*R(1,J[EO
M-_B*NBL]BLAA<F0D<F:I0G+(_*6A8QO*4E:DF9*M&:H;EQ@`FE#"87O?C!WK
M>M;P4G*5GM'+/V4S&]GR-#S*XBZ>E$G>I@)<;RGKLS87U_?%LC<E($VY_I'Y
M(QW<#C`E;+V6#0O%UKQ=:UJ+)IJX4E]R'D5[,U"H83D_,+CD8@C\[F=H-K&=
MR>@RB.[GT[FTKL-WE*IH,F8D:Y>FE4W<E*+1FA$I-G%^(#6TR79,T1?)F7\0
M+@E_YF\6?_?NKN]&$4E4V;G1PKD;NV1^/<M^-C\_/2]*ULS(S7;7#H[NSFO/
M`F0MS8VH9&>L7KUBDP)91)0!F&#%H(=;WO6L#.?Z28!ZX1_WS3?W\FDY(\HS
M@_23`/7"/^^:;^_BDY'E&<'Z28!ZX1_WS3?W\4G(\HSA9LZY'4!5S`9*[,NJ
MK:ZBQ*I,A-DLZG4;B+`4M6BV!&C,>)`XM[<!4K&'>BB]F:&9O70'6\BDQQA,
M3$VB;L)_B2>SR_\`.KB#]X^H.]^$TG*6$'+DY[)IXECY-7/F5Q*5OTC?'*1N
MYPN5==DIU+J[0ZL(&L/"F2ST@L@`XW3S`5H!?B@"-*,S6O'..V.+)IJRE27:
M_/98RAQ=Q)N>-!HC7^`'5D)MCG,.!)P(8>>XG/;LW1X()LI7L8WQ9ORCF:C,
M*&X@))"IV:!,GT5)?)L)'.<O`:,,#-'&[F?Q@$WL38B:4&U%^U2([2-O3EI4
MH!^0D2<C7DR"@AUH```UK6M:UK6NC%$7R5G\0+@E_P"9O%G_`-^ZN[T8125R
M1/FCQ`GK\CBT%Y1\?9I)W$*D;?'(G<$!D;\O"B2G+E@D;0SORQP5!2(DQAQN
MP%BT646(8N@(=[TI)PXLQ?I)@'KA'_?--_?R:3DCRC.#]),`]<(_[YIO[^*3
MD>49P__0G\8#`Q9'Z5K6+V$_6FQQ]0CFLC3O"9>O,D4G6M28N1J(XME`F"*K
MWI5$XHHEKA$&M2\&M:%&:[*D!)ZL1QH-#P593P&!YO/\Q9_%9N_Y&4I]4\4R
ML\6VC:X=9"Q@2`_9E?9Q6_K)D_P5&\[/1L[N/W[^SH=FS$P.ZOL@/F2O3]Y=
MU^HF@\Y/;OU8Y.C1LTXYNLN9K&`P/*P]JG_$CYO_`+R]L?\`5;AE9XM].V&@
M>0DP)<%>?-_!OD=&?@5%GH:=NGH\[5NGJO'+(6=8?S?SGY'2;X%6Y75MU=$Z
M=T=4SBN?F]@?R,B_P(ASB=4\97GA!@,"S+&^;V>?(R4?`B["8XP\>?*-S`8$
MOB._Z?8O\F;/\$1GI/.GC*LX0OBJ/GMX\?O+\;/KVKW,_;LU8YK^O?&.28%G
M(W,!@<!_YE/^&#*OURU%\+N&1/!?1N>=9E6I@;B<`_M:U/\`[[^K299KZ?V:
M<<F?N_7JQS23<[7"8&S_``<^VQQ@^5]E_P#'*[,Q]VV.K3U<9Z)3><S8P/_1
MG\8#`8#`8'F\_P`Q9_%9N_Y&4I]4\4RL\6VC:X=9"Q@2`_9E?9Q6_K)D_P`%
M1O.ST;.[C]^_LZ'9LQ,#NK[(#YDKT_>7=?J)H/.3V[]6.3HT;-..;K+F:Q@,
M#RL/:I_Q(^;_`.\O;'_5;AE9XM].V&@>0DP)<%>?-_!OD=&?@5%GH:=NGH\[
M5NGJO'+(6=8?S?SGY'2;X%6Y75MU=$Z=T=4SBN?F]@?R,B_P(ASB=4\97GA!
M@,"S+&^;V>?(R4?`B["8XP\>?*-S`8$OB._Z?8O\F;/\$1GI/.GC*LX0OBJ/
MGMX\?O+\;/KVKW,_;LU8YK^O?&.28%G(W,!@<!_YE/\`A@RK]<M1?"[AD3P7
MT;GG695J8&XG`/[6M3_[[^K299KZ?V:<<F?N_7JQS23<[7"8&S_!S[;'&#Y7
MV7_QRNS,?=MCJT]7&>B4WG,V,#__TI_&!:DTFL=KZ/JI1*E*Y(RHC4I*@]N8
MWV1*PF+5!:5/HMJC;:[.QX1'FAT(19`@@U_:%O0=;WH,?U+/Y3,95R$CDH31
M\@-3W63`(V<PDN)(ET6<J9IVU&M2^;<%JO1T@*-LLY.>-.%.FV$@&@%].A&&
M#)DQXD25E,)*4(']9L\`C`B9X^\/)8-!%XNPG&MJ-262/>_Z`BWK>]>')HBM
M%(]/&WS)-NPTJ^*L4*Q\_AYT'\PRXE.OM3;K6DIUZ8LR'4P'1+FWK&M8'9=5
M14&]F(UY)"DL(MAZ0[V'6A:\.O!O*3Q;:-KB3D+F!(#]F5]G%;^LF3_!4;SL
M]&SNX_?O[.AV;,3`[8^R5DZ-GIR\TA[;)%8]\DG([RK5&7QW2^*.BZ%#H&U3
M<A4)]&Z\3P@\;QM:WK>]>'6<GLC^>K')OIFFG3CFZI^GC;YDFW8:5?%64HM6
M/G\'IXV^9)MV&E7Q5BA6/G\'IXV^9)MV&E7Q5BA6/G\/+=]J.I`M]HSS75EE
MJ20*.25JG!*6)CT:HL(Y2O%H"A*I`6H3FZZ?"`8="#OP;UE)XM].V&AF0L8$
MN"O/F_@WR.C/P*BST-.W3T>=JW3U7CED+.L/YOYS\CI-\"K<KJVZNB=.Z.J8
M)7<Z;@5_!0[99KO88=&0[V&$2D8=[TR(M=(1!:MA$'?1X-Z\&\XZ.B9BL\5X
M^GC;YDFW8:5?%6*%8^?P>GC;YDFW8:5?%6*%8^?P>GC;YDFW8:5?%6*%8^?P
MLZQ)TW#K^=!TRS76Q0Z3!UL4(E(`ZWMD6ZZ1"$U:"$.NGP[WX-8H1,5CB\AO
M,W28#`E\1W_3[%_DS9_@B,])YT\95G"%WUFI`BN.@%9A:DX"?DEQO.$4C3'K
M%1@07I7PM@3I4P#%"@W?1X``#L0M^#6LS]NR<<U_7NCO_P`2U?3QM\R3;L-*
MOBK.6C:L?/X/3QM\R3;L-*OBK%"L?/X/3QM\R3;L-*OBK%"L?/X<&/YC^4HW
M;V9DH1DMDE2CW<-2F>5=(P^M236@.R_>P[5N"!.GT8+I_LAV+I%^3(F++Z)_
MD\]'*-C`W$X!_:UJ?_??U:3+-?3^S3CDS]WZ]6.:2;G:X3`V0X7.)35S-XR+
M3DZ]267,;(#LEL;UCHL%LSCK=8-;+1H"3U)@0[%TBWH.]!UX=^#68^[;'5IZ
M^,]$G3T\;?,DV[#2KXJSGHUK'S^#T\;?,DV[#2KXJQ0K'S^'_].:]*.9O%6%
M2ITADKOJMV)]8'`UIDO7Y`G+98D[D#++/:)E*0Z%%X>[$&'`"-*YK$AX!##K
M8-;$'I)I.39K"%#:8TPL2^3NC0UID#A-'Q/)92K("+1KV_)8U'H<G=%NQ"%H
M2DJ,1-N1:V'0=>12%ZZ.G6]["N8#`\WG^8L_BLW?\C*4^J>*96>+;1M<.LA8
MP)`?LROLXK?UDR?X*C>=GHV=W'[]_9T.S9B8'=7V0'S)7I^\NZ_430><GMWZ
ML<G1HV:<<W67,UC`8'E8>U3_`(D?-_\`>7MC_JMPRL\6^G;#0/(28$N"O/F_
M@WR.C/P*BST-.W3T>=JW3U7CED+.L/YOYS\CI-\"K<KJVZNB=.Z.J9Q7/S>P
M/Y&1?X$0YQ.J>,KSP@P&!9EC?-[//D9*/@1=A,<8>//E&Y@,"7Q'?]/L7^3-
MG^"(STGG3QE6<(7Q5'SV\>/WE^-GU[5[F?MV:L<U_7OC'),"SD;F`P.`_P#,
MI_PP95^N6HOA=PR)X+Z-SSK,JU,#<3@']K6I_P#??U:3+-?3^S3CDS]WZ]6.
M:2;G:X3`V?X.?;8XP?*^R_\`CE=F8^[;'5IZN,]$IO.9L8'_U.W?-67/%R<[
MVFF*GOKD/`%#Z.HX"Y,\0>/:44ZPU\[QNVY019+[J(5E1[OQTM9@N9'(D#$"
M9KY`V,+$:E$L6;7IBQ:-A>.'#_B077+;,&:O8(T6$^(I-/VJ&QAMG$D;B-I6
M^03!"R(4LF?$"79"7:9$[/11YY1?DB_$`9K7BAZ.C4J+RP&`P/-Y_F+/XK-W
M_(RE/JGBF5GBVT;7#K(6,"0'[,K[.*W]9,G^"HWG9Z-G=Q^_?V=#LV8F!W5]
MD!\R5Z?O+NOU$T'G)[=^K')T:-FG'-UES-8P&!Y6'M4_XD?-_P#>7MC_`*K<
M,K/%OIVPT#R$F!+@KSYOX-\CHS\"HL]#3MT]'G:MT]5XY9"SK#^;^<_(Z3?`
MJW*ZMNKHG3NCJF<5S\WL#^1D7^!$.<3JGC*\\(,!@698WS>SSY&2CX$783'&
M'CSY1N8#`E\1W_3[%_DS9_@B,])YT\95G"%\51\]O'C]Y?C9]>U>YG[=FK'-
M?U[XQR3`LY&Y@,#@/_,I_P`,&5?KEJ+X7<,B>"^C<\ZS*M3`W$X!_:UJ?_??
MU:3+-?3^S3CDS]WZ]6.:2;G:X3`V?X.?;8XP?*^R_P#CE=F8^[;'5IZN,]$I
MO.9L8'__U>_EZC>8#[56N&J/71:!3K(!48]2--*;TG!;.I@MI7A*BAU!$*XK
M#AY:C,BB+<I@AP]IY;,HN2X`<"BPKR""U*PF.:T;7=*:3)H@4?529\1RI<W(
MS4I)R:%P2;V1(!C6*"TI6TL2KN/2F5+B@&&ZV:,A$8`@O6S#-@+"(6I58>J^
M>SJ1W%=L2<7Z(32!0H<;*:)#%HNXQL44F+JNE)SU4SNX*9?+$<PD$5AJ>/KG
M)44!L$F5NN^DC0%):1N)Y0S8\25J8C"2G'W2\<\`C"^HL3Z[`\4(O%WY0QI;
M5Q9(NG_^(]A%O7AUKHR:*UHI'Z0HS_7(.Q<S^(,4*Q\_AYT'\PRYI'?VIMUK
MD76>KFPZF`@ZV@7-I_27545+'XR1R3)%9>O&#X-B!K0M>'73KPY2>+;1M<2<
MA<P)`?LROLXK?UDR?X*C>=GHV=W'[]_9T.S9B8';'V2LL9F6G+S1K]NOE]\D
MG([74H[(70GR8Z+H4(>E2UM:Q-H?2#?2'Q_&UX.G6NG6<GLC^>K')OIFFG3C
MFZI_I"C/]<@[%S/X@RE%JQ\_@_2%&?ZY!V+F?Q!BA6/G\'Z0HS_7(.Q<S^(,
M4*Q\_AY;OM1U1*[VC/-=8G\KY!3R2M4XKRZ=0D.\F9*5X@^43*RB%)`^C?A"
M8`(M?EUK*3Q;Z=L-#,A8P)<%>?-_!OD=&?@5%GH:=NGH\[5NGJO'+(6=8?S?
MSGY'2;X%6Y75MU=$Z=T=4P2N[`C0*_@H!;?_`!@PZ,AWT0V8BUTA9$6M]`@L
M.PBUTZ_IUO>MYQTET3,5GBO'](49_KD'8N9_$&*%8^?P?I"C/]<@[%S/X@Q0
MK'S^#](49_KD'8N9_$&*%8^?PLZQ+`C0Z_G0`[?_`!A0Z3!UTPV8AUTB9%NM
M=(A,.@AUT[_IWO6M8I)$Q6.+R&\S=)@,"7Q'?]/L7^3-G^"(STGG3QE6<(7?
M6:HE#<=`+%'E?()N27&\XWR"=0K.\F7>E?"%Y-,D*/4GCZ->`)8!"W^36\S]
MNR<<U_7NCO\`\2U?TA1G^N0=BYG\09RT;5CY_!^D*,_UR#L7,_B#%"L?/X/T
MA1G^N0=BYG\08H5CY_#@Q_,?RUE>?9F2A$AV[>7%<-2F:ZY')&V$^*6[+]BZ
M53FU(TNA>'P!V/QM_DUO(F++Z)_D\]'*-C`W$X!_:UJ?_??U:3+-?3^S3CDS
M]WZ]6.:2;G:X3`V0X7.:1HYF\9%RWK/5RIC9`1]40+G(_I,XZW66#Q4C:F5J
MS->,+P["#>@Z\.^C7AS'W;8ZM/7QGHDZ?I"C/]<@[%S/X@SGHUK'S^#](49_
MKD'8N9_$&*%8^?P__]:1IR::Y`_>U(J@J+0F6JPQB/<4GR:S"(LO-R5I!,KG
M=%K@;FN<#IODK4''B#LL>)CJ]42?*8O,$1Y;@J-<4YR,HQ&='-:-LNXF2JQE
M":4IJM7N1R:N:DK*`228*UZ^72"$P**Q5[E*YU=5+ZZ+9&ZL34@7O:MR>UIR
MP\Q28:,Y6:,X>]F"$+89-P&!YO/\Q9_%9N_Y&4I]4\4RL\6VC:X=9"Q@2`_9
ME?9Q6_K)D_P5&\[/1L[N/W[^SH=FS$P.ZOL@/F2O3]Y=U^HF@\Y/;OU8Y.C1
MLTXYNLN9K&`P/*P]JG_$CYO_`+R]L?\`5;AE9XM].V&@>0DP)<%>?-_!OD=&
M?@5%GH:=NGH\[5NGJO'+(6=8?S?SGY'2;X%6Y75MU=$Z=T=4SBN?F]@?R,B_
MP(ASB=4\97GA!@,"S+&^;V>?(R4?`B["8XP\>?*-S`8$OB._Z?8O\F;/\$1G
MI/.GC*LX0OBJ/GMX\?O+\;/KVKW,_;LU8YK^O?&.28%G(W,!@<!_YE/^&#*O
MURU%\+N&1/!?1N>=9E6I@;B<`_M:U/\`[[^K299KZ?V:<<F?N_7JQS23<[7"
M8&S_``<^VQQ@^5]E_P#'*[,Q]VV.K3U<9Z)3><S8P/_7D475'N'UM<Q&Q<]\
MPN-KI?L8M>+P.(HW/C_4EF\EZ;GZ&9"6P:$PF>>(>UQ%1%)B8+36;(8N[&I5
M(M"4GG&_^H*%HK$<+.Z&2J8#`8'F\_S%G\5F[_D92GU3Q3*SQ;:-KAUD+&!(
M#]F5]G%;^LF3_!4;SL]&SNX_?O[.AV;,3`[J^R`^9*]/WEW7ZB:#SD]N_5CD
MZ-&S3CFZRYFL8#`\K#VJ?\2/F_\`O+VQ_P!5N&5GBWT[8:!Y"3`EP5Y\W\&^
M1T9^!46>AIVZ>CSM6Z>J\<LA9UA_-_.?D=)O@5;E=6W5T3IW1U3.*Y^;V!_(
MR+_`B'.)U3QE>>$&`P+,L;YO9Y\C)1\"+L)CC#QY\HW,!@2^([_I]B_R9L_P
M1&>D\Z>,JSA"^*H^>WCQ^\OQL^O:O<S]NS5CFOZ]\8Y)@6<C<P&!P'_F4_X8
M,J_7+47PNX9$\%]&YYUF5:F!N)P#^UK4_P#OOZM)EFOI_9IQR9^[]>K'-)-S
MM<)@;/\`!S[;'&#Y7V7_`,<KLS'W;8ZM/5QGHE-YS-C`_]#LHZHUQ?M`W&[M
M7U634F;^6L/B2BL:Q87Z@)<\1MUY517B^2AM1ZK&#ADO(:2:GST24:1)I&8Q
M+6X0CCT9:()FQPORHD<S26IX1'U4B4L<KD1*0U*4)JA<<<I7(#]JU!:8(TK(
MTE'KE)1`C/'-$$.]%EZV+?@UO)48&J:Q+%=+^ONM9L=X\=CC'7,TK7:IIC"!
M>J9)6]68Q/"QO/B4JE12B%!-AJ(EO&][;Y":YE.@S4@$74N@GE#85X?1M)A)
M86)_=O+`$/9C.C3JBR?%%XOB'".6)MA&+^G6M:WX,F(KS5F:<E']-#O4R;^]
M*+XUR:?,(\OZRA+>VC]F=SUY5^T$M2ZJ,XQ3N9UQ(HS5S>T/X72#->E2N/5[
M'F1V*TC=9:C6E]5<D1A?2(O6A>+TZZ=>'*3%VVC5'C=QTL'V1'M'JJC6YA8/
M%B9QF-:D$,BNW98_P`\C4@L*9,%?0UL\FAERI1Y9]F4H0(2A>)Y,!BD(C!`+
MT(88I*WEIGFO;\$/VJ?_`(<SWM)6O??%)//3FZ!\-Z0M7CC`)I3%VPU?`+.A
MMDK?2:(NBEL6+FGTAA4%E;-Y=0SKG)N,Z_'WQ(I#Y,X?0`[6A=`M"#KK]&SN
MY?=-=<3&3;C-F)@=L?9*R(QKIR\TP8[)'36^23D;UEI0IE*76QT70NO);,-7
M)Q>5!XO3O7B]&M;UX<Y/9%=>J^*-],TTZ;3B75+TT.]3)O[THOC7*T^83Y?U
MD]-#O4R;^]*+XUQ3Y@\OZR>FAWJ9-_>E%\:XI\P>7]9>6][4=1M7[1GFNIVG
M4I-G\DK5-VF6`"4J(V.4K]^24%@&8$!H/Z-ZT+>M;_+F<\9=&G;#0S(6,"7!
M7GS?P;Y'1GX%19Z&G;IZ/.U;IZKQRR%G6'\W\Y^1TF^!5N5U;=71.G='5,#K
MN9&AK^"A]#9J+Q8=&0^,%J1;"+H946O&#O;IKI#O\F<=/F'1,WG^,KQ]-#O4
MR;^]*+XUR:?,(\OZR>FAWJ9-_>E%\:XI\P>7]9/30[U,F_O2B^-<4^8/+^LK
M.L29&BK^=!]#9J'QH=)@^,)J1:"'I95NO&%O3IOH#K\N13YA,3>/XR\AS,W2
M8#`E\1W_`$^Q?Y,V?X(C/2>=/&59PA=]9J-I+CH!3I.I5[(Y)<;S=)D8`FJC
M]@O2OM^23EC&6$9H_P"C6MBUK>_RYG[=DXYKZ-T=_P#B6IZ:'>IDW]Z47QKG
M-3YAKY?UD]-#O4R;^]*+XUQ3Y@\OZR>FAWJ9-_>E%\:XI\P>7]9<&?YC^1F.
M?LS)0E%'),V:W<-2CZTZ($R=)KQ'9?OQ-F%+E`]#'T_V=>+X<KJBD<87]<UU
M<)>>CE&Y@;B<`_M:U/\`[[^K299KZ?V:<<F?N_7JQS23<[7"8&R'"]>)MYF\
M9%84*]RV"8V0'JC826H6&>/QUNL'C%E&G$`V$'3TBZ1:Z-:S'W;8Z_\`K3U\
M9Z?^).?IH=ZF3?WI1?&N84^8:>7]9/30[U,F_O2B^-<4^8/+^LO_T9'<@X4W
M@\\N!7.1QLX8M357_(F)6$VV,FHWCL\6G>[--+_BKP]RI_F3Y78[$KR2<=J0
M`Y+4CF@=4TA?IR2F."<<C#L(X6K%.,NWN2JM6-02$0Q0_*X?#8K%%4J=!ODH
M4QJ/-#$HDCV8'83'A^.:T:4QX=#`[WH2A1LP[>OZ18%U8#`8&@?M,_LH&?O+
M\#_^=G&_(E;3Q;^9*J*5S/\`MS<P_P!9-6_\4..F=7IV=V/MXQT:]9JS,#NK
M[(#YDKT_>7=?J)H/.3V[]6.3HT;-..;K+F:Q@,#RL/:I_P`2/F_^\O;'_5;A
ME9XM].V&@>0DP)<%>?-_!OD=&?@5%GH:=NGH\[5NGJO'+(6=8?S?SGY'2;X%
M6Y75MU=$Z=T=4SBN?F]@?R,B_P`"(<XG5/&5YX08#`ISPUIGQH=&5;LW2-W;
MES6KV0+0#M)G!,:D/V2,01A`;HH[?B[V'>M;_)O`CS?_`*PGLW//G)?_`-T(
MI^S7(I"_GJ:M)OY>?@4;S8>N/PG>_P#T$;^+48N,@[5AQO3_`+EKO;,MA*LL
MQP]`-IA,^F9D)V`G2?0]';$+9F];T'2AYS1F.W/Y:SV=\(JFSIHS/7(T3Q$*
M]FDH:@K;+BYZ,3DP1MR=4(59!=<DC.3;5)`>4"$8-B!TZT+7].*$:Y:,1W_3
M[%_DS9_@B,]!QSQE6<(7Q5'SV\>/WE^-GU[5[F?MV:L<U_7OC'),"SD;F`P.
M`_\`,I_PP95^N6HOA=PR)X+Z-SSK,JU,#<3@']K6I_\`??U:3+-?3^S3CDS]
MWZ]6.:2;G:X3`V?X.?;8XP?*^R_^.5V9C[ML=6GJXST2F\YFQ@?_TI9M[PR/
M+^5C+[L<SVR#2&3(N-$EC_&^2/M3M>G)AJSE!!7M0<WH10Y)91[3/)($MH:C
M=O`C5LG<]H]&'I-%MY4+<N#I7DJF`P&`P-4K=X+<-[]F1UAW7QFI>TIRI;T#
M4?+)Q`F*0/QS:U@$4W(3'%P2'*!)D18]A+!L70#6_!A,3,<)96IRBZ;X\Q(R
M!4;64+J>%G/"R0&Q>",*".,ACVXD(TRYU&WMQ1*?:Y6G;R`&&='C""4'6_Z-
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MTF^!5N5U;=71.G='5,XKGYO8'\C(O\"(<XG5/&5YX08#`8'SJU2="E4K59H2
M$J-.<J4G"T+824Z<L1QQHM!T(6PEE@WO?1K>_!@<1VGG_P`/5?M%7>Q$]X1X
MV$NW#N$UNW233/+=-JN<DWG-GPV-%FBCVA^Z);0Z)U&];#H&BS0[\;(6I-'5
MOD9]GN]OU-6?_P!$/F2B.,(B,=_T^Q?Y,V?X(C.]RSQE6<(7Q5'SV\>/WE^-
MGU[5[F?MV:L<U_7OC'),"SD;F`P.`_\`,I_PP95^N6HOA=PR)X+Z-SSK,JU,
M#<3@']K6I_\`??U:3+-?3^S3CDS]WZ]6.:2;G:X3`V?X.?;8XP?*^R_^.5V9
MC[ML=6GJXST2F\YFQ@?_T^YOM'V:U2^?]2RRNJV%*GB/,O'=XA,1=HGR9<HA
M=\L9[DDS^<O=W:I276M2"^-"J.-4M6B=!M[CHK240DCJ$AN3CA>.'%W.:K(E
M*^IH%8NJ?GKC))?&X6]NU7-"F%-TPB*J4-"%Q=6YX'8DMKYD"9$3U0B%P.MA
M5[&4+11!@_[&I4:[<6[^FUPW)R28I6EG+"SQ8==.D)@\SJ*8UR?"V-\'.6C:
M8;W+87&%$N<Y(GBB5W5B`I<$R-2M,3(SC4I`%!Q,Q2(;CO#D](3"0-<<.>RQ
M@$(TTMT;D&B!Z%T!+V!:8`9FQ!\/2'P:R8ISE69GE"C^D$O]057:-A_/Y-(^
MR*S]3T@E_J"J[1L/Y_%(^Q6?J>D$O]057:-A_/XI'V*S]3T@E_J"J[1L/Y_%
M(^Q6?JBY\OE"Q5S:Y>'KV\;6K,LFL?*H1J4ZL1'B\5>/``=*A*(1!GE2PZ'_
M`&=^#QNC?AUO.CU;9ZL_9QCHP1FK,P.V/LE75_1TY>9+;%CWE/ODDY#VK+=V
MM"'1@J+H70B?(K#0&[V#6M;\;HZ-]/\`\,Y/9$>>JLXHWTS/CII&*NJ7I!+_
M`%!5=HV'\_E:1]DUGZGI!+_4%5VC8?S^*1]BL_4]()?Z@JNT;#^?Q2/L5GZG
MI!+_`%!5=HV'\_BD?8K/U:&+7N3_`(GL9.]"E.E.N!DY*TB]WF7QA$;Y!UX,
M2KR_EO(Z"$S6@>)T^-OIZ?Z,BD5XK5GQV\VX5B/\MW7\ZT*!J@!W#I-H0_2)
MB%XH=LJW6Q>+H_IWXNO#T:Q2/LB)FL?Q0_*\^;^#?(Z,_`J+.S3MT]'/JW3U
M7CED+.L/YOYS\CI-\"K<KJVZNB=.Z.J8'7;_`"W5?P708&J&'4.C.@C](F(/
MC!TRHM:%XNS^G7C:\/1O..D?9T3,UG^*\?2"7^H*KM&P_G\FD?9%9^IZ02_U
M!5=HV'\_BD?8K/U/2"7^H*KM&P_G\4C[%9^IZ02_U!5=HV'\_BD?8K/U/2"7
M^H*KM&P_G\4C[%9^IZ02_P!057:-A_/XI'V*S]6'N0[]+!T!>0#((J*+%3UF
M!&;N0L0]%`%"GO0C-@`?L0]`#OIZ->'?1D4C[)B9K'\442._Z?8O\F;/\$1G
M<YYXRK.$+OK,T\BXZ`.2I1+5!?)+C>,E($XH@2DP-Z5]L).CCMZ**V/?@\86
M]:U^7,_;LG'-?1NCO_Q+4]()?Z@JNT;#^?SFI'V:UGZGI!+_`%!5=HV'\_BD
M?8K/U/2"7^H*KM&P_G\4C[%9^K@S_,?NT@6>S,E!+C%#VA-NX:E%M88\-2T(
M1A=E_B%^02&C.WLS?Y>CHU^7*ZHBEI7]<SY7AYZ.4;F!N)P#^UK4_P#OOZM)
MEFOI_9IQR9^[]>K'-)-SM<)@;(<+U*U)S-XR'M[:-V5!F-D:`B`J3(Q&!%QU
MNL(Q:/5""0'R8=[%T;WX>CHUX<Q]VV.O_K3U\9Z?^).?I!+_`%!5=HV'\_F%
M(^S2L_4]()?Z@JNT;#^?Q2/L5GZO_]20!S,D$89?:G<=_=9%'YBM<`<7FY,G
ME].V/,D57'`Y!K6-&]0FPT?)BI(/#9?*GVQFP*@/HQ+#"=I6Y2<C4`T).='-
M:-LN_&2J_()!(#33P$E`./"6$XX)8`FG!)\;1033-:T,P)6AB\76][\7IWT?
MTX'ZX#`8#`8$4KF?]N;F'^LFK?\`BAQTSJ].SNQ]O&.C7K-69@=U?9`?,E>G
M[R[K]1-!YR>W?JQR=&C9IQS=9<S6,!@,#E*;QL]I`=?:#D2+D-PBU-F^H7:E
MB6L/%B]]1846>9FRSE4O-1;Y>;=A/Y;LQ$EEFZ7!3:3"&'9`A["8&+K5T\+N
MC\[TJ#64R"N,3FK@P21:6&I"3$Z4Q5J/K-*#$Q!QZDXA.,[IV``S#!!#O6MB
M%O73N41QA#/KSYOX-\CHS\"HL[=.W3T<NK=/5>.60LZP_F_G/R.DWP*MRNK;
MJZ)T[HZIG%<_-[`_D9%_@1#G$ZIXRO/"#`8#`8#`Q)?Z)8Y41=;<W)%*]P7U
M)9")`@1$&JEBU8JASR0E2)$I`##U*E2>8$!98`B&,8M:UK>]X(XPB(,;3+T[
M*SISZQN<LXAK;R3BQ4E;GC%FE)"0&`%__B__`)@##O6\Z_\`31]F$^O76?XO
MSTXK!/YD4##[.%*"F@F0FQO52V?M_+8%"T]M(?#&?41]T0-![BF,(`IV7HD1
MQ8@:%L0=ZT_TT?8_SU_5EVF&"9.5Z<?2$];6T5Y#D3Q_=%2APJ*S6EO1-K+<
MD(>'9Q7N;K%$;<@0MS6A./...-+++++%O>_!E/9KTSHF(FZVC1JC5$S%DO'.
M=J8#`X#_`,RG_#!E7ZY:B^%W#(G@OHW/.LRK4P-Q.`?VM:G_`-]_5I,LU]/[
M-..3/W?KU8YI)N=KA,#9_@Y]MCC!\K[+_P".5V9C[ML=6GJXST2F\YFQ@?_5
MD.6RWVW<_,:)7C.Z]:T_'2FN1]+5%`I`Q\A*73,[;9T)Y$RVN-3.5QZ1\?9)
M-W>3R1WL-O9D3`B?FY4VJSUK<E6EJ'$X_<+1P^7=S)5,!@,!@,!@<BK^]E](
M[DOFVKJ8N0;+#$]K/<5?U46=J673`YF61FKX#66RR)`CN.&@6)ER6!%*]:$@
M+$48H&#QAZ#H6[Z?9JTQ2**ZM,:J3-6D7)/V=ED4)%*\DB3D/")*.<<AN.5'
MFI%-`OS8!N2WM=,+JA7(BSBN0*W:E1&T\L$M+3;"`*D9&BA&%Z%L8;?[:\H(
M]6F:\<=FPWX/D^_\J8A]V]Z__(S'^VO*$?YZ?G'9T2X:<6U/$ZNY="E\^(L9
MRF-CK[#<'Q)$3(2A3'*X?"8:2UHV,Z53(\)1"&$DFB-&N'LPT\?0$`=!UF>J
M9U3,SQ6B(B(B.#;K(28#`8#`LRQOF]GGR,E'P(NPF.,(8]>?-_!OD=&?@5%G
M;IVZ>CEU;IZKQRR%G6'\W\Y^1TF^!5N5U;=71.G='5,XKGYO8'\C(O\``B'.
M)U3QE>>$&`P&`P&`P&!H(A_BD2?]P2"?\B+%PGEW;]X08#`8'`?^93_A@RK]
M<M1?"[AD3P7T;GG695J8&XG`/[6M3_[[^K299KZ?V:<<F?N_7JQS23<[7"8&
MS_!S[;'&#Y7V7_QRNS,?=MCJT]7&>B4WG,V,#__6DUP8?$*V>;T\@R%]Y*1Q
MVBMGR"W"JYDD[+8N*%M7G2TS@D9FTVA$/*D2V0KY96MIO[`>L0*B6AF<)'L#
MHE1.!X#UFH6O1UBFCU(H_'U3I%8:NGST2:E`GC+<\L3"K6%G*"RE!Q;G)%K<
MTDA1D#$:+1AH1#T'Q0](MZUDJM3.,LG?W.Y>1T?=IF;9J)LDA[ZTS-BLEWE\
M,CR"26%9@6FH%T15LK2Q5Y8E:QQH0)UZ5N/7F*$AJ<U;Y`T19BPF>$-OWAU=
M6\PD#=&')^`8`0C#D*YB2`3BT+HT68%V=&\P8A:\/2`(@]'].^G)[J]E(])9
M-]'4@]^89WDQ3Y*S]9/263?1U(/?F&=Y,4^2L_63TEDWT=2#WYAG>3%/DK/U
MD])9-]'4@]^89WDQ3Y*S]9/263?1U(/?F&=Y,4^2L_67*/VB?(IX4%5S5#1Q
MBYA3"1U_RGX;W(_.M<<9+=LZ$#A=8WW6EK2XUIGU?Q:1P]Y<VZ*,2CQDB98:
M>%6#:<0=':V#43U6T\[<OAT0J:^5=QP\F:Q^F+LBS<>O7-P6FV8(OIR8`-;Q
MA+-/.A5G;BTJ(0';'TD*!I-$*`ZWLL0M:WO)[JS6.7_&3/263?1U(/?F&=Y,
M4^2L_63TEDWT=2#WYAG>3%/DK/UD])9-]'4@]^89WDQ3Y*S]9/263?1U(/?F
M&=Y,4^2L_63TEDWT=2#WYAG>3%/DK/UD])9-]'4@]^89WDQ3Y*S]96=8DDDH
MJ_G015X_@#N'2;6Q[>(=O0-;9%NMBWH,C$+>@Z\/@UO>*1F1,UC^,H?=>?-_
M!OD=&?@5%G9IVZ>CGU;IZKQRR%G6'\W\Y^1TF^!5N5U;=71.G='5,$KN224-
M?P4(:\?QAU#HSK0]/$.UH>M,B+6A:T*1A%K0M>'PZUO..D9NB9FL_P`97CZ2
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M0>_,,[R8I\E9^LGI+)OHZD'OS#.\F*?)6?K+2+V@G$D'M`^.CEQUF*&P*^97
M*61:6#D<:45VZ.A2B+*CU2=(!*Z28*39*H1^]#%O?C!UKP9%(S3&J8FOBX-_
M_JS5#]-G(7WCI;O5CQC-;_2?JUYXV_RYU87E%+"D3A;=X-AL+Y"\C*7(*:&>
MIC2%""D;HFE7('%5MRD9!H75R1Q8!ZL)>A)PJ!CT2(1>@BW'C&:9]DQ_^5RV
MI[$J!>SY?*8OB-6/:\K<5=H.,!$US5MKI(SA32&G;:<C5038J]N#GUTH;`'0
M-;+\EL(A>-O6_%Z=/5%/9IOBBGLUSJT:HG3BJO9V.4P-D.%RI6BYF\9%")L4
MO"@$QLC0$"0]"F/-T+CK=81B":Y*D:0.B@[\;?C&:WO6O!T[\&8^[;'5IZ^,
M]$G3TEDWT=2#WYAG>3.>GRUK/UD])9-]'4@]^89WDQ3Y*S]9?__7[Q/E&,7_
M`'YFV&?09JSD:/EW$W1BAQ'`.HUE#*^/A4WCJYYY'K^8)_'17)D=P1^)F*93
MIV%9*=Y+FJ8AD+;-EFECW"];<;)"V2H8#`8#`8#`8#`8#`8#`8#`8'Q.3>C=
MVY>U.!/6$#FB5-ZXCRAI7ET:T@:923Y4@99Q?E"3!!\8`@BUT].MZWX<#G8D
M]DMP00I4R)'6%BIDB-.2E2IB>4/*XLE.F3EA)((*`&[M!`644#00ZUX-:UEO
M/5]I12,H_#4M5[/'BF7SV8J6!$[)#6:WB%++14QK_N1Y+[\I.FRYH7$T+Y[L
M[M[;^#R#`[*$_5@JM(Q>4\<16S`A'IYZ_M*?'33;#;17[);@@N2J42RL+%4I
M%B<Y*J3'<H>5QA*A,H+$2>0:`5W;",LTH>PBUOP;UO'GJ^THI&4?AT3;6]&T
M-R!J;R>KH&Q$E;T)'E#3?((T1`$R8GRIXS#C/)DEA#XPQ"%OHZ=[WOPY5+[<
M!@,!@,!@,!@,!@,!@,!@,#0/V=7S6W]^_P">T)_YBW'D0MJY=&%O:_\`S)47
M^\NU?43?F:^K?IQR9Z]FK'-PJSK<Y@;/\'/ML<8/E?9?_'*[,Q]VV.K3U<9Z
M)3><S8P/_]"1+>KKP_K+VC];UR9Q[XS_`*8IA+J1M-5:%J\JW&J['7S6T+7D
M3.UKJEJ!%#Y[JS9;'W6'Z6!;U:V.@6K5B-,#H*/TIU"T1,Q6KNGDJF`P&`P&
M`P&`P&`P&`P&`P&`P&!P_5\]N,!GM`6"W02Z="KE)P[EU<*)1^@7D#U4J;.-
MU0F3HF':7=7:<MJ#V)K/4:,T3LC02]ZV/0MZ#N%J31W`R53`8#`8#`8#`8#`
M8#`8#`8#`L"RH=(IU%S6"+VO/Z8=3%J-4";UJW5:ZR@@A,,0CFXI)<-:VO"]
MHG`(M!.$-H&H#K6O)&E;Z=[#6[CIP]=..#NY*&7E9R1L&*OLYM"S)+75C-7%
MH44D,^N"3/TVFTE7.5?\9:_L!$<KF<D5.9"5`^(V].:()($_5`Z3X3,UY-:O
M:_\`S)47^\NU?43?F:>K?IQR4U[-6.;A5G6YS`V?X.?;8XP?*^R_^.5V9C[M
ML=6GJXST2F\YFQ@?_]&1;S6E#P@]H?QT0H.3=PP="W._&+;W5K'(;CC50'-L
MNY,QR*)D#TVUI-(W'I_/[2>%Q+"6A?FYY:28\M<5;EY%.W)2U,+1PFSM#-%D
MW0Q]4IKN/164RH!J72%FFDR=X%'U!(U!85IBJ3,<$LAQ1FITFQC*`!I/T<8'
M0!"*T+9@95:7\0Y#=#G/[?#;"*7+5[PK6O3PN>FRVXY'*Z>D$YE[,QU1$FZ=
MK]US)FM/#])EJ=\AC<W%K&\*4YV,<SU*1T5$SPANV\&R@LPG3`A8%9.P"VH$
M\.SBW&`,\;^R$D")F=`F`V'^G8A!WK?Y/RY-E;\E(ZS8_F6$]IGWNEBV9?*,
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MC'8ZS8_F6$]IGWNEBV9?*,=G*SVM1TO,IRC`OC=&TJ+_`+DFW>C6IY<UZKR_
MZ"[Z\F'9"QA;2M%;#XW2+RG3K>M>#?3X+^NGGIQR5U5\=58Q5Q.SK8&!LAPN
M&Z`YF\9!,Q"!2OU,;(\D4YJU")&(.^.MU^5V8H2HG`X`@E].PZT4+IWX-]&O
M#F/NVQU:>OC/1)TZS8_F6$]IGWNEG/;-K?*,=CK-C^983VF?>Z6+9E\HQV?_
MTNK$]M=+,/:Y0Y'-+G-ML%<\HH_7M>KWVO\`A?QM<Z%/73$I(92[!+K;I><<
MA.3#"XK74UM)W$G1A5+]J#]IEH%6]*-QS7C:E09*A@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#DU[7_`.9*B_WEVKZB;\S3U;].
M.2NO9JQS<*LZW.8&S_!S[;'&#Y7V7_QRNS,?=MCJT]7&>B4WG,V,#__3G\8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`L"QZH
MJVXV`F*V[6L`M2+IG-.])XW8\.CLX8"'E(G5I$CL2SR=N=&XIS3)5YY19X2]
M&@+.,#H6M#%K88-_["N#'_A?Q.^[I3_<[!66D?`WAMQ!F%<7<NEO%3C=*5K3
MS=YT1-J62.C:P>U39%HCRLM:.Q2--ZASBZHY''XQ'VY.A;D9>PID2,@LDD`"
MP!#I65IY='0R"<3.*U6R=!-JRXS\?JYF;4!86URZ"4S7,1D[:6XHCVUP+0/\
M?C;>ZHP+VY4:0=HLT.C23!`%TA%O6RK8'`8'_]2?Q@6I-#)P5'U0Z[211=*M
M&I>HIYHX.[7'QD[4%Z6[5+6-L>'(LT"3Q]E:`0+0C-:T+8=;WO08#IJK6]HN
MOD!;":%G0E/)'ELA+"G,+5(]R\IC,72B;6DI0GG:&!3,IW+%3:4(POQ36^.)
MEB;>B5PMC)F;0V(>%DC3&$A9&-M=BA`%L\Q<_FLXRC-"Z`@+++9'71P1!\/C
M>,#HWX.C\N396_*%(]U9_P"IT?[;*>Z&+9E\HQV/=6?^IT?[;*>Z&+9E\HQV
M/=6?^IT?[;*>Z&+9E\HQV/=6?^IT?[;*>Z&+9E\HQV/=6?\`J='^VRGNABV9
M?*,=CW5G_J='^VRGNABV9?*,=CW5G_J='^VRGNABV9?*,=CW5G_J='^VRGNA
MBV9?*,=CW5G_`*G1_MLI[H8MF7RC'8]U9_ZG1_MLI[H8MF7RC'8]U9_ZG1_M
MLI[H8MF7RC'8]U9_ZG1_MLI[H8MF7RC'8]U9_P"IT?[;*>Z&+9E\HQV/=6?^
MIT?[;*>Z&+9E\HQV/=6?^IT?[;*>Z&+9E\HQV/=6?^IT?[;*>Z&+9E\HQV/=
M6?\`J='^VRGNABV9?*,=CW5G_J='^VRGNABV9?*,=CW5G_J='^VRGNABV9?*
M,=CW5G_J='^VRGNABV9?*,=CW5G_`*G1_MLI[H8MF7RC'8]U9_ZG1_MLI[H8
MMF7RC'8]U9_ZG1_MLI[H8MF7RC'8]U9_ZG1_MLI[H8MF7RC'8]U9_P"IT?[;
M*>Z&+9E\HQV/=6?^IT?[;*>Z&+9E\HQV/=6?^IT?[;*>Z&+9E\HQV/=6?^IT
M?[;*>Z&+9E\HQV/=6?\`J='^VRGNABV9?*,=CW5G_J='^VRGNABV9?*,=CW5
MG_J='^VRGNABV9?*,=CW5G_J='^VRGNABV9?*,=CW5G_`*G1_MLI[H8MF7RC
M'8]U9_ZG1_MLI[H8MF7RC'8]U9_ZG1_MLI[H8MF7RC'99\XM;=9,)DILDZKZ
M]C!2E,B-D<XMMOB;"4L6"$!(D,=WZ.H&\"E4,.]%E[,T,>];T'6\6S/Y98_#
MG7[-;D!"Y-%KJA4-FE*2N7._-/GA,6^+,]VQM=)U\>>N55JOZ1_;8^VMK@Z.
M,95MC@4I2.)9?5U:,TM0'>@&!R(IFMJ\K6Y.HGNK/_4Z/]ME/=#)MFK?*,=C
MW5G_`*G1_MLI[H8MF7RC'8]U9_ZG1_MLI[H8MF7RC'9__]6?Q@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@6_)8G%IHUC8YC
M&H_+&4PXE2-HDK,W/K6-0GWL2<\;>Z)E201Q`M[V`6P>,'>_!O6!;4:I^I(6
MZ`?(=5U=1-Z+).3`=XU"8RQ.@$ZC6@J"`.#6V)5823PZUH8=#\46M>'6\%61
M<!@,#__6G\8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`_]>?Q@6K-$<W71]4FKN0Q6+2H9J7:%YFD-=Y['TY(%!8
MEI:J,L<[K=Q6&J$FA@*&!V(T28+0Q!-T'98@T+X:4U:U:W'?DHG$0<&%OL`Y
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M`8#`8'%KD_[1Z\Z?Y#6K44$@53N,>KERB320ZRTR8&/3FHD%:PB?*E!H6=S1
M(2"2#9AU<L&@[%L)'C;WTBZ-::/7YQ,U5U:XTTBC!7XL/*3Z-Z"__K8GQ_E_
M\/[?_%?]8^LMA>)OM%+NN[D-"*?GT$JMK89@TS-7MVAYDM+=T*N,,!SVGUHM
MZ<EJ,Y,J\ALL>O%"+73K>M^#HRFOU^$1-:K:=4:JTAT/OKD&UT0=729PCBZ1
MJK-E0H+'$J!P2(#CY@YD%I(:RZ$M+ZKH4KE:Y$V!.--))2;5>7,%L`!:WFO$
M58#M/G&LJ.0N,$DM8LQEAL+9(W]QC:.S#1IY2T-,3:96P-M1+#*_`[V%/YT8
MN5,[0P'MK.J4O;<:1H?5S$RHX49AF7(ERB%BRR,F0-,X0R!JJ212R6$RX9$B
M2FWA*U<09EC5##8OMO=&F-N!92AR&)[3J^IB-$E3*3RRTYXHMX[G9QS305OL
MI5(94DA+A!4%B"?E5<SQ,C:XX^Q&13V)!?\`9T?`*/O<RA\75+VUN6:)6F%F
M(RS2BCG)M*5BDJW/>5$<CU:RZ;0Z*2F82.*6+5]5GU\],DFKN0`EEP2ROXQ"
M#'1)(XR8^-T?<";);5XE1+:L,`1LU/Y':].H2%"C^6CF51CNR160%O$D(:)9
M'H1)D;JH@<X3M*!ILTYV25JJ>G!9'DA;&58B]D4$,O70IC%I@DVO$!UU%U@4
ME4Z^Y:4U9C_'(U&UDQ3N<KVW$L6Y+74YBB%:O>ZZW;K`T!<)"PMR,+P^5B2H
M>B$VQ^4`E1J`':*4$B(T*2QJV\VXR4J3)YA#G..FG2RSV!X:&]8X/,OKANK"
M*R6:+72VXBX1N-N<14O\:CNUK64AV\HW)$>6J1K%*491QHHKUF<U*K@K1-!,
M1#].)?"T@E:^)M;!*"@)T^HI54R`X/C^CCCPACK(8SW5'-!5G@V`1ZTT.@[`
MB<#$@HK,HY;5T@J^VK&AH5$Q/J"'%2B2,*@MTC84;@:\RN.FQ%X=#V5R$S2=
ME>X6O(=46DRA:V^*6(PC>CR/*"DK79N<]-IXK&WZR5IM?KI&DNY6A1DD/4N;
M'(F@5-FGSLZ.N;6P)75W+W$:F=GY,2<VHW#3=H@M2E3+E!*,P4R?G87/&B84
M<S1]OD2%^L*1*X`D9(*:K.:EJM1/BFE]2(!.93>[H=.J6OUQ\@T47Y4LU`F"
M+RH`J4QA@I*I1[G!1B]L+7R5]514LML<W1U=SF"9JX4UE-M<R>XQI39DJB;0
M@&X?HHACJ]F$[*+&02@-+'T&C2A4BDKX9N5=)R6)(YA%I*ME2-QG*NM&YHC$
M??'^3KYZABBN>*HLDCK4@5.1KF1!4)KR+^QHL+:#9^QZ#@H_2L.4]+7$_HH_
M7\A=G<YW;%CNP.JF(RMGCTD1-T>@4K7"87YX9T+8XG)HY9S(KV4$S1@P*S`@
M"(:1:!,*3#&<8YBHC(_'Y78\&'#8Y,:SE5LQ9PCDA4SLS<4A4O@L.D)4H1CB
MT5/8'E,KLEH4`+3^Z*0:<2C>U(!$A":*,O5CR1I^XW-$TUS*!R):N8'&4@`4
MT.Z0*5@2%PI8W.;EM<B3;;"96R6$TN;+I1HL;HVJ=J"`C`4=X@I*Y:>LG=KP
MG<M-CZB+JTLTM"".C$I<$SJ-$]559TPJU\$6XHRR4ZQ(K=X:>>0,(0[V08#I
MUK?3A#*&`P&`P&`P&`P&`P&`P&`P&`P&`P/_T9_&`P&`P&!'HYH<6;*D_*FY
MIS'[:X:L#1.G&#/:1BM[D4_UM/6KW*J:OX4>2[1=%3DT3$$JE,4&J2G!7#\L
MF/!O8`;Z=9KH]GA$Q3FKJT>5)JUD_P"T6X_IO]G5]\>4_P#XX9?_`'CZJ_Y?
M/_QMAP8XOV/#N4]?S^1VMP^D;3$V&?Z.8::Y"/MFSE>:_1HYF(,2QQ=4$(3:
M;D8U/E%)^UO26#6N@`NGP9Z_9YQ$46TZ/&LU=N[#J.NK7*:2;!C*>2%,0G@;
M0!2M=$@4![ZT*6->K(TVKD?0N"WJQ;3'[Z3D2C0%"812@LLT.:U5+C=&5C%)
M$DE[0PN`Y6C5/RT,F>I;,I0_JU4E9XQ'G<]V=Y-('=>^#,8H8UI">NF']33H
MP`3^2#XVA$U?D\T-5T@GAEDO#&Z+90H40E8M`*9S@J+.2ZMG)6]0%P=X"1(R
MH$\.,0>UFUS>H5-IQR9<40I`+1Z9.8415AZPN$%&3.LGBN&EE<8F0=3@J;C"
ME-*)P[,<<:VVM)-5<+?G"$+I:"+3620B-2<T"-P=R5+GL1"<6U6C$R8PDFLL
MP(*%JYO9'*/A8W9P0/,_A%H.I[_-9S)GIQF];O,,?X,\*Y)(I(Z2(\F..=>L
MXB$0E6T'DD6B1DB),-+,(6R#BG0Y:>'H2X6M`V06&P6`1]E!-I^%@%%ZQ2.2
M2NTD@8-2G3+,7"$Z=CCFQP>"%SBC6>34E'A4DDF@)K*XF+C]44:<HT[LL2ZD
MX1!Y8)!'5'N])U/N<[Q>IGFC6)7Y)6]'D*^HU;(%C7Y,\)I1OENLF!&K`!0$
M54A;QBI5UD1LM>8P\/\`)#U'E%#Q(Y_8LB6J4'N%,HWJ,*C'N6+]*8*%HL)[
M!J/&:$QA-<SS])/+C\I@JM$/"KCEI$XH1Q"4J0/)PS7Q8NM^YU[P_%&1BN8<
M)M?WY;8*A\?6/4?J2.E!;U:@Y"`UL`H"3I08<:8*RN:.\;*];J^M*O9`E'(6
MZ[IE,Y[:AZ$Q=#12*1S@]+[J'H!11P;G&/`2MS:C2$&)5>ENPI`GG*#E9AR@
MP54M!Q`H%KD:"8-T7DZ*4MRAS7DR!/;%OE.ZAX=V6U8ZKD3HN#/-*'J5`:+M
MDY2=V6"/<DFW/QR#RS$Z09`K+Z6CB50C`U!8&2(/#3']BCYRN/-UBV:CCSNO
MBZMN6LCW(&(B8@:9')$I[.CT-S7DJ7!06C(+..,+)+"$5E_9/$OCV0SACX:Z
M3FLH59ZT3:KD4N7)3CU542NCU.E):R0'];3J*MF[HU#)-\<D056S]AZT`H\`
MK*\7:D(`^QMDBSMZ<KD<:D`Y3'G@VV;7U-V1^,:79@-<&JQRYJ"P4(SF)^7(
MA@+<PE#2+#B1!V6:,.Q5\D(X]TY6ZQA6P>$I(V;%].X(\4@<WWJ+04^1V(1-
MR3(FP]T.;2DAD>@32E+)\EY).!'K9(0",-$,5E9Z/B'0:%(U(D\6DGDX\:V&
M1<\^U+;6.,/"TO89&E2PIV5SD]TAC<<]E$J%25K.2)EHDB72@!H4J;10K*L4
MGQT@-$KY>OAB0"4<H;*ZBB<@HHT!3+7]/Q`B#5A$`*5:MQ=GP<:8`&Z-<W%4
MJ<5IR@?CF!)`G(((JRQ$X?'(,UJF6+-WN6V+9--)@J3=;7+?*R.PYB_3^8./
MEG%4K4`]V);)EROR(1Z(3^7\D0`LD!98`N;`8#`8#`8#`8#`8#`8#`8#`8#`
M8'__TI_&`P&`P&!YO/\`,6?Q6;O^1E*?5/%,K/%MHVN'60L[[_RUG\3Z*_J:
MMWX(;\F.*NO:G#\O8/<DSW4>ZA(>5.F66/2Z>)&23%Q-<[P0U@.(D\6;GLQT
M:/<F1S1@VL:&=?Y<G38ZK2%0CTP2MJ"[,HI=K=+^,UKVI89S;&4+M25).Z:P
M4L9(=T:-Z>:M=G2NH$Q"L*N6)CGS>GK.4JGXI2?'1DC/`U.S<L<CD0MN8]&P
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MU`!)SR]$*DPFC"L<J:]4(X,?$:\E,-6M%I%K+C<W!;&26ZS$;CSFI^:(G,#'
MJ2*1R%SB=',[^MW(5B(*E&W*--Z`TX\\XI'"9HKK.\>T&?&:,A7ER^+.K34D
M<+E1IC#1@Q2.XF2B+`W+!I=:0OB8I@D%Z)6<`!$EHRAD]&TNB41NQB%E>5N_
M.QCD438$:*:2UJ37G5_NQ-UQ-%I&]SIQX1\7`VFV2-@;HPT.6S6)7*K'.;7!
MK,;%*4IA"2:!S,.2CW*+,72>E.0VX3[/1N:(D^'R.I^.3$Q6`26:A&X,-EL$
MKX8O0F51--39E*A*UX8:[EK<M?B27W_[2-P2%I5(UQ9*B$Q2Z^4<K]H*<\J7
M)+$9&0W&67%U#)!Y>930][B\C0N+-*&*1V#%6`HA/$*L=2B'@SJS;IV?B"5*
M-$]"\NWJ#19;*.&\SY1(Z;ETZ2O[LZ,JIO02$MR:*[9%T7;E_)CV>DJF+*O+
MB[B*+2-*GB=>SU4D<$9)A@$Z,\"=0HV)$H4"W)];6=[21'&Z_:5SX\+5KG5-
M=O$UF[E$*6<9&P7<\U\S%R.,'Q=A0Q9A75>US=&O&O"C)]U"E:L@!3F6W>5.
M2+G\66N0CGS1)D%E%4F1(P[2,$P.K4I`U5$K@"YJUQWEY[&XO"^6E*IM^EM)
MR1TWITJ'7B,)S0)&(XDXG;H<FE%GW63$KB>8A*8O-VB0V[&XMRHJ!P8-K&6#
MG/<ZHU*R5-*YD<\L$>11N-O2%FG#G)&T*8:`@\Y`VE!-`I,UUE0(8<?!\QX(
M@8&6-'R.H:\3CM^2/\VG3]3\UB=25_)UO(-QAQ$O4/ADF>R55%-J2(.!W5'M
M0Q@1K$[8F*5HFUP/%";-S*'?;OEU25Y-[";V^/R^>N"R<R6%2-":WN5=0:5N
M*]YBE=EIVU"A-W,H9$E;>A<QK_*B,=BE8MC\398`2B55XXQ>50RM%D<E_N][
MH(;9Y"G,^Y+(%\I>10-SY`6<ZUD-0_.KF\NB].97"YJ$FZRI,4%)MEEF>*,`
M@!(9VP&`P&`P&`P&`P&`P&`P&`P&`P/_TY_&`P&`P&!YO/\`,6?Q6;O^1E*?
M5/%,K/%MHVN'60L[[_RUG\3Z*_J:MWX(;\F.*NO:]%3+,3`8#`8#`8#`8#`8
?#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g893535g33p05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g893535g33p05.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0WJ4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@`````````````!3@```38````&`&<`,P`S
M`'``,``U`````0`````````````````````````!``````````````$V```!
M3@`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"TT````!````:````'``
M``$X``"(@```"S$`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!P`&@#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#L7##JMLR&=9R*J2'.%,[F-W;G;G>JU]G\W_-[W_\`%IJ&XSJB\]9R
M+&VZ-:0`6ONWY/N]!C'-W,99^=_-_P`WZ?Z#9T0JK`(#&@'D`!!Q[/4?:PXQ
MJ;4[V.($/@N][/\`-24XU[6VVDLZWD5MN+MM;&LVL:0[)_.KWMK;52YC;=__
M``:CL8?3>SKN4&\OAK#N(AS?4:ZISJMK:MFQGI;_`%?TG\\N@VM,$UZCC1NG
M;Q2VM_T?GPWPV^/[J2G!QVTTV6AO6+K&-=4X-LW.VNFVZS<_Z5C;\>G^;]39
M7Z?K?X=1^SWAWIMZSG/.QCM&T:B![F[ZO4_2.MH9_7?_`,<N@AI,FO7F?;V^
M:18QW-4_$-\-OC^ZDIRL?#^T@NHZGD.MJ!:';@X`.LLL][/YFUWIN^S,M_X#
MU%:P.G9&)9+\V[)J#-C:;-D#W;_4W-9ZKG[?T?N?]!7&@-G;7MG4Q`GMXI]Q
M_=/X?WI*9)*.X_NG\/[TMQ_=/X?WI*9)*.X_NG\/[TMQ_=/X?WI*9)*.X_NG
M\/[TDE/_T/54"G*]6RZL56L]$QN>W:U_/\RX_3^BCH%&95>^YC`\&AVU^YI`
M)$_0GZ?T4E)-[O\`1N_#_P`DEO=_HW?A_P"22]5O@[_-/]R7JM\'?YI_N24U
MLS.MQ:W6_9;+*V-W.<UU8_L[7V-1JKKG@FRA]9!@`EAD?O>UZK=7L!Z9DZ.^
M@?S3_<KAL:#$.T_DG^Y)2M[O]&[\/_));W?Z-WX?^22]5O@[_-/]R7JM\'?Y
MI_N24K>[_1N_#_R26]W^C=^'_DDO5;X._P`T_P!R7JM\'?YI_N24K>[_`$;O
MP_\`));W?Z-WX?\`DDO5;X._S3_<EZK?!W^:?[DE*WN_<=^'_DDDO4;X._S3
M_<DDI__1]50*<RB^VZJLNWT&+):0)U^B2/=]'\U"P<\9=V56&@#%M-)<'$R0
M-QD%C-OTD>K)JM?8QD[JC#@01W(]L_3^A^:DIGO'G]Q2WCS^XI;QY_<4^X>?
MW%)33ZNX?LS)Y^@>Q5O<//[BJG5M>FY(`).P]BKFX>?W%)2V\>?W%+>//[BE
MN'G]Q2WCS^XI*5O'G]Q3/>X-.P;G=@9:"?ZVUR?>//[BEO'G]Q24UZLG)?:]
MCJ6-%;@U[@\GEK;):WTOY:L;QY_<4#'</7RN?YQO8_Z.I'WCS^XI*5N'G]Q2
M2W#S^XI)*?_2[_HV/DUY_4[KVN8+KY:V9:0!L8]LMW[_`$FU_G^FM"G,Q[K+
M:JW2^@Q8T@@C5P_.`W?0=]%9G0&G[9U=^P!MF62U^P,<Z&MK=ZFVNG?L<W8R
MS])^B_PMEGJ+4JR<>U]C*GM<ZHQ9'8Z^T_YKDE,_49XKRG_&@]W_`#GKVO<T
M?8JM&N<T?SF3^Z0O5M[/$+R__&4.G.^LM9R+<AEGV.J!3578W;ZF1!WVY..[
M=_824\7NL_TCS\7N_P#))]]G^DL_SW_^25G9T;_3YO\`[#T_^]R6SHW^GS?_
M`&'I_P#>Y)+Z!_BG>?V9U'>YSHRA&XEW^"J_>E=UZC/%<5_BM^QMZ;U#[-9:
M]IR1N-[&5D'TJ]&MJNR&N;M_EKM=[/$)(5O;XI]P\_N*SOK!<6='R'UV%CAL
M]['%I$O8/IM(<N/^W9'_`'+N_P"WG_\`I1)3W6.1Z^5S_.-['_1U(^X>?W%>
M>C,O!)&5:"[4GUGZP-NOO_=1\'-R#GXK3E6N!OJ!:;GD$%[06EI?[D:4]UO;
MXI);F^(204__T_0.CNO.;U07;A&0-C2][VANQ@;Z?J/L8S=MW>G5Z7_%J_4_
M$+K/1=7N:?TNPB09=_.;?Y6_Z2;%PL?$-OH;QZ]CK7AUCWC<\[G^FVU[VTM<
M[_!U;*T]->(U]IH;6+''],6`27:_SNW\[7\Y)3/U:OWV_>%S7UB^I72OK!U!
MO4,G,NHL;4VG92ZO;M:ZRP._2UV.W?IET^B6B2GS_,_Q9=$Q\2V]G4,ISJV[
M@"ZF/G%(1C_BJZ$"1^T<L>1=3_Z076]5]>S%MQZ,=]SK&0'--8;)/T3ZME;O
M^@K5-CK`2^IU)!@!Y82?Y0])]J2G(^K/U=Z?]7,>_'Q<E][<BSU7.N<R0=K:
MX;Z3*_S6+8]6K]]OWA2T2T24YW7<@LZ5>^FS;8W9M+2)'O8N5_:74?\`N0_\
M/_(KM[\>C)I=1>P65/C<QW!@[A_TE4_8/1O^XE?W)*>3_:74?^Y#_P`/_(HN
M'U#.=FXS7Y#RQUU0<#$$%[9_-714]$Z0ZW(:[%K(8\!NG`V5N_BCU]$Z178V
MQF+6U['!S'`:AS3N:Y%3;]6OC>V?B$E+1)!3_]3U5#KKH:YYK#=SC^D(Y//T
MO^DB(-6+C56VV5L#;+H-I[F)B?\`.<DI)L;X#[DMC?`?<EL9^Z/N2V,_='W)
M*5L;X#[DMC?`?<EL9^Z/N2V,_='W)*5L;X#[DMC?`?<EL9^Z/N2V,_='W)*5
ML;X#[DMC?`?<EL9^Z/N3/IIL86/K:]CA#FN`((\P4E(<=K?7RM!_.-_\]U(^
MQO@/N06=.Z>QX>S%I:]ID.%;00?$$-1MC/W1]R2E]K?`?<DFV,_='W))*?_5
M]50:</&I-IK8&F]Q=;J3N)DF=W]9&224U+W8%+VU/]*NVQKG5!X`!V;=WN/M
M]N]BI/LN])X8[`]6`*WEQB==SWLV_P#@:U;*J[6[;&->V9AP!$_-0^QX?^@K
M_P`QO]R2FC8]H?\`HGX;F2X^]P!C\QOL"B+7;_=]AV1V>9G_`#5H?8\/_05_
MYC?[DOL>'_H*_P#,;_<DIK4V8AGUW8HT$!C@=?SM7;40-Z<";]U>QT5S+=@(
MW.T_E^Y/=1@45FVRAFUL3%8<=3M^BUI<J1;T<9!S1B/-NP5P:G-]LM]WH6!F
MU_O^GZ?J>E_P7II*;F_I?[]'WM5>ZQ@MFAV&ZHP(>X`C7W.]@=N5MF+AO8UX
MQV`.`,%C0=?'12^QX?\`H*_\QO\`<DIH,<(<;+,,'<=C6D$;(;LWN/NW[_4^
MBI565EX]9V&*Y,['2Z(]OT@W\Y7?L>'_`*"O_,;_`')?8\/_`$%?^8W^Y)2.
MEW3K[+*Z0RQU6W>6B6C<-S6[XV;MOYG_`*425AE==;=M;0QH_-:('X))*?_9
M`#A"24T$(0``````50````$!````#P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`
M<P!H`&\`<````!,`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'``(``V
M`"X`,`````$`.$))300&```````'``@``0`!`0#_[@`.061O8F4`9$`````!
M_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`@("`@("`@("`@(#`P,#`P,#`P,#`0$!`0$!`0$!`0$"`@$"`@,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P/_
MP``1"`%.`38#`1$``A$!`Q$!_]T`!``G_\0`JP`!``$%`0$!`0$`````````
M``@%!@<)"@0+`P(!`0$!`0$!`````````````````0(#!!````4#`0$+"04%
M!P$&!P```@,$!08``0<(%A$2$Q055I;65Y<)TU24U)75%Q@9(9)5V%DQ(M=X
MN*8WMSA8F#DC03,DM7>946%Q,B4U)A$!``(!`P(&`@,!`0$```````$142%A
M`A)2,4&!D2(3\&)Q,@-"L<'_V@`,`P$``A$#$0`_`-QV8Y=JOP[F/Q&V=WUW
M:H9=`-'NE*'Y\CT<:T^G:'R"4N&28[DPQPCQ\NOI_D@&`F/CCJ<;6L);SSR#
M0[\VQ^YN5&XJ8C1)&3^,%.H1+Y#"FK2>NR'',<RW1CBR1S]5GZ-LDE=9EK,P
MQ$<AXX.+B@L3MK4J"DDC^:U/"@"I"G*``M<05O3C$21:=.[),4\5B73M-C['
M40TM<I:KIOJ'U3Z<56%5F<&EKQZPRC2`B(=<M/M\X'X^,,=6"S:ZMUFZY<8+
M/5*E8B[E@+*N>)9T^.NB*B;Q:&U7F]JU;JQ9-:M-Z3PE\KYT>L`7=TZFP<RP
MC6?&,(*2RTQ2@$=620J0$*V)*];@0#;S^&W`ECN"RUZ?+SM=NI_Q",TO[4#$
M#K!)'I4S_BC5YX?*>;M<*RVFR(PRS#VI#(1UDR%+.F*/PXP[C[:R*VY_:E"`
M!(#=P)!ZU.*Q]"(CT2US+/\`..</$(!HH@^=I=IEQO`M*[1J0ETFQFQXZ79@
MRJZRK)CSCUK9(R[93@^0XY'8%$!,EC7%8F;#5BE>H"EN(!>Z*B1I%TMK.7B9
M+=,,DS!"C\1R?-V/]%;)IM;M7.>7*>P^&2]K69Y(:T\>D$4Q<UPX+;D1X&@7
M)W9X(2*(XC(NJ$4C+%O+%661QOU>5L\522'YX#CQVTR";L/_`%`Y%X<YF94F
M9VYS>_C*DB2B911W)Q4/'K>J,C#XU%@NN-$\E\F",W"KKA!N&EG3IXZTPDY>
M*\[Y;QFO>T^.I'@Z30O6YI=PDZXU:\QM;5GYH9I_FI9'3?CGCV=:?5]L>LTB
M;HW81C8WC="GMO5G$)GU,:0HW%KTZ^/DH6I;Q>\PH-/^O]]P]B2%XKRKI(>&
MQI:F7+.0'`W*XHLJRDGQZ?E5[P2YXM9TA4><RCB5#.)%('IM5%KRA'JR3`63
M'+2.,7&&:\G^,,VX;U*1W3-/<&I"Y>QKL!QO4`=&<KJ9$IQQ,,_)TBYL38R9
M/A8W*LSQ&!M3JA72!U4F10XA(L")(B5F%G%%K.G2[>C!_BO3_,V1,/PB^DY'
M%F[4/(]7^.\)2@_/R)W(D.3])">4.3JRRQI3XI1KX;$)DUQH7!/%KN"E$LN8
M5=O4$@*4J%D\:\T&\)^(-K?RTC\+K-,DC:%_E66<4>)W.%.&<=9#7Q>)ZE_@
MQCZ!NF+$TD;2X6J1P20I)2)R:6M&83(@I1%E+Q*Q#6FD)BS$:MK>A+Q%6K7G
M))D7CW&`V/'4%Q#I]FC]D!1-@O-R\IYOA=YT[X83LB>)($2EPQ:T7+*=G(#G
M>]U1Y1=T95AV%59F*8&THZ]I+!/!HQIKKU(.$AR[,$$%<G23G(26%H?YQ)G?
M-+OC2%M)?%4C5'VH3BZN#8B$HX$!2<G=.&$6]%OIY+,7RJ'ZOOBVNV,I<]P+
M.^FGX:2C&.H3!>%\\B:,S(IW&<<1?4GCF73O$.3V*1H\<LH)HF<W"(F,KBUG
MD,IJ!>I(N!0I`8&]UG3B6+X-XZ,6D>)IYEV3:<GZ+,^'].:_+V9&5'DE'('V
M`Y3=M2\CTV8JP.<$V#L36L<<DN4:->^63E2,MM:S"QB2'V%PE+7IW>F.>-/)
M9TCQQ'<;Z0S<D9DR!GF;X#306+9Z:T4+6.[#B,65HM,H=E:;XQAS=)X6_$6$
MC<C5;<SK6>Z-8,M,O,*3)UBTZ=]$V=,>N^^HG4MJ1TZN.,D.*77`;N]H6]LF
M$]7DYAG#`R2<N,E9)!A]RQZPD-V+)*::`]J>VV0/Q)I9Q`5049J@D`ZDQ41-
MM5.E755KGR'J#62-CFFH?+,)B>K/6-#-0,7FV(X+&=*T-T_8N.FZ+&E\?YC2
M8LCCZ=E5$^MZ%+R>VO;\8=?_`/8$)2K7$?&IB&1,\^*]+<G:/E*Z!8Z>,.33
M.GAH:@]7\7G,?RF>XO>)WO'+P@B3?'&HU-!H\H>EQRAVLL+=P'-PDXB=Y9*/
M?<(%9''7U2#Q_P"*2W1+(9^$LNP0Z+LV+-)+'GA\RK/)TXM4^S4@C>`&W,$^
M>\(XW70*[/E=L8$A2HAU5$2TER3K4Z@8F^Z<DU0!:=/G&65/#T\3-CUXOF0(
MT'%HL:O$2AT!R.RF-LX'D=B?H9D$#C9,B<WT,*A:>/9'B2I"`A]92P.*1,8J
M*$D<5Q5Q&!$Q3:+59*!0*!0*!0*!0*!0*!0*!0*#_]#MAF^CW3GD9WSP_3+'
M?++MJ:QFQ8>S>JVMG3?MMCF,IGM&R1W@&J3H4T;XDFD2P/&V@"!<9PVZ8<*X
M`7"6YT6:L\/W2*O6R1Q5XDX59+IEI\R#(3MO<FE\H2_2O'FN*X&=^#+F8"DF
MPC"RIB.+D!*2NG!;]Q+5F"&,0N7@DOAUZ.):RO;$]8?N(E_SAD;4<K=FK(65
M(]+T.9<NV$#)<OCDZCTX:YK$"IF2+@EK8TN")H,(W"K);%VL&PN52;]!NC7@
M47)V$(:<T(=.KUI%2LQ"]]4Q*V`'25I96^X\,B_+9L74C43!I`K.=#$HWP*L
ML5^.6N(=KBYRHD=\-_1A%HJ?#6?#8K-"S)6,<N."MTR-EB02ITGF%U):K%#D
M\3I_G3G-WAK@%RK%-;2J<#6=*FW4X4O`7N7=1U2R+GC1SISU*OT2EV7("K<Y
MM!$CDW1"?P^=Y&Q/D1A:W<99CFSH<@XEET'F861:87OAHA+A);B$._![I@]\
M(F865+_#QT<3V9Q;($OPLA?)3$F?'C$E5JI?D,#?(VS$QA)V-2LDQY-+B(YE
MQ1"CDX!MZB5)'E00,-KV'NVW:%SE7Q:&]+8U@E]\8"LL%JNOK@N>&;Y%`*VJ
M(4=V4OE`-@2X(0"Y`OP%F:UK1ZW_`'ED'"_OT+EC^->&WHA:FA42S8E.=4SU
M-L49)4/KQEK,4S?UTCP@Z*'K$1@)I),BO<F%&8*X*S!H&4"VS&$`[EB2"+_<
MI1U3E4_IPZ,3FW,;4ZX:VG39\BUX/E`^:Y#RM.71WA=G\R5IXBQ/<QG+X\P&
M,M\I,NYI$,?4-:5$X6"I(`6<$(["YT5PG03I;2S:"Y(1P>6(9UCUL@30TRAO
MS5G-`[2)!B]0%5`2\IGH\DD6S6=&#0VXN=,;/I^\MO!C$#]VA<O9`-$VE2#+
M\+2F!8W)0J\&2S,F2L-NB:=9`=T\<DVHU$[I\M/Q'*$O<$4C)FJ&1*MZ4XA6
MI$(3["0EI[A!<(N5GP_P]M-.%R(F^:?L<(8'/\/"SP^:?EK]-LO2^#XLF&H&
M-L;%.[ML$<\C#9R8*]&15M,,CZ0*5M0\&>8VEH5"M2>:+F?%4=!.C..Z'\&&
MXR0/B683293F69;R]/$<=;XDCF>49TJ)4R!R:8PUW&BCL<;DJ1,WMB``QV3(
M4A0;BN.XKW$S<K(QCX5&@W$$<F,,A&$G$N$3['[QBZ4P65YDSOD:"KH2^O;/
M(W%L20O(V3I7%V1==]84JHEQ0)$SFD.+N(A07PAF_4=4SYKJOX;NBXS"F2=/
M:K#/*.,,PO\`&93DU&[9$RL\3*92"%K6-?$7-WRNZ3I9E<9\9.C:,"&P'L`$
MJ8JZ<L(2##2QBYN[7F@T,Z3FQ'J$;4N%(R)KU5#:#,]-*Q9(7)HG@F!&K1,=
MN2G%Y5-T8`TV7G'IPLQ3<$I::)6&UE5[G4+G35Y8AH5TR0A9C%R9X7+%[IAK
M(4ARIC9UF.:,X9$=8U.)3"BL=O;J!TR!D>3+W1&?#"0(2FY<8I;4@`V&0G*-
M_?H7*Y,6Z0=/6&<HS#-4`@RY'E.=-;@P/TSD4\R-/70F-NLDO,'&*QD,_ETG
M1P>(K93?E`QI9"F]N$J"$S@=\$-["YG1?>(\%8IP3'9-$\5Q0$9CTQGDWR9)
M&TQXD$@+=)MD=X/?YH\F'2=V>E)`'MV5&&W2%#+1$6%O"22R]P-"9OQ1(8?"
M@T!QE)(V]CP,-"W2G&F1,-N;=;*V;%#>FQ7E5V3/LX@4=0J\D'I(?&7)X364
MIDS2!$!K-,.NAXMPY_"2EZIRRDTZ"=)K1D9'E8.*>69DUQ9VA;*9,)UDJ=QJ
M/QR00I)CF1H8U`9K,7^!1LZ3P5$6U.BI`V)U;FBWQ:HTVPQ[ZI<^"]\`Z4\'
M:8$S\APG'))%VR1)V)$J9W?*&5I^R-C9&;.@6!FB3)D6;2QI@K"U`>5(24#(
M2WHPA,M;@MP`+!$S,^*1-$*!0*!0*!0*!0*!0*!0*!0*#__1Z<!YZR%B?';7
MEQ0^IT,>F&L'587J*7H!0V4Y7:62`:B)'@O&K;%XI*9"SM\G@L#CD69(_(;,
M-EDC"F)1G-:0XY0=>HU2@6S[G)L=9?!\42""XY2H0^+AF-S6J,?VE=W1WTQZ
MF<-M$-1"2*9"U@)#)U67W$Q^.L.YJHH8[)N*G7)4$"H_\>R5:A<S')8RPY(<
M(+.@RE=X3.<X^8GA9D>30=PU%ZZH5BN>1-M2`?'(UW9X^W)"EL=6K#QN2)7<
M=U1JVW!6+%?_`%AYBUAR3`.'HXRP%W3GO<,R9DV>SJ(/:''Z&+N\'RIX@^>,
M8(4ZN0R>>1^<JWY[''74AI(BS6Y&-S@G*4.5CB#TZ)4*N6SG3G,<PY<:=1#M
M*ITS($C?FO.F'<6$QR&(DKC!VW&.3<A0YNE#PM=5[LAE[^I3A0_](Q(G1`+:
MR]^4:8H4#%4FM$!M+^?]1R?!6BM(AR4=F(X[PX56J'))+VP))?E/(\RQ_%,,
MH4^'D<E)=$1Z.2NC[.3T[@\.8'-X.5)[A/`)2H&I)BS$:Z>:N0[5IJUDV-F"
M5@70U.UY.FVC-@B&1')JPX]I6YSS]DT4-RDA8X1A_/F4Q*H&TQY:@71=0^.B
M-WXR)20L,5V)X2PJ+9#8M3^9ULKC.&99E7'6.CVW)VK>+2+4')XFT$-LL*T[
MN^-5T"@Q$7<9*R1IDF4WA>25;D[G$J!A-;82[G(B$-U0#6T5YK/QCG*;X3\,
M#1/)84A`XN\V:<"8Z<Y,A31`2*(M4V`(A;)TA.2<@8YA)"US4D%-#,)Y?"$1
M3R[HKG`6VM=&I>1,?*7HE6J_5ECB)0H$S9XV1+<]1C)6&L$G"2PMV(+U+$9M
M;H/@5WFM\>S&:PX1L[QC-K2"1-"![4(&P4'>+EG$$#OP(J']Q'/T\9\HR[$I
M&0L7X-CPLKZR):Z96E\8;U2"5.^'7/#0$T2,1.,HCS0F7/ULEN$A?CP'`6FM
M;086@"GM90L1BF!=+>I344RX?T1X6Q3%$XT\*T-^'3)2&9Z/PXT(LF(,DQ!J
M89X:[/60LTPJ=MS.UL3`8W,0XQ''501)RS+K>.$");QEF(U_E*['.?-1,LG<
M#+>I_&28EFW4AX@^FEA96>`-Z5VQLFTWY$U"L6+\A(WM>XNI4HDQ3=@\PER2
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MC.V(\,YPAF`\;X/5X/F4HQIA2$OS.[Z79CFXG*9Y$Z*N>N@F+(OD.=1C'QS*
MY(FE<R!,3\M.ZDE,==()?8:U->*CS(W#3AF+4'%9U&,+S]%B7$&&WC2;@G+D
MR10K!CGA%;'35<YR!CU(")SF/.LF*ES6YMZAV2,3LK;0-+2DLH;R%]S1#6H7
M-'M01^:I9&L:Y#.1P3!&I72PU2'%T?ARF'O5HP4\X4:<@3QIRB_EO*'(T`G\
M':GXI:Q+DS2FC*AI"G'=46Z&DDT-_-L"P!*)+.,$84FDS)XM,)?B3&\HE:?@
M@D\!)9!#F9V?2>!#8(2N"=%9H=[:UK!W-RJS++=`H%`H%`H%`H%`H%`H%`H%
M`H%`H%!__]+NN;\.XO;'9R?$\(83G1SFZK)`E+DEN\V;)TN;FAL<)+&4[N-<
MFB+BY$L2<U5=J`C`I6\*K-"-4>><8%U6B<6"::>&-1\)QQ,@3''69FZQIJ>6
M+$;A*B#3+)M^83)E[<G/<`WO<*TX@L9UAB`&]@&1.+'7)$=&H^:).2PIDXC&
M9N'<A/%G0#Y&"";B37N43''HL*Q`$.X%&J#8TJP#+6%0>`_'L!5'(%*F#Q!0
MH:@/);6H/C3*<<VER,\Q5(2T!IB(1B,#ZJ-&8ML7<-E1@KB-WU[WO07$A;F]
ML`>4VH$3>6J6K'%26A2D)`*'!Q4&*W!>>`@!835JY6:(TXT6Z,TP5Q"O>][W
MH*0S0V(1T\2J/Q2-L2D0G,0E#,QM;8>(3VL3N+R(1J)*09<3NX)"CU5]W_Q!
MQ8!F;X0;7L'E0P"!MAC@<VPF(MYSL\(9"Z&H8VS)#')_:S[*6Q\<#$Z(L2QX
M;E-K&$*3+B.)';?`%:_VT'H<(5#79&<WNL2C+F@4/)<C/0N#"U+49\A*-`>4
M_')E*4PDUY+.+",*H0;GV$&U["W;6H*@8P,1S.9'CF5I-8#4HD1K&8W(QLYB
M,>[8:0QL$3=$-*.U[[I=P7!?=_90>)##XDUM[$T-D6CC<U1=5QV,MB%D;$C?
M'5G`+4O&V)$G2EIFA5Q9R4E\(G"6/>*#`[NX,5KA_"Z%0YT)"G<HE&7%."0%
M2P!"YA:U9()20+?D24)2A*8`,@)';=`LM;C(;_;8=!^2R"0=PV=LX0V*+MD+
MIQ1+CD=:%.RXD90"$@H[PR,?(ETI)00%W3<%O`AM8.Y:UJ"I$1R/)A(QIV%F
M3C;G-X>F\9#6A*$A>9"<XJ']V1B+(#=*YOBAW5C6'@WIJD:HX1@A7,'<0?DV
MQ6,,[:N9FB.,+4T.BAQ5N34VL[>A;7%4\"&-V4KD*5.4E5J'09@KJ!F!$(^X
MKW'<6[>@((K&&M*Q(6R.,+<BBX1AC*-`SMZ-+'0F)#V\P+$G3IRRF@)B!4:1
M>R>Q>Z28(%_W17M</.X0J'.T<.ASK$HRYQ%1P?#Q9P86M;'#^"7`="N&9%*4
MQL,X-S+"I#OBK[AX;&6_?M:]!2+8JQ>&+"@X<;P*T*&KX^.'VA\>M%AKK&A/
MLM%'[-W)(E=C@6'PER=_OK6ON[M![G;'L!?FIK8GR#Q!Y8V/@.169VC3*XM3
M1Q6Q84W);<L1')&_BX206+X(`-Y8-MS<W+4%'DF(<92QNE;:\PEA$7.8BI@4
ML7-B2T??7J&*T=F\^,J9*P";)$!G$A#8JQ):H`0%VM8.Y:UJ#(A999)99))8
M"BB@!+**+"$!998`V"`LL`;6"```VM:UK6M:UK4']T"@4"@4"@4"@4"@4"@4
M"@4"@4"@4'__T^_B@4"@C'D?5GBW%CY)VN4)Y79HA13TDEDV0M*,Z&Q^8,V*
MEV;OAZYN2AU2+D\K<\6(+NR8RZ7DC</3)35Q2Y8D2GEIEK%T_%DZ&-DTM$G^
M&)7CA#6YLD;QCI^6JF^UP\5=D[IBV=Y&B*EO<`WWQ5RG,9MK6OP@`7^RB+S7
M.K6UV+$YN2!N"=<5B1+EB=)8VX+6N.Q=U!A=AW!85MW<W=S=H*=M;%><T?\`
M;+=ZS5J<)<9-K8KSFC_MEN]9I4X+C)M;%><T?]LMWK-*G!<9-K8KSFC_`+9;
MO6:5."XR;6Q7G-'_`&RW>LTJ<%QDVMBO.:/^V6[UFE3@N,FUL5YS1_VRW>LT
MJ<%QDVMBO.:/^V6[UFE3@N,FUL5YS1_VRW>LTJ<%QDVMBO.:/^V6[UFE3@N,
MFUL5YS1_VRW>LTJ<%QDVMBO.:/\`MEN]9I4X+C)M;%><T?\`;+=ZS2IP7&3:
MV*\YH_[9;O6:5."XR;6Q7G-'_;+=ZS2IP7&3:V*\YH_[9;O6:5."XR;6Q7G-
M'_;+=ZS2IP7&3:V*\YH_[9;O6:5."XR;6Q7G-'_;+=ZS2IP7&3:V*\YH_P"V
M6[UFE3@N,FUL5YS1_P!LMWK-*G!<9-K8KSFC_MEN]9I4X+C)M;%><T?]LMWK
M-*G!<9-K8KSFC_MEN]9I4X+C)M;%><T?]LMWK-*G!<9-K8KSFC_MEN]9I4X+
MC)M;%><T?]LMWK-*G!<9-K8KSFC_`+9;O6:5."XR;6Q7G-'_`&RW>LTJ<%QD
MVMBO.:/^V6[UFE3@N,FUL5YS1_VRW>LTJ<%QDVMBO.:/^V6[UFE3@N,O27(&
M$Y,H6%/;0:D27*LJ5%N2(:9-<X=@$V4'A.N43<T=]P.^O;?7^RU2IPMO_]3O
MXH%`H(JS[2G%)YF9#FU0Y)FN3,#&L(CB5+%&%6@%,E,5D<*13N9@<2U-YJYQ
MF-290G:B#;)BB`BO8^ZH):4*4MZ4R;A7$;;AF).$<1.8GA8_2V4SJ1.);0TQ
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M`%F$@1)`DFW#<TH*8D)9MP7WP+F`L"P1W`+[;;MK[EZEC__5[^*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#__6[^*!0*#!
MTRU(X5Q])'**S*:@8G%F;'=S>5RE@E)L69[L4+<\DNC*[3A*R*(6V2]/CMF5
M/P6,]P+>368FZTM*--N&7%+WQ_DF(Y.:E[O$5;H:4T/!\?>VV0Q>4PF3,#V0
MB;W035(8A-F6.RN/KC6AW1K22UB(@1Z%80I+WY!Q1@QX+ZH%`H%`H%`H/.K4
M@1I5*LPM0<!*G.4C*2)SEBHT!!8C1%IDB8!BA4H'8.X`LL(AC%>P0VO>]K4$
M"_J*XM[`=?G_`+>VL7^#E2VNG>%OB\4#`@925!A8FUNAFQ[`?+"8>+0=JTM*
M3HLE<4S.JDI4?OB7E8Q@3.RPE*8LL3=,!2:`NX[#$$-UG3O"X/J*XM[`=?G_
M`+>VL7^#E+.G>$[&EQ*>&IM=R$[@D(=&]&XDI79N6-#JF*7)BU):=R:7$E,X
M-;@2`VP3DYY99Q!EK@&$(@WM:LJA0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M#__7[^*!0*"!>?-#[?G>>OLE-G"N"L3PT.#FL9X[>8J+R'+-\</>,(KD67,I
M\\2X\=`PF/N"019(&(#HY":D!![D!$F&E4EB:2/P]C:0P(62GV8R1FDTSRQD
M(K(<G51F.KHK&$"Q#CK'N+FIL869TD<M=24Q,8QJ@,4&*'`\9Z\U08`))0BR
M"B,GNK`Q/H20/C*TO($PAB3A=6Y&XA($98-C!$A5DG6*$98%M]<.YN[EMW]E
M+F"HGQA1OA[`>8\0Z-,OJ56YRG3&(/A[`>8\0Z-,OJ5+G)TQB#X>P'F/$.C3
M+ZE2YR=,8@^'L!YCQ#HTR^I4N<G3&(/A[`>8\0Z-,OJ5+G)TQB#X>P'F/$.C
M3+ZE2YR=,8@^'L!YCQ#HTR^I4N<G3&(/A[`>8\0Z-,OJ5+G)TQB$"UL'A=O$
M_C*&T0B_$A:"YRJNDY`:>*W5!U"8\)"INGXIP5SPE#N&P]S?6#>]MW<O4N;\
M5J.GP\T]/A[`>8\0Z-,OJ56YRG3&(/A[`>8\0Z-,OJ5+G)TQB#X>P'F/$.C3
M+ZE2YR=,8@^'L!YCQ#HTR^I4N<G3&(/A[`>8\0Z-,OJ5+G)TQB#X>P'F/$.C
M3+ZE2YR=,8@^'L!YCQ#HTR^I4N<G3&(/A[`>8\0Z-,OJ5+G)TQB#X>P'F/$.
MC3+ZE2YR=,8@^'L!YCQ#HTR^I4N<G3&(/A[`>8\0Z-,OJ5+G)TQB#X>P'F/$
M.C3+ZE2YR=,8@^'L!YCQ#HTR^I4N<G3&(/A[`>8\0Z-,OJ5+G)TQB#X>P'F/
M$.C3+ZE2YR=,8@^'L!YCQ#HTR^I4N<G3&(/A[`>8\0Z-,OJ5+G)TQB#X>P'F
M/$.C3+ZE2YR=,8@^'L!YCQ#HTR^I4N<G3&(/A[`>8\0Z-,OJ5+G)TQB#X>P'
MF/$.C3+ZE2YR=,8@^'L!YCQ#HTR^I4N<G3&(/A[`>8\0Z-,OJ5+G)TQB'M)B
M$23HEC:GB\=(;G`1`EZ`ED;2D2X28RQJ82Q*!,$A2).;:P@7&$6\%;=MN7I<
MY*C#_]#OXH%`H%`H%`H%`H%`H%`H%!`1=_RD1C^02=_U$8ZHOEZI]T0H%`H%
M`H%`H%`H%`H%`H%`H%`H%`H%`H%`H/_1[^*!0*"P';*^+6&3'PI\R5`&:9)8
MXMF"F).TQCK=)D\2;23U#C*3V%8XDNI,<0)TI@SEPBK)B@%B$(=K!O>P>Z"Y
M$Q_E"/DRS&<YAV1(LH4'I")+!9,RRZ/GJDMPA5)B7E@6N#<8H3"':Q@`F7$"
M][;MK;M!>-`H%`H%`H%`H%!`1=_RD1C^02=_U$8ZHOEZI]T0H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H/_TN_B@4"@UK9?TCY$GN?I//`(HW)<;R96Y.[I
M$'/*LMA3`])EVF"<Z?7=E<XFQ0)\6MF1Y,&7\5M.FM[1JT,<L2GLA&-ML6[%
MO1+O3]$<APJ`#9LD.YSBZ"DTE<&%M5S5^R8OB,.7N9IT9B+EDR5MK5*I\X-"
M"^Z:X.)1BH(C>+74+`IP*SR,L.K*C>0DA5G.Q-B!#$"[4_OK$(5S+!L+AAL;
MBW#4AMO+;VQEQ6#]NYN;M]T5:C;#LOGLO[PI]UEJVE1O[FP[+Y[+^\*?=9:6
M5&_N;#LOGLO[PI]UEI94;^YL.R^>R_O"GW66EE1O[FP[+Y[+^\*?=9:65&_N
M;#LOGLO[PI]UEI94;^YL.R^>R_O"GW66EE1O[FP[+Y[+^\*?=9:65&_N@6MB
M#3]3^,I.-RC@KZ"YRIN/;B:75<('4)CPJP;+KO\`QT)&]%>]RK&<%<6X*X=]
M:U[2]5KX^J>FP[+Y[+^\*?=9:MI4;^YL.R^>R_O"GW66EE1O[FP[+Y[+^\*?
M=9:65&_N;#LOGLO[PI]UEI94;^YL.R^>R_O"GW66EE1O[FP[+Y[+^\*?=9:6
M5&_N;#LOGLO[PI]UEI94;^YL.R^>R_O"GW66EE1O[FP[+Y[+^\*?=9:65&_N
M;#LOGLO[PI]UEI94;^YL.R^>R_O"GW66EE1O[FP[+Y[+^\*?=9:65&_N;#LO
MGLO[PI]UEI94;^YL.R^>R_O"GW66EE1O[FP[+Y[+^\*?=9:65&_N;#LOGLO[
MPI]UEI94;^YL.R^>R_O"GW66EE1O[FP[+Y[+^\*?=9:65&_N;#LOGLO[PI]U
MEI94;^YL.R^>R_O"GW66EE1O[FP[+Y[+^\*?=9:65&_N;#LOGLO[PI]UEI94
M;^YL.R^>R_O"GW66EE1O[O:3%VTA$L0`4R(1"X1`CC#I?+5"T%TYEC"^)N2A
M[-<6\(A6W!V3FE6-#^Z/?!^REE/_T^_B@4"@4"@4"@4"@4"@4"@4$!%W_*1&
M/Y!)W_41CJB^7JGW1"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@_]3OXH%`
MH/QNI3V4!1W/)LK&28I`EN:"R@:<H991IX2-]PHB2S3@!$.UM[80[6O?=O:@
M_P!)/)4E`/3G%'DF!WQ9Q)@#2C`_LWP#`7$`8=VW[;7H/UH%`H%`H%`H%`H(
M"+O^4B,?R"3O^HC'5%\O5/NB%`H%`H%`H%`H%`H%`H%!"*693U_-TIDK?#=&
M^GN41!#('E'%)*]:VY+%'F11M,XJ26)]=HL1H_DQ$:<W9K`4H/;P.3@!&:8(
MFRD^P.%&6HRP3DO6'KUQ2^8:C\GT+8`,7YTRN5AR%7:]=TD5IRI:=CO(F3@&
M/9AVB]*)"S[-XQ<@W.+">/C(B0<'O1B&"+4997^+_B1_Z&M-'^_N5_DCIJ5Q
MRF;`7*;/$-CSGDB*,<'G*QO`=)HE&I>HGS"PN5QF6&A:YBKBT)42%,`NP164
M#:4-[W%>W!6W-V]97?0*!0*!0*#_U>_B@4"@T_:G=*&<,C9\R+-8)%35)4F9
M'M(ROBI7C!-$SV-=I:R%BIP9G*:.+J'/T5E<CEDE`VDM#8D4P)$A,L]\!9^/
M5*R8U$Q2<^F6!N<(0Y=5FXZ^#T8G66Q3&`XHO>%DF06-`Q9BV'N:,YKQP^26
M!,QTDGL1>GX1#6O4EF7=N,'B"L/4E@J3_*0CJW+'$)(4C^[,5RA#N,;42Q'"
M4V'8-@A.L^,KR`(2][>X>#L7?[;[M[_9N/1/51MFGKM"E_H4!ZCU;V2I[I-F
MGKM"E_H4!ZCTO8J>Z39IZ[0I?Z%`>H]+V*GNDV:>NT*7^A0'J/2]BI[I-FGK
MM"E_H4!ZCTO8J>Z39IZ[0I?Z%`>H]+V*GNDV:>NT*7^A0'J/2]BI[I-FGKM"
ME_H4!ZCTO8J>Z4"UK`[?4_C*?;B47-OH+G)UEW%(7QH)=M0F/`72V!:(<2X`
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M(D9GR@:OS>-)K)X@G`(^P"A%[AUC2MX8*^\W]@"#+\-&HB?EKY)Z[-/7:%+_
M`$*`]1ZM[,U/=)LT]=H4O]"@/4>E[%3W2;-/7:%+_0H#U'I>Q4]TFS3UVA2_
MT*`]1Z7L5/=)LT]=H4O]"@/4>E[%3W2;-/7:%+_0H#U'I>Q4]TFS3UVA2_T*
M`]1Z7L5/=+VDLCD4B6)1R^1*#U(B+DN1R:)!6M]BC+#,"C+3Q<AN&%2&V\'Q
MA.?>P;_N7`+[:>A6[__6[^*!0*!0*!0*!0*!0*!0*!00$7?\I$8_D$G?]1&.
MJ+Y>J?=$*!0*!0*!0*!0*!0*!0*!00#UM?WI>&U_/X@_HZUBU,-1_P!?PGY5
M9*!0*!0*!0*#_]?K)U4:E-4V()"YJV]9H%TY8=2.Z9@BV4]:6HM\BRK)[H-`
MC<5=XY%8PR-31'4B6PU!``+']0XG"(N==&65>VZ6(C=(/2-FO)&=L=*)E/6C
M!*IO$XG)(=E#3/G))G?">5VQ$J7-;N]1&1;/1EW9U#!(&Q2VKT"LA1P"L@80
M*CKA,"4)BDK*(4"@4"@4"@4"@4"@4$!%W_*1&/Y!)W_41CJB^7JGW1"@4"@4
M"@4"@4"@4"@4"@4$`];7]Z7AM?S^(/Z.M8M3#4?]?PGY59*!0*!0*!0*#__0
MWW^-D_Q>+Y:T*O<JD^(L>-Z9)JC),R-F+33+M7$=92E3-AHJ\?)PM%V&0<.H
MDRS@!\MB+*4M8T("BC.!5J@#DM\?"6S/P[7UADNCG#[W&9G`,@LBWX@<2E^+
ML#/6F2"N_%LI3=(IY#P?(FYI>(3Q!608E4\,G+Y26$FKP;X"H(KUF?%-:B($
M9MPBVY#S5+)84P2Z#%PC`<X.6Y9AK`YNLIE4^RA$I1C)@01)M0EJU,M5XC@:
M)T6GM@$AY2QS?F81=[GHC`46]&6-(C*[Q_$`&MTB#=$4J:72TN-<1A<DQHIE
M$3+=1DL$Q?,;R]V?)+!GY^1%6$H1+%%CC+@LI$G0\8X@F$^*1+JE>%(2;-+L
MG:A`$.YXCVL+G8X-[!W@0ANL1\#<%[7W;[HMW=_[-RK%><(HO)4SYWM_14'O
MJEQA-<G)4SYWM_14'OJEQ@UR<E3/G>W]%0>^J7&#7+RK4\F;4:MQ<9TRH&]`
MF/6KUZV.)TJ-$C2E#/5*U:H]]+(3)DQ!8AF&#$$``!O>][6M2XP:L2?';%W^
MJ;!726"]=J7&%J3X[8N_U38*Z2P7KM2XP5)\=L7?ZIL%=)8+UVI<8*D^.V+O
M]4V"NDL%Z[4N,%2@VMS)CN_B51MXMJ,PY=O!H;FS:*16?X=R.6M,SW`%0&49
M^UO$[.1Q!0CP@N;8VY0!7L"X;7%:7%^"U->J<GQVQ=_JFP5TE@O7:K<82I/C
MMB[_`%38*Z2P7KM2XP5)\=L7?ZIL%=)8+UVI<8*D^.V+O]4V"NDL%Z[4N,%2
MRVB3R9R1I'%NG3*O;UZ8A:@7HHXG5(UJ-44`]*K2*B'TPA2F4D&!&68`0@#`
M*U[7O:]+C":O5R5,^=[?T5![ZI<8-<G)4SYWM_14'OJEQ@UR<E3/G>W]%0>^
MJ7&#7)R5,^=[?T5![ZI<8-<G)4SYWM_14'OJEQ@UR<E3/G>W]%0>^J7&#7)R
M5,^=[?T5![ZI<8-<G)4SYWM_14'OJEQ@UR<E3/G>W]%0>^J7&#7)R5,^=[?T
M5![ZI<8-<H%ZTVV5@R?X<5CY0A/$9KT0@3"#'`$V3*/E`U?BLH&'E8SC`+$@
M&#>;H?M'86[^[N7DUIHU%_+7R3TY*F?.]OZ*@]]5;C#.N3DJ9\[V_HJ#WU2X
MP:Y.2IGSO;^BH/?5+C!KDY*F?.]OZ*@]]4N,&N3DJ9\[V_HJ#WU2XP:Y.2IG
MSO;^BH/?5+C!KDY*F?.]OZ*@]]4N,&N7M)020")82=(D9RXT1%T:T+"$HM&$
M!EA'A,1\ICLJN>7^[:_"`WE_M^W]E-,+J__1Z:O%9D.4T$GTMQYB,\0T&%GY
M1FE;F*_AP0:3O>8`/;$S06V+3))-HTU+S8G#K+W5U`8@N82<\'C`,%AE(#][
M):X^?A;)?A:ZC<MY>P@AQ[G?%6KZ(Y5Q8D<$[UD'5-@AZQ"HR%''*=3,G''%
MGEP)1H)G/67&Z!I*DYZ5.66-TN,^UQ!/"*Z#E&NG@VAU62@4"@4"@4$:-:/^
M3K5C_+1G;_"V546/&'R2ZP[E`H%`H%`H%`H/K::+O\G6D[^6C!/^%L5K;A/C
M*2]$*!0*!0*!0*!0*"`>MK^]+PVOY_$']'6L6IAJ/^OX3\JLE`H%`H%`H%!_
M_]+:YK1PCJ]RAJSSB\(]/6L;.6-W'4#CQC=QX:U;1/'.(9GI!C>*,?+)1IW,
M@B?)#"ZQF0/^6DBIQ=5X`MSB,D\80FEW.,&9'2*KQANN\-MNR5&-(F-8'F9G
MDD1RA#5V24#CC^=S=!D#(<'@!^8,BCPFR3.2(GZ1W=7$G#Q3*`"D:HSAP%[M
MMRX;@#88Y>.B=U$*!0*!0*!01HUH_P"3K5C_`"T9V_PME5%CQA\DNL.Y0*!0
M*!0*!0*#ZVFB[_)UI._EHP3_`(6Q6MN$^,I+T0H%`H%`H%`H%`H(!ZVO[TO#
M:_G\0?T=:Q:F&H_Z_A/RJR4"@4"@4"@4'__3Z>/$+A7A?XI?F7+>J['KLWY+
MRVMNVI73"BO-4/R;D(B(!9$SF]2Y9@&20]P=HY"T;LW%+75_4<31DGI4XCMT
MQ.2*:-1U>$>":>CR!:5(=BI2X:18='(SCR13*<)7MR:69^;WV33F`S%_QO,U
M,R<YB2&<R&0,<IB:UM$I=C3S[!2V"6.Y-@54F_-*VB-=.I9FGRC).093AAWS
M,W2K%NGF<SQ_M'9_E%UBK_,9=%9+!,51&)8A5R-UQ$^R=C0,[Y)5*0E@$X!>
M4D>,,WP7&]S2QNSOI?=E[HV9:`D>9C(\9MF6KM^%9#.%LH>'MX@%\6XN<7LX
M$DFUS)=)FY%EUPE"1.L7G*#+`3<`48).23N"4B74+Z()/(9S22.PA\8NZIEB
MD(@[@>#X&R-6EN`5K[N^WV^W?LW-RK%>:*+P<_\`/8?[,>O>]/CNFIP<_P#/
M8?[,>O>]/CN:G!S_`,]A_LQZ][T^.YJC;K++G-M(&JRZA9$Q)_EMSGPX26YX
M`=<GX82CA;%"&Z#`$VX-W>WO:]K7_;:]--UB[A\G:N;T%`H%`H%`H%`H/K$Z
M-"YS?2!I3NG61,*?Y;<&<`$YN>!G6)^&$7X*QH@.@`"-L#<WU[6M:]_V6M73
M3=YYNY22X.?^>P_V8]>]Z?'=-3@Y_P">P_V8]>]Z?'<U.#G_`)[#_9CU[WI\
M=S4X.?\`GL/]F/7O>GQW-3@Y_P">P_V8]>]Z?'<U.#G_`)[#_9CU[WI\=S4X
M.?\`GL/]F/7O>GQW-3@Y_P">P_V8]>]Z?'<U.#G_`)[#_9CU[WI\=S4X.?\`
MGL/]F/7O>GQW-4"]:9<UMD_PXN,JXN(=]>B&R2Y#>[`"%5\H&K^]A*;&.8[F
M)^`L9;>AN$6_N&^[N6O:\FM&HOY?PGIP<_\`/8?[,>O>]7X[LZG!S_SV'^S'
MKWO3X[FIP<_\]A_LQZ][T^.YJ<'/_/8?[,>O>]/CN:G!S_SV'^S'KWO3X[FI
MP<_\]A_LQZ][T^.YJ<'/_/8?[,>O>]/CN:O:2"6V1++*%,<$XW$1Q`PE"YA1
M`#8RW&>.%#<!GFB$5N[S>#!N"_;NV^RFBZO_U-_7BSSG#N2LQ8NTP94TO>(E
M+300'),K;,[Z+(=(G&2)69Q/QH4_X_BZ!O89-'<G1"0GA1FRXEP`4&/+VEE,
ML0<-:0>1):XYN&S'P^6Y.U:0L1HDF%\F:?T8=OE"/&>:'A<^9?3HUV3IHN23
M;*2QS0-CB1D++*=2&6O",\D)S<X/AJ08AB)N,52?&=4S:(4"@4"@4"@C1K1_
MR=:L?Y:,[?X6RJBQXP^276'<H%`H%`H%`H%!];31=_DZTG?RT8)_PMBM;<)\
M927HA0*!0*!0<>V2I%-G7,^HE0LR;E_?)]4.J%I2$I<PY0;T2%I8=0F2F1D:
MFYN;Y<E0-S8T,[>0E3)R"RR2$Y(``#8(;6KT\.'">,3/'5RY\^4<IB)T6ERA
M*NTO,O?;ESKK6OKX=K/V<^XY0E7:7F7OMRYUUI]?#M/LY]QRA*NTO,O?;ESK
MK3Z^':?9S[E'=&Y8^*&16]R_)SPJC+Q:0QM2Z9:R>X*(^_A;7)E"^,ARN7'&
M-+P%G>EB2RDBY9UDRLXK?;PT81/KX=I]G/N5CE"5=I>9>^W+G76GU\.T^SGW
M'*$J[2\R]]N7.NM/KX=I]G/N.4)5VEYE[[<N==:?7P[3[.?<<H2KM+S+WVY<
MZZT^OAVGV<^YO[\)EY?GC3/)K/\`(Y-)C6K-V06IO62N2/LJ<DK84CC2HEO+
M=9$X.;EQ(A0L-&`NYMP`N8+>VMNUY^<1'/E$>#M$S/'C,^+9W6%*!0?_U>D3
MQ9(MD/.KA!<483U3L.,9#C&"Y)S)D?#<<U3-&GS(L\"P/6)WB'%20]&Z)I(A
MQVYP=KF;9=R4V):FMX=FYQ4#N4DOO9+7'3682U\+DMZ*T*X.!(94BF;MO\H"
M4/R+."34D*Y(\R9#&A9G;.#:ZO3-D*31=`(IL=E3>HNV$NB-0G1`*2DDE`L)
MR\93_HA0*!0*!0*#`NJI:R-VE_4@X29F'(XV@P+F!;((\6O4-9CZR)<>R(]U
M9BW-((*IN&Z(`&$6/*O8PFX]^&^[:U"'S\_G(\$G]'&9_P"^G/\`[\K.F':N
M?<?.1X)/Z.,S_P!].?\`WY33!7/N/G(\$G]'&9_[Z<_^_*:8*Y]Q\Y'@D_HX
MS/\`WTY_]^4TP5S[CYR/!)_1QF?^^G/_`+\II@KGW'SD>"3^CC,_]].?_?E-
M,%<^X^<CP2?T<9G_`+Z<_P#ORFF"N?<?.1X)/Z.,S_WTY_\`?E-,%<^X^<CP
M2?T<9G_OIS_[\II@KGW/H&:55K(XZ7]-[A&68<<C:_`N'UL?CQB]0Z&,3(JQ
M['3VIF,<U8A*G$;6@&61<\V]S#K@WXK[M[UIQEGJ@4"@4"@4'''.?[W]1W\V
M.K?^IC*U>O\`S_IQ</\`3^\_GDH-=&"@4"@4"@4"@WW>$5_EIFW_`*^Y%_\`
M*XC7C_T_OR>GC_7C_#:96%*!0?_6WEZO?"?U0YRS[F3(,/:/#QF4,R-J'QGG
M]M?M16.\NR#-ER,?8LQ]CJV%Y'*HFI3(C\'.)<.4`4,)`O\`Q:9P/L(\NQMB
MB93<<HBO%NLTLP.?8QP-`()DZ,Z?H;-H\3($SM&=+,0>H%@9I3J98_+V0B`1
M*0'*'9F)&P*TIC@$T=PF.PU1A=K%C!:U9GQ2!HC69D_4UEQ'G[*6-&%6UQ5K
MC=W;&6*['.^.4Z-_RHYZ8%>=VR=Y43R$3].TV)64XX:.ZME;D8&U8SFJ%HW%
M":K`W%KP2BTKS9TG.,%*Q^DLRET@89K,8;('R9*L6.HU#Y%78QH="HY(L-1"
M#0.219,L($6F4DMQ"THP)J9<`E:G4)R1+/;J<^DA)NQMS2XC$(?&`NKTL9@E
M!M8/!W)$D8'VYXAWO??6%8O>[EMR]]W[&B:^2C<=GW-J(=.'K^'M73*:XC\]
M#CL^YM1#IP]?P]IIDUQ'YZ''9]S:B'3AZ_A[33)KB/ST1LUEK)P+2!JL"HCL
M4*3WTVYSL>:3,W<\XLF^,)18T91`X&F`<8`&[<(+F%V%?[+B#^VS3*Q=QH^3
MM7-Z"@4"@4"@4"@4'UB=&BR<!T@:4PIX[%#4]M-N#+$&G3-W(.,)MC"+V*&:
M0"!J0$F#!N7$"QAE@W^RPA?MOTTR\\W<Z))\=GW-J(=.'K^'M-,IKB/ST..S
M[FU$.G#U_#VFF37$?GH<=GW-J(=.'K^'M-,FN(_/0X[/N;40Z</7\/::9-<1
M^>AQV?<VHATX>OX>TTR:XC\]#CL^YM1#IP]?P]IIDUQ'YZ.2.6L$F/RIJ#4'
M1]Q":?JGU7GF!1I'!:CL,[4EE,P7%%@D"42M+NB_Z9MRB[F`W!;T.[N6]7^=
M=''5QY_VG\\E*V;D7X"]>RUWD*W<98-FY%^`O7LM=Y"EQD-FY%^`O7LM=Y"E
MQD-FY%^`O7LM=Y"EQD-FY%^`O7LM=Y"EQD-FY%^`O7LM=Y"EQD-FY%^`O7LM
M=Y"EQD-FY%^`O7LM=Y"EQD;O/"F!-FS3Q-TJ:-LXBK9XGYEKOC^[,2_=,:8B
M+]Y`7#W8(2KVO:X!\-??V^W<M7E_TKKY:O1QOIXZ>39KQV?<VHATX>OX>UC3
M*ZXC\]#CL^YM1#IP]?P]IIDUQ'YZ/:2IEHD2PQ0R1TIQ`(CB"4F4.1Z)2$1E
MK*;K%XX@G/0B**W;@L!,HX07V7N"W[U-#7#_U^C[QK\391RCC/'"K'6080@2
M8_:\K3F3XIF^HH6G-!(T["G@;DBS4)]$H3M<J;L`EHE/'FQV$!FXO)>'/'8X
MI,`R2UQF$]=`::1EZ2\5.<LR+%<J/LO-R!D=3+X-.3\EPSBV3\H37(K7%(M/
M5-@'2IAQXTR@B/)5=P@L,EK#N!#:U@VJ3XIBT105\5C#JN,='2.,+DYG,ZB/
M&N*]G;UBXU@5G!4*V,Q6H3F*!LZI0&QAB:XKDC':PKAO?[:"H-C6V,K>C:69
MN0M+4W)RTC>V-B1.@;T*4D-@$ID:)*64F2IR@6W`@`$(0V^RUJ#W4"@4"@C5
MK/"(>CS5>``1#&/35G4(0AM<0A"%BZ4V"$(;;M[BO>_V6HL>,/DDUAW*!0*!
M0*!0*!0?6TT7?Y.M)W\M&"?\+8K6W"?&4EZ(4"@4"@4',Z^:[]5D:R#FZ,,F
M5.),<6U(ZFHLPH=A\<*>(L4;U!9*8V5#QE7#SUBKB36@**X4XPPXS>;XP8AW
MN*_IX?Y\)XQ,QJY<^7*.4Q$Z/+]0G5_VN_V!QAU*K7U<.UGKY9/J$ZO^UW^P
M.,.I5/JX=IU\LGU"=7_:[_8'&'4JGU<.TZ^63ZA.K_M=_L#C#J53ZN':=?+)
M]0G5_P!KO]@<8=2J?5P[3KY9/J$ZO^UW^P.,.I5/JX=IU\LGU"=7_:[_`&!Q
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M,]&F9R2B&E(:6WC`$Y*;:U9GQ3<HA0*!0*!0*!0*!0*!00$7?\I$8_D$G?\`
M41CJB^7JGW1"@4"@4"@4"@4"@4'''.?[W]1W\V.K?^IC*U>O_/\`IQ</]/[S
M^>2@UT8*!0*!0*!0*#?=X17^6F;?^ON1?_*XC7C_`-/[\GIX_P!>/\-IE84H
M%!__T>BWQ*Y=BK.6H?!&DZ&H/#%S+J*:$TW4J<5:[3\F*I%&A3!L@KU'&_&Q
MF.X;*&ML?)DSLYBI>W.:A&O6ID[:8C)/`(5[26HN(F=:;#M!NGF2:5-*.*L$
M2\['IDEANW*YW(Q.R+(_C=J4SC)$PR#:/PUO<RRG<UCC14J"WE+%P;+W'BUU
M:K_Q!QE5)FYM+VB-;F;]:\TQAD#,;:DA12#'^(RG*$()0^QE<[M$_P`VGZ?2
ML_M$=5RILFS.MQM$6J-.R(Q6Y7CLB2J;)UQ)BEM4`1A6%B/!+#"<YFDI59>B
M60#XPY2G#V4$V/%TCAS"ZQ1@DY+KBC%N6D#HDBSU*9NXL!J-!E`MN.*&[KK'
M'(1*`B+"=8@H2RZZN*QN"2)(P.S[<T0[#`U',1(DU@6#<(CKOCTS`$$S?7L'
M@[F7^R^[:WV;KU3T4;:5Z[/9?Z;`>O%6MTN>V3:5Z[/9?Z;`>O%*W+GMDVE>
MNSV7^FP'KQ2MRY[9-I7KL]E_IL!Z\4K<N>V3:5Z[/9?Z;`>O%*W+GMDVE>NS
MV7^FP'KQ2MRY[9-I7KL]E_IL!Z\4K<N>V3:5Z[/9?Z;`>O%*W+GME`M:_NWU
M/XRHV'E%C;:"YR39#QN%\:$7?4)CP=U5AVE_$N`"(-@7M<ZQN^O;<!<.Z*TK
M7Q6_CX>:>FTKUV>R_P!-@/7BK6Z7/;)M*]=GLO\`38#UXI6Y<]LFTKUV>R_T
MV`]>*5N7/;)M*]=GLO\`38#UXI6Y<]LFTKUV>R_TV`]>*5N7/;)M*]=GLO\`
M38#UXI6Y<]LFTKUV>R_TV`]>*5N7/;)M*]=GLO\`38#UXI6Y<]LFTKUV>R_T
MV`]>*5N7/;)M*]=GLO\`38#UXI6Y<]LFTKUV>R_TV`]>*5N7/;+D,F)HSLKZ
MASC$YR0PW57JR-,2*!)Q*$HS-2F5!C3GB2'JDHCB17WHKE&F%W%:^]$*VY>_
MJ_S_`*<7'_3^T_GDH]=&"@4"@4"@4"@WF^$X].2'3G-R$L2D+P5;/60A66MJ
MF*%)A"$U1'=+L!WDS4LWY?\`V[I5@_\`PO>O)_I_?EJ]'&?CQT\FS[:5Z[/9
M?Z;`>O%8K=;GMDVE>NSV7^FP'KQ2MRY[9>TE[<C42Q4.(2).>F$18EM.4Q(2
MUPL:98!@D9B>4'MP`I@WWX^,*"+W#;]RPQ?93U+V?__2Z3\]>%WJ/R3F#*>0
M,3Z[6##4,R-J1Q/JL105RTA0[*+_`!C+^'XOC2/1=T)R8Z96CCXXM)0\9D"Y
M/LE3(N)K%20PHTM0I$?*:CE&&U'!T4RM!\71>+YNRXBSME!KY:VGRJWXY:<3
M(Y3QV1.SBR\#C]C>I"UL'(<>5I&T7!+#N-"1W4BW@SA`#6?X98H,9/&%L/R*
M6J)X_P"+L?O<T6,BV-K)0[Q!A<7Q:PN+6K8ES2M<5B$Y2L0JF)Q4H1EF"%:Z
M)4>G_P"Y.-`,6N&%P.$XX8RXSC^)1R%QXI4K7`98NSH&-LX\O-N>N6B1MQ"<
MDQ:M.OOS316N88+[17O>@NR@4"@4"@4"@4"@@(N_Y2(Q_()._P"HC'5%\O5/
MNB%`H%`H%`H%`H%`H-9LG\*339*)=-9DHDV:VMPGLYF^0WI"SSY"F:2I%D&5
MO$TD@FU*HC*LU(B/?WU2845<T=B@#L"U]RUJW'/G$5'+1)CC.L\=5%^D5IIY
M[9][Q6OJC3[.?<=/'M@^D5IIY[9][Q6OJC3[.?<=/'M@^D5IIY[9][Q6OJC3
M[.?<=/'MA%+4MX<^&\73C1JPQ2>9N);\V:K4N(IT%=-F=::HAINGC4/DD9+:
M:.)ANW.&T^-FP?#AW1<"`PO<W#+WL^WGW+'#A-_%*WZ16FGGMGWO%:^J-/LY
M]R=/'M@^D5IIY[9][Q6OJC3[.?<=/'M@^D5IIY[9][Q6OJC3[.?<=/'M@^D5
MIIY[9][Q6OJC3[.?<=/'MA-33MIV@&F*`*,<XY4258R+)*\2Q8LECP%[>53R
M]A1EK3CEI:-`58FQ2`H(`!*#8-@_]M[WO69F9F9F=5VCP9XJ!0*#_]/OXH%`
MH%`H%`H%`H%`H%!YU:HA"E4K5(A`3(TYRI0,)9IP@$)RQ&FB"42`PXT02P7O
M8(`B$+]EK7O]E!`SZGNBKM-F7^WW4=_"2BU*'2O7MI@,\0%@RZ"73H6.4FCN
M78X42CX"Z@>*E39QS5"9.B8;I;XNLY74'L36>HL98FY%@EWM<=A7L&\6II,7
MZGNBKM-F7^WW4=_"2JE2G6TNB)\:FQZ;#1GMKNWHW1O.,3J4AAR)P3%JTAIB
M182G6)1F$&AO<LTL!@+WW!!L*U[6(J%`H%`H%`H%`H%`H%`H%!`/6U_>EX;7
M\_B#^CK6+4PU'_7\)^562@4"@4"@4"@__]3OXH%`H(:Y%U'SZ%9;F<!18XX^
MV,F-WZ3P$I4T9)(?LU31E@,AFQD%QD]IH0IQ@\/EK-`21-=WVS\(HE8H`ANG
M37-$6M&7\`Y.<,LX_!*7C9\EY)?7IB=VQA;\@LHF-P9E-DRAH>X]E.'P*>Q]
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M6++XFVJ&0IQ<`A%?='=.4;8H/[P]Z'[:46__U>_B@4"@Q*_82@$FEBV;/0)H
MKD*MK6M20X&4\I(VV,6<6%3&%KQ`8\AF2:.XXERA@7*$HGQ@2MKSP:D[<5;I
MQMQA<T"Q]%,9L&S401+DK<-Q<WA8I>'^0RQ_=WAX5F+7)WD$KEKJ^2F1NJHX
MS>W4KUB@X)("R@BL466`(7I0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M0#UM?WI>&U_/X@_HZUBU,-1_U_"?E5DH%`H%`H%`H/_6[^*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!00#UM?WI>&U_/X@_HZUBU,-1_U_"?E
M5DH%`H%`H%`H/__7[^*!0*"'N0]7C#CG)N1H([1]":@QCC);DEY/',VMJG$E
M)1QY8_B:<<8]>$"$<W%8=D2(U60Y%)4RUP+*.$`5A6HM,UXIR<;D<F;H72+K
MH9+L;32T#FT<5N3<]D('Q1#8=D-N,:WQJ'=([MR^'3YJ4V,WA)A9QQA(RPC*
MO>Y&075^9V,)(W9P3H`J!#"1<\0K6,$78-QV#N!%]H;#MN__`%JQ$SX"B[?P
MSG"W_?'Y.G3.$N,FW\,YPM_WQ^3ITS@N,FW\,YPM_P!\?DZ=,X+C)M_#.<+?
M]\?DZ=,X+C)M_#.<+?\`?'Y.G3."XR;?PSG"W_?'Y.G3."XR;?PSG"W_`'Q^
M3ITS@N,FW\,YPM_WQ^3ITS@N,FW\,YPM_P!\?DZ=,X+C)M_#.<+?]\?DZ=,X
M+C)M_#.<+?\`?'Y.G3."XR;?PSG"W_?'Y.G3."XR;?PSG"W_`'Q^3ITS@N,F
MW\,YPM_WQ^3ITS@N,FW\,YPM_P!\?DZ=,X+C)M_#.<+?]\?DZ=,X+C)M_#.<
M+?\`?'Y.G3."XR;?PSG"W_?'Y.G3."XR;?PSG"W_`'Q^3ITS@N,FW\,YPM_W
MQ^3ITS@N,FW\,YPM_P!\?DZ=,X+C)M_#.<+?]\?DZ=,X+C)M_#.<+?\`?'Y.
MG3."XRB;(_$FT.Q&0OT4D>H>(M<AC#RZ1Y^;#FV6&'-SRRKCVUT0FF)X\<G,
M,2+DPRQ"`,0+W#NAO>VY>HU4H,ZL?$)T:S;(6A%TBF=8Z^-^-]9J.?3I6A9Y
M<(J,PTO2_J@APY"Y7''07`WAD\Q;$6Z&PA<,M+MN;E[WM%B)U_A,WZH^@3_4
MK#?94RZLU4J4I8;G'$^08NRS2'3=H?8O(D07%E=T]EA)"]$,8RPGEE+$J=2`
M-QEWMN#`&_V?LJU,IX+FV_AG.%O^^/R=.F<)<9-OX9SA;_OC\G3IG!<9-OX9
MSA;_`+X_)TZ9P7&3;^&<X6_[X_)TZ9P7&3;^&<X6_P"^/R=.F<%QE[29;&U"
M)8XDO",Q"WB("L4A$+@TXE)EBB+&7WF[:YIE]RW_`,Z5*W#_T._B@4"@C]DG
M3C#LP/*]9DI_F<JC9S,_-C'C]0O8VR*0YPE,(>L=R*5Q=8Q1YKFY$I<8C(UR
M8M0K>%A2`2HTU$4F.&(=POG&F,FO&B*1@3/DCE;],Y,.8328RT]I-D4JD=H_
M'XBE<7$J/,T<CB/D^)1)K;224#>C("F0EW$`1PC33`R10*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#_T>_B@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@__TN_B@4"@P/E/4CBK#DB;
MHM-W=:D=W"#9`R,,")M4+4;3$L;1UQE#^Y/[B#>H&/CC4S+KMH%)A8W$2!78
MBPK)5`BRU;(./)M;(4712D$6E<0(<!#$E:IBE:4;P8DWI9B9Q"4RO+\@$A7%
M&6&2,*B]Q!^V]K41Z);D*`P$M"=.IQ$(44YC/+;39;)66.%N!B4)0E):$;PM
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M8TV=&>92=EFA=WPYP97U>]3#&KV<OQ0YXJ:$CI`%$@:6L4>:T+D-8>W$F$D+
M5!JD0N#-6'G"+>E,KX'PZCPC"%432K6E6<ZRR535U!&8T5"(6@>9>[GN[D@A
M$%3N;TGA\9)4'7$6CLL5FF'C.4J#SU*@XX8G5E!WCS`_A(`^L;.]`3",$F"[
MMB)R"G$;8-C1$!6$'6*$98`;"N'<W=RV[^RB*)\.<>\PX9T79/4:+<Y/ASCW
MF'#.B[)ZC0N<K$R$9@W%S,C>YC$8^00YNR=A9FV/XQ6S:42%\4I5K@6SQF&0
MB,2*729S`UMBI880@0J3"4210I,L$@@TP`U>R!IL(9-BK9-H/&X2^1MV&Y$)
M5MH8C;E!2YE=5S"^-+FU.S.@>&5\8'YL4H'!`L3D+$"Y,:G/*+.+&`(U7?\`
M#G'O,.&=%V3U&A<Y8JGTBT^8SD$2B\OC$60/,WXMLZG(@:1>6KXWD[$>'R.%
M4(VDXE)OIYG&.);\((.X6K&=?_I$'"`-5#49#TXILND8--@#S\1524:].E+T
MQY6/BAK64-`4>\AR61BPS&?(:52YD$'+N5^*$J3+$C,";N@L-:NV1YJVX<Q]
M'5,JE$.B*)E2+F-N/4$PUL6F!5R)];8VU%V3I6TT\03W9V(+$*P=P`17$+<#
M:][#5=7PYQ[S#AG1=D]1H7.5JK&W#J&;Q[':F'1$$JE,5F4T9D-H:V#)41^!
M.\$8Y,J,6A;;I$YJ-QR0T@`4,83#K'B$"PK%&7"+G*ZOASCWF'#.B[)ZC0N<
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MN01V0Q]\;5")>WKTJ9:B5D&$G%`,`(-AJO3X<X]YAPSHNR>HT+G+%609%I\Q
M@ZL[+,8Q%F]P?F-VD;841`TB\)S4R33&6/W`\9J)I.+)&5*,OL1-@"O88P*1
MF6M<!)H@C5:$QRSIG@F1/A4_XZE9TX&QN\E2-T8TDYNG+8ZL,?3Q@]]=&*4P
MC#LAB<@3,IDS:TZNZ%<HNG7+BDAE@JKW)L-<I"?#G'O,.&=%V3U&A<Y6K-6W
M#F/HZIE4HAT11,J1<QMQZ@F&MBTP*N1/K;&VHNR=*VFGB">[.Q!8A6#N`"*X
MA;@;7O8:DM;<.0A.QJ9%#HBD)D4KCD+:A%0UL5W/D$K<BFED2C"F;3!$%*5Q
MX0B-'N%EVONBO:WVT-5U?#G'O,.&=%V3U&A<Y/ASCWF'#.B[)ZC0N<GPYQ[S
M#AG1=D]1H7.3X<X]YAPSHNR>HT+G+__4[^*!0*!0*!0*!083S)CZ7RU3C:6X
M]=X\V3?%4T72UH0R](Z*XK)T3Q!Y=!'F-/!K0J+7LEU"*6<;3.:<E6>D4HP`
MN2:G.4$F%A$A_P!!S])5*58?E8J/.,T*F[[F]TBS"J2'/T^O,<D9/P.^0-.L
M=U>S*?`64<L.+TVB/.4GJU3:@--OQCASA"UFP'P[':)Q9.V&2+'A4B:BLSN$
M>6*(6W3"$L60)O`(##H+DELQF[LC/%4ZM@=H59V6-9H%`3SQ`L-8I.X16.4O
M4]$!\/Z6P])CU$&91!`U0>?NLQ01MF0O5V5C:WK4UHUU#*8Q'@J+$%)TJ<W3
M<])[C+3HTYZY[+4A3)PW-)#4M*#4%IX=\S%Y1*;Y$WLH<@Z4LS:>$UU12ZYC
M>[Y0"@"BD1IR(PLVS>UV27X0!0@GWO>UP7M>U")11F_AUO\`(\EY3D\?DF)(
ME$9QC=7C)FC+3C.[,TI8XER)IXF4$:Y/%X<NB;=(FW'S1BA];";C6<H*B7S>
ME*T">W%RHMJT\Z!Y,[L/)R1XQ#&"',[*O)D*8X.\@Q_IZ79)3XV3-N0=."%.
M\MA\:R7"#X`J=2%]RT7#/TA6JT@FLL9Z98+6_/?#ME\Q<9<I0S?'L>->QY6N
MMD[?#5`YKE5#D'47A/.B1DS6YN`W%'(D:.-8P4Q`5PE'IBD)I!H4AJ&XV0`M
M?D3T$$1MRB<H`MBVV4+8]*;/$9&K2GOC_!DF%M1V7<OY08X;(S6MI4L,<GV/
M<M*XDF2MZ9N2@:[71F)P(0E)P"UE_3YF)$;1-J638HO(F-XQ`L:)&9"G`U"_
MRO&!&3$SAJ(RM#7A1((ME+-4T)R"#CY"\@(!G).-`="UQ;6J:!:['?04OD;]
M(5$A>\=N+(\Y'8Y<_P#_`/(N`'S,34FU?8HU-`(S@:<YJ6J6.L!C&.%$1CUA
M)SD9:)W5;PM"B-NW!%IH8-QD+#V/"<?%GMQC6T3'*+A%D+.DNWL\;@TIRC,I
M9`(2T-U@@);FN!0I\0,B=.0$"8@E`$L@(20@#:I.K+M$*!0*!0*!087S-CV4
MS4O'4A@CRQM,WQ-D*V18P1*D3BMBK^H40.=XV>8Y(.2%B-T;TKI%<B.%DZXC
MC`F]>%.I$E5EE#2G%13=-#S])9$T2M[R.A:7B9O#W)M0HX>R*FZTN?626I<E
MZ?=B3G->YC8BM/N0D1:IO-4A-Y3N:L//*+.6F!"+8UQGX<CQ"8K&&=PE<#7O
MT3D<CEK<Z+H>FDL0O/1XA=\?1#**?&+BW-<>22-OE2Q*^*4J@YP4&FH2;&NB
MD\LM2&4O4_2!^'M,HDD4HQ3>&HV\QSF[FVQ]D:W0ECCEIW,=%,[=&QE26*1(
M4B.\DTT2!4:%(D0I3E<A`<6E3VX4D(M+#4;I\><V[0\E2%L8^6M*NJ;3X5R@
ME5*.!>=0/PAY'D)G%KVWS9'_`(;'\9*M_P!4WC)>\_\`M%52$>)QX>K/+GG)
MTKM\/2YG-H[JF&RRI9%^,/;'DG*LL@<GP#D(3E<D2SES`!S`[B:U18[*FQ0]
M*#&\1(E*FYD6_!67G1-)W29S>1@ET)2[12.4OPY$DC3JDGTY3RO/6/\`,;.Q
M93>@NIR1^:<-,4..C46#P1PR6\\C@A("RE"=8+(5HFE$7>VES/ET*")CE.(W
M5Q<X_&G5GD&83\;Y`535QR=FM68ZK4DCS$_I%%D=UI)00!/,6J+F\`L(0-M2
MVQBB%`H%!__5[^*!0*!0*!0*#6CJT@><\9:FL)ZXL!8L6YX%#<6Y$T]YZPQ'
M'F.L.1))B2:R.)3Z/R_&2J6.#-''238^FL0N8<UJEA)KDC7C*2C+,N,0HU'A
M,2?45FWZ9GB7=U>GO\SU/0K]H/J*S;],SQ+NZO3W^9ZGH5^T'U%9M^F9XEW=
M7I[_`#/4]"OV@^HK-OTS/$N[J]/?YGJ>A7[0?45FWZ9GB7=U>GO\SU/0K]H/
MJ*S;],SQ+NZO3W^9ZGH5^T'U%9M^F9XEW=7I[_,]3T*_:#ZBLV_3,\2[NKT]
M_F>IZ%?M!]16;?IF>)=W5Z>_S/4]"OV@^HK-OTS/$N[J]/?YGJ>A7[0?45FW
MZ9GB7=U>GO\`,]3T*_:#ZBLV_3,\2[NKT]_F>IZ%?M!]16;?IF>)=W5Z>_S/
M4]"OVA27OQ/B84VJ9/E#0/XBN+L?,X!+)=D>2X1QN_QB$,1`!&N$FDR#&F;I
M[-`L#2G`(U6<B:5HR"0W&(&]#>]EG3O#)^5O$8P%`%&*V/'K9DO5-/LTP<C*
M>.L9Z6HHBR?,7;$ZD91!&4W0Q:_1B)Q*`'K3@IB7!X=$!:I589)%C3"C0EU*
ME8WU%9M^F9XEW=7I[_,]4]%K]H/J*S;],SQ+NZO3W^9ZGH5^T'U%9M^F9XEW
M=7I[_,]3T*_:#ZBLV_3,\2[NKT]_F>IZ%?M!]16;?IF>)=W5Z>_S/4]"OV@^
MHK-OTS/$N[J]/?YGJ>A7[0?45FWZ9GB7=U>GO\SU/0K]H/J*S;],SQ+NZO3W
M^9ZGH5^T'U%9M^F9XEW=7I[_`#/4]"OV@^HK-OTS/$N[J]/?YGJ>A7[0?45F
MWZ9GB7=U>GO\SU/0K]H/J*S;],SQ+NZO3W^9ZGH5^T'U%9M^F9XEW=7I[_,]
M3T*_:&`=2V3=2VO_`!2^:1,8:*]36GF/9O&BAF9\\:F$N)H+'<:8?5KTBF<K
M8>Q0O*V2'_(,YD#`D4M3>WA(3)B5*TL]2;Q<)FX(J-;;H4"%(UH438@)"F0M
MR1,A1)PB&()"1(2!.F)"(P0S!!*)+L&UQ7O>^Y]M[WJLO70?_];OXH%`H%`H
M%`H%`H%`H%`H%`H%`H%`H%`H/Y$$(PB`,(1@&&X1!%:P@B"*VX((@WW;""*U
M]R]K_MH-:OAY^'K'M#3QJJ=T6S:PW-N?Y7+,<V8[KS/A_I\X7E;&V'2P."!"
M6TI(;(I`_GA2(;"1!"N+_?,,"(=1J9NFRRJR4"@4"@4"@4"@4"@4"@4"@4'_
MU^_B@4"@4"@4"@4"@4"@4"@4"@4"@4"@4%FMF1L>O4H<80SSN&NTT9TQJUVB
M#9*&1?*&M&G7&MAZMQ8$JXUV1)B7(@:<9AI(0!/`(N]]_:]J"R<LY[@&%S6T
MJ:#D&]6L$JF;BH8HZYOJ:+P&"FQ\F;3V4'MY)@&F+18<I;[JC+[]1O%%QE$F
M%DGB*%/YD>?,?Q7(B+&SL*0V=5!L51+GQ)&W9;#X^]3U6YH(''9!)4Y`T#<_
M3):SG$HD^Z*]CAI2SKDC7MX50I8:K5SCE!"Y?.7.,94;6K'$T.A634:R`N(7
MC'2A/&8S-C7R4H"3CM['K0R9M;EPJ,:Q1<E98K@>-%*$Y):2FHA0*!0*!0*!
M0*!0*!0*!0*#_]#OXH%`H%`H%`H%`H%`H%`H%`H%`H%`H%!IT=H1A!>=D5;J
M"S7"&;&:C4SJE&UQQ-!6Z[NWS->P29-,KSN92!O?657#V?')`SQHW9BLVV=C
MD`C'!69R(F*C6*A;,;QKH9%"<H$X"U'1M%![83SLGU!JHCCZ*R1,JP2Z->/O
MBFH0CQ/$8.V,,]CS2U).259B9X66)<U7_P"-7[TCB@U\X2MEL&C0L@3!SD^=
M2RV\&8-/1V4HN5BYUM97F`C(;(LTKIT+\C<3BFM")T?(:B>2RREI+C=E1G#4
MM`3W&RBIZ,(/D#P4HPAE="MU!Z?DD(>LT.8I<_0S!H"HA&\K'PIH:DR+22R-
MN0GDIFU.HER$]R(<&51,'HR;+%5@-W'@A1$Q=;\&W.JR4"@4"@4"@4"@4"@4
&"@4"@__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g893535g40n54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g893535g40n54.jpg
M_]C_X``02D9)1@`!`0$#P`/```#_[1ZL4&AO=&]S:&]P(#,N,``X0DE-!`0`
M`````%4<`5H``QLE1QP"```"```<`E``"')R,3<V,S8R'`(%`#1-:6-R;W-O
M9G0@5V]R9"`M($E414L@+2!&=6QL(#$P+4L@,#,@,C8@,34@-R!032YD;V-X
M`#A"24T$)0``````$`1:DP@(_"\\`L5B)M&)AAPX0DE-!#H``````.4````0
M`````0``````"W!R:6YT3W5T<'5T````!0````!0<W138F]O;`$`````26YT
M965N=6T`````26YT90````!#;')M````#W!R:6YT4VEX=&5E;D)I=&)O;VP`
M````"W!R:6YT97).86UE5$585`````$```````]P<FEN=%!R;V]F4V5T=7!/
M8FIC````#`!0`'(`;P!O`&8`(`!3`&4`=`!U`'````````IP<F]O9E-E='5P
M`````0````!";'1N96YU;0````QB=6EL=&EN4')O;V8````)<')O;V9#35E+
M`#A"24T$.P`````"+0```!`````!```````2<')I;G1/=71P=71/<'1I;VYS
M````%P````!#<'1N8F]O;```````0VQB<F)O;VP``````%)G<TUB;V]L````
M``!#<FY#8F]O;```````0VYT0V)O;VP``````$QB;'-B;V]L``````!.9W1V
M8F]O;```````16UL1&)O;VP``````$EN=')B;V]L``````!"8VMG3V)J8P``
M``$```````!21T)#`````P````!29"`@9&]U8D!OX````````````$=R;B!D
M;W5B0&_@````````````0FP@(&1O=6)`;^````````````!"<F1456YT1B-2
M;'0```````````````!";&0@56YT1B-2;'0```````````````!2<VQT56YT
M1B-0>&Q`6`````````````IV96-T;W)$871A8F]O;`$`````4&=0<V5N=6T`
M````4&=0<P````!09U!#`````$QE9G15;G1&(U)L=````````````````%1O
M<"!5;G1&(U)L=````````````````%-C;"!5;G1&(U!R8T!9````````````
M$&-R;W!7:&5N4')I;G1I;F=B;V]L``````YC<F]P4F5C=$)O='1O;6QO;F<`
M````````#&-R;W!296-T3&5F=&QO;F<`````````#6-R;W!296-T4FEG:'1L
M;VYG``````````MC<F]P4F5C=%1O<&QO;F<``````#A"24T#[0``````$`/`
M`````0`!`\`````!``$X0DE-!"8```````X`````````````/X```#A"24T$
M#0``````!````'@X0DE-!!D```````0````>.$))30/S```````)````````
M```!`#A"24TG$```````"@`!``````````$X0DE-`_0``````!(`-0````$`
M+0````8```````$X0DE-`_<``````!P``/__________________________
M__\#Z```.$))300(```````0`````0```D````)``````#A"24T$'@``````
M!``````X0DE-!!H``````S4````&``````````````%````!T0`````````!
M``````````````````````````$``````````````=$```%`````````````
M``````````$`````````````````````````$`````$```````!N=6QL````
M`@````9B;W5N9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L;VYG
M``````````!,969T;&]N9P``````````0G1O;6QO;F<```%``````%)G:'1L
M;VYG```!T0````9S;&EC97-6;$QS`````4]B:F,````!```````%<VQI8V4`
M```2````!W-L:6-E241L;VYG``````````=G<F]U<$E$;&]N9P`````````&
M;W)I9VEN96YU;0````Q%4VQI8V5/<FEG:6X````-875T;T=E;F5R871E9```
M``!4>7!E96YU;0````I%4VQI8V54>7!E`````$EM9R`````&8F]U;F1S3V)J
M8P````$```````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO
M;F<``````````$)T;VUL;VYG```!0`````!29VAT;&]N9P```=$````#=7)L
M5$585`````$```````!N=6QL5$585`````$```````!-<V=E5$585`````$`
M``````9A;'1486=415A4`````0``````#F-E;&Q497AT27-(5$U,8F]O;`$`
M```(8V5L;%1E>'1415A4`````0``````"6AO<GI!;&EG;F5N=6T````/15-L
M:6-E2&]R>D%L:6=N````!V1E9F%U;'0````)=F5R=$%L:6=N96YU;0````]%
M4VQI8V5697)T06QI9VX````'9&5F875L=`````MB9T-O;&]R5'EP965N=6T`
M```115-L:6-E0D=#;VQO<E1Y<&4`````3F]N90````ET;W!/=71S971L;VYG
M``````````IL969T3W5T<V5T;&]N9P`````````,8F]T=&]M3W5T<V5T;&]N
M9P`````````+<FEG:'1/=71S971L;VYG```````X0DE-!"@```````P````"
M/_`````````X0DE-!!$```````$!`#A"24T$%```````!`````(X0DE-!`P`
M````%+(````!````H````&X```'@``#.0```%)8`&``!_]C_[0`,061O8F5?
M0TT``?_N``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/
M%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!
M#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`&X`H`,!(@`"$0$#$0'_W0`$``K_
MQ`$_```!!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!````
M``````$``@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%1
M81,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"
MHW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W
M1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%
M,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55
M-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=W
MAY>GM\?_V@`,`P$``A$#$0`_`.JS:;ZLM]6/:VBFL5LKI;>VH,:VNMH8VCU*
M_2:W]S8@1F_]RA_[%-_]+(O4:V'+?=:\4ML<YK7/<UK?T&S&L/J/(:S])LV>
MI_I%6-F**8.92*FN,@VU:$.VEWT]^S=_A/YO9^E_FDE-EAR!7#K`]XDFS[8!
MH=![6W>:&[[87.+<@-:22&_:VF!.C9]7\U0:S%AP&709]I_3TZ$$/_TG\A1:
M[%9?6QN72+7@NK_2UD$`OJ>YK]WI^RRJVIW_``B2DD9O_<H?^Q3?_2RD]N;N
MTR0/:W_M4W]UO_#(-@Q`=S\NDEQY%M1UD-UV/]GO=^<I%F(\APR\>"!'Z>G4
M`!F[^<_DI*91F_\`<H?^Q3?_`$LC,=<&`.>+'-,O?]M`D$\>VWVJ3>DYME+-
M@WTD!S"UU9!!U:YKM_NW;DXZ+F@.'IGW`#Z5?8AW[Z2FN1F22,D`3H/M3=!_
MVZF+<V#^M#_V*;_Z65EG1L]CMS&$.'!W5]_[28]#SG$DL,NY]U?)_MI*16#-
M]1T9('&GVIH[#_A5",W_`+E#_P!BF_\`I97:.A_:Z_7]<U;G.:6%@<06.-+O
M>VS:[W5HQ^KKRP,.7[6\#TO_`%)YI*:3'7AC9>U[FQO><P:Z_NB[V_N(,9O_
M`'*'_L4W_P!++2'U<AKF_:OI1_@_#_KB=GU>?6[<S+AT$3Z7C_UQ)3F%N;!_
M6A_[%-_]+*=@S?4=&2`)X^U-'_HU7C]6R9G+U//Z/Q_ZXG?]7-SR[[5$F8]/
M_P!2)*<V,W_N4/\`V*;_`.ED=C[0UNYP?MC>[[:!N_S;?9PKA^KSW-:PYDM;
M]$>EQ_X(F'U;]I'VKD@SZ?AN_P"$_E)*<V,T#7*'_L4W_P!+)GMSMCOUH<'_
M`+5-_P#2RU&?5Y];MS,N'<3Z4_EL4'?5DEI'VOF?\%X_]=24_P#_T/0*31Z3
MVVU>L779`V!@>=GJ.]5VUW^#_?\`W_\`A'J%V9T6JTU65-+AMVEM&\.]7Z'I
MO8QS7;_6_P#!+/\`A%2?U%^-=D"INQ[+;6OM]1@W-+W6[?2M_/K]7]!9^_\`
MZ7^:0K;[7.(J=?C@00VG+IVDC:7;/5#]SK7-W6O>W?8^VW](DIOOZCT0$.=2
M362X&[[,XL'I@27O]/VM_2>G6[\_])L1:<SI&58VJIK;'%WIB:2`'!IR(_2,
M;^9[MW[_`/+62,G+>][J\K,#+G.L-7VC%+1O,MI8ZVGUJF5_1K8RW_OZ+C];
MR,9MEMILRZ7[=HLLIW,(EKF_H&5NLWN/^C24[GV;&U_0UZ\^QO\`<H/Z?@/#
M0_&J(8"UOL:(#@YCFM@>WV6V-_MK)/UKK`)^RNT_X1O_`)%;=-HNIKN`VBQC
M7QS&X!T)*9````"`-``G23$!S7-)@$03,0#IRDI=(?2'Q7/,QLBF*Z,//;74
M8#*\UI;#';][6NN-[JK/\+O9ZWJ?H?0V?I%MX58KQZ@&/KW?I#7:9>TV'UGU
MOVES/8ZS9[/T;/\`!I*1=,_HG_7K_P#S]:K8Y"J=,_HG_7K_`/S]:K;>1\4E
M.>VK(=T^J^HVY&0]M;BPWFH'?M]5VZ'-;L:YS]FS_@T'U,\L#Z\/*?N!+?UN
MO:=)9[A:[V/0NIU8IZ-AVY`QAL8QC;<NDWM9ZE>WV5,V_G-9NW_H]BHE_33D
M5-N=TFQUCF5.;Z#P^"=OZ,%UGT?W/YO_`(3V)*=(W9@L]/[+D%Q+?:,NO<`Y
MK'/WL=8WW5V.LK]GJ;_3_EJ8_:4O#L6V03Z8;F27-#]FXR&[-S/TO_?_`-S'
M8.GEC'?Y+-C',K:T8=FCFZ0P3ZWMOJ8]C_\`@U-QZ>Q]5K?V4VQSK'AS\>QK
MM];BZ:VR'N]-H_3N_?\`TJ2G1JR,MSZA92^NMQ/K6?;6N]-H+&MLVC^<W/>_
M_MM7F-]/*J#+7OKLKL<0YY>#!IV.;/\`77/V.P!O:Y_2B+&1M?CV'<US][>;
M/TK+'C\W_#KH6UMJR,:IH#6UTVM#6\"/0$-_DI*;*2222G__T?0<7$Q+6VV6
MT56/-]P+GL:XP+'1[G!&_9W3O^XE'_;;/_(IL'^:L_\`#%__`)\<K*2G/SZN
MGXE3;/L-%A>\5@%M;!+@3N=8]NW\U4?MV)/_`"5C@CN;,?\`N6W;33<S9=6V
MUG.U[0X2.^UR%^SNG?\`<2C_`+:9_P"124Y7V[%V[CTJ@-F"[?00..=N[]Y%
M_;KF-`;B-%8AK2V^K;!AK=K1[MFO[BT/V=T__N)1_P!ML_\`(I?L_I__`'%H
M_P"VV?\`D4E.79]9VUO+'8IW")VVM<-1N^DUJ!E]?PLW&LQ,K"-M%PVV,-@$
MB=W+-KNRW/L&`.,6G_MMG_D4OL&!_P!Q:?\`MMG_`)%)3C44=,S:+NI?8:V5
M%UC,@BQQN<'DNO=NK<S;[['/]#Z=N_\`0_X+UMK$P\?$W-QVEHL>'N!<YVH:
MRK\\NV^RMO\`YVF;@83+!970RMX@^P;02/H.>QFUECJ_\$Y_\U_@T<<CXI*:
MG3/Z)_UZ_P#\_6JV--55Z9_1/^O7_P#GZU5+.N.998UN,'BNQ]<^O6T^QQ9N
M].S:YN[:DINUXCJZVUUY-S6,`:ULL,`:-'NJ3_9[#!.3<2.#^CT^'Z%4/V[;
M(`Q`XF``,BKD_F\IOV[9J/LHW#\S[15NB`=W[NWW?O)*='T+?^Y-W_@?_I%(
MX]DS]IMD<']'/_GE9C_K"6,<]^*`&$-</6872Z(VAH=N^DA?\ZZ_^XKO^W&_
M^124['V>R(^TW1X?HX_\\I,Q]MHM?;9:YK7-;OVP`[:7?S;*_P#1M6/_`,ZZ
M_P#N*[_MQO\`Y%6^F=;9U#(=CMI-9:PV;BX.X+6;8`'[Z2G322224__2]&P?
MYJS_`,,7_P#GQRLJKTUS7XSG-<'M==<6O$$.!L=[O;[?<K22E))))*4DDDDI
M22222E)#D?%)(<CXI*:O3/Z)_P!>O_\`/UJR[^I88ON!P<)[FVV,<;+:VV$L
M<YGJ6,LJ_P`)'[ZT^F?T3_KU_P#Y^M1S1022:F$G4DM$G\$E.%^TL,D`=/P'
M%T#2^KD_FZTIOVGASM_9V#/@;J@.`1_@OSMRWOL^/_HJ_P#,;_<E]GQ_]%7_
M`)C?[DE.#^U,,3_D[!!;((-U0(+20YONI\E+]IXA^C@8!G@>O7,?`TJU;U&A
ME]M+<.IPI?Z9<Y]3),-,['M]K?>ALZM2]@>,"N"8AUE((_K-<$E-(?6#`(G]
MF8_^<W_TBIU?6/&K=NIZ?2QY$2QX:8YCVTJT.JL=JSIS'#3464=^QW;4#.S<
M?)P[*;L#94\!SG575->`TBP;75?I/S?S$E-SI?7/VCE'&]`5$5NLW"S>?:6M
MV[=C/WUJKG,2FK,P[<D>O7B5'98/M)]1P;'J;?2V>FRO_1V?TC_MFVVQ9A&U
MMKL?+S6,I#G7NLO?6\AXW[:F7BOT_2;MMKLM_0_]I_S[K*4I_]/T;`(]&R=/
MT]^A_P",<K$CQ"Y^[,QZ<BYIZM]AM;:]KJ36+&C]):_?M>W^<M]2O_MM"/5<
M!K@7?61H>TN+IK8![MOL]'Z'MV_N_P#HSU4IZ61XA*1XA<X>L8.R#]8JA;J-
M_I-`&HT]'^:W_F>]K_\`K?Z3U(-ZIC0YS?K*QPUU-%;FC1H[-V^WZ:2GII'B
M$I'B%S=?5,%P<QWUB;<QS7,(;6UKY>';+!=2/48^O_![$W[6PB][V?62O:1H
MWTJW!H'YWT?/^<24]+(\0E(\0N:9U?":&M'UEK=`B74UDDCSCZ2,WK&`*@T]
M=J?8/SS4T`^]MFK*O3_P;?1^FDIWY'B$X(D:CE<T.J4-;_XI*WN`TW45ZG4^
M[:W_`*E$KZOA,LK?;]8*[&,(=8STJV;H^DW>UNYC'I*=;IA'V3G_``U__GZU
M6I'B%1Z86NP@YIEKK+G-([@VV.:Y%=D-:7':336=MM_YK#Y_O-9_A[&_S'Y_
M^']!*;,CQ"4CQ"JY>9BX58MR[6TUN<&!SIU<07;?;N_-:Y5#]8NA-$NSJ@!R
M3N`\/W4E-Y^%@6/-EF/2][M7/<QA)/\`*<0F/3^F3_1<?_MMG_D52'UCZ"1+
M<^DCQ!)&G]E)OUCZ"[Z.?2[OH2=/'1J2F[^S^F=\3'/_`%MG_D5G.Z1E[CL'
M3@TM?#G8TD.+7>C[6EGLJM+/4]WZ9G^@1!]8^@GC/I^\_P#D4_\`SBZ%_P!S
MZ?O/_D4E(ZNF]08[>#A5O]IFJMS`7->UVZQK2&6MKI]3[/ZC-]%O^%4LK$ZY
M=9ZC;L*0T;-]=AAP8?I[;&MNKKRG-R*FO9_@O]);ZM,O^<70O^Y]/WG_`,BG
MIZYTC)R&XM&4RRZP$L#9@D?F;S_A?^#24__4[)W1*\U^3<[+R:6W77,?346>
MF0'.J=[;*K'?I&?SGN4A]7@..I9OCJ:3K.[7=CG\Y6J,O%J%U=EK6/;;>\AQ
M`AOJ.]_N/T$9N;B.>YC;6E[`"YH(D`B6EPG\Y)3GN^KK7M+7]1S'-(@@FGCP
M_HZ1^KP)D]2S9UF'4B9^EN#:`URT'YN+6TOLM:QN@W.(`DF&ZD_G*0R:#$.F
M>.._S24YA^KC'.#SU#,+APZ:0?\`HXZ?_F\`[=^TLS=!UFG\[:YT_J_N]S&?
M25^O/P[9]*YMFV`[:08GZ/=2=EXS6E[K`UH$EQ(``'F2DISG?5YCV%C\_*<Q
MS2QS3Z&H=(=/ZO\`3]WTU6_YE=+_`.Y&3]]?_I);#L[#:X,?:UKG-<]K20"6
MMCU'B3]%FYN],_J&#6T.LO8QK_HES@`?@924Y'_,KIG_`'(R?\ZO_P!))?\`
M,GI9T^T9.NGTJ_\`TDMO[13^]^3^]!/5^ELLV/RJFO!(+2]H(+?I#;N_-24U
M,3+LQ,445X>1DMKW[+*@TAQ%M]?INES-KF^DS?\`\:BV9%_JNVX.4ZCU"VT#
M8&NVE@]?TB_>^MV_Z+/Z1Z3_`%*_])79T_IF90793'.>YUU9<USV$L-E[=FZ
MMS=OLOL^@B.Z3TAUEEGZPUUSB^W9?<QKG&)+ZZ[&UNX_=_ZM)2LK_*S*J7T9
MV'MM8\7!K:W-+F9#'>YWK^QK/9=_Q]*@/JXT.<\=1S0Y\%YW5>XB-NYOH;7;
M-OL5O%HP\6RQ]3[CZC6LV6/?8P;2YVZMMA=L<_?[U8^T5>)^Y)3F?\VZ]Q?^
MT,P.,20:A,1$[:/Y*3OJXQPVGJ.80#($TCB?#'_E.6GZ]7B?N2.15/)^Y)3D
MW_5;'R&M9D9V7:VLDL#C5H3S]&AJ%_S*Z9'](R?\ZO\`])+;^T5>)^Y+[15X
MG[DE.)_S*Z9_W(R?\ZO_`-))ZOJ;TRO(9:^RW(JK]WH6[8<\&:W.=6VO]&S_
M`$?Y[UM?:*O$_<D<BJ#J?N24_P#_U>RMZ=@9;WNR\:N]S+[MIL;N_.L9_P!3
M8]1?T7HU@:+,#'>&-]-DUM.UD1Z;?^#V_F*QMR!9<*S0]GK6D%S[&F2\[FEH
MH=]%+]<\,?\`[<M_]YTE-2WH_0ZIR'=.I>_<V-E0>[<=M3?39^;_`&%59C_5
MO8*V=)`K+A#!B';O<',T;'T_3]17L[?]DL^UMH]#V[]ME\_2;M_FL?U/I+/_
M`%#26GOM_29WA[MOZM^ZDIE=3]6[FM;;TTO#(:W]6<8&GZ(.;_@W[6^I3_A/
M\(E]E^K,0.DMCVM@8>OM]U3=L;O9N_1J+?L$#8T[=-NVS.CRV[<9(_8/4=[3
MZL^[])G;I_E?JVY)2GN^JHFI^!6-KMQ8[&`A\-9NV_O[&,3-?]4V!P;A5M#V
MBMP&/])GT?3?^]7M/T%!W['W'>VO?^=NLS-W]K=C;DW^1/W:?^W,O_WF24NX
M?4Z"7=/IC62<<?$RM-F!TV[T[[>GM8+Y--EU</.[=O:YKO?1ZOJ6?H7_`,[O
ML_PGZ-9?^1.[:8[S9E_^\RU<5N0*,5S"QV.X'[&RY]\-C_CL86;G-_F/7]_H
M_P!&_1)*1T9]%%9K=7<[998V:ZG/;](NV[V?NM<U$'5<8\59)_ZP]5F5=(E_
MKW6?:=[C;Z`RBP$N/MFEK&^UO\E3-?0H;-V1$>SVYG$_FZ?O)*3?M7&T_19/
MNB/T#^YV_P#5).ZKCM=M=5D`@@:TOY,1[OH_G(!K^K^TS;D1WEN9']I(5]`V
M-VW9&S3;#<S;VV[?S?W=J2D_[5QB)%>0>.*7'G4<*#^N=/8XL=ZK7-,$&H@@
M^;4%M?U=W>RZ[=_);ESY?147U_5;>=]KMTZ[VY.[^UO&Y)2?]O=-_>L_[;*7
M[>Z;^]9_VV?[U7]/ZI_Z8_YN1_<EZ?U3C^>,_P!7(24V/V]TW]ZS_MLJ+NO]
M,#22ZSC_`$9_O0?3^J?^F/\`FY']RBZKZI;3-QB-?;D?W)*?_]DX0DE-!"$`
M`````%4````!`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'``
M```3`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``0P!3`#8````!
M`#A"24T$(@`````!1DU-`"H````(``@!$@`#`````0`!```!&@`%`````0``
M`&X!&P`%`````0```'8!*``#`````0`"```!,0`"````'@```'X!,@`"````
M%````)P!.P`"````"0```+"':0`$`````0```+P```#H``ZF````)Q``#J8`
M```G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I`#(P,34Z,#,Z,C<@
M,#DZ,S$Z-3,`<G(Q-S8S-C(```````.@`0`#`````?__``"@`@`$`````0``
M`=&@`P`$`````0```4``````````!@$#``,````!``8```$:``4````!```!
M-@$;``4````!```!/@$H``,````!``(```(!``0````!```!1@("``0````!
M``````````````!(`````0```$@````!.$))30/]```````(``````````#_
MX0%(34T`*@````@`"`$2``,````!``````$:``4````!````;@$;``4````!
M````=@$H``,````!``(```$Q``(````>````?@$R``(````4````G`$[``(`
M```)````L(=I``0````!````O````.@```/``````0```\`````!061O8F4@
M4&AO=&]S:&]P($-3-B`H5VEN9&]W<RD`,C`Q-3HP,SHR-R`P.3HS,3HU,P!R
M<C$W-C,V,@```````Z`!``,````!__\``*`"``0````!```!T:`#``0````!
M```!0``````````&`0,``P````$`!@```1H`!0````$```$V`1L`!0````$`
M``$^`2@``P````$``@```@$`!`````$```%&`@(`!`````$`````````````
M`\`````!```#P`````'_X3HZ:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP
M+P`\/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.
M5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B
M('@Z>&UP=&L](EA-4"!#;W)E(#4N,2XR(CX*(#QR9&8Z4D1&('AM;&YS.G)D
M9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS
M(R(^"B`@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*("`@('AM;&YS
M.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+R(*("`@('AM;&YS
M.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(*("`@('AM;&YS
M.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(*("`@('AM
M;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(@H@
M("`@>&UL;G,Z<W1%=G0](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]297-O=7)C945V96YT(R(*("`@('AM;&YS.G!H;W1O<VAO<#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W`O,2XP+R(*("`@>&UP.D-R96%T
M941A=&4](C(P,34M,#,M,C=4,#DZ,#@Z-3<K,#4Z,S`B"B`@('AM<#I#<F5A
M=&]R5&]O;#TB4%-C<FEP=#4N9&QL(%9E<G-I;VX@-2XR+C(B"B`@('AM<#I-
M;V1I9GE$871E/2(R,#$U+3`S+3(W5#`Y.C,Q.C4S*S`U.C,P(@H@("!X;7`Z
M365T861A=&%$871E/2(R,#$U+3`S+3(W5#`Y.C,Q.C4S*S`U.C,P(@H@("!P
M9&8Z4')O9'5C97(](D%C<F]B870@1&ES=&EL;&5R(#$P+C$N.2`H5VEN9&]W
M<RDB"B`@(&1C.F9O<FUA=#TB:6UA9V4O97!S9B(*("`@>&UP34TZ1&]C=6UE
M;G1)1#TB>&UP+F1I9#HW-S<Y-#-%0C,U1#1%-#$Q0D)%1$%%1#9&-D5&-S0X
M,B(*("`@>&UP34TZ26YS=&%N8V5)1#TB>&UP+FEI9#HW-S<Y-#-%0C,U1#1%
M-#$Q0D)%1$%%1#9&-D5&-S0X,B(*("`@>&UP34TZ3W)I9VEN86Q$;V-U;65N
M=$E$/2)X;7`N9&ED.C<W-SDT,T5",S5$-$4T,3%"0D5$045$-D8V148W-#@R
M(@H@("!P:&]T;W-H;W`Z0V]L;W)-;V1E/2(Q(CX*("`@/&1C.F-R96%T;W(^
M"B`@("`\<F1F.E-E<3X*("`@("`\<F1F.FQI/G)R,3<V,S8R/"]R9&8Z;&D^
M"B`@("`\+W)D9CI397$^"B`@(#PO9&,Z8W)E871O<CX*("`@/&1C.G1I=&QE
M/@H@("`@/')D9CI!;'0^"B`@("`@/')D9CIL:2!X;6PZ;&%N9STB>"UD969A
M=6QT(CY-:6-R;W-O9G0@5V]R9"`M($E414L@+2!&=6QL(#$P+4L@,#,@,C8@
M,34@-R!032YD;V-X/"]R9&8Z;&D^"B`@("`\+W)D9CI!;'0^"B`@(#PO9&,Z
M=&ET;&4^"B`@(#QX;7!-33I(:7-T;W)Y/@H@("`@/')D9CI397$^"B`@("`@
M/')D9CIL:0H@("`@("!S=$5V=#IA8W1I;VX](F1E<FEV960B"B`@("`@('-T
M179T.G!A<F%M971E<G,](F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N
M9"YA9&]B92YP:&]T;W-H;W`@=&\@:6UA9V4O97!S9B(O/@H@("`@(#QR9&8Z
M;&D*("`@("`@<W1%=G0Z86-T:6]N/2)S879E9"(*("`@("`@<W1%=G0Z:6YS
M=&%N8V5)1#TB>&UP+FEI9#HW-S<Y-#-%0C,U1#1%-#$Q0D)%1$%%1#9&-D5&
M-S0X,B(*("`@("`@<W1%=G0Z=VAE;CTB,C`Q-2TP,RTR-U0P.3HS,3HU,RLP
M-3HS,"(*("`@("`@<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O8F4@4&AO=&]S
M:&]P($-3-B`H5VEN9&]W<RDB"B`@("`@('-T179T.F-H86YG960](B\B+SX*
M("`@(#PO<F1F.E-E<3X*("`@/"]X;7!-33I(:7-T;W)Y/@H@(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H\/WAP86-K970@96YD/2)W(C\^_]L`0P`!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!_]L`0P$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!_\``$0@!0`'1`P$1``(1
M`0,1`?_$`!X``0`!!0$!`0$````````````$!08'"`D#`@$*_\0`<Q```00"
M`0$!!@L0"PD*#`0'!0(#!`8!!P`($0D2$Q0A5Q46%Q@9,966T=76(C1!45-4
M5EAA=':2DY>SM#,U-E5Q=9&4L;78(RDR-VARI]+4)"4F0DAW>(&AMB<X0T=2
M9W.XQM/P\2A%9L%&8F6"AJ2F_\0`%`$!`````````````````````/_$`!@1
M`0$``P````````````````#P<9&A_]H`#`,!``(1`Q$`/P#^E[K$ZC-T:\WS
M9ZM3;Q+!@80ZLO11[8L#*;:=F5^!+E*P[.%2I*LN2'5N*PM]24Y<2EO&$8SC
M@:P>O#ZD/.=/]Q*M\1<!Z\/J0\YT_P!Q*M\1<!Z\/J0\YT_W$JWQ%P'KP^I#
MSG3_`'$JWQ%P'KP^I#SG3_<2K?$7`R'7-X]8-M!R3M;V'@TW$?B,/B8*]</6
M=M$XL/`Q9JJJF'BP>ACALN+%I(>A_BV91!G"5J;2XM`5R3LWK7BSRX]R^QW%
MAJ<8O;\J+/U9,'S*S7DE_1F8&GQ67HIZ0.?!&8DL>%=G3X\H60;?C)1%<6V%
MJF.H3JP!5.MW(GM!F.*MB'7@<7O*&X<E0VII4>X1<!(%**QQZ9@::QB<]%1'
MROQ?L7E,N/X0+*]>'U(><Z?[B5;XBX#UX?4AYSI_N)5OB+@/7A]2'G.G^XE6
M^(N`]>'U(><Z?[B5;XBX#UX?4AYSI_N)5OB+@7M5>J_J$G`]DRI>QISSX:E0
M20US(:LIS%FN;$H(A;Z<-A$H<RL:5(Q<I=\(A*7EN>#\*AMQ`63Z\/J0\YT_
MW$JWQ%P'KP^I#SG3_<2K?$7`>O#ZD/.=/]Q*M\1<!Z\/J0\YT_W$JWQ%P'KP
M^I#SG3_<2K?$7`JP/JIZFK`5B"8FU6HC\K+O>R32*"`%LH88=DO.2BQ@9"'1
MDI9:7EM+LA+LE_P<2(R],?CQ7`R,5V=UNA(%C)D[B_'C59^:T21C.MWY<J.+
M9#R2I0'!CQ7)=B"BXUC`RIIH(S.&LQ"L:6I_$=,EV.'R]M3K58L*ZR[>FTD(
M]8A7&=*\:UC@",K4]3#<8J1LO@,5^,RM^5'B)2HDI]Z?(C0&&WILF.PZ&*%]
M7W4BVM;>=HS5>#4IO*FPU3<;[4YRCOD.(`Y0XG/>Y4A6%92M.<*[[..W'`^/
M7A]2'G.G^XE6^(N`]>'U(><Z?[B5;XBX#UX?4AYSI_N)5OB+@/7A]2'G.G^X
ME6^(N`]>'U(><Z?[B5;XBX%[;)ZL.H,+L:_!QNQIT4:*NEJ&CXN`U86F/"@G
M9\6(PEQX*XZO#+#+;6%.K6YGO<Y<<RYG&>!9/KP^I#SG3_<2K?$7`>O#ZD/.
M=/\`<2K?$7`>O#ZD/.=/]Q*M\1<!Z\/J0\YT_P!Q*M\1<!Z\/J0\YT_W$JWQ
M%P,JCMM=9Q>#7B@K8<,B/L;LIF/,@D=62HXER"`=M<U%I=99<15EPZRQ).3$
MG\C\Q8,*?B0EJ5!FQ8P1R>Y.LP,.N)8G>U1X5$EB(EB7VZZ>>:R>S"4'ECHL
M:$]*,"B#!(?*BFA;,L4]%FQGVYJVW6\Y"#<M\]6-'@UTJ6VP,FC;2DJL)-KL
MG7=CCRVPLEF(0<4X'&RTLMMRGO%6W'<H;>D1YK3:LKB24M!8'KP^I#SG3_<2
MK?$7`>O#ZD/.=/\`<2K?$7`>O#ZD/.=/]Q*M\1<!Z\/J0\YT_P!Q*M\1<!Z\
M/J0\YT_W$JWQ%P+U9ZKNH-6NIQ=6QYV2;=W$C&Y/H-6,93">!FI;S'>>@O@E
M)4]'9=[<MX<3EO\`9?!Y6G@65Z\/J0\YT_W$JWQ%P'KP^I#SG3_<2K?$7`>O
M#ZD/.=/]Q*M\1<!Z\/J0\YT_W$JWQ%P'KP^I#SG3_<2K?$7`O*D]0W5CL$I@
M'6MGQG"[N6$0H)9_6U?>*S93Z8T$4&2<AP/18K.E+;8B0("I,EUQ6$J:2COG
M.!<;6U^M=X2#,XNKC4,_.'0(F);NLX,J&LRZ69"RCL*9&8E5T89<!&<#"QUL
M>.E)'..)D81(A+E![-[1ZVGE7=#5U>4O7QBQ5^P-JQKEEQ9FI1")&R#PK$B&
MS(L,@0*$D3$Q`5F9AL9&S(SG&7HZ'@Q)Z\/J0\YT_P!Q*M\1<!Z\/J0\YT_W
M$JWQ%P'KP^I#SG3_`'$JWQ%P'KP^I#SG3_<2K?$7`>O#ZD/.=/\`<2K?$7`O
M;6W5AU!FMC4$.2V-.E#2MTJHTA%R&K"$R(4X[`BRV%.,A6W48>8><:RII:',
M=]C+;F',9SP.Z_CLSZHK\1'^IP.$W7S_`.,U<?XHI_\`W8&<#33@.`X#@.!F
M^A;F5KNJN"J]58+-G<M%<M*[IDE/\=DOU(U%/5\20&]F8DD'$)PT3GAJ'8S4
M^:B)-F^'=&C_`!8),[>DV0:;GP*L)$B8>NK]K@17HLPG(BCH&Q6;:LX2\=GO
MRITJ=DI<RY%A+J\,H0U#@)QX!E3B@MXMM8@1U@*U>T/4T)@EAQR1+G&C1MSQ
M\9#+0H^`(\G+>&5.+);-3'B[`6*RZ4DMPO&)"8T1N-P,4<!P'`<!P,ATK/\`
MP:V[_P`W@W/^EC6'P8_DX&/.`X#@.`X%TTPZ)K=G#'35:@7`:+F>-O5LK)E1
MAQ-;;3F(S4UZ$I#^8S,S,>2['\K4QN/F'*PN,](2L,RGNHTX='VR&NOP/'+`
MJW-P#4LD3FDP`J_8`XN`J/WKD8=-CSU`6T#%R(*,!89`C"@-Y8R-0.#]JO4E
M9JH7A$H0>&IN/1:32'HS14V+>D-T29!GB"."8:<.(,YD28*6BH[$C(X@/DRX
M3S7S3$E@,`EB3Y@J2+RFV&I)4A-)R&H4=N'$;>GR52G418K6,,Q8R7'5)CL-
M]K;+26T(0A..!3N`X#@.`X&0]N_XV-G_`/.'=?\`O(2^#'\F.!CS@.`X#@.!
ML,-WRT"K],KH.B"H`ZO#K.,L,;T9+N1;PW=ZU*JMQ(&FDK:?CERPR5X*!/C3
M,Y`-1H\43'8B^,(E!;9[<14]C8Z)`D?':V$/I8;P,=R5EL`'H+@EJO0H69#K
MSTKP(P&.'//RWG'G<-.RE9\*OO<A:EXNDJZRP:\P(XD76:P&J0`/$6XN./&"
M&7''U9>=QX1Z66+RR9\H^O"?"%"DUU*$M+;0V%D<!P'`<!P,AL_XIR7_`#AA
M/^[=@X&/.`X#@.`X&4=4[#A:R/R;&]58MD*)'R8@24^4FBY%<FRVEQW#8EV*
ME:4EV8SKJ!TM]AQP8_ELC!\"09C2&`KY/=I8E41=5]`A<1R'Z4(A,XW((+(&
M0E`?,NU,1)8>DJ@1L#DFGF9LR/%;E$40!+S[C;D>:Z0"YV>IFQQHVVHT>N!4
M-[;LMZLA9.9)3P33M^A38$N`0BMR6X=D@@69CDZJLEXZTAS2GRR,.K=4RH-:
M.`X#@.`X&0]1?XV-8?\`.'2O^\@WX<_RYX']*O`YA]6.YM7T_=UD`V?IWIVP
M3$0?77'[08/$(,^<W)!P9##3L>./D-(3"9<;B-9PZK*T-H5G&,J\@:W>N-TA
M]J!KSWT%_BC@/7&Z0^U`UY[Z"_Q1P)L;?>H9B&W(G1E292'9*83:XY\Z\AR6
MMM;R(J%-A585)6RVMU#">UU3:<K2G*4+[`\'>H73##<9Y[HZH3+4QE4F(X[9
M#+:)4=,B1#4_'4H/A+[*9<63&R\TI;>),:3'RKPC*\(#Q]<;I#[4#7GOH+_%
M'`_?7&Z1^U!U[]+]U)?VOI?M1P+EE[RT:Q30-D]:3KQ:BUEM@3,/TPDDY937
MQ5+GXD^-8%9>>Q*],JV_`.(PW&Q#RXTK*I3W>A;/KC=(_:@:\]])?XHX#UQN
MD/M0->>^@O\`%'`EQ]^Z>F,RY$3HTI$J./:2_/?CV`X\Q!84KO4O2WF@JFXS
M2E8[W#C^4)5GMQA7?8SG(?4C?>H(GC7C71E2(WB4Q0Z9XP?/,>*$$>%[^#(\
M($3X"8C+#O?17N\D?W)[^YX\"YWH0O7&Z0^U`UY[Z"_Q1P'KC=(?:@:\]]!?
MXHX%XUG?^F9878;\?I3H4%H93H,Z=%:LQ1:#$5V_4@<@;)5D5C+3+4V?",)6
ME*EYDBX[/@^\=4X@+.]<;I#[4#7GOH+_`!1P'KC=(?:@:\]]!?XHX'O%ZA-,
M39#,2'T<4.7*D.I9CQHUD-/R'W5Y[&VF&&@ZW'G%YSC"$-XRI?T$^7R![8WW
MJ#+:'L=&-)RRY"<(H>P?/>"4/:E+@.STN>@G>KA-SFGH;DK&?`-RF'8ZG,NH
M6E`0O7&Z0^U`UY[Z"_Q1P'KC=(?:@:\]]!?XHX%S4[>6C;):`H)723KR(DE.
M1&5)],9*3X'OD97WWB[HI+;OM?X"U8QV9QVXSP+9]<;I'[4#7GOI+_%'`>N-
MTA]J!KSWT%_BC@?J>HO2*U80CH_UZM2LX2A*;07RI2\Y[,8QC`G.59SG.,82
MGRY^AG@59>[=6MR$Q'>B:HMRES(H]$5PQ8D25SYR<KA04,*!8=S,F([%Q8R4
M*=DIS_<4KX%(]<;I#[4#7GOH+_%'`>N-TA]J!KSWT%_BC@/7&Z0^U`UY[Z"_
MQ1P+PV%O_38V_7@=/Z4Z$9FP+A9H4PQ)LI-F05E134YB02D-H%+;:>G.M.2W
MD)6M#:G%HPOL3C@6?ZXW2'VH&O/?07^*.`]<;I#[4#7GOH+_`!1P)N-]ZA4P
MF4GHRI&8RX[TM,C!\ZJ.J+'?3&D24O8"]YF.Q(6F.\_V^#:?4EI>4KSV9#PD
M=0NF(JTM2>CFA1G%,QI*6W[(9:6J-,CM3(DC"5ATKRS*B/,RH[O9X-Z.\R^T
MI3;J%*#Q]<;I#[4#7GOH+_%'`>N-TC]J!KSWTE_BC@7.=WGHX4+I<Y/23KQ[
M-EK4LTIOTQ$F?%%,7*V5W$?OT"LKE=\BOHEY??PAU/C/BV,89CLJR%L>N-TC
M]J!KSWTE_BC@/7&Z0^U`UY[Z"_Q1P*E#WIJ<BTEZ!T64Z:RN;'&H>B&K!):4
M0EJ2B)!2XR$6A4R4M:,1XN%9>?RK&&D*RK&<!"7U"Z8;99DKZ.J$B-(4\B.^
MNRF4LOKC^#\.AEU0;"'5,^%:\*E&59;\(GO^][]/`\O7&Z0^U`UY[Z"_Q1P'
MKC=(?:@:\]]!?XHX%X-]0&FLT"<2QTI4-,%NX#(2A'IE*>+NRG0A>0V24YZ%
M]]AYAEER(EOO>][R4M??_,X[0L_UQND/M0->>^@O\4<!ZXW2'VH&O/?07^*.
M![Q^H33,M2T1>CBAR5ML/RG$1[(:>4U&BLJD2I#B6PRLH8CL-N//NKREIEI"
MG7%I0E2N![.[[U`RAQQ[HRI++3+<!UUQT^=;0TT4CIEC'7%+"X2ALC%6F3!6
MO.$2XZL.QU.(SA7`A>N-TA]J!KSWT%_BC@/7&Z0^U`UYY/:_X4%_)[?_`/2/
MNY_ESP+FKN\M&FF+.ZKI)UY'R#K4HVA/IB)O^,JCD1</$;M6*QECOL3N_P`O
MM]KB?!X;[WL6K'`MGUQND>WM]:!KSM\OE]-)?M\OM_\`Y1]'Z/T^`]<;I#[4
M#7GOH+_%'`]H_4+I>7(9BQ.CFARI+[F&F8\>R&GGWG5>1+;338=;CCBL^1*$
M)SG.<*3C"LX[<!,7O74R',M+Z+*:AU/HCWS:S=@2O&1#2Y!;M3D)C./0R.VX
M_/\`)_N-E"W'^\0G*N!3?7&Z0^U`UY[Z"_Q1P'KC=(?:@:\]]!?XHX%X:]W_
M`*;)7ZCCH'2G0@TV?<*S"AF(UE)O2!4J4:@L1R4=M8I#;KT%UUN6RA2T(<4V
MA&5]BL\#M;XY'^L&?QL_ZO`X1=?'_C-7'^**?_W8&<#33@.!ES7.P!M/B)C$
MV"4I#=]IEM:9CM1WHOBE?"W@<21EN1-C8S+E.V03X-*<8:?B17\R9$=3+")(
M6W<;1#LL*D,QH+8YZMU.2"GLQHS<6"J6[<[A8D.CVVY,A:F%0;!$;=6_X!S,
MS$Q&6?!):>="Q^`X&1"?DU/2>SR=NPMG]O9]'_@YJ+X,?R8^EP,=\!P+^HYT
M+7$GR$Z48;,N!B(NO1X0Z+.%9D'1),*1G&5.G!CK>8@TA*CC668\MI<D@J;-
M2J,.?$F@N?8>QQ-O;N#4$7F!Z.;,G7*`ZF#&BNN"I23J6DF5M3I7?F,9)15O
M)82]'[?&LIDK5A/?AAK@.!D.E?N;V[_S>#?^W:^L<9_[,YQ_!GLX&/.`X%WT
M&P1ZG>:=9Y?C68=?LX(Q.;@>#S,>@CRD27-CQT.OQVW''XC;C*&G9#;+N5]X
M\ZTA3N6PO=G9`ENH0:WD4K,F/K$M3W".($;,ST5G;)-W%I;4S,_PGH0D:099
M=7EE,A,],A"8RV<)DK##/`<#(FIO\8]0_C9O]"]P,=\!P/5A3:7F<K<>90EU
MI2WHZ,./M)PI.5.,IR]'PXZTGM6VG+S.%.8PE3Z$)[]0;+C]QU(!.J$8</*E
M:_4;E1BL')H&-06:K]:EF)Y12.]L<YM=A(D"\PE'[^6W":\:\09S"'P(J<AK
M'P'`<#(>W?\`&OL_'T/5#NG_`'D)8X&/.`X&8P.QAHJJLAI,*5/FQP=O%-HE
MQV)0Q2[`4JDR"E:7)K;F8D=L)-\8QWB,MO+BY:;>PX\M@+-O-BB6D\T6A1E1
M&4UNE"%QULMQT-RZY3*_7I_BS++SZ$0E3ACZQ^,O8<\2\64^RRZI3+86=P'`
MR'=,_P#!O46?H^IX2\O\&V-G]G\GT.!CS@.!F?5%ZK=`D,&)[UA>*^F*M+DP
MH0R%*%HJX>S5JSD\17W[`/<R?)R@$:.SX<>J##C0<8RX_**-3:\%I62U0SM;
MJHIH:R.E@Y5C=EI@PVHHUQ!=8E<13"<27G7)"<07L2<NMM)QC+7>>&[58;"Q
M>`X&0V?\4Y+_`)PPG_=NP<#'G`<"[J786*X5GSI7C2X\VI7JOJ;B80IQ;]EI
M9X`/R\AU]AM45HF2AR9G:XM;;#+KS#$F0VS'="^+-L<2:K9()'%*C/2@NI!T
M>;XA&:D//T.F1:Z840DHG/*<9?FLJ<$J0TI;L+P*Y*(;F?`X##/`<#(="^<]
MB9_]7A+_`+#U;QC^3'`QYP'`JH;T,P4@Y-22<(3F4VDD^&C1IA5J"K.<2<08
MTN6/C/2<L)<0A$J6PPK*N_=5G'?-NAGF=N,$^IME`M^1':![,!1I$D1$;GPH
M=GUTFCU2+%=4=FNX2-3'B,F)<F5(F2XS+L_'CTV2J-D-<>`X&0]1?XU]88^A
MZH=+_P"\@W'`_I5X'!/<FY-:[LV39+P2U#M!V=)<BC5>E[:8"%#S%$1TBX#[
MD!_3%C>@R946(R[)9R8FM-2EOMM2%MLX6H,8^,:I\S>[OSM5O^SYP'C&J?,W
MN[\[5;_L^<!XQJGS-[N_.U6_[/G`>,ZIS_YF]W?G:K?W/\GS[F/Y,<!XQJGS
M-[N_.U6_[/G`>,:I\S>[OSM5O^SYP*U(LNLY%=%UI>E]S8A"#)TY&>3M:OIE
M+EV&%7!\QI]:M`Y9S';:K,%45"([3J779F77)"7&&XX47QC5/F;W=^=JM_V?
M.`\8U3YF]W?G:K?]GS@/&-4^9O=WYVJW_9\X#QC5/F;W=^=JM_V?.`\8U3YF
M]W?G:K?]GS@/&-4^9O=WYVJW_9\X%:%V768B%8X$;2^Y7&;.&8!S\O[6KZG6
MHD>Q`[(AR'EO0+2&W\SZ["96MY,AK,-V2VAK#ZFI,<*+XQJGS-[N_.U6_P"S
MYP'C&J?,WN[\[5;_`+/G`>,:I\S>[OSM5O\`L^<!XQJCS-[N_.S6_P"SYP'C
M&J?,WN[\[5;_`+/G`>,:I\S>[OSM5O\`L^<"M5VR:TK1L:=@:7W,[,%R<26&
MY>UZ^N.M>,93C#J&=`,.J3V+SCYEU"ON^3'`HOC&J?,WN[\[5;_L^<!XQJGS
M-[N_.U6_[/G`>,:I\S>[OSM5O^SYP'C.J?,WN[Z7^-JM_P`/VOGT_+P'C&J?
M,WN[\[5;_L^<!XQJGS-[N_.U6_[/G`_<RM48QG*M-[LQC'?9SE6V:UC&,=BL
MYSG/K>\=G9VJSY<][C"<9]I..P-QM(Z5T?U5XOU_FP-JTTOZ<IT@H+BWJI&1
MRWCZW3*GH,MW6(^0TTAZ0^QXI(8>6RA#"L3I2U+4@,Z>Q[:+_?\`VO[Y*C\@
M.`]CVT7^_P#M?WR5'Y`<#]]CWT9GV[!MC/\`_DE1^[G[`/IYS_+GZ?`_/8]M
M%_O_`+7]\E1_A^P#Z><\!['MHO\`?_:_ODJ/R`X#V/;1?[_[7]\E1^0'`KA7
MH0TJ6@5J"^=V>EJLA)`2%ED_54.+C/V,_8UJEK<HSB7Y"9EAE)2MA$=O$1,5
MI3>7F7I$@*'['MHO]_\`:_ODJ/R`X#V/;1?[_P"U_?)4?D!P'L>VB_W_`-K^
M^2H_(#@/8]M%_O\`[7]\E1^0'`>Q[:+_`'_VO[Y*C\@.`]CVT7^_^U_?)4?D
M!P*XCH0TJFN/UQ)W9_BD@W$-*5FP57QOQF)`FP6TH=](V&<,9:FN96WF.MU3
MN&\I=0G"D.!0_8]M%_O_`+7]\E1^0'`>Q[:+_?\`VO[Y*C\@.`]CVT7^_P#M
M?WR5'Y`<!['MHO\`?_:_ODJ/R`X#V/;1?[_[7]\E1^0'`>Q[:+_?_:_ODJ/R
M`X%="]!VEA#1YJ*=V>M)D%(#R\OV&J+RF(_-@3%+C>#HC7>2,.PF<)6[AUM+
M67<*9RO*5-A0O8]M%_O_`+7]\E1^0'`>Q[:+_?\`VO[Y*C\@.`]CVT9C_P#B
M#:_ODJ/T\9^P#Z>,9_AQC/`>Q[:+_?\`VO[Y*C\@.`]CVT7^_P#M?WR5'Y`<
M!['MHO\`?_:_ODJ/R`X%?J_0;I>NV:NV&`<V@Y.!'0YF$B78*J[#7+&$(TZ.
MB4TS18SSD9;S3:7VVI##BVE92V^VK*7,!T`]#(OTWOQT_P#R^!R9[G+\Y;H_
M"*M_HK#P-%(FXM[:<.=7>[:MN?<V]7J1UYZIZ)NFO1VX+X,3KNTVF^2]&5C9
M#UGE5>I`Y65P+!L:]IH4R-G$&IR:]`BEA%B<@/>&"MENZR[F@[/M-#?`]/:H
M6I@/5V'W-#JQJYV'9`>W='^C"UUO5^&5M[,6'4-7V;;4'&O]8Q+JT0LMTKT.
M;<^]A]]Z!,ABWIC[I7O37_3G1Z#;"6E=@F(QSI=T94^K/8&YKK8]-9V#LO0]
MRW%N$AOK<5B4K%AM.L<4YB(3%5BR1FY]EO\`7J!#*QY%<+E'PMW>G=3MY[^T
M56M3ZZ;IO3MMG;](T</('&[I<@VU;;/ZENHL_H^@E.D`6RFKG7X#U+JDS=4O
M8QDA)Q4JO:*R"6(?LZW'TAESV8/>!B5U42=>:$UR]4-,65.I-4C;ELR,UL^P
M;:7U)T?IRJ@.^TAJR2+^TS>95C,V24YFI!$45D%$C%++;GCN)$$/VY]UXWK2
M&=I5*Q4[ICK5_P!677J\2NWVJZW\)J?8M7Z4T:K%/:WU,B6/9M=ZWS=-B;%)
MZZC@1R<*%NTZ;:&:L9;)1JXP%\W?NN6P*9?]X@"NK]9!H>M-0:9M%;J\^^9,
M&?3QMN\Z@U6;5N38-7F%*AHVMZ3V9LLK7-GUF]`X%VR/JZ+#7_'8!.4@,%'D
M]U0ZBYE3ALUBE=-AJR")/7,8M.U&K)?I6AC^H>C6C4HW-W;KYX=XU99U0/7J
MZ*UTW'D39T4H:JU@>"V10M"2C(0.M+K9ZAJ.GN9V[09>3K6O3M-$.K/K&U*`
M<=)*FZP@'.D@1L"M8:EQ'9)&-1PFYMC%QZGF8<R2[5,O,OHE-*C/AAOIL[H7
MU5Z\K%[";ZNM)A[%V7U9@HS=TZE9$NMZ=Z7J/M7HZ!]58&E6617LAB&(C\Y;
MNL=?"O1J#!D&93Q-H@^AEH:9#.-W[K-U"#P-(V-6M%:U$4M/1ATL]7VSZE?C
MEPCWR/&WIOVRZ8L-*I!`/%]!G$-0H`NTU2Q6(7#6U&;<9+`92SC;5:"J7?NF
M^]C]AZB]<:V`ZF#6NN53KMBTL0S)+V';>C272`U#B@MC[RJ4M3X=ZO;NQ*63
MUM`8#P($&?,JL5R5L,20-OBPUIA=?G5OKRQT?J!GW#5^[Z["[FETA[:V[6!M
MQN0G7QR=LCJ\V7K@U9->UH$LI3Q.Z)%9FB1-[LDB+'&1;%49("*&]`4#Q8(,
MI'^[3[1BJZK2@'3%*EB=$5OJ")PZZ3*R(5YHI71.UJ[KL?$VZ'7:V2<R/LP<
M2(FVEUNO!4Z^*N5NO$I-I9.-'$AG*S]TMW/K#JVTSTP7ZI::LINP;(TGIO>$
M77\XH-CZYOF\JS-M5=>J-DO=U#W#8,.`(P.)2(@#1<\#@6Z\JP;"J!YV'6W0
MU]TYW8?J4VQIRW;$`:PZ=K]8*MTD0.KPI6]56>VV)^G`:7MZ%1=MZLV%$E%8
M\D!LPY0FK/L;5X],ES$=ZJDJV4AV-I4>P2`["=%N^[;U.Z8D[R/A`0.HWC9&
MSEZ00'CFHDTWH@%<RM9UE<[0P;?==18;R'"KN/8/;B"\A#@3,>*TOPV70VRX
M#@.`X#@.`X#@.`X%+.?M*8_BLA^J/<#G=W-O]Q&R?PI$_P#8)7C^CR<#I+P'
M`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`DQ_\`!D_>R_TC7`C<!P'`<!P'`D1/
MGJ-]\,_I$\#('`Y$]SE^<MT?A%6_T5AX'0I-,IZ4(:35*VEMJR/7-MM((7A#
M=PD2'I;]K0C$7O461^7)D2GCJ<8*.2'WGERE..K4H"*;4&RD@XBJ5M!J6],D
MRS"`8M)25((P(0H@_((8BXEO/3A8T<-F.N/*7*@0(4-]2X\5AML(Z:%14UE-
M*32ZFFFI3A":DFN!\5E*$O\`C24I`XA^A6$XDXQ)PG$3LP_CPV,>$^:X'N1I
ME/+DH)DM5*T4,"T0FQI4B"%S20YL:3C&QS<&=)BNRHB(!F%#+PDQW6TQ2<2-
M/8PW*8:=0'B]0Z/(F3B#],JC\\F3$FB4YZNB')A$P!=;D`BTZ2N&IZ63"OLM
M/"9\A;DH<ZTVY#=96A.<`Q1*.GQ7O:;5,>(V&1;H7971&/$[7+?7*EV>+V0_
M]SV&5)<<D2#37>$GGUK><DJ<4I60]D4RGMN61UNJ5IMVX]YBWN(!"TN6KP<=
MR*WZ9%IBX4<[R*Z[&1Z)YE=['=<93V-K4G(>#M!HK\9B$_2ZF]#C5R73HT1V
MN!W(T>HS\1DSJJPPN'EIJN3$PXB98-M"1DC$6-AZ*O##7>A,?J=5DNPWY-:K
M\A\>(D@![SX8<Z[!`S?%/'`D-QR,I<81+\0@^,C6<HAO^)Q/"LK\79[P(\ND
M4L@V::GU&KS6K(\.DV)N6`%26S\@1&C0Q+YI#T1:2CPN)"AQ1SL[#ZX4:)&8
MC*::8:2@/HG2J:;=EOF:E62[Q`7!!SWB8$5/=FA19!PL-$2W)<1U<D6.*NND
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M:R5>Q+:DR:P1(A4/,1I2^P-G*G5*W1*M6Z33@H^MU*H`Q58K%=$1D0Q0*O@H
M$<8'$#8K?8B/"'0(S$2,PG&$M,LMIQG/`N#@.`X#@.`X#@.`X#@4LY^TIC^*
MR'ZH]P.=W<V_W$;)_"D3_52^!TEX#@.`X&MO4IM;86M(&HP^K`M,+7;<&XQ&
MJ1,B_P`PY%JX-,RD7Z\S#)%JNL/%IZDPZ(\-C0HRHV/&234IU_P45QB0%F_W
MP#_([_TU<!_?`/\`([_TU<!_?`/\CO\`TU<!_?`/\CO_`$U<!_?`/\CO_35P
M']\`_P`CO_35P']\`_R._P#35P']\`_R._\`35P']\`_R._]-7`?WP#_`"._
M]-7`?WP#_([_`--7`?WP#_([_P!-7`?WP#_([_TU<!_?`/\`([_TU<!_?`/\
MCO\`TU<"U3^VNK[4]GU&G:`?IM+TO9>WJCJ8IZ0I.SH]H&9N+9/Q<O`S8$."
MGDPGQJ%/1I&/[LVOO&W&\]\YP-[N`X#@.`X#@2(GSU&^^&?TB>!D#@<B>YR_
M.6Z/PBK?Z*P\#>[9NSJAJ*IR+E=)1-H8B>+##QX"OGK=:+'8#L]@6"K-2J%5
M'&+-:K(:(R6(@T(!%3Y[ZE+>RRB+'DR&0N"IVRM7JM!;A3S4"Q5FQ0&288R-
M>P_"G0G\9[QUM>.]6AQ"\+:D1GT-28LAMR-*9:?:=:0%AW[?FEM5VFF4?8VS
MJ93+AL5QUFBUJP&X@\U:W&"(H0]@'`>7B1.PR4-AQ[KC*,H;EDX3"U87):2H
M,O?3[/Z/+V8Q[?E[?;[.W/9G/9V=G;A.>S(6A1KY3MF5F%<Z%8!]HJQ*28AP
M#8M;CD&5*`&B%=,LM+=0TYE0\V*)#7^U&.R3#=3CODXPK(681Z@-*!W-OME=
MEU,<G0(X45W3+G$VXHW64$T&?L@YVVE'L('"W7:_'R;>C/2O&H0I^'.G1X\8
M@/=D!Y:ZZB]#;=FBQFK=LT?81$Q7S]J@,5`]#/-OUVL6.)3K`0Q)'+?C-J"V
MN6V`*PWGVYP\I_N65%;7A>$AF;'9]'_]_P"'R>WY<^UY<9QY?^O@?#KC;+:W
MGG&VFFT+==<<4EMMIM&,J6MQ:N]0A"$XRI2LYPE*<=N<XQC/8%A:WVQJO<82
M59M1[,U_M.N02LL%-L&N+E7;P#B&X"653PTHM6")2#'*P42&%RQSKZ)<=+S2
MGFD>$;[X+_X#@.!ZMM]^AY7;V>":PYC'T^UYIKL_D<SG_JX'EP'`<!P'`<#U
M8;PZZVWG/>X6K&,Y[.WLQP/+@.`X#@.`X%+.?M*8_BLA^J/<#G=W-O\`<1LG
M\*1/]5+X'27@.`X#@:>]5?[M>B?_`*807_W?^H;@;A<#2[K]V/N#5>A0)G13
MYAG8EKWCTZZXB+KPFG&+#Z#;,WA3Z'9F:_'V$S(HT4S)`%Y\<:6M[::Z'EOM
MDBS\6'%<D-AIV[UT]7.FQ=BJ&Z=':O.V;50'1@C96U,;&M-:I8BX[U)%<@K+
M;8E6U)=HXG7]#J]=+O[:M0!;\2-=YM6$UH`U4[`4L]*`YW4[8CM4N=H1TIDJ
M\4I^J=%WW&L;C>BM?V6=]64CJF.>O`:"9UP'K:]$:<A[$(IO&Q"EC$FF3%8G
M0K/3M=C&B!D<%#(=U?V_`DGF'^B<TTD'H6O;>4\SO'7QQ$Z4?JE2L#Q4&Q5X
MYPS==-5LC8B02R[1UX#MRQ":T2(S*XRXF4,&A<71OU[;FV+MRG:4V_4@Q>3L
MZW]5YX'L*N&V)\4-6-?;NW$'U]5!]2&46IVEC7,#7=)K[=/WIL:M5<1L[!0>
M.E$&=CN-A+&&+]/=T!ZPJ\#W(7V9IT;N1==;ZA=T)P%LDRK9J5"H_4GM#IJI
MNJJ6"KNB7BI0,+):RC7XY:[60N=T30B-IN3<BPS'JMK,8%;5W5;?1$@*'57I
M2IIMJ2WKT:JSS-P7L13;*1V-NOJ%TK7KIK<IC0I`I9]5D'=,!;XP<+A*P656
M[7F/#&DXZ!E@(A\=4?7%U+O4;IZO6A!9RD(W]T@:RW4W3F:Y3[59ZW==H]6G
M0+KN."8,W4*U7?3`$UGO[:`-GTP1Q];41SBS&1\9H$V]!"):.I[KUUF3'5#:
M),$$W)7*KIHMKG4E=UDU<H?5R6V%NVXUZZ5Z;=`L'T-K=DUKJJ/08]W3KF2'
M"4FZDSFR"L@KJJ6"%H#)G6CUA[VTX7V](I%@KX(%K7;VAJ>JKHK(6R[3M=+/
M:M-[+-3-.5X[.#B[U>MC7>8'UA&IQ@L+R8KM)N`K614?M@L+EQ`QOM'KRZOP
MN_NHZE1-7&M7ZNJ=<U"_0K7<M3$C?I*H1OJ6I^EMJ]1EB\2.-.W(>'IQFY;/
MKM3@J'P!U0JD,K9TMX&VQO@1]T=>?5MKG5'1;MH?27"IVWT;=%XW%JP70)49
MS:(.MWG4.I==F@S!5,\Y0&#LG;U=VO'"HL40@T%D/PITLB,#DL<#9KH+Z@=Z
M[*,M4;=%FB7HT)U-:)]G/0ZD/J.85YU[U;=1VC))5R`,$BFFQ>Q:_01#U=CN
M18D;"=?F2@UM_!F:MH.GG`T[ZP,Y_P#PN8[?)Z\327D]\WP8_DQ]+@;B<!P'
M`<!P'`D1/GJ-]\,_I$\#('`XH]%VQ:MJF@[ZN]PE28XF!:J$-CQH$1XB8.6&
MS%2%8J=5KPJ,G,HO9K?:3(BLUD/&3F05.%!\!C&5RD+X'134VIK,4LT7>&\(
ML7&R,19C&OM?1YC!:N:'KA5A4::/'S(^7(%@VI8![F8NP=@Q?"QF8SK]%HC[
M=0;,&;N%N;%U_8],V(]N;3X2<?J9^;(/;OTJ&:R[++RG>QPMM[4XY.<-M;):
M;2J9>:1%PU&VW&:<+"TL[095Z?`U0W'I"]=0.^NEKJZT'=:F;UY7]/V@0ER-
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MNZE&ZU#(L-0;1"C1WGL0VA\`+:V+W*\CB_*V/IW9I@99W`RC;]^NU[N3.P3&
M[B'47J':]HV$=?I(X16WH1'7]&)TJ(%A!H0.(Y,@PH]<BP'ITY`8_+]SIZT"
M,3J_PYU-0I<OJ%M51M]/A1MB;"KE6JMBJNV-BVE!-RLHI=A'"*Z6H1;6E5ME
M!9;M"[I%IQ$*6O4;,BOVH`&Q731T:=2.G.JK<>]ME=2%DVW6+N$N,2I561<9
M(RIP,V$U4R];KI#6$C79*;"'ZZC!BE>J%I>W3;B<`#,=C1Z_$=/V1Z8&9NC#
M1&X=1N;RN._<:GE[7W9LJ)=#1S4!*R+JF``&LC*51:@+KQ^HU95:#4&G`0]?
M&-^,6<J;?03/&3ZY)!H?!#=W@.`X$AG]CE_>Z?UJ-P(_`<!P'`<!P),/YY9_
MS\?T9X%N6.RUNF@R=GN%A!U2LA8V9IFQV0M`!@A$-*DI5*)ER<B*.@1L+6A"
MGY<AEI*U)2I:<YX%NU;:FK[S*@PJ3LBA7&83K35S&Q*M<*]8))"GOEIH!FUP
MHXDA+=EUMTZ.(A&SK"'!;A>!-'(E*F17V4!?G`_,J2C&5K4E*$XRI:EY[U"4
MIQVJ4I7D[$XQC.59[?)CMSP*-7K-6[:/]%:K8`=E&8DR(7HC7RL$U`S+BK\'
M*BYF#GY,;$J,YGO'F/"^%95\RXAM>,=\%:X%+.?M*8_BLA^J/<#G=W-O]Q&R
M?PI$_P!5+X'27@.`X#@:>]5?[M>B?_IA!?\`W?\`J&X&X7`YU6'NJ?22#S:H
M+IFZ&"]`MUAHMD"4^GR+P4BD:W0MC;8*$48ITP[$6)C4/6%\.3LN2VB87%9(
M0CXL--\%'="LT[N@.M-G=2M.T=K,<3L--+TC>]DL>X"HTY6*C$.:5<T?F;7Z
ME,-BXD.V(C,[@=;N<]J3#;J1$/$@N)F*(NKB!ZJ[I+TRL`:+:ILG9D"L;&$9
MNM8/3=3WEF`K4#Q6D`!F]S:4B5S*MITZ;V'58("W6:,)471,G%8@U8$$>*C@
MMKV5+I':A&2I$U?P8<!*@)*F3VN+*($QPY.1N4/!MC<Z=':9EU%^XZ$V7K]L
M]$5(BKN@H:*3WT>P!)TX#G=4^D5N98P[9R^3[/59%+&EZ8)UY835R9LEUM5)
MH<6FHK`AJ:75;Q5YV)4J>6KZHS<UX^2>B5_!U(HRY`#"VR.ZS":I!LLT'I6T
M-NU:Y[PHT@->%&0=C/$=(;HZ:M3G"M6&`JU98Q`:\C?K\YZ`0*";"P6"BPPX
M29]$BTH`%X%>ZV].=:NUDAVQXG6=?B*)2)4(J9&%P]^>W$9VKU1:PO.F3%#,
MP1RPEBH;W2]<)TI<HKE)=UJ;$$MS/]Y5F0V5NW7ETZ:_N6LM?V$_9DS-N!M4
M6VJ6.%2[#*I<>M[IM<S7^MR]GL>(2(]4CV.ZI%UMA!U$)Z/./BWI++,!LQ,%
M!A-WNJ/3E,FZI8JHG9U@@;0V+0*E@K/H=@I<4!0=I:TV9M77^]I3=PA"))/4
MMKJVIKL4#GAK+KKHJL68H_$8:`OLR`K&LNZ']%N[;=KL71BJ#MIW8>75ZU,)
M4Z.*]&G]:0*OL6OXDV`[F%!*O"(NS0%HJU9%D#%R!$2MF\/5PARF;'C5</:S
M=>S%?V50*BO6CX^CW7J,V#H-6W[)89@>@CYNNSM4UW-@SS#%5GP06S+=M*R&
M`VM:%9)8L-?:S0[`3%WMFS$PE.?#'-Z[IG*UY/V+53O3I8Y][UU;[,)FC*UL
M.N%Z>1K-#T<<ZAM@RHVP7Q0X0C8E*UZ"Q$-:R3"D98N%EIXARVM!2A:S5X/G
MJ([H_4.G[;`("+TNS<)&V^G>BWG7]U]-#51-WS9=W-["BZ%T&;@.T@O.$PK4
MJO7DA&MLLL5<J4B071#H97+Y.4D-KND_J<C=3].+V3THII1`,QJL@\*9L>+9
M!EB=M:&U7O4`1@G$!*^EUN/!V8NKR6'!K#ZBE9(SVTY%D!;SX4/K`_Y+G_3$
MTE_\3<#<3@.`X#@.`X$B)\]1OOAG](G@9`X'&7H8IM5V'1^H:CWD`,M51M,X
M(&L%?,QD3!I47,C6)I^+)8<QE.<*QV+;=1G#\9YMIYAQF0RA:`VPUSLNT].5
MI`:1WI8R5GUG9B,6OZ!Z@[+,7*(*(2U8:#Z.WJ<DJ_Q@>5`_6.T"+C<?;["&
M*Q:)#.WF84[:86W8+!.ZW9LRNUZ7*&]&0V4_!LUE@O.1)O5K.B/98F5>JS6%
MMOQ>FB*^V[%L]GB+0]OIY#]?K[R=.H*%=HAB#?-1W?8>MKI5IVLI%K!Z.K6F
M]DV_8`T%L;9FHZ`Q)J6V^GD57X[CFMA$X+;;9"IY>X,5/5EN=$U:QA%6)<R?
M$B!UJP',,+N'K*JNM;<;U9(ZQ=@;3*ZGZHZAM`#LNL[3F4JI;INN^A>L>D$M
MJ,IL.MPX3=D"C[5Z:K,-UZ=FT43JFND+;>?2\N,.+3`VA%6#JY.]S5V]JHV2
MZA]?=3FO^H`9T[#-FDFY)[<DBGVWJ,UTU2]L-G:E**#[2V*TILH2U<[E4S96
MM)F5:[.Y-M-"">((:MT+JL[IG0FMF;M/ZFVK;"NQ-.=.$8%K>X478-SH.AK!
M2K]LC1>];UZGM,D@K':O3*7HP;:?H2`,`CI:I["%V\E*"UH.J,@,MGNO'NG]
MT@[+I(#IK%ZLL$7I>O\`>*59!^FMVW(P3V+"Z;9.QZW;M<$[,-C4(HDWM6'Z
ME8'45[K"K%7CS@LC9I=P<=9H5@"Z6.K#KS#^J+FBT\7=I<]V18@]VO/3[U$,
M5@M&H_<\M/;M\6K>L)^U`Y:D-7_<S=MUH@-'.HP)MY24J4-L-V@&X-@#,VC.
MNOJ,V+U?TK2&PM8@-:U*\QMO3V:>6U7ML7>05?UK0-4V&O6^+N,X?B:QV#!O
MIS81)F8"K%*AD]<LA8E>M,IZR$GDCPZ]<!P'`<"0S^QR_O=/ZU&X$?@.`X#@
M.`X$F'\\L_Y^/Z,\#5#K;TQ;^H;I5W3I>ARA,&X7^KQPP.6=>S&%1I:#@F>M
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MN;?[B-D_A2)_JI?`Z2\!P'`<#3WJK_=KT3_],(+_`.[_`-0W`W"X'/FY:;[F
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MYBG#EV5_T\!FMV7>T%ACE?;),3+78"`SOWU2<0,A=QP/T"2+W9[,4,=/B]BS
M+U4C]E8:V#4H9N=M#5VSPL&ISB`)JS1(_I\`;@JM>KOC$J"T:D78(,K!9V01
MA,#4AJ[4[OW-SJ+VIBEYT?`)VC:3-CNQ8K8`@"12BF;YI/I:ZK+@7)%0MS,5
MJ6U9ZB;T66/$Q2)P<]::E-?5-G165'#@5;1YON4F_=3HL5*%:%"47&`^OA+-
MEM-(K!Q0FMWW=MHI!N`U%NC]BKS]IN:NH.W5DZ2>!7ZU2%;0*$T.+:LB4AEW
M<^VNYR`M5F>JZ[W30UXKFJHHH2&ME:V+1[#/*6'IUG2-[4[5E$>8M\878=F5
MRRAX]HJM$CSLG9)M4%+S7@)..P*Q#U/W.S6/I(K+U7Z<-4%K39@?4/1*@7)T
MRCVF;8Z,%*2A-SK@646@%7(-%K<^QPDP@R'*S7*[/LHG$*,"GF([X1JE7.YN
M`PE"LU-L?33'IU,VO(BZYE"]J5.50@6YWH(IF*!K,!-M?J+-U"CX(=-3J\2)
MDA3HS47-3&!T*PI8>+M5[GC;=GUI^;L#1-NV)'W_`&VY4JIS-OU(U*9WBJ!7
MT7`""I7IC=01.#K'$KVQ)]0=%SYU?V4L9>(\(8<2-DLAKUK>3W'6UZ\,!JDW
MTZ3M$JQC;Q2SW&X5^/K.,=CWJ[ZPGSI.=C6YDR#)F#LNY!C,J0$&UV_@+7+B
M2"EF$6A^)+#;&[O]`%VV3,,WRW]-)O:=$JE0LA'T9V+1LVBGTO7`LW>*;9"`
MM5B;D@*]5@.\BMJ''I4.+!B@=E12ZIF19P6^X&8M`:JTGK&F+DZ$C@TT&])J
M-B$SZT::/ULB"KVM*-K"A)JY*-*FP%54/K+7U*`5UL;)=@N#1;<Y+LN9-G3I
M08NZP/\`DN?],327_P`3<#<3@.`X#@.`X$B)\]1OOAG](G@9`X'\PNMMW;GU
M@?(5C3TI*2-X-QV%"VP`L[,*$8TB1$&LQD3XDEQM:ESGT=ZUWN%^$[7%82VE
M6`R>1W=U:;A"6RA'1VO=EU"<E^LW*O'ZIJ&TT4Q&DMQ\219E!9J;5#8E]R8.
M@2,2'90U9,D)$N961+#84D*_3NH?K>.B,(IK0G`@':0>L_$(]5UX&0#L)%:!
MP8$L1*9@/"X$=2&X;LUR+&!A<898)31Z5([`MTGUD]9(@C-%$"2&YL$N6K\A
M#%#KLYA1<`Z^R8@QIL$7(@SG!RXDE4C,*3(;PPSE]*LM=BN!=`7J6ZZCT%\D
M/\)XBS&M<C$F50JY#1(<H\:-*LX^(F0+0Y)*C6Y;"5C&T9F.NJ=89:<?COMM
MA9T#K4ZORDL/!'EDRI=@,-5\(TWKX%_OJ<>DM0VA,%:A"42""I3[#.8C65.H
M<=0A>,94GM"N6+JSZT:N]%8*&`[N)PV>8B2P-?H-J&OC14E^$6DMEZPR9&=Z
M(F1GHQ="IF'A;S*FY[,52^\P'U"ZMNM0@(/%&2#:8=76/R29DT6N19N'C1IB
MLQ&8,!\0U,(/J,J8A/QHC;[T5[OD.I2K'9P+?QUK]7/AV8\@_!&9>+-`_&#-
M,JP0?'+.N9;\2GE3`Z"-&+9[,KEK(2HS4)E#S\MUEAE;N`M\GLS?FH=L7JYM
MT;4->W,?'"XVS-@4C5NF2]V,CW'68X<9?M@4044)3LI='0DPA-C,N/-(8'+:
MAI1XFM05.;UT=5XW*$$;%%'K6N2VE$ZAU^(M;L.4["F(3A\0WG*HDMAZ+)3C
MM4S*9>8=2TXA:4A!]?WU._9F']YM8^+>`]?WU._9F']YM8^+>`]?WU._9F']
MYM8^+>!T?Z#][;*W@%VE*V,7B%WZ[)K$<4N()&"L,,D?'WIF'$C8T=+_`'ZH
MD=25.X4IM*<]G9WZN!O;P'`<!P'`<"3#^>6?\_']&>!&X'\_IGN@&^]$VOJW
M8)+*=35FKVPFQFKYM/(`)'3K71UGVS:ZY2]9V^,.U;1+7I7:%7K\8;7S4.W[
M1V8-O4B!)L8VQ2S!2K@#`4FP=T:ZGJN4O?4O%U,:MFN+/IKH-1K[3"+`/#5S
M3LWJ<UE:ML76\;)L-HS1*^0Q7K($9US-LABSU:)!R7I\9ST%1,,)?"ZB/=.>
MIO7L7<>VMCZDI&-=4<!TEWZ5J000)'=A5776_M8CD';/5+E5XQ"L[8#@-W6`
M#6)9L,A^#D1Z,2FTC,CG&TAVZUJ2N9K75",;&"#ZWL$O3:P3O%;$/ORA=>MY
M`)!E64$.D25+DRH0DP]+'193^<.R68R'G$I6O*4A>G`I9S]I3'\5D/U1[@<[
MNYM_N(V3^%(G^JE\#I+P'`<!P-/>JO\`=KT3_P#3""_^[_U#<#<+@:#;_P"B
MKIPM6P;+U#[5V+:Z*->K3]NOXV3<J76-98(Z\U?LG7([;QTK8ZS)L(*9K;65
M[M^'/%+L'UKAA39V[U,Z\.Q,;#&UC[E)TT7JM0A[ENV@ZWXGJAL6?1,U3:6U
M@=::#8Z>(@Y0*Y:JMFOCX>]ZQQE-PR=J1I3Q62LO3Y%3QB.RT%>LG<M>G"S(
M2T^9V8+3FY]0=YD9"DZ-$7-*=2._]6=15RC3UO:^E*EC:_;=0U:MTEI[.98R
MC.E`Y:<=*.CSHP,'6?N;E+UUOG0]UK&^&=<ZY8W#7;=8JU?B-:G6/<>TQ74'
MO_J@HM#K7C(6OQH*QEGW?LF!6XE3GPRSU0Q-8L5?O90;`L@@,[VKN<_2LWU*
M.]4=BL-L#;"N=QDJA@YEMJX^CD#]BIK@!NL!@4^N9F3')-GBO[D'CFR\HP[M
MF.NQH?>"Q6:^T$+ICZ'^E75>R@=NTYMZTWZV:%'AM=E`B[_KJTM`9(/INTCT
MP11UY&U>I#R8H^N@=/-3,R8<F2'<5<)UJ(M0&0DD;7P@8\C=S0Z1LP*=,&;S
MV:S6:S`I.KE,0]AZG?!6ZV:W*;KAT9RPSWM=RI2K[7\=0.SJNP#K9.OBI[1>
M#@S52)\..*,!4CO<LND\U6KM5F]K;3!2(5=B5:[S0]SU<DT!U^8Z1J-TG'JZ
M9B%=;%!((1?-/:M`'RAF4'AV*-:6"M@I]@K@:2H,P%_[]Z#=%;^.!;0O8UD&
M68[K"D5NO!!]GJBZ=LW&D56VT:6M)Z*[6YML(,:TLVR"=K6O6MGJ(RQ,E(L6
MZQ;$%0/'LABBL=Q]T@YK"AUO9E]V-=-B@6:2NTWUV-J6?$/1:MIBBZ/>UZU2
MK%J$IKYW6:J/0@H,=DK3)NR6HT9):7L!ZSR)AN0&5IO<PM&2B&G9C5[W6.CZ
M8WE9>H04$@6.D(`VW8MFZE(?5"[.NXR1KJ2B=Z$W.!&IP8J#<KULCZO2NHR[
M+.<=64X%A5[N9_3+=XM7ONO-Z;;*)JL\XK4M[I-QTU98.OYD;:^V[B6C522O
M51^KV1P-9=J;/I<EF_P;T[#'3'($[OK2"@FH`29W<I.DFLB&8Z[->JU7&<@J
MU`'GRNK[#7V&9G3CK?HS`5M4?9>M[3"+^B=,I%7R-B'?18A+V26>GP'5(DB`
M8\.B.I-<#M0:RH^KA-AN%K%T*M#:R/L>P;$_:[H9C"XZ8S4ZR'Y#;#A(F\A*
M?"/-1HL5M*$1XD.+#9:89#7SK`_Y+G_3$TE_\3<#<3@.`X#@.`X$B)\]1OOA
MG](G@9`X'\H8"RV:C;$%WBJBUDR5<)D74-+B3WXJT3&I$&1&DNCG8TR/XQ"D
MR&FY,25%GQU*Q)@OL.L-/)#)J>H;:;=U@WAFEMHFPW"3\D7XC9_0@[-GQ:E`
MQ)L:6I[)(\G$6B5-Z?@B4?DEC@I=BG25%Y2GT!2Z9OC;5+$W0;#K*2$F_D;0
M4LA<B%+>B$F;:6A7C4AG,5<>-&>@2QN2(UYF.E<>9,>RE2FTX2V%\R.J[;KY
M!\BUKT/!?DDR<Y280FUMM,QIDO9<^!`@Q,DUP1RQ<G:E@[TG`AQRL]F$)1.E
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MRH;ZNV2U).G>QY;,AMK`7"KJ$V@X_?WET*"I5^G&B$E/H99$($OV*BS==F_`
M,MSD12S$BLD)6(,6R1#$408\$5AQ\+Q):E!CS<-\NVY;$-LYZGNC"(X*U7TM
MBHUD?B.#X1`A*%XR@Q)*24R8D6<B%+E^,X<+9C^C!),H]/*SYH8E]+QS]XS'
MN9/_`/D<!Z7CG[QF/<R?_P#(X#TO'/WC,>YD_P#^1P.P/<OH$Z#7=U8FP9</
MPDZF>"Q+CO1\N82@OA66\.H;ROO,YQWW>]]A"E8PK/9E..!U#X#@.`X#@.!)
MA_/+/^?C^C/`Y\;,[H3J_5G6-5.D6QBDQYABC#;O:-C3[970M=HD`ZU=LBI1
MV,5>C,,`XLVGBP5B*D30F?`L>TM0BP(&U(MQ"570Q[N3NE]=TSN'J=UJ;U^)
MG#>E_5,_:!]^)L9U6R[Q&AZ8?V_B%1]4Q*$17,',--)"V"SD;@.$5:-XW:#7
MBX,=.6P%OZE[J57[OLERB[#UJQIH0(=I8>UVZYF=N`X0NQG.D.Y=8MP;@QM@
M=.^MXJJWK[7]68C%B5Q,42T83)DGS5%K8:50'-BAF;8W5'T,["<Z?:ON@L\P
MQM6Z0[SHD;N73^YM?`3MSUV1EOU\\\]L*AUD"*E0R$?!VD>G=X=$LF,!;34V
MB\=X$3="Z\=T%Z34PJ^1E[#LHJ%<0T6Q4:0=TQO(`WL($0V#K75HPQKK)K6T
M#U01I>[[@UL*"S*9@ZR9BVP<?&*EUQ,LO&#<_@4LY^TIC^*R'ZH]P.=W<V_W
M$;)_"D3_`%4O@=)>`X#@.!I[U5_NUZ)_^F$%_P#=_P"H;@;A<#FUW0SH?MO5
MRJD%:38JT$,`-#=8.FG6[6<NH@<GUR>H">O@=B99JK9"(3S6+$Q`>*AS`EQ@
MB%(3);4OQ\*.'S@PR'[GGU*PY]F@-]6%ZKM9&Z_ZG@FE)`K;FZSYO7EZVZ,U
M(/U/:3C9\VPJ]#M7/B=R%8P.U'2T,22M]>G5M#$\5!FU\+<ST$];T<6&9$]3
MT(>F>N_C356G[6Z@+:,UU6#^S^FO95<A4.\VX@9OM\*1UZ0OH.62V#*@2@0G
M>=I$!)$BMB6:^4#`U+Z!NLO<6P;=&W1;MBAJ)3=H:XL`VS[`WAL!!_:)BJV?
MJM>LM]H`JE;0O<S3[Q&H[/T^#:%U$U1JTU#K#D`*/PF).=E!MWM7N?>]=OC>
M@0]:^I!4O8O2=!T,K8+Q(<Z>$W6Z4N349VWMK5\^4AY..[!N+M81#"$K`,PM
MH?*)(<D!L6.R-$0Q;IOH/ZG=96BK`Y@[2$4#J3I;HV@Z5L+7%XV5KR=N235.
MH/5NQ"MRWKBMPPUY`7XE5J,3F0Q]=*;`J9.R7'9;=IL;P&^S:R@+&LW<I]V[
M'J5Z5:7NEZDW78-KVV@D%H8NT3=.U>L[2T=&T/5[IKFC*I%033MK:`JX<,0H
M1#&2<VYFYENFF;M5L&1C-?#8;>W<UK%L2=U'3:19Z?70.Y[YTLWV96<N%ZNC
M99'1T"^9NP_;9NI`42FY=^L-F$6WTW"H-@*^F:N1"I&`\ZRTVL/CJ#Z8>J5K
M4FJ6:==SFP-FZSZ03NG[)=*$Z,UI9;+=F-E=+5U.HJ\$99Z,_4@NZ:KI^]T4
M^2J%E%V"G#YPB4#B%R.(T5@,-ZIZ"^L^SZ@-E+QO_9NHMF'M0RJW2`7J\;.L
M9:@V:7UE]1>[I:;@2:L5QKYN>?Z?=CZZT@NXSYNQ[%4(HTPF!@RD`'>(!F;I
MYZ4^I"B=5&OR5VVGMZQZ=U;HFL3[<]>-EN78=L/J1S#O=#&X!&&(-*F6ZI5S
M4]I;;M3]GU?4&7KK4M:6>&BP6K-F*"@PU3NYK]7M)J-BK`'J-@"JZ]:1)E.K
MP>X.HJN4O9,1S8V\KO9/3!::^4%7'2#DR%M*E"GQFD$Q1%M?U7#DW%$V)8I<
M"`%:-=`G6-CTTX/[WA[B%V32-+T_'@F+IL`?/$[1AC>GX!8.K5`HK+74%W<E
M,I-RL9FJL-,O`H5?`':<?+[$O^QUFP[>\#3OK`_Y+G_3$TE_\3<#<3@.`X#@
M.`X$B)\]1OOAG](G@9`X'(GN<V?]Q;G_``BK?Z*P\#I=P'`<!P'`<"0KYU9^
M^)/Z.)P(_`<!P'`<!P)#/['+^]T_K4;@1^`X#@.`X#@28?SRS_GX_HSP-(MH
M=SXZ6-P;98W?=J.>E;'BWJA[2C%!VQ=AB0S&S]9C@@*E;$Q3(%F9I3MN$5FN
MAJJZ3D5Y[!:MCX8HTR19B1,L!7;WT3:1V)<-R7&QKV6A[J!I)37^XJT%VSL$
M#1+W6RNKB.GG4&Z.)/Q*S)(0Z.3>C"2WH?B>,)LP3D&0R4AQY2`L^Y]+G1:_
MLT8'V!$K;FP]N'[1;@]%L]_F,3-BS8?2TYTH7)L53I9IERQ"X_3K+>KQT:.A
MOQ(Z'7K/(:06PLD@/F?W.+I6-V#7%JM-:OUTL&JQM:#50G>-R[;N3KP2EV\]
M=:@&M#-DN9&+=1=;*V>P1!42VL&6V0Y-X:[AYIF)F.%"G]SRU>Y=.DZ0-+&<
MZJZ2K7:-@4>A6XW>=BV)%I>#5T)K@")V%=KP9(U_5&M\`H-@&:[9&3&'[55Z
M"39*P&`!&&<#H-P*6<_:4Q_%9#]4>X'.[N;?[B-D_A2)_JI?`Z2\!P'`<#7#
MJ1U%?=J0=3$M8VVH5&ZZBV^*VL'DWNK&K=5BJX5(OU(E!28NOVFGET8>AWM^
M='F13+?@I0]IIQAUEY:D!9GH)U^^<WH]_,9NG^T1P/=T)U_^#C=NS>COL\"K
MO>S1FZNWO?&'_(KMZB.SM[_OLX[/H9QV^7@>'H)U^^<WH]_,9NG^T1P'H)U^
M^<WH]_,9NG^T1P'H)U_><WH]_,9NG^T1P'H)U^^<WH]_,9NG^T1P'H)U_><W
MH]^E_B,W3_#]L1]/.?Y>`]!.O[SF]'OYC-T_VB.![>@?=`/%LY]4WH[[S#Z<
M?XC-U=]WV6U_Y1'9V=F/X>W@>/H)U^^<WH]_,9NG^T1P'H)U^^<WH]_,9NG^
MT1P'H)U^^<WH]_,9NG^T1P'H)U^^<WH]_,9NG^T1P'H)U^^<WH]_,9NG^T1P
M'H)U^^<WH]_,9NG^T1P+:,Z2ZM-GV?5#NU]H=.F:9K/:U5VS-@:]U#LL):#,
MFGMDL0A$4M9-T6<5!8EOD<9DR'`DMU#3><MI[>W'`WGX#@.`X#@.!(B?/4;[
MX9_2)X&0.!R)[G+\Y;H_"*M_HK#P.EW`<!P'`<!P.6W6-L?=H[J,USJ[5>PB
M%08M]+KN68OC;<$/@X7MMN&.$ISN(,UUI"HP^"U(=9;<4AJ,UA++BD_-!KI8
M3O7?7D@\9O%T-D#AG8`1H'7%Y-&(,C6IL-7S\@I#C".R%"D$CHIL+)6ZM)5)
M&&IM*<S8#4H+(1MGKA<9#26SFWEQK"]E@)(P&D>!)O)B3B#B(KV!>4+\&/$E
MISN<J[&8@LI)<4AB!+<CA>H8[UXF(Z'LW6ZB7)(V^D!T(M(;9+$7]<I9Q8@T
M<1&&3"<<OA][Q6`P4B0&9;S+BLOML)S(R%EP]K=<I'+*8)C<4G+\XL-9PR!F
MJRZ1!-F7S$!M.!&<N2A[=:L6),=.,N-N@#4;"</#9S4</0;M/KE,>)9$FMN$
MDD83Q&"N$*=D-2X,6:''RY3#K(Y3:VXDRP@6I:LKPF+Z-"W)&6F9T=QP/B'M
MGK2D$@`Z5=MB!/3$=K-<'SSK*QH[!2WSR8T&U(D/#.UO,F6$.(RA"'7V_08L
ME;&7![[>`R+:RG7'4@)VPXVN>L(T$H4H@W6G2LR?Z#DXEVGN6%R!-JP^3#`B
M%:ZL*"TLHT/<9_WKFQ8\H1.1/2&,7MP];4>.]+>LFUFXC`7TQO2UC5IAM@LO
MR8WHFJ5Z'>`Q'\:B3(F5>$[YN3$EQ\MJ?B+0@)8S;/67,N@B@DMBWBK68XVA
MT7`MK3P5R7AQV1';2AET.Y*5E<V+,@+SB/X.'-@S8T]4=<`@F,$HOM+K""4&
M3L8AMTND'#NS]$DQHIT9.)M$F6R6,%4M0H4B(]6I$X*6$PSC$UZ/))P7(Z49
M;>AN2`Q;Z[3J0\[UM_G$3_9.`]=IU(>=ZV_SB)_LG`>NTZD/.];?YQ$_V3@?
MJ.K?J21G"D[?MR58\N,^,1.W&?N?[DSV9_@X'YZ[3J0\[UM_G$3_`&3@7QK;
M=_6!MFZAM?4+8UOL-L.*<7"&)(PQ\>/`B+BX*6*P%?0HABMTP!B5%<LEGD#R
M&(.9@T*&&6>ZV*HTVTAVH$]'&OB.LC]0VT0*;0OMX]+A2\;ADORP-Y3:Z@MV
M91C&MRL2;)*ZP@ZN)OOD-50*^7<EU8@^1LI0O8[Q9;K;;.%H:[V'=]?7>!T\
M]0LYF9>YD>>[J#;[4&*'K?436P\5V;-2J'#;9%5?>56$L+F[#UY#1'''1L:5
MLG6\;TI^F:LZW#9[@.!2SG[2F/XK(?JCW`YW=S;_`'$;)_"D3_52^!TEX#@.
M`X#@.!(>_8XGWNK]:D\"/P'`<!P'`<"3CYT5]\H_1.<"-P'`<!P'`<"3'_P9
M/WLK](UP(W`<!P'`<!P)$3YZC??#/Z1/`R!P.1/<Y?G+='X15O\`16'@=+N`
MX#@.`X#@<E>MZL;A3U%4#86L->7&T.5S7(AF*8!T@W:A,0RQ9KLZN,^Y`'3(
M69T6,0BS/%75X>CXD09*F\I=:4L-?57#K8?2ZT0U)?BT61)CS)L,IIBRRXLU
M^%`US%A.2&5!L8[Z++U53#B,L>!4^<@S9DO,E!4E'DA$79.M1^-B)-U/L6>P
M\VW'*(F:=L[V#L10;8-?GPC&,!DID1C`K9]OCD_!(CNJ5,C2HBXDJ#%=0$:8
M7ZR2*W'9FG=@RGU1[:/COYTW9F7(`NZ0!0TL)AXC!8Z$P6H8(6T+9=2Z[`Q&
M2EI_LRYP*M.NO7"11+1+UEM-YJ7,OTQ^*G5]\8'*1LC%T],<18IB&T)DLHD[
M`LTP5(FPI!$8]*BM1Y^(,&+$8"L5Z]=6(JKO5(ST\7>Q!H='])]9'O:JMT(:
M&>P8UJ125F#F`+D<FVJ)K,9'D"8OH-&E%9LJPR7G"$@EZ*!;%HG=5EE@:U9=
MTQM]96A6X]L668):]M,]RQWD];YMP7.D0X]8@1H08=/G3EC0B$RO`S3=EFXF
M)9--P!X4$2CK!%*L[S&I-J3';8<(6,V^2U9<R$A<\I2KQKM_P3SXMQQB*BM;
M$L,*,QA2D,R'!KB%)\2;2H+R(7?K:(Y\(O4E_CN)K4ZJ,9BZ=MC,:*&)2'I,
MF*R*R,6'6VW)D*D#8<D:^-!/-0'0$,4X)%K@!:AM?5U9;X,V/8=.;-.64,QX
M,3DKK;8<P>.D^BKYKT0'0'V5-#'LE)#\OQ0<N&)1X=<7`OQ)3[*@CG4=8=BK
M!.EE=5[6>JQ0;XA,`M:KMT<5XXJ]2MA/V2/`9#-PXMGEV`@0;E&6&67W!,QT
M%V(%HC,,AAKU`=[^93;?YN+C\3<!Z@.]_,IMO\W%Q^)N`]0'>_F4VW^;BX_$
MW`8Z?]\*SA*=)[=5E6>S"4ZWN><YS]+&,!L_R8QV<!Z@.]_,IMO\W%Q^)N!7
MM>T/K`T=L</N;36J=HB;Z#BI$E!!?7=[33]G4S,K,V7KR_1X@-UY0N0]E<NN
MV:%%D'*&?>4<"(F0I-AKEE#^@+776)J.XZ8L^X[A*(Z:3K-AJ/NNA[/A/@KW
MI^S9B1)6*O::_EI<^9-,)GCW:+)!QB,;9$$L"G4C)I)L>TZ&*ZC5KKU!WBN;
MZWB!)T^J5`@Z:Z=.G\TE#<VEOR(4L<SN3<D-EQZ-,W67#D)<>MU++LH5I,`4
MEP&U$-A$SA86&V/`<"EG/VE,?Q60_5'N!SN[FW^XC9/X4B?ZJ7P.DO`<!P'`
M<!P)#W['$^]U?K4G@1^`X#@.`X#@2<?.:OOEO]$YP(W`<!P'`<!P),?_``9/
MWLO](UP(W`<!P'`<!P)$3YZC??#/Z1/`R!P.1/<Y?G+='X15O]%8>!TNX#@.
M`X#@.!(5\ZL_?$G]'$X$?@.`X#@.`X$AG]CE_>Z?UJ-P(_`<!P'`<!P),/YY
M9_S\?T9X$;@.!A^U]/\`IV[[+INWK70@YK8U"2RFLV*0X01EE4-V9*".E14:
M8R$L\JJ3B94E1I=F&F9-$+&39>EO`R1HI+F!F#@.`X%+.?M*8_BLA^J/<#G=
MW-O]Q&R?PI$_U4O@=)>`X#@.`X#@2'OV.)][J_6I/`C\!P'`<!P'`DX^=%??
M*/T3G`C<!P'`<!P'`DL>U(SCVO%U_<_X[>.W..^\G;G./IX[[/9C'T@C<!P'
M`<!P'`D1/GJ-]\,_I$\#('`Y$]SE^<MT?A%6_P!%8>!TNX#@.`X#@.!(5\ZL
M_?$G]'$X$?@.`X#@.`X$AG]CE_>Z?UJ-P(_`<!P'`<!P),/YY9_S\?T9X$;@
M.`X#@.`X%+.?M*8_BLA^J/<#G=W-O]Q&R?PI$_U4O@=)>!3#:U-ABRT*4A:!
MD]:%HSE*D*3%=RE258SC*5)SC&<9QG&<9QC.,]O`_GSU&'WYN`#<#%?W1=8D
MBI'-?!%#)UUMN7B:KX0-QU36'T$\LQXE;'@"AXRX_GL2(B27VE9\66G@5<SK
MOJWB6*<$`W;8=GCM69=:$DXFRIHU9Q:K-BGQ"\<(6M,4S#`3;,M`)H[-A-!F
MS*TBW2&)>,,\"B-U+J\>4[G%KOB([+<23B=G<$=4";!F5\3;,$PTMJXN1["*
M@U8X*LI@E7UE8@4)+;(%7(D3*G.!=5DUIU3@QLJ0-VE<;<8$[`NNO3P6M;*)
M3'H<VHG:#5F2@MMRQL%#8\K8M@"1;V(@5N36I:H\6T-"Y4Y+#`6N3IW6((>@
MQBMEO\!9,S$KHK$W<<%A!0M/AQR$:&*<<NN&2?A8TE"\OP5OQ6GTS8CSR),*
M6PP$S.O>L]$M,!TYL1F>HGD/@?(W%`CS_'$6R-1U/>)/79N3Z&8M4X>$6<\%
MZ"ID%!*_'O`%![[X5/7=(ZC+L7L(4QN&]4F?7@='L$M!>Y6:<U#%;`=&J"%+
M`X,-NYK0J$-+0CUADE$)E`0:GI4\=X9E47@>)>A=5#)"@P:WLB[VQ.Q:[6BX
M"1$VCD<G)4]10%[EUV4B=<D9@3A@P_'5'<*9&I/1FWB`=IV.TZAH*1`I'664
MD#8D,QL]4LM$+38<5[:2HDK$4'86*D1>G19EMCO"TILTJ.#AX))A+*DUYBC,
M2W$.8P'WK,)OC9;7;$WG;P<R/?Z;028PQ;-A-SX,RYVH/48<I*D9R.D.PR)?
M$J4*R08FI'CB3^>]6TRS)"V-N$]V:FM$2N$-Q;!)9G@!=BB2&K5;X#J8A/,A
MM#,N'(*+PS*9>BOI=1'E3&.\PC*9>'U.QXX8P]6';GG2V-[?;^[>S>WC&<=O
M[9^WV9SC^#.?I\!ZL.V_.EL;W[V;XSX#U8=M^=+8WOWLWQGP'JP[;\Z6QO?O
M9OC/@/5AVWYTMC>_>S?&?`>K#MOSI;&]^]F^,^`]6';?G2V-[][-\9\#*6CM
MJ[0(;KT\/G[(OTZ!/VEKV%.A3+A89,2;#E6X.S)B2XSQ%;,B+)94II]AY"VG
MFU*0XA2<YQP/Z0.`X#@.`X#@2(GSU&^^&?TB>!D#@<B>YR_.6Z/PBK?Z*P\#
MI=P'`<!P'`<"0KYU9^^)/Z.)P(_`<!P'`<!P)#/['+^]T_K4;@1^`X#@.`X#
M@28?SRS_`)^/Z,\"-P'`<!P'`<"EG/VE,?Q60_5'N!SN[FW^XC9/X4B?ZJ7P
M.DO`IY=AV2(*1V4Y6Z\/G,M(3V84MUV*\AM&%9RG&,J7V)QVJQV9SVX^CP.!
MU9Z>.M:F#"(BK4NRA1Q9V2^1BQ#-/PW*>EUNQ4]]UQ3AAQS*\UVUV`:WE"T^
M!P17*9RS+9B2V0O7&N^Z$)E1YJ0UH\=BEX9IB7XWKOQEN7`*,FXC6).)/A<B
M&3D=HZD"I?H&HVE!=P;DFM4G@4C&G>O%(IT+BMV5(U8<>!;91/H:78@@77H%
M1CPALO$[QT5A^KB!8$LZ,DQ9!\5#8AFG2##?9P)3VJNOUZ1-E^E^RQY9&>7+
M3),"9K\=(=*V`Q3K$:*)>'RXSC1(B>U_3S$LBRIN6LB%1-RXEZ80<E`>U'UY
MN389-=,),OL$B)MA$9G5\.`N>8!.U4P^\+B/,#);9<$Z^-+1I4-Z*38?DJFL
M/.S'W,A=A*F]=!R%6AQ_5\PC$$$E3[(XR1J`@K=V'+C"NBQ)HZ),0S$$=Z)C
MX7>P@<P9'R[`@$7(SA.#%E-!CFT:%ZU+>7V$8*Z\+)>VC/8(6^+'(T]N%-\3
M)MEAD*.VZ;?>@CQ,EB.V-C,/I\7C1(T5Q3S+>$*"N#=7]?PEH>Q`K5@:C#H,
M`=$BNO:YE14P1=<#U,?%=C2Y+\>4W#!`0D-G,M#JVG!D,AV8(M^-Y#V:UEU_
M,)=::K!=,63)-RR$#P>KU"3,RQ2X4\O,L`E2U#+!,D3!@V0S*.12,F"Z-@J'
MKCXA1\MA;=;T)UMU&.W'K%"(!.\."K&J7`]39LG(*`S8^RB%3B^92BI$>,/B
M1YF(&G3'PS<^(Q)P/2\VEU(4:W=,G6'>Y\0G9];E2$@>.;$CVX\JB"8`X8U)
MES\0!HH.1@#($7QV?.G.,0H;27)LV5*=2I^2\XL+6]99U/\`>Y7ZDI?O<*PG
MOO1NJ]G?9QG.,?N@]O.,9S_3P/GUEW4[YIB_NW5?E!P'K+NIWS3%_=NJ_*#@
M/67=3OFF+^[=5^4'`>LNZG?-,7]VZK\H.`]9=U.^:8O[MU7Y0<!ZR[J=\TQ?
MW;JOR@X&2--](W477=NZML1K6)2"%KVQ:0=,SG"M<<;@BA=I%3B$QQM@TZ^X
MB-%9<=4AEIY:T(QX!.5*RWP.^/`<!P'`<!P)$3YZC??#/Z1/`R!P.1/<Y?G+
M='X15O\`16'@=+N`X#@.`X#@2%?.K/WQ)_1Q.!'X#@.`X#@.!(9_8Y?WNG]:
MC<"/P'`<!P'`<"3#^>6?\_']&>!&X#@.`X#@.!2SG[2F/XK(?JCW`YW=S;_<
M1LG\*1/]5+X'27@?+CC;3:W75I;;;0IQQQ:TH;;;1A65K<4KL2A*<8RI2E9Q
MA*<95GR>7@8F]7_1'GKU)^<BG?'/`>K]HCSUZD_./3OCG@/5^T1YZ]2?G'IW
MQSP'J_:(\]>I/SCT[XYX'N]U`:'4W&[-V:BSE+"L*QC9-,[4Y\:?SV9Q@UY/
M(M.<8[/:SCL\G`\?5_T3Y[-2_1_\Y%.^CY,__G/T<>3/T^!^>K]HCSUZD_./
M3OCG@/5^T1YZ]2?G'IWQSP'J_:(\]>I/SCT[XYX#U?M$>>O4GYQZ=\<\!ZOV
MB//7J3\X].^.>![XZ@-#>*J1ZMFH^^S(0KL]4FF]O9AMS';V>C/M=OD[?I_3
M\O8'AZOVB//7J3\X].^.>`]7[1'GKU)^<>G?'/`>K]HCSUZD_./3OCG@/5^T
M1YZ]2?G'IWQSP'J_:(\]>I/SCT[XYX#U?M$>>O4GYQZ=\<\#V9Z@-#8P]G.[
M=1)[65]G;LFG>7.5([,8[3/M^7R=N?:^[[8>/J_:(\]>I/SCT[XYX#U?M$>>
MO4GYQZ=\<\"HB=SZ>/DH88%M?6ILN0>Q'@"A%[JY(E.D9QE6&(<&$5>DR7LI
MQG/@F6EN=F,_,^3/`R5P'`<"1$^>HWWPS^D3P,@<#D3W.7YRW1^$5;_16'@=
M+N`X#@.`X#@2%?.K/WQ)_1Q.!'X#@.`X#@.!(9_8Y?WNG]:C<"/P'`<!P'`<
M"3#^>6?\_']&>!&X#@.`X#@.!2SG[2F/XK(?JCW`YW=S;_<1LG\*1/\`52^!
MTEX%*._M(9_BHA^J/<#^>?I]TI2]HT_8):UEB`6:"L5&A`9\:=%:AI#($WR\
M;.D2H;\:0[-EC:!124T3WCD5IF=EKP^)+><M)#)QCHKS/MC\*N6]L((*7R-7
M04<O#R81`&%;RS2A@Z?8XCT!B;>&TRV+0_5FQ41]REIS8?&VU=]`R%DL=)F5
M#)-@>V%&P`0#!6B/,;KRTO,5\QKZM;)0Y9L/&D0JL5)BK+@%3X:Y92':;<.F
MAFB$!EGQO`7O:ND.O)BEQ%7L\X2>KFS]FUMTE>8B!HTO3ZY=]'4<08ER8TU<
M<0B"_MADXT3;AO1;-7G,E,(#>#BPG0M,KT>$!)82(7<WYLXQ;GJM&%PZ>ZV=
M8<@U-NW%WY8\K81L),B`.1-4R.B&)CA3#8[`Q^3()^)Q`JAOHLEUE#\FP[)@
MBQ<4VH;*L3]3(MUF/$3L49K_``MTR^48;2=<28B69FM99\:=!#K*\F5E05GT
M3#'\CIWEC6=VU[""]LONK:]KJ>L=5H3TMN`>L1$,BX@Y42(T0DE,5-DA-%39
MT?,5I!`9)EXQB,COEA>H_HUFRYH^-)V+!ALS!3$Y<A-:?D>-./V/4==;)5MI
M1ECTQTJ4_MR!Z'7!I<)N?.K-C'-AV\QV7I(8_O\`TZ3]9:\$['-FD'(KMKK5
M?F#!@V7%$2\G&;Y->CB+<\]E,Z:+8HKD$['2%8<#DC#,=?A<PLYDA?ERZ:P,
M^9M*=2B;E;":MKU:(2H9F6]:")*8;H*KZ[)).CX0]RO!5(9=K\`GZ'$F'3$@
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M#P0:&#$X2ZVZ:BL1`TB=PVEYU++BW&4N+PTZMO#2W6NU6$+4UW[N&\K1C&<H
MPXYEIS/>]^XC.%<#XX#@.`X#@.!L/TF>3J0T_P#A;'Q__JR<?T>3^#@?TH\!
MP'`D1/GJ-]\,_I$\#('`Y$]SE^<MT?A%6_T5AX'2[@.`X#@.`X$A7SJS]\2?
MT<3@1^`X#@.`X#@2&?V.7][I_6HW`C\!P'`<!P'`DP_GEG_/Q_1G@1N`X#@.
M`X#@4LY^TIC^*R'ZH]P.=W<V_P!Q&R?PI$_U4O@=)>!$(1LS1\Z&A:4+EPI<
M9*U=N4H4^PXTE6<8QVY[W*N^\G;C/DQGZ/`XX^Q@WKSH5+W&,?Z_`>QA7OSH
MU+W',?Z_`>QA7OSH5+W',?1[.W_C_<Q_)CZ7`_/8P;UYT*C[C&/]?@>BNY?7
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M*]^=&I>XYCZ'M?\`'^AP/OV+Z^>"RYC:-1[/")1V>@QG_P!'*O+GO_N9QCR?
M_OP//V,"]><^H^XQC_7^[G^7@5L+W./;%>092#W'7!GI@"S*V87#$F&W9H(@
M]'D$!BWL9R\S&G9A,,S41W&LS(>9,&0I<&7+C/A1?8PKWYT:E[CF/]?@/8PK
MWYT*E[CF/]?@/8PKWYT*E[CF/]?@/8PKWYT*E[CF/]?@?:.Y?7Q>',XVC4<>
M#;4YGM#F?+C&<8[/\/Z:L?\`;P.6?4N0&],FT-\:LM;TLR9TOIBI[8&314/+
M$/99"UW2BTIJA5;,I].8]@%SMD50H4=G9\#&`OE"ZVVQHF3)2&>X]`T;'@J7
M:NJK6=/+C->-;&M(@J"N+K-7'LT$)LT\&EV&$-<KI"TUBDGQUF/5061E6<=6
MWD6"4'9%*S+0&7=4PNG/3=QUUN>Q=5NO%UP->K:.?@NU38(TU%FZW=&P+ZJP
MB)X)!>G!*@NS5R59+7:QP>JAAMBKY6<98&F14V8&ZAONK734!O,6N%$V\'41
MUZZB->7_`&)9*G;!@FF'.G2+6Y%B)QX$&NFI%DJ1+!]]]ZRQ9$*-5QHB47LK
M(X>OPK09^MW7GT>T2PW:K6W?M$"&==#XY2Y-R))!V`(B/E:R$D8P;BCWPA&4
M&(W*KHLXX20G$:C&.CR%HC"1SV)>`^9O7ETD#)MN&F=T!`).ATNG;$M8VQ`[
M=72`FBWLO6J]6[6N":KT"5+"/G;C5Q!2</9EM5P@;A1;-D0^XI"0^P'7OTBF
M28V#`W,)65E$0@YH#)KUU@63!@QMROZ.AU]^MSZS%.Q;,G:5HK=7GUB4/9L`
M?T?"F2XZ#7RD`M(#>WT6A_2F>YI+_9.!R;[G+\Y;H_"*M_HK#P.EW`<!P'`<
M!P)"OG5G[XD_HXG`C\!P'`<!P'`D,_L<O[W3^M1N!'X#@.`X#@.!)A_/+/\`
MGX_HSP(W`<!P'`<!P*6<_:4Q_%9#]4>X'.[N;?[B-D_A2)_JI?`Z2\!P'`<!
MP'`D/?L<3[W5^M2>!'X#@.!YOOQXD=^5*>9C18K#LB3*?<2S'CL,HRZ\^^\Z
MI#3+33:5*==<4EM"$Y5G/D[>!:WI^HGV:U+WQA_]LX#T_43[-:E[XP_^V<"1
MZH%#\45CT[5+MS(1V8],@?VDM.8^O/H>3'_VX$?T_43[-:E[XP_^V<!Z?J)]
MFM2]\8?_`&S@/3]1/LUJ7OC#_P"V<!Z?J)]FM2]\8?\`VS@/3]1/LUJ7OC#_
M`.V<!Z?J)]FM2]\8?_;.![L;`H>,2.V[5'';'5C'_"0-Y<]^WY/GSX/+V?3[
M,AI1M#I$Z-MQ;,([8V"3&GK82*/EW\R-A#O0IIV3IXII)V)&&9D+8:&9J959
M/T/[51E6V"+L;C:I<)",AC8OW._H/.!BU:('BSM:+TXO5\UGU<".:X.,V34$
M#0MFV8&K[AAP0.V?9M2P45$S:&(7@Y;4\T82.:L%@-EB`8YZ@]*](1.X7$<&
MU_O+=5FLDK9NQ.I+UN=\,YF5C1^]8]&!;:`[-36#XB1:*!L-.J*K(@:,KWH[
MM2W1*?:"NMJ_,]#3S4H-@8G0ATD[9!6BY5LA8['0MX5[?!")FL;`?FT;T!ZM
MJ$*IVU2E!3&3*B"H5N!PHA,?@?(<'BRKSDL;'996F(V'S.[EYTBS+AL"[M4X
MR-+[-D!"5M0/.8;8DGPQ^H67TPP'I$*25$D2Y2D!WCT8<2C@R3CQ64X(00+3
M)K@:A=9W1KH%%KW!C3E-W'=.J7?X1RT;#$:Q.SK.6I>G']RZ6VMLF]OB25KK
M"*Z^;,:#AA]4BQEDC7:UW260K&LQDX/7R+=)#876W0YH78VS.E'J,US=(]XU
MEK"R[:W?$/F9=DM&R]M[DVS.K3+AR^WLJ;BYP#ILZH!I;U!(5..5`7C7M)@.
M^@C%,F@)0=D.W'W/^S_4X'(;N<OSENC\(JW^BL/`Z7<!P'`<!P'`D*^=6?OB
M3^CB<"/P'`<!P'`<"0S^QR_O=/ZU&X$?@.`X#@.`X$F'\\L_Y^/Z,\"-P'`<
M!P'`<"EG/VE,?Q60_5'N!SN[FW^XC9/X4B?ZJ7P.DO`<!P'`<!P)#W['$^]U
M?K4G@1^`X#@8DW]_B(W7_P`TFR/^YQG@<,=`]/E;W,!<D3+.0#V/%XB"(0IG
M,)$<U7(0G!>V8&OR6'%)L@H8MVP1&GLYB2@P4TWX-<S$1I\+NC=+==-1Z.T,
M)6D/(*HZ>GSY@ZX-=KY"'N*BOW:UR*\Z@8*R-?UZ/'DB,J'-FG$2PD=^;*FC
M'(F(\L,0WO3PNH7J_"6RDV33*W0HFP`1=N<&)2RHBUC@+5'3@B(<D@RG?6.W
M`AAN8#7)B+9BEY(]U+#*9+(9K=Z2P*]:1KV/.V*:1G:G"GXE=;P-S,?V,0J\
M#8,V$VUF*EU=4BTPN'=3AOOB>"!8?VS7&'L,MA47.C^JQ-K`:Y/NTE&ML5(F
M0N-T:.4K"0MH!WC&KRPQLL[/16XR$6TE6R<840E>C:@IF,)=:185J:9#%8'1
M-5:U[=R^P+%-J]RKNQ+;K0?"Q-C>(N6JNA8$B")R'P%DE2CA2P2EBI<MDB*C
M@X"5EI2928^8<@*]#Z+KP0*3A<2^ZSR[$V3*U:SB2<(#Y)&R"SE?KEA0-'D1
M46?,2",V2/&>;C,.N38HPN2@I>AI!OFP@#^CK816,2GP#M:=&PJ_7K-$GR/1
MT8@J--Q43'V8T$N(@EF"@F,I4J8.ECT/>)ICS5*1"+A9!$*[2^BVSV<K)3,N
MM?A5\5?)=')%X,$S+ER9`^2^'F30`>?!$3"T-JTQU5M<M2(T1,OOWXSDU,64
MR@+5?Z6K'+J8ZX!S85J%+H\RU,QB$HL\^2=#@K=:S3??L5J+#JS2:Y5)+D%J
MRRVF995^.+8*RI"IF1X8^W3I`_I$O`$G#8(_DC)L\%N6`64\$S-J-E(U@M&?
M04&C'\+1*A8?;=99>BNLNIRU(4I*TH#$%4K%@VGM?5NC*D>K].L^WSL\$.O%
MQ4A-8K$<4-=,%Y*(CDB&JUW1\5'E9HFO(4J,0MY9ES$B4+KPJR'1`?U4=.O3
MKK3I?UH-UCK`9(8'LR'3%CL9AYJ=;K];Y[3#9F[78TVQ&R8LAC,:.VZZVQ&&
MBAL4;7*Z-#UH.(#P`U,W<EGHFLT7;%`BS#>H]Q[&@@KSTWUN.HC;W-IWJ>\\
MO9?355&%)?*V`M(P1LN[=2C$-#CX2%9=U5[(>X@KY$VH%"O?6B2\5I-4HNGM
MK4?8&X+.(H%$MG4-K.QZWTY3K'8I1R'"([%LLU^-_=V\@U^EC7XZ?"M&SK(8
MIM(`31+]M58`@;M:,T;7='UTG#B$REPO-P*8L^T]IV?$5RY[.N;D5B&\?/OQ
M&6(<*%"B,1P]3J@=B%6*16(0VKU<8/#CF&.!JUU`#6^D.R3>IS7&4.4N]7>M
MPMZ]/\)2,3-G6^VF!]>$[$T,'PI.%]1,R8_$BFJ(.0W#WR/82U(\1V",%'20
M;:>JQ$^P3:'O+D_[5P.;_<Y?G+='X15O]%8>!TNX#@.`X#@.!(5\ZL_?$G]'
M$X$?@.`X#@.`X$AG]CE_>Z?UJ-P(_`<!P'`<!P),/YY9_P`_']&>!&X#@.`X
M#@.!2SG[2F/XK(?JCW`YW=S;_<1LG\*1/]5+X'27@.`X#@.`X$A[]CB?>ZOU
MJ3P(_`<!P+&V?69]UUIL.FBGH<<K;:-;JP.?(./-0&)YZOSQ4-Z:['CRY#41
MN1+0N2Y'C27T,I6IJ.ZXE+:PX_Q>YP]1,#P6(-\UE#PQ(S+9Q%M%YC^!EY:R
MQF4UX&C(\'(RSG+.7D=CF6LY;[[O/)P)CG<\NIAY,%+NRM?.I&1'1XU+EROZ
MTCX#\3,!Z%!PJDYQ$B/05*ANQF/!LN1,YCK1EG.4<",KN;_48Y$4VN^ZQ7%R
MW&@JCKM5Y4SF/%4Y(B1\LYHN6\QXSJG'8[.4^#9=6M;:4J5G.0D,=SQZF(RF
MUQME:]CK:0AMI3%QO[2FFVXD2`VVVINDIRA"(,"#"0E.<)3$AQ(R<89CLH0'
M@KN='4>N*]!7L+6RX,EYR1(AJME[5%?D//,R'GWH^:/EEUYU^.P^XZM"EK>8
M9<4K*VT*2'S([G+U&2_"9E7_`%I)\+/<*N^,6J]/>%*.XPETDYX2CJ[^>XE*
M4N3%=LA>$XPIS.,8X%QUCH3ZKZ<>AV6N[2UQ!,PCL2S(D+LMPGL/GX,O$Z(5
M(#R6OY8XK+9F(1([XI$F)<<[[+B59SC.`I>.Y]=4"7)CV-HT/#I'+*B#N+ML
M+#D]4=C,:.J8O%+[Z5EB-G,=G+^5Y:8SEI'>MY[W@>;?<].IMEM;36S=?M-.
M3LE%M-W/8"&UD\OLRLD5H32L)5.S)CQY&9><9D9?89>\)X1I"DA^9[G9U,2&
M9C"]D:Z<8DPVH\UEVXW]34N'&D+D,19#:J/E$B.S)D.R&6'4J:;?>==0E*W%
MJR$6?W.3J+*J2LI?]:$EH7(<0J?:KU,4AR6]F1*6E4BCN92N3(SE^0K&<*>>
MSEUS*EYRK@6T8[EIN8^/?&$[/JAV,ZY'?;<CV>]P9T&;!DL3QA063@TB,1$F
M!!&-&)AC`R5%)B"<2&1'2X\Z*S(2&]NO^I?;O2[5!>K>LH>8V==UPTB](;1U
M&$*VZ3U$E&U9CBM6FH"0M=B5CJ":9PU)G23#-<UW<JTP6V1&/5\?6-D#:2&7
M=6ZMN!6X.;_Z@'!93=107+$U:K"):RM'Z?*.46Q(?UYKR1(8BY*GRV8L%[:6
MT7X4(SL(S"C1HL4%1052J(0,W7*EU78=4/T>\`!EIJ5I%R@]@KQF*B:,+"YC
M?@WXTEA:<ISC.,]^VZA2'H[S:'V'&9#+;B0U9';W.]'+:J#U!3+UL35+B<PM
M"[H'`SVP+\9(*QEL'T^[2@A(9`V;VM,<\$'U-L%QG+6XDYBUJV2XFUV&26S`
MO/6&NKOL'8(?J(ZAX#$*]0_&&M/:>:GQC-;Z=JX8:\4FK7-AK>$VG>=H%/KA
M;"V#"7('`1LB5K?7,OTJ^F6R[(#=_@<B>YR_.6Z/PBK?Z*P\#I=P'`<!P'`<
M"0KYU9^^)/Z.)P(_`<!P'`<!P)#/['+^]T_K4;@1^`X#@.`X#@28?SRS_GX_
MHSP(W`<!P'`<!P*6<_:4Q_%9#]4>X'.[N;?[B-D_A2)_JI?`Z2\!P'`<!P'`
MD/?L<3[W5^M2>!'X#@.`X#@.!)Q\YJ^^6_T3G`C<!P'`<!P..N[=@=5$?J/Z
MY9U-N%V':KZ?NEJ/;J</&6"H#J^+V#8M$[A)CYBJ61U%8[%L.8JV@@16+F+L
MRJ1:Z5&PU3!%B'RI`ET--B/5QU;D-:&-;]/6WMV;[)[FC])E:UAN.'K;7,F\
MT/;AD/M':'5S1Z.5DT[7VMK\"INL]4!WG#-E9(-:\L^RU5DB;(2(<.`(#9C:
MG51U9[!Z<>YN[3Z=&"<#:VT;44+;BUD4`16<7TEIOIXV]L/9^D2BYPM]ZM.7
M+8.JRE"`'X?H4_",SP\_"VX^51'`TO`=;O5-;J^"MPC>VW`NUS'3'2]E]/.C
MW-:U`FC>^V;+UG=65&>H%]J#FN3=AQ%?U92]956R3ZW8*NO70;"+W(,,2(SQ
M*0&]_39U;;YNO="=FUR\P-C-]+^WRV\:!TUO%:G7H%!BVGI6(4^I6656ST%;
MEN(9V#/&;FLTZ?:TPQ;K`.O0:DS);25?C!KSJWJZWVD1>[A;-T')_I!ZY!0;
M:8]VU4VQOZ]Z:!G5ULG6Y:8;U0&TJ`LFM*:SK]-):+VLG>]@.DJ\A%[\=J0O
M!%QH+^WGU']7D;HVK>U=4W.RQ;]=>NWJ/G:SD3*9#\8V+TQZY-=4FU-94=D7
M.K#CXFO;&U7J.L`JI8R4`46)CB@`EDRI1MF80#5VR]9W=`K?K[<%+UP4VP[O
M/<6]_59Z>(57US299S6W2T:Z41O433ZI)'V.(,"X\1MY^AZRO+-F?DW)ALS9
MU0^_/H#P9(;.!.Z$[HV3UD],-^I`3:$#H]-0>F+6&UQ#%.`O5"%MOJLUQ<[M
M#DVBQ$.\N(XOKJP6OIOK&(H:(Z!C^C.P4VJ<-F0@L<@']&'AF?JK?\K?^MP.
M0_<ZGF6H6YO".(;[ZQ5SL[]6$]N<-V''S/;V=ODRG[OE_P"K@=*O&XOUPS^4
M3\/`>-Q?KAG\HGX>`\;B_7#/Y1/P\!XW%^N&?RB?AX#QN+]<,_E$_#P'C<7Z
MX9_*)^'@>RIL/Q9I/C+/?)?D*RGPF.^[U3<?&,]GT<9RVK&/HY[/)VXX'CXW
M%^N&?RB?AX#QN+]<,_E$_#P'C<7ZX9_*)^'@/&XOUPS^43\/`>-Q?KAG\HGX
M>`\;B_7#/Y1/P\#V:G0\-R>V2SC*F<)3CPB>W*L26%9QC';VYSWJ%9^[C'DX
M'CXW%^N&?RB?AX#QN+]<,_E$_#P'C<7ZX9_*)^'@/&XOUPS^43\/`>-Q?KAG
M\HGX>`\;B_7#/Y1/P\#WBSH:)#2E264X2O';G+B<8QC/T>WVOY/:^CV<#P\;
MB_7#/Y1/P\!XW%^N&?RB?AX#QN+]<,_E$_#P'C<7ZX9_*)^'@/&XOUPS^43\
M/`>-Q?KAG\HGX>!2CDN+Z"E\>,,^460_\HGZT=^[]W@<\^YO/,,T?9&'74(5
MFTB,X[]>,?,X$N8S[><?1[,_!V\#I#XW%^N&?RB?AX#QN+]<,_E$_#P'C<7Z
MX9_*)^'@/&XOUPS^43\/`>-Q?KAG\HGX>`\;B_7#/Y1/P\#V=G0\MQNR2SG*
M6<I5CPB>W"LR7U8QG';VXSWJTY^YC/EX'CXW%^N&?RB?AX#QN+]<,_E$_#P'
MC<7ZX9_*)^'@/&XOUPS^43\/`>-Q?KAG\HGX>`\;B_7#/Y1/P\#WQ.B>+*1X
MRQWV9"5=GA$]O9AMQ.<X^YV_=_@[<9[>!X>-Q?KAG\HGX>`\;B_7#/Y1/P\!
MXW%^N&?RB?AX#QN+]<,_E$_#P'C<7ZX9_*)^'@/&XOUPS^43\/`]F)T/&'NV
M2QCOF%83VK3Y<Y4CLPGR^WY/+]+';V^WC@>/C<7ZX9_*)^'@/&XOUPS^43\/
M`>-Q?KAG\HGX>`\;B_7#/Y1/P\!XW%^N&?RB?AX#QN+]<,_E$_#P),*7&S,B
MI3(;SG,F.G&$KQG.<Y=1V8QC&?+Y>S[G;_!P,D]O_P#,K_Z__NX'`_ITW;0.
MG34>_-O;/G%!]*KEPUL,(R`8`O:"RR-VM::%6H0\"!B3RY&22L]G"#TMPXCJ
MF\S,NN8;99=4D.A%`WO2-ASL!X4*\U0[D&'L&0.RM=776Q7Q(\?NE<%QFV;D
M$#M2C#\NA'IS@&&](-0P3H`]-A1Q-D!3"*MC*T0H,GIC*@DH,Q$R.N9$5$F1
MY.)41MQMER5&4RM>'HZ'76VEOM=\TEUQM*E84O"<AA0)U)ZJL)SJ$`C"TU^1
MTQY`^JI+0/=?'1&[%K89M>`\"EQ52,'FTU`Q#?D^)(RIF>E\?A"W6^^R%EZ)
MZT]!=11.(#U\<ML$\4UF)W2""[`UML#6DRSZ?.O0HXG9U1>O-;!C;9294DF/
MC+.5R<3CP)$R$R3\3<F14O!M`DF.4J`C$^%E91M;HQ"93&5DFFVD2''8&/"=
MLQM#"VWUKCX6E+*T.*REMQ/:%D[)VSKK4.O[-M38UL&UF@4]E;MAL+V))!F&
MX@HT";'1X8F//)E#<L^\Q7QP$3"G&RAZ3%"#ATDM(:B*#SU[M&O;'KK-E'"[
MQ58CY=X''';/U]<]46.1-::;D-98K&PPE<.OQ9L=U#L*2U`4T]E$N+E2)H\A
M&C!>;)P*^I:&#`MY;3K3#B&B$5Q3;\B9)',,.80[GO'GB,.9`9;5V+=FQ)$9
MM*W6G&TA@>H]5&H+KK:U[5"DC[]5I=TN%#/-,58Z5LK)RD;&*:K,N1:G7X9F
MPSQ>;B'GQ89&&.?9?A1WB"\-18\IQ@,\MFP[J9*FBPUW$..[*EJ1/C+3%C,2
M)41^1(REW/@([$L>0BO.N]ZAN1!FLJ4EZ*^E`8HO_41IO6A&2$M5W@HL[&N#
M6VV*:"B%;5="VO*]/&BBEG`U&L0B]@/062):##1Z$#I;S[KKJX[;K,28]'#+
MCY49&5)1))0&%PT1')B7ID=I45N>ZXQ!<DI6ZG+"9KS3C,13F$8DO-K1'RM3
M;B<!BO=&]:%H;5=DW-=\V<C0JC$>(V(A0*;:-CSA8B%EW)<[+$4@6<),`:_'
MC3)UC./1VQ-?'0I<XO*AL1GG$![Z=W53=X4H)?:E&MX818T8D!1VQ:3:-:6N
M;`=Q-7`+-U"\"P=D0'-1QT^<!*N#6X1P;%?)"WY4!O$G@?"MYZ[SMRMZ4C%'
M2%RM6MK'M<8\/;:E5Y-/K-KK5)ER)!U$C$/!"99+8-@"1;'C,PAXN4?;:\"+
ME+;#*BYT)OQS*ID5"1V.^(J7(:PF`GQ=,O.9F<J[(J?%5)D]KZF\>`5AW]C[
M,\#%>H=Y:]WA57KK02CTNM^G+9-(&D"+'H<@\0U3=#=`MQ.OI?=RLM7V+'7B
MC$(NQC#$N,QB3G#:5]F`R8T9#OQ7)S!8<]"9\!X66U.C.16_&XT29%P[(0XI
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M2$.2&'H[:F>_PM]EUM.<J2K&`DNE1K&'E/D8#.(TR..DY<EQT)CD):(KD6$]
ME;B<-392)T)<:*[E+SZ9<;+:%8D,J6'Y@H,RZAG!*#EUUEB0VSB9'RZN/*:F
MO1GT-^$[]3,AH:1=8=2G*'6H$YQI:VXDC+80BUHK8`4X=-V`*("LC9AATL3*
M0H0U`D?"63GDU39+S<?Q"&.:<GR9??YCL0TJDN.883G.0HHJWUC8&NX5XI1P
M;9ZC;ZBBQ5BPAY*98LV$,"LSAI&#);\CT>7%>:=:SY%?-X2XA"\92D-*>YZ?
MN-V%^%`S^J5\#H=P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`?_?@.`X#@.`X
M#@3A6.TH-[/+G,^'C'T?;DM?=X&=.\5]+_MQ\/`_G&IG3FOJPZ;^H[1*+(W4
M4VO8VA#CYU<:?*RQ"UQMT%LZ=":2+*!B,>09@TV0&AD(9.))%2"3))MQUR%X
M)87AU#]RH8W&:V)$J.UE:^INP*7T]TR++(PK;L#:%`;T7>-J[`=L5'V-:;M)
M.Q+;9B6PXM?:L)";-E`:CZ:0[*)S!R(R+#&9GN.I^T['.WLMO\76TVO1D35$
MAC7M!.58IKJ?%Z9BG3HN+J>=!V''@"-3REDE7AG51<1/&#)4@L+;(S"4P7;P
M:Z,T:,[F'C5@/>T,CLL6$F[>Q7Y8T!T]5ZV:`U,#)!M-B-4/H/:R";"/P+J(
M*O"&K06'6`E*B$CA6Q351XBC;S#(8WE=RAV%=*%I@!M3J!HM@,]->E-/Z.TN
M"$Z6)LZL)575]TU5<+$WO:LEMI3S&V(6VF=/5&KVROP3M)K@H"X6\1$D9<WP
MJ0^!G<BSHZQT<T-WQ7:<Z%J'4%7#1*@:HGBR=?A=0)K<!N?2M%#+#LBS5/25
M!H$W:L=S7LRJ@/5*%8K,D80O)4#8H@6J!>NGNY82=;])VP^G"9N,;'L5EV%J
MG9]1V'3*"2&!*Q>])3J$6HEMFZSL%\L08G))$M=5_P!.X6"5"QSPEK,#)-)/
M#!^.%7ZE>YY;<ZL902Q;6W%IE%K3K*VZ>*O"M#68F#I86RVZKVV-M71<6R;J
M)$M;;[$N5E8N-=I!*PQ,#YXW#0YE=9RBP!KX4[B?"FS;:=8V71FK<>'[<D#;
MF_JIEVTB;O?.L&G=2=0V`H\@XR3=M="IH`YJL><8E1BZ8MHGR1<\4*>FA)(?
MI;N+Y@QC:2\[GU^!F7>=NR=`,5'34P!:K`G=G4G1-[2!NYK/C8,M>RP^NQ^N
MQU?UX.;$@4"29XJ6<=6T/C1)@77/[D*;C)NA&E;BH-2ME]#=48JWV)W2HX_F
MY1]]]2=+WQ6(-SA3K`RFQ1:(#JL^BCII%^01!RC+=QJ+@8B'B1%AC$QW$(R[
MKP;2!FZ]>RID/2/4MH)L_8]/F"LNM4W=&Y']PTDAKI^5LB<7J1.AR)).G2(L
MPO8V"%/MEV@Q),*58ILU89#VYW'4EM`SMF?G==.%LWVT;=L\,VWJ!_U2+4UN
MG:]$V61IN\[YF_O)VA2=:QZ0U7M7!6@%?0*CR!;SRFVZ]B*6#:A/01-&=*_5
MYTOU+80:G5[J7V=N&R5IROT[`\!JK76Y)89L[KT)5H92./PPP&:LL5#@I8<<
MY/L+LY(UA>)67PMOJ1[G*YO>_;2V=`OE-`VNQ@^FNCZW1:M:RKO7:CJW2-R/
M7>]ZK/"8=SJ!`O1=WS;&1!WH96SM1ES:DN5791"8)-FX4H-::CW%(0,L^IR=
MGV?1#06@I!322ANEF@EQ'G*[U4[#ZI,S]16&'=$!=5.W8G<0%!MI&'4C!N#K
MFHN4ZID!`NRRLBPJ`/N.AL.J.5E;^J5@L+%FUZ_8VS.D7UT_?=:J&T=C;1-R
M>JJM,[10_N^\60]?H)')9XO608N10@`B"`8K98T-4%/H?<:S=%(U`TWO*N6`
MI1^G\M0*;*+Z^L<-_7>V2%+VD'=OFN<5O8H(.%J4^[[3+7XI2C=?L$>5(45A
M2WY\Z;6#5)#WF]Q<@11<P%3-J4,'6'ETD<W0[-I-JZZWGCZCTI1.G&#<;%2T
MW:L1CVUP-GF7+<M8M1B>2'M6:PQXIH.5G#8%CB!=47N2)@;&O\8;NRJ2!MB/
M].<F'6KAJ<M?A%\K73HX)A0Z_OX_:MG3=@7X;L6L537P2[5&K6^AZQ49H\6U
M1Z&[Z/DZXP'YKKN/HNAVK5%D(;6&7*3J6]]-5AK!`G0FQI0%6=&W#<FW+/4*
M7ELZ2;I@&][@VRV1'`A;KT"I4&L#*&V\3']ZY@-ZP_2.-$=5MAZF\;-VQ)4:
MI8*O-4:5L[8$FMLDQ]DOYN:F0&?LCE?F4K$>Y,(KU%4']!*T3A2C`QIF5/7X
M,-4#W0+U)6*N[KH4OJ$TPC7^TNJV1U/I#$M%7:RO61J9L2%:)&H-RL/;R#A]
M@ZLS50]>JK]=$#*@Z88KT-@Q/DBY4Z"^&!ZMW&0]2:L7!UK<NIVYQ6B:<J[T
M\QT]KG,3%ZZW_=MX7ZKFHH'9=1<FZGWKB]E*SL^E"I5?G%@L$"":L+59'S0A
M<*M0NXR1*Q/II,YM*IEBE*O&EK,!*`]6#:W*`CM?=4.W^J*]L59A)`@-KA38
M)[8-4JD:8-@M)KM1IB@#>9X0A'&"V1CDUW(K:U0%ZVK-2N&M=G3;+M#1\7;U
MAL>K<`M:$-==/CN\-P1-@;_U^_N-ZR=06U-N;EME1$7$Q$-M2,#Y+8Q$$;3(
M!5U09D:[CH&A4M5>1M83:3]8UYTQ:UUR9V)KUVSB&:/HF]6?9FP=;6@"S;QD
MMO5N][);2X*Q56HV"ONURAXBU2,4.5])`.3"GS^XZSGPT&OC]W4R#&%]/?4C
MIJ,55I%PB_@CU(2MG&"$FOU<_LL[3-6T_7EGV<7*4@;J012[BZ`8'T6S7H^`
M@K7.#K+K77D74^C:AK6)!JH]-)UN-KLIFCUY52J+A0>`0T9G5ZMN$3$@,,*%
MTS2<>!-,ER#.)?9/+E9JGYTD-4NYY_N-V%^%`S^J5\#H=P'`^>WV_:_ZNW/\
M/;]+M^[GLQP+(J&S-=[!F6T?1+S4[A.H-DDU"[PZR?%FY%3M,%.,S:]86!TJ
M0X*+1%=\W)@34LR&GVGX[C:'F'FVPOG@.`X#@.`X#@.`X#@.`X#@.`X#@.`X
M#@.`X#@?/T/;\O\`#[7\F?+]'R>3R8SV8PK&.!4P_P"VPO\`C&%^LM<#._`_
MEPI77,*Z/Y-C&$=<D;WF\DL3V785EC@4CD@5RHZFW$/AROC.9/HHA2<I4SX+
M+"DJ\)WZ.P+]]FPJ^?+ZWZP8Q_SA#O)G'9V^3TIX[?+V^3/EQ_#P&.[85?/_
M`"?;!]''^,,=G_J[/2G[>/;SC'M]F<9QWOM`]FQJ^?)ZWP]V_<V&.]OLSC.<
MY]*6,^3V_I9[,]N4X3WO`>S95C[7L]^<0?\`)'@>J>[4UU3+DE'3M9%1V%M-
M/OIO\'+++CZ75,MNN8J'@VUNX8=4VE2L+7AIWO4Y2TYE`>>.[85C/?9QT^6'
MYE/;G/JA#L]F.WLQG.<5'R8[Y24X5GR9QGM[,*SA.0],]VSJG@D)QT\'\.X6
MXI3GJC0,]^A2&\-H[STI=B?!J0ZOO\>5>%YQG_`QV!Y>S95C[7L]^<0?\D>!
MZM]VJKSZ7UL].UD=1&:\8D*:O\%Q,=C#K3.7GLIJ&<--8??89\(O*4>%=:;\
MBEI2H#7=J:\_AW+/3O9'O`-JD/9:O\%:66$93A;[N45!6&V496WA3B^Q&.^Q
MWRTYRC/`\O9LJO\`:]GOSB#_`)(\!GNV-7^U\/\`W.W88[[GM9]*.>WR_<QV
M8[/*K/M`]FQJ_;C'K?#_`/#C88[.>WZ/D]*79GRY\GM]]]/_``L<#[1W;*I]
MZXE?3S8%.*2GP:\;%'X\'G"TYSG*?2EWJDJ1C.,=OD3C.%>7*58X'Q[-E6/M
M>SWYQ!_R1X#/=L*Q]KX>\G_K#'X^YV?N2\O9V8^9[?:\F?:QG@/9L:O]KV>_
M.(/^2/W,<!GNU]7QC';T]V#L5\TG.=A#\=J>^RC*DY]*7EQWR<HSG&<X[["T
MYSE7EP#V;*K_`&O9[\X@_P"2/`>S95C[7L]^<0?\D?NY_EX'HUW;*II7C+O3
MR>6GL5VIQL4>G.<J2K"<]N*CV_,JRE><=OS6,93]'MX'G[-E5_M>SWYQ!_R1
MX#V;&K_:]GOSB#_X?L1^GP'LV57^U[/?G$'_`"1X#V;*L?:]GOSB#_DCP'LV
M57^U[/?G$'_)'@/9L:O]KV>_.(.^2/`K%>[L16[R?"4EG1!P<[<"XRJMD7+Z
M/DMP'+#.:$HF+C)J[*I"(JIN)"V4.LJ<PWE&'&\Y\)D-I.YY_N-V%^%`S^J5
M\#H=P'`U?G$+;U/6T[J/49XK4]35(K*KV^]\U^2Y")O%(3G@C6CM'&F>Q2;Y
MC/?P-G;.'K4QJ)A;U7K+[VWG9LW5P93V7TCAQ@:E6;IA@U73^UM/56+4*%%C
MPG1NO+QKP<Z[,3I7:L`4P_+FTJ;+>ESJ]:H\8A;=96V?+N5?P5C%;M4KN$'4
MFVQ6U!1="Q!:EWVEE?2SM#5]H\6;M^N+>W&:ENA#3<-Z1#GP)T-Y@O5+6&D3
M:Q=ZQ,&VBLDB(@@P_D,M\#FYU>]T8!=*.T!NLINJ"MRD3*6&MBB\.W10K7^^
MQ`W!3$\2D`B2\+9]"/"9<Q)PVOPZ488;[WM6&K/LV%7^U]L'M><,=V?R^E/[
MN/I8[/:SCM[.!^>S8UC[7T_]W_PB#_\`L[:EV=N>W/MX\F,=F,_1R'LONU5>
M;::D+Z=K(AB1EW##R[_!0R_EC*<.X9<S4,(=4UE:$NX;SGO,J3A6.^S\T'C[
M-E6/M>SWYQ!_R1X#V;&K_:^G_H_^<,=[7D__`$GY<^3/TO\`.QC/S`?J>[85
ME2L)QT]V#*LJPE*4[#'YSE6>S&,8QBH]N<YRKL3CV\YSC'9G&,=H>F>[9U3P
M2$XZ>#^'<+<4ISU1H&>_0I#>&T=YZ4NQ/@U(=7W^/*O"\XS_`(&.P//'=L:Q
MC_D^'O+_`.L0=]WZ=3\F,Y^E[7E\F>\X'J_W:JNQ75L2>G:S1WV_F7&7[]!9
M=1GV\8<;744K1G*<XSY<8\BL9Q_Q<\#Q]FPK'>XSZWRP=[G.<=]ZH8_&,J3V
M95C&?2E[>.W&<XQGR8SCM\GDR'L]W:JO1\MX?Z=K(SEUIM]K#M_@M^$CO)[Y
MEY'?U''?MNI^;:<3VH<3\TGOL>7@>/LV58^U[/?G$'_)'@/9LJQ]KV>_.(/^
M2/`]$=VSJ>$NI5T\GW%*3A+2O5&@)RVO#K2LK[,5'YOM:2MO",]N/[IASV\<
M#S]FRK'VO9[\X@_Y(\![-E6/M>SWYQ!_R1X#V;*L?:]GOSB#_DCP'LV58^U[
M/?G$'_)'@/9LJQ]KV>_.(/\`DCP,$ZB[K!::SO&YEKL(+$]%;`M3AAFKOST&
M;+K!$QMEA^162.6H220SPC>),^N/)8A.*[Y\/Z'3G9^2@?T2ZIOE.V@+J=XH
M5@&VFJ'G(DP68%/X=CO)PZG#C+R?F7HDZ$\A<8B-F-L3QTUIV%/BQY3+S2`V
MCX'\<Y#<`G1NY8]Z*-$)"U:HZA:N%:&.DHKV;1<J`8K-6\8GA#5</"A^#Q2#
MZ(EP!L:<%P\/SQ$MB?'CNI"<,ZV-;LU2@*N:+SL=(C7@*M6G19V-*GZS*W5C
MJ?-[K.[`DV*R74R5DF%TPEBIC##H<C;24F;-8/63`SQQ9$,75?JD$T;;6W-D
MYO\`LS:;MNTG;J72)MR18ZN9`%#]Q&'`U3??JFR\&:_7`H^))7X>E6T=&AD)
M;\,1#3"RN7)#UK&W^CR/6:@];=3E#]SC`SKEB7/%2)S+]QE:PW*/GE#UB=O*
MBEV&6O:-AU'8Q$5V`"G4.#4C;4<E-=?7BQ!7YVY^B&37'(>='=A=H.,:C2H-
M?>'R7R0^F:`E/*=E)N"V,>B&R@V_<RI#D-S#E8/UV"ZCQ//H>-"[7]^]%$.&
M9IU?JEU&T"R6C6MG-Q(M&KC:R<ZC6CJ\)QDD!!6SGAJXL4!M;35:6OPDQUX0
M#./1X?CXV&P0"0?ZD^B>4EX*'U;:H6O&0]N`N4X97H-7,'QAWJ)T]M)B(1M0
MVX29TR-B@UNYUJ"P:?((KQM@(_`R^VT/)CPL8AMOH;>AV*(UJ6=*GE@[HY9Q
MJI9`L^B'J:[[8@FZR#BWPBFHN1;^:Z>F93*9\],^-3;8<6VTHO($3@MJA;(Z
M,06I]<C;3KRPV;:8/-Y?MA(G61.`Y!P]K#=8D"-2\)L`]\R.$;'(Z5,P9!AA
M1:!&$6"3&F-,JP&?"[;'OWI0%Z^W]7M240[4"^TZQ;ZO!0NKQW_&&BNR=/WF
MO*],LRY3I=:K(D;3+((Q3(0:<U@DJ`9]%GD26X0L+_(]>]!L6P2;5EJKY;5D
M+4<FD@8Q87-L!PR8L<'1D"T03C!>T/PQ%-8CZMG9"UNM+&!DD)DXW+&R"]D(
MR60M,)M+N>`P6`C2=874E,'[&M)"9+(5<0Y+BZ[.JV>Q#$BWL6IR"=+UV--U
MA-KB]A#+9']$A):.2SB#.7F(&(+)L+I:D"]%1M8!M@ZFM-:*"I&Q=F1XT,S:
M(?BPIN*?*`AD0P)BE)9(VUBQ5UM\O%=`9??$1ID""TSWX9$A]3U!8VIU3V,+
M==A:U@[=I6OJO0+W1P;F;L%])UZU,?FSS*8]IK$N9:#==HI>'9;`@S"S;;45
M(&""($4W*;C!<5HZA>B&Z61VWD-&3XD\M?)-A,B98%E.9,ERZW<J2L\\X!N,
M2*]"LE*(TH*G7<.L^ERN7`:6L2LV08V\.MX8EV+L?HNEZ^P*H>H+S*M_IWL\
MUPP>)B*M/>`2K5>Y]?EY>K+!05&3FIF:.&(5F,/;%#R-44H(B(F07,V0-GS?
M5]TD;1M-"E;BK6Q+)4*-F=$769=>$61!N$2JO3Y7I'BQ$S9FS%.'LPJ/LQ$.
MOU">)@Q;"Z`L\-]B;9K0N&&*JA<^BRSM4JJ1=;1!-IA5R1`;MEF:!!P*;-G3
M)\>^?N*[3L>L5JQQ&-DPJR5@"R18&R_G,R6TF6_,E5TZ%]'MU=`H^]3`4C74
M^X:^K=YLH<#B(*+3`C&O"&_29R4Y3TS[8+GP?&M43IC`IYQB#);.R6ICR&2B
M4E&@UUZ@,].R=!Z<=UJ-KHK8I-^OOGQP^4*+V2"$':JI\.QNVHP"M5A8>DGM
MK.W$^-BGAE0LL0=+9#OUV(-!P4-AI!P'_P!O_K^7/`<!P'`<!P'`R3IG_'!J
MK_G'H_\`WI$X_HSG^7/`_IY[GG^XW87X4#/ZI7P.AW`<#`(\@4Z5RY.Q`!Y`
MUTY6`L2/[!HHB)()%],G34^04L&T=<B8;;TTE1BQ.5,-[1UP-8>FCYT@CL.B
M0G"CUHK5K#/VU.H(+4@M3B:Z9&;3V+M,8HEJ6KA3;&0M@#*CPI#NQ3]G'M%(
MP'40".5%3K#>&HY)+Z20<!4A]GNEGJE9.!B_7.NG*>Y8+/9CCEWVK?7H$_8V
MP94'`]PY)&-RD!J^`$8D34537=.:G3X-&I46=-;#QYI$N6*6*Z62W6ZR!E#@
M<`^N_98/3O=)]*[-LJ"#@.G:TJ!6>V*;4\16WX_L.,WB*VB8.7X3PTAGYMN?
M%=0COUM.I=;3G(:PB>M*G/ZFB";QZ<;086+WB-L>HI2[`?US<".R\5IBEG3]
MMNFP#UG4O7OH%DT*(36;)9(IB,)@C9L0>Y+E0PM4?U2U(1U88WPNZ[2MM/P$
MW[Z6*T:A.`26MT;)UOL.L4RCUE`FYD(0@*`*V8/"S/J4H!&%B82"(8;&DLM#
M(P765ZK]"[BHP,;O>F$46F+=2MN>GT>LQ9WI=P=V]J*>8C`'[/9Y&#*9NH:]
M?H$]%MR56>M,D-.L$LA,>DEHX?C^V>YY.&BDR3IZZ*#3+9KDJT/!!QH^8N&/
MJ%2'7R,^X4LL^-`K[ULAVRSB`U92"?(O3D!S2W:^1@1J2&,J9N[25*VUNJT5
M\=::WJ^X4,Y506NQHQ1AHR2-Z\*5_P!&)V)=H"5J,F!=I*+#"%6JJ7&IQ!)<
MF[`J$(T!JZ&`OS7/653:QK3IFT\;"EYU,H<,ZO:\I*C"R3<[.T]NW4*Q0X;%
MI@A8KDP==P*;!8\08%ED-Q)%?:)H`^-L%0I]?W)T1HEU%1K2LYCLIE2(WB4W
M7&CL7-^2:UY#V77@895ZK_?5H]2J59UTLXLC"FU.U;&,Y0.\)''VD,%6D[NZ
M+;,+(.VG75C9E-]/H'7%5KPRC5.*P$O(:K;$@>FF=:AQJ"8(E6[=(UZ9CGVF
MX7HN*Q8&;&(E2&(HV8%N6WJZ'/G>M*92[)L0`.WY6Z9!H<<?+E!L,&A%^U>3
M.33L<>:2V-7-IE:M03QN+F>]+C$LAGL)@$)/>!?@_?/0[+N4CTP:TL\76(G=
MVX;C6*4$J\&<(>U]:0^EPU3$D11RWR&1QB3!J%Y>-304B(4:)+JK$<W$%H2^
M!"P=\;JZ7]A:H<"56KVJ-L0#6]7U"BGIP:%ER*`I8\.-G!CA(@=)N,AV83)A
MP7(K\4><EEI*&[&^=%R82:J'/G@.`X#@.`X#@.`Q[7;_`/79V8SV]N/N9SY?
M\'&,^WG"^]R']#/<@>GWJ)I9N/M2PGRM#T]:VV7X6NBD93S^P7WDX0-M>!4W
M"<UB%';2P^-/(0T4L4/Q=IEM8!]J6\']'_`_GQZ7NFS2.^L;%E;=H(^Z2*R9
M'1@;LT@=@J'LD\%W)K;>!!,<ES$AR%&4K+R'E(PWC",M_P!T[0VQ]CKZ+_,2
M`^G^WUU^4W`>QU]%WF)`>[UU^4W`>QU]%WF)`>[UU^4W`>QU]%WF)`>[UU^4
MW`>QU]%_F)`>[UU^4W`>QU]%WF)`>[UU^4W`DK[G/T5XA1G<:'K_`(1<J6VM
M>#]U^:2VS!4WC./3-C&.]R\YV9QVY5ESM5[7;D(WL=?1?YB0'N]=?E-P'L=?
M1?CVM$@/=ZZ_*;@/8Z^B[S$@/=ZZ_*;@/8Z^B_S$@/=ZZ_*;@/8Z^B_S$@/=
M^Z_*;@/8Z^B[S$@/=ZZ_*;@2F>YT=%BV)BU:'`94TVRIM7H_=?)E;Z$*[?\`
MA-\UY,_1^AGL[.S/`B^QU]%_F)`?3_;ZZ_*;@/8Z^B[S$@/=ZZ_*;@/8Z^B_
MS$@/=^Z_<_\`U-]S'\F/I<!['7T7^8D!]/\`;^Z^W]/]TW`>QU]%WF)`>[UU
M^4W`>QU]%WF)`>[UU^4W`E0^YT=%CDG"7-#U]2<-OJ[,GKKC&<H8<6G_``;-
M_P"DGMSY/H?0SV=H1?8Z^B[S$@/=ZZ_*;@/8Z^B[S$@/=ZZ_*;@/8Z^B[S$@
M/=ZZ_*;@/8Z^B[S$@/=ZZ_*;@/8Z^B[S$@/=ZZ_*;@/8Z^B[S$@/=ZZ_*;@?
MGK!ND.M9Q8@>E`8\T`[#0B<V;M[CL(H+_P!WCY2&W[$ZRM4>7'8>0A]IQI:D
M)PMMQ*E8X&!^DG:5&TGHO=NU-EF7J_1:26%%;(9CA#]BD087B;4/#C(*KC#5
MA*.KDR6&&X8D3-F/*=3A$?.>_P`\#HC2-E578%=#64*NQ"8I[+Z1P?8-(NVJ
M;MA;,\V.2DCKO:->I]_"JFO5XS(%)-5H?Z,B8.3HA$X,\Q.<"",VW1#&U+'I
M@89\<O\`5*)6-CG!C$:2Y$B5:W6J]4L/(P62UD8[.58]<6T?-%-R5$!JAZ%S
M8S")<5:PIEYWGK37EBU74K"><=LFZ;I.H>N@P(65LLTV=$#YQ.PNOI!1)R!`
M.L0!LMZS6$PJ`%!K\#%GSV9TN%'?#4.J=3_01I:U[J#U`O*JUL!6@C#V+'<U
MWN&)'EE`FS`.O#X+71JV5EBK6*KTO9NT1V3E5TZ5(5"F']AE+7)$BY=S+EBH
M="FB@Q_$-3!*"\DEX7T/RS+C.XG^`0I;_B64.93+RRVC*WL,>%\&WA:EX3WO
MD#[P1@=ZE?CT3O53%#DJS)8[U4]MQ;3D'&<+[%2T.H6VJ-CL>2XTXWE.5HSC
M@:5[VH_0SL_?5-H6[0H,SO&SUF,(JL4[ZH`AHW$&1S]DCUP58(#@RES+`V)C
MG3[5:9*KM+PF&1)I'.CH$AZ.$SV.OHO\Q(#W?NORFX#V.OHN\Q(#W>NORFX#
MV.OHO\Q(#W?NORFX#V.OHN\Q(#W>NORFX#V.OHO]KU"0'9GV_P#?^Z^7_P#Z
M;@/8Z^B_S$@/=^Z_*;[F/Y.!)7W.CHKQ!C.XT/7\.*E2VU+P?NOS2&V8.6TY
M3Z9L8QWN75]F<=N5=_COO\'&<A&]CKZ+O,2`]WKK\IN`]CKZ+_,2`]WKK\IO
MNYX#V.OHN\Q(#W>NORFX#V.OHN\Q(#W>NORFX#V.OHN\Q(#W>NORFX#V.OHN
M\Q(#W>NORFX$J/W.?HL4S-4K0]?4IJ,EQO.3]UQA*\SH;7;Y+-\U\PZXC.,_
M3QY>WV@B^QU]%WF)`>[UU^4W`>QU]%WF)`>[UU^4W`>QU]%WF)`>[UU^4W`>
MQU]%WF)`>[UU^4W`>QU]%WF)`>[UU^4W`P/J+N8.IJ=O&Y[9M@H23K4:UKF:
MBU;'\;(5JNBX[<?$0K9G"KDAXX2\<PX]`"OJ?%CTM-2YTDO(DLQ10=806,)+
MB\)QC&$S(^,8QC&,8QAQ.,8QC'DQC&,8[,8\G`SIP.,7<_OG;</\?UW]'8.!
MT5X#@.`X#@.!,5^UL3[\G_H!O`A\!P'`<!P'`FQ_G4A_[)C]::X$+@.`X#@.
M`X$P=\]X_P#9R?U1W/\`3G/`A\!P'`<!P'`I9S&/04OY/:%D.S^:/<#D)I[1
M:NI?I'ZF-$)L[-+7LIP2!39Y`)VT,!E8:AD$RI%?CGZN^395F"EEZ*S8@S_@
MW5+;FM+0G@7$ON7F#5LI-]LVT*!"MM#;Z:XM9G:YTG9*VU6(NA.I[9W4(=S3
M2%^WSMJYUN;M8-LV?K@_*S<2:!L>/+-*B&1!--('!5NG?N8L+1E<W+6G=L"'
MFMN=,5;Z7W3^K-1P].6Z,(JS>S8T';=E.QKQ<,W7>A:'L=<BU;`?A!U'#X&`
M92+@MKP.CA]:+[F)7]2;*U-M$O<M>F2VK]@VJ]Q:K1M#"]9:X8<.:*J^D8'I
M*J/I[N'I#L3J:@#OE\M3!4TY>;="9E-"JRW!'8A!4[-W+S6-IKG4.V5LSA._
M[[VK:+QZ=K",LMH#T:DV_<U"W`?UG7-;F]ARZ;`BV!_7P4+;;'68=4EW%488
M5L@TA@+%%Y#$]F[D:T8LVJR@'>0RK5K3N\;WN?7U5%:C(#&Z)BW=5#O48/JE
M"F5/;E1@AQ0FM2YVG9(^S!+K370TE%QJ]'I5EC-]Z%BENXKQ3E!UM226^0KD
M77>P]I7","AZHO0/7R1&S4:W[8@057>HT/L^%?JG(UVW-KFTK3N6\FV'K&9@
MR1;X&%70P,.DFQ^GG9U\ZI-+;O)[?J$G46G0QB35M$E=2G)TR%>[("-5@ILZ
M'L4;N,(-5=8X(L1KE>?L6M;.)K-6.VJ"*$L'K(_9HH;8<!P'`<!P'`F*_:V)
M]^3_`-`-X$/@.`X#@.`X$R)^P$ON0T_UE!Q_1Y.!#X#@.`X#@.!50?[<#/OV
M/^D3P,Y\#C%W/[YVW#_']=_1V#@=%>`X#@.`X#@3%?M;$^_)_P"KC>!#X#@.
M`X#@.!-C_.I#_P!DQ^M-<"%P'`<!P'`<"8.^>\?^SD_JCO`A\!P'`<!P'`I9
MS]I3'\5D/U1[@<2A51V'?>@SJYIFIH9B=L6PQ@HZJQ`*Y;9=V<[(%K<Q%5!)
M")GS$1,EUY,8I`?=B^&2F:PIQ*FPL#=G2OU"UG8A"GT&FWRU7R/TOZEJW3SN
M/0ZKSIW2^J=X)ZENHBYVNVGX%UZ@;Z5#B@5+MM$F7\*;NNQ9.Q@T:97PXC,$
MQ"J`T,\ZAJ_60-[H]=-\6[7QJ+T_;AL^Z-),1W;V9(KIM)UC6=?-:9V$0U8^
M!A@Z@$M]GU;L<D)MX^VV@M:%;VAPCU;IT0&,D3PTPIW3MU^#]K42;(%;;DZU
M#=9T7JSEC[!:R#<J3/VYU,-:S?HI9;!">MNAZETK3RVSC@+P9$9Z$["AE(,3
M))"8DP,J-;D[M@YJLP0*:P`BKDO8]7'F&1M,#$+%0Q;]6OCEFQ5QK0TP"O\`
MKEF]0:#`B$0<:^VV-72L]+MDE^.R;;2PNE</NCHS85\,%8FS;2=@[?O>QZ5'
M6$K\_5E3$F^YL['C5*!K1U<QTA(%L]4?BU'(4BV>/CQLU%6-+C.G;G:3Y$,>
M]375QW0?INHEJEWFTQ:XEEB_'-?W-VE:3B6NZW!/2]I._P!(U?`H=IL`E!RA
MC]Z6C;M`L!^F"K'LB.[5J?7T(,E3S4DH']"@9XG(K53DF4.-F'ZP&>+-.M)8
M6T3=C8<GM+CI2E+#B):G$K9QC&$*PM"4=[V=H3^`X#@.`X#@3%?M;$^_)_ZN
M-X$/@.`X#@.`X$R)\[DOO-/]90.!#X#@.`X#@.!50?[<#/OV/^D3P,Y\#C)W
M/Y"UQ=P]XA2L8/5[MRG"LXQ\S8?\+.,9[,>3V^S'D7CMSY/('1?P+OU)S\17
MP<!X%WZDY^(KX.`\"[]2<_$5\'`>!=^I.?B*^#@/`N_4G/Q%?!P'@7?J3GXB
MO@X$IQIWT.C=C;G;XY/SV=ZK/_D!W9G">][>SMQG&,^TKRX]I..!%\"[]2<_
M$5\'`>!=^I.?B*^#@/`N_4G/Q%?!P'@7?J3GXBO@X#P+OU)S\17P<!X%WZDY
M^(KX.!+8:=Q&GX\&[V^!C^3O,X[?]TMY^BGM[>SYKYGZ'9G[G`B>!=^I.?B*
M^#@/`N_4G/Q%?!P'@7?J3GXBO@X#P+OU)S\17P<!X%WZDY^(KX.`\"[]2<_$
M5\'`E#V7?&<=K;B>QJ3G.>]5V^6,[C'ESCL[,YSWN/NXQV9[?:"+X%WZDY^(
MKX.`\"[]2<_$5\'`>!=^I.?B*^#@/`N_4G/Q%?!P'@7?J3GXBO@X#P+OU)S\
M17P<"E&V7O04Q_<G/VKG_P#$5V]OBKOD^C[?;Y,8QP-!.YYH7FF;$[U"E?\`
M"<7CR(RKRX%.8_XN.WMQGL[<9QE..SZ?DX'1#P+OU)S\17P<!X%WZDY^(KX.
M`\"[]2<_$5]S[GW,?R8X'YX%SZDO\FKX.!^^!=^I.?B*^#@1)0N--S&S-',2
M\PI34Z'F5$;D9B3F$K0S,C9=;7X"4RAQQ+4AKO'FTN+2A>,+5C(5>6R[WD'^
MYN9[(2,=O>*]O#[^<]O8GV\8[,^7[GM=O;D(?@7?J3GXBO@X#P+OU)S\17P<
M!X%WZDY^(KX.`\"[]2<_$5\'`>!=^I.?B*^#@/`N_4G/Q%?!P)3C3OH=&[&W
M.WQR?GL[U6?_`"`[LSA/>]O9VXSC&?:5Y<>TG'`B^!=^I.?B*^#@/`N_4G/Q
M%?!P'@7?J3GXBO@X#P+OU)S\17P<!X%WZDY^(KX.`\"[]2<_$5\'`EQ6G?%R
M7:VYY8;:<=B%>WZ(P<Y_XOM]F,Y\GT$J5V?2")X%WZDY^(KX.`\"[]2<_$5\
M'`>!=^I.?B*^#@/`N_4G/Q%?!P'@7?J3GXBO@X#P+OU)S\17P<"IA&G,&!F<
MH<3CQR/VY[Q79CL<3V^WCO?I=OEQWN%)[<9SY.!G'@?S5Z[W2`T-KW9EW.!S
MEEE3]@:YHM2I]80/<LEUONPK*]3Z95`OHP0$B&I9@X7AM.3"9.%`'0<2R$QY
M#$-?A`R",[H)HD$=N-"WZ:']..UJ&3DPS]!V#8P1!<P4Q6ZQ;V[=53U=DD!A
M^J.5VVC"$F<M(XB(3$.Y,"8$<(0EH#\"]T6Z9#NS+9KEBZP13>ORFT`]WN-I
M*`ZO5`\K5HVADRL^!.,%(Z[%7R+5Y3&A'`J)4:/+#OX(-QH9BM33`4C<W=$=
M3:;N%(KLX)8+`#V'IG8FVZO=8*4C`;[U%&&B8^GDFC,>'/$$[ID!/$UR=.CM
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M96[UL?&U5+%:X`[)G";,LU*#326,"[!%8AE`H^1!F>27C+;#J>P,]4OJ7T+L
M6PC*G0]IU2W68L&E'HX,!-<)$XHZ%-+C963$2,PMVOSF"5>L`[(@^@:640`F
MX*82I0DBU'"PIW71TBC8>9Q#?VOX;2))J*XT\1?;G-.UX/`L9?+PQ43T298C
M5PE#L+<IZ*B--`NK,P79`Z._)9"U#_7?IAC>6N]%T4V!V<>N([:I"PSZC9X<
MR/2%:RU["V%B'-Q'B2X168=@3F(>8\4JPZ!>>8=)MYS(984%@:M[H[KZRC]:
MFMR4LMT\5K=&II>Y-37.[6RG%J=;JR-G5`:2`K)"22"@B^,2;[551*O-!_[[
MH*1XXDE++.-BG`SV]UI])\<M7`;O4!K%).U-!'0<;%FAKQ)S8WI[(:-)D-Y5
M&%D):A!9S(PL]"(QHXDK*F16(HZ8^R%*]?;T=X7$1ZXK6"E3>]5'PBP-N8\7
M7."P6I\A:&U(B"WE6*NS(Q:7E@9(#G0Q]F8X#*0B+X5FQ=9_2E4S!"OV+?NL
MQ9H9:ET>8->LD1R4FXM-&ER:TPVQE[QPU#?KQ<7.'P\OR()Z*FNS&V#LJ$.D
M!8%^[H;TIZ_+@J]-V1&-'SMIE4_`@!#D2I@4I'KQZQQI5E9E^(N!0)6-724,
M387D+%$)K,C,9]V(-+RAP7#3>N7ICM>OJEL*9MRD5>#:`!`RY#-6,;V!I0`)
M2#-L#S"T5UT-*D5S&Q:3!<FCYLD<8FVFN-U^64]'A.)88QZB>Z':UT</U4<K
M8:/MNN;3IN\+V//@KY3JJ+B!-`M5E5V&M3+=-'Q9]OS+L3@:!4U2()3TQ!B0
M&<F$2;4P@+HM7=$^E"FU2'9B^QV');TZBC"-+&Q?1.^5PE>R8(0V/L5:B/N/
M#YU0(V(7!V%!0_(ETLA)C"###)B>+'SPJVO.O3ICOR0T'U4:E7K0>L1BNBZD
M1/C9Q5^1"MURJ8-:Y`=X@+;>MCM(+2`T!<_$Y4M.:\\TW8F'AJ`H9WKTU"B]
M4RH:_DP=G1++2>H>VFS%?.MQ)%.F]/\`5Z%;)E:,@)P[!%HC;A5^'RQ#TU0Q
M#8]$8JR@F.)Q7L!B^N=TRI?_`(&&MIZNL.GL]0=-UCLG4QBT7G7#M0LE"V/9
M*6`?)/V1=@'>A%@IS5]KQFP5*>-:)R1DK*@+A5UF0VP&TP_J]Z92BZ@U#W90
ME/WY.':?%>+IAS#T=PEZ"P)L.',;CRTCS9KO0U:(2&6H-I+OQA==D%)\F/&<
M#X$=8/3&=EAAPG=E%G%;!8Y54&!62BL'<G(+`F7+CS@:V4%A$2-#/@)CQ8M#
M@B$0CP*6J;X`T.<E!]@.K[ICMA"LB:MO#7ME*W(]Z7*L+`'6#!(V1R@8XV]!
M@CL2)3@60T;"/1K*II-;E1S0:1'+.-%8"I(8#M77G)@;?MVI*!H6Y;2FTNL;
M1NA">!MU."OE*SIJP4RFW]ZO#[)*'1R1B!=;9(K`\,\9@N$9=?(NYDQDK:1P
M-8"W=LM-Q:T=O@/4UWL]$B2CPZNDQ=FI>+.8F@=55O;[\LS0%$5VFL5=RNV-
M@2Y;G(90,.MC#@$J]!<6E_@;AA.LV(3VH]H#8.J;3J[9JB0L'.@E3]5L`3Q>
MZZYV??J-9`AVOD)+!D`>CZAOE8EN2&!!0+<(84-(%/MV"#,P%P]''[F;E_'L
M'^K\\#<?@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X%QTW]V-2
M_"4%_6T/X<_RYX'07@?S;ZPTW4=ZZ^VMK^Y.F8$-=RHUF#6"KD?0:V5&WTT]
M(M%1M]6,9CS$B[!7;`)'DQ\AV)+BKRRJ(1@S($F7$?"Q=C=S(AW;;]/V`C=F
MSE+,UW?X3J!V,1*4E.X]E1MMTG5.O`U>&8A:K3K$%4!M/H1<#*%@:95W@;!K
M)>I.P;(M1J&%=,]R<Z:S%@*%4V;<(FO25G)X#7HBR5%BHT>R'@FF@<BV569)
MH4N\^C<3&@=5$QL:QW.Q5V&3K658`*@DRH^8&7]N]!VK=^@B0?=%SV;L0B6T
MO.TM-M925K\-8EPG[X&V.+OD9-1UW7*\.V'6K-70[P0@,`1*WXK$S',54OXU
M.<E!A!7<B^F9HJ>,"+'M`#/+FP=P&3!^-/S"]/V$"LE4MJ+[5+0>U`:MT<J2
M/5"+-+UHO8#6MY>21=M-'9;=@X'A<U9[EUH>JKO<^!>=SR++>+'4+JBWS3]#
MR?I]YHN[+IORM7*I)AZXAA&BL*^7DMEV%8`U@KTP)%'#98-Y;<R3-#&@[N4M
M/]5O9AD[L[8D[4FRA.N3-UK\2QAHEPV]M.K[CO\`NZP6G:Q*+08D>%!EWVT`
MK&%CZJET#Q6<)?&+B,`%9'2@J87N/W3I6F7E`=C;T%&93C29EE@D=01C!"`]
MJFZZ5L0\FRUIE`$I(O&O+V;&W.U$0LJ^&3.&+?FUQ[?),'2H5.[]R(Z7MAEV
MBUKL.X2'@*)2J"T/39J@P/3#U]K4#K.JF\H9H29BSPZ%60]C4I<M8:79XV5R
M0KM?>>KR@R)J7N<&G-/7VO[$KEVV4X=KU:MU:;1"&Z1UW%,XND0G`)E[0_I;
M3&KS%E(0HQ1UX%",E9=:"F6(MH@`&[7A\Y(#&U%[D1TV4`W-L(FZ;FDE"5(N
M%$(O2R>KH:2`^ZZK+:>+&B**]J<$DG;LU8LY,?LY#QHM8+4RFSW%^REIYI\J
M&0]5=S8TGIZP4DS4[ON)X7KQS9$VI4XQ8*9+K`TWN"BQJ+LT]G#%`AV"41MS
M4*)9)3$D^X'$69I]^NBPH><1!RPL^3W*'I_/:_JNO;]?MX;,@:UI(/7^FRUS
M/Z\R0TW70-BKEG8](XBM:PK5)EEB,^I5V-8#UZJ5S,6`,+C@3$R:)[^&L,*6
M'N1X:;<@5/!6Q(WIH(VJH[`W%67958&'MHVVIUJ\UO$A5-H&H*+5Z<0-C[>H
M47.TJUUP#*')D$9>N9MP1#M#(9,`=Q\Z:*\,V&+CW';KOJE:3.:`.D&L:5`%
M&J":LU$M2'$2JAI6M^C-G#3:`*B#++<6[.3<&SRK!=PLZL:^-"\Z[W+'INJN
MY:[NH"3OL`U4=P$MU5D"AG52A0FS&I%DG&0J;(O5BMJ3Z:2)6602<K1?8I&/
M#FC@S@MR`W`\$X%F0.Y`=.XBP/VT3LK?(^WODH1)VU,E]3.G)3D:%M0-,P9E
M2].R6[5-.5K;UEK)NRW!FP7&6)@5UYNQQRXI928%R([DSTL9KMJK4I_9,^':
M=5:@U3F3+/5K$L!'TR,U@-"76OHBTZ,/C7BT^HSK"9?99&`2KEED5&`RJL0Q
MTDG`FA=Y;N:73M8Z3KNAV=RS'0^N*/U$4@6O(K4]>]$_7*N"'[G;R(FF:OK-
M8'WFNR`0^91K!40%8R()-++E8QXLO,[@8Y'=R-Z<Q+EDE#[QN)DN?*"[5'LK
MZ]-3[=6K_`V!3=G2K\#MY'3$NS.E#MSI4$J:K5A+'M:.Y(%&H%%@-X%>A(52
MO=RCZ?JW7K)78E_WJ\W:=@:LV42*N6JDPC;=DU'M/:FW:ZH;/":Y%8&QYUHV
M]9F"^8;#4_T*A@60L\(1ARR1`/?5'<J>GG4%M7=*W;-L2C+]/V%3929\W6(\
M?.B;,H%*UQ8S4L=5-6UJ,]:'0U$$%7#F48E&K7//6>V^F,N9F2%A]O=RSTJ4
M`ZW#VO:F^;M-TV(U55M36*SF-5OS]?TC4!T%8JW2PH(9J(70I@<O/JU61<B=
MAIQNVVJ)71D0G95M(D)D!;$/N/W3+!(UXPU:MMK+AHV!\Z7(=U#)CF14>VS[
MH'%0`;NGE5G5D2L&2<STIKT.%U+-K<9;:!$R(_'C260C`^X[=,8:1!SFW[>G
MP&[`)L1H9W^FZ\Y990RKA*A+C$+/2--5:^!8EL#@(V=B*I-MJ<W91*65+7R=
M8B!.6^Z%S:^[E'T_ZW-:Y-5ZZ;20]K"Y`KC7UM"]"5\Y*Q6<P,@ZR9V%3=&5
MC:LZM1T0<1B;;5[C&[5`ES!MS.6(>IB+'"]C'<_:^:V5=ME,[RW'1IUNC[5K
M>(&L%4&N81KK=5BJ]]V'3B9BS4J\'53"6Q@$RRP+A32-#L8@>2:!Q)';$DDR
M@8TL_<?^D\]3BU(#R]G4$<4M=G/MD:29ID4X.KEMU-6-/$M6Q2AZA6!<W6K0
M"FU\]`$'D&#<2YP463TQK?REA(9UA=&@`#>QNVB6R[]L.\Q+8Q>[G;MD-U@C
M9[HNI:KV3K;7E5CHI8*A4:DTVF8VG;K8R'J=!@.%;/+:G3Y6,8E8EA5>CC]S
M-R_CV#_5^>!N/P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<"XZ
M;^[&I?A*"_K:'P.@O`X&](O^!LS^.A.?Y<&<Y_[>!N5P'9P'`<!P'`AGC-:K
M`465L%A$`4DBI0:THV4@"X[RA\01*2F,Y.>C^&>S@BYEU"5KSAM+>>\1V+RH
M+/\`53UAYQJ'[[Z]\8\!ZJ>L/.-0_??7OC'@/53UCYQZ'[[Z_P#&/`>JGK'S
MCT/WWU_XQX#U4]8><:A^^^O?&/`>JGK#SC4/WWU[XQX$Z-LK5;T,B^O9E$0[
M%:CKCM^G"N8\.IV4TTZGL40[Y?@VEJ<[$9[4]F%*QE/`@^JGK#SC4/WWU[XP
MX#U4]8^<>A^^^O\`QCP'JIZP\XU#]]]>^,>`]5/6'G&H?OOKWQA]S'\G`>JG
MK#SC4/WWU[XPX#U4]8><:A^^^O?P?OA]+R<">,V3JN7,0Q)V71&&5-25^$].
M%<1V*:C/.M8[5D,I_NCK;;>.WRJ[_O4_-9QP('JIZQ\X]#]]]?\`C'@/53UA
MYQJ'[[Z]\8\!ZJ>L/.-0_??7OC#@/53UCYQZ'[[Z_P#&/`LRQ;N%**B:7J(+
M(W]M>PL3B`36.LSU5?+>@(;#3AZTV,Z7,CZO2ZP+0ZQ#2<M9<5"*6$@%JHA<
MVP&A\)T+XU_L&N;+K;%GJ[\O,;QJ<**BBT"4'L=8L8>4X/L%2M@`@VR3K=KK
MA1E\6?`E&&)XR='=9>9[,MN+"Z"O[5DOO"9^KN<#27I3MU4K=?M;%BL]>`/R
MC4)Z,P9-C1;LAI$'*5.,-SI+*GFDKSA.7&\*1V_\?R<#:WU4]8^<>A^^^O\`
MQCP'JIZQ\X]#]]]?^,>`]5/6/G'H?OOK_P`8\!ZJ>L?./0_??7_C'@/53UCY
MQZ'[[Z_\8\!ZJ>L?./0_??7_`(QX$Z=LK5<9$%3&S*([F3`:E/XS<*ZKP+ZW
MGT9:[$3^U&,(;;5V+[5?-]O_`!D]@0?53UCYQZ'[[Z_\8\!ZJ>L?./0_??7_
M`(QX#U4]8^<>A^^^O_&/`>JGK'SCT/WWU_XQX#U4]8^<>A^^^O\`QCP'JIZQ
M\X]#]]]?^,>!.<V5JM(V)+1LNB*DOSB,9UCTXUS/@V8K`IR.[WF)_?X\,Y,D
MHRI2N]5X#L1C&4JSD(/JIZQ\X]#]]]?^,>`]5/6/G'H?OOK_`,8\!ZJ>L?./
M0_??7_C'@/53UCYQZ'[[Z_\`&/`>JGK'SCT/WWU_XQX#U4]8^<>A^^^O_&/`
MG1-E:K?8)N.[,HC:X<!N3&1Z<:YCQAY1,=$4UV*GYRKLC2I#_>HSA78QE7;W
MJ%8R$'U4]8^<>A^^^O\`QCP'JIZQ\X]#]]]?^,>`]5/6/G'H?OOK_P`8\!ZJ
M>L?./0_??7_C'@/53UCYQZ'[[Z_\8\!ZJ>L?./0_??7_`(QX%[:TOE!.;`IH
ML7=ZD3(2;$,S%@CK*%FSI+D:4U*RVQ%CS'7GLX0SE:TMMJ5AM*E_0[_@=+N!
MP-Z1?\#9G\="/Z#/`W*X#@.`X#@.!JAU9T\9L.1TGT$T_.BA[SU%)IY:2,=C
ML$XPNRN4$).?'/2XTV*U.9C3G5PW9,*7'1(PVIV/);PIE0:,3NERFVXNSG4N
MR(JP[]P`:YS'L?HF9D>GB97BEG/#AIF#5*O@W'%BPTYB'ENLCI!FPI9KX9LI
MB3"*RPF#^A^Q+=1**7D/&"^."7W7HXHLHA!`RPFL;1/Q9H\AEJ/2;BD'M0)'
M"TVQR&2!VQCC8:([A$<=/*!0Y'2Y'MMQW:S0+"V)J.KKQ9*:/38DRRI1WTLU
MN[V>21LI`9!CP0(J0,U^:9:/D&((Z2=DPH++3$'!.:)"N6WIXUV!N6[18"#L
MC8$+4'J;AHU4K1`>/N=CFVR%*R>M\B3FGVMF#6P!&)&A2HL6OR5XE6$%%S-;
M0ZY*6%+&]%UDF!0IZ9?*Z-'3ZIBVSWUC#4AIJ"[006R645^0B.W&MZ(]>/1Q
MYJ:'>\1"6MI0*7(4V]&(OA[M=#]X]-D6FR;;7&R;CNS'94Z.S,77HX_5UNM-
M).ML6`AZ%#)MF=*U2<3;J;;S9&!5GXI\PY`3EZ(T%V@.@HJZ5!,678@YL83R
MI+TNM@"Y%,MZ1`V@Z,C56<2:&#;/,?(ZN)IE#X3J"$824%%$1G\KFQX`8QT[
MHNG;6HB4LXM$/8A;>FOM,`B3MB&0Z?'7L()?"\0V7KN:21.+R)72VXDB#'L\
M?,OT26^E^)F&F/*"NCNCPO;*TFS4VP,20\74)+9JC4YI_`TTJ#8-U,1A[;3D
M8>3KLHU7=/$YPN#)@G&VY2DME2P[QE+48*/U+],Z=-OV:S5XFY/I#.W;EK@/
M$D]CQ02FO%+!"'MG9KS8[,L@1CUV=,:?$B)(-R-CP>2R"\<F&'!J%P'`<!P'
M`<!P*24F.QW`D&/,`BI%CLU<J;%BN!)P)1:H]9"T80W:K\?;CRU5^DU]4KT2
MLQI,9[,$8P\YA&583G`?UV=&G1SKGH^UTZ`K4CTW[`M^8!;:NVR4-B,?V$>C
M,.)B8;8:=DHK])`)ERXE'I,"7(&UP;(D/O22]D,6.R'`PSUJZK@:J@7+K+UT
M4`5*RU4''G[MJ)PG&`4_?=1"LL#QT9^9(4B&%WL(C8B@M46_*,YMSJQ>I[CB
M6&F5`YK\+;CE4G*DR;1!*"T&*XV40-.07A9H>D@+Q+3!+C7\>&'%(F'<1Y\!
M[L=ARVWH[G8XA6.!QCIM'IFP]M5VM["+'`5-12MIVFP%JXB&LS`B4/7%PO6'
MX<>;$EQY.$R*VUB3#4TV[,AJD16)$"2ZU+CADNP="Q>-+L/H1?JE'%U(-K_T
M5)%#T"9'*'+/1H-R(S0RX3<1WTM$(STEREO9BS7RW8B"_(1XJ0*1PHY7H9N`
M<BP'(7FLC2DZRT"J#F#,$R*9?)[&V7N+6X94F0N.\J##9>T\2/O2'F<^'%&(
M#<)$J?AN-)#Q7T16S(<H;9N(Q$6(,05AL$:Y9!DYAAS7MDV*VBYQI$7.-?J]
M#*H3A.+L#B66Y4P#*\*L65S.BA,]8^8CG+4-E[(K[H^FWX_1S1:`%-.1F%TR
M?28ULD2WI+<:"'GJ:O0Y--$E9K#ET)P28X=(82B#+(!*)="5IR2<2$O%;0-F
M;+LU$!1[$IR#8I,6M6@[6),B2#@)($<V!R2#\8@UV-"4\9A$P\D8\Z^4C0,!
M\">C:/8JM52->MDU1FX5]F9&=N0MZCA@9B1U+`=!LQB"7&3DF6IE)A)(L*\.
M.("LNQ9#:B*I,,=,"@'NB^RA::<N7IW"*9&UPK:8`,B%/!K#)&A:H*N4^,9%
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M:O0Y\]X2$"O#^BPJ3E(KPZSQR9QFU`A!HF/BR,CP4`OJLEL]Q3PD@R-=G*A#
M&(&)4V(:7W[\G(X>,G24I==#\V[T;3]?TR=8()IF26H-,>F["%MK=E-SSP_=
MNT-7&3%?ES8X6,BKP&:>!PJ*PLQ8L3";<J6)AC)F)<4-&.`X#@.`X#@.`X#@
M.`X#@.!MOT'_`/C=Z*_"]S^I"W`_KAX'`WI%_P`#9G\="/Z#/`W*X#@.`X#@
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MVXGYE<GM\,I/D4O./)P+E)]#^_+5!%NEMJ4^7'H888'`-*>/L>AHN//=S!8A
MXB@6,>&C2ISSN9CZES,ISV*D.>!80D+49Z`MMQ^S+%_IC&<2&Y>,LS+,WV2F
M<.):DX[P.GLD-8==PV]^R(PXYA*L86KM#[1T#;>;1X-O85/;;\!XMWB)UG2C
MQ;OW7/%^]2'PGP'A'WG/!=G@^_>=7WO?.+SD/R3T";<F80F9L&G2DMN/.HQ)
MFV9_"'9*\.2'$8=#JPER0O&%O+QV*=7C"EY5G&,\")['KL[[-*'^4L'Q)P'L
M>NSOLTH?Y2P?$G`>QZ[.^S2A_E+!\2<"9`[G3M&?*1%:N]!2I;<AQ*W%V+O>
MR/'=D*QGO0F<^5+2DI^GGL[<\"'['KL[[-*'^4L'Q)P'L>NSOLTH?Y2P?$G`
M>QZ[.^S2A_E+!\2<#S>[G?LF0T['D6_7[[#[:V7F7LGG6GFG$Y0XTZVL&I#C
M;B,Y2M"TY2I.<I5C.,YQP-X.EO:NT^@NIP==]1I[%_Z7X'>P*5L6MP[3;;5T
M]-I1A`VGW`5'#R;'8]-RW?!BZ<;%0RQG5\UV#6RL>3KF0.(Z]"^21.Z]3EV"
M;;VV%)U+7E2)),Z$T(:2A$NOS&TNMP=P[B@MN/1)VX9L5UQ=4JBW)8O2XJ4M
MAE4O84LR:'!E`K^U9+[PF?J[G`X]5?INN&[FI1BL6("$:!J4)E8*N%&GW\D(
MZEN8:]#X4K&6'([CC#Z'%MY6VM2%MY2I6,A=6>@/;F4NHSL"FY0\PS&>1F99
MLI=C1L(Q'CNI]!^QQAC#3>&6E8RVUAM&$)3WB>P/I_H%V])3E$G85/D(5X/*
MD/SK.ZE7@ER'&NU+@=6,^#<EREM]N/F%R9"D]BGG,J"N>LMWSFMSJBK:=357
M2AQJR$!RGSRDSC3$!X8W.E2E`_'7E)A/+CY97(7%7C*77&<NM-.)"@N=`6VW
M<2<.W^FNXF.(>F8<F69>);S>5Y;=D]\'SX=QO+CF4+=[Y2<N+RG..^5VA]+Z
M!MO.)RES85/<2J2B8I*YUG4E4QMOP2)6<*#YQF2AK^YH?S_=4M_,85A/DX'Z
M[T#[?>0\V]L.H.MR%N./MNSK.XA]QUQAYU;R5",I<6X[&C.N*7A2EN1V%JSE
M33>4A-G=S\W&QAE;VQZ>]Z*Q5$'.V=:59=Q*RY$=Q)[\1_='76H^$.J5W_A&
MDH;5G*<=F`IN.@';*5-K3?J6E;3"HK2\2[+A349:'&UQFU8#=J&%MNNMJ93G
M#:D.N)RG*5JQD)2.@W<K:LJ;V354*4[E]2D$K4E2G\^!QE[.4B<9R[G$>/C+
MF?F\^`9\O]R1WH1T]`6VT(0TB_TU#;<KQUMM,RS)0B;V)3XVA&`^$IE=ZE*?
M&,8P[V)3CO\`LQC@27>@_<[ZVG7]EU9YQEY$AEQTG:W%M/MX[UM]I:Q.5-O(
M3G.$.)SA:<>1*L8X$)/<_=K(4\I-[I*524+;D*3)LF%/MN*2MQ#V<!L9=0M:
M4K6E??84I*5*QG.,9X'OZP?;_?95ZH=0[[*\.95X]9^^RYAC,7"\Y]".WO\`
M$52HV%?X6&%99[?!YRG@3)/<_-Q/#69<G9%/DQITV;%6P[.M+O?/#\19^774
M."5-KPITRMYM6>U6'W)3G^&XI3@4;V/79WV:4/\`*6#XDX#V/79WV:4/\I8/
MB3@/8]=G?9I0_P`I8/B3@/8]=G?9I0_RE@^).`]CUV=]FE#_`"E@^).`]CUV
M=]FE#_*6#XDX$N-W.G:,ED@^F\4)*1\1$QU*EV'M6VN?!@80WC`7RKPY.0O/
M;G&.\0O/^%V)P$3V/79WV:4/\I8/B3@/8]=G?9I0_P`I8/B3@/8]=G?9I0_R
ME@^).`]CUV=]FE#_`"E@^).`]CUV=]FE#_*6#XDX#V/79WV:4/\`*6#XDX&P
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M15??5,^2W`>M(ZXO.15??5,^2W`>M(ZXO.15??5,^2W`>M(ZXO.15??5,^2W
M`>M(ZXO.15??5,^2W`>M(ZXO.15??5,^2W`]6>E#KGC.)>8V75FG4X6E+B;5
M-PKO7$+;<Q^Y;VEMK4E7T,X]OR=]VAY>M(ZXO.15??5,^2W`>M(ZXO.15??5
M,^2W`>M(ZXO.15??5,^2W`>M(ZXO.15??5,^2W`>M(ZXO.15??5,^2W`>M(Z
MXO.15??5,^2W`^'.D7K?=;6TYL6J+;=0IMQ&;3-SA2%X[U2<_P#!;M[%8SG&
M?X?I>3@;!=,G1E9M:5D_%V'81C94N9:E18M8<>(Q6(4>(EC"Y4N?!'Y\9>>R
MZK####C3;26E9?4MU33`;,>M^#?9`3_FT7@/6_!OL@)_S:+P'K?@WV0$_P";
M1>`];\&^R`G_`#:+P'K?@WV0$_YM%X#UOP;[("?\VB\"7,T4)F)AI6>(HQ"A
MHAHRF/&^;0VZ\[A:L9]I6<OJ3GL\F,)QG'ESG/`B>M^#?9`3_FT7@/6_!OL@
M)_S:+P'K?@WV0$_YM%X#UOP;[("?\VB\!ZWX-]D!/^;1>`];\&^R`G_-HO`E
MN:*$.#XP_)TEA$:9.F)=\7B]^M4]D<RM"D]G9A+>!R%)SVY[<NKQG&,8QVA$
M];\&^R`G_-HO`>M^#?9`3_FT7@/6_!OL@)_S:+P'K?@WV0$_YM%X#UOP;[("
M?\VB\!ZWX-]D!/\`FT7@2XVBA$9DBPDZ27@C#1#7G+$7&6DH(P2&'$XQ_A*R
MN"EOLSV8PE:LXSVIQC(1/6_!OL@)_P`VB\!ZWX-]D!/^;1>`];\&^R`G_-HO
M`>M^#?9`3_FT7@/6_!OL@)_S:+P'K?@WV0$_YM%X%3":3%!"XTNT;(/NC9C$
>Q#+D>/AMQ;#F%X2M2>Q6$JRGL[4^7L]K'`S=P/_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g893535g40w79.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g893535g40w79.jpg
M_]C_X1L[17AI9@``34T`*@````@`!P$2``,````!``$```$:``4````!````
M8@$;``4````!````:@$H``,````!``(```$Q``(````>````<@$R``(````4
M````D(=I``0````!````I````-``+<;````G$``MQL```"<0061O8F4@4&AO
M=&]S:&]P($-3-B`H5VEN9&]W<RD`,C`Q-3HP,SHR."`P,CHQ,SHQ-@```Z`!
M``,````!__\``*`"``0````!```"J*`#``0````!```"#0`````````&`0,`
M`P````$`!@```1H`!0````$```$>`1L`!0````$```$F`2@``P````$``@``
M`@$`!`````$```$N`@(`!`````$``!H%`````````$@````!````2`````'_
MV/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)
M#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`?`"@`P$B``(1
M`0,1`?_=``0`"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$`
M`04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!
M``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U
M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#
M(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F
M-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`],SLP8=;+'-#FN>&NEP:
M=0X^P'^<?[?YM4F=?8X-)H<`0"=9CZ&Z-/=]*S_,K_[D,1.O/+,)L3K8T&--
M/=_*;_U%_P#Q7Y]>*;P(<X@-(>3(,PT@>HV/\&S?[TE.L>O-VDBAQ('&X1,.
MTW?U]K?_``7_``:F.NU$QZ+^8[<;MLQ/^C]__@7\XL_$P\[)K]=OI.J+H9`>
MQVAV_P#:BO\`>_\`.T5O2NJR=_H[--NTD.\_I`I*;(Z]66R:'@Q,2WF&NYG]
MXN9_T_\`"*1ZY7K%#R!,<?R_/^35_P!N_P#!6*F>E=3#S[:75QI[CN.O^:G/
M2^I%PVU4^GK+7.=N_P"C[4E-W]MT3_-V1IK':6B?^D]W_6_^$K3?MJJ/YE\Q
MQ[>8X^E^_P#H_P#P3^;5/]F]2:1Z=%,3[M[W3QVV%)_3^I"/2QZB>#O>1I_9
M24W?VU0.:WQ,<#B8F)W?0]__`*D3?MRB-:K-0-/;X,_E?O/<W_K?_"5*G9T_
MJ1:-E%9</WW"/EM]W^<H6=-ZGM&RAF_0_2&W[Y]1)3H?MJC_`$5D]A`_E_RO
MY-?_`&]_P=WI/^V:)_F[(GF!Q+?=]+^4YW_6_P#BUGMZ=U/9K0P6>3AL_+O3
MLZ;U(L_245[^P:_V_P!KW;DE-_\`;-6V?1LF)V^WF-VWZ?[WL2_;%'^CLB>8
M'$D;OI;OH^[_`,SWJDSIG4=OZ6JN>!M>?'^4F9T[J,_I,>O:#ILL=,'O[G-W
M)*;HZU1(!JL$^0/[G@[^59_VS_PE/JO^VL>)%=G$Q`\'?ROW@QG_`%S_`(Q4
MATWJ!<=U%.P<18Z?^D-J<=/ZAO/Z"KTQJ/>[=\TE-W]L8_[ED3$P.)C=S^Y^
MD_\`4B8=9H(!].P3Y#^3_*_>-C?^L_\`%>I2.!U`.`;C5FOQ+]1_94,BO+Q6
MBRRJME9(&Y[M9B8VUMM24Z#NLT@$BJPD`D#VC@./[_\`)9_V[_QOIV\>]F17
MZC/HR0/'3Q_=7/"X/F-A;M:6[>1)'TF_F_\`![5L](,X+".)=',1N,;=&^W^
MIZG_`!MB2G__T/0/K)_0&&)BUA_ZK_@[/^KQ_P#C_P#!V8_3\2K)S<9EL/J+
M;ZW,W'W!VO;;]'TUL?6,@8-<F";FQQS#OH^YKO\`MME[_P#@O\)7E='83U3#
MMW&&C(:1V.\N<UW_`($DIM_6K&QZ/JYELK8-I<+&M<2X!Y>+98UQ/^$]_IUK
M'LZ'TY]0.,S:YKO>;'ES="6VM`:RO:_U1_Q:ZKJ_3OVG@OP_5-(L+2YP&[1K
M@\LVRWZ>U9?_`#4O$1U3*T_EO_\`2J2G%Q^@5^K.0^MU9^FVH%KC(_-=9ZC6
M_I-K_HK0Z%AXN-]9'LH!VLQ7;=Y:3+C0]WN:UBM_\U;Q,=5RO+](_3_P56.F
M?5]^!GG,=EV9!=6ZLMLDG4L<UWJ/L>[V-KV;$E.PDDDDI22222E))))*4DDD
MDIY#-Q<;(Z]U,9-E]==;66'[/9L.E=6[</ZI=_+6=91CC<ZO+>*VDEAMLR`X
M-X;O],;=W_%K=S>CYUO4,K,HLR*3<X"*VTGVL:QC8=;D?0=L_=K0CT/J@C]9
MRC$2/3Q>_P";K;[=B2G-.)A?L_(NKR,EV5BL+W`6N](:N%7MLV6_09[O[:Z?
MIF)1=T;"J?N=6QC';=[O=#8BWZ/JM]WT7K(?T#J+JG5.R,E[+&EMC15BB1^Z
M^+FKH.FU64X--%F[?4T,)>`"=OMW[6/N:W?_`,8DIYVZ@49>4UA/IRUK6DAT
M"O;7[MY_/^GNL6WT$@].;$:/>#]'G<9W;'.]W_&[+O\`2UUK&RF.'4,ZPR18
M]NP:_F$-=]'^4MKH1)Z;7,\NB=W&XQ&\-]O_`!7Z'_1)*?_1]`^LD_8&1,>J
MS=$Q&OTMK7,V_P#'>G5_PBQ^CL>>KX=L^QK;FO$?G.W.:[_-8M?ZRAIPJ@8G
MUV;9B9A_T=WNW?\`%?I%D=':[]KX;A_-[;MP_E$GTS/]1KDE/6I*%MM=+"^U
MP8T0)/B=`$$=1PC_`(4?<?[DE,GYV(S*&(^P-O+/5##(]L[9W_0_L[E']H]/
M!C[53/AZC?$U_O?OMV*CGX'0NJ7-MRCZCF@-;#G-`VDO8X;-OO:YR!^PN@[6
M[7N!8YKVO#M?:+F,;Q]%M6395_VW_A$E.CF=9Z;A>E]IN#1=NV.:USV@,<VN
MU]ME37LIJJ?8QMEMWIU5JR[(QV"7VL:-.7`<G:W_`#G+*HZ5T&IN&QC0ZOIX
M>W$K>2]K!86OT;9NW>EZ;?0?_@E3OZ!]6J*F`,L>UH%88+8]H][?Y^RMCOTW
MZ?\`?]9_^C24]!]JQA_A6>/TA_+/C_P5O_;=BA]OPW`N9D5$-:'N(>T@-,;7
M_2^B[>U<T_H_U;<]TT7`O=O.V^L#<0\.?M9D?N6W4_1]/9?;^^IUX71-QL>R
M\%[R^QKGX_O.VK>7BJSZ-EF-CV>W_"T?X.CU/42GHVYF*^`VZMQ<`X0]ID%W
MI-<-?SK/T?\`72MSL.JFR^RYC:J6>K8_<(:P@N%COY#FM7.'I_0G[B&7M#WM
ML<QMM3?TK(?5=N;;O_1/;7M_2>CZM'J>E_A+%CXO0:Z\B@LNL;DT,Q;6FRD?
MHZF[*?YBROWL9L97?_.?^")*>@QNIX&52+ZKF["2(?-;@0\XY995<*[:GMO:
MZGT[&;_5_1HAR\5HEUU8&NI</S7"M_?\RQWIO_EKG_V5T'+#K<RV][]WN=?8
MTN<[GUIJW>W\ST/Z-7Z?]&K_`,)-W0?JO:-K3[2V;&L=&X@_S]CF-]3=[WU_
M3]+_`+9Q_22G?.3CM?L=:P/`)+2X3`^EI_)4FO8\2QP<-#H9T.H7/CH/U=LW
M-]5SWO<7GW`NWDLL=8UNS]ZFI_I?T?\`X'T5;Z9A=%Z79:_%LVOO#1;N=R6%
MWOVPUK'?I/=L_P"#24ZZ2#]KQ]!OU/`@Z_U=%)F12]VQKI=KIKV^DDIY?,#_
M`+?GN<?T9<-@,1H0+/I?REM]!+3TYI;'T[)B.=[IW;?S_P![U/TW^D6)EFW]
MHYP,E@<WT@)[D>IM_MK<Z%/[-KY(ET3NXW';MWD^S]WTOT/^B24__]+T#ZQ[
MOL+(F/6;NB8B'?3VN#=O_&,N9_P?J;+*\7HSK/VQAM$^D6VEW]<;]G_1]1;'
MUFC[#5,3Z[(F.8?]'<Q__1?C_P#'?X*W&Z*]W[8Q*P/T9;:\G31S0]C0/[+W
M)*>EZB)J9H3^D'`!/#OWEBEW51O_`%5CB#[72T;A+N6_X+V^G[]UG_%?X-;7
M4@#0V1/O&FI[']U9I#9/M;X\/24UF/ZJ2[?AU-ALL.X/]W[KFQ5]+^NCT.N<
MQWVBAM+IAK6_I`1&KM[-J=NR>&Z?UPI$@-D%HB-=STE,0QLQM;KI]!P'_F/_
M`%"J#JV"RR66&NQNYI(J>>Y+]S;&6?Z#?^_L5P$<M+=PX_2/'\%`LH#0W94&
MEV_;N_.UW/V[?I^YWO24@MZSB/<['MO.]IW.J],M<-OO._;3^8@NOZ:T5Q8'
M>L-U8!>XN'Z/Z+6L+OH^F[8[\S])_A5;;5C#;#*@&QM@M$1Q'L2>RAS`U[*R
MT"-KG,(``F/<Q)36?F].<YILM(<^"R008!-6X?HQ^C_0?Z[T2GJ>(R*Z[G;2
MYQ`+&P"XNLL#G64>S:_Z?YE"L&NESA+6D@R/YLD&=W=O[SMRB,>C5K:FAI`:
M0&U00`6MGV^[Z22D`ZGAOWVMO<XAK'.<V&^UT>B0VNIG_<IO_"_]\MRXD#>X
M$@M,/9P>1_*0GXF.9+J&F9GV51)^2L-!F2'2>?8SOXI*8LI96[=4',=^\US`
M?\Y1?AU/U?67$N+I(K/N=]-_]I%V]@TQ_P`6W_R26R!]`_\`;8_@4E+>D\O9
M8XVN?4#Z;O;+9]KMG[NY7\&AC:F6>[<=Q,D_2<27N<SZ.]4&L&GLF/\`@R._
MDY:6#_1:](T.D1W/9)3S>8^QW4,]CA^C8X"L_P!8[G\M=^=_76WT&/V:TZ27
MV$Q'.YVZ?:S_`*?JV?OW6K"S7N/4,ZLB&UO&P^._WO'MV?\`5_\`DUN]!G]F
MLF?I/B9XW']Y[_\`T3_X7H_FTE/_T^_^LI(P&1_IF3'P=V]2O=_F9'_$?X2K
M%Z*]S>LXE6WVN;:\N_J![&CG^6MOZR`G`9''K,GPB'?2]C__`#YC_P#'?X&[
M&Z-9'6,2F-7-M?)[!OJ5[!_6W_NI*>CZD6BAI=HT/$DG:!S])_YJQ7V9.X[?
MLI&T_P#:ET[I/IC^H[V^HMO(S64E[#5:]P;(+*GO:9!_.8-KN/WE5LS+G;FU
M,>US2!N=C6@&>=NEG_4)*<^JW,+QO&.&[AN+,DN.W7=M!_/_`'58+A&KB/A:
M$SLC+N#'/K>TC:6@4W-(W<[_`$V;?T?^$W)-^T;A[;9K.AV7P8=OW']_W_O^
M_P#ZVDI33#YWNUX_2-,)W$G\]P_M-*&&.+2(N(>=Q.S+!T!\6AS?I_03V"TM
MW-;99;(D/^UM&T-=^=4Q^VS?Z7_6_P"NDI=Q($%SSYRQ0+X/)UX^@4C]L#8]
M$D-)<X3FRX`_H_3NV[ZG,]2[U:_3?ZOZ+_1J(?ELYQ]6O#G?I,YQW>[:[8:/
MH>KO_D65I*2%Y)(!=$]JVG^*=LS]%Q[F:VA#(R7-</1<VPZ!S;,YS9);NW5^
ME7Z?Z)SOS_IIVW9YL9=]E,O.X^_,&T@[QOK-&S\UGL_XRO\`XQ*3':&RX"1J
M?T0,*.YLMD"3S^CY/WI,MM:*]U=K+&R8;]JL88=ZC)]2NM[[/I^QS/YO_@U)
MI,&L>O',[<H\!E7M?K[?^#_XQ)2S2PZ:'Q_1D*1->D[?\TC\A4238T"+X<#P
MS*&CBY^KFC]Y_P"]_HT9F2^IU@:QSG./J.#J<AVI]OLWL]C?9]#^;24B:ZOQ
M9X\.'\5IX$?8ZB.")'P)TY5=F:`"+*GAS7%K@VBQP,'Z3',:]KFN;^>K./F,
MO(#:[6$MW?I*WLCCV[GM#=_N^BDIYG,?NS\ZK;'IV#7QW'?X.6YT"?V:PGNY
MY'^<[^17_P"CO_#%_P#.+#S7L/4,ZN/<Q[2YWCN]S9W;?H?1^DMOZO$'IC?'
M?9/'.YT[H?9[OZ_I6?\``4_024__U.^^LQ`P:YB?79$QS#OH[GL_\#9>_P#X
M'_"5X_1+6?M?%J(]SFV.:0(AH#]PT_>=_P!0MGZR[OV>R)CU6[HF(AWT]K7,
MV_\`'>G5_+^@L3HEC/VSBL=_.GU2W7AH;9Z@_P`_TTE/0YO3!DVFR:9<`/TM
M+;?:!#FRXM^DJ5F.VK(LFH/<V`+&X8<)AKJ]EC7?I-C?:GZGCY[\DNH`$ODE
M]9M:YFUK6L'IASF;'^I_HD.G'S0'#(8+'3[3758P1&N[</WOW4E+LHQ'!Q-&
MUKQNVG",AHFMS)A[?H_19^XG&-C%PW-:YL'>/L#@'2/=^;N_?4Q19)FEWQ+'
M)_1LY])T_P!1R2D9HJ>`T@$.($_87=FO95NG]R-S7_\`%I/HQ&M>T-):V'-K
M=@NL+1.X,;L9[_Y"(VJS_1/_`.VW+3PFO;C,:\%I]T-/(&X[!_F)*<H545CW
M#U#JXQ@NEQ:[UIT:&_X-VQ#=CX\U[6['5$%CF]/<8G@L]CO3]SG_`/G"W+[J
MZ*++[#%=32]Y\FC<Y<H3G]7N:^\AE;SH'V%M3./96QL-NMKWM8^UWK?I_P";
M]&K^=2F_Z.$RP2UH.W>*_L#]&@_R&[]VNSZ2=U-.UA$.:PD0<"P@26RYK?ZS
M_P#T9_PBI5W9O2'M>W<:Q)LK:XOHL8T&RST"]S_2RFU^I;^C]&I_I_I*_P!)
M6NK:6N:'-,M(D$<$%)3ABG$;ND;@US-[1A/ES8=7L]K/Y'Z*S_/]11KQ\-I#
M=HV%I:YOV&QI<UP]X<=NWW?G[6K3;BXEY>]KKOI.:Z+;F`.:2U^QOJ,V_P#6
MU,X;FUEN/=94XN!<]SC:8'YH^TFW:DISL/$PK[=MU;7D[B6_9;*-3W>^SV?O
M[F_G_P!A7_V7T[:6_9V!KI)`$23RD,7-'.:\\\UU^7\A-]DSH'Z^^>_Z.OQ_
MJ)*9#I?3@[>,=@=,R!W\5.G!Q*+#;34VMY&TN:()&G/^:J>2SJ];F"BU]PCW
MG;4T=P"V8=O_`'_S%/IXZH+B,PEU>TZD,`W$@MV^G[_:Q)3A9CVG/S6M_G!:
M`\^,_P`W]$;O;]%;G0)_9E?,;GQ,\;G1MW>W;_Q7Z'_1+!SGU?;\UHUL]4;^
M._T/^@MSZO%IZ8TM@DOL+B(YWNW;MH;[_P![U/TW^E24_P#_U>\^M.W]GU3$
M^NS;.WF'_1W^_=_Q'Z;_`*:QNA>G^V<3CU`VW8`!]"';_=/[WIK>^L0)P6`$
M@>JW=$Q'N^GM<UNW_C?4K_ZYZ:Y_!#*,VK)+'/=6RUOMTT?]-N_\RW\YB2GJ
M\O-&*YC33==O#C-3"\#;'T_W?I>U`=UAH!_5,LQK`I/98M.5AFIU+*<RMA+9
M?9<YI.P.X>2YWY_]M.S+QR2QM>=66Q[WW.$3_*FQ)3U*JY.<,5VZYH91,&PN
M`/:7[?H[&3[_`-)ZG_!K%Q.K58EC]E&4^6@3<_<P07?0<9_?_KH[^N4?:VO=
MB6OM`ACI!8W]YS/W7;3[W;/4V)*;]75J+VW/H8]U=+6N;:\&NMY>)8VJRW;N
M_EV_S7_@BKMZ_2/39#K['N@&ACG,VN^@]UO\W6W\_P#G'_HO^-]-4+^IU7V'
MUL?)<VWZ3&6DU@0&_0]C&_VO\(K7_.*NFMC?LUU@$-#@0\_]<<?=_G)*=+-H
M^V]/OQV':;ZG,:3(@N$-+OSES549>,]N32=N&][K'UNK&10\@/L::\ANQN.U
MX]EOY_IT7+4L^LU5;=SL9Y\FEI/S:J6?G]+S'>O?T]]MK!`?6_;<!YNH<U^S
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MXV:&#J6>6G](;1ZHX@1^C[L_ZI;WU<)/2JY)/N>-23$..FK[=O\`X#_X7H^@
ML&YGJ9N3D"MS'9#FO)(,``.:W:Z/?_*6_P#5T$=*K!_>?K\7'^17N_\`!O\`
MPQ<DI__6]$ZUB9&71550T.<+-Y<2T!H:U^OO:]^YSO8WTO3_`.,]+?59F,Z)
MU1NUOZ,#0..X^+)_K>USW?\`6=G^%997TB22GFOV-U?T^*YV_1WGG;NVR6_O
M_HO_``52_8G5-T#8`"0#O/$V#=&W]QM7_;G_``.^WHTDE/-CHG5"1.SX[SI_
M-?R?Y=W_`&Q_W8_0(]%ZK!,,)B?YPSNVN/.S]]M;/^N>I_@_3LZ1))3SPZ+U
M&8]FV8G>>-T3MV_N?I-O_6O^$4?V-U0B88#$_P`X=#%9.NW]YUC/^M_\-^AZ
M-))3SO[&ZJ."TQJ/TCAJ/5V]OY-/_;W_``'Z=CT3JFX:L(F"[>XZ;J__`"5K
M]G_!?\-ZE/1I)*>;_8O5MLC;.V=OJNY+.-VW][]%OV_\+_P2<]$ZD7$.+"W=
MSO=XN9NV_P#%_P#0M]'_`(2SHTDE/-_L/J)'T6#@GWGGV>7\I_\`VU_PU7I(
M]#ZB.&LT'[YU_G/^JV5_]O?\!9ZW2))*>;_874/HAM<<3N/$[=T?U7>I_49L
M_G$AT;JD;@QH/.TOUF&OV[H_>_1;_P#OBZ1))3SO[&ZGP`R`>=Q\7C=']5C'
M?]=_X.Q1/1^J'EC=8_/XGTY_-_EV?]LV?Z6E=(DDIYMW2.J['>QKB!(;N$D^
M\QK[/S6-_P"N_P#&+7Z3CVXV)Z-P(>Q[Y)VD.EQ(L;L_-?\`\)^E5U))3__9
M_^TC>%!H;W1O<VAO<"`S+C``.$))300$```````/'`%:``,;)4<<`@```NMB
M`#A"24T$)0``````$,1:$M(D8C[&N2]^!L-7,1PX0DE-!#H``````/<````0
M`````0``````"W!R:6YT3W5T<'5T````!0````!0<W138F]O;`$`````26YT
M965N=6T`````26YT90````!#;')M````#W!R:6YT4VEX=&5E;D)I=&)O;VP`
M````"W!R:6YT97).86UE5$585`````H`:`!P`"T`9@!P`&<`+0`R`#``````
M``]P<FEN=%!R;V]F4V5T=7!/8FIC````#`!0`'(`;P!O`&8`(`!3`&4`=`!U
M`'````````IP<F]O9E-E='5P`````0````!";'1N96YU;0````QB=6EL=&EN
M4')O;V8````)<')O;V9#35E+`#A"24T$.P`````"+0```!`````!```````2
M<')I;G1/=71P=71/<'1I;VYS````%P````!#<'1N8F]O;```````0VQB<F)O
M;VP``````%)G<TUB;V]L``````!#<FY#8F]O;```````0VYT0V)O;VP`````
M`$QB;'-B;V]L``````!.9W1V8F]O;```````16UL1&)O;VP``````$EN=')B
M;V]L``````!"8VMG3V)J8P````$```````!21T)#`````P````!29"`@9&]U
M8D!OX````````````$=R;B!D;W5B0&_@````````````0FP@(&1O=6)`;^``
M``````````!"<F1456YT1B-2;'0```````````````!";&0@56YT1B-2;'0`
M``````````````!2<VQT56YT1B-0>&Q`<L````````````IV96-T;W)$871A
M8F]O;`$`````4&=0<V5N=6T`````4&=0<P````!09U!#`````$QE9G15;G1&
M(U)L=````````````````%1O<"!5;G1&(U)L=````````````````%-C;"!5
M;G1&(U!R8T!9````````````$&-R;W!7:&5N4')I;G1I;F=B;V]L``````YC
M<F]P4F5C=$)O='1O;6QO;F<`````````#&-R;W!296-T3&5F=&QO;F<`````
M````#6-R;W!296-T4FEG:'1L;VYG``````````MC<F]P4F5C=%1O<&QO;F<`
M`````#A"24T#[0``````$`$L`````0`"`2P````!``(X0DE-!"8```````X`
M````````````/X```#A"24T$#0``````!````'@X0DE-!!D```````0````>
M.$))30/S```````)```````````!`#A"24TG$```````"@`!``````````(X
M0DE-`_4``````$@`+V9F``$`;&9F``8```````$`+V9F``$`H9F:``8`````
M``$`,@````$`6@````8```````$`-0````$`+0````8```````$X0DE-`_@`
M`````'```/____________________________\#Z`````#_____________
M________________`^@`````_____________________________P/H````
M`/____________________________\#Z```.$))300````````"```X0DE-
M!`(```````(``#A"24T$,````````0$`.$))300M```````&``$````".$))
M300(```````0`````0```D````)``````#A"24T$'@``````!``````X0DE-
M!!H``````U$````&``````````````(-```"J`````X`10!X`&@`:0!B`&D`
M=``@`#0`+@`Q`#(`+0`Q`````0`````````````````````````!````````
M``````*H```"#0`````````````````````!````````````````````````
M`!`````!````````;G5L;`````(````&8F]U;F1S3V)J8P````$```````!2
M8W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<``````````$)T
M;VUL;VYG```"#0````!29VAT;&]N9P```J@````&<VQI8V5S5FQ,<P````%/
M8FIC`````0``````!7-L:6-E````$@````=S;&EC94E$;&]N9P`````````'
M9W)O=7!)1&QO;F<`````````!F]R:6=I;F5N=6T````,15-L:6-E3W)I9VEN
M````#6%U=&]'96YE<F%T960`````5'EP965N=6T````*15-L:6-E5'EP90``
M``!);6<@````!F)O=6YD<T]B:F,````!````````4F-T,0````0`````5&]P
M(&QO;F<``````````$QE9G1L;VYG``````````!"=&]M;&]N9P```@T`````
M4F=H=&QO;F<```*H`````W5R;%1%6%0````!````````;G5L;%1%6%0````!
M````````37-G951%6%0````!```````&86QT5&%G5$585`````$```````YC
M96QL5&5X=$ES2%1-3&)O;VP!````"&-E;&Q497AT5$585`````$```````EH
M;W)Z06QI9VYE;G5M````#T53;&EC94AO<GI!;&EG;@````=D969A=6QT````
M"79E<G1!;&EG;F5N=6T````/15-L:6-E5F5R=$%L:6=N````!V1E9F%U;'0`
M```+8F=#;VQO<E1Y<&5E;G5M````$453;&EC94)'0V]L;W)4>7!E`````$YO
M;F4````)=&]P3W5T<V5T;&]N9P`````````*;&5F=$]U='-E=&QO;F<`````
M````#&)O='1O;4]U='-E=&QO;F<`````````"W)I9VAT3W5T<V5T;&]N9P``
M````.$))300H```````,`````C_P````````.$))3001```````!`0`X0DE-
M!!0```````0````".$))300,`````!HA`````0```*````!\```!X```Z(``
M`!H%`!@``?_8_^T`#$%D;V)E7T--``'_[@`.061O8F4`9(`````!_]L`A``,
M"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,#!$,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.%!0.#@X.%!$,#`P,
M#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!\
M`*`#`2(``A$!`Q$!_]T`!``*_\0!/P```04!`0$!`0$``````````P`!`@0%
M!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)"@L0``$$`0,"!`(%
M!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<E
MDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D
M]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'
M!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q
M)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75
MY?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1`Q$`/P#TS.S!AULL
M<T.:YX:Z7!IU#C[`?YQ_M_FU29U]C@TFAP!`)UF/H;HT]WTK/\RO_N0Q$Z\\
MLPFQ.MC08TT]W\IO_47_`/%?GUXIO`ASB`TAY,@S#2!ZC8_P;-_O24ZQZ\W:
M2*'$@<;A$P[3=_7VM_\`!?\`!J8Z[43'HOYCMQNVS$_Z/W_^!?SBS\3#SLFO
MUV^DZHNAD![':';_`-J*_P![_P`[16]*ZK)W^CLTV[20[S^D"DILCKU9;)H>
M#$Q+>8:[F?WBYG_3_P`(I'KE>L4/($QQ_+\_Y-7_`&[_`,%8J9Z5U,//MI=7
M&GN.XZ_YJ<]+ZD7#;53Z>LM<YV[_`*/M24W?VW1/\W9&FL=I:)_Z3W?];_X2
MM-^VJH_F7S''MYCCZ7[_`.C_`/!/YM4_V;U)I'IT4Q/NWO=/';84G]/ZD(]+
M'J)X.]Y&G]E)3=_;5`YK?$QP.)B8G=]#W_\`J1-^W*(UJLU`T]O@S^5^\]S?
M^M_\)4J=G3^I%HV45EP_?<(^6WW?YRA9TWJ>T;*&;]#](;?OGU$E.A^VJ/\`
M163V$#^7_*_DU_\`;W_!W>D_[9HG^;LB>8'$M]WTOY3G?];_`.+6>WIW4]FM
M#!9Y.&S\N].SIO4BS])17O[!K_;_`&O=N24W_P!LU;9]&R8G;[>8W;?I_O>Q
M+]L4?Z.R)Y@<21N^EN^C[O\`S/>J3.F=1V_I:JYX&UY\?Y29G3NHS^DQZ]H.
MFRQTP>_N<W<DINCK5$@&JP3Y`_N>#OY5G_;/_"4^J_[:QXD5V<3$#P=_*_>#
M&?\`7/\`C%2'3>H%QW44[!Q%CI_Z0VIQT_J&\_H*O3&H][MWS24W?VQC_N61
M,3`XF-W/[GZ3_P!2)AUF@@'T[!/D/Y/\K]XV-_ZS_P`5ZE(X'4`X!N-6:_$O
MU']E0R*\O%:++*JV5D@;GNUF)C;6VU)3H.ZS2`2*K"0"0/:.`X_O_P`EG_;O
M_&^G;Q[V9%?J,^C)`\=/']U<\+@^8V%NUI;MY$D?2;^;_P`'M6ST@S@L(XET
M<Q&XQMT;[?ZGJ?\`&V)*?__0]`^LG]`88F+6'_JO^#L_ZO'_`./_`,'9C]/Q
M*LG-QF6P^HMOK<S<?<':]MOT?36Q]8R!@UR8)N;'',.^C[FN_P"VV7O_`."_
MPE>5T=A/5,.W<8:,AI'8[RYS7?\`@22FW]:L;'H^KF6RM@VEPL:UQ+@'EXME
MC7$_X3W^G6L>SH?3GU`XS-KFN]YL>7-T);:T!K*]K_5'_%KJNK]._:>"_#]4
MTBPM+G`;M&N#RS;+?I[5E_\`-2\1'5,K3^6__P!*I*<7'Z!7ZLY#ZW5GZ;:@
M6N,C\UUGJ-;^DVO^BM#H6'BXWUD>R@':S%=MWEI,N-#W>YK6*W_S5O$QU7*\
MOTC]/_!58Z9]7WX&><QV79D%U;JRVR2=2QS7>H^Q[O8VO9L24["2222E))))
M*4DDDDI22222GD,W%QLCKW4QDV7UUUM98?L]FPZ5U;MP_JEW\M9UE&.-SJ\M
MXK:26&VS(#@WAN_TQMW?\6MW-Z/G6]0RLRBS(I-S@(K;2?:QK&-AUN1]!VS]
MVM"/0^J"/UG*,1(]/%[_`)NMOMV)*<TXF%^S\BZO(R796*PO<!:[TAJX5>VS
M9;]!GN_MKI^F8E%W1L*I^YU;&,=MWN]T-B+?H^JWW?1>LA_0.HNJ=4[(R7LL
M:6V-%6*)'[KXN:N@Z;593@TT6;M]30PEX`)V^W?M8^YK=_\`QB2GG;J!1EY3
M6$^G+6M:2'0*]M?NWG\_Z>ZQ;?02#TYL1H]X/T>=QG=L<[W?\;LN_P!+76L;
M*8X=0SK#)%CV[!K^80UWT?Y2VNA$GIM<SRZ)W<;C$;PWV_\`%?H?]$DI_]'T
M#ZR3]@9$QZK-T3$:_2VM<S;_`,=Z=7_"+'Z.QYZOAVS[&MN:\1^<[<YKO\UB
MU_K*&G"J!B?79MF)F'_1W>[=_P`5^D61T=KOVOAN'\WMNW#^42?3,_U&N24]
M:DH6VUTL+[7!C1`D^)T`01U'"/\`A1]Q_N24R?G8C,H8C[`V\L]4,,CVSMG?
M]#^SN4?VCT\&/M5,^'J-\37^]^^W8J.?@="ZI<VW*/J.:`UL.<T#:2]CALV^
M]KG('["Z#M;M>X%CFO:\.U]HN8QO'T6U9-E7_;?^$24Z.9UGIN%Z7VFX-%V[
M8YK7/:`QS:[7VV5->RFJI]C&V6W>G56K+LC'8)?:QHTY<!R=K?\`.<LJCI70
M:FX;&-#J^GA[<2MY+VL%A:_1MF[=Z7IM]!_^"5._H'U:HJ8`RQ[6@5A@MCVC
MWM_G[*V._3?I_P!_UG_Z-)3T'VK&'^%9X_2'\L^/_!6_]MV*'V_#<"YF140U
MH>XA[2`TQM?]+Z+M[5S3^C_5MSW31<"]V\[;ZP-Q#PY^UF1^Y;=3]'T]E]O[
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MS+;WOW>YU]C2YSN?6FK=[?S/0_HU?I_T:O\`PDW=!^J]HVM/M+9L:QT;B#_/
MV.8WU-WO?7]/TO\`MG'])*=\Y..U^QUK`\`DM+A,#Z6G\E2:]CQ+'!PT.AG0
MZA<^.@_5VS<WU7/>]Q>?<"[>2RQUC6[/WJ:G^E_1_P#@?15OIF%T7I=EK\6S
M:^\-%NYW)87>_;#6L=^D]VS_`(-)3KI(/VO'T&_4\"#K_5T4F9%+W;&NEVNF
MO;Z22GE\P/\`M^>YQ_1EPV`Q&A`L^E_*6WT$M/3FEL?3LF(YWNG=M_/_`'O4
M_3?Z18F6;?VCG`R6!S?2`GN1ZFW^VMSH4_LVODB71.[C<=NW>3[/W?2_0_Z)
M)3__TO0/K'N^PLB8]9NZ)B(=]/:X-V_\8RYG_!^ILLKQ>C.L_;&&T3Z1;:7?
MUQOV?]'U%L?6:/L-4Q/KLB8YA_T=S'_]%^/_`,=_@K<;HKW?MC$K`_1EMKR=
M-'-#V-`_LO<DIZ7J(FIFA/Z0<`$\._>6*7=5&_\`56.(/M=+1N$NY;_@O;Z?
MOW6?\5_@UM=2`-#9$^\::GL?W5FD-D^UOCP])368_JI+M^'4V&RP[@_W?NN;
M%7TOZZ/0ZYS'?:*&TNF&M;^D!$:NWLVIV[)X;I_7"D2`V06B(UW/24Q#&S&U
MNNGT'`?^8_\`4*H.K8++)98:[&[FDBIY[DOW-L99_H-_[^Q7`1RTMW#C](\?
MP4"R@-#=E0:7;]N[\[7<_;M^G[G>])2"WK.(]SL>V\[VG<ZKTRUPV^\[]M/Y
MB"Z_IK17%@=ZPW5@%[BX?H_HM:PN^CZ;MCOS/TG^%5MM6,-L,J`;&V"T1'$>
MQ)[*',#7LK+0(VN<P@`"8]S$E-9^;TYSFFRTASX+)!!@$U;A^C'Z/]!_KO1*
M>IXC(KKN=M+G$`L;`+BZRP.=91[-K_I_F4*P:Z7.$M:2#(_FR09W=V_O.W*(
MQZ-6MJ:&D!I`;5!`!:V?;[OI)*0#J>&_?:V]SB&L<YS8;[71Z)#:ZF?]RF_\
M+_WRW+B0-[@2"TP]G!Y'\I"?B8YDNH:9F?95$GY*PT&9(=)Y]C._BDIBREE;
MMU0<QW[S7,!_SE%^'4_5]9<2XNDBL^YWTW_VD7;V#3'_`!;?_));('T#_P!M
MC^!24MZ3R]ECC:Y]0/IN]LMGVNV?N[E?P:&-J99[MQW$R3])Q)>YS/H[U0:P
M:>R8_P"#([^3EI8/]%KTC0Z1'<]DE/-YC['=0SV.'Z-C@*S_`%CN?RUWYW]=
M;?08_9K3I)?83$<[G;I]K/\`I^K9^_=:L+->X]0SJR(;6\;#X[_>\>W9_P!7
M_P"36[T&?V:R9^D^)GC<?WGO_P#1/_A>C^;24__3[_ZRDC`9'^F9,?!W;U*]
MW^9D?\1_A*L7HKW-ZSB5;?:YMKR[^H'L:.?Y:V_K("<!D<>LR?"(=]+V/_\`
M/F/_`,=_@;L;HUD=8Q*8U<VU\GL&^I7L'];?^ZDIZ/J1:*&EVC0\22=H'/TG
M_FK%?9D[CM^RD;3_`-J73ND^F/ZCO;ZBV\C-927L-5KW!L@LJ>]ID'\Y@VNX
M_>56S,N=N;4Q[7-(&YV-:`9YVZ6?]0DISZK<PO&\8X;N&XLR2X[==VT'\_\`
M=5@N$:N(^%H3.R,NX,<^M[2-I:!3<TC=SO\`39M_1_X3<DW[1N'MMFLZ'9?!
MAV_<?W_?^_[_`/K:2E-,/G>[7C](TPG<2?SW#^TTH88XM(BXAYW$[,L'0'Q:
M'-^G]!/8+2W<UMEELB0_[6T;0UWYU3'[;-_I?];_`*Z2EW$@07//G+%`O@\G
M7CZ!2/VP-CT20TESA.;+@#^C].[;OJ<SU+O5K]-_J_HO]&HA^6SG'U:\.=^D
MSG'=[MKMAH^AZN_^196DI(7DD@%T3VK:?XIVS/T7'N9K:$,C)<UP]%S;#H'-
MLSG-DEN[=7Z5?I_HG._/^FG;=GFQEWV4R\[C[\P;2#O&^LT;/S6>S_C*_P#C
M$I,=H;+@)&I_1`PH[FRV0)//Z/D_>DRVUHKW5VLL;)AOVJQAAWJ,GU*ZWOL^
MG[',_F_^#4FDP:QZ\<SMRCP&5>U^OM_X/_C$E+-+#IH?']&0I$UZ3M_S2/R%
M1)-C0(OAP/#,H:.+GZN:/WG_`+W^C1F9+ZG6!K'.<X^HX.IR':GV^S>SV-]G
MT/YM)2)KJ_%GCPX?Q6G@1]CJ(X(D?`G3E5V9H`(LJ>'-<6N#:+'`P?I,<QKV
MN:YOYZLX^8R\@-KM82W=^DK>R./;N>T-W^[Z*2GF<Q^[/SJML>G8-?'<=_@Y
M;G0)_9K">[GD?YSOY%?_`*._\,7_`,XL/->P]0SJX]S'M+G>.[W-G=M^A]'Z
M2V_J\0>F-\=]D\<[G3NA]GN_K^E9_P`!3]!)3__4[[ZS$#!KF)]=D3',.^CN
M>S_P-E[_`/@?\)7C]$M9^U\6HCW.;8YI`B&@/W#3]YW_`%"V?K+N_9[(F/5;
MNB8B'?3VM<S;_P`=Z=7\OZ"Q.B6,_;.*QW\Z?5+=>&AMGJ#_`#_324]#F],&
M3:;)IEP`_2TMM]H$.;+BWZ2I68[:LBR:@]S8`L;AAPF&NKV6-=^DV-]J?J>/
MGOR2Z@`2^27UFUKF;6M:P>F'.9L?ZG^B0Z<?-`<,A@L=/M-=5C!$:[MP_>_=
M24NRC$<'$T;6O&[:<(R&B:W,F'M^C]%G[B<8V,7#<UKFP=X^P.`=(]WYN[]]
M3%%DF:7?$L<G]&SGTG3_`%')*1FBIX#2`0X@3]A=V:]E6Z?W(W-?_P`6D^C$
M:U[0TEK8<VMV"ZPM$[@QNQGO_D(C:K/]$_\`[;<M/":]N,QKP6GW0T\@;CL'
M^8DIRA516/</4.KC&"Z7%KO6G1H;_@W;$-V/CS7M;L=406.;T]QB>"SV.]/W
M.?\`^<+<ONKHHLOL,5U-+WGR:-SERA.?U>YK[R&5O.@?86U,X]E;&PVZVO>U
MC[7>M^G_`)OT:OYU*;_HX3+!+6@[=XK^P/T:#_(;OW:[/I)W4T[6$0YK"1!P
M+"!);+FM_K/_`/1G_"*E7=F](>U[=QK$FRMKB^BQC0;+/0+W/]+*;7ZEOZ/T
M:G^G^DK_`$E:ZMI:YH<TRTB01P04E.&*<1NZ1N#7,WM&$^7-AU>SVL_D?HK/
M\_U%&O'PVD-VC86EKF_8;&ES7#WAQV[?=^?M:M-N+B7E[VNN^DYKHMN8`YI+
M7[&^HS;_`-;4SAN;66X]UE3BX%SW.-I@?FC[2;=J2G.P\3"OMVW5M>3N);]E
MLHU/=[[/9^_N;^?_`&%?_9?3MI;]G8&NDD`1)/*0Q<T<YKSSS77Y?R$WV3.@
M?K[Y[_HZ_'^HDID.E].#MXQV!TS('?Q4Z<'$HL-M-3:WD;2YH@D:<_YJIY+.
MKUN8*+7W"/>=M31W`+9AV_\`?_,4^GCJ@N(S"75[3J0P#<2"W;Z?O]K$E.%F
M/:<_-:W^<%H#SXS_`#?T1N]OT5N=`G]F5\QN?$SQN=&W=[=O_%?H?]$L'.?5
M]OS6C6SU1OX[_0_Z"W/J\6GIC2V"2^PN(CG>[=NVAOO_`'O4_3?Z5)3_`/_5
M[SZT[?V?5,3Z[-L[>8?]'?[]W_$?IO\`IK&Z%Z?[9Q./4#;=@`'T(=O]T_O>
MFM[ZQ`G!8`2!ZK=T3$>[Z>US6[?^-]2O_KGIKG\$,HS:LDL<]U;+6^W31_TV
M[_S+?SF)*>KR\T8KF---UV\.,U,+P-L?3_=^E[4!W6&@']4RS&L"D]EBTY6&
M:G4LIS*V$ME]ESFD[`[AY+G?G_VT[,O')+&UYU9;'O?<X1/\J;$E/4JKDYPQ
M7;KFAE$P;"X`]I?M^CL9/O\`TGJ?\&L7$ZM5B6/V493Y:!-S]S!!=]!QG]_^
MNCOZY1]K:]V):^T"&.D%C?WG,_==M/O=L]38DIOU=6HO;<^ACW5TM:YMKP:Z
MWEXEC:K+=N[^7;_-?^"*NWK](]-D.OL>Z`:&.<S:[Z#W6_S=;?S_`.<?^B_X
MWTU0OZG5?8?6Q\ES;?I,9:36!`;]#V,;_:_PBM?\XJZ:V-^S76`0T.!#S_UQ
MQ]W^<DITLVC[;T^_'8=IOJ<QI,B"X0TN_.7-51EXSVY-)VX;WNL?6ZL9%#R`
M^QIKR&[&X[7CV6_G^G1<M2SZS55MW.QGGR:6D_-JI9^?TO,=Z]_3WVVL$!];
M]MP'FZAS7[/^N)*07X]M-->#161]I>]^-78]AM>]]?V4/?5B,;73B5,>_(LL
MW?X+_A:ZUTESS@X+2R'MH%;7;N[`6UO=N_>V>]8F%U#I^"UUV+TYU;K![W%V
MZYP_E.LWV.;_`-<5NKZQFUF]N';H)+28=_9;"2FZ[JN&YM[:+6V64UOL.W])
M!9+7MV5NW;ZW?X+V)G=0]-U`N+&![0YYF9)]GZ#][;;Z?[_\ZJK?K"YX)&':
MV)_G/9,?N^TJM7U#?;N;1G,VOG;:]S6^.W\[<Q)3ICK&'Z`M>+*R9_0FMQM$
M?O4UA[V<[O=]#_"*Y78RQN]AELD201P=OYWP64/K"W<YKL/(86@'<]H:TS^Z
M]Q3'ZR4BPU_9KMP$[MHV?]N)*=&Q^:'$5U5.;V+K7-)_LBE__5*5;LHOBVMC
M&0?<UY<9G3VNJK_-_E+,/UCK#@W[+<29U#9;I_+;[4S_`*R,8X-.)<[=P6C<
M.-WTF;O\U)3C9H8.I9Y:?TAM'JCB!'Z/NS_JEO?5PD]*KDD^YXU),0XZ:OMV
M_P#@/_A>CZ"P;F>IFY.0*W,=D.:\D@P``YK=KH]_\I;_`-701TJL']Y^OQ<?
MY%>[_P`&_P##%R2G_];T3K6)D9=%55#0YPLWEQ+0&AK7Z^]KW[G.]C?2]/\`
MXSTM]5F8SHG5&[6_HP-`X[CXLG^M[7/=_P!9V?X5EE?2))*>:_8W5_3XKG;]
M'>>=N[;);^_^B_\`!5+]B=4W0-@`)`.\\38-T;?W&U?]N?\``[[>C224\V.B
M=4)$[/CO.G\U_)_EW?\`;'_=C]`CT7JL$PPF)_G#.[:X\[/WVUL_ZYZG^#].
MSI$DE//#HO49CV;9B=YXW1.W;^Y^DV_]:_X11_8W5")A@,3_`#AT,5DZ[?WG
M6,_ZW_PWZ'HTDE/._L;JHX+3&H_2.&H]7;V_DT_]O?\``?IV/1.J;AJPB8+M
M[CINK_\`)6OV?\%_PWJ4]&DDIYO]B]6VR-L[9V^J[DLXW;?WOT6_;_PO_!)S
MT3J1<0XL+=W.]WBYF[;_`,7_`-"WT?\`A+.C224\W^P^HD?18."?>>?9Y?RG
M_P#;7_#5>DCT/J(X:S0?OG7^<_ZK97_V]_P%GK=(DDIYO]A=0^B&UQQ.X\3M
MW1_5=ZG]1FS^<2'1NJ1N#&@\[2_68:_;NC][]%O_`.^+I$DE/._L;J?`#(!Y
MW'Q>-T?U6,=_UW_@[%$]'ZH>6-UC\_B?3G\W^79_VS9_I:5TB22GFW=(ZKL=
M[&N($ANX23[S&OL_-8W_`*[_`,8M?I./;C8GHW`A['ODG:0Z7$BQNS\U_P#P
MGZ574DE/_]D`.$))300A``````!5`````0$````/`$$`9`!O`&(`90`@`%``
M:`!O`'0`;P!S`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H
M`&\`<``@`$,`4P`V`````0`X0DE-!`8```````<`"`````$!`/_A#W9H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O`#P_>'!A8VME="!B96=I;CTB[[N_
M(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^(#QX.GAM<&UE=&$@
M>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#
M;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C`Q,B\P,B\P-BTQ-#HU-CHR-R`@
M("`@("`@(CX@/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R
M9R\Q.3DY+S`R+S(R+7)D9BUS>6YT87@M;G,C(CX@/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(@>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C`O(B!X;6QN<SIP9&8](FAT='`Z+R]N<RYA9&]B92YC;VTO<&1F
M+S$N,R\B('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C`O;6TO(B!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O
M,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z9&,](FAT='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B!X;6QN
M<SIP:&]T;W-H;W`](FAT='`Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N
M,"\B('AM<#I#<F5A=&5$871E/2(R,#$U+3`S+3(W5#`Y.C0T.C$Y(B!X;7`Z
M0W)E871O<E1O;VP](D%S<&]S92!,=&0N(B!X;7`Z36]D:69Y1&%T93TB,C`Q
M-2TP,RTR.%0P,CHQ,SHQ-BLP-3HS,"(@>&UP.DUE=&%D871A1&%T93TB,C`Q
M-2TP,RTR.%0P,CHQ,SHQ-BLP-3HS,"(@<&1F.E!R;V1U8V5R/2)!<W!O<V4N
M4&1F(&9O<B`N3D54(#DN-RXP(B!X;7!-33I);G-T86YC94E$/2)X;7`N:6ED
M.C$V.3,W03-&041$-$4T,3$Y-T$R14%&,D0U1C(U-T$V(B!X;7!-33I$;V-U
M;65N=$E$/2)X;7`N9&ED.C$U.3,W03-&041$-$4T,3$Y-T$R14%&,D0U1C(U
M-T$V(B!X;7!-33I/<FEG:6YA;$1O8W5M96YT240](GAM<"YD:60Z,34Y,S=!
M,T9!1$0T130Q,3DW03)%048R1#5&,C4W038B(&1C.F9O<FUA=#TB:6UA9V4O
M:G!E9R(@<&AO=&]S:&]P.D-O;&]R36]D93TB,R(^(#QX;7!-33I(:7-T;W)Y
M/B`\<F1F.E-E<3X@/')D9CIL:2!S=$5V=#IA8W1I;VX](G-A=F5D(B!S=$5V
M=#II;G-T86YC94E$/2)X;7`N:6ED.C$U.3,W03-&041$-$4T,3$Y-T$R14%&
M,D0U1C(U-T$V(B!S=$5V=#IW:&5N/2(R,#$U+3`S+3(X5#`R.C$S.C$V*S`U
M.C,P(B!S=$5V=#IS;V9T=V%R94%G96YT/2)!9&]B92!0:&]T;W-H;W`@0U,V
M("A7:6YD;W=S*2(@<W1%=G0Z8VAA;F=E9#TB+R(O/B`\<F1F.FQI('-T179T
M.F%C=&EO;CTB9&5R:79E9"(@<W1%=G0Z<&%R86UE=&5R<STB8V]N=F5R=&5D
M(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G
M92]J<&5G(B\^(#QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)S879E9"(@<W1%=G0Z
M:6YS=&%N8V5)1#TB>&UP+FEI9#HQ-CDS-T$S1D%$1#1%-#$Q.3=!,D5!1C)$
M-48R-3=!-B(@<W1%=G0Z=VAE;CTB,C`Q-2TP,RTR.%0P,CHQ,SHQ-BLP-3HS
M,"(@<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O8F4@4&AO=&]S:&]P($-3-B`H
M5VEN9&]W<RDB('-T179T.F-H86YG960](B\B+SX@/"]R9&8Z4V5Q/B`\+WAM
M<$U-.DAI<W1O<GD^(#QX;7!-33I$97)I=F5D1G)O;2!S=%)E9CII;G-T86YC
M94E$/2)X;7`N:6ED.C$U.3,W03-&041$-$4T,3$Y-T$R14%&,D0U1C(U-T$V
M(B!S=%)E9CID;V-U;65N=$E$/2)X;7`N9&ED.C$U.3,W03-&041$-$4T,3$Y
M-T$R14%&,D0U1C(U-T$V(B!S=%)E9CIO<FEG:6YA;$1O8W5M96YT240](GAM
M<"YD:60Z,34Y,S=!,T9!1$0T130Q,3DW03)%048R1#5&,C4W038B+SX@/"]R
M9&8Z1&5S8W)I<'1I;VX^(#PO<F1F.E)$1CX@/"]X.GAM<&UE=&$^("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@/#]X<&%C:V5T(&5N9#TB=R(_/O_N``Y!9&]B
M90!D0`````'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!`0("
M`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`__``!$(`@T"J`,!$0`"$0$#$0'_W0`$`%7_Q`&B````!@(#`0``
M```````````'"`8%!`D#"@(!``L!```&`P$!`0````````````8%!`,'`@@!
M"0`*"Q```@$#!`$#`P(#`P,"!@EU`0(#!!$%$@8A!Q,B``@Q%$$R(Q4)44(6
M820S%U)Q@1ABD25#H;'P)C1R"AG!T34GX5,V@O&2HD14<T5&-T=C*%565QJR
MPM+B\F2#=).$9:.SP]/C*3AF\W4J.3I(24I865IG:&EJ=G=X>7J%AH>(B8J4
ME9:7F)F:I*6FIZBIJK2UMK>XN;K$Q<;'R,G*U-76U]C9VN3EYN?HZ>KT]?;W
M^/GZ$0`"`0,"!`0#!00$!`8&!6T!`@,1!"$2!3$&`"(305$',F$4<0A"@2.1
M%5*A8A8S";$DP=%#<O`7X8(T)9)3&&-$\:*R)C495#9%9"<*<X.31G3"TN+R
M565U5C>$A:.SP]/C\RD:E*2TQ-3D])6EM<75Y?4H1U=F.':&EJ:VQM;F]F=W
MAY>GM\?7Y_=(6&AXB)BHN,C8Z/@Y25EI>8F9J;G)V>GY*CI*6FIZBIJJNLK:
MZOK_V@`,`P$``A$#$0`_`-_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7__0W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW39C<SB,P<BN)R5#DCB,G48;*"BJ8:G^'Y>D2&2JQM9X7?[>NIDJ$,D36=-
M8N!?W[KW3G[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z_]'?X]^Z]U[W[KW1.OFO1=F'K+#;
M@ZP\DV3VIN.NS>6A.2JL-3X[&P[*W:*/=PRE`J5%'7[0W%]C50O42/BTC,K5
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MR=I9'=;T]!F*&3&PO,J9>>E*11T<`;W7NO?%KY4]O[F[^[+VCW#M;>&V-L5&
M0J*;%5.8I(3M3;N2P>`R.8W1797/5\U#/L<4^2QDV)H-NU%-#5/B:?'YR8RG
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M.;JR^X</4FGV)O\`-=%A]KIN"?*[JV[UW+BH]Y93,UN+P\4V.P-1]G45%95+
M2/41,C2#W7ND%\;/FQFMS]!]I;MW[L#>E%NGHQ<?@:_;>?HLI#V!N?.2034T
MU-74-+C\UBZJFI,_3RTL69PV0S]!E<;`,O&ZQ3I"/=>ZX_%?YI9;L#>W9NS-
M\XW*OMK:L.X<[ANT<EB#M['YZ/$_PNM>&DQ29?<5)CJ+<&(R9R-!0S5T61PL
M,8Q^4AAR),*^Z]TP]4?.C<V[_DE@]@YC9N>Q>![!Q^-H(J7(X7<=/A,#F/\`
M*ZVDJ=O[JK*2CC26DQ<]'!DL7F\3A<ME,ED97QOFH,%6S2^Z]UC[B^>&8V3W
MYCMM;?VMO7+;8Q&4R>UO%1;2S55M/=M4L54L^0J,[!C3FJ:9\MC*BDHZJCH*
M[$4"T0FGJIAF*2*'W7NE9\O?FID^G\LF"V1@]T5W]W3M+,[@SN(Z_P!U[T@T
M9N>IJ:F"KQ>&.,EDV[M3;](^0S20U#9"I9X,=3)%65$3'W7NG[N'YHG%=%[1
MWCLC:FY\GOKL/9^0W51;)VGCYMQ;TQ,&+JZ&A;`4M!74^!HZ?<NYLW5IAL=/
ME'Q])3SO-6N)X*">%_=>ZQ[0^<U-G/C-7]R0X?\`O%N*@WRO7-+!0;9WAMW'
MY"MGK*.--Y93;N>H_P"/[9VYC,94S5%8E1,8VJ*&2E6JCFD58_=>Z3GQ@^=E
M+V5L7MS+;DQV55.L-MUV[\'6Y[%YK%;AW'109+.8[([8SF-QV)SB1;BP&8IJ
M"D\F/%9][_$XXJ>GEGI:C5[KW7#XT?-G*=C_`"#["Z4WCA-TXNHBR<DN'DSF
MS<UBZ'#9"'!U&8R6,H=RH*C#9':4_P!G/0X>6I2CJZBHPU;4RZ%K\=3>_=>Z
M;>J/G_7]@=Z8_9E3M;*8W:V[=P+M#%T>6VUFJ"#!Y"GRN<H8L[0;ZCI9<7N"
MAR5)08V84QI5%6=QT9@J(!C\FOOW7NE'W%\[TZ][RSG6F&VUF<K!M#!55963
M28/--M3+UM#5[?J,RN:WICL)E*'9J+BILK3XN>H?3)E<)4T]1`RU=!+[]U[I
M5?);YDT/2F\.O-I8:&BJ1V)1#)87(4>+R.X:S*3&FFRE?D9L;C_M*?$[(VAA
MUHJW/Y2JJ$8TN5@CI`U0K+[]U[I^[N^7:=?]';3[3V]M'<.3K=W?:4M5M[&T
M0S6[]J926M_@U3AI-L4L<];D\B=VQ28"*LBAGQD&4DAFJ'^Q,DZ^Z]UUM7YC
M[>SW06Y^V::-,A/MK<-+LK%UC4E?1X_>-;7X_"U^%WI#CI:>GJL9@LKALN,Q
M44`DEJ\?10RPRLM3&\2>Z]U#^+_S*P'=FW=S9'+5"K48K`9[L#$BGPF:H,C4
M;(P.5JL)FX,MB*BA$E!N+`96E1OMA^Y48[)4$J*[O,5]U[I!_'[Y^8GM_M_(
M=:3X^G:"IW'E\%CLAC4K)DQ=91_QA***2J2E6ERV-DR^W,MM^KE@\@QNY,!7
MQSS&FJ,<\WNO=0]R_P`P?";:[\J=AUM%(-D8)9I]T5%-M_=.5RV-VS49N3:^
M+W?)-C,)-CJ&63,8VMR24+5,]77[81:RGI59;R>Z]TN/D+\OWZK[=V?L#&(8
M,/19JDINP\I5X6O:.GGR&)Q^=P-`V6>EJL5C-K9ZDK5Q4N7E\$=#N3)X>"29
M:>>LD@]U[KA\@_FSM38NT>J*W9.?QL-7W-MF#>V"RU7BLUN#+X_9=;2X\TF5
MP&PL#BLOG]Z[@%3EXYGQE-`\D=#15LLFCQ`^_=>Z6V:^7>T:#X_Y[MU\AA-N
MUF$R^<V/D:[=<\E#LK`[PP^-K,D<[E,K2R5DM9L*HPU/'F:>>A-555.-J88U
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M^PFV7CZ2&C&;RNYJ/;&O("&NAI]KFMB>3)4^7HL)_$WR]9C,A0HN'.56DR^`
MS-+-)XZ%:B;W7NHU)_,!ZRJ>[,SUFU510TN"W.FS,CY,I1+4TSS9Q\)3;R&0
M2.7;$N'>I3[B:A?*P9*FPTD5=]O(\C4T7NO=9_DC\ZMH=!]H[<Z\KY,6*Z.H
M-?G,/4URUNY=TXAML5N<&,V;A,%#EZG%YBI=8:7'56X7P6+R.;GI<>E2!425
M-/[KW2N[\^96Q>F]L]/9^>MQ\%#W%/@*O&9FJK8<K08O;V8IJ+(ID0-J)N;^
M,1/0U33S5=(9L908FEKLG+4M!1A*CW7NI>Y?F9UQB/CO1=^T>3VS_#,M7U>`
MHXJS=N,GQ-)N*CJ<A1U-%497!KEIJ]A-CS]O!2TTE74O/3QO'!Y6>+W7NLFR
M_F%U]F>D-Z=O9"7(5%%UKMS#9[<1HL9.U1G<?G\/2Y/`Y;`X:".7,B++5$\F
M/EII*5:FCS-#74.B5Z1G?W7NH7QS^8&T^Z\OF-L5%?@4SN,HMX9ZJGQ6148K
M$TFU-TC`YK;M;)D_L:NMK,#%6T=5'E*>)L=E<55T]?&8!/\`;I[KW2$ZM_F#
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M]^Z]TU?'GY<;1[>ZZW!O"JR-&HVWM:3L`5%3-1[?R.2V'5R9F7'93,;5R\M!
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M[FVT,/5SSTTV*HCC(\K@IZBKAIQ79;#ME(98JJ`"+)TYFEBBC2EE)]U[IGV9
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M8J2(9+"YBLIHZ>ECSDV.JH<G1PQ!GJ*`U)T*U#4V]U[I.[%^=W6>].W:SK@5
MN)HH*K(8+!;7I8<B,CO'(9'/;BW)MG'Y?/[<I@*G:VVLCF-I5U/#4U*?;$FA
M85#ME*6$>Z]U.[.^;?7/6O;K]<9/.;2CCP=-7_WGI:O<^+H]R?=TV.Q^:GFQ
MU#4U$5)!C,3AJT2/+4RQBLJ5GI8BLU)*K>Z]T[]^_,+8W2NY-D[9J,OM.%]U
MP4^8.>S^XJ"#"RXR2&JKJ?$X>FQM36;ARV:S6.H)9DFIJ*HI:"F9*NHO`21[
MKW4OM[YD=4]7]/[<[<J\U#38#>FV*O<^W\GDZ6JDI*&@H::AJJ\9K'XTU&7.
M:HEKO",3!&]=/7QM2`)*#I]U[I45GR?Z]AZ>SO:U!E<)DTP=?4[5-`^?H\3B
M:S?T5)#/18!]T5D;XW$8;,&J@J*?+U2I1'%5,60N::1';W7NDUT5\P^K^Z.K
M\QV32Y[!046WML#>N1?'9./(4E3L^HAK9:#<-"T!GD9)IL=44E12`RU>/R4$
ME%4K'5H\"^Z]TT_'_P":'7_>.[<_LL3XK;^>H,AG\=AZ*HS-(\V8R>T$IIMY
M86@.LT>9FV]09&CKX:V@GJ*;*8JJ%9$L<4<EO=>ZE=-_,CJ_N+M#=G76W]W[
M0R%?C*N"+%83'9*-]V8ZEFQDN3QE7NS%M62S8Z+>F-I9Z_$"6&CG:F@ECDA+
MQ%V]U[H-=H_.S:>Z_DWNCJ?'Y>@KMGXJ3;.V**KCVYF\;13;CSGB<9W!]GY6
M6#8/8$%%7UT&+SF&Q,C5^VYZW$R2M4ME?%2>Z]T9G-=H;BS>:W9MSJFAVOE:
MK8V4BVUO#<.Y\AD#@,%N*OPE#N"GHX(MLTV4GRM7@\56+-E:&HFQ=33>>D%Q
M'5">+W7NEKU3N+<N[NN=G[HW?C:#$[@S^%ILM6T.,,_V,<=:7GQ\T$=5+/4T
MWWF->&9H)))'IWD,;.Q34?=>Z$'W[KW7O?NO=?_2W^/?NO=>]^Z]T$?<?;N&
MZ@VK6YRM@@R66_A6X,EB,-492FP='40[;Q$^8R^4SN>JXJBGVUM+!TD0ER>4
MDAG6AIVUB*9RD3^Z]U3-A.]XOD!1X+<6S<1UYMWK[>%?3&OW7U+M[*U>0E.Z
M\=N/LQLKMRORV(P]:M?O[;&,QU9MV"E%74Y_+2U=)D:3$A_\H]U[H`>OC+N;
M+[8FZ^W3NOHF786X:RC[.I.TM@UF+P-%E\5VG2T-+T=VGMZAE?9^_P"M?!2'
M<TN(V97QSODJFOQ%1F*"G58T]U[H3X=G91MJ8+H.GW3%4;MQD]3VGOOL#MO<
M51G]O56PL1DL(N.[8ERE%B-OX'M#9>ZMLXFHQLM!CX,.^&3%N<U'1SU\F23W
M7NGZLV?FY-E9?HC/YW.[CWMVP^;RO7&Z-P[X7,4&[_X-ELKNS(]D4T^0Q<4&
MU-O=`XRBQ>/K:9O*N<@KIIVQV93'T=96^Z]UUAY9MB[>&Y][;LPV3'9U-7K@
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M-3#/#G!'3FEE]U[KU5M?&5=)4]50Q;PQ_P`B,)DINRDVWG>S=I;NW]MC)[<Q
ME1V!BN]>Q:/&4E#MW^Z\&2R\QP[?PR+"-N>"FRLN(:JK1&_NO=8Z''8/:B9[
M`;JSM9A=Z;^AVWE.OC0YJNS=%V%M3&STFSL9#T7M:1]H;CW9+U3BFG?+34TU
M)N2JV7EH:3)F>IFIPGNO=2J2IFVMF:;-=P;ZVQ-A':OZZQ>Z]K]@X7^ZN%[#
MGC7.9&BW3C*^G7;=%VEO;*;4H1@<;'-71T6ZX(:RC96IJR1_=>Z><SBM\56&
MVUF-V95]K;)QOV%?NS)Q[THMO;[ZPZNVBC8W;U;N3^,5W\>ZOW/C,[N.JKLW
MN"<S4E'DTSE'F8X*+[!??NO=.>&V7V#N*BKI>DLWBMP=:[AJ,]AL3NJ;/PY'
M,Y/;^/S*;8RD'7&-HS#B]P;8J=D;9>@I"),928+'-24M)35->C)![KW26VYA
MLY(8MZ])[JI=Q;6H)'J>XY-[[EQ.XZ,[BS%'D-PXR'9D$657%;D[]FWYCL=5
M[FCGQU,N[]T)#`]718>ODE]^Z]U%&`R=4^,Q6VMZU-5VGMG,YG/=JT_8V[7V
M?A-AY+9E/!#JWQD:9\ANO86'RN+WC6UFT*3<"9.BP>&K\A'C!)4QT]')[KW3
MIE:7M/-4@V_O3L+,U?>.9R4>XNKJ:>LP6WH-S8C<#T]1@)]H"DW`-TT'3&'V
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MJ;SZNIAF\C-5T%`E*T#/59.?)PY+&TF/JO=>Z8,FN_*G;O7TFS*ZHW!6T`7+
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MJU8\</=>Z[ASW==+2[FT3=OY[;^!SF+AV]N.+!TN`[LVCL6AQ&XJS=%3LW9V
MWJ:JPE??*;3:';M)@<?65--B9:7&US5L.:?(4ONO=<,U)VI#7[HQ'4$=7D=D
MT_6FZ<3N#:T.,VCA,!L/?F6.,ST^^]D9/&YV7;^X_O*7=$[Y#%&HJ<AE-UPY
M`2Y/$MCJ6FJ?=>Z5>6J<U6IUM0;4W=N;^.1R8O;&_P#+8K"8/%-48RD$6SSN
M+=&5J<O+7X_>E!7X2FQ6&S>9H$QD.%RAS$V/KW<5=/[KW2=P^;SV3V/F]U4.
M,WECNVI<7+M[:.$BV]A-QYW8E!N+"T>_J'9&,S]'NS'9R?;V[,KC:FMK:6DR
M,=!3Y"KAP,64I4G,1]U[I_P=74OFM_KO>CW9A\J(\/7;+RF3H=N[SI:Z7+5&
M9SE!OOHVEAS-3C-RU=!DM]+)6TM7XJF7[*K\&)E;&I52^Z]U'H1V7O.3;NUN
MX,7N?`5&=P\>*W!4[RQDN!V7NO(Y;.9";^`P4,^X:W)X.D.8V/3YVO%=6X?+
M+#34]739&KBSHIX?=>ZY4.Y.T\UDGS\]-NC-[`;MO*Y;:_:4L&W<1%2[5Q$]
M!N'`F?9-'%65N^<95Y.:6"&*GQU'**M*?"&&FI%DK)/=>ZB[YH\\U?O_`&QU
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M,16[IW1O[+;\FQFV,YCMIOGOM-QX#;V<WAC<5CM6S,7V5ELY35AV]NG`U==N
M'PR;>RN1R&'QM574^0I$@_A,E&/=>Z:)-O=H=HS[;V7N[`P;+SQZZEJMMU<6
MR<S3889JDOD*C$;!R%*<9V53XS$8C9R)34L?\/J]#9>AK<<V)R5)J]U[K-3Y
M'L+>.W:#9V9DV]L;K`9K)XZE[%I^J]FT>RQMG'Y6AP6U8JOK[-8S(K'N+?62
MWC3B>FP<M.^-QK8AJ#*U&0I\Q%#[KW4ZLKNTMK4F^MA8G&4NYL1)4[4.;W;@
M<;#49+8NYML5E9C]_4F=RNYZ6NQ&XHMCY3%QQX/(92+.(V;R#9'/14=-5Q51
M]U[J%)2;[V,:%NO\7A=_1=B;(W1O3:T4=!F9-QP[:KXLCV#MA<G.L3U=?L;N
MF>;(S9[`XRKQ6'VKB*2:BP=/75+0T(]U[K%A]N5>U8-N;]V[6;7S&^LIO2E@
M@@I-BO3#;.4P%;3;3[(Q:1X7#XS$T66V%5Y"GAJJK!XR*+,YMZ.>O_AT=%65
M4?NO=/\`D*7*UL&Z=XU>%V9MS?VW,_1YUL'GMD8#<M9B,YO2>LQ^(V7F,7MR
MFR.4ED[0J<$_\/W1D:3+9.@$U738J6<U@C?W7NIN:H<EOK+5NY]W1;?V778W
M%4V^\MM[(=?+FXJC8>!V_A:C)UJ*S/N'>NU=H2Y>DFI\-4U5'B:S"S4D65HZ
M"OHIX8_=>Z2RTFX=ZR;;VWOO9>SVQV3R.ZZ>DIJ.CDAV9G,[N;=F0VSM_8G2
M_9F<H8ZCJ[/MD(A5P93%T^$JX\V9VHJ6KQ2T]6GNO==93-;H:G%%DJ?:VYNF
M,;N3)+MW/Q]5$]21;%J]O9.LBR]?US/MO)8>CWSL2;!U6`,TU-7T59@:"M'\
M8H,Y-%#+[KW2BJJ#=G7N?SFT=H[-Q-1B-L8+"2Y?!4>,W)-4Y5ZO.4VV:79N
M?J<]AHJC=&/@FW)2YU:G.S9>>?*RT%'#BOX.:ZH'NO=0ZF&3:55LBIZWUY#/
M;B?+;ISN)VC0U-3N3/0;@AK*#&[^V94+%11=:4ARFRLKCZS%XZIQ>)H<<U=_
M"V>MJ*"FJO=>Z8()7P>#A[$\77M3N_\`OK0XW=^W:#:M51XW)[WVI2_Q/+[9
MPTN1QN+79>]]CX3=*5E9EZ.A;.9*IHH(ZBHI5QU;,GNO=.PI]PY/(;ASV\Y]
ML;:W7TAD109BFWWMJ7.4#U>^LCN;`X7,5D.(V_44V:S6]<_2U.,7,YNKS"T^
M::JFQ(J8I8S-[KW4&>FJ>P\[CU[MHQ@,7A:+`]RX2DWAMRHRN0[*?95%C=_[
MJ1?X1C-OYR/J_K&CK:&DK=MR24V'RV&IJ#[N@H\C65-*WNO=-=35]K;\IJ+K
M_.YG!4NR=[PUF"_CN*V]4TN.WU%F.P\MA5P6S)8ML15O7V\=SS5=%E158B&@
MAI:QH9:8Y/&0)D%]U[IHK]U;^P^.WCLF>FV13;-PVYJRGCWGD.JL/@^IZO8&
M+VQF*]\IO_K_`">VJZ@&=;8E/5;?AI\A-4_=8?%5@J:RES`IJ-_=>Z6&8R&]
MNILGN[K/:^)FRDU3@\9%#N:FQVX)LSB]S[JWKM[#-1[_`,CN3;F5KM]PSG=6
M/S[9S<QJ)HJRHH<?28V/%M69#W[KW3!MQ\QU7D-K9+9N*P?8M%N:CS6^ZO;/
M3NQ*W';CR&SI,9FL!69_JO=58L.'VWA\S7T>2ACP)DPVU\'15%964U1--5T-
M%/[KW4"'(;WVAM?"=MXB+KK)YX;NVI)O[$TVRMPOF\A@\3G-KUV_=M1XW`;)
MRM%LSO&+`[EPM1ELC145)E,E+@Z&"9\5)CZBIC]U[ISR]'E-RIO_`'J4VS3]
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M@2[(W.F87>NV]R44M`V)Z\P>&K\=EEKY\379_%"O:.KIIZ>BH_?NO==5.7W-
MT?0;GV?3[%QNYQD^L,OD<G@MG0_?[\I\INS,[1P_][*K-[RV[@:'<DLE;F<5
MEZJFR=33T6*B7"8Q:9Q/49/W[KW4+&T>3Z(KME;BPNU,)V)F\Y5Y[=U6.N]E
M4E#OROJ*C`-38[</6HQT>/VUA)\[4UV8Q]3M?#R_PJ:HJ<S(M1DII:*"H]U[
MI/Q5D_7^"VWVQ4#"UFZ-W56*QVYMF9O;D>SZF?:VS<+M?()1YUZ79E1A-I;K
MV1@\IBZFKSF'@AS5;AX,=3"@IIJ6OJ*?W7NE;44$NZZ?=O;&XJKKG`[AQF_,
MSB,@N[NO6BR]/OG";CW5UYM.'N'(8W%KC7H,QGHI\915.5R=7C,!7S5%105&
M1BEBA;W7NI@R59VKNK'OV!MO%[238N"P.8S>/WCL"JS$V9I7PM#NZ.EV3N"D
MV_D]Z;UZGVSMC.9/'UM!4T](N3V]^Y6K25<DE(GNO=-^,K\AV))LS8_9.!P^
M02CW#O9-KTL/7_BV-!74FY*G`4%-U_NO);-AKML=FUNX*K&YF')8-A/09&J$
M=%#64$,]4?=>ZEU6X:F2.+#[N@V9N/8F<WM34^?S&TME34G469@@ZQW,<9D=
M_P`&\XZMY)=O4.SI,5554NFNR=+2F)Z^GKJ>&F'NO=9,C7S=8Y+<>RMK4=!D
M<S@L+38Z/9^W.OLAN+MJIJLSF-F4-!@-UY3+X<8S>-!MZNW-1[ADJ-PQ2M)6
M5E%YD^TJ*RN]^Z]UW(F!ZBR6SVZPQ6!K(9*3+Y;(3;#VYNNLWOD)J-=V4^*@
MV#FZ;:E5MF@VIONHVYF\6U)3-1X#;M*V3J8'R4DV-C;W7NL6,6MQ.?Z][%VC
MCMB19K=<N6VYNZAP.TZS$=DT]:^#CDRJ;#W)@*'"4^,R_7NX=VPXK(8FDKJ7
M'[EKZE*_(Y'&S>9&]U[IAEHHZFCVIB,K5;2BW)4YS/;+R6/P$/\`==MTY[:M
M%ANV)NI\5346+JLC1=@Y+:U7CJNMHZ7"46\=U2P"CDJ4DQ2U/OW7NALZ>K>G
M<MF*'>&5[[[XAPN_\KG-RY':>7K<5MG'9C=?5<^/VGNK$[B3K[&K6Y%=JIN&
MG?<%9#5U4576H6R.0,V-EIJ;W7NK9J6IIJRFIZRCG@JJ.J@BJ:2JI98YZ:II
MIXUE@GIYXF:*:":)@R.I*LI!!M[]U[K/[]U[KWOW7NO_T]_CW[KW7O?NO=`[
MWM1;!R/6NXZ3L/$9[/X5J"21,-L[^+KOS(5"/$L=-LF7;=7C]RTN>J))%B2>
MAJ*:2%9"S311ZW'NO=4I_;=3[AQ>!W#\58,]3;;RL?86.Z^VEMV/94F$VGLW
M<`W+GNTL_7X>7[K8M#M[?LN/R:_L3MF-PU4=!*\>2IJ6J@F]U[ISBZ\V[OK(
MT.(ZKJMA8J7[+I'9%;C-^;<FWI6](TYWC68W%8S*=-T\NW=MTO9^Z\#GIY_X
MK51BIJEGCR4-##)#-?W7NG^+9VV=^;6I\1MW&82HVO%19_L/K_:<M'T<D>!H
MTJ=Y[9@ST!W#N3"04>WZR"3,O)C,E_N$DHI)5BIX9A$WOW7NI=9UK3[PI-MT
M[;:I<GUDM17=>XS;BYSJ?%M*^Z%P:[\W`F=EWOMO<<&YL=EMLX^G:B2FJ<7/
M3U)BAC:)(ZE/=>ZE8K!Y:NQ.:@K,GA8MK[`R&#VCO3.4D_4,^W,+@MF93=>5
MP-`])MSMFAJML;FH15'[L;?AIZLS7CCKVIFDC7W7NF_%]74,5-M_"8O!9#$9
M['8O,0XK;$>?ZQR!P_6V0VWN#-U"PS9/M">AW;20RU-5F12529:6DBGBCJHV
M9(S![KW7L%U?DIZO&;NVA3;I&5WSN&#=4T&V,CUE44F[]Z[6W((::N@;/?(U
M\CM2BPU9@WI:C&0QT^`CJYC1P^2GD\T7NO==U6P<K0X;,Y/*[1>MVYG8I>L,
M]''F>L-MXO=VWL.V1W'BMMS87&=^X*BVKBZ/=\G\6G.UJ6"OR>*I1&U3+.(I
MQ[KW4JNZGWM!/6;:WQBZW&S;;PHSL$=5BNF*3(97$PIM["Y>LW)@$^3\E'NG
M9V$EBHA%)F?N]TR5T<<CS3&>,1>Z]U$AZTS\E+C\(,-4-_>;'XS&[3W'EMM;
M3IN\-U[<P^]\CF=NT6<WG!WUBJ6HP\&97[>HV[4KAR(:!$262.*H\GNO=.-)
M@M:4V],_C*+=35NXO+N+><<6T<+4]F;Q;;^X\'NW&=4`=[9.CZ\R&-H7AK8)
M\;31XZ;(VK)I/((57W7NHL?5^[OXKE\/CMH15^]]NU^,@K)MW8G%G`YL4>>-
M;D-U9S:]#WRU!F>QXTI*7"?QB@2KGBKA4)2R2RU2/3^Z]T]#9%9E-UYJOBZR
MJJNGSFV-RYG#[6WACJ>IHI,3N;;%)697;U?N"#Y!4=5O'8]+M:MK(Y,+D*."
MB$VN2EC22"1JOW7ND_B-LT6\MO\`5V3DZU['P>+QV.HH,+E8\/#@,_C<MCX<
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M?9>0VM74.\=KY/.YZ+'5\U%7',]EYI?D`J[MJL)G)Z"KHZ/!_8YB\<2K41HQ
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M?<63QN'K<OG\+M/.YRAW&FZJ#9&4GK!+#*6CR$`$"L)8Z1H$]U[K#1T^\LJ^
MR\E4=$?)79];%M#,[43('8F7S>Y]A/NK;&/Q%?!T?CIMS1Y2CAP\-/*),QEI
M-$N0JWJ:-:%;1^_=>Z451L_/2X.GH<GT[WC7TVU^S*3=B[>IL+F\_C,M5G*U
M,NVLSC8,I4U>X:_.S4V1&:W$((@T4T6C)?<TTSHWNO=2LYM'=U9C.R\#6]6=
MQ9[$=DQXG`[AR&5H=R5R;CJ*C:N?V_EY.UMM3UDFW<9/0;QR$>1DI<'6^;*3
M&CFA@I(E96]U[IXR./S]-F]L;AFZZ^3ACVG6UE`D>&VKE*7>,[M1X2#;&-VY
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M)*?=>Z564V3N:BW1C,U'M#M/)?P/;S;2EVO-3K_#I]JY#,Y&*LV;74^:V?\`
MW5DHMNX'<%.]-F5J*!Z2EI():F&9Y5II/=>Z151UGV'18/:&U-H;%W#L##['
M?&XREAZZFWWA99:2@PFY(Z;(]8Q5NV:G"1;FR&:RE52309GRTLN09I]/C\U5
M'[KW23I]C[OQ']]:?;76>8V_1;TK7WSNBOQF:R%-D-X;DWP<.[R39A=A5N-V
M%4;.Q-)72U46-6MH]RP2U4B3K_D_OW7NE.NR=UX?LS/[EH-C;Y@WMG]H;9PN
MXN_8*?)TF_,S@=G31T;=?Y_;M#L[,U>&QVZ<508ZCIZNDPPR$C4RTU7`:DHB
M^Z]TGCUWE]IYCK3<N=PF?FW#UQ6Y6DZIF?;NZ:S(]7ONO&38_$8/;3[4V3E:
M+>-)31X.OK8:W*0U5/:LJ/N,C,"%/NO=)W=W6G]]J&MCW?M#>_8&U<MV0^]=
MN=95?]_Z?9\&:3<]'N-,KCZV38^+WYM_=>\\;F6CJC/%(E*Z']NB:KA6+W7N
MF[?$L>\<CO-]_P".[,WM@>V=K4V,W#@:^F[NR^S<]51/6TLV"@Q6P^J\-N+K
MVGQF=JLA5M6)D9:"OKJ-6<5C".:'W7NA:I:;<-&-CIA<[O/`X'KW86*KL+M^
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MQ`M::7(SU5>_D^T2-BONO=(W.]C;'PVU-TU5)N;=M;5;B[`KJW=VS=J8G>HI
ML*FWMYI!L_<>\,SF^GZVIW#6[5HXZ7'Y/#8]H:..EJ9*F:HK0TFKW7NEYF=[
M[2H,[W56X7?6=&<W+4;"VYNK<4VP]^TU-N#=>T]M/7;EQ.R]H9OKVLH.NL7'
M65N.R5'/)49*AGIWFACDIYF0)[KW2IJL_L;+9/:>=J-U[@VSO#![/WQL"DW7
MA=CY[!1;3W!G\3MG;F6SJ&;:#R=D[BVU7;E,5'6Y!(,93Y;+^6I2I2%)*7W7
MND?2;NVI70;.KMR;JRHS.*W?A*&FQL6)J:Z"AFVG09,XGL8;S?KX'?V`WNE>
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MP1435$E+(3[KW3?D]T=89S`5F'WGO2IHL-B=TX*MQ^SVK:BBRFU<"VY<A7Y?
M-9/=4>U<;F(J+L:J<@8Y=-+X@DU"RK-+(ONO=2<_V?L'==9V3B,IW5DZZIR2
MX&JFJ\%YMIG.;CK):NDVV.N:FI@I]S])_P!W)XOMFJ*6H,5/753I4B<5`0^Z
M]UFE[=V=%NG;^'H^X:/-;1SNVL;58#/U&-3<C[5VOL.?$T<6R\CLO/TAS_9&
M[>RI,$ABRB21Y"&EK'J4A,8DEG]U[I/83=N)V!L_KG`CNF:'([>KS@Z6OW!N
M6EW;F^KLIEZC,[AR>^-Q]B5FVZ?'=A8RF3/8K$Q8RMQ4+18JGBI*:FGJ&BDB
M]U[I4R[HVKA5RV`VIWIF*&IW144N^$AFCQU'G*K#_P`4HI(J#92Y*NIX]HG#
M5Z-#68:."&U,ZZIYH8WBI?=>Z?(]V[=R.X<G7T/=.(VADMU[,PNC$8_"X6HP
MM9N&@R^5S%5-U7UW399<9M#=^XIZV@H,EG96J<?D\A%,AI&1V>;W7NN<_8V'
MKLCL'(U'>#X/*4>"&`Q&WMQ5^*./VSDLW@L1M^.@[FI,9'38/M;>-+FL;6Y3
M5`\9P>M!&DH:(#W7NF*7<>!W=M;`RY[LW+-0;;[&Q^YJ/#0[D,4FSJ/9FXC/
MOK<6\-Q8O+XA-U;-WSA\F<Q3[;EB@I:D5$:11TVB1O?NO=>S^Y*K<.(WICZ[
MLBOW%+NC!;>CV(,#C-J[1J=L[LRVWY(\+C]OR;>R42]:R?=B*-9&DD0-5PT>
M1-1*\I?W7NA-PO8RT^23,P]C??[9H*.EK8*?=5%L_<N/QU)MK[;*9['G%4&>
MDW;NS<NY:#$3^3*5\LE0V2FFDI?#2W!]U[I*X_.R;9VU@\-A.VLZ&VU-6>>K
MW?GMG[AW#5;GWCNC.[I.8K]PY3=5#4[SVIAY*LPM@8Z>CK`\L-"]XH_')[KW
M4>'*4]-B.RO[F=AY[$0;WWINC?.U]Y2;QVN*Z*J^UV=DJ3$['JZS)8E=F/+6
M293`G#4\-'-CY8&\9F0L(?=>Z?<7N"AR^]=S9W$]KQ8G-[AVMCMHPYC#9K8^
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MS=?8Z7L2EAV'AJ['R5$W]VB]+4S55*8(JB`0\>Z]UGSU1N2/,]@YWKS+;BRF
MYMP8"HW%D8=N[DZDS?7N;3;F)JZ_-X3J_9F>W9N*3!;EWI1TB4FYZNEH<@AQ
M\44B26$[2>Z]T&51MRBV9!ENUDHWR&[L/)L;;^'W%D%P=1V1W'M_&93$[AH=
MFU^XLAM;-QH^WI\I38V#(XVKASM7$D]1056+UR3P^Z]TH-B=#;F[:R?4N6W9
MO'KG9FZ-ITV4S&Y1M[=F7R$4L]1`M-UEB1F<G6U>X=\;AV/C,W6OD*V&KP5%
MN;)U$=;G:+-P&.FD]U[JXO!I@=G4&U-C-GJ5L@N)_A^#I<G58>BS6>AP-'`*
M^JH\3CX,722_;0E9)XZ"DAI:57`2**((H]U[I6^_=>Z][]U[K__4W^/?NO=>
M]^Z]T#_>6+ZRK^N\_4=KU1Q>UJ/'UD=5F*7[K^,4D.4IVQE70XB+'4M=DLG/
MGJ6I:BDQL5/5#*Q3-2/3SI*8F]U[JCK<&W=N[3PF+Q'Q%Q':_7U103=AOM*B
MW)AEJ->W]JPQ3;^ZZI]C9#<>"P6)VK/CYJNAA$MJO9^/K:9:>#'4M5-41>Z]
MT)VT'I:G=?7NY>O<-M2BV-O?-==;S.<W/-N7>&7W-C,/V_M#`-V/N3?]//FY
ML?V[L#'[BKL'C85RN0AIC4"(UE5#3/Y_=>Z1VTZS`4>U<?JVKOK;6X=K=*05
MM%O?(G(T^S&R@[(WI!AHJ2?#/3R9Z#K>.7^^9IX9Z?'QYT4TL50M:5HY/=>Z
M4*Q]'T^5P&`H:G;>-7K7=FYL9M5<GU>FT=O[\W5N'KB7>^?7H&GKMR2[3S&^
MME[5V_+@I]RTBF.DW/G:O'152567:>+W7NFBGP/2N[.N]P[HC;I#%TFX\_VA
MNS<6P>R]O[SH)*3L+%[_`-MX_>O4/;FS:E\G4]D9;`;NS4.!R>UJZHG$)I,?
M!%":*.T_NO=+K;/4V*WUN/L3?F#W)U!F,U4;?SFQ>TLI05^]JFM>F@ZZDVKB
M-I[9SM5@*,XO:-'M&HJL@V&HLA14DN<:2NJ15+304\/NO=!OD,CA\31[<VY3
M87J^/'==X:NDV#58;;M1LE]H5%#0;6HZ>/9--BL]N*3K)]P8QC1TN0QD4>7K
M=NU-?-%"H\]6WNO=++;?5+[Y,])MO:'QLBVV-VX7>;R;IW'-N_;2[D.Y-R4&
M`W)FJ';\&<EWOO+%T]=438?+R5]$*^*AHGJT%/CXD7W7N@_K:SI?9U!N/)9[
M>GQ;VYMBHZZQ>[=\;TK]V=J3UT/664RNW^D,MD5WU_=Z0U>T<GNO;<$.-I(J
MRL%'5UT]94I-(HG]^Z]TM=T3X':=3FY-VX/I.GS6T?[U;>Q=.*C?E3@=EOU*
M)\UOK%4N,KZ6EW!MK!UFV\731/4XWRMN'&PP0?<K(IFJ/=>Z<<[U7B]J]=[8
MW/%U5T1NK;F0RV.W?LIJ7=>0V_D)ZRLPKY+!YPXO*KB,5GNP\;-GI-S5V9F*
MU[_:/73T4T]+3^/W7ND(FY-N;QSVZ:NJZWZ0&1W_`%-+B-T?Z0NSZS'[UW)N
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MI*"A7+&ORQ>*>CPQQF@BGACD]U[I3;MQ']W-^;I&=ZUZC3,3;0RU)597`]MS
M'LB&*CPNY8<#5#?,^WSD\AMBLV5&^7PFR,7B8X)-RU57-,%BB:-?=>Z=-L2X
M+/9K:F;VCTGU;59?KR16VS'1[OQ5\)B88MHB+`;6H\959'<.S:?:U+25,35^
M$H:N*7'EF2H)^X#>Z]TT[BZ]ZRZUH<CU_OG9?0FRJBEV_6;SCV=5=C[FBVW3
M;5?-;FIZS-=BP4NT9LOGZE<AN1ZZ>LJJ_P`N0J(Z:CC6.@A>%_=>Z4SQ];R/
ME(/#T]30Y#(;G3=QI.U<C_>:DDZKP^Q)-\IE=RTG7L*[SGVOA\G3R4N-Q]51
M023YI?+/+*\#1>Z]TI-F==;*WHU7+L3:'2&:?:^*P^VIML[3[3C..P6!BQW\
M9VWDL'@X=L9!NO*)\?F*0RQP4TN22FQ,,0JH8I:T2>Z]T@\?/LC;.&QN&7:>
MV:*GI3-O?JS`XSLG9%:V3R^)PM)B\CGJ/9^V,=3UG]_FJYZJIDJ*2KJY$K9)
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MD=K;LW=F\3OH38M<17;PW)NO!Z:2MK1@ZZ@KJ&&.NQ2U%1`B#'?;1RGW[KW6
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MYE"2KE,[55$<;C)PT=#"GOW7NF_`[6V/5XGJRKP6T<EC<3U#69/(P8,;UR.\
M,;L*1LE@H<[#AYVWODJK=];2X\0&*;+19['5VN66EB\\/BB]U[I#;HV=L?9L
M&ZL@,!58TY+<\F_]V1;][;VQ40ME-JUU1B7K-]-F=]XK)X!\A5[@CQ,-3BY\
M#14L$,%&M+4*94F]U[I0YW(=8Y'>':<KYS&U.ZZ^++]1[Q6;MC:>8SF!S?7>
MW,)F\UL_'=;_`&D'7C5^#P#197+Q)38O(U%)44X?(Z4H88O=>Z:MNU76V\<C
MALUM9:_>N`Z_Q,^T<ECL1VY438GK>?*4^.W%64F`PU75Y/>&3ILKL5J>J6+)
MT.:C$B2Q4SI5J\LONO=,%+U]A^O=A4N'RNR:N':5%42Y>OK:_L84>"WI7^>>
M:FW'78.&&HW)D=TMB6G@QU`*C'XS&_PC[=*`44GV4GNO=+'.["SU''W1F_\`
M1OV:V;W?B:RNFW?E>Q\;)7?P.B@QF-BQ^>-%EGQ=)EH,_CW#KBX\+F?'7R5"
MUJU`4P>Z]TB:C*;!ZZR6(J,?BLQ45^P>K]_;(PE#@.W\-197KJ*+'%-_X_:O
M\;W*,!!M?K]:UJ:K7+G,YC&KB%D^[6(U!J_=>Z:J>LVUA-I[9@@H-Y4%9U]G
M9=W9_()V_@J&NQ6=DV[B=W8[(9:DF[0SE9N#,9#9DJ[HBQ^1JI=EY-&H:L4P
MIX:>C3W7NDP\E5G,7E,WM'8GR"S?7O>F?Q':>U]X;)[ZFR."[0V=ELG_`*2J
MO<)BZXK\=N;K?;38+"M28VBVXV"HHJ'(U4M/'4Y">I/OW7NA/I\W#6;GSM'C
M^G._*3-=@;`JJK+8N+>=#B<QBH]KXW"[<BVOM[KF9EV;A,I3X/,TV5R-65GR
M%?2%/-42RH8Y?=>ZDY>"GQ-9LW+[DV)W5B)^E8=Z5=)5XSO%*#$8+:>4W=2"
M3?&X*[?6=HJWM;/XH9.2@HGS(R5+3559D/LU\U33/2>Z]TF,WF,1MC#5.-K-
MI;\VYCCN*NSU43WP:3;>9W+M;:N6J]TU^(WW!OS!9JEJMO8.>2;,8##G^#RX
MW&3T]11)'-55+>Z]T]U6ZL1-N[>VTJK9O;E5N'M?!T&"VAA\=\@]EXO=6Z,8
MNV]NUU/$F!P6YQA-EY*'"T<U10Y?;U13Y+*U&.F:2:2LDHX??NO=*;"9F?`[
MFESU1UO\E::LV7L^/;V6-7E)MQ;9V1)MZ3-F6BH-KU>7K]I;A7=&.SS--G,K
M-4YFBP\L](S,SUL:^Z]U$V[EHS@-MU>`Z1^0F]MK]:Y>NI\-MN@WKD,[&8HL
M#19^GKYL_N7<$NZLSA1)C:#+8^ARSS80&MQJT41@IQ`GNO=1,_N;*T5)N[%[
MJZU^45$.S:W-=A9BNI^X=L;5GAP^4RE#49K^\F;;>%".KL5USC(((:BLVM#3
M+@:6OF($F1D#^_=>Z4&)RE;'N+/Y;;VW/DU09`[3'5513YK>V!W9_"Z23:.1
M7#55#UO1;PF&6W/)M7%4N;;(5*#)_P`(>EDD5/+4L/=>ZGXO<N<.Y<%!C=O?
M)6>NZ@Q.&R--B4WY+6[/J<=5URR:I-T2[KI(.SLIEMIQ33+!FHH?MZLSU4*K
M$D5,ONO=(2LS=?-MS`TV9;Y>;5PE;VY73Y>GS&\]QQ1YJNJUW1+#B=I;QV[D
M(Y=I[-P-!)%5/@J`/A)<-12TE1'#/Y)C[KW2[J\OOS<>[=UJG^G;"9/=&W\?
MLW!+N;<NXMJTFX,'5Y;"Y.>OQ6)3-1;=H<MLG`XS*S_WKPLD]3+3UJSR0KX%
M1O=>ZEXW<^Z,9N';56M)W9#)UAMW<V#JY<KO(TF.DCAR63W9D\EE]CYK<4%;
MFJ^7;69HZ:GW%N65I*7&&HK*FF$SHP]U[IJ_AFX8<9CZ)JKM/`8Z/<];N;/9
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M#'1=EYC++N"GDK9\G44\%`U.U13H*>RO[KW27J<+O3+;5Q5$.WNYIJG'9;*;
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M::CP50\-#+5Y-`V3:"*TGNO=2*.NRN,QV[<=6]O=H[HEW]E,?F<GB\UG<73M
M1T.Y)-W9*EVUU?&"*';<5'@YZ.MEJ9_XE4R/!43.TD<=/"?=>Z[C?=D&5WQN
M.'MCLJBRT/7])C,=CJ^=:G%[0I'VM%02T7]P:S))%FZ_=]:%S6-S\[L\>-$4
M+"-H7?W[KW2OCIL_C\[UW1S;X[4J4V-E:C)8C$'-T,>2R/\`":W^\60I^QJ.
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MU:(]J]TUZ[=^\R^Z:";`96NDW+EJO';?CQF3SD@QN0AFV4F5@9GQK%:N@1J>
M,5:+]Q._NO=-^XY,ME(-]QR=Q=_X"+>6;QU75UVR]C5"9S$X[/Y^9HL+UQ5K
MB\[0;#RF0P=,D&4I98<C4+/25M;%3I15,8E]U[J>DV?Q6X<M)6;Z[5><[(H-
MK]:;'EV#E<KLO!2;6VI#MG.;ER&W,%"<_N_&]@9:&#)0Y:6MBJ(8M:+!`HJ6
M]^Z]U[!3UU+D^NJ:OWMW;F,GL["_;Q4V3VM1YJJB2J:#+Q;C[?BQ5#@Z/?-#
ME<A7R.[8ZEPTDM53PQ1TT<$<C2^Z]U!JZG)5>,HY:S)?(VKQU?F:[*S;FK-K
M[5HHL5M?*8D8O(IM#<%#BA1;2VOCH*P228JHQ==N.AB-2WW:RB*:/W7NG?-U
M60K\UO=X=V]E45=N;;+5NWC4]7UD6`J\2CXG%T2;'P4VWZJ--PUU0*5JS(9"
MHK@$>DJ7I$"U"S>Z]U#H,GCSD=N5M;O;M[`XS9U/%@MM8NMZNFI-NYG/9E*V
M7:\&X4JL#CY]W9=,;,#'_#J;;Z1Y*KK7C:I%1110>Z]TEJS=NTJK;NUX<]VQ
MVON!Z?,5&YJQ6ZZIIGE??^4I\IMC%UDT^S\%A(^CJ6?;YIL)B?MEW))B(8`,
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MI:TE53UU+35M)*L]+64\-533+<+-3U$:RPRJ&`8+)&X(N`>??NO=2/?NO=?_
MU=_CW[KW7O?NO=`GWUUEC>S=A9''U.Z9=BY/'03U&$WHM;4TL.VZF;Q15%94
M"GRF&D$4]*K0--!5T60ITD9Z*LHZC14)[KW6OM-B]H_$KK'"4V"[$ZP[!VNV
M]$BP.^8]S5.5Q.Z<S0UF]<+B]D8[>F5I\^U95[*ABKZ2GH:Q**&JECJZK*Y;
M+5<$-++[KW0^;9P&-P'>NO%SU'9'8W:^]?CYV1VM/)D\[C=UY1,;V#L:MVKW
M%M-,?C=E;/R_7APSU%+5X:JV]C_XW7?Y;#34E-`P'NO=)+9V]L3-MO&4.6[.
MD^['Q(Q>9SO5N,P.8J,;MS'M\F-U8Y:F#.4NX,$E<^_]T4\.*R$5-0S*V,QC
MU'@A8"J/NO=-O?7QZ[Q["W7D<GM/KC$9>2>BVMUWN@;QH<%F]H-L:#K+=V<J
M,QC9]L[$G%;U'G96K:K+87!U:;SJ\^*2GJ:JKIJNCT>Z]T*&QMX;^&U.E<E@
M^I/D/F\AU)B=UXW[3<V)V=FJK([`J<]A=IX?=&_-A4D.TMW[#W3N[%>7,4&"
MGH(=XY/;L*1-DZJ8S"#W7N@<[=^+O=O:6X-Y;TAQ@W[B-H=G1XFCV9\N:C=^
MRX]E[.VGN7;>Z\1#\3<STQF,7UM_#=^9BA\4TV[=F9*M+>-LI4Y''P21/[KW
M1=JSX^]_G?/;%?E?C%LO:.;WBV>J\SUYL#<^`W[UYA,7V'O`M7[4R7]P<9UU
M6=C;2JLWN>GR,\;8^ESD.3K\C7TU;!MVE&#D]U[I;=8?##N[=&/Z[PV>Z,ZR
MZ\W1CIL_)F^S<%V;N\]RK_$*G$5^Q=[9*/XC;>Z#P&;W/L=L5'7G;^:F@VYB
MIIZ:+`?;4\E3!)[KW1A<9N#N/;F)V-E<[AOEGNW)=?TKYG/=LY7KKK>@WYOX
MYS==!L#';BR<,%/A-O1;HHZ^N.7;:&/4;CDHJ.*CRV7K((Z5HO=>Z&3LC<79
M`KN\U_T(?)^JQM4O8HVKO#%8KI^K[>I=Z[1J<9M>;$;&@+9?;M!_I>P4L>2V
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MF]LX'K#8=#D.T^NLIMTYK&[_`*G*XG:<?4O;66P&)HJ[#X_Y`0=1;IZZW1O/
MK/=\BT;X?([*W!B/%6M24F0QK4GG6;W7NB7[K^+/9.W=L8O!8SI[XTX?!8K>
M._<_G,5UAV'7;QD[BJ=Y5F-W#DNHZG&=B8*7M:CV`@QD<]/0[3W)1U=-NF*F
M-'+'CWJ*>I]U[J;L;XX=G;PJ=Q4&Y?CMTQV509S`C&YN;Y`;NZLKLYUC5-MO
M([.IXZO.8O8,DNXY]P4+2QY2NV]+B4IMO4-#%A*''Y<9&OJ?=>Z';:>Q>R_C
MY+N_"56S.[>QL+E^L,-CMH](]:8C=^[>CZ/>T.^:_;V3W-TQO3Y!=A;X[:W!
MF,QBJ+'5];M5ZO`[/BPM)!]Z*H?<*WNO=#)ANP.R=M;>Z\IJG;?RHR<G6>[N
MWJG<^WJO:76IV7N;:^S)=OXK.[:K*7;`J(,]DM]39J?)X$XM5604]<,89&I8
MWD]U[H`NR.A>R.[9]Y96CV[3;PVYM[M6BI=L_'7Y#[E[)^.&W=@;BP$-/EX,
MAT_N#HG>&V]K;KH]RSU4U1)BNP,/D,O3N6@J,G74Z>.3W7N@`W9T?VEB-T]@
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MICIFG_C>(\M=C=B_QKKBLQ%!N3;N`E&^\C%08RM7$8G$[\K<K/#3YK["';5!
MDLJ:C8<-#/2*\GNO=&"Q/5V]MF//VUUWM=?BUM[<&4VMCX\+USV!O3Y6;WK]
ME5DV(VE_=+?OQTGIY/B]M;`5V7Q_VTF:DDFBH:2-LHT=/712_>>Z]T;.NW^M
M%OWMK+8*3L3939/JSMK'TVV]L=7XKLS<.Z,QM2FPC;@S6Q\Q48V+(UE77M)*
M\,=9%XJJ*.6EQ\;TU'3N/=>Z"?>3=@;WP756Q=F9/=W7'>%!-G\<U5NG8=5M
MC!=WX[%;7K-VY_:F[.R.J:>#=O1>Q^RL7Z!G^OJLSUE300Q5_FE(I_?NO=%1
MW[U1N[83[>#_`!=VI4Y+86_]]Y_=/:VV?DE/\B<[BMLK_!*ZAPF'WKV.Y^1M
M?D\'@<`N3W'-@#_>'$Y-(H,-IH*NN8^Z]UWM_;.[8^QJO,;H^.]#V0^1KL]L
MVG3<6X^J>M9-NY9MN9+$;3JMTFDSM9C.M=I4^"<T>W=O;)-?B*^.&KS=-)-G
M$J::3W7NC;[`P^^>F::KVAV_#OG)TV0ZZK-W[=ZQZPW_`-P=V=5X>3;U508G
M+4>Q/DKWIDJ7?D9HY,Q-%5[0QX.!K8J:"1)*?RFG3W7NA)Q^ZLQ/M.LP&V8^
MP]T5?77:?9^/SNRZGXQ[#V]B]TS8'9.$?<P?,K]MM_,9"@PVX8XJ>;'U--6S
M0K)1TXJ:B@4S^Z]T`W=^V.Q>^:_MS<77E1E]S[(V=B*#%+U]V?O'O?XE]<8'
M<L&%H=P0;DZ_[8ZKI-HYOO5:K;V;A\\&^H1EMMLLPIF+59CC]U[HM&>P&[<)
MNW/=O8;I>GZ\V1OFJ.XL/G,!F.M=Y=7[<SNT9*.NWYE]Q[TV/G8*'<:[VP4<
ME>KU12MQ.4$2;9C.7JJV*?W7NE'UWU!V)+68G9.-^*.(VINS&9K-SMVO1?+S
M</QZ@GV]!A*C*XN"KK_C<-T=QUNX]J9G*38.:#.XV2/>M30ON%DI<A755./=
M>Z,SE]P9S;O4>\L5O'=_9N]NR-JY??\`NM]\?[+;64&7I,#L&AIZK.466V)G
MY8:OM?<E%2P3T^,WE/CAN3<]`M3"M.IJ"T?NO=")O.MHX=\=R9S<F7Q_8^(V
MYL>IJ/XAM_XN;FQ";3WA3;%V;N/&3-18ZDFJ]]5F#VU1Q#";>K#38W+31M3Y
M#)T[4(A]^Z]T2?>VQNZJS`]=97LGHW>/RQP79VPMS5]'O[!_(O>?3.X\[4YM
M:2+IJAC^%/8W]P>E.MMZ105E/50T.%6K;"5E--'BW::J:I'NO=!70]*]W0S;
M+ZE_T,YW<.\A68_.9C'C:-/L2CW3_HTJ\EFJ;-SX[(9Q,%%M[<C9W%S4.Q%J
MVVMM'-YI-PPU^6JL;_!%]U[H8-O=6]WXG:^\][T'7_9W0NQ<5G>IJ#+;1RW:
M>0^2.+J<'2+M@[[VAN;X+[>VSO\`VSN3%#$YM5RNXY-_4DV5F9MQ4YPP0!/=
M>Z/73[KVJO=VZ4VUB,]A-O8#`=GXFJJL[\;ZWL3[C?>U^JZNIK=W[0WR*;<T
MFYX<GM3+1TG\5:">BR.-H9L3#45M56R2'W7N@NS^`RN=Q/4&Q>H)6Z[[OIY\
M?+7F/IG([8W!EMA^:JDJL?M+<QVWNF?XT;-DP#)!'OVGQ>8R]2J%(J:@0$)[
MKW12.PNE>W?[LTN+W_\`&WY`46Y]H5FZ]P[AWK7_`"$WK\H<'3[&H,K09.3;
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M6ZV^/FZJ+X\]CKV+OF@SF:Q6Y_\`9@NS^LMV4'R`V?58(3/18+:^5VY38^J$
M])6XY`FH^Z]T7_<^S^T]@]J8NNQ.Q_D-C-MY2'#XJJEWIM'>6]X]][KVI'@J
M_?N[Z+&/V)V9@J>3=FSL++08*A?^`CK[)4]1D,HN;Q]6V-/NO="A@NI^R<SC
M<5A\)M+Y:==]AKO?;M!N?+X#OJBV-,>O,C!256*23(=JY#L[J?>DFW<W2I3[
MB6BP>/RV^3KKZ6EI,4[T8]U[H0L_54V&V%N+;W8<_3^6^0>VMX]A9NKSVS_C
M_N7);4Q-!0XI(MUP]G8/`8K;>#K=\9O8=<*+<&5Q^%BVKDXA!+_#<A/+3_;>
MZ]T-/9&XNEZ/L/<,NX=O]>#`5^*VA)49["]>;CVALOJ'L[;'2.(W'1XGM/-K
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MWU#O?/[W[`Z_R'V>5VP^.P?3DL\>3HW'\1;[B6BKJBK9*"4^Z]TGWGV[G\3L
M6'J3<'Q[_P!F&C[$V4N&SV],-EY9\K@]P;)I]R8OL?K_`!V4Q&;VNF[\UU_`
M),-G,YCLKM:"43I0?PQU>.?W7NBO]DT'>V+V3NRGR6U_Y@;]E_=9NOGS'8G:
M6VMY;?@ZNK=J4NYI:';>XNE9-M],4M5DJR21-KY>JVUD%V4155&4IY:#Q8Q_
M=>Z8]ET^8BWS34F9PORKKZ"OV3MK;&:W/\<H>\XFP]+1KF]S]5;IQFW=L;BV
M[5UFRJLSX^KW'1U5/5UM92U>,K<?)'M&:;'Q>Z]T/W7%?OW`UU?AODWN"2+K
MQ-O]@4-7!WKN'H3M7Y.X&KVWC,9B<_DMH;PZ<V3M_IW(]'=@;5=:BIQF\I*S
M*4^16*)U2A,<7OW7NA0Z[W?U?7=8O1%>A6W3MGO&HI\SC,5U?W%E]P;BRU'T
MAD]P;8-)7[N&)WYN[-[?Z(S<%?%GJJ>HBTR?;F*DAT1+[KW06]DQ;MR&2W/A
M?A_N[,Y#;U9M3;-+NO:GQVWMTCMKY)Y'?6[\%49G`;IWIV9\A]I;EZTW)UEC
MMGBL&%Q>WJ3"ICZV"JEJ8*@TOC/NO=`KF<GN"G[B1,31?*FGV?2R4<6;7N6A
M[LS$4N_ZC8<:[HR&>FRFY<I0[BV9ONHV\(]M46R8,;48#,T66RN4IYMMY"&B
MA]U[H0.NJ#=5=L+-9#KQ/G7G.U,AN_'QXE\1OS'8O!C9.5QU7D<ENK;^W^^D
MK_CO2XVDH,K05V8IJ/;XVYE"E)_=K[:`U$4'NO=#!)N6*HP=7MOMO,=";G[F
M.Z=Y9^6@V9C'CR6ZJ3;NU!3[SWCV?N/:2Q;=R_9F!V:JB>DVDU%MT5,9BR"O
M3/%!%[KW0OTVYNFQN5*+;6,ZMRNTDZ^ZHQ^R<1U?+D<1F-G]FT_363K-J;3W
M%2Y2>"M?+4G6TQEPU&L5/N63'/!'14VMYE/NO=%@CW+W!%0[4S.[XODOG^FZ
M39T^(QN<^`LVRL9T"C1[=SM-M3;77."VU@J[YD[?GH\]***:/-U#TE=70)5U
MVJBCDH1[KW0*XOLSL&?;K1R;H[8S]1BZU,/NK(85>U<3E9<=2U<>47$U>Y*L
MT7<"=0;AP]168R/)5532=DT^2A1J6G79PDC3W7NAVPNY>W,S@ZNKZ^SGR\?I
M&;![1P6X,O\`/^MV#M?K'=>S=WX]\IOBIWSB]YXS'?)RDR-5D:@[=HVVO34D
M-!5T@-&]92S"5_=>Z,*NXNCE[?PK;>S_`$?415L?9&;$V_MS;RVFU9ORKZ1K
MI.P]Q;`JL)38F'.5N%ZZJTH<C79,QY5:)Y:B:HAJ(:3R^Z]T'=9EY)=O=15&
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M."RL4'?FV^OZJ.7`T50]*9H\A5Y*D@::/[+W[KW0,[!W5D-U5/\`>S<F^*_.
M5.6P>#I.LKYK)T^Z=UU%//7Y'MWK4,^S\)!W7L3KK`48J3GLHT*;"S<\U/B(
MZZ4F/W[KW1U-\XG=U)MO=D=)M*CVW109K8&5P\N-H*7^)Y>#%[&['%;TVV(K
MJ_,U]#E,0L<.+HL75?[A/X)2(_\`$*?[F*EI_=>Z""F:HRRO'OB;;R=#Y;=.
MQ*[*Y:MR6<VY)@NYJ_\`@U#N7![VB[*KZ/+]<[.HLFE-18*MQZY&;)304<-#
M35=)+44[^Z]TFL!E=]T78'QDH>K>U-TYK9N\]K[@&"K-OYO*03=B8K!02M58
MSKK$4&W?[OXJAV"V/P<F"S,DDNWLOA<ID3N"&FFE>I7W7NKV]N4^<J-L8RFW
MK'C:O./1(F96EA5J"HF5CI=J=_)`LTD2HTR(7A2;4(V9`I/NO=*7W[KW7O?N
MO=?_UM_CW[KW7O?NO=%9^8/5.[NW^F,]MC:$;YRL1):VJZ\FJMN4F$[,IDIY
M(FV?N4;OQF8VAE<)7K*PFQN;I*S`Y`'Q9"FG@)7W[KW5%.R=K=E_#O:6+H^]
M]O93?N2Q5+OC`[CWQ-CL;F^ZJ"EW?F6H\#@L7B<3D<A%B>KLCF:C$9.?(39`
MP1Y"L6FV]+A*Q5ID]U[H1=I9O%;`[AJ>NMS]J;?DWOE]T=%9FBV/F:ZLIJ+I
M)Z#L+:64FZ"V=G-XX7*;LV%LC?FY*:++Y&MR5,<A7Q7H9&2O6>LD]U[IDZ0D
M[-&P]JU69P/6&1ZQQGQBQ,W7^+?$X)^Q=@YK';CR^8W_`+]K]W4E+DM\S9;L
MK;&:CQ&.Q<-;35=/)CJC(2,]+5*@]U[I_P!V;BZRVOOW<>TL[)N3KG)=J?*>
MCV7T'L[`;8WWURFZ.W<KT_@LCMO<N?W3FZJ+);VSF],'2XN6+<6)FQU#ALT-
MM8<54<594QP^Z]TE,32&EVOM#<552Y38FU,OU_MW?>0VCB.S]P;(VMN'"8_#
MXO`X*J[3BRF7VQF$CVQCMP5FX*O&',PT\IIQ14U6\2SI)[KW2>P'RWW]DL5E
M:GK7NW;>"W!\=-JUT.^Z3L*.JV#7;VW1A\CM#$U&8W;3=A35%?U)U?FL5GL+
M2;33)U#XJIC7*_:QK/'19&7W7NC(]%_.3>.Y^],UTOV1U+'2[;V=F.O=E5=7
MD,!N_8W8VX<WV5MF#*UVVJ#:J[MKXL5V#MS/8O+9ZIV76PS9^MV35192F:6"
MFG:7W7NKLQUGLD,K-AFE9)(Y5-1E,Q4^N%&CCN*C(2AD6-RNDW4@`$<"WNO=
M,^3Z4ZPS*>/)[5@JU^W:F4/DLRGCB85`_:,62C,,J_=2%9%M(I:X8$"WNO=)
MMOC+T<V-CQ)V)!]G%15&.6V=W.M8U'51RPU,,N27-C)3">&9XV9Y68QNRWTD
MCW[KW2H'3/6:",1;5IX%ADFFC2FK\M2QK)/4)5,WCI\A$A$<T8\0(M"MUCTJ
M2#[KW4B7J3KV>9II=O!M6+.&:`93-)1-CC5-6F%L>F16A:5JIRYF,?F))N_/
MOW7NN%1T_P!;5=51UM3M:DGJJ"J@K*:62JR3%9J:KEKHA*AK=%33FIF)>&4/
M%(H5'5D1%7W7NF&J^//3M9Y/N-G(_E%<LNG.;EB\D>1KX\G50/X<S'JIFK8P
MZ1?YN+E4"JS`^Z]TX9#HOJ7*:/OMCXF81XXXE$5ZZ",41JX*X+XZ>KBC-0E1
M3)HG(\Z(NA7"77W[KW4(_'SI[R4TJ[*I(VH:Z;)4"P9/.P18^OGQCXAZO'P0
MY2.&@F2@D*QF%4\3_N)IE`<>Z]U@Q_QUZ=Q>)DP='M%QB9HJJ.:AJ-R;LKH9
MFKZ6FHLA53&NSM2\N1R,%'%]S5,34U#H'D=G&KW[KW42I^,W1]95"LJMCQSS
M+!)3JLFX-U&G595A26=:/^._9K72Q0(C5(C^X:-=!<KQ[]U[J+'\5^@(:B*K
MBZVQ25$$<L,4JY#/`K#+3"D\)'\6TM%3T]Q`I!6G+NT01G8GW7NLE!\7>AL;
M3_;4G7U&(Q,M0LE3F-RUU5'.DDDHEBK:[,U%9"YDF<DK(-1=KWN;^Z]TH8>B
MNJZ:2FEI]KF%J:2ID"Q9W<B15)J\1)@I(\C"N8$.5IX\7*T<,54LT=.S&2)4
MD)?W[KW4`_'7IIJ9J:39<4PDFKZB:JJ,UN2HR=149-X)*^HJLQ/F),K55%4]
M+$6DDF9[Q)8C0MO=>ZA3?&;I*67&S?W*6%\1&\>.2GS^Z(*:F,E*E#+-]C'F
MA0S5<U`GV[SR1/,].6C+%&*GW7NN,/QFZ9IIY9Z/:CX]9/"?ML7F,SBZ-9J4
MZZ*J%+CJ^EBDJ\=4$S4TKAWIIF9XBK,2?=>ZEXWX\=7XFKR=51XO*:<S-D:C
M(T=1N#,U>/GJ,H8I*R>.BJ:R6"E:2I@CJ+0B-/N8UE(,@#>_=>Z@#XT=5BGQ
MM/\`9[DTXBGDI<;*N\=RQ55%`]7'5B.GJX,E%4QB+Q^)+,"M.S1?H)'OW7NI
MO^R\]<AYYXX<_!D),?%C:7+P;BR468P\%+X10/@,FDHK,%+BTA"TOVK1)3ZG
M**&=V;W7NFUOC+U@:NBKUCW'%D,;2STU#D(MPUJ5]))*TTD&0I:WFJI<KBZF
MHDFH:B-TDHIG9X"A)]^Z]TW1_%+J9#3K)!N&LI$:DFK<;D<TV1QN;K<?D?XI
MCLGG*.MIYXLEE,=5%C3U#_NPJ[!"-1)]U[K)EOBIU)E:NFR$=+N/!9&CAJ::
MER.U=RY+;&0@IZIK20Q5V%DHZJ,1TI:GB97$D%.[)&R`^_=>ZC4WQ3ZZI)JB
M:'.=B?OX>JPR1-O*K,-''589\*V0HD%./M\U!$(9X:L$SPU-+`Z,!&%]^Z]T
MT0?#?JREE62ESG9U)&$QJR4='OW)T>/J/X;CY\:/N*"ECAI9EK*2ID6=2NAP
MY`55)7W[KW3?3_"/I^EJZ:K@S/:B?8-22XRE7LC/+18FHH8LM#35.-IU=5I9
M8AF9&X)76D36O&I]^Z]TXQ_#GK!8,5!-N+M2M.(FR4M-45W8>7JZAHZY0E%2
M2R3*P%'MI6F_A4<804!J9C'8R$^_=>ZS#X@=8+65^07.]G)75U#%C!51]@9B
M*:AQT5(M']CC6BT?:4<D0+/&+HTDCO;6[D^Z]USB^(O6T:9"&3<7:%939%*Y
M):6OW[DJZGC%=CZC'*(DJ8I#IH(JJ1J97+K"[FPT^GW[KW48_#GJ]UQ<53N'
MM*LI</7Y7(4=)5=@Y66!7R4=*E-2M9%F..V^]('QL`<14;N^D:6*^_=>Z167
M^`/46;J<?4U^^N^2N-R%1D8:2D[;SF/HIY*K+PYJ>EKJ>@AIQ6XN2LIHO\DE
M+4VF-?1JNQ]U[K#EOY>O1N;62'(9_M^2A=ZMUQ2=DY./#PC(5T]?D5AQ2TWV
M"??O4&.5O&7:$*@8`#W[KW2GJ_@OT#7Q/2UV-W/5X^HQ&#P.0QD^Z*]\?E<3
MMIXFV_19.`*/NX\-X0*8DAH@3I(+$GW7NHM9\&.I*[)#)U&Z>X3-!-M^LQE.
MO9666@P.3VW25%#0Y?`4(A^VQ&3J:6<)5R0JOWBQ1"8.(U`]U[IUH?A5TY2%
M#55G8&;*5M5D[YW>N0R#-DZ^MJ:W(Y)W:.-VK,D*N2"H:]IJ=V1P=3$^Z]U%
MJ?@ST)7R4!RE!NK+4^&J:ZLV_19/=-=6TNW:NMCR4:U.&,RM4TT^/&6G-*[2
M.T#/=3?W[KW4@?";I6-J:2F;>U+/3Y"/*O4INRJGGJ\A#2044%54O6P50,E/
M#`/'H"!;L`-)*^_=>ZBR?!7X^SQL*G"9RIFFCJ8ZNLESDJUE;'55DV0EBJIX
M((2U.M9(LB1*%AC,,050(U`]U[I4Y+XK;*S"9.GRF].VZVAS&6;*U^/DW[51
MT<JM5QUW\)C2GHX9*;!I4IJ2FB9$0$A;`*![KW4W(?&39N2J36U.\.U?NY<G
M09.LGAWY7P-D/X7'$U!CJ^.*!8:G$T^0C-9X"H62JD=GU*Q3W[KW3<GQ*ZP2
MOCK&R?8$U,D-.LF$J=Y5]1@*JMIJZDR<>6K,1+&]+4Y$U]#'(Q8&)BMBFDD>
M_=>Z?J?XT=84]+04JTF288U(/M)S44*3I5Q-.\N2D,&.ABFR-8]5(99'1KZO
M2%``'NO=/,70?6U-$T=)AQ1.^O754*45#6R,TDDPDFK:*CIZN>59IY&UNY<^
M1@6(-A[KW4FLZ1V5D"SUG\8DGF$3UE5'E)::LR%6$5:FOKZR!$JZRKKRMYFD
M=@P"J`$1%7W7NH%'T9@Z."KIO[T;QJH)*PU&/CK*S$3+AZ7QTL"XVE'\%05T
M7V].\3U-=]U7S13NLE0ZZ`ONO=,V1^->R<K7#(9+)9_*3J8A&N8GH<O2104%
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MD97K6!=3K9!I)M[]U[KG)\?=N25,LYS^=,<M?19`4U11;4R4:R4,'AAA>7+;
M<R%56TJM)*1'4R3HJSR(!H(4>Z]TZT?1VU<>V-GHYS#78<T?\(R(VMUT:[$B
MD;@8JH_N4'H"4"(ACL:=(HUAT!0/?NO=*&HZVH*ZE^SR6;S&6IUJ*R:&'*T.
MT:^*GBK:H5$U!3PS[7,46-\8$/A`T-"%5]152/=>Z9:OI^CKA4&JWANV6:30
M]-./[M034=3#15-#35JRTNW*>6LJJ:GJY(D-2TRK3N8`!"='OW7NFP=&8Y20
MN[]R>!Z"AQT]*U%M&6GK*?&T"4%":Z*7;3K6O1*97IS+J%.T\@C"HVGW[KW4
M"D^/.!H?+%2;HS\=`<H<M1X^7$[$KH<75&I@JM6/FR.SZNKB=9/NPCF1GC7(
M3A"!XA%[KW4\]!;2AJ_NL55U6'8O4$BAP^THY4BR!1LU!3UHVZM?319UWJ'J
M@LMFFJY94"2Z'3W7NLM9TAC*NFR5-_>?-QIF\EC,CG#_``W:,G\:;$T2XRD7
M)ZMN7J9OX;&E/)/<32PQJ'9B-1]U[IH_V73;+G*2U6>W!5U>5B@@FJI9H$T0
M4=#)042FE@BBH:B>E@GE03RQ/4202&"21X`L2^Z]UY_CQ@IH\7#5;ARU9#A<
M978[%)5T6&G7'!Q218-Z&)Z$TE&FVJ:C2*F6.)2R`!V8"Q]U[I,S_&628-;?
MOC:4X6IF8;*V_*S93&TPHZROB>>66:$5,$M2])&&(QD]5(].0NF,>Z]TRR?%
M[=\=1DJC&=Y9+'_Q3;-;@JJG/7.RZZDJ*ZNJ6-1F<A352/'F/-BR*.6CK//2
M31C6ZF2S+[KW3S5_&6MFS"Y&F[9W9%0QPPPIB*NAHLE#,!2#'5D>0JZB<5F1
MIJ_$7HG65BZ46F"-UC4#W[KW3>/BSD%J(ZR'MW<5+D:42_89VDVWMV#<L(%/
M34%#2UFX`C9')XS'8RG--'32L8Q"^@60!1[KW4E?CE582+<65J>WLM%)E*/'
M2;CW#E<1C!69*@P5/DR\.Z<E)704^4P$4-9?[6=5I(HHVU*WD=O?NO=5T9_O
MKK3;N?\`X+UCV)N;/Q5FWT[8R><W5MC%Y#;.YNO,CNBEZQH=Q[<HLEF9\IE\
MQN/-PU,F,R-50BDEIL++/''-'%$DONO=(&E[FR.ZSC?[X9+/TF>QF8@QN=ZW
MVYE=O9S<^R-A;\Q&/P%5O^+'9>JVW@L!@=BX2L:#>%#CJS(YO()448@CHH<E
M3*_NO="OLW?_`&.FT<1F]R4>!C6#?G6&:W1MVBP,^_-I;S-)MO?LV%W!L3-U
M4&WJW:./R&T-MXC<2[B,D];7TU.V&I:,5:`3^Z]TGNV#7[ARU!'O7#[)IMPQ
M[,PM?NW<.*ZSKLM-BJ'_`$J8#(;(HL1V-0QT-)MJ:@H=PQ9*BQ<./IGR<V2J
MI:Z8UF)*+[KW6?<&`V7M_#[[QV"V9O2A_O!V1T;DJ+'U6;QZ[8W'68G!]C8[
M96YZ."DGQ5.FX=SI11KD$B:6HR>X<9*U7`:Y:CS^Z]TR8O=>=R\5)TV<EN&@
MH-TP]8MM/M.3#8RFCW?BMWU&/-%U`V>G.\Z#>/=`W[(/[VI/_`ZV##4.2DAR
M&+CIUD]^Z]T^P_('M_H;>_66'Z_P^"['C[`SV_QV=)#CL=MO;\>4AQ:T>TOX
MIN+*9C&X7;-7A-P8&M@WK)3M32X>IJJ(4>-S2:O)[KW5TNSLY5;EVKM[<%=C
MEQ%=F,/09"MQD56^0@H:NIITDJ::DR$E'CI,C11S%A!4-3T[3PZ9#%&6T+[K
MW2D]^Z]U[W[KW7__U]_CW[KW7O?NO=%.^9&2[<Q?3^5J.K,1N'+1:)5W:FPL
MUEL)V9%B"U.L/]RZ["8O,9J@\DK-]_6XNCRF<HZ12V.QF0J2L'OW7NM<;KO/
M9&IV?US1?,?/0[9BVE@^WWRV#SF=SN+I,;N7>,>_?M]^;E[`W!-G)Z#?N(>C
MK]N45/@LQ44E;L6"1MZ-C!''1P^Z]T:3K>N[+G[BP6`RF+V9_=W#X;I"3XYY
MO/N(-UUW7?\`':6>NW_FL3L:KDZ%K>_6@GHJ+;\^,G@Q,&WTJ*W'U$C31Q5'
MNO=2_C(U4O1^)JL9TSF.N89O@?U%M[%=U9'.5FYL;NO9])O?<&2Q^#CV114=
M3M^:OZDS4QD&1K:BE#4&;/VE0\QD5O=>Z)7_`#"=PX3,]Q?(27<>Y-P87/X#
MX<[+_P!&38;;&'W.M5V7OC,TOROW3M;9U3D<G02]7[IWM!\9]OXF2NTXW$4:
M2EH<A+DH:.@J?=>Z/MWUFLMV-U+LW<6"ILCM_"XJ@FVWD:#<%;C*?:.>HMQ[
M7AT4^\\CNBMPXJ_[ST6\Z[!)F*VFEHX:;^,P)3??55%$GNO=`?TYC?\`272;
MKWAF:79>\=LU>R'WUNK:NP]V8NOQ";LZ?QVRZ':=;N'[W/;I[%V+U_M#:<6!
MQ.)J"];3YG:5=CLG`,;4R35<'NO='Y_E\=F_#')9X46P^E:GI'M/;,+]>XRH
MWI4UM:%I-TQXC(5VU-AYO<>[-S2T])F=S[7JJ"I@QLTU'5YK;U5$U3/5QLI]
MU[JY#W[KW58/\ROYH]L_#O'=(5G5N.Z/K(NP]T;OHM^9+NO*=AXO';+V/M/;
MU-GL[V+2/L/`YD5&!V'0R29'/I4M#.,3%(U`E76B*CG]U[JN#9/\\;NS>'2>
MW=S8;I;I7<7;60[:W%B,QBI=V]F[.ZUP?46W-Q8';%'N'.[P79>^:+";OWAE
M*BOJ&HJ>JRTNU]O+2Y?)TS++)1)[KW0N9O\`GC8W,;WZ\R74_4^*W)T-#M>B
MS?>VZMTY#M+;'9^SLA4;=DW%N7%;+ZNJ>H4W%N*IV%38^KBIHYJ>)]Z9&"HH
ML;]LU(9JCW7NG_9W\ZK&YGN?>F3W-U?B\/\`"W!M#B,%W)MJ3N+L'N6KR&6R
M%92[,W5G^D]I]+Y#(8';&]XH::8T,U1'DL%CLMAZ^N.C*K3TONO=,FP/YV=;
MK[/JNZ.G=G[+HIZ#+9GXX4.W=Z[^S68W_P#P.';[Y#`]D:NIGHNL\.\>9>2D
MW9D&I:"OJ*#+T%-CY9\)/)5^Z]TRQ?SN-S8[IY<9NSIW8.*^8&1W#3QX;J6@
MW?V%D=D2==9F3<$F,WK-N5.LQ!_I%H(L(:5>N)JZDW#FJ^6D6FG@3)4Q3W7N
ME%V+_.GS=+MW8NVNG.D-J;U^16+W90XCY*=9;IWOO[9NS^I,*F8PU,V=VGVA
ME^H:#:_9>UMWX?+PU]#N2CE3!X?%U<.0R#M3AT]^Z]UGS/\`//ZUSV\NOLIT
MIM+!;]^/]!)6R?)+L?<.;WALS<O4U-B]JP[BW=3X'9M9L*HR^Z\WUL@J&KJ2
M.`MF6HZJCQS-5TLJ^_=>Z?\`9?\`.SV)N+N?<QS/7=/AOAQC:B+"8/Y*X[+[
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MU3M_*+]M/`\DL(D]U[J_["5T^3PN(R552S4%3D,705U30U$$]+44<]7213S4
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M?(T>1HQ-25`D7W7NHV'_`)N?QRK^C-\=RYG;79>R\QM&B6MQ73>\,3@L-VUV
M"E;EMUX;%#8>UGS\E3G53([+R=/EG4*N"JL9D(:S0^/JO'[KW3COC^:QTAL[
MH79W<U+U_P!M;NW/NZDQ]3)T/MK#[?G[AVF*S);&QC2;UP5=N*BI-KXZJF[(
MP0QE95S14V7DSF+CIG:3)T:R^Z]UF[._FO?'/KO</5^)Q6W>U.TL/O\`PF%W
M'N?=O6>VL7G<-TUC,^NY/M:3MF&LS^,RFUMU8D;0RM3F,(\!RV(QF(R5;44Z
MP8ZL,7NO=**?^9W\>*7Y.9/XZU-'O*+;N)Q^WX*SY-FFV])\9TWUN;(T^)Q7
M7`[(AW%(!N!LO5PXR6I:F7%PY^9,0]2,DPIO?NO=,_7W\UKXP;WWAWKMC*ON
MWK+&=+8Y<OB]Z=GT>#VAM3NC%IM4;SJ*SIS)5^>$>ZUFVW-3Y+&@^$YO#UD&
M2H/N*%S.GNO=,NVOYN'QPW#U#VAVA4;/[IVYN#K?*5F)QG1^X=D4=!W?VS5+
MNG+;.QD/3FR3G6&_ZRJW%A*NBK:>DJ//@JVDJJ?)K2R4TH'NO=1=\?S;^A]C
M]`[6[FGZ[[DSN\]R;BVOM:I^.6W\#MZN[RVUD-PXW:69J<QN#;C[FAH*78>*
MQ.^,34#<253X>M3+8TTT\@R-&9?=>Z6G<?\`-)^-?455U#3T]/O[M%.U:_;4
M60J>J]OT6YTZEQ.YWW'%2Y/MVF?,4.0V=D8)-FYN^$>&3/SKM_,FGHIOX1D1
M3^Z]T'O9_P#-\Z&Z\R&[:'#]<=L]GQ[3WOD>NGR77\_5-9C,OO&)L(^W<+1U
MN7[.Q$.'EWUB\R,K@I<T<539C"QK5T<E0*FCCJ/=>ZMB%[#4`#87`-P#^0"0
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M]]5T2&G3W7NDCL;:&%ZHV=VAU%N;;DU7V3\?J?`[&VQNS=N[Z?<_:&V,;\AM
MJ["[C[6??F8H\Y+0U.S-U_)/!=FK3PUL,+G$3AJ4)C9*=F]U[H\/:V0R^9P>
MX10=U5W8&7V[W5T5FH=I8_%4=1G]E;K.VM_)5[5VWAM_)B:/$U&Y\=X\YAL1
MD*^IF:*K7[;R4<M"9O=>Z+Q29.;<NTNU^G-AYG#U/8N1R?7>_L+MP4*86CVQ
MLV')86;;OR'[3W!MC`4F7Q\.[<3@M,E3FL?EZ<S9""7,4X#SSCW7NG;J7N/I
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MKFL1V-OO--GL!LD]B;KW3MILM'M'*TN`SM%-!MOXV[7^Z;`YG%9;:=:K[BQ=
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M35#SQ4*5BXVC\6-HZ2GC]U[HMN'_`)7E!UKW9NGN/I[<VT<'D=Y;EV-D,K59
MO";I.[8\?L#>VUMU;+6NW'B=UPT6Z,-UYA\%48C&;<GQ]-CL@]6<KDJBHRAG
MGJ/=>ZMS]^Z]U2=_.EW=B,!U]T]M^IZOV[O#.[^R':FU,)OK<F%P6[H>M*0=
M=5NY,WE:38>[-_\`7&Q]]1U!VW2RY#'[@RE)C8\;235L)J<C1T=!5^Z]UKM;
MMVCB]L[LW9UIL/;VS\!3[P[O[WP$>R-I_+;YF]*?$;I3K+K7X?\`QL^4G:.*
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M,@'AHO`T5HE=_=>Z;L=\<>[MBX?(86OV7VWL7;N6JXZO=510_)S^>/55.\)<
M'BY,?6U=5@9/Y?<6&KX\;09)*.NF6DBGKZ&LJU<R.ZM'[KW67.=*=X9RF@I-
M[[,[GPM'4B&G&!Q_RO\`YV$>`Q^,S3IN4X?'4>\?Y:6ZL9C,1D-^3RUE&M:L
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M:[,3*=G;;V[D\WMBOW/LZL^=G\U3`[6R=7+1Q8NC6FV__P`-3P_<PJN':BJE
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M>ZX2%U1VC3R.J,4C+!-;@$JFL@A=1XO^/?NO=<E)*@L-+$`E;WTFW(OQ>Q_/
MOW7NN_?NO=8Y4,D4D:R20M)&Z":+1Y8BZE1)'Y$DC\B$W&I6%QR"./?NO=<P
M+`"Y-@!<VN;?DV`%S[]U[KOW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=:^O\`.$R/3>5[;ZQZNW!7;JRO9N_NML0DVS\;DJO8FWYN
MN:'O+9T,$)[+P&V-U[\&_MS;LKO-MO;>&I5HL[E-O1IF:RAI4I_N_=>ZIJVU
MM?<$,5)M?;>=[(W9FL'M?Y5Q+7_Z-/A3E>R-I]`=-_*G>OQXP6>^3/R=^4WR
M/Z<H^V][]@;FSM2*NA18=NUE+EDI7QT/V]3`GNO=.:Y7=-3C((*W:.+QV/\`
MXWE\LFQ\ET=_(TV7UI+B3BY<;C.M<SUS@OYCV1@W#UWMR<056*HZV:&3)O1J
MD]8QLX]U[I%M@>P:=QD:G#8+<.7.W8\7C:'=G1W\DO.;%VY03U,BXVBV!L+#
M?S/,?@-M9FCJ*NMHJ6:CJ8J6"BKZV.)9(&TP^Z]T_13=MXW-8O<@Q!W3D:*C
MQ]!BZC=_1W\F??>Y>O\`;F'AK?XSM#KW>51_,YHINK<#V-E,D)LOBONWBR,N
M/A>!P6JDJ?=>ZA3XWMUCFZW"X?-X:JDEW#X=R8WH3^35D]\T&PLE)B%QNP*7
M=D_\SZDCRO3^R,!0T]%B,;425"8R)ZN:6K0Q0/#[KW43(;4WYG5Q]%MSK7+;
M/=?M:C+U?5?QH_E)[7EW6N-J:;)97+=OX;;?\S?#INN7>3QR*\532'&52U+U
M444PAE\GNO=/HVUV=#.T]%UEL#9^%JI]P9.DP2_%S^4;0?'^#:F4S%:L/3LV
MS)/YG\FU-Q4%++3QJ^1>-,E$V++TU;%623RK[KW4-\;V-'@Z/'Y_J2CS&.2C
M>##X_>'Q0_E!'9;UN0JZ>GV]EL=LK-?S1Z'$;>R^T4KI_P"$YN*MII<6]3+(
MHE2>.&/W7NI\&#[<I*TT=5L&BW[G]R-1Y/!9;=?Q>_E19?*[>P^*KJDY?`[2
M["J?YG&"RFWL<,@D<^0H*2:5ZBE6.=YZ@?<O4>Z]UWL]^TL57PY<]?U>\,PF
M=S0IMQY3X??RPJGL7=^VX,32X_#];4O:6"_FDR[[S&V-G5T=/)MN.188*BFF
MEIE@>(4_VGNO=,:U>_\`8&T=R[ZW1LG.T&R=I[1HJGN'MG;WPC_EQ#?3+N7<
M$E#@M_\`<9Z2_F8[SR_8=?'N3==+'%2U.WA%CU<1U=4QJ*Z>I]U[J=F^O9]K
M=L[OW;N7M[LKI_=?8O>?;7QW[XW)\<MC?'>GV1M?#].]OTW5FTMJ[%Z![%CJ
M\Q@=F;LV'MR@W$PJ\I+DNN1##EJ&NJ8VIJ&'W7NMZ*"2&6&&6GE2>"6*.2&:
M.43)-"Z!HY4F#.)4D0@AKG4#>Y]^Z]TE]_'.+L;>1VQ2M7;D_NMGQM^C2NJL
M8U3FFQ54N+A_B5`KU^/#UQ0&:G5YXAZHU9PJGW7NJ3_BM\%>WL9WI0;QWC)V
MAM38F"I(*7-T&]WV))@.P,=M_!ILROV_B-NX'<FX=WX3;'96XZBNW?209')R
M?P<K(:FB-?F96H?=>Z7/RQ^&/?F]N^<1E>J-^;_P.S\U79#-T-1@I<+%@,%E
M-RU^U*;*X#<5;)5#=&W,+M;*X9MR05>'6CFR>.J*["222!H(Y?=>Z+!_,.GP
MFS<3W3LMJG-?P6AWGU%C<[@L)MU-T]K;KPF2?KN+`R8C(YG&U6V<<V>['Q&+
MBHI:B@R1S6?:.CK9:.AK)Y![KW16_CW1P38SY#9G!S4F3QTD72>ZMX5F;K*K
M-U>WZRAWEO?;_6^R<;N#L;`T>8JNI]ZY3+Y6BK-P1S[GJ\)NJGRN`A6BQN.H
M)&]U[JPCL_([BIX=_5&^=@]>[<VS-N/I*/.9YZJKQ&[,Q40;6[%VU4=9[CPV
MW\GF-Q[+QV"JJBO7;^:2IKJ40%)(:I)T^QIO=>Z#:GRF3?J[(3898*/N#IO=
MO5V&V-G<!59JM[-IMSR4%!E=PXS=M)VICH\YF-F87"QYFIB?%1YVK&)IZY=N
MXZ:J6!S[KW3G\>LO\0?^,)[G[G[$[FK-\X?(_(++TNX^S::IJY\_NU:[;D??
M^-RT6.QNXL%LSKWK"//XJ5:#;=;%M_%0Y.O%14N@RD$/NO=;`6%FPU3A\34[
M=EQE1M^HQM#/@I\+)2RX>?#S4L4F,FQ,M"6HI<;+1,C0-"3$T14IZ;>_=>Z<
M_?NO=>]^Z]U__]'?X]^Z]U[W[KW1;?D[W;LSIO8-6=SX+#;PRFY<7N3^[>RM
MS5(Q>U]RS[;Q#YRO@W+G9L%N:GQ&%IH8T:=X\=DZYE;_`"2AK)5\7OW7NM=_
M+=I[/^;&T<!4[6VQU#MG<&\\/N[LG-Y7;^WJW%1[+Q6QL%GNQ-E;;VSEZ.JP
MFXL'!O+`4]369FNIJZNQE<M7DZ#,0;:R4M/4Q>Z]T*^-WOM'LWY*RQMNG)[9
M[$Z:WET)A>P=DXNL7$8/KWM+*[LQV:Q&*V)2X>@WKM"?9!IQ+5;DJZ3==91?
M9T\]#719V2O25_=>ZR_'I][2];Q15NX=H5^QD^#]!%U[B\/%@:?=/7N)Q&T]
MP#+/OT&.IIHJK>\`AH<+AJ":DR--D<?4SU4]30UQBI_=>Z+S\CNH\G\@^PMM
M1[/PNX,3UUN;)X3XL?("7<N[]M-5_'7K':N^>G>_LAO+:6"V#N;(4>"R4\6'
MW)UF5FRE%48_(;TQM+5C[:JDI']U[JYCX-YRDW+V-F-T4\-%C:S=W3VWLYF,
M2HQ8R$-=2YJ#`Z9I,-%3460AQ;8J2B^]>,556\)>0E1&??NO=6B>_=>Z][]U
M[KWOW7NJ9_YTW9N[MM_'NGZF2CQ=#T_WUMSM_97<^]:V@F?([;P>.ZVS&<P$
M&W-T55!EMI=;9[);CI*?PYO.4E3`WC-!C53.UN*EC]U[K6YS&=.7[/SM7'FJ
M:KH:_NG^8=3[BK,+M7&['H,/58C^73_+:&3DS>(V]5507>.(QAI&R67GD;(Y
MBJJF-1$*I*C5[KW6YCE_G)\1L#D:O%9GO[KW&U]!'5RUD-5E)8UITH998:DR
M3FF^W!62!PHUWD",4#`$^_=>Z[I/G'\1JVKIJ"G[_P"NS65<T<$%/+EGII&E
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M@PN!W[A(J4M344&]893JF>:CC]U[HI'76S_EH/C!W1LE]K=\[1S</P"Z`Z[W
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M%14U,TO9>SHHJ>EI"BU=5.\F858J:E:51)(UDC+`,02/?NO=4_?SL>X.K.P/
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M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U17_`#?>PMD#>O0?3_\`<FG7M?+TL^_\
M!W+N/-[XVQM?8VQMO=I]64V]-CPU.W*!\-N:J[6HS_#ZNER=72X;'E**?)$I
M-2(_NO=4W=<[>I]P?([K#;VYMER+MG._(#>69RNRMTR#-[<PU5N/_A1,E=_=
M+*4VY\93;NSN[(L0)7RE+EJ6)(&06B\41<^Z]UMS5OQ3^+.2)7(_&WH"O9H9
M8"M;T[UU5%J=V!FA(GV[(3"[,-2_I)//OW7NN;?%CXNZ8`WQQZ#T4T5%!3!N
MH.O-,$-!5RU>/A@!V]:**BKJEY856PCED9ELS$GW7NJ+OYRV%I^AJ_J:LZ,H
M=O\`55%7=9_('<$^P.MNO4Z9S/<?:.VL3MC(]94/7_R/VC\6_DI@9^^,-,^2
MIMK]5;GP=-@NRYLW-%+4EZ!8_?NO=`SD,O\`(:K[IJ\GMKI?:>WOCU1?S-/A
M=U!7[IW7T[LS'?(?KSI/?WQY^.6Z.XOC-4=1X[HG<?6=)T/79G?>8J=Y[GH]
M]4%3@,O79BC@H7$*6]U[HNNX>W/D/%UG\[-Z;9^*.?Z3Q';7Q5[H^0/\NC<$
MOQ1Z=QM3U17]0[^FVWAMJ]$X_:&W,YVDU=VI\?MS;<W[4T6],!B,E!N:ORU+
M2TRQ02H/=>Z@=N2]W=/;:WIL#?\`FLWL;>NV?YC_`$UU-F=J[PI-@?Q3JOXV
M[E^,7<F]Z/<=+\\MG_"??F5W%T%W_P!BX6DS]'D\7UBF6V;EX9MN5[4E3-5F
M'W7NE#V_E4V'NSXV-M.NQW9^T,[T[\5L[GNM>L=H;=[%WU\@MU;J[]BV?W!O
M?J+=>[O@,O6O\P;+9[;&<IMO;LPVXQU#F-A8?$1Y=5I#4F<>Z]UM(CX4_#95
MC1?B5\952*A&+B0=#=6!8\8LOG7'1J-JV2A6?UB$6C#\VO[]U[K&OPE^&**4
M3XC?&%4*TZE%Z#ZJ52M(P:E4J-J`::9@#&/[!^EO?NO=42_SM^@.D.H-D;<J
M^FNF^F>J,KN#XY_+O#92IV?U[MC8.-SM!-5?'8MC]W5^RL5B<K4X>G,8J(U`
MF"5D$,FCT:E]U[HO^7K^N>K_`)%8?LONW857F^M-P_*SYV4V\-JX?L+>.'J>
MR<M#\W)MZ]'Y_>5/C\2:;/P]69?%OE7V]D,M0[/:IEDDQ@R><:?&#W7NMO6*
M19HXY4#A)4211)')#(%=0RB2&9$EB<`\JRAE/!`/OW7NN?OW7NO>_=>Z][]U
M[JB#YR;8INY,3\RMITE#MB#>>:@P'7/5>&S6<Q+KVGW9MG"-VEUOM#.[,3(4
MN1W9C<CN/8.#HCCQ4+5STE8PI8HWF=F]U[HF_1>XMG[]VE\G^_=O979)I_DK
MENEH]NK2)ENOZCL[975&V]CX_L/>^)VU79"MW-0;(VI\C.U=V;<:/&)34F-&
MUHVD)JZ.1G]U[HU<]+MB+:F[)-K;9WQ1M/V/\?(*#=ST^&J)<@^8V-O,X')[
M'7`.(MT;HPD,U-DLI1UD<%/7;D&12N!R)ED?W7N@NVTFSNJ.O-W]Y[:VS5;?
MW#L2OZ*V4^X=STN:VULKN;IZ#,]=5F.VSL/$Y=M[56X-PKESB*6L#/A9:FO5
M,<V3Q9DG1?=>Z$GJSXIX_OW)=';K[6[+Z0J^P\)N+>NZ<Q6;:JZK([<W1@Y<
M3N1NO:3K?:V=S'^YR7K?9^ZJYEK,I1XT5]+D?N<[@ZNII*:KE]U[J^7:VV\9
ML_;V(VSATD3&86BBH:02F,R&..Y9W$,<%-$9)&+>.&.*".^F.-(PJ#W7NG_W
M[KW7O?NO=?_2W^/?NO=>]^Z]T`GR6H>H\EU#N2C[JQ%?GMGR")H,3MW(9G$[
M[K,_"LLV)3K3*[6S&W]YXWL-&C=\9/@ZZDR\4BEJ:5&%_?NO=:V_8L?66X]K
M=;[K^%-%OC$RY_;^^<[M/*[9W[MM*^EZ+ZUWO6;UW?NR+>E=6;BZSW!0[DS%
M!7Y?(X'&5F&W/7XV1)ZZ3,0)7X>;W7NC&[9KZ>LWWU[F.O'VO@NH=O\`6'3]
M'E]K8=?M3M_8V^>PL750=5[PZNFCQLS[\R>X,13YC%5\^WMO_P`:H98(\9%C
M`RR'W7ND9\6,)C\OTS6YQ^MNP=IYR+X!=:4]7O'![QW4M-V;AI7F?)YVOI*B
MMI=I9?<FSAGXJJ*EKL/DZ*H_C-144U9'5TE7C1[KW0DT/5G7N*WWO++[NWEV
M-MK.=B?(^"+=>S=L]&X?:N.W_P!>P?&[$8O"8?L+#X3-Y/;/=?4&"6OJ,I49
M/,4=''75*15=;CE-/3U1]U[H^_\`+ZVQ_=?:^V\:U+(DU%U!M?'U%;D>K%Z5
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MY[:74&/`W=-A:<-08G"9/'5>X*>=H)9*>L9:DS1O5C[@+[KW4<XSM"IDD^T[
M'WG0RR4DN%^SIMW8JIV[39Z=)\C4X?%U.:S5/2U>9CHJBJAR2-#DJK-R/]Q2
MK2^B.'W7NLF1B[6EPE5%@>S/X;4&EH*C$R8[?M5D\,^T<1'1P8..KI<M79B?
M:N1J,E!)3R5$59723(B4^BY+^_=>ZQYC!]R!=S4%)VWD,?+F<-)4(<SO:OR^
MY:/)97>D&+KZ6'`565S.TMKU6V3')##7T5-/-2UQE=(XXF*)[KW3+03=N0T-
M5-1=D09.DH,A)0M%G-Z[CR67-9@ZN/'UV%KJ6KI\944#Y"MK8E:H\-13,LZ,
ME'`E,RS^Z]U@A7M"G$-!2[LK]SU53B,7E:+^(;D[)-?+@%`I<G6T5/0XC)5T
M.;I-Q04JH:BF.B.=Q3H5)C;W7NGVCSN]<=A<O45NYH,CD]HXIX:]X<+O!-KY
M;.Y7&3T&0IHMP4]9N"JS=97;DA@2G-,*:H-+4-5FEB"Z8O=>ZFUE?OR_\(IL
M>U9E\3#MJ#<F<W,^XZ7'UC9'^(AMJ;>DIZS'8R7<6W*M(YXJNH*T<H)*552[
M.I]U[K-E3NVBKH<?/MF>LAQ^$JHJ3-Y'&;FJ\M34.,QE'GMH4M+F<E18FDK,
M96YT9"2II)8WR$DE'3Q^:*!HO?NO=5T?S89:Z7XC[^JLA@JK#-7_`!L_F9TY
M>#<==+32BF^!O9-515]-A\]2*U-7%/"E<:.GAJ!75<RZ9O"96]U[HJLF_N[=
MG=R5V]/CJNY-X?)#J;YP_P`Q#;G4?2N9GHZO+9;![XK?C!E=_P"U\-B-P;/K
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MU[W[KW5''\W+L2*JWS\:>B)-@X*DK<_OKK_LS`=Z[QV1M/<^"VKEMH]O[+7^
MX&*R&],I1;=Q=;O0QQ4V2DJH,FM/1U,,R8ZL8&2C]U[JEO:N">;M_:>WLKBM
ML;@&<[JKLMO/9^`S^4J,7+F,[_/\3)[BJ,&DN4R69S^VXJQYL54;6J*RLR+2
MTDNFH=4*CW7NKN*S:73$]/DJROZ9ZUR6YZ++XE\D(J+)4.:DSE?.*69)TILN
M^.S<`R\T:QK&`!3123S&30VCW7NBY?(/NGXZ?%G+;.I]X_%"BR.0W+M7/[]W
M'G:2JVQL7$[9VM19.7$U6*Q._=S[S@ZXS&X<KF<=4P4.(Q\B4J04"Y&>I@#1
M:_=>ZA8_Y<=.[#[0S6P7Z"GP&)GWEM3:55OS;%;)++N#!5N#VIOK=N]UV`-R
M_P!^,E@.FL%VMC'K:6(5&7GFJLC54<=3#13(GNO=8-N_,CXQUFZ]GX"MZAH-
MD5F[NR-R=(8S<`WUC*/<J8/!Y+LB&EW$=BP[LSFZ,O!/N38^6K<C@*(19=J?
M[>KBBEDJ8H1[KW37C/E?T1D-K[PJ<7T#O_$YO'IU]O"IVOF=YX:FS^>WUNSL
MVCZKP<>Z-W?W[EQ6Q-S[>Q&[:3+Y+;FY*O"5N.AKV::K>6DJM/NO=/6*^6WQ
M:G=:/;77O8D$M5L;&;6VE2TF:R5+N?*9K+X[%[QCZ$QN-QN]X_O]][VI\\L^
MW\A*U%@=S45/4U5)72)1F_NO=)_<7S`^)%!M.'<.:ZU[&9LT^9H:^GH^T<9@
M*''YT[SWMTIDY9-TUW9N,Q^](\Y_HDRU/-7X>:MQ$^,C299HUEDE'NO=.$?R
M%^!F,%3N&GZM[$R]+@HJ/#;9W;%M[*C;F[LQF=A;?W3NSK_;"UW<^+VECMR;
M.V%V-'6S/DOM*1:)9WHJRLK*>\?NO=&.QNP/B[N'#;/R6.ZKJZJA;"-N?8`W
M%O3?Y&%V[4[9P>XO[W[KS%#N&CRF*SF,IMUK29F6I_B,SRNZ17,<QC]U[JO+
M^99LCJ3;O56S=L].;9J\+2575_S#J*['8BOW'NC,5597U/PSQV:SN,I>P\CD
M,A59"HP]-$83#-]G'3R"F$GDFN?=>Z9,/V%@^K_DC2=Q'KK8WR*P6#^7'SDQ
M6]NJ-KX3>;'![S[E^<K4W7.Z-]IDTJ-G3]Q;+H\+!/MB'[;.B2J2NQU#C,1F
MJB7-U'NO=;>R,'57`8!U#`.C1L`P!`9'"NC6/((!!^OOW7NN7OW7NO>_=>Z]
M[]U[JE7M3;NZ-S_(O/2[%?<9W;A_EYU?ALCN3:E/UI'5[9V#E>O:_-[G+?Z3
M\_C&JZV"DH$6DEP?\4R:3M(4Q3I3^1?=>Z`[LS8G=S8[9.Z=Y=3S=8T0ZVWI
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MGFCC`'NO=:X&2Q>U_C[L?8=-\7.UL7N#9DWCV[L'>NZ.LLK3[/\`XE@LGNO;
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MK[>W963]Y9R+(QP)IS']W,'48G'-'%E98Y?=>ZN1^`NQ:[KO9^$VG64]/2G;
MO5^R,++'2U>Y<E2FNHZ&ECR1I*W<^3S%?!C8:U'BHZ1IR:2D2.&Q:-G;W7NK
M$O?NO=>]^Z]U[W[KW5*7\ZG%_)3(=(0MU[CESWQFBV#W*GRHP5#--2UU7MFI
MV7)2[>&?7'[YVAN7,[/ER$["6EQ+1>"I1*C+3_P-,A!-[KW5`6_=GC%=Y9G%
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M:VV(H<U0>>OW))N%\=MZFJA18C`8>7-/-'!KI\C#&A1VG656/NO=.,6/[&R.
M,&$JV*R)08*6.KW%E**B@J\]3Y2KHZ_>F`RNV-PY*BQD..IH8I\M@XZ:ADG=
M6FATO"\3^Z]TZS8'M?$,T.5E?=%%!A,\BT]--A<=C9,0L..-91XW<(GQ6:>E
MWQBXX8\?6_<R3&O@F:HA@IY0)?=>ZK,_FAT.])_C#V#%OR#'4V7'Q?\`YBL6
MWI<154,&$QRTO\OO=M.KT,>'J<K$<3%DWC>EK`D&3GJ:IH6#H)'C]U[HOM?F
M_DEMWOO/P?&/$]@83Y(TWR^^=^X.@*7)X^GWEM?>&+W/V7\9,+WY!C:BFV[G
M<0=EX>:LEBW=+DWBPV.HHX:Z@IWW524<DGNO=;E5":YJ&C;)QTL62:EISD(J
M&6:HH8ZXPH:N.CGJ(::>:E2?4(W>.-V0`E5-P/=>ZE>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J
MB?\`G#]O[HH=R_'[H6MVYM:BZTW1N/:';$>^LUD<=2[BRO;?6W<?7+[!Z_VG
MD)6_BNRZ6J2NJ9\QD\24W5544HI<()#_`!`#W7NJ6NH:V&F[OVU4TE-A:=*?
MO/.9[`;,@P5!MB:*MIO^%#V<G_RRBQ6:RVTMDY6'/9NMHH8<1-5FF@CK9@$A
M:"CB]U[K8$;L/<"8G<-1-A=CBOB2IIL5'0["KY,)59JCEJ&JOMZNBP65R>WJ
M"GI@:2*NKH\@CRB6*2&&'3+[]U[JNSY_/OM-W]=YQ.HLAN;J?<O54FT,QMY.
MJZ[L>+>&Y\CO.FP<&RJ7KO9FSNP<?F\9N'";AE6:6<8&GR&/JUCI<K'X'A;W
M7NI6)Q^]N\>_\)UQE]M[YPM;M?`;*ZSWIV,=N[OR.X<G!TIUITY0;@Q>#K<K
M1X'K;;M!VEOK.Y2GH,CC%S]=CI<;D*^::"G9$7W7N@_V]V9OC=_R,K=TXK8=
M%24O>,G;G7&X=F0[$[-VSG-B;KWEG>V]B;)R4_W/5HV]CL[B]R5,>2QV[LAE
MJ'$';N1E5:B23[9G]U[I&[/WQOS/](=O8NBZFP^TJ&/JCK'K3.]A5O5G84/:
M>T)=P]_];55#B^X-R[[V8-YU.W\%YMR&JV+C]O[@EPN&Q,56<BR5<`C]U[I&
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M>[9H-LX+>^=BRW5NQ&K:;=68SU+CZ+`XK:F+;<5/235NTHL[BLSL%,=CZ-C,
M9Y9_O$4(\]5/)'[KW5:7\V>H_O-TQUXV3BW;18NMZ4^6`;`_Q-8][8O;XSGP
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M&LGQSP5<T<M-D5I,@V.E4RK25#`)[]U[K7GQF&W[\+>OMJ83LB)^V<EL';'9
M.$R^:P^\8:W&X2+=5!7X"3%]?[GWE*M%O=,MUY5T5?E,"LN:RFY]U1U=7E::
MAHJ-ZV+W7NE?C\=N/KSNG/8#'YO,?P+LZMZ)J*+%=8197";<ZB[5VGF]MR87
MHW974&PL=FJ:?XE#`SUE?D,KC\OD8LID3#14LF4H:.:E]^Z]TX?$J/==5T5C
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M83,;'CVSVU_>KXLY/L;`[`F[[%1BL%14]<F`W7F\#M?NE=AO5)5Q[?K:JG.*
MF89RD6KR&/I*8^Z]U03N:LVIMO>^[\K6=N?%ZMW9M;N'Y^P=ETNZOF/M+HJO
MW9M+Y;]"?!O#=5=]="=C]@=?]P[`W]M+K7_0Q4X3*!Z.;#?WDQ[QRQ002/2C
MW7NADRWS(^0.7AS%8>[NHA1UU-BLYG\E0_S#?Y<5-_=:>>:EK3F:^DF^!,5;
M@(MSK5"BH5C\,%0LR2T[S+)"[^Z]UGE^5/=R0U%-D.[>N-F4T2TN-.[4_F"?
MRYJW(T]4J.LM)'%2?!G;^3VS&]`TPKUCF8SS4A@JF,PM%[KW6!_FSW)`T4-%
M\G.MJW(0[>@S,^4@_F`?RK<-4TV.AI:G&X+=N9I:?XA4[[KP>)^Y>GHY:N2'
M#NV0ECBJ20%E]U[I24_S7[>J\M*E%V]U))G:F6&EW=6M_,#_`);&9GKJNGQW
M\6A@FPM!T!-EDI,['AS+!63.(XZ>C6T-7'&]1'[KW28'S@[9RU2^1JN]NF11
MY_$NT)7Y\?RB*@8/%4N0I(\ANG(Y.KZ+Q=7338^HIJ96EBI9:.DT)$DGI$+^
MZ]TXQ?/OO^EH,:U;\F^F9I*&G0T=8?G[_*+RF-RV:R4<8IJU*FJZVI=O9'=&
M9Q<2UU#5SM#2P4\(,"(U9*I]U[K-2_/'OJ#%5/V_R-Z0Q5!F<GD:6GRL_P`Y
M_P"4A7UU#AJ.G7`[NQ^W,IA]HS;9?^$8BIA7*4M++4S4%/!>H,4X$H]U[IQK
M?G-VO3T>0%5\MNC:;(0#!U^,%1\L?Y25#E5V;2"BI,3O[^,Q[8DPV)QU3`8:
M:2DR$%6:_P"YBF@JI"5<>Z]U"E^;7<+U^X,91]]=1U>0HH($FQ.&^8O\IBA@
MRN39Y=&S,L*3&M/M"JSE/B15C[N@A!A=#8F-YH_=>Z#;OKY7[[^2/6&]MD[K
MWGT/N^7<_1'R8V)US#NCYX?RP-D[`VIN?Y"]?/U'D]T;\KNDZRHWON*;#;6R
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M^>??\]<E^O>]H3%@:K[2"O\`Y>7S;H*W&?;2R1U69Q./H)HJ*..N:MA-==98
MI:*.%',+-,&]U[IMI?GC\E\3!_D_7O<U-#+-+B=R9+&?RP_G7ALTF>I)*;'T
MHQ]#AX_LHMJTD[2TM.*M6_BVH,PIYP)6]U[K&WS]^2&:CHZ5NM^Z\;4H*[^+
MT\?\JS^8%B,#75%)02Q39N3-Y.BEI,;E%$L_W,:5,L58)HJ3Q-->)_=>ZGGY
MZ?*"&AV[1P;![JFCA@65*'-?RROYB5)D,KC#4333XN&HH,;2C"4'V%<DE(I6
M.JAI*:$"Q9D;W7NHT_\`,!^45(E))D^L.[I\[)DZ2DQ/VG\L?^9=29!\3DZ=
M7R7W\F.VY691H,TIAB>O<4K4LQ5S"TCN7]U[J?D/GC\@*Z2&E'5/>E+7U5+E
MJ^OI*_\`EX?S"TS.W<M@<I5"?,9BAEVI/0"GDIJR6+;Q>J@6LD@66%9X&:*/
MW7ND_B/YAO?JT,D]7UC\EL[!D\;15<.2H?Y</\RS:5)EJ.9UH:`Y"OQ_7\CY
M;<3FEBHPJPQ1PQT[HL(\[>/W7NE,WS3[ZHZ''29/J'O6OH):6>)IX_Y?_P#,
M13)(N4J5:2DI=JXO8U=3XM,73Y(2XF2"JIU2DA:LD`E)C]^Z]TV/\]NRZB".
MES/3?>&Z<`W\0Q<N7R/\LS^9%24(4T^:P]',*G;_`%A5MNB;+5*2T2&G$,:U
M'EK482()/?NO=%*^9.\^P/ECM*EP\'0/R2DW;MG"[KZVVCL_;/\`+[^:G6>4
MW_NGY`]G_&K)98[E[<[AV)2[1V-BL%MCJ\UF4R>2K77*SRT\/ECJ=$7OW7NE
M5M'L/O3:'R8V!O\`^/U#2=H]QTW?W\PS;"=;G:.`QB9C86^/GWG<SVEMJ+<%
M;LBDR>1W12STU/+D<UBJF2AVGC(Z'(Y&MR=#5"@A]U[K;E0LR(SIXW95+IJ#
M:&(!9-0X;2>+C@^_=>ZY>_=>Z][]U[KWOW7NM=7^9EG)HM@_.;KD;DKMN8WM
M$=<[*W-G*V62NW'7[4WT^)V=EL'UIE-R2)LK:F0VKA]S9;)^7(PU&-H*,5-;
M*\,=/4E?=>Z++UUN63)O\Q*#9E'O3']<5O9'QRW!5X/?JU.PM[3Y;`=-X'I.
M;J*/:&(S"93"Y3;&-^-NV]RU`*U#9ZDRO\3>-L+D<;(?=>Z.]W`^Q:S!=H9?
M#T^XJ.KKNSNB*;.9;*593:G\%K>K=ZU=%NC!5&RGQL6-@QV<I#6YK(T[-'2[
MAH:A9%CGAJ2WNO=`S@,)EMTTN^>FZ2CWQMG(=K9;K>M7O#L6DJO[O[CI\L,'
MB-J]<8K;U=FMZG-]B;:FBP[[D;;-=MFHI,9%D?L*[$5-.Q;W7NE5M[Y<?('J
M;?O6.!V]AMG;DV]O"'L/`8_=>?H\;2;4IZ7#TM?F<!_>ZO2NVE!LRNQ^\=KY
MREWI3XH4..V//D<:)*/)S,4E]U[J_;8NXLANS:&W]QY;;U9M3*9;&PU.1V[7
M5$%9-BJX%HJNFBKZ6U/DJ'SQLU-5($6JIFCE")KTCW7NE9[]U[KWOW7NO__5
MW^/?NO=>]^Z]T53YA[3[8WGTWN#!=7R4U2M=05]%NK;L6,FR.X=Q87(11T,E
M-M^./<.TUKIZ.&>:=L:N7V[/DY$BCCSN)`>=_=>ZUS.M(Z#I_IW;<7S)HJG;
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M?"O!2;8S.Z\!)0TF--!MS`1FEPE=C<E@GJ(J?'T61R51682MK,0^[,QE:*>I
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M1V\-C?%7%;8JZ?9G<FT^R<1G^_\`LG*Y_';]HJ7-[IHLOUK'@J+>>)FK<3_'
MH)Z(866..KFQ;&;<&=5/=>Z#O:7\L?Y^[IPG=LF]^S\7U4V`DQ6VNG.M=F=T
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MNO\`9V&@VK'F^J]M;*QW6%%@:F*DRL61J=HU<5'(]%0S""LJXIL?CY9?=>Z4
M&W/Y=/S-JNW]Z;!W!W;N_;O3\/\`>5\;\BL-NOJ[-]B=A4&YL7O9,739WK+)
M=)4NR,/D/%F8<1GZ>CH*6GCIOOIZ2>JEW-EGI/=>Z2&ROY<7S3W+EOD`N[]R
MCJS:6.S%#B.K^NMN=D;4K]A=_;/PF0P"U.VM^UXZKR^Y>NMIY''824X3)45.
M<_B9)Z"3QQ_P6EIG]U[I+UGP`_F$2?%'=6[X\SF_]-%1F#_`_B#4;_Z5W+LB
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M7N#&DCHGT#,`"?=>ZG>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JAK^:+U3O[LGO_:L&R>K?DSG!
M)T-4T.3[<Z*H]X#'[!I#N3=^G;&6H\?N;`[?[4H-[U]53PYG:=.$S45$E-EX
M*F*6AI(Y/=>ZJ?H_Y?78;[8Z%VOE/@A2=L[T[XV3N#-;P[8[:^.-3N.?;79^
MWLWO-L3N3Y6[IWCNW%]J;SW-E-Q5<=0]7E*;$-4[.J*>;37;DHZ>1O=>Z'E_
MY:>^E^2>"Z&I_A_\99$KMV9_MK='R'S7PZVUD/C,N[<%C<TFT,IBNNHNS:VM
MP>U,QA*3#E<'%DHRF[(\A034XPCTD[>Z]T%'4_\`+$[0W=E]]XJE^"'2_6N"
MZNV/E<7V+BNZ_CG@,WNKL6:3';6I<EU[\2NQ]K=O4V+Q\.Z=MP9J+$9*NEJZ
M#'1OB'JPF:J,V]/[KW4K:/\`+LW5O#J#.?(JO_EV](X/"[7R%%FH>D\O\3H<
M-\D]]Y?96([".S]P8!)>S(\CMG:F"W1E,;+EL-4TM9E\H]1D9J.F,N)V[+4^
MZ]UEW3_+@R.U>G]C]K9CX*;"J*'=]#O5]K];=9_&6II.]]F]H;XW#M;'561^
M1\6+[+J,;G]H;@V5AJNBQF)H8FQD&:CQ[UM918_)Y>:+W7NF[L'^5UV)@LYU
MEM>K^#O1F2W'V+L3'YW`9#J?XU2T'1NT:B#:\QGZJ^2Z0=N5F8S&[L/N3)U;
M9&II%Q&&R>&K/+1&HRV)I:=_=>Z%-_Y<.[:OO6C^-)^(_P`:)MSQ9O-][GN6
MO^+575_$[#[EI=U[KGPF1IL%DNUZS<]%L_/;=HL)!!MZFK:BKH-S055)&D6#
M\->?=>Z"O9'\L??&\]R=F[+Q?P6ZNVG1=<=;2OG=V=Q?'O>&13?&2J-I[2H=
M^;-Z%W<>^L-7;A[)W%629REV[E:JJ3#8VA.+R4M0<V<A%3>Z]U#PG\O?<.9Z
M.['[EV]\,NM\?LC:FX\?O_)[7W-\:]X4_P`G,O\`W)J>P*S#8[H@9/MK#X>#
M`8'.XO;XW#A<QCZB&>GGS45$<FE-AGJO=>Z4#_"GM;8O5>!^1N$^'.R*K$[A
MS-5OO;6P-E="]I5GR`J.P\QC.OMO5&)[:VS6=L4N"DZ3S6"Q>57;E-CZ3$UU
M-D8\>]7]A%G,R:/W7NLG8?\`+KW/UIB^O8U^(>W<[N7L;;.S*;96`ZYZ$[;S
MO4]#_I.AW95;XP?R^VU%W7/E=P]A;,W[GUS<M33R4>.P^#,R1/-/BJ-:CW7N
MFFE^,_R'ZWWAOS^`;8^0E9U7M+Y&4?6^U>D]L=<_(*MZ.ZHZYCWAA8=Q=P;6
MQ6RC0;CBZTP/8>,ER>UMF8FBSL$6+S=1N+*M6O\`?4D'NO=;DGOW7NO>_=>Z
M][]U[KWOW7NM<C^86K46?[LW+1JE?#M_N3JRCS,F5@P<M;B,;O/*]?[)RNY(
MH=P9#%4&0VIUW#N=,F<35Y''87-:9*?(M)1SU*I[KW18^HL+1;0J.V=L;DP.
M+VOOGHJ3X\;#Z]W!CZ;*Y;`Y6'L"?LO>NZ(,5O3>FX<MDMZX"B&)27)Y6E&$
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MO+64E1$?&?=>ZH`Z;[`J^[=B[0S/R'W3NFCW?EL/V+79O<$78<&7PFZZJBR^
M8Q&W=Y9+<.*FI*J/$XK?./&V\'BZIY,7FZO'8_*8Q,-)2"H;W7NA%V[NZJW-
MOK(T&\L"!E=C4G4><VUN/<&%&WM\]W[?R.\C4[H^1V^>N-WXG=7<.W=R]:R8
MBDIZ[;,U1-DY*DM-DIH!303O[KW2(^(C;'?I#*YB/)YK(=@[5^%G6^,SM7OU
M:>EQFUHZ6)#BL'T;0R9"'*9S:5%A_P")X_,9#&)/5&L;'4^41HUC(]U[I4;F
MR/5W9';6"[1WSN6IW!O_`.-WR1WKB.M\-1[TV35T/<>[-L]-[*[?SG7>XZG:
M,-%@C1=#[OVKC=^X_&[BQ5'4UN^L)2XZ!_\`*GF7W7NK,?Y<%?4G:N$P^3CI
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M*KYS_->@I:2-ME;;JDS./P]#6YFKZBW_`(O'[%[.SNT\UNENEIMWT66S^P\U
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M=/6ZOGQ\FL=O[=>UMK]68'=#[/\`[S;]PFV*7K[M"ASW>735?6X2JZ_Q_3^:
MR;TV+R/?)V#@=W9BHPD].N/K<M2X[#"HI'J_O/?NO="GWC\M>_>M,1MV?9>$
MPN[\W6_'OJG?J[:R_27;]/N;<6[-[5V[*/>.XC08'(5U/MC#[`IMO451D=OU
M#M6XTY4"MKHKTBU/NO=!+NWY[_)/$3;DJ,%L_8E)M_;^2Z!VU6;KWGM?<&;V
MOBMW]SX3=2Y7:]77]9;OR]9N`]=;BQ^.J<EN/"0Y#;E;B*B2*A=\FGVWOW7N
MFR7YM?.7<NZ]PXG;?56T^M9J;=75.T!M3MSIOM.NR6T<_NK9_>[[W.4SVUMY
MTF.W9LG%;GZ,6MPV9QR!\OB=SXWRT]#(R+/[KW3KL7^8#\I-Q=>=?;[FZ(QN
M9S>Y.O\`([]WWU7A-M[[3?\`L?%[?HLFLT>!Q16KBW;O'>6$-/O##;=FJ*&6
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M%`V2SF'KL@^2ZZ[%HJG%=H[@ILGOW&8CKM\OD:RBPE53I/0TM#%2*T)U2I3>
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M?KJJ[7V7E-S9'%X7J7%T/6_;?;W<&9.>^/\`UGM/>W9FV=]["Q&TL"<=DMJ5
M&?IX\ZF5PT='E=Q[DJL%N+<.WJ:'.5<<V+`EC]U[HU_\LW&KM_#0;<AH_P"[
MM-ANG>NL?_<^FZXP_4.$Q.0Q\(I,Q-MKJS;E3D]N]=X;^*++3MBZ&LGHTK*>
M>2`^)Q;W7NK8??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
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M^O\`!YK;N)V?UALK;-?_`*3'J]\X#<PI8:F7%5>S:G,YJD\%7E,7(TY/NO=.
M'0?Q-V]VQNGH_LS<W:O16W]][5J-V9ND@V[F\SEJ?"8G*5XK]H8SK;$/N3`4
M61W!UO3;_P`QB:>NS-!B<S21YJGJ,CC<@T=%+-[KW6POM7;&)V9M[%[8P<4D
M.+Q%.8*832F:>1I)9*BIJ:B4A0]15U4SRR%0J:W.E56RCW7NE![]U[KWOW7N
MO__0W^/?NO=>]^Z]T`/R6W5UQMOJ?<]/V9L_*]EX7,XRMIEZPVVF*GW1OM*.
M'[ZNQF'BSFX=IX2GCIJ2)IJJLR&4QV-HZ=6DJJJ&*[>_=>ZUP\KF^LN\MJ[$
MW1\7NLZ;8F0R\V_:O$/M[M3`4^0V1UAMVAW#NO,8#;&_,;MW<53D<!6YFDES
M,FUZQ,+35V+S,F8V]79^;%QXFI]U[H2MSYK#R=CUU-M6NV-MFDZ^ZOZWI)MD
M3XW$SUFQ<W/V173R]%[GV]O]]H97*93<>-JVFAHJK;>*J_M]+B'#34\M.WNO
M=-_3.V*Z;HO?^;DZ>S&V:*H^(_7.'VOO.J?,YNE[0Q\6TMISIO\`W7+GDPIE
MWIM;<65JL9C)JVF>7)X3.5)HJBEFBGHI_=>Z)WWQGZ/`]I[MW+T_0XO&='_#
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M7NO>_=>Z][]U[K&T2M+'*2^J)9%4"218R)=&HO$K".1AXQI+`E>;6N;^Z]UD
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M)EL-NK[?`T>6W`7J8JFLIH85]U[KAU[\=^UOD#V)\=]_;/ZNS/3%)MO$[^QW
M8L6"W%MG'[GV+39)(:VFPN_J+=&.I-[[4["WY43XZ?<M!G,3D=S8;,[;1=OY
M7%8Y_-4>Z]UL4[(P>9VUM/!8+<&Y*G=V8QE$M+6[AJZ.FH9\BZR2-$6IJ4>-
M4I8&6%&<R32)&'FDDE9W;W7NE5[]U[KWOW7NO__1W^/?NO=>]^Z]T6CY:[(Z
M4WATCO*?OG,56T-C[<Q<V8J^P,2QBW!L@PS4SIF<2W\)S]/7E*N&`R8ZLQV3
MQF1T+#6455`6B;W7NM<'<&UNKNFL%UYAOBMV-739J.DW)B^M,ED.N-PY7.9#
MIS/S;FPN[NW=X[&HJG'YZ7;M#70UVV,9O++1Y"HVW2+C\1BZ'`P5ZY>#W7NA
M>K=N_P!WNT,Z>M\1MG[OL/8W26]Z+L7<2+F]Z[N%%DEQFZ.Z-Q]A;GK-QYBJ
M[;@ID--2QUVY,K2S8V"5HZVK\TLY]U[ILZ#_`+H5'Q\[0QN*S._]VQ-\7>MC
MN2AWY)KPXWKN/:&UL[DLETU6Q256=PW7DT.-RE#6#%UC8NIR<5!25L-'6PP3
M3>Z]U59W?0Q;X[&WAE^R]T09*GKL6R96EW12H\>+7;O0&VMJT'6&TM@=7+F\
M%O:.7J:HCRNZLS4IG8L+U51C<V/I*7>BB6G]U[K:H^!--N+^.;JR&[FJHMUU
MNQ]K5&ZL7D1B9:W"[AK9WK,ABXJG!Y3+XZ3&T7D5(?WY9W"^2;QS.\2>Z]U9
MK[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNF[+5,E+CZF6&2.*8JL4,TIC$<$D\BPK4,LKHDHIO)Y#'<&33I')'OW7NFV?
M,U4,RI]G(`D.N1*E8X7E1&7[FL$T51/%2TE%""SF1/W&940EN/?NO=9Q72?<
MQ2/D,?\`;S&4T]"NF&IEIS'23&HEDJ9UD\E'3R&1T6-?1(+_`()]U[ISI)WJ
M(?))$()!)+')")HIS&8Y70!I(2R:G0!K?5=5CR/?NO=2??NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6MK_,(GQ5+
M+W?L#$8J>@W5V)\FNC=PX_(UTN&P%'A*'8&[<9O[=NZI\[EI\E'L_9N5R.'P
MR9O<<&+SJT=!#+-6XQX8%+>Z]T4SKO<>YMR9SL*;-9C<^0S_`&GN7J^1=T3[
M)H>E=M]DT/6]!OK8M#O$=)Y-US/6&Y=Q)C:7'56%RE1G<Q@8(Z>KK:F.GR6-
M@A]U[H__`&A_>^LV]V/E<AM;8L.2HNP.JMIX//=289<=NC-18#8';.:J-B9"
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M=IX&3,3XRJQ3IG<IL3(8O>&%`HJV3[?,8.JQVX\2[-)C:^CDDD=O=>ZUPJ79
M>_\`X+;9V1B]L[LZK[W;$==[_P"OMO[6Q6X,M75^]=_QY>IG[!VULK==3C*3
M938S;'6F9I]P[UQ--3Q09B7#U64W!1YJ6":HF]U[H0,]L+'=;]Q=HUL%5V!N
MRGW_`)CI_?.X-T[*?'KUTW:U3'E<5LRIV%C4_A6W\1LNMV4E3-/3RT*TDV3C
MJ/MZ>2GIL8%]U[I;]/;FEK?CMV#LVJ[`V5O9MK_&/K7;V'V=LG`5>+K-O8P]
M7[.W97].56-^UH.NAO/<<B4&6_A]5DH]P4>,Q=1-&^0QU27I/=>Z(5\D^L=L
M;S[;[)ZMVRG7^^=G_.G:/Q<ZUIHYMNS[_P`5N+LOXM;PQ?6'R?EPVZH33U^`
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M#(QAK$-15T3>&DE6*2.EPBF)Q(LFLD)&I8\M[]U[K'+#-4S_`+<536O*)9*:
M26!:"A-;C:7[5:RMK8:9:A5K7J08#&LZ,$U(`!<>Z]U*IPTD\1BK*6>*683T
M]1-4TE9)41O%"M;18\I#Y/LXX5#%V9I68>HD&X]U[KN&-O)'))/E)YJ:)HD?
M^'RT:O4UDD:2UTL4:T]%5%(ZA+JZ,$$;,/4&]^Z]TX-45-.D,`U5;01%,A7R
MH8FC9*-I$JA2P0JM6:B=0&CA*A-1M:UO?NO=1XY!14D$:5N,C,=;2TU2(Z<_
M;I),\:5-)3PPU(>GFFJ'8H9&?QZO6&`)]^Z]U)Q^0:L#+)2UE/(LU?&#/15-
M-')'1UCTJRHTR\)4`!H]1#2IZU&@@GW7NG/W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=8Y9/$FO1))ZD73$NM_6ZI?3<>E-5V/X4$^_=>ZR>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM<G^
M8IM7)[BZ-^>^8V['6YFEV+OZE[*W-MN7`T530;BVOTC3X3N#L_9M?'FZ_.8(
MOV#UOALMA\?_`!:EDPV5US1ST+)&JR>Z]T779&S7P\GS4?&X2#);&HN]>FNK
MMRP926LW%B3N78G6>#W)E\+M^6`5NZNT8*C/;_PU-C\GF<C!GXZO'T4]9*TF
M.I,=1^Z]T<_NZM$_7_8%0NRLWM:LFW7U,[;HWQ69BNVGN?`S]9]B38.AH<S1
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MD]U[I4>_=>Z][]U[K__3W^/?NO=>]^Z]T4#YK=8=D=J=-Y;`=>T$>\!]M7+G
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M1#5Y:@GCW'M',S)C-NXO^%U\OV%=5B@JZ#1,DGNO="#U?L_Y`9#$Y_";7V%C
MI<+O/LOMVBV)69O?_1-7G]EUW5/36WO[J8SJ[.;#KJ2?'UO<>6QI7=&#W,!6
MQ4U)4XW)U&.$2SS>Z]T<S^6NDLU?F\I6T6Y\!ELEU5U]7Y?:&ZYMIY;/[6RM
M?&DV5Q.X]U]?S5G7^[=PP9%)&EK\-5U]+/%)'JJIIED;W[KW5M7OW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NBI?.OL'?/5'PN^
M5?9?6.X5VCV-L7X_=L;GV)NQ\;B\RFV-WXC968K-N[BDQ.;H\CA\G'A<K'%4
MM!54\\$HB*O&ZDJ?=>ZJM_DE?+KN3LSH;Y6[Z^9GR/J]\4W47>&*VK2=B=HX
M[8/76U]M;7'66Q*^KJ*;<N*V[L+#UV$S.[LQ5U"U%;3QM!).M.C")(HT]U[J
MZ*J^0'0U%UIA>YZSNSJ2EZ>W+/A:7;G:]1V/LZ'K;/U.Y,M%@=O4^$WR^97;
M&5FSV<G2CHU@JI&JJIQ%&&D(7W[KW4[M;NWISHK;\.Z^ZNU.O.I=M5%2U%39
MWL;>.W]F8JKK4@DJGHZ2MW!7T$%55K31/(8HV9PBEK6!/OW7NFX_(7H)=@;=
M[6;O#J%.KMX5,=%M/LA^RMFIL/<]9,:Q8J/;V[VS0V_F:N1L?4!8Z:HD<F"0
M6NC6]U[IKP'RA^,^ZMP8G:>U_D1T9N/=.?2FDP6VL#VUL'+Y_-1UJ5\E')B<
M-C\_49'(I5IBJHQ&&-Q(*:4K?QO;W7NH#_+7XJ1JKR?)GX^QHQ8*S]S=<HK%
M*(9-PI;<@#%,<14$#Z0G7^GGW[KW2]QW</4F8WG#UQB.TNNLIV'4[=@WA3;#
MQV]MM5N\ZC:55#25%-NB#:]-DY,W-MVHIZ^!TK5@-,R31L'(=2?=>ZF;5[1Z
MSWUF-Q[>V1V)L7>.?V=+#!N[";5W;@-PY?:T]35Y/'T\.X\;B,A5UF#FGK\+
M60HM2D3-+23(`6B<+[KW1+_YK';W</0W\OSY(]L=!9[*[8[=VEMS:S[,S^"V
M_MC=&:Q=5F>Q=G;>R53BL-O6*HVA-D!@\M5+#-DXY:&C<BHG1XXF4^Z]UKN=
M(=Q?\*#?D]TYEOD/\;?DAM_>O66!W/V/U[D]NY'9WQUV_P!LUNYNJJH8W/Y?
M;F`W;T36;,SNW]PUYE;!LN;HJFKCC05$4&L,WNO=6A?RA/YIV\/DKUMVMLSY
MF;BZWP/:G0&*V3NC+=UT*TG7G7_97678N6S.!VKNS<>*KJN?:_6V]:#<N&DQ
M%?0IDC1Y*H,55CXXXI7IJ?W7NKLLOV?UIM_;&*WKGNP]C839N=3'R83=N7W;
M@,;MC,QY:):C%28K/5N0AQ603)P.'IS#*XF0@I<'W[KW4[>._-C]>8I,[O\`
MWGM38V$EJXL?'F-X[BQ&V<5)7SQS2PT29#-5E%2/5S14\C+&'ULJ,0+`V]U[
MK%N+L+8.S\#0;JW;OC9^UML96JQ%#C-Q[BW+A<)@<E79^2.+`T=!F,G6TN/K
M*K-RRHM)''(SU+,!&&)'OW7NFO!]O=3;FS@VSMOM#KO<&Y&DR$*[>P>]=M9;
M.&;$23PY6(8F@R=17F3&34TB5"^.\+1L'L5-O=>ZFUG9G6^/W!+M.O[`V10[
MI@J\703;:K-UX&FW!#79N)9\+12X::O3(QU>7@</2QF,/4(08PP/OW7NL>[>
MTNLM@314V^^Q=B;*J)Z45T,&[=W;?VW--1-4BC6KBBS.0HGDI6JSXA(`4,GI
MOJX]^Z]T\[@WAM+:6+BSFZMT;=VSA9YH*:#+[@S>,PV+FJ*J-Y::"+(9*IIJ
M22:HBB9HT#EG520"`??NO=/%%6T63HJ3(XZKI<AC\A2T];05]%4155%6T55$
MD]+5TE5`\D%32U,$BO'(C,CHP()!]^Z]T%NV>[NK-_Y[)[<Z\[4ZOW?F]O3Y
M>DW'@=N;VVYN?<6,JL6#3SQ3X3;V9K<C124&14Q5,53'%*C*5L&M[]U[ILS/
M=74V)KLIA,OV-UA29;;+?8[CP^8[+VO@J[#Y*MHUKZ.DS.'J\S-58W^+T_KB
MBK4298"3I92??NO=9Y>S^MTQ]#-CNT>M\/MK/UL>V=JY6#>>S),9E,R\0K*F
MEPAGEEI<GF5^YCC^Q1Y2R2"32+B_NO=.VY,_08&;!TF<R^,P=7N"6:DH:"OR
M>.Q]9F:G%44\T_\`"HJ:OH*ZNKJ6AB^\J/M740T415E""1U]U[I-5/;W5U+"
MM6_:/7E1124T,S54^^-F4%!/3U=$C4=5/EHJVEB,M28)(88X9&C99`;F-3I]
MU[I6[:W3M?*5[;6P^Z]LKE\+A*3^*=?[>S>$RF9VY'44-+5029'[&JFKJ2/[
M/)TS12-'#%()8G5F$BEO=>Z@578VP*3<^(V%7]E[1VMO6OJP3U_D=Y;9DWGF
MI,K3SU5-28_&5&8DS:>;3))%]O"'*Q-XK(H/OW7NE949_;FWZ*LR=9D<#@L5
M$?)797,U]-A8GJGJ)Z.*IK*BK2GA>*NEIV\=2SGS6.G4.??NO=0*?<\:86FS
MCU6$K,3+B9\_5;HQ^=H:7:SA(4FA-/D*V>03XF>*1`*M281^IBMR![KW2FPV
M6I<Y04N4QM;BLGC*RG66ER.'R464H*EQ++%-]K5TZ?;U$$;1V#JQNVH$"W/N
MO=-(W[L8[H?9`WGM,[TCITJY-H#<6'_O0E+*-4=2^`^\_BRT\@%U<Q:2/H??
MNO=*SW[KW5'7\V;^:SN3X89K9_07Q\Q&Q=Q_(S?>WFW769/L*CW1N#:?7FV,
MA65N"VE1P;1V08MP;X[7[)W#1U%-M?`_=4$%6]%*\\P4PQS^Z]U5/O'^8C_.
MZ^!&\=@;O^9F*VEV'L?LR:&KV#U;N38_3FRT[-H,=3IN3L/8FWNQ.HL]69WK
M#OC:^Q8*G)XK"Y[%9;&Y%:>:!:NJE@F:/W7NMKSI;O?K/OOH[K;Y$]>[AI*O
MJWM386W>Q=M9VOJ*.C2+`;DQE/DZ>/+N*J:DQV2QWW!IZV$RM]M5121,=2'W
M[KW0HT.7Q64H_P"(XS)X_(X\:[UU#6TU71CQC5)_E-/+)!^VINWJX'U]^Z]U
M"3=&VI'2*/<6">61XHXXTRU`SR23OXX8T1:@LSS2'2H'+'@>_=>ZFUV6Q>+\
M)R>2Q^.%0S+`:ZLIZ3SL@#.L/W$D?D9%()"WL#[]U[K+1U]#D8C/CZVDKH5D
M>)IJ.HAJ8EEC-GC,D#N@D0_47N/?NO=0)-R;>BRRX"7/86+.NL3IA9,I0IEG
M2=9'A=<:TXK&69(7*D)9@A(^A]^Z]U+JLKC**>&FK,C04E34)))3T]564\$\
M\<-O+)#%+(DDJ1:AJ*@A;\^_=>ZSTU72UL*U%'4T]73LSJL]--'/"S1L4D59
M8F="R.I!%^"+>_=>ZXO744=5'0R5E+'6S1^6*C>HA6JEBU,ODCIV<2O'J4BX
M!%P??NO=8_XIC;@?Q&ANSU4:C[NGNTE"I:MC`\G+T:J3*/K&!ZK>_=>ZR-74
M2F(-64JF><TL(:HB!FJ1<FGB!?\`<G`'Z!=O\/?NO=8:_+8K%?:C*9/'XTUU
M3%147W];34?W=9.=,-)2_<21_<5,S<+&EW8_0>_=>ZDU%334<33U=1!2P)R\
MU1+'!$@Y-VDE947@?D^_=>ZZFJZ2F2*2HJJ>".>6*"!YIHXDFFF_S,,3.RK)
M++_947+?CW[KW4CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=4%=X9';U+W7/B<Q68JN???SJR&S\9LK<>_TV/@-_&?IC
M,TF_,1N#8-32Q8KOK"83KFMR#G`U-74"I^Y9?X?5*[+#[KW15,=0_'/8VVH.
MOOCIN2JP>QZ'8&/SG6NW-X;_`,DV:W7M.7OY).QNV-S;&J_N9.R<]A-^826K
M_O9D;L&;%18N:IQ,,GOW7NC6]Z9E!B.WL[@.P=W;AR<N_/C\:O:F2HEP>6VC
M6TO4G8YS5=04>^:#,1T8WAC\G!D13ST19*/*I%%42T<N.FA]U[H"ESN$W#B-
MZ?'SKNKJ\EV-@]R]9=L4-9_#<G!L[:75F4GH(=G][;WPL]'AY*#=O88QM)!F
M<5F3N3&89<KCZZHQ]3`U35I[KW2DZ@[VV'T=O#I#86ZOB=@=R[@_BF\:SKN@
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M+O[^6;VME<7G<71=Z?$#Y3?&')TF/DP^W<WLW=.Y=L]O=HY;"8N-LC1]?[`S
M6$\^1PN-@D:2HW3C=R4$`FF8:_=>ZN'RW7FP?F]_PH)[VZ:^4,5/V)UIT7T#
M23=<]4[XI(&VC44F*VUT[7?W=PE")J)*^NRFY>V\SNK-31"6JKJ:GQE+5JU!
M04X]^Z]T"/\`+_\`B'\?^Q?GO_,R_EH=B]:IV7\&>JNU<!\B>LNG=S9[=D&&
MZE[IVMN*;;^,R6#JL-NG%9-1F=J[X,`68U+UM/@:2JK'>H999O=>Z2?\DCXC
M]%]A=??*3Y*;^ZGV77]V?$W?6=C^-6]J62KP%7UU"_16?D:KI,#@<W2[9R6#
MRLF\JRJHY:O'3T-1#.DRF2JAD,/NO=5__P`O7H[XM]B?'_KO%;V_DU]\?.RA
MR&=P'7U1\C^MZW+[;PW7VRL[3[+VYENM=]-MK/XK([CR'3]#F*JLJYWII*U*
M2J:"U.8IQ%[KW1W/F/O6+X9?S=^T:/XZ[.BH^R:SX;]:?$3X[5.&VUN3)938
M.2W+T_A9(-Q[FW9.,CNS>.`ZKZIZJJ<XE!C'J:PSXJ*>65U3(&+W7NKAO^$]
MVW_C?C?Y?.VMY=&Q8.N[,[#W_NFK^3^])Z[&9K>N^.[*')U$M5E]W[HQ=*AS
M,64V-64&9P8U/`<7E8IPQEJJB63W7NAZ_GA"BJ/Y6?RNI*I9*B*NQ76.*6&G
M&MI:W(]W]9T-'`[+25_@1JVHC#N8F\:DMQ:X]U[JA;X/[/\`YKG;_P`/=QXS
MX0;XV/B.DMU]B]O8/,M7;\VKL?>&1WBT#4/:F3R&Y,WU7V%OC9D^X]U9,_W>
M.+G6HHX*`5%686J1&/=>Z$/Y0_RU,I\(OY2OROS'<.[L#V+VAWIV5\*\?N_`
MX?$4<_675_4?5/R$ZPJ=E=.[%QN1PWEW,D5?-55N>KZNFB3<^7JO*U)3A([>
MZ]T57YB?)7>G>O\`+L^(G0VZOAQVUUGUCU+-T[3[<[\[(VALZ/H_Y#87&=75
M^V9:;I;:]=BL5329S=F#K*O*[?IJVBI*6&CHVT>:1H4?W7NC\?SQJ_%_*CY/
M]4_#J'</66U\;T1\?>R/DQD:KM.;"1[5R'8N5PN0HMG=:R83=$383(9W=FS]
MOUN-IM0I\ACXL\U12B8)4)%[KW1>^XN\*#Y`_P#"=#:VV90N?W+T]WMTQ\??
MX;N!=O05M+C]J;_V]E.LXJRKR4-73X6MP?26=PPEK#%3U,E31S(BQM)I'NO=
M%&W+UGT_W"GP;Z\^!'PY[/Z%^?VZ]K]7;@S_`'YN3$XOI3$]A[BBV=!G\SVW
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MH_?NO=$C[UZOZ6WQ_-S_`)A$'8_PL[E^=&`I^R:;)T/7'QIFEPW8.R]X3[/Z
M7A._.U-Q;5S&ULGF=LS9`5^(P]#E&R%)0F;5,($,,I]U[I6?/#XW_'CJOX4?
MRJL;T/\`&K>GQIVKVY\G-Q]MY_HKO'+9[=O:&PMV[[SG4E/ONLJAOZ?<591[
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M[RQ6*V_&O^DK*8[,"AK::2ES69Q<M*:.1)(K>Z]T6SXW]JX+M/\`D"?S#?C=
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MER-(87H9(IX9@OEII&]U[K95_F&U7P(H.FMH5O\`,0PVP<YT\G<&RH-DT>_]
MH[AWM3'N.II<ZNSFP.!VIB,WGIL]'C4R+AX:=HX:1)Y)BL*.P]U[K7\^5='T
M%\V?E%_+"^"'1&4RNW/Y:N]>NL#VK@-A]:SYS8'6O<6W=R9'MW>2U*[=DQ^(
MR4<6RGZ,6GH#E+2457N"L:"@6K--D*;W7NE9L386V?Y?G\SSO?X1]%9_?5)T
M/\F?C-V7N^KV1N/-YWL+&;4W;/TGO7=V'RR29B:OSN0R^WX.I\I2T^0KZJJJ
MZ[&9>+'3?=-1T\U/[KW5$/2'6?\`+RA^'6;?L_K#M.7YSX6@ERO1U)UUL?L3
M;W35!L^@VIUY3[:G[#EBQ.WNE<KN+[B.MES<:R3[E0LD@*9-(IT]U[JSWYQ]
M?[QH_B__`"0\/_,/I>RLMD8&[HPOR1R.^YQENZ,3TCE]S];UL.RMT4VT:O<N
MYLUV30=4G%T5?78V6HRU=E\:/OI2U14LONO=(SXM;XZA^/?S#[X[Q_E-T_<5
M)\-NC_@QWGVCW)1=ER=AXWJ67L##]<;KS'6V+W7+O"GJJJOES?8=/@OX'25M
MMSXNEQN;DI($P=0\LGNO=9-C_P`O39':/\I[M/\`F<]D=I]BYSYG;=WOV5W-
MMSY!578>XJ#)%.GNQZW8%14295<G-3KN/-1[2K*ZBSU)40MA,L:,X^6EHJ/[
M9O=>ZE?,_<6S_E=2_P`G?O'YD9"LWMU[NKXP[UVS\BLGL'86ZZ[>&]<;3[PP
M&U=Z;MV?4;.I).PFRNXLQ@X*N.EP-([T%37+41NM+(&;W7NC)_RGML[3@_FA
MY;+_`,M=^]4^`E#UAFE^1<7<53O3#XRHW;GMJ)/L7(8O`[QK8:JJRTF]L9!3
MXN&LQ5%F:*"ESYU_8-`DGNO=$E^6/96[-^_)GO7^;SML1_W+^,_\Q+K;H+KG
M-;GTZ<CMOH+;<M;%7[?6IT-M39M?4XS<^%KZ:-$J\Q/O%*@NPTB/W7NA\_G"
M_"KXI=2]C_'KNWJG/=BYF/\`F5_(_/[I[3J<UVEN6?`YK%=GY;K[.)E.IQ5Y
M;#IU/4R/N^.HBEHH%,U"HAJW*0PI[]U[I:_,WXF])?"C^8W_`"3>@.E,1ORJ
MVAC/D!F^Q*67<V]\YO+(8S<_97R1ZQR^[]T;EJ\M/"M3'G*[330//.@2<1^"
M&:8R+)[KW3O\:?B[UU_//^2_ST[M^5F;[)SNV>ANS-R=4_%O:E9D*:AINFZW
M)9C>>%?*XB:G@,.3I,!0;'Q=1'B*VEJ,:^4JZVO<5)J8&B]U[HEV>[AWOWY_
M*(V!T3W3O:IWOF^D_P":WT=T!@=R]L1[HW4,=LWM;:FZ,5U]@=[5&YI:+=6^
M-I[,R._9H!45]3/72[3BIEU354*Q/[KW0U?[,5FM[;"_E_\`Q.[`AS-9\C_Y
M?O\`-0Z:ZLQ^)ROV<6\JCI[%9/.;!VSFMPMGZB>>:3:5/35NWJJHI9ZZ6HQU
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M[G.3HJ3%2`F&HI(/=>Z$3J#<V:KNE\Y65W:DN[J2B^,.P-I4'6>SMO9/#8;K
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MT'W+T/E,O+@,;W%UIO+K:OSD%++6SXBCWE@:W`U&2AI(,AB:B>:CBK3(JQU=
M+(64:98VLZ^Z]U4)M'^2]N3"_P`O3YG?!?._*6FR64^76ZYMS2=S8+I.CVSE
M-F25%'L.EJ5R&W:?L*KDWS75,NRFE^]J<C35ZI5B&6>H6GC8^Z]TO?G7_)CZ
MW^;/7'QGPL_:%9U9VS\;-G;7Z\QW;6`V-C,L-Z['P,&VYY=M;EVE)F\53S8Z
M#<>V(LGB8WK)X\1-4UD<:215M4LONO=*OYC_`,K_`'7W+\CL%\R_BG\DLE\3
M/D[C-JKMC<&ZH.N]M]D[>WN,51_PO:V1RF,W!+#+BJW'8"JJ\1D5C^XH\UBI
M:>.HIO/04-3![KW0B?RY/Y;&V_@C0=H[VW3V=N7Y"?)KO[.#</=7?&\Z9*7(
MY15R^=W'2[-VCC#4Y";`;*QNY-U92O*RU-36Y"NKGFJIG6.EAI?=>Z#O^7]_
M*LD^!W3GRSZCQO?%7V53_)#<^?SFW,K7[!BVW%UAC<KLB7:=!@J?%KNS<`SE
M+05M1+7R'STJ33S2E8X_(;>Z]T0;IO\`D4_-_P"//5N(ZOZ-_G"=O=38"CH*
MZ?)X/8'36T\%M[+[TRV'CQ^7WM+%4Y[+9=<ME*VF@J9S)53NS16C>+\>Z]U8
MCUQ_+0S6V?GWM+YV[[[LQO8F>P'QSP'2^4VG7]9PTV2SF^<;L/;>R<SW1/O6
M7==;)'N7<5)19.GDIUQRK!C<@U/')^Y4O4>Z]UW\!?Y;.X?@9W)\ELAM'MW;
M^Y/C1WG6+FML=+'863Q&>Z^S&.R]8NV8FW5+O7+X+*XO`;#RC;:T4N'QC5>/
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M\JXU8A&I8Z9%]U[IDVQ_)UZJ[`^2ORX^17S:;9/RM_T^]C[8W5U1L+<VU,A#
MB>B=N;/H*?!8O#8W)RYMIL]65>"VY@E9S3TZT<E#.L9>*J95]U[HJ^[_`.1A
MVG4]!_./X\[*^3&S*;8?R<[2ZJ[.ZNQ&Z.NMTUV+ZMFZZ[*W3N:;!Y^CQ^_H
M)]SQUNQ<CAL0E=#-25LM=@:>MJVJ$9J,^Z]T8CY2_P`J#L+N7:G\OW</47<_
M7O4GR-^#^W.L]M)V?F.KZG>F*W3C^N\;LZMI:7#XM-PX.;;],-X;/)C%I&.)
MR]?3W1I`WOW7NA<W'_+>W#OSYD?-7Y#[X[0V]6];?+CX=8SXJ46P<7M.NH]T
M]>+#BZ"ARFXY=R-FFQ>ZUGK_`+NLI"U%15=&[1Q^5T5?'[KW1`MX_P`A+?VX
M_P"6-3_!NC^1'7\/;.XODKN/Y$]H=TY3JO(5>VMS55;M'?.Q]O[=H=DX_<V+
MJDCQ>VLIA8&EJZRHC$M'4SB%GE15]U[HR_\`PS'U/VA\L/DO\DOFAM_JSY-;
M0["VKT!UWT/U'4[7S.-Q?4VR.H=IC;V2?,S9#<+46>SU9DZJIK*.>%:9*6.J
MJ5LQF`C]U[H#-F?R%\?3YGYZ=<[G[4VE6_$GY2G8NZ^@=J87;65R_8GQW[$Z
MRS64SW5.Z8<IO/)[AV]NR#8B;GR..&LJV;P30T%?Y(@S'W7N@WIOY&'RS[RB
M^/'2GSL^9VR>[/A_\6]S4M7L/K':?6U;@\]N_:N'BBI<-ALI+7U7V^TZN3;\
M+;>EJ:FKW35XO;M54TV#J,5-+]TONO="[OS^51\_,=\P?E=\K_C3\T.K.D<O
M\B\B^)Q"R=8Y7=&Z-H[`679N6;'2Y?/2Y?`SY3*9O:($H@QD8I:>8F*=FU(_
MNO=+#N;^59\N/E3\6MK;-^4_RRV1V9\JNE^^-^=M=(]H46P:G;W6DVUMR['C
MVMA.O^P-I8!,%E$J<!E9Y,Q19O'.:_%Y>BH:J#R1Q/2/[KW7?1W\LCYP=B?+
M3X_?*_\`F3?*SJ_N+*_$BGRK=$[*Z.V1D]L8_)9?<V(RF.S.;['RN2H-N4LV
M0I*MZ&J#X[&1'(RT4*RF"&(PS^Z]T9VM^`W9]1_-PQ7\PJG[#Z]I^JZ/X\#I
M^MZ\&V<R>S:[.^'.0FN;=0JQ@O[JA\A33K2M`U1'/3L4=%EE63W7N@[VI_*_
MW34_S`OG!\C>W-S]8[V^.'R]Z)SG3K]94F&ST79>.7<=#U!B\LV:W%6H^%&(
M^RZ^K#3)C_!)35$M/,?),K2I[KW1$\G_`"9OYC5/L3?7PJVC\Y^IZ'^7AV'N
M:LJ<SB-R==YK/_(.EV]7?89'(5$^1@HL7@MQYW<&X<6E9EZ2HRE/A<I75-34
MS4W@FGQM1[KW0Z;;_D5]?;G^1U5_LQ.*ZT[1^#_4/Q<Z5^-GQ-ZB;+[]7N#;
M/^B>HH<O-O?M'?N)@V='E\CE=S5>9R/V5'/)CC69$3O!Y8D<>Z]T&F7_`)(G
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MTQJ:N6.**-ZB5RD:*0H]U[JN[^9+_*JV-\],EM/LS%[L'7W=6R-HY/8`K<MC
MJG</7':G7%;EUW12=:=M;;H\ABLO4;>PF](DS.-K<36T&1HJ_5J>HII)::3W
M7NJOZ[^2=_,*^2^Y=CX#YS?-O$;MZ?VO'NQ)7VGO'LC??9NW*?/UT%!4T/5.
M9W;M?9M+MW-;IV;2BDK]R9N3/97%2RZ\7'`REV]U[JP3YG_RM-R;LR?Q3[:^
M`F[.O/CIWC\/-K4W5_5E'O/%;@RW6TG5D$2T6$QM0F,DR>4ILWU[%69&HH?-
M35U)GDR=90Y=)4J(JNC]U[I%_&G^61\H(NU/D[\K?FKWWU_V=\I>V>K-X]*=
M/U75F'W)M;KSK/9>X]G4FW/XIGJ27^'29_*O68Z%Z&B2B^WP$$M>T,U959*H
MG3W7N@-ZA_DD]LX[^5'OSX+=T]B]0Y/N>O[WJ.]>N-[]92=C8#K;:&=CQ>T<
M#3P/'6PP[LB3*8&@S=+6K#$T0&89XEU*"/=>Z&3?/\N;YI]M;=_E/3=J=H=`
M[D[/^#>[6D[YWPE?VF:;LW:6'W7UY18S);1Q]5AGK<CO7>77&P(JG-?Q.IHJ
M>GW)(?%-4TAO[]U[J[#?77>S.R-B[ZZUWEM_'9G9?9>V]Q[3WO@YZ>(4NX,'
MNS#U&!S])7JJ#SG(XJI>%W:[%;<\#W[KW6M;E/Y0_P#,WH-@;Q^&/7WR[^.6
MV/@YNW=U)N?,Y2KZQR==W+N63+;E@S^\Z_-[6_@1V=19+*5]-'D*C&T.4@P^
M1R,6M?L8*B>E]^Z]T;/?_P#*1W9C/D?_`"G=W=![TV%@>@_Y=>V)MG;BPN_8
M<U5]L[MQ,-#04JUVW=P8?#28Z?*;MJZ45F=6JEHZ:HJXTD5+>E?=>Z:MO?RW
M/F%\>?GE\Q?D=\6^T.G:7H+Y5=1]C4L756[\SOS;.[=E=];HQ5-G-K;PH:G:
MNTZ_;G]V=O\`;4^9R7W&I\K38W<573PK(8:<>_=>Z+]UW_PGLV9MOX/8/:>[
MJ;KW='S\P/6U=@(.R&[([T/QQJ=T'=&2R`HZC9515_<#:N[MIU"8K<%7_!6R
MU49ZBIB9*HI.ONO=/G<?\J/YQ=O_`!Q_E?\`5^=["^..0[$^#/9V8;?FY\MN
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M>79--EL)M;*'9V;Q]5N7:77-3MS;6>W)3MM+`8?'8_;=9EUJJ^L&/\]?5)/4
MNR>Z]T*WS,_E*[M[H^</6'RNZ6W9M3:VW,KNWJ#<GR0V5GJNIQ<^>R?3G8.R
M]QXS>FRUH]H[C@RVYMR;3VU#BLC05E3BL?4#%TDLLLCO);W7NKVO?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UKT_/+>>
M7V=UC\W\9UQ@:==_Y_L?#[:VCO2/%5.6@V=V+W'@O]#^%SV&K,;AI-P;=WQB
M\?OFNKEK,8M17T`HC4QQU2>58_=>Z)YUW'U5UYUSWAUABL3UQAZ#:G8W66$Z
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MN]H[^R&&\LW36)WQEJ'`Y3<>'H=YTE)N^F?[*CG%'55?NO=;!&U=J;=V1@,?
MM?:F(HL'@<6M1]GC:"%8:>.2LJZC(5U0RJ+RU>0R-7+45$K7DFGE>1R78D^Z
M]TH??NO=>]^Z]U__UM_CW[KW7!T61"C@E6^H#,I^M_U*0PY'X/OW7NBT_*GN
M;KWJ3K',IOC;VVM^S[GPFX(<1UENS);?P^`WQ3XBBBJLU29_+;KIZO;.'VU2
M4]3%][5U\<E-%YHU*NSJI]U[K76^YVW\R-H=>G9VQ^O-J4&7RF[<YN2@VC1;
M@QFW*67;9KNP=@=;[:W=#2X7?RU^5>EES%!69>.KVS49RJJZ4X['UT%%D%]U
M[H2\CN&AWGVQN_=#[M[!V%VKUCNCIW8/;FVJW/X9<[LK>M=N!=\8GXL[#PCU
M>7V@-H;AQ&W::LJ,K3[BW12T:BH:HBR$T_D/NO=/GQ@VI-2?';`[WR_6O7NS
M::I^%."R>Q>QL+/AZ_<'8^R-P'$Y?.;DW!C<GN3"9?;F6HZZK2.2H?%RTM?'
M7SJG\/FT"H]U[JKKOS:?9>V:OY"[TS%'19%^G>NNC-R4FS\A08#`46_=K]G]
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MFEK!+$`-KM];BU_?NO=8(ZR)OM4F_P`DJ:M7:&BJ9*=:MO$H>95CBFE65H5(
M+:&8*#>_OW7NLR-(9)5:()&I3Q2:PQE!4%R4`!CT-QR3?Z^_=>ZR>_=>Z][]
MU[KWOW7NF#,;KVMMVIQ=%N#<N`P59G*O^'X2DS&9QV,J<Q7^"HJOLL7!6U,$
MN0J_M:263QPAW\<3M:RDCW7ND75=Z=)4(S1K>XNK*,;:SN`VON(U786TJ<8#
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MYM7>NP<WG\$^U*G=6$VSOC9^<R^WY=\45-4;<J-RXW%YB:LQ"9V*:`4#SHIR
M*RQFF$JLOOW7NL^?[SZ4VI@Z[<VZ^W^KMK[=Q>4DP>4SNX>P=HX;#8S-0ICY
M)L/D,K7YB#'T>5BCR](S4\DBRJ*J(E?W$O[KW396_([X\XS,UNW<EWQTSC]P
M8W*8K"9'!5O:&R*3,T&:SO@_@F(K<9/G(ZVERF8^ZB^UIW19:CR+XU;4+^Z]
MT]XCNCIW<&?W=M/`=L=:9S=.P'K4WWMK$;[VMDL_LE\:&.13=V&HLK-D=MOC
MPA\XK(X3%8ZK6]^Z]TX;0[1ZR[!IY*O878NQ-[TL6=S6UY:G:&[MO[EIX]S;
M;5'W%MV2;#9"MC3.X%)%-;2$_<4H8&5%N/?NO=.L>]-G34$&5AW9MF7%U-*:
MZFR4>>Q;T%11#ZUD%8M4:>6E%_\`.*Q3_'W[KW3`W;O5G\.VGEHNQ]AU.-W[
MGSM78M;3;QVW+2[TW+'55=%/M_:52,F*?<>;I:C'5*R4E&TU0AII04U1L![K
MW33B>_NB,]382LP?=?4F:I-R[@S>T]N56)['V=D:;<&ZMLU,='N3;6$GH\S-
M%E=P;?K)5BKJ*`R5-)(P65$8@>_=>Z?ZGM/K"BW#!M&L['V'2;LJJ?.U=+MB
MIW?MZ#<-32;7C:;<M5!A9<BF2FI]NQ(6KG6(K2*"92@]^Z]TC-O=\="9_.5%
M%@NY.M\QG:K`4VZ8\;2=D[6RE5+LRJDI(L9NO'XRCSM24VEE)*R,T^06,4]0
M7N)#Q[]U[J=)\A.BHJV;$R]R]54N<@W,FR)L#D.PMIX[-T^]Y9C30[+J\55Y
M:+(4>ZY:K]L8Z2):POQX[\>_=>Z<<CW7T_A3*N>[5ZTP3Q;_`*3JIDRV_MJ4
M+#LO)I238GKUA4Y:+Q[[RU-D*>2GPQMD94J(RL)UK?W7NI2]P]2/404B=I=<
MO5U.[\SU[34J[WVRU14;^V[4+2;@V/!",F9)=WX*J=8ZS&*#6TLA"R1J3;W[
MKW2WFRN,IYHZ>?(T$$\R121035E/'-+'/+X8'CC>17=)IO0A`(9N!S[]U[J-
M4[AP%%05&5K,YAZ3&4E&^0JLC4Y.B@H*:@CCAFDKJBLEG2GAHXX:F-VE9@@6
M1239A?W7NH%!O?9F5S:;:Q>[ML9+<<F!I]U1X"@S^*K,W)MBKDIX:7<:8JGJ
MY*YL#4RU42QU@C^W=I$`<EA?W7NE/[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZUO\`^9%C9ZC_`$UP
MY-<QD-OT?>?2&4RV&R?9=/U=6[AK\YGZ_;W7V!V?N9$I,1B,H=S5Z/ALBU;1
MYC%SJU1"\[+XU]U[HD'QTP(@;?--MG"X?9^=P^8ZHV3/LG!=:4746ULQD\K1
M]A;VV[A]M]#[D?<57UQC,3U57S5$NS,_7XK*[%KY)ZF$UZ[BC'OW7NK).Z:G
M`56UOD,:W?FZ\KFZKO'`;LW;@=UU.^Z;"=:TS]==J/A,YL&+>U#5YK&XNAC%
M%D8ZNFQ[14U?*K15,M-!2FE]U[H(]HU%9L;<FY_D-4#<>Z*7KC=/76Q]Q=2"
MK>KZLV%C!B:/^[_9/7NY)X-M5==OGL>LKF_CE7E$S5/7U>7J8X<=F"],E-[K
MW67K_P"'7:O>N[/C5O7!;#PO7&W]JX#?_P#>C#[4[-P-3M[K^DWCB*F"EI-Z
M[<AFRT>_3O[(QI-NFFQE;FVS>[-IT590[AVU##$8/=>ZV*-C[:GV=M+`;8J<
M[E=RSX7'Q44N<S4\E3D:]D+-KFFGEJ:IHH=7CA\TU1.L*()9II`TK^Z]TJO?
MNO=>]^Z]U__7W^/?NO=>]^Z]T!/R./3B=5;AE[PQ5)F-F_;U%,E"L#5&YILG
M64-7!"NP4HY:?<(WU'2M-+CFP[KEXY8_)2$3(I'NO=:W*4=/G=N=;/\`$U.P
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MZ*NFFP>W=F_'CLK#_+#XN[+P>_\`);4VQE-HU7^E3"MAL@:YGJ<7M;,I73R"
M"."N/NO=7/\`\O7=>5WAE=R;@R^3^_KMQ]:==;JK($GR%70XZNSU$M16QX>K
MRNV=H9>KQE;5I)4QRY#'45<8Y462%0@9O=>ZM(]^Z]U[W[KW7O?NO=,>YMT;
M:V5M_,;MWEN+![2VKMW'U.6W!N;<V6H,#M_!8JCC,M9D\QF<K44F-QF/I8E+
M233R)&BB[$#W[KW11C\Z>M\K0Q9OKSJWY+=N[5J\)/FL5O#K?H3?.0VWG/MZ
M[)8]\7A:S/TFW*G(Y.2HQ;F+1#]O/$\<D4KQR*Q]U[KE/\UL3`E<?]EJ^9$T
MM''++#30?'K<,M1E%BIJ*I*XI17Z*IV%6R*I9"7IYA_8N?=>Z;O]GLVW]TM&
M?C?\RUE:FR51<_'/='C#8F:CBK*8R"J*FI"5\<B`766+4R,=)M[KW2@@^:&T
M:BFJJA.E_D^#18ELK54[]%;I2JAE\=+4Q84P$ZGSU1CZL5,=,MRT".;AD91[
MKW4VK^8VRH<=25N/ZK^1F?J:F2D2;#8+I'=]9F,<L\U5#4SY&GE@IJ>&GQ)I
MU:K997\23QL-08Z?=>ZC?[.AL,5HHWZN^1JWM&M6O1N])Z)ZUZVIIZ?&1STU
M+/Y<C5T%-]_'&H-Z&1')#MX_?NO=9?\`9RMC"KQN/;J[Y&K7Y*6IC-(.C-[2
MR4"45EK:C(O!22P4]-2U+"%G5WO+PNH`L/=>Z>(OEAL^4UUNM/D'HH<G0XQ7
M3I'?%1]^<A4UU/!78Z&DQ]155.-5*'S23>-1'!+$[`!Q[]U[IX3Y-['=,M*=
MI=QQ18ABLTL_3^_8$JV$<#Z,=Y<*K5LAEJ%BTJ-7D-K6]7OW7NNJ3Y,;5JGG
MB?KSO>BGIQ,STU;TKOV*J:."*DG:6.GCQ,LTD30UBLK!;,%>W*,![KW6=_DI
MLJ-9S+M'N6)J>&:H>.3IGL1)FIJ>:G@FJ(83@/)-`DE2/4@(*J["ZHY'NO=<
M:;Y+[(JVTQ;4[C`%3-1R23=-=B4\,-3!1S5SQ3S3X"..&\,#!2Q"O+:,$R,%
M/NO==0?)?9E0U2$V7W<BT@D:6:?I'LNGIG2.6G@:2FJ9]NQP5<9GJ`@:)G#,
MC@?YM]/NO=)O_9N^M9*U:&HV3WI3RO64E/A7K>B.RHAN&HJ*$UY?;,;[>-3E
M314NHS^*/5$%<D:59A[KW6%_EOU_C`\<^P^_VN*><UG^R_\`:$5/D):QW7QT
M#+MH+7UZ1QEV@A#2E%NJGW[KW3B?E%U[DA#'#M3O!:L5D2+'2=)=C39&GC^Z
M!IYYDAVW5-28W,"F9$=](ECU+PUA[]U[KG3_`"PZZ>NCQ4F`[;>O1RE<\/2_
M9BTF/'AEJ$J*YY-O%Z*GGBC!3R>ME96MI-_?NO=2U^5'77D@67;G<--!4I6R
MT]=4]+]EQ8^>''Z!4U$-:=MF"6!7D50RDC6P7@D`^Z]TX+\F>M66!UI=_F&:
M"EJ9*@=:[V-+0P5J*]/-DJD87P8^"3R(HDE98RTJ`,2P]^Z]TG)/F3T1!093
M+5F7W?CL/@\G/B,UF,IUEV)B\7C*Z"*>4135F0VS315'W(I95@-.9O,Z%4N2
M`?=>Z*Y\B]M_%3Y9MM[=.\=Q]UXV+![?R4.S\]L_KC>F)R.)K*F2:##]@[2K
MLOUYD,IA-V[<S>4BFPU=&D?DK$6(1U4;R02>Z]T7&C^/_P`,<?2;)PE-W?W/
M+M;9>W^U-@=5[;FZ8&7HL;M3M.!L'V_#G9J7I:6KW?EPV=7%Q9+/,3MB5HZ5
MXTJI:HU?NO=3Z?X[_P`LG%^-\]4[ZWOM2?"43YK9VXME=H[UH<UD,G3';^V-
MWU-+C-FUE=M;(T^/R224HQ:8FD:LOE9(C6&2J/NO=(M?B+\)ZW.IV-F.\>V<
MOW94;3V=M/8'8HZ3R-(-AT74.Z,'E=AYNCZ]I>IS@E[5V71;7H:>IK,C$*@5
ME)!DQ14U;2T,]-[KW4/</0W\O"'K?-[.I^T>T:3:S82LZOV+B\_T5NK=4G7^
M%W_V;UQW[%MO%8S_`$1T.X\WLC);TZGER+R54LE%+3Y:O2:L\CQ.GNO=+#_1
M)\5Z3<'8NY\M\B]XT.Z<_C<3N;"P[5^.T&WGV3N3;F]^E>W:W>DF-I>N\SD]
M_8ZBW=T!MZIHZ7)U-=28:@2J@AD$M3YT]U[H!-S_`!3_`);LN\-A;MI/D)VK
MANP*7O[<':^+AKNEMP;FVWV/VWE\3M;=TU=O#8&<ZDJL'N>LVUMBGJ*7&UL?
MVD=+BLE%03RU,=#0QP^Z]TQT?P\_ED4M!O;8U7V3V-F,-O,[SW/C*G(_%+M*
MH[,ILMNO:]'U_09K>G9E-U-#4;]VOL^JQ<D^(QM?3T^,'W)@E%12&")?=>Z-
M%O?"_P`NKLS>&^]\YO>O9PW#VCOK-YC.5>RN@.Y=J/D-\IT?MWI;,'(UFU.I
MZ',Y[')BL7'DUH<_4U^,J<G5M>.HB<1'W7NDKU9MWXG=?=7[7VITK\F-]]>I
MUQOSN+<^W-]8#XI]@8*NJL;V]M.MVAO&ER%'_H\QJ;EWWA0L=;3[F@,=5#7T
MT/W%/-"?"_NO=!DOQ8_E?ICMHTFXN\/D#N;8W4U!MD;?V-F^K^R)<3C-DU67
MW#N*/;>\,50='TM?N&DW5AMU5.'R'\2C:>KQ!AIZA7F42O[KW2LFZ@^%53U_
MU[T_E?E+NB;'[#RG9^USA-M_&C*85,3M;?FXNO\`/3[2ZOP&(ZTJ:GJ+>6T<
MKUCBZT9ZA>IR82NRM5.HCK*23'>Z]T+N7VA_+7/2?6?2@W-D]O[>ZVINT,-C
MMR4O0N_DJI-V]L]8[CZHWONV7(93JRMQV!W)E:_?*Y&*:)X8Y,U%31CR%1&?
M=>Z0E-U=\)-O]B=N[AP?R&Q\FU^\<'V]B=\[7[%^/&Z.R]YFH[:V!4[;JWV'
MVENG#MNB/`8C;SU55N:FK(L[+D(2XKJNCIHR@]U[I/YWH#^6YNKK^3KSLSN7
M*5=+D^M,5\==W[NV#T7GNI,55=4T/=#=PX;K3;.\=L=;RC8>PDRL^+Q5%)3Y
MN6:?$8VG#5U1.9*EO=>ZS9+$?`C'=J=%=TT7R1P&.W_L3M"B[=SVY=]_%'-9
M_<W;M1G.O.JNHZ'<&X<O7;*P-=C]R;GJ.KX,Q3;N"2U5179&JJJ%TC99%]U[
MKW4G7O\`+LZ\[9PW;NY/DMD.QJW9VY\CN?K?;E7T_N+$94M5;OW7O&DW5V/-
M0;(K=T=O]D;;W%N"L2/=LD=#41XF!8*E''W-14>Z]TEL+U9\*H-V87/8OY:;
M<DW!@][=@Y*HQ=?\3,@7R.SNRI]U9']_'M@Z'-Q?(#'8S>=?`.P8Y1755.*<
M3XYD@5&]U[I9[DZK^,&87:F1[,^;N]DW;L7877W36U:O9G26>V7@<'U]L:/&
M[IV'#G]H9';.\ZIMZ8O.X*;*1YVIKJ5()JNL@@IJ>-Q%'[KW23K^B_@M'%@*
M+%?-KMO`;5Q>[<AM_"[?GV1N26DBV#7=DX[LS>G4==52[$HI'Q$<NPML4.W*
MZ01_W>QFTL:L"U*M4FK]U[H>/C%/\0_B!V%G]R4'R.H<Q@:[8U1M/^#93XT;
MAV[NF"MI]QX*>;<,?8V*VI'D*S$5E+#2)7XVGIH\54Y5Y*^-8#^Q'[KW5@%;
M\\/BACFD2M[9IX/#N.':50YV?V`\5-N"H)6"@J9H]IO#3"64>,32,L'E(37K
M(4^Z]TFZS^8[\,*"DJJ^H[F3[.D%;JJ:?K_M*LBJ/X;((LBN-:CV1/\`Q9J!
MF!F%+YC$A#M92#[]U[K+2_S%?AU5SO3Q]MU,4L=&]>16=:=N8]#3)C8,PS1R
MU^PZ:*67^&5"S")6,I17(4^.33[KW3A1_P`P/XA9`E:'N&FK'7)1XF6.FV9V
M+-+35LT*SPBMB3:!DH:6:)P4J)@E.U^')]^Z]UQKOY@_P\QLE=%6]U8R&;'Y
M7%X*H@&U]^2U$F;S=%3Y+#X>AIX=JR39/*Y3&52U-/3TRRS34RO*JF..1E]U
M[II@_F/_``TJ2%A[;KF)RU9@E#=6=QQ^3*4$=1+54T7EZ^3RK''22$2+>)]!
MTL;>_=>ZCU'\RKX5TLBQ5'<53%(T44ZJ>K^XB3%,NJ)_3U\19UY_K[]U[J.?
MYFGPD4%CW-46`)/_`!B[N0\`7/`Z])/OW7NG>7^8O\-X(I9I.X'6.%Y(Y".N
MNUG(>*DHZUP$38S.X%-7Q&Z@@EBH]2L![KW3_+\\/BA!-/!+VQ"LU.U.DB#9
MO83$M4Z_"L17:3"H)T$MXRV@"[6'OW7NL"_/KXDM-D8$[<@>7%1R2URILSL1
MPD45(U:\L++M$I61BG0^J$R`OZ!Z_3[]U[KE_L_'Q(\LL![AH4EA&6:1)-J;
M]B*I@Y*6+)R7DVJH:*GEK8U5A=96U",L4?3[KW67_9\?B;Y**)>WJ*1\A)D8
MJ01;5WY,)&Q+TD=>7:+:SK!'"U=%9Y"J2!B4+!6(]U[K&WSV^)"U^9QA[CQO
MWVWYLA3Y6G&V=\EJ>3%2K#D?$PVP4K8Z21AJ>`R)8@@D&_OW7NI:_.KXG-6P
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M2JTG>.S$5[!2TF2`;5%'.+?[COS%,K?ZS#W[KW6$_.GXAH4,_?W7]'$TD435
M5?D:C'T,!ED6))*NOKJ2GHJ*G#N-4LTB1(.68#GW[KW1L/?NO=>]^Z]UK[_.
MS9E-VGA_E%U1AY]PX?N;L'?*;?Z'W%@MM[EEI<;V[@]FYGM#J7*YW=-10YN@
MZ]Q&![%V!0$9:?\`A]!65=4(:20G[@'W7NBB]<2[)K^J^P>T-RX?MG:-+\JN
MP>O>ZNI-@[VP-?MW-X+X_;:W!M'I#K+K;?N?FI:VCFW`]8N9W;)2YFHK,SCL
M=G*:**5M0@C]U[HY?<5?VFNR>QVR,^V,UBL?O/K.7JZ/:&2PF<W-3QXW;7>M
M%58+>6!P&:2`4NWZN#)8^L@I:^FPU<D"P8^&)WK(S[KW0.G!B'<E0>WJGS_$
MVASVP-DX#8>/Q.ZJ>IVOV]M[!S;GWKO%L!N6/<>XMQ=`QS55-G>NZ;9L]+N7
M%93'4U-3S4U`LU1)[KW2,V5C^SL]W1\4\A\=ZCM/`=:?W/S^XJ>6@I,YN&3=
M^U,X^)JMK8G'T^T*E-D;?V+NV:DQ68VK7Y%]O8G"X6+/Q9G%;@KTFIA[KW6R
M_L,;U7:&!_TC/@7WL:$-N'^[*U0PB5KRR,L%$U;:><T],4CEFT1)-,KR)%$C
M+&GNO=*WW[KW7O?NO=?_T-_CW[KW7O?NO=%H^5O2/5/=W4N?Q';64Q&U\!A\
M;DJV;>V:?&QXS;&,G@1,])F4S4\&`R&W:Z@A"UM'DO+CIPB-/$XC4>_=>ZUR
M,13=<_'?IWJG;?QG[+P';&U,%0;CW9M/)4D?8SX[M[(8&NW)B]Q[_P`X,!6Y
M?LS:\?376U-#MO:.Y<G4RP0';C4V%8U%12XT^Z]TN-YX'']:=BYG(8RG3=F"
M[%JNM,]N&?*2--W1V=O3#3UL,'S7@RV>7&4=:-HXV"&@:E3$8]8S42U+^&6:
MH5_=>Z676NY*[`_&[O\`IMQ=M4N^<SB?BMU#)A-BX/:67R.#Z#I,IU5LK<%%
MUC-EJ&7'X7=SY7;6%.X*05,0KZ^/&"JIJVJ^XJHQ[KW3UU[C^LLG%L;=&Y]L
M]\9'<F`WG\ILAEL'0]X=3;^VKLS#[WZUI<#'OK<V]$3;%!2)-U_+%'AMHY.I
MK:6"/-G"U0R1I(%I_=>Z/I_+@FJ*A:N6KSF\L[D(.H>L\3F*OL',;<W=OULM
MAZ&.DF&^M][`IZ+K3>&X8:8Q115F#@2BEQR4[QLZMK;W7NK5O?NO=>]^Z]U[
MW[KW56_S.&3[-[^ZRZBW#C9:KJ[KC:6#^04-%34[[@H]V]S1;\JMO=?4>[]F
M?P\IN3;^P,'@LSG<92R355#+N@8RHK*&9:&`GW7ND_X<YF<I54BU612KJLCD
M,;'E_P"\]"<5FY\/6QUE1#2R;@VQN6LCK?X<TDM359*GBG"QJE*WW-V]^Z]U
M%K<3EZ:DCR5/7U&"R<T>9J=L2Y2/#92/.3Y5J;'0U[KCL-]U@:7,14S_`';U
M,E-))(J,]/-)3%7]U[IFR&6S6)QV6R&6W!N./$U.X,)FWR>-QV4RU+0*E12S
M5VRHJ+:FW8I<]C9\C5I*V6D>C:GH8?*OVD*K"/=>ZE9B?</DQ/WTC01UT<-)
M6U^,CE;+_P"Y&3/5*0T6,AV3AJ:6A+S.\332BI*58'GHG,L?OW7NO9E*K`9F
M;$U57EZ$C^(X;:@Q59O/.XFAQ\:5.$CJ,/08JBKOM*N2GK#)6UYJJN%FI_`(
MWBDCJ5]U[IOJLON*"&K^TDSM'@MN3382CV[BZ3=);*UV9VZE%6;DK8*BM?%Y
MT_QJM>OKZJ&DKLBC"9J7R".2-_=>ZX"JW+C<;+1X:NFER,CX/=D^*P]#N:7`
MU>3V^N0?.5F-QU+31[DPE'2SNS-'"U3/%3WFC$KO/22>Z]U-3?%34[YRU)19
M[,RY-'PV8QV)ILQN?(3_`&7\,I\Q4PT=)2U.**T%722R?PN.=:FNIU,IB(:1
MX![KW2BIMZ;UJVG\68S3UNW*F9*'/4.`S5'22FGG>+.9%9\W_$IXZ;[RE%)6
MBBFEJ:6%`1*JU",GNO=2,MN_=%3D)JJ;#Y6MABCK/M<,=LY3+Y1*&J..P^)@
M.W:;/OMRDG--42S6F%:\%-4S/-:GUSR>Z]UAIMY[L@BK(9\ACLG&Z55(<3$F
M9PV(I4IZEHZ.1\?00^*+^ZM+2`UT52E2E'3(AAE=GD1O=>ZD9+?6Z<=D0*$9
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M)34<T@Q-/FG^U%)CHJJ*L69*EV,K:_?NO=,&W>\J+<45%3'#"I-=@<?_``Y\
M=N_95,:^>OR#&@HJ*DS=(U/'DZR##U,L==3S3XRDQ-+%-)&KL8U]U[J/6=YU
M.`RM-0UV)PNXW.-QM518^ERM9GZ^OAK5B?:ZSXO*0T<U/D<_#2Z\:PD2*B6C
M*M-'')!Y?=>Z5;]ET=;046?BAKL]CX*+);CR,FW\O2;EVIG<3M*LJ),QF,;6
MO(<;155=/")I)J^4R5K034[2&>)6D]U[H'>D*;^8/\E.N-I?(;J_<GQ4Z+ZM
M[EVWMCL+JO:79.W>Z?D'VU6=<;A%'G]D;E[&[&VKW)U)M2+)9O9DM)5TFW:'
M&5=-MXU30/D*V822>_=>Z%&'H/\`F4P0T*1=N_!&%Z:5FG$'1/R1BIY8_.E3
M4R"D/R=DI9<MG:J%9ZVMJ$GD:4@E9?%&??NO=/G^AC^9$[5<LG:?P7#OCWIL
M<HZ0^1%J:K%<AAJ,R]+\CL?_`'EH/X>TFNC=:934:&$@52#[KW6$](_S(8'J
M9:/MKX0//D\C4RY&3*=+_(W(I#B4!FQV/H8&^24<9K#4QQQUE2VG[N`L6C$I
M#CW7NF+*=!?S#H?O\K2=K_!K;5;54T:5F:I^E/D-D:VEJ7R.0DJ\I0M5_(=4
MHY)<=6BDCAA6)8HY'TO98U'NO=`52Y#Y5YKL3+=)8'Y*_!#,=CX3L3';$RM)
MAOC/\GY*''[[HMEP]RY;KO=N]L+W74;7H=VCJL?Q)<?/E(JJ*DDI3-"XEBB?
MW7NF?96\_DIV?V!!UIU7\JOY<%3OK(U/;$M7M0=!_)?/XW?U9TOO&'87;7]S
MMW9COO!4&^*7IWLO*4U'G\=B:BOAQ-=)'251IPL5O=>Z8-E=O]S]BY;JW9?5
M?R7_`);V2WAW7N?O':&RL9)U'\M:/=6^=W?%JFR>V^^</386O[=Q^0VG5=;Y
M:O%/D(<DLD='#51*AJW:DD/NO=,E5V-W;DZZEP;_`"9_EHY3,#Y2)\'ZO%3=
M3?+?#U"_*-=HU&\=P]3R/3]QU.1K-WUNS::HKJ,53_P]:31(M9(-`/NO=/U;
MD/D/'VC_`*!:CMC^5X_;>.S=-L38VVY>LOERF/P_:\>RLKV=L[JJIW$_;5=M
M6BWCBNG8J_<`PR5HS.3HI&K_`.&Q4Z:Y/=>Z?-F5GR<W9V7N#KK8';W\N'<6
M_=H=F5/7O9VTL9M/Y>OGL%VEMO9N-WYF:/<N1Q_9\--B,A-LO+)D*"DR$0Q]
M6`)J:262&2-/=>Z%'?O7WS7ZQVKGNP>Y=_?RW=N[`P/CCR>4RVQ/D3A,71T]
M33#$;22>5>TV7(Y[+[UKL=C$IHH6GR$,L4$0GJV2.7W7N@"WEV%\A>HNG-H;
MFW_VG_+RV?UAVQ_#:78&YLAL#YHRY;<&[,_F,*_\`FPE?7Y7+T65SNX*^6+&
MXZ2GH\D,DM*D4$M1&Z+[KW3AV%F_DWUENK:6&R?;/\LW9VZNQ&P^\=CT62I?
ME))D&VIN#.;5V)A]R9SPY7)/L_:^]=X[KQ^#J<AE9*3$9/*U%%2AC/(]*_NO
M=._;,'??6>XNO=B]D]B_`O9F_P#<5#M"F7;]6?E1OZ@^WW=O)]FXO^)8>.1Z
M3;VVMT=G[BI\=@<GFWHT>N>6FI93)3$)[KW25S--\ASVKE>F#W)_+\KNT*#?
M>W.KNQ.OIJ#Y49J9MP=Q==;A[#V+B<AL_$9'[/#5NX-B[5JLM$\E4,50T0JF
M1J:3P.ONO=&(J?BA\\Y<YMVLIF^#T$$NRZS:F],K5U'R-R&3^TJ\3D$FPNV\
M5!78JAEP59E11I,:ZI:9Z5&9Q)/&C-[KW2CPW1/\QBARE:TM+\(*7%54@I!+
M1[[^5=9D_P"`T6+I:#&4<:UD,28K)AJ3]RIQT]'!>HE<T[EBK>Z]T[4W2'\P
ME)*P21?#.&BR&0^YJX(-\_)BIRM5#!%224Z9#<%?CII<C%6Y!)I\C3-3)!55
M#0U$7V\D3K/[KW4/)]&?S#ZVB)@I/A,,K7TW@R\V5W[\J<I0I3#)?>08O&TU
M/%B0D%$@U+4.-4DAC`BBC@17]U[H/NWLA\K_`(WX3%]G=W[0ZYW'TR-W=?['
M[!W/U%W5W=O3L?K;$;\W'C]ET_8XV9V-@=OXG<6T\1NO-8\Y>DQ>5P]3C,=4
M562'WBT\U/+[KW0VYS9N2IX3_'=[[@;+4^1J<3E:W!S;G3%YG*4#Y/%2_P`:
MH$K*Q?L<5'5^:I*QS4M56I!(REG#O[KW3!B]K;OS&0JXZC>V;FIJ*II\G1;C
M>+/8.HIMZT=?1F.NP%3"]5A=MXFHPV*@HG:3[<T\1DCG@#2A_?NO=)T;5S4V
M2I8,/O-5HY<EBL/2UE16;PS-37K)EYIVP^5I:3=$])B%@^ZCRR5E09OXA422
MJU='$SA?=>Z4J[1RV!HLQ%393.5^=;.1Y]ZO,97?V3K*K>6$IS5XU(YQF<'6
MY+%&C>>:GI-,E*<I``8@&"Q^Z]TTG:VZ<;V%\=\]G=WY7.'+_(?8E,G\+GR$
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MTK3X?IP;'R_:E%A\Q@,?O+^[4>Q:KN-Z#+[9,>ZSMB+.&-*F&*I`-,[0O[KW
M0]?RSZ[Y4YCK'([E^0N[.R][[.WCLWHG>W4^YN[(.FZ/M;)Y'>/4V&W)VU+6
MX[H_&8C:V)V'_?')QC`T5=3QYFB/W<-0!"E,H]U[JR[W[KW51K_*CY/[*^:.
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MJIO=>Z#_`*L^<'>-%\>L]\B*+Y42?(#:W4O67P!^67RDH*/:74>Z,QL'KOM+
M']F9GY>=5=>8?JS9N$R5%5[:VU@:/,XS"9<U6Y:"EHI*>.KGFJ(Q)[KW5UGQ
M1RO<^?\`CIU)N/Y")14_<6Y]IT^Z=Z8V@I8:./`U&YJJKSV)VQ54]/1T%.N6
MVMM_(4F.KFCB6-ZVEE92P(9O=>Z'7*KJQ>24Y.3"AL?6*<S":)9<3>GD'\3B
M.2@JL<)*#_.J:B*2&Z>M66X/NO=4*T'SGSF:ZUZZZ[I_FA-_$-L_S`INA>[O
ME=!A?CQ3)6=(9K$_(??_`%5DL?N'^[=?T!C*C?&*Z[P&*J*^'&?>01508TD<
M]9#,?=>ZMC^&W8FZNV_BMT'V=O;<%#NS=6^NL=K[FS.Z<;AHMO4&Y*G*T"5*
M9VDPM.!28^'+4[I.$I[TW[EX28BA]^Z]T+7:>[*'876/8V^LG4YBBQNR]A[O
MW9D*S;U'C\AGZ2AVYM_(YBKJ<'09<'%5V8@@HV>FAJ@:>68*LGH+>_=>Z)+_
M`"\^V.U>X\-W-N[=7;6%[AZCJ-W[$DZ&W#5;KZ"W5VIC\'D^I-E9S?F%[4?X
MT(.JL15TO8&3K6Q%)&\N2CQ;QFJ=@87;W7NAX^:X=OB#\FUCIVJG/1?9X6G6
M>.F:4_W0ROH%1,#%%_KMQ[]U[HR=!_P!HK&X^TIK$`K?]E.;'D7_`*>_=>ZE
M^_=>ZIE[5P>6W-\H-HT<&YMCX"OB^5>3J<5!N?LW?/762S."P/1>]:_=>(P6
M'VQB,MMSMN"JQU0BY?"YVHHX:7&M)-3203E$G]U[HHN^XMPY*!<WOCM+JKL?
M(Y/977M=V/7]?[^W)B=_87>F/[FFV]64VV.M\1@MN]7UNV.V<'BZ>DS6;^XI
M:JGW,J.E`BR/++[KW0M=K4SXKJ7>NYZGJE]JT#=T]=UFW:S)9&LK,5W'@ZGJ
M_?='3T^<H*[&8S*8+=5'COLL9DZ6I2+)T.X\/%D#K>*GJZKW7N@@H*"MW[7Y
M_P"/]7M')XGJ3=&8ZXH-J]IU68H,Y#V'G*6JJ<PWQIV?GEK<KAQD?C)GH#49
M>JWL^1Q^Y?!"L%0)8X:QO=>ZF8/Y"=R=2]\].;3Z(WMB.P=I=L97?>8[#BP^
M#V-002YT)-+0C/9FKJZS=W8O9U#D\73X?+TN7EI=W9>IRXJL3!5T<,,A]U[K
M8KVCD<YE]LX/)[EPR[>SU;CJ>?+89*DU<=!6LO[T4,[1PRM`Y&M!(D<R(P61
M%D#*/=>Z47OW7NO>_=>Z_]'?X]^Z]U[W[KW10/F3\<=T?([KN#`;.WY5[-S^
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MN;:Z!VMO*/?_`%)A=O=+[H[/K8<?LNBWONS8G\P_N?&=#?'W8VQJ;:QVYF-K
M1_';L+<T_8\>4(6;>%5/-2HM-$/)#[KW5R/\MK%-MK(]@;,.XQNF/9F`VU@(
M=R1;4VML"EW3+1*F/R>7CV#LJ@Q6SMEO1Y7&2TBXS#TL&,HJ2.GC0-,*B23W
M7NK8/?NO=>]^Z]U[W[KW5=?R`S62VW\BLWEX:?&R8^3H'8U&:N2:>DR^*R$'
M8_8V0_C&+J:-I:R2HPN.CFK%@C2-I!"RAGU:1[KW20/9>6BGK<A68FFI<#3P
M5`W1/-M_<>)P=6,()WQ\FT:ZEQ;',_=8^J2=9#`7,H*1@MI'OW7NHV,[1?,8
MRJ\N*J<5A:"MF*Y+.TV?Q57283%U%/D:FJRU!2XV3<.2W)%7SU,)CD,:%8@`
MS(6]^Z]UC';LV+I*G(UM!E::FQFXZK#FO>$RX<8A,97Y?$[EQFZ\)3R5N6HW
MAQ[_`&VJG&N227'U):1(E;W7NG4[]K6IL<*6CJ<E"CKF$SW@W'1WQIPWW[0M
M10(^-H6H,=#415;4WW%66'W31F(M[]U[KBG9$QQ.*GH\7/A<+D*Z*OI\?39W
M&U=7/3TU;/0X>7'TE+7M3YQ!+1Q/MN:F:"BRU/050G<J]V]U[IJ?>N-J/[L4
MR4M%25NZ\A.V.Q^Y,=0P2[L.+RV3C\=10R3F?:]3@\E2&2F1%@-"T?AD/CE)
M]^Z]UBDW_M**J@GJMR;9>CS+563HLS0TDU%`M7'K@P^(Q&0JJ[[BHR.2^R\6
M5-)4,E)EJ=9J6%S43*/=>Z46)W1UD/NX)*_:>$S5-@L<TJ8?;F+Q^5V_3SX[
M,4&"ITW!01K+2KBJBIF2FEE*5%-FW:FD6+R%/?NO=3H=P]>U^!RR4.Z-JYC`
M08J.OP53'NG!>*MQF.E?'4E74O2.8]OY23+T,T%=!CHI8JR9J9O'*[(1[KW4
MH5_7=35+CI*VA&2DIW\8VA#A),M35(V_15:UU3-DWIL5E*1*>DC-(`\;)Y'9
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MN;R99,KC\:FVZW<]+E*W(5)HZ>;'`TSTWECQOWTC>=&988_?NO=3YME;+W')
M1[=7)_?5.':.*.L^\QOW<]`9Y,-CHJB"GION,O08U*OQU=%CZMXON9V--`%E
M"1^Z]US&R\%)+B\34;DW!4T\%5E:3<=?'NDT>8BF-/C\30&JIY<VN3BP>4:-
M%H@T3U)8BGR$FEXG'NO=1_[D8+$SYFCW-O0Q;.RV)EVQ4'!5J[8AS.'S%#7P
MXO&06W7-19BIQ"09"6MADI*2CKP\<,*,ATK[KW0:_'SMWY-?&GH3J'X[9[XJ
M2=FCI+`[:ZEVCVWU9W[T)MS8/973_6N+Q.V>O^T*C"=E[TVGOG:.X=T;8Q49
MSVWWQ=1#C<G'/%3U]33O#,?=>Z,ABOFCV!4U<.,S'PS[UPV4BI/N<U!#OWXR
M9REP;^&6=H*JLQ/><XG:-8)(W:-"L<R%6(4%Q[KW66F^8_9"3B#,_#GM_$MY
M=$FCM?XJY+P1'0PK)/M>^`&HTA+.[1F1PH&E6U#W[KW6>G^9VZYFBA_V4KN^
M6IFJ\CCT&/WQ\8\C2"NQDCI5T;UD/?2*E12DQ)4(5U4TLR+(%#!C[KW3+E?F
M'O:6&::7X7_(S(#$P)75^,I-X_&@-CZNG@C=()S3]]H]56U%6]3%`BO)330T
MR5`(6:(GW7NBC]/[JS'0V_NU^V>M_CA\Q-O[>^0W;6[/D%O3X^+N3X;9K"[G
M[KWGM+`;!W+G8MQYSN:3?.V\=6X[K:'+G%0UL&,BR1>>.<PSBAC]U[I"=-]5
M;3Z<[5ZE[$P?PT^960;HA?E#D/CKU?N+.?%R#9W2.6^6_8I[([MK*#=6.[F@
MRF?GW16UDM#A_P".UE12X/"-+31@2EIV]U[H/NO>NNM.J>[=B?)C#_"?^8A5
M]I['["WQO>F"9?XKYVJ[4WSV#TL_3.X$JMCP]U4W]W\9F-G+'FJJ;'-A::MW
M"BU60>IFC\9]U[I2YSKC8&Y.]:/MS%?$C^8]A]\U??'3O?>]MR;-C^,M/LC=
MU?\`'?+=PY#KS;.[Z&L[MFHLK18K%]MC"9+)4<?]X\EC,?B:3[V6"DF]^Z]T
MXY'KGK[,_(B7M"3XR?/R+`4ORVQWSH'4]-MSXWQ]<Y'Y-;(Z$EZ*7?N/W%4=
MHT6\:'$Y#;=5'75>$DK3%7[GQT$T#I$]3157NO="IL2#9^#^3..^4U%\3_G9
M4=P[@QG<%')G9]O]`XK$[EV9OW(T>ZL3U5ORDQ?;\<>4;KVOV]4'9>1RP6KH
M8:RKI(\C]G6/"_NO=";WC\EE[YZRWCU+O3X._,@;#W=!@*7<LV0ZM^,O8>S]
MR;*R$V*RF0P>[-N;A[IS5!6;9W73>3"9*&&*/,4(GEEI:B@JX(JVG]U[HNN8
MRFW-P_'?X]=*9'X[_P`SRIV=\1^X^@>YL=OS>&U^H>R.QMSY+X[]BT&_=J;2
MW/G,_P!Q[FWIGZ7)#&01U51213YB/"QB-JL5/D)]U[I+?*[;W5_R?W-V3V3O
MWXI_S$]OT7<'0/6GQ6[KVE@-D=!FGWYU-@^XI^Y=F87'U4_<TF6V=NZ/<FZ,
MKBJS(PU0-+B,_4F6&GJ8:3(T/NO=#6>SVQ7R<W?\CNN?CG\[-A;P[HP'4/6O
M=&VJ7K+X\[IH=YKT1N7=N5Z\I*JIS_>&4GZYR&0VYV#GJ!Y*<0TM?CI_-&(\
MC'!,_NO=%\DWEL&C^9FX_GMMGX__`,S/;G:^XLCMS:VY,7@MA](;BV+O;JG8
MO7E=M'<G2TFW*+NS*X.KQ&0W/2XK<@R12+==+GZ""GQ]8:"IK,?+[KW5@;_S
M(3#+%#5?!?Y^4TCXRHKI5;J;JNH^VKJ>!I?[NL:'O&K%5GVE1H7CIO/!2RJP
MJ9851V7W7NI=+_,3K*MZ>./X)?/@//39"L-^L>G6BIZ7'4]/42SSU$7?<E,$
ME-2(H]+L6J%:(@2#3[]U[J5'_,+GJ*F2CI/@[\\JFK7(4F.AA'5/5]*M9)5M
MH^XHZG(=V4='-14KAQ/+Y`L/C?58*3[]U[IJS7\R:AP<53Y_A7\[:VOI`99<
M+B>J>LLGEY*,T25D61HJ6E[J=,G03.YIA)3/-IK4-.X6:R'W7NBU?+;Y$[_^
M7G2.4^.6W/B=\GNBZ;M/=>PL3O+M+Y#X?8'6F"V5L#`[[QVZ=Y93:F)VWVAN
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M:.F6NK:NH&8^26XYL%7TF/S-!/+15&IXX8I9=3Q2H8O=>ZC4G:WS`R>Y<?79
M;<_QWV?O2BQSX&AGW'\8-U;MW%7TU8HR%>F$W=@OD9@8L3CZV3'5$?V=53P"
MEJZ=)*M61U"^Z]U@;M/Y/IMJ''97=GQO_@W\<FH-OXV#XC[RS&WVS4.7KJ.*
M&G:C^2*8FJSM-GT%1555-$E#2Q2RJCSU$1=_=>Z=/](WRJ&9KL]4;_\`BI+E
ML>E74;DAQ/Q@W?6;HH<Q086NI1%+NP?)2KHYB^&2*DAC:`U<L50:=#=XU]^Z
M]UR3O7YPNU?-C.V/BCD\%BJRKQQR0^+_`'/AQ5&,3I0?:_=?*&:"-H<C$N.J
M2X2.6M>-(1&)59?=>ZF4G='S@FDKX'[H^,&+7%/IFFW+\.N^'EK:9:"EK9,A
M]O@?E3YL6F)=VI<LDD4C455*AL(R-7NO=0/],G\P415==7[X^)&.EQ^%-4\E
M3\:.Y$HKY."2LQOVVXIOE.,9E</60TB2H]*VJK66`J$=D5O=>ZPIVK\X\1CJ
M?#[7W1\/7IU>,)0TGQ@[NH,=)7K50Y#+5V+H\?\`(3[.CYJG:/'U3+7&MI)4
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MGVFZ?B#11XS'0!\-B?C3\@\BV+AA,-"*?&4=#\A:-<EA\3++#%)4QK2QA6`B
MC;0P'NO=.66[R^=M!AMU25N]/A[556W-E[EWI74-1\?._*''Y.BV_MVIS%5M
M9*ZJ^05120U=5:&*HKB9X:&2<0/2RRAK>Z]T,G5_7'RZP&Q]KUW7F?\`@_UW
M%NZFPN[=UX3;'Q;['V_BVK<UA**IR+TL&#^0V-%7EH9BL*U=4C-+#$I=%-E7
MW7NLW:G3GSD[:ZWW7U;GNYOBQCL#V%MK-[0W=E,)T/V_1YRDPFX*1\57OM>6
M;Y&5--1Y:/'U,KPSU*U$2S!0T+*3[]U[H_<,2PQ10I?1%&D2WM?3&H5;Z0JW
ML/P`/?NO=8ZNJAHJ::KJ&=8($,DK1Q33N%'U*PP1RS2'GZ*I/OW7NJ5.]*ZG
MVWN+NSL#+S18OJ#K'O[<G9O;64I-]X_9C;(I]E]$[NRT79U3AIX,@>P:[#9F
M@HS3X85V(6IK6I34K/"[1CW7NB=8?LG>G<76U#OVKZL[`ZFV'LO'=>X7>G1%
M1N#$8A_CKW-LWMS'X?<VTJ_;K?Q''9C>!P&?PV=VO-!DF:AV_F7-2*V4R,ON
MO=#1V%D<-'6=V9;"[TWGF-RTO974E)N7".V6P6,HZROZ]["K,7V3L66:HS-+
MDWW7MB:CKXVH9ZF+(R92>G6JAAF\5%[KW0+8O<O]_H^V?BK35WWO<&*S/5/9
M]/NI=J;WR=#A=I9_<]%2=/[_`,=2;Y@V1E=O]@;BQ\.*Q<-/209[(X2LJ))8
M,75Q0RRCW7NA%ZJ^2T7Q][TZ+ZKQO1G5&Z\WN=-VXNBI\0])#NSJ+'9S8M;N
MG86R^N<C744=+C:S?>*VEEURM!0UV>I::>&CH\UF<2!#%![KW6P-L+>V%[&V
M?@-[;>-2,3N&@6MIX:V.**NHY5DDIJW'5\=//54RU^,KX):>?Q2S0^6)O')(
MFEV]U[I7>_=>Z][]U[K_TM_CW[KW7O?NO=$\^:VQ.\-_]35&(Z4W##C:MH\S
M3[AP9H*JIJ<]39+$ST&+JM6/S&`RN4H-N5\WW<V$H\E@:G+R"(#,T$<$B57N
MO=:X73\&!Z<Z9Z&Q7RLV)7["AV+#V'LBCQ?8^W<WD=C=82;BH-P[7'6U?LVK
MQM4F5[>W#OZNGRNW-Q0X&CJL%@-U4M,U-G8&59?=>Z%VOINP]J9_<<'8=%7;
M?WO59;K^@ZQC/9%/O3<&Q]HY6GRN'SOQ\W/G<H^WE[*WYD-T8AI,%N7.Q4[Y
MG'4@A$](7*+[KW3WUKB$VC\>?D/!C_CUE-BYU_C5\5\M4=S5^'W/N"F[)WE@
M>J>O:&'=V`J\]M/`[,I=O4F/6JQVXZJ2KHLO405%/*U/D(93-[]U[JLSLT;U
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MN9[L[`^0$?Q"^/76?ROWG\>*2DZ5V;T[V;U'WCN?Y([8WQTCLS)YWJ6DW!0X
M3J'KS:>U\M@\ME:A9(\CC<C291)H<JU4ONO=*O/_`#HVGU_NCL/(YKH#,;=H
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M76U?7.'V;\)^PLW/WCO'LO9N7V)MKOKH6CV[M?LKI;K7'[NRU%U_DJ#!_P`0
M[DBQ'16:_BDN6Q=+'##!4UV-R-,E30MI]U[I%8W^8"FZL+592C^,&_XX<ML/
MXQY+'4.T_DYTG5TN-I/E4G5C="[@S5=!MJDS4&W_`"=F0T,NZ)(WVXFY\?/B
M*8QM/!(_NO=";A/FY59'K^3<$/QPW)1+N'N+=73'4>U<O\D]B5S=P[ZV?NWN
M./=6/VYNJEQ]'@NL^PJ2GZIS-?M_968K%W'O7$9&GH\=4*59X/=>Z&_Y48GY
M`X7?73&:Z<^3.=ZYZ_[([6Z2^-+KMO9O7N7SVVNQNY<QVMD>SOD#D]O=H=6Y
M*MVY+A<-B]K8G!8:BK(:"%WR`R=&7=IW]U[H!]J_,'=N'VSNO;'9/1&Y,GVU
M\?>N/F+'V?5;5[8PF[)]_;C^`&)Z8H.V\OM+9^$3#;CI:OY$9_LJB;9%%1)A
M*:&LEGAR%)`DL1D]U[H6-\_-+^`[\W9MO$?&/Y%]O;(VS\:,?\P\=OCX_P!?
MUYONM[6ZQW768-=D;!ZPZ1V]EHNRLGM;?.\YLC1T>JKI\?356%J9F\L3Q5#>
MZ]T?]=EU(RJU^9W!BIZJOR$%?)2X[*YY)J05/\,K*7`Y'"P5%;39_!4THFFS
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M08O,1U/[QB5)A#$:7SO[KW65,OOC`14FT=XUNYML5N/W-@LE-7_P?;34F7H(
MH,A7T:8"IW+7YB@KMKHR!\HE52RY`8^J40)=5=?=>ZQP;B[`PTE-A8:6/QTU
M1`[Q4NX</]YG*&@?)5E+NM,@*Z6*FVM)59,15F2AH8&CI98X"K"=IHO=>Z;:
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MP>`G2)X&9ZZMIZ@R3B-880/=>ZR-O',9C.1UE/35Z8>6HJ,]F\5C\='A,E2X
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MK[9R&8R>8CEQ;PUF3D;.[6K\GA#6Y'!#*9N?;,N)Q]`N"PL$F5^T6$1RQY2K
M1Y"4>":WNO=0\+V7E(\%E\]NG^/UJUM'!D=OY',TE/3Q;;D9L'B)*=!B:>GB
MK,K%1-3TT]36#545,M/&C>))&7W7NIV-WXU-C][9FMBIZ5</!DYL=NO*;7&:
MBHSFOM!@]UPTU7EDQM;O2MQ>4%+7TTR,(Q&9:B>Z,']U[I3;;W718;)9N7(X
M?#)BL)!6)%@\=@8<I##09-JBL;*0YV.";(T^1GHHXZFIHZR7QTM&@,%6O#CW
M7NF";?&WVR%11HN&Q.WZ3%8O.TE'68&/;]#58/)M35BYC#8VC2GI9<;`13QP
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M^Z]U`I\1L;(8BHQ5=7P9/%Y7%T=-G)(\=VGDQFVAH:X[>BI)\<*:LK:">BF%
M1"GWT%2L6B*1'($@]U[IVQ^W-GX6/!TM,D.2C@IX\G=*3</\/Q\PCJ88IJRC
MJZBD?"4F.JIZEJ3[D5C++6>1"JHH/NO=-S;:VE0R5V.=\QD*K,Q5$E2D=3NM
MZW(X"GR-)79%VBR^\!'ETHLE##-_%\>U1'Y8XC`!&6(]U[J;7;=VY2ST^>RH
MES^8IJV:IJ=QI1YC)_8++5_P6EPF+QX-+2TE+Y:EIIZR.(>)!K-1`[>4^Z]T
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M%#%`BU3*M0\/OW7NDCO39&-78?963IJ,U=+G.M^Y:?)9JBQ>TJ"GGP2;'W+7
MU\S8VNQ./VWF5S61R)I9*/&VGIHZ2.:HJ'1FT^Z]U8!UZP?8.QW"Z`^T-M,$
M`D&D-A:(Z;2WE&F]O5ZOZ\^_=>Z5_OW7NO>_=>Z][]U[K6B_F,UU++LCY-]<
MYMB^/[4^1NR=L5>R:?"UN:R6_>O*S.[9R?>;8W:^UI\)NG=%?CNH<#7>.BH\
MA35F1\P">>2..$^Z]T5#J'?Z9^3N"GVY33[:E[4[SZR['I:')[XR^]%WSVMU
M[U[C:#<._P!>SL/FLOMS<^ST?K?;.9H-R[+ITVW7`M1XRHDJH:]Z?W7NK->V
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M59A*VAIJC$U..:-J&6@DB4TK4OB`C$`BL%4`:0+6%K>_=>Z=/?NO=>]^Z]U_
M_]/?X]^Z]U[W[KW1(_GCW5V/T5T[/O/93T^WL#3&MDWOV,YP[UFT*"!:5<3C
M,4VYZ>HV7M;([TR%2:*+=.XUFVUMQE$V0@F26,+[KW6O7TGOO'=O]4=39_OO
M>6_\IV5E.L.P&R><K=PONB@WPU/E]YOM_<':F_\`)_P+=&?H>JNSL9+LS;^V
M,TZT.9W9A(,S@YL(SP5(]U[H1L]5;HS^_-V'?^U8\UG=N/A,]A\=FL?7[?JN
MR^C\_@JN3>WR<WOU?G,=E^X,-V-35M9'@J?$_<1TVSX:A_*LD<4M14^Z]UBZ
MFR.)K.@^Z:Z;N#?_`&M58WH3XN4-7'N.GSV`P^PJBLZ>ZRW+6;`V/55^8J,9
M4;-SN(PE9D8LC4X*.BBS5,(\?5WUQ>_=>Z(;\B.F8\%NSY1=.Y?K2BSVY^R]
MN?#/=G3U)LZABW)''D>_\WMCX8;@Q&-Z,W3)7U6_:G9F[NNG.Y\GEM4N(Q44
ME7MN'&5DE362>Z]ULZ_"3<U7NCMOOZHK:'1-05%)0Q9=Z>:F.6I8\]FX:)L<
ME1A<963;7AQM-3G%RU<U;6/!(P:70B#W[KW5EGOW7NO>_=>Z][]U[JLCY*T^
M0J_E'!3XZIK:>:?HS9E'`8,QD,)+'EZKL+L:3"U6(>CQ]529G*4DE)-(V/KI
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M_2'Q[PV:[>Z\R?QWW1U3V-TGV;MW"X&;<G4G8/3^X-ST&T\AUKL"/`9'JH;4
MJY=S9&A.SI":6;;DLM*]05@I:@^Z]TD-P?$C>6^Z_=6:S'R%[2R\]9U3N3JS
M-;O[%Z]VKO+(Y7";HD[<SG964V[N/;^'P]%L3;>]\]V]`<GLO"T?\)CPFVL/
MAHJ5\<DT\GNO=.O5_P`0MN]9'XTYC$=I;TR6(Z"[,^4/:'7&(CZFPN.PRY+Y
M5])/U1OSK';]/BZ#%T6+@VWN#/Y_<U%$::+[?*9%,;,C4D&MO=>Z2.T?A!L;
M:.QMW;$@W=N#?&2K*7^7]TJV\\;TYB!VOLGKSX5;GZUSVQ-O,]'D5VE_</L/
M>/5\&1SAI:UDP]=-4VIUDE@6+W7NGFB^(5)F.O\`LKJ++]C;LFZ5[$S'98[/
MZOW9\?-CTVR-P4'=N^>S-ZYW='8.:R.5:IKNU-C;IWOCZW9>ZJ3(467V/+MO
M"4U9%7+-4Q/[KW0]=T]8;G[BVGT#X^T^Q]J/\;OD'U/WKM_*TO7V/WP^XLUT
MYC<GM_KG'[I?=DV+SV(V9NB@W'4C-Y"5:K<.7R%3/61I2TM/*6]U[I(2?&/"
M47;$W?-/NC>6`1>S/DCVSV3MN/JCKO+S]E;(^4F]^J\YNCJO>^Y*/.4-9F.N
MZ&3HBDQV*S$`BR1Q-2D<\,DX13[KW0=;0^'N:ZEVK0[>V3\A._=D;SQ'P2VC
M\'=E=Q879G6FT>Q^N-C]5]P[Q[4P/8FTZL9:?:6:KJC;FZ(\<FB6'&KM?&)5
MT]0U;52QCW7NK&<;ONOA6CJIL;NBHK(:B2+/X2G7;=!18@"C@@Q6W5K:VDQ=
M3!'75%//7_:HP?*4]8332()(R?=>Z3F/WMEIYUSN<K*K<E-/C:\TD53BMFU>
MX:+<'\)C?,R;<K)WI\5A\=38^.JAILOEV^^R'G2E6)C!&K^Z]U*S':%#7XT;
MCP6W*O<\,F*S62V[+6[;IJ6@2@QDTVS:O!8F)_MZZ/<4<M5-)BIJB412P@TB
MNDJ"FE]U[IHR^_L/0T6:I<Q340HL!2[;EJ3!]CC)<`^4R@IZ/)UH&,R>6VW@
MTKZ>3&5]314LU;3"N)@ADBED:/W7NNMU[KBV[,D4^,VS)N6EVG0U]90TDN$&
M$Q--GQ%7OF35U5-19ZOHFQ52@HLA`U2]0L6L&G=$O[KW3G%W#AX\8:_.468I
ML*N%I<CMNKP.(BK4^UAH<9]O'C:N7&4^,BR%;03,J/KCJ"L.N:PT2GW7NGC(
MY6"ACHFVU+B*JO6#;-92%JM,WDMRUN=J&QB)OV&CQ%=DL_M6@R4[JL\L'\2G
MJD-XG4)+[]U[JLC>O\S+<%*>QNP=D_&!NQ/A?T]N&HV#V_V_M#==7N_M`;KA
MR]-M^OW[MKHP;6RF:GFQV[(YJ:MKJREGF;R04E7/!4,1![KW0L=K?./L+;O;
MG;G4'7_Q<Q7=VU.F-L]3;KWAN+!]G8O`;PV_LKM':,6\*W?6Y-O9W;M9'CJK
M!8AZ=:I$J,E7U&,J)Y7CAIHPI]U[IBJ_YAN7W!6=&8_H#XK/WUE.]_C]E^]=
ME[8B[$H>K\QC<!LS=^6Q.<VY%NZBVWN?:&8KMOS;5RM3/"F1ICDC%3M#2_;S
M21)[KW2YS'SXRG7_`%5M;,=R_%G=&QNW>P-^8KKKK/XP5&Y\!N[>>YZC>="N
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MH>*^;G3-+U/TUVM3=69N?`]R]NX/J"/86-JL769[K[>V[\B-OYF#=%=%N+SY
M2LQ4U(D5)6TL<3M23B>D<P0R:?=>Z-8<QLFKR2UF<_@N7J<HF)Q>XVI\?CZC
M#N,AC,G!B<?54G\5J,7CJ&JIT@6`0M62U5=#XAIFUJ/=>Z+[1?)?K#LGY.;K
M^-.8V1E:'/=>[:Q^0V=OO)[@PN1Q&]Z'&;>VYG=Y[>VY2QUN4W=LN7`8'<=#
MD0M;"*O(4L<U5'%.M(FKW7N@LWA\_.FGZ?ZY[:I>MMX5.].WM[;]V+TQTOM.
M;;.[.PLUN#;^XY-IYG=F/STU-2[9VYM"BH,=*9\E54!I*J9Z>D#U$Q<P>Z]T
MH]L?,38V]-N=L;/VK\9^V\7W%T1%M&%_BG!BMFY;N;</7^YI<!MK;O=/6V5W
M'75]+N+';6QN96>5*:B&7IZ>,PQ53030(WNO=8.AOFKMCO?.2X[:_P`8NY*"
MFJ=R;EP>9[EDK=BYO;.R\YL:ER#1T.Y4EH(*S;6+R<]!*BRTT$9GRN8*SPR3
M'R1^Z]TN=A?(KH[=O97REZ>I=EYG:>;^-^'S>?IZFIQW6,6+[0V9C*&*.IRF
MSZR#$5,>-QVW,VL*X&EK9S65,606M=%A5V'NO=!L_P`[=I0[>Z'RVVOCGV]O
MG(?(;H=NT:+:W7F3ZNWQG-H;3Q>;W!B9/XK'NB:8;XR>TZ7#R3TLE)3R4;8^
M8K3F:-CI]U[I29/Y1=;;`Z%_V8?LSKCO[HW;66[8PW5FS/C_`+MZWAV;O_>?
M8V11Z':V/V;LVMH#C#D-]154E9`1-011M%))5`H8Q-[KW3YU%\I.K^VLWO'8
MN=V7V;\<^U=O;3W#E=T]9?)S%;67*Y?:.,@:J7LO.)!'5UFXL5@MK5\:Y6L8
M0##82IIC5>1DFB3W7N@'I_YBO061DV+G:C;/<6P.IM[[F;8/4GRD[2Z\W$G3
MU7G<Q*N.ITAK:6$9.AP>6JL()L/D3320X^216DB17E"^Z]T\;Q^;.W^K^U<E
ML+>7QZ^52[XI]Y;AQ.S/X'L:>H@[!R&R*V;![DS77F-Q>XJ"/=&)I:B'S8=)
M:.HIGK9Y9ZK'F5TT>Z]T8+J[L/8_R"[?W?L5Z'<^Q\OU'UWUOV7V!@=^F/9`
MQV-WV\F0VYMV;^ZU7)N'&Y;:Z5U.^X*&IBA:?*0Q+'42*@CC]U[I.?&KNCK/
MYP83>VXNJ*?,146TMXP81J/>NSZ"&LP.+K*FMJ:?>N'@.=J\6</N'9^(R,-!
M2SPF7"R15(J!YYJJ)O=>Z+WC/GW\?31;?K9<%WML/J#,9VHQTG?._P#:&?H>
ME)X<I45.-H=S5.9BK\WA\)@,?D\3#$:W[/[-'D-)"`D<T,?NO=&VP.[]L=C=
MC=T=#[!S>5Q_<G1D/6."[@R61QE?3[>EV_N7;QW+2S[$W#4Y3"TN[_O]O9NE
MC7-4:12T3U;!DJ_M3;W7N@([B^1/3OQC[-W?U5F:+?67[2VOU_MSMW<];L#J
MK<'8>W:+8&YX&Q>UPLV(W+A\9@*VOS,M-C4J\DXQTTUHE@JTDM%[KW1A^I=O
MXSLK9^T^SMMP;QVG2YBJRU/B\-VIB=U83=1R<^4R&*J<5EZ+*3)B\'O2IRUZ
MB/&N(*BHIIA512?:S0LONO="50=;&>FK<9BY,+MO`R[9@VW@ZG`XVJWW6U%=
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M&#'5\^<EI,5AL_1U@PF0R>SZ=,JF3ITW)AI12G^(2R1R(L*U`=_%H]U[IRI]
MD[JIIY!F]O201TWW.0RV-I=T8NLK:7%Y>KJ\7E#1_P`.KJ;(10R29*$58J28
MX8(7C2)_'`6]U[IMEP^Z**G:NH,CLRGS6/-%0T&6DR%!@=OY>OP>ZHI<345<
M$-;_`!?;:U%70R))*TC13S230A5@.GW[KW4^'$[OIH#-%NS*C(41PF2R<44N
M+W%15F/S.YB^0W153[EJZFEBQ1%-38T0T[M4OCG-1%%',+#W7NF"+;4T]$,=
MD,!BZZ/&[B$]9@:C=>(RU=CJVH^XILC-MNOG0LF0R=#5QR3"5IUIH*44E"*>
MKE=#[KW3ED\?6T-3BL.U#F9VH,C24]#B\COK&X@9W%S5-3DLEB,ICYJ"I&/H
M-NY>U?)(1)6:-,,)*QN7]U[KG44N[LC45-)2[CDPN6KY<?#49VDR#YK);RGQ
M,VX-RIDJ.>JQ]10;6I*>LA00"!?"U`5,L4,].A/NO=0LMA\S'N7+T9W2(ZVN
MBPE9]]M&OS.W\G2XW>`Q.(>'!QX\5-'M?(8[*1/C:'*DFJRXFJ9/M]2)4#W7
MND_N>JR6.Q7:L&/>CK_N^M.T:?(46$W7F*6GH,.VSMR35F6H-I5.!3R2T<LD
M<D"C_<CEL@DGK(\H/NO=6H;!B6#8NRH4EFJ%AVEMR)9ZFXJ)ECP]&@EJ`RHW
MFD`N]P#J)X]^Z]TK??NO=>]^Z]U[W[KW6M!_,+CVAB=L_*CL7-9^;:M%M'OS
MK^6LWQE-];IPW]W\33[OVSC>T3B\IA*7)T>SZS![4W!35M%EIZ#)5."B5S1P
M*U09%]U[HJG4&(R6VX>ZJ*&IHLCB=B]T_'3J+`4>!C?HS;N%\G61[!S'3)V5
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M\?19(5>[MLOD##CLW21P1Z?=>ZV$<#@,+M;$4.`V[C*/#X;&Q-#18ZAA6&G@
M5Y'GF8*.9)JBHE>661BTDLKL[LSLQ/NO=._OW7NO>_=>Z__4W^/?NO=>]^Z]
MT6OY0=[R=%;$I\CBL9!D=W[JKGV_LT9K%;FK]GQ9QH?-"FY6VCCLON>L:M`$
M%#B<+19/<69K)$@Q]!4L)3%[KW6NK%W'F_G-@]E[FVS@>M]D8W<^>[$[)FR=
M%M+'9BGQ^X]B[7RF7VGMW:V.?.28&>L?:6//]Z-[[1W%#1[>S$-;MG=LBP55
M;3T_NO=1=Y]@4_8>[NW<5A=P9"'`[1Q/5V8S&$DZ_P`WN78>![GJ,ID\MD>S
M>F-_[!H,KM'=&P=XT.1>6\,>&Q1KI:.6E%/``*KW7NA1V##OEN@>[,Y69/JU
MZV'H+X^4.Q9-C4_6U?O^#861ZRZNW-N#978]'0UM)N)]U;GWPE'48_(5BK05
M<%).,[''3PI,WNO=`CLJCZTRE?LC=6\=H?Z4OD-T;W)\QZOIOMO9_9>6W6U=
M3Y;"BH[@[+[2W'N7$8VMZSWQ0YT3X;;]7'39'%[*W9#%DZBLH()X'?W7NK3O
MY3NYZ3<^-W!5TV=VWNV"/KK8,.)WGM7L#<7:>(WAMN%:B+!YNF[#W,7RV^J1
M*=#20YBHDGJ:C[62!W84J/)[KW5R_OW7NO>_=>Z][]U[HB_;N9H<9\CJNFF:
M2B;(]+;/AR>7CJ*RF^SQ--N[M"KACGAQ\;5N<HJS(1"&2CB2KDU.K?;E27]^
MZ]TF<-O;`54,"4U2DD-/M:ARN/$&[%JJ"+$Y3(F.EB.9&4EFAP\ZNU=#(D-3
MCZI)BD(0TAI_?NO=8JO?.`J(Z%LK,:;/X)*O'2TS;@BH:?#Y;/4D;-BJ#+5.
M0K8,O%/@8HQ4SU7GH:9ZF!D@5G7W[KW3.N_\92?>ULM8M'623Y'(1T]7NK9U
M7D:"AVUEJVBRKTF2^]E6CKY<E*)*6ECEK33":;[O14M%&ONO=2*?<.VJ&BCQ
M<%3@,GCOXA:EKJ#.8JNVU'D:BA6,86=L+MRCCH*&BP<,AIYQY*O)([ZC'IE0
M^Z]U"G[$VUC(L;EZ+<5'3[<JX:A*#=IGVPM!6Y:2HEHLI1F"#`YK^"U$4(\]
MXI%B62>%4F#JB#W7NN%9N+9U'/'B<Q1;<H7Q%1B**''ST6&7<-!%GLQ%%3*F
M,HMIUU1`LZ4/DB`F6AR$ZJ50%A*GNO=9;8.>?`X_'XS;M+4_Y/X:$8;&FMQ>
M3KS!087,4$+;*IJ>/-2U>,G5XJB.&EBI(XWC<J\CR>Z]U['4G7,N+GI<33;"
MKZ2.6OIILA0[:VLN'FE2?QU!H:^OV=2X>7,U-;AZ@R42T@FG5&JRLE-&:B+W
M7NGM*+`5&9$M/D,:E;MG-R)239O'XJ2CVU693%4:UF`R!EP@;[3"U]$DN/A.
MLU:D:BQBC/OW7NHBXW:L%=$U'5[+HH:.DEJ#0Y#:^&HX*R&>KF@IJ*HI:K&Q
MU-1FJ"=O.:>-11R-6+411F1G8^Z]UG7!4E56T,TD^/K*JKSHJH(J[9^);(56
M/CJ:MJ+&U24L!S:X/$5$E)'#!(FDB!9:1"ZBWNO=1,538V66#(KGZ/<DF/:L
MR5#E*W%I@MSSY?&2RUD=4N6K,5CZJ&J;'4`IGFQL=*IQYJC''(S0Z?=>Z]1X
M:G>CJ,F=[@)/0U514Y7;^!E&T<9F*J*B.<HL73_;3O1X04N'8U]/))9YX@L$
M:R!R/=>ZD-A<3(::3[^"CCKZFMM6XFDVY-B\E'C&BR5?MN%HZ1I*BB-`1'6R
M321QO]NJJBD2LWNO=)W&8>BBQ8-1%MVFI<=CYZ"6?'I4Q;2I]O9F7[RJP^4V
MSG<I-6UN,P=7.J4Z55.U`,?XXJ)'6+GW7NF>+%)A:?!XNBJLW_'<3/1X?!XJ
MOJ*!:ZJILS+3JVW\ZV)R/ER^R*K*4#5=$:.2-(XG6.5#J4Q>Z]TXUG7VV<Q5
M5.;ILSG<=6U<N2KJF7$U+9;<^;DSIGIJ49G)4F1-0F+P5#4559`9ZAB1)3U(
M>1?%2^_=>ZP3;1HY:VDQM57YR@HJC*QS*99*^ARWAB6HQ7]\H,MC,QCZRLH:
MO"H9RP6!*Q4J)'B2L9$;W7NM=_N'?'QUVUN/O#NO;57O_P"&G\S;:?;V^\)%
M\?\`J7>^:WG4]H9Z+)T^$VUO2"JR.)PFT:+:V_MO9^+(9ZELF-S&4D1A)723
M1*_NO=&F@Z1[-[W^9_R-VY@OE)O'H'LW8OQY^-..[7R6T<'M+*M7X+?^S\<.
MP^JMZ[&S^>4X##X7.8ZII]NY:MJTF@-9-C6BJ:5///[KW05_([H;XY]%_(GX
MH=`=B=Z5WQ[Z;V5\3M][9V]V7@-QML3MZ#)8_L>;<>VLW@##C\QMRMVWN+L*
MNF>NG6@CBQ];1NJ"FHFI4/NO=*;=^`Z.P>R?@IVKL/N/>WR1^-WQO^4G8^Z^
MU_D#1=A)VMOWKC.=@8O'93'Y#LB:L%!/68VEQ>9BH\+0U%*N1Q.-'W<?D+4F
MKW7NE3WQ\H\%W5\4/Y@&QNM*S:'8.U.K.A=C;KK_`)&[>S6,QVV-R;IW5N&D
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M_(:G^16P:?K3K/JE_CTV1Q?][LIG9OM=[':^5J<VV^\)MQ:3<`Q.U-V8;/M2
MU&+SM303"OGE4A1&YJ(_=>ZK[[OZTW#E/D-\R>_>NJ')0]F?&;M#H'L*7^[^
M.I<$TFQJC8<%/W-L=<5"U-'F-NT^V*F-<A5R35M;E*/$U])J0:6'NO=`[L;/
M;9ZLF_EY=B=B;LQN&ZL%!\L^K\KV[C-OY?=NS,3G>P^PJG.=7UXKD>N6.9:;
M+TM155V-R%3%3[=HZB6!"BY!(?=>Z/5L3^Y?<G\R_+;QZV.>[%Q/4?Q^V)UC
MO3<FV-UY5]G46\*^JQN87+TVYXS%5YG=6*HL:U02LH+TE)&4J`Z3>_=>ZP?`
M?%3?Z/\`Y'T&(K\]7U,/R^[>W%@WH\;E<-B(-O9BIIGVMF#A-O0XW<>SMY"A
MJAB:^'<0!O3,702B(^_=>Z)KV)UUE-J;B^7GR<P>,W/G,/T/\U.T^F>YMARY
M3*92HK/B]WEU!0X3L+&55#3>#)[1.$[*KQ44>4EIZG)Y"DJHZ512X^-II/=>
MZ:#UC6KN_P#EP8S&=S9#X^[@QG\N[<VKY%TF.V_5U&PJ+*9+,PX[#;(ABCIM
MMXC`91(Z''Y&FQDL>$P=(S0I+4U50![]U[H?>T\51["SO\OW>'8/R%WMWCU[
ML'Y19[9N]?D75[LJZ+:M)N+?^$.<V,L.W]GQ9_"TN+PU)CZR*"6HG_BE-)5P
MQS20R^!8_=>Z#ONRD[GWYV=\G^H*?</3_<.Y<]\)?E-N/JS.=*;+P>7W[_<6
M;-[:S^&ZQ[![[STE55U\IQ6`I9:U*.KEBR:9`0O"U1*A3W7NLW?_`&?U]V/_
M`"X>EMG]:;\V*=X9"BZ$ZIZIZEQ=4V\]Q8?N+;&[\=09?+0[.Q&?W55]<5-1
MDIHHJ.2=!-2XLIKLE9?W[KW1G._,+O.7YJ?RLMN[MR^[*BCH-W]Q8ZL:GCJ=
MHY"@W#C-G1X6LW#]]M#(5M+7O497%2MCLO1F2*.)VEG*S5&J+W7N@%[J[,SO
M3?<W\U3=V%@W*]+5?&SX[]9=>XO,X6N7:V:[5WRB[:I\)G6QT?\`'EHBDU3E
M,A60FIQ\,OEK$D<*D<WNO=-WP_DK.C_E;M7K9>A>V.BJ?MOXW;1Z\J\)W%02
M[:K\]V9\<]EY')YKLS;9Q<N5V[DJC.UV<JL55O-HKL=-7/3I1O%6ET]U[HK^
M)/?-3\&]S93>?:.Q=P]-[,AJ][;U^%F<RM%MKL?>G6&WNX:_<-/N*EW3C=Q9
MC=V.R63R=:*C'4/\/H\;+%YYA-204XIY/=>ZLHZ4WI28WYL?-3(9&3!4*Y#8
M7Q<K,=A*G(8W;.9HGH=@[;W35;'C@WGNO$[>I-Z8#`YQA+AL=(N+"GS-41&5
M5]^Z]T$&\)>Y,=\]/D16=5=Y=8=2[PS_`,<?B_N(;IW]-!OG;NXHLU6U=?M_
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M:?WKKH8IZ;)5-#3?P'=LU%EMOU50L-'_`!&BH9(:_:58\.$@:*CIYZH5%)5"
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MM`']U[J97=F39"77MO!XM6&.HJBEK*_*R09";(PU&&EQ-'6P[BV[B,9##5XW
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MN8R5(BY_/1R8EI<;3B.`QPU#)[KW16\1L?=G374NZNJ:[L<=F9O>F[NM.S^X
M.SMO[6H*C"]J=[=F]XT>XX>V-E]C4.=K-M8C;6;Q6.3:^U,/#3/DFH\$\,='
M]T]0B^Z]T,'=])L.KQ/>";)Q6?VQG:SN':&[=T/D,'B,[LG;>-FZD[2J\1N[
M8V#QN3J*O;\>[\/E7K:U\6T=*V0_B\=Z61,@![KW2)AQ&UM@[L[5[[P<6>W7
MN%MZ]7=69[`=F[ZW8FVQAL;B&H-GYO86Y<E@<GF:KMG<.WLWFX-XY[8ZYW=-
M92Q!(Z>&*>MJ5]U[I5=/?!_?/;F]?C]V1FLEU=DJ3;VTM\5N8P+[CK,!M]Z#
MNFF:@W/@:78VR*.MVYF\%NC8E565>>H-NYU=E[XW!0T>:S=!525$BTWNO=;!
M6Q=GT'7^T,!LS%Y'/Y;';<Q\>-HLAN?,56?SM13Q,[1?Q#+5I-15-$KZ$O98
MXE5$"HJ@>Z]TK/?NO=>]^Z]U_]7?X]^Z]U[W[KW1>?E#E>JZ3IG>N,[=VAD^
MR=J9;!U;5G6>W/!)NO>E+CIJ2IJ*3`PSY[;$4+T4K1235<V1H*2C2TD]3#'Z
MO?NO=:U&_I^L.Y]L]-9CXJ]35_6N'WE2[IK]ITO76ZWQ^8ZHV)UENK=':.YL
M7A=X[2J<GM++9G=E;DZZ>AVU2U5)*F$SO]XMMU&Y$HCCE]U[H3>R6PN<S._Z
M39.X*7;6/VQLKHOJ23J^#$;;>JZ8R5?/O3<^]-A;H7<=-M_L+=W8>[J9J?)Y
M#;E9B*"BK('>>88VHI)4]^Z]T'?6L6SJ78/?V.Q_0NZNK_XGT3TOVJ^X<FO8
M>;Q.^J3_`$-;&V_NCN3)8C)4^.ZY&U,/C9&VE#30U*9):;+SS1)74`D9/=>Z
M,/M+M[*YC;E4,!W?48]=FY'NFFV371=K;>[6K>PZO/TB[SW[._84&Q<!)0U'
M5G4NK<V=IL<N;GVWMZOQ6,J8UKX*F"/W7NCL_P`L.2JS66[MW+5397):LABL
M;0[ER>1QN;3=^#D>IK,'N*GR^V'CV%)43TRO#4#!PQTDH@BE=(I6=6]U[JW3
MW[KW7O?NO=>]^Z]U7AW_`+:J,]\B,NT=-N2NC'06SZ66DPV[<3L_'_;CL'L&
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M&CRO\3H9\925F?R<N`V_3[9W=B(ZC35R0P+(T_V[13*LSGW[KW31_HVWW3C"
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M4\.5CJZ:GCF5GD8E/=>Z<O[L[RCHZD-1Y?\`@.`Q]73+3BB#O7;ISU52&JWA
MD]T;FS\53G,KMRGI9"D4L%$8U6+[0Z&"'W7NIHV_N23*/D,13UE;5U68@CS,
MAVYG,ANF.#&4$$.W<_EJ/(;JIUQ\>`K<29Z*2O:&?'+6U4:4\]/*LZ^Z]U.I
M=JYN"K9T;.G[Q,=4UE%%E9J?+8*L^RKY]J9.@VMF,E)1Y/,8/-0PR22T)>FD
M66,SRJ3.5]U[I)?:;QR"QR465R>/K9,'44=)#2[>VYB</2Y=MY34D&1&(RV\
M8(]Q4>&H\H?,6^W>3R(_F9H94E]U[K/G\3N::BI_X-M_[BIIJ@PTLF"H:*B@
MF>N,U9215#9#>]%C<EAZ>L$(:F@DK9J^<K'%(^N:'W[KW3?)AMR5-8(<31X#
M,[DPR&BW-DZ[;F*R.?KXL9#]XT?7NWYM[3+MJJV[1,D$L%>?OL:DKFLI&D;7
M[]U[K#DZ3PR18\B&JH<K3PALC"<%5[JV7%25*8FLRU+34N>GKI:;$0^9\G+0
MU)=*']LT\M0JZ?=>Z@;CV=V?0-E<QM&7*C:5.N&I,>:2+:N4_@E.E.E/#@LA
MC<;FJC%YN+(TX22.J>:LJ)J&>G\,,TR+[]U[I8UM9GWQ>=JLI25\&/QT=;C9
M,S18K%96DH=KR44,>2IDW+2K7UN'J#NVH`;SN]71X]&$RZF97]U[I*9#K;=-
M5N^DSM#)3460QM&V*;);3P/7U9F\-18B*MDKI:K<62H%RE/BMEXR"9,52U%.
M$E;)0?:TX>./Q>Z]U,3'9',-7#<6!Q6!SB0[>K9MP86GQ[T>^8L?B%RVQ<+V
M!DZ#"R97)8;(FEUX:GS-55K`8)ZN84WA>G]^Z]TSU&V!'C5H]QXG:6_\=A,)
MCION-R;'VO69B)D-/C,_LZBJ)J3-3UU%7Y]HX!-BO''+5T:UD\4R,WC]U[K+
M'LO);5@W'LT;+P."Z_SQP^:J=C[#HMF8C9#5TADI<JVZ(\3BLY2YG*J42K\D
M$U;)601.L2P0Q1T_OW7NF.'`XJAV!E]F9_:^Q/[E93*/54^.P.WL+G=@5^2$
M--0??'%P;+I,%OFESU#4+D<M4S4-?#4MBXZN,-3T?W7OW7NE1NZ*GW35YQ<M
MLK8LV:WAC</AX*:MVCMC?.,SE8D979NR]^R8O;.Y,7O#`Y>@5),+CWK%DQE<
MM.88XE222/W7NDM5U%%N;'MM[+[>VIE<E5G;&-WSOG(;?V[)FJ:JV_E?XKMI
M=\UD^V,U7[@AZTR$=50[2F4R24YE:*GII2?N/?NO=-VV-G[&VW79G"8OIWJW
M;N8JCE<)O:DQ'7J8_;21[TH:62MQE5N;_1SCAG:+[R:J:MQ!DJ<;D**1(:M:
MEXC21>Z]T];@V5M"'+[=V_ENN-C-M#KW*8U^E)<GBL#48G8-314M3B]DOM/"
MUVS,C0[)^RQ55+`M?C'HJ9Y9!2Z:4Q1P/[KW0HP;@JJFIW3!2TB5F"@Q.*P[
MT7WU8M%G\?DZ;(4-/N>CK<IC]I5L6;I:G'I,TD/W=%%54WV[O&[*R^Z]TAZC
M';"P.0R.[,/M;;./_CN,BQ>Y]P4^(S>:R>Y1A*%\#1[8W0$V[AWWG@5Q%)]I
M4S9*1HJ5&G$E66=-?NO=(ZGV]US5;3S74U!U#LNCZ\PE;1M@>JJ+:6(RW7U;
MM>OC?+4FTMI[7R]-0=4X*;-)DJZMJ*VAS2PT<5<[0++^Y`WNO=+/9NWMK=98
M"BZYZHZLQ'5^`QAJ<7D-MXS$;<VCM7#Y3'93`M19O*RC-8W(9;=5%1%)()88
M##CX:<1U,3":%F]U[I3;)V_L#8]3N:GV;L_:.V1G]Y39O+X@8&E&6W5O;<V4
MT/F]PUE)D'I'7=)QE37YF>OBI`XEBFU/&]5"_NO=)3"8#HJ"D[*PV,VKUS3S
M]YUVY-_]MXJ?%X2BI]];FR=)6[8J<]V\IK:^BRNX:ZAIV>NK,E-]NV.CA:**
M(QQTT/NO=([-]+?&;=>"VOLZO^.'6FYMF=;;=CVMLVMJ-L82FVOLW;V)K*K=
M]!A\!5U647<D^T(LY/53T\5)DIX*&I2U532:Q4^_=>Z4J];_`!SVITOFNL<)
MU+UC@>F=W9+>)W?U.^P]L5VP>Q&Q`H,MN!Z/;6.W%NV27,5T=3!5"LDK(\A#
M.M/5Q"E=6]^Z]T\=7[,Z:Z!Q%-M_J;J_J;KC([Y.W\C4;;HL'4X;*5.47(5T
MBQ97<=749"'$R85,0M>M+19>5H*=1*M(YG18_=>Z#R@V'\4-E[CKNS.L^D]C
M;:W]EMP93/;AWAL+8#ON+*5V6J9J67-XZ''8Y*I<EFZJK5\A60XZ*>9`C(\+
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M>Z]TY=K_`!]^#_8&2S_=79?QSZZ[0W-N3(8C+;YW%N+9F\]RY7<F?VU24&T_
M[Q8_;N`R2XV.BQR[;@Q^7KEIZO(1TRJTYK3Y&;W7NHF=^*7P9WE5;:H^R_CQ
MUIE)=L;<V+L[;FW*C&[ZJMV8'K_:"P9';V$V!5T>Y:9JK;VU\JZ18^NI26I,
M?KI'U`2Q'W7NAHV)MSIW8?75!U=UUB-N]?\`6>T<,^3P.S<%N7>%!G-JMO/=
M.9EEJ*K,R[@R=?/FLA59>OK9Z;[N2&1XS)XY#"0/=>Z$3'OUG04<V:J]X11+
MCL(N.\\.=W3`:6+R52T5\%1UE)193-221R2R/)(D\-,0S2^,*/?NO=<I=X;"
MSR9)J:7-QP"GMG*BC&=GK,E%38Y3]QL&8YJBKYJR22=5,D6J?RPQ*D<LM/$6
M]U[I2#<6P<K1UU3-F:RH,F%2MR--)EMZ)D\M0XJOQU/-51X:IGBR=92)5S4,
M?EI):>2N`F\ZZ()-'NO=91%M^IRSTL.3SV8J<!#0U,KT&:STN!HO!2-+)A:Z
M0[@\>=7R4D[S5=0]12R&E\<^K[50WNO=1*2AVECILG+'N7<U;BUP,BY"'(9"
MNJ*/[#,5=<6R69JVSQ2KK,[N:E=XY&A&4IXXT6$0K$@]^Z]TY0IL:FI,@$@J
M<@NY)<,U138+^*5<-!)MR*`4=')4TLXS=5,E7>>.2DE@J$@0.2\,C'W[KW34
M:C9%O#2Y3)3XVEGQD--B<<NX:=Z#)MK,%!C<2V0@JQAMQY!*EZ2MJ9Z>6C&N
M+6D8+/[KW4N&+:]#0'&D0T="(\?0U51&&J[Y:GJTVY0[?@2?-U5-1;:R(K@/
M''*IBE:/3]PBK(?=>ZCK0[8FJ:AGRT-!58FNQ]705%4U=3/@J?+K4)F=MU%*
M*W[-L+NLT33-732*'H$**%8`>_=>ZXU&W<(J1U<>:DJI89,)#B*EJE*FGP67
MIZ>4[2-1AVR<%1)34,$U2H)6*AJ1)(\[F1X67W7NN,.T\71#+TN.RN.Q]=AW
M,>3K_P"&44&3VY+E:[[K-NL%?D9J./\`B=!"*NJJ'$LM,)X8@#4@CW[KW7GV
M;MK)K5T%=GH:V3(3TCA,H9:VBW9)AH88L'N&6@R%6!1C#4C1SRL_BDGABD43
MD3FWNO=)6+;>$G;&Y[$=AUV2HUH*58\XE%C5KLE1^2*CPF*SM#75!I-MX]LM
M35(I1#2I#4WD4^M5F]^Z]TZ?W;V_0X^6:2>AQ>(QU#-505N%JH=KP[?QTN3$
ME.8,5C6EHX,GM7&5DL;-6!VRD,[5$C"I6-C[KW3C)L+!UO\`$0E57SXJ:CPM
M5D8JG$8RCIJB*HQ,4N-R.32@%#G,C459P6/S,U%'%`)$T3EDE$BR>Z]TG:7K
MS`4.1S%##D(ZJ;,OCC74-#2[0H55ZV@-/19&GDJ9:O/Y&/)TTR?:TH>.F9:*
M1RBU#/?W7NO=@=<^#9W9V0JZ*NK4JNJNR\:?LZ786-H*"EI^MMT4DM3@LSBW
MJ\IG!D8Z!_LF9#_"ZJD!4%=49]U[JQK9-CLW:1#R2`[8P-GEMY7'\*I+/+I"
MCR-]6L`+^_=>Z4_OW7NO>_=>Z][]U[JBG?\`)MR/Y+561W7C*;*4&$^76^,Z
ME//G^Q<1N-*#%='Y2ES69V\=DUF-VK4XS:]/615U6=V+/1T8CIWH%>L>.6+W
M7NBX[OVOC=G8W:^Q9.KMH],]B;0ZWZDH*"GQ'8';&[<GBJ#;_P`CZV?`1[LH
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M>NP4]!F:+:M%!M+)[MW9E,%M[.Y/`;EWUV-@&Q^*S64JL;M^IEVKM_)U$&1D
MQNU*"GI*<[;2K7+K[KW2_P!U[2H*/>VY=Z]=XN/;]+V;L';L>X.P*^IQ<>:[
M!VO7Y7*8O='R)Q_8FY$W)O#&=D4&.P$F%S<S9G,XYL9#`)Z[(_>27]U[IBZZ
MR/6D_1G=[XGL7>VYJ5>CNC(,W#NK^)T:[,W/-TST_DJ+IW`9#+[Q;*#K^IV9
MC'R]'BJ?%Q8J#<%!%+!+0.9:2J]U[HKGR4W+N'/_`"5['[HS^V]O[#J_CG)\
M)\1UYMC=V;GV_O3';NK]Z0_(?YS3]8;8P6/&V]ZR]V=&Y^#;.Y(`U7]S5TT:
MYI8\9(U6WNO=;$?\OV&JCWIWS))M:FV?C/XS38S;^W<;%0T>!P&)VSDLGM>E
MQ.W,=B9CCX,-'CL/2NDY@IZBJ9F9@Z!']^Z]U:![]U[KWOW7NO>_=>ZKW^1D
MN1I.ZZJIQ6'W=E9ZCK#K^CG39#U,67IVI]X=FU>/K\W4-44V/@V;3F6I6I(,
M]2:AHK0N`L<WNO=!_-O+)5_W=93[;W%5T45;712IBZ6#+0M$L],:">EGG?)4
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M''R1U.*I,A2UG\*45RLJ+#X_=>Z<\9V#F`M!]QAZL5#U\&W*C$U*TN-W3JCJ
M)JNO)Q&5I\G0T=)24T$V6JXJ:6H>C2@:61X90\7OW7NL]7O_`!>6JL)28V>2
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MLA?W7NE-E.Q\5'D:[&5M1%7Y1:<4XAJTI]O8Y'JI,LS4TE;_`!&<9*OQD<#E
MJG'4L4\,;DQ"H=61O=>ZDR=K8!\5331U><ECGJS0T^-CI\UE\?7-C:3&I0&H
MJZ62"6J&)RLCTS3F(TV1C@E\FB/A?=>ZXU6^]MX^5\E44?EQ\^W98Z&JS$5=
MC=N[?H<=DFJ7J9,[6U62Q[X$UDSS43>61\;'KFA:14D1/=>Z:(]Y]>9N.AK)
MZFKP/\9RN+JXDV[*E37G#4<4<F/W7FI<F*ROHJNIPM-'5S4NFJDAQE6TU6P#
MQHONO=2!O[$8ZOEQ6!I)*F))4GJZ?;VVL:-N2U,^,I\J#BZW'5V1F@W110Y.
M"*FJ:Z1Z?[Z?7$SDF"#W7NNJ?>^S,O+6/CMM4V-S&1ILSEGQV2EI:S'5^:R.
M33&[MQ-76&IQ+;>-+5XBF7*U]0RJ:Q8]$`)<^_=>Z:)^T-NP-6566VUEZBGV
M]!%09C-K1+BHJ:7,U<E3BZ@3S93#83<V.FR%77^>*ACEJ*,1,A$\3H6]U[KO
M`[PV]-1T%73[;I*C;M;5QS8^.3#_`,)JZVJR.+@Q^X::KQ6=R-/5;?R=#C5B
M>$Y$?:N$0+:8LJ>Z]UQ7<G6,5)3[BR-%6Y';DNY<[$N<S6(K\A5U6[=L096"
MFK,;D,K/DZR%I*G$R#$23K'C<K/]K'XX7F9C[KW4?(5FUJ''TV/J:&IHZ"I-
M1AU_BT%7C),-B-W21P9E]XXZHDKLK%D\UD:J"A)FD:K>K>GCI1#&[!?=>Z?Z
M[<>&R+XN9-M[EQ.XMH9V>*CPPPM1#NBG6NI<Y/0P4DDU92YG)RT5(IIVEJI8
MZ+&5$\=/5$F10/=>ZX??;#GPU/EL_@Z?;/\``TG0X>JV[52Y2L.41<G)MRNV
M]0M!)D,]#6RFKJ/LRU74/5-^Z!%'(?=>ZG/D^O*.7..E?CY/X175-;O6KVY2
MS35,5'38ZCIZ#)Y.AK:Q\GC?O\SEZ>"''S-5P5.5C2>:1W+N/=>Z:JC*=9[D
M@>KHZ!CF<SFM[U^8BR=/CZ'(Q[JH<7C\3N')U.+RDU&E94;@J*.CI:%5:&AJ
M7/D#3.FKW[KW4V=-CPXG$9JDP%/M[*XRIV_)25=%+1;GQ^)W(SK'CZ&MEC\5
M%2P5>2IPD$2HT68R8D860%O?NO=-\&1V9]E7S**LUN.ARIQ];78^JJLL-T[>
MVY3FOAKL7##18R+<U9110T5)1L9J9:*.2$N`EC[KW4K;%%MT!Z(8B$8YL?F(
MZR>ISM=18:@JX,*^[]U;?C7*TBI325D>6EE:E@26D:JJY8ZI'6")1[KW4"OZ
MOZ^J<GE:>AVID)*/(:S4X>C<2TM3)GL/035,6QJ7%ZJ(YBI-'23P!#)1+(B,
M9!&_VZ^Z]TJ)-F81<#MZ3%XZ1:&6:GIL9MF@Q>.T9G%46%KSC*/+R4V.H9Z*
MIS=;2P29&6=5AFJ02WD+B,^Z]U`Q_5FW8<)EJB7#U,]%5I5TXII,[2Q4V$@Q
MI2IQ-3@L5-BZ>BHY,3F)IJIZR9HX*>H$.1GCT/X3[KW372=08T19;<XI:2EK
M*"FH<8A@7,+N')8^OK:7'T<M?54E'!7T=32P+3G%9/&Q1B8B>25):*15?W7N
MGJ+KVO&X1N/.5&R\EN*I_B5.]=05]5EXJ;!59I<)D=WXVEK\7+@-O[@?)Q4^
M,CGIOVJ+$NWC5I-+GW7ND[4=5U./S&.K<A'MRFJL=%7XZ>KHI]XC=F`HZZO5
MOXE7R45,U#C^PZBFEJ(35R5K?Y-+3I)$O)/NO=2$ZWPU)6QP_?5)W1'3OD:1
M\CFMR4`R.&@>GKZ3&435M-%.,MBZRJFU3S@5\>.J)8D67R!G]U[J2W4<-13P
M&=8X,;C<W34N7QL,U;M_;&9KMLU<U9MW$OA*O`Q&MK\.M8U7_EJ&FKZR>\LH
M=@S>Z]US&P:W*T-'#N5Z:>&GM@JIJNLW3C]UYBC>D2MR-+45-8LF5ILPKQ24
M])4-Y<EI<NL%,9I`?=>ZB4W5^0KZJOIA2I.<Q2Q54F263+097(5%`96R*[HJ
M*'+G%X_`18*L>*C3&QU>5>>.&H"701R>Z]U$PW6S8#(UQB&-SV:%1CL(^5HM
MP[ZHMPTVW5PST8VTU:,O!6U<E/'!25LN)G@H$>6HDJV64L"ONO=2<?UMNJEP
M&+&9J<!C,5/EJG&IME:_(IBZW`5D%3!G4J#0U^8KZS<<U3F*ML;.AI**EEED
M*13&2(K[KW3'C=DU^/\`X+FL=@<+'N#:TM9_=O<-?0[BAJZ_/_:3XBIW'N!*
M?)5<&3FRE%5A]N+72HL>.$\MO,T:M[KW3C/U/O6JQU;49*N(F2:DH6P=7654
M6=I(8JNDDR4^0SU+D9H#-JQ5/5BH\=.]!3TO@GG\4\RI[KW2DI.L=S4.6H:>
MDGQ5*,G68?<66$^*S-/N+$;GJ#/_`+DJ<R[^S=3BJC"41\B-C1%B6GJS41JS
M00O[]U[I23;"W718B6CBR&&Q./J\I49>AR63QM7DY<14T],,?DZ2@S>6W)4R
MG#9B*&9$$=>\8#HJB0?>N/=>ZA5.U-S91*!:^>LS&%IL_+EGVF:3;U`<XN8C
M7'T>`W!5TV\Y8<>^'J]592FADEIZB,$Z$ED`;W7NHM-L'.T%?4Y:CJ]OX&CV
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MU9#'[LIIZ&FP65K,PV`V]3YK&4LE8E#D-QT6'W,]338>NH;+'5!WGBH5%.8G
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MEGGJ+U&/-3/5^>-S24.GQS>Z]TI*?;6[I*R6+`YJ'+08%<FM1EJ;>V'Q%7#C
MS@JV')Y&BHJ?;V5GS%7!02^''Y3(5%732C%NTJQ1201Q^Z]USQT.YIH*>L6H
MTTT7\1J9:'^.8O(T%158Z6JJXX\WNS;N*W'787$9_'A):EY:LNM./#XONJ>`
M>_=>ZD8W.;HJ,;4E\YMK^)TXIL=0I#4XQ9\\E53557D*?[G"[?I,DV/J4=;2
M5*8]::1):B-))9#&?=>Z3G9"5K[+[%JZ_<.44S](=B1X+%33JM2M'/U9N+[B
MC:FBI:*BRU97-41104DF.CB@CATL_D9U'NO=6?;(97V7M!D$81MKX!E$4;0Q
M!3B:0J(HG`:*.Q]*GE1Q[]U[I4>_=>Z][]U[KWOW7NM>7YF;JINKZ;Y0=G;0
MQ&X<]WEUWVU7Y+H'!X//;NBI<]W/VGM,=8;$HMS;&Q57B=O]C86AW+F(LF^*
MR]-702##QR4DAE5T;W7NBF=2T.W\5UUW!C>S-U]I=JYKI'>_4_QOP/\`>_%[
M@PFZ?D;U+0[_`-L]J=,]U;]V2*W'8O)Y[LS9.\I,33YGP8\O08Z*".FBF@9S
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M_P`'.XZ_%5NR.LILYL>O@I,13Y.GWSDQ#BZJMW!3YVGR,.*I)GR%%&RT=4WN
MO=55]S5NW=J[D[8W'V7_`!7=FX.M]V453V3NI_X?V-E\5G<_UGUMN;8N#3=F
M^SMF7;T^SZ'.T!QVW*)Z,][TU5)LK+-'B,!!-6^Z]UM<_P`OS;VX=JYSM?!;
MEJ&KLK2C&M6Y5\_-O!\W6G+YW[VOEWA%1X?%YF:&N,L0B3&8FJH:98(IJ;28
MI7]U[JSCW[KW7O?NO=>]^Z]T0+OW+X7"]YY*NJJ#^*U:]-;/@R--D=QXS`8:
M@PTF\.R*JGKWGJJ">MB6LKJ&2"H>&1HQIA>>+1$I?W7ND)CQLRJGJ,C#A(\9
M14V+CGS&\&IMDTKTFVMMT]-/DIFJ*:MIJ_(8&<P_;01K3PU:R4J$ZA,FOW7N
MN\;G=G'&4!R,6&P=$%JZ>:IK:7;T&[<8^'RU)%+C:7+X9YFKO.]1]S4NR//$
M)(8`JRZG]^Z]TW96':&`IGH%Q.+H(*.*7/2-+E<?%B,M]CDI\SA,=B)Z&">F
M@Q$N<I0):>(,\U9415$S,Q=%]U[J76KAX,Q_')TVKEMQUL+U$.4RU;ATIY\7
MN;`UC9"IQ^+Q%+5325]"8(X(43_<HDU1JU?:@*_NO=11@=JU#T&'H\?7Y^#&
M5;R8_$U;Q2T58L"??X';N(H<MBDJ:*NV[+`*G&)'&N0JX]#R)Y9"$]U[K%2T
MV&KJ;(X.EJTKZ+'8VLQU'/62;:&.J<?A*2"FR"/MU<.R4\=;J:CGIXH+4-<M
M*Q=/+$![KW7*OV[MI<ECJ^MGBFRL2U.$R<B0T.VI,,)/NC1;5:C7%A=M1X[*
M+$]14>J9:U$6,.(@6]U[J96[,P+3SR39[/1U=0:C&O5TM<,#!6YK#8^CHJ`[
M=K:/&#+5&6OA#%DZV+R">D:0SQH&M[]U[J>V`P\TN1B7+54N0H<I$<MC(:'-
M5?W>3HZ.1*=I88U^VQF$GQM1YO%%5!*B<%IZB21Y(C[KW4Z?:V)1MWTLTU#'
MB'@6@S6)JJ;/56?IL3MF&'R46W\K41X_'I0O(%BU"-FH-"PTJJL*,GNO=97V
MU040>;R9)ZK<.(@IZRGQ^.EJJ5X(\1--,)X$DJX\)A*>C9WJZ.25ZZI>)V\J
M5`$?OW7NG;&[7HY1@#1XO[>/%FKJ*."2FPM=693^+4U50Y.*MF=(UQLD0JJN
M?'-/%+'5!$2.&.1))1[KW2!R&T<9#B*3-5#;LRV#HY-Q?;KF88AC",^(IXJ"
M;'3YZ2:N7:$&/J:>KCG,]+54$TTLLK26`]U[K+6=:PS)48UGS5)2&NS>9Q3X
MO!+#24%7N'"46W:^HVYG&W+3RY1JW&^"CJZ2>U`*&G@$4<#@SR>Z]UW!U9BZ
MS#8J@<U#X&"*BIL-A*;#UN(@P&=A/A-#B<;7;S>HQU<BT#,DL-7.CQ7:,-+<
MCW7NG"MVK)*\]+39O;.%JLO!/CY**/$Y#);AR]/1^*ADDQ>+R6Z,33R4..,R
M1M(CR4-+).]00YE)'NO=9Z;K"BW'32Y',U)SV%K:C%8C.8C+R)GZW/8\Y'(4
MU/A<36T>\*O:&F?&F-`\]`%C03RZ(Q/,J^Z]T@J7IK<5#5M6+N.'+U=/'5R5
M]"B+LD9W&5%6/X/!A,A1[FSF8V75[7W#2TU3-/04LD%?%":#(?<4A1#[KW3Y
MMG8^X,-&^%KLU-NNA$>0V]O.?);>H,74Y:GDK:B6&BCPV+W/0X2HG3(O5S([
MC[-VG1(P$9U3W7NL:=%X#*RU&3R%-/G*G+1YK*5M1D\/%68FBSO\,CP-9O'.
M[*_OT^%B_B6#K66:.G:\DE*)FB>2-"?=>ZX5G5\Z&@I=V4.&RNT:&6H?#4;[
M/QM3DZ6%),5093(8S*9/?N2`VAGL/2K'!!4.U1CY(HS33A-<#^Z]U'QO6V0C
MR,^3I<KE-U5"+2C<$2XG:U%/N?*TL==DJ_&YG)/DS096FF1#D4^RB#*C1J\?
M[LLJ^Z]UQV]L%)XIZC;]%@Z*OR]7EC45-+387(XK/;<F-?'N_`Y>@7(5>#I*
MK)8^5A:19)Z?Q2Q05QD52ONO=-T_7M1][DZ5*3"09/)8O<V1;:==0X-:F:OQ
MM<BU&1PZC<-#G,KLY-MU*U,E-43T>0I*B-FDD(.KW[KW4/);,RM?!G:V#<FU
M\SMQ5KX<?/#M7%4:;*PFW,9CI\!M<8VHFSN:R>%K*;&1UE505TD<DBB.H67(
MR(*;W[KW2JEV8E?79C<]!2ST^<IB<KFX*BMR&X\EC8:W&+_#,EC)6QGADQ-<
M*K["LJ/`9H*"B<4U-&LJQK[KW2.I.L_X5DMG[IPM=1&DCKYZJFI&V1B8H\O0
MR8G&8?/;,2*JPZ4\6*IHZ]VQ[5K4]91AI!$],%)A]U[KK<O4];CH\[DJJKHM
MS[4K,+C\GAYI\05K\+_"L?B:4YG%B/;V?K,SE\[38^LEJL14TU314L$4:PSQ
M:G1_=>Z;-R=?;EJ-K;;VY08VCG&(H<+65$E'A<CE\O#5X?\`BT_\<H]JU>V]
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M51TBS0U%1417-3Y=,)]U[I%5&3R[X[+5]=D*W-QX3$5N$Q>4:AW%+GVBR`QM
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M.W+@,1/EZVBQN/RM$E/7Y"JCI)I%I-2N(S22O[]U[K"G81W/45.`P$\='G(<
MG]OFL%MW/T=#E*O.">*NCHZG+155!A1AJ"@J_NZD,)#2P:(&II'J/V_=>Z47
M^DR>/[9:Z;:]5`U7F-OX+S;SHJ^OW/G:26GKLCCGV_4X';?WF?@P5)#5+15$
M(IJ>G?[N&:>HTJ/=>Z[D[8DB\8:HHH/ML3D,WE:6HW3@Z>#!X4UQFECW-XXY
M/X=62I#2U-&U2CIXIXT>2:2+P^_=>Z;JKM(00UCTL*&KDS6$R$^)GK<]N&&/
M&[@S\V)Q^?K,K-5TU%!5>*F-1+B,=XP:9`4?2AIW]U[K*>T,C+69MYZ?,SU>
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MN/3C(8:C(8?-1"@P=6TL^+U4M,LDT0GJJYW<1!C_`).?=>ZQXSM2BR`Q[Q/B
M,UCY\EFX,F<+N3/8*@V\89J##4U+19ZJQM!A:E)\Y4S4LSBFIJRA=S,84`<O
M[KW4+_2AA\=B*RB2LRF,K\9)1T,T:-O&NJ,I4Y:9UH<I35.5H:S)UM/,U*(L
ME5XZLCG#-)XO,YC@;W7NG0=EXZ7&X'/`TN0P6:QF;S.&GH\CE6QL6WZ*3+M%
M+F*6.*M%/4P8'#2@(PO7ZGHXZ>!]87W7NLV.['KJRD%&:3`S9+(XVKW%C?L:
MW<U%1UVRME54T63R&7ES-!43YC+U,]93"6"2*#6L[K`K11B3W[KW3I%V/48Z
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M2_Y9]S[KW2%F\F;R^ZOC/C\7_`MQ4^ZNJ\SD>T\OMC'4&*FQ$NVJW=.Q]N]9
M=>5$N9K>V/DQ!1T7\%WN,%74^Z<4)6FII9Z85.+B]U[I1=??)[L[X_\`9?1F
MS,!LWKJJRO8^QM_Y#+;IW!#F-U;:VAL;K8C,U6.R_8>U&H=E=78RFVYMK+G,
MX_:E!!MO:^=^RI:O&Q""5YO=>ZV'MC[MH]][2P.\,?CLWB:'<%`F1I*#<6-D
MQ.8AIY7=86JZ"5G:$5"()(S<K)$ZNI*L#[]U[I5>_=>Z][]U[K__T-_CW[KW
M7O?NO=$F^=W5W?W:_3TNWN@LOMY,K(,W2;FVKN:$38S<>&RN"K:"*NCH#D,%
M3;MR^V*J3[F@VYD,O@\)F:QXQD,A!!`1)[KW6NAT[A8OCCU7T3MOY!=2;]H-
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M=0[*HOA=OB&E^3N\-S=4;TKJO>(Q7RRZ,BZZP^$*Q15>Z*^@6*"%6I`']U[K
M8,_EY;ACW3GN\<[%69>:',YZEW-%39[:65V3N.";=E=E,KE!O';>>:ES6&W)
M295):$05=#35GVM%&T[2`PE?=>ZL^]^Z]U[W[KW7O?NO=5V?(7$R5/R'K<K0
MXZHS%;C>B-K3R8R@.2GR,LE+OKL*IP+"@PACJ:S;@S`U9F*L8T\M*B-"4FB8
MM[KW2-KMC&.')5\>'B/\0JC&E;2Y++PRO0TSTLZ[;VPS;?JZ+&U5)7SA)WK(
MU>KT'UTTFN1?=>ZPY/:V;J(XTR#UB1;AH::HED2@JZ3=E%*<@:S%8NKH&V_'
M_"MR45+EDB_R#(K%3K`AK/NO2J>Z]TQR;!S=)+1TU#_'4F^^;#P1T5;NJ;;.
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MK:M$5+N3&+!+38D9JO\`[S4D^XMR5"S2:*Z>C"F:-@D22`F/W7NE5B</FL8:
MFI.,W%409'#U5+C*&FV]3[EK<WFYY*NMK:>.MW!O23%YA_OS'AX*:>NTT^:A
M^YJ(M<OD]^Z]T[O0[AHQGHJ>+(97#&##R2(N)AI\K5U=/CL=3U5%3U.+:-8<
MK03,E0?!$M/#CZN9I?W_`"2^_=>ZR5`Q>/HJ)HL!N"HS^$KJ_;FV<K!C,GC<
M;#55-!3MC4VM01[QQN"H=J9O#R@U>4JD6?(2TDLM=3HTE(??NO==S1[GILG)
M5T-9N&GH\O5E\UF:G;CU=!69G#T_\(H\+42_?XR&3/SQSQ08N6FQ:?[CA+--
M+!K\TGNO=2H,%&F'JH:?;L-*#!2R[<J=S4FW<@=UU&4K<EO&;`9W!;,A_B5!
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MC]MK7X?<$T&XJ:CQ<4<+C#3K%1PTKU%7)%2!3&T<K`^Z]TH]P;AW+1X^KQGV
M^-K:VHQ\?\._O%7S5[U4TPAFS.*Q^7RE/7*<%F6RL,CSYQRK/']M01Z?VH_=
M>Z<C%NN*3)T-9FJ"N_NM!1O3[ZK)GV]/3FE:EI,CF\+A,#'38_)Y7;,=8D7A
MRU+3P&!88:F,M)*S>Z]TE\1NW<@JJJ"I;-9.MPFVZ?,U=#D?X;M^/&SX^4FF
MI,+GLAA<14R8>L7+/4SB&.:%A'50*M,BQ._NO=<S-O%,K%55-#CJE8:K*C)2
MVR]:^XL_`\+[>KZ"I=)LE42[AK8IJR.IE?'38E5$,/D25U;W7N@WJ>S]Q28F
MGK]U[;^[84M339O,4E/23YN@RF*?)YV;%XG')!0XO<PI\16+BS-"DM0<W433
MTGEC+!O=>Z4GWN^XLCM[.;-K[U6XJ$9;&XO<E1F\-GJ:FH,YA9J7<NYZ:::M
MRN0IJ;;.0JL7-1T9HLHR0I4HH@F>`>Z]TQR[XR]?/E5W;%58VOPE+1UF(S'\
M/W%6T<U?62MB,5/N'"9:MKJB?$X>>CGUY>DJ9HGHZB@CFC*05'OW7NG[,YW?
MD"M%D(:+$U=)EXLC1[SIMJ;QW;LK<E30T=+!M_;\$M+D<AGY<;5Y"M2CDGIW
MDKJ.:9JMT9(-2>Z]UGW%V%O&";)RT<&WMO9#)S1TN-R.;&8WQ05N*B@6FJ'?
M)IYJK(9?;^7D?**U5#)!'C//&7CJY889?=>ZS4>_]TQC<FY<-48[;\.)5ZG%
MYO);2W8-PP[Q7(KC,C25^)AIIJBMVQF<2U-!A9*E8J.:"=)H5B%/4N?=>ZYT
MV]-YQT^:K(<[A\3A7S2[:K:2;K_/&3'[JJUJ9-MTM?GZJ.KSV<SD.2QT[UE;
MK^SR$4\86J1J>19/=>ZP4N]=T9VH^UI\)D8<ZLF'S&+7([8R=-))O*HPTE91
M5VQ7RE'#E\;L6KHJX_Q&HKY9%^XF6.FE!=HO?NO=8,UVMNB/:&WGI-MXVFK]
MW5>4J,;0[CVKO(Y=:J@P4%77)D*G,TLN(I#E:R:FC-!4M#4I154!D7U.![KW
M4^A[$W"=NYROKL/_``7(5-=N>IQ%#DZ#(41W/6XG*0TU33;9QN(H5@R-+C,A
M1BLIKFIEEQS325095\GOW7NF?:/8>]ZNMK14IM?"_;8:DFGI6VOO#<-938G<
MU2:[$2;F3$T\&=$5<:JG:JEHHH7PZF4-"*>1)5]U[J=G^S:W'[AC6.AH=F1U
M\E#CJK*9^-ZNI_AM!1KC</N.#'PX_)TU+L'^.44U!HJIVR`2&.I4:ZHGW[KW
M2KW)O7=-53;4\&TX<_7;AK\G5X^7%-58UZFHDPG\/;&5&;;'S5:[RK,7%6M%
MA*,"'^`Q15$$C3RZ1[KW4!-Z-'D:3-5-/@AE,O4Y/!80962LKZ_<V0>HQN+F
MHZZLK$CH:P;>VS62(TE'I-/F4@,BN#Z/=>Z?TWSCH<:((!BJ_:E-C\EDZULM
MN.NJ,U69TY"IH<6^XZ;&4L32TU/D</)"RQI%54..25Y$_P`H)/NO=1Z/LB(^
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M)JZ/'">EPE!N`Q1XZI:.."FK&N\A:,1O[KW3I_>K:%:<S6C,,^0P64K5RE5!
MD$S=7M[(805.*S>1I:Q*%TK-R3TB/]I`%9BT*I(&:(!?=>Z053O+`U&023)Y
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M\[F:6IK*Z*?^(QXJ"KB6TJT^!&1W)N#);BR,24\M,(6DKIYH4`(4#W7NN=/'
MMZOE&>RG\;J)Z"FJL0^#DDR6:.W:E:NKR4`BQ$V*KI<AE\;DY)((WIT:J$"M
M21(4C/A]U[KE4X[`Y=HL)3+E:;QIC1-FZ">K2JK:J*>58IL+GFPDE9G<M,T]
M12G[B.O@2>!DB'E@,Z>Z]U*&'Q-/.:2'.[YHHT2KJJ&GQ>2S,]7)496#'4V2
MS%?%#2_<SU5545CF*3S0I`9)88O'+]/=>ZRYO`XO)UE74Y3(9^6>LK*3$3G<
M&7K9]M92NQ%(7QM73X>"IDH]T1XRF96GH4`@J1XZ>=Q)&TH]U[J)]WMB9:66
MGR6^\?BSC/X>8"N6HL?G*>EFI\3+0R8&F1&RU=3Y+-&JD^PTU<5+"'4&)`Z^
MZ]U)K-M;9J:7-8F6L\$60K57,&KQ59-DLW4?9TE,]?/+!G*:>.F2H:$T+1&"
M0Q76J6=7$K>Z]UEFV5MO%/55%)39/'U(SIS>6CI),OB:JNW!5X0:]P4^3J\[
M0"B;(/1^"&E(GH:""H,7C*L94]U[J)0;4VKC<K!%X,ECLUA:FOR=#_=Y<O!5
M2T5'2PYBBH\;@AGZJ3,3XFEJHTGF4M%/5T^HPQR`R^_=>Z:J7;6`P39"22ER
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M=T60SDM[]U[I`=E[.QN/Z;[LW"9L?%F8^G^T*G%YLX/'/'3?PGKW<=-B9X8,
M+/15%--AHIJG['&B,2P*O[\Q=I%'NO=6>[471M;;2@6"X##*!XUAM;'4PMX5
M`6+Z?I``7Z>_=>Z?_?NO=>]^Z]U[W[KW6NU\XJ3.5.`^6^4VCCZ*KR.U^]-C
M]ATN&_O`N%DFW1T'1XSN?$UD[PUE!N3*29/'8S+50I<4&E6+$M%(LE/432Q^
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M12U`AFDII@DB&VN"IA>.139DD1E8!@1[]U[IW]^Z]U[W[KW7_]'?X]^Z]U[W
M[KW1-/G%V+WAUKTOE\YTAMZGR^5./W",OD#D*G&9''1Q8.J;$T>*S4.W]UT>
MR:G+9%Q_OY:W$YRBPWVX#XNL>IC\7NO=:[75&]\1V7U5TCN+Y#;V[%H,QD<3
MO>J:C[5S%?CJ_/9?-)N[9N-W;OKMO`9C%[LV_O7`[_&>VUA<+G<_+BLO-B*'
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M1")Y`_CG<M$D<7NO=6T>_=>Z][]U[KWOW7NJ\/D7D,AC.^*BM@QF7DH:;J;K
MRLDS>,Q=$:/&5^,[![#KJ3^\>4K,IB:6JVR+?[D*6HGACIZ21Y@Q#R`>Z]T&
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MJ/`58QK9+9E!F<=0SU9IL*,GC71\QM8U=9-!28I)T=<C45$$UP5+'W7NGNC[
M<W.N":>KIZ+`R8Z%X,!EJBKP&3PV<RYIZ$-")TRW\-H6A:KEQ%1/)HA?)Q.R
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M"9G#2YFMQL%!CZQ\)3;@>OQN0II)LBKTCU]%5X[_`"91)&KM[KW7/%=LS24N
M0VU_"Z2DW!6T+;?P\=?49./`;[JY<;FHX=Q2[9HZ/)UF"6@@HJJ";(YDP@5:
M4Z!DE,CCW7NDQ/W4M+A-J5-%,L.._@^V\WFLW@QG_P"#A\M0238"3*1U$.+R
MF6AV[/15;D3%IXT>&%(TU1B7W7NA,V9O#*P562BW%MR:"J@2E608O^^-2LR5
M^)HZQ)-XPR8[(8:CJ*LY-X)(I9C64%%)!*L<LA+>_=>ZF/O-:BB3)RX)<33-
M!79R45T^>I#0;2AC`RVYX*9<903;HS.'K:2>GR%H(I97IZ9*7U5$9/NO=3:K
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MM:]J/`;G!I0\5571G-4@RM;CXJ8(D2T=,QT#W7NG5]N=;5T4E/AMOM-+EUR>
M1EPN(J(I\4N;H*A)*S&R?Q+#5=3!EJ5J(U%152@O61,E.E1-$Z0I[KW75)!U
M2V,3*YA#31YJHS5=6A),RN5Q^V,5M_,8?*44*90T>X$IH)J4TQEGQ2/4+IA+
MU`A>3W[KW4S;."ZMK<[]GA,5'_%*:?)83)3UW\0FE3.U"45+039#);DQ\616
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MSZ+`TT6)RFS8WQ8.#KOO%BI<>N$_W&5U=*\DB/6:9X/=>ZCT^P]H4B0QIE9\
M=24L"45168S&Y&@K]P#%5M0N>IY8LMAZQJ#(Y"ER21,T,4<&BEAB,+1L=?NO
M=.5)L/9WF$.<FH*+'4=/DMPK'AOXY_>-</CJ,PTV:QV4A9\E6YZIR"HPR5'#
MCD2G,B^*2G,17W7NN,W7N(W!C7?&U=9BTAW#3Y.IS=)N'-44BX>&M>KR-4F=
MI:(1[FDRT-5$M7+)3O35$D$<8JYY%:H7W7NI53U?L.%&EC.,KWR]0U1+4UK4
M&#I]MQ3SPRYZ+::T]1%6;:J,U7R30M-!4QY"J9I(VR`BC(;W7NIJ[(K*V2CC
MI<SNAA3UB0H-Q4U<NU<9%35LE?\`<OMG+Y;(464RB57BH(Q5Q9&CAAITLLD3
M$#W7NF__`$';3Q-75/19ZJHI<3BY:*,Y[)U6?K%Q%16RP5*YA:BN_A\65K*U
M3/YQ2PTT3.\3Q2J7A;W7NHU7U93Q_P`>K\7)C<36Q3U,=,U=A=V4E+A\6:>@
M`J?LJ?<,^K*YW&U$DN6F6.*6:6,5(@IM"1K[KW2Q?9F,A_B&)@JMQ39;(ULV
M4@R5<<E7XG<%1%@*+'`8C'TNXQ6XC,Y""I6I:FH:FGHS2I,TE&DT<4R>Z]TC
M,=L.(9VLKH*ZN2IBFGCQ67I!+]O5G(FL2;+/64V;BW'"#)"\[5$%5'/)"=#P
M^&.*$^Z]UEH]IY)<ANJHARV(@JZK^-T.(IFV_D)):#'Y"CH9\S45M/)NH8O&
MS[OQ;&&DH)(FJ5J]##QF5@/=>Z@TNR%.6QU$!_D3S9/#1TF;HL;-CL+M^GDI
M&I<U1`[MJ1B\[N]YEA$$E+/#D;JF0AE");W7NG3^ZF+I\:^&H!A7HJ:MK(C3
M08.MQ8J,-4T]'1YG:%+CLKO#(5>/S-4F*HOLWBC@A:HF>1X()Y86B]U[J'EM
MJU])2UU)D\K35J5\5?65VV<Q2U6X-NX+.-529VO>::MW/D,=3/15'VL4>,ID
MI88I8/VI3/ZC[KW4_;NRHW7;V<S59D\WDYL?%5;@S.#JL;3P[=HWJ%RM5ELY
M/5;F@EI=N[JF0%*>B:5W$PBC5(WDO[KW3>FV#DJ^&/$+#B%&SJAWIJO:&&Q]
M'A\1BHFI(Z7P8;<-)59C(;\S-0L59#`RTL?B$9,;2-*_NO=3IMGSM%5T]+39
M*GJL1M>JP^,%-MF*LKH*ZKI(HLE%B\9C=Y8R@Q!K\E+#3T4--*E;0,JT\53$
MD?F;W7NIS;9BJI:ROQE<];7KE<:DM=2X/;FX:&C$,,^*S4FW\93U--_&LK!A
MY*7'4@$4>2HJEY%^XJ1&U_=>ZA5&%A6'%TT3YX+4XK$Q#!XW:&U\EEZRNHZ_
M^`5,\,%5F9:S<$\D&!EIYZCQEHHOV!+(7?7[KW35D=OYG'4N/Q%/2S5>)?+R
M8Z)'PNWX1CI,0U&^.7*4<&=Q^#P],U/1U"4E5'4/DU5IY)D8-$![KW6/^'5$
M#YAJ>&@I1@:_,28_+AL;05>-RU'/#25E#6U&WJW%S1++AHJ.."3]AYIA'.RC
M1*6]U[KJ7;%13QX_*4-7'3T<T5%2;9ILY7;8P6$IH*RIKJR/$-EX7K:JHEI*
MVO%.%JE$,E<K+22K(T,T?NO=<\3BLC0U\]5EJS)3TM10[@I\3CZ^3:K83/;G
MQK[CW#%N?-X;`0P9C^_&/Q?DI2TM<(Q0S)3".15EJ&]U[KT]-NG'19.OR+;E
MFK\?13X_,95,GL:JJ,I@L7C*5\O5X]:>"/\`C^8K:I8*F.D0Q0I44\7@*(SQ
MI[KW6;`567EI(XHZTIA\*V-K,MF\O-1XJ+'YJNH:.KK,PU)HBHL1D,Z\S-7Q
MTZ1MCDI$DHZDM+XC[KW0:=JTVX3U)WAC\G&]#D(^JNWLM'M.DRNW\_B:&FPN
MU-PP4%5'D,EB)J3.2U]*U5#D*YGD2BF<^2)6@C(]U[JW;;#T\FV]O24L:0TK
MX/$O311S?<1Q4[4%.T,<=1=O.B1D`/<Z@+_GW[KW3Y[]U[KWOW7NO>_=>ZH@
M[#V_O7*?(C(YG8>P\GN_*8'YL[J&XUH-F87=,=-LFOZ`SXR5'E-V97)PYSJ:
M7<TE**7%9RBBGQ\4IGIJ[[9:JG=_=>Z`ROV/V#@\-MNHWITEM3J[$5/6_P`:
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M-!OAMM5F&QO:5/OOL*JPV<H^M\/CSGH*?,8C`Y>;`T[96MQYR\U-%+3P>Z]U
ML7XFCQ6/Q>.H<%38^BPM)0TM/B:3%0T]/C*;&Q0HE%!CH*14I8:*.G"B)8P$
M"`:>+>_=>Z</?NO=>]^Z]U__TM_CW[KW7O?NO=%)^9'R+ROQSZOBS.UL;15V
M_-V9"7;>PI=P[9WON;9<.YA0SY"CI-PX[KRCK]ZYNMS/VQI<9A<'!69[+UDH
M2CI9EBG:/W7NM=.3MW>GS6P&PMTOE^J=GG<8WCV35;NW'@:K`XRJK-CTN1W'
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M9`&=`86A=_=>ZM1]^Z]U[W[KW7O?NO=$3[TQ6W<GW1F:G-T.,JYL1U)L(4B5
M-#7ULC_Q;?>_8DGS"QE:;^Z='-1VG-.QKDDD)9#$R!_=>Z@U&W,52UL-!DZ?
M&T]*V+3'U%)3XBJQN#I<M25PQ=#38G->3%X28JD4")23&LJTJ+./,[J8O=>Z
M!+_2Y\;:W=.'P^%WOL_+YVEWYFND*/%9?`[BRE!+V;LO=$VVMP]<[B_C6-I\
M;C<Q0[DI:G%8R#,5D,M7DXI$QLM4J2PGW7N@\W7W]\.ME]D[WV7O;NCJNBWY
MU]MVIPG:&)RL^YLC/LBHQIV]E:1FRO\`#)-M[3AH_P"]-%`[*89IJK)0T^HL
MT^GW7NG2J[[^._\`>*CZOH>Z-DTO8>;W'F^L*3;.,PG8\SU'95'V!5]3R8:I
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M\=*:6DK/^`OVJ^AHI'B]^Z]TST>TLS)BX(*NL@./J*FH.7@GRU1C:N7<M1)"
M128[)5.9S=92R8B+UU<=&P$T],52,--[]U[I\AZ_:JK%K:K)MBJ0>7<-1'25
M\>,IZAEI9J#$UU'B\?7RK)M]\>U1/6)4F7)RUNM9V;Q+%'[KW2,AZTJL36;A
MRF9AQL]=E,?XYH*RHS-,]2M<*2I>7$Y[-9[,5./Q&#I:F5*=8=,;22//54\\
MBL8_=>ZFT77.?KJMXO[P_P`5I7S$^XXD7/9;%R;LJLOC*[)P9>CW#1Y?*0[0
MJPV1:.NQD<)I,[31"4(`T@;W7NDYE>K=XY.ICR>/HL+]SD\Q024#9(JN(CW9
MM'&Y&@V;3B2K+YO.&G^^GKZ>H^ZI%HF5:-7$&@)[KW3/@.KLJ*K^(45;756Z
M//MZ)&6LHVQM;E*1)Z_";@JO*V3I:2OV5&:V(P4HC^^I)%-2Q!3W[KW2HHM@
MYK*U%!43?;;AA,%+AH<++7X"JGQ=#E,M&U5GMLY&@IJ(9F7**31UU-4H:R2*
M$UL+P.>/=>ZRR;%K_P"%?9MN))(Q+GJ>KW%62?91ONZ/'U<L.YX-=-25&:K\
MCD5:(34K2&))Y4K#-`H(]U[IUQFU\P9J;,9"DQ$T^0BS.+$N'$XI-O455BJ'
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MQIIIYJ;!02XNGHI8_)`C'P2NH)/NO=8ZC9&X,CDZ*&8C%_<5%3L^?=M1OS*Y
M29('PU9",7E,7MK'XJ:3(X['2TU.T"O2T06:&HFAJI8;M[KW46BV9N+"'^[)
MJL^M8V)FKLT,'N"ICGPKU=*,-69N#-3G';6KMQ;MBIJ?"T$P_P!P=.M5)/5T
MC.5G3W7NHN/VMDXE9HLED<E14C9G%;DJ-O3;CH<CAX:BCFS-)/D,<])!E]O[
M0Q8HEBI*:4U-31$,)9*V&1A[]U[I,U>$W+CL31BO@H9,/-658J'_`+[;S&Q\
M/$^&K*O";?V]M/%T\DV>IL'5Q+1PFJ\5&U;+'4PM(U/I]^Z]T^8Z/>2XG(UV
M2W9OE,S79310NF<W%G-M9"4X_%S?WEI`<)30[0P4\4$%+29>FF$<U'-4I4JL
M\T2CW7NI&V(\U/DZ#$"'+XO%8K;&XZ^A@V_09Q:NLQM6])C\=-L[(TE!7X?#
M=6TV422FBQ^1=,VB"%H4*@AO=>ZX[DB[(H9MQTU0=V9`+5[<>6BSL>V*CL"#
M&U59%3QAA2X%]OS46.+K2RR5:3118QJJA2(QE)5]U[I@R61W?DJJD?%5VR:V
M';-)1U]'35^%W'B\?!A,'FL=)DLDF<>BEDJI<30Y*6E@;'ZZ:;(214/VZP05
M3#W7NH]7D=VR5\N4RN9W,%IL5/35>3KI(J6/&)6Y%:JKRFY:[^&L^:R.#9VG
MIFADA$QI12,OVL0#>Z]TX4%9NO(U.(3%[;W7MQ*6OSE?D<AD)<Q0OD,CD8*_
M$X^LIDR[O!@<CN>+%EJS[Y8*?%1)3^I-,I]^Z]U+IJ#<+4T,NK9><SD6+:6+
M=]7G,0,9@LI4_:QDX?'U\AQTU-L"JJ1]ODZUHJ)JV3R0DK+"Z^Z]U-7)]AG%
M;@*&DDCJL<^*V/N+=>X,=CZ7)T^(F3$Y^CFE>6=YLE+1Y1Z6(QLU=+3A*Z<O
M%$`?=>Z=\"_-$'K=Y9FNDW7,-M9O,UN'S6:I,A7T'W-3OBNCQ#5U9A,1!06Q
M4WF3Q0T$:UL\8J=,7OW7NGC';BRYIGW!-D?ND,;N*6*LP-8(<54T]729'^XT
M$\U-3UF,JL5+5G*I(#5#[:=Z>BB$R!?=>ZC'=>TL148TR)N[>E=B'P=)F,5@
MZS!5M?'FOX<JT5=C:.MEQ8W9ORJ0A*:6#TZ8S'+%$DH'OW7NLDO8N:^ZBP:U
M6V4H\GB6AGW"F=AEK=Z8.FKZ+%9&&:G7.P2;?CR>1O\`:5=,)J0YA1$TI4Q*
MWNO=*O\`B<V&S%11MFLI5:9IY,3'E\U'DLBD&.CK,IG-SS4%#D:G*9N:&ER#
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MN)W'FH%Q<B4.2IS)79&>26H9JNG%%`[QAC[KW6':NYLU5TE/EIJ0X$[H1L.U
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MZ]UA?<TU)4!Z-:6OGB^QR&!P2YZ?`8H05\U#/''4XVNVA&T&'GI,RB54GW<D
MT4J$U$4,#2/%[KW65M[13KDZI,CN%8H:S'4U8M-M;[IL'484-5IG*G"8G;T4
M.&H<S41BEIYTK*J:LD5/$DBR1AO=>Z4-9ORFQFC[JFW'6Q+ASE\Q6Q;=K*K(
M_;A5@CHX:;#X5,OMBM@;(T*9(%%:+7'9/*)$'NO=,]/OVN6@B$<6>AQTM`?M
M:Z7!)5XA9J:LF6?(8_:E#M>KR.Y*K/M22TU/7PP_;QZ5*EWTI)[KW3TV\Z*6
MD=Z.FW5)7T<56E#2Y1\?/KP<LL%6N7S_`-C09N@DJ8<6E/*LDM1-5C4()H::
MH8TY]U[I+#=>,H:TT>.:7RA(96K76&NR--)D(ER>&DDVI5;;H*./;-704;SP
MTL;SSRU983+&$B+^Z]U,I=[0TE'#1C^*R5E-NB*#-`TM7@S'35603'XV.NR>
M3P%'+FX:C6D)I6Q\51"8YZ>:IB`C0^Z]U-IMW0TF6H\?3PYDY",U<>.CH*F'
M)5])@\+!55CE8*&@J(\A0PYYYHL8D"4-04HV1DU3!)/=>ZG56Z,40OC3>&8C
M\D=710-55=;DZ>CS0(-5%#20Y%8\1EF0RT^0JJ-9ZG(0"F$$<R+$WNO=!KVC
MN2GR_1_=E/48M\;,_26_?'4[BKL_EZVL:;K7<3XVJRTTV(BH,933Y1J>:KHG
M@DIWFD+U,JS:H7]U[JS[:OG_`+K[;^YYJ?X#A_N#J1KS_P`/I_+ZH_0W[E^1
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MBVIOK(9#>?0VU-NY'=G:&!ZRQN9K\,NYG[`[8H:K(9S;VTLSAJ49G'9J:KP1
MGKL93^7W7NA`[MW?MW/Y;?RXC+[0V-N/!TO3.*J-CP81MM=Q;3VKNNEW!">C
M>Q-K[P$F:K9*[%XC+P842K45M:6ROW4^).*O%[KW6/:^U,K2=%]\;NR/12;'
MQU5\9>CLYLC=453NR'#=FX>AZ?V+@4[GGI,CE*7!9#<F#WW(<-215F.EK:/"
MY1IL;424XJ(V]U[JMWNO<5M^?,G.I44^^,AE=S=);2VIV1NJ',X^BPF(^'W5
MVQMV=49.EZ_SV>IY^T/[J]MU%?E),A/2BBZUDK*?-9AZC`U]-%/[KW6T+_+@
MJ,'D:SNO+;?ERM9B,CG,?6XW(9[&YO$9"2AR.0W!D*2EI:3-04SST%)CZBG5
MYEBBJ%GU15*))$J+[KW5I'OW7NO>_=>Z][]U[JO?Y+X3<.=[,W/24`RT>(;J
M?8T0EPNV:W,2UV?FW+V@E/05,U+44:5U7C(C!74=$TT2ZA(TOD62)![KW0*0
M[.W),ZU0HH#2UDU)2P?<=<[MEPFU(,3%C,;3;DK0NY,A/3U,V*J99Z.C'CBM
M4TKU+(J%O?NO=$NQOQ.[VQ7==!OZFQN8V_E,G\Q^_.V:C?FW.U<]BZ?'?'/N
M'N1M[[RZ-[:V'4(NU_D-LKL3"4F*GV]!2PBMVAN^CFFAS%'15<DS>Z]TE?EC
M\1^Y>T7^0^.VAB<3C,;VM\/.G?CSM%<_NC([:D/;&P_EON'O'?6YZ5*;`Y3^
M!;?R6S<G34[9R:MJ,G7YBDIJ=XZ>E@@JA[KW37A?B?WILGN["]N8[`FLVM1[
MJ^5>`KZ>/OS?N7R$/5WRB^=.]OE1E]P;_P!L8JCJ\IVCO3KCJW=,"[5P$F6\
M6-WY6SY*.I:GIVJYO=>ZG]Q?%_LOM3?VY,I@J_:[;&[*[KWC\AHZ$S"',XWL
MN+^756?"?:?7.X]AT^.SHK.GNO-XQ4N[%J*2MKE_@L4L`2IR$?VY]U[HO-)\
M*/DB_1/9W7F7WA09;LVF[\[L^3W5O8==O>CJ*_87;6>ZCVG#M+MNIR*TLDVX
M>N\I\U\]O*+)42BBKJ'8E<TU2:MQXW]U[I5Y_P"-GR%SV8^1$=%6T.RJ'NOY
MH5GR4VSVEA.X*G+;KZ7HL-E]M1[6I>IMN9;&?:[*WS#MK$R;AW'635IQNX,E
M3X.BA*21RU$7NO="-V!\:.W>P^@_C)L3&[8ZSP7;75?Q8^27QB[6ZPH]RH>K
M]JU'R5^+NQ>A\[OGK;-3/7U^\:?KW<FU&S]?C)Z.+/5N)S%=31QR5`C,ONO=
M#I\:^F=Q](5W<VX-Q[AS.Z\UV3WGNB79V(J-[8NMPD_56T=H[;VYAIMITV7C
MV_2;/[A[,IL+'F]YXR!JL1UQI8JIW-.CI[KW1G(FJJG)>*NBG&;2.BHWR=!D
M*3,T#4YP:8C<%#BZW-Y>'&U@@RU%1LJ-%&L4U0AI)JB$N_OW7NG:MK\SB(ZB
M@CH<9C1#&5RT])N;%M796FP557U6)EJ:VHR&9PV'GDGJ$,609HA5QT,<,9"L
M9%]U[J%`N0@V]MYYJ7=HJ)<&(Q5;[Q;TF[I:Q<G334>=J*.GK?N<?D\GNG$P
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MZ=EWMN2#[NHH-L;GVM4UN/J)<O4YREWU#MW%I`ZRP5J;5R&SZR:"AH*VE93F
MZ`QR5XI]<BK'+<^Z]UACW/F<SF,?-''N#(553CVFDQ&+W!6K51?P*EJYJF@W
M7NG$X3/8G;,5!BLO"SQY&GI*O.TQU(AB24^_=>ZR93<6]<EBE@D6,XIJ.FRN
MX<;E\=E$Q-72S1JF,H*VER.&BSLYH'I):2G_`(:D?@BI?N:A(9YDI9O=>Z=I
M<CN4NJRR3S+E,A]H:?.)O>BI:W=U/]O%A\77Y"EVK//%AL6M/.](T,%*DM9%
M54_C=ICXO=>Z:4WQN/(U]3ADHZRCQ^/K<?FH<#6I4Y[(05#4&5JL;5P9=(L'
MA<G55%72M-'39*=1!2U=.DD?E993[KW4"NW5N[)A<9GMM4+[?RV4P>;S.6BQ
MN\Q!L3/U,12GR^;@S6#H\O$<>E?'+]Q"D8F>2(20$LAD]U[KNJW7%N:7-FOB
MSE%499S_`!2GS#X:N$%%MBC-7%CZF.HQN-\^+Q>7BC6.HHJ&6D,C*T]5'I=H
MO=>Z\>UMXF%=P8.E3-85*=,91/FXJ?%TD>3AI_M,;-40-+4Y-:BIH_MHXZ2B
M_B8@AD#AZB6?1'[KW3'3[_7-;AH:>H@S^RLYMG+U%`F+Q>.W'EYL-5_89./(
M-D\Q0RT-,\5%4N32:Z.J@J$JJ>2H2%TBB?W7NL>%WPN/IJW(4QDQX@PV]&RJ
M8W)SY?$UM;AX1-B<C625<>6I\/D\A"LD%354@CEH9U1JV@@IZ=K^Z]TQT&ZZ
M[+/AZ&EFFW'@8WJ/M5?)K!"9<@8<M2YS%PTV2IJVG>ICCHXH(*^5&>`2R0Q@
M22I'[KW3B_9];B9**+&U-6F9@RDM3N6FRE4,6:F">F&1GHLUC\QA<HN-K*RM
MI)):N.CJFH#&BE$+,DDONO=>I^UZI$S='AYFR-#7M48[&X^'&455#C),]2U%
M'@,7-A\%45M%G:>CJ,K-(R>&*5Z)XHZ^*D\P:/W7NE7M_?LE/EZ&BHJ/(UE9
M6XZ2(YG)9/'8*GJ<_54V)KID3`9&IQ%+034E3C@E,:ZJD@A%+"M+&T,C,?=>
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M]<E8E/6TM)B**B&:R]-08NHKJ7)MCZ[`4.,6@QC,E'%-75-!'%4J(:>H3RZO
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M`:9U--XI(EA,6KW7NDW/A<=3@8NJFR$--58UG;%4F-B;[AXJB/(9*#;^$K=S
MPTV#CF@1VD2G:3P4HLO@C,BM[KW3\V3V]3Y#%3";+0Y:JRCU^1^QFR6)Q]#3
M9*">?"Y#,2U6=A:FHGFJY0E'2F7R&6.ZQ:"J^Z]TVUD>VLI,-LR&JK\:5ER%
M948D8B@P6<"TKXZ2I7/QST\E?#7_`'5-]KCZR52M94+->H941?=>Z?:C.[<J
M'S6)&5:@R\,4.,5,A!G*K%8:H,E!(L\4])59::*LRDU,D4DBF'_)Z-A-+$2K
M>_=>Z8,O4;0I8(DER-'DTK\M38/&T=#DJM:B&GI\5JRE7)M]<W%B*X5LZ^08
M]Q/01:`1)43$/[]U[I\IJ/;\]5N"#)YFAGW16X_`4VZ<M')"M:^1K-#X^7%9
MN/+3SX*DCIB(6H:59/)4TPE!/ID'NO=2YZ;;U`<\U1E,?32)2RUM7DI,QN&M
MJ%QV/A#XY<I`U365$64K8,H':H@E^]GDG<LH0$-[KW69(\1D*^'+X2OCIXIX
MJVLI,C+E,E44E3)DZ5ZAY*W'Y'/34$6/RE#2R!YWHC"?'(UAY26]U[IMEEH(
M\=2UD>X*JJ2B;&3))B6RD-32YFDJ?L!BA29"K@FQ.2J9':;S&)*F2.`25+NB
M$^_=>ZYR4=!!5K34>Y,4F5CFS>=IIJ.7!3UD])7M5+D'EEERM3/4[9QU+33-
MYJ`15LDDH`0Q,PC]U[IJ7:FSZ"KKL=6"&6AC%-#_``V:?+?Q3&_W>:FK$IY9
M4W-48Z5JW+UBY>6&<I2R&=+%D0>_=>ZA8K;F)DQM.M-5Y7.R8M#'5SPC*XTR
M0USG^*S4%3C,\F)-!AS50K$T])7QPTZZ5#!D*^Z]UAPFTMCT^"IY*;[AZ#&R
M`XX8F!J3&U$E61-134N(Q]<U2)EJI6HX(9G^U6`JR)#9W]^Z]U-QVU</55$]
M7+F)=ST%4]<[4453]_C,;#A\='CJBAR5?)EUWE-*,JJR4N3A:GFIY3+!Y'IW
M0I[KW6.HVAMBGQ%/'7Y/R&2G7)-&V-2EI:C)U^0I8I]QX3:IK:JOB@R2P1TT
MK0M`K5;R3W#J"_NO=(KO;`XF#I'N^-7.&Q=1TYV?6#""/&FN6HK>O=R8FIGI
M;5#4E5@\M4RRRQ4M-$THT&:!D+M(WNO=6>;;"KMW`A(8J=!A<6$@@:9X(%%#
M`%AA:H"SM%&/2I<!R!SS?W[KW3U[]U[KWOW7NO>_=>ZUNOGNF27K?YA;;^ZR
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MPE;+MV@H*$3>Z]UM&?`S#83;FX^W\!@4R=+A<+/CL'A</D&SS'##!YG<5!GY
M*F?/03UM9GMPY@?=UXGR%=44A$41\0(3W[KW5DWOW7NO>_=>Z][]U[JNCY99
M#<O3/;&`[ZR>9KEZ2W1U]0]-[YJ6QM=6[;Z9WY3[PJ<WUKW%NY<36#)Q;*W'
M-N*LVKFLH(#3;;%719.LD3'0ULU/[KW34G<>&S)Q.;H7I*[:N^:6F_NAE,-0
M9F27<U-%%41XZ8;KVKJQ$\M7FX3)##CC]O*]-,'JWE01-[KW2GJ]\T=)XJ?<
M4.5HH:.EHI\\<;1[AK(33U_WU=/7??XW#8^L%=FH**M>CBC2NK:EXI_N76Q@
M3W7NDX-XY1Z^>NR^+RD64IGJ?XG_`'?FW#B:''TDN/GFP%=CLG/44^/SN\<I
M'D8Z.&JI7IA#(LB0V6,+%[KW2HH\\)*O#P2X[(5=7E*H5-'C,5B]Z24T>)&5
M2FI):VDT8N&DR]#121LBSL1D0DZ'Q^9B_NO=)"AW]7)3X(FOIFEKLAE,32O6
M;-WM3C,T7WT$DN,H1D<Q%B:ZL&3'W$)EE6FJ87$$(EE5G3W7NIPW'3>E7CSU
M+,BS')U.5KMT18):/^'YC<$F=ID_CB4M/A,104\OCDJW:N>>(4T*B"61![KW
M4"/?4&0H\1)45U7)@\]6Y<4-#AL5NA\K4255=0Z,=)55&>HQ/115T\3_`'\D
M(IJVBUE(J@E]/NO=*+';D>KJDR4L.8FG;-+)/546`S6*VMC*C'TLN+DQE;#/
MN66III:6`(:"2GI6CA37/-'Y=;^_=>Z;L)O?`[G>AQT.0S*+E,(!@\G64V\=
MOOEL'AXJ^IR&6P^<R2U4^33`9&CFJ*BIEE@>>LBC\8?4DS>Z]T_?=XW(Q3;;
MDQ.7QTE3BJ7.M%NE-T5,4D<#5<\&Y\7E*7(G)T$U/-1SS5%/3RK7S52A@I=H
MPWNO=0ZK<F&H=N1[@S&1R>,IZJDFSAR03>E%F1]K64J'+T6(:LC@IUQE;D'8
MPU,D;RP5H:-DC=Z9?=>ZR02;:VNE;!X<QE<[42XK"RTT+;LW%55L]131X;^%
M3309"EQC1?;U\:S_`&,5*T+4LL[M,8E`]U[KHYC'B6@KJU-XC&5=14?9;CK)
M*D8[<FY9JL8FF3$.V7G&0R#T..EI:.GK*>6ACQB3-+X:DVD]U[J#78BEEHZ3
M!5D6>H\3XL2X-6^6^^D2'<68RU)5'-IN%JBCACS3H)XX9F$4[QEHF"Q1^_=>
MZP;AP^WECGS60H-Q5=%B*K<M#B(WH,YDQ#65.-KYTW%3U,DGWDV2B2N6#1'!
M'+E*AIY)"U3%(_OW7NF[.X?#Y*67'Y/;^=;)989+^&%,;5QX/#_8_;T>:@ER
M3TD^+Q`GJ*YI)*Q89)6>.6"20H&T^Z]UAAVELS&_Q^.DAQ]'BJ]*B+,3MA:I
MM@K31QUE;-D*3#PRPX+0D]3)4MBYZ)A.:M8G00QF+W[KW2D&)V^U%1T,M1D\
M!LJOAGQ%!B_L:C;.V<YML;5@PI%#D*!)CLK#TIJ34M31)!DI9W2"&,!5E]^Z
M]U(QT&(R"TM%-5O739G2**:LK4=\4\=31?P;(5TN?CK3B\YBJJMAG@2,M4YX
MQAM6H$GW7NFI,+B$Q64?;M!!DVR6Y:?)/7Q1XO#TU;DTQ]1]S#D174LM*TSR
MQ1U=?D9O+613+%`+PP*(?=>Z8:/:VW(9Z<XF*GQ]3C(<1-49/;]/@:-4Q=7$
M\\U37YA%GG_A.8QLDJB6.5HXHZ<2HJ-47/NO=2Z:+:M/3BM?+47\/S^4JJ:K
M9<+B\.VX*^AKX<M4T4V:VQ%"E#D(LTUHH$9)99:O[AW92ZK[KW3W28C%8BB<
M9"JQ^W*;%UWW.1I:JBV_3XS-U^0S;FJK\KC!%/0XBE>GR$BTJ11@/*K-%$0`
MQ]U[I@RG76TJN19<YB\='25>+DI:VDHZS&8EZA<'B<N,9739?&TU3743UN/G
ME$:('B>.94;S/?3[KW2/QG66'Q,JU=&TM4DN.I5HIJ(KMZFJ<91SSY#)X>5H
M\3!1QRP-EZ:+7/":6FBIP\31!B&]U[KE+B]O9#;M)59C/87+;9A?=&9-+F<+
MNK<5#EQ4U5/)F&BR.7QU)NK+XG*8YHU\2K)-!(:EZ&-Y!"R>Z]U)AP>VE2MH
ML7G<A5R2Q12RTV/EB@2O3"3T6.W-AZ_;U5C_`#9[8E-B8<8"QCGJ&2ABJXIE
MJFG+>Z]UGK-H;9KI6CHYXX*C0]3D?N*A,EA<L^/AEH9<?5R+CI*;(5&6AIZC
MQ0H5KT@5:<`/.4'NO=(=ML0B5LG/O*CRM'2X>KARD%75ST=+)739:EII*>B>
M"CIL[0Q;;Q%+!%#+55$RQR5+4D(DIG:2/W7NF'/[:VWDZ["2+N_(5&/$V1Q^
M+Q4U4N&C@QN`R-)DI\<DNW\='18K<F"IZEEQF?6619$DGI?(7FUQ>Z]T*.W-
MF4M37S-+)14,NXTK*.4+D"U76E'H\IM^(O44"X.E&=&,B3^(U<\<KX^,*DQ9
M@H]U[H/?[@X!\U-64V0JWR<]8N;R*TV?GEKJ#&X[/RP5$^%6@P&/S.%QM+63
M2T6'I8B,ECXH*@(LL4T4C^Z]TZU/4M5438V63*)')4Y<^6MJLP*7<Z+5G(+D
M/[O45-*U!4555'6P_P`#EJ8GJFJ$%'+!'2(BK[KW3?#U26I,55Q28["S4S9.
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MNO=*L=59:/*246&:/^!U-)E*UY,10-2Y:IR?W=16+MF+`UVX%RM50P3&2IR%
M37-)39"*)UB*B?T^Z]U@?J^8TB-/DHJFIIZ/0^XZ?'R1#/OD:^C#XO%Y>NS*
M[=H1+`TDL^3J4J%Q+R&C554Q6]U[IP@VKG6@BJ:3+I79.DPRU\-+'$,A64N6
MQ%4E)M]A2R;BI\14X^OVY*)JZO@6)7R>NH4!78M[KW3$G6&3>3'L:"GA@VW'
M_&]N05-4VY*:EJWI\I'%G(J:;?\`3_P[,39)ZH2U4E56U$;2_;CP1I'(/=>Z
M26[=BUU=6UDV#R%'3;D2/&8C,9G&RP5N3VQ%3TN/Q0Q^5P;[KJZC-XFFSD\5
M?+18ZGKB*=A2EWD1JKW[KW4;%=<YG/3;DR.3DQ"4=.\66VYD<3GYLE75^XL7
M?*56?R&*3)05$<E5D=QSK@]<=,]`T.AF2FJ0WOW7NNL?L'(;BS514T-+2^3#
M"FQNU<-2Y+$4F.PV.I,B[;?Q6-3&[L1J&EJZ_P#W+@L[Y2&JHWI7DT$4\GNO
M==UG7R87'18S;BRU-?KIZ;=6^\CD(7IJFLR<U?'G,I_`]LYNKEH=WX/.FFI6
MKHJZ.*HI*PQV0Q51'NO=-]!UIN!L::7,4-2M+CW?,FKJ=S?PU_+DI)HJ'/&G
MI,ID]<U=2Q`24YK`:E1`)&AJ::\ONO=+/^Y.0VC!MW#[:ZVVA3T,=%%F):#&
M;MQ/GI\E%/C9(LCG/[T;I*;JS>,%/$D-1`/#532D%(/&KO[KW2.;!;UGJ\CB
MZ\5F0J:C'UV*PSY'<U1AZ3<>&R^,H*6JS.Y*.F5Z3)8IFAKI<A"\!\^6C:I4
M1&HB4^Z]TY4>S*J@F_?W;F-MU\SU6-I\93[9VYO45&,I:BFW"M.-K4-57S;=
MIJ;%-3UD$+O4K!2^9Z>K#1RHWNO=+2DVAGJJ'(056"H)L1#N_*-C\6V0V^TH
MG>-,MEJS$YW"TT%1)-G,DD5=+CW+U>,R+:J?7$HII?=>ZYT6QMQI28"1(*I'
M6IP&3SV*RF[Y*]LKE7EJ,%C,AF*Q,=%55V2VY@Z62O-<$IXY9=5#)`&4D^Z]
MU)DV*^7SV*GR.(.Y1-/3U56V5R5!M7%I/2U%2^WHJFJ7&T%-O+-[HRE940B2
MF^QBI,;`8740U$3CW7NNOX5F\>@RU.[4,N'S0./K:[=F&R<E=ESB,AMG&TN6
MW%!@\OCL:?X)!-+)#41M)725(@BJ)78H/=>Z:ZK;VX\$/MHJ,15&#RM))0;@
M@AP"U>UL;F\;_#<CX<'!M'^.UF(H\W7&(-XTGBJ--0T<%$\\(]U[KV7V=5T]
M#F,?34GCQN<A@VEA<;BL;D,E0BJK:V`TE;*7VZ\M1N&KI&GCJJ25*F6L\@"?
M:QQQ`>Z]TW5^V,[DZYZ<Y"LJ:J1,W#M.CP&YL[487"4>%H9]O+D\'BL9U=28
M_`3Y2:EJ(*F.MKTH46H2)HI6@5O?NO=/\^!R6+P]77XPS5^0I:+,UR9YZMYZ
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M]U=,JJJA5`55`554`*J@6``'``'OW7NN_?NO=>]^Z]U[W[KW6L[_`#!]M/6;
ME[+W-0)@JC<NV?E?U'BL'_#-LMN3,92N[=JUZWH=M9>B.:QT%=M6BDJ4KMPX
MJI:AQ]?2D5-54LE&(V]U[HKO2>SMQ[>VQVE0Y'$T>`[2V%WU\>Z/!9_,[@W'
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MH)\A)E<?+112BDC>5T]U[JV/^6T=PR)\@*C/1XJ%ZG?F`XQ^W-P[8FK:ZDV[
M'1Y#,56%W!459V['EVA2=,3!4Y`4<KS325DOW<:1>Z]U9][]U[KWOW7NO>_=
M>ZX2Q1S1R0S1I+#*CQ2Q2HLD<D<BE7CD1@5='4D$$$$'W[KW14<G\&?B=E=R
MY#=LO2VW*#-90TS5K;?K]Q[6Q<DM(BI!41[?VUFL3M^EJAIU-+%2I)([,[,S
M.Q/NO=,P_E^_$D?P<GJRK:3`1U\6'J).R>V)*NACR<DLM8D59)OIJIE=IY-.
MIV\0D<)I#L#[KW30_P#+>^%DLT=3+TI3S3PX;(;>BFFWWV?-)'A<FXDJ\<C2
M;U8K3EQ>.W,%SXBES[]U[K./Y=/PY6EK:*/J.HBILA7OE*R.#LKMJ`S9!XZF
M,5ADAWXDJ3Q)5/XRK#Q$*4TF-"ONO=2Y/Y?'Q%EH!C).K*UJ,8^3%-'_`*3.
MVQ)+C)<A_%7H9ZD;\%544IKR9-#NRC4RCTL0?=>ZQ5G\O'XAU^1&4J>KLH:S
MS).YA[5[CI:6=XIS44Z5-!2]@PT%53TDC'P121/%`GHC55X]^Z]UVG\O+XAQ
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MK<?2':'R/VET=N//;`V_0;YWEM;+TN_Z_-/WWLO9VV)<M1=@==9*'LS)XK+;
M3WW2)40[>FR=31"LA5*AE@IIHI3[KW0*;`[&_EW[EI.O=Q_Z*]_[5J^]^^,K
M\9MJK7YS>U?C-P9],;39X;NPN7P78>5VSF.F<GEZ_%XFEW+B9:C&C/Y6BH04
ME?T>Z]TE:_,_R_\`KFM[%W%@OC?V?G).KL)\E=W;^K=L]A;@ST.V=H_&#MG;
M73/=F8PE'5]QFCI\K0UM7%F3BJ=*/*5N(HIY6A->8:.I]U[H;^_NM_Y>7QRZ
M0QW>^]NO]S[CZVW#FMG8/"S[*WOVKO')9:'N_<.'Q!W1AL=)V)`\^#Q6(S4N
MX,QD('\N+VY05]>O[=.X/NO=!1NBM_E^=;=J]D]"Y/HOM^3?W5F=V(<EBSO_
M`+!J7SVQ<[USFNP\7W+L3);B[AI)]S;#V/5T=1@\Y54K??;?W!41)40)#64M
M54>Z]TJOB]A/A+\A,_3[2Q71W9?6&_*/HKICY#;7VQN[MCL.9-Q]&]X8[*/L
M/>."R^U^U<YA\FT64VU6XW/T[.U119BG8R&IBJ*>LJ?=>Z#/;V_?Y?%=M[;N
MY*+H;LFBWHW9S],#KG)]B[P3>.$^1E7VGMK8FTNN-PT\_:D^+:K["K=S1[HV
M[N9Y9\#D]K4TV:AK?"JE_=>Z]7=__`G9&^J[9>>Z5[BP^\J7;/R+FHZW*[_W
MA+M_.=T_'B3(-V3\>FW7F^UH*.#N?=.V=P'.;3FKUAP^Z,#42RT>2\M+44L/
MNO=&Y[(H?AETY#T\^\MN9VCG^1/8VP^I\'3XOL;>.67%;D?'9:LVSDMRU$78
MBTN'P&S<A418E,M3-*,=D,KCZ6$K]Q`/?NO=%CW'W!\&-A#LZLK>HM^I3]4]
MF;<Z=W93UW<^2H<5M;=>YMT;BVGLUNY-K[F[CH:KI+$[J&SXLIA<]O+%XS"9
M'"9K$UU/D6CR!\?NO=..?[>^)6TXNT:?=/07;FV,9T+B\C-O+&OW#53[@QD4
M.UNF>P=[QY/8NT^YLMN;+[`Z]H>Z,+_>K,+39'`8B:GJF,DM+#%/+[KW2UVA
MO'X@;O[=V=TY'U=O#"YWL;JC$]KR>?O+5ML["S-+N+.8K>^V#B.YJG;O;77"
M4VW(A5;EV1)N"CPDV6Q<.1^Q^Y;P>Z]T$M=\B?Y>V&ZGVUW+MKK;M;-87>^^
M_D3MRLQ=9V-NC;^Z]I[K^,FRM_;V[$J-PT&]>WJ&FV[63[$ZSK*[`R1SJ]92
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M/;7;H[OK;^0WYUQB.T,"N\>Z-T[$`.Y.U).H\=M/$8ZJ[RHI^R.QMU[EV(,I
M1IBX:^#/8:EAR5/6U+3P+-[KW0S=-;D^$?<G3W8'?D6'WUM7J;IFEW%5YCL'
M<O;V_<U@H-I;;V&NZMTRKD\'V7N2NH).M\0M70Y[;N4CI,SM//X^NH9J*&:,
M&7W7N@)K/D!\2=C[<PV3S?0OR`VK7;OCZ.W/L^G[7[JFVMCI>N^\\;V#7['[
M$RV]]W=W2[>V+M?'+UW74^Y\<]0,AA,E-C(ZFB/W<$H]U[HUN[9OC;M&D^.N
M/INN^U<MOGY.2#;75/7F)[#WS'G*ZG@V!D.VMT_W[R2[^_NW@]J;1VYA)9LE
M55%94TCUDT,-,*F:LB63W7N@.P_<_P`4FR#Z>IOE+@L=0=@[3Z.SU17=B]D)
M3X7Y)9KJ^?LO`]&[GHZ'MJN@&Y=O4&2I\2<S++)M_&;GRM/1)7HTTDR>Z]TC
M:CY<?`6MZOV+V1MWK?Y)[DP.Z/A;NOYO9"FVYD>PJ?<O7'2FR<WL[;^[,7O,
MR]H4,>,[CP^5W16_[@:&JJZYCMO-2++_`)+&U1[KW0Y9WNKXK8[N*MZ9VCL/
MN;L'?4>6Z9P.RY]L[NW$VP^Q-Q=N[*W?OZGQ?7FX,IV'2X/,TG7'3FRJC=.[
M,E'`F-Q>)KJ0+45%=7?:M[KW2-QGR?\`A;E\S)L,;2^2<F^Z?;&R>P,;L[/U
M_9&.["S./W;VK/TSV%CJ=\_O^BR%1NKH'>M#(^_<!5U:Y#&8>*GRE/3U^/GH
M*B;W7NAN[HS_`,<>F.S=D=3YC;'<^[^P>U,/E-Q;:V?L_?6YJO-;GQ&WLE@,
M#N&LVYC=P]A[?FWSE-E4N3I\ADJ'#MD,SBL*DN0-.*5))![KW038ONGH#+Y>
M@ZZVWTE\IZ_>E9NO?^QMM;8QG85%C\KFMP=.ID<CW+0XO<?^G2D-'!UG6TM+
M2Y">LJJ2.NK\K004+5AE<P^Z]T_;)^07QB[2H:O?75FV?DQO38FW\103[YWY
MM+*=@8;$]>[ES>PLEV#7[!WQM^LWGM_<>-WKMC;-/!'N"$XZ6/`Y#)T=#630
MU3R10^Z]T+G0.7Z*^5NRJ+>>Q,'W7CNL\10;.W'LK?U7V/N'";/W_#OW8N"W
MQ4U6R-V[&[+R#[_QVQVS$>*RE9)--C*7<%)64U)-4FGGD'NO=`1D/EM\0]N[
M/PG9.0P/>?\`=/-X&F[!ZJSV;KLE!B^Q>N\YW%LSH+)]A[3R6]MZ8S;^-VSM
MS+]AX//U467J<954&V<G3YJ&G%SH]U[H8=];LZ`ZVZ+VQW[N'_9@SMS>.4V;
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M![KW08==;W^-&7S?1NWZ"G^2&U-X=W]8[][9ZDZXWEN_LO`5E/M7K"?!4N4Q
MK(^]VVGB,YNJCS<62Q>-GKWFRF/AJZU`L--521^Z]UAZVWCT%OG'?%;*86G^
M3-"?F31[UWWU_D<QV+NM<EB:+#=?R;SJ*+L-Z??U4N$H*O;$*C'4U$*Z*.K*
MK^W<R>_=>ZA=6]M=#]R=F5_5.VZ?Y0XC*Y6;:]9-6[B[)J,1B<:V4ZLQO=F`
MGQF+J^SJG=HHLMM7<D/W55CL94TR92+[:NEBFCBU>Z]T^5^[NB,_WSN3XWU>
M6^06)W#L_)8?`;HR51W+'@]K95:GK&E[BQU6\=9V?'OK<FW:3:>/D@JJBEQD
ME/05+R1U(BCD6;W[KW22C[F^.>>V?U3F>N<I\J>[LKVED>UZ39&S=H;TWK%O
MZGQ_1QRC=AY+.T6Y]U[/3:^/V16-1T].M7/%D<E79+$T\456]5$#[KW4C:7;
M?QS["[0V;USAJOY7;:W3D^ZMW]*4V"DWMOK;>,AWEU?T/@^]MVS;SHJ3>S5>
M/VX^V-Q14D\M1&KU.XP\#1`F.:3W7NGW<6[?CYUGV%E^MJO<WR<J:?9F_NK]
ME[_[`C[`WKD>O^O][_(BL1.K]G;RW9F]T19&=:K[S%P*(8:^EPT6X<6M5+`:
M^,^_=>Z?/BQE>H?DAM_*[VZ^RWRIH\!%38UJ&K['[2W/`(ZG+U^6DR5)08['
M[\SE;MW=6/FQ+0Y7%Y:*BR./IIZ8K31P54,DONO=&%F^-&UI,BV13L/O6F?[
M?(QQTM-W/OE,?#69%J0G,I1/DY(7S-$E&(Z:=PY@C>15`$CW]U[KNK^-&TZO
M[8G?O=U+)#6?=U$E#V_O.D&2C/B+X_)T\.06CJL5++%Y'I_&L;.SDCU,#[KW
M3/+\3]HS0ST\O9WR%EBF5M"2]W[XGCI*@RI.E?103U\E/39&GGC5XYU3R1LO
M!`+`^Z]UPH?B?MBBIZ&F?MGY&9&*AR%?D@,IW=O"M-5-D<C4Y*HBK6>H!GIU
MEJ3'&O'B@58T(46/NO=.&:^+FT,U/251[`[QQ5701RQT=7A.W=VX^>#6L@A?
M4M5(LTM&\K/"T@<JYN;V`'NO=3Z;XS[#IIJ"H_O#VC/-086KP2RS]G;N:6JI
MLE0C'Y6KK94R,<E1ELK3J#/5$B8N`RLK"_OW7NE;U/T5U/T?1[@H^L-G4>VW
MW9GJ[=&Z\K)6Y;/;CW1N#(LK5>5W%NG<F0R^Y,W5-H`0U-5*L2C3&%7CW[KW
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MC/A.H-I?P;<._:3,=A]3Q4WASN+I4V?,V/I7%3GZ6-J9:KW7NI'6_P`S/D)L
M#M?J?8_4VX]N[JZVWQE-]8/=>]:S9V,3JW:D>R*?&ST.!H<\V6QXIZG;V2Q5
M7@]TI`<1DJ'=NZZ6#"[>W>R@K[KW6RCL/<>2W=L_;^Y,SM;+;*RN7Q\=57[6
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MV3F$=#M=L6]`-LY)EH:JFJY:R*3W7NA/V7B*'';1K]QT736TMV[7V%E/DS19
MC<T%#W=35>X#W!N+,8S'[KZVVAN_?>X^P7RU%DX*W;\T."KUFQ-?15L-(F)I
M)8%F]U[H_'\J_;M7@,#WQ3TN0@RVS<?V'BML;*RL61W?5)E,/@-NTTZYBGQ^
M_,QE]X8F+*1YF,RQY1OXA)41N\TLUU\?NO=6P^_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z`_NONN?IBFVI40=-=X=P?WIS51AY(.E-F8[>-3M=*>AD
MK?XQNN+([CV]_#<+.8_#'+$:B1IV"Z+78>Z]T`:?.*O;(96A/PK^=B)C*>LG
MCR#])[:&/RQI))(UI\5(.RC/-45@CU0B6.%65AJ*FX'NO=.?^SI5!$)'Q"^;
M)\U754MO]"6,4Q"FJ(88ZJ;R;Y0)25D<IFB;D^-&#A'LA]U[J=3_`#%EF/[O
MQ1^9=(@_C!=ZCI>B<(,1CWR$?[=)O&JGE_C!3P48C1S)4$*_C'J]^Z]T"NY=
M]]6;WWAVGNC>'PY^:>?K.T^HMN]%[U@RG6.3;;6;ZR=]_P`K8'%86EWU'3XB
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M_&:FEP9R_P`+/G=O7(;*W'AL_M;/U_7>[\UG\#5GX\8?XKY.DQ&YYMZTN;DP
M>>Z8I8\;N"E:HEI\O4B2OJ5GJU%2ONO="1TOGNE/C=D*F?KSXC_-G(9Z79>P
MNH/[Y9SIS<&Z<Y0=5=)8ZHVSUKU[B\SELTD]!L+;%%/55]'24J*E979*LKY_
M/D:RIED]U[H/9NO_`(JNN"R%9\)OFM/NO"[<V7MG"[XGZZWO6[]H,7U+VA2]
MX]6UDNY(-Z5#RYC8?8LS5&$JJDR5U)"]30DBAGGIY?=>Z:=[[7^*N^MO;PVK
MV#\#_F]V#M?NK$[S?L[!9KI3/5E#N'-5G96+[C_O3N98-RT%70[XCW_M6@K=
MO5="\7\*:FIXZ84BQQA/=>Z5V^L!\7^R8MX0YOX._+7'XS=.W<]MFMPVV.@\
MALS%4>:WMOC%=A[M[&VWCL!D<8N([1SN\-O8S)Y/<\02MKI<31^::9H(T/NO
M=.>/V/TYV%O*.LR_4GSZAW;V5BZ7JK,;SWOLK.TIHNO-S;B[`S.1VEV-N#)1
MU%!N7JM,GN[)2RXS<'\;H,-2U5-#0T])#%!%%[KW0U[(ZG^)G2W<M!\:NO\`
MLS=>Q.TMU;`C[BVOT?A>R=S)4T'6_6.WNJ.A*'=N#Q[FJFH-I[8Q6RL!AO#4
M534E?,TAJ8:N1Y&'NO=/%/\`R[?C;CJ/&8?`X[>FV]LX$9ZIVKM+!;TRE'MG
M86?W7A=X;>W;N;J_&2"=>I<EO+#=A9V#.4VUVP^*SJ927^(4=48Z<P^Z]T]Y
M+X&_'W([NR^\8L=NO#3UVX)=TX7;NWMTUN#V/L?.Y+I'-?'?=-=LC96/CAVW
MA/[[=49V6ARL;4\T4]3%#6QK%6PI4#W7NHE9\!>B9\#N'9N.R';&W>O]RTU!
M%7=?;>[7WCC]II68GKG:W5.*RT=.U?/DZBOQFS-E8R*!:FJJ*:*LI%K5B%8S
MSM[KW0(0?+3^7IGNR=X?!:D^9N,I>\=U]R;JP>;V1'V_NK:/;,'<<&7H]]9/
M9.Q,_23[?I=OY''5<$1&#PSI3RPR-":>1JN;S>Z]T+\/\N[XWT@W4^-QFZ<-
M4[RQ>U*#,SX+/QX6".NVI\@]P_*)-PX3"XO'4NW-M9C/=T[HK<KDDQU%2T-2
M)?"*9(@%]^Z]U$R/\N/XXY61I\C#O>NJLCLS<FQ=X5&1W/'E6['PFY^]Z#Y'
MU<O8T.6QE=2;ORU'VG235-/5U,9F6DR-=2N9(*N9&]U[K-MW^7MTSL_<AW-M
M'>7>&V*N/9^0ZRQM/A^T<E3P;=ZBK^UJGN.+J?:E5)139G:FS<%NVLE@Q#X^
MJILOA<)X\505M/CZ>FIH?=>Z$K8'Q!Z<Z_Q'<V'CH,OO1/D3+`G>59V)E)-T
M579F-I-A4_5U-0;E@$>/Q5;5-U[0TV*K<F],V8S<,`FRU77U;/4M[KW0?8?X
M!=!X&HP69RE=V)NRMV5D>IJK:N0WQO!MRC:FS>B&W--UOUIA:*LQW\,H]AX9
M-V5WWJ^!LMFG:*7)5U9/3T\L7NO="IW%TAUSW%)L++9H[FVGNCJ;/R;KZD[)
MZPR%1A-^[+R^3VQ7[;SU+B&I\;D*2MP^Z-EUT]!68RNHLAC*VE*,\(J*>EDA
M]U[H,]P?`3HK<6X,AN`UG8^'CSN\J'MC<>W<7O.8;=W'WEB.MZ?JK;W>F;H,
MG19.>H[/P&U*&C>.=)H\=5Y3'TF1K:.JKZ:&H3W7NH^/_E[]`[?^[GV<^^-E
M93.TV<BWSE<!G\?+)V/5[E_T0C/9'>V'S^#SFUZ]LDO2N)!HZ:@I,7#]UDFA
MI8VR-4TGNO=)6N^"_P`/NB<$>R:2LK>CL)T[#MW>VV.P9=\T]%2=(KL&I[3R
MN<W9B]R;^BSU-"N[L/V_N'&[HGSTF3ARN"J(:"8"DHJ**G]U[H,OC'T5_+A^
M5'6NW>U/CGOVA^1'5V`[-ZUWSL_=&'[,R^[8-H=W]&;SW?O;^_-+G9)XMWT7
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MKW08YO\`EV_'_<.T<9L7*UG9-3M;:N%V5M+KC#2[TDGH>K=B['[@V5W71[#V
M125..GI$VOF]S]<X/'Y),E'DJJJVYBZ?$"=*"-81[KW0X=_='[/[?Z/W)U!F
M<KO+9&P*S;\F)RU#U1!B:;)5>SJ;%5&.R&RJ;`U6U]U8O);?R^#D>C?&KC9O
M)$52%5D5"/=>Z(\G2_Q"IZ;=*Q;;^4R;9W/MS/\`7>6VK-TYW[DL9'U_E$>G
M["V#CDRG6&1W%1;;W]NFLIL[7RTU2E9/EJ.*IH:J*".6-O=>Z=>OL%\9^H]X
M;"[`PN-^9&8WCUMB.US/F<CT5\@,A/VKFODCD^NLQV/O;L2FQ/4..H-X[R>K
MZQQ#!Q'2Q8E(72.G0-8>Z]URWG@_CQO_`#OR2SDQ^9>#SGR5P6TNO-YYO;O0
M7=.+RNU-L[-P38%ZGK#-5_2=76;7P.Y<14RQ95A)5)5R2N\<<<GJ'NO=!%OC
MXY_!S=N4S>7K-H_+^ABRG979/;.V,+M/HSY"8V@ZF[2[@ZXVQUONCL?J2*#I
MYJWKS<6*J=J4^Z,76T4ROA-W3U65I3')53(WNO=&,[EWC\;?DATSG/CKW/UW
M\J]W[`W)18#"Y_(5WQO^2NW\UE9=NU6)SF/W&FZMM=:X:LQF4&6Q4,SUE#]J
M14!U144E??NO=(_>.UOB_O#>N)[$-%\LMN;RVIO[K#?O7F7VW\?^\Z->K_\`
M17M+)[(QFQ^N\?6=*U^/VQUINK;>X,K3;@PL,7V^63+U@<J)0$]U[I+;5ZL^
M/NUL5U518G?OSTD'1`AH>FJ_(].=L5.4ZZP\?76Z>OL]@<1+/\>T?,XW=6V=
MU.:R7+IDZL5E#0O23T\E+&/?NO=+38F&^-O7':-1VCM:'Y94U74Q[.1]MUOQ
MZ[NRN'1=B]6XWJ+;U/!F,ETG4[[I<<FV<5'/54<.8CI<AE'DJJN.=WL/=>Z3
M&_.M_C?V'OCNGL6JR_S&P-=W1#B8=]T^W/CSV7CJJB$/6E/T[1?W$W)7?'NM
M[#VA'/M>ED^^CQ.4CCJ9*F8U0:GE,)]U[K+6=6_&U]\CLOK_`"'R]ZBW?'O'
M=.]MO5O77Q_[+PM!M2@W;L#K_K?MK8V#P&;Z#RV)CV7VG2=<8'+Y*CK(:JK&
MY,;%EL9-252,_OW7NG?;VROBQMWLO;_=5%C/EG/NC;??/:7>N-%?TA\@*JA;
M?O<735#T[NVCJ\=+U&,G5;4_N;C8YZ:!I/'%E?WFF=],2^Z]TZ[OVQ\7-\=C
M;@WQN#`_)V2@[*W/U!V5V%UV>C?D">LM^[]Z*J*"?JG>6ZL+4=6U%5293;TF
MU<0L]%!5T6/RO\#QO\0I*GP1EO=>Z$7HG<7Q^^-'6V)ZWV-M?OZ:AI):G(Y/
M<.;^.?=^5WMO'+Y2MK9JK<F]\YC.J:.7<>XYC'XIJNH3S^*.(-9?'?W7NAD/
MRBZW#1JVW>]`984G4GXU?((J(Y(VD0.PZU*QR%5MH:SAK`@$V]^Z]UW_`+-!
MUMH+_P``[PX@BGT_[+;\@?(1*"1$$_T:ZC4I;UQVUH?J![]U[KNF^3_7%544
MU-'M[O)9:NMHJ"(S_&WY`TT*S5]3'20R3U%1UK'!2TD<L@,T\C)#!'=Y&5`6
M'NO=&)]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5&';1ILO\`
M(:CDR&:W?MO:^%^;>;IJJEV[#L?'UV[-X5?QPWE0;0Q=')NB&H[%W)D6W"T9
MQ<6TI/)2--4RSQK"I67W7NBP)1[+Q&S=I93;51V>]>>I_BG7Y6B[DQ.Q,OO_
M`!FZ:_N'?.2V7VKE.R,3%E>_9=P[6VE@ZZ.;%/02XQ,2B1U=/2ULIB]^Z]T)
MW8N<P,^&[1R6(SN_6Q>8[-ZZW3N#%;@Q>-KIZ'';NZ>[LDH^[=J1[AW)D8:;
M9VY,1-29"KQ;!\6F0FJJ/53RRR08[W7N@FH\QM_MK$]H?';;!Q65WI)G>HM]
MYFNRM'E*G;NX.O\`=E#C<)MGN3>^%_AW7F.I,_V8U;2R5>/R";BQ^#H<A0U:
M8NI>%JND]U[IYZ6^1NQ>J]]?'GJ;</Q2V_G=VY;'ILWJG!;CSE=)3[%PJ8W"
M[OV]NO*9?,X+=U-A,MW;L/9.7W!MJ7+S9;(C'[2QM#E\]0U%33K![KW6QQLK
M>6WNPMJX/>FU*X9+;VXJ):_%UPCDA\].SO$QT2JK`I-$RDBZL5NI92"?=>Z5
M'OW7NO>_=>Z__]??X]^Z]U[W[KW1/OFQNGN[:'3U=F.EXZ5)T7)T^Y<E%45=
M)N'#4U7B:NFP&5P];2XW/RXRCQVXY:>HR%13X?<.0>GA%+2XJIDJC-2^Z]UK
MJ=*5^V-]]0=5UOR%W-OFCW3BL3O_`">+I^R]RY2BJ=KYS<N%W=L;.=W;JK<E
M7?WKK>ZAN>@RF&P-!E=UY2.MVE08ZKS,V.>/QP^Z]T(=:_86ZCFTW=M^LVS5
M8;8.P\1T%+NV5\3NO>/6"4F:&^<WV3T]M*H3KX][OGW$-%B\)7T=)!2Q5F@$
M>(5/NO=.?5;;)R/QZ[\I**BW=AMUUO2_QZR>XZSMN;!YBBAR]1U3U;@LCE.G
M,5BML5NY=SXG!86*;`;FR3/"8JR>B>NIYG2*5?=>Z*QV3OR6#OO?L74<'95=
MT1UN.HL1O+&X#*YZ/K+?-;\_]Q/2_+7&[\WQOC(2_P!T]K_&;XV83`Y;:L]1
M5?;;2K8YJJ%B/N![]U[J]K^5[M2CV/#WOMW!0;DH-IP;]3'[7HMX[ARNZMUU
MF&V9B<9L:#<>X\[F,CE,A7[ASN1P-8]9/-)')/HB(01JGOW7NK8_?NO=>]^Z
M]U[W[KW7O?NO=%GWW\>=F]@=ER;LK>W_`)`[=W,,3!(-G;#^1G9NR=I08P11
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MB21K$MR6C9-'NO=9J#K+N2@GKJ[^Y_S0\.`FRF#G%3_,&VME*2FHJZEH*JHR
M>8BR6YFBARF/AD26C%2TD\2/=F1)+'W7NLM+U?\`(1(L?)+UA\W2]95TZY*F
M/SZV3418FFH9)9*.L@JCN&"HKWD9M4\(*K."$E,J*%'NO=3:7JGM6'+T=!64
MWS5QV6J8J6OAPU7\Z=B5<F0BH9))*A*>@FS<M9+1B2=DGDC2/6-*D@(@7W7N
ML8Z;[PIJW(S4VSOGD[M0)AXJAOG9L:JI9Z>'(?>IDJ/&Y+=,]%1Y&5FTM.T"
M3M3KXCZ?2?=>ZSOU!WA3"CI*;9OSKGC2J:I-;_L\NQ)9(&@4HZ5)R&YY)*RE
MRRVO$RR)`1>(0$L3[KW7,]/]YI*U6NUOG5+,5I(/#_L[G78@$,GFJIRM.V<6
MD#TM14^-Y-/G<1*J,8Q9O=>ZE_Z&^[O+2'^!_.333AV;_G-3K[QSE+2(E4O\
M3U2B4IH&FP`;FWU]^Z]U)I>M.]'6H,VQ?FM3L6Q\R)-\T>N)23$\"300F#/N
ML<>C4\VH_N6;2;D#W[KW3?/U-WM3TP,.TOG+6RCRP>)?FQUJDQ2IGEF-299\
MU##JI`0B<Z@EA9B"??NO="#U_L#N2DWIL"KS&SOEKC\7B=T4%3DZC='RPV#N
MC;PHG%5'45.[-OX_,U%;NC"TRPQM)0Q!GD,JZ%)#V]U[HH'\Q#XD?*'N/Y1]
MA]E?'[;&[\4^X/Y6O;GQAP'<.RNS<'U[NK;7:O9/RAZ1W%B:#9^3DW9@-S;;
MW'@^N\'N+,#*0QK0R+"M+/4(\D4,WNO=%6[9^-?\U*NCP^0JG^0.Z>QX^Z/D
MK!U%N[K+OW";0V;UGW;DN\NJYN@/EEVUL*I[.@VYN3XIY#H#8F7^ZV#4T6YT
MPM9F<CC6VS,,TDN-]U[K-\E/A!\N<12[\DZQV[\O<MMO-?S`=UEL7LGY6=E;
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MO;N_XT?#CJJC[2K?D%NG8^4Z9@P/;OR][0^0%1FNU]L[L[(RF4[_`,;@*W9F
M*J=VXO"T])GZ/*4>'6GCIZ!ZR'W7NA`V1T+_`#/MP?+CKGY3]BXWN?"XG*;8
MZ*QV^]D87NZKP>+VSO>+X0;^VIV]BSTA0]P[FZ#R?1NX/DAC\?\`QN>EQ2;Y
MHZVLQ^1P&4$<53+%[KW01],?'/\`G']3MMBOJJ[NW?.;ZR^-OR%^.?3>$WM\
MA:?/[?K=T]@=<=$[SZI[B[SK:_,5N-W7V%L;N'LS=^$3<LL.1>';.Q9*;QM4
M5-+45?NO=+S:7QX_F14.[OB#LCN["_-'>^!^/^5GZ@ZYWKTE\L]I[5+[JZI^
M66VL]C?EK\M=Y9S,8:C[HZY[?^'=+%BZG#9G:6XZG(2T^X<><#CLMF,960^Z
M]TR=2]=?S$.E</M+LW</6OS1[!W=U7\YAVAW9UUANRI=Q;T[SZ`WYM;Y7["R
M&+V+_I*^8^Z>MNP</M?>F]]C984%%0=;4F#P='2R1T-?78YI![KW4^H^%OS2
MVE@,]F:3+?,O=79\'Q(_EPT.8CVW\T>S]W;3R'R-K/DMAS\VH<709OM>BVS4
M9K:O36R\'4U52D$&/R%)59&IH86K:Z=6]U[K/C>DOYCZ4'RDV92[?^=V*[S^
M0.^-W=%;\^0,?RMV=1?'J@B[(^4FY=S;/^2WQRV7E6WIOKIC`=%_#2HH\/2Y
M';5'MZ&.M^WQ51MO+9JGDR]/[KW0D;?R7\Q*IV5\A-D=E=;?/7!=@=S_``>Z
M'ZZVQO+IK*=,;IQ'2_R"Z)V]W?MOO3?_`%UD>P>W=IX1-T]RU%7@LOBXU@QQ
MW%:EIFR&/J0M73>Z]U,['^*'S$^0W\EO</Q^S?5N9F[JV_VI@=^[2ZR['[@W
M7FMS=[=4=6_(_`]R;=V]DL]W9O3L_<O4&X.S=CX8T6-VKO#=.ZHMI3_;8VMR
MLE-#Y:?W7ND3V[UOW_VO2]F_)_9_P/\`D]\;>M.[ODCL?(]Y];?'ON&7J+^8
MY\C=@]9_&#L#K/JKL#=F-V1VMA=D=.P]?_)*OV[)%18;=\U7F]IX\Y#-4LE-
M&]%6>Z]TF,7\=OYM.%[FS79G8FX.Z\_GMP=0R;&WOE.J^_-X5.SLYVC0_P`L
M&JQ4=#L#J+,[TQG2&P^I]P?+!FJ/[V4&W,?NRF[)QE-*HIMO96=J;W7N@^WG
M\2/YH_5?Q.Z0@S/9'S([GW5OF@WCN;&]/]%=_P#9])V-\?/E3NWXO]3;,^/,
MW<7>/8';=?O_`']T'M;O[;N[=U=@1UN<J-FXO-;BA2';U;A:9*>/W7NA1I>J
MOYI_7OR%^2_;%11=[[VVUO\`V9\M]N;5VIMSMW=^[=@[@[;K,'\9-G=)34O4
M/:6]]Q[%Z8Z@P&\LEO?>6S\[L^'&YJ2AIJ_'9VG!7'1S>Z]U/P_0'\R"?;76
M&UL]E/FC-V3\?^@_YB73-7NF@^3VX\1L;NO=O7%#12_R_.T-SY3';[V]C^R=
MW]@8GLNMBJ-Q9;"4=;E,U@#+GJ&ECI*2)O=>ZA574O\`,WIMY;FQ,E1\SI]Q
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M:C;W9$V-GE7_`(<-@>.NDI/'3[R^+RY604<4B_>T\<N9>B;&UQK`49F61G@%
MXT`(?W7NLSX#L:E>DJ&_X<'JEJJNDF>EBW?\9)4HXX4CA,%:HR\,J4DK,9)O
M$\LK$-8VLOOW7NN%'MKLB@AR%0U5_,*K7QZ1T"TE7NSXNSRY)9EAJAD,65KX
MH9GB-X7>9X&4A@$(*L?=>ZY1;/[(DJJFC.6_F#0Z9Z>!:V;>/QB^QD-2)66>
MEFBFEJ/M8"EIF>)60E;*P)(]U[K!C=L]D3S24OWO\P^`_:09(U.6W9\7HZ<>
M"0P?PZ.>GK)[UT]]<D04H4Y\@/'OW7NLU5B^R(*G28?YA<^FB6M#4>Y?BW+2
MO=II_L;OEXG_`(B#2^,H0$`E7UV+,ONO=98</V'054]1K_F#5P:GIE6";</Q
MEFI;_:1U$I@C^_A9*F)JD12%R%>:-M!9%UM[KW355X[L<1TD'V_\Q[7>)7DH
MMP_%AF334&E9ZR=LR(F'^3^5O'K+12!@+G2/=>ZGUT'8]/D991COYAU0D\)Q
M^G&YWXM28RG_`(35&/\`B$,<^<IZE9,L265]+&6$`LD9(!]U[IFJ&[+C6.=,
M!_,JF:BFI*Q:6GSGQ*#5WV'W)^SD$VZHHI(:_6!,K/'K]'J6S6]U[HR\'0V<
MK139)_D+\D\>]11JSXN?<O72FD>IJ9,@T53%3]=U4/WE)]Q]N3'-(@CC"AFM
MK/NO=.,W1&:F!`^0_P`@H;SS3WAW#L%"!-4/4>$%NMV_8B#>-!]1&`+D\^_=
M>ZE;>Z2S&`W3C-S2=^=[[@@Q]5+43[6W%G=C5FULM%+255+]EDJ.DZ]H,C]K
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M#`2YC:0W355XBJF$4$=#7(LN*0Q3SU'NO=`5GJ_,4/6$^-Q$FUXOD#0=G['R
M'1K8JIGW+VFV[:A'QF3W+O/,]HY#+Y''X3);5.4J]F8N@-#7&,5DF#E66'[2
M3W7NG;HFM^$^S=W]';<[53NL9>IQO<53M;+9C<N73!YS-U53M*;OBLW#74=5
MMZMW!M3+9+%Q5&6J=LT.*V'E:R#*Z\:4GJ?N?=>ZV1\/)BI<1BY<%]G_``23
M'4,F'_AR118_^%/31-C_`+&.%4ACH_M"GB5`%"6``'OW7NG'W[KW7O?NO=?_
MT-_CW[KW7O?NO=%:^6W?.Y.@.LY]S[2VHVY,[6KD:6@JJFAK,KBL+4PX^22D
MF;;V.KL3E-[YZKKY(4H-NTE=CJK,:9DCJX#'J/NO=:]^QM^=A_,G;VR][]O;
MSQNWI-U3UNXNR(ZG$F*LS.Y>M,3N+,=?_P!S^N?)7;<J-HX#*4-.-P5N/:GW
M%@MT86?#URYN@GFHU]U[J)V)N*'M6M[1[`R>-?,X/9&Y^C,CD=W8N?-G'_('
M=&.EJ]S[I[IVMOM/[K8'<?QLV'#7+"]'#C(UIZF)!*M,C/%#[KW2QV@F1J/C
MMWG39#LJN[`II_C5\:X$I9\3E=IY7I]<EL'J[<.;ZX<5K+M;([*R&VL=!E,+
M4SR3U#5.!K8:*:>*=X%]U[JKCM[$XW=_9/R"J-U;IV#"-^9ALGW91Y%\GM+J
M_!R=6=,['Q.UJGL+8=5C<]_%=KYBDK<7A(,CF*_)TG1DZT?82PQT>;ID]^Z]
MUM8_R^HLM20=BTNXE>'<,D^/KLM3#SR5"9#(5>4R^0&['RE5E-PQ;]@ERZ0Y
M!:ZK>IFCCBF:.)9(U]^Z]U9+[]U[H*.^<!NW=?1O<VUM@5570[[W+U1V)@-E
M5V/KXL77T>[<SM#,8[;E519.>T&.JZ?,5,+QSOZ(7`<\#W[KW50VWD_F283K
M;>5%B?\`9@GGQ^Q_CUUYTM@LGCOC]_'=NC'?%=-X;YW_`)S)97%U-5N[L*K^
M3VWALS)C/5Z8*#'5\=8R24C39#W[KW2@W/N3^9%59?=F^-M-W!MK:>1W/VGL
MK*[7W=UKU?N^;86#K^DNF]W]5[WZYV1UWE</O7>>`Q'>$VZ]N5E0,M6YHT-1
M+(T4D5'CYQ[KW068_:/\PVBWIVGW57;0WMU-N#N_)?'_`*^W.=H8#8'>^_.D
ML-MCXS97`8G<^QLO4MMC+=N=?XSY55M+D]U8RK&-IQA9ZR:''02U.0K&]U[H
M5=S9?^9'BLZV>P.2^0>]HZKY.[MJL9LZ;K[XT;:V5@>G>N.]>I]NT.W,F]/#
MC=[93:';_1.X-W9Z@R4F7JL@M1B(:<BDK6IHY_=>Z*]L3XN?,["[,^.^T<!U
MWN6KPWQ?^2F:R_5FS^P]G],;>Q/4&^-L0_-;'4O8FQLQM3(8C*;HZ`WOL3M;
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M'X_[8R*=8]UY>LI9'VEM.G[_`%R[X";`T4U?EMNT]5YLF*9,=73^Z]TP=+=K
M_P`RSM?I3JWLO'578U=M3OOI[$=B;/W7EMC],83L'KWN_._'79>;VMMO<^Q\
M=AQBT^*VZ.X)LE+'75"5NXZ4S"&KJZ?$BFK&]U[H0WW[_,FQ,^6SV3A[;SV9
MJ_E9OQ<#UY@>F^GAUWC.DMD;@ZYH,;M"?=#S4.\J_8^]]K9S<F4Q>Z:JL@S-
M:^)@IVIZ.J=:6H]U[I&[%I?FCU_V+N;(YO9O=^4VI2XBNV9N;M,[.VENON3$
M[5_V=SO^:>/K*2*+*S;TQ<73F<VEG*2"7'Y>HBQ%34-3QO70-00>Z]T*/0V\
MOYEM%O\`V"WR*H=U5]!2=K=-;"W_`(39?675K];UVS-W_&7>F0WWONDW'19F
M'>XBVKWOC\`<G74[+18RKK*RAIJ7(T#1U-'[KW05?&#(?S%]N;?Z=QNY]G;W
MV!B-AT7QBK]_]:4/4W5U#MK>E1V=\C?DCM7Y1S39:ER.:RT-7LKK/([(W?X,
M174<T%0)985K8ZBKQ\/NO=/+]X_/#/;L[CW[TQDNP>X.J>L.U_DQU;V5M"KZ
M[Z9QU92TFQN_MIX?8C_%REV_/3[H[-[`V;L"GW+BLQ%N++T%+7?:!UABRT=/
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M`)G6T#V'7T-!V=V@]/OCNOKO`8S<?4_3^!QN-ZUZL[0ZD_N[WGMQ=GKC<SNS
ML+LSIS*[NJ<!C)Y8<1F,K14\7V5%+&M-7>Z]T)/3';/RVW7\E>J>ILMV?5;B
MV?DNHMJ]^]GY7+=#8GJ3<&R,7M2DW)UKE^G]W[(RN8W5N;:NZN_MY;FP>[L8
MU=-15N,Q^ULS!"OCF6&#W7NB9UWR2^?.WMD;$?NG(]Q=0[VK.Q?B-\?]W9G_
M`&7#IJKW?VAV!N_M'Y4===V#H'[NESVT-Q5(V_A-D[RPM5+3UF'HJ!9)4I:Z
M*HJ*5?=>Z%RIWI_-EVUU;AL;N&#<==W7L+9TE;NC/[*ZLV)F]E]J["JNB^W*
MN3>=!M^AQ>3Q.*^3&"[LPVU1/M"@KX\352ULM/0Q38NH>MQ_NO=+*L[-_F(;
M:ZWWU/FJ?M?/;EV7\E?CUD]L9+"]`[3EWEW%T-O?H3KO?W:'4^$H-M8_=>WM
MC-MONK*YS;<NZ\GBG;$PT0IZN3G^,#W7NDW-V_\`S1,MA^R-I4N)W]MK=^"R
MM3UYB^P7^,VTJ[;ZY9OGU+M:F[-VCCJC><E+OK`4WP:W/19F2_BQTE9AY9HW
M->:C%CW7NGO$=@?S*H=Q5.*W'FNPJ+;.[?E/W3UOLK?\OQ:VQNNEZ^V#UE!M
M?"]';I[!V)LO=&W=WYCJ+Y`3KN+*9O<$34LV/GBQL<)Q%*[_`''NO==['[O_
M`)@F(IEJ>Q-N=\;@VYO1-L5>:W!A_CMM"DWCTY3X/Y<;UZ>W:FR]D8ZAK*K<
MAW3TQ_=[<J+DZ/.5<&,-9FZ:E>`C%0^Z]T`'QOS?ST^.GQRVIT;A.NNX-GUO
M37PPS^YMATU5\>I^TZ?N'NN3`]]5&]-MYO-87+C&]==A[5[<Q6UJG;>'GJZ;
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M`R&-ARF%7(92DCB-5$?=>Z5&_>[_`.8UC-U97*XKJS>F(Q^UNN^D-Q;:ZKIN
ML-J;^C[.P>[]I;7;Y*Y?>';&ULS5[<VOWA\>=Q5N7FP>U\=+24V\&QD--CZ/
M)I7I/2^Z]TD-_P"_/GCN#&;REH=X][R;-V"?@1NC;NYNNOB)7[$WUV=C]T=]
MT</R#RF,V)NZNK]TKE]E[&VY!/N?:M1!#HH*ZN>.FJ:6>FH8_=>Z`39>(^9D
M&Z.G-Z9CHWL*7*]>T_25'#U)E.MMVS;>FS6:^4OS!_O?F,-VM7;DR]?UM4YK
M;>-ZWS>XJILAEL?C\5D8FR%%)14J4--[KW0\=:]Z_P`P<5_QF;=%/W7N&JWK
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M.6R46T:-*#JV3&]&/!EUEQB1_P`=HDR-;0K+)1SXA?=>Z%.L[U_F);IW'MC;
M^WMD[PV-A=U=U=5;,WWN>OZ-QNXLATY+-V5W1B>U]NX2DDS='A=T=4TW76S-
ML9.EWW*^2I(AG5\<M3/5K28SW7NDKL[Y(?S(-P[CV7MS+[$W#A,;E\WN[<.&
M[5I^@-T9+K[L_=V&WEB:FC^.>X-HR8.@[,^+W6];UW4U5#!O;><`-/N6%V.5
MR%%3+_$O=>ZC]1]M?,-H?EEW`W7W>R;RWU1?""1=N[SZ)R.TY>H:3*-4[.^3
MS]0;0K?)1=V570<-;D<C&BO+59UZ*)*>7+4OV#UONO="MUAV3\^HLKO7,]B9
M7=>X]H]+]&;[W?C]OX;XTT&'W/\`*G-G<G<V$ZRS&ULE5YW&T>R=X5FS-K[;
MSF2V;'3FOBR64B@<TT51]I#[KW0;X'Y'_/Z#%;:V[)A.P<YGL+1]V[-RN^-Z
M_%_<&T4W"N#W7DJ3J3Y,[TV?MW#5T=1L'/[7:DIJW;>U*JFW5C<M+!D_X+D<
M7)646/\`=>Z0&_\`Y._+'K;`96LKL+O7ICLK?KXRHRE9G^NZ#M;LZH&POC7C
M\EN+L=MJ;=J:GJO=?277/85-`-Y9/:&,Q+0T.<QU.OVF4>9??NO="K%\M/FA
M7K7]A]<[-W3VUU+NJ;M_%[.KJ;HG)XJ.#8_7.^.H*O:'R`V14T%=55_8>)[4
MZFWQN*MP&+90-S'"TU1B;Z9J:N]U[I*]C;W^7W87=7QBQ&\<)V96[)ZO^0G2
M7:L.7ZSZ&W[A-J]N]79#K;NEMW[[[`KLQ00[GZUR>P]X/CL"-I5*4>1R%8:>
MMDQ\N.RL,F/]U[H>.Z]BR=K_`"S^!N],-UUW0O7'<&`[DW5\@:',TG:FVL-M
MW"T/26!RG46([<PD=0F)V!N?%;RCABI,/6?82#+"L8AZI'$GNO=$P^/^[?FY
ML/HKXE[+[(P7>F9S\%=UGVF*G=_QW[.W-F-BTU?C?E?AMU;#[+R6SMSKG,P=
MF9'$;(RE129"9<Q+094TZ1S--%]I[KW1EJ_Y`?.ZFV!\:Z"HP&XL)NO=</;U
M;NC?='TW6]GXWLKM/K[L/:\74/3F5H]L[:VM#T1TS\CMD9#+/!O+<.*PV1PD
M5#$E><96*SUGNO=)#$]T_P`Q_L+$]418^GW+@4[+V]\A-Q[]Q4WQGW3M+=W5
M&Z-M?'G9V?P'1>7W9NV;`;;H*BB[_P!Q97$[7W70P9''YO$XN-6K:NL$M0_N
MO=%RH<C\M]V;!V1/E-I?(B>.3`INGL'(;IZ+[7AWOV7G\+_*YQU'A,QV+MK(
M;FH<MM7L7;/R3Q\F&HDVC-@Z2LW88I&II,C'#DYO=>Z,UN'Y&_-7%[`[:K]G
M;0[*V7O/9D=/UYUITE)\:MZ]P8W$R[8VCE>Q^MNRJKM"7)XW+=K8/OO`8&EV
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M7LO`X_%9YJ7>^'PM%O)<KVA04]+L7:^(BS:;6K=MU?5N&SU=B]A+NS$R[YVK
M0[A2DHOLYXQ/4^Z]UL7;'V3M?KC:>$V1LO$PX3;.W:3[/%XZ&2>?QH\TM34U
M%1554L]97U]?63R5%34SR23U-1*\LKO([,?=>Z57OW7NO>_=>Z__T=_CW[KW
M7O?NO=%C^6/=/7?374FYJ_L+;V`WO1Y3;FYYUV'NNHPN-VIN3"[;P\N<W;+O
M'<6[*>38NT]GX?`P23UN1STM+BU)C@:7S5$$;^Z]UKK5>[\9\IMJ;2/2O7O5
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MOBQTT%)D/]*75VXINJ_FA,F\<7FL3LS`4G26R>G\-N_<<%&KR5,5='+EXRAB
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M`)+U1S>U:(8:HS>]XMRUG5>+H)<*^5DKZ.O?PT25,PJ$/NO=')Q/SIR68^,6
M:^3F.Z,W+G-M#'=>;EV/B]G[QV5O/)[]V/V/L?:>^:?=N*Q&W\I5;FA;9M!N
MB6/,89L><[)_":N3&TE?&:8S^Z]T43IK^9[7XG<OR#_TO;@V-N3K9^]^_:+H
MSL>NWKMS9N&PVU.O>D_BGV=MOK:OH(-FX_.Y7&YJL[QR,6,S<\%3F)9(:>*K
MHHUJ8'3W7NA(VY_-<QV9R&.&5Z=IML;5HNI]M;U[#WIF.V]IK2;#WEO+Y4]C
M_#[`;8J\13T$[3;0HNTNLZVKS6YJJLH*+#X5@[QRUJFB/NO=&.ZN^9N8WIV]
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M9>'ZNW[L.M[)VEO>AR>U]W)N3`R=78_M';.`H,/LJOW%6;?WSNVF;)X>BI]S
M';V'DSN%J:49,ZH9)/=>Z:]P_P`TB#:>UJ3?^XNAZ_'["J^K*7OJDSA[;Z[K
M,GF^C7[$Z,V37=B[;V]AYLQ+6T=#CN\8<DL-948\S)B9TUQI5XR:L]U[J?U]
M_,DRV<WYNOJ3</2E7FNQ]J9KY#[HR-'USNK#56+IN@NC/E3O_P".-?OMYMSU
M&(CKM\8VEV5_%LIMNBGJ*R.*HIPA26NI:8^Z]T$M#\\NT^R.FOYE';>RMU;9
MVQCNG?A]U-\C?C__``_,=<=BQ;)J]_\`QBWAV\BYO(4=!3X#.1RYW`P>5*NJ
MR%"S";[6K:F*%?=>Z'C8G\P^NS&_-L]#YWI'.5O?5;1U&1RNW]J[^V#DMLR;
M;Q>4^.-'6[BH-V9BNVMCI<]-MSY'4&X9-NF*/)4N,Q==J!8T7WGNO=!S@?YG
M%1W%LBNP^QNL,_LOL;>/1_=/<>S\IC-X=9[]79O6&QM\;QZAPO==;BLCD,+1
M[DH8=Z;9;)2X6G2KJHZ!Z>&6-ZZH%`/=>Z0FT/YG^8DZ0V6G>7QYFWA7;WZV
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MU:5`/=>Z#RI^?/9NT)<OLK?,VX*^+"_+7-[/@[JV/3=89=9=@8#YQ8?HV7JK
M?NPI\=3UNQ\UD-I[FHL?C\BE'43Y^&&JDH:F+*1A??NO=#[LG^8I-V-F>E-K
M[/Z+K:C<???7=3W)UL,UV[UIA=N[TZOQJ]:?W@J-E9PUM94[@[%V=-VA2PYG
M;4U%03T,M%5,*B2'[6:J]U[I`;:^8>3ZL^/7Q<[3P71G5F%VWW?NWO;=':NV
M^LYZ/;<7V>T.I.\N\MR[CZWP<4--)N#LW>N:ZW>6?&9-8\G/--5_>&"I25HO
M=>ZF[Y_F,[O/QT^3G8_7_4^$QG:'QZE^-E52XG=N\Z//=3[PP_R)P/46^L+-
M1]DX)<+CUGQ>U>R)Z7(M=:2@K*:*J%148^HAJ)/=>Z0^QOYCV[NKHNVXOD%M
M>MWCM7'?(CY";"ZN[8P.:V+B:2H3:OS%VA\=-O\`5F^-N+%M\[0GZ]K.V\'0
MR;BF^YI,K24$]0[FLEIXJSW7NAC[2^7O86R.P/A_N/==#!T7L3L38/RTW)W%
MU/V97[&ES25?5FU-N9+8,T^^L'7;AHL#%%EF:WVDTC3)F8(:JG6K5:9/=>Z1
M]3_-PZAVE1;5R7;.P]Q]=T&>Z^C[)S=7!G\#O2FV3M3:_>6[OCYWCNC<-9MO
MRT+[.Z0[`QNW8<E74DM1/6_WRQD=/2^?SQ1^Z]TMNO/FIL3:F4^1^W,_\=,K
MT9NGJ?J#<ORQ[%VOC:+%'(=F,FV\1N+?NX]JY#"8'$[6WSG:7)U*X7+U=7D8
M,Y3YRF\&1HJ:-Z:>;W7NDE_L\/8G9WR8^)O3>RMMKL#9W8F]-U9GL'<M+N?8
M^[:C=NRL5\5=F?(/96%VI-48G*4KXG,U79$%)N)H4HLK1G%I)CJF:CK8ZF3W
M7N@XW/\`S#>[=C;XW/O[<O7&.K^G.M*SYS;?WWLW;FZMGI-)L;XJ=\=,['IN
M^*'-YJ.#=%-N6CVYOZKI*K:DL:TV1E7[M)Z.$0O-[KW1CZGYG;V[1ZO^2V:Z
M*ZXHL!DNMMI=VTG6/;G;F[MHX;I"O[3ZD[$WWU%7[+[(KES<.Y.O<]!NG9JY
M9::OHA0R[>KZ2HEK8)9)J>#W7NB5];?.7=O2G8>3Q._^M5GS&^Z#Y%[@[?WI
MW#@>D?C]WO7]J]2=D?%[I/HWJJMDZ=RN\>L.[8I,7WA08JCW5AZ[)M61R4--
M%3TL]+/12>Z]TR)_--Q'9N?P`WS\38^P-D9#8/PL[/\`CGLNJRNR]X]KQ_*K
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M`%_O*CZVD^1T.QJ[(U>ULIE^K.QLO5X7>.+QM4V/-7MJJEI8U:HBQB>Z]THN
MM/YFN3P71^W*W?\`M:E[?WIUO\.NG^]>].U=F[QV)M[8\NX,=@>B:SY05^8H
M5:.FV(G5FVNYZ;>,]-$E1"V)BJ("*204BU7NO=+_`'!_-/V/#M#NC?.R^I]P
M[GP?2$>:QN?H\WOSKS9&YMP;[V[2;Q[%J^N]GX+)YBN&?W!N7XP;3B[5VW41
M3G&YG:&9Q\S5-)Y9F@]U[KE4_P`SREFWCNS:6VOCKV#NA\7O?<NQ-B3X_=^Q
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MZK,]9RT^;Q4S&LH*:JU032S05:TGNO=`[1_S,-S]+#L+>?R5V9F&V!EJS)9G
M;J;>RO6M14=)YC"?#3K+Y,U'2&YY\5EJ?^]C9ZERF7K*+<_E:GH8:BG&3%'1
M**X^Z]T,?<GS*[/HNO.A:?\`N@?BMN?O[Y<_[*A6]A=NU.U=T;6V53OMSL7,
MX+LKKFKQ^3EP._Z?N#+[*HL)L-\M%C:?(9'.4[U-*2(:.M]U[ILJ_FCO/XZ[
MSW_\?NPWS_RS[+ZQVID.[MX[YV3M/:'4U-LGI'>%7V_5=;?W[BJ=P-M2JR&V
M(NH*_'[DS\`PN,BDJ\<T=(:BHEIX_=>Z#;$?S->P]X]@]5[>/2[]<;6WYN'X
M7H,D-Y=?]B9F%OEGA>XMP;:VKGH<+N*+#18G*X_K_&$9W"U.5DHOXA(PHZB.
M%I/?NO=)/XL_S&>\-R=>]?T>_P#94W=?R2[PVUTCV-L+IO:]3U+UCA*?!]Q]
M-Y[Y`[AQVT>R9]^YG;^YMM=>;(Q\E)0RY>/&9?*346JTT;U%72^Z]THM]?S&
M>IJCM#';_3H'9N[\GT#V=NW9M=V8NZNLM[[RP_QUWU\3.XOD]5=K]#;CP5?D
MJ?[O>N`^.%539C;#9"@KI:?&@L9QX/?NO=&TP?SFQ^:ZFV%V1+U'O#!5_;G<
MW7O3'4&'S>8P$>W>QZKM+:>$W]LW?^"WSC9<G1#K>IVAEIFJ*UZ3[M<GC*R@
M@I:F44S5/NO=%9V?\[.TN_5^87:/52[CZ^ZVZ;^#^'[*ZKQ.\=N=;Y/&3]O[
MFH.W\I5YO?=.N<&_?XOLK.=3R8R/'TLZ;5RV(D:MAR$TL\+4WNO=9.O_`.:K
MCML=6[<W-WELC,2XG:_4.P,EVEW7C,OL/#[=W!W)NKXB];_+0;=V%UG#N*NW
M@FV<UM;>E9!%5U`5,-+C6-<QH3_$S[KW0J9_^91'L*:LQ'9WQ]WEM#=VS]Z[
M8ZW[4VM0;VV5NVJV=N_M/;>Z]S]&SX.NPE0U#O?9G9M'M=89,E"U+48.HKXA
M648B@R$M%[KW29Q_\U3'IA-J[NWA\8>V]D;.R\G1.?W/E*[>/3F?S.R^J/DW
M/O*DZ6[,FVKM/?F:S&ZHZZHV?)+GL/AA79/#44K31)7&GJ8HO=>Z=X/YH&$J
M=V;0V=1=%[IRU?N"OV3D\YG,5V;U`NRMH]5[]Z?K>_<7VI7[KSV[=OT5?BL1
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M*V@I!*CQ(XM[KW6&J_F/;0Q'8.\]F;FZIWIMK$X7<7:FPMF;RR.X-D3XS?\`
MV/U/VWUWU!EML)C\;G*W)[/QF<S?;>W:F@S&62GQZT]7*M8U)/%'%4>Z]T7K
M)?,7Y(S?$&J[%Q>9Q9[7G_F/5_Q.T8+:&RMTY6@V96_-2K^/M/M3`QY'=^T.
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MWMG<-/%COD%B*^#%_?TV4>AIJZ1X8Q3Q^?W7NK+_`'[KW7O?NO=:Y?\`,>@R
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M[K71W..KMF[/ZWHOA>_;V$VGNW"]O9C`3Y'`[?HJ#:'5&+WGGH.\-S;SZZWQ
MBL5L^3;=1N'(Y:DJ:JAJI\J<GD:"+<.-Q^$6IRD7NO=*O<55B-KC/0]<8_KV
M+IW#=#])T&.3&Y3(86IGVQE\KE,!GI^T-Q;9W'6]>;&R6WMM@+BVV_F\CG`L
MU+&17P,((/=>ZC];;@3!]&=Q[&INGMR8>3<O17QZR>Z>P-Y;NW+)DNP<QM/K
M3KMJ;.;<P>*VQ#MW8^U=L+E:K9[8['Y.7<K"MQKN*JAD+TONO=*S9NPNW:;:
MR;:P/1^3W!7[IJ?F5G-AY/+[5VMM+)#%;6PU#C/LX-N;2G.Q-R83Y%U%'3XG
M=6"Q-;CZ^7"8^"2C:6:HKG/NO=6*_P`KC%+B-J]AT%)2FBQU!D,!0Q42[!I.
MHJVCG;;V*RLD&[>HL;+_``GKK<T7\6^WBQE'&*6GHJ9!&1=D7W7NK7/?NO=!
MYV[OC9_675/9?8W8,/W.P]A;!W?O'>=+]G2Y%JO:VV]OY#,9ZCCQU;)#1Y&6
MKQE'+&E/*ZI.S!&(#>_=>Z)ML_M_%;2Q=%O;O/XH[+^.G6NY.K-OG9>>I,MM
M+?\`O:OEW.:S,U/Q_P`UU;L39G]Z8MY87:^W8\MD,=@CN+!Z*6415<PHFE]^
MZ]T[TGSA^`FVMR9]MM]E]?3;ERDFR,OE<EUWL7<6YZO>68[@VI0[UZWH\7F]
MB;/RT?8.]>T=IRP5N$QE!/7YC-PK:E@F:-E7W7NI>#^6WP#IL/193;?874%-
MMC/=:T'<`SN%VPT&U!L?`X'<G;6)K,[GZ';B8#"[AQ6W=OYC<-)@\A/3YZ*"
MAK:R*C`@G=?=>Z9=P_+/X';1ZOR^9H9]D9W9F7ZLWI\J*+:6U.M'F7LG9.QL
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M)IK1-[KW2*ZX^2G\N[K3:.P=C;=[/ZOP>*Z;P%9AMJ5VZ<.^`R&W,+LKHO)=
ME9C>;YC-[;PT=!B,ET5LROSLFXT,.,R^)H*J:&HFCBD"^Z]T+.-[4^&>V,3D
MMZ82?JK"4&R.Q3US#E,)L>"CKV[/WSMK`[Y?:VQ*;&[<3+;OW/N[;.Z:.O:+
M`1UTM='*Y.MH9Q'[KW2#R/?7PYQ6R>R(^F<7TIV5NGKCXT[S[ZH.K]E8W;6,
M3,]6YG;%#O"GC;*4NWZO#;<VYVBTF.7R31M'5ZQ,T$XIY`GNO=1=I?*GX$[E
MV)M'OG-[FZ'V5/'N(9.JR.[Z7;&%W)UQVCO+8?7^\MWKF:[,XK&9?;>X8]E[
MWV]5YG+RI2QMB:Z@JJF84LU.[>Z]T]X/Y)?R_,<FYMH[?WST'B*/^_#],[RP
M]!A<)A\+_?#^\M/MJ;:6YE3#4N(^VBWYNN+#2R51^PCW#D5QSR#(3_;M[KW0
M>]T_,3XA;(;:N?FVAM+L:+`=B]RR;AS";1H(<EU7NCXI],9/LWL#(T^.S6W7
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MAH<'2;LFQ%1DMW;;PVRAGSC8*W`R2;BV)G<1382KJ*6?^+8FMQZ4_P!W330)
M[KW01;9^1_PHS&2[GQ65V9TIM[J+H*KV7G=O]CR8/:E?M#=E1W'UIN3>.Y=P
M;0PM-MA)Z40;)V]7U&1R-&*NGR.WXY:\SFACG:/W7NL^\-U?%[NWY/\`7GQ\
MVW083,[AJ,M2_*K>V\.M,AC\&N7W;\5]R]69#KK#[\S6/P,7^D*AHMP]DXC(
MI%19:>6D;')3UD:TE0T<WNO=,W9G?.S.H^W,MU(/A/A*C,8K%]Q?+7`9>/*]
M%X''YC"=1-UUB=Y]^0+-5/5XK=]?N#L*AHX9G4Y]H:2>>I$$8IEJ/=>Z=]C_
M`"M^'^Y]@](UD6TNJ-K;1>HKNS-RX;.IL'`XCXU;YJ^H*3O_`"&:R=%D:/'T
M/]Z,GBNTXYX\OAHV.1&;EKHII8)Y9&]U[H=\YVW\0]@;!V5AMQ5O7&SNO>\,
MC48?;6T<MLLX/$;JJ*JLQN$S#9W9-5MZF;$XO'U]=14F6J\Q1TM'CI:BGBK9
M(6DB5O=>Z"&J^5/\N6@Q&4P-)NCI'*Q[BW'V-M^78>%V?C:W);UW-2[8Q/8F
M^*:EVJ,$G\>CW=L^FQV>3(O&<;N#$_:Y*&IJ:/Q5'OW7N@OW=\V?C-2X/K?&
M[?Z;V%NK#9L4V&ZSQ>=JNNMIX/;'7^4^(U3\N][UVYDRU#6T/3E!0]'8]D7%
MY..C_BTQ07CQZ5-93>Z]T9`_(7X<8;!Y;#[BS75&UJ?9'5-!V#O+;4N+PM?A
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M[.Z[[/\`CIU+L'9_7>ZNXNK-QS=A8CI_*;?RO^@KY/;/V1L^/%;/DI6W%FMN
M;^[/W]CLWA'BQ<E%1;DE-,[KEB@D]U[H2NHOEQ\7NY^E.@OE5VMMK9?2^8SU
M)W;+U5C^UDVK5;YVK#U-+O:D[0I]DYBGIIJD-_<GK2MS=32XTQU3X2E:2:`"
MFF6+W7NO;@^0_P#+YVYL.JV/0S]$93#==;/WGWAANG<'M+:>36@Q6VNN(^\]
MQYK:.Q:2@3%Q;LR_5V^UW%2T],L>0KL=F_O0K4\TTH]U[I*8+O\`^-?8O>'Q
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M/0X&HHI*:>;$UM-1^Z]TJMN=]_R]6ZT7^`;@^-D'5&+WM@<Y4T6$INOVV7AM
M]18+#]Q;3W<^#HZ:.*/(Q[-AHMY4F=BHVBI<-3C,FJCI*=JJ/W7NHV-[W^.N
M/[H[8^+75/5NS-WYG)=`=C_(G>>.V1)UR-I[YK\=OZKZTWCUUN6D2J%&^Z\W
MN:N>*M>MC>A66>I2L>.;R*_NO=)GI+O_`/ET[JZMV/NG&CXO]6-G]J8WL#,=
M=Y0]3XK*;`RN#^-J[AW%19Z*BCBQJ9+K?XYY.KHJO(0DTL.TH:B.*8XT.H]U
M[J+W/\AOA%TQUQ7=%0]9=8;LZW&Q.B^T\KT_AMD[.QG3\W2GR#[]QG5."[&B
MHLCAX>MLOBL=OFM&5JJ")7R$Z+'/##)++$6]U[H6J2D_E\YN7JO'46)^*N6_
MO/29G"]014^$ZTK:3+P=A5.\YLYM[:,J44E'--OK(;:W$\^.B;RY2JQF28Q2
MRTM48_=>Z+A@.X?CI!V-FL'VE\)-J=";/^,^#V7LO<_=':E=\5<9L'HK9E'3
M9#/_`!]Q1GQ?8.5RFU=M9&#*N,)34U/$FW:K*K`\=,*B1O?NO="^F8_EBU6"
MAA2#XA?W>VSD>BGH:+^`]:T]!CLI24F?I/C;38G'G'1(]70Q5&4H-FTU-&S0
MSO546/19C+#[]U[I-=A=D_R].CNE=R]\;-V%\>-RX;;%%U=W/@H>L-M=9T39
M_=.Y*LX/H7<-+N*AH:7"87+YRO[#:+$Y:LJ(OL<=E:JI#I1M4,?=>Z$27LCX
M([`ZREZTWM5_&/J?:M.NTLONCJ*HK.NL9M;"[GW:U7E\%]EBJ*GH,+FLC4[@
MVQ6KC<C00,U5D,1,:9O/3.L?NO=.N>WS\6]E_(?$_%.MZVP]'OKY(]19^MS^
M4QNQ\$-F;HVGU/A:3`X;J_M#<M,\554YK(]?5V8FVWA\A#/!5[>P.;\3+%2S
M1O[KW37A-U?R[]LS[EI-OS_&+$5&W:S;^Y]QT.,Q.QH)<6-T=;)UIMO>9HH*
M#5%@,MTPW\$ILS`G\.;:,;TXG_AD3JONO=!W4=O_`,L;I_`[PK=OR?'M:+HS
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MKCOHU]'5;"VS-19`=H8G%8+LE<A1R8UJ:OCW]B<%10YE9D=<DM'":@2-$A7W
M7NILOQSZ`GV-G.L9>D^JFZXW-N(;OS^Q/[@[8&T<ONY:Z@RB[LKMO+C!BYMT
M)E\535JY$Q?>+6T\=0)!,BR#W7NF2F^.>RO[^56Z\L8\WM>BZUEZIV%U15;;
MV?3=?=;;4S:1)OY-M4=#@*?,35G8L-%1T^4^ZK)J?[*AAIX88D:?S>Z]TXXW
MXS?'3#3YBIQ71'4&.GW#M?*[(STM'UUM*!\ULK.X;";>SFSLJ8\2OW^U<U@]
MM8ZDJ\=+JHZF"@ITDC80QZ?=>Z?\OTET_GEE7*]9;&J?N=XTG858R[:Q5+)D
M-\46`Q^TX-UY*6DIH)<EG/[J8FEQ3U$YDDEQ=-%2.6IXUC'NO=.6:ZIZTW'N
M*?=N?V'M3,[DJL$^V*W,Y/!X^MK<AMYX<I3C#Y*2>!QD<?#39VOBBCG$BPQ5
M]4B:5J)@_NO=(O<?QC^.V[]K]?;)W1TAU;GMF]3T=3C>L]J9/9.WZK;FP\36
M;5KMBUF%VKA9*$X["X.LV3DI\1-101I22XR5J5XS"='OW7NH&?\`BA\:-TY*
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M-58"J:.HW%FHXL=5^Z]T(.\^O<-MSM#NS*/D,=N#<G;V`ZOW?N?/9:LP=+NW
M=O85%M_<.(VYWO49JC3"[<'6,=&^0CJL-D]MX446XUK)JFEQL]3!J]U[I+[3
MS=%F^L=]14/:W8F4J<%TQ\5:+.;GIZ31C31[BZOZIR=#UA14TDR9J2F7%#)5
M^"HZJCJ</D]QX>*$5-!YWHI?=>Z=*W?_`$O3[6VKM?=&S-[;)[ES?6/S'W-\
M?>F<MLNMV]3T4D.\MY#Y$XK([#W#FLS2;?QG8$>'R--L*.?*5D^\Z>AST-#6
M2JM+#'[KW5P/\N&LFR5%O6L7;N&VK0P879&'I\1A-J9_9&B/&[?H)L>FXML[
MJGGW!CMSTN%R%+YA/)(SPS1N1`6\*^Z]U:%[]U[I.[PVCMG?^TMT;#WIA,?N
M79V]MNYO:.[-N9:!:K%;@VSN3&5.&SV$R=,WIJ,?E<76RP31GAXY"/S[]U[H
MFNT_@5M':>(V+AH^^OD]N&#J*MVY5=*5.[.RL)F\CU'%MFBWCM^DH=N9!MET
M]9N>+(;$WO6;<KY]U/N&NK\.D"SSO4Q"I/NO=`QV5_+>I\5A=C;?^,V^=S=9
M8JG^4'QF[:W+2U.YZ1(=@=:?'[KZ+K:/:_2-'4;)W)B\?E*_!8JCDD@S-/70
M9"KEK)YZF.6577W7NA%@_EC_`!IQFU]Q;%VX_8NU]C[EV[3XJLVGA=XEL52[
MGI>G=X=&1]H4)RV-RE6G8U3L;?%<]962RS4V2S`@R=93SUT$<P]U[J?NC^7/
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MZS";KR=%N&BR"5#[FH\A4PY.2ICGE5_=>Z6&W/A!U'M;I_I?I_&YSLNI@Z`[
M&A[9ZR[`SF\7SO96.[`IH]W4$&?SV?R5!/C]X^/;F^<CB/MLK15E(<7)'"8B
M8(73W7NN>Q?@_P!+=;=>]O\`5NS)-WX;97<W66&ZHSN,AS5(\^!VWA]D9G8I
MK-KY*3%-D*?<&4I-P5=?5UE;)7/+E)FF`5/VO?NO=!=3_P`LSHG';XVEV5A-
MX=P8C?.S<KLVOQF=;<>T]Q15E!M#H[8G0,FV\WMW>FQMS;3R^#W1L_K7"UN1
M\M`:Q<[1)74=122<>_=>Z4N._E\]2X?<O7>\<1OGMS';GV!C>V]LUF73-[-K
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MWC-LYK`9E,7F,GL+OC-057V\L='55$-%4S0234JNWNO=!AO;^5_\=>P(MTIN
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M`Z;[4S>+W!N[JOL/^_6,W9D,KM.+)8>#^#FDJ*&OP,">"@J8(+QGW7ND_M/^
M7#TOM?']<8B?=_:.X<7U3UCV!U!M"'(9?:V(KVV1V#U?M/IBJBW/G=G;/VQG
M=Z[@V[UGL?%XO%9?+5%9DZ.&D0B9B/?NO=-E+_+,Z5AI<7'6]@]X9S(8J@6@
M3,YK>F&J,C6:/B1F/A='D*_[/:M!25&63J/.3U/G$2E]P-]\X8%H&]U[IPJ?
MY<W69V;NWK;$=N=_;:ZXW=G<ENBJV7A-Y[>&,H]Q[FZ]RG6F^,I%6Y/9V2S>
M0I]WX/+RU3XROJJO"8S+K%78VBHYXHRONO=9<?\`RY.FL3O#$;XQ^[NR_P"-
M8/*/7T,.5K-D;AP<]%F>C.I_C]OS;V;VYG]C9'";@P/8NS>D-LU>1BK()9:3
M,8[[C&R4*3U$,ONO=*GMKX(]6=T[XW=O/>FZ^R3%O/<77.[,EMS![@H-O46)
MW+U7B5Q&S-Q[.W-A<-0]B['W%CH6F+UN)S=)+4I53P3^6ED\`]U[J)V9_+\Z
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M>1Q?\)EJ*2III!.0ONO=+V+X`=3GX_\`5'1.`WQVU@,!U5N[LW?FTMX1[CV_
MG=_FO[LV[W-MCL:FS&:W+M;-8K+09C;_`'[N*&&1Z(34LDE--&X>G4M[KW4#
M:_\`+=Z0VKM.?9E-NCM/)X>KK=HU%<V9W'AJNMK*39WPXJO@U1XV2JAVW2F"
MGR'2U4U1520+%.VX2:Y)(T8T_OW7NI.T?@CTWC^RMO=NU^]>P]V;@VK-O>IK
M*?<>3V><5N*?>?0O5_Q>S^4SL6&VOCZJ."LZSZ+PXC>BGH;U\=5.Q*3-`GNO
M=(3'?RU.D*#KWK_KS.[X[5W3M3;71^1^(5*FZ<GMA<MG_BYELYM/,XOI7=&6
MPN`P<^1H<0NQ:/'T>9CT9V3'SSQS5,TM0\WOW7NA!_X;TZG7/Q9JFWEV/C:2
MAW#LC/83;>+J=FT.WL%#US\MZ'YF[0P>-HDV:TB8JB[3II:*<O(]35;?G^U:
M83QQ5:>Z]TP9+^6ITZ]!#1[9W[VOLB;$9#8>Y-I5^W\ELZ6;9^]>L/D#V]\B
M-D[IQ5'F-EY+$5AI<_WMNG!Y#'U]-5XO+[;R7VU53O40PU:>Z]TH-T?`3HW=
M&"W[A\WE<ZNW^Q.X.L.ZX:?$?W?VRFP-Z]6]<;&ZQV55=/Y#:>'PF0Z[_A^$
MZ_H989:&?S>6:KB9WI*EZ8>Z]T7>H_EX[WVQWQ0;IZXW+#3[%ICLK%TM9NC+
M8W->+:F4[4^0O9O=>1RNVSM*FJ(^YL>OR`S&(ZYW%CZI%V]C,E4).#:J3*^Z
M]T*N"_E?=*;5R766X-O[X[.3<W46W^L=I;*RV=DV!N:E@VOUUT%D_C1D\+F=
MOY78<FW]Q4W975N1"YT5M/,HRE-%58]:%1)!)[KW0D=4?`OJWJ#?$V\]O;P[
M+R<$.P^ZNK-N;4SV8P-1M_:'7/>G:&/[AW-M;!OCMMXO.52X/>]&YQ-;DJRO
MR%-CYVI99IU2)X_=>Z`K=?\`+AV@,7T9U?B*+<.]=H[<W'T=3;M[1W7OC&8/
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MW;&,[?I<)O?<=%MZ#&=BXO!9_$14N`&9QE55[<Q\M5#CZB'[N<O[KW2^V]\`
M.LMO9;`UM/NG<\E%LCY$P_(;K^`XW9_\;P50V6[5W76=8;@WG+MV?=F_.L8]
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M)%X:_`%Z.O6IET54?NO='EVKA,AMW"0XO*;ISN\ZY*W,5LVX=R1X*'*U`RV9
MR&6AH6AVWAL!B(<?A(*Y:&B1*59%HJ:(3/-,))I/=>Z47OW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>ZH3[CW_F-F?)?+C;F],YBLGE.^.V,/311]A4.U:6-LQTC'29M_[D5N)RVW
M>R\QM[`4\^0P-3GZW&X7`34E0:DH]1$3[KW0/[NWA/O_``F<V)@^W-_=K/MS
M87PUS>S]Z9+<^VJ?;F]=N;T[+R.Y>NNPL#M67`8FOVMN[N09EX(GHJR?&X_;
MP&.K(X:ZB#/[KW2K^0K;GHL'VSG,]!U+M5MT]G[!VGM5L*:7=&^]WQ8_JGM7
M>.(ZUWCX=PY^E/7.$6>OQE+AH:Z2GQ)Q[Y.BF$<@HZ?W7N@;Q]3+NW<&5ZGK
M,=@HOCI7KL+95'VU0;RP&[)=R[^P=7293M[I+MO><.&V'6TG4/2&[J&EEI\Q
MFL?4;3W)C<3-B`E55U*HGNO=-U-W!V[L#N#XT5G1_<Q39/:&;W\^YJG-;F@I
MJ+?>Y%V^T5)L#";4"-N#L+'=.UF*V_%@,73R[ER^Y\3N:6<[BVY0B*6G]U[K
M9DZ\RF[LUL?:V6W[M^FVKO+(86BJ=Q[>I*J.L@Q>4DB!J*=)8JBLBC:]F:%:
MBJ6G9C$*BH">9_=>Z67OW7NO>_=>Z__4W^/?NO=>]^Z]T3_YI].=I=R=4'$=
M4;D2ESF*JIZZJV-D8=JI@^PZ:6E:&#'2YO=>VMW8C:NX\-7".KQ63R&(W'AJ
M.4225>"R<HI#2^Z]UK@[8Z>[7^&51L@=T;-A[1WOM[KO=W56\-SX/<&([`W)
MMW;7;.X*G9N:V#M7`U>7DW!MSJG?.Z:_;N[-UY3,YC<5>-R9H)CZG;,4E51T
MONO=*/=F`K^O.W>Y-E56]W7";FHM@T&XMH;9Q9J.H=C9[(466QK]";6R.4P^
MZVV[UL,E2TE=]WA<I>@DCJ7J$J)(:I9_=>ZY;>R5?EOCW\G,]N#=/2/\:A^*
M_0%3B,%L/-'#[KVV=B;.ZAW5F]D=B;>CHZG)S=I[DJ?L\[79"BR[UHIFEQTU
M)32>*JC]U[HJGR$W_FL3W?WQDZH=GGL#8/?WQ+S^QLA@-I[8WMBYL?\`&*3;
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MSBO.(,PDF0I_X7[KW0T=8_.3?R=/[-SVY:63?_8N6^;_`%C\4-_[3W9U?6_&
MG?'3TG94NS:ZOP^\=HYW?._L!N?=^R]N[MAR-/6X#,5&'W!CJJE:C:23R>3W
M7ND'\;OYJ$&3Z&ZTK/D'M;<%;W[O5,=C-K4NP-BSX3:'>NY-R=G?(;9&VL3U
M1A9=T[PW/ALQ%C_C]7RY&BSJT$D4U33&$RQU*Z/=>Z'/M3YH[TVGVYTY3T/5
MW9>"ZKR7QCROR-WS29[;&S<3N[)9[=6Z^O\`J_K7H;.X[=^^=MY?KGL.CW7V
M+#65RP4^6U34;T$GA<J9O=>ZQ4G\S?K7<.S<CV1L+J#NO?W7FU]H[)S/8VZ]
MM8+`5QZPW7V'A=N[CVWL+>&TJ7<-5O\`J:^FP>Y(*G+9/#8G+X?$1W:>ITK(
M8_=>Z3=7_-&Z^P.W=^[\FV!V%V+U_M[*;ZS6(W+UKC.NC1OUCUYM?H;<.YMR
MX^?+=S3GLR*FH>\*2NIJO`Q@5T,<U)'1K5TMZKW7NDMN[^8GN+<>[]F8OK"E
MI]EKC>R]N[5[8V#V%UY)N?>M#1[.^;NV/B-W]1XG<^R^T*K:\LV`;=E)78YZ
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MT-JF*.909O=>Z9]M_P`P;.=BS?)7L;8>R,W3]6?'?X<S=TG;N[\+AL1E=P=N
M#*]P4.=V+GMRQ[TGR&W,CUYN'H;-[=K*>EPV0P]=.9,A2YF:G6E6H]U[I.T7
M\SS']5YGMG,?*#:6>V9U+C*2DWGLW?.#P>#KH]A8RB^&VR/E9O3J3L?'4.^L
MIN[=G8."Q-7FI:+*[=P=3@JN".&DEGAK`!/[KW0U;V^96?S>.Z#P/7.S=P]6
M[B^1'R*W1\?\5OGOC8^=P.U-J+LS8N^^QJG>6%Q%?4[=F[%C[.PNQ&H]BK%5
MT=+F:BO%2TA6CEHY_=>ZEP_-"CZNW7OSJ3N:JBW_`-@=6;BZ_HM^;EZAV)F\
M%MG;>'^0.=WI1?&R@SN+W5N7*3ONO=U'M`TN:J<?63X7%U]3!45$E%1SM]M[
MKW2%A_FD=<KB,1NG,?'WY,[:V=5;+Z?[6W!N+,;5Z\JI-G],]\;QR^P>L^U,
MIM?;79VX=XYG"Y/<V%E%9CL/C\EG\;0D5<]`L7OW7NE))_,DZ\-9LC$XOIKO
M/=FX.R\1U=O/86W=FXKK_,93/]7]Q;3WUO+979SS5W8>&PN'VQ%A^L\Y_%UK
M*N&KQ#T:F>+Q5%/++[KW0';^_FI0UF0P.V^JNGMSUAW!)\I\#FMR;F7:N:IM
MJ'I/XX;3^0VPNS<9MO!;_P`=C^RNK.Q=H[^Q=;$M-GL7DYZ9G@B19R"ONO=#
M-5?S'.K=O8_(U,>S.Q]X8G'#?.W]NY39F$VS28[>N[>F-][#ZQ[;V]MW$;CW
M5B,I@9ML[BWY!-2OEI:>CK\?1U34\\CQ0K5>Z]TJ=]?S#.K>N/CYD?D!NK8G
M9U/!MS>_9_7V].M,;2;,S'8NU-Q=*2;RD[51Z3'[SFV[N:CVEBMAY"N:7"9'
M)"HI1&T8-Y!%[KW3#G/YF'2^V=W=G;7W%L?M?"4?7&=[/V73;KK\5M&3`[[[
M`ZIKNH*#,[-VI#C-YY'/4M9G)>\<"<55Y>BQ=#4#[H32TYIP)/=>Z3^,^:G:
MFW]B'<FY>L9=Z9S,_P`QN3X?X[;.(AQFT\SM;KO/=L#9>(W9EWCW/N_;VX\Q
ML[;4HKJ^:GKZ.EKUC=E2E8&$>Z]T&W2G\TC%U.Q-M;>[GVOG<GW[F9<%2;>I
M]@[0I\%L/N2LWMWCWIT]M4=719'?>ZLGC%I<ETI505L&;J*6L9YZ>>GBGIZA
M&'NO=*[>GSFW-B^X.DMK[9ZI[,VWU?G?AQF/E?NG`[WVSBMI]N9S/;HWWUQU
M7U5\>9L%V!OS:.<ZQ[0H-Y]A)-EXLA35XDJDAQ:`222,/=>ZP5G\S_K2MV)#
MO_8W2GR.WGU?@>NMB[[[)[#VWL/;<M+U%F^QMITN]\-LOM79T&:;LW"9>BVW
MDA79W+X3;V3P>W7O]_64ZW/OW7NDEN'^9?M;;F/W3N'.;![=[>VU@=Z]MUV(
MW7TQL3K:;:NT>H.KMO\`0&Z,IO3=&X\UW95T79=%+0]Z8RJQ>2VK*T6Y*!RD
M&+%32RB7W7NE;N+Y][KS^Z=IXS9.'H.K8<9FL##W)M3N;:7\3W/MK%;<^5^,
M^-_>%!@-S;![)RNU:_/[7&2IZ['U$$.1Q1HJV"M,M2LC4L'NO="9M/Y\=;S?
M'C=WR"I^J.Z<)UM@6V%G,!F,IL2>"D[&V9W"F)S.S.W-N9B.JFVVVQ<EC=QP
M5V7JZBOB.VD\J99:$P-;W7ND-MW^8IMR&/(T=1UAVEV'G,_VSOO;&U-H]4['
MPU?NB/86W=T=1;/.X%FJ>RLOL_L`87.=U8JJKI=NY.8_P6HDRL=`E#33SM[K
MW6+&?S*^H*K;O9B?Z&OD3%N38_5J=E0;%RVU-A-V3V7M3&=M]A=![EKMGO3]
MCR;6RF:VOO;KFO62BJ<G15==C9:>NQJ5=),'3W7NG.G_`)FW5V&R?8%/GNK^
MW:39>V*'<&<V%O?$X3#9+"]@[<VK\.MF_,W+4V/BR>Y,1E<;N9>NMS24U/23
M4XHVK($C>K1I&$?NO=/^:_F4=84F6W+@L5U-\@LM/CX\#3[-SN/Z^Q>3V]VS
MN#,](4?R4JMG]62XO=E;EMR[OPG1=4<]+1S4=(M04^QII)Z]DIF]U[IPQ/\`
M,(Z9R^V/D'NG&[=[2H\G\>=P]?\`7^X]HY?9G\+[(W'F^RLOC=O]:QX'J;*Y
MK#[QPL6[=U;AAHZ:;.8_"03%RZS&""9X?=>Z0&TOG7NCMWY&YGKSKG9F=VEL
M7J?H/O[?W;T^]=NXC<^9J>Z.L^VJ_I<]-8MMM]DT]+AZW965VI4YN:KIOXMC
M=R8W+4<=+5T,B3,_NO=('I/^:7A<E5R;5[-ZRR^"QN+POQ,BQW=&WX(]O]-[
M\W/\D_C[M+O#+R?>=@[BI*;I2#%Y#=?V>+Q6ZLXU9E&,5+25%9D)$I6]U[H9
M?D'\\VZ@[GV#MG!;.RVY.IL%N+OK`_(C>U-@Z')283(=1?$[>/R;I]J=>>+?
M6*S-?O;^'[?HTJ(Y<+5XN>.L:G6L@JXF4>Z]TGNV_P"8UB]C[EV7N7;>U\WF
M^E\'A.[L[W9&-G560[*J<9L'XA[`^7VT\IU/%2[MH<'7T=1L?>HIZU*V-WJL
ME&U#3&.>-34>Z]T.6ZOG-U=M7J#L/O/^Y?;VY.NNO=X;CVVV6VEL['YN3?&W
M=I;#C[%W#VOUK3Q[BB_OIU3C]OI5@9.F;RSSXZI6&GD5$=_=>Z"CM?\`F:]6
M[!VMV+E-I]:]J]B;HV3M[OW/X/:]+AJ+;U/OQ/CSUYU-VMN:#!YRNK:PTB[L
MV%W%C:_;[U-(AR"T]2KI"R1^7W7NF?KG^8A3T6_.XM@]][4RFWJ[`=C=T4G5
M&3V=M&I;&YG9O5^*Z.R1ZZW<9]Z[CK8.^*`]W4`J2D-%MNOC)^TJ5FIJR"'W
M7NO=A_S.>O,'!G]M[:V!V[1=@[>P^^\ANV?<G5U=F]F=2R=;=L4O3V[V['J=
MK[H6MRU'1[JKJ8T\FVI,Q%74-;#74\LM&L\L7NO="/DOYB?3^,WMV5UR^P^Z
MJW>776X4V31XC";,P^Y!V?V-!L[?O9VX.KNI*W;>ZLQ1;U[,V9U-U]4;FS6"
M22'(XV@R.,I9HAE<A3XYO=>Z]L;YJ4_:'R+VILS9&$JX?C_D^E/D'OW*=K[S
MVMD]H)7;LZ+[,ZEZ_P`O1[<J\SN"BR5'A,+5[WRM/E8\QM['L*O&,U/5.D,T
M9]U[H*MZ_P`RO$5\G4V'ZAZ]WO/N3LGL78,E/0;RV+4UU7F_CYO+J'NSNW`=
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M/IGP61Z#[7['Q/R;ZFV'L;=64KWQV^,+A\)V_DL'!5XW(5&W:3[&1,?6-`T,
MJ^Z]T-';&1QV-QOR,S^V=F9#&93"]N;:7<6ZZ05%%@:_'[+Z=[=BR\.$W)C,
M1AZ7%;SCEI8#D6IZ?PR[GIYHCC&M4357NO=0*G(Y[?FZ\[\8ERFY=MY;:E+U
M!G-F]I;JV304>-BVFWV>ZNM=A[+I]QP5&3[7[NK*$4'][$P"8[<,9ER,=!/6
MSQ5F/7W7NH76GR.WM\8NUNA^O=N=+8'>U1O.AWS.M>**.?`XB+!;/SN1VUB.
MNM\YNIP^WMGP;=:'/8K?%7M^#&[%V"LM!AI*5*Y*R)_=>ZV-]@;NCW[LS;F\
M(\1E\",_C8JY\/G**JH,ECYBSQ3T\L-93TLLT"SQL8*A4$-7`4GB+12(Q]U[
MI8>_=>Z][]U[K__5W^/?NO=>]^Z]T3KYKM\@#U4U/T.,W%-7'*4.[<ILPS/O
MK`8^IQDB8W<&'HZ&GJ]QY3#8FKURY&DV[%)NJI(@CQBZFF(]U[K6GZN3&;?Z
MOZCW/\J]G838VS=NGM3)MGZVNWVF8V9+W%@L]LM(-QX_,Y?)R8/M7=C4.5S%
M+N2&CFBH=C96GH=TTE:(!$WNO="[%D>X:?=>_P#9&5S69ISB-F;7W-T[CJI\
M7B=ZYOK#$PUM%14F3WIL##XOXTT'RG:JW!'DHYL:_P!TN$6MIJ6F_P`K$--[
MKW7#9&WU/Q,^1&ZML]/YS94.Z_C5\6\;LG%19///M3M2&IQ/6M/MGLV1]$>U
M:F27<&8GVU2PTQ?,46)K9*=):RC,9@]U[HB7:NTMR;'R?RC7;]-5[FZPV-VQ
MF*[=6.I<QO'`+N-^YY^GZNHR]2FT*_:VU\IL'%XSMN`8W.T>*I\CT[F!.N,H
MMSR;ER/V/NO=;//\M?$P;?H/D?MZAS,57C=O]X[GPE'B8HL9BXZ1L5F]P4-7
MG*+:F&@AP^U,1N&K@84E+2::<PT89(XN5]^Z]U9O[]U[K%--#30RU%1+%3T]
M/%)-//-(D4,,,2%Y9997*I'%&BDLQ(``N??NO=%7G^8W5%=+4?Z/L3V;W+CJ
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MU5FY/A]W/E\?O;9^`V%O"2M^.=#)/O#8&`J\S/MW9F?AEK$R.=V9ALCG<BE/
MCZE)*""6MJ$"`5+"3W7ND_G>QOBCN7*[EK\U\/\`LW=66W7L+:?7F\C5_'ZG
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MPXV/*)E&J%R4;TC3B0F)B/=>ZP/N/X7YO`_W;R7Q'WGA\.N&H=GT>/J^FJ+!
MSTN/K^P:[/SX?$RXW,Q9'"5.V-Y9VISL\D3TTV.^[EK8I!Y&8^Z]T[;I[2^+
M6YYL5F=U?%OMS/;AQ&V8]FX6DS75!;>%!M3:F8QN[,'18ZCRNXZ?*)BX-P[;
MQV6Q53$;?Q*&EJ(9%JU1E]U[I.2)\)XJH9S&?#3L7!UU?LB3%4V2V3TCD-H2
M2;?I<]%E:/%4.0VAE<-!09G%YS<$[XJ1)(:NDD-5%0RH1+&?=>Z=LCG_`(?5
M<+;+S_PQWY38KL;&[QFR.*R_06/BP6:BW)AMIT6[\=E(QD7HJBJW%A]BX>*L
MBLX9,-`M04^T&CW7NI4_9'P_K=S1[CD^*.\ZC=,^XY]S3[C3H:@CK\?E]J[I
MI.R*O?M5G151?:"EW_CZ7+2Y5)C)59R.*H9Y:E-:>Z]UBQVX?A]1;!W1U_AO
MC5V3MOKO>^7_`+TY;#;>V#DMLXG([E:7^)TE)M^3;^YJ&HQ%=62T[B"EQ;4U
M*5:6.PCED5_=>Z;=TY;X45:;UH<Q\0M[9C';IRG76[]R4U#T>TN'S^Y=K8.E
MPFS,K28Z#(04M/N3#;6C7'R2Q0T\]3B(FIY&GHP4]^Z]TX4>>^'^-V7O?:&.
M^(_8.'VQO3);5RNXMI8_II,/+NC,==;=VYM;:NX\+0TF9I9VR76^T=E82"DR
ME"T4N)H\=0K#-&U-&L7NO=/>W=Z_$;#X[/Y[`_&G=^.HNQ^K:'K3=-1%T^CG
M>776UL9D),1UIFHA73MGJ6BI]YURQX^03+#492I\VB6JF,GNO=-5)-\0L17X
MS;$7PUW_`"5<&;VUFL725G12YQI9X.ND^-%%NF-ZW(Y&6JQN&Z=U;7KYW+:-
MM1O3S*]*"OOW7NE!F=[_``RJ.G<GU=OKJ?.1]`TD3YZ:/=NP,_N7:<.1ILW)
ME15X&:EGW'ND;EVUGDCJZ6HQL?W.*J!#+32PM&IC]U[H;^MNC/B;NO'=>]I]
M8[1V+N;&X?8F0V)L7>F#R55G()-D3U^>CK]OSY)LE5?QH8O+YC+1Z<@:BKQE
M95UR*89IJD-[KW3)M'X7=6[([]Q'<V`Q^!I=O;0Z%ZYZ)ZUZN3:&'CPO6&.Z
MTW9OS<N%R^R\S$\=?102TV_)*/\`A\T4\%(M#324CTY617]U[I;[9^(WQIV;
M%LZ';'3.R<,G7VZ,IO+9/VF.<2;7S^9QNZ,+6SX:62>26BH%P6]<OCJ>A5OL
M*3'9&>D@ACIY&B/NO=)-/@5\-(\'2[:3XW=5#`T=(N/I\4=M4[4:XU>MZ[IP
MXMXF8^;%2=2Y!]L/2OJ@DP"0T#(:6G@BC]U[I02_#?XO3XO>F$GZ4V5/A>PV
MVM)O+$3TE5-B\W/LRHP=;M^KEQ\E6U)2UU/DMLXVLGGITBFKJ['TU34M-401
M2+[KW3SFOBI\;=Q8W)8?.](=:Y;$9GL#>/:F8Q5?M7%U.-RO8?8NULOLCL3=
MF2H9(&IJ[*]@[0W#D,;G6E5DS-'D*J*L69:B8/[KW27SWP@^(FZ,74X3/_';
MJK*8JMKM\Y.NH:G:M!X*_(]E[0Q6PM_5U<(U1JVJW5M#`X^AK'E+M)%CJ0W#
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MKV-LF#:>S*K`9#<>+W'G>M,1M38-!7Y+==1DLM6;;SN!QF.IMJU-75U%+DZG
MQS8>GJIT@J::":1']U[HI?=."_D^;5W?TQL3L;"?'`5'RZQV>PW5=#2#)5^"
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MI'<V!RFWLCU%W?4XC8N(P/\`&D_BE#'M^CBH8<;$`9#[KW1@\U\&/AQ646$I
M,KT#U\*/!U.=;"M%05-"<4^Y^R:SN;.B&KI*VFFIZ3(]F5E9F'CU^(55?5A5
M$=94I+[KW43=WP"^'.]Z08C=?0.T,[AZK);(R<V)J:K.1X03];=69/I7:<38
M6'-P8]\5'U%EJC;%;0K":/+X68TF0BJ8`%'NO=/65^#GQ6S&#RVW*GJ/'4V)
MS._.O>SYXL-N+>>W:J@W]U3L["=>=?[HV[D\!N3&93:>1VYL+;E'A8_X7-1Q
MS8J'[699('D1O=>Z?6^)WQHIMO;^VYDNI]IY;"=I8O&X#?4&ZOO]U5.XL!M_
M.9_=^V]M-DMS5^6RM)M[:&Y=Q9+*87'4DT-)AJZKFJ*&*GE=G]^Z]UCH?C+\
M;<'N+.;XHNML1%NZ3J'+=%;@W3-5;@GW!F>J]T;DR'8&:VGE\WD<H]7N"3<.
M[\]59.IKJB:?)5&1K)99*@RR.3[KW2%VW_+_`/AQ@Z;"##=`[?PU!C=C]8==
M/MN7([E?`9[8_2V$@VSU/MKL':K;CJ]L]CT.PL!14U-C1N"GRCT\-'2@->EI
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MOMJ2)I6;W[KW2;@^`'Q!HVV?-C^F,7B\AU]4=;U.QLWB-S;YQ&Y=H'J78_\`
MHSV)3;<W/C=T4NX</C<9UY_N$J:2"I2ERN+`IJ^.IB`4>Z]T][3^$?Q?V/DL
M-E-J]6T^(FVMOCL3L79-)#NK?$V%ZZW7VQM7.[)[#JNL=O5.YI\#UGC-S[;W
M/D()L;@:;'8V-ZN2:*GCG/E'NO=+_K3XZ].=09NNW-U[LY<%N/,8J7%;@SSY
MS<F7R^ZFJLM)G,AG]X5^;S&2J-W[WS&4<25^X<F:K.Y`1Q)4U<J11*GNO=#9
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NM8+^8WC:S$[GW]FHMO2YF&H^5/4^VY*NIW'/MF?>#=
MHU>\MLT?4.WYL#6U]3LS-9FJIM5'N-<7+F,C,T6%HY47(UKP^Z]T6OHYL?!L
MOM["U6],WC<UL_Y%].[<WD^X,+C<)68'>R;6VQNG*/2]4XS;]1U]U@^8VUGJ
M"MW1UXU4U-UKDJ#^[V&9,8B22>Z]T=WOHT,^*^0:47:N5W;63=_[;CIMDY#;
MV]=[-US1CI+L[+X_>+;&S&:H!NBGW-MII<U5+1>*(KEEJH:PU5-3QQ^Z]TAL
MQDL_NS:^ZNC,7NBHR/<V)J-F=I4F#P&X*IZO9E!09>CW!2=FXVNZ^S=3L_&=
M+=D;<QRT]'3^;&15N1S5+#49*"69*-_=>ZS=9=G_`!BZ'[@^/FVODGT9FYLU
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M4V[_`!R?%[?Q6?VW@L1M/"XFHJ,A1/BJ*+(96CQU)#@9(::@PTE=-BH%IHJ2
M(QLJR>Z]T"'47S!Z3[VW'L?;O5._=A=H3;XV'D^U=N;?IZ+NG:^=[#Z?P<]=
MM3<_9>T?[VX["TFZMH;/WG3-BGJ</%/4-6*J5B4K2%HO=>Z&P9C?)FGQN2V+
MEJ>9,?`-P32]>2ST$QURTFUI324LL&#P]-5FJ1*RBHXZ[]F9YY&9B6/NO=<Z
MK>&YXZFKEPFP*6I)=\;AZ6':&[,0*NL'GJ(,UM_$5R;>FWE%CXY(]5'",/!.
MT<T?DJ8Y$;W[KW3=4Y#<E"TT-+U_03TT--#GZG'5E!%B,.M54PTN5FJ,)FH_
M'F*S.Y&M:6;(+/Y::DJ*1L=`5\+2O[KW2O\`O][4V:HZK-]3X?&;<KZPTU;G
M3M^GW%$N(R,KU&+QT\.+HILEB\AB*F%YZA?'43BHJ9%F`@@6K]^Z]TBZ?+]G
M5`_BM9U=A\S455-7B@>IQ])04T.-$ZUDF-R.6>HJI\1L>5I(:-)*FDDSU962
M6BB\$35'OW7NG4Y/>,]9)3_Z/(*%*"HHZK'9O<&UC53[BDGQZ05]#G%@KX,]
MCO[KT](D;T,T2UX@*21FI,#1/[KW62LSV[Z6FB.>ZZV%MW(5>0H8GRF\:VA@
MVY%35A'\5RKP[<DS5'!3U$*3U]/.X@%3'("[T^M@ONO=9*6/=N"RQ1=A]=T:
M-0X2FJ\E2XRBC?`U>4K*K&)BEQD--EZ:7$1Q(LCUU/45"/0@1&,SS>-_=>Z\
M6WUDZ[)ANI-ITV0I*2KVSC9<M!LIZG/T"^.>#<&WJO'5?WM-M>FR*$?8Q5]%
M4%V#S1)+&J#W7NGFBJMY'(-6TVQ=FY.3)T>+ESL])@5HL#!38[)PT60I*WQY
M*)*T"&O26EIIQ]HE;)/)$)"TSCW7NL<&;WQ246(@K=C;>=:?/"*E7#PX+<^+
M@FHL`],^/HJB7'8-:'$9N2(ZLQ+(F-6E1AS),I;W7NNGR^Y:=8<?)UIB7I9Y
M$J8Z2J&SZ6'#TF#K*G)5R8ZFIGE_OSEML5=1/!6XR<T@U5):G\X2WOW7NFS^
M\V9R5'55=+MC:ZQR:::&;%;,QU;'7[HEF#9RGR<==%)AZ#9,>(/VC,NJL@R=
M5$T0DHI)R?=>ZBY/,Y_%4-;5Y#8'5]1!0U%'C,KF\/\`PC=&-QD4+4N.QIR%
M'6SPN&QU23!-2.*O^$JDE2"T`\`]U[K+/ELM109!*W96RX9:;)5E-%-/CQGZ
MR&F0U%745&4..PM7-B,<:2"DADRL(BK4R%2E+40/&89S[KW6<;PK::"HEBP.
MS<;F_L:A]L5V+CQE!]C3UDO\0K:G*Q)'/28R#,9N'(22@O#)D(")9EDG;2GN
MO=.E+O))&FR(VUM>/`U*4E!D#CQA%KVP57BL?1R09['1(TN)QU1):BQ8H[M4
MM-%(@8R>GW7NN1K:[!"6"##=8TU5C%6DQTFW<6<;6097%,<<*,_[@8TVS]KD
M(8H(!!&TJ1I42SQKJ2_NO=8NHJNMV'\GL9-M>GH\-M/Y`3[JINT\'CHI$VIN
M3M?";'HMY[?[/PR1U+46)[6.+P6<P&]M$>K<4='AZ]V\E*S2>Z]U9C[]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>ZZ-R"`;$@V-KV/X-CP;>_=>Z9SBYY:62*J
MR51451>*:"J"+3I35-/=J:9*:G:..14ELSQN6CEM9AIX]^Z]T1'Y,?.7$]/0
M;4HNH(=G][;KW)W'+U3N/%T6]Z2BQ'6=9A]LY?-Y.AW)7[?Q&XVQVY<MFL=2
M86ECS$F)Q-%69)JK(Y&BI:"<2>Z]U0'D.]_D7\I?])5)0YKMG>-'\LI:[L./
MXZ;@JI=S=?87H?\`A&.I\3MWKOK_`!&WZWL;N:3J3N.GQ^!WK5X--L[.W!0#
M(/3;FKL6P5?=>Z%&A_ET=J/BM_+V%O?K+HJ';^/SP:3LC?/1^W<-/AMZ;WVM
MO?;M.:5-M=[[WV#A=B[XEQN*P=16YZFJ**CRU7#!3)/E9'?W7NHNS/CUB>Q:
MO=U9M#YT_"*IJ>EZC+UW;E9@.VMHYZ#9$V.W`J[JPF6??'2N9P76&(VWO[,Z
M*V?%4^(K:"6IAQ=2\43QP^_=>ZX;V^#OR?Z@R?4?:-/UE7]G3=,[SVVVV^UM
MMY'#;@[!WSBY,MG]QQ[@VGNOI/:M7CNJ8=Y[@W#"N:W15]53K2;:H#'4S*T_
MFC]U[ITZG_F$?(3H0]Y;DR.ZLI\L*_?>,INR=/=/<&VMF=?=<8WKK;N>R_=>
M\N@]P;`VSN7`[AZ$BJI\?MNGI<%D*S=-)NB">OR6W-NXPQK4>Z]UL7]8?(3J
M/N/)3[2VGOS:U3V;B-G[$[`WMT_5Y_!GM3JW!=@X*#*;>;>.S::HESNW:J;R
M/&KU403[E)(P]UTCW7NAEFI9##47I?O)HY;4K3UICF>*9*=*ADJ4A\E$"-0*
M)<,%_`:P]U[J721UD0>*IF6I1%B6"I;0M5.='[SU4<,%/31MY?TB-;:?KS[]
MU[K)+`TD]/+YG6.#REJ<1P-',[JJQR.\D3SQO!SI\;I?4=5Q:WNO=8*FB>KB
M$-1.C1?=I,\8I*=XYZ:.36E'/'5K5JRFPU2+H>X!73[]U[J?[]U[HGGR1Z?[
ME[(WKUMFNO=X5N+P.V\9N:+^&4G8V[^MXMI=D5E7@*G97<.1I=ETCMW+B-J4
M%!D:&JV1G)X<!EH\C><%@)(O=>Z(2OQ%_F'4%+V1B-I=_;BVW@>P>L*OJG;N
M-R7>.\]QUW5.^L5E*#=6>^2V$W?F\=F]R9:N[YRV.EQ_\"8QR=?TE87QDE1`
MTE$GNO=*&J^&GSXFZUS0W)\K,GNSN"#:>[\3A=T[7["['V#2U]1#7_'K']=5
MM1M>"H?8$&\HMA;(WO2YJNDQST%=FMPQU\5-3>>9*7W7NL&ZOB;\WOXCE]S[
M?[:["KMO[CK*.JQO3=+\A<QM.LV91;4FVQ_=C$[B['GVYNFLWA0;CJ*:JGRM
M%B&P$M!":E(,I7&HACA]U[KV"^*O\P^7<&VL=O#Y`Y!:[([5JXMZ]Y;1[9W7
M'+L^@H=SX#-;8ZSZTZARV%79FX<G2;@Q<]=D=W;FH*W*9S;5?5821Z)UI9X_
M=>ZXT/QH^?=7#NG']B=@;DWGNS<]5BLSE]W;3^1^Z>K.L:?(28O.XJEH.O<-
MMK`#LO:F$V3N3+4>?DQD[O2Y:GQGV$\U1Y"TGNO=6K].X_?V(ZQV9A^TLM+N
M#L+#X:+$[KW',<0&W-E<7+-02;F2#!T..QM!!N..G6NBI%C,E''4+!+)++&\
MK^Z]UBI^[NF*NIAHJ7MWK"IK*C>61ZY@I*??VU)JF;L+$439/+;$A@CRS2R;
MRQ>.1JBHQ8!KH(`7>)5%_?NO=9*ONCIV@KL)C*[MCK2BR6YL:N9VYCZO?>UJ
M>NW!AW%&R97"4DV52HRN-=<A3D3P+)$1/'ZO6M_=>ZE5';755(V+2J[,Z^IG
MSA485*C>>W(6RY>A?)H,6LF24Y`MC8FJ!XM=X%,GZ03[]U[J'D.Z^F\3F<CM
MS*]M=98S<.(P61W1EL%D-^;5HLSB]LX>(SY?<61Q=3E8ZZBP6+@!>IJY46G@
M07=U'OW7NGS*=B=?X/`;DW5FM];.P^U]FU=70;OW)E-S83'X#:M=0/!'74>Y
M,Q5UT..P=71/51++'521/&9%#`:A?W7NDLW?O1*5;8]^ZNI4KTW7A]B/1-V/
MLY:M=\;AA-1@-FM3',B9=UYRG'DH\<5^\J4]4<;#GW[KW4RD[LZ:KQF&H>V^
ML:U=O;K;8F?:DW[M6H&#WPF=Q6UWV;F##E7&,W6NY<[0XXXZ;16"NK((/'Y9
M8T;W7NH-!W_T/E<T^V\7W9U'DMQ1[IGV-)@*#LC9M9FDWK35+4=3L]\73YF2
MN7=-/6*8GQYC^[20%3&&X]^Z]TJG[%Z^CE\,F^MFI,(IJ@PON?"+*(*;+5F`
MJ)O&U<'\5/G<=443M:R5<$D)(D1E'NO=)QN]ND$C@F?N3JI8:K$T&>II6[#V
MBL=1@\J9!C,U`YRX67$Y(POX*E289M!T,;'W[KW3Q2=J]7U]-N6MH>R-A5M'
MLLJ-XU=)O#;U33;3+:](W+/#D7BP1;QM;[HQ7TG^GOW7NFK</>72FT<T=M[K
M[@ZMVQN)=OQ[L;`[A[`VGA<T-JR_<^+<IQ>2R]-7#;\OV4VFM\?VS>%[/Z6M
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M5128V.32]<DBM`'#`GW7NIT_8&PZ6%ZBIWMM&G@BBAFDGGW)AH88X:C)QX6"
M5Y)*U42*?,S)2(Q-FJF$0NY"^_=>Z5WOW7NO>_=>ZUVOF?LG([LS?R<QNQ:[
M-8CL^3M_:.\NNLQM'#YUJZ'>W3>"/;FW\+0;AH7F_@NZ-PMM_*8H4[2TD=9+
MN"G=&53()/=>Z!WI;*YH?&SL1^PM@;MV)O;N?NWK/Y';2VINW1B]P['ZT[@[
M]JMO_'WH'<NY:/&R]>T&_=E?'/$[<I\_3P54M9BA5P8\I6&AFG7W7NA4[.VI
MNG;&SNU4KZ?KJHESG=^`DV+E/N<7M2EPF.W5TS\@::GZ^W%EMJRYS#878N$K
MJJNCPN[Y)(:3+K-2038BG82,?=>Z025F9V]M`[ZQ>U]T47?O6'8O4NU7HZ#%
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M=[!W.F"W-!M38N'IYHQ6UK4%=(&GBCCIIF>P]U[K7'RU//\`+/KS;TN#V'T9
MUYL*HEWCNC=/7>W,17X+$[,HL'5)O_86?VIMS9]7C][T.6[*QLM-F9*O(SY?
M:+8'+Y."K@VSD)WR0]U[J3O?L#:>[.TNX]R[@ARF)[`Z_P`ITYL+M39U'FZJ
M+</7'=F_X*O)87XN=9X#"8G=/6U=UMA=I8YLMF]UT6X*C''3/1LN0EK(V/NO
M=0=BUL^!Z"^1F[LEV/LG.(WQ_P#B+-CPE$N.Q/7!QW6W1>47KO*TF*VSF:_,
M[KVS5T#[UK:I\GD,FL/W"5:5M*&D@]U[H8:?J#INF2CVOOVH^4-/N/,;A_F$
M[<W5M/(P?&RD1)]W;@ASM;W%N78VT*U^HL_@)HZ+`8O:]-FHI:B@R&6AJ,BZ
MU0GF7W7NK&/Y6%?_`!+#?(NMR@SF+WE6=L4M3O#:6Y\;@\=NC!91L-XWK=UK
MMBMGVM_>W/U$4T^1BP\4.'@G732>1"7/NO=6O^_=>ZKD^9.*SN6[Y^,T.$R%
M-1PT^Q/D?5Y^"LJ,C!2Y#;\4W20R%-5+BE;(5%,BL'9*;34ZPFAT4N3[KW3.
M<+N:G3-9W?&YWQ.U<!@<QE9FS"96BD3![?VIDI-R2905.5:EAP4.%QL<#YA9
M&):*2FK))'(D7W7NM:CH/NC`8CXC?R+MQT.;V5NO>GQ>JOEM\EN[=FX;<5!)
MDNOND]N;)[-Z^_N_O#+XNLR=%LFD[-[!WCMK;=.,W/2469R>42%EK)4D?W[K
MW1F.@\WWCO+=_P`2.FM\?+#Y&8'LW8GS]^3?\N[NZNP_<]=B\MO6BZ=Z5[J^
M2&UNU=]46+R]9MW<?<.ZX\AL.AK)W6M@_N_CWQM,QIZEW]^Z]T$G2GR([/J>
MHNN\CO+Y/]S5V[^U/EG\?-LY#[;Y=;RK1N;I?L'^9MNWIWMSLW/Y*KDQ=/\`
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MT0VUG>O<115;(\*T[)`M%GXJMY/##/*8'IX_-+(9'="ONO=16J.V)XS4S[*W
M#)3TTV#IXY#B\;4;@Q,%7.9ZS^";9@SN-VAD$I\15QQT-5.T%/32B:()Y$#>
M_=>ZYQ9+LF+(T%,O7V]:NLI:Z')S0_P/&MA)),I1?;2Y3:&:GW-29:&GI9ZE
M8#2_:OA+$S2JT&C3[KW3SC*GM%LD\AP0II?O@/XK787'X6>KEHL7#6XG<6+Q
M60>L&-J=K"@FH(*=:B1WJ9W\LP\<#GW7NHLM=VW+B<7+%UY24V8H8((JQQN#
M'[>P`_B.1\>2JI(Y:2MP&W?[IXF62:56CJ(*ZJC6-%E9N/=>ZCTI[AK,GCXV
MZX_AF+R]'D8,U##BMBQYF&DB$%1A!+591_X+E]V+/1/5!(88:5*)FJ7$A5XQ
M[KW372YCN6E%;'-UCA<K15WW&9STF`W3-#BMNY.OCKUS.:R$T\E71P4N2ACB
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M?NO=>]^Z]U6S\]OF)O/XY-UC!U?7]6M0?WSR57\B]W[SR4>6H/C_`-1X7968
MW)_I-[)V_B\_B,SM/JO^-4]%3YS<TOEBQ-)4(D4$M564S1^Z]U2#U/U#B>Q]
MK=P;LWKLZ;I3XA](9'L3M#L[-[AZWBW_`)+#TV%SH[9SNT<SU3A<'FX?D#WE
MB,WA*O=6V]K5^&SN"Z=AJJ-\KB\[V4U8F!]U[H;<_P#)?=VY,_ENJ?@WTCNK
M&]6=<]M[?^2NX>^OC]WSMA-I?,#J?+=)TO:W7^<[Z^8'8%-'5]3;CWGNK=."
MRN9BW/-G8=X;/PV1Q\.=%6#AI?=>Z+[3]&]0X?$9NBG[.WOB.O\`MG?/;F[L
M?V/U#UGBX-@]A[,[J:IW]V?T[3_(/YC;RVKUQVE6XG*[1I_X!NW:6`K,GB*'
M;5#G*FM\<=0M'[KW0V=D]7]3=O[MW#D:_;O9>Q>V^G=Z=T_)B/&5';_P8^1&
MWNM]V=H=K;0W!V_6[CZ:W'N_9.!WIMW:.2KZ;$1M)EJV+"/D*?[ORUKT^OW7
MNE'U5E^ZNL/DMMFMV#\B]X[VV;O/;?4^X.X.D\/U8>B^U^E^A?BE_I!W!M#J
M?XN?![>53)B^P.F.Q-O9O&X//[BZUDS6=5\95"D&17*T$&+]U[H7-@;:VC_,
MSZ;[W^0N5ZQZO^,-=0=KY`;?[!CW/#O'IKO7$==Y.:3:F4^0>$>BZ[R$/8.R
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MS<6\)DDWA4S4K0U&0DBE(7W7NG6A_D]=`XCK_<W7F#[$[:Q&-RS=K_W5JZ:?
M833]54_<FS^CMJ;KQ/6-/)L=J/;.WJ&;I,9+%8\)+2XZNS^16-#3"DIZ;W7N
MFN@_DR_'/;V]<KN3:VY]U4NV=RP;TP6?ZYW-@MB;UVICMA]D;+VOLKL'K_KA
M<QMI:OKS:^[J/;4DM12PO5TL+92NCIH8(I@B>Z]TYM_)M^,DO6E5U-6;H[8R
MFTLSM+=/5>ZZC+;BQ-9N_=71N\?DG5?)#.]*93?2X*#=J[(GJ%Q^T5:*K3(K
ML[$4M%]R9D-4?=>Z>)_Y8%-5]+?(_H;+?(_?N[]D]_[DQ'9%/5]A=;=+[SW+
ML7N*FS.*S&>[+CR%=LFGQF],GN%MNXT>/+44TM'44SUD,XK9?N$]U[I2[W_E
MA=3[OGVC50;\WCB:W"9NC_O9DZC;?5NYLMV1L.?J/J'J3>.RMQUFY-B9"/%9
M/>M#TCA,E-N?$18_<N/KS4_8UE-%,(X_=>Z"/#?R:^HMNYCJ#<V$[B[*H]U?
M&[?^=WM\<<VNW^L8&ZWAS^Y=J9>JPVZ:3%[-QD/>52NW\-D\.N6WJ<WEHXL[
M/6Q3Q9.GHZV'W7NA,WK_`"JNCMV;TW!V;1[KWE@.Q*GO+LWY%;,S<&-V+D,-
MLCM/M#_0-/DLV^TJO:@PF^8,#EOC_C:_&T^?7(1)75U3/4"HE2C>E]U[H*L7
M_)(^,>,SVQ,L^^NV\W1]7YW+YG8&,W+4;`SRX>#?^<J]Z]XX#)O7[$>CW9MO
MO#LRK?=69H<I355+3YZ>JJ*&.F%5*GOW7NL=#_)=Z9I=@9[`UO:^_P#.]A9W
M</QXW8O8F:P&Q)L?@,E\;\YDL]L_;&UNMJ+!4.SL!U575.5GBJ-O0(%6FE>*
M.I5"H3W7NE!E?Y/_`%3D=B_*O8L/<7:%%2_,S93;8[NR(HMG5M3+D,EV?F^R
M-W5.Q*3(8*IQNP-I;XBW/D</E-O8^)*"IHJ@5#$Y)#6O[KW0H[O_`)8W4?9.
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M`7=G4OP'W]L[>62H.R/EU/UON"IPNXMM;KZ]Z%V1A=T]#Y--S[LJ\QE8.PL=
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M1Y/`9'^\_9_67<.]]W=;?$_=>[LCMW?>]MJ;TI=VT_?^4P_9N8K9<]C\'U3@
M.J,[7XR#*+7XB@QVY,GELK4Y&='HI899?=>Z7W?5)MS(X7Y"TR==5FPMK[K[
M*V1BMV[[S$\VZ]Y]BX&A^.':-'3)0X5\%@JBE[#P66VK#@)?XDJ;G@I,1.L4
MU7YZ$U'NO=!I'0;(ZS.YOE)C*"NPNZNM<ITKL#LJBK\#D<3A-[8_`YC&MUSU
M9M'$;FSN^L[3]R[0W76+55^=PU1A<KD(HH'_`(G2O++3U7NO=*GIGXQ8SN[L
M+H7<O8G='Q_H>S.L,9F:C>>!I]P9#)Y3:V[:N@EQ5#C.K*#+O@,;O*IPF-WY
M44N5RU3B</'EH,QBIL[A*G(1LM7[KW6QCLG9V&V!M7#;/V^<@<1@Z9Z:B.4R
M59EJYEEJ)JJ5IJVNEFF8-45#E(UT04\>F*%(X42-?=>Z5/OW7NO>_=>Z_]#?
MX]^Z]U[W[KW1>?D_G>FL%U+EW[NQ53N/;F2J(L3@-I[?AKZOLC=>\JREK%PF
M"Z>H,!6X_>=;VK41+.^(&`FBS43QO-3/&T9=?=>ZU<J\=#979'4./^(F%[,Q
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M#V;3T=#N'"XM*ZF_BE1B&HT$E5/3`>Z]T5S:='MSL["5DO7';.)KMFUD,]!N
M*#;^+R>[,3/13Y&BBR6$W9BLC5R[IPV1R=92_99C`9.FH<U"(7C-.JRR*?=>
MZ?JOJ/*5=)N"GJ,CB\:NZSAX,\N!Z3Q44N]JZFRU1-MK*=EXC)8?+XW=^"I*
M&FBI9(EIVBI:&CC:-Z>I@$WOW7NGFFZNJVR4L\5<E5-B]-HLUL6IP&X\;N^C
MIX:5]Q8/>F/BAWG4US9&KE29?NGFH,?4QTWF<1F(^Z]U,R73*#+9&2F^TPT.
MX*.CJ-VXB'IG9"8;LRJHYQ##-ED795-7[EP^$Q\%6CX[*.T\$M1%(FB96\ON
MO=<*SK#<576PSIO7*Q;@C@FH*,4^S=W108W"YIGS;18/(5\51G,%BJ.DIWH5
M%/7)B$EB1O`T\&KW[KW40=?[FR6&I?%NO>!R]23545;1?=4&)_W!8W%P8[)3
M8C)54-94INS)5LKPPS22T7W=6LDD*Q4I>3W7NH>6ZDS-124%'B]P;XH<WAJB
M//U@-+N":#(Y_)U]=1?QO=6.>L4'<5'15,9DF\4(?(>6:#RP,"_NO==IUIG)
M<)/@XLSO:IQL&1HX:G$[6@R#BGRNZBS3Y3&5F7R%;-34F0@2GEK\)BD!&/US
M02Q5=UC]U[J#+U-NC^)Q9&IR&0J`E!/D,MAZK&;GGQ.,I\'!(<%NC;%3-D*X
M;:S-)414\M14B2OIEIHHZ0"6I<CW[KW2BI>K=YT^YZS+)E]X223T]+*TLV-J
M99ZS;=5MNFI8\7N!)*T[9GGQM6]4V/J8I5R/V]27<ZXE1_=>Z>,3U]O;$BKK
M:K/[PCK<Y%A?O$D?(SUK24&/KY<?CL35I41[AHJJ>H#5,B57VXEQ$9A31.T,
MWOW7NFK_`$;;]GCRU5F,]OG%U,T$K4&TL;A8LCAZF@,17&4%+6[RR%=E@M7F
M\A7U6/J:6"GK:..>FH"76D9Y?=>Z>Z_8^[IJK*09+^*R-68VKB.*DQN4GH*2
MG,=''"E(:"*AR.5RN6S%.5&'2=1%+42RQF*%O`ONO=<8NJ=U4T6$--D,M)#C
MHYZ;'2Y*AW%NN"IQF0$E568;-"**FJ]TYW`Y&J!QDPJ(KQ*H/W"H_OW7NL,&
MS]Z9&:"JT]@Y7;=%1S5S4]3FL1F<KN-\3D\C+6_<4F;Q9QE1A<L95</2E:W'
MS*RQL@D*+[KW3,W7._S!7B>3)Y%<DF:&>D2BQ64;,84T+Q8BGHIZ^KFVWB,C
M!424TTM1Y]-;]FU*T4;5_OW7NI=1MKMN7`P/'MVGS5?2T<5-C<37T.-Q[0Y'
MQT@J9?/72K#08'.UU"TM)+DQ4?PR:`05'W=)#+[]U[J50[7[;I'@KH<&E;E,
M=-0M%E)Z`YBH-'.^1%;48N?(4<F.RU5EXJ]:>+'Z#`J+#4PM3T4C*?=>ZFU&
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MNW>7R9W1OVERV3VYOS%;FK5W#3S9#`YK:&5I,_/N*3W7NA(Q&Q)\5L#!9G#]
M:5=!U?UUV-N[`]>_'#-=`[N[WZIZNW=U[M_%;BV#/\AMH;>EH)_E;\L>XMP8
MF#&;CWOC\INK;O2F9C?;M`N.SJ3YF3W7NCV?'S^5YN"ODQW8OR'[)WCEIM\[
MLVQVKO\`ZESN5;<&3KLC@MC=D;`VYM3?V]Z.HH)MPUF1ZG[FR>U.R5J#FTWQ
M)AL=,:Z''BHQE1[KW1I=V?RW>G]Y3OB\ON[?PZTH1NVBVAT_C7VI@=A;#V]V
M/V'M'L_L?;&UHMM[8PN=CPNX=U[#Q,M#%55M4N`2F*XX0:^/=>Z(KO'XH_(O
MIK;6&ZZWG@,+\H>M\7L;?6`^/VWMGX?<NW,_2?+C?G=&"S>SN[>QM_XVJR?9
M.P>QMRT%=N/>6ZNS<%E]J8K9,]5D*7&T-3Y*&*H]U[HN/<'8>3^25#U)TKN/
MMOXZ?*W!_'KM7=G<.(H.S!F]^?'_`.7FWNH^N\\W;?3G:)V%U_32=K_(?XKS
M96HW;M&OQVV1M+LB;!K6-0T67Q6:3!^Z]U@V-L?J[Y(_#3<]/T'L[L_9^XOA
MI)MS=N&RF'[<V;W!V-NGXR]LY*O^3VT^KME]P]:S8W`[6[1^.:YN+,;$VM!)
MDQUYFML8.AI9Z[%Y)YJWW7NA._E8]HXWJ/N./JS#?';;.*WC\JL[4Y'M?-=)
MUW7NU.JNNJWH'K6IP>5W9M/J#`SU6X=O=-[LRTN%K,/49VI3<LYWQ3>6%J2"
M%8?=>ZV/_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=`AWEN7M[;&*V34]/8+;>X,CD>PL%B-W4NY,1NK+0T.QZFCRM
M3F\MCSM.9*FBRE))1PI#)4QR4A>4*^DLI]^Z]U5#N_>_<W:N(3</=O\`*UP?
M8_9F!&<RN4>:#(.J;NV9"*OJZ/9V4K<+F\ACLON+H[=N]8(ZVGFEI<?N)L;B
M:FMBERLL6-]U[IWPW;??O^G&"KV%_+RH5H-O9F3=F4[;WY@]X#L'#=8;(^(F
MY<CUYAJ_=6;@K,SN+Y$UG8^_*_8G\-HJC*TN*PN2JM-75K*S>_=>Z?/C9@]P
M]R=CX>D^0_P:Z;VGUQ@_C?L_<N*[&V;MS>51@,]VUD,C)V)O38^VMG9S&4^0
MK\#LS,=F963'R97&TV4I-Q+DI*'S25DI@]U[I`9'L_M.DQF=[2I/Y<U'L7LZ
MDPO<G<='BLC!OC";[R/96-?(XS9&]Z7L+85!/3[!VON+J>MQR[JIGJ%W%75N
M5K,(,<\5)4SS>Z]TO^L\GW7G>R%?;OP+Z@ZSS&U^[^GXLMWO)MS=V-V+VWL3
M%4VZ]AS]F=58_!X7%;MQ63V!LO=>X*+%Q[E08\T.0AFBJ'I*M3%[KW5S7OW7
MNO>_=>ZU]_E'FJ+9/8WR`[L["BQ]1T[T7VQE]_\`8>+K-][HP><K<G@^D,BW
M4]3M/;N!BCPV[-P4^[7B@QM%EZE*2*IR1E$<K)XG]U[HK.([*WSW'UQNK?F\
M=KKT;A]K3_'/8'975.-:FK=E]!]Y;3[_`*_9?8O5W7^.RZ5>V9-[X"IIHLGM
M3*T\$<V.V]6T'@Q]5.C.ONO="=WUN_8U=5=_8FMWC48C>.*WEL7-[GH>S362
M;=EZFI^D.U,AB>V^J<'D9LQ@%RF?W-EL3E:V:(M14N1J:N%'I9WJ88/=>Z1M
M&^,VWO;=G?\`EM];[[*V_C-P]);8[7Z1&"Z^J#TV^-VP]+GN\:>EQU3M/:5-
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M9/!X*IVAFL9%]ME:&NK8,?6P:5J`ZJH]^Z]UK=Y_";0^(VW]AUO0'R2'9.V:
MW>4FRJ/!YO`Y*HVWV16)39S9U#VOG<SAJ6JWOA]W;+Z]>LV9LMZVNI,$U1M^
M*#!5G\8>@Q\ONO=++M;;&'P>[-VXK"X>+<M3ORAZ+W]G>P.Q\Q)4;E[.W#B\
MED=AX;N5\SNG$MV1A/\`1EBH_M`V7@H:#,9RT>9%*6EFG]U[H*=AY;:-5L#Y
M%83855VEC.PZCI?8VYX]R]C0XO+Q5&\HN@^L<7G<GM^CP^UJC-;8Z-VE08ZJ
MQ,]/6Y:3)TN^LE10Y2G1$QTX]U[HDG9=%V4^Y^YMM=<[8HMH;:[\WU@*K;8,
M0[3WW!LWJ3ICKK'TE)C-V+BMUT^W<8C[5BS^$Q^#:OR&_JQ*[;V/3#YVCEJU
M]U[K:&_EA92CW-G/DOO#"T=71;5W/OS^,[=H:NJV]4U6'K,SNG?N;W?0YI-L
M9C,X6FSU;GLE]S.::4P3!A8F2.55]U[JVSW[KW7O?NO=`#V!\5OCCVEFSN??
MO2O7FX=T$2:]TS;<H:+<\AD:%V:;<>,2BS4TBO`A1FG+(5NI!]^Z]T%:?R[O
MA9%CJ/%1]`;2CHL?2YJBHU2OW.M1#2[B+',PBN7/"N<5OD:Y:0E`[!"H9K^Z
M]TZ-\!OAXU/+2MT)LPP34-?CIDOF;RTN5<2Y/R2?Q7R/49"8>2:<DSR2^MG+
M&_OW7NL5=\`/AWDI*N6OZ)VK52UJ4\=1++7;D:312R&:%89/XX'I0)O6WB*:
MW`9KL`??NO==4_P`^'=)%#!2=%;7I8:<L8XZ>OW-`EFI)J)DE$6=7SPFFJ'7
M0^I+L6MJY]^Z]UGH?@/\/,:TS470>RHO/1K02JPR\T;4:+(J0"*?*21HB"4Z
M;`%38@W5;>Z]U)?X*?$9VJI&Z*V:9JVA..K*D?Q9:RJI/M:BC1*BL7)BJFDA
MIJIUCD9S)%<%&4JI'NO=2ZSX0_%"NI(*&;I#9\5/3%F@%"N4QDL3M/+4LZU.
M-R-)4B0S3N=6N_K87LQ!]U[IKQ_P(^(&*I$H,=T7M2DH4KZK)I2156X!3+65
MDT=14.(3F3'XGJ8DE$5O$DJ*ZJ&4$>Z]UWC_`(%_$;%-,:#I7!4XJ,CB<K.@
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MQI*`%&JRJ![KW4YOAK\96GAJ'ZEP;RTM1)5TA?([B=**HFP53MJ:6AB?,F*B
M:;"5<L+>)4#:RYO)Z_?NO=)G_9`OA[XW@'1FV5II,:^'>DCR.YXZ)L9(L"O1
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MA5`L![]U[J3[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZKC_F<;FR%)T/A]C;
M-[^QO27:F_M^[7HMCX:IKGI:ON#'TF7H,?O#KNH&,P^X=T4>T:K%[@BFS60Q
MM#-)1TZ(DI6.<ZO=>ZI*ZA^1VP_CEM[Y!_*7*'=NZ-Q=AKNKJ?K;"I48O=VY
M`,5LS(=B=V=DY/+Y7?G0&\-V;5Z9^+?3>QJ>;^"Y*+<]!B<?0P00U.5K8XYO
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M+54<ONO=`=VAMW>OQH[M[2ZAZP[JQ_Q*V_M7=E=V)2;]PE?6ST/1W5FW=RXW
MK[`9V7K6'&9K#]AP;AZU[(VLV=CR31PXW"8-*JU.9#.?=>ZVO]OY[";JP.$W
M/MK,8[<.W-QXC&Y[;^?Q%939'$YS"9BBAR&*S&+R%&\E)78[)T%1'-!-$S1R
MQ.K*2I'OW7NG?W[KW7O?NO=>]^Z]T0GYB?%#?WR4WST1D]M;[H-H[0V)D=P1
M[_IYLUV#B,Y48//9;953DCM)-CYS`TM=D\]M;`Y7`5'\0GB%)39C[NFD6>G\
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M"*&'`4>3QU9F(:9Y\<9ZF@>";W7NBR=(;X_O1%OK['"83;NR.T_DEU-\@ZW'
M[)FJ>V.HJ3LS-8O;#9[MZ'M+$5\U%VZO9O96SZW,8C+P4^,QN\Z66KJ\5#'1
MTLC+[KW1SNWLIO2LPG<N-J]^;`WWA:CM[9N[*3;.PJ3:.1W?B.P<AUSWMD^P
M<A1I+A]OXZNVED,I15BXK*9W'TT55B*FA#-%/35$]5[KW2);;S[HI\X_=.+V
M[3_&7=_9NR=J8&OR6>R^\ZC#_(#?51-6;LPK-W/41[NVWUG5XYH'V:-DT,.X
MTSM?3R8NEK*25WC]U[H%.O*WO?<78GQ^K>D.QNU*;KO<-1V%G*2CZWVYNK%;
MOW;A\?MRAV[1_P!QZ'KZ"AZUQ77O7VXH,1'M)J:*HV=N"DDRK;QJHJ^BK*;W
M[KW6V;L`;Q&RML#L%Z*3>G\'H_[R-CXH8:<Y,Q@R@I2RS47W2J0)S3M]LTX<
MPA8BBCW7NE?[]U[KWOW7NO_2W^/?NO=>]^Z]T3[YI=`[][^ZN7"]:[FPN*W;
M@YLC78_;>]"@Z^WB:_'2T!H\_4R;8WNFVL_B)'6LP6X/X%GC@<C&*E<=5.%"
M>Z]UKHKU-\@?A72[+SO8N57M[<G66U=P]:YN:IWK@*ZERN\NV:E]I9RAVO35
ME8F1RL=-M1]KY;=6)IJFKJLYNZL.4KJ3;V)=ZRF]U[K-O#KFJVMV[VM4U.XZ
MV>LWCM?J_"U_6FWY:?;_`$OL+?6>2HIMN;='56#?>B8CXS4F(FJ*R%-J[QS_
M`)L_1G7_`!)*<LONO=3NO=V5.\NH.^MM_P"GS<._Z+!_$OHS9>Z=FY+;>4P!
MZWW3E_CEM/<N.Z=Q&?P/W'4^[,=7=>&3>46?*UU?0Y;&M'A\E-!%5T$/NO=$
M!^0W1VT\?V-\GMJY_`ON#>&ZMM?!O>G59Q`DS-3AZ#Y0]@;8^+VT^OWJI=X;
M?R^].P=G=\=2YFNAW8\5+6[/IZF7+XDQU<U4M1[KW6TU_+Y\2;R^0M7'!AT_
MO+N6#*I78R.GC_C$>&S>YMOK6(<<_P##JFE,,$<IG6.G,U553,M/#';7[KW5
MG_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJ"_FLYN'%Y+XB44
MWQ\QN_AF^ZH<</D'FSO*CP'Q[,F8V3''M_/Y?K;;6XM[T6([RGF3'RPMX<%5
M'$*M>)YEH:>3W7NB!_&G=7Q_V+_+B[=WQ\FOC)A/EKT[LKY,T%%OS!9':>Q>
MU,S3[?R_QWZ)_C/9V'Z[[6I\37;LS<N4EA%1@,53?WCK?N'EIZ.:H5Z<^Z]T
M>W^7:>KV[(V)5];]=;,ZAV]FOY>?16:V5U=LOL:+M?%;!VWD^_?D7F,SM>#?
M[(C;FJ<7E\Q3QY"2E:>@ILBLU/#-/#'!/+[KW0M_S)_C;UMVCUV>[>V/E+O#
MXV]<]"[(WYE.QDS6$ZK[:^-.Z]@Y&+$9+/57=?QZ[WV%V3UIO7+;<BP%\%E:
M6AI-P8^2KG@IJB2.J>FD]U[JD&#KW^6Q-\1/ASV)U)V-\RZ&CZ1^0WRH^'/Q
M5VCN[X[]=]R]G]Y=^=];CQ^>WWC:?X[]S]99;KK!8N'"=25%1M-,MC=E8?;.
M$@D1X:.9TBD]U[H3LCV3_+OBP7PY[3W;O+Y?_)JCZYV!\O-X=2?'+H?XZXWI
M;+]%8K8W9.&VO\G^Z>Q^K_CUM'HZIZQ[!^..8:?9M:M!6TN8KJ7/Y."FQN9;
M(S3-[KW2(W#0?RYNELU\;NLNIOE9\O,)L+X>]XX;Y8]/]W;,ZRV!V-\;_A)@
M/YDV)J-L_'SJ#MW,[VZ]EJ#TQV!_?_*+LP"BR&1VU#F(VS>5H:6*ED/NO=;/
MW2^R.R-@;,;`]J]U9SOO=;YW-Y([[S^RMA[!JX\3D*PS8G;D&W^N\+@\"M'@
M*2T*5#QR5=0;O+(Q("^Z]UJSY;/;3V)N_P#E983.Y7'[CW'WQLSI?9N+R^T-
MN[+3N/J7&=6_*K=/:VTMT=/'>':VSZ;KV/O:;*-@<ZT5#N/,;UQF$>/!T%3)
MC:R`>Z]TOOYAFY:/;GS7^1N9JZ9<O74";9Q.+V5DLIV?M_;?9^"K^GOC37[Y
MV;N5.J-O;PKM]X:BP\"2Q8O.T<>+I\C70U%,E34J\7OW7NME7X^Y/&9GHCIG
M*X3JW+](82OZNV'4X3IS/4&(Q.9ZMPTFV,8<3L'(XK`U==B,75;4Q_CHFIH)
M"E/X?'9"I1?=>Z%_W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6.26.(*
MTC:0TD<2FQ-Y)76.->`;:G8"_P!![]U[K5O_`)DV1P5+EOEEN#+;FK,-C=D=
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M)*`2>Z]U&ZO^;?R0V/OOKG:VP]V]=+U[NZ@[)QF2['Q^R=I0[:P^9V48:&+%
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M7N)=G9#`'$UW9.5SWW.?I=QT6)CJMCXW,G'HNZ!+2B;W7NC"9K);WVMO?M"@
MW#O*G0UNW]BTW1W5%-%MC*5?66Q=QO-3[JZH[.RE51[5W/2=U]E9C,'(8_<.
M9I%H4Q&1HU"0U,[PT7NO=0^OYMSXGJGL+;.5V7T)+MJE^)G4VX=LXK951B)-
M[8"CJMB]6;KAV_VKM>?'TG8-+O\`WEGZVDR[R:ACZVAK,ICZG&42Z*R3W7N@
MWVEG>D.RJK;6_-ZQ#L7MCI[O#Y=[VZAWHW9F?W_MQMO[8V]C,GV_F.P=T01T
M->V3ZR3(5=;U<^6C7$[5W>XFJ9<6K1GW[KW5TG\J')2[CV9/O.?<\^ZVWKUG
MUAN6DS-;V#3]O2Y;'9+`4=50Y3&]NXR.7"=FXK[>=:1LI3U$CFJI)8IQ]Q'+
M+-[KW5P'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[J)D,A08F@KLKE:ZCQF+QE'4Y#)9+(5,-%08^@HH7J:RNKJRI>.GI*.D
MIXVDEED94C12S$`$^_=>Z*1L?Y^?$'LGL+;O6.R>Z\)GMS;SS^Y-J;$KH,%O
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MT$\DD$7NO=728OY5]*[B[XKOCGC<OE,CO;&Q9"-\R-MY7_1O5;VVW309[/\`
M5N'[#FIEVKF^W=I;=DBS.3V_1SSY'%XTBHJ$BTL%]U[HE>[/Y3/7^X/B=V9\
M5J+NGL&'%]E_*W?_`,N\MNG=6TNJ^P!7[W[`[5R?;N3V+N7:^Y=FRXW+]8#<
M.2\+P4,V(SS4<2QQ9:"\A?W7N@BS_P#(SZ7F^.G3O0&S.Z^Q-I/U;6]\YK);
M]R6PNDM[YK=N]/D]74M5W#VC18_<?7DE%U[V914B5-)LZIP34F%VQ!4J9,5D
M9:6BDI_=>ZA_)C^3U\4LK5=;=D]B=KYWK[XU_&3HKIWK?*;#DVAUE59N+J3X
MS3T^<VW@X/D/5[1E[YQ^+W+3X>FI-QB3+9/*Y*C$U/C*K&25]6\_NO='B^0O
MRCPE;\5:_=72643-=D]X55/T+T5@9AD*3+Q=]]DG(;2PV`W30XVCR>3VK7]8
MY.&OR.ZX:J.&3`4NWLG]Z:9J.<Q>Z]U5_P#'_:M`/YBG5>'Z_P!T_(?:_7?7
MW6V"^..R<-UWU+T+NSXY=Q]?_#/9]9BLAV'\B>[\+VMVC#6[LQ6Z=UTV$P6/
M.`V3V3LG*R)0M3)BZO(RU/NO=%C[CW16_(WY']ZYW8G977O6N]^S-V83XZ=1
M]XY_)[NH^OZ2M[6WACMV=);SQ&X]I5=/39;>."V'\<MLY&AP-3$E)F\GFL?!
M+5Q*]03[KW6U9M7&9;"[8VYA\_GYMUYW$X'#XS-;IJ*"EQ=1N7+4&/IZ7)9^
M?&4)-%CILS61/4-!"3%"TA1/2![]U[I^]^Z]T&W<7:^S^B>J.QNZ>PY<Q3;"
MZIV9N+L'>M9@-O9O=F7Q^T]IXNIS6X<E1;;VW0Y//9E\;B:.6=H*.GGJ'2-M
M",>/?NO=.76W9.P>XM@[0[3ZLW?@-_==;^P&.W1LS>6U\C!E<!N/`9:G6IH,
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MII\G3FKDI:22GQ\,HGJY((`TJ^Z]U#Z*[\V-\A-M;CW%LJDWAAJC96^]Q]9;
MXVIO_:&;V1O'9^^=J_9393`YO!YNFA<F3&Y6CKJ6JI7J:&MH:V">":1'!'NO
M=#9[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZUT_E([2?)7L'8?9$
M592]2=I=N[[ZLWO#)MO959E:C!=G?%_(QXC/8?<Z[GAW1LC;^&Q]%79(UD%$
M)ZW)8BGBG?0E/#-[KW18^HZ.OP'6%'A-N[ER7;&QJEOCAV3O#O;+[)K*K;_R
M0[&[O^153OK+]RU&\Z/<&VON\SV_7)65^-6AQL,.V-O86@Q58U)D'CIHO=>Z
M%K<5-!LO(=W4^'H.[YZ^I[*Z)W&364NQ<#@,;MY>EN],EA,7M08RBR&&I.[\
M=0&:DWR*F.3&YW*456)8%K9JJ23W7N@FQF6VEWUMOM?HO9,;GL#L2;J#NB'*
M[VP%7#LN'![]_@N!ZY[EK\EN/;NS(>O-Y]I5\E/AJC"08C<&'P\.6Q^0EP^0
MCI*N>'W7NE-\=OESMSK7<?1_74WQ*ZL[$JL=5[IP&V)Z'&XVESVVZK;VQ4K=
MIYC:-978S=];CI-\X#9N0I8159+<F2PN.VTC;ES./26,T_NO=;-_7N^<)V7L
MK;F^]NK6IAMS8V/(T<61IA2UU/=WAJ*6IC22>FDDI:J%X_+3RSTDX7R4\TT+
MQRO[KW2R]^Z]U[W[KW7_U-_CW[KW7O?NO=$D^>O=/9_171N9WMUW%3X>CIJ'
M.?WG[)D./JI.N$CQ,S[>R?\`#<M@=S8FGI,MG3'2S9:KQN8I<22CRXRM66T7
MNO=:U.W^VLQW'@NJD^26=[1VUN"JQ^X][G);BR6XZ7+;MWSN_(9G%[-;>6X:
M#+[:@P]+@^V-G18W`]=YW*24M5-28_,0':CTT-5)[KW2]W)/NFJ["[$?<^VJ
M2.FPG6'4F7VGVECL5'+VEV7U/3;IRN'WQV]O':4,F\OD3+V-@]WUKX^GP2[A
MJ4JIXW=X*BFC%7)[KW3WLO:.,V-US\H:K;G0N1ZUV?N[IO:F1RG9N;W9FU'=
M%-M+IG8&'@^2]%L_9=:=M;8R@VOO&@Q]-B:YQ-61[C>"DSM3#03TT/NO="'U
M;\ALI3;>ZVKX?DC%LE\!NCY.Y#9^PZ[<?36X*OM_=V'P--D>RNKX=S5>P-J+
M@9?CGLJARF[,[C8Z.NJ1AZFFBJHY:X5-*/=>ZL;_`)8F:P^::OR&,R[[IASW
M4>P=TXS<]1'B9JB;!Y@K'28F*OV1BL'U4U#0ST<DD0V]0X^BJ1-]RM+%YB/?
MNO=6]^_=>Z][]U[HM?R4^5G57Q7P6V\QV2VY*ZLWCDLEBMI[9VAAES6X]PU>
M&Q4V:RZ8^"JK,7C`U%C8=2I-512U4SQT],DU3+%"_NO=`9GOYDG2>!R&SJ`[
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M#`8;<U!C^J\+M7#[BW[WMF*#&9?1D_MUV]@\?6*:4Y=ZM*BGI_=>Z:JCIKY\
M5$,F0C^;W5N/SDE:,@N)I_AY0U.PJ933JK8*/'U7>AWM/ADJ%U"5L\*X@F\P
MX"^Z]TP[>^5W<G4'9VP^G/FUU=M/9:]M[KI-@],?);I;.Y7<?0&_^P,E%6U&
M#ZWWW@]UTU#O[H'LO=T=(8\%15[[@V]F:Q?LJ;/-DI:6@J/=>ZL(]^Z]TE=\
M[ZV7UCLS=78O8VZ]O;%V#L?`97=6\MY[LR]#@-L[6VU@Z.;(YG/9[-Y.>FQ^
M+Q.,H:=Y9YYI$CCC4DD`>_=>ZK1Z3_F/;F^5?RDVUU#\<NB\SD>BL-A*_?'<
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MV!LGK^BRU8V/Q59O?=>"VI2Y/()3R53T./J,]7T$-;6)2PO(8HRSB-2UK`GW
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M=?OG^7_VU1_(7"=H]5]@8O:&1KI:WY);WW!NKN[XG9/#4'6]+VAM?/\`<'>D
M6&VRN+I,;VKV\=W4DN$HZ##TF.JZE/=>Z4O;O0W:W1'6>U:K/TO8_3NS-U9S
M`9G%?)O+[@S8WYT1U7V?14N0[+V#W[C=E=B5/6_0'R+RV]:K%8'L3MC9N2HS
MV#M<YB>/<."W+5M6Y#W7NCYXG^9GM/I[HKY$=E[]R^5[?VU\?NSMK]%]?_P.
MF2K[:[QS\6P\?NS<N_`^/PV'V56=?96(9K)X+/42G'U&T-MU.3JZ@SBH5/=>
MZ&*;^:'TK6?(G9OQPVMM3>FX]S[SWWM;KV@W(IP='M9,]N[#5?8NWU2HBR>0
MR%50[OZ#QM;O_;M:M.,;F\!C:Z%*F')4DU$ONO=5Y=Q_)KY$]O9[HO,=@;BJ
M?CE'DFSF"SGQ;R'7^X.ULGWYF\2^3SFR\MT_T?!#M3?GR0Z1[YV[F*G9V_L=
MNB#"5&Q:[#4V3I/X;3N^<JO=>Z+G\E>H-_?%;KO"U.-^-W<>R]__`"1QFY>A
M/C=UOTWG,!V?M+XF[8W/A*#:M=L/;?;>3WGL&NVW\P.U]B134^U627&;3H\1
M15>R\5N6#+9$YW-^Z]T/N0VCM7^6O\6.T<?04^V]L_)CY04U5G,C1?'[96\8
MMW]!=`[CGQ6`J(=C8W<^2W9VSEMZ'=F9JX=F4&<R&1J:KM/=L=!1HV)H:A:;
MW7NN/\M_XE5F[>Y=I;O[A^*VP\QU;LW9>%[CZ[[@7*X;+8/:'R<QF8VW@ZS$
M]9[CV]N:I3NGKK#;8PE!C]GY+(XR%-O8W:*21_;U64FI(_=>ZV3??NO=>]^Z
M]TGMW;:H=Y[4W/L_)SUU+C=U[>S6VLA4XNH%)DZ>ASN-J<75SXZK:.84M=#!
M5,T,A1@D@!L;6]^Z]U33\/LQD?CYO;K7.7DI^N?DUO7=OQU^16%FR6$Q>`ZW
M^?71M7N?94W:^+PT==A\135GR^BV-51[AIMO8>*CK-UPX[*-JJ,M6SR^Z]U=
MO[]U[H+.[.[.K?CEU7O+NWNS>%#L#JOKW&PYC>F\\G2Y.LQNW<5-7T>,7(U\
M.'H<CD%HXZROB$LB0LL*,9)"L:LR^Z]T)M-4T]93P5=)/#54E5#%4TM532I/
M3U-/.BRPSP31,T<T,T;!E92592"#;W[KW0#?*JB%=\<.ZT&8RV`J*7KK<N6Q
M^7P$ZTV>HLO@Z"3,X9L'.Q'CS4N6H(8Z0B[_`'#)I!:P/NO=%(S^\>MN]_EY
M_+]W]UGB\QE.Q*'IWLCNW<N;QFXUP/\`<GXK]T]8_P`,PF.[1VR,C0U6Y*3L
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M]*^'%/74:92II*BOI\:U5`M?/0TDM/!55D-&7%1+24T]7$DDBJ41Y4!(+"_N
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M^26<S--F!\H<UDYZ/</5,L1.]N\-D4N0V/L/)KG\_M+<N`VIV'-M?.93.9VG
MI/M,Q'14<\&+HWH*R+(?>U%4/=>Z5S?#3Y-OU.^QS\N-S_WGI>W]T;XV]N:?
M)[]R4V#P.7VEB,!MRHGRV4W95[IW'GMG;RH:O>--B,A63;4FR62DQ<U!)BJ>
MFCC]U[K-%\&^Z,1M7=>.PWRS[%R>>S>P.H]CXNIW3G.P*VAQM+M$[BR/<'CJ
MX=^'.8^J[[RV6IXJW*T<\.8P='21_85"R1H1[KW3!C?A+\H8:N"J;Y:[AP4>
M![YV/W%@:'#[B[6W%3Y396&I-NX[,=`;FGWQOC-UAV+C<3C*ZGH<A"[U>1ER
M;U60@::,!_=>ZM3]^Z]U[W[KW5!OR1H\(GRSS&Y<EM;96\,KLWY![>JL-3;^
MV/A]VIL]<U\9MVXS/;PV5NS%Y+;^?VQNR#!YF!(\+1?>YC<+304J(Y6\?NO=
M%WW[CVQ&>VCM3>NR^IAW!U_B_BWL>KR?0/6&7V;E\ABLMWW3;MEQ)[.I]Q;J
MV_3[<J\1N*FR,N+?"5-#65D8KZ;(5/F>A7W7NF[L3(;;F[<[AH-M]\[WW36X
MR;:&^8>F]XXG>V9V7C,7F^J^_DROR+Q<&1:;R/VS/D_XA-14F1JLXE'DW9!'
M0BEH8_=>Z16<WEF]P]=[VZ\ZYSE'%VK1[_V=V5U)L;;&3?*9G$[N2AQ>%K>W
M:7+XO/;PJ-O?&W<E0M/@,,*JMVQ*^YZV"6/(8-:U$]^Z]U)Z/[5^$W7M%T%U
MK\@NC=\4_P!IE^[]A["I<GN?+UN2R.]<L^VMW=I_WRDS>Y=N97LKL3N3=]-5
MC%1)1TB;I_@U<^$I*P5%0M3[KW6T?LK<&V=U;2V[N'9DU/-M;*8FCJ,%]M1R
MXV.GQXB6**A?%3P4E5AZK&^,T\U%-##/1S1-#+'')&R+[KW2H]^Z]U[W[KW7
M_]7?X]^Z]U[W[KW13OF#\A,M\?.L)LMM.DQ,_8.Y%R.-Z_DW7M[?&X-ES;FH
M:,9&#"92AZ]H*_=>:W!GJ:.2'"X7'*,AF:T>&`@+(Z>Z]UK<U/<N^OG'A]A;
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M2/!SXRCSF3QF%AVWCL;428V@P<&%QM*(5IXH:9E`>$,CZV]U[JS/W[KW7O?N
MO=5__/;H/M#NO#]49'JK"8'-YK8FZ\S4UT?\6BV=V!C<?N'#ICOXQL'L&OJI
M\/MY\;4TR/74LV.J9JX>"2GJ*66D`G]U[HEM%_+\[PWAN#X\XSL;#4&"V=@L
M'2TFY\CMC?\`@<YN'JO:U;F^W.R\[L2/.[@VG45>Z]YC>.Y\!ATRN!QV&P4N
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MKW7#=7QE^9U9D>M]S8CJ.@7<&Q=N;4?'RQ]L];ZLB=I9ON2NVALS?5/6X`4,
M)VC7[TQ=96G",^&W#1K)!-#%+2TP]^Z]UG[(^''RR[.[![&W+NCKO8-0V<W;
MM.23/87L]MO2;CKVW)10P[ZVSC8J"LK\+M'KS9<550U^,R58N?SE#7^.EJJ>
M2BIE?W7NKU??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1-?YA'8N>ZM^%_P`@
M]T[4S=7M?=-7L?\`N+MG=E!EX]OY#9VXNU,SB>K\'O+'YR6>G3$Y#:.4WA%D
MH*@M>*6E5@&("GW7NBI_/N/"=C;6Z&_E:=>YO+;S[D[GK^G-Y;CS&?R7]^]V
M=.?&/XU]I]>;UWM\FNUJ[*5\61GRN9W!L>AVSMFOK95J<YOO+QSPB>/'91J?
MW7NB6?)'^='VMO+,4F!_EYX;JC?D65W%D-K;-S&=V3VI\A]R[XEA7.PX+LK-
M]<]`9"FJ^E.A-^;AVZ^)V7F-QY#^-]ARRSUF*Q=+BJ.')9+W7NG'Y%[/_F4_
M/'?'1]36_%[-=9_';:NP:/,4>`W]OOJ'9.;W-\C<O'MZLQ?>G874VY<AWWA>
MNMM=+9'%5,VT<3N#`]E9O$5V1CS@PT.XL7CI,?[KW1V?Y6_2O='5N([[D[?R
M^.VT,;W+O/8.V>ENOMN;LQ?5>,_A&5;=.[N]*G?G;-;NWO+Y!=P_(3>>[:[.
M;BWYN3<5:^50TT2TM)5PU[U'NO=6O^_=>ZJ0ZY^9'07QD^$79/SH[7W1NV79
MG<O=W=O:&`V_1XNIW+V7O[,YG?FY=J=9=4]3;(ABH<ING=>3V%UY01T./B54
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M.2P>*Z1Z-Z_RM#L7`5C;E&1Q.\,CV=O[*9'L3>&ZH]NH*">.*EP6&(=I%H/*
MJR^_=>Z-+[]U[KWOW7NO>_=>ZJC_`)E?PPHNW-K;T^2VSHNTMW=T];=&[DV1
MB.E,7O?<<W27>.QIZ[(9C<_67</25'5TN,[6VMNW%Y6NILIBJ6?%9?/T6C'0
M9&D9H9HO=>ZIZZ1^0F2^(F\ZK<?9>QYLCL#![EV[VWDMO?*23;>Q=V]9U^7Q
MQZ\VMV?W!N+<6`GZ^^-_?^YL/FJ[!=<=CU.8H\)VUMJ-<+O^KV_NN.3=N:]U
M[K9YZ=[XZL^0&"RE9L7,M49'!O3XS?W7VYL95[:['ZYR^0@EDCVWV7U[GH:3
M<FT<G54\3R4Z5E.D&1I0*FCDJ:22*>3W7NBS=X_$'XO[4V=5]A8K9/;76%/L
M'!U]'38?XA/V=BZY-O[ASE'5[IQV$^/W4<64VEO*3<53(7RL<>ULA7UE*9P=
M:O*K>Z]T0OK[<OQ9W#OI-L_Q[YL9W`[^W)MRD^/.9Z_KMZ9NK[ZZ[QVU8,#E
MM_T;]"]>;>[&Z>ZHZ:S&X,IM#^+[FR&%IL=3N(Z:L2.MBIQ[KW5OG3?Q?Z!^
M/\F2K>H^K=M;3SV;IHJ+<&\VCK-P]A[EHX)Y*JGH]T=D;IJ\WOS<U)354SRQ
M1U^1J$CED=U`9V)]U[HO?RP^>75G0^.W%M+;V2VQO/MNBEP6$AQ&3J,E)L#9
MN]]WY%L7UUM[L?/;>QN=R1WSO+/PB+;FQL%293?^[*I!%B,5*GEJZ?W7NJ#M
MM;4[\^2WR"ZG[%W#LCO/L+([^^0.P\+O3L#8NWZZAJ>EZ[^!9[&;Q[2S_8.V
M-QX3:GQ][B^,N*.6V[AMDR3[OVWM/:6;FIDGW=O'=>=S</NO=;._QP^/.Q_B
M]U;0=3=?5VZLI@://[NW/+D]YY^JW'GJW+[TW+D]T90R5DXBIZ/&T=3DS34%
M#2PT]'04,$,$,2I&+^Z]T._OW7NO>_=>Z][]U[K72.\=N_'WX9_S!^G=W]P]
M/[3[N^-WRK[Y^3/7&"S&]<%!N>EVA3]Y)\H.C\SDX\E/33Y#=N\L-%&DZTWF
M/W=9]JRQ:A3K[KW1T?G1_,OQOPY[=^.VR?X'MW<>,[%J<!+V#M/)Y2FV]VA5
M4/:NYX>K^H(.MSN+.[:V1BS0;ZDKLYO#);CK:3&X39^V\E*K/6/31-[KW7/>
M/\S_`..?979>X?C;\=7V-\M>P]N;NVEM;N3I?'[IVY@<MO;IS>N*S=+V7NSX
M\OO_`/AO7ORBEZ8IVI*G>V$PN1F@H<3+4P35*Y(4^.JO=>Z#[X(?(2AVG\B<
M[\+-N9/<U5U*=L]X;HZ;ZO[6DQL'R$^)0^.G:NT>H-Y=!;TPVWJC<L>5^/&X
MJ+>.'W5U#N7*Y1JU]LU[8OS5=-!CEIO=>ZL4^6/1&/\`DU\<.XNC*YJ.&?L'
M9>0H-NY'(*S4F"WSC'@S_7NYYE2"I8_W5WUB<=DEM'(=5*/2WT/NO=$5^`/;
M.]]\?!GL[)],8/9N\OD;U7N?N'J*/;V\<DNWL+1]U;5K*S<='U;V!G,52RY7
M$;/ZOW3OIL.D"4L-7182D5(J6*<Z#[KW5K&W4S\>W\%'NRHQ%9NF/#XQ-RU>
MWZ.LQ^`JL^M%`N9J,)09&MR60H<1/D1(U-#/4U$T4)57D=@6/NO=4VTOS*ZG
M^%'>OR9H,KM/M_*?#S*]O;IWIVI\A=K=0[VSO5?Q+^0N6P..W+W-MKM[<(R^
M8W)/UUO.LGI]Q_WDQ&`.V]L93+U-/DJJ*">*:G]U[H8.X?YA'<^QOE#MSH?J
M3X$=V_(WK_<W7^U=TX?NWKS=.V,)A<KF-XX3>6XL:^*@WG0X78*=78&BVK2T
M.;W-DMVXR?'YO/8RCAQ=6E3]RONO=`WV;US\\?FUO?HG-;UP>0^+?QSV%\J:
M'>-/L_9)PV!^9$&T,5U1V9@SN;?_`&36;]WCUGL/;M=7[J?;]?0;(I<YN2JA
MKUKL7G,4T1DC]U[J3TQN+YG_`!;Z5V7\4.@O@1A<UEOC5'EIMX[ESG9F/Z^Z
M+[.ZEI=X[NRF%IOCQOB2'=F]>Q?DQVSM>*&NK8-W8[#8['[IK:E]Q9]C/'7U
MWNO=#ON;YR?(&KV9UWV)TS_+Q^3O8^([(INQ]G0;$WQ3[5Z%[7ZZ[HVY54B[
M!@[DVYV5FJ6CV?\`'[?4%+E$J-]XJ?<38R:"D:/%UL%='*ONO=%C^1NY?YN?
MRHZEPG66QOC'N+X'5%3VAL?(]R]J=?\`RRZ,[#[GJ.G,!EX<UN7;/QFDBPU%
MM*'L+=[T45%)D=VSX&@QU$TUH,CYFA7W7NDKT_A^Q>I?GK\F?FO\K_C3\F<[
M\D>SNJ>KNI^@]H]![1R'?'2.ROCBV)VYN2NZFP'9V.EQVW<1W+3=Q87)UF\Z
MW<G]SL`[STC8IZRC,E?+[KW1Q>K<+WGC?Y@VX>X>V.NMUX3:'R&^(76&R]B4
M.!W#7[QVET3NOH[L#LS=N^=@]K38B=]F4V^NRL?W+CJW&9JAB>BJ#MVOQBU<
MXI:*>O\`=>ZLO]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=:Q'\RO/4VP-R_,3L+8_6^`G^1&Q=Q=:9;H3LG=,=
M&N/Z1[C[6V?M;X[===K;3W'DJ.LVMM#=F=RG:ZQU62S)6&EBH:9EIJG[='B]
MU[HJG2F/ZWZXQ_<W1]#1[GP6Z.@/D3TUTCT;797?U'O_`+"V9\5>Q\UM;Y(U
M6R>S\CDJG=<&!AQF_P"GW3%C(,C6MEVQM2T*S(AAC/NO='Q[3R%76MVK19#L
MSJ;>NQ5[:VYN"KDVC4+@MP[4W)%U7WE#V968S<N`P$9QO5.*S5<Z87)2PY>L
MI$J#23_=F17?W7NB]56XL1MOK_=V9V:N?;N[J/=VUMF[<K]F[,QFTMV;YWK%
MM_:&],[\?MGY:;&=?U?;_7?5.)V_7U^-GR&(RM-0UV"AR<F"S45'`R^Z]T\?
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M/\(D6ER/E=H8?=>Z&`_.L?Z4N^NNJ?9-%6S]9[3[FR^P:),W64NX-\[AZ.Q6
M&J=Q82L@FQ#XO'4>Y\EE*F+%U,-1.Z1XJJ:>)28P?=>Z![9_\RW/[B@WM+)U
M/'/2;9&UZB;<&/BWS0XC;M)N?+[(1ZS,8_<.TL9N'>&V<!MCL;$Y"?-[:ILC
M!532/2PTPD,+3>Z]T+&]?F?V7L7HGH+MO<O3%!@LUVGL[.;RWMM)MQ97<=1L
MZAPVU4W5'2X2/`;>DRFX:VNP\AKY%EIZ-,?0TU0:IHWB(/NO=&7^-/=E3\@>
MKJ3LB7:N2VO25^;S>/PLM;1Y2BH-W8#&U?AP^_=L#,4./KZG:6[Z)EJ\?,T=
MI('!#-]3[KW0_P#OW7NO>_=>Z][]U[JL+Y/_`"5KNZ-W;U^#OQ(ZRZM^2?=U
M!'BX._,[W+AY]Q?$KXF8NOI1N+:^3^0+PT[KV5V?DJJCI:O`=8X"?^\57^S7
MY2IV_BFARK^Z]T8SXK?$?9GQBPV^,H^X]Q=N]Z]UYVDWI\C?D9V**&I[*[MW
MI243X_&OE!0008C:'76R<9,^.VCLW#14NW-IX@FFH*96EJIZGW7NASZVZIZN
MZ:VTNS.H.MM@]5;/6OK,JNU.M]G[>V-MM<ID61LADEP6V,=B\6*^N:)3--XO
M))I&HFP]^Z]USWYVCUOU=2XFN[)WYM'85%G<HN%P]9N_<&+V]29'*-33UGV5
M+4Y2II89)DI::21O59$0LQ`]^Z]T%T_R]^+E)0;5RE9W_P!3T-!OFFS]9LRI
MK]ZX.A3=5'M>C?(9ZKV^*NKA?+4V-HXR[R0!T8<*6)`]^Z]U'R/S)^)N)QF3
MS63^2/25!A\'MFFWGN#*U79.TX<;MK:=;7U.*HMP[GKGR@IMM8FLRU'-2135
MS4Z254,D*DRHRCW7NJH/A]\<NEOCUD-JY_YA?)/XU]K4G251V=\9OA%M?%;A
MEJ-E=4]0[VON;<FZNQ:'>F4R$-1\KNZNK.P\#2;VR-0JX_#[;GI,;BWCI,UD
MYLQ[KW5M?QZZO^*O66*W-COBOUWT5L#!/EZ%-V4W16T=C[7PTN:J-O8;.8R'
M+C8V/H:":M_NMFL?4P1O=HZ&J@9`(I([^Z]T8CW[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=5O?*7^7]MWM/=/;'R.ZKW%O+:_RIS73&7V1U[4
MUV^LI)T_#N^AVMN/`[2W!N/JW+4FX.O<OD11;@FQ]1/DL1DZ.2ED1JBBJC3P
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MJ3ISJ;K#9&S-N=`Y+O?=HHLO@]S;!BI]_4.WJZ9-R;NJ\G$%G]U[K82^+OQ8
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M"KEIYXI(G*'W7NEU!M_`4N;R.YJ;"8BFW)EZ#'8O+;@@QM%#F\IC,/+738C'
M9'*QPK7UM!BYLG4O30RR-'`U1*4"F1[^Z]T[^_=>Z!M)OC[T+DI,='-T[TSF
M.\>P<]NJ6A679?7F2[>[4R6,HI=S[CDI@V(JM_;_`*_#X>G:OJRM7D9::EC,
MKE(UM[KW46A^3/QORD6)J,9\@>DLC!GL=G\Q@YZ'M78M7#F<3M3R_P!Z,IBI
M8,[(F0QVV_`_W\\1>*CT-Y62Q]^Z]U,B^0GQ_EJ]LT4'=_3TE=OK`9/=FSJ2
M+LK9;U>\-KX/%#-9G<NVH$S1FW!@,/A`*NIK:42T]/2_NNZQ^KW[KW6&3Y(?
M'B#:M1OJ;OGIF'9%'C</F*O>$O:&R(]K4F(W#1Y/(X#*U.??.#%08W.8_"5D
M]'.THBJ8*2:2-F6)RONO="CM_<&!W9@\1N?:V;Q&Y=M;@QU'F,#N'`9*CS&#
MS>)R$"55!E,1EL=-4T&2QU=32+)#/#(\4J,&5B"#[]U[IW]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW6K;_-*K:K_2WV))_$.UDP4W;/0&-WEB^IZC9&`W
MX]3C:W)93JJ7JJISNK<&;[7GWE0%L#+3QM2I+%6PUTR4$4L0]U[HBOQ%.G%X
MZDVQ)2XC`8#L3XKY:;'[9HMQ;/Z&J!N_&[J7:.6Z\_TI5^4[4W+T]N+;E=#5
M]:Y":KK*^F:JS<^>DAF2DU>Z]U83N>CSF"[.[MKMQ]48SJR+=>XMEX6C[,VK
MCL_G*ZCQ6T>KOD9'2](8:*JPS8Z'<G44=)7:F5*S$38C#H:5)(IJ:F3W7ND)
M1P[>ZOVAC^ZJ'`YJJ[)V5@OC_P!9[TW+09+'X':N].O]O9?;%1UOTO@MNY5M
M]UM'V31Y^DARD6-P>1BW?N.FIXZY:_'4U4TB>Z]T_=/?&&7Y4;QZ`W=O3M;I
MW8/8'3N[LWFM^8C&;CS%7M[(OA\/D9>H:GJ#!5N6BQW8='LK#]A5=549BEEP
MF*S3Y2F&=H,L:(03>Z]ULJ=8]=[?ZFV#MCKO:RU`PFUL<*&FEJVA:KK)YIYJ
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M/=>ZV"_@CE<3GMQ;WSM&7KJW,;,V+DZK,56+W5MNO9,E2"O_`()/M/>+1;@V
MV^WYZEZ::GK($J141R79HQ'[]U[J1WU_+ZG[S[:[([3K^YZR@3>NPJ_8^+V-
MEMAXS<VRL?156S<?M:GQ^[,1/G,:-];6HLI_$,ZE"S4%2N9JX)UK%./I=/NO
M=-]%_+RRE)V-M'><G?>XYL?M^EZ^I\I24V!GQV:W"FV,-U]1;TAR63BW1/CZ
M\]B9CKFFJXZNJHY\AMRGR.4I,?.L5:K4WNO=#3TC\7]V]3]]]R]P9?MVKWCA
M.SWW`]!M%\)68U\>^=[$S^^<?-F:R3<62Q5;/LC#9F+;F*-#08X/BZ02U0FJ
MY993[KW0<?(CX4[R[P[HA[6A[5PU+B\!M^C.U-@;IVGF,_M>;<^$P&[:##8;
M>M#B]W[>@W/U?D,]N7[_`#6+98Y\K#Y:*280,FCW7N@+RW\K+<&3V[M.A7Y&
M[@BW1L[;?3[[?WI+B=QS9S"=C]-]?U&S=I[JHZFDW]CGK\)@,GDJS*8J@JO)
M54E3,JSUE7")(IO=>Z7--_+9FHMW46;I.Z\K_"L3+'18>&OV[+E,I0[<PF5W
MEO':<#I4;CCVU6;OI^QMW_Q/+9N;'N<M24247VL`FGG?W7NHVR_Y=V^]B]6=
MW[-P?R"KH-U=C;4H=M;)W))@*FO79DLFZ!O;>554566S60W!-@]Y;@9X(,)1
M5=%CMNXLF&@'G>2J;W7NEAN'X0]DU^V/CUB,!W/MC`;BZ2R/:.2H]WKU=25D
M^V:S?O86$WSMVMZTPM5G):#'MU_A\.^VH*7,-E*/(XBI:2K22I17/NO=`M@/
MY;G=>)R]%EV^0.U8#C*;?.'Q&.H=E;AJJ'$4&XVW1CILW2#/[MRZ+N7L7!;S
MRK;N:".D\^0R#S4<L(B@$?NO==[>_EF;[Q>V-[457VAMELIO*HZSW#E,$O\`
MI)S.RLON?;V1ZVK]]8MJG<V\<IOC977.5AZLQ<&*Q.V\EC)J>5&JZRIJY/#'
M![KW397?RUNY,QMS(4F<[3Z[RV0W#V!D=P[KP>0C[<R.W<[C*_JM.LZ3/KFL
MAOJIW/MS?&$QADH(H<&V(P55@7-%44KNS5'OW7NK'/C%U1O/IGJ?';)WYO([
MRST&8SN25Z>NSF0P6U\3D:]Y<+LC:53N6HJ]P?W3VKC5CIJ%*N5Y8XUT@A`H
M'NO=&#]^Z]U[W[KW0>]M;&R?9O6._NN\-V#O3JC)[XVGG-JTO977-5C:#?\`
MLALY038Y]R;+R.8QN8QV+W1BXJAI*&KDIIOM:D)*JZT7W[KW31T?T7U/\;NL
MMM=/=)[)Q&P>O=JPU(QN$Q2S2RU60R57/D\[N/<&7KIJK,[IWANG-5<^0S&9
MR51593+Y*HFJZR>:HFDD;W7NA9]^Z]U[W[KW14OE/\2=F_*_&["QN[MT[LVF
M-@[CKL[C\ALXX.ES9CS&*EP6:CQ>=R.(R&8VEF*G#5$U-!E<3/1U]-%43('9
M)70^Z]T5O$?RI^ML1M*KV#0]S]MX+9FY=L4^PNR,)LREZZVE_I,V%@-V5^[]
MD;=W'7T6R:FMQ=3A*O,5M-DLAAWQE;N.AJC#D'E6.'Q^Z]T_X'^5UTSM;=';
M.3V]O+>V/VKW5MC-[4WKM%\=L2NJ*?&Y3,U.:HTVYO.LVE-NJG./FJ`DDF3G
MRU37K#&U3-(Z!O?NO==YO^5?T!FNRM\]I'<W:%!G^R-XX[MG>E!2;FII-N;D
M[TV_OS;&\-I=OYS`U^-K,?E\KMC"[.QNVHL%4))M.LV_2QPUN+J9XHJB/W7N
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M=>_&WHCJGL+MWM?KKJW:6TNQ^^J[`9'M_>&*QYCS._*G:]!48W;XS$\LDJBD
MQ=+63^.G@6*G\M1+*4,LLCM[KW0UQQ1PQI##&D442+'%%&BQQQQH`J(B*`J(
MJBP`%@/?NO=<_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=%S[R^+G5OR%S.U<YV-2Y.OJME[2[1VE@*2&L08>.+M?';<QV:RF3
MPU1!48[.9##C;%-/C5K(YJ6FJU$YB>5(FC]U[HI4?\K[K[!9C<$^Q.Q,GMG;
M>Z^KLMU-N';F;Z]ZW['ER&WJS&8A**LFW!O[!9S+5^5&;Q\LM<<@:ZGJ\7-'
MC(8J2FI*0P^Z]U"S?\K+8^Y=O83;.?[J[*KL2_7^-V5V'%#AM@4=7ON?;F0A
MS^T*JCS4.VCN/8FW=O[EC$[X7%5L=+E*2.*CKGJ(%D\WNO==[?\`Y5'5-#NI
M>Q-P]E;]RO8=5UG#TWN#+[;QNS=B[8W3UG0=']C=)X/;.<V%AL#-MV>/;T7:
M66SU#*BH])F*AQ#XZ*:II)O=>ZL[PV*H\#A\5@\=##38_#8VAQ5!3T\$-+3T
M]'CJ6*CI88*6FCBIZ:&*"%56.-51%`"@``>_=>Z<O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]UK5_S%=MR;SJOECL_`9;K^7L3.;WV/O#J#K_=^-VZ\F\>
MVND-L1]L[!AVAL-[9'MO?*9+:>4>*GJX/M(ZJ>AE:2I(B@3W7NBK]"R;2[$V
MQVWW'4;JDRFXN_OEKT-W3TB=U8V@P.[>W_C%MW>>-^*74W=G:V!AK(:\]A[G
MRV!S&<K<E#0T7\:2,92:ED#IXO=>Z,]W!A=H[8W]VS1;4;L"#S4NQ/XC6=C5
M<^+ZB.,'57R$K(=V4%:,M79#';NW16R4\F[*W&PPT,F8FKJT)'E8*NG/NO=!
ME01)M*>M[?W+O6;L/HZDK.HZO=_4FU1MK`[%VOC,]D,3B]\?(?#;6ZS@PT>]
ML/W'29NJVS4'>ZT.W=N0U<TM>930PT_OW7ND-U7\/._>Y]P]-[]Q'454M/MS
M=_=V8W]UOD<AM/KG>NU'W[BJW$;&QO=J[CCR6=PV8S$&-Q$N3Q^2QN2S6Q\?
M@:,[06D^]BJ8O=>ZVINK-N[FVEUSLO;.\L^VZ-TX3;V-Q^<SAGJJM:S(00*L
MR05^149;)TM%Q3PU=<7R%7%$LU6\E2\KM[KW2^]^Z]U[W[KW7__0W^/?NO=>
M]^Z]T6SY.?&K:WR;V51;3W)N#=>V'Q5=-78_,[3W3N3:]=2BKIC1Y`+6[:S&
M$R5'4349*1UU'44F5HT:04=72F:5V]U[K7OVMMFE^)G76P]@8#L#87;FVMLY
M[>]72;AVEN>GQ_6V\]Q[CI]R["@EPW9;THV#LS);.VOMZDJMP[/QM`M-EFQM
M=FL[!E((PS>Z]T_[RZ[K]C;AWR,48-[8??.1ZJW]OC/XNDIMD9*N^0FRX,WA
M<#\@-H97;1VKL[,;'GVSFA5C;U5018]/M(_X?20U"KXO=>Z2W6^"P.)V7W8]
M+MCL?KVOQ/0?3&X\W5X6KK:#:VZ\P.K]CINWL2E_C6&R>"@PF+$U=AL14469
MQ\TE!G8IJNDK],%72>Z]TN^M3MAZFMCA[DZDVC2]B;D^1&Z-O=<["W)V.^_N
MY8=E==KF.D]]]:5.Z_\`C(F?79.[W;-8*LV[-)3T>3I\A'A9*V"2:/W[KW0[
M_&SY$[0^/6U=C)0;EZ@GR>=ZGZ8I:]XM]9K);2G;>N,RL^V:K;&Y]T/#N+=%
M;ELGM;.R5-(ODFQ]/1?Y3'35`>!?=>Z.AM_YL[RW5UQL_MO`8G9&2V-O:IJ:
M/$56-ILQ6Y)&H,WD]N93(5%+D\_MND3$XO+8QEDF-0$E$L*Q%FE4^_=>Z3^X
M_P"8$^)RN#V_B]T]"Y+([@PPW#)E*_=^$Q&'V9M_&YB;;>Y,QO`+V/D=$>$S
MT*PY!::H>#`FKIDRE13-,I]^Z]T[87Y?=V[CGBH\9C.@:=%PV2KZK<,^\7W!
M@)%H\4F:Q^;Q']PMT[NER^#SN-BJI8O'(!3+3@SSJDR2>_=>Z#C&?S&MUYS,
M)C-OMU'F)\ID.J,?MC#2XS?N#W-FINX)\=2['A7$9"ODG-3N"KK)$9Z5:S'X
MP0EJBL9F">_=>Z>I_P"8S'''BIHMT]-5+[DRW6M!M_%PT>[URKKVEGJ+;&WD
MR--59>EJJ%CGZP01S3P4R5M,4K:=6@<`^Z]T(VX_EOV#L3(U.,[$W#T!L:*C
M.1G?=>[,G%L[9E5CZ>KBQD572Y3>_:.V:EXZ#(31#(/'%,M-]S3QMI>:/5[K
MW0?8CY_YW.19$8[=WQ[BR%/FYL#_``;<&=P6U-P8O,8O)9'&[SP%5M[/=TTF
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M"SNWND]@9"+,[.I:N3L/?.6QU"F,["DQ]'U]+6U=%`\&T\IO?--5XVGBSCXZ
MGI*^*.*29VFC#^Z]U#VO_,?S>Y/O<C4X?JS;6WX=I0]A8ZISFX\[2YC+;)R6
M\LIU7MVN&"JZ6@R&*RV>[6VYE\0E!5(E=$V*F9H#KB+^Z]T(.+^;.\\QUU)V
MECL-U_D=K0U%;AZM*&KJURV.W%ALAE,-N.CJ4RFX<7@I,)M^JQ$]94949!*!
M:.,QM(D_`]U[IDR?\PK$8K*XW#5>_?CX)\SEJ_;\&1@WGALC@<1E<!_#<ANF
M+)YO"]@Y7'U-3MS;>5@R.3H4DBK<-CIEKJ]8*7U'W7NG_%_,CL_/SU!VQMWJ
M7=F%3'G<IW1MS>N,W'AJ3:4E73PT^8T;%W;OG(9;'F"JU/D(HHJ$3Q&GU>66
M/W[KW0"[G_F5]G4F,I<?MS`]&#>6>JMAT.SZ?=VX-UX-MSY'L3=V"V+M?';?
MV)#]SO\`W!)G-Q;DIEBJH8(Z&GB!>:8!XBWNO=)]?YGO:.$2CS&Z&^+V6PLM
M/1T\V,ZXW)V+NO/G(?W[AZQEKS51T*XG%XK/;]^XH,935GBR3+1S5,D7VJB8
M^Z]T.&ZOEW\E.ML[5X'M.F^(77\L58*>GR&Y^WH-L8N>."KR!R(II=X;KVW5
MY6MQN%J,56SPTL#^".K*NP=H4?W7NDSA_P"8/ORHH=W/)G/BON'.;8W9N#;+
M[?QW8B['=:ZDC$^.VQ4Y3L+>&.HD[$P^,23*YO`.(<M28B2CJ4IC'7P-[]U[
MH9IOF%V#BL+@<]N39NR\30[EWEBMGXZ''Y?(;JR/GSJY6JQU;3Q;6FRV(S$<
M&,P\LU7!2U[5E,]H988YK(?=>Z#6'^9#CLE)64N,S72QK\'DMDP[I@3-;VSD
M>UL=V#O%NM=IG<[X'`5,NU]P9/LJ2/#38RO2"JQTXDDJ%$/BDD]U[I7;,^<6
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M692EKI:&`+*"WDADC7W7ND[EOYAV.H,Q18C&;_\`C[N?)YB;<%-B,5@MU[>R
ME'][M3`TNY]P46<WE@.V-PX?`&EP63IZR-GIY:AZ".HK9*:&EA>5?=>Z%+:G
MRRW7V#)C(.M*_I/L:3-4]/78^IVKO3!9S%G$UM334-%GON=E[\WS63X*JGE,
ML%4M.L512/#("C.T:>Z]T7O(_P`SMJ/#4>?IX>MFQ5=@%W1CZO<*[XV9#F\3
M3[W_`+@Y2/;DF8HIESV1H,_)#'/%2>?[(55.:HP^8!?=>Z]NK^8UV'L_&Y+(
M[EPO1NW:O#2]DU&Y-L5>[\WDMS[/QW5R4&&WS2Y3%T;TU;N#,;%WHTM+7-B(
M*O'9".:,454\D-1[]U[I49SYH?(;;F0J*7=F"^-6Q,=6["CWIB,]N;L*LI<1
MAXZ=Z*JR4>\:K<.;V7%CS_`*7*5T$*,)M%&ZR%#3S'W[KW3!B/YAN_<QCMS"
MFR'Q4BRFWLWMK&4N0R?<>WL/LS/X[,8S"[@I<[3;EK-\M3XNG[!V[D7K-GPU
M/JS5&/NXW>D1IF]U[IYW7\J^\Z),EV4,/U57[<V9NF@VWMB7;N]-_38O=%)O
MZ?!XNC^XV[@J^KPG8.066LAEH:A'84],M15TT;H6O[KW2&/\QSM&HRV6Q>,R
M/P\JI\?M3LK>K4=1VEO&@RN-VUUCG,)M+=^:W!C*W#T^0Q&-VANO,1TN0>>&
M%JC[JE-&LPE+#W7NE5B?G3\@LONG!;`QFSOCOE]W;EI]_P!)A:BF["W'1;6R
M>X>K,0E9OJCQ&8J*.H;*8S$3S"2:I*TXIXXY(B))0"?=>ZX;E^<WR#VHFZ:K
M<&W_`(U8.GVC0Y&:MH*[L.KEW/DC@=N5FZ-R9'#;5CSL6>K<;BL)BJJNB18#
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MQ2/[]U[J'GOYBF?VUA<7E\OB>MM.:R$U+CAM_*U^\$E:.#&U5/BA)A,JT/\`
M>'*Q2U245)(\-16F'73Q3`.H]U[H2X/E?WG6;BJL#BNO>K,\*B2B;;F1V_OR
M#<.)S&/FR]'AZK()D]M9/.NOAK:HTXC>FATU"-K=8HY94]U[HONZOYF^Y]N)
MN2L>J^.5+BML-V)D,Y6[BW3OO!/@-J=8Y]MN[QW/D:?^#5PRU%@,I!4TTZ8I
MZZ6>IH:I*99OMY"/=>Z4N5^>O<^%R>8PN1A^+,.2P<E=0Y&GEWUOV*>ARF.V
M73;_`,JU?CTP53EJ+";7V;50Y7-5KP!,925E-#,!7N:-?=>Z7>(^;/;.4ZMV
MEVC0;"V!NS!;PV91[FVSE^O,CNW>>V]^-E<@B8?(['S6*QTU+4;4R&-KZ1HJ
MNK:GG>=I%>&)5#'W7NNL;_,)DRE!6T]-M;:W][1)E'QFV9-V8O[_`"$&'H\%
MD<O38Z.#*U%)N')8##9C^(5_\.JJFG6GT04\E36BHIJ?W7NG+>?S5W]L#;\V
M]=\8'J3K_8N&R.#.X]V;\W5N;!8Z'"[@-%38XXEDPE9#E<[55E:@I:*FDJ:F
MNF>.E@B:H9_'[KW07Y/^8IOZ*NGVOC8OBP-X8;<7:6$W/!F.ZLGBZ3#+TWA\
MENSL".HQ=5@:?/4F2V]L+&'/SI41Q0'&R,T,LQIJC3[KW2Q@^>&]CE(L;4Q?
M&R,;AR-%B=B51[F%'%N/*97&)N'"8B'^+TN-CGSV?VG(N7HZ-9$\U"P`E^Y:
M.GD]U[H8,W\L=\[3ARE3N?JFEI*7%9"=*B>/*[H@$N)5J:2*KQ4M=LJ#&Y^J
M;%RFN6"CJI):B%@D2-(K`^Z]UPVI\T/[YX;+5FW=F[:S&8Q%%B:^MV]A^P*_
M*YG%TVX]N8O<^W:C<F"I=A-N7;])D<9G*21Y9*&00"1HR#4QO3#W7NI6YOFA
MC=EYC([>W7MG:N#W%3[=JMST.VJWM3$0[EJL+BD1<QE\A@9<!'DL!A5K*BFI
M\?4U2*<M/6014J/*[1I[KW24;^8#MH/G:6FVKMC/Y/:>6EV]O+'[2[IZ_P`[
M-LC<\>'Q^[SM/=RS-C)\=N:EZ[KCN*LI8(ZK[+%IKD<.Z*?=>Z>J#YPPYN2F
M&V^JZ[<Q>LVJ:[$8/L'960WEC-O[UQCY?:6ZJC9U/4R99\/NVBAD;$E;M6&)
MPPA8`'W7NG#)?->BVW+30;PZ@[(VS+-)603FKPFX):6FFQ.'KL[GWCKUVS'0
MY&AV[B\?+45U12R31T].IE;]M68>Z]UZ?YB;GAP55G!\:.W'IZ`1S5E6ZT-%
MMY,=/%-6TN7IMUY**BP-=B)\4(:G[F*9H%%0D9<277W[KW2<J?GG!24]3,_3
M>X*JJHDW$V1P>-WWL&HW'B#LNFQM3O:7,XFIRE%_#\?M*GSE#/757D>GIZ2I
M\SLH0CW[KW3;)_,(Q\6.?)/TON9*6*EQM9]R_8/5JT==!D*&#/+)AJ@;G9\C
M&^SIOXW3N8X4JL6OFC.EXO)[KW2UQ'S%W)F\?B\IC_C1VW+0YY)*C`5:UNT9
MZ?,T$453429&B>CR]4TM)!3T_DFLI>*-U9ETLI/NO=,M-\V=US5$U$WQB[-G
MR4%/1U$V&Q.=VOE<\CU6*BS[8Q,*DU/D*S/P[?J(ZXT5,D\K4K&0>A68>Z]T
MY57S)W;AILA+NCXO]K[:PF)Q=5E,GG,GG-ATD%+%3T$^08I19'/8ZOKH(4$,
M=1-31S1TLTUI"%1W'NO=(JA_F#57VN*J<_\`';?."&0QV1KYQ%V!U3G8:5\.
MKUF;Q]+5XG=,U-G<IM[!24^3R5-0M/44&/J5GFC5%8CW7NI]=\]LA3OA8J'X
MZ[]R]5N'%4.7PN*H-Z]:'<&5@K:0U,,&'VY+N),WN&LK%L]$N-@K$K:=TFB<
MHP]^Z]U`;Y_YXF:CB^+O:3YJFQE3D:S&G<FR&BQ\A*-C<9EZ^DR57%@<K/3E
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M\MLW%;U?!_$=]R[=ZF[`ZCS/5_4E?F>XZ^9=M8/KK%UE=V#UUL7/4JXZLQU=
MF*JJV_B:2"2GAR$B2B-?=>Z4F_\`,;SW/NOO:+&=TYOMBKV;V)LW,;=Z\GV?
MO3;W9N![6J>JNZ(:[)T-=O'#[0VF=O\`9^TLO/FMM4$4,U)38[)4D%(E31_;
MU<ONO=(*EZ^W+'"]'VS6['Q_QC["WMT<^1HJ#'[OAWY7?([+TFW,GO*FF@[=
MJ1FY=BMM6L2JV5'LF:KS^+W!2T"4<"/7STTGNO=`9TB.Z]T[L^-M;\?MU=B4
M'5N8S';N0VK5];Y?MS<.\\UUWC5AV;2MB(Y::EZYPNSL?)AMNUFPJNM:?%R0
MKN&'<L)F,T$?NO=;9/6T>]HMA[4B[&GIJK>\>&I(]QU5-%1P?<UZ*5^XJX,8
M\F)@RL\`1JU*)FH4JS(*9C`(R?=>Z6_OW7NO>_=>Z__1W^/?NO=>]^Z]T4WY
MB]9]F]G]4UF)ZSG;*UM+%E6RG7,M;CL9C>Q*6OQDV/AQU=6Y.IQ^-JGQ4LYJ
M(,=DJF/!5\MER$<T2*GOW7NJ*^J]O]A_';KS8F&[MVC$-R[/V+O7`[E3'8NH
MJMR[.GW9#5XC.;8@I]IT5&N'VWO2OR&*R?\`%<A-%38S^*SX?;E4F0K(D]^Z
M]UCW1USFMJMOZOW3N2#)RYB7KF3;TD^W&W1U)TLG6$F6I<I\)\ING?$P[FK<
M-VGN.9\W7297$TT]"M&8LB8IJ^5W]U[IZZMR^S=Y[$[%H]O]J;QW!6475_Q]
MP68QM1L/.IB\3V#'T5MC.X+8&%W@=R45)N/9,L-&,C1038R;"OE=JU$>-R--
M4>6EE]U[HMW:G1F^>TL_W'O&GVML39.UM][:PLV_\5O)=M[?W3L6EV=UQMC=
M-#BZK='7>VH,G)LT4V!.6ZEW!UDV/6O,II=PT<57!52Y#W7NK$]L[PW1G=U=
M(;@R/5W94>`AZ>PVU,UMO,UO2>[=FPYG=>Z]V8BFRN;&W,;LG;&9SU+D<6*K
M-MB\3AS@\I60UE3C*ZGIJG5[KW1(-P_%KNW*Y3KKY*TS=)]_5N([-7L7,XWY
MJUV?V]\E>LL3%3;CV9ENK-N;ZZGW[O+XZ3]7322Q4M!3-U3%31X&MC>KQ\U=
M#!/%[KW17H?C%W+#2[^V+)MC;NS,7F:K:6[JG!=?;YZF[)V'+3+FL1CNO]T;
M@R*[0IL#FJKH^HZYA&R\?2T+8R.@I\74[XQ&Y:N9HH?=>Z,QMGXE]S]H4*]A
M=4;.^.7QRW`FU8MOQ]S_`!UQ>9W+W1M;<DFXMQ9+L_=W5?8NP]T_&'IO;&Y^
MS,A4TN2EQNZ/[WT=!D\FSU2U^+IZ>B3W7NC>;2K^P*[L#X\;\K>O_D7MW`;0
MEV5BMR=[]AR]&U/:6Z8NP*[=&.S5;NG:6._@U$^/V=CZ"OKLCF:"FQ&W,#CL
MI)E,7C\EDB)7]U[ICWMB.PMZ]2U>TI=P_*GK3<O:==LRGVOWOMC.]'47R-PF
MV]Z[MFPM)MW<N7K*J#:E'MVCR#PU>:VO099LP]#4N]%N&D58\</=>Z*-OSX.
M=G[4G[IV7'UY\0L_G.RLOLOL*7M'X_YC<_679ZR[3P&;V\^Z\_MKY"'Y5X#<
M>\<D,C_#=T9"#<&-@R^`K\RE935M6M--#[KW08;3Z&WY+O39]-N/KOJ_/X>C
MP&SW.VNYMW[;_NY2;-QV9I\L-J]9;?W#TUW++%LSJ7.;1I\OM;&STU7N'#YN
MJBK=RU^X,3.8J7W7NCC=1_';OSI/=G5_:6?GQ.U8MQ[OS<NYNK_A)MC=F,VK
MV"N;QV>R=)+WYDNTNVMV82KI*9<0E.,CL7KO:T6.KR%^^HZ7^'HONO="KMK/
M]L3;#[DV)2;`^1G7B[MFZ3SFP,#1Q_'/(83KW_2/NK.SS;>.2KLF]+@]O]7K
MBU>67.09+(PS96DSM?&U;)D57W7ND'VGT=V5\H<GBL+L#:6[^MJ=^K,YF]]]
M7_([;^T]\?#?NO=NY]P5;;NQ??.`ZG[JV?VM'\E-N4])'/3;@BS^Y<`^-\E1
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MQF[9W+N7%_)>@R'67<$FU^XI]Z;#VI\[MJY>+Y`]%XS%;I?;VX=K]&]Q]9[K
MRW3_`%_UYN^KQ%74[4AW!UO-]IC:SQU!R4DX`]U[HI69^.W;O7F2W+U_+UUU
M5LRLRF)V]G<)B-O[FK\/C(=E9.2IQ^U^LZ3(T6Q,7+0=3]:35V1S6TQEL-!+
MCJ@129QMP8@-C(O=>Z'/;/PW[V[.;`9ZHV)\4.DY>KJK=.2I-X;*VCO/-_)+
M!]P;_P!R9/-5'<O6^4V+O3X>=8[?[EW<^2ILOE8<Z=W;,BW=-++C9AC&&&B]
MU[HT<&Z.Q"_QZS=%U[\I4S6P<CTK%+VCD-R?'Z;L+L?;V_\`=LFS]Y;F[9S6
M=?:.WL_N3:..QF5,RXN#'87&?Q2MKTI,A-'0U!]U[KEF(^VH>N]Z8C+8+Y>8
M?=>Z,W19W:/8T#=(;2[QV;3[QW-5[+WG.F;&XLQM#8B[9IH(ZG<N'KZZ+)YG
M$5,M1B,Y3Q.M*GNO=%>["^%/>6S5[)ZWQNROA!EMR;^FP.X8N[-AC</3O=/7
MW\`W#69S-=BXVM[@QORAH<KNS/X2H,,209+&4T&*KI:AJ3)124]3#[KW07;7
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MG>_<'<>.JL9!EJ?>N/S%/B1)!--)@X:;RH_NO=$4W/\`'_N/;]/L=CU?\3]L
M4_46RL=@LCOGH+>^1VW55NY_](VZJG;'9>&V+N3:,>[H:39>Y]XTDVT,BV:W
M'#AZJ'(Y?-IF,--3XQ?=>ZQ=8?%W?V[)MTT,'2WQ/W/ELU4YK9N.;N[-93=V
M:VI0[HW=M?(;CGS&.VCL*'?F\:WMJBVQ_&M\2X_>..2OSL=/54,N`P=5/MX>
MZ]T=7;G5G9OQ[H=X==[URN^NPL9GH-A;2H]M;.J]DX#XG]!MN+(Q[.R^Z_CC
MM;?.]NY^T.K6P=1&E5D/[R[EKL6E4XGQ^W8C&B)[KW0DPU78C;1Z-R$_6_R;
M:BZYQ&>QV0V5V+D.CJS;^4HQVK#L;`XC(;3VMV!B\UV[@L7B\:FX(,;*<;49
MS!K!7ME(LD7Q[^Z]T">_/B'W;V7N#,]VXG9_7.[$ZYWAD<?B]M?-WJ7`[MWW
MC<'L[>PW1D\/\<]X]+[JJ=M=8=7;HBJVI<3%E^OVG<C[ROILA#4RQM[KW1.]
MV?';Y%4FZMPR83J3IO:VW>P\#O+,;AV7U;VD:[K[;>WLONR.GW/MFK./V3L+
M-S=4QXS?$N5IMMMCZ+/T&73)5U;7G&Z,#+[KW0T[$^!O<O:]-LB/&=,_!G9>
M/V#%N;<Z=J?W=[&[:[;S.?W;/C:;;79&WY>KJGX4X39/R"W-B\30U&YQ+E\M
MM*OJJ-:S!4^%IZC[(^Z]T83`T?;V#Z_Z>FH\#\Q]Q;OV)7;/&X^[-ZUGQUSW
M<&?FA[&JM@X7$;UV]N$X?;V[\MM"BH)*R6LQ`HJQ\5"'JLO7S00L_NO=*CLN
MFWSC/]F/KEV;\J:R?>.:[GWGMC=,%3U!MSM;8O\`H]W-'LF:LZSS>4RN\TZ[
MRFZ<!5"LQ%9G:6==Q8F"DAIZ'",7J4]U[HC_`&3\'^Y-CTV>JLWLKXL;]@[9
MZNVQM#)]J=K09;J?Y;P;@K-WXS<51VSW'OG?-=\GNO\`<7>.S1@X9<?-AOX5
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MN`RW8^,VIL`Y7"=_4F0ZHW%\@,K4=;9/:/3K=8;CVGUGD=L8*2#,-1Y..>LF
MW=)GIZ]*4)B*S<L_WZ4D$*C&257NO=%@^3'QZ[,^1D7=._=GY;;>^-B[)[#V
M'LNAZ/\`EM2=O])=']>0[<VYC-[UV^_B;2?'WLW:IS]0Z[@AJ1_?S;]95TU8
MYAJZ\4R54;>Z]T7WL'J+?^.W!N#=]1T7C.O]G=AT^X,]M78&T]X=59?;.=Q,
M6\*'<>\\GNBKZYPW5$6WL/W-@ZZGBWM$%I]W1YEU?8%:L)JZ67W7NEU@_B%O
M7?M;L?8&U>A^@=L]DXO>V1W!O_?&[M\;IZ]WI--F=GIMC![FR>]/@Y2]2Y&C
M[-VW3XJ/#X;%G)Q;8BQ"8ZI:&',+6U4WNO=&9J:WN/9W0U+U^^2^3_<?<W5?
M^D2MW/\`)G<O6O4F>[+RV2ZXR@V75]>[#Z^SIDVYFY\]3RS/)75E;75V3CT2
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M@Q?:/7M#UW7[J7<>Z.Q,/MC)[O\`C-MSL;:V#I4EW/M)!NVERN,C>J@HC5I`
MONO=$7[!^(>^HJ*FR-?\3H\?N#%;]WEO'=7=U7\T:'Y-9#;O6&:Q6',^W%WI
MV]F-N]_==[:CW'B#6-7;9VN^5V_!B:-,+%55&4R7OW7NF/KGXV;XW;O^IR._
M?B10]O8O;>T,YC*S*[HH^N>F=U46Z\M@]PUFU=]R2Q=O8S(XD9#.[PCAH]I[
M;H\KMZKJIX]VUU3%NR*;!P>Z]T<[K_K_`+!^.>+K\'O^K[?GZ8R?4G8+X7XW
MTV].[_E?G3+B\CMW$T/9G6OS$[5Z\V9V5U%5PUF7A']Q,/\`Q6@BJ%GK8UH]
M>KW[KW2N?(XNFV54;=6IWA%NCI7NK>V6JL56_P`O//[9GW9_"^F,1NG?>1P%
M5A8,O@5PVX^MJVFQR5<&2C99*5(M.4J,>8']U[I)]O\`5/>V^]R]EYKXX4&X
M<IL[#XK:=7!U7U/NW>'PCR8WY)L6AS^VLQGOE9/U'OAOEKL"NH*D3TYJ<EM^
M?`5ZNE1A805HU]U[HAG8G7F]^O\`MG*=I8CXJ=[=4XVLSN`W#08_L';=3FZ2
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M.X*S<(I-N[SQE%U$E)!@=O,V`E@P$U-C!E*&:GD@F]U[HG^WM@_*&NQ6T]U]
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MKO[#[8SNX<)3]%8_?>"W'LSK3M;_`$+4DNW]J;^W#B]Q;&JJ*::FB6FAI@&]
MU[HNG9^`^1F,I8\3G:3^8UB=[X_<V[)\QD>Q\O2[[P^W^FZNCVOMS=F(':?Q
M=DV=TM#N^NR^8RE9LO=F8VM6-L_RU]1G8LABJF"G3W7NDWU=M:F;(93&T>S?
MF%/UGYSU]MB3XJ3_`";VKMN'?=/BMWY+9.Z8-M8;/[1WOM_'9G!OBZ;>"[SF
MJ9LMD8L9F\61LJ6JHH_=>Z-5TT=\;?["V/E/EWE-U9#86$ZJ[,W/UYL3Y";@
MZ&[_`/FMD=N8REP5)VGG=B]H_'[:N!V/7_'C,PS8_"9/"[WBKJFL-+124\T=
M,/)'[KW4K(8;%9WH[=%'LBEZH/9]1W'MR;#Y?JC:/8?7W:V,P^<V7B,WC:7%
M[MRV0K,3D>_,EUZ,+3X.C;,5>3R>VZ')4N$JJ3*S0Q^_=>Z+QTIM_"QIUSMV
MKPF-I)I<GU4?CI2[KJNQL9F\!@ZRL@B^26<VA3Y>FW?N[JWX*YV.HAJ<=B]_
M04,]5GYJP;?45*TR+[KW1\][;:SV#W5VGF-W87KBJQ>\>V\5_="7`)@I,CM6
MEI>FOD%M3<'QKW968:KER.(Q6U:G`U59@<C#-%1U^,6E\,-)5.V,3W7N@^V[
MM,YVFW-T]F]BOLW9/<]=UU4[L[3PN5GH,)E,!F(=HXO)_'>KRVQ*CL"AQF\N
MNJJ1,AE%6KP^*KZ2.KJ\GD,14005*^Z]U`V/\F_DGUIDNNL!U[V9A-YX/*Y[
ML_";\WZ^UME18C;]-L1\5B,;MG(;OSE,F2[(W-U;N3&IC=_?<U%#FZS+[TH5
MVRF?JBU.WNO=;'?7FXLWNW9&V-R[DVMD-E9S-8FFK\EM?*,&K<343`WBE#+%
M4PI.@$L<55#35L,<BI54]/4++!'[KW2S]^Z]U[W[KW7_TM_CW[KW7O?NO=%,
M^9%?VY1=3U,?5D.36*ODK:/=N2VME<UA]]8['/CJAL6-JY/`8S-YG!R9',+'
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MD*&IRV-R*;+GV6:G$8FOR\D\V/A0UHADGJVAB]U[I29[%11;`W9+M#KCX_9S
ML&@["J,!M_\`W_V[*W$;TVU/M#-XNFWOE\?4SG-;EV9MS>FX5DKZ3'LF(J\#
M%"DR14U&Z/[KW4"KV+CYMS;PV_18'X_;[ZZQ77U=O/9V[=N;YQFTZW-[E=]@
M;7VMM["Y1Z_/4W5FX?L*'-(E)2Q9J7(0UE77U-6E5)2(GNO=.&UMD8J2/J'"
MQX?XP[;?)TN:A['VWC.P,U_!MNRT^[=Z2XP[/H*[*K2[:7'RU^'9GS4V1J8*
M*@J<=31GS.R^Z]TPU.`W'F]NG=>_<)\2LGV!3]B8+$4FU=W[GFB?(=:;:QU%
M%CM^9_)0Y!\ED]P56YZ2OR-`T4M/BJK-92B?SF@@Y]U[K%G=DX#;^^=_R[#Z
MB^.8VELVCK<7UMF*SL#?.W\WV;MS?>]\/N+<>/ZMW_!4G*[=PNRL+24]-N#;
M&$IFF2O@J8UK@*Z(>_=>ZC/UYN^;=?6N+_N]\6X:;<&P<_7=W[I%;4XK:51N
MBJZ\W?LIMBY4UF7.TMC;VQVZ&H,QBJHXV3*3:OMZHB.":L/NO==X/#U%/L7K
M'+G8GQ>QFY*4;=P6_(9M_P#;2X[;VR_XGLS$[>>2"!L1O[-;,@VWA,ICZ;*9
M%JD--4/6S4J0BFA/NO=+6LV]O''U&[-P[<P73"[GV=N?`-UI@(NR-\Q'>.XZ
M'([W:I@QF:I\Q697?&WHYJZBJ,[2[=IZ2F."HVPT3O4&MDI_=>Z;8=G/3;FW
M#B)MK_%W`[9_N1DL_6]E0=J[FP.S=O;BJ\/B0F.PF#Q4>=Q^(H*+LULG++#5
M:MPRU/VV5EEG2CIG7W7NLV`V-0YG)])0;KZJ^-T.)R6]LCE>V*');MW1#7]?
MP83+9RMQ$.7P=1/DZ^'-9O`4]+2TN<SV2KA44=/62K2I7USPI[KW2-EZ]K=R
M=65>'W'UI\7LAV!@\VT&3Q.[=W]A9%M\0IM>/<%#V`<]M?+TNX\YMNFWU0!Z
MJ3!TN/Q;4-'%2+YJ*!Y(?=>Z7V7`VSOOLG#8';'QEJ.NY,34;BVED<EG=[X'
M*[OWUD(MF+A8VW?@:^6BVD*#:V.W#0Y+;^*IZS+05T\.0FG5DAIYO=>Z1FX<
M7N[.97J<1]8?&G;>(W%5T^3WI3;PW-O!,'L2'$R[R.=7L':-7FJ?:^V&W)NF
MOVS4XS)Y6MESZ1Q/%]O*U5.(O=>ZQ5F&I:/;D>>AQ7Q*AWO5[NCI\[6TM'VW
MN&E;%C$[3P%;O(8;/9O!Y+=PVWNK%94SRU4E'C\E4SX])%>@QRRU'NO=++,;
M5V]CL!VE'3[#^-.[*/`U.V=R[$J]H;GW]03;]IJGL/=6'W;U_B<U79.2CVA5
M3;"Q&+@@BVM3/73UN+R53XO-D:9$]U[I/U6`QE?N;`908+XCMDQUJM?V#D<I
M#OW`[2P79N)ZLH]L8W8]-M-:_.83:$=9NBO<5M+D:G+Y>GP<E(U.8XX*IX_=
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MXZNS^7R6.DILEC=FYS`-_"\51T*Y:&BF@:=9IIQ[]U[I6Y+9^*J-PR8:?KCX
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MJVLKMC_&;#=A4N[<7F=WU_\`&/D+G:?-["Q5-D\E5[AP8H>RZ2LJVI<CCZ*I
MH)QD*M)GCJJ=Z:*HF('NO=(?KCJ+XJYS)[4K^S]D?%K;>UMW46&?MVHVWV[\
MB!N+%U&ZHJ7.UVR,#D<CV319H1T^,C%;D\M2Q"/^)R4^*$*TD,U6_NO=+_>?
M4/\`+H;<V8@?`='M'54]4VV,UN+L?N3-5&5V+NIXMM;"W-%7Y3NB+(9>"AW+
MC#BMUPUZT-7C(],F/1UM))[KW22R76WP4R6U9<]MKJ/H7']K/C,?F,W6;L[;
M[VQN&RNZMGYC===E<;CLO7]F2Y2BBW5C,?0UVTZVJ0U'V$E963QPNL4#^Z]T
MPTNP^LL?EJJBQNR/B#M:JFZUQF^H<_E._.[<;M;:':V7^SS&.S=1N2@[8S<>
M?VKM_'ZYLICZ?&RS25%-`DC+YO(ONO=#?OG;/0-)C,EE>K1\7:'`S_Z+\-@<
M1OCN[N:NW)@%W+CLD_=-1N3.T&_*FKJI\9#2#'X_%4E=34U51S560G$AI(8Z
MGW7NF7)Y'KR3:&<S=1LOX_87<M9B<^N3VS6?-7M?(5=;@:R)-KO29?-8[M?&
M2TM-E<IEI*NF@DJ*Z9\#BJN`)2&H@BC]U[J97;6^-%++MB"CV)U+5XW;6)W?
M5[BH,[W=V+BLSB*;;U!G!D-M=3[?PW<6?I,]23UV5Q>4QF1JZC!RU.+CFJ&,
M(J(!'[KW2DWGL_XZ;M@Q^Y>OJ;I+;VQ]T=7[<D3&]M=^=GX'+97NM-UY;$U.
M#I<7ANZJC&8;%83;U+_E4T-3.CPU@@;[T1FE/NO=).HVYU+6YB3;E2_Q?VGL
MK-Y#<M)CLM4_(G=U-_#=P8_:N!J$QM1L?+_(B#`[H;-9*DFQM5(LCU6W9<8)
MY:.&*LCF3W7NGGL+$=([/BW/CMOTW6V5V713U]73/A_DSV#'O;,Y+;ZT6%V7
MLJ78&Y/D7B,;F\_O6MIZ.IBJ012XW!B19HXI*:$3^Z]TZ[GVYT)C-W[LQ^TL
M7@Z/&U6(VKO'$[EQ7<6]]T[57&9G;`C[$3:>1IOD+2P]M=@#>U2J9NA_A]%2
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M7QVV]2YGKO/4LW8D?R)P%-3_`.F6CVQ6T]+BL)@5WMBFK\+A=]Y05-1-39J&
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M>Z>)MX8N7>G;C8S=F^,?MG`8:AW;M/=&-^8O0\]+O7(?WH&,K\?MX9S/US//
MC=NS?>??;MGEHLUD(#$$I*:C$K>Z]TD\7G:C=3[>Q^^MR5E5B]S]=Y'?FYFP
M7R]ZXW+U-M;L>@V#7;J;8VP,O1;DQW8&Z\)MSL?;D$U+C(H#MNCK:UH:V>9I
M89%]U[KDV7VWF,"F8Q])NA\[G-PYG;&X<1F_ECT?2QU.*I<CLW:_][,L(=YU
M^VMF[G7K[-96MHEQ=3EYJ7*L^-T-'//4T_NO=1*G$;2I<;N>LVG5;@,>%R-/
ML/;LU/\`*SH>MR4*85MWQR[HQQW%7;O@P/V<V%QT-=6[A%%5U(SE6_GG!I(_
M?NO=*/$[>ZTJ-P8*LBHMZ[1W!AMJ;@[(Q>YS\B>N]E9NGW!)A\#O7&X_%UU3
MN*GRF7QN_,_4YFMK7G9,1CXXJ:AD:.61S#[KW4K8-9MJ->MYMPU'<*Y7L7=F
M\L9OX9'Y.]:29:CQ8W)D&QV]-V[CQ^X\96XZK:GQ6.3(_P`,AJ\5G*3*O]P\
MT0A9O=>Z3[Y7,S==Y";"P=U;KWM4;SR:8Z#$_)OINGJ8J'-[#_BN+W":^7>&
M0V;5['I13U^WJREJ359*>AQ[AJ6"OTLGNO="1-482AWGV?MN1-V;_P`;UYA-
MNUFUS6_(;![MJ:?8<VX<'0XVKV+!E\S1X_`XN;;U!_$)J6MJ(9:RK$DD4AQ\
M<D;^Z]U*KJ*-MR[56GV]NO.8K-8F-]TU?^EOIG>>XJVHIL#OJOPN#WTN$Q8S
M%-346XJ!!3T^(@J\#54:2"I\LL>.I']U[IGVY49*2@P-7)0=FXM=T;XK>MLC
M/0=X]60O+MJGK\-C*7L+M;8./@3!$9S;\L]'*F!AW#_"7AI(:@2S25KQ>Z]U
M)W;6YR@VYO63%;0[$\=/O'$XO)G']Y=??<;@BGR&>SU?B-J8:#=%'#N&HS61
MP5#BFJ-QU&'\-!F:JLI5\'AHV]U[J9)NC.TV^JK&4>&[1;`T'4>>W@N:R/:F
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MW?\`N3>V$H:/L]=Y[2.)["P&(^/W>]-M3'5]37[<7:$6[>N\9MCQ91:N@F:.
MH@6HDGKI9FE?W7NDG5XC&[W7L+H#:^V\5B]V]I9;IC?_`-GE,1G*+J'*9S<5
M'M_[/==,\;[$&:[@E,-7-NG9[P[CBQC>&O?%U:TE4K>Z]TH^N^Q=K=&;U^-O
M7&]?C#L'LV@K,GOC#;0RNRI!OK$==Y_:>TQ3TM=M>ISN/K&PE7FI-EUM)N2H
MSF;W)D-OUM%BTS.9I35T%/![KW6P-M#<D&[]L8+<]-0Y+&0YS&TV13'Y>DEH
MLC1^=`S05,$JKJ,;W"RIJAG2TD3/&Z,?=>Z4?OW7NO>_=>Z__]/?X]^Z]U[W
M[KW1$OG7\@NY.@]AT.8ZHZZK=URUWW$<N4H)L359BOS<BM1[=Z[V9A,K-28F
M3>F[<I41-#5YBKH,;#2P3+":W(O28^H]U[JCJEW?D>[-D]+[I[%[7K*KLZME
MIMS[EV'3[EFR.Y\WWML7,G&8'>^6H\+L_)S'%;+.,J,A'@:7;6.W3+_`:JEG
MQ?\`#F++[KW4&JH9.ZMW;JSK[0S_`/>R/?O6WR5EV?F<]OG9>3RD^R\KD*?J
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M<E$M'*94K/W_`'7NGKLENS]N3YB*LR&Y^X=P[ES]=1[;V?U;W#NO%]TYC9V?
MR?\`%*[L6/=M3VEM[9VVH:+KK;V2H\]0ULB2ST%/4UE'X*C'5<Y]U[KEE-O5
MNK#YN#<:5VQZRDIH-M;*VAOSL7!Y/?\`CSMVKP?4&Q.I,71=I8^AVCE,3N[=
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MVLSNNJZQQ[Q0;XJ2PCFFR$RY.`X]H7]U[J-V5C<WUEELO1;JVO6;^V4E=+3;
MD;:':N[?/T)TIA-QX?96RHNQ:K%[PK\QV;NFLW5O&"NR6(Q^+KX*Z:GHC48Z
M&EJ8JJ7W7NGK=>V.U-D[=JJW$=?0=G;KS6Z]PY'9G4.P.W=VXV;=N-I*^D>J
MW[3;GD[;HH-L53XGK;/L,165KSYF@IG2G%2]%'2K[KW4_<%`F1VY2]B8K<FU
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M?<&_Z3.]&=1X`'!TNY=\8>'L'(4';*;BQW8>W\W_`'>@HZNHEBKH:I,<IE64
M^Z]UFW[L[MYH6Q>U8]F=B[_RHAQG7FTL!W-NG8VX]];YSF,R^VJ+<NVJZGWS
M68?KW'X"EV)GH*A,A)1T=95QO%YJF:&GH6]U[IZS=?00;!RO<F'W31T^VL?M
M>7+T>T8]Q;ZCR%3EZ>#"5&PNI=C[8J-\-3=3[I?"9BFI&SL^*I%R-)4/5LB1
MZ\DONO=,FW,'N7.[3Q%1GJW"='Q[,W)V%T_W-U[ENYMQ[NS_`%740Z-B3;JK
M4R.Y1-W1/FMRY:.EIZVF3*>3.9&*C7)5\`%+3^Z]UCZS3<&5HL=B-P[*EZ26
MCSFT^RZ/;&1[=WKE-Y9CJC([?R>Y.H=XY+?M;V/@:'#3[`P6VLO69[;C9>6>
M?`I(])'A!4E![KW43'4.6CW-N/"9?#U&"Q>^8]S;/QO:^([/RCY#Y#8W:+4.
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MWQ6[VRU;W1M?(X?=^VILICC49A,5GZF"G6:<Q5E`/=>Z;MC[5W/OK$[DQ-)B
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M#[JW;A]VUO7%-`_:VY]^9+?.<W[G,)G*+/;'PM13SX_&UE2:6/)U3M%7S4\H
MC]U[I=;DHM_"CW@-H;DI]X9C>N'Q"]1[#P'8/8F!R.]=SRG'XG&;=K,G4[D%
M+U)4]9;WWUMQY,@E+1JL,M`_CQ[RU<4_NO=1-CTN;_N?MS?-3VA0[3PN!QN)
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M]U[I_P`[@MQ?W2JNTH*K:$&T,CLG=>4I-H3=F;\VKN;L2HQNYJO>&Q.F-N4-
M1N:DVYL?)8ZMW/09:;-U=!28+[;."I@CI<6OGD]U[I([1V9NJMP6)WGE*'KK
MJW%SMN[&]U]-YS=&X\UO[K_LF7&XK8&3PV2R&T.PLAAMV093<.WZ-\C+1T52
MN/SX.&A:M)DCC]U[K-UAB.U=RQ5^XJ?9NQ^I\#1[N3=51MK<_;,N4W)N_I^O
MR3]C=;]G;2['BWSDZ1-B8?8.-RF:;$5-3+DIX0*N9:151??NO=9L7B]Y[DW9
MO#:VV=CXG&X6>GVO%M#MC>^_Y<?M3N7.8O`?W5[4Z@ZSVCE-TU.[^H<\^_=V
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M7ZMWK0;:W`V7WCV1V+O'!Y^IQNX,%'1T-8E)/41QU4%,M0ONO=.6S-DY?*0Y
M3+U_6<'0F8VGG9,_6[4[+EBW?V-U_NK-YDT5;N'L??M/OZOPF\-@S[+WKB(,
M%58I)*S#PUE/+4M2#)M"GNO=-.V-I;/WWN+<776V.I=HXZGJ*K'T6U][Y3?%
M?78OY$]7YBFQ&TZO=G15?@M\/GMAUM7V9M:K3);=RDL=8)Z(TGV+14\[^_=>
MZ>%P^!K=_55+)M7;3I4[JR\&Y.Y\GN?;>+ZL;=;8V@W+D>NX>N)-WRU]%W=B
M.@ZAYHLNLAQE50DU@EJ$J?7[KW06YKK?";)&&VKG^H-C[AP-%2UFS=^X>A[`
MSU'_`*`>O<%69/'4$G;6WJG>&=DWS0UO:.Z(,8V*Q,5;4-6QJ@D6GJ:))O=>
MZ5>\=B[BV?25)/7FUNUMU[VK<_N6BZTZNWI)2]R;\W#F9]LX_=/:G6N%SN4J
M]C[-P,6S=AYM:G&M6)3M+C:Z.G2-::65/=>Z7E!U5L#:BMOW;.V/C])M#.X6
MDQ^1PU%NB/+8C*;8Q>YCO'`]9=451W))A:#=D4>7VY'DY6R$-!4YC-TCPS24
M1C4>Z]TB=D=687<6.V=NZHVMU]UUN'%5.Y-I]B5G8F'QU?NS:?9*0X_:>9I>
MY)=KYRGQ?:O:6=W'45U#CZB.2.KH:**6EIU^[@DA'NO=-.`VIM/=U#O"@W'U
M!U]MS)]=[[VIVCD]L;BS6"[!["I-LI4;ES70??+;DI<SEZ+`=8PX2/+YZFVW
MN*3.9##X9Y\E6"K5(I_?NO=*F'J[8VY,OC\3V!T?L'*P[\QT&(K^R=I;1V0-
MI[^R6,2JP_9M1\9]B[KRE8W6F],3OLX7%5*9Z]/+EJ*"F-II$C]^Z]T\;3H,
M-7[OIL3NGK;KG`YC$OE<7NON''3;,HNOI>Q,?3#,XK:V]-DUL69SLG9N_.DL
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M[KW2@Q6&Q=9N#LO9V0ZFZ?P]3MO;..AQU51#`U/0G8&Y]OT=9F>WML;2J<OU
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M`@]U[INGVK@S_=C,8S:_6F.V!0[2Q]3VE+68;8E!#L.E_AV&J.Q,#VS6)UG1
M0[:W3A-YTF:,FWHXL4D,V)JZN&7%TV.J8ZKW7NF'#[+?>D>.H]O](;1V]5[=
MWSB<=OG;]?L?KRC[$VE2;A@JLOMW=]+5Q=%5>V\KUYNC'-3+C7=)&GHPSS2S
M.8S+[KW4[:>WZ3?.7W-1;(ZZVC5T,&;DQ])4U75/2U3@,S0XO:LVT.R]V_'3
M<]/U4M+V#FMG=N4$Z3XIIZUJJDR=)`F2I9%$,?NO=-V<P2P]D3==_P"B/'X[
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M%7DFA]U[JC+IFIWS\A-AYGN;8/4O0G4N`QU/DZ6LW#U/55>W\AUO19O=%5@=
MY56W$VQ0[PV=L/?&9Q,CXRD*0;F_AM,V0R3U-&9I4G]U[I.];[(IN_\`LFKV
MGL==B=E8K8O:/8&QJC8>0Z^7:6/RV5V+LS=F,Q?98K\/A<DFW=VX*2FK:2IP
M^0R%!EJ"2FIX7AJJ/*24]5[KW3KT_4[>^1.>Z>^.%#V?!W!D.NL7MOL6IP&+
MV4N!Q\^X*/%M0;)KLSN#$8/;>2H9J/;M-)0;I;-4.)RF;CK%R6&FQJ0S!?=>
MZ0<F9ZWP.1VU\09^S*:CR^8PF(EP^U1LA]M97,]3X/<5=-MS%[KEI=@54+;S
MV)'(:BMR4U!4;`@S%+0[.IT*RJ\WNO=+GLBN;XJ[TSO2>3WIBMMX[LK=6YL?
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MKLK`G>U?\=)=V]F"D*T68VC3[BVWE\9NBAP:=C2XW<U1C-RT&`Q^X>ZMQXW-
M8_*S92JLV)Q64H\5C4ITH,I"\WNO=+CMS=.)^)_:N[^L<AGMS;4SW86\]F8C
M#X[:N/S>=RU!O;<.SX\A2XK;%/B\)#A-S8&IQU53SQ;)QSQ4TAJLQGQ,LV`^
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M,[`WG3UVX.UL_P#Z-\;N:DR>=P/74^U_[I;XQF,BK=_5FRJ6CR"[8HNT,SB:
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M9Z"KP?6%;N:H.4Q76&_*>.ORW8>W,/E4BP\6>IJ"BJJG:O\`&(U69ZJG-/[K
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MV7L^+<C=4[/VA1Q;4R%1M78&[]QC)P]<87:4F/-3M7<W>.2VM#`*[`TKMD>P
M]Q#(%*JB2CC,ONO=2NQ,?L_XV===7_).'#]@XS&[YQ^\<^=EUU)E<3B8]DU&
M4V_/O3;':^ZZ_&Y'#]?5]#GY<718SLO)T]?N/#[4@!@KO'3S5'OW7NG^FPF*
MW3U1'\D<1'V[48:EWO2;<VCN^HZYW37]F0U^&9MWXV'$=;9J&E?(==Y.*KK'
M$&0K8*'/9/\`A5%4QDQNTONO=!_U5D-E_*':7</=.4G[DR>S^L\#NBM;=VV!
M78;$X_;>*I*'%XW"=/=A8B3"[AW-58;(4E1BGWA%C\5EAB:K=N*FFF6GIM/N
MO=/O3N;H/ES\@8>B-Y1[[W7FMCY@9+>M)D]HYG:>$QT6`HZ:"E?+UU!FX=O=
M<9X5=#72Q;:IJ2JIJN@HL'FJ.J9<N:JI]U[H(=K;QH]T;GZY^)U?E^\=U4E7
M5U&VL]LK([7K:_<>ZNNLKN]UVCC-]9/+5F"SN#_N(<M%7?WPGFK:S-9R2LP%
M10_;X9$?W7NE%W;E=M_''LG)]04E7V?@]LY3<V6PN#V9@.OY<A@J7?\`_<&F
MFW'L;IS&4,N$H=W4C;:J()A@Z2?;V"V1ME&SM%+65M%5QT_NO="!W%CZ+X4T
M..WE3[S[+Z^QO8/7.UL[N?&[;VYEMQ4E;NC/SO+M3?1RV<Q^9R5!VOF]QP5L
MN3Q]4H;=NY:'`X:MGCBR1FE]U[KC3=>T/5'2/6?R)I*CNC8N]NQL=O:GW9E*
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M`25NU:+MRGVY.D./P&8SVVY(:G#9BNRB;EQ<:[J7[2>LC8>Z]T&6]^P%PN[<
MU\7WW7V_DI-YUU1E-G[<W-MFOW%OZ)\WOF?;&_,SF=R8>;&;BWKFL1EY*VOK
M<\E4,'M+<"8C#5E'+#E:>2;W7NEOWM18;X:[R["ZCV]O#?.PJKLFLP%%MOK_
M``NSJ/<6&AWQG=M8["UD75=<N(9-S;6K\7FL<K;(QT%!)_N4W%N$R1O@5@B]
MU[I[[:J*#X<];=>=@X#/]D=0C/\`4(W;%C<AL=JC$4;;JW'1ZXZS?78&'RVU
M-F]PTV4%-!35.XZB*EJMN8>@QD#"IR-3-)[KW62HZSCVKU'AOEA4;KW-C-P;
M)[:GWC2;QH.IMPUM1/0;%VWFJG>>T-\];[TAR^\,='F=L5V2R^,PT-7/C<7N
M:HJZ6)VIVIZ1?=>Z8-K8+9GRVZE[<^5>.W!OS)KA(>N(]G=BX2')1/MG"U.Z
M\/15E1LFI5JV3*8?.9_`55+7[KP=-/D,SLF*)A20U=89XO=>Z5_4<N#^7&_=
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MK34=-1P3>Z]TILE@=G_''9O7_P`D=[YW*;3VYDMJ=D9#(&'-92NB[+V=1U>$
M;-9VNRV[<:<WUUOG;&Y*R@H\1NC)Y2EJ,-MN:?(S1560@8Q^Z]T\8_8VQMYX
M#+?)W<):,1=EX.I.[9]K[BR>5K,E3XBESG4VW<-LNJP[X_;VU<WU7G30Y!=N
M1TIFK(J2-*M*2JKXG]U[I+X*@ZW^4&VMQ]E;8KZ3.8K8_4&\-T5&6JL7FMZY
M7;NW<)F:'<.3RL6%R-#%M7=^X(\AD:*K2OQ-'614=/4Y+$SX^JK<)0QGW7NE
MM'E-K?*;?6W^G\9F\=V=V+L#<-)3[LPC8B/8^Q=U]J[;VIN"N3+T-50R5&7P
M^W9<-A,K`=NYPXO+54'@RYD@&8F,ONO=!KD=T=4Y#:VT/CAN/LC<>5@RV$H9
M$S6WNNJI<T^V6W#)BZ*FQ;[>V519FDWI/DI8)<O493%T^S*VKII=K>..CIZ6
MH?W7NE7O+=6W?CKVSO'8VZ=[X#`]G]@;Q@Q&S=H839E7N--B=R1]3XW.[FI\
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MTF#VGL_;TF:VI1UF.H-M]@;DK*2HQ:[4KH<EL[(TN0P6`J9S6[:-#'@*RDRU
M%&\1]U[J+@LCLWL_.[2^.6&[.V#NK?FP\5M''X79^0V[#5;5W7V$F%-5@]_8
M^BRF-P.=WH<O4QK1Y%][UN+J-S+D*C+8VIIGI(G7W7NDUD-R]+G9F\OC[6]D
M[2PF1FVZ*FA6OVO19;`[6H:O<%)BLC@:W"5VP%R+=HY?<V2KAC6K,9FMBL^0
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MS=<=)9K.YW;O7,.W]M)%B<EAL&E=O#?NZ7Q\^Q9^OL;U_L7!XR/:^/\`O</_
M``#(XNAS&'JLAAAH]U[K!L+>&)^2&Z>KNI=H=O;9;(8FOK<[MC.[:V]D,-NS
M+Y=14[HQV`V_N3&8^DK=M[-R>YJ'.P4&X/)MG=F,["PF2KV,U+(8_?NO=)>?
M=^R,3A-Z]#S=E[!Q^U,3N!:*;>>3PF)QF^=GUVTZ?$[1AS&\-F5"4M!N#<-;
M@\K4U>W-N3X<P8[KMY*!<I-D?LYG]U[I>YC></Q][2WMTWN'>.$S._ZK;F*W
MI6[9[/W!7;CWHF5W_D,7D*?;N[\AEIX=T3]*9G==5@Z.OJ*.NKY$W;5[?$M+
M]BTWC]U[IKK-QTWQUJ.D=XMV1_?&ERFS/[T;)E>-<QLS=^Q-LIF-ZUVZ]@8+
M!9O;^G-[_H,[EJN0X[*8K#OA=M[DKE@J7S$-+4>Z]U,@Q]9A=N4_>9[#VIE-
MN3[USV6PVRJ;."K^.1W=GX:;;K;4H:K#5V!H-Y87K[;V-HJ_#_[C\!FZVHK,
M)!E`K;>9I?=>ZYT_VO95-V;W[@]S9>LZ^V5M_;=5+2;3R"5!K4SF7S>7W96]
MU[?J]S96GS/;.X>X:S(8O)8G*25>.Q.>P=5)3255!)'XO=>ZDFCQ?<_8N`V[
MLG>6R,6O7756YZ.BR/4&>IAOJFVQ/LO_`$>1YG;.U,5NFCJ*'KSJC9VXH\]M
MJ.DK%Q^6VO4U^W:ZBH:K(PU+^Z]U.PNZGWYOGK?:NPMR[/R./ZTVYOK&04G2
MV6BWEWQNNDQ^V-\5^YZ7KNHHZK'[3BH`E-Y,MKQ^?QF/W^:S%>$F:'(Q^Z]T
MDML;:W]287J7(14W1^^>P,I79;=^,Q.4:BKMG8!\CURVS=RY+K_$1[KW!CZG
MOS>?64U/MS,PTF9CWC-35=1DED63(2I+[KW0\=)GXU=+]F;*ZK[NZDWIM:BQ
MPW=M;JF;.E<Q28C'46%GWMN>K[0I]GQ8K:LN1.UL:]%7RT%"U#CTQ5522H;U
MM3-[KW5_&"EPD^$PT^VGQDNW)L5CY<!+A#2MAI,))20OBGQ#4/\`D38QZ$QF
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M%8Z*H8I0P@>Z]T][$^*/5G7?;N1[;VYBX:2NDQ&1Q^`PR1U`H=LU>XLSE<WN
MS)8WR5TT"/FZK*.$CC@A6E66IT$_=2^_=>Z3#?"'HY^X*GMN7`02S5.]:;M`
M;:DIH_X52=F09G&;FJ=T4$D;QR4]/F=YX'&;BKJ$JT-5N;%4F28^:&S>Z]T]
M]K?$'J;M[?\`CNP-S4V16L+4G][<33UU7_"-[+A\978;;4N5IGJ=-#6[=PF=
MS&-BEI/$*C%Y_)TM0LT=5=/=>Z=^ZOC%UYW-CM@TU?14N'J^M)):7:[P8RBK
M<6-JY&+%4^<V1D\+5)]G6[8R7\`QE6D(\;4V3P^/JD:],$?W7NIFX?C-UGG>
MJMJ]30T^6PV)V'G,;N[96=Q>4JJ?<V`WKC:ZOR+;LCRT;QSU65S55F*\90OZ
M:^#(U44@"S-;W7NLNS?C3U1M'JO/]0';E+EMH[QDDJ=[4-2)J:FW)52T&*Q`
M#TE)41QXS'46$P-#CZ2DIC'%2T%%#"MPES[KW3)T7\6.O^C<YN+>&.J,INK?
MNXXLCB:K?.Y:B6JW`-J5NX:O=0V]),9WAJ#4;DR%1DZ^K*"HR64JIJJ8ZY+#
MW7NDMU#\*>INF^S*SL3;D,LD6,^_CZTVT8Y*/%=:T6;I:BDR]!C8:2L3'YB"
MDI*RHHL*]32BHP>)JZBAIY##/)?W7NG?,_#_`*GSG<N([;KJ&62+$YG^_$6R
MO-7IMV/M:'+T66@[(H88,E!!C\I75%%#+EJ58&I<S78_&UE4K5&.@?W[KW4W
MN'XI]>]P[NQ&\LC-DMOY1D@Q&_CM^JK<;_I+V;28W.4&.VWN2;'5^/F^XPHW
M#718_(@O54./RN5HX2L.4JM7NO=.G<?QHV'VQL?;NTX8(-I9#8F,EPW7>?QU
M+45`VEAZW&TF!R^WSB(LEC:;/;5SNW*1:&MQ=8\E%4Q)&9$9HHRONO=/]1\>
MNJ&ZIHNG*+:U+CMGX6=<MML4]1D?XUMO=\&5GW#0[^P^Y%KH]R46_:'=-2^5
M3,Q5D>3_`(@[3^<2LS'W7NF[J'XX];]3;%RVS8<+B]TU&\<=#0=E9_<&(HJV
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MZR]Y_%CKOOC*8[-[@ER^"S,6)&ULYEMLUU3B<EN79J5M1E:+`9*LHIZ:4S[<
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M8+,Y=5GRFVMA-4T%7!LRAK7>6>HIFJ,72M65<C&JR)HJ3[AG%)`$]U[IJV=\
M1^J-D=MUW:F&Q[Q!*&C@VGLP/5+M'8]<E5GJ_)9+;^#-:^&IYJG)[ER%92::
M5),75Y?+24TB_P`4JE;W7NN][?$OK3?/;>-[5R<F:A4TOBWEL6FRN138G85=
M25%!58?+;JVP*Y<'79&G;&TL=;+)2R296FQV.@J6>''4J)[KW3IW=\8^ON],
MUM3<&Y5J:+*[=,F/KY\>\]/_`'FVQ.M6R83+M1U5#.:[;F3K'R>W,FLGWVVL
MP6K*!XI9)O)[KW3[VKT'LKLWKJCV!]CCL`-NXQ,;L7+P8BER']SXXL<F'%)3
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MM'XV=7]I;7VOM?)8*DQ=+LG#U>V=IR8V`PQX;:.5Q^/PV=V@E)%+!#4;9S.(
MQ5+%-1R7@UTE-+I\E/$5]U[IT/Q^ZS;J[;?4;8S)/MG:-9BLUM[(2YK)3;KQ
MV[L-E'S]#OM=T33R96?>XW++)DY<C*[S3U\KRR:B[`^Z]TR]3?&OKWJ_KW=&
MP:FG??J=AC,CL[,;SBBRU5OV#-PUF/EPF8I:K[BF7:&(V]6##8K$+>BQF$@A
MH85$$2K[]U[IEZ0^*/7?1V[=S[[Q%5G-Q;OW!CO[L46:W%DJZODVYLB/*-F$
MVUA::IK*FDHY\ODUBJ\YD(DBJ]P5U-!4UIDEAC*^Z]U#V%\/>HNN>RL+V%MG
M&MC:;9VW*W;6P-F40:EVQM2GRN7S&=R%>:432'-92FR>X\J<9-47;%Q9BO2*
M_P!R2ONO=3^ROB5U!VMOB'>F\,*N02HJL-D-S;;D1&V_N[);>-'_``FOSU`;
M05M0]/BZ&FK3*DAKJ+&45.Y$5.JGW7NIG?OQLVYWM3132[BSNQ]R1XZGP;;I
MVPT<64?"P;AQ>Y*>,,6B89;`Y3'&JPM878XFOF>I2.1B5/NO=/&__CEUAOWJ
MW'=2S8.'#;:V]B/X+M$8PSQS;9QQQKX.JQE#,*B.M&(S>VYZC$9.!9XWKL16
M5-*TBK,S>_=>Z[P/QWZ_PO4&2Z;GBKLS@<Y&]3G<GEJC[W+Y#<!-#/3[D22K
M6H@H\CB:W%TDV/6-/#1&D@6-;1CW[KW4?I3X[;-Z6V[N/"T%3D-R5N\*RMK-
MRYG-E/N*Q<@U34UV.H*>"T6'PU;F<ED,K+1P$0?Q7+5U0BI]P47W7NFKK'XN
M===6=B;E[$P<3SUV7)3!8^>EHH*/:---14V+J*?$1T<,$"^+`8S'X>F=8XY(
M<)BZ.E<RF(RO[KW3?'\2>L:?MVF[6HZ>:C9-RYW?=;MN`%<;E=\YNJPV2?+U
M[F4B?&4FXL0,[%0F,A-Q/]^LBLOC/NO=<>X_B5UQW-O;;6^,PTV&R.,R-#7[
MD?$4..7(;N."Q^1QNU9)\W/"^4PN1VQC\YEJ&EJ:5U88S/92F*WJQ+%[KW2@
M[L^,_6W>6V]K;:W1CD6@VBWVE!2%#58O*[5JXZ"FS^P=T8Z26,Y_9&Y:;%49
MK:"25%FGH:65F)A`;W7NG;+_`!\Z[RO6.'ZL6ER-!A]N9>GW1MS,45>T>YL+
MO>ER]7N%-]467>.1X]VR;BR%17O6:-?W<[RIH?25]U[IIZF^,W5_5/5%;U+1
MX''Y7`;AQ\N/WE'44TL=+N6DFI#C5Q512RU=7,NW\;A-&,HZ26>=HL;!'#))
M,P>1_=>Z@]'_`!?V%T;DLGN##5&4SNZ,E!F\;)N3-SQ39.3$9S<7]YLA%5O!
M%!'4Y#*Y:.*IK9M*I)4H6AB@1C'[]U[I/]4?#SJ_J/LW.=D;?I_-55#EMLPU
M%/`M?MR"HILM1R8J;,4ZPU6=PV$H<U54V&BJQ)-04U;4I)-4:H#3^Z]TVU?P
MNZOJ>]Z?N?[.F*ODCNC+82HH*.LER&[*+<L&\\`:?)U,$E3BMMXO?AGW-)24
MQCGJMP-%++.U)$*0^Z]U)[M^'?7G<_8NRNQLA%28_+8//TM=NF^+HJJ;=&'A
MPE;MRKH%K9(ONZ&KR>V:V?"SR:WB.(KJE8XXZKP54/NO=*CO'XR['[CVA@=O
M-08O'U>TJ%<-MJ3(T+9?#T^W:BHPSY3!5V*FF5JBEJ%P-'/#-%+#5P5U#3R"
M8QB:&;W7NI>>^,^P,ATMC.EL(*K;^)VU/_&=JY=(J#)5V,W@M5D<H=TUM'7T
M<V(RE77YG+5535Q/3K"[5,GA6!A$T7NO=<.I/C%UMU9U!7=-)B,?G-J;@P]5
MA=U8BHQ=%1;:RN.K::IQ[XBDVM21KA\;AJ3"SICXHU1IY:6GB:JEJ*GR5$GN
MO=)OXV?$W9GQVDS^6QTL>7W9GZW._P`2W-'0T6(JL[2Y?,1Y:HS.Y:3$TM!0
M97>>;J:>*?(UK1://J6DCIJ=FA/NO=,/5_PAZHZN[ES_`'%BJ=ZS-5KP28.I
MJZ?'G/4"`YDQXW+[FAH(<]N##;=CSU9!AZ>IJ72GIZV45`J94II8/=>Z<=X?
M#'J7>?;D7:.7Q--7BLCS4N:PN3IJ>N2++YHX!\EF-JY"6G.4VS6;F_NSCDRY
M@G"U,6.IQ$L+&=IO=>ZF?(;XJ[5[SW5UQOFHI<$VY-CY6CIJH;CQ&.SN)RFT
M_NYJXPK0Y/&9-*?/[6S4D>9PTB".`Y6DA%:E1`JQI[KW3EW)\4.L>VNH<-U!
M+CI,5MW:E//!MN@2IDKL9/15N&R.W<[M[=5'FH\Q#NC;V\MN9BMQV6%:D]9+
M#6RSQ315HCJ4]U[IYQ?QKV%1=59[K`ME<?%N[,T>\=R9[;.3K,!D8M_T;X"K
MIMT[3@AEFQNSX\9DMLT4M%C:*"/$PI3B)J9XY)EE]U[I.=!?%K:'36S<[@'H
M,-'7[FQF4VUE*?:%)_=O:V/VM49C<.1IL7M?!8Z&@IMNR9"?<55D,E+3(DM3
ME*R5VD:**E6'W7NF'H[X9=>]*[UW'O&@T9"IJ]RMN+;[BG2@RPR,FV(-ERY[
M?N;QPH:SL[<XV?04&+@J\Y]])2P8\5$;??5=;4S^Z]TGJ[X/[*ROR(R'<N9.
M-W!B<P:/(96DS]%%DMT3MB\_-NS#["BW!]I!D_\`1ACM\3#.K05%94HTL46-
M,7\*CCIE]U[IP[V^%^V.ZNR]O=@56:>E:.J:/<E/D:&@RU;C<;)MVJVO75?5
MN7GH3G^M-TYO`5LU'49'$UU%*DK4V02];CJ1E]U[K/\`(?X:;*[KVMUQ@8*;
M#D=9IM_&XK$[OH5W)MG+83;==A\OMY,OB\A#D**3+[3W1MW&YFBJ_MGGGEHI
M<?,_V&1KDD]U[I2[D^)FQ\QT?1=.4E34Q-09B;=\VX<HU3FY-U[WR?\`$FW5
MF-^466JZ^/=^.WJ,W709"@KVJ:7[6H6*-`E/3K'[KW4#H_X?]?\`4'3F8ZJB
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0U[W[KW7O?NO=>]^Z]U__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g893535g42e44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g893535g42e44.jpg
M_]C_X``02D9)1@`!`0(!>@%Z``#_X5%7:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87`O,2XP+P`\/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](EA-4"!#;W)E(#4N,2XR(CX*(#QR9&8Z4D1&('AM
M;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN
M=&%X+6YS(R(^"B`@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*("`@
M('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+R(*("`@
M('AM;&YS.GAM<$=);6<](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G
M+VEM9R\B"B`@("!X;6QN<SIP9&8](FAT='`Z+R]N<RYA9&]B92YC;VTO<&1F
M+S$N,R\B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!44&<](FAT='`Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]T+W!G+R(*("`@('AM;&YS.G-T1&EM/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O1&EM96YS:6]N<R,B"B`@("!X;6QN
M<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+T9O
M;G0C(@H@("`@>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O
M,2XP+V<O(@H@("`@>&UL;G,Z>&UP34T](FAT='`Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]M;2\B"B`@("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@("`@>&UL;G,Z
M<W12968](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O
M=7)C95)E9B,B"B`@("!X;6QN<SI%>'1E;G-I<T9O;G1396YS93TB:'1T<#HO
M+W=W=RYE>'1E;G-I<RYC;VTO;65T82]&;VYT4V5N<V4O(@H@("!X;7`Z0W)E
M871E1&%T93TB,C`Q-2TP,RTR-U0Q,CHU.#HQ-BLP-3HS,"(*("`@>&UP.D-R
M96%T;W)4;V]L/2)!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I(@H@
M("!X;7`Z36]D:69Y1&%T93TB,C`Q-2TP,RTR-U0Q,CHU.#HQ-BLP-3HS,"(*
M("`@>&UP.DUE=&%D871A1&%T93TB,C`Q-2TP,RTR-U0Q,CHU.#HQ-BLP-3HS
M,"(*("`@<&1F.E!R;V1U8V5R/2)!9&]B92!01$8@;&EB<F%R>2`Q,"XP,2(*
M("`@9&,Z9F]R;6%T/2)A<'!L:6-A=&EO;B]P;W-T<V-R:7!T(@H@("!X;7!4
M4&<Z3E!A9V5S/2(Q(@H@("!X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC
M>3TB1F%L<V4B"B`@('AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/2)4<G5E
M(@H@("!X;7!-33I$;V-U;65N=$E$/2)X;7`N9&ED.D(Q1CA!,T,Y-$9$-$4T
M,3$Y.$(P.#A#,44V.#@V-#`U(@H@("!X;7!-33I);G-T86YC94E$/2)X;7`N
M:6ED.D(Q1CA!,T,Y-$9$-$4T,3$Y.$(P.#A#,44V.#@V-#`U(@H@("!X;7!-
M33I/<FEG:6YA;$1O8W5M96YT240](GAM<"YD:60Z,30X0T$R.#8S.$0T130Q
M,3@W-S-$,3$Y.41#.3DS-S8B"B`@('AM<$U-.E)E;F1I=&EO;D-L87-S/2)D
M969A=6QT(CX*("`@/'AM<#I4:'5M8FYA:6QS/@H@("`@/')D9CI!;'0^"B`@
M("`@/')D9CIL:0H@("`@("!X;7!'26UG.G=I9'1H/2(R-38B"B`@("`@('AM
M<$=);6<Z:&5I9VAT/2(Q,S8B"B`@("`@('AM<$=);6<Z9F]R;6%T/2)*4$5'
M(@H@("`@("!X;7!'26UG.FEM86=E/2(O.6HO-$%!45-K6DI29T%"06=%05-!
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M,F5N-4MJ<$M7;7`V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!341B
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M8B]!23%8*W5':U=L8R]N8EAP)B-X03M0<U-*1#=)9U`O12M73DQA1&9Z2')R
M;F4Y;$@K<650-G%985933W0V>518-CEC9E)+-"]J:7%O;FU(6$9.4F5Z9E-X
M4#8V-#!Q3&@X)B-X03LU82](,6Y7541S-DPK<T%(1VQ96F5F.$%/5$9X86%S
M.%-A5D)F865O54-72U9O;5EN8W-P26M&2TAP5$)35U<K6'8X06Y)5'E"<6A7
M)B-X03M/.6MM,&DT8F%L,&Y+2W9T2DAZ1E!D9W5#;&5I,D=O,D=O5WDS5FAC
M>%AD<R]W0FEE0C%K42]*;$I'2V]J1EA9<3=&6%EQ-T9867$W)B-X03M&6%EQ
M-T9867$W1EA9<3A7,'91+WIC=3=36%AR8E4W<4Q53&)33TYT65-Y<S!D>'$W
M9EA%=5EJ1DY-24DQ:6UE36=Y46XW2T)'5E99)B-X03M&5DU,=4@X*TE9.5IH
M=&)I4S5E3D=45')P;#!T4DIX=6]V4F4R6#1+3SEO2F97*W-$:4I+96U/3TMP
M3DY,+WIK3G!E<&%L95!1855,)B-X03ME4SEK;'5:8D]E,U-5-EE/4TMQ,'5&
M5T<W:DA%26=6=FE*0G)U<6@Y3C%,.#@Y6C!D.6(X=GI4,U%U5D9V85A%<C9C
M07DR.35Q240K)B-X03MJ6#9Q4WEF5FQK:VE(>$QU:&%M2V\S6&)4+VY)93=J
M,4LS:64U4WIU;W)V-F]B4U13-&)I2UIP-3!T62]63$EY44,S5THS6E<Y54UW
M)B-X03LT=#EO2W%Y3'ET869M-6)E84Q:9%1D,CAU+U=B=C9X2$I*87IF=7!P
M.5)L:F9M4SEX.$%&;7%+1V]&86Y(63A66'!E2W5X5DDY6C@S)B-X03MA9G`U
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M>6%H84E,;3!U4'%I3$)D*VY9<W1Y1$=I=$ET<7`Y3&M0=$YZ2$DX5E8R<E$O
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M;SE55BM-1E58:#<X841&5G9K;CAU=&8X-FU7-#`K4T-+0S)L:FEI5S1-:3AN
M;#5(,41W:FMP)B-X03MX4E,S>#`R-E9.4FER2310>4\X,GHR,&LX5GI:34DU
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M-'A"67@V9G=U-FAL-#!Q9#A66656=4IF=&XP52]K42]%9FTO8B]!1U`S-'%Q
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M4&)&5V8O.$%/3EAN0C=V5$QZ>79D4'EK<U`X05-B0W`S.4-2)B-X03MQ4TE0
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M:%%O9FED96-Y4G`X87)W-B]T5G=,5'IU0S1V2FDX.%-H<FEF.$%V8GE115)G
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M5F1I<G-69&ER<U9D:7)S5F1I)B-X03MR<U9E969N:'%),#=Y=G`Q-F1K9S%7
M,F%4+U5+>4(O*T9*=VA74&=G9T5';U!1-%5/>%8U,S5V,511-R]!1DTP.'DS
M;6E35U`Q:7EU)B-X03M);VAD:4M38C!M9$@O9$]I5F=.6%!I2T)T:75"25DO
M=S`T0T)P4'I"=C-J:BM.;S598G-L>D5%;4966B]%8S$R-4UP,DI!>%9K;FM#
M)B-X03LX=')056YS2F9-,3,U:'5R*TY7:5-A0S115S9W96]R1G966G=H66]6
M24Y'<4XX5DPP1$-H5'5B;3-T64AU3&U625E):'EK;&M92W%J)B-X03MX2D]W
M>%9*=E4Q6%<Y;U1*<'5K3B]U-&=P9#-#;BM25'9!:"]M4'@K05AR:7%B5TYJ
M6C).<W1T6G=R0D%L94M)2V)K,4I0:5-D>51U)B-X03MC5F5:9FU$9"]84$YJ
M44$Q:C`R,U-,-5-Z;C%8+W=#145E0E=.4W=+>6Q704MK54E/-$E/2U5-<&$S
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M)B-X03MF-51F4E4W67%O5S)J5%0S0U@R<U-,8UA-6C4R.7%L9G$P0C=&1E`R
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M35-39FYI<5=V6DA69&0P:E%5-6-T4G5O65<T9F%!;&M%67`Q+VU08D9)9F0Q
M)B-X03MV<E=J6$YX.5=T-RLS;75#,'E#1T]61V9N87-Q6$,X45-A>$TV<30O
M6DI&975"0TUX5DI)9E!(:W%A=VXQ0TAZ0G!S;&AB37%83C1L)B-X03LU03!-
M8E`X05I6-4$O1E,S87!X5DUB6%9T2W4W:')E,7993&DT4T]/9#19<%5D>$9-
M0UDU0W%K:TLY4&AB;V4R2W).33%Z4F16.68Y)B-X03M&-FAB6"\Q5GI&8R]6
M<&\U=E1K2%9(-$9U3&5X>%9'-'%P6&0U85=6<DQD,VLX9'1A=TM:2C=I6FQJ
M:E)&1E=:,UEH5D%(56Y&5EA&)B-X03M867$W1EA9<7`S1G9$8S(X='9/9VMH
M;5)O-5EZ,%I71D="*UE/2W9K1&YE+VPO-3EV=%!N5FIB,CAZ47IP,VMT,E!+
M3U%6-SA#<D0W)B-X03MS2W983&$U9W5B94\T=#-%:TUQ:#0U1C9&5'5$:%%Q
M67$P>DMQ;&U)0V=62D]W04=+<$MD5'9T5TIJ,%4K;%HW:516,U5-<$A3;'%H
M)B-X03LR:U`O04)99F<X3V4T>%9I.78U<C%85$9G:3!Z>6QF6$5L,6%M-W9R
M;68V=VHO5T52>3A-:VHR-TY*2BLW-&]E:'%!2T1!;6Q.+WI7)B-X03LQ>C%L
M=&]V2TXU3&4P3'I7461Z3D9(>4E6,U513GA$+T%,3F0K=F)I5V)7;60V4F4S
M5C592E!D,G!S<F=T26ML=7A,54UC:E(X;%ER)B-X03M'5U8K4$I4>$914FA1
M9W9/5CE*6F573E%L:5ER4$I(.5AT,DA54S-$0T=-+U$X9T]+=E!L=$5H:5-*
M0E)),4-+4%I245EQ<%!$:7%()B-X03ME3$%Q9SA72V]0:6)886AA,CA!2VU0
M-54O6B]6.'5I;%9+0FQ$2U%63S1)-D5(1D-K,&5+5DYK>%%P<VU+54YE5'A7
M<T1Z>6UI24LP)B-X03LW:SEG4&YI<DLO.$%N1VIY>$PU:B]->'1C=59*='1$
M:DXP-4@R9EAK0FET,"MG8VU(*W!G4UAT;#DK46M&>'%D.7%%5W1V1V(K5RMU
M)B-X03M*<E9R9FYB=DQE,SAD-2LX:CE696%E;D-K17$Q2'%)0CEN1D-H-5`O
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M*V-B8E=7,6ET-$Y9:&I186)(<#`V4U=!:VIE9%5D2DPX27,X9$QL9WEH6$I*
M)B-X03M506<X<3=+=F%C5F1I<G-69&ER<U9E4F9N-RM7,&UU-EEV;4Q3-'5E
M<39B1U)C=V]+=%!B1&9A;E9O.7E0158Y:&A6-'8U1#@X=&]S)B-X03MN,4<O
M3%!P8VAQ<$<U:%EN9&=/-FXY;V934&11.55V3F(P-C%T;W!Z3#8S,6XO95-+
M2#DU2D]4=4)%;RLQ."MG1S5)1RM&54=U;#-U)B-X03MQ<TID84%J=$%A>#91
M:F-O>C1'-6-F,W`O=T%G9D%0.'%G8D97+TU/:6%L<5@Q55=/<5!P9W1M6C(Y
M2E=033!(04AJ2D=/27!U<$)Q)B-X03M$,DY#1E='-G0U5'8Y1'-%=3E7.#58
M=C9/5F]L=E!5:G5P,6,O174O0V0R45!Z*U9E4&9Q17%E:S9.9C9X9E@P9'`U
M,75:2D<Y3S17)B-X03LS0S-C6CE",%8Q9FDX,&)+1V,O-W%)1DMJ86]#2W-T
M.'8K5G12,'I6<FTO=DY9;3%-4WA,1$)(34A(<'%O544O,VI)4S-#<$E18C%W
M)B-X03MO479N;55Z6$]K-F%T84Y*2F54539&3&1/0W%F*V5K-G0O<V-64U-3
M1$979E=&<#5%;%,Q;6<X<6%P93(U5U-/965/2U9L:TI&1C0P)B-X03MM8V-H
M43%+<U!994%60E(V6#51:G-Z4%`U5#%A5EDP8U-3;4]D62MA=E)W>D-904=-
M<54U92]X25-V>$MR0G`S-65Y,D581'EV<E5L)B-X03MY,%5B971(2$E56DA9
M=#8S.3@Q5#9C5#!P4E=O9&PO6E994C5R;#AU,T8U8G1O5F<K;E)*8F]L-41)
M6&%T,$,S<4UV3U-:9W910W`W)B-X03M9<7AL;S)T5TQ)0S%U9#-J07%6+WEK
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M:3ES:WIK>E<V3VMS:DI,0W<K25`X63E6=G1+<#E9+VM&2&,K6$AS:#5P*W91
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M3W%..&4V<U8U)B-X03M6+V90,S<T<6M.+TI09#-C,3%/43`Y=S=3>7-&0V=U
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M<U9D:7)S5F1I)B-X03MR<U9D:7)X9C@Q=GE(6%=*5'$O;%-/0S%V07!.>G`O
M.3)K>D5L=55:<G=2="]S,$-N<C$V;%AG:7EE669,3W)34D@Q=$XQ1T$X2F]8
M)B-X03M"52M.2%)T;5AV=G1I<D\Y0B].=3)F:D1R8T)H9G`Y86="6E!M>6)S
M4#EJ6#59555Z=E1T5S`S56]F5W-,;4\U:F]#5$=W2D9F-6@Q)B-X03M5*WAX
M5D99<71K:U-+3C5*1T-X;T-Z<V5G04938U99>#5C<S57,%-#-FU1<E!F;#<V
M6E0Q5G)P>DYX+S)04&HY1TMO:6$Q.7-646-T)B-X03MT-UEQ:$IB9C)X5D-Y
M45EQ:%I)3593<E5T43`V=T9B=61):C)4<34K4VER67%W,U8O3U5S=%DY4%%W
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M0D="*TQI>'`X63-X=&%:6D0K86YK<59657108DM"44-32&]+9%`S6F9#:6TU
M4'I$.&IS3G12*VHP6B\K<65+)B-X03LP9S5V4"]K>6A+,R]!0U!G25IV-&]-
M5G!+3'(X>69,2TU1:5A%=R]M4TY14"M(6E1J83!K5CDK6G!93W1N64%(.6E3
M5C8O96EG9CA!)B-X03M%<T9P<&IM;RMC3F9V3U%.>#9%6DYE14$T52\R42M0
M+T%)8D<P,'0X=2M2+T](;6EF:&]M;#-&.%=.1VY685)!,3,U>E!X:E@V5W=+
M)B-X03LY=SAK9C@T;WA+63=V>FQF*V]F=$A43$5K3#AP2GE!,WI#2U`Y8D9B
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M2'9"9F%B3W9H-FMY3CEX:7`K3TMO0U@O;D<S.'DQ86EP6GE$*UIB:6<O-%I6
M3TMR62\K8V%V)B-X03MZ3&1Q36QL1TMF86$T,B\T5E=/2W!P8F8X-'%E8T@O
M,W$Q9E0T=CA!:D8V.'8O16\T<T-S:3!R+T%*>$\P;$M(5CEF=4HY.3!T255G
M)B-X03MO4$1L25HO*TDT<3E!.'4O:V8X06QN;U)74T12-#=Y-%=H1GAF13-,
M5DA1.%@O9&=J+TI567%Z;4M+2TM.66]K5T].0E)%54)604A9)B-X03M!67%U
M>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMV.$$O.6L](B\^"B`@("`\
M+W)D9CI!;'0^"B`@(#PO>&UP.E1H=6UB;F%I;',^"B`@(#QD8SIC<F5A=&]R
M/@H@("`@/')D9CI397$^"B`@("`@/')D9CIL:3YR<C$W-C,V,CPO<F1F.FQI
M/@H@("`@/"]R9&8Z4V5Q/@H@("`\+V1C.F-R96%T;W(^"B`@(#QD8SIT:71L
M93X*("`@(#QR9&8Z06QT/@H@("`@(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F
M875L="(^<W0Q,3PO<F1F.FQI/@H@("`@/"]R9&8Z06QT/@H@("`\+V1C.G1I
M=&QE/@H@("`\>&UP5%!G.DUA>%!A9V53:7IE"B`@("!S=$1I;3IW/2(V,3(N
M,#`P,#`P(@H@("`@<W1$:6TZ:#TB-SDR+C`P,#`P,"(*("`@('-T1&EM.G5N
M:70](E!O:6YT<R(O/@H@("`\>&UP5%!G.D9O;G1S/@H@("`@/')D9CI"86<^
M"B`@("`@/')D9CIL:0H@("`@("!S=$9N=#IF;VYT3F%M93TB2&5L=F5T:6-A
M+4)O;&0B"B`@("`@('-T1FYT.F9O;G1&86UI;'D](DAE;'9E=&EC82(*("`@
M("`@<W1&;G0Z9F]N=$9A8V4](D)O;&0B"B`@("`@('-T1FYT.F9O;G14>7!E
M/2)4>7!E(#$B"B`@("`@('-T1FYT.G9E<G-I;VY3=')I;F<](C`P,2XP,#`B
M"B`@("`@('-T1FYT.F-O;7!O<VET93TB1F%L<V4B"B`@("`@('-T1FYT.F9O
M;G1&:6QE3F%M93TB2%9"7U]?7RY01D([($A60E]?7U\N4$9-(B\^"B`@("`@
M/')D9CIL:0H@("`@("!S=$9N=#IF;VYT3F%M93TB2&5L=F5T:6-A+4)O;&1/
M8FQI<75E(@H@("`@("!S=$9N=#IF;VYT1F%M:6QY/2)(96QV971I8V$B"B`@
M("`@('-T1FYT.F9O;G1&86-E/2)";VQD($]B;&EQ=64B"B`@("`@('-T1FYT
M.F9O;G14>7!E/2)4>7!E(#$B"B`@("`@('-T1FYT.G9E<G-I;VY3=')I;F<]
M(C`P,2XP,#`B"B`@("`@('-T1FYT.F-O;7!O<VET93TB1F%L<V4B"B`@("`@
M('-T1FYT.F9O;G1&:6QE3F%M93TB2%9"3U]?7RY01D([($A60D]?7U\N4$9-
M(B\^"B`@("`\+W)D9CI"86<^"B`@(#PO>&UP5%!G.D9O;G1S/@H@("`\>&UP
M5%!G.E!L871E3F%M97,^"B`@("`\<F1F.E-E<3X*("`@("`\<F1F.FQI/D)L
M86-K/"]R9&8Z;&D^"B`@("`\+W)D9CI397$^"B`@(#PO>&UP5%!G.E!L871E
M3F%M97,^"B`@(#QX;7!44&<Z4W=A=&-H1W)O=7!S/@H@("`@/')D9CI397$^
M"B`@("`@/')D9CIL:0H@("`@("!X;7!'.F=R;W5P3F%M93TB1&5F875L="!3
M=V%T8V@@1W)O=7`B"B`@("`@('AM<$<Z9W)O=7!4>7!E/2(P(B\^"B`@("`\
M+W)D9CI397$^"B`@(#PO>&UP5%!G.E-W871C:$=R;W5P<SX*("`@/'AM<$U-
M.DAI<W1O<GD^"B`@("`\<F1F.E-E<3X*("`@("`\<F1F.FQI"B`@("`@('-T
M179T.F%C=&EO;CTB<V%V960B"B`@("`@('-T179T.FEN<W1A;F-E240](GAM
M<"YI:60Z,30X0T$R.#8S.$0T130Q,3@W-S-$,3$Y.41#.3DS-S8B"B`@("`@
M('-T179T.G=H96X](C(P,34M,#,M,C=4,3`Z,#`Z,#<K,#4Z,S`B"B`@("`@
M('-T179T.G-O9G1W87)E06=E;G0](D%D;V)E($EL;'5S=')A=&]R($-3-B`H
M5VEN9&]W<RDB"B`@("`@('-T179T.F-H86YG960](B\B+SX*("`@("`\<F1F
M.FQI"B`@("`@('-T179T.F%C=&EO;CTB<V%V960B"B`@("`@('-T179T.FEN
M<W1A;F-E240](GAM<"YI:60Z0C%&.$$S0SDT1D0T130Q,3DX0C`X.$,Q138X
M.#8T,#4B"B`@("`@('-T179T.G=H96X](C(P,34M,#,M,C=4,3(Z-3@Z,38K
M,#4Z,S`B"B`@("`@('-T179T.G-O9G1W87)E06=E;G0](D%D;V)E($EL;'5S
M=')A=&]R($-3-B`H5VEN9&]W<RDB"B`@("`@('-T179T.F-H86YG960](B\B
M+SX*("`@(#PO<F1F.E-E<3X*("`@/"]X;7!-33I(:7-T;W)Y/@H@("`\>&UP
M34TZ1&5R:79E9$9R;VT*("`@('-T4F5F.FEN<W1A;F-E240](GAM<"YI:60Z
M0C!&.$$S0SDT1D0T130Q,3DX0C`X.$,Q138X.#8T,#4B"B`@("!S=%)E9CID
M;V-U;65N=$E$/2)X;7`N9&ED.D(P1CA!,T,Y-$9$-$4T,3$Y.$(P.#A#,44V
M.#@V-#`U(@H@("`@<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/2)X;7`N9&ED
M.C$T.$-!,C@V,SA$-$4T,3$X-S<S1#$Q.3E$0SDY,S<V(@H@("`@<W12968Z
M<F5N9&ET:6]N0VQA<W,](F1E9F%U;'0B+SX*("`@/$5X=&5N<VES1F]N=%-E
M;G-E.G-L=6<^"B`@("`\<F1F.D)A9SX*("`@("`\<F1F.FQI"B`@("`@($5X
M=&5N<VES1F]N=%-E;G-E.E!O<W138W)I<'1.86UE/2)(96QV971I8V$M0F]L
M9"(O/@H@("`@(#QR9&8Z;&D*("`@("`@17AT96YS:7-&;VYT4V5N<V4Z4&]S
M=%-C<FEP=$YA;64](DAE;'9E=&EC82U";VQD3V)L:7%U92(O/@H@("`@/"]R
M9&8Z0F%G/@H@("`\+T5X=&5N<VES1F]N=%-E;G-E.G-L=6<^"B`@/"]R9&8Z
M1&5S8W)I<'1I;VX^"B`\+W)D9CI21$8^"CPO>#IX;7!M971A/@H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*/#]X<&%C:V5T
M(&5N9#TB=R(_/O_;`$,``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`?_``!$(`2@".`,!$0`"$0$#$0'_Q``?``$``00#`0$!
M````````````"`4&!PD#!`H""P'_Q`!>$```!@$#`00'`PD#!P@&!@L!`@,$
M!08'``@1$@D3(3$4%2)!46%Q%H&1"A<C,D)2H;'!8H+P&"0S-'*RT1DE-U:2
MHN'Q-D158\+3)B=#9)34<W1UDY6EL[7$TM7_Q``9`0$``P$!````````````
M`````0(#!`7_Q``Y$0`"`0($`P8%!`$$`@,!`````0(1(1(Q05$#87&!D:&Q
MT?`3(C+!X01"4O%B%"-RDH*B,[+"TO_:``P#`0`"$0,1`#\`]_&@&@&@&@/#
M?(]K#O@A<"[G=S;GM:<"P^5,%[GLB8]H'9[77`FV]]=<N4FK9%@J_"MVKZMK
M5S,Y(^4BIF0(66B:TJH9.KOCK6EF=5W+1@WP1JE@=&E6=7:V?\3:Y;-U.]'>
MWN^S=MWP]N+C.SGPGLIV\X3RKNDR8XQS0\BY!=Y+S7CAOE$M.4=Y43+6*31<
M=5X)9.R3WHS*1;R53FPDEW<9,-`@A3#&,4VL3DVDJM*B=-,Z]236R;>U;H':
M;NJR;N?W7;5=X$;M*<7JSI[@MK]VHTFXOV(8*LR%GK;S*5$HJKFLXWRK,)0T
MFU0KL(LM%R8+Q[.,(^>L7DG+")1^9)1E'%2TMW:SU7-D7NQ1[0;>5G?*&3\'
M=H!.0[O(E_P#A_?!MH+'56JU`G^3GE0SQA(PY6U:K]>&10JTF]J2+1],$F)Y
M8\A+ED)5<K)+@6XD8JCBK)N+UNO7[$K=J';(X]W?Y$HL1C/;%N7'">5K1=:=
MCG<BE"T2U4!68HZ\DU=N,G5JCW:R9"PE!V!U%+MJE,9,K$&E,J.HXZJ+!LX<
MN&0K*#CFU54JKUOV4?.C9N.T*#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0%KV
M"[TRJ%$]GME<KX`7JXF9J.C3F#CD.A-VY244,;]DI"F,8>`*`B.I2;R3?1$-
MI9LPC.[NL"08G(%S-,N"<\H04/+OP-Q^X\,R0C3\CY</A^(\`(#JZX4WI3JT
M1CCU]\S$LOO[QPW$Q82GW*4,7D`.^]31")Q]PE,E(2JP$'XG;D/\4]67`EJT
MN]^GF5QK8QU(]H/(G$P1.+V3<`YZ3R-J7>";X"9)M!L0+\R@L?\`VM67`WEW
M+[U^P^)R\2SW>_O)YQ'T&HT-L`\\>E-[`\,'P\4IYB`B'^R`?+W:M\".KEX+
M[,C&^7CZE#5WV9I4$1(PHB'R2@Y00#Z=_8%A_$1T^!#>7>O0C'(ZP;Y<W<\]
M%-'Y#`.>/X2H#_'W:GX,.?>,<M_!'<1WW9G2$!4C*"YX]RT),%`?KZ/8VX_@
M(:CX$-Y=Z]"<;Y>^TN)EO^R(F(>L:52W0?M`R&<8"/T%>3DNG[P-J/@1_D_`
M8WR\?4O>,[0A,1*29Q<<H>'4O&6L#C\^EHZ@4_NY>_+YZA\#:7>OR3\3EX_@
MR9#;[\1/Q(25A[I!*#QUJ*QL;(,R<_!5C+*.S<>__,`\/+D?#57P9\GV_@G&
MMF9B@-S>";&)"LLCP;-0_`=W.@]KG08?V3*SK6/;B(#X=1%CD$?U3CJCX<U^
MU]E_*I.*.YDU:]TAN_KT4XN550E+<S/(U.-6L,0D_L\>F#4RCZO,SO"N)IFF
M5\R,=U&IN4"@\:B8X`X2ZZ%BZM`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-
M`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`:B^SO[*W'&TBM9&=9AHV`,O
MY@L^YW+.=:EEA+%T%(W"J0%YE(R4K-?:6RT0![0PD:TX:O5B'C'R;)LY>'6C
MS%.HJ81>4L3M5*B5*[(L7<AV?&["O;P\H;TM@64=NT-8MS&-*OB_=1@;=K2+
ME;<*Y.;4B))6:K=$%\>N4+(A-Q]1(6MKP"J:40_;"_5?/G*,R]8%!26%1DFZ
M.L6G1JN:R[2&:'88[E4]N^\C`RFY'#+(N^C.VW?(N8IJB8R?XPA*WCF@H.)S
M*>.L;TFMH.(F$:O+82(A*$F+A)JYHS!=.UG+)2+U!86^(JQ='\J:577HZOWL
M2,K78BU_;EN]VH;H]G&8+[4S8A9WO'N8H'-N2;UEMS;L,6^M%K\16,?N+,$Z
MTK:U&=/)BR04&Z1+5W,X,0NZ;)ECS`J(?$<DU)*]U2U'OW&!,&]B)N!I&\;!
M.XFZ7_:/55<(Y6L.1K/F[;-BB]8-SSN8AI)S(ND:!EW&54G(;;=5X*:%ZBSN
M+NF55Q(3,:U,BNHZ?2,Q)2(.:PM?,ZJE&ZI/=6KT[3TTZ&8T`T`T`T`T`T`T
M`T`T`T`T`T!PN7+=F@JZ=KHM6R!#*KN'*I$$$4RAR91594Q4TR%#Q,<Y@*`>
M(CH"-MXW;X3I0K-R6,]MDDNH/0*>@66)U!R``,L=5M!]/4'!P3DU52``CW(^
M`&T7"F]*=;>&?@5<TN?3U(CW'?U;WPJH4>GPT`@/40CZ=<.)V0$OCTK)-V_J
MQ@U5\OT:Q9-,OB'4?D!#5<!:MOI;U^Q1S>EO$C!:MP&9;D*I9S(5B%NKU`=C
M%NP@8\Q!_P#LU&,&2/;+$`/``<)JB/')C&-R8=%PX+**ZN[*MMYLQ"HH=4YU
M%3G444,)SJ*&$YSF,/)C',81,8PCXB(B(B/B(ZN0?&@&@&@&@&@&@&@&@&@&
M@,$[G,S,-O6W_+69GYD>:%2Y:5BD'`@"+^S+IEC:E%*"(AP67L[Z(C!'Q$/2
M^0*80Z1K*6&+>R\<EXEH1QSC'=I/IJ^Q'G=WG[II'<L7:DS":<3$'@[9/M6Q
M*S>*+F4,]MT=ANI3N3Y9T'(AZV/D&9G()\YY%1RA7(\5!+W94R<W#^E-YN[]
M^/:;O-]64G#/:![U]OQFI,2[G,O5B.9='HM<=6Q[::<EW8<$XI-P]?U$>"@!
M!ZH4W40I4S=1"E*%G%/0@W`8)_*6=V%(%I'YVQ=C'.<2B)`<2T0#S%%X<`/!
M5%%I&'0GZ8?I``431:T./Y/UD.X`AR"C5P6CIX@W?;=_R@/8!FPT?$W>RVK;
MO:G@I(&8Y8A!&JJ/3]/65I?:JM/0+:/)R/$E;0J!1Z#=X@D(I@I3!+;WY@W-
M5"Z4[(-?86RA6RM7>K2B?>QEEJ$[%V2`D4O#](QF(9T]CG9/$.3(.%`#D/'Q
MU4%S:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`
MT5[DNUZMF*<+]ICN/QCB6IW_`!!L"R=BG;O`.YBQ2\0_RUGB2R!0*GG=D=^R
M:/6T!5,4$R;6X:-%&-DW]ALS*964>,HPK5,PT4*N"K1R3>62O3OH_`J.)^T^
MW-U+=7@/;+OOVI8\P2UW38WRGD'"F4,39Q_.Q!F'#E(4R-=(FZP#BI04Q"(I
M5!([M&7(<Y`D#L8]NQDB.9%[!B'%87*,JX:5JJ9]KU)@U?M4^SPN5+R=D6M[
ML\4R-%PS6*1;\G6H9"390M0ALD.91G1$Y![(1;1-:=M#N'?-8FIL!=VI=P+)
M$84JDK%E>"'"2:6%U>7.A7<4]I=L.S;B+)V=\:;H,8SV*L+MTWF6+0\D)"L&
MQZT<@J$<YM<!;(Z#LT0WFU4%VM<6=0Q$[(_06CX$TB^24;E!QDFDTZO);D?L
MB=M'L4A=K^X/<MB3+M=S4CM\@8V1G\>1WVHH]OD)JS`JG1812,MU0;3\.RNS
MU(S&#M;BMN:VJJ!S>FF*F?@,$JI-4KE]^[59EPH]L9L!@]O^WG/^5\^U+%T1
MN-HZEPJ%:>M[;:+$BI"*GBKZQ5B:S4WL^>+HEL9S%5E;<[@(VN.W\.[79O#-
MN#`&"56DJTL_[ROL9=R]VF.PO`^/<195RKNBQA6*!GMF63P]8TY!_84+]$]V
MS4<34(SJ\=-20P49ZP9)3<X[9-8F!=.D&<T\8.U"HB"C)MI)U6?+O,"9)[5;
M%0WC9'&;;7](W`X[W7;J[-MAL.0H2P236.I,Q4H`LO-/(02Q)VUF=-%E6Z'!
M%THER@NFZ9R3E,Q1$2H.DJVPI.E,ZF;*WVHFP"W;@?\`):K>Z/'$MG,UKDZ&
MWIK<\Z5H_O$,<Z,G3(JYK0R5#E[6T<IG8J5V+L[N8&1#U:FS._$&XB,,J5HZ
M9]FY;8]KGV;1<F0.'3[O,6)9(LEZDL:1U966GT5D+U%3ZU6=5V<D58,D/5W:
MMA;N(F-6LTA$,YEV@L2'<O@2.8H8)4KA=*5[,ZF/-]_:_P"T'9;$YJHSO,F,
MI[=5C3%5AR!7MO\`*SDM'.[!-1U:5LT#3YJRQ\/(P=8GK,P*V7B8&3D$+))-
M7\<M%P[WUE'@Y",)2I1.C:5:9?T=;$_:9Q,[<)-YF9]AG%V)*]L'PEO/N,BA
M;[1,9$I`9/CX.2G$K%6RUH&)<?PJ<L=M$V%B\<S,BZ1(5Q$-RG$0##M5UDXY
M>3K]B1.`NTDV,;I,HS6%MO\`N6QUE#)T#!'LKVJ5]Q*D<N8-`S9-[(03Z2BV
M$19TXM1V@E,IUN0EEX585$99)DJ@N1,'&256FD3>T*C0#0#0#0#0#0%G7/(-
M+QY&C+72QQD`S$#]SZ:OR[>&(`"=./CT05?R"Q0$!%%DV74`/:$H%`1U*BY.
MB5??@0VEF0)R1OU`!<1V+*R!OUDRV2U%'@?,HJLH%HL`_P#O$%W[\!_5!Q&?
MK$UO'@?R?8O4HY[+O]^I!:[Y4R'D=P*]SMDO-D[SO$V*SCT>);GY\#-8=H5O
M&-C!X!UHM"*&``ZSF$`'6RC&.22\^_,S;;S,?ZL!H!H!H!H!H!H!H!H!H!H!
MH!H!H#0=VY>7EE*GA/:W!/#$DLHVL;W<4FY^%D*?43&90Z+M,1X,SDYQX^ED
MAZ1$'-*YZB@'2ICQG],-W5]/?D=/Z=4Q\1_M5%S;]I=II\103:HI-D4P21;I
M)HHIE#@J:21`(F0H?NE(4"A\@U4@RO5,&YJO=)MF2Z1B/)=OQW0RJ'NU[K%&
MLT[3ZD5!N1XX-8[)&1CF(A@;,U$WKGU@\0]&9'*[7[ML/>Z56X)33_9C[V*Y
M!6Z7?X+N[B2I3?%#V:I<+6+38+P6/RY1;1D**D4J]"0+]5)C5(2I23'(3E^L
MR)4+0JUJC_KL`NV#2N);^ZT]\@1T9[9]QDC7J-;8_`>99"KY/DC0V-["RQE=
M'D-?I8K-](^K:;(MX51I9GQF$7*/DFT,J\65:1<FY2(=&/>'1FJW7>"LX[S'
MNAV:Y%E0QS>LJX`R+!/P8VBOM'DU5'Q'S3I,:(NM.D2I,I+N!$@KPMJAWB*:
M@%[]H!R`!32>=P>@3:;^4NY1JIHZL[Q<6L,H0Q!207R;BM&/J=]12`0[UY+4
MIVLVI%E=&Y-P2%>X^;I$`OZ!RIR)Z.&WB#T];6]]VU3>5"EE,`9?K=ME$FA7
M<M1GBQH#(M?)P4%AF:1,E9SZ+5!81;C,-&CR`=*D/ZOEGB72J:C36:!+O4`:
M`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`\=Y=L^;<K]E
M%VT'9\XTI3R\;JZQVBE@EDZ$63@X2:N-2O.=\!YNI61"/[3*0L4C$7#&L1.6
M"(=RDDT4?M8!TW0*H[[ANJ-L24X2=EASST:TYFY/"W9#[7-NL78,NT2FY%NF
MY)?`=LQS6K7F#,5ZRO,4\UKIKV.FZ_1_MM99&!J_KEX\6BW+]@BDNG'.GL<W
MD6T5)2B+P9N;E:R6R27?0UDM.S`W)0?8X=G[C:J[>ZHIN7VF;G<6[J\Q[;9*
M8H4$OG]OCC(^4)*9QK8KJU>O:;+2\[`7*-DFCFP3KZ*.S8GB^HS_`-`:)C3&
ML<FW:2<4[VKK3.QULM;,-VV]JY=HQNINVPMU0J_G;:KAO;G1=HM]SK2:!D[.
M<]CW+%/R5*98F;U1E;15*+;J.6IM&&-/M@J[9SZD7%14V5"LNGBA@K&.&*EE
M)MRHVERI:M=?`LW%>RSM&[[B7M*:7*43/\GC?+>QN5Q%@\F^FP[;+)N_M6;B
M#RRIB.:,;/E9&5Q,QAT'4>Q7R5886#7GY""D(YA'`VGWB(.4:PRM)-X<2C1/
M9Z]"J7[`G:*WI;9^V/M-S_0J;!]FNVVQ2C7!-NVD4+.T5G^I6)_2G57SWN!L
M\A-W2O;5[54X*-R$U@\6V599<+"T7-".+D6:A&XBL4I73>*JJI-4Y*E,6E^\
MPK@G"NY#83?^RLR1:,'8[RWFS'VQS-^VVZ;-+7N2V\8QS7274CFS)%V9YJHK
M*_78T#:JQ,0D^I6K1/5-U+##5DDF6:]&)WS=(2VI8[T3DFI4=,FJ.B*'V9VW
M'-N9\-=G;DC&V+XIY2\,=K]NDRQDU:D3U=^P]#Q\LR8U\DI57<E(1"MHI[&;
M:NH.#7K+&0<.6C(BI&*28&`@F;2<TW=PBN=>>W:5JA[(^TFL^2MEDKE3;7FJ
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M%*/^VW*F&S5&];-6I>M_"I_+SV=F\V6C=U*$?A"5<JY`["_;IM/IY"VF@D&:
MW!TJ,JZ%GQPD*MK(5J^BE6#LBDT_%K5W`HB+.<<%,03!BC\E\N)B=GE7,G/0
M]F6<*MO/['#)+/$1(3'FV789?\,YMFV#^G-6M`NTCB2M04'47;%G,!(RP*6-
M*9;H.*ZRF(=NY4=NU'B2;H7"HKB5)JN<DUG>[J_(WV:%!H!H!H!H"@66TURF
MQ#F>M,S'P40T#],^D7!$$NH0$2(I%'E1RY5X$J#5N15RN?V$4E#B!1E)MT2J
M^0;2S-<V7-]+UR+J%Q#'^@M_;2-<)QL11ZJ'B7O8>%6`[=J7D.I)S+`Y5.F;
M@\6T5*!@WCP=9/L7J9N>UN?O\D`)ZQ3MIDW$S9)B1G)5T;E=_*.UGKDX<B)2
M`HN<XD13Y$J2*?2BB3@B1"$`"ANDE9)+H9E&U(&@&@&@&@&@&@&@&@&@&@&@
M&@&@&@&@/&QNIRO_`)1N^3.>34'/IM2Q\\+B+'Z@&[UMZKJ1UXIX^CU>1`[6
M5EDK#/I#[/Z&SE]GX<K>+B2>BLO??WG7]'"A'67SR[<O"G:BQ#%*8.!#G^8?
M0=6*&Q&A[[8G'NWZB8SB\0R:N4,:XSW"X?J>14LF"SHZ=3W,2,X.1K--8H3I
M"KF9RBC5K%(TFO6D^0&\(SAFE=<R-2EGE;C3!5QJVZTKRVY]09>LO:J(NLG(
MY`IF#92JLD,T9>SL2O/<O$FA3N5SVW5K`&)&24DQQE74BUW`:\/+6JKL%8M=
M[-Q\T6K.)*)7:.K-*Q@M2NE*]M=P5^?[7F25-$/:5A<]+EFN/58%X,?;<?,F
M#.^P6VVT;<,3W&NO*M@BJWP\)B:.N5DN%8J]^ON091K)OV\-"7&N1,:W[Q@Y
M];9WK>X--3ETY>N%W;QPN[=N53KN73E51=PX64,)E%EUU3'4554,(F.HH8QS
M&$1,(B.K@ZQNG@1-P```B(B/```>(B(^X`]X_#0&6.SSWI1NVG?[AW/(P4I;
M:1A1AE^5?Q4,LFV4M5AG\(Y)I%28+R"O4DQ@W%PLL(U<ORHNU&S([V:182)F
M39J;-MR>%9:FKAAX;<OJE2BVNGWTSVR/6ULK_*3<<7EVRI6]2CM\23+IP"#/
M+..6DS-XY4!57I0+:*HNO,6^K]T02D5E(ES;F3A4QG#EE`,TS'+#AM?EJ9'I
MFI%ZI>2ZK"WG'ELKMXIMB9D?P-IJDPPGX"79G$0!Q'RL8NY9.DP.4R:G=+&%
M)4ATE`(J0Y"T!=6@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@
M&@+(C\:X_B;_`&/*L73:Y'9(N-?K]5MMW8Q+-I9;-7:FXE'57B)^602(ZEV=
M>7G)@T*F_47&-+)O4F@I).%"&"NFB+WT!!_?QV@NWSLX,/PF:MQ3BW'K-DO$
M;CZ`AZ'",K':Y:P2,/.3XBTB'TS!(#&QT179-Y*2"K]-%F4K9(>M=XV24%HQ
M<G1=;VU2^Y+*AWFKY+HM*R1391"8IV0JK7+K49A$0!"7KELAV<]`R"'B/)'\
M6_:ND@`1$2*AQSH5=K/-%Q-)&/D$#.F#YF];$471.X:.47*!%FRADG*1ED3G
M3*HW5(=-=,3`9)0IB*`4Q1``(Y[H=V6)-I6W')&Z7([J7G<6XM9Q3VRJ8];1
MEGFU4YBT0E1;IQ3-67C&#M=*6GV/I22LJU%%L5PIR=1,J*@E)R:2S93<W;<]
MHF[NL8]=[D<)XAR[%F2:RN/BY:J5;F9:)5LC)F]49U]W*)K/X]S)H)L_6D;$
MO02D#-&Y72;HK5`Q`3:R;71T,W4JEXSPQ3*QCS'M7I6+<?UY-&`J%,J<1"TZ
MJ1!7*ZRZ,3`046A'Q;4[MVLX<`T8MBJ.G:SA<Q%%U53F$5K=W9=SV3C8QHK(
M24@QCV"'2"[UZ[0:-$1,<J905<KJ)HI]2ABIEZSAR<Q2A[0@&@(]Y>W38WP=
ME+;EC#(#2RQY=T%OGL<XXR$@SB%L<M<E1E=4M%>Q_:)E2;0E8JRY'BF4Y^;P
MC6"DXR=?UZ3BW,E&R"T0VE!*54WM=K6F5>S4DEH0-`-`-`-`-`-`11SGNMIV
M*/2H&#!"W7I,#)FBVZ__`#5"+<<`:>?(B(E63'VAB6@B^-T]#I2.*HDN;2'"
M<[NT=]^GKD5E)+*[\O>QJ<R%D^[91F335SFW$FL4QP9,@'N(J*1.(#Z/%QR8
M@W:)\`4ISE*9RXZ"J.UW"W*@]48J*HE0R;;S+`U8@:`:`:`:`:`:`:`:`:`:
M`:`:`:`:`:`:`B;OESL7;?M4S+E5N[!I/Q=4<PM,.!P!8;O:U$ZW5ED$^0.O
MZMEI-O,.DD^#A'QKQ43)D2.H2DY88-ZTHNKMX9E^'''.,=&[]%=^!Y"\40!J
M_2(A)8H@]DB&FI`Q^>\,XD@*LF"O5R;O4F@-4%.H>>M(PCP(\!A%42[SHXDL
M4WLK+L_-7VF1M6*$BMHCVOQ>Z3;Y+VIA4Y:OPN7Z#-R<1>[!$U2ES",+8V$H
M2'M5DGV$I`0L!++-$H^5D)U@XA&[-RL>7*6.])4)#R?OT!MCR]F+#-.NUJQ_
M<*A2[PTROMO@;5F!VYM^W&Q3^!):/B\L5^6Q*UN>&L,05(R-:E$9NHWW%BM,
M;X]F*YF&?H0W^5LD#3Y&%2II79NF=ZTW=KV>F>H-:N^;$5/Q9EELYIN7Z/EM
MG?(R1M3E2@LJI'UVJ@G9YR`B8J`8T[(&2(]I2)*"AXR?QTA.2\#=TZ3)0I;A
M1JK)=+=S:.5*-4WK>O7GF"%FK`CWDNYR$[)%QO3!%P_>J"VFGB!^"(DX$5V`
M+%Y!-)),#'E5P'A-,IFGM'%PF&<G5X5V^GJ;<."2^)/)9+?G3R]#)M*IT?2X
M9.-9@55RITJR3X2]*CYUT\"<?,2()<BFV1Y$$D_$1,JHJHI:*HN>IG.3FZOL
M6R]YEUB3WA^'^/+_`!Y:L5)D[/\`?WNAV-VPMAP/D-]&0CMZB[L^-9_OIS&=
MR!/NR'+/U19PD@1XJ@F5L2PP:\/:&;?J183C5,ZA3PXIY]X/;;V=_;3;;]\8
M0V/K&HA@_<2Z23;_`)M;/*)*P5T?E*`+*8QMJR;1M.JK#PL2JR:,;;$0,NFQ
M8SK&/<S)LG%KFMP;EM5`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`
MT`T`T`T!Y6^TM9[AMZ/:G4O!V#-M4#N?QGL9V[7:5RK1+_DMMARA262MW=*E
MJ.)7-LDJ_8F,U+5?&;V`FZS'H,'#AG+N9Q8QVB;-R1Z-8TC!MRPN35**KI&^
M5M?>9KU8GR1D_LU]@>Q3</6+='Y4V:=N1MUVCY9CHQY-M)<,;-CY@2K]CK]N
MKIVJ[>O1M>GI"DU>Z5U^U(DVI;29C7R0JLGJT/3K]F6=%.4EE*#DNK7G6_:7
MWN#HU-V7N/R@?`V)<*7%':VT<]F>6!Q13[=DVHXYJ*>4J:G(Y7NTC.58LW<6
ME"-)"FME1C45"O+!!)MJ<]=Q\&=+T"=_>B";D^&VUB^:[HW;+.FN6SN0REH%
ME#;>^W!I.(?S>O<47+;/LMN]'A]M^*\RXMV_6J6C\VTV&GK)B*F9=LMPM=H0
MCC*&AY_(#:0.RL<N5^\9H-8]1J0PMKPZUKB?U--I<VDJ="<V[6/VJQV[C>DM
MVL%4R+8(FQ;0MN<3V7R_V=R].UK@F%'2&2Z[AI6@M7,-#9?6S0,"N<T^=HLC
M*!(O5W+.`==;H4CBP1P4K5XU;L;K^VEO4M%]3WD??>S#E>V\HN<KSMQ;=FG,
M5>K-'57S7=!@=X;_`"S+JP+3(D5BQJ_O33,$CMX4HT,1>51+/&N+>(6>J(RT
M#-R#`3_-<.E<6Z58TTK:E>SP(=TFO56:[.[83-WR[ITBL4W=OOUER1V[O#61
MLM[-[C.RTS'1T=%;M9?&<P:WU#(T4DW>$H$BK69TLA/S5L60?Q'JR5=B+-TG
M*B3>&.32DO\`C7-;\J$\)6Q3MC["O;4SK&(W6'KU$=IGA2K[68J+L>4+%5;=
M;&^;2R%5O^`?SP]62X+&]A2>W,E(KLRNX>1K..E3MU$VK@K9N*T_W)7JL#;=
MMJ7:M7*_W/2GM3_R7/\`*O[0+\RILFFS9]O,0_Y3Y;E]K_L66R_9&Q?87\V?
MK\`@/5PP?K49S[(B+3T[T7UC_G'<Z&+K2-<KTRWO7\FPG0@:`:`:`X'3IJQ;
M.'KUP@S9M$57+IVZ63;MFS=`AE%EW"ZIB)(HI)E,HJJH8I"$*)C&`H".@-8&
MX7>.\F#/J;B-XM'Q`=XUD[JEUH2,F'B11"O<@56.8B'(#*"!)!R/`LP9(D!9
MWT\/A4O//2.G;Z>>F4IULN\U[F,8YC'.8QSG,)C&,(F,8QAY,8QAY$QC"(B(
MB(B(CR.MRA\Z`:`PMN)RJZPEA7(&3HZ(;V":K4.B6MP#IPHT;3MLG))C7:G"
MN'*)%%D496R2\4P441(98".![HHJ=(:K)X8MY[=6Z+Q+16*265<WLLV^XBMD
M/M&,=U(N7J_5Z)=KSD;%,25P2N$]0U^)MDPIDJNXA;1[606F92P5MN\OMHB6
M<>O:*E'/)R(7-.U6.LD:4BZE7Q%\R2JX]+NJCON]:<BT>$WA;:2DZ5VLY96K
M9:/.SHRYIGM"\'UVTWZG3<+DAE/8YK,I8YQD2`@WSMP>$M%/I4E!Q\1'6AW/
MEEAMEX@8*%6EXB)@;:Z566I\W/LTR.E)^)&K5[<N=/-TV>C87"DTG:C:6=,Z
MNM6J4HJNETLTCN.=^^*4(R?53HV9'UIJDKDIG:,=,*=$N+M7H;$;2NO;[<Y9
M`+06O-:E#HVRNI)/1L1I&3D9((6,BW<TT?QS2/B1OG55JJ7M2KZ7J/A2JKQ5
M4FFW9XLEUL^R^5#Z6W_X,2E440CLCJU%>>"K$R@2HD3QU]I5,/I9P;P8RSB5
M0EO6"U',Y.JF6#,G&RD>[93"D<D+1TZGXD>=-Z6K2M*].SF/A2Y5I6E;TQ8=
M.9T_^4"Q&6'83R]$S<SBS0M(M=H</*`W;FQY2LD2B4+1;A>6ZE@!Q'1-HDO3
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MVR1QX!@V"1@*FW6%,>"&%HA>'"C=<?%1:%<@GR9`YL.*ZN,.U_;PKX'3P%AC
M/B<L,>KS^WB:UU&:8A^B`$Q```"@'"?`>0``![(`'@'2'``'ZNH(*>=,Z8\'
M*(?`?</T'R'0'QH!H!H#!^6,@'@B)5>M=;BV2_0B4K4!44C47(]"9RE+R/K!
MUU`5DD'M)%'TLX%#T<%Z2E2RS\O>AKPX5^:7TJM>=/MOW&0,'[=[^>KVFT5F
M@7*ZJ5J,":R+9:S5IRQ1-*AS%5<`I8):+8O&<#%I@W75<2,HNT;NE6ZRQEA1
M;I@DBL.=*OW0CB3QNWTK)>_:,X#@3.94:JX-A?+!6][BI"=I"XXZN`(W*$B(
M\):5F:JJ,/T6&*C(LQ9*0D(@SQHRCQ!XY62;B"FK56ZMF9EX9,VH[@<15>D7
M*]8NN$56KY!QDU&3`5R=5CHES,SUDKT75;._]6D8UZ\/7-7D'J5.D'*<]ZJ<
M1KX[(J;Y(-$T\@6XIMQW"$LX4A3`^9B7,8F.GPJ)\7W<MG&"F)%"'B9H(`8,
M)7U3*2[EM%1TD#3T-[(N$&+995RJFD95;KO!WX[;CG!RSJ4E6Z+;I>TV:Z7Z
MHU^B5JO6:3R@E.XI2KCFWNC5*+B%9AHA!O+$T8*+E+Z8TE8^5;N6S4T>90RJ
M[*<J7!Z%>S0[>^]8=E(W;UOY=V.T4N.>%K<5FJ39/WF2L<.F:_J]6*RC'F1-
M,W&$CU4S)NYHR"]]A%$7))!&U$522B*.%;Q]]/=`>R"JVNLWFMP=QIE@A[54
M[-&-)JO62OR+66A)N)?HE792,7),55FCUFY1.51%=!4Z9RCX&\]9@K^@&@&@
M&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@+/ON0J#BJI2]^RA>
M*?C>BU\K,\]=;[986GU*$)(R#2(CS2]CL+V.AXTKZ5?L8QF9X\1!U(/6C)`3
MN7**1P+0Q-N$P%GM*=7P7G#$&:$:NI')65;$V2Z7D9*NJRY7IXE.=4I\U,$B
M%)0D;(FCB2`MS/2L'IFP*@U7%-6N0HUFJ'\;;A,"O,;V+,C7->)U\15!Y.QU
MKRDGD.I#CNLOZO*G@K(RG[IZW^SD.Z@)M)2(F$)"2;JQLF0S!V5%T`I:$T=:
M4==J7[B%^XC;_MOWAJX;W'UC>KF;#!Y%F3&6-\P[1]T4-3:OE5C<IAVVBZ:V
M45;W?'%VDWT\K)-X%U!Q`V[U@99JSE3'CVB3$2FU543UHU6G/=$J=JVUS$.S
M7!M-V]X-AY*(Q_2_6[AJ><EW5@L<U,V*9?6&R62RSSX?2I>=GIR2?2+YR8J+
M=(5B,HYHQC&K-DW$-N3J\_:/[EC;+C?-F5=OV5\AGL$R]VTVBRW[&U.&09$H
M(Y%GJ^:L1N0+%!GC%7DS:J/#NYI*ANAE6S&O.[#+2H1[J5+&/8T$Z)K>Q(;0
M@:`:`:`ITO+Q<!%OIJ:?MHR)C&RKQ^_>*E1;-6R)>I1550P@```>!2AR8YQ*
M0A3',4HDFW17;&5V:=MQVYV7RT\<5FL*.H?';5;@K?DR#ZSJHGY3?RX`(&39
M%.4%&$2(B1,0(Z>@H[!%-EU\/A*-W>7@NGKW&,I5MIYD2=:E1H!H!H"Q[_CN
MJY.AXV`N+):1B(NVTR[(,4GKIFBO.T&T15RK)WP-54A>L6EAA8Q^O&N149/O
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MQ]%OLG)V%A86%&IT%:9"`K]GK6&)N+QXM8(TB<DA6D@?,1C$[`/I$1A!IW3J
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M(43'.80*4I2AR8QC#P!2E`!$1$0``#D?#0'BWR1E$VY'=;N#W!]^9W`2=J7I
M>/51$3)!2ZR1M$0JZ"8^PW,]A(N&DG!4>2B^E9(PG.=5113E3Q2E+3)>_P`:
MG9)8(0AK3%+J_P`U.UJQF?)BE,'!@`P?`0Y_Q]=`=!5G[TAY_L&'Q_NC_0?Q
MT!T1`2B(&`0$/,!#@0T!C3)>0FE%B.4N[<ST@4Z<2Q$>0`WZIGSDH#U`U;B(
M<%\#.5NE`@E`554:RE3J:<.#F]DLW]ES]\BQ\84-VR45N=J[QU9Y85'"178=
M2T>DYY$ZJH&#V'[DIN#E`"BT;B#8H)F.NF$1C2[S?OQ)XDT_DC]*\:>:\\S;
MQB3>;1\<;:JWAMS2,N-;C3[QE^U,;!B_-KS%-9N9,SU:DT>8<9)90-;<VF>D
M:I3*S.5JLLV=D8P;J-N$HVFV;J./)Q<W+BVVZZ4RK^,[^AD2JRMVMT-/5NRP
M.),87K'KM>L;A86E6-S>X(]AJLIG`V%JK$S:D]7JA!V2;>8\PYCFV8VB9FQS
MU@O$G]KD)B2NBB$8VAV\8<LM-.M>]ODN0*E`=KE2:5,4B6K.&LG3"+6-VRU"
M[0%[S)'3M<C:;M@K7H%8=8BBTZ"B%4O]BO1666):VV16U&9W&*/Z*T71GY1=
M-@YTSR6_;E3+W48R4[3>`BJ=!XNJU#RJ-'K;_#4&WLELRXG-Y:L^-ZKG.YY_
MS-$VRY,*S$)*2N5;C.55A$MHYDA!5"`IK9HY;61[)/I%5@Z:\M+6OD"Y77:G
M4FVL+G"7O$N36L?=HFS2<U/XOR['T/(#F]W3=K<=T-X1;6U2DS*D-2[T64H=
M$FV\<S]=,V.-X21:N7(&+'MCCM3M5;42^UD#4)>;7+7^YVR\V![*24Y<;)-V
M>7D)J:E+',O)&=DG,F\<2E@G'+V:G)!5=R<SN7EWCN2D5Q.[?.%G*RJAK@VJ
M=E]VMN6^S_M+.FV,\KDC;!/2P*VS&JCD%I.H*/5@%]<,7KO5DT8F:3$QG<E7
M%EV]<MGZ5)Z,9+K-;''5E&O4'O\`,+YIQAN%QI5<O8=M\5>,?7*/+(0<_$JB
M9,X`84G;!^U5*F\BIF+=$583$-(H-I**D$%V3]L@Y1.F&.5F#*.@&@&@&@&@
M&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@-2W;34AME39:WQ&ZRY@?#9
M,F;@=O$$E.[D7%A1Q59'E?R="Y#CZ'-(5N*DW<FK:GU*;M$HAVK"QDF@DZ:.
M[##]XF[*+P=)5HW1/+/)W(6;#*)!Y?R/VE'9FYUQMMZBD,$S>W.0M&<]@%-E
M=G+3*T3?Z_+7N!J5Y_,_9H^>B+51'31]#/(]I;%VSZ/D+-`2+91ND_<S@F5E
M"2K>MI4E1JU;JE\\N?3"?9=[-FVZ_L5JU@VN7!ECR3HF\S(V2\>2MEJ:&3Z0
M>QX3W(O[15X#)>/I>4BT,B4*8-$$B[+7GTPT,]263?&<++LRH.!,I4XC=*U2
MKIG%5H]&<&,I6=V3Y7HU#KM*4WDW%'<UN?7Q%2Z.M0=L&%;?O,M--F<B[M+S
M2BW&:EZ?C/&VUK$`FP1C*&3EIV1G\GWS<-'O$FTG#D<Q8?4G^U4C5MMO"G1)
MZMMW=E9*FQZ,-J^XJG;M=NV(=R-!CYN(J68*9&V^*A[&@@WG8870JMG\/*%:
M+NF2KJ*DVKV/.[8.G4<_!L#V/<N&3A!8XS:<6T\U8S_H0-`-`-`=9X\:1[1T
M_?N4&;)DW6=O';E4B#9JU;IF57<.%E!*FDBBD0RBJAS%(0A1,80`!'0&FO<W
MN.>Y<EU*U6UW#/'40Z'T5/VT%;,]0,)2S$BF/2<&A#`(Q+!4H"B00>.B%>*%
M19]?#X>%5?U/PY>IC*5>GNY$S6I4:`:`:`:`:`:`PCGZ%N,W1$DJ-2Z_>9YG
M8(IZ2-EI1A`3L4T`'3-U:<<6*6CI.(K^3*T1X$M4):5;D8MW;=4BKA$RJ9M5
ME5JR3NL_-;-9HM&E;NB[^]:K<A[A_9Y9J<?91*V:K4!6RX;K&7*KE:>9$C'$
M\ZJMQK-I95"L.9\D1'O;?ZO=V(Q;`L!&D6[GG,]86;)(LF<#44*8+*U<71IT
M7//S+RG7XE&Z2::6E4U>FG+E:IW`VV9CQ'>H28VUMXBO596U(0LPQN-K>7*7
M+3&+;%\/ZSDYF\_:^:&%F*Q3G=8?P57EXRQ-(''V"FD.\B"QEQ;N9PR3K'*M
MTVW7)5NW:VE'9<QCC)-3JWHTJ?RT5-75-USE5736R36AD-`-`-`-`-`-`-`-
M`-`0&[37/'^3[LSRY96+WT.T7"++BZEF(?NW'K^^)KQ3ATR4Y`2/82M!8;&V
M,`&$%8<OA[PSXDL,'SLNW\&O!CCXD5HG5]%?QR[3S$8YJ*M1I%?B3I\.B,2/
M)(O'!RR+_EX[3/[S>CJ*BV*;S[M`@"!0#C6451(UG+%)ONZ:%X:DJ-`-`67>
M[=#TJ!<3,J(*'#E&.9$.!',@],412;(CP(E+X"HNJ)3$01*=02F,!"'AM)%H
MQ<G1?TMR/^.:?)W.84R7=BBH9PH"L!'J%$J12)C_`)L[*@?GNV+0/9C4C<F7
M4`7R@F_1JN*13;Q/L]^7>:SDHKX</_)\]5UWVRT-GVRG!U3S9FI:'R":.7H=
M,H=UR/:(=U=4J-)65E68PJ4=`U^048/E9&4<3\G#NWT&S5AG+^LLK`H6TU-)
MLM8XNTG16SR1@;2+EM+[.VC9)LM>>-'4[79VR[BS1D@QSLV;-L:T+;WM%HF0
M9V<9^AJ3WVDDKCN$FK14\7M)6;E6DO&PY(\75K.<7J=:R:3JM.UMTIW7L"OK
M8#V.9)NN`L/VFK1[>PU3,.P_9H[MN/<CL6B^4)?(V%+%.YVL[ZM0C!)L@RJN
M6):O1B=N(\EYB1F7QF3^;"**UAF:KNU:M9997WYI;>J%&VZ;-=FB%RKR<\T@
M\I.L49RQ9@S/<O+YZK5%J%3?0-=?9`SMG%K%RAQ5O-0;6OJPUBNO1B*D!=&M
M`G)=Z#^4ND4C%G*71-55N=,^EZ\^@..L[;MFN:LOF=2-+KZ3M7&^+,X9B=ES
MO'U"#1R!NILZ5EA:)6,?0[*#B8NGXAJES:-[\FRR'3T*[)Q,0V6E8A-H[@+>
MK+?5I6VYZMY=05`FP?85)T^44+=T*0UN6Y1U0JAD6\9KK*(0V-)_=0AC"H2-
M#4KKNS5RT3%<Q&SD[)D:BY5KM%M46L=U;SVN*JL6R)/,4JJFV5.6M-]-/$&O
M'M#\3;<\.7;'M5P3`V:JS`UJ>=9#K\]=JU=TVP!:9!K1GRKF"M=K>0EHDZTW
M[^U0DN>"(=4L9/P5<C(">C^^M%MJK?3W0&O'5@;+NS9[4RZ]FIDA68DWCBQ[
M>;F^:)Y8QFL_!,%^D"-R7*C).52MF60(AH0"I)E`C6U1J(0$P9+HB)B"K-)J
MKMS^Q*3;HE5\C](>%EF<_#1,['&4-'S48PEF)E4Q25,SDFJ3QL91(1$4U!06
M()TQ$1(;DHCR&L2"IZ`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:
M`:`QEF'#&*-P6/+#B;-N/:IE'&UJ101GZ9<XAK-0<CZ(Y2>L7!FKHANX?1SY
MNW?QDDU,A(1C]NW?,'+=T@DL02FTZIT996W+:GMRVC4MWCW;5ARD8<J,E**3
MDM%TV**S4FYE1%-MZUGI1PHYF)V03:I),T'<P_>KMF:*3-N=)LDFD4')RS;?
M4O3$>&,4X%IY<?X:H-:QM2B3,Y82UFIQR<7$%F[+)+R\_*`U2]CTR6DW*[YZ
MK^LLX5.H;Q'0AMO._P"+&)\A;)-IF6</0&`<G8#QW?L0U:;5LU>I=MAQG6D1
M9W3^5E']G92,@LO-I667D)V==SE@]9C,3JTY-&F'K[UM(`X$J33JG1\B0U4J
ME8HE8K]*I5>A:E3ZG#1M=J]7K<8SA:_7H&':),(J&A8B/1;L8V,CF2"+1DQ:
M()-VS=)-)),A"@`""X-`-`-`-`:L]X^X0TX^=XDISX0A(QQW=RDFRGA+2C<_
M/J%%0@^U'Q:Q0&0$!_SJ23]'X*BQ,9WT\+AT^=]B^YE.5;++S-?>MR@T`T`T
M`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T!YK^V-R:;)^Y/!FV:*7])@\8Q"
M^5[^W2/U('G9W@D''2"?/)5X^`CDU$1`I0%M>_US";A+GXKQ24?XW?A]O,ZN
M%\G"GQ'G)J"^[\?#8A@("`B`@("'F`AP(?4!T*G65;)J\C^J?]X/?_M!Y#_`
M?GH"FJH*)?K!R7W&#Q+_`.'T'CY<Z`H<[.1E;BGLU+N2M6#%(55E#>)C#^JF
MBB3D!5<+J"5)!(OM**G*4//G1NBJ2DVTEFR*<''2N;+6>W61)1M3HE8R$3%&
M,/=.`3.!@9D$.GO`,($5F'@>*ZG2R1$J9`!IFJS=7DO=/R;2:X4<,?K?U/;W
M6W?J2@(0B9"IIE*1,A2D(0A0*0A"@!2E*4H`4I2E``*4```````XUH8&P&F]
MGGES)5-Q38J4[@&3V^5.EVJ=')%JH6/*U#$RYE7(F+\+QD!-R5Q=O['*7]WC
M6?>(1+N"@)U$4^IE#RD,+:<=UQ)>*MRI7S\`5&Q]F?F./PU6\E1$O4Y6ZK1%
M^LM[Q`I9:@PNU5J]0S^&V^/L4)&?:AU*W2&FLC)N&*DPPAX^'2[Z,3AI"QJN
MW)6+$NRU'U509?GM@F>-N#.5S+MPS!UWJCK[H`?PBDM0*%F",QQ@2U-,37B^
M4B)B\BW"0L1E+*ED9D^=4Q99*!CJDB]@[--24JHSB8Q)VDMN:W]Y@L;)_9:9
M,J+,KRLWNI2S\N3LMT";KUTG:/2I.E0F`JS676:,GW^:2O=AJ-:I%/O4R^I9
MG:D^Z6=+!5E0Z9JZPM=,4Z_C?9>]]J@C[D?8?GS$U0OE^O@8W@Z=1)2M1(3R
MF5*.LTOCJY4:M9+JGYJ2(3!W62BSE$N%<L[<E4;R#AG$R!G4LA'IL9(S.V)5
MI?N]??:"&>I!UG;QHP;JNWSE!FU0*)UG#E4B"*10_:.HH8I"A[@Y'Q'P#QT%
M*V5V80G,Q*OG8PF/8E>?DE!$@/SMUA:)_LF40:AT++$)SR+ET9JV2$`.8%TA
MYUG*>W>;1X25^(\*VM5]OVN^AU8S$TQ/NR3>29AQ(N1]HL0V<?HD2B/4*"KA
M'I202Y_6;19$D@,`&*[,(B&H5)/YG?;WY(/BJ*P\-47\GF^?]]R/1#V;W;%9
MRVI9]6FLY7N]9APCDUW#1F58>S3DG99BMHL$$(F(O-$)(.%_5TE5(Q-!DM7(
M\&L78*RS2@1;MW4=6W\-=Q35E1K(Q/T!*;<:MD.IUN]T>?C+33K?"QUBK%CA
M72;V*FX27:IO8Z28.DA$BS9TV6353-X&`#=)RD.4Q0Q!<N@&@&@&@&@&@&@&
M@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@(K;K,W?FGI/JF#=
M`G=[>DX90YDCAWT/'%`$Y&>$`\4U404!K%B;IZGZOI"8*DCW*>M.'#&[_2L^
M?+M*2E2VK\#2R8QCF,8QA,8PB8QC"(F,81Y$QA'D1$1'D1'Q$?$==AD?S0#0
M#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0'0E)./A(R1F99VA'Q40P=R<F
M_<G!-LRCV#=1V]=N%!\"(-FR2BRIQ\"ID,;W:.UWD@>,&&O,AGK,^>=S$RFN
M57*5]E"5I)T`]_'T^-6(W@XT#"(]9(^%;P,*)@-QUP0^`>6N6/S.4GJ[=/=%
MV'1Q_E7#X2_;&K_Y//[OM,D*(IJAP8/'W&#P,'T'^@\A\M6,%)KTT*<JU43Y
M$OME^(![0!\P_J'(?'C0T4T\[/P*:[<MF35P[>K(MFC5%1PY<.#E30002()U
M553G$"D3(0HF.8P@```B.A<A?).I//\`<QCXT7,=CJO."J+K@!DQ=FY,3TD2
M'#@9"0("A&**A1".9"HLHF"IU4E\[S?^*]^]D;-K@1J[\262VW[M7JR4S&(C
MHR/:1;!HDT8L4"-VJ")>DJ*1`\`*/B8QC#R=0YQ,=50QE%!,<QC#H<>.3;DW
M=NK.-5H=/D2^V7Y?K`'S#W_4/J(!H7C-/.S\S97'[CM\]><8HA4<)RR"F+`V
M\9PI<$ZPK=2G>5C:74)JK8MMTFR-W;J8Q_#A:YZU6&6#HA9&V3;J;</VX*)-
MB5I&]]]5F_OH7,;1V_+<=49.NS;J/JIG2=$P?5XLU@J3X4)NE80S&VSA5NL%
M9)MZSC[7E>&^T-Y<H']%L[U)ZV3]"(99,&%>?BJ4[L@5@>TGS\,'!Q@5_$)9
MJ%ABU,]\^PBA[W,4-WE)SF>S4*7FU9M1%2L7G(CZ0FKF5BP83,RVDY.$]<MX
M*2?1R[`N=-M`=-'M&\\"4R,[6\176/DHO/D%<XBW4V1?L,B0FXW*T1FR_1MP
M]#LD<Z6!KDB"B9ZMR,(Z@YJ.*Q;1SR4DHU!)J1A7/3;146@,$9\W<YAW"P$-
M`9/D*\$/6KG;KZQ1@X)I6FC>0L]3QQ0TF(M&!THMM7:=0\34>G4F*:,VK>O5
MV(%H0[@SA98TI)>0-?UFS)%LE_5-3:J6B:4,**7HI55(\JWB`%(=$!7D#!Y@
MFR+W1R\\.R"`AJKFEE=^!K'A-WE\L=:Y_CM[BWFF.;E>7"4ID6879LP,"J$"
MS,0#IE'R+W1.IDPY*(%%3I=O3EY(N9-0.H,VV\RSG&"IPU5_R?;[6AF^#KL+
M6V@,H2/;L$/#K%(HBLN8H<`HY<'$R[A3C]M90X@'LEX*``$&+DY.K=??@5K0
M@^!(`^7@/\-74VL[KQ!Z9.P([3I;#-WC-E&;I\X8FR3.]WA:PRKH1;8[R1-N
MA$:>HLN;AK4\AR*P`Q3(8&\/>'":X-RH6J9D&25)76>JU]KN![9]4`T`T`T`
MT`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T!3Y:5CX.+D9
MJ5<ILHR)8NI*0=JCPFV9,D#N7*Y^.1Z4D4SG$``3#QP4!$0#17LLV,KLT&Y@
MR5)98O\`.W)^*J;=VOZ+"L5#<^JX%H8Y(QB4`$2%4*D)G#P4^"+/W#MP`!WP
MAKNA'!%+O>[]V,&ZNIC'5B!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H
M!H#6#VNV<E<-[,[K"Q#DZ5NS6^98>KJ*!Q]*.SLJ;AQ<%2(D'OCHGI[":B15
M()2HOIB.`YA,JFDKGQ94@_\`*WKX>9MP(J7$3>4:R>ULJ]MS170JHA3J57*L
M4A!&*BVZ+L2\=*DBJ`N9-<HE\@7D%G*Q1`1$`.`=0\<CDE1)&<Y8YREN_#)>
M%"X%69@Y%+V@_='CJ#Z#X`/\!^HZDJ=$?#GGPX\^?#CZ\^6@(49,M\GF&UDQ
MC0%`]0M5NNQSB0B+1YZ,J7OE3'3,!5(I@IP5``,'K20[ONQ,B1LJ?-O$\*RU
M?OW4[>%'X4/B3NVOECJK97U?<D9WJ]6BZ;"M(&)0[ENV+U**'`._>.3@'?O'
M)P`.\77,4!,(>R0A2(I`1%),A;I)*B.6<I2DW+/RY%P:DH712)J.KETJ-AF(
MTLS$0-H@)J4B#%3,65CHN5:/GT:8JWZ$Q7S9!5J)5?T8@KPI[/.@-YFX/M"L
M<)YEI=TP?E>#<#:,B9GMN2K%'4[,,G7:I09O)E)RCAY6*I&9%'B+?<Q7).L2
M[NR3-/8HXKF["I3(J;DK#5HQTYC<\-NZG-\Z:>-,MC3']ZY]BZ[Z>9K/W<36
MV.XUK%%XPY+6`V3IV'C6^3*FY5GUX*C1L-0Z+%1%/:$FZ?7H^/;T^?:VFFT9
M.JV._LY;%E?I<U:YB*O#J<CE;*J;KEI[\\KY*A923R(-ZL6,1W#,=8K)CL6!
MAL4UU=T5C&J%,W26$>DI'3XI5$B&ZO8%%L1TX*<.A1)/GJ"KFEE<TCPI2O\`
M2LZO;E[1CH*QDK**A'5O?&K%<,8JB4,@F9)90G(&+PP,<3]?A_K$LJ=5(P]:
M+4R8@4*TE+.RV_'J:8N'P_I6*6];>^BRU,S5BE5RHH=U"QZ:2QB@5=^MPO(.
M?CWSHP=0$$0ZNY1!)N4WB1$HZNDED8RG*6;[-"Z1(`_(=0X)\F5.(0$//633
M68/YJ`-`?1#G2.15(YDU$SE434(82'34(8#$.0Y1`Q3D,`&*8H@)3``@("&@
M/T*^Q1[0<=[.VA&K9!FP?;A,$H1=4R*=XL`R5TKJB*B--R5TF$3N7$RT9K1%
MI7*910+5$OI)PFS;3\2B<#<WH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH!H!H!H!H!H!H!H!H!H"!V^C)QH"GQ6-XQQW<C<E/6$UW9N%$:W&KE%)$_`@
M<I9:5(0I3%$2J(1;]NH`D6X';@QJ\6BRZ_@SF]-\_?O(U0:ZC,:`:`:`:`:`
M:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`\R?:@Y&'-V^G'N%V"_I=2VTU'[46
M1`INI`;Y;2QDVHFIP/<+"UC0H214U.M5!3UVW`I!%<NL)_/Q$E?`JOK]]/$Z
M(_[?`E+7B/"NBK5__;P,,J-@'D2>R/O*/E\_F'T\OIJ#G.F8IBCP8!`?G_3W
M#]V@(?YXR=(RLHGB#'8&>V.54!E//V9^!8I*E$5HE)P0>E)04>I29=&,"<>S
M*H@8P+'<^B9R;^E=OOS_`+.G@\-)?%XEHJ\4]7O3R6KY9WSCG&L?CB`3CFO=
MNI)T":\U*%(('>NP*/!"=0=9&37J.FS1\`*43K*!WZZQC6BJ+GJ0^+\25[;+
MEZ[^BM?9B%.'!@`?YA]!\PU8AI/,Z2C8Q?$GM!\/V@_X_=X_+0S<'I?EL=;0
MH-`8SNV6*A2"J(/7GK"6*40+#1HD7=@;CP!V?J!!B3Q`3>DG*L)!$Z*"W'3J
MKDESZ&L.#/B9*D?Y/+LW[#!R@Y2RX83&`*13W'DF7OB*O&YOB412>R?64>?:
M%A%JEX$I1.7QK\TN2]]_D=*^'PJ?ODM:V3\K=K,IU+&=6IY"*,6GI<F!?;EG
MX$7>=0A[7HX=(),R#X@!6Q"'$H@59580ZM644NNY27$E//+99%]B`AYZL4/Y
MH!H!H#C$GP_#6;AMW`XQ`0\]9M-9@:`G5V<6\6;V.[LL;YK;.'9J89Z6GY;A
MFW>*>OL761TT0LR(-4Q*+N0A!19VR!0ZB%4L%?BTU3>CG7(<#],R&F(JQ0\5
M8(*0:2\).QK&8AI6/73<L).*DVJ3V/D&3E(3).&CUHNBY;+IF,FJBH10@B4P
M#H"I:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`T+
M[@[\;)&6[?84U^^BT9`\)`B!NI((6%$S%HJCY]*;\Z:TH8O/@L_5\N>`[>''
M#!+>[ZOW3L,&ZNIA?5R!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H"
MU[O<(/'M,MM]L[H&5<I5:G+9/O!Z?\VAJ]&.I:27`#&*43)LVBQBE$Q>HP`7
MD.=0VDFWDKDI-M)9MI+JSQ]8/?SF3I7*VX:WE,%HS?D.Q6@_48RI&T8,J^51
M9M3'`IB,VK]T^CVR1`*F1E&L2$*!$B$)S\-M5D\Y/PKIVU78;\=I./#64%XO
MWD9V6;B'ZY?H8/\`C_0?PUO\L^OB<Y%S<'F(:*R2J%6'T^_V$B:+)%L3TA:&
M;NS]PD],@0#F/).CB*40TZ3"90?2U2F2320=X<1X+)U;\.OV-^#PL?S2M!5O
MO3[+7N*)AG#Y:)%J3,V(.[M-D%:5=*G](,P26,"PQJ+@1.)U14'O9)T4QO2G
M0`4#J(H(J&B,:7>;'&XOQ'16@LN?-_9&9S$,0>#`(?R'Z#Y#JQ@=91`A_$/9
M-\0#P'ZA_4/'ZZ%E)KF=(Z1TQ]H/#XAX@/W_`/'@=#523R,?W6_T^DMQ5L$F
MFD[,GUMXQITN99T'CT]TS*8!(F80$H.'1F[4!#I%<IN`U#:7H2N&^)DJ\\J=
MN7NQ'5:VY3RT<[:HLCT^JG,9-2965.BX<)@(E-_S@4@+',(!XMX=+]$<12<O
M#)CU:I64LK+?\^G::KA\/A?7\\]M%V9=_<7G4\.UNJ'(\>)C/3(&[P9*13*=
M%-;GJ$[-D(J)(FZN#E57,X=%,`F(N0!$NK1BES?O(B7$E*V2V7KF93U8S+MH
ME#N63K;"4/'U:EK?<+&Y4:PM>@VAWDB_50;+O71DTB>";9BP:NI"0>+F29QT
M<T=/WR[=FV7739`E6R[/K<^[BK7WN/)-O=Z[?J%CV+Q:1LXDKO=Y*^8LO^:D
M9:FHQ*3^%F*[!XRQ\]MDM+IRY6RD=,0:D6,@+I4$*XEOSZ`KE7[,[=_;([)G
MH6*9II;L;/<1,QQ\[1,-EN)<T1MMFJD^IB[?OZ_,1XPU-DWJ[HLT0BZ[F,B8
MT'TP^28:8E;GJ".D_MISU5<5Q^;;)BRV0F+9-U%M&ENDF)6K033BTNW@G+AB
MHJ$LQC)YQ`32$%+OH]O%3*\8\2C'CI1$Q0FJK2MP7&PV=[H96K4*Z1>#<@R=
M=R?-UNNT-W'PIWKJQRMR:R;ZH)-8AL=690;6MA"R\A6Y)]'M8R=CXUZ_BWCI
MHW46*JKWRS!=:6P/>2M;DJ*EM[R`>SKUN-MZ#`&C#T=:M3EAEJI7)=&7%^$,
MJUM=B@IB(I_1(&4M[N.<EK2<J4G4,8H[^^F8+7+LUW2*4!;*(X+R"G0VY1,M
M/N(4[<A"$OSC%K@_J]=1.7$K'(352I29B,#!&3!FS>0]&*\:'7-Q=G3WS!>M
MGV!;F8J?M3"KX[L%[K%9R2OBTEYC(>2K\-,6)OD1MB-5TRBKDWKUJ;0".3W2
M5">3\I!,8J,M0FA)5TQDB*-29-4UYTUH\O?VN#`&<</6O;]EW(>%;RO!NK=C
M2T2-3GW5:D32\`YD(U0"*.(B2.V9JNV*Q1*J@HNS:.`(8".&K=<JB)(![@OR
M>K=LIGO9NKA6S21GM]VNRK*EE%PMWKM[BVPD?26-79Q,(#W<,5C8:0V02)W;
M6)JD.*BAE76@-^.@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@
M&@&@&@,2YVN!J)B*^65)7N7C:!<,8Q0#<'3E9DR<-&JIAYF,@]?HN!*7QZ$C
M"(@4#&"T%645SOTS963HF:"==QB-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-
M`-`-`-`-`:A.V?S*\HVUR.P_6EQ"Z[C[I$X^C6J2G=NSUF.=,YBTKHB'(F1<
MN0KM8>D`INMI:%2^&LN,_E45G)I4]\Z+M-^`ECQ/*$7)_;U[#695JFUIU6K]
M78E*=E`1#&,34`O2*HM&Y$E7*@>8*NE@4<+&Y]I14YA'D1U=16%1T2]LRE)R
MDY/-NIB?.>7HG#]7,].*#ZR2I5F];A5#>+AP4H`H_>%(('+%L.LAW)@$AG"A
MDF:1R'7%9++B4A=.[R6I?A<)\25,HKZG]NK_`"1YP;BF34>.,LY(%9_<K"=1
M_'(/R_IXM%V7_7W"0E*"$@X0$J31J0A"14=T-RIIJ*"@TSBJ_-*[=_S[R\M.
M-Q5_\<+0C9TUIIT\V2<4;F+XE]HO_>#[O?\`=^&KG,=8Q0,'!@Y#X#H"R[=:
MJS26`R5BF6D8W$#=RBL?K>.S%#D4F3-(#N7:GQ*BD;NP]I0Q2`8P0VEF6C"4
MW2*;\EU>1%J6S#D')2Z\1BN"<1$3UB@ZLT@1,%RE,'B(KF!5A&")!$W<HC(2
M1B@55L9(X"0*8G*T5VOWZG5'@\/AWXC4I6:BGEV5J]-D5"J8/A8YQZXMSI6W
MSRQ_2%U'QE5(\K@1Y,<R2YCK2*G/(&6D#G34``-Z(D<`XE02N[OP_),N*VJ1
M6&.RS_'9WF<"$(F0J:9"IID*!"$(4"D(0H<%*4I0`I2E```"@```!P`<:N9'
MT(`(<"'(#Y@/B&@.HHV`?%,>!_='R'Z#[OOY^H:`SKMLS>QV]9'=7^0QS`Y(
M5/3+?5XR/G7!&:M;D[3$*Q#>Z5YXM&S31I9J^FNNI$NW40_*V,NLLU*TDB,I
M)E#552M`;+('M5(*W/\`,T]EW%K-(D[2,H'JM3KMBM)E+/;,F8>P7M1;5I>V
MBIZUJ$+1]OM-R4X@;$!Y23^T=K<^E)2!W2HN*N+5*<K[*K?;GX=PPP':B7=K
M,8I=0N):9!U_"61JU><:U5G-V!PQ@H_&.%$<.83K;A_('=R4L;&ZBM@OZD^_
M<*R-EN-KG5UR1C%=!J@PYWNU=]M7WY`QQG??B^S%M[C-NL#B*K8LJ;>=P]8I
M52K3+Y9O)/\`$>-K%C]N@A$&8,VS5G97UC?WN<</5Y>Q/[<X=O)>P3"1HY**
ME1HVZY^M?=D"7.(^U%J;B4I=$LN.JA@S$E?1D7[]M6HJTW&$DY`FV>\[<F]<
M2AZO,4>>I,7*0V0;7/H7B!<6JZ0=OF%)B81NJ8E*RC"[WK7UKT?@@6ID?M-<
M=1\^TI>-,!P%SPIB1YMKFMOK6X35UJJT!>-MM(LD)$6&R0\79Y>2MM'F+G>K
MM;V]%L=H4D0"1;GE+#Z8^F6RQ1>]W6NU\Z;`Q)%=IU?F]N97&?QM6+1(ITW;
M[1Y<KZ8DFA)V'PSGMEN6MR;OT1L4K<N:<M,QF[D@T3219-7;MBP*H54%2L%J
M5>OBJ>^WL%Q,>U2M+>E8WJ<EA&DVA:E9>I68)9[<+)9;8SD;#5<QN,US:]):
M6'UE+8J?9+M"ZC;(GV4L8U>7CG4LG&T^'4FI,[A@Y\O"F_;YUS!K1R):QO\`
M?[S>E&1XU2ZW"S6T\>H_6E56!['-/9@S-24<II.)([47@H'?N$DUG@D%PJF1
M10Q0EQ37.F8-LW8/;CEL`]H-CNNR$@+2F[@F$AA.Q)'5X;&F9\R,ECQR"!A!
M,[\U\BH.!;+\@J@SL4F1$Q@<*(K9N+73<'Z%>J@:`:`:`:`:`:`:`:`:`:`:
M`:`:`:`:`:`:`:`:`:`:`:`:`:`:`@IOWL1F&-JM6TE.A2Q6KTM8H#_I6,#'
MKG53$/>4'TC&J\^XR1?CK;@+YF]EXOVS/B:+W[N:FM=1F-`-`-`-`-`-`-`-
M`-`-`-`-`-`-`-`-`-`-`-`-`-`>8K>M>3;B>T>=P+17TZB;3:>A`)D(/>L%
M\@S`!(3:P`/(D?MI.10BUR\$#TB@!P4P`)E>>59\2U\'.E_[\N_I_P#C_3\^
M*_#^EXECY3R#7,45*0MM@7Z4FX"A'QI#E!Y,RBA3BUC&)3<CWJPD,9502F3:
MMDUG2W"2)]6^)A7S7VZ[&,(2XDE%=KT2W?NY`S%5(L.9KBMG'*2/>,5''748
M!5,P,3I-53^AG2;*@(!!19NH&29@,:5D.^?NC*%[TS_%5FW*7=[T1T<6<>''
MX7#S_<[=O:]<J$T%&Y3^)?8-\O(?J'N^H?@.M#D+:GYR&JL>M*V*391$<B'M
MNWRY$4A-P(@DEU#UKKGX$$VZ)5%U3>RFF8P@`FTLR5%R=(JK(CV?<//7!^K7
M,+UMU(.1'H5LS]J`$1(81*#ANR7$K5FESXIO9M0H#XIFCRGZ1UFY-VBNWW]S
MI7`C!8N-)+_%.[[=>SO*;7L$J2+_`.TF4IQW;)M82J'8BZ<'8I"`]1$G#LXD
M<NDTN>"-FY63)(`%($UT>`U*AK)U?OWH1+]118>%%06]%7NR7B2%9L64>U28
ML6C9FR0(":#1J@F@V23#R(FBD4J9"^_@I0#GQ\]7.=R;=6VWO6YQJLP'D4AZ
M1_=']7[A\P^@\A]-"ZGO^?,IYB&(/!BB4?@/]/C]0T+IIY,^="1H#Y,0IPX,
M`#_,/H/F&@.DHV,7Q)[0?#]K_@/W<#\M`=;0&U;:7G'#L)MP@<?9J5QPC6ZO
MV@^R[(4]`_9*KH7>WX<A1S<ZR^]L3Z.B2VS(5>@&,I%QB;2>=S36OHSJ47#H
M,TIA9!Q5IU?.+[[6Y`F1E/>5"4>UTFHS][PKF>YWW'^;(?/N88BY-+8UB\5I
MY7S#9,85%.S5&890&1U$L3V!V,5@V=?/HJ2EQQ#2IEG%OJLRAF5,/54I2VM+
M]+I7R!K!WJ53##5WC+(.*LMQE\?9$K3=:<I,4M#.V>+X&OU#'[:DP3(\4^=R
M,/&1C=_-8W8U>\I-,AMOS6+VNR)&;72'4->-;VI]]W[Z:`@R)1#Z?'5@?.@&
M@+BJ-IFJ-;*Q=JV[,PL5/L4+:8%\7GJ9S5?DFTM%NR\"4>IN^:(+!P8H\D\!
M`?'0'ZKN)<A167,5XTRM!`!87)E`IV0(@H*`J!(VXUZ.L3$G>!P!Q(VD4BB8
M`#D0$>`\M<X,@Z`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:
M`:`U9]H%*F6MV/83JY+'UN5E0)S^J:8DTVAC<?V@@RAS_8^6NG@92?->']F4
M\UT-?>MR@T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T!C'-.4(7"F),
MD9:L(E&(QW39^V.4#*`F9\I$1R[IG%(&'_UN7?$;1;,GFH[=HIAXF#42>%-[
M*I,8N4E%9MI'E(VZNR5C$UYW!95EB-9O*EGL63;;.O"F*JY1>R3LS7]%[2KA
M>4DW,G(QR"(JKNU)Q!!$BBJA"CEPZ1@YMYNK['YMOQ1OQOFXD>'#]J4$N?XU
M=LB,\6SLN[W)*UYM#9W&8CJ3H[.#A!.8@/`(<BOJ\ITQ`JCU\4J+JRR*)C&0
M1%O&-52E*V5;9_-Q7BI\JM3WX]>AI)Q_3PPQ=>)+-[<^2V6N9.%VK#0<495X
MK'0\+%M2%%5=1O'QT<S;D*FF'>'%)NT;HIE*F0.2)D*!2%``X#5CDO)T56V^
MK;9#R\[GVJTB:KX<A75UG5A.D24.T<C%(F#V3JLV:8)O9(B(\B=RMZO8)`!5
M@6=H<\T<[TC=G3#]/;%Q7A6U57OR5>UE@QV%K=?)).S9JLSV2<<B=&NLW1>[
M:D,(&%L==OTL8Y#D.%6D*B`'\%/3RJ]7)1;O)]GO[=YI\2,%AX2HM]^=\^TD
M-%5J'K[%..@(YI%LDOU6K5(J9#&X`!44,'*BJQ^`ZUEC**J#XG.(^.KI)9'/
M-.3JVV^;\MCLF*8H\&#@?A_CS^H:&-&LU0^=`-`?!TR*!TG*`A_$/F`^8?=H
M2FUDRGJLS%\4_;+^[^T'_P#M]W`_+0T4T\[>_`Z6A<:`:`XE$B*>8<#^\'G_
M`./WZ`Z2B)T_']8O[P?U#W?R^>@.'0#0#0'P)`'R\!_AH#C$!#ST!_-`?HR=
MB1DE3)?9G;;';MT+F4IL7;L;2(&,)Q;)T:\V.%K[7J$>>$Z@E7#E+P`)D4*F
M4.DA1'&7U,&US50-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-
M`-`:@M][@5LS1:0CR#6@PB`!\.N9L;D?Q%QS^&NK@?0_^3\D8S^KI_9"S6Q4
M:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`TE=MIEI9CAW%^VN$E$(Z
M;W!7YD:P+K+D2;1^/J,[CY.1>2AQ.F5FP"RO*U(G=.5$VPL8&9ZA$B"QT<>,
M[*/\G?HM?[V.C].KRFU50C;J\J=E>]&A^SS$ANDN$1BR@+.*]M\Q.S8-%98Y
M?1DGC*':^KV\PZ[TI$_2WC5LHVKC%R3EFS]*EGB"9CO&Z&26.6%.D(WKI16K
M3>F5?4U27`BYROQ9Y+9O3UW=EN7U9]Q^.<7QS#'>(H<ESE(U(L5%,8,5%8!L
ML`B'MR+<JSB=>++&,Y6]6%<B_7.N=Q)HN3G,.CXL8+#"].[\]AFN#/B-SXCP
MJM757[M%HMMC&`8KR]FEXE/9EL:\'#=X#AE3XT2(G2*//24C!,5F$6?NS=/I
M3X9.8$.4794S`!BY4E*\K+96\,EYEOB\+A6X<:O63U\F_!9-5)!U>CUJC,O5
MM<AFT6F(%!=4A!4>/#$\E'CY43N79N1$2BJJ8B?(E1*F3@H722R15R<[MU][
M:="X5$2*>/'!OW@_J'D/\_GJ2#I*(G3\PY+^\'E]_O#[_N$=`<!B%.'!@Y#^
M7S`?=H0TGFCIJ-C!XD]H/A^T'_'^`_(=#-PIE?S.KH4&@&@.%5!-7]8.#>XP
M>`_?\?O^[C0LI-=-BFJME$N1_6)^\`>7^T'B(?Q#YZ&BDGR>QU]"PT`T!UU&
MY3^)?9-_W1^H>[ZA^&@.D=,Y!X,''P'W#]!_IY_$-`?&@&@&@.,2?#\/\?X^
M>@/<U^31V=26V+Y)KJYQ,I4MRMP0:DY$>[C)K'V,99$.!_5ZI-67/P'@///F
M(\Y3^KJOP#T1:H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H
M!H#3KOE%,<VD`ARG,6FP`*E`?%)3TF6,!#_`PI&24`/W5"C[]=7`^A_\GY(Q
MG]1#G6Q4:`:`:`:`:`:`:`:`:`:`LV>R-CZJ]?VGO=-KG=\]YZ^L\)#]WQY]
M?K!\WZ>/?U<<:BJW7>2DWDF^B,*S^]7:!6>LLUN?P*V63Y[QJCE6E2#XG'GU
M1\;,NWH>/(``M_$0$`Y$!U&.'\H]Z?D67#XCRA+_`*OT,*SW:I[`:YU^G;CJ
MV[,3D.F!K5_L_6(>0$/7:E*)FY'P`W6!/>)P+XZK\6'\O!OR1;X'%?['WI>;
M,*SW;:[$H?K]7V3(UJZ.>GU#CF6;][QY='VG7KG'5[N\[O\`M<:CXT.?<67Z
M;B[)=7Z5,*SW;\[8VO66MXCSG-'+R!32S*AU]!00\A*=M=9]8""/D)VQ3\>(
MI@/AJ/CQT4O!?=EE^EXFKBNUO[&(7_Y0$217,QHFTF<G'1_!`7^4@37\1X*)
MHN'QQ+**\CX=)'Q/'R..J_'_`,?'\%O]+OQ$NSU:.C_RN._^Y?\`1CL.?.^]
M_P!7$:#FF]![7ZHB-?:UT%0^9!3`?/PT^+-Y0OT;'P.$OJXJ[XKS;'^5KVX-
M[_\`1[:VQIO??Z/G$<C7NZZO+_I.N3ON^/\`[QSQ^UICXS_;3_Q];C!^F6<V
M^VO_`-4/4_Y01>?!W+,:,Q7_`%2^E[9H?NBF\Q[R$;R]A2X\NE93O`XY`O(B
M(O\`??+_`*KRN*_I5HW_`-_O3R.I(;*^V4LC%Y*WK>K%T"(9M7#Z7>+YZR#6
M6\>P;I&7>.7*E%IZ48W;-T"'5<*+/FS5)$BAU%BI@(Z8.,\YTI_DUY(?$_3J
MB7";>GRKNNZ^#-&6XA.Q&O4FV>Y]EMS1ZF@G$2^4&[^[V"KM7#Q=T0T5!6:Y
MG]9R46JL#HB<B#./B95<7"D0:3:&!ZKC+/ZL6[OGU9U0I3Z%"N4;)VY+O+5K
M-G3FHAI2;'>@H&/V9RN'T5"1$L\<6!\?I%P_D$X]!7UJ^6[HA>_FGYFL<4J"
M<7'$;(@V*3T;HN6OOGD1)4>)0QRT;:27)5R[%?5U):T3(.UG'30J5;ECIOS)
M@FYG'M>LCR:=\@'6"KPT*`(IGX`3M6*;5H)@`P(=7)ANG!9?<YI\/]1Q/JI3
M1)I)=GW=7S,@_P"4EA;_`*YB'R&NVOD/KQ!B'/T$0^>IQQW\'Z&7^GXO\/\`
MVCZG]_RBL*KE$!N:8AY>W`V<@@/Q+UPI3?>'A[N?/3''?P?H2N!QEE'_`-H_
M_P!'4-GS#AA$4;LW,`?LJ1-@3'Q'W"I$D*;[AY#X>_3''?P?H77#XO[H=S37
MA)GR7/.)##TA<V?C^\PF"A]XFC@+^(^.F.._@_0GX<_XLXSYLQ(<?8NL<0PC
MY"VDP)R/Q$6(`4/B/D`>[3''?P?H/AS_`(LXOSSXN_ZYQ7X._P#\MIBCOYCX
M<_XL'R[BY0.1N<*`^XW>J@;R]_*//W"'A\M35;KO15\&3_:Z[G7'*N-O`2W2
M!,4>>!]+Z3>`\>)#%`P?AQQY#I5;KO1F^#Q$Z8)/G0%RICDWB%S@/[S](O\`
M`P@/WZC%%:_?R(^%Q/X2[CD+D_'9QX"Z5P/?[4HU('XG4*`_0!YTQQW\'Z#X
M7$_A+N.0,EX]$>`NM8\?C-,"A^(K@`?>.F*.X^%Q/X2[CKJWS'BGB2[50AO_
M`-O1@$'ZAZ3X?4.`^(#J:K==Z+J'%6<)-=+G5->J.41#[:5(?F6QPY@'Z"#S
M_P`=*K==Z+X9O]DO^K]#["ZTT0`0MM9$!\0$)Z*$!`?(0'TO2JW7>B,+V?<S
M["XU$P<EM-<,'Q"<C!#\0=:56Z[T*/9]S/H+75%`$`LM?.'OXF8XP??PY'2J
MW7>A1[/N9P&GJT<1[BQ09AXYZ`EV!A^[AQSQ]?QTJMUWH4>S[F<(3\$(](34
M2(^7`23,1Y^0`MI5;KO0H]GW,^_74-_[6C/_`,>U_P#FZ56Z[Q1[/N9]^MHK
M_P!IQ_\`^-;?_,TJMUWH@]I_Y+_)).]NNY=H@N5=)MFFO.@,DN55$#O:,R2-
MTE(8Q2J"5@3O#>9R]T`^!`UG/-=/NP>GG5`-`-`-`-`-`-`-`-`-`-`-`-`-
M`-`-`-`-`-`-`-`-`-`-`-`:/]YDJF.YN\1:BI2%C:;CR3/UG`I4DY-E,M^L
MPF$"D*/J<_)AX#V!$1\-=?!^CM9C/ZGV>1"2>S1AVJ]?VGRQC2N=WSWGKZ]U
M>'[OCSZ_6$JWZ./?U<<:TQ)9M+M1"C)Y)OHF85GM^FRVM]82>Z/!RAD^>M.'
MR)7+(J40\RBE77TJIU@/@*?3U@/@)>?#48X+]T>^OD67"XC_`&2_ZLPK/=K=
MV?=?ZR*[@&DHN3GA"!H>3IGO!#S`CME3%([Z"=Z0#>91$.1"OQ8;^#]*%_@<
M5_L\8KS9A6>[<G8_#]?J\V7[5T\]/J&@-6_><?N?:>R5SCGW=YW?SXU7XT/\
MGV+[LM_IN+M%=OI4PK/?E`.`&_7]F,&YAF..>[]?/:77.KX=?J^;M7=\^_I[
MSCYZCXZTB_!>I9?I9ZRCV5?V1C!;M[KC95#M<;[-I*76`PE366R3*3JAC#Y`
M>+@<9)&(8/#DI9(XFYX#I\QCX[>4+]:_8G_2I?5Q$NSUE]CC_P"5)[3JY?\`
M1OL,7[I;_1N7.'L[VI%,IO(YGL?)5QB7@/)1;I2ZN.HHA[(OB\1Y0\),?!X*
MSXO6DHKPN/\`*%[=R]_^C^!&--[_`/T?_P!7U0KW==7E_P!)UI=]WT\_^L\\
M?M<^.F+CO2G8ON,/Z59S;[6_)#\W/;^7KPG,AL:4FK^Q]H<!P7<%'W=YCN'D
MG/LA^UWJJOO$QC>.E..]:=L?L*_I5HW_`-K][IY#_D[^U\NOM73?$6#:K?Z=
MBSSMFH3<&_6`\77JK&PRA2@/`%],$O/@4`#QT^'Q7^_LQ2^RH/B_IUEPJ]8Q
M^[8_Y#W<!<O^D_>\^>][_K`?9^ZWGJY_7#JL-_@.\Y^)RASYB7W:?!;SGX-_
M<?ZF"^GA+O2Z919>4#^3ZXK;]'VGW%Y`F...\]0TRN5SK^/1ZPDK5W?/NZN\
MX^>I^`M9/N_+'^JEI!=[_!FN![!_9I%=!I6T9VLR@<"H22N538M3C[P(G!T&
M+<ID'X&>*'#Q_2>7$_`AO+O7H4_U7$VBNQ_=F:8'L<NS]A>@SK#DM8U4^!*K
M/9,R2;DP>\[>(M,.R4Y]Y5&QD_']3RXM\&&U>U_:A5_J.*_W4Z)>E3-<#V<N
MQFN='J_;%BIQW?'3Z^@SVGGCRZ_M.YE^\^?>=?/OYU/PX+]J\_,J^-Q7^^78
MZ>1FJ!VU[=*KT?9C`6%:Z*?'0,%BRC1)B<>0E,P@D!`?GSS[^>=3ABLHQ78B
MKG-YRD^LF_N9=CXR-B4`:Q<>QC6I>.EM'M&[-`O`<!PBW333#@/`."^`:L5.
M]H!H".&Y?=?A+:92%+MF.V(1)7!'!:[5H\$I"Y7%\@4!,PK,`"R2SPQ3G13=
M2+E1G"1??H*2\FP2534-64E!5?8M7T+PA+B.D5U>BZ^ZFFII6=YO:[23>7NJ
MTOM<V-B]2=Q=<8F4^UF48]NL59!SPX1:GM1E^A,Z,Y*M6M`AENX<P4):):.>
MK+8TGQ?\8>?/GY=IO7A\#+_<XF^D?.GGS1@_M8L;8DP/5]J^RC!-685.%G;(
M^R9<P;CZ1.SCQ$$Z/5K-:)A;KD)V143D;Z)G3XXHL4&I6<8@U8))LV\<5)88
M1MJ_)-[Z_8MP92?Q.+)UHJ+SHEHK++MW(`V.@26,9=>]XZB&\M!+`4UNH1D"
M*I.&B7(GDH$AR*"W>-R"=3N40,(")N[25;F.TU5JEXJM<UZ>WGD$U-8)MIKZ
M9IWZ2ZZ9]AF>HOZ->()K8:ZQAW;!P'2H48UD5TQ=%*45F+]`$C&;.T!,`'3$
M1(<HD6046;JI+'LFFJHYI*<'254^N?0N`:U7#")C5^$,(^(B,4P$1'XB(H<C
MI1;+N*U>[[V4]S2:NL(G+7H(%/[42P,4?EXMQ$OG[O`/W=*)YI%UQ)+-M]M_
M?NI1EJ;6"CTK5>OCQSQU0L:8/J41;"'C\OOTHMEW(T4F\I/O9UC4RGG`2GJE
M;,4?,#046(?@+72BV7<B<3W?>SI*T"FB`]%2K(@(#R0T#%"`\^X!%IY<>'!O
MO'2BV7<B<4OY2[V=`:'22CP--JP#\!KL2'_^'I1;+N1%7N^]G`./:"(<#2*C
MX^\*W#`/X@SYTHMEW(G'/^4O^S]3HJXVHP")BTRKF#X!`191#Z%*U`!^X`^F
ME%LNY#'/^4O^S]3IFQU0C#R--K0#Y>S"L"_P*@`<_/CG2BV7<ACG_*7_`&?J
M<*F-*`H'`T^OEX\A3C&J8_?T)EY^@\Z85LNX8Y_REWM^93U<844H#_\`1*#,
M7]XK!(HAQ\>D`,'W#QQYCYAI1;+N1/Q)_P`F=8<9T$?#[)PWC\&H!_$#<A]0
MTHMEW(?$G_)G'^:_'_\`U4BO_P!VI_\`,U&".WB_4?$G_)G&.*L>CX_96.\?
M@+D/X`OP'T#3!';Q?J/B3_DSX'$V.S#R-68\C\%7I0_`KH`#[@^>F".WB_4?
M$G_)G`IB#'9_$*TU*(>X'4B4!_[+P/X\Z8([>+]1\2?\F=0^(<>>1JRB'O\`
M!]*E_B5^'(??QI@CMXOU'Q)_R?@_-'$.'\<B'`ULGC\).:*/XA(@(?<.F".W
MB_4GXO$_EX1]#X_,WC?_`*N?_P`WGO\`_J:8([>+]1\7B?R\(^AQ_F8QS_[!
M4_\`XM,__G],$=O%^H^+Q/Y>$?0]M/Y*S6(*IX!W61T"U,T;KYAICY9,SERY
M$5E:6L@!@.Z56.4O0V*4"@;CV1'CD1$<YI)VV*RDY.LG5Y:+R/53JI4:`:`:
M`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`\8';D[)6>^3M'8*@N
MLMN\7?9#;A#VX2-:D%M&PM36=O$.4Q0/::TDP/'+/F1R.CED@-Z89,$$A]LV
MT88TE6E*O*NO5$QXGPL3PJ3;2VI1=.IKS@?R?O!;?H^T^>,LS'''>>H8FGUS
MK^/1ZPC[5W?/NZN\X^>K_`7\GW(E_JI:1BNM7Z&:H'L,-DD1T>L7&9K3T\=7
MKV^Q;;O.//J^S%3KO`#_`&!(/P$-3\&'^3[5]D5_U/%_Q79ZMF:H#LB>SZ@>
M@X8%),."<?YQ/Y!R?)]?'[[,]R)&#X^?#$.?(?#PU;X4-O%^M"KX_%?[J=$E
M]C-4#L"V3UOH&.VN847%/CH-.4.$LY@$OD(FLK:6,8P<<]1A$W/CSSXZGX</
MXKNKYE7Q>(\YR[VO(S5`X,PG5>C[,8>Q97.ZX[OU#CZI0_=\>71ZOB&_1Q[N
MGCCW:MACLNY%'*3SDWU;,GI(I-TR(H))HHIE`J:21"IIIE#R*0A`*4I0]P%`
M`U)!R:`:`:`:`:`:`:`:`:`:`:`:`U#;LNU$BJ=;/\GG:!6!W%[E)ETM!H-Z
MZ@O.4NERA0.1QZR<1BA?M++Q8%.J_C8YXVA8,J+I:S6"//&NXM7*7$H\,%BE
MRR7K]M3>'!JL?$>"'.S?3KI:^A:NVCLOYFQ7=/<MV@EJ-GK.DH=O(M*+*.DI
M;'])Z#F<,X^1;)$3B+$K%F4%-K78QFUQ]"G%PBRCY\OHDFE$>&V\7$>)[:+K
MH^BMU)GQK8.$L$-]7SKG]WKL;H$TTT4TT44R)))$*FDDF4I$TTR%`I$TR%`"
MD(0H`4I2@!2E`````-;'.>13>#=OSZ=IMEN734]-KN$(Q#',0(CWJ;=U5600
MLRS-YD*8EVF[F[2```""CR/Z8HF-S2^;B/:-EV?FIU/Y/TT5DYNOC5/N2/I1
MM[T_^R(_R'_C^.I,5/?O]^^1'BUTFPT:><Y(Q8W`SM<>\N-&`13CK4U*8QU7
M3%$A1!O-)@=54HI%ZEU!.HW(==5TTE*M4O'M6_3WZ/=.,U@GE^V6L7IV>NV6
M7*/=*[D6#3G:ZX$.DP(2,:X`$W\2^*4!58OT`$125(//0H7J17(`*(G,41$)
M33NCGG"7#EAEV/1K=%TF(8@\&#@?Y_,!]^I*'&8A3E$IR@8H^8"'(?\`G\!\
MP]V@*8NP$.3(#R'[AA\0_P!DWO\`H/'U'0T4]^\IHE$HB4P"`AY@(<"'W:&A
MQG(4X<&#GX#[P^@_X#XZ`Z2C<Q?$OM%_[P?=[_N_#0'7T!Q*)$4\PX-^\'G]
M_P`?O_AH#I*(G3\>.HO[P?U#S#^7ST!PZ`ZZC<A_$OLF^7D/U#^H?7QT!TCI
MG3'@P?00\A^@_P!//Y:`^-`-`-`?P0`P<"'(:`ZYT1#Q)X_(?/[OC_/ZZ`X.
M./`?`=`-`>RK\EU7(MAC=J0OZS7+5!;*#_:&D.790\^/`CLON`?'Q]VLI_5T
M7Y&GOW[9ZEM4`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T
M!Y*.TTOA:+VTV"TW"P(,+M@(]#?'$W3U&FW#AU#(\#P!A7LL9"(@41#Q/U%Z
MC%*4=^%9QZ2\U]S.64N4EY)?<D/KI,QH!H!H!H""N>)[<!$[CL#4.A9FBZC3
M,TN;^T<Q3K%T!97E=-CJA_:E59K+/I5LXD!L+M(Z"J:Z;<(Q)7EN*XD`HYRQ
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MU>KE(@\=[I)C(T3/W&9A;(A<\`6"B0;!E`/KI2:0LQB)AY=(1B=M<JK7+$HI
M872JD5&OJ@C#72/B/:U)5O2\6LJT\4G?E>?A++$ZXN&E1)JDTWHW>VCI;.]J
MH/:.V5>$<*QNW==S:X-#<:]MU?D\A3%290\=MOK>)KA8G3%U;\3P5K>J6"O9
M68^IF,U1*P^3FHT6+M`D4^"?:/B.GTW6*JK3Z4F\U7)[:#X2_G;Y:.F>)R2R
MDUG'?+N-EM4L+6VU>MVMBBNW96>`A["S0=`0'*#6:CF\DW1<`D=1,%TT7)"*
M@FH<@*%-T',7@PZJZ3W,7:Q7]`-`-`-`-`8RR[F3&.!Z/*9&RW<H>D5"(+PO
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M\CSA@+#4&G66YRO)P3YCZS#/9IV0IQ`0`YT&1R$\#")S%`"F$0`8;HF]DV2E
M5I+-M+OL>,G:ZWF+)'Y#RO8#^E6#)%WE)21=F`>MXJ#AQ)/WA1,)AZ7,U,R@
M'+U"83H`)A,(`(<L-7N_?F='ZE_-&"RC'S_"1)I1N4W/3[!O?X>`C\P]WW?@
M.KG,4]9#]E0OT-_P-_3\0T)3:R(^WC'4]`SBF3,5"FVM)"B:P5TWL15S9%'O
M%D7"!1(0LH;CJ37*9,5U0!7O$'G*ZU&FFW'M6_OOSN;QXD9QP<2R_:]8\T_?
MC0R5CW(4%DB&.^CBJ-)%BIZ)/U][[$I!2)1.11L[1,4AQ3$Z:GHSL"$(N4AR
MB"3E%RV0LG7[K8RGPY<-T>6C631>:C80\4_$/W1\_N'R'^?UU)0Z@@(#P(<"
M'F`^`Z`XE4$U@X.7D0\C!X&#Z#_0>0^6A*;6125V2B7(D_2$^(![0?4OO^H<
M_$0#0U4T\[/P.EH6.%1$BGCQP;]X/ZAY#_/YZ`Z2B)T_,.2_O!Y??[P^_P"X
M1T!./9C@C&.5X'<G<\Q-+TXIF,L7U9E`K8VK+RYW%ME7*65J31*(>&J:%HI;
M*Q/`CG=O7;1,S98^)<.V[<[DCX42,'-6Z42U[J+,$P+_`-D+6,<HW1I8MR[!
MU96D]<"X[B:[5*>^&W5BIYN_,<S"5BWV7(RVQ-VNUI8V-E6HF(K%AI;29A&T
M'.Y`8O9M,(^,?+W2NWO,%,S/V:N&HQINPOU"RE>*I2,,L\Q2N+8>V5BC/SWJ
M$P-/PF+K+..G8Y=;7D:[>\SGL%*I=KA\=2M<3=,"C+O(Z2.K66$*3LLZTJ^N
M7@#&&(]D.*<G;1*5;YN>N=-S7=*YN^SE7K&SI+VST"0Q7MVK=<81%8N,NM=8
M%C3"3M_A+U`Q,W#5:XSDE9+!7XMV@S;-XYK+RY4;VLN^^WW!EO+'9>8M97^;
MKD=D"Q8V-]E,KP](9Q-*<Y$IQK3M`PC7Y3<7>LTY#F;]"'QO`VS,3"X5FM,J
MY!VT(QXLW%2)BHLD0SE84WZ[NN5%W>[@Z^*.R^QNUS_#8GO5XM%GG:(GE^-S
ME&W;'\[B+!+>VT/!ZUO284O<,UMSUM/PM5RG9,>T:YK/F%.GC(33:R1D.M`2
M#([HYVVKEJU?5<T"RIOLJJQ7*?E*<G=P#^(G*HIGZ$HD%,4.HPSNX6C;:DE!
MW0LM!R.7TKQ%U^YY4*[QIC9]5*C?)!4XQ-EO4=2T9IA"J3CRMG37?+38$"MW
M6$<>[<<TVC"=)R;,Y4F<;R<M4<E3KZDM:7#1N08"5=Q<_7:N"5MM+JPQD*X:
MBS=3SY.!,XE4WK5I%*L6K>4D+)MW:IL",&I!\F(4_F'C\0\_\?70'6,D8OEX
MA\O/[P_P&@/7O^2DR(2>'=\*Y3=1$=Q%0CR?``C,;LF!P+\A5;J&\/`1,(^_
M6,OJ?O*Q>2HH<XU[VWY,]8FJE!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH!H!H!H!H!H!H#PM?E%=ADJCVC.*;7#*]Q,5C%%0L,4OX_H9*%LQ9)BKX"`_
MHW39(_@(#X>`AK6'[>DO-$9XES__`"C931+A%9!I-2O4&?KB+A7(:R1P]0',
M1K,QZ#])%42\<+MP7[AP00*9-=-1,Y2G*8H=:=54P+LT`T`T!QJJI()*+KJ)
MHHHIG5665.5-))),HG4444.($(F0@"8YS"!2E`3&$``1T!@&N9:VUY:^QF1X
M6ZXULCJ'>75&AV&1?1C*:C7#,\Y5KJO74IST&8;-W#>NSC9V_:-R,Y:$8+23
M9P\A3I/%*IQE1IITK3[_`-[<BS4E54:RJM-&JTMJJ=2WGE`V;Y%K,`R>5_;[
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M/8IORNW35L]<Q[1=C%2*[1BC7"FJTK1;!QE2K3I6E7OG]F9@U8J-`-`-`:WM
MY_:3XEVJJ?F_KC57,6X67,@PKN)*BJ=ZX82<CT)Q@W-['I/58CTE19$S.OM&
M[RTS'?-2M(QNQ>!+M\Y\11LOFEMMU],S;A\&7$N_EBLY/[;^2(=XB[/G/.\2
M[Q>XSM*K+(+M4C>G47;1"NEXF$KT:X.1=%E86S!T<E:8G3(@#N`C';BW2W=M
MC7*SI/FKN*6HN'*34N)_U_K^]R\N+'AK!P>V;NWT]<MD;S*]78"I0<56:M"1
M5<KD&R0C8:"@X]K%1$5'MB`1NRCXYDD@T9M42!TIHH)$3*'D7Q'6]*65D<S;
M;JW5O-N[*SH!H#53VRV6OS8[';K#-77HTQERQ5C&,<)#\+>B/7:MFL?"8#U&
M;N*U6)6*<'$.[)ZT3*80452`V7&=(-;V^[\J=IO^GCBXJ>D4Y/R7BT^PTTXA
MJ'V0QA28#H[ETT@6;A^F(<=,G)E-*291]_)7[QP3J$.1`H"(%\M9Q5$D4XLL
M7$F_\GW*R\$7TL@`CPH42F]P^0_CY&#\0^&I,RGJMS%`>0ZR>\>/=\P]W\0^
M>@*:HV]Z?_9$?Y"/]?QT!@7(.-I8LR3(^-7"<)D*/3_SML;@D5<F!`**D3,H
M\D2.NL1(B;=V<Q`,)4BK+(G2:/V%6M5GY\F;0XBI@XBQ0>MZPYKER_IWKC;)
M$/D>/<D(@I!6N&/Z+9ZJ^Y3?Q+U,PI*&!,X$468J*E,5!T5,O`_HG":3@#)Z
ME.O)[%9\-P>\7],M&C("S?GP4+P/N,'G]P^(#]!Y^G.I,RGJ(')XA[1?B'F'
MU#^H>&@.#0'57:)+<CQT'']H/>/]H/(?KX#\]"T9-="D+-U4!]H.2^XY?$H_
M4?</R'CY<Z&BDGUV.#0L2MPY5MW%2JM;N>W2TY@K+S-%WL%"JM2PE9,@QU_R
M;*XXKB$G9'S"KX_%.0G82H1E])&J2+@5.Z7LDNQBT'*2%F,PATUI;?2OJ"GH
MQN^M"A6NM-F.[%+%^#;<M8KO`-V^7R4+$%\CWHSZ\Y:(M,H5^@VUC(J&G%9*
M50BIEH\4-)G637.9<8^7E?ID"\K)7^TMM%$EVENAM\MAQG-Q-IMT\ULD?GN5
MHTM!GDXZWW6SRZ$FDO`OXE297B;19YIZ55F>4683<HY%V=NY%\O^/@#KY(QE
MO[PW3J3BZ3DMQBF';LWQ<ZQY"U69RO(X6LTS?Z]$9DH]7I[=L1"G3%T9*7(L
MLI7(9JYE(RW*S"K9-1^FN[4)Q=[=M*[7!;ECKN]^%QYN`KF0+3GJG0=5F*MD
M7/&%\C67)]6F)TV4;$:+1RU:\=68632RMW5R-7(VP6J:17EUYRU59R4L@BX=
M/HZ;566M'T!PW%CO-M&!H'<G?,HY0L^,+%,([;JQ(6'+]ALL[+1[]O*6-:C,
MJ^O8)&6;40KK'H*+Q#Y!E#.YB*B#LX]\HT37:1\M:45KNV5/[!(2Y[:NTOB6
M&2:G:LS7MRRAX"I9[OU1?[B;&^0FK5.52\Y&C`=Q2\^I'V'+D'7,(WF9DU%P
M6=Q3R@C'IS9YL8!D^BL;6SJLE[U!K.R7#6V!OEIC+_)+RU[)*K.[J\>RCB:E
MOM;)E))V-I89-V91TZM4;,/'D=:S.5G"Z=D:2B*KIT=,SA6RRMD"QM2!H"FS
M$DC#1,G+...YC6#M\H`CQU%:H'6$@?VC]'04`\1,8`#D1#1VN2E5I;NAZQOR
M0%PH[VT;PW*Y^M=SN`JKA8W(<F46H"*ASB'F'4<QA`?(1Y`/(=<YKQE24=L*
M2[&SU^:&(T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T!XEO
MRGW'\E%[H=NF2R1ZY(&WX2G:N,D"1Q:K6.GW0[QZW.N!>[*Y"&LT&)$C&`YT
M4A.0H@FH)=(;=?\`\^@+%[*3,Y+GAB8Q-)N^N=Q3*G4BTU3\JKTRSN',@Q$G
M6/>+>K)P)IFKT]2;-FO#H>P51(H],':FWD935'7?S-J>KE!H!H"G3#9V]B91
MG'N$&C]W'/6S)TZ;`];-G:[95)LX<,Q.F#M!%8Y%%FPJ$!=,IDA.4#]0&#5A
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M3T)CQ8U3::22JJU7R+Y5%)6K*CJ[+6IG2J=G^?\`.'^<>\3..2.W[W(]J7J5
M#H!(FD5.\S>/\=8JQC,4F"E7;YL@ICBHTZ>E1E7J1)25N%K6DT0C46#8@67#
MO6VMDK*R4:=%YE7Q;45=%5NK:Q2E)-TU;2VHKYF-DNS=NJE"90LC;L2DL<)1
ML28MCB56IWJD1<S5\76E:]JW>PV&`NR5K4R[9;RC`6H;&<\G#1#B$=,E(6;4
ML;^4;5^&Z9K)*R:32=;WS;O72F5R?BJN3HW*5VG1M4HJQIA2JM,]*$E=LVTF
M=P/>?M98+=5;R=/"%)Q>UDF5)9U*::S,+=<@WFVS)$8E0(DS>X2]^57DG*B!
MIV17AV#R8?OWZC]X\M"#BZMIVIE2]6WY]2LYJ2HDU\SEG6U$DNQ*BTH[)$Y-
M:&8T!0+3:JU2*]+VVXS\15ZQ`,E9&;L$](-8J(BF*`<JNGT@]51;-D2\@4#*
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M?EX7%XFM,*[O5KN+*6:D.(\AW9_B`?S+X`/\!^>ARE*7;&)X*%ZB>XP>(?CY
ME'\!^'.@*:HV$/%/V@_='];[O</\!^N@*<HW*;G@.@WTX#[P]WU#Z^.@*>LA
M^RH7P]Q@_H;^GXAH#!>2<5O9:0;7JA/BU[(\*7EE(DX(UG&Q"@48>=2`HIN4
M%DP[A-=1,XD(((KD4;E3]'JXUNK/WF;</B46":Q<-Z:KFBO8PRFTOR+V%F&!
MJ[?8#]#9JJ[Y(LBHGT$-(QW683.8M<QR&35*90[854B*G425:.W<Q=:JEUFO
MOT*\3AX*-/%"7TRWZ\S**C;S%/\`[(_T'^@_CJ3,IJK<IA'PZ#AY^'O^8?U#
MQ^N@.B=(Z8^T'A\0\0'[_P#CP.@.(0`0$!`!`?`0'Q`?J&@.@NP*;DR/L&_<
M']0?I[R_Q#Y!H7C/1]_O,V-8JW>T/'.#L0U:P04M/2-3JVZO`.0*?7YIS3+3
M(8KW%HU^Q1N1:#?%JQ:Z[$VF`L"=C@I5E,Q$CZ5%-H-EZO?1TQ)KPM<-6^J:
MZHT33R9=D3VDE9BFB*I</9`>3>/)C-K_``@XF=P,Q98]NRS?B2M8?EFF>`LM
M*EIW,3BMPM79R4(O%S^/F9BK&JGJUE46<;&-&'N=*JFSK:]O>I)S$[45\C;6
MUE3Q7+F9(92J.1S0?YSE2H*-JOM(5VMGK_7]CQ1`DAWHW(7@M1(W1YK8L7'5
MZZU&#GI3+*]?P"LP/:N0]*=P=@JF"[0>TNF>V:O9#2M>:1F:F]J^VW$+_$[/
M\U\$QQS"O<8VVWMYF1FU[*O+V\M<D4D%XV-=K/9-1=@M2N5=-][@Q98-Y.,9
MG$.4JK6Z]9*RSC-JL%M!P[4[U:#Y+O\`/PUPW)-MQ60<C7F_QU*I=;.VJBM>
M<UJMP#6)B3QAK-5R0S"4;1EAD64J-'VUM;)42\?[!&3$^Z>:PQBB#HM9I\-*
MV2K[H,?;F8&RV-4LK!(RN/:5:ZK'5^1IXLT32!%'UD0G"2A)]J9JI%D;D8'.
ML5XWEJKKRH#*&2.T"LM[R%C^_0=,+BX*3@.MXCEJK0+5.1U7R!8*<TF7-7G[
MK%JJ'0GZ?#6R186-''MA)8&+QO$C!RTI)(R;MX2,*OK?7WKOZ`PONHS]0]P3
MS'[^GX7@L1NZM6EXJQ.8E2KJN+/).UFR_4JM5Z+1CO(J'.BX]3/KF-VR,[]:
M2![9D.SJ`P,RE*FM??O8$15$3I^(AR7]X/+[_A]_A\]2#BT!@K/MB"+J24*D
M?AU8794C%`>#!'L3)NG1PX\?:7]#0$!X`Z:RH<^`@-)NU-_?H;<&-95_CYNR
M^[/9G^1_5^5:[3-UUH7:F3A9O<-!0L8[-X`YD*YCB&>2Z1`$`Y*V1LL0(G`1
M*8ZYB?K)F#60X[^9+9>;/7EH8C0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#
M0#0#0#0#0#0#0&AW\HKQ%&W[L\)?(*K3KF<&Y/Q]<H]\F4O?H1UJF4\8R[$Y
MQ`3>@/%;I%.W"9..IW%1RIAZ4!`;0^KK_8/%AL]SNKMYSQ4;RY75)5GJIJQ>
MD$^LP+5*;502?.12)R=92%=),;`W1)P9=Q$I-^0*L?G>+HZ]_0K)57D>MMNX
M;O&Z#MHNBY:ND4G#9RW4(L@X;KD*JBN@LF)DU454S%434(8Q#D,4Q1$H@.MS
M$YM`-`-`-`0^WXHWLNUO*$MCB[7ZD6JO1:,TR<8Z/'(STZ5%RDU4KRKQQ!S$
MTQCG?I97;AS4'5>LP*L6Z3:>;L%9%F^IQ*X'1M/EY?U<OPZ8E5)I[Z<\_.JY
M$.\H2.9K-NON&/JSDS+5)OUBRXC1ZDSB)&W+T*L[9)[:#.NI'*C6GF=-\?2#
M^N9Y63?I6UV5.RIW6-C:DA+MV:I(\:.KFTFTZT5W3#@SI96=^MC185!-J+2C
M5Y5<UQ/IK]5X:94;EFJF1,29*R'AW)="Q?=AO^6(VSS5LI-0M:$G<UX5HW7R
M`N6RR+-.[3=VMMY:TR4(TK9Y&\V]U-5?'M*D;S"S#^$O80:$Q;BU%UE6M'>F
M=[N[HZJ[;4576A624DVJ1HDVK;6R24:[)4<G1I-&T'6ID-`-`0WW=[Y\$[-J
MQZRR1.^M+G)-%%ZGC"NJMW5SLA^3IHN#-3*`G!0/?D.1S8I@6[$H(N$&!9.3
M(E&KTG.,,[O99_@TX?#EQ'\JMJWDO>RN:M:MMPW>=J+88C*.[^3FL";7&KU*
M9HF`ZZHXC9VS,N1,PD'K9ZD5P@+EL<>NZ6QFI+N457'V/K4%#RR+]#+#/BWG
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MO$%*59E-XI^P/[H_JC]/>7^7R#5`4M9OX]*A!*;W&X\?#X#Y&#\0^_0%.5;F
M*`^'63Z<_B']?$/GH"G*-@'Q3'C^R/E]P^[Z#S]0T!A3)N*PMJK*S5M\:K9'
MKWZ6`LK<.[[WNP.(1<P4I#^EQC@#G3'K36,@553A)PU5=,G56M5:2R9KP^)@
M3BUBA+.+\US\SEQ?E3[7.'E/M[`*MDV`+T3,"KP1"22(4!]<01C'.#IBN02K
M&(DJL9`BA5"*.&ATG2EXM3L_EFM-'S_KK<<3AX5CC\W#>3VY2V9F!5$!\#E^
MA@_H/]/Q#1IK,R*>HV,7G@.LOPX\>/F'O^[\`U`*:HV`?%/P']T?+[A\P_E]
M-`=0Q3%'@P<#\/\`'G]0T!Q'(10O2<H&#X#_`#`?,!^8>.@3:R*6NP,7DR(]
M8?N#QU!]!\`-]/`?AR.AJIUSL4\0$!$!`0$/`0'P$/J&A<XSID4#V@\?<(>8
M?0?^/AH#I*-S$Y$OM%^7F'U#Y?$/KX:`Z^@.%1$BGC^J;]X/ZA[_`.?ST!TE
M$CI^8<E_>#R^_P"'W_QT!Q:`ZZC<IN1+[)O^Z/W>[[OPT!KURY:@M-S?J-U0
M5C8K_FF.$IN4U$VIS^DN2"'LF!R[,L=-0`Y.W!N`\]`:QDZOP.SA1PP6[N_M
MX'Z6_P"3/8U+C_LC,&3)T/1GN5[KF7)3],P`!S&/DF>H<8N?C];TJOT2&<I#
MR(^CJH@/`@)2U.?BNLY<J+P7W-^>AF-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`
M-`-`-`-`-`-`-`-`-`1VW;X'C]SVV;.&`I`S5(<HXYL=:B7CT!,UBK0HS,\I
M\XN!4U3"2!M;2&F1`B9S\L0Z`ZN-%9I[`_+8ME5L%%M5EI-MBG4':J?/S%6L
ML(^)W3V'GZ_(N(F8BWB?(]VZ82+1PU7)R/2JD8.1XUT9W0/0?V8&Y@F2<;GP
MI:9`#W;%[!,*^HY5Y<3N/@4(W8]WU#U*+U-=5&%<%`"E)$K0(E[U0'9R:PE6
MSS670RFJ.NC\S:CJY0:`:`:`:`:`:`:`X7#A!H@LZ=+(MFS9%1PX<.%"(H-T
M$2&466664,5-)%),IE%%%#%(0A3&,8"@(Z`TJ[C.TZM5_O"VV?LZZJ?-F8I`
M5V,IE%FT0D<?TE(AP;/)*'</!)"S(1RB@"M;9URWH4>L+04E+2#H6R.,N(V\
M/#N][4731]7;J=$."DL?&>&/\?W/ENNBOTS,D;1.R^KF,K/^?W='9#;B=S4R
M\3G7L]9EG4Y4Z?,"!#IJ03>9(*T_-1YBD(SLDRV12C"MV9:U!P1F973B8\))
MXI/%+/E^>WN(XG&<EA@L$,J*S?6F^J[ZFVC6I@-`-`-`-`-`86W'930PC@3,
M&6EE$TU*!CRU6..*KT]#F<91+G[/L.#\D$\E.'CX](#^P*CD@&]D1U63PQ;V
M7CIXEH1Q2C'=I>)Y:MBM-7C\-N[?(=ZM)Y`M$O,G>+B873AC'*>IFXJG4Y.L
M)Y%I+NP4.(BIZ9UAR!NHV?!5(UW?E8V_4NLU%91BE]_0F&JW,4!`Q0.3W^'/
M_:`?+^(!\=;'.4I5GYF2'^X(_P"Z8?Y&_'0%+6;@81`P"0X>_C@?O#W_`%^'
MOU5Q3Y/=?<%.6;B`""A0.3X\<A_Q*/\`@!UDXM9]X*4JS$.3)#U!^Z/ZWW#X
M`/T'@?J.H!2E6Y3"/AT'Y\?#W_,OAP/X#\>=`4]9#CP4+R'N'W?</N_@/RT!
MAS*&)V=[;LY*.>*P%U@#>E5>UL>4WT<Y3,*B;9T9+@[J-54_TJ(\G1$YU6X`
M)UTUX:K1IT:R9IP^(X-IWA+ZHO)KES]LI.,,JOY:37QUD9FG`9,B$_:1'I)&
MVUDF4PEF8$_LIJBJFD==RT2#@I2J+-RE32=MH^\)XODG]7@_SW<MBW$X:24X
M.O#??%[/:AG`Z/O)_P!D?Z#_`,?QU9PV[C$Z2K<IA\0Z#?$`\_J'O^OG\]9Y
M68*<LW$`X.7J+[C!Y!]_F4?P^_0%/4;&#Q)[0?#]H/\`C_`?D.@.KH#A6;I+
M![9?'W'#P,'W^\/D/(?+G0E2:R[M"D+LU4N3!^D)^\4/$/\`:+YA]0Y`/>(:
M&JFGR9U-"QPJ($4\?U3?$/?]0]_\!^>@.B=(Z?ZP>'N,'D/_``^@\:`X]`=9
M1L4WB3V1^'[(_P##[O#Y:`PYF"\)4>L.$R\FFIU%Y&Q"9%`(=`RB!DUY01$I
M^4XX%DU"%Z3=ZZ.V2-TIG4.2LG1<W;\FG#ACER5WZ=OE4@-"0LK8YF(KT$Q<
M2DW/2;"%AXUH3O'4C*RCI)C'L6Q.0ZW#MVNBW1)R'4HH4.0YUB=A^L7F2G6'
ML\^QHR/3L*V`:K=MJFQRQ-*C<HMJQ<+M[_0L9.7+JZHM9-F[CG#Z4MS=]9%R
M/6"S5=X]5%5J*9Q2T.%?--5_=)5[6:2*UVLF[U_L+P-4<CY#>43>]3=UVQ>(
MR79FD35P5S?M5W7)!>\=9'C&+B!&#,QMM.E4J9=%:_&H.(.UUEP+A:'?S"3%
M(:8(XW;Y:2IG9QLUWJO1FTW,G;4-<?6[<G)XVV:9USSMFV89"=8LW6;F:59L
M;P\-CR[0*C$EZBJ=CRRS;*W9-)CP9%!.XNHD8I&&,19Z[%*!/'S;\54,JR2<
MKQ5[[7R5=#CS'VTY*MDC/./]ONSS+.Z=EM^P3BO<];K_`$N^8]I5*'`V2<;(
MY1-=0<W9RSESR,;6WC%2&IT1$3EEMW_.BT>R:(P[HQA"AE6256U?=-+3KGD;
M!<+;\MK&:Z/@6U1N9<<TRQ[C,>T#(F.L2Y`R!1ZUEU\PR.Q2<5Z)+1'-A-,R
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M5O-N$W+N,FKU0HRNEFL6UG,5;"IUBNUG,MB?]S`JM*BZGX5X65A4U)R3E49"
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M4:;BZ-*NKHNO0@[F?MF-PN=F6P"\8`V]9XVW[>-PO::;<\3U3<5:GN+9FN[A
ML(OKC<Z9DFBS%/!67M^,7=M>-H^2KYG4>89V*K=C7@[:V6AUT'@LH)8DVFU!
MNE[.E5R=-?(]3^AD-`-`-`-`-`-`-`-`-`-`?GX?E`6V^2PCO]MN0FT49G1]
MQL)$Y.KCQ%/ADI96<>PK618[O0`.J4+9(\MHD4O:%-"X1RHF$'`%+K!U5-@:
M@<4Y.M6&\@U?)-,>>B3]7DDWK<IQ.+5^U,!D)"(D$R&(9:-EF"KB/?)%,0YF
MSA04E$EBIJDNG2Z(:35&>N'!N9JEGS&E=R73EP%A,M^[D8Q14BCZO3K8B82U
M?DP(!>AY'+G``.)"$>LU&DBV`S-ZW4/NFFJHQ:I9F7-20-`-`-`-`-`8'W"[
MEL-;7**XO^9;@RK45^F1AXPG#RRVJ223!0(BK0*1P>3$@;J3!44P38QZ:A7<
ML]CV!57:=92455OU?0M"$IND55^"YLTIG=;SNUXD3(L0E]K.Q<7HD5<J`H:V
M97CVR_28GLF:GMAUS$$#((G:8Y@UP,5PO;YR&3*XQ^?B_P",/-??RZG1_M\#
M:?%\(^^]\C9SM$Q[AC`%VS%MAPWC%G4H_$M;PY8YJ_.)0LO;<F2.2V=X5,ZM
M;I2*:N?2H0:BIZ.!9!S%@6750B(F`9M2M5]8*,6XI4HHU>KK7/N\;4,9N4E&
M<I5Q.22TC2F76OAJ7BZWP;?VL%6;",S9W3&X5*F76O(QU+L<E)R,)?LC-<55
M<&\2P8N)%:2D+H\;QQ8I%NI(%34*Y!`R8AS..-*WHTGD]73+K^"/ARVR;3NL
MU'$]:9+H62OV@.'I:O2TA34;(,W'-H610CLB4Z_4",D6!\S5;"-S(QEU*A,J
M/92B76T-:_.,F$>\10L1V\:Y>-&024K%U^)'2NF::U47H\FZ/F3\.6N7)I_M
M<EKJE5<KEVI[Z,!K2LU$MG&0GAHJ.R-*L)%EBZ]NX:XL<4V*-J%W7H,HWA%&
MMR+$6N40KZAH,[HOIJ:S@YDXSN7ZT_$C5J]JZ.CI9TWO8CX<]EI^Y6Q*JJJU
M54J_FQ;[GM#MMK6";V`\A?W#,(B\3\VC'8SN4L]J$)C2U,*??Y:WH1<6\"$C
M*I+R3/UE(K*'8J-ET56#AX==LDM'Q(\]=,J.CK0GX4ZTHM*?,KN2JDKZHG`F
MH19--5(Y5$U2%43.4>2G(<H&(<HAX"4Q1`0$/,!YUH9GWH!H#3%VX^55:?M(
MB,91JIQF<VY'K]?.R1$0<.:W4SC;Y0Z12?I%.FP1]09'2*'"A9$2F'@>A3'C
M.D:?R?@K^AT?IHUXF)Y13?:[>52,^.J*2@X[I5,(0@#6ZS#1+@Y.!36?-6*)
M)!SU!X`=V^])<G$."F.J82@!?*\*84M4E7NOXF,Y8I2ENV_3P+B6:>?A]/WO
MN'R,&KE2CKLO,0]D?B`>'/\`:+[OJ'W\CH"E+MP'V52<A[C?\#!_+\0T!2EF
M9R<B3](7QY#CV@#YA^U]WX:`I:C8IN1)[)OA^S_X?=^&J."TMRW!35VQ3>"A
M.#>XP>`_</D8/D/(??K-IK,%+6:G(`^'>$]X\>[^T7Q_$.0^/&H!2U&P#XIC
MQ_9'R^X?=]!\/F&@,39-Q9#9&C4$G2B\-8XA0'E:M,?RE*P4@0Q54ED54SIG
M5;&533%PV[T@'Z"JHJ(.DD7"4-5^SV+PXCA76+M*+R:]ZEH8WR?+I3@8KRTD
MC$9#:)\0\R0"I0E]8$Y(C(1BW2DD$DJ5,PKM"IH"LH53ND4'*;B/:S'B-/#*
M[\^:?/W1EYP37Q.'>&JU@]GRV9GU5`2^!R\A[C!Y?C[A^0_RULG&2^VJ,3IG
M1$/U?:#WA[__`!_#[M4<&LKKQ!3U&P#R)/9']WW#_4/XA\@U0%/6;@(\'+TF
M]Q@\Q^_R,'X_=H"GJ('3\?UB_$/=]0]W\0^>@.'0'379I*\F+^C/\0#V1^I?
M+[PX'WCSH64FN:]ZE)5051'@Y?#W&#Q*/T'^@\#\M#5-/(X>.?`?$-"3JJ-@
M'Q)[(_`?(?I\/Y?(-`4B0>-HIFZ?R*Q&C-BW5=.G"P]*:+=`AE%53&\>2E*4
M1]GD1\B@(B`:!7LLV:SLDWAU?K2\F5.\38)_YG#M#C_JL:B<W<]10$0!PX,8
M[IR(";A94R93"DFF`8-U=3MA#!&FN;>[]Y&[/\G%V6,=W7:.4FR6UB+S&NUN
M+)N"LR*J1C,Y:UUN:BV.*ZZLH'4F!UKP]8VQ9HX34;R<+2YR.5+TN.=05XLL
M,><K=FI^CQO!P0\W0[5]PNW./LC:GOLWX@OF,&EJ>1JLPUKSBY5Y]")3#B*1
M>1ZTBBP.\!PHS3?-#N"D%,KA(3=8#E3HT]FGW,U,;H.PZ@=P53[.%U#Y<8T3
M,FQ6KX"QM;;^A4'CR+SCB[##>HR!:K+PK>Q,',:9&YU+[2TQ9Y(S#:NFL=B2
M<M9)PY:.V8NN(TY6JI-NE<F]:TVMS*;ESL>MQ\B_WD8EV];R:MB79YO_`,LV
M?,NX+'5CPF6[91JEJR66+2S&WQ-=RVZ(B$HS)+:)08G2L$*8:S&B@SC".%FJ
MKV0!37RMQJXI)7HK955-.M]2050[*=KCV^[Y9BDY,91M$W3[+</[/,>51Y7'
M;V2Q9#X?P?)X7AI^;F@F44[<5=D[92!V35A!J@#11`SHQU@53%<5HVR;?6K3
M[,C-FU[LT-M^$L5;6(C)6(\(YCSYM@Q?C?'U<W$3&)*Q]O$76-$Q/`3%:G)=
MO,V6M$C9)1Q)0S9M.JJ13E=55NN"IS*"#DVY7:4FW2MK^90^S=[.*J[%,0R%
M'LSC'V5\@.,Q90R@QRDWQQ&P-@CF=_FQE6,$W?R#B<FTSPB!E&GI:,LDDN"A
MQ1;-B&,00E+$]E1*E=C"V?\`LX-R$7NURKO$V%;D,=X5M6Y>E5.C;HL1YOQ,
M;*V(LH&H\2>NU.\M6<?+Q$C$66(K:BL0O&]VM'3`.Y)R[>HEEY=K("RFL*C*
M-<-7%IT:KIWD4S]@YDM_@'<!MXLV\!G9ZWNSW:X5W$[CK&3$B-/D[C4*3%1T
MEDG&5;@*E:6%?IC.U9(8-9^D*QA#QU%K,/"5HT=,+-E)4P?$^922RCA5Z[WR
MYWW[21F/^Q'PGMDWF;9]V.RR?E,)ML6QN2*?G"@6^U96S$CFG'UV@FL5"0$;
M.9!R--O*0I3I`9&P,B,B.XI_+#$+N8\AHP3.1'Q&XN+O6E*45&NBN2UWJ[9-
MU66KEA;,FT#=O*[=LF8;4MK61Q_<8N?O>W+-=?M\>@Q4CLJ8VC++`MW$S6E$
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M]A.]1!*F_:GS:PROMPJN`G;Z&=%L!C4E)H6ONIM1NZ+/K+MWY&*3E!9`7:C6
MO7QIZ#'];I]3KT^;%M<B92^Q8W:5VI;0MO\`.[Y*-9-JFQG>!C'<KA2EGP&L
MPR79H&@7V?N;>J9'O;:]E9*R,*RL,O7JTZAH,L:IZX=RLPU6+&0,5'B7-5;4
M;RBT[[VJK>\CTBZ&8T`T`T`T`T`T`T`T`T`T!J'[:G9(]WG[-Y]*DPOK?-&%
M'BV4,7MFR0'DYU-DS,WNU&9"!3K*J6JM`HXC8Y$`-)VR`JK<YTT^HX6BZ/P!
M^=08IBF$I@$IBB)3%,`@8I@'@0$!\0$!\!`?$!\!UL"9^RO=G+[8,A@>1,\D
ML76U9JSO4"CU*J-BD,*;6TPR`F`H3,.50XJH%Z2R\:*\>J)5PCW;&T982LHU
MZGJ8KUAA+9!Q-FK4HSFX"=8-I2'EH]8KAE(,'B15FSENJ7P,11,P#P/!R&Y(
MH4IRF*&V=T8E8T`T`T`T!JBW@=I_4L06/\Q&W"NGW#[G9EX>"CJE6$7<W6ZI
M-'ZR=S9'$(8SJ9FF9RG.XJ4$L1RU*V=!89:N=R0'&4^+1TBL4N5TN[/H;\/@
MN2Q3>""U>O3ES?973$>WKLRKOE2]-]S':.VI3,&5'HHO(3#ZSM!Y0J4W*H+I
MG&3B$>)(2128*GY)3:\DC2FRWI)Y):UF?KBC$>&V\7$=7MMU],B9<916#@K#
M'67[GTU77/:FNYWUG6H-W`U0)"#AW\DS=IU>M^EL(]V_CZ^W:^GIP,/WB*SI
MG"-7#+TLL>V.C&MUVO?`BFJEU;<NXY[W?>^N_4CD\P-CVUYQN65*OE[(U>OJ
M*N/8+)M7QYD.(9PRYZ8P5G:?"7JMIQ4B^:G<P=I5?>A/7+%>0A)\KM`I6KU!
M<U<*;;JZVJD]LJE\345%Q5/F<6TZWLVG7EWHL6N]G[A&MKQBB,UE"3;U\:.W
MJ\?-7%%^PJT'CK+,=F>I5B$1]3)'2A(VYQJ8G!VJ\E'D2LM'O)1;H:+MH7#2
MU>FN5'B7<R7Q)/;6MLVXN+;YT?2NA5C[+L!RQ589-_9'*L"2VQ[UJUM#)1Y'
M&R)GVL;IY5*023CSJ-EU\@5Z%=1A'":9B5591B!5_24WY6".6W/*LL7F/B2Y
M7H\OXQ<%X5[2.[/LXEK)?K*;(]R32P^$9EV-I=*I,[:5#Q`Y4RI3,IG<QL3<
MBSD'3VL=,TXCF7@&ZENB+:_E72+Y-C5FK&K(U^'7-VO1+FT]:[<RWQ:15%\W
MRU;2OA36:NZUUI3F[F>X[8+@N.A+I!%<WETVOU!RWCFPK.)Z-3<*0.:[%`6J
M\JLBL8%FS8/UYJNLW$49LT(QB$5G3)HP!F+9!K9<.*KG=-?]LROQ)565G&2Z
MPJHYWLG3,F88[*'C14<.46<=%,1.N[>+IH-VK)BAU*N73E44TD44$$C*KKJF
M(FF0IE#B4H"(7,SM(K(N$4G#=5-=!=,BR"Z)RJHK(JE`Z:J2A!,11-0ABG(<
MAA*<H@8HB`@.@.30'FO[2Z?'./:0[=<%MC^F0.%:RUN%B;";J1:SDPJ>]2K=
MRGXE*C(5VMT)KR8`.J:1*F/202''GXE)<2,7DL^V_/D=7#^3@<26L_E7EX5;
M["02[0?'D/KX>/\`>+[P^G\M7<6LK]--?+WD<I17#$!\@`/]T?H/F4?\!\11
MG3._F"BKLQ`1Y+P/S\_N'R,'WC^.M$T\@4A=IY\AX>_P\/[Q?=]0U(*.LS$H
MB)/#Y#^J/^R;^@_B&@*4NU(<1ZBB0_[P!P/WAY&#Y^?'D/&@*4LV,0!`Y0.3
M]X/$/O\`>4?\`(Z9V8*:HV$/%,>?[(^?W#[_`*#X_,=9N&J[O>?O,%+6:D.(
M^'=G]X\>_P#M%\/Q#@?CSK,%+7;&+[*I.0]Q@\0^XWF`_(>!^7&@,79)Q?`9
M)@QB9<BB3EJ?TN$FV8@G+P,D7@4GK!<O2;]8A._;B8$G)"%`P%53072AI/[%
MX3EPY57:M&MF8TQ[DZPUBP-\39E.FE8S_HJA=1#NXB\LRF*FBDJL<"D0GB]2
M:1TE`*9TL)45@*^4;GDX3:='GH]_S[ZWG!27Q.']/[H:P?\`_.WNDCU&P#XI
M^R/[H^7W>\/Y?36JGO?GK[]]<2GJ(^(@<HE-\?\`'@/U_`=7:4O5<_R#IJ(C
MP(&+U%^/^/$/K^`ZSE%KFMP=!1L(>*?B'[H^?W#Y#_/ZZJ"FJ-BFYX#H-\./
M#GYA[ON_`=`=$Z9DQX,''P'W#]!_P.@.,0`P"!@`0'P$!#D!^H#X#H"G+L`'
MDR(](_N#^K]P^8?0>0^8!H:*>_?^"EG(=,W2<HE$/<(?R]PA\P\-#1-/(@SN
M(RL69=*4.ON>N,CW`?:!XD;DC^0;GY+')F*/M-8]4O4X'GA9\0I0`"LRG6SG
M+3O]^[G3P84^=Z_3VZ]I%/69N?IJ?DV79]2>S/9!^=7(\`I!YMW:/(3)5A8/
MT10EZUB^-8N4\152104(55F^4C9B;O$@S5[MVR<79.'DT$7T*HBD.3BRQ2ME
M&W;K[Y'HDT,AH"S\AV1S3J!>;>R;H.WE5I]FLC1JZ%0&SES!PKV30;N!2,14
M$%E6I$U13.13NS&Z#%-P(`KM+<B#V9FZ^V;XMC>!-U%YK-=IUKRW$6^1EZU4
MSR2E>BU*[D:X4QLG&GF'3Z2,1=E6VSM?TITJ8'3A<$Q*D"9"BTEADUL1EP_V
MN>`8#`-<R[O`SM@^J.+YG;-^'Z!+8:IFXN1I<^]Q-(.!/6A;7+'"-O1O36*1
M3;R:2L8A`V&QK(1%#>3SEXR;KB7!U:2=DG>E:/H_>J,Z5SM8>S_L^W*[[K6&
MX:'9X7QO=?S;7B6GJED&O6ZOY$.9L5M17&,)JJ,<F/+7(@[15BH6,J3Y[*H%
M=.(]-PA'R"C41@E6E+TKFLMZY4[3-VU7>GMKWJ5BSVK;ED8MV:T:P?92\PLG
M6;=1;G2K"9OZ4C&6NC7Z!K-N@SO&Y558YT]ADV$H5N\".=NC,G@("'%QS5/>
MZL:U>U^[6R_=G9:<*4C#&'(3.=LLE8O.:<U0TBYE4G..]O&/)&OQ$M<FP1;]
M@"+V8DY:4:1#V0%W&(*UR0*[:*=:.A>$,5;TR2ZNM/+Q1L$W`=H)M%VOXBQG
MG#-.7F%:Q_F<U=3Q,XB:_;+O8<C*6J(;3\*6GTVC05CMDVFO#O&C]PZ90RC-
M@B[9`_<ME'K,BXJHR;:2NL\K=N1BB.[7CLZ)?"^0=P<5N9KK[$V,;E6L<VRR
MI5#)2;D,A7"(2G:W1JY6G-+0M-UMDE%J'<#!4R%GI!@9G*H2:+)>&ETV(8)5
M2I=W[/MVG)&]KAV><C@U[N-4W&1,/B:&RK#X1M$U8J3DROS=)RE/$65BZI?*
M3*TMK=:29RBW<N?7EGK\764F;9P]6FB-$%5R!@E7#2]*YK+OH8,RAVX&RZ)V
MM[G]Q&#+:[S7.[8V<*E8\4OJ?ES&%E>6"W^D_85M(HVG%JT_7JI;2LG:C3(2
MU5?5)@DCU2D@S%0A1$KARK%.V+)V?W\,R^@[9;8Y7<.8`RGDW(=@I\KGW$I\
MO1>/(/$N<L@W*NU:$>+P-ZL,[7*OBUQ;(>AU2W1LY`-\@V2L5VNVM*(6FJPM
M(Q2J:^@P2JU3)T=TO-T);5W>GM:MUBVZU2L9GJL[/[M*C9+WMU81A)=U^=&J
M4^O&M5HEH1TG&"R9%@H(BKR29SCB*D&RB*[`[0)%!9H05HU6V6?*I*+0@:`:
M`:`:`:`:`:`:`:`:`:`:`:`\'_;W=G,ZVT9Q<;G<75\4<#9ZGG#N=;1C;HC\
M<Y@?@XD)R%412)W3&#O'=/+56Q*)6Z,C]I8-%NQ91D.F[UA*U-5X@\]^K@V2
M[#]\3[;[+HXYR(Z=R.&IQ\)B+<*NW>/91XIRK,1J)0.LM`.U3"K/0Z!3*)J"
M>9BTC/\`TYG,6C*F>7E[U*3C6ZS\STF1<I&S<:PF89^SE8F49MY"-DX]RD\8
MOV+M(J[5XS=('.BX;.$3D5162.9-1,Q3%,("`ZV,COZ`L/)>4,?8<ILQD'*%
MNA:338)'OI*=G796K5,Q@-W+1LF`'<R$D\.7N8^*CD'4E(N!(V8M'#@Y$S0V
MDJMT1*BY.D4VWHC1;;MT&[?M.+),8EV5Q,SA+;:T>J0U_P!P]C3=1$S.,O`'
MK*-=M#>DQOI38Y3-ZC5W"UI>H*M%+/-UF&D7S)#!RGQ'2%HZOWY*^]CI4.'P
M?FXCQ3T@M.OJ[9T39LZV?[#L%;-*YZ+0(<9Z_23,B%LRK9$&[BWSYS="CAJT
M4`#)5NOF7(4Z-?AQ30.5%LK+.9B11&14UA",,L]WG_1CQ.++B/YG;2*R7KU9
M-35S,U?;U,'9UR_EJ->X]IMQ=1T3@2TT;&N1JGF-KBYOC;+^2[E$+R=WM"$5
M;J_=)NN4N`HU9F%8J*C;$A/2*[&+&OR0%=/83*<9.5E^VB>*E)-YYIVISTLZ
M&W#E&,;M?4FXN-<44LE9J]6KM45>W%-YVS;Q+DQR6!YV_P`>^F4<]S54<0&:
M'%/<*W:Y9+QK0<12LO\`92ZQ:2C&B84QRYR62OKK'@$9RUOHGT1U-KR46I#C
M-UN[XGG2[:2K1Y45:<^PE2X::LJ+!6L:V2;DKIYR>&NRK8MW+FW3>TO#9%Q_
MC=/)ZM:F\@YBMM`LKG<',OYZ`.[CZ!3,=^LII_G.H6)I%KI15VRPQ;N@R!'L
M;5-H1#^C0)S!(,8E'B72K2KHW+2R5?FZO72VTQEPZQ;PY136!4=VW^UJN2TL
MLRNO=MVXZ#G\@R;/'^4[1!9)SYG6PWR'KFXM"D6&\1;&KU>J[8+@[M;?)L1)
M15!CV2-A?W.NQ3Z)MK>52@6*M+GJQ5JY&$G#)5LW64J_-2JI2+;3K3-M9UTH
M1B@TDY1348I-PJDZMS5*.^U:JFJJRS<;T#=];+4N[:2V5;A8\)9,QM5S91<9
MK?0>-;$EM\Q)!P^6:>;'+NW1J]NG<TY73FX1S9K/4'$.$-*+2TA:8N5C7Z,G
M"4ZO.J<57%9X4JJE56KW6MV3)P6D4I1DZ8?F6.3<:.CIABUK6JI=.A=U@VK;
ML8ZJTJA1$YF:V24U@:L%>9('<Q8H9#&N[&3<LF-XR;=B&OK"R6>EU6O14$&/
M:74(ZUU?T]K9`>5E&0L[VS+RXSHDJOY;O$[3U;O5THL*55R(Q<-U;PJD[1P5
MKPU5J*M1-MNK='=7M0H60]N&\^^J;IRR\5D&;A,C56SUF!AI+,3&-=R*-DR=
M26:4-1F\+F=#'+VFQ>*HRS2[,EWQSB"?9R3X]0D%+<RG[%(/8PS>*N*ZIG35
M97HU2KR6U[DQEPX_#RJFFWAV3S^6J=:92DGG;3=+782.K5?@ZY#MUVD3`0\9
M"1;1T^>2CEM'13)!BR;N9.1=/I"171;())K/G[UX]=J%,X=.G"ZAUC[JUMCG
M=[[E8$0`!$1X`/$1'P``#S$1T!Y3=L\N;<)O&W@[H%1%Y%2%K?56FO3_`*8B
ME?>2QTH4$S^(=]&TVH5=J=0O2`)/^E(`34$H8</YISGIDO?1'5QOEX7"X>M%
M)KLOXMFQ%=F`^9?IR/\`NF_H(_76F%J\7V/7W[9RE%<,1#G@.?CX>U]Y?V@^
M8>/T#5?EEG\K\/?7^AL2V=T3$LKB2VJY2B\<V""N&;<<05W);<FQ5`FJ'B&D
M0D_8+W>X9).7C+=)G!S9H%O&QL`5<DW8(V-C%6T@0JT<XSEBC*U4Z-IJZ;TT
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MT*U.VEE<4*MS^9%[%*LPCYFN5"JP\(G&W]2PC?7+E"Q72U5>\8>>Q$]`2+:2
MK5FI5?CBNUC4E)1S['M5Z9:*_6I%+5M[MOGV4VH:DE68#R*0](_NC^K]P^8?
M0>0^FA4QOD+'-<R/`.:[9V0J)*?I6;U+A.0BGQ2F*A(1SCI,*3A$3>\#HKIB
M9!PFJ@H=,T-)YEX3E"6*/:M&MF88I60;%C.P,L59G>=^D[-Z/C_)R@"G'V-J
M00(A%SZZAA*TFVY3(HBLX5,=0YDTW:RW>-9*1JFTZ2['Z^_4TE",X_$X>:^N
M&J>K6Z_OI*!9N(!P<H&+^\'E^/@(#^&M$VLC`IRC80\2>T'[H^?_`(_S^NM(
MSKG;R!3SH@//'LF^'N^\/=]WX:."=U;R!TU4`-X'+P/N,'G]P^_Z#S]-9M-9
M@IZK<Q0'PZR#Y^'N^8?U#P^FH!35&WF*?_9'^@_T'\=`=02B4>#`("'N'0$3
M-PV;$:XV<4BK.2GLCI,4Y>10.`C`-52^+=!0H^Q+N4Q\P$#L&Y@5]ERH@9*D
MI4LL_?B=7Z?A-_/*T=%_+\+Q[S7SK([C=9V#79[/]_.^RBH66NC*X`P&^B,N
M9S=O&P+0DA'P[T[FE8Z>`J06SQ;(]I8(1CV).=-=S3(^Z2#<3&BC%,,^)/#'
MF[+[OL\Z'ZI8`!0`I0```````.```\```#P``#P``\M#C/[H!H"PLJ0<E9\8
M9'K<,@5U,6&A7"#B6QED6Y7,E+5Z18,4#.'"B3=`JSIPDF*RZJ:*0&ZU5"$*
M8P"59I\SS_=EL':R[--O^US9??\`LQ*T[Q[CR?\`LK=\_I[X<*$<PE.N^5IN
MTV>\I8JB8&?D95:EPUL?.4JO&VM=]9#0A4&CQDXDDTFT5Y/P]2\L$FY*3J[T
MP^%:_8PQM\[,/>'26'9QM;GBF(;_`.3WVE^Y[<AE-(]\QW)$KF+<@NG+RA6I
ML#6RN233UTY]%<DAX/UA8(E=--5Y'M%$@,62SG'YN<(Q75%L;F>R9WE9+?[T
M+[3::!)E7M6<+;Z,*5"&S%6\=SV;,=8]HEAJD_&U>_QDB^#$.1!<V=63J-CN
M*40M#2<<=[W(JK-U=`IQ6%?X.+M6[=<M5:ZU-EO93;3LK8>O^Z[<)F?"F1<(
M77<'(XKAPC<Q[KR[L,S7*%Q9`S47'6;)MNA2N:7'NF:<T$/4F<'-S,BA`I+,
M)@6I&,>=\*3E6B332KE'"K[(B%EOLI]Y^]+?'OMW!9%SY*;0\;9"QJPV;X>A
MX*D8;SL_RGM1<PZ@9$1EDYZ8EE,>1%XN*2EL:,4205T26GWI'@11V"`*BRG&
M,8I+$T\3K54EIEG3G4AK)XBW>[-\;]C/=L^1N"G^XW8%E7=1A/'F!LN[CL78
MPB]SV&K[5(&K4JXXUR3.2TO1:Q:,;4X\#%14!;W<;/I+1$2_"*%1N@T?":QE
M\2E:22=:-T=:TWNR-N'=J.Y/?E3]X^=,/U*M.LC8D[:.,W*/,682SLPJ,#<Q
M@Z0N6^T_">Y9)E&U5+)=.<W",<P65P1CZ^YF`EK&QX"1C&CL6;C'"FW3X=*M
M<U1M;6RV)K2G97[K<A8>R!;R[:[;1LI9FWZ[+<LW2EYJW?UW<=E2<Q%MQ7N+
M:9OF3;W)/V>/?7815O4CV59J4]89F1AF+5D_(X68,DQ%<:3S32C)?+'#>6BU
M\J:$N-V79Y;H<OYT[8^VTJD0JE<W>;(,.8AP7,O[C5(\EQR11X)PC-0+]F:5
M-*UOI72;QS69LS&+AESJ(G"1*R35<(B(RBE"O[9-OHR,>X[8]OCR?`[/,EL]
MF&8*7F#&>RB-VWR]NVG;\,981W,XXME'GI.,B:M?+)89]_@O)NWVWL6C._)1
MM7*[N,<\M\K"SZA0@R-I`%*/S+$J8JTE%N+JLU^Y/NL;7-GU&WQ8@I_9Y8NW
M`X+Q#ENR0&,\JL]S.YJ+L./X2>P+/>@SLCCFN4RKLHB.?W)[<&CJ#H5_GJ4B
MA'KR366LD@O(LWIGCE[Z%9.+<FFTFU1;[U[;HVU:%!H!H!H!H!H!H!H!H!H!
MH!H!H!H#%6;\*XYW%8HO&%LM5YO9Z!D&#<0<_%K])52D4$BS*3C'0D.>.G(6
M01:R\%*H`#F+EV3-^V,59N0=,KH'YL7:`['<C[!]PEAPY=2N):M.A6G\67\&
MIF\=?Z&Y<J)QTJGT@*+6<CC%&*M4,50YXF:;K`B=S$NXF2?[1=5Y@A#JP-BF
MRC??8=NKYM1;T9_9<,OW8B9H0QG,O17#I43+RM<*H;EQ%JJG,O*UWK(FJH92
M1BQ0D#NT96\94L\O(I*-;K/S-HVZ/M0MNFWJHP[FK3;7->2KK&M7M`QO0WQ'
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M+"#"1BF-566F,G5*5GEE;7-Y:46[4J6H5E"V*-XYY_\`'1T?[D\G\K3>I/'6
MAF-`-`1.WTY;_,?M$S]D=)SZ')Q>/)>'KS@#]!T;3<>ZIU773`!`QS-IZ>CW
M0D((&$B)QZB%`3EK-TA)\O.R\R_#CBG&.C:KT5WX&FSLZ,:?8K:U4I!PW[F2
MR#)S=[><EZ5!0?N"1$*8#B'MI+0$+%O4R_JD%V?I#J,<QLN&I*":UNUVY]J7
MME_U$L7%?^-(]V?BV32<Q_@(@`<>/(@'L_WB_LC\P\`^>M5).V3V9B4)=F(>
M9?I\/[IOZ#]^I:3S!5J/CZ6R3>Z;CZ`*D$[>+3`5*),N(D0)(6*5:Q+15V8H
M")6J2SLBCA4`'NT"*'\BZHZQ6\4JONOW^^8S_';,+/;DIFXTN=AY7%47D`M:
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MWJ-K4\R@\>U:JWNUT^T+HM+`WA)R?<1HU<[./;NHN"5L=M?1];@_22RD5(/H
MQ_55?2Z):MNZZ5\%<4R5<[U\\]J,N^T[%*C#O\CU]EG%A*6?'F:KMCE[6"PE
M?/.N*I1K6O!R<^G66U[7O2]F<U]J[N,5#L*:[JLJW01K$=>G%TD6$`J^([?+
MG%-.MJM5I6E.3=:ZT%.>M*:]U?>^1KPM-2FZG.RE?G82;KDS$NCMG\!98QW#
M3T:H``H1"3C'R2#IFZ[DZ9SH+HIF`#@8.2F*(Z)U5?*Z[RI9ZK<IA'D.@X>?
MAQX_,/\`R'YZJXI\F"G+-_#I4(!B^XW'AX_`?,H_@/W:R::S!85XH%?OE??5
MNQL"244]+XD'@CMFX*`]R]8.``3MWC8PB9%9/QX$R2I%4%%DE*M)YEHRE"2E
M%T:\>3Y$=ZI>;)@V;88WRR^5E*2_5!E0<FN`$$T"`'2WKEL5,(@V602+T(/%
M3F!$@<G45C0.M&53<71Y:/;9,VE&/%3GPU22O.'_`.H]=?=99'0(H`'2$/:`
M#!P/)#`(<@)1#PX$/$!#D!_CJYSE/6;@(\*%$#>XP?T'R,'X_=J5)K(%/5;F
M*`\AUD^/'E]0]WU\?KK524E1ZVI[]U[`=$Z/O)_V1_H/_'\=5<-NX'15;E,(
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M$E)%!0/2&58ADDRPE,@S&Z8N#:IKNO2)V2G).1'%.3FVWV+9&Q30J-`-`-`-
M`-`-`6I>[S4<8TFW9'OT_'U6CT*M3=PN%EEENXC("M5R.<R\W+OUN#"1K'QS
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M:.8./H<?C[(36)QO9U8A&:6=9!N],9Q+>8C)\)M`0T[MO*EZUK7*_-7Z)FPC
M0J-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`0CW[;%,2[^\'2>)LCH$B;#
M'^E2^,<D,V:3F?QS;S-P31DV13'1-(0<CW:+*TUM1R@UGHPI2E78RS*'EXR4
MZ.H/SC-SVV3+NT/,EKP?FJN*0-NK+D3-W:(++0-K@%U%0B+?4I-5%`LQ6IQ%
M(RS%X5-)PW6(YBY5K'S4?)1K39.JJ"/VI!F[8SFW'6W[<S<<A7_&$+>DB$J\
M6RLBK4'ENQ\5Q#E%U-TQ)ZN$25XNF/<R/4@WE5V9`;QTU'I*/6TC$6E.3:3R
MZJVA,\3X<8IVNVM'?7[:5[SUO8_R)2LIU6-NN/['&VBLRR?6TDHU7K*50H%%
M9F\;J%(ZCY%J)@(\CGR+=\T4_1N$$S^&NE-/(YB]-`-`-`-`-`46P5RO6R*6
M@[3!0]DA7#B.=KQ$[&LY:,6=1$BTF(IRJQ?HKM5'$9+,&,FP6.D*C.09M7C<
MR;ANDH12N=Q6F5BV6V*,8L\@/LKM,>TQMDZ3CRQ,CD!"M1"5Q?1Q46K;T-U8
MB-"RBR(M6+%H<JCHPJ-&#%J<3-V;9-***M:*N]+]Y-72E73:MNX)XGQ>E/UB
MV$QY2@M-+CWD54;*:LPQ[!6HZ0]*]/9PDR=F:2C4'OI\@+HK5REZ0,C(F5ZQ
M?O!645:T55DZ*J%71JKH\U5T=,J[T,@:D@:`:`T5]NA?)%QBK`^W2MJ==DS?
MEANZ]"2,(G>1M32;1C-@X(4#"5%]:KE7G*!C%ZE%H<X)=7=+`&'&=HQW?X^_
M@=/Z9)2G-Y0CW5U[DR1]5I,=2JA5J;$D`L54JY"5J.*)>D/08.,;1;3P#_1F
M%!J3D`'CGGCXC=-P235LE3WV^[<V-3;>K=7VW.9PP$.?9'GX#X&^X?(P?X#D
M=6:4K^*\@4)PQ`0'PX]P^'A_>+[OJ'U'D=1\T?\`);Z^_L#OTFR3&.+U3L@5
M\$@G*1:(&V1`.`,=N>1K\HUE6::W2)1.W57:$3<)"8.\1,<@CP;4U4DU7--?
M8&=9'=UD2*92%3HS.$AZ(@ZG6U5CY>#CY.R0E4E<I(9>95MS.)%:@])&W!JV
M=F?(M6JTH5$J+\JC)%BR8U^&M<^65:4K[_)-=LOM6M.\L]_NXS2ZBI5@L[J9
MW\J%H9#:S5"&-;H^M72Y.[]9Z5%V(4!?LJG+VB0D7JT:`J*HMY*0BVCMO%O%
MVAZX<+NFXV=JTJE1/KXUO<CW[V["FLMX><(J3L<@5[7'B-PN>5KQ;(>0K;)>
M(L,GF96K.;RT?-RF35")</J769&+:LG+1:'?Q:#EBZ3/U<L"?TWI2VJIE]]N
MTFKWW\<S&^2<VRE_QVG2G,4R8O9C*=DRW=G\;'Q<-$R$Z^@8FIU:(@Z[#M&<
M?"PE5@&$EW*:28JNGEA>][P1F@=:$\+KLL-'I>K[Q7SK[Z?<M./W`9FK">.2
MU&]3](<XNJDM2*M)TJ5DJI*FJ\Y=Y?(4I#RTI!O&3R69/+-,NG:S5XH9!5%)
MD@HD8C1$2Z)1E76M&TZ.C2I6C_H5=N7O2Y\O-RV8E\KVK-JD\@IDRX72`N\Q
M9%V"3Q<7=9GFUEB8)LT?&=,DZBA+QE>5"NF;J,DVU7KL>W!"/CO1E9P1HHTL
ME1>O7._-BKK77W;H8?RC>K'E:W.[G9_5J4FO&5^$;M(:/2BXB,@ZG`1E6KD1
M'L41.*#2)@8>.CTCK*N':Y6_I#UTZ>*KN%9225%[J0W4Q:NV`WLJD\0\C!_0
MP?R'[PU(*6LT.3D0_2$]_AXA]2^//U#ZB`:`I:C8!\4_9']T?+[O>'\OIJC@
MM+<MP6?;*A`7.%?URSQB,E%R*(HN6ZX#[O%-9%4@@HBX0.!56SE$Y%D%2E41
M4(<`'636C1,9.+3BZ-$7X.PV+;?+L:7D)X\G\/R;DK*E9!5**KRH*J#^@KMJ
M$A>`8)E`P-'8@)44""=KPR378P]4\/RR^EY2U7)\C=I<9.4;<57E'^?^4>>Z
M_%9=`5-=!)PBHDZ:KIIK(.$#E50615*!TEDE""8ITU"&*=-0AA(<I@,4P@(:
MT<6KYK='.=)1L(>*8\A^Z/F'T'W_`'\?4=5!2G"21"**J&*@5(ICJ'.($3(0
M@"8YU!,(%(4I0$3&$0`H`)A\`'5E-K.Z!`+.NY]-/TVH8S=E45`5&LI<$!`2
M)\<D6;5T_P"V<1Y(:8_4('4:-`YA1?ITXG%3M'O]#LX/Z>M)<16TCY-^G?L0
M(.<ZASJ*',HHH8QSG.83'.<PB8QSF,(F,8QA$3&$1$1$1$>=8'8?#*.?RTFS
MB8EB\DY23>MH^-C8]LN]D)"0>KD;LV+%FV(JX=O';E5-!LV;IJ++K*$22(8Y
MRE$#]);\GV[&;_('QJ?<CN'K[,V[O+L`DW1A79$G2N!L<R14'A:0W4X.FG?K
M$8C=WD*1;F,$<1!E38U0J#&??6(<G%XF)T7TKQ>_IWGI3T,AH!H!H!H!H!H!
MH#6;VH&W_=)N5Q;BG&^W6/PQ9JNUS54;UGS'.:[G;Z)6,M8\H1E;+!8U?SE.
MI=YD5*Q-W]E6)*Z0WJIK]H8*$/`J22,?)23=T+0:3;=<K-4MSO3L>AYM,48D
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MA:8"[[^,HWC)^?\`)F3;<9:R.#3=&I4V^82V/2.R"4E)NMVJ555%5R;_`/%4
MC3M5CT^[>K=D>_X$PI>LPTHN-\LW/$^/+3DW'Q"N"%I%_GZG$RMOJ94G:J[M
M`*_/NG\6#=VNN[;^B]PY767344,,G1-TNJNCW1F#0@:`:`:`:`:`:`:`:`:`
M:`:`:`:`:`:`:`:`:`@OOS[/_!W:`8H5H&4HX(FV0J3UUC3*D0T;GMN/9QRF
M4!6:'4%+UM7)!1)N2QU1ZX)'S+=))5-6.F645,QLIM9`_/*WD[+LX[&LO2.(
M\V5\6BX^D/J=<HPCA>G9#K::_=(V*IRJJ*0.4?:2))1C@B$O!/%`8R[-JL*7
M>[)IY`@C7O\`TTR%_P#IZO\`_P!B)J%]4NSR+/Z8]OF2OP1N,RIMTLX63&\^
M=HBY.B$[69`%'E7LK9$?9;S,5WJ13J$*)R-I%HHTEF15%09/D"JK%4NFUD4:
M3S/15M@WXXBW&(LH%9RE0<GG3(1>D3KU+NY5P!?;/4)@Y6[>>3-XF"/%-I.(
ME*J8\8HU1]-5U4D^3V,G%KIN3BU8J-`-`-`-`-`-`-`-`-`><W<&[-N1[9"E
MTQ$?3JMM;H<;)R*20@=LE-QL>:Y>L""/40CI&X7:F1#P_AT*0A4``JR74//)
MI\95RBOSSU:[CIO#]+)KZN(Z=CL__52?:;17,>("/LB`^//!>#?WB_M?4/$?
MD&NC/FCSLN3*`X9<`/)>0_$OX^91'_RU1QUC;R+QG3._F4)S'\\\%'GCZ'#Z
M#Y&#Y#]W(Z*5Z25'X&B:>107#(0Y\/#W^'A_>+[OJ'U^DN*S5GIM[?O6LE"<
ML`'GP^@>[^Z;S#Z#]_AX:C$XVDNU>_SR!07#$0$>"B(_3V@^H>1@^8>8>7AJ
M^=T"BKLP$!Y`./\`N\_S*/\`@-4<=8V?A[][4%%<,?@`_01\?[IO(0^0^7S'
M457[U1[KN_.W+*HHJ[3]8.GZ^'X@8G]0^H_#57%JZOS0**X8^`\!]`'Q#G^R
M;S*/P`?X!JRGOW@HJ[,0$>0'G_O<?R,'^`UHFGD"D+M`$!#I\/I[/WAXB7CX
MAY:`HZS,Q.1*']T?_A-[_H/C\]`4I9J0XCR'0I[Q`..1_M![_KX#\]`4M=L8
MG@H0#%]Q@\2_CYE'\!^&H:3S!;$_6HJQQ+^#FH]M+0\FW.U?Q[P@*)+HG\P$
M/`Q3D$`4263,1=!8I%D#D5(0Y<Y0SU6VI*;BTTZ-9,B0QD[)M;E4(>=5DK-@
M.4>`A$3ARJ/)?&CEVMPG'R@$**CF!.JITIG(4>/%1HFF\ZV$A2,GPW1WASSC
M[VITN=%(\=57R\5*ZR4Z+-<_>64BK?DF@TZNM[3-6./0BY!N1S$G:+$?*SB:
MJ9541AVS8RBC\%2'3,"R`"V3(<JKA9)$14"\\"6*O2FO9[U,%"4G1+*SV75F
MLK,>XJS9..O$1I5:[3NH2EBTE0]/E4RF]A2;=)#PH4W`'"-;F]"2,(`J9ZJD
MFYUS2DWR7O,ZH<-0OG+?;IM[Z$4G`<+JA_[PX_B(C_753KCDNA<%,IEMR+;*
M[1*%6YNXW2WS#"O5>JUN-=S$]8)R4<$:1T5$Q;%)9V^?/'"A$D&Z"1SG,;P#
M@!$!+:2J[)'Z)?8A]@-4-D;.N[GMUL5"7G=T^:(R-5JZ@M)JH;=472`"5"(5
M**["P94[HXIS%R1%:/K9Q4AZ4JH5-[:)\<O$XKE96CXO\<N_8].^AB-`-`-`
M-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`
M1GW6[1<%;T,52.(L\U!&QP"YE'L%,M#D86RDS_<'1;6:FSP)++P\PV*?I.`I
MN8R3;=<;.1TI%.'+%:4Z70/`#VF'933W9GWRO/'>3PRI7,XR=K=5E^VISVO$
MKT'14:W'P["?D5))^Q>VN60F7;J181Y$&C-!@BX:K.R/54V&D'5R?0ENR6U?
M%FL75R#[344143614.DJD<JB2J9C$434(8#$43.40,0Y#`!BF*(&*8`$!`0T
M!LUVW=IYE;%(,:QEA%UEJCH=VW3?NW94[_"M2B!0%K-N1%*QI(DZC`SL)A>K
M#W:*<^R;IE3U=3:L[KW[^Y1P6EG[[C>GA3<GAG<#%%D<9W./E7J:(+2-9>&"
M,ML/^J!PDJ^Z,5Z5%-0W=!(M"NXE=0#`TD'!0ZM:*2>7=J9M-9F==20-`-`-
M`-`-`-`=&4DV,+&2,Q*.4V49$L7<G(O%AZ46C%@W4=.W*IN!X30;I**J#P/!
M2"/&@/.GV4L=(9BR#N^W>SK94'64\H/X2$47(`F9-WDB\O5AC"FY-_F[="<I
M3-`B0@DW3C"I!U])`3YN'''CEJW:O>_"F1T_J&H_"X5;QC5\[43\'WFXUU&@
M/@)?CQR/^X?^AOEU:O\`-%^Z,Y6D\RVG<8(=0@41^/`>W_>+Y&#W<AXC\@U=
M33SL_`S<&LKKQ+;<Q_'/@`!]_3S_`#(/N_E\=6L^96ZY%"<,O$0$OC\?VON'
MR,'R'^?E6CC=76WG^/=;J>2??[]_:@N8_P`Q`/J(!_O$_F(>'O'X:E235'9Z
MI^_RC0H3AE[C%\/=\.?[)O`0^@_?X:AQ:O%TY:>_:!07,?SR(`//R#@_'S#R
M/]WC\-%+1V?W!07#(0Y\`X^/')?O#S*/W<?#5VD\P4==F`\@(>/N^/\`=-Y#
M]!^_QU1Q:^GN]_V"B.&0AR(!S\1X_P!XOC]XA]1U'RRM]+]_;IV@HJ[,!#Q*
M''XA]0-YE'Y>'X:K>#]T8**X8B`CP`CQ[OVP_H8/X_#XZO&:USWT]^`*,LT\
M_#^'AS\P\R_T^>K@I"[,!\R_3X_W3?T'[]`4A5L8G(<=9?'D./$/J'O^H?@&
M@,9WR]4G'D>,E:Y]E#%.4YFS-0XK2#\2!XDCXU`JCUR/5P4QTD3((B8HKJ(D
M$3A64E%5;]2T8REDJ\].\UM9JW135[C)FN5>.3@:L\9NFCI=ZD@[FY=J=(Y3
MIK]0+,XU!0!\4&OI#DHE`P2(%.9(.:?$Q9*BZ7?4Z>'PDG%RNZKHO4A>Q<.%
MV#,BRZRQ&R:B#8BJIU"MT?2%E>Y0*<P@DEWJJBG=I@4G>*'/QU',(Y&\OJ?O
M1'9T*F0,)X!S'N;RU7,+8&Q]8LFY,N+TK6#J];:>D.3D`J9G<E).UCHQT'`Q
M:)A=S5AFG;"$A6)%7TH_:-$E%BC5-*";LOR?I(=C/V'V+.S:J;+*F32064-X
MUGAQ2L-[(AZ97,4L))OTOZ/B@'J":R0'24.RLEY5;M9NS$[]FU2AZ^LK%.1S
M<3B.=LH[;\WZ:&_#0S&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@
M&@&@&@&@&@&@&@&@&@&@&@&@&@&@,3YMP7B3<=CF>Q-FVBP>0Z!8T0)(P,ZW
M,<J3A,IP:RD4_;J(24'.1YCF5C)V&>,9>-6'OF3Q!3DPLKH'CWW_`/Y.MDS%
M#:<R?LLEIC,U&:]_(/L.3@-S9;K[,H'65"J/VR;2-R.S;$*?NHQ-I$7#N@;,
MV#"VOU%7`Z1GH^_U!YG)*-D8:0?1$NP>Q4K%O',?)QDDU78R$<_9K';NV+YD
MZ32<M'C5=-1!RV<))K(+$.FJ0IRF*&@*8?\`6'[OY!H#OQ$Q+0$DSF8&4D86
M8CEBN8^5B7KF.DF+@GZB[-\S51=-EB<CTJHJD.7D>#!H#9Q@SM4LTX^*SA<J
M1[/+U<1Z$?6+I4D'>&J!>"`8)MLW583/=$Y.8LQ&*2+Q0`!:<2ZA.%U-K.Z\
M??4HX)Y6\C;[AK?;MKS6#1G"WQK5+,ZZ"A4;\*%7F174X`K9DY<N%(&87.;D
M$T(68D'(E+U'03YXU=3CE6CV9FXM:$P@$!`!`>0'Q`0\0$!\A`=6(&@&@&@&
M@(`]J#EK\SVQW.LTW=>C3%LKB>,8,"GZ%EG>1':-8DO1C\@)'#*M/9V5(<H@
MH0(\QDQ!0"B&?%=(/G;O_!KP8XN)%:)U?9?SH6'V;&&#8IV480C'+06\Q;:Z
MIDN:$2"DY5<Y!=*V2,[\@AR"S.M/(*,43.`*$%B!3E*H!P"O":C%)V;O72]U
MX41''I/BR>SPIKE;S3[R93N,$O5[/@'F/3X?WR>9?J'@'SUM9\UWG/5QSO'?
MW]RVW4=_9^G/_P`!_P"@C]?#6;AJN[T]]I=-/+\ENNXP!Y'I$!]X@'!O']XO
M'!P^?GQ\M54G&W91D.*?+H6P[C1*`^S[/WB0?_B(;W?7P#XZT4D_0S<6O4MY
MPP$!'V1^0>0_W3>1@#Y_Q'4M)HA-IE"<,0'J]GCX^'A_>(/\1#ZCJOS1_P`E
MX^^_L-5)/D4%RP$/(/H'[(_[)O,/H.I^67/W3WV/8L4)PRY$>2B`^/NX-]X>
M1P^@?344E'*ZVU]TM]@4%S'\<\`''T]GGYAYD^[P^&IC)2Z[`H:[,0\!#CWA
M\?[IO$!^@_?XZEI/,%%<,@'GP\??P'^\7W_4/'X_#5/FC_E'7MS]_F@HKAF(
M?L^'Q\1*/T'S*/R'^`:BBE=6>WG^/=!1EV0#SR`\_'R-Q_(P?^0:A.4;>#!@
MW(V8<88S*JG:[7'-Y$A1,6#8G]9SBAA#DA313+OG+0%?)-=Z#5KSR(K@`"(6
M?$BE=TY:EHPE+)=N2-?&4MZUFEDW+'&T0G5F(B*99N6(WDI]0@CP"B#4>]BH
MTP@/!B'"7.`\'2<I&#PQEQF_I5%WO\&\>"E]3J]EE^2#$Q-2]@D7,M.R;Z7D
MW9Q4<OY%TL\=+&$1'VUESG.)2\\$)R!"%X*0I2@`!DVW=NK-Z4LK(HCO_57/
M_P"KK?\`],VH)6:ZKS+7C/\`4T_D93_?,/\`70F?U/L\D;?^SB[&/>!VC<U'
M3-,K2V+,!@[[N>W!Y"BG[6H=P@MW3UI0HL?1)+)=@2Z%TBL8!1*"9O4BM+)9
MZX*Z"J@S<DNNQ^B3V?'9F[7^S=QH-*P550=W&>:,PR5F2S(M'N2,CR#4I3`,
MK*IHD+$UQJN!E(6FPA6E?B>HSD6[V:=2<S(C.4G+/)9+8V$:%1H!H!H!H!H!
MH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH!H!H#5GOY[(W:SOU:N['9(@^+LW@U[J-S50V#)&<>'21!)HWOL&?T:-R!%H
M%302+ZS59V-HT;IL8:SQ#054E+*373;WD#QE[S>QPWK[-W$S.S&/G.6L2QIE
METLMXG;/++"MXQ/DX/+9744C6JD=PAW7K%S-Q?V<;NCF;,;)*%("Y]%)/6G4
M&J?5@-`<9_,!_P`>'_GK*>:Z`D9B7=QN(PF#9M0LGV!M"MNDI*O-*IV6KE1+
M^L@WA)TC]G&E4#V3JQ)8]UP`"1P0Q2F`ISCDWY^9#BGFC93C#MB)%$&[+,F)
MVSX`Z"N+!CF1,S7Z2\`8X5:Q+N$%UCA[9C%M+)+K`0(@0A@!/5<?^4>U>C]2
MCAL^_P!_8V!8[[0K:;D4&Z2&46%.DE^GJB\AM7%0.@8WZI59B0*-7.;GD!!M
M/..!#QX`Q1-JN)"63[[%7&2T[KDP8><A+$Q2E*_,1<[&+^*,C#R#238K!P`\
MI.V2R[=3P$!]A0?`0'WZN5*IH#0GVS$A(9=R%LQV9UYRKZPRUE1I8IU%N/*C
M%NZD6=`K,HH3@P"V12L-Y>KJJE!%NG$&6-U%(84\.,ZX8[NOV7W.G]/\JXG$
M_C&BYZT\%WF]QO5V$)%QT/%-$F47$L6D9&LT0'T9JQ8-TVC-LCSR=,B#=)-)
M,!$1Z2``>\=2I6HU5>)S%&=QGB/)1`WW`?[C>1P_P'CJUU>+JMMM=_R"UGD5
M^L(%\/'D0+R']\G[/U#P#S'5E).V3Y[\BKCM9[W]2UW<:(>9?IX\@/\`LG]W
MT-]_AX:EI/,C$X_4NE-:=I;KJ/\`UO9\??X>UQ_:+X`</F'B(?`-9N#65_?4
MO6N1;3N,#@1`H`'/PY((^[P\TQ_A[@^.BF];\_>91P6EN7O(MIU&B`\"40'S
M#R`W']DWD8/D/E\QUHFGD9M-9EON&(AS[//GS[/\#D_F(??\-0XIWR?+WN2I
M-<RA.6`#[@]_`#Y?W3>8#\A_AJ,37U*VZ[O>O(U4D\GV:E!<,!`1\!'P\OVN
M/IY&#Z!S[@U+499=ZW^Y)0G#$!`>"@`?3V1^H>91^8>0^7CJ*RCG=;^^>5?Z
M&";YF7$./`7+;<A5B+=-^>]BR2*4E-EZ>>>F%B@?2YO$./\`4N`-[(CSX:/B
M06;IRU[D6492R3?/3OR(5WSM`J*P[]M0*E-6=R'41.2FU$J_$B;]E9-N0)"3
M=I!X"*2Z$2J?Q#K)^MK&?$@_I3KOEZU\#5<"6K2Z7?H05R5NNS7?!5;*V<U7
MB'!3@:(IZ9X1'H,/!DSR)5EYQ<AR<$426E#H'`3!W(%.)=9RXDI43>6UC6/"
MA'2KW=_P1C.<ZASJ*',HHH8QSG.83'.<PB8QSF,(F,8QA$3&$1$1$1$>=4-#
MJN@Y04_NC^!@'0%'T!M_[,;L@MTV_?(=`M['$RT?M>876NNLCY,R(\EJ32[/
M3HV=9J7"LTF19H#9+=.RD,A*1""U,:N&<1)JI)S=@KAC)NRBKFEEGRT?,]:&
MTO\`)AMCFW7-MKRKD68LFY2LM;,K*8;Q/DN+C4J92(<X).$&^06K)55#+\U'
M.^^;LUY9G!U-Q'`09>E2DB8CQL*2XCERRK0](L='1\/'L8F)8,XN*C&C:/C8
MR.:H,H^/8,T2-VC)BS;$2;-&C5NFF@V;()IHH(D(DD0I"E*`H=S0#0#0#0#0
M#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0
M#0#0#0#0#0#0#0&J7>%V-&Q[>%ZTGIK'1,291D.^7_.EATC"I3#R05Y4%W:*
M\1FO4+<9POT&D'LO"#8G")3(-;#'F4%8ME)K7L8/+ANO_)Y=ZN!_6EAPV$)N
MAH3/OETST5,8#)S=DGU#WC_&DP[74D7`AT$294BPW*1<&$Q_0$"%'BZFGG;R
M!HDLE=L%2FI&M6J"F*S8H9TJPF("P1CV&FHE\B(`LSDHJ20;/F+I(?!1NZ02
M63'P,0!U$[I/2_OP!0]9@:`X5_U`_P!H/Y#J\,^P%6KMLM5/>A)5*S6"KR(=
M/$A79F1A'H=(B)>'48Y;+ATB(B7A3P$1$-:BB>:J2JIO:![O*2"2;',T]-M4
M^`,VN3*&N(KE#]E60L4=(3`<^\Z,DDJ/O4\1YMBEN5<8O2G3W0LRA;X?6W:0
M8RW+[EH9];_S=T9W`P4/08V/:`W<DK5H1B798Z:F6[3I9O;--3A^[?I?\[F:
MK(HID(($QE+YZO3T_)MAI^GDHZRJZ]4K4Z+LJ>@2"[739M8@*,F^R/3#*``F
M&QT8[ONQ'S*J%1D[24_'O%/JY^/NU;''?P.7!+;Q,BL>T*V3SX`#'.T"@)_V
M)BO7B`*`^0@)IRL1P)F`?,P&$GO*82^UJ5-9IT]\QAEM]_(KQ=VNU-_XMMPF
M)`YXX]+NT''F#D1X]I\[;`(!TCR!^!`!`1_6`1OCA*TFD]ZJ_H11[/N9Q.-Q
MFVA4O43<)@W@X`/_`$K4,.0$.0`Z1I\#%-\?`!`?U@ZO#4XU']T9+_DJC"]G
MW%J/]QFVI(#".X+"`](\"0F5J,L8!\@Z02G3J!\P,'A[Q`-7QP_E'O2\RF"2
MO%/FK^^\Q[*;L-KK,ICJYVQHJ!?/T*S,)%3CCG]2/.Y%7P#CV2B//`<!SQJC
MEPW^Y5W+)2><6F8GF]]NT:-[PBF7&3PY>>$HNK7>3*J(>0$69UM5L41]QA7*
M3X&X\=9XHIVEVJOH6P-K+/H8-L?:4;;X\3%BFF1+((<@0T96V#-+GW"*D[.Q
M*X$'S\6QS!^X(^5UQHK.KYI>M"CX,M&ER=;>#,`6WM088B*@4[$<BZ5Z3B#J
MR65K'IIB`B)1/'Q<;)BX`Q?$P!)-1*//M'`.=1\:KHHY[W\/R6C^GJU67<O'
M,BY;>T9S]8`42@T:72T1Y!-2'@3R;X@#[SKV5Y,LS'#W&3CD"^`>QY\JM96]
M\ZG2N#%9MRZV\DB,=NSWF>^(.&EKR7;I5@[,!W,9ZW78Q*YB@(%[R)C19QIB
MD`QN@@M>@G(])0YTJWFV:*$%E%>?F8/5#A0_^T(_CX_UUSRS?5ECCU`*>^#_
M`$0_[8?[O_CH#HE*8YBD(4QSG,!2E*`F,8QAX*4I0Y$QC"(````B(CP&@-R>
MR_L(>T`WG>K9U'&ZF!,42`(K&RAG-M)U%!['J=)_2:I23LU+S:_2&_4M&/F\
M(QJKXP$35M+,J@*@*N:7/H>NS9'^3E;"]J?JBU9/@W.[++##N'!K%EZ-9EQU
M'2"72)E:YAYNL^K?HXG(11,MZ>W]ZV7+WS%^S$0(49N3?+H;]6+%E&,FD=&L
MVL?'L&R#)BP8MTFC)DS:I%1;-&C5`B:#9LW1(1)!!$A$DDB%33(4A0`!4[6@
M&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@
M&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@(R[@=F6U?=0T!MN!P1CO)KE-J+%K/S
M4&FUN4:R-U<M8B\PQXRY0S<3&$_=14ZS)W@%4Z>LA3`!HSW!?DR6V6Y^G2NW
M;,&1,)2RW>*MZ[;&[7*M&2,')DF;/TES6[I'HG_T2CV0M=F52+TK%:+F(9)4
M#1MN"[`+M$L(>G2-9H=;S_6&G>*A+X9L:4E,@V#D4N^H]G0K-P<OCE``59UV
M)L::2O)".UT^E8P&GN^XZR!C*8<UG)%&N&/K&T4,1U`7>LS55FFYTS`10BT7
M.LF#Y(Q#"`&`Z!1*(ASYAJT/J\O?0%A:V`T!F##&WD;CB_>ON4EF'?0N$JI@
M2@5QRJB(%2R'F/*$2LB[9KF$`.JPH5!O,>^33`XHIV5D984P<(=[C/ZGV>2-
M&_\`:C'>3?8O[\#!^JF8T`T`T!0'8<.5?J`_B4H_UT!UM`-`-`?"@<IJ!\2&
M#\2CJ5FNJ)6:ZHH6MS<:`Z8-7#Q\DS9MUG3MVLBW:M6R2B[ARX7$B:*"""13
MJK+*JF*FDDF4QU#F*4A1$0#6,OJ?O0&SO;EV,/:1[G/0'M*VSW*G55]W:A;O
MF,J.):X1FKQW<DU1NAHVR3[`_("1>J5Z?,H7DZ:9R%,8*E7**U[C?5MW_).F
MQ_5TKNVW0JJ])DSOZ+M\@`1(/'28Y$LFY"8*'.4WBB9,,6HG``%1-WR8`(*N
M>R[ST.[4NRBV#;,E8V6PEMXJ"%XC2D,CE"[D<9#R21V7CK?1]HMRDHO67"W!
M>^2IR%<8&`H`5F4.0$4;;S?OH;$M"!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH!H!H!H!H!H"A6*KUFWQBT+;*[!6B&<?ZQ$V*(CYN,7\!#],PDF[EJKX"(>V
MD;P$0\AT!`C*W9*]G#F;TE2X[1<2L';KK.K(X\BGN))`ZY^1%VHZQ9(4\[ER
M)Q[Q11WZ1Z0?GTDJQ3'*:<36K!K=RC^3+['K85RYQKD/.^)I%3J]&:DL-;O5
M7;=7(EZXNQ5M*R..@>`+S=$N2`(&ZCB"A;8WR!B3.'8F90PGV7>2MI.V-TCN
M+RYDG<Y5<QV&>=H5/$KF2K<'!M(1A$@6WWE>&;)5UI",S(I&LYSO)&:EG;=J
MW2<K)(U;JZC['G(M'8T=IY4.\]:[/LD.^ZY$WV7?TN[\]/GW?V+M,_WWEX`C
MUB;]GGD-0"-UKV,[TZ+WAKAM'W+5Q%+D3/);!V2VD>8I?UCI2*E:!@LF'O41
M<*$`0$!-R`Z`QFM@#.[9)1=QA3+:""11.JLMC>XI))D#S,HH>&*0A0]YC"`!
M\=`8QD(V1B71V4JP>QCU+_2M)!JNS=)\B(>VW<IIJD\0$/:('B`_#0%K/PX<
M#\RE'^'']-`7=5<79,O9B%I&.KU<C*#TD+5:C8+"8X\\<$"(CW@F'GPX#D>?
M#0$DZMV<^_NZ=V>N;+MT+UNKP"3]?!V1HN+4$?W):6KS&--P`@)N'?L`8IC<
M`8HB!).I=ASVJ%R%,8W:/:HQ(_`F6MMUQ72P2(/')U$+7>X=Y[(#R*:;918?
M$"I&$.-`29JGY-=VF%C,D28B,'T(JHE*=2V972>$;@<0`QE@HT!<SF*F`B8X
M-R+F$"CW93CP`@3>Q3^2>WMT9JYSAN_J4"4G09["XIQK,6TSCQ#K1:V>W3]*
M!GP'(D<JU%]R(``M`YY+HY[+O]/R:.>R[_3\FT#$?Y,_V;F/1:N+VVS1G-XG
MT*.D;[DA2N0JRQ1`1!O'XKBJ!(H-1$.0;NIR04X$2J.5"CP%7.3Y="KG)\NA
MMUP3LMVE[9$4"8$V[8CQ>\02[@;!6J5#)7!TF!.[`LE=G;9U;I8>@1+UR<V[
M/TF,'5[1N:E:MYNI)S0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#
00#0#0#0#0#0#0#0#0'__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g893535g43g25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g893535g43g25.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0V04&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@`````````````!'0```<L````&`&<`-``S
M`&<`,@`U`````0`````````````````````````!``````````````'+```!
M'0`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"O,````!````<````$8`
M``%0``!;X```"M<`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!&`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#N7=-M=:7&K(I:'6.'IYCFUC<7.]38-NQS_4?^9[$F=*O:V6C*]^YT
M#.L('#F_VKGN?]#_`#UM65LL8:[`',<(<T\$*A5EV;V5"MH8';=*KFPR=C1K
M5L;M_K[$E-;[!E;"T5Y.@>Z79CMQ<7,V5"SW.96[TF?0?7L]Z;]FW5A[/3RK
MF&6R[,>Z6@-VO#;'?3>ZM:]1WL#G5FLF?8Z)&O\`(+FJ>UO@$E.*.E6`[657
ML8UE@D9;@;#8-NVP#=]'?^A?_@/3_1J=N%>]H+J;VN.TN-.4YKO;OJ8PN::M
M[-GZ7_C+/^#6OM;X!+:WP"2FEC=)JQLAM]=^0X@.#F67/L:Z8VN>VYS_`'5_
MX-7DVUO@$.VW'I+1:]E>_1NX@21KI*2DJ2KC,P7;=MM;MQ(;#@9(Y&B1S,%H
M!==4`1(ES1(\>4E-A)`^U80):;:P1$@N`YF/^I2^UX7^FJ_SF]OFDI.DAUOI
MM;OJ<U[9(W-((D<ZA3VM\`DI_]#TC&R'YHS*C-0IN=0VQAA^C6.W^X>QWO\`
M;_GJVUI:T#<3``DQ)CQ6?TUSK1U`U179]JL;N)-@EK:V;]L4_FM_F]W_`%Q7
MVBP-`<X.<`),1)[GE)3D8N+B.:UV4[*HMVV-]V9D&LMM<]IVO%S:?5_2?HO\
M/B_]I]GITJV.C8;=L697LJ=2)R\D^U^[<YTY'ON_2>S)?^LU>ST[?T52NN:7
M-+7;7-<(((D$'YJCE8]^-B7.Q'^P5O/V<DM''_:>Z=^-_P">O^)24R_8V)MV
M^IE0*O0_I>3.TN]3=N^T;O7W?]JOZ3L_1>MZ:!E]&9M<^BW*,U-I>S[5D:L;
MMAU?Z?V9/Z/WY+?UF[_3?I+/4M_:K6@>I18P=R`+/_/+WV?^!J-G4L=@;^EK
M8XO:TMNFHP3'M;;M=N24X%SJV6.K=^T7E]+:RZJW*>W8WLUU=_Z/);Z+?5O9
M^M6?X2VSU;5%][+?4!KZF1E!LEMF2P>QN]C:MM[/LEGM].UE/I/L?_2%=ZWB
MX>0!:/1OW3M#C[6V$:._1NW[;-OOVK'LZ78XDLQ<.R>1^FW.+C^E`VOVL]3]
MY%3IX]0ZD;VL=FL-SFB[??DT[=@]IJV7M]!G^D^R^GZ_^%WK6=T?&>UPLMR7
M%[VVO(R;V2YH+0&MJN8VNGW>_'9^@L_PM;T3#H9B-9BUMVG;N)#?;H=NSG\V
M59AWB/N_VH*:;NCXCMP+\F'V^N0,K(`W:^QL7^S&]W]#9^J?\`G'2<0.W!V1
M/KC)_I-\!XGV!OK;6XWN_H7]#_X!6X=XC[O]J4.\1]W^U)2/&Q:\6EM%3GEC
M22#8]]KO<2]VZW(=;:[W._.>BP?$IH=XC[O]J4.\1]W^U)3_`/_1]&PK<@MS
M"YH?8S(>UC`[EH#/3G<^UM7L_P"+_P!)Z7Z176EQ`+FP2!(D&"JN)1;B#+MN
M(L]:YUS16TR&;65L9MUWV;:U8=-C!M<ZLF#(`GQVP]KDE.9T3J+3CU8N2!3E
M/-AJ8+/598T/?[\;)=M];:W^>I_G\?\`PE?I>E;9JN`>TM<W<UP@@P00>Q59
MW3\>VAU&1-]3X(:\`;2/HOJ])M?IV-=^D]1GZ1EGO5',MZGTO#R'-<_+QF5/
M-5P;OR*2&DM-M<?KU3/WV?K7^DKR_P!)>DIV)C0#\B'=7ZH:"/HO:_4`_1.[
MO]'^LH#,I`$^IQWJLG_SVJV7USI^-Z6^ZMILM95%KC7&\QIO;[G?R4E,^H4X
MUF/;6YC/5V%[00TN]ONX^2QNGTX=V76'5L+&S8Z6@"&C_P`EM6IE9WU?S:35
M?EXSF\@FU@+3^\QV[VN6-TFKI8NM?U',QGBI^REAM9M?&OV@MW_1=^8Q)3O-
MP,9UXR*@16:RR:['MG7=_@GMKVHOV5S?YNZY@\-S7_\`G]MKD-O6.F.R!C,R
M*G.-?J`ML81`.SL_?_T%;996\2QP</$$'\B2D`KS6_1N:X?\)6"?_`K*?^I2
MW=0;RRJSS#G,_P"CLM_ZM6)2E)32Q3GV4->TMKG>'5VS8YK@]W^%KLVO;M5Q
MI?M&\`N[EN@GRDJ-+Z75@TQLDQ`@2"=VG]=3E)3_`/_2]3>]K&E[R&L:)<XZ
M``=R4PMK(#@]I!`(((@@\%43C]<-3ZSE4;BT"NWT72#_`(3U6>KLL;_4]%'M
M;LK;M?56]AFTN;[3(/;=[-UGN^DDIL>HS]X?>@98]:E]`V.KM:YEDO+##O:=
MKJ_<WV[_`'I5.8Q@;DV4NM<2)8`P'28#'OM=_P!)1N:\F<>VEC6M+=KVAPW?
MFSM>SZ/[B2DM#W[(N<S?.FPDB.VK_<A90MM+16]@:PM>#O+27-)]KX8_]%]!
M39Z/I@7.J>[DEH#6F#N:0USG_P#5(5OJ2XTW4-:7-#=[=T2-6^U]7N_<]R2F
MS78=@]5S-_?:=/Q3EU1Y+3\PH-=C'0FMSF?2B-#'_1^DIM%+OHAIC72#RDIH
MVX;7Y/K^GCDAIK`?!&PNWS_-[]W\GU/31'=,Z,XR[$QG'Q-;#_WU3-.7ZLA]
M/I;I(-9W;?\`1M/J!O\`US_P-6/39^Z/N24TCTGHA_[28P\Q6P'_`*(47=,Z
M76-S*B""(%+WM.IC_!O9]%7O2K!)#!)YT"C;475/;5M986D,>6[@#'M<6^W<
MDIS^FX56/CMQ2+JVUA\/]5X:=[WV1[[[KG/_`$OTK%HU^G6P,]3=$ZN=)U,\
MJ%-5X<XW>DYIG8UC""!.FY[GOW^W^0Q%-=9$%H@\Z!)3_]/U596:W%^TV&QU
M?+-S7>C.^`VO=Z[=_J?GU>Y?-222GZ,8WI_M]U`;/LV_98G=[MFG[R/LQ'$"
MQ]3&@M+G$8Y![AKAMW;]OM7S8DDI^E**NC5N?ZEV+=I#I;2#S9J[8&_\+_X(
MK%O[%U]7[-Y[MD?1[S_P?_@:^8TDE/TT[]A;'S]EVQ^DC9Q+?I[?S?HHV+^S
M/5?]D]'U8'J>EMF).W?L_E;E\OI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?_9
M`#A"24T$(0``````50````$!````#P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`
M<P!H`&\`<````!,`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'``(``V
M`"X`,`````$`.$))300&```````'``@``0`!`0#_[@`.061O8F4`9$`````!
M_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`@("`@("`@("`@(#`P,#`P,#`P,#`0$!`0$!`0$!`0$"`@$"`@,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P/_
MP``1"`$=`<L#`1$``A$!`Q$!_]T`!``Z_\0`O@`!``("`P$!`0``````````
M``<(!@D$!0H!`P(!`0$!`0$````````````````!`@,$$```!@(!`04#!PD$
M!`8."04!`@,$!08`!P@1$A,5%@D4E58A(E24U-47,=(CEM9GIQ@H06&1"E$R
M)";PH5(S)1F!T4)#8S1$1;:8V#E9&N%B@E-U1GBX>2=7=S@I$0$``@$$`@(!
M`P,$`@,``````1$"(5%A$C$B08%2\'$RL4(#P=%B$Z'QD>$C_]H`#`,!``(1
M`Q$`/P#TB<V(CDTTY]\-=9:WYN;VU+KCF)/;SB;!3*C7-)/XW6Z.BN.Q+O'*
M4-W;-76&845MMDA#N)+Q1R_`!>*E;@B4$RDC454Z.</JL76,J/)2TN.-\-'T
MWCER4N7$6OW_`&%R#9Q".\]OT/8SVD+Q=6J-#T[L#:!YR9K;=M-%81U9E7"C
MIRJR:$<D:K.RK.OC56Z,]2C>_(O=_`?:O&[55ID$=H:.YNJ77BO:]OAK.KO;
M[I6W52J'7M-OD:>^2<'@W4>[&(<*UX'?603(X;,A%T+=:]8B)M.1O6DC[=K.
M!V;I#C1/[+C(CA^[YK;Q93FTH#7CG5VJ8FX6FD3D+6S/:Q/_`(EWQA+4*<73
M:`6'9.&+)-0'957*2&+3KO/R@WF9ZG.S]LZRNZW%.CVRI:IUMR$X9T2U\DT]
MHHT>YC+;;L>K;S(U2'U.E7U)J1J;FJ6]M#2KY29;F4</Q*BT<M"K."+6,:\^
M4VR?K=Z^2WIN#4T%II]/U[6JO)RL0]P1OYD9R;V-Q?H=@N=A86JD(4)^WH6N
M+P^J<E$P5A\8E'BSQN4[F);HK)',M.ND39#>M$2%HMWO&[.,,QK=-EPTT;S9
MU3$U;;D'LEWLK6N_KXPU92(28<'IU*9Z^L[B_P`TQ;BFH>23*R7,Y5,B9,6Y
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M6J\.]+['K],,TC"LHV[679E_@YR>2>IL22ZKB0BHALB9-1P=`H)`)2%,(B+Y
M*]8E"R_JI2B^R4H>"XV2$IIZR<JMD<(=;[:<;8AF$O;N2]!@;*[:0TGK1&HR
M4A5]:6RS5-Y%M;#XD]=(`G[2O&$3,F519UYUI7*L^O/`78*["5'C3(2.P[MK
M31DK2*:^VR$6E9-Z[2V_J75MXT`C,&U@Y7;RVI8_=$--N9$61UG[0RQ/#VO=
M&5Q:]>4@2?K=Z^2WIN#4T%II]/U[6JO)RL0]P1OYD9R;V-Q?H=@N=A86JD(4
M)^WH6N+P^J<E$P5A\8E'BSQN4[F);HK)',M.ND3;ND/5QN[.M<.[=?N)(:<J
MO,-PPF:K>MJ;YC8O6-<UY8(O7DC3)B6V)4M872`87V^%NCI:)K<T,"!V,<51
MR_;.'`M$%G7SJ[OG+S"W-QKY5R*5,>.+!1:5Z:?+'D@KJQ1DR4A[-LK4\]5C
MU26EGJ30+`@QCF;A9-R5NY(3V0ZA^P90I1`1$3'VK^YWWR^XW+\,K):N6,QR
M/2YN<>M[6>U5J6H&GH]AK;8M-XWOM]5;9>BDJ+1ZX_/K6O.6Z$7),YQ>:;BT
M<IO#G%54J12U$WIX=UZ2&\N:&Z['K.UWRX\A]J<?[MQ#@[WLVZ<A=2T_6L%"
M\GI2R0`,H/CK8X36^N9[8VNI*GJ2"ZJIDI>)2(FBJE*J+*"BH@RB/MCG$OU#
MM]T(WES;FM9G:=$W)ZC'*'BSJ_=EBW4@>9B-C)6^[OM1ZT=:_4J,[+1FL/8J
MNI%EF"2!CQ1DS#X:HB"1UA,1\;+B\)/4V7YJ;-@];06AG=&=0VB9K9>_7<GL
M5.:=Z+VE&[MNVE&.AI*);4>/&?LDPZUY+3*;Y5>*`L2@13V4PJD`23%?*M_$
MWU$=O[JY>-$-NK;-U[I+;^Z>2>B.+52@-=:?5U';9/CV$N68/LF_/;#.\@&.
MRG497'<BD1.-@JUWP'9IG>'24%,3$1'+8;MO?VN-@UW>-+HG)N\<>K3Q\925
MOVWLF!U2P='I58I8OU[25%]O;4MKU;8HPR#%7OEH])\L5-/MHJ%`>T-2(\:*
ME\8N4'(_6/I;[*YR<F9BS;SL?EW:_(_6=0N<5K;5%L1T*T:BZT[2K')ZJUW$
M51*9LU1ADIUQ*%A%U2*3HI]V*:"2))\+,1VJ$:%]938418;*PO'"\];KNMKE
MQ(CMLV&-Y$P%D<U2A<U2,CZ8M=?@T]9QBEQLR`K+DG(0'#%O'G;_`*&2=%4`
MP+.O+O!]6[;DON![JBC\+&=H"6Y8<GN&VM;$[Y*PU=3MNV>-8OI-X]L$6\U*
MZ5IE-M-2:`\!X5:3<LG956H-G)2I.5UG6-T/Z_\`5CV+L[DQQJV%1=)<C-FZ
M4WKZ=-DV\]XU:3@]:7BW5#:\7R69Z\D;W*2UPLFL`?UNO-85[#%=)/DO:?$&
MBHQQ#*',W6==)U^7\\2_5.W0IQ3XMIS6LIWDUR(VG0^:F]=@+V&[U33X5/37
M'/?VQJF1=\\:U2;B):WJQS:.@XN+;-D$5EVQE'CYNGU<'6LXZSKHW1\5MY?S
M-<;M(<A/*_DG\9=:5/8GE'QOS)Y<\T13>3\'\?\`"(#QCV'O^Q[1[$U[WIVN
MZ)UZ969BIF$_80P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P/_0
M]R%OU)IG8FX=1[&M<5'S6X>.I+?9M6NB6>992M*;;:K4IKFSS"]8BIMG&S$?
M9X!L\8(J2K)X@FHBH9MW:Z8G*$*.>#?#?8>NINM):\93M#V)R!EN8*LI7=E;
M%1=N-_6I^K,R&WJ7?:Y>&]DJLF^<.U11+!2+*/2074211(BJ<ABW,,&>^E3P
M+>P-*K7X&N8Z(URCM-O1DX#;>[ZR]J[?=EA2M&T4(F7KNR8N801MLJEV52=^
M)4&2BK)`$F:RJ!U':=W?;)].W@E>8O64)?-(U%I$:]I<3I2AQT5:KCK]H[UZ
MV>A*16IYQ&H6NM$V-3E9=`ST(*<\49.'HG<&0.L<Z@BY=3L+@3Z?FW]G7*U7
M#6M.DMC%5UI9[['5_9MVJ"3=_JU1HZUC;[10J1>X"NM)NMLXPC5I+.8XCL\6
M!V1ECLE%4#"YB.&1P?#GA7L"R;&VU3*^TGC[=2V'$[(5UYNS9A-96Z2V37I"
MK['EI/7U,V,AJKSU9(.=<)O)I*+3G`.X%8')5A!0!<^'>*<`>(#ABC%O]*P\
MO%H<7:CPP)%3UBNL_%GXUT*5&<J&N5XV:LS]DZ5@9@0=(S:B9[#WY"',_,)"
M"47*,2\$_3]80<MQT2@6\<ZMMJ9[)L=8;<C=Q1^X+C.,Z?)4QC(6>XH;:0W'
M:X%"C23J-3CWTDYB0CE5$@0[H1#(MSY9A;/39X/W9_1G]@X_5E4-=TVE:[K\
M3%S=TKE8?436[M-_0JE=ZA7+-$U79L!4GZ)%V#:R,Y9)NL0JA0`Y0$*ESNRY
M?A)Q6;.%IISK5)NJWY5J<Z%WJ]YV"DBAR<2K8UA7:JPJ6XK9-).NE%$T,8`K
M@`'>"P[SY^"Y8MN;@)P]W]N"+WIL^ESTCMMU6X.J1UJK&]-X:U7EZU5'LC88
M:*-"ZTV?4("<:1SJ5<.1%5HN8Y5![P3$`H`+F-&31'!'B;`[T6Y(Q&G8MEMY
M:U3]^\;)8;HI76^P;7&*PUGV(PUNM9%-9QNQ+%&+&1?3S>'2EW11_2N#"`#@
MN:I&>ON#/I\M[^G,:WUY17^P]([_`+KO1TE`;-ML]+Z[WQM>'K)+3+62#3O,
M@2*<34-4XA1I!R3<(IBG'ME6+)`4DS@+EE;/A=PUM-]W%=X&K$=66ZO=@U'=
ML+3=R[0CZ6]M.S*<:-V*-OU55=B--<1.R[-3K@55Y)GB&]@[J03=`X*=1-81
M<N7<.!/$.U5O357NFMW$A1]`5&A:\UG4)+:.UD*,QJFO5X9/7T%;JF6^(5C9
MY:^_AV)V:EH;3+CVM%-7MF6^<(N4TV+C[IVW;9B-X6:DLIS9D)K2UZ=83DC(
MS;F/'6EXDHZ6M=4?U(\GY.EV4V^BD!55=QZ[D"%%,JA4SG(87/A`>L?3>X5Z
M=EI6;U]I)I%24I2+-K5LK)WC9EL1J5!N7M(6BH:T96^Z3S'4\#-@]6!9O6$X
M@@@J8```,/51VF?E9S6>M]>:'U?3-6:\BD:?K/6%6BJG4H=Q,2LFA`5B!:)L
MHUDK-V62DYAZ1FU2*45WCI98_3J<YAZCA/.JJ%2X$\$M-;FJ>SH+6\#7-N3.
MP]CWJBEL.T-A3",IM:\LI^R[%MU2U[<+Y*5-[?7$$=^LH]9Q9G\?$MQ(B=!F
MV(1(MS+B<+N(</PUB]Y[#V/?:G;MX\G]O2^X=[;+C*U':RISZPR;AZ,#5:C7
M%9.26B:M6T9!T=`'K]\_=OW[QTLL8SCL)B9NDD4OAIQ)I>\W7(:F:QKD?N2Q
M/+?=VT\WLMF?Q[:9OS5G&;!OE.HCVQO*)5;%>F:J"$Y-PT6S>RQ%"E=KK`<`
M$7-5\)=W%J+5W)'5UTTUM*-5M^MKHW&O76OQ-LL]6/*-6;]L\=0;V=HL]7[$
MU;J.6A$WC9-VD5P@)T%RG1443,2)K5S=@Z;UGM+4EGT3=JHTDM2W&EN]=S],
M8.Y.ML7%+>QO@Z\`R>5A]#2T*T",Z(IF9.&ZJ)`#NS%$`$!=:H#FO3]XBV'S
MYXQJ3VS\3?Y=_/'^_NS6_C?\J/7\`?\`Q6YH>&^0NO\`Y'[/XI_YQ]LPMR[F
M$X.\7*Y;H2]PVL/8[77-_;5Y0PTKYUV&X]CWINV,=0^S[S["ZMJ\:X\S1KQ1
M/PQ5$\.R[7::-$#`!@%R:0X.\7..,[1++IG6'DV;UIIJ<X_4E[YUV'8?!=16
M/8Q=LS-2]FM5MG&DE[9L`H2'M[M-Q)I_\PFY*V_0X+F5*N47I44B_:GTYIGC
M?3]):ZJ^K&F]XN%E]F..0MHME$0W_*GG+G(4F>INZJ?+65C)S,W,.I*MVES*
MU^4,X;(&21:MQ15E+&6[8WQPTK$<;]`:8T%`RKN>B=.:RI>N&<\_0*U>SQ:E
M`,896<=LTUG*3)Q,+M#N3H$4.FB*O8((E*&5)FYM-6$,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,#_T?3GR3U#OR8Y8W[:6H(&Z-WFP=:ZYX63
M=L10<,HNL:EV@QV%:IW<M9<(&3"5E-%7YRR<IG,)Q:GE7A"@0%%`5C452+=0
MUCE_K.:TWJJJ1M]U5I_6[NJU?4T4>IWZPP<M5:MOS9\9?JO?(VK4*QP$,E9]
M41D2SAGMIEJ_#QL.YC7\6Y2=>WD3$UK+(-=V'G+?;([9R;?D!K_7=ONG$6:.
MWD(273N%#1N,QR0B>4=(-<+E2XIS)1M8CZY42.I./BV,,T.\3>07<HKH.CC1
M80:QO.TZCXZQ]YB+O9;7KKU!+8@ZDIV*,:S*Z.UCR'WI4-4;`M"C5FT([;RV
MFHRNR"TL*29)$KPKP?\`QCJ(TU_969_IJ]/]":7U'"Z/NT?R>U)&;,<;^V^M
M0)&.C+I)2^DMJU_:5NC-E]$HG<!^5U^G6SY"&C9&7=,7<HW=RK5D[B4TTQ>O
MG1;GCMI"_<?-(7C:[^-;W3<=BXU:MB2:KU51FNF_:Y32VOK@[JU;1C+/;;ZS
M<[CL4O<5HF0L,BX30<%9QJ)VB+=B4@U)FYX5,UY7.2MPW'H6Y[9+R!=:UUKS
M`>O*1(I06V(B29:^V3Q2!HR)=H:4@(K8\W1HK?'M$._E;'%-$H]"2=^TE8PJ
MI"H1=*Y9KO?7LE9[/ZA.O&^@+U?-G[SEZ&;CS:TM<3["IP,^EQIUM38#:*._
MWL.UIFO2ZKV/$J/E'#28"QLUH\RL<S<.>Z(<1\:N'=K3S0>;1VTO`R>R==TZ
MJ:PY`KO9>^-',/K\=BZ/LVO+%HV[FNLM!1E`K^O=UP-?ESO&5>7D$&5>E72$
MXZ&42319C19IC?["XX73.ZMQ:5O6]I/9SY?;E>XY+4$UWLD;!W"Y-)[1FNI.
MF-8&P>$N]=UDL"XGG(LGBL7*LWSU-)5<B:)JGRUQ!QSV`I8=.JU.E7*5;0#7
M0DY76CSCULBMUJ4M\;S3V5O_`&I1J%.[&K-2NG">C:@0F46<2^7;,PLU/\+9
MH@\4BVB",:ML-Y,R/)=':LTUUJOM=JF6BZI5X\(T&`CI/6<WM5>_7-/;[/?\
MLZA)-O"55M2T(#J:578M2QBSQ2'45G.P1&LQ3!]9:YW?I[AWN)G2"[80V-+\
MP^1]I<(2#A6S;"0TI8/4"V`\LUFUI%VU&0:NK38^,CES/5XO<JEE99XW<D(H
MHY#M1=+A#=$K^[Z1+;+5$O+:&T;=]];KNB=HJM+6DN0]CFE]-<5XOCB]DXB3
MJ;JQDH#WPRV-WJ\I'H+IR\;&(6HZ:'C0"-/MR[>MS>>Q-TKUPB;OL*\2W'S2
M$K8R5JIR\7KO4VX8D>.REYI=0CGE6/KG=Y;?:1MLZVL,%(.I&N%0<QKYLFW)
M&K%&CMU5N=E8JSFU5^7W%/VZWZZYU^.0=GC:NM%TV4HV[(1/C2^I<?-U]A`0
M5O=:K4E!@2RBQX^PBL0TF+A-%!9J-$BZ7G=L[5I'J`4K6.QMQ#)T^TH4OCI:
M-P-'</<:A;W7'/7%Z9,95"PPT#8TF3'9%J[]RTG6Z<@+!R4BP`W41,(GX0!>
MGG/C8U`VF+JL;*C(B\ZFVGR:IU9=5EDYG:Q*7:/7UMIWB),P*C)VW>SU/K`A
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M%$8;$D*EJ*UZ1AFG$WCSKR7J\O5S5V1M'*"@Q^XC[0M#5%103W*88-IZ`8N;
MB@#YK<%@(9*0>DCB*8)1I6H3G!$1L%97=WY&34Y":<].799J[.QT"O$3.X=I
M;EMU6YG4><C6M,9.7L)3]256*4=0Q54_+@2R\BF*3U5NZ0&C/6UEWTK4*ZM>
M7?*>*N3O<J49RT;5^H3ZB=4UHHAM_P`OI<7QK-/=0MLK)KHC56RSNGFE+;Y-
M64<R1PF"'$HT6FX'WBW;)XO4:ZW>=LEFGIRS[D43GK<2'3L4G766[=BQM-<2
M(5UNUKQC>3F3`J1X],K$Z)2&;]41((U)\K?80P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&!__2]_&`P&!%TWNO4]9LDG4;'?ZW`3T-`REF
ME6TT_)&-(^&@X<MBFG#J6>@A#HN(BMF\3<MA7]I0C/\`:SIE;`*N%J7>T38E
M*V;"JV&B6)C8XIO(NX=ZJT[]%S&R[$$CNHN6CGJ+:2B9%)!PDMW#E%)4S==)
M4I1253.8C-,!@,#I+%6JY;X=W7K9`0EH@'XM3/H.Q13&;AWIF3QO(,C.XR20
M<LG(M'[1)=(3D-W:R9#EZ&*`@'=X#`8#`8#`X,I%QLW&R,+-1S&7AY=B[BY:
M)E&C=_&R<:_;J-'T=(L7::K5ZQ>M53IK(J$,FHF82F`0$0P.GJ%+IVOH!E4Z
M%4ZS2*M&=]X;6JA`Q=:@(_VE8[EQ[%#0S5E'-._<*F4/W:9>T<PF'J(B.!DV
M`P&`P&`P,5N=$I&QX!S5=ATVJWVKO%4%W=;N=>B+1`.EFJ@+-5G,/.,WT<NJ
MV5`#)F,F(D,'4.@X&0LF3.-9M(Z.:-F$>P;(,F#!D@DU9LF;5(B#5HT:H$30
M;-FR"92)ID*4A"%````#`Y.`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&!_]/W\8#`8%&-\Z1WIO&^6Z!E&VHD])+:BV+2M:R<A9IV6M-0
MV)LO5UKH\WM"TZHDM5OZA?'#)M8U(&/CQLT>U;0,C++.`>K/DFK,L37[I&XU
M:5M>FZ9>(:5D63)_<-C.[NP8!=+MN5U763FI4NMN(V8VOLUO$[#V9(/Y.KNI
M`KV7(5:.;/T8IOU8QS7"3JG[P^R_$;3W`3[RR_2:[GA]E^(VGN`GWECZ-=SP
M^R_$;3W`3[RQ]&NYX?9?B-I[@)]Y8^C7<\/LOQ&T]P$^\L?1KN>'V7XC:>X"
M?>6/HUW/#[+\1M/<!/O+'T:[GA]E^(VGN`GWECZ-=SP^R_$;3W`3[RQ]&NYX
M?9?B-I[@)]Y8^C7<\/LOQ&T]P$^\L?1KN>'V7XC:>X"?>6/HUW/#[+\1M/<!
M/O+'T:[GA]E^(VGN`GWECZ-=SP^R_$;3W`3[RQ]&NYX?9?B-I[@)]Y8^C7<\
M/LOQ&T]P$^\L?1KN>'V7XC:>X"?>6/HUW/#[+\1M/<!/O+'T:[GA]E^(VGN`
MGWECZ-=SP^R_$;3W`3[RQ]&NYX?9?B-I[@)]Y8^C7<\/LOQ&T]P$^\L?1KN>
M'V7XC:>X"?>6/HUW/#[+\1M/<!/O+'T:[GA]E^(VGN`GWECZ-=SP^R_$;3W`
M3[RQ]&NYX?9?B-I[@)]Y8^C7<\/LOQ&T]P$^\L?1KN>'V7XC:>X"?>6/HUW/
M#[+\1M/<!/O+'T:[GA]E^(VGN`GWECZ-=SP^R_$;3W`3[RQ]&NYX?9?B-I[@
M)]Y8^C7<\/LOQ&T]P$^\L?1KN>'V7XC:>X"?>6/HUW/#[+\1M/<!/O+'T:[G
MA]E^(VGN`GWECZ-=SP^R_$;3W`3[RQ]&NYX?9?B-I[@)]Y8^C7<\/LOQ&T]P
M$^\L?1KN>'V7XC:>X"?>6/HUW/#[+\1M/<!/O+'T:[GA]E^(VGN`GWECZ-=S
MP^R_$;3W`3[RQ]&NYX?9?B-I[@)]Y8^C7<\/LOQ&T]P$^\L?1KN>'V7XC:>X
M"?>6/HUW/#[+\1M/<!/O+'T:[GA]E^(VGN`GWECZ-=SP^R_$;3W`3[RQ]&NY
MX?9?B-I[@)]Y8^C7<\/LOQ&T]P$^\L?1KN__U/?Q@,!@,"IF]N8VM^/4M;HV
M[5J_R#:CZZA]D6":K+"JOHY%A9&>XWE;@&;63M\//R-CF_P-FR$*BR.Q:_H5
M';IN@959$M)ID=R:JB7DE&R>P*JPDXF8CH!_%.YAHA*IS$LA,.8QBE&'4!\[
M5?-ZW)G2%%-0IRQ3X0'_`&)UW1*1W8>66@JQ8H.O2>QJSV)CSJ1S/MYZ!4KM
M<<4)O&.YUM9'QI5->..5G(G7*<J*J!&[)VLLHDDW4.!:E+E=V)0[=,6*OU:X
M5RP3=3=*,[)%Q$LR?O89RC(R4,X3>H-U5#I^RSD(^8+#\I4I!@Z:G$KALNFF
M1F6`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P/_5]_&`P&`P*F7+6G&;<.S-W5B5M5/E]QWS1#?0FP*]
M$6BG.=F4K6B3&Y2JPQD2*3ZTU!Y(1G(4'+E99,6ZZ#V+4,EV#)BL76N'$B^%
MVMX+9MGW'!6S8\1LFS6II:C6AO(5!R\C#-9'=+[P)!&3I3]G-P)V^_+`Q3)-
M)RKEE'`P;LUVQ(UCW`OX1Q4.&O&*11DHC6UN=,3PT'<M;R:="4U5&V%A0Y&:
MLFMIZ@669AZ`G;+!$Q<E3I^":/YUR_FFCQO)&0?ED$U7!!<K):QX^4;4\_(S
MU9<3RY56,S#UN%E7,8M#T*`L=OD[Y8J_42,HB/D21<S:Y/VE0)%S(K(D;H(-
MU$6R)$0%JDR/-9-MO9222N.OPX[0]S0T5+L%9V')=UKN^,4SC;C2..HG*'U[
M`VGV>NJJ`(H&*JX?%[220&#?73QJY]M?^+93F&S`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'_UO?Q@,!@
M,#6[L/AUM&Q;GV[M&J7*FQ+:_69K-MX^S$?7=C+U^0H'&*@6RFNZ/;Z[8]>4
MB3>QVA'QD+*T83#I0)9%-TR60:G0<1J)8S*<)]\/8N@,E-W>(N:Y0-4P&SY%
MU+&&?WC9Z)J4^N'K_P`RV?7]]=:FABV-TI:B-TF]F1<V%LU?MD(B2]N?OQ<;
M.XB."ET;R""$[M(M@JOFJX6.2A7SF?[<VI9;'Z@5F0=3!6BK!@^F$I;EK5GJ
MRW<D*:1J/M)"D538F2J6FCCAQ[V?J6V3]DV1MF;V?(2\(HR7FG4NU03FW+YW
M#OD2SU:3I3.0=.Z(E&J1D-)N[#)*&C'"I?96IU5>V)E8S\+-8?\`]N*'^J%>
M^[LMSNS4;,Z(0J92D(4I"$*!"$(`%*0I0`"E*4``"E*`=``/D`,BOZP&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P-31_47G-;O-W2>[X.L-*S2)[=!]>QD!!6:,
MM-OJ.E=Q\G:K:5H4T).[<0L\W':ST!XDJ,FUI;?V\KHY^XC0,[:1JKJEA97F
MO$P^Q3ZM<:PO#VZIVS8#%2M0,59+).H4'7MDI=:<[`=-H.I/XI!K92WME+Q2
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M`VK`1L;),'319Z^?D2-%-G75D45JS*]\GK#1[E#Z]/J9:9M3B`T0YGQ;W6+8
M0L!9^0-HV51JE#^W+QB[N2AHFUZR=A*/T&YED6"I%V[5TJ'LQA2%ZWZB\/:X
MJ&M,3IRTEI\M2G.QSRSZSUUO)L*778W04O=WJT(B#KOI:(9<DJ^$>T3<&"26
M:2A5%69&[-20BUR_"L<X-A/)#CI&6'4R4>YWGK^^/8UV]?0T)6[#?XK9NC:/
M53P<[&72^2=1HI8_9,@O(C-10RCEQ[`@P25<G,T6%>4O&Y&WR^T;5-NTW3HY
MPYVEJRR[)9PEA5B)649(0=XT_6CH-E!OE%J<FJR@MAOY`4SS;1%\JP1;I.D@
M7%<M2JM!2G.FYNG,&:MQE.G8:V734^L(*4<5V=@Y%B^V=7^-5B#<\]75KN^4
M0UE"%Y"`P7C".P6]N9(`264(]*9*+259?F<[JVN];VV4UF^LTG:M7[,VC/HU
MF;BXR/3K.H[MK2B6";J8SRXDF&EM=;.8R<"DJY2(O&FZJN2B)3FJ5K3EPO-:
M,FHF^2"=!6;.-6VDFMKXR=6MDA[-LR2W1:=$5^/KRR\2B>4UZ[N51<N'MH>I
MQ31A%G!8$%UVLHUCA3$]L\VI6O<?+Q?Z;2&2&Q(:C<TIIJRG;)'N*7"O^&ME
MLVO+F_-/D29!9_$[E%MEXB+!..=2,:==1P=A[*X[L5JRR7YMP<8WN+].AR;B
M(JJT[(+3(S)3,H>D4W9UOU7>+KL)I&0\M/49G`R]%D9`C4K*2<*0Z8N5P:BT
METHL4[B`YCP=DJ-YN,=KN[MH>O72AT>IR<]$S=8@;I+[(W'(:*KQ"S=BK\8G
M'C#W=@5>?!JE*%A8EXV5.95X9=@W%,6J7.)K=)1Y7XG6JK*9;WU_JUNYG+O%
M,ZF[O+"V;NKJR`V>/BI<K.M@QX^SSH)%9L07"[N)9M4'"[U4&8IT#3U%:)+1
M%6E(B@60%+DTA7T/%V":K]=D6K6Q7#AW4HI2P$7<.F\(41YD0SIP<RBB*",:
MX^>8%43"*6-TMNUUMN?N3$81O#L*S'-4^[*LHZ<ELL3M?>>GKHU1D.I&\U6P
ML.E5'</(%;LE7D>^3.JV1/\`,P4L-A#`8#`8#`8'_]?W\8#`8$&7WD!3M763
MPG8D5:*C5U(NRR#79\HSB3T%X\IU%F=FV:$1.PFWEO3?1-`K4G)G<K1"46<D
M>N@F[.[*#<Q:9=JO945MNFL;U!1,Y$P<LLY"(+82PJ,A(,4#@FG)&81$U-+1
M)'!^T46<A['*-CD,FZ:H*`),(D7`8#`\\?J`^NM>N#/(N5X_EX!["V9[#"-[
M#&75WM4:7'6R$>/GC)M.5:/A]2[(!_!'.U[LZRKI!9%T!T5$2B0#'3HUCC<7
M:_2?/JWJ>G:/.X>)^V0G@U:KLC^7PC]JI;>J<P>*!H,J$0$X$"+0OBII+R]W
MA87JZ]DZ!V,?%I6M6T7?_-*;"_\`AAW/_P!8.;_]F#)?#?2/R;SK!S_MD+Z=
MO\]Z/$S<3Z>'6<+?B\>?:&;>YD=2\^PKYF:\@$:XG$:U'E?#++2O@!E@@4S/
M?8>OZ'+\6Q6M6T8__-*;"_\`AAW/_P!8.;_]F#)?#?2/R;S-E>H#:M?>GLVY
MSDXE[DEYUSKNEW=3C^HLUCK=&NK;*P\2NSF)!&,E9Z/K\'XH9ZO)C7S*A%I@
MY.S2`3$3OQ;%:U;1G_\`-*;"_P#AAW/_`-8.;_\`9@R7PWTC\F]'=W/JX:>X
M`L.;J/$[;-CG76O-;7E]H5=^UA+37E;XM7T9*/L<FWB)^=BF%0\:.H[=FKXJ
ME00[:S9N`G!*_#$1<U;1@7_-);$.8I">F#=#G.8"E*7D%.&,8QAZ%*4H<7Q$
M3"(_(&2^&^D?DWD\D/4!MF@^"$'S29\3=N7*7F:?JVUNM(.'C:N66I?B,A#.
M'S.\23*'MDU6D:<$H9%XL>"4.5T0B2J2'>&,E?BV(BYJVCE#_-'[$7611)Z8
M-W.=95-(I$-_SBRQS*'`A2HHAQA**JIA'H4O4.T/R9+X;Z1^3>-RP]02S\9^
M$U<Y?L.)^W]@R-BA=93"^GC.V5:L%,#8D4TEG2>Q)%A'7*5JJ-2%P+)\IX,X
M,22,D@<B0*&43OPQ$7-6T=-O\T;L9TX0;(^E_>5E7"R2"2+;?TZX<*J+'*F1
M-!`O&$#+K',8`(0!`3&$`_MR7PWTC\FY[FSZF3KA]Q=JG(1#B]MO8=HM0T`Z
MFH7JHTF5J3:[0"\Z\=7:?;0-V/")U8Z`1SP$XYR8LHLDW."7:,<EK2V(J<NM
MM+#3_--W9V[:M2>F;<%3N7"+<B;3D++.W:AEE"IE(U:AQF3%RX.)NA$P,7MF
MZ!U#KUR7PUTC\FXWFUZJ3#B7QHK&_JKQVV'N><L-AID*]UH23/2752;6J`EI
MMY+6RP-*Q>U(MM!.(PD>H`1J@*2#M%(3)@?M!J8F(MC&<<IKLT[QW^:9NCZ0
M8,O^K.NA_;'C5KV([D!*R,@?VA<B/981_P#+4U]N>&[?1)'O4^]/T+VB]>H9
MOAOI'Y-O_/#U6F/#G051W14>.&QMWRMFM%>@9"C^)FH?DQE-P4G++2=ML+"L
M[%-&KLGK)*/*@#`Z2SM<"=^00("FIB8BV,9C*:MJ(@O\TE<I>:B(L_IFWU0D
MC),62A(+>\K.S0I.7*:*OA$*/&^-"7D@3.(H-A<-P75Z$%1,#=H,WPWTC\FW
M3U`?5>CN%6FZCM*H<<]B;ZD;1:V%==UEO*^16-3:NXEY)&D+/9F%9V,+%R*[
M<K5!N5BHFX7,8._)V2]YJ8F-6,9C*:B6I&M?YHN[6"Q04&7TRM@K^+RT?'&2
MKN])2P3YDG;I)!7P6"-QQBBS,H5(XB@U,Z;%74`""JF`B<N;X;Z1^3;'ZBGJ
MS,>#.NJ1>*9QRO?(AU;K6YKKUA'SRE#@ZLV;1IGQ'TU9&M1V&N1W)*]$F;;P
M\I%^[6,*Y!3*134Q.+&,QE-6U6T/_,_7&Y7:HU)3TUKXW2LUDAH)5Q![SD[%
M,-DI60;LE7,;`GXZPQ)AXW36$Z;8SMJ58Q>R*J8#V@S?#<XQ$7V;#O4:]1S5
M/!FAU>V4WA0'(LVU]@OUKBT9LH:A0,?.QC0TNTM%OGVNNMC&E+5*O'RPL1<,
M@65%-TI[04Q.RIJ8G'X8QF,IKLUE:X_S&$3L+8E)I<CZ3S]JVMVTX*8>R$!L
M-K;YYE;)64;-E[]%UIQQNKJ4]=F1516(L>09N53$Z"Z3_P!<,WPW.,1$SV;.
M/48]4BC\"JMK&6H/#>6Y#)[#=V>N2Q8Q9EKNM4N(@8BE-D&,S.,=>;&%5S96
MS&.;L8\S-!%9I!#U5`&2*0ZF)Q^&<9C._9KFTE_F-4]@[9I^O"^EM.UMMM79
MM5):9NI;,3LTX,N]GHX0NRU;-QWJ:%KGX!9(CXAW4DT4`S8#^TI=@#ES&LU3
M4XQ$3/9L/]1/U6Z9P`::XEM=<.)S?;O:5GM4]8)*)>--9P==GX1K%IDFIFQQ
MNO-C+R=TL!)M0J'?-FZIVR"YO:#=D29J8G'X9QK._9K[TW_F(&F_>0VFJQ9O
M2WEV<S8;K6:>VV4TV*GL"Y4")FIE-H\L$,R?\=JV[59U]-^L]62++1R8)%5.
M99,.T;,QK-4U.,1$SV77]3+U/=5\*HW4L)!<#$N3D!=UKBY5]L2A*13*8]9O
M(R06:I+%U=M!NZG[&\D5':B(MF0G!$RW>+&[0$LQ./PSA65UDJ[QB_S!D_R)
MY`Z8TH7TO[?7$=F7:AT/S9`[,-;G=1BPECH0MA&$?:`I;!>OT0\JN_.9668(
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MUM$W"OUN"\U.3%1X^3GI@3=(:;7F',S9+XWMC38B<=+U"`=2L-:K?#S.BM?L
M73>,-$HMRR3J5(JP[2?=@<P%3%9.-1?9*OJC^J:UX+;.7T8AZ>5TW!`[IU\R
MN=VV!!W]YIEG:WCB8EX9W`!8-?:WOKZT/XQE&)>WJJ2;5PFD^*@HB**H&53H
MF,7K:(_3M]8:&Y6;FIO#Y#TPK3K"A72.LZ\K9_/2^VHF/5@VT]?O$MBMKGIZ
MCIR+.8L?M!U962F%G)IA^4XE77<"(H6<:B^R1/5/]4Z%X<[LC=,RWIN6K?#6
MP5S6^QW>QW-Q_#2/G9&F7F+MU3B(V5J>LMDK6^,J5FHL8L[0<OT$!50*U<,U
M6P_I4ICC<7;;GP9VVPY'<;-6<C_P(E..T[M.HHMWVL+"D/CE5@Z38[37:S"H
M.E(.M'6IQT2.)6#`D>P0492_M)6Z9W*O:J3I-6M]A#`8#`8#`8'_T/=7M+<F
MM-+0L?/;,M;2M,YB43@H%K[))S,]9)Q5NX>$A:M5Z^QE;+9Y@6319<6L>T<K
ME0144$H$(8P"(MTVI^0>H=W*S;/7%M&4F*VE'N+#6)NOVBD7.#9R_M'A$C+4
MF]0E:MK"*EA9K%:NE616SDR*A4SF%,X`68F$S813?;?%&3W5L&ZS=YVHK(:T
MM^K)_4S+69J-$.3TN&M4$JULDW5;#(R;V+-9YRR)L7[ES)PLBFHUC&\>"16I
MW0.2W24].Z,B]3PEW8C-+S$KL:]'V#;)"'BV%`C!G"5.GT9HE7H&G^P(P,<G
M6J''`L0%EE'3T7#A0X]_W9"3JE+RM&?2K'^N%M^^\)4<GE:,^E6/]<+;]]X*
MCD\K1GTJQ_KA;?OO!4<J:N*^P_ZPF(9]_-]T/#2Q.>WYEL?M7>!NZK)`4'WB
MOMH-^R;J*0*=T)OG"7M``YO^S[9KV^ERO*T9]*L?ZX6W[[S#51R>5HSZ58_U
MPMOWW@J.3RM&?2K'^N%M^^\%1R>5HSZ58_UPMOWW@J.3RM&?2K'^N%M^^\%1
MR>5HSZ58_P!<+;]]X*CD\K1GTJQ_KA;?OO!4<GE:,^E6/]<+;]]X*CD\K1GT
MJQ_KA;?OO!4<GE:,^E6/]<+;]]X*CD\K1GTJQ_KA;?OO!4<GE:,^E6/]<+;]
M]X*CET\WK>JV)H+*81EWR11,=`75EL;L6JYB&3*X;D=RKA$JQ`-\G:(8H_D$
M!#Y,L3,>#K"E6R]6S.OG0N.II*NN5>PREB)"`I&-U$C.2(7J5N[``^:8/T:H
M!U+T'M$+VQRC+]V)BOV1/WP?W?X#FD.^#^[_``'`=\']W^`X#O@_N_P'`=\'
M]W^`X#O@_N_P'`=\']W^`X#O@_N_P'`=\']W^`X#O@_N_P`!P'?!_=_@.`[X
M/[O\!P'?!_=_@.!_9#F4.1-,HJ**&*0A"$,8YSF$"E(0I>IC&,8>@`'RB.!;
M;6F@DCMR3%^0.8ZQ.TTKJ:Z[8R!3!\U:4<M54ERN/[2HIG*!/D[8B(B0O/+/
MXQ:C'=8LM4BB%*0CBPD(0H%(0MOMA2E*4.A2E*$V`%*4`Z``?DSDU4/OE:,^
ME6/]<+;]]X*CD\K1GTJQ_KA;?OO!4<GE:,^E6/\`7"V_?>"HY/*T9]*L?ZX6
MW[[P5')Y6C/I5C_7"V_?>"HY/*T9]*L?ZX6W[[P5')Y6C/I5C_7"V_?>"HY/
M*T9]*L?ZX6W[[P5')Y6C/I5C_7"V_?>"HY/*T9]*L?ZX6W[[P5')Y6C/I5C_
M`%PMOWW@J.3RM&?2K'^N%M^^\%1R>5HSZ58_UPMOWW@J.3RM&?2K'^N%M^^\
M%1R>5HSZ58_UPMOWW@J.3RM&?2K'^N%M^^\%1R>5HSZ58_UPMOWW@J.3RM&?
M2K'^N%M^^\%1R>5HSZ58_P!<+;]]X*CE_]'V/>H-M*E:WXM;7C;#O^E<;;CL
MRAW?7FH=E738[S5"<?LR8J<LXKO@UZBG+:;K\LU<,P<D=L^^6:@AW_<K%3%(
MZ5CSX:]_2-0VI=+G?MR1G)*<VMH241OU,DM7V_FG(<X)W75SC&G'IWK1RALE
MW"-V$4\ED2;!?235BY13%C*0I%T5%D!.E(:R^(K5OBRL&`P&`P&!H`NVK^<C
M_G\[O%:F->1NU@H$OLFHP3BS2#^IL]1QD\C0VM%D#GA&"3UPX/+$,NGV$$E7
M2BCPJJ*W9,7K$X]*^'*LNU_+81JCG37GUH1U)R0J<AQPW20Z35.(MZ@DHUM5
M,(H$>TZYJ`6,5;OG*9@1374[I0QR)-W+M01Z9G'2\=8;C+6ITE?8!`P`8H@8
MI@`2F`0$!`0Z@("'R"`AF&GW`8#`8#`8#`8#`8#`XKYBSDF;E@_;(O&3Q$[=
MRV<$!1%=%0.R=-0ANH"`@/\`V,"A.W]0.J*X--0A%WE4<J`':,)E7$*NH;H5
MJ\/T$QVJAAZ(K#_;T(?YW9,IVQGMI>KCEC,:QX01W@_Z/^/_`.C-URQ<OS5<
MIH)*+KJ$1113.JLLJH5-))),HG4444/T(1,A`$1$1```.HXKDN5%M'^H/I3;
M%$@[?97*FKI2R/780=2FE'T])24*O<=>4^JR[9W"0YVJCBU.=O555-@'5VW+
M.(B<HID45#$91,:RZ9891->4LL^8O&N1\#+'[8@7ZEFN)*#74&+6=>.INTK,
M8N6:L8MJWB5'+UI(0DTVD&KU,IF+J-4%XBL=L0ZI=:?DG7/9^$MS.XRP$##6
M2=VS"0L9/2MH@XTDLPL4=+C,4H8XMIC'U=>0R-@B'L*>89$63=M4#=X^:D*`
MF<H`I+C\CKGXIR[+RHU8QUCR!V+2YQCL-3CK3+M;+E789VLQ=*J4V`LDSX>U
M?O6(MUF<RXJKUFWDFY73$[ALN4ASG05(5\3,3X2LKQB?EC&KN8M`ND?&M;U'
M2.I;T[V6ZU"ZJ,X9:P1R-_+&5">B(EM>(!BM6#I6F"V!"+QAGBC!9VK($;E1
M]H*9,$3?F=5G'*/$W#!Z1Z@VF9P\^O=W;37,+#U>N61G87LB_GH>8&2HFR=C
MV*/;NHVOI)M5JO5=62KD!5$#R!4#%03%4`3-(RCYE9PR^'?[(YG0FM-WUC5\
MI1)E]2YNKZ?GYG:;279-V]5<[UO-[UYKEG(TZ0;-)MVRD+/22MW+A!0RS0T@
MCVFPE*H8MF:F(O1(QF8N]?\`9E<9S;XM3*$8ZC-QUQVVF:O,W*,<)M9\J#NN
M03&S2;Y^192'(F51:-I<PX9MS"#F10BW:C1-8C=42KC\CKGLF#6.WM;[FKJ]
MLU=;XFZUYK+O8%S)PZJIT6TO'D;K.F"Z;A%!PBL#9X@N3M$`JS9=)9,3)*$.
M:QKK&3,]HTE);=-PZ71:M4%7#EPJF@@@@4ZJRRRI@(FDDF0ICJ**',````(B
M(Y:Y+E>[3^F6U11;V&QHIN;2J3O$&YA*JW@2*%Z=VETZIK20E'HHJ'4"=>RF
M/3J<_'+*](G1UQQK6?*P>8;,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?_2]A7J
M,5>Z3O%[8\U6-N0FH*_1J=>[?LN8DN.[7DE+3&O(VC6$+##U*H.+YKX8>R"W
M4[Y"1*[,"7="4X)IF.LF6/*)/27<[*0XXNZAL8MW*&N9B`H-/&_<?M7\>Y\]
M1K%$J\9&'<0NK.0/(B,MBH@W-WLN\DV+Q9;MIBU[!"JJ2%R\MI.5DP&`P&`P
M-8;[D1IAOZC\7'K7I@1XGHF3T0=`6$T)B[:EMVUE>.I@F+&"3VURDD807Z^R
M!T^54,Z5/3Q\VQ<=_/PO=M?36L=X5A:H;2IT/;H50%1;%D$!+(1+A8@)F?04
MNW,C*0DAV``.^:K)*"4.R(B41`<1,QK#4Q$^84('5O+'AF(N]$RS_DSH1CV>
M\TK='W9V53XI(PJ*(T*Q(H]))%!,HE2;IHG``,!4X]4_5;-WCEYTEFLL?&L+
M4Z!Y<::Y$I+,*C-.(*]1OM"=@UA<4"0-]@W#(W8?$5AEE3A)-FA^G>+LSKI)
M=0*J*:G:3+F<9C]EC*)_=9S,M&`P&`P&`P&`P&`P..[:-7[5PR>MTG3-VBHW
M<MER%41705*)%$E4S`)3$.01`0'`UT[DU8YUU*@\8%57JDHL8(UR?MJG8N!*
M*AHMZKV0#O2E*8R)A$152*(]1,4^=\<^T<N4X1'[*UWJOJ7.D7&GH2SB!6M=
M5L-:1G6:!7#N%5G8AY%IRS5NJ=--=Q''=`L0AC%*8Q``1`!S4^$B(B8E0RO>
MFSJ*LS=(>1UIMIJ_1-F1.S(RL/';J02<.V.L=<T*1@W4R_D74N,/+3VIH"Q`
M0J@>QR+!--#L()I$2SUB&^\ZN;K#T\-?:J9U5C7;];$/)X71C%3;)A"Q-N6A
M[/JAWJ*&+(V!@V)[58*?7W0*M)$K=/M+I)]42E`0%&-5J3E=W"NEY]-:>J%&
M@:3HVS2,E+V1U>("]VJ:/2:I76U,V*]TA)VE&3K+&KOW#TPSNG6THU4B@;R"
MBPK(.5U!<^V(YZ:5#49ZW,+7T3@CKO7>J^1NIZ_9)8(GD+3+)0'LZZBXQ6T5
MRL3D;>V$>Q/*)D1"R#6#;#?BR,Y(F()]D%.VH999748U$QNQ.5SC.S"_^KEI
MSBPZNMTQMR_V*S:^VK&;GF)"<BJ:Y;V^_P`3<M66%E,%CFT"T;4]9M5]4,*R
MFI%=PX\#Z('54*"H+NGC5>WF*^*819_3CBTJ7!:X@)Q2U0=BO^C%+S,659M$
M.JO1=1DV`XGW$%'L8]^2?EK_``5O>5M1NH=!-LE*BY[1BHG(:=-*7OK=+*;:
MXAU_<&[8W;L]?K3'1C2L:YA)+7<4R@BP-CE=26_8-ZUY.3,H\8.YOL5ZU;`.
M^*T:JMDUG+!J90YBD,0VIQN;EF)J*I!MW]/""5URU@:I>K._>U?0E1UVQJ\@
ME7FD%>;WJ#26P-0:HMTU**1B\S7S(,K\X5?M6;DC-==NU/V2%2<E=YG#3Z6,
MM=8^?]5H^+&BCZ!UPK7Y&QR]MN%OF&%RO4U+IPZ:J]H)2:=1DV#%"O1D3%DC
MH:N4F/8HF30*9?V<5C_/4-TUC%0SE64MP^C-/A5FJ%LLC8!LKU#M,&2Q`$8)
MFN0H]3IG+U3EG!!Z*#_K(D'N_D,*@9SSSO2/#6.-:_*R><VS`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`__]/VD\[HN"FN%G*V)M$]*U>LR''W;+:Q6.$J4C?9
M:$@E*5,A+R;"EQ=@JCFT.&<?WAP9&DF+=QT[+A9-`5#`6/,*>^CW2UJ3I#9S
M!?7/X:F=[5.\"*_E>U)Q6]O#RC6T?$/)VG^0/(>$L744N[\3=2;%V/8[CV7N
MTB*J2%R\MN.5DP&`P&`P&`P&!57?W#W4>_UF]CDVDA2-H10HK5[;5"<C`7B)
M=M`'V$[B0:]V$PV:G`.P1P!E$B]0051$1-FL<IC]F9QB?W5E3W?RCX=G3BN3
ME==;XTFU,DW9<A]=1O\`O37F0'!!)7954[T![M$G=BJY$Q!ZF'H[?KF[`:K'
M+^.DI>6/\M8;!-:[4UYN&KM+EK.VP]PKKOH4'T2Y!11HOV0,9E)L502?Q,BD
M40$[=TDDN0!`1*`"&8F)C26HF)UA(&14=[0VM0],U-Q>-CS+B!K#5VT8N)%M
M!6&PG3<O3'*V*,=6(J9E!3,)![2@("F0`ZF,`98B9FH29B-9=3I_>>KM]P#Z
MT:IL;BSP4=(A%.GZ]<M5;*#T6C9^4B"%KA(-T\1,U=IF!9%-1$>UT[7:`0!,
M3'DB8GPEK(I@,!@,!@,#I;%7XNTPS^!F6X.8^10,@N3J!5"#\ADET#B!NZ<M
MU0`Z9N@]DY0'Y?R98FM8)BVK?8-,D]?65[7Y+JH1,>_CGP`)$I*.5,8&[M,!
MZ@4P@42J$ZCV%2F+U$``1[X^T7$N$W$TI+S;N-WH?$CD-<];V)*IW6L:MM$U
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MLT"2D3QIC$H*LVV2#6TN@_Y0<KJ.ZO$7`4;:EP@XZ1NM5J$9XG'*3LT1%5L#
M%VL[*T3$)<_,[?UE>L57[_TAR?\`K,N0K.FU%R\UWJF0MUN1UC:(QVQ]JK],
M4A-A<?:INIGK]^_O6T:TRA;K).Y]=DUE#2;E$K=HJJ6+='2%-1VR/^N+G6?U
M+:1JS7FS:?L':MEN>T9*Z5:XOFCFEU9X[<+MZ4U1EK$Z79-4UVZ:"!54)%$X
M'1$!$%/93`9!BS./2,9N?9RG*)B*C5LSXYZI"572V!86PC',UA\MM%B]2/GR
M!Q*I*J`;Y#-F"I!*B'00.N`F^3NP[6,YK2):PB]9\+Q9R=3`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8'_]3V>\YF+>T\9ML:LD(_91(K=%%N&J)*XZSU-:MY
M2.O4+G6I.)"URVJ]>RT?L6X1#3OQ*=K$).3*F$$UP*B<PB6/-JW^EWK".TS1
M-E4:#@S^#O[8QN"=MB^!5I]/NKR+B1A&,.>&2U=L2=7O=JGXX(05',NK'-6I
M4%$4"G.)"B:0N4VVEY65<-B[SD-5[)@H:YQ=+8:PF:]>K(]N"-TDU+74:WKJ
MG&M=JV!<:BYIS.'B]>1+TJ,,N\0F7;A.1E8S]"8KM4&A:T?MQKWJOOK7LS>9
M2NM*4O&;$OE,/`>/M)QW'-*Q8'#&(\?=M")L65E=PYFRS]FB=P@T=*'22<.4
MBD74$Q2??$(_Z<S^LH_GY:G9#Q"/^G,_K*/Y^*G8/$(_Z<S^LH_GXJ=@\0C_
M`*<S^LH_GXJ=@\0C_IS/ZRC^?BIV#Q"/^G,_K*/Y^*G8/$(_Z<S^LH_GXJ=A
M_"CV,63.DJ[8*I*D,FHFHNW.FHF<HE.0Y#&$IR'*(@("'00Q4[#7YLOA-"1]
MG=[:XG;##CCMTX*+.FL(J@IJZY'[8N`C[73@3=,6K59P`"(H-UFJ8B*AF2RO
M0P;C*?&47#$X_.,U+KZ-SIE:!9&.K.:%*3TO<W!_98?9<4J>4TS=0(!0*^9S
MR2CPM>45[914(JLNBWZ]7"C41[HLG"]<9(RK3+RNEL>;A9+4]]>QTO%OV;[7
MEI<LG;)^T=-7C9Q6WZC=PU<(*J).$%TS@8AR")3%$!`1`<S$3<:-3XE%W#=\
MR)Q3X]D.\:D.74U+*8AW"13%$(9MU`Q1.`@(9<HGM.GRF/\`&%E?$(_Z<S^L
MH_GY*G9H\0C_`*<S^LH_GXJ=@\0C_IS/ZRC^?BIV#Q"/^G,_K*/Y^*G8/$(_
MZ<S^LH_GXJ=@\0C_`*<S^LH_GXJ=@\0C_IS/ZRC^?BIV#Q"/^G,_K*/Y^*G8
M0UNVBQFQ*FJ5FY8>980JSZ"6]H;@=<P$`SJ),85`#NY(B8`7J(`58J9A$"@;
MKK&9QGAG*(F&L1T@FNFNS>MTUD5"G0<M'2)%$U"CU(JBN@L42F*/R@8I@_N'
M.UN6FSCBR8B!RBR:"51XG('`6J`@=^D=)1)\<.QT,\341(8JH_/`Q"B`]0#%
MFB#H[>.DYF@[)VM&NBO=>:O2M\C:KIY,FV\"]:TA-Q9;9+U*4?0C9M?(J,>1
MBQS/X<SYFL_;G*FJ=9,W2=HJ_A:UB*UEEM3V#1;14X[8GL3VFQ]R!ZW*3954
MD=9VEZ6'\6140F:]=X^#L*(!&PCET@5RB'>QI/:4P%N('%VCR3%35,@0FZ$R
M>I@VE:@TD3*/(I+N'L*@],JC(1B4A&I]VJ5<5$I679E61#Y2N'2(&#MJ$[3M
M"?4H<N7(#1U!E_`9,6[E9I"ZVET%X"#9RT7X9L+;S?35.*S?,Q%N84-A3'=J
MD(/^R)F45_Y08[1#48W\)N8KU!\N[B8T];>.8\S3V^,8C%.%V)XQ46;#VMF@
M)U&QH]9D*2/;*44C(]DO02=`7#.FTIHU?25=@6UA"G7*TC$A]MFGIS%3*WC$
M#D[XB9S"!?:G9C`DD'R]#G[0AV2FQ.51RN,1,U3:<P-"1;)I&QZT>T8L&R+1
MFU1<(E2;MFZ94D4DP[P1[)"%`/E^7_3G#679R_$(_P"G,_K*/Y^*G8/$(_Z<
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MDW:LAV?;E#.!+;+:'IK56L(*;K%`H-9JM<L=JF;M-047&HIQ+ZT6!=%Q*RQF
M"@*MD5%SMTBD33*1%!)(B:1")D(4"3KY93Y/J7PM7/<D9]EPE1L>3ZE\+5SW
M)&?9<%1L>3ZE\+5SW)&?9<%1L>3ZE\+5SW)&?9<%1L>3ZE\+5SW)&?9<%1L>
M3ZE\+5SW)&?9<%1L>3ZE\+5SW)&?9<%1L>3ZE\+5SW)&?9<%1L>3ZE\+5SW)
M&?9<%1LQ^TZDU==H-]6[9KVFS\'(I]V[C9&NQ2Z"GY>PJ01;`HW<HF'M)K)F
M(JD<`,0Q3``Y;F/DZQLTW\I=1/>`M1E+KI;8T0XU??';^IN-!;69&M@)OK"Q
M>(KOM<S(E&9:!#LSF74[Q9N<A4"BX=.SG31'IC/?28UW<\L>NL>'X<2/4`TU
M`Z<IE"O>C+T]?ZY@8JLS=TIM$B+G7`;-@7;14I..!=M9B,=/V37J<@HK]XL1
M02")0Z`RPFYFS'+&JG%>NF<U^!]X%%..V+KB&<JG[LS>YUM:D@@H/9Z`L^M,
M)%1($Z&`>\*X,F'R_.Z@8`S..<?#5X<+45H^HKFT"0IYM<6M@(=0>UHU8G6@
M@/9'J#F+%TB(=#!_W7]H9G6/+58SXB&2>3ZE\+5SW)&?9<A4;'D^I?"U<]R1
MGV7!4;'D^I?"U<]R1GV7!4;'D^I?"U<]R1GV7!4;*!WW4LVMS%U]7H[:]T@Z
M;<JE;MDO:9&1M++`,UM>3&O(Q&MLTUZRLZ"!L"4VX,]`ZIUQ,<>[4('R9N)]
M9T8G'VA?SR?4OA:N>Y(S[+F&ZC8\GU+X6KGN2,^RX*C90CDSKI"H61K9H9H1
MK`V;ME5;MR%2:Q\TV(47"*:9``B*3]#HL0H?]V"O0`*`!G;_`!S<5/ERSBIN
M/"K#Y,K]B\8F7<-BO6KAH9PT6!%T@5PB=$5FRHE."3A(#]HAN@]DP`/0<Z5#
M#6WI/B)MW1VKK1K*+DM*72L6JNPE(GJ-;6M]-2+#`U/5;RB$L#EJ1X\&(LVU
M)=-DO:&Y&[MB1BD9!#OC@50<1C,16CI.<3-ZNYM7"^P6SCMH?24_8JE;%M8W
M^WW:QC:6\M+5IPSLNO\`>E>AJK7&LT2P2*T+09?:D<VB/;SF63B8=,PG[\I"
MBZ:1!&<1EEE'S_\`2LLGZ6L\^9O8HCS3187R*]B(>(4A7GAL5=Y35/$.DREN
M:L`K0M&C^2L>@9Y\N\2*#M8LNB<XBJHX`D_Z_P!OU37_`&QSY_W_`-V<.?3<
ME%K,\G&\M18YK!WM&S:RBHEW:(6*J$*'-J4Y&JPH0$0R9P2C5+64H>';-3H+
MM&TGT,D5,A2.`=/V_4I_V:?K:F9<%=+7'5VXMU/96HEB*PRI-3H3*\*5&6H[
M_:]GCMM;UN$U<IF-G&K>0G+(,)<(M&0ER&<,7PE2]E<K)D$J5QBIG33_`-IG
ME$QCKK_Z>GO26I8FLT=BI8H./>V&<`DM)!*1[9TLP*NF7V.+*#I(YD/9&_05
M2]`'OSG`>H`'3GGE<Z>&L<8B-8U2]Y/J7PM7/<D9]ES#51L>3ZE\+5SW)&?9
M<%1L>3ZE\+5SW)&?9<%1L>3ZE\+5SW)&?9<%1L>3ZE\+5SW)&?9<%1L>3ZE\
M+5SW)&?9<%1L>3ZE\+5SW)&?9<%1L>3ZE\+5SW)&?9<%1L>3ZE\+5SW)&?9<
M%1L>3ZE\+5SW)&?9<%1L>3ZE\+5SW)&?9<%1L>3ZE\+5SW)&?9<%1L>3ZE\+
M5SW)&?9<%1L>3ZE\+5SW)&?9<%1L>3ZE\+5SW)&?9<%1L>3ZE\+5SW)&?9<%
M1L>3ZE\+5SW)&?9<%1L>3ZE\+5SW)&?9<%1L>3ZE\+5SW)&?9<%1L>3ZE\+5
MSW)&?9<%1L>3ZE\+5SW)&?9<%1L>3ZE\+5SW)&?9<%1L>3ZE\+5SW)&?9<%1
ML>3ZE\+5SW)&?9<%1L__UO6[ZBLIN9A7=-M-,4376U9B;N6PXN1UEL6YZ>IS
M.R`71FS9*"F8D^XV$G#SCS7-ACV]E<,FB!UU&$2N97LM2KF`L4C/TC]FRFZ-
M6;BV@I6M+U6!F]G5Z`BX[2-ITW<:\O/4C4&N:S?YF7F=,0\)#EF;-<V;J5(W
M>)"N@P?-@0,9D+8PR%RT;9\K)@,!@,!@,!@,!@,!@,"*MTUVOSVL[T><@H>9
M/'4BXN(\\K&,I$S!<U?>B9=D9X@L+5812((F)V3=2A\OR!ECS"3XE$O">NU^
M,XPZ)EHV"AX^5E=3TP\G)L8QDTD)(QHELJ8S]X@@FY>&,J/:$5#&ZF^7\N7+
M^4_NF/\`&$R7+3&H-B=L;YJW7MQ4/VQ]HLM.K\R[(97KVU$7C^/7=(+&$>O;
M(<I^OR]<D3,>)68B?,*K63TU.)$TZ))0M&FM>S*9CG3F-?W2SP;I$Q^O9,W:
MNI&3B&IDC"(E%)L0?[!Z@``&N^6Z=,6-APGW92^R.F><N]:^@V+U9Q6ST(O;
M<:3L]GNT"(R:T/'M&XB`]0(S,7J/7L#\O5VB?.,)UGXRE\*U]3R@`422?&O?
M4>01[PKUM.T6VN2@!A[*7L2=<JK,YA$`*8QEPZ`/4H?(;'_YSO![QM+Z',;D
M92S`EN'@IMYDBW[P7\QJ29BML-NY3`3F=)L89JB@W1(F'SN\?F*4"]H3AUZ`
MZXSXS@[3'G%W4#ZF'%.0=IQEJL5QU9-*%$QH79-!LL0]0$#&+V72\.TGXMKU
M%,P`8[@I!$HE[7:Z`+IDO?%C#_DKH.V<S=%O:WMNC3$>;2>W8T\FRGF2D8UE
M9N>I4A%Q,C(=X#2+EG;&I/E2MG)T5NPF3J7],CWCK/6=/E+B<HU^&PZ-GX&9
M['A$W$2O>-RNB>&R3-]VVIN[[+DGLJRO:;F[TO0X?-'M!\ORAF&W;X$?;2I*
M.P:/.5LY2>V+MA=0ZQ^R'L\RS`RT>IVS?(F114.Z4'_[I0X?VY<9ZS:3%Q33
MXL19NLJW7(=)=!0Z*R2A>R=)5(PD43.4?E*<ARB`A_8(9Z7#39^?;'_@`8U/
M78[8_P#``QJ>NQVQ_P"`!C4]=CMC_P``#&IZ[)QX^48;UL6-*Z2%2&KW9GY;
MJ4!25!FJ3V!D?M?-,#Q^)`,3\ID2J?Z!$,YS6+6,1,^&U?/.[-<GJ(:AUQ=:
MQJBUVBKM9>P(;HU'0TI)9U)(JDJ5MO#)O8H4$FKU!N*$FB<2G.)!6+U^8<HY
MO"9BXX8SB*A?JIU2OT:LP5.JD:E#5JLQ;2&@XI%5PLE'QC!$J#1HFJ[6<.5"
M(I$`H"H<YAZ?*(YB9O5OPR'`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'_]?V
M8<X])Z%W#I-^^Y#VBXT:AZP5EKN_ME#O[_6M@1BGE5L%*MM44L<<Y:+N8'8U
M.M;^!?1W>%-()OP32,FY[A0A8OX<+AU)\9IHVX)CC0Z5<PTI-ZA7L2+46052
M"18\==20.O:I2D8P`CVD)6]:0T4@X;]I5=M*>UHJJ?HR))";TM=7"&`P&`P&
M!KO>^H]0&/+!MPY/Q\Y<+[3=NTW*$LUTTV5H1Z!YZC-=N]SA8/-Q7@Z<C+%+
M(@YG`9]TDD;M"03="B6M+;$,(8#`8#`8$4;KK>Q+AKJ>K&L9VK5VR3J"D4M)
MW")D9F)3A)!NX9RZ1&<8\8N0?J-E_P!`IVQ(0X=3%,'R98J]4FZT89Q?UGLO
M3VJH/6VQ[/4+5Y.:1U?J+ZI0TI#E2J\5&-&;5"9"3>.SO9<7"2ACK)@DF)#%
M`"`(#C*8F;B#&)B*E8K(I@,!@,#I)ZLUNTLQCK/7X2QQY@.`L9Z*82[,05+V
M%`%M(-W"(@H3Y#?-^4/D'%UX&C+9'IFT.7Y15^F?B!*0[':%5VALQRG7:?6(
M.*KCFMV*HM65?K]?8$3C&L("-J.4I.SVB%0('4PB81ZQG/7PY3A':K7F<>F!
MPP=(-RJ:K<M7A"E,[>1M\V*V*\7$@`LH#)U;G[5FB=7J8J:12@0![(#T`,SW
MRW:Z8[."'ID\>VG9\!LN[ZMV2]U_N_M24;=6P=GNV?\`M;-]T;(]D.R4.@_(
M'41QWG@Z1R^!Z>R$=V1K'+SF?`")>[6!/<P*%.@7L]RBF#&`BC)IH]!Z`8R@
M=.GY.GRN_P#Q@Z;92HKO?BALK5UQ(T;\E-FS*$\P\9+-V!JWE';YVJX63?@X
M44?%`SU-V45%3=HQU"K$,8>HCUZX9=H<\L:E"OX>;W:!T8\@O:.V4.W[?KJO
MF$HDZ]@""LM("':[0]H0[(C\G7K_`&;9?1@N3#?KW&Q=?R/4.O\`TA6UV?8,
M7KT(7V%@?J0_]HC\H?V!@/:>4[,1ZI:6E@$H'Z$&V(F#L]KJDF)SQY044#^T
MP&*'R?*'RX#S=R4:B/?ZQH\H`%!0/#;0#+M`':[2`#(OA_3&[/R&'H0.H=?[
M>@7<T%M7EKK*K.))/@U+7!I;%FLR%B@]RTUNN>#;%.V;-D89.)F73A=!4'*J
M9#*HG5!8.A0*)3FY9]<I_DZ87$?Q3N;FMNN-`1L7`OD4V[!R**^6D6UP$&9A
M(4RJ(1\6V%P\*/;_`-G#Y>@%$3`!ODQUCXSAKM/XRI?S&]0>#G8.@T62T7NK
M75M@MJ:XVA)PVTZ\SIKA>J4Z=/+I*12"[YS).7,P_CS-TSJ-4FQ`(H8%#F+V
M,UCAYFX\,Y9>(K5>*M^IYPRL/8(OLY]6G)PZE;62E7%K_:J!@.]CH64BDQ*5
M,#?.<``@<H!U-V@+GIELUWQW3]6^5_&:V@0('?>IG2R@]$V;B]5Z,D3CU$OS
M(R5?,I`P=?[02Z?*'^D,SURVEKM$_*;XN9B)QJ#V$E8V89F'H5W%OFL@U$>@
M&Z`X:*K)"/0>OY?R9%=E@,!@,!@,!@,!@,!@8?:-A4"CJ,TKI>*?4%9$BRD>
MG:+-"P"CY-L9,K@[,DL]:&<D0,L0#B0#`43!UZ=0RQ$SX@=_$R\3/QK.9@I2
M.FHB01!PPE8EZVD8U\@(B4%V;YFJLU<HB8H@!B&,7J'Y<@['`8#`8#`8#`__
MT/9GS6VE1:1K"/U]<]*;'Y%*[[EY/6$+IW5<%49RV63V>H62\V*50)?+%5*H
MP2JE8J+N0277>D6!\BW(W*9<Y.R6'<\0M=Z$K6J:_LSCK$N(C7F_:7J79T,B
MJDDR2<0"NIJ;"4V0)$-T46\6^D*?&,EWX%[1EY!198XB=0PB)OY6LPA@,!@,
M!@:GWW_OS*O_`/Q/WS_]W^N<GRU_;]ML&5DP&`P&`P&`P&`P&`P&`P-=FP]V
MTZ*YP:P:N8^\J$JM#OFMIJ09Z^N+Z';VK84[K%_66Z4NUAU8YRP<-F"HKNTU
M#-FHD$%3D'-Q'K+$S[0V)YALP&!4KF#5O%M>1]F13`SFIS"1EE.R`B2*FQ2C
MW(`/3M!UD2L_[N@#G3_'.M,9Q%7+69VQ_P"`!G;5R]=CMC_P`,:GKL=L?^`!
MC4]=G:0D8[GIF)@V(=I[,R;&*:%$.H"YD'231#KT_L[Q4.O]V)TBUBI^&\.(
MBVD)%1D,P3[IC$Q[.-9I@`!V&K%NFV0+\@`'4J209Y?.KOX=C@:XN>^F]52\
M%1+U*:_JLA<9W?.BZQ,65Y$-'$S(UQ];8^)>0CI\H0RRD6YC?T)T>O8,F(@(
M?*.;PF==?AC.(\UJNO#Z@U7`5AG2XC7=,9U&.,[,PK1:[%JPC(7[I9\]!K'+
MME6K<KIZX464`A0`RJAC#\XPB.;GS>K51XI&-DX<\5[8"OC.@-5@HN!P6<0]
M1BJV\5,H"@'4.]K:$2[,N;O1'O.WV^O0>O4I>E[91\G7'9"$KZ8O$=RZ%_7*
MG;=?R(]L0?TK8EP:.$U#J'5[Q`)J4G4&_94$HE(F0J1>[+T(``/6]\DZ8NN#
M@19JX(#K'F9RHJ"*8?H(Z=NZ5SA$#!W0$!.'.A`LS)))()IE`X&/W9.R)Q`1
M#'>/G&$Z[92^!HKU`JH;LU3F=4KPS3_YEEL?3D%&B8.B)0!Q)PR<],*&`A3`
M)N_Z&$.UV0$X]E>$_P!I6?Y/@6+U/ZF`)R.O>+NU4D^GZ6J6*UUB16^801[2
M]G>PD>'SU/DZ-2=!3/\`E`2"+TWD]]H??YL^5]9`$]A<!=A!W74%WNN-AUW8
M/>_-4.(H1<)%.1+V0%,H`#M3MB)QZ@)>P+KC\9G;+YQ?1]2;6,(;NMD:8Y,:
MI52_\:5NVI7#1DW#HL83BJUEG+X4RD1$3"9L00'KT`0`1QTGXF#O'S$L\K?J
M+<-+0)",]VP\:N;L@9&R05MK()&,8I0*=W.0#&/-T$P=3$6.4`ZB(_(/2=,M
ME[X[I]K6_M%W($O*FY-6V(ZPE*1"'OM6?NNV<42E2.T;RAW22_:<I@)#D*<!
M4*`AU$,E3'F%N-TL)J)K)D52.15)4A5$U$S%.FHF<H&(<ARB)3D.40$!`>@A
MD5_>`P&!1#U"JQ6I?1\?+2U>@Y24C]GZ@CV$E(Q+![(,6$OL^J-I9DS>.6ZK
MALTE&_Z-PF0Q2+D^:<#!\F;PG5G/PLO=+I5M*5ZHL(^H2#I"=LL?1*92Z#&U
MUBHXEW["6ET&$>VE)6L5R,:IL(9TJ857*"?S.R7M',4IL-1#&-4<GM*[EC8Z
M3I]SCD4YY4OE=C8W+.N3EK8FI%?V(:7KU>E':$X]CF]3LB#E<3-TU6P$5[Y-
M,$Q'"T_:Y<F]$TNBV78#G9](G8FM:_NVS1856WU:<G)^IZ^@IZPV=Y5XU&:3
M\;%C'UE]U%,X)%.V4`YR`0XE%2S%CN34$FM`MXW:NMY!Q:7KV.K"#&\UAVM8
MY"-?%BY%A`I-Y10\N]829P;KI-P4.DN()F`#_)A$D8#`8#`__]'U'^KS7]:6
MS4&DZGMF(T'%4RW;YBZQ);SY,UN=MNH>.POZ%?'C?8$U"0UHH[%28G7D:E78
MM6:FXB!2?RZ7M;KJ9%!>2UC\OW](VO:KJ&HMUT[4$?H:;J5.WL]KC7>/&:KR
M]2TWR$[C6^NI16^0D7)7+8,<6>@'\NXKDN,/-RL(+V&,+=P505VC5!ERVQ96
M5-=A;1D(KD`E18'><9$M6M`M=JVQ7)QG0D:QI>A(TJ95JNPE)I[&H3Q+_(W>
M-!V@SE))2&<5AE*KG9I"S3=*EK2Z9KQHV)+774GG.PVQS=8-W:K.G1+G(1$9
M'6VTZZ)+J)TRQW&`J<+"0\5.3L:8KM)%O&1IO#%FBCAHU='703$IR\V0?TAW
M[HF/L&6IV9L\V0?TAW[HF/L&*G8L\V0?TAW[HF/L&*G8MXC.6N__`%(=!^M]
M;]XL:SMR]5;7<6A-Q]2UO4%[(RL/I[,[O5U+9%L(,C0">$.'IB>).W'=&96P
M`<&62,DF<N=;=8ZSB]<W&+F]QFYA:Y9[.T!LIA=X(Z;,DY&MF,BE:*5+/&XK
M^7KM71:GD*Y-(]@X`18O=."D%5LHN@)%36-?#G.DU*QOFR#^D._=$Q]@RU.R
M6>;(/Z0[]T3'V#%3L6>;(/Z0[]T3'V#%3L6>;(/Z0[]T3'V#%3L6>;(/Z0[]
MT3'V#%3L6>;(/Z0[]T3'V#%3L6>;(/Z0[]T3'V#%3L6>;(/Z0[]T3'V#%3L6
M>;(/Z0[]T3'V#%3L6>;(/Z0[]T3'V#%3L6>;(/Z0[]T3'V#%3L6>;(/Z0[]T
M3'V#%3L6>;(/Z0[]T3'V#%3L6>;(/Z0[]T3'V#%3L6>;(/Z0[]T3'V#%3L6>
M;(/Z0[]T3'V#%3L6>;(/Z0[]T3'V#%3L6PK8[J#MM"M]<*=TJO+5^3;,R#$2
M_3Q'V916-/\`*PZ?HWZ:9O\`L9<;B8E)UB8:6_:"_P"D/\#9Z7`]H+_I#_`V
M`]H+_I#_``-@3]QF9LY#;U?=ONT9E`-Y&=7!-JX=&`[9J9JQ.*:"2RA03DWJ
M!NUV?D$`_((@.8STQEK"/:&UOS9!_2'?NB8^P9PJ=G:SS9!_2'?NB8^P8J=B
MU5^2^L++OAO4HNM;F;:W@:Q9*[<E8]YIN3O#F1M53FDIJ`?ED3V6KF9,FRR(
M%5;=VJ"P?*)@_)EQTOU28OY6,K,^:.KT,PM%C-9;$TCFK>:L#*GRU>:3,DFD
M4KJ1;P1/%"Q*+I4!,5`'*X)@/3MFZ=<E<+;O/-D'](=^Z)C[!BIV+/-D'](=
M^Z)C[!BIV+/-D'](=^Z)C[!BIV+/-D'](=^Z)C[!BIV+/-D'](=^Z)C[!BIV
M+/-D'](=^Z)C[!BIV+/-D'](=^Z)C[!BIV+8%9:MI.Y@J%PU_3;6"XF%<++K
MAM.@L)Q6,<5?%*^Z[P3F<J"/7KU%0W_*'J]H\&FR`[)PXX16H%`D]%U-KWHB
M)O+<';*:("(G']&-0/!BB'4X_(3L@`=`_(`=-=L]TZX[(F5]//BTP4,K0[/O
M;5*@G%0A]>WNVL3I*"=)0#IGGH:PG[8"D'01$1_M_*`"%[9?,)UQY?G_`"K[
M:KW4=><_.0\6"8=&R.PJ\[VDDF7HB`)G)+.(M(Q``%`+T(`$[1>@?,$#KCYP
M*GXRD\$]1&L%-X+R0TGLP$P$4R;!U'/U%18`*8`((T>J'*!_TH].I_E,D3M&
MZ&/CUG^V3WW?3[]]0FL!VISC=I_9!$NT*Q]<W69J@G(4JIA.BC=W;MR/R`7H
M4"'4,("`%$3!V77'>3ME^*F?,SG]<9JC,]37;CE8-37A:T46\>RV2V-9IBK"
MU*T!-I*LU6D)$N'2<C,0!6Q%0("0I]Z8#"8A0'6.%3?;1G+.XJM6TU*8T1S%
MU?JJY2B:M@IJ5@A]CMJV]@T)N+7L$3%S<(YJ]OCY"!F8V1;P[R8<IN$4^P;V
MML0Y%>R'SN4XS$TZ1E'F$97;A?Q_V!;YFT6.U;56CIZ8FYI]16QF#:F(.K#2
M)C7DL$$B%`-8JJ+VK3:C=9:*DF3MP5%N5951-L@0DJ6NS]KYP_TUM!:??;#V
M+MRVRUJU++:>LDQ(Q-'0>R<'(5G9%28SZ"47J"/C:_;:]#[4E2LW,4W8(',8
MGM2#DO>E55)V9&WXR:G3NLW?W=^VK*6.YW'6MYV4L]95Q-ILF<TQ:86W:D-8
M64=K)@A"-Z#)5]H1N%>"$._01`LD=\;Y^*E.RW'FR#^D._=$Q]@RU.R6>;(/
MZ0[]T3'V#%3L6>;(/Z0[]T3'V#%3L6>;(/Z0[]T3'V#%3L6__]+V>\V-<Z]O
M>CK%,;9WENG0FLM:,9K8-[MFE;@YJDH\J\+`R7B\;8T659MKZSP(-%3+A&H,
MEEW+I)($R'/V2&+'G1&WIU#K!/4MHC]3WKE]>*Q%7`L>0_,2N7VKVV!.C7X?
MNH2D1=^H.O'B5(1:B10GLC11J5X=8`4[8&(43RV"81'LKJ/5,[./K/.:QU[,
MV63;+,I*PRM+K<C.2#-Q$C`+M'TL[C5G[MLO!"+(Z:BAB&:#W(@*?S<#OZO3
MZE2(TT-2ZM7*A#F<JO3157A(R`C3/%R))K.S,8IJT:BY630(4RG9[9@(4!'Y
M`P,CP&`P-3[[_P!^95__`.)^^?\`[O\`7.3Y:_M^T?<JO25;RNSGG+CT^-EJ
M\+^9"*KJ2DI.M(&3TENM=<_MCN&W!KYLT>Q)BSC],JCI^@P=(KK&.X>1[YT*
M:R2B,OB=8<+B]ZL3]ELMCQ']2C6J7#;EJFD@W@)B9=`CQ_WR4RIFR$[JN^.'
M;Z(CU9)P3NR,G$@Z;'<=&Z#Y1X)V2"]R<?G'6&Z[*R8#`8#`8#`8#`8#`8#`
M8'72LLPA&*\G)K&;,6P`=RY!NY<$;I]?G+K@V16.BW2#Y3J&`$TR@(F$`#KC
MR,>A=BZ_L92FK]XJ$WVP`2A%62'?G^<!A`#)MGBAR&^8;J`@`@)1`0^0<M3L
MEQ/B699%>>W911K&P[U70'NR0ENL48D0HAV?9V<L[0;F)U`H]@Z!"B7J`#T$
M/D#/7C,3$2\\^985XW_X3_C+FKA#QO\`\)_QEQ<#8CZ?S/Q&8V18C_*,=&0$
M*@<>GR^+.I!\Z(40`?\`4\&1$WRA_K!^7^SC_EF*B'3_`!_+9:Z>-&*)G#UT
MV9MR_P"LNZ72;HEZ`)A[2JQB$#YI1'\OY`S@ZL-3V?KM>41@F-TKDK.+F,5.
M$A)1K.3`]V<"*'/%PZCY\FDD8?GG,F!"``B80`!Z6IV2XW9WD4P&`P&`P&`P
M&`P&`P&`P&!0/U!*-27^G26A]3JL]LQMEZ5BC6)W7XEQ.FBW&S:TT7C32ZS0
M\@+!9JX42.CWG=F3.8H@(&$!WA,WY8S\+O5RJUBGQWA%2KD#5HGVA5UX77(>
M/A([VI<"%6<^Q1C=JV]H6*F4#'[/:,!0ZC\@9B[\MN^P&`P&`P&`P/_3]L_,
M6%D;)Q/Y(U^(I,MLJ3F]([,BV6OH*5L,+*W5=]495L2KM9&H+MK8EXWWGLYR
M19O$5TU#)-BG6.0ABQYA13T<J_O6LZ9W5";_`*O;JM<(3>TA`I-[2MR3=HOD
M8NA4;Q1Y69/D[M7:ELG:VA8G3QHVDHARWKLB#;VAGWPJ**C(7*KBFWS*R8#`
M8#`8&LM_Z8E3?\P6W-0W+;FXUV4TED00J#/;=&2UB371;_%[(>:("#/J=2QA
MI&6L$0B5U"A+@=5N`AWY5.B@%O2J;-,(KCRAXE\?^9.LI#4O(C7,-?ZHZ[Y>
M,6=D,TL53EU$A23L-,LK04IBLSC<.@=\V5("R8"DN55`YTC%B9CPTJ?_`/07
MT:#?_G;U#?3=B%/_`*K[E3QEJ35+_P"RE=Z37HXG_P"'D1:_^8$1_2SPUIEQ
M+=GQFY5Z!Y@ZTC]L\=]DP.Q:>[,1N^-&JG;SE9E12!56`N%;>D;SE6GD"&`P
MMGJ")U$A*JGVT3IJ&K,Q,>5AL(8#`8#`8#`8#`8#`8#`JCNWB+KC;9'DM'(D
MI%V6[U8MAA6J0,Y)T<1,)K##%%%O(BH<1$RZ9D'0F'J90X!V!WC_`),L=/,,
M981/[M35_@M_<99Y*)D9NU5=NJJ<86=K,_*MZW.)I=GMF8.FJ[9)0P$`.];+
MIIK$*(=M,"F*(]XZYQ=0Y3&6,H*GKI,6>8?S\](*R4Q*+BZD7Z_<E6=N3%*4
MZZW=%3(94X%`3&Z=3#\H]1$1S416D>/M/+J?%Q_Y?_&7_MY=?U:'BX_\O_C+
M_P!O&OZL9G7=N7VHQ<C"U6XS];C99<CB2;P4HO%&>JII"B07#ABJ@Z.0$A$O
M8[?8$!$!#Y1S,XQ.LQ_58F8TB5R='<1-E[F%G<]HRTU5ZDZ$CA`THHJ[N5B:
MG^=WK!"1%?PIFN4/FN793&.'9,F@H0P'S&7^2,=,8U;QPF=9\-L6O-7435D.
M6%H]>90S<Q$@>.R$[Z4E%$@$"N)646[;U^J`G,)0.<2)]H0(4I?FYPG*<M9E
MUB(CQ"0,BF`P&`P&`P&`P&`P&`P&`P*K<IM);+WQ6X6GTW8%3I-?;S,+8IPD
M]39&SR+^7J]@B+%7#1[MG9H-)@S1>1@E<IG26,N0X`4R8AU'6,Q&M,Y1,^)6
M'J3:T,ZW$-;K*Q$Y:D6A23DM`Q3B#AW[T#'$Z\?$.I&6<,&XD$H`F=RL("`C
MVOES+7[LBP&`P&`P&`P/_]3U[>I3R$U?HCC+;HO;8;8C*KO")M>DS7C5$3!N
MWNNG=UI=A;)7"?F[1;*36JK$QY$S=V[?2+=`[LR2(F`50'"Q%SH@'T7Z6I3>
M-ET3,OL60:S&SS/8:6M^O*/J^G/J[&T6F5J!2U/5:)N;>#'R@PCH(B2KQW+)
MO'#\%B"@1%)$1D+EY;@,K)@,!@8Y<'$BTJ-I=0XK!+-JY-N(L6R7?N`D48QT
MHR%!#L*]\M[24O9)V3=HW0.@_DP*)Z>C.95DUI6):7LEIAGTE7:#(JM[_:=4
M5>\*33S7E:7O#Q\>&X^[EA`K[^XJ.5&#!1G#R;!7VH%BE;*,V;,LTQUKIKDE
M&0>](XK.<=R6P&K^&</FEXA$RWU^KMK=E]=W!*14L<;)4DDYJ:9@*2BLW2;R
M,89PV;HH%BJ\P7"+<:/TH''_`'FRV=4I.Q)2K2GELECD6*P6Q@0-:ZAE+9RS
MDB:,5@8BRN$15<5;9M#8=N(%S'$&!0-[0`UR$.M4N%Q^.-4M%#X]:'HUX(*=
MUIFF=7U2X)F?I2ID[17:1!Q%@(:406<(R0EEF:P"N10Y5O\`7`Q@'J))3-@:
M2N3/I)NHC94CRU]-'9).&?+`I'#N>@85N"7'O>O>+B\=0>SZ"@T?Q,6>5<]%
M#NVK!RS,YZN%6!WIBODI6S49?&6L.]XI>K"WFMD-N)?J!:Y-PQYF-!;,64)9
MUQ0TQNI15;V)K.Z9V`[=O8=TE-/2B1M'JR#LJJI@09O7RQ54TEDX_,:PW,96
M5>.4NW]D:(TS9]I:NT=(<@YZJ$"4E-?QFP:AK-T2JL6SI_9+(%DNQ@B#DK\<
MT,L+0@'=.O\`51(8_P`@EC7Y1QP4Y1;"YA:+A=[73CU*\>X&[)14]K&/EMF4
MW92U[H$W!1LQ%79->I)-5JTD[6>J-_#I)NWD$Q0$YTRE.7!,5-6N=A#`8#`8
M#`8#`8#`Q2[4>J[%K<E4KG"LYV`E$A3<LGB?:[!P`>Y=M%B]E9D_:F'M(KI&
M(JD<.I3`.6)F)N)U28B8J7GWY7<9;'QSL2;QJHYF]:S[M1*LV-4A!<-''8.N
M-=L'<D321EVZ!#&35*4B3Q$@J$`IBJI)>G#/M'+CECU_947Q,?\`E!_@&;_7
MRP_HD@HH<B:8"HHH8I$TR$[1SG,(%*0A2@)C&,8>@`'RB./U\C=OQ"X2M*@T
MBMF;EC$G]S6(1]`4M\DFLPJ9#@FHU?33<P&3>64H?.*B?M),A$.H"X`!1\^?
M^2],9T=L,*UGRV:9R=#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`_]7V
M=\S.-FQN4.MX6A:YY+[)XQNV-I;SDW9-:&EF\E;85*-D&"U/EY"M6VAVMC#.
M5GQ'!S1TPR5,J@0#B=/M$$L37PQG@?PS;\)=;6W7+6Q4.U(V6\.[GXW3M5/=
M:2KU9]%1K)TM>GLILG9DIL"TK.V1U#3#EV@N=N=-$Z9A2[TXF;7CPA@,!@,!
M@,!@,!@,"KW*_AKQSYL:V<ZNY%ZXB;O!AWR\#,=GP^X4N553`@3E*M34I9:O
M29>R7M]T<6[HA>Z<I+(B9,Q8F8\--"=JY^>C.<B&R5[IZ@/IMPYC@78C)!-_
MRDXS5DBA0;EL[-9PBG>J7!-![)ESJ^QIHI]H%X9$B3-6>&M,N);71Y,Z*Y8\
M,-P;<X^[(KVR:/+:9V:07\*X,21A9#R),JK0=I@7A&TY5;"U(H456,@W;N2$
M,4_8[!R&-6:F)BV/>E9_[MSA!_\`IHU/_P"BD?DCPN7\I7\RLF`P&`P&!J:E
M^5'/EEZ@,#Q,::/XSK:UL$),[H:7I?:%^3N1.-E3VS1M<6B;5A25,T03::;6
M\H.&D2"HL%E"&`SHA0^6-5%7;;+E9,!@,#"=C:^K&U*58*%<&(/X"QL3LW:8
M=DKALJ!BK,Y%BJ8IP;R,:\3(NW4Z#V%4RB("'4!L34W"3$3%2\K&Z==6'2&S
M+5K6S]3/JZ_%-H_!,46\U#N2E<P\VT*)U`!O)QZI%!(!C"BH)DC#VR&`/3C,
M91$P\\Q4S#8OZ:G'%"X2:^_;DP!Q!UF2/':^8ND@,A(V9F!#OK(9-4HE6;5X
MRA4VIPZE%\)S`(';=!Q_DRKUAT_QX_W-XV<'4P&!T<M9ZU`*(HSMA@X55P0R
MB"4M+,(Y1=,INR91$CQPB90A3?((E`0`<#MFSEN\;H.VBZ+IHZ12<M7394B[
M=RW7(55!=!=(QDUD5DS`8IBB)3%$!`>F!^V`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P/_];W\8#`8&L'DW>K&MN*[4W2,EO>)VE7M,;#FIYS&&V])42V2$KJ
MJ>+3M<ZLK3XLAJ`NRXPR"5I+--6J*[:3CF,6*[D\N_;H1J(W\+*\:WTTG"[<
M4:-]J3.NV^VP1TK^)J]Z4O+S7YM7ZM4G55GV\'K/8SV,1V^M:BM59I85#-B%
M!H)F`,^M9E8;QN3^#[']:J7[4X2YVD\;D_@^Q_6JE^U."YVD\;D_@^Q_6JE^
MU."YVD\;D_@^Q_6JE^U."YVD\;D_@^Q_6JE^U."YVD\;D_@^Q_6JE^U."YVD
M\;D_@^Q_6JE^U."YVD\;D_@^Q_6JE^U."YVD\;D_@^Q_6JE^U."YVE\-,R)R
MF(>FV$Y#E$IBF<5$Q3%,'0Q3%&T"!BF`>@@/Y<%SM+S(>J]Z>MDXZZ]VMS4]
M->L;@T%M&4BG,%R'U9IH:ZYUCLS5%C:2<9<[$\U5$OYM!M)5U&1*\7]@9BQ;
M(%7D`;H.DU'N28V=,<KFLHT1-Z4/)WUH:APHUG&T;@;"<G-,0Z3J&TU:[=N#
M7V@KBCKN-9QI()HTC;>^C%;;2V1@<)Q<H#4RSM,W9*JJDBF8R+7*,;UELD'U
M-?44@!$]]]$W?T>W+W:YSZ]W[1]JN?8!.*:RB;2%H$8960(8H]EJ!NV<O0PF
M*`@.+X9ZQ^3^1]:*Y5HY0VAZ4'JA5%%-7N';Z`X]#<(HBRR)G#%%C+N)>K1<
MBJNGT[PI5BBB8#E^<8@AB^#KME#KG'^8.X@PG0+UHKG%K0_=JG.E>^.0QBB*
MK3NPDFJ@,+G*AW\2*@`YZ"*:8_D,/4.MLZR[JN_YB3TKK`H5!7==NKSE1QW"
M*-BU%L9HFH`D`_?FD&<!(135OU$2]I=PD/:#\G00$6FZ=<OQ_HG6M^M'Z:]J
M(D>,Y1:X:@LDLL0+)8X*FG`B"PH'!5.WRL&=!4QPZD(<"G4)\\@&)\[&FZ5E
M^,IVKWJ)\*[;V0K')SCQ/*F(U.+:+Y&<>GCQ('OR-2.62.U3.VJRQ@$H)J$(
MIVP$HAV@$,:;GM^,M;D[S]XI_P#70ZP@D]LU=S*?R7;&T0'L,[7Y&$_%B^[L
MTSL2J4LUS83#FCI2\M5ZB].5,\D4Q'14FA^RZ7014GSY:J>O\9\MZ#:R.GC=
M!VTJTXZ:.D4G+5TV?TY=NY;KD*J@N@NE:C)K(K)F`Q3%$2F*("`],K%SM+]O
M&Y/X/L?UJI?M3@N=I/&Y/X/L?UJI?M3@N=I/&Y/X/L?UJI?M3@N=I/&Y/X/L
M?UJI?M3@N=I:I_4VTE/[)BM:[%JE-F$K3'V6'UK(BNK7A"1CKO,(1]5*L>/F
M9!SU8VUZ5NE\T"]9,W7Y0#.W^+*KB]'/.)FIIL<U=6D=5:\IVNH"FV/PJH0+
M"&16%Q4B*/5FZ0"_DUR^:C`#J5D#JN5>GR=ZJ;IT#Y,Y3-S,S+<:1$4SSQN3
M^#[']:J7[4Y%N=I/&Y/X/L?UJI?M3@N=I/&Y/X/L?UJI?M3@N=I:9O5^T!I?
M<L;Q#MNT-%-;39!YN<0M0C-3XP:SIQK/8^\J]'7FA$,QM1@",M[%P=!<#E(`
M@?Y54P^4$M8S.ND^&W2EQ$5KJG5/7U(UK+5NET6LP--J%=CEZJ2/@*O6(MK"
M0$*P(I;%%",HJ*8I()`8QA`B8=1$?EPS<[2R7QN3^#[']:J7[4X+G:3QN3^#
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M1OFG*`ATQ]IKLS?QN3^#[']:J7[4X+G:3QN3^#[']:J7[4X+G:3QN3^#[']:
MJ7[4X+G:3QN3^#[']:J7[4X+G:3QN3^#[']:J7[4X+G:3QN3^#[']:J7[4X+
MG:3QN3^#[']:J7[4X+G:7__7]_&`P&`P&`P&`P&`P&`P&`P&!#7(S_\`U[WM
M_P#X:V?_`.A$YA8\PK1Z5G_NW.$'_P"FC4__`**1^2/"Y?RE?S*R8#`Q2QT2
MCW$IR6ZFU2U$4;IM%"6.NQ$X4[5)8SE)L<LFS=`9NFX.*A2#\T#B)@#J/7`@
MNQ\(^&%Q,<]NXB<8+4=1PF[4/8]!:IG#'=)(F;).3FDZFZ$SA-N<4RG'YP$$
M2@/0>F%N=T#6'TB_3-L_;\2X4:$;=LCI,?+U.1J/0KO_`)T2>5%H7NSD_P"]
M&+T,A_WL28J#MENT7W#T%^&C_P!6>FZJ9FMT/QZLO'"X<G)?2D?*/D6`R&O]
ME:SU@IKJ.NB<FE<HVEV5:\^(N52.32J`HJ(-W:8+)JMI6K?:>O+9.O\`Y=?T
MI%5EE4]%6YL11510C9#=FWC(MR'.)BH(F<W%PX,DD`]DHJ*'.(!\XPCU$50S
MWR?D7_+V>GLW#N8S^8F&CTS&*RB8SD#=D8Z-:]H118L4EE%UB-&J8@1,#J'/
MV0#M&,/414=I"^@3Q0;!W$3OSG5!1J9C`SAXCDS(H1D<@)A,5JR27J[E8C=+
MKT*!U#F_TF$?EQ1VGA\+Z$NIF@"A!<]?5)K$40QA:04#RQBVT2P!0PJ+%9HN
MM6/'!"KN#G5/VE3B*AS#U^7IBCO.T`>BM/Q8F9U/U7/5>KT$0W:9Q(<J'JHM
MC*%*9R8RL;`PC-0R[H3J=2M4^@&`![0@)C*Y7M_QA^*WH][Y;D]BAO6!]1;P
MD'#9Z1M;MDA=Y`C]JL@Z1<A+2CQNJ!6SMLFJ@0$P!!0@&*/:^7'VG:/QA^X>
ME?S;C!,A6O6AY=M8\X]\=*TU"N721]J,4J:ADY:1M319)H*:9.R@4@$(;M&Z
MB)QQ7)VC\7S_`*MOU-8PPI5CUNMM-&*A2J+)6OBGK>[OA=]3%.HA)2&R&2C5
MH9$"`"!2=`.!C]H>WT!7)VC\3^17UC*\84ZMZTR4PBZ*4[M2V\'=)JK(JI"8
M$R,RR,M<.PD8AQ$XD40ZCTZE-T`0:[EX_B!Q2]<N',(1WJK:8N)'!2]X:V\/
M-85\T>9(3=D&!:K7%`=%=`I^D%<?F=V7L!\INK7<O'9I>]8#CIZV#-CQL7V/
MR19;_J\AN6HUBA#H-C#:+/5>0%GM$%&ZA4F(V/5J+^5L<E8A3"`F1461@W:2
MAA59'6*HNFVL9QUT;=:+0/\`,95^C5&+=;A]-RR/V54KR<@]V6QW,>_&DTX5
MD609V9[1J.-1E)MN](<CAXS.+=TOVE2"!#%`&J>FTLL&]_YAV)$KE_I'TP[:
MW.;N?#*M:-[04BD<Q3'*\4>V:\GCS-$N[[!DRE%4QE"B'S0,(-4]-Y?!Y!>O
M7$@HV?\``#B1;'!>JI)*K\B$8*.43,0!*U*RLUM._P#:4S@(&.8Q4S=H.GY!
M$6I6.\OAN<?K+P)DWED]&"/E8TYQ;^RU?G#I%>2]H.FHHDH;PUM:U46I`2'M
M',U['42E[93&*`M=EK'\GT?4R]1J,!1"R^B9OAK()]5!2JW(6B72.%L)`,F8
MLM'Z_9I'<B/:`R)2&,3H'RB(]`7PG6/R`]7SD'&@FYLWHZ^HVT8&Z)J*5;69
M[I(D<F()DREB6#!DX,V$2B!EA,4I/DZAU$`Q?!UC\H?"^N#%19E&=T],KU7:
MQ,$.!RQI>*+9T869TTS(.5#2U^KCI(ZJG;#L]P8G9*!@.(F$I5KUVF'S_K_>
M(;/N5K)I+F]38]4W=FE[/QJDVL:BX,D=5-JHJPLLBL9PMW8E*":9P$0Z]0*`
MF!:=9X?V'^8C],=H)D;+L#:]*D`-VB1-IT7LEK(JM3%**;Y-*.A9-'V193MD
M*)E"G$R9OF@'016=)9_$^OMZ2DPN@U0Y:M&CA=(5.Q+:;Y!Q""(E3[TZ2\A(
MZG;1B:I0`2]._$#F^0@FZAU7!URV2-%>M-Z6TRBHNSYEZO1(DKW)BRK6XP*P
MG[!3]4VTY5XYPLET,'SR%,3KU#KU`0!<'7+9)\5ZI'IQ3#ALV:<X>+Z*CL@J
M)&E=RTB";D*5`S@0<NYN7CVK(_=D$`*L=,PGZ$`.V(%&W"=<MDD1/.[@_/(J
M.8/F3Q4F6Z*O<++Q/(?44BBDMV"J=RHJSMZQ"*]@X&[(B`]!`?[<%3LDZ(Y`
MZ&GU6B$%NW44VN_2[]@C$;)ILDJ]1[@SKOFB;.:6.Y2]E(*G:(!@[L!-^3Y<
M%3LU0>M7OO2U+T!QS7LNT*3&@MS?XQ69NB$^P>O'-?UMLF#M-^F&K&/5=O74
M?4(!5)R_433,5N5=$#=#+)%/):QB;;DH>]4JPT^&V%!6VMRU#L4/%V"!N<?-
MQSJKS$'.(MUX:7CIU)P:,>1THB[2,W6(H)%04+V1'M!E8=T,M%`DX7&3CP0:
M(HN7:PO&P)-6[A+OD%W"G>=A%%9'YY#&$"F+\H"(8'88#`8#`8#`_]#W\8#`
M8#`8#`8#`8#`8#`8#`8%<>5VM-R;@TA;M;Z-V=5M1W*WME(%[;[?13[$B25.
M69O(VS1A*\G-U\Y9"1CW8E0<@X`6YP[79-^3"Q5ZHO\`3^XX[JXG<>:QH7<.
MXJCN5KK=C"U/64Q4]=+:[\#U[7X",B8R#FVZ]BLBL],$=M%ECOA42$Y52D['
MS>HB9B9N%WL(8#`8#`8&F&<<\Z%?5+J6ZV?`J;=Z&KVJ[?Q-6VH')+02"2])
MON^-679SO\M*6L1;PG%5ZMT9=P>M^PFEG/>`F0X*@!#3Y:TZU>K<]E9,!@,!
M@,!@,!@,#3YZK]^V"Q2XO4W7_%WE!OE>I<I^-O).QSVC=:QUVK<13]%[>A;9
M:*R^?N+3#.6U\FHF/.,4T.@5FX,(=\[;EZF"2UC\ZMJ]"M1[U1:7=U:O;*.I
M<:G7+4I2[[&-X2]5`]AAV<N>KW2&:/Y5I$6ROF>>R2+5)TY3;O$5"%54`H'&
MLLLP&`P&`P&`P&!'LEJ/5$TU%C,:QU[+,C'(H9G)4NMOVIE$QZIJ"W=1JJ0G
M((_(/3J']F%N=T>2G$;BC-N0>37&+CU+O`2*@#N4TMK>0<@B03&(B"[NM*J@
MD0QS"!>O0!$?]."YW19*^FOZ>,RW.V>\&.(Y"**E6.K'\>-3P[PRA3";J,A$
M51B^[)C#\XO>=D__`'0#BCM.Z/)7TA_3,F7!'3OA3HA%1-$J!2Q52+!-Q(4Z
MB@&.TA',>T46$RH]5#$%02@!1,(%*`2H7MENBV4]"?TGY=LJU=\/ZRDDL<JA
MS1>Q-T0CD#$4!0`2>0NR6#Q`@F#Y2D.4IB_-$!+\F*@[9;M,_JY>A?PUU;K;
M25YXN1$QQ_F;)R"U+HNQ1H6"];2KLZSW5<8VI-+.Z0V+>9B:82E+76%PFDR?
M-VSY$QTE2%.*:Z:8:QRF;MZ&H/AVVU3PTU+Q6U@X2M"VEZW5(JHV2Y6(*H*U
MEJS9RX;762[FA[.BW*OF1<7P1+B)=L#`;NCB)"`!JQ>MHO'A?M,MEB[*_DM6
MVMQ6K?8;5,-9!:4K\;R*-;MM5793%EM^,;4B?:U=KHIG!GCJ4FAYE*1))N`^
MQ$[1`%LX5XJ[A1K6F:LPW!86S'5NJ^+.O7JT'MC;=!3L#S6.QZ^KO.:>1-->
MM&<BXV'IYF^C&*KPZSD'RZ7:.T%,CQ,7#$&>G>3U!UX[)?K_`"U^=QD[JX3R
MM7W%R/<V*P42OLJ1!3-#-#4BDRUDAI`9&)=2[NVQY)"?G>JK>0(5)XZ5(-%Q
M^.$/?X'1&J(G:9Y,VQ6=*A0N!9JQN[?+MIQ9N#AVQE+0_6<.Y^0CS*@@LZ.H
MH*RB8F[1@$!$3Y37A#`8'__1]_&`P&`P&`P&`P&`P&`P&`P*4['WQN*"Y'RN
MHZ%4XRV1$10..]M)#I4&[R$O)FVSLK?51OLA([196!IKJA1E$JFJVLNS;R[0
MAY=<KABFX!5TW,W+44C[8.PN8CJ6I@-M?VJAB=I9ACF5<@JY;HFR;!2N6F&U
M%@]@OJW*[-)5M>2M3E+AXF_<.X5%L1L54'2;@C41BZ,>NVQ^3LCL6\+4QOMQ
MK0AM\.S>IAJ6;9-X/39+7Q7CY&Q:Z"8UV6Q3FPBUV>V6Z,T(E(2!SH*]E`Y&
MD+VAHG#CY*[Z?W2//M1Q<5H.0T-4I0B,[66$&P1M87Z],47;_P!BKT0,9L&<
MH*$0]G8I10!8O%C$3;-4P*D6I-4N1A#`8#`UQZ1Y)\HMJZTJUX8ZCC+:>S:Q
MT?>B/8:E3NLHA*<V+7K?,W>LQ">V]DQ2-PB:<2.@UF\W&2"[1ZG.=T5,3-E%
M,+4.M6V7RTCH_=$D>`OYKDGK??1(2I'UNO+5>L;9&V0D1Q'C=;R\-69"/MT3
M:Z8^=/K@[/(S<7"R*0>W.62!#E$:.OB+SRF3N"!._P!O.J&WM]3)JM]+:I>I
MR=WURIMR68;TD=V-#ZZ:2=-L%%U*@FYI23A&$=SRW<B#>2<'.0XT6UXR2M_F
M*!-.]AGMQWY-B7EK7SW.%D(24-3FLP=&N]PG/U6AVN18@U*(`[E8.+<KJ@H*
M*2C(&CE<2L3A#`8#`8#`8%-=Z[SVM1-R4O7.NJY&69&<U[(W):'-K^^6J7FY
M1ELW7=.)"DM56F6T#K:)4A+4]75EYEDZ9-5$"JJ?HDU"'+6B/]V;%Y0J559>
M`K5THTZUGK4B:NZ[H2^P)ID=IJ7:K_5RIK>,=9ZO<ZW;MI1$$H^.U911H<1;
ML)8A6;MPJI%T8QN38_+(UKM(ZLC[^@XC*_-,&<5&ZODE::,;#Z1WD>P6N!E+
MA1#(S6PDN1<#7F4*Q5=KM9:'*P7;-5F$DY=JU(I*VFI?>C[:6O1M3[8CG6SV
MD<MD02M-1+!`9&K[YT_'Z!F+H9Q58::B+O,:REIHK)N^517D8QJ9TJV]L(]5
MP2NWA#`8#`8#`8#`8#`8#`U:^I5QCYD\J(_4M.X[6SC+5J-1=D:[W1.*;IC-
MINK8]V-J>YM+93642ZHSH8<*4\%H"<F@LW*^5`1!!PA_K!):B8AL3UJ79!-?
MTXFX5J0XVF6O1@;`7UJVGF6OUK6#8GC*E.:6AV_L3>O&>=H6I'JRKDJ70#F$
MW4<K+-\!@,!@,!@,#__2]_&`P&!UZDM%)2!8A63CTY4T>O+%C%'C8D@:*;+H
MMG,F5D90'(Q[=RX33.MV>[(=0I1$!,`"'\0\U#6*.;3%?EHR=B'G?>R2L._:
MR<<Z]G75:K^S/F2J[9?N'*!TS]DP]E0ABCT$!#`[/`8#`8#`8#`8#`XQ&3--
MXO(D:-B2#ILT9.GY$$BO'+-@J]78-%W0$!=9LR7DG)T4S&$B9W"@E`!.;J')
MP&`P&`P&`P.,R9,XUFTCHYHV81[!L@R8,&2"35FR9M4B(-6C1J@1-!LV;()E
M(FF0I2$(4````,#DX#`8#`8#`8#`8#`XPLF8O"2(M&PR";91D1^*"0O",U54
MUU6A'78[\K91=$AS)@;L"<@"(=0#`Y.`P&`P&`P&`P&`P&`P&`P*)S*W)N>Y
M#;&BZ7(6^,HL%,PC:,?2BM"B==)UR2T/*+R+&-6EJE9;@\MCK;,A#N6\BDPF
M(Z-!DX!9(R0.8R4+I3H;!I_DS,WG7TS8)EW/'B;)174;.MK[69!'7<;7MRZK
MN.R%GPPFL]#EE"[3U7`3-;2*V@91ZS!15NHY!A+N@;#1@CO2G(2>M!+=,5*?
M-!.K?8;5N"A.[G4W#[>U6M&V:M<M4T1/NKNK78=[QMUTT<P#]NX=-(>P]THW
M36=,W9U<BW"8N,&H-IZUM*#V^-G,])O].Z]A]G['N@TB8LMAVI5J+K"E'3UA
M:*VZ5N3C6DBC3I*0F6UK22=FG%V[ID8Y7#PJ525X\(8#`8#`8'__T_?Q@,!@
M4IY*:!L>SK78YJG5JK+O+1PPY;:*D9B8=FA2R5KV@]T>IK*!L4G!JM+<>N=*
MQ.&.X:*=N.(904C)*KD$Y8FD;ZIC]I\:-5S+=6O'4LFVN3U;CJI^*CB@M+06
M-O==H-4<3NQV&@FK;53*49V"`D$V3:LH-FRD(FP6=@:44D%%;C%W:93XI:;^
MIW]P_P#$''KRGMP?U._N'_B#CUY/;@_J=_</_$''KR>W!_4[^X?^(./7D]N#
M^IW]P_\`$''KR>W!_4[^X?\`B#CUY/;@_J=_</\`Q!QZ\GMPPJH73DG;GUZ8
MMF6CF9Z+=5Z6[474OIROW2%=K=B%ZW!/Y4VYD;(1,"F^=VDC#^00RUCIY2YX
M9K_4[^X?^(.3UY7VX/ZG?W#_`,0<>O)[<']3O[A_X@X]>3VX/ZG?W#_Q!QZ\
MGMP?U._N'_B#CUY/;@_J=_</_$''KR>W#"KS=.2=&8P3YVRT<^).W6F4M)-N
MI?4S(.KG8F%=;/5!4^0S=DL_!10H?.,4H@'RY8C&=TF9C9FO]3O[A_X@Y/7E
M?;@_J=_</_$''KR>W!_4[^X?^(./7D]N#^IW]P_\0<>O)[<']3O[A_X@X]>3
MVX/ZG?W#_P`0<>O)[<']3O[A_P"(./7D]N&+P%GY+3\K=XI%KHQNI2;.TK#I
M50]^,1\N[I=1N973<I?G)HD:VY-$0-\[O$3#^00RUCIY/;AE']3O[A_X@Y/7
MD]N#^IW]P_\`$''KR>W!_4[^X?\`B#CUY/;@_J=_</\`Q!QZ\GMP?U._N'_B
M#CUY/;@_J=_</_$''KR>W!_4[^X?^(./7D]N#^IW]P_\0<>O)[<']3O[A_X@
MX]>3VX/ZG?W#_P`0<>O)[<']3O[A_P"(./7D]N#^IW]P_P#$''KR>W!_4[^X
M?^(./7D]N#^IW]P_\0<>O)[<,*JUTY)VF<V3!MV6CFJNMKJPI;Y=92^G3DG3
M[75!V*1ZU*3YR3=-E?D6PE/\X56YS?ZIBY:QT\I<Z^&:_P!3O[A_X@Y/7E?;
M@_J=_</_`!!QZ\GMP?U._N'_`(@X]>3VX/ZG?W#_`,0<>O)[<']3O[A_X@X]
M>3VX/ZG?W#_Q!QZ\GMP?U._N'_B#CUY/;@_J=_</_$''KR>W!_4[^X?^(./7
MD]N#^IW]P_\`$''KR>W!_4[^X?\`B#CUY/;@_J=_</\`Q!QZ\GMP?U._N'_B
M#CUY/;@_J=_</_$''KR>W",/Q/Y'^:_*OA>DO:/Q/_##VOOKWW/M_P"#'XS^
M*=CIV_9/#/\`8NQ_K]_\_P#U,M8U>OA+GA__U/8;1_4?XHW[9L=JF,M5ZAIV
MP[*N6G:58[GIG;U+UAL+:&OY*;B+=1:'MJRTF-UM9;/$25==H^Q(RGM#A5(2
M($5/\W%KUF%TRV&`./0LY#F$)@U>$"R;(1"?(43G@^@+C_TP0A1$6W_/``=>
MSA&`;.W=K33](?[$N\Z^+58Z4;0;A>HU:W;)F%9MV[]A;P\?5-;P-LM<M**/
M/T?L[5DLL4_R"4,+5JZS?J1<*J_4Z!>G^[V*]/V56'5WKUBA*7LFS1D92V-O
M:Z^D+AL)Q6Z;+!J6JQE^>$@W4C:O!6;:8[3-50CDATRK.L^*7#DHBN6DC,DH
MRBYPD#/,9=D5P1!Z$58X-8'#!ZD`]OV64C%S`<AOD43,/7Y,([[`CO9&U:1J
M:+B):[2$HW)89Y&KUN)KM5MM[M5GL2T5+3W@M8I=$@[+;[)(H5^OR$BNDQ8K
MF;Q[!RZ5`B""JA`[6IW^F7FE5C8U5L<9+TBYPT'8*S9$EO9X^6B;*DU5@W*)
MGA6RJ1Y$'J1")*E(L"IP3,0%.I<#OEYB(;'<IN92.;G9-W;MX1=\V2.T:L$6
M3E^Y<E45**#=DWDFZBQS="ID73,80`Y1$.>4Q3E*<ABG(<H&*8H@8IBF#J4Q
M3!U`Q3`/4!#\N!_6`P.LCH:)B595>,CFC!:<DSS,PHU1(B>2EE&;*//(O#$`
M!7=F8QR"0G-U-W:)`_(`8']3$JR@8B4G)(S@D=#1SZ5?G:,7TFZ*RCFRKQT9
MM&QC9Y)2#@J")A(@W1575-T*F0QQ`HA7"3YF<<8>@TC9TA?9!&F;#C+5/5N0
M3U]LQU(IUBAJE0OMRL]::4Y>ST2C4)55,)V<G6<=$PW?HB]<(`LD)RU*RIW[
M%,K(QWK0A9)4B$<8[E$I7ZRC=5VFBR$3@#I4[5`ZH%)VA%,AC!\@".$<<TU#
M$[[MRT83V8[=-QVG[4OLZCR1<0[1-;JJ'='=2S15JF!N@G<I'3+U.42@'9X#
M`ZR4AHF;2:(2\<TDD6,G&S+--XB1<C:6AGB4A%2*)3@()NX]\@15(X?.(H4!
M#Y0P.SP(SNFW]?Z]MFM*1;I>0B[%M^?D*MKY!*KVR5C9FPQD,\L#J*>6&&@Y
M"NUQR,/'KKH^*.F17((G*B)S%$H!PZ[N[75HV',ZJCI&?9WR$CYN7/"6:A7^
MF)3<-6IYG6+'.4J9N%8@H'84'`3TFS;/7L"ZD6K4\@S%50I7C8RI:^4E>*1G
M^T#XBQZ-'96#K_:V_P#LSXZ2*Y&3C])^A=F0<IG!,W0XD4*/3H8.I'UK)1ST
MYDV3]D[4*V9O3$:ND'!RLY`%C,'9BI*',#9\5NH**G^HJ!#=D1Z#T#FX#`X+
M2,CV#B4=,F;=JYFGR<G+KH)%35D9!*-CH9-X\.4`%=P2*B6K<#&ZB"2!"_D*
M&!SL!@,!@,"+=R[JUAQ]U]+[2W!;&U,HL$M&MI&;<,9>6.5S,2+:+CFK2(@(
M^6G)-RX>.B!W;5LL<B8'5,!4DU#E"17<E',!3!\_9,A5[/=`[=(-A4[;IHQ)
MW8+*$[?:>OT$0Z?E573)_K'*`A^:\Q$-CN4W,I'-SLF[MV\(N^;)':-6"+)R
M_<N2J*E%!NR;R3=18YNA4R+IF,(`<HB'/*8IRE.0Q3D.4#%,40,4Q3!U*8I@
MZ@8I@'J`A^7`_K`8#`8#`ZQA#1,6ZFGT='-&3RQR:4S/.6R!$EI>60AHFO(R
M,@H0`,Y=I0<"R:%.;J8$&J9/R$`,#L\!@,!@,#!=B[)IVJ:V-JN\D[CXH\I#
MP3)&*@K!:Y^9G;!((14+!5RIU**G+59IN2>N"E2:1[)RX,4#'['8(<Q0^TG9
M5'V+3878%0L#:2J5@([&,DW*#V%4%>.=O8^4CG\7.MHR7AIF'D8QRV?,7C=!
MXR<ME45TDU$CE*&4A+10^R])./'VTC95ET>-A]K3>=KV-1K^D_V@COL#W8DZ
M@IT'L]>F!R&KMJ^0*Y9.6[QL<RA2.&JR;A`YD53HJE*JD8Z9C)+)F(8`'YIB
MB`_*`X'(P&`P&`P.C\LU[V_Q7P:.\2\<\S>V^RI>T^8?+7DWQGO>SV_$?*O_
M`$?WO^M[)^CZ]GY,6/_5]'.O/3^Y;B-"U3L6S<=*WH;5_.^^\WHFQTJ8V/>M
ML7>75W+=]T:MI<O`3M'UW5Z+&15DLS7QQ5G+2R[YNU,V041(JH<\IN<H\_-*
M"W/TR^1G';4&^-L6UA3K?M.5I?'I]I^J\6(2=L;V6YH:<W]*WC5NQV&MJ?I#
M25.UQ2Y1A-MH)R8J;LU9A%7@*R#H@"Y.H[1--P5-XW\K>.7IWT?C_P`5)O3R
M?*1.N*+6[8^Y)FQ,J;';*V1(S-WW+L6/"KT2\N[+.$OMC>GA6CUD#'L'2.Z.
MJDW%JX?"7$S<^&O7;GH[;RV1J[CQ4(0=&4R6U9HF[:F=MB[CVQ,I5'85DWPQ
MV_\`CR\N26E(-_RF5L"L060EZ+<(>`K/F&1=N$#E`I%%%+VC5N<XM:8LNF&N
M^4;/6-.5USLSDKM';T<\T^2YI&N41<TZ\5I>=K(7!PNBWW-8E(M0TZG"@E`D
M["(-"%#MY69^%I<(J1RZT5:][U_5T?6DX.5;4/:25]L%2F=@W;33FU,4*#?*
MM&H5_=>LJ]9ME:LG(*PVIG)@]A6Y'$@U9KQBRJ;5ZOU+$T@K8O$+;MAXH\?>
M-D;(:BLK*@P+6I[&1LD3782/-`L=;V&FP`:_=RFE=KQ;(U45E$&A@3@(9_+Q
MI%!"1C1470<1;UF43Z\]-ZSMG=$GMOMM,[$MT'R&T%LBU666\7M4Q.:VU;Z>
MVL^,MFJ2DM9*4G(2JLIO>J25A;Q[HQ8]RQ<IOEU$Y`ZC5,6V#<6]5V'2&@M;
M:FL[R&>RE#B7T"F>NN'SF":PJ$Y**UB*B#R,=$NDX^$K2S1FDD+=(B!$`33`
M4R%$:DZRG["&`P&!JN'AIOBM:MUO`4J:U.^O$3H3E%QTMPV:PW1G58B$Y&7J
MJ7*-V35UX^FR;ZQ3-"4IJ)'%?79PJ<\5X)#3#$&:)UHU<.VYD<.-P;MI.O=:
MZIF-;M:S0]52=8@9Z[/T8:]UC8<4YHZ]'ML9:#Z<VQ95HPH5$AG2</)U1^W>
MHH.S.7YB(I-:D3Y1_)>FH>?<R$I9:WHR>FIUQZG+NQRLK'NY%]/.N7F]92_<
M?',L\=TI1Q)N-;:_>)QL@=<3FA5BF1BQ=H?IAE+?^C:/K>$GJSKNA5NTR*4O
M9Z_2ZM"6.61<NGJ,I/14&Q82\BD\?(-7KM)[(-U%2JK))JJ`;M'*4PB`5EFF
M`P&!`.[]5V'9=BXZ2\$\AFC;46_HW:ED)+.'R"[ZO,]6[6I"K.#*SCGZ;F9-
M*WEHH5-P9L@+=-8PK`<I$U"Q\HTU9KOD*IR1V'M_>4#J%Q#&B;!K_2;ZB[1N
M4S)Z^U0XG8.7-#NZ3.:6JK!:W[/E(!E)VF3"PN$43Q48P9MC),U';H:5HI"W
M]/'?-DV7(W;8S[1*\;:KCIV3V37X%T#>L;"B=9<ET]N23UY2X+0U$C4#3=$D
MY6.2BIEW9W(.7BJ3R<>E>.W9HMQ\+#<=^$<GHC:-!OL0PU;`H0D[SV2N!Z:B
M]82\_1.07)*'V=QSJIC$J\823C]5:MKD=#+,W*Q&L&HR2:1@N6A`5P3-MD.5
MDP&`P&`P&`P*(<[^'4SRWUVZBZSM*TT:XP-*V+"4:&!2DFUH_LM_A6U>5L-T
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M41J3K*?L(8#`8#`8#`8#`8#`K%RQTU:=X:ZKM6JIX-PM!;/H-_E*[/V>Q:^;
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M@[>/]H;*IRA')U0<N'"*529NEE,(8#`8#`8'_];W\8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`_]?W\8#`8#`8&JM+E9MY[R+OM!KUTIMDE*ARG9:8BN.Q:8JSM%@U
M,[U70[K9=JK7=.0</HUM1I&UJJJ2GL1H5-)H:.<%4?O6AT8U44D*][UY,US<
M&O=8OZ0RJZV^"4MQ1U(=$NQ8K7K;55[DIWE`2QV=E&1)7;VT:)6C5*DDLP*8
M+`==(OM0$!(*E0IC6^3VR>2%]H45+I!.:^KW(#@UMC7]B\$C8VR,D]K3G)N&
MN%&N;*KO):N0<WKQ;5+$KN*]L?R<*Y?J-9%VJN4`)%JG-4]0/D.OK[12\:SC
MI.Q3'&_1[ODY/,:W#QS/0F\IF=C(;>0V1Q9WT74:I+TF1ZQKB+E7/LU<<2S.
M0D45&)>PN*A;EYNKD5(\:^.E@CY[7D;M#;NZ835\I>:NQAMFTT:-8;!>X*!V
M3&M:W97E7<3$G58J+FUF[25=132464:E7<-2=3U-+G91+=._.3V^ZGN36\P]
M@*'`.[W"T^\:T*.MW^S*/71YC:OU/`Q3JC^-V&VV"@;%U7-21K"\FXQ.+F1,
MBM&J^$O#MCQ8B(I("O+OE!2HKD+&5R`UQ7D=$Z_WU&P&GI-OK^'M5,8Z:MC>
MGZ-N$'KJK6$;H^I>Q:M&E=/P4BD814)5FI".46;;NWHJ-%X=6[:VFWY76[0.
MQKK`;`;0NL(^P0[_`%U`P#5E#.8^'U@:;=[KBB3,G;=8WBW6.U23FKLOT\!+
MUM+]$X&0CWG?5/A4'7?(#<U(K[RI7SD6W@D_YB?4&9V_;NSZ4RN3W7,AK;DI
M,H<;-&.ZY%.X1>/2W9JZQ$L,"BY'VEW7XU&)@`2,_BE$8M1LLQ=^1.T8RI<3
ME]E2L-Q0)N74DE==T7RU5HDU%ZLVM&U36TG&Z'*]L<@C5ZE/V>:M\T+=[-^U
MD<)U5>,;IC(R#59*I4:J];3YG<BZ?6>0EFKBE;FKCK[7?.FP26DBZ^DPG-'M
M./<#L-[Q\O\`89[Q55:;CMR+5:)."#IMW%A"?37A!*TCW9EHL1&C*K-O[E9K
MC8=]CIJZU.Z5G7G(37^G_8VNHU*TK9*]MG0++9KJS+RJ=LFQ8K:]O,RBVC>X
M(*!XAJHUD!>/5@D4!$1*-:#SMV;)ZFB[M*[1KUU8WC2&BK78KG3]<Q%7B^-^
MZ=L6.KQ`:\NTS:["I2X*$6@9MR_<N+$I[;72QQGCE!XC)1D<85PQQCRQY4[1
MUGL2<GR0-;3UAHS2ELF*[&4JQ-G]OV78^9')[2#R18S83$1+5^.CZSQZCI9S
M'IH*&5<21.@MVP'1<"H3@?EKMU.7V16)NYU.#C(/D='4:Y[XKT)`6S2&B]-6
M&,WC)5J61GTY0JB6S(]]K2`K=RC[<1(E/GK.WE5TEH-RR(<5&C"$^6O+=\UO
MUK45K<3#Z<UEH78B<+^$LRS)O6*V)S!Y4Z73L;$TS8EIR@P.Q-#Z9@K2S9$*
M\?1CR?:K'4%L@LS?BH2_R<VGNG4O)2?GJ9<IA[$(\-[K9M?:9?1:<G5+ULJJ
M7+M3\C'0C$K>TW&PTNJ2*,T\C89<)=S'-/9T1(1<1$1%Q]OWE.4&T:YQ6Y[;
M;A[75MKMN.>K=F7?2&YXRJDA*OL)_5./YMCN6#IBTDG\#:"4R^HK,'4A%&28
M*IB#`Y/;V+XYQ47"NNR.0%T<;;TA/R5N)OC6NC=]RFR8_:&L-42;=\%L<^G)
MZE[O9^G6%*CYI\%EG]<*UF".W8E=$E$G-G0A7ZQY)LJJ<:5^N'<Z\YN[CL[I
M]7;UL.E:WUC^+\M7FO*Q6"KMEK:=.6T71]DT^`<V2->DTO&6FRW*Q2K)*=,9
M]`$)!*PA2N9==!\<5_\`**.37(KDCM2D<QM7+1E5;0[*A<DZD363\U6)L8E9
MIHNXK3VXJ;2X>T/-M7"'VN,:B_5*:*+%JL[`V19N$7,<L$@6(C19`O*S;24^
MYKOXST"0T@?9$;77/,]#7B#>I5UVXU=:K?-:V7CS3BM(*_B[O#,(TDZNX.S;
MA(A!N2GGB%74)4;)AG^0VWF_'[BI<[HZAM&2VXY^)A=T[+F::\1@-41BFL-A
M6]C8QK%OE#A0B;`N-5AXQHE957!(CQTK%R8\D+?MU-+E5K4?,KE9L#75SV0=
M_5'4=4=:Z!E')6NH+`"*3C=&_;WKJ_;6=0I;"G8RUO0VL:4XLCBMIF4D'P)'
M05=)'*`J19B+2K"\O=HPMCB36:U5JRZ4=3?(:C4#>[&GFCH3>LS6M:Z-N&F7
M==&/<R,7)3TY<K#>:RT)#`#*W/ZP96+0Z+((&%0B[1G-G?&PYR%;RM[I;J[M
M=J<.:(?CZAKA9O9;M2=V\7^)6VM\[)2L",L5]%IZC=[MG9T!1;%91;6)*RD1
M6/*QOLXJ&XRI6NNWNKU^Z5&5;SE7M4/'S]?F&I5BMI.'E&R;R/?(%<)HKE2<
MME2G`#D*8`'Y0`?DRLLAP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!_
M_]#W\8#`8#`8&O*=Y#1^D;ULVLUO2#>.M=UWS6"NXR0L>R2V'8;FWTI:-7W*
MUA:WJ'80R=7&*UPQCD"5D\X*:B8DDDXIVFLB8M6[=_S:=QM^E-9.=2+*6YCO
M33^MFK1K=DC-7>K=H2<34Y+=KA=W5F3B):U#8@2T*>"<(E>/%&C%3OT!E$TF
MXI(^S>4`:U>QSE[KR>\IR^HK#LZ%F[`,U3Y2S3D!3[A=7&I(&&EZH>,B]H-X
M.K$<N(RSR=:7]E<JJ-"O31TFDT%.(WYGZK&01K+Z/L;38"[;6YT=>,G5)L=H
M._V@O!L*_%.2UBY3$7`.4)BQLFKD\PYC$$P<%<@<S(#N2"F*GYW:TDWM(?5"
M+F)NBV-2=;3-VESQ5)B(F6A]7$V::KI/+K*5^-1LC-I)1K9]XDO'1S5=X='V
ML[AF]1;"G>%YOZAF88)&B-;=>'+^'BI.OMH6"_V>8-,ZV=;9;IHO73QN@*49
M1H]R]D#D$_LXMP;%!1ZZCVSP5+I4^9B;*006L5$\+ID/Q5U_REV!<&SR\31Z
MW`7"$V].RD(SCJ]J^;KYEH)EJ)P9%67G(4\H=V5%FDJND9,XIF;_`)C:LBDK
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M9O.U2VP[R`L4.NX8.&CY!&3B)!9`QT54E2E.(D.4P`(!EF`P&`P,-O5#@-C0
M?EZQKVEM'@];ORKTZ^7G7$V1PV*J0@)V;7ECJUD2:JI+G(L@5V"#A,PD5(<H
M],#LJI5:W1JS`TVG0<96JI5XEC!5VOPS1)C%0T/&-TVC".8,T"E2;MFK=(I2
ME`/R!_IP,@P,3KE&JE2F+[/UV'1C)?9]L9WF^/4EG:I[%:X^C4O6C.8<D<N%
MD6RR%'UY#1X$;E22%-B4XD%4RASAEF`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&!__T??Q@,!@,!@41N=CXMS^P[)&2-;NEAVI'[=J&KTU(^1NM4L3
M79"U'M.T(N%UQ<9FU4Z/KK%"C-I27<A"2+)B_65.B`.I)<C=0NK+*DGPJO#A
MS:*T_P!2S<M`7IY67LV\FVP69K>HKD5"-P8OG<X^2L#EW+<E->1HQZBHG1FI
MMJV.T,Y!=(RHU<./NW#:_P!B<U$;/KRQMM(4)HNT"6V!%S5`9TYS`S%-E)-H
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MU:J2*D8H`<1THI'@W<MUC(]@HU8Y(6GC?*JN-/6:E2%<IU2V7;*_#6J32"$I
MC7:#2E3^R[LA#VV#L0V*FO%:-/S*CI](%B&$@S</6)%URKG;*C5(L3%<8K#$
M-JK69'5KN*GK_79R)BZ?:X=L9QL>OP#6Y5E6M&K<N@[9V*.J-`+(MD&!DU`B
M(Q54""U36'!JZ:@ZYXY[$C&$U2:6>,#69V6EH:2:M[A0+15F&C7=PJ474XIZ
M1S`VB/@X5.U3#4I"G(D_92"I%@614[.#5(EDT)IJX/+%(V?7-8G)"V%M);`]
MD6`.'<@%WU]`:IMO5P8_>MC6#7-6CX=R*(IBHR:D(/\`:(D=-*<9M&3:1VLM
M0&+]@,I*S"$4XE+`>%CG<\NN]GD86%\7")@HJ=DW`OGK%DB@R=R!4W:R1W*:
M:I2W+/:SK2ATU\:3J]8C(5^:,<0QG3(BA51BW5CF;<X9=3J'#N5;+87KP0Z=
M>^<G'\G0`(SG`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`__TO?Q@,!@,!@5,YH>0_P!OGXB^=?P_P#9A_$7\-_PG\T^7/#)
M'KV?Q3_1^U>T=SX=X#_O7XK[)X5^GPL>5(IK^7#QV0]N_F:\$_F!F/.O<?@G
MY:]L_P"LB7\N^-=?]\_PV_FP\;\,\&_WE\`]K\3^;X9D7X89&%T">Z\?`>K;
ML;Q2=ZXJ+Q1MB-M4O+$\J(4VX(<=XR,+K!VQ)&ZI4EG#-U;7TT+MX1RSB6JS
M0RCP7;$:ZNZO7\L_X\\D?9_YE/Q#\QD\]_AU_+?V.GG?BUY@]J[/^^_X5=QX
M)XK^)'^Z/E_Q[I\O8P:Z(T;?R<^4-,>&?S3>7OP\XP?AOX%_+IX-[3_*'/>5
M?Q`\%_W*_%7^6SV_Q[SG^F\.]F\#_P"C?"<+KJEC7'\GWG6O>3?QT[WS1>O`
M.Y_"_P`I=YXMZO?MWL/A7SO+G:_%'PWN?E]F\I]K_P`[835^&D?Y,OPOW5Y6
M_&[R3^".SO:/-WX:>:?*7M5=_&+\,_#?]^?$//\`[%XIXE_N]XI[/W'_`$7[
M%@F__+.8;^7KS1;/'_YA_P`2/Q/XU_B1YC_!WQG\0?YVJA^'7C/D?_<KL?B%
MX1XOX/\`[/Y/[/L__2W>X-:X?MM#\*O&=Y>._P`X'E_\5=K^Q^0OP=\+_'G^
M7!?Q+\)?+O\`_5?S3^%OB?E_S+_T#X]U_P#+_!\&SJ^&Y>/H[_B5-?+6<K@-
M7[;1J3.<;:_.T-(%Y1[M4NTA-26N':>MR6%:WJVE&F,ZLU,T3I2#Q99R=-=L
M@WJ3;8-HCR=X7LKR7YF]F_'+;WF#S1X7W_G'SB_\T^#>%?H_+/BO;\/[_P#V
MKV?L]]\_K@GX3EA#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
/#`8#`8#`8#`8#`8#`__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g893535g46f49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g893535g46f49.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[1"&4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@`````````````!`P```5(````&`&<`-``V
M`&8`-``Y`````0`````````````````````````!``````````````%2```!
M`P`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````#>H````!````<````%8`
M``%0``!PX```#<X`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!6`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#L*^BW-<\C`LJ?8_;ZS,PN<QC;*\ACV>HP?SEE+?4_PO\`@OYO^;3N
M@V'U`ZG-L$-8&OZC:6.!_1[]CG[6/H]/[1]#^<L71N>QL;G!LS$F.-2JF9]I
MM;OPLC;Z;'[ZZFL>]Q(_1;'7.;6QS(_/]CTE.#=]7VY?ICJ6%E7,+@=KLOU1
M7ZYQJK:?S;K*,?[+5D?I/^'1F]-SZGV6-HS;'CAASYK=+'4[6>J[=75[_5W_
M`,^^ZOU+/46AC'J]ECC?::*ZG-)]2JL![3[[&UNIR;MFW^:W6?G_`.D6C]HH
M_P!(S_."2GFV]$O9C&BO'SV!@+&;>H&=@CTV->ZSZ+=NUF[WHEO176Y#VV86
M0ZBZTOL`RXK.\/JN?95N:[])4[],RO\`G/\`/6MU!^4[TQB.M`(<7OI%+N`-
MC3]J>SW/_P`%L;_QBLLN8*V>H[8X@2UY;N![[MAV;OZB2GFC]77>J2ZKJ!;8
MX&!GN+&:Z;6/LW;*WN]:G^<L9Z?^#6G5]6L.II#,G,$NW3]JM^E.YSOI^YS_
M`,_>M,7TG06-)^(6;@V=1^U,9D6W^BQA+GW,QP'N!V-'JXMCOI_SS&,J^A_.
MI*=9)#-]`T-C?\X+(R<KJUMK7XOJX];P&N8YF.\-@V?I=UF5CV_I-U?YMO\`
M-_\`&)*=M)9>!G9<-&2RUP=S98VJJ!`]UC67V.^E_)5K*RMM#OL_Z6T^UK:W
M,WB=-[!<YM;MGTMKDE-I)8+,WJCG$G[0R&M);95C`$D,;^B<W*]MC7;[;O5?
M_P`7]!:>#?9Z(^U6M-KCI(8TP>/;7;>W_II*?__0]/N;C.=6V]K'.<7-K#@#
M,M=ZC6S_`,'NW+SS_&QBX;*NE>E56T&RZ=C6C\VO]U=CT!SAT^C[079%S[\@
M"S8XM86/N9["]OZ&G8STZM_^?8N3_P`;3@ZKI)`(_27\@C\ROQ24\5]7**#]
M8^E`UM(.92""!'TE[?\`8>F?]QZ/\QG]R\3^K?\`XH^D_P#ARG_JE[GZK?!W
M^:[^Y)3Y5U3%Q1U7.'H5P,FZ/8W_`$CO)=)]0\/!=3G^I140+61+&_N?!8'5
M/^5<[_PS=_Y\>NE^H+@VG/D$_I:^`3^9Y(J=3KV%T[]EV[<>B=]7YC#_`(6O
M^2N:LPL+TW_JU'T7?X)GA_476=>>T]+L`!'OJY:1_A:_$+F;/YM_]5WY$E/3
M=-PNG'IV*744R::YEC/W&^2I9F#T\YUWZKCN`;7$U5GL_P`6+4Z98T=-Q`0[
M^8K_`#3^XWR5++(.=<1/%?(CL[Q044&'@]/&=3^JX[06V3%58[,\&*YU3"Z<
M.F9A;12'"BTB&,_<=Y(6(0,ZDF>+.!/9O@KG5;&GI>8(=_1[?S2/S'>22EV=
M)Z5M'ZEC\#_!,_\`(H'3\+I[/6C'I:67OVPQ@B""(AJT6?0;\`JF"]K?M`(/
M\_9PTGN/`)*?_]'O^@?:Z^EXC+*2USW6F\/+6.K!?;8W]&QUN]V[8SZ?\NS9
M_-+DO\;9)JZ3(@^I?IS^96NOZ([,LP:7N<&@79(R&/9+H%M[6,I?6:F-;6__
M``GI/]6E<?\`XVMWI=)W$$^I?P(_,K\W)*>-^K?_`(H^D_\`ARG_`*I>Y[G_
M`+GXKPSZM_\`BCZ3_P"'*?\`JE[G%W[S?\T_^224^7]5_P"5L_\`\-7?^?'K
MI?J"2*<^!/Z6O_J%S75/^5<[_P`,W?\`GQZZ7Z@[_1S]I`_2U\B?S/BU%3M]
M?+CTJV6Q[ZN__"U+F;/YM_\`5=^1=-UX6?LNS<01OJX!'^%K_E+F;/YM_P#5
M=^1)3UO3'/\`V;B0V?T%??\`D-5+,G[==(CVU_D<KO3!;^S<2'-`]"OL?W&_
MRE2R]WVZ[<03%?`CL[XH**L.?MU,"?;9^1JN=5<_]EYDMC]7M[_R'*GB;OMU
M.T@&+.1/9OP5SJHM_9>9+FD?9[>Q_<=_*24VV?0;\`JN"7`9$-G]/9W\PK3/
MH-^`53!%GZQM(`]>SD$]_P"L$E/_TO0.AX]9Z?C/9OJ;3;>YK6VE[;-UES?5
MN?\`X?UM_P!H]_\`A%R/^-L15TF3/Z2_4_U*UU?1VTG#PK,C<RTVWOQ&26@-
M>;W,;LJ_1^FW%^AZGL9_VV@_6+ZK].^L`Q1=DV8QPWN?6:#7J7;?IBZNYKOH
M)*?)_JV0?K'TF-?URG_JE[IM/[Q_#^Y<CB?4O!OSL;JU_4;[;L')L?6-N/6U
MSFWV7/\`5]#'JW^K<YUCOZ_Z/8NKC&_D?>$E/FV=B95_5,]U-3K&C+M87"(W
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M'>2RNEYN%EY=!KL8[2[V%S=\-(K]0U[M[6/^FS?_`(-ZTNJ#'_9>9MVS]GMX
M/\AR2FZSZ#?@%5P6DC(U(_3V>'B@.Z_TNNRNHW->'A@%K',<R7;N7A_M]-M>
M^S^Q^>]3Z<_%N9?8U]=C77V%KVN#@=1^<TI*?__3](Q**NF48N!6VRUI<YK+
M`V0W2R[=<Y@:RIG^"9_+1LBMF17Z;G6,;()-9<QQC\W?7M?_`)J>^ZRHL<&!
MU/N-]A='IL:US]^V#ZGO:UBHO^L/3:WU,??4'W@.K;O(EKAZGJ>YC=M>SW;T
ME-K'Q:<=Y>UUSW.:UGZ1SWB&C:/:_P!N[]]ZL;QX'[BLN[ZR]+I#"^YA%H#F
M;2XRTO-/J3Z8;Z=;V/\`5_<1OVWA0T^JP!V[;)<#[&BU_M->[^:>RS_BTE,[
M<(6VV6_:,EGJ`C8QQ#6@AK?T;=OM^AOW?RWH]#134VK=99M_/LESC_6="J#K
MF"1/JU[9@NEVV9V1O]/9])R%7]9>E6SZ=];HX@N]TDM_1?H_TGN;L]J2G1N-
MCJGMI=Z=A!#'EA<&G][9[=RJ4XV;7D,M=E![-?6;Z`:ZP>[TM]K3_@FN;^:A
MV?6'IU?JA]U8-#Q78V72'NGTV_S?^$V^Q0?]:.D5EN[)JAX#@X.<1!W!KBX5
M_G;')*=7>/`_<55ZAF8E&,_[1<S']1KFL=:.3':N6/MV_N,0SUO!:[:ZZML:
M$ES@T':+8<\U[6_HWM>C8^6S+K];'].VN7-W!QY!VO;]#R24QZ?E8UE/HU6"
MY^,!5<YC'-&]HVN]KMVWC]]ZM;QX'[BH@W#AC?\`./\`Y!+=?^XW_./_`)!)
M3G9F9TRK-KR;<JJL8K+&6U[=Q_2NH8-SF_S3M_I^S9^DWK0HR:;Z674DOJL`
M<QP!@@\'A+]+_HV>/TO'^PG!N`@,;']8_P#D$E/_U/4<G^CV\GV.T;`/'YN[
MVK$H=G>C:-G4-=GN+JR\`[W_`*!KVLKW-?\`HK/_``3_`(3YT224_1X&>77-
MGJ`+RW:X_9@QKOT<>GMWOV_Z3^<K_G_ST[69P<"Y_4'.ELM/V<-ASMI^@T_S
M'T_]+L_TJ^;TDE/T4\YS,9H>.HVASFMDG']1I8V66[:O3]1M[_;9O_\``E;H
MHL?A`69.;67.&TV!OK-+=WTO2KL9LM;_`*UV+YJ224_2[L*P2YV?DEK@16US
M&2UQ^BZO90R[>QN__K?_`%Q3^Q7!K6NS\HOW?3#:_P!US==N/Z>W\_\`XWTU
M\RI)*?I:K"L!`;U"\VA\VN:RL;G;:@YMK?0VM^AO]_Z39;_.>DILP;PZLCJ.
M0X-(,!E6QS1'L.S'^B[^2[_H+YF224_522^54DE/U4DOE5))3__9.$))300A
M``````!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P
M````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`#8`+@`P````
M`0`X0DE-!`8```````<`"``!``$!`/_N``Y!9&]B90!D0`````'_VP"$``$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("
M`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!`0("`0("`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`0,!
M4@,!$0`"$0$#$0'_W0`$`"O_Q`"P``$``@,!`0$!`0``````````"`H&!PD%
M!`,"`0$!`0$!`0````````````````$#`@00```&`@$`!08)!@L&!`8#``(#
M!`4&!P$(`!$3%A<)$A05U997(51VUI>W&#AX5;566+@*,4$BD],U)C:V=SDC
M)"4G-QE1<3*883,TI]?80R@:$0$``@`$!@$$`@(#`````````1$A,5$"07&!
M$C(#8?"Q(E*10L$3H='A_]H`#`,!``(1`Q$`/P";JVD;G(ESZ+;;73=NS-4U
ML]\10<"@=.Q>Z39`W[&3&\QK*=L.312#FM4J,B,BK@7F4/?%!9[*4X+`B+,`
M2-0(<:<IBVR]6M`_$#M_8JFYW?,AD%92JBZPT(ELON*:J+D+GSJ&+F6N\2NH
MZW<69]:JQG$@>HTB:6*RAO0W0Y(<:09D(S%!P%!)F(B:39M*[]G-?]@_%>;Z
M8UUV4G5KVL.HY7JS,$&OUD3:A%SE"]/:Y;7W(I^2A(@I:U#)&=>G(1>=""M?
M20HQ`,/'D@35,)C;<H9OVR/CFJ:\0N],)[PGZ"06S(:/A$KL[4"&UG8"TJ<0
M2N']@O"Q(`*K$XX3`J>EB&4MI+H:RIF9S"I2A6!4FA!G+%U6U_(]M_'5.E.N
ML@55O8\5B]YR&26!V0>-<EBQ-6R91L`NBK5KO<@8CKC.YRP-#71T-"])'-6;
M%'00Y.:O6/1I#=AN+8E;<6(64_>,(9!]6-G%P+\G6P)4(\2L]ICR+3>-II!0
M)S2IA$"J!A=F)KJ8X2Q=;:&+">FL+PW@R[EFXPF+4%%!'QBGXXQPP9'L'NIX
ML.O$'D;=8]A6E'H[$[AV2R+8Q)J)7897((K"M<*^L&EV`J"O<6!"`TT]6B]/
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M6E#%3]HU0GGL%C]4&OT#<HK9;7BW4[H@DCFB9EAL<RN3)S@@5]`%K%9[9Q;F
MF%[>,5&H0MGCC-]D2(C-ME]EH*A)B.B4,EMMU'7]7,UA*=:SVVORZN/>9;%M
MCYDX,S6O>U[(<0A0MR8:9:G/5'G*V*?BQV6[?>,VD<+J1.,:MJ+2$G42DY;%
MC(AJ5)'RK*ANEU%1@+01NI`M;[*EUFRUPRYRL"$R/2"3,#(8`X:YJRG;%)B5
MBM;<&;>((W[$7KI)H78<SK+:B8WJT1N7S.:ZO/%$V_,(S;\R.88['C8YL6IU
M2*I];34T)"Y&KHDORC:$A1IRT!J--D!N"215SHUE;-X>*-8K1>FK4KH_8M#&
M9#$_$2:GV*,.N(936Z:BI5X=2ARU,J*.W7':X.[52-HOU,Z-:<]&Y"?'=T-(
M0*U"L1I20(J,[^K1S)K?Q)-H:MH'7>4UQ;LVJVK[VU;B5?.&PVO%EZ_,<<2D
M:J68TW9&;.25"UPV>J:6JB>D,[6W2=2(LY<J/\D3@H&+.`,5_&+E)XZ<^+MI
MY,XOKBV36Y;3BU)HJPC3=+5^NC-)J1L6@2*5E<EO.\91LG(&=X>6&=T[."DK
M:QL*QV3&*2DZ`A0C<,JQB$Q/QG%@>O.^_BURR#5?<PS]AKNI`A[TIG=X29+I
M3%XQ+,1R2SA\2[!UO1\=C=?Y.NF"O%:9;G4^3,Z<2U(<H),1'-R<S.,L28VY
M,.4VIXI35)(]M8XTUM;]H.:Z1LM,OMAMVM.&5W@YXO$TO\QI)DL&-UXL5C`I
M8J((9%BAM;X<Y/JAI7)7`!`L*//<L3\<KP8M9KOXKMRPU]D%Q1S;UQE-GZC:
MPK04N@U?DCK6BFR81NO%V*QB7&)%P%R9JZGY$#C`9@MR6F;URE.X8'@(6PA`
M`IB?CP2=L;;/QK$:K:,<(AEZ*Y+'&6YCF^#IM/6M9#ZJ<HU?,#8Z/*H":8@C
MJIV$.L>IU[@J="SU,GRG3=<J+`FP4`XMBE;<&QS=C/%Q@EJU'74A[^;1C,3\
M0"UJ;FDBCFH[;#I-?>M[>KI9=`;&4S$VC)'1D5A"-&^2DH]:D61(UP0HQ&IG
M,XQ(I.(8E;?^%F3E<'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P/_]"PNJ\6FSTE
MAAJ(RKX;VS`X/-.K'7!$CRR)MG8%M&U5A9D'"UB?@+#6!IUR=,V4@SYV$U:U
MIC,X/R6,C)DMWVLI9/%6M1:R1>2"UBE,A:$$X9X[,R8PKKHA^FL:5>'A%]UW
MJ2UXV/UUHT$1<&(^3$C&W/"Y?D]A4HB$YYSN:M3-BT[?EN]@\3N%J9*H8E-;
MV/*V7-CM;,IL*(LD/:(G#:\F]JQ&I(!)I*UR:T,S][5YDL^:,.(6IF,,+2G'
M*<)2L$")$L[7EV[XBMBUO;\SA#7K3+Y5%:MV$D]2RA>ROE;*7V:Q:.Z0,>VS
M@_0P+[:,/1QQ_80R`DQ2F="SDRQEZ@"4W+JH/1-PK#-N^BM^()L984\@M95?
M<:IOB$7EC^S6*]15.U5Y,W&#KXHS2.*-CV%R6*6R0A?)@2F1$+4Y(G'"!Q.)
MP(E'UAM28J$1$_B574A9L)G^LX&GL>MF:42[92N7-#.H=(:Z+A[_`*O-3O5,
M93+%,D(ETY5L6Q07QM?$IZAF=4/HTI*0::O&)-+7MCH_M'L_4FR-/RJS=P-2
MJGN2,UY1&M>WU5Q-)#8-<#\BA.W+O9D=@<,(07,!ECC/<C".K?)>E):YM;S,
M+R0A$6$G(ABJREMAA\4&''N#?"#]9[ZC<Z?Y-)*TJB"GG4D(-E6!6ELO-%6G
M%(R_-MMGQ-B;ZML*/*DZU<[JFU*L0)QJ&S"T/5%FK.WY;=ANZN;5LAVI*(U3
M/8%-G5DN]NK^Q+$(KQ_JU195"'1&-V;&WQGA%LF6&:G@D\G:)":(*1$D>@)%
M8T*[J?-U)U2L+1SKCQ&+#CT8<5E]P!IF#[EOLF2I%U*M\<KV$L#!`=@'W69E
M9GYTNB]37=]GEFV>WHP,S<U)#!C+6]0#"A6$DE3%K1C>/%FKM<TV1-K1IF=`
MU4[NX@[J)<*/Q)6Z18Z64[8$_E=<6G#EEC*GN0NZH5?N;65EC:E384:(D*A0
M,@\:DA9V_P`OHL#Q'8Y2%:6'4M&ZIRF#VY04#D#R\TFJ04FU5]1D+8H[4TA8
M)-(28#<#=&G:&N2.[V')39$EJUSQY*\."`C28">*XS+9)/BK0-X4*T<.UOV8
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ME[Q5%H2:GLQ6:P)/;":S+8JR%,%=('.6LME3YOMQWJ0U6QJ$#*I3EIWYJ`<>
M+(UIB.6O;\LWIKQ.:QNRQZOK6+U-<9BZ?M;<?(I*VML3EL/J9_>1V4!LBUCO
M<-E;[Z(="CJQ4)G+("C`LSDY(4*WJ5>'$EN63MJVO#O$$.21>0V+<T:CZRIY
MJ.^8S6^OD1K"82NVIJW5/:A]/.Q<OM*726-:_-;^[^9*5;G#7("!8@2JP$^=
MJQD'8,%:,RJK?ZD&%15]1LNOEA4[#I,YJZVI-$S,U0HX&N'7=_0+56QFF.Q^
M$SXX<0C-4V_8;6@%YP@1%N+:(:QJ*5D@\G(J<[9-#O$EK>=SV)15AJ&ZRXM)
M)E":[76>YI*S3Q6.3>R\2X,$8U[0@LMSG:P#LHA2HI2K2M)J1`)2E$89D!AX
MDU2G1CA#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X'_T;S9M`TD<]=HS:I@
M0W[MU(+/R[YC+5AP%8LK@W=G)9N)3A-@T<G?:^_X.J6YSD\YOQ@D0L@QC'!<
MO&;M8-=VA::XM=+UPWKCVYI:3U*.+-:<PYN8JW5T\T)CLE$!P:%OJE<9'"Q"
MQD867(4G3U```"6Y?0AUKH!L`K+;Z=KU&!=Z*\\"FC#85A3Z"D;)+V;KL`(Q
MUGHR41M`O)Z?_EJD91F/Y0`YP2YU>BY4%2CQ+'V=NE6PA?,I1DL<CDJF/H#7
M=[,*A+Q6P#G-8(KK%BC%?OZQER8/I'EL/$FSG)70'`N7PQO6^A(<NE3E$ZA@
M$:63AC41J8F,<;;FPN3,BQO;&I:@>DZ,DE,X`7-K*D(/&8`1AY:8L(Q"P#'0
M6Y>`GU$U<3(HJWEZ_P!292PB3.$RBH#X,P*ALTK=G./O3E(4QZE$<H&[+G>(
MM"HTXP0QC4-"`S.?*1)<E"YU>U'=:-?(BR3>-Q>EZUCS!9+V3(Y\T,T09FYO
MEKRE6A<4:U\3)4A1:[*!>'KDX!XZM.8(0BPAR(72+G5^,AU@UVEJ(3=)Z4K5
M^1"72MT"G=8DT+0$NLYL@%PR]U2Y/3#&D=9!:A89"I4E9`>-W#A5Y6#<>5P7
M+4M8:(T?4VQ3]LQ%R%I<W=8F\PEH9B(Q4L9C$2C\@,A8G8AL-@59Q"925:I)
M@#82%7)GA^5$DE#"68#)QF1"YJFXG76N@'QH7,#Q3U>N3,Y)3D:UM61EL.2J
M$YUAYML81%C(S@(PVCGM"`8>@9;QC"L&0G!P/`N6%LVDFH$><4KLSZT4FA7(
MF$472F@KJ,F%DQP<;>H:)C`E/;S4GHOLE)')LP3D&2\('%41C'5*3@C%SJ^=
M3HUITL9&Z.*]9Z85,K2X.[JA0J($P'`*<7[,:R\K##3$8E"DYRS"V;)N31C\
MO+0A^*)^K%SJS=EUEU[C;PK?X_35>,CLNE2^<J5C7&&U#D4Q=F*P8R[28LE.
M26G3O;JPVQ)DJI06`!B@M^7=9D65)N1"YU8\3IQJJF6*G%)K[4Z%P6Q]%%E*
M]OAC,@7#86]'$FY(WA5HTQ"@H!;=`F-.(8!!-,3M",H8A`3E!"+G5_:+3S51
MM<3'9MUWIYO<3(RTPW*M!`8XC,!%F)NB+.T,9.$Z`L!#>WL\`8D98`8#T)&=
M$3_\I,2$`N=63R[7*B)['BXI,:HA$ACA4ZD%G%,[BQI3415ARM-)D<FF1180
M@R7(7]',W8E8IQG!B@IR4@'G(3AXR+F'AJM2=7UCE'G<W7VGRW&)QA'"XNI1
MU_&F_,>B;8RR"-M$?9BD#<F);6MD8)8Z(D!1(0!0IG%26GZL)YF!"YU>A%=8
M=>(-(8S+8;3->1>3PY(Z(8V_L49;FQV;$KTYRMZ=BPK4A)1ZD3@]3M[6FC.R
M8,2QW6'YSUJDX8Q<O.7:DZQ.4N?YZNH6JE$RE*IP7R.1#AC)AR>G%W-;#G=T
M<30)0X4NSN:RI!*U8L><*<D`R:,71P7.K\W/435UZ5SE>ZT#4ZY=93FE>ITM
M40EC&KDKRCE:&>$NS@I\TP=Z3S.&Q,\F'EB`::[)BE8Q"4%@,P+G#%B%>Z+:
MO5?9I]KP^J(FW21,FAR.&)01V.%,M7IH3')!%FDNMT:-F2*(YUK5*G'!N<G'
MB`):?U&20'&@&+G5+KA#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X'_TK_'
M`<!P'`UW/+9KFL%]?-D^EK7%U]J3IOK.ODSD(_`Y/.G9M=79MCJ+)))P"E:U
M&RJ.K&=DHD1N`$^7UQQ(!BK:N7;?Z\(:^9+1Q/E#G"I(]I8ZPN,<A5@2MQ=G
M=77*FW@ID,9C,5=I2>4DK!"H?59^$74(FU,<<H&4$DWR"U+/5E[TP@50U&JM
M&#%G6"YC9H8+$C;#4[^[`P^XPVHUA*@Q&%:<?&'$@HLPP`CE2$].7@1Q0R\$
MJ7TM5U5&\LB60HK(A@&I4TP][ZUR?VYE5(VVP&].ZPDUW;'D]`Z,9TH0*BS$
M1"TD@\_RN@(/*QG&`^J`6]5MJHDSA6]@Q":IE;84]$=G7YN<E`FA0I.1IW0:
M).>):2WJ52<8"SAEA+,$'/DYSP-B\!P'`<#6=G6_`*>;F-QG;HYI,R=\[-1A
MHCT4ET\E<F?@L[M(3VN.0R!,4FES\I11Y@7+U.$B(["9"C.4&Y`24,80U67N
M=K4KC2&7LME@EC"ZOBF-LZF"1*=3]4]/**MFZX%:5D:85&'YX>@)JR=2'D9R
M4@T@*,0A9'Y19@0EJ6[J]GT:M&&1^P(<8\GQ>4(LN+$J?XK*H4Y+6_S@X@A>
M*.39ECTE1HE^">N2&GI"@+$@RU!&3$YI1@R,RX#@.`X#@18=-T];65^=XNZ3
MMV22%K<Y$RHF<=:VH-?-GF(3YJJR6M-3$%0DP=SN<5L1\1L[D1$O31J!<J++
M/"7D>.DM2^XG<C6(XHLT=R11#@542^[CBW;TFRJ6^L8!(C8C-I(\)'=O1*F,
MV*RE.>W+F]8`AS3K4J@D:?`TYX2Q4MI5G;$'MYI=WB#+W=03'GXR,2%MDD0F
M,"DT>D!;0S2'#4_Q"?,$9E;*K41^1-Z\C"I$5A0A6D*"LC*-+&(C8_`<!P'`
MCV5M50([&E=5*;"3-$QA('H4DQ(F*51B*HC(TCA3A(T::PI"Q-E?.[FP(+&8
MCEJ1$Z*%*4IU3B-+"$>,\+4MAAMJJAJ`HP697PE8W1D8P)0S.."4">Y*F-61
MQG"1ARR:)TD"0@9J)/C'6JRP"$4$0<9SPC"H7L[K]/XXDED:MN%C8US09(4Q
M[XZ@B*PR.EJ<(^T66B7!8W@J/'*<X"4N&G"D.\K&2S!8SC.2U+9J:<PI8_(X
MJCF$652AQCA$P;XVFD#2>_+HDJ4&)$TI1LY2L3@JCBE44(HM<`L289@<AP/.
M<9QPC*>`X#@8G.YU$ZSA\AGTZ>TT=B,4;#W=^>58%!Q2)"GZ,9$!,C)4KEJD
MXP02R$Z<HU0H.&$HH`S!A#D,%@&PM,V884BBD]:LOQCV\1L4,DR=T@=AI9#'
MTI"]Z9'&MYV@C<\:W1N;51*HPA2W%&82'%G]&23`#$6I8M$=N==9L^N,<9[+
M0H71O=%[*5B8,<JKUOD#DUREZA#DGA+U/F*-,M@!0RZ.KFXTQC4.)0%:89>1
M8%T=(J6R%%OU:0T(7X$_BB]G<GAC84#@RO*-^3JG21KD+>U$$Y9#7`0BC#7(
MHTX[HZA*D\M4>,M,68:`CZ"K7JT]I]/D65`#F+!.%.7HJ91TQI\WR6]'8/\`
M20''*/J<DQQQ'Y7E^3Y*!3GIZ"#?)#-D2U&Y(TCBW*TR]O7IB%J!>B/*5(UJ
M-44`]*K2*B!F$*4RD@P(RS`"$`8!8SC.<9X'T\!P/__3O\<!P'`<")^QVG58
M[1.T7>[$D-EM3G`6-[15XH@LQ%%`PF6.TCA4M0V:WITS<>FD$VBL@KUI4M13
MZ!W8DQR7RQMI@Q"%DL32-UJZ6ZI1:B:^USL*]G"MXFOGD:S"E<_D5"GO,QEC
M/5[143.QM+3;-</D*?9,2R-J9P;C43/EY;7X):Q":3Y(2>18F;N(1*>=:_#^
M,/:8M&=Q[`F_?!-)%%X,2Q+*WNNND$CE4NNF6R:OY+9</HZ7XA"B=SC<=Y5`
M7OLB0R0!JI'Z'7D82&!&+G1[.L/AC:>VY6,"NJOKOG5A'F1Y9`16%$F^!#@J
M^6U[$Y)J[<RZ%1^SJGDBM9&)$N9WPA)Z4&\)2LB+6MA^2PHS\*)W3&%)X:W>
M'Y4^L%N2FX8+,[->'J5PXR$K6.2JH$GC);5@R%%MZDQOA4`AQKP]L++7K6V(
M7%Q-6..$`#"U!ZC(BQ$U)F\$[>$.`X#@18V90U0M45&=.=B2=;)XTSA:MJ"8
M)I?5,>D3S(G:-.L(>HPRL=Q1^71*9@=F689*,1Y:U2@I0-,:3DLT(!9+')!*
MG=7?#(@E@U5):JLZ*R^TI=+;1:8C:$9>ZUL"7R]4PZKI(!8<"EELQ"%."HF,
M1>L2RY0)O<G-(22_+0*,9$!00C%%N7236R;5-8%%5E(:+EXI]4Q$;)BD)F(B
M59(G]L@"E3`SEHLK6IC,4B](1LX&5!:4E,J\GKB,9(&6+-2<\6\.$.`X#@.!
MS#L"F-!H9)Y"0[7G65*[%1>Q'S8!5:BFPZ.:;[KU98UE/<U4"/*L)G>&YOKA
M\7V()D`C<F<U&N;3T@#!G+BTZP);GHA=+Z?\+B/.SUVRV%V.>IW(7"93=-/6
MI-:+Z9.&^40JSK&LE[K)/7%,#J"RHL)SLR76*Y.T;:G,$=>7):>0K;FX@M`G
MF#K\M'937^EFREV"9!06/-+466A8#I;4@F$U%!0*5[[)&&-,Z@QE05M#8)#F
MQD5I(V0JZM(WAZ]:I4*1C&,\6>5S,VWSPAP'`B/8&]&LE621VB,\FTG89$T/
MS?&<-HJ=NMQ&_O3EE<$E+!E#17:])8A28UM4%K#V$QR3H#21%J1E#QY/"U*"
MNPNDV@<DOVQ7>R]LQU)>%S/C"]*HJAM/6NO9^6XO+O3.8^W,YKI7(+=D4<?'
M>EV4")E=W-W:A*U"@Q(G+5FDG$S!8F:RP1O@OAV>%6!;"(I`=UY),S\+JYA#
M.QQ.Z*`G*`TJNX18"IO;I6ABE8.+3'Q2B,P)[\[>U06U2I6M/4I5A2P9A:I4
M+W;M&SH%H+X:4RJ57$8%M&^+T#'%J^OAU?3+.IA+9,$@3>,FY(A+)JTO-<(G
M2%0U0DE*1S4`>VQ(7A*82(WJ\YR(3!+W1P2LBJ#PZ88S:VGH[>A5Q..M5;QM
MDU[;V:RB[=DH&Q"E'"TT\A-*T^>M;I=-78H64@G1FC!QR8LH12,*5.6,O`QQ
M2ZJ7:*B;S?U<7JR=@E$@;H!"[.<FKLY+614UPVPE#VEBBQT#(F!H"V.RX^/*
MPG-1^2W9!U8<JDQ&#2LCJ5,-_<(<#G[L;LGI[+4=DZWW5:,LJ50A60]%(IG(
MJ\LFMHW`9*J?%TBJV6-]S6'6P:22K<RJO35[`K5KEC4XJ6H6,`5%8&4,L1.<
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MZEKAJIZK:ZJ=C=Y&_LE:0F,P1G>Y>X)G64.C5%&=&R-ZV0.2-"V)%KL>D1`$
M>84F(+$9TY"6`/0'%<MA<!P/_]2_QP-96S;L*I2*ER^<G/V4"M[9XRT-43B4
MIGDLD4D?U/FC.PQJ'0MH?9,_.BPS`A=6E2F=4068<9D!)9@PC-^2&[J@75[!
MK7Q9,-;ZYLM@CTH@<P?GY!&F:4,4K9"))'ES6?(3FP1GI1B4@5%E""$[!6>D
M0,=&<8%/,^T9KW[]J:^D^$>O.%J=#[1FO?OVIKZ3X1Z\X*G1H2ZPZ=7VHBZJ
M=7W70#(BWS-M:L,EOU\A`(B=-:)H>1J@J5:_K3BDR`L2<0<@ZHSI%G`O@Q@1
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M6RW%`6].-))I36LO<1+`F+51YB@#M537U(RS"LEEY.Q\(AA$6,8X/$D\.T)E
M\,;:Z>[:KU7!T,FE4H61]1L7AP]-JIK4DVI21MSF^.TZ<)02S+X+/EQ?FZ)<
MC\A1Y!H18SUN#1BS/7]QT\UHK!JJ&L;SKHN&LKS,'QO+DUXQR4NQ2J;2Y[FC
ML28\O$B/7J$Q+J_'`(P8(0PDA#Y8C#/+,&)N<:;G^T9KW[]J:^D^$>O."IT/
MM&:]^_:FOI/A'KS@J=#[1FO?OVIKZ3X1Z\X*G0^T9KW[]J:^D^$>O."IT/M&
M:]^_:FOI/A'KS@J=$6GZ$Z,2BRY7:;]>4(6R"9N@G=Y2I+[CC`WX5BA5<0/R
M4*B-/K-($2?#-5K6/(`+N@:CKLC\H`\%A&+3\JUQTHEDBE4D5[EN:-5)1MI:
M0*:\Z,7+H@SME6R^E"(M%)=(8D]V`FB?=E8DB0!;ECNM3)UC\N=TX27L[TD&
M+<Z)](+]UQ:T*)L07A3*9"W)$R%$G#:,+$$A(D)`G3$A$8_#,$$HDO`<9%G.
M<]'PYSGE2IT?7]HS7OW[4U])\(]><%3H?:,U[]^U-?2?"/7G!4Z'VC->_?M3
M7TGPCUYP5.B!EDT+IA;#W;;W,]Q`N1ER.)2B1)#[7UR<"F=C+A,VKG,%C"]Z
M@3J_H($"&6.^)DS6H6*B&U8YGNB'S5W,$OS%N=&9V15>AEI/+T^26\(`6L>T
MJ!&=ANN.N0%HTS8AKQ`C+;QKC'!43U)-8M@ND9A@LF8-%T](@^14QT>&ST/X
M>+5(H!(%-NUA(@5RX*W%ECLIM.J7R*+SU=:)JK"!^8E1.4KD2BCB,DY.'_9]
M2N*`;C/0$(,1;EI.K=2]3:[=[>8'#<JM9+04_P!>I7K9#*9#(:N:54`A%DQF
MOXU9[FOGADI>#IK(9:77"`XO(VQO0(!#-"!*,(^C`N<,,4C9)6VD3]%)W&V_
M95#"G*P%UHKG.:0?9=E8Y,UBN&P)58DW*848WU;"D05SI-'%*6:8SG*2T)WD
M];D\.#^#'1L*L#M2:J?VV4,NQ%:N+TV4Y!J,(-66%2C"UX@U=OTM?XP4FB\`
M:X7$V96C.F2E/Y#<A1H@I2B2RTX,@$(=3'1OG[1FO?OVIKZ3X1Z\X*G0^T9K
MW[]J:^D^$>O."IT1BL:+:46A*)I+I-?L#PZSQ!"&Y[`W7)7:=&`BOX[:\98!
MH"#CE0TYWH^XW81PA#'Y9P$X@X!@H6#!CHB3&=!_#-AY<F!&]BD30.1QJ41(
MM6@O.G43BPL<O43)R=TK8YHV%.X./_')^ZKB_2YKG@(U/F^<"0@`D#,%O=HP
M-5X>VCX8784$;=S(F='Y=,DTFC2&2SFKEQ-?!<U]/.<[>V(^(OT#>#;/?U=5
M""V/.5A30Q$+"0ELIYB8TY:+G1/:6Q71>:2I#*WFY*U(4-RZ(+$K:PW7$HRW
MDE0>O+1K./-B91'GEM?$+6ECENNF<E)EI/2H`1G&<%@,+-J8O5?D&ES\Q3>-
M&WM`$C//:.<]?'<DF\8HO5)X"ZBE`U(T+H_O3RZB?\"EROR%:H]3C'07C(,X
M#\(QT2$^T9KW[]J:^D^$>O."IT?4BO\`HAR6)&YNNNI%[@O4D(D"!%9$.5+%
MJQ4:`A*D2)2'DP]2I4GF!`66`(AC&+&,8SG/"5.C;?`__]6_QP-+WC3@+FCT
M;;DLTD=<R>$3EAL2$SF*H8NZ/$=DS$2XMW6@;)BQ2./.")T8GM<@4E'I19$G
M5C\@0!^2+!8FGFM6LM*$T[55&2Z`QFVH'3D0AT.AR>X8Y&K$6`30B+)(>TO:
M\3ZRG(#9,H9DGDJ5A*<@1HS3.@(0CR'A+>%]B[3K]4[6CZ":M^:O"W.JL!^\
M^T32%241J\XU33=55DX.]MS!$[+Z]KR(PM8YHR(<4>2D<54;:&T]:F)/SY82
MS!"`$?PXQT\DN]F<J97.6AP'`M6?NNU.U';L\W$36O5E<6>G8XC31[*18<(C
M,U)9SESS8A:XYK*DC8Y`;S5@$I031%8!DS!8<"Z?)QT6'&_*%PC[%VG7ZIVM
M'T$U;\U>=,[G4^Q=IU^J=K1]!-6_-7@N=3[%VG7ZIVM'T$U;\U>"YU5B_&\U
M]H6%;-T>SPVD:AB30MHB0N2UKC-:PQA;E;B78!:4MP5(6IE2)E"T";/5X-&'
M)F"_Y.,]'P<T]<1,S<.-^[=&V*F<W'CNHJWW:P#V-COJ[FO;M_6&7?O_`'G^
M3NHJWW:P#V-COJ[CMV_K!W[_`-Y_D[J*M]VL`]C8[ZNX[=OZP=^_]Y_E9&\"
MG6;6^=Z[;%KIQK]2,R6M&V[TRM2R5U3`Y$J;&8.N6M+N%I;U#NPK#438%U=U
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MM7LRRHE#O2=:N1Z-F9;CEC:S-*4U9&3C$[8TMR<LA,0#."B"0!``(0AQC&FV
M(K)EOW;HW8;I;2^Q)IC^J+K#]`=5?-/G7;MTAQW[_P!I_D^Q)IC^J+K#]`=5
M?-/CMVZ0=^_]I_ECDPTKTW2Q*4J4VI>LR=0GCCV>G4$4/5A1Q!Q38J,*.)-+
MBH3"C2C`X$$0<XR'..G')V[=(6-^^X_*?Y3^U"U"U->]3=7GIZU>UV=WAWUV
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M)/%->ZDCLB9U0I;'B!*6IZ:(BC<F]0(@X8,C)-`+(!YQT]&<\BQ,WFZ&_8NT
MZ_5.UH^@FK?FKRI<ZON:]0M361R;GIEU>UV:'AH7)'1I=FNE*U0.38Y(%!:M
M"XMRY)&2E2)<B5%`,).+&$PLP.!!SC.,9X2YU2)X'__6O\<!P'`<"I]^]??=
M[U._SEFO^"">26FS.5'7G+0X#@6\_P!TS_ZA;L?(RC_SW9?+#C?E"ZQSID<!
MP*J/CQ?>MH7\/<D^L@OFGJSGDX]GC'-Q:YNQ.`X%G7]W^^[9LW^,E\_9BU9Y
MYM_GN>C;X;?KC+N]SE3@.!6JV9^_+N!\IJ7_`&=ZNYMZLIYLO9GMY-<\U9G`
M<#K]X3_W)8K_`)[;K?MM;#\\L^6[G+T\-O*/LZ.\@<!P.'E/?UIL1^+[:SZ\
M)ES7;XLO9Y-S\Z9G`Q>;_P!RY?\`)=__`#4KX6,X3MTN^YUJ=^&BB?JMBO,'
MIG.4E^$.`X$-O#H_T^-$OP;:P_4E!^%G.>:9/"'`@)XH_P!P397Y&M7^,HSP
ML9I]\(<!P/_7O\<#3]O62[P9B=DL.CALDL(^(RJ11%"^M%AMU;'J8NW9<%*:
M:VE%(!-F""X.)QG*8I=@M2XF!ZI,`8LB$`L/WH^QU%J474%NNZ%(R*['J:O[
M'<VU(::<A:%$PA[3)EJ%*>?CKS4B`QQ$6`8\>6(`,9S\/"2]KO3KW]+&K^<,
M_HN7MG1+C55:_>HY?&I)0&JI#$\HW,U-<,S-/`F$(0BBQPLH`1B\H`?@$+'1
MSG=$QFT]<XRI,<Y:G`<"VK^ZGR=@C5@;H&/KHE;`*X=2@$PE(A!P<(EZLC)F
M`>2$73D&#,=/_GSK;$S=,_9.$+F_>G7OZ6-7\X9_1<Z[9T97&IWIU[^EC5_.
M&?T7';.A<:G>G7OZ6-7\X9_1<=LZ%QJJZ^./)&*2;3T8>Q.:9S)3:_R(H\Q,
M(0@E&"L4L80"\H(?AR'X>:>N*F>3GV>,<W'7FS$X#@63?`9FD5CFN^RZ%\>T
M3:K-W">519"D8PC&G'K-J\2`W&`@%CR!&$#Q_P"8<\\^^)G=N^N#?;,=FWE_
MF7<?O3KW]+&K^<,_HN<]LZ+<:G>G7OZ6-7\X9_1<=LZ%QJ=Z=>_I8U?SAG]%
MQVSH7&JNOL&\-C[NQMXY-"PE>A.E%.`+4D9SDH8BM>ZP+,QC(L!ST@,#G&?@
M_AQS;UY3S9^S^O)A?-&9P'`ZG^%G/H:R::1QL=9"WH5Z:]MT>O2GC'@TKKMU
M-@U!7E8P6+'\LDT(L?#_``9YYIB;W<Y>BXK;RC[.AO>G7OZ6-7\X9_1<G;.A
M<:G>G7OZ6-7\X9_1<=LZ%QJ=Z=>_I8U?SAG]%QVSH7&KCC2*U*Y*;_7H3P*4
M:O;G:E0F4%YSDLXDR[IB(!@,YQC.0B#GIQS3;DR]GET;QYTX.!B\W_N7+_DN
M_P#YJ5\+&<)::;67`TFH6JJ51*&PE0FUNHU.>4,PS`RCB:QBY9I8L8+ST"`,
M.<9_^..8U.CT3,7.*2/>G7OZ6-7\X9_1<=LZ)<:G>G7OZ6-7\X9_1<=LZ%QJ
M=Z=>_I8U?SAG]%QVSH7&J.OAT?Z?&B7X-M8?J2@_(ZG.>:9/"'`@%XI0PEZ`
M[,&#S@(`0MK&,6?X`A#,8UD6<_\`PQC'"QG"7W>G7OZ6-7\X9_1<O;.CFXU.
M].O?TL:OYPS^BX[9T+C4[TZ]_2QJ_G#/Z+CMG0N-7__0[-13?.]*L\1!GUNE
M]E[*W8(F\V>H;.1+C]8`PU*SRASKJ&QFS2J7A6ML1L^JZU42:V6P2!>.<.`E
M*9"L-/,79*SDZ.ZPO!9"DL8C4T872+3&/,<LC#VF$B>HY)6E`^L+NC$((Q)'
M1H=$ZIO7IA#!C.2S2Q@SG&,]'P<KA^44B,4@D?;8E!XQ'H;%68HTAGC,496V
M.Q]J)/4'*SB6UF:$R-N0E'*U!AH@E%@P(P8A9^$6<Y#(>!4^_>OON]ZG?YRS
M7_!!/)+39G*CKSEH<!P+>?[IG_U"W8^1E'_GNR^6'&_*%UCG3(X#@54?'B^]
M;0OX>Y)]9!?-/5G/)Q[/&.;BUS=B<!P+.O[O]]VS9O\`&2^?LQ:L\\V_SW/1
MM\-OUQEW>YRIP'`K5;,_?EW`^4U+_L[U=S;U93S9>S/;R:YYJS.`X'7[PG_N
M2Q7_`#VW6_;:V'YY9\MW.7IX;>4?9T=Y`X#@</*>_K38C\7VUGUX3+FNWQ9>
MSR;GYTS.!B\W_N7+_DN__FI7PL9PG;I=]SK4[\-%$_5;%>8/3.<I+\(<!P(;
M>'1_I\:)?@VUA^I*#\+.<\TR>$.!`3Q1_N";*_(UJ_QE&>%C-/OA#@.!_]'L
MIX<T%D==^)=>T7?HO%5V&9[F364Z0>U_$?LN*U,L15]"O3-=-[]=\#:M?9*K
M>W4\Q[6&+W96Z(%+L-,V"\T*3EAG%W/C"RXK5I4"8]:N4IT2-*4,]2K5G%IT
MR<DO'E&''GG"`424`..G(A9QC&.5P_I,I3K$Y"M(>2J2*B2E*54F-`>G4ISP
M!-(/(/*$(LXDXL6!!$'.0B#G&<9Z.!^W`J??O7WW>]3O\Y9K_@@GDEILSE1U
MYRT.`X%O/]TS_P"H6['R,H_\]V7RPXWY0NL<Z9'`<"JCX\7WK:%_#W)/K(+Y
MIZLYY./9XQS<6N;L3@.!9U_=_ONV;-_C)?/V8M6>>;?Y[GHV^&WZXR[O<Y4X
M#@5JMF?OR[@?*:E_V=ZNYMZLIYLO9GMY-<\U9G`<#K]X3_W)8K_GMNM^VUL/
MSRSY;N<O3PV\H^SH[R!P'`X>4]_6FQ'XOMK/KPF7-=OBR]GDW/SIF<#%YO\`
MW+E_R7?_`,U*^%C.$[=+ON=:G?AHHGZK8KS!Z9SE)?A#@.!#;PZ/]/C1+\&V
ML/U)0?A9SGFF3PAP(">*/]P397Y&M7^,HSPL9I]\(<!P/__2[):J&,!WCK;1
MB94S,,\$CL\EY<'YOKIPG1CT57T$"K*8Y"EH57/&^&IB<%$$(16.`H'5#R-M
M!D62<3B[GQAW@V.@5G3N`21OK(=:R)Y.BKXW-=878T(EE,RZ3KLI>S;Q82XF
M&3:4%M<,7E8<2T;>E_X@>0`@P9.!X4$US#]M8:F<Z0UVJNH'$AL;'B!PY-&U
MHF*0'2UL$XIQJ<J'9"[+89`"S0.:@W*OS4MD;D:$1N4J<G"<DO.1.,RV#V8F
M7O+=?9N)^JN6XT<]55K]ZC:7QNH#54;M*EDA+,N&9A))4M;,WA3CQ"RLB-"-
ML1IAF9&'X.@6<XQ_%SG=6C3UYSBI,<Y:G`<"VK^ZGMKNXV!N@%ID:J/"*AU*
M9/&F;FMPRJ"-ZLC``C"YI5(2L%9#G.,@Z,Y\KX?X,<ZV\<&?LRA<W[,3+WEN
MOLW$_57.KC1EU.S$R]Y;K[-Q/U5Q<:'4[,3+WENOLW$_57%QH=577QQVYV;M
MIZ,`[2%3(3#-?Y$,HY2WMC>).#%BEXR4$#8F3%F8$+X>D6,YQ_Y<T]><X<'/
ML\8YN.O-F)P'`LF^`RSO[AKOLN<U2]:P)P[A/)0T:9H9%X#3@ZS:O#$IR<Y(
ME)X1C`,(/)P+`,8!C.,=.<]/GWUW;L/JF^WPVX\/\R[C]F)E[RW7V;B?JKG-
MQHO4[,3+WENOLW$_57%QH=3LQ,O>6Z^S<3]5<7&AU5U]@TBY%NQMXG<74YZ5
M@E%.9&X'I4:(TT(]>ZP$`.4Z`DA,'!0,X#C.`XSG&.G/P\V]>4\V?L_KR87S
M1F<!P.I_A9L4F6::1Q2WSAP9T9E[;H]2W$,D>6%)_(W4V#+,\E0N0'JC.N-"
M(S/E"ST9%T8Z,8QCGFFKW8<9>CAMQX1]G0WLQ,O>6Z^S<3]5<EQH=3LQ,O>6
MZ^S<3]5<7&AU.S$R]Y;K[-Q/U5Q<:'5QQI$E0G4W^0K6#<%)6W.U)9ZXPDA.
M8J-#=TQP,\9"8!:<H1F?AR$`<!Q_%CFFW)E[/+HWCSIP<#%YO_<N7_)=_P#S
M4KX6,X2TTVCDN-U"U5-)L1S2DF:W4:84F!'HN:!.4.L8N(L@)AS8,TP)0<X#
M@0LY%G&.G.<YYC<:/1.<XI(]F)E[RW7V;B?JKBXT3J=F)E[RW7V;B?JKBXT.
MIV8F7O+=?9N)^JN+C0ZHZ^'1_I\:)?@VUA^I*#\CJ<YYID\(<"`7BE8$+0'9
M@(19`(4+:\!'C&!9`+,QC6,"P$6,ASD.?AZ,_!PL9PE]V8F7O+=?9N)^JN6X
MT<]3LQ,O>6Z^S<3]5<7&AU.S$R]Y;K[-Q/U5Q<:'5__3[UZ5*:8EV[R^4U]N
M?KK<EBO"J:2.<BJ:@-BHG.+/6D,Y#')3IZ^/6Q<TUJC;^WD-Z'"L;1$T"M6!
M.'"8E"`00XCJ;K)8-Y7)P'`J??O7WW>]3O\`.6:_X()Y):;,Y4=><M#@.!;S
M_=,_^H6['R,H_P#/=E\L.-^4+K'.F1P'`JH^/%]ZVA?P]R3ZR"^:>K.>3CV>
M,<W%KF[$X#@6=?W?[[MFS?XR7S]F+5GGFW^>YZ-OAM^N,N[W.5.`X%:K9G[\
MNX'RFI?]G>KN;>K*>;+V9[>37/-69P'`Z_>$_P#<EBO^>VZW[;6P_/+/ENYR
M]/#;RC[.CO('`<#AY3W]:;$?B^VL^O"9<UV^++V>3<_.F9P,7F_]RY?\EW_\
MU*^%C.$[=+ON=:G?AHHGZK8KS!Z9SE)?A#@.!#;PZ/\`3XT2_!MK#]24'X6<
MYYID\(<"`GBC_<$V5^1K5_C*,\+&:??"'`<#_]3H+X14^J1Q\224/L/O;O3L
MFX8[81-@,1U.(JM<61,TP.M[#-,6F5I=1-5R$#5)Y&HCPURJ!X=O2,?5E`5`
M(Z#E$C-IN\86D[<ME)6S.L(:D[=(K$41Y\D$0@*LV9@52LB-%%*WL",NOJ^M
M.:*1(4)F3.J:X^[KCA8"62F,&+&.5Q#Q];+N+V#H*N+O.CF8:.<1PQX<XIAR
M5/QL:<D*U<UO3(:L4L4;>#5;6Y-IQ)I*UJ;'-.:`1*M$D5`-3%B8J6<]Y\-^
M.NOLK+/4G+4N;56OWJ.6,<BH#54EI/6'&)KAF9IV%+.\MH<`'"R@!R$;F@1@
M-SY6/X`Y%G'\>.<[HF&GKSE28YRU.`X%M7]U/DK1'+`W0&['*B0JH=2@",IF
MMT<\B$4]61D?EA;$2P1.,8'CHR/`<9_BZ>C/.ML7;/V90N;]Y\-^.NOLK+/4
MG.JEE9WGPWXZZ^RLL]2<5)9WGPWXZZ^RLL]2<5):KKXX\B:9%M/1A[2<I.+3
MZ_R(HW*EM<VT6!BL4L>,!+<T:,PW'D_QAQG&/_'IYIZXJ9Y.?9XQS<=>;,3@
M.!9-\!F8L$>UWV71.JA:4H-W">50`IF5[<@9)'K-J\4$63VUN5D`'D9`OY&1
M8'C&,9SCHSC.?/OB9W;OK@WV^&WE_F7<?O/AOQUU]E99ZDYS4K9WGPWXZZ^R
MLL]2<5)9WGPWXZZ^RLL]2<5):NOL&[(7O=C;QQ;C#C4ALHIP`!GHUB`W(BM>
MZP+'TIEZ=,I!C`PYZ,Y!C&<?#CIQS;UY3S9^S^O)A?-&9P'`ZG^%G.XRS::1
MQM<%3@6L37MNCUP"(_(5I6.NW4V#4%^2J0M2E*;TE&ASGR1B\G/P9Z,XSC'F
MF)O=SEZ+PV\H^SH;WGPWXZZ^RLL]2<E26=Y\-^.NOLK+/4G%26=Y\-^.NOLK
M+/4G%26XXTBL3N*F_P!<D$,:97MSM2>0(P@],8(HR[IB(&1IU)9*@D6<9^$(
MPA%C^/'--N3+V>71O'G3@X&+S?\`N7+_`)+O_P":E?"QG"6FFUCQ%+J%JJF.
M6.83D^MU&D&A!&90:#!I-8Q<LS`3268PHT.!!ST""+(18^'&<XYC4O1,XRDC
MWGPWXZZ^RLL]2<5*6=Y\-^.NOLK+/4G%26=Y\-^.NOLK+/4G%26CKX='^GQH
ME^#;6'ZDH/R.ISGFF3PAP(!>*4,)>@.S`Q=.`@A;6,6<8R+.`AF,:SGH"'&1
M"ST8_@QC.<\+&<)?=Y\-^.NOLK+/4G+4N;.\^&_'77V5EGJ3BI+.\^&_'77V
M5EGJ3BI+?__5L2Z?4=$:?V[C)3KXD\PV6N2+I+,I!^KEW+G6272'1:L*GE$2
MBKH@S8\QAX'NN2%I[\\2102(Q_?W]0F*&B.0'H`SJZF</'!VMF,-BM@QMSA\
MV8&R3QAY`G+=&-X3`5MZT*16G<$F3B!_!D:5<D*.*%CH$6:6$8<X$'&>5R0V
M&1&NXNRPF!QECAT0CB(+>PQF--B-F9&A$$8S/-T#:@*(2IP#.,$8/R0XR,P8
MABSD0LYR&3<"I]^]??=[U._SEFO^"">26FS.5'7G+0X#@6\_W3/_`*A;L?(R
MC_SW9?+#C?E"ZQSID<!P*J/CQ?>MH7\/<D^L@OFGJSGDX]GC'-Q:YNQ.`X%G
M7]W^^[9LW^,E\_9BU9YYM_GN>C;X;?KC+N]SE3@.!6JV9^_+N!\IJ7_9WJ[F
MWJRGFR]F>WDUSS5F<!P.OWA/_<EBO^>VZW[;6P_/+/ENYR]/#;RC[.CO('`<
M#AY3W]:;$?B^VL^O"9<UV^++V>3<_.F9P,7F_P#<N7_)=_\`S4KX6,X3MTN^
MYUJ=^&BB?JMBO,'IG.4E^$.`X$-O#H_T^-$OP;:P_4E!^%G.>:9/"'`@)XH_
MW!-E?D:U?XRC/"QFGWPAP'`__]:RU3EGU@\^*+;=,MFA#]7$R@BN1V$1M.2;
M,V]IEYTBKZ/PJ6/2UGQ`6:%)&Y[;XTQI49)3XYD+C%V'(LHIP-<NB<75?C$V
M[/<KDX#@5/OWK[[O>IW^<LU_P03R2TV9RHZ\Y:'`<"WG^Z9_]0MV/D91_P">
M[+Y8<;\H76.=,C@.!51\>+[UM"_A[DGUD%\T]6<\G'L\8YN+7-V)P'`LZ_N_
MWW;-F_QDOG[,6K//-O\`/<]&WPV_7&7=[G*G`<"M5LS]^7<#Y34O^SO5W-O5
ME/-E[,]O)KGFK,X#@=?O"?\`N2Q7_/;=;]MK8?GEGRW<Y>GAMY1]G1WD#@.!
MP\I[^M-B/Q?;6?7A,N:[?%E[/)N?G3,X&+S?^Y<O^2[_`/FI7PL9PG;I=]SK
M4[\-%$_5;%>8/3.<I+\(<!P(;>'1_I\:)?@VUA^I*#\+.<\TR>$.!`3Q1_N"
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M6OWJ-ODJ.@-51/LC1O90[AF82"DS`%G$09B%E9$8(P+FOZ[`@_!Y/0'H_AZ>
M<[JX0T]><J3'.6IP'`MJ_NIZ)_66!NAAB?4K&,N'4IE2-2RA><*`B>K(P6$`
M1."#J,EYQG.<](O*Z?XNCX>MM8W#/V90N;^@["_3YJ]B"_G%SJXT98ZGH.PO
MT^:O8@OYQ<7&ACJ>@["_3YJ]B"_G%Q<:&.JKKXXZ-]1[3T8%]>TSV</7^1"(
M-3,X6<)!>+%+P(L105Z_KLB%\/E=(>C^#HYIZ\YY.?9XQS<=>;,3@.!9-\!E
MME2S7?9<UCDZ)E2!W">2S$JF.`=QF*,:S:O"&HPI$ZH<@`,L0`^1Y&>C(,YZ
M?Y71CS[Z[MV'U3?;?9MY?YEW']!V%^GS5[$%_.+G-QHN.IZ#L+]/FKV(+^<7
M%QH8ZGH.POT^:O8@OYQ<7&ACJKK[!IW-+NQMX2[N1+LN#**<R8M(;\-A1@1:
M]UADL.$852S!>2R\X#G/69\K..GX/X.;>O*>;/V?UY,+YHS.`X'4_P`+-JF2
MG32.'-4O;VM`.]MT>H0GQ4#D:1Y.ZFP8#?*6Y>4F3NM."(>/]F'R<"\GX>CI
MSYIJ]V'&7HQK;RC[.AOH.POT^:O8@OYQ<EQH8ZGH.POT^:O8@OYQ<7&ACJ>@
M["_3YJ]B"_G%Q<:&.KCC2):HE3?Y2Y4!:L+VYVI`I5EIL(RU)V+NF.!G`2X-
M/PG",7PX!Y8NC_QSS3;DR]GET;QYTX.!B\W_`+ER_P"2[_\`FI7PL9PEIILS
M3PS4+54:><-B=./6ZC1D$#AI9XR"15C%\E$B/R_E]<(L&<!R/R0^5G'3T8_@
MYCAH]$W<I(^@["_3YJ]B"_G%Q<:)CJ>@["_3YJ]B"_G%Q<:&.IZ#L+]/FKV(
M+^<7%QH8ZHZ^'1_I\:)?@VUA^I*#\CJ<YYID\(<"`7BE8%G0'9C`!8`/,+:\
M`'D/EX"+,QC6`BR'IQY6`Y^'HZ<=/"QG"7WH.POT^:O8@OYQ<MQHYQU/0=A?
MI\U>Q!?SBXN-#'4]!V%^GS5[$%_.+BXT,=7_T.Z.OL?GK9XY^Q;XYYV7#!9#
M&G9,45)(^I152&5,D?\`.8]DB4+7E41)HAB&2%28V%H&]$0A/4H$YIIZDD_.
M)Q=S7;&JQ/RN#@.!4^_>OON]ZG?YRS7_``03R2TV9RHZ\Y:'`<"WG^Z9_P#4
M+=CY&4?^>[+Y8<;\H76.=,C@.!51\>+[UM"_A[DGUD%\T]6<\G'L\8YN+7-V
M)P'`LZ_N_P!]VS9O\9+Y^S%JSSS;_/<]&WPV_7&7=[G*G`<"M5LS]^7<#Y34
MO^SO5W-O5E/-E[,]O)KGFK,X#@=?O"?^Y+%?\]MUOVVMA^>6?+=SEZ>&WE'V
M='>0.`X'#RGOZTV(_%]M9]>$RYKM\67L\FY^=,S@8O-_[ER_Y+O_`.:E?"QG
M"=NEWW.M3OPT43]5L5Y@],YRDOPAP'`AMX='^GQHE^#;6'ZDH/PLYSS3)X0X
M$!/%'^X)LK\C6K_&49X6,T^^$.`X'__1Z2>&O,V>\_%UEFQCEKY9%3RJR8):
MBMU+?>V2\INE)Z2-N1:Y[=)EK%6H&]L3Q9P-C6&U%*E_DO;.8:64J;_,EILC
M-INPVU:Q3MK=,_J>KY(.F8^G?KF,0L"V%)Y?%'$VL3"EDZC,<>RGV</TTIJI
MT4D`S.ZDUH9'>>QA2]+P$IR#L9-QGE<1\Y,^UXM4FXZ%J^VAN1#OF8P=I?G%
MU0Q)3"T:YQ\UZIY5ML0',K*,96\UR3G93)RI"_E=3Y&27%<7D"DTDX6R[O/A
MOQUU]E99ZDY:E+56OWJ.6,<BH#54EI/6'&)KAF9IV%+.\MH<`'"R@!R$;F@1
M@-SY6/X`Y%G'\>.<[HF&GKSE28YRU.`X%M7]U/DK1'+`W0&['*B0JH=2@",I
MFMT<\B$4]61D?EA;$2P1.,8'CHR/`<9_BZ>C/.ML7;/V90N;]Y\-^.NOLK+/
M4G.JEE9WGPWXZZ^RLL]2<5)9WGPWXZZ^RLL]2<5):KKXX\B:9%M/1A[2<I.+
M3Z_R(HW*EM<VT6!BL4L>,!+<T:,PW'D_QAQG&/\`QZ>:>N*F>3GV>,<W'7FS
M$X#@63?`9F+!'M=]ET3JH6E*#=PGE4`*9E>W(&21ZS:O%!%D]M;E9`!Y&0+^
M1D6!XQC&<XZ,XSGS[XF=V[ZX-]OAMY?YEW'[SX;\==?966>I.<U*V=Y\-^.N
MOLK+/4G%26=Y\-^.NOLK+/4G%26KK[!NR%[W8V\<6XPXU(;**<``9Z-8@-R(
MK7NL"Q]*9>G3*08P,.>C.08QG'PXZ<<V]>4\V?L_KR87S1F<!P.I_A9SN,LV
MFD<;7!4X%K$U[;H]<`B/R%:5CKMU-@U!?DJD+4I2F])1H<Y\D8O)S\&>C.,X
MQYIB;W<Y>B\-O*/LZ&]Y\-^.NOLK+/4G)4EG>?#?CKK[*RSU)Q4EG>?#?CKK
M[*RSU)Q4EN.-(K$[BIO]<D$,:97MSM2>0(P@],8(HR[IB(&1IU)9*@D6<9^$
M(PA%C^/'--N3+V>71O'G3@X&+S?^Y<O^2[_^:E?"QG"6FFUCQ%+J%JJF.6.8
M3D^MU&D&A!&90:#!I-8Q<LS`3268PHT.!!ST""+(18^'&<XYC4O1,XRDCWGP
MWXZZ^RLL]2<5*6=Y\-^.NOLK+/4G%26=Y\-^.NOLK+/4G%26CKX='^GQHE^#
M;6'ZDH/R.ISGFF3PAP(!>*4,)>@.S`Q=.`@A;6,6<8R+.`AF,:SGH"'&1"ST
M8_@QC.<\+&<)?=Y\-^.NOLK+/4G+4N;.\^&_'77V5EGJ3BI+.\^&_'77V5EG
MJ3BI+?_2L:ZZ;%7O*O%.V*IR?SRV%5>QR63I'7,*7)E+!6B6',T'A9S<>G:D
M6H"IE?E1;\H<!$.8[G2JCNGH-91#!GK)Q=3'XP[6OK`Q2AI6,,E96F1,;B`!
M;@S/K<C=FE<66<6H++6-R\E0C5`+/)`,.!@%C`PXSCX<8SRN7H)DR=&G(2)"
M"4J1*24F2I4Q0"$Z9.0`)1!!!!00EDDDEAP$(0XP$(<8QC'1P/VX%3[]Z^^[
MWJ=_G+-?\$$\DM-F<J.O.6AP'`MY_NF?_4+=CY&4?^>[+Y8<;\H76.=,C@.!
M51\>+[UM"_A[DGUD%\T]6<\G'L\8YN+7-V)P'`LZ_N_WW;-F_P`9+Y^S%JSS
MS;_/<]&WPV_7&7=[G*G`<"M5LS]^7<#Y34O^SO5W-O5E/-E[,]O)KGFK,X#@
M=?O"?^Y+%?\`/;=;]MK8?GEGRW<Y>GAMY1]G1WD#@.!P\I[^M-B/Q?;6?7A,
MN:[?%E[/)N?G3,X&+S?^Y<O^2[_^:E?"QG"=NEWW.M3OPT43]5L5Y@],YRDO
MPAP'`AMX='^GQHE^#;6'ZDH/PLYSS3)X0X$!/%'^X)LK\C6K_&49X6,T^^$.
M`X'_T^]6G4":I=XLNT-_-`IXYMN7.5D,,PB;56<QKR71.PJ]J9=%7.<7Q'+`
MS,5L34-T4&;#8>KBQ:1M`+"PAV7`,#U<XNY\8A8.Y7!P'`J??O7WW>]3O\Y9
MK_@@GDEILSE1UYRT.`X%O/\`=,_^H6['R,H_\]V7RPXWY0NL<Z9'`<"JCX\7
MWK:%_#W)/K(+YIZLYY./9XQS1'U.TS5WIY]+ITZXC-:)HNM>&A4U2J$(GZ5/
MH9W&:Y01T'I=>N'#BCI#)@9$N<T&21A+"`H`^N"8'3=NK+-GMVWR?/46K$9G
M"39R/3)RE\1LVEX984IB$?\`.H<(,C65\B>5:MB]"F+#7R6&FF,AI:Q4RY$C
M:R?)4F&FA&66.SNJM"(N]4&N=.5G7]W^^[9LW^,E\_9BU9YYM_GN>C;X;?KC
M+N]SE3@.!6JV9^_+N!\IJ7_9WJ[FWJRGFR]F>WDUSS5F<!P.OWA/_<EBO^>V
MZW[;6P_/+/ENYR]/#;RC[.CO('`<#AY3W]:;$?B^VL^O"9<UV^++V>3<_.F9
MP,7F_P#<N7_)=_\`S4KX6,X3MTN^YUJ=^&BB?JMBO,'IG.4E^$.`X$-O#H_T
M^-$OP;:P_4E!^%G.>:9/"'`@)XH_W!-E?D:U?XRC/"QFGWPAP'`__]3M?J=8
MOA_ZV>)A.==H0R3RI9D*02&I&&66!NL?(XQ/;"9&B`H6Z'+]?938QJAG&\)Y
MH0U010-(L-7G(CD:`D@9)I14XNYN=KL5NLR['R6CIS'M=?,2'QUC9A*Q<UOS
MJR6:`@#XQFNR"MQIG6(MH9"[1$#FG3''2)@.(6&$B)6)Q]!Y=<Q7%FNK#98K
M9KW`FFSF(Z'3A(CD:10TJ%!RUT0M()4_@ARY[`ML"UPI9*XQ#T>L<D09$\)D
M3@<<F)/$24#&!.<TV7V8F7O+=?9N)^JN6XT<]55K]ZC:7QNH#54;M*EDA+,N
M&9A))4M;,WA3CQ"RLB-"-L1IAF9&'X.@6<XQ_%SG=6C3UYSBJ%T`XZ_-4S,<
M=B6>RGZ+HTB=4Q-E<JXTF"ID:=U;SR2YH5(4IYKC"SFXM06L3-YJ-P.\L."E
M!6<9SSEI-\'>*^KPTHD6_E1[-55L7K^Z-<!:G^-.$"L9FO9MI'T#+WO9`FM6
MF$+8SJDX/D/0P"O5L=->4:B-JD3$_/*9*@4KTR14H(KFIJJ<5]XGBH)#M;<[
MW0\R>9_5;I(T"R-2Y])$2K=U!L=912;S3)D5@ZE6P(99Y\F:E*AG;52ML)3G
M'IRSC!AX=1DL4?NI[:[N-@;H!:9&JCPBH=2F3QIFYK<,J@C>K(P`(PN:52$K
M!60YSC(.C.?*^'^#'+MXX./9E"YOV8F7O+=?9N)^JN=7&C+J=F)E[RW7V;B?
MJKBXT.IV8F7O+=?9N)^JN+C0ZN`OBU:4;AWI>]23BEZLDM^QYBJ1[BCTYMLK
MH:!GL#RIF('=.A-03^PZW.7E*4.,F8.3@4A#G^2(0<_!SK;NC;,S2;MO=%7Q
M<\J_T9\66J7X<HK+6*Z8!(S&]6TF/<0V"U5C[F:UKLE"5MYJQLV93'&HSC""
MS,EBSD/6E%CQC`P`%CN?9MG/;+F/7NC+='_/_3SV:JO%D?9#:6MK35^QZUVB
M]?ULMM"O#-BM?@-!%>6&=/VJO4JI0MV1+CKJTO>8&_)Q(DB@\11*80%9199Y
M.#9_LV7XXG^O=7G%=?\`IC'_`&SO$B_4KG_TRZA__LCR_P"W;I*?ZI_:/^?^
MG=_PA=6MEM>Z-NEBNQB?:*D4UV/=YXQ0Y6Y5#.U:R+F4G1D+(D"AU@TDL%E1
MC6OT*<"`I<K\'A+2A,$4#!H<CSF8F9FFD14;8MU?[,3+WENOLW$_57)<:'4[
M,3+WENOLW$_57%QH=3LQ,O>6Z^S<3]5<7&AU5U]@TBY%NQMXG<74YZ5@E%.9
M&X'I4:(TT(]>ZP$`.4Z`DA,'!0,X#C.`XSG&.G/P\V]>4\V?L_KR0IV(V-35
M"WA88LVF26T75QAS<QQY2RR0YJ`3,92AC)+LI7-Z(I(Z"1'*LB"VI585RD>`
MAQU8!"-!=VZL(S3;L[L9\6G+-W6#$()04JC@(Z^)K4C+I+Y;*LLLN6L438HF
MQ19TDZK$8:\CDB;)Q\H*ZG"H[`DB4`C1X/\`)Q@4G?AMKBZV^NYW1/!T%YHR
M=3_"S8I,LTTCBEOG#@SHS+VW1ZEN(9(\L*3^1NIL&69Y*A<@/5&=<:$1F?*%
MGHR+HQT8QC'/--7NPXR]'#;CPC[.AO9B9>\MU]FXGZJY+C0ZG9B9>\MU]FXG
MZJXN-#J=F)E[RW7V;B?JKBXT.KCC2)*A.IO\A6L&X*2MN=J2SUQA)"<Q4:&[
MIC@9XR$P"TY0C,_#D(`X#C^+'--N3+V>71O'G3@X&+S?^Y<O^2[_`/FI7PL9
MPEIIM')<;J%JJ:38CFE),UNHTPI,"/1<T"<H=8Q<19`3#FP9I@2@YP'`A9R+
M.,=.<YSS&XT>B<YQ21[,3+WENOLW$_57%QHG4[,3+WENOLW$_57%QH=3LQ,O
M>6Z^S<3]5<7&AU1U\.C_`$^-$OP;:P_4E!^1U.<\TR>$.!`+Q2L"%H#LP$(L
M@$*%M>`CQC`L@%F8QK&!8"+&0YR'/P]&?@X6,X2^[,3+WENOLW$_57+<:.>I
MV8F7O+=?9N)^JN+C0ZG9B9>\MU]FXGZJXN-#J__5[[ZSL$I?/%_VCD$KETY2
MM;!)IJT,D+E%:;&.;/+&C$1JUVB2]MD[DF=]481'8:N3+3V9:V*D$O=5&3L'
MD=6>8,R<7<^,+`/*X.`X$3]L-'=7-X8]$XKM%6'>>PP9Y6R"+(.VMAPKT6[N
M*'#<L5^=5Y+8DM6]<B#@'5J##B@_PA#@7P\+$S&2#G_^?OPB_P!4K_[\[-?_
M`)GY*A>_=JB$_P#@F>&*BWWJ:E4NLW55G)M0MA;1>XUWS;!#\]G4&N;6*)Q9
M\],F6N-_3>BX_8;PG\V)5EHS_//+.*,,*(&6J%[MU7?%+W__`#]^$7^J5_\`
M?G9K_P#,_%0G?NU2]U,\.W3G1IQFSKJU3_=<OL5$QM\R/[P+2FWIA'&SW-2R
MD]58DWEQ+?YD<\*1>4E"0(SK.@S(L!#@-29F<Y36X0X#@.`X'*2@;OADD\2_
M;9*WLMO)4\]I[6:O(B_R#7R^XG#'J74(_P"V2^TFXF=RJM6:&$)F))-FH21:
M<O+0/7G@,-ARP6!X#.+J8_&'5OE<G`<!P'`Y'7_X;MN6GL#:UV5[LM7-?MEJ
M*(6N6P^9:VR:S%S0NB$!C<#R-+*639>JTZE(XIXX!1U8VL(R1FB#U@\8QGG6
MW?.W"*2=NW=5VT1+_!^NZ?Q]?%)OM'K?+(TY^;^D&*0:.39U:UF4BDE:D&>B
M6;N&D#,2K$Y9I8NCRBS`!$'.,XQGEGV;IPF(I(V;8FXN^?\`XB52?A22F^EM
MTHEM@:?L>*"V,=J@;QGZ*/[[AY75=!:^*C\O3%BVZ:L,'FK`[)6Y,WARJ`D3
M-Y>`G"#G`"YWS^L.NV(_MN_G_P`39_[6&S7ZX]$_^RVP/_W@YU_LW?#G_7L^
M?Y_\=)].M>G/5K7^,4N]SE!9#RSRRWYB[S)KAZB`MCHYV]<M@7"O(;HBKET\
M5,R!F53P:$D)KNN,-+38-$/&1Y`'/.9EUHD[P'`<#AY3W]:;$?B^VL^O"9<U
MV^++V>3W;!N>GJE.8$UJ6O6M9J)6:M(BZ>P9U%X8=)#FT;>6XDL!4C=&TQX-
M0&.R4)P4^#,E94E8%T=8#ILS$9RXB)G*+>@JM"LT,];:K6V)!4=GO+::],]<
M*I<P)YZZLY!2T\YV;8>:X`D*YM)(;5`Q'E)Q%!`09G(N@`NA<97B5-76#TIO
M_<N7_)=__-2OE(SA.W2[[G6IWX:*)^JV*\P>F<Y27X0X#@0V\.C_`$^-$OP;
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MZ3L2ZPVR8"KE"T1`DIVE;G,)#&6\XED0ML?+/-#UJD@PTP./(P/&!8Y7+S=:
MK'G=IZ^5;:UI1AMA4OG<,139TC+.%U$F:&Q^P<[QTHQ&ZA$\HG0V+*$9JU$=
M@1R1:,TC/E9+Z<B<)EG/>?#?CKK[*RSU)RU+FSO/AOQUU]E99ZDXJ2SO/AOQ
MUU]E99ZDXJ2W+V77\MQXG=6R5-KYLTXUS%->;?U^=K80U*I-KL,JMJT]:9XP
MR(AV,=RG$R$-#/7#H6YK,HPJ$RHL(`)S@BR,+MF\G5QVYNH7>?#?CKK[*RSU
M)Q4N;.\^&_'77V5EGJ3BI+.\^&_'77V5EGJ3BI+.\^&_'77V5EGJ3BI+.\^&
M_'77V5EGJ3BI+.\^&_'77V5EGJ3BI+.\^&_'77V5EGJ3BI+.\^&_'77V5EGJ
M3BI+.\^&_'77V5EGJ3BI+.\^&_'77V5EGJ3BI+.\^&_'77V5EGJ3BI+.\^&_
M'77V5EGJ3BI+.\^&_'77V5EGJ3BI+.\^&_'77V5EGJ3BI+.\^&_'77V5EGJ3
MBI+0-T<L**HWK>3)ZMR#A7OE;RPCR(Y)3O*3FP"H0`$/!#09DD>1%YZ0#\D>
M/X<XQC..E$3BZF<N2>7>?#?CKK[*RSU)Q4N;.\^&_'77V5EGJ3BI+.\^&_'7
M7V5EGJ3BI+.\^&_'77V5EGJ3BI+.\^&_'77V5EGJ3BI+5_X/M5K'!)7L5'I[
ML12,"D9>VFSRX^-3NTX1"Y,D2.=S2U<WGKH[)WMJ>D(%J,\!I77$`R,L>!8^
M#.,\[VS$14RXW[=TS<;9JD>[RL'5JY5L)87OQ`-;)36@;SCEHS^/S>Z==P*T
M$*A>3I*Q517HX:U1Q:HC+S/FUG.<S'YP7N`T"(0/.C<C\G*:G^T4;8W1?X3=
M?+7SI;L`G.TM)7=8VW'AN*H94)$ORC8HUL$PH)&!_DITC84LP$K7'J>T#BRU
MZO3HTB%4L3H4RY4O4!P+(T^25XQ-PM3&V=L;=US\)SS#=33=5$I2F3;::S*%
M"B./9"=.1?%6&G'G&MBHLHDDHN5",---,%@(0AQG(LYZ,<O=MUAQ&S?<?C/\
M.INFUCQ%+J%JJF.6.83D^MU&D&A!&90:#!I-8Q<LS`3268PHT.!!ST""+(18
M^'&<XYG4MIG&4D>\^&_'77V5EGJ3BI2SO/AOQUU]E99ZDXJ2SO/AOQUU]E99
MZDXJ2W,#1'?'1N*:)Z:PV5;K:IPV71K4K7B,21A?-B:999/%9&S4[$&IX:'A
MC>Y6%4TOS&YIC"5"18GP80H*$6:7TA$'G+N8FYP1XEUDZM/NQ50WD\^(SX=-
MOKM<:BN!YK*1V1L'KY#IS8>T<\3K(Q`U5K!J]K;(ZVU%5L!-/2MZEO+6.P5K
MPH4X1X.2$&GEQJJE^&M%Y:_0S>78':.[-P_":;V2QJX25U7:RCMPH$BD;"P(
M)>CF2M!,(2Z1:*M<CD,[E#HZN[W)E<E<5P3R$*-,D`GR<9@3=1%2W7XC.\VE
M%@Z4W]"X!N#JY.IE(8NTH(_$89?]42F4OR_,NCIH4+)'F*6+W=V6B**$+!*<
MDPS.`YZ,?!PD1-Y.L7>?#?CKK[*RSU)SJI<6=Y\-^.NOLK+/4G%26=Y\-^.N
MOLK+/4G%26__U^J7A!J$<>W'Q'8R4K0"D=:V,59-"1R>;F'OFFYM7/+7&*UK
M#89MN">/]/S964PNZE`RFHVIK\R7A4&-`?1H@Y%(=[LEHZ0QY@EK`^125L;/
M)HO)F=SCTDC<A;$3TP2%@>D1S:\,;XSN1*EN=F=V;E)A"E,>682>28(`PB"+
M.,UP]8(0@"$``A```<!"$.,!"$(<=`0A#CHP$(<8Z,8Q_!P/ZX#@<CJ^WVVC
MMUI,=*VU'1R&.(YL2P2&R&>:2!V88DVG''A`B'"7B%PJ83F6$>:``XA83%;2
MU%N214):H)"?@,=5$<6KP;R;+XUWQ(,J"CK$*L<TE'+1Z\V"B(?H8EU(,MOS
M<ZM3C?2+0%3N"293V<#4!7B$7U(!8=#2U/"U%MCTMLUN3/7-&?)V9C8&])=U
M5L%E1QQJB5-[Q`PS2S;;A,RI"//YS@G9I,=7L:C46?%,LP6I)4IWH62R\%*D
MYB0E0Z]<KDX#@.!J>\K9;:-JN66F[-"U^0Q4EK&-H0.#(TJ5Y[P^-C`B)PZR
M1Q:6!L)PM=2Q&J%BDA.05@0QCP$.<\$8N?<F\3HM<QQP4"U_N".=L72O&=IN
M^Y8PB9M3&=5-G1B;EISE=T-DTE:G].SJG0Y`28UX-2.+F1U:=2(H0#A1U7R\
M"RO$S?XN.GE<<A%9";[4I:F9VM0RVQEK8[0Z5WA"=A)8D$ZC0L*H@R$5.IH$
M:62G#+(4]6\A.#E-E)DI4LC:V%JOOM);^O)NJ=\BE:MS8ZUE94E3N\%GJJ6.
M:.6U',JYB+VA?&I0U-RAF:YXAGP9&PX&`96(N:T+<K51SR)(VB8J'3GE<G`<
M!P'`UQ/)S5C(J8:\L&P(E$GFV0NT8AL;>9T@ADJG*C)*1"[-T$+],-$D='A&
M%[3!R)I%E6E,4DB"(`QEYR$-Z.@GAZ:@2FRS*OMZ)PV4OLO:XM:+=/\`<>?V
M0H!8\@\Y-:FQ_8+ENB:)V*R)&5'#0EY\W3O#@0@$7Y1A9&0@+-RFS"K*KFR2
M7M174_A,^3QI\71B1GPJ5,4J)8)*V#\ARCSV:Q+UX&I\;QYZ#TA^2U!6?@$#
M'",VX#@.`X#@.!`3PN/N":U?(UU_QE)N%G-/OA#@.`X#@.!#;Q%_]/C>W\&V
MSWU)3CA8SCFDM7/_`$]@?R,B_P"9$/!.<LSX0X#@.!__T+J=6Z7ZYTQ/!V77
M4,D+-,QIW5*)R<+5MV5(\D/6>ER#A@ET\?H[@1V?_2+"3`BO_P"/(.%N4H#S
MR4Q)RE2<4G3IRC#SSSS`%$D$E`R8:<<:9D("RBP!R(0A9QC&,=.>$?XF4IUB
M<A6D/)5)%1)2E*J3&@/3J4YX`FD'D'E"$6<2<6+`@B#G(1!SC.,]'`_;@.!\
M+8UMC*@2M3.W(6EK0E8(1-K8D3H$",G&<BP2E1I2RDZ<K&19SY(`XQTYX'W<
M!P'`<!P'`Q::0F*6)&G"'S9D1R.,.PV\;FR..#!(5^6MS1O"("HLHPO)Q)3B
MWDF"+%G(#/(\D>!`R(.0^U9&(TX,'91?'F-=%O,DK;V:6-*!2P>CD6"<(D'H
M<Y.-N\R283E]45U?D%^0'R<8\G'0'X*X?$EY^52Z+1Q:IRV.S+E0K9&Q2?EF
M?^HR^M.33DHS/1CUYL7YV1T]4IZL/6!%Y..@/Z:XC%&186XLL8CS0X%,C=&B
MES6RMJ!87'&CRO1,?+4I$Q1P&1K\O/FZ3`L$$=.?("'IX&0\!P'`<"%FX^J[
MQM0143`FDD9C$?ATU>I%*G-ZCI\ED2-$NACXP-SK6A.%K<BCUEL3LY%+&9^/
M-'EA6$@6E$*3B@%9+$U;3)?ACU]%91#WVJ)J7!&YI?HD]2]G4535ZL4I[`7+
M3-[0XMK5PQBKA+&U:.<4DWE+%)R5T$K:U:@HL*=46B6I)2]S%9CX82N9F3`;
MA?7F^)@"YF-7A-6(NN)A>R;U?<HO)OPO,L43F&6+I'L(ZCBSJG/2I8RB1(TY
MC>Y9`8<8+2OU.U<^R\RSID*G9TM0RZ3)'M`VI69QC3`P$H6A,UC4E,:^6R\D
M<ODQQ(EC\XI#&]&XJ\@&4WI`@\D529M+3A#@.`X#@8A/FV;/$-D+96\K8X/.
M5C>,F,RV2Q!1/F%A<LC+R!<Z0Y)*82HD*8!>!!RG`[(<YR+&>MQT=&0C3I#K
ME:6JM*,]*6)=$4NEIA^,(8([QRGEE1*VAD-4KG!:B?TZJU;1!(UQ[FO&,"DL
M;>$HK&"\E#S_`"^%F;X)B\(<!P'`<!P(X;94._;-41/J*9[5=ZA;;/CT@@\V
MD3'%8S+'%U@$OC3W%99%B$DI(/2-@GEM>L]"Y/Y"Q,(K&2AASG.>%B:FV=4I
M!)C6E;QV$SJSG"WW]@).1"G+G%8U#5K@VEG#PT(C6&))DC(1Z);<%IL&`!UA
M^"^L,SD8A9X26U>`X#@.!__1O\<"'N[5'6CL+14]JZO)1&&TF7Q@YC=8U)6P
M1('_`"<],BW)R"9X(?B8JZM[:B4Y1"5L+XVFKQD>?)%",)Y!I8FF1:=TY+*&
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M%(G,`RCR#5PA%I\Y2#+.7&AVSJD_K1?ULWS)!,[P9B)-0:M;9HCD+8NB\E32
M!^(LVQJRE)+&E,A#,9F%`70("QF=#A!/=$BW`Q)2```,ZW&B3MKBFAV8F7O+
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M,9#`94TS<V+2"!S=I@;.8Z!45A'V(IFMM>6]N,:2EN![L)@:R7)206G7I\\M
MQH3MJ+MTB[,3+WENOLW$_57%QHYZG9B9>\MU]FXGZJXN-#J=F)E[RW7V;B?J
MKBXT.K__TK_'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`PJ
MPZYA%L1)?!+&CC?+8>Z+&%>Y1]UP<)N7J8S(&N4LF5A1)I.5!*-^94Q^2A9R
M4=U7D&!&6(0!!Z2^'Q)UC6(8Z1:..4/"B0MP8HO9&Q9&@M[6).)L088E"4QK
MPB;A(RLD%=5Y!.2@>1C'DXZ`^%57=?KE1RY;!8<L6J6YT9U"Q5&&10J4-#X8
M(YZ:SE!R$9IK<[G"R-40+.2E`LYR8$6>![+7'F!C*1D,K&SLY+>UI&-`2UMB
M)O*0LC?Y64#.C+2$$@3-:+(\]2G!@))?3GR0XZ>!['`<!P'`Q2;0>)61&'*&
M3EB0R:*O`D&75B<P#,;W$+:Y(W=&4L)`,OSA.!P0%#$6+.2S<!\D81`R(.0_
M57"H:OBX(0OB496PLM&B;@1!6PM2F+@;VT9!C<@`P')1M(4:`Q*4(@K!7D%9
M+#D.,9#CH#X3ZWKM4H&L4P*%J%9B1Y0&*CXLQFJ!H9$F"CD"(9YB$1HDCZD!
M@I87G/D*B\8"9@0?@X'\,E9UO&GC$ACE?0B/OX6M*QA?&2*,+4\89$*-$WHF
M?#F@0$+<-:-`VIB"D_E]262G+`$.`@#C`9OP'`<#_]._QP(Z;([$L&OL%=GL
MM.TS"P\MF7.'U1B28:9-+T:9X9VN0/J5O;&>5RTV(01"[^EI"O;&1W.;&A*>
MH\V.$`)8RQ%OLUGO=)L71,,NPAAS&RI.7*"E;&C7N$C(2+X?+9!#7?T.Y*(]
M&G=\:E;E'#CD!QK4@5J$IA0C$A!HA$A).#8/>3'?R=/OHHM+YG<M)<?)WDQW
M\G3[Z*+2^9W%%Q\G>3'?R=/OHHM+YG<47'R=Y,=_)T^^BBTOF=Q1<?)WDQW\
MG3[Z*+2^9W%%Q\G>3'?R=/OHHM+YG<47'R=Y,=_)T^^BBTOF=Q1<?)WDQW\G
M3[Z*+2^9W%%Q\G>3'?R=/OHHM+YG<47'R=Y,=_)T^^BBTOF=Q1<?)WDQW\G3
M[Z*+2^9W%%Q\G>3'?R=/OHHM+YG<47'R=Y,=_)T^^BBTOF=Q1<?)WDQW\G3[
MZ*+2^9W%%Q\G>3'?R=/OHHM+YG<47'R=Y,=_)T^^BBTOF=Q1<?)WDQW\G3[Z
M*+2^9W%%Q\G>3'?R=/OHHM+YG<47'R=Y,=_)T^^BBTOF=Q1<?)WDQW\G3[Z*
M+2^9W%%Q\G>3'?R=/OHHM+YG<47'R=Y,=_)T^^BBTOF=Q1<?)WDQW\G3[Z*+
M2^9W%%Q\G>3'?R=/OHHM+YG<47'R=Y,=_)T^^BBTOF=Q1<?)WDQW\G3[Z*+2
M^9W%%Q\G>3'?R=/OHHM+YG<47'R=Y,=_)T^^BBTOF=Q1<?)WDQW\G3[Z*+2^
M9W%%Q\G>3'?R=/OHHM+YG<47'R=Y,=_)T^^BBTOF=Q1<?)WDQW\G3[Z*+2^9
MW%%Q\G>3'?R=/OHHM+YG<47'R=Y,=_)T^^BBTOF=Q1<?)WDQW\G3[Z*+2^9W
M%%Q\G>3'?R=/OHHM+YG<47'R=Y,=_)T^^BBTOF=Q1<?)WDQW\G3[Z*+2^9W%
M%Q\G>3'?R=/OHHM+YG<47'R=Y,=_)T^^BBTOF=Q1<?+_U+_'`QF8PZ.3^-.T
M/EK=Z6CKV240Y(,*UR`1P"%)*P@12YL5(G%(<0J3EF`,)-+,`,&,A%C..!$?
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M5M4T*VU[U@N77+1MD5RV5C3[$I,E3$0\-CL.=8`*.MXRW=27Y(D9I("CL\%7
M226L&]E]7IMK(*O>6ZHF*OV.:6?`WV!JW2`L=L1])!HHUO,/L5E1G;"/=H2]
M#8JLT:T2(VNVUO2L#J@4$N9HDJD2PDQ$0T3;GB#[C0AP(/"]:WQM@LJZ]^8/
M4CB_1)GCK)'FC2>\'6E8G%+(F=R[7TY#G&672NZQS6JF]>E5-[7'E@VYG6"/
M-&VBH1[SMWLE3MLW/-R%U3D3N^]E+O@[?-9^J;ET%K5OH*EJ:DT*HDF1VAME
M353&-,S4SL!A*YH4-RT2>//K@2A<CG$K#26H23M[Q`MNH!6=IWB^RC5VO8!`
M;FAU9*HJCCB&>SYMC:?6R/7I9,MAZZ5[0T_$-@I.WRB4I&Q%'8ZI0K%\93+7
M%!E:N\W29)473>F[6W5P:YW&CE4*F$%<(AG1[8.VX=1\MBK\0[6!/8*^UB:6
MYA=4$W;G14*$LDA]..*9(S*%22,MKP7D`1J0.#:(BXZOQC6^=J-U`;V3U`^4
MSM0KU19&-WKZYZ59GECJ2R%DIKAOF[FPO30T36T1@5TXI<0'OPVE[4=<RGI^
MD*19U^`BL8:/N?Q'+=JE+)"8SM#I5:9,!UX>-AV&9-<(<TS'M/,DDI5Q_P"R
MI3B6/[$2DEDGC0!(B\X5EJG]T$?,H^'#9@!:HQ:6(C27JR_=3>M9,7(F(OFM
ML0C4G>-[F^%,<GI6QY%)H8WZ5J$:EO%+G)->[`BDTAL8Y0<V.(4Z5L3-911:
MM.`TWRTV25#'$?BI6PJL-N=%DQUS114FU-1(>9K*VPZ9NVR4BK;9#5VE;XL2
MWFYX3V>J`J9Z8.LIU7@"BBQB=2RQE>4K-*4"3J.+.W!Y6O/B2[6[(OT<K&`R
M*@2GR;[%T]"V>TI#6):](VU'9^I.QVR[H-96M5[66:TM5D-!E`^;HTBR7G&)
MB74"5S2E*2!GB6LQ$->Q?Q2+QK&OJ]5*R:]E!#UJ?9EHPN#-[C([@GLBM&&,
MEUSR0DW`_2:_WB]:H@<<C4-;W5"O/CDI1.S4E<49;DF7&MJ8E9VVD!'-Z-J)
M];47UPJ^X-3K(4S2[VJMF;;6&U-,)151[:Y:DVQLI(F)I@K'L,H;7&=0ATKA
M.@&:&5'$8;'Q&-2C"H`/)XJ*NFTU^X%OSVA?"@V%1S.O::QLO84;#;C$YL"]
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M7L?)"%E3UJWEMJ61/L&>"W9\)R[HT))A28*T[8ZLDF._-_R>R+?I!DFE`S6'
MQ"&N$-7R1E7UM`WRWHT_ZNJ[/6[$TZ8JVI?)PI)03)QPW(69CB4H:STC,Z&#
M>DZX(TC8*C-@%7^)1=T?C%05L&[=59[')I$-/D#OM%'HQ)%%;:H.-P,=G)GV
M$W@4MM]81*Y?@56MZ!J4N#K%%'IN2%C<D)1."DYBSM^)2]/WTM=1J/0ULJ7V
MF(0YVUMA)-;7W8Y\87TW7QFKR.3&Y8XQ;+-,?<)NS*$\0M]/6#63'2G&1@0%
MN4J1>4L5D=7A02L91>COB<;@RRHU5V-#KJDLA,`JJ3S.;O+/6=H*(_*%BW=[
M873^(V,VN@[P69B5%PB&UXWV))Q"RY.9Z%H6IDRD@I>`YM6O;%TVNS^*%+82
M[6&RV;9.MLN@4'7;,Q:';+L+:ZPNK[FF=4450UNPN/QGSBSY0P%OR1]L:21]
MZ1(GA>)S61X04(DAP#B<K3M8-$/%0N5XLB-$R:<:M,K4196C$,?*(3L,C0W'
M)X-M/K12EQ6Q<#.\N=OKQM<5I!UL9U=@F8CZE$5&6!<!>IZXK"S"U[8IWKBL
MICDXC$<FL.?&N3Q&8,+/*8K)6-:0Y,DACD@;T[LQOC.XI1F)7!K=FQ64H3GE
MB$6:28$0<YQG&>5P][@.`X#@.`X#@.`X#@.`X#@.!__5O\<!P(F;FO;"VU5%
M&AVK\FTGJ67WKPUUS!U\R4UZQ.MJQ^Y(=8M=+Y5-4;-)%3#$XO)X.0[N62FQ
MT,5I$`T@$2L:@*<PL(I,WB7QN/+9Q6,AI%5"[-KI\A,%##(NOELRKQ?.I7>,
M_J)U1)K(AE0'LD2AC>GC"%[1.K\B9U#F!U,2B0)5"(_(I:]ORWUK'=TKO@V5
MQNW]>X!7)\3F5PQ"/A@<LFUW0E6NJ&?&5G9!KS,I#KK343A;@]O[@`YC;1'*
MG5_:_/50DY`42D.*DQ64M-/6^\2C"^-22UJ+9F6CK+LNY:QIV9,$C#8EH2^U
MZ]GKC6)+"\TNCKIO`P.%RR)I6)H\:W2%]/4G&(TSD6@4+,$ERU[?G%F=@;WU
M!#R/2+)`7DNU`SQBJ]9'IA'4\6=VDPN9:UL,T1.[\C],83]EV'95D5DD@,-3
MJSR320C"$O)G*E?.#WJ@WGU<V6FC'4=<M+W.7)X=+&/<BTT*:Y#"8BM@+)!Y
MC(G>72AH7/40;A.J:WV'*4XI2I-4+WK"<S`%1:LLD5,8HUUSXM&LEA1B)OEC
MU\XU]#9=KS5FP$N=9#%I4KCL:G,_K^V;&>H(K4RNMX8AE:%@CU-K26Z8(LFM
MD@7G)TJ<)1IA(39:]LMK2GQ,--XZB7=NVB9QL">92]F8$DRJ[+*1,)C5T\?Z
MCL0<57/9J=B,<*[E\46-R]0L4HA`ZG`2!'8&#`JE2^-Q\4S6H;HR2#$(M5?7
MR1!=CF"YW*O/0\9:0U`&%-DG-8<R!0@D3DF>%\\1MF%"5.$!2L?4*>KS@WJI
M:]LO1B_BA:@C:5)\706.EA[2R2IW5/S#4KL=#$KM%8;:UB/T33.D?`K:ULD%
M'*4DZH@23)S<M"W8,)5F%*T9JA9VR_R.>(1J\>[/;(9$%*1NADRBGH];$(D&
M9((K&)C66LL[1VC-%$=:,Q^%-XGS9MH:BQM2Y]"L*3&KB%!A)2XMO%2VO4VY
MM$WBA>%T!B$_.5M$94S4),CJM\8TIL8E$<>I(UR<]_\`1RYE:6"P<1IQ2I%2
MH\K+@L0FEX`//59,J5*!NN6[CE,CY1,Z>TXA.+3M^./VTTW-77_)6ZOE,.@&
MO>K4(R&O;&DFNC:K=9>!K71N**&5N8D482NC$X'*'D)G3UT68UG!G\3\52BY
M1.YI7]55*V.\H;&/6URJ)N#+(9'7*>S?8957K(>S25`D;G)95S-6*_8:-IG9
M[SAV\ZRY.Q*),H4H1)EBSME._6JVHS<['E^(B$,9Y8QMYR)Z<JX#,977"0O,
MWGL6!%(Q:\SJ*FE<B?V@^#&*'UH`SI5#(8M2Y-`,A6B5JZDX.>M*>*M%9U6\
M5?#-8U$5D\EK57=%6M,1<I)*JIS%TL`J.5SDY_M<%*Q;$,>X4LOAHCST)"Q.
MR(#RM"E+5G]8/R):SMQS2(0>)!JBX&)V!7'+'8F)N3N#DUNTIJ59'H`63'F2
MV)"QJT$D=LIHP@+?RZ'EY30<,X@K*E@,ZP9`%"$Q54J7SQ7Q/-/'(W+NQ"EB
M")N1*5UF5J$0+!59QEV<IK95;-S=-9\V*E#*>^.\^J=[:D@TIJ\E6>2484<-
M,H)/'+7MEKUKON"ZP5LV5]16M)*_7C7C7O6ZRK-<IS/^RMA0^LI\M>&^$(&*
M).,-FZRT9_7D9A"MT<T[N^,62Q$DIT:M6K'DLL9YSB]E;XI.BD=8$[W)T\F@
MY<X:6Z0,S1+*G41UXL.!R+$]5&3A@0+"BP2R+9/K=Z"8$H9JY6I*3EIDJ@US
M;`K5G;+==<;IZ?6-*ED<(>H_!76.'$QF(.%HL;37;7-4KA,[$JX*.I7N1C2)
M)8B43.MY`UX2H!]:?E*(PLD:8\DTVI4HX4_XJ^JT^J4$T=X0XQQED<TM%([Q
M^%,:6U6MLB$)35G*@678"B)-9"=D3N546_%7UV2*$QRMF5*E+29E0M0YP;+7
MMFWC[%>(#K/)XS%H8YBNB%U(Y2_':>TV0J:5*0EK)NI3;^S(K.:T5-"<Q38K
M'+)'J,YLJ5G/3%DK4RDM5U(P91]>(B>K-(GM+1M44'2C5JA`&&5165,-YK$9
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MN(/$=E+TDC07EW@S,B03YF,<#I$E:`HREX3L])!9YI0J4W>$.`X#@.`X#@.`
MX#@.`X#@?__6O\<!P(S;;/\`1S#3IWV@F!7*(.^3>MXTTL+62K].KK$>IPQI
M:V%&W1$YL2B,R1!-,HU*%V"XMPFY02$\*DH8`BX6+O!#X-PZ)4NSRJ.N]82:
MM8J1,J-J&9NDB3C+*5SJ16DGL"&M\E4&SIRF#B_L5DWJO?Y$\JR1FFG*'!2L
M5J\%9Y%QG%MVO[WTK9$.P]MPAY*:1:W.^U1]MEDKY&:YX%'GR-V?L?+V2""=
ME9TM9S)24A,`ZID!H,*1>;(1EE*<EG5*G"&F$RCPLI*]V0*PDE6UC,Y9"D5O
M6%$+GFY4)S'(O;%E/!J:QHZ4NFYM<PAYL2P:P*?%SG$U:9V4*L-#FXF`-7-I
MQ\P7\L&2NE?>%+B16!(I'/\`7E=)8D5%F.UG"6;,A>%T=6-+Y6\>8CK&#(;2
M6>C)4[R*L8LWK'!T"!T>U3.A3+3E0RBR^,#\L'RZR3GPNZPBS3;]23^E:?,>
MJY994N#85Z-2.91NO[*::=8XX.7H9O93Z>P,[LR0>$-S5UQGFI:1*VID0@E&
M%@,8$]TM>6>/PZ))&I;!V%>WR*`:3P/3E19;94CI%K+8%U:5K:=JIM?M>'1P
M6O<ERF6PNTZO,7O:,0FYXRC\U(5+3$JY25@8O:AU9>&BP&/Q5@V)7S+;M@W!
M*+/5I+2V'9(7>=?SC8*V;&O:,16&`C%GH76J%;BLERW#4GC)R!0_($8#U`UQ
MX33\L#\NC=S3!O#BNP$(BL:E5$V:8].MY/4#:8E>*62N<I<IR60NOI0S!CT]
M5.4MP(YP2KW4O&5134L"C6!"F4$)3BZF,-?HYMX=`IE6=;U[-(M:LNMN1R4#
M3(J[V0[92%H7UO54@C,CE<CLU;=!4I(=HU6]P*4H<(W!9(A%/&%2=,9A.)4E
MBXZ-9U$Z^#Y8DK:V>NG&FB%2".QBZHTK=;&519NL1E51)I:UZ@3'(YLVN]A(
MH;&]06A=*6I\;3T;>ICB9R7DY6!/4X8'Y0W60/0"J'372P84_P`<5,-UNR+3
M*I':M)\JFE<2IQ-9IH..QYV6M$D=FE8.,EQQ\9$:[)Q@TC@\F)3>E0>2(FIC
MB\9IF'AF;)T_20'24U@W0-DA5GQJDF*9V8HJF7**<K=;(JSL@MJ2'3..S.1T
MN\,U,J1N8%8U3,\LC4!2O`:45G()@OY0S!#%O#'LG$*J!DD.K<P5RA;9,RKF
M`QNUH>YOL@4V1,'6<SU_@[0R2XQ[<R3)I`3W!.:WA&4S*XT6)#YKEH)PEN"8
MYI6U/0E5T@6XEUI'G!C]+M[>VNISC+II+%3D2VR"92E.I7+)C(7]6J=C7V?N
MIZA<,8EJOS@!9YIA:=,`DEV\<K6*B"(Y`(D57C<".U;3CGK_``%LPY/V2HY3
MSR.LQN<(3&Y=LJ5*%6.G8UG)Z@9RS'HHOR3L=8=UI;EB<ATIU<E<:##I#4+(
MZQH#<A:0-*AUDV"`H&P%MEMY`3"GPM1@2/%ZRS)8_+ZP(G@8O*\HI/DD7+"9
M#X?>M;O6T@J1IBBN-02=R2'OEIM9;DHF"JTFZ(6G*[J#&Y@[64*:N9R1_LR;
M.CHXN"8U.]&G+3<EK2A9`(`N<VY;`UFHJTIPSV//:[:I#,65(PMP'0Y:](B'
MIKBDA-ET49YFS-CFB8Y\R126'F.C6B?$SBE;G(8E*8LH\61Y%RT#67AM:J5I
M"(O%$T->WI\BY3)A-9BF=3MELSKF)%*T"<MJF46DS(]1%A4DSM\RH9&4YO8U
M!CPM&8D$)4?D8N6^T.L=%M;;-&EN@"1"AL.$26N)@6D>)(0<[PN82N?3B1LO
MGA3R%8WA<97:+\MZ]*80J*-<18*,``LD)8N7C2/4'6Z6/+P_/U5,BMS?J_.J
MQV,(7O[:F5P-0V-#*>P^CFQW1MI`3&>/H$F5)9(%?FR(@KK?()+"$7+1D1\-
M77!GDEH2&:-"FT$]D/A+HEBTG2LS5#X.C2L>P<7(;HHQ1%MCY90SHWM%,TB@
MT\9P!>D0'DE$*R<*!"YP;YE&IM"36"1*NI=#'&2,$$7/#E$')YGMBKYZPKI"
M)QS(#T-J*):.SPB?278\A;@3P(*I*/"<W`B`@+"+E@27P^=.$+FF=D=%QU,H
M3-(V(24EWEH&5P9LL<FC29L?([B0^@)"B:F":O21`6N3*`MQ+PN"EZGSQ3U@
MN7\M7A]:@,J(#>AIY/YH)#+&ES*732QG44H99RE*2REAG)SK,%IT_CSGU.#\
M-[V)P1$+!C5$E%J3##1"YU9[$-2->((N+=8S7"5&\!51Y>H?%L@EKX_NSI%I
MB^3]D>9`^OS^YN\D?$\PDJU<8N<#E*M48?Y)YAA8``"+EA,%T'U5JZ10>3UK
M6AD&<:]3L;?'26"83<#46S1QB96)H8E+,MD2UL-:B^R[2M4!"4`Q>XMA"E6,
M\S)^3A<IB<(<!P'`<!P'`<!P'`<!P'`__]>_QP'`@GXEG;7[%5Y]@?1_:'LL
M;U?:+[/_`&%\S\O'GG>1]I?_`)7]@^K_`/KNM_W[_P!'FW^TXE=N<*T;UZ9[
MA;&Z[N][J^Q55>C^]?L#Y/E?8EBG6=NO,/\`^Y7E>:?_`$GI3^3Z:\V\C_>>
MGD=\8=0/#8[7=U6S_8WMKYAV73>A>R7<AY7:[[!'A_\`9[R^_C^TO?1U/6^F
M_3_]A^T_I7TW_M?-N(<[LX<H';MC]GB]^J[PO3O<Q$^U/<MW$=R7:K[;_BC>
MC>]CSO\`Y<=V_F/I;T)V-_L9Z5\\\^_WOLWPZXPWO6WIGSK4SLSVC[4=X5_=
MG>[OL#WE>D_MB5!T]AN]S_D_VO\`,.OZOM5_PCS'K.C_`'SS3@U:$UI](_:0
MTU\X[<^C^[74SS7O6[+>;>E/M+^%IZ;[LO1G]J.P'5^9^:>>?\&[3^D?1/\`
M+])\FBSEN21J_M-]C_=3SCMET?\`;D\,'L+VZ[I/0G9;O0VO[+=W/HO^7W0^
M1_4W>-_;'S?R^T/\OE2<XYRSQV]+=TUQ=X/8/TCWMS#M)V@[%>AO-_\`LF;-
M==Z.^S%_9;S#T?T=5V4_WKT=YQU?^^^5PG&/KBWGI+Z8^U]L?VR[3=I.Z:_N
MT_>[V&[R^L[CO"Z\P[PNX?\`Y3_W:\S\U[(?[/L]Z-\\_P"/>E."<H8[X<'I
MG[5VNG:'M?Z2^R`G\R[?=@>T/9CN*U1[.^ANZ_\`LIW;]3UOH#TA_:_JNN]-
M_P"U\WX)RE!>9];]E:;>G/+\Q^S_`%/YKVT\R]$=F_LC>+-Z(ZKNZ_M'W5>B
M>K]&^>?VK]#_`-9_\1Z_A>,-EWOY_P#]N&K>V_=5Z6^TG>76=G.S7;#S_LLZ
M^B>SOV>O[%_:SZSJNS/5?\-].^CO27\CSC@C.494?G7>9(>S_9/T%V`L+M!W
M#>A_3/4=ZF]79O[,/>=_S&],]/E=A.S/^\>3UWIWX/(X.'5+?PW?2/::G/3'
MF?I;[7T?]*>:]EOZQ[W?&H\]\GL-_8GS/SGRNI]#_P#"_P#U>:?[#J^()_PM
FF\K,X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g893535g52a68.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g893535g52a68.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0F$4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````]0```D`````&`&<`-0`R
M`&$`-@`X`````0`````````````````````````!``````````````)`````
M]0`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````!N<````!````<````#``
M``%0```_````!LL`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``P`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#TJSIF%:^ZQ['%V0TMM][P""&5_1:_:SVUM^A_W]Z;]E89@.]5\$.&
M^^YT$$F6[[7;?I?Z[%<224BQ\>O'J%56[:"3[W.>Z7$O=NLM<^QWN=^\IN>U
M@EQB>/.!NT^Y25+JU#\C#=2U[ZMY##94[9:T/_1;J+8_16^_^<24V/M%?G]Q
M2^TTS!=!\%S_`/S1/_EIU?\`]CWJ#OJ96\R_J'57GB79I)CP]S4E/1'*I!@N
M@^!3_::O'CE<Y_S*I(@YW5(.G],/_D4C]2J3J<[JA)YG,/\`Y%)3T8R:CJ#/
MP$H.=G5X^%D9&[9Z-3["XM)`V@NW:-=_U*Q!]3X$-ZEU<#F!G.&IU/9./J@"
M0']2ZL6GD.S7.'^:X)*:`^O.-WS&#^P[_P!()_\`GSC?]S&?YC__`$@NF_9=
M'^DM_P`\I?LJC_26_P">4E/.4_7;&?=6S[6UP<]H(#'3MGWQ^A_<_E+KVN#F
MAPU!$CYJA=T[%JJ?:^QX96-[B]YV@-]\O_D^U+&ZOC95AKQ[*K'#D![IB=N[
M^;24_P#_T/4;JO5I?5O=7O!&]D;A/=N\/;_T50KZ&*W!]>9D,<."!3IS_P!U
M_P"4M-))31_9V1_Y8Y7W4?\`O,AW8=M+6/?GY#VBROV/]$-=#VG:[9CL?_FN
M6DJN?19?1Z=;S6Z2?4`#BT@.VN:Q_M=[]J2D_JU?OC[TO5K/#A]ZR?L'5?\`
MRQM_]AZ/_(J+^F=2L&U^?:X3,?9Z>1\&I*=GU&?O!+U&?O!8?[&S00[[;9(X
M/H5=DOV-F#3[;;_VQ6DIV_5K_>'WH>3E5TX]MV]GZ-CG^X@#03[BLP=/ZHT!
MHZA:`!`'V>G@?V4/)Z3U7)H?1^T[&>H-I<<:DB)]VX0U)2(_6QH)'Z(QW#A!
M_JN]1+_G:R)BO[QV_MI8_3<3(?D`X=E8Q[G4AT8[@\-`/JMV>YC7_N/]Z,[H
MF&"8H>X#N*Z8/P24B9]:&6N#)J9N($EX!U.WV^_Z2Z$%K@'""#J"->?!93/J
M[@!S7@-.TAT;*X,&?W%J@`"!H!P$E/\`_]'T]U];P646U^J=&@D.U\V-<QSO
M\Y!><VLCU,FAH/!=4X:_/)3BJFNXO92\NW<\M$P"YFYWM_L(ECF/C?0Y\<2T
M&-8_.24@%V23'VO&U^C^C.L^'ZTI,=G6-W5Y%#Q(!VU$P?\`V)0ZL.S[6'C8
M*-7>DZIVFOYK_7]-C_\`K"NBMC6[6-#1,P!&J2D/I]1_T]/_`&R[_P!Z$P9U
M*3^FI_[9=_[TJTDDIHOMRF2'96,US8#@:R")UU_6?W5-ASK!->30]NH);4XB
M1_Z$I9N&_(`])S*G3)<YKG3IM_P=M'_25BFOTZVL]L@#<6C:"?SG;9=_U22D
M`9U*3^FI$<?H7:_^S*6SJ43ZU/P]%W_O2K28B4E.><!]6]_ZJT/<;+'F@@;C
M])[IR/SU$4`O%?J86YNC!Z`F3)AK?M.Y:3FM<"UP!!Y!U"IX^%?7D&ZVRNQI
MGVBMP(),[M[[K?\`J$E+MKSZZ_;90QK?S120!_[,[4*RS/?L;1FXH<Y[9/I%
MPVS+V[?M7TGM]K5H$2"#W52K`=7E>KN8:?<6U;'2'$AVX/=:YGM_XE)3_]D`
M.$))300A``````!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S
M`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`#8`
M+@`P`````0`X0DE-!`8```````<`"``!``$!`/_N``Y!9&]B90!D0`````'_
MVP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!`0("`0("`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__`
M`!$(`/4"0`,!$0`"$0$#$0'_W0`$`$C_Q`"R``$``00#`0$`````````````
M!@0%!P@#"0H"`0$!`0$!`0````````````````$"`P00```&`@`!!0L(!@4(
M"`4%``$"`P0%!@`'"!$2$Q0)E-055975UA>7&!DATE065E?76=$B4I-8&C&2
MTY:H06$C)'0VMCA1,G6U=[>(N'&T)34W@3-V)PH1`0`!!`(#``("`P`#`0``
M```!$5$"$F%2(3$300-Q(O`R0H&AP='_V@`,`P$``A$#$0`_`/?Q@=#">].(
M^Q=IMQO:^1N'%Q(:FX>Y'0AJ/`ZB8<+X</M(3NO"]"7R?]?*NRHXFZ)&.F+:
M=1ZT"LJ.E2F%8BO-3Z,F1ND4CTU/TUQS<7NH-2<#VYY;B`M?%?8^*SAJXI=N
M["X<;S5M2DFH*;TII2_;.JURUE*ZVI=`MT'3I&RTUK!.F$JI*(N5'Q@;+D<B
M4F"D3,Q1W#]GF&R]@Z:U?Q*[&XO+=Q"2N_-15>Z2M+;PNFH'3-&GIQI#S+Z,
MUK$T:A1=WC5:.JZ4@GI9>?E%5UR'4=))._U25F;4=`U7XL.TMN/`AQ$\2R^V
M-XN-=M^'[B1=V79EQCM+TB"KNZ*GQ)JTS4ZO"M*:SAJYM-9DRU]!/6EE\,D5
MC6\D18&ZH'%!,L;I%8AV4K=KAL2EZGV!$V/1E"<\3.JMTTG2K?4Z&X-GVQOM
M-E9-$LMXHV&D3U&X;+9;9>W,ZZ=1*59NZ^PA6`I*O%I@J0)(K*LZ^??A(8SM
MF(Y?U`WNT:(>:XT%N/AHE=]'V1;;3:7LC-6R!HNP[K9=(Z@:5;54W1[??ZRC
MK\P"WL=BISN6;/2+L&JO1@194U]^?+/G`!V@-GX\:[LM5[IV>T<>)IU&N=$O
M!6.RIJE3D!L^*GUX])A-[6TUIIK.W37+R'`LR2,;2U<==80582;Q`YS)B8I^
M4*X,;[Q&<13SC1J1^)NW;2T!%N*K0>'3C#C=::HHEH>[(+#V1CO-75C:NT]O
M0-@4+6]K18-HB:=Q+MLL]*Y;@ZE2(G7*)I%/'EI#P_\`&!Q6:,TG)[GNFSK_
M`,9MSV%VB,YV?.N-5;)E]8ZMJL8\1V?:J/2;H%II>JD'[.<G'D.T;R9W)7#%
M%)=19)`HI@F<LQ%:>O"<6_M7MF</ZO%<G(T&/VULFG<4]]JT)IVP;3M@ORTK
M4G#=JW9NU6^G?5?PO6YRWIE/;+.W3AW9P:,(TST7CR4,*Y&HJFM:-H^S[XG[
M3Q-<7'&M9AL-N/J26T%V:FW]1Z[L4JJ\C]=,M^Z)V!L"PMXN/*<S"-D9I0S,
MTD9`I2N'#8IAY>:&$F*1#M[RLF`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!__T/?Q
M@0"+U5K:$LNR+E$4>LQMKW!X!]:=A9Q+1"6O_P!5J\6IUSZUO2)@M,^!*R0&
M+;IA-T34.C+R%^3`QKI3A%X6N&][*RFA.'G3FH)><;]3F)O7^O:Q69Z48`=%
M4L:^G(R-0EG,619`JA6IUA;E5Y3@0#F,(EF9GW*XZOX7.&[25NM]]T[H?4FK
M;I?B`E<K-0*!6:G,6-+KAI%1&3>0D:R561<R)NLK$Y0*NY`%5`,H`&`5F?RN
M3?AUT2UTZ^X?&VI:$AH^2;SC20U2G6XXE%>-K-8']KL"#BN@CX.52F;+*.'S
M@!)R*NECJ&Y3&$<%9]_E%['P?<*EQ+-IW#ATTO;4K+;ZUL"?0M.N:M8F\O=Z
M=`IU:K6I^WF8QZBXG(.LIA'-W!B](1B(H<O1&,416;J>I\&G"51+/5KM3N&O
M1]=N5'J@4>G6N+UG46]BK%1!N^9A7X.:"*&1C8[J$FY;<Q)0O^JN%$>7HCF(
M(K-UUU[PG\,FI(78]<U9H#4.MX#;R*K79\+1=?UFJ1EZ9JLI..%C964'',6\
MG'IL9MZDFW.444B.UP(4O2J<X5F[BT?PE\,O#0ZL3[A^T3J_3CRW-XYI9W.O
M*A$5A:>;1"CQ:+0E%(QN@9XDP5D%S)`?E`@JFY/Z1P3,S[E>$N&O0"$1%P".
MGM>IPD)MY/?\1%DK,85C&[M2FU[(EM-FW!#HT+RG/N5'@2)0!P#@XGYW*/+@
MK*+V[@TX2]@.)9W?.&W2=U=3MZ=;/EW%LUM5+$J_V(]A65==W5<\O&/##9'$
M+&MFYW8<BQDVR/R\J28E%9NG^N-%Z;U`]E)'5NLJ70'\W6-=TJ8=U6!80SB2
MJ6HX!>K:PKCQ1FDF9>'H=;=*,8M`W*1FV.*:8`4>3"597P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!KQQ';1LNJJM!S%83C%
M'<C/A&.`E&JSM$&PQSUURID1=-3%4Z5N7Y1$0Y.7Y,WAC&4S5G*9QBL-.??(
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M@Y1%)(.=^N/*/_1G+.(B:0Z8S6(F67LRT8#`8#`__]'W\8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
MTKXXENK:YK;CHEE^@M)UN@;)]*X6Z*"EC]$W2Y2](LIS>0A>4.4P@&=/U>Y8
M_9ZC^74#7]V:VGH=S-K62/K#5H1ZY<(W-ZPJ[Y*-CYD]<<S2K*5>(N$80+"B
MHQ([.!45'21DRF$>3E[5B[EK-E7&;CUC)-)YX-WK,62L3L[7;"C-SL3$NH:0
M@+7-4Q<9-N\>IJ,&K^<@'!6:BH$*Z3`ID^7EY,5BYK-A_N/6,992U5[=JRWE
M"P4K8GQU)V)(QAH^*DZA$B$X\.]*E$.I%Y>&`,TU^89T!S"GR\WY58K2IK-*
MT7%/:6LE6DL_2V-1%&,"X;M9QZG;Z^=I#.G;MXP:MI9R60%&.<.7T>X13(L)
M#'504(`"8A@!6+E)LJ`V-KT7)&07RF"\4E"P:;0+1""Y4FSF0(2'(AU[I3RA
MSN4P!N`=,(J%#F_K!RJQ<I-G`79E"<5U>UQ-KA;)`H2,=#=?J;Y"U)K34PO&
M-HF';%KYY$SB3D5YIH"2)0$XE<IG$`(8#8K'LI/JB,-=Z:^>31(-%S.=8`L"
M5\Z4K,ZDPA7MFN5GU]"Q<ZNHQ*:(?O+C3I!AR+E(FFJB43G*55(QY6#65WG-
MP:TKZBR#ZZ5Q1RSF6,'+-&4W%.W<"Z?201(+3[9)Z*T,Q9/N4CE9P!"("4>?
MR"`AEK%RDV2-C=J9)RW@&-MU8D)SHU%O`S&?BG<MT*2:*RJO@Y!VH\Z-))PF
M8QN9R%*<HC\@ARJI2;(JZW3JZ-H\7L27N<-"U>9I`[%C7$LXZC)/*@2""RKR
MC6"5#PV[%M##TJB*+=1<O)S>9S_U<5BE:^%UFM*>5W<[1UFS0ZT[V)16K7PB
MWA^LN;=`((>%W<:[F6L7TRL@5/PBYAV"[M-#EZ4[9%14"B0AC`K%RDV)#:.L
MXD7@2NQ*+&C'28PD@$A;H!F+&9*UEGIHAYUF03ZM)E90#Y86Y^:J"3)<_-YJ
M*@E5BY2;.539.ND7!V:M^I23M-U+,E&JEI@B."/8!(%YUH=`S\%2NH5$0.[3
M$.>V+\J@%#%8N4FRU-MQ:P?ELQHRZPDP-0"!&>3A%U)M9L:U(,W%929H123Q
M:8<6`L@@1DFR*X4<K*D23`RI@)BL7-9\>%D-OG7R4BZBUU;`W=1#1-Y:2KU:
M=(%+04?>#RJVXG4A6A6@+<BIG1R&:$8'*_,J#`P.15@UEWH\*'_X3KG_`&A8
MO^_'V</V?[2[8?ZPV/S#1@,!@,#_TO?Q@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M1ZQV%&N-4'2S=5R5=QT`$2.4@E'HSJ<X1/\`((<A.3+$529HA_K18>*G?[Y'
M]&:UY3:#UHL/%3O]\C^C&O)M!ZT6'BIW^^1_1C7DV@]:+#Q4[_?(_HQKR;0>
MM%AXJ=_OD?T8UY-H/6BP\5._WR/Z,:\FT'K18>*G?[Y']&->3:#UHL/%3O\`
M?(_HQKR;0>M%AXJ=_OD?T8UY-H/6BP\5._WR/Z,:\FT'K18>*G?[Y']&->3:
M#UHL/%3O]\C^C&O)M!ZT6'BIW^^1_1C7DV@]:+#Q4[_?(_HQKR;0>M%AXJ=_
MOD?T8UY-H/6BP\5._P!\C^C&O)M!ZT6'BIW^^1_1C7DV@]:+#Q4[_?(_HQKR
M;0>M%AXJ=_OD?T8UY-H/6BP\5._WR/Z,:\FT'K18>*G?[Y']&->3:#UHL/%3
MO]\C^C&O)M!ZT6'BIW^^1_1C7DV@]:+#Q4[_`'R/Z,:\FT'K18>*G?[Y']&-
M>3:#UHL/%3O]\C^C&O)M!ZT6'BIW^^1_1C7DV@]:+#Q4[_?(_HQKR;0>M%AX
MJ=_OD?T8UY-H/6BP\5._WR/Z,:\FT-/.-'9]53UU6G<_)Q=48I75JV3?6*8C
MHMFX=N8*=53:(N7J[=$SDR+10X$`PF$I#"`<A1S6$:S-99SFL4B'2A)TKAID
MX2RP!MQ0K1C;(>+@)L&NR*287<1%6G8EN*P60>).V#EL\D=GR1%B+HJE%(K<
M2`15$JH[ICY\LUR\>'PTI/#<P<Q+YCNJ+:R%8D+9*4I^38U!4<4IY?I>3FKT
MI"E79K-GI+6ZEE2N"2B<B1`@%ZJ#<Q0-BF-RN75:_59PH$;04:UV?56L)46T
MXVI=?/>M>RT)4PLL_6K//*LF4^SEPF3R<W5TEC%F#2:273*E2(F4$014QN;9
MV72*HO#'`)1(5W;-:KSFO*RJ];>0UZUZQ"O*S-DOEC?!$Q!&0UQ!K_\`V3*L
M4FQF1VK=BJF5),BJ*:I5,?Q)7.RCCM;<+,0Y34C=K5UBP28!`IP#/8-$95X*
MJ9_7I-Y6SQ3-N@@L66>U.-,^EE.=8GI&:::TB=,.8*F-RN=DI@8;AQK57^JL
M3MJLH-DD-;D82*FPJ:O*Q;S5$17H>G2;)543,Q>M4:RU47*L@LW='Z0BB1D5
M#)#?ZQ%*I_:M:++!570D3*/)5]OJ(GEI=>`=61!]=]:LVUN?5;8%MV;!2ED"
M(CX]R=^WM=S=*+)L56$<X;$1;&:`V3Z$TI'99G+JM:E"X>IQ]-OKKN>IV$K^
MU7&<B8U"]4^+C82,N=JA;3,PZ(M5@DW02SJM1Q7:B[E40ZK_`*L#;I%>>IC^
M9*Y1ZQ26FP7#[2K,TMK#=L(_F&YG:CE=_>=:H*2RCN+)#]',O(.,AI21C&K5
M,IT(T[CP4D[*5T#;K)$U2V-8FM2=IBFJ(N]7\-DI7ZI6)O?:4W#TJE/Z#7&[
M_8NL2C'5]_KFXZM.#<S"$9`A($J=X>$.Y2!-5VJDV,[%P#5$I)3'Q%2N7G^J
MME]<\,M@<6I[.;IC95_<`E22[]SLFAD>&1EJON*HJ-TEFS-N)TF,/O&:3:=-
MTQFJ:3)!,0:M$D`4Q\^?\_R2N7C^O^?Y#@L5#T+*S$)*P^^*_`G9VV9G9!1&
M]45Z[3@YRL[IC)&LP"L@1T@Q;/+!NJ0?*+NTWK@I.1),Z8)MA04Q[$3E2FO^
M>/\`\70E"X6D(L8-ILZIM8155XJ^ACWRBR<7*%&_VC9T`VD6,XE*(+LZA<[>
M\<L4@`J:Y!(@_!Z@7HQ4QN5SLO=?AN'>NPUA@V^Y(%\UL:E:?KK26Q:4LYC)
M^HO?"-?L4$=`C9&)>Q+QLR,T:)D\$L21C5)JT02(=-2_UN3M-/ZL=V<_#50F
MEWOMYX@PL"-O40CKLU83-*FIO9+-_(L6D/3WE;HE:6L%D=+H%1A4&D(V:KNX
MDB;54BW-45/)UBLSD1M-(C%W$<#7'UHFUA2^'FPL=IZ>VQ9'%B<42O;LUC9M
M<M=C"FL^G'C&D3\HW4@):>CXK_3K12CE"4Z(#&(W.4B@DY9^<JTEUQBF/N)=
ML^84P&`P&!__T_?Q@,!@,!@,!@,!@,!@,!@,!@,!@,#3'C2VE<=8577:E2MS
MNCA:;ZM!S=BCI2B0#]G'-J=:)U`J,]L;6NXZRQ2<R42@BHFK7%CK@H`$>-3@
M4CDL15F:T.57M#ISQ=T=\N[:1#E9\HLS<J/%5X8%5'2CB.CH>/7.X.<3B=!H
MU1,(\I$4RB!"ZQ]L9>F+LVP8#`8#`8#`@,KLRGPEUAM>R3N61M=@C'LU$,DJ
MK;'C%U$1;N-82TF,^RA'%>;,8=]-L47BJKM,C11^U*L)!<H`H6BXO[W3HR2@
MHA]8HQ&0LTBZB81#K`*E>R;*)\.N&/6$04;-G!8@07*58Z8J$.3F<X3E`117
M3MIKM9AIVPSLPQCH:LMUG4\^66`R<6F@T1?'*Y31Z18K@S5PD=-$"BJJ"I`(
M4PG*`ASM;!!O6K=ZVEF!VSH6!$%#.4DA.K*(L7$<W,FJ8BJ;IZA)MC)I&*"A
M@73Y"_KEY0JSR,>F8Y%'[(ATWJ$<H0[I`IB2#E)!=LP.43@)7KA!RF<B0_KG
M(H40`0,'*1^%DXTYVZ9)!B<[M99NT(5VW,=TNV!T+A!N4%!%99`&2PG*7E,4
M$3\H!S3<@8@E^([2,`K9DIS8<-#FI[B5:SXR:4DQ2;*P+29>SIFBSEBDC,-X
M5&O/2O%F1G"395N9)0Q5>0@JPM)LGE=O]0M3&3D(>93Z.#?FBI]I*M7]=F*[
M*%CF<P$;9(&PM8N;KS]2&D6STB+UN@HHR<HN"@**J9S!50USJU@<332'FV+Q
MS79PU;F42G,BHRFRMF+SJ`@X(ETYSMY)`Q3I<],XJ<A3"8!``YRVNN*3,+7T
MII@M,6*"F[/!,D%RKGE:_7'E<CYR69*(\]!9E'/;=&)J&`W_`%GB?)R@(\@4
MK>\TMU*NX)M;:VXF6,3!3SR+1FXY1\VA+0_?Q5;EEFQ'(JIQT])Q;ENT6$.8
MX61.0@F,')@7SPG&\C@WA!CS6CA-F[-UMOR-7:JB:235P/2<B+A154I2D-R&
M$Q@``Y1#"'A.-Z44/"#'IBJI-S(];0Z4JZRBZ**(I])SP555:JE*7DY3&3,`
M?*4>0+/.W2H5>(=6"QVBOP4&R0>.74M+3#!A'H(1ZI6[Y0[MRNFB`-'!@34^
M7E*H8"C^L(!A5FG-I:]K4LVA)RUQ4=(N6;*0!-514[=LTE57B$(K(OT4E&$4
M-C=1SE&+(Z51/*+MEDF@+*)*%**.2B[+I&R62KZFSA)1-!O&/7#5PPE(66;,
M)MJ9]!23F#G649,MHR>8E%=@Y.@5!ZB43H'4*`C@I1.\(8#`8#`8#`Z'/_\`
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M[CC_`#CC3/J?3#M!\.[C:_APV+W''^<<:9]3Z8=H/AW<;7\.&Q>XX_SCC3/J
M?3#M!\.[C:_APV+W''^<<:9]3Z8=H/AW<;7\.&Q>XX_SCC3/J?3#M!\.[C:_
MAPV+W''^<<:9]3Z8=H;4\%G#SNOA0XCJ%O7B)X?K[!ZFI@S06*WNZ\,TSHJD
MU"/X.,N;Z/BCR+P8^"D9!-1RN5$XLD!.Y#]9$!S6&,XY1.6/AC/+'/&<<<O+
MT,SM_I'%)?-#:6X;;97MM;5>;YT5LYC8=9RS*WLM*576NS:U>K5MJVV.O*2$
M;36T?5(1ZQ:$=+H.9-U($:(IJ@LH7.G[,L9QI$^7']>.495F*0]76<70P&`P
M&!__U/?Q@,!@,!@,!@,!@,!@,!@,!@,!@,#1/C6I6^+RQH[+552/+P$1.1LG
M.V*DW^XU#=%>,]EV4#8G-&1@-P</L04C77DI*KD7>622*L^(BV-".DSF4*6*
M+IQ0<1V@^%G5^M9/?&VH[7,+-.V->KTOLN1<A/3\A'UXSA<LB<K99X[FRM$^
ME>J&3#D6,/.$#&`!N,Q$^69B9]0T2^+!V<W\7.IO*,IYJS>V-TTRZR?%@[.;
M^+G4WE&4\U8VQN:9=9/BP=G-_%SJ;RC*>:L;8W-,NLGQ8.SF_BYU-Y1E/-6-
ML;FF763XL'9S?Q<ZF\HRGFK&V-S3+K)\6#LYOXN=3>493S5C;&YIEUD^+!V<
MW\7.IO*,IYJQMC<TRZRP1N'CG[,W<3LKJ6XT]9QA0U=LK5QV[99RZ15C=EV/
M55BD)!0KF*Y#.(]75;=)-,0Z-0CM3G?*4N3;&?R1CG'_`"P';=Z]F3<+1=K3
M*<?6M5W%P4FT$H]_#DE8F#BI]AMVON2QT9(-58Y"=BJGN%TPCWJ"+9(@Q,<J
MZ;/#%>E?2N-VJ9]7-/[Q[+.;)9RCQT:X`T\I:&R'A-J>=2+$W,F[O#CBR(2+
M(Q+M=FBN_P";\&3LASW#)-LS*HFX$\L>65QNE,^JSAM7LH@CK''EXX->"YFF
M]]29V)V[LTO9H]S>JYM2)+)BZG9"5A6\I49;;\J\B5XIA$*$*"1'(N52F<F5
MQNM,^J1S?$!V7LQ,O)E/CMU[%OU[RUMK*7C!E(ZRQ*`7#:=XD^K3,7X/1E+=
M(2&X9F.)+RC603;PHI)%9B_ZQ).%<;I3/JY*_P`0'9:0,U%V1/C?U<6;BY:B
MRC5>,BV\*RCRT2T:+F$6<#'LHH25YO9X/0L>QF"-3E1>+23]P5-(BQ&R=KC<
MIGU1Z][E[+^^R&RWK[CZH,438SO8;ATC#HO$Q*78<9:F*XS!GY'Z$N[JZEO>
M#%*MTHXB2*ZR:Z;@Z@+)RN-UB,XI_5DS8O&QP$W&(7<!QQ:#E[Q.;8T_?[!)
MV2+E0I36*U5*1;QE`PM*2:R3I:-*#)=P"#N4.]<.GBW_`-2;D!MU:[1=(QRZ
MRQ2QVOV6,7#!7V7'G0'<.[0K32>83[=25;3["GLX5M!1;A)JTBBL(HZC%T9V
M@TZ$ITG*:#;JB+<"*2N-UIGU9A)QI<`+!EKY&#[0C5L?(4O66X-5N)=[#2$X
M\5K^WY^B6!PYKPR;M3P=*TM:@,VT2O,C8SK-@Y9(9!R*CA6UCLFN75AE[M[L
MS7-.N]2:]H308WUB5B8J]EDFK>84?$8R]^XB+\1.%E7;]Q:X]O"R'$2Z!D1:
M5=*<ZO1(.5738K]H_E<>RTSZI@^X@.RU<.K<^;<<&KD5K=9[#:WK-[$M)6"5
MD[7;^*6PS*\M".H<&TZX+&\5,BV:J+CRI.8*+<J@N1)5LK:XW2F?647HN\NS
M1C):N3ENXY-5*.*7L??5GKS2M/9A-]+06V+'MQ:#7OEO?Q"4U;[M6(>]QKZ-
MD7"73P$LS=%:++$<F7&5QNM,NKE?;C[+IZS>-B<=6IXU63AYF)E%HF".Q:NF
MKG75=US"1B5?(!JLRK[)*G1<T]038@\<SS=99H[CFCQXR65QN4SZLS[.XVNS
MSOKIZ6)X[]/UF"M,UJV:O\",1)R9)AQJF;93<&M6)!-S%NJHN\4BV23HJH23
M4Z,>B4B*0J.CN;MC=(QRC_E+]0<?_9T:Q2ZS)<<.K;5.C0]<:U*\33?0,0UJ
M6K&]A2J[9C#E;RSDC]=S:Y!R^<KO7!G"[CD("*":2)$98Q^4G'*?^6:_BP=G
M-_%SJ;RC*>:LNV-S3+K)\6#LYOXN=3>493S5C;&YIEUD^+!V<W\7.IO*,IYJ
MQMC<TRZR?%@[.;^+G4WE&4\U8VQN:9=9/BP=G-_%SJ;RC*>:L;8W-,NLGQ8.
MSF_BYU-Y1E/-6-L;FF763XL'9S?Q<ZF\HRGFK&V-S3+K+K"XN.U2U3MRYZ;]
M3FK]G;(UUHS>,IL"5V9&A5H:-O;`-*;MU"]3UI`6&>C9ZP-&TEL]%TD[=)QZ
M3Q-FJ5`#@9-0UBM8RB/"3$1$XSE$3,-R=7[-IFXZ%6ME:_E@F:E:V(OHMZ**
MK5P0R+A9D_8/V3@I'#"4BI%LJU=-U"@H@X1.0P<I<ZQ,3%8<IB8FD^T^RH8#
M`8#`8#`8#`8#`8#`8&YW9+0<+$\&=><Q4/%QCB4VSQ'+2:\?'M&2TBJTXA]H
MLFJKY5LBF=VHV9HD23,H)A(D0"AR%``SRY>Y>FW\.RW(&`P&`P/_U??Q@,!@
M,!@,!@,!@,!@,!@,!@,!@,#KZX[[#LN%CM>I5Y:H4^DN[`H64VD_W_:=$VV"
ML24/.OHRLQEBCM/;)K,2SMQX]%@DI("Y\*O71(XC--15)SA8=47;><)N[N,[
M3O`MI6C3K"0V=,V[9-T6DMK*%I[A..8T)O,*QEA^K]/8IHV"'CWZ3-420S#K
M"Z!E#MVYC"D52OA<<HQK,N@#^7-[0'QSP\^T:S?A[C26OKCR?RYO:`^.>'GV
MC6;\/<:2?7'D_ES>T!\<\//M&LWX>XTD^N/)_+F]H#XYX>?:-9OP]QI)]<>3
M^7-[0'QSP\^T:S?A[C23ZX\G\N;V@/CGAY]HUF_#W&DGUQY/Y<WM`?'/#S[1
MK-^'N-)/KCR?RYO:`^.>'GVC6;\/<:2?7'D_ES>T!\<\//M&LWX>XTD^N/)_
M+F]H#XYX>?:-9OP]QI)]<>3^7-[0'QSP\^T:S?A[C23ZX\G\N;V@/CGAY]HU
MF_#W&DGUQY/Y<WM`?'/#S[1K-^'N-)/KCR?RYO:`^.>'GVC6;\/<:2?7'D_E
MS>T!\<\//M&LWX>XTD^N/)_+F]H#XYX>?:-9OP]QI)]<>3^7-[0'QSP\^T:S
M?A[C23ZX\G\N;V@/CGAY]HUF_#W&DGUQY/Y<WM`?'/#S[1K-^'N-)/KCR?RY
MO:`^.>'GVC6;\/<:2?7'D_ES>T!\<\//M&LWX>XTD^N/)_+F]H#XYX>?:-9O
MP]QI)]<>3^7-[0'QSP\^T:S?A[C23ZX\G\N;V@/CGAY]HUF_#W&DGUQY/Y<W
MM`?'/#S[1K-^'N-)/KCR?RYO:`^.>'GVC6;\/<:2?7'D_ES>T!\<\//M&LWX
M>XTD^N/)_+F]H#XYX>?:-9OP]QI)]<>3^7-[0'QSP\^T:S?A[C23ZX\G\N;V
M@/CGAY]HUF_#W&DGUQY7GU*;^TX^C=(7SA^W*GLRKM656CH*B:KO5]B+_P""
MT48QA,ZRG:E7Y.'M,).=$4R0IK%4:G,*3HB*B9P#O&<1C%?$O/EA.64SC/B7
MHQX"^SHXC]6<.5>C]AQE6JEQM]BN&R)FENK`+EW2C7J>=S;*KR"\<P=QZDS&
M1JR/A#H%542R!UP(<Y0`PS'.(B:W,L)F8I/BC<KW-]M_2:AY9?>:,OTQ9^>7
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MBJ+90RJ(G;\3.W&I^8<Z:1A+TK<W)\@?)R9QF:S5V]>&_N0,!@,!@?_6]_&`
MP&`P&`P&`P&`P&`P&`P&`P&`P.O'M`),JE6JL-(4E*PT^.=N['?;@ZEM%L8O
M7K%VD:KU@TD;<^^=&(0[NXS<JHSCY%!TX(FNW.GS3+&33,6/_:P[V8JQ>X.S
MYC%P."\=`[G8K`K(,Y90%6FGX!NH"DI'1\1'R1P.F/*X0:-45A_7(DF40(6X
M^X3+U+.>='(P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P,BZQ_^
M_._^R''_`,ZPS.7IK'VSIF&S`8#`8#`8#`8#`8#`8#`8'7#P^[">:D[/S:6U
MHZ.;2\AK)_QV;"81+U55!G)O*7OSB`LC6.=K(<JZ+9ZO&E34,3]<I#"(?+A9
M]LF;\XR(735]A-71%-?7>[3LCK-BU33E6\/7FRM[W-JC5K^+E9\[5^A$6&,B
M=KM)INU7(7K39/\`7,@11)4XB*_PL!>T`UBM=G]*8U&[R:D39)>+E;`Q2A/J
M\WKD99=#U=O>6+M[+LE[!7I1[Q"0QD/!R3M51-L[,0#E(B9<4E;VW:&ZW=A&
MG0U[L8R4AK*3W2*O.I)^@U='1.IK'X8230MRRTK:G-<V\Q7)6617,^*S=1,&
MHE78JNQ25X'COIYV,,]8ZKVK-+3U3862,AH%G59>QOWE@KFY;14:]&5YM9QE
MY>0L4;H:>`%&J2J+=4[0IS<@R!HT49:X;.(`O$3`W:TLJVW@8"OW1*LUYXA8
M&\Z:P1ZM-J-K+*.DT63(\0[#ZT`D=J<#'2$G(8W.`P`)BC__U_?Q@,!@,!@,
M!@,!@,!@,!@,!@,!@,#'=AU30[5;H&]3D,X=V6MMSMHQTC.V&/8J$Z"6;LE)
MB"C95I`6-W`EGWYHI>1:NEX=5\Y58G;J+JG.&F?$-5FD-O[@/J55BS(1->9;
MXA86*:=.X!C#PVJ85@P:)F6.LX43:,VY"`8YC'$"\IA$>4<N/N"?,2SI]6+%
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MLCW*K\W%8N4FR=:^AI6/FG2SZ/=M$C1:R15%T3ID,H9VR.!`,8``3"4@CR?]
M`9G*8HN,>68LPV8#`8#`8#`8#`8#`8#`8#`TAX)#0I.%!8UD\'#7B[/XN33P
M3!6YX@84O$]NX93PH1V!FAX[J(*=."H"F*7.YWR<N%GVPCISBVX:K^TUXRKF
MA*JQ5V-3KE&0]-J,-2Y^RFD:[8C60NL$(:.AHV#<C(T2<=W1RD9^BBS0,X(=
M-1T8_+%I-V16G&3P8MF"L]&1\0V9V-]*.*K(FI=?KB.T7SJ2/8;0\JSV=5A4
M'[A-6NH2[Q2049'=J)HF2%P\3%).I26UC+5VG;/+4O:#6C5QU*1<9/RE/E3P
MAV!69-CRM(N4[.^`7"#1HG9I>8H<,[%^Z:>%6JS40(JD*K@JA%<V:::MSQW`
M,VVLK/(0L)+5I]"MD:K-/(FN2ZR"$Y`.XU(KE=A"2:[9(CMJ<A$%CIE!0HB4
M.10JFL17H"`*N2!@X>$(Y!B5R2(C&4:5P6+C6D-&%7*S01!4(Z(CT&B`&Y>A
M;()I$Y"$*4`__]#W\8#`8#`8#`8#`8#`8#`8#`8#`8#`8&FVZ_\`FZX)/_4E
M_P"645A8]2W)PA@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@>9?6?%?VE5;UYL/4FJ^RL:<1FB1V_Q4UN(V$_WS
M3:RQV-6Y[B#VT$^F]JLHU4=,F@NI)W'J)*B/2D1$W_5.&3S9TF,>WE?+#Q)]
MIU;9*8F;/V#%+GY6P&2/-2$MQ!ZR?.I)1!M`LDEG2SB,.91P5E5XY#I/^N*+
M%%,1YB90!YLE,>SA7XB^TT<)]&?L%:60"F?G1,VXA=:LUF:DG*-YM^M'+M(Y
M%>-<.)9HDX%1N9(X*D`P"')CS8ICV9`?\6_:)[<<4_4/%'P(O^";A\V'>J%1
M=C;QA-\5NQNHJMV"T142I24"UU%H_K#?8'3EA3RA%$@8I/!Y#%$Q1#6-:^F<
MHBGB6^'%GP]Z`TSPW7+:6L:+1M)[&T35'5PT[?*#6XRLV9E=H-LF%8J:LA#(
M,W]GCMC2B:$&_CWQW:,DG(#TI#J\PY;$S,Q$^F)B*5=BD8NZ=1L>Y?-NIOG#
M%HN\9\HCU5TLW34<-N4>41Z!8PE__3,M/__1]_&`P&`P-5ME;6O>O]HW%NG7
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MU.)*O4S8\_8:K.S$0XUK%>J5ZL[:QHN)R<63;/GZG@UD5@[<"D.SG*R8#`8#
M`8#`8#`8&FVZ_P#FZX)/_4E_Y916%CU+<G"&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!IMP#_`/+7&_\`C)Q4
M_P#NIW3A9]MR<(8$9N=,JFQ*K/4>\0$7::C9XY>)GZ_,M4WD;)Q[D`!1!P@H
M'])3`!TSE$JB2A2G(8IRE,#T-<JUP7::@)NLR\B^VK?V-$EFL[KRH[1W!L38
ME(H4Q'G6-%2E>JUHL$A&+2,(1;F1[B0*^7CRE+U8Z0@`Y=I2C;/(K__2]_&`
MP&`P.D;:_''VM%2VELJJZX[)?UCZ\K-_N5?H>P_>.I4']?:9#6*1C:O<_`CI
MH9U#_6B#;(/NJJ"*C?I^C,/*4<GFS<1CV0#X@?;-_DQ_XHJ'WGBLV-<>Q\0/
MMF_R8_\`%%0^\\5FQKCV4K/CV[8^.:H,8_L6&S!DV(";9FSXF]>M6K=,!$03
M0;H,"))$`1_H*`!CS8ICV57Q`^V;_)C_`,45#[SQ6;&N/8^('VS?Y,?^**A]
MYXK-C7'L?$#[9O\`)C_Q14/O/%9L:X]CX@?;-_DQ_P"**A]YXK-C7'L?$#[9
MO\F/_%%0^\\5FQKCV/B!]LW^3'_BBH?>>*S8UQ['Q`^V;_)C_P`45#[SQ6;&
MN/8^('VS?Y,?^**A]YXK-C7'L?$#[9O\F/\`Q14/O/%9L:X]CX@?;-_DQ_XH
MJ'WGBLV-<>Q\0/MF_P`F/_%%0^\\5FQKCV7/1W$EQS[QXX^%R*XL^!?W3*[!
M0'$%(5*Q>MNN['^MLTYH<8V?0O4H5!)6-ZDQ`%^E.(E/R\T/EP3$1$TEWRY6
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`TVX!_P#EKC?_`!DXJ?\`W4[IPL^VY.$,!@,!@?_3]_&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&!IMNO_`)NN"3_U)?\`EE%86/4MR<(8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8&J/%O:[+4:76GM8G).!=N;05JX<Q;M
M9FLLV\$R*O0*'1,4QD^E3*;D'Y.4`SI^N(F9K#&<S$126@/KKVW]XUO\N/O[
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M8YSB)C"=50QA_P"D1'//E[EZ+.PS(&`P&`P/_]3W\8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8&FVZ_\`FZX)/_4E_P"645A8]2W)PA@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@:8\;/\`N#5/_P"7E_[EE,Z_J]RY_L]1_+K2SLY-
M<W/$Q2F]^D]=A"6E68B+.TJSMXBE7WD?UUR^IK$RH(1M@?S[-,#WAH9`KQBT
M4?$2<"U*MT"G)G:*T:UFE4R]>>K19GD"V90[-%N+AVNG7[,H6-,-FDJ6@PEP
M)#&/#S3^W0[N,:L'0(OGCYNH@@DHH02A:PFLV6.$XC]53CRP-D9Q9!&'E(6,
MC9!2+E56-M5GZEKRV1:556;,5@F)ATELN.:DBDN66,Y$0!L)1*89M"SC,47>
M=W938>.3F&A9&QPZ=2?WZ:DH,8<J%9I<8J9)_89U&;F(5ZDBV,@Y`S5!)P_Y
M[)PF#?I$Q(-K":RH(7?50DFTE(2T=8*?$Q]?V!;$I:RIP0LY.L:OG4J_=YMB
ME79^P2"32%=NVQS$=(-EU$728D3,;I"DE8-9?@\0NLD[,XK3F8<,EFT:Y>KN
M'\9)L3MWK",M=@D(5[%.V:,Y&R36K4UY*@#ALD1=@*2J)E`71Y[:#6:57Y/<
M-(>Q;.9AGCZ=C'E]9:W*]CHUTDV)9G<Y]7'"17$J2,0>,XB7*=!XJU,OT*J2
MB?(90AB!:P4EQ26Z*)&7%C0E5YYQ:7K]TP/&,:G9G:S'J\)*3Z3]V5**$XP\
MDSAG)&;Q$%F[M=!1-(YA26Z-6*T-9I7\*-'?VH5S<PER;E$&:SLPKQ4\V334
M;EG3*PZJKB*231M!?JO)@$080E3&CG)0;B9!4"*Q<UFS\6X@-0-BOE'5S;,T
MHME*/I9P\BYYHVB2PC2TO9=E+.7,4DWBYJ-;TB8Z:/<&3?)GC')!1`Z1RA-H
MN:S96'W?K`CA-F:R*]?<2B4(RC"U^S'EI27.ZE&+B/AXHD,:1F744_@WK>0*
MU26&,<,UTG?0J)'*6U@UFRUM=[5:4J=+MT!"6^=;WNCR>QX6'0BF4-84Z;")
M0*DO,O(RV2M=Y$V2EH8$`B*BZKGK1%&Y5D1Z3)6/!K-9B?PYZ/NZL7U[')14
M5/LXJ?DKW$U2RR7U=\!VQYKNPOJ[/$A!C+%)RI074BW#IIUMHU,X9('5``$H
MEQ$U)QF&9,TC>+LIO^2VH?\`BKQ+?^Y#:N>;+W/^?EZ?Q'\.QG,A@,!@,#__
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M1UWK2A2>SY!*#83^T&E4KYXV'F9%1]8'%(O-G%DHFR+(BW($'4WJW2J`FERH
M\SG<\Y"FWA$1/\LY5F/X=6_OG\/_`-J9/^Z]A\WYU<V.9W>W!_98>?@9IW*/
M(JSV'ZUSC4L;?&HO9_JK-EX0!RS,W=-!!LP2+T:!TT0YG+S.41$92%K,(PSV
M+P/,(QQ#,PG6\6[$RCUDF?:8(/G/UUE-BMW[\HR(B^E(ZZS3E^R=JB=RQ45Y
MK<Z292D+-8L;3=5*;2X*%G;AZJM8%7+A>&>B=53:2A4):OL:C&PUA8(GD!1C
M+2P9T.)(25;E2DO]3*85Q,=03M8L;3=5S^YN$2>KK*M!8;7"LXV%>U]BX@FU
MV9N_!,BNU=2#&8*LBZ87!E).6A3NVTVA)-7@G5ZPFJ"RP'M((RF)JMDIM7A"
M<U"]5.)L5EB/KQ3KW3%)-=GL"QKP,?L,S]U8AKS6R+2;2&1>RKX':S=J5N@N
MHW0*<HD01!.:Q28-IK$OE_L;@AE#/UI%2QO'\H"@2$TNZVR>Q.S*Q\M#JJK6
M493P^9PK!3CJ-,IUGI#1BO4Q'JI2I%:PNV5UT#;_``:%9RK%.0M"*<U9(.VO
MW#=SM9O)#/UH6XP#QG,(22<M&)116B9$6[99%L5,@$Z/F?JY:0FTK(I>^!A5
MU./E2V!1[9?#`3CL[G;)G,@2?;7IK,(JKC*](1L^3V5-F.D02I@J]Z4I041;
MG2FL+MEX\N1'8'`N@S*P3;28MB3#FP$!5'9:ZQ)QVA>D%I8CI=ZHZ*_*&R9I
M1-4#\Y%=V59,2JH-CHM8L;976L;IP5N).SN9*7L\I%6>)7BG-?=%V7X/(:58
MWJ/LTLX,1\5:4G[&AL64%:0<BH^24<G426(H/.!K!M/A)Y+;/!9+DFTGZTXJ
MA8GKE_+M4R;,:M'"S^;DK+)I)-&CQ!LQ83%BEG#Y\U;D2;/7AP67344(0Q;K
M";3=SO\`<_"$\J$/26\_;X:&KD"]K%>5@U-D1TM$5Z01;-W$&C+IK&?/8,R3
M%L7J#L[EB)6J!11$J*12J12AM-:J^H[XX2*2[3?P4S8"/DU+*X25>LKU(-6K
MNY306.V.8F%=`I7Z\:?G>5RNG&M&:`&,)$R$2Y"`B(@F9E(;)QPZK1\$0&N8
MVS;2V;;Y,L!0-<P\6Z@WEIG#-G#]9-Q/3K9M#5Z$B8IDX?2,@Y-T3-DW44YI
MS`5,\F:?R8XUK9N%P#\6VP>%V+U5PT<3VH:W4J;L;9]KBJ-N_6^RWE_KT+L?
M=VS++<JIKG:%>F:%19>M>%9NTA"L)UB,G&+R(H)N`:`X(?..6.4>9CP[XSCE
MXB?+T$9A3`8#`8'_UO?Q@,!@,!@,!@,!@,!@,!@,!@,!@,#K4[1FS0+6O:VK
MD[K6#MB(V^,EVMLVSIVC["X>:<^F70:^:O-F7'8$@C%:U(U+;5'BDFQ924BA
M&MG/(@*)U2G+#GX@4>K;JX`FX!"!T$3NU'DK14BUP.BU'!$Y*^5!!LB6$_5_
MU0")IE!#F\A2A\@7'W"9>I9KSHY&`P&`P&`P&`P-3;CQ41>L[]9*SLF#CJ]5
MH!S'-D;3$S-FMDO)J35*V/L&+30IT1KWK!7!:QJR55=)E>*BFL5)%`71U0`)
M5JE?2M+QD:&!.<%S/V%@XK#>:?V./?46Y(2,)$5:4OT%<I^09^!#*IUZFSVK
M;"QD7Y><U3=19B)G4Z=H+BU@UE'77&EKIK6+W+&CY(9ZD7S;>N3P71218N4M
MFJ;5;HQQ7$;D,*->0M<U2ZF>S$BA.=VA$J]()3D(*@RL&LK?=.-.M4?8^S==
MR-/D7;K7=AHM=(]93#8%)=Q<)/APC'#E1D\8M",F\:?B7B3I=`N^.N6.>],#
M0>J=:5-:Q$IQ6N)R#7K)YV^5R1J#KP#HJS-F$&J\OR<G&<1]H<4G5B$:,1#,
M9Q66?6]HI'/D58U%)FJ7I065:_ZP"I2RUUOC*U!/RL['J/)&/18W*+J$"Y&+
MF'2TZK(MN&I@NJ\C2123VM2,3>N*&"@W<>[+UINX1<**`4J2Q458-99"J6_:
M7?'&IE:<#V8@=P05YL%;G3)&8$19T9>);/"O8YX1-^@N\6E>:5,Y2*HBD8JI
M"GY2A:I3VQVSXTM*R+JWBQ=3[JOT2H*6ZUVU&)`T##@C;W]-6@')^L@^+/IO
MF(.!2Z'HQ:KI'!01$Q2JPNLI!'\6VD)=V$?#3T[,R#IXYCX"/B*5<)%]<G3#
MPBK*$I#-I"JN+:G#L8M9V[48E63;M2BH<P`4X%5A*2XXCB]T18%81."L\G+)
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M9$U)BC8+"&`P&`P&`P&!U1]K+K^2VE0^%2B1#UC'R,[Q9%ZN\DA<`R1\&<*_
M%-,J]-U5%PO_`*1"/,4O-(/ZY@Y>0.40L?[8_P`__)7_`)S_`(_^PZM?A_[)
M^V='_K3WF?.KD?#_`-D_;.C_`-:>\SX#X?\`LG[9T?\`K3WF?`?#_P!D_;.C
M_P!:>\SX#X?^R?MG1_ZT]YGP'P_]D_;.C_UI[S/@/A_[)^V='_K3WF?`?#_V
M3]LZ/_6GO,^`^'_LG[9T?^M/>9\!\/\`V3]LZ/\`UI[S/@/A_P"R?MG1_P"M
M/>9\!\/_`&3]LZ/_`%I[S/@/A_[)^V='_K3WF?`?#_V3]LZ/_6GO,^!1LN$G
M>&B;[0=]5-E6=KOM9OIP9C7,'(JQMDLM2M4$[K]A"I.K"SCH4+7$(N$WK1)=
MRV*[!!1J"I17^7.5?$Q'IK&8_MC,TJ[`:-0]R<;UEU91ZMH7;^M--M-HZPV3
MM_;VXZV373&-K.HMCUS8OU+UXP=/W<[:[_:IZH(1Y'+1N,=$HJ*.CN14(FF;
MGGG6-:.F&&L[3,/35G)LP&`P&!__U_?Q@,!@,!@,!@,!@,!@,!@,!@,!@,#2
MWB_M&X*%&U6T:RO[NLM'\HG7)2/=0T:>K-3]1FYCPS*V%MIG=EI:2DF+)*-C
M6:461F]?*HH"NDX62*L6/X:B=H+Q`UKA\M7`?M?8T)=7$?S]N1\A$1L37PMK
M:4G=4PP`C)12LU#031TU7*8KI-!ST:2@"5(#%`,UA%<H9R\8RUY^,%PT_8?>
M?]VJ#^)N==9<MH/C!<-/V'WG_=J@_B;C63:#XP7#3]A]Y_W:H/XFXUDV@^,%
MPT_8?>?]VJ#^)N-9-H/C!<-/V'WG_=J@_B;C63:#XP7#3]A]Y_W:H/XFXUDV
M@^,%PT_8?>?]VJ#^)N-9-H/C!<-/V'WG_=J@_B;C63:#XP7#3]A]Y_W:H/XF
MXUDVAC2T]H_P-7=\O)6S2>VIU\Z<,G;AR^JM&.JJYC:]::HQ6,)-I$#GMJ[=
MI5H7Y/\`]I\H'](@(-#=9WO:`<`,@Y?/7F@]IKNY-=ZO).!JE)*K(%E+%?K5
M,,WQD]JD%W%3L[M*Q*R#-3G-'Y)ARBX3414Z/&AN&[0#@!.XFG)M![3%2QNK
M)(3A/JI20;2<K;Y:0F[-..F8;5!H>P3+Z5<%6D.8#T6RHM@5!MR)`T-W),=H
M-P%6"P3]IG=';@EYRS2,-+S#R2@:F\35E8!6B+1TDS8K[:/'Q#[I-85P7"K-
M)`[P(-D#@50;)`5H;K-+<>/`E)48VO6NL.(2"@U;%JNQ.7L0TJ0V=VKINYU>
M[46-7MLKM.4L81D2]J35H@4CDBS%B)R,56JG1JIM%W5H<>O9\@,68G#_`+32
M&&FH>Q1XHU>F(]',P#?7R$.]7Z+:Y.O&8'U/67!"+]*GUV!8NA*+ELDJ5H;K
MDEVB/`T@UKK5OJ??S<*M(V"5BG;88UO*J/;:]+(VM2;FD=TDE[.E9WA"GD4I
M-=VB^YH`L4Y0``:)NC[7CE[/)DR/'M-![A;MU6K-FN*457B.G*$=(0,G&@[?
MAN+KSM2+=UMIU5110RC9,%4DC%2<N2*M%W5Y./?L_$F3*/;Z#VNT0C$7B$6H
MQK=/8O8HDB\0?/S14FSVRA(QBSU9N!55$%4U%$3'2,(I**$,T3=05+CMX":<
M_?2<?J#=[U\YMSZY1ZDG7M?JH5F0>3[*RD95*.:;(91=<BFDE$L>1-L@0[A.
M.9E='7ZHW%-HNZK<<>79\NXHL`[T%MES70%Z"E;<5ZI+5IR@\A6M<(P?5Y3;
M9H60BHB`8HLHMFN@HUAVJ1$V*;<A0#&B;KY:>T:X([D,$I8-6\0#IW7`KY8R
M2;!$1LLH6IR:$Y64YN5C-S-)"T(04\V(_;)2BCQ)-]RN`+TQC'%I)O1<J'VE
M_!5K-J#2D:DW7"IEB8:O)JC"5&3>H5RME>$K59;2,QMB0D&U8K2<@X+&QJ:I
M6,>1=0K=),#F`6DF]60/C!<-/V'WG_=J@_B;C63:#XP7#3]A]Y_W:H/XFXUD
MV@^,%PT_8?>?]VJ#^)N-9-H/C!<-/V'WG_=J@_B;C63:#XP7#3]A]Y_W:H/X
MFXUDV@^,%PT_8?>?]VJ#^)N-9-H/C!<-/V'WG_=J@_B;C63:'$OVQ/#&U06<
MN*7O%%NW24776/6Z`!$D42"HJH<?6;\A2$*(B/\`T!C63:'45O[M-=^\3-FU
MW>=>T;6%'U5K/8KW:6I*M>XRT2U^MR3_`%ML'5S&1V+/05L90E:"7J6RG[U&
M.C63T8]RHWZ5V\*D<BDB,IIE%&YG"*XS6OY=D'#GN^+XAM2UW9D?$KUQZ^6E
M86S55V[3?.JK;JY).8:Q02KY)%L1\BUD&ACMG'1)=9:*)+=&GTG,+TB:Q5RR
MBDT_#.65#`8#`8#`8#`8#`8#`8#`[;.%#_\`"=<_[0L7_?C[//\`L_VEWP_U
MAL?F&C`8#`8'_]#W\8#`8#`8#`8#`8#`8#`8#`8#`8#`ZZ>T'/8&D7I^2C;\
MWJ+1.W6!BUB6II:L62?LKRI2BK):&V>TXP>#.-JZ4/7F<HHO'K61565(?_1M
MUB-U286/R@W')P6Q7%YK#AP8S&R;)67.L!7EV\PY81%ND[(>>I+&$=*SKIK8
M%&"\B?HRN%'+5\[055$XE45(8JF;P\35C/U,.N7X,U9^_P`G?9_'^E>==N'+
M7D^#-6?O\G?9_'^E>-N#7D^#-6?O\G?9_'^E>-N#7D^#-6?O\G?9_'^E>-N#
M7D^#-6?O\G?9_'^E>-N#7D^#-6?O\G?9_'^E>-N#7D^#-6?O\G?9_'^E>-N#
M7D^#-6?O\G?9_'^E>-N#7D^#-6?O\G?9_'^E>-N#7D^#-6?O\G?9_'^E>-N#
M7D^#-6?O\G?9_'^E>-N#7D^#-6?O\G?9_'^E>-N#7D^#-6?O\G?9_'^E>-N#
M7D^#-6?O\G?9_'^E>-N#7D^#-6?O\G?9_'^E>-N#7D^#-6?O\G?9_'^E>-N#
M7D^#-6?O\G?9_'^E>-N#7D^#-6?O\G?9_'^E>-N#7D^#-6?O\G?9_'^E>-N#
M7D^#-6?O\G?9_'^E>-N#7D^#-6?O\G?9_'^E>-N#7D^#-6?O\G?9_'^E>-N#
M7D^#-6?O\G?9_'^E>-N#7D^#-6?O\G?9_'^E>-N#7D^#-6?O\G?9_'^E>-N#
M7D^#-6?O\G?9_'^E>-N#7D^#-6?O\G?9_'^E>-N#7D^#-6?O\G?9_'^E>-N#
M7D^#-6?O\G?9_'^E>-N#7E3/.Q;J;YHZ9.=\SIV[QNNU<$"@L"B=%PD9%4H&
M+:P$O.3.(<H?*&-N#6GFKK_7[)#CVIMF'5>LZ%3=TU&%3"/J&W%-E5.@,%JN
MT*W:PSR_56?=FL\1-,6ZB:3Y.);S*:JB9E$3F`W(&-YQBDQ5TTQRFNU'?_PD
M]EA&</>C:QK^T;0>6&\K.YJV;"FX.*11@']XMLFXFI\M>0?]$\2K\<LX*S8]
M,1-8[5N0ZI2J&.&9C]DQ'I<L(F??ALK[D56^W$_Y.COG9KZS9GYQ<]R*K?;B
M?\G1WSL?6;'SBY[D56^W$_Y.COG8^LV/G%SW(JM]N)_R='?.Q]9L?.+GN15;
M[<3_`).COG8^LV/G%SW(JM]N)_R='?.Q]9L?.+GN15;[<3_DZ.^=CZS8^<7/
M<BJWVXG_`"='?.Q]9L?.+GN15;[<3_DZ.^=CZS8^<7/<BJWVXG_)T=\['UFQ
M\XN>Y%5OMQ/^3H[YV/K-CYQ<]R*K?;B?\G1WSL?6;'SBY[D56^W$_P"3H[YV
M/K-CYQ<]R*K?;B?\G1WSL?6;'SB[9_65!::SI["H,9!S)MF"[]<CQVDDBNH+
M]XL\.4R:(BF`)F6$H<G](!G/*=IJW$4BB?Y%,!@,!@?_T??Q@,!@,!@,!@,!
M@,!@,!@,!@,!@,#3CBJ@&6S&:5$/98FIK4:,#<4NO;[7:M?U>:J#-G::],/T
M[AK^[TJYMT=<R"C.3ER=8+#]`Y9MWYDP?(N&Q89%>NU'^L-8OUC3!UGM9K[M
M4]AB&L!/F4<UY@L<TY`L?]1A)@QCB+EHC_HFRW.3)^J4,UA^6,D(S;!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@9%UC_]^=_]D./_`)UAF<O3
M6/MG3,-O"7NKC_XON)39MLV@CQ(;LU!4CV^R-M6:TTQL&=UC7*52H:>?QE<;
MV)"IO&@;"M;QFS*ZE74T9^W4=K'2012:II(EZX_KB8K+&7[)QFD1'AZ"^S?X
M_P#8NS>`[B"V]OLI+M?.#M[LR&M-H9IL*\?:U?H&J(';T'.2!FC0D#"VQ_7;
M`2/D^KH@V*[;"ZZ),JX(DYS&LS#<?VC&8_+<WW[=30D:5Q?VTS47[",N=CL!
M6D/:+5`$IE0A.(>R-KO3['#U8$[K6;Q6^&2S2M>.DW:N92*037(B4Z[=%>+1
M*E.-GA[:0UJGI:S3=>C:2[7:6=:STZSUP8T8VUW.D6-PB6:C&7A=I4[5KR:9
M2*C'K().(\Y"=(91$%124TJ'$SJ2\3YZS7I>67F">%'`-'5;FX]16%A7%OC9
M2T))O&2*RE6:6*BR<3U[F]`I)($2()@70,J*+&RXGZDQ@Z;9K\Q6I,/LN`3O
M-$(F,M:9,FNC*TUF[M^PDX.OJ0M!:PTCL&%1D!\(2#)F6135.[Z)-R9`41,O
M'EPW`1LNXL5O9-7SV`CF#MYK#8R*,G(6MM,/:RPAP^K)EIM[.L*O,N&R3,C@
MZB$.Y/R<TS87`I*^.^-#A_8/8J)>6B30G9I%T$=71K,ZI87,Q';@C=!R]72A
M4&2L@I9HG;<LC#*M2$-SUQ.=$RJ2:BA125#!\;6AIM@Z<-YR;<OV"L`T>0\1
M3[A-R9Y"?H$UM1%K%QK2`+,2Z337E<?RBCA)KU<Y&:Z")U7B"[9,4EDS5/$/
MJC=<A.Q^N+"XG#P)7JRCP\-,1L9+L8ZY6W7[Z5K,G),FK*RP[:WT:29&=,CK
M(<]`IN=S%4C')1FS`8#`8#`8#`8#`8'_TO?Q@,!@,!@,!@,!@,!@,!@,!@,!
M@,"*6FB4>\EB276FU2X$@)1"<@BVFO1%@+"S;4!!M,1)99F["-E&X&$".$>8
ML3E^0P8%)=:^_L#5BBP%N!VZZBBG3J&3#FG3`H<T2IJ<H\N:B:),58[]6UB_
M;CNZ5>]\NT,ZR>K:Q?MQW=*O>^-H-9/5M8OVX[NE7O?&T&LGJVL7[<=W2KWO
MC:#63U;6+]N.[I5[WQM!K)ZMK%^W'=TJ][XV@UD]6UB_;CNZ5>]\;0:R>K:Q
M?MQW=*O>^-H-9/5M8OVX[NE7O?&T&LGJVL7[<=W2KWOC:#63U;6+]N.[I5[W
MQM!K)ZMK%^W'=TJ][XV@UD]6UB_;CNZ5>]\;0:R>K:Q?MQW=*O>^-H-9/5M8
MOVX[NE7O?&T&LGJVL7[<=W2KWOC:#63U;6+]N.[I5[WQM!K)ZMK%^W'=TJ][
MXV@UD]6UB_;CNZ5>]\;0:R>K:Q?MQW=*O>^-H-9/5M8OVX[NE7O?&T&LGJVL
M7[<=W2KWOC:#63U;6+]N.[I5[WQM!K)ZMK%^W'=TJ][XV@UD]6UB_;CNZ5>]
M\;0:R>K:Q?MQW=*O>^-H-9/5M8OVX[NE7O?&T&LGJVL7[<=W2KWOC:#63U;6
M+]N.[I5[WQM!K)ZMK%^W'=TJ][XV@UE+J9496`E%WCXS04E&"K8O0+'4/TAW
M#54.4IDDP`O-1'Y>7^G),Q,+$49,S+3R2\;?`OP%:]XBKJRKG:.T_A7<668?
M7K8.DIG4QMZL-:3%PDEI>2D&<S6+A4RZ4KDTY76=I,;*#IHW.XZ1OT;4R:.:
MC/+&*1/@G&,J3./EW_\`!_PB<.>B^$]IHO5D@WVQJ78\79)VY7F3F8FSFW@X
MV;'`TM-NF)RM%;0<HTLL(9)FWZ@!&R,6@W02$2)%,.5;#7;1^IMCOY"4O%$@
M[+(2L&2M2+N226.J[@4ZUM"G$BU1373`6Q:QNJU,@```>AG'(<O*8HE(CEBX
M8M"6Q%RA8-90$@F\<VEV[`QI%L9RK=Y/8$Q<B+J,WS=15M:7VU;'X00,(HNT
M9IVBJ4R*ID\+64CJNF*%2[@YNM?BB,I,]94J4:W(A'D9P,*_M4M=K`WB5$6*
M4H/UHM4L+U\#IRY(*R"70E1`#@<E5J;\.VF&O@4B-%8@UK3LKBLQIY";6AJP
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M,(.7$:@9`5$;!<K%L&91!,#BDFD_NEMDI$Y2E``7=GY.0O(4")[@,!@,!@,!
M@,!@,#__T_?Q@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#R?\(;Z&AM03T;>5HZ&W97[=?G?%HWL
M*S5G:6N\W-FFG>S9W8`OC)/.9,RW3.F+MU_H%H<S<4#=6*F`=_UTUAR_9$[S
M;\.QWLND++[E/$:OKN6E:/K67WWOE]PGV*-J#^YLH+7#Z!JI%;-KZC,F;IQ8
M*>;>@6U_#,FC=1LZ:J$ZLF9N=,H\9I6:>G7S3&ONC/`[RXRF(P#>#TO&1]41
MC*L23>WB"W)L#8"L0[N;^`MVR(A.LU"H,+`VK-=32F&U1FPJUVE(XHAU<DBH
MFP-%\)E*;@XNW%R:UFL:]KO@9].P\4XN,UJ'9*4?78=[/:LCV%P<,5]B0Q;&
MUMU=L=EE5(Q!VS>4XT(1E+'565*=04AAL^_^-J1?05W6T[,U9[ZA+:X4U074
M^RK-78'9]KL?"@I1W-WM$?.QRERZK&SMR%1I!M49*MM&CXKQ%TN@*9XM(9LU
M7O?B3MFP-=5>[ZZJE10OYK[8):!7A)Z.M6LZ+KYRW;EDIP96X@I9U;[(6>(C
M8YRWCF"+-PW>.%$G)#$01J3$+;-[/XC*I47LI`U:[VS;2EGN+&XUNQ:UL\YK
MZ`:1L=LV4UXPUL:JM:>SFX&XSD7"1"4TG+2"L8PDTGD\1-5)8$!X8UV]Q-\:
MVKJ1N#9JFI:.XKNO(/;]CCX)QKS8`.`B:=L?<=1JSZ3N">Q4V3Z/3I-*@[8^
M<)1+4KZ,DS$1*S*JDZ3BTA(+AQ)\840I(M*=HD;HDVC=P/(2Q.=/[5J;2V)5
M_26R+IK=XWK3RRRDO4WQ]QTII4)*'F'#5S,H2S"2B'`ION@:5*0NC;=_&#$S
M,O"2^MHZ49)/KFDA8XO3FU7HP<9"<65@U\G<9:/^L[%A8X>0X?E8V?@Z[7I"
M6L$@9%TY7.W;`U(\'ADO0^U>*"X;&-#;AU5#TNE.Z<ZDFSR.K5E8O(BS16M^
M%FPJ,)&Q2-GEX:52L-RVW=6#=NBT;G9?4Y5`5WBB3A;!X;G80P&`P&`P&`P&
M!__4]_&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P-8ML\%/"%OBX-=@[HX9M';1O#-%HV3MEYUI4
M['/K-(\4^H,WTI)1:[N39LBI`5)%R95),G*4I0*(@)8F8]2V0CHZ/AX]A$1#
M!E%144R:QT9&1S5!C'QT>Q0(V9,&#)L1)LS9,VR14TDDRE(F0H%*```!A%;@
M,!@?/-*!A.!2@<Q2E,;D#G&*03"4HF_I$I1.(@'^3E'_`*<#ZP.)=!%RBLV<
MHI.&[A)1!=!=,BJ*Z*I!351624`Q%$E"&$IBF`0$!Y!P.7`8#`8#`8#`8#`8
M%D966N24S-5R.L$(_L-;+'FL4"RE6#J9@"R[;KD4::BT%U'T663:!TK<5R)]
M,G^L3G%^7`O>!__5]_&`P&`P.@S9O'/VS,5LO9$/J/LNJKL'5<+L&[0FM[X[
MVU!1CNZ4:&L\I%U6U.HY6Y-56#F?A&B#I1$R:8I'5$O-#DY,GFS41C,1.R$>
M_MV[GY1=-]M%>].<5FRZX]CW]NW<_*+IOMHKWISBLV-<>SB7X_.W7;(+.%^R
M-IB:+=)1990=SU\0(DD05%#B!;P(B!2%$?D#EQYL4Q["''YVZ[E!%PAV1M,4
M1<))K(J!N>O@!TE2`HF<`->`$`,0P#\H<N/-BF/9R^_MV[GY1=-]M%>].<5F
MQKCV/?V[=S\HNF^VBO>G.*S8UQ[*5[V@?;I1S91X][)"EH-D>9TBIMS0!BDZ
M10B1.4"7@QAYRAP#Y`_RX\V*81_TJO?V[=S\HNF^VBO>G.*S8UQ['O[=NY^4
M73?;17O3G%9L:X]CW]NW<_*+IOMHKWISBLV-<>RE==H'VZ3+J_6NR0I:/6W2
M+)OSMS0`]*Z7YW1(AS;P;D,?F#\H\@?)_3CS8IAV57O[=NY^473?;17O3G%9
ML:X]CW]NW<_*+IOMHKWISBLV-<>Q[^W;N?E%TWVT5[TYQ6;&N/92J]H'VZ2#
MEHS5[)"ED<ONGZHD.YH`3+=63!5?FB%X$H=&F("/*(?YL>;%,.RJ]_;MW/RB
MZ;[:*]Z<XK-C7'L>_MV[GY1=-]M%>].<5FQKCV/?V[=S\HNF^VBO>G.*S8UQ
M[*7X@?;I==\'?"0I?7>J]=Z#US0'.ZKTO0=-SOKQS.;TOZO)R\O^;'FQ3#UL
MJO?V[=S\HNF^VBO>G.*S8UQ['O[=NY^473?;17O3G%9L:X]CW]NW<_*+IOMH
MKWISBLV-<>RE2[0/MTEW+MFEV2%+.Y8]!UM(-S0`&1ZRF*J'.$;P!1Z1,!$.
M01_SX\V*8=E5[^W;N?E%TWVT5[TYQ6;&N/8]_;MW/RBZ;[:*]Z<XK-C7'L>_
MMV[GY1=-]M%>].<5FQKCV4K7M`^W2>]8ZKV2%+6ZHZ69..;N:`#HG2'-Z5$>
M=>"\IB<\/E#E#Y?Z<>;%,.RJ]_;MW/RBZ;[:*]Z<XK-C7'L>_MV[GY1=-]M%
M>].<5FQKCV/?V[=S\HNF^VBO>G.*S8UQ[*5EV@?;I2+9-XR[)"EKMEN?T:I=
MS0!2GZ-0Z1^0#W@I@YJA!#Y0_P`F/-BF$_\`2J]_;MW/RBZ;[:*]Z<XK-C7'
ML>_MV[GY1=-]M%>].<5FQKCV<2_'YVZ[9!9POV1M,31;I*++*#N>OB!$DB"H
MH<0+>!$0*0HC\@<N/-BF/80X_.W7<H(N$.R-IBB+A)-9%0-SU\`.DJ0%$S@!
MKP`@!B&`?E#EQYL4Q[.7W]NW<_*+IOMHKWISBLV-<>Q[^W;N?E%TWVT5[TYQ
M6;&N/92O>T#[=*.;*/'O9(4M!LCS.D5-N:`,4G2*$2)R@2\&,/.4.`?('^7'
MFQ3"/^E5[^W;N?E%TWVT5[TYQ6;&N/8]_;MW/RBZ;[:*]Z<XK-C7'L>_MV[G
MY1=-]M%>].<5FQKCV4KKM`^W29=7ZUV2%+1ZVZ19-^=N:`'I72_.Z)$.;>#<
MAC\P?E'D#Y/Z<>;%,.RJ]_;MW/RBZ;[:*]Z<XK-C7'L>_MV[GY1=-]M%>].<
M5FQKCV/?V[=S\HNF^VBO>G.*S8UQ[*57M`^W20<M&:O9(4LCE]T_5$AW-`"9
M;JR8*K\T0O`E#HTQ`1Y1#_-CS8IAV57O[=NY^473?;17O3G%9L:X]CW]NW<_
M*+IOMHKWISBLV-<>Q[^W;N?E%TWVT5[TYQ6;&N/92_$#[=+KO@[X2%+Z[U7K
MO0>N:`YW5>EZ#IN=]>.9S>E_5Y.7E_S8\V*8>ME5[^W;N?E%TWVT5[TYQ6;&
MN/8]_;MW/RBZ;[:*]Z<XK-C7'L>_MV[GY1=-]M%>].<5FQKCV4J7:!]NDNY=
MLTNR0I9W+'H.MI!N:``R/64Q50YPC>`*/2)@(AR"/^?'FQ3#LJO?V[=S\HNF
M^VBO>G.*S8UQ['O[=NY^473?;17O3G%9L:X]CW]NW<_*+IOMHKWISBLV-<>R
ME:]H'VZ3WK'5>R0I:W5'2S)QS=S0`=$Z0YO2HCSKP7E,3GA\H<H?+_3CS8IA
MV57O[=NY^473?;17O3G%9L:X]CW]NW<_*+IOMHKWISBLV-<>Q[^W;N?E%TWV
MT5[TYQ6;&N/92LNT#[=*1;)O&79(4M=LMS^C5+N:`*4_1J'2/R`>\%,'-4((
M?*'^3'FQ3"?^E5[^W;N?E%TWVT5[TYQ6;&N/8]_;MW/RBZ;[:*]Z<XK-C7'L
MXE^/SMUVR"SA?LC:8FBW24664'<]?$"))$%10X@6\"(@4A1'Y`Y<>;%,>SH)
M[8'B9X^W6R.'3B%W;PS*<!.\&D%:*OK_`&MJ;<X)7G8-*C'</.K0KP]5M+J=
M3BJ?*SI5D%A,DB4TLHD<%!.0"26L8C\36':7V1?:)]M)O92M1%UX9$>)'1Z_
M44E-_;$3)P_/&,0J9%`)./V(,.:K[01CVP](HWCH"1EG!Q`RKH.=SLL53*,8
M_/E__];W\8#`8%LF9J&KD6]G+#+1D%"QJ(N9&7F7[6+BV#<HE**[V0>JH-&J
M(&,`"90Y2\HA\N!B+2.Y]8;=;[`8:ME"3$3JV^O->R4DB_BGS&5E$H*!L[B5
M@E&$M(O5Z\HK9#-$'+M)H9VNR74;D59"V=.!2C.&`P(_9IFOPL6<]DE(V+8R
M2R,&@,G*,(DLC(RXBS80[)S(NF3=24E%U`2;I`H!U%#`!?EP(QJ>^1.QZ2QL
M</!66KMT)&P5I>MW)DTC;3"/JA/257=M)J.9R4JFR665B>L(E,L*AVBR1SE(
M8XD*/3(^`P(C<IBMQL81E8'C(JDTJ=G"0JLQ$0\G:)AJ@K*(0-?-,R<0T=S#
MHC$PIIBNF7D*)CF(F4QP%*OC7]VC-C4Z!N\*V?-(FQ-#O8]*0&-47.U*Y7;I
M.T7<-(S$))QSXJ'3LWK%V[8OFBB;ANLJBH10P3'`8&+-F[`IM*8HKSR@RLM&
MKP\^TJ<-)P2=K7CSV&+KJ]C:1$O-PHO(2`<395GIRG$02(8J9%5Q214%*LIX
M#`8&&KEM"K5K8-9K$E"621D0^KO6IV*3B3PE0#94^[I%,-8$74XQG'9+;98Q
M=D@:-820-#)&5>"U0Y%A%/RS+@,!@0-Q88IKL^)J:T3,%G)NAV&PQTZ!HXT`
MK%5:PUB-F8DQ2RHRR4PW>7!@L43,0;J(JCS5Q.0Z8"GY3S`8#`QM&6^%/M*S
M4)&'F&]A1K,-;'TJ9Q!O(=W$KKGB(TPH1T\_G()9=VDY2;!)L(\LB9B[,S,Y
M*T<&3%/RR3@,!@8NUK=X:W/-CQT=7;35Y&E;!D:U/L+:U8LG4E('AX2;2LL&
MDSEI47-3FF<LGU)T?H.L&15YJ?,*!C"E&4<!@4SUZSC6;N1D7;9A'L&R[U^_
M>KI-6;)FU2.NZ=NW2YTT&S9L@F8ZBAS%(0A1$1``P,2:%VK0-SZUC[UK)5RK
M3UYZZ0,>9\JP.]44J=QG:RZ>K(L9*4,R;S*T4+]H@Z.B_38ND0=MVKCI&R0I
M3PS)@,"+7F:0K5)N%C<P5CM#:`JU@FG%:IT6K.6ZQ(142[?*P55A4%$5YBQR
MR:`MV+4AR'<.E")@(";EP/BAV&,ME+JUEA6SIE$S4%&OX]F^6CG#YFU6;)BD
MT?*1,C+1PO6I?]&L5)RL4BA3%YPB`X$LP&!BO<5_K.O*?X3L\1:;&C*RK&%B
MZQ2(1Y8K;8),Y7$L9I"0[$Z;AXK'Q,0ZD'``<O-9LUC!SC`!#"E60868C[##
M1,_$.D7L5.1C"8C'K99!RW=Q\FU2>LG2#ALJNV<(N&RY3E.F<Y#E$!*80$!P
M+G@,#%NUKJPHT;6)*0J5GM_A&\U2O1K&J.:H@_;SMAE4(6%=+)6JV5-)TQ(^
M?%Z<&YW"J*`'6.ET*2BA!2K*6`P&!A*];:IM/VEJRA3478G=@NRLJC#34:A'
M'K=9.LD#1F6VO'4PQ<,36ATF=I&`DW=&<NDCD`"B'*(I^6;<!@,#!ZNWZ.CO
M%OJM9G+)75W#]6:OU7,`FQ<D\%.K;U5O!&L(79:/\&,EC>'"PPU[K:)X_P`(
M^$2F:`*?EG#`8#`UKKO$#2Y.YL8-O4;U'S%FEC0,^[?)595C59B.M&U:##L9
M\D=<)%VIX<L&G9M!LM%(2+<A4TE72C=-3G%%&RF`P*9ZNJU9NW2#)S)+MFRZ
MZ,<R.S3>/U44CJ)LFAY%VPCR.71R@FF*ZZ"(','/4(7E,`8FU?LRLWITJWKD
M'9(Q*7U[K3<Y'TV2((U>Q6X@M@Q+)$C&=E'J$W$_4E?P@DHBFU3Z='JZSCE5
MZ(4HS%@,"(;`N337E)M5[D8R6F(RGP<C8Y5A!!&'EE(F(;G>RB[-.8DX:/6.
MRCT5%S$,X(<Y$Q*F!U!(0P66GV^%=VJYZUC8>8C7FNVU;>/7+UQ!O(Y\VN1Y
M]S'"P6BIZ6D&[D@0JJJS:108NDT%VZH)&273.(I2&2<!@0F^VJ/J</'N):*E
MY2-G[34J*X-$>#1/&K7^PQU-BY*0+(2D8J,4G,S;9)<S7K+I,JW/*B<I3B4>
MVGT9PP\)7$5NNQ;^V-H-:X;<T_*(Z/B!WO'MK.QI#&FQ["QQRVOJ.^F;#3(J
M.F0N!99K,=3)*/A=E<%5ZOU40+YB*1/AOJ4I2%*0A2D(0H%*4H`4I2E#D*4I
M0Y`*4H!R``?T81__U_?Q@,!@,"B:QT>Q7D7+)@R9N9AZ21EW#5J@W7E9!*/8
M1"3^152(11\]3BHIJU*JJ)C@W;))@/,3(4`K<!@?"B::R:B*R9%4E2&3524*
M4Z:B9RB4Z:A#`)3D.41`0$!`0'`L]=K5<J$2V@*G7X2L03(RYF<+78IA"Q+0
MSIPJZ<F;1L:@V9H&<.ECJ*"4@<]0YC#RB(C@7O`8%KG(.$L\),5JRP\78:Y8
M8N0@Y^`G(]I+0DY"2S19A*P\Q%/T7#&3BY-BX40<-UTSHK(G,0Y1*(@((2#A
M*U$L(&N0\77X**;E:1D+"1[2*B8YJ01$C9A',$4&;-N03#R$3(4H<O\`1@73
M`8%%(1L=+LUH^58,I-@XZ/IV,@U0>LU^B5(NETS9R11%3HUDRG+SBCR&*`A\
MH!@5N`P&!'9*GU*9G(*SR]7KLK9:OUSZLV&2A(Q].5WPBD"$AX"EG395_$=?
M0*!%NKJ)]*0.0W*&!(L!@,"B/'1ZL@UEU6#)258LG\<RDSM4#R#./E5XYS)L
M&KTQ!<MV4BYAVBBZ1#`18[5$QP$4B"4*W`8#`BT;1J5#6:Q72'I]6BKC<.H?
M6VV1M?B6-FM'@N/91,9]8IYJT2E)OP=%QK9LAUE57H6[=-,G(0A0`)3@,!@6
M&"JM8JQ9,E8KD#7"34HZG)@L%#Q\066FWH)@]F),L>W;@_E'8)%Z5PKSUE.:
M'.,/(&!?L!@,"B81T?%(';1C!E'-E7LC(JMV#5!F@I(3$@ZEY=^=)N1-,[V5
ME7RSIRJ(<]=PL=0XF.<QA"MP&!;Y6)BIV-?0TY&Q\S#R;99E)14JS;2,;(,W
M!!37:/F+M-9J[;+IB)3IJ%,0P#R"`X'U&1<9"1S&'AHYC$1$6T;L(R+C&C=A
M'1S%HD5!JR8L6J:39HT;(D`B::92D(4`````P*[`8%@L]4JUUAW%=N5:@+;7
MWAVZCN"L\-'3T.Z4:+IN6JCB,E6SMDN=LY2*HF)B")#E`P<@@`X%Z001;(HM
MFR*3=NW2300003(DB@BD0$TD44DP*1-),A0*4I0```.0,#EP&!;WD3%2+F)>
M2$;'OW<#(*2T&Z>,VSIS"RJT5)0:TE$KKIG5CI!6$FGC,RR(D4,U=K)"/1JG
M*8+A@,!@1N1IM0F)V'M$M5*W*6:O%4+`6*1@XM].P95N=TQ8>7<M59",*KSS
M<X$5"<[E'E_IP))@,!@6,*Q6@L0VX*]!A;!C!A1LX1+`+$,,9=-R:)&:ZOX2
M&,,Y2(H*'2]$)R@;F\H`.!?,!@,"(%U]023D79B4BH$LD(M-N86P%K4*6<B'
M%E<RCVQKQ<L#('\>M8'DX]5>F24(9VJ\7,J)C*J"8)?@,!@6:*KE>@NB\"0,
M-#=!#0U<1\%1;&/Z&O5WKWU?@4NJ((]'#07A-SU-J'(@UZPKT92](?E"\X#`
MHI&.CYB/?Q$NP92L5*LG4=)QDBU0?1\C'OD#MGK!^R<D5;/&3QLJ9-5)0IB*
M$,)3`("(8%C@J-2JO+VBP5FGU:NSUXD&LM=9N"K\3$2]OE637J3.2M$E'M&[
MVP2#1E_H4EG9UE$TOU"B!?DP)3@,"B?QT?*H$;2;!E(MDGL=(I-W[5!X@G(0
M\@UEXA^1)P11,CV*E6*+ILJ`<]!PB10@E.0I@"W5^JUBI-G;*JUR!K+.0D7,
MP_:5^'CX9L]EWH)%>2CM".;MDG,B[*@0%5S@950"%YQAY`P+]@?_T/6['5+B
MZJT-*05-3NL?!MEMIA6YB1F-0S>V+/9G%3UGZJ['MYQ=K)L"GN:L$\UM",RY
MKSF-E7BG@Q4L4W*9ZH<OA2SU<[1#KD\$5M(C6-%S$I-R1^J])6&4;PAX*/$L
ME2Y2;V%26,O;TK(@8D['ST;&Q9F3ERK%/ND;-4'0\++9*YVD'@V0-#W%I*3B
M@[UD(MWU#3T&SA)-.K<8$!H]O"Q!FD@F,/(/Y/5<BZ;3+N>4;O$3@X<F1)($
M4'A*H"Q\74+Q#:;HMQE[--4U_<MG&M+F-KVLEX![J2(-Q9EI-DV%+1=5:2L/
M;)1-IJKH@@U6+,'"KA)V@@HN**X\4EO!KU==S4H]9RLJX6,ZFP,JNH=54P)S
MTFFF!E%!,80(F0"A\OR%``_H#++./I-<BF!@C=3+8'AS1%DHT%8[0PI.WI*P
M;`K=7G*]#24Q3'^CMT4UJB9*UV:IP,TV9WVUP;LS1=X'-%N5P0AE&Y.0-0TH
MGCY7V;9;I**6LE280^_8>AT6#LNCVR23FVHZ54UNYG>N-%(:UL:>YJEH7@W[
MMNQF>LR#=I(`BQ=/SD+XHJZE'=HNG%G>VZP1[J379Q<2_BFK33C(K:,C*/P[
M*SUIJ)6\<^10V?8[2CL9-BC+/WM80?+,^F;HQY45"CPBK1_VADU9[!78V:GF
M!ZWL"IIO).6@M'-*X?4DQ7S22S)!Z>OJ/)G=[`[Z+&4<QQ5ZB"J<RDUZ,X1J
M01?#)[J.XZ0MJ8IV&1-6$MLU\CIHQ8Z,%"4U^ZN^T6<P:/GY%FG+U>G1&M9.
MJ2"ZBT/.6A[/QCIBW1;LW`OLJ>$2F]2<4[KA_P"'>"8S>QY/?]<T@O0;U9K/
M>:F2"BKM.5:!B;%L67L=>M4=)O-E5B3C5G%8ETH>SH.DE%FLF@D>17DFP\5F
MRGF(?M#X^!N1:Q:9EXX<:YJD5KJ)DZWH%U-UVU*5C6HO;19[H^MP,;+:8NU,
M+(A.1`Q)8=XSD$W4;+`LT3;.QX6B?@..=/:]8MYYJ7C'DXZNFL'+>+94"6H$
M77[Y<Y)>JV2K1[&OV*8CU-2:Y.SLDBZMJJ"<O8*PO"MG(H2S1-[%\,J[BUOQ
M!R>S+=(ZL?;$BX*9L^A[(_LZ=LIS"4:L:?MG0JUTH>JD92URD<GK^:U97[2\
MF(Z;@XQ96?47(@Z?LIAPV3J1,,9%KG:)S%GDK6XL,M5BMV>V(FLULKK34S#1
M<192<)<S"'DH=HM'15\M-97BMHL*K)O310J+IQOA-*.9/W_21?#L*U<VN[/7
MM2;;(F%;!>$8=`MDF'%=@ZF[?/\`G'-TK^O5FRW"N1LB5`2$<E823EF=<ISH
MB1,Q4R5E/<"%3RZZ=MH:*:RJ:+EU8@<)$4.5)<$H%PHF"R91`JH)J`!B\X!Y
M#?*'RY;I/O%-<BF`P&`P&`P&`P&`P&!TNWOAVXV91QNHM;<VQ-E9K%Q3/8))
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M8N$17D#A%\)H]KO:)*3$DV0V01E"M;'.Q\`HRI.D9-U-T5#<=Q90D[9++(RD
M3]6]BN=3J0[[HV57DX95-$Z*B#5^LH*%3PSAPTUGB+A;/MR1WY8[#.)33NHC
M1TG4E2'58;1<+&R%:=KQL76&;)[!V>;+!MY>:3!)")5<RI3,DTS`X;-1-/PV
MXPA@,!@,!@,!@,!@,!@0J>773MM#136531<NK$#A(BARI+@E`N%$P63*(%5!
M-0`,7G`/(;Y0^7+=)]XIKD4P&`P-4N)NM;(ET(Z3IT!>;M"Q]`VG%JTO75]1
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M6"DCKZ3FBS,BB*8!(`T4;N`ZD:IX7N"IW&TYV[2)*\WJ>=:X@MYS=FDV597U
M5`-'>O'S[C7K477)",:1B4K,TMA4GNH'O4WKE_+I.EW;@'"S]H!VH\.PW"&`
MP&`P-'-H5#;=WK,$O2SVV735U_NNNQ):W?E*2[K&W)NP0B>L=BV%\I98)25K
M53;QLB17H"R+QCTP"C'/>F,#=*8SX\L6UJF<<E)D'K&&FI^1KR7$#?K8^C'_
M`*DWK"U4R^;XW=<V<?6K').S6F@4-K0+5!'EE'S.?L+)^S0CX=D9IUIT4UX2
M77,!Q_(M)IWL383>6E6%(F9B*B6M*T]6(.2VE%'H3N/I;:2C9FZ2TOJ^SK,I
MMJVEG*==FD&;TQG+=!PDV4`>%F-6N/:8V=KL+#89MAKFOV34DS=CU&6U$S-.
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MSW_$,KEEC'TG61HP&`P&`P.N.Q2_&E5+ENB^U9-G-TYML9S3ZE3;I'6>R1WU
M8D2:F<QNQHZK46E)WKP-3DFUE8BA#/9A:9<397+A)%*(`JD:\.!ANWC5Z&FR
M-GU;7H5*84VNTN3JM:NVI=8G7S6J[%D:I2)=O6#3]8V!LH+S'5]NZ:`BU@W2
M<=84WZK)-O'N05J4A/=,7WB<O&Z:>OMJDN=:5YKJ?<Y+AK^*K\^ZK-;NY;QH
M@NMSO-M.WZ]2VA)SM/\`#SYD,*U9$B$UWC)WTSI(YDQ-/PWFPA@,!@,""V+_
M`'QU[_M=E_X><9;LS[Q3K(T8#`8#`8#`8#`8#`8#`P#Q,^M`VJ#(:=+)FO#W
M9>AXTO@E\I$N@J$GO;6\?LLZLRA7[4X@XQ/6KF7,]?IQ[I5BS!5<A`,F!@+'
MMKA1K_QP0MUJFN+M6]?V2"BK#5Z9:MBEIFS%;++1:-7;N)+92CN*C*UJ!RQM
M,JT<F-U"0;KPJJJ""\6(JG!L/"-T3?O&J]KM!&XZ:9U][(4VG.=D23K5>R)E
MWK:7?QVI.EE"P,-:B.]LGM#NR605H:#%G(5$8DI9,ZO-,*HI#<GAO6OSCAXT
M*XVL$L&T5]+ZN6V2$\U,QG0ORM'@CW$)ID8ZAFDL%B,YZRD)C"FMSB\H\F"?
M<LT80P&`P&`P&`P&`P&`P&!!;%_OCKW_`&NR_P##SC+=F?>*=9&C`8#`8#`Z
MPZA8N/*GO(F4>L:]9H"_W>Q,EXW8[*_3;JE-*_M*W-&!B^K/6HV2H%V?KZ:C
M>HJ/6DK6X`E6,X</!5FBD+&O"Z53>?&TL%56L>F8Q):SP='GWS0FNKRU9QUE
ML=:TO*/M4F6^N+YQ33QRMOM"+RTR@.8J.=U<Y7#4BKQ!ME2D,T<.UMWQ<MD;
M(E=N0\A6H0VK=)EB*J6G6.L5VI;$&U;Y]:-5BIBQ2,DGL>3@6(5YN[LL9U:'
MF&Y6B[-NFD;G*"6X&$,!@,!@,""ZV_W.C?\`:Y[_`(AE<LLX^F#^*J-WQ.QV
MH*]H*<D*M-S^TIN-MUI:+)-V-8JX:%W>]A;!/*KU"ZMUHF)VFSK:P-%6A$)-
MV5!BLLFBY4$8W%/-6O+_`'5QW##;+(;5%%1?PNN][2E41@:/MZ1GS7BE5^47
MUQ57ZDQX`I\PXM<GU(6S^OOYIE*'.NBD5J*1#K"D++M?=7&[):?V:UK6KEJM
M:G^M[>A`V&O:OV%-V6J[6<ZZO;MAJR!K36SJ+V=Y#6IA$HL]EMUB4]VX=@`,
M@`O*(BCM*PA@?__2]_&`P&`P(+K;_<Z-_P!KGO\`B&5RRSCZ3K(T8#`8#`8'
M497..#BNAM)\4>VMD<+LRG9M0<2E6I-6U`BQ=15G]4VP=7:4L->:!(0K^\LK
MU=:O==GF;3$A'`G%*-2**)%3%NHD2-4BL1$H=&]I_P`1+M*FOR\`>RI)E;-9
M7_93:-96V-A[4^6I'K.BE]=UNOV6-C9"S['2L>KS"XC&*;ET2*L$6[!+D4,0
MRIKRA%6[3GB=>[,G#V+A=<PE%E>&Z/O-/;O[E`.:,7:M8D^,9VO3D]K5V*EX
MJ.LVYX?5E>300G'3./K:<)(`Y.1XZ:(/E36*>W<'HG9#W<&F]:[0DJU)TZ1O
M-0AK%(5:89/XZ2@7K]J51W&NV<DW;.TCME^<`#R'2.7D,DJLD)%3UF?;+&`P
M&`P(+8O]\=>_[79?^'G&6[,^\4ZR-&`P&`P&`P&`P&`P&`P.O*V<1^^HSM#-
M;\.D-2FCC0L]2V\E9[2:D61Q,MIAQ2-U69])EL_AEK$M*Q'3-*K,81^FQ<L4
MI"75CW*I7KM@"9:12OY:L*]J)Q'-GFQHD_`Q=';W6D<"LS)-)N2;5QTZ:[+U
MQIBQOF,M,UR,;%A*I?)6X/'*RYT4?J_40?+KLVK]-TE*KK%T-O7:@\7#FM6"
M1JO`SL"L3%++HJTC`MKK0KQ8+\A9[+IHUIHL!%QR+YT\K=UAMARK>*ML<W<L
M&[>!76$X/U@8-55UB[L3X6N*BQ<05WW!5)C7Q*W#ZZB=32]3O,0ZF)2K[)C]
MA5=]+2DA'KR,-$N:XYB):/.D$/)IMYE)HJBY6;@@N@JK69BC=/"&`P&`P&`P
M&`P&`P&`P(+8O]\=>_[79?\`AYQENS/O%.LC1@,!@,#4CCAVWNO2/#9L+8'#
MYK=;9FT(F,=*PT=U!.8C:ZR9QLA+S%OF8(DY7Y.P,H:,C%"H,&*XN74@NV3$
MH(BJH0L16?+6/=?'CO;5&R-8:V@>%FPW\VT-:ZIM<9;4'$S&1$!:-F+6NE$K
M%R3:0<NS@W$'MDE69/\`FNU1;15C.]#GE8K%&+2/=6+WW:@<0Z-JE8!KP!WS
MJ+?<3G7D?,3&TZ)7B%C&$W;8DS>RM9=5LK3KK/L:VUD8=K)BU:2S>4`K%9X5
ML"SM4UB[[T#VB>^9];7%,V9H6</89_B0]2=AF'+=]$6A"D2I8I>M[H+1XZM(
M,WM*F9">68D5BUWP1;*`</Y7JJ8O_!(F(=T&5DP&`P&`P(+K;_<Z-_VN>_XA
ME<LLX^F*]HWG:57WKPR5BLD@W.L]E678];V6BO59B1L+`\)J:YW>K3#"V-K`
MVAJW&%G:RDS71<QCH[X[PA4W#<2<Q>-_B77K.]I?Q#PMRW13FW!#=["YTTXV
M<"SZ)E9A&-ND9K2XS]-D9RM/GU620-%G3L5"G!4_TO\`]#G9)0O*K$J)J2JZ
MQX\L?;([3;BR5@T8ZF\%%W@+`-;U/;1E(R]ZTNCJP>'-G5AA/1FNXD7:D7>*
MW9*X=S$)RK-=8D1)2!3O#-"MC*B*1=W`Z(V,[V]IC5VT)".:PTG?:-7+3*P3
M0)HJ5=EIB,;O)6MF+9(BO6`KFNR*BK)<'T>P=@L@;I6R!^<D2LRRQ@?_T_?J
M91,ADRG4(0RQQ31*8Q2F54!-184TP$0$YP22,;D#E'FE$?Z`'`^\#A<N6[-N
MN[=KHM6C5%5RZ=.52(-VS=`AE5UUUU3%31113*)C&,(%*4!$1Y,#B<OV+)1H
MD\>M&BK]P#1BDY<HH*/70D.J#9H14Y#.7`IIF-S"`8W-*(\G(&!Q1\C%/RKE
MBG\>]*T5!%R6/=-G)6RZB9'`)+@V.<$53I+%4YIN01*<#?T"`X%PP/A-1-9-
M-9%0BJ2I"J)*IF*=-1,Y0,11,Y1$IR'*("`@(@(#@<(/68@\$';80CCBG(""
MZ0@P4!J@^%-X//\`]5.#)RFMR'YH]$H4_P#U3`(A]MG+=XW0=M%T731TBDY:
MNFRI%V[ENN0JJ"Z"Z1C)K(K)F`Q3%$2F*("`\F!2(S$0X7;M6\I'+NG;=9VU
M;(OFRJ[EJW5!!PY;HD5,HLW07$"'.4!*4X\@B`X%QP&!1'D8],KPZC]DF2/6
M3;/SG=(%*Q<*HMG"2#PQC@#991N]1.4I^:82*D,`<ABB(52:B:R::R*A%4E2
M%4253,4Z:B9R@8BB9RB)3D.40$!`1`0'`^\!@,!@,#Y$A1,4PE*)B<HD,(`)
MB<X.0W-$0Y2\H?(/)_DP/K`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8'R)"B8IA*43$Y1(80`3$YP<AN:(AREY0^0>3_)@?6`P&`P&`P&`P&`
MP&`P&`P&!\E(4A0*0I2%#E$"E`"E#E$1'D```/E$>7_XX'U@,!@,!@?_U/=A
ML.ESML<4&3K=AB:Y,T*ZJ6YJM.5IY:8R03=4FZ4=[&N(YA:*BZ1.=A=%5DER
MNQ!-9`O.34*(A@:9NN%CB0;3M:BX_BKV/+U]5C>"V>ZS$W/QUCA%)NB[!K,0
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M$<BE6C-2=539M4&_1%`PI=>.N_7%>$-0X/-I(J.>3BBM:3:9D=IR5P10A+<H
M>[.;_H&`TI!.+$K+;<ERK.*7+UQO94"I$2:%?!U=@WC$/EP5X7F@<,&P8*HW
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M-F+=C!D78H`PCXYMTK50?^&%VO!7LPDM*.G7%!9E82?;5=2QU@L%=7\=/6"!
M4UB5]89-U;=RVR4?/99AK4K4@KK+*M6\@J@"IVQ"(9%KPV4T#K6XZRKECB+I
M<9.WKN;E8%JN+^8E)5*`HB;Y4E7@VP2"HI-_]&99WT9""9DBZ2CNF<(,&ZHU
M)9XPA@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?_U??Q@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
4@,!@,!@,!@,!@,!@,!@,!@,#_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g893535g70c89.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g893535g70c89.jpg
M_]C_X``02D9)1@`!`0(!>@%Z``#_X5!M:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87`O,2XP+P`\/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](EA-4"!#;W)E(#4N,2XR(CX*(#QR9&8Z4D1&('AM
M;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN
M=&%X+6YS(R(^"B`@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*("`@
M('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+R(*("`@
M('AM;&YS.GAM<$=);6<](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G
M+VEM9R\B"B`@("!X;6QN<SIP9&8](FAT='`Z+R]N<RYA9&]B92YC;VTO<&1F
M+S$N,R\B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!44&<](FAT='`Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]T+W!G+R(*("`@('AM;&YS.G-T1&EM/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O1&EM96YS:6]N<R,B"B`@("!X;6QN
M<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+T9O
M;G0C(@H@("`@>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O
M,2XP+V<O(@H@("`@>&UL;G,Z>&UP34T](FAT='`Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]M;2\B"B`@("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*("`@('AM;&YS.G-T
M179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R
M8V5%=F5N=",B"B`@("!X;6QN<SI%>'1E;G-I<T9O;G1396YS93TB:'1T<#HO
M+W=W=RYE>'1E;G-I<RYC;VTO;65T82]&;VYT4V5N<V4O(@H@("!X;7`Z0W)E
M871E1&%T93TB,C`Q-2TP,RTR-U0Q,CHS-CHR-RLP-3HS,"(*("`@>&UP.D-R
M96%T;W)4;V]L/2)!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I(@H@
M("!X;7`Z36]D:69Y1&%T93TB,C`Q-2TP,RTR-U0Q,CHS-CHR-RLP-3HS,"(*
M("`@>&UP.DUE=&%D871A1&%T93TB,C`Q-2TP,RTR-U0Q,CHS-CHR-RLP-3HS
M,"(*("`@<&1F.E!R;V1U8V5R/2)!9&]B92!01$8@;&EB<F%R>2`Q,"XP,2(*
M("`@9&,Z9F]R;6%T/2)A<'!L:6-A=&EO;B]P;W-T<V-R:7!T(@H@("!X;7!4
M4&<Z3E!A9V5S/2(Q(@H@("!X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC
M>3TB1F%L<V4B"B`@('AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/2)4<G5E
M(@H@("!X;7!-33I$;V-U;65N=$E$/2)X;7`N9&ED.D%$1CA!,T,Y-$9$-$4T
M,3$Y.$(P.#A#,44V.#@V-#`U(@H@("!X;7!-33I);G-T86YC94E$/2)X;7`N
M:6ED.D%$1CA!,T,Y-$9$-$4T,3$Y.$(P.#A#,44V.#@V-#`U(@H@("!X;7!-
M33I/<FEG:6YA;$1O8W5M96YT240](GAM<"YD:60Z,$8X0T$R.#8S.$0T130Q
M,3@W-S-$,3$Y.41#.3DS-S8B"B`@('AM<$U-.E)E;F1I=&EO;D-L87-S/2)D
M969A=6QT(CX*("`@/'AM<#I4:'5M8FYA:6QS/@H@("`@/')D9CI!;'0^"B`@
M("`@/')D9CIL:0H@("`@("!X;7!'26UG.G=I9'1H/2(R-38B"B`@("`@('AM
M<$=);6<Z:&5I9VAT/2(Q-38B"B`@("`@('AM<$=);6<Z9F]R;6%T/2)*4$5'
M(@H@("`@("!X;7!'26UG.FEM86=E/2(O.6HO-$%!45-K6DI29T%"06=%05-!
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M,F5N-4MJ<$M7;7`V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!341B
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M.5)S=BM795`O)B-X03M!24)F-EEQ-S9J6F8X<SAF+T%,+T%%>%8S,4=Y+W=#
M5V50.$$T0F8V67$W-FI:9CAS.&8O04%#+S!X5C,Q1WDO-5HT+RM!6"MM2W!8
M)B-X03MR>'0Y4'-B=2MI=&]M93%S<G$T4D=18U,P4W%W0G`X<U996"]!274Q
M=B]L;C`S+W!&:R\V<C1A43<O1C)T+SA!3%!P=B]33$HO=T)6)B-X03LX858S
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M>'`O>$59<7)9)B-X03MQ-T9867$W1EA9<3=&6%EQ:V9N2"]J9S9R+S)Z3#<O
M:S)-5F5B6DI$0W17+S579EI/1C!X;V162W)'-&QD25E);31I9C%),U%U2$1-
M)B-X03M8:#1L5W`X2C-7=313<7AA<"M:6E--5&%.87$U:VA79&ML5V=2,VLY
M5C0V>3<X13E0-U90:35D4FA66C5.=5!Z0G55=6)$>DUI,GIX)B-X03M217)F
M>$EN<6PU5RM!2U%'='E9,55K,%9H=71D=V%H5D-Z=79Z67198F1:8D\R,4%K
M:C9W,'IX4GEI<T-U,4=H6DDV97-Z25!G<E)E)B-X03LY95%65W<V<BMB+S%Q
M,4PV3EI'1U-,+U,P859&5T]65VM!-$US<G12;#1(-TQF4C%X5E!F2W-0;7-W
M3F1E64QM:SAK:S5&9TDT5E-.)B-X03M'9&92;S!B4T@T5E4O='0Y<F-M;&-+
M1U9A3B]X,TQ$-3-(+U5(4&EQ5#9R<$YN<&8U=7A7='8U6G5,<4<X,4LQ=D<Q
M0V$Y,4]51U5M)B-X03M":F-*06Y+,S123E5G>6UI;4YU9T5A:TIE-'8Y:S1&
M4WDW-S1Q:W0Q,W=O63=Q;6LV5F1U,&PS6E%816I,=TQY>$DU2V=/=D=R03=C
M)B-X03M:6$90.&\K2GA6:F1L-5,X=#916D=S3$-/2U-363-$>DY74U%Y:T5C
M+U5K3'97:G-/=F,K3T955C5D+SAM4#5B*V0W+T%.47(T0V]E)B-X03LQ645U
M>%8R2W5X5C)+=7A6,DMU>%92<V8Y-')F+VI';B]%4FEQ=&ER<U9D:7)S5F1I
M<G-69&EQ4BMC9BM/1'%V+V)-=G8K5%EX5C5T)B-X03MK:TY-0U9)0F]33FHO
M=%5X5F@K<651=%$Q1S)S-$IT86515S=3<S=Y>$=2-E-G04Q%+W%+-D)A8D8R
M9&HP6FET5DMR4RM13E)H<V)7)B-X03LP<SEF=4Q.8E-"65DQ9T1P2%5'6G58
M<')+069I;6HK,54P:F]X4$DT16]3."],2%5B,C)J=#=V>DID>F]I>4)H25I7
M-4\Y=#9+='9.)B-X03MT>&0U2$DO841C1#A)1TLR;FYL:E)D9C`K+S%A8E4W
M-S8Q83--<2]O*T534U-E;$5R4TAC3T%Q16@Q6&EG<%)2,4\K1D1)8U9296IF
M)B-X03LX9'EW*V1X+S%">C1Q9SE:.&]A:&,O;E-D8F949%-E>"MS5UEJ=G)7
M2S%L:%E*.5=:=6,X:S!5,$UC571Q3U-Q:C%":W`Y<S%#6'-R)B-X03LO6D]"
M57-U*RM+<$QD9#A+16]U=2M+<%!D9#A+;TQY-R]W0U1(.'0O3SDO-FA8=T91
M.7%W2F1I<G-69&ER<U9D:7)S5F1I<6I9+S=X)B-X03M7+SA!>&I4+T%):4U6
M5G-69&ER<U9D:7)S5F1I<G-64U!Z:B]!36-(5F8X071M6#,O2G-9<3@R>5-(
M67$W1EA9<3=&6%EQ-T956&\S)B-X03LO2&-S4&YC9CE18RM+<3%J6658=DQ7
M=3-G,68X>%`P6F10<70Q<5(P15@Q:$)"-F0S9$YD2DA*1E!&-B]X<$E/9G@W
M,2M%:F))<&5N)B-X03MV8U)E9W-Q;C%),T%+3D=#-$E)<4-/24\S=FEQ5C-6
M>D=A-U`O=T%I,R]P:%9*-W%65%A:=BM"8BMM2T5P=5A"<C$K-#1Q;$YZ=EA#
M)B-X03MQ0C!*:$@K679L=&UQ4E<Y,E5&:B]V2R]:86Y!5D0R6#8U1B],2B]Y
M2VLO-7!W2F0Y8VDO;&LO-4939C@P-'$W-C5&+TQ*+WE+:R\U)B-X03MP>%8S
M,7E,*U=4+VM62B]Z5&ER=G)K6#AS;B])<50O;6Y&6&98278U6E`X06M62B]Z
M5&ER=G)K6#AS;B]!0TMK+W=#86-69#EC:2]L)B-X03MK+S5&4V8X04Y/2W%&
M;&1X0WIG2$=484Y0.3%32#EK9C5/2W$O=T)C:2]L:R]W0U)5;B].3TMU*W52
M9GEY9CA!27%4+T%*<'A6,S%Y)B-X03M,*U=4+VM62B]W03`T<3<V-48O3$HO
M>4MK+S5P>%8S,7E,*U=4+VM62B]Z5&ER=G)K6#AS;B])<50O;6Y&6&98278U
M6E`K4E5N+TY/)B-X03M+;T15,'1,*T]7>6U%>7<S5G)00DM5:F--1FQ#<5-T
M5D\Y1#19<7@W+T%':V8Y6$A5+SA!:UA&+S)466)6,RM!3DDO-G5/<"\X:31V
M)B-X03LK>6)',60O9T134"MR:G%F+TEU3"]S;7AT6&8T03!J+T%+=4]P+SA!
M275,+T%,2G-B5C,K04Y)+S9U3W`O=T1)=4PO<VUX=%AF-$$P)B-X03MJ+W$T
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M.4I6>"]W03$T<3<V+W%N+T%&8V(S+W!+=5`X06UV1EAF6#E5)B-X03LO=T-R
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M;%AQ4U-13GA41DM8;E(W+T%%.5DU=%,X*U1X24QM5U`Q27DP)B-X03MS9$%Z
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M.4YG<3EZ9C=*>%9,3'9V:7)Y2#AX4'IJ=%!+1W9N4S=R4W`W<4I9<F5D-VU&
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M)B-X03MP4T,S0C`Y5BMR24DT>DA*3$=3:7`V645H4FQ-=$4K2#0V-V)D.%98
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M5F(P:3`X.$QE5U9X<2MV,FLY)B-X03MR8G!,3F9W=T9%5F]8:5I92E%216I5
M-3AI87-&,D)(5$%Q>7DP+SA!36U#0S%%;71756QU231%37)(;7IT-C(U1&U!
M8W95:4E59'EF)B-X03MF9D-Q6F58.4XX-GA8.$4K=F%J1&124G=42DI(8FYG
M:&ME5E=J8C`O4U-V1D9)-49V:W96:6]E>"M1+RM/2%DO3RLO-FI$9TM755E&
M)B-X03MD:7)S5F1I<G-69&ER<U958C<O94LT+S1X=CA!.%)/2W9-.6,O36IZ
M5EHK94QR4W1$9W,Y63`V1S1T-V$T:G5:27)$,$IP;S1U34UD)B-X03LP,#=M
M9#-E5F%+3&5O3%5R=&A6-E19,TTQ,7!T=&-Z,C<R:S`X2U-3,FMP579%>G%'
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M0EA9<3=&6%EQ-T9867$W1E9')B-X03LK+S-I=5`X06I'+R]!0D4T<3A#:C!Y
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M;WA6,RM&4$QF+T%&3&UN+SA!)B-X03M):3,O04]A359D+VA4>3,O04Y3-7`O
M.$%Y270O*V%-5F0O:%1Y,R\Q3&UN+T%026DS+S5O>%8S*T903&8O575A9B]Y
M270O.$%M:D95)B-X03M88E%*6E-15S%N67@R,79(2$PV8T500TY">61'3D95
M041C,7A61RMR8R\W-"]W0TA'2W4Y5S4O,W@O=S1X5C-Q,U`X079J+VAX:7)V
M)B-X03M6=68Y.&8X041J1EAE<F,O-S0O-&-9<3<Q8FXO04AX+W<T>%8S<3-0
M*RM0*TA'2W%.-TQC;7IN<D)196TY5'E(.'!X5C1F<D]S86UV)B-X03LU>FDR
M;4@Q85I.5G,T-UE1>C-$=U(R:&%(;7-S2U=F,5EY,TAR<35,>F-O>DEO0BMY
M4U9E.78X05I/0E5S=2LK2W!,9&0X2T5O=74K)B-X03M+<%!D6599.6-K:GI"
M66M':$9N<7!"2"]!1WHU8U941#E'86(O=T%S:U`X07E,5"MM2W)*3$1326M,
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M63`O-&E-0U9B1EA9<3=&6%EQ-T9867$W1E9&+SDW678K36-N)B-X03LO16MX
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M4U%01GAJ54%/)B-X03M!1G`X4W%117(Y4#AU9FQZ9#).-4MK;"]:4C)T<6LY
M>DUY;VI,14M297)(2DA'>7EC:&%T.&-:64AM.40X4F]Q=71R2#AR8E!32710
M)B-X03M'<EA::&EV<#=U275K;G)2,T5%0WAY07(V06])54MV4FPK9%%#3592
M3VHS6#5B4F$Q2W,S,6PW.$])4#E/:EHT-4IN=6)I2G!64TYF)B-X03M42F%6
M,D)F:GA8:T9(16QL>%8V6&A1;4AL;B]L2SE(+T%/33`S+U5*4&=+=E0W2"]!
M2&ET+W=$:D=N+T529U-R67$W1EA9<3=&6%EQ)B-X03LW1EA9<6]V+T%,,GAF
M.%DU4"M*2FEQ=&ER<U9D:7)S5F1I<G-69&EQ:F9F-WA82"]!0FIF+VE*>%8U
M8G$Q<C56;2].5U9,-F95-U<V)B-X03LK=6%F8TQB4C)45#)L,V12>'`Y6&M&
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M5F5N,E`K.%9V)B-X03LO=T%9,"\T:4U#5F)&6%EQ-T9867$W1EA9<3=&5D8O
M.3=9=BM-8VXO04)*3596<U9D:7)S5F1I<G-69&ER<U958C<O94LT+S1X=CA!
M)B-X03LX4D]+=E!D1B]+<EAD1S@X6%!M87@Q*S)23#(U=7!,>3%/;3%L;70W
M=397-4U-;'=,:V-M:D,K;D9)52M%9G,Y<U9E:G8Y:S1Q;&PS)B-X03LS>%9*
M8G)V:%%L1C$S>%9*-W)#<DAB<B]!23<Y;"]Z0C9T+S-4<&-644=P+VU8-5,P
M.34T,W5*2G`W85IR865'2TIY>5-Q4T-P-6A&)B-X03LO6DY..3EY3F=4:6Q+
M9%,O=TYQ5CA,>6)5<G1(;7556DQD23-!*W,P:'%G5F]3+TDO5C1W-E8K13EG
M5&=1:SDW;U`U9'9P.$9V4')6)B-X03LS03%Z67=7,$EN04HT6&,U=DE#-%=*
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M-455;U-/3DU+1V(K42]-3VMA=C5U,#5.4&Y->E<P>D=91T]33V=L<W`R:DDY
M4E8U0FPS0DAB07(R0W@O,VET+RM-868X4D=")B-X03M+=&ER<U9D:7)S5F1I
M<G-69&EQ:2]W1'9B1B]X:FLO-&MM2W$R2W5X5C)+=7A6,DMU>%8R2W%..2]V
M1F-F.%DS+W=#26Y&5F)&5VXK)B-X03MY8U93>3<W-'%K=#$S=V]3:38W-'%K
M.3%H5FHQ=W)0-6ES1E5&;6$P,55+;S-*2C`K5V=!>%9F8U=8;$\T9#-U3&5W
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M2D]S;T@K=U`O)B-X03M!1%9I<45K,$%Y9&)I;BMW+W=#8G-647-N;$)8-C-2
M2"MW+S5U=S)Q16LX9WA39&(Q:"]Z>D@O3E=.;W!,3&XX<V12:C%/=S%84CEA
M)B-X03M3>C%$5#)K36)81G`Y6FI+>E)M2F=55V%!.4<R4$Q','!J*VAF>E$O
M-FUR5%`K-$Y*+S)8-$9D*VAF>E$O=T-P<3!Z+T%,9S!N+UIF)B-X03MI<G8P
M3"MA2"]5,6%:+S-"<%`X07-V>%8S-D8O3D0O<6%T32\W9S!N+UIF:7)V,$PK
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M4"LT3DHO,E@T<3<Y0R]M:"]W0E16<&XO04A"<%`K>2]&6&9O6#@P4"MP<3!Z
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M='=K,3%91%5.-U5)4UDQ:EE,)B-X03MZ-3!,9FE&57)N.'I033`S;695=DPY
M;"MJ3$8W3S=V5FEV.$%54DM)1W0W2S-S-51(.$UI8W!M83A9;'%G2VDQ-&Y&
M54QO+S5S96-D)B-X03MA.'DV5&$V9G!#2%1R>3`P<3=V65!Q,7I*3$9(<4AQ
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M<C9F,51P-F,O,68P*U!B,'9R2'`P+UHY4VTS3$971$PO>7)$+VQA,FLK:C8O
M,75L=BMH=G$O)B-X03LV4#A!,&0O=D4O,6(P=E0O04Y/.4PP3UAP+S=O<C!X
M5FY7<V8X<3$Y1S0O5%`V1SE(-C90<E@Q>C9R>"MV*VUL4%4Y5&(Q+U0Y4'(X
M)B-X03M82&HR<&EQ8U=F-D,O4T9Z.5,K<2]P2#!94')F;RMN-C-O9D@Y5SE4
M:CA81"LX.4]U,S)Q9#A64C)+=7A6,DMU>%8R2W5X5C)+=7A6)B-X03LR2W8O
M,E$]/2(O/@H@("`@/"]R9&8Z06QT/@H@("`\+WAM<#I4:'5M8FYA:6QS/@H@
M("`\9&,Z8W)E871O<CX*("`@(#QR9&8Z4V5Q/@H@("`@(#QR9&8Z;&D^<G(Q
M-S8S-C(\+W)D9CIL:3X*("`@(#PO<F1F.E-E<3X*("`@/"]D8SIC<F5A=&]R
M/@H@("`\9&,Z=&ET;&4^"B`@("`\<F1F.D%L=#X*("`@("`\<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B/G-T.3PO<F1F.FQI/@H@("`@/"]R9&8Z06QT
M/@H@("`\+V1C.G1I=&QE/@H@("`\>&UP5%!G.DUA>%!A9V53:7IE"B`@("!S
M=$1I;3IW/2(V,3(N,#`P,#`P(@H@("`@<W1$:6TZ:#TB-SDR+C`P,#`P,"(*
M("`@('-T1&EM.G5N:70](E!O:6YT<R(O/@H@("`\>&UP5%!G.D9O;G1S/@H@
M("`@/')D9CI"86<^"B`@("`@/')D9CIL:0H@("`@("!S=$9N=#IF;VYT3F%M
M93TB2&5L=F5T:6-A(@H@("`@("!S=$9N=#IF;VYT1F%M:6QY/2)(96QV971I
M8V$B"B`@("`@('-T1FYT.F9O;G1&86-E/2)-961I=6TB"B`@("`@('-T1FYT
M.F9O;G14>7!E/2)4>7!E(#$B"B`@("`@('-T1FYT.G9E<G-I;VY3=')I;F<]
M(C`P,2XP,#`B"B`@("`@('-T1FYT.F-O;7!O<VET93TB1F%L<V4B"B`@("`@
M('-T1FYT.F9O;G1&:6QE3F%M93TB2%9?7U]?7RY01D([($A67U]?7U\N4$9-
M(B\^"B`@("`@/')D9CIL:0H@("`@("!S=$9N=#IF;VYT3F%M93TB2&5L=F5T
M:6-A+4)O;&0B"B`@("`@('-T1FYT.F9O;G1&86UI;'D](DAE;'9E=&EC82(*
M("`@("`@<W1&;G0Z9F]N=$9A8V4](D)O;&0B"B`@("`@('-T1FYT.F9O;G14
M>7!E/2)4>7!E(#$B"B`@("`@('-T1FYT.G9E<G-I;VY3=')I;F<](C`P,2XP
M,#`B"B`@("`@('-T1FYT.F-O;7!O<VET93TB1F%L<V4B"B`@("`@('-T1FYT
M.F9O;G1&:6QE3F%M93TB2%9"7U]?7RY01D([($A60E]?7U\N4$9-(B\^"B`@
M("`\+W)D9CI"86<^"B`@(#PO>&UP5%!G.D9O;G1S/@H@("`\>&UP5%!G.E!L
M871E3F%M97,^"B`@("`\<F1F.E-E<3X*("`@("`\<F1F.FQI/D)L86-K/"]R
M9&8Z;&D^"B`@("`\+W)D9CI397$^"B`@(#PO>&UP5%!G.E!L871E3F%M97,^
M"B`@(#QX;7!44&<Z4W=A=&-H1W)O=7!S/@H@("`@/')D9CI397$^"B`@("`@
M/')D9CIL:0H@("`@("!X;7!'.F=R;W5P3F%M93TB1&5F875L="!3=V%T8V@@
M1W)O=7`B"B`@("`@('AM<$<Z9W)O=7!4>7!E/2(P(B\^"B`@("`\+W)D9CI3
M97$^"B`@(#PO>&UP5%!G.E-W871C:$=R;W5P<SX*("`@/'AM<$U-.D1E<FEV
M961&<F]M"B`@("!S=%)E9CII;G-T86YC94E$/2)X;7`N:6ED.D5#,44S.3@V
M-#E$-$4T,3$Y.$(P.#A#,44V.#@V-#`U(@H@("`@<W12968Z9&]C=6UE;G1)
M1#TB>&UP+F1I9#I%0S%%,SDX-C0Y1#1%-#$Q.3A",#@X0S%%-C@X-C0P-2(*
M("`@('-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#TB>&UP+F1I9#HP1CA#03(X
M-C,X1#1%-#$Q.#<W,T0Q,3DY1$,Y.3,W-B(*("`@('-T4F5F.G)E;F1I=&EO
M;D-L87-S/2)D969A=6QT(B\^"B`@(#QX;7!-33I(:7-T;W)Y/@H@("`@/')D
M9CI397$^"B`@("`@/')D9CIL:0H@("`@("!S=$5V=#IA8W1I;VX](G-A=F5D
M(@H@("`@("!S=$5V=#II;G-T86YC94E$/2)X;7`N:6ED.C!&.$-!,C@V,SA$
M-$4T,3$X-S<S1#$Q.3E$0SDY,S<V(@H@("`@("!S=$5V=#IW:&5N/2(R,#$U
M+3`S+3(W5#`Y.C0Y.C4W*S`U.C,P(@H@("`@("!S=$5V=#IS;V9T=V%R94%G
M96YT/2)!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I(@H@("`@("!S
M=$5V=#IC:&%N9V5D/2(O(B\^"B`@("`@/')D9CIL:0H@("`@("!S=$5V=#IA
M8W1I;VX](G-A=F5D(@H@("`@("!S=$5V=#II;G-T86YC94E$/2)X;7`N:6ED
M.D%$1CA!,T,Y-$9$-$4T,3$Y.$(P.#A#,44V.#@V-#`U(@H@("`@("!S=$5V
M=#IW:&5N/2(R,#$U+3`S+3(W5#$R.C,V.C(W*S`U.C,P(@H@("`@("!S=$5V
M=#IS;V9T=V%R94%G96YT/2)!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O
M=W,I(@H@("`@("!S=$5V=#IC:&%N9V5D/2(O(B\^"B`@("`\+W)D9CI397$^
M"B`@(#PO>&UP34TZ2&ES=&]R>3X*("`@/$5X=&5N<VES1F]N=%-E;G-E.G-L
M=6<^"B`@("`\<F1F.D)A9SX*("`@("`\<F1F.FQI"B`@("`@($5X=&5N<VES
M1F]N=%-E;G-E.E!O<W138W)I<'1.86UE/2)(96QV971I8V$M0F]L9"(O/@H@
M("`@(#QR9&8Z;&D*("`@("`@17AT96YS:7-&;VYT4V5N<V4Z4&]S=%-C<FEP
M=$YA;64](DAE;'9E=&EC82(O/@H@("`@/"]R9&8Z0F%G/@H@("`\+T5X=&5N
M<VES1F]N=%-E;G-E.G-L=6<^"B`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`\+W)D
M9CI21$8^"CPO>#IX;7!M971A/@H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*/#]X<&%C:V5T(&5N9#TB=R(_
M/O_;`$,``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`?_``!$(`5T"0`,!$0`"$0$#$0'_Q``?``$``@(#`0$!`0``````````
M!@<("0,$"@4"`0O_Q`!M$```!0,!`08*%`H'!00%#0`"`P0%!@`!!P@)$1@Q
M,I?6$A,4%5AQ@K&RLQ87&B$W.%165UER<W9X@8.5EK?5"B(T.4%"0[2VTADS
M456UN-,C)$5WN24F4O`U1&'7X3I&8F-YA9&2H:;1V/'_Q``9`0$!`0$!`0``
M`````````````@$#!`7_Q``[$0`"`0$#"`@&`@(#`0$!`0```0(1$B$Q`S)!
M45*!L=$3(F%QD9*AP3-"<H*R\`1BTN%#HO$C4V/B_]H`#`,!``(1`Q$`/P#W
M\4`H!0$:E<4C<R:NL\J9&Y_:^J25?4#HF+5I>J2+#"2?THRUP],+L898`MS=
MM88MSAK4VG5.C,:3Q*)=<$X<*L+I6-8@#<`"]NA9DMN$V]OT`_L\ZJZ2>TR(
M)-5:T^Q!%^&<4EV%T&/XJ#\7=_%:4UOUO<52G*RW:=:\B4E:IHJ_<AKAB;&A
M=A7+@\;!_6<5L3VX+VW/U?T?HK83DZUD]'N8\7WLA2[&>/P7'T$/80[F[N="
MWDV_5W?_``_VU=7K?BS"&+8!"B[BZ",,P=R]MS<1%6_4W?[/[?/I:>M^((6M
MAT6`+<`P-8?/#P)2[?JW_P#92T];\00I?'&$O=Z!I0A\X/%(!;AO?=_12KUO
MQ8(8X-+87:_0(4P-RUN*4&WZ]K?H_P#9YU;:DM/OQ!"5J<DNP^@*`'<Z+<W`
MVMN?C;G>JIU5*-^+!"W`XTL5^@,$#<Z9Q;WMP6MN<']GZ*VKL5K?KWT!K+VG
M6J-_TU:9Y`Z1.0JF?(<]<TD#@RM,=:RQO5.`!K7U\3@O80@7:8ZB<NIE=@]`
ME>%C1T5["-+".)S:R>-[N3W\CMD(6\HD\%UGVTT;WZ'J'T"2?3EK:T=8`U.L
M>+L?EFY1Q^V+Y4VHF9&(A@R$SB.CN1HX7:]A&!)8IPTOS:D$=8!BA"G2J^@"
M!0"O/;GM2\67*"C)JBN>KP]#,#>]X/\`8LA7T&D_DI;GM2\SYDT6I>"&][P?
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M"&PBS2Q6L(`P^>&]MVU5"<K4>M+.6EZS&E1W+!Z"8O>(=-L2839'+H9C",,*
M(M)U>^R,EE96A&)6<0C3=5N;F:F1)[J5B@A*1TX\'3E)Y)!?1&F@"*;<]J7B
MS;*P27@5MU;H&]=&F'Z[X[^^J6Y[4O,^9MC^O_7_`$.K=`WKHTP_7?'?WU2W
M/:EYGS%C^O\`U_T.K=`WKHTP_7?'?WU2W/:EYGS%C^O_`%_T.K=`WKHTP_7?
M'?WU2W/:EYGS%C^O_7_0ZMT#>NC3#]=\=_?5+<]J7F?,6/Z_]?\`0ZMT#>NC
M3#]=\=_?5+<]J7F?,6/Z_P#7_0ZMT#>NC3#]=\=_?5+<]J7F?,6/Z_\`7_0Z
MMT#>NC3#]=\=_?5+<]J7F?,6/Z_]?]#JW0-ZZ-,/UWQW]]4MSVI>9\Q8_K_U
M_P!#JW0-ZZ-,/UWQW]]4MSVI>9\Q8_K_`-?]#JW0-ZZ-,/UWQW]]4MSVI>9\
MQ8_K_P!?]#JW0-ZZ-,/UWQW]]4MSVI>9\Q8_K_U_T.K=`WKHTP_7?'?WU2W/
M:EYGS%C^O_7_`$.K=`WKHTP_7?'?WU2W/:EYGS%C^O\`U_T.K=`WKHTP_7?'
M?WU2W/:EYGS%C^O_`%_T.K=`WKHTP_7?'?WU2W/:EYGS%C^O_7_0ZMT#>NC3
M#]=\=_?5+<]J7F?,6/Z_]?\`1U<APC3ZOPG/9_B=IQLYFLK(Z'LTP@:AF<P-
MKVV!+."8A>V-2H*3N2`T1)MNE*`J$P[EC_$O<-ZJ$I.<4Y2:;O3;:)DJ)W4:
MIHH\49K5S*%`*`XCN)\MJ`@+SP#]P#QUZ$0PW^R*X<N`7N;^'5K,??R)6?O?
MN0-SXHOG>^&MR>G=[DO%][XD!<.$SNO`KH80)PXP^V'Q=`0%?QOE#X-Z`K]R
MX+]H'?H"!N?%%VK>,M0%?.'`9W7AUTRFC?[`@+GQA?.]X-/^/]V@>>C;(X$R
M7D*.2C.[W)6QBQ3@&,QAL@L0)":Y/4SEF09Q%&672%<(!B=''6M(C=6EN16,
M$Y.:U5&#]U$A0KR5IO*<6XVJW15RUMRO?9H\#U?QII24:5E-NKU))M+QX]AZ
MG]@?HVSUH@T]*H-*I['\J:=,XQ+%FIO"SZC`H997CR69-@C&JR;C.51E<>N+
MZW6W(NY15\CCLM;'12AEKD[M<8<G=*@5\"LI)2=:4:JGJN=SXUW&_*AS%`*`
M4`H!0"@%`*`4`H!0"@%`*`4`H"F-0OH/3+WIE_B-GJH9RW\&3/->[BBYZDH4
M`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`4]J"]!#*GP(?\`]Q,JH9\?JCQ1CP?<
M^!KNVW;>@=MFWD9K=$21R;'+,&C)O<6YP3$K$#@@6:Q\!)UB):C4`,3JDBI.
M880I3'EF$GDF#*-`(`A!O.E?5'\D5''<^#-2.]-TL=C1I_Y&L=<W*]UB&S'R
MKD<+<]J7F?,;TW2QV-&G_D:QUS<I8ALQ\JY"W/:EYGS&]-TL=C1I_P"1K'7-
MREB&S'RKD+<]J7F?,;TW2QV-&G_D:QUS<I8ALQ\JY"W/:EYGS&]-TL=C1I_Y
M&L=<W*6(;,?*N0MSVI>9\QO3=+'8T:?^1K'7-REB&S'RKD+<]J7F?,;TW2QV
M-&G_`)&L=<W*6(;,?*N0MSVI>9\QO3=+'8T:?^1K'7-REB&S'RKD+<]J7F?,
M;TW2QV-&G_D:QUS<I8ALQ\JY"W/:EYGS&]-TL=C1I_Y&L=<W*6(;,?*N0MSV
MI>9\QO3=+'8T:?\`D:QUS<I8ALQ\JY"W/:EYGS&]-TL=C1I_Y&L=<W*6(;,?
M*N0MSVI>9\QO3=+'8T:?^1K'7-REB&S'RKD+<]J7F?,;TW2QV-&G_D:QUS<I
M8ALQ\JY"W/:EYGS&]-TL=C1I_P"1K'7-REB&S'RKD+<]J7F?,;TW2QV-&G_D
M:QUS<I8ALQ\JY"W/:EYGS&]-TL=C1I_Y&L=<W*6(;,?*N0MSVI>9\S-G9@,;
M+&MGOK4C\<9VN/L+-JWU8MS0R,C>D:FAJ;TKE'2DR%M;4!)"-"C3EA"60F2D
ME$D@M8!8`AM:U>:/Q?O?%G6>9'Z(GH'KD:*`4!Q'<3Y;4!`7G@'[@'CKT(AA
MO]D5PY<`O<W\.K68^_D2L_>_<@;GQ1?.]\-;D].[W)>+[WQ("X<)G=>!70P@
M3AQA]L/BZ`@*_C?*'P;T!7[EP7[0._0$#<^*+M6\9:@*^<.`SNO#KIE-&_V!
M`7/C"^=[P:?\?[M`U<;6?TAV=^WC3[7L?5,_@O=^2.W\?XT/N_&1[)-$OI,M
M(WQ8L"?95%*\I;Q?>^)D[0P4`H!0"@%`*`4`H!0"@%`*`4`H!0"@*8U"^@],
MO>F7^(V>JAG+?P9,\U[N*+GJ2A0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4!3VH
M+T$,J?`A_P#W$RJAGQ^J/%&/!]SX&OG;5_FZ9Q_SKT4_YS=/]3I7U1_)%+'<
M^#,!J^@>84`H!0"@%`*`4`H!0"@%`*`4`H!0"@+MV;?I#M<WQP]7'^*QZO(O
MC?>^+.\\R/T1-^=<C10"@.([B?+:@("\\`_<`\=>A$,-_LBN'+@%[F_AU:S'
MW\B5G[W[D#<^*+YWOAK<GIW>Y+Q?>^)`7#A,[KP*Z&$"<.,/MA\70$!7\;Y0
M^#>@*_<N"_:!WZ`@;GQ1=JWC+4!7SAP&=UX==,IHW^P("Y\87SO>#3_C_=H&
MKC:S^D.SOV\:?:]CZIG\%[OR1V_C_&A]WXR/9)HE])EI&^+%@3[*HI7E+>+[
MWQ,G:&"@%`*`4`H!0"@%`*`4`H!0"@%`*`4!3&H7T'IE[TR_Q&SU4,Y;^#)G
MFO=Q1<]24*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@*>U!>@AE3X$/_P"XF54,
M^/U1XHQX/N?`U\[:O\W3./\`G7HI_P`YNG^ITKZH_DBECN?!F`U?0/,*`4`H
M!0"@%`*`4`H!0"@%`*`4`H!0%V[-OTAVN;XX>KC_`!6/5Y%\;[WQ9WGF1^B)
M56W"D6TPTQ1'+.M3`NOYAP-IIQW#(&V),'I\*P6>S%]R&]OR.)$];WZ40=YZ
M03)9`_-'5!RQYZC9&Q,N<+)1](ZE/Y';)V&U%QJV\:M78ZS!K5^U?A`NBO2.
MDU>Y4VJV.G:(,"K&8\LQN'8/PRZ/$.9,CRJ-Q`#G#ER[$K8UY+5,3I*&\Q4V
M$'1CKDA+5JVE:J`478X5'HI.RH.M].LZ77ZSV0MZ](ZH$+HWGA4H')&F7H5(
M+"L!0D6$@4)CP6&$([!-),`8&PPA%:PK6$&U]VU#@<YW$^6U`0%YX!^X!XZ]
M"(8;_9%<.7`+W-_#JUF/OY$K/WOW(&Y\47SO?#6Y/3N]R7B^]\2`N'"9W7@5
MT,($X<8?;#XN@("OXWRA\&]`5^Y<%^T#OT!`W/BB[5O&6H"OG#@,[KPZZ931
MO]@0%SXPOG>\&G_'^[0-7&UG](=G?MXT^U['U3/X+W?DCM_'^-#[OQD>R31+
MZ3+2-\6+`GV512O*6\7WOB9.T,%`*`4`H!0"@%`*`4`H!0"@%`*`4`H"F-0O
MH/3+WIE_B-GJH9RW\&3/->[BBYZDH4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`
M4]J"]!#*GP(?_P!Q,JH9\?JCQ1CP?<^!KYVU?YNF<?\`.O13_G-T_P!3I7U1
M_)%+'<^#,!J^@>84!_+B#;SKBM:_XO#>UN-?H0__`)A?BA_MOYUO/H#^=$'<
MW>B#N;NYN[MMS=W=S<W?[=WSMSAW:`_5`*`_E[VMY][VMP6\^^YY]_.M;Y;\
M%`+7M?=W+VON7O:^Y?=W+VX;7_LO;]-J`7%8-MT5[!M_;>]K6_\`QO0'\",`
MO.",(K\.X$5K]Z]`?J@%`*`_E[VM:][WM:UN&][[EK=N]Z`_G1!W=SH@[N[N
M;F[;=W=S=W-S^W<\_<_L\^@/U0"@+MV;?I#M<WQP]7'^*QZO(OC?>^+.\\R/
MT1-BVT@9]*#[HAU$(-;ZNS?I@O"0*<FN1)BPIW;0HWQI51)?%A-Q"I<.:IIP
M5&APE,E2+1KI7UH0B0KBE)B,_D7&U:5G.T?O'L/%#IQ@&S$R"TM4^U)ZD-J5
M*M%V$-2V`<.1?#.IE?&$6,F-7F"&S^;8OE,_CL:ELCNPX9O'8$-"[.\/:8PY
M&(95'CD9">/KW(U+E5AW>O\`X=FYZ%D[3BVW''1IU^.L_P!#<H!19199`2P$
M@+``D!00A*`4$-@EA+""U@!+""UK`"&U@V#:U@VW-RM/.?P[B?+:@("\\`_<
M`\=>A$,-_LBN'+@%[F_AU:S'W\B5G[W[D#<^*+YWOAK<GIW>Y+Q?>^)`7#A,
M[KP*Z&$"<.,/MA\70$`<+VL*][WM:UNAO>]_.M:U@WW;WO\`HM:@*^<Q@#:]
MQ#"&W0A%NW%:UNA#NB$+=O?@M;S[WX+6\^_G4!`EYI9Q5C23`&E&`",LTH83
M"QAN.U["`,-[A$&]O/M<-[VO^B]`0!PO:_3+6O:][;N[;=\^VZ+SMVWZ-W]'
M]M=,IHW^P($Y\87SO>#3_C_=H&KC:S^D.SOV\:?:]CZIG\%[OR1V_C_&A]WX
MR/9)HE])EI&^+%@3[*HI7E+>+[WQ,G:&"@%`*`4`H!0"@%`*`4`H!0"@%`*`
M4!3&H7T'IE[TR_Q&SU4,Y;^#)GFO=Q1<]24*`4`H!0"@%`*`4`H!0"@%`*`4
M`H!0"@*>U!>@AE3X$/\`^XF54,^/U1XHQX/N?`U\[:O\W3./^=>BG_.;I_J=
M*^J/Y(I8[GP9@-7T#S"@,;Y#IP;9!DQ3DPS(4\1*U,_Q3/KQU,*+'1\LW%,=
ME<=1QP(5\:6.@XU(@2Q2\/"`YR,-;Y$A2/T641]T-<%*V;*K6KQ3T4N5*88/
M3VX4*MNE*+"2K?7K-.N-*JEUV%SJ:3&B:1$[1;BO")4F8C,Q)-H>C:56+@NJ
M(4^2KB=2SZ]G`41.QW7LDDEJ/)6&K#$04999I81GA,&$%^-58I55Z3#3G:L3
MTNO2.5'9Z&MJES5C0^^[69#L>LK/9&IR11"2Y)1.$0?LBYX@F.8[!X]B*<Q!
M1:%QR2.$0:EPFEY;,ZP"=L2AF+-EBB<,$GC#DM`>@3-C4VJB'9-MN2FTW=62
M5R>&':GKKP(Z.-BTE>E!NKDG?2K5UEJ^ZC32O['U&/:'2]5#\(O@\NQ)S6+-
M#N7\Q9BLRQN-2Q8RY3C"6.)XVN=HRQ*&A8WG(W12\!'$2W:,(G"Y)A*]0@3%
M=7)G2.BO^23=RQ6'_EQKR2K)67\6,8U;58NM:-\;R@G_`%$YFRK$YWCO*LU\
MG:2$YDT"3"/.CBAQ$CDC>?D#*'3WEK=/*2<G:%E)1=:FY>VM1SBYR!F3JK)G
MAS5GF?B3:;33=:.#6;I^F[5W5*48Q:<52L<JGC2Z-V=?I??2XMN-:A9GI83Y
M>S$)>`W!Y.T3UNQ+,4>ZU(%2H]P=VU0[XM>4CI=(-U:RT\QCX6%<!,J`E77D
M2`@TFYUB17U2<;3^7I)J7@J=N)+BIV8_-T.2<=U+7HZX/`VA0+&"W-^E['$1
MU=L[/DR2R>*QF49'9W9F2-39:3JA%R4EL$TLI3:D3BBBA2G9RA$%@N<8U65*
M!'GG&FF=DK44IWNYOO.+:C-O)MI)NR]-,/4U#Z=V5/I]T'X[SA@)GB,"SODO
M4`##+QD1;'2I"-=$7S5'((<0TO#:M/L4K;436A:DP0HS&]Q`F0%V1N*13N*0
M\8]7)QE&Z3=&Z5NM/D=YNUE91FVXQA:I72LFG<6+DO55K`QYG.<XT1Y.CKR?
M@UVP)&"VV5(=/..6C.MYRV,3G*I#(2Y=+V2=-RV1G.S@TP]+AQ`K:&I>UIT+
ML$Y6:K,*V4YITK6S95]E6JJ^YNN.%GUQ)4(."E9?6MNJM-PLUHE1-/"KM7O1
M0[S1K"SM-]3C/!(]E\TW&^5,FZD\2M+>HA6&VH43)Q[#9<-@D$08R'R2Y:5.
M<7D+*C&X/N4$S5&I888$"*)(T:LLHI;DY4KU7;2P6"=*:<=+QU!Y.*@VXWQC
M"3OE?::33=$KTW1*]:[C&/%VJ_4?$<&Z<8!!LT$($JK3?.\O*)R^G8%N<KES
M/.UC`1C&02#-<ECC.8Q0]$0FD$F+:5BW*9Z&3IC"NA;40%"65.2BDG\KE7JX
MUP=K5BZ7ERA%RFW'YU&SUL*5M*RGCHO4;M1*M6>I3,67,.ZH8[D;,./,-H(=
M@#3JX),($-40?`9K>,NPJ.S&7OD9F"IQ/D2YN9Y(L4L45/@KDO:BBVY,HD12
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MQ7%--35`X`P+\<I;9:>3$*R?.D:CZI`A>$J@H+TY)HB6MC%W(AS0.W]T\SJG
M!6;+E)Q3LQHZMNKONT=A[E&1O1M+,TM3>8,U`V-B!O0FF'64&&HT:4I,F,&?
M;SCQC)+`(1UO.,%>X[<:AP.\=Q/EM0$!>>`?N`>.O0B&&_V17#EP"]S?PZM9
MC[^1*S][]R!N?%%\[WPUN3T[O<EXOO?$@+APF=UX%=#"!.'&'VP^+H#`C:&^
MD9UD?%?SK]E\GK'@^Y\"\G\3)_7'\D:)CS=1J7)&RE4YHM@X^*$:8]3Q^*2L
M;)9L:]"9RM&#>887D<F8C.:%*X;:&/AN4PEV0F*^O030W2B1VMSOZM:9KIY=
M-3OU*9:S:K:C6M/_`-%A2\K=MUDYHAN#H(T,6=,:Z9VG&6SMA.<8)%G/'D#/
M2:@,@O-I,C%%8V0^@3`;D#*>R-S(T,,%("XEOSD6N<$SLT%&M-56B5]*13[W
M^K]P#R:<GU7.N5<7>ZQ5U]:XN_&[51WGP7S+FH.,NNM;5%`,JH8K)HAI]V>V
M39PQJ8!&)`WY1=Y)BT\Y8U.1SB4$459;V<7\PX,4(;W,:E>BND<F],W73*S;
MJY5OI!N[&L5X;@HP?1P:K6645:THE+13%W:;NPW\+#.G%EF[G0]-*N9T.[N[
MG1@`+<W?.W=S=W-W<MNUW_X_W:/*:O=K/Z0[._;QI]KV/JF?P7N_)';^/\:'
MW?C(]DFB7TF6D;XL6!/LJBE>4MXOO?$R=H8*`4`H!0"@%`*`4`H!0"@%`*`4
M`H!0%,:A?0>F7O3+_$;/50SEOX,F>:]W%%SU)0H!0"@%`*`4`H!0"@%`*`4`
MH!0"@%`*`I[4%Z"&5/@0_P#[B950SX_5'BC'@^Y\#7SMJ_S=,X_YUZ*?\YNG
M^ITKZH_DBECN?!F`U?0/,*`4!!P8QQJ5,!Y"*Q[!RY\8$0#)P")L`)@,`B>I
MA`')0M]GH01)_P#8"");>UR?]E>W0?BUE%6M%772_P`3:NE*NFJKIKP.PEQY
M`$,J5SI%!X>CFR\H1"Z8I8RRIY4M(&`)8R5<A*1`=U!0P!"`19RL8!`"$-[7
MM:UJ45:T5=>D5=*5=-5;O`KJ9(=-^#8J^SN:,6(\:1(JSB2_R!PCD78D"@<N
M&F0NJ-4:6WE#<54J,+1HUJ$(%*E^&6G3G$*Q`+!;'9BJM12[EI-5N3HK4GJ5
M7AR]"HE&:-!,(Q[$)^.4:>8[C>7J+MD-?T;9$TC"YK8DX#=+MB"R%ML`E9&7
M<\Q==`820H974T9]R4RT8A7RN323ZM'A<J%6<JVU2;:Q5^FZ_OP[253_``AB
M+5+CR%=;Y$<7B&0S"-YF=6S'R>,(XUF<1#DV2YI,ERI5'EZ]>T.SJWMCLY*V
MA4T/+N`OI2IUN69N!UQ4DM55*ZE_>8I2@W=UDG&^M8XITO5ZOQKW&5%401DN
M%0TEH21\J)1DIA0.('="R%L+4!H1.Q;@-V+=$C:%)9&F<0.AACD!:22!2%P&
M-8$VR@0C+Y1845#:O&KU8Z,*>!`Y`KP@IS!#(Y)FV#KLUFQUVD\%N[1I"X3!
M-'&%800[.3$^J&P\]L3(%KB0$T!#DE,N:JZ,LH?1#%;'9M*M+6BZ_<S5:LMJ
MMFJ3ONJ\*HZ>.B<`9`4O\[QO'\=O+BWSY];)%*FB(M25V!D6*J%+.^C7.AK0
ME<5,@:SE*Q"<Z7-..N%0H+)6&%'&=$5EWI+'&FD.TJ)MJZY5T.CP[;KB4*L/
M8C7-R1G6XLQRL:$#LH?T+4JA$94-R)]5W+NJ>DB$UL&F3.RFY15U#D24!8=<
MLNYAPK@#N;1:EX(RU+6]6+PU'T9!C7',L<4[Q*8!"I*[)&X]H2ND@BK$\N*9
MI4]'U2UIUKB@4J26Y1TPSIZ(LT*8WI@^F%"Z(6ZHM2U8!-K!M=S:)F$(0!"`
M`0A`$-@A"&U@A"$-MP(0AMN6L&UK6M:UK;EK>=:M,/U0"@+MV;?I#M<WQP]7
M'^*QZO(OC?>^+.\\R/T1/D;>79T0W5;A&59\G&LN;:7X_AK'#*A>FYZD+J7I
MQ<V=OR8V21<_9(A<=9G>2RF56)5F-L%2L*=4YJYB3#DB)O6J+`3G<CKDYN+H
MHIU>_<]!YSI*DV"TE9U+3D;;.[2[,D+N<B<'S&#^RYF7M<W)95R9X3L)I$CP
M62R@.6+$":R%6X'HRV]=9,N"N0FIP*R1U_\`KHA!>'^1_H;E%%D%%$$@"642
M6`HHL-MP("RPV```;?H"$-K!M;^RU#S'\.XGRVH"`O/`/W`/'7H1##?[(KAR
MX!>YOX=6LQ]_(E9^]^Y`W/BB^=[X:W)Z=WN2\7WOB0%PX3.Z\"NAA`G#C#[8
M?%T!6<B;&UZ0+V=Y;T+LT.J0]N=&IS2)U[<Y-ZQ.8G6(5Z%46:F6(U:<PPA2
ME4%&$'DC&4:`0!"#<"J'B&0]0)B&HB<:/'%4*ILBXSF)K-%&VUR;PL[BWL(A
MI179T*]I++:UJ1ONG(5-P`(CRS$P0E6"OKB8(:C]#L'SP>WDFY$R1C6*)8(X
M8U6P''Q..`PX^(.]U*=V3L+;,,?2TW'[RYMBLQC72''RF,N:ECL!N-,$$-C+
M8U7L\/U;CI#*.&"3=:U=:UW-56FCK?>6LGQ3C=BC8XF@A,9NPCCL;B:U$M9F
M]PZ\1^'(2FF,-K\<N3GG/Q#(WD@3MUG8Q9=,#H[E7#<8[WZ3222IHIX41%IU
MK5UJWO>+6JO8?IRM:U[VM:UK6L;:UK>=:UK6#N6M;]%K5O\`Q_NT8:N=K/Z0
M[._;QI]KV/JF?P7N_)';^/\`&A]WXR/9)HE])EI&^+%@3[*HI7E+>+[WQ,G:
M&"@%`*`4`H!0"@%`*`4`H!0"@%`*`4!3&H7T'IE[TR_Q&SU4,Y;^#)GFO=Q1
M<]24*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@*>U!>@AE3X$/_`.XF54,^/U1X
MHQX/N?`U\[:O\W3./^=>BG_.;I_J=*^J/Y(I8[GP9@-7T#S"@%`*`HG4B2U*
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MHVN'DB5)7D#.!6KD21F3`2(3`NQ84Y#>0,HNY6GDM-JBPQQ6KU(C866N:L*4
MJ5PI1TQ,4)KIWR=!,CYP>,:-&I4Q-C;53I3<L%B!,,XRMI\A\Q;X4ISZZM)#
MH]NR";,*Q8<ZD3UU=0OZ1I*0&H5JIO((6$F0XM6J*5TXV;Y8:6M?:RU*+4:V
M+\GE%*Z*O5;&"5'JI1L_,:TXY(EN1,6.LX9-29:6::O-6$5RH+R89QCK5;`(
MKS%\Q^C<"&U[;4$7Q\\O25I&R/"`#0D?^N`4B=S6DJDA("BW9;M7RDG?+-\;
MD_4.44I4L70@XW0?6ZJ>B]I5NOIC2X^;@_`^HN?R[1B"9/NI3$CI$<%ZEHW)
M,H)F%0FEK(4CSHN2P&)2=\R1#Y(WHQ/D'1LZEG3.Z,MV=F-"@7-AYB.]S3=C
M&3L5M+JR3>E7W*]:C92@EE**$JRR;4=#ZM[2BU@\:8,@\1Q=DV#-^*(KEV':
MGI/AL&IC66Y3:.X]1SIARO-9"K6LP\/Y,=V2!&P^6/4;5F`>WI+)(P0EBJ%U
M7%.*\2=H5)@7Q)I14E*EJ=4JUKH=%?3'!4UXARBW-IP4K.3LMTLJBZT56JKV
M.]TIKKLZV8[T^R+1'AQXDKL_/CTL7Y9ZL=)0Z&O3\I"GS5D5*ELY.AIRBZPX
MA&0G3!-+.,3V*)+`EO9,$JUNF2S([^+.66HLI*E*4C@J+-CH,]:Z'(4`H!0%
MV[-OTAVN;XX>KC_%8]7D7QOO?%G>>9'Z(F7FV(TF9-UM[/'/FGK#76M1D^1E
M0.30YD?'`AJ996YX[R-%)\*(N#BK.3(4=Y&CCJIL;5+DJ1M:=Z/;#W1<A;RU
M*PCD7"2C)-X+W31YG]1^F_7,X/V<X-A?9IXM<I/KA2Z-<LQA^Q=,<:HP[-C5
M;BZ-19LR@TA/:$*\<<ZO=8.>^%KK/<28#VI8M5ENLS)%(F`H=4X75DZ1M)J_
MKQ=:<:-<#W$-9;@4V-Q3N>0J=2T"0MS5)2KDI5+@!.6%:>F)%^,40<IL:825
M?SRRQ!#?S[4.!VCN)\MJ`@+SP#]P#QUZ$0PW^R*X<N`7N;^'5K,??R)6?O?N
M0-SXHOG>^&MR>G=[DO%][XD!<.$SNO`KH80)PXP^V'Q=`0%?QOE#X-Z`K]RX
M+]H'?H"!N?%%VK>,M0%?.'`9W7AUTRFC?[`@+GQA?.]X-/\`C_=H&KC:S^D.
MSOV\:?:]CZIG\%[OR1V_C_&A]WXR/9)HE])EI&^+%@3[*HI7E+>+[WQ,G:&"
M@%`*`4`H!0"@%`*`4`H!0"@%`*`4!3&H7T'IE[TR_P`1L]5#.6_@R9YKW<47
M/4E"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H"GM07H(94^!#_^XF54,^/U1XHQ
MX/N?`U\[:O\`-TSC_G7HI_SFZ?ZG2OJC^2*6.Y\&8#5]`\PH!0"@%`*`4`H!
M0"@%`5+E?!.(<XHV9%EB`,$V+CBI6MCY[J2<6XLBAP3A2N-VIV0G)'1`6Y)B
MRB'-.E6%)W$DD@M:4>$@FP)<5+%5Q]<2E*4:V6U7&FDG$2B,7@4:98="V!IB
MT5CJ$IL8X^Q(2&UI:T)&[TM,C1I@%DD@Z(0C!WL'HS3AF'&B&:8,8J225%<D
M8VVVVZMXLD5#!0"@%`7;LV_2':YOCAZN/\5CU>1?&^]\6=YYD?HB9"[=269S
MA&RNU8R73TND[1/$$8B@'-[A0UA4M8L;K<@Q1#E5W9#T`REB.Z+'BB1C=W).
M:2<TQZ[PZE*4AB("LCD=,G2W&NOUT>M#QBKLF:%<5XKUGXCV?V<\P.N2S]36
MS@R]LW/(^GF1V7LB9K8,5F1C*R^1W/BS?=*-O>LJ97;'-E6EL*0^4J6=FCR9
MU:PIV]=FE]R]&SO258N:5+,E/"B573@L-!_I+,XG,;0U#>RTY+R-M0B=RD@K
MB2%.8DI5UY:45Q"N).!5<T)(KB%>Y=@WN*_#6GE.Z=Q/EM0$!>>`?N`>.O0B
M&&_V17#EP"]S?PZM9C[^1*S][]R!N?%%\[WPUN3T[O<EXOO?$@+APF=UX%=#
M"!.'&'VP^+H"`K^-\H?!O0%?N7!?M`[]`0-SXHNU;QEJ`KYPX#.Z\.NF4T;_
M`&!`7/C"^=[P:?\`'^[0-7&UG](=G?MXT^U['U3/X+W?DCM_'^-#[OQD>R31
M+Z3+2-\6+`GV512O*6\7WOB9.T,%`*`4`H!0"@%`*`4`H!0"@%`*`4`H"F-0
MOH/3+WIE_B-GJH9RW\&3/->[BBYZDH4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%
M`4]J"]!#*GP(?_W$RJAGQ^J/%&/!]SX&OG;5_FZ9Q_SKT4_YS=/]3I7U1_)%
M+'<^#,!J^@>84`H!0"@%`*`4`H!0"@%`*`4`H!0"@+MV;?I#M<WQP]7'^*QZ
MO(OC?>^+.\\R/T1,P]L)DS+6&]G3J,RA@R<3K'V5(@W051$'['6.X]E22'N#
MSDZ&1@3'>$R<LUL<&-_3OAS3)G&Q*I;&X^J<I*@;7E4T%LKCR+@DY).C5^+H
ML'I1H0TV;9G9O8B;()D1RV/>H"`:G"(HS$Y%R5AC0[I];UJV;":"$DM=6">I
M9/CZ5'H7URZM6#./9&)0H*5W+5(;7M?='5Y.3^>+6A.3PT:SV/T.!Q'<3Y;4
M!`7G@'[@'CKT(AAO]D5PY<`O<W\.K68^_D2L_>_<@;GQ1?.]\-;D].[W)>+[
MWQ("X<)G=>!70P@3AQA]L/BZ`@*_C?*'P;T!7[EP7[0._0$#<^*+M6\9:@*^
M<.`SNO#KIE-&_P!@0%SXPOG>\&G_`!_NT#5QM9_2'9W[>-/M>Q]4S^"]WY([
M?Q_C0^[\9'LDT2^DRTC?%BP)]E44KREO%][XF3M#!0"@%`*`4`H!0"@%`*`4
M`H!0"@%`*`IC4+Z#TR]Z9?XC9ZJ&<M_!DSS7NXHN>I*%`*`4`H!0"@%`*`4`
MH!0"@%`*`4`H!0%/:@O00RI\"'_]Q,JH9\?JCQ1CP?<^!KYVU?YNF<?\Z]%/
M^<W3_4Z5]4?R12QW/@S`:OH'F%`*`4`H!0"@%`*`4`H!0"@%`*`4`H"[=FWZ
M0[7-\</5Q_BL>KR+XWWOBSO/,C]$3##6!M:4.SGVW>6[9\?=3V0M.;KHI@;/
M%,(XD7WF,68,J/LPC#UY/P8TEF0X9"&E:./1^1-"V5MP1R$0G<ION`U&X+32
M>6ZO[VG=0<LFK*5;3J\'3O+,\U=[/KV`=>'([B3_`/L!65['Z<S.AGV>)Z=J
MTY'$=Q/EM0$!>>`?N`>.O0B&&_V17#EP"]S?PZM9C[^1*S][]R!N?%%\[WPU
MN3T[O<EXOO?$@+APF=UX%=#"!.'&'VP^+H"`K^-\H?!O0%?N7!?M`[]`0-SX
MHNU;QEJ`KYPX#.Z\.NF4T;_8$!<^,+YWO!I_Q_NT#5QM9_2'9W[>-/M>Q]4S
M^"]WY([?Q_C0^[\9'LDT2^DRTC?%BP)]E44KREO%][XF3M#!0"@%`*`4`H!0
M"@%`*`4`H!0"@%`*`IC4+Z#TR]Z9?XC9ZJ&<M_!DSS7NXHN>I*%`*`4`H!0"
M@%`*`4`H!0"@%`*`4`H!0%/:@O00RI\"'_\`<3*J&?'ZH\48\'W/@:[MMTO0
MM>S;R*YN:Q(W-K=F#1DO<'!>H)1H4"%'K'P$H5K%BM0,M.E2)4Y9AZA0>8`D
M@D`S31A`$0K3I7U1_)%+'<^#-3&^HTP]D=@;E?Q]SAKW6X;4?,N9PL3V9>5\
MAOJ-,/9'8&Y7\?<X:6X;4?,N8L3V9>5\AOJ-,/9'8&Y7\?<X:6X;4?,N8L3V
M9>5\AOJ-,/9'8&Y7\?<X:6X;4?,N8L3V9>5\AOJ-,/9'8&Y7\?<X:6X;4?,N
M8L3V9>5\AOJ-,/9'8&Y7\?<X:6X;4?,N8L3V9>5\AOJ-,/9'8&Y7\?<X:6X;
M4?,N8L3V9>5\AOJ-,/9'8&Y7\?<X:6X;4?,N8L3V9>5\AOJ-,/9'8&Y7\?<X
M:6X;4?,N8L3V9>5\AOJ-,/9'8&Y7\?<X:6X;4?,N8L3V9>5\AOJ-,/9'8&Y7
M\?<X:6X;4?,N8L3V9>5\AOJ-,/9'8&Y7\?<X:6X;4?,N8L3V9>5\AOJ-,/9'
M8&Y7\?<X:6X;4?,N8L3V9>5\AOJ-,/9'8&Y7\?<X:6X;4?,N8L3V9>5\AOJ-
M,/9'8&Y7\?<X:6X;4?,N8L3V9>5\AOJ-,/9'8&Y7\?<X:6X;4?,N8L3V9>5\
MAOJ-,/9'8&Y7\?<X:6X;4?,N8L3V9>5\C-/9@O3-(]GQK5?H\[-C\Q.^KC5B
MX-+TRKTKHTNB!2Y1TQ,M;G%":>C6I%!8K&$*4QQI)H+V$6,0;VO7FC\7[WQ9
MURBI"*=SL1-@46T($QG:79+VBMLH&K3\BZ7F?36+$5X8!.2T%M,QB$MM,K3O
MR4G#7C/O%+(.L%X>C"59==5UZ,ZFLG/Y%N754:8-NO>;!*$B@.([B?+:@("\
M\`_<`\=>A$,-_LBN'+@%[F_AU:S'W\B5G[W[D#<^*+YWOAK<GIW>Y+Q?>^)`
M7#A,[KP*Z&$"<.,/MA\70$!7\;Y0^#>@*_<N"_:!WZ`@;GQ1=JWC+4!7SAP&
M=UX==,IHW^P("Y\87SO>#3_C_=H&KC:S^D.SOV\:?:]CZIG\%[OR1V_C_&A]
MWXR/9)HE])EI&^+%@3[*HI7E+>+[WQ,G:&"@%`*`4`H!0"@%`*`4`H!0"@%`
M*`4!3&H7T'IE[TR_Q&SU4,Y;^#)GFO=Q1<]24*`4`H!0"@%`*`4`H!0"@%`*
M`4`H!0"@*>U!>@AE3X$/_P"XF54,^/U1XHQX/N?`GK]%HQ-8Z;&IE'&&6QQQ
M*17<&"3-#>_,BZZ,].N276-3JG5(55TJU,G6)^GD#Z0J3DJ"NA-*+&&32KMZ
M[IF['7!7)'`.;]#:O6_%C>NZ9NQUP5R1P#F_05>M^+&]=TS=CK@KDC@'-^@J
M];\6-Z[IF['7!7)'`.;]!5ZWXL;UW3-V.N"N2.`<WZ"KUOQ8WKNF;L=<%<D<
M`YOT%7K?BQO7=,W8ZX*Y(X!S?H*O6_%C>NZ9NQUP5R1P#F_05>M^+&]=TS=C
MK@KDC@'-^@J];\6-Z[IF['7!7)'`.;]!5ZWXL;UW3-V.N"N2.`<WZ"KUOQ8W
MKNF;L=<%<D<`YOT%7K?BQO7=,W8ZX*Y(X!S?H*O6_%C>NZ9NQUP5R1P#F_05
M>M^+&]=TS=CK@KDC@'-^@J];\6-Z[IF['7!7)'`.;]!5ZWXL;UW3-V.N"N2.
M`<WZ"KUOQ9\?+L*AL!T[Y18(+$HS"V*T7?5EF6)L+5'&FRQ22"RA59N9TB-'
M92?8LOIQ_2>FF]+!T8A="'<O)Y\>\B>:]W%&-6URU+Y"T@;/74-J$Q+.(;C[
M)T`;X*?"9!.V)9)X^<Z.V3H6R+(_UA0M3R<XN\I8W!WCL?Z<B`V(7QR;W-[<
MF1E1.#TWP=()2DD[T]7<^!Y_M3&I'\)-TAZ?8GJ8SSEK11$<9O+]`&*;#)B"
M=Z?,,AR([-[$TO&2VUH@*LHYH;'AU0('T6-EN1')&8?TQ*VKDY9AP!U2R4G1
M*5;Z=M+[O]T-T.RVU>ZLLP3G5]I*UU,&+$>J+1?*,2II1+L,#7!Q_D&#YTA;
MG-\?/[>F7BZ,MQLVLZLY<:2D92QHG)H3J8ZT.J1R`>.<XI*,HUI*M$\51WFU
MZ5QACE[0-FD*,2YM,/(4#3@6+D(KFD"N(H75#<I2*;="*][]#8ZP!<`PBM6I
MM8'-I/$H5UP7BTKHKEQL\.X$-[?]XY4+A-O;]9[O^BJMRUKRQY$0BFKUI(*X
M89QP78701\X.YT7_`!Z27X!6W.%XO6J4J2=<*:%IQT?^:"8JK2?[<0QPQ/`2
MPBZ!D-M_6<+T_BX+VW.,Z7_^/Z:J$FZWX88+&NE"2HVE^W$+6XTA1=Q]`T&6
MX?\`BSU?]7=_2XWJVV\=!)#%L!B@!#Z%L,MY]O\`B3M?]3=_2NO2KPU?OZP0
MU9#XZ`5^A0#MQ?\`U]QO^C_VJ[TK^T3!"5\<9B[?B)!6_%#?SU:T7G]%>WZR
MB_Z*6G_XDN`(:X-*`NU^@(O;<M;<W3E`OU[6_6-O^BEIWWXXTNX`A2].27TS
MH`;FY<6Y^,._`+<_2*_Z/TU<FZ1[5R?$$*<#3"[BL"]K?UGZH;\%K;G&M?\`
M^/Z:JO5KILU]`:O]K2L4CT$9Y)$9:Y8A8QL(/2R[;O0Y@Q\*WXU@6%;<%:U_
M.O;=X+^=YU1E/A/NCQ1V_C_&A]WXR/5WHRP/BMPT?:45ZN,G&JUVFO!:Q4;:
M1RHJQBA3B^+''&6+)>RRB[#,&(70%``6#=Z$``AM:UO-:EK]$;*,;3NTO2]9
MDIO?,1^M8_ZSR[[^I;EK]%R,L1U>KYC>^8C]:Q_UGEWW]2W+7Z+D+$=7J^8W
MOF(_6L?]9Y=]_4MRU^BY"Q'5ZOF-[YB/UK'_`%GEWW]2W+7Z+D+$=7J^8WOF
M(_6L?]9Y=]_4MRU^BY"Q'5ZOF-[YB/UK'_6>7??U+<M?HN0L1U>KYC>^8C]:
MQ_UGEWW]2W+7Z+D+$=7J^8WOF(_6L?\`6>7??U+<M?HN0L1U>KYC>^8C]:Q_
MUGEWW]2W+7Z+D+$=7J^8WOF(_6L?]9Y=]_4MRU^BY"Q'5ZOF-[YB/UK'_6>7
M??U+<M?HN0L1U>KYC>^8C]:Q_P!9Y=]_4MRU^BY"Q'5ZOF-[YB/UK'_6>7??
MU+<M?HN0L1U>KYC>^8C]:Q_UGEWW]2W+7Z+D+$=7J^8WOF(_6L?]9Y=]_4MR
MU^BY"Q'5ZOF-[YB/UK'_`%GEWW]2W+7Z+D+$=7J^8WOF(_6L?]9Y=]_4MRU^
MBY"Q'5ZOF53F["6,F/%TJ=6N.G)EZ0MJNG/O(),HL"YKZUD&;I*IY.('T11I
M@?\`:%"Z'HNB#N#L$5JA.5I7Z]"U/L)E%)-I<=9,Y3BW3I!FRSW->L</9KJ2
MD5G>4Y">X^V76'A,&0DLO=I0D2W4G`)-$418WII@2C!`!>P!7M-N6OT7(JQ'
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M4D')S@=,+,!:H2E:C?\`,M"U]Q+BDG=>D]9<Q&GW$8B"17BQ][B*+O>_DFEW
MGWN"U[\#]_;4VY:_1<C;$=7J^9R[WS$?K6/^L\N^_J6Y:_1<A8CJ]7S&]\Q'
MZUC_`*SR[[^I;EK]%R%B.KU?,;WS$?K6/^L\N^_J6Y:_1<A8CJ]7S&]\Q'ZU
MC_K/+OOZEN6OT7(6(ZO5\QO?,1^M8_ZSR[[^I;EK]%R%B.KU?,;WS$?K6/\`
MK/+OOZEN6OT7(6(ZO5\QO?,1^M8_ZSR[[^I;EK]%R%B.KU?,;WS$?K6/^L\N
M^_J6Y:_1<A8CJ]7S&]\Q'ZUC_K/+OOZEN6OT7(6(ZO5\QO?,1^M8_P"L\N^_
MJ6Y:_1<A8CJ]7S&]\Q'ZUC_K/+OOZEN6OT7(6(ZO5\QO?,1^M8_ZSR[[^I;E
MK]%R%B.KU?,;WS$?K6/^L\N^_J6Y:_1<A8CJ]7S&]\Q'ZUC_`*SR[[^I;EK]
M%R%B.KU?,;WS$?K6/^L\N^_J6Y:_1<A8CJ]7S&]\Q'ZUC_K/+OOZEN6OT7(6
M(ZO5\QO?,1^M8_ZSR[[^I;EK]%R%B.KU?,JG.6$L9,.(,B/+5'3DSBVQ9R5H
MU`I!)E-B3RBMT`[D*GD],;:U_P!0XDPL7ZP;VJ\G*5N-^G4B9123:7'61W:0
M8MTP9ET39_@.LB7$X^TZN,23.$]R`)T*9UD&,87UI>XO*65<:C<@BD#5+D#$
M:Q-=FQUO(702:.79W@#L)K6<CM%M23CCH/%?'I'LM)6[8]A.KG\(-U/:K=*>
M+Y(P/L?TRR+3%JYC[`\$Q,T/D<8I5(W-NG21T9D*0NS.*Z*)-KD4R'K$<<<8
MP)06<G'>D[W')*,G\UI:<:(]INDO0Q"M*63]8&:$,UEF1<FZR\YN67I_))88
M&XF&/(E;Z'&6*8Z3U0L-!$\7,4A<F)B.5*S#C4Q_24Z=J:$K4RMHX.3:BL%%
M427J^]Z3-T[B?+:A)`7G@'[@'CKT(AAO]D5TZ<`N[\.U4LV6[B1#.6_@R`N?
M%%\[WPU63T[O<3SGNX(@+APF=UX%="2!.'&'VP^+H"!+N,+N>]0%?N?!W(/#
M%0$"<^*+M6\9:@*_<OVO;%X=7+"/=[($`<^,+YWO!J_D^WV!JYVLWI#,[^ZQ
MG]KV/ZC*?"?='BCM_'^-#[OQD>R/1+Z3+2-\6+`GV512O(6\7WOB9.T,%`*`
M4`H!0"@%`*`4`H!0"@%`*`4`H"F-0OH/3+WIE_B-GJH9RW\&3/->[BC5YMRV
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M`)&L=<W*6(;,?*N0MSVI>9\QO3=+'8T:?^1K'7-REB&S'RKD+<]J7F?,;TW2
MQV-&G_D:QUS<I8ALQ\JY"W/:EYGS&]-TL=C1I_Y&L=<W*6(;,?*N0MSVI>9\
MQO3=+'8T:?\`D:QUS<I8ALQ\JY"W/:EYGS&]-TL=C1I_Y&L=<W*6(;,?*N0M
MSVI>9\QO3=+'8T:?^1K'7-REB&S'RKD+<]J7F?,;TW2QV-&G_D:QUS<I8ALQ
M\JY"W/:EYGS&]-TL=C1I_P"1K'7-REB&S'RKD+<]J7F?,V,;+Y"B;-C*V-K:
MC2M[<WNVME"@0(4Y21$A1)-7>H-.E1HTJ<!9"9*F(++)3IR2P%$E``66`(`V
MM;R1^(OK7Y':>#^E?B;PD_Y.1[R5X`:@'-0"@%`*`4`H!0"@%`*`4`H!0"@%
M`*`4!3&HGT#<I?`YV\35Y//CWDSS7NXHUY[=?#[[G/98ZHL>1.!95R?,7!'C
M%PA\%PO%W&;3]]DK3F+'ZUKLAB+40I<'UE;#2[O$N(2$#5(HFW/3LEN4J;R3
MBX.N3=)IW+'%T6#TFH"&[0V2-$2C+2[?@NNH5"Z-C$U-R])&=**JT<3JT2(E
M,>6QA<--0%Q34$PL74)*SHU)*;I91YQY@!'&"W#_`/K'S?[/7E0XG$=Q/EM0
M$!>>`?N`>.O0B&&_V173IP"[OP[52S9;N)$,Y;^#("Y\47SO?#59/3N]Q/.>
M[@B`N'"9W7@5T)($X<8?;#XN@($NXPNY[U`5^Y\'<@\,5`0)SXHNU;QEJ`K]
MR_:]L7AU<L(]WL@0!SXPOG>\&K^3[?8&KG:S>D,SO[K&?VO8_J,I\)]T>*.W
M\?XT/N_&1[(]$OI,M(WQ8L"?95%*\A;Q?>^)D[0P4`H!0"@%`*`4`H!0"@%`
M*`4`H!0"@*8U"^@],O>F7^(V>JAG+?P9,\U[N*-:6VN]!/2C\?S3O_A>1:0S
MX_5'BBGFS^E\4:XAYJQ<4YJV@V8-Y*QO735`NN<0X$HDAF.6MM=YXI4.9J,#
M84U1),\-J=]>QJ[,[>\*@1\]<%^`:VE^RU'7K],?#2SA9>K&GK6EW;1T6_`J
M_$FLO3KG"6$PC'4Y6.$D7LRJ2,")\A4[AA,OCJ$PHM8^PIPF4:86^7MB:YQ9
MAJB/*G#H4PNKNAZA_P!YHIQDZ)]N#7%(J63G%5DJ*M,4Z/4Z-TWF4-40*`4`
MH")M$[A[]*I?!V:0MKC+H`7'39G'TQW1N,<+EJ%2Y1H;F3T-ND!>4"-4J0WZ
M(7322#!>=N;E95-M5O5*]E<#:.B=+G6CUTQIW5)96F$`@.48'E!F>I!!I`4]
ML\>E,HA;RNNB<VLM#)86YGL\F;3`/*)O-,LU.*8].8M)+,;E%B[G(U:A/<)M
M\33O3N55X8FM-8JER>YWHH:&:ZM+.0)RT8^BF3P.#U)'A?'HFZ'Q.;-<)F;^
MUB-`N9H=D-UCB*#2AQ*,)&62G9)"M$X&VL6V76CO:U2LI!NB?8L57N>!3R<T
MJN-R57>JI:VJU6]%^8[R=!LL,:Z28_?0R%E;9))(@M6@;W5ML1(HB[J6*1-W
M2'A"WJC+MSJC4I+J2B1HE-R^G(E*A.(!HJ33O5^CP):<71JCHGN>!/*TP4`H
M!0"@*6:]0N(GJ;D8Y;I0I.F*B:S?'1+29%9BD+%,L=1EFF4N9KNRR/IV8%V^
M,2!J>$:\QP"V/J90:&/K70]$O*33:5:5OJU@\4JOT*LR2K2ZB>*P;HM.O>M)
ML+V9GYG(CX0:X?\`.!J&KR+XB^M?D=IX/Z5^*-W"?\G(]Y*\`-0#FH!0"@%`
M*`4`H!0"@%`*`4`H!0"@%`*`IC43Z!N4O@<[>)J\GGQ[R9YKW<4:_=8VF;5&
M\N^JK,L<VG3QI.P_)\$PUEB*)?"$"B)Z:I!`9[CJ;SS,XI,Y9"CB)?:5PB&S
M*%.B-62PD-:"=K7(3HKZW61+H.L6KE8M.KTXU5$L-'J>?W$A^8<XIU3AC?\`
M"D9J[,J7,,&P%:1O&E2<PR,K<NY*9ID_P:&MTAFF0(^T+U$F;8#*KM3LE5F,
M"I8@3-A3J)R=V9(X/W]\#HZ+'(Z*YU;M=R/;70X'$=Q/EM0$!>>`?N`>.O0B
M&&_V173IP"[OP[52S9;N)$,Y;^#("Y\47SO?#59/3N]Q/.>[@B`N'"9W7@5T
M)($X<8?;#XN@($NXPNY[U`5^Y\'<@\,5`0)SXHNU;QEJ`K]R_:]L7AU<L(]W
ML@0!SXPOG>\&K^3[?8&KG:S>D,SO[K&?VO8_J,I\)]T>*.W\?XT/N_&1[(]$
MOI,M(WQ8L"?95%*\A;Q?>^)D[0P4`H!0"@%`*`4`H!0"@%`*`4`H!0"@*8U"
M^@],O>F7^(V>JAG+?P9,\U[N*-:6VN]!/2C\?S3O_A>1:0SX_5'BBGFS^E\4
M:K9]I_Q.KC\]>6O"4*E4Q=&O+#R0W[B.++Y7*LFPHN*S%,;,"T:E1'UV1F9K
M:(L_R8)"@\IN)2G'E*`(0%7]CBJ-V4W>^]M4=^BJN.*E*[K-)4[:).JNTTJV
MD:EL4P34,I>HGC_&</U3(8`APCF.*2Z(:L8C#53?A9U<\5+H_"HU@/.IS.PR
M=Y2#EP6B-DA9+F-"N&IB5SL%(!.64W\DI7)*25F2:E\MU%9E=7=HI6FCO)PO
ME)PM6HM/)UZRM5DYQ=5A?WW'SFF+:ALA1N)-`,0:HH/Y!=FJ\X$D3K=G(C$C
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MQK'Q\IQWJ"GVE,G4E(9)-\!LN,)3C1_2M"G&'6B+/,4Q<;FS)&1S,9H<C`*?
M7"//+\T'D.0G!U2QR[8J).I9HE=)QM.L:-:+J1M-TKK?>A;C5T<5.PE&3DI*
MMJK3=E1M6;JI/5:J9OZ2\)SH&BO/.)5D:E^)Y!D67:H$$-09!-5CE#"U9#72
M!)#'9Z<A*W12Y*2$SBC5*7DI>Y"<#B3EI2U:(RQYEP3L25\6W*E<57#_`-(R
MDETD953HH5IA5)5IJ[M!C)'W74_Y#]%V'XE@?,\&5X`E6"8AF^-RC!^*)'B`
M]KBDE88O),J0K)4E;Y$\.#X:B.5.[<XXT.3N+(V.,@DB]T1&-?5RN>M2$5&2
MLM53BG&[3:OTZL+RG8M923E%VU-Q:E)254VDTJ+4J2TJA5,SP9G!=CZ)X^=L
M&3Y<T*\K:UI46N!#9S-`(G^53PU3C;HX5'<@8Z9&A7)&Y08OBF49^N=8Y%P&
M'J4*$)RA689+C)I*R\9O!O'"ZJW/P*M1M-VE6SDUBE<EUJNCK3!Q5[/JN$9U
M11W%TZ8'?$&H::2[,^STPYC9A<&5E<W8Q@RM"D4L03)%-W!>Y)%4<D1):]*N
M`<J":YR,)0"FJ[FX'I2#M:E1]63M9.*P>*QK^^H3@Y+K02CEI2OV71JFM:.Q
M]EY;"3%$[#J%7N.4\':BI[/%4ETX*<`Y-@LE=HU!\90!@A<;2S5`]R>[F:P1
M,EHD2:2*)[%7EA4N4[NI&4C2K;N!2NM2=J^,FZQLM5HKEIP5-*HZ]I%I6:1E
M&*I.TFJMN^E%C5JE'<DUV'PL<X?S:BS3C)0=BS-[9J7:-5DOE>==1+HO>?*>
MFVFU2YS`^T=:7PV1J(V[-;O%%L-98M!43$4Y1QV;#CQI6>Y!O3<496EU9*5N
MKEH<=*K6FZA3E&S+K1L/)I1A3K*=RU5N:;;JTT\76I66,M$DP6Q#3^&<XLRM
M=UD&EC44ES60Y/\`D(@:[)+*\D*<)M4K3@?BRP.3=8T:N&LXRRTH3T2%60E$
M>@2F%8H.D:Q>;*N.*;LUW.XV64594<;LI!QN6%':I=X]_:0K,F*-5TPA,%ZJ
MQ%F,[*L"TR::"H3,2(UD>82Q5-V8PA?D4*.5D9$C\2Q%)8TH)$3(4ZZ(2V>S
MXV_^P-`G,`,K)*;2ZLJJ,:7/5??6[M5&V]"1L904GUHV7E)U5R5EX74K)-8.
MJ43T:HX9$$SF7($D:9R'CJYW>0.EFPDMRLZ2),A2/+D,\PJRD+DX(&UO;5*H
MR]E=FU$G:^C`B)"FMZ:+&FM^./[N/)5ZS,O9F?F<B/A!KA_S@:AJ\:^(OK7Y
M'HG@_I7XHW<)_P`G(]Y*\`-0#FH!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`IC4
M3Z!N4O@<[>)J\GGQ[R9YKW<48,;:?39F+5KLU-2>#\#)3'C)S^VPB0,44*7%
MMQDX30+(\1G3U#"%AJA*4%<_,\=7)VE.<H((<'@+>VJ#TY"PP\J#I!J,DWAP
MN:KNQ/(L_-V;]6Q>MK2'@G9"9JP2[ZQ,D:'EN-$$HQ4XX[Q/HN7:;,?1R#Y`
MG"R2JX8PH6=0ZJ$DM1H7TH$<<72-S1_-<C'%[=5$:?,TU[O2O,[*D;,G-.RI
M5HZN56VNW2JUWW'^A*SHE#:T-3<K7'.BI`VH42ES46W%#BH2I2B#EQ]NB'N'
M*S"Q*#;=&+<&8*W1"X;Z><[IW$^6U`0%YX!^X!XZ]"(8;_9%=.G`+N_#M5+-
MENXD0SEOX,@+GQ1?.]\-5D].[W$\Y[N"("X<)G=>!70D@3AQA]L/BZ`@2[C"
M[GO4!7[GP=R#PQ4!`G/BB[5O&6H"OW+]KVQ>'5RPCW>R!`'/C"^=[P:OY/M]
M@:N=K-Z0S._NL9_:]C^HRGPGW1XH[?Q_C0^[\9'LCT2^DRTC?%BP)]E44KR%
MO%][XF3M#!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`IC4+Z#TR]Z9?XC9ZJ&<M_
M!DSS7NXHUI;:[T$]*/Q_-._^%Y%I#/C]4>**>;/Z7Q1AG7N/.*`4!5F25N&A
M+H"QY978_*<%4O02+&C;.EC(F/53N(C+7MCE$27HTJZF4,0U0%B$398;FEL8
M)0G#8(3!AQV;JTQJJZUJ-5J]JN%&U7!Z'30^W$K_`#WJ(4X7<(C'8_B/(>8Y
M=+F^6OQ##!;1U`G:(Q!42)?)7I\D,M>F%B0C`4X)265HLL-=)`MN:D;DXS2K
M[N2E9I=5WNBI@N_]948VJMRC%*BJZXNM*))MX7ZBM1:],0K#M,I$?9,A/0M4
M2Z(E1!4*&O;8Q1Y!+D+XJ3&R27*D=X;=\0J&!P1+(BS2%UD(>DF.04=V7I#D
MHSI%U:5ZU-%*5[</`WHY=>K2L8WJM:I7+&E^-*;[B^<XYA)PK$&^0@A4NR*^
M2&61V"Q&%0E,A->I!*I2K$E:D@USNN;&-B:RK%*%;J_/CDB:VQ"F-...$9<D
M@W9.RL&ZNB2UOAWDQC:=*I))MMX)+U?8DJMF**G:'1J[%%QM.&LBN60'?(>4
M\6R/&*I_Q?''B$3'#9+,;.$CQ)Y).&N"+$":TB9.MCDUR542Z]=$92<-EAET
M@9Z1:G6K5&TJ..-[=-.\OHG?UHTI&2?6O4L*)1;[U2XS).R<QQS&23*&4@E8
MD:`,[0Z29--'=CM:'*'<Y&C+:WMY9W%SCYB@ER7)FT2EM<UK>>J-!U*J.+&`
M=[K=5W;UQP.=+Z+K:J)W]R:3]"K&/6CI,DKPPQ]@U$8E=WN4211$(^V(9FSG
MK'61IQI2NM:0D*CHAG*SER,AL,OT*=W/5$$-1RPTT`+Y;@W125<,?W=KT%/)
MS2;<))*]W.[]]#\O&M725'WAW8'O41B5K>V$+[=X:ULR:2%K>;&7!2U/B)00
M,^PPN:!Q1JD@VJUKN1QJ<WJ9(<$%Q4MPVEX_M_9B%DYN]0DU=H>G#<]#P.L#
M5QB]?E?$N.F!S:I"P9BQG+LG1C)C9(F@<0&UQ)S;&LY"$\1G^\JUBAQ$`'2C
M@W2G(U2544!06,`,MJJ6AJM:W"PU&3=UF2BT\;T^1'8;KDP6[P"09(R!*H]A
M^-,^9IYA5O63B3-*<B1OL%=1MAZ]H/`(`3T;@66)Q+`6$RZ%`$2A::62$1MB
MG&E7<JM7]AKR4JI).3<5*Y8)ZS)V$3R&9*C:.88_D[),8JX*')*@D,=<$[HT
M+%#.Y*V9T+2KDHS"#[H71`L0J+EC$$"E,:7NWN&]4FFJIU6LAIIT::>IW,EE
M:8*`4!E%LS/S.1'P@UP_YP-0U>)?$7UK\CT3P?TK\4;N$_Y.1[R5X`:@'-0"
M@%`*`4`H!0"@%`*`4`H!0"@%`*`4!3&HGT#<I?`YV\35Y//CWDSS7NXH\[NT
M`=M<FK_:FS?1;IRUJ3S1A`M,^A\&J$I;CA,XC4Y)R(JE:!L3-<R&SR",+ES`
MIM(&%&8E<5[PR-2!C<#B8NY+WU0:5'[X'>-F,+4HVK4J=R1IX3S7:#QG0!CG
M;].6T,SA(,HO6>R4LATZ*%2Y)@U?C1OS(]8?40H,-1OI,1*;5SA'#'`YH3Q,
MAJ+;'*YZ0*:5I`R,\=*1M/)651*YZ:T3J]/ZM!_H(4/,<1W$^6U`0%YX!^X!
MXZ]"(8;_`&173IP"[OP[52S9;N)$,Y;^#("Y\47SO?#59/3N]Q/.>[@B`N'"
M9W7@5T)($X<8?;#XN@($NXPNY[U`5^Y\'<@\,5`0)SXHNU;QEJ`K]R_:]L7A
MU<L(]WL@0!SXPOG>\&K^3[?8&KG:S>D,SO[K&?VO8_J,I\)]T>*.W\?XT/N_
M&1[(]$OI,M(WQ8L"?95%*\A;Q?>^)D[0P4`H!0"@%`*`4`H!0"@%`*`4`H!0
M"@*8U"^@],O>F7^(V>JAG+?P9,\U[N*-:6VN]!/2C\?S3O\`X7D6D,^/U1XH
MIYL_I?%&&=>X\XH!0&.&I/&TYRU%6V"12-X(>V=Y5+"Y<X9WB3CD)I8&^R<L
MM*NC4"1B;4LBD`C33A$W=)-'4;?U.`^YZP8[)[3).2HK---I5\%K*@U%U=JJ
MPLNE>]Z/!F"D\T0ZF(AC"*X1P;EKR<XP>Y$_R'-[3DW)DIQPH?&I2C;D31BC
M&!\*A,P6XTQ"IZ6XGR6/,SD!W<"3[MB=^3IEJ\PWF\G*BBI57S5;5>Q43I'6
MCJLI!MRE&DJ)1LQ4J7MN4K35J6IO#49+R_3U/9=#]%S6B8<8P!1I\S5`\@2V
M(19X?%$/:(I$87-XKUA@"Q3&DBYU.3]?FBR(MX;F(LT@M8,]46:66%3=EM0P
M5EIM*M*)-47B0I)/*8NU%I-I5JY1=7?V/"MY\_.6G?.S=&,FN6E;+DP290R[
M)4UWL_+^89HX1"`1%:Y.CS([8>:3V";-<#?C1'IF!A&@CHDK(SJ!GH[E*VAL
M#=*,K[,G5N^K=$NRYT[!&4:QMQ5F.S&-6]%K"O;5W[S'15HYRXGQ7CR+"TS:
M-)F?$%&7&Y9$YM-<AS$\Q1DUGCP?+7*RA+($K<5\U<)$C<ED]0NL//7.2%"P
M"C4J9E!`4Z*+#HE9@Z5Q;TZ:M>-VJG9?21M-V\HJTHTHK"O5LIT2I<J.Z^J:
M9>4ZTCY">-G:DTAMTL8I#D%%CK'T/O)Y(K=$D;5K(O)XT].`+J2VYV=2VA,A
M:5+6R6&V&GC2$-Y2@A-81O2:<'T=BJK1=US3)4UTMNE%5NBT53[N\@65=$F1
MIE+M2L@8%&/$1&7<^:2,H1*ZM:YI5:"/8);8JDF"=WZEC2@*%V6'-3P*/)D)
MR]*L"MZ)<M:Q*E(08X-N5*4;@U]JH]'AH-CE$K*=>K&<=&,J]O;><D'T3Y&C
MTNPZ_NJG'JA/`M9.H_4&^](6NAZI3#\M-\H3Q1,WV/C105$F1*')C,=TBDU*
MA1V;PC1.R\:-+86V'5.[/E+QPWZ^XQY1-25]^3A!=\;-=.#HZ>J*^Q'LVG%$
MZ:;$6=H]A[(T$Q!!-1##)(RMLMD:$]_R=F9UR!"5S&V/,61HE!+2P./4KDH5
M#;SV]P$:F0$+DNXK%,<GFVJ-)237>VU0J66S[+E%R<*-771C1U:>EE+R7`$H
MT7'8+GG5.*4AT)U!:LGB'QE[8\J..(4>/LYMK02PI':30+&LG/@4LC;2R)$C
M.W+(\)I>"C'5F:WDP:>UCL<7"RZJJ<W\U*/N3I3]=Q2GTE8TDZPR:;K&U:A6
MK2<E:3J]-5C0SZV9D7D41T88K:Y0Q*(VZ*7;*3\6TJ65;'!E-,ERU.']A5$L
M+D`MP:$#FR.+>YM:%8`*@AL6)+&6L*KR>8M_9\S.>6:>4DTZYM]:X12=^F\S
MTKH<A0"@,HMF9^9R(^$&N'_.!J&KQ+XB^M?D>B>#^E?BC=PG_)R/>2O`#4`Y
MJ`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@*8U$^@;E+X'.WB:O)Y\>\F>:]W%&H
M#6]L6L@:JM7LHU?8CV@N;M($NF&)8UAV0-F'(^Y)%KM$F`VZI2VNLJ8\GPIP
M<F=X6EH%JMB5HQH+*FU&</IYA)0RX.T<I2-EQC*E]]Y@0;^"\Y%4882:<3]K
M1J0/T^H%@G%%@\V!.)F)4B\;\IE0UJ;'@LX7BA"H4F6*Y`)04U!-N]*E#G<?
M5IQAPA737UL1KKT^)ZW:'$XCN)\MJ`@+SP#]P#QUZ$0PW^R*Z=.`7=^':J6;
M+=Q(AG+?P9`7/BB^=[X:K)Z=WN)YSW<$>;W;B.L[9,I:$9%`'F0-SMC99JIS
M[UN8G5<WVD%]-V+XGG3K.O3)#RB75.X)((N;;H5A:@HXMP/)L5>YU[73T;_2
MC.V0I3*5P=F-_P#9V??]1K@OK+RCBW.^MC6)C=P42\O..(H9*<0IY0H6N<,C
M$*DNMF4:7<>ST^/K7U@:TZ,W'4`8)6B2&O#&W+5[PVDN[JE1*UQX5:*4EB]>
MB]KV7_ATL)QR<)74DTZ8W9.TU6FNM?3092E:Z]99@XQA&0R3&<%F,UU41S#+
M3J2FT3QP.\?ACMBQWR(H1S;"^/<YS^-1G*!SRS&1V--[O/D+?)&1>@7)VU.M
M.,7)MJ^Z^E>-:-I/]N.?1P:M*TTH.5E5O=;-S<8]72[GI2P,9L$Y7F[5E7'J
MUU>XIDF5*M9>UF6ESII,DPXZ-PB&'$4@1K("T@EJUN)B+PX!%=N97DR6$M[*
M>2G:'`"NW78[$[]\K^RB[</$J:5+KET>1U5O>F['W+/?MHQEY1BK$DF8I!CA
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MWQ8L"?95%*\A;Q?>^)D[0P4`H!0"@%`*`4`H!0"@%`*`4`H!0"@*8U"^@],O
M>F7^(V>JAG+?P9,\U[N*-:6VN]!/2C\?S3O_`(7D6D,^/U1XHIYL_I?%&&=>
MX\XH!0"@%`*`4`H!0"@%`*`4`H!0"@%`91;,S\SD1\(-</\`G`U#5XE\1?6O
MR/1/!_2OQ1NX3_DY'O)7@!J`<U`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0%,:B
M?0-RE\#G;Q-7D\^/>3/->[BC0'M>]J?M&-GEDO,-L?Z6K3K3DNQEB!WPOJ$3
MXXETE@F/Y\YY`CK%D5IS;(VEW`QD]?$0W2,05C4J(@Y`D4BB*\DZ0ISS$1D'
M>$(S2ZU'5U5VJZGOV:C[7]/;J,]H_P!IGR2SK_W84'1K_P#2'BN9Z2:'(XCN
M)\MJ`@+SP#]P#QUZ$0PW^R*Z=.`7=^':J6;+=Q(AG+?P9`7/BB^=[X:K)Z=W
MN)YSW<$47.L:8XG3FS/,VQ_"9B[QA)*4$:=95%&*0N4>0S9C'&YFB8USL@5J
MFE)+HZ::PR=,@-3DO[*8-K=0*T(Q$7Z4,3:P;5:5HZ87KP=Z*5.T[:?D3<K9
MD6"\.HVA7`4>*%34DQE"DS<IQ<A5+'1#C8]$2R`3&P%$YN"]Q20\98H\F7KE
M:PEN`H4G&#RBU(VU+:EC7%XZ^_M*H4:5-,B;&JC#"?3WA<G$BEV+D"C&I6,X
M<"$*'\/07"_'QH+/9I.?`]++L%W,2B<0A++!938(`VLHM2\!;E6U:E:PK5U\
M:U/BMF!L&PLYA50[#&*(FIBKG(GV,*(UCJ(,1\<?)FWE,TP>6$UK9TIC.ZRM
MG3)FJ2N+>).K?6U.0A=#E24HLH*BU(QRD\9-UHG5MX8>&@IY+I5TQ1@MY+CN
MG7!K("0()$U/H6S%$%1V>&F862D2MH<ND,0.K6B2)T2),^-:CIC>Z)D:1.L3
MG$IB2P*+4O`VW-XRDZ4:ZSNIAIT:-1T9#AK#[LGD"-UQ3C9S226/LD1D:5P@
MT76)I!$XN>,V,QA[(4M9A3K'HZ:8,UB95X3VUH,&,;>F3B%>][DE2-RO5_;2
ME!:EM2N;:O=S>+[WI9V7*UK7O:UK6M:QMK6M;<M:UK!M:UK6\ZUK6X+5T^3[
M?8DU=;6;TAF=_=8S^U[']1E/A/NCQ1V_C_&A]WXR/9'HE])EI&^+%@3[*HI7
MD+>+[WQ,G:&"@%`*`4`H!0"@%`*`4`H!0"@%`*`4!3&H7T'IE[TR_P`1L]5#
M.6_@R9YKW<4:TMM=Z">E'X_FG?\`PO(M(9\?JCQ13S9_2^*-:&4,YPC$4CQ/
M&IA9X+59CFY./XNN;T)*IK12!64&[?:0*1JTYC<B<EQR)F1*24ZRYCLXH4QA
M90#KG`]CDDTGI=/_`$XJ+DI-?*JON[#J(M0>.5F6LCX=NM6(9!BF(LDRFSXY
MEHF^'M+>^DEK"41C\I7@L!T0M:EM>'4D]*0E0MCLVJ1+!74"++6E:<=*57JO
M%EV5+1)T2TNG9Z=Y-S,F8W*86>5&Y!A!<7D*PEN8)(9*V$#"^."@TTA.@9W@
M2^S>YK#SB#R24J)0>>::2:6``AECM;:JE:JFNMQE'5JCJL51U7>0F$Z@<=32
M%%9%$XVAT,.C,,E87^=.,;CR`ILG346[,X%IPGY4!M5%%&E)59;E=(4)88$M
MN.<"K].MBDFJX*B=717/#3Q-<6G3%U:NKH=+KKR>*,B8_2+XVU*IS#DSI,2"
M541;5$F925\J3*+!$G4QM&8M"H?"#PC#<DYL+5%FV$&X!"M>V[M5=>K\+\>X
MRCO='18W8=Y"E&>L<MV+)SF5\<E,>@>.GC*#+)W)W3!+/3*<23B2X^DPTJ1&
M<L-7`62&*N!<>3I^C<'@I0VEE(2UZP*$&6E1R=R3:>YTXX&V7:4<6[-%]237
MHU743$62<=`+5G#GT*`4@9[R%<:*4L02T3!8AK57?%8[K[!3L]DKXRJ;N9UP
M(K$/#6=T_I;@D$=M5K6O']UHRCU/5@<2[*&,VQD99,Y9$@K?&Y(:61'9`NES
M`D9'\\[HNE$LKL>X%H'4TWH!=++0J#QCZ$70VON7W%5C54>#JKQ1U:HZK%4=
M5WGQ2,W8G-D4YBQD]C*%YQN<U$3(AS>$#84S#>F8;^AZ<J7'D)QANUE'*%`R
MS!!2]3J`*+EC(-"%:C5JJJL;Q9E<Z.^M*7UHZ/U)&RY$Q_(U8T$>G4.?EQ3*
MEDAJ-ED[(Z*RX\N"`:)^&G0KCS@,JP!A8DKH(%D*@(P"*/'80;W53P:>\4:Q
M36C#2M!U$^4\8JF`4K2Y&@:F+@6+6X<D3R^/G,`'!M1*7)Q0B>"W$3<%8@;D
M:M>M2W46/2HDJE4>`L@@TP*JI6JIKJJ"CK2CKJHZ^!T$&8<9NTV9\>-4S872
M5R"%CR$QH&UQ2KBW:(@7%-]GAO6)334BP@T\WIB>R<XP:A*4H6$V&F3G&@RU
M%NB:;I6YZ!9=&Z7)T?8]1UHIFC'<OE$DA+?(6]',(S)WN+*(NZN32CD+FHCR
M1O6.3JR,MG$YS<6(HIQ*#UR"E+"$TE2`TLKI.Z+5)-TTWW:;C7%I)TN:3KHO
M_P#"0(LDXZ<BI*>W3Z%KR(8(T,P.12EC5%1,1%CA'ADIA"XP#$(FR91<VSI=
M+<NQ!UQ[EBA]"JGI5V-^!E'=<[\+L>[6<*C*&,TD<;)BKR)!4T1>E!:-FE2B
M6L!,<=E9IAI125L?#'`+8O4&&D'E%D)51IHS"30!#<18[656-53744=:4==5
M'7P/BY$S1CK&($I<FD3;9Y7+(LE015$YM!LL7D2V7,T*;G5"P*7%(N5,Z9X>
MTHG)P(+&2E1DJS0].-)L0,Y)8XW46EU=.+"3>"N5;]%R;Q[D6I6F&46S,_,Y
M$?"#7#_G`U#5XE\1?6OR/1/!_2OQ1NX3_DY'O)7@!J`<U`*`4`H!0"@%`*`4
M`H!0"@%`*`4`H!0%,:B?0-RE\#G;Q-7D\^/>3/->[BC";;+:G772!LXM1><X
M]#HM.9.Q-T*C\59IQ'T$IAZ.2S?(<4B#+)Y`PNI*EL="(<N>2I4W(7%.<B6/
MC.U)%(;%'B&&#K!6II5I_I5]<#1WJ4@6U^V66!D.TAFVU1MJL0PU^Q@YYLTR
M3"#IV_%LK8<AR^.Q=QCN-)"*1NZ!5T"Z2)A(7.+0?&BY.Q$K9`U")`WV9%PM
M/)S=E0I6M)5ONPJN-[]SUY,[F4]-#4\$%*""'9M0N9)"HOI*HDI>F*5%E*2M
MT72E!8#;`.+W;]`980=V^YNT.)W3N)\MJ`@+SP#]P#QUZ$0PW^R*Z=.`7=^'
M:J6;+=Q(AG+?P9`7/BB^=[X:K)Z=WN)YSW<$0%PX3.Z\"NA)`G#C#[8?%T!`
MEW&%W/>H"OW/@[D'ABH"!.?%%VK>,M0%?N7[7MB\.KEA'N]D"`.?&%\[W@U?
MR?;[`U<[6;TAF=_=8S^U[']1E/A/NCQ1V_C_`!H?=^,CV1Z)?29:1OBQ8$^R
MJ*5Y"WB^]\3)VA@H!0"@%`*`4`H!0"@%`*`4`H!0"@%`4QJ%]!Z9>],O\1L]
M5#.6_@R9YKW<4:TMM=Z">E'X_FG?_"\BTAGQ^J/%%/-G]+XHU`ZGL#O^<56/
M4S0J1MJ:.I<HC->3E'2UL>D+[C]P:X#)&HCI)O5*R.S:S*]E\%B!H"S[A-L#
MI8O7.+E2FBOK%I/QH<H24:UOK2[6E)53[U5&*+]I!SK)TCC+G8^.)9_+VZ%3
MC(;>S/;88D>9LSZA194<($WK91%I(R*&N.P-)'8;$'>2QEV9UBN),0'UML@&
MK5%Q8D[W2KHW36I.5+ZJY4I6JJKRU.*=+W%52[%9I6B:Q;;HGI9,HKISRA$I
M`@R4MQ\TY+-=EV;B'G%T]F,%Z<V"RJU85:FZ7&JHUCN.XW2++EXC=4DQ:8U'
M3S;MT_=7%$XR9Z.?R7VE%JCI7.N;5R=G4DOEPIIQ,<D[K5E*S223^6UK;E\U
MS;T)7*E(IC/2?F3&:/#;VXQ>(SHS%;5AA.[8\!)$R='(%T/P!+\4NSDS+WI`
M-ILZQ60R).XQ_KYU*0N:!NIQ2]`Z`0A-Q0DK+QLV;JXTC3T;X[]<XMSQ5IRZ
MS6ASM7TUK&G@?F<::]0#N28D98'`8ZB,;\+NS;&<=2"'1^&M9F.Y^?D!WB+V
M[2*`..27UR;'!0M(@MV611:`A-<#5BA!'=U60LQQD]"5RN325SKJJZ8*]+N5
MYBE%7MMYU[JW>J5NE3OJFZ:[C)%XP1,G72=J%PP(EC,EV2W#5RMC!:I9T;/T
M>8LIY6FL!,<%O4AMT9@$,M83G$P"4\;4M"?8OIXTH1CMQ;A*.EN5-\FUZ&*2
MZ2$KZ1Z.NOJQBGP95DVTNSF2MN4I4TQ]BC<QEFHC$67DC2UK(>-Y=('`\0XB
MBYT`-?Y%$93%2E,<F48D3]%4#RP.<6->V9F<+]:.NEW9MFPZ2N2;DGHP25V#
M5SP35*FJ:5E8I1E%XTJY2=:)IWII.^M*H@#MI<SP;'NMC8V)PE2YJSX!Q(-D
M^)@2*//.67&*")22B2!PN)I;H1($D>&_3AFPO&FAT%+C;7$ODY'_`&O;+$J4
MHJ.UJK?2E79PTNREO-4XUJ]#@U=*CLUOI:ODJT5IM4TK`F4>TOY`4R")'RJ%
M1$363+=,,ZD!JMV;'4RRK%&*G.&R9I5)+(!V<%R"2E-CTV+0G'(EQ9Q:@!I2
MM*8"U67552IU&[]*5'W]YEM)-)O"<5HSI)UQTJYGPI7HJG+MCD$3BJ:%Q!]6
M*-:X71U0C2(BUC;G/)3M)X`T.*A,R+1J6MSC8&)BD9)S<Z$LJ$H"4#8[$MJ=
M&9C@Z7?W?F=RWJE=!JRB4D[W\*[MA%)^M:7DAAVER<KYS#)K,V`%FYNS5!9D
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M%EU=RSU*UII==WW4U4>L6U17R=(6;.B^M];[E6N%:]A3K)I6SN8W@)DL,;G`
M@&$XE`5+.5D"#1,E')(/E3'D]`''Z?'6-8\S1R.)2F-X5XPO)4DF4G.J)&WY
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M.4C2F-NVZZEG)-=BIV;3:ZG$RBV9GYG(CX0:X?\`.!J&KQ+XB^M?D>B>#^E?
MBC=PG_)R/>2O`#4`YJ`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@*8U$^@;E+X'.
MWB:O)Y\>\F>:]W%'/G_`V+M3V&<B8"S3&29?B_*,>/C4M833STAAZ0PXA8C6
MH%R49:MM>&9U2('IC=4AA:MJ>6]"XI1@4)BQ6@M-IIIT:-%F-/P;333%IW`G
M'*>I_5[J,PMB>0MDDQMIMR_D=`ZXH:E3&9NL:%]:4+.D3NC,W%6"2)J8D,12
MN*<-V]R"K9E"]K6#H\K*^BBF\6E>_P![:GHSH<CB.XGRVH"`O/`/W`/'7H1#
M#?[(KITX!=WX=JI9LMW$B&<M_!D!<^*+YWOAJLGIW>XGG/=P1`7#A,[KP*Z$
MD"<.,/MA\70$"7<87<]Z@*_<^#N0>&*@($Y\47:MXRU`5^Y?M>V+PZN6$>[V
M0(`Y\87SO>#5_)]OL#5SM9O2&9W]UC/[7L?U&4^$^Z/%';^/\:'W?C(]D>B7
MTF6D;XL6!/LJBE>0MXOO?$R=H8*`4`H!0"@%`*`4`H!0"@%`*`4`H!0%,:A?
M0>F7O3+_`!&SU4,Y;^#)GFO=Q1K2VUWH)Z4?C^:=_P#"\BTAGQ^J/%%/-G]+
MXHU3SS4G&8%))*SJ8A.'UAQ\7%S<ISQA3Q@45QH7+Q`,:12`IVE#3)W3J5L.
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MA^1TN/7IA<%TA9$D8-C<R>5LA5N`TR5"6:SR2S(MX4BVW6Y4P5*NM:-7W:S+
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MG`R*.9EFMX6')BF%*YGW9DC\Y.;3("&G8RM*J\=#=+TK]'AVXF2C9=_;=IIH
MKW_N@QUB^MARC>'2<IYDQY+DP'%RRT_']:PXLC;1%X-`98K9$R&SC(,Q70RR
M361)3>E,T?<UTJ?5K:\*$L81-HF$UWE3I&LD]+NHJ)/ME?NO[-=O)]:S%IW1
MVG>U71&Y=]U-+O+P<]3:,;C)DD,Q5E/(#-&EJZ.+)Q&&V)FQ0N<IX6":)XN<
M4[3)FDY!1B=4V,JZ6*6!+!F:1NJ5J>90W=3/"IIJU>Z)NEU52E:5IC7?2E^)
M%FZ]I/4ZUI6E<*;JUHL,*U_#]:3:YX]BLTDN,)\E)(QKC2?YD>V4,*51;$B;
M(S64YMZIVN=/+OCNVW:Q6EYY,3;I2[L$)6MKA)T;6ZGF-!<J=R;3P3>%%7?O
MNJZ8I.XIY.C:36+4<>M1TNNNONOHJX'V7C6=$&D2S=QSD42>^5I=AF-N+HX8
MGB3/-)O`72<M<Q31YXF>3X\W%H6HR#*!(U#\I95$A.>VMOCZ-R<D$K21K;?8
M\6E@JM5KBTM&_<Z.C>M9JDUUFTG2E:1>-I85III=7*R./1<DCS%(2F]V:2GU
MG;7@MJ?D(FQ\;0.2,E8%`\-PQF"0NB.QW4Z])<PSJ=46:58PRP;#%2=4GKW'
M-W-K&FE8;C+S9F?F<B/A!KA_S@:AJ\:^(OK7Y'HG@_I7XHW<)_R<CWDKP`U`
M.:@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H"F-1/H&Y2^!SMXFKR>?'O)GFO=Q1
M$=7\#U#9,TZY#AFE+,+3@/4"Y>1-9CC*[ZPI).R1E>P3F,R)X3NS$O:WM&O;
M9-&6EZB2T*EG="B$[Z8J$@5=(Z2."XM)IM56E8?NL\TTKV]FK79TS-LQ3M%8
M9I!U/D`7=9UV2M#>H:%J,DM@B+#$);,<%R!P"^@7J@%&V+&M8<1L'3+`(+-L
MHZ$I0.JR<9JL')=DE=XJ[B>@;0GM&-+NT6@LFFVFZ5/BY3`W)M9<D0.:1M=$
M<@8Z>7DA:H:F^4,BJZE$*SB4VN=D3HP.SXQ*U#8Z(T[J8M;'!.F'.47''3A?
M6IG&=Q/EM0D@+SP#]P#QUZ$0PW^R*Z=.`7=^':J6;+=Q(AG+?P9`7/BB^=[X
M:K)Z=WN)YSW<$0%PX3.Z\"NA)`G#C#[8?%T!`EW&%W/>H"OW/@[D'ABH"!.?
M%%VK>,M0%?N7[7MB\.KEA'N]D"`.?&%\[W@U?R?;[`U<[6;TAF=_=8S^U[']
M1E/A/NCQ1V_C_&A]WXR/9'HE])EI&^+%@3[*HI7D+>+[WQ,G:&"@%`*`4`H!
M0"@%`*`4`H!0"@%`*`4!3&H7T'IE[TR_Q&SU4,Y;^#)GFO=Q1K2VUWH)Z4?C
M^:=_\+R+2&?'ZH\44\V?TOBC5//=-<9GLDDSPIE\W8F'(0(N5E2!L1\9#%LE
MEQ"X"VH#\<[1AUDS3U6UD)8\_BB$BC@GZ.HTC8NN+I-C[^MP3K>TGBE2^G>F
M\+KCBIM)7*ZM&ZU5=5].U53HS[K#@2'QTZ!'HG*2FCQWDC+F4&2RI8UC"J?\
MSN&0W*4(W2Q3,1<]G0'Y+?0,"=)="M2E)&D+BX.HR%@U^J"5G'JMM?=6M?$.
M3=<+XQCNC92W]55WD`F>DJ+3&=R2=^3V>QY3*IUB[)3JU,J;'9J8<RQ"HA*B
M(*BGA^@3W*RV(L>/HX<LB09#Y&SEX'%T*;DZ]T6'FXX)MNKO:>C%4IHKH6FA
MJG1)4BZ)Q3=:T=:X.FEWTK0^>+1\P&R-TEQ^6,M&2@QC=(Y&Y,!5`4\HC#,[
M2^,310WJI,1`2WW(J`"V(,S(%KRVNGK2KB?7)A=V]S+>G=0N6%M2P:T:6GBE
M5X::J@MNE*1I6NFE:-5I6BQKU4KZ/0?A@T<QF(!+<X1DO(T'FYRZ;J7J=Q1#
MBUK7O:/(?D5%)&<<5OC8_'C2@"HA4:<68YAA[8[-CNWJ74;FL6R"4FON=&E@
MVFZU=VFE;J46&A(.;>,8M77=:ZFG.K6]XM^BI]V)Z4HCCYS;`X]F^2(/"$JO
M'[H[XTC[RSDQF4/.,HK'(7&'%[=U+`IG70J(Y#HB@E;8VRYO:)B7&T)<@0K4
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MRE.W25O32&S`D6G%D.2AT6N*PM;I6+I=>XTI5TKH5?;2MO5&M)*M'<I5K2^F
METNN+<FV'8S/'Y7(7A<^IEJS%&0<.FE-JEO)2AC.25D97/JXL"IL6&V?4AL4
M;@M*D1XF\@LY;98V+Q&$#34U6_L:\:5X$ITN[4_"M.)3KQH\AD@?F-S>YWD-
MU9HST@^.QIR%!5P&!>1!S('8UBE:N#G3YF:3FXX]W51-LE:6**)`I5J!LW6E
M:M95$V%K=VB[53&E>VE:=E+BK;U+OOUUO5:/56E::2T,48(AN&%3J."JWQ"U
M/<?@[,XQ@TYIM&S72"Q\F*))H2WHF=$8CES[&F]A9I.J1J4[0ZIHVR'`94BX
MA4K6:HJ.&FEVBZZOAN[#')RI716_3??2NI.M.]E,2#1!CQ[;B6I/-\B,J(R"
MSG&[P)%Y7R]P=8G/Y5()>]I$[G((`\JHNNZXR9U1`>(<*/N:EH$C3.*I:L:V
MMP18X)Z7@UHP=^J[O7&\KI'6M(N]/3C%)+!WX8.J)M'M,C9&GFRMORAE,$:5
MNR:4R.!DN46;8U*YH7#4D+6R1Z4L\3;I/8EY3(4K\\1)MD#?"5<I(`ZACI)(
MU*%1J@E@Y:Z55&Z4J[J[JTKH)<JXJ-<*WUI6NNG96E::2(H-%T0;XXCAA.2\
MICAZN&PB`Y!CII^/[),JQ?'2>[7%D,N/3P!.M;C@1@*6&/BV#J8BKDL60I$C
MT:K<"NN@LL*E*RI1)JZ]+"MU>RZAMMUK15O:QN;QI?KOOJD\"</6FQD7Q044
M9IY.HTD/R!D[(3A<@N#R)O>U>6I;))G*&&0Q69PN1PQ^CZ-XDRH<:`Y1T]Y8
MPH6X1;RH.NZ&.BPJ-5:JV]#QT---->O:9:=:M)W16GY4HIU33K17WT>HMO'$
M"8L6P&'8XC%UMX]!XXTQAF$XGEJ%PF]F1E(DPU1I)"5-<\995AC`D2(T1-[]
M)1(TB0!*8JDJ)):%0QMR;;Q;;>\S7V9GYG(CX0:X?\X&H:O&OB+ZU^1WG@_I
M7XHW<)_R<CWDKP`U`.:@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H"F-1/H&Y2^!
MSMXFKR>?'O)GFO=Q1H__``AG7II,PEI;G.C_`#F9E9WR!GR+8WED>@V+'D['
M;Q)X1'\\0Y7*"",P+,?Y-C<,,NV1.0=6IG:&/8GQK)4L1)"4YZ3N"6#MDXR;
MJJ75QOQ3T?N\U28PVE/X//H&QRLDV@S2ROSSJ6:#HZG@2#(T'FR;(\T?'&0M
M#6O&AS7D6(9%.Q\K(:E:Y[+1PZ-(43NL;$S(B:4Q[@2H3CHX926?*B]%NNKO
M/8)B_31A'%.5\YY_@&/BHEES5$;CISSO(BG^3N-YDXXQC[E'H2,UD='I;&&`
MYB:7IU2'F1)E8+/9ZHUP?;.;A8M4`<&VTEH5:;\2^3N)\MJ&$!>>`?N`>.O0
MB&&_V173IP"[OP[52S9;N)$,Y;^#("Y\47SO?#59/3N]Q/.>[@B`N'"9W7@5
MT)($X<8?;#XN@($NXPNY[U`5^Y\'<@\,5`0)SXHNU;QEJ`K]R_:]L7AU<L(]
MWL@0!SXPOG>\&K^3[?8&KG:S>D,SO[K&?VO8_J,I\)]T>*.W\?XT/N_&1[(]
M$OI,M(WQ8L"?95%*\A;Q?>^)D[0P4`H!0"@%`*`4`H!0"@%`*`4`H!0"@*8U
M"^@],O>F7^(V>JAG+?P9,\U[N*-7VW)?&2,Z?-,+_(WAKC["T:\M/BYU>WMP
M2-30V(B6G(HCEC@Y+SB$:)*4'\8U0I.**+MYXAVM2.='ZEQ*HVI)*KLNY7Z4
M:SM]1IA[([`W*_C[G#7LMPVH^9<SC8GLR\KY#?4:8>R.P-ROX^YPTMPVH^9<
MQ8GLR\KY#?4:8>R.P-ROX^YPTMPVH^9<Q8GLR\KY#?4:8>R.P-ROX^YPTMPV
MH^9<Q8GLR\KY#?4:8>R.P-ROX^YPTMPVH^9<Q8GLR\KY#?4:8>R.P-ROX^YP
MTMPVH^9<Q8GLR\KY#?4:8>R.P-ROX^YPTMPVH^9<Q8GLR\KY#?4:8>R.P-RO
MX^YPTMPVH^9<Q8GLR\KY#?4:8>R.P-ROX^YPTMPVH^9<Q8GLR\KY#?4:8>R.
MP-ROX^YPTMPVH^9<Q8GLR\KY#?4:8>R.P-ROX^YPTMPVH^9<Q8GLR\KY#?4:
M8>R.P-ROX^YPTMPVH^9<Q8GLR\KY#?4:8>R.P-ROX^YPTMPVH^9<Q8GLR\KY
M#?4:8>R.P-ROX^YPTMPVH^9<Q8GLR\KY#?4:8>R.P-ROX^YPTMPVH^9<Q8GL
MR\KY#?4:8>R.P-ROX^YPTMPVH^9<Q8GLR\KY#?4:8>R.P-ROX^YPTMPVH^9<
MQ8GLR\KY&Q'9?K4;EL9FUQ;E:5>WKW;6TM0+T1Y2I&M1JM7>H,]*K2*B!F$*
M4JD@P!Q!Y(QE'%#`86,0!6O?R1^(OK7Y':>#^E?B;PD_Y.1[R5X`:@'-0"@%
M`*`4`H!0"@%`*`4`H!0"@%`*`4!3&HGT#<I?`YV\35Y//CWDSS7NXHU=[0;'
MFO;.RG5!B>):--'^H;`%\/XE<M/_`)<[JY(GZ?9D;\S8E>IE%IZJ;,O0MR9X
M?&8D1/Y='CFTN)762:-1U(J>'=*L5,[Q!UC95EUDG5UIH5'2EWB87I)W^$C(
M%2=:BV<&R\1+$IQ:A*K2.XDZI,>4*PRCTYY.I0!I)Q0[6&686((P"M80;VO:
MUZ%4R.N?IR/3W0Y'$=Q/EM0$!>>`?N`>.O0B&&_V173IP"[OP[52S9;N)$,Y
M;^#("Y\47SO?#59/3N]Q/.>[@B`N'"9W7@5T)($X<8?;#XN@($NXPNY[U`5^
MY\'<@\,5`0)SXHNU;QEJ`K]R_:]L7AU<L(]WL@0!SXPOG>\&K^3[?8&KG:S>
MD,SO[K&?VO8_J,I\)]T>*.W\?XT/N_&1[(]$OI,M(WQ8L"?95%*\A;Q?>^)D
M[0P4`H!0"@%`*`4`H!0"@%`*`4`H!0"@*8U"^@],O>F7^(V>JAG+?P9,\U[N
M*)_+H1"Y^U689W$8O-F.RHE=9FES`U21JLM3A-`G66;GE(M1V5$`..`2HL3T
MXH)IH0##8P5KR56F!66]=TS=CK@KDC@'-^AM7K?BQO7=,W8ZX*Y(X!S?H*O6
M_%C>NZ9NQUP5R1P#F_05>M^+&]=TS=CK@KDC@'-^@J];\6-Z[IF['7!7)'`.
M;]!5ZWXL;UW3-V.N"N2.`<WZ"KUOQ8WKNF;L=<%<D<`YOT%7K?BQO7=,W8ZX
M*Y(X!S?H*O6_%C>NZ9NQUP5R1P#F_05>M^+&]=TS=CK@KDC@'-^@J];\6-Z[
MIF['7!7)'`.;]!5ZWXL;UW3-V.N"N2.`<WZ"KUOQ8WKNF;L=<%<D<`YOT%7K
M?BQO7=,W8ZX*Y(X!S?H*O6_%C>NZ9NQUP5R1P#F_05>M^+&]=TS=CK@KDC@'
M-^@J];\6-Z[IF['7!7)'`.;]!5ZWXLZV78O&89IVR/&H?'6*)QQMA$GZW,$:
M:&]B9$'58%:Y5U$U-:=*A2]4K5*E8HZ007TY4H/4&=$<:8,50SX_5'BB98/N
M?`OA/^3D>\E>`&I-.:@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H"F-1/H&Y2^!S
MMXFKR>?'O)GFO=Q1YG]K3C;939*U9:C9EJLSWKSQ[E/3CI]P]/LJQ[3^_,#3
MC])CB3S^!XLA;C'T3C!)$J=9*ME&7(P6^)P.1=BT8E2VQ8`(!@-@]$')))1B
MZMTJK[E5\#259S_!P]VVYJ\VO>[N_P!\Q;_W6T.E,IL9/P_V?Z/E#RD;E<;;
M96T&-#J8Z%)##R#Q#9WMWCZWHR!7$"P7%C6MZ\!=[W_VA05-BC;?BF`':VY6
MITU;TGZ.J,:KK7<4*ZX4A95A="MGOG!#?\?*&13.$V]OUY.+_P#WS^&MMR_K
MY8\B(Q35^M^Q!7#$,1+L+H5<U_6XV19X/@%;<XTBO_\`K5]))J3ZMU/E6DF-
M\E737@0QPQ=&"PBZ%3+K_P!9QIY-!\%[?^)^O\N[PUL)MUK2[^J[>PR2HVD0
MM;CJ/%W'T*B3^=T7&F<L%^KN_K/-]WY:NO8O!&$,6P9C`(6X=(+[E[;G12J2
M"X0;OZSI?_SYU+3[/!`AJR)-0!7W#7K<MT/&D+Z+AM_])PO2O8O!`A*^/MY=
MMT)CE?\`%#QGAU'^M?\`\2R__P#'Z>&MM.E+M>"_\':0UP:TI=K]")7?SK;G
M1+UH_P!?<_6/O_Y\_AK*OL\%R!"EY`"^F=#<SSKBW.B.-'^MN>?T0[[O_G=J
MY.Z.%ZU*[#`$*<#1%B%T-@?M.,6`?!N?^(-_E_MJOE^WV!J_VM*PX>@C/)0K
M$="*^,K7N%,G"/SLP8^%;<,"78P/GAMN[@K;MMT-]VU[VJ,I\)]T>*.W\?XT
M/N_&1ZN]&6$84OT?:45QZZ?A/6Z:\%JS@I\HY&2)PFJ,7Q8XRQ"5+)RDR8FP
MQWL4G3E%$$@Z$LHL!80AMYK;PNT?+'1A6Z_>;*,;3NTO2]9DIY0T%]7Y%Y6<
MF\ZZVW+LUYL>1EB.KU?,>4-!?5^1>5G)O.NEN79KS8\A8CJ]7S'E#07U?D7E
M9R;SKK+<OZ^6/(6(ZO5\QY0T%]7Y%Y6<F\ZZ6Y?UU9L<-6`L1U>KYCRAH+ZO
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MR!=.0N,D5(S[6`:*X+'$&6+,L`T'0F``,-0G*TL-/RQ6O4D\29123:7'66MY
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M5^1>5G)O.NEN7]=>;'D+$=7J^8\H:"^K\B\K.3>==+;_`*^2/^(L1U>KYE79
MLPU#F7$>179&LG0U;=$7E6G`OR7D%S1"-)2&#!92WN$D4H5A-[V_'3JTYQ!H
M=T)A8@WO:JA-VHYN*6;%8OL548XQH[M':681@>#"()%=?D3=N47>^YEC)EK;
MMP6OYUK2NUK6_LM:VY;]%3;E_7RQY&V(ZO5\SE\H:"^K\B\K.3>==+;_`*^2
M'^(L1U>KYCRAH+ZOR+RLY-YUTMO^ODC_`(BQ'5ZOF/*&@OJ_(O*SDWG72V_Z
M^2'^(L1U>KYCRAH+ZOR+RLY-YUTMO^ODC_B+$=7J^8\H:"^K\B\K.3>==+;_
M`*^2'^(L1U>KYCRAH+ZOR+RLY-YUTMO^ODA_B+$=7J^8\H:"^K\B\K.3>==+
M;_KY(_XBQ'5ZOF/*&@OJ_(O*SDWG72V_Z^2/^(L1U>KYCRAH+ZOR+RLY-YUT
MMO\`KY(?XBQ'5ZOF/*&@OJ_(O*SDWG72V_Z^2'^(L1U>KYCRAH+ZOR+RLY-Y
MUTMO^ODC_B+$=7J^8\H:"^K\B\K.3>==+;_KY(?XBQ'5ZOF/*&@OJ_(O*SDW
MG72W+^NO-CR%B.KU?,>4-!?5^1>5G)O.NEM_U\D?\18CJ]7S'E#07U?D7E9R
M;SKI;?\`7R1_Q%B.KU?,>4-!?5^1>5G)O.NEM_U\D?\`$6(ZO5\QY0T%]7Y%
MY6<F\ZZ6W_7R1_Q%B.KU?,JK.6&X>R8@R([HEDY&K;XLYJDX'#)60'1$(TLK
M=#92W.,D5(5A.[QB%2<XD=O.&6*WG5<)-SCA>]F*]4JDRBDFTN.LJ/:M:MGK
M0?H1SYJGAL$9)U.(0UQ)HC+7($)RF/!?)O.HS!VAWEED1B9<JCL=6R`A[5-Y
M*U$8Z&H$S04X-AB\#BEY':$;4E'7[7FAK-61]OWL\,+(]>NIC-VD#4-A&,.>
M/W+,FF=GQS"8Z\1N-9"E#!%T[9%YE&<0PMQ7O#<YR5M9A.":;R5.W.2@EU"W
MSAD2+1G#HEDY.S&,DWA*NE+2JN[]N/7>UKPNC8W.8$ZI(!Q0I%X$JXFZ=:F"
ML3EJ`IUB>]Q7(5$V,L6H)N*]RC0C!>]^AW:'$[)W$^6U`0%YX!^X!XZ]"(8;
M_9%=.G`+N_#M5+-ENXD0SEOX,@+GQ1?.]\-5D].[W$\Y[N"("X<)G=>!70D@
M3AQA]L/BZ`@2[C"[GO4!7[GP=R#PQ4!`G/BB[5O&6H"OW+]KVQ>'5RPCW>R!
M`'/C"^=[P:OY/M]@:N=K-Z0S._NL9_:]C^HRGPGW1XH[?Q_C0^[\9&SG71#8
MUD;23L.X%-&VSY$),3$"7]B-5KDJ1U*:]!$[?&\M6)O4I#S"TKNV(%Y0.G6#
M90E*%>U[6O:_GR:3FDU57\&7)M6VKG__`*1C;O#])'L*L'TM*OO^O5T<-E''
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M_;3HX;*'23VF;EM`:A0KV+FD92K/.5*3]-.'S#E"@T9YYQ@E;)<1AIQHA&&#
M%?SQ#&(0KW\^][UY(9RW\&=<KC/ZG^1N'J0*`4`H!0"@%`*`4`H!0"@%`*`4
M`H!0"@*>U!>@AE3X$/\`^XF54,^/U1XHQX/N?`MM/^3D>\E>`&I-.:@%`*`4
M`H!0"@%`*`4`H!0"@%`*`4`H"F-1/H&Y2^!SMXFKR>?'O)GFO=Q1IKVN&SV/
MS<CR_J'R_M3M1.D32BW8K;67*N(8\K?G'"5V)NL8WN:]WAZ.:(4,C<)BK<43
M>-B(BKDY/[H-M:T*5S<%21..#M"5*)0C)UN;5_B>827.&S+?X#%H-(/PAS7E
M.X3BY0T/^.L;K\`ZE71C8'J'V"?$3(@R252EC+,[,1J<DF)JS3VLB/#Z59&N
M:DP1F`';K_\`Y1OQOCIQTG^CM0\IQ'<3Y;4!`7G@'[@'CKT(AAO]D5TZ<`N[
M\.U4LV6[B1#.6_@R`N?%%\[WPU63T[O<3SGNX(@+APF=UX%="2!.'&'VP^+H
M"!+N,+N>]0%?N?!W(/#%0$"<^*+M6\9:@*_<OVO;%X=7+"/=[($`<^,+YWO!
MJ_D^WV!JYVLWI#,[^ZQG]KV/ZC*?"?='BCM_'^-#[OQD;8-67I>-@][F/_\`
M3RR37#)?$CO_`!94\)_OSH5[#SB@%`?P0K!M<0KV"$-KB$(5[6L&UK;M[WO?
MSK6M;S[WOYUK4!TA.;:"Y(1N"$`E!I)"<(E9`;GGJ"^G)R2;7,M<TT\J]C22
MP=$,TN_1@L(/GT!SEJDQIRA,4H(,4).E=5)RS2QG)NG@N81U04$5QD].+M<9
M73`AZ8"UQ`W;6W:`YZ`4`H#@LJ3"4#1A4$75EE`/,2V-+NH`08(0"SAD6%TT
M)0Q@&`!@@V`(01!M>]PWM8#ANY-P2EIUUZ*Q+;<VSB;=418I!<DOIQUEIES.
MA2W**OTTWI]R^EE_CCW`^?2H.FCD4?<6OKXWOK,N9;]%N/"-S1*FN_0&6*'_
M`-H$'C2?BFWL6+_;?BF7L"^X+SJ5TZ`<I3VRGI#5Y+NUG(2#`E'K2G!(8D)-
M%<L(2S5(#;DEF"$:4$(!CL*]S"[6MNC#NJZ=`.Z0J3*K&"3*"%-B3C4QUR#2
MSK%*"!=`<G,N6(5BSB1?BFE"W#"Q><,-K^=0'/0"@.(_^H.]Z,\"]`9L;/O\
MRMI!^+-AW][9*\,,Y;^#/1E<9_4_R-QM2!0"@%`*`4`H!0"@%`*`4`H!0"@%
M`*`4!3VH+T$,J?`A_P#W$RJAGQ^J/%&/!]SX%MI_R<CWDKP`U)IS4`H!0"@%
M`*`4`H!0"@%`*`4`H!0"@%`4QJ)]`W*7P.=O$U>3SX]Y,\U[N*,+]L1I,R;K
M;V>.?-/6&NM:C)\C*@<FAS(^.!#4RRMSQWD:*3X41<'%6<F0H[R-''538VJ7
M)4C:T[T>V'NBY"WEJ5A$'2$E&2;P7NFCS5:E=,&O0]\S=",/[,?'"N2ZZ&O1
MOF:)2#&DIQTW`V;VJ#%D?AS)E)(0H;&Y:)@3+7R)%NP78#W$XV<WNIIX'B9`
M4/T>`.J<+JR=(VDU?UXNM.-&N![?6LMP*;&XIW/(5.I:!(6YJDI5R4JEP`G+
M"M/3$B_&*(.4V-,)*OYY98@AOY]J'`[1W$^6U`0%YX!^X!XZ]"(8;_9%=.G`
M+N_#M5+-ENXD0SEOX,@+GQ1?.]\-5D].[W$\Y[N"("X<)G=>!70D@3AQA]L/
MBZ`@2[C"[GO4!7[GP=R#PQ4!`G/BB[5O&6H"OW+]KVQ>'5RPCW>R!`'/C"^=
M[P:OY/M]@:N=K-Z0S._NL9_:]C^HRGPGW1XH[?Q_C0^[\9&V#5EZ7C8/>YC_
M`/T\LDUPR7Q([_Q94\)_OSH5[#SB@%`0C)4$;\GX_F6.G9T>V5JF\;=HPY.L
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MTI2JHJ55:LJ5$ZJE>Z[7X]LV8+K.%/\`YN3R=J2HU-13KC1IUH^WL.W)<T:M
M!39Y3M.I9W:FIKV@\5T<)&KRL,4+2`PZ:P)A4K)8<H417JY5)F5S6C>(^!2J
M-0%+AGE/)3VV&$-Z8Y3KG?\`(H8+2L</<6<FDJPJ^AZ2MJ6*;NQP>GTH[R$R
M;6'GMOA+3CY;J`=F>>QK,VL"$JIV7&<&P]3.XKI_=&QNC3E)I=D0JT&C:Q(<
M[IAN<>A6.I%)IF0$M.ENQC3*5SR<I4I:OK/1%54>UT7HZZ:%+)QK6Q5.&3E2
MLW1ST*S>\,9.BTXE]:&LD2;,&I1%DZ:*$JR6S;9]:>'V1K$20E`F6/"J?Y`Z
MO6%HDU@IDEU2@`U!B9*`I*2:8,M,000$LD%0;<DWB\FOR9&42C%Q6"RTTO+`
MQ5R,-L\E^;R,CFJ"-.2O:J-:?4,9TU60Q"B(\51^\=)G9R,0+E8_.F068,B&
MM&!KL=9KZL&$=T]1+37-Z7K>"Q[/W47&O5LJL^@ZFNMN5:=M*TTD4U-EXE1M
MFO\`0Z2S(J+3AO5\4*<A$XM4(5.(DVH$6:F@IJ#&Q,1AL4)>3<:@W7TN."L3
M<XH%G&W7`LT(,G3KV,VS&M,VU:6[#4;"U7).=;=N5+5;5BSVWTM85W7&<V#]
M!3DOF&4WO)6,,18,Q'DO$<*QVMPEA"1KI.T2E\CDZ2SNV2)$>]PJ.LS4_D$)
M$\<:CV9F&[HDJI<XH71I>4R)T,M9.K=4HIQ2LIUK?6O+]KSEE;DDY3:DW:FJ
M-)IJBHVZ7UO>ZE39ECO&45Q>DE*.*IAIP3*>R[)#\(8$175,GFCF)S=U`"&]
M&@1E%]'TD@`@INJU02.KG96Y/*IQ<UG5)+#2V][.+DY4KH2BNY?O*ZB+!K3!
M0'$?_4'>]&>!>@,V-GW^96T@_%FP[^]LE>&&<M_!GHRN,_J?Y&XVI`H!0"@%
M`*`4`H!0"@%`*`4`H!0"@%`*`I[4%Z"&5/@0_P#[B950SX_5'BC'@^Y\"VT_
MY.1[R5X`:DTYJ`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@*8U$^@;E+X'.WB:O)
MY\>\F>:]W%&HC;S:T8QA_0IJ;Q%B+53B?%&KA9"H@M9X&HS'#X+FE1`'B9,%
MYN;!FAR?FR06>WK'A,I(91M907AQ)ZL3Q81DB&UAO!VR<:R3<6XUOHFU^UQ[
M#S9:DM/&R(TK:6,9:G-FYM$'P[7\UR/$:W&#FEU`Q4$EF4EDLLC:6:CR_#%*
M5G\J".(6%=()$_'S8^+1U`%J\CTK.?4R\],M'12G)M3AU;ZJR_1Z]5/]G^@Z
MU]<>MC=UXZEN[]0I.NET/3.H;N/4Y?5W4?3O]KU+U3TWJ?IO^TZ3T'1_C;M#
MSG9.XGRVH"`O/`/W`/'7H1##?[(KITX!=WX=JI9LMW$B&<M_!D!<^*+YWOAJ
MLGIW>XGG/=P1`7#A,[KP*Z$D"<.,/MA\70$"7<87<]Z@*_<^#N0>&*@($Y\4
M7:MXRU`5^Y?M>V+PZN6$>[V0(`Y\87SO>#5_)]OL#5SM9O2&9W]UC/[7L?U&
M4^$^Z/%';^/\:'W?C(VP:LO2\;![W,?_`.GEDFN&2^)'?^+*GA/]^="O8><4
M`H!0%8N^1L46R1%<5O$BC"K)SHE>91%HD=8EQ?R$T<3I^NKT6262INQW3)G0
ML!"M:8WFKBSE)3>)5TA8$K*JM*JN--/?V&T='*ERHF]%7H(#$,ZZ9LG9`F^*
MHA,\?RJ?`+<4\UCB9&2<>^%1HX#&\$'JU*`MMF`(X>>%J=BD"QXLRC,ZC6A2
M[MRZQ2@VTFF]/;S-<9I*332NH^^]=U<5K.KDG.>EG3XXPR$9(F&.,;K32^O$
M/8%B!,C(9$9JTQIM(0D-S<:BB#0:X*E#=:1.-V=K,5#6)K+Q&`5`"<HQHFTM
M2]^SOP"C.56DY:WC7L[7A=>R<KISA1%D*-XO5N\)OD>9FNDX8(H4G0K'MQ4Q
ME"C5+Y6:4E3']1+$:!2D&D>7(Q(I5E?[-M4*+D&@+5C6EU<::>__`&*2HY*M
M%<WHOT>).%$,ARL282N)QI4)$[GR!&)0Q-9PDC\J%T:E[37,2BN0[J!?C'N1
M70+#1>>8<*_GUM%J6LRKUO4=QMCD>9AA,9V)F:3`(RV\`VUK1(1@;RCS5)2$
M(DI!0@HRU)YZ@M-:]B0'G&FA!8PP8K[1+!4,J?T<>8#$[LD,8V<:5_&<8^IA
MMJ(2=Z,4$A3J#'8FY-RW$9Y``$'"6!.$:2$)8[B`&P;*+4#'T.7M+T9Q?EMW
M(70UFQ1A.7O<'RRF0PI8FCD6ES&:RF/;4LCR..A"Z')3GIE,-5,[:YHSS%!0
MR51PB#;DS6-'A1.CNTK<79FY1Q<I)-7WM/"^O89))%*=8E3*T@[&)52<E2F,
M"$0`F)SRPFDC"$00B#818@BL$00BM:^Y<-KVW*H@[%`*`4!Q'_U!WO1G@7H#
M-C9]_F5M(/Q9L._O;)7AAG+?P9Z,KC/ZG^1N-J0*`4`H!0"@%`*`4`H!0"@%
M`*`4`H!0"@*>U!>@AE3X$/\`^XF54,^/U1XHQX/N?`MM/^3D>\E>`&I-.:@%
M`*`4`H!0"@%`*`4`H!0"@%`*`4`H"F-1/H&Y2^!SMXFKR>?'O)GFO=Q1K6VK
M^%]FOC#"N8]?FL?2;CS.TBQI#8^U@/=VX0Y9+UREY0Q+'D(2.0U'2$*==)9$
M@0&N0T2L+(VJ%[P:D6%(3"#(.L+3:C&35>UI:V>;YQBJG32VQ/4AKX_!X=+&
M*-#LDD$202::X_D(7O+&((_.W5"U,$AFT:#DN3N9QJ<]S0D*&=[@>/3%;J>F
MCRE9'WYP0MYHZ*^Z.5DY=M:.FK]?N>\I*I3K4R=8D/*4I%9!2E*I(&$PE0G/
M+":0>28&]PF%&EC"86,-[A$`5A6O>UZ'`_1W$^6U`0%YX!^X!XZ]"(8;_9%=
M.G`+N_#M5+-ENXD0SEOX,@+GQ1?.]\-5D].[W$\Y[N"("X<)G=>!70D@3AQA
M]L/BZ`@2[C"[GO4!7[GP=R#PQ4!`G/BB[5O&6H"OW+]KVQ>'5RPCW>R!`'/C
M"^=[P:OY/M]@:N=K-Z0S._NL9_:]C^HRGPGW1XH[?Q_C0^[\9&V#5EZ7C8/>
MYC__`$\LDUPR7Q([_P`65/"?[\Z%>P\XH!0"@,"IWAP*37UIURU$L9I4:)1C
M;/J3*>1&"*)4G5SRK;L>H(83.)*@1%FKUYB1$Y(H]9[5GG`3)U:=!T)0#`5#
M77BTM$JM+NI5^)T4O_G.+?S0LIOZJT7A7<8(8`Q%J&+>-(N+F.#3'&60-**'
M667/LKY`QTZJ,6K73*:MY;X$OC+R8M9V_**22KW=!*W%#'GGIJ<MN&)P4IC2
MK#KG&,NHDFG%3JVG9OPH])UG*/7DVI*?1T2DK5U&TZ)V:87KN1/=5"/-ZA<V
M88E^*YI/%>2<8FQ[4IJKP!IT<GMZD>/1S&0K6'">/6-6]N;='U_6L\8G^0OD
M@>TS-US,<VED,=5H2DB5K-:;;76E&+=56Y1T+MX5,R=G/32I*L,G*=U:*LFZ
M+=1)NBK<K\D7S"C<W:R=&V4<>XC.8&4C%6<&W)$P30\E`\INB@N,F3&[3D^0
MITUUJAY2-R%P9&0F1.*M0GNC<$*$SH2S@WNG6@TOE=72_"-*LA2_^>4BY?-&
MRJW8NTTO"I\O67A60YESGAIM41F=2#&:3"&ILJ46C3C+&EAM+E+1"5&/$3\K
MC*]N"<N4NZ%0JCS<O.,`J<$%QDISAI[VLFJM7-JS.N.-%3#T&3E9C*])VH4K
M2M.M6E<,;VM#->*[3YJ+C.)G4,4A>>1RK)6SA07R0`]=D1]=7K4:@RU!.H$*
MP#LO7G(9\W0X3XF0M2"R-6BCA"HA.E+1%&6KG9DHW*57DW7'.M*F^F&FAUMQ
M<DVX]7+=7!4R='JT.[O98V3-)\]B\DU0/V,87FZRV$9$T9S'3NH02K*CP46^
M/SC&B]14DC1"Q^6IY&X*D:8\4]7KRW4Q"6G'8T20H`@4<&FZ*5S@U1MXYS6-
M;\<:=QBFG8M.-&LHI71K2CLIW74>:?)RII"S++,*[1U^0.>H]F?91J9RH]0#
M"<7$D307+L><%6/SVV5#BBF(+Y!)RG6W5Y);DROZ-&I(CB,))=A(50U&N#LY
M3.SI-16#PH\*O<S8Y2*ED<RB@DY-5<7UKJZ-'B5QJS;9/'W?4H^3.-YE<\AI
MYQIF08BRC$9<ZE8RQ[C%6KQLU.N/)(A:I:D;V1Y7O`WM.NB+K&E#R^OKBVRA
M&F$C2'O9425+55*UU;+6"5USY4K6_"\V#3LI.-EV[46NLY4D[2JGHI>FJ4:[
M#TGUZCR"@%`<1_\`4'>]&>!>@,V-GW^96T@_%FP[^]LE>&&<M_!GHRN,_J?Y
M&XVI`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`I[4%Z"&5/@0__N)E5#/C]4>*
M,>#[GP+;3_DY'O)7@!J33FH!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`IC43Z!N
M4O@<[>)J\GGQ[R9YKW<486;8W'FGG*VSJU"P#4_EU+@7%DB00\BV85S,\2%%
M`IRDGD:<,;.RYF84JMT<FU1.DC"TNR%,%.8N:G%:C`N;S%!:TB#I!M232J]6
MNZ_TJ:>GG07MP=?>-X1IEUI:K-*YVB%\58YD62,BX<:GA1EW/4!C+FR3&.$D
M%.,"CA*-R?536R/1B]83#2D#H4G=EZ&161#8G(=+63BVXQE:OHG@GAH?/O6C
MU:($*1L0HVU`0!*A;TB="B3%[O2TZ1(2!.F(+Z*]Q=`226`L.[>]^A#;=O>_
MGT.)S'<3Y;4!`7G@'[@'CKT(AAO]D5TZ<`N[\.U4LV6[B1#.6_@R`N?%%\[W
MPU63T[O<3SGNX(@+APF=UX%="2!.'&'VP^+H"!+N,+N>]0&IS2W/G);JCVC3
M'*IJN5ML:SKC1OB3/()&H/0L#:JP]&EJM#'&]R6#(:D*AP.-5J$S820G.6&F
M'F`$>8(=Y6=+=P.DTE')4258-OMZSQUF+2?79J)>7>&Y)ZTX4(PADO6*[Z.H
MYCR[9,#<T1IT!)7^',N09(]VE1+`N/(>F2\@DL$21=O/20]00))(+*;C<;*N
M["CE3MU%='&C596ED^DK=9:HG175P=$ZN_08O*MJQG0+*8<NQSC(+\1C5ZQ^
MO;R&V6!Z5K@39+?HFVXU+3&3$1WD)41]G(>QLIBBTG.NXD*"I.4DMT%]<VTE
M==&GW5I3'N+Z&%<99U;VOAV4ZX8W^F!N@W'$+>A"\&(C7<*(JSH:VDGIFXUQ
MLG*LN,0)U*A6I(1#4]-$E)4*E)Y1%RP&J#C`B,%W^3[?8\QK&VLWI#,[^ZQG
M]KV/ZC*?"?='BCM_'^-#[OQD;8-67I>-@][F/_\`3RR37#)?$CO_`!94\)_O
MSH5[#SB@%`*`4`H!0"@%`*`4`H"DI!ILP!*\B(\MR7#F.GS):!0V+$TT<XJT
MJWZRYD``MD<3UAR80E;DR@*)`SN*NQZYK`G3!0*$X4Y%BYLQK6RJZZ%6Y*-E
M2=EZ*W%VU1(H!0'$?_4'>]&>!>@,V-GW^96T@_%FP[^]LE>&&<M_!GHRN,_J
M?Y&XVI`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`I[4%Z"&5/@0_\`[B950SX_
M5'BC'@^Y\"VT_P"3D>\E>`&I-.:@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H"F-
M1/H&Y2^!SMXFKR>?'O)GFO=Q1J_VWVH/2#&](T_TJZB]84-THRO4DQ,:"+OC
MKB20ZA7PB-L<_C+U(G,[#L2;75U5L;RW,3M$TTD<NLZ%L<UIKBT.9CTQ@3A@
M[9-2M54;5.VFC7ZFMC2ILS]>.2\`8SDVE'\(BGDUP`&/)6/'#I%<'K'AH0L4
M=M=F(C90GK.9SVTFQFR/K&;'7D*1RCO406=0@0W1A2E"G.*;KDDGIO\`]'K.
MH<3B.XGRVH"`O/`/W`/'7H1##?[(KITX!=WX=JI9LMW$B&<M_!D!<^*+YWOA
MJLGIW>XGG/=P1`7#A,[KP*Z$D"<.,/MA\70$"7<87<]Z@,#<E:$]'N2IP[Y,
MGFGC&<JG[\L1N;S+'AB"I>7%P1$ID:16J57-#<9Q"5"D(+'N6Z$M.6']6LHJ
MUH6LI-*BE)+56XZANE73@V9:5YX;\+8^1Y?5JU3F?/"(\C`]7=W`NZ5P?2[V
M#U(1(7!,,PA?("$Q;TM+./"J7&V/.Z-18TO,MSLV;4K.JKH1!STUX$$K4+A8
MEA`EAN70YZ,4W94]S1YD*Z(!>1A#W-T4G!88[V7W\_I@Q&W!<T5QWN44E&[&
M]]]UXM2UO-L_;J[B8.?&%\[W@UT^3[?8DU<[6;TAF=_=8S^U[']1E/A/NCQ1
MV_C_`!H?=^,C;!JR]+QL'O<Q_P#Z>62:X9+XD=_XLJ>$_P!^="O8><4!7TIR
M*U1.98QA2U$X*'#*;U(V-F5)0IKHV]3&H<]S16:Z7.4%'A(/;V)2E372$J3+
MK#2+&@+(N8<#&Z-+76FY5-2JF]5*[W0AQ^HG%C.Z9/0324,N/$>+9\RXZ<WV
M=/S%'&9Z?WS&<.RFE`Q*U[D592$N/3%.`\D\*=8$]J=U%DPF]+98/+25:NE'
M2_6TG[FV7U:*MJ-JB3=%:<>*]2Q`Y`@8TJI<&;1$2)$HC218L#)&:Z5(KF=V
MP,/2JE%EMR2%$KN],UHT2:,!C[=V;+-855UZ7INU6M:-.O#QT:S*/4]/ICX:
M2M)EJ3P]$XYEIZ1S>+S)XPQ"IG.9G!XA)XX[3-(VP1$I4OR:[,%T`:F6)52;
MK0?9>)(G0NYY"%Q/2'&6#6.<56].F*35;NRIJA)N*HU::2;32OPOH2.)9DA$
ML<YPR@=43,[P)_E#.[MCRZ-"1P,;HC=K`\2Q.BLO,4@BI![ND3&.ZHI.0G4B
MZ2JN2,95AZFG7LKZ:>XQQ:IVT]<%WGV9'E3&,/CS3+97D2#QN+/Y:<U@D3[*
MV)J9'T"M`-U279'1:N)1N_5;868XI+-YRD2E$`2HBQA-KCHVDJMI+744;=$F
MVL51U\#Y:[.&&&PJ'*''+6-4)&0DZ=7`SU<XC2<B9I%AJ5.D61<XUR"6^I%2
MA>@3)U3:)20<J7(DQ9@CUB<LW+4;NLK\+U>+,K^J[L;G=WZCJ1'.N+)L1E%6
MPS%B/1X:D;W&,B+#'AH`DCBV/-Q3F[*W%2!P-)0-21/=4`Q>XC1%%GM;N4;8
MN[<IN`I)UOS6T^RAKC)4JGUE57.^N%->[6?%A.IG`\]C<'DK+E."D%9"A2?(
M$>9G671I#([QDQK>79>L7,MW8Q4CLP$1J4)Y&,71IV5?%I(C6J"SF1P"04HN
MCJKU57KMY/P>H.$DVJ.YV71.E?\`=U-=4?:(S]@U3$#,@)LQ8Q40<IX#'C)<
M1.8T='02`905!;%=W+<A(>O)J89:DEKZ=U<<E,+4E$#(,`8+;4:5M*F%:JGB
M+,JTLRK2M*.M-=-1\PC4?A%3,?(4GR5##G*^,R\O@<"Y3'1L1N/S%!Y5Y"4Z
MA=;DF-Y:=.-U.7!#=O+9[@<A++)A='66HUI586L52G[?W"S*E:/&SVUU4].^
MX^EY?^"[0XO(=\R8OM`SGGR.%3(4\C`8R9(;`N9=B"]W<[-UW@)(1'C;;*.K
M0)@B4")L0$1EMM1I6TJ85JJ>(LRK2S*N-*.M-=#[F+<CLF680USV.%*2F5X6
M2%(BZJ&D,,-#'I([QHY66:A4JTAJ5:I9SEB$TE098U$>G,'8!@A%@1=I5[_1
MM>QDDXNCQN]54L&M,.(_^H.]Z,\"]`9L;/O\RMI!^+-AW][9*\,,Y;^#/1E<
M9_4_R-QM2!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4!3VH+T$,J?`A_P#W$RJA
MGQ^J/%&/!]SX%MI_R<CWDKP`U)IS4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`4
MQJ)]`W*7P.=O$U>3SX]Y,\U[N*/)EKXU-:&=,NWTR=D/:#X^2Y7Q:1H0Q_#,
M<Q][Q<T9E;&2=/4O;W4*XJ(R*QS2D_[N!G*<#F).8),8^KRB@A,=#C:CA^T/
M3&,GDU9=.LV[Z=W[W%!;(#;>;/30;`]7>,YNIRG'8-/];N9LOX#C$1QRJ>FJ
M/84E;=$&J%-HB.O!%F%6G11VQ![':YMDEB2QB.,,.&,0V>3G)Q=U;*3OTZ3W
M8T/.<1W$^6U`0%YX!^X!XZ]"(8;_`&173IP"[OP[52S9;N)$,Y;^#("Y\47S
MO?#59/3N]Q/.>[@B`N'"9W7@5T)($X<8?;#XN@($NXPNY[U`5^Y\'<@\,5`0
M)SXHNU;QEJ`K]R_:]L7AU<L(]WL@0!SXPOG>\&K^3[?8&KG:S>D,SO[K&?VO
M8_J,I\)]T>*.W\?XT/N_&1M@U9>EXV#WN8__`-/+)-<,E\2._P#%E3PG^_.A
M7L/.*`Q^SA`IW('K$&0L:DQEUEF()J\2(,5E[PXQMEEC')H)*(*]M@9*UL4F
M5,+ND)D1#RT+!L#HA4*&P36N)2DN%W-!,DVXM4K%MT=U:JF.@J+2M)UI)4N2
M;JFFL6M6O28WO.G+-#N>_9&5-\*)R7-,QN635C5$<O3Z"JL>(K8?AF'(ZAB&
M3T$$<2).H$R0A*KG#5,L5J(T^&OBH+<D3#CC:8\2XRQNJY5N;5+E&YTOPJZQ
M[L+Z4TJ*^BC9O2=>LY7JMU[N:E54[6?,3:9]0J!E%#!*\0O3?*7;27*)C,>N
MCM$CFERT_N..#Y8S1N`1S'?6!2D?DV/4_D85IG&)MJ2[B>0?'&E,B2D'8XSI
M3JWV:N]9M-%-.[N1MN./6N6425*W3M4JW)OYK[GWUO(/(=(&HJ6-\C;79RQY
M=2Z8:U2XI"YF9&E0(^:XYQ;BC8[(F/&[-BMHBL`94KJTMI4D:FVS\_GA=5KD
M<_/ZIC+M)L>3D]*PDL72_4K-V&OA?JG!-72NE"6"KU7?UK3;K6[!=BK=][-.
M!Y0.2,<>:7(DN5YMSEE]G=S6)'(%?2],&7(M'RLQI75Y):TJ*-/C<&(19S:5
M*Q=U$9($S.V-:M4XNA=T^RC>E6]RDN^+76[L+NTR,E1UP48M5VXOJZ>UU[*F
M:D]Q>HD\WT^/[64PIF3#TZD,G7(%832C0('#$60,?-)4<2IT"A)U8A<I6W&]
M`H/;24S60L,3*!J2DZ-1;57%K"-?5-7$*5%-7UDEZ23O\##P.DW,3!%<F1%C
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MFR!`<@<0,C4X/TV'2ER=B,53^K>M8.[1P.CRBJFJ_$G-W+YU'"]WJC]-W<MI
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M+LG+<=#N1-FT;>G+1`;\8D(;0^ZB/J'56L,`O!JC*JE=6KN;>JE:TQP^7"XE
MRBU2]*E*I)?-6E*X?=B9.:;L;/\`B+#$0Q]*+QN[ZR'2D]<"'C7#C)'7Z8R"
M1IDK-=R0-:T*-&C=TZ4!1Z$FY(B1D@N:4`!QE03C%)XWX=K;[-9,VI2;5:78
MXW)*\O*J).(_^H.]Z,\"]`9L;/O\RMI!^+-AW][9*\,,Y;^#/1E<9_4_R-QM
M2!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4!3VH+T$,J?`A_P#W$RJAGQ^J/%&/
M!]SX%MI_R<CWDKP`U)IS4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`4QJ)]`W*7
MP.=O$U>3SX]Y,\U[N*)Z[P6$R!9=P?H=%7M>(L!-USO'FAR67**W;%%74K$A
MQURR[7O8`+CZ$&[?H;6W;U!1\SRJL7^QO`OJ?'ONZ@)[0'$=Q/EM0$!>>`?N
M`>.O0B&&_P!D5TZ<`N[\.U4LV6[B1#.6_@R`N?%%\[WPU63T[O<3SGNX(@+A
MPF=UX%="2!.'&'VP^+H"!+N,+N>]0%?N?!W(/#%0$"<^*+M6\9:@*_<OVO;%
MX=7+"/=[($`<^,+YWO!J_D^WV!JYVLWI#,[^ZQG]KV/ZC*?"?='BCM_'^-#[
MOQD;8-67I>-@][F/_P#3RR37#)?$CO\`Q94\)_OSHPE=-<D`95CDV.,2EI3F
MS1',3\ZHB[-AIB61XGE\TB"2`AO96'ITFR*?CB=.<%"`/4CDV1XU0,XNRI/<
M7HZ3L>$GOBVJ;Z7>!SZ-ZUC%;I).O<K44]393V4-7F6(TFR"FB<>)4HV#%>M
M&8WD[LG91.C#*]/>08?$F%J;VE(X=2/#`@')0MR@2Q`<Z2(;PPN75#>!GD"=
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M=U$_?V,E%)0:=;4:OLZTE=X?M2E&G7[C]=`'F?KH^0U(4Z^"-#*B.R1C01]G
M_(3FL;&V*Y#--D:8K$DKC=D1SG.6F:63D,34`\3:XO[DE4M94](J5[M*TZ'?
MU7K3W5HRNC=;-;^L\'A%5JKNLG\K6.FBO)!%M9K-/SXDRPB#N,F?Y$Y9-:GT
MZ,S""O\`%X8#%*C'(Y._#EJ)Y-9Y.RF,.36!]81Q^RQP<#C26-Q;&AS$O+;"
MRB=+M=;TTK-*NNFYUN[C'"E6W2B354ZNJ=%30ZIJ^FO`ZT.U@IG&&QN4BA<L
MD<-9F+"";*N2QG19IO&I/F&&P*5MW3(D0X=4N9;2T9%B$@FYC%T*-A02``6(
MJ0&M[@D1E.ZM'2D:OMDD\.RJ;U&O)T;556LJ*^]1;6/:TTM="8O&K6*LT,C\
MU,A\O<$DA9<X/:9K:"4*]YL5@TYR)>DI:4*HLM0J?!MIG6G</+()"8$QQ/2E
M`-,!5JZM'A)I=W,FPZTJOE[NM2FCMO)]AS-S;EZ$OLS0M[44B8G%8AZJC,XB
M60XX]`2LZ!XNL891$G!6C/`6%?UL7(G-,T.K>\(5Y!J`:&R%Q7HRM*O;2YIK
MQ0E%Q='7"MZ:?@__``QS*UJ6*CS9DQ\@,NC,9D&(HCDB/19X6PRP36"=S6(Q
MA@FTHDZ-S5)X8S)K2FSC(1.R@2>.Q-O6OKJG*<P=9@3;TM45E.EVEI)UT8WZ
ME>4X7N*:;4FJJNA.J2TX7:W<?A9K6;T4RQ44H1)C$F6(7,T,&@K#(X5*%,^R
M:VY,AT.CMHG/&AX.BZN+N#:YNKM9[4N;>E3M)Q)KLB1/Y13$);O7:KDJ.KK2
MYX>M*7A9-NU_5JK::HFI-U5*UN5WA=>7%G+).0X?D+3?&(JWCZRSZ>2,O("U
M`-C4K@L$1Q](Y@>Q-Y;Z5^,%S,:AJ%2U$F)<A(6HY`WJ6]P<DQX*DVG%:VZ]
MR528I-2;T*J5^M+W]>QE9QK77#Y(%\;T<2$Y2U+;&!4;B\0G^/IQ=\=<MR5X
MBD<C#L_1Y]4,$2E#&Y,BU7.&UR7*$C`RALY-[F_^<GO*RB>B^ZY-/%TI584T
MUP171M4K<NM5M-9J3;PJU>J4Q[#^R35M-(5.FUOF^&7R+1-+B?*4PDZ0U>S.
M<K.EL+GL"A<9;(6H)>4C/(&*7*9HTI&A:>2BZN72ME-6JXZ"/29+8YM.^+2I
M)O7<TE376OKV,*":=)7UBEC2C3;;N;NHZZ;L'5$H=M5CHQ.J>#.>%Y7Y;BN9
MQ2(I,?-\GAZLA41.X/DJ:Q24DRTYQ1M%HX<#%,R9GH:@M.ZM+BR.(T[6ZHP-
MRAUUSI=9=:I4NTIM.N%.JZZC+%U;2LWWT>AQ35-?67CH)#BC4RRY>G,R@K9'
M;MAL6\EZ=6,^71%;(VQ3$9(3&%"6:0%(Z7F,(.D)A_7N(#<VQ0D>(^28K6JV
MA<8C;5>J56U2E*ZJW.EZQ5=&M&2@XI-Z:4N='55N=*/M[=9MTV??YE;2#\6;
M#O[VR5XX9RW\&=LKC/ZG^1N-J0*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@*>U
M!>@AE3X$/_[B950SX_5'BC'@^Y\"VT_Y.1[R5X`:DTYJ`4`H!0"@%`*`4`H!
M0"@%`*`4`H!0"@*8U$^@;E+X'.WB:O)Y\>\F>:]W%%SU!0H!0'$=Q/EM0$!>
M>`?N`>.O0B&&_P!D5TZ<`N[\.U4LV6[B1#.6_@R`N?%%\[WPU63T[O<3SGNX
M(@+APF=UX%="2!.'&'VP^+H"!+N,+N>]0%?N?!W(/#%0$"<^*+M6\9:@*_<O
MVO;%X=7+"/=[($`<^,+YWO!J_D^WV!JYVLWI#,[^ZQG]KV/ZC*?"?='BCM_'
M^-#[OQD;8-67I>-@][F/_P#3RR37#)?$CO\`Q94\)_OSHQI>M)>&7^4/4O<6
MAU,>7W+$!S,L$6\*"TI<OQRU*VAC(2IK`N`B/+271_4R!BMT21Z72>1J%>[U
MV4`OZG!/Q4MZ5/#&NNIRMR223N47'<W5^W@CADNDS%THLX@6*I<C*>4.>&E[
M);GL@DMW:-1;TT23(C6LL>VJ;A2^2&/L+PPF)!)5C4J:4Q5U2I$:M2*\<(O?
M:K?C:=7ZX&6WV76:786,.+KKKW4D\RT]PF929?.!N,JCLY4.$1>&F7QEU3(W
MF+NT,9IA'&Q>P@7MKFU;JV.SV5L3X@>FUY:7=L=C2%;>*Y90P:XINMZ=SJL5
M2[37%.CT!2:5,5?<]*;3IKQ2>L@#QHUQ@ZLPF0B0Y*8R'6*3F&3M8RRTLEVR
M<QY(D"Z63(,X<US4O5G+WB3NKL\#=(Z9'7!-=T7-*101'S0M`,L+"_!IWXIN
MKKOONIX7&J;5]$[TU58.*HJ;M=<-9<D,Q+&8*Y9!7LJM]&1DI9'G.0-"UQ`<
MV$.L>@T?QR!S:.DI4[@@5.L5BD:1.MNN!R<9[,F6(2$"DY<8KI*E:::7=RIW
MX)>'>2VVDME47=5OBV5"5H_QX*YZQVEF3I%)4[?#VJ)S5[D[>?,8$@@+V*11
M,J./:1A1&.2AM=;V-5.<X*F#L_).FM<D7O#4K7(E66%K>BCTJF%Z6ZKOH5;>
MA12O;5+G54=4ZZ-5*8JC+#C^"HNR.K'(5C_-I7)V5HR,SBDDLD-G-R=2LI+(
M<ME!RXHA$A:DEPW@D=3,K>P-K(QLJ-,<G0-)05`[TLKM;HU5Z:TKAW+"A+=:
MJB2NN2U)I<7C5L@J#2'BYK)8VMM<IPAB;<BQBF?H,1(BK12?+,.M,=8X`]35
M*-M&XK71K:XC%D+E9G=&-ME"*/M*"4MSTWHRTEEA7*^BI=H=*)5TW46F^BK4
MISDZMTK??2]6FVTM[;[&W2E3@+T@8Y`N$I%*<IB1HR\DE1)F(FYK8WP`O+"\
MYWF'D04,R!M>2#SG@ZSDTKGIV>W%B&02@:E:5FL8V&986N6FBKA7&G[V87"V
M]2T5NK6ERK6[#50L_'F&H]CTJ;FE/,EE3_D=Q)<YI+)4I9Q/KXH2,B6.MX32
MHXR1Q@2%H&A&2F)ZWL:0T\RYJM>:L6'&J!:HTK>VWBW2MRHM%/3O);K2Y)+!
M*O?I;?J1,W3-`@-$2;&=YG494P3&\.Q?$G^.R6[>^M#!!'9F>8\ILH$B/1N#
MB!8QHRW(IV0+V1Z0C6-SNS+$*LY.)95V*HDE1ZOWP-M.^J3JVW76\?W%:&1X
MK1SAV[,\-3D"3/*J0L\Q;WN0K7=,E?UKM-9?&YXXS).H9&UH0L<N;)7$8V\Q
MQQCC>SI&!8T(CV]N*-)".V6(WZ:X[W6MR5'6^XVW*M;E2E%HZJ:2OQ5&TZUK
MI+8G6((ADDB,D3*SJ[`C":4)$XK+^H3'$J905^QW(+N8V\E*(9BV/21UL$:'
MJ"Z9<:6K3=*Z2`NU.*=*WTKZJC]&2FU6FGFGI[4BFB='$!Z*RIQG&5WIX31N
M$1IF?7"2,A+E&B,8R4,JQJXQTIHB[6U-;I"W,;@6D-*;!(Y$A>79'.44K+56
MN5-A:6W<EHT.JP2I3W=2K;T**O;I3&TJ23JVZ-=MVBA]E=I.QN\D)`2-YR!)
M5?D?R1')`ZO,IN-UEZ/*+M'Y`_*7I4B0(NMBYJD$4C3S#SX87%"XDJ8VXEE)
M2MZ<**EA:WIOK>ZTK7P7@9:=]$E?%]UE-+T=]:U/N,.F^%M#\TS!U?9M-)NU
M3-JFUYG+7E"J?'!<P0>:8]CS0L+:6=F9BHZQQ[($K$A:FQH;@C>'98^+CECH
ML7*56J*3K>W6M6^QI;DFPY-W425*46%[3>-=*7`YHQI\BD2FQ>0O)'.I,Z,K
M1+V:'():^I'AOA#1-G1`]21M855FI+(ER56L:D!:0,M?I,-F0I[-[(8W(QFD
MC**3K5NE4D\%7&FGQ;NNP#E54HEA6EU:85T:="5<6;3]GW^96T@_%FP[^]LE
M>.&<M_!G;*XS^I_D;C:D"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H"GM07H(94
M^!#_`/N)E5#/C]4>*,>#[GP+;3_DY'O)7@!J33FH!0"@%`*`4`H!0"@%`*`4
M`H!0"@%`*`IC43Z!N4O@<[>)J\GGQ[R9YKW<47/4%"@%`<1W$^6U`0%YX!^X
M!XZ]"(8;_9%=.G`+N_#M5+-ENXD0SEOX,@+GQ1?.]\-5D].[W$\Y[N"("X<)
MG=>!70D@3AQA]L/BZ`@2[C"[GO4!7[GP=R#PQ4!`G/BB[5O&6H"OW+]KVQ>'
M5RPCW>R!`'/C"^=[P:OY/M]@:N=K-Z0S._NL9_:]C^HRGPGW1XH[?Q_C0^[\
M9&UK5RH3I=.>P@/5'DIB`!CW1G'F@)*!T6STR0`/1&&""`/1"$$(=V]MT5[6
MMY][6KADOB1W_BRIX93]^>)\[R0,/]]M'TDC_P!:O8><>2!A_OMH^DD?^M0#
MR0,/]]M'TDC_`-:@'D@8?[[:/I)'_K4`\D##_?;1])(_]:@'D@8?[[:/I)'_
M`*U`/)`P_P!]M'TDC_UJ`>2!A_OMH^DD?^M0#R0,/]]M'TDC_P!:@'D@8?[[
M:/I)'_K4`\D##_?;1])(_P#6H!Y(&'^^VCZ21_ZU`/)`P_WVT?22/_6H!Y(&
M'^^VCZ21_P"M0#R0,/\`?;1])(_]:@'D@8?[[:/I)'_K4!Q'R!AZ2=_VVT?U
M1G_$D?\`X+__`%U`9W[/O\RMI!^+-AW][9*\,,Y;^#/1E<9_4_R-QM2!0"@%
M`*`4`H!0"@%`*`4`H!0"@%`*`4!3VH+T$,J?`A__`'$RJAGQ^J/%&/!]SX%M
MI_R<CWDKP`U)IS4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`4QJ)]`W*7P.=O$U
M>3SX]Y,\U[N*+GJ"A0"@.([B?+:@("\\`_<`\=>A$,-_LBNG3@%W?AVJEFRW
M<2(9RW\&0%SXHOG>^&JR>G=[B><]W!$!<.$SNO`KH20)PXP^V'Q=`0)=QA=S
MWJ`K]SX.Y!X8J`@3GQ1=JWC+4!7[E^U[8O#JY81[O9`@#GQA?.]X-7\GV^P-
M7.UF](9G?W6,_M>Q_493X3[H\4=OX_QH?=^,CU:88TTZ?-3FA31=%]1&%\:Y
MKCD>T\X%?V)CR;$&68-;0]BP]&VX3JW(WM(K(2+Q(52E)=22`)MTYYI5Q=`,
M5K^0Z-M2=&U>\'32/Z)79A]@+I-Y#H#]RT%N>U+S/F/Z)79A]@+I-Y#H#]RT
M%N>U+S/F/Z)79A]@+I-Y#H#]RT%N>U+S/F/Z)79A]@+I-Y#H#]RT%N>U+S/F
M/Z)79A]@+I-Y#H#]RT%N>U+S/F/Z)79A]@+I-Y#H#]RT%N>U+S/F/Z)79A]@
M+I-Y#H#]RT%N>U+S/F/Z)79A]@+I-Y#H#]RT%N>U+S/F/Z)79A]@+I-Y#H#]
MRT%N>U+S/F/Z)79A]@+I-Y#H#]RT%N>U+S/F/Z)79A]@+I-Y#H#]RT%N>U+S
M/F/Z)79A]@+I-Y#H#]RT%N>U+S/F/Z)79A]@+I-Y#H#]RT%N>U+S/F/Z)79A
M]@+I-Y#H#]RT%N>U+S/F/Z)79A]@+I-Y#H#]RT%N>U+S/F/Z)79A]@+I-Y#H
M#]RT%N>U+S/F/Z)79A]@+I-Y#H#]RT%N>U+S/F7QDF!PO%^FQ=CS',6881!(
M<QQIABD1C#8E9H]'61`_LY2)J9VI"62D0($I=K%D)4Y1910+="`-K54,Y;^#
M.<\U_NDR4J2A0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4!3VH+T$,J?`A__`'$R
MJAGQ^J/%&/!]SX%MI_R<CWDKP`U)IS4`H!0"@%`*`4`H!0"@%`*`4`H!0"@-
M9&4]K9H]T[:HW325JCE;KILGXVQCDD!F64VVS?AO*<0D0#`H)'%\FMYRYE8D
MZ%R2/$<?R\B`A13;(V!W0I%;HC`A<5XI0DU:2JNS%=ZY5,M\T2./2[3E/Y-%
M'UFD\;>X&Y.#-((\Z(7ID=T!Y&Z2M;'9M/4H%Z0ZUKW*4I%!I)EO/`.]7D\^
M/><YYKW<3("H*%`*`^>YH3'!*),4XKFL=Q@'U6W=1=4AL"^[<%NKT2]/T`^`
M>ZGN/<XH@W\^FZO[V&-5TM=Q$#H$-1_73*7CW;6M?\>-6\ZU^BMQ8S;]/GUM
M>Q>O,Q1I@WZ<CYQF+41W]9*I<+A_;Q^W#Y]^".V_36J5-"O[WQ9EA8U?IR.B
M;AID.\XR1RT6[N_^MLEN-P\5AMP[E%)K!*_OYBPM;\?]'0,P/%C=WICW+!;O
M#_OS3;AMN?H9+?HK;;[/7F+"[?3D=`S3I"#=VYCI+!;O#_VDW6_1N?H9[;GG
M?V4MOL]>8L+M].1T3-,6.S?/&ME8MW<_XLCMP<'`UVI;>I?N\6%V^G(^>;I.
MQ8=_6'2H7!_QDBW!Y]N*W6_32V^SUYBPNWTY'1-T>8?.MN&6E(O_`+]#;].[
M^A#;]/\`YW*6WJ7[O%A:W^[CH&:*,(F[O3$TH%T6[N_]X!VW=V^[?@2V_3_9
M6O*2=*TNPN%A=OIR.@;H5P$=YYC?*!;N[_\`.11;AX>*1;AITLZ4NIA@+"UO
M]W%/9QV4>D;4#BN:8BG[%,%$9FS6%"L,12]P2K4"U(K3.C(\H3"@A!=:QOB!
MM>$9"H"AO4J4)29R1K6\U2D//*2:LNE"HJQ)2BW5=W+2C6$A_!E<.-B)&VMN
MT(VC#>W-Z5.A0($.9(LD1(420H!"5&C2D04LA,E3$%EDITY)8"B2@`++`$`;
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M'DF="((P]&4;!A`%T(PA&'H@WW!!"*WGVM>@Z5[,/+_LYO,T>*?;%-I%RV1O
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MYCS-'BGVQ3:1<MD;YD4'2O9AX/F<*C\&;Q"K(-2J]H9M'%28\`BCTZC,\8.(
M.+';<$6:49!A%F`%;SA`&&X;V\Z]KT'2O9AY?]G-;\&CQ1;SK;1/:16M;SK6
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MH.E>S#P?,TDZMOP=75-F35H5B+2S),^Y`PQCJ/MC9-=46N;(B0F)6F3P9=V=
MF'$B!LBQ,SED<8FHUN2N+U&8P^,BR9`>650Z-76:RE:.D<JE&LJ5>"BM';?=
MRO/07LS]@K%-!#`LM*M6NHK*[I)$][2W'46F+QBK3DX&J"[=4668I:W1V42A
M<5NB2!?I#(!"4)PV.(9&DTTPJVIM--8K]]/U''*3Z14HDM?S>)Z!:P@4`H!0
M"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*
M`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!
M0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`
M*`4`H!0"@-1DTVA>38SMD\1[-U)"H(HQ7D+3`Y9R<YTH!(/+`12%$;DXLMH0
M#+>2XY9F':#M]QV4,AR[=5K.A5VW2.E"[/4<ZWJ5*>!=;MM8=FHQIHDL=-;^
MF]*DG#@O;(RJ\LV/G)EJAL76;'`]2>G4FE,[8D<>C0G/3T)O9PJR%1'5US4B
MH)(RQ)UZKNQN,@\]ZLM-&ER$M&1=0F<<;8DA<A4%I(V^S&4-S>3*%1J8"T*>
M+)@FFKY*?9","XPIB2N`RD`K+30@2[IM#$G)T2J^PBR+75HW<<#'ZH4.IG#*
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M76Q]F&1/2A5:Z5&UL;HX+EJK_=DA!QU[`H;8DE6RZ:Z$AS[M$=#>EN:H,<:@
M]4N&\4SYQ2HUY</E,O0D2)(WN'_H]R>&I+=4K8&U>&PC$3B^%-R)646:<G/,
M**,&$%&355%M=Q3NJC63.L?9+V?B#`$UTER#%6J[+S?&)=(<G9')3ODPQXZ.
M,"+0+M,AS),6EJGTN7MLF<3D)!*>5(E)Y\=Z4B&6LN%2$4G:JI7)M46GMNN1
M:&3-I3H%PXJG#?D[5Q@R'.N-I>C@$Z8W6=-7D@C,S7E.*A/&W&/IC%#T%TZG
M:7)2H3E(#;HTR,Y0LN02&P[@HR>$7?A=[EQOVJ?3;&,%D:FW_.F+&O3VL9T3
MZAS(IFK%;'KBV.9]DC::V24"T;<Y'N*X5FU`@0'*'!:Z7ZUIDIKA_NU#*.M*
M.NJEY6^(=H-HCSZ_P**89U1X7R/*\GDR4^!16,39J72>2!AJ%8Z2HM''NF@>
M"E3`UH%3FZ(UB),K2-H`.!A%D9Y!QH.,EBFJ=FLQBVS.O[).S9T=`U'8JAD'
MG<I%EB$0#K'D$#\-@ZVRA%)%2M;T,<>&-QZN3C92`IK]6]3]":=TTDR_07"*
MA&W*C=+F4;KJVI6?X%J3P[H"T!X(AN>=9V4L>I<J2=7DMX<6G#F&(*I3*5)3
MI,>M+JQ.C@>:E0JW-0GO)F'K<WG1PE%:2O<K:V:PV,52U)TC6EV+?85Y@G:A
MZWL(ZTL/Z&MJU@'#&.9'J63K2=.VH#3B]R)7BF729"(!%H:\-,M>Y([%.BYR
M/1,/59:]G<&Q]>(J4LB1C%*4LD2`X1<7*#;IBG2J6O5^]A3J':D;6O/VL+71
MIPT6:6=(^1H_HQRRH@3LYY)E\QA\B<6ER?)FU1!48:HR$TL[@Z.08.\W7W0D
M($20X)%Q@(*4`Z$K_7T=#;$%&+E)JTM"K@;']DWM'WK:(8HRPIR3B<O".?=.
MF6GG"V;L>('F\@8$<H:0"N!TCSF*PC@(52E,[M2AK4J7$YN<V)<$MU=$!Z%>
MH$SC9:HZIJJ9M9H0*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`
M*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`>8_+'
M_P`JGTR?_9YO_P"\ZA*'5?!?U^R-,&CW39@&0_@VVT$S7(,.XY?LP)LGY(.;
M<H/,19'.?LEH<X8D%&TT?EJU&<^L"%K&N=#"D+.N1)#!O#S=02;9V<+*!TDW
MTT55TNNK<71=_P`/QK6)L`)[KX'&3='5]DAB1%$'S,J$AYPNBSH5C"1B=U<L
M+?TZV/W<B`K<5F*%KN08C0+3(&YKC$P6\M:E&7V<JHUJIO#&E<+MYPZZ)!L[
MIGLL=K%+]G1BW*$)@"_55IU;,CS1Q(`VZ=\ES]MS#=6:OTV,1$P>D;/&VM`[
MEJ71,AB4#268I!`BDC6>@(0D-8R-M92"FZNCIKI1XZ?$LW;(:1\7:8]%6R\\
MH_&>-<2:=3=0V%9+JBD3G`7&6P9YE"N$Q]+#LC:C6IB/32?)C&F;U.1T\@NY
M.MW1W2O2J/-J].X/3<2,,G)RE*K;;BZ7W]T:W+AX$*P\;BB*ZR-5&IZ)ZB-*
M&I=9CG9NY_.S]I[V=^!LJX;Q)E#%J.!O2M&F?,LP]\?(+%IHL>P1%N<'AB?R
M)0WI6=I.;4)4@9U)U`ZV8QI)5DJ2FU5;KG3=O-9.3Y;!'[3+LVI'$9QL]X!U
MQU<8ZD\8TH:4($].N>L.1Y1*94>Z/V?M0.0,B3W+Q:XAU&T([PZ8KBTTC6NK
M:[LJU4UP!O+1OW]UZ"TFI277?5=7)W.B6"I?[;S8OKG206*[1+:4S["6KC1U
M&)W(&%E;=1VF':<XI;8XWS9$U0GK:4PZ=<F/C>^/$O1R%D;D[@PHH.X8[=Q(
MY'%"!+79,WLKPTB8ULPK&5+Z2@];TKL>N[@$^4&;+V,/P7V81S!;9IUCX]=D
MV:VC&D==)D\0].4V9]Q@0MD,*6Y`>I',`Q64.]W%Z;&]Y?WD3.)6>SH'1P:T
M"%6=FE=TN*"5'EE6O4=^[3VF8>AC3;@'.VT5_")GG-.'<<Y6<8A.F1ABBC(,
M19);>,MTW19[42JS`![1K2V=:\&Q&-W4.C>%.Y%V:4P$ZLD/3+&:3)M0R5'3
M%^%*&G1G3B%L6MD5,LN-[])-&F-MI7-EVJ9I1I71X:TL"5Y0-&4-V;&^QQUF
MQ1'C\HM";H2P`->904VIC`NKZD+4CH_B92F<X7:ZTT>ALJQE/]`F2_PD[0S*
M-GNW8X)QO?3[EYKR`ZX<A0(+C)WR.BPCG\Z]FAK2LD?:E3\VPI9$$DD7M#?9
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M[\D:([P_4HT^3)1CN`-4W/R23))GG`MC*<#7&5Q8UD%$;LSP-O/1&*C5(Y*I
M$*Z42,H1V+#>^+-;2ADZQ4KGBZ4I3B>F[9P;.K&&S?PU(L:0>7S#*$QR-.73
M)V7\O9`.)-EN19V[D)TJAS5%$#."W-J9.FM9`VC6N:D*I4YN3@ZN3HZ+EAVG
M*4G-U=U+DE@D;":$B@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0
M"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0$)48S
MQPKG:'*2K'\)4Y.;&<<>;<C*(HQ'3MO8#+J[F,:&7F(!2!(SCNX+[C;2'`M$
M*ZU7>Y-^J3NC"NC0?$;,'8598*[XO9L/XN:<9R`Y4I?L=MF/XF@@KVH6W3"6
M'N\12M)3`Y'*Q(T@E1JQO.&HNE37-$.Y!70A5ZSJ3/`&!\C0)GQ5D+">(YYB
M^/$MJ9@QO,\;PV40)C3LR2S>SD,\/>V9='FPEJ06LB;2D3<0!"DM9,E"43^)
M05>LY+8&P:'&Z;#8<,8GMB%%TCJ/%5L=1"V-TG4JVSDEZF@UF?R,$=3.(0KR
M.E-8.DK;65%]"?:QE!5XUOUDS?H7#I3%5L%D\3C4CA+DV!97&'/S$UN\5<&<
M`"RP-*V/."50T*FP!91184!Z0Q*$!98;%6"`-K`0G%N`<$8-9G:.84PIB3#\
M>?CK*7QBQ;CB'8_9GE18LTFQ[LUQ-F:$+B=8DXXJQJP@X?2S30=%T)@K7&MM
MXMOO(0U:--(#$SO,=9-*>FUFC\C>T<FD+$U8,Q@WL[])&\M:4@D#RV)(N2B=
M'M"4YN1:-V7$'KTQ;@M`2H`%6?8P+3UO5BS[N4-+FF;-[JU/V:=.N"LO/C"0
M6F8WG*&(\?S]U9DQ)@CB4[4XRN/NRQN(*-&,TLI&<26`P0AA#80KWN";6#:[
MG0FKKB;%;Z9!37O&>/WDW%ZI*NQF8ZPR..!F.UJ*R$*-7!1JVTX415)`MC:%
M*H8+MYJ>S>AL4,%DA'2QE7KQQ[3L,>,<;1AVF;_&\>P>//N1U!*K(;TQQ-A:
M7:>*DX5P4ZF9N2!O3K)0H("YN023GPY<84%P76`(-E:CI@&M3:88.ED2T02D
MG23D6+:34&*UQD[>X;%\#8IF^+,GQ@\1A,AQY+\9R!K11\#=(%ZU&ZJ'ANN2
MK"H1'%JTKB6N'T@5%JUUE6MV+33UU[#4]L:<&RC5YJH9-HGF:5XS87+3!CE\
MP=A;`^`\%,N%,614,[!+@/TL$G;99(+K%JU%*9D%8BZ@(-5.#XD6==243*F:
MC\6AZTOWU+FZ1LJO6=6VZMTI34>I">8WQWE-B\B^3X%"\CQFRU.Y6CL\BS'+
MV*SBD":!(OZT2%"XM_5J4!YX4ZKJ?IY(3C0EF!L8.U].1ULAXKQAER)*8#E?
M'$"R=!5MR!+(7D*'QZ:1-4)*$04PE,<DC<Y,Y]TX1B"1<U&*Y(1"L7T-KWH*
MTO5S(_B'3_@?3ZT+8_@;"F)L*,3F>6J<V;$V.HACIL<E1(1A*5."&(,[0F7*
M2PFF6`H5%FG!L89:P[=&+=&MMXMOO=231K&>-X6_2V50['T(B<HGRTERG<DC
M4486)^FKBF-6GIU\M>&M`E<)&M3G.3B<2J>%"P\HU>M,`8$:H^Y@RI-Z`4`H
<!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H#__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g893535g87g90.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g893535g87g90.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0JN4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````T````G`````&`&<`.``W
M`&<`.0`P`````0`````````````````````````!``````````````)P````
MT``````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"!(````!````<````"4`
M``%0```PD```!_8`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``E`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#T7(QZ:WDNM;6RUSI'Z3Z3@7NG9<UC?\Q"C%#"[[2W3W./Z0P->WK>
MI6K#KW6TOLQ+*JK;`"QUS20#I_.U-?4]WM_X1B&3U7<8RL.-8FI\CZ>S_M3_
M`,3N_P"N_P#6TI:O#JR&6,;8U[&N-=@<VPC<QVXQZMWYO^8B.Z=8\%KK0YKO
MI`BPSKJ-<CZ.U`NLZK54^WU<.[TQN],5O:2T%ILA_KV^[TO5V^SZ>Q`Z=G=3
MS&V%YQ*PSVAVQXET,/T'V-_X3\[\^K]Q)3>/32=Q-DNLC>3O,P=P@.N]FW:W
M;M_[^F/3'>W]*`6@@&+`=2'1(OW>G[?YM0_RCM,78>[M^C='#_\`AOWO2_\`
M!%8I<X,(O=0Y\F"SVC;/LT<ZSW;?I)*0T/P<.Q];K8L$R";(`.W_`$C[&_N^
M]669N,][*VOEUD[1![#<Z=/;_:0K;\IKJVXPQW50-YLL+73/NVL96]OT/Y:I
MY/5,_&:TW4XY#A])EKG"1LEI_0MV_P"%_P"V_P#A/T24["2RJLKJ-M/JMIQ&
M[A+`^UP)T=M+OT/MWN]/^Q9_P?IVW*K)9-S:6/DZ,?N$?FNW.KJ^E^[M24O9
MG8E5IJLL#7@200>/C'\I.S-QGO8QKY<]SFM$'EHWO''M]J%;=DM],8OV=S-O
MO]2PM,RV-NQC_P`SU%4RNH]1QZ@^RG&=)#3MM>1,$@._0_O?Z_Z1*==)9-&9
MG9%8MKIQ16Z=I?8YI,%XG:*G_P#!_P#@O_&6W*WS2/6]$6Q[MCI;/\G<UKDE
M/__0]"+,JSI]=>+>*;XJ(M>PO@-<Q]K7-8:]_J,;8QWN_/4G=3]&ZO'RVFJV
MV0QS6.?6[:WU'N;8V',]O^#M9ZG_`!E?Z1'>ZG%;!<::F@-:`T;1I]$>UR3[
MJ6O:U]CP\F&`LUD^WV_HTE(OVK@FU^.,NH7,8VQS"-0UY<QCRW=^<ZMZJ=-R
ML3`QV8V3U#&-MMCS7K$\OVMWO]VVIJT!=3ZI8+'>L0)&SW;1Q_@_H^]-8[']
M2LVN/J-)]$N8-P)&T^F?3]NYJ2F(ZE@'C-QC_;;_`.E%.G*IOW^A=7:*G;+"
MP;@';6V[26N_T=C'J3VL?H_>[XU@_P#HM!QF85;KAB>Q[G[L@5L`)?`9NLAG
MT]E;6I*1OKS*\DYE-SKF.J8QV$X0SV%[_5QW&-F2_P!3;^D?Z5NRNO\`1?SB
MJ=2S<;J.!97AY%%EK+`U];_86N81ZK+6V>ZJRMCO>RQBU&VM)V"Q^]H!<W;J
M)X_,4:OLS!8:"6ASRZTL8!+_`,]UFVO^<24AQ^J85F/5;1<+:;&-=4ZJJQS2
MTCV%NS=^:BXV:S)]7TRX>B_TW>I397[@UK_8+=CGL]_\Y]!%;8U[0YECW-.H
M<&R#_P!!,VUKIV6/=M,&&\$=OH)*:SLVZF\MR&MKPRQGI9<2W>=PLKO;/Z#_
M``?I6_S7_@?J2ZG5DWX%]-.U]KF^QKF$`D>YHW'Z/"-NK>TU.>YT`"QA8#HX
M<.;L_.52C!P&4V-=;=D5%]ABUSW,8UYDX[&`-K932UWIT^W?56DIG1D8V-13
MCOR<=MC6-&QL:Z?28W=N<UW[VU$Q\VK*KL?1:'-K>^I_Z-PA[/;8WW0FPL;"
MQ*&58+#30UK6L;6P`;6C:SW;/=[486M>TEECW#4:-[^'T$E/_]'TG.]'>WU/
MM&Z#'H>K$?RO1]BK?JW_`'?_`/!U\U))*?I4_9XT^W3VG[1_!0K+R/UMF8P_
MX/8ZQ_L_-GT&5?\`@_ZU_IE\VI)*?I7]6_[O_P#@Z0^S2/Z?_P"S"^:DDE/T
ML_[+N,?;HG\W[1']E1<:0TFL9KG_`)H<<@`G^4Z'_P#4KYK224_251);^MMS
M&73[@QUKA]^.RK'_`.V/T:G^K?\`=_\`\'7S4DDI^E3]EG3[=':/M$?]+W)G
M%@$T#-==IL#S<ULSW=8U]7_;K?2_TOZ-?-:22GZ386D?K#<UMOYX8ZYPW?G:
MUMKI_P"V?T7^C4V_9MP_IW(Y^T1\U\TI)*?_V3A"24T$(0``````50````$!
M````#P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<````!,`00!D`&\`
M8@!E`"``4`!H`&\`=`!O`',`:`!O`'``(``V`"X`,`````$`.$))300&````
M```'``@``0`!`0#_[@`.061O8F4`9$`````!_]L`A``!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#
M`P,#`P,#`0$!`0$!`0$!`0$"`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"`#0`G`#`1$``A$!`Q$!
M_]T`!`!._\0`M@`!``$%`0$!`0````````````<$!08("0H#`0(!`0$!`0$`
M```````````````!`@,$$```!@$"`0<)!`8&"`,)`0`"`P0%!@<!``@1$A,4
M%5:7"2'5%I;6%U?7&"+3E%DQ,B/4M3=!=7:V=PI1<4)3)#A8&6&AT6*2LC-#
M8S0E)B<1``(!`P(%!`$$`00!!0`````!$5$"$B$B\&&!D5(Q07$RH;%"`Q/1
MX6(C,U/!\8)#8__:``P#`0`"$0,1`#\`]:WB?69(ZOIFE%[':3S335+MY.U6
MMK#G[%($,36,U5SVTVN/V*8;)G,LQ#'T6(PJ/&:M-Y($H0<[D6,`SG1EM]_@
MYLY\4JZ-O,7?FJ/MX=W%?2;=1>E=;;]Q=IS^OJRB\MK"IJRK*6&1Y;9!R*&0
MB;NKG8\F?(TQ2()P`+DS*L5<'(YO&0JDFL9Y$JN'BO;E7*;NL=A^WRF4C6IM
M;<'34>%-+3E1;^URJBMH\9W>N"^3DQ&'22.N#6;%W10R!PVN)F%3ER#@&DI@
M9$<D8JI_"/QG96^NL(4LE(PY.V3"*THX)ZZ=;!<C+U6EW5M'.W3`N!@AR*-X
M0.M!UV8'$<>'/!X19/3JE//$#)"B,23$LZGQB[ECE//<^FU,4HT/2BA]F^Y*
M,826Z<E96^L-T;'/7]Z(<T,V20EVG-A5^TUXI5@C\?,,5N9)P\)Q&=",&>DN
M*J5:/Q,=SB*>WA'F-JHRRW5UWE[:]OE"5](G*5U@XQJ(;C*(;)_%9E.,CBZV
M;IHB>]JBQC5*V8U?DX#BF+)Y2<DD"1"T(@N3QHKH<4.[^"U!&ZP8Y%2<`D5A
M0BX"W=&^M);55^ZVM=NEFHY37+JN7RR/*0ES0Y<F42)L8<!3)C#RDJI&).O-
M2,5I)LA(?%OLQDOBUZ?:J'JV4-E40U\5&2I?N2K"KR9J]M.W4F[FFP(ZFL-]
M;U15'39^-PS-SR62N3%M^1.QRS`4ZI$2DF.GJ9G9F^.Q+"\/*E=R</EA-0(;
M)O6NJZOZX8?',+4VW^IU-Q.,`MF?L()^TR:/Y!'BVH#:)_/)=F-$):8YIS5*
M8@HT01JT8S9'B.MFVF7QFI:>?F#=%#$;!6TQ)G,XO9%,;0OQ7;^X)53#G6FW
M!5$(^XL]A3.G#P"<G9*:<,TE*:G2&`3A%E:%(QDLX?%BNQO/=%KO1].*&60M
M7B`(JC*'=&8(I=9EL@M=A@)1%C2:PVAE@L(9+%22I,60(*]5DE:GR(1H0J0$
M)TEQYD<)?%KEH&&W+QCL?C,G2(-NNUJ;)VJ46*IKF`MZF8W9N$@-A.L5A]A*
M&4]U?X\S0)2LZ`VN1ZR7X0$%-J@X@*92<D8^A32'Q<KMKF3;D7MP9:PL>()9
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M#1R:91&(QPZ?&/3H^+6-K)`V-"DYN)=4F<+@)&.BU-B5'B"7,T;@=N>WT,/I
M&TU&Z#T!=JMMBE9;(9353S%(Y(+*^JQP2O@\#*6+:BA41:EB,(#N8-6O9*8X
MS(_)H2-&R.)+OZNV'[G+;H:M(7%9:_2'==9=81U=;5@2TJ+1ALK78G"MR"A0
MTI&".NJQH:U@VQ63AK(`(LU<I&?E03SX\EI+BH3/[W'^+PNIK9QM+W.1^N(J
MY3#<M43I<!532:6I&`/5<0KYAG4X9F&;O;E&F$:M`)Z`E1EXRM?W,9Q(6QD<
MU&34Q:2*W5HDBZI!,YUN^\.%5%+FO*O*]W1Q.WI9-Z[C,X3MK`-/7E.1NQH:
MD+2!:5/13AN3L(#H(LSDKB_L_9QY=![/0UK(\::;G0*R)^=3==$-\6@T`LY2
MA1V`\NSE23*_[QHCMBDU>[F".H&PF#6<WQ1]6RP@H!I9!9#0N*-`(A+TPY)<
M>93V/XV;U'R[F50Z(4,ICU;.F\YTAMASBV'*/5_<\8VM$5EF-0>JGUI9GY',
MKCM4%C=-1(TQX48D20`BLF!4X-)2,3$:8\3+<'7CU<,VF\'!<E6SS=O><5B\
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M90O3\?6[NG=J:"F4A<5#?(`+%J-,H;VU0-0EPDN,&>0;Q<+0BJ/;O!$%'BGR
M^T'>\)`\26P;RBT;6/#3&][MN4!Z%5Z^6(LBR622Z,1^*@>,HP&*C$R,UN;`
M)^0IPO3)&/JY,=N#Q<=U7T[65-8A7%50202"@=V=HTM*&AUD$W=&!7M(W1,5
M"3A5-HK((VD8L]?1]Q5.;8`DY<0F4)0=+Y91HPDI&*-A=_%D[JI78^PFO=L]
M@OBB7WOM[W8S#*K;]9,-C%<R2P8O#=O+C6MC9E$]2OK9):ABKY,E;@6GP2O4
MNC0JR$!"@1G#0BC62V.'BI7%7TXFE42^M*TDTQJE!=L$E[4UR]X16DHFFWW:
MJ&^7C<$\UL!@+31W;19TL*ZB9U6%?.@Z4F."H-..R@)2,5$EAK_QG75Y7UF=
M-8Q0S;`IA:>TJ.3*WXC;2Y\K"L(UN>J*\9\X1:<2EY:(\V1NVJKD=3M[>Y)U
M)V$H@/Y.#2TIV"P')+B0)`_%MLH]RM3<4_',B)NE=#;64%:T\\2E215R*QIU
MN0W35@>O0.TGD$0BD672AAKU&>L<WMW9&L.$@`*%I00E<4C'T+;+_%MONP(T
MNL(M+$:UKV2['JAO9DJQMF)K39`[)4;R9/0T^%#K$0-_37I"B#$<&K$Q))B<
MEE4D\O&#5`S<I&*7<V=LKQAIY"GS<6B;*9@3J"I8WO/7-L/!/'E7:<"5;0CV
M9&W2C<#$T[`G3PZ`WZ:[A.C:A.HY02S$P0&+ND",(2%;Z&S%'[\[,GEZ+Z$L
MF,4#!)='[QC,`=B4MJRPU1*8E8FTI+N<B9-3H7:`H%4SGD<"Y%HGP"P+0BRC
M3&*$_P"T-+)`(U".J.J9&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@
M&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@/__0]U-MS*%0F*%N$V9S
MI.0YO+6P1R'M[$5)W^8RUT,&!ECL;83L<TM=E.2S#1&FB)2($A)ZQ6>F1IU"
M@H$4"2PH,Y-,(9K';&RKI%/%2U#%ZCM9YK<J8+W"/K#"N@M31'I;+8[(51!*
M<I65AH6K\%ISBA9R`6<A"!2!M7;J>]C:`V12QTC%+D,:,:PS"#&/>9Y,42UN
M;6`:+#CE?F72EN:E)!"7(>F+B4Q@`!&$L6,"ZE659U"`6RAM(L*H0N-;Q]8F
MFB`J60S"V!19$O-:G`B4)0.&#XM'TCHU#3'!5A(3%GIA%BQ@9><8$U+:\V/1
MC<V-9Q#O6L@->V&,.D78VA_KP3A)XP8X92Q5QC13J]M;>Z,)"D)HT)Q9_1^)
M)F$^1&8Y.1=2N<+.V_D)GZ6NMA4Z2DBTL2P^3R=PED*+31R=-IG-H8L_/2EP
MP4T2Q`:MY)2%0:6L*$;P"#&1>434NQ<KIQ;-5]?%26LU=BJFQQ4ND(+>8L?-
M5+,M1LJUW/7QH*D;Z<V*T"YN-4B,)R482<F$/.0C*SD#"+7NW;O33'8<BL&7
M5PU*:EJ]SF$NCQCK$\3)JKE&1Q"27'52Y,Y@:WM3DM&A(&$M,M6GE$`SD9@<
M9%AF"3'=I7E>PNN']QKN=+(E-J6FEW+<1`-62QIKJF:W0U\9*Y/(CHQ9+DR2
M1D:T%E-622H:=*!+$XC#$H#B`<YD()B'85#QTD(#9Q4;$GB4F#$PA')8:V$Q
MF9/JER;01H(1+2`,TF>%A"PC"/\`9JE!H#@<@0L#QH-3]?9=4[0@0G<N$O(G
M23.$(;6MO<8.%4X/KS-FR!31H1!>'9K1*EB"4.0$[VC`;E7E0#*<1)JO):<8
M:E4FE-+/9TF:4<CJYW419WC4$F3:F=XFO.CC^K=$R.'0V3(RE!IC0[J7I824
MV-RH)9PU1H`D%Y,$'&1"J,EU1.<E3Q<V3UPX3&6(9$@21TQZC*N2R5MACHL:
M)8B3M`E)CH\H8H])U"5Q+"686@5`,+.P`P(@X`UT>-W.W!DC-C298WJ!):VN
MENH9^:T\<8SWIQED<>\M0')B;<.&!NL5A6$;NM&IY0#D:2/N@RB<C2Y+$+#-
M@U,PI@*V;Q)9*:P"X1\DB1V1&5+W%,+61.YA3&)7Z;LIJKGVTEP"62(M4O+`
M$W`09P+/`.A"P(I[MO#'&!^;II2.(C,W!9"XN\HI%`\1R5NBE>).X1-@<2%G
M5CZX*'-!D!R!.,TP9Y.<"!D8/(+J1@Z;M=I"5_>H<JL*LU`4%D/E:V:M4NT0
M;XU`+`AD>,D!C;9JU_<6LEL4\AFPB1&Y`HP-R(Z,$03"#<%!#)X73"I&=_4M
MSG**Z:I2&,NDY6(5SW&4+^&'8)3$/4P4I5"DIQQ&<)V@D"IP&'HO(2@P89P+
M#R1"#T+#M).O-'>Z2<5\OM&(T8[QN.!Q:J!7'Z_IO$D.>YQ*XI`P2(46B:1^
M=6U,0^R).B*-/3M"9,:I"42,`A=?0EMIL2B9`:N=&.<U*]GMQLO<'-Q:9-#G
M(U"=#$[<S3Y:N6(UIPTQL42NZ1(\&&"#E"6J)*4Y!@P`1"$;V9?U8UL]L4.=
M('(9-&DL78IF\RB*LT+=8-6T.E#X?`V"1/*-;)FV1+6MS6'J"/\`^=:GDQ.B
MP::H`4FSRQ"P2<YVC23.3(W5XL6JVM/5"M*SRUR<Y=$D1-:KGH!*1$UR-8J<
M"@0Y6[`,+**(4B3#/P((0A%QQC0D%KL6U:HKBMK)L=V4L3VP1V+6%*9,TQPZ
M-N3U+2ZZB3F^R]C;T"EQ0HGZ1IH^QG%C3*#P8`$&`G#*+P(00-8K59=B>\-K
M]!Y=;;,YQ]ALB6TC(H%"[[D]2M,QL%XRFCDFJJ:1F&3"'^G[F\)F`2$E&H*5
M&J$(E1*00DRI4$X75>QMB*0TG#W,V'F/U7QEZB4>.G:B,G.T5:'>-Q5J;PM:
MF:*6@U00N:6%O:D^$YCD,L!!1`.0(S`<<-"%(EL:@R&7TQ13NH"8ZBFRN,>E
M*63PPME26,XJPL*Z/=>%+L(2)LO7*,(C4G.X7&FCP2(&1"Y.0(TE.ZRFX!M[
MB6Z^0H7QIA%DQ:MI0D*+96LZ<#8IJT)9&A$\($;H:G/]!HDX+7=V"2L5`0MK
M>N.)R=@O&#!8EP9I8%E4M6SW%(7(?10R6SZ0PUE9X0@]$QRE62_2W#(SRD^-
M+5Z!R415DDKH,1RXHH["8XP>0!$:+(<A#,93[@:$7S-]@#&KBC^*MC84[O+X
MS.U<G0^*/$\?+?;SB,N9\F39;Y5%%51/*I\2@)"O2DGDF@`=D2C!`:EPJ^\M
MNUPH(J[5?):^E<5FD5:7>%2)J<8AA!(DU@9FKF=%FYE,<"9<ED*A/`'=6YMR
MIL3##E"I";@2A&M*3!J6]XW/;88;((TQ2RRJOA2A:Z/<0KAS>Y5!TC.^B88)
M&9U*$\7=$;RJ)9&YDC3XWX5`7=6\1#("`!A9R09P0R[7\_5(*IKC(FC=F;-"
MV'8K.?1B$K67T[<FFSR2HVU0\I8>]L.&-7)<3`'0C%J]O3E85X4Y.*+XFX!3
MH8[2DTH-IJ^"UNW(4-6(&!X14<R59:J^,(9@5,ZT;VEJ1P_.>OW]JGDH0M38
MA4%*VMQ>`+">:/+4&?K8#4EMBDM-2%8Y-,9?ZR?'!._+H:[MC$ZQ5S6$2>-\
MZ_N<5<D3>>>>4_,'/#6GH30X4)>4(X8`\<BT(0X5N2VLK9J@KAXDL`:']UGA
ME:5P0_BB^&VS'A=5-7WPJ/K1:G5+TKPQJ8Q:[,+)PLINDN9F"RP&Y,2F*!89
M/49>JYL=D/E$-=H3/(W)`&MJF11E>Q2AD?BVA0K;CT![NU&KD#H!L5\^0,H1
MAF"3.<!G`<\K&A#)BVEJ)4#5DMC>4J,.*4F*2T:8"@:@A")L(/&<$O!@CB6T
M>4X!9SR@D9R7C/)SPT!<-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`
M-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`?_T?<U<=8N-DM4341J
M5`@\^KJ;-]@U[+5+%Z4M;1(DS,_Q-S3OL6ZW8!2%@DD(ESNT+4Y:]"HPG<!&
MIU*=262<`5$#S':Y/[$=QOTQM>#&NDPBU9PNVC(_33JUE.K#4%LR^TH0JJ3+
MM<$D<*FE.#YB:G7.*Q3*,C5(TBY$4@/3@QH),=/V*L@V%>TD3!K2KEM=VC!0
MO)-?I`JR%5D7PDO<N0XY$C+.$H87M($&"N=")0KX+<&E&8YO4+)@T4V=VVY(
M']:YV2QU8Z-=R[P)E61<9K_&)2@1WKN@E-AX<)O.HM:3<OD\9FU?A2<XWM.8
MJ]).G$G&+RG5M3'IPDR2`["BH7%Y8PJ;."^.,F9X(RIWY5$GA6X,R*&[J[KW
M-GI@.4HL66REW3O6;;3,A@ESJ>JSED+7J#U1IW,DTDEV9=G4VC"E&\QRW(<C
M=(W/9A)X%%W:J)9*J?A<?G47>(U(F%J@4EO1RDJ%T5EO)AI2AMDC8S(0&*4Z
M)G2IERXI2$EZJG92P5*MKXYEF1KBFKVW8;9B,USC"+KYX0PK8HV[(V]@>'M(
MYIRSG%0WM@)`:Y`2A!QSE`%($/!5@)+!:FR)=9V;-:!VBV,L/G3G=$Q:$X*W
MRX3ADL*ZMOTKV]NZZ03@<Y2$3&#,<>F2E4B9NJV]<`2-N2]:82(2R1!).UH[
M;H)<=J5G8E@HD,F9ZW@MK0\J"/"%2L8G]79DCIQ^`[/9&'4AI=4+""ILE=6N
M"!>E5#<`G<2AI0X-"8->['V$-<[C#8S$SP*%>EL?<[,'GI".SFB+2Z.[HK(>
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M/(C.3^'.ED;I-'G%PKD:^6,FX$)!8H.D6-;1.;5NVZK3K.P`MHY*2!6Z4Y$]
MQ$PBIA7+*S(D+KSYIJ/))9.(6>1ETPV,G30J8,+G93,&%.RK<&ZQ=N!601RI
MN==RLUQ.+`2SF6#F_0Y_$$C@>>2WM)36S`P04@RL.6'-Q)HJ22IL;9(JF$LN
M.31^R(_'B;K;[-B4B9'ZJD\S;62`6[5FWVNIH@BB<V:L2-MF2EPH8#J!T.(4
MMBDQU$4X-*_*1.=H),Z:MJ8$EI$3=XES/)(NTVM*+4CT5>(0<O?4BZ:4B"FY
M&W/,R=)@YD/8CRPC6$JP-20X*<\U(?TC)F5.@DUL)\,E&4QNS$?;ZMX"]42"
ML#'%^;[86Y8[`+VEH]H7O0BT-1;@FRH42=3!$IBD]O7QAS=AGKU@`/1>#2A$
M!)D^['9G8%K$V'+(?8)S@6UU/<+'5=)$H'AF;0.TUVMV-1:.%H%P[28JG;FE
MR?Y6E=B7%PBXW9&>`U+ET"VF%DI`3,?N'9#+9](HB<N>&QW>Y?*8G$;'E5?P
MUIJFO6+;)%(+/H7.*W?(<HG<H?I%(+<A]AJV7I:$9A!:I*SJ!)D:5B3EF0LF
MQUU;1HW<MAIK.5OA+++8S%J_;:W<,,)C@.$2NNK.'9[7)<@+?FLA]:7->4F1
M+V@T!1*E$48`1W`W.`4DD')O#QPS-<W2L%E-XWQX?QNL"G$M3;B)-,Z[2G3N
M0S\>6QQ2;LH\WMTB3O,A-&4NC:2+)S1C/RM1K"U1Y0PDNDNV*S*6MDQB*N^T
M(H+(&N_<-2594A)TT1RC<+4;Q7,JD,BE#;8+-'WY(UOT@6O"-`A864."C^A#
M-%@!:D(3R,\<MI<L/F+9)&:UF&/DLUYRJVFAU;Z_EJ:QVN-S^01>53VM29:U
MW,U1)W9)6\Q[(%(7B,NK4-*%%D;88M;R5X@GD6#<1LJE&X&:R"0+[S7,<;<8
MK94:8(H9&Y6[)XN&S=ND^H9W"2B26Q'Z_=T)#C,RY(`Y5&Q2#*E.<AP[`0GE
M%)`GD9;*=I2E59+C9\&F,0C3LIEB=[0QR3U47-8.A9E-+,M(R)O''$4VAW/R
M)9%V!.4@=@'D!0(1&H#4JQ*<,&0G2"F<=E,8EM7[9*:L28R"15WMXK<$17-,
M8<IK5SI84J1U2DIELE*J30"?L\@8&`$$=Y.F6,.%"TAQP_`P:HY"/(%03ZF!
ML>QB5MB>%M3G=S3)6MH?Z)E\T>GBISA67*I714"8*S;%[!/2+++*A#?(HO'"
MU"E,%M<!IGE>Y*TYQ92\U($)Y%PK'9"]P:5PR2/-I1-W)KY@VVPJ,-L5IS$%
MR9#-M+;N&:HTFD"G%C20ERD;ZCOO.%*M*0WMR;+5CHS<4%4()(24*/8K(D=<
M@BB:[$C=,HO5.V*LJIL-GK(U&K@I^U*=6I(X#+5S0LL-SS(721Q2QP,;^4G6
M-1*THI:81T4IP"D1A)DJ/9DR5_E*HA#@A4PZ-SHJ3IJM6PLN0%/%9HMI,"VM
M+ZB0JET\C"03\\LE>DK$CTN-Z&48K$F4H3@XRJT$E@I[9NZ$;0%-)V@^*!S:
MR'2(R:RWA[P3+70Y)$%L%:H?#I&M1NJ9+(GN/4[6;!%G)S3J\D+ER,]P*Y83
ML`$$ZR6Q?X=L;]((PI9IVH(A,7?IR)!73H*VR6`B#SJRF6WU42#[O+VK0#PK
M;)^D6')U+Z2]M^$`T"43;G#848:$F7,6T*PHDK9GB(73&6!TBMJR*<PQCS5L
ML?:WB,5EL.E,3D4088I)+R=Y$U+5ITFPXDFI'Y-'4"M*'"5A)*.4EG!)9H!L
M67UW&(0P-MG1Q_,BKS&CG4$NJQ6ZQZ41AKV;5MM&D$=6,"&RVA0F.D*>N@/8
M%.5QY*4"PQ`-,IY.%F0DVBH&K'VFZX;X+()P;/%+<N<#D3CT.1(F]G:#C`!:
MHPQES.;V9-A,C&C*"41EWD3RK!C.0`/+3`3IB`>I-.A!H!H!H!H!H!H!H!H!
MH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH!H!H#__TO?QH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H#_]/W\:`:`:`X
MXRKQ=H]#K]F-#/=-"1KX3N)A59/4I460$EE24?*)496KKN!5!S`AY)41JUAI
MF0<9`8:(_"LL_K(O.>8S)-8Z23,I\5[:*A0LBYR<[);`O8$CCA,OK.2)US5%
M7**UC/FF</*3)(CD,3=(!;C.\E'<!'@3B/3FDEKTYB/"1BRM<?$YH0R:U]`H
M8PV1.7JQ;>C=6,)[?&>IFI:VOTNM>`'V4T.,@5-Q3W"F>;4N_MQV2<86#&F+
M/`2)&I2J3[),2'JC\9G:S)J-J^R[@<'*I)S-FZ'&OU<G-3N[GLRJ4UK&;2/=
MF%Q$A19ED.01B5)C`*DI65RH>>:)1C.R$L4DKM<DM/'BK;28\BC+H_/,V:&R
M8@LP4;5KHB84>Z^ZE/,A2,Q.R87BDF&Q:XU\\MS<Y"1!:UCB@,("IP+(.59)
MBS(8WXEVV*4R*+1%O6SY/)YK+4$%C#&YP9S;E[K*5[[33?AH*`H,"64K0QF_
MXG)U8#!`$EC+GE89@(DZDDE(Q>I0LV_!2V7C9=.VM5B*+%1;<O!=K,`>J\FD
MEM5XL&P;#V]I=SC"L<HJ94\&*A,?2U><;E>I$XN($CBE-+SD2;`58PC22$5G
MC`4FLJUB?8DW$OELOM24[<"2!`=%8HNJ8;(F%(QF1)$<OPSD/")SAR2\FI<%
M(\LK*X+TAQ1Q:7!(QC+DEQ9MGNBW?LU`ULY3*&QU%;DE:+KI6CW6&)7F3-)S
M3(KGL>+5\@/6"B->6A+'`YG])P+<-[2PNCBX8*Z.F)&>8`.:1*316*>+M*[&
MD<!B-?;98VX/TYJR,V@5Z3[A\QUH0)W:C+"NQZ9<NC52TKSTYJ3U\<VD=+)0
MF#/4!RO*;#2CTQ<DN/,ZVT[9;1=%1U9<4?0.C4PVS7$'LMD:WQ.%(]MK1.XR
MUREM0/"4`S0)G1&C=0%J"\"%@!P18QG/#CJF7IH2/H!H!H!H!H!H!H!H!H!H
M!H!H!H!H!H!H!H!H!H!H#1;?IOCB^Q6OX#.I%&V^6^FMA>BY[8NFR&"A9HBR
M0^53^?S@*]<S/F'8Z,1B)&@1M99(#GAV6HD!9I1BH`\"I2158OBCT[!+\B]3
M)F&4R2).BFU84NGK.S.*GK^ZX-/=MU:QZIJI:BR,BG[L]S3<.E;%RO!B1"WK
M$X?VQI.3SB))<="'*Y\8:-RQQ@L<?:6D**33E"_K\HF1Y/6IX<F9D>\-\+5S
M8;E'VX:)(HC^T9P.'ALZW5DY.4Y&G#T9.!<D8\R4E_BQ425%V%8TLTG>9L>K
MITB50XMH?D((^3<3M0B**#3.ZIAQTM1-D&X)I5Q0"Q.W%/11"D9YK>4F4&E)
M&+)3H;Q#:GW`F5/%XW&9M&+:N.GH;=<6KB:-N$',0:>5LKL..RMSDS-UZA+@
MRLU$8S]:D$GBZTQS.$V1\08I&H(/:O%0:&ZG9)8-I54DA4P01O=]-V.(Q*93
M"S8SF";,[0?*<LB83F=)J:BJF%MSE/&@DAO+*9W0TX#HB#_^0<,@J27'4E5N
M\1ZIIIN8@&VBLB!2>4+[PEE.V@I5*R2"(86RTMN(LUDD\>7LPGUAEB1]DFW5
MW8S$^%B=4A.(/RI**,++*-2,=)+-O/\`$=8]KD*KF=P.OT-ZL4[#=:A2K13"
M2Q=*S(Z.KYZGTDR%0PU798A&JBV$]'E6Y`9V)K'_`,4YN2)`6>J)I$I(;7>+
M([)Y_<["EVZ(5D&H)Q<S+"DX+IY<M515OW"'4&%W@\)156O8I2_&J0@=<MAD
MC0EC*R).F5J3>:R="QS.RFJ9&@&@&@&@&@&@&@&@&@&@&@&@&@.7$&\5&GI+
M9FX^NWJ/G(%%*VE!ZL@)4-DB2Q9==;W-K4GE&IDS9#FUK:LPUY26G72\@2-8
MN/+PR*$+N<H(2+"^$DUCHC7$_P`;2&EUE54X)JI88O?&^Q%=S!5KY&AAM3N,
M0VSVQN79XH&4)H>[.DBECM$8&U*%*5,U&=#0/@#>48<7E/E(Q-C6/Q5Z7-,A
MSG.XI+ZMA\J67JVJ'R5)QK%3`92FZ6$;3S9"]$QY*[,3?"7FQ9PE3FKCW(I2
MC6&%D82GEY,4EI&++6A\6BH3).M;7"L[3+BR&-VU.W:4MS">I5PR$4]2FV>[
MY0NGL3<R&5_:WY'&=S#7E4A;P.H$6"L8&>(X1Q"9(Q9,KSO76N\NVH(J9KN-
MV'7NZ6W;9J1JGLHL=[KY4RJ:<CMNRR1RQGC*&JIX5+XH^L=,.8V11ER;<N(E
M*,?`I,?E2721ZS[$3IO%UVO!ALGM=Y-D[%4[)7%&V:W/+DQN+?,G2,78CN]W
M0.X((\)&I4O;FI@HUT78`S*GEQ4I"SCPI`$EEF'22XLV:V[[KHQ=C$XN3OAG
MB3DJW#;E:/@K44Z*',4S2[?[9F->@D2(TQ`CYE0_,T8+<SDV<9"FZ1DL)AF`
M\O-(U!I?*_%6=8_&XQ)4&WUN=$]MY,/HQ&IN%:W+WAM;-XM*;0'\^YT::H7=
M32RY,^7BW/"-,0"394EHEC>>-&N)R7F256\SH)MNO(^^X/(Y`YQ'T'D\&M6U
M*;FD=3/WI8QIYA4LV=H4^JHM+1,T;-DL9<%#7@]*J-;6Y2'!@B3TQ!Y1A8:1
MZ&P.A!H!H!H!H!H!H!H!H!H!H!H#_]3W\:`TOW$3V_&-^?&FCT$@<'`B!IEA
M>'>NGM?"$LD/D[1EI-:I4TQ!]4.BHUJ*7)7A&'I8B\+FX9!:4DMW=&P4GZ1V
MY&XN]$1M>TSAPD!C$WR-4T1>#2>8J&ML<U;@@1F.9\4;7E"E&<M:5)6,<\+`
MA$BSC.0\D6:K6U)F4M#7%3$-J*Q]4RA7M<>E$C62-/+UCZ;M@FXW97)TD_06
MHF?52\4+RI4.9%CM:9[":,618<DY9_ZX`YQ<>:[C+Y_)8$]2[*TC,7'4>SXQ
M"PE=<X+:$.U*7HF\`7]KC3$[%X2I8.45S*IAA;.WX!PY!:!J1IB\!(3$E@8\
MUW&7S^2]`A.T@IR=7DG:DO(>'N:,EC.;NGVK2].Z*9W&Y`^2MBEO6!,&`K(?
MFR42AU<2E!8P&87.Z\_.<F+50CF/-=QE\_DMB&L-FS8@:FMOVDKT:!B41A4R
MID^UN;%A:3X9%\0B+B;A!A>#$86:&XZI*"7D(>KLY3"P(D6098\UW&7S^3')
M[16RRQ(XICSUM8D:,ST0EL*9)(S;9)BBE</:IF;,E;LHB+V9`U)K,YDNMA/B
MY*=@(\)U;LL,"'_BE&#6/-=RY?/Y/G#:5VLP!]H=[B=.W*S%;<D4R'6S"@HN
M=(&$F83R-MT-D-FOJ9OK](L>["/B",]L+6&'X3@2+CL='R,*8:=CS7<9^OKV
M)H/44$JE!DV44+.3I<;/VNU39(9MVL03P99+)79M2-$X$NS$>?S)FVL3AL)*
MOCSH&L64^,\WGAICS7<F7R1.UTAL:8Q@,9MF06HP#,TQ[!K?M/EZ,W+(Q8A0
M6=M&81"`#,3-X*VCP2\"SG@!C0A\H4I&`,>:[ER^?R398TDIRW8T.&V;3=E3
MB+#=61\RQR.@K,<6\+U&W5*^1]V+)-BN>9<65Y0DJDIP,X,(4%`&#.!!QG3'
MFNY,HKV(<=*<V1O6&P#KLW`M3,S>QM#6@-VF2OJI&S1MD71IC8RFD$%"V=1M
MT<<U*`"+)64N42@P@1>2QB#ECS7<N?S^399)=$30)4R%#`K@1(D2<E(C1I*+
MLU,E2)4Q824Z9,G)B@"2$Y!(,```&,!"'&,8QC&-,>:[DE<^Q4>_*.]B[H[D
M;2]EM,>:[B5S[#WY1WL7='<C:7LMICS7<2N?8>_*.]B[H[D;2]EM,>:[B5S[
M#WY1WL7='<C:7LMICS7<2N?8>_*.]B[H[D;2]EM,>:[B5S[#WY1WL7='<C:7
MLMICS7<2N?8>_*.]B[H[D;2]EM,>:[B5S[#WY1WL7='<C:7LMICS7<2N?8>_
M*.]B[H[D;2]EM,>:[B5S[#WY1WL7='<C:7LMICS7<2N?8>_*.]B[H[D;2]EM
M,>:[B5S[#WY1WL7='<C:7LMICS7<2N?8>_*.]B[H[D;2]EM,>:[B5S[#WY1W
ML7='<C:7LMICS7<2N?8>_*.]B[H[D;2]EM,>:[B5S[#WY1WL7='<C:7LMICS
M7<2N?8>_*.]B[H[D;2]EM,>:[B5S[#WY1WL7='<C:7LMICS7<2N?8>_*.]B[
MH[D;2]EM,>:[B5S[%$=N%AB9:B;5$:MLAQ<P*S&U`=3=EE+7`"`!1BX:)*.-
M!/5@1`.`(W)818+P,.1<..-,75=QDN9B,MDE,SU:B<9M2]B2M:VQZ8Q-`H?]
MO=CN@TD:L)"A;)PR$X5Q(T(&Z5MK80G7%\.2H(+P`7$.<XRQYKN,ODB%94>R
MIQ4NZU?L_.6+7]K(97M:HVJ3$U:ZMJ4F'$I4ZY6.$Y4*!)@UZQ"+,$+)H#6=
M&9@6#$Y0@L>:[ER^?R?4BJ=EZ4*0*7:$>D"WC;#&["7:I,$V&P3,981C7AKY
MB$%]6@0^]F3@+"1S8<%/Z\OAS:DT(F/-=R9?/Y+X5$-J)!AII6UQZ+-4`J(I
M0:';!-^=4%4$I)64H2H-]"^</)JU40`QC`/(@MX@XR5@.F/-=QE\_DLU:0';
M?45EGVE`*?M^.O*:JF.D8@R-=$S]KB-;54S2)PEYT*KZ/M,%;T[&S/LK<.L%
MH!B49$<G(`5DDDD!6&/-=QE\]F7I7$MJJ]J<&);MBD2IF=8Q9\*<FP_;1/C$
M2Z)75-$]BVW'%)`H?DLYGL:=I2W=X(SCD+EX`G&X$/''3'FNY<ODIHK!=H\%
MFN+'A>U5UB<[P_&RC$KCNUV:L[V&1'MU@-!KT%:@A1!H7$;7:TE3Y-Q]KF7Q
M8#CR3QXRQYKN,OG\F46F7MVO$EA37'MZF%GI(RJ<%;$BG.VZ?R5"WFO"`34\
M`+0NL/4I#4KPUC$E6$&`&2J3#$4:`98A!RQYKN3*/23#S*[V?GS0FQ5.TYP5
MS@A\.DY,F6;6IHL=`20^2&S(3_@Y5"C0]<E2XX3H2IX<\0X<%!8@&XP/#'FN
MXR^?R;$>_*.]B[H[D;2]EM,>:[B5S[#WY1WL7='<C:7LMICS7<2N?8>_*.]B
M[H[D;2]EM,>:[B5S[#WY1WL7='<C:7LMICS7<2N?8>_*.]B[H[D;2]EM,>:[
MB5S[#WY1WL7='<C:7LMICS7<2N?8>_*.]B[H[D;2]EM,>:[B5S[#WY1WL7='
M<C:7LMICS7<2N?8>_*.]B[H[D;2]EM,>:[B5S[#WY1WL7='<C:7LMICS7<2N
M?8>_*.]B[H[D;2]EM,>:[B5S[#WY1WL7='<C:7LMICS7<2N?8HG+<+#&=`L=
M7>-6VU-;>G-5KW)RINRT*!"E)#D9RE8L4QHI.F3E`QG(AC$$(<>7.=,75=QD
MN96^_*.]B[H[D;2]EM,>:[B5S[$!+X5M-=6E"Q.>UM[<&=L9U#`WMJW;'.E*
M1(T*ITVV><C(*.AHP@QFQV=,^A'_`/,`[$A5!%@[B/+'FNXR^?R8DKHS8JN*
M()4[+$PRDL?4Q5,6':3*B@D1M;')3#EC&5@F"E\VV*HG-G5L,*QP`-`M&1G&
M2L!"%CS7<N?S^3(7*N-GCPDDC>Z;3%Z]NF"2<()0W*MK,S-;GY%9DKC4\L-(
MYMXH3E&J3S>;0YK=W0`@<%KDA*4F\HX/+TQYKN3+Y_)3SROMLL[22LP=&V3%
M)=+";`R;9D/VZ2]NL9D<[1KQ@JF=/\>D3A7CJ%"\R*OHFTM:H9A!Q*A*U(@F
MECPE)Y#'FNY<OG\F=1GW!1"/TU&&"CK'1LVWMN1M5+$&4+:"PZN4J&#.%:$B
MC:U9%SUJ-6.!NZMK-/YS)QR14:`P0N<'Q8\UW)EZ^O8C=SIO9&],*2+O&SD3
MK'4$>B<30LSCM2F"UO11F",DVC4/84B=1"#`)FN.QRRI"@3$@Y("T3TM(X<T
MI-")CS7<N?S^2;X3,ZGK9H5,$`J&S(>R+I!(Y4L:X_0-E-B%3))>]+9)*7PY
M.FB8"S'-_?W)0L5FYQRSE!PQBSD0LYTQYKN3+Y(#=Z-V0ODNFTY<-HSWF2V6
MA)0V.J1;<;,:D-@92SE@LU"Z3=B:HRB899)&NP(RC=T;LO2J'-&N`,PE07D\
M_G&/-=RY_/8V#A4[JJMXPU0JOJ@L:#P]C`I+9XO$]O%@Q]@;`K5JER6Y1-+7
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M$/;$2QR<XQ;K:VMZ50N<'%?3-FI$*!"D*&H5K5JH^,`)3)$J<L1AA@\X"``<
MYSG&,:8NJ[C)<S__U??QH!H"%V[_`)B)C_@O6W]^+7UK]J^2?N?Q_DFC62C0
M#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0$+3+
M^=%)_P!5VK_"HUK2]+C+^UI-.LFAH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH!H!H!H"%]QG\A[<_L#)?X:?K5OV1+OJ_@FC62C0#0#0#0#0#0#0#0#0#0#0
M#0#0#0#0#0#0#0#0#0$67I_)*XO\++"_ND[ZMOVM^27?5_!__];W\:`Q-UGL
M%85CDWODTB;,O9VDA_=T+K(V=N6-3$I6!;DSTY)EBPDY"TJ'`82`*30A)&=G
M`,"R+/#0&!MW_,1,?\%ZV_OQ:^M?M7R3]S^/\DT:R4YZ[I;_`+DI6S%9T.'"
MW*-E5$UO<<ADTF]:PU#,9T.32YL=VX"F5+(U(4PDZ(3*:)>2[C2I"0&APVK#
M#AFI!4BV/6XC<Y,FB9.=00RJY#%HX)S-+FT7L2/O!YZIGL](0>P)0F&O\91B
M1U7S*I8L=S&T2P;D:I0)\$(`"6A"]R_0;=O+919<-B2Q1MU#&'V:RIG=7A!=
M<?42+#""+,+A!BX]&6IRD)KF_NTG<5B`[)QI!!O0>!82AGE8T$>I'#A;.YZ.
MYJ]FL2QX=4LGDR=<HL-38SW2<:C+'AN970R)+X(G&6Z2-]:W<\HG,L3*"C3!
M.W(2-BUH3'"4)X72A+Q=Y6=))^^.U9$IY]1L;ER1)))$WO=;F&!3M[:U.#WF
M)R!N6KVDV%@9G-0J,+<\%/65[,:0%202ZMXT])'<LB'=<X.C(G*@4QK"5RMY
MNYWBS5')I-*[2R8FO"6AURA<R$$.EZ)$]'/LL0$E,_,8RI`UN28M64<M(4F&
M!!:)AN3W#Q+T433&.4M6[D^/%3&G-<PLA@BBK#,ZK%JFS#^LGQY=L99(V..X
M;E"E*UJU."9"4>G`(]`("H(1]*XW16;.0O[,7F!O/H@EC:B;RRN']CL1/$TJ
MV755E_4JW*-J5[80M#!I=)%+:D6M"-285&>F\RH+4&$D0L(BL&YZ]G!'%&J(
M6)6DI?W5,A;UN/3.@#I"ZN"V3SE.YJX]&"9BQ]'D&2T44*96=1DPHII=78:E
M8Y."5+P"$3_<NY&W*C?STB^.T^!`8D<#V=MD=C,4/>GL+="X.I$K:U<FE#20
ML2+9W*W-*5Q2E<E/&32QC"-Q)/2TB19HCNGL2SX==R^LTE?S-QK<N*-2-^B;
MDPNK*VO[FKE0)(0^936*\,0'MEB;8RR10SGNJ)6S)I$4E5=)PG`K7A'H86DW
MG6JO6HX]'6:BI&]*QN;6V\NZ*]$I=WD*9Y1QXLM&PS9>H5)G02-N=C34R;"H
MT]VPQ$-^#DJEV`$&63_=Y/J\F397LD:J78)VJJ&)STZ,2"S6EB3'/*R7U2Q2
M;H;_`"9XC2].P<S*)44W]+9B#1BBN5/.'=(-1)`@^0]V%SKHJ*2QJLHO)&%.
M;%FUPG4;D<3EK$UN3W:9L,=,N3#'+-6&HU;1"US=(,MXG7AA.>()JPH>,A`$
M(FVD-RD"G$49\RVS:M03]YE,S;"XBFL6&N#F665/I$U11K0A1J&\Q\&<P$(\
M)U)*4&'`(@G@#G!N,Y"":Y99]:P)0D23FPX-"U:\D:E"EEDM8(ZH6IRA\T8>
MD(>'!&8I)+,^R(0,"#@7DSGCH0K8]/8++6A;((I-(G)F!M&H+<7R/2-G>FA`
M8D(`J5%K7)M6*424:9*8$PS`QAR`L6!9X8SQT!B;=?5&/"]&U--T5.Z.CBI(
M1-[:W6+#UJ]>L4F!)3)$:-,\&J%2E0:/`0%@"(8Q9QC&,YT$.A?Y99]:P)0D
M23FPX-"U:\D:E"EEDM8(ZH6IRA\T8>D(>'!&8I)+,^R(0,"#@7DSGCH"MCT]
M@LM:%L@BDTB<F8&T:@MQ?(](V=Z:$!B0@"I46M<FU8I1)1IDI@3#,#&'("Q8
M%GAC/'0&)MU]48\+T;4TW14[HZ.*DA$WMK=8L/6KUZQ28$E,D1HTSP:H5*5!
MH\!`6`(AC%G&,8SG00Z%_EEGUK`E"1).;#@T+5KR1J4*662U@CJA:G*'S1AZ
M0AX<$9BDDLS[(A`P(.!>3.>.@*V/3V"RUH6R"*32)R9@;1J"W%\CTC9WIH0&
M)"`*E1:UR;5BE$E&F2F!,,P,8<@+%@6>&,\=`8FW7U1CPO1M33=%3NCHXJ2$
M3>VMUBP]:O7K%)@24R1&C3/!JA4I4&CP$!8`B&,6<8QC.=!#H7^66?6L"4)$
MDYL.#0M6O)&I0I99+6".J%J<H?-&'I"'AP1F*22S/LB$#`@X%Y,YXZ`N<6FL
M-G*`UUA,MC,Q:R%(T1[E%GYJD*`E8666<-(:L:52M.6I`4<`62\BP/`1XSPX
M9QH#)M`-`-`0M,OYT4G_`%7:O\*C6M+TN,O[6DTZR:,<F$H;81$I3-'D*D3/
M$(X]RAU"B*`>L$VL#8J=5P4A)AI!9RG*5(+FPB&#`A\,9%C].@(,8]W5".S>
M0L<)RW1548'G%#3(E"/I*)-SLZ#ES&Z,:M\B[A'BTE;/2T;LA<%;46WH1*AJ
M0IQ`,$+#/QAW>T!)`*%;7/$1S,4\A84[]S)IC6N7ABZ*7N(B@I\'N2%%'F50
M>-U4+4Z0EJRW+>EB)"F,%@(94)MU502`,/\`=R\&VT?8)LS20E/7A[(O+D;G
M`3F#,E:T;H^/4?8DZA,T/X7,DY2K(1J6P@P\HX>!IL'A!11+=?7,XC5B2Z-,
M\T<6"M&N,/KXL`V,X3%;-)V04C*6-B$4@POPK:64/2%C<K*2.H2AE#*2G!4)
MLG!!EA=[,1[8ZNJ2*3%4G9;J!1SD2'T/3+TD@.D*"*I9$>W+Y>C6D11:\NJ7
MH^3`!=%")42N+1"0&EJA!`5;B:J:HK%I=)'Q7%T$O:W1W:D;NS.ASJ!,RN;2
MQNA:Y&RI7?"50F?GY`WA#D><*%ZY.F(R:<>4`806-?NSV^-Z[J\ZRF$)A;\J
MCZQ4>=EL:$"A`_)(NY+E#Z]8;60QG;I"X)T9JHA0<7D\\`09'G/D"&?5KW15
M*_19')X\X/+^)<V1]U3QUG8EJR2*$T@9Y._!+;T80A1/:EH;(*_]-+;U"L12
MMA7H@<XN(RFR$&-"WBU&G-;$[@7*$"ES"OSS75[2[D(11V+-T\GA:]TC;X]L
MI8JZ@3RB=W;):DP&25.$R,2MP*4(R0@S]RW&TLT.CBR.$Y2$.S:XB936_#5(
M#E2Q]$]N4911]D*3M)N9%(7J2,C@WMB!!TE8ZKFQ<0C+/-1*P$A!_#QN+J1H
MA4CGN)(:Z,4:<7)F5!:6AW4N#@\-L/\`>`)`R(C42<;J4LA.0NR=:5G+::V"
MPLPIZ+Q.P$%I=-V&W1D;GMW=[9C#<U1QJ1O;VY*Q+R4+<TNJQI1,"\]4-%@G
MH\JZ]1J&;(1"ZZ0*`+$/2$F>>T$.AD;QN!IMA=5+*ZSQK3."4THDPL*=S4D&
MFG,CE).0B7)$)Z!QR0R-"E0=T<TWHX"LX-Y`N&,B%.IW&4DDP@Z183,6-Q<'
MAJ)(R4Y"5$.$;9&>22I,YI`(1*64<.8'U.L>LK`$!9DW.F+<D!3J,E"PR2HG
M)FZ9QICE33A0!O?6Y,XD$+`%%KD>3P8R<@<"23E!1#BWGX$0H+"8/!9Q8@\K
M/#CH0R'0#0#0#0$+[C/Y#VY_8&2_PT_6K?LB7?5_!-&LE&@(6L>^8-5<WKJ"
M2O#J4XV4UV$],ZY$6V*42!MK)M9'62J7)$-U)DBL($C\2(&&U`X9!@(QG\R7
MC`\@88];R-MK*RD/@[4CR\AR:%SU'$S>8:8IER5!!&>QS014:DM*A>31161M
MAG*+.P26I<TB4T9:E044(6&79/NMV^&!9PJK/C;2J?72",38A=E.4AZM\LE.
ML40YK1F\@Q"Y&NH6U2'GDAQZ4L:8W`S0\C.=!#,1E.\BL8FG>5ZYEF1[0RV>
MLI50^`+AS6S&VPB?L-!D)Z=)9FP@0'#;,];A<UN$K'ANXA$N"MP)'@(,\D>X
M.+1@]E(<(U.>,A;XPZMAPV=N:TY3?)LBX*9(?(7IF+@@&?`,A4XD&6L1QX1I
MT>%:DHXDL0O8KC9B++#5ZV.RI"ZJ'1L:&U\,)CZN,N:IUB,VFI`2EC7(E[BW
MFDL\!7<X0O2)%>!"(&$H1!X#LBP8XIW34"C.5D*[(:TQB%0])E7/M[\466.-
M(2G:2F8.&TX),21IC4$N+B>$0B$#8H)6'C+2G%&C"&6-+O!H!7)7V*`FZ<#O
M'$CTM>$8B!B=$1+"76.'$"F,$9.F2162OM9"B&G.;2SR5R)>2<`L:0?$()(;
MK@B+M-$D);`NBY4L$L()>B$A`F#K!%$XK.1M@U0E85P%9T4F;>L*%T;HY@#1
M!P9SA8P!""%CM[E)$EI!<9D:H7$QT:-`5%CQ+U*J:LSO+X&V%)\J0YRYS.NX
MZXR1*5QQT1G1&97Y1JLEI3`ADH/&XZD8^Z&,[W83.UKBBL'#Z:0Z$HL`S&FJ
M7YP%T$@PUC-#'W]M.$`)V1A,=$).<8/7)"S@AGU5;@JH2,LJ?12-4-/#$;8L
M?$/H[)$[T7EX5O38WHD;,M:4KDXN8WN-N3<>G)+&:B<VU8D58)4)%)90A9#]
MU-`HDN%3I9+*T<&YQ=CR'$"THY*WLY2P+JM.R6E.(&A0NS<I:1*2QF)C'Y,:
MU%F#<2Q)L"PRZG[D:-3I$3B99#!EJ<(M'YJC>B<K5#"?&90OAK>QN07U.C-:
M,=,-L1A-$3D["@A(\HU)I8$RDHT00SZ*=Q-,I$V%!\X2!,R%MX-@&M^.D'/O
M,@711J;_`$9):C)#UPX21M.1%(NB]+&H!R<%\1!XA#,^ADUC\^9S7V-+`+FT
MMV>&@*DLY(H*4#:'$]$%<E/1*5:90V/"8HM<A."/.%"%22;P#R^3@0RS0#0#
M0$67I_)*XO\`"RPO[I.^K;]K?DEWU?P?_]?W\:`UIM[;<AN>3%/<GG#\D;&V
M/&LD<8&YIC1J9A4N*U(JD#L$;PUNJ9Z4/86])GFW!.J+0*VY$L183*2,F&BR
M4CE&Y2X7T](HM/G&)#;:2K<E6L$RLTF5NY89E:!1`EAKZ0?R3R\E"&(P'`1H
MC,Y%_1K6F*E>YC7)P_8SCT"MGX\.G=Y!/W#25XB'Y'+?>=X'U$[\K6;;GONW
MK743ILAK5!"ED2+BL=0',#*YO3JW%GMF6=<E"I(4OZCB85@KEA%CE8R+'*S'
M#]C:=UJB2X;?_!/I#;526XK;_6UN6IBO=TD<Q%;:)?@QQT=5S.6QR!@3DL:\
MMN1@8CB$<G6"YTDKEFC&'!N3`%@`%I0C=S:<FI#1_E>MDK,[-CPGM>_C5#4X
MHG(@LU[C!91AR%24J*`:-''DBL!8QE8P+)1I1F,?JC"+AG$A4-9W51M-O.\#
MVBM^-KMUT7W;]L*9TVPQI@92J)%Q..MYS"R.;V[-P3FWJ9<G"J*4R!1C(RN;
MP,.0\H.18R+)P_8B=UJB2X[?_!/I#;526XK;_6UN6IBO=TD<Q%;:)?@QQT=5
MS.6QR!@3DL:\MN1@8CB$<G6"YTDKEFC&'!N3`%@`&Z4(W<VG)J0T?Y7K9*S.
MS8\)[7OXU0U.*)R(+->XP648<A4E*B@&C1QY(K`6,96,"R4:49C'ZHPBX9Q(
M5#6=U4;3;SO`]HK?C:[==%]V_;"F=-L,:8&4JB1<3CK><PLCF]NS<$YMZF7)
MPJBE,@48R,KF\##D/*#D6,BR</V(G=:HDN6W_P`%*DMM=(;B=OM;6[:V*[W1
MQ[T7MA._XCKHYK&D+$_1XDMB6EMR,MA4%(9(JSDTDKG#AB!@[)A998`W2A&[
MFTY]#4AF_P`KYLG8WAJ>DELW^)6SN2%T2A&^1DH`E#>J*5DX&:BCZ186')A.
M.(B32C<8\H1A%PSB0J&L[JFTN\[P/:*WXVNW71?=OVPIG3;#&F!E*HD7$XZW
MG,+(YO;LW!.;>IER<*HI3(%&,C*YO`PY#R@Y%C(LG#]B)W6J),@H3P<=NVU#
M;ON-H."O=F3"$[F&50P6F-_D99$@RP"CCO'"B8X8SHT;>@4(DKZK-YSHPS#A
MF!P;SI98"\5)>A'==HZ'!:7^'MX3FWVYY;&I*R;PWQSI^1P$\D^+RYG?FN0/
M;Q&A6$VL2HU'#(N>U#/1M"HL1I+@`LL*0\1JI&(&,Z8I,UG>U.A..^$GPM-[
MMFJ+POE+NQ03J'Q**0%P10OJMEXL)BZSWJ+C5L;X6_"0.RGJ-P,$BP-(N+2G
MDJ5",LL*Q02:3(G>M%!7TZ#8)M)I'>9MPC$)ODNN;Q@T.+DRJ7SL69C(44_V
MRG6HS,3TA;(LRJ*C<&]GE1J#D]"?%!BP9@U)8TQ.20(2D3<VF:CQ38_X7$>9
MZ:N8,`W<8:%S7-[&>V=UM",A>46:99*KFKRABS*VP!`LL%L5$V(69E24O8C`
MM;8N68$7S00YF*]2Y7ZJ4=&[@VW^'IXM>YMW?)P#<DU6["*YPPN>&]Z:HS'1
MQR&31Q90I\$+$4TPC=2'B1BSS8>B`-R,XO(,K4CB4GUBFS.5UB]H-_Z)\&+;
MU1VW*]]O-<2FTXW"MS:+#;:AC\_()%)EC$!B<F)(V-:LIK8VUAP6G>%!HA!2
M&'C&9@)HQ%AP4&0E*]0W<X;>IJ-'_P#+`[*(X_,DA16K?1RQA=VUY2$JGB+]
M&-4M:PE<04HZ+'DJKF##2,8'S9I9G)SGDB#GAG$A4-9W5-FMY/@;4/OLMM-=
ME\W!;:J=IXDT0K"J*!BL?;3&-B5NBQN+$UY9ER8D\HUW.Y0BN;"/CQ$'(N(L
MG#]B*ZY*)+O1'@H4AMTH;<)MRKJV[4!7&YUI`R6L6]!CC@]KVPEH<F5,G9W0
MEM189>82NZC/**+Y1HC.!N3"PA`&Z4(W<VG)J='_`/+`[*(X_,DA16K?1RQA
M=VUY2$JGB+]&-4M:PE<04HZ+'DJKF##2,8'S9I9G)SGDB#GAG$A4-9W5-FMY
M/@;4/OLMM-=E\W!;:J=IXDT0K"J*!BL?;3&-B5NBQN+$UY9ER8D\HUW.Y0BN
M;"/CQ$'(N(LG#]B*ZY*)+O1'@H4AMTH;<)MRKJV[4!7&YUI`R6L6]!CC@]KV
MPEH<F5,G9W0EM189>82NZC/**+Y1HC.!N3"PA`&Z4(W<VG)J?'O\L%LGC;^Q
MR)':E\J%;`\-CTE3JWB,=$/4M:TA<02JZ''T:OHYII&`CYHXHSDYSR1A%P%B
M0J&L[JFS.\GP-J'WV6VFNR^;@MM5.T\2:(5A5%`Q6/MIC&Q*W18W%B:\LRY,
M2>4:[G<H17-A'QXB#D7$63A^Q%=<E$DS['O"O@GAZL$_CNW2X[#0)++>&5ZE
M:B7M42E*M2ICR):A:"4G2&Q,D0)TI3DH%GFR<&&B-_:#$$!8050O8ESNN_<;
MT>@5L_'AT[O()^X:LKQ,P_(>@5L_'AT[O()^X:2O$0_(>@5L_'AT[O()^X:2
MO$0_(P@R/R]DNVH1RBP%<U+4,]G!1E*8VP,.&\9;7'\G&`&RIR!*<J`C#C.#
M..`\CR?ISIIBX0UR4LV@UDT<[O$UW92#:'MS,F;#MRLK<D";R'-:O4<KIL"Y
MABS+(HW(3E4HE90HW+2>H!&("T'(/0B2GGK2RC#0"&`!CT]BI3I,''78OO2?
M]Y>X9@HUQV-6W3K3)VYW>I#:LKJ"!/T/9U$,CKN],RNQ1.E4Q@E8%Y6I\H4R
MI4I5*#7=8GX@&(8C2[*\0[;DI_L(KO7Q2[&I>Y;6J<_P_=P\H#!9I,H."6+*
MUBB',U:&YO<:V!*""14V_A-9Y?!0\TG,"N6%*&E2'`3C"AX%F2O$*RYK_L-Q
M[BW36'7'A_4-NK'M-O.5^\-Y71<[;D53<*2RFE6)V?'QX-?GPXFOG5='HF[/
M==-"IH-`U(R1`5-N0]%%A.5FRO$F-S;69%^RG?U8^^:V&7:F_;0+TIBMY`G<
M9:Z2]\K>(&5W$G."(2Y1&E;\F+J^%)FC"AYCB-*VG$J><*<NB!+*X?;+2O$K
MMN6N9#EQ>+G;NWB\;6KUNV,[DG)3`[9EZ(J;!@479O2]R8USY%TD^0D`IY\3
M@32%B/&)"82M5%=6'$@)-$0`KDLEXC"Y_P#V&U5R[W;#@>QFBMU*O;+><O<;
M">3(VHV_YJ>!$R>IVA<_N<H,?9(J)@3NL11YZD=9L[BB-&TIPJ3%"`TW)!O-
MEBND3B16W9-9D/[$_$/F.Z?<9%*LQL_N:BBC6^8O_O==JT@C@P0Q4E(-EQIC
MT:IJZ)`;BY0_M9)!9P%0C#',U/CFQ8$(8(FF_J5VW)?]AK;9WB=S';]<=TUB
MU;(MSSTACM@&15$\)(E$H<UN+)6CO*6J,.$7:(K30DB"-/Q$A=%7$*UP$ZH7
MH\E2J5I#<%X2E^T*VYI;S=6UMVK]6&RJC=X!>T.UI-*+&DJ)M6TIBD:R+G56
M%D`E)*>82EZ#73R\)T#TGB*3"=:8V$&.*5P2!5#+SDLD5TB<2*VZ8S(VV@^(
M/+-\=[,U(3'9[<U7,CZ!]F+E9\KK6#/,;BKY&,3:;M+P]G*ZOB66E<NE,N=L
M-ZXE7THEY><C*#RCAF`B:>F)7;<E.9K[9_B@3>C;"NNA@[&-R=@1]FNJ<+1N
M;Q7T#1MTE7-J45=(I2PL+72"]H:V)T@K00E0X2GJ0'-1F.6>HYXTTU*\0K+G
M#S-VK9W&RBG-C-,;S$&SNVW5^NE^!%Y'1372M?LTYK!I4*'<Y%))6O;:Z<G%
M"R+U%8L74Y^6M)Q2&-0,"2\PE3Z2O$8W2U_81/L>WLV!O?W;*H/*]IFX&MQ6
M.P/B^0V;8%:5_(*_AI,9@CXWA+?$BNGX>007,T*I0TY5*5:U4:J<"TX0X(&(
M):5XAVW)?<UWOSQ'7VK+TF%?&>'1?#V?2MFRZ/,TF15=#8ZDF"1D1N]>I)`J
M:$E).B5:PRV)")/`28J6D*DO1LB-/+`#.9*\2JR[_P`ATBL+?=N`V_;`-NNZ
M-@H/<N[YL)Q0PY5M_!`8]Z=5.R)"I6B;)%-7DZ"2)Y.:WOT72C1+%J(DY>%V
M3F'C`>;R!V5XF<6VUF81L6\57<GO/W"1^CG#;MN5I9H>6:3.SC:<F@\5=(C%
M,,#(M=T@9*)95\4)0IGY4C"WIC,*1C$N4D`P4((Q#`R7B'8TIS.Y?H%;/QX=
M.[R"?N&K*\3,/R'H%;/QX=.[R"?N&DKQ$/R'H%;/QX=.[R"?N&DKQ$/R(FOB
M%V8CIFS53E<[D[MZ:&/IZQJ'!H8A`XIBD1HSD0UB5#A4F`I!C(!#+S@P.,\0
MYQGAG5M:R6A&G#W$M>[BR/\`J$GWJ?3ORZU)7B:A^3'NXLC_`*A)]ZGT[\NM
M)7B(?DSSX>(?ODW+43N8?*?;]B6YO=NP0**E(8]="..0I/%WYMM>'L2Z<-48
M2LVSVS6T]KP'D-#@,:_!IBM`>6(D`0!$.9+P_4VK&U]_T,UJ:\[8F>P6YMW*
M_9#N%@5@5$N%7$4VNCK^L!RZS808SP."F>A[FKVPQZ2%UPVQZ1'8<4A484H"
M"V10:26I4E"YMDO`F+F,_P!#5;;QXC6Z&Q+LIRM57A?;J:N:9985<14ZPTD<
MB*K%=-R=W.:V^7&$.>R*$-P6F#H7Y:I.P>[MR<M$-1SAP"Q#XLEX%=CC_L)D
MWQ;S]P.TS=++:PKOP_\`<7N.0QG,3ER&]XO#X"S,LKD<C"VV6M=8^*.[.;*3
M*%;!+UXR3UPG(*O+HD4!R6```Y&R7A^H5C:^_P"A+$`W'7G:^RK<'OIE^SS<
M]';EA,J8F!/MR=XK`'&:74@C:B'MK%)F5<Y[:F)[61N,D31<)8/$56%D)VQ:
M$KI0L&E@9+P_4F+E+/\`0U:HKQ6-W\^N>HJW??#EW<UHT2VS8DWJIZ8WQ1Q]
M!!.C2DK)1/SD;]LFAC:<5&8(<).I-4.S>6!K),"-0`&,YT5R?[/U*[(3_P"3
M]#+][>^.Z=L.X:4TU`=@^X/<;%XVUE+D%OL49KUECLG/M"NV%LFQ3"GC^SZR
MD1Z03"65'W$T3B$T\;>80,D)98,C-I.,/U(K94O^3]#/XQN2M*X]@>X;<Y)]
MHFY>!V+&)L])DVW=-#ZF,GEM&R=_JE;)9M&I&Z[76F2%(EZPL@]Z6E1=4:47
M'C1)S#SB>!-E--X"&KDL]#7&C/$[W06O<]:5K(_#NWB5VPV+.X3%'V?`6-CH
M5"&Y6%@AQTM4-[ILXA38%L9HRU)0NPANK<6J:D/(5G#*+Y.HFO#]2NW1_P#)
M^A(.]O>=:.V"^Y31<`\.ZZ=QD)C;!%<(;388!53)%).G?FU!,#VUA01_9I93
M<>TQ9Y<#$>,B<`B(7)U(`$$@\IAM)QA^I%;*E_R$V17==:]S;&;PW<S_`&>[
MAVZSH')G!@;ML[_!JK=Y7;")R)JF.+9.P/+MMD9)`='RV<E&%R.!&57,)HP,
M)721)\!!943A^I,6FEGH:<[;_$"W'6O=,;J9\\-?=O$XG>\[K:$SF5.#;$)(
MP0MA3R);ENDB^/N>R"$L)C3$7"3N3PO5K'-(H,"<H.4+!!`#`)DO`T[=/^PG
M'?%NSNG:7N4E]-5UX=E^[C(]&TL<?D-T12#5XQ1J5.DNB871U41TJ-;-[(1'
M=1J9,O0'J<N(5&'43B/FBS#3#3F2\`K&U.?Z$N5]>=UVCLRNG?M+=H^Z-CMN
MK1$59'=JK[$*Q=)%:4:02>GG4J4QY0Z;7V.3.;(VKT[>H6*SXVX81EQ0X*3!
MPRCPY2O7$F.J69I;3.]N\[]N6H*@F'A5[GZSC\ZGU>PMQLA%%X:,4$9\V8BF
M9,B=.G;)("A'&H]+CAO3GE2\H"<%=)/,.QG(\B9+P*[&DW_8=11[EMQ56^(`
MQ["8?0^Z4ZEW=<0XF[K&B-5Z.M&]9,HHJLAW<4K8;M[5Q_$487Y<-F.$*3I.
M@G)S$R5'@M.F3F,EX?J9QTG/]#K+[N+(_P"H2?>I]._+K5E>)(?DQ[N+(_ZA
M)]ZGT[\NM)7B(?DQ[N+(_P"H2?>I]._+K25XB'Y,CBXH#/T=1VFL6WI-W=&E
MKF;J5;2KBM5)TKFF(C+F:>W*5#=`T;@0G6E!R6,9!Q1P0BSD`PBQ@6+:U*V^
MY&G#U]C_T/2_&]T,W?/$R>Z-JJQXA<D,CRI^46:Q->Y.KW610UI1X:XR_M*J
MHFMV7'M!U66`_')%:(II;)&06QAZQ5GY5<5<]S4;9.S.J9(7;O\`F(F/^"];
M?WXM?6OVKY)^Y_'^2:-9*-`-`-`-`-`-`-`-`-`-`-`:*[P&N?P:O9A.:?:T
M;G*CFI6%C:UR90L;D\I/Q@"(]0C2JD9QZ%0(0C,EA-+QSH.3RL8&'&.EKE->
MYEI2F_0Y7.FY'<P^OT-Z]V1H'4EH(8YDF>7*4$NY\1D2Z/,9ZQ"Q&+(H`Y'*
MV<B1K4@UA'-E\HLTC!G*`>'%W>(2M\BTIMW.]-@72]J=-IKQ/>@2";G19Z9%
MF(JD>H^WO+2@A[(F"XGKRS79S+4+#%C@ORSHTJ--SJ8+F/!(%K=KM$6Z;BP-
M&Z_>G%P.)A.S`+HTNZ\3VE;V!Q.BW4Q\E>9,ZOCDX$]2JU[XI*#@M<OSE*0Y
MK5*K.,$94FY!I-WB(M\CN%0\$1.2A593DQ-Z%P="F]-SY:9+E<ZG-`5`$QCD
MX%%A-<TK`:K/*2<X(0"S!F"!@/\`3+W[(EJG7V-KM<S8T`T`T`T`T`T`T`T`
MT`T`T`T!"TR_G12?]5VK_"HUK2]+C+^UI-.LFAH!H!H!H!H#X*DI"Q.:E4E!
M.(.!D!A8OT"#G_1G'#(1!SY<9QPSC.../+H#E[O!B.ZYFEM=J]NTIAS"P(FZ
MQ%$A/FQRHU"^.I[,WC@S,H;$K2O"<G)>$AI:M1SA1J<A3@TD!@L""7I:^AG1
M?;T-.ETC\3-I:UCF"3T;*BD2*8"7I(\AR%Y.4MS),2VU!$DRAE$B<7A;*QMA
M:,QP-2$(4Z7)2Y,J--..+L7";#X%_P#<9>P09T<;&J1KG;"5<RJ31MH>!M;"
M%GE;!7Z2I"7)E*8)0CDKVQ/;9(#>>/`G2)C#0EA-5`!DX]#$V=!%T._;`K7C
M\]L6(*?3)TDDKAZ*.RH]H.8B#YC7)C)$XY*#4ITN86M5#D$I`<`M.?A`=E&,
MA3]LT`4,3;HT95"3O$J02.G(]))544\2.%H1AFL1VC[44@,,KE$HLM6_N@4R
MAJ1G)79X8V]D(R,GCC#HK38++3)P+S,H:$V.8.X46C93`B!@W(#W(X&,K%6,
M9X8SG@+*<C(O*$@O./\`PR/...?Z,8RW)4H,IU"C0#0#0#0#0#0#0$+[C/Y#
MVY_8&2_PT_6K?LB7?5_!-&LE&@&@&@&@&@&@+0]LJ1\1#2*>(!>42=2#&.=3
M'<.&#`<>'*#G_:#GR"Q_X\,X$:DX[[@63?6Q6C8YE23*L&&.*6N#((:CG1RY
M:WI4D:8)Z[R)Z`@3QY8%(X3B62%K;QJ,F*,)V]LR8,OG"P%"W#?H3:M+EJ0$
M^RCQ16MBBQC*]T1)WMUE$-;W50D;QEM21D43)^3NSZ<CRC*&WL@8>I0+'4!:
M]P58+3#`VCRJ&$LY%PG^,JW1)XABM28ZQ*SJN5K%[?%XW,$;G(%9;8C.*21<
MF2K6)E:XZXI&"3L@$;U@0TBI!A>L>4ZD80$H"4>47#*PHTK7X@BYJ+:4]LPT
MB406U&56B-6O164SM`Q,0)(["DHVUK7K9"G>UKVI8D:-P1I!)^KBU.,YX`6"
M1<)L-D]O8-\LAO4<<M-QKITJLI))W$3[&4($^<-1RM.EBQ)Q64I#B5*THDXC
M5`.7U?A,>('+..$5DEJO7T&U^GJ=>&IJ2,Z,M$C!G``8XF&#X9-/-SC'*..%
MC&.4,7#_`%8QY,<,8QC6#7H7+0#0#0#0#0#0#0$67I_)*XO\++"_ND[ZMOVM
M^27?5_!__]'T_4\_*F/Q7-PM>)[$?W-*KKI%(G6*R2U8(\+5(EB"*RQE.;:\
M<+>9[.;XS$13M:W-IB"OG%@2)>!9DAZ88:@(GN:_:C;6_MTRNFGF8,;#$DEC
MN\:J5VL,<<C"U_>)<SJT2](0VFRR,QR,/[HVPYX0C6FX<B"S\)36\)1^`97I
M1:I(,I>;%@L&W`/ZN9RIEBI#O2]=8;1R!:6TB5B(FMHF'EE%KLDF\Z0!0#(P
M9Q@0.5C&<8SK:3=NB]S$I7.7[&:?490_Q<@/K*V_?ZF-U"Y6U0^HRA_BY`?6
M5M^_TQNH,K:H?490_P`7(#ZRMOW^F-U!E;5#ZC*'^+D!]96W[_3&Z@RMJA]1
ME#_%R`^LK;]_IC=096U0^HRA_BY`?65M^_TQNH,K:H?490_Q<@/K*V_?Z8W4
M&5M4/J,H?XN0'UE;?O\`3&Z@RMJA]1E#_%R`^LK;]_IC=096U0^HRA_BY`?6
M5M^_TQNH,K:H?490_P`7(#ZRMOW^F-U!E;5#ZC*'^+D!]96W[_3&Z@RMJBS2
M&\=O4D9'1A<+:@(D;HC.2&YQ)&S(RLF!_9*"N)W#!Z8[`3`9_H&'&=%;<G,$
M;M:B4<.+&:]PKC,K4Q#;'@RR%/((4@KE03))0TCC^8LYI%\B4F#C3*I+>&R7
MJR%92HQ.M3KE3:J*)(5-XDW.G=MS,)I1HY(JG#9X@*QXDZB`W9432SJY#)5<
M60O344:8UQ\<HYV)-:L8:J<CC#"8>8(M<(1R@S*XLO)9N2^6(1J_V:*G9I-K
MXZF6T(V;IHK="1GN"SXN]TL_)!JE<G&Z`R5%'4MG@D>3I'51)RBY%D!RE"N6
ME]"R6A$9E2>?C!RTE.FBR4^Y&[6E"AG?AJOG;VRMB!H;[8@!*)M2)T24OTE;
M<Y"2G+"4#(Q<]CEF"P'B(6?*(6<YSY<ZY.VYN8-S:O=%P^HRA_BY`?65M^_T
MQNH7*VJ'U&4/\7(#ZRMOW^F-U!E;5#ZC*'^+D!]96W[_`$QNH,K:H?490_Q<
M@/K*V_?Z8W4&5M4/J,H?XN0'UE;?O],;J#*VJ'U&4/\`%R`^LK;]_IC=096U
M0^HRA_BY`?65M^_TQNH,K:H?490_Q<@/K*V_?Z8W4&5M4/J,H?XN0'UE;?O]
M,;J#*VJ'U&4/\7(#ZRMOW^F-U!E;5#ZC*'^+D!]96W[_`$QNH,K:H?490_Q<
M@/K*V_?Z8W4&5M4/J,H?XN0'UE;?O],;J#*VJ(GE5[4TKMBI'9-9T*/;&ANL
M@MS7%/Z`:5`8Y-K`4@`J.P=R"1+#$X\%XS^MD&>'Z-56W0]#+:E:DL?490_Q
M<@/K*V_?ZF-U#65M4/J,H?XN0'UE;?O],;J#*VJ'U&4/\7(#ZRMOW^F-U!E;
M5#ZC*'^+D!]96W[_`$QNH,K:H?490_Q<@/K*V_?Z8W4&5M4/J,H?XN0'UE;?
MO],;J#*VJ'U&4/\`%R`^LK;]_IC=096U1C,ON;;Y+F!>R*K=@!8E!>1HU/I&
MVY$B7E!%E*J#C!^,YP69G@/&,XY9>1!XXY6JE>G*3(W:UZHX$S?:]'(]&5#@
M1N:MV&1-+9,AFAWH9(GLUG<Q6`\0\@F*MS6Q.1^%Z1?+4*D]+A$2)2L7R`_/
M`8Q@X]'8JLBOE^FI@TPH^JD4O1OJO>\OA,LC3&QP)^4GV$PM4E=&QEEYTN]'
M)*]F2UOEK8%5T,E(,*!6VK3$J<03CC@X*"1,;?(N7^TL$=VX5]8I[\@8][=I
M/LX$]K8Z2^=<EL\U0J(V!JDSPRQ]*%2S#PTM*"3DEB*:$Y#8F;E1)'(Y6#1F
ME:G.X.^/VG9_9<75]`UVBCUA7\GE\K9E#PC3OED2PA3,CTR]S5N)J]\&N7*3
M^LU`%82LBP(`!8`,999)1H22Y=;=I:I@BN3;>B-U?J,H?XN0'UE;?O\`6,;J
M&LK:H?490_Q<@/K*V_?Z8W4&5M4/J,H?XN0'UE;?O],;J#*VJ'U&4/\`%R`^
MLK;]_IC=096U0^HRA_BY`?65M^_TQNH,K:H?490_Q<@/K*V_?Z8W4&5M4/J,
MH?XN0'UE;?O],;J#*VJ'U&4/\7(#ZRMOW^F-U!E;5#ZC*'^+D!]96W[_`$QN
MH,K:HB6^+XIE\IFS6=GLV&.CJZ0Q]0-S<@?42I8M6*D1A*=.G3DF#,---,'C
M&,8Q_P"6K;;=DM"77*'J2S]1%+]OFO\`#.OF_4Q=!E;4?412_;YK_#.OF_3%
MT&5M1]1%+]OFO\,Z^;],7096U'U$4OV^:_PSKYOTQ=!E;4?412_;YK_#.OF_
M3%T&5M1]1%+]OFO\,Z^;],7096U'U$4OV^:_PSKYOTQ=!E;4?412_;YK_#.O
MF_3%T&5M36[=4\4K?E,6!7Z6Q$:)UE4*E<.+6H4KAA=U;+F-:PN12;)R(LD:
MHE.OR>GP,6`\^7@/$.!BSK5J?H_1D=UNCG5'%:QZ&B;0BL!F==WEWP=(VMC/
M8Z[HTGE)A4#C1C](DC>G;U@7(TI,SNBT"E(WM@!\Z9D@\!)1I82BDVG:M=65
M7>D6ED?:<J9-*IHYLF^976GIU84HM-[C\>G<.8S25MA2!!,,J2LGOX%)P\ID
MZ<"<M>6K9C"DR8[J[)HEQB]BO(F6D8F-0C;C7<@FTJ<87OAM`R:R$U9#74AN
MD)S:O?)=7[&3%WA80D<G7"B6Y9FUL4$G`)RI3)F]0,H@9)&2A!*VWV97?Z3;
MH>A2AI[3=6UM&(XY64G=I"E8V=&]O#GUVO=%I[<WD(BNG+U*=8J6*L`*R,XP
MPXX9BDPP>1BY7'6+DW\$3M7N3-]1%+]OFO\`#.OF_4Q="Y6U'U$4OV^:_P`,
MZ^;],7096U'U$4OV^:_PSKYOTQ=!E;4?412_;YK_``SKYOTQ=!E;4?412_;Y
MK_#.OF_3%T&5M1]1%+]OFO\`#.OF_3%T&5M1]1%+]OFO\,Z^;],7096U'U$4
MOV^:_P`,Z^;],7096U(YN&]ZD>*CM-I;9LVJW%TKF;MR!*6G<PC4K5L9<TR5
M.`1B$`,#./-"'&19QCCGRYQJVVO):>Y'=;#U/__2]6,"721;XF5H/"N1S)RA
MZJ%"BD:CISO/\L\;5LD<BI3MTV`.3@8SQMI7/L>=%*%]ZM1-CF-8#*92H-6E
M#53W->R.H^J9(7;O^8B8_P""];?WXM?6OVKY)^Y_'^2:-9*-`-`-`-`-`-`-
M`-`-`-`-`-`<I=\K+B+6(Q2D@."4LT9!!/%@/#G7B/#)1JS,Y#PQY6Q6BQ_I
MXASG_5W_`(G*:H<?Y%K)I)Z3X_WN/_/_`-==3&AOML09,/\`*)?-%`.<)C;8
MD9V\8N/)PXOIAQB@XK^C)J9O;A%BXYX8"I_1GCQQR_E>B1T_C2ELZ?ZX'4:`
M:`:`:`:`:`:`:`:`:`:`:`:`A:9?SHI/^J[5_A4:UI>EQE_:TFG631CC_,(C
M%<HPRB4QR-B<3@IF_#^]MC/E>H&,)8"$>'%4GRJ.&8,(<!!RA9%G&.''.@,@
M+,+.++.),`:4:`)A1I8@C+,+&'`@&%C#G(1@&'.,XSC.<9QG0']Z`:`:`:`:
M`Y<[^JOCKUGDR-LRYPVSV93'I8VA5."`I<H;@IP&IU*MK5(5A1+JU#++$`!H
M>>`0;@7$(A8SV_CU3M9SOT::.7DNVP;;YW),2Z55[AUD.'M?(\.'I;.D7_[E
MS7EN:Y9T5NE"1%^W7%!'S?-\T'AP"'`?)K;LM>K,J]K1/CL9?3&TVH&VYX0[
M5@PK8E(5CZ]%F)6UV7JV=S<YDW-+"[21^3NQSBN6*VAB:LY)YM0447@Q0/)8
MS#1"S':K9N1<G=M;/28V-R1G;4#2WE8(0MB-,@1DAX<"DR0D!!(/)C&/LE@Q
M_KUY_4ZE=H!H!H!H!H!H!H!H!H"%]QG\A[<_L#)?X:?K5OV1+OJ_@FC62C0#
M0#0#0#0#0#0#0'!_=KM]K4RX)2EET?6+R7)E`A;1$R26,J8^$O+@!_&PY1LC
M\VI36L#ZGY)P!`SA08A)$9RN9*Y'HMBY)OU.3;M<(U5?=KVVZ2RPF<O=>].E
M)"4M$4ZBE\\($%,4E.1@+RD32DE`/.$QXP\H1619X\<YSGAG5PMF?<F;B)TX
MY&P6SO931>=Q-=36$Q=;%QU8Z3>R%B5L>'-6U/SS*&LY@/4R0+X>[J5YX5#R
M+*8`#R<%A-.\@@?9#B]*U2O4U;<[G#>AZ"-<3H-`-`-`-`-`-`-`-`19>G\D
MKB_PLL+^Z3OJV_:WY)=]7\'_T_2_M@L.X73Q";FC\LD5F+ZJ5.&X!-7J"2V]
M&K'80*XK;!K`K"A9(E9422P=C2FLZY(S,[C`'EU:R$!A"B0!,Y854-/T.S.J
M9(7;O^8B8_X+UM_?BU]:_:ODG[G\?Y)HUDIQ?OFQ)&Q^,;L\IAOW56E&(K:5
M.V?8<MV_()5#TL+<W>NT@`P)*6RJX@H?,M\Y);9`>X%97C/5B9LB3#3!*,P9
M/<TOJW!V@U3(T`T`T`T`T`T`T`T`T`T!S]\1IGP;2S%*"@YZ3&)NWA--X\,%
MMCXWN"%4'AP_28XEH_+Q\F`Y_P!/DZ_Q/<U'L<_Y%I)Q(])L_P"]S_[VO1_\
M3B=VO#[9L(]O:)_$#'.3"521XY[RY&80W*BXP6#(LXQP`4<Q&\`XXXQD6<_I
MSG7F_E>X[_Q_4W?US-C0#0#0#0#0#0#0#0#0#0#0#0#0$+3+^=%)_P!5VK_"
MHUK2]+C+^UI-.LFCQ8_YAZZ87?FZ*![>(IZ"==;3(<MF4NE;\BC[@>OL^PP-
M#S%JE/&]`-*/BZ&.LZ=P>4N.<3*#G(DI07D:?&,56Y3J:RP2<>K/39X>N\2G
M-Z6V2MK+J=0Q-*I#$XZQ3NL6L71E-4RYL:R6]WAHFL_D+"F)L<$)Q+4KY',+
M41(1EBXX&$$]B/1M&\6A!H!H!H!H#5/>A'L/5"25Q`#E*XBM:90EX8SQP%.K
M"V.&>(?+@(&ET/'G'EQG(,?Z\;_C<7(Q>IM.&_I-_P#<S_YZ].IP-XMA#9B4
MW"X/IV.6GAD67KB1\,YY#H\&DLJ4.>/#&,#;E*S/']/$./)_3CG_`"MXP=/X
MUK)V2UYSL-`-`-`-`-`-`-`-`-`0ON,_D/;G]@9+_#3]:M^R)=]7\$T:R4:`
M:`:`:`:`:`:`:`YF^(BRX0):ZG9(,ASE0Z1)Q.X8X#P86%X92^5C@+'-\ROS
MPSQQGE>3APSQ[?Q-ZHY?R+T9R]])O_N9_P#/7;4Y'6;P]&3!D)G$X-#Q->9$
MFCJ48\9Y6$C`@+6G#*X^3!9ZI\Y(N'Z1$?\`AC7#^5RTCM_&M&SH=KD=!H!H
M!H!H!H!H!H!H"++T_DE<7^%EA?W2=]6W[6_)+OJ_@__4]6]%;4L59O4LB['1
MPVO(WV:++F0!9ZXI"JH3:CXR3^=E6M&Y/.9VQURS6&_6$4VKS6EY&:^*&]S0
MM*5Q4%*G-8H4)H:;T]S8J[:"E-H2:2.K:&K4Z!YK8%?)U#W'7%1(^#C*V)\>
MW=P<TPAEJ'9C0L8?1-3@.!1UR./5\A5S^2BZ1,OSZGL!1N$D>($[PYI.#35>
MY<A2Z.O4A+/+S-[2Z,%"!FE,8$E&`6!\YDP1V!XR'A@/#/':C'6IC7)Q0R=:
M1N&0HU:T4KJ!0%&F/5"3HJNGJM8>%.4,W)*1*3:HC5*DW`.266'&1#'G&,>7
M.IMHR[JKCJ>%F_V/Q'+'WEG6])MMU]Q#>W8L[-NW;DWH(U%^9BL1H)8U$19B
MC[>OFSB$V+Q9D<227D@X)Q2PYR/$:!3RQY')MQ:AY&X<IRL(/0_0'BNV\Y2)
M!5.[MAA.U:SRD;:0N-L&L9P!F*=3DQ?/$2<T%BM8XP-2<+E$K0D&LR@OB<%0
M23DO`NF"A-)G')JYVMH[#(`WTZ(DCDV3ZC'%N7IB5B%P05],UB):D4%A-3JD
MBI/;1A"E,>4+`@#`(01!SC.,YQK&VC-ZU7'4J^KMQ';&E^[:<?-?3;1C=5<=
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M61D\-NN-.5*@2X%!6@EJ)3/4A;E2]0Y'K<9:`,SX0RKU*DPPM4I6B/4`,XD!
MP1DLS7"^ZQ-Z2SK:KFEK".E;%$[[CK6E:&^:U0<F2`Y(5#O#+-?G10+_`&CU
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M8ZC;K(RTJ$\!F!+>G+"VL&7$+BD,LDY2L&<7DO!&2CR,%"P+(L&8SC`:L8>C
M,N96J)8ZNW$=L:7[MIQ\U]3;1FMU5QU.-N]#P'*@WM3M'94PD$4J"9B72AWE
MCW0E?HH@NLI]EB]$XKW^Q%<I63E9('A(H2"Z,:$PCFPJ#L9P+E8Y,BRC-*Z]
M>ZXZF"2CPQ+KV,*4U_["W5F2O$6(1FRNHH7'7)&1+6Q&T)4;^X`87%[>RY@H
MD(6T!ZYH!S1F5`\FM@232TQ!>[79&+6ASN5TY3J;N;,M]<QW?M2IK02^F(';
M3$$W,CJ]]@,U$YY3D"R`3U&E8[22A?V?B'.#P@`%4@,QR5!80")-.76JWV<"
MVYW>ZDWQZNW$=L:7[MIQ\U]9VT9K=5<=1U=N([8TOW;3CYKZ;:,;JKCJ.KMQ
M';&E^[:<?-?3;1C=5<=2F5I-QJ9*I4$R6GW`X@@TTI"DKB6@5+#"P"$!*F&O
MN%$A">>+')#DXXHO`LXY0PXXYPV\QNJN.II1;.YY=AGG=36E-857KZ]120,Y
M\?E=%V6V+5A3DVK$)1C.^H;)DD;SA28(71'#!IR+G2^7@8L8QC.U:E%R]/DP
M[M&F_P`'%'TCS_O/_A_]=>CCU.)O?L]O]AIUCGKJML:#Q-UD;DP-Y+1)*]G,
MZ>'-,TD.!I)S7F(/[*F;4W//!@3,*<_MA@#R<\0X#GG_`"+)I1^3I8XG4ZSP
M22[B)XTA?"#81&&Y0$LQN%,JAEK$N<B#,"SA04S9NE4](2L</)A:G2C'C.!`
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M0J8L<2?TC!"HY$G%DS(L*$[2X$)Y==B-5)1'N999(TC82K5DDB,5F@`D3J#B
MY-OC^2JVYN)78V]K<>X6=UW`IPY6!`HJXS*%Q:5KXN*M44I%&ULA8T+NJ812
M:*72Z1>1B9SU@D^5[:I4(%G-\ZG-,)&`>;-OC^20ZKL9IZ,7Q\7H#W+N7S;T
MFWQ_(W57'4>C%\?%Z`]R[E\V])M\?R-U5QU'HQ?'Q>@/<NY?-O2;?'\C=5<=
M1Z,7Q\7H#W+N7S;TFWQ_(W57'4>C%\?%Z`]R[E\V])M\?R-U5QU+%)$.X"/M
M*AU33Z/2<:;@(;5&Z4"<[#)Q@0C3DZ=VO!H)5<R$/'FBS1'CXXP66,7DT6+]
MOS_H1Y5X[G,C=1N$8K%JMZB[C<#2YRN,R5G</=TX49+ZXE1+BF4F-*SEN3U+
MWIO2GMR)T/$<GR`1P@A%C@'];'6RW&Y:?DQ<Y3UU^#F+Z1Y_WG_P_P#KKMQZ
MG(ZL;:MQ#3"*L@L#CUP-9DP=3G-9[N6&@)A84I+<G5[6C*2F/+7,V-J=%AR3
M!9F`%A`,DK&`"QQ#C(N-ULW-QI\G6VZ$E.OP=(&-JW`O#6E<5=AQ>.G*0B'E
MH?*8!ET2AY6<%]*PS7>\H`"-!C`\!"H$,.,\!X"/&0XY/&GY_P!#>ZO'<NWH
MQ?'Q>@/<NY?-O2;?'\EW57'4>C%\?%Z`]R[E\V])M\?R-U5QU'HQ?'Q>@/<N
MY?-O2;?'\C=5<=1Z,7Q\7H#W+N7S;TFWQ_(W57'4>C%\?%Z`]R[E\V])M\?R
M-U5QU'HQ?'Q>@/<NY?-O2;?'\C=5<=1Z,7Q\7H#W+N7S;TFWQ_(W57'4>C%\
M?%Z`]R[E\V])M\?R-U5QU(XN*.W214=IG.MIPAP:R:YFYKD@25(X-JI<@+C+
MF-8C3.([0<`(%"E/@0`'9(/P4(6!9+'PY.;:[96WW(YAZ^Q__]7U7[9[CC]D
M[VMSL*DU`P6(VI7+\\X165#935[O)5L*;7MXA$?S:+,QV@^6$VN,PB#8TO3:
M>N86U,(AT&B,)+/;L*ET--:+4ZDZIDA=N_YB)C_@O6W]^+7UK]J^2?N?Q_DF
MC62FDT\V/16P-W]7[S'&[-P+3-JC8W&-1*N&*30)-4`6%_(2DRQK7L2ZM7*7
MG)9@-O2FN."GPG)AB4O)>2L8$$0LZ1!*NX7:U2.Z&+YC%P0M$^Y3D'%LDE2<
M&V81<X[[728](DX.F(^!P0F#3CYU$H$'&#R30<0YJN=OH9:3]3CDOI7??X9*
MU5(MO[XLW);8B51[@[UPZ)E2YWCB$P_GE9YL<1"&XLZH)`Q9$ZL`C$QA@1'K
MT("PA!GI-M_KI<<XNL]-4=(MIGB';?MV:9*TQYXS"+.RGYQ=5\O4IDSV88`.
M<GF1AQQDMNF"$'($+&4N<*P%!Y9Z8C&<8UBZQV_!NVY7?)LC>M[U?MKK*07%
M<CZYQJNXMT++^^-,.FT[4MQ2]62A)4F1ZOH[*9,:B*./#D\\M&,E*5@1IPBR
M@B'C)M*=$5-(W76VXNK8E=%0O;A)*WG29>MBKZYQ27PE6Z(VUX<6)0K]&IXP
MQF4H4QC@UG=',4HB0*B.0H(R8G-*-&(U&A*N@&@&@&@&@&@*98C1N*-4WN"5
M,O0+TQZ-<A6$%*D:Q&J*$0I2JDQX1DJ$R@D8@#`,.0C#G.,XSC.@."40\/-"
MBW_.\-<FLU;0L:94US-R99SAZ1R9W9Q4M[!`E9_`03<(I8C5%&%&B$-2U-^<
MF9Y1^,Y[9[)_<<L-T1H=\RRP%``44`!918`EEEEAP`!8`8P$```#C`0@"''#
M&,>3&-<3J?WH!H!H!H!H!H!H!H!H!H!H!H!H!H"%IE_.BD_ZKM7^%1K6EZ7&
M7]K2:=9-#0#0')K>SX<OO.D`-Q>U]U%5&YN.*\/Q:AE7^C[3/5Z0D?)&>I(R
M24P3)1@."P.'*`E68&,M>$6#.D$[MOC2[ZF+K9U7J?+9/XCF;&D'TY[J&S-3
M[FH\L!'LEOK?Z-M5@.110<%EEI#PDIH],U@>2/*'@6D<,F@,;\YP:%,4NLC6
MWT%MTZ/U.M6L&QH!H"'+MHFNK^AZJ(6"S%K`<T>)E?4N`$2",.!H,8`YL3ER
M!&I3@#`#)A0N6G4A!@!Q9@/LZU;<[7*([5=ZGE8W$5'-MN5L.U62D)J]27DA
M=&'=(08$B61UQ/.(:'AO3!,/,+&J,(&2:1RAB)5%&%<H?)P(7IMOR4Z'!VPX
M9W;V.[&F6H(\QV9:K62\7"Z)2W),V.)8%+?7)"@.#$J%$F-!D!DK`0+&5BL6
M,Y3&YR0GX!`,X_C?_([M%Z'6VQ+5^ITOUR-C0#0#0#0#0#0#0#0#0$+[C/Y#
MVY_8&2_PT_6K?LB7?5_!-&LE/(-_F,++M!5:=3Q^?U=,DNSRHT73R)2I.BC?
M&K8W!V&VF-Y"5K22.4LA\E(KF!*S@$Y1%FGI5"UU,-"%,F&<&IVIS<M"Q<[=
MKW&S_@T>(@NA570+9KNW9Y!6KI#&MG;MNUKS90WYC]ETU(4X'FI$Z]_;E[G'
M@@!$UZ9,R.R-6H9'-K)2\VHYP10E55K:E>A+KDKH;U_]3TM:R!H!H!H!H!H#
M3+=OL\AVY.,*UZ$E#&K9;$><QF:%D<WT\2<`LD1^5<P'G'%D4Y^P`T6!GH!9
MYPGB'G23MV7NU\C-UJN^3S/,%>65(K?244BCZPJS%,J/AQK`KSDH3>[(CSBW
M,Q>>7@X!+:U$)35*A2'EE`2E"-QD0,<<^EW0LI4'''6/<]1&V#:C7^VF*D)6
ME,2^3UQ1%!ED\6D`&YN*@6`&*6]I$,'+:(X4H#CFDQ?#)F``&>(TW'*QYK[W
M>^1VMM5OR;3:P:&@&@&@&@&@&@&@&@(LO3^25Q?X66%_=)WU;?M;\DN^K^#_
MUO551=?J(/OQLIN?;TJ>1&$MET3&"[?622$K)U5C1>%CL%C2N1JVLJ'M<AYZ
M>.B5*XN('IZ=R$1IX`M)21":`&H:?IZ&Y%K[A6ZIY,@BZZ$2J1K'B/.;\SG1
M]9$@)U8V,LYP=FM::^R1E)858H^B6K4`UXTY+GEM5ITXQ*"@EF4R4A4VB37>
M[XZO<B9X\C>Z.K%4V#D3BD83%)9DQM%3R`$NIR0SGRBE`,F%\.67D6,"QC.M
M>MJ^3,I7.7[$I^]>K?B3`?7&.^<=2'0LJJ'O7JWXDP'UQCOG'2'02JH>]>K?
MB3`?7&.^<=(=!*JA[UZM^),!]<8[YQTAT$JJ.:6[+8UL^W'*5<ZB-E0.E;J"
MIPZI9]#9+&B&]X>2C>DE*Y;'4KLA)7+1J?VF7%(:D<L'<DP9QV`<T+=MURTB
M48N5K]&I.26Z+?QO%VA4%:NUJ]4$/W`G71`I325+VPTS!,_&GN<_87&+`<G*
M2M723I,C8VU><K.3/!+>]`P5RSCC"1%X$NMM:FW1T+8WE#>U'13P[/%9VBOF
MS^A(K9%EMM86G5T!C%,V-!GIEEY@F*75BV)82I.`[)(^K9CVY]2LY+F0(M4;
MA.F6@+.$$P`\8PK;G[&[G:GZG0UJWZ;,GC(0I-RU0DY&H`FQUK+VYBQ@PS(,
M!$(3V-O"!/CEXY1N<X*#Y>(L<,\+C=0F5M216[<_MI>`<ZT;AZ-="^>RGYQN
MMJ`K@<_@(!Y(Y::0&AY[`#`YY/ZW`6,\/+C4Q=&)549(FNVF5G)Z';E8JN4+
M(`]&GT5/Y0\8XY"'FG87$6,9_1^G3%T8E5.-S3?C5_WJW2K`[]IBNK!MVXJ;
ME540LED&!41=D.6?0@JM$Z[J0HX\MKA+HFFP$87$2_"W(#LC$F`:2&0Y@WIA
M,':'WKU;\28#ZXQWSCJPZ&)54/>O5OQ)@/KC'?..D.@E50]Z]6_$F`^N,=\X
MZ0Z"55'SQ:-4!-&?BQ:]P>86428=B71O!IA1`CADE#,PX<L19(U!F0ASG@'(
MQ9Q^G/%#H)54?3WKU;\28#ZXQWSCI#H)544JVV:Y+1*QM]B5TH7@2J!HDZF;
MQ].G/5A*'E,2>H`M.&02:=@(1#P`>0ASG.`YX<-(=!*JC0789O[DVY\&X$RZ
M&C;O4Y=+7"ZTDVCK_<$39`93+(9E7B>N`\O,3A'0HRFZ6UY:%A?/Y<@GJ,B`
M1@@&3HI?L:NQMC4Z">]>K?B3`?7&.^<=6'0S*JA[UZM^),!]<8[YQTAT$JJ'
MO7JWXDP'UQCOG'2'02JH>]>K?B3`?7&.^<=(=!*JA[UZM^),!]<8[YQTAT$J
MJ'O7JWXDP'UQCOG'2'02JH>]>K?B3`?7&.^<=(=!*JA[UZM^),!]<8[YQTAT
M$JJ-?TV_S9@KNL6W5-N1JPVZ0'JDHH'B0EX<<'HHV=+U1?3A%X9N),;3C59_
MXGAD`>3CB/[.I[Q[E]LO8V`]Z]6_$F`^N,=\XZL.A)54/>O5OQ)@/KC'?..D
M.@E50]Z]6_$F`^N,=\XZ0Z"55$02ZR:Z/M^G5Q,^A1R)"VV:!:K*E+$8E1B5
MMD=`E"J4`7Y*3B4C*%@O`\XR/(<XQQX9U4G#T(VI6I+_`+UZM^),!]<8[YQU
M(="RJH>]>K?B3`?7&.^<=(=!*JA[UZM^),!]<8[YQTAT$JJ'O7JWXDP'UQCO
MG'2'02JHT*WK[7=L&[^/8<C+*KR$7,PI.$-LYLE,<"JP)/RS4C'+"2'$!KW'
M,GYX@S@05:`S]HG,P')Q)^K7=;[:&;E;=[J343:=XB<UHJ<%;5=\SNC,6-1R
M-GA%\IW5+(&1>@,#DAJ]+9,WC/2OC*KQ@LHE_P`?MDYF!!=<!,`H/*U=9*RM
M);=&EQTDJ#Q"]DU]RJ20FH]RE83.41%*<ND+2D>3&XQ`C3JD2$Y4%0]I6Q&M
M(+6N!1.1)S#<8,SD/Z0#P'DM?0Z/12_0V,]Z]6_$F`^N,=\XZL.A)54/>O5O
MQ)@/KC'?..D.@E51K7=,`V^W38]"6)(+%KC*ZE)FODG,F2F-#R^-QS0I.0-1
MP\KA8$!!-&]J7AP9@0.:(/!C&!'<K6D[DFH]2/%QJC3CQ3?%K;=@$'JF259#
M*XW&/E@31P:7>.([@3-+S'HS$"6R32MT3LL>C<M5N"=;%R5R++B::F(8EYZ-
M4:G<2N<2#PTU[&[4KIU-\89O,VW/]?P*:22^MOL36S.(1R2'M.;R@:]`WK7M
MD0.JQK;GM>M8#7M,W&K<E`4Y1)!G@#@P1!61<@-2;]$9;2;4E`Y[]-F33@0E
M6Y:H3<!4939ZLE[<]9YS&#,Y$$+,->(2?]GG@;C&2L\<?:^T'C<;J#*VI@+K
MXGVQ!GP?E7N%CYW1QA+,ZJB]@OF1"%G`<9(PR1%PRI!C(O*(OEAQCRYSC&,Z
M874)G;4P%S\7O8@@R?A+:3\]X)+Y98FRM+"*PJ%R,"YDCKF.-`@F8%]GB;@L
M''_:X>75_KNH,[:F`./C6;,D(^2F+MUXQS/.\XW05`4#)G$>.C<'>3-9G/<`
M8SQY/-\!8^W^MP?UW$_LM(_7^.IMB+R5U75M\+`YP+GLKVBOFW)><9#R,%!3
MV$ZX-P+''CG.0<.&/)GCY+_4ZHG]BHSSM[JO$6<;S\0*&;RH6HO*$;?MNTDJ
MJ/6)7+3;$J1FS-!&Y02Z7"O86R..J)A;$R-E*;0+&\)0R'8YK'TL9H!8`7EV
M/<YT1V5RVVOU?"/<*RW?34B9VF0,EK5TY,KZV('EH<4\RC^4Z]K<TI2U`M(R
M)P"+)*I(>`8>.,9Y(L>34AT,2JES]Z]6_$F`^N,=\XZ0Z"55#WKU;\28#ZXQ
MWSCI#H)541!?]DUTY4E:C>W3Z%+UZR#2%.D1(I2Q*E:I0:WG!+(3)B%YAQYQ
M@L\`A"'(LY_1C6K4\EH2YJ'J2_[UZM^),!]<8[YQUF'0LJJ,6E;]MXGB-,W3
MAYIB9MZ-3TU(@E;C!Y$C2K,%&$85IDKN<L((4\P<,'.!#@?(%G''AG.D.@R5
M36/=/MWV@[J:X0P>2RVM(H[Q5JPVUK-(P^Q!(Z0$M.G`2A;4"(EP2)5L2`$D
ML!S0(1:<90<<T(@T)9Q>K7=:]$2[&[U:.;^W[>Y:&Q.?H-L>[A[;[(J`!I2.
MNKRBCN"6]1,.183HA&K$9JE6^Q1%P`$U$>$#RS!R+`0J$^$Q.-.W)96K4PKL
M7#<H[KMMT4\\-Z)U:[4KI>VN*4A:A6III'#$ZI*I+":0>2/#CP$`PL6,XUSA
MT.DJJ*[WKU;\28#ZXQWSCI#H)54/>O5OQ)@/KC'?..D.@E50]Z]6_$F`^N,=
M\XZ0Z"55#WKU;\28#ZXQWSCI#H)54/>O5OQ)@/KC'?..D.@E51K4T5_M]:=T
M4JW.$6)6X9!)*W986)%B51W.2WE,N."\R?)F7+!9:U='&UJ;P"#C(^:(.QG.
M,&"P.S=CC&A-LS*-E?>O5OQ)@/KC'?..I#H655#WKU;\28#ZXQWSCI#H)54/
M>O5OQ)@/KC'?..D.@E50]Z]6_$F`^N,=\XZ0Z"55'S-MRJ""QG'V=7I)1>.4
M,TV:1LLL`?T<1C&Y8"''^O.D.@E51"LZWR[0:X`8*5;B:L+-*QC)J%ADZ29.
MI7*X<G!C/#>OW4O(L9XXQDG&<X\OZ/+JXW/V)E:O<\R&[?Q):7GOBL;7[3KN
MR[W#M;IE\K%@W'/K'9UDUO7JV3O,K6K(0Y*ZY-4MS8X1"OUQJ!9*,JD7.O3>
ML.0GE<@DH><NUJ>1TM:=L>[]#UN8MBK!8P(-EP`018QG&<3*.YQG&<<<9QG#
MCPSC.-6'0Q*JC]]Z]6_$F`^N,=\XZ0Z"55#WKU;\28#ZXQWSCI#H)541G=-F
M5POIRV4*&P(0M6K:SG:1&C22MA4JE:I3%G4E.F3)R5XSCU!YP\!``.,B$+.,
M8QG.=6U/):>Y&U#U]C__U_3U!GWGO&5NB-);!S@"#;O'WMXK),KFJ`@Q0Y-=
M>H6B7'LB[+G&)&N3IVU0F7.R3+4B;B3FE&6%:O4.`DT]S7[4SJ$]596,D='-
M\D-<P-^>GIL0LKP\/40C[HZ.S,V+T[JVM+FX+FX]6O;&]T2%*2"#1C**4%`,
M"'`PXSBF2/\`+(RO6X:5A>&AK=@IZ8K@1`7-O2+PD",G%JX,$3A44;@O(\`Q
MQR'AQX8X_HUK]J^3/[G\$I>@D([&Q7U>:/W/4EU+"H/02$=C8KZO-'[GI+J(
M5!Z"0CL;%?5YH_<])=1"H/02$=C8KZO-'[GI+J(5!Z"0CL;%?5YH_<])=1"H
M<3/&"\/6(7;#ENY]=?JZCD^URD[1>H-"6>)5X"*/<Y4,[H['KG-QD9&!&/$O
M"UMC,26$`S2@%<$W[10/`I+3F=32B,<=&1IX9/A#[>6^MF7<98$^!N72;F:<
MK>5/D;D<<C#>R1&9GL2%2YJ(J^P56W')5[0:K6M*T/)"<8:G`([(5"?55UVK
MGU)<K7%N/H=&W;PI]A+O@8C*&3H3LI^CEGM-@6DVY)QQ&()P$J:;`;S%`1&9
M^V:29G.,8QGCC&,8UG=4SA;0C9U\&G9$X\[T2.6"Q<X6$`.JK!=3N8%C])Q7
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MP[YYZT-8<\4Z#%>O!F2<BQ@1V1&([F;$X\FGY$+[)`.&,\,\<XR++^W_`&C^
MO_</^T%N'9_V$9\0&?%)#?VJ@/44X8N*C]3CT=OMYQ*._9!#]L0@B_HX<,8S
MI_8O>T8/R/S_`+5^\EI%@QCWZOS@,[&0*`OP)X,LH`<A$7E.%9+)"#EBSG/*
MS@)6<8QCRYX\,/[+?$8/R&?#9W_-V<*VC>LQK5H,\D)#PEDHD.0#QD)@AA4M
MCV2(80Y^SC*<7E\N,ASCCIG;XDPN\C3K?;5WB/[,]O3[;^=Q#;83XH>6>%1&
M)UW!WB62)?(Y+TKD+<-Q=9&IRF^/LZ%8XGF'\"LA2<UCB::6$4=]L.%J:MLN
M=REZ'&'P\9;N)KG<''*LVHKY;&T-T+VNM;)>K#I]Q<86VW'%RUH&%VEJR;US
M,4#`[R!4_&MZL&""Q@5*4PU60E@`,N)V)J/2#=RO=KF$YT^#TQ^XKQD6C.#O
M37;=*<&XR7T7T)IM/A-G&<"P?D7N<C@A9SPY.,8,,QY?*']&=:G^/F<XOY'[
MZ%^,@T?\-Z`[;91R_P!OUAU!3B?F>5^SZ'R.3'>/-\WR^/,"_P#F?KYX<D*;
M*LD7T1_/3_&00A$FSM.VWNV$W*!ERZ-3@1+<`SG]N$DNWV[..7C]`<)RL_\`
MLXSI_P`?DR[_`!1^YN;Q7D/_`!;CX?NWM2B)R$2@AMB(1KC09S@/)3!3W:Z'
M<OE"QY<)S>&..<XX<<X19YL;_%#ZH?$2:LX/>_#1AJ]*9C)19+%"7T:H)^<X
M&$PW*1S?QA3X+"+&>)(,9%G'V\?JB1;YDF[P/WZW=XK3^Q>_"ED+@H,_:E&,
M,!G@TX"?U.0=E'7$@!@[EASGRF@SR<X^S_3EC;_Y"Y/P/S'B07&@QT-X\**>
M!<R,Y`K#A)*6W`3..<X#T%5M\5J$V<`SCB$1@L\?+Y./###_`/09/P/Y%XK;
M*C+Z6\^'I.FQM(#@UP7"2I!%HTX>'/'<5=:H"!!+Q^CEF%!S_3G&F#\R9_[#
MCU47B71R9>*S'-Z$AKF'P[:K9:5IV<%L[K'XXH4Q"!J70!L?N-S=R$!*'&17
M8K4=,6\D)A+`K$GSD82@"US:<9SI)VT^D;HG_0]I7H)".QL5]7FC]STEU,PJ
M#T$A'8V*^KS1^YZ2ZB%0>@D([&Q7U>:/W/2740J$.R^'1$NXJ:3%Q6-EIE39
M:`E*<#&V`(4"(:XX(C)Y04N"S<DB'G(.5C/)SG/#].JFX>I&EE;H3%Z"0CL;
M%?5YH_<]274L*@]!(1V-BOJ\T?N>DNHA4'H)".QL5]7FC]STEU$*@]!(1V-B
MOJ\T?N>DNHA4'H)".QL5]7FC]STEU$*AS#\7_&V*JMB%S6=;L&CQBV+,^4]3
MB9B&Z.R<ZWY#Q98&WLCLF2]("E/>%0#W0K):@CJE,I.-),"1]DKG;K)<%="@
M\=GATW/8M=7["*"V^[C*_CBO=>M:&":O4X0-3S'<76WB=U<7<!.3Q`IJ[L1<
MV7/IK*1AO2%X5K!I,*\\@(!%ZFVUIS,_J+E=<GI#3T^#U$X\.KQ%G\.!RG>1
M"F@W(1FB!$T[^`K"E1G&3R@B;XA#^*8O_P"GGD8P'_9`#6L[?$Y875/W_LW7
M-(A9S.]^$[=2<X+3F)O1>5/8E2`(Q&B3Y5/-M%`3XP8,60AR0<#&<Y%PX^33
M^Q>UI?ZWY%W0^!=6I^2\RS<3:3]GB,2C*%E8&O)HL!$%.(O+D?).:R2'AC.1
M<YRL8SPY/'R/[70?UKW9QHWN>#+O=JF]5<[VSU2P[F*G>F;,-@[+[Q&\RPX<
MTIFIF4RAZL)#(8I5T/1G3:0J5041+4J=AIT"<)"@T6<<Z;C-Y90=%9;CCDUK
M)TU\.#P3FN#T$G:-\</C;M/S743O#D5<VO8*CT8@KZVMKLCA4V3&,$22D3.&
MO"A8B.-0*W1`<G"4$LW/-<X:5]R4+T)=;;<Y]SI:U^%/L(:LE#+H5.L.`G"0
M,YTL&U7'!^<8!@9YJ55.#&\*@P0.5D19(,!SG.`X#C/#5SNJ3"VAGK7X=VR5
MHZ/T3;?71O1>5S?6B)>]\KE\OCTCKEP7],X<O/#G>7R?)PX<,<)G=48VT,_;
M-G&TIGP3T#;)0A9B<_"DA2?4L%6K23PC"8`TM<N8U"P`BAAQD'`?V,X^SPU,
MKJLN-M$9\@HRDVHL1373U6-I0S.=&6@KZ)(RQF\D(><$!.T%A$9R0XQQSCCP
MQC2740J%_#7%?`+.**@\13A/!DLW*6.M*0S(<A$'B$Y,D*-`,.!YY(@BP(.<
M\<9QG2740J'))R_R_7A8.3H:Y9H>7)2U2C*I>VD7]?BA&XGFFY.6FKE#G9#@
M[G&N0Q"R>/I6!BR+.0Y#GRZAO)G3.IMM](4?7$0J6M:[9F:!0-I+8HJTNISG
M,EK8T$FG')T`Y)-E\BE#B0DY[(">E+3\DDA`4#(2@``%+J9>NK1(GH)".QL5
M]7FC]SU9=20J#T$A'8V*^KS1^YZ2ZB%0AW<'#HBCHZUE:.*QM*J3P21&IU*9
MC;"%!!H&X[(#23BDH3"C`9QQP(.<9QG5M;R6I+DH>GL3%Z"0CL;%?5YH_<]2
M74L*@]!(1V-BOJ\T?N>DNHA4'H)".QL5]7FC]STEU$*A'5J[;Z1NB$/-?6!7
M,7=(^\D\D0DS2A;75L6`P+"5V8W="G)7M#NB$+.2SR1A%PR(`L"+&,`BN:UD
M-)^QPA61>[_"0L`:IWC0-PFRZ6O)01+EK0V+7F'GK%.`X"(Q20(J)S$H`^&`
MY$4R/_''#)*GCA)UE7KUBXYP['6T[H4U+]OM_0-ILFJ$T'E46=L"+PH31]J*
M6MB\H(,JV9\;#D0%K,\HN<#SJ<\`!X"((P\HL8!BY/).&=%#4HE/T$A'8V*^
MKS1^YZ2ZB%0>@D([&Q7U>:/W/2740J#T$A'8V*^KS1^YZ2ZB%0>@D([&Q7U>
M:/W/2740J'/#Q0[Y7[)MIDFW!5;!]NSI)XM)(PB%&;?:'DM++&]^6C9<1^#M
M\'0]</,]6/*Y%E*0880B`D"I./.+`5RM274J2;AD74=XE^RB0;<:>M"Z)Y0"
M6R)U`6>4RN+T_#I;+6=E?',GI"B.IDAL472!I7-.3`IE1#GS)A*PHT.19`'`
M\Z2O:E$N=MK:([E/B^[2PK2F>J]NLYM![/,$4E3XA</C:-:/(N24!%D!\A?C
MS!\,YR'+:#.,9QPXYSG`=X7>]QC.WV1B8=U^_P"M\./<?X<$6AJ!>/!2)TLJ
M)KC`8`;CB!0D>Y5[I8^<`/'ASXB3$^,XSC...,\$6KUO)-S]+#]^D_Q7[D\L
M\MNFZ39S#.6-JB[7%FYZ2!,^UD"137,&4JE02L"Y/`]]Q^KY,Y_6RRL7HFRX
MWOU:+ZP^"&RORKK2]-T%FV$XJ30J%PF%K2-"K)F<"YW'7<P<Y^>K-%D7D.&F
M+S^GB#RZ?VOV0_KJS;6#^$ML>A.,&FU>OF[B`&`E+Y[+I*[@"+`<XR(QG:W)
MBCZC!@N`A<M)G..'`&0XSGCEWW/W-*RVAPEM_P#R^-IHMP,8AU32*=RW:O8K
MVJ=MPTZ?+4IF(31.LGKR6ED#A"8$10ZU(G)@+8`:_*41RC#V`92)*-HR1T@S
M$W0U.C.FW1M;EZ'J"H[;O#Z7I^MZD4'8LGW;Q!FAB:<3=AC!TOD3='T@&YJ6
M2-2ULZ!&N=@-I!11RC!03%(B^=,R(P8Q9LNIEPWZ$J^@D([&Q7U>:/W/274D
M*@]!(1V-BOJ\T?N>DNHA4(QNR&0]+3-N*DL4C292FK&>GIU!#$UDGD'DQ5V,
M*.)-+2A,*-*,#@01!SC(<XXX\NK:WDM?<ER4/3V/_]#U9;?MN^YV&;X+EN:R
MWM[<J;EPK01UTPNEX3>TB8FW.4[2O<>-0-LC=6%OB;;)&XXX\F.IF-<DC.`8
M1)'')``<_#3:A5.HVJ9(7;O^8B8_X+UM_?BU]:_:ODG[G\?Y)HUDHT`T`T`T
M!@UC5A6MP11=`[;KR#6E!W,Y$I<H98T28)O%'!0V*RE[<>NCLF;W-H5G-ZX@
MLX@1A(A%&@",.<"QC.@]#[U]7->U-$&BOJK@D-K.!,'3^H817T79(9$&3K5S
M6O;IU1&HXA;69MZR>7)0K4<R2#GE2@PT?$8Q"R!F6@&@&@(4(VU[<TMM"OQ+
M0-*)KU$<I4BNDBJX*3;0E"QA-BJL\5C%L(9CDY5%SQMI@NF<H:`8DXLY*SD&
MA9?I.A->A!H!H!H!H"D7H4KFA6MJTL1J)Q2*4*LH)IQ`C4JLD:=06$].84>2
M(91F<8&`01AX\<9QGAG0&J.U;8GM:V4>\#Z:*W<*]]Z2F/K9WTZR;6L+KU9%
M^ONI5?\`_ILXF75BDCTF6\Z8CZ.-7S@>?R;S1/-BMM^IMSH0:`:`:`:`:`:`
MQF:1!AL&'RJ!RI.M5QB:QQZBDB2-SR]1U>J8Y"W*6EV3(W^-N#3(&52>@5F`
M`J0JDRL@6<#*-`,(18`\VZ+P%*D'O>5C<=J59!\/@RN<0U)$B=W>Z(Z?)IHB
M"[2<FV>HA.Y2XQ<ZNAR.-FL(I'EI3-Q&7,&!*Q")%->AO+2?W'I5CC`VQ2/,
M,790K0,\;9FM@:0.+JZOK@!M9T)#<@"O?'U:Y/CRM"E3`P:K6*5"M0/B8<8,
MP0A9I@O.@&@(6F7\Z*3_`*KM7^%1K6EZ7&7]K2:=9-#0#0#0#0#0&G.WCP_M
MGNU"=2NR]O=(L5:3B<-*ICE4@;'V8N:AX:EKPD?U2,Y/(I&\(20'.Z$H_(BB
MBQX$#&,9P'.<9%;;]6;C:$&@&@&@&@&@&@&@&@&@&@&@&@&@(7W&?R'MS^P,
ME_AI^M6_9$N^K^":-9*-`-`-`6:0QUAEK&ZQF4,[;(8Z^H5#8\LCPC(<&MT;
MU0,EJ$:Y$J`80H3F@SPR$0<XT!P.N;:Q?7APSQWW,;*53E*J449-76C2;H8N
M>BF5C*$)2IZ2D+,Z<^Q5J`(8T[D4+#PREXXG&'I^DFBZJY7K&[U.;3MUM]")
M=G?C_-UO[C[UB&XTFJJ=HZ),K^OIQ;'HS;$AL><NJ.6MK:6RGN2`R0Q=V%&&
M<T\ES/)1-H%*T11Z?!:8)P0<TF[FD=7"M5S-PI;XV]!%K0,U3U3<%JOAPQ%H
MR`MK3&&]>9GA@HM$/IT@D1HQBX\<9:PYQCAPY6<YQC?];]V<_P"Q>R,0#O0\
M4VZ>4"DMDR*O&M<'.4KM9*-X)5D$B^SA4D>9T[UDP*^1G/*P+J\\(\8^R#.K
MC8O6XF5[]+3\^E?Q;[KQDZV=W+)4#4JSC`V:OW)0VO",K.,A&0(FM6&*H5!6
M`9_VWHX1G'.!9_ITR_C7I:,;WZW'&7Q1?#2W547)*_MV.HISN^KR+%HS'5R*
M#(UU@/ENO/7O5N44!C;?:TE+CD79&S`RW!:H+3X<%O)&87@!>3LN_5;=$;ML
M47++<S?7P4?#M?6:%6#,=VFUBO/0NQ71ILVC!3):YOTJBX'L"U)-8+*ZWEK'
M',L:`#FE*<4)2MI+-*$I4`'RP\SG$R>L:(MUMNDZW'I,BD#@\$1]7P>&12&H
M.2$'08I'6B.H^0']4'1FA&C)Y(>'DQR>&-9EOU$&5Z`:`:`:`:`:`:`:`BR]
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MM,^F"]S(190'<^:A1+*V;4JI4`OCD`#%!(!9\F1A_3JVXY*&Y)=,/1$L=8[B
M.QU+]Y,X^5&IMJR[J+CH.L=Q'8ZE^\F<?*C3;5C=1<=!UCN(['4OWDSCY4:;
M:L;J+CH.L=Q'8ZE^\F<?*C3;5C=1<=!UCN(['4OWDSCY4:;:L;J+CH1+?"/>
MW*::LN,4DAV^0VUY)#WF/P68R&S;(+;(@^/243:3*\]64TY*S%\;)4C6HR\$
M&%FK""@&<"Q#%B/&-&Y*IE2M#Q[;9/"3\2$G<G!88MVZTY&6/:Q,W&2$61=;
MO+<T5?;+%Y@WQJ715G<&ZOY?(7EON=L<CW)*-:Q(!Y;RS%`NCJ"P$#9.+4E$
M%BW<W=,^W%#V:Q*(V;`$.&R"4SMIA3;@.`8;XE)I!&T.`8SQP#"1FIQ&1@.,
M^7AR>&KM?JV8U7HEQT,NZQW$=CJ7[R9Q\J--M67=1<=!UCN(['4OWDSCY4:;
M:L;J+CH.L=Q'8ZE^\F<?*C3;5C=1<=!UCN(['4OWDSCY4:;:L;J+CH.L=Q'8
MZE^\F<?*C3;5C=1<=!UCN(['4OWDSCY4:;:L;J+CH.L=Q'8ZE^\F<?*C3;5C
M=1<=!UCN(['4OWDSCY4:;:L;J+CH.L=Q'8ZE^\F<?*C3;5C=1<=!UCN(['4O
MWDSCY4:;:L;J+CH.L=Q'8ZE^\F<?*C3;5C=1<=!UCN(['4OWDSCY4:;:L;J+
MCH.L=Q'8ZE^\F<?*C3;5C=1<=".+B7WN.H[3`\12I$S2.N9N%T4-M@3%:XD-
MPHRYX6G($:JLT"96M*39$(HHP\DLPS&`B,!C.18MN,K5^I',/1>A_]+W\:`:
M`A=N_P"8B8_X+UM_?BU]:_:ODG[G\?Y)HUDHT`T`T`T`T`T`T`T`T`T`T`T`
MT`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T!"TR_G12?\`5=J_PJ-:TO2XR_M:
M33K)H:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`A?<9_(>W/[`R7^&
MGZU;]D2[ZOX)HUDHT`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T!%EZ?
MR2N+_"RPO[I.^K;]K?DEWU?P?__3]_&@(GG]XU;5Q[DGGTH]&Q-+&U2-48K9
M)$>E,:WEY5L*'+<M0M"I&[N&'%";SZ)(,]:D3XPH/*+3B":(6"WMW_,1,?\`
M!>MO[\6OK7[5\F?W/X_R31K)1H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H
M!H!H!H!H!H!H!H!H!H!H!H"%IE_.BD_ZKM7^%1K6EZ7&7]K2:=9-#0#0#0#0
M#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0$+[C/Y#VY_8&2_PT_6K?LB7?5_!-
M&LE&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@(LO3^25Q?X66%_=)W
MU;?M;\DN^K^#_]3W\:`C6;U#7]BJ0+I8S*UCB2AZM2N;;(I-&W5"BSE;@XIN
M=(R\L[@W"6)G)4E4C(,+,4H51Z4T0TQQI0Q9,2>:(B4FL(Z3R1D9W./):\BD
M,8&C(ER<YJ/87N6."DPLM*-.G"A-0OB8HK&!B%C)(L<G&.&<Z5T*$8=J;EFO
M>Z-NJW;[7R"61^C&^P7UV>W)F:XPE=G\AP7&-$`G%AJ\-R%NPZNSPHRV04\`
MRDI`QI4XS%IF,D)#@YF3J566OV,4L:RMH=9O;#'G&K'N4+I+'(Z^,JR!B;Y`
MPKU\I4MX&6+9>5<W9R&E_<FMPPYIL.04"54V%C.*.&+&"\LG48*AG-)&[;[R
M<I*T,U*R2(N478XY(UB6:"9P96-,EEEFP9*>WG1*?RY,(:*65`^HU`#ADCQE
M*`TO!A!Q1HF3J'9:O8EIYVR5PKDD.<&R,,Z)C:E#V9)FP2MYP-Z(6,YR1J++
MP%4,`LH7,83L\H0/('R<<^35R</74F*E:%^<MO-3EMR\;174>5.P$2H;6E<G
M5\0-REQ"09E$0O7I1N2E$B.4X"$TXM,H&6#.1!+'G&`YF3J,;:&EE13&K[/7
M45@W;ZR,S1;\3JA8N5^DDG4+F25VAM\G&X4(&]()M+1ND)96>#C:,.1BE.-4
MZJ1EX*+RD$$]DZEPMH6PO<!L^7+VYL8*%L>2K'*6'0\KJA/$RT73CGS;,P1E
MT2NSS;#2SOD9G2O=Q"S6=R;%"Y&>D6'GFC(*($(3)U&"H;;UE7&W^U(.Q3MD
MK036A>P+BS&A^,/)>F5T9W1<Q/K(ZA:I`[M`W!E>VQ0E-,1K%:(T9.1ISSB1
M`-$R=1A;0N,(VR5PSQ5F;)9&&=]D*1.86Z.Q:MY$!:>)0<8`P.352<S.`D#`
M'R@#^KJNYSH]"*U1JM2*Y?$ZSCEHND`Q5]<H&=-2D@M=-,I1-9"S-K>9&I,S
M,CT7*`]".2M#`WM[SA9E6%2;D6"!A,P0']KB9.I<+8]#`#Y;0D8C].K+!V]R
M%I?;3KU_LE>ACY@ER&%1B+R^IH6[.[V1+)#")H:2<NN=E4IT*=E.>\)A'%G(
M2E96$QC)U&%NNA\*WLK:W9<OAD004#/X^9/'%"UQY\D88F%D-4N\!L>R6+*K
M#!:L@>TI3U&:F?A%9RBSDHY%@M1@G)Q&3&3J'8E[&S3IMDKA3*HHYM\89TD>
M;$\C+D32)6\X&[GKTZ`MD,!@*H9><-IY!PL\H8.'.>3E?T7)P]=28J5IH95]
M.]+]@6O\2Z^<-,G48VT'T[TOV!:_Q+KYPTR=1C;0?3O2_8%K_$NOG#3)U&-M
M#4\E]H,[<1/*2]SA937`:J?9\LDBDR4(G%Y=XNOCP7YL8&I<!*VN#`G;90E"
M0Y87XPH<251&"@ED!/.F3J7"V%H1Z7?6T\\Z(HDNV^TU3M,>H,HFDD$"Y]O!
M+E^VEJAXW->;<Y3'_P#TKGNPB1)($JM48EYQ28L"F))`8:R=1A;1&V]95QM_
MM2#L4[9*T$UH7L"XLQH?C#R7IE=&=T7,3ZR.H6J0.[0-P97ML4)33$:Q6B-&
M3D:<\XD0#1,G486T,[^G>E^P+7^)=?.&KDZDQMH/IWI?L"U_B77SAIDZC&VA
MBKAMDK@^8QEV11AG3QEN9I4D?F7*MYP8Z.CF?&AQY:`.%0B\A:26]>$7*&#.
M.E8X8%Y>2R<.HQ4^FAE7T[TOV!:_Q+KYPTR=1C;0?3O2_8%K_$NOG#3)U&-M
M!].]+]@6O\2Z^<-,G48VT-6MS)E14`5"C$%)LTNZ_5NKG)<B?GU#Z)5]%SV`
MF7SIQ*1`=51,;CF9*DZ>Y&%@0-@3@#4C"$8>,R=2JRU^Q9YS8FU>`RZ=0]UH
MN;KU<&E[?`#')G+CJEJD<S<HC3DX)86'I5F(71,,N/7<TF#5NJ5L;\&$*2L*
M,F=&"I9.HP5#.:2-VWWDY25H9J5DD1<HNQQR1K$LT$S@RL:9+++-@R4]O.B4
M_ER80T4LJ!]1J`'#)'C*4!I>#"#BC1,G4.RU>QL)].]+]@6O\2Z^<-7)U)C;
M0?3O2_8%K_$NOG#3)U&-M#$G;:_6BN71!W0Q1D3,3.FDI3\V#4.^3W,YS3-Y
M3.81G"D8<80')S1#XC!Y!XX<K^ADX>HQ4K30N,GI>B(E&I#*G2`MW5D98W:0
M./-K511G0&9`H<EG-FKWI$A+'T=,+@(XXDK&?*,8`\18F3J7&VAKP"9[/T,3
MA<GEU?O$+/F[?;BYNC3S'I@IDZ3-'M\K=K!3.K&T&KW5H4HVN$N1Z8E:0F5'
M"(PE&24O&%'IDZC!4)7K.([9K:;W)QB,%-P6TJDJ1<F?VF61MP*&L0DKB3`H
M'DU&I-2BYP9/.A#DO)Y!H,9SR,YTR=1@E[&13G;)7#S#I*TQ*,,[#)G%F7I&
M%Z-5O(2VMT/(&!&M&(I4H,P%.=G`L\D`\^3]&=57.5/H1VJ'"U,J^G>E^P+7
M^)=?.&F3J,;:&NKF;MZ:)UZ`K*1>,.94Y-ABQ62M0'(D9&55(MK?(QA#+L+#
MVQR<]P4="$LHH:@D@2HPX!8B`E&S)U+@J&.+[*V-H%+BDS'7%:<T.<J:G++3
M#;%=TR0Z'1HZ:NZ@2YN3J4!C>*%D9=2%`#1E')<"QC//%FDELG48*AM;].]+
M]@6O\2Z^<-7)U)C;0Q5KVR5PFE4K<W",,ZN/.:>.%QUI"K><C:#T"=>6]F#P
M)4`O&'(\\D6.2,?'F_+R?Z63A:ZC%2]-"GF%4TA#S8@6?5I3D"6S-KAH3D*T
M\`&<YV1N:A,ZN(5CVF--;PJ&\*<04P3S\&*`"YOFPF#!,G4N%M",$ANV(IMC
M*N3U>XQ9=*7:3-*!M,1/4DP7Z*3=A@+F[*'6(.+\S%L&'V3H.2NR?A/S1^1Y
M%C`!YPR=1A;0NE1$[3KN":."0I:8$MH0/Q?I#')Q%!K&IR./*3JD)<APWF*P
MA"648;@&,B)`I)Y>`B'R<,G4.Q+V)#F^V2N'B*O+9$XPSL4A5IRRVMV,5O(0
M(CPJ"3!F"R4J4&8P(@`P^0`OUM57.=7H1VJ-%J95].]+]@6O\2Z^<-,G48VT
M'T[TOV!:_P`2Z^<-,G48VT'T[TOV!:_Q+KYPTR=1C;0ARU6?;!4+G6[))X6T
M]<6E-V"$1AM`[91J3U+[(H_%LN80NC\AZ:D;7F5MQ1Q*7GUHLJP"+)&`)HBY
MDZEPMH8&?-=F!3D4SE0B1KG52(WH;>@@5EJ3UQ7I,QP9O6)<A2X*,;GN>R)*
MR(E6183G+Q#^W@@HTX#)U&"H;$L%)T#*&)EDK##6AQ8Y$TMSZS.!9SV66N:7
M9&2O;EA9:A82>6!4C4`'@(P!'C`N&<8SQQIDZDQMH7;Z=Z7[`M?XEU\X:N3J
M,;:#Z=Z7[`M?XEU\X:9.HQMH8E/=L%:/\+E#)&(HR,TB=61P0LKJI4.^4[>X
MJ$XRTJL[`%*D62R#18%G@6//#'Z,Z*YIJ?0.U0X6IEOT[TOV!:_Q+KYPTR=1
MC;0U@8)9M(=48USO7+G$B%-X-%$QSKQO>3C)@_RGJC$*E<:)9G5T/<*[F)CV
M0%"]8!A",/+.R/"4.5&IDZEP5#,JB)VG7<$T<$A2TP);0@?B_2&.3B*#6-3D
M<>4G5(2Y#AO,5A"$LHPW`,9$2!23R\!$/DX9.H=B7L3*LVYTZ:D5%)H,U$J3
M$YY:<[*IVX%'C*$$HS/!>+/`LS.,_HS^C5R=28VT+-$-M%8M43B[7)8FT/,C
M;8ZR(']W+5O`@.KVC;4R=U<@",5DF9`N7%F&XR(`,\!>4.,^31W.7'H%:H4K
M4A:S#=O57/CTQ/%(O#DH9T3"[`.9UJ`PMR9'2(V[.'-S1%K9<B4?_I&&D7T(
MDXP!4J%82"R@9*-R>"9.I<%0^4BDNS*,RUV@RZ++5LI9I#&8PK:V*+3V0"&Z
M3!<>SQ\"=2SEK49I2R0(U#<//.8$G6$9`<$L(R1FLG48*A.46IN@)G&(Y,&"
M$-ZEBE;"T21E4G9?49RAI?6].Z-IYJ14L*5)334:H`A%F`"8#.>2+&,XSC3)
MU)C;0HA;9*XS-R'@,89\1,$55-AK%TMYYP<A,=T:I.[X#TKFN04VE&D\><Y7
M$?ZO#RXN3CUU&*GTT*>Q*HI&O()+9XJJPIZ10Y@<Y(X-K6M/+<#VQF2F+W,Q
M,)R>T*,0TJ`@P[(1&X$,)>0@P(>0AS,G4N-M".'8K;5&")6JEU5.;&GC,Z=(
M(0:C1O$LS(5C7"E]@G+V9/#W-\5C3AB[4I.-*-+*4I3"<E'%@,^SIDZC"VA]
M8&9M&LB7.$+BL/5GN[>X2EL$H<8W.F9F6K8<YY:7HIK>74"1O<N"PE1S&21B
MPH*2G&E\HL.!B9.HP5"8WC;?4BII=$K9"FE$Y*6Y:G;U@E3O@*1:<F-+2*19
M"N&+&"#Q!%G@'.?)^C.KDZDQMH4\<VV56WQYA0/D/:7-Z1,S6D>'("IXR!P=
M$R$@EP6AR-84/(5:L`S,<0ASP%Y<8_1H[G/J%:J%Y^G>E^P+7^)=?.&F3J,;
M:#Z=Z7[`M?XEU\X:9.HQMH0Y>S/M@V]UZXV+.X6TDM:,W*9*DP[9;U#JM+0+
MW@]&C5/3\V-8%!#*T+%>0FGEB,+2C`5@PX190YDZEPM?L8G-Y+LRKR22&*2B
M)N:=XC)CN6Y%-\-L=Z(,]'*_9K2E`FQ2SI%I+L&,021(%ZW";)@BP*P@#@9@
M#0%LG48*A-,0J/;_`#=B)D+'`D^$1C@^-)I+B4_MB]&[1E]<HR_-RU"L6%GD
M*6Q]:%*<?DR`0BLB`(0,A%EDZC&VADWT[TOV!:_Q+KYPU<G4F-M!].]+]@6O
M\2Z^<-,G48VT,;F>V2KGJ'RMGC\096I^=HV^MC(YGJ7?)#<[KVM4E;5YV`JS
MQ9*1K30&"X`'G@']7/Z-%<Y6H=JAPM3_U??QH!H!H#&Y5#8A.VD3#-XK&YDQ
MB4$JQ,LJ8VN0M(E2;E93J1-SNE6(\J",CSR!\CE!XYX9QQT!;'*LJW>7L$F>
M*^A#M(RTZ)(7('**,*Y[+2MI@SFY,!U5(#5X4Z`TP0B08,Y)0A9R'&,YSH"]
MM,8C3">H5,<>8V92K3$(E:AI:4#<>J1I7%Z>$R10<C3DF')D[O)'%466+.0`
M4KU)N,8&>:(0%\T`T!BB""0=J7L[JUPV*-KI'8\GB,?<D$>:$:]BBB3'!+&&
M=8G1EJ&R/)L8X%HB!`3`Q^@&-`6=HJ&IX^400PUA7C(2F79=$Q+1"HTVE)W+
M+C%GC+B06C;"0%+LN\&9%7/!Q@SI+.A-X\M(0(L#-6UK;&9(!O:&Y"U("S5)
MY:)M2)T*0!RU4<N6'`3)2RB0FJUJDPXT6`\3#3!#%Q$+.<@5V@,9D$+ATM)6
MII5$XS)D[BTGL#@1(&%K>25[$J4IUJEE6E.252!4TJ%B,HX:8>!$C-*`+(<B
M"'.`,-6494:^35U*U-?Q8;G4K-)6.N",,K<!GAJ65O,(?W54P,@4V&MK=@.E
M>M9B9824!2DYHS!(P8.-P()9EJ&"0=L4(%;;#8HWJFHU,<UJ4,>:$BAM.1-K
MRRHS4!R=&68C-2,\C<$A0B\AR6F7J"@\`'FA$!E>@&@&@&@+$ZQIB>NFC<6M
M$<J7L3C&E#CA.46Z]1.O(RX-9+F`&%Q")286`P18!X#DP`1\.4'&<`83#Z0J
M*!QV-1:+5O"VQGB*1"D822XVSC/19;UD6<R5O2QHQ*370QX@[,N-5"%D\Y>U
MI%`QY.3E#`$LD5M:VQF2`;VAN0M2`LU2>6B;4B="D`<M5'+EAP$R4LHD)JM:
MI,.-%@/$PTP0Q<1"SG(%=H!H!H!H!H!H#&9)"X=,>J?2Z)QF5=0N9+TQ^DC"
MUOG4SPF__'=FGK-*JZN<R/\`8/)Y!H?Z!8T!B3=254MLML"=EP2-JY?9[PTO
M4SD#HTH75T=%#''8+&6E'A8O(4*$K.A0UNSG%HRQ!3!7),*L`P>(1F0DS=IC
M$:83U"ICCS&S*5:8A$K4-+2@;CU2-*XO3PF2*#D:<DPY,G=Y(XJBRQ9R`"E>
MI-QC`SS1"`OF@&@&@/BI3)UB<](K()5)%1)J94E4E`/3J4YX!%'D'D&A$6<2
M<6+(1!%C(1!SG&<<-`87[KJSR0PI<UW!<IHLA>6N,)_1&/\`,1QLD:,]ND+<
MPE=7\VT(7YO4F$+24^"RU1)@@&X$$6<9`R=N969GY[JEI;&OI'-](ZN0)4//
M\SR^:Y[HQ17.\USHN3RN/)Y6>'Z<Z`N>@&@,<50^)+G1&]K8M'%CTWN9CT@=
MU3(V*'1"\FMJ1F-=D:\Y*-6F<S&=`0D$>`83<IB2RLBY``AP!:4U85JCZ;T.
MO(,DZR4N2UQZ-$F`CIZQY;CFAX5K>:;P]*4NK2I,2J3#.4,].8(L>1`%D.0,
MYT`T!1+FUO<RRR7)`B<"B3@*22ER4A664H+",)9Y8#P&!`<`)@L8'C&!8P+/
M#/ET!'J6E:B0G1`QOK6%-Q4``YAA+<W1UL0,D6.=W:/OBY>R,"-.2R(';+O%
MT*@I86GPK3&$YR28#G#>6$F9M,8C3!R.HH\QLO-I@HB^J6E`V\VC!S?(2`Z&
MG)Y"8',@X%X^QCD8\GDQH"^:`:`:`:`IE:)&O*`0O2)EI!:E$M`2K(*4E`6-
MJPAQ;E8"S@#`%2@<$I1Y!F,<LHXL(PYP(.,X`P:,U-64.2Y21J"19J+&YJ'H
MXTIF1G+E3PK<FAX4.RQR5%'N"US,=(\W'\^<:,W!C>ES@6.CD\@),Y1(D;:C
M2-S<D3(&]`F(1($"(@I*C1(TI0"$J1(E(`60F3)B"P@++`$(``#C&,8QC0%3
MH!H!H!H#",5G6^"R"L5]",%)9<&?I2\11AP6FG@!@,!-B`80<DF7`,+"+#D'
M@LP+&,\YQQH"]M,8C3!R.HH\QLO-I@HB^J6E`V\VC!S?(2`Z&G)Y"8',@X%X
M^QCD8\GDQH"^:`:`QQYA\2D9F#9#%HX^FA.:%(3'ED;'0P*A@4KEC"?@:Y*>
M+!S(K<U)J07ZR8Q0:(O(1&"SD"C#7L!"\+I"&#Q`+^YK6UR<GP,:9</#@XLY
M_2FA>N<L(NFJUK4I_:)C3!B&09]H&0Y\N@,F1(D;:C2-S<D3(&]`F(1($"(@
MI*C1(TI0"$J1(E(`60F3)B"P@++`$(``#C&,8QC0%3H"F6HD;DC5MSBD3+V]
M>F/1+T"T@I4C6HU10R%216E/`80I3*2#!`,+&$0!@%G&<9QG0$;+Z0IYR2A0
M+*Q@PVW,L<)VK:BHTU)6AWF#JT/;$Y2*0M*5,2VR1S7-LB6!,,<"E/*--P=G
M]L668`),V21B-(%@W%!'F-$X&*5JT:](TH$RP:QR-//<58U1*<!XE*\]4:,\
MS(N6:,P619SD6>(%\T`T`T`T!3+42-R1JVYQ2)E[>O3'HEZ!:04J1K4:HH9"
MI(K2G@,(4IE)!@@&%C"(`P"SC.,XSH#!BZFK(N0RV6"@D64R6=*4RJ6OK@S(
MG)S>QI(F1!4Q"I6X%*30-Y42)RAPE+R!-S)ZCB7RE*@1H&<I$2-`4,A`D3(B
M#%*U:,E(04F*&L<EA[BXJQED@``2E>X*C3SS,XY9IQ@ABSD0LYR!4Z`:`:`_
M_];W\:`:`Y-S6F=Y&U#<+=-][/H5`-R-0[DI&R3^X-L,NG*2GY]&;9:XLTPU
MRL*G+*=FQRABQ%,6*/(1N[4_='_XU*`290`!P\D0UHU#]2N7;Y][S8J,1+/"
M-W$C4DX*YT3;?>V%Y0\HTDL[&"'-KL%4A58"$S&,Y`//)%C(18"+&0X=!"\B
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M%9&'!HR[DVWFF`+R+'+$64*?$A,&$/'.`Y&#&<^3CC].D\ABO(F2A_$5I>XK
M,34+-8G;6V+<6L;3G1IH[<M"LUW*YD@1!,RY.-8OA#B]0>SVY'E.:/E,KHJ4
MY3DF'"(``LW)=(U[^QB=A^)I6*&QY53.W.H;VWI6I!7$QCG[9MRB+6Z5_6TA
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MBO(C:R8]O*\0Z1T)7-J[.%&U#;5`KMKN^K9DEIW+6D[GEB%U*\*9#&ZJB$#J
MUT?S6=)(Y*E2=:.+LJ1"`W8-Z.#G,%Y-#13KJ5-,QCQ!_#UBZ/;K!-NK)OJV
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MV`L!,-P58!C/()"8`1@N`<9XYTGD,5Y&Q&W7?U0.XQVF4+1&S:F[AK9LP]V/
M0^X:)J*EMV%L.21'YD;A'WA4H:GF+%D@Y0W9G7N386'(!"48"85D=(TT:_F^
M*6TV2J>BMFFU'<SO086)>I;%%KUQ'XO`J'<G)O5A2.C=%K7M>2Q)!-5;<9@?
M+$SI%Z7/`&<'9+,"/4DN-7!2?7MO5_*+W+]]&W'VYTGD,5Y#Z]MZOY1>Y?OH
MVX^W.D\ABO(?7MO5_*+W+]]&W'VYTGD,5Y#Z]MZOY1>Y?OHVX^W.D\ABO(?7
MMO5_*+W+]]&W'VYTGD,5Y#Z]MZOY1>Y?OHVX^W.D\ABO(?7MO5_*+W+]]&W'
MVYTGD,5Y#Z]MZOY1>Y?OHVX^W.D\ABO(JD6^K>TO5$(R/"-W'`-4#P66-;>N
MV1N2A%G&<\3USA8*5$F!Y/UC#`!_\=.@A>10PZI-Y6[;<'1]X[NJX@NV*F-M
M4A=K'JS;;'+'27%94PN5QBKO#&N=VW8$;1-\`;F2$,<B7&-#8RY5&Y6JC>E*
M#2@@P()232]3_]?W\:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`TRWV;,8;O
MCH=UJ9\>QP";-SFU2VH+I:6DQRF-+V,PKTJ]HF\0&D>8TZ$K0!3B3*2T[DA$
MH2G#!SH!<@814X9+^W';_7.UVE:]HNJV-O8XC7\<;64GH2(I&>^N:=*2!XE3
MV(`C35\CD[B$Q:O4G&&G'J3A"&,6?+H&Y<LF[0@T`T`T`T`T`T`T`T`T`T`T
M`T`T`T`T`T`T`T`T`T`T`T`T`T!H5XANPN&;_J3(K1TE:JJK`CLC:I'7%V1]
MDZVF->F]+)13-`T=&>XRO.;)U"#US0L3=8%)1"4$J32CQ)2BLBIP;<5;5\"I
M6NX=5%7QAKAM?P%A0QN*QIF3%I4#8UH"^0`.`@Q@1ZM4;D1ZE09D1ZI288<:
M(9I@Q9$]3/=`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`<[?$!\.:LM
M_C35*>5/RJOY)6T\;W%=-8ZVJS)/+:==BU+;;=#K75JD47<D40M>/JLIE1G2
M#P)3BP'=&/QSA1B"JZ#?F.QR/Q!A9HK%&1IC49CK8B96"/,+>D:65D:&U.6D
M;VMJ;$)1")O;T24H)91)0`EE@#C`<8QC0A>=`-`-`-`-`-`-`-`-`-`?_]#W
M\:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`XK>(-0^_P`E=R.$VVA.4F''/=[4
M4X2MB:SVB,LZNXJBGE@0]T@1[%()G'TX6:TJ<OA6YK#<%EMV7&!-XSSL*L)2
MSIJ:41J6MZ:_%_KP4[K^KFADDM<P8J!P.JY$I=:<<Y?(H#'<PMD)FL6?+"EH
M7(^R5C$!P/E!$Y2G(U2H!AC6<$99(%[4;??U,OVG0[Q-H=,MTY=JLL10(K':
M)%85*O#I(8DJK]OOAUC$':7?,Z:6:2V!8\?@2EX3A.CS6S&*4R9*WNX'`>#U
M#6<>#C2#:WP^H#N3K*A7>&[J'9^D%D-MVWL>S2&36H;<+R_5FY6?(W&MG,Z7
M'MS2:!";%51`$"(:1":E;P$8-1-QN3&Y)2./8WAT(-`-`-`-`-`-`-`-`-`-
M`-`-`-`-`-`-`-`-`-`-`-`-`:$>(!4-^6U!JM1;=WF2,LI2V@IB\[4QN;!A
M*M'35Q5E8E*6'+"E9[VRIEKQ5(;`13-K`#)Z\+G'",HBC%'(+&*H]S1ZGX1X
MNU6PC;XB)0L3U*I;)I+(=QHYC*8)+4#`\L[]7E<Q-N?1.4[.<$U8R*FX8J><
M9@ZP]Y12-QZ2I3'X*/;E\U*\=2PU]&?&&77KMXMRSXD4!K86>8P&ZFYLD-"H
MWHB"S2R=I[VZE1-G;9XX5_(%R5QC,K5-SDJ1HW5'!DBUOR(R0F-ZIU:EVPS>
M:H*^WFM&_F][$MIX3NFV6752D;*H;H_;#LZQ"*O+'/C$T?:@U$YL3%ACG3M"
M"S')_>087%F*U04I*]00$I.AIG2.9T0T(-`-`-`-`-`-`-`-`-`-`-`-`-`-
M`-`-`-`<H/$,I'>'8%@UG)]K+I*BV0JM;)!8S>P6*VP[/IQ4[M$;RVY-R5M?
MI7'FEP3V=8L050]Z-Y/-@:GO(EIP$)9N!1FK8]R!F9@\8^K8TFA4*9XS+D,>
MHZMC$[L^2"KWI3)+-?6:#/EY82OLPF.).V6BSV`MEQ,<ZR`Y04UIZJ*.$`83
MS@M1M)*VB1'Q)8[NUDLOW%,(<4G9T+CQLJ<&A[JG*Q/9T2JR"L3$N>XLBFLG
M''HP<-O>"%P(ID`E4I-*4Y)PSBY10.(T*-WIO>2SQIFAB!MW/R)Z-WU6)*VB
MVF;=`UG*ZWVLI+.B,M93Y#')1?T506GB=Q=C$R-$<=4+NA8$2UQ.4(",A);W
4$-#LUJF1H!H!H!H!H!H!H!H#_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g893535g87n98.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g893535g87n98.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0YF4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@`````````````!1````14````&`&<`.``W
M`&X`.0`X`````0`````````````````````````!``````````````$5```!
M1``````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"\H````!````8````'``
M``$@``!^````"ZX`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!P`&`#`2(``A$!`Q$!_]T`!``&_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#T)O0VL9M;G9H&[>";RXC]YLV!_P"C=^X[_K:3^A[ML9^8R`6N+;M7
M#>^YNXEOYGJ[/^*].I::A=8:F;@QUFK1M8)/N(;NUCVLG>])32R>D#(R'7_;
M,NHN(/IU7%K!`:V&UQ^=L3.Z."'C[9E@O+2"+8+0TEVQAV_1>YWZ3]_^HC,S
MW.+`<6]N\Q[FC3Z.KX>=OTDW[1>-#B7ET"=K01,Q`<7-W)*8NZ5,C[7E"9XM
M[$[MOT?S?HM?_.?RU#]C@U,K.;ERSU-MGK'?^D'YVFVSTO\``^HW]&KU3_4K
M99!;O:';3$B1,':7-0L]K78=P=MV["3ZCBUD#W?I'L]VS]Y)2`])!>U_VS*]
MIG:+2`>-':?R5%_1@]K0[-R_:7&1;!]PV_FM_-_,_<3XV/F4.>14"YX`+WY%
ME@T-KQ#+*_:W=9_7V?\`%(S;>HEH)QZP[@M]4^>O\TDIEA8GV2GTO6MOUDV7
M.WOX#?I0W]U6%6>_J&YNRFHMGWS8Z8C\W]%^:](6=0#F@TU%OYSO4(\/S/2=
M_+_/24V4D!K\W?[ZJPPD:AY)`ETZ;!^;L1TE/__0]1;D8[F![;6%CA+7!P((
M\04_K4[BW>W<!)$B8\51_P`DF`[$U,:'&<>0UD:5'\VW8_\`<_2?N6).NZ<Y
MGNQ'NVDEK3C/.HT#F_H]K=R2FV^U[ZYQ'5V.U'N=[=);RS?^>%6NS[\*+.H-
M8S%+@TWUDD,)_/R`\-].G?[/5_,_POIUH(K-VZMW3Z\;'O;+_4VFYSP98WT,
M7>SV_3]?[7OJ?_@_\)7S^=D.N'V?`ZVX4R]N0VIPR8],M'H,K98>J^I;[JW.
M9=;]"S])5[$E.[7G8G2LN[`ML'IV$WXM;!+AN,Y./LKW/_1W/^T>[_!Y7I_X
M!-U'K#7]/RFLQ<AP--@W%H:-6G7WOW?]%<_T'J]V5<_IV+C58SL4;WWMJ-36
M5:5LVTW^I?ZMG\U[;/\`K]:V,@L%99EY5KF7`L(@-:08:6AK&/?[M_[Z2G1_
M;6.UQ;=3?3!B75DC_P`"]1+%ZF>HGU>FFNW%8\L=:XGWP6!S\?T]_P"C;^GK
MW/\`YRVOV?HOTJSK6W9>.11EO=7>W1KX:'@GW,]>MC;J&W-_1/?L]1BPLGJE
M>4U]199TK)I#JOM+&_9S6ZN:_3KO%GV9]6GH?I?T?]3Z:2GM+.H8['.:T.M]
M-VRXU#>*W0Q^VW;]#]':VS^HHMZENK;9]ER!N$[37#AJ&[7-GZ7N7.]%ZK<[
MT^CX6;A.R*F;KG,+'MVNW/#L#'JL]7)N=#OM?KW_`*&S]+^L_G](,;?8+J\F
MT`3+`06DG]YKF^W8DI0SMTQCWR`#!9$SMT]Q#?SE%O40YT#&R`.`XUD#D-_.
M]WYWYR!7=B8]M(&;=8TM]@=-C'M>'/8_U17[_P"19ZG_``:T:[&65ML8=S'@
M.:?$'4)*?__1]54+;-@@:O=HT?Q_JM4USGU@RG7&OI[8VY;2_*UAPQFG;Z(;
M_P!W;?T-G_`?:$E.1U7*S/K$Y]&-DOQ.B?1LR:M+\S]\8[_\!T[\SU?^U/\`
M@_4I52KZI_5NMH`Z?6_:(#K'/<[3^5O_`.I6OS^01H`!X!.`BI#BXU6$0<3=
M3$P`YSQ!Y&VXV_25IN=FB=*7>!VO8?[6RQS4.$\)*9/RLVP.:;&T[A&ZAIWC
MS;=>ZW;_`-MJKC]*Z=0S95C5[29)L'JN)\76Y/JV._SU9`4PDIQNH?5'H>:T
MN;0,._Z3,C%_1N:[L_TV;:G?YN__`(12Z+U/(/4Z_J_]:HR,D#=TW*>7"C+#
M3[6Y%$BJW,9_@W7M_P"M_:/3MR=GLL_K'2Z>IXKJ'M_3-#CB6@[7UW1^@NJL
M_,>VYE22GLZG,=6"P0T:;>(C\W^RIK%^JW5G=6Z/A=1L`%N75^G`$`75DTWP
M/S?TE=BVD%/_TO4KC%3R/W3^1<KU$@_6&]OYPPL;_--F7_WY=8X;FD>(A<EU
M8^E]8<:QQ`9FX1J;/)?C6^KM_K;,U)21K)1!4GJ$JRVN45-4UJ.R%<-2&ZM)
M36VIT4L4"U)3&5!SD[M%$27`#4D@`)(9?49IJZ;=CCZ./U+-J;\!:_\`\DNJ
M7-?4BMW[$Q[W#7,NR<R?Y-UMKZ7?VJG5N72H)?_3]56%]9,%]V*;J:S;DX3_
M`+70QOTWM`<S+QJ]/YS(QGW5U?\`#>@MU#MKWM$:/;JTI*>9Q,AEK&O8X/:X
M-<Q[?HN:X"RJYG_!W5N]1BT*WB%B=6Q,GHM[L_#J==TISG.RL1GT\=SW>I==
M0W\[&?:Y][J_\!;;=_@+_P!#;Q<VG(I;?0\65/$M>WC_`,Q=_614Z9(47`%5
MVW(C;0DI?TY2=5`E3:\)K;`&I*:%VA5#J`NNJ;A8W])SW?9J3^[O!];)_P#0
M/'];+_ZRRO\`PB/U#.Q\1GJWN,..RMC1+['GZ-5%8]UECEH]$Z9DL><S,:&9
MMK-@K:=PHJ<=[Z]_YV1<]M?K?X/]#37_`()]EJ4ZV!C58]+*J6[**&-HH;X,
MK&QH_P"BK29K0T!HT`T`3H*?_]3U51+V-(#G`$R0"?#E20;\3&R"TWUMLV26
M[M8D;3_T4E+O:RQY#'`6LB8U(GC>U<WG?5=E5UF7TAPP,IWOMH,G&M/YSW5L
M_F'N_P!)5_VTMW]D]-'&-6#L%0=M!.QHVUL]P=[:VGV;EEOS;V-=@Y,-RB-M
M5K0&UW4C1U^.V?9L^CDT._F/_"SZK$E.2WJ-3*B[(L9396\UVTN>"[?#;&^@
MX?TECZK&/;[*7_OUJ5?5L%_T<AFFAEVWC_C-BGT;%JMR[,L!H?EV%Q>TEQ])
MGLK_`$A_?;5^8NA=TS"R@;+L>BS<3].ECR>TRX(J>7M^LG2:7FI^6PV-@.8P
M[R"?H_S>[=O_`#=B3<OKG4FC]F8+Z:S,YF>#16T>+:7?K%[OZE?I_P#"+H[^
MC-I+,OI[*ZLO'#A6UC&UML8Z'78EKF#VUW[&?I/\!<RJ[_24VEHSL%S6V/;:
MVR!(MK?N:3IM/M=7N_-_1H*:/2/J[7B7?:[K79N<06G-N`;M:?S,/''LH9_T
M_P#A%N,8UC=K?GXD^:DDDI22222G_]7U5)"?7:XDMM+`>``TQ]X3>E?/\^Z-
M.6M_\BDI?(>&UQ,%YV@S'/\`YBN9ZQGT^G8YMM;2/T5)=#@'.]CG-;]+<VK>
MNE%5\0;R3X[6_P!R3<<[IL?Z@_=+6_P:DIQNDL:UCG,<"VIH8-L1/EM6ZQNU
MC6_N@#[E$8]#3+:V`S,AH&J(DI22222E))))*4DDDDI__]DX0DE-!"$`````
M`%4````!`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````3
M`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``-@`N`#`````!`#A"
M24T$!@``````!P`(``$``0$`_^X`#D%D;V)E`&1``````?_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@!1`$5`P$1
M``(1`0,1`?_=``0`(__$`*@``0``!P$!`0`````````````$!08'"`D*`P(!
M`0$!`0$!`````````````````0(#!!```00"`00!`P,#`@,&!`$-`0(#!`41
M!@<`(1((,4$B$U$4"6$R%7$6@4(CD:%2)!<*L6(S)<'1&')#1#6U=K8W>!DY
M$0$!``(!`@4"!00"`04``````1$"(3%!46%Q$@,B,O"!D:&QT4)2$^$C4\&"
M,T-C_]H`#`,!``(1`Q$`/P#=;+]J_P"2SCFLU??Y&I5NW:;07'\E]MK49U?)
M^Z;COU7Q;["7%1I4;F;C2LT+36-=I](TEAQ.H_X;9+-^VJH[<A8;42T9RWC5
M>OD'^1+W3<7O5KQ%Q1QQ*U?4X_LWNM'*W/AKG!<[>N/^(N=>`^.>,JVJ99WO
M6)=7LG(NB\O3;E,YV(\S(36?FCP0P'$AE/;.Z?U'\B'ME#YOX%X@V/ABMNF[
MOG_DKACFC9J+@_E'7=1L-5HO9;D[@+3>6..=RG\H[1&T](@:97WEO1VD"^81
M"M(KB+AI,^*`,3%N4_X-]O?<+FKUC]H;WE32]=T3D*E]$.+_`&%XLLN+]!Y"
MTZPJ]ZYBXMYQ?M=&77;OM.\2;C;./]QXLC2F%1EL.MM7$>,_&4XT),H62686
M,XB]U/;#2M/]1M-UV/I'*M][/[[_`.D;UQNVY<N<Q;/HW+-;+X-W3<KO:+79
M=']:K)G2Z?UWG[W<2*&OI)3-/>4\-*;V:S+=8;+B<K_^EGOE[5>P._-Z]SAQ
M%K/!,-[E6#J?^VK/B_E-W<H2YFC^P^PVO$\Z97[?LU14;9J+O%-58*W2[8HJ
M&X@NSHC-3&DO5#TXEDBJ_9+G;VOX_P#>"!QUPNW73-.Y"X[]3].@O<@:/N&Z
M\8Z-LG(.]^ZR-YY`_P`?J&RZ/+EW=?!X_P!4;G,KMV&E04LM*+"I#4A`DF&'
MBOY$/?FKJ=HY=<XY@V+&W>F_I#RQJG"/_H%OUK#XYVOD[>MGU'V+Y+C7L??-
M3M]KU[BA]45Z\UB=.B3!#MJ=W_)5$6HN;"W+B+QZ%[V>_.^:Y=W[W$7#6F%G
MDCTTXEHXDS0.5-K=DV'LMMO&^O[?R<^[4\DU5=-T/0J2_L;81(LI:VT/L,2)
MZ1!>DSR8B@-P_D<]P+&NX9TI?"TF):<E\6\C5',UMJO$/*^N-:UMSEC[#Z'J
MG(/$/(SG(=LY0Q8%UQ!!L)M'8TLYZ`S?UR6[U;\AH=#$Y9#W/LK[0\=<=?QT
MZ%I].]L-WSMZ]UT/DK;MEXXWOF'DVIY/;XATQ_6;R[KCOG'4.JHV-FG3IVTW
M%A-O;$+9;956MHD/6,88G*P?"WO5[Y/^NB]ZO:/C[D65Q%ZB>I?)W(M[:\`\
MOZQOFV<H\M<G[?I_,E+(U2JW>/`1.X(T[C6W5LJJ^#'3-N@FQBPH%:^U6MEL
MF?S7RU+W:]H^3]T9T^!K&I\14&SVWMM%XSY$VKU_YJVM/)AXVYEW;C[@O2Z6
ME7NNG1=!W:SXYK*K;K2=?ON,73,E3,"JBH#[L,F)%@^%?Y$?<:'QOP!0;UJU
M/R/OFZ<7>DEQ8;@_Z\<P:C*MKCDK=.:M$]JHVVQ(&R.:S1;=PG9Z;K-;+?":
MB"]=3Y,YJN:@6,"O@ELBJ6/Y"O?>IMO1ROV7UVX^GQ_9/B+B7EO>[:ITKDF@
MUJ',Y9W*%"M>(:C8+O>I\[0>0>%^/K&+;VQEU>SNW<J6B.S`KH[;\ULF)RO-
MQ[[4<\<R^J7"O(?(\-[B[<=F]S>&.(^2K/3]-V/C?7D:M,YCU>K,/1)6Q;QO
M5]L6E;[=R86I)V!3]7(M463_`/\`;:J051F!B9_)CWPK[O\`O93Z39IY,9UG
MD:7QIQ![9\I\L74+U8Y/@<E-;7QERI?:!QUQ=KFAP^7-6U>XF*<N:B_=>_=U
M[3^JQUQ4N)?+EVV7$1>N?R-^]-]IFE;&YP=QW66-%27=QRM63.*N8VE;LO5/
M=+5_6R=!XW:=WUJ5QR=KXUV9>V07+-.T*@F"I*FYD5XR8[)B)KLO\AOO/7ZG
MM%YJ_`VH;9<,>TG)WJ_0UL+B'EEO6XMYM6C3[#U:VYG:SR4JVW;2HV_1(E1R
M#/?H]2=AR;9,9N-7"(J9*)B):K^1'W_L.4.8>+J_UVX^URPUOG#2.&]*M=TT
M#D9J%1L;1[.:%P57;UM42FY.F6>]:=N6@[>_O$6PKF:.!4P81C)?N&U&>@N)
MXH;F;^2CW=XZG<W4FN\!:WLRN._9C_TGK>0X/#O(T_BFDT%.N<AV%).O[^=S
M)JLS9=JVZ^TN+`LY9;UJGTQVVB!'^Y4S:QRP)B<<LQ>1/:'VRHN?_47B[6N'
M-61JOL_INC[#<7=CK>Z;*GB"[T^S9VKV3UW;]JIMCI:!E;G%5M%CZ:[)C0?*
M_CR%NIL6U)A-U,3%N6N/3?Y$_P"1Z)I_#&B:;ZW45EM-GZ;:1R'7V?*^J\I6
M\GD?DV?PKM>YVLV/MEGRQ4WRD:SO5!"H;+7Y$6UNY*I+\U^V@_\`E6)<Y:QK
MSSW7=USWP]ON<=;YJN[3C!/!NK\8;7Z\[/Q98,ZOR+K>U\H1.>/8OC*7ZZZG
M^\VJRCU5M'W?AZ;+H-WKA6?E:NK9L(_Q_@VVX3$X;\^JR=`Z!T#H'0.@=`Z!
MT#H/_]#OXZ!T#H'04G-T+2+/<J'D6QU#69^_ZK37FNZSNLRCK9.U:_0[.]62
M=BIJ:_>C+M*RLO'Z6(N6RRZAM]4=OS!\1T%6=`Z!T#H'0.@=`Z!T#H(*PK:^
MVBK@6L"%9P75L..0["*Q,BN.19#4N,XN/)0XRM<>4PAULD90XA*A@@'H(WH'
M0.@=`Z!T#H(*;6U]DF,FQ@0IZ8<V+91$S8K$I,6PA.!Z%/C!]#@8FQ'1Y-.I
MPMM7=)!Z"-Z!T#H'0.@=`Z!T#H'0.@__T>_CH'0.@=`Z!T#H'0.@=`Z!T#H'
M0.@=!#3)L.NBOSK"7&@0HR"Y)F3'VHL6.V"`7'Y#ZT--(!/RH@=!Z,/LR669
M,9YJ1'D--OL/L.(=9?9=0'&GF76RI#C3B%!25))!!R.@\79\%B5%A/S8C,V<
MIQ,*([)9;E3%-,NR'4Q8ZUAV0IMAAQ:@@'"$*)[`GH(OH'0.@=`Z!T#H'0.@
M=`Z!T#H'0.@=!__2[^.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T%DO8KC*XYBXAV
M7CJBL8-397UCIC[=C8_B,:)&H-YUK9+%P(D4VPQ'I?\`C:AT1VY$*3&=D%"'
MD?B*R"SBL)>6?77V<XYUV/0>N6Z39.A5_+&K<@*JT\A7^I;K(K;FHV^BY`T.
M!1ZGH9U*JU.\W[<F=K>=KWJZ%5LQW&(=2E$2*VY%S.ZYNA>NG/5?SAQQR5OV
M]:]?:QI=/,C-T;NV;7M%Y3.2[OVI,&JA75YJU?*VU-!H_+6G4ANK)YFSMQ02
M)4M`?\#(J9F+&?71#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@_]/OXZ!T#H'0.@PO
MXW][N"=\T_7]LGVEGJHV:5LS];7+I;W;/VNJT=AQVJOW78KC2ZB]H]3URUU3
MF73KAZ19R(C%;'V%M$EQ!CR5-%Q37?Y`?5N]JJ&=.WNSU&TV#4WMTBZCM^F;
M?5[<Q2L1[V<X)-1&I9Z5V:JO6YLUN&PZ_)>@,F2VA;!2LC%57.]R_7NDJ;VZ
MV3>7:2NUA6]+V*>[IO(SE;K[.A;5R9J5HSL$]>EQV:2[D6W$=ZQ%KI/XY=A*
M@J:@)F!R.M\83GD3GU[57=N8U;2Y&T.\>\10.;MX-[:R=%35Z3=_[X;UZ%`B
M3M?MKJ;N-N_QW;9KY$."U#;B*_<R&7EL,O#"2#W-]?(6OTE[L^Z2=0-O)LJE
MZNV+3]]JYU5LE+I=/R!9ZW9QK#5(<J#;.:C?PK"N;?:97=1)D=VO3)0^T5C%
M2"Y]XN$HXI6M;D[9LUI:;MK6HNT2N.>4M=O41[G9M/UJXN:BFO-#C6NU?[4=
MW^F>FQ*YA]]IFUAK<_&W*96L8J=U7N]ZM7NR1-.I.6JZYVJ?!UBQAZ]4Z]N5
MC;R(NX?[)31%J##UQY]4AQSD>C;E,X_-7NV3*):&%E24C%95]$.@=`Z"UO-,
M*XL.,]EB4T:PG+<_PR[JMJ&WWKFWTUB_JI&_4M&S$!EO7EUI#5A%A(9_ZJY3
MS81]Q'0:Y^/N-_>OBO6+:+5,WEI<W>M4ULAR#M.C7+,/<F*/DL5E-<5?*>_[
M1`<>7MIK7-WNJF5`3:4[].U31&9<6W?ZC5PN):2OY$+*1954.N3KR:H2(R-F
MKO\`T0E0=EGP=?\`=&QBS];C6]K:V$?6[C8XG#$!8M($"P2Q)ED-Q_\`[C*8
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MII=6PB?SBQ>\IS?VEBQQ36/5T+_\UWEJ/QU&M36[6YHFP,O>RCE`EA39CE%=
M)81.:_'&F3UCC/DD7LKQ_P"XF]<#R=3T^TW>7NC&]>RNNON:QL7$NJ6F]<6;
M!P?[":UPQ8[7)E.4.O,I7O5[J*'T0#738R@)Q89D1P_''"YE$W[I1N9ZVGN9
M469PM3[99-L[8[`XRDW6WZL^94V0O>JZOL==GTO[-F7&A:^]0Q&Y'YXS[EM%
M=;_$N0.,>:B[:@]L-?T>1&X\U?:FN8Y?(%XUR#R?<;/Q_M%3M^G.'D6?07G&
M>J;;R8_54\&/L#E`/\+90J4UM')FQ(3@?0A\CC\DKOZ?W\G6T"0W96"XD#EZ
MRV-B+23^):"L5J-?RM[`ZQJVMS4+5(L[#CVWXJGZ'>73,IR7?(##_P"U<%B%
MP`.%><3'WC$#=I'(9J7K1KB>;+XZK=HA<<UU>]RZXW8MQ*C<I_'-Q>295`U9
M,M.IDPFX24UDAIE:79;#[\@7"@#QO[5[CM/(6R;;_O)5;5<"<SZAPI#V*SX6
MK-IC[ON.K<9MU5QL#G'4M5+4;P_M#6R0ZZRK)46)$U]N*W)6B2]*<D#AYO1?
M?JIUFLGPJVSM=@KV.14N:Y`LN&&94FMI>:(D'C?5H6Q;'<2Z>E>W/A:@9FR[
MV;"V.7"F6,A*XR7BVS%B\,W>'85O`TN3'NHUA#>5O_+LNLBV;;[$F/JT_EG=
MI^EM-Q9(2_!KT:A)@B)'4EO]O%_&T$("`A-972Z!T#H/_]3OXZ!T#H'02RZI
MZ_8::VH+=E<FJO*R?3V<=N3*A./U]G%=A366YD%^--B+=C/J2'67&W6R?)"D
MJ`("SCOK)P*Y)M93?&6O057>MVVHV<>I_?TM=)U^^9X_CW$+_%5$V%6,NV$7
MBK76G)#;*))9J([?Y/!)22YKSA^LG"=?66E)!U"7$HKRKE4MU0L;CO+=#;5D
MFPFV3<6RI$[**N<*MV>MFN4ZRI=7"2U$AEB*RRRV,U!W?JEZ_;&U?1[GCF#-
MA[2UNC>S5YN=F8K=A/(-QR#L&SR+NLC7;,"UG.W7*NQ284A]M;]2[;/F`N-E
M/B,JVW;AGCKD*Q=M]HI9SUC+UYW4;653;1MFJ+V#5'G9CYUC:4ZI>4C>UZ\R
M]92E,PK(2HS"ID@MH29#WF10&P>H_KQM%K:W=YQS'EV-ZJ`J\<;V+;X,>Y-5
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MU,M^.^V2"`MIU`4.WR.A&+?\=F_;ERIZ)^I7)'(>PV&V;SN_`O'&R[9LUJMM
MRRO;ZVUR%*L;2<MIMIM<F7(<4M92E()/QTB[<6LS>B'0.@=`Z!T#H'0.@=`Z
M!T#H'0.@=`Z#_]7OXZ!T#H'0.@=`Z"CMIW[5--DTT"^LW6K3879**2EK*NWV
M"_LVH!B"TGQ*'7H%I<N4]+^_8,^=^#]G`2^VJ0ZT'$$A6/0.@=!2'(.AZGRG
MHFY\:;Y31MATGD#5K[2]NHI@)BW&M[-5RJ:ZKG_$A:42Z^8XCR20I.<I((!Z
M#7K_`!J<A[=KVK\E^C?,5E.LN:?1N^K.-&-BMOLF\K>O5Q&DSO7+E]@E(3*=
MN=!B(J;4MK?+5U3R0\X'7/$%OCXMG/1#H'04;R+_`/V^WO\`_DW9_P#^"3N@
MPV_BM_\`^;OI!_\`XT<3?_TG7]%O6^K/OHAT#H)';;+0T4_6*NWM(T"PW2\D
M:UJT1]2@[=WT76MAW&15P@E*@J2UK&IV,TA12/PQ'#G(`(32-*:EH<6S^7Q:
MD2(JBZP_'/Y8KRX[W@F0TTIUH.MD)<2"VL=TJ((/01'0.@=`Z!T#H'0.@=`Z
M!T#H/__6[^.@=`Z!T#H'0.@M%N/'%Y;<@Z?R9I^U5VM['K6M[3I-A$V#5W]M
MH+S5-NMM1O9[:84+9=1LZG8:^STN-^TF-35QOPR)"),22HQG(I6&CO\`')K4
MK7[VAG<A?E3:\#[UP.R_'T:!&9>B[=H3VAM\J[+`5?2(VQ<US8TMQ_8;Y'[+
M_<):BMEB&W&3Y3"^Y.E_Q^:["W+:-UUS>?\`#6%G3<GU&F0W->N)-%Q<SR.]
MRV^N+J>EP-]IN.+.@;=Y@GKL*R[H[6)8O,,R&A"E-H?0P>Y*N(>?.-O5[E_5
M?03DQ&Z:==7R=AV#U[Y3WB`:[BKG1[;MLV'>;GBOBK8)FV[I8P;OB!G9XE%%
MIKZ<W;2HL=@QQ(2IEQYY&,SW-D?59:I??N-(]9^7."/Y(M<8>32\3O-<$>W$
M6"TMQR[]4.4MA@M)V^8RREU^:]P)R:_"V%E#:`H5\FR\UAO/4:G,L;$[;ESC
MBF9;>D;;4R@\TV\RBH?_`,TMYIY`<96G_%B6A*'6U!25**4E)!S@CK4EO9B[
M2=V-^X>^'"&INN1EW$)V6TI2##F7E/#FK4/C\5="D6]LI'QDF.",]QUJ?'M6
M+\D[18^S_DQTPK6BAU^=8%(4<1];W2<V2,E+:)4BHHHCJE`C"DK*,@Y(^FO]
M7FG^R^"V.]?R16TO3MMA-<;7CR)FL7T<OMZ?):0V'ZN6UY*,K>65I\0O)/@<
M#Z?3J_ZC_96.'\>'OZCC[TA]4M+L-0LG(VK<$\=4B9Z-4NY+<A%;K\./^9,J
MOMY?[A+R492M,=`.<^(^.LZ_'G67+6^]F^T\V?\`1_R4\235-HM4,U95X)6N
MT.P:REE9[K"SLFMPXGBG/=0D?C!']Q!R+?BK/^SR9*Z=[6<.[HR'JW8$AK*4
MJE,.0[F`%JQ@"7K\NU2E&3_<M+>/K@=^L73:-3?557)OL+PQP]Q1N_-O(7(6
MN4'&O'FOR]DVO8G9[+Z($&*D!N,U"CJ<G3;FSEK;BP8#3:YDV:\U'8;6\XA"
MLWCJW/JZ,-M5UOEC^0KUDH-MYNTQSU@?VG8>9K_C/44+7M.ZQN'^4>`N8."=
M`N.2($AZIBZWR!(U_F)Z_E5L=Y]$?]K'C.*9>=?1&C7$J]^A^I-1Q[S!`Y4H
M-AK(;4*9R,XNFAZBMB8]1[Y>;#?1=+C39&S3M;H=6UR=>-/-JK*2%<27H++;
ME@(!=@.5,\89@=$8Y>Q?LKIGK;#XPG;B(RH_)7*5!QTV[)NZ^D:HH%C#L[2]
MW&6J>%*FUFKU=6IUYAE)?>6XVVC"ECHLF5.2/=;U_C1KQ]=]M+CE`B5*EP(_
M'>^2;6145SG+*+?8:VL8UYR;94%3_P"A.W?DE-(4VZ:8I8_,N97)F#"$XF]T
M>'>4-GH^/_\`+QZ/D?:-GY:I==TX.3[65/J.->2N9M'JKR3,34P6:YW<:/@^
MYN4QG$XKD,_MGGE..PES1A2%A[[<6ZSN-#K.\,Q]7K[O@S:/8(6XO6K:QCZ'
M$C\B;=HRFM1BUK>QV=CMO$G$>R[!-:C-._X5ZN3`49+DAEXC%QE/+7WNX*H=
MJO\`6[]_:Z"/K576/V]Y>ZS84L.'LEON-KIU=H\NNM40[V%L\QRL38-H>BMQ
M_P#%2&Y2G4M!:D#">U_NCP;=R-13KMU<7T;>X^XC3DU^I;B;?;;/3=@XXUV?
M6ZQ4/:ZTJR2)/)L!QYYQV.B,QYO+!8CS788PF[?M5QOL6H7&T\:JL-\,';^*
M./H+2J^WU6LE[IS1`T*VTRMGVVP5+#M5%@TG)=1.NC^U?FU;+RV#$=L4""L8
MY29CVOU_7]UWC0>6*1&BW>FO1HC5G3SK[;-/O[%7%,GF&=40-JG:9J,&-<Q=
M/J;24B,^E"W(U6^\O\22TEP82IOWV]9GXR;"'M]]84_^.DVTC8*[0MWGZY`K
MJW55[U>R;"_BT+M3"3K>F0YME/2MX*CL0'DD%XL-/#%2.%_('P'5ZN;WE&YD
M<76:;O8*QNBN:[89:[*NHMGY3HE[#KTTZ_7C8JI,'A^YF23$:<6PIEN.@/.S
M*X3ABKEK]J..X[L:SEMW#.C6T>:SKVW-T]Z^Y97FO<E0.*-QKY>NBF;LZRKI
M=RV>BB1[(EV-.78/K`:C1#)>&'__U^K#0/8_V:U'5]=V?D33[#=H._Z;;[/K
ME=L[=%JVVS-RT^[K*^SXPTJ+H6J.4C]MRM7;;#>TBLNW6;=3E!<+L7D1EH<A
M1JR=GW-]W.9F)\.V9XCI9%'_`+>OXEK10[E$J-%VVOY1XQU:;=U7*LJ95\>[
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MO0J)UJT>8>D6L5P.O-M>,J+B>(GW,YRTN)N]59\0#DVUI^:>:];C7_\`N>FX
M]J-*U2LYE]A(7&$'E.RVBDU/6M4CWV@<?Z]#HIR),U=BU;Q)DE3KLF(;089<
MU?L"U4<*\D\X\K:M<:3KG'6U<SP+"HI*K8MXV4:EQ+R+M>A-[`*'7Z-^XM9V
MQ1]559M1JV/,1^UDM_B=>3_U#4QSA)^`?=[U']I&D'@/V$XPY'LCY?EU>LV.
M-7;W"\&B\K_*<>WPJ=YJ?%"59_=5[."A8^4+"199UC*?HBP_LCZX\+>U'$VP
M\0\\ZE7[9HMPAN852'E5UOK%Q`\G:S;=4V*,IFRU;9J-TER/.C.-N(!4A?FR
MXZVLLMG,:E.//=KE[TMVV]]5O9/<:OV+UZDHUV_KI[2-VU:OD7?]4C3H=5&X
M[Y=XNI_+:[_D?5?W"6CME<R::]C-F1,?CS$OJ=UKI;<7HSMO,9UZH/D_FSG/
MVFUK9-%_VDF!QUNU):ZU>P]Q0'&[77;Z%(K;."O4Z60Q6L_N($I:`N5+G**5
MX4D$==IIK.KC[MK9RQ?]/_5GFR1H]]P_SY+Y#FQN#]J?XUT:WNK"P9U/D7BR
M#55D[CW9JJ*R\W76#\+6K!JJL/)#JV9T%U"W%+\P)K?;,8Z-;3-]T[_RV):Q
MZGZ+1M-H;IZ]H(`_MCMC&/CX&.GO9]JZ</A?38*0/V<-/CCM^-L?I_0=/?>R
M^V);O'&^G-:1N)1'B!3>J["I/9`^Y-1+(Q@_J.I[KA9)F<,4?X[..-4M_0WU
M&ERF(RY,O@'C9Y\K2@J+KFMPE+)S]23U-=K[9QPUO)[MO5E-:^ONEV:%)-?"
M6%#OEEL@Y^OQ\=:]]C'MC'S>?470:Z)8[2MR%JK-+`FVD[9DV"*!%+7PF%RY
MUC*N0]%370X49E3CSRW4-MH05*(`R->^)[?!J9TC1^;O<;;:+F=JRN-I]0>'
M]Y7=<!ZKR4BPG1.?-SUQ^3`5S!?1W36WTC1:&:A2-:C3GGB]*:7+6@-J4PYC
MZ=[GIJW?^N8GWW]FZ?0_Y%+31'6*;GFDE:TVE:&E7-PZ[,HL$^(<&Y1(2%5Z
M!@K<5;1&V4#"?W)^>FWQSLS-[.*V:\?\R\=\EUD"TU;9*Z4W9,QWX;*YD3SE
MM2@DQW:]YE]Z':L/^0\'(KKR%9'?)QURNMCK-I6MOE3V\Y?]M^0MH]6OXXYT
M%B-K%C(UGV(][+*N;O.)>"I"$E%IHO#L9:A`YBY\;C+"BTRXJFH2ZPN4XXIU
M1BY]&Y).=FP'3?7_`$W7^,M+XWW&?L7,KFI<57'#\W>>7+5>W;UNFI[5"HX>
M[HW&Z?0S_EY.Z?[=B*GK*`7/PI2,)R#4RI3D7U#X9Y#UB?K`JIVE-VL1%59W
M6E+JHNQ3*'/)ZI>OFTV"HV,QJNU/,VSIF?@0T_*9NI3#CICONM+$MBYNI\+<
M8Z)8Q+73-69UB9$1<MJ-+97,"+9)O]BV7;;`W]>Q9(K]E6C9MSMYT55BU*5`
MDVDM<8LF0[YC*2R?7/A>PUO8-3MM"I[FBVBQM[*ZB6H?E+DJN::ZUF1!9E%Y
M,J#41M3V&;4QHC"VX[%9)=CH0$.N^8S41:>OO#MO>V^T2M)AL;+>O+E6NP55
MC=T5U*GF93V$:U%I26=?-8N:J;0QW:^:TM$JN7^4Q7&?W$C\HR3O7WARQ_:.
M2M&K_P!Y7O;++K;>/-N(5_56.X;%JVV[);U&Q0K&/>5-Y:;-I-5.5/C2&IB)
M,%M:'4GRR3*91^$N)8>K7ND0^/\`68>I;))UN=;:_$KVXM8Y/TW7=/U33["'
M'8+8J;#4J'CZC9JWXGX':Y53%=CJ;>90X!E)+/USX8O('["^TB/?I-W%V95A
M?W&Q7E^YLL#4+;0X&R.[-:W$S8GMAK]2O)4./.5*,IA+OFAQ+J4+2,H1KUAX
M"9J+2A;XNUD5%TSLD>VA%J6MJP9W#6;+3=G1)4N6IQS_`#6KW$J$^?+*F7U=
MP3GHN:C8OKKPQ`=E2:W2(M3.DVT2[19T]ML%1;UL^&[M3Z#07%;;1;36H4E_
M?+]R5%KWHT68Y?VBGVW%64TODRFB.$.+T,R8?^TX+E7(B0H@IG5R'*J*(>[S
M^1U2(,13I$27/W2>)\IQ!!D.QH_GE+#8`R__T._CH'0.@=`Z!T#H);,NJ>NE
MU\"PMJV!.MEN-U4*9.BQ9=FXRIA#S=?&?=0],6TN2V%!L**2XD'^X9#7A[8<
M+?Q^<X7<FFYC]?M-Y^Y?KGHKG[3C34A+YQH)*3^6O<M.3]+G:O?<5PUO,)+,
MV[V*BK_RH1_UPL(Z8RLMG2M4]GHWNCQ%)V2/Z3^Y_+FAT&N;<OCZYX0]AYC_
M`+54^D2T4+5_!7K^_P#+G&M/($-A<V'`_8ZY=['7,?F>=%H\J%(A]:FEO2I=
M]9UGZ,`>:??+WFUZ)N6O;AK5EM>S/P'J5_G?@C?]HY2@HF7>O7D/CVYT7B7E
ME"J/1JO8-HI'1-E5T.6Q8-PI:(K1?3'DG4EU[<^,9OMME]W'A4?Z0<V^@W'U
M(O9N5N>K7;_8>YL&6^15\G:YO\SF:WVR4\IIBF&O6-#,V:]E11X1H\:M1,;:
M0EMM'_*.M3?63$O/[IMIO;G'T^71O#XW]E..]AKTS]:XVW^OU\NS(E;LVYUF
MN\?TUE+KI*H4Z+'A;7L=9M[;T*8TZR\'*I)9?8<;6$N(*>KS>[-X]7KR)[77
M.HQ:Y>LZ%`W1<R>B%-C:)N>B;18Z[%7G_P"\WM9L>X<8I%8TH*\Q"D3I'_35
MXM*5XI5/9XYJ2Y\(H:7[465S=KUZD5R'M=NVK#U?Q+H&M7S\=L9\7Y,*1M6R
MV,2,LC)<<0`C_F(3E0W[9)T3-J+B3?;&ZLQ/B:G;5U#(BO,M5?(,[CB@DM/*
M7#,2T-K1;5)O5I\&Y"7(;^O0U)\D*2ZOP*5YS%Y_-.)^@^TUS`D194GAE,&S
MBOPI<.3OF]%Y4>4RIB2PX[4<:36T$M.%)+;V1GLKMGJYU\$Q?%3&@\2<^\):
M+J?&^AZWQJ-+T6@K-;U?7==Y,O)SE91U+"(E=7(G\@4U382RQ&:"?R29+CB@
M,J63GI+K.,5?JMS;R^W>5O9329K*]SXKWN%3-0K)VUN:>@U_DBECRD2V36O0
M9&B[:'XU.Y6ETRE6*HZX;R$H\GTG\I?3>QSAC![`;KN7N'.X[X?F;GK>L>L+
M[T[9?8EJ';7^H;ER9%HY4)5#PW-N:^%L^O:GHFQ/EU^]?;M'Y4N/%5"4F('$
M.2<[:9L\&M=I,W^YG_2>PG$E19:KQ/!U&RK4"@CQ=7BZ50-6_'5;14L5$*!2
MU^SU#<76*QR'"C(;C5GDU)_$&PVR0I`,]MEQ*F<YM6_Y9Y(]6Y?[RAW_`&FI
MTM;S"4K=Y$I[?1:=\R$92Q#V#<:RFU^S?/EX^$:4Z?,%/R".M9L[IC/1SW>W
M?KK['ZQ/Y=7ZF[P=-];+G68,ZWH:;E15AKG-=I9/HL-CA4.JZ[-0YQ^Q$$1R
M%9SV)$"9:I<_&E:V5.?CFVNVUOMX_P#5O7;763W<W^&?7HA[418VE\;ZSZY6
M^S<,4ME7-,U_'&J3G;G1:C8H3]72;[%E<=<H0;BBH:9OD*Q>B.S:YZ!8V4IM
M4XK69$F5T]NMF9$VN\O/,;V=<]J=^UJ=4:_R30:;O5C95[EBV>-)SFC[NJ.W
ML+&O.J;XSY.MFJ>V3"F6U<TI%=M<BYGO2T_LZ=7Y8[;G.ZX]&Y<J*VG^4C@E
M[?Z?A3@34.6O9_GZ;>0JK9N(.*]%MJZVXD@FR5"NK_F_9-[8U;4^*JZE1'>P
MW92T2I3_`.%+31:>3(&6I._9='G#BSDR[NN<+?6=+IMYV;<N&Y^O\!;K;R=2
MF(X4W^-I>ZUG[690[LG]I54U]L-I"F&TJ6;.79N/KB6<9N%7PW%B=N5E*;B/
MW7T+8M@CZ!)U.NUB\Y^W7D!F0N?03'4ZEL_M'RUR?:4]Q$>9K9SM9M/%V^N-
MK=_=3Y%9;J8:8@_]5ZSK!F+T<$5?LY"W_4M?Y5W"YN]?UW@[C_:N3ITZHBQF
M9WL1L%9/I-HU#5MCB:U3T>Q<;UL=AZR+,%3LB#8IB?F?"72TN+<8\V,'KKZX
M>X7"G$FMZ=K]BUJ<LZ]7Q'(:+/CIZ3`Y1J.(O7G2:3<M^@U-2K5;KBR)M>D[
MJ_91Z1QO9KROLJQZ7YV:GY,$6RJIU#C;W#U?EG6KNZV>X?O.53Q9IO+-J(E-
M::U_A>/JVRON6>0JNQUS5D5VE-6%Q4FITFMG/MRW(.YNNO,I=KUQX`S&U7JL
MG0.@=!__T>T^![3Z[&TFBY/W.F=US0-\H9.Z<;.4JMDWK>+GC^MI)FUW.Z[9
MI.NZ:O\`V;55>H-1[%UM$ZR?0);4-Q#=BMJ&Z7"26_O1Z^57^2?5L\Y5?0V/
M(\:ZGR-8W&*R_7\4T7L!:[M;:BX-;D1=RB5$SUMV:,7(SJ(SHBI<:?<,B"W,
M&*J&X]RO7W7K_:-?O=NL*ES1Y)B[G<3=4VAK5]5*KGD77HKU]M`J54=<S87G
M%=U%C%;X+[L=/@"'6RH8JF]E]V.--/V6SH]KUOD/5*^ET74^0[2_VK3;VE:8
MHML7S:8D(4BH$G8V-A8@<%VDXPYD2)^2&H>*_P!R@QB,*SF>WGKQ47<NCV/D
MO7]27!IN1=AE6VW2VM:U^/1\3[#LNL\@7$N\MW(E?`J=>L-0L7%RY"V8ST6,
MM]IQQH>70Q6(]A_+1P-N,^1KWJ5QI[!^\>RL2Y-6^_ZX<5W$SC*GM60C\;>R
M\W[\K2>*JZN<6ZD*E1+.P2CR_M)[=3*^V]^$O#O\OOL`0$QO6/\`CTTR4IKR
M+[LOW"]@X02GR<_'^`Z-P-7AT*P4J%P4.?"E(;S(<GTSS7;XF]%-+XSG[/R#
M[!<Y\Q>W>T7^M/TE_8^S]_K&R<9Z_72K.';VG^P^(H.MT_'''\:PFU['Y/V\
M1U\M-):+Q0/'JS/9+<]N%:;/IW%FX<=7G"%!QGJNL<'[)0S];V'7(>K1M<I;
MS6;-EJ'85%=JM;&K(532SX(2VMQ;8>4VH@,MC[U;DQS>:Q=KV8YSTP(-I;ZS
MK,6!6:YH4>!J]!KD)MN%`AJ_V]4SW`M#"&U,2G$RFFT_:DHCI00!Y'/2=/-S
MK3UQ#P!HULO=-U]^?2?U=]>UZUL4I>BW\O>M#VC1]CKKRSL;2QC0]<E2Y,.C
M>8GO&1-+XCFWF6"G40D*4ZGJ2?Y:QNV_V[VL;?<#V#]$;"S:TC1=&]2-QKM0
MU^3K<>TWO8JNNU_66[*0\[<P./>-6M8N*&@N'W'4!Z_3%B6#_P",(9/XV8DG
MIC7^[!)OVRU]<9^T&L<&3MC1PQL,;4JW88L6.WJ%=RM0;1QY#=BO.O\`Y]?H
MM]YNUQ5,]*<E*"EQHRO%/VI;2C[5)MKKGV_S_P`K==MON_C_`(;UO2'@WE'V
M,U"IYS]C-BNH?'][^69HO&=1;TZ1N5,"U^SVW8MGU*VL$-ZW8#S7$A09H7+:
M_&Z[(0VL,N:]UQPQ[9*V[536OZA51]?U6HJ=<I(P4(E-KU?$JJM)^P.>$6&P
MV)2G`D>3@:6M7_,HGOU.OJ/HVDA79MDI25!04YW"?+NI:2ZZMQ*SV^6DDG`(
M[9%P*&I^2]7OZ/6]DK;ZF33[<VM6LRYTANG=N_QL29:FH4*YJX,YQ]J)#>=4
MW^(.)::4LI\02)^9BIE!W[7)KU<Q`V/5ISUO(L855&A7E1+=MI5(@NW42N99
M_&N=+J&P5R6VU%3`&7`D=7'F*N9NUL+\U_GCK/R^E:FU`8"1APJDL-_H"7$'
MZ8Q\S''06VY-X1XWYJCNN7T>PUW;"EMR%R-HC\;7=_KEH^UI3D]42;7[+";;
M)1^WM6+&*?(J2&UA+J6;.EX.+V<_'LQ[->P/HORO*X=Y;Y'H+&KF5*=ETO;=
MCI8.YQN0M'LI]E6P)K%`WKW"-/KTYJ15NQK"`K8KEV"^@A3DALM.OR_)9UPW
M/CFTS,_C]7[K'OO*Y9U^333-4X_L],GB*[8R1M8TZI4Q6^4^+9)UZF>Y%KZB
M8P_&0MM^#;5UCY`!$I*DC-]TK-TNO?EDK6UN@\X\<5UOQIP!Q+S+O.GP(D57
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MW(HF2$MM,FQY`#JY-U>79"?^O<OO3%KRI3OX&D^1GM\#W6WZF;,:3&FQV9<.
M0Q+BR&TO1Y,9UM^.^TL90ZR\TI;;K:P<A2201UEI[]`Z"E=UW;6N/=>?VC;;
M!VMIF+&@I_S1ZVUN9DFXVK8*O5-:J*ZHHX5E<6EI>[)=Q(46-&8=>?DR$(2D
MD]!35CS)QO4[!IFIS]GA1MGWNS;JJ37'TO1]@BR7M"W3DMES9**2VS<:G&=U
M'C^U>#EDQ%3^6,6#AY000G9Y(X[$:LFG?=+$.[36JII9VFC$:W3<O1H]0JL?
M,[\4]-J_,91&+17^=;J`CR*D@A6G0.@=!__2[B)_K=PG9L3X4W18CU796,^T
M?HA;;"SK;$BZ9M8^S,5FM,6[=#35>Z1[V<W?P8<9B%L#<V0FQ:E)><"BYJ2[
M)ZK<*[1L.N;!8ZI&0BAL.2+*;0LQZYRBVV1RM7<J5^Y-[8Q.KYL^?"L%\V[5
M)5'8DQF'95R\MY#H2REL93>%ZT\$08UQ$3QGKTUG8I%)+V0W8F["]LTW7MAV
MO;*R=LTF^F64G8IPV;>KB=(?FK?=F2K*0Y(4ZIQ1),HV'Z^</PK*DN1IS4VU
MUZ#!K*NPNKK8]@EHKJB1L,BB@S7KRXL5VT36AMMJU5-R_P`Z:J+92H\0,L/N
MMJ+FI?6>L?`-0FK:@<4ZBB'3ZBUHD&K?@KFTG^TV]5F:.NGF44YZ13V;4W3I
M[E7*<DL//3(/BR^MQ"$!(S?%>FNKJ^H@Q:RI@0JNM@LHC0JZNBL0H,..V,-L
M18D9#4>.RV.R4H2$@?`Z(IG9MWJM<>37>#UI?2(JY42EA>'YE-!8:;>FRG2F
M)61G720E3R@MT(6&4.K04=63/HEN&/6U;(U_CW-]Y'OZRIHZ-A^W?1/F-U>G
M:G"@H6X_8.NV#C:9\N*T"5SWT@=E!L,(5XC?3B,7GJY@/Y(/_<":=0TEEQ5Z
M+7"=KV^:U-J;KFZ1`L$:YJC(:5#4K1XMNTP=GOPX7%-3ULJK6T>"D*EI44IS
M=I.G5UU^.WG;B.<_A_\`DE]V.#)F[3=`YVV!,CD6^D;5N;FVU&K\@.7>SRH;
M$!V_=?WFCV"3&LE1(C#:E,+:2XW'90XE;;2$IQ-]IW=+\>M[,HH7\R'.5^AM
MCE_BCBGE7P2`NSE?[PJ+]]3BAYN.2Y>Q[%3,`(3A"6*]AIK`'CXCQZW/EL[1
MB_#KVVJOJ#V[]&.:V7(G,?'W)W"=R\V_X6%!:/[7JJ3A(2F19\=2.+]N3'><
M`(C.U%HU@GS=P`5[F^EXVF*Q_KWUYUVRJ.L]2^).=([T[U5YFXTW&ZDMNE.M
M:\FFU7D",VEM:%F=1\@ZRQR2O\*>RI32W0K!4VZ00KJS76\ZWE/=OK]^KK&]
M4-F8M.`^--*L(/\`M_=^/-(U+5-QU*5EN16V5'2,0'0PIQM"9U0XIDN1I2?)
M#B1A90H%*;BQC,N<5>UZ-(C.N'\86'%^7?#;RO(Y2A*UG\,CQ\P$_<GQ3V[G
MJRX1YJ44'Q6V\,G[2EI:P0>Y^YI*PG!.#G'_`./5S%8@*]2]6FP]#K[K?]HM
M87'$"PI=>KUOLU<)5%,V+5MO:CW=7`=BPK:TJ=GTJLEQI+[7@E;&7&7%HCKC
MY]OFONZIYI'J_J&A;;K&V:WM6SL/ZS(C*,2"W6LQ[:MB<.<:\-L:U;.UM<VI
M_6EUO&%;:KAJR!:M-O-%I#80JXDN<GNXK*0_F\4J2RK[B0"ZM+*4XR4EPJ/Y
M$A8'P$DCZ@=,QE.:J"\A25*`0''TN#"2T&_'\8)90K[U+5\%6`DY)5V[&6JY
MY?Y5/:STEWKF+1-"O^=;.)MW`3.]P]IB<>Z-;;LD;#M#^INM:G)N6W86LR;3
M5UZPI+D8/N-QI,QQA]QIYMQIO&=,\UN:[XXC#32X]MN#+%UPK_'[M7*0A^;]
M9R3[%-\+\1MRUJ=5^61'U^/IS^R27)"SE#C%^E10D+7D>)ZUU^WX_P!3I]WR
M?HK?:97\D;,1UW0_1OUIU%Z*2U`LJ[>Y5CM4):%!;+U+8P^:M9K:]V.XI:T*
M5&24E84,*'D7_9VUA_U=]ZP-YM]G?YB=4IK*IWVZY[T/7OV_XK&VU.ML'(T>
M(A(CM)_]1Z15[80@E".SS=LAUX*\UK<*@H\]O]G>.FL^*]++6O;U_P#:[V!]
M7^0#R7PIR;LFH;/*D_N+SPF+L*C;$J=<>?C[=26!DUFQLR%O.%1E-K<2IQ2D
M+0L^77.6SHZ76;3%CKE]%O\`W#'"/*<*BT7VXBQN$N0G)$&L&XU\6PG<4;))
MD)0PB9+F*58V.DI<D-_]<6'Y84="PLS"`0WTFTOE7';X[.G,=%6J7(9AQ]JX
MWV&!/I[EM%K'BL/MS]5V&)(2V]^6,&9"6H[SS2QX3HZPHDI6Z'D`(7J\\5SE
MQT5=O?M/P9P]J4W<>=>1]/X3J:N&)5A*Y&V*LU^"ZL'P,6AGSGF&MFFNN^*6
M8L(.3W%.-I,=+CB4'%F/1N<\3JP9_P#]@?L#[,*_QO\`'9ZG[%ONL3'OV\?V
MK]IF]@X&];FHRWOQM;!IVN3:]/,_,]20A04FKK:Q"#_^T>22@Y]&\2?=6P"%
MH.^;=P34<?<T[#I&Q\B6.HTE9R+L-!H5?*T&^V&,(;UY(@Z!O*]G@N4-I(CK
M08TLN'P<*F_PK\`W4[\,?9GH/HEEI</C>UY/Y;MM.B6%Y<J>LKND?WV?>;1Z
M\;=ZX;)<6_(J*!G8;J;9ZKMKEA_YLO);L&DLX-8EFN8&4%L?\?\`INP:!O\`
MH47E;EC4&.4H9K^0+G3;UFMN]HASH?,;>P1K6XM&+N^G,[!<<V65O)_/-=4]
M:18RWE/1S+C2AEGYT0Z!T'__T^_CH'0.@=`Z"@=WW0:XTS6U;;,[:+)I2Z^"
MX2IB'&"BTNXM0VMM:*]AW[4("D+DN_\`304@..-63/HEN/5BCR7R9QYP3H>X
M\M<K;G%H=8UV&[LFX[EL3J6&WG64LI06T@H7(>?<93'APXX4H'\4=I!*$(._
MX8YOJX8?Y$OY1>>OY)^0$\&<$4.WT_!RK9<36N.M=BR9.W\GO,2$K9O]Z;JT
M%1KVU-!]FNS^TAI`=DK<6A"F<6W;Z=8[ZZ32>[;JJ_UQ_A9M;2)"V3V8W%_7
MP^E+R>/-#DPY-JP/%+@;OMK?8FU[+ORE;$%A\8[IE9[=;U^'_*L;?/\`X1M;
MTC^/GTYT"*W&J^`]%NG$EG,S=8*]XEN+;#.7"_M;MLA*LHR0T&TDGX^Y0/6:
M:3^UQOR;W^ZLA*3ASB77F_QT7%O'E.TTAUI3=7I.N0!X'R"V_&+!:&/!Q85\
MA63G()ZUB3I(SF]ZG_\`LC2O`-*U#5U)3V*54%6`VHI\/(>,(_\`U!@'X[#Z
MC/3$3E;?>O6S@7DO\'^]N)M)OI5=ARNM#1Q*VZK5)4M]+T"_JT0K:"52$^>&
MWDCS'D1Y`$3$O6+-MITM5[J.FOZ`*U&G;CO=<*9I;4(W&WV^YK0UAH,1F['=
M9-_=1*^$H`(BQY+,7Q`04$)3XL3\BVWU7BK_`&;YBU!M]&W\=U?*55'0E0LN
M/;*+K6WO-_C0'6AJ6WS6];G2$NI6M3RKR,5)P`UY#"I=?!97PU_)+ZF0)?\`
MB^0+O>>'[M"OQO4_)?%O(>JLH<\DMAU&S)H7M+LXQ<5@OPYTAGR[>7Z8O'5K
MVV]%<-^^WHXXE*O_`,[/U_A9[ABWY>T6DEH3@8"X=[909Z#@@_>@$_.<8/3.
MOC%]NW^-2&Z_D=]"*'*9/M/Q'</J22B-I^W1MZFJP%+"68.D"U?DJ^W^UL*7
MC'Z@&9GC#V;7^VI9']_N/-H=<8X9XGYIY04E33"=DD<?V/%&D!2TA1D2]BY?
M&G7$VN;0I/D]4P+5PI4%(;6E04-3-Z0QCK8LSRW;>QOL!52M;ON4WN`="M?*
M/;:SP,\MW?K6N<92V]66_-.PUZ+&/$D'(<51TE)+2THM&2XA2AU?9GK6??)T
MG*V'#WI_ZY<&B&]QSQ1JU7<0U(<&SS(`V#;2\B.EHRE;)>KLK:.M\`J4&W&V
M_P`BCA&22=376=(FV^VW79DHB*%(3XI(*4I#92"E`\!X8`..V!D)[?(/;L36
M4P,)#@2,>14,)))*O)('U\596<]C^OU[G(?IJFU^2'$@^1PX/$K'XTIR0<@A
M62KL$Y`3W[#H,1.;O1'UEYZ;FO;[Q1KZ;V4AU*MPU>*WJNW)?/BL2%W-,([M
MBI"T`I3,1);&590?-Q*LW37;K&]=]]>E<[GNI_%IR5ZWLV6^\:2+'E+B6*7)
M%@\U!!W+2X@*B7=A@0DEFVJ&$)RNQB(0EL94\PR@!Q7#?X[KS.8]&GRS;B\;
M+H_Q<_S`\F^DM_3<9\G3K?D'UFL)S4>51R7G[&]XP;E+2W(N='+RUN*ITI/E
M*J`0TH>3L;\;Y6E_.NV.+T:W^/W<S[G6SP/Z8^E')4V![9U4^T]G]JY"D/[=
MJ',_-.ZS^6INKP[*:FWJ:OC>KN6!IVBUNLO$L16(M6W,C-,_@D/O>!2-XD<?
M=MTZ-O.@[PY>`T-^8[&TPHZ7B6<(BWL%*6\6U>C)2A8_(D28X*C'6H?+:T$R
MSO.BRY]5S>LJ=`Z!T#H'0?_4[^.@=`Z!T%);GM;&IU/[H,&=:3'1"I*I"BER
MQL7$E2$*4E*U,PXS:2[(=\3^-E"L!2RA"K)E+<,;YEE"UZOO=MVZX8'X8[UY
MLE].6S#88CPF'77W!)>637UU;&_^D@$-(CHQY=RH;\HQZN,+W?\`9#G+^8[V
M#D<&^N\J?0^H_%-VVU:[E,1)8UK8;-N0MMW>[]#18<LT.EIS_;].%?E<;3^Z
M=_&I95&SB[WVZ_:ZS'QSW;?<V-^K?I[P_P"J.KHI]"J$2MHG1D1]HW^W:8>V
MK8G/R,.NH>E(0/V%.E]A"V(4<)9;\<D*65.J[ZZS6<.&^^V]S;PRJ[DY/G_R
ME2@#]J?M.,*'DO[DX).,Y_[-L/KP*<E0(\$C)`*21X^`2$]SD'X!`P$X[$'H
M/L(\$#']P3@)QY%2NZ"H$C.`>_\`W?KT'[XI64CQ*@H!.`4I`5Y))6@9"0.^
M?IC'Z9S!]!L'[%>/<Y2#C)0%D#^X%("CV[8[@_0GH"D@)2H$J/DK*`#G.?%.
M2M/VCO@=CG!SCJC\"0X4I!64D*P`0H'S4L@AP?;A/QVP`DG'SV#S_:M2&R'F
MT/92A*OR)0M(R<$@+&#Y*5^I((^O4$$]0U,D>#];`D(6O+B7849UE:E^*<J0
M6EC*^YSCZ=^@_8FKT%:<P*&HA+)4L+A5D2,X%NI3YNEQB,A:E.-I3Y93G[03
M\#H)RAE*0KR`24C"O)2?,8)^_P#'@'*\C!(^@^O5$6B.,G"?$8SGX02K&"`E
M2E@>0Q@9\OIGZP12(YPVH8`[`'O@J);4.Y`*01GZ?7H(YN."0HC"2A/GY.9P
M2K[N^0"?)6`1D9/Q^@31E@@]O`*^[OXIRH8)"C]G8GS`[=N@B4Q@YV\?$X!5
MC)4,)!()QD`@G`[_`!V[=0>:H((3GQ"L.!2N_EYA0(3_`,QQX)!P21VS\'JB
M1V%8A]+C;K:'$N)6EU"T^84A04VX%Y'DM"QVP>Q^,=^@YU_Y(_XP8K<6_P"?
MO6[7D1'8K<JXY`XLI8I3&DQVRER;LFCUT9D(CRV$J6[,K6DH:=;0I<9*71^%
M[C\GQ_W:O1\7R]-=K^:Q'\07\I6Q>CW)D/C?DJTGV_K)OUPTWL%:\O\`>#C6
M_G.(91O=%&>"_&N4OQ%M$;*0ZR/W*`7VO![EKMCB]'7Y-,\S[G?-6VL+:*:H
MV?5[)N1&>8AWVK;%6.-RD(1*C(=A6,9X/K;FP9<%W[TJ<<1+86IO*PI6>G3J
M\[(O1]M1ME27I#"*^[KW/V=]5!SS_934^02]'4?N>K+!"?RQ7?\`G;.%8<0M
M*<68]&Y<JSZBG0.@=`Z#_]7OXZ!T#H(6;-BUL.583GVXT*%'>ERY#I(;8CQV
MU.O.K(!/BAM)/8$]!C6Y8N[1;/;3;M+:2I(C4<!Y"&GJ.F><!9;<64*2U96A
M2EZ7A2B,I;\BAE'73&)ASSFN>_\`D[YIW[VMY,E?QX>O.P_X'6:J'`NO<#E*
MK651=5UFP2J12<45LE#L@/W^W-1?S2&4`#]N4)=\F3*2BXMXC4LUGOOY*GX@
MX9XZX(T:JX^XQUN'KVNU,=#:41D><^SE)0A,FWN9Q"I%E;S5)\G7W%9*ED#`
M&.NLDUF).'';:[7-ZKIH3V2/$>1(0I"<*4#V!."GOA`[_(_IC)ZTCW3YA2,@
MI./%.0/)&/@*';`&!]"<'!&>_0?2$K"4)2K\>""L!(7E0^Y((\3G&",X)';Z
M]0?OCW`[8"O#QP"4XR"HX3E20,'L.X[_`%[4%-I^4^)))*N^1X^2L`@E/R4_
M\JB2<_7J#[2C(21Y)4/D%'DHJ*CE'T4D``#YP<=_CH/4)RL`@E.?$E(&20H!
M25`*(PV5?`_U_KU0_$E0/=2B`#]Y;.1Y*'D?-)3W[#YP,XSCN(/M"`$$*6`2
MC">Z5IPHI+8&&_N)([Y(PHXS^E[CT"`%$E2NY('B4$J3\@E20G!#@((^XCMW
M'4'[^%!0H#Q)4G*@5I\BI*5^8/<(`"5?&"`?CYZ"(;8!("2HD%03Y!)\3W\D
M]O%0">V<?.?GMT$8TT1C&!XI(([J)*_Z*`"O).3\D]@#WZ"+2CX"U%.4J\@/
MM&`$^.$@!OR(^,8`^H[]@CV&P!XCQ&<>6?CR.%Y`2I1((2.WT/Q\]PC4I[$)
M(^XE.?)6>V2%=_D#'?O\]01R&Q_<O_P>/]JAY`>)([X[=A\=OUQ]"HC\*5`$
M%24J"0I6?'*@"#YX3C"@",9'SW!Z"$?82H*44E(SW4?+">P'8+^TIP"/]/Z=
M$4I90$DG"5#/Q@)5X^8\<C!QX@9P2`<#`&#WL',!_)!_'+L4+F[5=O\`774C
M8U_.NR/4;FD5[L2$U7<HRHLZU3%IUSI,>)%A[NF&ZN-'6MMMNR)8;(2\RRWY
M_DTY]TZ5ZOB^3,]NUYC95_[?_P#D$M'W9OH)SA8R(>PZXW:.\)R=C;,>U3`I
M$O.;/Q/*:L0T\S8ZX(KDJ`TZE3C<1N1'(0W%;09K<S%ZI\FN/JG2NJQFREZG
M:Q-HA(4Z(K"(E[7QUK=_R>OE]:W4L-H9`?G5GWO0RI7FM:5L@H0ZH]:QF8KG
MG'+*&+*C3HL:;#?;DQ)C#,J+)96'&9$:0VEUA]I:<I6VZTL*21V(/7-T>_0.
M@=`Z#__6[^.@=`Z"Q'(UTJ]NV=1BJ"JNE<BV>QD#S3,L\-RJ>D6DI4VIN&E;
M<]])&<B/@]E)5J<3+&USPUR?R+>WW_YH'KU;;+K\=&P\O\@VT#C3@W44()?V
M;DC;5K8JD/%*D_NZZC/Y)3PRV?Q1U("@MQ/6O/'))F^36KZS\)JX-XT;I;6S
M7LG(>V6LO>^7-TE+,B=M_)VS!J5L]P_)\6UN1FY3?X(OEG\49I([*)![:SVS
MS[N>VWNN>S(=*D>?_/@`'!R`1_;GR(_^F%9!R.V1_7K3+UQC(`\D@?C=5]G8
M=T*PK[D$%0P4@Y)R/UZ#T2E20H`_\@[_`-N,I*4$]@DYSCZX_P"\0>H*D@D8
M2$X5E02,?=@8(4`4_/SC`/T`ZH]%!2LC\>2K.%@'*<`>6>Z_$9^,@9_X8Z#]
M4V#]RAW`R>Z1X*4KL0/$(.0,@$G(_7XZ@^T(!2<*!4@@-KP<DA1^XM_`5C[0
M2/GOW)'5'TE.5(!3D?:DY'R<X0HA*D_)SWS_`&]_ZET'JA(&`"GZ*/VX`&?N
MSD#*TI)QW)`S_3J#[""D+23W4D%)4@GN?(%?D`>^#WS@D$_KT'TE'D/+Q3XJ
M_&0,9'D5A([Y`*?(^7Z!.`.W01"4_<%=@K(!)`PG"<=R$@_<E(`/<$]_]`]4
M^2LD`H'WD!:25'/CD%7BG[D?09_XCH(AM+8Q\Y^<I[G&$^("R5$>61@%1."/
MCH(H>2,X3D@J3Y*!"!\*&!XD*.#XE789'?OT$<RA03AP$Y.%?V`%9*O+.5!)
M/BH=^WU..H)@U\`_IX8`^/@Y\20@A0(^?C_\`C4*`QG!\@E2E'X(P3C)'W'/
M<C/8C/UQT5%@)6GQ[!&3WPG&"@8\AE8(*DXQ_K^HZ#S7C/BI)2%#MD]\`(20
M%D#!3DD?HH_/;HB3S&4J"DG`SYJ)*L=U).3CL<Y\<`Y^/^!"U6YZ]'O:]+"L
MM2(ME3[#3S&\)=JMBUJUA;#KUQ&4$N!J537E=&D-J"5?<U@@]QTQGA9<5S@?
MR\Z-:>NGN!Q%[G<+_FTJ5S.VQR:VY!;_``)HN<N.[.M9WQM;3)#+K5RF=63Y
MK:SB9)GS`M)0LY\_R3V[9CU?%9OI=:[,O3_V(HO;'UNXEYTUQ;4>-R%J,:=9
MPO-+[='M<".Y4[-4/_C6EU;E->09,18"TH4&%*[@Y&LS$KC9BV,V>*+-486^
MFR%DFF6BVIBMSR4Y27+\EQ45LJ"7'!563;J.P"6F'F$#Z9SMXM:^"\?66CH'
M0.@__]?OXZ!T$GV"X9U^DM;M]M3S=7`DS?V[9P[*<9:4IF(R?%7_`%I;P2VC
ML<K4.W5DS<%N)EC97,/18OG/6X_:RS(M+B1'5(0B?96*D2YKS03^8-`.+'X4
MCNVTE*$D`#&_1S<ZG,EK2^W?OC?[[=./V&@^H.TV_&'#=2S+97KMGR=0:[2V
M?.^WSHW@H2K;6[;D'48%>%.8CNQ9#A;4I*%IUK,[<]C:^W3SO\,H$$!1)5YI
M\?+L4'R26P'&PD#R)\F\#MD#MCKJY/<I))3@CN?+'BD*`R2I"L%7?&0<@#N>
MX&>@]?#(*2`0E?CD#N2`/M4KQ;QYE7TQW((_H'LVV3X)2/+&/+*LE2_Q`^2B
M4J((*4_`PD$9^H`>A:&2!G`\E`J!4"/(%"NP\B`I1_\`E`/SW[A$?B\@0,Y`
MRG)5@@9P""?KD`XSCMWST'Z$J&%$`D8*<C/T\3D_>00I/C_P_7MU1]!A2?M\
M<^*2%83E!4A8QY$94<$8&?D'';/4'TA)"O$'Q22`D'OE0.$J[Y*<G.>V<GH/
MU*4Y22!XD).2!@'X5E7D?O/B0%?I\_3H/MMM*L]T'*@%Y\,J&0G)QD8RHCX`
M&!\=![(;6@DI("0"4E20`%9_M/DDE*DX(.,]L_7H/0%0!)*O+)2.RL?:"H*4
MHD*!`SC/?'P?U#V2D'!*4D^6$E7]P20G(!'AYY"<`_W=SGZ]!Z(S@@^845`$
M?/XU86"G'W.*4%=SV^`/^(1+(3A!3X^1"DI"0!@)(*4^7BH)PKZC.<?&.@C&
M5X`SX`G[0$H)"BGQ"NW9/D#WQCX3U!,$Y"1D^2E))&<#R`2#]I&"?Z'O\'^O
M01"5D=L?&2M6<$!`QY#Q)[^/P1@9P.@B&U$$8*4$8.3]I/W8/D<@*R$DCX[Y
M&.BOE2LI^F`2$G_ERD8.5K0H`_:2,_\`QZ"!?SC`\D$`=@G^X8`PK",DK<'Z
MG.`>W;HBDY^"%C.<@``)*U%*D]DJ'G@^25?!SD'Y/THU"_R[\:M[OZ<;A;QX
MY38<)\AZ+RS"6%J*UZ]NLR1Q5O$.'%^Y#49%]>T$^3XX/Y%*=/RZ>N7RSC+O
M\%QMCLO_`/\`MG>:9.S>O/-G!TV<X](XMY&K=JIHP:+Q@Z]R-7E26D-A."@[
M%K%BX,G!5(5V_7GKS,-?+,;2^+IJUMQ%;O>IV304PS:L7&L/MNE"DM-RHG^8
M9\5^2RCSM*-MM(*EJ*G!@Y6K-O2L3BQDGUALZ!T#H/_0[^.@=!:CEN8$5.O5
M"B?QWVUUL:2E&?/]M51IVQ^60E7BT9M,PA9/90<\>_D`=:]V=NC'OE;>&N.N
M,M^W>65EG3]-V39Y#)=2S(6BKIYE@I2B6Y+[0>_"H*6M"QG*O$D@G4_9ES#_
M`,:JK&ZX0HMRO9*Y=[R-4;/RKL;B_O6UN/(?.W-RKI]#P2IR0_;ZUJFOON+4
MO*O!*%=VB.M_%TM/FZXC9"A(&1CP\1Y`@%25%?T\L@*\#G/U`'Q]#U<D8ACL
MD$*.`$JPD.?:<J*?+(3W&!D9).<?/>"+;C*R4J&582@]T*(\D*.5>2<Y!.,$
MX('Q@'(1K<-0&>Q&<_<D$9"\A(^U>`DCL?T_X=!%(AK*3WR,#R(^U06A*BH>
M1'V^6?T&``.@B4PDJ+:%?*2<GY[@>*<8_M^[L<GMWZ`89)\@$)'F23DDG[0D
M$*(P.Z<=^Q!_X=!]B*1]PRA"0?$^21A(\U`Y(3@C^J1^A^@Z#R7%/Z)./`G/
MB022"E)`(\CE7<?4?7Z=!YJ84@CQ"AWRHI5CR!5DJR$J(<2`3]?ZC/0?@9!!
M.5CP5YJ`4CR)\4^1\24``'O\D@?H>W0?I9QG[?J5XQC*7!G!\L]_$]P,8'<_
M<>P>R0H#[4H)`\NZ`D`$?>/+'GX]QC./^/0>BDX)\OM^4^*_+.?@8)S@>2CC
M)'TZ`E.1E2.W<**@$D`D^1P#@@K[GZ#/?/ST$2,>.$K4/J>RDA1!"B._B,]N
M_8@'_CT'N@)20!CR`3_:2I)\R5DJSV\O(]OID9[=NBHE"R,)[J..P)'D<A1&
M,*&<@_3YSU$1/EG[R20K[@?[22#^G89S@X'<_P!.XZ#V#X4"05!6"H*R""5@
M)2KRQ@$`9Q_3_3IA7PI8'B`?+Q`"0/[T8!2?N5D.#MW^@_\`B1!/.IRDY4/E
M/97W>7EXY5D(\@2""._;_3HJ13,+\NQ3Y$'!RLI(\02I)65@>6#A621G^O51
MCMSIH7_JOQKRQQ;^5UQ?*O"/,>BT\%/B&5[6O4%[SJ5EGQ*G7ZR[T5H):'9Q
MM]PE8*$YQOSK8WI<;2M+'_ML^1).N^Z7(7'JI'XJSD?A.XD+9\E_^9N=.V.@
ME5C82DA/DFMN;`A1\@/CQ(41UY].\>GY>DOF[?+B4B(S%N$X+U%=:_;K.5%M
MUFLLXK\X!P!(0IR"VMG.$MC\B<J*4GRZ>3@RPZYNAT#H'0?_T>_CH'063Y9"
MEV^CMA[\25.[&25+6EL.*@1([;BL>2"ML2%>'DDC)Q\$@ZU[L[=F"7\@-HFG
M]&_;RP5AK]EZ[\OR"J.%O*"6]*O%-K`0R$$H(^XJ*4GX^XYZOC?))UGJT0_Q
MLP$PO7#1G8_[AMES2M!0VT2Z8:77-5C7$M37D%MH<>L+UUUT#MEP$COGKI\7
MVI\WW-B<9']F0?%).1WP`!XJ\DDE)"?$9Q_:>^/DCHY)PQ'S_:I1(2G'W(1G
M&0M2,_"23C[AWR,CH)NS'0`.R5*'B?@$X!3^7&,*2D#LD]B2/^("9IACOA`!
M`R22I7EYC!.%*\<!8S\Y.>Y^@@C$0,G``*,$>(\ADE2?$'^U63C`SW/Z_7H/
M=$()3V`[=D_^,`>('P0<$?T.0?TZ+(^A#[$^)^BOM`&/$H[)!*0?$@_/Q_3H
MCY$+))4%8\OM`![Y"O'`\1A?D1W(&#^N,]!YN13D_<L@E(![G/VY24*()1G_
M`+<'H(`QB`E(`[^2RKLDY*?$XP3XE./T';.#\#H(=<8H4H@$#`R4@J&<E*0H
M8\L`#Y^,?\.J/D-)^<`CMY#L<G[0D^)*SGR&.Q[XQT5])94,%1)2<!10`/$X
M*2E)RI.,]^^/Z_H(A^$@?>,$E2R@`H*4A7=2DC!/EC]?K\]4?(0%>05C/DDA
M/D00GR!P%!7<Y'8_KC^@Z#[3X=RE/BD8\<$^7VY6?$`A7]J<]AWQ]3GJ#Z).
M?M!424+(QG*NX!`[GR6%?VX![=_ID/8$I;4$D@JP"7/+OCR(\5?<GY&<Y.?^
M[H/I*U'!!7C`3@!(('DD*2D*P221C/;(_4=`2KNK[D*2$I4I).0E/8^0)4?Q
M@')&2"<9[X[A^*<!4/[",*)(."K^WL@J^#Y#]<]N_P"O14"Z[@@!1"%!8^B#
MDI\4AS(4#DD_0Y'51)93BE>7=0&'.Y`0`2E?B?(+2H8"^^<8^F?H$DJ)+$#D
M'B^Z?/VU&_U[",C"GGMGK;?0V6U+:^TH:.V?D[A6?Q@'']R9MT6=7,9_$)&3
MQ9_,'IV@LAV)&B;GSMQR8SJ7$/\`[?7Z#='6XCB2XI27D+UI&0I2ON3\E6.O
M+K]UCV?)SIGT=[FUQTO:Y?PT.J+CM//_`!.?8@)6["?;.7D,X\RO"@.Q2592
M59[])UCS7HRP@OJE0H<E:0A<B+'?6E.?%*GFD.*2G))P"K`[]<W5%=`Z!T'_
MTN_CH'067Y225WVC-`I"G4;2A(.2I1_:5BD^(`.`E20<GLDX/SCK4Z5G;LU]
M_P`B3#EGZ&>X4&.4H=E>N7+R4!Q#WBE4C1[IH!82^\A*TH<!4?$$#&.W8:QU
M]*DZZ^L:#OXL]D>OO7+5VENM/,0=<UIEEUMOQ0I=6;76'6/+&'%QO]J)95\X
M=;4?UQOXOM3YOO;1XC?V^.<842E1\BH*!4H^?AD`D$9.#C_X=')/XS21XD^>
M`@@9\.RD@8"D@)"O`D'_`$(P1V/05`S$)2A63C/]H21W3@A('F,$^1.?ZY'4
MR)Q'ADH.?MQXE*2GRP?N4/\`E\"4A8QGOGZG`/14T;B*('D@*)(PI6`,XSCQ
M*L`!:,X[?]V.AA$F%A/<)SVR.P.<I."K`!`5V_0D_P"G0P^C"!5W!)*@`0?C
MRSDY)*DY/8_K^G<=!YJA$9("2"0#]JB`K)'<D]CVQ^O]1U!#NQ`3DGN"CR!&
M0"1\G*2<Y.._?_M[,F$N5#\B?_I@`@]P/$DE1`[=Q]_S\CL>W;JB%<B$+&$@
M@E*`%*2E2O%6$*)2HX"O$_ICY&.@AS'&?$E`^%*P5?\`*?(>1*^X(5V'U/\`
MH.@\OP)1VQX!0/SY`!L)5A0'VD')'_?CZ]$?BF$=_M.$.)*2KN2DA*PH>8`^
MX)Z"&6SD$+__`%H1X#)SD^.%$+!5]X.>^2?^SH/@H5@$CL.P``3]R5'[@<]B
M<?!'SC]!T'Z6R$_:".RODDX'=61G)'D!E(_3Y^>@^5)_4@'*TE*$Y`/E\DD^
M.01G'?YSW^@>"R1D@'(5_?XX0`/T3]P4!^@P/^WL'PIU9*O$$)&`I./M"N_<
MJ)4D*`SVP?C^O00[CI4M1*B"H]TD=LC/B/,C(*B?K]OTZHAUK_ZGEY`]DC/E
M@8!*L`?"CX]AE0&2!CMGH)3)<*@I6$96A(2%*/W`'"`0D^*B4*R>Y!Q^G<!3
MS[@:N=-=1G_I\@\>J"2XME)_)NE+&(6IM*_R>*9/F$JP%*P"?KTO19U<ZOI3
M7(@_^X+LX5<RIJ'4^VWN"TA"#D1J^)#YNBH2IQU6`@-^+?DH_*A]3UY9]]_-
MZ]O_`(IZ1W7W"&W*:V6?)#;-=/0^"E`24H@K0$E.$A"?!21Y>0#?XR,IP1UO
MO'!D[3__`+IJ^V/_`+="[?I_Y9KM\#_X=8O6NB8]0.@=!__3[^.@=!9GEUK\
M;VCV.$'\6P3ZW[RH!/\`D-?M).2/-ML)4:OQ\B2I*E)\1D]:U[L[=F*'M!KO
M^]?6_G73TLMRE['Q3R%2K4G+H=<LM9L8Z&TH3AY1!<*DM)4?%15VR!UJ,N8_
M^(&^:N_5C7HB%1BK4UVVH2%(3)_*EP\B\D[JEB9Y-M,_:UO2%H+;BR$K^X)/
MAY:^'[:OS?<V[0?N4GOG(4D>)22"H(^[!*NR_H?U`^,]=7%5\9L]L+`(*4G)
M.59[@*\AV``^I(/;J"J(S(&/M!SA140H'*5'X44@8!()'S@=%RJ*+$)*<)3G
MZ`=B`GQ/CY940/D?\>W]8)LW"*O^7/RHI"2K*#C.,CNKZ9_7OWZ*B_V(P20"
M`D'R&3D)&!XX`*3W.>V<]##Z_99`)^?'MV/VX3G![X*4X)/].@\EPLC)2!@I
MP/\`F`2$]_@)(3@=_C'^O0QU0;L,`*/@0/'/]I/U*0,^()/QG/?X!^O41`.P
MTH/;!\24_:#W.$A/8H[D8)&#\]54$Y%4.Z4CQ^2,@*RKY`![=R/DD?;\]6(@
M'86,]E=QX$Y\L]@"3E1&/M[9SVSG/00JXP3Y'!(6<DJQ@=B$DY(([_H`<'M_
M5_(AC'R0XH%6/N`^[(\1Y*\25$D@@#/SC_7/0>*V?'&`H]E>.<J4._89*DY0
M#\]_IGN.AYO$M*"B4E>5823WS\I)^4D`IP3W/P?UZ"'_`!*2G/C]2YC."2C"
M583GXR2GZ_)_3L1"J_)\'S\@DJ\E$!?;'?S*@%#)';'QV['MT$(X""?O/V%)
M((.2GR2<@Y\EI6/^'SU1"K4/NR1]OVX_NR3XDJ_M0L9)'T/Q\]^@A77>V3E)
M[)4`"KY`\3V!.$%0/Q_ICX`02U?*BD$*!2M(^"H*4$GQ(4DI)R>V.Y^>W02U
MU20%J4?+(`2,#/Z!2"<86%_KW&>W02&:LIL=0_ZF/R\D<9L*6H+4?-[D;5FD
M-',AO!6Z0CN20HY\5=TF7I5G5H,_BP87R3_.'R-O"O-P0N0O:CD=YQP?MG@+
M?8=DKOR^+'FEATN[2GR"3A`)P>W7FUYVVKU;\?'K/1V[;4\6M:OW&G%EU%)8
MH0XM?X7#^>&XI"&_/*&BX$X!2<K\^Q&#UN=G%EC$CB)%C14J*Q&CLQPLC!4&
M6TMA1&3@J"<_)ZYNB(Z!T#H/_]3OXZ!T%L.6HR5ZU!L2A;AI=GUR<E#:?)Q0
MEV+="\4X!\/"/<K45?\`*E)/6M>K.W1:6Q@NS*F;7(90MA^.XRM*AY!:7F7&
M"7!YOMDH"T@8*25`^.$C*=3Q9<:?\93<GBCE+VA]>[!)J6^+/87D#6TUS38#
M<VUVQLPJ-8*1E$*KHN`K$MN!*4?^>;3DEU`ZOQ<;;1KY>==-O)O+K2I6,G)6
M,D`$I)!!2,]SW']H/?MCKLX*YAIR$84>P1Y#S5GN&R"?(I("",`#X'USU!6$
M)E(`'P58[J/W*)5CN!V3V`^,]1540HX/C]H([8QVR$]O,Y)!'BD9^1D]QT6*
MA;B*\?[?/RPKQ'CA*EC&`"200H_U^GZ]03!$,J4DJ!^T`X^<_<%'[59PHH[C
M^@_[)E7W^P/BG'PE`/VG[L_<,D'N`0>W?O\`'SD]4>+D''9+?8@GN`2C.!V[
MGLD`#^IP.HB$>AK/<#OE78!(">Q2KR_M!^OQ\9^G5RJ5O0\I"BE?<$*&0KN/
MG'9`(PD#MV)'?'1/X2UZ$4Y!0@*RGLH9/PGOG!4H#YR,]\_'UJ>B7N10<X2H
MDG/GX@>23]H4"`"0/+/R1W_7IV5`/1<_D6K)22>X!*2"O`^%#*<)!.._V]C^
MI$$M@^)!\2#W2GN0/A7W)R5`*\_]?@G'P:(1Q@]R%?\`*1V\A@=OJ?'!`[)'
MZ?Z8`0SD?QQ^3L,*('P5#L`!Y*(*@H=C_KV[]PAG658SG[0D@D)`)_YNQ'W`
M*2#G`)Q].B(-;02HCQ4HY"3C)RK.0K^Y.$!(^#V&/TZ"6.I./$$]VVQV(\?R
M)"CDX2DK2.PQ\8_U[A*U?<,M^.5D)P"?H2#XI[^2B<XP<#_X42Y94`<.)("U
M9\3C)"<I(^<@_3X[C],$!!+(`/Y$D)RH_3^U/CY=@,Y/;MW(.?\`4!`+60DJ
M!\0O*.Q*%`@=\^8\B?'[0`3W)_J>J)6Q):_W?QM7KEHAMSN0*:6N4^VI^-'A
MZ;%L>1KI4MX+#<5K_":7*"''#XI=*0G*_'.=NC6O5IN_]N%J<OD7V\]GN>YD
M5YU%5I:H+KBTMI=78\H;L]M+S+:T?MXZW0UI2ORI1A("QV`4GKS:?W5Z?EXF
MNKL>M4?OT5M4,LIM=@UVH4DJ)6IN5;16YBD!M(7_`-*O=45#L.Y[I`!&_%Q9
M6=<W0Z!T#H/_U>_CH'04UN5,YL&J;'2L8_=65-8182E*"0W/7&<,![R4"D%B
M:&UC((RGN".W5EQ94O,K'FGF&SKZZP9>)%A!CO+BAA2$H5)BJ4I+H65A"5,>
M*?$^(\E9/_RZ8<F'.FBR^!/YG>;:*M@241O9CB)OF'CB)%83FRWKC]J#NMS5
M4CI#B6[O<*WB[9Z-LO(_(%[(4>(+C9Z2XWRZ?=\>/"MK6KW-?>5E3;5DAB;6
MVT"#90)L=669<"?&1+ARX[C?DE4>0TX%)(R/$_\`+UZ'F\ETZ\?:"224`9\L
M^0'BI(QD!7=*1_I\=\]0BN8"!]N>^?$`X/B2I1(!&5!7SD?3'SCJ*K"&VD);
M4/$G`Q@?:HK'R3_:!GZCZ]2JJJ,QYJSA)\0.V2"H!(SDX"NV.V?CZ]14V1&`
M\5=NQ02/A*L!)QA2?('.3_0#Z]0B*_;>0"$_VI[#*1CNI*@"$G`!\?GM\]7Q
M,/-4,X(2@@GX!QD#X\L9[`$]\]O^/14$Y#`^0H]U'/8`X[=O$'L!G.1G/1$M
M=B@A15G"P5$90/N!5]JL*`(4".W_`'CH)2[%R"H`'*5=U!(/8I5@*R4@DGO\
M?7MU1*7(X_(#@X(4H@A/?Y.,82!@'.>_<?7'51*W(YR,)6D_1.1CMA9[#'<_
MI^OST/5+UL=RD#[L_'QD94H!.?+[L?7(^0?Z]#U0BHI3E7B>X\RG`!SC*4J(
M'R0,_!/TQ\=$]4$[%'W`)\4@]D^(^WOV("2"K"D]_G)_IGJB&7'*PI0'VX'E
M]Q)'8@`J6%XP`,'&<_3]0@78Y`)*",!((("NZE`Y_P#$K[?@GN<_KT$FE-#"
MQY'"@OL,^9!![J&"D+'QY'N<#&.B>*G)2/Q@A6<I*BE61_XB24H4H#RR#]03
M^OZT2=Q7WJ\L*`RV,A`QY?<`H$H2LA1[#)^H_KT$(X1YI!.<X*00.^0I*?+&
M`"E0)^I'C\_0!!+5A)*4E/=(()5Y*5D$Y/<XP<@D`X^H[=!B[[1\D#C+@WV+
MY`#ZF6N./7;>Y$-['X6H/(7+[J.&^*Y+LA#GY"MZ3L%R$,I`4XML$.(P0<?)
M<1T^.9VGJG?_`+<7A29H7I=M'+,B"I-AS?R7=SH#[C:&G'=8TQ+6I0FDJ6XA
M183>09[R%$'/Y,@>.%'CK]N'3Y+G;T=$&L0USMVU1CQP*QJWV2>A3:/%1CUZ
MZ)MIU?Y'<K1.NFG6D*^Y/X0OR4I.>K>C,ZQD?UALZ!T#H/_6[^.@=`Z#%Z37
MHHMFV*@\D($.P>NZIMQ:$*_PFQH$I3T8%0<;:A6+,F)G*_L8SX]P!TG3+G>*
MT"?SL<9[%J^A\">]_&T0'DGU"Y4UJYM)302N1-T>_N:UF0U-#27VG(7^Y8\!
M*D*;<#4.5)6H)"E^4VZ2^#?Q];KVL51QQ<T"':Q&FO(>XQY&U.@YHX,D)6HL
MGCK>84>7/U9DK'XOW''>RR'(QCM^28-//JFU'S6>NVMSPY;2];U[LDZM\)[@
M]^R@K"0E25**`000`H#X'B#V^,Y/587&K5@@?VY*1E0("L`90`!VR4_UQ^G?
M/4:5[7*"DH*/JH`I4KR\@%$`D=@<C`';`!^>H>:KXF?D)[`X!![G*D?\X.!Y
M)5GX_0$=^HJHFD^1^X$CQ4DJ/P20>W;/D<]NQR,?(ZBHU+:E`C/ED*2?()Q@
M>/A]O?&/G^F/GMT'PMD9\3GLDE(`"LDY'DH'(`P!G^F/Z9"%<8SG((_\.2`?
M$C`RH@D@]OD]QG/02YZ-D9`RK(RKL1C`3\J*@%>7U_I\=4PE;S`*5$#[2,+\
M1^G89)4<I2.B).]'"B3V3E7EA8Q@J^1Y83V2/U/QW['&:)4Y%SCNK/CV4`.P
MR$Y.>^,X[_3],9Z(@7(Y7W2E1^#@X']R21C[ON5DY['N0<'.>@A3$P4_9\9&
M`1\'S4K[01@`*R/_`,G5'B86<91A6"?MP01@X*<Y2E(^!V_U^>AW>*JX'R!`
M..W8@?/B,A)\B#G^OQ_ICH=DL>@_\I20,CX^<)P`K!('R2?Z'L.B*:FL*`)P
M,))6$^*01WR%*3]H(_K^O]`>J*+G`E:E)RD#)61@'Q!3X9![I.?K\X[8P,]5
M%+O?\Q2&P"EQ942%?!5XX3E2!V';]5#Z=!`.*./,I!SD'_F\4X!\,8`2?$`G
M``^/].@A5D`(`P,D#S)4!X9)'B2?[4C]2G./CMU1IE_E,W/8=CXKX6];N/U?
MNMZ]R><Q:&LCN*6^]QUQM<QN/>+ZF6&4_@.O[=R':S=@B/MI?4XAD*+H;0EL
M>?Y;FR1Z/BDDNUZ2.L3UMX<H/7C@;BWA766&VZKCK3*C6&5MI/Y9<B!"8$V<
MXAP.N";8SEN.NE/WJ62>P)Z<=)T8MSF]V4'$L`R5;%M+Z0M<V:G7ZYXH0<U]
M`IQJ:XP\E2BIM^^>DH5GNHQDE1.`!G;M&M5YNLM'0.@=!__7[^.@=`Z"S/+-
M>N(NCV^.VVI$"0FCO`O[4JJ;9]K]C)<("E.JK[Q#*$)QA*);J\CQ[ZU[QG:=
MU@N7N*-8YMXHY!XFW&`;/6>2=3O].N6%?C"7HEK`D0/W27`TZ69"#**F5_<A
M"DI5_<GR.OX9\,=7,#Z+HY`H]5YE]"=L1^7V9]$>0=@VGA9B6N-"F<D\47,M
M<JVTV%*G.Y:J=WK96(JW'6XD&5.I'W4D0_$M+9ZS^&]\7&W:_P`MG^B;;4;3
M1U&PTLHR:FV@,3(3CC;K#OXW?M$:7#DI;E0)L9UM;;[#J$.QW4J:6A*T*2._
M69CA>.%ZZN2%X*RD%*1]H*LY)42"2#\^7SGM^OUZAE<.L?\`(9)RDX\,$I5G
MNGL>WT)[Y[YR/Z3HLJMX4ELE)"E$DJ6$93CQ!(_L\5>1[@9'T&<G'6<*J>+(
M20,>/D/'/?R)(05JR0<*`5]>^1T5,D/]L!14`5)[.=TX/882/$C.#G],?Z=0
M%N`D`*/<Y`[@X^",)/\`\F3\C&._0>165#!_N.#XDX`\4=TCR42/Z_/S_7N$
M(X4X"E*\3XE.2.PP%$^0'C_X?CZ9^,]!!+0"2D8QV[9(4H^0.>Q"OO21_H/Z
M'JHEKJ/+R3YX*QC'?&,$*4<D`X4`<Y[=\GH)>N.7$D`9R1DCR!."`!Y*`(\4
MYQG&>WZXZISXH8P_[24_0G."A1`/9S!5^0$`$`=L#_N9'XJ"%9`"CV/<^(`)
M^,`A.`#D'L,>.,Y'3()@Y.3G/S@J'D<=AA63@D$'_7_3'0>CE?\``*0`?,?*
M?+*3XX`PH8P<'_7YZ9$AG0\!0\<)5Y90/+![X^3XCP!5V_7_`+.B*"M&<>9`
M_M2H+R1C_P`)"CY$%*?U_P#R=:1;:VPGS\3XJ3]J5?:`,$*4D>'CA6.^0<X'
MSCOU8BC7%@%2`#W"U9&%'[0CQQG*DGZ=NW?Y^,40BRD$9RKR`)3YCN4I3]ZN
MX#H7D]\D$'ZG)Z"EMD9M+5BNU6D?6SL6]V;&GT4IIMQU5?-M69"IEX&PE2WH
MVKTL.7:/I2D_]"&X<@`J3+<19,U@EZ*<?U?O1_*ER?[/1X!F>MWI;4U7"G`Z
M%%4JDGV6JU\G6==5!>D.E$N`AIZVODCQ2M*K*$H_>,J\\YMV[1Z-OITFO>\U
MU&V<AZ-$;5'S)L9C[%=2M/$A<FWG.-5U:WY-I6E+)>?22L#[6RI?Q@"\.;)G
M7*2-K=%5440^;-7"9B_F*$MKE.H3F3,>0C[1(FR5+=<Q\K63USO+IT3KH'0.
M@=!__]#OXZ!T#H(&SKH=Q73JJP93(@V421!F,*[!V-*:6R\C([I*FUG!'<'N
M.G08RQF9<!^;K]H^X;B@EF"Z^DH#MA$66W:NV0V"G'^3A+0XM3?=EU*DY*DJ
M!Z=>>SGTX<_?\O\`PUM_`'*G$7\HG!E5,E;!Q!-A:;[#T-0C\3FW<239+C7^
M5DQRH*=?I425L+<=2X(Z'(TA2@W`3XS./JGXC>N++I>_\JWB;3J;R]6Y_P",
M9C%MP-[+R*Z^_<0"AN'H',NSAMZ0'T%P&LI.8I;P=#9;;5&W!,A#RERKAMMK
MKK9.,\5RLMZSZHR+J+/S2`7>XPI6?KDE/]BL@>2B2<]A^G;OMA<B!/4`@'.%
M%)4/N*!]Q'D`<^)([9QC^G6?X56T*Q\4IRO/C_5'<Y5X_)QC`.0HGOV^>X<+
ME5$2S`\L'[0"0,(*BH94%9`2$^15A6?K]/TBIPW/R#]R>QQ@E04D'O\`<>Y)
M\AW_`.\CJ<"*$W(`22/[L84/D''DG[@%%/\`W`=!]B6%*RE?=(3V!S@J`_M(
M`'8G.?(@8Q\C'17PF4DC!*4^(\2.RLY``\B/(X"\G.3WZ!Y)4,9!!;/;NE/B
M>R1XI[]_T.">HCR4A.<$_3L"<!']O?!*<C'<`X\OGY/5*^/#/B4@X/983V[E
M*2D>.?N5V_H!G)^>@!@`G`^OB4@>(^_Y`.$GL%`?/R>@]_VR"$_:E1PGNK/8
M9"B"`<@`(SDY)/0PB&H22<$`8`2<)Q@@XP0?M2GO@#MC_L'3*O5V&A*"`4$=
MSCP2`<`^2LG.58QWSV_[R%'V[.//Q3\JR<9[D]\)QY*[I_XC`&!U8BU-R>[H
MP,C`P/$DY6?`@^*DXR!^N._59JT]JZ`I8/B,*_M\TX4"X2D9\<8[`8^"?U/6
MD4<\.Y2GMG`(0E9'W$?5(2<'R)P3VQCOCH(-9P<CQ2WXD$)`"LJ\AXY!SYI`
M^"3]!]>KYC`+W3YUV/C;BV8WQ>9=SSE[`7%IZO\`K7K=>E2[-=E=3V*7F?DZ
MKC%24J>H%*8UFIL4+:=AVDB7E*XSJUJX_)MVG5V^/7O>G5NZ_CN]0*'TD]8>
M/^&X/[>1L<6O%YR)<QFG%HO^0+]IB7LMB6W!^1Z)&5XPH9.%_LF6D$?:D]8Q
MB8[&U]UM9[:%3N7NUN7LD*57:B@Q(142XF5L<Z(XF6ZEUP^933U<U2%``H,B
M8K"BIH@-NGJ:SGE?[K#9T#H'0.@__]'OXZ!T#H'06DY/UQQQEK<:V*9%A2Q'
M(UQ$:;4X_;:UY.2'F6T-)+[TNG?6J5'2C*U)+[;:2XZGK6M[5G:=UG-AUW7.
M0=0LM3V2N@[%JFZ4<BDN:N:U%EUEU26T9Z),BRH[GYFI,9^#*"5%64K;."1@
MDZZ,N5C5Z>\_C)Y[Y`]$>6X,?;_4CV8C[%8^LFP[I/L:_6H-[>>3CG&&Q;)$
M9D3]?G1;Z3';;GQ$F7"L%,SV6_S35?@2X^GM>C=^J3>?=.O]67/KCS=!WFL:
MU^3;R[*UK8TMVIL;F/&@7NPTE9-9JK-K8H4,_P",C<C:';/(J]IBPC^U$XQ[
M**D5%Q4NO]==LS%ZN6^N.9]K,VLM/(>*5GQQYCY(R`E&5D)3X@^6<#)SC]3U
M6,JSB692`5*P2"1W!QC)"3A1"1D]NQ[]\9Z*J5BU`(/F4_3[CV."#X)^\)R`
M/G].HJ>,VB2#ASR[*&`KR^?CLK[,$#ZG'S^O3!PC6K3`))2#@#^@)"@,94/E
M*L`'OC^A[P3%JR*LG\HR3Y$*&%9\L@9/GV'U!(^OZ]G\"*:G>?D2KY[DJ&`.
MP'W8\@D@*^,]_K_2+GHBFY)4$DX(RDGMC`"<I.593W)QW^#^O5P([\J"0K^W
M^U0(R?$`$J[@#&/$C^A^O<#J")2I/8*.3A`!*0M7VC(5W)2``,=Q\$].%1+8
M'B4?*@$X*?$J4/(?=D)R>RO]>WT['H)FCOY*.`H]S@D'Q'CC!"3]BOU)^G4'
MN@#/?QR">R@03G';[B#X''Z'L>@\WEH"%J2,'P7C(!R``?N!(4K!5^@^/Z=!
M;V]?/W]E`$$G!_Y3D'"?N!&<#&/^\'JQ*LU>O`AP)61XG)PKX)5E.5IRD?0`
MGY_7K496CM'P5J\%^"2O[/'[<X<!();PK!_U^.WT!ZTBFW?)02G'_,3DJ3_<
M%8^[*$Y)P>YP22.W<]!1&U6+2FY5,]L$?48#%':[7N^]3'(;5=QMQIKS?Y]M
MW6R>G%4.,^Q"0J-7!:74KL'6UJ0J,Q**)M<+K,U0O\='`3GM-[!VO\BF]:E,
MHN)]-UYCB7T.XZMXTE#E#Q/K:7ZECE!ZNFE4R/:;BE4IZ*MQ*W$HF/K*G6S$
M=ZX=_<[[7$]GZ^K?K+<ER50*VJ0AZ\NI"(U<TE2TMM+<,A4J9*6VI*O\?6-,
MJ>>P#D-E*?O*/*]&&1>N4,+6*2!1P/-3$%HA3SN"_+E/.+D39TDC`5)G3'5O
M.$8'FLX`&!UBW-RZ=$[Z@=`Z!T#H/__2[^.@=`Z!T#H,;=JUYS2KL.M('^SK
M^8A$-:4J\==N);@\ZN04J`13V#RE.Q5'"6GG%L92/VZ5;ES/-BS%\F)'NEZ?
M<6>[G".R<.<F141OWI;L]5V>$A`N]*VF(CQJMAIYC_E^WDP%2%H<;5EEQEQQ
MEU);<5TQG,O0ENMS.KCTVMWV.](^?K3CSE-4ECES7'H]C(O&JQN=1^QF@TD>
MPJZ?E[2D6$B''L.0JJB?>@[)7?O(K]S7_D+LABSCHN(#-S/\OY;XLS_9_'_#
M=OZX^R6G\]:O&M:29$A7S$&),N]?1/7++#4EYZ,S;U+TB-"E6.LS)\)]EM]<
M:-)CRX[\.<Q$L(TJ(QWUVFT\W#;6ZWR951;964I"B3\`>7VA2B`/N*B!D8R/
M@XS^H-95+%M%`)*5`9.1A1'U\DCO_;\8';MV[X[]1>R?1[)0^3C[B`/CN".X
M^X*.2DX^<Y^,=^@FC=D?A*OG!.3@$!."0KQQC`_0'Z]3`F;=B4X()R,CR"<E
M/?OXY!(['_O_`*],&4T9G]P<D*!'_A/VG.1V4D>2@"#\=NW3"^:9LV([^0)*
MBH]_(*PM(2!V(!\1]"/Z?'4,ILQ.QV/D24DX[*"D#!RCZD]L9[$X^F>BIFS+
M0,>/8D@!16%J0>_B,)!`_7``S\8Z@F3,SR/=7C\_W$=CD_W?:<@$X[XQC]>A
ME,Q+`Q]V/NR2<)24_<?%..P4?$9QG]>HK[,I*?A6,_<20I0*<_\`,M)\4I*S
MG'_QQVHE\V=XI``\E@=BDC(R#E2LX`5D'M\#N?Z=(+<7E@E7F2?CR()4D#R[
MGN!DY5D9R>ZOZ=7#*S5[,'BX2KQ/F<#&/$I`\`I(QC"N_?)[_7K2+7V#ODZ"
M%`+!5W[]@<^)^?$!&>WU`S\_(J+&\U<S:MPKIDC:ME<+\J06H&MZ]$5^2VVK
M8)+K3%92T\=L2'GI4V0^VC+;;Q0E0(2M1""MDZK)FL0_6GASEO\`D0WK;]0V
M:SMJSUDA;C06?LU95]U_]CY+V;37WK'4/631K"OF-09>JZ;,G.R-IM8BE(>F
M>,&,ZZ65V,SA;[K<]/QP[3&DXZ]OZNH^NKM=TG4H%130H%#0Z]7QJRIK*IEN
M+`A0X:2F'71*YH,-M1FV$AM#2$)\BD`)*@D)=:RO5QSJ<BO0]L]Y&#-_;L!F
M/$6@!RAH\M+CU9.3B=++*'II3XY<2AL^7X`M6;>TZ-28YO5=+K+1T#H'0.@=
M!__3[^.@=`Z!T#H(*RK8-O`EUEE&;F0)S"X\J,Z#X.M.#!&4E*T*2>Z5)(4A
M0"DD$`]!C7<5-CIT]JDLWG9-5,><_P!O["M!*YK:&T%%3:.(*&F+^,E/96$B
M:RGS;P0\TWN<].KG99Z,1_<CTPX@]VN-I''O)=;*@VM:^FUT+>Z-;D'>./\`
M:&BIR'L6L6*VU*94)3'BZD$LOLI\%)^[`M\UELN8Y$.6/7CV1]!.6$5UVI^F
MV9N>9FJ[U2*<@<<\V,)<985?Z9<HB6M=H?)LNHCQHUQK=E$G1K5;#.(ME"_;
M?L7.99?J_EO,LQCZ?X_X;,/6#WET_F!AG7]O>CZQO,%N+&F+DMBMJ;&8J.I:
MDR6US+).K7$QI@OMQ'I4F#,!7_C)]FB/)<8Z:[R\7C9RV^.SF<ZMA\>P'8C"
MP/CY)_($J1A*2<83D`G&1W/Z=;<T\8GE7;)&2KNM6<^7SCR6D]B.X/CW_7H)
MNS.![%1&!A14<J\E'*@1CN`5$DX&/CXQU%3-N=@KR<8[''B"K.!A2A@'!^H/
MQ\_0]03-J>E)(*L=O@8&#Y#(24J!P@#N<$?J>JB8LV9*D]S\]BDX[E.<I'T.
M$D_I@XSU%3EFT\AXJPH_4A142`"K(..W8X/].BINU9]R%$^!)^#E6%$C((/P
M?]?CZ?/4$U9M$X'WXRK"<D8'D`1@`C(621]0KH91[=F@)(#@.2GN?J,IR.Y!
M4?IG)R.F%?2[5*D]E=NWB!Y8[Y^@P2%X^1GH)-.MVRD@+2L=D@D@@I(R#@X5
MXGMW^I_[B96XN;@$K/DE0!`)&.R@2I&2,J!/D,?&?^/6DRM1<SDO%8/=1\<_
MW`_"R.ZBHD840".WZ'JHPG]E/;;1.`*M#3S,C<^1+N++DZEQ_0*2Y96RX[[T
M1,VPE)0INIHF;!HL/25@J"@4)0M7;J;;8]6M=;MSV89^K_J7['_R#\V3^1N1
M[Z;JU!5O2JG9N1:7]S'UWC+6)BG&[3A_UQ4^5-VF^V\92F+O;\N-T[:BAI;U
MH?&!QMMYOX]/ZNO&LX_'G?Z.LCB[BOCK@7C[5>-..M;J-/X_U&KCU=%55K;<
M6#75\1M?DIQ<E2I"WGGRM^0\M2GWGEN.NJ4XHJ+T9N>]7HT747;R7!V^]CN,
M5T7,C6J64S^)YZ05?9LMLV>_Y2D%4&.0$M(7^9:?S>'XI;VC4G>KZ=8:.@=`
MZ!T#H'0?_]3OXZ!T#H'0.@=!!SZ^%:PI-=916)L&8RMB5%D-I=9?:6,*0M"@
M0?U!^01D=QT&.^Q:[8:$IV2^J1;:CY$QK19<?GZ^@ASQBWJUJ4Y)A->1#,[Y
M^$R/OPZ[TESZL68]%`;OH6C<MZ9LFA\AZUK^ZZ9LT)==>4=_`CV=)8190^YE
MYAUA<9:`Z"`K[BA8"AW("2.7OV\_B%Y6]<-B?YF]-[#;MGX_K3:O1]'JY:9O
M,'%U5/9>-I5:N;)EQGEOC6;#=5'GZY9B2])C$-.HM$J_:],=NWX_&&IMX]?V
M_'FQ\]?O;NXT'_!TFY6>L\=U5@J17U<[9#?5WKG>3X<EBNF-1MB8KM@V_P!8
M-EBSW4L3:B;#N-.BRO)@,:FVVN.W9;KYZEUFWEM^/U;?XG(T"!)J:K;XT_CZ
MZO417J*MVM=8Q7[,B9'$V'(TC;JZ=8:/R+#EPUM/)?H;*Q::2\A#OXW?)M/6
M;2]^7*ZV+FL6@&/!8*3X@'[23E(6<D*0"`#V`\OT/6F4R:LP$Y)*,D^*ADCR
M[Y^U1.,DG'?Y'^G45&HGC)PM()2/'PP.V02H^2U`%&,'X[?/41%HL2#Y!>4$
MGMA*?M/C]`3G./J`/^_(1[-L"22L`>(QE22"$G.0#]I3]IQ_^E^F<A-&;;(`
M\CG&#D^1\OC*2I0"L]\9.<9_X%31NW(*594K_P"9.3A64E)_Y?D#.?GH(C_-
MI/B0Y@9)QYE`'W)2.W9(\CV']?IVZ+E".WX`(2K/D2%%'B>P[]P/)(R!_7(_
MIT3/13MAL3:!X!>5*24D@D%)4$8.24A(^WOWZ"P?(7->F:15W%ML%[6Q(E$P
MPY<2I5A`KJZD1*6EJ(YLEY9S(-#K<28[V8>L941MU1*4%1[=+9K.:36[=(U(
M\U_R%66USX.K<.MV:F;V;^PH)]=56K][NDQR2RBOC<?:C%8C[QNDR6YXH1),
M6MKHDA)+\6_KO,*YW>WIQ/W=9I)UYO[?FS)],OXC]ZY-N*_FGWBC286M2UP9
ME9P&Y-:GW>P,(4ZY4CF2VK'%UR*.M===<BZ=4!NC@-OK9(1'68*,K;X?CT_J
MZ.(T77M0JJNHK(U;7UL*)%JJ:HI8C;!"`VU&B5M+41?/R6EL-H#++*CV2&P<
M]W/9E=C2M!F&3&V/;FFT3F%I?J->;+:XE4I/>-.LRVIQF9>L))"/QJ,:,<%`
M6ZE+HS;VC4G>KQ]9:.@=`Z!T#H'0.@__U>_CH'0.@=`Z!T#H/E24K2I"TI6A
M:2E25`*2I*AA25).0I*@<$'YZ"R-_P`:S:A:[#1$M&'A:G]/?<;9C!2EI6IS
M7);Q_#7.*2"C]H]_Y,I("%,)3@[FWBS=?!0T2V8F*>BMNR8<B/(0U.KID617
MV4-81^9:'X$E/[AM1:"?'\J4M+`!3E"DGJX9RP*]J_XYN#O9!%YL;$5OC?DJ
MV2$/[CKD..[6[8[%CJC5[/(.HS4?X3<V&&'0AF<2Q=0&%+$*?#)"C9:O3T:5
M&>$/=O\`C]K]JI-$<UOF7B"O>+FX^K&XI1MG%>V4=C)C2&K;C*LO_P!]?Z8W
M;J?+7[&.Y(_96:'$/P;E"$SG+[>)=?T['OF<;?KW9L\"7?!/LSQVQR1PC)V?
MU_GP6X4'8-/$-NUTRDV^4\U6OZ;><7S9Z85(PQ=2I`BMZS/U\2FTL2?RNQW6
M@NS/:LW&;+/S5I>L<B:$VA_<]4>MZ'\86UO7&#5CO&M*8\GT?OKFB@0$;QJ[
M"$Q'''7WZ]^HBH'>Q</]VO=XL^W/2O.@W?6]EC*E:YL5%?QFGG(CDBHLXEDV
MS)C@(D1WOVCSGX)#"E#R0H^22H=L]:EST9YBI$SL?^'&,`#/BGQ*?[\I^TG.
M21C!_ICH(A,Q>3EU*O$@A044A*\#N3X8(2%`?(R,'ZGH/9%OXG(<RD_"BI:?
M$=DG)7@)\5=AY=ONSW'P$+/W&MJV7I=I9P*V)&;#LB1-E0XT>,VE8"ER'GW6
M4,(_ZH`*E#!4!D9'026)R54W$)ZTUER;MU;%9+\NTT^KMMMJ:V.DH)D6-IKD
M.RKJZ.4N_:\^ZT@>"SY80X4S,\5Q>.&+G(_O)PAHZGX5ER9H#5RPVXG_``5%
ML_\`ZI[0ES]J7&F7->X2C<F+IIW[AU`<8OI-&6VDN%QQ"PA*\W>=N:W_`*[W
MX:_N;OY1(E6\*74-,OG[^<ZS'KE\H*DZH'W3(\8,FMX.XFV2\WJT<GNNK#2[
M/>VJ]T(;;>K%J_*UUG;:][AO7XYVY0/"?\?_`/(#[\7M'N7(];,X@XS8D/V6
MO;=S;20(7^WHME(97+D\1>L]`U1:7I4N2ZX?R2)D-D348=<=D+R3C'X_X:MU
MG&<^G3]723Z??QO^MWI\?\]K%3,Y`Y8LHL5J^YIY%?9O-]F,?MVS^Q@REL(C
M:I2LMLAM,.O:BQTI0T%()2"JL6V^C/.*JSN)+]1J]>S:V32PW*D)<=CTM.7&
MDJ;?MY_BZ8KZD.)6(J`Y**,*2@X)2SX]$Z]%Z=2T*'KSHMK&1_F]E<:+3EJ\
MR&6(32DA*X=)!*WDUL521A:O);[V/^HXI(0E&+<^C<F/57_44Z!T#H'0.@=`
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M+CC9WN/F*;9MBV*HD<DUNF2ZRB2=?H9T:\G5EAOM9!FK@E]N)+DH0^6E'`&*
MK(>Y/K3_`)+0J=WE.NB67)UKJ]+HD2PH]LKE[%:;K2\97^K1(RI]!&;C*N:_
MF364M*?+2!*MFXJBF4AYEL8JY7*]=0G69MU/AM_YJ$TU"U^R94Y&L&+2SDMP
M:V.F3&4W)>@+L)2%OQR5M+0DJ4@E((UKG.&=L86X;22%%7[@H<)4ILJR\YW3
M@.^;*6T$^&$C\GR?+(P3UKHPUW^PT]5AR8XY%0T\K6(%(]^,.HE,V-RXZY!U
M"`ZM./Q,.;;8/NE2<^'^**R!YG'77HQ>K1SJWLF]P%[.^S6J2(DO8=-VW;Z6
M?Q=HVCTL6UVK<>6=?X0X<N(\G\3"XD"N;V1WDM%S:V5D_'A17X:E/O-^!SGW
M8NS?MSKI8KRF]@?>CE>UL+_AZMU[CO5-9AQ&JY6NU%-NU<U64,-_7*Z,KE_?
M;ZFU;;9+5M:R0L4.FV4)4\>4>;-81Y!C:]Y$^B=K4#S'J?O/7:].V_E+;>)N
M5'Z1F%$E?L/5C4>>-G:61'D0FIS]%ZH[-?,F"6B7'_V[D5I:4++Z!@F77O=O
MV:FTO$U_=A2/:NZH9TK_`'YR+H^K(<;G1WV+;3_<[C!BDC?N99_81J6K@<;Z
M^)C2WT_E<;(4R72IO\1<4T9G'_V?RUC/3X_WCU@>_P!J$%B49/+?KV"`E"5&
MF][-BDN1XZR^APOO^\U>ZB4MPDK$>.V'"!]H'BA+W?\`Z3]SV7_QW]OZ(1?\
ME_'B:UN#7[#P]N%VJ>'(L5OA;VTO$/1@%/J8D5O*7L5R/"=0PX7'?-MLN`!*
M$)0C\A5/=/\`R?M5]E_PX]9_1CC"]MN?8>UVL6II=^J=4Y`VZ.GC>YXW]7N%
M]7OIV][G(2W'T@;-.XFT[9G4R6$.+J&*JXC/H0$-*$K"G4YSSSG#6.)C&?5E
M6/1S^2#VA5!DW?KMR9??E?\`WD7<O<?V$LK[6O$)6DO(XV?O+W<-;D1_)!91
M&F_M&D(PAD@'&O\`V_K6<S_/])AF_P`0?P!<FV:8KOL+[2MZC2@J<D\;^LVJ
M1=32U!8#*UPWM^N&VK:VA!QT(4B;!=='B%%PK*?!SWO'EPGNG;3GSY;G/67^
M-GTW]468LSB7B&B3M<1+CCO(>U)<W?>0Z^$J?4=FN1)F529GW*<9B%AH$C[!
MV'3ITC-VMO-9I)LA8234TE7/NIK:^\*C@-/-QG4L`,"9:J=8JZ=(*TJ2)#S+
M6?(`'&"QCE.O1<*HXQN;0M2=UM!&CH'_`$J+79<IMU22MY13:;(1'GN*=;>P
MXW#3&PL'_KNI..L^Z3HU[?%>.NK:^GA,5M5"BUT"*CPCPX3#<>.RDDJ(0TTE
M*`5*)).,J423DGK/5I'=`Z!T#H'0.@=`Z!T#H/_7[^.@=`Z!T&.W+/J[Q)R_
M4\C0[ZED5]MR5K&U4%O?5=A/1^TMMJXULN(WM^BZW(E/Z<_R)6\?V:JF-=2*
M]ZQ16H1#_,8J0T"Y1$OU9X'L51G+70T73S,U%A*D7NQ[=>2K^8SM^D;U$>W"
M5;7\R1N_^.V3C>C<BIN%3DQ(U:S$9"(@4PH9JJV.$>,6Z#4M7EZV[?4&C6-C
M::M6;;?[+N;-6_;:3L_'$^-Y;9<W3TVG>T;<K.L$"2IZ"W%EJ2AE)""DF5/:
M?ZS<):#1Z[J^H:6NCU?4EZ*_K6KQMGW%W6:69QM&JHFGVD#7I6P2*9FYKV:2
M+^>:&/W=@MKSF./K4M2BYK$[G;E;UK])N3_7FOWOBS9N-N,.2MRY)A1O9/7[
MJTI.,.-N5.0=JIMO8T;EV=4;!%L(>I\JWH=<8_RS;FLP5U<6.&FXC),"+,W/
M/++/D&T1<;+64K3C2Z_7HXNIBO$NID7-G'?C53+"D*&5P*EQ]Y8SXG]TRH*!
M'72=,N>W5;39;S_;NOR[,K;=EJC,-5@*T-)=E2EH;AQPX@J\&UO)25?=Y(;2
MM0*@.]G-PPUD73JMNMPW7/NN/[);"09JW,/2I]R)6LT]C$(RDM,:K6VM_P#@
M)'XW9#3F.X)ZS$8ZUI4X2X3HN>>:MZYR<=G_`.W>3D\N\Q;H8,MV(Y><'W7(
M+.B^NO"[$F(Z%5S.V4G$\:=.6S^-Z;7RE-^808_AG2==N]=-[9C7M&YG7M?@
M4M71ZM7168]6Q9UM2U'KX[4:.WJ_$<)$F9^UB,)2AIH<BRU-_C0E(*%^(&,=
M;<VS?CC5HVJZK6P3%0FRLF46=NI(2XHV\]E+CR'PI+:7FX2%(;;4>Y2V$_Z\
M;<W/9M.Y]3K+SK@LHE*5.NDJ$]F$H.A\N90AU]L)PL)"$%0/T&,J&6?`4C+X
MJX<M):GIFB<?SIDI!S+EZWK\F1X(2%H:"YL(NJ6EL@H!^Y!'@,!/9FKZ)G`T
MGCJA8_!4ZWI%16LE+K4>)6U,%ED+"_RAE28K9+KCCBG04C/DX",DG#-%JN?N
M)^!O8OB7;^$^4&Z2PU7<Z[]LJ/72&8M[2VK2ESZ+:*!Z(E4NJV:CM8[,NMD(
M2HIE--I4AQ'DVIBWK"7%S&+GIESYRI2;E<>C/LO&OM@]D.,J.1<<8\@J@/4<
M#VJX$BR?V%'RK32;B341!MU#]E;M,4/.)38,&4AQYMQXLYG'%L;VF9[M9Q6S
M]C2.0[9T%^)0:[&&`V]9S7KBQ8+C;RG%?XJG_!7NA#CJ$@"Q0H_B'W'Y-S(S
MBU6=;Q'3-E#NPV5GLCH(48SS@JZ?S"TN9_QE:6E2FRI/=$MZ4@Y[@]NI=KV7
MVQ<R!7P*N*U!K(,.NA,)\6(<",S#BLI_\+4>.AMEM/\`0`=9:1G0.@=`Z!T#
MH'0.@=`Z!T#H/__0[^.@=`Z!T#H'0.@=!;OEO0N-^4.,MYT#F#6:/<.,-HUN
MSKMWUS8XJ9=/94'[=3\P2D$I<8<B!D/LR&E-R(K[2'F5H=0A:77@SCEHBXIY
M0V[^.S?].]<O8^UM[_U6Y-L8%1ZK>SFW3E3)?&-FZPF%2>LG/^Q..?B8=JJ:
M`S'U;99(9CRH#26E_:PZF#KI<=DQ-IF3ZF;?/NR2)"HVL5TC]M^YDHUZ#XJ3
M^2/96L=^5?6:7@/(+U_4VWW4$N+0IU?B3E*<==7*M<'L9N,O7>"^4=CTN*B)
MLVP:_`XMXKAL_D*Y?*?/EC5<.<628T=L&1^[U_7)]?8+:0/),:4ZH@`$B[6R
M=>5TF=O)1WK1JM'IN@W5A2MKDZ[/W!55JI(0VN7PWZJZ_7<8\?(92A08:;N-
MAU=F4D)[/*GK6<J43U9Q(S;FY9W<5:L[-W.MJGRIU6N1*/6WWT^2E*NA%5ON
MXSD%*/O19RG(:'E8P5I(/?[>EZ4G+8<ZMJ*AQV2XPPRU&6MXH2HMI;98274N
M*#X;0M(9(PI.!V[C`!Y=&UQ]"TVG7J=5-O:.JL+B[CIN[-ZQK8TJ2';,_O(\
M)TRV%+0*N(ZW&2@!*4_BR!DDG-O/'1N3CHJ<Z%HQ))TO4R5#!)URG)(`P`3^
MS[@#J9OB8G@]F]*TUI)2UJ6LM)((*6Z&J0D@G)!"8@!!/?\`UZ9OB8G@J!B/
M'BM_BC,,QV@2K\;#2&6_)1RI7@VE*<J/R<=^HK"OW@]1E>T6B:W<Z#M!XM]F
MN#[Y?)'K-S5#;)FZ'R'%CAMRHNDMMNJMN.-_@M_XK8ZQQM^/,@.^2F75LMIZ
M++CKT4]ZH>\U'S-IU+0\TZQ><$^QM#L3O%_+?%^S:YL\2DI.4:NT9ULJUK=7
MZI6IVVF[_=/-*U>8+!0M/W;<1I3LQ"V^A9X=&<$O9*&#:,44FV@IO941%C'H
MFWT/W;U8NT@4BK9NHCEVQ541K2TCLOR_Q?MHZG4EU:!WZ(G?0.@=`Z!T#H'0
M.@=`Z!T#H'0?_]'OXZ!T#H'0.@=`Z!T%HN6;9*H=3J39*G-CG-.6@24@M:]6
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M*(ZL]@$K``[*P<9ZWP:QGAE@`````````!@`#L``.P`'7-T?O0.@=`Z#%+F/
MU7J>7^1(/(\C>-FUBWJZ/1J*L9I'IJ8D5K5=YM=ILK)^M_RS6OW-S.J;R3%J
MI-A!EKURS$>WA8F1FL%EPQU;_C1T>)7Z[$JMFIJ:74,Z\Q/LXNG[+<S9:=6Y
M<X6Y4K'J25NO*6VS]27/7Q!^RL8\-\5LERU?F,Q(SY?$H9\5347H#"UBPX^.
MO<F_X>@T'D7CWD>#25NC1ZIYJUT;4_7#4Y[%);4NSUCM/&WJ#P18(N8[S4ZO
MFM;=,+L5<J-&E]1<MB/59.@=`Z!T#H'0.@=`Z!T#H/_2[^.@=`Z!T#H'0.@=
M!B_;6#E[L>PWJ@'XSLEJCHFG5$,IJZ-<AMR3X-.E3Z9MJY)E)6$Y4P$)PHI[
M[G$PYWFL<N8]P5`;LWX:VYRZ!#-=3L+RDV&X;`S%A5\=Q7BE;?XC-::[%0`D
MK)/DD];UC-K%1JG#K:::.\Y)-A+C\4UDPJ6'I@>4J\Y5OORI)+<J<(4AHK']
MLJ(,?W#K:-?^@6T'E7F&YY5<Q(UWD+FK>N6HG[<M>*/7WTCK7^&.&6$,)\W&
MJ_;N:K*SVF)YCR>"B4);'SG7O?%O;B2>#.FOJI$AO_#R?%R?8OT6C32GX=M=
MD>5R%RDXTLA)_#-J7$MG_P`*VL?((ZTYMAG%L)<:@E3VD-!ZTLYSS>4J<;$*
M$XFDB_W/L-^#J(27"H@I!4?N(^.>W-Y;G1>+0:Y,_?)$XJ2MO6:)0\0Z\K%A
ML,G\$5PY66UKCUU1)!'T_=9(RKMG;IAK7JR!ZPV=`Z!T#H'0.@=`Z!T#H'0.
M@=`Z!T#H'0.@=!__T^_CH'0.@=`Z!T#H*'Y$OG]?U6>_!646]B6J6D\$EQP6
MMHHQV)#;8*?RFN:+DI2?)/DAA0R.K)FI;B,?Y[T34M:=>2VK]E15SK,=/EE:
M40FV_%EL$M.O/NE@(23]R%_'B!GK?6^;#!#>[N4JU'VIFR=3CF^>8)46+/D;
M<GY%9K%87`KNEI^<^ZILY4T'8[GT2>NTC%8Y^R^ZVW#_``GR=;Z<ZY)W?6]0
MJ>%N*5Y5^[N.?^=;6IU>FGH88!>ES(E]L=;-=4V`H-_N3E*4K4,;6R<=:UK)
M=IX1;#U^X[H-.D7.LU"D#4>/!Q[ZRZK*_$&3_LGULH'-CY,N)*6RMKPV#E:U
MLH,U9)4XZT`OOWZU)B<);F^=9C:*U(DV,*PD,K_<5.M6&Y38[H\E#8^1)S\N
M%"R`K_S5+4P514CNH-/I`[$9J1L*UVL_P=!4UY>+H@5K$5844*"5B(XREU:`
MPEP*?>3Y))*._;N<D\>MK:[O$D-/^#M;X]U[+L%E,;SXDM0*M:=?@--K0`E4
M=]%4J4C'UE*/R3UG;M&M>F5U>LM'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H
M'0?_U._CH'0.@=`Z!T#H+8[_`*5L&V3Z&757U96QZ-JU=3`L::38ID6E@PU#
MCV(DL6T+\"X,!4EE`_$OM*6K)P$]:EDSPEF<<K.;_P`)<D[92&HK-HU2L=6^
MP^]8*BW7YWA$4V]'96E3DH8_<,I)5Y=DIP$]SG4WUESBLW6WNPY1Z*^Q\:RA
MV/\`ZHZ%9E%];[58HD2MBC.3;IQHP-?0D?[9E-&-35)2TGR*27&FUC!&>M_[
M-?"L^R]JL/R-_'Y[A[5;\&SW]@XVV"HXNY%VGFC8Z)6Q6$=6S<EM:Y=UW'9;
M>DT$1IVDU^UV23(/YU(4VY&B+2VHM_9+OK;K>T6:[2;>-4YQ]Z6^Z7'_`!Y3
M:I8ZA2W\QJCE5]Y.@[7J3CLBQW_<YNV\J6?E)N(#\A=@Y*`:6E/Y5$=D]:]^
MGBS==O!DCQEQWSW77$Y?(G%E[5L76Y(LYDBJB,728]73&-%IF2*>39)+,N%3
M,%?AG\9?4#XJR0NVN.*2;3K&8-O=R6X$D,5FR1K53#C=='MM:V6N=?EOR?VM
M<VA=C`C-E+\U:4!0)P0DY4`G//$_)JY\&55#4LT-)44D=16S45D&M;<*0E3J
M849N/^98&?\`J/?C\E?.5$]<[<VUTG";=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#
MH'0.@=`Z#__5[Q-Z&[*J(R=#5`1;&Q9$I=@EE3:*XQI84IM,C_I*4F=^W+@_
MN+'Y/#[_`!ZLQW2Y[*"8M.>8\JW:7K.JV,%.P[VBFD2+%N'+-!'EPY.A.2?V
MLY3+AM&YKL21_P!)IZ''A_N%"0\I,=YP<I#`LO95RUID6FO:K'J6M9F1+M^!
M-KW'I.QR:6F=B6T2/(GK4D0MA;D,AKS;83$=>6I,AQ$=*[])R\:Z7[,4,9+,
MVJUC>)$W8T%4A^555*J/7GF=+\DI<A/TS5HJ&)ER"3&2\N1""A_T7VFT/I.4
MX=OO8B-'6XG2=+M)!B%346//_P`8!,1?VS'XG9$G99B2S(UROBOA24Y;?L0D
M^7[9Q+L^GQ.40UL'/OXH"GM$U4..O5;4]+=JR%QT2*1YZUDH:.P*:4U7[$I$
M="0\M;L-O\X'Y'2Q'<'/@I5%Q[0'02R]J>M_[^?COQC)C3:-$.(9+-JVW;LO
M/WC\)NPKY:XSC<%<.7&+#(\Y3SCZT1K].?(YQYKA&PY:4:^0[11$.AMU#D*N
MD4O[#\PV.PB2I%VFPM%SG&_]I"+,K&8$MLNV!=9F.L-%"DS@Y4K$VCV(=D6S
M+V@Z>EZ&P^J,U^_E,5ZWG+5:*Y$2]=M5*N2NI0E3X_8P4LAQ3I7^5M,!]P<D
MVZ]CG'8HAZ=J#2&&M.D2?_NL9ANPESX[4G;ZY3[MG9O5M?0R$KC)D(8?>D@^
M;3?PH.#E<'4['DR5<3VMOH:*NH_RVZ:N36R/*>(\-.N?X9^P:_RMDV9%Y^_L
M2ZRW]L!4!*/RR$O(=+@Y7&ZBG0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.
M@=`Z!T'_UN_CH'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.
M@=`Z!T#H'0.@=`Z#_]?OXZ!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'
50.@=`Z!T#H'0.@=`Z!T#H'0.@__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
